PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Faklaris, O; Cottet, M; Falco, A; Villier, B; Laget, M; Zwier, JM; Trinquet, E; Mouillac, B; Pin, JP; Durroux, T				Faklaris, Orestis; Cottet, Martin; Falco, Amandine; Villier, Brice; Laget, Michel; Zwier, Jurriaan M.; Trinquet, Eric; Mouillac, Bernard; Pin, Jean-Philippe; Durroux, Thierry			Multicolor time-resolved Forster resonance energy transfer microscopy reveals the impact of GPCR oligomerization on internalization processes	FASEB JOURNAL			English	Article						oligomers; lanthanide; vasopressin; V1a/V2 receptor; quantum dot; multigate mode	PROTEIN-COUPLED RECEPTORS; MOLECULES IN-VIVO; BETA-ARRESTIN; LIVING CELLS; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; FUSION PROTEINS; QUANTUM DOTS; FRET; HETERODIMERIZATION; DIAGNOSTICS	Identifying the interacting partners and the dynamics of the molecular networks constitutes the key point in understanding cellular processes. Different methods often based on energy transfer strategies have been developed to examine the molecular dynamics of protein complexes. However, these methods suffer a couple of drawbacks: a single complex can be studied at a time, and its localization and tracking cannot generally be investigated. Here, we report a multicolor time-resolved Forster resonance energy transfer microscopy method that allows the identification of up to 3 different complexes simultaneously, their localization in cells, and their tracking after activation. Using this technique, we studied GPCR oligomerization and internalization in human embryonic kidney 293 cells. We definitively show that receptors can internalize as oligomers and that receptor coexpression deeply impacts oligomer internalization processes	[Faklaris, Orestis; Cottet, Martin; Falco, Amandine; Mouillac, Bernard; Pin, Jean-Philippe; Durroux, Thierry] CNRS, Unite Mixte Rech 5203, Inst Genom Fonct, Montpellier, France; [Faklaris, Orestis; Cottet, Martin; Falco, Amandine; Mouillac, Bernard; Pin, Jean-Philippe; Durroux, Thierry] INSERM, Montpellier, France; [Faklaris, Orestis; Cottet, Martin; Falco, Amandine; Mouillac, Bernard; Pin, Jean-Philippe; Durroux, Thierry] Univ Montpellier, F-34059 Montpellier, France; [Villier, Brice] Hamamastu Photon France, Massy, France; [Laget, Michel; Zwier, Jurriaan M.; Trinquet, Eric] Cisbio Bioassays, Codolet, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier	Durroux, T (corresponding author), INSERM U661, CNRS UMR 5203, Inst Genom Fonct, 141 Rue Cardonille, F-34094 Montpellier 5, France.	tdurroux@igf.cnrs.fr	MOUILLAC, Bernard/M-3896-2014; Pin, Jean-Philippe/Y-6668-2019; Faklaris, Orestis/GQY-4946-2022	MOUILLAC, Bernard/0000-0002-3906-8673; Pin, Jean-Philippe/0000-0002-1423-345X; Faklaris, Orestis/0000-0001-5965-5405; Durroux, Thierry/0000-0003-1091-6066; Zwier, Jurriaan/0000-0001-9017-5856	Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale [ANR-06-BLAN-0087-03, ANR-09-BLAN-0272]; Fondation Recherche Medicale [DEQ20130326522]; Fondation Bettencourt Schuller; la Fondation pour la Recherche Medicale	Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)Centre National de la Recherche Scientifique (CNRS)); Fondation Recherche Medicale; Fondation Bettencourt Schuller; la Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	This work was supported by research grants from the Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale (ANR-06-BLAN-0087-03 and ANR-09-BLAN-0272). The work was also supported by the Fondation Recherche Medicale (team DEQ20130326522) and the Fondation Bettencourt Schuller (to J.-P.P.). This work was also made possible by the Plateforme Arpege of Montpellier and the Region Languedoc-Roussillon. M.C. was supported by la Fondation pour la Recherche Medicale.	Albizu L, 2010, NAT CHEM BIOL, V6, P587, DOI [10.1038/NCHEMBIO.396, 10.1038/nchembio.396]; ALPHA B, 1990, PHOTOCHEM PHOTOBIOL, V52, P299, DOI 10.1111/j.1751-1097.1990.tb04185.x; Alvarez-Curto E, 2011, MOL PHARMACOL, V80, P1033, DOI 10.1124/mol.111.074674; Bazin H, 2002, J Biotechnol, V82, P233, DOI 10.1016/S1389-0352(01)00040-X; Breton B, 2010, BIOPHYS J, V99, P4037, DOI 10.1016/j.bpj.2010.10.025; Bunzli JCG, 2010, CHEM REV, V110, P2729, DOI 10.1021/cr900362e; Comps-Agrar L, 2012, FASEB J, V26, P3430, DOI 10.1096/fj.12-203646; Cottet M, 2013, BIOCHEM SOC T, V41, P148, DOI 10.1042/BST20120237; Cottet Martin, 2012, Front Endocrinol (Lausanne), V3, P92, DOI 10.3389/fendo.2012.00092; Coulon V, 2008, BIOPHYS J, V94, P1001, DOI 10.1529/biophysj.107.117275; Doumazane E, 2011, FASEB J, V25, P66, DOI 10.1096/fj.10-163147; Feinstein TN, 2013, J BIOL CHEM, V288, P27849, DOI 10.1074/jbc.M112.445098; Gautier A, 2008, CHEM BIOL, V15, P128, DOI 10.1016/j.chembiol.2008.01.007; Geissler D, 2014, INORG CHEM, V53, P1824, DOI 10.1021/ic4017883; Geissler D, 2010, ANGEW CHEM INT EDIT, V49, P1396, DOI 10.1002/anie.200906399; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Herrick-Davis K, 2006, J BIOL CHEM, V281, P27109, DOI 10.1074/jbc.M604390200; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Juillerat A, 2005, CHEMBIOCHEM, V6, P1263, DOI 10.1002/cbic.200400431; Juillerat A, 2003, CHEM BIOL, V10, P313, DOI 10.1016/S1074-5521(03)00068-1; Keppler A, 2003, NAT BIOTECHNOL, V21, P86, DOI 10.1038/nbt765; Lin HL, 2013, J BIOL CHEM, V288, P11203, DOI 10.1074/jbc.M112.439950; MATHIS G, 1995, CLIN CHEM, V41, P1391; Maurel D, 2008, NAT METHODS, V5, P561, DOI [10.1038/nmeth.1213, 10.1038/NMETH.1213]; Milligan G, 2010, CURR OPIN PHARMACOL, V10, P23, DOI 10.1016/j.coph.2009.09.010; Morgner F, 2010, ANGEW CHEM INT EDIT, V49, P7570, DOI 10.1002/anie.201002943; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Rajapakse HE, 2010, P NATL ACAD SCI USA, V107, P13582, DOI 10.1073/pnas.1002025107; Rives ML, 2009, EMBO J, V28, P2195, DOI 10.1038/emboj.2009.177; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Sartania N, 2007, CELL SIGNAL, V19, P1928, DOI 10.1016/j.cellsig.2007.05.002; Selvin PR, 2002, ANNU REV BIOPH BIOM, V31, P275, DOI 10.1146/annurev.biophys.31.101101.140927; Serradeil-Le Gal C, 1993, J CLIN INVEST, V92, P224; SerradeilLeGal C, 1996, J CLIN INVEST, V98, P2729, DOI 10.1172/JCI119098; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Zhang Y, 2006, ANGEW CHEM INT EDIT, V45, P4936, DOI 10.1002/anie.200601197	38	33	33	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2235	2246		10.1096/fj.14-260059	http://dx.doi.org/10.1096/fj.14-260059			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25690655				2022-12-28	WOS:000355209500003
J	Patel, V; Carrion, K; Hollands, A; Hinton, A; Gallegos, T; Dyo, J; Sasik, R; Leire, E; Hardiman, G; Mohamed, SA; Nigam, S; King, CC; Nizet, V; Nigam, V				Patel, Vishal; Carrion, Katrina; Hollands, Andrew; Hinton, Andrew; Gallegos, Thomas; Dyo, Jeffrey; Sasik, Roman; Leire, Emma; Hardiman, Gary; Mohamed, Salah A.; Nigam, Sanjay; King, Charles C.; Nizet, Victor; Nigam, Vishal			The stretch responsive microRNA miR-148a-3p is a novel repressor of IKBKB, NF-kappa B signaling, and inflammatory gene expression in human aortic valve cells	FASEB JOURNAL			English	Article						inflammation; aortic valve calcification; mechanotransduction	MATRIX-METALLOPROTEINASE EXPRESSION; INTERSTITIAL-CELLS; TARGET PREDICTION; ENDOTHELIAL-CELLS; VALVULAR LESIONS; SMOOTH-MUSCLE; IKK-BETA; STENOSIS; DISEASE; CALCIFICATION	Bicuspid aortic valves calcify at a significantly higher rate than normal aortic valves, a process that involves increased inflammation. Because we have previously found that bicuspid aortic valve experience greater stretch, we investigated the potential connection between stretch and inflammation in human aortic valve interstitial cells (AVICs). Microarray, quantitative PCR (qPCR), and protein assays performed on AVICs exposed to cyclic stretch showed that stretch was sufficient to increase expression of interleukin and metalloproteinase family members by more than 1.5-fold. Conditioned medium from stretched AVICs was sufficient to activate leukocytes. microRNA sequencing and qPCR experiments demonstrated that miR-148a-3p was repressed in both stretched AVICs (43% repression) and, as a clinical correlate, human bicuspid aortic valves (63% reduction). miR-148a-3p was found to be a novel repressor of IKBKB based on data from qPCR, luciferase, and Western blot experiments. Furthermore, increasing miR-148a-3p levels in AVICs was sufficient to decrease NF-kappa B (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling and NF-kappa B target gene expression. Our data demonstrate that stretch-mediated activation of inflammatory pathways is at least partly the result of stretch-repression of miR-148a-3p and a consequent failure to repress IKBKB. To our knowledge, we are the first to report that cyclic stretch of human AVICs activates inflammatory genes in a tissue-autonomous manner via a microRNA that regulates a central inflammatory pathway.	[Patel, Vishal; Carrion, Katrina; Dyo, Jeffrey; Nigam, Vishal] Univ Calif San Diego, Dept Pediat Cardiol, La Jolla, CA 92093 USA; [Hollands, Andrew; Gallegos, Thomas; Leire, Emma; Nigam, Sanjay; Nizet, Victor] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Hollands, Andrew; Leire, Emma; Nizet, Victor] Univ Calif San Diego, Sch Pharm, La Jolla, CA 92093 USA; [Hinton, Andrew; King, Charles C.] Univ Calif San Diego, Pediat Diabet Res Ctr, La Jolla, CA 92093 USA; [Gallegos, Thomas; Nigam, Sanjay] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Sasik, Roman] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Hardiman, Gary] San Diego State Univ, Computat Sci Res Ctr, San Diego, CA 92182 USA; [Hardiman, Gary] San Diego State Univ, Biomed Informat Res Ctr, San Diego, CA 92182 USA; [Hardiman, Gary] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Mohamed, Salah A.] Univ Clin Schleswig Holstein, Dept Cardiac Surg, Lubeck, Germany; [Nigam, Vishal] Rady Childrens Hosp, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; California State University System; San Diego State University; California State University System; San Diego State University; Medical University of South Carolina; University of Kiel; Schleswig Holstein University Hospital; Rady Childrens Hospital San Diego	Nigam, V (corresponding author), Univ Calif San Diego, Dept Pediat Cardiol, 9500 Gilman Dr Box 0731, La Jolla, CA 92093 USA.	vnigam@ucsd.edu	Nizet, Victor/AAF-3190-2019; Mohamed, Salah A./O-2955-2018; Leire, Emma/B-8026-2016	Nigam, Vishal/0000-0002-9652-8146; Leire, Emma/0000-0001-9161-0442; Hardiman, Gary/0000-0003-4558-0400; Nizet, Victor/0000-0003-3847-0422	Australian National Health and Medical Research Council; Larry L. Hillblom Foundation; U.S. National Institutes of Health National Heart, Lung, and Blood Institute Grant [K08 HL086775-01]; UCSD Department of Pediatrics; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL086775] Funding Source: NIH RePORTER	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Larry L. Hillblom Foundation; U.S. National Institutes of Health National Heart, Lung, and Blood Institute Grant; UCSD Department of Pediatrics; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Lifesharing for their assistance in obtaining the human valve tissue. The authors also thank Drs. I. Banerjee and S. Lange for technical assistance. They also acknowledge the University of California, San Diego (UCSD) Microarray and Biomedical Genomics Microarray Core Facilities for their assistance with the miRNA-Seq and microarray experiments. A.H. was funded by a CJ Martin-Biomedical Overseas fellowship from the Australian National Health and Medical Research Council. A.H. was funded by the Larry L. Hillblom Foundation. V.N. was supported by U.S. National Institutes of Health National Heart, Lung, and Blood Institute Grant K08 HL086775-01 and the UCSD Department of Pediatrics.	Aggarwal A, 2014, ANN BIOMED ENG, V42, P986, DOI 10.1007/s10439-014-0973-0; *AM HEART ASS, 2004, HEART DIS STROK STAT; Balachandran K, 2009, AM J PHYSIOL-HEART C, V296, pH756, DOI 10.1152/ajpheart.00900.2008; BEPPU S, 1993, AM J CARDIOL, V71, P322, DOI 10.1016/0002-9149(93)90799-I; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Davies MJ, 1996, HEART, V75, P174, DOI 10.1136/hrt.75.2.174; Du W, 1995, J BIOMECH, V28, P1485, DOI 10.1016/0021-9290(95)00096-8; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Edep ME, 2000, CARDIOVASC PATHOL, V9, P281, DOI 10.1016/S1054-8807(00)00043-0; Fedak PWM, 2002, CIRCULATION, V106, P900, DOI 10.1161/01.CIR.0000027905.26586.E8; Fondard O, 2005, EUR HEART J, V26, P1333, DOI 10.1093/eurheartj/ehi248; Freeman RV, 2005, CIRCULATION, V111, P3316, DOI 10.1161/CIRCULATIONAHA.104.486738; Gould RA, 2012, ACTA BIOMATER, V8, P1710, DOI 10.1016/j.actbio.2012.01.006; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Hishikawa K, 1997, CIRC RES, V81, P797; Holliday CJ, 2011, AM J PHYSIOL-HEART C, V301, pH856, DOI 10.1152/ajpheart.00117.2011; Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026; Jian B, 2003, ANN THORAC SURG, V75, P457, DOI 10.1016/S0003-4975(02)04312-6; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kaden JJ, 2005, CARDIOVASC PATHOL, V14, P80, DOI 10.1016/j.carpath.2005.01.002; Kaden JJ, 2003, ATHEROSCLEROSIS, V170, P205, DOI 10.1016/S0021-9150(03)00284-3; Kang HB, 2007, STEM CELLS DEV, V16, P615, DOI 10.1089/scd.2007.0014; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292; Meng XZ, 2008, AM J PHYSIOL-CELL PH, V294, pC29, DOI 10.1152/ajpcell.00137.2007; Mohamed JS, 2010, J BIOL CHEM, V285, P29336, DOI 10.1074/jbc.M110.101147; Mohler ER, 1997, ARTERIOSCL THROM VAS, V17, P547, DOI 10.1161/01.ATV.17.3.547; Mori N, 1996, BLOOD, V87, P3410, DOI 10.1182/blood.V87.8.3410.bloodjournal8783410; Naito Y, 2010, INT J CARDIOL, V144, P260, DOI 10.1016/j.ijcard.2009.01.022; Nigam V, 2010, J HEART VALVE DIS, V19, P459; OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163; OLSSON M, 1994, J AM COLL CARDIOL, V23, P1162, DOI 10.1016/0735-1097(94)90606-8; Osman L, 2006, CIRCULATION, V114, pI547, DOI 10.1161/CIRCULATIONAHA.105.001115; OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844; Panda H, 2012, REPROD SCI, V19, P786, DOI 10.1177/1933719112438448; Park EK, 2007, INFLAMM RES, V56, P45, DOI 10.1007/s00011-007-6115-5; Robicsek F, 2004, ANN THORAC SURG, V77, P177, DOI 10.1016/S0003-4975(03)01249-9; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Satta J, 2003, ANN THORAC SURG, V76, P681, DOI 10.1016/S0003-4975(03)00529-0; Smith KE, 2010, BIOMECH MODEL MECHAN, V9, P117, DOI 10.1007/s10237-009-0165-2; Soini Y, 2001, J PATHOL, V194, P225, DOI 10.1002/path.850; Song LB, 2013, CELL RES, V23, P274, DOI 10.1038/cr.2012.174; Song LB, 2010, BIOCHEM BIOPH RES CO, V402, P135, DOI 10.1016/j.bbrc.2010.10.003; Steinmetz M, 2008, J HEART VALVE DIS, V17, P187; Strum JC, 2009, MOL ENDOCRINOL, V23, P1876, DOI 10.1210/me.2009-0117; Szeto K, 2013, WORLD J PEDIATR CONG, V4, P362, DOI 10.1177/2150135113501901; Tanaka K, 2005, J AM COLL CARDIOL, V46, P134, DOI 10.1016/j.jacc.2005.03.058; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; Wallby L, 2002, HEART, V88, P348, DOI 10.1136/heart.88.4.348; Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408; Ward C, 2000, HEART, V83, P81, DOI 10.1136/heart.83.1.81; Yanagawa B, 2012, J THORAC CARDIOV SUR, V144, P256, DOI 10.1016/j.jtcvs.2011.10.097; Zhao HR, 2004, J BIOL CHEM, V279, P8592, DOI 10.1074/jbc.M308708200	57	58	59	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1859	1868		10.1096/fj.14-257808	http://dx.doi.org/10.1096/fj.14-257808			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25630970	Green Published			2022-12-28	WOS:000354114600021
J	Shiozaki, K; Takahashi, K; Hosono, M; Yamaguchi, K; Hata, K; Shiozaki, M; Bassi, R; Prinetti, A; Sonnino, S; Nitta, K; Miyagi, T				Shiozaki, Kazuhiro; Takahashi, Kohta; Hosono, Masahiro; Yamaguchi, Kazunori; Hata, Keiko; Shiozaki, Momo; Bassi, Rosaria; Prinetti, Alessandro; Sonnino, Sandro; Nitta, Kazuo; Miyagi, Taeko			Phosphatidic acid-mediated activation and translocation to the cell surface of sialidase NEU3, promoting signaling for cell migration	FASEB JOURNAL			English	Article						sialic acid; phospholipids; gangliosides; PLD1; cancer	MEMBRANE-ASSOCIATED SIALIDASE; SITE-DIRECTED MUTAGENESIS; GANGLIOSIDE SIALIDASE; PHOSPHOLIPASE D1; APOPTOSIS SUPPRESSION; MOLECULAR-CLONING; TYROSINE KINASE; GROWTH; EXPRESSION; BINDING	The plasma membrane-associated sialidase NEU3 plays crucial roles in regulation of transmembrane signaling, and its aberrant up-regulation in various cancers contributes to malignancy. However, it remains uncertain how NEU3 is naturally activated and locates to plasma membranes, because of its Triton X-100 requirement for the sialidase activity in vitro and its often changing subcellular location. Among phospholipids examined, we demonstrate that phosphatidic acid (PA) elevates its sialidase activity 4 to 5 times at 50 M in vitro at neutral pH and promotes translocation to the cell surface and cell migration through Ras-signaling in HeLa and COS-1 cells. NEU3 was found to interact selectively with PA as assessed by phospholipid array, liposome coprecipitation, and ELISA assays and to colocalize with phospholipase D (PLD) 1 in response to epidermal growth factor (EGF) or serum stimulation. Studies using tagged NEU3 fragments with point mutations identified PA- and calmodulin (CaM)-binding sites around the N terminus and confirmed its participation in translocation and catalytic activity. EGF induced PLD1 activation concomitantly with enhanced NEU3 translocation to the cell surface, as assessed by confocal microscopy. These results suggest that interactions of NEU3 with PA produced by PLD1 are important for regulation of transmembrane signaling, this aberrant acceleration probably promoting malignancy in cancers.	[Shiozaki, Kazuhiro] Kagoshima Univ, Fac Fisheries, Kagoshima 890, Japan; [Shiozaki, Kazuhiro] Kagoshima Univ, United Grad Sch Agr Sci, Kagoshima 890, Japan; [Takahashi, Kohta; Hata, Keiko; Miyagi, Taeko] Tohoku Pharmaceut Univ, Div Canc Glycosylat Res, Sendai, Miyagi 9818558, Japan; [Hosono, Masahiro; Nitta, Kazuo] Tohoku Pharmaceut Univ, Div Cell Recognit Study, Sendai, Miyagi 9818558, Japan; [Yamaguchi, Kazunori; Shiozaki, Momo] Miyagi Canc Ctr, Res Inst, Natori, Miyagi 9811293, Japan; [Bassi, Rosaria; Prinetti, Alessandro; Sonnino, Sandro] Univ Milan, Dept Med Biotechnol & Translat Med, Milan, Italy	Kagoshima University; Kagoshima University; Tohoku Medical & Pharmaceutical University; Tohoku Medical & Pharmaceutical University; Miyagi Cancer Center; University of Milan	Miyagi, T (corresponding author), Tohoku Pharmaceut Univ, Aoba Ku, 4-4-1 Komatsushima, Sendai, Miyagi 9818558, Japan.	tmiyagi@tohoku-pharm.ac.jp	Sonnino, Sandro/R-4154-2017; Prinetti, Alessandro/R-4206-2017	Sonnino, Sandro/0000-0001-8180-5908; Prinetti, Alessandro/0000-0003-0252-2593; Shiozaki, Kazuhiro/0000-0002-0523-838X; BASSI, ROSARIA/0000-0001-7409-4730	Ministry of Education, Culture, Sports, Science and Technology of Japan [23110002]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The authors are grateful to Dr. M. A. Frohman, Stony Brook University, for a kind gift of PLD1 expression vector, pCGN-hPLD1b, and also to Mr. T. Wada and Ms. S. Moriya, Tohoku Pharmaceutical University, for their valuable technical assistance. This study was supported in part by Grants-in-Aid for Scientific Research on Innovative Areas (No. 23110002) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Albohy A, 2010, GLYCOBIOLOGY, V20, P1127, DOI 10.1093/glycob/cwq077; Da Silva JS, 2005, NAT NEUROSCI, V8, P606, DOI 10.1038/nn1442; Dominguez-Gonzalez I, 2007, BIOCHEM J, V404, P31, DOI 10.1042/BJ20061483; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; Han JM, 2002, MOL BIOL CELL, V13, P3976, DOI 10.1091/mbc.E02-02-0100; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; Hata K, 2008, ANTIMICROB AGENTS CH, V52, P3484, DOI 10.1128/AAC.00344-08; Itoh T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000393; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; KASZKIN M, 1992, BIOCHEM J, V287, P51, DOI 10.1042/bj2870051; Kato K, 2006, BIOCHEM J, V394, P647, DOI 10.1042/BJ20050737; Kawamura S, 2012, CELL DEATH DIFFER, V19, P170, DOI 10.1038/cdd.2011.83; Lee CS, 2009, BBA-MOL CELL BIOL L, V1791, P862, DOI 10.1016/j.bbalip.2009.04.007; Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328; Magesh S, 2006, J MOL GRAPH MODEL, V25, P196, DOI 10.1016/j.jmgm.2005.12.006; Mazie AR, 2006, J CELL SCI, V119, P1645, DOI 10.1242/jcs.02858; Miyagi T, 1999, J BIOL CHEM, V274, P5004, DOI 10.1074/jbc.274.8.5004; Miyagi T, 2008, J BIOCHEM, V144, P279, DOI 10.1093/jb/mvn089; Miyagi T, 2012, GLYCOBIOLOGY, V22, P880, DOI 10.1093/glycob/cws057; Mor A, 2007, NAT CELL BIOL, V9, P713, DOI 10.1038/ncb1592; Nomura H, 2006, ONCOL RES, V16, P289, DOI 10.3727/000000006783981035; Papini N, 2004, J BIOL CHEM, V279, P16989, DOI 10.1074/jbc.M400881200; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rodriguez JA, 2001, J NEUROSCI, V21, P8387, DOI 10.1523/JNEUROSCI.21-21-08387.2001; Shiozaki K, 2009, CANCER SCI, V100, P588, DOI 10.1111/j.1349-7006.2008.01080.x; Sonnino S, 1996, GLYCOBIOLOGY, V6, P479, DOI 10.1093/glycob/6.5.479-e; Stace CL, 2006, BBA-MOL CELL BIOL L, V1761, P913, DOI 10.1016/j.bbalip.2006.03.006; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; Wada T, 2007, ONCOGENE, V26, P2483, DOI 10.1038/sj.onc.1210341; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang Y, 2001, EUR J BIOCHEM, V268, P2201, DOI 10.1046/j.1432-1327.2001.02069.x; Yamaguchi K, 2006, BIOCHEM BIOPH RES CO, V346, P484, DOI 10.1016/j.bbrc.2006.05.136; Yamaguchi K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041132; Yamaguchi K, 2010, BIOCHEM J, V430, P107, DOI 10.1042/BJ20100350; Zhang Y, 2014, J BIOL CHEM, V289, P22567, DOI 10.1074/jbc.R114.576876; Zhang YQ, 2009, BBA-MOL CELL BIOL L, V1791, P850, DOI 10.1016/j.bbalip.2009.05.013; Zhao C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594	39	17	17	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2099	2111		10.1096/fj.14-262543	http://dx.doi.org/10.1096/fj.14-262543			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25678627				2022-12-28	WOS:000354114600041
J	Preta, G; Lotti, V; Cronin, JG; Sheldon, IM				Preta, Giulio; Lotti, Virginia; Cronin, James G.; Sheldon, I. Martin			Protective role of the dynamin inhibitor Dynasore against the cholesterol-dependent cytolysin of Trueperella pyogenes	FASEB JOURNAL			English	Article						host-pathogen interaction; bacteria; mammalian cell survival; lipid rafts	PORE-FORMING TOXINS; LISTERIOLYSIN-O; LIPID RAFTS; BOVINE ENDOMETRIUM; INDUCED APOPTOSIS; PROTEIN TOXINS; STROMAL CELLS; IN-VITRO; ACTIVATION; AUTOPHAGY	The virulence of many Gram-positive bacteria depends on cholesterol-dependent cytolysins (CDCs), which form pores in eukaryotic cell plasma membranes. Pyolysin (PLO) from Trueperella pyogenes provided a unique opportunity to explore cellular responses to CDCs because it does not require thiol activation. Sublytic concentrations of PLO stimulated phosphorylation of MAPK ERK and p38 in primary stromal cells, and induced autophagy as determined by protein light-chain 3B cleavage. Although, inhibitors of MAPK or autophagy did not affect PLO-induced cytolysis. However, 10 mu M 3-hydroxynaphthalene-2-carboxylic acid-(3,4-dihydroxybenzylidene)- hydrazide (Dynasore), a dynamin guanosine 5'-triphosphatase inhibitor, protected stromal cells against PLO-induced cytolysis as determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (85 +/- 17% versus 50 +/- 9% cell viability), measuring extra-cellular ATP, and kinetic assays. This was a generalized mechanism because Dynasore also protected HeLa cells against streptolysin O. Furthermore, the effect was reversible, with stromal cell sensitivity to PLO restored within 30 minutes of Dynasore removal. The protective effect of Dynasore was not conferred by dynamin inhibition, induction of ERK phosphorylation, or Dynasore binding to PLO. Rather, Dynasore reduced cellular cholesterol and disrupted plasma membrane lipid rafts, similar to positive control methyl-beta-cyclodextrin. Dynasore is a tractable tool to explore the complexity of cholesterol homeostasis in eukaryotic cells and to develop strategies to counter CDCs.	[Preta, Giulio; Lotti, Virginia; Cronin, James G.; Sheldon, I. Martin] Swansea Univ, Coll Med, Inst Life Sci, Swansea SA2 8PP, W Glam, Wales	Swansea University	Sheldon, IM (corresponding author), Swansea Univ, Coll Med, Inst Life Sci, Swansea SA2 8PP, W Glam, Wales.	m.sheldon@swansea.ac.uk	Preta, Giulio/AAW-6182-2021; Sheldon, I Martin/E-1567-2013; Preta, Giulio/N-7141-2016	Sheldon, I Martin/0000-0001-7902-5558; Preta, Giulio/0000-0002-8318-4698; Cronin, James/0000-0002-0590-9462	United Kingdom Biotechnology and Biological Sciences Research Council [BB/K006592/1]; BBSRC [BB/K006592/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/K006592/1] Funding Source: researchfish	United Kingdom Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was funded by the United Kingdom Biotechnology and Biological Sciences Research Council (Grant BB/K006592/1).	Aguilar JL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008076; Alouf JE, 2001, CURR TOP MICROBIOL, V257, P1; Amos MR, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.115972; BANGHAM AD, 1965, J MOL BIOL, V13, P253, DOI 10.1016/S0022-2836(65)80094-8; Barrias ES, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0007764; Billington SJ, 1997, J BACTERIOL, V179, P6100, DOI 10.1128/jb.179.19.6100-6106.1997; Bischofberger M, 2009, CURR OPIN CELL BIOL, V21, P589, DOI 10.1016/j.ceb.2009.04.003; Cassidy SKB, 2013, TOXINS, V5, P618, DOI 10.3390/toxins5040618; Chen X, 2014, J BIOL CHEM, V289, P11162, DOI 10.1074/jbc.M113.531855; Cronin JG, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.092718; Davson H, 1936, BIOCHEM J, V30, P316, DOI 10.1042/bj0300316; DUNCAN JL, 1977, INFECT IMMUN, V18, P688, DOI 10.1128/IAI.18.3.688-693.1977; Gutierrez MG, 2007, P NATL ACAD SCI USA, V104, P1829, DOI 10.1073/pnas.0601437104; Ge MT, 1999, BIOPHYS J, V77, P925, DOI 10.1016/S0006-3495(99)76943-2; Gekara NO, 2005, CELL MICROBIOL, V7, P1345, DOI 10.1111/j.1462-5822.2005.00561.x; Gekara NO, 2004, BIOCHEM SOC T, V32, P712, DOI 10.1042/BST0320712; Gelber SE, 2008, J BACTERIOL, V190, P3896, DOI 10.1128/JB.01965-07; Giddings KS, 2004, NAT STRUCT MOL BIOL, V11, P1173, DOI 10.1038/nsmb862; Gilbert RJC, 2002, CELL MOL LIFE SCI, V59, P832, DOI 10.1007/s00018-002-8471-1; Girard E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029042; Golstein P, 2007, EMBO REP, V8, P829, DOI 10.1038/sj.embor.7401042; Gonzalez MR, 2008, CELL MOL LIFE SCI, V65, P493, DOI 10.1007/s00018-007-7434-y; Gonzalez MR, 2011, CELL MICROBIOL, V13, P1026, DOI 10.1111/j.1462-5822.2011.01600.x; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Harris JR, 2011, J STRUCT BIOL, V173, P38, DOI 10.1016/j.jsb.2010.07.010; Hotze EM, 2012, BBA-BIOMEMBRANES, V1818, P1028, DOI 10.1016/j.bbamem.2011.07.036; Huffman DL, 2004, P NATL ACAD SCI USA, V101, P10995, DOI 10.1073/pnas.0404073101; Jost BH, 2005, ANTON LEEUW INT J G, V88, P87, DOI 10.1007/s10482-005-2316-5; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kao CY, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001314; Kirchhausen T, 2008, METHOD ENZYMOL, V438, P77, DOI 10.1016/S0076-6879(07)38006-3; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kloft N, 2009, BIOCHEM BIOPH RES CO, V385, P503, DOI 10.1016/j.bbrc.2009.05.121; Lum M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084975; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Meyer-Morse N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008610; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mulherkar N, 2011, VIROLOGY, V419, P72, DOI 10.1016/j.virol.2011.08.009; Olsson S, 2006, MOL IMMUNOL, V43, P607, DOI 10.1016/j.molimm.2005.04.011; PAGE B, 1993, INT J ONCOL, V3, P473; Pavlovic D, 2000, EUR CYTOKINE NETW, V11, P267; Pokrajac L, 2012, BIOCHEM CELL BIOL, V90, P709, DOI [10.1139/O2012-029, 10.1139/o2012-029]; Porta H, 2011, PEPTIDES, V32, P601, DOI 10.1016/j.peptides.2010.06.012; Preta G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047328; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Rinaldi M, 2008, VET IMMUNOL IMMUNOP, V126, P199, DOI 10.1016/j.vetimm.2008.07.001; Robinet P, 2006, TRAFFIC, V7, P811, DOI 10.1111/j.1600-0854.2006.00435.x; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rosado CJ, 2008, CELL MICROBIOL, V10, P1765, DOI 10.1111/j.1462-5822.2008.01191.x; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sandvig K, 2002, FEBS LETT, V529, P49, DOI 10.1016/S0014-5793(02)03182-4; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; Sheldon IM, 2009, BIOL REPROD, V81, P1025, DOI 10.1095/biolreprod.109.077370; Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Triantafilou M, 2002, J CELL SCI, V115, P2603; Turner ML, 2014, ENDOCRINOLOGY, V155, P1453, DOI 10.1210/en.2013-1822; Wang M, 2013, J NEURO-ONCOL, V115, P323, DOI 10.1007/s11060-013-1232-1; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200	60	40	41	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1516	1528		10.1096/fj.14-265207	http://dx.doi.org/10.1096/fj.14-265207			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550455	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000354115000036
J	Sasi, SP; Rahimi, L; Yan, XH; Silver, M; Qin, GJ; Losordo, DW; Kishore, R; Goukassian, DA				Sasi, Sharath P.; Rahimi, Layla; Yan, Xinhua; Silver, Marcy; Qin, Gangjian; Losordo, Douglas W.; Kishore, Raj; Goukassian, David A.			Genetic deletion of TNFR2 augments inflammatory response and blunts satellite-cell-mediated recovery response in a hind limb ischemia model	FASEB JOURNAL			English	Article						apoptosis; muscle regeneration; proliferation; TNF-TNFR2/p75 signaling	NECROSIS-FACTOR-ALPHA; ENDOTHELIAL PROGENITOR CELLS; FIBROBLAST-GROWTH-FACTOR; SKELETAL-MUSCLE; STEM-CELL; RECEPTOR EXPRESSION; MYOGENIC DIFFERENTIATION; SIGNAL-TRANSDUCTION; ANGIOGENIC ACTIVITY; IFN-GAMMA	We have previously shown that TNF-tumor necrosis factor receptor-2/p75 (TNFR2/p75) signaling plays a critical role in ischemia-induced neovascularization in skeletal muscle and heart tissues. To determine the role of TNF-TNFR2/p75 signaling in ischemia-induced inflammation and muscle regeneration, we subjected wildtype (WT) and TNFR2/p75 knockout (p75KO) mice to hind limb ischemia (HLI) surgery. Ischemia induced significant and long-lasting inflammation associated with considerable decrease in satellite-cell activation in p75KO muscle tissue up to 10 d after HLI surgery. To determine the possible additive negative roles of tissue aging and the absence of TNFR2/p75, either in the tissue or in the bone marrow(BM), we generated 2 chimeric BM transplantation (BMT) models where both young green fluorescent protein (GFP)-positive p75KO and WT BM-derived cells were transplanted into adult p75KO mice. HLI surgery was performed 1 mo after BMT, after confirming complete engraftment of the recipient BM with GFP donor cells. In adult p75KO with the WT-BMT, proliferative (Ki67(+)) cells were detected only by d 28 and were exclusively GFP(+), suggesting significantly delayed contribution of young WT-BM cell to adult p75KO ischemic tissue recovery. No GFP(+) young p75KO BM cells survived in adult p75KO tissue, signifying the additive negative roles of tissue aging combined with decreased/absent TNFR2/p75 signaling in postischemic recovery.	[Sasi, Sharath P.; Rahimi, Layla; Yan, Xinhua; Silver, Marcy; Goukassian, David A.] GeneSys Res Inst, Cardiovasc Res Ctr, Boston, MA USA; [Yan, Xinhua; Goukassian, David A.] Tufts Univ, Sch Med, Boston, MA 02135 USA; [Qin, Gangjian; Losordo, Douglas W.] Northwestern Univ, Feinberg Sch Med, Feinberg Cardiovasc Inst, Chicago, IL 60611 USA; [Kishore, Raj] Temple Univ, Ctr Translat Med, Sch Med, Philadelphia, PA 19122 USA	Tufts University; Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Goukassian, DA (corresponding author), Tufts Univ, Sch Med, Cardiovasc Res Ctr, GeneSys Res Inst, 736 Cambridge St,CBR-340, Boston, MA 02135 USA.	david.goukassian@tufts.edu		Goukassian, David/0000-0001-5270-5270; Losordo, Douglas/0000-0002-6857-7506	U.S. National Institutes of Health (NIH) [R21-AG02677]; U.S. American Heart Association [0630113N, 14GRNT18860032]; NASA [NNJ10ZSA001N]; NIH National Heart, Lung, and Blood Institute [HL106098, HL091983]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL106098, R01HL091983] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. American Heart Association; NASA(National Aeronautics & Space Administration (NASA)); NIH National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank A. Perepletchikov, clinical pathologist and our collaborator from Steward St. Elizabeth's Medical Center. Dr. Perepletchikov submitted full histopathologic reports of all H&E-stained samples, analyzed the data, and contributed to the writing of the sections pertaining to these data. The authors would also like to thank A. Kiladjian and J. Schawb, graduate interns in our laboratory, for all their help with frozen tissue sectioning, immunofluorescence staining, confocal microscopy. and data quantification. Supported by U.S. National Institutes of Health (NIH) Grant R21-AG02677, U.S. American Heart Association Grants 0630113N and 14GRNT18860032, and NASA Grant NNJ10ZSA001N to D.A.G.; and by grants from NIH National Heart, Lung, and Blood Institute HL106098 to X.Y. and HL091983 to R.K.	Aggarwal S, 1999, J IMMUNOL, V162, P2154; Akbarshahi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042654; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; AUGUSTINVOSS HG, 1993, J CELL PHYSIOL, V157, P279, DOI 10.1002/jcp.1041570210; BECK LS, 1993, J CLIN INVEST, V92, P2841, DOI 10.1172/JCI116904; BENEZRA D, 1990, ARCH OPHTHALMOL-CHIC, V108, P573, DOI 10.1001/archopht.1990.01070060121061; Biressi S, 2013, DEV BIOL, V379, P195, DOI 10.1016/j.ydbio.2013.04.021; BISCHOFF R, 1989, MED SCI SPORT EXER, V21, pS164; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; Cabral A. J. V., 2008, EXP PATHOL HLTH SCI, V2, P9; Capkovic KL, 2008, EXP CELL RES, V314, P1553, DOI 10.1016/j.yexcr.2008.01.021; Chandrasekharan UM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003743; Charles KA, 2009, J CLIN INVEST, V119, P3011, DOI 10.1172/JCI39065; Chen SE, 2005, AM J PHYSIOL-CELL PH, V289, pC1179, DOI 10.1152/ajpcell.00062.2005; Chen SE, 2007, AM J PHYSIOL-CELL PH, V292, pC1660, DOI 10.1152/ajpcell.00486.2006; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Crameri RM, 2004, J PHYSIOL-LONDON, V558, P333, DOI 10.1113/jphysiol.2004.061846; Cunningham O, 2009, GLIA, V57, P1802, DOI 10.1002/glia.20892; Duran WN, 2008, AM J PHYSIOL-HEART C, V295, pH2221, DOI 10.1152/ajpheart.01050.2008; Edelberg JM, 2003, FRONT BIOSCI-LANDMRK, V8, pS1199, DOI 10.2741/1166; ERNST DN, 1993, J IMMUNOL, V151, P575; Faustman DL, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00478; Frasca D, 2000, BONE MARROW TRANSPL, V25, P427, DOI 10.1038/sj.bmt.1702169; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; GORDON HM, 1992, J IMMUNOL, V148, P4021; Goukassian DA, 2007, CIRCULATION, V115, P752, DOI 10.1161/CIRCULATIONAHA.106.647255; Grounds MD, 2002, J HISTOCHEM CYTOCHEM, V50, P589, DOI 10.1177/002215540205000501; Gu Q, 2006, J CARDIOVASC PHARM, V48, P320, DOI 10.1097/01.fjc.0000250079.46526.38; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Haldar M, 2008, DEV CELL, V14, P437, DOI 10.1016/j.devcel.2008.01.002; Harrison ML, 2007, J CLIN ONCOL, V25, P4542, DOI 10.1200/JCO.2007.11.2136; Hill M, 2003, J ANAT, V203, P89, DOI 10.1046/j.1469-7580.2003.00195.x; Hoefer IE, 2002, CIRCULATION, V105, P1639, DOI 10.1161/01.CIR.0000014987.32865.8E; Hoffmann J, 2001, CIRC RES, V89, P709, DOI 10.1161/hh2001.097796; Hohenberger P, 2003, ANN SURG ONCOL, V10, P562, DOI 10.1245/ASO.2003.10.005; JACOBSEN SEW, 1994, STEM CELLS, V12, P111; Jasielska M, 2010, INVEST OPHTH VIS SCI, V51, P3874, DOI 10.1167/iovs.09-5003; Kadi F, 2004, MUSCLE NERVE, V29, P120, DOI 10.1002/mus.10510; Kaiser GC, 1997, GASTROENTEROLOGY, V112, P1231, DOI 10.1016/S0016-5085(97)70135-5; Kaiser GC, 1999, EXP CELL RES, V249, P349, DOI 10.1006/excr.1999.4488; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kamihata H, 2001, CIRCULATION, V104, P1046, DOI 10.1161/hc3501.093817; Kassar-Duchossoy L, 2004, NATURE, V431, P466, DOI 10.1038/nature02876; Kishore R, 2011, ADV EXP MED BIOL, V691, P433, DOI 10.1007/978-1-4419-6612-4_45; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; Kronke M, 1992, Immunol Ser, V56, P189; Kuang S, 2008, TRENDS MOL MED, V14, P82, DOI 10.1016/j.molmed.2007.12.004; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; Kuru S, 2003, ACTA NEUROPATHOL, V105, P217, DOI 10.1007/s00401-002-0632-4; Langen RCJ, 2002, AM J PHYSIOL-CELL PH, V283, pC714, DOI 10.1152/ajpcell.00418.2001; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; LEEUWENBERG JFM, 1995, CYTOKINE, V7, P457, DOI 10.1006/cyto.1995.0062; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Li YP, 2001, FASEB J, V15, P1413, DOI 10.1096/fj.00-0632fje; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542; Maddahi A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-107; Marinho A, 1997, PATHOL RES PRACT, V193, P267; Mizoguchi E, 2002, GASTROENTEROLOGY, V122, P134, DOI 10.1053/gast.2002.30347; Mogford JE, 2002, J CELL PHYSIOL, V190, P259, DOI 10.1002/JCP.10060; Monden Y, 2007, AM J PHYSIOL-HEART C, V293, pH743, DOI 10.1152/ajpheart.00166.2007; Nissen NN, 1998, AM J PATHOL, V152, P1445; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Oshima H, 2014, ONCOGENE, V33, P3820, DOI 10.1038/onc.2013.356; Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758; Reed MJ, 2000, J CELL BIOCHEM, V77, P116, DOI 10.1002/(SICI)1097-4644(20000401)77:1<116::AID-JCB12>3.3.CO;2-Z; Renault V, 2003, AGING CELL, V2, P71; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Ruspi G, 2014, CELL SIGNAL, V26, P683, DOI 10.1016/j.cellsig.2013.12.009; Sack MN, 2002, PHARMACOL THERAPEUT, V94, P123, DOI 10.1016/S0163-7258(02)00176-6; Sadoun E, 2003, J HISTOCHEM CYTOCHEM, V51, P1119, DOI 10.1177/002215540305100902; SAINI A, 1993, LIFE SCI, V52, P1759, DOI 10.1016/0024-3205(93)90464-E; SARZANI R, 1991, HYPERTENSION, V17, P888, DOI 10.1161/01.HYP.17.6.888; Sasi SP, 2012, ONCOGENE, V31, P4117, DOI 10.1038/onc.2011.567; SATO N, 1987, J NATL CANCER I, V79, P1383; SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904; Shi XZ, 2006, GENE DEV, V20, P1692, DOI 10.1101/gad.1419406; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Speeckaert MM, 2012, AM J NEPHROL, V36, P261, DOI 10.1159/000342333; Spencer MJ, 2000, NEUROMUSCULAR DISORD, V10, P612, DOI 10.1016/S0960-8966(00)00160-7; SQUADRITO F, 1993, EUR J PHARMACOL, V237, P223, DOI 10.1016/0014-2999(93)90272-J; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tan JN, 2010, SHOCK, V34, P236, DOI 10.1097/SHK.0b013e3181d75ae3; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; Taubitz A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068167; Trendelenburg AU, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-3; Valdez MR, 2000, DEV BIOL, V219, P287, DOI 10.1006/dbio.2000.9621; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wajant H, 2009, RESULTS PROBL CELL D, V49, P1, DOI 10.1007/400_2008_26; WONG GHW, 1994, J IMMUNOL, V152, P1751; YAMAURA H, 1980, EXP GERONTOL, V15, P145, DOI 10.1016/0531-5565(80)90086-8; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zammit PS, 2006, J HISTOCHEM CYTOCHEM, V54, P1177, DOI 10.1369/jhc.6R6995.2006; Zhang Y., 2013, MATH PROB ENG, V2013, DOI DOI 10.4018/JIIT.2013010101	96	3	3	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1208	1219		10.1096/fj.14-249813	http://dx.doi.org/10.1096/fj.14-249813			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25466901	Green Published			2022-12-28	WOS:000354115000010
J	Mazagova, M; Wang, LR; Anfora, AT; Wissmueller, M; Lesley, SA; Miyamoto, Y; Eckmann, L; Dhungana, S; Pathmasiri, W; Sumner, S; Westwater, C; Brenner, DA; Schnabl, B				Mazagova, Magdalena; Wang, Lirui; Anfora, Andrew T.; Wissmueller, Max; Lesley, Scott A.; Miyamoto, Yukiko; Eckmann, Lars; Dhungana, Suraj; Pathmasiri, Wimal; Sumner, Susan; Westwater, Caroline; Brenner, David A.; Schnabl, Bernd			Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice	FASEB JOURNAL			English	Article						bacterial translocation; innate immune system; microbiome	INTESTINAL MICROBIOME; INNATE IMMUNITY; INDUCED COLITIS; GUT MICROBIOTA; BACTERIAL TRANSLOCATION; INDOLE-3-PROPIONIC ACID; HEPATIC-FIBROSIS; STELLATE CELLS; PROTECTS MICE; DISEASE	Translocation of bacteria and their products across the intestinal barrier is common in patients with liver disease, and there is evidence that experimental liver fibrosis depends on bacterial translocation. The purpose of our study was to investigate liver fibrosis in conventional and germ-free (GF) C57BL/6 mice. Chronic liver injury was induced by administration of thioacetamide (TAA) in the drinking water for 21 wk or by repeated intraperitoneal injections of carbon tetrachloride (CCl4). Increased liver fibrosis was observed in GF mice compared with conventional mice. Hepatocytes showed more toxin-induced oxidative stress and cell death. This was accompanied by increased activation of hepatic stellate cells, but hepatic mediators of inflammation were not significantly different. Similarly, a genetic model using Myd88/Trif-deficient mice, which lack downstream innate immunity signaling, had more severe fibrosis than wild-type mice. Isolated Myd88/Trif-deficient hepatocytes were more susceptible to toxin-induced cell death in culture. In conclusion, the commensal microbiota prevents fibrosis upon chronic liver injury in mice. This is the first study describing a beneficial role of the commensal microbiota in maintaining liver homeostasis and preventing liver fibrosis.	[Mazagova, Magdalena; Wang, Lirui; Wissmueller, Max; Miyamoto, Yukiko; Eckmann, Lars; Brenner, David A.; Schnabl, Bernd] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Wang, Lirui; Schnabl, Bernd] VA San Diego Healthcare Syst, Dept Med, San Diego, CA USA; [Anfora, Andrew T.; Lesley, Scott A.] Novartis Res Fdn, Genom Inst, San Diego, CA USA; [Dhungana, Suraj; Pathmasiri, Wimal; Sumner, Susan] RTI Int, Syst & Translat Sci, Res Triangle Pk, NC USA; [Westwater, Caroline] Med Univ S Carolina, Dept Oral Hlth Sci, Charleston, SC 29425 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Novartis; Research Triangle Institute; Medical University of South Carolina	Schnabl, B (corresponding author), Univ Calif San Diego, Dept Med, MC0063,9500 Gilman Dr, La Jolla, CA 92093 USA.	beschnabl@ucsd.edu	Westwater, Caroline/AAZ-9217-2020	Westwater, Caroline/0000-0001-9329-2513; Miyamoto, Yukiko/0000-0001-5650-699X; Brenner, David/0000-0003-2573-525X; Anfora, Andrew/0000-0003-3849-1784; Pathmasiri, Wimal/0000-0002-5199-5744; Sumner, Susan/0000-0003-3381-6084	U.S. National Institutes of Health (NIH) [K08-DK081830, R01-AA020703, U01-AA021856, 2P42-ES010337]; Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [1I01BX002213]; National Gnotobiotic Rodent Resource Center at the University of North Carolina in Chapel Hill [P40RR018603, P30-DK34987]; NIH Grant [P30 GM103331]; NIH Eastern Regional Comprehensive Metabolomics Resource Core [1U24DK097193]; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR018603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK097193, K08DK081830, P30DK034987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA020703, U01AA021856] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P40OD010995] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002213] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Biomedical Laboratory Research & Development Service of the VA Office of Research and Development; National Gnotobiotic Rodent Resource Center at the University of North Carolina in Chapel Hill; NIH Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Eastern Regional Comprehensive Metabolomics Resource Core; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs(US Department of Veterans Affairs)	The authors thank Drs. Richard Glynne, Alan Hofmann, Reiner Wiest, Balfour Sartor, Dimitrios Moskophidis, and Eric Johnson for helpful discussion. The study was supported in part by the U.S. National Institutes of Health (NIH) Grants K08-DK081830, R01-AA020703 (to B.S.), U01-AA021856 (to B.S. and D.A.B.), and 2P42-ES010337 (to D.A.B.). The project described was supported by Award Number 1I01BX002213 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development (to B.S.). The authors acknowledge The National Gnotobiotic Rodent Resource Center Grants P40RR018603 and P30-DK34987 at the University of North Carolina in Chapel Hill for providing GF mice. The MUSC Gnotobiotic Animal Core is supported by the NIH Grant P30 GM103331. The IPA analysis was conducted under RTI Internal Research and Development Funds and in part by the NIH Eastern Regional Comprehensive Metabolomics Resource Core (Grant 1U24DK097193). None of the authors has a financial, personal or professional conflict of interest to disclose.	Abu-Shanab A, 2010, NAT REV GASTRO HEPAT, V7, P691, DOI 10.1038/nrgastro.2010.172; ADACHI Y, 1995, GASTROENTEROLOGY, V108, P218, DOI 10.1016/0016-5085(95)90027-6; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Bjorkholm B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006958; Brandl K, 2010, P NATL ACAD SCI USA, V107, P19967, DOI 10.1073/pnas.1014669107; Brandl K, 2009, P NATL ACAD SCI USA, V106, P3300, DOI 10.1073/pnas.0813036106; Cesaro C, 2011, DIGEST LIVER DIS, V43, P431, DOI 10.1016/j.dld.2010.10.015; Chen P, 2015, HEPATOLOGY, V61, P883, DOI 10.1002/hep.27489; Chen P, 2015, GASTROENTEROLOGY, V148, P203, DOI 10.1053/j.gastro.2014.09.014; Chyan YJ, 1999, J BIOL CHEM, V274, P21937, DOI 10.1074/jbc.274.31.21937; DeMinicis S, 2014, HEPATOLOGY, V59, P1738, DOI 10.1002/hep.26695; Enomoto N, 1998, GASTROENTEROLOGY, V115, P443, DOI 10.1016/S0016-5085(98)70211-2; Fouts DE, 2012, J HEPATOL, V56, P1283, DOI 10.1016/j.jhep.2012.01.019; Frances R, 2008, HEPATOLOGY, V47, P978, DOI 10.1002/hep.22083; Gabele E, 2008, BIOCHEM BIOPH RES CO, V376, P271, DOI 10.1016/j.bbrc.2008.08.096; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Guo X, 2008, LETT APPL MICROBIOL, V47, P367, DOI 10.1111/j.1472-765X.2008.02408.x; Hartmann P, 2013, HEPATOLOGY, V58, P108, DOI 10.1002/hep.26321; Hartmann P, 2012, GASTROENTEROLOGY, V143, P1330, DOI 10.1053/j.gastro.2012.07.099; Henao-Mejia J, 2013, J AUTOIMMUN, V46, P66, DOI 10.1016/j.jaut.2013.07.001; Henao-Mejia J, 2012, NATURE, V482, P179, DOI 10.1038/nature10809; Hritz I, 2008, HEPATOLOGY, V48, P1224, DOI 10.1002/hep.22470; Huang HJ, 2007, HEPATOLOGY, V46, P297, DOI 10.1002/hep.21695; Isayama F, 2006, AM J PHYSIOL-GASTR L, V290, pG1318, DOI 10.1152/ajpgi.00405.2005; Iwaisako K, 2012, P NATL ACAD SCI USA, V109, pE1369, DOI 10.1073/pnas.1202464109; Jeong WI, 2006, HEPATOLOGY, V44, P1441, DOI 10.1002/hep.21419; Kang JS, 2008, TOXICOL APPL PHARM, V228, P295, DOI 10.1016/j.taap.2007.11.010; Karbownik M, 2001, J CELL BIOCHEM, V81, P507, DOI 10.1002/1097-4644(20010601)81:3<507::AID-JCB1064>3.0.CO;2-M; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; Kim SC, 2005, GASTROENTEROLOGY, V128, P891, DOI 10.1053/j.gastro.2005.02.009; Kitajima S, 2001, EXP ANIM TOKYO, V50, P387, DOI 10.1538/expanim.50.387; Lai WL, 2005, FREE RADICAL BIO MED, V38, P1585, DOI 10.1016/j.freeradbiomed.2005.02.024; LIN RS, 1995, J HEPATOL, V22, P165, DOI 10.1016/0168-8278(95)80424-2; Maeda H, 2003, FEMS IMMUNOL MED MIC, V39, P81, DOI 10.1016/S0928-8244(03)00224-4; Manna Z, 1996, GASTROENTEROLOGY, V110, P1150, DOI 10.1053/gast.1996.v110.pm8613004; Nakanishi Y, 2006, APPL ENVIRON MICROB, V72, P6271, DOI 10.1128/AEM.00477-06; Nicholson JK, 2012, SCIENCE, V336, P1262, DOI 10.1126/science.1223813; Ostman S, 2006, EUR J IMMUNOL, V36, P2336, DOI 10.1002/eji.200535244; Paik YH, 2011, HEPATOLOGY, V53, P1730, DOI 10.1002/hep.24281; Pascual S, 2003, HEPATO-GASTROENTEROL, V50, P1482; Pils MC, 2011, INFLAMM BOWEL DIS, V17, P2038, DOI 10.1002/ibd.21587; Rabot S, 2010, FASEB J, V24, P4948, DOI 10.1096/fj.10-164921; Radaeva S, 2006, GASTROENTEROLOGY, V130, P435, DOI 10.1053/j.gastro.2005.10.055; Rath HC, 2001, INFECT IMMUN, V69, P2277, DOI 10.1128/IAI.69.4.2277-2285.2001; Rivera CA, 2001, AM J PHYSIOL-GASTR L, V281, pG200, DOI 10.1152/ajpgi.2001.281.1.G200; Roh YS, 2014, HEPATOLOGY, V60, P237, DOI 10.1002/hep.26981; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Schnabl B, 2001, HEPATOLOGY, V34, P89, DOI 10.1053/jhep.2001.25349; Schnabl B, 2008, NAT CLIN PRACT GASTR, V5, P496, DOI 10.1038/ncpgasthep1200; Schnabl B, 2014, GASTROENTEROLOGY, V146, P1513, DOI 10.1053/j.gastro.2014.01.020; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Seki E, 2012, J PHYSIOL-LONDON, V590, P447, DOI 10.1113/jphysiol.2011.219691; Strauch UG, 2005, GUT, V54, P1546, DOI 10.1136/gut.2004.059451; Ubeda C, 2012, J EXP MED, V209, P1445, DOI 10.1084/jem.20120504; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; Wang LR, 2014, J HEPATOL, V60, P1259, DOI 10.1016/j.jhep.2014.02.012; Westwater C, 2007, FEMS IMMUNOL MED MIC, V51, P134, DOI 10.1111/j.1574-695X.2007.00287.x; Wigg AJ, 2001, GUT, V48, P206, DOI 10.1136/gut.48.2.206; Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106; Wise MG, 2007, J APPL MICROBIOL, V102, P1138, DOI 10.1111/j.1365-2672.2006.03153.x; Yan AW, 2011, HEPATOLOGY, V53, P96, DOI 10.1002/hep.24018; Yin S, 2010, GASTROENT RES PRACT, V2010, DOI 10.1155/2010/750904; Zhang W, 2010, EUR J GASTROEN HEPAT, V22, P1481, DOI 10.1097/MEG.0b013e32833eb8b0	64	115	120	1	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1043	1055		10.1096/fj.14-259515	http://dx.doi.org/10.1096/fj.14-259515			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25466902	Green Published			2022-12-28	WOS:000350633000028
J	Heinrichs, D; Berres, ML; Coeuru, M; Knauel, M; Nellen, A; Fischer, P; Philippeit, C; Bucala, R; Trautwein, C; Wasmuth, HE; Bernhagen, J				Heinrichs, Daniel; Berres, Marie-Luise; Coeuru, Melanie; Knauel, Meike; Nellen, Andreas; Fischer, Petra; Philippeit, Claudia; Bucala, Richard; Trautwein, Christian; Wasmuth, Hermann E.; Bernhagen, Juergen			Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis	FASEB JOURNAL			English	Article						cytokines; fatty liver; hepatic fibrosis; hepatocyte; inflammation	FATTY LIVER-DISEASE; ACTIVATED PROTEIN-KINASE; HEPATIC STEATOSIS; ADIPOSE-TISSUE; INSULIN-RESISTANCE; CHRONIC INFLAMMATION; LIPID-ACCUMULATION; MIF; MICE; OBESITY	MIF is an inflammatory cytokine but is hepatoprotective in models of hepatotoxin-induced liver fibrosis. Hepatic fibrosis can also develop from metabolic liver disease, such as nonalcoholic fatty liver disease (NASH). We investigated the role of MIF in high-fat or methionine-and choline-deficient diet mouse models of NASH. Mif-/-mice showed elevated liver triglyceride levels (WT, 53 +/- 14 mg/g liver; Mif(-/-), 103 +/- 7 mg/g liver; P<0.05) and a 2-3-fold increased expression of lipogenic genes. Increased fatty degeneration in the livers of Mif(-/-) mice was associated with increased hepatic inflammatory cells (1.6-fold increase in F4/80(+) macrophages) and proinflammatory cytokines (e.g., 2.3-fold increase in Tnf-alpha and 2-fold increase in Il-6 expression). However, inflammatory cells and cytokines were decreased by 50-90% in white adipose tissue (WAT) of Mif(-/-) mice. Subset analysis showed that macrophage phenotypes in livers of Mif(-/-) mice were skewed toward M2 (e.g., 1.7-fold and 2.5-fold increase in Arg1 and Il-13, respectively, and 2.5-fold decrease in iNos), whereas macrophages were generally reduced in WAT of these mice (70% reduction in mRNA expression of F4/80(+) macrophages). The protective MIF effect was scrutinized in isolated hepatocytes. MIF reversed inflammation-induced triglyceride accumulation in Hepa1-6 cells and primary hepatocytes and also attenuated oleic acid-elicited triglyceride increase in 3T3-L1 adipocytes. Protection from fatty hepatocyte degeneration was paralleled by a 2- to 3-fold reduction by MIF of hepatocyte proinflammatory cytokine production. Blockade of MIF receptor cluster of differentiation 74 (CD74) but not of CXCR2 or CXCR4 fully reverted the protective effect of MIF, comparable to AMPK inhibition. In summary, we demonstrate that MIF mediates hepatoprotection through the CD74/AMPK pathway in hepatocytes in metabolic models of liver injury.	[Heinrichs, Daniel; Coeuru, Melanie; Knauel, Meike; Philippeit, Claudia; Bernhagen, Juergen] Rhein Westfal TH Aachen, Inst Biochem & Mol Cell Biol, D-52074 Aachen, Germany; [Heinrichs, Daniel; Berres, Marie-Luise; Nellen, Andreas; Fischer, Petra; Trautwein, Christian; Wasmuth, Hermann E.] Rhein Westfal TH Aachen, Dept Internal Med 3, D-52074 Aachen, Germany; [Bucala, Richard] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA	RWTH Aachen University; RWTH Aachen University; Yale University	Bernhagen, J (corresponding author), Rhein Westfal TH Aachen, Inst Biochem & Mol Cell Biol, Pauwelsstr 30, D-52074 Aachen, Germany.	jbernhagen@ukaachen.de	Berres, Marie-Luise/AAN-5351-2021		Deutsche Forschungsgemeinschaft [SFB-TRR57]; U.S. National Institutes of Health grant [AI042310]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI042310, R01AI042310] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); U.S. National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank all members of the Q platforms of SFB-TRR57 for their help with the immunohistological stainings and cell isolation procedures. This study was supported by Deutsche Forschungsgemeinschaft grant SFB-TRR57 to J.B., M.B., C.T., and H.E.W., as well as U.S. National Institutes of Health grant AI042310 to R.B.	Agarwal N, 2005, HEPATOL RES, V33, P92, DOI 10.1016/j.hepres.2005.09.012; Asare Y, 2013, THROMB HAEMOSTASIS, V109, P391, DOI 10.1160/TH12-11-0831; Assis DN, 2014, HEPATOLOGY, V59, P580, DOI 10.1002/hep.26664; Bacher M, 1997, AM J PATHOL, V150, P235; Barnes MA, 2013, HEPATOLOGY, V57, P1980, DOI 10.1002/hep.26169; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Berres ML, 2010, J CLIN INVEST, V120, P4129, DOI 10.1172/JCI41732; Bijland S, 2013, CLIN SCI, V124, P491, DOI 10.1042/CS20120536; Borghese F, 2011, EXPERT OPIN THER TAR, V15, P237, DOI 10.1517/14728222.2011.550879; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Chandran M, 2003, DIABETES CARE, V26, P2442, DOI 10.2337/diacare.26.8.2442; Cusi K, 2012, GASTROENTEROLOGY, V142, P711, DOI 10.1053/j.gastro.2012.02.003; Day CA, 2002, AM J GASTROENTEROL, V97, P1872; Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI23621; Endo M, 2007, EXP BIOL MED, V232, P614; Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973; Fujii H, 2012, J GASTROENTEROL, V47, P215, DOI 10.1007/s00535-012-0527-x; Heinrichs D, 2011, P NATL ACAD SCI USA, V108, P17444, DOI 10.1073/pnas.1107023108; Hori Y, 2003, EUR J HISTOCHEM, V47, P317; Ikeda D, 2008, ENDOCRINOLOGY, V149, P6037, DOI 10.1210/en.2008-0158; Kabir SM, 2014, ADIPOCYTE, V3, P97, DOI 10.4161/adip.28110; Kim JY, 2010, J MOL BIOL, V397, P917, DOI 10.1016/j.jmb.2010.02.016; Lee Yong-Ho, 2005, Curr Diab Rep, V5, P70; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Miller EJ, 2008, NATURE, V451, P578, DOI 10.1038/nature06504; Miura K, 2010, GASTROENTEROLOGY, V139, P323, DOI 10.1053/j.gastro.2010.03.052; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nanji AA, 2001, J INTERF CYTOK RES, V21, P1055, DOI 10.1089/107999001317205187; Ricchi M, 2009, J GASTROEN HEPATOL, V24, P830, DOI 10.1111/j.1440-1746.2008.05733.x; Rinella ME, 2008, J LIPID RES, V49, P1068, DOI 10.1194/jlr.M800042-JLR200; Sahin H, 2010, NAT REV GASTRO HEPAT, V7, P682, DOI 10.1038/nrgastro.2010.168; Schaffler A, 2005, NAT CLIN PRACT GASTR, V2, P273, DOI 10.1038/ncpgasthep0186; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sozio MS, 2010, SEMIN LIVER DIS, V30, P378, DOI 10.1055/s-0030-1267538; Takahashi Y, 2012, WORLD J GASTROENTERO, V18, P2300, DOI 10.3748/wjg.v18.i19.2300; Tanaka Y, 2008, J PHARMACOL EXP THER, V325, P655, DOI 10.1124/jpet.107.135822; Trayhurn P, 2013, PHYSIOL REV, V93, P1, DOI 10.1152/physrev.00017.2012; Verschuren L, 2009, CIRC RES, V105, P99, DOI 10.1161/CIRCRESAHA.109.199166; Walenbergh SMA, 2013, J HEPATOL, V58, P801, DOI 10.1016/j.jhep.2012.11.014; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yaddanapudi K, 2013, J IMMUNOL, V190, P2984, DOI 10.4049/jimmunol.1201650; Zernecke A, 2008, CIRCULATION, V117, P1594, DOI 10.1161/CIRCULATIONAHA.107.729125	45	39	39	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5136	5147		10.1096/fj.14-256776	http://dx.doi.org/10.1096/fj.14-256776			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25122558	Green Published			2022-12-28	WOS:000345894500010
J	Rajasekaran, D; Zierow, S; Syed, M; Bucala, R; Bhandari, V; Lolis, EJ				Rajasekaran, Deepa; Zierow, Swen; Syed, Mansoor; Bucala, Richard; Bhandari, Vineet; Lolis, Elias J.			Targeting distinct tautomerase sites of D-DT and MIF with a single molecule for inhibition of neutrophil lung recruitment	FASEB JOURNAL			English	Article						covalent inhibitor; 4-IPP	D-DOPACHROME TAUTOMERASE; ENZYMATIC-ACTIVITY; CRYSTAL-STRUCTURE; CYSTIC-FIBROSIS; CYTOKINE; HOMOLOG; MODEL; GENE; DISCOVERY; CD74	We report a new inflammatory activity for extracellular d-dopachrome tautomerase (D-DT), the recruitment of neutrophils to the lung on D-DT intratracheal installation of C57BL/6J mice with an EC50 of 5.6 g. We also find that D-DT and macrophage migration inhibitory factor (MIF) have additive effects in neutrophil recruitment. Although the tautomerase site of D-DT and its homologue MIF are biophysically very different, 4-iodo-6-phenylpyrimidine (4-IPP) forms a covalent bond with Pro-1 of both proteins, resulting in a 6-phenylpyrimidine (6-PP) adduct. Recruitment of neutrophils to the lung for the 6-PP adducts of D-DT and MIF are reduced by approximate to 50% relative to the apo proteins, demonstrating that an unmodified Pro-1 is important for this activity, but there is no cooperativity in inhibition of the proteins together. The differences in the binding mode of the 6-PP adduct for D-DT was determined by crystallographic studies at 1.13 angstrom resolution and compared to the structure of the MIF-6-PP complex. There are major differences in the location of the 6-PP adduct to the D-DT and MIF active sites that provide insight into the lack of cooperativity by 4-IPP and into tuning the properties of the covalent inhibitors of D-DT and MIF that are necessary for the development of therapeutic small molecules against neutrophil damage from lung infections such as Pseudomonas aeruginosa in cystic fibrosis and immunocompromised patients.Rajasekaran, D., Zierow, S., Syed, M., Bucala, R., Bhandari, V., Lolis, E. J. Targeting distinct tautomerase sites of D-DT and MIF with a single molecule for inhibition of neutrophil lung recruitment.	[Rajasekaran, Deepa; Zierow, Swen; Lolis, Elias J.] Yale Univ, Dept Pharmacol, New Haven, CT USA; [Syed, Mansoor; Bhandari, Vineet] Yale Univ, Dept Pediat, New Haven, CT 06520 USA; [Bucala, Richard] Yale Univ, Dept Internal Med, New Haven, CT 06520 USA; [Bucala, Richard; Lolis, Elias J.] Yale Univ, Yale Canc Ctr, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Lolis, EJ (corresponding author), 333 Cedar St, New Haven, CT 06510 USA.	elias.lolis@yale.edu	Bhandari, Vineet/AAS-3365-2020; syed, mansoor ali/I-6957-2018; syed, Mansoor ali/G-8986-2013	syed, Mansoor ali/0000-0003-2697-7832; Lolis, Elias/0000-0002-7902-7868	U.S. National Institutes of Health [AI065029, AI082295, AR049610]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI082295, R01AI065029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049610] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors are grateful to Wibke Schulte and Melanie Merk for the data in Fig. 1C, D on the comparative effects of ISO-1 and 4IPP on MIF and DDT tautomerase activity. The authors thank the staff at the X25 beamline of the National Synchrotron Light Source (Brookhaven National Laboratory, Upton, NY, USA) for assistance in data collection and the Yale School of Medicine Keck Biotechnology Research Laboratory for mass spectrometry. This Work was supported by the U.S. National Institutes of Health, R01 grants AI065029, AI082295, and AR049610.	Adamali H, 2012, AM J RESP CRIT CARE, V186, P162, DOI 10.1164/rccm.201110-1864OC; Al-Abed Y, 2011, FUTURE MED CHEM, V3, P45, DOI 10.4155/FMC.10.281; Almrud JJ, 2002, BIOCHEMISTRY-US, V41, P12010, DOI 10.1021/bi020271h; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Arjona A, 2007, J CLIN INVEST, V117, P3059, DOI 10.1172/JCI32218; Bhandari V, 2012, AM J RESP CELL MOL, V46, P668, DOI 10.1165/rcmb.2011-0074OC; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Brock SE, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.378299; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cho Y, 2011, CHEM BIOL, V18, P1089, DOI 10.1016/j.chembiol.2011.07.011; Cho Y, 2010, P NATL ACAD SCI USA, V107, P11313, DOI 10.1073/pnas.1002716107; Coleman AM, 2008, J IMMUNOL, V181, P2330, DOI 10.4049/jimmunol.181.4.2330; Cournia Z, 2009, J MED CHEM, V52, P416, DOI 10.1021/jm801100v; Crichlow GV, 2012, BIOCHEMISTRY-US, V51, P7506, DOI 10.1021/bi3005494; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; DeLano W.L, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fan CP, 2013, P NATL ACAD SCI USA, V110, P10994, DOI 10.1073/pnas.1221817110; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Fingerle-Rowson G, 2009, MOL CELL BIOL, V29, P1922, DOI 10.1128/MCB.01907-08; Gadjeva M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000826; Hare AA, 2010, BIOORG MED CHEM LETT, V20, P5811, DOI 10.1016/j.bmcl.2010.07.129; Iwata T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033402; Jorgensen WL, 2011, BIOORG MED CHEM LETT, V21, P4545, DOI 10.1016/j.bmcl.2011.05.127; Jorgensen WL, 2010, BIOORG MED CHEM LETT, V20, P7033, DOI 10.1016/j.bmcl.2010.09.118; Kobold S, 2014, ONCOTARGET, V5, P103, DOI 10.18632/oncotarget.1560; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Lubetsky JB, 1999, BIOCHEMISTRY-US, V38, P7346, DOI 10.1021/bi990306m; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Makita H, 1998, AM J RESP CRIT CARE, V158, P573, DOI 10.1164/ajrccm.158.2.9707086; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; McLean LR, 2010, BIOORG MED CHEM LETT, V20, P1821, DOI 10.1016/j.bmcl.2010.02.009; McLean LR, 2009, BIOORG MED CHEM LETT, V19, P6717, DOI 10.1016/j.bmcl.2009.09.106; Merk M, 2012, CYTOKINE, V59, P10, DOI 10.1016/j.cyto.2012.03.014; Merk M, 2011, P NATL ACAD SCI USA, V108, pE577, DOI 10.1073/pnas.1102941108; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; ODH G, 1993, BIOCHEM BIOPH RES CO, V197, P619, DOI 10.1006/bbrc.1993.2524; Ouertatani-Sakouhi H, 2010, J BIOL CHEM, V285, P26581, DOI 10.1074/jbc.M110.113951; Pasupuleti V, 2014, J BIOL CHEM, V289, P3713, DOI 10.1074/jbc.M113.500694; Plant BJ, 2005, AM J RESP CRIT CARE, V172, P1412, DOI 10.1164/rccm.200412-1714OC; Rajasekaran D, 2012, BIOCHEMISTRY-US, V51, P5642, DOI 10.1021/bi3001566; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rovai LE, 1998, J LEUKOCYTE BIOL, V64, P494, DOI 10.1002/jlb.64.4.494; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Singh J, 2011, NAT REV DRUG DISCOV, V10, P307, DOI 10.1038/nrd3410; Stamps SL, 1998, BIOCHEMISTRY-US, V37, P10195, DOI 10.1021/bi9806955; Subramanya HS, 1996, BIOCHEMISTRY-US, V35, P792, DOI 10.1021/bi951732k; Sugimoto H, 1999, BIOCHEMISTRY-US, V38, P3268, DOI 10.1021/bi982184o; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Swope M, 1998, EMBO J, V17, P3534, DOI 10.1093/emboj/17.13.3534; Swope MD, 1999, REV PHYSIOL BIOCH P, V139, P1, DOI 10.1007/BFb0033647; Sydnor ERM, 2011, CLIN MICROBIOL REV, V24, P141, DOI 10.1128/CMR.00027-10; Takahashi K, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-33; Wang XQ, 2009, ANNU REV IMMUNOL, V27, P29, DOI 10.1146/annurev.immunol.24.021605.090616; Winner M, 2008, CANCER RES, V68, P7253, DOI 10.1158/0008-5472.CAN-07-6227; ZHANG M, 1995, FEBS LETT, V373, P203, DOI 10.1016/0014-5793(95)01041-C	57	47	48	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4961	4971		10.1096/fj.14-256636	http://dx.doi.org/10.1096/fj.14-256636			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25016026	Green Published			2022-12-28	WOS:000344050900032
J	Denicol, AC; Block, J; Kelley, DE; Pohler, KG; Dobbs, KB; Mortensen, CJ; Ortega, MS; Hansen, PJ				Denicol, Anna C.; Block, Jeremy; Kelley, Dale E.; Pohler, Ky G.; Dobbs, Kyle B.; Mortensen, Christopher J.; Ortega, M. Sofia; Hansen, Peter J.			The WNT signaling antagonist Dickkopf-1 directs lineage commitment and promotes survival of the preimplantation embryo	FASEB JOURNAL			English	Article						embryo development; cell differentiation; pregnancy	IN-VITRO CULTURE; WNT/BETA-CATENIN; GENE-EXPRESSION; REPRODUCTIVE-TRACT; HUMAN ENDOMETRIUM; ESTROUS-CYCLE; GROWTH-FACTOR; BOVINE; PREGNANCY; PLURIPOTENCY	Successful embryonic development is dependent on factors secreted by the reproductive tract. Dickkopf-1 (DKK1), an antagonist of the wingless-related mouse mammary tumor virus (WNT) signaling pathway, is one endometrial secretory protein potentially involved in maternal-embryo communication. The purpose of this study was to investigate the roles of DKK1 in embryo cell fate decisions and competence to establish pregnancy. Using in vitro-produced bovine embryos, we demonstrate that exposure of embryos to DKK1 during the period of morula to blastocyst transition (between d 5 and 8 of development) promotes the first 2 cell fate decisions leading to increased differentiation of cells toward the trophectoderm and hypoblast lineages compared with that for control embryos treated with vehicle. Moreover, treatment of embryos with DKK1 or colony-stimulating factor 2 (CSF2; an endometrial cytokine known to improve embryo development and pregnancy establishment) between d 5 and 7 of development improves embryo survival after transfer to recipients. Pregnancy success at d 32 of gestation was 27% for cows receiving control embryos treated with vehicle, 41% for cows receiving embryos treated with DKK1, and 39% for cows receiving embryos treated with CSF2. These novel findings represent the first evidence of a role for maternally derived WNT regulators during this period and could lead to improvements in assisted reproductive technologies.	[Denicol, Anna C.; Block, Jeremy; Kelley, Dale E.; Dobbs, Kyle B.; Mortensen, Christopher J.; Ortega, M. Sofia; Hansen, Peter J.] Univ Florida, Dept Anim Sci, DH Barron Reprod & Perinatal Biol Res Program, Gainesville, FL 32611 USA; [Denicol, Anna C.; Block, Jeremy; Kelley, Dale E.; Dobbs, Kyle B.; Mortensen, Christopher J.; Ortega, M. Sofia; Hansen, Peter J.] Univ Florida, Genet Inst, Gainesville, FL USA; [Block, Jeremy] Ovatech LLC, Gainesville, FL USA; [Pohler, Ky G.] Univ Missouri, Div Anim Sci, Columbia, MO USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Missouri System; University of Missouri Columbia	Hansen, PJ (corresponding author), Univ Florida, POB 110910, Gainesville, FL 32611 USA.	pjhansen@ufl.edu	Kelley, Dale E/B-1783-2014; Hansen, Peter/AAI-4693-2021; Kelley, Dale/AAY-2430-2020; Ortega, Sofia/ABA-3654-2020; Mortensen, Chris J/A-4084-2011; Block, Jeremy/AAC-6408-2021	Kelley, Dale E/0000-0002-4767-6978; Hansen, Peter/0000-0003-3061-9333; Kelley, Dale/0000-0002-4767-6978; Ortega, Sofia/0000-0003-4027-7314; Block, Jeremy/0000-0002-6279-8543; Pohler, Ky/0000-0003-2429-0893	U.S. Department of Agriculture Agriculture and Food Research Initiative (AFRI) grants [2009-65203-05732, 2011-67015-30688]	U.S. Department of Agriculture Agriculture and Food Research Initiative (AFRI) grants	The authors thank Central Beef LLC (Center Hill, FL, USA) for providing bovine ovaries, Luciano Bonilla for assistance with embryo production and transfer, William Rembert for ovary collection, Eric Diepersloot of the University of Florida Dairy Research Unit and the owners and personnel at Alliance Dairies for support and assistance with the embryo transfer experiments, Douglas Smith and the University of Florida McKnight Brain Institute Cell and Tissue Analysis Core for technical assistance for acquisition of confocal images, and Glaucio Lopes and Accelerated Genetics for support of the trial. This research was funded by U.S. Department of Agriculture Agriculture and Food Research Initiative (AFRI) grants 2009-65203-05732 and 2011-67015-30688. A.C.D and P.J.H. designed the research; A.C.D., J.B., D.E.K., K.G.P., K.B.D., M.S.O., and C.J.M. performed the research; A.C.D. and P.J.H. analyzed the data; and A.C.D. and P.J.H. wrote the initial drafts of the article.	Aparicio IM, 2010, REPRODUCTION, V140, P83, DOI 10.1530/REP-10-0040; Atli MO, 2011, ANIM REPROD SCI, V125, P94, DOI 10.1016/j.anireprosci.2011.04.001; Bauer BK, 2010, BIOL REPROD, V83, P791, DOI 10.1095/biolreprod.110.085936; Bazer FW, 2013, J ANIM SCI BIOTECHNO, V4, DOI 10.1186/2049-1891-4-23; Berg DK, 2011, DEV CELL, V20, P244, DOI 10.1016/j.devcel.2011.01.003; Bonilla AQS, 2011, GROWTH HORM IGF RES, V21, P107, DOI 10.1016/j.ghir.2011.03.003; Bridges GA, 2013, J ANIM SCI, V91, P3002, DOI 10.2527/jas.2013-5882; Cai KQ, 2008, DEV DYNAM, V237, P2820, DOI 10.1002/dvdy.21703; Caneparo L, 2007, GENE DEV, V21, P465, DOI 10.1101/gad.406007; Cerri RLA, 2012, J DAIRY SCI, V95, P5657, DOI 10.3168/jds.2011-5114; Cheung LP, 2003, FERTIL STERIL, V80, P727, DOI 10.1016/S0015-0282(03)00772-6; Clementi C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003863; Denicol A. C., 2013, SCI REP, V3, P1; Dobbs KB, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.113183; Fan XJ, 2012, ENDOCRINOLOGY, V153, P1063, DOI 10.1210/en.2011-1826; FARIN PW, 1995, BIOL REPROD, V52, P676, DOI 10.1095/biolreprod52.3.676; Fields SD, 2011, THERIOGENOLOGY, V75, P1466, DOI 10.1016/j.theriogenology.2010.12.007; Franco HL, 2011, FASEB J, V25, P1176, DOI 10.1096/fj.10-175349; Gad A, 2011, HUM REPROD, V26, P1693, DOI 10.1093/humrep/der110; Gad A, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.099697; Giritharan G, 2012, REPROD SCI, V19, P243, DOI 10.1177/1933719111428522; Green JC, 2010, ANIM REPROD SCI, V121, P24, DOI 10.1016/j.anireprosci.2010.05.010; Green JA, 2005, THERIOGENOLOGY, V63, P1481, DOI 10.1016/j.theriogenology.2004.07.011; Green JA, 1998, REV REPROD, V3, P62; Han H., 2010, J ENDOCRINOL, V191, P505; Hayashi K, 2007, ENDOCRINOLOGY, V148, P3496, DOI 10.1210/en.2007-0283; Kao LC, 2002, ENDOCRINOLOGY, V143, P2119, DOI 10.1210/en.143.6.2119; Kelly KF, 2011, CELL STEM CELL, V8, P214, DOI 10.1016/j.stem.2010.12.010; Kuijk EW, 2012, DEVELOPMENT, V139, P871, DOI 10.1242/dev.071688; Lazzari G, 2010, THERIOGENOLOGY, V73, P748, DOI 10.1016/j.theriogenology.2009.08.001; Lim KT, 2013, THERIOGENOLOGY, V79, P284, DOI 10.1016/j.theriogenology.2012.08.018; Loureiro B, 2009, ENDOCRINOLOGY, V150, P5046, DOI 10.1210/en.2009-0481; Macdonald LJ, 2011, MOL HUM REPROD, V17, P626, DOI 10.1093/molehr/gar031; Minten MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069444; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Morris Samantha A, 2012, Results Probl Cell Differ, V55, P203, DOI 10.1007/978-3-642-30406-4_11; Ozawa M, 2011, FERTIL STERIL, V95, P799, DOI 10.1016/j.fertnstert.2010.10.006; PARRISH JJ, 1995, THERIOGENOLOGY, V44, P859, DOI 10.1016/0093-691X(95)00271-9; Peng S, 2008, REPRODUCTION, V135, P367, DOI 10.1530/REP-07-0191; Pontes JHF, 2009, THERIOGENOLOGY, V71, P690, DOI 10.1016/j.theriogenology.2008.09.031; Rizos D, 2010, J DAIRY SCI, V93, P1022, DOI 10.3168/jds.2009-2605; Robertson I., 1998, MANUAL INT EMBRYO TR, P103; Sagirkaya H, 2007, ANIM REPROD SCI, V101, P225, DOI 10.1016/j.anireprosci.2006.09.016; Sakatani M, 2012, J DAIRY SCI, V95, P3080, DOI 10.3168/jds.2011-4986; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Satterfield MC, 2008, REPROD FERT DEVELOP, V20, P935, DOI 10.1071/RD08069; Sousa NM, 2006, J PHYSIOL PHARMACOL, V57, P153; Spencer T E, 2007, Soc Reprod Fertil Suppl, V64, P379; Tulac S, 2006, J CLIN ENDOCR METAB, V91, P1453, DOI 10.1210/jc.2005-0769; Tulac S, 2003, J CLIN ENDOCR METAB, V88, P3860, DOI 10.1210/jc.2003-030494; van der Horst PH, 2012, MOL CELL ENDOCRINOL, V358, P176, DOI 10.1016/j.mce.2011.06.010; Xenopoulos Panagiotis, 2012, Results Probl Cell Differ, V55, P185, DOI 10.1007/978-3-642-30406-4_10; Xie HR, 2008, DEVELOPMENT, V135, P717, DOI 10.1242/dev.015339; Zhang RJ, 2012, J CLIN ENDOCR METAB, V97, P543, DOI 10.1210/jc.2011-2108; Ziebe S, 2013, FERTIL STERIL, V99, P1600, DOI 10.1016/j.fertnstert.2012.12.043	55	77	78	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3975	3986		10.1096/fj.14-253112	http://dx.doi.org/10.1096/fj.14-253112			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24858280	Green Published			2022-12-28	WOS:000340845900015
J	Buttari, B; Profumo, E; Domenici, G; Tagliani, A; Ippoliti, F; Bonini, S; Businaro, R; Elenkov, I; Rigano, R				Buttari, Brigitta; Profumo, Elisabetta; Domenici, Giacomo; Tagliani, Angela; Ippoliti, Flora; Bonini, Sergio; Businaro, Rita; Elenkov, Ilia; Rigano, Rachele			Neuropeptide Y induces potent migration of human immature dendritic cells and promotes a T(h)2 polarization	FASEB JOURNAL			English	Article						adhesion to endothelial cells; cytokines; DC maturation; MAPKs; neuromediators; transendothelial migration	IN-VIVO; STIMULATES PROLIFERATION; RHEUMATOID-ARTHRITIS; ENDOTHELIAL-CELLS; SYMPATHETIC-NERVE; PEPTIDE-YY; IMMUNE; STRESS; NPY; RECEPTOR	Neuropeptide Y (NPY), a major autonomic nervous system and stress mediator, is emerging as an important regulator of inflammation, implicated in autoimmunity, asthma, atherosclerosis, and cancer. Yet the role of NPY in regulating phenotype and functions of dendritic cells (DCs), the professional antigen-presenting cells, remains undefined. Here we investigated whether NPY could induce DCs to migrate, mature, and polarize naive T lymphocytes. We found that NPY induced a dose-dependent migration of human monocyte-derived immature DCs through the engagement of NPY Y1 receptor and the activation of ERK and p38 mitogen-activated protein kinases. NPY promoted DC adhesion to endothelial cells and trans-endothelial migration. It failed to induce phenotypic DC maturation, whereas it conferred a T helper 2 (T(h)2) polarizing profile to DCs through the up-regulation of interleukin (IL)-6 and IL-10 production. Thus, during an immune/inflammatory response NPY may exert proinflammatory effects through the recruitment of immature DCs, but it may exert antiinflammatory effects by promoting a T(h)2 polarization. Locally, at inflammatory sites, cell recruitment could be amplified in conditions of intense acute, chronic, or cold stress. Thus, altered or amplified signaling through the NPY-NPY-Y1 receptor-DC axis may have implications for the development of inflammatory conditions.	[Buttari, Brigitta; Profumo, Elisabetta; Domenici, Giacomo; Rigano, Rachele] Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy; [Tagliani, Angela; Businaro, Rita] Univ Roma La Sapienza, Dept Med Surg Sci & Biotechnol, I-00185 Rome, Italy; [Ippoliti, Flora] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy; [Bonini, Sergio; Elenkov, Ilia] Italian Natl Res Council, Inst Neurobiol & Mol Med, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); Istituto Superiore di Sanita (ISS); Sapienza University Rome; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR)	Rigano, R (corresponding author), Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, Viale Regina Elena 299, I-00161 Rome, Italy.	rachele.rigano@iss.it	Businaro, Rita/AAG-1866-2021; Buttari, Brigitta/I-3030-2014; Riganò, Rachele/B-4256-2015; Bonini, Sergio/T-6594-2019; Buttari, Brigitta/ABB-4858-2021; Profumo, Elisabetta/B-4255-2015; Domenici, Giacomo/AAG-6224-2019	Businaro, Rita/0000-0002-7890-8524; Buttari, Brigitta/0000-0002-0575-4106; Riganò, Rachele/0000-0003-3014-3523; Bonini, Sergio/0000-0003-0079-3031; Buttari, Brigitta/0000-0002-0575-4106; Profumo, Elisabetta/0000-0002-7261-8884; reverberi, massimo/0000-0003-3671-6783; Domenici, Giacomo/0000-0002-3947-5930	European Community	European Community(European Commission)	The authors thank Dr. Giuseppina Mandarino for the linguistic revision of the manuscript and Mr. Massimo Delle Femmine for the graphic support of the figures. This work was supported by a Marie Curie International Reintegration grant (I.J.E.) within the 6th European Community Framework Program.	Bedoui S, 2004, TRENDS IMMUNOL, V25, P508, DOI 10.1016/j.it.2004.08.005; Bedoui S, 2002, J NEUROIMMUNOL, V132, P25, DOI 10.1016/S0165-5728(02)00278-3; Bedoui S, 2003, J NEUROIMMUNOL, V134, P1, DOI 10.1016/S0165-5728(02)00424-1; Bedoui S, 2001, J NEUROIMMUNOL, V117, P125, DOI 10.1016/S0165-5728(01)00328-9; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; Buljevic S, 2013, RHEUMATOL INT, V33, P2867, DOI 10.1007/s00296-013-2823-z; Buttari B, 2005, BLOOD, V106, P3880, DOI 10.1182/blood-2005-03-1201; Chandrasekar B, 2004, BIOCHEM BIOPH RES CO, V319, P304, DOI 10.1016/j.bbrc.2004.04.185; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Cutolo M, 2006, NEUROIMMUNOMODULAT, V13, P277, DOI 10.1159/000104855; Dave ND, 2011, IMMUNOL ALLERGY CLIN, V31, P55, DOI 10.1016/j.iac.2010.09.009; Decressac M, 2009, NEUROBIOL DIS, V34, P441, DOI 10.1016/j.nbd.2009.02.017; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Dimitrijevic M, 2013, AMINO ACIDS, V45, P41, DOI 10.1007/s00726-011-1185-7; Dunzendorfer S, 2001, J IMMUNOL, V166, P2167, DOI 10.4049/jimmunol.166.4.2167; Elenkov IJ, 1999, TRENDS ENDOCRIN MET, V10, P359, DOI 10.1016/S1043-2760(99)00188-5; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; ENQUSELASSIE F, 1993, INT J EPIDEMIOL, V22, P632, DOI 10.1093/ije/22.4.632; ERICSSON A, 1987, IMMUNOL REV, V100, P261, DOI 10.1111/j.1600-065X.1987.tb00535.x; Feigin VL, 2000, EUR J NEUROL, V7, P171, DOI 10.1046/j.1468-1331.2000.00016.x; Fenteany G, 2004, CURR OPIN HEMATOL, V11, P15, DOI 10.1097/00062752-200401000-00004; Ferreira R, 2012, J NEUROCHEM, V120, P93, DOI 10.1111/j.1471-4159.2011.07541.x; Ghersi G, 2001, PEPTIDES, V22, P453, DOI 10.1016/S0196-9781(01)00340-0; Gregory JL, 2009, MICROCIRCULATION, V16, P735, DOI 10.3109/10739680903210421; Han RJ, 2012, FASEB J, V26, P3528, DOI 10.1096/fj.12-203943; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Haug SR, 2006, J DENT RES, V85, P488, DOI 10.1177/154405910608500602; Heilig M, 2004, J PSYCHIATR RES, V38, P113, DOI 10.1016/S0022-3956(03)00101-8; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kawamura N, 1998, NEUROIMMUNOMODULAT, V5, P9, DOI 10.1159/000026321; Kuo LE, 2007, NAT MED, V13, P803, DOI 10.1038/nm1611; Lee M, 2005, J BIOL CHEM, V280, P125, DOI 10.1074/jbc.M408858200; Levite M, 1998, P NATL ACAD SCI USA, V95, P12544, DOI 10.1073/pnas.95.21.12544; Li LJ, 2011, J CARDIOVASC TRANSL, V4, P351, DOI 10.1007/s12265-011-9271-5; Li LJ, 2005, ARTERIOSCL THROM VAS, V25, P2075, DOI 10.1161/01.ATV.0000179601.19888.19; LUNDBERG JM, 1989, NEUROSCIENCE, V28, P475, DOI 10.1016/0306-4522(89)90193-0; Macia L, 2011, IMMUNOL CELL BIOL, V89, P882, DOI 10.1038/icb.2011.6; Maestroni GJM, 2006, ANN NY ACAD SCI, V1069, P195, DOI 10.1196/annals.1351.017; Maestroni GJM, 2000, J IMMUNOL, V165, P6743, DOI 10.4049/jimmunol.165.12.6743; Malmstrom R E, 1997, Acta Physiol Scand Suppl, V636, P1; Manni M, 2008, BRAIN BEHAV IMMUN, V22, P80, DOI 10.1016/j.bbi.2007.06.016; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Medeiros PJ, 2012, INT J CANCER, V131, P276, DOI 10.1002/ijc.26350; Medina S, 1998, MECH AGEING DEV, V102, P249, DOI 10.1016/S0047-6374(98)00014-1; MICHEL MC, 1990, AM J PHYSIOL, V259, pE131; Michel MC, 1998, PHARMACOL REV, V50, P143; Mitic K, 2011, PEPTIDES, V32, P1626, DOI 10.1016/j.peptides.2011.06.007; Mohr DC, 2006, BRAIN BEHAV IMMUN, V20, P27, DOI 10.1016/j.bbi.2005.03.011; Morris MJ, 1998, J NEUROCHEM, V71, P1519; Movafagh S, 2006, FASEB J, V20, P1924, DOI 10.1096/fj.05-4770fje; Nave H, 2004, J NEUROIMMUNOL, V155, P1, DOI 10.1016/j.jneuroim.2004.05.009; Naveilhan P, 2001, NATURE, V409, P513, DOI 10.1038/35054063; Pacak K, 1998, AM J PHYSIOL-REG I, V275, pR1247, DOI 10.1152/ajpregu.1998.275.4.R1247; Patberg WR, 2004, J RHEUMATOL, V31, P1327; Reiche EMV, 2004, LANCET ONCOL, V5, P617, DOI 10.1016/S1470-2045(04)01597-9; Rethnam S, 2010, INT ENDOD J, V43, P492, DOI 10.1111/j.1365-2591.2010.01704.x; Ruohonen Suvi T, 2012, Indian J Endocrinol Metab, V16, pS569, DOI 10.4103/2230-8210.105574; Scheiermann C, 2012, IMMUNITY, V37, P290, DOI 10.1016/j.immuni.2012.05.021; SCHWARZ H, 1994, J NEUROIMMUNOL, V51, P53, DOI 10.1016/0165-5728(94)90128-7; Singer K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057929; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Straub RH, 2000, J LEUKOCYTE BIOL, V67, P553, DOI 10.1002/jlb.67.4.553; SUNG CP, 1991, CIRC RES, V68, P314, DOI 10.1161/01.RES.68.1.314; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P5485, DOI 10.1073/pnas.79.18.5485; Thorsell A, 2000, P NATL ACAD SCI USA, V97, P12852, DOI 10.1073/pnas.220232997; Vezzani A, 1999, TRENDS NEUROSCI, V22, P25, DOI 10.1016/S0166-2236(98)01284-3; von Horsten S, 1998, BRAIN RES, V806, P282, DOI 10.1016/S0006-8993(98)00772-0; Weissmann G, 2010, FASEB J, V24, P4129, DOI 10.1096/fj.10-1101ufm; Wheway J, 2005, J EXP MED, V202, P1527, DOI 10.1084/jem.20051971; Wheway J, 2007, CURR TOP MED CHEM, V7, P1743, DOI 10.2174/156802607782341046; Wheway J, 2007, PEPTIDES, V28, P453, DOI 10.1016/j.peptides.2006.09.030; Zhang L, 2011, PHARMACOL THERAPEUT, V131, P91, DOI 10.1016/j.pharmthera.2011.03.011	72	40	44	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3038	3049		10.1096/fj.13-243485	http://dx.doi.org/10.1096/fj.13-243485			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24699455				2022-12-28	WOS:000337949400026
J	Slominski, AT; Kim, TK; Takeda, Y; Janjetovic, Z; Brozyna, AA; Skobowiat, C; Wang, J; Postlethwaite, A; Li, W; Tuckey, RC; Jetten, AM				Slominski, Andrzej T.; Kim, Tae-Kang; Takeda, Yukimasa; Janjetovic, Zorica; Brozyna, Anna A.; Skobowiat, Cezary; Wang, Jin; Postlethwaite, Arnold; Li, Wei; Tuckey, Robert C.; Jetten, Anton M.			ROR alpha and ROR gamma are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D	FASEB JOURNAL			English	Article						keratinocytes; melanoma cells; retinoic acid-related nuclear receptors; CYP11A1	VITAMIN-D; CYTOCHROME P450SCC; TRANSCRIPTIONAL ACTIVATION; INHIBITS PROLIFERATION; CHOLESTEROL SULFATE; NUCLEAR RECEPTORS; TH17 CELLS; METABOLISM; MELATONIN; PATHWAY	ROR alpha and ROR gamma are expressed in human skin cells that produce the noncalcemic 20-hydroxyvitamin D-3 [20(OH)D-3] and 20,23-dihydroxyvitamin D-3 [20,23(OH)(2)D-3]. Chinese hamster ovary (CHO) cells stably expressing a Tet-on ROR alpha or ROR gamma expression vector and a ROR-responsive element (RORE)-LUC reporter, and a mammalian 2-hybrid model examining the interaction between the ligand binding domain (LBD) of ROR alpha or ROR gamma with an LBD-interacting LXXLL-peptide, were used to study ROR-antagonist activities. These assays revealed that 20(OH)D-3 and 20,23(OH)(2)D-3 function as antagonists of ROR alpha and ROR gamma. Moreover, 20(OH)D-3 inhibited the activation of the promoter of the Bmal1 and G6pase genes, targets of ROR alpha, and 20(OH)D-3 and 20,23(OH)(2)D-3 inhibited Il17 promoter activity in Jurkat cells overexpressing ROR alpha or ROR gamma. Molecular modeling using crystal structures of the LBDs of ROR alpha and ROR gamma revealed docking scores for 20(OH)D-3, 20, 23(OH)(2)D-3 and 1,25(OH)(2)D-3 similar to those of the natural ligands, predicting good binding to the receptor. Notably, 20(OH)D-3, 20,23(OH)(2)D-3, and 1,25(OH)(2)D-3 inhibited RORE-mediated activation of a reporter in keratinocytes and melanoma cells and inhibited IL-17 production by immune cells. Our study identifies a novel signaling pathway, in which 20(OH)D-3 and 20,23(OH)(2)D-3 act as antagonists or inverse agonists of ROR alpha and ROR gamma, that opens new possibilities for local (skin) or systemic regulation.	[Slominski, Andrzej T.; Kim, Tae-Kang; Janjetovic, Zorica; Skobowiat, Cezary] Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; [Slominski, Andrzej T.; Postlethwaite, Arnold] Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA; [Wang, Jin; Li, Wei] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA; [Takeda, Yukimasa; Jetten, Anton M.] NIEHS, Cell Biol Sect, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; [Brozyna, Anna A.] Nicolaus Copernicus Univ, Dept Tumor Pathol & Pathomorphol, Prof Franciszek Lukaszczyk Mem Hosp, Oncol Ctr,Ludwik Rydygier Coll Med, Bydgoszcz, Poland; [Postlethwaite, Arnold] Dept Vet Affairs Med Ctr, Memphis, TN USA; [Tuckey, Robert C.] Univ Western Australia, Sch Chem & Biochem, Crawley, WA, Australia	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Nicolaus Copernicus University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Western Australia	Slominski, AT (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol, 930 Madison Ave,RM525, Memphis, TN 38163 USA.	aslominski@uthsc.edu; jetten@niehs.nih.gov	Brożyna, Anna A/D-4902-2014; Skobowiat, Cezary/J-5007-2012; Jetten, Anton/C-3736-2019	Brożyna, Anna A/0000-0002-3195-9965; Skobowiat, Cezary/0000-0002-3881-0231; Jetten, Anton/0000-0003-0954-4445; Slominski, Andrzej/0000-0001-8963-3995; Li, Wei/0000-0002-9522-4474; Wang, Jin/0000-0001-5420-5704	U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases [2R06AR052190, 1R01AR056666-01A2]; West Clinic Cancer Foundation; Department of Veterans Affairs Program [1IPIBX00107-01, 1R21AR063242-01A1, 1S10OD010678-01]; National Institute of Environmental Health Sciences, NIH [Z01-ES-101586]; Japanese Society for the Promotion of Science (JSPS); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056666, R21AR063242, R01AR052190, R21AR066505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101586, ZIAES101586] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD010678] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); West Clinic Cancer Foundation; Department of Veterans Affairs Program; National Institute of Environmental Health Sciences, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Japanese Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The project was supported by grants from the U.S. National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (2R06AR052190 and 1R01AR056666-01A2) and the West Clinic Cancer Foundation to A. T. S.; Department of Veterans Affairs Program Project grant 1IPIBX00107-01 to A. P. and grants 1R21AR063242-01A1 and 1S10OD010678-01 to W. L.; and by grants from the Intramural Research Program of the National Institute of Environmental Health Sciences, NIH (Z01-ES-101586), and the Japanese Society for the Promotion of Science (JSPS) to A.M.J. and Y.T.	Antonov J, 2005, LAB INVEST, V85, P1040, DOI 10.1038/labinvest.3700303; Bikle DD, 2011, EXP DERMATOL, V20, P7, DOI 10.1111/j.1600-0625.2010.01202.x; Bikle DD, 2011, DISCOV MED, V11, P7; Brand DD, 2002, J IMMUNOL, V168, P490, DOI 10.4049/jimmunol.168.1.490; Brozyna AA, 2013, HUM PATHOL, V44, P374, DOI 10.1016/j.humpath.2012.03.031; Brozyna AA, 2011, HUM PATHOL, V42, P618, DOI 10.1016/j.humpath.2010.09.014; Carlberg C, 2000, ANN NY ACAD SCI, V917, P387; Chen JJ, 2011, BIOORGAN MED CHEM, V19, P4782, DOI 10.1016/j.bmc.2011.06.084; Dai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070392; Elias PM, 2014, BBA-MOL CELL BIOL L, V1841, P353, DOI 10.1016/j.bbalip.2013.11.009; Elias PM, 2012, J INVEST DERMATOL, V132, P2131, DOI 10.1038/jid.2012.246; Fischer TW, 2006, INT J ONCOL, V29, P665; Guryev O, 2003, P NATL ACAD SCI USA, V100, P14754, DOI 10.1073/pnas.2336107100; Hill SM, 2009, INTEGR CANCER THER, V8, P337, DOI 10.1177/1534735409353332; Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Huh JR, 2012, EUR J IMMUNOL, V42, P2232, DOI 10.1002/eji.201242740; Hyter S, 2013, FEBS LETT, V587, P529, DOI 10.1016/j.febslet.2013.01.041; Janjetovic Z, 2010, J CELL PHYSIOL, V223, P36, DOI 10.1002/jcp.21992; Jetten AM, 2001, PROG NUCLEIC ACID RE, V69, P205, DOI 10.1016/S0079-6603(01)69048-2; Jetten Anton M, 2013, Front Endocrinol (Lausanne), V4, P1, DOI 10.3389/fendo.2013.00001; Jetten Anton M, 2009, Nucl Recept Signal, V7, pe003, DOI 10.1621/nrs.07003; Jin LH, 2010, MOL ENDOCRINOL, V24, P923, DOI 10.1210/me.2009-0507; Kallen J, 2004, J BIOL CHEM, V279, P14033, DOI 10.1074/jbc.M400302200; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kim TK, 2013, FASEB J, V27, P2742, DOI 10.1096/fj.12-224691; Kobayashi H, 2005, FASEB J, V19, P1710, DOI 10.1096/fj.04-2293fje; Kurebayashi S, 2004, BIOCHEM BIOPH RES CO, V315, P919, DOI 10.1016/j.bbrc.2004.01.131; Marciano DP, 2014, CELL METAB, V19, P193, DOI 10.1016/j.cmet.2013.12.009; Mohan V, 2005, CURR PHARM DESIGN, V11, P323, DOI 10.2174/1381612053382106; Myers LK, 1997, LIFE SCI, V61, P1861, DOI 10.1016/S0024-3205(97)00480-3; Nguyen MN, 2009, DRUG METAB DISPOS, V37, P761, DOI 10.1124/dmd.108.025619; Palmer MT, 2011, J BIOL CHEM, V286, P997, DOI 10.1074/jbc.M110.163790; Peiser M, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/261037; Pike JW, 2014, J STEROID BIOCHEM, V144, P5, DOI 10.1016/j.jsbmb.2013.11.004; Plum LA, 2010, NAT REV DRUG DISCOV, V9, P941, DOI 10.1038/nrd3318; Schmuth M, 2008, J LIPID RES, V49, P499, DOI 10.1194/jlr.R800001-JLR200; Skobowiat C, 2013, BRIT J DERMATOL, V168, P595, DOI 10.1111/bjd.12096; Skobowiat C, 2011, AM J PHYSIOL-ENDOC M, V301, pE484, DOI [10.1152/ajpendo.00217.2011, 10.1152/ajpendo.00217.2011.]; Slominski A, 2005, ENDOCRINE, V27, P137, DOI 10.1385/ENDO:27:2:137; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2005, FEBS J, V272, P4080, DOI 10.1111/j.1742-4658.2005.04819.x; SLOMINSKI A, 2013, J STEROID BIOCHEM, V137, P107, DOI [10.1016/.jsbmb.2013.02.006, DOI 10.1016/J.JSBMB.2013.02.006]; Slominski A, 2006, FEBS J, V273, P2891, DOI 10.1111/j.1742-4658.2006.05302.x; Slominski A, 2013, J CLIN ENDOCR METAB, V98, pE298, DOI 10.1210/jc.2012-3074; Slominski AT, 2012, ADV ANAT EMBRYOL CEL, V212, P1; Slominski AT, 2014, J STEROID BIOCHEM, V144, P28, DOI 10.1016/j.jsbmb.2013.10.012; Slominski AT, 2014, MOL CELL ENDOCRINOL, V383, P181, DOI 10.1016/j.mce.2013.12.012; Slominski AT, 2012, INT J BIOCHEM CELL B, V44, P2003, DOI 10.1016/j.biocel.2012.07.027; Slominski AT, 2012, ANTICANCER RES, V32, P3733; Slominski AT, 2012, FASEB J, V26, P3901, DOI 10.1096/fj.12-208975; Slominski AT, 2011, J INVEST DERMATOL, V131, P1167, DOI 10.1038/jid.2010.425; Slominski AT, 2011, AM J PHYSIOL-CELL PH, V300, pC526, DOI 10.1152/ajpcell.00203.2010; Slominski AT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009907; SLOMINSKI AT, 2014, ANTI-CANCER AGENT ME, V14, P77, DOI DOI 10.2174/18715206113139990308; Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004; Solt LA, 2012, TRENDS ENDOCRIN MET, V23, P619, DOI 10.1016/j.tem.2012.05.012; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; Takeda Y, 2013, NUCLEIC ACIDS RES, V41, P6992, DOI 10.1093/nar/gkt447; Takeda Y, 2012, NUCLEIC ACIDS RES, V40, P8519, DOI 10.1093/nar/gks630; Takeda Y, 2011, NUCLEIC ACIDS RES, V39, P4769, DOI 10.1093/nar/gkq1335; Tuckey RC, 2008, FEBS J, V275, P2585, DOI 10.1111/j.1742-4658.2008.06406.x; Tuckey RC, 2011, DRUG METAB DISPOS, V39, P1577, DOI 10.1124/dmd.111.040071; Van Belle TL, 2013, TRENDS ENDOCRIN MET, V24, P561, DOI 10.1016/j.tem.2013.07.002; Wang J, 2012, ANTICANCER RES, V32, P739; Wang YJ, 2010, BBA-MOL CELL BIOL L, V1801, P917, DOI 10.1016/j.bbalip.2010.02.012; Wang YJ, 2010, J BIOL CHEM, V285, P5013, DOI 10.1074/jbc.M109.080614; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Zbytek B, 2008, J INVEST DERMATOL, V128, P2271, DOI 10.1038/jid.2008.62	70	192	194	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2775	2789		10.1096/fj.13-242040	http://dx.doi.org/10.1096/fj.13-242040			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24668754	Green Published, Bronze			2022-12-28	WOS:000337949400005
J	Stremmel, W; Staffer, S; Wannhoff, A; Pathil, A; Chamulitrat, W				Stremmel, Wolfgang; Staffer, Simone; Wannhoff, Andreas; Pathil, Anita; Chamulitrat, Walee			Plasma membrane phospholipase A(2) controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis	FASEB JOURNAL			English	Article						cJun N-terminal kinase; detergent-resistant membranes; lysophosphatidylcholine; ursodeoxycholate-lysophosphatidyletanolamide	URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE; CELLULAR UPTAKE; BINDING; TRANSPORT; PROTEIN; METABOLISM; SYSTEM; OLEATE; DRIVEN; SERUM	Excess hepatic fat accumulation leads to nonalcoholic steatohepatitis (NASH), a serious threat to health for which no effective treatment is available. However, the mechanism responsible for fatty acid uptake by hepatocytes remains unclear. Using the human hepatocyte-derived tumor cell line HepG2, we found that fatty acid influx is mediated by a heterotetrameric plasma membrane protein complex consisting of plasma membrane fatty acid-binding protein, caveolin-1, CD36, and calcium-independent membrane phospholipase A(2) (iPLA(2)beta). Blocking iPLA(2)beta with the bile acid-phospholipid conjugate ursodeoxycholate-lysophosphatidylethanolamide (UDCA-LPE) caused the dissociation of the complex, thereby inhibiting fatty acid influx (IC50 47 mu M), and suppressed the synthesis of all subunits through a reduction in lysophosphatidylcholine from 8.0 to 3.5 mu mol/mg of protein and corresponding depletion of phosphorylated c-Jun N-terminal kinase. These findings were substantiated by an observed 56.5% decrease in fatty acid influx in isolated hepatocytes derived from iPLA(2)beta-knockout mice. Moreover, steatosis and inflammation were abrogated by UDCA-LPE treatment in a cellular model of NASH. Thus, iPLA(2)beta acts as an upstream checkpoint for mechanisms that regulate fatty acid uptake, and its inhibition by UDCA-LPE qualifies this nontoxic compound as a therapeutic candidate for the treatment of NASH.	[Stremmel, Wolfgang; Staffer, Simone; Wannhoff, Andreas; Pathil, Anita; Chamulitrat, Walee] Univ Heidelberg Hosp, Dept Gastroenterol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Stremmel, W (corresponding author), Univ Heidelberg Hosp, Dept Gastroenterol, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.	wolfgang.stremmel@med.uni-heidelberg.de		Stremmel, Wolfgang/0000-0002-8545-1753	Deutsche Forschungsgemeinschaft [STR 216/15-4]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank Weihong Xu for assistance with the mouse hepatocyte preparation and Dieter Stefan (Institute for Immunology, Heidelberg, Germany) for performing the FACS analysis, and the group of Dr. Joachim Fullekrug (Department of Gastroenterology, University Hospital Heidelberg, Heidelberg, Germany) for technical advice and reagents. This project was funded by Deutsche Forschungsgemeinschaft STR 216/15-4. W. S. designed the experiments, analyzed the data, and wrote the manuscript. S. S. performed the experiments. A. W. prepared the figures and performed statistical analyses. W. C. and A. P. contributed equally by providing conceptual advice and experimental support. The authors declare no conflicts of interests.	ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Balsinde J, 2005, CELL SIGNAL, V17, P1052, DOI 10.1016/j.cellsig.2005.03.002; Bao SZ, 2006, J BIOL CHEM, V281, P20958, DOI 10.1074/jbc.M600075200; BHAT MK, 1993, BIOCHIM BIOPHYS ACTA, V1166, P244, DOI 10.1016/0005-2760(93)90104-H; Bottcher RT, 2012, NAT CELL BIOL, V14, P584, DOI 10.1038/ncb2501; CHAM BE, 1976, J LIPID RES, V17, P176; Chamulitrat W, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00024; Chamulitrat W, 2009, HEPATOLOGY, V50, P143, DOI 10.1002/hep.22955; Digel M, 2011, AM J PHYSIOL-ENDOC M, V301, pE785, DOI 10.1152/ajpendo.00079.2011; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; GORESKY CA, 1994, CIRC RES, V74, P1015, DOI 10.1161/01.RES.74.6.1015; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Hoffmann MJ, 1999, TOXICOL SCI, V49, P40, DOI 10.1093/toxsci/49.1.40; Hsu YH, 2009, J BIOL CHEM, V284, P23652, DOI 10.1074/jbc.M109.021857; Kakisaka K., 2012, AM J PHYSIOL-GASTR L, V302, P677; Kishimoto T, 2002, CLIN BIOCHEM, V35, P411, DOI 10.1016/S0009-9120(02)00327-2; Krarup NT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040376; Lehmann R, 2013, DIABETES CARE, V36, P2331, DOI 10.2337/dc12-1760; Marzluff W F Jr, 1978, Methods Cell Biol, V19, P317; Milger K, 2006, J CELL SCI, V119, P4678, DOI 10.1242/jcs.03280; Pan YH, 2007, J MOL BIOL, V369, P439, DOI 10.1016/j.jmb.2007.03.034; Pathil A, 2012, HEPATOLOGY, V55, P1369, DOI 10.1002/hep.25531; Pathil A, 2011, J HEPATOL, V54, P674, DOI 10.1016/j.jhep.2010.07.028; Pohl J, 2005, MOL BIOL CELL, V16, P24, DOI 10.1091/mbc.E04-07-0616; Puri P, 2007, HEPATOLOGY, V46, P1081, DOI 10.1002/hep.21763; Schattenberg JM, 2006, HEPATOLOGY, V43, P163, DOI 10.1002/hep.20999; Seki E, 2012, GASTROENTEROLOGY, V143, P307, DOI 10.1053/j.gastro.2012.06.004; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; Stremmel W, 2001, LIPIDS, V36, P981, DOI 10.1007/s11745-001-0809-2; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; STREMMEL W, 1987, J BIOL CHEM, V262, P6284; Sun Q, 2012, EXP BIOL MED, V237, P178, DOI 10.1258/ebm.2011.011261; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123	35	27	28	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3159	3170		10.1096/fj.14-249763	http://dx.doi.org/10.1096/fj.14-249763			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24719358				2022-12-28	WOS:000337949400036
J	Nichols, JL; Gladwell, W; Verhein, KC; Cho, HY; Wess, J; Suzuki, O; Wiltshire, T; Kleeberger, SR				Nichols, Jennifer L.; Gladwell, Wesley; Verhein, Kirsten C.; Cho, Hye-Youn; Wess, Jurgen; Suzuki, Oscar; Wiltshire, Tim; Kleeberger, Steven R.			Genome-wide association mapping of acute lung injury in neonatal inbred mice	FASEB JOURNAL			English	Article						bronchopulmonary dysplasia; inflammation; quantitative trait locus; cholinergic receptor; muscarinic 2; cardiac	NONNEURONAL CHOLINERGIC SYSTEM; BRONCHOPULMONARY DYSPLASIA; RECEPTOR STIMULATION; IN-VITRO; INFLAMMATION; DISEASE; STRAIN; DELETION; AIRWAYS; SUSCEPTIBILITY	Reactive oxygen species (ROS) contribute to the pathogenesis of many acute and chronic pulmonary disorders, including bronchopulmonary dysplasia (BPD), a respiratory condition that affects preterm infants. However, the mechanisms of susceptibility to oxidant stress in neonatal lungs are not completely understood. We evaluated the role of genetic background in response to oxidant stress in the neonatal lung by exposing mice from 36 inbred strains to hyperoxia (95% O-2) for 72 h after birth. Hyperoxia-induced lung injury was evaluated by using bronchoalveolar lavage fluid (BALF) analysis and pathology. Statistically significant interstrain variation was found for BALF inflammatory cells and protein (heritability estimates range: 33.6-55.7%). Genome-wide association mapping using injury phenotypes identified quantitative trait loci (QTLs) on chromosomes 1, 2, 4, 6, and 7. Comparative mapping of the chromosome 6 QTLs identified Chrm2 (cholinergic receptor, muscarinic 2, cardiac) as a candidate susceptibility gene, and mouse strains with a nonsynonymous coding single-nucleotide polymorphism (SNP) in Chrm2 that causes an amino acid substitution (P265L) had significantly reduced hyperoxia-induced inflammation compared to strains without the SNP. Further, hyperoxia-induced lung injury was significantly reduced in neonatal mice with targeted deletion of Chrm2, relative to wild-type controls. This study has important implications for understanding the mechanisms of oxidative lung injury in neonates.	[Nichols, Jennifer L.; Gladwell, Wesley; Verhein, Kirsten C.; Cho, Hye-Youn; Kleeberger, Steven R.] Natl Inst Environm Hlth Sci, US Natl Inst Hlth, Lab Resp Biol, Res Triangle Pk, NC USA; [Nichols, Jennifer L.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Curriculum Toxicol, Chapel Hill, NC USA; [Suzuki, Oscar] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA; [Wess, Jurgen] Natl Inst Diabet & Digest & Kidney Dis, Bioorgan Chem Lab, US Natl Inst Hlth, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Kleeberger, SR (corresponding author), NIEHS, 111 T W Alexander Dr,Bldg 101,MD 201, Res Triangle Pk, NC 27709 USA.	kleeber1@niehs.nih.gov	Kleeberger, Steven R/F-1807-2019	Kleeberger, Steven R/0000-0003-2948-8452	NIEHS, National Institutes of Health, U.S. Department of Health and Human Services; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK075020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES100513, T32ES007126] Funding Source: NIH RePORTER	NIEHS, National Institutes of Health, U.S. Department of Health and Human Services; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank L. M. DeGraff [National Institute of Environmental Health Sciences (NIEHS)], L. Perrow (NIEHS), and H. Price (Alion Science and Technology, McLean, VA, USA) for assistance with animal breeding and exposures; the NIEHS Histology Core for tissue processing and staining; and Drs. D. Cook and M. Fessler for critical review of the manuscript. This work was supported by a Director's Challenge Program and the Intramural Research Program, NIEHS, National Institutes of Health, U.S. Department of Health and Human Services. Author contributions: J.L.N., W.G., H.-Y.C., and S.R.K. conceived and designed the experiments; J.L.N., W.G., and K.C.V. performed the experiments; J.L.N., O.S., J.W., T.W., and K.C.V. analyzed the data; J.L.N. and S.R.K. wrote the paper; J.W. contributed animals.	Baleato RM, 2008, AM J PATHOL, V173, P927, DOI 10.2353/ajpath.2008.071149; Baraldi E, 2009, EARLY HUM DEV, V85, pS1, DOI 10.1016/j.earlhumdev.2009.08.002; Bhandari A, 2009, PEDIATRICS, V123, P1562, DOI 10.1542/peds.2008-1962; Bhandari V, 2006, SEMIN PERINATOL, V30, P185, DOI 10.1053/j.semperi.2006.05.005; Bokodi G, 2007, PEDIATR PULM, V42, P952, DOI 10.1002/ppul.20689; Bose CL, 2008, ARCH DIS CHILD-FETAL, V93, P1455, DOI 10.1136/adc.2007.121327; Cho HY, 2012, ANTIOXID REDOX SIGN, V17, P1066, DOI 10.1089/ars.2011.4288; Cho HY, 2010, AM J RESP CRIT CARE, V182, P170, DOI 10.1164/rccm.200907-1047OC; Coalson JJ, 1999, AM J RESP CRIT CARE, V160, P1333, DOI 10.1164/ajrccm.160.4.9810071; Collard KJ, 2004, ARCH DIS CHILD-FETAL, V89, pF412, DOI 10.1136/adc.2002.016717; Dauger S, 2003, CHEST, V123, P530, DOI 10.1378/chest.123.2.530; Deng H, 2000, AM J RESP CRIT CARE, V162, P2316, DOI 10.1164/ajrccm.162.6.9911020; Flint J, 2012, NAT REV GENET, V13, P807, DOI 10.1038/nrg3335; Gatti DM, 2009, BIOINFORMATICS, V25, P482, DOI 10.1093/bioinformatics/btn648; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P1692, DOI 10.1073/pnas.96.4.1692; Gu F, 2009, BRIT J DERMATOL, V161, P209, DOI 10.1111/j.1365-2133.2009.09219.x; Gwilt CR, 2007, PHARMACOL THERAPEUT, V115, P208, DOI 10.1016/j.pharmthera.2007.05.007; Hallman Mikko, 2003, Semin Neonatol, V8, P19, DOI 10.1016/S1084-2756(02)00196-3; Hillman NH, 2011, AM J PHYSIOL-LUNG C, V300, pL232, DOI 10.1152/ajplung.00294.2010; HUDAK BB, 1993, PHARMACOGENETICS, V3, P135, DOI 10.1097/00008571-199306000-00003; Jobe AH, 2011, CURR OPIN PEDIATR, V23, P167, DOI 10.1097/MOP.0b013e3283423e6b; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Joss-Moore LA, 2011, MOL GENET METAB, V104, P61, DOI 10.1016/j.ymgme.2011.07.018; Kang HM, 2008, GENETICS, V178, P1709, DOI 10.1534/genetics.107.080101; Lavoie PM, 2008, PEDIATRICS, V122, P479, DOI 10.1542/peds.2007-2313; Leontyev D, 2012, BLOOD, V119, P5261, DOI 10.1182/blood-2012-03-415695; Lightfoot JT, 2004, PHYSIOL GENOMICS, V19, P270, DOI 10.1152/physiolgenomics.00125.2004; Londhe VA, 2011, PEDIATR RES, V69, P371, DOI 10.1203/PDR.0b013e318211c917; Ma JX, 2002, BIOCHEM PHARMACOL, V64, P1447, DOI 10.1016/S0006-2952(02)01393-X; McClurg P, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-61; Mosha KS, 2008, J CELL PHYSIOL, V215, P771, DOI 10.1002/jcp.21356; Newton-Cheh C, 2005, MUTAT RES-FUND MOL M, V573, P54, DOI 10.1016/j.mrfmmm.2005.01.006; NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357, DOI 10.1056/NEJM196702162760701; Oenema TA, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-130; Ohashi J, 2001, J HUM GENET, V46, P478, DOI 10.1007/s100380170048; Parker RA, 1996, SEMIN PERINATOL, V20, P206, DOI 10.1016/S0146-0005(96)80049-8; Parton LA, 2006, FRONT BIOSCI-LANDMRK, V11, P1854, DOI 10.2741/1928; Pletcher MT, 2004, PLOS BIOL, V2, P2159, DOI 10.1371/journal.pbio.0020393; Profita M, 2011, LIFE SCI, V89, P36, DOI 10.1016/j.lfs.2011.04.025; Prows DR, 2007, PHYSIOL GENOMICS, V30, P262, DOI 10.1152/physiolgenomics.00232.2006; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Sato E, 1998, AM J PHYSIOL-LUNG C, V274, pL970, DOI 10.1152/ajplung.1998.274.6.L970; Saugstad Ola Didrik, 2003, Semin Neonatol, V8, P39, DOI 10.1016/S1084-2756(02)00194-X; Stoilov I, 2006, ARCH BIOCHEM BIOPHYS, V456, P30, DOI 10.1016/j.abb.2006.09.029; Struckmann N, 2003, MOL PHARMACOL, V64, P1444, DOI 10.1124/mol.64.6.1444; Thompson A, 2008, BIOMARK INSIGHTS, V3, P361; Tiozzo C, 2012, ENDOCR-RELAT CANCER, V19, P111, DOI 10.1530/ERC-10-0327; Trakhtenberg EF, 2011, SCIENCE, V334, P47, DOI 10.1126/science.1213099; van den Buuse M, 2007, PSYCHOPHARMACOLOGY, V195, P273, DOI 10.1007/s00213-007-0888-7; Vancza EM, 2009, TOXICOL SCI, V107, P535, DOI 10.1093/toxsci/kfn253; Verhein KC, 2009, CURR ALLERGY ASTHM R, V9, P484, DOI 10.1007/s11882-009-0071-9; Wallace JM, 2009, J BONE MINER RES, V24, P1002, DOI [10.1359/jbmr.081259, 10.1359/JBMR.081259]; Warner BB, 1998, AM J PHYSIOL-LUNG C, V275, pL110, DOI 10.1152/ajplung.1998.275.1.L110; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wray JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007421; Xu J, 2014, AGING CELL, V13, P19, DOI 10.1111/acel.12145	56	17	17	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2538	2550		10.1096/fj.13-247221	http://dx.doi.org/10.1096/fj.13-247221			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24571919	Green Published			2022-12-28	WOS:000339883600014
J	Ghosh, AK; Sardar, AH; Mandal, A; Saini, S; Abhishek, K; Kumar, A; Purkait, B; Singh, R; Das, S; Mukhopadhyay, R; Roy, S; Das, P				Ghosh, Ayan K.; Sardar, Abul H.; Mandal, Abhishek; Saini, Savita; Abhishek, Kumar; Kumar, Ashish; Purkait, Bidyut; Singh, Ruby; Das, Sushmita; Mukhopadhyay, Rupkatha; Roy, Syamal; Das, Pradeep			Metabolic reconfiguration of the central glucose metabolism: a crucial strategy of Leishmania donovani for its survival during oxidative stress	FASEB JOURNAL			English	Article						metabolic flux; NADPH; PPP	PENTOSE-PHOSPHATE PATHWAY; AMPHOTERICIN-B RESISTANCE; TRYPANOSOMA-BRUCEI; GENE-EXPRESSION; TRIOSEPHOSPHATE ISOMERASE; PYRIDINE-NUCLEOTIDES; PARASITIC PROTOZOA; GLUTATHIONE LEVELS; CELL-DEATH; REDOX	Understanding the mechanism that allows the intracellular protozoan parasite Leishmania donovani (Ld) to respond to reactive oxygen species (ROS) is of increasing therapeutic importance because of the continuing resistance toward antileishmanial drugs and for determining the illusive survival strategy of these parasites. A shift in primary carbon metabolism is the fastest response to oxidative stress. A (CO2)-C-14 evolution study, expression of glucose transporters together with consumption assays, indicated a shift in metabolic flux of the parasites from glycolysis toward pentose phosphate pathway (PPP) when exposed to different oxidants in vitro/ex vivo. Changes in gene expression, protein levels, and enzyme activities all pointed to a metabolic reconfiguration of the central glucose metabolism in response to oxidants. Generation of glucose-6-phosphate dehydrogenase (G6PDH) (similar to 5-fold) and transaldolase (TAL) (similar to 4.2-fold) overexpressing Ld cells reaffirmed that lethal doses of ROS were counterbalanced by effective manipulation of NADPH:NADP(+) ratio and stringent maintenance of reduced thiol content. The extent of protein carbonylation and accumulation of lipid peroxidized products were also found to be less in overexpressed cell lines. Interestingly, the LD50 of sodium antimony gluconate (SAG), amphotericin-B (AmB), and miltefosine were significantly high toward overexpressing parasites. Consequently, this study illustrates that Ld strategizes a metabolic reconfiguration for replenishment of NADPH pool to encounter oxidative challenges.	[Ghosh, Ayan K.; Sardar, Abul H.; Mandal, Abhishek; Abhishek, Kumar; Kumar, Ashish; Purkait, Bidyut; Singh, Ruby; Das, Pradeep] Indian Council Med Res, Rajendra Mem Res Inst Med Sci, Div Mol Biol, Patna, Bihar, India; [Saini, Savita] Natl Inst Pharmaceut Educ & Res, Dept Biotechnol, Vaishali, Bihar, India; [Das, Sushmita] All India Inst Med Sci, Dept Microbiol, Patna, Bihar, India; [Mukhopadhyay, Rupkatha; Roy, Syamal] CSIR, Indian Inst Chem Biol, Div Infect Dis & Immunol, Kolkata, India	Indian Council of Medical Research (ICMR); ICMR - Rajendra Memorial Research Institute of Medical Sciences (RMRI); National Institute of Pharmaceutical Education & Research (NIPER); All India Institute of Medical Sciences (AIIMS) Patna; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Das, P (corresponding author), Rajendra Mem Res Inst Med Sci, Patna 800007, Bihar, India.	drpradeep.das@gmail.com	GHOSH, AYAN/GYV-5906-2022; Mandal, Abhishek/Y-5333-2019; Mukhopadhyay, Rupkatha/AAY-4304-2020	Mukhopadhyay, Rupkatha/0000-0002-4120-2966	Indian Council of Medical Research, Ministry of Health and Family Welfare, Government of India	Indian Council of Medical Research, Ministry of Health and Family Welfare, Government of India	The authors thank Prof. Siddhartha Roy (Director, CSIR-IICB) for allowing A.K.G. to perform the PPP flux measurement experiments in the laboratory of Dr. Syamal Roy. They also thank Prof. M. P. Barrett (University of Glasgow, United Kingdom), Prof. Paul A. M. Michaels (de Duve Institute, Brussels, Belgium), Dr. Scott M. Landfear (Oregon Health and Science University, Portland, USA), and Prof. Greg Matlashewski (McGill University, Montreal, QC, Canada) for their kind gift of Tb6PGDH and LmTKL antibodies, LmTPI antibody, LeGT2 (P1L) antibody and pLP-NEO2 vector, respectively. They also thank Dr. Vahab Ali (RMRIMS, Patna) for his kind gift of LdTryR antibody. The authors are extremely grateful to Mr. Amar Kant Singh and Mr. Subhas Kumar for providing technical assistance throughout this study. This work was funded by the Indian Council of Medical Research, Ministry of Health and Family Welfare, Government of India.	Akerman SE, 2005, J BIOL CHEM, V280, P564, DOI 10.1074/jbc.M406367200; Allmann S, 2013, J BIOL CHEM, V288, P18494, DOI 10.1074/jbc.M113.462978; Barrett MP, 1997, PARASITOL TODAY, V13, P11, DOI 10.1016/S0169-4758(96)10075-2; Berg M, 2013, MOL MICROBIOL, V90, P428, DOI 10.1111/mmi.12374; Bhandari V, 2014, ANTIMICROB AGENTS CH, V58, P2580, DOI 10.1128/AAC.01574-13; Birkholtz LM, 2011, BIOCHEM J, V438, P229, DOI 10.1042/BJ20110362; BOVERIS A, 1980, BIOCHEM J, V188, P643, DOI 10.1042/bj1880643; Chawla B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026660; Deschacht M, 2012, PARASITOLOGY, V139, P1429, DOI 10.1017/S003118201200073X; Diaz-Albiter H, 2012, J BIOL CHEM, V287, P23995, DOI 10.1074/jbc.M112.376095; Dolai S, 2009, EUKARYOT CELL, V8, P1721, DOI 10.1128/EC.00198-09; EGGLESTON LV, 1974, BIOCHEM J, V138, P425, DOI 10.1042/bj1380425; Garza-Ramos G, 1998, EUR J BIOCHEM, V253, P684, DOI 10.1046/j.1432-1327.1998.2530684.x; Gazanion E, 2011, PARASITOL INT, V60, P19, DOI 10.1016/j.parint.2010.09.005; GHOSH DK, 1971, EXP PARASITOL, V29, P103, DOI 10.1016/0014-4894(71)90017-8; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Grant CM., 2008, J BIOL-LONDON, V7, P1, DOI DOI 10.1186/jbiol63; He SS, 2012, ANTIMICROB AGENTS CH, V56, P2428, DOI 10.1128/AAC.06386-11; Huynh TT, 2003, J BIOL CHEM, V278, P39794, DOI 10.1074/jbc.M306306200; Jeelani G, 2013, BIOCHIMIE, V95, P309, DOI 10.1016/j.biochi.2012.09.034; Kapoor P, 2000, TROP MED INT HEALTH, V5, P438, DOI 10.1046/j.1365-3156.2000.00565.x; KATZ J, 1960, J BIOL CHEM, V235, P2165; Kim DH, 2013, MOL MICROBIOL, V88, P841, DOI 10.1111/mmi.12243; Krauth-Siegel RL, 2008, BBA-GEN SUBJECTS, V1780, P1236, DOI 10.1016/j.bbagen.2008.03.006; Kruger A, 2011, ANTIOXID REDOX SIGN, V15, P311, DOI 10.1089/ars.2010.3797; Kumar A, 2014, ANTIMICROB AGENTS CH, V58, P6172, DOI 10.1128/AAC.02834-14; Maugeri DA, 2003, MOL BIOCHEM PARASIT, V130, P117, DOI 10.1016/S0166-6851(03)00173-7; Mishra J, 2013, EXP PARASITOL, V135, P397, DOI 10.1016/j.exppara.2013.08.004; Moreira W, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.83; Mukherjee A, 2013, MOL MICROBIOL, V88, P189, DOI 10.1111/mmi.12178; Muller S, 2004, MOL MICROBIOL, V53, P1291, DOI 10.1111/j.1365-2958.2004.04257.x; NYAME K, 1994, MOL BIOCHEM PARASIT, V67, P269, DOI 10.1016/0166-6851(94)00139-1; OGBUNUDE POJ, 1983, MOL BIOCHEM PARASIT, V9, P279, DOI 10.1016/0166-6851(83)90084-1; OstoaSaloma P, 1997, EUR J BIOCHEM, V244, P700, DOI 10.1111/j.1432-1033.1997.00700.x; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; Papadopoulou B, 2003, ASM NEWS, V69, P282; PASTAKIA KB, 1987, MOL BIOCHEM PARASIT, V26, P175, DOI 10.1016/0166-6851(87)90141-1; Perl A, 2011, TRENDS MOL MED, V17, P395, DOI 10.1016/j.molmed.2011.01.014; Pocsi I, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-182; Pollak N, 2007, J BIOL CHEM, V282, P33562, DOI 10.1074/jbc.M704442200; Pollak N, 2007, BIOCHEM J, V402, P205, DOI 10.1042/BJ20061638; Portal P, 2008, MOL BIOCHEM PARASIT, V160, P42, DOI 10.1016/j.molbiopara.2008.03.007; Purkait B, 2012, ANTIMICROB AGENTS CH, V56, P1031, DOI 10.1128/AAC.00030-11; Puskas F, 2000, FASEB J, V14, P1352, DOI 10.1096/fj.14.10.1352; Qian YM, 2008, BIOCHEM J, V415, P123, DOI 10.1042/BJ20080722; Ralser M., 2007, J BIOL, V6, P10, DOI [DOI 10.1186/jbiol61, 10.1186/jbiol61]; Ralser M, 2009, NAT BIOTECHNOL, V27, P604, DOI 10.1038/nbt0709-604; Rodriguez-Contreras D, 2007, MOL BIOCHEM PARASIT, V153, P9, DOI 10.1016/j.molbiopara.2007.01.010; Rosenzweig D, 2008, PROTEOMICS, V8, P1843, DOI 10.1002/pmic.200701043; Rosenzweig D, 2008, FASEB J, V22, P590, DOI 10.1096/fj.07-9254com; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Sandoval JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025573; Sardar AH, 2013, EXP PARASITOL, V135, P715, DOI 10.1016/j.exppara.2013.10.011; Sardar AH, 2013, J PROTEOMICS, V81, P185, DOI 10.1016/j.jprot.2013.01.011; Shi WX, 1999, J BIOL CHEM, V274, P21114, DOI 10.1074/jbc.274.30.21114; Singh R, 2007, J BACTERIOL, V189, P6665, DOI 10.1128/JB.00555-07; Sudhandiran G, 2003, J BIOL CHEM, V278, P25120, DOI 10.1074/jbc.M301975200; Tian WN, 1998, J BIOL CHEM, V273, P10609, DOI 10.1074/jbc.273.17.10609; Tovar J, 1998, P NATL ACAD SCI USA, V95, P5311, DOI 10.1073/pnas.95.9.5311; Van Assche T, 2011, FREE RADICAL BIO MED, V51, P337, DOI 10.1016/j.freeradbiomed.2011.05.011; WILLIAMS JF, 1987, INT J BIOCHEM, V19, P749, DOI 10.1016/0020-711X(87)90239-4; WILSON ME, 1994, INFECT IMMUN, V62, P5133, DOI 10.1128/IAI.62.11.5133-5141.1994; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672; ZHANG WW, 1995, NUCLEIC ACIDS RES, V23, P4073, DOI 10.1093/nar/23.20.4073; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701	65	30	31	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2081	2098		10.1096/fj.14-258624	http://dx.doi.org/10.1096/fj.14-258624			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25690656				2022-12-28	WOS:000354114600040
J	Tsiavaliaris, G; Itel, F; Hedfalk, K; Al-Samir, S; Meier, W; Gros, G; Endeward, V				Tsiavaliaris, Georgios; Itel, Fabian; Hedfalk, Kristina; Al-Samir, Samer; Meier, Wolfgang; Gros, Gerolf; Endeward, Volker			Low CO2 permeability of cholesterol-containing liposomes detected by stopped-flow fluorescence spectroscopy	FASEB JOURNAL			English	Article						phospholipid vesicles; carbonic anhydrase; aquaporin 1; BCECF; carboxyfluorescein	CARBON-DIOXIDE PERMEABILITY; CELL-MEMBRANES; EPITHELIAL MEMBRANE; AQUAPORIN-1; DIFFUSION; WATER; TRANSPORT; CHANNEL; BLOOD; PROTEIN	Here we ask the following: 1) what is the CO2 permeability (Pco(2)) of unilamellar liposomes composed of l--phosphatidylcholine (PC)/l--phosphatidylserine (PS) = 4:1 and containing cholesterol (Chol) at levels often occurring in biologic membranes (50 mol%), and 2) does incorporation of the CO2 channel aquaporin (AQP)1 cause a significant increase in membrane Pco(2)? Presently, a drastic discrepancy exists between the answers to these two questions obtained from mass-spectrometric O-18-exchange measurements (Chol reduces Pco(2) 100-fold, AQP1 increases Pco(2) 10-fold) vs. from stopped-flow approaches observing CO2 uptake (no effects of either Chol or AQP1). A novel theory of CO2 uptake by vesicles predicts that in a stopped-flow apparatus this fast process can only be resolved temporally and interpreted quantitatively, if 1) a very low CO2 partial pressure (pCO(2)) is used (e.g., 18 mmHg), and 2) intravesicular carbonic anhydrase (CA) activity is precisely known. With these prerequisites fulfilled, we find by stopped-flow that 1) Chol-containing vesicles possess a Pco(2) = 0.01cm/s, and Chol-free vesicles exhibit approximate to 1 cm/s, and 2) the Pco(2) of 0.01 cm/s is increased 10-fold by AQP1. Both results agree with previous mass-spectrometric results and thus resolve the apparent discrepancy between the two techniques. We confirm that biologic membranes have an intrinsically low Pco(2) that can be raised when functionally necessary by incorporating protein-gas channels such as AQP1.Tsiavaliaris, G., Itel, F., Hedfalk, K., Al-Samir, S., Meier, W., Gros, G., Endeward, V. Low CO2 permeability of cholesterol-containing liposomes detected by stopped-flow fluorescence spectroscopy.	[Tsiavaliaris, Georgios] Hannover Med Sch, Inst Mol & Zellphysiol, D-30625 Hannover, Germany; [Itel, Fabian; Meier, Wolfgang] Univ Basel, Dept Chem, Basel, Switzerland; [Hedfalk, Kristina] Univ Gothenburg, Dept Chem & Mol Biol, Gothenburg, Sweden; [Al-Samir, Samer; Gros, Gerolf; Endeward, Volker] Hannover Med Sch, Inst Mol & Zellphysiol, AG Vegetat Physiol, D-30625 Hannover, Germany	Hannover Medical School; University of Basel; University of Gothenburg; Hannover Medical School	Gros, G (corresponding author), Hannover Med Sch, Inst Mol & Zellphysiol, AG Vegetat Physiol 4220,Carl Neuberg Str 1, D-30625 Hannover, Germany.	gros.gerolf@mh-hannover.de	Itel, Fabian/AAU-2465-2021	Itel, Fabian/0000-0002-4161-2383	Deutsche Forschungsgemeinschaft [EN-908/2-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors thank the Deutsche Forschungsgemeinschaft for their support of this project (Grant EN-908/2-1). They also acknowledge the Swiss National Science Foundation and the National Center of Competence in Molecular Systems Engineering (NCCR-MSE). F.I. thanks the Zentrum fur Mikroskopie (ZMB), University of Basel, for access to the electron microscopy facility.	Bienert GP, 2014, BBA-GEN SUBJECTS, V1840, P1596, DOI 10.1016/j.bbagen.2013.09.017; Borgnia MJ, 1999, J MOL BIOL, V291, P1169, DOI 10.1006/jmbi.1999.3032; Borisova MM, 2012, BBA-BIOENERGETICS, V1817, P1314, DOI 10.1016/j.bbabio.2012.02.036; Boron WF, 2011, CHEMPHYSCHEM, V12, P1017, DOI 10.1002/cphc.201100034; CORVERA E, 1992, BIOCHIM BIOPHYS ACTA, V1107, P261, DOI 10.1016/0005-2736(92)90413-G; Crank J., 1964, MATH DIFFUSION, V1956th; Duttingdorf HDMZ, 1999, ANAL BIOCHEM, V269, P45, DOI 10.1006/abio.1998.3075; Echevarria M, 2007, J BIOL CHEM, V282, P30207, DOI 10.1074/jbc.M702639200; Endeward V, 2006, FASEB J, V20, P1974, DOI 10.1096/fj.04-3300com; Endeward V, 2006, TRANSFUS CLIN BIOL, V13, P123, DOI 10.1016/j.tracli.2006.02.007; Endeward V, 2005, J PHYSIOL-LONDON, V567, P253, DOI 10.1113/jphysiol.2005.085761; Endeward V, 2008, FASEB J, V22, P64, DOI 10.1096/fj.07-9097com; Endeward V, 2014, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00382; Endeward V, 2012, J APPL PHYSIOL, V112, P1466, DOI 10.1152/japplphysiol.00835.2011; Endeward V, 2009, J PHYSIOL-LONDON, V587, P1153, DOI 10.1113/jphysiol.2008.165027; Erbakan M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086830; Forster R. E., 1969, NASA, P275; Forster RE, 1998, P NATL ACAD SCI USA, V95, P15815, DOI 10.1073/pnas.95.26.15815; Geyer RR, 2013, J MEMBRANE BIOL, V246, P915, DOI 10.1007/s00232-013-9593-0; GROS G, 1976, J GEN PHYSIOL, V67, P773, DOI 10.1085/jgp.67.6.773; Gros G., 1976, THESIS U REGENSBURG; GUTKNECHT J, 1977, J GEN PHYSIOL, V69, P779; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; Hasselblatt P, 2000, PFLUG ARCH EUR J PHY, V441, P118, DOI 10.1007/s004240000377; Herrera M, 2007, AM J PHYSIOL-RENAL, V292, pF1443, DOI 10.1152/ajprenal.00353.2006; Herrera M, 2006, HYPERTENSION, V48, P157, DOI 10.1161/01.HYP.0000223652.29338.77; Herrera M, 2011, PFLUG ARCH EUR J PHY, V462, P623, DOI 10.1007/s00424-011-1002-x; Hill WG, 2000, J BIOL CHEM, V275, P30176, DOI 10.1074/jbc.M003494200; HOLLAND RAB, 1985, RESP PHYSIOL, V59, P71, DOI 10.1016/0034-5687(85)90020-9; Hub JS, 2010, J AM CHEM SOC, V132, P13251, DOI 10.1021/ja102133x; Hulikova A, 2014, FASEB J, V28, P2762, DOI 10.1096/fj.13-241752; Itel F, 2012, FASEB J, V26, P5182, DOI 10.1096/fj.12-209916; KORN ED, 1969, ANNU REV BIOCHEM, V38, P263, DOI 10.1146/annurev.bi.38.070169.001403; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; Missner A, 2008, J BIOL CHEM, V283, P25340, DOI 10.1074/jbc.M800096200; Musa-Aziz R, 2009, P NATL ACAD SCI USA, V106, P5406, DOI 10.1073/pnas.0813231106; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Nyblom M, 2007, PROTEIN EXPRES PURIF, V56, P110, DOI 10.1016/j.pep.2007.07.007; OBRIEN JS, 1967, J THEOR BIOL, V15, P307, DOI 10.1016/0022-5193(67)90140-3; Prasad GVR, 1998, J BIOL CHEM, V273, P33123, DOI 10.1074/jbc.273.50.33123; Rigaud JL, 2003, METHOD ENZYMOL, V372, P65; Segel IH, 1976, BIOCH CALCULATIONS; Siggaard-Andersen O, 1974, ACID BASE STATUS BLO; Swenson ER, 2002, CLIN SCI, V103, P567, DOI 10.1042/cs1030567; Tanford C., 1961, PHYS CHEM MACROMOLEC; Trandum C, 2000, BIOPHYS J, V78, P2486, DOI 10.1016/S0006-3495(00)76793-2; Uehlein N, 2003, NATURE, V425, P734, DOI 10.1038/nature02027; Uehlein N, 2012, SCI REP-UK, V2, DOI 10.1038/srep00538; WAISBREN SJ, 1994, NATURE, V368, P332, DOI 10.1038/368332a0; Wunder MA, 1998, ISOT ENVIRON HEALT S, V34, P303, DOI 10.1080/10256019808234064; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686	51	16	16	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1780	1793		10.1096/fj.14-263988	http://dx.doi.org/10.1096/fj.14-263988			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25609423				2022-12-28	WOS:000354114600015
J	Wunsch, D; Hahlbrock, A; Heiselmayer, C; Backer, S; Heun, P; Goesswein, D; Stocker, W; Schirmeister, T; Schneider, G; Kramer, OH; Knauer, SK; Stauber, RH				Wuensch, Desiree; Hahlbrock, Angelina; Heiselmayer, Christina; Baecker, Sandra; Heun, Patrick; Goesswein, Dorothee; Stoecker, Walter; Schirmeister, Tanja; Schneider, Guenter; Kraemer, Oliver H.; Knauer, Shirley K.; Stauber, Roland H.			Fly versus man: evolutionary impairment of nucleolar targeting affects the degradome of Drosophila's Taspase1	FASEB JOURNAL			English	Article						cancer; development; leukemia; protease; threonine aspartase	SERINE-PROTEASE GRANZYME; NUCLEOCYTOPLASMIC TRANSPORT; TRANSLOCATION BIOSENSORS; NUCLEAR EXPORT; INHIBITOR; PATIENT; ISOFORM; SYSTEM; CANCER; ROLES	Human Taspase1 is essential for development and cancer by processing critical regulators, such as the mixed-lineage leukemia protein. Likewise, its ortholog, trithorax, is cleaved by Drosophila Taspase1 (dTaspase1), implementing a functional coevolution. To uncover novel mechanism regulating protease function, we performed a functional analysis of dTaspase1 and its comparison to the human ortholog. dTaspase1 contains an essential nucleophile threonine(195), catalyzing cis cleavage into its alpha- and beta-subunits. A cell-based assay combined with alanine scanning mutagenesis demonstrated that the target cleavage motif for dTaspase1 (Q(3)[F/I/L/M]D-2(1) down arrow G(1)'X-2'X-3') differs significantly from the human ortholog (Q(3)[F,I,L,V]D-2(1) down arrow G(1)'X-2'D-3'D-4'), predicting an enlarged degradome containing 70 substrates for Drosophila. In contrast to human Taspase1, dTaspase1 shows no discrete localization to the nucleus/nucleolus due to the lack of the importin-/nucleophosmin1 interaction domain (NoLS) conserved in all vertebrates. Consequently, dTaspase1 interacts with neither the Drosophila nucleoplasmin-like protein nor human nucleophosmin1. The impact of localization on the protease's degradome was confirmed by demonstrating that dTaspase1 did not efficiently process nuclear substrates, such as upstream stimulatory factor 2. However, genetic introduction of the NoLS into dTaspase1 restored its nucleolar localization, nucleophosmin1 interaction, and efficient cleavage of nuclear substrates. We report that evolutionary functional divergence separating vertebrates from invertebrates can be achieved for proteases by a transport/localization-regulated mechanism.	[Wuensch, Desiree; Hahlbrock, Angelina; Goesswein, Dorothee; Stauber, Roland H.] Univ Med Ctr Mainz, Ear Nose & Throat Dept, Mol & Cellular Oncol, Mainz, Germany; [Heiselmayer, Christina; Baecker, Sandra; Knauer, Shirley K.] Univ Duisburg Essen, Mainz Sci Screening Ctr UG & Co KG, Ctr Med Biotechnol, Inst Mol Biol, Essen, Germany; [Heun, Patrick] Max Planck Inst Immunobiol & Epigenet, Freiburg, Germany; [Stoecker, Walter] Johannes Gutenberg Univ Mainz, Inst Zool, Cell & Matrix Biol, D-55122 Mainz, Germany; [Schirmeister, Tanja] Johannes Gutenberg Univ Mainz, Inst Pharm & Biochem, D-55122 Mainz, Germany; [Schneider, Guenter] Tech Univ Munich, Med Klin 2, D-80290 Munich, Germany; [Kraemer, Oliver H.] Univ Med Ctr, Dept Toxicol, Mainz, Germany	Johannes Gutenberg University of Mainz; University of Duisburg Essen; Max Planck Society; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Johannes Gutenberg University of Mainz	Wunsch, D (corresponding author), Univ Med Sch Mainz, ENT, Mol & Cellular Oncol, Langenbeckstr 1, D-55101 Mainz, Germany.	wuensch@uni-mainz.de; rstauber@uni-mainz.de	Schirmeister, Tanja/N-6886-2016; Knauer, Shirley K/E-7931-2012; Stöcker, Walter/AAB-9704-2019; Gül, Désirée/AAB-5965-2022; Krämer, Oliver H/L-9266-2015; Heun, Patrick/AAH-7390-2020	Schirmeister, Tanja/0000-0002-4587-5076; Knauer, Shirley K/0000-0003-4321-0924; Stöcker, Walter/0000-0002-1515-6994; Krämer, Oliver H/0000-0003-3973-045X; Heun, Patrick/0000-0001-8400-1892; Stauber, Roland/0000-0002-1341-4523; Guel, Desiree/0000-0002-2446-5756	Fritz Thyssen Stiftung; MAIFOR Mainz Support Program; Zeiss Foundation; Interdisziplinarer Arbeitskreis (IAK) ChemBioMed	Fritz Thyssen Stiftung; MAIFOR Mainz Support Program; Zeiss Foundation; Interdisziplinarer Arbeitskreis (IAK) ChemBioMed	The authors thank Sandra Friedl for excellent technical assistance. This work was supported by Fritz Thyssen Stiftung, MAIFOR Mainz Support Program, Zeiss Foundation, and Interdisziplinarer Arbeitskreis (IAK) ChemBioMed. The authors declare no conflicts of interest.	Beck P, 2012, BIOL CHEM, V393, P1101, DOI 10.1515/hsz-2012-0212; Belanger KD, 2009, J CELL SCI, V122, P3931, DOI 10.1242/jcs.056887; Bier C, 2012, FASEB J, V26, P3421, DOI 10.1096/fj.11-202432; Bier C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034142; Bier C, 2011, TRAFFIC, V12, P703, DOI 10.1111/j.1600-0854.2011.01191.x; Bier C, 2011, J BIOL CHEM, V286, P3007, DOI 10.1074/jbc.M110.161646; Blink EJ, 2005, J CELL BIOCHEM, V95, P598, DOI 10.1002/jcb.20415; Buller AR, 2013, P NATL ACAD SCI USA, V110, pE653, DOI 10.1073/pnas.1221050110; Capotosti F, 2007, MOL CELL BIOL, V27, P7063, DOI 10.1128/MCB.00769-07; Chen DY, 2012, CANCER RES, V72, P736, DOI 10.1158/0008-5472.CAN-11-2584; Chen DY, 2010, CANCER RES, V70, P5358, DOI 10.1158/0008-5472.CAN-10-0027; Clausen T, 2011, NAT REV MOL CELL BIO, V12, P152, DOI 10.1038/nrm3065; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Docter D, 2014, NAT PROTOC, V9, P2030, DOI 10.1038/nprot.2014.139; Drag M, 2010, NAT REV DRUG DISCOV, V9, P690, DOI 10.1038/nrd3053; Eissenberg JC, 2011, TRAFFIC, V12, P1821, DOI 10.1111/j.1600-0854.2011.01285.x; Fetz V, 2009, SENSORS-BASEL, V9, P5423, DOI 10.3390/s90705423; Fetz V, 2009, INT J CANCER, V124, P2033, DOI 10.1002/ijc.24182; Fortelny N, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001869; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Habtemichael N, 2010, MOL CELL NEUROSCI, V45, P297, DOI 10.1016/j.mcn.2010.07.003; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Jans DA, 1998, J CELL SCI, V111, P2645; Jun L, 2001, CURR BIOL, V11, P1381, DOI 10.1016/S0960-9822(01)00419-5; Khan JA, 2005, STRUCTURE, V13, P1443, DOI 10.1016/j.str.2005.07.006; Knauer SK, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.25; Knauer SK, 2007, CELL CYCLE, V6, P1502; Knauer SK, 2007, FASEB J, V21, P207, DOI 10.1096/fj.06-5741com; Knauer SK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018253; Knauer SK, 2005, ANAL CHEM, V77, P4815, DOI 10.1021/ac050413o; Knauer SK, 2005, TRAFFIC, V6, P594, DOI 10.1111/j.1600-0854.2005.00298.x; Koppen M, 2009, MOL BIOL CELL, V20, P4216, DOI 10.1091/mbc.E09-03-0218; Kosugi S, 2009, J BIOL CHEM, V284, P478, DOI 10.1074/jbc.M807017200; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; Lighthouse DV, 2008, DEV BIOL, V317, P59, DOI 10.1016/j.ydbio.2008.02.009; Marchant DJ, 2014, NAT MED, V20, P497, DOI 10.1038/nm.3508; Masson O, 2010, BIOCHIMIE, V92, P1635, DOI 10.1016/j.biochi.2010.05.009; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Overall CM, 2006, CANCER METAST REV, V25, P69, DOI 10.1007/s10555-006-7890-0; Padeken J, 2013, MOL CELL, V50, P236, DOI 10.1016/j.molcel.2013.03.002; Pandey UB, 2011, PHARMACOL REV, V63, P411, DOI 10.1124/pr.110.003293; Rawlings ND, 2012, NUCLEIC ACIDS RES, V40, pD343, DOI [10.1093/nar/gkr987, 10.1093/nar/gkt953]; Rosorius O, 1999, BIOTECHNIQUES, V27, P350, DOI 10.2144/99272rr02; Schlingemann J, 2005, LAB INVEST, V85, P1024, DOI 10.1038/labinvest.3700293; Smith M, 2004, J BIOL CHEM, V279, P43805, DOI 10.1074/jbc.M404942200; Stauber RH, 2012, CANCER RES, V72, P2912, DOI 10.1158/0008-5472.CAN-12-0150; Tenzer S, 2013, NAT NANOTECHNOL, V8, P772, DOI 10.1038/nnano.2013.181; Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092; Ugalde AP, 2010, METHODS MOL BIOL, V622, P3, DOI 10.1007/978-1-60327-299-5_1; van Deursen D, 2009, BBA-MOL CELL BIOL L, V1791, P229, DOI 10.1016/j.bbalip.2009.01.017; Wunsch D, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.22; Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200; Yun CW, 2008, J CELL BIOL, V183, P589, DOI 10.1083/jcb.200807185; Zhou HQ, 2006, MOL CELL BIOL, V26, P2728, DOI 10.1128/MCB.26.7.2728-2735.2006	54	8	8	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1973	1985		10.1096/fj.14-262451	http://dx.doi.org/10.1096/fj.14-262451			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25634959				2022-12-28	WOS:000354114600031
J	Ortiz, A; Lee, YC; Yu, GY; Liu, HC; Lin, SC; Bilen, MA; Cho, HJ; Yu-Lee, LY; Lin, SH				Ortiz, Angelica; Lee, Yu-Chen; Yu, Guoyu; Liu, Hsuan-Chen; Lin, Song-Chang; Bilen, Melmet Asim; Cho, Hyojin; Yu-Lee, Li-Yuan; Lin, Sue-Hwa			Angiomotin is a novel component of cadherin-11/beta-catenin/p120 complex and is critical for cadherin-11-mediated cell migration	FASEB JOURNAL			English	Article						adhesion; E-cadherin; OB-cadherin; prostate cancer	UVOMORULIN-CATENIN COMPLEX; PROSTATE-CANCER CELLS; E-CADHERIN; BETA-CATENIN; N-CADHERIN; ALPHA-CATENIN; ENDOTHELIAL-CELLS; VE-CADHERIN; IN-VIVO; PROTEIN	Loss of E-cadherin and up-regulation of mesenchymal cadherins, a hallmark of the epithelial-mesenchymal transition, contributes to migration and dissemination of cancer cells. Expression of human cadherin-11 (Cad11), also known as osteoblast cadherin, in prostate cancer increases the migration of prostate cancer cells. How Cad11 mediates cell migration is unknown. Using the human Cad11 cytoplasmic domain in pulldown assays, we identified human angiomotin (Amot), known to be involved in cell polarity, migration, and Hippo pathway, as a component of the Cad11 protein complex. Deletion analysis showed that the last C-terminal 10 amino acids in Cad11 cytoplasmic domain are required for Amot binding. Further, Cad11 preferentially interacts with Amot-p80 than Amot-p130 isoform and binds directly to the middle domain of Amot-p80. Cad11-Amot interaction affects Cad11-mediated cell migration, but not homophilic adhesion, as deletion of Amot binding motif of Cad11 (Cad11-Delta Amot) did not abolish Cad11-mediated cell-cell adhesion of mouse L cells, but significantly reduced Cad11-mediated cell migration of human C4-2B4 and PC3-mm2 prostate cancer cells and human HEK293T cells. Together, our studies identified Amot-p80 as a novel component of the Cad11 complex and demonstrated that Amot-p80 is critical for Cad11-mediated cell migration.	[Ortiz, Angelica; Lee, Yu-Chen; Yu, Guoyu; Liu, Hsuan-Chen; Lin, Song-Chang; Bilen, Melmet Asim; Cho, Hyojin; Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Lin, Sue-Hwa] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Yu-Lee, Li-Yuan] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Unit 89, 1515 Holcombe Blvd, Houston, TX 77030 USA.	slin@mdanderson.org		Liu, Hsuan-Chen/0000-0001-7857-0204	U.S. National Institutes of Health [CA174798, P50 CA140388, CA16672]; Prostate Cancer Foundation; U.S. Department of Defense [PC093132, PC080847]; Cancer Prevention and Research Institute of Texas [CPRIT RP110327]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA174798, P50CA140388] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate Cancer Foundation; U.S. Department of Defense(United States Department of Defense); Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. C. Wells (Indiana University) for providing the p80-Amot and Amot deletion mutant plasmids and Dr. J. L. Kissil (Wistar Institute) for providing p130-Amot, p80-CC, and p80 Delta CC 3xFlag plasmids for our studies. They also thank Dr. H. Zeng for generating PC3-mm2 Amot-p80 and C4-2B4 shAmot cell lines. This work was supported by the U.S. National Institutes of Health (Grants CA174798, P50 CA140388, and CA16672); the Prostate Cancer Foundation; U.S. Department of Defense (Grants PC093132 and PC080847); and the Cancer Prevention and Research Institute of Texas (Grant CPRIT RP110327).	Adler JJ, 2013, J BIOL CHEM, V288, P15181, DOI 10.1074/jbc.M112.446534; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; Bratt A, 2002, GENE, V298, P69, DOI 10.1016/S0378-1119(02)00928-9; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077; Chumanov RS, 2011, PROTEIN EXPRES PURIF, V76, P145, DOI 10.1016/j.pep.2010.11.010; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Ernkvist M, 2006, FEBS J, V273, P2000, DOI 10.1111/j.1742-4658.2006.05216.x; Ernkvist M, 2008, BBA-MOL CELL RES, V1783, P429, DOI 10.1016/j.bbamcr.2007.11.018; Ernkvist M, 2009, BLOOD, V113, P244, DOI 10.1182/blood-2008-04-153874; EWING CM, 1995, CANCER RES, V55, P4813; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Huang CF, 2010, CANCER RES, V70, P4580, DOI 10.1158/0008-5472.CAN-09-3016; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Jiang WG, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-16; Kiener HP, 2006, MOL BIOL CELL, V17, P2366, DOI 10.1091/mbc.E05-08-0745; Lee YC, 2013, MOL CANCER RES, V11, P1401, DOI 10.1158/1541-7786.MCR-13-0108; Lee YC, 2010, J PATHOL, V221, P68, DOI 10.1002/path.2687; Leung CY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3251; Levchenko T, 2004, ONCOGENE, V23, P1469, DOI 10.1038/sj.onc.1207264; Lira CBB, 2008, PROTEIN EXPRES PURIF, V61, P220, DOI 10.1016/j.pep.2008.06.007; Murali AK, 2012, J UROLOGY, V188, P632, DOI 10.1016/j.juro.2012.03.114; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Oas RG, 2013, MOL BIOL CELL, V24, P704, DOI 10.1091/mbc.E12-06-0471; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Pece S, 2002, NAT CELL BIOL, V4, pE72, DOI 10.1038/ncb0402-e72; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Ranahan WP, 2011, CANCER RES, V71, P2203, DOI 10.1158/0008-5472.CAN-10-1995; Sheth P, 2007, BIOCHEM J, V402, P291, DOI 10.1042/BJ20060665; Siu R, 2007, MOL CELL BIOL, V27, P208, DOI 10.1128/MCB.00707-06; Sugihara-Mizuno Y, 2007, GENES CELLS, V12, P473, DOI 10.1111/j.1365-2443.2007.01066.x; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang CJ, 2012, BIOCHEM J, V444, P279, DOI 10.1042/BJ20111983; Wei CJ, 2005, J BIOL CHEM, V280, P19925, DOI 10.1074/jbc.M412921200; Wells CD, 2006, CELL, V125, P535, DOI 10.1016/j.cell.2006.02.045; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Winklmeier A, 2009, CANCER SCI, V100, P261, DOI 10.1111/j.1349-7006.2008.01048.x; Wu CS, 2011, J BIOL CHEM, V286, P23511, DOI 10.1074/jbc.M111.245209; Xu G, 2002, J BIOL CHEM, V277, P49989, DOI 10.1074/jbc.M206454200; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111	49	24	25	3	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1080	1091		10.1096/fj.14-261594	http://dx.doi.org/10.1096/fj.14-261594			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25466890	Green Published			2022-12-28	WOS:000350633000031
J	Chondrogianni, N; Georgila, K; Kourtis, N; Tavernarakis, N; Gonos, ES				Chondrogianni, Niki; Georgila, Konstantina; Kourtis, Nikos; Tavernarakis, Nektarios; Gonos, Efstathios S.			20S proteasome activation promotes life span extension and resistance to proteotoxicity in Caenorhabditis elegans	FASEB JOURNAL			English	Article						aging; daf-16; longevity; proteostasis	GENE-EXPRESSION ANALYSIS; OXIDATIVE-STRESS; TEMPORAL REQUIREMENTS; HUMAN FIBROBLASTS; UBIQUITIN LIGASE; FACTOR SKN-1; LONGEVITY; PROTEINS; SYSTEM; DAF-16	Protein homeostasis (proteostasis) is one of the nodal points that need to be preserved to retain physiologic cellular/organismal balance. The ubiquitinproteasome system(UPS) is responsible for the removal of both normal and damaged proteins, with the proteasome being the downstream effector. The proteasome is the major cellular protease with progressive impairment of function during aging and senescence. Despite the documented age-retarding properties of proteasome activation in various cellular models, simultaneous enhancement of the 20S core proteasome content, assembly, and function have never been reported in any multicellular organism. Consequently, the possible effects of the core proteasome modulation on organismal life span are elusive. In this study, we have achieved activation of the 20S proteasome at organismal level. We demonstrate enhancement of proteasome levels, assembly, and activity in the nematode Caenorhabditis elegans, resulting in life span extension and increased resistance to stress. We also provide evidence that the observed life span extension is dependent on the transcriptional activity of Dauer formation abnormal/ Forkhead box class O (DAF-16/FOXO), skinhead-1 (SKN1), and heat shock factor-1 (HSF-1) factors through regulation of downstream longevity genes. We further show that the reported beneficial effects are not ubiquitous but they are dependent on the genetic context. Finally, we provide evidence that proteasome core activation might be a potential strategy to minimize protein homeostasis deficiencies underlying aggregation-related diseases, such as Alzheimer's disease (AD) or Huntington's disease (HD). In summary, this is the first report demonstrating that 20S core proteasome up-regulation in terms of both content and activity is feasible in a multicellular eukaryotic organism and that in turn this modulation promotes extension of organismal health span and life span.-Chondrogianni, N., Georgila, K., Kourtis, N., Tavernarakis, N., Gonos, E. S. 20S proteasome activation promotes life span extension and resistance to proteotoxicity in Caenorhabditis elegans.	[Chondrogianni, Niki; Georgila, Konstantina; Gonos, Efstathios S.] Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Athens 11635, Greece; [Kourtis, Nikos; Tavernarakis, Nektarios] Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion, Greece	National Hellenic Research Foundation; Foundation for Research & Technology - Hellas (FORTH)	Gonos, ES (corresponding author), Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, 48 Vassileos Constantinou Ave, Athens 11635, Greece.	nikichon@eie.gr; sgonos@eie.gr	Tavernarakis, Nektarios/B-9684-2013	Tavernarakis, Nektarios/0000-0002-5253-1466	U.S.National Institutes of Health National Center for Research Resources; European Union ("Proteomage") [LSHM-CT-518230]; Thales "GenAge," cofinanced by the European Union (European Social Fund) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) [ThetaALambdaHSigma APi:10479/3.7.12 MIS380228]; IKYDA fellowship; John S.Latsis Public Benefit Foundation	U.S.National Institutes of Health National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); European Union ("Proteomage"); Thales "GenAge," cofinanced by the European Union (European Social Fund) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF); IKYDA fellowship; John S.Latsis Public Benefit Foundation	The authors are grateful to Prof.Osiewacz and Dr.Zhang for antibodies; to Dr.Ninios, K.Voutetakis, and A.Pasparaki for technical support; and to Drs.Bano and Troulinaki for discussions and reagents.Nematode strains used in this study were provided by the Caenorhabditis Genetics Center, supported by the U.S.National Institutes of Health National Center for Research Resources.This work was funded by a European Union ("Proteomage"; LSHM-CT-518230) grant (to E.S.G.), a Research Funding Program: Thales "GenAge," cofinanced by the European Union (European Social Fund) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) [Theta A Lambda H Sigma A Pi:10479/3.7.12 MIS380228] (to E.S.G.and N.C.), and an IKYDA 2012 fellowship and a Scientific Project funded by John S.Latsis Public Benefit Foundation (to N.C.).	Alam H, 2010, CELL METAB, V12, P30, DOI 10.1016/j.cmet.2010.05.004; Ben-Zvi A, 2009, P NATL ACAD SCI USA, V106, P14914, DOI 10.1073/pnas.0902882106; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Brignull HR, 2006, J NEUROSCI, V26, P7597, DOI 10.1523/JNEUROSCI.0990-06.2006; Carrano AC, 2009, NATURE, V460, P396, DOI 10.1038/nature08130; Chen QH, 2006, FREE RADICAL BIO MED, V40, P120, DOI 10.1016/j.freeradbiomed.2005.08.048; Choe KP, 2009, MOL CELL BIOL, V29, P2704, DOI 10.1128/MCB.01811-08; Chondrogianni N, 2005, J BIOL CHEM, V280, P11840, DOI 10.1074/jbc.M413007200; Chondrogianni N, 2003, J BIOL CHEM, V278, P28026, DOI 10.1074/jbc.M301048200; Chondrogianni N, 2000, EXP GERONTOL, V35, P721, DOI 10.1016/S0531-5565(00)00137-6; Chondrogianni N, 2008, IUBMB LIFE, V60, P651, DOI 10.1002/iub.99; Chondrogianni N, 2008, AGING CELL, V7, P717, DOI 10.1111/j.1474-9726.2008.00425.x; Chondrogianni N, 2014, MOL ASPECTS MED, V35, P1, DOI 10.1016/j.mam.2012.09.001; Coburn Cassandra, 2013, Frontiers in Genetics, V4, P151, DOI 10.3389/fgene.2013.00151; Cohen E, 2010, AGING CELL, V9, P126, DOI 10.1111/j.1474-9726.2009.00541.x; Doonan R, 2008, GENE DEV, V22, P3236, DOI 10.1101/gad.504808; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; Gerstbrein B, 2005, AGING CELL, V4, P127, DOI 10.1111/j.1474-9726.2005.00153.x; Ghazi A, 2007, P NATL ACAD SCI USA, V104, P5947, DOI 10.1073/pnas.0700638104; Grune T, 2003, BIOCHEM BIOPH RES CO, V305, P709, DOI 10.1016/S0006-291X(03)00809-X; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Guisbert E, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003466; Hassan WM, 2009, HUM MOL GENET, V18, P2739, DOI 10.1093/hmg/ddp209; Hines JK, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001309; Hoogewijs D, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-9; Huang QA, 2010, APOPTOSIS, V15, P1292, DOI 10.1007/s10495-010-0466-z; Kahn NW, 2008, BIOCHEM J, V409, P205, DOI 10.1042/BJ20070521; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kirkwood TBL, 2011, CURR BIOL, V21, pR701, DOI 10.1016/j.cub.2011.07.020; Kruegel U, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002253; Kwak MK, 2007, FREE RADICAL BIO MED, V43, P809, DOI 10.1016/j.freeradbiomed.2007.05.029; Layfield R, 2003, AGEING RES REV, V2, P343, DOI 10.1016/S1568-1637(03)00025-4; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Li J, 2008, PLOS BIOL, V6, P1870, DOI 10.1371/journal.pbio.0060233; Li WS, 2007, DEV CELL, V12, P235, DOI 10.1016/j.devcel.2006.12.002; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Link CD, 2003, NEUROBIOL AGING, V24, P397, DOI 10.1016/S0197-4580(02)00224-5; Liu G, 2011, EMBO J, V30, P2990, DOI 10.1038/emboj.2011.195; Liu YZ, 2007, MOL VIS, V13, P31; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Matilainen O, 2013, CELL REP, V3, P1980, DOI 10.1016/j.celrep.2013.05.012; Mehta R, 2009, SCIENCE, V324, P1196, DOI 10.1126/science.1173507; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Myeku N, 2011, METHODS MOL BIOL, V793, P273, DOI 10.1007/978-1-61779-328-8_18; Oliveira RP, 2009, AGING CELL, V8, P524, DOI 10.1111/j.1474-9726.2009.00501.x; Paul S, 2008, BIOESSAYS, V30, P1172, DOI 10.1002/bies.20852; Pickering AM, 2012, PROG MOL BIOL TRANSL, V109, P227, DOI 10.1016/B978-0-12-397863-9.00006-7; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Sanchez-Blanco A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002047; Taylor RC, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004440; Tonoki A, 2009, MOL CELL BIOL, V29, P1095, DOI 10.1128/MCB.01227-08; Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030; Van Raamsdonk JM, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000361; Vijg J, 2008, NATURE, V454, P1065, DOI 10.1038/nature07216; Vilchez D, 2012, NATURE, V489, P263, DOI 10.1038/nature11315; Volovik Y, 2012, AGING CELL, V11, P491, DOI 10.1111/j.1474-9726.2012.00811.x; Weissman AM, 2011, NAT REV MOL CELL BIO, V12, P605, DOI 10.1038/nrm3173; Wilkinson DS, 2012, METHOD CELL BIOL, V107, P353, DOI 10.1016/B978-0-12-394620-1.00012-6; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Wolff S, 2006, CELL, V124, P1039, DOI 10.1016/j.cell.2005.12.042; Wu YJ, 2006, J NEUROSCI, V26, P13102, DOI 10.1523/JNEUROSCI.3448-06.2006; Yasuda K, 1999, J GERONTOL A-BIOL, V54, pB47, DOI 10.1093/gerona/54.2.B47; Yun C, 2008, P NATL ACAD SCI USA, V105, P7094, DOI 10.1073/pnas.0707025105	67	93	96	1	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					611	622		10.1096/fj.14-252189	http://dx.doi.org/10.1096/fj.14-252189			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25395451	Green Published			2022-12-28	WOS:000349370400023
J	Maslova, K; Kyriakakis, E; Pfaff, D; Frachet, A; Frismantiene, A; Bubendorf, L; Ruiz, C; Vlajnic, T; Erne, P; Resink, TJ; Philippova, M				Maslova, Kseniya; Kyriakakis, Emmanouil; Pfaff, Dennis; Frachet, Audrey; Frismantiene, Agne; Bubendorf, Lukas; Ruiz, Christian; Vlajnic, Tatjana; Erne, Paul; Resink, Therese J.; Philippova, Maria			EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by T-cadherin	FASEB JOURNAL			English	Article						malignant and benign prostate epithelial cell lines; gefitinib; NVP-AEW541	GROWTH-FACTOR-RECEPTOR; FACTOR-I RECEPTOR; PHASE-II; ANDROGEN RECEPTOR; BINDING PROTEIN-3; EXPRESSION; CARCINOMA; PROGRESSION; GEFITINIB; PROMOTES	T-cadherin is an atypical glycosylphosphatidylinsoitol- anchored member of the cadherin superfamily of adhesion molecules. We found that T-cadherin overexpression in malignant (DU145) and benign (BPH-1) prostatic epithelial cell lines or silencing in the BPH-1 cell line, respectively, promoted or inhibited migration and spheroid invasion in collagen I gel and Matrigel. T-cadherin-dependent effects were associated with changes in cell phenotype: overexpression caused cell dissemination and loss of polarity evaluated by relative positioning of the Golgi/nuclei in cell groups, whereas silencing caused formation of compact polarized epithelial-like clusters. Epidermal growth factor receptor (EGFR) and IGF factor-1 receptor (IGF-1R) were identified as mediators of T-cadherin effects. These receptors per se had opposing influences on cell phenotype. EGFR activation with EGF or IGF-1R inhibition with NVP-AEW541 promoted dissemination, invasion, and polarity loss. Conversely, inhibition of EGFR with gefitinib or activation of IGF-1R with IGF-1 rescued epithelial morphology and decreased invasion. T-cadherin silencing enhanced both EGFR and IGF-1R phosphorylation, yet converted cells to the morphology typical for activated IGF-1R. T-cadherin effects were sensitive to modulation of EGFR or IGF-1R activity, suggesting direct involvement of both receptors. We conclude that T-cadherin regulates prostate cancer cell behavior by tuning the balance in EGFR/IGF-1R activity and enhancing the impact of IGF-1R.	[Maslova, Kseniya; Kyriakakis, Emmanouil; Pfaff, Dennis; Frachet, Audrey; Frismantiene, Agne; Resink, Therese J.; Philippova, Maria] Univ Basel, Univ Basel Hosp, Dept Biomed, Lab Signal Transduct, CH-4031 Basel, Switzerland; [Bubendorf, Lukas; Ruiz, Christian; Vlajnic, Tatjana] Univ Basel, Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland; [Erne, Paul] Hirslanden Klin St Anna, Luzern, Switzerland	University of Basel; University of Basel	Resink, TJ (corresponding author), Univ Basel, Univ Basel Hosp, Dept Biomed, Lab Signal Transduct, Hebelstr 20, CH-4031 Basel, Switzerland.	therese-j.resink@unibas.ch	Bubendorfl, Lukas/H-5880-2011; Bubendorf, Lukas/G-5299-2015; Kyriakakis, Emmanouil/AAS-5754-2021; Filippova, Maria/GXH-7313-2022	Bubendorf, Lukas/0000-0001-5970-1803; Filippova, Maria/0000-0003-3124-3155; Frismantiene, Agne/0000-0002-2018-2986; Kyriakakis, Emmanouil/0000-0002-6796-0431	Novartis Foundation for Medical-Biological Research; SwissLife Jubilaumsstiftung; Stiftung fur Herz- und Kreislaufkrankheiten	Novartis Foundation for Medical-Biological Research; SwissLife Jubilaumsstiftung; Stiftung fur Herz- und Kreislaufkrankheiten	The authors thank Boris Dasen for performing quantitative RT-PCR experimentation. This work was supported by the Novartis Foundation for Medical-Biological Research, SwissLife Jubilaumsstiftung, and Stiftung fur Herz- und Kreislaufkrankheiten.	Arcaro A, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00030; Bosserhoff AK, 2014, MOL CARCINOGEN, V53, P635, DOI 10.1002/mc.22018; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; Canil CM, 2005, J CLIN ONCOL, V23, P455, DOI 10.1200/JCO.2005.02.129; Chen C, 2005, CANCER, V103, P76, DOI 10.1002/cncr.20727; Chi KN, 2012, CLIN CANCER RES, V18, P3407, DOI 10.1158/1078-0432.CCR-12-0482; Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002-9440(10)65229-7; Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077; Cui YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055069; Dhomen Nathalie S., 2012, Critical Reviews in Oncogenesis, V17, P31; Di Lorenzo G, 2002, CLIN CANCER RES, V8, P3438; Fredette BJ, 1996, DEVELOPMENT, V122, P3163; Garcia J., 2013, ASCO ANN M S, V31; Gennigens C, 2006, CRIT REV ONCOL HEMAT, V58, P124, DOI 10.1016/j.critrevonc.2005.10.003; Harman SM, 2000, J CLIN ENDOCR METAB, V85, P4258, DOI 10.1210/jc.85.11.4258; Hebbard LW, 2008, CANCER RES, V68, P1407, DOI 10.1158/0008-5472.CAN-07-2953; Heidegger I, 2012, ENDOCRINOLOGY, V153, P4633, DOI 10.1210/en.2012-1348; Hellawell GO, 2002, CANCER RES, V62, P2942; Hussain M., 2012, GEN CANC S S5; Jones HE, 2004, ENDOCR-RELAT CANCER, V11, P793, DOI 10.1677/erc.1.00799; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Korcum AF, 2009, UHOD-ULUSLAR HEMATOL, V19, P223; Kuniyasu H, 2000, CLIN CANCER RES, V6, P2295; Kuzmenko YS, 1998, BIOCHEM BIOPH RES CO, V246, P489, DOI 10.1006/bbrc.1998.8645; Kyriakakis E, 2013, CELL SIGNAL, V25, P1044, DOI 10.1016/j.cellsig.2013.02.001; Kyriakakis E, 2012, J INVEST DERMATOL, V132, P2275, DOI 10.1038/jid.2012.131; Leo S, 2011, CHEMOTHERAPY, V57, P115, DOI 10.1159/000323581; Liao YD, 2005, HUM PATHOL, V36, P1186, DOI 10.1016/j.humpath.2005.07.023; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Massoner P, 2011, AM J PATHOL, V179, P2905, DOI 10.1016/j.ajpath.2011.08.026; Ozkan EE, 2011, MOL CELL ENDOCRINOL, V344, P1, DOI 10.1016/j.mce.2011.07.002; Parker-Duffen JL, 2013, J BIOL CHEM, V288, P24886, DOI 10.1074/jbc.M113.454835; Pfaff D, 2010, BRIT J DERMATOL, V163, P353, DOI 10.1111/j.1365-2133.2010.09801.x; Pfaff D, 2011, J PATHOL, V225, P512, DOI 10.1002/path.2900; Philippova M, 2006, ARTERIOSCL THROM VAS, V26, P2222, DOI 10.1161/01.ATV.0000238356.20565.92; Philippova M, 2013, EUR J CANCER, V49, P2048, DOI 10.1016/j.ejca.2012.12.026; Philippova M, 2012, CARDIOVASC RES, V93, P498, DOI 10.1093/cvr/cvs004; Philippova M, 2009, CELL SIGNAL, V21, P1035, DOI 10.1016/j.cellsig.2009.01.035; Plymate SR, 1997, ENDOCRINOLOGY, V138, P1728, DOI 10.1210/en.138.4.1728; RANSCHT B, 1991, DEVELOPMENT, V111, P15; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Riou P, 2006, FASEB J, V20, P2291, DOI 10.1096/fj.06-6085com; Roddam AW, 2008, ANN INTERN MED, V149, P461, DOI 10.7326/0003-4819-149-7-200810070-00006; Rubin MA, 2001, HUM PATHOL, V32, P690, DOI 10.1053/hupa.2001.25902; Salzberg M, 2007, ONKOLOGIE, V30, P355, DOI 10.1159/000102452; Schayek H, 2010, EXP CELL RES, V316, P1479, DOI 10.1016/j.yexcr.2010.03.007; Stavridi F, 2010, CANCER TREAT REV, V36, P122, DOI 10.1016/j.ctrv.2009.06.001; Stemmler MP, 2008, MOL BIOSYST, V4, P835, DOI 10.1039/b719215k; Sutherland BW, 2008, CANCER RES, V68, P3495, DOI 10.1158/0008-5472.CAN-07-6531; Traish AM, 2009, BRIT J CANCER, V101, P1949, DOI 10.1038/sj.bjc.6605376; Wang XD, 2007, DIFFERENTIATION, V75, P219, DOI 10.1111/j.1432-0436.2006.00135.x; Wu JD, 2006, J CELL BIOCHEM, V99, P392, DOI 10.1002/jcb.20929; Zhou Q, 2006, FEBS LETT, V580, P5161, DOI 10.1016/j.febslet.2006.08.068	53	13	13	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					494	507		10.1096/fj.14-249367	http://dx.doi.org/10.1096/fj.14-249367			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25381040				2022-12-28	WOS:000349370400014
J	Babino, D; Perkins, BD; Kindermann, A; Oberhauser, V; von Lintig, J				Babino, Darwin; Perkins, Brian D.; Kindermann, Aljoscha; Oberhauser, Vitus; von Lintig, Johannes			The role of 11-cis-retinyl esters in vertebrate cone vision	FASEB JOURNAL			English	Article						visual cycle; retinosomes	RETINOID VISUAL CYCLE; RETINALDEHYDE-BINDING PROTEIN; LEBER CONGENITAL AMAUROSIS; MONKEY MACACA-FASCICULARIS; DELAYED DARK-ADAPTATION; ALL-TRANS-RETINOIDS; ZEBRAFISH RETINA; ISOMEROHYDROLASE ACTIVITY; FUNDUS-ALBIPUNCTATUS; PIGMENT EPITHELIUM	A cycle of cis-to-trans isomerization of the chromophore is intrinsic to vertebrate vision where rod and cone photoreceptors mediate dim-and bright-light vision, respectively. Daylight illumination can greatly exceed the rate at which the photoproduct can be recycled back to the chromophore by the canonical visual cycle. Thus, an additional supply pathway(s) must exist to sustain cone-dependent vision. Two-photon microscopy revealed that the eyes of the zebrafish (Danio rerio) contain high levels of 11-cis-retinyl esters (11-REs) within the retinal pigment epithelium. HPLC analyses demonstrate that 11-REs are bleached by bright light and regenerated in the dark. Pharmacologic treatment with all-trans-retinylamine (Ret-NH2), a potent and specific inhibitor of the trans-to-cis reisomerization reaction of the canonical visual cycle, impeded the regeneration of 11-REs. Intervention with 11-cis-retinol restored the regeneration of 11-REs in the presence of all-trans-Ret-NH2. We used the XOPS: mCFP transgenic zebrafish line with a functional cone-only retina to directly demonstrate that this 11-RE cycle is critical to maintain vision under bright-light conditions. Thus, our analyses reveal that a dark-generated pool of 11-REs helps to supply photoreceptors with the chromophore under the varying light conditions present in natural environments.	[Babino, Darwin; von Lintig, Johannes] Case Western Reserve Univ, Dept Pharmacol, Case Sch Med, Cleveland, OH 44106 USA; [Perkins, Brian D.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; [Kindermann, Aljoscha; Oberhauser, Vitus] Univ Freiburg, Inst Biol Neurobiol & Tiephysiol 1, D-79106 Freiburg, Germany	Case Western Reserve University; Cleveland Clinic Foundation; University of Freiburg	von Lintig, J (corresponding author), 10900 Euclid Ave, Cleveland, OH 44106 USA.	jxv99@case.edu		Perkins, Brian/0000-0002-9348-6542	NEI NIH HHS [EY019641, EY017037, R01 EY017037, R01 EY019641, T32 EY007157] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007157, R01EY017037, R01EY019641] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; Bilotta J, 2001, DEV DYNAM, V222, P564, DOI 10.1002/dvdy.1188; BLANER WS, 1987, J BIOL CHEM, V262, P53; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029; Clark DT, 1981, VISUAL RESPONSES DEV; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Fadool JM, 2003, DEV BIOL, V258, P277, DOI 10.1016/S0012-1606(03)00125-8; Fleisch VC, 2008, J NEUROSCI, V28, P8208, DOI 10.1523/JNEUROSCI.2367-08.2008; Fleisch VC, 2010, PROG RETIN EYE RES, V29, P476, DOI 10.1016/j.preteyeres.2010.05.001; Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; Isken A, 2008, CELL METAB, V7, P258, DOI 10.1016/j.cmet.2008.01.009; Isken A, 2007, J BIOL CHEM, V282, P1144, DOI 10.1074/jbc.M609109200; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q; Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001; Lyubarsky AL, 2005, BIOCHEMISTRY-US, V44, P9880, DOI 10.1021/bi0505363; MALCHOW RP, 1986, VISION RES, V26, P1655, DOI 10.1016/0042-6989(86)90053-2; Mata JR, 1998, J LIPID RES, V39, P604; Mata NL, 2005, BIOCHEMISTRY-US, V44, P11715, DOI 10.1021/bi050942m; Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1; McBee JK, 2001, J BIOL CHEM, V276, P48483, DOI 10.1074/jbc.M105840200; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; Morris AC, 2005, INVEST OPHTH VIS SCI, V46, P4762, DOI 10.1167/iovs.05-0797; Nakamura M, 2000, INVEST OPHTH VIS SCI, V41, P3925; Palczewska G, 2010, NAT MED, V16, P1444, DOI 10.1038/nm.2260; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; PERRY RJ, 1991, J PHYSIOL-LONDON, V433, P561, DOI 10.1113/jphysiol.1991.sp018444; RANDO RR, 1991, J BIOENERG BIOMEMBR, V23, P133; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Rinner O, 2005, INVEST OPHTH VIS SCI, V46, P137, DOI 10.1167/iovs.04-0682; Rodieck R.W., 1998, 1 STEPS SEEING; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; Saszik S, 1999, VISUAL NEUROSCI, V16, P881, DOI 10.1017/S0952523899165076; Schmitt EA, 1999, J COMP NEUROL, V404, P515; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; Schonthaler HB, 2005, DEV BIOL, V284, P421, DOI 10.1016/j.ydbio.2005.06.001; Schonthaler HB, 2008, DEVELOPMENT, V135, P387, DOI 10.1242/dev.006098; Schonthaler HB, 2007, EUR J NEUROSCI, V26, P1940, DOI 10.1111/j.1460-9568.2007.05801.x; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Suzuki SC, 2013, P NATL ACAD SCI USA, V110, P15109, DOI 10.1073/pnas.1303551110; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; von Lintig J, 2012, J BIOL CHEM, V287, P1627, DOI 10.1074/jbc.R111.303990; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; Wenzel A, 2005, J BIOL CHEM, V280, P29874, DOI 10.1074/jbc.M503603200; Wenzel A, 2007, INVEST OPHTH VIS SCI, V48, P534, DOI 10.1167/iovs.06-0652; Westerfield M, 1994, ZEBRAFISH BOOK GUIDE; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707	54	15	15	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					216	226		10.1096/fj.14-261693	http://dx.doi.org/10.1096/fj.14-261693			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25326538	Green Published			2022-12-28	WOS:000347378600021
J	Diensthuber, RP; Tominaga, M; Preller, M; Hartmann, FK; Orii, H; Chizhov, I; Oiwa, K; Tsiavaliaris, G				Diensthuber, Ralph P.; Tominaga, Motoki; Preller, Matthias; Hartmann, Falk K.; Orii, Hidefumi; Chizhov, Igor; Oiwa, Kazuhiro; Tsiavaliaris, Georgios			Kinetic mechanism of Nicotiana tabacum myosin-11 defines a new type of a processive motor	FASEB JOURNAL			English	Article						plant; processivity; homology modeling; molecular mechanics	MAXIMUM ATPASE ACTIVITY; SKELETAL-MUSCLE MYOSIN; F-ACTIN ORGANIZATION; CULTURED BY-2 CELLS; CLASS XI MYOSINS; PLANT-CELLS; ENDOPLASMIC-RETICULUM; SURFACE LOOPS; GENE FAMILY; ADENOSINE-TRIPHOSPHATASE	The 175-kDa myosin-11 from Nicotiana tabacum (Nt(175kDa)myosin-11) is exceptional in its mechanical activity as it is the fastest known processive actin-based motor, moving 10 times faster than the structurally related class 5 myosins. Although this ability might be essential for long-range organelle transport within larger plant cells, the kinetic features underlying the fast processive movement of Nt(175kDa)myosin-11 still remain unexplored. To address this, we generated a single-headed motor domain construct and carried out a detailed kinetic analysis. The data demonstrate that Nt(175kDa)myosin-11 is a highduty ratio motor, which remains associated with actin most of its enzymatic cycle. However, different from other processive myosins that establish a high duty ratio on the basis of a rate-limiting ADP-release step, Nt(175kDa)myosin-11 achieves a high duty ratio by a prolonged duration of the ATP-induced isomerization of the actin-bound states and ADP release kinetics, both of which in terms of the corresponding time constants approach the total ATPase cycle time. Molecular modeling predicts that variations in the charge distribution of the actin binding interface might contribute to the thermodynamic fine-tuning of the kinetics of this myosin. Our study unravels a new type of a high duty ratio motor and provides important insights into the molecular mechanism of processive movement of higher plant myosins.	[Diensthuber, Ralph P.; Preller, Matthias; Hartmann, Falk K.; Chizhov, Igor; Tsiavaliaris, Georgios] Hannover Med Sch, Inst Biophys Chem, D-30625 Hannover, Germany; [Tominaga, Motoki] RIKEN Ctr Adv Photon, Live Cell Mol Imaging Res Team, Wako, Saitama, Japan; [Tominaga, Motoki] Sci & Technol Agcy, PRESTO, Saitama, Japan; [Preller, Matthias] German Electron Synchrotron DESY, Ctr Struct Syst Biol, Hamburg, Germany; [Orii, Hidefumi; Oiwa, Kazuhiro] Univ Hyogo, Grad Sch Life Sci, Kobe, Hyogo 6500044, Japan; [Oiwa, Kazuhiro] Natl Inst Informat & Communicat Technol NICT, Adv ICT Res Inst, Kobe, Hyogo, Japan	Hannover Medical School; RIKEN; Japan Science & Technology Agency (JST); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Hyogo; National Institute of Information & Communications Technology (NICT) - Japan	Tsiavaliaris, G (corresponding author), Hannover Med Sch, Carl Neuberg Str 1, D-30625 Hannover, Germany.	tsiavaliaris.georgios@mh-hannover.de	Oiwa, Kazuhiro/D-7721-2011; Preller, Matthias/P-1176-2016	Oiwa, Kazuhiro/0000-0002-1281-113X; Preller, Matthias/0000-0002-7784-4012				Amrute-Nayak M, 2014, P NATL ACAD SCI USA, V111, P2536, DOI 10.1073/pnas.1316390111; Amrute-Nayak M, 2010, ANGEW CHEM INT EDIT, V49, P312, DOI 10.1002/anie.200905200; Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BAGSHAW CR, 1977, BIOCHEM SOC T, V5, P1272, DOI 10.1042/bst0051272; Behrmann E, 2012, CELL, V150, P327, DOI 10.1016/j.cell.2012.05.037; Bezanilla M, 2003, J MOL EVOL, V57, P229, DOI 10.1007/s00239-003-2469-7; Bloemink MJ, 2011, SEMIN CELL DEV BIOL, V22, P961, DOI 10.1016/j.semcdb.2011.09.015; Chizhov I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064797; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; deSa MM, 1996, MOL BIOL EVOL, V13, P1198, DOI 10.1093/oxfordjournals.molbev.a025685; Durrwang U, 2006, J CELL SCI, V119, P550, DOI 10.1242/jcs.02774; Esseling-Ozdoba A, 2008, J MICROSC-OXFORD, V231, P274, DOI 10.1111/j.1365-2818.2008.02033.x; Fujita-Becker S, 2005, J BIOL CHEM, V280, P6064, DOI 10.1074/jbc.M412473200; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; Goodson HV, 1999, J MOL BIOL, V287, P173, DOI 10.1006/jmbi.1999.2565; Hachikubo Y, 2007, PLANT CELL PHYSIOL, V48, P886, DOI 10.1093/pcp/pcm054; HAMPP R, 1982, PLANT PHYSIOL, V69, P448, DOI 10.1104/pp.69.2.448; Haraguchi T, 2014, J BIOL CHEM, V289, P12343, DOI 10.1074/jbc.M113.521716; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; Hodges AR, 2007, J BIOL CHEM, V282, P27192, DOI 10.1074/jbc.M703968200; Hoffmann A, 2004, PROTOPLASMA, V224, P201, DOI 10.1007/s00709-004-0068-0; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Ito K, 2003, BIOCHEM BIOPH RES CO, V312, P958, DOI 10.1016/j.bbrc.2003.10.202; Ito K, 2007, J BIOL CHEM, V282, P19534, DOI 10.1074/jbc.M611802200; Ito K, 2009, P NATL ACAD SCI USA, V106, P21585, DOI 10.1073/pnas.0910787106; Jedd G, 2002, PLANT CELL PHYSIOL, V43, P384, DOI 10.1093/pcp/pcf045; Jiang SY, 2007, DEV BIOL, V304, P579, DOI 10.1016/j.ydbio.2007.01.008; Joel PB, 2003, BIOCHEMISTRY-US, V42, P9160, DOI 10.1021/bi034415j; Joel PB, 2001, J BIOL CHEM, V276, P2998, DOI 10.1074/jbc.M006930200; Johnson KA, 2009, ANAL BIOCHEM, V387, P20, DOI 10.1016/j.ab.2008.12.024; KACHAR B, 1988, J CELL BIOL, V106, P1545, DOI 10.1083/jcb.106.5.1545; KEYS AJ, 1968, BIOCHEM J, V108, P1; Kliche W, 2001, EMBO J, V20, P40, DOI 10.1093/emboj/20.1.40; Knetsch MLW, 2002, J MUSCLE RES CELL M, V23, P605, DOI 10.1023/A:1024498805771; Lu HL, 2006, J BIOL CHEM, V281, P31987, DOI 10.1074/jbc.M605181200; Mauch S, 2011, IEEE ACM T COMPUT BI, V8, P27, DOI 10.1109/TCBB.2009.47; MCLEAN BG, 1990, CELL MOTIL CYTOSKEL, V17, P276; Meagher RB, 1999, PLANT CELL, V11, P995, DOI 10.1105/tpc.11.6.995; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; MILLAR NC, 1983, FEBS LETT, V160, P141, DOI 10.1016/0014-5793(83)80954-5; Muller M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070636; Murphy CT, 1999, BIOCHEMISTRY-US, V38, P3785, DOI 10.1021/bi9826815; Natesan SKA, 2009, MOL PLANT, V2, P1262, DOI 10.1093/mp/ssp078; Nyitrai M, 2003, BIOCHEM J, V370, P839, DOI 10.1042/BJ20021519; Onishi H, 2006, P NATL ACAD SCI USA, V103, P6136, DOI 10.1073/pnas.0601595103; Peremyslov V, 2011, PLANT PHYSIOL, V155, P1191, DOI 10.1104/pp.110.170720; Peremyslov VV, 2010, PLANT CELL, V22, P1883, DOI 10.1105/tpc.110.076315; Polak B., 1969, REV FRANCAISE INFORM, V16, P35; Ponomarev MA, 2000, BIOCHEMISTRY-US, V39, P4527, DOI 10.1021/bi992420a; Prokhnevsky AI, 2008, P NATL ACAD SCI USA, V105, P19744, DOI 10.1073/pnas.0810730105; Reubold TF, 2003, NAT STRUCT BIOL, V10, P826, DOI 10.1038/nsb987; ROBERTS JKM, 1985, ARCH BIOCHEM BIOPHYS, V240, P712, DOI 10.1016/0003-9861(85)90080-3; ROESKE CA, 1989, PLANT PHYSIOL, V90, P330, DOI 10.1104/pp.90.1.330; Rosenfeld SS, 2005, J BIOL CHEM, V280, P6072, DOI 10.1074/jbc.M412717200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANTARIU.KA, 1965, BIOCHIM BIOPHYS ACTA, V102, P39, DOI 10.1016/0926-6585(65)90201-3; Sasaki N, 1999, J BIOL CHEM, V274, P37840, DOI 10.1074/jbc.274.53.37840; Schindler TD, 2014, NAT NANOTECHNOL, V9, P33, DOI [10.1038/nnano.2013.229, 10.1038/NNANO.2013.229]; Shimmen T, 2004, CURR OPIN CELL BIOL, V16, P68, DOI 10.1016/j.ceb.2003.11.009; Sparkes I, 2011, MOL PLANT, V4, P805, DOI 10.1093/mp/ssr063; Swenson AM, 2014, J BIOL CHEM, V289, P23977, DOI 10.1074/jbc.M114.562231; Taft MH, 2008, J BIOL CHEM, V283, P26902, DOI 10.1074/jbc.M802957200; Tanaka H, 1998, BIOPHYS J, V75, P1886, DOI 10.1016/S0006-3495(98)77629-5; THANGAVELU M, 1993, MOL GEN GENET, V240, P290, DOI 10.1007/BF00277069; Tominaga M, 2003, EMBO J, V22, P1263, DOI 10.1093/emboj/cdg130; Tominaga M, 2013, DEV CELL, V27, P345, DOI 10.1016/j.devcel.2013.10.005; Tominaga M, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00211; Tominaga M, 2012, J BIOL CHEM, V287, P30711, DOI 10.1074/jbc.M112.346668; Trivedi DV, 2013, BIOCHEMISTRY-US, V52, P4710, DOI 10.1021/bi4004364; Ueda H, 2010, P NATL ACAD SCI USA, V107, P6894, DOI 10.1073/pnas.0911482107; Van Dijk J, 1999, BIOCHEMISTRY-US, V38, P15078, DOI 10.1021/bi991595h; Van Dijk J, 1999, EUR J BIOCHEM, V260, P672, DOI 10.1046/j.1432-1327.1999.00172.x; Varkuti BH, 2012, NAT STRUCT MOL BIOL, V19, P299, DOI 10.1038/nsmb.2216; Verchot-Lubicz J, 2010, PROTOPLASMA, V240, P99, DOI 10.1007/s00709-009-0088-x; Vick JK, 2012, J INTEGR PLANT BIOL, V54, P868, DOI 10.1111/j.1744-7909.2012.01180.x; Weiss S, 2000, J MUSCLE RES CELL M, V21, P423, DOI 10.1023/A:1005690106951; Woodhouse FG, 2013, P NATL ACAD SCI USA, V110, P14132, DOI 10.1073/pnas.1302736110; Yang Y, 2006, P NATL ACAD SCI USA, V103, P5746, DOI 10.1073/pnas.0509935103; Yang Y, 2005, J BIOL CHEM, V280, P32061, DOI 10.1074/jbc.M506765200; YAZAKI Y, 1988, PLANT CELL PHYSIOL, V29, P919; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u; Yokota E, 2009, J EXP BOT, V60, P197, DOI 10.1093/jxb/ern280; Yokota E, 2011, PLANT PHYSIOL, V156, P129, DOI 10.1104/pp.111.175018	89	9	9	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					81	94		10.1096/fj.14-254763	http://dx.doi.org/10.1096/fj.14-254763			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25326536				2022-12-28	WOS:000347378600009
J	Westermeier, F; Salomon, C; Farias, M; Arroyo, P; Fuenzalida, B; Saez, T; Salsoso, R; Sanhueza, C; Guzman-Gutierrez, E; Pardo, F; Leiva, A; Sobrevia, L				Westermeier, Francisco; Salomon, Carlos; Farias, Marcelo; Arroyo, Pablo; Fuenzalida, Barbara; Saez, Tamara; Salsoso, Rocio; Sanhueza, Carlos; Guzman-Gutierrez, Enrique; Pardo, Fabian; Leiva, Andrea; Sobrevia, Luis			Insulin requires normal expression and signaling of insulin receptor A to reverse gestational diabetes-reduced adenosine transport in human umbilical vein endothelium	FASEB JOURNAL			English	Article						endothelial dysfunction; human placenta; nucleoside membrane transport	SLC29A1 PROMOTER ACTIVITY; IGF-I; ISOFORMS; RESISTANCE; MELLITUS; WOMEN	Reduced adenosine uptake via human equilibrative nucleoside transporter 1 (hENT1) in human umbilical vein endothelial cells (HUVECs) from gestational diabetes mellitus (GDM) is reversed by insulin by restoring hENT1 expression. Insulin receptors A (IR-A) and B (IR-B) are expressed in HUVECs, and GDM results in higher IR-A mRNA expression vs. cells from normal pregnancies. We studied whether the reversal of GDM effects on transport by insulin depends on restoration of IR-A expression. We specifically measured hENT1 expression [mRNA, protein abundance, SLC29A1 (for hENT1) promoter activity] and activity (adenosine transport kinetics) and the role of IR-A/IR-B expression and signaling [total and phosphorylated 42 and 44 kDa mitogen-activated protein kinases (p44/42(mapk)) and Akt] in IR-A, IR-B, and IR-A/B knockdown HUVECs from normal (n = 33) or GDM (n = 33) pregnancies. GDM increases IR-A/IR-B mRNA expression (1.8-fold) and p44/ 42(mapk): Akt activity (2.7-fold) ratios. Insulin reversed GDM-reduced hENT1 expression and maximal transport capacity (V-max/K-m), and GDM-increased IR-A/IR-BmRNA expression and p44/42(mapk): Akt activity ratios to values in normal pregnancies. Insulin's effect was abolished in IR-A or IR-A/B knockdown cells. Thus, insulin requires normal IR-A expression and p44/42(mapk)/Akt signaling to restore GDM-reduced hENT1 expression and activity in HUVECs. This could be a protective mechanism for the placental macrovascular endothelial dysfunction seen in GDM.	[Westermeier, Francisco; Salomon, Carlos; Farias, Marcelo; Arroyo, Pablo; Fuenzalida, Barbara; Saez, Tamara; Salsoso, Rocio; Sanhueza, Carlos; Guzman-Gutierrez, Enrique; Pardo, Fabian; Leiva, Andrea; Sobrevia, Luis] Pontificia Univ Catolica Chile, Fac Med, Sch Med, Div Obstet & Gynaecol,CMPL, Santiago 8330024, Chile; [Westermeier, Francisco] Univ Chile, Fac Chem & Pharmaceut Sci, Adv Ctr Chron Dis ACCDIS, Santiago, Chile; [Salomon, Carlos; Sobrevia, Luis] Univ Queensland, Fac Med & Biomed Sci, UQCCR, Herston, Qld, Australia; [Guzman-Gutierrez, Enrique] Univ San Sebastian, Fac Hlth Sci, Concepcion, Chile; [Sobrevia, Luis] Univ Seville, Fac Pharm, Seville, Spain	Pontificia Universidad Catolica de Chile; Universidad de Chile; University of Queensland; Universidad San Sebastian; University of Sevilla	Sobrevia, L (corresponding author), Pontificia Univ Catolica Chile, Fac Med, Sch Med, Div Obstet & Gynaecol,CMPL, POB 114-D, Santiago 8330024, Chile.	sobrevia@med.puc.cl	Fuenzalida, Barbara/GXF-7867-2022; Westermeier, Francisco/AAL-4145-2021; Rodriguez, Maria/AAB-1401-2021; Sobrevia, Luis/H-9608-2016; Farias, Marcelo/R-6063-2019; Salomon, Carlos F/L-2167-2013; Guzman-Gutierrez, Enrique/H-3536-2016	Westermeier, Francisco/0000-0002-4476-4198; Farias, Marcelo/0000-0003-0473-2295; Salomon, Carlos F/0000-0003-4474-0046; salsoso, rocio/0000-0002-8218-1882; Sobrevia, Luis/0000-0001-5802-2243; Guzman-Gutierrez, Enrique/0000-0001-6589-5667; Fuenzalida, Barbara/0000-0002-5128-570X				Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS81, DOI 10.2337/dc14-S081; Antonov J, 2005, LAB INVEST, V85, P1040, DOI 10.1038/labinvest.3700303; Belfiore A, 2009, ENDOCR REV, V30, P586, DOI 10.1210/er.2008-0047; Brierley GV, 2010, ENDOCRINOLOGY, V151, P1418, DOI 10.1210/en.2009-1006; Burnstock G, 2013, PURINERG SIGNAL, V9, P541, DOI 10.1007/s11302-013-9381-4; Colomiere M, 2009, EUR J ENDOCRINOL, V160, P567, DOI 10.1530/EJE-09-0031; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; Farias M, 2006, J CELL PHYSIOL, V208, P451, DOI 10.1002/jcp.20680; Farias M, 2010, CARDIOVASC RES, V86, P45, DOI 10.1093/cvr/cvp410; Frasca Francesco, 2008, Archives of Physiology and Biochemistry, V114, P23, DOI [10.1080/13813450801969715, 10.1080/13813450801969715 ]; Guzman-Gutierrez E, 2014, MICROCIRCULATION, V21, P26, DOI 10.1111/micc.12077; Guzman-Gutierrez E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041705; Hiden U, 2009, CURR VASC PHARMACOL, V7, P460, DOI 10.2174/157016109789043973; Li GL, 2005, ENDOCRINOLOGY, V146, P4690, DOI 10.1210/en.2005-0505; Maguire MH, 1998, J CHROMATOGR B, V707, P33, DOI 10.1016/S0378-4347(97)00581-1; Malaguarnera R, 2012, ENDOCRINOLOGY, V153, P2152, DOI 10.1210/en.2011-1843; Malaguarnera R, 2011, J CLIN ENDOCR METAB, V96, P766, DOI 10.1210/jc.2010-1255; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Metzger BE, 2007, DIABETES CARE, V30, pS251, DOI 10.2337/dc07-s225; Molina-Arcas M, 2009, CURR VASC PHARMACOL, V7, P426, DOI 10.2174/157016109789043892; Osses N, 1995, REPROD FERT DEVELOP, V7, P1499, DOI 10.1071/RD9951499; Phy JL, 2004, J CLIN ENDOCR METAB, V89, P3561, DOI 10.1210/jc.2003-031888; Salomon C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040578; San Martin R, 2006, PLACENTA, V27, P1, DOI 10.1016/j.placenta.2005.01.011; Santoro M, 2013, MOL CELL BIOCHEM, V380, P259, DOI 10.1007/s11010-013-1681-z; Savkur RS, 2001, NAT GENET, V29, P40, DOI 10.1038/ng704; Singh SK, 2011, GROWTH FACTORS, V29, P278, DOI 10.3109/08977194.2011.616200; Sobrevia L, 2011, PLACENTA, V32, pS159, DOI 10.1016/j.placenta.2010.12.011; Sobrevia L., 2009, MEMBRANE TRANSPORTER, P1; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Vasquez G, 2004, J PHYSIOL-LONDON, V560, P111, DOI 10.1113/jphysiol.2004.068288; Wang QW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059845; Wang YH, 2013, J OBSTET GYNAECOL RE, V39, P647, DOI 10.1111/j.1447-0756.2012.02009.x; Westermeier F, 2011, DIABETES, V60, P1677, DOI 10.2337/db11-0155; Young JD, 2013, MOL ASPECTS MED, V34, P529, DOI 10.1016/j.mam.2012.05.007	35	39	40	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					37	49		10.1096/fj.14-254219	http://dx.doi.org/10.1096/fj.14-254219			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25351985				2022-12-28	WOS:000347378600005
J	Di Paolo, A; Racca, C; Calsou, P; Larminat, F				Di Paolo, Aurelie; Racca, Carine; Calsou, Patrick; Larminat, Florence			Loss of BRCA1 impairs centromeric cohesion and triggers chromosomal instability	FASEB JOURNAL			English	Article						mitosis; aneuploidy; chromosome spindle-attachment	AURORA-B KINASE; BREAST-CANCER; DNA METHYLATION; HISTONE H3; SPINDLE; PHOSPHORYLATION; HETEROCHROMATIN; CENTROSOME; CHECKPOINT; CHROMATIN	In contrast to its well-known role in the DNA damage response during interphase, the function of BRCA1 in the maintenance of chromosomal stability during mitosis remains to be defined. In this study, we uncover a novel role of BRCA1 in preserving centromere integrity in mitotic human cells. Using immunofluorescence and chromatin immunoprecipitation approaches, we report BRCA1 association with centromeric chromatin during mitosis. BRCA1 depletion impairs centromeric cohesion, leading to an increase in interkinetochore distance and in unpaired sister-chromatids frequency during prometaphase. Moreover, BRCA1 loss partially decreased accumulation of the Aurora B kinase at the centromere. We found that proper recruitment of the DNMT3b DNA methyltransferase to satellite sequences is BRCA1-dependent during mitosis, suggesting that DNA hypomethylation contributes to Aurora B mislocalization. BRCA1-deficient cells exhibited decreased ability to correct improper Aurora B-dependent chromosome-spindle attachments and to align chromosomes at metaphase. Finally, we show that BRCA1 disruption promotes merotelic kinetochore attachments that represent a major mechanism of aneuploidy in human cells. In summary, we report here a novel function of BRCA1 in maintaining chromosomal stability through its contribution to the mitotic centromere integrity necessary for faithful segregation of sister-chromatids during cell division.	[Di Paolo, Aurelie; Racca, Carine; Calsou, Patrick; Larminat, Florence] Inst Pharmacol & Struct Biol, CNRS, UMR 5089, F-31077 Toulouse, France; [Di Paolo, Aurelie; Racca, Carine; Calsou, Patrick; Larminat, Florence] Univ Toulouse 3, Univ Toulouse, F-31062 Toulouse, France; [Calsou, Patrick] Equipe Labellisee Ligue Natl Canc, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Larminat, F (corresponding author), Inst Pharmacol & Struct Biol, CNRS, UMR 5089, F-31077 Toulouse, France.	larminat@ipbs.fr	calsou, patrick/AAB-5123-2020	Calsou, Patrick/0000-0001-7951-9806	Association pour la Recherche sur le Cancer; University of Toulouse; Ligue Regionale contre le Cancer Region Midi-Pyrenees	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); University of Toulouse; Ligue Regionale contre le Cancer Region Midi-Pyrenees	A.D. was supported by a Ph.D. fellowship from the Association pour la Recherche sur le Cancer. This work is supported by grants to F.L. from the University of Toulouse, the Ligue Regionale contre le Cancer Region Midi-Pyrenees, and the Association pour la Recherche sur le Cancer.	Amor DJ, 2004, TRENDS CELL BIOL, V14, P359, DOI 10.1016/j.tcb.2004.05.009; Bae I, 2005, CELL CYCLE, V4, P1641, DOI 10.4161/cc.4.11.2152; Bakhoum SF, 2009, CURR BIOL, V19, P1937, DOI 10.1016/j.cub.2009.09.055; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chabalier-Taste C, 2008, BBA-MOL CELL RES, V1783, P2223, DOI 10.1016/j.bbamcr.2008.08.006; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Filipponi D, 2013, CANCER CELL, V24, P528, DOI 10.1016/j.ccr.2013.08.022; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Gopalakrishnan S, 2009, HUM MOL GENET, V18, P3178, DOI 10.1093/hmg/ddp256; Hayakawa T, 2003, J CELL SCI, V116, P3327, DOI 10.1242/jcs.00635; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Iacovoni JS, 2010, EMBO J, V29, P1446, DOI 10.1038/emboj.2010.38; Jin SQ, 2009, J BIOL CHEM, V284, P22970, DOI 10.1074/jbc.M109.009134; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; KALLENBERG CGM, 1990, CLIN RHEUMATOL, V9, P136, DOI 10.1007/BF02205562; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kawashima SA, 2010, SCIENCE, V327, P172, DOI 10.1126/science.1180189; Knowlton AL, 2006, CURR BIOL, V16, P1705, DOI 10.1016/j.cub.2006.07.057; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyoshi Yasuo, 2002, Breast J, V8, P77, DOI 10.1046/j.1524-4741.2002.08201.x; Monier K, 2007, J CELL SCI, V120, P101, DOI 10.1242/jcs.03326; Pageau GJ, 2006, J CELL BIOL, V175, P693, DOI 10.1083/jcb.200602055; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Salimian KJ, 2011, CURR BIOL, V21, P1158, DOI 10.1016/j.cub.2011.06.015; Sankaran S, 2005, MOL CELL BIOL, V25, P8656, DOI 10.1128/MCB.25.19.8656-8668.2005; Sgura A, 1997, MUTAT RES-GEN TOX EN, V392, P97, DOI 10.1016/S0165-1218(97)00048-7; Shang Z, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2013.49; Slee RB, 2012, ONCOGENE, V31, P3244, DOI 10.1038/onc.2011.502; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Tirkkonen M, 1997, CANCER RES, V57, P1222; Tomlinson GE, 1998, CANCER RES, V58, P3237; Tu ZG, 2011, DEV CELL, V21, P1077, DOI 10.1016/j.devcel.2011.10.010; Verdaasdonk JS, 2011, NAT REV MOL CELL BIO, V12, P320, DOI 10.1038/nrm3107; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yamagishi Y, 2010, SCIENCE, V330, P239, DOI 10.1126/science.1194498; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125; Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371	50	12	12	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5250	5261		10.1096/fj.14-250266	http://dx.doi.org/10.1096/fj.14-250266			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25205741				2022-12-28	WOS:000345894500020
J	Velenosi, TJ; Feere, DA; Sohi, G; Hardy, DB; Urquhart, BL				Velenosi, Thomas J.; Feere, David A.; Sohi, Gurjeev; Hardy, Daniel B.; Urquhart, Bradley L.			Decreased nuclear receptor activity and epigenetic modulation associates with down-regulation of hepatic drug-metabolizing enzymes in chronic kidney disease	FASEB JOURNAL			English	Article						cytochrome P450; chromatin immunoprecipitation; pharmacokinetics; uremia; histone modification	PREGNANE-X-RECEPTOR; NF-KAPPA-B; ARGININE METHYLTRANSFERASE; CYTOCHROME-P450; PXR; METHYLATION; HORMONE; CAR; HEMODIALYSIS; HNF4-ALPHA	Patients with chronic kidney disease (CKD) require many medications. CYP2C and CYP3A drug-metabolizing enzymes play a critical role in determining the pharmacokinetics of the majority of prescribed medications. These enzymes are transcriptionally regulated by the nuclear receptors pregnane X receptor (PXR) and hepatic nuclear factor 4 alpha (HNF-4 alpha). Expression of CYP2C and CYP3A is decreased in CKD; however, the mechanisms by which this occurs is unknown. We induced CKD in rats by 5/6 nephrectomy and used chromatin immunoprecipitation (ChIP) to determine nuclear receptor-and epigenetic alteration mediated differences in the promoter region of the CYP2C and CYP3A genes. RNA polymerase II and HNF-4 alpha binding was decreased 76 and 57% in the CYP2C11 promotor and 71 and 77% in the CYP3A2 promoter, respectively (P<0.05). ChIP also revealed a 57% decrease in PXR binding to the CYP3A2 promoter in CKD rats (P<0.05). The decrease in PXR and HNF-4 alpha binding was accompanied by diminished histone 4 acetylation in the CYP3A2 promoter (48%) and histone 3 acetylation in the CYP2C11 (77%) and CYP3A2 (77%) promoter loci for nuclear receptor activation (P<0.05). This study suggests that decreased nuclear receptor binding and histone acetylation may contribute to the mechanism of drug-metabolizing enzyme down-regulation and altered pharmacokinetics in CKD.-Velenosi, T. J., Feere, D. A., Sohi, G., Hardy, D. B., Urquhart, B. L. Decreased nuclear receptor activity and epigenetic modulation associates with down-regulation of hepatic drug-metabolizing enzymes in chronic kidney disease.	[Velenosi, Thomas J.; Feere, David A.; Sohi, Gurjeev; Hardy, Daniel B.; Urquhart, Bradley L.] Western Univ, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON, Canada; [Hardy, Daniel B.] Western Univ, Schulich Sch Med & Dent, Dept Obstet & Gynecol, London, ON, Canada; [Urquhart, Bradley L.] Western Univ, Schulich Sch Med & Dent, Dept Med, London, ON, Canada; [Hardy, Daniel B.; Urquhart, Bradley L.] Lawson Hlth Res Inst, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Urquhart, BL (corresponding author), Western Univ, 1151 Richmond St,Med Sci Bldg,Room 216, London, ON N6A 5C1, Canada.	brad.urquhart@schulich.uwo.ca	Urquhart, Brad/E-4221-2015; Hardy, Daniel/GYU-8976-2022	Urquhart, Brad/0000-0001-8324-1472; Hardy, Daniel/0000-0001-5445-273X; Velenosi, Thomas/0000-0001-7016-9037	Natural Sciences and Engineering Research Council of Canada [386569-2010]; Canada Graduate Scholarship Doctoral award; University of Western Ontario Academic Development Fund	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canada Graduate Scholarship Doctoral award; University of Western Ontario Academic Development Fund	This work was supported by the Natural Sciences and Engineering Research Council of Canada Discovery Grants Program (grant 386569-2010), a Canada Graduate Scholarship Doctoral award, and the University of Western Ontario Academic Development Fund. Images used to generate Fig. 7 were from Servier Medical Art (http://www.servier.co.uk/medical-art-gallery). The authors declare no conflicts of interest.	AHMED JH, 1991, BRIT J CLIN PHARMACO, V32, P57, DOI 10.1111/j.1365-2125.1991.tb05613.x; Barrero MJ, 2006, MOL CELL, V24, P233, DOI 10.1016/j.molcel.2006.09.020; Cui JY, 2010, NUCLEIC ACIDS RES, V38, P7943, DOI 10.1093/nar/gkq654; De Martin S, 2006, CLIN PHARMACOL THER, V80, P597, DOI 10.1016/j.clpt.2006.08.020; Duranton F, 2012, J AM SOC NEPHROL, V23, P1258, DOI 10.1681/ASN.2011121175; Dwivedi RS, 2011, KIDNEY INT, V79, P23, DOI 10.1038/ki.2010.335; Gu XS, 2006, J BIOL CHEM, V281, P17882, DOI 10.1074/jbc.M601302200; Huss JM, 1999, ARCH BIOCHEM BIOPHYS, V372, P321, DOI 10.1006/abbi.1999.1496; IBEANU GC, 1995, BIOCHEMISTRY-US, V34, P8028, DOI 10.1021/bi00025a008; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Leblond F, 2001, J AM SOC NEPHROL, V12, P326, DOI 10.1681/ASN.V122326; Leblond FA, 2000, DRUG METAB DISPOS, V28, P1317; Leblond FA, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017575.50319.77; Lempiainen H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018216; Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840; Luoma PV, 2008, EUR J CLIN PHARMACOL, V64, P841, DOI 10.1007/s00228-008-0515-5; Manley HJ, 2005, AM J KIDNEY DIS, V46, P669, DOI 10.1053/j.ajkd.2005.07.001; Michaud J, 2005, BRIT J PHARMACOL, V144, P1067, DOI 10.1038/sj.bjp.0706138; Michaud J, 2006, J AM SOC NEPHROL, V17, P3041, DOI 10.1681/ASN.2006010035; Michaud J, 2008, J PHARMACOL SCI, V108, P157, DOI 10.1254/jphs.08042FP; Naud J, 2012, J CLIN PHARMACOL, V52, p10S, DOI 10.1177/0091270011413588; Ni SQ, 2009, PHARMAZIE, V64, P252, DOI 10.1691/ph.2009.8769; Noh H, 2009, AM J PHYSIOL-RENAL, V297, pF729, DOI 10.1152/ajprenal.00086.2009; Nolin TD, 2008, CLIN PHARMACOL THER, V83, P898, DOI 10.1038/clpt.2008.59; Nolin TD, 2009, J AM SOC NEPHROL, V20, P2269, DOI 10.1681/ASN.2009010082; Okabe H, 2003, PHARM RES-DORDR, V20, P1591, DOI 10.1023/A:1026131216669; Park SH, 2001, J BIOL CHEM, V276, P43031, DOI 10.1074/jbc.M107597200; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Sohi G, 2011, MOL ENDOCRINOL, V25, P785, DOI 10.1210/me.2010-0395; Souidi M, 2005, TOXICOLOGY, V214, P113, DOI 10.1016/j.tox.2005.06.006; Sun GD, 2010, J AM SOC NEPHROL, V21, P2069, DOI 10.1681/ASN.2010060633; Sun H, 2004, DRUG METAB DISPOS, V32, P1239, DOI 10.1124/dmd.104.000521; Sun H, 2010, CLIN PHARMACOL THER, V87, P465, DOI 10.1038/clpt.2009.247; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; TALBERT RL, 1994, J CLIN PHARMACOL, V34, P99, DOI 10.1002/j.1552-4604.1994.tb03973.x; Tian YA, 2013, DRUG METAB REV, V45, P166, DOI 10.3109/03602532.2012.756012; Tian YA, 2009, BIOCHEM PHARMACOL, V77, P670, DOI 10.1016/j.bcp.2008.10.023; Tirona RG, 2003, NAT MED, V9, P220, DOI 10.1038/nm815; Urquhart BL, 2007, J CLIN PHARMACOL, V47, P566, DOI 10.1177/0091270007299930; Velenosi TJ, 2014, EXPERT OPIN DRUG MET, V10, P1131, DOI 10.1517/17425255.2014.931371; Velenosi TJ, 2012, DRUG METAB DISPOS, V40, P1508, DOI 10.1124/dmd.112.045245; Wauthier V, 2008, MOL ENDOCRINOL, V22, P1962, DOI 10.1210/me.2007-0549; Wu Y, 2012, J PHARMACEUT BIOMED, V58, P78, DOI 10.1016/j.jpba.2011.09.017; Xie Y, 2009, J BIOL CHEM, V284, P9199, DOI 10.1074/jbc.M806193200; Xu DX, 2006, EUR J PHARMACOL, V536, P162, DOI 10.1016/j.ejphar.2006.02.029; Zanger UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/j.pharmthera.2012.12.007	46	28	30	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5388	5397		10.1096/fj.14-258780	http://dx.doi.org/10.1096/fj.14-258780			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25208844				2022-12-28	WOS:000345894500031
J	Dumitru, CA; Hemeda, H; Jakob, M; Lang, S; Brandau, S				Dumitru, Claudia A.; Hemeda, Hatim; Jakob, Mark; Lang, Stephan; Brandau, Sven			Stimulation of mesenchymal stromal cells (MSCs) via TLR3 reveals a novel mechanism of autocrine priming	FASEB JOURNAL			English	Article						proinflammatory cytokines; interferon type I; biphasic cytokine response; functional polarization; Poly I:C	TOLL-LIKE RECEPTORS; STEM-CELLS; PATHWAY; PROTEIN; INDUCTION; MONOCYTES; THERAPY; REPAIR; BETA	Mesenchymal stem/stromal cells (MSCs) are emerging as important regulators of innate and adaptive immunity. In this context, both proinflammatory and anti-inflammatory effects have been described for MSCs. The mechanisms mediating this functional plasticity are poorly characterized at present. Here, we investigated the inflammatory responses of MSCs isolated from human nasal mucosa (nmMSCs) upon challenge with different Toll-like receptor (TLR) ligands. We found that TLR3 ligands induced the strongest release of both proinflammatory cytokines [interleukin (IL)-6 and IL-8] and type I interferon by nmMSCs compared with other TLR ligands. Notably, TLR3 ligands triggered a biphasic cytokine response, with an early peak of type I interferon at 4 h poststimulation and a late release of proinflammatory cytokines at 24 h poststimulation. While the early interferon response was subject to direct stimulation, the proinflammatory response was regulated by factors released during the early cytokine response, which subsequently enhanced sensitivity to TLR3 ligation and amplified the production of IL-6 and IL-8 but not that of interferon. Taken together, our findings indicate that TLR3 ligands polarize the inflammatory phenotype of MSCs in a time-dependent manner. Thus, our study proposes a novel model that helps to explain the strikingly dichotomous functionality of MSCs in inflammation and immunoregulation.	[Dumitru, Claudia A.; Hemeda, Hatim; Jakob, Mark; Lang, Stephan; Brandau, Sven] Univ Duisburg Essen, Univ Hosp Essen, Dept Otorhinolaryngol, D-45122 Essen, Germany	University of Duisburg Essen	Brandau, S (corresponding author), Univ Duisburg Essen, Dept Otorhinolaryngol, Hufelandstr 55, D-45122 Essen, Germany.	sven.brandau@uk-essen.de		Brandau, Sven/0000-0002-2702-4163	Deutsche Forschungsgemeinschaft (DFG)	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors thank Kirsten Bruderek and Sebastian Vollmer (Department of Otorhinolaryngology, University Hospital Essen) for excellent technical support. The authors are grateful to Dr. Karl S. Lang (Department of Immunology, University Hospital Essen), as well as to Dr. Ulf Dittmer and Dr. Katrin Gibbert (Department of Virology, University Hospital Essen) for the critical reading and helpful comments on our manuscript. This study was supported by a grant from the Deutsche Forschungsgemeinschaft (DFG) to S.B.	Baker BJ, 2009, TRENDS IMMUNOL, V30, P392, DOI 10.1016/j.it.2009.07.001; Bernardo ME, 2013, CELL STEM CELL, V13, P392, DOI 10.1016/j.stem.2013.09.006; Brandau S, 2010, J LEUKOCYTE BIOL, V88, P1005, DOI 10.1189/jlb.0410207; Cassatella MA, 2011, STEM CELLS, V29, P1001, DOI 10.1002/stem.651; Cho HH, 2006, STEM CELLS, V24, P2744, DOI 10.1634/stemcells.2006-0189; Dumitru CA, 2012, J LEUKOCYTE BIOL, V91, P591, DOI 10.1189/jlb.0411193; English K, 2009, CLIN EXP IMMUNOL, V156, P149, DOI 10.1111/j.1365-2249.2009.03874.x; Francois M, 2012, MOL THER, V20, P187, DOI 10.1038/mt.2011.189; Hemeda H, 2010, STEM CELLS DEV, V19, P693, DOI 10.1089/scd.2009.0365; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Jakob M, 2010, STEM CELLS DEV, V19, P635, DOI 10.1089/scd.2009.0245; Khabar KSA, 2007, BIOCHIMIE, V89, P761, DOI 10.1016/j.biochi.2007.02.008; Krampera M, 2011, LEUKEMIA, V25, P1408, DOI 10.1038/leu.2011.108; Maccario R, 2005, HAEMATOLOGICA, V90, P516; McCormick C, 2005, SCIENCE, V307, P739, DOI 10.1126/science.1105779; Melief SM, 2013, STEM CELLS, V31, P1980, DOI 10.1002/stem.1432; Melief SM, 2013, HAEMATOLOGICA, V98, P888, DOI 10.3324/haematol.2012.078055; Miao ZN, 2006, CELL BIOL INT, V30, P681, DOI 10.1016/j.cellbi.2006.03.009; Nagai Y, 2006, IMMUNITY, V24, P801, DOI 10.1016/j.immuni.2006.04.008; Nathan S, 2003, TISSUE ENG, V9, P733, DOI 10.1089/107632703768247412; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Opitz CA, 2009, STEM CELLS, V27, P909, DOI 10.1002/stem.7; Patil C, 2004, IMMUNOL INVEST, V33, P213, DOI 10.1081/IMM-120034231; Pevsner-Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood-2006-06-028704; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Selmani Z, 2008, STEM CELLS, V26, P212, DOI 10.1634/stemcells.2007-0554; Stagg J, 2013, CURR MOL MED, V13, P856, DOI 10.2174/1566524011313050016; Tomchuck SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039592; Waterman RS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010088; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Zhu JK, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/781235	31	29	30	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3856	3866		10.1096/fj.14-250159	http://dx.doi.org/10.1096/fj.14-250159			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24830384	Green Published			2022-12-28	WOS:000340845900005
J	Cui, HHL; Ditiatkovski, M; Kesani, R; Bobryshev, YV; Liu, YY; Geyer, M; Mukhamedova, N; Bukrinsky, M; Sviridov, D				Cui, Huanhuan L.; Ditiatkovski, Michael; Kesani, Rajitha; Bobryshev, Yuri V.; Liu, Yingying; Geyer, Matthias; Mukhamedova, Nigora; Bukrinsky, Michael; Sviridov, Dmitri			HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis	FASEB JOURNAL			English	Article						HIV; cholesterol; metabolic syndrome; vessels; macrophages; reverse cholesterol transport	HIGH-DENSITY-LIPOPROTEIN; CHOLESTEROL EFFLUX; TRANSGENIC MICE; PLASMA HDL; T-CELLS; INFECTION; DISEASE; INFLAMMATION; MACROPHAGES; TRANSPORTER	Patients with HIV are at an increased risk of cardiovascular disease. In this study we investigated the effect of Nef, a secreted HIV protein responsible for the impairment of cholesterol efflux, on the development of atherosclerosis in two animal models. ApoE(-/-) mice fed a high-fat diet and C57BL/6 mice fed a high-fat, high-cholesterol diet were injected with recombinant Nef (40 ng/injection) or vehicle, and the effects of Nef on development of atherosclerosis, inflammation, and dyslipidemia were assessed. In apoE(-/-) mice, Nef significantly increased the size of atherosclerotic lesions and caused vessel remodeling. Nef caused elevation of total cholesterol and triglyceride levels in the plasma while reducing high-density lipoprotein cholesterol levels. These changes were accompanied by a reduction of ABCA1 abundance in the liver, but not in the vessels. In C57BL/6 mice, Nef caused a significant number of lipid-laden macrophages presented in adventitia of the vessels; these cells were absent from the vessels of control mice. Nef caused sharp elevations of plasma triglyceride levels and body weight. Taken together, our findings suggest that Nef causes dyslipidemia and accumulation of cholesterol in macrophages within the vessel wall, supporting the role of Nef in pathogenesis of atherosclerosis in HIV-infected patients.	[Cui, Huanhuan L.; Ditiatkovski, Michael; Kesani, Rajitha; Liu, Yingying; Mukhamedova, Nigora; Sviridov, Dmitri] Baker Heart & Diabet Inst, Melbourne, Vic 8008, Australia; [Bobryshev, Yuri V.] Univ New S Wales, Fac Med, Sch Med Sci, Sydney, NSW, Australia; [Geyer, Matthias] CAESAR, Bonn, Germany; [Bukrinsky, Michael] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC USA	Baker Heart and Diabetes Institute; University of New South Wales Sydney; Center of Advanced European Studies & Research (CAESAR); George Washington University	Sviridov, D (corresponding author), Baker Heart & Diabet Inst, POB 6492, Melbourne, Vic 8008, Australia.	dmitri.sviridov@bakeridi.edu.au	Sviridov, Dmitri/E-7943-2010; liu, ying/GXF-4294-2022; LIU, YING/GZL-7252-2022	Geyer, Matthias/0000-0002-7718-5002	National Health and Medical Research Council of Australia [GNT1019847, GNT1036352]; U.S. National Institutes of Health (NIH) [HL093818]; Victorian government's OIS program; District of Columbia Developmental Center for AIDS Research (DC D-CFAR); NIH [1P30AI087714]; May Stewart Bursary; Elizabeth Mary Sweet Scholarship (Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093818, R01HL101274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI087714] Funding Source: NIH RePORTER	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Victorian government's OIS program; District of Columbia Developmental Center for AIDS Research (DC D-CFAR); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); May Stewart Bursary; Elizabeth Mary Sweet Scholarship (Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from the National Health and Medical Research Council of Australia (GNT1019847, GNT1036352) and the U.S. National Institutes of Health (NIH; HL093818), and in part by the Victorian government's OIS program and the District of Columbia Developmental Center for AIDS Research (DC D-CFAR), an NIH-funded program (1P30AI087714). H. L. C. was supported by The May Stewart Bursary and The Elizabeth Mary Sweet Scholarship (Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne). D. S. is a fellow of the National Health and Medical Research Council of Australia. The authors declare no conflicts of interest.	Asztalos BF, 2010, J INFECT DIS, V202, P614, DOI 10.1086/654817; Asztalos BF, 2003, AM J CARDIOL, V91, p12E, DOI 10.1016/S0002-9149(02)03383-0; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Bentzon JF, 2003, ARTERIOSCL THROM VAS, V23, P257, DOI 10.1161/01.ATV.0000051387.70962.79; Breuer S, 2006, BIOCHEMISTRY-US, V45, P2339, DOI 10.1021/bi052052c; Chung Soonkyu, 2010, J Biol Chem, V285, P12197, DOI 10.1074/jbc.M109.096933; Cui HL, 2012, J LIPID RES, V53, P696, DOI 10.1194/jlr.M023119; D'Souza W, 2010, CIRC RES, V107, P217, DOI 10.1161/CIRCRESAHA.110.216507; Ditiatkovski M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068802; Dubrovsky L, 2012, BIOCHEM BIOPH RES CO, V419, P95, DOI 10.1016/j.bbrc.2012.01.137; Duffy P, 2009, J SURG RES, V156, P257, DOI 10.1016/j.jss.2009.02.005; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9; Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620; Getz GS, 2012, ARTERIOSCL THROM VAS, V32, P1104, DOI 10.1161/ATVBAHA.111.237693; Glesby Marshall J, 2005, Curr HIV/AIDS Rep, V2, P68, DOI 10.1007/s11904-005-0021-7; Hanna Z, 2004, VIROLOGY, V327, P273, DOI 10.1016/j.virol.2004.06.028; Huang MB, 2004, J VIROL, V78, P11084, DOI 10.1128/JVI.78.20.11084-11096.2004; Jongstra-Bilen J, 2006, J EXP MED, V203, P2073, DOI 10.1084/jem.20060245; Kay DG, 2002, AM J PATHOL, V161, P321, DOI 10.1016/S0002-9440(10)64184-3; Klingenberg R, 2013, J CLIN INVEST, V123, P1323, DOI 10.1172/JCI63891; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Libby P, 2009, J AM COLL CARDIOL, V54, P2129, DOI 10.1016/j.jacc.2009.09.009; Mujawar Z, 2006, PLOS BIOL, V4, P1970, DOI 10.1371/journal.pbio.0040365; Pourabdollah M, 2013, HEART LUNG CIRC, V22, P19, DOI 10.1016/j.hlc.2012.07.051; Quehenberger O, 2005, J LIPID RES, V46, P1582, DOI 10.1194/jlr.R500008-JLR200; Rose H, 2006, METABOLISM, V55, P90, DOI 10.1016/j.metabol.2005.07.012; Rose H, 2008, ATHEROSCLEROSIS, V199, P79, DOI 10.1016/j.atherosclerosis.2007.10.018; Singaraja RR, 2006, ARTERIOSCL THROM VAS, V26, P1821, DOI 10.1161/01.ATV.0000229219.13757.a2; Sudano I, 2006, AM HEART J, V151, P1147, DOI 10.1016/j.ahj.2005.07.030; WARNICK GR, 1982, CLIN CHEM, V28, P1379; Yamashita A, 2008, HISTOL HISTOPATHOL, V23, P127, DOI 10.14670/HH-23.127; Yu BL, 2010, OBES REV, V11, P560, DOI 10.1111/j.1467-789X.2009.00699.x	33	34	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2828	2839		10.1096/fj.13-246876	http://dx.doi.org/10.1096/fj.13-246876			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24642731	Green Published			2022-12-28	WOS:000337949400009
J	Koeberle, A; Pergola, C; Shindou, H; Koeberle, SC; Shimizu, T; Laufer, SA; Werz, O				Koeberle, Andreas; Pergola, Carlo; Shindou, Hideo; Koeberle, Solveigh C.; Shimizu, Takao; Laufer, Stefan A.; Werz, Oliver			Role of p38 mitogen-activated protein kinase in linking stearoyl-CoA desaturase-1 activity with endoplasmic reticulum homeostasis	FASEB JOURNAL			English	Article						bioactive lipid; fatty acid; lipidomics; phospholipid; unfolded protein response	POLYUNSATURATED FATTY-ACIDS; INSULIN-RESISTANCE; ACYLTRANSFERASE 3; CELL-CYCLE; STRESS; MEMBRANE; MUSCLE; PHOSPHOLIPIDS; PROGRESSION; SENSITIVITY	Endoplasmic reticulum (ER) homeostasis is regulated by a network of signaling pathways to which stearoyl-CoA desaturase (SCD)-1, p38 mitogen-activated protein kinase (MAPK) and the unfolded protein response (UPR) belong. Because all these pathways are located at the interface of cell cycle control and cell stress, we hypothesized a cross-regulation. Interference with SCD-1, either by small interfering (si) RNA or the specific SCD-1 inhibitor CAY10566 (EC50 1 mu M; >= 24 h), specifically induced phosphorylation and thus activation of p38 MAPK in NIH-3T3 mouse fibroblasts (1.5- to 2-fold; 48 hours). During lipotoxic and cell cycle stress, prolonged activation of p38 MAPK due to SCD-1 inhibition induced ER stress, the UPR, and ER/Golgi remodeling as shown by Western blot and immunofluorescence microscopy (1.2- to 3.5-fold). Specific inhibition of p38 MAPK by Skepinone-L [half maximal inhibitory concentration (IC50) 25-50 nM] reversed these effects (at 1 mu M; 48 hours). The specificity by which SCD-1 modulates the phospholipid composition and inhibits p38 MAPK signaling (among survival/stress pathways), thereby preventing ER stress (but not other SCD-1-dependent responses), suggests selective protein-lipid interactions. Palmitoleoyl/oleoyl-phosphatidylinositol (PI) was accordingly identified as potential lipid mediator using chromatography-coupled ESI tandem mass spectrometry. We conclude that the negative regulation of p38 MAPK mediates the protective effects of SCD-1 on ER homeostasis under distinct stress conditions.	[Koeberle, Andreas; Pergola, Carlo; Werz, Oliver] Univ Jena, Inst Pharm, D-07743 Jena, Germany; [Shindou, Hideo; Shimizu, Takao] Natl Ctr Global Hlth & Med, Dept Lipid Signaling, Res Inst, Tokyo, Japan; [Koeberle, Solveigh C.] Fritz Lipmann Inst, Leibniz Inst Age Res, Jena, Germany; [Shimizu, Takao] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 113, Japan; [Laufer, Stefan A.] Univ Tubingen, Dept Pharmaceut Chem, Inst Pharmaceut, Tubingen, Germany	Friedrich Schiller University of Jena; National Center for Global Health & Medicine - Japan; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); University of Tokyo; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Koeberle, A (corresponding author), Univ Jena, Inst Pharm, Chair Pharmaceut Med Chem, Philosophenweg 14, D-07743 Jena, Germany.	andreas.koeberle@uni-jena.de	Koeberle, Andreas/ABB-2356-2020; Shimizu, Takao/AAV-7052-2021	Koeberle, Andreas/0000-0001-6269-5088; Koeberle, Solveigh/0000-0002-8008-494X; Laufer, Stefan/0000-0001-6952-1486	Deutsche Forschungsgemeinschaft [KO 4589/4-1]; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Cell Science Research Foundation; Takeda Science Foundation	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Cell Science Research Foundation(Cell Science Research Foundation, Japan); Takeda Science Foundation(Takeda Science Foundation (TSF))	The authors thank Kevin Schomburg and Christoph Seidel for expert technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (KO 4589/4-1 to A.K.); Grant-in-Aid for Scientific Research (S) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (to T.S.); Grant-in-Aid for Young Scientists (B) from the MEXT of Japan (to H.S.); the Cell Science Research Foundation (to H.S.); and Takeda Science Foundation (to A.K.).	Ariyama H, 2010, J BIOL CHEM, V285, P22027, DOI 10.1074/jbc.M110.126870; Back SH, 2012, ANNU REV BIOCHEM, V81, P767, DOI 10.1146/annurev-biochem-072909-095555; Bolognesi A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055537; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; BROTHERUS J, 1977, BIOCHIM BIOPHYS ACTA, V486, P243, DOI 10.1016/0005-2760(77)90020-0; Cao HM, 2008, CELL, V134, P933, DOI 10.1016/j.cell.2008.07.048; Dobrzyn A, 2005, J BIOL CHEM, V280, P23356, DOI 10.1074/jbc.M502436200; Fritz V, 2010, MOL CANCER THER, V9, P1740, DOI 10.1158/1535-7163.MCT-09-1064; Fu SN, 2011, NATURE, V473, P528, DOI 10.1038/nature09968; Guijas C, 2012, J LIPID RES, V53, P2343, DOI 10.1194/jlr.M028423; Gutierrez-Juarez R, 2006, J CLIN INVEST, V116, P1686, DOI 10.1172/JCI26991; Hodson L, 2013, PROG LIPID RES, V52, P15, DOI 10.1016/j.plipres.2012.08.002; Ide Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061204; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Koeberle A, 2009, BRIT J PHARMACOL, V156, P952, DOI 10.1111/j.1476-5381.2009.00070.x; Koeberle A, 2013, P NATL ACAD SCI USA, V110, P2546, DOI 10.1073/pnas.1216182110; Koeberle A, 2012, J BIOL CHEM, V287, P27244, DOI 10.1074/jbc.M111.274829; Koeberle A, 2012, FASEB J, V26, P169, DOI 10.1096/fj.11-184879; Koeberle A, 2010, FASEB J, V24, P4929, DOI 10.1096/fj.10-162818; Koeberle SC, 2012, NAT CHEM BIOL, V8, P141, DOI 10.1038/nchembio.761; Laganowsky A, 2014, NATURE, V510, P172, DOI 10.1038/nature13419; Liu G, 2007, J MED CHEM, V50, P3086, DOI 10.1021/jm070219p; Liu Zhenqi, 2009, Endocrine Metabolic & Immune Disorders-Drug Targets, V9, P38; Doria ML, 2013, J CELL PHYSIOL, V228, P457, DOI 10.1002/jcp.24152; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Ozcan L, 2012, ANNU REV MED, V63, P317, DOI 10.1146/annurev-med-043010-144749; Peter A, 2009, DIABETES, V58, P1757, DOI 10.2337/db09-0188; Pinnamaneni SK, 2006, DIABETOLOGIA, V49, P3027, DOI 10.1007/s00125-006-0427-9; Rahman SM, 2003, P NATL ACAD SCI USA, V100, P11110, DOI 10.1073/pnas.1934571100; Ralston JC, 2014, INT J OBESITY, V38, P1449, DOI 10.1038/ijo.2014.35; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Rutkowski DT, 2010, J CELL BIOL, V189, P783, DOI 10.1083/jcb.201003138; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Vessby B, 2012, NUTR METAB CARDIOVAS, V22, P176, DOI 10.1016/j.numecd.2010.07.011; Volmer R, 2013, P NATL ACAD SCI USA, V110, P4628, DOI 10.1073/pnas.1217611110; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang YQ, 2009, J NUTR BIOCHEM, V20, P982, DOI 10.1016/j.jnutbio.2008.09.002	38	22	22	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2439	2449		10.1096/fj.14-268474	http://dx.doi.org/10.1096/fj.14-268474			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25678624	Bronze			2022-12-28	WOS:000355209500021
J	Martinez-Bujidos, M; Rull, A; Gonzalez-Cura, B; Perez-Cuellar, M; Montoliu-Gaya, L; Villegas, S; Ordonez-Llanos, J; Sanchez-Quesada, JL				Martinez-Bujidos, Maria; Rull, Anna; Gonzalez-Cura, Beatriz; Perez-Cuellar, Montserrat; Montoliu-Gaya, Laia; Villegas, Sandra; Ordonez-Llanos, Jordi; Luis Sanchez-Quesada, Jose			Clusterin/apolipoprotein J binds to aggregated LDL in human plasma and plays a protective role against LDL aggregation	FASEB JOURNAL			English	Article						chaperones; electronegative LDL; atherosclerosis	LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; EXTRACELLULAR CHAPERONE CLUSTERIN; APOLIPOPROTEIN-J; ELECTRONEGATIVE LDL; PROTEOMIC ANALYSIS; PROTEINS; ATHEROSCLEROSIS; ACTIVATION; INDUCTION	Clusterin/apolipoprotein J (apoJ) is an extracellular chaperone involved in the quality control system against protein aggregation. A minor part of apoJ is transported in blood bound to LDLs, but its function is unknown. Our aim was to determine the role of apoJ bound to LDLs. Total LDL from human plasma was fractionated into native LDL [LDL(+)] and electronegative LDL [LDL(-)]. The latter was separated into nonaggregated [nagLDL(-)] and aggregated LDL(-) [agLDL(-)]. The content of apoJ was 6-fold higher in LDL(-) than in LDL(+) and 7-fold higher in agLDL(-) than in nagLDL(-). The proportion of LDL particles containing apoJ (LDL/J+) was 3-fold lower in LDL(+) than in LDL(-). LDL/J+ particles shared several characteristics with agLDL(-), including increased negative charge and aggregation. apoJ-depleted particles (LDL/J-) showed increased susceptibility to aggregation, whether spontaneous or induced by proteolysis or lipolysis, as was revealed by turbidimetric analysis, gel filtration chromatography, lipoprotein precipitation, native gradient gel electrophoresis, circular dichroism, and transmission electronic microscopy. The addition of purified apoJ to total LDL also prevented its aggregation induced by proteolysis or lipolysis. These findings point to apoJ as a key modulator of LDL aggregation and reveal a putative new therapeutic strategy against atherosclerosis.Martinez-Bujidos, M., Rull, A., Gonzalez-Cura, B., Perez-Cuellar, M., Montoliu-Gaya, L., Villegas, S., Ordonez-Llanos, J., Sanchez-Quesada, J. L. Clusterin/apolipoprotein J binds to aggregated LDL in human plasma and plays a protective role against LDL aggregation.	[Martinez-Bujidos, Maria; Rull, Anna; Gonzalez-Cura, Beatriz; Perez-Cuellar, Montserrat; Ordonez-Llanos, Jordi; Luis Sanchez-Quesada, Jose] Res Inst Hosp St Pau IIB St Pau, Cardiovasc Biochem Grp, Barcelona 08025, Spain; [Martinez-Bujidos, Maria; Ordonez-Llanos, Jordi] Univ Autonoma Barcelona, Biochem & Mol Biol Dept, Cerdanyola Del Valles, Spain; [Montoliu-Gaya, Laia; Villegas, Sandra] Univ Autonoma Barcelona, Biochem & Mol Biol Dept, Prot Folding & Stabil Grp, Cerdanyola Del Valles, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Sanchez-Quesada, JL (corresponding author), Res Inst Hosp St Pau IIB St Pau, Cardiovasc Biochem Grp, C Antoni Maria Claret 167, Barcelona 08025, Spain.	jsanchezq@santpau.cat	Villegas, Sandra/D-8789-2011; Villegas, Sandra/ABF-8206-2021; Rull, Anna/A-9438-2017; Ordonez-Llanos, Jorge/AAE-3088-2020; Ordonez-Llanos, Jorge/N-1126-2019	Villegas, Sandra/0000-0001-8644-4304; Villegas, Sandra/0000-0001-8644-4304; Rull, Anna/0000-0002-8907-7754; Ordonez-Llanos, Jorge/0000-0003-4896-5832; Ordonez-Llanos, Jorge/0000-0003-4896-5832; Sanchez-Quesada, Jose Luis/0000-0003-0224-591X	Spanish Ministry of Health (Instituto de Salud Carlos III/Fondo de Investigacion Sanitaria; ISCIII/FIS) [PI10/00265, PI10/00975, PI13/00364, PI13/01330]	Spanish Ministry of Health (Instituto de Salud Carlos III/Fondo de Investigacion Sanitaria; ISCIII/FIS)(Instituto de Salud Carlos IIISpanish Government)	The authors thank Carolyn Newey (Sant Pau Biomedical Research Institute; IIB Sant Pau) for editorial assistance. This work was supported by the Spanish Ministry of Health (Instituto de Salud Carlos III/Fondo de Investigacion Sanitaria; ISCIII/FIS) Grants PI10/00265, PI10/00975, PI13/00364, and PI13/01330. M.M.-B., A.R., M.P.-C., J.O.-L., and J.L.S.-Q. are members of the Quality Research Group 2009-SGR-1205 from Generalitat de Catalunya. L.M. and S.V. are members of the Quality Research Group 2014-SGR-00885 from Generalitat de Catalunya. M.M.-B., A.R., M.P.-C., J.O.-L., and J.L.S.-Q. are members of the Cardiovascular Research Network (Red de Investigacion Cardiovascular; RD12/0042/0043) from ISCIII. The authors declare no conflicts of interest.	Arrondo JR, 2003, J BACTERIOL, V185, P4226, DOI 10.1128/JB.185.14.4226-4232.2003; Bancells C, 2011, J BIOL CHEM, V286, P1125, DOI 10.1074/jbc.M110.175315; Bancells C, 2010, J LIPID RES, V51, P3508, DOI 10.1194/jlr.M009258; Bancells C, 2010, J BIOL CHEM, V285, P32425, DOI 10.1074/jbc.M110.139691; BANEULOS S, 1995, J BIOL CHEM, V270, P9192; Banfi C, 2009, PROTEOMICS, V9, P1344, DOI 10.1002/pmic.200800566; Benitez S, 2004, BIOCHEMISTRY-US, V43, P15863, DOI 10.1021/bi048825z; Bergmeier C, 2004, CLIN CHEM, V50, P2309, DOI 10.1373/clinchem.2004.034439; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; Gelissen IC, 1998, BIOCHEM J, V331, P231, DOI 10.1042/bj3310231; Hevonoja T, 2000, BBA-MOL CELL BIOL L, V1488, P189, DOI 10.1016/S1388-1981(00)00123-2; Hochgrebe T, 2000, BIOCHEMISTRY-US, V39, P1411, DOI 10.1021/bi991581b; Hoofnagle AN, 2010, ARTERIOSCL THROM VAS, V30, P2528, DOI 10.1161/ATVBAHA.110.212894; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Ishii T, 2001, ATHEROSCLEROSIS, V158, P215, DOI 10.1016/S0021-9150(01)00416-6; Ishikawa Y, 1998, ARTERIOSCL THROM VAS, V18, P665, DOI 10.1161/01.ATV.18.4.665; Karlsson H, 2005, PROTEOMICS, V5, P551, DOI 10.1002/pmic.200300938; Karlsson H, 2006, J PROTEOME RES, V5, P2685, DOI 10.1021/pr060180x; Karlsson H, 2009, PROTEOM CLIN APPL, V3, P663, DOI 10.1002/prca.200800138; Kim HJ, 2009, ARTERIOSCL THROM VAS, V29, P1558, DOI 10.1161/ATVBAHA.109.190058; Kujiraoka T, 2006, J ATHEROSCLER THROMB, V13, P314, DOI 10.5551/jat.13.314; Navab M, 1997, J CLIN INVEST, V99, P2005, DOI 10.1172/JCI119369; Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1932, DOI 10.1161/01.ATV.0000174589.70190.e2; Oorni K, 2000, J LIPID RES, V41, P1703; Parasassi T, 2008, FASEB J, V22, P2350, DOI 10.1096/fj.07-097774; Park S, 2014, REV ENDOCR METAB DIS, V15, P45, DOI 10.1007/s11154-013-9275-3; Pettersson C, 2011, J INTERN MED, V269, P306, DOI 10.1111/j.1365-2796.2010.02292.x; Poon S, 2002, FEBS LETT, V513, P259, DOI 10.1016/S0014-5793(02)02326-8; Poulakou MV, 2008, IN VIVO, V22, P537; Richardson MR, 2009, PROTEOMICS, V9, P2468, DOI 10.1002/pmic.200800613; Riwanto M, 2013, CIRCULATION, V127, P891, DOI 10.1161/CIRCULATIONAHA.112.108753; Rubinow KB, 2012, STEROIDS, V77, P454, DOI 10.1016/j.steroids.2012.01.002; Sanchez-Quesada JL, 2004, CURR OPIN LIPIDOL, V15, P329, DOI [10.1097/00041433-200406000-00014, 10.1097/01.mol.0000130093.54381.22]; Sanchez-Quesada JL, 2003, ATHEROSCLEROSIS, V166, P261, DOI 10.1016/S0021-9150(02)00374-X; Sanchez-Quesada JL, 2002, J LIPID RES, V43, P699; Schlatzer D, 2012, DIABETES CARE, V35, P549, DOI 10.2337/dc11-1491; Schwarz M, 2008, THROMB HAEMOSTASIS, V100, P110, DOI 10.1160/TH07-12-0737; Stahlman M, 2008, J LIPID RES, V49, P481, DOI 10.1194/jlr.D700025-JLR200; STUART WD, 1992, BIOCHEMISTRY-US, V31, P8552, DOI 10.1021/bi00151a024; Sun H. Y., 2009, CLIN CHIM ACTA; Swertfeger DK, 1996, AM J PATHOL, V148, P1971; Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890; Trougakos IP, 2002, EXP GERONTOL, V37, P1175, DOI 10.1016/S0531-5565(02)00139-0; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Van Lenten BJ, 2001, CIRCULATION, V103, P2283; Vareka I, 2009, BIOMED PAP, V153, P117, DOI 10.5507/bp.2009.019; Vigano C, 2000, BIOPOLYMERS, V55, P373, DOI 10.1002/1097-0282(2000)55:5<373::AID-BIP1011>3.0.CO;2-U; WITTE DP, 1993, AM J PATHOL, V143, P763; Wyatt AR, 2010, J BIOL CHEM, V285, P3532, DOI 10.1074/jbc.M109.079566; Yerbury JJ, 2005, EMBO REP, V6, P1131, DOI 10.1038/sj.embor.7400586; Yerbury JJ, 2007, FASEB J, V21, P2312, DOI 10.1096/fj.06-7986com; Zandomeneghi G, 2004, PROTEIN SCI, V13, P3314, DOI 10.1110/ps.041024904	54	20	20	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1688	1700		10.1096/fj.14-264036	http://dx.doi.org/10.1096/fj.14-264036			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25550461				2022-12-28	WOS:000354114600008
J	Chernoivanenko, IS; Matveeva, EA; Gelfand, VI; Goldman, RD; Minin, AA				Chernoivanenko, Ivan S.; Matveeva, Elena A.; Gelfand, Vladimir I.; Goldman, Robert D.; Minin, Alexander A.			Mitochondrial membrane potential is regulated by vimentin intermediate filaments	FASEB JOURNAL			English	Article						cytoskeleton; mitochondrial respiratory chain; rho 0 cells	DEPENDENT ANION CHANNEL; AXONAL-TRANSPORT; DESMIN CYTOSKELETON; BRAIN MITOCHONDRIA; IN-SITU; CELLS; DYSFUNCTION; DISEASE; PROTEINS; FIBROBLASTS	This study demonstrates that the association of mitochondria with vimentin intermediate filaments (VIFs) measurably increases their membrane potential. This increase is detected by quantitatively comparing the fluorescence intensity of mitochondria stained with the membrane potential-sensitive dye tetramethylrhodamine-ethyl ester (TMRE) in murine vimentin-null fibroblasts with that in the same cells expressing human vimentin (similar to 35% rise). When vimentin expression is silenced by small hairpin RNA(shRNA) to reduce vimentin by 90%, the fluorescence intensity of mitochondria decreases by 20%. The increase in membrane potential is caused by specific interactions between a subdomain of the non-alpha-helical N terminus (residues 40 to 93) of vimentin and mitochondria. In rho 0 cells lacking mitochondrial DNA (mtDNA) and consequently missing several key proteins in the mitochondrial respiratory chain (rho(0) cells), the membrane potential generated by an alternative anaerobic process is insensitive to the interactions between mitochondria and VIF. The results of our studies show that the close association between mitochondria and VIF is important both for determining their position in cells and their physiologic activity.	[Chernoivanenko, Ivan S.; Matveeva, Elena A.; Minin, Alexander A.] Russian Acad Sci, Inst Prot Res, Cell Biol Grp, Moscow 119988, Russia; [Gelfand, Vladimir I.; Goldman, Robert D.] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Russian Academy of Sciences; Northwestern University; Feinberg School of Medicine	Minin, AA (corresponding author), Russian Acad Sci, Inst Prot Res, Cell Biol Grp, Str Vavilova 34,Room 113, Moscow 119988, Russia.	alexminin@gmail.com	Zerkalenkova, Elena/U-2515-2018; Gelfand, Vladimir I/D-2545-2013; Gelfand, Vladimir/M-1974-2019; Minin, Alexander/K-5340-2015	Zerkalenkova, Elena/0000-0001-9634-5828; Gelfand, Vladimir I/0000-0002-6361-2798; Gelfand, Vladimir/0000-0002-6361-2798; 	Russian Foundation for Basic Research [06-04-48452-a, 10-04-00414-a, 13-04-00931-a]; U.S. National Institutes of Health [P01-GM096971]; Russian Academy of Sciences; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM096971] Funding Source: NIH RePORTER	Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Russian Academy of Sciences(Russian Academy of Sciences); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors are grateful to Dr. R. Evans for the cell lines, Natalia Minina for excellent technical assistance, and Dr. P. Chumakov for several useful advices. This work was funded by the Russian Academy of Sciences and Russian Foundation for Basic Research (Grants 06-04-48452-a, 10-04-00414-a, and 13-04-00931-a; to A.A.M.); and the U.S. National Institutes of Health (Grant P01-GM096971; to V.I.G. and R.D.G.).	Allen R, 2002, FEBS LETT, V514, P347, DOI 10.1016/S0014-5793(02)02433-X; Avsyuk AY, 1997, DOKL AKAD NAUK+, V357, P130; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; Brownlees J, 2002, HUM MOL GENET, V11, P2837, DOI 10.1093/hmg/11.23.2837; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Capetanaki Y, 2002, TRENDS CARDIOVAS MED, V12, P339, DOI 10.1016/S1050-1738(02)00184-6; Chada SR, 2003, J EXP BIOL, V206, P1985, DOI 10.1242/jeb.00263; Chernoivanenko I. S., 2010, MEMBR CELL BIOL B SA, V5, P21; DeFlora S, 1997, MUTAGENESIS, V12, P431, DOI 10.1093/mutage/12.6.431; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Helfand BT, 2011, MOL BIOL CELL, V22, P1274, DOI 10.1091/mbc.E10-08-0699; Helfand BT, 2003, MOL BIOL CELL, V14, P5069, DOI 10.1091/mbc.E03-06-0376; Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.053850; Holwell TA, 1997, J CELL SCI, V110, P1947; Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480; Kawamata H, 2010, MECH AGEING DEV, V131, P517, DOI 10.1016/j.mad.2010.05.003; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; Kojima SI, 2004, BIOTECHNIQUES, V36, P74, DOI 10.2144/04361ST02; Koopman WJH, 2008, METHODS, V46, P304, DOI 10.1016/j.ymeth.2008.09.018; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kumemura H, 2008, BIOCHEM BIOPH RES CO, V367, P33, DOI 10.1016/j.bbrc.2007.12.116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETERRIER JF, 1994, MICROSC RES TECHNIQ, V27, P233, DOI 10.1002/jemt.1070270305; Maloyan A, 2009, CIRC RES, V104, P1021, DOI 10.1161/CIRCRESAHA.108.193516; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Miller KE, 2006, J CELL BIOL, V173, P373, DOI 10.1083/jcb.200510097; Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283; Minin AA, 2006, J CELL SCI, V119, P659, DOI 10.1242/jcs.02762; Monge C, 2008, MOL CELL BIOCHEM, V318, P147, DOI 10.1007/s11010-008-9865-7; Nekrasova OE, 2011, MOL BIOL CELL, V22, P2282, DOI 10.1091/mbc.E10-09-0766; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Perez-Olle R, 2005, J NEUROCHEM, V93, P861, DOI 10.1111/j.1471-4159.2005.03095.x; Rapaport D, 2003, EMBO REP, V4, P948, DOI 10.1038/sj.embor.embor937; Rocha M, 2010, CURR MED CHEM, V17, P3827, DOI 10.2174/092986710793205444; Rostovtseva TK, 2008, P NATL ACAD SCI USA, V105, P18746, DOI 10.1073/pnas.0806303105; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Scaglia F, 2010, DEV DISABIL RES REV, V16, P136, DOI 10.1002/ddrr.115; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Sorokin PA, 2011, ACTA ICHTHYOL PISCAT, V41, P95, DOI 10.3750/AIP2011.41.2.04; Tolstonog GV, 2001, DNA CELL BIOL, V20, P509, DOI 10.1089/104454901317094945; Uttam J, 1996, P NATL ACAD SCI USA, V93, P9079, DOI 10.1073/pnas.93.17.9079; Winter L, 2008, J CELL BIOL, V181, P903, DOI 10.1083/jcb.200710151; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147	47	56	57	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					820	827		10.1096/fj.14-259903	http://dx.doi.org/10.1096/fj.14-259903			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25404709	Green Published			2022-12-28	WOS:000350633000009
J	Gaffney, PM; Barr, B; Rowe, JD; Bett, C; Drygiannakis, I; Giannitti, F; Trejo, M; Ghassemian, M; Martin, P; Masliah, E; Sigurdson, CJ				Gaffney, Patricia M.; Barr, Bradd; Rowe, Joan D.; Bett, Cyrus; Drygiannakis, Ioannis; Giannitti, Federico; Trejo, Margarita; Ghassemian, Majid; Martin, Patrice; Masliah, Eliezer; Sigurdson, Christina J.			Protein profiling of isolated uterine AA amyloidosis causing fetal death in goats	FASEB JOURNAL			English	Article						amyloid; mass spectrometry; protein misfolding	GENE-EXPRESSION; SYSTEMIC AMYLOIDOSIS; FIBRIL PROTEIN; EXTRAHEPATIC EXPRESSION; SERUM; A3; CLUSTERIN; APOLIPOPROTEIN; MECHANISMS; PROLACTIN	Pathologic amyloid accumulates in the CNS or in peripheral organs, yet the mechanism underlying the targeting of systemic amyloid deposits is unclear. Serum amyloid A (SAA) 1 and 2 are produced predominantly by the liver and form amyloid most commonly in the spleen, liver, and kidney. In contrast, SAA3 is produced primarily extrahepatically and has no causal link to amyloid formation. Here, we identified 8 amyloidosis cases with amyloid composed of SAA3 expanding the uterine wall of goats with near-term fetuses. Uterine amyloid accumulated in the endometrium, only at the site of placental attachment, compromising maternal-fetal gas and nutrient exchange and leading to fetal ischemia and death. No other organ contained amyloid. SAA3 mRNA levels in the uterine endometrium were as high as SAA2 in the liver, yet mass spectrometry of the insoluble uterine peptides identified SAA3 as the predominant protein, and not SAA1 or SAA2. These findings suggest that high local SAA3 production led to deposition at this unusual site. Although amyloid A (AA) amyloid deposits typically consist of an N-terminal fragment of SAA1 or SAA2, here, abundant C-terminal peptides indicated that the uterine amyloid was largely composed of full-length SAA3. The exclusive deposition of SAA3 amyloid in the uterus, together with elevated uterine SAA3 transcripts, suggests that the uterine amyloid deposits were due to locally produced SAA3. This is the first report of SAA3 as a cause of amyloidosis and of AA amyloid deposited exclusively in the uterus.	[Gaffney, Patricia M.; Bett, Cyrus; Drygiannakis, Ioannis; Masliah, Eliezer; Sigurdson, Christina J.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Trejo, Margarita; Masliah, Eliezer] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Ghassemian, Majid] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; [Gaffney, Patricia M.; Giannitti, Federico; Sigurdson, Christina J.] Univ Calif Davis, Dept Pathol Immunol & Microbiol, Davis, CA 95616 USA; [Rowe, Joan D.] Univ Calif Davis, Dept Populat Hlth & Reprod, Davis, CA 95616 USA; [Barr, Bradd; Giannitti, Federico] Univ Calif Davis, Calif Anim Hlth & Food Safety Lab Syst, Davis, CA 95616 USA; [Martin, Patrice] INRA, Unite Genet Anim & Biol Integrat UMR1313, Jouy En Josas, France	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Sigurdson, CJ (corresponding author), Univ Calif San Diego, Dept Pathol, 9500 Gilman Dr MC0612, La Jolla, CA 92093 USA.	csigurdson@ucsd.edu	Drygiannakis, Ioannis/AAW-7545-2020; Giannitti, Federico/ABF-8941-2020	Giannitti, Federico/0000-0001-8799-6848	Linda Munson Fellowship for Wildlife Disease Research; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [T32OD017863] Funding Source: NIH RePORTER	Linda Munson Fellowship for Wildlife Disease Research; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank pathologists Drs. Mark Anderson and Asli Mete at the California Animal Health and Food Safety Laboratory for the careful workup and diagnosis of these cases and Drs. Lesley Ellies and Mana Parast for helpful discussions. They also thank Jun Liu, Tom Yang, and Carlitos Chen for excellent technical support. P.M.G. was funded by the Linda Munson Fellowship for Wildlife Disease Research.	BENDITT EP, 1977, P NATL ACAD SCI USA, V74, P4025, DOI 10.1073/pnas.74.9.4025; Buxbaum JN, 2009, CELL MOL LIFE SCI, V66, P3095, DOI 10.1007/s00018-009-0109-0; Chapwanya A, 2013, VET IMMUNOL IMMUNOP, V151, P157, DOI 10.1016/j.vetimm.2012.09.042; de Oliveira EM, 2013, INFLAMMATION, V36, P1107, DOI 10.1007/s10753-013-9644-9; Desikan RS, 2014, JAMA NEUROL, V71, P180, DOI 10.1001/jamaneurol.2013.4560; Eisenberg D, 2012, CELL, V148, P1188, DOI 10.1016/j.cell.2012.02.022; Enqvist S, 2009, J PATHOL, V219, P473, DOI 10.1002/path.2607; ERICSSON LH, 1987, FEBS LETT, V218, P11, DOI 10.1016/0014-5793(87)81008-6; Granel B, 2006, MEDICINE, V85, P66, DOI 10.1097/01.md.0000200467.51816.6d; Gruys Erik, 2004, J Zhejiang Univ Sci, V5, P1226, DOI 10.1631/jzus.2004.1226; HUSEBEKK A, 1985, SCAND J IMMUNOL, V21, P283, DOI 10.1111/j.1365-3083.1985.tb01431.x; ISHIDA T, 1994, J LEUKOCYTE BIOL, V56, P797, DOI 10.1002/jlb.56.6.797; JOHNSON KH, 1988, AM J PATHOL, V130, P1; Kluve-Beckerman B, 2002, ARTHRITIS RHEUM-US, V46, P1905, DOI 10.1002/art.10335; Lachmann HJ, 2007, NEW ENGL J MED, V356, P2361, DOI 10.1056/NEJMoa070265; Larson MA, 2003, BIOCHEM BIOPH RES CO, V301, P1030, DOI 10.1016/S0006-291X(03)00045-7; Larson MA, 2006, GENE, V380, P104, DOI 10.1016/j.gene.2006.05.019; Lidstrom AM, 1998, EXP NEUROL, V154, P511, DOI 10.1006/exnr.1998.6892; LIEPNIEKS JJ, 1995, BBA-MOL BASIS DIS, V1270, P81, DOI 10.1016/0925-4439(94)00076-3; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; Lu JH, 2014, P NATL ACAD SCI USA, V111, P5189, DOI 10.1073/pnas.1322357111; McDonald TL, 2001, VET IMMUNOL IMMUNOP, V83, P203, DOI 10.1016/S0165-2427(01)00380-4; MEEK RL, 1992, P NATL ACAD SCI USA, V89, P7949, DOI 10.1073/pnas.89.17.7949; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Murakami T, 2012, AMYLOID, V19, P15, DOI 10.3109/13506129.2011.637145; Nilselid AM, 2006, NEUROCHEM INT, V48, P718, DOI 10.1016/j.neuint.2005.12.005; Obici L, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13580; Olsen HG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076695; Paoletti AC, 2006, P NATL ACAD SCI USA, V103, P18928, DOI 10.1073/pnas.0606379103; Pepys MB, 2001, PHILOS T R SOC B, V356, P203, DOI 10.1098/rstb.2000.0766; Pinney JH, 2012, ANN CLIN BIOCHEM, V49, P229, DOI 10.1258/acb.2011.011225; Saremi B, 2013, J DAIRY SCI, V96, P6944, DOI 10.3168/jds.2013-6495; Segawa T, 2013, VET IMMUNOL IMMUNOP, V152, P218, DOI 10.1016/j.vetimm.2012.12.006; SELINGER MJ, 1980, NATURE, V285, P498, DOI 10.1038/285498a0; Shilov IV, 2007, MOL CELL PROTEOMICS, V6, P1638, DOI 10.1074/mcp.T600050-MCP200; Simons JP, 2013, P NATL ACAD SCI USA, V110, P16115, DOI 10.1073/pnas.1306621110; Sipe JD, 2012, AMYLOID, V19, P167, DOI 10.3109/13506129.2012.734345; SLETTEN K, 1974, EUR J BIOCHEM, V41, P117, DOI 10.1111/j.1432-1033.1974.tb03251.x; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843; WESTERMARK P, 1982, CLIN EXP IMMUNOL, V49, P725; WESTERMARK P, 1982, BIOCHIM BIOPHYS ACTA, V701, P19, DOI 10.1016/0167-4838(82)90306-5; WESTERMARK P, 1986, BIOCHEM BIOPH RES CO, V140, P827, DOI 10.1016/0006-291X(86)90708-4; Yamada M, 2006, J VET MED SCI, V68, P725, DOI 10.1292/jvms.68.725; Zhang Y, 2013, ASIAN AUSTRAL J ANIM, V26, P1665, DOI 10.5713/ajas.2013.13199	46	5	5	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					911	919		10.1096/fj.14-256081	http://dx.doi.org/10.1096/fj.14-256081			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25422367	Green Published			2022-12-28	WOS:000350633000017
J	Jung, IH; Choi, JH; Jin, J; Jeong, SJ; Jeon, S; Lim, C; Lee, MR; Yoo, JY; Sonn, SK; Kim, YH; Choi, BK; Kwon, BS; Seoh, JY; Lee, CW; Kim, DY; Oh, GT				Jung, In-Hyuk; Choi, Jae-Hoon; Jin, Jing; Jeong, Se-Jin; Jeon, Sejin; Lim, Chaeji; Lee, Mi-Ran; Yoo, Ji-Young; Sonn, Seong-Keun; Kim, Young Ho; Choi, Beom Kyu; Kwon, Byoung S.; Seoh, Ju-Young; Lee, Cheol Whan; Kim, Dae-Yong; Oh, Goo Taeg			CD137-inducing factors from T cells and macrophages accelerate the destabilization of atherosclerotic plaques in hyperlipidemic mice	FASEB JOURNAL			English	Article						ApoE-knockout mice; MMP; advanced atheroma	RECEPTOR-DEFICIENT MICE; SMOOTH-MUSCLE-CELLS; DENDRITIC CELLS; CATHEPSIN-K; REDUCES ATHEROSCLEROSIS; ENDOTHELIAL-CELLS; IMMUNE-RESPONSES; POTENTIAL ROLE; BCL-XL; APOPTOSIS	CD137 (4-1BB), a member of the tumor necrosis factor receptor superfamily, has been reported to be expressed in atherosclerotic plaques, and to promote lesion formation. However, the role of CD137 in mediating atherosclerotic plaque stability and the possible underlying molecular and cellular mechanisms are poorly understood. Here, apolipoprotein E-deficient (ApoE(-/-)) and CD137-deficient ApoE(-/-) (ApoE(-/-)CD137(-/-)) mice fed a chow diet for 66 wk were used. CD137 induces plaque instability, which is characterized by increased plaque necrosis, decreased collagen content, decreased vascular smooth muscle cell (VSMC) content, and increased macrophage infiltration. CD137 also increases the infiltration of effector T (T-eff) cells into plaque lesion sites, resulting in increased interferon- (IFN-) expression. Interestingly, T-eff-cell-derived IFN- inhibits collagen synthesis in atherosclerotic plaques. Furthermore, CD137 activation increases the apoptosis of VSMCs, possibly by decreasing the antiapoptotic regulator, Bcl-2, and subsequently up-regulating cleaved caspase-3. In macrophages, activation of CD137 signaling boosted the oxidized low density lipoprotein-induced expression of matrix metalloproteinase 9 via the p38 mitogen-activated protein kinase and extracellular signal-regulated kinase1/2 signaling pathways. In summary, activation of CD137 signaling decreases the stability of advanced atherosclerotic plaques via its combined effects on T-eff cells, VSMCs, and macrophages.Jung, I.-H., Choi, J.-H., Jin, J., Jeong, S.-J., Jeon, S., Lim, C., Lee, M.-R., Yoo, J.-Y., Sonn, S.-K., Kim, Y. H., Choi, B. K., Kwon, B. S., Seoh, J.-Y., Lee, C. W., Kim, D.-Y., Oh, G. T. CD137-inducing factors from T cells and macrophages accelerate the destabilization of atherosclerotic plaques in hyperlipidemic mice.	[Jung, In-Hyuk; Jin, Jing; Jeong, Se-Jin; Jeon, Sejin; Lim, Chaeji; Lee, Mi-Ran; Yoo, Ji-Young; Sonn, Seong-Keun; Oh, Goo Taeg] Ewha Womans Univ, Grad Sch Med, Dept Life Sci, Seoul 120750, South Korea; [Jung, In-Hyuk; Jin, Jing; Jeong, Se-Jin; Jeon, Sejin; Lim, Chaeji; Lee, Mi-Ran; Yoo, Ji-Young; Sonn, Seong-Keun; Oh, Goo Taeg] Ewha Womans Univ, Grad Sch Med, Program GT5, Seoul 120750, South Korea; [Seoh, Ju-Young] Ewha Womans Univ, Grad Sch Med, Dept Microbiol, Seoul 120750, South Korea; [Jung, In-Hyuk; Kim, Dae-Yong] Seoul Natl Univ, Coll Vet Med, Dept Vet Pathol, Seoul 151742, South Korea; [Choi, Jae-Hoon] Hanyang Univ, Coll Nat Sci, Dept Life Sci, Seoul 133791, South Korea; [Kim, Young Ho] Natl Canc Ctr, Program Immunotherapeut Res, Immune Cell Prod Unit, Goyang, South Korea; [Choi, Beom Kyu; Kwon, Byoung S.] Natl Canc Ctr, Div Canc Biol, Canc Immunol Branch, Goyang, South Korea; [Lee, Cheol Whan] Univ Ulsan, Asan Med Ctr, Dept Med, Seoul, South Korea	Ewha Womans University; Ewha Womans University; Ewha Womans University; Seoul National University (SNU); Hanyang University; National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); University of Ulsan; Asan Medical Center	Kim, DY (corresponding author), Ewha Womans Univ, Dept Life Sci, 52 Ewhayeodae Gil, Seoul 120750, South Korea.	daeyong@snu.ac.kr; gootaeg@ewha.ac.kr	Jeon, Sejin/GWU-7864-2022; Choi, Jae-Hoon/R-6224-2016; Oh, Goo Taeg/AAQ-9995-2021; Jeon, Sejin/GRJ-6826-2022	Choi, Jae-Hoon/0000-0002-5265-3463; Jeong, Se-Jin/0000-0002-6375-5334	National Research Foundation of Korea (NRF) - Korean government (Ministry of Education, Science, and Technology) [2012R1A3A2026454, 2010-0020878]; Korean Ministry of Health and Welfare [A090204]	National Research Foundation of Korea (NRF) - Korean government (Ministry of Education, Science, and Technology)(National Research Foundation of Korea); Korean Ministry of Health and Welfare(Ministry of Health & Welfare (MOHW), Republic of Korea)	The authors thank Mi-Rae Park for caring for the knockout mice. This work was supported by National Research Foundation of Korea (NRF) grants funded by the Korean government (Ministry of Education, Science, and Technology; 2012R1A3A2026454 and 2010-0020878 to G.T.O.) and a Korean Ministry of Health and Welfare grant (A090204 to G.T.O.). The authors declare no conflicts of interest.	AMENTO EP, 1991, ARTERIOSCLER THROMB, V11, P1223, DOI 10.1161/01.ATV.11.5.1223; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Chen KC, 2011, FASEB J, V25, P1718, DOI 10.1096/fj.10-174904; Chen Y, 2008, ARTECH HSE BIOINF BI, P33; Cheong C, 2012, MOL CELLS, V34, P341, DOI 10.1007/s10059-012-0128-9; Choi BK, 2009, J IMMUNOL, V182, P4107, DOI 10.4049/jimmunol.0800459; Choi BK, 2004, J LEUKOCYTE BIOL, V75, P785, DOI 10.1189/jlb.1003491; Choi ET, 2005, ARTERIOSCL THROM VAS, V25, P1020, DOI 10.1161/01.ATV.0000161275.82687.f6; Choi JH, 2011, IMMUNITY, V35, P819, DOI 10.1016/j.immuni.2011.09.014; Choi JH, 2009, J EXP MED, V206, P497, DOI 10.1084/jem.20082129; Clarke M, 2006, AM J NEPHROL, V26, P531, DOI 10.1159/000097815; Clarke MCH, 2006, NAT MED, V12, P1075, DOI 10.1038/nm1459; Clarke MCH, 2010, CIRC RES, V106, P363, DOI 10.1161/CIRCRESAHA.109.208389; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Drenkard D, 2007, FASEB J, V21, P456, DOI 10.1096/fj.05-4739com; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; Gough PJ, 2006, J CLIN INVEST, V116, P59, DOI 10.1172/JCI25074; Guo J, 2009, CARDIOVASC RES, V81, P278, DOI 10.1093/cvr/cvn311; Jaffer FA, 2007, CIRCULATION, V115, P2292, DOI 10.1161/CIRCULATIONAHA.106.660340; Jeon HJ, 2010, CIRCULATION, V121, P1124, DOI 10.1161/CIRCULATIONAHA.109.882704; Jung YJ, 2009, IMMUNOBIOLOGY, V214, P291, DOI 10.1016/j.imbio.2008.09.004; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; Kitamoto S, 2007, CIRCULATION, V115, P2065, DOI 10.1161/CIRCULATIONAHA.107.688523; Kockx MM, 1998, CIRCULATION, V97, P2307, DOI 10.1161/01.CIR.97.23.2307; Kuzuya M, 2006, ARTERIOSCL THROM VAS, V26, P1120, DOI 10.1161/01.ATV.0000218496.60097.e0; Kwon BS, 2002, J IMMUNOL, V168, P5483, DOI 10.4049/jimmunol.168.11.5483; Kwon Byungsuk, 2012, Immune Netw, V12, P176, DOI 10.4110/in.2012.12.5.176; Lee SW, 2012, J IMMUNOL, V189, P2697, DOI 10.4049/jimmunol.1201248; Li L, 2009, ATHEROSCLEROSIS, V204, P40, DOI 10.1016/j.atherosclerosis.2008.08.008; Li Y., 2014, PLOS ONE, V10; Libby P, 2013, NEW ENGL J MED, V368, P2004, DOI 10.1056/NEJMra1216063; Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Lutgens E, 2010, J EXP MED, V207, P391, DOI 10.1084/jem.20091293; Newby AC, 2007, TRENDS CARDIOVAS MED, V17, P253, DOI 10.1016/j.tcm.2007.09.001; Olofsson PS, 2008, CIRCULATION, V117, P1292, DOI 10.1161/CIRCULATIONAHA.107.699173; Samokhin AO, 2008, ATHEROSCLEROSIS, V200, P58, DOI 10.1016/j.atherosclerosis.2007.12.047; Schober A, 2014, NAT MED, V20, P368, DOI 10.1038/nm.3487; SHAH PK, 1995, CIRCULATION, V92, P1565; Shao Z, 2011, J LEUKOCYTE BIOL, V89, P21, DOI 10.1189/jlb.0510315; Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915; Tabas I, 2010, CIRC RES, V106, P58, DOI 10.1161/CIRCRESAHA.109.208488; Thorp E, 2009, J LEUKOCYTE BIOL, V86, P1089, DOI 10.1189/jlb.0209115; Timmins JM, 2009, J CLIN INVEST, V119, P2925, DOI 10.1172/JCI38857; van Wanrooij EJA, 2007, ARTERIOSCL THROM VAS, V27, P204, DOI 10.1161/01.ATV.0000251007.07648.81; Weber C, 2011, J CLIN INVEST, V121, P2898, DOI 10.1172/JCI44925; Wei DH, 2013, INT J MOL MED, V31, P400, DOI 10.3892/ijmm.2012.1201; Zheng GX, 2004, J IMMUNOL, V173, P2428, DOI 10.4049/jimmunol.173.4.2428; Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x	50	26	31	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4779	4791		10.1096/fj.14-253732	http://dx.doi.org/10.1096/fj.14-253732			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25059229				2022-12-28	WOS:000344050900017
J	Ribeiro-Rodrigues, TM; Catarino, S; Marques, C; Ferreira, JV; Martins-Marques, T; Pereira, P; Girao, H				Ribeiro-Rodrigues, Teresa M.; Catarino, Steve; Marques, Carla; Ferreira, Joao V.; Martins-Marques, Tania; Pereira, Paulo; Girao, Henrique			AMSH-mediated deubiquitination of Cx43 regulates internalization and degradation of gap junctions	FASEB JOURNAL			English	Article						connexin43; DUB; ubiquitin; endocytosis	INTRACELLULAR-TRANSPORT; UBIQUITIN ISOPEPTIDASE; CONNEXIN DEGRADATION; SORTING MACHINERY; PLASMA-MEMBRANE; AUTOPHAGY; ACTIVATION; PATHWAY; PROTEINS; SIGNAL	Gap junctions (GJs) are specialized cell-cell contacts formed by connexins (Cxs), which provide direct intercellular communication between eukaryotic cells. Although Cx43 has long been known to be a substrate for ubiquitination, the reversal of this modification by deubiquitylases (DUBs) has never been described. Here we report that the DUB-associated molecule with the SH3 domain of STAM (AMSH) interacts with Cx43 and mediates its deubiquitination. In this study, we demonstrate that Cx43 is modified with lysine 63-linked polyubiquitin chains and that these increase the interaction between Cx43 and AMSH. We also show that AMSH is recruited to GJ plaque sites at the plasma membrane, where it mediates the deubiquitination of Cx43. Using siRNA depletion or overexpression of a catalytically inactive mutant of AMSH, we show that by decreasing Cx43 deubiquitination, both the internalization and degradation rate of Cx43 are increased. Overall, these data strongly suggest that AMSH-mediated deubiquitination of Cx43 protects GJs from degradation.Ribeiro-Rodrigues, T. M., Catarino, S., Marques, C., Ferreira, J. V., Martins-Marques, T., Pereira, P., GirAo, H. AMSH-mediated deubiquitination of Cx43 regulates internalization and degradation of gap junctions.	[Ribeiro-Rodrigues, Teresa M.; Catarino, Steve; Marques, Carla; Ferreira, Joao V.; Martins-Marques, Tania; Pereira, Paulo; Girao, Henrique] Univ Coimbra, Inst Biomed Imaging & Life Sci IBILI, Ctr Ophthalmol & Vis Sci, Fac Med, P-3000354 Coimbra, Portugal; [Ribeiro-Rodrigues, Teresa M.] Univ Coimbra, Dept Fis, CFC, P-3000354 Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra	Girao, H (corresponding author), Univ Coimbra, Inst Biomed Imaging & Life Sci IBILI, Ctr Ophthalmol & Vis Sci, Fac Med, Azinhaga Sta Comba, P-3000354 Coimbra, Portugal.	hmgirao@fmed.uc.pt	Pereira, Paulo/AAD-8375-2022; Girao, H/I-7591-2012; Marques, Carla/AAC-9838-2019; Catarino, Steve/GQI-2873-2022; Rodrigues, Teresa/GYU-8199-2022; Martins-Marques, Tania/AAJ-6686-2020; Ribeiro-Rodrigues, Teresa M/A-1585-2018; Ferreira, João Vasco/E-1753-2015	Pereira, Paulo/0000-0002-9908-2290; Girao, H/0000-0002-5786-8447; Catarino, Steve/0000-0001-9644-6960; Martins-Marques, Tania/0000-0001-5798-3923; Ribeiro-Rodrigues, Teresa M/0000-0002-5169-6090; Ferreira, João Vasco/0000-0001-5897-7461; Marques, Carla/0000-0002-1817-4813	Portuguese Foundation for Science and (FCT) [PTDC/SAU-ORG/119290/2010, PEST-C/SAU/U13282/2013-COMPETE]; FCT [SFRH/BPD/68749/2010]; FCT Ph.D. grant [SFRH/BD/52294/2013]; FCT grant [PTDC/SAU-ORG/119290/2010, PTDC/SAU-ORG/113542/2009]	Portuguese Foundation for Science and (FCT); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); FCT Ph.D. grant(Portuguese Foundation for Science and Technology); FCT grant(Portuguese Foundation for Science and Technology)	This work was supported by Portuguese Foundation for Science and (FCT) grants PTDC/SAU-ORG/119290/2010 and PEST-C/SAU/U13282/2013-COMPETE. S.C. was supported by FCT postdoctoral grant SFRH/BPD/68749/2010. T.M.R.-R. was supported by FCT Ph.D. grant SFRH/BD/52294/2013. T.M.-M. was supported by FCT grant PTDC/SAU-ORG/119290/2010. J.V.E. was supported by FCT grant PTDC/SAU-ORG/113542/2009.	Agromayor M, 2006, J BIOL CHEM, V281, P23083, DOI 10.1074/jbc.M513803200; Auth T, 2009, EXP CELL RES, V315, P1053, DOI 10.1016/j.yexcr.2008.12.025; Barriere H, 2007, MOL BIOL CELL, V18, P3952, DOI 10.1091/mbc.E07-07-0678; Bejarano E, 2012, MOL BIOL CELL, V23, P2156, DOI 10.1091/mbc.E11-10-0844; Catarino S, 2011, BIOCHEM J, V437, P255, DOI 10.1042/BJ20102059; Davies CW, 2013, BIOCHEMISTRY-US, V52, P7818, DOI 10.1021/bi401106b; Fong JT, 2012, AUTOPHAGY, V8, P794, DOI 10.4161/auto.19390; Girao H, 2009, EXP CELL RES, V315, P3587, DOI 10.1016/j.yexcr.2009.10.003; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Laird DW, 2010, TRENDS CELL BIOL, V20, P92, DOI 10.1016/j.tcb.2009.11.001; Leithe E, 2004, J BIOL CHEM, V279, P50089, DOI 10.1074/jbc.M402006200; Leithe E, 2004, J CELL SCI, V117, P1211, DOI 10.1242/jcs.00951; Leithe E, 2009, J CELL SCI, V122, P3883, DOI 10.1242/jcs.053801; Lichtenstein A, 2011, J CELL SCI, V124, P910, DOI 10.1242/jcs.073072; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005; McCullough J, 2006, CURR BIOL, V16, P160, DOI 10.1016/j.cub.2005.11.073; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; Nathan JA, 2013, EMBO J, V32, P552, DOI 10.1038/emboj.2012.354; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; Sierra MI, 2010, J BIOL CHEM, V285, P13990, DOI 10.1074/jbc.M109.061309; Taillebourg E, 2012, AUTOPHAGY, V8, P767, DOI 10.4161/auto.19381; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; VanSlyke JK, 2000, METHODS, V20, P156, DOI 10.1006/meth.1999.0933	29	32	32	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4629	4641		10.1096/fj.13-248963	http://dx.doi.org/10.1096/fj.13-248963			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25070368				2022-12-28	WOS:000344050900005
J	Saura, M; Marquez, S; Reventun, P; Olea-Herrero, N; Arenas, MI; Moreno-Gomez-Toledano, R; Gomez-Parrizas, M; Munoz-Moreno, C; Gonzalez-Santander, M; Zaragoza, C; Bosch, RJ				Saura, Marta; Marquez, Susana; Reventun, Paula; Olea-Herrero, Nuria; Isabel Arenas, Maria; Moreno-Gomez-Toledano, Rafael; Gomez-Parrizas, Monica; Munoz-Moreno, Carmen; Gonzalez-Santander, Marta; Zaragoza, Carlos; Bosch, Ricardo J.			Oral administration of bisphenol A induces high blood pressure through angiotensin II/CaMKII-dependent uncoupling of eNOS	FASEB JOURNAL			English	Article						BPA; hypertension; endothelial dysfunction; superoxide; AngII	NITRIC-OXIDE SYNTHASE; ENDOTHELIAL NO SYNTHASE; CAM KINASE-II; GENE-EXPRESSION; REACTIVE OXYGEN; ACTIVATION; ESTROGEN; ASSOCIATION; RECEPTOR; URINARY	Bisphenol A (BPA) is found in human urine and fat tissue. Higher urinary BPA concentrations are associated with arterial hypertension. To shed light on the underlying mechanism, we orally administered BPA (4 nM to 400 M in drinking water) to 8-wk-old CD11 mice over 30 d. Mice developed dosage-dependent high blood pressure (systolic 130 +/- 12 vs. 170 +/- 12 mmHg; EC50 0.4 M), impairment of acetylcholine (AcH)-induced carotid relaxation (0.66 +/- 0.08 vs. 0.44 +/- 0.1 mm), a 1.7-fold increase in arterial angiotensin II (AngII), an 8.7-fold increase in eNOS mRNA and protein, and significant eNOS-dependent superoxide and peroxynitrite accumulation. AngII inhibition with 0.5 mg/ml losartan reduced oxidative stress and normalized blood pressure and endothelium-dependent relaxation, which suggests that AngII uncouples eNOS and contributes to the BPA-induced endothelial dysfunction by promoting oxidative and nitrosative stress. Microarray analysis of mouse aortic endothelial cells revealed a 2.5-fold increase in expression of calcium/calmodulin-dependent protein kinase II- (CaMKII-) in response to 10 nM BPA, with increased expression of phosphorylated-CaMKII- in carotid rings of BPA-exposed mice, whereas CaMKII- inhibition with 100 nM autocamptide-2-related inhibitor peptide (AIP) reduced BPA-mediated increase of superoxide. Administration of CaMKII- inhibitor KN 93 reduced BPA-induced blood pressure and carotid blood velocity in mice, and reverted BPA-mediated carotid constriction in response to treatment with AcH. Given that CaMKII- inhibition prevents BPA-mediated high blood pressure, our data suggest that BPA regulates blood pressure by inducing AngII/CaMKII- uncoupling of eNOS.Saura, M., Marquez, S., Reventun, P., Olea-Herrero, N., Arenas, M.I., Moreno-Gomez-Toledano, R., Gomez-Parrizas, M., Munoz-Moreno, C., Gonzalez-Santander, M., Zaragoza, C., Bosch, R.J. Oral administration of bisphenol A induces high blood pressure through angiotensin II/CaMKII-dependent uncoupling of eNOS.	[Saura, Marta; Marquez, Susana; Reventun, Paula] Univ Alcala de Henares, Lab Pathophysiol Vasc Wall, E-28801 Alcala De Henares, Spain; [Saura, Marta; Marquez, Susana; Reventun, Paula; Olea-Herrero, Nuria; Moreno-Gomez-Toledano, Rafael; Munoz-Moreno, Carmen; Bosch, Ricardo J.] Univ Alcala de Henares, Dept Syst Biol, Physiol Unit, E-28801 Alcala De Henares, Spain; [Olea-Herrero, Nuria; Isabel Arenas, Maria; Moreno-Gomez-Toledano, Rafael; Munoz-Moreno, Carmen; Gonzalez-Santander, Marta; Bosch, Ricardo J.] Univ Alcala de Henares, Lab Renal Physiol & Expt Nephrol, E-28801 Alcala De Henares, Spain; [Isabel Arenas, Maria] Univ Alcala de Henares, Dept Biomed & Biotechnol, Cell Biol Unit, E-28801 Alcala De Henares, Spain; [Gonzalez-Santander, Marta] Univ Alcala de Henares, Dept Med & Med Specialties, E-28801 Alcala De Henares, Spain; [Gomez-Parrizas, Monica; Zaragoza, Carlos] Natl Ctr Cardiovasc Res CNIC, Madrid, Spain; [Zaragoza, Carlos] Univ Francisco de Vitoria, Sch Med, Joint Translat Res Unit, Lab Cardiovasc Pathophysiol, Madrid, Spain; [Zaragoza, Carlos] Univ Hosp Ramon & Cajal, Div Cardiol, Madrid, Spain	Universidad de Alcala; Universidad de Alcala; Universidad de Alcala; Universidad de Alcala; Universidad de Alcala; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Universidad Francisco de Vitoria; Hospital Universitario Ramon y Cajal	Zaragoza, C (corresponding author), Univ Francisco de Vitoria, Sch Med, Lab Cardiovasc Pathophysiol, Madrid, Spain.	c.zaragoza.prof@ufv.es	Moreno-Gómez-Toledano, Rafael/Q-6662-2018; Bosch, Ricardo José/S-7828-2017; Moreno, Carmen Muñoz/N-2952-2016; Reventun, Paula/AAK-9265-2020; Zaragoza, Carlos/AAH-9275-2019; Reventun, Paula/C-7764-2018; Marta, Gonzalez-Santander Martinez/N-2987-2016	Moreno-Gómez-Toledano, Rafael/0000-0002-4834-289X; Bosch, Ricardo José/0000-0002-9094-1204; Moreno, Carmen Muñoz/0000-0002-7105-1628; Reventun, Paula/0000-0002-6221-8780; Reventun, Paula/0000-0002-6221-8780; Arenas, Maria I/0000-0002-7825-0654; Zaragoza, Carlos/0000-0002-1706-8592; Marta, Gonzalez-Santander Martinez/0000-0002-8901-1077	Ministerio de Ciencia e Innovacion [SAF2009-12009-C02-01]; Instituto de Salud Carlos III [PI12/02825]; Eugenio Rodriguez Pascual Foundation; Ministerio de Economia y Competitividad [SAF 2012-35141, SAF 2008-04629, SAF 2011-28375]; Spanish Society of Nephrology; Comunidad Autonoma de Madrid-Programa de Actividavies I+D in Biociencias [S2010/BMD-2378]	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Eugenio Rodriguez Pascual Foundation; Ministerio de Economia y Competitividad(Spanish Government); Spanish Society of Nephrology; Comunidad Autonoma de Madrid-Programa de Actividavies I+D in Biociencias	The authors thank Dr. Irene Cuadrado-Berrocal for her technical assistance. This Work was supported in part by grants from the Ministerio de Ciencia e Innovacion (SAF2009-12009-C02-01), Instituto de Salud Carlos III (PI12/02825), and Eugenio Rodriguez Pascual Foundation to R.B.; Ministerio de Economia y Competitividad (SAF 2012-35141), Spanish Society of Nephrology 2012, to M.S.; and Ministerio de Economia y Competitividad (SAF 2008-04629 and SAF 2011-28375) to C.Z. N.O. is the recipient of a research contract from Comunidad Autonoma de Madrid-Programa de Actividavies I+D in Biociencias 2010 (S2010/BMD-2378). The authors declare no conflicts of interest.	Aitken RJ, 2013, INT J DEV BIOL, V57, P265, DOI 10.1387/ijdb.130146ja; Babu S, 2012, BIOCHEM BIOPH RES CO, V426, P215, DOI 10.1016/j.bbrc.2012.08.065; Bae S, 2012, HYPERTENSION, V60, P786, DOI 10.1161/HYPERTENSIONAHA.112.197715; Bodin J, 2014, TOXICOL SCI, V137, P311, DOI 10.1093/toxsci/kft242; Brunner H, 2005, J HYPERTENS, V23, P233, DOI 10.1097/00004872-200502000-00001; Cai H, 2001, ARTERIOSCL THROM VAS, V21, P1571, DOI 10.1161/hq1001.097028; Cai H, 2008, CARDIOVASC RES, V77, P30, DOI 10.1093/cvr/cvm010; Carwile JL, 2011, JAMA-J AM MED ASSOC, V306, P2218, DOI 10.1001/jama.2011.1721; Chalupsky K, 2005, P NATL ACAD SCI USA, V102, P9056, DOI 10.1073/pnas.0409594102; Chou Wei-Chun, 2011, Environ Health, V10, P94, DOI 10.1186/1476-069X-10-94; Gong H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054198; Gonzalez-Parra E, 2013, INT J NEPHROL, V2013, DOI 10.1155/2013/437857; GORDON MS, 1992, J HYPERTENS, V10, P361, DOI 10.1097/00004872-199204000-00007; Herranz B, 2012, CIRC RES, V110, P439, DOI 10.1161/CIRCRESAHA.111.253948; Kabuto H, 2003, ENVIRON RES, V93, P31, DOI 10.1016/S0013-9351(03)00062-8; Karbach S, 2014, CURR PHARM DESIGN, V20, P3579, DOI 10.2174/13816128113196660748; Knowles JW, 2000, J CLIN INVEST, V105, P451, DOI 10.1172/JCI8376; Kobayashi T, 2012, CLIN SCI, V123, P375, DOI 10.1042/CS20110621; Kotchen TA, 2008, AM J HYPERTENS, V21, P1074, DOI 10.1038/ajh.2008.257; Kurosawa T, 2002, ENDOCR J, V49, P465, DOI 10.1507/endocrj.49.465; Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172; Landmesser U, 2007, CURR OPIN CARDIOL, V22, P316, DOI 10.1097/HCO.0b013e3281ca710d; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Li H, 2010, AM J PHYSIOL-HEART C, V298, pH688, DOI 10.1152/ajpheart.01014.2009; Li HG, 2013, CURR OPIN PHARMACOL, V13, P161, DOI 10.1016/j.coph.2013.01.006; Lopez-Rivera E, 2005, P NATL ACAD SCI USA, V102, P3685, DOI 10.1073/pnas.0408217102; MICHEL T, 1992, J CARDIOVASC PHARM, V20, pS45, DOI 10.1097/00005344-199204002-00014; Muthalif MM, 2002, HYPERTENSION, V39, P704, DOI 10.1161/hy0202.103823; Nishio S, 2012, J MOL CELL CARDIOL, V52, P1103, DOI 10.1016/j.yjmcc.2012.02.006; Palomeque J, 2009, CIRC RES, V105, P1204, DOI 10.1161/CIRCRESAHA.109.204172; Richter CA, 2007, ENVIRON HEALTH PERSP, V115, P902, DOI 10.1289/ehp.9804; Rodrigo R, 2011, HYPERTENS RES, V34, P431, DOI 10.1038/hr.2010.264; Sag CM, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-013-0385-6; Sangai NP, 2014, TOXICOL IND HEALTH, V30, P581, DOI 10.1177/0748233712457438; Saura M, 2002, CIRC RES, V91, P806, DOI 10.1161/01.RES.0000040397.23817.E5; Shankar Anoop, 2012, J Environ Public Health, V2012, P481641, DOI 10.1155/2012/481641; Silver MK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026868; Spary EJ, 2009, J CHEM NEUROANAT, V38, P185, DOI 10.1016/j.jchemneu.2009.05.008; Sriphrapradang C, 2013, ENDOCRINE, V44, P441, DOI 10.1007/s12020-013-9889-y; Tabima DM, 2012, FREE RADICAL BIO MED, V52, P1970, DOI 10.1016/j.freeradbiomed.2012.02.041; Tarin C, 2009, ARTERIOSCL THROM VAS, V29, P27, DOI 10.1161/ATVBAHA.108.169623; Taylor JA, 2011, ENVIRON HEALTH PERSP, V119, P422, DOI 10.1289/ehp.1002514; Teeguarden JG, 2011, TOXICOL SCI, V123, P48, DOI 10.1093/toxsci/kfr160; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Wetherill YB, 2007, REPROD TOXICOL, V24, P178, DOI 10.1016/j.reprotox.2007.05.010; Yang YJ, 2009, ENVIRON RES, V109, P797, DOI 10.1016/j.envres.2009.04.014; Zhao YY, 2009, J CLIN INVEST, V119, P2009, DOI 10.1172/JCI33338; Zhao YY, 1998, ACTA BIOCH BIOPH SIN, V30, P445	48	65	66	1	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4719	4728		10.1096/fj.14-252460	http://dx.doi.org/10.1096/fj.14-252460			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25103225				2022-12-28	WOS:000344050900013
J	Gu, HM; Mickler, EA; Cummings, OW; Sandusky, GE; Weber, DJ; Gracon, A; Woodruff, T; Wilkes, DS; Vittal, R				Gu, Hongmei; Mickler, Elizabeth A.; Cummings, Oscar W.; Sandusky, George E.; Weber, Daniel J.; Gracon, Adam; Woodruff, Trent; Wilkes, David S.; Vittal, Ragini			Crosstalk between TGF-beta 1 and complement activation augments epithelial injury in pulmonary fibrosis	FASEB JOURNAL			English	Article						C3a; C5a; CD46; CD55; IPF	TGF-BETA RECEPTOR; MESENCHYMAL TRANSITION; PROTEIN-KINASE; ANAPHYLATOXIN C3A; IMMUNE-COMPLEXES; EXPRESSION; INHIBITION; CELLS; C5A; TRANSDIFFERENTIATION	The epithelial complement inhibitory proteins (CIPs) cluster of differentiation 46 and 55 (CD46 and CD55) regulate circulating immune complex-mediated complement activation in idiopathic pulmonary fibrosis (IPF). Our previous studies demonstrated that IL-17A mediates epithelial injury via transforming growth factor beta 1 (TGF-beta 1) and down-regulates CIPs. In the current study, we examined the mechanistic role of TGF-beta 1 in complement activation-mediated airway epithelial injury in IPF pathogenesis. We observed lower epithelial CIP expression in IPF lungs compared to normal lungs, associated with elevated levels of complement component 3a and 5a (C3a and C5a), locally and systemically. In normal primary human small airway epithelial cells (SAECs) treated with TGF-beta 1 (10 ng/ml), C3a, or C5a (100 nM), we observed loss of CIPs and increased poly(ADP-ribose) polymerase (PARP) activation [also observed with RNA interference (RNAi) of CD46/CD55]. TGF-beta 1-mediated loss of CIPs and Snail induction [SNAI1; a transcriptional repressor of E-cadherin (E-CAD)] was blocked by inhibiting mitogen-activated protein kinase (p38MAPK; SB203580) and RNAi silencing of SNAI1. C3a- and C5a-mediated loss of CIPs was also blocked by p38MAPK inhibition. While C3a upregulated TGFb transcripts, both C3a and C5a down-regulated SMAD7 (negative regulator of TGF-beta), and whereas TGF-beta 1 induced C3a/C5a receptor (C3aR/C5aR) expression, pharmacologic C3aR/C5aR inhibition protected against C3a- /C5a-mediated loss of CIPs. Taken together, our results suggest that epithelial injury in IPF can be collectively amplified as a result of TGF-beta 1-induced loss of CIPs leading to complement activation that down-regulates CIPs and induces TGF-beta 1 expression.	[Gu, Hongmei; Mickler, Elizabeth A.; Wilkes, David S.; Vittal, Ragini] Indiana Univ Sch Med, Ctr Immunobiol, Indianapolis, IN 46202 USA; [Gu, Hongmei; Mickler, Elizabeth A.; Wilkes, David S.; Vittal, Ragini] Indiana Univ Sch Med, Div Pulm, Dept Med, Indianapolis, IN 46202 USA; [Cummings, Oscar W.; Sandusky, George E.] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; [Weber, Daniel J.; Gracon, Adam] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA; [Wilkes, David S.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Woodruff, Trent] Univ Queensland, Sch Biomed Sci, Therapeut Dev & Translat Program, St Lucia, Qld, Australia	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of Queensland	Vittal, R (corresponding author), Indiana Univ Sch Med, 980 W Walnut St,Walther Hall C406, Indianapolis, IN 46202 USA.	rvittal@iu.edu	Woodruff, Trent M/B-4861-2009; VITTAL, RAGINI/AAE-9052-2020; Woodruff, Trent/AAS-4629-2020	Woodruff, Trent M/0000-0003-1382-911X; Woodruff, Trent/0000-0003-1382-911X	U.S. National Institutes of Health [NIH-NHLBI-LTRG CS11-99-0002, NIH-NHLBI R01 HL109288, NIH-NHLBI R01 HL096845]; ImmuneWorks, Inc.; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL109288, R01HL096845] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ImmuneWorks, Inc.; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank K. P. Lipking for analyzing the immunostaining intensity in the clinical tissues. The study was funded in part by U.S. National Institutes of Health grants NIH-NHLBI-LTRG CS11-99-0002 and NIH-NHLBI R01 HL109288 to R. V. and NIH-NHLBI R01 HL096845 to D.S.W. D.S.W. is a cofounder of ImmuneWorks, Inc., a biotechnology company involved in developing therapeutics for various forms of lung diseases. The other authors declare no conflicts of interests.	Addis-Lieser E, 2005, J IMMUNOL, V175, P1894, DOI 10.4049/jimmunol.175.3.1894; Akram KM, 2013, EUR RESPIR J, V41, P683, DOI 10.1183/09031936.00213411; Bakin AV, 2002, J CELL SCI, V115, P3193; Boor P, 2007, J AM SOC NEPHROL, V18, P1508, DOI 10.1681/ASN.2006121343; Bosmann M, 2013, FASEB J, V27, P5010, DOI 10.1096/fj.13-236380; Boulares AH, 2003, AM J RESP CELL MOL, V28, P322, DOI 10.1165/rcmb.2001-0015OC; Braun MC, 2004, J IMMUNOL, V173, P4190, DOI 10.4049/jimmunol.173.6.4190; Carrozzino F, 2005, AM J PHYSIOL-CELL PH, V289, pC1002, DOI 10.1152/ajpcell.00175.2005; DREISIN RB, 1978, NEW ENGL J MED, V298, P353, DOI 10.1056/NEJM197802162980701; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Fernandez Isis E, 2012, Proc Am Thorac Soc, V9, P111, DOI 10.1513/pats.201203-023AW; Fregonese L, 2005, J ALLERGY CLIN IMMUN, V115, P1148, DOI 10.1016/j.jaci.2005.01.068; Fujita T, 2002, AM J RESP CELL MOL, V27, P542, DOI 10.1165/rcmb.4775; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hecker L, 2009, NAT MED, V15, P1077, DOI 10.1038/nm.2005; Henderson WR, 2010, P NATL ACAD SCI USA, V107, P14309, DOI 10.1073/pnas.1001520107; JANSEN HM, 1984, CLIN EXP IMMUNOL, V56, P311; Jayachandran A, 2009, THORAX, V64, P1053, DOI 10.1136/thx.2009.121798; KAPANCI Y, 1995, AM J RESP CRIT CARE, V152, P2163, DOI 10.1164/ajrccm.152.6.8520791; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Kohl J, 1999, MOL IMMUNOL, V36, P893, DOI 10.1016/S0161-5890(99)00111-X; Li M, 2011, J CLIN INVEST, V121, P277, DOI 10.1172/JCI42090; Li QJ, 2010, J AM SOC NEPHROL, V21, P1344, DOI 10.1681/ASN.2009090977; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; Liu F, 2011, CHINESE MED J-PEKING, V124, P4039, DOI 10.3760/cma.j.issn.0366-6999.2011.23.036; Loverre A, 2011, AM J TRANSPLANT, V11, P1248, DOI 10.1111/j.1600-6143.2011.03529.x; MELICONI R, 1990, CLIN IMMUNOL IMMUNOP, V57, P64, DOI 10.1016/0090-1229(90)90022-I; MOLINA H, 1992, J EXP MED, V175, P121, DOI 10.1084/jem.175.1.121; Nishiura H, 2010, APOPTOSIS, V15, P966, DOI 10.1007/s10495-010-0511-y; PHAN SH, 1982, AM J PATHOL, V107, P25; Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963; Polosukhin VV, 2012, EXP LUNG RES, V38, P135, DOI 10.3109/01902148.2012.658595; QUIGG RJ, 1989, J IMMUNOL, V142, P877; Sacks SH, 2010, EUR J IMMUNOL, V40, P668, DOI 10.1002/eji.201040355; Singhera GK, 2008, EXP LUNG RES, V34, P579, DOI 10.1080/01902140802369372; Sun L, 2009, FASEB J, V23, P3808, DOI 10.1096/fj.09-133694; Suzuki H, 2013, J IMMUNOL, V191, P4431, DOI 10.4049/jimmunol.1202242; Tang ZY, 2009, J AM SOC NEPHROL, V20, P593, DOI 10.1681/ASN.2008040434; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Varsano S, 1996, AM J RESP CELL MOL, V15, P731, DOI 10.1165/ajrcmb.15.6.8969267; VARSANO S, 1995, AM J RESP CRIT CARE, V152, P1087, DOI 10.1164/ajrccm.152.3.7545058; Vidyasagar A, 2008, AM J PHYSIOL-RENAL, V295, pF707, DOI 10.1152/ajprenal.90240.2008; Vittal R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076451; Vittal R, 2013, AM J RESP CELL MOL, V49, P47, DOI 10.1165/rcmb.2012-0389OC; Vittal R, 2013, AM J PHYSIOL-LUNG C, V304, pL401, DOI 10.1152/ajplung.00080.2012; Wettstein G, 2013, FASEB J, V27, P1549, DOI 10.1096/fj.12-220053; Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002-9440(10)62351-6; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yadav UCS, 2013, FREE RADICAL BIO MED, V65, P15, DOI 10.1016/j.freeradbiomed.2013.06.008; Zhou BY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0038827, 10.1371/journal.pone.0038241]	52	53	59	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4223	4234		10.1096/fj.13-247650	http://dx.doi.org/10.1096/fj.13-247650			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24958208	Green Submitted, Green Published			2022-12-28	WOS:000342222700004
J	Kother, K; Nordhoff, C; Masemann, D; Varga, G; Bream, JH; Gaestel, M; Wixler, V; Ludwig, S				Koether, Katharina; Nordhoff, Carolin; Masemann, Doerthe; Varga, Georg; Bream, Jay H.; Gaestel, Matthias; Wixler, Viktor; Ludwig, Stephan			MAPKAP kinase 3 suppresses Ifng gene expression and attenuates NK cell cytotoxicity and Th1 CD4 T-cell development upon influenza A virus infection	FASEB JOURNAL			English	Article						interferon-gamma; signal transduction; innate and adaptive immune response	ACTIVATED PROTEIN-KINASE; PHOSPHORYLATION SITES; GAMMA EXPRESSION; IN-VIVO; 3PK; PROTEIN-KINASE-2; RESPONSES; PATHWAY; MICE; MK2	MK2 and MK3 are downstream targets of p38 and ERK1/2. They control the mRNA stability of several inflammatory cytokines, including TNF-alpha and IL-10. Whereas MK2 is expressed ubiquitously, the expression of MK3 is restricted to muscle, liver, and heart tissues and T and NK cells. Using Mk-deficient and wild-type (WT) mice, we demonstrated an inhibitory effect of MK3, but not of MK2, on interferon (IFN)-gamma expression in T and NK lymphocytes. The results provided evidence that the inhibitory effect of MK3 is based on negative feedback phosphorylation of p38 and ERK1/2, which causes decreased binding of Stat4 to the IFN-gamma promoter and reduced expression of IFN-gamma mRNA and protein. Consequently, all Mk3(-/-) mice challenged with the Th1-inducing influenza A virus (IAV) survived the WT LD50 virus dose. The reduced disease severity in the Mk3(-/-) mice was accompanied by a > 10-fold reduction in viral lung titer and an increase in the number of activated NK cells and enhanced Th1 activation of CD4 T cells. Thus, our data describe the protein kinase MK3 as a novel regulator of the innate and adaptive immune responses.	[Koether, Katharina; Nordhoff, Carolin; Masemann, Doerthe; Wixler, Viktor; Ludwig, Stephan] Univ Munster, Ctr Mol Biol Inflammat ZMBE, IMV, D-48149 Munster, Germany; [Varga, Georg] Univ Munster, Dept Pediat Rheumatol & Immunol, D-48149 Munster, Germany; [Bream, Jay H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA; [Gaestel, Matthias] Hannover Med Sch, Inst Biochem, Hannover, Germany; [Wixler, Viktor; Ludwig, Stephan] Univ Munster, Interdisciplinary Ctr Clin Res IZKF, D-48149 Munster, Germany	University of Munster; University of Munster; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Hannover Medical School; University of Munster	Ludwig, S (corresponding author), Univ Munster, Ctr Mol Biol Inflammat ZMBE, IMV, Von Esmarch Str 56, D-48149 Munster, Germany.	ludwigs@uni-muenster.de	Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652; Ludwig, Stephan/0000-0003-4490-3052; Bream, Jay/0000-0002-9149-7643	Interdisciplinary Center of Clinical Research (IZKF) at the University of Munster [Lud2/010/11, Lud2/017/13]; Graduate School [GRK1409]; Collaborative Research Center [SFB1009]; Deutsche Forschungsgemeinschaft (DFG); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070594, R56AI070594] Funding Source: NIH RePORTER	Interdisciplinary Center of Clinical Research (IZKF) at the University of Munster; Graduate School; Collaborative Research Center; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors acknowledge Ludmilla Wixler (University of Munster, Germany) for generation of the IFN-gamma reporter gene construct. This work was supported by the Interdisciplinary Center of Clinical Research (IZKF) at the University of Munster, (grants Lud2/010/11 and Lud2/017/13), as well as by the Graduate School GRK1409 and the Collaborative Research Center SFB1009, funded by the Deutsche Forschungsgemeinschaft (DFG).	BAUMGARTH N, 1994, J VIROL, V68, P7575, DOI 10.1128/JVI.68.11.7575-7581.1994; Baumgarth N, 1996, J VIROL, V70, P4411, DOI 10.1128/JVI.70.7.4411-4418.1996; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Bream JH, 2003, BLOOD, V102, P207, DOI 10.1182/blood-2002-08-2602; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; Guess AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054239; Guo HL, 2009, IMMUNOL CELL BIOL, V87, P579, DOI 10.1038/icb.2009.60; Hegen M, 2006, J IMMUNOL, V177, P1913, DOI 10.4049/jimmunol.177.3.1913; Hitti E, 2006, MOL CELL BIOL, V26, P2399, DOI 10.1128/MCB.26.6.2399-2407.2006; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Johnson PA, 2000, J GEN VIROL, V81, P1737, DOI 10.1099/0022-1317-81-7-1737; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kondadasula SV, 2008, BLOOD, V111, P4173, DOI 10.1182/blood-2007-01-068908; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Liu TG, 2007, AM J RESP CELL MOL, V37, P507, DOI 10.1165/rcmb.2007-0077OC; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ludwig S, 2006, CELL MICROBIOL, V8, P375, DOI 10.1111/j.1462-5822.2005.00678.x; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Luig C, 2010, FASEB J, V24, P4068, DOI 10.1096/fj.10-158766; Mainiero F, 1998, J EXP MED, V188, P1267, DOI 10.1084/jem.188.7.1267; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Ogilvie RL, 2009, J BIOL CHEM, V284, P11216, DOI 10.1074/jbc.M901229200; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Prickaerts P, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-12; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Ronkina N, 2007, MOL CELL BIOL, V27, P170, DOI 10.1128/MCB.01456-06; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Seternes OM, 2004, EMBO J, V23, P4780, DOI 10.1038/sj.emboj.7600489; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; Soutto M, 2002, J IMMUNOL, V169, P4205, DOI 10.4049/jimmunol.169.8.4205; Tudor C, 2009, FEBS LETT, V583, P1933, DOI 10.1016/j.febslet.2009.04.039; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Voncken JW, 2005, J BIOL CHEM, V280, P5178, DOI 10.1074/jbc.M407155200; Weiss ID, 2010, J INTERF CYTOK RES, V30, P439, DOI 10.1089/jir.2009.0084; Young HA, 2007, CURR TOP MICROBIOL, V316, P97; Zakowski V, 2004, EXP CELL RES, V299, P101, DOI 10.1016/j.yexcr.2004.05.027; Zhao WP, 2011, J INTERF CYTOK RES, V31, P629, DOI 10.1089/jir.2010.0154	40	8	8	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4235	4246		10.1096/fj.14-249599	http://dx.doi.org/10.1096/fj.14-249599			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24935968	Green Published			2022-12-28	WOS:000342222700005
J	Fridolfsson, HN; Roth, DM; Insel, PA; Patel, HH				Fridolfsson, Heidi N.; Roth, David M.; Insel, Paul A.; Patel, Hemal H.			Regulation of intracellular signaling and function by caveolin	FASEB JOURNAL			English	Review						cholesterol; cell physiology; cellular organelles	NITRIC-OXIDE SYNTHASE; ONCOGENICALLY TRANSFORMED-CELLS; CARDIAC-SPECIFIC OVEREXPRESSION; ANCHORAGE-INDEPENDENT GROWTH; DOMINANT-NEGATIVE MUTANT; PLASMA-MEMBRANE CAVEOLAE; RAT-LIVER PEROXISOMES; BREAST-CANCER CELLS; ENDOTHELIAL-CELLS; IN-VIVO	Caveolae, flask-like invaginations of the plasma membrane, were discovered nearly 60 years ago. Originally regarded as fixation artifacts of electron microscopy, the functional role for these structures has taken decades to unravel. The discovery of the caveolin protein in 1992 (by the late Richard G. W. Anderson) accelerated progress in defining the contribution of caveolae to cellular physiology and pathophysiology. The three isoforms of caveolin (caveolin-1, -2, and -3) are caveolae-resident structural and scaffolding proteins that are critical for the formation of caveolae and their localization of signaling entities. A PubMed search for "caveolae" reveals similar to 280 publications from their discovery in the 1950s to the early 1990s, whereas a search for "caveolae or caveolin" after 1990, identifies similar to 7000 entries. Most work on the regulation of biological responses by caveolae and caveolin since 1990 has focused on caveolae as plasma membrane microdomains and the function of caveolin proteins at the plasma membrane. By contrast, our recent work and that of others has explored the localization of caveolins in multiple cellular membrane compartments and in the regulation of intracellular signaling. Cellular organelles that contain caveolin include mitochondria, nuclei and the endoplasmic reticulum. Such intracellular localization allows for a complexity of responses to extracellular stimuli by caveolin and the possibility of novel organelle-targeted therapeutics. This review focuses on the impact of intracellular localization of caveolin on signal transduction and cell regulation.	[Fridolfsson, Heidi N.; Roth, David M.; Patel, Hemal H.] VA San Diego Healthcare Syst, San Diego, CA USA; [Fridolfsson, Heidi N.; Roth, David M.; Patel, Hemal H.] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Insel, Paul A.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Insel, Paul A.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Patel, HH (corresponding author), Univ Calif San Diego, Dept Anesthesiol, VASDHS 9125, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	hepatel@ucsd.edu	Patel, Hemal/C-7325-2019	Patel, Hemal/0000-0001-6722-9625	AP Giannini Foundation; U.S. National Institute of Health [HL091071, HL107200, HL066941, HL115933]; VA Merit [BX001963, BX000783]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL115933, R01HL091071, R01HL107200, P01HL066941] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000783, I01BX001963] Funding Source: NIH RePORTER	AP Giannini Foundation; U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs(US Department of Veterans Affairs)	The authors thank Drs. Piyush Patel and Ingrid Niesman for help with summary figure and compilation of electron microscopy, respectively. This work was supported by grants from AP Giannini Foundation (H.N.F.), U.S. National Institute of Health HL091071 (H.H.P.), HL107200 (H.H.P.), HL066941 (D.M.R., H.H.P.), and HL115933 (D.M.R.), and VA Merit BX001963 (H.H.P.) and BX000783 (D.M.R.).	Asterholm IW, 2012, CELL METAB, V15, P171, DOI 10.1016/j.cmet.2012.01.004; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Bagnoli M, 2000, ONCOGENE, V19, P4754, DOI 10.1038/sj.onc.1203839; Blouin CM, 2010, J LIPID RES, V51, P945, DOI 10.1194/jlr.M001016; Bosch M, 2011, CURR BIOL, V21, P681, DOI 10.1016/j.cub.2011.03.030; Boscher C, 2013, MOL BIOL CELL, V24, P2134, DOI 10.1091/mbc.E13-02-0095; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Cohen AW, 2005, DIABETES, V54, P679, DOI 10.2337/diabetes.54.3.679; Cohen AW, 2004, DIABETES, V53, P1261, DOI 10.2337/diabetes.53.5.1261; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V285, pC222, DOI 10.1152/ajpcell.00006.2003; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Feng YY, 1999, INVEST OPHTH VIS SCI, V40, P157; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fridolfsson HN, 2012, FASEB J, V26, P4637, DOI 10.1096/fj.12-215798; Fuhs SR, 2011, J BIOL CHEM, V286, P14830, DOI 10.1074/jbc.M110.214270; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Gervasio OL, 2008, J CELL SCI, V121, P2246, DOI 10.1242/jcs.032003; Gkantiragas I, 2001, MOL BIOL CELL, V12, P1819, DOI 10.1091/mbc.12.6.1819; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Hausenloy DJ, 2007, HEART FAIL REV, V12, P217, DOI 10.1007/s10741-007-9026-1; Hayashi T, 2009, TRENDS CELL BIOL, V19, P81, DOI 10.1016/j.tcb.2008.12.002; Hayer A, 2010, J CELL BIOL, V191, P615, DOI 10.1083/jcb.201003086; Hayer A, 2010, TRAFFIC, V11, P361, DOI 10.1111/j.1600-0854.2009.01023.x; Head BP, 2008, FASEB J, V22, P828, DOI 10.1096/fj.07-9299com; Head BP, 2014, BBA-BIOMEMBRANES, V1838, P532, DOI 10.1016/j.bbamem.2013.07.018; Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042; Horikawa YT, 2011, J AM COLL CARDIOL, V57, P2273, DOI 10.1016/j.jacc.2010.12.032; Hu G, 2008, CIRC RES, V102, pE120, DOI 10.1161/CIRCRESAHA.107.167486; JACKLE S, 1991, J BIOL CHEM, V266, P1396; Jeong K, 2012, TRAFFIC, V13, P1218, DOI 10.1111/j.1600-0854.2012.01378.x; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kirchner P, 2013, J BIOL CHEM, V288, P7363, DOI 10.1074/jbc.M112.429076; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Krajewska WM, 2004, CELL MOL BIOL LETT, V9, P195; Kwon H, 2011, J CELL MOL MED, V15, P888, DOI 10.1111/j.1582-4934.2010.01079.x; Kwon H, 2009, J CELL MOL MED, V13, P1549, DOI 10.1111/j.1582-4934.2009.00391.x; Kwon H, 2009, BBA-MOL CELL RES, V1793, P1325, DOI 10.1016/j.bbamcr.2009.04.015; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LAZAROW PB, 1978, J BIOL CHEM, V253, P1522; Le Lay S, 2006, TRAFFIC, V7, P549, DOI 10.1111/j.1600-0854.2006.00406.x; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li WP, 2001, J CELL SCI, V114, P1397; Liu LB, 2008, CELL METAB, V8, P310, DOI 10.1016/j.cmet.2008.07.008; Liu LB, 2008, J BIOL CHEM, V283, P4314, DOI 10.1074/jbc.M707890200; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; Maniatis NA, 2008, AM J PHYSIOL-LUNG C, V294, pL865, DOI 10.1152/ajplung.00079.2007; Marchiando AM, 2010, J CELL BIOL, V189, P111, DOI 10.1083/jcb.200902153; Mastrodonato M, 2011, EUR J CLIN INVEST, V41, P642, DOI 10.1111/j.1365-2362.2010.02459.x; Meshulam T, 2006, BIOCHEMISTRY-US, V45, P2882, DOI 10.1021/bi051999b; Minshall RD, 2003, AM J PHYSIOL-LUNG C, V285, pL1179, DOI 10.1152/ajplung.00242.2003; Minshall RD, 2002, HISTOCHEM CELL BIOL, V117, P105, DOI 10.1007/s00418-001-0367-x; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; Mundy DI, 2012, MOL BIOL CELL, V23, P864, DOI 10.1091/mbc.E11-07-0598; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Niesman IR, 2013, MOL CELL NEUROSCI, V56, P283, DOI 10.1016/j.mcn.2013.07.002; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Orlichenko L, 2009, MOL BIOL CELL, V20, P4140, DOI 10.1091/mbc.E08-10-1043; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; PALADE GE, 1953, J APPL PHYS, V24, P1424; Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841; Patel HH, 2007, FASEB J, V21, P1565, DOI 10.1096/fj.06-7719com; Peart JN, 2009, AM J PHYSIOL-HEART C, V296, pH1705, DOI 10.1152/ajpheart.00162.2009; PEDERSEN JI, 1980, FEBS LETT, V121, P345, DOI 10.1016/0014-5793(80)80377-2; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Pol A, 2005, MOL BIOL CELL, V16, P2091, DOI 10.1091/mbc.E04-08-0737; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; Roth DM, 2011, PEDIATR CARDIOL, V32, P329, DOI 10.1007/s00246-010-9881-8; Sanna E, 2007, EXP CELL RES, V313, P1307, DOI 10.1016/j.yexcr.2007.02.005; Sano R, 2009, MOL CELL, V36, P500, DOI 10.1016/j.molcel.2009.10.021; Sasai K, 2003, J BIOL CHEM, V278, P25295, DOI 10.1074/jbc.M301913200; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shiroto T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087871; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Sun Y, 2009, CIRC RES, V105, P676, DOI 10.1161/CIRCRESAHA.109.201673; Tagawa A, 2005, J CELL BIOL, V170, P769, DOI 10.1083/jcb.200506103; Tsutsumi YM, 2008, CIRCULATION, V118, P1979, DOI 10.1161/CIRCULATIONAHA.108.788331; URBANI L, 1990, J BIOL CHEM, V265, P1919; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; Woudenberg J, 2010, HEPATOLOGY, V51, P1744, DOI 10.1002/hep.23460	104	122	128	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3823	3831		10.1096/fj.14-252320	http://dx.doi.org/10.1096/fj.14-252320			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24858278	Green Published			2022-12-28	WOS:000340845900001
J	Armani, A; Cinti, F; Marzolla, V; Morgan, J; Cranston, GA; Antelmi, A; Carpinelli, G; Canese, R; Pagotto, U; Quarta, C; Malorni, W; Matarrese, P; Marconi, M; Fabbri, A; Rosano, G; Cinti, S; Young, MJ; Caprio, M				Armani, Andrea; Cinti, Francesca; Marzolla, Vincenzo; Morgan, James; Cranston, Greg A.; Antelmi, Antonella; Carpinelli, Giulia; Canese, Rossella; Pagotto, Uberto; Quarta, Carmelo; Malorni, Walter; Matarrese, Paola; Marconi, Matteo; Fabbri, Andrea; Rosano, Giuseppe; Cinti, Saverio; Young, Morag J.; Caprio, Massimiliano			Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice	FASEB JOURNAL			English	Article						obesity; adipogenesis; aldosterone; metabolic syndrome; uncoupling protein 1; UCP1	GLUCOSE-HOMEOSTASIS; METABOLIC SYNDROME; GENE-EXPRESSION; ADULT HUMANS; IN-VIVO; ORGAN; ADIPOGENESIS; MOUSE; OBESITY; DIFFERENTIATION	The mineralocorticoid receptor (MR) controls adipocyte function, but its role in the conversion of white adipose tissue (WAT) into thermogenic fat has not been elucidated. We investigated responses to the MR antagonists spironolactone (spiro; 20 mg/kg/d) and drospirenone (DRSP; 6 mg/kg/d) in C57BL/6 mice fed a high-fat (HF) diet for 90 d. DRSP and spiro curbed HF diet-induced impairment in glucose tolerance, and prevented body weight gain and white fat expansion. Notably, either MR antagonist induced up-regulation of brown adipocyte-specific transcripts and markedly increased protein levels of uncoupling protein 1 (UCP1) in visceral and inguinal fat depots when compared with the HF diet group. Positron emission tomography and magnetic resonance spectroscopy confirmed acquisition of brown fat features in WAT. Interestingly, MR antagonists markedly reduced the autophagic rate both in murine preadipocytes in vitro (10(-5) M) and in WAT depots in vivo, with a concomitant increase in UCP1 protein expression. Moreover, the autophagy repressor bafilomycin A1 (10(-8) M) mimicked the effect of MR antagonists, increasing UCP1 protein expression in primary preadipocytes. Hence, we showed that adipocyte MR regulates brown remodeling of WAT through a modulation of autophagy. These results provide a rationale for the use of MR antagonists to prevent the adverse metabolic consequences of adipocyte dysfunction.-Armani, A., Cinti, F., Marzolla, V., Morgan, J., Cranston, G. A., Antelmi, A., Carpinelli, G., Canese, R., Pagotto, U., Quarta, C., Malorni, W., Matarrese, P., Marconi, M., Fabbri, A., Rosano, G., Cinti, S., Young, M. J., Caprio, M. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice.	[Armani, Andrea; Cinti, Francesca; Marzolla, Vincenzo; Antelmi, Antonella; Rosano, Giuseppe; Caprio, Massimiliano] Ist Ricovero & Cura Carattere Sci IRCCS San Raffa, Lab Cardiovasc Endocrinol, Rome, Italy; [Cinti, Francesca; Cinti, Saverio] United Hosp Univ Ancona, Ctr Study Obes, Dept Expt & Clin Med, Ancona, Italy; [Fabbri, Andrea] Univ Roma Tor Vergata, S Eugenio & CTO A Alesini Hosp, Dept Med Sistemi, Endocrinol Unit, Rome, Italy; [Morgan, James; Cranston, Greg A.] MIMR PHI, Med Res Inst, Clayton, Vic, Australia; [Carpinelli, Giulia; Canese, Rossella] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy; [Malorni, Walter; Matarrese, Paola; Marconi, Matteo] Ist Super Sanita, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy; [Pagotto, Uberto; Quarta, Carmelo] Alma Mater Univ Bologna, S Orsola Malpighi Hosp, Dept Med & Surg Sci, Endocrinol Unit, Bologna, Italy; [Pagotto, Uberto; Quarta, Carmelo] Alma Mater Univ Bologna, S Orsola Malpighi Hosp, Dept Med & Surg Sci, Ctr Appl Biomed Res, Bologna, Italy; [Malorni, Walter] San Raffaele Inst Sulmona, Laquila, Italy; [Matarrese, Paola] Ctr Integrated Metabol, Rome, Italy; [Young, Morag J.] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia; [Young, Morag J.] Monash Univ, Dept Med, Clayton, Vic, Australia	University of Rome Tor Vergata; Prince Henry's Institute of Medical Research; Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; Monash University; Monash University	Caprio, M (corresponding author), IRCCS San Raffaele Pisana Res Ctr, Via Val Cannuta 247, I-00166 Rome, Italy.	massimiliano.caprio@sanraffaele.it	Matarrese, Paola/A-4369-2014; Caprio, Massimiliano/J-3020-2012; Marconi, Matteo/AAC-4623-2021; Marzolla, Vincenzo/K-7769-2016; Quarta, Carmelo/AAC-1629-2020; Rosano, Giuseppe M. C./K-8718-2018; Armani, Andrea/AAC-2071-2022; Malorni, Walter/G-5874-2016; Canese, Rossella/B-3969-2017; Cinti, Francesca/AAY-5534-2021; Marzolla, Vincenzo/AAB-2300-2019	Caprio, Massimiliano/0000-0003-0722-7163; Marconi, Matteo/0000-0002-8648-5904; Marzolla, Vincenzo/0000-0002-2943-7631; Rosano, Giuseppe M. C./0000-0003-4023-2263; Armani, Andrea/0000-0002-2130-1596; Canese, Rossella/0000-0001-9093-6803; Cinti, Francesca/0000-0001-5170-7055; Marzolla, Vincenzo/0000-0002-2943-7631; malorni, walter/0000-0002-1223-7000; matarrese, paola/0000-0001-5477-3752; CINTI, Saverio/0000-0003-0362-5017; Quarta, Carmelo/0000-0002-1352-4239; Young, Morag/0000-0003-0450-5375	Italian Ministery of Health [GR-2009-1594563]; University Tor Vergata (Progetti Ricerca di Interesse Nazionale Ministero dell'Universita e della Ricerca); Associazione Italiana Ricerca Cancro (AIRC); Australia National Health and Medical Research Council (NHMRC) [990503]; Victorian Government	Italian Ministery of Health(Ministry of Health, Italy); University Tor Vergata (Progetti Ricerca di Interesse Nazionale Ministero dell'Universita e della Ricerca); Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Australia National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government	The authors thank Vladimir Patchev and Steffen Borden (Bayer Schering Pharma, Berlin, Germany) for providing DRSP and placebo pellets. This work was supported by grants from the Italian Ministery of Health (GR-2009-1594563 to M. C.), University Tor Vergata (Progetti Ricerca di Interesse Nazionale Ministero dell'Universita e della Ricerca, 2009 to A. F.), Associazione Italiana Ricerca Cancro (AIRC; to W. M.), and the Australia National Health and Medical Research Council (NHMRC; project grant 990503 to M. J. Y.). The Monash Institute of Medical Research-Prince Henry's Institute (MIMR-PHI) is supported by the Victorian Government's Operational Infrastructure Support Program. The authors declare no conflicts of interest.	Baerga R, 2009, AUTOPHAGY, V5, P1118, DOI 10.4161/auto.5.8.9991; Bao JF, 2013, NMR BIOMED, V26, P1663, DOI 10.1002/nbm.3000; Campion J, 1998, MOL CELL BIOCHEM, V185, P177, DOI 10.1023/A:1006871309864; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Caprio M, 2007, FASEB J, V21, P2185, DOI 10.1096/fj.06-7970com; Caprio M, 2011, ENDOCRINOLOGY, V152, P113, DOI 10.1210/en.2010-0674; Cinti S, 2001, P NUTR SOC, V60, P319, DOI 10.1079/PNS200192; Cinti S, 2012, DIS MODEL MECH, V5, P588, DOI 10.1242/dmm.009662; Cinti S, 2009, AM J PHYSIOL-ENDOC M, V297, pE977, DOI 10.1152/ajpendo.00183.2009; Collins S, 2004, PHYSIOL BEHAV, V81, P243, DOI 10.1016/j.physbeh.2004.02.006; COUSIN B, 1992, J CELL SCI, V103, P931; Cousin B, 1996, J CELL PHYSIOL, V167, P285, DOI 10.1002/(SICI)1097-4652(199605)167:2<285::AID-JCP12>3.0.CO;2-7; Cypess AM, 2013, NAT MED, V19, P635, DOI 10.1038/nm.3112; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; Fallo F, 2006, J CLIN ENDOCR METAB, V91, P454, DOI 10.1210/jc.2005-1733; Frontini A, 2010, CELL METAB, V11, P253, DOI 10.1016/j.cmet.2010.03.004; Fu MG, 2005, MOL ENDOCRINOL, V19, P2437, DOI 10.1210/me.2004-0539; Ghorbani M, 1997, INT J OBESITY, V21, P465, DOI 10.1038/sj.ijo.0800432; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Guo C, 2008, CIRCULATION, V117, P2253, DOI 10.1161/CIRCULATIONAHA.107.748640; Hamilton G, 2011, NMR BIOMED, V24, P784, DOI 10.1002/nbm.1622; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; Hirata A, 2009, CARDIOVASC RES, V84, P164, DOI 10.1093/cvr/cvp191; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Jaffe IZ, 2010, J CLIN INVEST, V120, P3891, DOI 10.1172/JCI40205; Jansen HJ, 2012, ENDOCRINOLOGY, V153, P5866, DOI 10.1210/en.2012-1625; Joshi AA, 2013, J MAGN RESON IMAGING, V37, P423, DOI 10.1002/jmri.23813; Klionsky DJ, 2008, AUTOPHAGY, V4, P849, DOI 10.4161/auto.6845; Leonardsson G, 2004, P NATL ACAD SCI USA, V101, P8437, DOI 10.1073/pnas.0401013101; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; Marroqui L, 2012, J MOL ENDOCRINOL, V49, pR9, DOI 10.1530/JME-12-0025; Marzolla V, 2012, MOL CELL ENDOCRINOL, V350, P281, DOI 10.1016/j.mce.2011.09.011; McInnes KJ, 2012, DIABETES, V61, P1072, DOI 10.2337/db11-1136; Mirbolooki MR, 2011, EJNMMI RES, V1, DOI 10.1186/2191-219X-1-30; Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823; Murano I, 2009, J ANAT, V214, P171, DOI 10.1111/j.1469-7580.2008.01001.x; Nagase M, 2006, J AM SOC NEPHROL, V17, P3438, DOI 10.1681/ASN.2006080944; Petrovic N, 2010, J BIOL CHEM, V285, P7153, DOI 10.1074/jbc.M109.053942; Quarta C, 2013, MOL METAB, V2, P153, DOI 10.1016/j.molmet.2013.04.002; Quarta C, 2010, CELL METAB, V11, P273, DOI 10.1016/j.cmet.2010.02.015; RONDINONE CM, 1993, ENDOCRINOLOGY, V132, P2421, DOI 10.1210/en.132.6.2421; Rosenwald M, 2013, NAT CELL BIOL, V15, P659, DOI 10.1038/ncb2740; Saito M, 2009, DIABETES, V58, P1526, DOI 10.2337/db09-0530; SBARBATI A, 1991, ANAT REC, V231, P293, DOI 10.1002/ar.1092310302; Seale P, 2011, J CLIN INVEST, V121, P96, DOI 10.1172/JCI44271; Singh R, 2009, J CLIN INVEST, V119, P3329, DOI 10.1172/JCI39228; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Stanford KI, 2013, J CLIN INVEST, V123, P215, DOI 10.1172/JCI62308; Tatsumi M, 2004, J NUCL MED, V45, P1189; Timmons JA, 2009, NEW ENGL J MED, V361, P415, DOI 10.1056/NEJMc091009; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Vitali A, 2012, J LIPID RES, V53, P619, DOI 10.1194/jlr.M018846; Wada T, 2010, ENDOCRINOLOGY, V151, P2040, DOI 10.1210/en.2009-0869; Whaley-Connell A, 2010, PROG CARDIOVASC DIS, V52, P401, DOI 10.1016/j.pcad.2009.12.004; Wu J, 2012, CELL, V150, P366, DOI 10.1016/j.cell.2012.05.016; YOUNG P, 1984, FEBS LETT, V167, P10, DOI 10.1016/0014-5793(84)80822-4; ZANCANARO C, 1994, J LIPID RES, V35, P2191; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915; Zhang Y, 2009, P NATL ACAD SCI USA, V106, P19860, DOI 10.1073/pnas.0906048106; Zingaretti MC, 2009, FASEB J, V23, P3113, DOI 10.1096/fj.09-133546; Zorriila EP, 2007, P NATL ACAD SCI USA, V104, P11097, DOI 10.1073/pnas.0611523104	61	98	103	0	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3745	3757		10.1096/fj.13-245415	http://dx.doi.org/10.1096/fj.13-245415			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24806198				2022-12-28	WOS:000340265400040
J	McGee, SL; Swinton, C; Morrison, S; Gaur, V; Campbell, DE; Jorgensen, SB; Kemp, BE; Baar, K; Steinberg, GR; Hargreaves, M				McGee, Sean L.; Swinton, Courtney; Morrison, Shona; Gaur, Vidhi; Campbell, Duncan E.; Jorgensen, Sebastian B.; Kemp, Bruce E.; Baar, Keith; Steinberg, Gregory R.; Hargreaves, M.			Compensatory regulation of HDAC5 in muscle maintains metabolic adaptive responses and metabolism in response to energetic stress	FASEB JOURNAL			English	Article						AMP-activated protein kinase; protein kinase D; skeletal muscle; exercise	HUMAN SKELETAL-MUSCLE; PROTEIN-KINASE-D; II HISTONE DEACETYLASES; ENDURANCE EXERCISE; NUCLEAR EXPORT; EXPRESSION; GLUT4; AMPK; TRANSCRIPTION; ACTIVATION	Some gene deletions or mutations have little effect on metabolism and metabolic adaptation because of redundancy and/or compensation in metabolic pathways. The mechanisms for redundancy and/or compensation in metabolic adaptation in mammalian cells are unidentified. Here, we show that in mouse muscle and myogenic cells, compensatory regulation of the histone deacetylase (HDAC5) transcriptional repressor maintains metabolic integrity. HDAC5 phosphorylation regulated the expression of diverse metabolic genes and glucose metabolism in mouse C2C12 myogenic cells. However, loss of AMP-activated protein kinase (AMPK), a HDAC5 kinase, in muscle did not affect HDAC5 phosphorylation in mouse skeletal muscle during exercise, but resulted in a compensatory increase (32.6%) in the activation of protein kinase D (PKD), an alternate HDAC5 kinase. Constitutive PKD activation in mouse C2C12 myogenic cells regulated metabolic genes and glucose metabolism. Although aspects of this response were HDAC5 phosphorylation dependent, blocking HDAC5 phosphorylation when PKD was active engaged an alternative compensatory adaptive mechanism, which involved post-transcriptional reductions in HDAC5 mRNA (-93.1%) and protein. This enhanced the expression of a specific subset of metabolic genes and mitochondrial metabolism. These data show that compensatory regulation of HDAC5 maintains metabolic integrity in mammalian cells and reinforces the importance of preserving the cellular metabolic adaptive response.	[McGee, Sean L.; Swinton, Courtney; Morrison, Shona; Gaur, Vidhi; Campbell, Duncan E.] Deakin Univ, Sch Med, Metab Remodelling Lab, Metab Res Unit, Waurn Ponds, Vic 3217, Australia; [McGee, Sean L.] Baker Int Diabet Inst, Heart & Diabet Inst, Div Cell Signalling & Metab, Melbourne, Vic, Australia; [Campbell, Duncan E.; Hargreaves, M.] Univ Melbourne, Dept Physiol, Parkville, Vic 3052, Australia; [Jorgensen, Sebastian B.; Kemp, Bruce E.; Steinberg, Gregory R.] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; [Jorgensen, Sebastian B.] Novo Nordisk AS, Diabet Res Unit, Malov, Denmark; [Baar, Keith] Univ Calif Davis, Dept Neurobiol Physiol & Behav, Davis, CA 95616 USA; [Steinberg, Gregory R.] McMaster Univ, Dept Med, Hamilton, ON, Canada	Deakin University; University of Melbourne; St. Vincent's Institute of Medical Research; Novo Nordisk; University of California System; University of California Davis; McMaster University	McGee, SL (corresponding author), Deakin Univ, Sch Med, Metab Remodelling Lab, Metab Res Unit, Pigdons Rd, Waurn Ponds, Vic 3217, Australia.	sean.mcgee@deakin.edu.au	Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082; Steinberg, Gregory/0000-0001-5425-8275; Baar, Keith/0000-0001-9337-6186	Australia National Health and Medical Research Council (NHMRC); Diabetes Australia Research Trust Viertel Award; NHMRC	Australia National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Diabetes Australia Research Trust Viertel Award; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank Frosa Katsis (St. Vincent's Institute, Fitzroy, VIC, Australia) for the generation of HDAC5 and ACC phospho-specific antibodies and Professor Doreen Cantrell (The University of Dundee, Dundee, UK) for the PKD plasmids. This study was supported by grants from the Australia National Health and Medical Research Council (NHMRC) to S. L. M., B. E. K., and G. R. S. S. L. M. is supported by the Diabetes Australia Research Trust Viertel Award and a Career Development Fellowship from the NHMRC. Author contributions: S. L. M. and M. H. conceived the research; S. L. M., C. S., S. M., V. G., D. E. C., and S.B.J. performed experiments and analyzed data; B. E. K., K. B., and G. R. S. provided technical expertise and reagents; S. L. M. wrote the paper; all authors edited the paper and approved the final version.	Backs J, 2011, J CELL BIOL, V195, P403, DOI 10.1083/jcb.201105063; Barnes BR, 2004, J BIOL CHEM, V279, P38441, DOI 10.1074/jbc.M405533200; Booth FW, 2009, J PHYSIOL-LONDON, V587, P5527, DOI 10.1113/jphysiol.2009.179507; Chang SR, 2005, P NATL ACAD SCI USA, V102, P8120, DOI 10.1073/pnas.0503275102; Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202, DOI 10.1152/ajpendo.2000.279.5.E1202; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Davis FJ, 2003, J BIOL CHEM, V278, P20047, DOI 10.1074/jbc.M209998200; Dzamko N, 2008, J PHYSIOL-LONDON, V586, P5819, DOI 10.1113/jphysiol.2008.159814; Egan B, 2013, CELL METAB, V17, P162, DOI 10.1016/j.cmet.2012.12.012; Harrison R, 2007, P NATL ACAD SCI USA, V104, P2307, DOI 10.1073/pnas.0607153104; Holmes BF, 2004, AM J PHYSIOL-ENDOC M, V287, pE739, DOI 10.1152/ajpendo.00080.2004; Hood DA, 2006, J EXP BIOL, V209, P2265, DOI 10.1242/jeb.02182; Hoppeler H, 2011, COMPR PHYSIOL, V1, P1383, DOI 10.1002/cphy.c100042; Jorgensen SB, 2005, FASEB J, V19, P1146, DOI 10.1096/fj.04-3144fje; Jorgensen SB, 2007, AM J PHYSIOL-ENDOC M, V292, pE331, DOI 10.1152/ajpendo.00243.2006; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; Leick L, 2008, AM J PHYSIOL-ENDOC M, V294, pE463, DOI 10.1152/ajpendo.00666.2007; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Li XN, 2009, DIABETES, V58, P2246, DOI 10.2337/db08-1512; Mahoney DJ, 2005, FASEB J, V19, P1498, DOI 10.1096/fj.04-3149fje; Marklund U, 2003, IMMUNITY, V19, P491, DOI 10.1016/S1074-7613(03)00260-7; Matthews SA, 2006, MOL CELL BIOL, V26, P1569, DOI 10.1128/MCB.26.4.1569-1577.2006; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mcgee SL, 2008, DIABETES, V57, P860, DOI 10.2337/db07-0843; McGee SL, 2007, APPL PHYSIOL NUTR ME, V32, P852, DOI 10.1139/H07-082; McGee SL, 2011, CELL PHYSIOL BIOCHEM, V28, P157, DOI 10.1159/000331724; McGee SL, 2010, CLIN EXP PHARMACOL P, V37, P392, DOI 10.1111/j.1440-1681.2009.05311.x; McGee SL, 2009, J PHYSIOL-LONDON, V587, P5951, DOI 10.1113/jphysiol.2009.181065; McGee SL, 2004, DIABETES, V53, P1208, DOI 10.2337/diabetes.53.5.1208; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Min Y, 2011, J THEOR BIOL, V270, P63, DOI 10.1016/j.jtbi.2010.11.012; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Murgia M, 2009, J PHYSIOL-LONDON, V587, P4319, DOI 10.1113/jphysiol.2009.174888; Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051; Potthoff MJ, 2007, J CLIN INVEST, V117, P2459, DOI 10.1172/JCI31960; Rozengurt E, 2011, PHYSIOLOGY, V26, P23, DOI 10.1152/physiol.00037.2010; Russell AP, 2013, J PHYSIOL-LONDON, V591, P4637, DOI 10.1113/jphysiol.2013.255695; Soyer OS, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000907; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Wagner A, 2005, BIOESSAYS, V27, P176, DOI 10.1002/bies.20170; Wang SB, 2010, J BIOL CHEM, V285, P19976, DOI 10.1074/jbc.M110.102467; Wang SX, 2010, CIRC RES, V106, P1117, DOI 10.1161/CIRCRESAHA.109.212530; Winbanks CE, 2011, J BIOL CHEM, V286, P13805, DOI 10.1074/jbc.M110.192625; Zabet NR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073714; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	46	35	38	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3384	3395		10.1096/fj.14-249359	http://dx.doi.org/10.1096/fj.14-249359			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24732133				2022-12-28	WOS:000340265400010
J	Pereira, RO; Wende, AR; Crum, A; Hunter, D; Olsen, CD; Rawlings, T; Riehle, C; Ward, WF; Abel, ED				Pereira, Renata O.; Wende, Adam R.; Crum, Ashley; Hunter, Douglas; Olsen, Curtis D.; Rawlings, Tenley; Riehle, Christian; Ward, Walter F.; Abel, E. Dale			Maintaining PGC-1 alpha expression following pressure overload-induced cardiac hypertrophy preserves angiogenesis but not contractile or mitochondrial function	FASEB JOURNAL			English	Article						mitochondria; heart failure	TRANSCRIPTIONAL COACTIVATOR PGC-1-ALPHA; PROLIFERATOR-ACTIVATED-RECEPTOR; FATTY-ACID OXIDATION; HEART-FAILURE; ENERGY-METABOLISM; SYSTOLIC OVERLOAD; SKELETAL-MUSCLE; BIOGENESIS; ENERGETICS; PROTEINS	During pathological hypertrophy, peroxisome proliferator-activated receptor coactivator 1 alpha (PGC-1 alpha) is repressed in concert with reduced mitochondrial oxidative capacity and fatty acid oxidation (FAO). We therefore sought to determine if maintaining or increasing PGC-1 alpha levels in the context of pressure overload hypertrophy (POH) would preserve mitochondrial function and prevent contractile dysfunction. Pathological cardiac hypertrophy was induced using 4 wk of transverse aortic constriction (TAC) in mice overexpressing the human PGC-1 alpha genomic locus via a bacterial artificial chromosome (TG) and non-transgenic controls (Cont). PGC-1 alpha levels were increased by 40% in TG mice and were sustained following TAC. Although TAC-induced repression of FAO genes and oxidative phosphorylation (oxphos) genes was prevented in TG mice, mitochondrial function and ATP synthesis were equivalently impaired in Cont and TG mice after TAC. Contractile function was also equally impaired in Cont and TG mice following TAC, as demonstrated by decreased +dP/dt and ejection fraction and increased left ventricular developed pressure and end diastolic pressure. Conversely, capillary density was preserved, in concert with increased VEGF expression, while apoptosis and fibrosis were reduced in TG relative to Cont mice after TAC. Hence, sustaining physiological levels of PGC-1 alpha expression following POH, while preserving myocardial vascularity, does not prevent mitochondrial and contractile dysfunction.-Pereira, R. O., Wende, A. R., Crum, A., Hunter, D., Olsen, C. D., Rawlings, T., Riehle, C., Ward, W. F., Abel, E. D. Maintaining PGC-1 alpha expression following pressure overload-induced cardiac hypertrophy preserves angiogenesis but not contractile or mitochondrial function.	[Pereira, Renata O.; Riehle, Christian; Abel, E. Dale] Univ Iowa, Roy J & Lucille A Carver Coll Med, Div Endocrinol & Metab, Fraternal Order Eagles Diabet Res Ctr, Iowa City, IA 52242 USA; [Pereira, Renata O.; Wende, Adam R.; Crum, Ashley; Hunter, Douglas; Olsen, Curtis D.; Rawlings, Tenley; Riehle, Christian; Abel, E. Dale] Univ Utah, Sch Med, Div Endocrinol Metab & Diabet, Salt Lake City, UT USA; [Pereira, Renata O.; Wende, Adam R.; Crum, Ashley; Hunter, Douglas; Olsen, Curtis D.; Rawlings, Tenley; Riehle, Christian; Abel, E. Dale] Univ Utah, Sch Med, Program Mol Med, Salt Lake City, UT USA; [Ward, Walter F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA	University of Iowa; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Texas System; University of Texas Health San Antonio	Abel, ED (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Div Endocrinol & Metab, Fraternal Order Eagles Diabet Res Ctr, 108 CMAB,451 Newton Rd, Iowa City, IA 52242 USA.	drcadmin@uiowa.edu	Wende, Adam/AFG-8878-2022	Wende, Adam/0000-0002-5536-4675; Abel, E. Dale/0000-0001-5290-0738; Klc, Tenley/0000-0003-0680-992X	U.S. National Institutes of Health (NIH) [RO1-DK-092065, U01-HL-087947]; AHA Western Affiliates; NIH [5T32-HL-007576]; Juvenile Diabetes Research Foundation; German Research Foundation (DFG);  [PO1-HD-038129]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD038129] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL087947, T32HL007576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK092065] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AHA Western Affiliates; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); German Research Foundation (DFG)(German Research Foundation (DFG)); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Jeffrey Lei, Sylvia Hu, and Li Wang for important technical help during the course of these studies. These studies were supported by U.S. National Institutes of Health (NIH) grants RO1-DK-092065 and U01-HL-087947 to E. D. A., who is an established investigator of the American Heart Association (AHA), and by grant PO1-HD-038129. R. O. P. was supported by a postdoctoral fellowship from the AHA Western Affiliates and NIH grant 5T32-HL-007576. A. R. W. was supported by an advanced postdoctoral fellowship from the Juvenile Diabetes Research Foundation and a postdoctoral fellowship from the AHA Western Affiliates. C. R. was supported by a postdoctoral fellowship from the German Research Foundation (DFG).	Abel ED, 2011, CARDIOVASC RES, V90, P234, DOI 10.1093/cvr/cvr015; Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Arany Z, 2006, P NATL ACAD SCI USA, V103, P10086, DOI 10.1073/pnas.0603615103; Boudina S, 2005, CIRCULATION, V112, P2686, DOI 10.1161/CIRCULATIONAHA.105.554360; Boudina S, 2007, DIABETES, V56, P2457, DOI 10.2337/db07-0481; GUNDERSEN HJG, 1977, DIABETOLOGIA, V13, P43, DOI 10.1007/BF00996326; Hu XL, 2008, CIRC RES, V103, P1009, DOI 10.1161/CIRCRESAHA.107.170795; Hu XL, 2011, HYPERTENSION, V58, P696, DOI 10.1161/HYPERTENSIONAHA.111.174128; Huss JM, 2007, CELL METAB, V6, P25, DOI 10.1016/j.cmet.2007.06.005; Huss JM, 2005, J CLIN INVEST, V115, P547, DOI 10.1172/JCI200524405; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Karamanlidis G, 2010, CIRC RES, V106, P1541, DOI 10.1161/CIRCRESAHA.109.212753; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lehman JJ, 2008, AM J PHYSIOL-HEART C, V295, pH185, DOI 10.1152/ajpheart.00081.2008; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Liang H, 2009, AM J PHYSIOL-ENDOC M, V296, pE945, DOI 10.1152/ajpendo.90292.2008; Lu ZB, 2010, ANTIOXID REDOX SIGN, V13, P1011, DOI 10.1089/ars.2009.2940; Mazumder PK, 2004, DIABETES, V53, P2366, DOI 10.2337/diabetes.53.9.2366; Mettauer B, 2006, PFLUG ARCH EUR J PHY, V452, P653, DOI 10.1007/s00424-006-0072-7; Patten IS, 2012, NATURE, V485, P333, DOI 10.1038/nature11040; Patten IS, 2012, TRENDS ENDOCRIN MET, V23, P90, DOI 10.1016/j.tem.2011.09.007; Pereira RO, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000301; Riehle C, 2013, J CLIN INVEST, V123, P5319, DOI 10.1172/JCI71171; Riehle C, 2012, TRENDS CARDIOVAS MED, V22, P98, DOI 10.1016/j.tcm.2012.07.003; Riehle C, 2011, CIRC RES, V109, P783, DOI 10.1161/CIRCRESAHA.111.243964; Rimbaud S, 2009, PHARMACOL REP, V61, P131, DOI 10.1016/S1734-1140(09)70015-5; Sena S, 2007, ENDOCRINOLOGY, V148, P6047, DOI 10.1210/en.2006-1559	28	37	40	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3691	3702		10.1096/fj.14-253823	http://dx.doi.org/10.1096/fj.14-253823			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24776744	Green Published			2022-12-28	WOS:000340265400036
J	Buler, M; Aatsinki, SM; Izzi, V; Uusimaa, J; Hakkola, J				Buler, Marcin; Aatsinki, Sanna-Mari; Izzi, Valerio; Uusimaa, Johanna; Hakkola, Jukka			SIRT5 is under the control of PGC-1 alpha and AMPK and is involved in regulation of mitochondrial energy metabolism	FASEB JOURNAL			English	Article						metformin; ATP; ERR alpha; PPAR alpha	PROLIFERATOR-ACTIVATED RECEPTOR; FATTY-ACID OXIDATION; HEPATIC GLUCONEOGENESIS; TRANSCRIPTIONAL CONTROL; SKELETAL-MUSCLE; GENE-EXPRESSION; PROTEIN-KINASE; METFORMIN; ALPHA; DEACETYLASE	The sirtuins (SIRTs; SIRT1-7) are a family of NAD(+)-dependent enzymes that dynamically regulate cellular physiology. Apart from SIRT1, the functions and regulatory mechanisms of the SIRTs are poorly defined. We explored regulation of the SIRT family by 2 energy metabolism-controlling factors: peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha) and AMP-activated protein kinase (AMPK). Overexpression of PGC-1 alpha in mouse primary hepatocytes increased SIRT5 mRNA expression 4-fold and also the protein in a peroxisome proliferator-activated receptor alpha (PPAR alpha)-and estrogen-related receptor alpha (ERR alpha)-dependent manner. Furthermore, food withdrawal increased SIRT5 mRNA 1.3-fold in rat liver. Overexpression of AMPK in mouse hepatocytes increased expression of SIRT1, SIRT2, SIRT3, and SIRT6 <2-fold. In contrast, SIRT5 mRNA was down-regulated by 58%. The antidiabetes drug metformin (1 mM), an established AMPK activator, reduced the mouse SIRT5 protein level by 44% in cultured hepatocytes and by 31% in liver in vivo (300 mg/kg, 7 d). Metformin also induced hypersuccinylation of mitochondrial proteins. Moreover, SIRT5 overexpression increased ATP synthesis and oxygen consumption in HepG2 cells, but did not affect mitochondrial biogenesis. In summary, our results identified SIRT5 as a novel factor that controls mitochondrial function. Moreover, SIRT5 levels are regulated by PGC-1 alpha and AMPK, which have opposite effects on its expression.	[Buler, Marcin; Aatsinki, Sanna-Mari; Hakkola, Jukka] Univ Oulu, Oulu Univ Hosp, Dept Pharmacol & Toxicol, Inst Biomed, Oulu 90014, Finland; [Izzi, Valerio] Univ Oulu, Oulu Univ Hosp, Ctr Cell Matrix Res, Oulu 90014, Finland; [Izzi, Valerio] Univ Oulu, Oulu Univ Hosp, Bioctr Oulu, Dept Med Biochem & Mol Biol, Oulu 90014, Finland; [Buler, Marcin; Aatsinki, Sanna-Mari; Uusimaa, Johanna; Hakkola, Jukka] Univ Oulu, Oulu Univ Hosp, Med Res Ctr Oulu, Oulu 90014, Finland; [Uusimaa, Johanna] Univ Oulu, Oulu Univ Hosp, Clin Res Ctr, Inst Clin Med & Pediat, Oulu 90014, Finland	University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu	Hakkola, J (corresponding author), Univ Oulu, Dept Pharmacol & Toxicol, Inst Biomed, POB 5000 Aapistie 5B, Oulu 90014, Finland.	jukka.hakkola@oulu.fi	Izzi, Valerio/Q-5720-2019	Izzi, Valerio/0000-0002-9960-4917; Hakkola, Jukka/0000-0001-5048-4363	Finnish Diabetes Research Foundation; Diabetes Wellness Finland; Research Council for Health of the Academy of Finland [138566]	Finnish Diabetes Research Foundation; Diabetes Wellness Finland; Research Council for Health of the Academy of Finland	The authors thank R. Tauriainen for skillful technical assistance. The work was supported by grants from the Finnish Diabetes Research Foundation, Diabetes Wellness Finland, and the Research Council for Health of the Academy of Finland (to J.U.; decision no. 138566).	Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105; Anisimov VN, 2005, EXP GERONTOL, V40, P685, DOI 10.1016/j.exger.2005.07.007; Benton CR, 2008, APPL PHYSIOL NUTR ME, V33, P843, DOI 10.1139/H08-074; Berglund ED, 2010, AM J PHYSIOL-ENDOC M, V299, pE607, DOI 10.1152/ajpendo.00263.2010; Buler M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049863; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Caton PW, 2010, J ENDOCRINOL, V205, P97, DOI 10.1677/JOE-09-0345; Chalkiadaki A, 2012, NAT REV ENDOCRINOL, V8, P287, DOI 10.1038/nrendo.2011.225; De Souza AT, 2006, NUCLEIC ACIDS RES, V34, P4486, DOI 10.1093/nar/gkl609; Silva FMD, 2010, MOL CELL BIOCHEM, V340, P283, DOI 10.1007/s11010-010-0429-2; Du JT, 2011, SCIENCE, V334, P806, DOI 10.1126/science.1207861; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; Feldman JL, 2012, J BIOL CHEM, V287, P42419, DOI 10.1074/jbc.R112.378877; Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Foretz M, 2010, J CLIN INVEST, V120, P2355, DOI 10.1172/JCI40671; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004; Funk JA, 2010, J PHARMACOL EXP THER, V333, P593, DOI 10.1124/jpet.109.161992; Gaillard S, 2006, MOL CELL, V24, P797, DOI 10.1016/j.molcel.2006.10.012; Geng YQ, 2011, J CELL BIOCHEM, V112, P3755, DOI 10.1002/jcb.23315; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Herzog B, 2006, J BIOL CHEM, V281, P99, DOI 10.1074/jbc.M509276200; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jeninga EH, 2010, ONCOGENE, V29, P4617, DOI 10.1038/onc.2010.206; Jiang WQ, 2008, CANCER RES, V68, P5492, DOI 10.1158/0008-5472.CAN-07-6721; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kong XX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011707; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; Marroquin LD, 2007, TOXICOL SCI, V97, P539, DOI 10.1093/toxsci/kfm052; MATTHEWS JNS, 1990, BRIT MED J, V300, P680, DOI 10.1136/bmj.300.6725.680-a; Miller RA, 2013, NATURE, V494, P256, DOI 10.1038/nature11808; Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026; Nakamura Y, 2012, FEBS LETT, V586, P4076, DOI 10.1016/j.febslet.2012.10.009; Narayan N, 2012, NATURE, V492, P199, DOI 10.1038/nature11700; Ogura M, 2010, BIOCHEM BIOPH RES CO, V393, P73, DOI 10.1016/j.bbrc.2010.01.081; Park J, 2013, MOL CELL, V50, P919, DOI 10.1016/j.molcel.2013.06.001; Peng C, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.012658; Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Rakhshandehroo M, 2007, PPAR RES, V2007, DOI 10.1155/2007/26839; Ramakrishnan G, 2014, J BIOL CHEM, V289, P6054, DOI 10.1074/jbc.M113.537266; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwer B, 2009, AGING CELL, V8, P604, DOI 10.1111/j.1474-9726.2009.00503.x; Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005; Ulvila J, 2004, BIOCHEM J, V381, P887, DOI 10.1042/BJ20040387; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Ventura-Clapier R, 2008, CARDIOVASC RES, V79, P208, DOI 10.1093/cvr/cvn098; Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386; Weinert BT, 2013, CELL REP, V4, P842, DOI 10.1016/j.celrep.2013.07.024; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yu JJ, 2013, SCI REP-UK, V3, DOI 10.1038/srep02806; Zhang PX, 2005, FEBS LETT, V579, P1446, DOI 10.1016/j.febslet.2005.01.046	64	81	92	2	50	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3225	3237		10.1096/fj.13-245241	http://dx.doi.org/10.1096/fj.13-245241			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24687991				2022-12-28	WOS:000337949400042
J	Hartman, ME; Liu, YG; Zhu, WZ; Chien, WM; Weldy, CS; Fishman, GI; Laflamme, MA; Chin, MT				Hartman, Matthew E.; Liu, Yonggang; Zhu, Wei-Zhong; Chien, Wei-Ming; Weldy, Chad S.; Fishman, Glenn I.; Laflamme, Michael A.; Chin, Michael T.			Myocardial deletion of transcription factor CHF1/Hey2 results in altered myocyte action potential and mild conduction system expansion but does not alter conduction system function or promote spontaneous arrhythmias	FASEB JOURNAL			English	Article						Brugada syndrome; Notch signaling; electrophysiology; heart rate variability	CELL-DERIVED CARDIOMYOCYTES; ATRIAL GENE-EXPRESSION; CARDIAC CONDUCTION; MESENCHYMAL TRANSITION; BRUGADA SYNDROME; MICE LACKING; FACTOR TBX5; STEM-CELLS; HEART; NOTCH	CHF1/Hey2 is a Notch-responsive basic helix-loop-helix transcription factor involved in cardiac development. Common variants in Hey2 are associated with Brugada syndrome. We hypothesized that absence of CHF1/Hey2 would result in abnormal cellular electrical activity, altered cardiac conduction system (CCS) development, and increased arrhythmogenesis. We isolated neonatal CHF/Hey2-knockout (KO) cardiac myocytes and measured action potentials and ion channel subunit gene expression. We also crossed myocardial-specific CHF1/Hey2-KO mice with cardiac conduction system LacZ reporter mice and stained for conduction system tissue. We also performed ambulatory ECG monitoring for arrhythmias and heart rate variability. Neonatal cardiomyocytes from CHF1/Hey2-KO mice demonstrate a 50% reduction in action potential dV/dT, a 50-75% reduction in SCN5A, KCNJ2, and CACNA1C ion channel subunit gene expression, and an increase in delayed afterdepolarizations from 0/min to 12/min. CHF1/Hey2 cKO CCS-lacZ mice have a similar to 3-fold increase in amount of CCS tissue. Ambulatory ECG monitoring showed no difference in cardiac conduction, arrhythmias, or heart rate variability. Wild-type cells or animals were used in all experiments. CHF1/Hey2 may contribute to Brugada syndrome by influencing the expression of SCN5A and formation of the cardiac conduction system, but its absence does not cause baseline conduction defects or arrhythmias in the adult mouse.	[Hartman, Matthew E.; Liu, Yonggang; Chien, Wei-Ming; Weldy, Chad S.; Chin, Michael T.] Univ Washington, Div Cardiol, Dept Med, Seattle, WA 98195 USA; [Zhu, Wei-Zhong; Laflamme, Michael A.; Chin, Michael T.] Univ Washington, Dept Pathol, Inst Stem Cells & Regenerat Med, Seattle, WA 98195 USA; [Fishman, Glenn I.] NYU, Sch Med, Dept Med, Leon H Charney Div Cardiol, New York, NY USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; New York University	Chin, MT (corresponding author), UW Med South Lake Union, Ctr Cardiovasc Biol, 850 Republican St,Brotman 353, Seattle, WA 98109 USA.	mtchin@u.washington.edu	Laflamme, Michael/AAV-6791-2021	Laflamme, Michael/0000-0001-5908-880X; Hartman, Matt/0000-0002-6238-1887; Fishman, Glenn/0000-0002-2366-8527; Weldy, Chad/0000-0003-4652-6422	John L. Locke Foundation; U.S. National Institutes of Health (NIH) [T32 HL07828]; NIH [T32 HL007312, PO1-HL094374, R01HL105983]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007828, T32HL007312, R01HL105983, P01HL094374] Funding Source: NIH RePORTER	John L. Locke Foundation; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by a grant from the John L. Locke Foundation to M. T. C. M. E. H. was supported by U.S. National Institutes of Health (NIH) training grant T32 HL07828. C. S. W. was supported by NIH training grant T32 HL007312. W.Z.Z. and M. A. L. were supported by NIH grant PO1-HL094374. G. I. F. was supported by NIH grant R01HL105983. M. A. L. is a cofounder of and has equity in BEAT Biotechnology.	Berul CI, 2001, CIRCULATION, V104, P2734, DOI 10.1161/hc4701.099582; Bezzina CR, 2013, NAT GENET, V45, P1044, DOI 10.1038/ng.2712; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Drici MD, 1998, CIRC RES, V83, P95, DOI 10.1161/01.RES.83.1.95; Fijnvandraat AC, 2003, CARDIOVASC RES, V58, P303, DOI 10.1016/S0008-6363(03)00246-3; Fischer A, 2007, CIRC RES, V100, P856, DOI 10.1161/01.RES.0000260913.95642.3b; GOURDIE RG, 1995, DEVELOPMENT, V121, P1423; Hartman ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093033; High FA, 2008, NAT REV GENET, V9, P49, DOI 10.1038/nrg2279; King IN, 2006, BIOCHEM BIOPH RES CO, V345, P446, DOI 10.1016/j.bbrc.2006.04.097; Koibuchi N, 2007, CIRC RES, V100, P850, DOI 10.1161/01.RES.0000261693.13269.bf; Kokubo H, 2004, CIRC RES, V95, P540, DOI 10.1161/01.RES.0000141136.85194.f0; Kokubo H, 2007, DEVELOPMENT, V134, P747, DOI 10.1242/dev.02777; Liu YG, 2012, AM J PHYSIOL-HEART C, V302, pH1860, DOI 10.1152/ajpheart.00702.2011; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mizusawa Y, 2012, CIRC-ARRHYTHMIA ELEC, V5, P606, DOI 10.1161/CIRCEP.111.964577; Moskowitz IPG, 2004, DEVELOPMENT, V131, P4107, DOI 10.1242/dev.01265; Moskowitz IPG, 2007, CELL, V129, P1365, DOI 10.1016/j.cell.2007.04.036; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Reamon-Buettner Stella Marie, 2006, Hum Mutat, V27, P118, DOI 10.1002/humu.9390; Rentschler S, 2002, P NATL ACAD SCI USA, V99, P10464, DOI 10.1073/pnas.162301699; Rentschler S, 2001, DEVELOPMENT, V128, P1785; Rentschler S, 2003, NOVART FDN SYMP, V250, P276; Rentschler S, 2003, NOVART FDN SYMP, V250, P205; Rentschler S, 2012, CIRCULATION, V126, P1058, DOI 10.1161/CIRCULATIONAHA.112.103390; Rentschler S, 2011, J CLIN INVEST, V121, P525, DOI 10.1172/JCI44470; Rentschler Stacey, 2003, Novartis Found Symp, V250, P194; Sakata Y, 2006, J MOL CELL CARDIOL, V40, P267, DOI 10.1016/j.yjmcc.2005.09.006; Sakata Y, 2002, P NATL ACAD SCI USA, V99, P16197, DOI 10.1073/pnas.252648999; Shiba Y, 2009, CURR PHARM DESIGN, V15, P2791, DOI 10.2174/138161209788923804; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; Watanabe T, 2010, MECH DEVELOP, V127, P418, DOI 10.1016/j.mod.2010.07.001; Xiang F, 2006, AM J PHYSIOL-HEART C, V290, pH1997, DOI 10.1152/ajpheart.01106.2005; Xin M, 2007, P NATL ACAD SCI USA, V104, P7975, DOI 10.1073/pnas.0702447104; Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030; Zhu WZ, 2010, CIRC RES, V107, P776, DOI 10.1161/CIRCRESAHA.110.223917; Zhu WZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005407	38	17	17	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3007	3015		10.1096/fj.14-251728	http://dx.doi.org/10.1096/fj.14-251728			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24687990	Green Published			2022-12-28	WOS:000337949400023
J	Jia, YJ; Peng, LW; Rao, Q; Xing, HY; Huai, L; Yu, P; Chen, YR; Wang, CC; Wang, M; Mi, YC; Wang, JX				Jia, Yujiao; Peng, Leiwen; Rao, Qing; Xing, Haiyan; Huai, Lei; Yu, Pei; Chen, Yirui; Wang, Cuicui; Wang, Min; Mi, Yingchang; Wang, Jianxiang			Oncogene iASPP enhances self-renewal of hematopoietic stem cells and facilitates their resistance to chemotherapy and irradiation	FASEB JOURNAL			English	Article						transgenic; self-renewal; HSC; antiapoptosis	ACUTE MYELOID-LEUKEMIA; CANCER CELLS; P53; EXPRESSION; APOPTOSIS; ASPP; GENE; FAMILY; DEATH; MICE	iASPP is a member of the apoptosisstimulating proteins of p53 (ASPP) family and negatively regulates the apoptotic function of p53. In a hematopoietic system, overexpression of iASPP results in blockage of apoptosis, which may play a role in regulating hematopoietic stem cell (HSC) numbers. To address this, we first analyzed the expression of iASPP in patients with acute leukemia (AL) and found it was highly expressed in patients with AL. We further established a transgenic mouse model in which human iASPP was specifically expressed in hematopoietic cells. Overexpression of iASPP led to an increase in the proportion of long-term HSCs, short-term HSCs, multipotent progenitors, and common myeloid progenitor. HSCs from iASPP transgenic mice had an advantage in long-term reconstitution potential. In addition, the hematopoietic cells from iASPP transgenic mice exhibited a significantly lower level of p53 dependent apoptosis. After irradiation damage, hematopoietic cells of iASPP transgenic mice had a higher level of gamma-H2AX expression, which lasted for a longer time. These results provide the first evidence that the iASPP can increase HSC populations and reconstitution capacity. Interestingly, in response to cell damage stimuli, hematopoietic cells can be protected against apoptosis by iASPP; meanwhile these apoptosis-resistant cells would have more mutation accumulation, which might be the potential risk for malignant transformation.	[Jia, Yujiao; Peng, Leiwen; Rao, Qing; Xing, Haiyan; Huai, Lei; Yu, Pei; Chen, Yirui; Wang, Cuicui; Wang, Min; Mi, Yingchang; Wang, Jianxiang] Chinese Acad Med Sci, State Key Lab Expt Hematol, Inst Hematol, 288 Nanjing Rd, Tianjin 300020, Peoples R China; [Jia, Yujiao; Peng, Leiwen; Rao, Qing; Xing, Haiyan; Huai, Lei; Yu, Pei; Chen, Yirui; Wang, Cuicui; Wang, Min; Mi, Yingchang; Wang, Jianxiang] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China; [Jia, Yujiao; Peng, Leiwen; Rao, Qing; Xing, Haiyan; Huai, Lei; Yu, Pei; Chen, Yirui; Wang, Cuicui; Wang, Min; Mi, Yingchang; Wang, Jianxiang] Peking Union Med Coll, Tianjin 300020, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Wang, JX (corresponding author), Chinese Acad Med Sci, State Key Lab Expt Hematol, Inst Hematol, 288 Nanjing Rd, Tianjin 300020, Peoples R China.	wangjx@ihcams.ac.cn	CHEN, YIRUI/R-5720-2019		National Natural Science Foundation of China [81270635, 81090412]; National Basic Research Program of China [2011CB964801]; Tianjin Applied Fundamental Research Planning Key Project [13JCZDJC29900]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); Tianjin Applied Fundamental Research Planning Key Project	This work is supported by the National Natural Science Foundation of China (81270635, 81090412), the National Basic Research Program of China (2011CB964801), and the Tianjin Applied Fundamental Research Planning Key Project (13JCZDJC29900). The authors declare no conflicts of interest. The authors thank Dr. Lu Xin, professor at the Ludwig Institute for Cancer Research (Oxford, UK), for providing pcDNA3.1-WT-iASPP-V5. The authors also thank Prof. J. M. Adams (Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia), who kindly provided the HS21/45-vav vector.	Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Chen JF, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-694; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Domen J, 1999, MOL MED TODAY, V5, P201, DOI 10.1016/S1357-4310(99)01464-1; FENAUX P, 1992, BRIT J HAEMATOL, V80, P178, DOI 10.1111/j.1365-2141.1992.tb08897.x; Hasty P, 2005, MECH AGEING DEV, V126, P71, DOI 10.1016/j.mad.2004.09.036; Jiang LL, 2011, CLIN CANCER RES, V17, P6924, DOI 10.1158/1078-0432.CCR-11-0588; Jude CD, 2008, CELL CYCLE, V7, P586, DOI 10.4161/cc.7.5.5549; Laska MJ, 2007, EXP CELL RES, V313, P2611, DOI 10.1016/j.yexcr.2007.05.006; Liu H, 2009, LEUKEMIA RES, V33, P1243, DOI 10.1016/j.leukres.2009.02.016; Liu WK, 2010, ONKOLOGIE, V33, P500, DOI 10.1159/000319692; LOCOCO F, 1995, EUR J HAEMATOL, V55, P1; Lu B, 2010, GASTROENTEROLOGY, V139, P2183, DOI 10.1053/j.gastro.2010.06.049; Meng AM, 2003, CANCER RES, V63, P5414; Milyavsky M, 2010, CELL STEM CELL, V7, P186, DOI 10.1016/j.stem.2010.05.016; Ogilvy S, 1998, BLOOD, V91, P419, DOI 10.1182/blood.V91.2.419.419_419_430; Podhorecka M, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/920161; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schnell MA, 2002, HUM GENE THER, V13, P155, DOI 10.1089/10430340152712700; Sgroi DC, 1999, CANCER RES, V59, P5656; Slee EA, 2004, ONCOGENE, V23, P9007, DOI 10.1038/sj.onc.1208088; Sullivan A, 2007, BRIT J CANCER, V96, P196, DOI 10.1038/sj.bjc.6603525; TRECCA D, 1994, AM J HEMATOL, V46, P304, DOI 10.1002/ajh.2830460409; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vilasova Z, 2008, ACTA BIOCHIM POL, V55, P381, DOI 10.18388/abp.2008_3086; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Zhang B, 2011, PROSTATE CANCER P D, V14, P219, DOI 10.1038/pcan.2011.25; Zhang XW, 2007, J MOL BIOL, V368, P1162, DOI 10.1016/j.jmb.2007.03.001; Zhang XW, 2005, LEUKEMIA RES, V29, P179, DOI 10.1016/j.leukres.2004.07.001	33	21	24	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2816	2827		10.1096/fj.13-244632	http://dx.doi.org/10.1096/fj.13-244632			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24668753				2022-12-28	WOS:000337949400008
J	Dengl, S; Hoffmann, E; Grote, M; Wagner, C; Mundigl, O; Georges, G; Thorey, I; Stubenrauch, KG; Bujotzek, A; Josel, HP; Dziadek, S; Benz, J; Brinkmann, U				Dengl, Stefan; Hoffmann, Eike; Grote, Michael; Wagner, Cornelia; Mundigl, Olaf; Georges, Guy; Thorey, Irmgard; Stubenrauch, Kay-Gunnar; Bujotzek, Alexander; Josel, Hans-Peter; Dziadek, Sebastian; Benz, Joerg; Brinkmann, Ulrich			Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies	FASEB JOURNAL			English	Article						targeted delivery; biotin; X-ray structure; protein engineering; pharmacokinetics	NEUROPEPTIDE-Y; HALF-LIFE; BINDING; DRUG; CONJUGATION; PEPTIDES	Humanized hapten-binding IgGs were designed with an accessible cysteine close to their binding pockets, for specific covalent payload attachment. Individual analyses of known structures of digoxigenin (Dig)- and fluorescein (Fluo) binding antibodies and a new structure of a biotin (Biot)-binder, revealed a universal coupling position (52(+2)) in proximity to binding pockets but without contributing to hapten interactions. Payloads that carry a free thiol are positioned on the antibody and covalently linked to it via disulfides. Covalent coupling is achieved and driven toward complete (95-100%) payload occupancy by spontaneous redox shuffling between antibody and payload. Attachment at the universal position works with different haptens, antibodies, and payloads. Examples are the haptens Fluo, Dig, and Biot combined with various fluorescent or peptidic payloads. Disulfide-bonded covalent antibody-payload complexes do not dissociate in vitro and in vivo. Coupling requires the designed cysteine and matching payload thiol because payload or antibody without the Cys/thiol are not linked (<5% nonspecific coupling). Hapten-mediated positioning is necessary as hapten-thiol-payload is only coupled to antibodies that bind matching haptens. Covalent complexes are more stable in vivo than noncovalent counterparts because digoxigeninylated or biotinylated fluorescent payloads without disulfide-linkage are cleared more rapidly in mice (approximately 50% reduced 48 hour serum levels) compared with their covalently linked counterparts. The coupling technology is applicable to many haptens and hapten binding antibodies (confirmed by automated analyses of the structures of 140 additional hapten binding antibodies) and can be applied to modulate the pharmacokinetics of small compounds or peptides. It is also suitable to link payloads in a reduction-releasable manner to tumor- or tissue-targeting delivery vehicles.-Dengl, S., Hoffmann, E., Grote, M., Wagner, C., Mundigl, O., Georges, G., Thorey, I., Stubenrauch, K.-G., Bujotzek, A., Josel, H.-P., Dziadek, S., Benz, J., Brinkmann, U. Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies.	[Dengl, Stefan; Hoffmann, Eike; Grote, Michael; Wagner, Cornelia; Mundigl, Olaf; Georges, Guy; Thorey, Irmgard; Stubenrauch, Kay-Gunnar; Bujotzek, Alexander; Brinkmann, Ulrich] Roche Innovat Ctr Penzberg, Roche Pharma Res & Early Dev, Large Mol Res, D-82377 Penzberg, Germany; [Josel, Hans-Peter; Dziadek, Sebastian] Roche Diagnost GmbH, Penzberg, Germany; [Benz, Joerg] Roche Discovery Technol, Roche Innovat Ctr Basel, Basel, Switzerland	Roche Holding; Roche Holding	Dengl, S (corresponding author), Roche Innovat Ctr Penzberg, Nonnenwald 2, D-82377 Penzberg, Germany.	ulrich.brinkmann@roche.com	Brinkmann, Ulrich/AAF-8216-2019	Brinkmann, Ulrich/0000-0002-5558-0212	Roche Postdoc Fund	Roche Postdoc Fund	The authors thank Klaus Mayer, Daniela Matscheko, Cornelius Gati, Elisabeth Graeber, Stephan Nothjunge, Michael Tischler, Helga Becker, Fabian Rodewald, and Ranjan Sircar for excellent technical and operative support. A.B. is supported by the Roche Postdoc Fund. The authors are employed by Roche. Roche has an interest in and patent applications for payload coupling and PK modulation technologies.	Ahrens VM, 2012, FUTURE MED CHEM, V4, P1567, DOI [10.4155/fmc.12.76, 10.4155/FMC.12.76]; Amiri-Kordestani L, 2014, CLIN CANCER RES, V20, P4436, DOI 10.1158/1078-0432.CCR-14-0012; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Behrens CR, 2014, MABS-AUSTIN, V6, P46, DOI 10.4161/mabs.26632; Boder ET, 2000, P NATL ACAD SCI USA, V97, P10701, DOI 10.1073/pnas.170297297; Danho W, 2009, ADV EXP MED BIOL, V611, P467, DOI 10.1007/978-0-387-73657-0_201; Dautzenberg FM, 2005, PHARMACOLOGY, V75, P21, DOI 10.1159/000085897; Dennis MS, 2002, J BIOL CHEM, V277, P35035, DOI 10.1074/jbc.M205854200; Doppalapudi VR, 2007, BIOORG MED CHEM LETT, V17, P501, DOI 10.1016/j.bmcl.2006.10.009; Doppalapudi VR, 2010, P NATL ACAD SCI USA, V107, P22611, DOI 10.1073/pnas.1016478108; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Hoffmann E, 2013, J CONTROL RELEASE, V171, P48, DOI 10.1016/j.jconrel.2013.06.021; Horwitz SM, 2014, BLOOD, V123, P3095, DOI 10.1182/blood-2013-12-542142; Hutt M, 2012, J BIOL CHEM, V287, P4462, DOI 10.1074/jbc.M111.311522; Junutula JR, 2008, NAT BIOTECHNOL, V26, P925, DOI 10.1038/nbt.1480; Kabat EA, 1991, NIH PUBL; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kontermann RE, 2011, CURR OPIN BIOTECH, V22, P868, DOI 10.1016/j.copbio.2011.06.012; Kornberger P, 2014, MABS-AUSTIN, V6, P354, DOI 10.4161/mabs.27444; KRANZ DM, 1982, J BIOL CHEM, V257, P6987; Metz S, 2011, P NATL ACAD SCI USA, V108, P8194, DOI 10.1073/pnas.1018565108; Midelfort KS, 2004, J MOL BIOL, V343, P685, DOI 10.1016/j.jmb.2004.08.019; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nguyen AD, 2011, CURR OPIN ENDOCRINOL, V18, P56, DOI 10.1097/MED.0b013e3283422f0a; Panowski S, 2014, MABS-AUSTIN, V6, P34, DOI 10.4161/mabs.27022; Paterson BM, 2014, ANGEW CHEM INT EDIT, V53, P6115, DOI 10.1002/anie.201402613; Reiter Y, 1995, PROTEIN ENG, V8, P1323, DOI 10.1093/protein/8.12.1323; Sassoon I, 2013, METHODS MOL BIOL, V1045, P1, DOI 10.1007/978-1-62703-541-5_1; Syed S, 1997, BLOOD, V89, P3243, DOI 10.1182/blood.V89.9.3243; Zac-Varghese S, 2011, CURR OPIN PHARMACOL, V11, P582, DOI 10.1016/j.coph.2011.10.001	31	10	16	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1763	1779		10.1096/fj.14-263665	http://dx.doi.org/10.1096/fj.14-263665			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25670234	Green Published, hybrid			2022-12-28	WOS:000354114600014
J	Qu, C; Bonar, SL; Hickman-Brecks, CL; Abu-Amer, S; McGeough, MD; Pena, CA; Broderick, L; Yang, C; Grimston, SK; Kading, J; Abu-Amer, Y; Novack, DV; Hoffman, HM; Civitelli, R; Mbalaviele, G				Qu, Chao; Bonar, Sheri L.; Hickman-Brecks, Cynthia L.; Abu-Amer, Samer; McGeough, Matthew D.; Pena, Carla A.; Broderick, Lori; Yang, Chang; Grimston, Susan K.; Kading, Jacqueline; Abu-Amer, Yousef; Novack, Deborah V.; Hoffman, Hal M.; Civitelli, Roberto; Mbalaviele, Gabriel			NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanisms	FASEB JOURNAL			English	Article						osteoclasts; IL-1 beta; PARP1; NOMID; cryopyrinopathies	POLY(ADP-RIBOSE) POLYMERASE-1; ACTIVATION; INFLAMMASOMES; TARGET; CELLS	Activating-mutations in NOD-like receptor (NLR) family, pyrin domain-containing 3 (NLRP3) cause neonatal-onset multisystem inflammatory disease. However, the ontogeny of skeletal anomalies in this disorder is poorly understood. Mice globally expressing the D301N mutation in Nlrp3 (D303N in human) model the human phenotype, including systemic inflammation and skeletal deformities. To gain insights into the skeletal manifestations, we generated mice in which the expression of D301N Nlrp3 (Nlrp3(D301N)) is restricted to myeloid cells. These mice exhibit systemic inflammation and severe osteopenia (similar to 60% lower bone mass) similar to mice globally expressing the knock-in mutation, consistent with the paradigm of innate immune-driven cryopyrinopathies. Because systemic inflammation may indirectly affect bone homeostasis, we engineered mice in which Nlrp3(D301N) is expressed specifically in osteoclasts, the cells that resorb bone. These mice also develop similar to 50% lower bone mass due to increased osteolysis, but there is no systemic inflammation and no change in osteoclast number. Mechanistically, aside from its role in IL-1 beta maturation, Nlrp3(D301N) expression enhances osteoclast bone resorbing ability through reorganization of actin cytoskeleton while promoting the degradation of poly(ADP-ribose) polymerase 1, an inhibitor of osteoclastogenesis. Thus, NLRP3 inflammasome activation is not restricted to the production of proinflammatory mediators but also leads to cytokine-autonomous responses.	[Qu, Chao; Bonar, Sheri L.; Hickman-Brecks, Cynthia L.; Abu-Amer, Samer; Yang, Chang; Grimston, Susan K.; Kading, Jacqueline; Novack, Deborah V.; Civitelli, Roberto; Mbalaviele, Gabriel] Washington Univ, Sch Med, Div Bone & Mineral Dis, 660 South Euclid Ave,Campus Box 8301, St Louis, MO 63110 USA; [McGeough, Matthew D.; Pena, Carla A.; Broderick, Lori; Hoffman, Hal M.] Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA; [Abu-Amer, Yousef] Univ Calif San Diego, Div Allergy Immunol & Rheumatol, La Jolla, CA 92093 USA	Washington University (WUSTL); Washington University (WUSTL); University of California System; University of California San Diego	Mbalaviele, G (corresponding author), Washington Univ, Sch Med, Div Bone & Mineral Dis, 660 South Euclid Ave,Campus Box 8301, St Louis, MO 63110 USA.	gmbalavi@dom.wustl.edu	Civitelli, Roberto/AAA-8260-2019	Civitelli, Roberto/0000-0003-4076-4315; Novack, Deborah/0000-0001-7101-5582	U.S. National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases Grant [R01-AR064755]; NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases Grant [5 P30 AR057235, R01-AR054326]; NIH/Core Center for Musculoskeletal Biology and Medicine; Shriners Hospital for Children Grant [85600]; Pfizer, Inc.; Amgen; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K08HD075830] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054326, R01AR064755, P30AR057235, R01AR052705] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases Grant; NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases Grant; NIH/Core Center for Musculoskeletal Biology and Medicine; Shriners Hospital for Children Grant; Pfizer, Inc.(Pfizer); Amgen(Amgen); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Dr. Marcus Watkins and Rong Zeng for technical assistance and Sung Yeop Jeong for maintaining mouse colonies. The authors also thank Susanna Brydges, James Mueller, and Daniel Kastner for their role in generating the Nlrp3<SUP>fl(D301N)/+</SUP> mice, and the Musculoskeletal Histology and Morphometry Core as well as the Structure and Strength Core at Washington University in St. Louis. This work was supported by the U.S. National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases Grant R01-AR064755 (to G.M.), NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases Grant 5 P30 AR057235, NIH/Core Center for Musculoskeletal Biology and Medicine (to G.M.), and NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases Grant R01-AR054326 and Shriners Hospital for Children Grant 85600 (to Y.A.). G.M. is cofounder of Confluence Life Sciences. R.C. receives research support from Pfizer, Inc. and Amgen and holds stock of Amgen, Eli-Lilly, and Merck & Co. H.M.H. is consultant for Regeneron and is a consultant and speaker for Novartis and Sobi. All other authors report no conflicts of interest.	Beranger GE, 2008, J BONE MINER RES, V23, P564, DOI 10.1359/JBMR.071111; Bonar SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035979; Brydges SD, 2013, J CLIN INVEST, V123, P4695, DOI 10.1172/JCI71543; Brydges SD, 2009, IMMUNITY, V30, P875, DOI 10.1016/j.immuni.2009.05.005; Castri P, 2014, BBA-MOL CELL RES, V1843, P640, DOI 10.1016/j.bbamcr.2013.12.005; Chen JF, 2010, J BIOL CHEM, V285, P36315, DOI 10.1074/jbc.M110.157743; Erener S, 2012, MOL CELL, V46, P200, DOI 10.1016/j.molcel.2012.02.016; Gurung P, 2014, J IMMUNOL, V192, P1835, DOI 10.4049/jimmunol.1302839; Hill SC, 2007, PEDIATR RADIOL, V37, P145, DOI 10.1007/s00247-006-0358-0; Hirai T, 2013, J IMMUNOL, V190, P4805, DOI 10.4049/jimmunol.1200901; Hoffman HM, 2011, J BIOL CHEM, V286, P10889, DOI 10.1074/jbc.R110.135491; Hottiger MO, 2011, FEBS LETT, V585, P1595, DOI 10.1016/j.febslet.2011.03.031; Ippagunta SK, 2011, NAT IMMUNOL, V12, P1010, DOI 10.1038/ni.2095; Kharkwal G, 2012, J MOL ENDOCRINOL, V48, P261, DOI 10.1530/JME-11-0061; Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002; Levaot N, 2011, CELL, V147, P1324, DOI 10.1016/j.cell.2011.10.045; Malireddi RKS, 2010, J IMMUNOL, V185, P3127, DOI 10.4049/jimmunol.1001512; Petrilli V, 2004, J CLIN INVEST, V114, P1072, DOI 10.1172/JCI200421854; Rigante D, 2011, RHEUMATOL INT, V31, P1661, DOI 10.1007/s00296-010-1787-5; Sagulenko V, 2013, CELL DEATH DIFFER, V20, P1149, DOI 10.1038/cdd.2013.37; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Shao W, 2007, J BIOL CHEM, V282, P36321, DOI 10.1074/jbc.M708182200; Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215; Sibley CH, 2012, ARTHRITIS RHEUM-US, V64, P2375, DOI 10.1002/art.34409; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655; Verheugd P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2672; Weber FA, 2013, STEM CELLS, V31, P2364, DOI 10.1002/stem.1507; Youm YH, 2013, CELL METAB, V18, P519, DOI 10.1016/j.cmet.2013.09.010	29	43	46	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1269	1279		10.1096/fj.14-264804	http://dx.doi.org/10.1096/fj.14-264804			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25477279	Green Published			2022-12-28	WOS:000354115000015
J	Poosti, F; Bansal, R; Yazdani, S; Prakash, J; Post, E; Klok, P; van den Born, J; de Borst, MH; van Goor, H; Poelstra, K; Hillebrands, JL				Poosti, Fariba; Bansal, Ruchi; Yazdani, Saleh; Prakash, Jai; Post, Eduard; Klok, Pieter; van den Born, Jacob; de Borst, Martin H.; van Goor, Harry; Poelstra, Klaas; Hillebrands, Jan-Luuk			Selective delivery of IFN-gamma to renal interstitial myofibroblasts: a novel strategy for the treatment of renal fibrosis	FASEB JOURNAL			English	Article						drug targeting; PDGFR beta; kidney; unilateral ureteral obstruction	CD4(+) T-CELLS; INTERFERON-GAMMA; GROWTH-FACTOR; UP-REGULATION; FIBROBLASTS; DISEASE; HEALTH; LYMPHANGIOGENESIS; ANGIOGENESIS; TRANSITION	Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequate treatment exists. IFN-gamma is an antifibrotic cytokine that may attenuate renal fibrosis. Systemically administered IFN-gamma causes side effects that may be prevented by specific drug targeting. Interstitial myofibroblasts are the effector cells in renal fibrogenesis. Here, we tested the hypothesis that cell-specific delivery of IFN-gamma to platelet-derived growth factor receptor beta (PDGFR beta)-expressing myofibroblasts attenuates fibrosis in an obstructive nephropathy [unilateral ureteral obstruction (UUO)] mouse model. PEGylated IFN-gamma conjugated to PDGFR beta-recognizing peptide [(PPB)-polyethylene glycol (PEG)-IFN-gamma] was tested in vitro and in vivo for antifibrotic properties and compared with free IFN-gamma. PDGFR beta expression was >3-fold increased (P < 0.05) in mouse fibrotic UUO kidneys and colocalized with alpha-smooth muscle actin-positive (SMA(+)) myofibroblasts. In vitro, PPB-PEG-IFN-gamma significantly inhibited colla1, colla2, and alpha-SMA mRNA expression in TGF-beta-activated NIH3T3 fibroblasts (P < 0.05). In vivo, PPB-PEG-IFN-g gamma specifically accumulated in PDGFR beta-positive myofibroblasts. PPB-PEG-IFN-gamma treatment significantly reduced renal collagen I, fibronectin, and alpha-SMA mRNA and protein expression. Compared with vehicle treatment, PPB-PEG-IFN-gamma preserved tubular morphology, reduced interstitial T-cell infiltration, and attenuated lymphangiogenesis (all P < 0.05) without affecting peritubular capillary density. PPB-PEG-IFN-gamma reducedIFN-gamma-related side effects as manifested by reducedmajor histocompatibility complex class II expression in brain tissue (P < 0.05 vs. free IFN-gamma). Our findings demonstrate that specific targeting of IFN-gamma to PDGFR-beta-expressing myofibroblasts attenuates renal fibrosis and reduces systemic adverse effects.	[Poosti, Fariba; Klok, Pieter; van Goor, Harry; Hillebrands, Jan-Luuk] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Div Pathol, Groningen, Netherlands; [Yazdani, Saleh; van den Born, Jacob; de Borst, Martin H.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands; [Post, Eduard; Poelstra, Klaas] Univ Groningen, Dept Pharmacokinet Toxicol & Targeting, NL-9700 RB Groningen, Netherlands; [Bansal, Ruchi; Yazdani, Saleh; Prakash, Jai] Univ Twente, MIRA Inst, NL-7500 AE Enschede, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Twente	Poosti, F (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol Pathol, HPC EA10,POB 30001, NL-9700 RB Groningen, Netherlands.	f.poosti@umcg.nl; j.l.hillebrands@umcg.nl	Yazdani, Saleh/K-9640-2015; Bansal, Ruchi/F-4649-2014; Prakash, Jai/C-8015-2014; Bansal, Ruchi/D-4796-2016; van+Goor, Harry/AAS-7712-2020	Yazdani, Saleh/0000-0002-5162-9904; Prakash, Jai/0000-0003-1050-650X; Bansal, Ruchi/0000-0003-2470-5876; Hillebrands, Jan-Luuk/0000-0003-3135-3274; De Borst, Martin/0000-0002-4127-8733; Post, Eduard/0000-0001-5885-0081; van Goor, Harry/0000-0002-6670-1577	J.K. de Cock Foundation (University Medical Center Groningen); Netherlands Organisation for Health Research and Development (ZonMW) [40-00506-98-9021]; Graduate School of Medical Sciences (University of Groningen, Groningen, The Netherlands); Netherlands Organization for Scientific Research (Veni grant)	J.K. de Cock Foundation (University Medical Center Groningen); Netherlands Organisation for Health Research and Development (ZonMW)(Netherlands Organization for Health Research and Development); Graduate School of Medical Sciences (University of Groningen, Groningen, The Netherlands); Netherlands Organization for Scientific Research (Veni grant)(Netherlands Organization for Scientific Research (NWO))	The authors thank Catharina Reker-Smit, Geert Harms, Marian Bulthuis, and Sippie Huitema for their technical assistance. This work was supported by the J.K. de Cock Foundation (University Medical Center Groningen). Microscopical imaging was performed at the UMCG Imaging Center, which is supported by The Netherlands Organisation for Health Research and Development (ZonMW Grant 40-00506-98-9021). F.P. was supported by the Graduate School of Medical Sciences (University of Groningen, Groningen, The Netherlands). M.H.d.B. was supported by a grant from The Netherlands Organization for Scientific Research (Veni grant).	Ahmed CML, 2003, J CELL SCI, V116, P3089, DOI 10.1242/jcs.00528; Aldigier JC, 2005, J AM SOC NEPHROL, V16, P3306, DOI 10.1681/asn.2004090804; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Bansal R, 2012, MOL CANCER THER, V11, P2419, DOI 10.1158/1535-7163.MCT-11-0758; Bansal R, 2011, J CONTROL RELEASE, V154, P233, DOI 10.1016/j.jconrel.2011.05.027; Bansal R, 2011, HEPATOLOGY, V54, P586, DOI 10.1002/hep.24395; Barisal R, 2011, MOL PHARMACEUT, V8, P1899, DOI 10.1021/mp200263q; Beljaars L, 2003, BIOCHEM PHARMACOL, V66, P1307, DOI 10.1016/S0006-2952(03)00445-3; Boor P, 2010, NAT REV NEPHROL, V6, P643, DOI 10.1038/nrneph.2010.120; Broekema M, 2007, J AM SOC NEPHROL, V18, P165, DOI 10.1681/ASN.2005070730; Chade AR, 2013, COMPR PHYSIOL, V3, P817, DOI 10.1002/cphy.c120012; Chang FC, 2012, J FORMOS MED ASSOC, V111, P589, DOI 10.1016/j.jfma.2012.09.008; Chen YT, 2011, KIDNEY INT, V80, P1170, DOI 10.1038/ki.2011.208; Cleland JL, 1996, PHARMACEUT RES, V13, P1464, DOI 10.1023/A:1016063109373; Duffield JS, 2014, J CLIN INVEST, V124, P2299, DOI 10.1172/JCI72267; Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461; Fioretto P, 1998, NEW ENGL J MED, V339, P69, DOI 10.1056/NEJM199807093390202; Floege J, 2008, J AM SOC NEPHROL, V19, P12, DOI 10.1681/ASN.2007050532; Forbes MS, 2012, AM J PHYSIOL-RENAL, V303, pF120, DOI 10.1152/ajprenal.00110.2012; Friedman SL, 2013, J HEPATOL, V58, P1, DOI 10.1016/j.jhep.2012.10.014; GonzalezCuadrado S, 1996, CLIN EXP IMMUNOL, V106, P518, DOI 10.1046/j.1365-2249.1996.d01-864.x; Gu F, 2005, J CONTROL RELEASE, V102, P607, DOI 10.1016/j.jconrel.2004.10.020; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; Kerjaschki D, 2014, J CLIN INVEST, V124, P874, DOI 10.1172/JCI74854; Kida Y, 2014, PEDIATR NEPHROL, V29, P333, DOI 10.1007/s00467-013-2430-y; King TE, 2009, LANCET, V374, P222, DOI 10.1016/S0140-6736(09)60551-1; Konda R, 1999, AM J PATHOL, V155, P1587, DOI 10.1016/S0002-9440(10)65475-2; Krensky AM, 2007, NAT CLIN PRACT NEPHR, V3, P164, DOI 10.1038/ncpneph0418; LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218; LeBleu VS, 2011, KIDNEY INT, V80, P1119, DOI 10.1038/ki.2011.300; Lee AS, 2013, KIDNEY INT, V83, P50, DOI 10.1038/ki.2012.312; Lee J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060900; Levey AS, 2007, KIDNEY INT, V72, P247, DOI 10.1038/sj.ki.5002343; Li JH, 2007, STEM CELLS, V25, P697, DOI 10.1634/stemcells.2006-0133; Li JH, 2009, AM J PATHOL, V175, P1380, DOI 10.2353/ajpath.2009.090096; Lin SL, 2011, AM J PATHOL, V178, P911, DOI 10.1016/j.ajpath.2010.10.012; Lin SL, 2008, AM J PATHOL, V173, P1617, DOI 10.2353/ajpath.2008.080433; Lu XL, 2012, UROL RES, V40, P717, DOI 10.1007/s00240-012-0507-x; Ma LJ, 2005, J AM SOC NEPHROL, V16, P966, DOI 10.1681/ASN.2004060492; Meran S, 2011, INT J EXP PATHOL, V92, P158, DOI 10.1111/j.1365-2613.2011.00764.x; MULLER GA, 1991, AM J KIDNEY DIS, V17, P680; Nikolic-Paterson DJ, 2010, KIDNEY INT, V78, P333, DOI 10.1038/ki.2010.182; Oldroyd SD, 1999, KIDNEY INT, V56, P2116, DOI 10.1046/j.1523-1755.1999.00775.x; Ostendorf T, 2012, PEDIATR NEPHROL, V27, P1041, DOI 10.1007/s00467-011-1892-z; Poosti F, 2012, EUR J PHARMACOL, V694, P111, DOI 10.1016/j.ejphar.2012.08.010; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Rienstra H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009095; RODEMANN HP, 1991, AM J KIDNEY DIS, V17, P684, DOI 10.1016/S0272-6386(12)80352-0; Sakamoto I, 2009, KIDNEY INT, V75, P828, DOI 10.1038/ki.2008.661; Seikrit C, 2013, NEPHROL DIAL TRANSPL, V28, P889, DOI 10.1093/ndt/gfs509; Shao XJ, 2006, J INTERF CYTOK RES, V26, P568, DOI 10.1089/jir.2006.26.568; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strutz F, 2000, NEPHROL DIAL TRANSPL, V15, P1535, DOI 10.1093/ndt/15.10.1535; Strutz F, 2006, J AM SOC NEPHROL, V17, P2992, DOI 10.1681/ASN.2006050420; Subramaniam PS, 1999, J BIOL CHEM, V274, P403, DOI 10.1074/jbc.274.1.403; Tanaka T, 2013, NAT REV NEPHROL, V9, P211, DOI 10.1038/nrneph.2013.35; Tapmeier TT, 2010, KIDNEY INT, V78, P351, DOI 10.1038/ki.2010.177; Weng HL, 2005, CLIN GASTROENTEROL H, V3, P819, DOI 10.1016/S1542-3565(05)00404-0; Wu MJ, 2006, KIDNEY INT, V69, P2029, DOI 10.1038/sj.ki.5000161; Yao Y, 2011, UROLOGY, V77, DOI 10.1016/j.urology.2010.10.015; Yazdani S, 2014, EXPERT REV MOL MED, V16, DOI 10.1017/erm.2014.18; Yazdani S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050209; Zeisberg EM, 2008, J AM SOC NEPHROL, V19, P2282, DOI 10.1681/ASN.2008050513; Zeisberg M, 2004, J MOL MED, V82, P175, DOI 10.1007/s00109-003-0517-9; Zhang GQ, 2003, J AM SOC NEPHROL, V14, P1234, DOI 10.1097/01.ASN.0000064701.70231.3F	66	54	58	3	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1029	1042		10.1096/fj.14-258459	http://dx.doi.org/10.1096/fj.14-258459			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25466892	Green Submitted			2022-12-28	WOS:000350633000027
J	Sato, S; Ogura, Y; Tajrishi, MM; Kumar, A				Sato, Shuichi; Ogura, Yuji; Tajrishi, Marjan M.; Kumar, Ashok			Elevated levels of TWEAK in skeletal muscle promote visceral obesity, insulin resistance, and metabolic dysfunction	FASEB JOURNAL			English	Article						Fn14; GLUT4; type 2 diabetes; AMPK; PGC-1 alpha	ACTIVATED PROTEIN-KINASE; BODY GLUCOSE DISPOSAL; NECROSIS-FACTOR-ALPHA; HEXOKINASE-II; TNF-ALPHA; GENE-EXPRESSION; TRANSGENIC MICE; WEAK INDUCER; DIABETES-MELLITUS; GLUT4 EXPRESSION	Skeletal muscle is responsible for the majority of glucose disposal in body. Impairment in skeletal muscle glucose handling capacity leads to the state of insulin resistance. The TNF-like weak inducer of apoptosis (TWEAK) cytokine has now emerged as a major regulator of skeletal muscle mass and function. However, the role of TWEAK in skeletal muscle metabolic function remains less understood. Here, we demonstrate that with progressive age, skeletal muscle-specific TWEAK-transgenic (TWEAK-Tg) mice gain increased body weight (similar to 16%) and fat mass (similar to 64%) and show glucose intolerance and insulin insensitivity. TWEAK-Tg mice also exhibit adipocyte hypertrophy in the epididymal fat. Oxygen uptake, voluntary physical activity, and exercise capacity were significantly reduced in TWEAK-Tg mice compared with controls. Overexpression of TWEAK inhibited (similar to 31%) 5' AMP-activated protein kinase (AMPK) and reduced (similar to 31%) the levels of glucose transporter type 4 (GLUT4) without affecting the Akt pathway. TWEAK also inhibited insulin-stimulated glucose uptake (similar to 32%) and repressed the levels of GLUT4 (similar to 50%) in cultured myotubes from C57BL6 mice. TWEAK represses the levels of Kruppel-like factor 15; myocyte enhancer factor 2, and peroxisome proliferator-activated receptor-gamma coactivator-1 alpha, which are required for the activation of the GLUT4 locus. Collectively our study demonstrates that elevated levels of TWEAK in skeletal muscle cause metabolic abnormalities. Inhibition of TWEAK could be a potential approach to prevent weight gain and type 2 diabetes.	[Sato, Shuichi; Ogura, Yuji; Tajrishi, Marjan M.; Kumar, Ashok] Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40202 USA	University of Louisville	Kumar, A (corresponding author), Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, 500 South Preston St, Louisville, KY 40202 USA.	ashok.kumar@louisville.edu		Kumar, Ashok/0000-0001-8571-2848	U.S. National Institutes of Health [R01-AG029623]; NATIONAL INSTITUTE ON AGING [R01AG029623] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Dr. Bradford Hill and Dr. Daniel Conklin of Diabetes and Obesity Center of University of Louisville for their help and discussion on metabolic cage analysis. This work was supported by the U.S. National Institutes of Health (Grant R01-AG029623) (to A.K.).	Atkinson BJ, 2013, DIABETES, V62, P2249, DOI 10.2337/db12-1146; Bennett G, 2014, OBESITY, V22, P1485, DOI 10.1002/oby.20726; Bogan JS, 2012, ANNU REV BIOCHEM, V81, P507, DOI 10.1146/annurev-biochem-060109-094246; Bouskila M, 2008, AM J PHYSIOL-ENDOC M, V294, pE28, DOI 10.1152/ajpendo.00481.2007; Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; BRAITHWAITE SS, 1995, DIABETES, V44, P43, DOI 10.2337/diabetes.44.1.43; Chacon MR, 2006, CYTOKINE, V33, P129, DOI 10.1016/j.cyto.2005.12.005; Chang PY, 1996, J BIOL CHEM, V271, P14834, DOI 10.1074/jbc.271.25.14834; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Christ-Roberts CY, 2004, METABOLISM, V53, P1233, DOI 10.1016/j.metabol.2004.03.022; Crunkhorn S, 2007, J BIOL CHEM, V282, P15439, DOI 10.1074/jbc.M611214200; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DeFronzo RA, 2009, DIABETES CARE, V32, pS157, DOI 10.2337/dc09-S302; DeFronzo RA, 2009, DIABETES, V58, P773, DOI 10.2337/db09-9028; Dogra C, 2007, FASEB J, V21, P1857, DOI 10.1096/fj.06-7537com; Feng F, 2008, ENDOCRINOLOGY, V149, P1505, DOI 10.1210/en.2007-1119; FRANK SK, 1986, ARCH BIOCHEM BIOPHYS, V249, P61, DOI 10.1016/0003-9861(86)90560-6; Fueger PT, 2007, DIABETES, V56, P2476, DOI 10.2337/db07-0532; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; HANDBERG A, 1990, DIABETOLOGIA, V33, P625, DOI 10.1007/BF00400207; Hindi SM, 2014, FASEB J, V28, P1398, DOI 10.1096/fj.13-242123; Hojlund K, 2009, J CLIN ENDOCR METAB, V94, P4547, DOI 10.1210/jc.2009-0897; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Im SS, 2007, IUBMB LIFE, V59, P134, DOI 10.1080/15216540701313788; Itani SI, 2003, DIABETES, V52, P1635, DOI 10.2337/diabetes.52.7.1635; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jensen Jorgen, 2009, Archives of Physiology and Biochemistry, V115, P13, DOI 10.1080/13813450902778171; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kalupahana NS, 2012, MOL ASPECTS MED, V33, P26, DOI 10.1016/j.mam.2011.10.011; KORANYI LI, 1991, DIABETOLOGIA, V34, P763, DOI 10.1007/BF00401526; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; Kruszynska YT, 1998, DIABETES, V47, P1107, DOI 10.2337/diabetes.47.7.1107; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; LIU ML, 1994, J BIOL CHEM, V269, P28514; Mcgee SL, 2008, DIABETES, V57, P860, DOI 10.2337/db07-0843; McGee SL, 2006, CLIN EXP PHARMACOL P, V33, P395, DOI 10.1111/j.1440-1681.2006.04362.x; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Mingrone G, 2002, INT J OBESITY, V26, P1165, DOI 10.1038/sj.ijo.0802053; Mittal A, 2010, J CELL BIOL, V188, P833, DOI 10.1083/jcb.200909117; Mittel A, 2010, AM J PATHOL, V177, P1732, DOI 10.2353/ajpath.2010.100335; Ng Y, 2008, CELL METAB, V7, P348, DOI 10.1016/j.cmet.2008.02.008; Nieto-Vazquez Iria, 2008, Archives of Physiology and Biochemistry, V114, P183, DOI [10.1080/13813450802181047, 10.1080/13813450802181047 ]; Ofei F, 1996, DIABETES, V45, P881, DOI 10.2337/diabetes.45.7.881; Paul PK, 2012, MOL CELL BIOL, V32, P1248, DOI 10.1128/MCB.06351-11; Pendergrass M, 1998, DIABETES, V47, P387, DOI 10.2337/diabetes.47.3.387; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; Ruderman NB, 2013, J CLIN INVEST, V123, P2764, DOI 10.1172/JCI67227; Sakoda H, 2002, AM J PHYSIOL-ENDOC M, V282, pE1239, DOI 10.1152/ajpendo.00455.2001; Sato S, 2013, SKELET MUSCLE, V3, DOI 10.1186/2044-5040-3-18; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Steinberg GR, 2006, CELL METAB, V4, P465, DOI 10.1016/j.cmet.2006.11.005; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Suzuki T, 2013, MOL CELL, V50, P407, DOI 10.1016/j.molcel.2013.03.022; TAI MM, 1994, DIABETES CARE, V17, P152, DOI 10.2337/diacare.17.2.152; Tajrishi MM, 2014, J BIOL CHEM, V289, P19985, DOI 10.1074/jbc.M114.568626; Tajrishi MM, 2014, CYTOKINE GROWTH F R, V25, P215, DOI 10.1016/j.cytogfr.2013.12.004; Tajrishi MM, 2014, BIOCHEM BIOPH RES CO, V446, P1219, DOI 10.1016/j.bbrc.2014.03.084; THIEBAUD D, 1982, DIABETES, V31, P957, DOI 10.2337/diacare.31.11.957; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	65	19	20	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					988	1002		10.1096/fj.14-260703	http://dx.doi.org/10.1096/fj.14-260703			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25466899	Green Published			2022-12-28	WOS:000350633000023
J	Edagwa, BJ; Guo, DW; Puligujja, P; Chen, H; McMillan, J; Liu, XM; Gendelman, HE; Narayanasamy, P				Edagwa, Benson J.; Guo, Dongwei; Puligujja, Pavan; Chen, Han; McMillan, JoEllyn; Liu, Xinming; Gendelman, Howard E.; Narayanasamy, Prabagaran			Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes	FASEB JOURNAL			English	Article						Mycobacterium tuberculosis; Mycobacterium smegmatis; immunoisolation; MDM; subcellular trafficking	HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-TUBERCULOSIS; DRUG-DELIVERY; HIV INFECTION; PATHOGENESIS; PHAGOSOME; NANOTECHNOLOGY; NANOMEDICINE; EPIDEMIOLOGY; PHAGOCYTOSIS	Eradication of Mycobacterium tuberculosis (MTB) infection requires daily administration of combinations of rifampin (RIF), isoniazid [isonicotinylhydrazine (INH)], pyrazinamide, and ethambutol, among other drug therapies. To facilitate and optimize MTB therapeutic selections, a mononuclear phagocyte (MP; monocyte, macrophage, and dendritic cell)-targeted drug delivery strategy was developed. Long-acting nanoformulations of RIF and an INH derivative, pentenyl-INH (INHP), were prepared, and their physicochemical properties were evaluated. This included the evaluation of MP particle uptake and retention, cell viability, and antimicrobial efficacy. Drug levels reached 6 mu g/10(6) cells in human monocyte-derived macrophages (MDMs) for nanoparticle treatments compared with 0.1 mu g/10(6) cells for native drugs. High RIF and INHP levels were retained in MDM for > 15 d following nanoparticle loading. Rapid loss of native drugs was observed in cells and culture fluids within 24 h. Antimicrobial activities were determined against Mycobacterium smegmatis (M. smegmatis). Coadministration of nanoformulated RIF and INHP provided a 6-fold increase in therapeutic efficacy compared with equivalent concentrations of native drugs. Notably, nanoformulated RIF and INHP were found to be localized in recycling and late MDM endosomal compartments. These were the same compartments that contained the pathogen. Our results demonstrate the potential of antimicrobial nanomedicines to simplify MTB drug regimens.	[Edagwa, Benson J.; Puligujja, Pavan; McMillan, JoEllyn; Liu, Xinming; Gendelman, Howard E.; Narayanasamy, Prabagaran] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA; [Guo, Dongwei] Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE USA; [Chen, Han] Univ Nebraska, Ctr Biotechnol, Lincoln, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Lincoln	Gendelman, HE (corresponding author), Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.	hegendel@unmc.edu	Guo, Dongwei/E-9024-2018	Narayanasamy, Prabagaran/0000-0002-9617-5555; Guo, Dongwei/0000-0003-3538-4852	U.S. National Institutes of Health [P01-DA-028555, R01-NS-36126, P01-NS-31492, 2R01-NS-034239, P01-MH-64570, P01-NS-43985, R01-A-1097550]; Nebraska Research Initiative; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI097550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH064570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036126, R01NS034239, P01NS043985, P01NS031492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG043540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA028555] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Research Initiative; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors are grateful to Janice Taylor and James R. Talaska (Confocal Laser Scanning Core facility, University of Nebraska Medical Center) for assistance with confocal microscopy. This work was supported by U.S. National Institutes of Health grants P01-DA-028555, R01-NS-36126, P01-NS-31492, 2R01-NS-034239, P01-MH-64570, and P01-NS-43985 (to H.E.G.) and R01-A-1097550 (to P.N.) and by the Nebraska Research Initiative (to H.E.G. and P.N.).	ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830; Banyal S, 2013, CURR OPIN PULM MED, V19, P289, DOI 10.1097/MCP.0b013e32835eff08; Batrakova EV, 2011, EXPERT OPIN DRUG DEL, V8, P415, DOI 10.1517/17425247.2011.559457; Bhandari R., 2012, J CHROMATOGR SEP TEC, V03, P128, DOI DOI 10.4172/2157-7064.1000128; Calleja I, 2004, J CHROMATOGR A, V1031, P289, DOI 10.1016/j.chroma.2003.12.041; CLARK SC, 1989, ANN NY ACAD SCI, V557, P438; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Clift MJD, 2008, TOXICOL APPL PHARM, V232, P418, DOI 10.1016/j.taap.2008.06.009; Cooper AM, 2011, MUCOSAL IMMUNOL, V4, P252, DOI 10.1038/mi.2011.13; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; de Faria TJ, 2012, ANTIMICROB AGENTS CH, V56, P2259, DOI 10.1128/AAC.05993-11; Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534; Dube D, 2012, DRUG DISCOV TODAY, V17, P760, DOI 10.1016/j.drudis.2012.03.012; Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0; Edagwa B, 2013, BIOORG MED CHEM LETT, V23, P6138, DOI 10.1016/j.bmcl.2013.09.011; Ehlers S, 2009, INFECTION, V37, P87, DOI 10.1007/s15010-009-8450-7; El-Sadr WM, 2001, CLIN INFECT DIS, V32, P623, DOI 10.1086/318706; Eoh H, 2009, CHEM BIOL, V16, P1230, DOI 10.1016/j.chembiol.2009.10.014; GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; Getahun H, 2010, CLIN INFECT DIS, V50, pS201, DOI 10.1086/651492; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; HART PD, 1987, J EXP MED, V166, P933, DOI 10.1084/jem.166.4.933; Hearn MJ, 2009, EUR J MED CHEM, V44, P4169, DOI 10.1016/j.ejmech.2009.05.009; HONEYBOURNE D, 1994, THORAX, V49, P104, DOI 10.1136/thx.49.2.104; Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/NNM.11.27, 10.2217/nnm.11.27]; Kang PB, 2005, J EXP MED, V202, P987, DOI 10.1084/jem.20051239; KUMAR BD, 1992, J TROP MED HYG, V95, P424; Kurosu M, 2007, J MED CHEM, V50, P3973, DOI 10.1021/jm070638m; Lawn SD, 2011, LANCET, V378, P57, DOI 10.1016/S0140-6736(10)62173-3; Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520; Lenaerts AJ, 2007, ANTIMICROB AGENTS CH, V51, P3338, DOI 10.1128/AAC.00276-07; Lienhardt C, 2012, NAT REV MICROBIOL, V10, P407, DOI 10.1038/nrmicro2797; Lillebaek T, 2003, J INFECT DIS, V188, P1032, DOI 10.1086/378240; MacMicking JD, 2003, SCIENCE, V302, P654, DOI 10.1126/science.1088063; Morgan J R, 1993, Respir Med, V87, P320, DOI 10.1016/0954-6111(93)90040-7; Narayanasamy P, 2010, CHEM BIOL, V17, P117, DOI 10.1016/j.chembiol.2010.01.013; Nowacek Ari, 2013, Methods Mol Biol, V991, P41, DOI 10.1007/978-1-62703-336-7_5; Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]; Olakanmi O, 2000, INFECT IMMUN, V68, P5619, DOI 10.1128/IAI.68.10.5619-5627.2000; Pandey R, 2003, TUBERCULOSIS, V83, P373, DOI 10.1016/j.tube.2003.07.001; Pandey R, 2011, NANOMED-NANOTECHNOL, V7, P259, DOI 10.1016/j.nano.2011.01.009; Pawlowski A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002464; Philips JA, 2008, CELL MICROBIOL, V10, P2408, DOI 10.1111/j.1462-5822.2008.01239.x; Russell DG, 2010, SCIENCE, V328, P852, DOI 10.1126/science.1184784; Schaible UE, 2007, PLOS MED, V4, P806, DOI 10.1371/journal.pmed.0040115; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; Shive MS, 1997, ADV DRUG DELIV REV, V28, P5; SMALL PLC, 1994, SCIENCE, V263, P637, DOI 10.1126/science.8303269; Smith I, 2003, CLIN MICROBIOL REV, V16, P463, DOI 10.1128/CMR.16.3.463-496.2003; Smith SJ, 1999, ANN PHARMACOTHER, V33, P27, DOI 10.1345/aph.18116; Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P547, DOI 10.1016/j.addr.2009.11.023; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; Venugopal J, 2008, CURR PHARM DESIGN, V14, P2184, DOI 10.2174/138161208785740180; Vilcheze C, 2007, ANNU REV MICROBIOL, V61, P35, DOI 10.1146/annurev.micro.61.111606.122346; Xu PS, 2009, MOL PHARMACEUT, V6, P190, DOI 10.1021/mp800137z; XU SM, 1994, J IMMUNOL, V153, P2568; Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524; Yu SS, 2012, INT J NANOMED, V7, P799, DOI 10.2147/IJN.S28531	61	28	28	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5071	5082		10.1096/fj.14-255786	http://dx.doi.org/10.1096/fj.14-255786			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25122556	Green Published, Green Submitted			2022-12-28	WOS:000345894500005
J	Reddy, AT; Lakshmi, SP; Zhang, YZ; Reddy, RC				Reddy, Aravind T.; Lakshmi, Sowmya P.; Zhang, Yingze; Reddy, Raju C.			Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages	FASEB JOURNAL			English	Article						TGF; collagen; MFG-E8	ACTIVATED-RECEPTOR-GAMMA; GROWTH-FACTOR-BETA; GENE-EXPRESSION; CELL-MEMBRANE; MURINE MODEL; DIFFERENTIATION; INFLAMMATION; MECHANISMS; CURCUMIN; DELIVERY	Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disease, thought to be largely transforming growth factor beta (TGF beta) driven, for which there is no effective therapy. We assessed the potential benefits in IPF of nitrated fatty acids (NFAs), which are unique endogenous agonists of peroxisome proliferator- activated receptor gamma (PPAR gamma), a nuclear hormone receptor that exhibits wound-healing and antifibrotic properties potentially useful for IPF therapy. We found that pulmonary PPAR gamma is down-regulated in patients with IPF. In vitro, knockdown or knockout of PPAR gamma expression in isolated human and mouse lung fibroblasts induced a profibrotic phenotype, whereas treating human fibroblasts with NFAs up-regulated PPAR gamma and blocked TGF beta signaling and actions. NFAs also converted TGF beta to inactive monomers in cell-free solution, suggesting an additional mechanism through which they may inhibit TGF beta. In vivo, treating mice bearing experimental pulmonary fibrosis with NFAs reduced disease severity. Also, NFAs up-regulated the collagen-targeting factor milk fat globule-EGF factor 8 (MFG-E8), stimulated collagen uptake and degradation by alveolar macrophages, and promoted myofibroblast dedifferentiation. Moreover, treating mice with established pulmonary fibrosis using NFAs reversed their existing myofibroblast differentiation and collagen deposition. These findings raise the prospect of treating IPF with NFAs to halt and perhaps even reverse the progress of IPF.	[Reddy, Aravind T.; Lakshmi, Sowmya P.; Zhang, Yingze; Reddy, Raju C.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; [Reddy, Aravind T.; Lakshmi, Sowmya P.; Reddy, Raju C.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Reddy, RC (corresponding author), Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, 3459 Fifth Ave, Pittsburgh, PA 15213 USA.	reddyrc@upmc.edu	Reddy, Raju C/GLR-5338-2022; Lakshmi, Sowmya P./P-1851-2018; Reddy, Aravind/P-1847-2018	Reddy, Raju C/0000-0001-7079-1520; Lakshmi, Sowmya P./0000-0003-1708-9462; Reddy, Aravind/0000-0001-8628-3467; Zhang, YIngze/0000-0001-8042-6105	U.S. Department of Veterans Affairs; U.S. National Institutes of Health [HL-093196]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093196] Funding Source: NIH RePORTER	U.S. Department of Veterans Affairs(US Department of Veterans Affairs); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by a Merit Review Award from the U.S. Department of Veterans Affairs and by U.S. National Institutes of Health grant HL-093196 (to R.C.R).	American Thoracic Society, 2002, Am J Respir Crit Care Med, V165, P277; Artaud-Macari E, 2013, ANTIOXID REDOX SIGN, V18, P66, DOI 10.1089/ars.2011.4240; Atabai K, 2009, J CLIN INVEST, V119, P3713, DOI 10.1172/JCI40053; Baker LMS, 2007, J BIOL CHEM, V282, P31085, DOI 10.1074/jbc.M704085200; Baker PRS, 2005, J BIOL CHEM, V280, P42464, DOI 10.1074/jbc.M504212200; Baker PRS, 2004, P NATL ACAD SCI USA, V101, P11577, DOI 10.1073/pnas.0402587101; Blakytny R, 2006, INT J BIOCHEM CELL B, V38, P1363, DOI 10.1016/j.biocel.2006.01.017; Burgess HA, 2005, AM J PHYSIOL-LUNG C, V288, pL1146, DOI 10.1152/ajplung.00383.2004; Diaz KT, 2012, J AEROSOL MED PULM D, V25, P79, DOI 10.1089/jamp.2011.0919; Fu MG, 2003, BIOCHEM J, V370, P1019, DOI 10.1042/BJ20021503; Garrison G, 2013, AM J RESP CELL MOL, V48, P550, DOI 10.1165/rcmb.2012-0262OC; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; King TE, 2011, LANCET, V378, P1949, DOI 10.1016/S0140-6736(11)60052-4; Kusunoki R, 2012, DIGESTION, V85, P103, DOI 10.1159/000334679; Lakshmi SP, 2012, AM J PHYSIOL-LUNG C, V303, pL758, DOI 10.1152/ajplung.00107.2012; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Li ZB, 2012, J CELL SCI, V125, P3957, DOI 10.1242/jcs.090365; Lichtenberger Frank J, 2006, J Inflamm (Lond), V3, P7, DOI 10.1186/1476-9255-3-7; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Michalik L, 2006, J CLIN INVEST, V116, P598, DOI 10.1172/JCI27958; Milam JE, 2008, AM J PHYSIOL-LUNG C, V294, pL891, DOI 10.1152/ajplung.00333.2007; Moeller A, 2008, INT J BIOCHEM CELL B, V40, P362, DOI 10.1016/j.biocel.2007.08.011; Narala VR, 2009, GENE THER MOL BIOL, V13, P20; O'Donnell VB, 1999, METHOD ENZYMOL, V301, P454; Reddy AT, 2012, J IMMUNOL, V189, P5411, DOI 10.4049/jimmunol.1201487; Reddy AT, 2012, PPAR RES, V2012, DOI 10.1155/2012/617063; Richeldi L, 2012, EUR RESPIR REV, V21, P147, DOI 10.1183/09059180.00000912; Schopfer FJ, 2005, P NATL ACAD SCI USA, V102, P2340, DOI 10.1073/pnas.0408384102; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sime PJ, 2008, J INVEST MED, V56, P534, DOI 10.2310/JIM.0b013e31816464e9; Sugimoto H, 2012, NAT MED, V18, P396, DOI 10.1038/nm.2629; Tampe B, 2014, J AM SOC NEPHROL, V25, P905, DOI 10.1681/ASN.2013070723; Verrecchia F, 2007, WORLD J GASTROENTERO, V13, P3056, DOI 10.3748/wjg.v13.i22.3056; Wang XM, 2006, J EXP MED, V203, P2895, DOI 10.1084/jem.20061536; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Xu L, 2012, INT IMMUNOPHARMACOL, V12, P556, DOI 10.1016/j.intimp.2012.01.012; Zhao CY, 2006, BIOCHEM BIOPH RES CO, V350, P385, DOI 10.1016/j.bbrc.2006.09.069; Zheng SZ, 2007, AM J PHYSIOL-GASTR L, V292, pG113, DOI 10.1152/ajpgi.00200.2006	38	54	55	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5299	5310		10.1096/fj.14-256263	http://dx.doi.org/10.1096/fj.14-256263			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25252739	Green Published			2022-12-28	WOS:000345894500024
J	Crisante, G; Battista, L; Iwaszkiewicz, J; Nesca, V; Merillat, AM; Sergi, C; Zoete, V; Frateschi, S; Hummler, E				Crisante, Giovanna; Battista, Laura; Iwaszkiewicz, Justyna; Nesca, Valeria; Merillat, Anne-Marie; Sergi, Chloe; Zoete, Vincent; Frateschi, Simona; Hummler, Edith			The CAP1/Prss8 catalytic triad is not involved in PAR2 activation and protease nexin-1 (PN-1) inhibition	FASEB JOURNAL			English	Article						serine protease; prostasin; enzymatic activity	THYMIC STROMAL LYMPHOPOIETIN; EPITHELIAL SODIUM-CHANNELS; STATISTICAL-MODEL; SERINE PROTEINASE; SERPIN STRUCTURE; HUMAN PROSTASIN; EXPRESSION; INFLAMMATION; MECHANISM; COMPLEX	Serine proteases, serine protease inhibitors, and protease-activated receptors (PARs) are responsible for several human skin disorders characterized by impaired epidermal permeability barrier function, desquamation, and inflammation. In this study, we addressed the consequences of a catalytically dead serine protease on epidermal homeostasis, the activation of PAR2 and the inhibition by the serine protease inhibitor nexin-1. The catalytically inactive serine protease CAP1/Prss8, when ectopically expressed in the mouse, retained the ability to induce skin disorders as well as its catalytically active counterpart (75%, n=81). Moreover, this phenotype was completely normalized in a PAR2-null background, indicating that the effects mediated by the catalytically inactive CAP1/Prss8 depend on PAR2 (95%, n=131). Finally, nexin-1 displayed analogous inhibitory capacity on both wild-type and inactive mutant CAP1/Prss8 in vitro and in vivo (64% n=151 vs. 89% n=109, respectively), indicating that the catalytic site of CAP1/Prss8 is dispensable for nexin-1 inhibition. Our results demonstrate a novel inhibitory interaction between CAP1/Prss8 and nexin-1, opening the search for specific CAP1/Prss8 antagonists that are independent of its catalytic activity.Crisante, G., Battista, L., Iwaszkiewicz, J., Nesca, V., Merillat, A.-M., Sergi, C., Zoete, V., Frateschi, S., Hummler, E. The CAP1/Prss8 catalytic triad is not involved in PAR2 activation and protease nexin-1 (PN-1) inhibition.	[Crisante, Giovanna; Battista, Laura; Nesca, Valeria; Merillat, Anne-Marie; Sergi, Chloe; Frateschi, Simona; Hummler, Edith] Univ Lausanne, Dept Pharmacol & Toxicol, Lausanne, Switzerland; [Iwaszkiewicz, Justyna; Zoete, Vincent] Univ Lausanne, Swiss Inst Bioinformat, Lausanne, Switzerland	University of Lausanne; Swiss Institute of Bioinformatics; University of Lausanne	Frateschi, S (corresponding author), Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	simona.frateschi@unil.ch; edith.hummler@unil.ch		Iwaszkiewicz, Justyna/0000-0003-3494-589X; Battista, Laura/0000-0002-9370-6736	Swiss National Foundation [FNRS 31003A-127147/1, 31003A-144198/1]; Swiss National Center of Competence in Research (NCCR Kidney CH)	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Swiss National Center of Competence in Research (NCCR Kidney CH)(Swiss National Science Foundation (SNSF))	The authors thank all of the members of the E.H. laboratory and Bernard Rossier for helpful discussions; Friedric Beermann and Denis Monard for critically reading the manuscript; Denis Monard (Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland) for providing the nexin-1 antibody; Nicole Fowler-Jaeger for excellent technical assistance with the Xenopus oocyte injections and measurements; Olivier Michielin for helpful discussion on bioinformatic approaches; and the facilities of the Mouse Pathology, Protein Analysis, Transgenic Animal, and Cellular Imaging platforms, University of Lausanne. This work was supported by the Swiss National Foundation (grants FNRS 31003A-127147/1 and 31003A-144198/1 to E. H.) and the Swiss National Center of Competence in Research (NCCR Kidney CH). Author contributions: G.C. and S.F. conducted most of the experiments, including phenotypic characterization of the transgenic lines; S.F. designed constructs and analyzed transgenic mice; J.I. and V.Z. performed and analyzed the bioinformatic data; L.B., A.M.M., V.N., and C.S. conducted and assisted in Xenopus oocyte injection, construct preparation, and immunofluorescence experiments; CC., S.F., and E.H. analyzed the data; S.F. and E.H. wrote the manuscript and conceived, designed, and supervised the study.	Adachi M, 2001, J AM SOC NEPHROL, V12, P1114, DOI 10.1681/ASN.V1261114; Andreasen D, 2006, J AM SOC NEPHROL, V17, P968, DOI 10.1681/ASN.2005060637; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Camerer E, 2010, DEV CELL, V18, P25, DOI 10.1016/j.devcel.2009.11.014; Chen LM, 2001, J BIOL CHEM, V276, P21434, DOI 10.1074/jbc.M011423200; Chen LM, 2004, PROSTATE, V59, P1, DOI 10.1002/pros.10346; Chen MQ, 2007, BBA-MOL CELL RES, V1773, P1133, DOI 10.1016/j.bbamcr.2007.04.013; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; de Vries SJ, 2006, PROTEINS, V63, P479, DOI 10.1002/prot.20842; De Vries SJ, 2010, NAT PROTOC, V5, P883, DOI 10.1038/nprot.2010.32; del Vescovo CD, 2013, MOL CELL BIOL, V33, P14, DOI 10.1128/MCB.00887-12; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; Fayard B, 2009, CANCER RES, V69, P5690, DOI 10.1158/0008-5472.CAN-08-4573; Feutz AC, 2008, J CELL SCI, V121, P1435, DOI 10.1242/jcs.018689; Frateschi S, 2012, AM J PATHOL, V181, P605, DOI 10.1016/j.ajpath.2012.05.007; Frateschi S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1162; Friis S, 2013, J BIOL CHEM, V288, P19028, DOI 10.1074/jbc.M113.469932; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hummler E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055796; Huntington JA, 2011, J THROMB HAEMOST, V9, P26, DOI 10.1111/j.1538-7836.2011.04360.x; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Jensen PJ, 2000, J INVEST DERMATOL, V114, P917, DOI 10.1046/j.1523-1747.2000.00945.x; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; Koyama K, 2007, BIOCHEM BIOPH RES CO, V357, P99, DOI 10.1016/j.bbrc.2007.03.081; Leyvraz C, 2005, J CELL BIOL, V170, P487, DOI 10.1083/jcb.200501038; Li W, 2012, BLOOD, V120, P459, DOI 10.1182/blood-2012-03-415869; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Magert HJ, 2005, CURR PROTEIN PEPT SC, V6, P241, DOI 10.2174/1389203054065374; Malsure S, 2014, J AM SOC NEPHROL, V25, P1453, DOI 10.1681/ASN.2013090936; Melo F, 1997, J MOL BIOL, V267, P207, DOI 10.1006/jmbi.1996.0868; Murer V, 2001, P NATL ACAD SCI USA, V98, P3029, DOI 10.1073/pnas.051630698; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Netzel-Arnett S, 2006, J BIOL CHEM, V281, P32941, DOI 10.1074/jbc.C600208200; Peters DE, 2014, J BIOL CHEM, V289, P14740, DOI 10.1074/jbc.M113.541318; Planes C, 2005, AM J PHYSIOL-LUNG C, V288, pL1099, DOI 10.1152/ajplung.00332.2004; Planes C, 2010, EMBO MOL MED, V2, P26, DOI 10.1002/emmm.200900050; Porret Andree, 2006, V337, P185; Ramachandran R, 2012, NAT REV DRUG DISCOV, V11, P69, DOI 10.1038/nrd3615; Rickert KW, 2008, J BIOL CHEM, V283, P34864, DOI 10.1074/jbc.M805262200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Soumelis V, 2004, SPRINGER SEMIN IMMUN, V25, P325, DOI 10.1007/s00281-003-0152-0; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stout TJ, 2000, BIOCHEMISTRY-US, V39, P8460, DOI 10.1021/bi000290w; Tully DC, 2008, BIOORG MED CHEM LETT, V18, P5895, DOI 10.1016/j.bmcl.2008.08.029; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Verghese GM, 2004, AM J RESP CELL MOL, V30, P519, DOI 10.1165/rcmb.2003-0251OC; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Wakida N, 2006, KIDNEY INT, V70, P1432, DOI 10.1038/sj.ki.5001787; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; YU JX, 1995, J BIOL CHEM, V270, P13483, DOI 10.1074/jbc.270.22.13483; YU JX, 1994, J BIOL CHEM, V269, P18843	65	8	8	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4792	4805		10.1096/fj.14-253781	http://dx.doi.org/10.1096/fj.14-253781			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25138159				2022-12-28	WOS:000344050900018
J	Maddipati, KR; Romero, R; Chaiworapongsa, T; Zhou, SL; Xu, ZH; Tarca, AL; Kusanovic, JP; Munoz, H; Honn, KV				Maddipati, Krishna Rao; Romero, Roberto; Chaiworapongsa, Tinnakorn; Zhou, Sen-Lin; Xu, Zhonghui; Tarca, Adi L.; Kusanovic, Juan Pedro; Munoz, Hernan; Honn, Kenneth V.			Eicosanomic profiling reveals dominance of the epoxygenase pathway in human amniotic fluid at term in spontaneous labor	FASEB JOURNAL			English	Article						epoxy fatty acids; hydroxy fatty acids; LC-MS; lipidomics; parturition	SOLUBLE EPOXIDE HYDROLASE; PLATELET-NEUTROPHIL INTERACTIONS; HUMAN MYOMETRIAL CONTRACTILITY; HUMAN FETAL MEMBRANES; ARACHIDONIC-ACID; HUMAN PARTURITION; EPOXYEICOSATRIENOIC ACIDS; PRETERM LABOR; 5-HYDROXYEICOSATETRAENOIC ACID; PROSTAGLANDIN CONCENTRATIONS	Lipid mediators play an important role in reproductive biology, especially, in parturition. Enhanced biosynthesis of eicosanoids, such as prostaglandin E-2 (PGE(2)) and PGF(2), precedes the onset of labor as a result of increased expression of inducible cyclooxygenase 2 (COX-2) in placental tissues. Metabolism of arachidonic acid results in bioactive lipid mediators beyond prostaglandins that could significantly influence myometrial activity. Therefore, an unbiased lipidomic approach was used to profile the arachidonic acid metabolome of amniotic fluid. In this study, liquid chromatography-mass spectrometry was used for the first time to quantitate these metabolites in human amniotic fluid by comparing patients at midtrimester, at term but not in labor, and at term and in spontaneous labor. In addition to exposing novel aspects of COX pathway metabolism, this lipidomic study revealed a dramatic increase in epoxygenase- and lipoxygenase-pathway-derived lipid mediators in spontaneous labor with remarkable product selectivity. Despite their recognition as anti-inflammatory lipid mediators and regulators of ion channels, little is known about the epoxygenase pathway in labor. Epoxygenase pathway metabolites are established regulators of vascular homeostasis in cardiovascular and renal physiology. Their presence as the dominant lipid mediators in spontaneous labor at term portends a yet undiscovered physiological function in parturition.Maddipati, K. R., Romero, R., Chaiworapongsa, T., Zhou, S.-L., Xu, Z., Tarca, A. L., Kusanovic, J. P., Munoz, H., Honn, K. V. Eicosanomic profiling reveals dominance of the epoxygenase pathway in human amniotic fluid at term in spontaneous labor.	[Maddipati, Krishna Rao; Zhou, Sen-Lin; Honn, Kenneth V.] Wayne State Univ, Sch Med, Dept Pathol, Bioact Lipids Res Program, Detroit, MI 48202 USA; [Maddipati, Krishna Rao; Zhou, Sen-Lin] Wayne State Univ, Sch Med, Lipid Core Facil, Detroit, MI 48202 USA; [Chaiworapongsa, Tinnakorn] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48202 USA; [Romero, Roberto; Chaiworapongsa, Tinnakorn; Kusanovic, Juan Pedro] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Perinatol Res Branch, Program Perinatal Res & Obstet, Div Intramural Res,NIH, Bethesda, MD USA; [Romero, Roberto] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; [Romero, Roberto] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA; [Xu, Zhonghui; Tarca, Adi L.] Wayne State Univ, Dept Comp Sci, Detroit, MI 48202 USA; [Kusanovic, Juan Pedro] Pontificia Univ Catolica Chile, Sch Med, Dept Obstet & Gynecol, Santiago, Chile; [Kusanovic, Juan Pedro] Hosp Dr Sotero del Rio, Santiago, Chile; [Munoz, Hernan] Univ Chile, Santiago, Chile	Wayne State University; Wayne State University; Wayne State University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Michigan System; University of Michigan; Michigan State University; Wayne State University; Pontificia Universidad Catolica de Chile; Universidad de Chile; Universidad de Chile	Maddipati, KR (corresponding author), Wayne State Univ, Dept Pathol, 435 Chem Bldg,410 W Warren Ave, Detroit, MI 48202 USA.	maddipati@wayne.edu	Maddipati, Krishna Rao/H-3569-2019; Xu, Zhonghui/F-3353-2018; Kusanovic, Juan Pedro/R-8616-2019; Maddipati, Krishna Rao/G-1859-2011; Kusanovic, Juan Pedro/AAM-5782-2020; Romero, Roberto/A-5268-2019	Maddipati, Krishna Rao/0000-0003-1445-791X; Xu, Zhonghui/0000-0002-6469-9178; Maddipati, Krishna Rao/0000-0003-1445-791X; Kusanovic, Juan Pedro/0000-0003-0640-2070; Romero, Roberto/0000-0002-4448-5121	Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), U.S. Department of Health and Human Services [HSN275201300006C]; National Center for Research Resources/NIH [S10RR027926]; Perinatal Virtual Discovery grant from Wayne State University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD002400] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR027926] Funding Source: NIH RePORTER	Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), U.S. Department of Health and Human Services; National Center for Research Resources/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Perinatal Virtual Discovery grant from Wayne State University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The authors thank Dr. S. Tucker for a careful reading of the manuscript. This research was supported, in part, by the Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), U.S. Department of Health and Human Services; and, in part, with federal funds from NICHD/NIH (contract HSN275201300006C). The work was also supported, in part, by a grant from the National Center for Research Resources/NIH (S10RR027926) and a Perinatal Virtual Discovery grant from Wayne State University (to K.R.M.).	Arulkumaran S, 2012, J CLIN ENDOCR METAB, V97, P489, DOI 10.1210/jc.2011-1991; Austin SC, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.03.014; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BENNETT PR, 1987, PROSTAGLANDINS, V33, P837, DOI 10.1016/0090-6980(87)90112-2; BERRYMAN GK, 1987, LIFE SCI, V41, P1611, DOI 10.1016/0024-3205(87)90728-4; BORGEAT P, 1982, PROSTAGLANDINS, V23, P713, DOI 10.1016/S0090-6980(82)80009-9; Brodt-Eppley J, 1999, OBSTET GYNECOL, V93, P89, DOI 10.1016/S0029-7844(98)00378-0; Campbell WB, 2007, HYPERTENSION, V49, P590, DOI 10.1161/01.HYP.0000255173.50317.fc; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; Earley S, 2005, CIRC RES, V97, P1270, DOI 10.1161/01.RES.0000194321.60300.d6; Edwin SS, 1996, PROSTAG OTH LIPID M, V51, P403, DOI 10.1016/0090-6980(96)00046-9; Enayetallah AE, 2004, J HISTOCHEM CYTOCHEM, V52, P447, DOI 10.1177/002215540405200403; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; FITZPATRICK FA, 1981, BIOCHEMISTRY-US, V20, P6129, DOI 10.1021/bi00524a033; Fulton D, 1998, J LIPID RES, V39, P1713; Furstenberger G, 2002, PROSTAG OTH LIPID M, V68-9, P235, DOI 10.1016/S0090-6980(02)00033-3; Gaedigk A, 2006, J PHARMACOL EXP THER, V319, P523, DOI 10.1124/jpet.106.109215; Glass M, 2005, J LIPID RES, V46, P1364, DOI 10.1194/jlr.C500006-JLR200; Gonzalez E, 1997, PROSTAG LEUKOTR ESS, V56, P57, DOI 10.1016/S0952-3278(97)90525-1; Henningsen A, 2011, CENSREG CENSORED REG; Herse F, 2012, CIRCULATION, V126, P2990, DOI 10.1161/CIRCULATIONAHA.112.127340; Imig JD, 2012, PHYSIOL REV, V92, P101, DOI 10.1152/physrev.00021.2011; JAMES K, 1984, IMMUNOL TODAY, V5, P357, DOI 10.1016/0167-5699(84)90079-3; Jiang HL, 2013, AM J HYPERTENS, V26, P271, DOI 10.1093/ajh/hps011; Keeney DS, 1998, J BIOL CHEM, V273, P9279, DOI 10.1074/jbc.273.15.9279; Kelly AJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003101.pub2; KIEL D, 1991, ADV PROSTAG THROMB L, V21, P403; KINOSHITA K, 1977, ENDOCRINOL JAPON, V24, P155; Krishnamoorthy S, 2006, CANCER METAST REV, V25, P481, DOI 10.1007/s10555-006-9016-0; Lee SE, 2008, J MATERN-FETAL NEO M, V21, P89, DOI 10.1080/14767050701830514; MACDONALD PC, 1993, J CLIN ENDOCR METAB, V76, P1332, DOI 10.1210/jc.76.5.1332; Maddipati KR, 2011, PROSTAG OTH LIPID M, V94, P59, DOI 10.1016/j.prostaglandins.2011.01.003; MARCUS AJ, 1982, BIOCHEM BIOPH RES CO, V109, P130, DOI 10.1016/0006-291X(82)91575-3; MAXEY KM, 1992, J CLIN IMMUNOASSAY, V15, P116; McKirdy NC, 2013, REPROD BIOL INSIGHTS, V6, P1, DOI 10.4137/RBI.S11602; Menon R, 2011, OBSTET GYNECOL, V118, P121, DOI 10.1097/AOG.0b013e3182204eaa; MITCHELL MD, 1982, PROSTA LEUKOTR MED, V8, P383, DOI 10.1016/0262-1746(82)90061-0; Mitchell MD, 2005, J CLIN ENDOCR METAB, V90, P4244, DOI 10.1210/jc.2004-2496; MITCHELL MD, 1995, REPROD FERT DEVELOP, V7, P623, DOI 10.1071/RD9950623; MITCHELL MD, 1981, J REPROD FERTIL, V62, P305; Morisseau C, 2013, ANNU REV PHARMACOL, V53, P37, DOI 10.1146/annurev-pharmtox-011112-140244; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Olson DM, 2007, FRONT BIOSCI-LANDMRK, V12, P1329, DOI 10.2741/2151; Osman I, 2006, J SOC GYNECOL INVEST, V13, P97, DOI 10.1016/j.jsgi.2005.12.002; Osman I, 2003, MOL HUM REPROD, V9, P41, DOI 10.1093/molehr/gag001; PATEL L, 1989, PROSTAGLANDINS, V38, P615, DOI 10.1016/0090-6980(89)90044-0; Pearson T, 2010, J HYPERTENS, V28, P2429, DOI 10.1097/HJH.0b013e32833e86aa; Pearson T, 2009, AM J PHYSIOL-ENDOC M, V297, pE647, DOI 10.1152/ajpendo.00227.2009; QUAYLE AJ, 1989, CLIN EXP IMMUNOL, V75, P387; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; Roman RJ, 2000, CLIN EXP PHARMACOL P, V27, P855, DOI 10.1046/j.1440-1681.2000.03349.x; ROMERO R, 1990, AM J OBSTET GYNECOL, V163, P968, DOI 10.1016/0002-9378(90)91106-M; ROMERO R, 1988, AM J OBSTET GYNECOL, V159, P114, DOI 10.1016/0002-9378(88)90503-0; ROMERO R, 1991, AM J OBSTET GYNECOL, V165, P821, DOI 10.1016/0002-9378(91)90423-O; ROMERO R, 1994, PROSTAG LEUKOTR ESS, V50, P97, DOI 10.1016/0952-3278(94)90154-6; ROMERO R, 1989, PROSTAG LEUKOTR ESS, V35, P81, DOI 10.1016/0952-3278(89)90169-5; ROMERO R, 1988, AM J OBSTET GYNECOL, V159, P655, DOI 10.1016/S0002-9378(88)80028-0; Romero R, 1996, PROSTAG LEUKOTR ESS, V54, P187, DOI 10.1016/S0952-3278(96)90015-0; ROMERO R, 1987, OBSTET GYNECOL, V70, P849; Rosner W, 2007, J CLIN ENDOCR METAB, V92, P405, DOI 10.1210/jc.2006-1864; SATOH K, 1979, AM J OBSTET GYNECOL, V133, P886, DOI 10.1016/0002-9378(79)90306-5; Schweiger D, 2007, J LIPID RES, V48, P553, DOI 10.1194/jlr.M600311-JLR200; SENIOR J, 1993, BRIT J PHARMACOL, V108, P501, DOI 10.1111/j.1476-5381.1993.tb12832.x; SENIOR J, 1991, BRIT J PHARMACOL, V102, P747, DOI 10.1111/j.1476-5381.1991.tb12244.x; Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; SKIBINSKI G, 1992, J REPROD IMMUNOL, V22, P185, DOI 10.1016/0165-0378(92)90015-V; SLATER D, 1994, BIOCHEM BIOPH RES CO, V198, P304, DOI 10.1006/bbrc.1994.1043; Smith WL, 2011, CHEM REV, V111, P5821, DOI 10.1021/cr2002992; Spiecker M, 2006, TRENDS CARDIOVAS MED, V16, P204, DOI 10.1016/j.tcm.2006.04.001; STRICKLAND DM, 1983, SCIENCE, V220, P521, DOI 10.1126/science.6573023; TEMPLETON AA, 1978, J REPROD FERTIL, V52, P147; Vidaeff AC, 2008, CURR MED CHEM, V15, P614, DOI 10.2174/092986708783769786; VONSCHACKY C, 1990, J LIPID RES, V31, P801; Walther M, 2009, BBA-MOL CELL BIOL L, V1791, P827, DOI 10.1016/j.bbalip.2009.05.007; Wenk MR, 2010, CELL, V143, P888, DOI 10.1016/j.cell.2010.11.033; WOODWARD DF, 1993, PROSTAGLANDINS, V46, P371, DOI 10.1016/0090-6980(93)90102-D; YLIKORKALA O, 1981, AM J OBSTET GYNECOL, V141, P487, DOI 10.1016/S0002-9378(15)33265-8; Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438; Zhang JH, 2007, ANAL BIOCHEM, V365, P40, DOI 10.1016/j.ab.2007.03.001	81	61	61	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4835	4846		10.1096/fj.14-254383	http://dx.doi.org/10.1096/fj.14-254383			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25059230	Green Published, Green Submitted			2022-12-28	WOS:000344050900021
J	Nielsen, RH; Couppe, C; Jensen, JK; Olsen, MR; Heinemeier, KM; Malfait, F; Symoens, S; De Paepe, A; Schjerling, P; Magnusson, SP; Remvig, L; Kjaer, M				Nielsen, Rie Harboe; Couppe, Christian; Jensen, Jacob Kildevang; Olsen, Morten Raun; Heinemeier, Katja Maria; Malfait, Fransiska; Symoens, Sofie; De Paepe, Anne; Schjerling, Peter; Magnusson, Stig Peter; Remvig, Lars; Kjaer, Michael			Low tendon stiffness and abnormal ultrastructure distinguish classic Ehlers-Danlos syndrome from benign joint hypermobility syndrome in patients	FASEB JOURNAL			English	Article						muscle; cauliflower fibrils; null-allele analysis	MECHANICAL-PROPERTIES; V COLLAGEN; COL5A1 HAPLOINSUFFICIENCY; VISCOELASTIC PROPERTIES; PATELLAR TENDON; PREVALENCE; FEATURES; ALLELES; KNEE; FORM	There is a clinical overlap between classic Ehlers-Danlos syndrome (cEDS) and benign joint hypermobility syndrome (BJHS), with hypermobility as the main symptom. The purpose of this study was to investigate the role of type V collagen mutations and tendon pathology in these 2 syndromes. In patients (cEDS, n=7; BJHS, n=8) and controls (Ctrl, n=8), we measured patellar tendon ultrastructure (transmission electron microscopy), dimensions (magnetic resonance imaging), and biomechanical properties (force and ultrasonographic measurements during a ramped isometric knee extension). Mutation analyses (COL5A1 and COL5A2) were performed in the patients. COL5A1 mutations were found in 3 of 4 of the patients with cEDS. Patellar tendon dimensions were similar between the groups, but large, irregular collagen fibrils were in 4 of 5 patients with cEDS. In the cEDS group, tendon stiffness and Young's modulus were reduced to approximate to 50% of that in BJHS and Ctrl groups (P<0.05). The nonhypermobile, healthy controls were matched with the patients in age, sex, body weight, and physical activity, to compare outcomes. COL5A1 mutations led to structural tendon pathology and low tendon stiffness in cEDS, explaining the patients' hypermobility, whereas no tendon pathology was found that explained the hypermobility in BJHS.Nielsen, R. H., Couppe, C., Jensen, J. K., Olsen, M. R., Heinemeier, K. M., Malfait, F., Symoens, S., De Paepe, A., Schjerling, P., Magnusson, S. P., Remvig, L., Kjaer, M. Low tendon stiffness and abnormal ultrastructure distinguish classic Ehlers-Danlos syndrome from benign joint hypermobility syndrome in patients.	[Nielsen, Rie Harboe; Jensen, Jacob Kildevang; Olsen, Morten Raun; Heinemeier, Katja Maria; Schjerling, Peter; Kjaer, Michael] Bispebjerg Hosp, Inst Sports Med, Dept Orthopaed Surg, DK-2400 Copenhagen NV, Denmark; [Couppe, Christian; Magnusson, Stig Peter] Bispebjerg Hosp, Dept Phys Therapy, Musculoskeletal Rehabil Res Unit, DK-2400 Copenhagen NV, Denmark; [Nielsen, Rie Harboe; Jensen, Jacob Kildevang; Olsen, Morten Raun; Heinemeier, Katja Maria; Schjerling, Peter; Kjaer, Michael] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark; [Malfait, Fransiska; Symoens, Sofie; De Paepe, Anne] Univ Hosp, Ctr Med Genet, Ghent, Belgium; [Remvig, Lars] Rigshosp, Dept Rheumatol, DK-2100 Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Ghent University; Ghent University Hospital; Rigshospitalet; University of Copenhagen	Nielsen, RH (corresponding author), Bispebjerg Hosp, Inst Sports Med, Bldg 8,Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.	rieharboenielsen@gmail.com	Schjerling, Peter/F-6194-2011; Magnusson, S. Peter/AAD-5903-2022; Kjaer, Michael/W-6842-2019; Magnusson, Peter/AAN-1631-2020	Schjerling, Peter/0000-0001-7138-3211; Magnusson, S. Peter/0000-0002-4308-5484; Kjaer, Michael/0000-0002-4582-8755; Malfait, Fransiska/0000-0002-5010-0304; Jensen, Jacob Kildevang/0000-0002-5505-5944	Danish Rheumatism Association [R 108-A2458]; Ghent University [08/01M01108]; Fund for Scientific Research FWO, Flanders, Belgium [G.0171.05]; Lundbeck Foundation; Nordea Foundation; Novo Nordic Foundation; Novo Nordisk Fonden [NNF11OC1015388] Funding Source: researchfish	Danish Rheumatism Association; Ghent University(Ghent University); Fund for Scientific Research FWO, Flanders, Belgium(FWO); Lundbeck Foundation(Lundbeckfonden); Nordea Foundation; Novo Nordic Foundation(Novo Nordisk Foundation); Novo Nordisk Fonden(Novo Nordisk Foundation)	The authors thank C. Bojstrup for preparation of samples, and C. E. Hansen for excellent TEM assistance, and the patients and healthy volunteers for their participation in the study. This Work Was supported by the Danish Rheumatism Association (R 108-A2458), a Methusalem grant from Ghent University (grant 08/01M01108), the Fund for Scientific Research FWO, Flanders, Belgium (grant G.0171.05), the Lundbeck Foundation, the Nordea Foundation, and the Novo Nordic Foundation. The authors declare no conflicts of interest.	Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; BEIGHTON P, 1972, Seminars in Arthritis and Rheumatism, V1, P246, DOI 10.1016/0049-0172(72)90004-2; Bojsen-Moller J, 2007, SCAND J MED SCI SPOR, V17, P415, DOI 10.1111/j.1600-0838.2006.00591.x; Castori Marco, 2012, ISRN Dermatol, V2012, P751768, DOI 10.5402/2012/751768; Couppe C, 2009, J APPL PHYSIOL, V107, P880, DOI 10.1152/japplphysiol.00291.2009; Czika W, 2002, AM J HUM GENET, V71, P1235, DOI 10.1086/344290; Dalgleish R, 1998, NUCLEIC ACIDS RES, V26, P253, DOI 10.1093/nar/26.1.253; Decoster LC, 1997, ARCH PEDIAT ADOL MED, V151, P989, DOI 10.1001/archpedi.1997.02170470023005; Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215; Grahame R, 2000, J RHEUMATOL, V27, P1777; Hansen P, 2006, CLIN BIOMECH, V21, P54, DOI 10.1016/j.clinbiomech.2005.07.008; HAUSSER I, 1994, HUM GENET, V93, P394; Iacono V, 2010, KNEE SURG SPORT TR A, V18, P1116, DOI 10.1007/s00167-009-1022-7; Kongsgaard M, 2011, CLIN BIOMECH, V26, P772, DOI 10.1016/j.clinbiomech.2011.02.011; LARSSON LG, 1993, BRIT J RHEUMATOL, V32, P116; Magnusson SP, 2003, ACTA PHYSIOL SCAND, V177, P185, DOI 10.1046/j.1365-201X.2003.01048.x; Magnusson SP, 2001, J RHEUMATOL, V28, P2720; Malfait F, 2005, HUM MUTAT, V25, P28, DOI 10.1002/humu.20107; Moretti Biagio, 2008, Chir Organi Mov, V91, P51, DOI 10.1007/s12306-007-0009-0; PALVOLGYI R, 1979, ARCH ORTHOP TRAUM SU, V95, P173, DOI 10.1007/BF00460115; Pierard GE, 2013, ISRN DERMATOL, V2013; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Reeves ND, 2003, MUSCLE NERVE, V28, P74, DOI 10.1002/mus.10392; Remvig L, 2010, SCAND J RHEUMATOL, V39, P511, DOI 10.3109/03009741003781977; Remvig L, 2009, SCAND J RHEUMATOL, V38, P227, DOI 10.1080/03009740802520714; Rombaut L, 2012, ARTHRIT CARE RES, V64, P766, DOI 10.1002/acr.21592; Schwarze U, 2000, AM J HUM GENET, V66, P1757, DOI 10.1086/302933; Sun M, 2011, J CELL SCI, V124, P4096, DOI 10.1242/jcs.091363; Symoens S, 2012, HUM MUTAT, V33, P1485, DOI 10.1002/humu.22137; Tinkle BT, 2009, AM J MED GENET A, V149A, P2368, DOI 10.1002/ajmg.a.33070; VISSER JJ, 1990, EUR J APPL PHYSIOL O, V61, P453, DOI 10.1007/BF00236067; VOGEL A, 1979, LAB INVEST, V40, P201; Wangkumhang P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-275; Wenstrup RJ, 2011, J BIOL CHEM, V286, P20455, DOI 10.1074/jbc.M111.223693; Wenstrup RJ, 2000, AM J HUM GENET, V66, P1766, DOI 10.1086/302930; Wenstrup RJ, 2006, J BIOL CHEM, V281, P12888, DOI 10.1074/jbc.M511528200; Wenstrup RJ, 2004, J BIOL CHEM, V279, P53331, DOI 10.1074/jbc.M409622200	37	36	36	2	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4668	4676		10.1096/fj.14-249656	http://dx.doi.org/10.1096/fj.14-249656			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25122555				2022-12-28	WOS:000344050900008
J	Lindholm, ME; Huss, M; Solnestam, BW; Kjellqvist, S; Lundeberg, J; Sundberg, CJ				Lindholm, Malene E.; Huss, Mikael; Solnestam, Beata W.; Kjellqvist, Sanela; Lundeberg, Joakim; Sundberg, Carl J.			The human skeletal muscle transcriptome: sex differences, alternative splicing, and tissue homogeneity assessed with RNA sequencing	FASEB JOURNAL			English	Article						gene expression profiling; biopsy; isoform; splice variant; novel transcript	GENE-EXPRESSION; MESSENGER-RNA; LIPOPROTEIN-LIPASE; EXERCISE; PHOSPHORYLATION; METABOLISM; ACTIVATION; MECHANISMS; REGULATORS; ATROPHY	Human skeletal muscle health is important for quality of life and several chronic diseases, including type II diabetes, heart disease, and cancer. Skeletal muscle is a tissue widely used to study mechanisms behind different diseases and adaptive effects of controlled interventions. For such mechanistic studies, knowledge about the gene expression profiles in different states is essential. Since the baseline transcriptome has not been analyzed systematically, the purpose of this study was to provide a deep reference profile of female and male skeletal muscle. RNA sequencing data were analyzed from a large set of 45 resting human muscle biopsies. We provide extensive information on the skeletal muscle transcriptome, including 5 previously unannotated protein-coding transcripts. Global transcriptional tissue homogeneity was strikingly high, within both a specific muscle and the contralateral leg. We identified >23,000 known isoforms and found >5000 isoforms that differ between the sexes. The female and male transcriptome was enriched for genes associated with oxidative metabolism and protein catabolic processes, respectively. The data demonstrate remarkably high tissue homogeneity and provide a deep and extensive baseline reference for the human skeletal muscle transcriptome, with regard to alternative splicing, novel transcripts, and sex differences in functional ontology.	[Lindholm, Malene E.; Sundberg, Carl J.] Karolinska Inst, Dept Physiol & Pharmacol, Solna, Sweden; [Huss, Mikael; Kjellqvist, Sanela] Stockholm Univ, Dept Biochem & Biophys, Sci Life Lab, Stockholm, Sweden; [Solnestam, Beata W.; Lundeberg, Joakim] Royal Inst Technol, Sch Biotechnol, Sci Life Lab, Solna, Sweden	Karolinska Institutet; Stockholm University; Royal Institute of Technology	Lindholm, ME (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Von Eulers Vag 8, S-17177 Stockholm, Sweden.	malene.lindholm@ki.se	Sundberg, Carl Johan/B-9356-2013; Lindholm, Malene/E-5125-2017	Lindholm, Malene/0000-0002-5763-7833; Huss, Mikael/0000-0003-0839-2451	Swedish National Centre for Research in Sports; Wallenberg Advanced Bioinformatics Infrastructure; Karolinska Institutet	Swedish National Centre for Research in Sports; Wallenberg Advanced Bioinformatics Infrastructure; Karolinska Institutet(Karolinska Institutet)	The authors thank Eva-Karin Gidlund and Susanna Appel (Karolinska Institutet) for assistance with physiological testing and biopsy handling and Science for Life Laboratory (SciLifeLab, Stockholm, Sweden), National Genomics Infrastructure (SciLifeLab), and Uppmax (Uppsala University, Uppsala, Sweden) for providing massive parallel sequencing and computational infrastructure. This work was supported by the Swedish National Centre for Research in Sports and the Wallenberg Advanced Bioinformatics Infrastructure. M.E.L has a PhD training grant from Karolinska Institutet.	Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Baron D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026952; BERGSTROM J, 1962, SCAND J CLIN LAB INV, V14, P1; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blekhman R, 2010, GENOME RES, V20, P180, DOI 10.1101/gr.099226.109; Branca RMM, 2014, NAT METHODS, V11, P59, DOI [10.1038/NMETH.2732, 10.1038/nmeth.2732]; Chopard A, 2009, PHYSIOL GENOMICS, V38, P291, DOI 10.1152/physiolgenomics.00036.2009; COSTILL DL, 1976, J APPL PHYSIOL, V40, P149, DOI 10.1152/jappl.1976.40.2.149; Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje; Dalla Libera L, 2009, J APPL PHYSIOL, V107, P549, DOI 10.1152/japplphysiol.00280.2009; Gordon PM, 2012, J APPL PHYSIOL, V112, P443, DOI 10.1152/japplphysiol.00860.2011; Guerra B, 2011, J APPL PHYSIOL, V110, P1708, DOI 10.1152/japplphysiol.00091.2011; Gustafsson T, 2010, J APPL PHYSIOL, V109, P721, DOI 10.1152/japplphysiol.00110.2009; Hangauer MJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003569; Hartmann B, 2011, RNA, V17, P453, DOI 10.1261/rna.2460411; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Khal J, 2005, INT J BIOCHEM CELL B, V37, P2196, DOI 10.1016/j.biocel.2004.10.017; Kiens B, 2004, J APPL PHYSIOL, V97, P1209, DOI 10.1152/japplphysiol.01278.2003; Kjellqvist S, 2013, MOL CELL PROTEOMICS, V12, P407, DOI 10.1074/mcp.M112.021873; Kohn TA, 2007, J ANAT, V210, P8, DOI 10.1111/j.1469-7580.2007.00661.x; Kornblihtt AR, 2013, NAT REV MOL CELL BIO, V14, P153, DOI 10.1038/nrm3525; Koval JA, 1998, AM J PHYSIOL-ENDOC M, V274, pE304, DOI 10.1152/ajpendo.1998.274.2.E304; Kraniou Y, 2000, J APPL PHYSIOL, V88, P794, DOI 10.1152/jappl.2000.88.2.794; Kulkarni SS, 2012, METABOLISM, V61, P175, DOI 10.1016/j.metabol.2011.06.014; Kurtovic S, 2011, MOL MED, V17, P665, DOI 10.2119/molmed.2011.00018; Larrouy D, 2008, AM J CLIN NUTR, V88, P125, DOI 10.1093/ajcn/88.1.125; LEXELL J, 1985, J APPL PHYSIOL, V59, P1228, DOI 10.1152/jappl.1985.59.4.1228; LEXELL J, 1989, ACTA PHYSIOL SCAND, V136, P561, DOI 10.1111/j.1748-1716.1989.tb08702.x; LIN L, 1988, CLIN PHYSIOL, V8, P391, DOI 10.1111/j.1475-097X.1988.tb00282.x; Little JP, 2010, AM J PHYSIOL-REG I, V298, pR912, DOI 10.1152/ajpregu.00409.2009; Liu D, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-659; Lundby C, 2005, EUR J APPL PHYSIOL, V95, P351, DOI 10.1007/s00421-005-0022-7; Maher AC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006335; Mahoney DJ, 2005, FASEB J, V19, P1498, DOI 10.1096/fj.04-3149fje; Mahoney DJ, 2004, PHYSIOL GENOMICS, V18, P226, DOI 10.1152/physiolgenomics.00067.2004; Malm C, 2000, J PHYSIOL-LONDON, V529, P243, DOI 10.1111/j.1469-7793.2000.00243.x; Martens H, 2001, CHEMOMETR INTELL LAB, V58, P151, DOI 10.1016/S0169-7439(01)00157-5; Melia MJ, 2013, BRAIN, V136, P1508, DOI 10.1093/brain/awt074; Millino C, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-14; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Noguchi S, 2003, HUM MOL GENET, V12, P595, DOI 10.1093/hmg/ddg065; Norrbom J, 2011, AM J PHYSIOL-ENDOC M, V301, pE1092, DOI 10.1152/ajpendo.00119.2011; Olsson AH, 2011, MOL GENET METAB, V103, P275, DOI 10.1016/j.ymgme.2011.03.017; POLGAR J, 1973, J NEUROL SCI, V19, P307, DOI 10.1016/0022-510X(73)90094-4; Punkt K, 1998, ACTA HISTOCHEM, V100, P37, DOI 10.1016/S0065-1281(98)80005-6; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ramskold D, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000598; Reardon KA, 2001, MUSCLE NERVE, V24, P893, DOI 10.1002/mus.1086.abs; Roepstorff C, 2006, AM J PHYSIOL-ENDOC M, V291, pE1106, DOI 10.1152/ajpendo.00097.2006; Roth SM, 2002, PHYSIOL GENOMICS, V10, P181, DOI 10.1152/physiolgenomics.00028.2002; Seip RL, 1998, EXERCISE SPORT SCI R, V26, P191; Seth A, 2007, CELL METAB, V6, P236, DOI 10.1016/j.cmet.2007.08.004; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; Staron RS, 2000, J HISTOCHEM CYTOCHEM, V48, P623, DOI 10.1177/002215540004800506; Stranneheim H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021910; Su WL, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-273; Thompson JR, 2013, J SURG RES, V185, P206, DOI 10.1016/j.jss.2013.05.054; Timmons JA, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-19; Timmons JA, 2010, J APPL PHYSIOL, V108, P1487, DOI 10.1152/japplphysiol.01295.2009; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Trygg J, 2002, J CHEMOMETR, V16, P119, DOI 10.1002/cem.695; Vissing K, 2004, FASEB J, V18, P94, DOI 10.1096/fj.04-2084fje; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang M, 2010, J INT MED RES, V38, P769; Welle S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001385; WOLD S, 1978, TECHNOMETRICS, V20, P397, DOI 10.2307/1267639	68	46	46	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4571	4581		10.1096/fj.14-255000	http://dx.doi.org/10.1096/fj.14-255000			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25016029	Bronze			2022-12-28	WOS:000342222700032
J	Bondia-Pons, I; Maukonen, J; Mattila, I; Rissanen, A; Saarela, M; Kaprio, J; Hakkarainen, A; Lundbom, J; Lundbom, N; Hyotylainen, T; Pietilainen, KH; Oresic, M				Bondia-Pons, Isabel; Maukonen, Johanna; Mattila, Ismo; Rissanen, Aila; Saarela, Maria; Kaprio, Jaakko; Hakkarainen, Antti; Lundbom, Jesper; Lundbom, Nina; Hyotylainen, Tuulia; Pietilainen, Kirsi H.; Oresic, Matej			Metabolome and fecal microbiota in monozygotic twin pairs discordant for weight: a Big Mac challenge	FASEB JOURNAL			English	Article						obesity; metabolomics; bile acids	GUT MICROBIOTA; TEMPORAL STABILITY; ACQUIRED OBESITY; LIVER FAT; ACID; ASSOCIATION; RESISTANCE; DIVERSITY; PROFILES; PLASMA	Postprandial responses to food are complex, involving both genetic and environmental factors. We studied postprandial responses to a Big Mac meal challenge in monozygotic co-twins highly discordant for body weight. This unique design allows assessment of the contribution of obesity, independent of genetic liability. Comprehensive metabolic profiling using 3 analytical platforms was applied to fasting and postprandial serum samples from 16 healthy monozygotic twin pairs discordant for weight (body mass index difference >3 kg/m(2)). Nine concordant monozygotic pairs were examined as control pairs. Fecal samples were analyzed to assess diversity of the major bacterial groups by using 5 different validated bacterial group specific denaturing gradient gel electrophoresis methods. No differences in fecal bacterial diversity were detected when comparing co-twins discordant for weight (ANOVA, P<0.05). We found that within-pair similarity is a dominant factor in the metabolic postprandial response, independent of acquired obesity. Branched chain amino acids were increased in heavier as compared with leaner co-twins in the fasting state, but their levels converged postprandially (paired t tests, FDR q<0.05). We also found that specific bacterial groups were associated with postprandial changes of specific metabolites. Our findings underline important roles of genetic and early life factors in the regulation of postprandial metabolite levels.	[Bondia-Pons, Isabel; Maukonen, Johanna; Mattila, Ismo; Saarela, Maria; Hyotylainen, Tuulia; Oresic, Matej] VTT Tech Res Ctr Finland, Espoo, Finland; [Bondia-Pons, Isabel] Univ Navarra, Dept Food Sci & Physiol, E-31080 Pamplona, Spain; [Rissanen, Aila; Pietilainen, Kirsi H.] Univ Helsinki, Obes Res Unit, Res Programs Unit, Helsinki, Finland; [Kaprio, Jaakko] Univ Helsinki, Hjelt Inst, Dept Publ Hlth, Helsinki, Finland; [Kaprio, Jaakko; Pietilainen, Kirsi H.] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland; [Rissanen, Aila] Univ Helsinki, Cent Hosp, Dept Psychiat, Helsinki, Finland; [Lundbom, Jesper; Lundbom, Nina] Univ Helsinki, Cent Hosp, Hosp Dist Helsinki & Uusimaa HUS, Med Imaging Ctr,Dept Radiol, Helsinki, Finland; [Hakkarainen, Antti; Pietilainen, Kirsi H.] Univ Helsinki, Cent Hosp, Dept Med, Div Endocrinol, Helsinki, Finland; [Kaprio, Jaakko] Natl Inst Hlth & Welf, Helsinki, Finland; [Hyotylainen, Tuulia; Oresic, Matej] Steno Diabet Ctr, DK-2820 Gentofte, Denmark	VTT Technical Research Center Finland; University of Navarra; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; Steno Diabetes Center	Oresic, M (corresponding author), Steno Diabet Ctr, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark.	mtjo@steno.dk	Kaprio, Jaakko/A-1820-2008; Hakkarainen, Antti/AAF-5928-2020; Oresic, Matej/K-7673-2016; Oresic, Matej/AAV-3978-2020; Saarela, Maria/AAY-5918-2020; Hyötyläinen, Tuulia/AAP-6266-2020	Kaprio, Jaakko/0000-0002-3716-2455; Hakkarainen, Antti/0000-0002-7367-2532; Oresic, Matej/0000-0002-2856-9165; Saarela, Maria/0000-0001-8842-7292; Pietilainen, Kirsi/0000-0002-8522-1288; Hyotylainen, Tuulia/0000-0002-1389-8302; Mattila, Ismo/0000-0001-9597-7831	EU [222720, 277713]; Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research (SyMMyS) [250114]; Novo Nordisk Foundation; Finnish Foundation for Cardiovascular Research; Diabetes Research Foundation; Helsinki University Central Hospital Research Funds; Academy of Finland grant [266286]; Carlos III Health Institute of the Spanish Ministry of Health	EU(European Commission); Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research (SyMMyS); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Finnish Foundation for Cardiovascular Research; Diabetes Research Foundation; Helsinki University Central Hospital Research Funds; Academy of Finland grant(Academy of Finland); Carlos III Health Institute of the Spanish Ministry of Health(Spanish Government)	This work was supported by the EU FP7 Projects TORNADO (project 222720) and beta Bat (project 277713), Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research (SyMMyS, 2012-2017, decision 250114), Novo Nordisk Foundation, Finnish Foundation for Cardiovascular Research, Diabetes Research Foundation, Helsinki University Central Hospital Research Funds, and an Academy of Finland grant (decision 266286). I. B.-P. is grateful to the Carlos III Health Institute of the Spanish Ministry of Health for a Sara Borrell postdoctoral contract. Marko Sysi-Aho and Peddinti Gopalacharyulu are acknowledged for assistance in data analysis. Anna-Liisa Ruskeepaa, Leena Ohrnberg, Ulla Lahtinen, and Sirkku Jantti are acknowledged for excellent contribution to metabolite analysis and Marja-Liisa Jalovaara for excellent assistance in the microbiological analyses.	Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104; Backhed F, 2010, BBA-MOL CELL BIOL L, V1801, P240, DOI 10.1016/j.bbalip.2009.09.009; Brohee S, 2008, NAT PROTOC, V3, P1616, DOI 10.1038/nprot.2008.100; Castillo S, 2011, ANAL CHEM, V83, P3058, DOI 10.1021/ac103308x; Catenacci VA, 2009, CLIN CHEST MED, V30, P415, DOI 10.1016/j.ccm.2009.05.001; Cruz-Teno C, 2012, MOL NUTR FOOD RES, V56, P854, DOI 10.1002/mnfr.201200096; Faith JJ, 2013, SCIENCE, V341, P44, DOI 10.1126/science.1237439; Fraley C, 2007, J STAT SOFTW, V18; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Grune M, 2012, AM J CARDIOL, V109, P1295, DOI 10.1016/j.amjcard.2011.12.023; Kaprio J, 2002, TWIN RES, V5, P366, DOI 10.1375/136905202320906101; Kars M, 2010, DIABETES, V59, P1899, DOI 10.2337/db10-0308; Kettunen J, 2012, NAT GENET, V44, P269, DOI 10.1038/ng.1073; Krug S, 2012, FASEB J, V26, P2607, DOI 10.1096/fj.11-198093; Matto J, 2005, FEMS IMMUNOL MED MIC, V43, P213, DOI 10.1016/j.femsim.2004.08.009; Maukonen J, 2006, FEMS MICROBIOL ECOL, V58, P517, DOI 10.1111/j.1574-6941.2006.00179.x; Maukonen J, 2012, FEMS MICROBIOL ECOL, V79, P697, DOI 10.1111/j.1574-6941.2011.01257.x; Naukkarinen J, 2012, INT J OBESITY, V36, P1017, DOI 10.1038/ijo.2011.192; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; Nubel U, 1996, J BACTERIOL, V178, P5636; Nygren H, 2011, METHODS MOL BIOL, V708, P247, DOI 10.1007/978-1-61737-985-7_15; Oresic M, 2013, DIABETOLOGIA, V56, P2266, DOI 10.1007/s00125-013-2981-2; Pellis L, 2012, METABOLOMICS, V8, P347, DOI 10.1007/s11306-011-0320-5; Pietilainen KH, 2005, AM J PHYSIOL-ENDOC M, V288, pE768, DOI 10.1152/ajpendo.00381.2004; Pietilainen KH, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050051; Pietilainen KH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000218; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Samuel BS, 2007, P NATL ACAD SCI USA, V104, P10643, DOI 10.1073/pnas.0704189104; Satokari RM, 2001, APPL ENVIRON MICROB, V67, P504, DOI 10.1128/AEM.67.2.504-513.2001; Sayin SI, 2013, CELL METAB, V17, P225, DOI 10.1016/j.cmet.2013.01.003; Schafer J, 2005, BIOINFORMATICS, V21, P754, DOI 10.1093/bioinformatics/bti062; Shaham O, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.50; Simoes CD, 2013, J NUTR, V143, P417, DOI 10.3945/jn.112.166322; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Vallim TQD, 2013, CELL METAB, V17, P657, DOI 10.1016/j.cmet.2013.03.013; van Dijk SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041388; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; Wang TJ, 2011, NAT MED, V17, P448, DOI 10.1038/nm.2307; Wopereis S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004525; Yokota A, 2012, GUT MICROBES, V3, P455, DOI 10.4161/gmic.21216; Zhang HS, 2009, P NATL ACAD SCI USA, V106, P2365, DOI 10.1073/pnas.0812600106; Zivkovic AM, 2009, METABOLOMICS, V5, P209, DOI 10.1007/s11306-008-0136-0	44	20	23	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4169	4179		10.1096/fj.14-250167	http://dx.doi.org/10.1096/fj.14-250167			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24846387	Green Published			2022-12-28	WOS:000340845900033
J	Chhabra, S; Chang, SC; Nguyen, HM; Huq, R; Tanner, MR; Londono, LM; Estrada, R; Dhawan, V; Chauhan, S; Upadhyay, SK; Gindin, M; Hotez, PJ; Valenzuela, JG; Mohanty, B; Swarbrick, JD; Wulff, H; Iadonato, SP; Gutman, GA; Beeton, C; Pennington, MW; Norton, RS; Chandy, KG				Chhabra, Sandeep; Chang, Shih Chieh; Nguyen, Hai M.; Huq, Redwan; Tanner, Mark R.; Londono, Luz M.; Estrada, Rosendo; Dhawan, Vikas; Chauhan, Satendra; Upadhyay, Sanjeev K.; Gindin, Mariel; Hotez, Peter J.; Valenzuela, Jesus G.; Mohanty, Biswaranjan; Swarbrick, James D.; Wulff, Heike; Iadonato, Shawn P.; Gutman, George A.; Beeton, Christine; Pennington, Michael W.; Norton, Raymond S.; Chandy, K. George			Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases	FASEB JOURNAL			English	Article						ShK; probiotic worm therapy; T lymphocytes; ion channel modulator; hookworm	MEMORY T-CELLS; REMITTING MULTIPLE-SCLEROSIS; TRICHURIS-SUIS THERAPY; POTASSIUM-CHANNEL; INHIBITORY FACTOR; NECATOR-AMERICANUS; SELECTIVE BLOCKADE; PROTEIN STRUCTURES; INDUCED COLITIS; K+ CHANNEL	The voltage-gated potassium (Kv) 1.3 channel is widely regarded as a therapeutic target for immunomodulation in autoimmune diseases. ShK-186, a selective inhibitor of Kv1.3 channels, ameliorates autoimmune diseases in rodent models, and human phase 1 trials of this agent in healthy volunteers have been completed. In this study, we identified and characterized a large family of Stichodactyla helianthus toxin (ShK)-related peptides in parasitic worms. Based on phylogenetic analysis, 2 worm peptides were selected for study: AcK1, a 51-residue peptide expressed in the anterior secretory glands of the dog-infecting hookworm Ancylostoma caninum and the human-infecting hookworm Ancylostoma ceylanicum, and BmK1, the C-terminal domain of a metalloprotease from the filarial worm Brugia malayi. These peptides in solution adopt helical structures closely resembling that of ShK. At doses in the nanomolar-micromolar range, they block native Kv1.3 in human T cells and cloned Kv1.3 stably expressed in L929 mouse fibroblasts. They preferentially suppress the proliferation of rat CCR7-effector memory T cells without affecting naive and central memory subsets and inhibit the delayed-type hypersensitivity (DTH) response caused by skin-homing effector memory T cells in rats. Further, they suppress IFN gamma production by human T lymphocytes. ShK-related peptides in parasitic worms may contribute to the potential beneficial effects of probiotic parasitic worm therapy in human autoimmune diseases.	[Chhabra, Sandeep; Chang, Shih Chieh; Mohanty, Biswaranjan; Swarbrick, James D.; Norton, Raymond S.] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia; [Nguyen, Hai M.; Upadhyay, Sanjeev K.; Gutman, George A.; Chandy, K. George] Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92717 USA; [Nguyen, Hai M.; Wulff, Heike] Univ Calif Davis, Dept Pharmacol, Davis, CA 95616 USA; [Huq, Redwan; Tanner, Mark R.; Beeton, Christine] Baylor Coll Med, Natl Sch Trop Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Huq, Redwan] Baylor Coll Med, Natl Sch Trop Med, Grad Program Mol Physiol & Biophys, Houston, TX 77030 USA; [Tanner, Mark R.] Baylor Coll Med, Natl Sch Trop Med, Interdepartmental Grad Program Translat Biol & Mo, Houston, TX 77030 USA; [Hotez, Peter J.] Baylor Coll Med, Natl Sch Trop Med, Sabin Vaccine Inst, Houston, TX 77030 USA; [Hotez, Peter J.] Texas Childrens Hosp, Baylor Coll Med, Ctr Vaccine Dev, Natl Sch Trop Med, Houston, TX 77030 USA; [Londono, Luz M.; Iadonato, Shawn P.] Kineta Inc, Seattle, WA USA; [Estrada, Rosendo; Dhawan, Vikas; Chauhan, Satendra; Pennington, Michael W.] Peptides Int, Louisville, KY USA; [Gindin, Mariel] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC USA; [Gindin, Mariel; Valenzuela, Jesus G.] NIAID, Vector Mol Biol Sect, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA	Monash University; University of California System; University of California Irvine; University of California System; University of California Davis; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Norton, RS (corresponding author), Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia.	ray.norton@monash.edu; gchandy@uci.edu	Chhabra, Sandeep/T-5468-2018; Mohanty, Biswaranjan/E-2080-2018; chhabra, sandeep/R-9942-2017; wulff, Heike/Z-2056-2019	Chhabra, Sandeep/0000-0002-5225-1333; Mohanty, Biswaranjan/0000-0002-6921-343X; Norton, Raymond/0000-0001-8893-0584; Beeton, Christine/0000-0002-2500-5874; Tanner, Mark/0000-0002-6516-0166; pennington, michael/0000-0001-5446-3447; Hotez, Peter/0000-0001-8770-1042	U.S. National Institutes of Health (NIH) [R01 NS48252, NS073712, GM076063]; Howard Hughes Medical Institutes Med into Grad Initiative; NIH T32 award [GM088129]; Human Hookworm Initiative of the Gates Foundation; National Institute of Allergy and Infectious Diseases (NIAID) at NIH; University of California, Irvine; National Health and Medical Research Council of Australia; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000932] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institutes Med into Grad Initiative; NIH T32 award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Hookworm Initiative of the Gates Foundation; National Institute of Allergy and Infectious Diseases (NIAID) at NIH; University of California, Irvine(University of California System); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Support for this work was provided by U.S. National Institutes of Health (NIH) grants R01 NS48252 (to K.G.C.), NS073712 (to C.B., M.W.P., and R.S.N.); GM076063 (to H.W.); Howard Hughes Medical Institutes Med into Grad Initiative and NIH T32 award GM088129 (to M.R.T.); the Human Hookworm Initiative of the Gates Foundation (to P.J.H.); the intramural program of the National Institute of Allergy and Infectious Diseases (NIAID) at NIH (to J.G.V.); a bridge fund from the University of California, Irvine (to K.G.C); and fellowship support by the National Health and Medical Research Council of Australia (to R.S.N.).	Anbu KA, 2008, PARASITE IMMUNOL, V30, P23, DOI 10.1111/j.1365-3024.2007.00995.x; [Anonymous], 2014, Wkly Epidemiol Rec, V89, P133; Azam P, 2007, J INVEST DERMATOL, V127, P1419, DOI 10.1038/sj.jid.5700717; Beeton C, 2005, MOL PHARMACOL, V67, P1369, DOI 10.1124/mol.104.008193; Beeton C, 2001, P NATL ACAD SCI USA, V98, P13942, DOI 10.1073/pnas.241497298; Beeton C, 2006, P NATL ACAD SCI USA, V103, P17414, DOI 10.1073/pnas.0605136103; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boitelle A, 2003, J IMMUNOL, V171, P447, DOI 10.4049/jimmunol.171.1.447; Broadhurst MJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001500; Cahalan MD, 2009, IMMUNOL REV, V231, P59, DOI 10.1111/j.1600-065X.2009.00816.x; Chi V, 2012, TOXICON, V59, P529, DOI 10.1016/j.toxicon.2011.07.016; Chu KM, 2013, INFLAMM BOWEL DIS, V19, P614, DOI 10.1097/MIB.0b013e31827f27f4; Correale J, 2007, ANN NEUROL, V61, P97, DOI 10.1002/ana.21067; Cotton J, 1997, EUR J BIOCHEM, V244, P192, DOI 10.1111/j.1432-1033.1997.00192.x; Cox GM, 2013, J IMMUNOL, V191, P1043, DOI 10.4049/jimmunol.1200485; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Dunne DW, 2005, NAT REV IMMUNOL, V5, P420, DOI 10.1038/nri1601; Elliott DE, 2012, CURR OPIN GASTROEN, V28, P551, DOI 10.1097/MOG.0b013e3283572f73; Ferreira I, 2013, INFECT IMMUN, V81, P2104, DOI 10.1128/IAI.00563-12; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Flugel A, 1999, NAT MED, V5, P843, DOI 10.1038/10567; Gaze S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002520; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Gocke AR, 2012, J IMMUNOL, V188, P5877, DOI 10.4049/jimmunol.1103095; Goodridge HS, 2001, J IMMUNOL, V167, P940, DOI 10.4049/jimmunol.167.2.940; Guntert Peter, 2004, Methods Mol Biol, V278, P353; Harnett MM, 2010, CLIN EXP IMMUNOL, V159, P256, DOI 10.1111/j.1365-2249.2009.04064.x; Harnett W, 2010, NAT REV IMMUNOL, V10, P278, DOI 10.1038/nri2730; Hartmann S, 1997, EUR J IMMUNOL, V27, P2253, DOI 10.1002/eji.1830270920; Hernandez JLR, 2013, INT J PARASITOL, V43, P233, DOI 10.1016/j.ijpara.2012.09.005; Hu L, 2007, J IMMUNOL, V179, P4563, DOI 10.4049/jimmunol.179.7.4563; Huys I, 2004, J BIOL CHEM, V279, P2781, DOI 10.1074/jbc.M311029200; Johnston MJG, 2010, INFECT IMMUN, V78, P1364, DOI 10.1128/IAI.01349-08; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; Kawakami N, 2005, J IMMUNOL, V175, P69, DOI 10.4049/jimmunol.175.1.69; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koshy S, 2014, J BIOL CHEM, V289, P12623, DOI 10.1074/jbc.M113.517037; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; La Flamme AC, 2003, INFECT IMMUN, V71, P4996, DOI 10.1128/IAI.71.9.4996-5004.2003; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leung JM, 2013, INT J PARASITOL, V43, P253, DOI 10.1016/j.ijpara.2012.10.015; Llamas-Covarrubias MA, 2013, CYTOKINE, V61, P759, DOI 10.1016/j.cyto.2012.12.032; Matheu MP, 2008, IMMUNITY, V29, P602, DOI 10.1016/j.immuni.2008.07.015; Mortimer K, 2006, AM J TROP MED HYG, V75, P914, DOI 10.4269/ajtmh.2006.75.914; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; Ovchinnikova TV, 2006, BIOCHEM BIOPH RES CO, V348, P514, DOI 10.1016/j.bbrc.2006.07.078; Pennington MW, 2009, MOL PHARMACOL, V75, P762, DOI 10.1124/mol.108.052704; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rangaraju S, 2010, J BIOL CHEM, V285, P9124, DOI 10.1074/jbc.M109.071266; Rauer H, 1999, J BIOL CHEM, V274, P21885, DOI 10.1074/jbc.274.31.21885; Ren YZR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004009; Rosche B, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-112; Rus H, 2005, P NATL ACAD SCI USA, V102, P11094, DOI 10.1073/pnas.0501770102; Ruyssers NE, 2009, INFLAMM BOWEL DIS, V15, P491, DOI 10.1002/ibd.20787; Sandborn WJ, 2013, ALIMENT PHARM THER, V38, P255, DOI 10.1111/apt.12366; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Sewell D, 2003, INT IMMUNOL, V15, P59, DOI 10.1093/intimm/dxg012; Shen Y, 2013, J BIOMOL NMR, V56, P227, DOI 10.1007/s10858-013-9741-y; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Swofford D.L., 2003, PAUP VERSION 40 B10; Tarcha EJ, 2012, J PHARMACOL EXP THER, V342, P642, DOI 10.1124/jpet.112.191890; Teixeira-Carvalho A, 2008, INFECT IMMUN, V76, P5810, DOI 10.1128/IAI.00419-08; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; Tudor JE, 1998, EUR J BIOCHEM, V251, P133, DOI 10.1046/j.1432-1327.1998.2510133.x; Ulrich EL, 2008, NUCLEIC ACIDS RES, V36, pD402, DOI 10.1093/nar/gkm957; Upadhyay SK, 2013, P NATL ACAD SCI USA, V110, pE2239, DOI 10.1073/pnas.1221206110; Valverde P, 2004, J BONE MINER RES, V19, P155, DOI 10.1359/JBMR.0301213; Vicente R, 2008, J BIOL CHEM, V283, P8756, DOI 10.1074/jbc.M708223200; Wammes LJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001655; Weinstock JV, 2012, NATURE, V491, P183, DOI 10.1038/491183a; Wu ST, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035470; Wulff H, 2004, J IMMUNOL, V173, P776, DOI 10.4049/jimmunol.173.2.776; Wulff H, 2003, J CLIN INVEST, V111, P1703, DOI 10.1172/JCI200316921; Zaccone P, 2013, CURR OPIN IMMUNOL, V25, P418, DOI 10.1016/j.coi.2013.02.006	76	55	55	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3952	3964		10.1096/fj.14-251967	http://dx.doi.org/10.1096/fj.14-251967			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24891519	Green Published, Green Submitted			2022-12-28	WOS:000340845900013
J	Lan, WJ; Yamaguchi, S; Yamamoto, T; Yamahira, S; Tan, MD; Murakami, N; Zhang, JY; Nakamura, M; Nagamune, T				Lan, Wanjun; Yamaguchi, Satoshi; Yamamoto, Teruyasu; Yamahira, Shinya; Tan, Modong; Murakami, Naoka; Zhang, Jingyan; Nakamura, Motonao; Nagamune, Teruyuki			Visualization of the pH-dependent dynamic distribution of G2A in living cells	FASEB JOURNAL			English	Article						GPCR; internalization; pH dependence; pulse labeling	PROTEIN-COUPLED RECEPTOR; RETRACTED ARTICLE. SEE; SURFACE-PROTEINS; EXTRACELLULAR PH; SMOOTH-MUSCLE; LYSOPHOSPHATIDYLCHOLINE; SORTASE; LIGAND; CANCER; TUMOR	G2A (from G2 accumulation) receptor is a member of the proton-sensing G-protein coupled receptor (GPCR) family and induces signal transduction events that regulate the cell cycle, proliferation, oncogenesis, and immunity. The mechanism by which G2A-mediated signal transduction is regulated by the extracellular pH remains unresolved. Here, we first visualize the pH-dependent G2A distribution change in living cells by a sortase A-mediated pulse labeling technology: the short-peptide tag-fused human G2A on human embryo kidney HEK293T cell surfaces was labeled with a small fluorescent dye in the presence of lysophosphatidylcholine, and the labeled G2A was chased at acidic and neutral pHs in real time by microscope time course observations. G2A internalization from cell surfaces into intracellular compartments was observed to be inhibited under acidic pH conditions, and this inhibition was relieved at neutral pH. Additionally, the internalized G2A was redistributed onto cell surfaces by jumping from a neutral to an acidic pH. From quantitative image analysis data, we conclude the amount of G2A on the cell surface was controlled by suppressing the G2A internalization rate by one-tenth in response to the extracellular acidic pH, and this acidic pH-induced G2A accumulation on cell surfaces may be explained by proton-induced dissociation of G2A from endocytic machinery.	[Lan, Wanjun; Yamaguchi, Satoshi; Yamamoto, Teruyasu; Tan, Modong; Nagamune, Teruyuki] Univ Tokyo, Dept Chem & Biotechnol, Tokyo 1138656, Japan; [Yamahira, Shinya; Nagamune, Teruyuki] Univ Tokyo, Grad Sch Engn, Dept Bioengn, Tokyo 1138656, Japan; [Murakami, Naoka; Nakamura, Motonao] Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Tokyo 1138656, Japan; [Lan, Wanjun; Zhang, Jingyan] E China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, State Key Lab Bioreactor Engn, Shanghai, Peoples R China	University of Tokyo; University of Tokyo; University of Tokyo; East China University of Science & Technology	Nagamune, T (corresponding author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	nagamune@bioeng.t.u-tokyo.ac.jp	Nagamune, Teruyuki/R-7708-2017; Yamaguchi, Satoshi/V-3211-2017; Zhang, Jing/HII-4294-2022	Nagamune, Teruyuki/0000-0002-2435-0270; Yamaguchi, Satoshi/0000-0003-4822-7469; Yamahira, Shinya/0000-0002-8402-4514	Ministry of Education, Culture, Sports, Science and Technology, Japan [246564498]; China Scholarship Council (CSC); National Science Foundation of China [31070742]; grant for the Center for NanoBio Integration (CNBI)	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); China Scholarship Council (CSC)(China Scholarship Council); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); grant for the Center for NanoBio Integration (CNBI)	This work was supported by a Ministry of Education, Culture, Sports, Science and Technology, Japan, Grant-in-Aid for Challenging Exploratory Research 246564498 and a grant for the Center for NanoBio Integration (CNBI). W. L. was supported by the China Scholarship Council (CSC) and the National Science Foundation of China (No. 31070742).	Bidani A, 1998, LUNG, V176, P111, DOI 10.1007/PL00007593; Chen AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027586; Chen I, 2005, NAT METHODS, V2, P99, DOI 10.1038/NMETH735; Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gerweck LE, 1996, CANCER RES, V56, P1194; Ghanouni P, 2000, J BIOL CHEM, V275, P3121, DOI 10.1074/jbc.275.5.3121; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; GRINSTEIN S, 1991, CLIN BIOCHEM, V24, P241, DOI 10.1016/0009-9120(91)80014-T; Hirota N, 2010, J BIOL CHEM, V285, P5931, DOI 10.1074/jbc.M109.066282; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Ishii S, 2005, J BIOL CHEM, V280, P9083, DOI 10.1074/jbc.M407832200; Kabarowski JHS, 2000, P NATL ACAD SCI USA, V97, P12109, DOI 10.1073/pnas.97.22.12109; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kraus M, 1996, TUMOR BIOL, V17, P133, DOI 10.1159/000217977; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Lombardi MS, 2002, CRIT REV IMMUNOL, V22, P141; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Matsumoto T, 2012, BIOTECHNOL J, V7, P642, DOI 10.1002/biot.201100213; Milligan G, 2003, MOL PHARMACOL, V64, P1271, DOI 10.1124/mol.64.6.1271; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; Popp MW, 2007, NAT CHEM BIOL, V3, P707, DOI 10.1038/nchembio.2007.31; Radu CG, 2005, P NATL ACAD SCI USA, V102, P1632, DOI 10.1073/pnas.0409415102; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; ROTIN D, 1986, CANCER RES, V46, P2821; Saxena H, 2012, BRIT J PHARMACOL, V166, P981, DOI 10.1111/j.1476-5381.2011.01807.x; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; Tanaka T, 2008, CHEMBIOCHEM, V9, P802, DOI 10.1002/cbic.200700614; TANNOCK IF, 1989, CANCER RES, V49, P4373; Tobo M, 2007, CELL SIGNAL, V19, P1745, DOI 10.1016/j.cellsig.2007.03.009; Tomura H, 2005, J BIOL CHEM, V280, P34458, DOI 10.1074/jbc.M505287200; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; VAUPEL PW, 1981, CANCER RES, V41, P2008; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; Wang JQ, 2004, J BIOL CHEM, V279, P45626, DOI 10.1074/jbc.M406966200; Wang L, 2005, MOL BIOL CELL, V16, P2234, DOI 10.1091/mbc.E04-12-1044; Weng Z., 2000, P NATL ACAD SCI USA, V95, P12334; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yamamoto T, 2009, CHEM COMMUN, P1022, DOI 10.1039/b818792d; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	44	10	10	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3965	3974		10.1096/fj.14-252999	http://dx.doi.org/10.1096/fj.14-252999			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24891524	Green Published			2022-12-28	WOS:000340845900014
J	Gallart-Palau, X; Tarabal, O; Casanovas, A; Sabado, J; Correa, FJ; Hereu, M; Piedrafita, L; Caldero, J; Esquerda, JE				Gallart-Palau, Xavier; Tarabal, Olga; Casanovas, Anna; Sabado, Javier; Correa, Francisco J.; Hereu, Marta; Piedrafita, Lidia; Caldero, Jordi; Esquerda, Josep E.			Neuregulin-1 is concentrated in the postsynaptic subsurface cistern of C-bouton inputs to alpha-motoneurons and altered during motoneuron diseases	FASEB JOURNAL			English	Article						spinal cord ventral horn; interneurons; erbB receptors; spinal muscular atrophy; amyotrophic lateral sclerosis	AMYOTROPHIC-LATERAL-SCLEROSIS; SPINAL MUSCULAR-ATROPHY; GENE-RELATED PEPTIDE; PERIPHERAL-NERVE INJURY; SOD1(G93A) MOUSE MODEL; LUMBAR MOTONEURONS; SIGMA-1 RECEPTOR; DIFFERENTIAL EXPRESSION; NEUROMUSCULAR-JUNCTIONS; CHOLINERGIC SYNAPSES	C boutons are large, cholinergic, synaptic terminals that arise from local interneurons and specifically contact spinal alpha-motoneurons (MNs). C boutons characteristically display a postsynaptic specialization consisting of an endoplasmic reticulum-related subsurface cistern (SSC) of unknown function. In the present work, by using confocal microscopy and ultrastructural immunolabeling, we demonstrate that neuregulin-1 (NRG1) accumulates in the SSC of mouse spinal MNs. We also show that the NRG1 receptors erbB2 and erbB4 are presynaptically localized within C boutons, suggesting that NRG1-based retrograde signaling may occur in this type of synapse. In most of the cranial nuclei, MNs display the same pattern of NRG1 distribution as that observed in spinal cord MNs. Conversely, MNs in oculomotor nuclei, which are spared in amyotrophic lateral sclerosis (ALS), lack both C boutons and SSC-associated NRG1. NRG1 in spinal MNs is developmentally regulated and depends on the maintenance of nerve-muscle interactions, as we show after nerve transection experiments. Changes in NRG1 in C boutons were also investigated in mouse models of MN diseases: i.e., spinal muscular atrophy (SMN Delta 7) and ALS (SOD1(G93A)). In both models, a transient increase in NRG1 in C boutons occurs during disease progression. These data increase our understanding of the role of C boutons in MN physiology and pathology.-Gallart-Palau, X., Tarabal, O., Casanovas, A., S bado, J., Correa, F. J., Hereu, M., Piedrafita, L., Calder, J., Esquerda, J. E. Neuregulin-1 is concentrated in the postsynaptic subsurface cistern of C-bouton inputs to alpha-motoneurons and altered during motoneuron diseases.	[Gallart-Palau, Xavier; Tarabal, Olga; Casanovas, Anna; Sabado, Javier; Correa, Francisco J.; Hereu, Marta; Piedrafita, Lidia; Caldero, Jordi; Esquerda, Josep E.] Univ Lleida, Dept Med Expt, Unitat Neurobiol Cellular, Inst Recerca Biomed Lleida IRBLLEIDA,Fac Med, Lleida 25198, Catalonia, Spain	Institut de Recerca Biomedica - IRB Lleida; Universitat de Lleida	Caldero, J (corresponding author), Univ Lleida, Dept Med Expt, Unitat Neurobiol Cellular, IRBLLEIDA,Fac Med, Av Rovira Roure 80, Lleida 25198, Catalonia, Spain.	jordi.caldero@mex.udl.cat; josep.esquerda@mex.udl.cat	Mostazo, Olga Tarabal/C-6620-2011; Esquerda, Josep E/A-7377-2010; Calderó, Jordi/A-7373-2010; Llorens, Ana Maria Casanovas/C-3984-2011; Gallart-Palau, Xavier/L-6566-2016	Mostazo, Olga Tarabal/0000-0001-7741-3223; Esquerda, Josep E/0000-0003-1413-2103; Calderó, Jordi/0000-0003-1972-0115; Llorens, Ana Maria Casanovas/0000-0001-8766-5555; Gallart-Palau, Xavier/0000-0001-5160-8794; Piedrafita Llorens, Lidia/0000-0001-8151-7447	Ministerio de Ciencia y Tecnologia; Ministerio de Economia y Competitividad - Federacion Espanola de Enfermedades Raras [SAF2011-22908, SAF2012-31831]; Fundacion Genoma Espana/Fundacion Atrofia Muscular Espinal [SAF2011-22908, SAF2012-31831]	Ministerio de Ciencia y Tecnologia(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Ministerio de Economia y Competitividad - Federacion Espanola de Enfermedades Raras; Fundacion Genoma Espana/Fundacion Atrofia Muscular Espinal	The authors thank Dr. Ronald W. Oppenheim and Sherry Vinsant for critical reading of the manuscript and for helpful comments and suggestions. The authors also thank Dr. Elisabet Dachs, Claudia Cervero, and Alexandra Eritja for help in some parts of this study. This work was supported by grants from the Ministerio de Ciencia y Tecnologia and Ministerio de Economia y Competitividad, financed jointly with Federacion Espanola de Enfermedades Raras (SAF2011-22908; SAF2012-31831) and the Fundacion Genoma Espana/Fundacion Atrofia Muscular Espinal.	Al-Saif A, 2011, ANN NEUROL, V70, P913, DOI 10.1002/ana.22534; Aliaga L, 2013, HUM MOL GENET, V22, P4293, DOI 10.1093/hmg/ddt279; Banerjee A, 2010, BRAIN RES BULL, V83, P132, DOI 10.1016/j.brainresbull.2010.04.011; BERNSTEIN JJ, 1976, J NEUROCYTOL, V5, P109, DOI 10.1007/BF01176185; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; BODIAN D, 1970, J CELL BIOL, V44, P115, DOI 10.1083/jcb.44.1.115; Brunet N, 2007, J COMP NEUROL, V501, P669, DOI 10.1002/cne.21157; CALDERO J, 1992, NEUROSCIENCE, V48, P449, DOI 10.1016/0306-4522(92)90504-U; Caldero J, 2009, J NEUROSCI RES, V87, P2447, DOI 10.1002/jnr.22084; Calvo M, 2010, J NEUROSCI, V30, P5437, DOI 10.1523/JNEUROSCI.5169-09.2010; Chang Q, 2009, AM J PATHOL, V174, P574, DOI 10.2353/ajpath.2009.080557; Conradi S, 1969, Acta Physiol Scand Suppl, V332, P5; CONRADI S, 1969, ACTA PHYSIOL SCAND, P49; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; Deardorff AS, 2013, J PHYSIOL-LONDON, V591, P875, DOI 10.1113/jphysiol.2012.240879; Destombes J, 1996, NEUROSCI RES, V24, P123, DOI 10.1016/0168-0102(95)00980-9; DESTOMBES J, 1992, BRAIN RES, V599, P353, DOI 10.1016/0006-8993(92)90412-3; Frank E, 2009, NEURON, V64, P593, DOI 10.1016/j.neuron.2009.11.030; Fujita Y, 2011, NEUROPATHOLOGY, V31, P42, DOI 10.1111/j.1440-1789.2010.01123.x; Gallart-Palau X., 2013, AMYOTROPH LATERAL S2, V14, P186; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hellstrom J, 1999, J COMP NEUROL, V411, P578; Hellstrom J, 2003, J COMP NEUROL, V460, P476, DOI 10.1002/cne.10648; Herron LR, 2012, NEUROSCIENCE, V226, P313, DOI 10.1016/j.neuroscience.2012.09.031; HOUENOU LJ, 1994, PROG BRAIN RES, V102, P217; Ichikawa H, 2004, DEV BRAIN RES, V150, P41, DOI 10.1016/j.devbrainres.2004.02.004; Issa AN, 2010, J COMP NEUROL, V518, P4213, DOI 10.1002/cne.22449; Jessen KR, 2005, NAT REV NEUROSCI, V6, P671, DOI 10.1038/nrn1746; Kanning KC, 2010, ANNU REV NEUROSCI, V33, P409, DOI 10.1146/annurev.neuro.051508.135722; Korkut C, 2013, NEURON, V77, P1039, DOI 10.1016/j.neuron.2013.01.013; Korkut C, 2009, CELL, V139, P393, DOI 10.1016/j.cell.2009.07.051; Le TT, 2005, HUM MOL GENET, V14, P845, DOI 10.1093/hmg/ddi078; LI W, 1995, NEUROSCIENCE, V65, P879, DOI 10.1016/0306-4522(94)00511-3; Ling KKY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015457; Mancuso R, 2012, NEUROTHERAPEUTICS, V9, P814, DOI 10.1007/s13311-012-0140-y; Mavlyutov TA, 2013, NEUROSCIENCE, V240, P129, DOI 10.1016/j.neuroscience.2013.02.035; Mavlyutov TA, 2010, NEUROSCIENCE, V167, P247, DOI 10.1016/j.neuroscience.2010.02.022; Mei L, 2008, NAT REV NEUROSCI, V9, P437, DOI 10.1038/nrn2392; Mentis GZ, 2011, NEURON, V69, P453, DOI 10.1016/j.neuron.2010.12.032; Miles GB, 2007, P NATL ACAD SCI USA, V104, P2448, DOI 10.1073/pnas.0611134104; Moran LB, 2004, BRAIN RES REV, V44, P154, DOI 10.1016/j.brainresrev.2003.11.004; Muennich EAL, 2004, J PHYSIOL-LONDON, V554, P673, DOI 10.1113/jphysiol.2003.056192; Murphy SM, 1996, J COMP NEUROL, V373, P200, DOI 10.1002/(SICI)1096-9861(19960916)373:2<200::AID-CNE4>3.0.CO;2-7; Nagao M, 1998, J NEUROPATH EXP NEUR, V57, P329, DOI 10.1097/00005072-199804000-00004; NAGY JI, 1993, SYNAPSE, V15, P17, DOI 10.1002/syn.890150103; Novikov LN, 2000, NEUROSCIENCE, V100, P171, DOI 10.1016/S0306-4522(00)00256-6; Oppenheim R. W., 1981, STUDIES DEV NEUROBIO, P74; OPPENHEIM RW, 1975, J COMP NEUROL, V161, P383, DOI 10.1002/cne.901610308; Ornung G, 1996, J COMP NEUROL, V365, P413; Peviani M, 2014, NEUROBIOL DIS, V62, P218, DOI 10.1016/j.nbd.2013.10.010; Prause J, 2013, HUM MOL GENET, V22, P1581, DOI 10.1093/hmg/ddt008; Pullen AH, 2009, EUR J NEUROSCI, V29, P551, DOI 10.1111/j.1460-9568.2008.06602.x; PULLEN AH, 1983, J PHYSIOL-LONDON, V337, P373, DOI 10.1113/jphysiol.1983.sp014629; PULLEN AH, 1992, ACTA NEUROPATHOL, V83, P488, DOI 10.1007/BF00310025; Pun S, 2006, NAT NEUROSCI, V9, P408, DOI 10.1038/nn1653; Rekling JC, 2000, PHYSIOL REV, V80, P767, DOI 10.1152/physrev.2000.80.2.767; Rimer M, 1998, MOL CELL NEUROSCI, V12, P1, DOI 10.1006/mcne.1998.0695; Rimer M, 2007, J NEUROSCI RES, V85, P1827, DOI 10.1002/jnr.21237; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; Romer SH, 2014, BRAIN RES, V1547, P1, DOI 10.1016/j.brainres.2013.12.012; RONNEVI LO, 1979, BRAIN RES, V162, P189, DOI 10.1016/0006-8993(79)90283-X; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; Rubio ME, 1999, J NEUROSCI, V19, P5549; SALA C, 1995, J NEUROSCI, V15, P520; Saxena S, 2013, NEURON, V80, P80, DOI 10.1016/j.neuron.2013.07.027; Schaeffer L, 2001, NEURON, V31, P15, DOI 10.1016/S0896-6273(01)00353-1; Schmidt N, 2011, J CELL BIOL, V195, P1171, DOI 10.1083/jcb.201107083; Sleigh JN, 2011, DIS MODEL MECH, V4, P457, DOI 10.1242/dmm.007245; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Slot JW, 2007, NAT PROTOC, V2, P2480, DOI 10.1038/nprot.2007.365; Song F, 2012, J NEUROPATH EXP NEUR, V71, P104, DOI 10.1097/NEN.0b013e3182423c43; Stassart RM, 2013, NAT NEUROSCI, V16, P48, DOI 10.1038/nn.3281; Syroid DE, 1996, P NATL ACAD SCI USA, V93, P9229, DOI 10.1073/pnas.93.17.9229; Takahashi Y, 2013, AM J HUM GENET, V93, P900, DOI 10.1016/j.ajhg.2013.09.008; Tarabal O, 1996, EUR J NEUROSCI, V8, P829, DOI 10.1111/j.1460-9568.1996.tb01269.x; Tarabal O, 2005, MOL CELL NEUROSCI, V29, P283, DOI 10.1016/j.mcn.2005.03.003; Tarabal O, 2001, J NEUROSCI, V21, P8072, DOI 10.1523/JNEUROSCI.21-20-08072.2001; Tarabal O., 2014, J NEUROPATH IN PRESS; Thomson SR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052605; Ting AK, 2011, J NEUROSCI, V31, P15, DOI 10.1523/JNEUROSCI.2538-10.2011; Tokuyasu K. T., 1997, CELLS LAB MANUAL, V131, P1; Turner BJ, 2008, PROG NEUROBIOL, V85, P94, DOI 10.1016/j.pneurobio.2008.01.001; Van den Bosch L, 2006, BBA-MOL BASIS DIS, V1762, P1068, DOI 10.1016/j.bbadis.2006.05.002; Vinsant S, 2013, BRAIN BEHAV, V3, P335, DOI 10.1002/brb3.143; Vinsant S, 2013, BRAIN BEHAV, V3, P431, DOI 10.1002/brb3.142; Vullhorst D, 2009, J NEUROSCI, V29, P12255, DOI 10.1523/JNEUROSCI.2454-09.2009; Wilson JM, 2004, J COMP NEUROL, V474, P13, DOI 10.1002/cne.20089; Witts EC, 2014, J ANAT, V224, P52, DOI 10.1111/joa.12063; YAMAMOTO T, 1991, SYNAPSE, V8, P119, DOI 10.1002/syn.890080206; Zagoraiou L, 2009, NEURON, V64, P645, DOI 10.1016/j.neuron.2009.10.017	90	49	49	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3618	3632		10.1096/fj.13-248583	http://dx.doi.org/10.1096/fj.13-248583			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24803543				2022-12-28	WOS:000340265400030
J	Ilmer, M; Vykoukal, J; Boiles, AR; Coleman, M; Alt, E				Ilmer, Matthias; Vykoukal, Jody; Boiles, Alejandro Recio; Coleman, Michael; Alt, Eckhard			Two sides of the same coin: stem cells in cancer and regenerative medicine	FASEB JOURNAL			English	Review						mesenchymal stromal cells; Warburg; epithelialmesenchymal transition; exosomes	EPITHELIAL-MESENCHYMAL TRANSITION; BONE-MARROW; STROMAL CELLS; TUMOR STROMA; TGF-BETA; ISCHEMIC CARDIOMYOPATHY; AEROBIC GLYCOLYSIS; PROGENITOR CELLS; TENASCIN-C; IN-VITRO	Multipotent stromal cells (MSCs) derived from bone marrow, adipose tissue, cord blood, and other origins have recently received much attention as potential therapeutic agents with beneficial immunomodulatory and regenerative properties. In their native tissue environment, however, such cells also appear to have essential functions in building and supporting tumor microenvironments, providing metastatic niches, and maintaining cancer hallmarks. Here, we consider the varied roles of these tissue-resident stroma-associated cells, synthesize recent and emerging discoveries, and discuss the role, potential, and clinical applications of MSCs in cancer and regenerative medicine.	[Ilmer, Matthias; Vykoukal, Jody; Boiles, Alejandro Recio] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Alt, Eckhard] Univ Texas MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, Houston, TX 77030 USA; [Coleman, Michael] InGeneron Inc, Houston, TX USA; [Alt, Eckhard] Tulane Univ, Hlth Sci Ctr, Dept Med, Appl Stem Cell Lab,Heart & Vasc Inst, New Orleans, LA 70118 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Tulane University	Alt, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ealtmd@aol.com	Ilmer, Matthias/H-9961-2019	Ilmer, Matthias/0000-0001-9597-1368	German Academic Exchange Service [Deutscher Akademischer Austauschdienst (DAAD)]; Alliance of Cardiovascular Researchers; Department of Defense Breast Cancer Research Program [W81XWH-08-1-0523 01]	German Academic Exchange Service [Deutscher Akademischer Austauschdienst (DAAD)](Deutscher Akademischer Austausch Dienst (DAAD)); Alliance of Cardiovascular Researchers; Department of Defense Breast Cancer Research Program(United States Department of Defense)	The authors thank A. E. Kadala for critical reading, discussions, and help in editing this manuscript. This work was supported by a postdoctoral stipend to M. I. provided by the German Academic Exchange Service [Deutscher Akademischer Austauschdienst (DAAD)] and by various grants from the Alliance of Cardiovascular Researchers to E. A. The cited work of this group was supported by the Department of Defense Breast Cancer Research Program (W81XWH-08-1-0523 01). Although the authors endeavored to give readers an overview of noteworthy findings regarding MSCs in the contexts of wound healing and cancer, it is difficult to be completely comprehensive within the scope of a single review. Therefore, the authors regret any relevant reports that could not be included.	Acharya A, 2010, OXID MED CELL LONGEV, V3, P23, DOI 10.4161/oxim.3.1.10095; Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alt E, 2010, INT J CARDIOL, V144, P26, DOI 10.1016/j.ijcard.2009.03.124; Altman AM, 2011, PLAST RECONSTR SURG, V127, P1467, DOI 10.1097/PRS.0b013e31820a6400; Antsiferova M, 2012, J CELL SCI, V125, P3929, DOI 10.1242/jcs.094789; Bai XW, 2007, BIOCHEM BIOPH RES CO, V353, P665, DOI 10.1016/j.bbrc.2006.12.103; Bai XW, 2010, EUR HEART J, V31, P489, DOI 10.1093/eurheartj/ehp568; Baril P, 2007, ONCOGENE, V26, P2082, DOI 10.1038/sj.onc.1210009; Beckermann BM, 2008, BRIT J CANCER, V99, P622, DOI 10.1038/sj.bjc.6604508; Block GJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010237; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Brabletz T, 2012, CELL CYCLE, V11, P215, DOI 10.4161/cc.11.2.18900; Carrion FA, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt64; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; Chen J, 2009, INT J ONCOL, V34, P1029, DOI 10.3892/ijo_00000228; Cho JA, 2011, GYNECOL ONCOL, V123, P379, DOI 10.1016/j.ygyno.2011.08.005; Choi SA, 2011, NEURO-ONCOLOGY, V13, P61, DOI 10.1093/neuonc/noq147; Chugh AR, 2012, CIRCULATION, V126, pS54, DOI 10.1161/CIRCULATIONAHA.112.092627; Cselenyak A, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-29; Devarajan E, 2012, INT J CANCER, V131, P1023, DOI 10.1002/ijc.26493; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Gehmert S, 2010, BIOCHEM BIOPH RES CO, V398, P601, DOI 10.1016/j.bbrc.2010.06.132; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Gonzalez MA, 2009, GASTROENTEROLOGY, V136, P978, DOI 10.1053/j.gastro.2008.11.041; Grisendi G, 2010, CANCER RES, V70, P3718, DOI 10.1158/0008-5472.CAN-09-1865; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardy KM, 2010, J MAMMARY GLAND BIOL, V15, P191, DOI 10.1007/s10911-010-9172-2; Hare JM, 2012, JAMA-J AM MED ASSOC, V308, P2369, DOI 10.1001/jama.2012.25321; Heo SC, 2011, BBA-MOL CELL RES, V1813, P2061, DOI 10.1016/j.bbamcr.2011.08.004; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736; Jotzu C, 2011, CELL ONCOL, V34, P55, DOI 10.1007/s13402-011-0012-1; Junk DJ, 2013, NEOPLASIA, V15, P1086, DOI 10.1593/neo.131114; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kong B, 2011, NAT REV GASTRO HEPAT, V8, P467, DOI 10.1038/nrgastro.2011.114; Kong DJ, 2008, STEM CELLS, V26, P1425, DOI 10.1634/stemcells.2007-1076; Kouris NA, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/414038; Krohn A, 2009, CANCER LETT, V280, P65, DOI 10.1016/j.canlet.2009.02.005; Kwan MD, 2008, HUM MOL GENET, V17, pR93, DOI 10.1093/hmg/ddn071; Lee RH, 2012, CELL STEM CELL, V11, P825, DOI 10.1016/j.stem.2012.10.001; Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538; Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542; Loebinger MR, 2010, BRIT J CANCER, V103, P1692, DOI 10.1038/sj.bjc.6605952; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Mahmood Z, 2010, EXP CELL RES, V316, P887, DOI 10.1016/j.yexcr.2009.12.011; Maier Harald J, 2010, Cancers (Basel), V2, P2058, DOI 10.3390/cancers2042058; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Martinez-Outschoorn UE, 2014, SEMIN CANCER BIOL, V25, P47, DOI 10.1016/j.semcancer.2014.01.005; Maxson S, 2012, STEM CELL TRANSL MED, V1, P142, DOI 10.5966/sctm.2011-0018; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; Metzele R, 2011, FASEB J, V25, P830, DOI 10.1096/fj.09-153221; Mohr A, 2010, STEM CELLS, V28, P2109, DOI 10.1002/stem.533; Morigi M, 2008, STEM CELLS, V26, P2075, DOI 10.1634/stemcells.2007-0795; Morrison CD, 2013, CANCER LETT, V341, P30, DOI 10.1016/j.canlet.2013.02.048; Muehlberg FL, 2009, CARCINOGENESIS, V30, P589, DOI 10.1093/carcin/bgp036; Mueller LP, 2011, CANCER GENE THER, V18, P229, DOI 10.1038/cgt.2010.68; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; O'Connell JT, 2011, P NATL ACAD SCI USA, V108, P16002, DOI 10.1073/pnas.1109493108; Oh JY, 2012, MOL THER, V20, P2143, DOI 10.1038/mt.2012.165; Ohkouchi S, 2012, MOL THER, V20, P417, DOI 10.1038/mt.2011.259; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Oskarsson T, 2012, EMBO J, V31, P254, DOI 10.1038/emboj.2011.469; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Patel SA, 2010, J IMMUNOL, V184, P5885, DOI 10.4049/jimmunol.0903143; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Peroni D, 2008, EXP CELL RES, V314, P603, DOI 10.1016/j.yexcr.2007.10.007; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Pinilla S, 2009, CANCER LETT, V284, P80, DOI 10.1016/j.canlet.2009.04.013; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 2012, NAT MED, V18, P653, DOI 10.1038/nm.2769; Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Rangel MC, 2012, AM J PATHOL, V180, P2188, DOI 10.1016/j.ajpath.2012.02.031; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Richardson JD, 2013, STEM CELL REV REP, V9, P281, DOI 10.1007/s12015-012-9366-7; Sadat S, 2007, BIOCHEM BIOPH RES CO, V363, P674, DOI 10.1016/j.bbrc.2007.09.058; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Singh S, 2010, BRIT J CANCER, V103, P1671, DOI 10.1038/sj.bjc.6605968; Studeny M, 2004, JNCI-J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299; Studeny M, 2002, CANCER RES, V62, P3603; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thompson EW, 2011, NAT MED, V17, P1048, DOI 10.1038/nm.2437; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Traktuev DO, 2008, CIRC RES, V102, P77, DOI 10.1161/CIRCRESAHA.107.159475; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Valina C, 2007, EUR HEART J, V28, P2667, DOI 10.1093/eurheartj/ehm426; Vermeulen L, 2012, LANCET ONCOL, V13, pE83, DOI 10.1016/S1470-2045(11)70257-1; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang MJ, 2006, AM J PHYSIOL-REG I, V291, pR880, DOI 10.1152/ajpregu.00280.2006; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Warburg O, 1924, BIOCHEM Z, V152, P319; Wu YJ, 2010, STEM CELLS, V28, P905, DOI 10.1002/stem.420; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xue Y, 2012, NAT MED, V18, P100, DOI 10.1038/nm.2575; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang SB, 2011, J LEUKOCYTE BIOL, V89, P85, DOI 10.1189/jlb.0910506; Yuan L, 2011, AM J PHYSIOL-RENAL, V300, pF207, DOI 10.1152/ajprenal.00073.2010; Yuan XL, 2010, CLIN IMMUNOL, V134, P277, DOI 10.1016/j.clim.2009.10.005; Zhang L, 2010, NATURE, V464, P1058, DOI 10.1038/nature08871; Zhang P, 2011, STEM CELLS DEV, V20, P977, DOI 10.1089/scd.2010.0152; Zhang Y, 2009, CANCER RES, V69, P5259, DOI 10.1158/0008-5472.CAN-08-3444	121	35	36	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2748	2761		10.1096/fj.13-244640	http://dx.doi.org/10.1096/fj.13-244640			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24675364				2022-12-28	WOS:000337949400003
J	Recchiuti, A; Codagnone, M; Pierdomenico, AM; Rossi, C; Mari, VC; Cianci, E; Simiele, F; Gatta, V; Romano, M				Recchiuti, Antonio; Codagnone, Marilina; Pierdomenico, Anna Maria; Rossi, Cosmo; Mari, Veronica Cecilia; Cianci, Eleonora; Simiele, Felice; Gatta, Valentina; Romano, Mario			Immunoresolving actions of oral resolvin D1 include selective regulation of the transcription machinery in resolution-phase mouse macrophages	FASEB JOURNAL			English	Article						docosahexaenoic acid; chromatin-remodeling enzymes; pharmacology	LIPOXIN A(4); PROMOTE RESOLUTION; HUMAN PHAGOCYTES; LIPID MEDIATORS; GENE-EXPRESSION; INFLAMMATION; RECEPTOR; POLARIZATION; EFFEROCYTOSIS; MECHANISMS	Resolvin D1 (RvD1; 7S, 8R, 17S-trihydroxy-4Z, 9E,11E,13Z,15E,19Z-docosahexaenoic acid) is an endogenous immunoresolvent that regulates acute inflammation and orchestrates resolution. Here, we investigated anti-inflammatory and proresolving actions of RvD1 after oral administration. RvD1 rapidly accumulated in the mouse plasma after oral delivery and dose-dependently (1-100 ng/mouse) reduced leukocyte infiltration in zymosan A-induced acute peritonitis. Using mathematical resolution indices, RvD1 reduced Psi(max) by similar to 50%, shortened the resolution interval by 3 h, and significantly reduced total leukocyte (by similar to 30-45%) and polymorphonuclear neutrophil (by similar to 40-55%) accumulation when administered at the peak of peritonitis. RvD1 also improved course and outcome of severe peritonitis, shifting it toward resolution. In peritoneal macrophages (M Phi s) from the resolution phase of peritonitis, RvD1 down-regulated (by 2- to 3-fold) select genes that control gene transcription, namely coactivator-associated arginine methyltransferase 1 (CARM1), and downstream genes, such as colony-stimulating factor 3, intercellular adhesion molecule 1, and monocyte inflammatory protein 2, which promote neutrophil infiltration and reduce M Phi phagocytosis. Congruently, CARM1 knockdown in human and murine M Phi s induced a proresolving phenotype, recapitulating in vivo actions of RvD1. These results establish novel properties of RvD1 and demonstrate that RvD1 modifies the transcription control machinery in M Phi s, as part of its mechanisms of action during the resolution of acute inflammation.	[Recchiuti, Antonio; Codagnone, Marilina; Simiele, Felice; Romano, Mario] Univ G DAnnunzio, Dept Expt & Clin Sci, I-66013 Chieti, Italy; [Pierdomenico, Anna Maria; Cianci, Eleonora] Univ G DAnnunzio, Dept Med & Aging Sci, I-66013 Chieti, Italy; [Gatta, Valentina] Univ G DAnnunzio, Dept Psychol Humanities & Terr Sci, I-66013 Chieti, Italy; [Recchiuti, Antonio; Codagnone, Marilina; Pierdomenico, Anna Maria; Rossi, Cosmo; Mari, Veronica Cecilia; Cianci, Eleonora; Simiele, Felice; Gatta, Valentina; Romano, Mario] Univ G dAnnunzio, Ctr Excellence Aging, Chieti, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Recchiuti, A (corresponding author), Univ G DAnnunzio, Dept Expt & Clin Sci, Via Colle Ara, I-66013 Chieti, Italy.	a.recchiuti@unich.it	Romano, Mario/I-7986-2012; Recchiuti, Antonio/K-7670-2016; Gatta, Valentina/G-5765-2014	Romano, Mario/0000-0001-8512-1458; Recchiuti, Antonio/0000-0002-1409-5261; Pierdomenico, Anna Maria/0000-0002-1788-6106; GATTA, Valentina/0000-0002-9999-5823	European Union [294187 FP7-PEOPLE-CIG-2011]; Regione Abruzzo under the Piano Speciale Multiasse Reti per l'Alta Formazione-POFSE	European Union(European Commission); Regione Abruzzo under the Piano Speciale Multiasse Reti per l'Alta Formazione-POFSE	This work was supported by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement 294187 FP7-PEOPLE-CIG-2011 (to A. R.) and by the Regione Abruzzo under the Piano Speciale Multiasse Reti per l'Alta Formazione-POFSE 2007-2013 (to A. R.). The authors thank Sara Patruno for SPE of plasma samples, Marco D'Aurora for gene array cluster analysis, and Dr. Giuseppina Bologna for FCM analysis of transfected M Phi s. The authors also acknowledge BioLegend (San Diego, CA, USA) and Cayman Chemical (Ann Arbor, MI, USA) for providing reagents for the initial setup and optimization of polychromatic FCM and RvD1 detection protocol. The authors declare no conflicts of interest. Author contributions: A. R. designed experiments and conceived overall research; A. R., M. C., A. P., C. R., V. C. M., E. C., F. S., and M. R. performed research and analyzed results; A. R. and M. R. wrote the manuscript.	Bannenberg G, 2004, BRIT J PHARMACOL, V143, P43, DOI 10.1038/sj.bjp.0705912; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Buchanan PJ, 2013, AM J PHYSIOL-LUNG C, V305, pL193, DOI 10.1152/ajplung.00058.2013; Buxton I. L., 2011, GOODMAN GILMAN S THE; Bystrom J, 2008, BLOOD, V112, P4117, DOI 10.1182/blood-2007-12-129767; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Chen XF, 2012, P NATL ACAD SCI USA, V109, pE2865, DOI 10.1073/pnas.1121131109; Chiang N, 2012, NATURE, V484, P524, DOI 10.1038/nature11042; Claria J, 2013, AM J PHYSIOL-CELL PH, V304, pC1141, DOI 10.1152/ajpcell.00351.2012; Claria J, 2012, J IMMUNOL, V189, P2597, DOI 10.4049/jimmunol.1201272; Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500; Dalli J, 2013, FASEB J, V27, P2573, DOI 10.1096/fj.13-227728; Dalli J, 2013, J IMMUNOL, V190, P6478, DOI 10.4049/jimmunol.1203000; Dalli J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01940; Dalli J, 2012, BLOOD, V120, pE60, DOI 10.1182/blood-2012-04-423525; Gavins FNE, 2012, FASEB J, V26, P4977, DOI 10.1096/fj.12-205971; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Goffin E, 2005, LANCET, V366, P289, DOI 10.1016/S0140-6736(05)66976-0; Gordon S, 2007, EUR J IMMUNOL, V37, pS9, DOI 10.1002/eji.200737638; Green E. L., 1966, BIOLOGY OF THE LABOR; Guilford WJ, 2004, J MED CHEM, V47, P2157, DOI 10.1021/jm030569l; Hecht I, 2009, J PHARMACOL EXP THER, V328, P426, DOI 10.1124/jpet.108.145821; Hellmann J, 2011, FASEB J, V25, P2399, DOI 10.1096/fj.10-178657; Kamaly N, 2013, P NATL ACAD SCI USA, V110, P6506, DOI 10.1073/pnas.1303377110; Krishnamoorthy S, 2012, AM J PATHOL, V180, P2018, DOI 10.1016/j.ajpath.2012.01.028; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; Lawrence T, 2007, INT J EXP PATHOL, V88, P85, DOI 10.1111/j.1365-2613.2006.00507.x; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Lee HN, 2013, BIOCHEM PHARMACOL, V86, P759, DOI 10.1016/j.bcp.2013.07.002; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Liao ZL, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-110; Maderna P, 2009, BRIT J PHARMACOL, V158, P947, DOI 10.1111/j.1476-5381.2009.00386.x; Majno G., 2004, CELLS TISSUES AND DI; Mattoscio D, 2010, FASEB J, V24, P3970, DOI 10.1096/fj.10-159921; Montero-Melendez T, 2013, CELL DEATH DIFFER, V20, P567, DOI 10.1038/cdd.2012.154; Navarro-Xavier RA, 2010, J IMMUNOL, V184, P1516, DOI 10.4049/jimmunol.0902866; Norling LV, 2012, ARTERIOSCL THROM VAS, V32, P1970, DOI 10.1161/ATVBAHA.112.249508; Norling LV, 2011, J IMMUNOL, V186, P5543, DOI 10.4049/jimmunol.1003865; Ohira T, 2010, J BIOL CHEM, V285, P3451, DOI 10.1074/jbc.M109.044131; Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470; Planaguma A, 2008, AM J RESP CRIT CARE, V178, P574, DOI 10.1164/rccm.200801-061OC; Pruss H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055859; Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957; Recchiuti A, 2011, FASEB J, V25, P544, DOI 10.1096/fj.10-169599; Rius B, 2014, FASEB J, V28, P836, DOI 10.1096/fj.13-235614; Rogerio AP, 2012, J IMMUNOL, V189, P1983, DOI 10.4049/jimmunol.1101665; Romano M, 2002, LAB INVEST, V82, P1253, DOI 10.1097/01.LAB.0000028823.53486.4A; Schif-Zuck S, 2011, EUR J IMMUNOL, V41, P366, DOI 10.1002/eji.201040801; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Shakespear MR, 2013, J BIOL CHEM, V288, P25362, DOI 10.1074/jbc.M113.496281; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Simiele F, 2012, FASEB J, V26, P1323, DOI 10.1096/fj.11-198069; Stables MJ, 2011, BLOOD, V118, pE192, DOI 10.1182/blood-2011-04-345330; Sun YP, 2007, J BIOL CHEM, V282, P9323, DOI 10.1074/jbc.M609212200; Sun YP, 2009, PROSTAG LEUKOTR ESS, V81, P357, DOI 10.1016/j.plefa.2009.09.004; Tang YN, 2013, DIABETES, V62, P618, DOI 10.2337/db12-0684; Tian HB, 2009, INVEST OPHTH VIS SCI, V50, P3613, DOI 10.1167/iovs.08-3146; Titos E, 2011, J IMMUNOL, V187, P5408, DOI 10.4049/jimmunol.1100225; Turner PV, 2011, J AM ASSOC LAB ANIM, V50, P600; WANG LF, 1990, TRANSPLANT P, V22, P2342; Weiss GA, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-89; Zhang MJ, 2012, ANNU REV NUTR, V32, P203, DOI 10.1146/annurev-nutr-071811-150726	64	36	36	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3090	3102		10.1096/fj.13-248393	http://dx.doi.org/10.1096/fj.13-248393			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24692596				2022-12-28	WOS:000337949400030
J	Smith, IJ; Godinez, GL; Singh, BK; McCaughey, KM; Alcantara, RR; Gururaja, T; Ho, MS; Nguyen, HN; Friera, AM; White, KA; McLaughlin, JR; Hansen, D; Romero, JM; Baltgalvis, KA; Claypool, MD; Li, W; Lang, W; Yam, GC; Gelman, MS; Ding, RX; Yung, SL; Creger, DP; Chen, Y; Singh, R; Smuder, AJ; Wiggs, MP; Kwon, OS; Sollanek, KJ; Powers, SK; Masuda, ES; Taylor, VC; Payan, DG; Kinoshita, T; Kinsella, TM				Smith, Ira J.; Godinez, Guillermo L.; Singh, Baljit K.; McCaughey, Kelly M.; Alcantara, Raniel R.; Gururaja, Tarikere; Ho, Melissa S.; Nguyen, Henry N.; Friera, Annabelle M.; White, Kathy A.; McLaughlin, John R.; Hansen, Derek; Romero, Jason M.; Baltgalvis, Kristen A.; Claypool, Mark D.; Li, Wei; Lang, Wayne; Yam, George C.; Gelman, Marina S.; Ding, Rongxian; Yung, Stephanie L.; Creger, Daniel P.; Chen, Yan; Singh, Rajinder; Smuder, Ashley J.; Wiggs, Michael P.; Kwon, Oh-Sung; Sollanek, Kurt J.; Powers, Scott K.; Masuda, Esteban S.; Taylor, Vanessa C.; Payan, Donald G.; Kinoshita, Taisei; Kinsella, Todd M.			Inhibition of Janus kinase signaling during controlled mechanical ventilation prevents ventilation-induced diaphragm dysfunction	FASEB JOURNAL			English	Article						muscle wasting; mitochondria; oxidative stress; STAT3	INTENSIVE-CARE-UNIT; SERINE PHOSPHORYLATION; MITOCHONDRIAL STAT3; OXIDATIVE STRESS; MUSCLE ATROPHY; DEGRADATION; ACTIVATION; WEAKNESS; P38	Controlled mechanical ventilation (CMV) is associated with the development of diaphragm atrophy and contractile dysfunction, and respiratory muscle weakness is thought to contribute significantly to delayed weaning of patients. Therefore, therapeutic strategies for preventing these processes may have clinical benefit. The aim of the current study was to investigate the role of the Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling pathway in CMV-mediated diaphragm wasting and weakness in rats. CMV-induced diaphragm atrophy and contractile dysfunction coincided with marked increases in STAT3 phosphorylation on both tyrosine 705 (Tyr705) and serine 727 (Ser727). STAT3 activation was accompanied by its translocation into mitochondria within diaphragm muscle and mitochondrial dysfunction. Inhibition of JAK signaling during CMV prevented phosphorylation of both target sites on STAT3, eliminated the accumulation of phosphorylated STAT3 within the mitochondria, and reversed the pathologic alterations in mitochondrial function, reduced oxidative stress in the diaphragm, and maintained normal diaphragm contractility. In addition, JAK inhibition during CMV blunted the activation of key proteolytic pathways in the diaphragm, as well as diaphragm atrophy. These findings implicate JAK/STAT3 signaling in the development of diaphragm muscle atrophy and dysfunction during CMV and suggest that the delayed extubation times associated with CMV can be prevented by inhibition of Janus kinase signaling.	[Smith, Ira J.; Godinez, Guillermo L.; Singh, Baljit K.; McCaughey, Kelly M.; Alcantara, Raniel R.; Gururaja, Tarikere; Ho, Melissa S.; Nguyen, Henry N.; Friera, Annabelle M.; White, Kathy A.; McLaughlin, John R.; Hansen, Derek; Romero, Jason M.; Baltgalvis, Kristen A.; Claypool, Mark D.; Li, Wei; Lang, Wayne; Yam, George C.; Gelman, Marina S.; Ding, Rongxian; Yung, Stephanie L.; Creger, Daniel P.; Chen, Yan; Singh, Rajinder; Masuda, Esteban S.; Taylor, Vanessa C.; Payan, Donald G.; Kinoshita, Taisei; Kinsella, Todd M.] Rigel Pharmaceut Inc, San Francisco, CA 94080 USA; [Smuder, Ashley J.; Wiggs, Michael P.; Kwon, Oh-Sung; Sollanek, Kurt J.; Powers, Scott K.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL USA	State University System of Florida; University of Florida	Kinsella, TM (corresponding author), Rigel Pharmaceut Inc, 1180 Vet Blvd, San Francisco, CA 94080 USA.	tkinsella@rigel.com	Kwon, Oh Sung/AAL-4116-2021	Masuda, Esteban/0000-0002-3175-2868; Chen, Yan/0000-0002-5690-5381	Rigel Pharmaceuticals; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD043730] Funding Source: NIH RePORTER	Rigel Pharmaceuticals; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The authors thank Joseph B. Shrager and H. Tang (Stanford University, Stanford, CA, USA) for useful insights, and Vadim Markovtsov (Rigel Pharmaceuticals) for helpful discussions and reading of the manuscript. I.J.S., G. L. G., B. K. S., K. M. M., R. R. A., T. G., M. S. H., H.N.N., A. M. F., K. A. W., J.R.M., D. H., J.M.R., K. A. B., M. D. C., W. Li, W. Lang, G.C.Y., M. S. G., R. D., S.L.Y., D. P. C., Y.C., R. S., E. S. M., V. C. T., D. G. P., T. K., and T. M. K. are employees and/or stockholders of Rigel Pharmaceuticals, Inc. Experiments conducted at the University of Florida were supported by funding from Rigel Pharmaceuticals (to S.K.P.).	Betters JL, 2004, AM J RESP CRIT CARE, V170, P1179, DOI 10.1164/rccm.200407-939OC; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Dasta JF, 2005, CRIT CARE MED, V33, P1266, DOI 10.1097/01.CCM.0000164543.14619.00; De Jonghe B, 2007, CRIT CARE MED, V35, P2007, DOI 10.1097/01.ccm.0000281450.01881.d8; Deuse T, 2012, TRANSPLANTATION, V94, P695, DOI 10.1097/TP.0b013e3182660496; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Hermans G, 2010, CRIT CARE, V14, DOI 10.1186/cc9094; Jaber S, 2011, AM J RESP CRIT CARE, V183, P364, DOI 10.1164/rccm.201004-0670OC; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Kavazis AN, 2009, FREE RADICAL BIO MED, V46, P842, DOI 10.1016/j.freeradbiomed.2009.01.002; Kim J, 2009, KOREAN J PHYSIOL PHA, V13, P491, DOI 10.4196/kjpp.2009.13.6.491; Kurdi M, 2009, AM J PHYSIOL-HEART C, V297, pH1545, DOI 10.1152/ajpheart.00032.2009; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Lokireddy S, 2011, MOL ENDOCRINOL, V25, P1936, DOI 10.1210/me.2011-1124; Maes K, 2007, AM J RESP CRIT CARE, V175, P1134, DOI 10.1164/rccm.200609-1342OC; McClung JM, 2007, J PHYSIOL-LONDON, V585, P203, DOI 10.1113/jphysiol.2007.141119; McClung JM, 2007, AM J RESP CRIT CARE, V175, P150, DOI 10.1164/rccm.200601-142OC; Meyer DM, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-41; Moresi V, 2010, CELL, V143, P35, DOI 10.1016/j.cell.2010.09.004; Ochala J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020558; Polge C, 2011, FASEB J, V25, P3790, DOI 10.1096/fj.11-180968; Powers SK, 2011, CRIT CARE MED, V39, P1749, DOI 10.1097/CCM.0b013e3182190b62; Reid MB, 2011, J PHYSIOL-LONDON, V589, P2171, DOI 10.1113/jphysiol.2010.203356; Shulga N, 2012, J CELL SCI, V125, P2995, DOI 10.1242/jcs.103093; Smuder AJ, 2010, FREE RADICAL BIO MED, V49, P1152, DOI 10.1016/j.freeradbiomed.2010.06.025; Song B, 2013, REGUL PEPTIDES, V185, P44, DOI 10.1016/j.regpep.2013.06.007; Szczepanek K, 2011, J BIOL CHEM, V286, P29610, DOI 10.1074/jbc.M111.226209; Tammineni P, 2013, J BIOL CHEM, V288, P4723, DOI 10.1074/jbc.M112.378984; Tang HB, 2011, FASEB J, V25, P2921, DOI 10.1096/fj.11-183798; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Vassilakopoulos T, 2004, AM J RESP CRIT CARE, V169, P336, DOI 10.1164/rccm.200304-489CP; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; Whidden MA, 2010, J APPL PHYSIOL, V108, P1376, DOI 10.1152/japplphysiol.00098.2010; White JP, 2011, AM J PHYSIOL-REG I, V300, pR201, DOI 10.1152/ajpregu.00300.2010; Wunsch H, 2010, CRIT CARE MED, V38, P1947, DOI 10.1097/CCM.0b013e3181ef4460; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zhang QF, 2013, J BIOL CHEM, V288, P31280, DOI 10.1074/jbc.M113.505057; Zhou LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021680	42	37	40	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2790	2803		10.1096/fj.13-244210	http://dx.doi.org/10.1096/fj.13-244210			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24671708	Green Published, hybrid			2022-12-28	WOS:000337949400006
J	Stancu, IC; Ris, L; Vasconcelos, B; Marinangeli, C; Goeminne, L; Laporte, V; Haylani, LE; Couturier, J; Schakman, O; Gailly, P; Pierrot, N; Kienlen-Campard, P; Octave, JN; Dewachter, I				Stancu, Ilie-Cosmin; Ris, Laurence; Vasconcelos, Bruno; Marinangeli, Claudia; Goeminne, Leonie; Laporte, Vincent; Haylani, Laetitia E.; Couturier, Julien; Schakman, Olivier; Gailly, Philippe; Pierrot, Nathalie; Kienlen-Campard, Pascal; Octave, Jean-Noel; Dewachter, Ilse			Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease	FASEB JOURNAL			English	Article						amyloid plaques; neurofibrillary tangles; GSK3; synaptic transmission; hippocampal atrophy	AMYLOID PRECURSOR PROTEIN; TRANSGENIC MICE; TAU-PATHOLOGY; A-BETA; NEUROFIBRILLARY TANGLES; MOUSE MODEL; HYPOTHETICAL MODEL; PLAQUE-FORMATION; MEMORY DEFICITS; MUTANT-TAU	Tau alterations are now considered an executor of neuronal demise and cognitive dysfunction in Alzheimer's disease (AD). Mouse models combining amyloidosis and tauopathy and their parental counterparts are important tools to further investigate the interplay of abnormal amyloid-beta (A beta) and Tau species in pathogenesis, synaptic and neuronal dysfunction, and cognitive decline. Here, we crossed APP/PS1 mice with 5 early-onset familial AD mutations (5xFAD) and TauP301S (PS19) transgenic mice, denoted F+/T+ mice, and phenotypically compared them to their respective parental strains, denoted F+/T- and F-/T+ respectively, as controls. We found dramatically aggravated tauopathy (similar to 10-fold) in F+/T+ mice compared to the parental F-/T+ mice. In contrast, amyloidosis was unaltered compared to the parental F+/T- mice. Tauopathy was invariably and very robustly aggravated in hippocampal and cortical brain regions. Most important, F+/T+ displayed aggravated cognitive deficits in a hippocampus-dependent spatial navigation task, compared to the parental F+/T- strain, while parental F-/T+ mice did not display cognitive impairment. Basal synaptic transmission was impaired in F+/T+ mice compared to nontransgenic mice and the parental strains (>= 40%). Finally, F+/T+ mice displayed a significant hippocampal atrophy (similar to 20%) compared to nontransgenic mice, in contrast to the parental strains. Our data indicate for the first time that pathological A beta species (or APP/PS1) induced changes in Tau contribute to cognitive deficits correlating with synaptic deficits and hippocampal atrophy in an AD model. Our data lend support to the amyloid cascade hypothesis with a role of pathological A beta species as initiator and pathological Tau species as executor.	[Stancu, Ilie-Cosmin; Vasconcelos, Bruno; Marinangeli, Claudia; Goeminne, Leonie; Laporte, Vincent; Haylani, Laetitia E.; Couturier, Julien; Pierrot, Nathalie; Kienlen-Campard, Pascal; Octave, Jean-Noel; Dewachter, Ilse] Catholic Univ Louvain, Alzheimer Dementia Grp, B-1200 Brussels, Belgium; [Schakman, Olivier; Gailly, Philippe] Catholic Univ Louvain, Inst Neurosci, Dept Cell Physiol, B-1200 Brussels, Belgium; [Ris, Laurence] Univ Mons, Dept Neurosci, Mons, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; University of Mons	Dewachter, I (corresponding author), Catholic Univ Louvain, Inst Neuroscience, B 1-54-10,Av Hippocrate 54, B-1200 Brussels, Belgium.	ilse.dewachter@uclouvain.be	Dewachter, Ilse/AAZ-5661-2020	Dewachter, Ilse/0000-0001-7202-515X; Stancu, Ilie-Cosmin/0000-0003-4271-0193; Kienlen-Campard, Pascal/0000-0003-1086-2942; Goeminne, Leonie/0000-0001-5870-5124	Belgian Fonds National pour la Recherche Scientifique-Fonds de la Recherche Scientifique (FNRS-FRS); Interuniversity Attraction Poles Programme-Belgian State-Belgian Science Policy; Belgian Fonds de la Recherche Scientifique Medicale; Stichting Alzheimer Onderzoek-Fondation pour la Recherche sur la Maladie d'Alzheimer (SAO-FRMA); Programme d'Excellence Marshall Diane convention	Belgian Fonds National pour la Recherche Scientifique-Fonds de la Recherche Scientifique (FNRS-FRS)(Fonds de la Recherche Scientifique - FNRS); Interuniversity Attraction Poles Programme-Belgian State-Belgian Science Policy(Belgian Federal Science Policy Office); Belgian Fonds de la Recherche Scientifique Medicale(Fonds de la Recherche Scientifique - FNRS); Stichting Alzheimer Onderzoek-Fondation pour la Recherche sur la Maladie d'Alzheimer (SAO-FRMA); Programme d'Excellence Marshall Diane convention	This work was supported by the Belgian Fonds National pour la Recherche Scientifique-Fonds de la Recherche Scientifique (FNRS-FRS; Qualified Researcher, Impulse Financing, Research Credits), by Interuniversity Attraction Poles Programme-Belgian State-Belgian Science Policy, The Belgian Fonds de la Recherche Scientifique Medicale, the Stichting Alzheimer Onderzoek-Fondation pour la Recherche sur la Maladie d'Alzheimer (SAO-FRMA), and the Programme d'Excellence Marshall Diane convention.	Allen B, 2002, J NEUROSCI, V22, P9340; Ashe KH, 2001, LEARN MEMORY, V8, P301, DOI 10.1101/lm.43701; Bolmont T, 2007, AM J PATHOL, V171, P2012, DOI 10.2353/ajpath.2007.070403; Bomfim TR, 2012, J CLIN INVEST, V122, P1339, DOI 10.1172/JCI57256; Brunden KR, 2009, NAT REV DRUG DISCOV, V8, P783, DOI 10.1038/nrd2959; Citron M, 2004, NAT REV NEUROSCI, V5, P677, DOI 10.1038/nrn1495; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; Dewachter I, 2002, LANCET NEUROL, V1, P409, DOI 10.1016/S1474-4422(02)00188-6; Dewachter I, 2002, J NEUROSCI, V22, P3445; Duyckaerts C, 2008, ACTA NEUROPATHOL, V115, P5, DOI 10.1007/s00401-007-0312-8; GALLYAS F, 1971, ACTA MORPHOL HUNG, V19, P1; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gotz J, 2001, J BIOL CHEM, V276, P529, DOI 10.1074/jbc.M006531200; Gotz J, 2008, NAT REV NEUROSCI, V9, P532, DOI 10.1038/nrn2420; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heraud C, 2014, NEUROBIOL DIS, V62, P100, DOI 10.1016/j.nbd.2013.09.010; Hurtado DE, 2012, J NEUROSCI, V32, P7392, DOI 10.1523/JNEUROSCI.0889-12.2012; Hurtado DE, 2010, AM J PATHOL, V177, P1977, DOI 10.2353/ajpath.2010.100346; Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Leroy K, 2007, AM J PATHOL, V171, P976, DOI 10.2353/ajpath.2007.070345; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Li SM, 2010, FRONT CELL NEUROSCI, V4, DOI 10.3389/fncel.2010.00005; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Pigino G, 2001, J NEUROSCI, V21, P834, DOI 10.1523/JNEUROSCI.21-03-00834.2001; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Roberson ED, 2011, J NEUROSCI, V31, P700, DOI 10.1523/JNEUROSCI.4152-10.2011; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Saul A, 2013, NEUROBIOL AGING, V34, P2564, DOI 10.1016/j.neurobiolaging.2013.05.003; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schindowski K, 2006, AM J PATHOL, V169, P599, DOI 10.2353/ajpath.2006.060002; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; St George-Hyslop PH, 2008, LANCET, V372, P180, DOI 10.1016/S0140-6736(08)61047-8; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Terwel D, 2005, J BIOL CHEM, V280, P3963, DOI 10.1074/jbc.M409876200; Terwel D, 2008, AM J PATHOL, V172, P786, DOI 10.2353/ajpath.2008.070904; Van der Jeugd A, 2012, ACTA NEUROPATHOL, V123, P787, DOI 10.1007/s00401-012-0987-3; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zahs KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00028	47	34	36	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2620	2631		10.1096/fj.13-246702	http://dx.doi.org/10.1096/fj.13-246702			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24604080				2022-12-28	WOS:000339883600020
J	Kuo, IY; Keeler, C; Corbin, R; Celic, A; Petri, ET; Hodsdon, ME; Ehrlich, BE				Kuo, Ivana Y.; Keeler, Camille; Corbin, Rachel; Celic, Andjelka; Petri, Edward T.; Hodsdon, Michael E.; Ehrlich, Barbara E.			The number and location of EF hand motifs dictates the calcium dependence of polycystin-2 function	FASEB JOURNAL			English	Article						TRP channels; kidney; ion channels; intracellular release; signaling	C-TERMINAL TAIL; NMR STRUCTURE; BINDING; DYNAMICS; RECEPTOR; DOMAIN; ACTIVATION; PROTEINS; CHANNELS	Polycystin 2 (PC2) is a calcium-dependent calcium channel, and mutations to human PC2 (hPC2) are associated with polycystic kidney disease. The C-terminal tail of hPC2 contains 2 EF hand motifs, but only the second binds calcium. Here, we investigate whether these EF hand motifs serve as a calcium sensor responsible for the calcium dependence of PC2 function. Using NMR and bioinformatics, we show that the overall fold is highly conserved, but in evolutionarily earlier species, both EF hands bind calcium. To test whether the EF hand motif is truly a calcium sensor controlling PC2 channel function, we altered the number of calcium binding sites in hPC2. NMR studies confirmed that modified hPC2 binds an additional calcium ion. Single-channel recordings demonstrated a leftward shift in the calcium dependence, and imaging studies in cells showed that calcium transients were enhanced compared with wild-type hPC2. However, biophysics and functional studies showed that the first EF hand can only bind calcium and be functionally active if the second (native) calcium-binding EF hand is intact. These results suggest that the number and location of calcium-binding sites in the EF hand senses the concentration of calcium required for PC2 channel activity and cellular function.Kuo, I. Y., Keeler, C., Corbin, R., Celi, A., Petri, E. T., Hodsdon, M. E., Ehrlich, B. E. The number and location of EF hand motifs dictates the calcium dependence of polycystin-2 function.	[Kuo, Ivana Y.; Corbin, Rachel; Celic, Andjelka; Petri, Edward T.; Ehrlich, Barbara E.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; [Keeler, Camille; Hodsdon, Michael E.] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA; [Ehrlich, Barbara E.] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Ehrlich, BE (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	michael.hodsdon@yale.edu; barbara.ehrlich@yale.edu	Celic, Andjeka S/AAC-1865-2022; /AAX-8408-2021	/0000-0001-9657-9704; Celic, Andjelka/0000-0002-1058-6872; Petri, Edward/0000-0002-3650-1523; Kuo, Ivana/0000-0002-9867-2408	Ministry of Education and Science, Republic of Serbia [173014, 172021]; U.S. National Institutes of Health (NIH) [1S10RR023748-01]; NIH [P30 DK090744I, R01 DK61747, R01 DK087844]; American Heart Association [R10682]	Ministry of Education and Science, Republic of Serbia; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association)	The authors thank Victor Vacquier (Scripps Institution of Oceanography, University of California-San Diego, La Jolla, CA, USA) for providing the sea urchin cDNA library. The authors thank Yifei Yang for helpful discussions. The authors thank Yiqiang Cai and Stephan Somlo (Yale University) for providing the PC2 construct and PC2 antibodies. Salim Acimi assisted with early Ca<SUP>2+</SUP> imaging experiments. E. T. P. and A. C. thank the Ministry of Education and Science, Republic of Serbia, for support (projects 173014 and 172021) during preparation of this article. The SEC-LS/UV/RI instrumentation was supported by U.S. National Institutes of Health (NIH) award 1S10RR023748-01 (Keck Facility, Yale University). This work was funded by NIH grants P30 DK090744I, R01 DK61747, and R01 DK087844 (B. E. E. and M. E. H), and by American Heart Association postdoctoral fellowship R10682 (I.Y.K).	Anyatonwu GI, 2007, P NATL ACAD SCI USA, V104, P6454, DOI 10.1073/pnas.0610324104; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bhattacharya A, 2007, PROTEINS, V66, P778, DOI 10.1002/prot.21165; Biekofsky RR, 1998, BIOCHEMISTRY-US, V37, P7617, DOI 10.1021/bi9800449; Brunet S, 2005, J GEN PHYSIOL, V126, P311, DOI 10.1085/jgp.200509333; Cai YQ, 2004, J BIOL CHEM, V279, P19987, DOI 10.1074/jbc.M312031200; Capozzi F, 2006, J BIOL INORG CHEM, V11, P949, DOI 10.1007/s00775-006-0163-0; Celic A, 2008, J BIOL CHEM, V283, P28305, DOI 10.1074/jbc.M802743200; Celic AS, 2012, J BIOL CHEM, V287, P17232, DOI 10.1074/jbc.M112.354613; Chagot B, 2009, J BIOL CHEM, V284, P6436, DOI 10.1074/jbc.M807747200; Chazin WJ, 2011, ACCOUNTS CHEM RES, V44, P171, DOI 10.1021/ar100110d; Dereeper A, 2008, NUCLEIC ACIDS RES, V36, pW465, DOI 10.1093/nar/gkn180; Dereeper A, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-8; Giamarchi A, 2010, EMBO J, V29, P1176, DOI 10.1038/emboj.2010.18; Gifford JL, 2007, BIOCHEM J, V405, P199, DOI 10.1042/BJ20070255; Grabarek Z, 2006, J MOL BIOL, V359, P509, DOI 10.1016/j.jmb.2006.03.066; Harris PC, 2009, ANNU REV MED, V60, P321, DOI 10.1146/annurev.med.60.101707.125712; Hateboer N, 2000, KIDNEY INT, V57, P1444, DOI 10.1046/j.1523-1755.2000.00989.x; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Holm L, 2010, NUCLEIC ACIDS RES, V38, pW545, DOI 10.1093/nar/gkq366; Keeler C, 2013, BIOPHYS J, V105, P2843, DOI 10.1016/j.bpj.2013.11.017; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Kuo IY, 2012, CHEM REV, V112, P6353, DOI 10.1021/cr3001077; Li Y, 2005, J BIOL CHEM, V280, P41298, DOI 10.1074/jbc.M510082200; Mekahli D, 2012, CELL CALCIUM, V51, P452, DOI 10.1016/j.ceca.2012.03.002; Miloushev VZ, 2009, J BIOL CHEM, V284, P6446, DOI 10.1074/jbc.M807401200; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Neill AT, 2004, MOL REPROD DEV, V67, P472, DOI 10.1002/mrd.20033; Palmer AG, 1997, CURR OPIN STRUC BIOL, V7, P732, DOI 10.1016/S0959-440X(97)80085-1; Petri ET, 2010, P NATL ACAD SCI USA, V107, P9176, DOI 10.1073/pnas.0912295107; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Sammels E, 2010, J BIOL CHEM, V285, P18794, DOI 10.1074/jbc.M109.090662; Schulze C, 2011, PLANT J, V68, P424, DOI 10.1111/j.1365-313X.2011.04697.x; Sharif-Naeini R, 2009, CELL, V139, P587, DOI 10.1016/j.cell.2009.08.045; Yoshiba S, 2012, SCIENCE, V338, P226, DOI 10.1126/science.1222538; Yu Y, 2009, P NATL ACAD SCI USA, V106, P11558, DOI 10.1073/pnas.0903684106; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	37	16	17	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2332	2346		10.1096/fj.13-247106	http://dx.doi.org/10.1096/fj.13-247106			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24558196	Green Published			2022-12-28	WOS:000335336000034
J	Sauler, M; Zhang, Y; Min, JN; Leng, L; Shan, PY; Roberts, S; Jorgensen, WL; Bucala, R; Lee, PJ				Sauler, Maor; Zhang, Yi; Min, Jin-Na; Leng, Lin; Shan, Peiying; Roberts, Scott; Jorgensen, William L.; Bucala, Richard; Lee, Patty J.			Endothelial CD74 mediates macrophage migration inhibitory factor protection in hyperoxic lung injury	FASEB JOURNAL			English	Article						apoptosis; endothelium; H2AX; MIF	RESPIRATORY-DISTRESS-SYNDROME; D-DOPACHROME TAUTOMERASE; PULMONARY ARTERIAL-HYPERTENSION; DNA-DAMAGE; OXIDATIVE STRESS; FACTOR MIF; HISTONE H2AX; CELL-CYCLE; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS	Exposure to hyperoxia results in acute lung injury. A pathogenic consequence of hyperoxia is endothelial injury. Macrophage migration inhibitory factor (MIF) has a cytoprotective effect on lung endothelial cells; however, the mechanism is uncertain. We postulate that the MIF receptor CD74 mediates this protective effect. Using adult wild-type (WT), MIF-deficient (Mif(-/-)), CD74-deficient (Cd74(-/-)) mice and MIF receptor inhibitor treated mice, we report that MIF deficiency or inhibition of MIF receptor binding results in increased sensitivity to hyperoxia. Mif(-/-) and Cd74(-/-) mice demonstrated decreased median survival following hyperoxia compared to WT mice. Mif(-/-) mice demonstrated an increase in bronchoalveolar protein (48%) and lactate dehydrogenase (LDH) (68%) following 72 hours of hyperoxia. Similarly, treatment with MIF receptor antagonist resulted in a 59% and 91% increase in bronchoalveolar lavage protein and LDH, respectively. Inhibition of CD74 in primary murine lung endothelial cells (MLECs) abrogated the protective effect of MIF, including decreased hyperoxia-mediated AKT phosphorylation and a 20% reduction in the antiapoptotic effect of exogenous MIF. Treatment with MIF decreased hyperoxia-mediated H2AX phosphorylation in a CD74-dependent manner. These data suggest that therapeutic manipulation of the MIF-CD74 axis in lung endothelial cells may be a novel approach to protect against acute oxidative stress.	[Sauler, Maor; Zhang, Yi; Min, Jin-Na; Shan, Peiying; Lee, Patty J.] Yale Univ, Sch Med, Sect Pulm, Crit Care & Sleep Med, New Haven, CT 06520 USA; [Leng, Lin; Roberts, Scott; Bucala, Richard] Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06520 USA; [Jorgensen, William L.] Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Lee, PJ (corresponding author), Yale Univ, Sch Med, Sect Pulm, Crit Care & Sleep Med, 333 Cedar St,POB 208057, New Haven, CT 06520 USA.	patty.lee@yale.edu	/AAW-1187-2021	Leng, Lin/0000-0002-0605-358X	U.S. National Institutes of Health [T32007778, R01AI043210, R01HL090660, R01HL071595]; FAMRI Clinical Investigator Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090660, R01HL071595] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FAMRI Clinical Investigator Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	These studies were funded by the following grants from the U.S. National Institutes of Health: T32007778 (to M.S.), R01AI043210 (to R.B.), and R01HL090660, R01HL071595, and FAMRI Clinical Investigator Award (to P.J.L.).	Ahmad A, 2006, FREE RADICAL BIO MED, V40, P1108, DOI 10.1016/j.freeradbiomed.2005.10.045; Arjona A, 2007, J CLIN INVEST, V117, P3059, DOI 10.1172/JCI32218; Barzilai A, 2004, DNA REPAIR, V3, P1109, DOI 10.1016/j.dnarep.2004.03.002; Becker-Herman S, 2005, MOL BIOL CELL, V16, P5061, DOI 10.1091/mbc.E05-04-0327; Beswick EJ, 2005, INFECT IMMUN, V73, P2736, DOI 10.1128/IAI.73.5.2736-2743.2005; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; Dai G, 2007, CIRC RES, V101, P723, DOI 10.1161/CIRCRESAHA.107.152942; Damico RL, 2008, AM J RESP CELL MOL, V39, P77, DOI 10.1165/rcmb.2007-0248OC; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; Gonzalez JE, 2012, ANAL QUANT CYTOL, V34, P66; Fallica J, 2014, AM J RESP CELL MOL, V51, P94, DOI 10.1165/rcmb.2013-0371OC; Faure-Andre G, 2008, SCIENCE, V322, P1705, DOI 10.1126/science.1159894; Fingerle-Rowson G, 2003, P NATL ACAD SCI USA, V100, P9354, DOI 10.1073/pnas.1533295100; Fingerle-Rowson G, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-22; FISHER AB, 1980, AM REV RESPIR DIS, V122, P61, DOI 10.1164/arrd.1980.122.5P2.61; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gao L, 2007, TRANSL RES, V150, P18, DOI 10.1016/j.trsl.2007.02.007; Guo Yubiao, 2002, Zhonghua Jiehe He Huxi Zazhi, V25, P337; Hare AA, 2010, BIOORG MED CHEM LETT, V20, P5811, DOI 10.1016/j.bmcl.2010.07.129; Hirakawa H, 2007, AM J RESP CRIT CARE, V176, P778, DOI 10.1164/rccm.200704-519OC; Ivashkevich A, 2012, CANCER LETT, V327, P123, DOI 10.1016/j.canlet.2011.12.025; Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kulkarni A, 2008, AM J PHYSIOL-LUNG C, V294, pL998, DOI 10.1152/ajplung.00004.2008; Lai KN, 2003, J PATHOL, V199, P496, DOI 10.1002/path.1291; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Leng L, 2011, J IMMUNOL, V186, P527, DOI 10.4049/jimmunol.1001767; Lue H, 2007, ONCOGENE, V26, P5046, DOI 10.1038/sj.onc.1210318; Marsh LM, 2009, AM J PHYSIOL-LUNG C, V296, pL442, DOI 10.1152/ajplung.00525.2007; MARTINS EAL, 1991, MUTAT RES, V250, P95, DOI 10.1016/0027-5107(91)90166-L; Mathew B, 2013, AM J RESP CELL MOL, V49, P269, DOI 10.1165/rcmb.2012-0291OC; Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331; Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100; Merk M, 2012, CYTOKINE, V59, P10, DOI 10.1016/j.cyto.2012.03.014; Min JN, 2013, CELL RES, V23, P1396, DOI 10.1038/cr.2013.113; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Montani D, 2014, PHARMACOL THERAPEUT, V141, P172, DOI 10.1016/j.pharmthera.2013.10.002; Nguyen MT, 2003, J IMMUNOL, V170, P3337, DOI 10.4049/jimmunol.170.6.3337; O'Reilly MA, 2001, AM J PHYSIOL-LUNG C, V281, pL291, DOI 10.1152/ajplung.2001.281.2.L291; Paine R, 2012, CRIT CARE MED, V40, P90, DOI 10.1097/CCM.0b013e31822d7bf0; Pasupuleti V, 2014, J BIOL CHEM, V289, P3713, DOI 10.1074/jbc.M113.500694; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PERO RW, 1990, CANCER RES, V50, P4619; Petrenko O, 2005, MOL CELL, V17, P225, DOI 10.1016/j.molcel.2004.11.052; Qi DK, 2014, J CLIN INVEST, V124, P3540, DOI 10.1172/JCI73061; Rabinovitch M, 2014, CIRC RES, V115, P165, DOI 10.1161/CIRCRESAHA.113.301141; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sauler M, 2014, AM J PHYSIOL-LUNG C, V306, pL487, DOI 10.1152/ajplung.00284.2013; Schwartz V, 2012, EUR J CELL BIOL, V91, P435, DOI 10.1016/j.ejcb.2011.08.006; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Sun HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060560; Sun HX, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-27; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Xin D, 2010, MOL CANCER RES, V8, P1601, DOI 10.1158/1541-7786.MCR-10-0101; Zhang XC, 2005, J IMMUNOL, V175, P4834, DOI 10.4049/jimmunol.175.8.4834; Zhang Y, 2014, J IMMUNOL, V192, P5296, DOI 10.4049/jimmunol.1400653; Zhang Y, 2013, FASEB J, V27, P4041, DOI 10.1096/fj.13-231225; Zhang Y, 2013, J IMMUNOL, V191, P1393, DOI 10.4049/jimmunol.1300052	68	24	25	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1940	1949		10.1096/fj.14-260299	http://dx.doi.org/10.1096/fj.14-260299			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25609432	Green Published			2022-12-28	WOS:000354114600028
J	Gawish, R; Martins, R; Bohm, B; Wimberger, T; Sharif, O; Lakovits, K; Schmidt, M; Knapp, S				Gawish, Riem; Martins, Rui; Bohm, Benedikta; Wimberger, Terje; Sharif, Omar; Lakovits, Karin; Schmidt, Mariane; Knapp, Sylvia			Triggering receptor expressed on myeloid cells-2 fine-tunes inflammatory responses in murine Gram-negative sepsis	FASEB JOURNAL			English	Article						peritonitis; inflammation; macrophages; Negative regulator	ESCHERICHIA-COLI PERITONITIS; CUTTING EDGE; OSTEOCLAST DIFFERENTIATION; PNEUMOCOCCAL PNEUMONIA; PATTERN-RECOGNITION; N-GLYCOSYLATION; DENDRITIC CELLS; INNATE IMMUNITY; HOST-DEFENSE; IN-VIVO	During infections, TLR-mediated responses require tight regulation to allow for pathogen removal, while preventing overwhelming inflammation and immunopathology. The triggering receptor expressed on myeloid cells (TREM)-2 negatively regulates inflammation by macrophages and impacts on phagocytosis, but the function of endogenous TREM-2 during infections is poorly understood. We investigated TREM-2's role in regulating TLR4-mediated inflammation by studying wild-type and TREM-2(-/-) mice challenged with LPS and found TREM-2 to dampen early inflammation. Augmented early inflammation in TREM-2(-/-) animals was followed by an accelerated resolution and ultimately improved survival, associated with the induction of the negative regulator A20. Upon infection with Escherichia coli, the otherwise beneficial effect of an exaggerated early immune response in TREM-2(-/-) animals was counteracted by a 50% reduction in bacterial phagocytosis. In line with this, TREM-2(-/-) peritoneal macrophages (PMs) exhibited augmented inflammation following TLR4 stimulation, demonstrating the presence and negative regulatory functionality of TREM-2 on primary PMs. Significantly, we identified a high turnover rate because TREM-2 RNA is 25-fold down-regulated and the protein proteasomally degraded upon LPS encounter, thus ensuring a tightly regulated and versatile system that modulates inflammation. Our results illustrate TREM-2's effects on infection-triggered inflammation and identify TREM-2 as a potential target to prevent overwhelming inflammation while preserving antibacterial-effector functions.	[Gawish, Riem; Martins, Rui; Bohm, Benedikta; Wimberger, Terje; Sharif, Omar; Knapp, Sylvia] Austrian Acad Sci, Ctr Mol Med, Ce M M, A-1010 Vienna, Austria; [Gawish, Riem; Martins, Rui; Bohm, Benedikta; Wimberger, Terje; Sharif, Omar; Lakovits, Karin; Knapp, Sylvia] Med Univ Vienna, Lab Infect Biol, Dept Med 1, A-1090 Vienna, Austria; [Schmidt, Mariane] Tech Univ Denmark, Natl Food Inst, Div Epidemiol & Microbial Gen, DK-2800 Lyngby, Denmark	Austrian Academy of Sciences; Medical University of Vienna; Technical University of Denmark	Knapp, S (corresponding author), Med Univ Vienna, Austrian Acad Sci, Dept Med 1, Lab Infect Biol,Ce M M,Ctr Mol Med, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	sylvia.knapp@meduniwien.ac.at	Knapp, Sylvia/J-3973-2013; Gawish, Riem/AAZ-2302-2020; Martins, Rui/M-9606-2016	Knapp, Sylvia/0000-0001-9016-5244; Gawish, Riem/0000-0003-4267-2131; Martins, Rui/0000-0001-8106-6324; Sharif, Omar/0000-0001-7899-2343	Austrian Science Fund FWF [W1205]; FWF; Medical University of Vienna; European Union [261382]; Austrian Science Fund (FWF) [P 25801] Funding Source: researchfish	Austrian Science Fund FWF(Austrian Science Fund (FWF)); FWF(Austrian Science Fund (FWF)); Medical University of Vienna; European Union(European Commission); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	The authors thank L. Riki Cheever for her valuable comments and intellectual contributions to this paper. This work was funded by the Austrian Science Fund FWF (W1205). R.G. is a member of the Doctoral Program "Cell Communication in Health and Disease" [cofinanced by FWF and the Medical University of Vienna (to S.K.)]. The research leading to these results has received funding from the European Union Seventh Framework Program (FP7/2007-2013) under Grant Agreement 261382 (to M.S.). The authors declare no conflicts of interest.	Anwar MA, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.28; Arts RJW, 2013, J LEUKOCYTE BIOL, V93, P209, DOI 10.1189/jlb.0312145; Arvelo MB, 2002, HEPATOLOGY, V35, P535, DOI 10.1053/jhep.2002.31309; Aziz M, 2013, J LEUKOCYTE BIOL, V93, P329, DOI 10.1189/jlb.0912437; Barrow AD, 2006, EUR J IMMUNOL, V36, P1646, DOI 10.1002/eji.200636195; Bianchin MM, 2004, CELL MOL NEUROBIOL, V24, P1, DOI 10.1023/B:CEMN.0000012721.08168.ee; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Bouchon A, 2001, J EXP MED, V194, P1111, DOI 10.1084/jem.194.8.1111; Bouchon A, 2001, NATURE, V410, P1103, DOI 10.1038/35074114; Broche F, 2001, Curr Opin Crit Care, V7, P105, DOI 10.1097/00075198-200104000-00009; Burckstummer T, 2006, NAT METHODS, V3, P1013, DOI 10.1038/nmeth968; Cella M, 2003, J EXP MED, V198, P645, DOI 10.1084/jem.20022220; Chen LC, 2008, EXP MOL PATHOL, V84, P145, DOI 10.1016/j.yexmp.2007.11.004; Chen QX, 2013, AM J RESP CRIT CARE, V188, P201, DOI 10.1164/rccm.201211-1967OC; Colonna M, 2007, ADV EXP MED BIOL, V602, P97; Coornaert B, 2009, J BIOL CHEM, V284, P8217, DOI 10.1074/jbc.R800032200; Correale C, 2013, GASTROENTEROLOGY, V144, P346, DOI [10.1053/j.gastro.2012.10.040, 10.1053/j.gastro.2012.12.016]; Daws MR, 2003, J IMMUNOL, V171, P594, DOI 10.4049/jimmunol.171.2.594; Ford JW, 2009, CURR OPIN IMMUNOL, V21, P38, DOI 10.1016/j.coi.2009.01.009; Gibot S, 2004, J EXP MED, V200, P1419, DOI 10.1084/jem.20040708; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; HAKOLA HPA, 1970, ACTA NEUROL SCAND, V46, P79; Hamerman JA, 2006, J IMMUNOL, V177, P2051, DOI 10.4049/jimmunol.177.4.2051; Hamerman Jessica A, 2006, Sci STKE, V2006, pre1, DOI 10.1126/stke.3202006re1; Henson PM, 2005, NAT IMMUNOL, V6, P1179, DOI 10.1038/ni1205-1179; Holmes C J, 1996, Perit Dial Int, V16 Suppl 1, pS124; HOLZHEIMER RG, 1991, INFECTION, V19, P447, DOI 10.1007/BF01726463; Hoogerwerf JJ, 2010, AM J RESP CELL MOL, V42, P349, DOI 10.1165/rcmb.2008-0362OC; Hoshino K, 1999, J IMMUNOL, V162, P3749; Ito H, 2012, EUR J IMMUNOL, V42, P176, DOI 10.1002/eji.201141679; Klesney-Tait J, 2006, NAT IMMUNOL, V7, P1266, DOI 10.1038/ni1411; Knapp S, 2004, J IMMUNOL, V173, P7131, DOI 10.4049/jimmunol.173.12.7131; Knapp S, 2003, INFECT IMMUN, V71, P6747, DOI 10.1128/IAI.71.12.6747-6753.2003; Knapp S, 2007, J IMMUNOL, V178, P993, DOI 10.4049/jimmunol.178.2.993; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kondo T, 2012, TRENDS IMMUNOL, V33, P449, DOI 10.1016/j.it.2012.05.002; Lagler H, 2009, J IMMUNOL, V183, P2027, DOI 10.4049/jimmunol.0803862; Lanier LL, 2009, IMMUNOL REV, V227, P150, DOI 10.1111/j.1600-065X.2008.00720.x; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Matt U, 2013, J CLIN INVEST, V123, P3014, DOI 10.1172/JCI60681; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; N'Diaye EN, 2009, J CELL BIOL, V184, P215, DOI 10.1083/jcb.200808080; NASU T, 1973, ACTA PATHOL JAPON, V23, P539; Paloneva J, 2003, J EXP MED, V198, P669, DOI 10.1084/jem.20030027; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7644, DOI 10.1021/bi00445a021; Park-Min KH, 2009, J IMMUNOL, V183, P2444, DOI 10.4049/jimmunol.0804165; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Peng QS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003801; Peng QS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000500; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Russell JA, 2006, NEW ENGL J MED, V355, P1699, DOI 10.1056/NEJMra043632; Sharif O, 2008, IMMUNOBIOLOGY, V213, P701, DOI 10.1016/j.imbio.2008.07.008; Sharif O, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004167; Sharif O, 2013, J IMMUNOL, V190, P5640, DOI 10.4049/jimmunol.1202270; Sun MX, 2013, INVEST OPHTH VIS SCI, V54, P3451, DOI 10.1167/iovs.12-10938; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520; van Westerloo DJ, 2005, CRIT CARE MED, V33, P1036, DOI 10.1097/01.CCM.0000162684.11375.85; van 't Veer C, 2011, J BIOL CHEM, V286, P36603, DOI 10.1074/jbc.M110.189126; Vereecke L, 2009, TRENDS IMMUNOL, V30, P383, DOI 10.1016/j.it.2009.05.007; Wunderlich P, 2013, J BIOL CHEM, V288, P33027, DOI 10.1074/jbc.M113.517540; Zeck A, 2011, J PROTEOME RES, V10, P3031, DOI 10.1021/pr1012653; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83	64	41	52	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1247	1257		10.1096/fj.14-260067	http://dx.doi.org/10.1096/fj.14-260067			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25477281	Green Accepted			2022-12-28	WOS:000354115000013
J	Pasiakos, SM; Margolis, LM; Orr, JS				Pasiakos, Stefan M.; Margolis, Lee M.; Orr, Jeb S.			Optimized dietary strategies to protect skeletal muscle mass during periods of unavoidable energy deficit	FASEB JOURNAL			English	Review						leucine; military; mTORC1; lean body mass	ESSENTIAL AMINO-ACID; GROWTH-FACTOR-I; FAT-FREE MASS; WEIGHT-LOSS; BODY-COMPOSITION; ANABOLIC RESPONSE; YOUNG MEN; PHYSICAL PERFORMANCE; RESISTANCE EXERCISE; HEALTHY OLDER	Interactions between dietary protein and energy balance on the regulation of human skeletal muscle protein turnover are not well described. A dietary protein intake above the recommended dietary allowance during energy balance typically enhances nitrogen retention and up-regulates muscle protein synthesis, which in turn may promote positive protein balance and skeletal muscle accretion. Recent studies show that during energy deficit, muscle protein synthesis is down-regulated with concomitant increases in ubiquitin proteasome-mediated muscle proteolysis and nitrogen excretion, reflecting the loss of skeletal muscle mass. However, consuming high-protein diets (1.6-2.4 g/kg per day), or high-quality, protein-based meals (15-30 g whey) during energy deficit attenuates intracellular proteolysis, restores muscle protein synthesis, and mitigates skeletal muscle loss. These findings are particularly important for physically active, normal-weight individuals because attenuating the extent to which skeletal muscle mass is lost during energy deficit could prevent decrements in performance, reduce injury risk, and facilitate recovery. This article reviews the relationship between energy status, protein intake, and muscle protein turnover, and explores future research directives designed to protect skeletal muscle mass in physically active, normal-weight adults.	[Pasiakos, Stefan M.; Margolis, Lee M.; Orr, Jeb S.] US Army, Environm Med Res Inst, Mil Nutr Div, Natick, MA 01760 USA		Pasiakos, SM (corresponding author), US Army, Environm Med Res Inst, 15 Kansas St,Bldg 42, Natick, MA 01760 USA.	stefan.pasiakos@usarmy.mil	Pasiakos, Stefan M/E-6295-2014	Pasiakos, Stefan M/0000-0002-5378-5820; , Lee/0000-0002-0652-1304; Margolis, Lee/0000-0003-1697-825X	U.S. Army Medical Research and Material Command	U.S. Army Medical Research and Material Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC))	The authors thank Dr. Scott J. Montain for his support in the development of this article. This work was supported by the U.S. Army Medical Research and Material Command. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Army or the U.S. Department of Defense. Any citations of commercial organizations and trade names in this report do not constitute an official U.S. Department of the Army endorsement of approval of the products or services of these organizations.	Alemany JA, 2008, J APPL PHYSIOL, V105, P58, DOI 10.1152/japplphysiol.00005.2008; Areta JL, 2014, AM J PHYSIOL-ENDOC M, V306, pE989, DOI 10.1152/ajpendo.00590.2013; Artioli GG, 2010, MED SCI SPORT EXER, V42, P436, DOI 10.1249/MSS.0b013e3181ba8055; Atherton PJ, 2010, AM J CLIN NUTR, V92, P1080, DOI 10.3945/ajcn.2010.29819; Bechet D, 2005, J RENAL NUTR, V15, P18, DOI 10.1053/j.jrn.2004.09.005; Bhasin S, 2001, AM J PHYSIOL-ENDOC M, V281, pE1172, DOI 10.1152/ajpendo.2001.281.6.E1172; Biolo G, 1997, AM J PHYSIOL-ENDOC M, V273, pE122, DOI 10.1152/ajpendo.1997.273.1.E122; BIOLO G, 1995, J CLIN INVEST, V95, P811, DOI 10.1172/JCI117731; Biolo G, 1999, DIABETES, V48, P949, DOI 10.2337/diabetes.48.5.949; Bohe J, 2003, J PHYSIOL-LONDON, V552, P315, DOI 10.1113/jphysiol.2003.050674; Bohe J, 2001, J PHYSIOL-LONDON, V532, P575, DOI 10.1111/j.1469-7793.2001.0575f.x; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Bouchard C, 2014, INT J OBESITY, V38, P236, DOI 10.1038/ijo.2013.77; Bray GA, 2012, JAMA-J AM MED ASSOC, V307, P47, DOI 10.1001/jama.2011.1918; Campbell WW, 2009, OBESITY, V17, P1332, DOI 10.1038/oby.2009.2; Carbone JW, 2014, APPL PHYSIOL NUTR ME, V39, P960, DOI 10.1139/apnm-2013-0433; Carbone JW, 2013, FASEB J, V27, P5104, DOI 10.1096/fj.13-239228; Carbone JW, 2012, ADV NUTR, V3, P119, DOI 10.3945/an.111.001792; Christensen PA, 2008, MIL MED, V173, P889, DOI 10.7205/MILMED.173.9.889; Churchward-Venne TA, 2014, AM J CLIN NUTR, V99, P276, DOI 10.3945/ajcn.113.068775; Churchward-Venne TA, 2012, J PHYSIOL-LONDON, V590, P2751, DOI 10.1113/jphysiol.2012.228833; CLEMMONS DR, 1992, J CLIN ENDOCR METAB, V75, P234, DOI 10.1210/jc.75.1.234; Cuthbertson D, 2004, FASEB J, V18, P422, DOI 10.1096/fj.04-2640fje; Dickinson JM, 2011, CURR OPIN CLIN NUTR, V14, P83, DOI 10.1097/MCO.0b013e3283406f3e; Drummond MJ, 2010, AM J PHYSIOL-ENDOC M, V298, pE1011, DOI 10.1152/ajpendo.00690.2009; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Evans WJ, 2010, AM J CLIN NUTR, V91, p1123S, DOI 10.3945/ajcn.2010.28608A; Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013; FELIG P, 1969, J CLIN INVEST, V48, P584, DOI 10.1172/JCI106017; Felig P, 1969, Adv Enzyme Regul, V7, P41, DOI 10.1016/0065-2571(69)90008-9; Ferrando AA, 2013, J NUTR, V143, P1852; Finkelstein JS, 2013, NEW ENGL J MED, V369, P1011, DOI 10.1056/NEJMoa1206168; FLOYD JC, 1970, DIABETES, V19, P109, DOI 10.2337/diab.19.2.109; FRIEDL KE, 1994, J APPL PHYSIOL, V77, P933, DOI 10.1152/jappl.1994.77.2.933; Friedl KE, 2000, J APPL PHYSIOL, V88, P1820, DOI 10.1152/jappl.2000.88.5.1820; Ghosh S, 2013, J APPL PHYSIOL, V115, P1343, DOI 10.1152/japplphysiol.01487.2012; Glynn EL, 2013, J NUTR, V143, P307, DOI 10.3945/jn.112.168203; Glynn EL, 2010, J NUTR, V140, P1970, DOI 10.3945/jn.110.127647; Glynn EL, 2010, AM J PHYSIOL-REG I, V299, pR533, DOI 10.1152/ajpregu.00077.2010; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gomez-Merino D, 2005, NEUROIMMUNOMODULAT, V12, P164, DOI 10.1159/000084849; Gulati P, 2008, CELL METAB, V7, P456, DOI 10.1016/j.cmet.2008.03.002; Han JM, 2012, CELL, V149, P410, DOI 10.1016/j.cell.2012.02.044; Henning PC, 2014, J CLIN ENDOCR METAB, V99, P956, DOI 10.1210/jc.2013-3046; HOFFER LJ, 1990, AM J PHYSIOL, V258, pE832, DOI 10.1152/ajpendo.1990.258.5.E832; Holm L, 2010, CURR OPIN CLIN NUTR, V13, P526, DOI 10.1097/MCO.0b013e32833c3c64; Hoyt RW, 2006, AM J CLIN NUTR, V83, P1068, DOI 10.1093/ajcn/83.5.1068; JOHNSON MJ, 1994, MED SCI SPORT EXER, V26, P235, DOI 10.1249/00005768-199402000-00015; Kandarian SC, 2006, MUSCLE NERVE, V33, P155, DOI 10.1002/mus.20442; Katsanos CS, 2006, AM J PHYSIOL-ENDOC M, V291, pE381, DOI 10.1152/ajpendo.00488.2005; Keller P, 2011, J APPL PHYSIOL, V110, P46, DOI 10.1152/japplphysiol.00634.2010; KEYS A, 1946, Bull Chic Med Soc, V49, P42; KEYS A, 1946, FED PROC, V5, P55; Keys Ancel, 1946, JOUR AMER DIETETIC ASSOC, V22, P582; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; KNAPIK J, 1991, J APPL PHYSIOL, V70, P43, DOI 10.1152/jappl.1991.70.1.43; KUPFER SR, 1993, J CLIN INVEST, V91, P391, DOI 10.1172/JCI116212; Kvorning T, 2006, AM J PHYSIOL-ENDOC M, V291, pE1325, DOI 10.1152/ajpendo.00143.2006; Levenhagen DK, 2001, AM J PHYSIOL-ENDOC M, V280, pE982, DOI 10.1152/ajpendo.2001.280.6.E982; Luiking YC, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-9; Mamerow MM, 2014, J NUTR, V144, P876, DOI 10.3945/jn.113.185280; Margolis LM, 2014, APPL PHYSIOL NUTR ME, V39, P1395, DOI 10.1139/apnm-2014-0212; Margolis LM, 2013, APPL PHYSIOL NUTR ME, V38, P396, DOI 10.1139/apnm-2012-0323; Mauras N, 1998, J CLIN ENDOCR METAB, V83, P1886, DOI 10.1210/jc.83.6.1886; Mettler S, 2010, MED SCI SPORT EXER, V42, P326, DOI 10.1249/MSS.0b013e3181b2ef8e; Moore DR, 2015, J GERONTOL A-BIOL, V70, P57, DOI 10.1093/gerona/glu103; Moore DR, 2009, AM J CLIN NUTR, V89, P161, DOI 10.3945/ajcn.2008.26401; Murphy MG, 1998, J CLIN ENDOCR METAB, V83, P320, DOI 10.1210/jc.83.2.320; National Academy of Science Institute of Medicine, 2005, DIET REF INT EN CARB; Nindl BC, 2006, J APPL PHYSIOL, V100, P120, DOI 10.1152/japplphysiol.01415.2004; Nindl BC, 1997, INT J SPORTS MED, V18, P317, DOI 10.1055/s-2007-972640; Nindl BC, 2002, MED SCI SPORT EXER, V34, P1814, DOI 10.1097/00005768-200211000-00019; Nindl BC, 2007, MED SCI SPORT EXER, V39, P1380, DOI 10.1249/mss.0b013e318067e2f7; Nindl BC, 2007, J APPL PHYSIOL, V103, P340, DOI 10.1152/japplphysiol.01321.2006; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Norton LE, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-67; Ochner CN, 2013, PHYSIOL BEHAV, V120, P106, DOI 10.1016/j.physbeh.2013.07.009; OPSTAD PK, 1992, ACTA ENDOCRINOL-COP, V127, P231, DOI 10.1530/acta.0.1270231; Paddon-Jones D, 2009, CURR OPIN CLIN NUTR, V12, P86, DOI 10.1097/MCO.0b013e32831cef8b; Pasiakos SM, 2014, INT J OBESITY, V38, P1015, DOI 10.1038/ijo.2013.197; Pasiakos SM, 2014, IUBMB LIFE, V66, P478, DOI 10.1002/iub.1291; Pasiakos SM, 2013, J NUTR, V143, P1811, DOI 10.3945/jn.113.176859; Pasiakos SM, 2013, FASEB J, V27, P3837, DOI 10.1096/fj.13-230227; Pasiakos SM, 2012, NUTRIENTS, V4, P740, DOI 10.3390/nu4070740; Pasiakos SM, 2011, NUTR REV, V69, P550, DOI 10.1111/j.1753-4887.2011.00420.x; Pasiakos SM, 2011, AM J CLIN NUTR, V94, P809, DOI 10.3945/ajcn.111.017061; Pasiakos SM, 2010, J NUTR, V140, P745, DOI 10.3945/jn.109.118372; Phillips BE, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003389; Phillips SM, 2009, J APPL PHYSIOL, V107, P645, DOI 10.1152/japplphysiol.00452.2009; Phillips SM, 2004, NUTRITION, V20, P689, DOI 10.1016/j.nut.2004.04.009; Phillips SM, 2006, APPL PHYSIOL NUTR ME, V31, P647, DOI 10.1139/h06-035; Pritchard J, 1999, METABOLISM, V48, P1120, DOI 10.1016/S0026-0495(99)90125-7; Proud CG, 2007, BIOCHEM SOC T, V35, P1187, DOI 10.1042/BST0351187; Proud CG, 2007, SCIENCE, V318, P926, DOI 10.1126/science.1150653; RABEN A, 1995, INT J OBESITY, V19, P916; Rasmussen BB, 2003, EXERC SPORT SCI REV, V31, P127, DOI 10.1097/00003677-200307000-00005; Rodriguez NR, 2014, J NUTR, V144, P797, DOI 10.3945/jn.114.193615; Rodriguez NR, 2009, MED SCI SPORT EXER, V41, P709, DOI 10.1249/MSS.0b013e31890eb86; Rowlands DS, 2015, MED SCI SPORT EXER, V47, P547, DOI 10.1249/MSS.0000000000000447; Sandri M, 2013, INT J BIOCHEM CELL B, V45, P2121, DOI 10.1016/j.biocel.2013.04.023; STEIN TP, 1991, METABOLISM, V40, P478, DOI 10.1016/0026-0495(91)90228-O; Stock MJ, 1999, INT J OBESITY, V23, P1105, DOI 10.1038/sj.ijo.0801108; Thorlund JB, 2011, SCAND J MED SCI SPOR, V21, pE56, DOI 10.1111/j.1600-0838.2010.01149.x; Timmons JA, 2011, J APPL PHYSIOL, V110, P846, DOI 10.1152/japplphysiol.00934.2010; Timmons JA, 2010, J APPL PHYSIOL, V108, P1487, DOI 10.1152/japplphysiol.01295.2009; Tipton KD, 2003, AM J PHYSIOL-ENDOC M, V284, pE76, DOI 10.1152/ajpendo.00234.2002; Tipton KD, 2001, AM J PHYSIOL-ENDOC M, V281, pE197, DOI 10.1152/ajpendo.2001.281.2.E197; Varady KA, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-146; Villareal DT, 2012, OBESITY, V20, P1780, DOI 10.1038/oby.2011.280; Walker DK, 2011, MED SCI SPORT EXER, V43, P2249, DOI 10.1249/MSS.0b013e318223b037; Welsh TT, 2008, INT J SPORTS MED, V29, P45, DOI 10.1055/s-2007-964970; Westerterp-Plantenga MS, 2009, ANNU REV NUTR, V29, P21, DOI 10.1146/annurev-nutr-080508-141056; Witard OC, 2014, AM J CLIN NUTR, V99, P86, DOI 10.3945/ajcn.112.055517; Wolfe RR, 2002, J NUTR, V132, p3219S, DOI 10.1093/jn/131.10.3219S; Wolfe RR, 1999, DIABETES NUTR METAB, V12, P322; Wycherley TP, 2012, NUTR DIABETES, V2, DOI 10.1038/nutd.2012.11; Wycherley TP, 2012, AM J CLIN NUTR, V96, P1281, DOI 10.3945/ajcn.112.044321; Xia XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077823; YANG RD, 1986, AM J PHYSIOL, V250, pE39, DOI 10.1152/ajpendo.1986.250.1.E39	119	35	35	4	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1136	1142		10.1096/fj.14-266890	http://dx.doi.org/10.1096/fj.14-266890			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550460				2022-12-28	WOS:000354115000003
J	Salminen, A; Astrom, P; Metso, J; Soliymani, R; Salo, T; Jauhiainen, M; Pussinen, PJ; Sorsa, T				Salminen, Aino; Astrom, Pirjo; Metso, Jari; Soliymani, Rabah; Salo, Tuula; Jauhiainen, Matti; Pussinen, Pirkko J.; Sorsa, Timo			Matrix metalloproteinase 8 degrades apolipoprotein A-I and reduces its cholesterol efflux capacity	FASEB JOURNAL			English	Article						atherosclerosis; cholesterol metabolism; high-density lipoprotein; proteolytic enzyme	HIGH-DENSITY-LIPOPROTEIN; GINGIVAL CREVICULAR FLUID; C-TERMINAL DOMAIN; DOSE DOXYCYCLINE; LIPID EFFLUX; SERUM; BINDING; SUSCEPTIBILITY; COLLAGENASE; INHIBITION	Various cell types in atherosclerotic lesions express matrix metalloproteinase (MMP)-8. We investigated whether MMP-8 affects the structure and antiatherogenic function of apolipoprotein (apo) A-I, the main protein component of HDL particles. Furthermore, we studied serum lipid profiles and cholesterol efflux capacity in MMP-8-deficient mouse model. Incubation of apoA-I (28 kDa) with activated MMP-8 yielded 22 kDa and 25 kDa apoA-I fragments. Mass spectrometric analyses revealed that apoA-I was cleaved at its carboxyl-terminal part. Treatment of apoA-I and HDL with MMP-8 resulted in significant reduction (up to 84%, P < 0.001) in their ability to facilitate cholesterol efflux from cholesterol-loaded THP-1 macrophages. The cleavage of apoA-I by MMP- 8 and the reduction in its cholesterol efflux capacity was inhibited by doxycycline. MMP-8-deficient mice had significantly lower serum triglyceride (TG) levels (P = 0.003) and larger HDL particles compared with wild-type (WT) mice. However, no differences were observed in the apoA-I levels or serum cholesterol efflux capacities between the mouse groups. Proteolytic modification of apoA-I by MMP- 8 may impair the first steps of reverse cholesterol transport, leading to increased accumulation of cholesterol in the vessel walls. Eventually, inhibition of MMPs by doxycycline may reduce the risk for atherosclerotic vascular diseases.	[Salminen, Aino; Pussinen, Pirkko J.; Sorsa, Timo] Univ Helsinki, Inst Dent, FIN-00014 Helsinki, Finland; [Salminen, Aino; Sorsa, Timo] Helsinki Univ Cent Hosp, Dept Oral & Maxillofacial Dis, Helsinki, Finland; [Astrom, Pirjo; Salo, Tuula] Univ Oulu, Oulu Univ Hosp, Inst Dent, Dept Diagnost & Oral Med, Oulu, Finland; [Astrom, Pirjo; Salo, Tuula] Univ Oulu, Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland; [Metso, Jari; Jauhiainen, Matti] Biomedicum, Publ Hlth Genom Unit, Natl Inst Hlth & Welf, Helsinki, Finland; [Soliymani, Rabah] Univ Helsinki, Biomedicum Helsinki, Dept Biochem & Dev Biol, Meilahti Clin Prote Core Unit,Inst Biomed, FIN-00014 Helsinki, Finland; [Sorsa, Timo] Karolinska Inst, Dept Dent Med, Div Periodontol, Huddinge, Sweden	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Oulu; University of Oulu; Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki; Karolinska Institutet	Salminen, A (corresponding author), Univ Helsinki, POB 63, FIN-00014 Helsinki, Finland.	aino.m.salminen@helsinki.fi	, tuula/ABG-2051-2021	Pussinen, Pirkko/0000-0003-3563-1876; Astrom, Pirjo/0000-0001-7150-2508; Salminen, Aino/0000-0001-7576-090X; Salo, Tuula/0000-0001-6039-0088; Soliymani, Rabah/0000-0003-0184-3352	Academy of Finland [1266053]; Helsinki University Central Hospital Research Foundation; Finnish Dental Society Apollonia; Sigrid Juselius Foundation	Academy of Finland(Academy of Finland); Helsinki University Central Hospital Research Foundation; Finnish Dental Society Apollonia; Sigrid Juselius Foundation(Sigrid Juselius Foundation)	The authors thank Ms. Sanna Juntunen for technical assistance, and Prof. Carlos Lopez-Otin for providing the MMP8-/- mice. This work was supported by the Academy of Finland (1266053), the Helsinki University Central Hospital Research Foundation, the Finnish Dental Society Apollonia, and the Sigrid Juselius Foundation.	Axisa B, 2002, STROKE, V33, P2858, DOI 10.1161/01.STR.0000038098.04291.F6; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Bench TJ, 2011, PHARMACOL RES, V64, P561, DOI 10.1016/j.phrs.2011.05.002; Bendeck MP, 2002, AM J PATHOL, V160, P1089, DOI 10.1016/S0002-9440(10)64929-2; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; BURSTEIN M, 1970, J LIPID RES, V11, P583; CHEN CH, 1982, J LIPID RES, V23, P680; Chroni A, 2003, J BIOL CHEM, V278, P6719, DOI 10.1074/jbc.M205232200; Favari E, 2002, BIOCHEM BIOPH RES CO, V299, P801, DOI 10.1016/S0006-291X(02)02745-6; FIELDING CJ, 1995, J LIPID RES, V36, P211; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Golub L M, 1998, Adv Dent Res, V12, P12; Golub LM, 2008, J PERIODONTOL, V79, P1409, DOI [10.1902/jop.2008.070623, 10.1902/jop.2008.070623 ]; Halade GV, 2013, PHARMACOL THERAPEUT, V139, P32, DOI 10.1016/j.pharmthera.2013.03.009; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Herman MP, 2001, CIRCULATION, V104, P1899, DOI 10.1161/hc4101.097419; Jauhiainen M, 2005, METHODS, V36, P97, DOI 10.1016/j.ymeth.2004.11.006; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; Khokha R, 2013, NAT REV IMMUNOL, V13, P649, DOI 10.1038/nri3499; Kleemola P, 2002, ATHEROSCLEROSIS, V160, P425, DOI 10.1016/S0021-9150(01)00594-9; KNAUPER V, 1991, FEBS LETT, V290, P99, DOI 10.1016/0014-5793(91)81235-Z; Kormi I, 2014, INFLAMM RES, V63, P329, DOI 10.1007/s00011-013-0704-2; KUNITAKE ST, 1990, ARTERIOSCLEROSIS, V10, P25, DOI 10.1161/01.ATV.10.1.25; Laxton RC, 2009, CIRC RES, V105, P921, DOI 10.1161/CIRCRESAHA.109.200279; Lindstedt L, 1999, J BIOL CHEM, V274, P22627, DOI 10.1074/jbc.274.32.22627; Madan M, 2007, ATHEROSCLEROSIS, V190, P62, DOI 10.1016/j.atherosclerosis.2006.02.026; MATZ CE, 1982, J BIOL CHEM, V257, P4535; Natarajan P, 2004, J BIOL CHEM, V279, P24044, DOI 10.1074/jbc.M400561200; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Park JH, 2011, BIOCHEM BIOPH RES CO, V409, P58, DOI 10.1016/j.bbrc.2011.04.105; Prall AK, 2002, J VASC SURG, V35, P923, DOI 10.1067/mva.2002.123757; Rader DJ, 2006, J CLIN INVEST, V116, P3090, DOI 10.1172/JCI30163; Salminen A, 2013, INFLAMM RES, V62, P711, DOI 10.1007/s00011-013-0626-z; SAMMALKORPI K, 1988, METABOLISM, V37, P859, DOI 10.1016/0026-0495(88)90120-5; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; Siggins S, 2003, J LIPID RES, V44, P1698, DOI 10.1194/jlr.M300059-JLR200; SUOMALAINEN K, 1992, DRUG EXP CLIN RES, V18, P99; Tuter G, 2007, J CLIN PERIODONTOL, V34, P673, DOI 10.1111/j.1600-051X.2007.01104.x; Tuomainen AM, 2007, ARTERIOSCL THROM VAS, V27, P2722, DOI 10.1161/ATVBAHA.107.154831; Tuomainen AM, 2014, EUR J PREV CARDIOL, V21, P806, DOI 10.1177/2047487312465524; Turu MM, 2006, ATHEROSCLEROSIS, V187, P161, DOI 10.1016/j.atherosclerosis.2005.08.039; Turunen SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034910; Van den Steen PE, 2003, BIOCHEM BIOPH RES CO, V310, P889, DOI 10.1016/j.bbrc.2003.09.098; Van Lint P, 2006, CYTOKINE GROWTH F R, V17, P217, DOI 10.1016/j.cytogfr.2006.04.001	46	14	14	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1435	1445		10.1096/fj.14-262956	http://dx.doi.org/10.1096/fj.14-262956			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550459				2022-12-28	WOS:000354115000029
J	Sim, CB; Ziemann, M; Kaspi, A; Harikrishnan, KN; Ooi, J; Khurana, I; Chang, L; Hudson, JE; El-Osta, A; Porrello, ER				Sim, Choon Boon; Ziemann, Mark; Kaspi, Antony; Harikrishnan, K. N.; Ooi, Jenny; Khurana, Ishant; Chang, Lisa; Hudson, James E.; El-Osta, Assam; Porrello, Enzo R.			Dynamic changes in the cardiac methylome during postnatal development	FASEB JOURNAL			English	Article						DNA methylation; cardiomyocyte proliferation; binucleation; neonatal heart; epigenetics	DNA METHYLATION; TGF-BETA; EPIGENETIC REGULATION; EXPRESSION; HEART; DEMETHYLATION; MECHANISMS; ENRICHMENT; ARREST; DAMAGE	Relatively little is known about the epigenetic control mechanisms that guide postnatal organ maturation. The goal of this study was to determine whether DNA methylation plays an important role in guiding transcriptional changes during the first 2 wk of mouse heart development, which is an important period for cardiomyocyte maturation, loss of proliferative capacity and loss of regenerative potential. Gene expression profiling (RNA-seq) and genome-wide sequencing of methylated DNA (MBD-seq) identified dynamic changes in the cardiac methylome during postnatal development [2545 differentially methylated regions (DMRs) from P1 to P14 in the mouse]. The vast majority (similar to 80%) of DMRs were hypermethylated between P1 and P14, and these hypermethylated regions were associated with transcriptional shut down of important developmental signaling pathways, including Hedgehog, bone morphogenetic protein, TGF-beta, fibroblast growth factor, and Wnt/beta-catenin signaling. Postnatal inhibition of DNA methylation with 5-aza-2'-deoxycytidine induced a marked increase (similar to 3-fold) in cardiomyocyte proliferation and similar to 50% reduction in the percentage of binucleated cardiomyocytes compared with saline-treated controls. This study provides novel evidence for widespread alterations in DNA methylation during postnatal heart maturation and suggests that cardiomyocyte cell cycle arrest during the neonatal period is subject to regulation by DNA methylation.	[Sim, Choon Boon; Hudson, James E.; Porrello, Enzo R.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia; [Ziemann, Mark; Kaspi, Antony; Harikrishnan, K. N.; Ooi, Jenny; Khurana, Ishant; Chang, Lisa; El-Osta, Assam] Baker IDI Heart & Diabet Inst, Epigenet Human Hlth & Dis Lab, Melbourne, Vic 3004, Australia	University of Queensland; Baker Heart and Diabetes Institute	El-Osta, A (corresponding author), Baker IDI Heart & Diabet Inst, Epigenet Human Hlth & Dis Lab, Melbourne, Vic 3004, Australia.	assam.el-osta@bakeridi.edu.au; e.porrello@uq.edu.au	Hudson, James/AAE-1605-2019; Hudson, James E/O-1775-2013; Ziemann, Mark Daniel/AAE-8466-2019	Hudson, James E/0000-0003-0832-9356; Ooi, Jenny/0000-0002-4800-6124; Khurana, Ishant/0000-0001-9050-2749; El-Osta, Assam/0000-0003-2969-9137; Kaipananickal, Harikrishnan/0000-0002-4662-659X; Kaspi, Antony/0000-0001-6576-5862; El-Osta, Assam/0000-0001-7968-7375; Ziemann, Mark/0000-0002-7688-6974; Porrello, Enzo/0000-0001-6105-7463	Australian Research Council (ARC) Linkage Infrastructure, Equipment and Facilities Funding (LIEF) [LE120100071]; Victorian Government's Operational Infrastructure Support program; National Health and Medical Research Council (Australia); National Heart Foundation of Australia; University of Queensland (UQ) postdoctoral fellowship; UQ International (UQI) PhD scholarship	Australian Research Council (ARC) Linkage Infrastructure, Equipment and Facilities Funding (LIEF)(Australian Research Council); Victorian Government's Operational Infrastructure Support program; National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia); National Heart Foundation of Australia(National Heart Foundation of Australia); University of Queensland (UQ) postdoctoral fellowship(University of Queensland); UQ International (UQI) PhD scholarship	The authors thank Prof. Eric Olson (University of Texas Southwestern Medical Center) for provision of tissue samples and for helpful discussions on the manuscript. The authors thank Ms. Sindhu Igoor (University of Queensland) for technical assistance with animal studies and Mr. Gregory Quaife-Ryan (University of Queensland) for advice on bioinformatics analysis methods. The authors also acknowledge Queensland Facility for Advanced Bioinformatics (QFAB) Bioinformatics and funding provided by Australian Research Council (ARC) Linkage Infrastructure, Equipment and Facilities Funding (LIEF) LE120100071 for providing access to the MetaCore program, as well as support, in part, by the Victorian Government's Operational Infrastructure Support program. E.R.P., A.E.-O., and J.E.H. are supported by fellowships and grants from the National Health and Medical Research Council (Australia) and the National Heart Foundation of Australia. E.R.P. is also supported by a University of Queensland (UQ) postdoctoral fellowship. C.B.S. is supported by a UQ International (UQI) PhD scholarship.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Beyer TA, 2013, CELL REP, V5, P1611, DOI 10.1016/j.celrep.2013.11.021; Cerda S, 1997, MUTAT RES-REV MUTAT, V386, P141, DOI 10.1016/S1383-5742(96)00050-6; Chamberlain AA, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000976; Chang CP, 2012, ANNU REV PHYSIOL, V74, P41, DOI 10.1146/annurev-physiol-020911-153242; Choi WY, 2013, DEVELOPMENT, V140, P660, DOI 10.1242/dev.088526; Felician G, 2014, CIRC RES, V115, P636, DOI 10.1161/CIRCRESAHA.115.304517; Haas J, 2013, EMBO MOL MED, V5, P413, DOI 10.1002/emmm.201201553; Hervouet E, 2009, EPIGENETICS-US, V4, P487, DOI 10.4161/epi.4.7.9883; Issa JP, 2014, J CLIN INVEST, V124, P24, DOI 10.1172/JCI69735; James SJ, 2003, J NUTR, V133, p3740S, DOI 10.1093/jn/133.11.3740S; Jjingo D, 2012, ONCOTARGET, V3, P462, DOI 10.18632/oncotarget.497; Kou CYC, 2010, BIOCHEM BIOPH RES CO, V400, P278, DOI 10.1016/j.bbrc.2010.08.064; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Movassagh M, 2011, CIRCULATION, V124, P2411, DOI 10.1161/CIRCULATIONAHA.111.040071; Niehrs C, 2012, TRENDS CELL BIOL, V22, P220, DOI 10.1016/j.tcb.2012.01.002; Paradis A, 2014, INT J MED SCI, V11, P373, DOI 10.7150/ijms.7802; Pirola L, 2011, GENOME RES, V21, P1601, DOI 10.1101/gr.116095.110; Porrello ER, 2014, STEM CELL RES, V13, P556, DOI 10.1016/j.scr.2014.06.003; Porrello ER, 2013, P NATL ACAD SCI USA, V110, P187, DOI 10.1073/pnas.1208863110; Porrello ER, 2011, CIRC RES, V109, P670, DOI 10.1161/CIRCRESAHA.111.248880; Porrello ER, 2011, SCIENCE, V331, P1078, DOI 10.1126/science.1200708; Porrello ER, 2009, HYPERTENSION, V53, P1032, DOI 10.1161/HYPERTENSIONAHA.108.128488; Puente BN, 2014, CELL, V157, P565, DOI 10.1016/j.cell.2014.03.032; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; R Development Core Team, 2009, R LANG ENV STAT COMP; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rohde C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-230; Sdek P, 2011, J CELL BIOL, V194, P407, DOI 10.1083/jcb.201012049; Stevens M, 2013, GENOME RES, V23, P1541, DOI 10.1101/gr.152231.112; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027; Wamstad JA, 2012, CELL, V151, P206, DOI 10.1016/j.cell.2012.07.035; Watson CJ, 2014, HUM MOL GENET, V23, P2176, DOI 10.1093/hmg/ddt614; Wu H, 2014, CELL, V156, P45, DOI 10.1016/j.cell.2013.12.019; Wu J, 2013, NUCLEIC ACIDS RES, V41, P5149, DOI 10.1093/nar/gkt216; Xiao DL, 2014, CARDIOVASC RES, V101, P373, DOI 10.1093/cvr/cvt264; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	41	47	50	2	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1329	1343		10.1096/fj.14-264093	http://dx.doi.org/10.1096/fj.14-264093			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25491312				2022-12-28	WOS:000354115000020
J	Bellner, L; Marrazzo, G; van Rooijen, N; Dunn, MW; Abraham, NG; Schwartzman, ML				Bellner, Lars; Marrazzo, Giuseppina; van Rooijen, Nico; Dunn, Michael W.; Abraham, Nader G.; Schwartzman, Michal L.			Heme oxygenase-2 deletion impairs macrophage function: implication in wound healing	FASEB JOURNAL			English	Article						inflammation; bone marrow transfer; clodronate liposomes	CORNEAL NEOVASCULARIZATION; INFLAMMATION; MICE; ACTIVATION; RESOLUTION; REPAIR; INTERLEUKIN-10; MECHANISMS; DEPLETION; SYSTEM	Heme oxygenase (HO)-2 deficiency impairs wound healing and exacerbates inflammation following injury. We examine the impact of HO-2 deficiency on macrophage function and the contribution of macrophage HO-2 to inflammatory and repair responses to injury. Corneal epithelial debridement was performed in control and macrophage-depleted HO-2(-/-) and wild-type (WT) mice and in bone marrow chimeras. Peritoneal macrophages were collected for determination of phagocytic activity and classically activated macrophage (M1)-alternatively activated macrophage (M2) polarization. Depletion of macrophages delayed corneal healing (13.2%) and increased neutrophil infiltration (54.1%) by day 4 in WT mice, whereas in HO-2(-/-) mice, it did not worsen the already impaired wound healing and exacerbated inflammation. HO-2(-/-) macrophages displayed an altered M1 phenotype with no significant expression of M2 or M2-like activated cells and a 31.3% reduction in phagocytic capacity that was restored by inducing HO-1 activity or supplementing biliverdin. Macrophage depletion had no effect, whereas adoptive transfer of WT bone marrow improved wound healing (34% on day 4) but did not resolve the exaggerated inflammatory response in HO-2(-/-) mice. These findings indicate that HO-2-deficient macrophages are dysfunctional and that macrophage HO-2 is required for proper macrophage function but is insufficient to correct the impaired healing of the HO-2(-/-) cornea, suggesting that corneal epithelial expression of HO-2 is a key to resolution and repair in wound healing.	[Bellner, Lars; Marrazzo, Giuseppina; Abraham, Nader G.; Schwartzman, Michal L.] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; [Dunn, Michael W.; Schwartzman, Michal L.] New York Med Coll, Dept Ophthalmol, Valhalla, NY 10595 USA; [Abraham, Nader G.] New York Med Coll, Dept Med, Valhalla, NY 10595 USA; [van Rooijen, Nico] Vrije Univ Amsterdam, Fac Med, Dept Mol Cell Biol, Amsterdam, Netherlands	New York Medical College; New York Medical College; New York Medical College; Vrije Universiteit Amsterdam	Bellner, L (corresponding author), New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.	lars_bellner@nymc.edu	Van Rooijen, Nico/Z-1578-2019		NATIONAL EYE INSTITUTE [R01EY006513] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034300] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY06513, R01 EY006513] Funding Source: Medline; NHLBI NIH HHS [P01 HL034300] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Abraham NG, 2006, CIRC RES, V99, P911, DOI 10.1161/01.RES.0000249616.10603.d6; Bellner L, 2008, EXP EYE RES, V87, P268, DOI 10.1016/j.exer.2008.06.007; Bellner L, 2011, MOL VIS, V17, P1144; Bellner L, 2011, INVEST OPHTH VIS SCI, V52, P3246, DOI 10.1167/iovs.10-6219; Bellner L, 2009, J PHARMACOL EXP THER, V331, P925, DOI 10.1124/jpet.109.158352; Brogliato AR, 2012, SHOCK, V38, P620, DOI 10.1097/SHK.0b013e318272ff8a; Chiang N, 2013, J IMMUNOL, V190, P6378, DOI 10.4049/jimmunol.1202969; Delavary BM, 2011, IMMUNOBIOLOGY, V216, P753, DOI 10.1016/j.imbio.2011.01.001; GALLILY R, 1964, P NATL ACAD SCI USA, V51, P1158, DOI 10.1073/pnas.51.6.1158; HOWARD M, 1993, J EXP MED, V177, P1205, DOI 10.1084/jem.177.4.1205; Hull TD, 2014, ANTIOXID REDOX SIGN, V20, P1770, DOI 10.1089/ars.2013.5673; Ito Y, 1996, AM J PHYSIOL-HEART C, V270, pH81, DOI 10.1152/ajpheart.1996.270.1.H81; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; Li SX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061799; Lu PR, 2009, CORNEA, V28, P562, DOI 10.1097/ICO.0b013e3181930bcd; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Marrazzo G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021180; Maruyama K, 2007, AM J PATHOL, V170, P1178, DOI 10.2353/ajpath.2007.060018; Mirza R, 2009, AM J PATHOL, V175, P2454, DOI 10.2353/ajpath.2009.090248; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; ODLAND G, 1968, J CELL BIOL, V39, P135, DOI 10.1083/jcb.39.1.135; Patil K, 2008, INVEST OPHTH VIS SCI, V49, P3379, DOI 10.1167/iovs.07-1515; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; ROSS R, 1968, J CELL BIOL, V39, P152, DOI 10.1083/jcb.39.1.152; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2010, AM J PATHOL, V177, P1576, DOI 10.2353/ajpath.2010.100322; Serhan CN, 2009, J EXP MED, V206, P15, DOI 10.1084/jem.20081880; Seta F, 2006, AM J PATHOL, V169, P1612, DOI 10.2353/ajpath.2006.060555; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sivak JM, 2011, J BIOL CHEM, V286, P44965, DOI 10.1074/jbc.M111.294967; Slegers TPAM, 2003, CURR EYE RES, V26, P73, DOI 10.1076/ceyr.26.2.73.14510; Slegers TPAM, 2000, INVEST OPHTH VIS SCI, V41, P2239; Uderhardt S, 2012, J MOL MED, V90, P1247, DOI 10.1007/s00109-012-0954-4; vanRooijen N, 1997, J LEUKOCYTE BIOL, V62, P702, DOI 10.1002/jlb.62.6.702; Wagener FADTG, 2003, BLOOD, V102, P521, DOI 10.1182/blood-2002-07-2248; Weis N, 2009, MOL BIOL CELL, V20, P1280, DOI 10.1091/mbc.E08-10-1005; Weng YH, 2003, J BIOL CHEM, V278, P50999, DOI 10.1074/jbc.M307644200; Willoughby DA, 2000, INT J IMMUNOPHARMACO, V22, P1131, DOI 10.1016/S0192-0561(00)00064-3; Xu W, 2006, BLOOD, V107, P4930, DOI 10.1182/blood-2005-10-4144	42	23	24	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					105	115		10.1096/fj.14-256503	http://dx.doi.org/10.1096/fj.14-256503			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25342128	Green Published			2022-12-28	WOS:000347378600011
J	Boccalini, G; Sassoli, C; Formigli, L; Bani, D; Nistri, S				Boccalini, Giulia; Sassoli, Chiara; Formigli, Lucia; Bani, Daniele; Nistri, Silvia			Relaxin protects cardiac muscle cells from hypoxia/reoxygenation injury: involvement of the Notch-1 pathway	FASEB JOURNAL			English	Article						H9c2; cardiomyocytes; RXFP1; DAPT; oxidative injury	NITRIC-OXIDE; MYOCARDIAL-INFARCTION; ACTIVATION; EXPRESSION; RECEPTOR; HEART; REPERFUSION; APOPTOSIS; ISCHEMIA; CARDIOPROTECTION	In animal models, the cardiotropic hormone relaxin has been shown to protect the heart against ischemia and reperfusion-induced damage, acting by multiple mechanisms that primarily involve the coronary vessels. This in vitro study evaluates whether relaxin also has a direct protective action on cardiac muscle cells. H9c2 rat cardiomyoblasts and primary mouse cardiomyocytes were subjected to hypoxia and reoxygenation. In some experiments, relaxin was added preventatively before hypoxia; in others, at reoxygenation. To elucidate itsmechanisms of action, we focused on Notch-1, which is involved in heart pre-and postconditioning to ischemia. Inactivated RLX was used as negative control. Relaxin (17 nmol/L, EC50 4.7 nmol/L), added 24 h before hypoxia or at reoxygenation, protected against cardiomyocyte injury. In fact, relaxin significantly increased cell viability (assayed by trypan blue and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), decreased apoptosis (assayed by TUNEL and bax/bcl-2 ratio), and reduced nitroxidative damage (assayed by nitrotyrosine expression and 8-hydroxy-deoxyguanosine levels). These effects were partly attributable to the ability of relaxin to upregulate Notch-1 signaling; indeed, blockade of Notch-1 activation with the specific inhibitor DAPT reduced relaxin-induced cardioprotection during hypoxia and reoxygenation. This study adds new mechanistic insights on the cardioprotective role of relaxin on ischemic and oxidative damage.	[Boccalini, Giulia; Sassoli, Chiara; Formigli, Lucia; Bani, Daniele; Nistri, Silvia] Univ Florence, Dept Expt & Clin Med, Sect Anat & Histol, Res Unit Histol & Embryol, I-50139 Florence, Italy	University of Florence	Nistri, S (corresponding author), Univ Florence, Dept Expt & Clin Med, Sect Anat & Histol, Res Unit Histol & Embryol, Viale G Pieraccini 6, I-50139 Florence, Italy.	silvia.nistri@unifi.it	SASSOLI, CHIARA/AAC-4023-2019	SASSOLI, CHIARA/0000-0002-1337-0938				Baccari MC, 2008, CURR PROTEIN PEPT SC, V9, P638, DOI 10.2174/138920308786733921; Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bani D, 1998, AM J PATHOL, V152, P1367; Bani D, 2007, REGUL PEPTIDES, V144, P10, DOI 10.1016/j.regpep.2007.05.004; BANISACCHI T, 1995, BRIT J PHARMACOL, V116, P1589, DOI 10.1111/j.1476-5381.1995.tb16377.x; Bonacchi M, 2009, J CELL MOL MED, V13, P3437, DOI 10.1111/j.1582-4934.2008.00503.x; Boni A, 2008, P NATL ACAD SCI USA, V105, P15529, DOI 10.1073/pnas.0808357105; Brou C, 2009, EXP CELL RES, V315, P1549, DOI 10.1016/j.yexcr.2008.09.010; BULLESBACH EE, 1988, INT J PEPT PROT RES, V32, P361; Campa VM, 2008, J CELL BIOL, V183, P129, DOI 10.1083/jcb.200806104; Collesi C, 2008, J CELL BIOL, V183, P117, DOI 10.1083/jcb.200806091; Croquelois A, 2008, J EXP MED, V205, P3173, DOI 10.1084/jem.20081427; Cuzzocrea S, 2001, BRIT J PHARMACOL, V132, P19, DOI 10.1038/sj.bjp.0703775; Della-Morte D, 2012, PHARMACOGENOMICS, V13, P1741, DOI [10.2217/PGS.12.157, 10.2217/pgs.12.157]; Dschietzig T, 2001, FASEB J, V15, P2187, DOI 10.1096/fj.01-0070com; Dschietzig T., 2002, CELL MOL LIFE SCI, V59, P1; Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001; Eefting F, 2004, CARDIOVASC RES, V61, P414, DOI 10.1016/j.cardiores.2003.12.023; Fernandez JW, 2010, FEBS LETT, V584, P4259, DOI 10.1016/j.febslet.2010.09.022; Formigli L, 2007, J CELL MOL MED, V11, P1087, DOI 10.1111/j.1582-4934.2007.00111.x; Formigli L, 2009, J MOL CELL CARDIOL, V47, P335, DOI 10.1016/j.yjmcc.2009.05.008; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Gersh BJ, 2010, EUR HEART J, V31, P642, DOI 10.1093/eurheartj/ehq030; Gude NA, 2008, CIRC RES, V102, P1025, DOI 10.1161/CIRCRESAHA.107.164749; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; High FA, 2008, NAT REV GENET, V9, P49, DOI 10.1038/nrg2279; Kompa AR, 2002, BRIT J PHARMACOL, V137, P710, DOI 10.1038/sj.bjp.0704922; Kratsios P, 2010, CIRC RES, V106, P559, DOI 10.1161/CIRCRESAHA.109.203034; Lekgabe ED, 2005, HYPERTENSION, V46, P412, DOI 10.1161/01.HYP.0000171930.00697.2f; Masini E, 1997, ENDOCRINOLOGY, V138, P4713, DOI 10.1210/en.138.11.4713; Masini E, 2004, ENDOCRINOLOGY, V145, P1106, DOI 10.1210/en.2003-0833; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; McGuane JT, 2011, ENDOCRINOLOGY, V152, P2786, DOI 10.1210/en.2010-1126; Moore XL, 2007, ENDOCRINOLOGY, V148, P1582, DOI 10.1210/en.2006-1324; Moore XL, 2014, CARDIOVASC DRUG THER, V28, P221, DOI 10.1007/s10557-014-6525-x; Nemir M, 2008, J MOL CELL CARDIOL, V45, P495, DOI 10.1016/j.yjmcc.2008.02.273; Niessen K, 2007, AM J PHYSIOL-CELL PH, V293, pC1, DOI 10.1152/ajpcell.00415.2006; Nistri S, 2005, CURR NEUROVASC RES, V2, P225, DOI 10.2174/1567202054368362; Nistri S, 2003, FASEB J, V17, P2109, DOI 10.1096/fj.03-0216fje; Nistri Silvia, 2007, Cardiovascular & Hematological Agents in Medicinal Chemistry, V5, P101, DOI 10.2174/187152507780363179; Nistri S, 2012, J CELL MOL MED, V16, P507, DOI 10.1111/j.1582-4934.2011.01328.x; Palejwala S, 2001, ENDOCRINOLOGY, V142, P3405, DOI 10.1210/en.142.8.3405; Pei HF, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-013-0373-x; Perna AM, 2005, FASEB J, V19, P1525, DOI 10.1096/fj.04-3664fje; Prasanna N, 2014, J BIOCHEM MOL TOXIC, V28, P174, DOI 10.1002/jbt.21550; Rakhit RD, 2001, BIOCHEM BIOPH RES CO, V286, P995, DOI 10.1006/bbrc.2001.5477; Samuel CS, 2011, LAB INVEST, V91, P675, DOI 10.1038/labinvest.2010.198; Samuel CS, 2004, ENDOCRINOLOGY, V145, P4125, DOI 10.1210/en.2004-0209; Sassoli C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063896; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Simpson P. J., 1988, P UPJ S HALL KAL MI, P63; TAYLOR MJ, 1994, J ENDOCRINOL, V143, pR5, DOI 10.1677/joe.0.143R005; Teerlink JR, 2013, LANCET, V381, P29, DOI 10.1016/S0140-6736(12)61855-8; Unemori EN, 2000, WOUND REPAIR REGEN, V8, P361, DOI 10.1111/j.1524-475X.2000.00361.x; Yu BT, 2014, HEART LUNG CIRC, V23, P152, DOI 10.1016/j.hlc.2013.07.004; Zhang ZL, 2012, MOL CELL BIOCHEM, V365, P243, DOI 10.1007/s11010-012-1265-3; Zhou XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-251	57	58	62	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					239	249		10.1096/fj.14-254854	http://dx.doi.org/10.1096/fj.14-254854			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25342127				2022-12-28	WOS:000347378600023
J	Mazzone, A; Gibbons, SJ; Bernard, CE; Nowsheen, S; Middha, S; Almada, LL; Ordog, T; Kendrick, ML; Lombardo, KR; Shen, KR; Galietta, LJV; Fernandez-Zapico, ME; Farrugia, G				Mazzone, Amelia; Gibbons, Simon J.; Bernard, Cheryl E.; Nowsheen, Somaira; Middha, Sumit; Almada, Luciana L.; Ordog, Tamas; Kendrick, Michael L.; Lombardo, KMarie Reid; Shen, K. Robert; Galietta, Luis J. V.; Fernandez-Zapico, Martin E.; Farrugia, Gianrico			Identification and characterization of a novel promoter for the human ANO1 gene regulated by the transcription factor signal transducer and activator of transcription 6 (STAT6)	FASEB JOURNAL			English	Article						TMEM16A; calcium-activated chloride channels; alternative splicing	CA2+-ACTIVATED CL-CHANNEL; INTERSTITIAL-CELLS; CHLORIDE CHANNELS; FUNCTIONAL-CHARACTERIZATION; CPG ISLANDS; TMEM16A; EXPRESSION; CAJAL; INTERLEUKIN-4; PROLIFERATION	Anoctamin-1 (Ano1) is a widely expressed protein responsible for endogenous Ca2+-activated Cl- currents. Ano1 is overexpressed in cancer. Differential expression of transcriptional variants is also found in other diseases. However, the mechanisms underlying regulation of Ano1 are unknown. This study identifies the Ano1 promoter and defines a mechanism for regulating its expression. Next-generation RNA sequencing (RNA-seq) analysis in human gastric muscle found a new exon upstream of the reported exon 1 and identified a promoter proximal to this new exon. Reporter assays in human embryonic kidney 293 cells showed a 6.7 +/- 2.1 fold increase in activity over empty vector. Treatment with a known regulator of Ano1 expression, IL-4, increased promoter activity by 1.6 +/- 0.02-fold over untreated cells. The promoter region contained putative binding sites for multiple transcription factors including signal transducer and activator of transcription 6 (STAT6), a downstream effector of IL-4. Chromatin immuno-precipitation (ChIP) experiments on T84 cells, which endogenously express Ano1, showed a 2.1 +/- 0.12-fold increase in binding of STAT6 to P0 after IL-4 treatment. These results were confirmed by mutagenesis, expression, and RNA interference techniques. This work allows deeper understanding of the regulation of Ano1 in physiology and as a potential therapeutic target in a variety of diseases	[Mazzone, Amelia; Gibbons, Simon J.; Bernard, Cheryl E.; Ordog, Tamas; Farrugia, Gianrico] Mayo Clin, Enter NeuroSci Program, Rochester, MN 55905 USA; [Nowsheen, Somaira] Mayo Clin, Mayo Med Sch, Rochester, MN 55905 USA; [Middha, Sumit] Mayo Clin, Rochester, MN 55905 USA; [Almada, Luciana L.; Fernandez-Zapico, Martin E.] Mayo Clin, Dept Oncol, Schulze Ctr Novel Therapeut, Rochester, MN 55905 USA; [Kendrick, Michael L.; Lombardo, KMarie Reid; Shen, K. Robert] Mayo Clin, Dept Surg, Rochester, MN 55905 USA; [Galietta, Luis J. V.] Ist Giannina Gaslini, UOC Genet Med, I-16148 Genoa, Italy	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Genoa; IRCCS Istituto Giannina Gaslini	Farrugia, G (corresponding author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.	farrugia.gianrico@mayo.edu	Galietta, Luis JV/HCG-8692-2022	Harrington, Jon/0000-0003-1293-5201; Galietta, Luis/0000-0001-8686-3461; MAZZONE, Amelia/0000-0001-6236-6962; Gibbons, Simon/0000-0001-5311-5993; Middha, Sumit/0000-0003-4135-6268	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057061, P30DK084567] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57061, R01 DK057061, P30 DK084567] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergeron C, 2003, CLIN EXP ALLERGY, V33, P1389, DOI 10.1046/j.1365-2222.2003.01785.x; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Britschgi A, 2013, P NATL ACAD SCI USA, V110, pE1026, DOI 10.1073/pnas.1217072110; Buchholz B, 2014, KIDNEY INT, V85, P1058, DOI 10.1038/ki.2013.418; Caputo A, 2008, SCIENCE, V322, P590, DOI 10.1126/science.1163518; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Cho H, 2012, NAT NEUROSCI, V15, P1015, DOI 10.1038/nn.3111; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Davis AJ, 2010, AM J PHYSIOL-CELL PH, V299, pC948, DOI 10.1152/ajpcell.00018.2010; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Dutta AK, 2011, J BIOL CHEM, V286, P766, DOI 10.1074/jbc.M110.164970; Duvvuri U, 2012, CANCER RES, V72, P3270, DOI 10.1158/0008-5472.CAN-12-0475-T; Farlow A, 2012, MOL BIOL EVOL, V29, P21, DOI 10.1093/molbev/msr201; Ferrera L, 2009, J BIOL CHEM, V284, P33360, DOI 10.1074/jbc.M109.046607; Forrest AS, 2012, AM J PHYSIOL-CELL PH, V303, pC1229, DOI 10.1152/ajpcell.00044.2012; Galietta LJV, 2002, J IMMUNOL, V168, P839, DOI 10.4049/jimmunol.168.2.839; Goenka S, 2011, IMMUNOL RES, V50, P87, DOI 10.1007/s12026-011-8205-2; Gomez-Pinilla PJ, 2009, AM J PHYSIOL-GASTR L, V296, pG1370, DOI 10.1152/ajpgi.00074.2009; Goujon M, 2010, NUCLEIC ACIDS RES, V38, pW695, DOI 10.1093/nar/gkq313; Huang F, 2009, P NATL ACAD SCI USA, V106, P21413, DOI 10.1073/pnas.0911935106; Hwang SJ, 2009, J PHYSIOL-LONDON, V587, P4887, DOI 10.1113/jphysiol.2009.176198; Illingworth RS, 2009, FEBS LETT, V583, P1713, DOI 10.1016/j.febslet.2009.04.012; Jin X, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004184; Kalay E, 2007, J MOL MED, V85, P397, DOI 10.1007/s00109-006-0136-3; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010; Manoury B, 2010, J PHYSIOL-LONDON, V588, P2305, DOI 10.1113/jphysiol.2010.189506; Mazzone A, 2012, BIOCHEM BIOPH RES CO, V427, P248, DOI 10.1016/j.bbrc.2012.09.022; Mazzone A, 2011, J BIOL CHEM, V286, P13393, DOI 10.1074/jbc.M110.196089; McDonald C, 2004, J INTERF CYTOK RES, V24, P729, DOI 10.1089/1079990042722909; Mercer AJ, 2011, J NEUROPHYSIOL, V105, P321, DOI 10.1152/jn.00332.2010; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Mills LD, 2013, J BIOL CHEM, V288, P11786, DOI 10.1074/jbc.M112.438846; Namkung W, 2011, J BIOL CHEM, V286, P2365, DOI 10.1074/jbc.M110.175109; O'Driscoll KE, 2011, BMC MOL BIOL, V12, DOI 10.1186/1471-2199-12-35; Phatnani HP, 2006, GENE DEV, V20, P2922, DOI 10.1101/gad.1477006; Rock JR, 2009, J BIOL CHEM, V284, P14875, DOI 10.1074/jbc.C109.000869; Romanenko VG, 2010, J BIOL CHEM, V285, P12990, DOI 10.1074/jbc.M109.068544; Ruffin M, 2013, BBA-MOL BASIS DIS, V1832, P2340, DOI 10.1016/j.bbadis.2013.09.012; Ruiz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043265; Schroeder BC, 2008, CELL, V134, P1019, DOI 10.1016/j.cell.2008.09.003; Simon S, 2013, CANCER RES, V73, P3661, DOI 10.1158/0008-5472.CAN-12-3839; Sondo E, 2014, BBA-BIOMEMBRANES, V1838, P89, DOI 10.1016/j.bbamem.2013.08.010; Stanich JE, 2011, AM J PHYSIOL-GASTR L, V301, pG1044, DOI 10.1152/ajpgi.00196.2011; Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085; Travagli J, 2004, J BIOL CHEM, V279, P35183, DOI 10.1074/jbc.M403223200; Trimmer JS, 2004, ANNU REV PHYSIOL, V66, P477, DOI 10.1146/annurev.physiol.66.032102.113328; Verkman AS, 2009, NAT REV DRUG DISCOV, V8, P153, DOI 10.1038/nrd2780; Wang M, 2012, CIRCULATION, V125, P697, DOI 10.1161/CIRCULATIONAHA.111.041806; Wurster AL, 2000, ONCOGENE, V19, P2577, DOI 10.1038/sj.onc.1203485; Yang YD, 2008, NATURE, V455, P1210, DOI 10.1038/nature07313; Zhang YP, 2013, ACTA PHARMACOL SIN, V34, P17, DOI 10.1038/aps.2012.140; Zhu MH, 2009, J PHYSIOL-LONDON, V587, P4905, DOI 10.1113/jphysiol.2009.176206	53	35	37	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					152	163		10.1096/fj.14-258541	http://dx.doi.org/10.1096/fj.14-258541			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25351986	Green Published			2022-12-28	WOS:000347378600015
J	Rovira, X; Malhaire, F; Scholler, P; Rodrigo, J; Gonzalez-Bulnes, P; Llebaria, A; Pin, JP; Giraldo, J; Goudet, C				Rovira, Xavier; Malhaire, Fanny; Scholler, Pauline; Rodrigo, Jordi; Gonzalez-Bulnes, Patricia; Llebaria, Amadeu; Pin, Jean-Philippe; Giraldo, Jesus; Goudet, Cyril			Overlapping binding sites drive allosteric agonism and positive cooperativity in type 4 metabotropic glutamate receptors	FASEB JOURNAL			English	Article						allostery; sodium	RESOLUTION CRYSTAL-STRUCTURE; GROUP-III; LIGAND-BINDING; PHARMACOLOGICAL CHARACTERIZATION; HEPTAHELICAL DOMAIN; MOLECULAR-DYNAMICS; STRUCTURAL BASIS; CLASS-A; MODULATOR; DISCOVERY	Type 4 metabotropic glutamate (mGlu(4)) receptors are emerging targets for the treatment of various disorders. Accordingly, numerous mGlu(4)-positive allosteric modulators (PAMs) have been identified, some of which also display agonist activity. To identify the structural bases for their allosteric action, we explored the relationship between the binding pockets of mGlu4 PAMs with different chemical scaffolds and their functional properties. By use of innovative mGlu4 biosensors and second-messenger assays, we show that all PAMs enhance agonist action on the receptor through different degrees of allosteric agonism and positive cooperativity. For example, whereas VU0155041 and VU0415374 display equivalent efficacies [log(tau(B)) = 1.15 +/- 0.38 and 1.25 +/- 0.44, respectively], they increase the ability of L-AP4 to stabilize the active conformation of the receptor by 4 and 39 times, respectively. Modeling and docking studies identify 2 overlapping binding pockets as follows: a first site homologous to the pocket of natural agonists of class A GPCRs linked to allosteric agonism and a second one pointing toward a site topographically homologous to the Na+ binding pocket of class A GPCRs, occupied by PAMs exhibiting the strongest cooperativity. These results reveal that intrinsic efficacy and cooperativity of mGlu4 PAMs are correlated with their binding mode, and vice versa, integrating structural and functional knowledge from different GPCR classes.	[Rovira, Xavier; Malhaire, Fanny; Scholler, Pauline; Pin, Jean-Philippe; Goudet, Cyril] Univ Montpellier, Inst Genom Fonct, CNRS UMR 5203, F-34094 Montpellier 5, France; [Rovira, Xavier; Malhaire, Fanny; Scholler, Pauline; Pin, Jean-Philippe; Goudet, Cyril] INSERM, U661, Montpellier, France; [Rodrigo, Jordi] Univ Paris 11, Fac Pharm, Chim Therapeut Lab, LabEx LERMIT,BioCIS UMR CNRS 8076, Paris, France; [Gonzalez-Bulnes, Patricia; Llebaria, Amadeu] Inst Adv Chem Catalonia IQAC CSIC, Dept Biomed Chem, Med Chem Lab, Barcelona, Spain; [Giraldo, Jesus] Univ Autonoma Barcelona, Inst Neurociencies, Lab Mol Neuropharmacol & Bioinformat, Bellaterra, Spain; [Giraldo, Jesus] Univ Autonoma Barcelona, Unitat Bioestadist, Bellaterra, Spain	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UDICE-French Research Universities; Universite Paris Saclay; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); CSIC - Instituto de Quimica Avanzada de Cataluna (IQAC); Autonomous University of Barcelona; Autonomous University of Barcelona	Goudet, C (corresponding author), Univ Montpellier, INSERM U661, CNRS UMR 5203, Inst Genom Fonct, 141 Rue Cardonille, F-34094 Montpellier 5, France.	jesus.giraldo@uab.es; cyril.goudet@igf.cnrs.fr	Goudet, Cyril/AAE-3415-2020; Llebaria, Amadeu/C-4287-2015; Rovira, Xavier/M-4669-2015; Giraldo, Jesus/F-9881-2011	Goudet, Cyril/0000-0002-8255-3535; Llebaria, Amadeu/0000-0002-8200-4827; Rovira, Xavier/0000-0002-9764-9927; Pin, Jean-Philippe/0000-0002-1423-345X; Giraldo, Jesus/0000-0001-7082-4695; MALHAIRE, Fanny/0000-0001-5930-9879				Abitbol K, 2008, J NEUROCHEM, V105, P2069, DOI 10.1111/j.1471-4159.2008.05290.x; Amalric M, 2013, NEUROPHARMACOLOGY, V66, P53, DOI 10.1016/j.neuropharm.2012.05.026; Becker JAJ, 2014, NEUROPSYCHOPHARMACOL, V39, P2049, DOI 10.1038/npp.2014.59; Binet V, 2007, J BIOL CHEM, V282, P12154, DOI 10.1074/jbc.M611071200; Bruno A, 2009, J CHEM INF MODEL, V49, P1602, DOI 10.1021/ci900067g; Celanire S, 2012, EXPERT OPIN DRUG DIS, V7, P261, DOI 10.1517/17460441.2012.660914; Chen Y, 2008, MOL PHARMACOL, V73, P909, DOI 10.1124/mol.107.040097; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410; Christov C, 2011, CHEMMEDCHEM, V6, P131, DOI 10.1002/cmdc.201000378; COSTA T, 1990, MOL PHARMACOL, V37, P383; Dalton JAR, 2014, J CHEM INF MODEL, V54, P1476, DOI 10.1021/ci500127c; de Graaf C, 2008, J MED CHEM, V51, P4978, DOI 10.1021/jm800710x; Dore AS, 2014, NATURE, V511, P557, DOI 10.1038/nature13396; Doumazane E, 2013, P NATL ACAD SCI USA, V110, pE1416, DOI 10.1073/pnas.1215615110; Doumazane E, 2011, FASEB J, V25, P66, DOI 10.1096/fj.10-163147; Engers D. W., 2010, PROBE REPORTS NIH MO; Engers DW, 2011, J MED CHEM, V54, P1106, DOI 10.1021/jm101271s; Fenalti G, 2014, NATURE, V506, P191, DOI 10.1038/nature12944; Flor PJ, 2012, BIOCHEM PHARMACOL, V84, P414, DOI 10.1016/j.bcp.2012.04.013; Gao ZG, 2000, BIOCHEM PHARMACOL, V60, P669, DOI 10.1016/S0006-2952(00)00360-9; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Goudet C, 2004, P NATL ACAD SCI USA, V101, P378, DOI 10.1073/pnas.0304699101; Goudet C, 2012, FASEB J, V26, P1682, DOI 10.1096/fj.11-195941; Gregory KJ, 2012, MOL PHARMACOL, V82, P860, DOI 10.1124/mol.112.080531; Hammond AS, 2010, ACS CHEM NEUROSCI, V1, P702, DOI 10.1021/cn100051m; Hampson DR, 1999, J BIOL CHEM, V274, P33488, DOI 10.1074/jbc.274.47.33488; Hermans E, 1999, BRIT J PHARMACOL, V126, P873, DOI 10.1038/sj.bjp.0702359; Hong SP, 2011, J MED CHEM, V54, P5070, DOI 10.1021/jm200290z; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; Katritch V, 2014, TRENDS BIOCHEM SCI, V39, P233, DOI 10.1016/j.tibs.2014.03.002; Kniazeff J, 2011, PHARMACOL THERAPEUT, V130, P9, DOI 10.1016/j.pharmthera.2011.01.006; Knoflach F, 2001, P NATL ACAD SCI USA, V98, P13402, DOI 10.1073/pnas.231358298; Le Poul E, 2012, J PHARMACOL EXP THER, V343, P167, DOI 10.1124/jpet.112.196063; Leach K, 2010, NEUROPSYCHOPHARMACOL, V35, P855, DOI 10.1038/npp.2009.194; Lebon G, 2012, CURR OPIN STRUC BIOL, V22, P482, DOI 10.1016/j.sbi.2012.03.007; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Liu W, 2012, SCIENCE, V337, P232, DOI 10.1126/science.1219218; Lundstrom L, 2011, BRIT J PHARMACOL, V164, P521, DOI 10.1111/j.1476-5381.2011.01409.x; Maj M, 2003, NEUROPHARMACOLOGY, V45, P895, DOI 10.1016/S0028-3908(03)00271-5; Marino MJ, 2003, P NATL ACAD SCI USA, V100, P13668, DOI 10.1073/pnas.1835724100; McDonald J, 2003, BRIT J PHARMACOL, V140, P61, DOI 10.1038/sj.bjp.0705401; Molck C, 2014, NEUROCHEM RES, V39, P1862, DOI 10.1007/s11064-014-1248-8; Molck C, 2012, MOL PHARMACOL, V82, P929, DOI 10.1124/mol.112.078808; Muhlemann A, 2006, EUR J PHARMACOL, V529, P95, DOI 10.1016/j.ejphar.2005.11.008; NEVE KA, 1991, MOL PHARMACOL, V39, P733; Nicoletti E, 2011, NEUROPHARMACOLOGY, V60, P1017, DOI 10.1016/j.neuropharm.2010.10.022; Niswender CM, 2008, MOL PHARMACOL, V74, P1345, DOI 10.1124/mol.108.049551; Niswender CM, 2010, ANNU REV PHARMACOL, V50, P295, DOI 10.1146/annurev.pharmtox.011008.145533; Noetzel MJ, 2013, MOL PHARMACOL, V83, P835, DOI 10.1124/mol.112.082891; PERT CB, 1973, SCIENCE, V182, P1359, DOI 10.1126/science.182.4119.1359; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Ring AM, 2013, NATURE, V502, P575, DOI 10.1038/nature12572; Rook JM, 2013, BIOL PSYCHIAT, V73, P501, DOI 10.1016/j.biopsych.2012.09.012; Rosenbaum DM, 2011, NATURE, V469, P236, DOI 10.1038/nature09665; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schaffhauser H, 2003, MOL PHARMACOL, V64, P798, DOI 10.1124/mol.64.4.798; Selent J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000884; Standfuss J, 2011, NATURE, V471, P656, DOI 10.1038/nature09795; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Venkatakrishnan AJ, 2013, NATURE, V494, P185, DOI 10.1038/nature11896; Vilar B, 2013, J NEUROSCI, V33, P18951, DOI 10.1523/JNEUROSCI.1221-13.2013; Warne T, 2011, NATURE, V469, P241, DOI 10.1038/nature09746; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Williams R, 2010, ACS CHEM NEUROSCI, V1, P411, DOI 10.1021/cn9000318; Williams R, 2009, BIOORG MED CHEM LETT, V19, P4967, DOI 10.1016/j.bmcl.2009.07.072; Wootten D, 2013, NAT REV DRUG DISCOV, V12, P630, DOI 10.1038/nrd4052; Wu HX, 2014, SCIENCE, V344, P58, DOI 10.1126/science.1249489; Zhang C, 2012, NATURE, V492, P387, DOI 10.1038/nature11701	70	43	43	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					116	130		10.1096/fj.14-257287	http://dx.doi.org/10.1096/fj.14-257287			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25342125				2022-12-28	WOS:000347378600012
J	Ayroldi, E; Macchiarulo, A; Riccardi, C				Ayroldi, Emira; Macchiarulo, Antonio; Riccardi, Carlo			Targeting glucocorticoid side effects: selective glucocorticoid receptor modulator or glucocorticoid-induced leucine zipper? A perspective	FASEB JOURNAL			English	Review						GR activation; transrepression hypothesis; inflammatory gene regulation	NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTORS; ANTIINFLAMMATORY ACTIONS; MOLECULAR-MECHANISMS; INDUCED ARTHRITIS; MULTIPLE-MYELOMA; TRANSGENIC MICE; GENE-REGULATION; CELL-DEATH	Glucocorticoids (GCs) are steroid hormones that are necessary for life and important in health and disease. They regulate crucial homeostatic functions, including metabolism, cell growth, and development. Although GCs are regulated by circadian rhythm, increased production is associated with stress. Synthetic GCs are a valuable resource for anti-inflammatory and immunosuppressive therapy. Natural and synthetic GCs transduce signals mainly through GC receptor (GR) activation. Extensive research has explored the downstream targets of the GR, and optimization of GC therapy has required collaborative efforts. One highly promising approach involves new dissociative GR modulators. Because transrepression and transactivation of GR genes induce beneficial and adverse effects, respectively, this approach favors transrepression. Another approach involves the use of GC-dependent genes to generate proteins to mediate therapeutic GC effects. In a third approach, drug discovery is used to identify agents that selectively target GR isoforms to obtain differential gene transcription and effects. In this review, we focus on mechanisms of GR function compatible with the use of dissociative drugs. We highlight GC-induced leucine zipper (GILZ), a gene cloned in our laboratory, as a mediator of GC anti-inflammatory and immunosuppressive effects, to out-line our perspective on the future of GC therapy.	[Ayroldi, Emira; Riccardi, Carlo] Univ Perugia, Dept Med, Pharmacol Sect, I-06132 Perugia, Italy; [Macchiarulo, Antonio] Univ Perugia, Dept Chem & Drug Technol, I-06132 Perugia, Italy	University of Perugia; University of Perugia	Ayroldi, E (corresponding author), Univ Perugia, Dept Med, Pharmacol Sect, Piazza Gambuli, I-06132 Perugia, Italy.	emira.ayroldi@unipg.it	Riccardi, Carlo/N-4610-2014; Macchiarulo, Antonio/L-2846-2017	Riccardi, Carlo/0000-0001-9257-3997; Macchiarulo, Antonio/0000-0001-9535-4183; Ayroldi, Emira/0000-0002-9073-7297	Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy [IG 10677]	Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy(Fondazione AIRC per la ricerca sul cancro)	This study was supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy (IG 10677).	Adams M, 2003, MOL ENDOCRINOL, V17, P2583, DOI 10.1210/me.2002-0305; ALROY I, 1992, NUCLEIC ACIDS RES, V20, P1045, DOI 10.1093/nar/20.5.1045; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929-7941.2002; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Ayroldi E, 2007, J CLIN INVEST, V117, P1605, DOI 10.1172/JCI30724; Ayroldi E, 2012, FASEB J, V26, P4805, DOI 10.1096/fj.12-216382; Ayroldi E, 2009, FASEB J, V23, P3649, DOI 10.1096/fj.09-134684; Barnes PJ, 2011, BRIT J PHARMACOL, V163, P29, DOI 10.1111/j.1476-5381.2010.01199.x; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Baschant U, 2010, J STEROID BIOCHEM, V120, P69, DOI 10.1016/j.jsbmb.2010.03.058; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Beaulieu E, 2010, ARTHRITIS RHEUM-US, V62, P2651, DOI 10.1002/art.27566; Beck IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069115; Beck IME, 2009, ENDOCR REV, V30, P830, DOI 10.1210/er.2009-0013; Belvisi MG, 2001, J IMMUNOL, V166, P1975, DOI 10.4049/jimmunol.166.3.1975; Bereshchenko O, 2014, CELL REP, V7, P464, DOI 10.1016/j.celrep.2014.03.004; Berrebi D, 2003, BLOOD, V101, P729, DOI 10.1182/blood-2002-02-0538; Biddie SC, 2012, RHEUMATOLOGY, V51, P403, DOI 10.1093/rheumatology/ker215; Bruscoli S, 2012, J BIOL CHEM, V287, P1242, DOI 10.1074/jbc.M111.316372; Buttgereit F, 2012, BULL HOSP JT DIS, V70, pS26; Cannarile L, 2006, BLOOD, V107, P1039, DOI 10.1182/blood-2005-05-2183; Cannarile L, 2001, CELL DEATH DIFFER, V8, P201, DOI 10.1038/sj.cdd.4400798; Cannarile L, 2009, GASTROENTEROLOGY, V136, P530, DOI 10.1053/j.gastro.2008.09.024; Cheng Q, 2013, J IMMUNOL, V191, P424, DOI 10.4049/jimmunol.1202662; Chivers JE, 2006, MOL PHARMACOL, V70, P2084, DOI 10.1124/mol.106.025841; Clark AR, 2012, PHARMACOL THERAPEUT, V134, P54, DOI 10.1016/j.pharmthera.2011.12.004; Clark AR, 2003, CURR OPIN PHARMACOL, V3, P404, DOI 10.1016/S1471-4892(03)00073-0; Coghlan MJ, 2003, MOL ENDOCRINOL, V17, P860, DOI 10.1210/me.2002-0355; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; Czock D, 2005, CLIN PHARMACOKINET, V44, P61, DOI 10.2165/00003088-200544010-00003; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Davies L, 2008, MOL ENDOCRINOL, V22, P1331, DOI 10.1210/me.2007-0360; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; De Bosscher K, 2005, P NATL ACAD SCI USA, V102, P15827, DOI 10.1073/pnas.0505554102; De Bosscher K, 2014, CELL MOL LIFE SCI, V71, P143, DOI 10.1007/s00018-013-1367-4; De Bosscher K, 2010, BRAIN BEHAV IMMUN, V24, P1035, DOI 10.1016/j.bbi.2010.06.010; De Bosscher K, 2010, CURR OPIN PHARMACOL, V10, P497, DOI 10.1016/j.coph.2010.04.007; De Bosscher K, 2009, MOL ENDOCRINOL, V23, P281, DOI 10.1210/me.2008-0283; De Iudicibus S, 2013, WORLD J GASTROENTERO, V19, P7947, DOI 10.3748/wjg.v19.i44.7947; Delfino DV, 2004, BLOOD, V104, P4134, DOI 10.1182/blood-2004-03-0920; Dewint P, 2008, J IMMUNOL, V180, P2608, DOI 10.4049/jimmunol.180.4.2608; Di Marco B, 2007, NUCLEIC ACIDS RES, V35, P517, DOI 10.1093/nar/gkl1080; Doggrell S, 2003, EXPERT OPIN INV DRUG, V12, P1227, DOI 10.1517/13543784.12.7.1227; Eddleston J, 2007, J ALLERGY CLIN IMMUN, V119, P115, DOI 10.1016/j.jaci.2006.08.027; Gaudin F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021546; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Gomez M, 2010, J IMMUNOL, V184, P5715, DOI 10.4049/jimmunol.0903521; Groeneweg FL, 2011, J ENDOCRINOL, V209, P153, DOI 10.1530/JOE-10-0472; Grugan KD, 2008, J STEROID BIOCHEM, V110, P244, DOI 10.1016/j.jsbmb.2007.11.003; HARBUZ MS, 1993, AM J PHYSIOL, V264, pR179, DOI 10.1152/ajpregu.1993.264.1.R179; He LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031717; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; Hoppstadter J, 2012, EUR J IMMUNOL, V42, P1282, DOI 10.1002/eji.201142081; Horsch K, 2007, MOL ENDOCRINOL, V21, P2929, DOI 10.1210/me.2007-0153; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Joanny E, 2012, BRIT J PHARMACOL, V165, P1124, DOI 10.1111/j.1476-5381.2011.01574.x; Joha S, 2012, ONCOGENE, V31, P1419, DOI 10.1038/onc.2011.328; John S, 2008, MOL CELL, V29, P611, DOI 10.1016/j.molcel.2008.02.010; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kelly A, 2008, J ALLERGY CLIN IMMUN, V121, P203, DOI 10.1016/j.jaci.2007.09.010; Kelly MM, 2012, BRIT J PHARMACOL, V165, P1737, DOI 10.1111/j.1476-5381.2011.01620.x; Kester HA, 1999, J BIOL CHEM, V274, P27439, DOI 10.1074/jbc.274.39.27439; Kino T, 2009, CELL MOL LIFE SCI, V66, P3435, DOI 10.1007/s00018-009-0098-z; Kino T, 2009, BIOCHEM BIOPH RES CO, V381, P671, DOI 10.1016/j.bbrc.2009.02.110; Koberle M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040730; Koromila T, 2014, J CELL BIOCHEM, V115, P27, DOI 10.1002/jcb.24646; Kumar R, 2005, J STEROID BIOCHEM, V94, P383, DOI 10.1016/j.jsbmb.2004.12.046; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Leech M, 2000, CLIN EXP IMMUNOL, V119, P161, DOI 10.1046/j.1365-2249.2000.01086.x; Li P, 2003, SPRINGER SEMIN IMMUN, V25, P19, DOI 10.1007/s00281-003-0125-3; Liberman AC, 2007, CYTOKINE GROWTH F R, V18, P45, DOI 10.1016/j.cytogfr.2007.01.005; Liberman AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035155; Ling J, 2012, CANCER LETT, V322, P119, DOI 10.1016/j.canlet.2012.02.033; Liu JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060705; Lu NZ, 2005, MOL CELL, V18, P331, DOI 10.1016/j.molcel.2005.03.025; Luz-Crawford P., 2014, ANN RHEUM DIS S1, V73, pA16; Luz-Crawford P., 2014, ANN RHEUM DIS S1, V73, pA80; Meijsing SH, 2009, SCIENCE, V324, P407, DOI 10.1126/science.1164265; Miner JN, 2007, P NATL ACAD SCI USA, V104, P19244, DOI 10.1073/pnas.0705517104; Murray MY, 2013, CELL CYCLE, V12, P2144, DOI 10.4161/cc.25251; Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007; Owen HC, 2007, MOL CELL ENDOCRINOL, V264, P164, DOI 10.1016/j.mce.2006.11.006; PARENTE L, 1994, TRENDS PHARMACOL SCI, V15, P362, DOI 10.1016/0165-6147(94)90154-6; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pinheiro I, 2013, EMBO MOL MED, V5, P456, DOI 10.1002/emmm.201201683; Redjimi N, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-83; Revollo JR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004389; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Robertson S, 2010, J BIOL CHEM, V285, P8061, DOI 10.1074/jbc.M109.087866; Romero Y, 2012, SEX DEV, V6, P169, DOI 10.1159/000338415; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Schacke H, 2004, P NATL ACAD SCI USA, V101, P227, DOI 10.1073/pnas.0300372101; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Schacke H, 2009, BRIT J PHARMACOL, V158, P1088, DOI 10.1111/j.1476-5381.2009.00238.x; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Shah N, 2004, BIOORG MED CHEM LETT, V14, P5199, DOI 10.1016/j.bmcl.2004.07.052; Simons SS, 2008, BIOESSAYS, V30, P744, DOI 10.1002/bies.20792; Smoak KA, 2004, MECH AGEING DEV, V125, P697, DOI 10.1016/j.mad.2004.06.010; Smoak K, 2006, MOL CELL BIOL, V26, P9126, DOI 10.1128/MCB.00679-06; Srinivasan M, 2011, J BIOL CHEM, V286, P44799, DOI 10.1074/jbc.M111.279257; Tuckermann JP, 2007, J CLIN INVEST, V117, P1381, DOI 10.1172/JCI28034; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; van Lierop MJC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048385; Vanden Berghe W, 1999, MOL PHARMACOL, V56, P797; Vandevyver S, 2013, ENDOCRINOLOGY, V154, P993, DOI 10.1210/en.2012-2045; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Vollmer TR, 2012, J BIOL CHEM, V287, P35212, DOI 10.1074/jbc.M112.400671; Widen C, 2003, BIOCHEM J, V373, P211, DOI 10.1042/BJ20030175; Widen C, 2000, J BIOL CHEM, V275, P39296, DOI 10.1074/jbc.M006943200; Wust S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008202; Xu Y, 2009, BIOORG MED CHEM LETT, V19, P393, DOI 10.1016/j.bmcl.2008.11.069; Yang NL, 2008, J CELL BIOCHEM, V103, P1760, DOI 10.1002/jcb.21562; Zhang WX, 2008, J BIOL CHEM, V283, P4723, DOI 10.1074/jbc.M704147200	116	58	64	2	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5055	5070		10.1096/fj.14-254755	http://dx.doi.org/10.1096/fj.14-254755			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25205742				2022-12-28	WOS:000345894500004
J	Menard, S; Guzylack-Piriou, L; Leveque, M; Braniste, V; Lencina, C; Naturel, M; Moussa, L; Sekkal, S; Harkat, C; Gaultier, E; Theodorou, V; Houdeau, E				Menard, Sandrine; Guzylack-Piriou, Laurence; Leveque, Mathilde; Braniste, Viorica; Lencina, Corinne; Naturel, Manon; Moussa, Lara; Sekkal, Soraya; Harkat, Cherryl; Gaultier, Eric; Theodorou, Vassilia; Houdeau, Eric			Food intolerance at adulthood after perinatal exposure to the endocrine disruptor bisphenol A	FASEB JOURNAL			English	Article						immune system; humoral and cellular response; oral challenge; systemic immunization	ORAL TOLERANCE; IMMUNE-RESPONSES; DENDRITIC CELLS; DEVELOPMENTAL IMMUNOTOXICOLOGY; WIDESPREAD EXPOSURE; MICE; INFLAMMATION; CHEMICALS; DISEASE; ALLERGY	The food contaminant bisphenol A (BPA) is pointed out as a risk factor in development of food allergy and food intolerance, two adverse food reactions increasing worldwide. We evaluated the consequences of perinatal exposure to low doses of BPA on immune-specific response to the food antigen ovalbumin (OVA) at adulthood. Perinatal exposure to BPA (0.5, 5, or 50 g/kg/d) from 15th day of gravidity to pups weaning resulted in an increase of anti-OVA IgG titers at all BPA dosages in OVA-tolerized rats, and at 5 g/kg/d in OVA-immunized rats compared to control rats treated with vehicle. In BPA-treated and OVA-tolerized rats, increased anti-OVA IgG titers were associated with higher IFN secretion by the spleen. This result is in accordance with the increase of activated CD4(+)CD44(high)CD62L(low) T lymphocytes observed in spleen of BPA-exposed rats compared to controls. Finally, when BPA-treated OVA-tolerized rats were orally challenged with OVA, colonic inflammation occurred, with neutrophil infiltration, increased IFN, and decreased TGF. We show that perinatal exposure to BPA altered oral tolerance and immunization to dietary antigens (OVA). In summary, the naive immune system of neonate is vulnerable to low doses of BPA that trigger food intolerance later in life.Menard, S., Guzylack-Piriou, L., Leveque, M., Braniste, V., Lencina, C., Naturel, M., Moussa, L., Sekkal, S., Harkat, C., Gaultier, E., Theodorou, V., Houdeau, E. Food intolerance at adulthood after perinatal exposure to the endocrine disruptor bisphenol A.	[Menard, Sandrine; Leveque, Mathilde; Lencina, Corinne; Naturel, Manon; Moussa, Lara; Harkat, Cherryl; Theodorou, Vassilia] INRA, UMR Toxalim 1331, Dept Neurogastroenterol & Nutr, F-31027 Toulouse 3, France; [Guzylack-Piriou, Laurence; Braniste, Viorica; Sekkal, Soraya; Gaultier, Eric; Houdeau, Eric] INRA, UMR Toxalim 1331, Dept Intestinal Dev Xenobiot & Immunotoxicol, F-31027 Toulouse 3, France	INRAE; INRAE	Menard, S (corresponding author), INRA, 180 Chemin Tournefeuille,BP93173, F-31027 Toulouse 3, France.	sandrine.menard@toulouse.inra.fr	Menard, Sandrine/ABF-8935-2021	Menard, Sandrine/0000-0001-8867-199X; Braniste, Viorica/0000-0003-1992-3609; Leveque, Mathilde/0000-0003-1253-3798	Agence Nationale de la Recherche (France) [ANR-10-CESA-005]; Institut National de la Recherche Agronomique [AP AlimH 2008]	Agence Nationale de la Recherche (France)(French National Research Agency (ANR)); Institut National de la Recherche Agronomique	The authors are grateful to Dr. Raphael Garcia-Villar for discussion and help on the manuscript. This work was supported by grant ANR-10-CESA-005 from the Agence Nationale de la Recherche (France) and grant AP AlimH 2008 from the Institut National de la Recherche Agronomique. The authors declare no conflicts of interest.	Appleman LJ, 2003, IMMUNOL REV, V192, P161, DOI 10.1034/j.1600-065X.2003.00009.x; Braniste V., 2011, MULTISYSTEM ENDOCRIN, P127, DOI DOI 10.1007/978-3-642-22775-2_9; Braniste V, 2010, P NATL ACAD SCI USA, V107, P448, DOI 10.1073/pnas.0907697107; Cabaton NJ, 2013, ENVIRON HEALTH PERSP, V121, P586, DOI 10.1289/ehp.1205588; Chirdo FG, 2005, EUR J IMMUNOL, V35, P1831, DOI 10.1002/eji.200425882; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Cochrane S, 2009, ALLERGY, V64, P1246, DOI 10.1111/j.1398-9995.2009.02128.x; Dietert Rodney R., 2012, Reviews on Environmental Health, V27, P117, DOI 10.1515/reveh-2012-0020; Dietert RR, 2009, CHEM RES TOXICOL, V22, P17, DOI 10.1021/tx800198m; Dietert RR, 2008, BIRTH DEFECTS RES B, V83, P547, DOI 10.1002/bdrb.20170; Dunbar B, 2012, MOL CELL ENDOCRINOL, V354, P85, DOI 10.1016/j.mce.2012.01.002; European Food Safety Authority, 2013, EFSA J; Fagin D, 2012, NATURE, V490, P462, DOI 10.1038/490462a; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; GALLIAERDE V, 1995, EUR J IMMUNOL, V25, P1385, DOI 10.1002/eji.1830250537; Goto M, 2007, BIOSCI BIOTECH BIOCH, V71, P2136, DOI 10.1271/bbb.70004; Houdeau E, 2005, AM J PHYSIOL-REG I, V288, pR630, DOI 10.1152/ajpregu.00482.2004; Iwasaki A, 1999, J EXP MED, V190, P229, DOI 10.1084/jem.190.2.229; Kelsall BL, 2005, IMMUNOL REV, V206, P132, DOI 10.1111/j.0105-2896.2005.00292.x; Kurebayashi H, 2005, ARCH TOXICOL, V79, P243, DOI 10.1007/s00204-004-0628-2; Mansueto P, 2006, WORLD J GASTROENTERO, V12, P7744, DOI 10.3748/wjg.v12.i48.7744; Marth T, 1998, ANN NY ACAD SCI, V859, P290, DOI 10.1111/j.1749-6632.1998.tb11148.x; Ohshima Y, 2007, PEDIATR RES, V62, P60, DOI 10.1203/PDR.0b013e3180674dae; Rogers JA, 2013, MOL IMMUNOL, V53, P421, DOI 10.1016/j.molimm.2012.09.013; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Skypala I, 2011, J AM DIET ASSOC, V111, P1877, DOI 10.1016/j.jada.2011.09.001; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x; Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1111/j.1365-2567.2004.01900.x; Yoshino S, 2003, BRIT J PHARMACOL, V138, P1271, DOI 10.1038/sj.bjp.0705166	31	52	53	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4893	4900		10.1096/fj.14-255380	http://dx.doi.org/10.1096/fj.14-255380			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25085925				2022-12-28	WOS:000344050900026
J	Armando, S; Quoyer, J; Lukashova, V; Maiga, A; Percherancier, Y; Heveker, N; Pin, JP; Prezeau, L; Bouvier, M				Armando, Sylvain; Quoyer, Julie; Lukashova, Viktorya; Maiga, Arhamatoulaye; Percherancier, Yann; Heveker, Nikolaus; Pin, Jean-Philippe; Prezeau, Laurent; Bouvier, Michel			The chemokine CXC4 and CC2 receptors form homo- and heterooligomers that can engage their signaling G-protein effectors and beta arrestin	FASEB JOURNAL			English	Article						GPCR; complex formation; allosteric regulation; transactivation; resonance energy transfer; protein complementation assays	TIME-RESOLVED FRET; RESONANCE ENERGY-TRANSFER; HIGHER-ORDER OLIGOMERS; SNAP-TAG TECHNOLOGIES; CONFORMATIONAL-CHANGES; REVEALS; GPCR; DIMERIZATION; ACTIVATION; COMPLEXES	G-protein-coupled receptors have been shown to assemble at least as dimers early in the biosynthetic path, but some evidence suggests that they can also form larger oligomeric complexes. Using the human chemokine receptors CXCR4 and CCR2 as models, we directly probed the existence of higher order homo- and heterooligomers in human embryonic kidney cells. Combining bimolecular fluorescence and luminescence complementation (BiFC, BiLC) with bioluminescence resonance energy transfer (BRET) assays, we show that CXCR4 and CCR2 can assemble as homo-and heterooligomers, forming at least tetramers. Selective activation of CCR2 with the human monocyte chemotactic protein 1 (MCP-1) resulted in trans-conformational rearrangement of the CXCR4 dimer with an EC50 of 19.9 nM, compatible with a CCR2 action. Moreover, MCP-1 promoted the engagement of G alpha(i1), G alpha(13), G alpha(z), and beta arrestin2 to the heterooligomer, resulting in calcium signaling that was synergistically potentiated on coactivation of CCR2 and CXCR4, demonstrating that complexes larger than dimers reach the cell surface as functional units. A mutation of CXCR4 (N119K), which prevents G(i) activation, also affects the CCR2-promoted engagement of Gx alpha(i1) and beta arrestin2 by the heterooligomer, supporting the occurrence of transprotomer regulation. Together, the results demonstrate that homo-and heteromultimeric CXCR4 and CCR2 can form functional signaling complexes that have unique properties.	[Armando, Sylvain; Quoyer, Julie; Lukashova, Viktorya; Maiga, Arhamatoulaye; Percherancier, Yann; Heveker, Nikolaus; Bouvier, Michel] Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; [Armando, Sylvain; Quoyer, Julie; Lukashova, Viktorya; Maiga, Arhamatoulaye; Percherancier, Yann; Bouvier, Michel] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada; [Heveker, Nikolaus] Univ Montreal, Hop Sainte Justine, Res Ctr, Montreal, PQ H3C 3J7, Canada; [Armando, Sylvain; Pin, Jean-Philippe; Prezeau, Laurent] Univ Montpellier I, INSERM U661, CNRS UMR 5203, Inst Genom Fonctionnelle, Montpellier, France; [Armando, Sylvain; Pin, Jean-Philippe; Prezeau, Laurent] Univ Montpellier 2, Montpellier, France	Universite de Montreal; Universite de Montreal; Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Universite de Montpellier; Universite de Montpellier	Bouvier, M (corresponding author), Univ Montreal, IRIC, CP 6128 Succursale Centre Ville, Montreal, PQ H3C 3J7, Canada.	michel.bouvier@umontreal.ca	Bouvier, Michel/H-2758-2014; Pin, Jean-Philippe/Y-6668-2019	Bouvier, Michel/0000-0003-1128-0100; Pin, Jean-Philippe/0000-0002-1423-345X; percherancier, yann/0000-0002-2410-5806	Canadian Institute for Health Research [MOP11215, CTP79848]; le Ministere de la Recherche et du Travail (MRT); Fonds de Recherche Sante Quebec (FRQS)	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); le Ministere de la Recherche et du Travail (MRT); Fonds de Recherche Sante Quebec (FRQS)	The authors are grateful to Dr. Jonathan Javitch (Columbia University, New York, NY, USA) for the generous gift of split v-YFP and to Dr. Monique Lagace for revision and edition of the manuscript. This work was supported by grants from the Canadian Institute for Health Research (MOP11215 and CTP79848; to M.B). S.A. received a studentship from le Ministere de la Recherche et du Travail (MRT). J.Q. received a fellowship from the Fonds de Recherche Sante Quebec (FRQS). M.B. holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology.	Albizu L, 2010, NAT CHEM BIOL, V6, P587, DOI [10.1038/NCHEMBIO.396, 10.1038/nchembio.396]; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Berchiche YA, 2007, J BIOL CHEM, V282, P5111, DOI 10.1074/jbc.C600270200; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; Calebiro D, 2013, P NATL ACAD SCI USA, V110, P743, DOI 10.1073/pnas.1205798110; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; Comps-Agrar L, 2012, FASEB J, V26, P3430, DOI 10.1096/fj.12-203646; Comps-Agrar L, 2011, METHODS MOL BIOL, V756, P201, DOI 10.1007/978-1-61779-160-4_10; Comps-Agrar L, 2011, EMBO J, V30, P2336, DOI 10.1038/emboj.2011.143; Damian M, 2006, EMBO J, V25, P5693, DOI 10.1038/sj.emboj.7601449; Doumazane E, 2011, FASEB J, V25, P66, DOI 10.1096/fj.10-163147; El-Asmar L, 2005, MOL PHARMACOL, V67, P460, DOI 10.1124/mol.104.003624; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Fung JJ, 2009, EMBO J, V28, P3315, DOI 10.1038/emboj.2009.267; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; Ganguly S, 2011, BIOPHYS J, V100, P361, DOI 10.1016/j.bpj.2010.12.3692; Guo W, 2008, EMBO J, V27, P2293, DOI 10.1038/emboj.2008.153; Han Y, 2009, NAT CHEM BIOL, V5, P688, DOI 10.1038/nchembio.199; Hanson SM, 2007, P NATL ACAD SCI USA, V104, P3125, DOI 10.1073/pnas.0610886104; Heroux M, 2007, J BIOL CHEM, V282, P31610, DOI 10.1074/jbc.M701790200; Hlavackova V, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002720; Jastrzebska B, 2006, J BIOL CHEM, V281, P11917, DOI 10.1074/jbc.M600422200; Lopez-Gimenez JF, 2007, MOL PHARMACOL, V71, P1015, DOI 10.1124/mol.106.033035; Luo YQ, 2008, J BIOL CHEM, V283, P24789, DOI 10.1074/jbc.M800649200; Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954; Martel C, 2010, RNA, V16, P585, DOI 10.1261/rna.1664210; Masri B, 2008, P NATL ACAD SCI USA, V105, P13656, DOI 10.1073/pnas.0803522105; Maurel D, 2008, NAT METHODS, V5, P561, DOI [10.1038/nmeth.1213, 10.1038/NMETH.1213]; Milligan G, 2010, CURR OPIN PHARMACOL, V10, P23, DOI 10.1016/j.coph.2009.09.010; Monnier C, 2011, EMBO J, V30, P32, DOI 10.1038/emboj.2010.270; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; Park PSH, 2002, BIOCHEMISTRY-US, V41, P5588, DOI 10.1021/bi011746s; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Percherancier Y, 2005, J BIOL CHEM, V280, P9895, DOI 10.1074/jbc.M411151200; Porrello ER, 2011, CELL SIGNAL, V23, P1767, DOI 10.1016/j.cellsig.2011.06.011; Quoyer J, 2013, P NATL ACAD SCI USA, V110, pE5088, DOI 10.1073/pnas.1312515110; Rebois RV, 2008, METHODS, V45, P214, DOI 10.1016/j.ymeth.2008.06.006; Richard-Lalonde M, 2013, MOL PHARMACOL, V83, P416, DOI 10.1124/mol.112.081950; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rivero-Muller A, 2010, P NATL ACAD SCI USA, V107, P2319, DOI 10.1073/pnas.0906695106; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Rodriguez-Frade JM, 2004, EMBO J, V23, P66, DOI 10.1038/sj.emboj.7600020; Roland J, 2003, BLOOD, V101, P399, DOI 10.1182/blood-2002-03-0978; Sohy D, 2007, J BIOL CHEM, V282, P30062, DOI 10.1074/jbc.M705302200; Sohy D, 2009, J BIOL CHEM, V284, P31270, DOI 10.1074/jbc.M109.054809; Stefan E, 2007, P NATL ACAD SCI USA, V104, P16916, DOI 10.1073/pnas.0704257104; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Urizar E, 2011, NAT CHEM BIOL, V7, P624, DOI [10.1038/NCHEMBIO.623, 10.1038/nchembio.623]; van der Westhuizen ET, 2014, MOL PHARMACOL, V85, P492, DOI 10.1124/mol.113.088880; Vilardaga JP, 2008, NAT CHEM BIOL, V4, P126, DOI 10.1038/nchembio.64; Viola A, 2008, ANNU REV PHARMACOL, V48, P171, DOI 10.1146/annurev.pharmtox.48.121806.154841; Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221	63	33	34	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4509	4523		10.1096/fj.13-242446	http://dx.doi.org/10.1096/fj.13-242446			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25053617	Bronze			2022-12-28	WOS:000342222700027
J	Ma, RJ; Hou, XJ; Zhang, L; Sun, SC; Schedl, T; Moley, K; Wang, Q				Ma, Rujun; Hou, Xiaojing; Zhang, Liang; Sun, Shao-Chen; Schedl, Tim; Moley, Kelle; Wang, Qiang			Rab5a is required for spindle length control and kinetochore-microtubule attachment during meiosis in oocytes	FASEB JOURNAL			English	Article						CENPF; vesicles; chromosome	CENP-F; CHROMOSOME ALIGNMENT; EFFECTOR EEA1; MEMBRANE; PROTEIN; GTPASES; NUMA; LOCALIZATION; RECRUITMENT; CAPTURE	Rab GTPases are highly conserved components of vesicle trafficking pathways. Rab5, as a master regulator of endocytic trafficking, has been shown to function in membrane tethering and docking. However, the function of Rab5 in meiosis has not been addressed. Here, we report elongated spindles and misaligned chromosomes, with kinetochore-microtubule misattachments, on specific depletion of Rab5a in mouse oocytes. Moreover, the localization and levels of centromere protein F (CENPF), a component of the nuclear matrix, are severely reduced at kinetochores in metaphase oocytes following Rab5a knockdown. Consistent with this finding, nuclear lamina disassembly in the transition from prophase arrest to meiosis I is also impaired in Rab5a-depleted oocytes. Notably, oocyte-specific ablation of CENPF phenocopies the meiotic defects resulting from Rab5a knockdown. In summary, our data support a model where Rab5a-positive vesicles, likely through interaction with nuclear lamina, modulate CENPF localization and levels at centromeres, consequently ensuring proper spindle length and kinetochore-microtubule attachment in meiotic oocytes.	[Ma, Rujun] Nanjing Agr Univ, Coll Vet Med, Nanjing 210029, Jiangsu, Peoples R China; [Zhang, Liang; Sun, Shao-Chen] Nanjing Agr Univ, Coll Anim Sci & Technol, Nanjing 210029, Jiangsu, Peoples R China; [Ma, Rujun; Hou, Xiaojing; Zhang, Liang; Wang, Qiang] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China; [Schedl, Tim; Moley, Kelle] Washington Univ, Sch Med, St Louis, MO USA	Nanjing Agricultural University; Nanjing Agricultural University; Nanjing Medical University; Washington University (WUSTL)	Wang, Q (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.	qwang2012@njmu.edu.cn			National Key Scientific Research Projects [2014CB943200]; National Natural Science Foundation [31301181]; Natural Science Foundation of the Jiangsu Higher Education Institutions of China [13KJA310001]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM100756] Funding Source: NIH RePORTER	National Key Scientific Research Projects; National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of the Jiangsu Higher Education Institutions of China(National Natural Science Foundation of China (NSFC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dong Zhang (Nanjing Medical University) for technical assistance. This work was supported by National Key Scientific Research Projects (2014CB943200), National Natural Science Foundation (31301181), and Natural Science Foundation of the Jiangsu Higher Education Institutions (13KJA310001) of China. The authors declare no conflicts of interest.	Audhya A, 2007, J CELL BIOL, V178, P1309, DOI 10.1083/jcb.20070113920070911c; Barr FA, 2013, J CELL BIOL, V202, P191, DOI 10.1083/jcb.201306010; Bomont P, 2005, EMBO J, V24, P3927, DOI 10.1038/sj.emboj.7600848; BUCCI C, 1995, FEBS LETT, V366, P65, DOI 10.1016/0014-5793(95)00477-Q; Capalbo L, 2011, P NATL ACAD SCI USA, V108, P17343, DOI 10.1073/pnas.1103720108; Chen PI, 2009, J BIOL CHEM, V284, P30328, DOI 10.1074/jbc.M109.034546; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Foley EA, 2013, NAT REV MOL CELL BIO, V14, P25, DOI 10.1038/nrm3494; Fu WX, 2013, P NATL ACAD SCI USA, V110, P15295, DOI 10.1073/pnas.1312382110; Galvez T, 2012, CELL, V151, P234, DOI 10.1016/j.cell.2012.09.013; Gregan J, 2011, TRENDS CELL BIOL, V21, P374, DOI 10.1016/j.tcb.2011.01.003; Haren Laurence, 2009, BMC Res Notes, V2, P64, DOI 10.1186/1756-0500-2-64; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Holt SV, 2005, J CELL SCI, V118, P4889, DOI 10.1242/jcs.02614; Holubcova Z, 2013, NAT CELL BIOL, V15, P937, DOI 10.1038/ncb2802; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Howe K, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.112151; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Hutagalung AH, 2011, PHYSIOL REV, V91, P119, DOI 10.1152/physrev.00059.2009; Kawasaki M, 2005, CURR OPIN STRUC BIOL, V15, P681, DOI 10.1016/j.sbi.2005.10.015; Kolano A, 2012, P NATL ACAD SCI USA, V109, pE1858, DOI 10.1073/pnas.1204686109; Krisher R.L., 2004, J ANIM SCI, V82, pE14, DOI 10.2527/2004.8213_supplE14x; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Liu ZH, 2009, J CELL BIOL, V186, P473, DOI 10.1083/jcb.200902071; Miserey-Lenkei S, 2006, EMBO J, V25, P278, DOI 10.1038/sj.emboj.7600929; Radulescu AE, 2010, TRENDS CELL BIOL, V20, P214, DOI 10.1016/j.tcb.2010.01.003; Serio G, 2011, P NATL ACAD SCI USA, V108, P17337, DOI 10.1073/pnas.1103516108; Silk AD, 2009, J CELL BIOL, V184, P677, DOI 10.1083/jcb.200810091; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Tanaka K, 2013, CELL MOL LIFE SCI, V70, P559, DOI 10.1007/s00018-012-1057-7; Tanaka TU, 2013, EMBO REP, V14, P1073, DOI 10.1038/embor.2013.181; Wang Q, 2012, ENDOCRINOLOGY, V153, P1984, DOI 10.1210/en.2011-1815; Yang ZY, 2005, MOL CELL BIOL, V25, P4062, DOI 10.1128/MCB.25.10.4062-4074.2005; Yu LZ, 2007, CELL CYCLE, V6, P330, DOI 10.4161/cc.6.3.3805; Zhang D, 2004, BIOL REPROD, V71, P740, DOI 10.1095/biolreprod.104.028282	36	28	28	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4026	4035		10.1096/fj.14-250886	http://dx.doi.org/10.1096/fj.14-250886			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24876181	Green Published, Bronze			2022-12-28	WOS:000340845900020
J	Barcomb, K; Buard, I; Coultrap, SJ; Kulbe, JR; O'Leary, H; Benke, TA; Bayer, KU				Barcomb, Kelsey; Buard, Isabelle; Coultrap, Steven J.; Kulbe, Jacqueline R.; O'Leary, Heather; Benke, Timothy A.; Bayer, K. Ulrich			Autonomous CaMKII requires further stimulation by Ca2+/calmodulin for enhancing synaptic strength	FASEB JOURNAL			English	Article						hippocampus; neuron; signal transduction	PROTEIN-KINASE-II; LONG-TERM POTENTIATION; INHIBITORY AUTOPHOSPHORYLATION; ALPHA-CAMKII; CALMODULIN; BINDING; CALCIUM/CALMODULIN; SUBUNIT; MECHANISM; ACTIVATION	A hallmark feature of Ca2+/calmodulin (CaM)-dependent protein kinase II (CaMKII) is generation of autonomous (Ca2+-independent) activity by T286 autophosphorylation. Biochemical studies have shown that "autonomous" CaMKII is similar to 5-fold further stimulated by Ca2+/CaM, but demonstration of a physiological function for such regulation within cells has remained elusive. In this study, CaMKII-induced enhancement of synaptic strength in rat hippocampal neurons required both autonomous activity and further stimulation. Synaptic strength was decreased by CaMKII alpha knockdown and rescued by reexpression, but not by mutants impaired for autonomy (T286A) or binding to NMDA-type glutamate receptor subunit 2B (GluN2B; formerly NR2B; I205K). Full rescue was seen with constitutively autonomous mutants (T286D), but only if they could be further stimulated (additional T305/306A mutation), and not with two other mutations that additionally impair Ca2+/CaM binding. Compared to rescue with wild-type CaMKII, the CaM-binding-impaired mutants even had reduced synaptic strength. One of these mutants (T305/306D) mimicked an inhibitory autophosphorylation of CaMKII, whereas the other one (Delta stim) abolished CaM binding without introducing charged residues. Inhibitory T305/306 autophosphorylation also reduced GluN2B binding, but this effect was independent of reduced Ca2+ /CaM binding and was not mimicked by T305/306D mutation. Thus, even autonomous CaMKII activity must be further stimulated by Ca2+ /CaM for enhancement of synaptic strength.-Barcomb, K., Buard, I., Coultrap, S. J., Kulbe, J. R., O'Leary, H., Benke, T. A., Bayer, K. U. Autonomous CaMKII requires further stimulation by Ca2+/calmodulin for enhancing synaptic strength.	[Barcomb, Kelsey; Buard, Isabelle; Coultrap, Steven J.; Kulbe, Jacqueline R.; O'Leary, Heather; Benke, Timothy A.; Bayer, K. Ulrich] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA; [O'Leary, Heather; Benke, Timothy A.] Univ Colorado, Sch Med, Dept Pediat, Neurol Sect, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Bayer, KU (corresponding author), Univ Colorado, Sch Med, Dept Pharmacol, Anschutz Med Campus,Mail Stop 8303,RC1 North, Aurora, CO 80045 USA.	ulli.bayer@ucdenver.edu		Barcomb, Kelsey/0000-0002-4050-0566; Benke, Timothy/0000-0002-6969-5061	U.S. National Institutes of Health [R01NS081248, R01NS076577, T32GM007635, P30NS04154]; Thorkildsen fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS048154, R01NS076577, R01NS081248] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Thorkildsen fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by U.S. National Institutes of Health grants R01NS081248 (to K. U. B), R01NS076577 (to T. B), T32GM007635 (to K. B. and H. O.), and P30NS04154 (to the University of Colorado Center) and by a Thorkildsen fellowship (to I.B.).	Barcomb K, 2013, MOL PHARMACOL, V84, P834, DOI 10.1124/mol.113.089045; Barria A, 2005, NEURON, V48, P289, DOI 10.1016/j.neuron.2005.08.034; Bayer KU, 2006, J NEUROSCI, V26, P1164, DOI 10.1523/JNEUROSCI.3116-05.2006; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Buard I, 2010, J NEUROSCI, V30, P8214, DOI 10.1523/JNEUROSCI.1469-10.2010; Colbran RJ, 2004, BIOCHEM J, V378, P1, DOI 10.1042/BJ20031547; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; Coultrap S.J., 2012, NEUROMETHODS PROTEIN, P49; Coultrap SJ, 2014, CELL REP, V6, P431, DOI 10.1016/j.celrep.2014.01.005; Coultrap SJ, 2012, TRENDS NEUROSCI, V35, P607, DOI 10.1016/j.tins.2012.05.003; Coultrap SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037176; Coultrap SJ, 2010, J BIOL CHEM, V285, P17930, DOI 10.1074/jbc.M109.069351; Elgersma Y, 2002, NEURON, V36, P493, DOI 10.1016/S0896-6273(02)01007-3; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; FONG YL, 1989, J BIOL CHEM, V264, P16759; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Griffith LC, 2004, J NEUROSCI, V24, P8394, DOI 10.1523/JNEUROSCI.3604-04.2004; Halt AR, 2012, EMBO J, V31, P1203, DOI 10.1038/emboj.2011.482; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; Hoogenraad CC, 2007, DEV CELL, V12, P587, DOI 10.1016/j.devcel.2007.02.006; Jiao YX, 2011, J BIOL CHEM, V286, P24806, DOI 10.1074/jbc.M110.216010; Lee SJR, 2009, NATURE, V458, P299, DOI 10.1038/nature07842; Lengyel I, 2004, EUR J NEUROSCI, V20, P3063, DOI 10.1111/j.1460-9568.2004.03748.x; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Lisman J, 2012, NAT REV NEUROSCI, V13, P169, DOI 10.1038/nrn3192; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; Loweth JA, 2013, J NEUROSCI, V33, P1411, DOI 10.1523/JNEUROSCI.4386-13.2013; Marsden KC, 2010, P NATL ACAD SCI USA, V107, P20559, DOI 10.1073/pnas.1010346107; Merrill MA, 2005, TRENDS PHARMACOL SCI, V26, P645, DOI 10.1016/j.tips.2005.10.003; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; O'Leary H, 2006, MOL BIOL CELL, V17, P4656, DOI 10.1091/mbc.E06-03-0252; O'Leary H, 2011, J BIOL CHEM, V286, P31272, DOI 10.1074/jbc.M111.233668; Pi HJ, 2010, J NEUROSCI, V30, P8704, DOI 10.1523/JNEUROSCI.0133-10.2010; Rich RC, 1998, J BIOL CHEM, V273, P28424, DOI 10.1074/jbc.273.43.28424; Robertson HR, 2009, J NEUROSCI, V29, P7929, DOI 10.1523/JNEUROSCI.6093-08.2009; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; Steinmetz CC, 2006, J PHYSIOL-LONDON, V577, P249, DOI 10.1113/jphysiol.2006.117358; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Thiagarajan TC, 2002, NEURON, V36, P1103, DOI 10.1016/S0896-6273(02)01049-8; Vest RS, 2007, MOL BIOL CELL, V18, P5024, DOI 10.1091/mbc.E07-02-0185; Vest RS, 2010, J BIOL CHEM, V285, P20675, DOI 10.1074/jbc.M109.088617; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	44	32	32	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3810	3819		10.1096/fj.14-250407	http://dx.doi.org/10.1096/fj.14-250407			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24843070	Green Published			2022-12-28	WOS:000340265400045
J	Camps, J; Wangsa, D; Falke, M; Brown, M; Case, CM; Erdos, MR; Ried, T				Camps, Jordi; Wangsa, Darawalee; Falke, Martin; Brown, Markus; Case, Chanelle M.; Erdos, Michael R.; Ried, Thomas			Loss of lamin B1 results in prolongation of S phase and decondensation of chromosome territories	FASEB JOURNAL			English	Article						nuclear organization; alternative splicing	GILFORD-PROGERIA-SYNDROME; LARGE GENE LISTS; DNA-REPLICATION; NUCLEAR LAMINS; HUMAN FIBROBLASTS; HUMAN-CELLS; ORGANIZATION; CHROMATIN; ARCHITECTURE; SENESCENCE	Nuclear lamin B1 (LMNB1) constitutes one of the major structural proteins in the lamina mesh. We silenced the expression of LMNB1 by RNA interference in the colon cancer cell line DLD-1 and showed a dramatic redistribution of H3K27me3 from the periphery to a more homogeneous nuclear dispersion. In addition, we observed telomere attrition and an increased frequency of micronuclei and nuclear blebs. By 3D-FISH analyses, we demonstrated that the volume and surface of chromosome territories were significantly larger in LMNB1-depleted cells, suggesting that LMNB1 is required to maintain chromatin condensation in interphase nuclei. These changes led to a prolonged S phase due to activation of Chk1. Finally, silencing of LMNB1 resulted in extensive changes in alternative splicing of multiple genes and in a higher number of enlarged nuclear speckles. Taken together, our results suggest a mechanistic role of the nuclear lamina in the organization of chromosome territories, maintenance of genome integrity and proper gene splicing.	[Camps, Jordi; Wangsa, Darawalee; Falke, Martin; Brown, Markus; Case, Chanelle M.; Ried, Thomas] NCI, Sect Canc Genom, Genet Branch, Bethesda, MD 20893 USA; [Erdos, Michael R.] NHGRI, Genome Technol Branch, US Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Ried, T (corresponding author), NCI, Sect Canc Genom, Genet Branch, Ctr Canc Res,NIH, 50 South Dr,Bldg 50,Rm 1408, Bethesda, MD 20893 USA.	riedt@mail.nih.gov	Camps, Jordi/AAG-3080-2020	Camps, Jordi/0000-0002-3165-3640; Brown, Markus Alexander/0000-0002-2069-0120	Intramural Research Program of the U.S. National Institutes of Health, National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIABC010835] Funding Source: NIH RePORTER	Intramural Research Program of the U.S. National Institutes of Health, National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Abdel Elkalhoun (director of the Microarray Core, National Human Genome Research Institute), Dr. Stephen M. Wincovitch and Dr. Amalia Dutra (Cytogenetics and Microscopy Core, National Human Genome Research Institute), and Barbara J. Taylor (Facility Head of the FACS Core Laboratory, National Cancer Institute) for technical support. The authors also thank Buddy Chen for editorial assistance. This project was supported by the Intramural Research Program of the U.S. National Institutes of Health, National Cancer Institute. The authors declare no conflicts of interest.	Bolzer A, 2005, PLOS BIOL, V3, P826, DOI 10.1371/journal.pbio.0030157; Broers JLV, 2006, PHYSIOL REV, V86, P967, DOI 10.1152/physrev.00047.2005; Cao K, 2011, J CLIN INVEST, V121, P2833, DOI 10.1172/JCI43578; Capell BC, 2006, NAT REV GENET, V7, P940, DOI 10.1038/nrg1906; Cremer M, 2001, CHROMOSOME RES, V9, P541, DOI 10.1023/A:1012495201697; Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119; Dechat T, 2008, GENE DEV, V22, P832, DOI 10.1101/gad.1652708; Ellis DJ, 1997, J CELL SCI, V110, P2507; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11-10-0884; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Guelen L, 2008, NATURE, V453, P948, DOI 10.1038/nature06947; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang S, 2008, EXP CELL RES, V314, P82, DOI 10.1016/j.yexcr.2007.08.004; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Lanctot C, 2007, NAT REV GENET, V8, P104, DOI 10.1038/nrg2041; Landry JJM, 2013, G3-GENES GENOM GENET, V3, P1213, DOI 10.1534/g3.113.005777; Lund E, 2013, GENOME RES, V23, P1580, DOI 10.1101/gr.159400.113; Macville M, 1999, CANCER RES, V59, P141; Malhas A, 2007, J CELL BIOL, V176, P593, DOI 10.1083/jcb.200607054; Martins S, 2003, J CELL BIOL, V160, P177, DOI 10.1083/jcb.200210026; McCord RP, 2013, GENOME RES, V23, P260, DOI 10.1101/gr.138032.112; Misteli T, 2007, CELL, V128, P787, DOI 10.1016/j.cell.2007.01.028; MOIR RD, 1994, J CELL BIOL, V125, P1201, DOI 10.1083/jcb.125.6.1201; Scaffidi P, 2005, NAT MED, V11, P440, DOI 10.1038/nm1204; Sengupta K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000199; Shah PP, 2013, GENE DEV, V27, P1787, DOI 10.1101/gad.223834.113; Shimi T, 2010, COLD SH Q B, V75, P525, DOI 10.1101/sqb.2010.75.045; Shimi T, 2011, GENE DEV, V25, P2579, DOI 10.1101/gad.179515.111; Shimi T, 2008, GENE DEV, V22, P3409, DOI 10.1101/gad.1735208; Shumaker DK, 2006, P NATL ACAD SCI USA, V103, P8703, DOI 10.1073/pnas.0602569103; Spann TP, 1997, J CELL BIOL, V136, P1201, DOI 10.1083/jcb.136.6.1201; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Takebayashi S, 2012, NUCLEUS-PHILA, V3, P500, DOI 10.4161/nucl.22318; Tang CW, 2008, J CELL SCI, V121, P1014, DOI 10.1242/jcs.020982; Vergnes L, 2004, P NATL ACAD SCI USA, V101, P10428, DOI 10.1073/pnas.0401424101; Yoshida K, 2010, J CELL SCI, V123, P225, DOI 10.1242/jcs.058693	39	41	43	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3423	3434		10.1096/fj.14-250456	http://dx.doi.org/10.1096/fj.14-250456			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24732130	Green Published			2022-12-28	WOS:000340265400013
J	Gao, XQ; Usas, A; Proto, JD; Lu, AP; Cummins, JH; Proctor, A; Chen, CW; Huard, J				Gao, Xueqin; Usas, Arvydas; Proto, Jonathan D.; Lu, Aiping; Cummins, James H.; Proctor, Alexander; Chen, Chien-Wen; Huard, Johnny			Role of donor and host cells in muscle-derived stem cell-mediated bone repair: differentiation vs. paracrine effects	FASEB JOURNAL			English	Article						bone morphogenetic protein 4; inflammation; angiogenesis; monocyte chemotactic protein 1; cyclooxygenase 2	VIVO GENE-THERAPY; MONOCYTE CHEMOATTRACTANT PROTEIN-1; MESENCHYMAL STEM/STROMAL CELLS; SKELETAL-MUSCLE; REGENERATIVE MECHANISMS; MORPHOGENETIC PROTEIN-2; STEM/PROGENITOR CELLS; ENGINEERED BONE; ANGIOGENESIS; RECRUITMENT	Murine muscle-derived stem cells (MDSCs) have been shown capable of regenerating bone in a critical size calvarial defect model when transduced with BMP 2 or 4; however, the contribution of the donor cells and their interactions with the host cells during the bone healing process have not been fully elucidated. To address this question, C57/BL/6J mice were divided into MDSC/BMP4/GFP, MDSC/GFP, and scaffold groups. After transplanting MDSCs into the critical-size calvarial defects created in normal mice, we found that mice transplanted with BMP4GFP-transduced MDSCs healed the bone defect in 4 wk, while the control groups (MDSC-GFP and scaffold) demonstrated no bone healing. The newly formed trabecular bone displayed similar biomechanical properties as the native bone, and the donor cells directly participated in endochondral bone formation via their differentiation into chondrocytes, osteoblasts, and osteocytes via the BMP4-pSMAD5 and COX-2-PGE2 signaling pathways. In contrast to the scaffold group, the MDSC groups attracted more inflammatory cells initially and incurred faster inflammation resolution, enhanced angiogenesis, and suppressed initial immune responses in the host mice. MDSCs were shown to attract macrophages via the secretion of monocyte chemotactic protein 1 and promote endothelial cell proliferation by secreting multiple growth factors. Our findings indicated that BMP4GFP-transduced MDSCs not only regenerated bone by direct differentiation, but also positively influenced the host cells to coordinate and promote bone tissue repair through paracrine effects.-Gao, X., Usas, A., Proto, J. D., Lu, A., Cummins, J. H., Proctor, A., Chen, C.-W., Huard, J. Role of donor and host cells in muscle-derived stem cell-mediated bone repair: differentiation vs. paracrine effects.	[Gao, Xueqin; Usas, Arvydas; Proto, Jonathan D.; Lu, Aiping; Cummins, James H.; Chen, Chien-Wen; Huard, Johnny] Univ Pittsburgh, Dept Orthopaed Surg, Stem Cell Res Ctr, Pittsburgh, PA 15219 USA; [Proctor, Alexander] Act Life Sci, Santa Barbara, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Huard, J (corresponding author), Univ Pittsburgh, Dept Orthopaed Surg, Stem Cell Res Ctr, Bridgeside Point 2,450 Technol Dr, Pittsburgh, PA 15219 USA.	jhuard@pitt.edu		Gao, Xueqin/0000-0001-5833-1548; Chen, William CW/0000-0002-6891-3557	U.S. National Institutes of Health [5RO1-DE13420-09]; Henry J. Mankin endowed chair at the University of Pittsburgh; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013420] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Henry J. Mankin endowed chair at the University of Pittsburgh; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors thank Jessica C. Tebbets, Ying Tang, and Minakshi Poddar for their assistance in producing the retro-BMP4/GFP and retro-GFP viruses utilized in this study and Mathieu Huard for his assistance in paraffin sectioning. The authors also thank Allison Logar (Children's Hospital of Pittsburgh, Pittsburgh, PA, USA) for the FACS sorting of GFP-and BMP4GFP-transduced MDSCs. The authors also thank Dr. Burhan Gharaibeh for assistance in formatting the references and Bria King and Adam Kozemchak for their editorial assistance. This project was supported, in part, by a U.S. National Institutes of Health grant (5RO1-DE13420-09) awarded to J. H. and the Henry J. Mankin endowed chair at the University of Pittsburgh. J. H. receives remuneration as a consultant and royalties from Cook MyoSite, Inc. (Pittsburgh, PA, USA). The other authors declare no conflicts of interest. The experiments performed for this study comply with the current laws of the United States of America.	Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Akiyama H, 2005, P NATL ACAD SCI USA, V102, P14665, DOI 10.1073/pnas.0504750102; Akiyama H., 2002, GENE DEV, V16, P2183; Alhag M, 2011, ORAL MAXILLOFAC SURG, V15, P31, DOI 10.1007/s10006-010-0241-x; Ando Y, 2014, BONE, V61, P82, DOI 10.1016/j.bone.2013.12.029; Behr B, 2011, STEM CELLS, V29, P286, DOI 10.1002/stem.581; Ben-Mordechai T, 2013, J AM COLL CARDIOL, V62, P1890, DOI 10.1016/j.jacc.2013.07.057; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Duran JM, 2013, CIRC RES, V113, P539, DOI 10.1161/CIRCRESAHA.113.301202; Gao XQ, 2013, CELL TRANSPLANT, V22, P2393, DOI 10.3727/096368912X658854; Gehmert S, 2011, CLIN HEMORHEOL MICRO, V48, P5, DOI 10.3233/CH-2011-1397; Gharaibeh B, 2008, NAT PROTOC, V3, P1501, DOI 10.1038/nprot.2008.142; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Hsiao STF, 2012, STEM CELLS DEV, V21, P2189, DOI 10.1089/scd.2011.0674; Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08; Lau KHW, 2013, BONE, V53, P369, DOI 10.1016/j.bone.2013.01.003; Lee JY, 2002, HUM GENE THER, V13, P1201, DOI 10.1089/104303402320138989; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Mastrogiacomo M, 2005, J CELL PHYSIOL, V204, P594, DOI 10.1002/jcp.20325; Misener S., 2000, BIOINFORMATICS METHO; Murnaghan M, 2006, J BONE JOINT SURG AM, V88A, P140, DOI 10.2106/JBJS.F.00454; Musgrave DS, 2002, J BONE JOINT SURG BR, V84B, P120, DOI 10.1302/0301-620X.84B1.11708; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708; Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153; Posner LJ, 1997, BONE, V21, P321, DOI 10.1016/S8756-3282(97)00154-3; Prockop DJ, 2013, STEM CELLS, V31, P2042, DOI 10.1002/stem.1400; Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211; Qu D, 2011, J BIOMED MATER RES A, V96A, P543, DOI 10.1002/jbm.a.33009; Roddy GW, 2011, STEM CELLS, V29, P1572, DOI 10.1002/stem.708; Sanberg PR, 2010, J CELL MOL MED, V14, P553, DOI 10.1111/j.1582-4934.2009.00903.x; Shen HC, 2004, BONE, V34, P982, DOI 10.1016/j.bone.2004.01.028; Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963; Stich S, 2008, EUR J CELL BIOL, V87, P365, DOI 10.1016/j.ejcb.2008.03.009; Tamasi JA, 2013, J BONE MINER RES, V28, P1975, DOI 10.1002/jbmr.1933; Tasso R, 2012, BIOMATERIALS, V33, P2086, DOI 10.1016/j.biomaterials.2011.11.043; Tasso R, 2010, BIOMATERIALS, V31, P2121, DOI 10.1016/j.biomaterials.2009.11.064; Tasso R, 2009, TISSUE ENG PT A, V15, P2203, DOI 10.1089/ten.tea.2008.0269; Tatebe M, 2005, CYTOTHERAPY, V7, P520, DOI 10.1080/14653240500361350; Tortelli F, 2010, BIOMATERIALS, V31, P242, DOI 10.1016/j.biomaterials.2009.09.038; Turner NJ, 2013, J TISSUE ENG REGEN M, V7, P139, DOI 10.1002/term.508; Usas A, 2009, TISSUE ENG PT A, V15, P285, DOI 10.1089/ten.tea.2008.0130; Wright VJ, 2002, MOL THER, V6, P169, DOI 10.1006/mthe.2002.0654; Xie C, 2009, AM J PATHOL, V175, P772, DOI 10.2353/ajpath.2009.081099; Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681; Zou DH, 2011, STEM CELLS, V29, P1380, DOI 10.1002/stem.693	47	37	38	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3792	3809		10.1096/fj.13-247965	http://dx.doi.org/10.1096/fj.13-247965			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24843069	Green Published			2022-12-28	WOS:000340265400044
J	Xu, X; Bi, DC; Wu, XT; Wang, QQ; Wei, GB; Chi, LL; Jiang, ZD; Oda, T; Wan, M				Xu, Xu; Bi, Decheng; Wu, Xiaoting; Wang, Qingqing; Wei, Gaobin; Chi, Lianli; Jiang, Zedong; Oda, Tatsuya; Wan, Min			Unsaturated guluronate oligosaccharide enhances the antibacterial activities of macrophages	FASEB JOURNAL			English	Article						innate immunity; alginate; phagocytosis; NF-kappa B; nitric oxide	NITRIC-OXIDE SYNTHASE; CYTOKINE PRODUCTION; INNATE IMMUNITY; SEPTIC MICE; ALGINATE; PHAGOCYTOSIS; CELLS; INHIBITION; MECHANISMS; PROTECTS	Alginate from marine seaweeds is receiving continuous attention owing to its wide physiological activities. Herein, we sought to elucidate possible effects of alginate-derived polyguluronate (PG) and unsaturated guluronate oligosaccharide (GOS) on antibacterial activities of macrophages. Our results showed that, in contrast to PG, GOS markedly increased the phagocytosis of IgG-opsonized Escherichia coli and Staphylococcus aureus and further inhibited the survival of intracellular bacteria in macrophages. In line with this, GOS treatment resulted in the enhanced expression of Fc gamma receptors on macrophages. In addition, GOS activated NF-kappa B pathway, induced TNF-alpha secretion, and elevated the expression of inducible nitric oxide synthase and the production of nitric oxide. Meanwhile, GOS stimulated the production of reactive oxygen species in macrophages. Moreover, guluronate trimer to hexamer (G3-G6) in GOS exhibited significant activity that increased the bacterial phagocytosis of macrophages, with the pentamer (G5), displaying the highest activity. Finally, our in vivo results further confirmed that GOS but not PG significantly improved bacterial clearance in murine acute peritonitis. In conclusion, GOS enhances antibacterial activities of macrophages via modulating signaling pathways related to innate immunity, suggesting that GOS might be a promising therapeutic candidate to improve the host defense against bacterial infection.	[Xu, Xu; Bi, Decheng; Wu, Xiaoting; Wang, Qingqing; Wei, Gaobin] Shenzhen Univ, Coll Life Sci, Shenzhen Key Lab Marine Bioresources & Ecol, Shenzhen, Peoples R China; [Chi, Lianli] Shandong Univ, Natl Glycoengn Res Ctr, Jinan 250100, Peoples R China; [Jiang, Zedong; Oda, Tatsuya] Nagasaki Univ, Fac Fisheries, Div Biochem, Nagasaki 852, Japan; [Wan, Min] Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden	Shenzhen University; Shandong University; Nagasaki University; Karolinska Institutet	Wan, M (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden.	min.wan@ki.se	Chi, Lianli/B-9149-2015; Jiang, Zedong/G-1317-2013	Chi, Lianli/0000-0003-1126-1022; Jiang, Zedong/0000-0001-7579-3680	National Natural Science Foundation of China [31000770]; Foundation for Distinguished Young Talents in Higher Education (Guangdong, China; FDYT) [LYM10114]; Marine Biotechnology Initiative Project (Shenzhen, China); Grants-in-Aid for Scientific Research [12F02093] Funding Source: KAKEN	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation for Distinguished Young Talents in Higher Education (Guangdong, China; FDYT); Marine Biotechnology Initiative Project (Shenzhen, China); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Dr. Renli Zhang (Shenzhen Center for Disease Control and Prevention, Shenzen, China) for the bacteria management and technical assistance. The authors are also grateful to Mrs. Lijun Yao (Shenzhen University) for assistance with the cell culture. This work was supported financially by the National Natural Science Foundation of China (grant 31000770), Foundation for Distinguished Young Talents in Higher Education (Guangdong, China; FDYT, grant LYM10114), and the Marine Biotechnology Initiative Project (Shenzhen, China). The authors declare no conflicts of interest.	Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; AKIYAMA H, 1992, BIOSCI BIOTECH BIOCH, V56, P355, DOI 10.1271/bbb.56.355; Eftekharzadeh B, 2010, CARBOHYD POLYM, V79, P1063, DOI 10.1016/j.carbpol.2009.10.040; Ernst JD, 2000, CELL MICROBIOL, V2, P379, DOI 10.1046/j.1462-5822.2000.00075.x; Flannagan RS, 2009, NAT REV MICROBIOL, V7, P355, DOI 10.1038/nrmicro2128; Gomes RN, 2013, SHOCK, V39, P63, DOI 10.1097/SHK.0b013e31827802b5; HAUG A, 1966, ACTA CHEM SCAND, V20, P183, DOI 10.3891/acta.chem.scand.20-0183; HAUG ARNE, 1965, METHOD CARBOHYD CHEM, V5, P69; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; Hollenberg SM, 2000, CIRC RES, V86, P774, DOI 10.1161/01.RES.86.7.774; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; Iwamoto M, 2005, FEBS LETT, V579, P4423, DOI 10.1016/j.febslet.2005.07.007; Iwamoto Y, 2003, BIOSCI BIOTECH BIOCH, V67, P258, DOI 10.1271/bbb.67.258; Kang HJ, 2011, BIOCHEM BIOPH RES CO, V406, P449, DOI 10.1016/j.bbrc.2011.02.069; Kim AR, 2013, J BIOMAT SCI-POLYM E, V24, P1084, DOI 10.1080/09205063.2012.735100; Kohchi C, 2009, ANTICANCER RES, V29, P817; Mo SJ, 2003, ARCH PHARM RES, V26, P244, DOI 10.1007/BF02976837; MORRIS ER, 1980, CARBOHYD RES, V81, P305, DOI 10.1016/S0008-6215(00)85661-X; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Pontes GN, 2007, J PINEAL RES, V43, P365, DOI 10.1111/j.1600-079X.2007.00487.x; SCHNEEMANN M, 1993, J INFECT DIS, V167, P1358, DOI 10.1093/infdis/167.6.1358; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; Tsai WC, 1997, INFECT IMMUN, V65, P1870, DOI 10.1128/IAI.65.5.1870-1875.1997; Tusi SK, 2011, BIOMATERIALS, V32, P5438, DOI 10.1016/j.biomaterials.2011.04.024; Xu X, 2003, BIOSCI BIOTECH BIOCH, V67, P2022, DOI 10.1271/bbb.67.2022; Yang D, 2009, J BIOMED MATER RES A, V90A, P411, DOI 10.1002/jbm.a.32096	27	29	31	4	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2645	2654		10.1096/fj.13-247791	http://dx.doi.org/10.1096/fj.13-247791			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24599964				2022-12-28	WOS:000339883600022
J	Aleshcheva, G; Wehland, M; Sahana, J; Bauer, J; Corydon, TJ; Hemmersbach, R; Frett, T; Egli, M; Infanger, M; Grosse, J; Grimm, D				Aleshcheva, Ganna; Wehland, Markus; Sahana, Jayashree; Bauer, Johann; Corydon, Thomas J.; Hemmersbach, Ruth; Frett, Timo; Egli, Marcel; Infanger, Manfred; Grosse, Jirka; Grimm, Daniela			Moderate alterations of the cytoskeleton in human chondrocytes after short-term microgravity produced by parabolic flight maneuvers could be prevented by up-regulation of BMP-2 and SOX-9	FASEB JOURNAL			English	Article						gene expression; F-actin; hypergravity; vibration	HUMAN ENDOTHELIAL-CELLS; THYROID-CANCER CELLS; LEFT-VENTRICULAR HYPERTROPHY; FIBROBLAST-GROWTH-FACTOR; SIMULATED MICROGRAVITY; GENE-EXPRESSION; MAMMALIAN-CELLS; SPHEROID FORMATION; ALTERED GRAVITY; WEIGHTLESSNESS	Real and simulated microgravity induce a variety of changes in human cells. Most importantly, changes in the cytoskeleton have been noted, and studies on microtubules have shown that they are gravisensitive. This study focuses on the effects of short-term real microgravity on gene expression, protein content, and cytoskeletal structure of human chondrocytes. We cultivated human chondrocytes, took them along a parabolic flight during the 24th Deutsches Zentrum fur Luft-und Raumfahrt Parabolic (DLR) Flight Campaign, and fixed them after the 1st and the 31st parabola. Immunofluorescence microscopy revealed no changes after the 1st parabola, but disruptions of beta-tubulin, vimentin, and cytokeratin networks after the 31st parabola. No Factin stress fibers were detected even after 31 parabolas. Furthermore, mRNA and protein quantifications after the 31st parabola showed a clear up-regulation of cytoskeletal genes and proteins. The mRNAs were significantly up-regulated as follows: TUBB, 2-fold; VIM, 1.3-fold; KRT8, 1.8-fold; ACTB, 1.9-fold; ICAM1, 4.8-fold; OPN, 7-fold; ITGA10, 1.5-fold; ITGB1, 1.2-fold; TGFB1, 1.5-fold; CAV1, 2.6-fold; SOX9, 1.7-fold; BMP-2, 5.3-fold. However, SOX5 (-25%) and SOX6 (-28%) gene expression was decreased. Contrary, no significant changes in gene expression levels were observed during vibration and hypergravity experiments. These data suggest that short-term microgravity affects the gene expression of distinct proteins. In contrast to poorly differentiated follicular thyroid cancer cells or human endothelial cells, chondrocytes only exert moderate cytoskeletal alterations. The up-regulation of BMP-2, TGF-beta 1, and SOX9 in chondrocytes may play a key role in preventing cytoskeletal alterations.	[Aleshcheva, Ganna; Wehland, Markus; Infanger, Manfred] Univ Magdeburg, Clin Plast Aesthet & Hand Surg, D-39106 Magdeburg, Germany; [Sahana, Jayashree; Corydon, Thomas J.; Grimm, Daniela] Aarhus Univ, Dept Biomed, DK-8000 Aarhus C, Denmark; [Bauer, Johann] Max Planck Inst Biochem, D-82152 Martinsried, Germany; [Hemmersbach, Ruth; Frett, Timo] DLR German Aerosp Ctr, Biomed Res, Gravitat Biol, Cologne, Germany; [Egli, Marcel] Luzerne Univ Appl Sci & Arts, Space Biol Grp, Aerosp Biomed Sci & Technol, Hergiswil, Switzerland; [Grosse, Jirka] Univ Regensburg, Dept Nucl Med, D-93053 Regensburg, Germany	Otto von Guericke University; Aarhus University; Max Planck Society; Helmholtz Association; German Aerospace Centre (DLR); University of Regensburg	Grimm, D (corresponding author), Aarhus Univ, Dept Biomed, Wilhelm Meyers Alle 4, DK-8000 Aarhus C, Denmark.	dgg@biomed.au.dk		Wehland, Markus/0000-0002-8160-859X; Corydon, Thomas Juhl/0000-0003-3588-6350; Frett, Timo/0000-0002-5572-1177; Grimm, Daniela/0000-0002-4991-3105; Sahana, Jayashree/0000-0002-6606-6315	Helmholtz Space Life Sciences Research School (SpaceLife), German Space Agency BMWi Project [50WB1124]; European Space Agency [CORA-GBF-2013-004]	Helmholtz Space Life Sciences Research School (SpaceLife), German Space Agency BMWi Project; European Space Agency(European Space AgencyEuropean Commission)	The authors thank the Helmholtz Space Life Sciences Research School (SpaceLife), German Space Agency BMWi Project 50WB1124 (to D.G.), European Space Agency Grant CORA-GBF-2013-004 (to D.G.), Aarhus University (D.G.), and Deutsche Gesellschaft fur Luft- und Raumfahrtmedizin (DGLRM) (Young Fellow Program) (to G.A.). The data in this publication form a part of the Ph.D. thesis of G.A.	Aleshcheva G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079057; BENJAMIN M, 1994, MICROSC RES TECHNIQ, V28, P372, DOI 10.1002/jemt.1070280503; Blain EJ, 2009, INT J EXP PATHOL, V90, P1, DOI 10.1111/j.1365-2613.2008.00625.x; Boonstra J, 1999, FASEB J, V13, pS35, DOI 10.1096/fasebj.13.9001.s35; Chavagnac C, 2013, ACTA ASTRONAUT, V92, P172, DOI 10.1016/j.actaastro.2012.09.001; Foldes I, 1996, ACTA BIOL HUNG, V47, P145; Freed LE, 1997, P NATL ACAD SCI USA, V94, P13885, DOI 10.1073/pnas.94.25.13885; Gao L, 2013, J CELL SCI, V126, P5704, DOI 10.1242/jcs.135483; Greenwald E., UNDERSTANDING PHYSL; Grimm D, 2002, FASEB J, V16, P604, DOI 10.1096/fj.01-0673fje; Grimm D, 2002, CARDIOVASC PATHOL, V11, P229, DOI 10.1016/S1054-8807(01)00116-8; Grimm D, 2011, EXPERT REV PROTEOMIC, V8, P13, DOI 10.1586/EPR.10.105; Grimm D, 2010, TISSUE ENG PT A, V16, P1559, DOI [10.1089/ten.tea.2009.0524, 10.1089/ten.TEA.2009.0524]; Grimm D, 2009, TISSUE ENG PT A, V15, P2267, DOI 10.1089/ten.tea.2008.0576; Grosse J, 2012, FASEB J, V26, P5124, DOI 10.1096/fj.12-215749; Grosse J, 2012, FASEB J, V26, P639, DOI 10.1096/fj.11-194886; Herranz R, 2013, ASTROBIOLOGY, V13, P1, DOI 10.1089/ast.2012.0876; Hu JJ, 2014, PROTEOME SCI, V12, DOI 10.1186/1477-5956-12-13; Hughes-Fulford M, 2003, ADV SPACE RES-SERIES, V32, P1585, DOI 10.1016/S0273-1177(03)90399-1; Infanger M, 2006, APOPTOSIS, V11, P749, DOI 10.1007/s10495-006-5697-7; Infanger M, 2007, CARDIOVASC PATHOL, V16, P291, DOI 10.1016/j.carpath.2007.04.001; Infanger M, 2007, J CELL BIOCHEM, V101, P1439, DOI 10.1002/jcb.21261; Lee JS, 2005, EXP MOL MED, V37, P427, DOI 10.1038/emm.2005.53; Legate KR, 2009, GENE DEV, V23, P397, DOI 10.1101/gad.1758709; Lewis Marian L, 2002, Adv Space Biol Med, V8, P77; Ma X, 2014, FASEB J, V28, P813, DOI 10.1096/fj.13-243287; MATSUOKA S, 1995, J EXP MED, V181, P2007, DOI 10.1084/jem.181.6.2007; Michigami T, 2013, CELL MOL LIFE SCI, V70, P4213, DOI 10.1007/s00018-013-1346-9; Niu HJ, 2012, ACTA MECH SINICA-PRC, V28, P1488, DOI 10.1007/s10409-012-0150-3; Pietsch J, 2011, CURR MOL MED, V11, P350, DOI 10.2174/156652411795976600; Pietsch J, 2013, BIOMATERIALS, V34, P7694, DOI 10.1016/j.biomaterials.2013.06.054; Pietsch J, 2011, PROTEOMICS, V11, P2095, DOI 10.1002/pmic.201000817; PITZKE P, 1994, ACTA OTO-LARYNGOL, V114, P81, DOI 10.3109/00016489409126021; Riecke K, 2002, ARCH TOXICOL, V76, P360, DOI 10.1007/s00204-002-0338-6; Rossi MA, 1997, AM J TROP MED HYG, V57, P321, DOI 10.4269/ajtmh.1997.57.321; Rothermund L, 2002, AM J HYPERTENS, V15, P644, DOI 10.1016/S0895-7061(02)02956-4; Rothermund L, 2006, J HYPERTENS, V24, P1857, DOI 10.1097/01.hjh.0000242411.50536.b9; Schmidt W, 2004, MICROGRAVITY SCI TEC, V15, P42, DOI 10.1007/BF02870951; Schnabel M, 2002, OSTEOARTHR CARTILAGE, V10, P62, DOI 10.1053/joca.2001.0482; Stamenkovic V, 2010, TISSUE ENG PT A, V16, P1729, DOI 10.1089/ten.tea.2008.0624; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Ulbrich C, 2008, J CELL BIOCHEM, V104, P1324, DOI 10.1002/jcb.21710; Ulbrich C, 2011, CELL PHYSIOL BIOCHEM, V28, P185, DOI 10.1159/000331730; Ulbrich C, 2010, CELL PHYSIOL BIOCHEM, V25, P551, DOI 10.1159/000303059; Unsworth BR, 1998, NAT MED, V4, P901, DOI 10.1038/nm0898-901; Uva BM, 2002, BRAIN RES, V934, P132, DOI 10.1016/S0006-8993(02)02415-0; Wakabayashi T, 2010, BIOCHEM BIOPH RES CO, V391, P1116, DOI 10.1016/j.bbrc.2009.12.034; Wang P, 2011, FASEB J, V25, P3401, DOI 10.1096/fj.11-184861; Weber M, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-124; Wu L, 2014, TISSUE ENG PART C-ME, V20, P160, DOI [10.1089/ten.tec.2013.0056, 10.1089/ten.TEC.2013.0056]; Zayzafoon M, 2005, IMMUNOL REV, V208, P267, DOI 10.1111/j.0105-2896.2005.00330.x; Zimmermann Joshua A., 2011, Molecular & Cellular Biomechanics, V8, P297	52	58	59	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2303	2314		10.1096/fj.14-268151	http://dx.doi.org/10.1096/fj.14-268151			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25681461				2022-12-28	WOS:000355209500009
J	La Sala, G; Marazziti, D; Di Pietro, C; Golini, E; Matteoni, R; Tocchini-Valentini, GP				La Sala, Gina; Marazziti, Daniela; Di Pietro, Chiara; Golini, Elisabetta; Matteoni, Rafaele; Tocchini-Valentini, Glauco P.			Modulation of Dhh signaling and altered Sertoli cell function in mice lacking the GPR37-prosaposin receptor	FASEB JOURNAL			English	Article						G-protein-coupled receptor; Ptch1; testis; spermatogenesis	COUPLED PEPTIDE RECEPTOR; ANDROGEN RECEPTOR; DEFECTIVE SPERMATOGENESIS; MOLECULAR-CLONING; MALE REPRODUCTION; GENE-EXPRESSION; LEYDIG-CELLS; RAT TESTIS; IN-VIVO; MOUSE	The mammalian G-protein-coupled receptor 37 (GPR37) is expressed in brain, in adult testis, and during the early phase of gonad differentiation. Somatic Sertoli cells (SCs) are located within the seminiferous tubules where they support the germinal epithelium. An adequate number of SCs is required for the complete prepubertal differentiation of germ cells and adult fertility. This study shows that Gpr37 and its ligand prosaposin are both postnatally expressed by SCs, whose proliferation and maturation are affected in Gpr37-null mutant mice during postnatal testicular development. Mutant pups show a delayed timing in sperm cell development, with a partial arrest of spermatocytes at the meiotic pachytene (e.g., 1.5-fold increase in Gpr37(-/-) P21 pups) and their increased apoptosis (e.g., 1.8-fold and 3.5-fold increase in Gpr37(-/-) P21 and adult mice, respectively). Mutant adults have reduced testis weight (wild type, 299 +/- 5 mg; knockout, 258 +/- 16 mg; P < 0.05) and epididymal sperm count and motility (e.g., 1.5-fold and 1.45-fold decrease in Gpr37(-/-) mice, respectively). Lack of Gpr37 results in the reduction in androgen receptor levels during prepubertal testis development, alongside the altered expression of SC maturation markers. It also affects the prepubertal testis expression of desert hedgehog (Dhh) mitogenic cascade components (Dhh, 1.3-fold increase in Gpr37(-/-) P10 and P21 pups; Gli2, 1.4-fold and 1.6-fold increase in Gpr37(-/-) P10 and P21 pups, respectively) including patched homolog 1 (1.3-fold increase in Gpr37(-/-) P10 and P21 pups), which is found localized in prepubertal SCs and is associated with Gpr37 in cultured primary SC samples. These results indicate that Gpr37 is a specific modulator of murine testis Dhh mitogenic signaling and SC proliferation and maturation.	[La Sala, Gina; Marazziti, Daniela; Di Pietro, Chiara; Golini, Elisabetta; Matteoni, Rafaele; Tocchini-Valentini, Glauco P.] CNR, Emma Infrafrontier Impc, Ist Biol Cellulare & Neurobiol, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Cellulare e Neurobiologia (IBCN-CNR)	Tocchini-Valentini, GP (corresponding author), Emma Infrafrontier Impc, Campus A Buzzati Traverso,Via E Ramarini 32, I-00015 Rome, Italy.	gtocchini@emma.cnr.it	LA SALA, GINA/AAF-5414-2021; Di Pietro, Chiara/AAA-7161-2021; Daniela, Marazziti/AAC-1062-2022; Golini, Elisabetta/AAX-2849-2020; , Elisabetta/D-9095-2015	LA SALA, GINA/0000-0002-1907-5948; Daniela, Marazziti/0000-0002-1582-9271; , Elisabetta/0000-0002-9323-7124; MATTEONI, RAFAELE/0000-0002-0314-5948; DI PIETRO, CHIARA/0000-0002-2680-1821	Consiglio Nazionale delle Ricerche Progetto d'Interesse Strategico Invecchiamento; European Union	Consiglio Nazionale delle Ricerche Progetto d'Interesse Strategico Invecchiamento; European Union(European Commission)	The authors thank G. Bolasco and E. Perlas for assistance with microscopy and histology; G. Di Franco, G. D'Erasmo, and A. Ventrera for excellent technical assistance; P. Grimaldi for assistance with SC primary cultures; S. Dolci for helpful discussions; and A. Ferrara and T. Cuccurullo for secretarial work. This work was supported in part by Consiglio Nazionale delle Ricerche Progetto d'Interesse Strategico Invecchiamento 2012-2014 and European Union Framework Programmes 6-7 (EUCOMM, EUCOMMTools grants). The authors declare no conflicts of interest.	BARTKE A, 1973, ENDOCRINOLOGY, V92, P1223, DOI 10.1210/endo-92-4-1223; Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; Beardsley A, 2006, J ENDOCRINOL, V190, P759, DOI 10.1677/joe.1.06867; Beau C, 2000, MOL REPROD DEV, V56, P124, DOI 10.1002/(SICI)1098-2795(200006)56:2&lt;124::AID-MRD2&gt;3.0.CO;2-J; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Chang CS, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.109132; Chang CS, 2004, P NATL ACAD SCI USA, V101, P6876, DOI 10.1073/pnas.0307306101; Clark AM, 2000, BIOL REPROD, V63, P1825, DOI 10.1095/biolreprod63.6.1825; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; CORTES D, 1987, INT J ANDROL, V10, P589, DOI 10.1111/j.1365-2605.1987.tb00358.x; De Gendt K, 2004, P NATL ACAD SCI USA, V101, P1327, DOI 10.1073/pnas.0308114100; De Gendt K, 2012, MOL CELL ENDOCRINOL, V352, P13, DOI 10.1016/j.mce.2011.08.008; Franco HL, 2012, CHROMOSOME RES, V20, P247, DOI 10.1007/s10577-011-9254-z; Godmann M, 2008, DEV BIOL, V315, P552, DOI 10.1016/j.ydbio.2007.12.018; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; Griswold MD, 1998, SEMIN CELL DEV BIOL, V9, P411, DOI 10.1006/scdb.1998.0203; Holdcraft RW, 2004, DEVELOPMENT, V131, P459, DOI 10.1242/dev.00957; Holdcraft RW, 2004, INT J ANDROL, V27, P335, DOI 10.1111/j.1365-2605.2004.00502.x; IGDOURA SA, 1995, MOL REPROD DEV, V40, P91, DOI 10.1002/mrd.1080400112; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jahnukainen K, 2004, BIOL REPROD, V70, P290, DOI 10.1095/biolreprod.103.018390; Koochekpour S, 2007, PROSTATE, V67, P178, DOI 10.1002/pros.20513; Kroft TL, 2001, BIOL REPROD, V65, P1663, DOI 10.1095/biolreprod65.6.1663; Latendresse JR, 2002, TOXICOL PATHOL, V30, P524, DOI 10.1080/01926230290105721; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lucas TFG, 2010, BIOL REPROD, V83, P307, DOI 10.1095/biolreprod.110.084160; Marazziti D, 2004, P NATL ACAD SCI USA, V101, P10189, DOI 10.1073/pnas.0403661101; Marazziti D, 1998, GENOMICS, V53, P315, DOI 10.1006/geno.1998.5433; Marazziti D, 1997, GENOMICS, V45, P68, DOI 10.1006/geno.1997.4900; Marazziti D, 2007, P NATL ACAD SCI USA, V104, P9846, DOI 10.1073/pnas.0703368104; Marazziti D, 2013, P NATL ACAD SCI USA, V110, P16486, DOI 10.1073/pnas.1314819110; Mark M, 2004, P NATL ACAD SCI USA, V101, P4453, DOI 10.1073/pnas.0400234101; Mei H, 2011, REPRODUCTION, V141, P357, DOI 10.1530/REP-10-0432; Meyer RC, 2013, P NATL ACAD SCI USA, V110, P9529, DOI 10.1073/pnas.1219004110; Moens PB, 2000, J CELL SCI, V113, P663; Morales CR, 2009, MICROSC RES TECHNIQ, V72, P809, DOI 10.1002/jemt.20733; Morales CR, 1998, J ANDROL, V19, P156; Nef S, 2005, DEV BIOL, V287, P361, DOI 10.1016/j.ydbio.2005.09.008; Notini AJ, 2012, SEX DEV, V6, P223, DOI 10.1159/000339723; ORTH JM, 1988, ENDOCRINOLOGY, V122, P787, DOI 10.1210/endo-122-3-787; Peters AHFM, 1997, CHROMOSOME RES, V5, P66, DOI 10.1023/A:1018445520117; Print CG, 2000, BIOESSAYS, V22, P423, DOI 10.1002/(SICI)1521-1878(200005)22:5&lt;423::AID-BIES4&gt;3.0.CO;2-0; Rey R, 1998, TRENDS ENDOCRIN MET, V9, P271, DOI 10.1016/S1043-2760(98)00069-1; Sanz E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066179; Sharpe RM, 2003, REPRODUCTION, V125, P769, DOI 10.1530/rep.0.1250769; STEINBERGER A, 1971, BIOL REPROD, V4, P84, DOI 10.1093/biolreprod/4.1.84; SYLVESTER SR, 1989, BIOL REPROD, V41, P941, DOI 10.1095/biolreprod41.5.941; Tan KAL, 2005, ENDOCRINOLOGY, V146, P2674, DOI 10.1210/en.2004-1630; Tsai MY, 2006, P NATL ACAD SCI USA, V103, P18975, DOI 10.1073/pnas.0608565103; Valdenaire O, 1998, FEBS LETT, V424, P193, DOI 10.1016/S0014-5793(98)00170-7; Xu QQ, 2007, ENDOCRINE, V32, P96, DOI 10.1007/s12020-007-9015-0; Yao HHC, 2002, GENE DEV, V16, P1433, DOI 10.1101/gad.981202; Yeh SY, 2002, P NATL ACAD SCI USA, V99, P13498, DOI 10.1073/pnas.212474399; Zhang CX, 2006, P NATL ACAD SCI USA, V103, P17718, DOI 10.1073/pnas.0608556103	55	15	15	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2059	2069		10.1096/fj.14-269209	http://dx.doi.org/10.1096/fj.14-269209			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25609427				2022-12-28	WOS:000354114600038
J	Tusi, BK; Deng, CW; Salz, T; Zeumer, L; Li, YQ; So, CWE; Morel, LM; Qiu, Y; Huang, SM				Tusi, Betsabeh Khoramian; Deng, Changwang; Salz, Tal; Zeumer, Leilani; Li, Yangqiu; So, Chi Wai Eric; Morel, Laurence M.; Qiu, Yi; Huang, Suming			Setd1a regulates progenitor B-cell-to-precursor B-cell development through histone H3 lysine 4 trimethylation and Ig heavy-chain rearrangement	FASEB JOURNAL			English	Article						promoter H3K4me3; Setd1a KO mice; B-cell differentiation; long-range chromatin loops; transcriptional regulation	MIXED-LINEAGE-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; COMPASS FAMILY; MICE LACKING; 3D STRUCTURE; TRANSCRIPTION; LOCUS; GENE; METHYLATION; MLL1	SETD1A is a member of trithorax-related histone methyltransferases that methylate lysine 4 at histone H3 (H3K4). We showed previously that Setd1a is required for mesoderm specification and hematopoietic lineage differentiation in vitro. However, it remains unknown whether or not Setd1a controls specific hematopoietic lineage commitment and differentiation during animal development. Here, we reported that homozygous Setd1a knockout (KO) mice are embryonic lethal. Loss of the Setd1a gene in the hematopoietic compartment resulted in a blockage of the progenitor B-cell-to-precursor B-cell development in bone marrow (BM) and B-cell maturation in spleen. The Setd1a-cKO (conditional knockout) mice exhibited an enlarged spleen with disrupted spleen architecture and leukocytopenia. Mechanistically, Setd1a deficiency in BM reduced the levels of H3K4me3 at critical B-cell gene loci, including Pax5 and Rag1/2, which are critical for the IgH (Ig heavy-chain) locus contractions and rearrangement. Subsequently, the differential long-range looped interactions of the enhancer Em with proximal 59 DH region and 39 regulatory regions as well as with Pax5-activated intergenic repeat elements and 59 distal V-H genes were compromised by the Setd1a-cKO. Together, our findings revealed a critical role of Setd1a and its mediated epigenetic modifications in regulating the IgH rearrangement and B-cell development.	[Tusi, Betsabeh Khoramian; Deng, Changwang; Salz, Tal; Huang, Suming] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; [Zeumer, Leilani; Morel, Laurence M.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA; [Qiu, Yi] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Li, Yangqiu] Jinan Univ, Coll Med, Inst Hematol, Guangzhou, Guangdong, Peoples R China; [So, Chi Wai Eric] Kings Coll London, Dept Haematol Med, London, England	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Jinan University; University of London; King's College London	Qiu, Y (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 2033 Mowry Rd,CGRC 356, Gainesville, FL 32610 USA.	qiuy@ufl.edu; sumingh@ufl.edu		Khoramian Tusi, Betsabeh/0000-0001-7072-2162; , Yi/0000-0002-3282-6072	U.S. National Institutes of Health, National Heart, Lung, and Blood Institute [R01HL091929, R01HL090589, R01HL095674]; Cancer Research UK [16753] Funding Source: researchfish; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091929, R01HL095674, R01HL090589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058150] Funding Source: NIH RePORTER	U.S. National Institutes of Health, National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Cancer Research UK(Cancer Research UK); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors are grateful to members of the S.H. and Y.Q. laboratories for their suggestions and comments. The authors thank Ms. Nga Tran for providing technical support during the revision. This work was supported by U.S. National Institutes of Health, National Heart, Lung, and Blood Institute Grants R01HL091929 and R01HL090589 (to S.H.), and R01HL095674 (to Y.Q.). The authors declare no conflicts of interest.	Ardehali MB, 2011, EMBO J, V30, P2817, DOI 10.1038/emboj.2011.194; Artinger EL, 2013, P NATL ACAD SCI USA, V110, P12000, DOI 10.1073/pnas.1301278110; Bartholdy B, 2004, GENE, V327, P1, DOI 10.1016/j.gene.2003.11.008; Bertrand FE, 2001, BLOOD, V98, P3398, DOI 10.1182/blood.V98.12.3398; Bledau AS, 2014, DEVELOPMENT, V141, P1022, DOI 10.1242/dev.098152; Bolland DJ, 2004, NAT IMMUNOL, V5, P630, DOI 10.1038/ni1068; Degner-Leisso SC, 2010, SEMIN IMMUNOL, V22, P346, DOI 10.1016/j.smim.2010.08.002; Deng CW, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003524; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Ebert A, 2011, IMMUNITY, V34, P175, DOI 10.1016/j.immuni.2011.02.005; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Ernst P, 2004, DEV CELL, V6, P437, DOI 10.1016/S1534-5807(04)00061-9; Gan T, 2010, LEUKEMIA, V24, P1732, DOI 10.1038/leu.2010.171; Guo CY, 2011, CELL, V147, P332, DOI 10.1016/j.cell.2011.08.049; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Heuser M, 2009, BLOOD, V113, P1432, DOI [10.1182/blood-2008-02-162263, 10.1182/blood-2008-06-162263]; Horcher M, 2001, IMMUNITY, V14, P779, DOI 10.1016/S1074-7613(01)00153-4; Hu DQ, 2013, MOL CELL BIOL, V33, P4745, DOI 10.1128/MCB.01181-13; Huang HT, 2013, NAT CELL BIOL, V15, P1516, DOI 10.1038/ncb2870; Jhunjhunwala S, 2008, CELL, V133, P265, DOI 10.1016/j.cell.2008.03.024; Ji YH, 2010, CELL, V141, P419, DOI 10.1016/j.cell.2010.03.010; Jude CD, 2007, CELL STEM CELL, V1, P324, DOI 10.1016/j.stem.2007.05.019; Li BE, 2013, BLOOD, V122, P2039, DOI 10.1182/blood-2013-03-486647; Li XG, 2011, BLOOD, V118, P1386, DOI 10.1182/blood-2010-11-319111; Li XG, 2010, BLOOD, V115, P2028, DOI 10.1182/blood-2009-07-236059; Madan V, 2009, BLOOD, V113, P1444, DOI 10.1182/blood-2008-02-142638; McMahon KA, 2007, CELL STEM CELL, V1, P338, DOI 10.1016/j.stem.2007.07.002; Mohan M, 2010, NAT REV CANCER, V10, P720, DOI 10.1038/nrc2915; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morgan MA, 2013, MOL CELL BIOL, V33, P1698, DOI 10.1128/MCB.00203-13; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Patel B, 2014, LEUKEMIA, V28, P349, DOI 10.1038/leu.2013.158; Salz T, 2014, MOL CANC RES; Salz T, 2014, CANCER RES, V74, P775, DOI 10.1158/0008-5472.CAN-13-1400; Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Testa G, 2004, GENESIS, V38, P151, DOI 10.1002/gene.20012; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Verma-Gaur J, 2012, P NATL ACAD SCI USA, V109, P17004, DOI 10.1073/pnas.1208398109; Wang PF, 2009, MOL CELL BIOL, V29, P6074, DOI 10.1128/MCB.00924-09; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	43	21	21	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1505	1515		10.1096/fj.14-263061	http://dx.doi.org/10.1096/fj.14-263061			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550471	Bronze, Green Published			2022-12-28	WOS:000354115000035
J	Hulleman, JD; Kelly, JW				Hulleman, John D.; Kelly, Jeffery W.			Genetic ablation of N-linked glycosylation reveals two key folding pathways for R345W fibulin-3, a secreted protein associated with retinal degeneration	FASEB JOURNAL			English	Article						EFEMP1; endoplasmic reticulum; malattia leventinese; unfolded protein response	RETICULUM-ASSOCIATED DEGRADATION; ENDOPLASMIC-RETICULUM; MACULAR DEGENERATION; ABERRANT ACCUMULATION; MALATTIA LEVENTINESE; EFEMP1; MUTATION; OLIGOSACCHARIDES; GLYCOPROTEINS; STABILITY	An R345W mutation in the N- glycoprotein, fibulin- 3 ( F3), results in inefficient F3 folding/ secretion and higher intracellular F3 levels. Inheritance of this mutation causes the retinal dystrophy malattia leventinese. N- Linked glycosylation is a common cotranslational protein modification that can regulate protein folding efficiency and energetics. Therefore, we explored how N- glycosylation alters the protein homeostasis or proteostasis of wild- type ( WT) and R345W F3 in ARPE- 19 cells. Enzymatic and lectin binding assays confirmed that WT and R345W F3 are both primarily N- glycosylated at Asn249. Tunicamycin treatment selectively reduced R345W F3 secretion by 87% ( vs. WTF3). Genetic elimination of F3 N- glycosylation ( via an N249Q mutation) caused R345W F3 to aggregate intracellularly and adopt an altered secreted conformation. The endoplasmic reticulum ( ER) chaperones GRP78 ( glucose- regulated protein 78) and GRP94 ( glucose- regulated protein 94), and the ER lectins calnexin and calreticulin were identified as F3 binding partners by immunoprecipitation. Significantly more N249Q and N249Q/ R345W F3 interacted with GRP94, while substantially lessN249Q andN249Q/ R345W interacted with the ER lectins than their N- glycosylated counterparts. Inhibition of GRP94 ATPase activity reduced only N249Q/ R345W F3 secretion ( by 62%), demonstrating this variant's unique reliance on GRP94 for secretion. These observations suggest that R345W F3, but not WT F3, requires N- glycosylation to acquire a stable, native- like structure.-	[Hulleman, John D.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; [Hulleman, John D.; Kelly, Jeffery W.] Scripps Res Inst, Skaggs Inst Chem Biol & Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Hulleman, JD (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	john.hulleman@utsouthwestern.edu; jkelly@scripps.edu	Hulleman, John D./AAV-8242-2020	Hulleman, John/0000-0001-8149-656X	NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025774] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY020799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018917] Funding Source: NIH RePORTER; NCRR NIH HHS [UL1 RR025774, RR025774] Funding Source: Medline; NEI NIH HHS [EY020799, P30 EY020799] Funding Source: Medline; NIA NIH HHS [R01 AG018917, AG018917] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Appenzeller-Herzog C, 2010, EMBO J, V29, P3318, DOI 10.1038/emboj.2010.203; Attebo K, 1996, OPHTHALMOLOGY, V103, P357; Baetens M, 2011, HUM MUTAT, V32, P1053, DOI 10.1002/humu.21525; Brockmeier A, 2006, BIOCHEMISTRY-US, V45, P12906, DOI 10.1021/bi0614378; Culyba EK, 2011, SCIENCE, V331, P571, DOI 10.1126/science.1198461; de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326; Djokic J, 2013, J BIOL CHEM, V288, P22821, DOI 10.1074/jbc.M112.439158; Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198; Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395; Gould DB, 2007, HUM MOL GENET, V16, P798, DOI 10.1093/hmg/ddm024; Guerriero CJ, 2012, PHYSIOL REV, V92, P537, DOI 10.1152/physrev.00027.2011; Hanson SR, 2009, P NATL ACAD SCI USA, V106, P3131, DOI 10.1073/pnas.0810318105; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hulleman JD, 2013, J BIOMOL SCREEN, V18, P647, DOI 10.1177/1087057112469405; Hulleman JD, 2012, FASEB J, V26, P4548, DOI 10.1096/fj.11-202861; Hulleman JD, 2011, MOL BIOL CELL, V22, P4765, DOI 10.1091/mbc.E11-08-0695; Ireland BS, 2008, MOL BIOL CELL, V19, P2413, DOI 10.1091/mbc.E07-10-1055; Jessop CE, 2007, EMBO J, V26, P28, DOI 10.1038/sj.emboj.7601505; Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kroeger H, 2012, INVEST OPHTH VIS SCI, V53, P7590, DOI 10.1167/iovs.12-10221; Kroeger H, 2012, ADV EXP MED BIOL, V723, P559, DOI 10.1007/978-1-4614-0631-0_71; Lin JH, 2010, ADV EXP MED BIOL, V664, P115, DOI 10.1007/978-1-4419-1399-9_14; Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599; Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199; MAY LT, 1991, CYTOKINE, V3, P204, DOI 10.1016/1043-4666(91)90018-9; Merulla J, 2013, TRAFFIC, V14, P767, DOI 10.1111/tra.12068; Mitra N, 2006, TRENDS BIOCHEM SCI, V31, P156, DOI 10.1016/j.tibs.2006.01.003; NARHI LO, 1991, J BIOL CHEM, V266, P23022; O'Connor SE, 2001, J AM CHEM SOC, V123, P6187, DOI 10.1021/ja010094s; Oka OBV, 2013, MOL CELL, V50, P793, DOI 10.1016/j.molcel.2013.05.014; PIGUET B, 1995, EYE, V9, P34, DOI 10.1038/eye.1995.5; Putnam EA, 1996, AM J MED GENET, V62, P233, DOI 10.1002/(SICI)1096-8628(19960329)62:3<233::AID-AJMG7>3.0.CO;2-U; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Roybal CN, 2005, INVEST OPHTH VIS SCI, V46, P3973, DOI 10.1167/iovs.05-0070; Ruggiano A, 2014, J CELL BIOL, V204, P868, DOI 10.1083/jcb.201312042; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Sercu S, 2009, MATRIX BIOL, V28, P160, DOI 10.1016/j.matbio.2009.02.003; Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722; Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285; TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; Vembar SS, 2008, NAT REV MOL CELL BIO, V9, P944, DOI 10.1038/nrm2546; Wallis DD, 2003, J CELL BIOCHEM, V90, P641, DOI 10.1002/jcb.10657; Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62; Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088; Zhang YW, 2010, EXP EYE RES, V90, P374, DOI 10.1016/j.exer.2009.09.018	48	13	13	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					565	575		10.1096/fj.14-255414	http://dx.doi.org/10.1096/fj.14-255414			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25389134	Green Published			2022-12-28	WOS:000349370400019
J	Fu, CL; Odegaard, JI; Hsieh, MH				Fu, Chi-Ling; Odegaard, Justin I.; Hsieh, Michael H.			Macrophages are required for host survival in experimental urogenital schistosomiasis	FASEB JOURNAL			English	Article						clodronate	CLODRONATE-CONTAINING LIPOSOMES; LIPID MEDIATORS; DEPLETION; MECHANISMS; EXPRESSION; RESOLUTION; FIBROSIS; INJURY; CELLS	Urogenital schistosomiasis, Schistosoma haematobium worm infection, afflicts millions of people with egg-triggered, fibrotic bladder granulomata. Despite the significant global impact of urogenital schistosomiasis, the mechanisms of bladder granulomogenesis and fibrosis are ill defined due to the prior lack of tractable animal models. We combined a mouse model of urogenital schistosomiasis with macrophage-depleting liposomal clodronate (LC) to define how macrophages mediate bladder granulomogenesis and fibrosis. Mice were injected with eggs purified from infected hamsters or vehicle prepared from uninfected hamster tissues (xenoantigen and injection trauma control). Empty liposomes were controls for LC: 1) LC treatment resulted in fewer bladder egg granuloma-infiltrating macrophages, eosinophils, and T and B cells, lower bladder and serum levels of eotaxin, and higher bladder concentrations of IL-1 alpha and chemokines (in a time-dependent fashion), confirming that macrophages orchestrate leukocyte infiltration of the egg-exposed bladder; 2) macrophage-depleted mice exhibited greater weight loss and bladder hemorrhage postegg injection; 3) early LC treatment postegg injection resulted in profound decreases in bladder fibrosis, suggesting differing roles for macrophages in fibrosis over time; and 4) LC treatment also led to egg dose-dependent mortality, indicating that macrophages prevent death from urogenital schistosomiasis. Thus, macrophages are a potential therapeutic target for preventing or treating the bladder sequelae of urogenital schistosomiasis.	[Fu, Chi-Ling] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA; [Odegaard, Justin I.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Hsieh, Michael H.] Biomed Res Inst, Rockville, MD 20852 USA; [Hsieh, Michael H.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Hsieh, Michael H.] George Washington Univ, Washington, DC USA	Stanford University; University of California System; University of California San Francisco; Children's National Health System; George Washington University	Hsieh, MH (corresponding author), 12111 Parklawn Dr,Room 206, Rockville, MD 20852 USA.	mhsieh@afbr-bri.com			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK087895] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08 DK087895, DK087895] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barrera P, 2000, ARTHRITIS RHEUM-US, V43, P1951, DOI 10.1002/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K; Barron L, 2011, AM J PHYSIOL-GASTR L, V300, pG723, DOI 10.1152/ajpgi.00414.2010; Botros SS, 2008, J PARASITOL, V94, P386, DOI 10.1645/GE-1270.1; Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009; Carlos CP, 2010, TRANSPLANTATION, V89, P1362, DOI 10.1097/TP.0b013e3181da0587; Cullen SP, 2013, MOL CELL, V49, P1034, DOI 10.1016/j.molcel.2013.01.025; Danenberg HD, 2002, CIRCULATION, V106, P599, DOI 10.1161/01.CIR.0000023532.98469.48; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Fu CL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002605; Fu CL, 2011, JOVE-J VIS EXP, DOI 10.3791/2523; Gommet C, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001421; GuhaSarkar S, 2010, J CONTROL RELEASE, V148, P147, DOI 10.1016/j.jconrel.2010.08.031; Hashimoto D, 2011, J EXP MED, V208, P1069, DOI 10.1084/jem.20101709; Katzav A, 2013, IMMUNOL RES, V56, P334, DOI 10.1007/s12026-013-8406-y; Leenen PJM, 1998, J IMMUNOL, V160, P2166; Leicester KL, 2004, LIVER INT, V24, P446, DOI 10.1111/j.1478-3231.2004.0943.x; Ramachandran P, 2012, P NATL ACAD SCI USA, V109, pE3186, DOI 10.1073/pnas.1119964109; Ray D, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001912; Schleicher Ulrike, 2009, V531, P203, DOI 10.1007/978-1-59745-396-7_14; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410; Thompson RW, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000023; van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; Wynn TA, 2010, SEMIN LIVER DIS, V30, P245, DOI 10.1055/s-0030-1255354; Yang DM, 2009, J PHARMACOL EXP THER, V330, P613, DOI 10.1124/jpet.109.152447	26	17	17	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					193	207		10.1096/fj.14-259572	http://dx.doi.org/10.1096/fj.14-259572			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25351984	Green Published			2022-12-28	WOS:000347378600019
J	Bernardo, BC; Nguyen, SS; Winbanks, CE; Gao, XM; Boey, EJH; Tham, YK; Kiriazis, H; Ooi, JYY; Porrello, ER; Igoor, S; Thomas, CJ; Gregorevic, P; Lin, RCY; Du, XJ; McMullen, JR				Bernardo, Bianca C.; Nguyen, Sally S.; Winbanks, Catherine E.; Gao, Xiao-Ming; Boey, Esther J. H.; Tham, Yow Keat; Kiriazis, Helen; Ooi, Jenny Y. Y.; Porrello, Enzo R.; Igoor, Sindhu; Thomas, Colleen J.; Gregorevic, Paul; Lin, Ruby C. Y.; Du, Xiao-Jun; McMullen, Julie R.			Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy	FASEB JOURNAL			English	Article						microRNAs; pressure overload; heart failure; LNA-therapeutics	CARDIAC-HYPERTROPHY; MICRORNA THERAPEUTICS; HUMAN JAGGED1; TASK-FORCE; EXPRESSION; PROTECTS; INHIBITION; ANGIOGENESIS; ASSOCIATION; ACTIVATION	Expression of microRNA-652 (miR-652) increases in the diseased heart, decreases in a setting of cardioprotection, and is inversely correlated with heart function. The aim of this study was to assess the therapeutic potential of inhibiting miR-652 in a mouse model with established pathological hypertrophy and cardiac dysfunction due to pressure overload. Mice were subjected to a sham operation or transverse aortic constriction (TAC) for 4 wk to induce hypertrophy and cardiac dysfunction, followed by administration of a locked nucleic acid (LNA)-antimiR-652 (miR-652 inhibitor) or LNA control. Cardiac function was assessed before and 8 wk post-treatment. Expression of miR-652 increased in hearts subjected to TAC compared to sham surgery (2.9-fold), and this was suppressed by similar to 95% in LNA-antimiR-652-treated TAC mice. Inhibition of miR-652 improved cardiac function in TAC mice (fractional shortening: 29 +/- 1% at 4 wk post-TAC compared to 35 +/- 1% post-treatment) and attenuated cardiac hypertrophy. Improvement in heart function was associated with reduced cardiac fibrosis, less apo-ptosis and B-type natriuretic peptide gene expression, and preserved angiogenesis. Mechanistically, we identified Jagged1 (a Notch1 ligand) as a novel direct target of miR-652. In summary, these studies provide the first evidence that silencing of miR-652 protects the heart against pathological remodeling and improves heart function.	[Bernardo, Bianca C.; Nguyen, Sally S.; Winbanks, Catherine E.; Gao, Xiao-Ming; Boey, Esther J. H.; Tham, Yow Keat; Kiriazis, Helen; Ooi, Jenny Y. Y.; Gregorevic, Paul; Du, Xiao-Jun; McMullen, Julie R.] Baker IDI Heart & Diabet Inst, Melbourne, Vic 3004, Australia; [Nguyen, Sally S.; Thomas, Colleen J.] La Trobe Univ, Dept Human Biosci, Bundoora, Vic, Australia; [Porrello, Enzo R.; Igoor, Sindhu] Univ Queensland, Sch Biomed Sci, St Lucia, Qld, Australia; [Lin, Ruby C. Y.] Univ New S Wales, Ramaciotti Ctr Genom, Sydney, NSW, Australia; [Lin, Ruby C. Y.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia	Baker Heart and Diabetes Institute; La Trobe University; University of Queensland; University of New South Wales Sydney; University of New South Wales Sydney	Bernardo, BC (corresponding author), Baker IDI Heart & Diabet Inst, POB 6492, Melbourne, Vic 3004, Australia.	bianca.bernardo@bakeridi.edu.au; julie.mcmullen@bakeridi.edu.au	Gregorevic, Paul/AAH-6040-2021; Tham, Yow Keat/ABC-8856-2021; Lin, Ruby CY/A-1636-2009	Gregorevic, Paul/0000-0002-7418-8945; Tham, Yow Keat/0000-0002-9790-1926; Lin, Ruby CY/0000-0003-4163-511X; Bernardo, Bianca Christine/0000-0002-4534-0549; Porrello, Enzo/0000-0001-6105-7463; Ooi, Jenny/0000-0002-4800-6124	National Health and Medical Research Council of Australia [586603]; Victorian Government's Operational Infrastructure Support Program; Australian Research Council Future Fellowship [FT0001657]; University of New South Wales Vice Chancellor Research Fellowship; National Health and Medical Research Council [1046782]; National Health and Medical Research Council; National Heart Foundation [APP1033815, 635530]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government's Operational Infrastructure Support Program; Australian Research Council Future Fellowship(Australian Research Council); University of New South Wales Vice Chancellor Research Fellowship; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Heart Foundation(National Heart Foundation of Australia)	This study was funded by National Health and Medical Research Council of Australia project grant 586603 (to J.R.M and R.C.Y.L), and also supported in part by the Victorian Government's Operational Infrastructure Support Program. X.J.D. and J.R.M. are National Health and Medical Research Council Senior Research Fellows (APP1043026 and 586604). J.R.M., R.C.Y.L., and P.G. are supported by an Australian Research Council Future Fellowship (FT0001657), a University of New South Wales Vice Chancellor Research Fellowship, and a R.D. Wright Biomedical Research Fellowship from the National Health and Medical Research Council (1046782), respectively. E.R.P. is supported by grants and fellowships from the National Health and Medical Research Council and the National Heart Foundation (APP1033815 and 635530). The authors declare no conflicts of interest.	Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025; Bernardo BC, 2012, DRUG DISCOV TODAY TH, V9, pe163, DOI [10.1016/j.ddstr.2013.10.001, DOI 10.1016/J.DDSTR.2013.10.001]; Bernardo BC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090337; Bernardo BC, 2012, P NATL ACAD SCI USA, V109, P17615, DOI 10.1073/pnas.1206432109; Bernardo BC, 2012, HEART LUNG CIRC, V21, P131, DOI 10.1016/j.hlc.2011.11.002; Bernardo BC, 2010, PHARMACOL THERAPEUT, V128, P191, DOI 10.1016/j.pharmthera.2010.04.005; Bostrom P, 2010, CELL, V143, P1072, DOI 10.1016/j.cell.2010.11.036; Callis TE, 2009, J CLIN INVEST, V119, P2772, DOI 10.1172/JCI36154; Campa VM, 2008, J CELL BIOL, V183, P129, DOI 10.1083/jcb.200806104; Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582; Collesi C, 2008, J CELL BIOL, V183, P117, DOI 10.1083/jcb.200806091; Cooley N, 2012, PHYSIOL GENOMICS, V44, P211, DOI 10.1152/physiolgenomics.00111.2011; Croquelois A, 2008, J EXP MED, V205, P3173, DOI 10.1084/jem.20081427; Dangwal S, 2014, ANNU REV PHARMACOL, V54, P185, DOI 10.1146/annurev-pharmtox-011613-135957; Dickstein K, 2008, EUR J HEART FAIL, V10, P933, DOI 10.1016/j.ejheart.2008.08.005; Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110; Friedman SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004700; Gridley T, 2007, DEVELOPMENT, V134, P2709, DOI 10.1242/dev.004184; Gude N, 2012, J MOL CELL CARDIOL, V52, P1226, DOI 10.1016/j.yjmcc.2012.03.007; Gude NA, 2008, CIRC RES, V102, P1025, DOI 10.1161/CIRCRESAHA.107.164749; Hata A, 2013, ANNU REV PHYSIOL, V75, P69, DOI 10.1146/annurev-physiol-030212-183737; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Hullinger TG, 2012, CIRC RES, V110, P71, DOI 10.1161/CIRCRESAHA.111.244442; Huynh K, 2014, PHARMACOL THERAPEUT, V142, P375, DOI 10.1016/j.pharmthera.2014.01.003; Ikeda S, 2007, PHYSIOL GENOMICS, V31, P367, DOI 10.1152/physiolgenomics.00144.2007; Ikeda S, 2010, CURR DRUG TARGETS, V11, P913, DOI 10.2174/138945010791591304; Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026; Kumarswamy R, 2013, CIRC RES, V113, P676, DOI 10.1161/CIRCRESAHA.113.300226; Lavie CJ, 2009, J AM COLL CARDIOL, V53, P1925, DOI 10.1016/j.jacc.2008.12.068; Lei B, 2008, J MOL CELL CARDIOL, V45, P404, DOI 10.1016/j.yjmcc.2008.06.008; Leptidis S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057800; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Li XM, 2009, CLIN EXP PHARMACOL P, V36, P1054, DOI 10.1111/j.1440-1681.2009.05243.x; Lin RCY, 2010, ARTERIOSCL THROM VAS, V30, P724, DOI 10.1161/ATVBAHA.109.201988; Matkovich SJ, 2013, CIRC RES, V113, P62, DOI 10.1161/CIRCRESAHA.113.300975; Meloni M, 2013, MOL THER, V21, P1390, DOI 10.1038/mt.2013.89; Nemir M, 2014, EUR HEART J, V35, P2174, DOI 10.1093/eurheartj/ehs269; Ng DCH, 2011, J BIOL CHEM, V286, P1576, DOI 10.1074/jbc.M110.128157; Niessen K, 2008, CIRC RES, V102, P1169, DOI 10.1161/CIRCRESAHA.108.174318; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Ooi JYY, 2014, FUTURE MED CHEM, V6, P205, DOI 10.4155/fmc.13.196; Porrello ER, 2013, P NATL ACAD SCI USA, V110, P187, DOI 10.1073/pnas.1208863110; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shiojima I, 2005, J CLIN INVEST, V115, P2108, DOI 10.1172/JCI24682; Stenvang Jan, 2012, Silence, V3, P1, DOI 10.1186/1758-907X-3-1; Taimeh Z, 2013, NAT REV CARDIOL, V10, P519, DOI 10.1038/nrcardio.2013.94; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105; van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089; van Rooij E, 2012, NAT REV DRUG DISCOV, V11, P860, DOI 10.1038/nrd3864; Wang XH, 2010, CIRCULATION, V122, P1308, DOI 10.1161/CIRCULATIONAHA.110.964684; Weeks KL, 2012, CIRC-HEART FAIL, V5, P523, DOI 10.1161/CIRCHEARTFAILURE.112.966622; Winbanks CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073589; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Yancy CW, 2013, CIRCULATION, V128, P1810, DOI 10.1161/CIR.0b013e31829e8807	57	61	62	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5097	5110		10.1096/fj.14-253856	http://dx.doi.org/10.1096/fj.14-253856			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25145628				2022-12-28	WOS:000345894500007
J	Kone, M; Sun, G; Ibberson, M; Martinez-Sanchez, A; Sayers, S; Nguyen-Tu, MS; Kantor, C; Swisa, A; Dor, Y; Gorman, T; Ferrer, J; Thorens, B; Reimann, F; Gribble, F; McGinty, JA; Chen, LL; French, PM; Birzele, F; Hildebrandt, T; Uphues, I; Rutter, GA				Kone, Marina; Sun, Gao; Ibberson, Mark; Martinez-Sanchez, Aida; Sayers, Sophie; Marie-Sophie Nguyen-Tu; Kantor, Chase; Swisa, Avital; Dor, Yuval; Gorman, Tracy; Ferrer, Jorge; Thorens, Bernard; Reimann, Frank; Gribble, Fiona; McGinty, James A.; Chen, Lingling; French, Paul M.; Birzele, Fabian; Hildebrandt, Tobias; Uphues, Ingo; Rutter, Guy A.			LKB1 and AMPK differentially regulate pancreatic beta-cell identity	FASEB JOURNAL			English	Article						islet; diabetes; insulin secretion; RNASeq	PROTEIN-KINASE; INSULIN-SECRETION; GLUCOSE-TOLERANCE; EXPRESSION; FAMILY; MASS; TRANSCRIPTOMES; MUTATIONS; BIOLOGY; SUBUNIT	Fully differentiated pancreatic cells are essential for normal glucose homeostasis in mammals. Dedifferentiation of these cells has been suggested to occur in type 2 diabetes, impairing insulin production. Since chronic fuel excess (glucotoxicity) is implicated in this process, we sought here to identify the potential roles in -cell identity of the tumor suppressor liver kinase B1 (LKB1/STK11) and the downstream fuel-sensitive kinase, AMP-activated protein kinase (AMPK). Highly -cell-restricted deletion of each kinase in mice, using an Ins1-controlled Cre, was therefore followed by physiological, morphometric, and massive parallel sequencing analysis. Loss of LKB1 strikingly (2.0-12-fold, E<0.01) increased the expression of subsets of hepatic (Alb, Iyd, Elovl2) and neuronal (Nptx2, Dlgap2, Cartpt, Pdyn) genes, enhancing glutamate signaling. These changes were partially recapitulated by the loss of AMPK, which also up-regulated -cell disallowed genes (Slc16a1, Ldha, Mgst1, Pdgfra) 1.8- to 3.4-fold (E<0.01). Correspondingly, targeted promoters were enriched for neuronal (Zfp206; P=1.3x10(-33)) and hypoxia-regulated (HIF1; P=2.5x10(-16)) transcription factors. In summary, LKB1 and AMPK, through only partly overlapping mechanisms, maintain -cell identity by suppressing alternate pathways leading to neuronal, hepatic, and other characteristics. Selective targeting of these enzymes may provide a new approach to maintaining -cell function in some forms of diabetes.Kone, M., Pullen, T. J., Sun, G., Ibberson, M., Martinez-Sanchez, A., Sayers, S., Nguyen-Tu, M.-S., Kantor, C., Swisa, A., Dor, Y., Gorman, T., Ferrer, J., Thorens, B., Reimann, F., Gribble, F., McGinty, J. A., Chen, L., French, P. M., Birzele, F., Hildebrandt, T., Uphues, I., Rutter, G. A. LKB1 and AMPK differentially regulate pancreatic -cell identity.	[Kone, Marina; Sun, Gao; Ibberson, Mark; Sayers, Sophie; Marie-Sophie Nguyen-Tu; Kantor, Chase; Swisa, Avital; Rutter, Guy A.] Univ London Imperial Coll Sci Technol & Med, Sect Cell Biol, London W12 ONN, England; [Ferrer, Jorge] Univ London Imperial Coll Sci Technol & Med, Sect Cell Dev, Div Diabet Endocrinol & Metab, Dept Med, London W12 ONN, England; [McGinty, James A.; Chen, Lingling; French, Paul M.] Univ London Imperial Coll Sci Technol & Med, Photon Grp, Dept Phys, London W12 ONN, England; [Ibberson, Mark] Univ Lausanne, Swiss Inst Bioinformat, Lausanne, Switzerland; [Thorens, Bernard] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland; [Swisa, Avital; Dor, Yuval] Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91010 Jerusalem, Israel; [Gorman, Tracy] AstraZeneca Diabet & Obes Drug Discovery, Alderley Edge, England; [Reimann, Frank; Gribble, Fiona] Univ Cambridge, Metab Res Labs, Cambridge, England; [Birzele, Fabian; Hildebrandt, Tobias; Uphues, Ingo] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany	Imperial College London; Imperial College London; Imperial College London; Swiss Institute of Bioinformatics; University of Lausanne; University of Lausanne; Hebrew University of Jerusalem; AstraZeneca; University of Cambridge; Boehringer Ingelheim	Rutter, GA (corresponding author), Univ London Imperial Coll Sci Technol & Med, ICTEM, Hammersmith Hosp, 3rd Floor,du Cane Rd, London W12 ONN, England.	g.rutter@imperial.ac.uk	Sanchez, Aida Martinez/ABH-5957-2020; French, Paul/E-8649-2011; Pullen, Timothy J/H-2143-2011; Ferrer, Jorge/A-3176-2012; Chen, Ling-Ling/AAY-3547-2021	Sanchez, Aida Martinez/0000-0001-5142-2527; Pullen, Timothy J/0000-0002-6853-5701; Ferrer, Jorge/0000-0002-5959-5729; Gribble, Fiona/0000-0002-4232-2898; Reimann, Frank/0000-0001-9399-6377; Ibberson, Mark/0000-0003-3152-5670; Rutter, Guy/0000-0001-6360-0343; French, Paul/0000-0002-0478-6755	Medical Research Council (UK) [MR/J0003042/1]; Biotechnology and Biological Sciences Research Council (UK) [BB/J015873/1]; Royal Society for a Wolfson Research Merit Award; Wellcome Trust [WT098424AIA]; Imperial College/Wellcome Trust Institutional Strategic Support Funds (ISSF) grant; Diabetes Research and Wellness (DRWE) nonclinical fellowship; Innovative Medicines Initiative (IMIDIA) Joint Undertaking [155005]; European Union; European Federation of Pharmaceutical Industries and Associations (EFPLA); Biotechnology and Biological Sciences Research Council [BB/J015873/1] Funding Source: researchfish; Diabetes UK [11/0004210] Funding Source: researchfish; Medical Research Council [MR/K001981/1, MC_UU_12012/3, MR/L02036X/1, MC_UU_12012/5/B] Funding Source: researchfish; BBSRC [BB/J015873/1] Funding Source: UKRI; MRC [MR/K001981/1, MR/L02036X/1, MC_UU_12012/3] Funding Source: UKRI	Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council (UK)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Royal Society for a Wolfson Research Merit Award(Royal Society of London); Wellcome Trust(Wellcome TrustEuropean Commission); Imperial College/Wellcome Trust Institutional Strategic Support Funds (ISSF) grant; Diabetes Research and Wellness (DRWE) nonclinical fellowship; Innovative Medicines Initiative (IMIDIA) Joint Undertaking; European Union(European Commission); European Federation of Pharmaceutical Industries and Associations (EFPLA); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Diabetes UK(Diabetes UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	G.A.R. thanks the Medical Research Council (UK) for programme grant MR/J0003042/1, the Biotechnology and Biological Sciences Research Council (UK) for project grant BB/J015873/1, the Royal Society for a Wolfson Research Merit Award, and the Wellcome Trust for Senior Investigator Award WT098424AIA. CAR. and P.F. received an Imperial College/Wellcome Trust Institutional Strategic Support Funds (ISSF) grant. T.J.P. was supported by a Diabetes Research and Wellness (DRWE) nonclinical fellowship, and M.K. by an Imperial College Ph. D. studentship. the work leading to this publication has received support from the Innovative Medicines Initiative (IMIDIA) Joint Undertaking under grant agreement no. 155005, resources of which are composed of a financial contribution from the European Union's Seventh framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations (EFPLA) member companies' in kind contribution (G.A.R., B.T.). The authors thank Dr. Gabriela da Silva Xavier for help with pancreatic morphology, Jane Srivastava for assistance with FACS analysis, and Dr. Isabelle Leclerc (Imperial College London) for useful discussions.	Ahmed S, 2010, SEMIN CELL DEV BIOL, V21, P350, DOI 10.1016/j.semcdb.2009.11.008; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Beall C, 2010, BIOCHEM J, V429, P323, DOI 10.1042/BJ20100231; Bramswig NC, 2013, J CLIN INVEST, V123, P1275, DOI 10.1172/JCI66514; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Courtney M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003934; Crombag HS, 2009, NEUROPSYCHOPHARMACOL, V34, P857, DOI 10.1038/npp.2008.80; da Silva Xavier G, 2013, J DIABETES RES, V2013; de Lau WBM, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-3-242; De Saedeleer CJ, 2014, ONCOGENE, V33, P4060, DOI 10.1038/onc.2013.454; Del Guerra S, 2005, DIABETES, V54, P727, DOI 10.2337/diabetes.54.3.727; Edelstein Arthur, 2010, Curr Protoc Mol Biol, VChapter 14, DOI 10.1002/0471142727.mb1420s92; Fromer M, 2014, NATURE, V506, P179, DOI 10.1038/nature12929; Fu A, 2009, CELL METAB, V10, P285, DOI 10.1016/j.cmet.2009.08.008; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Granot Z, 2009, CELL METAB, V10, P296, DOI 10.1016/j.cmet.2009.08.010; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Ishii K, 2012, DEVELOPMENT, V139, P1734, DOI 10.1242/dev.076539; Jacob LS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001225; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kawashima H, 2012, INT J ONCOL, V40, P31, DOI 10.3892/ijo.2011.1234; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Laybutt DR, 2003, J BIOL CHEM, V278, P2997, DOI 10.1074/jbc.M210581200; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Marselli L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011499; Martin Daniel, 2008, P51; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Nie J, 2013, P NATL ACAD SCI USA, V110, P13857, DOI 10.1073/pnas.1307698110; Palmer CL, 2005, PHARMACOL REV, V57, P253, DOI 10.1124/pr.57.2.7; Partanen JI, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0111; Pullen TJ, 2013, DIABETES OBES METAB, V15, P503, DOI 10.1111/dom.12029; Pullen TJ, 2012, DIABETES, V61, P1719, DOI 10.2337/db11-1531; Pullen TJ, 2010, ISLETS, V2, P89, DOI 10.4161/isl.2.2.11025; Rahier J, 2008, DIABETES OBES METAB, V10, P32, DOI 10.1111/j.1463-1326.2008.00969.x; Ravier MA, 2005, DIABETES, V54, P1789, DOI 10.2337/diabetes.54.6.1789; Ravier MA, 2010, METHODS MOL BIOL, V633, P171, DOI 10.1007/978-1-59745-019-5_12; Reimann F, 2008, CELL METAB, V8, P532, DOI 10.1016/j.cmet.2008.11.002; Rother E, 2012, P NATL ACAD SCI USA, V109, P18132, DOI 10.1073/pnas.1206147109; Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048; Rutter GA, 2008, FRONT HORM RES, V36, P118, DOI 10.1159/000115360; Rutter Guy A., 2001, Molecular Aspects of Medicine, V22, P247, DOI 10.1016/S0098-2997(01)00013-9; Rutter GA, 2009, MOL CELL ENDOCRINOL, V297, P41, DOI 10.1016/j.mce.2008.05.020; Sakamaki JI, 2014, NAT CELL BIOL, V16, P234, DOI 10.1038/ncb2919; Scully Tony, 2012, Nature, V485, pS2; Sia GM, 2007, NEURON, V55, P87, DOI 10.1016/j.neuron.2007.06.020; Stange Geert, 2003, Methods Mol Med, V83, P15; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun G, 2010, DIABETOLOGIA, V53, P924, DOI 10.1007/s00125-010-1692-1; Sun G, 2011, DIS MODEL MECH, V4, P193, DOI 10.1242/dmm.006833; Sun G, 2010, AM J PHYSIOL-ENDOC M, V298, pE1261, DOI 10.1152/ajpendo.00100.2010; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Talchai C, 2012, CELL, V150, P1223, DOI 10.1016/j.cell.2012.07.029; Tamarina NA, 2014, ISLETS, V6, DOI 10.4161/isl.27685; Tarasov AI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039722; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Thorrez L, 2011, GENOME RES, V21, P95, DOI 10.1101/gr.109173.110; Upadhyay G, 2008, ONCOGENE, V27, P5845, DOI 10.1038/onc.2008.202; Vencio RZN, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-119; Wicksteed B, 2010, DIABETES, V59, P3090, DOI 10.2337/db10-0624; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zambon AC, 2005, P NATL ACAD SCI USA, V102, P8561, DOI 10.1073/pnas.0503363102; Zhu MX, 2005, PFLUG ARCH EUR J PHY, V451, P105, DOI 10.1007/s00424-005-1427-1	65	59	60	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4972	4985		10.1096/fj.14-257667	http://dx.doi.org/10.1096/fj.14-257667			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25070369	Green Published, hybrid			2022-12-28	WOS:000344050900033
J	Liu, JL; Wang, LL; Su, ZH; Wu, W; Cai, XJ; Li, D; Hou, JD; Pei, DQ; Pan, GJ				Liu, Juli; Wang, Linli; Su, Zhenghui; Wu, Wei; Cai, Xiujuan; Li, Di; Hou, Jundi; Pei, Duanqing; Pan, Guangjin			A reciprocal antagonism between miR-376c and TGF-beta signaling regulates neural differentiation of human pluripotent stem cells	FASEB JOURNAL			English	Article						microRNA; SMAD signaling; promoter binding	HUMAN EMBRYONIC STEM; GROWTH-FACTOR-BETA; CULTURE-CONDITIONS; MICRORNA TARGETS; SELF-RENEWAL; EXPRESSION; EMBRYOGENESIS; SPECIFICATION; MAINTENANCE; CONVERSION	Differentiation of neural lineages from human pluripotent stem cells (hPSCs) raises the hope of generating functional cells for the treatment of neural diseases. However, current protocols for differentiating hPSCs into neural lineages remain inefficient and largely variable between different hPSC lines. We report that microRNA 376c (miR-376c) significantly enhanced neural differentiation of hPSCs in a defined condition by suppressing SMAD4, the co-SMAD for TGF- signaling. Downstream, SMAD4 directly bound and suppressed PAX6, the critical neural lineage specification factor. Interestingly, we also found that SMAD4 binds and suppresses miR-376c clusters in undifferentiated hESCs. In summary, our findings revealed a reciprocal antagonism between miR-376c and SMAD signaling that regulates cell fate during human neural differentiation.Liu, J., Wang, L., Su, Z., Wu, W., Cai, X., Li, D., Hou, J., Pei, D., Pan, G. A reciprocal antagonism between miR-376c and TGF- signaling regulates neural differentiation of hPSCs.	Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, South China Inst Stem Cell Biol & Regenerat Med, Key Lab Regenerat Biol, Guangzhou 510530, Guangdong, Peoples R China; Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, South China Inst Stem Cell Biol & Regenerat Med, Guangdong Prov Key Lab Stem Cell & Regenerat Med, Guangzhou 510530, Guangdong, Peoples R China	Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS	Pan, GJ (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Kaiyuan Ave,Sci Pk, Guangzhou 510530, Guangdong, Peoples R China.	pan_guangjin@gibh.ac.cn	Wang, Linli/R-5688-2018; Su, Zhenghui/ABB-9503-2021	Wang, Linli/0000-0002-8380-6135; Pan, Guangjin/0000-0002-2378-7198	National Basic Research Program of China, 973 Program of China [2012CB966503, 2014CB964604]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDA01020202]; National Natural Science Foundation of China [31371514, 31200970, 81301340]; National Science and Technology Major Special Project on Major New Drug Innovation [2011ZX09102-010]; Ministry of Science and Technology of China [2014DFA30180]; Bureau of Science and Technology of the Guangzhou Municipality [201400000003-2]; Hundred Talents Program of the Chinese Academy of Science	National Basic Research Program of China, 973 Program of China(National Basic Research Program of China); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Special Project on Major New Drug Innovation; Ministry of Science and Technology of China(Ministry of Science and Technology, China); Bureau of Science and Technology of the Guangzhou Municipality; Hundred Talents Program of the Chinese Academy of Science(Chinese Academy of Sciences)	The authors thank the members of their laboratory for assistance. This work was supported by the National Basic Research Program of China, 973 Program of China, (2012CB966503 and 2014CB964604); the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA01020202); the National Natural Science Foundation of China (31371514, 31200970, and 81301340); the National Science and Technology Major Special Project on Major New Drug Innovation (2011ZX09102-010); the Ministry of Science and Technology of China (2014DFA30180); the Bureau of Science and Technology of the Guangzhou Municipality (201400000003-2); and the Hundred Talents Program of the Chinese Academy of Science (to G.P.). The authors declare no conflicts of interest.	Almeida CA, 2004, BIOCHEM MOL BIOL EDU, V32, P239, DOI 10.1002/bmb.2004.494032040373; Avery S, 2010, STEM CELLS, V28, P863, DOI 10.1002/stem.409; Beers J, 2012, NAT PROTOC, V7, P2029, DOI 10.1038/nprot.2012.130; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Boissart C, 2012, DEVELOPMENT, V139, P1247, DOI 10.1242/dev.073627; Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529; Chen G, 2012, STEM CELLS, V30, P623, DOI 10.1002/stem.1021; Chen GK, 2011, NAT METHODS, V8, P424, DOI [10.1038/nmeth.1593, 10.1038/NMETH.1593]; Chen JK, 2013, NAT GENET, V45, P34, DOI 10.1038/ng.2491; Conaco C, 2006, P NATL ACAD SCI USA, V103, P2422, DOI 10.1073/pnas.0511041103; Davis TH, 2008, J NEUROSCI, V28, P4322, DOI 10.1523/JNEUROSCI.4815-07.2008; Delaloy C, 2010, CELL STEM CELL, V6, P323, DOI 10.1016/j.stem.2010.02.015; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Fu GD, 2013, HYPERTENSION, V61, P864, DOI 10.1161/HYPERTENSIONAHA.111.203489; GATHERER D, 1990, DEVELOPMENT, V110, P445; Glazov EA, 2008, MOL BIOL EVOL, V25, P939, DOI 10.1093/molbev/msn045; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Grocott T, 2007, NUCLEIC ACIDS RES, V35, P890, DOI 10.1093/nar/gkl1105; HOGAN BLM, 1994, DEVELOPMENT, P53; Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Iwaki J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069496; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Jovicic A, 2013, J NEUROSCI, V33, P5127, DOI 10.1523/JNEUROSCI.0600-12.2013; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Laddha SV, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-10; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Moody Jennifer, 2013, Methods Mol Biol, V946, P507, DOI 10.1007/978-1-62703-128-8_31; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Oshimori N, 2012, CELL STEM CELL, V11, P751, DOI 10.1016/j.stem.2012.11.001; Packer AN, 2008, J NEUROSCI, V28, P14341, DOI 10.1523/JNEUROSCI.2390-08.2008; Pankratz MT, 2007, STEM CELLS, V25, P1511, DOI 10.1634/stemcells.2006-0707; Rosa A, 2011, EMBO J, V30, P237, DOI 10.1038/emboj.2010.319; Sakaki-Yumoto M, 2013, J BIOL CHEM, V288, P18546, DOI 10.1074/jbc.M112.446591; Schaefer A, 2007, J EXP MED, V204, P1553, DOI 10.1084/jem.20070823; SCHMID P, 1991, DEVELOPMENT, V111, P117; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Smirnova L, 2005, EUR J NEUROSCI, V21, P1469, DOI 10.1111/j.1460-9568.2005.03978.x; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Tippmann HF, 2004, BRIEF BIOINFORM, V5, P82, DOI 10.1093/bib/5.1.82; Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031; Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494; Wang LH, 2013, NAT METHODS, V10, P84, DOI [10.1038/NMETH.2283, 10.1038/nmeth.2283]; Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408; Wang Y, 2013, STEM CELL RES, V11, P1103, DOI 10.1016/j.scr.2013.07.011; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323; Willems E, 2008, DIFFERENTIATION, V76, P745, DOI 10.1111/j.1432-0436.2007.00257.x; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; Xue YT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070573; Ye G, 2011, J CELL SCI, V124, P359, DOI 10.1242/jcs.072223; Yoo AS, 2011, NATURE, V476, P228, DOI 10.1038/nature10323; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhang XQ, 2010, CELL STEM CELL, V7, P90, DOI 10.1016/j.stem.2010.04.017; Zhou JX, 2010, STEM CELLS, V28, P1741, DOI 10.1002/stem.504	57	14	14	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4642	4656		10.1096/fj.13-249342	http://dx.doi.org/10.1096/fj.13-249342			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25114173	Bronze			2022-12-28	WOS:000344050900006
J	Doria, ML; Ribeiro, AS; Wang, J; Cotrim, CZ; Domingues, P; Williams, C; Domingues, MR; Helguero, LA				Doria, M. Luisa; Ribeiro, Ana S.; Wang, Jun; Cotrim, Candida Z.; Domingues, Pedro; Williams, Cecilia; Domingues, M. Rosario; Helguero, Luisa A.			Fatty acid and phospholipid biosynthetic pathways are regulated throughout mammary epithelial cell differentiation and correlate to breast cancer survival	FASEB JOURNAL			English	Article						lipidomics; gene expression; mass spectrometry; Kennedy pathway; basal-like cancer	LYSOPHOSPHATIDIC ACID; GENE-EXPRESSION; MICROARRAY DATA; OVARIAN-CANCER; IN-VITRO; MEMBRANE; CHOLESTEROL; METABOLISM; GLAND; LINE	This work combined gene and protein expression, gas chromatography-flame ionization detector, and hydrophilic interaction liquid chromatography-tandem mass spectrometry to compare lipid metabolism changes in undifferentiated/proliferating vs. functionally differentiated mammary epithelial cells (MECs) and to study their correlation to breast cancer survival. Sixty-eight genes involved in lipid metabolism were changed in MEC differentiation. Differentiated cells showed induction of Elovl6 (2-fold), Scd1 (4-fold), and Fads2 (2-fold), which correlated with increased levels of C16:1 n-7 and C18:1 n-9 (1.5-fold), C20:3 n-6 (2.5-fold), and C20:4 n-6 (6-fold) fatty acids (FAs) and more phospholipids (PLs) containing these species. Further, increased expression (2- to 3-fold) of genes in phosphatidylethanolamine (PE) de novo biosynthesis resulted in a 20% PE increase. Proliferating/undifferentiated cells showed higher C16:0 (1.7-fold) and C18:2 n-6 (4.2-fold) levels and more PLs containing C16:0 FAs [PC(16:0/16:1), PG(16:0/18:2), PG(16:0/18:1), and SM(16:0/18:0)]. Kaplan-Meier analysis of data from 3455 patients with breast cancer disclosed a positive correlation for 59% of genes expressed in differentiated MECs with better survival. PE biosynthesis and FA oxidation correlated with better prognosis in patients with breast cancer, including the basal-like subtype. Therefore, genes involved in mammary gland FA and PL metabolism and their resulting molecular species reflect the cellular proliferative ability and differentiation state and deserve further studies as potential markers of breast cancer progression.	[Doria, M. Luisa; Ribeiro, Ana S.; Cotrim, Candida Z.; Domingues, Pedro; Domingues, M. Rosario; Helguero, Luisa A.] Univ Aveiro, Organ Chem & Nat Prod Res Unit, Mass Spectrometry Ctr, P-3810193 Aveiro, Portugal; [Wang, Jun; Williams, Cecilia] Univ Houston, Ctr Nucl Receptors & Cell Signaling, Dept Biol & Biochem, Houston, TX USA	Universidade de Aveiro; University of Houston System; University of Houston	Helguero, LA (corresponding author), Univ Aveiro, Dept Chem, Campus Santiago, P-3810193 Aveiro, Portugal.	luisa.helguero@ua.pt	Cruz e Silva, Odete/AAH-5595-2020; Williams, Cecilia/A-6677-2009; Domingues, Pedro/E-5202-2010; Helguero, Luisa/B-1221-2013; Domingues, Rosario M/K-7444-2014	Williams, Cecilia/0000-0002-0602-2062; Domingues, Pedro/0000-0002-8060-7675; Helguero, Luisa/0000-0001-8237-2390; Domingues, Rosario M/0000-0001-5357-3601; Cotrim, Candida Zita/0000-0002-2489-274X	European Community Fund (FEDER); Fundacao para a Cienncia e Tecnologia (FCT) [PTDC/SAU-ONC/112671/2009, PTDC/SAU-ONC/118346/2010]; Project Ciencia; University of Aveiro; European Union; Quadro de Referencia Estrategico Nacional (QREN); COMPETE [PEst-C/QUI/UI0062/2011, PEst-C/QUI/UI0062/2013]; RNEM; Texas Emerging Technology Fund [300-9-1958]; University of Houston	European Community Fund (FEDER)(European Commission); Fundacao para a Cienncia e Tecnologia (FCT); Project Ciencia; University of Aveiro(European Commission); European Union(European Commission); Quadro de Referencia Estrategico Nacional (QREN); COMPETE; RNEM; Texas Emerging Technology Fund; University of Houston	The authors thank Celeste Resende for technical help with mammary gland histological sectioning. This work was supported by federal funds through Programa Operacional Tematico Factores de Competitividade (COMPETE) with coparticipation from the European Community Fund (FEDER) and national funds through Fundacao para a Cienncia e Tecnologia (FCT) under the projects PTDC/SAU-ONC/112671/2009 and PTDC/SAU-ONC/118346/2010 (L.A.H.), Project Ciencia 2008 (L.A.H.). The Mass Spectrometry Center, within the Organic Chemistry and Natural Products (QOPNA) research unit, is funded by the University of Aveiro, FCT, European Union, Quadro de Referencia Estrategico Nacional (QREN), FEDER, and COMPETE projects PEst-C/QUI/UI0062/2011 and PEst-C/QUI/UI0062/2013 and RNEM. This work was also supported by grants from the Texas Emerging Technology Fund, under agreement 300-9-1958 and by faculty start-up funding from the University of Houston (C.W.).	Abraham J, 2011, ALCOHOL CLIN EXP RES, V35, P2113, DOI 10.1111/j.1530-0277.2011.01563.x; Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; ALESSANDRI JM, 1990, REPROD NUTR DEV, V30, P551, DOI 10.1051/rnd:19900501; Anderson KN, 2014, BREAST CANCER RES TR, V144, P1, DOI 10.1007/s10549-014-2852-7; [Anonymous], 2002, NEW COMPREHENSIVE BI, DOI [DOI 10.1016/S0167-7306(02)36009-5, 10.1016/S0167-7306(02)36009-5]; Archer A, 2013, J LIPID RES, V54, P1300, DOI 10.1194/jlr.M033977; Aued-Pimentel S, 2004, J CHROMATOGR A, V1054, P235, DOI 10.1016/j.chroma.2004.07.090; Aydogdu E, 2012, CARCINOGENESIS, V33, P1502, DOI 10.1093/carcin/bgs161; Balgoma D, 2010, J IMMUNOL, V184, P3857, DOI 10.4049/jimmunol.0902883; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BARZILAI A, 1991, CANCER, V67, P2919, DOI 10.1002/1097-0142(19910601)67:11<2919::AID-CNCR2820671135>3.0.CO;2-Z; Bligh E. G., 1959, J BIOL CHEM, V234, P469; Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004; Cotrim CZ, 2013, ONCOGENE, V32, P2390, DOI 10.1038/onc.2012.261; FLESHOOD HL, 1970, J BIOL CHEM, V245, P4414; Fuchs B, 2008, ANAL BIOANAL CHEM, V392, P849, DOI 10.1007/s00216-008-2301-8; Gibellini F, 2010, IUBMB LIFE, V62, P414, DOI 10.1002/iub.337; Goni FM, 1999, PROG LIPID RES, V38, P1, DOI 10.1016/S0163-7827(98)00021-6; Gu YC, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1841; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hilvo M, 2011, CANCER RES, V71, P3236, DOI 10.1158/0008-5472.CAN-10-3894; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; Irwin ME, 2011, J CELL PHYSIOL, V226, P2316, DOI 10.1002/jcp.22570; Ivanova PT, 2007, METHOD ENZYMOL, V432, P21, DOI 10.1016/S0076-6879(07)32002-8; Iwabuchi K, 2010, FEBS LETT, V584, P1642, DOI 10.1016/j.febslet.2009.10.043; Kihara A, 2012, J BIOCHEM, V152, P387, DOI 10.1093/jb/mvs105; Kovacs A, 2005, J PEDIATR GASTR NUTR, V41, P454, DOI 10.1097/01.mpg.0000176181.66390.54; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Kurabe N, 2013, CANCER SCI, V104, P1295, DOI 10.1111/cas.12221; Lamb CA, 2005, J CELL PHYSIOL, V202, P672, DOI 10.1002/jcp.20143; Doria ML, 2013, J CELL PHYSIOL, V228, P457, DOI 10.1002/jcp.24152; Doria ML, 2012, BREAST CANCER RES TR, V133, P635, DOI 10.1007/s10549-011-1823-5; MacLennan M, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2646; Madesh M, 1996, BIOCHEM MOL BIOL INT, V38, P659; MERCHANT TE, 1991, BRIT J CANCER, V63, P693, DOI 10.1038/bjc.1991.157; Mida K, 2012, J AGR FOOD CHEM, V60, P10657, DOI 10.1021/jf302757j; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Olayioye MA, 2005, J BIOL CHEM, V280, P27436, DOI 10.1074/jbc.M413330200; Orr G, 2005, BIOPHYS J, V89, P1362, DOI 10.1529/biophysj.104.056192; Osman C, 2011, J CELL BIOL, V192, P7, DOI 10.1083/jcb.201006159; Panupinthu N, 2010, BRIT J CANCER, V102, P941, DOI 10.1038/sj.bjc.6605588; Patra SK, 2008, BBA-REV CANCER, V1785, P182, DOI 10.1016/j.bbcan.2007.11.002; Polyak K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a013417; Pompeia C, 2003, CELL BIOCHEM FUNCT, V21, P97, DOI 10.1002/cbf.1012; Prydz K, 2001, BIOCHEM J, V357, P11, DOI 10.1042/0264-6021:3570011; ROSANO TG, 1976, J CELL BIOL, V69, P581, DOI 10.1083/jcb.69.3.581; Rudolph MC, 2007, PHYSIOL GENOMICS, V28, P323, DOI 10.1152/physiolgenomics.00020.2006; Sampaio JL, 2011, P NATL ACAD SCI USA, V108, P1903, DOI 10.1073/pnas.1019267108; Shen ZZ, 2001, GYNECOL ONCOL, V83, P25, DOI 10.1006/gyno.2001.6357; Silvente-Poirot S, 2014, SCIENCE, V343, P1445, DOI 10.1126/science.1252787; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Simons K, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004697; SMITH TAD, 1993, NMR BIOMED, V6, P209, DOI 10.1002/nbm.1940060307; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Sterin M, 2004, BREAST CANCER RES TR, V87, P1, DOI 10.1023/B:BREA.0000041572.07837.ec; Storch CH, 2007, J PHARMACOL EXP THER, V323, P257, DOI 10.1124/jpet.107.122994; Vaughan AM, 2005, J BIOL CHEM, V280, P30150, DOI 10.1074/jbc.M505368200; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Williams C, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2256; Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335; Yamaguchi H, 2003, BIOCHEM J, V374, P715, DOI 10.1042/BJ20030381; Yamauchi Y, 2011, CANCER RES, V71, P4989, DOI 10.1158/0008-5472.CAN-10-4108	63	33	34	0	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4247	4264		10.1096/fj.14-249672	http://dx.doi.org/10.1096/fj.14-249672			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24970396				2022-12-28	WOS:000342222700006
J	Guan, YJ; Yang, X; Yang, WT; Charbonneau, C; Chen, Q				Guan, Yingjie; Yang, Xu; Yang, Wentian; Charbonneau, Cherie; Chen, Qian			Mechanical activation of mammalian target of rapamycin pathway is required for cartilage development	FASEB JOURNAL			English	Article						mechanotransduction; mTOR; chondrocyte; Shp2	LONGITUDINAL BONE-GROWTH; CHONDROCYTE DIFFERENTIATION; MATRIX DEFORMATION; CELL-GROWTH; PLATE; COMPLEX; MTOR; MECHANOTRANSDUCTION; STRESS; PROLIFERATION	Mechanical stress regulates development by modulating cell signaling and gene expression. However, the cytoplasmic components mediating mechanotransduction remain unclear. In this study, elimination of muscle contraction during chicken embryonic development resulted in a reduction in the activity of mammalian target of rapamycin (mTOR) in the cartilaginous growth plate. Inhibition of mTOR activity led to significant inhibition of chondrocyte proliferation, cartilage tissue growth, and expression of chondrogenic genes, including Indian hedgehog (Ihh), a critical mediator of mechanotransduction. Conversely, cyclic loading (1 Hz, 5% matrix deformation) of embryonic chicken growth plate chondrocytes in 3-dimensional (3D) collagen scaffolding induced sustained activation of mTOR. Mechanical activation of mTOR occurred in serum-free medium, indicating that it is independent of growth factor or nutrients. Treatment of chondrocytes with Rapa abolished mechanical activation of cell proliferation and Ihh gene expression. Cyclic loading of chondroprogenitor cells deficient in SH2-containing protein tyrosine phosphatase 2 (Shp2) further enhanced mechanical activation of mTOR, cell proliferation, and chondrogenic gene expression. This result suggests that Shp2 is an antagonist of mechanotransduction through inhibition of mTOR activity. Our data demonstrate that mechanical activation of mTOR is necessary for cell proliferation, chondrogenesis, and cartilage growth during bone development, and that mTOR is an essential mechanotransduction component modulated by Shp2 in the cytoplasm.-Guan, Y., Yang, X., Yang, W., Charbonneau, C., Chen, Q. Mechanical activation of mammalian target of rapamycin pathway is required for cartilage development.	[Guan, Yingjie; Yang, Xu; Yang, Wentian; Charbonneau, Cherie; Chen, Qian] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Orthopaed,Cell & Mol Biol Lab, Providence, RI 02903 USA; [Yang, Xu] Qingdao Univ, Affiliated Hosp, Coll Med, Dept Orthopaed, Qingdao 266071, Peoples R China	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Qingdao University	Chen, Q (corresponding author), Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Orthopaed, 1 Hoppin St,Suite 402, Providence, RI 02903 USA.	qian_chen@brown.edu	Chen, Qian/C-4354-2011	Chen, Qian/0000-0003-4406-5618	U.S. National Institutes of Health (NIH) [GM104937, AG017021]; National Science Foundation (NSF) of China [81271978]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017021] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation (NSF) of China(National Natural Science Foundation of China (NSFC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank C. Phornphutkul for helpful discussion and critical reading of the manuscript. This work is supported by the U.S. National Institutes of Health (NIH; grants GM104937 and AG017021) and the National Science Foundation (NSF) of China (grant 81271978).	Alvarez-Garcia O, 2007, PEDIATR NEPHROL, V22, P954, DOI 10.1007/s00467-007-0456-8; CARTER DR, 1987, CLIN ORTHOP RELAT R, P237; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; Dance M, 2008, CELL SIGNAL, V20, P453, DOI 10.1016/j.cellsig.2007.10.002; Dane B, 2009, CLIN EXP OBSTET GYN, V36, P259; Donahue SW, 2001, AM J PHYSIOL-CELL PH, V281, pC1635, DOI 10.1152/ajpcell.2001.281.5.C1635; Duke PJ, 1999, ADV SPACE RES-SERIES, V24, P821, DOI 10.1016/S0273-1177(99)00077-0; Forriol F, 2005, CLIN ORTHOP RELAT R, P14, DOI 10.1097/01.blo.0000156001.78631.e9; Forwood MR, 2001, OSTEOPOROSIS INT, V12, P77, DOI 10.1007/s001980170161; Germiller JA, 1997, J ORTHOP RES, V15, P362, DOI 10.1002/jor.1100150308; Godin LM, 2007, BIOMECH MODEL MECHAN, V6, P391, DOI 10.1007/s10237-006-0059-5; Guan YJ, 2011, FASEB J, V25, P4457, DOI 10.1096/fj.11-185132; HALL BK, 1990, J MORPHOL, V206, P45, DOI 10.1002/jmor.1052060105; Henderson JH, 2002, BONE, V31, P645, DOI 10.1016/S8756-3282(02)00911-0; Holstein JH, 2008, BRIT J PHARMACOL, V154, P1055, DOI 10.1038/bjp.2008.167; Ji BH, 2010, MED HYPOTHESES, V74, P871, DOI 10.1016/j.mehy.2009.11.026; Kanbe K, 2007, J BONE MINER RES, V22, P318, DOI 10.1359/JBMR.061104; KIM YJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P1, DOI 10.1006/abbi.1994.1201; Krejci P, 2007, J BIOL CHEM, V282, P2929, DOI 10.1074/jbc.M606144200; Lamb KJ, 2003, INT J EXP PATHOL, V84, P191, DOI 10.1046/j.1365-2613.2003.00353.x; Lee DY, 2010, J BIOL CHEM, V285, P30, DOI 10.1074/jbc.M109.010512; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Mackie EJ, 2011, J ENDOCRINOL, V211, P109, DOI 10.1530/JOE-11-0048; Moore DC, 2003, J ORTHOP RES, V21, P489, DOI 10.1016/s0736-0266(02)00234-6; Nowlan NC, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000250; Phornphutkul C, 2008, DEV DYNAM, V237, P702, DOI 10.1002/dvdy.21464; Phornphutkul C, 2009, J ORTHOP RES, V27, P1157, DOI 10.1002/jor.20894; PINES M, 1991, POULTRY SCI, V70, P1806, DOI 10.3382/ps.0701806; Pitsillides AA, 2006, J ANAT, V208, P417, DOI 10.1111/j.1469-7580.2006.00556.x; PROVINE RR, 1980, DEV PSYCHOBIOL, V13, P151, DOI 10.1002/dev.420130207; Ramage L, 2009, SCAND J MED SCI SPOR, V19, P457, DOI 10.1111/j.1600-0838.2009.00912.x; Robling AG, 2009, MED SCI SPORT EXER, V41, P2044, DOI 10.1249/MSS.0b013e3181a8c702; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; SCHNEIDERMAN R, 1986, J ORTHOPAED RES, V4, P393, DOI 10.1002/jor.1100040402; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Sibonga JD, 2000, BONE, V27, P535, DOI 10.1016/S8756-3282(00)00352-5; Soulard A, 2009, CURR OPIN CELL BIOL, V21, P825, DOI 10.1016/j.ceb.2009.08.007; Spankuch B, 2006, CANCER RES, V66, P5836, DOI 10.1158/0008-5472.CAN-06-0343; Sparks C. A., ONCOGENE, V29, P3733; Studer D, 2012, EUR CELLS MATER, V24, P118, DOI 10.22203/eCM.v024a09; Stuermer A, 2007, EUR J CELL BIOL, V86, P37, DOI 10.1016/j.ejcb.2006.09.002; Ueki M, 2008, ANN BIOMED ENG, V36, P793, DOI 10.1007/s10439-008-9462-7; Villemure I, 2009, J BIOMECH, V42, P1793, DOI 10.1016/j.jbiomech.2009.05.021; Wong M, 2003, BONE, V33, P685, DOI 10.1016/S8756-3282(03)00242-4; Wu QQ, 2000, EXP CELL RES, V256, P383, DOI 10.1006/excr.2000.4847; Wu QQ, 2001, J BIOL CHEM, V276, P35290, DOI 10.1074/jbc.M101055200; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64; Yang WT, 2013, NATURE, V499, P491, DOI 10.1038/nature12396; You J, 2000, J BIOMECH ENG-T ASME, V122, P387, DOI 10.1115/1.1287161; Zito CI, 2007, J BIOL CHEM, V282, P6946, DOI 10.1074/jbc.M608338200	51	25	25	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4470	4481		10.1096/fj.14-252783	http://dx.doi.org/10.1096/fj.14-252783			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25002119	Green Published			2022-12-28	WOS:000342222700024
J	Liu, XY; Li, L; Wang, YQ; Yan, H; Ma, XF; Wang, PG; Zhang, LW				Liu, Xiaoyan; Li, Ling; Wang, Yuqiu; Yan, Hui; Ma, Xiaofeng; Wang, Peng George; Zhang, Lianwen			A peptide panel investigation reveals the acceptor specificity of O-GlcNAc transferase	FASEB JOURNAL			English	Article						OGT; amino acid preference	LINKED N-ACETYLGLUCOSAMINE; MODIFIED PROTEINS; POSTTRANSLATIONAL MODIFICATIONS; NUCLEOCYTOPLASMIC PROTEIN; TETRATRICOPEPTIDE REPEATS; FUNCTIONAL CONSEQUENCES; DIRECT IDENTIFICATION; TRANSCRIPTION FACTOR; INSULIN-SECRETION; MASS-SPECTROMETRY	O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation) is widely distributed on nucleocytoplasmic proteins and participates in various physiological processes. But O-GlcNAc status on numerous proteins remains unknown. To better understand this modification, computational analysis combined with experimental study was performed in this work. Structural analysis of many O-GlcNAcylation sites indicated that the modification occurred predominantly in a random coil region. Frequency analysis on many O-GlcNAcylated peptides revealed a signature sequence, PPVS/TSATT, around the modification site (underlined, position 0). Based on the sequence, a peptide panel was designed to investigate key positions affecting O-GlcNAcylation of peptides and their amino acid preference. It was indicated that 3 positions (-2, -1, and -2) had an important role for this modification, where the presence of uncharged amino acids with small side chains could confer high reactivity. The amino acid preference at key positions was further investigated on bovine crystalline alpha via site-directed mutagenesis. The preferred amino acids were Pro > Ala > Gly at position -2, Ala > Thr > Val > Lys > Pro at position -1, and Ala > Gly > Arg > Glu at position -2. Altogether, these findings suggested that a substrate (peptide or protein) with Pro, Ala at position -2, and/or Val, Ala, Thr, Ser at position -1, and/or Ala, Ser, Pro, Thr, Gly at position + 2 would have more chances for O-GlcNAcylation. To test the rule, 2 O-GlcNAcylation sites on sOGT (S52 and T449) were predicted and confirmed by Western blot. The present work systematically investigated the sequence signature for O-GlcNAcylation. The result will contribute to predict-ing the O-GlcNAc status of a protein and further functional studies.	Nankai Univ, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China; Nankai Univ, Coll Pharm, Tianjin 300071, Peoples R China	Nankai University; Nankai University	Zhang, LW (corresponding author), Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Weijin Rd, Tianjin 300071, Peoples R China.	lianwen@nankai.edu.cn	WANG, Peng/GSN-5263-2022		National Basic Research Program of China (973 Program) [2012CB910300]; National Natural Science Foundation of China [30970644]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was financially supported by the National Basic Research Program of China (973 Program, grant 2012CB910300) and the National Natural Science Foundation of China (grant 30970644).	Ahmad I, 2006, NUCLEIC ACIDS RES, V34, P175, DOI 10.1093/nar/gkj401; Ahmad IU, 2008, J MANAGE ENG, V24, P1, DOI 10.1061/(ASCE)0742-597X(2008)24:1(1); Akimoto Y, 2007, GLYCOBIOLOGY, V17, P127, DOI 10.1093/glycob/cwl067; Alfaro JF, 2012, P NATL ACAD SCI USA, V109, P7280, DOI 10.1073/pnas.1200425109; BHATNAGAR D, 1988, BIOCHEMISTRY-US, V27, P1988, DOI 10.1021/bi00406a027; Boeggeman E, 2007, BIOCONJUGATE CHEM, V18, P806, DOI 10.1021/bc060341n; Champattanachai V, 2008, AM J PHYSIOL-CELL PH, V294, pC1509, DOI 10.1152/ajpcell.00456.2007; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Gay LM, 2011, NAT CHEM BIOL, V7, P134, DOI 10.1038/nchembio.529; Goodwin OY, 2013, J BIOTECHNOL, V168, P315, DOI 10.1016/j.jbiotec.2013.10.008; Gorodkin J, 1997, COMPUT APPL BIOSCI, V13, P583; GRIFFITH LS, 1995, BIOCHEM BIOPH RES CO, V213, P424, DOI 10.1006/bbrc.1995.2149; Gurcel C, 2008, ANAL BIOANAL CHEM, V390, P2089, DOI 10.1007/s00216-008-1950-y; Hanover JA, 2003, ARCH BIOCHEM BIOPHYS, V409, P287, DOI 10.1016/S0003-9861(02)00578-7; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hart GW, 2011, ANNU REV BIOCHEM, V80, P825, DOI 10.1146/annurev-biochem-060608-102511; Ho CC, 2009, PROTEINS, V76, P213, DOI 10.1002/prot.22341; Kastrup IB, 2000, TISSUE ANTIGENS, V56, P129, DOI 10.1034/j.1399-0039.2000.560203.x; Khidekel N, 2004, P NATL ACAD SCI USA, V101, P13132, DOI 10.1073/pnas.0403471101; Khidekel N, 2003, J AM CHEM SOC, V125, P16162, DOI 10.1021/ja038545r; Khidekel N, 2007, NAT CHEM BIOL, V3, P339, DOI 10.1038/nchembio881; Khwaja TA, 2008, J CELL BIOCHEM, V103, P479, DOI 10.1002/jcb.21412; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Krzeslak A, 2012, CLIN EXP MED, V12, P61, DOI 10.1007/s10238-011-0138-5; Lazarus BD, 2006, GLYCOBIOLOGY, V16, P415, DOI 10.1093/glycob/cwj078; Leavy TM, 2007, BIOORG MED CHEM LETT, V17, P3851, DOI 10.1016/j.bmcl.2007.05.008; Lefebvre T, 2002, J CELL BIOCHEM, V85, P208, DOI 10.1002/jcb.10119; Love DC, 2003, J CELL SCI, V116, P647, DOI 10.1242/jcs.00246; Lubas WA, 1997, J BIOL CHEM, V272, P9316; Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547; Ma XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063452; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; Rexach JE, 2008, NAT CHEM BIOL, V4, P97, DOI 10.1038/nchembio.68; Riu IH, 2008, BIOCHEM BIOPH RES CO, V372, P203, DOI 10.1016/j.bbrc.2008.05.034; Sprung R, 2005, J PROTEOME RES, V4, P950, DOI 10.1021/pr050033j; Tai HC, 2004, J AM CHEM SOC, V126, P10500, DOI 10.1021/ja047872b; Vosseller K, 2006, MOL CELL PROTEOMICS, V5, P923, DOI 10.1074/mcp.T500040-MCP200; Vosseller K, 2005, PROTEOMICS, V5, P388, DOI 10.1002/pmic.200401066; Wang JL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-91; Wang Z, 2007, MOL CELL PROTEOMICS, V6, P1365, DOI 10.1074/mcp.M600453-MCP200; Wang Z, 2009, DIABETES, V58, P309, DOI 10.2337/db08-0994; Wells L, 2002, MOL CELL PROTEOMICS, V1, P791, DOI 10.1074/mcp.M200048-MCP200; Whelan SA, 2003, CIRC RES, V93, P1047, DOI 10.1161/01.RES.0000103190.20260.37; Zachara Natasha E., 2009, V534, P251, DOI 10.1007/978-1-59745-022-5_19; Zhou F, 2013, BIOCHEM BIOPH RES CO, V438, P427, DOI 10.1016/j.bbrc.2013.07.091; Zou LY, 2009, AM J PHYSIOL-HEART C, V296, pH515, DOI 10.1152/ajpheart.01025.2008	46	22	24	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3362	3372		10.1096/fj.13-246850	http://dx.doi.org/10.1096/fj.13-246850			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24760753				2022-12-28	WOS:000340265400008
J	Fahrenbach, JP; Stoller, D; Kim, G; Aggarwal, N; Yerokun, B; Earley, JU; Hadhazy, M; Shi, NQ; Makielski, JC; McNally, EM				Fahrenbach, John P.; Stoller, Douglas; Kim, Gene; Aggarwal, Nitin; Yerokun, Babatunde; Earley, Judy U.; Hadhazy, Michele; Shi, Nian-Qing; Makielski, Jonathan C.; McNally, Elizabeth M.			Abcc9 is required for the transition to oxidative metabolism in the newborn heart	FASEB JOURNAL			English	Article						cardiomyopathy; neonatal heart failure; sulfonylurea receptor; mitochondria	K-ATP CHANNELS; SENSITIVE POTASSIUM CHANNELS; FATTY-ACID; CANTU-SYNDROME; DISRUPTION; MUTATIONS; CARDIOMYOPATHY; ACTIVATION; INHIBITION; DIAZOXIDE	The newborn heart adapts to postnatal life by shifting from a fetal glycolytic metabolism to a mitochondrial oxidative metabolism. Abcc9, an ATP-binding cassette family member, increases expression concomitant with this metabolic shift. Abcc9 encodes a membrane-associated receptor that partners with a potassium channel to become the major potassium-sensitive ATP channel in the heart. Abcc9 also encodes a smaller protein enriched in the mitochondria. We now deleted exon 5 of Abcc9 to ablate expression of both plasma membrane and mitochondria-associated Abcc9-encoded proteins, and found that the myocardium failed to acquire normal mature metabolism, resulting in neonatal cardiomyopathy. Unlike wild-type neonatal cardiomyocytes, mitochondria from Ex5 cardiomyocytes were unresponsive to the K-ATP agonist diazoxide, consistent with loss of K-ATP activity. When exposed to hydrogen peroxide to induce cell stress, Ex5 neonatal cardiomyocytes displayed a rapid collapse of mitochondria membrane potential, distinct from wild-type cardiomyocytes. Ex5 cardiomyocytes had reduced fatty acid oxidation, reduced oxygen consumption and reserve. Morphologically, Ex5 cardiac mitochondria exhibited an immature pattern with reduced cross-sectional area and intermitochondrial contacts. In the absence of Abcc9, the newborn heart fails to transition normally from fetal to mature myocardial metabolism.	[Fahrenbach, John P.; Stoller, Douglas; Kim, Gene; Yerokun, Babatunde; Earley, Judy U.; Hadhazy, Michele; McNally, Elizabeth M.] Univ Chicago, Dept Med, Div Cardiovasc Med, Chicago, IL USA; [McNally, Elizabeth M.] Univ Chicago, Dept Human Genet, Chicago, IL USA; [Aggarwal, Nitin; Shi, Nian-Qing; Makielski, Jonathan C.] Univ Wisconsin, Dept Med, Div Cardiol, Madison, WI USA	University of Chicago; University of Chicago; University of Wisconsin System; University of Wisconsin Madison	McNally, EM (corresponding author), Univ Chicago, 5841 S Maryland,MC6088, Chicago, IL 60637 USA.	emcnally@uchicago.edu	McNally, Elizabeth/W-4909-2019	Kim, Gene/0000-0001-6461-1992; McNally, Elizabeth/0000-0002-1221-719X; fahrenbach, john/0000-0001-6785-9707; Stoller, Douglas/0000-0002-4064-4324	U.S. National Institutes of Health/National Heart, Lung, and Blood Institute [R01-HL078926, R01-HL57414, R21-HL93626, K08-HL098565, F32-HL097587, U54 AR052646]; American Heart Association National Center [11GRNT7600070, 0630268N]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL098565, R21HL093626, F32HL097587, R01HL057414, R01HL078926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U54AR052646] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association National Center(American Heart Association); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported by U.S. National Institutes of Health/National Heart, Lung, and Blood Institute grants R01-HL078926 (E. M. M), R01-HL57414 (J.C.M.), R21-HL93626 (N.-Q.S.), K08-HL098565, (G. K.), F32-HL097587 (J.P.F.), and U54 AR052646. N.-Q.S. is also supported by American Heart Association National Center grants 11GRNT7600070 and 0630268N. The authors thank Stephen Archer and Glenn Marsboom for helpful conversations.	Ardehali H, 2005, J MOL CELL CARDIOL, V39, P7, DOI 10.1016/j.yjmcc.2004.12.003; Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; Bienengraeber M, 2004, NAT GENET, V36, P382, DOI 10.1038/ng1329; BROOK WH, 1983, J ANAT, V137, P729; Brown DA, 2010, CARDIOVASC RES, V88, P241, DOI 10.1093/cvr/cvq231; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chutkow WA, 2002, J CLIN INVEST, V110, P203, DOI 10.1172/JCI200215672; Chutkow WA, 2001, P NATL ACAD SCI USA, V98, P11760, DOI 10.1073/pnas.201390398; Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje; Dhar-Chowdhury P, 2005, J BIOL CHEM, V280, P38464, DOI 10.1074/jbc.M508744200; Elrod JW, 2008, CIRCULATION, V117, P1405, DOI 10.1161/CIRCULATIONAHA.107.745539; Finck BN, 2002, COLD SPRING HARB SYM, V67, P371, DOI 10.1101/sqb.2002.67.371; Flagg TP, 2010, PHYSIOL REV, V90, P799, DOI 10.1152/physrev.00027.2009; Flagg TP, 2008, CIRC RES, V103, P1458, DOI 10.1161/CIRCRESAHA.108.178186; Foster DB, 2012, CIRC RES, V111, P446, DOI 10.1161/CIRCRESAHA.112.266445; Garlid KD, 1997, CIRC RES, V81, P1072; Grange DK, 2006, AM J MED GENET A, V140A, P1673, DOI 10.1002/ajmg.a.31348; Hanley PJ, 2005, J MOL CELL CARDIOL, V39, P17, DOI 10.1016/j.yjmcc.2005.04.002; Harakalova M, 2012, NAT GENET, V44, P793, DOI 10.1038/ng.2324; Hill BG, 2009, BIOCHEM J, V424, P99, DOI 10.1042/BJ20090934; Hong MY, 2011, FASEB J, V25, P2456, DOI 10.1096/fj.10-176669; Jaburek M, 1998, J BIOL CHEM, V273, P13578; Kakkar R, 2006, CIRC RES, V98, P682, DOI 10.1161/01.RES.0000207498.40005.e7; Kuramoto K, 2012, J BIOL CHEM, V287, P23852, DOI 10.1074/jbc.M111.328708; Lascano EC, 2002, MOL CELL BIOCHEM, V236, P53, DOI 10.1023/A:1016198011919; Leu M, 2001, ANAT EMBRYOL, V204, P217, DOI 10.1007/s004290100206; LOPASCHUK GD, 1992, CARDIOVASC RES, V26, P1172, DOI 10.1093/cvr/26.12.1172; Makinde AO, 1998, MOL CELL BIOCHEM, V188, P49, DOI 10.1023/A:1006860104840; Miki T, 2002, NAT MED, V8, P466, DOI 10.1038/nm0502-466; Pike LS, 2011, BBA-BIOENERGETICS, V1807, P726, DOI 10.1016/j.bbabio.2010.10.022; Pilbrow AP, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-64; Piquereau J, 2010, J PHYSIOL-LONDON, V588, P2443, DOI 10.1113/jphysiol.2010.189670; Pu JL, 2008, J MOL CELL CARDIOL, V44, P188, DOI 10.1016/j.yjmcc.2007.09.010; Rodrigo GC, 2004, CARDIOVASC RES, V61, P570, DOI 10.1016/j.cardiores.2003.10.004; Russell LK, 2004, CIRC RES, V94, P525, DOI 10.1161/01.RES.0000117088.36577.EB; Stoller D, 2007, J MOL CELL CARDIOL, V43, P445, DOI 10.1016/j.yjmcc.2007.07.058; Stoller D, 2009, AM J PHYSIOL-REG I, V297, pR1144, DOI 10.1152/ajpregu.00081.2009; Stoller DA, 2010, AM J PHYSIOL-HEART C, V299, pH1100, DOI 10.1152/ajpheart.00084.2010; van Bon BWM, 2012, AM J HUM GENET, V90, P1094, DOI 10.1016/j.ajhg.2012.04.014; WARSHAW JB, 1972, DEV BIOL, V28, P537, DOI 10.1016/0012-1606(72)90001-2; Welling PA, 2009, AM J PHYSIOL-RENAL, V297, pF849, DOI 10.1152/ajprenal.00181.2009; Ye B, 2009, CIRC RES, V105, P1083, DOI 10.1161/CIRCRESAHA.109.195040; Zhang HX, 2010, J MOL CELL CARDIOL, V48, P71, DOI 10.1016/j.yjmcc.2009.07.002; Zorzano A, 2010, SEMIN CELL DEV BIOL, V21, P566, DOI 10.1016/j.semcdb.2010.01.002	44	13	13	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2804	2815		10.1096/fj.13-244459	http://dx.doi.org/10.1096/fj.13-244459			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24648545	Green Published			2022-12-28	WOS:000337949400007
J	Moeton, M; Kanski, R; Stassen, OMJA; Sluijs, JA; Geerts, D; van Tijn, P; Wiche, G; van Strien, ME; Hol, EM				Moeton, Martina; Kanski, Regina; Stassen, Oscar M. J. A.; Sluijs, Jacqueline A.; Geerts, Dirk; van Tijn, Paula; Wiche, Gerhard; van Strien, Miriam E.; Hol, Elly M.			Silencing GFAP isoforms in astrocytoma cells disturbs laminin-dependent motility and cell adhesion	FASEB JOURNAL			English	Article						intermediate filaments; extracellular matrix; glia; glioma; cytoskeleton	FIBRILLARY ACIDIC PROTEIN; CENTRAL-NERVOUS-SYSTEM; HUMAN-BRAIN TUMORS; INTERMEDIATE-FILAMENTS; GLIOMA-CELLS; LENTIVIRAL VECTOR; COMPLEMENTARY-DNA; STEM-CELLS; EXPRESSION; MIGRATION	Glial fibrillary acidic protein (GFAP) is an intermediate filament protein expressed in astrocytes and neural stem cells. The GFAP gene is alternatively spliced, and expression of GFAP is highly regulated during development, on brain damage, and in neurodegenerative diseases. GFAP alpha is the canonical splice variant and is expressed in all GFAP-positive cells. In the human brain, the alternatively spliced transcript GFAP alpha marks specialized astrocyte populations, such as subpial astrocytes and the neurogenic astrocytes in the human subventricular zone. We here show that shifting the GFAP isoform ratio in favor of GFAP alpha in astrocytoma cells, by selectively silencing the canonical isoform GFAP alpha with short hairpin RNAs, induced a change in integrins, a decrease in plectin, and an increase in expression of the extracellular matrix component laminin. Together, this did not affect cell proliferation but resulted in a significantly decreased motility of astrocytoma cells. In contrast, a downregulation of all GFAP isoforms led to less cell spreading, increased integrin expression, and a >100-fold difference in the adhesion of astrocytoma cells to laminin. In summary, isoform-specific silencing of GFAP revealed distinct roles of a specialized GFAP network in regulating the interaction of astrocytoma cells with the extracellular matrix through laminin.	[Moeton, Martina; Kanski, Regina; Stassen, Oscar M. J. A.; Sluijs, Jacqueline A.; van Tijn, Paula; van Strien, Miriam E.; Hol, Elly M.] Netherlands Inst Neurosci, Amsterdam, Netherlands; [Sluijs, Jacqueline A.; Hol, Elly M.] Univ Med Ctr Utrecht, Dept Translat Neurosci, Brain Ctr Rudolf Magnus, NL-3508 AB Utrecht, Netherlands; [Geerts, Dirk] Erasmus Univ, Med Ctr, Dept Pediat Oncol & Hematol, Rotterdam, Netherlands; [van Tijn, Paula] Hubrecht Inst, Utrecht, Netherlands; [Wiche, Gerhard] Univ Vienna, Dept Biochem & Cell Biol, Max F Perutz Labs, Vienna, Austria; [Hol, Elly M.] Univ Amsterdam, Swammerdam Inst Life Sci, Ctr Neurosci, Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); University of Amsterdam	Hol, EM (corresponding author), Univ Med Ctr Utrecht, Dept Translat Neurosci, Brain Ctr Rudolf Magnus, Str 4-205,POB 85060, NL-3508 AB Utrecht, Netherlands.	e.m.hol-2@umcutrecht.nl	Hol, Elly M/F-1891-2013; Hol, Elly/J-2025-2019; WICHE, Gerhard/AAA-3227-2021; van Tijn, Paula/E-4866-2012; Geerts, Dirk/K-8260-2015; Stassen, Oscar/I-9075-2014	Hol, Elly M/0000-0001-5604-2603; Hol, Elly/0000-0001-5604-2603; Geerts, Dirk/0000-0002-6386-8187; Stassen, Oscar/0000-0001-7485-0903; Wiche, Gerhard/0000-0001-9550-5463	Netherlands Organization for Scientific Research (NWO; VICI) [865.09.003]; FOM [09MMC06]; NANONET COST [BM1002]; Austrian Science Fund (FWF) [I 1207, P 23729] Funding Source: researchfish	Netherlands Organization for Scientific Research (NWO; VICI)(Netherlands Organization for Scientific Research (NWO)); FOM(FOM (The Netherlands)); NANONET COST(European Cooperation in Science and Technology (COST)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	This project is funded by The Netherlands Organization for Scientific Research (NWO; VICI grant 865.09.003 to E. M. H.), FOM 09MMC06, and NANONET COST BM1002. The Netherlands Institute for Neuroscience and the Hubrecht Institute are institutes of the Royal Netherlands Academy of Arts and Sciences.	Andra K, 2003, J INVEST DERMATOL, V120, P189, DOI 10.1046/j.1523-1747.2003.12027.x; Aumailley M, 2000, J CELL SCI, V113, P259; Choi KC, 2009, NEUROSCI LETT, V463, P182, DOI 10.1016/j.neulet.2009.07.076; Chung BM, 2013, CURR OPIN CELL BIOL, V25, P600, DOI 10.1016/j.ceb.2013.06.008; Colognato H, 2005, TRENDS NEUROSCI, V28, P480, DOI 10.1016/j.tins.2005.07.004; DECK JHN, 1978, ACTA NEUROPATHOL, V42, P183, DOI 10.1007/BF00690355; Delamarre E, 2009, AM J PATHOL, V175, P844, DOI 10.2353/ajpath.2009.080920; Farin A, 2006, GLIA, V53, P799, DOI 10.1002/glia.20334; Franco SJ, 2011, DEV NEUROBIOL, V71, P889, DOI 10.1002/dneu.20946; Goldbrunner RH, 1999, ACTA NEUROCHIR, V141, P295, DOI 10.1007/s007010050301; Gregor M, 2014, FASEB J, V28, P715, DOI 10.1096/fj.13-231829; Heo DH, 2012, J NEURO-ONCOL, V108, P45, DOI 10.1007/s11060-012-0801-z; Ho CL, 1996, CANCER METAST REV, V15, P483, DOI 10.1007/BF00054014; Hol EM, 2003, MOL PSYCHIATR, V8, P786, DOI 10.1038/sj.mp.4001379; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JACQUE CM, 1978, J NEUROL SCI, V35, P147, DOI 10.1016/0022-510X(78)90107-7; Kamphuis W, 2014, NEUROBIOL AGING, V35, P492, DOI 10.1016/j.neurobiolaging.2013.09.035; Kamphuis W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042823; Katada K, 2012, J PROTEOMICS, V75, P1803, DOI 10.1016/j.jprot.2011.12.018; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lepekhin EA, 2001, J NEUROCHEM, V79, P617, DOI 10.1046/j.1471-4159.2001.00595.x; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Menet V, 2001, J NEUROSCI, V21, P6147; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Middeldorp J, 2010, DEVELOPMENT, V137, P313, DOI 10.1242/dev.041632; Middeldorp J, 2009, FASEB J, V23, P2710, DOI 10.1096/fj.08-127696; Moyano JV, 2010, MOL BIOL CELL, V21, P3654, DOI 10.1091/mbc.E10-06-0523; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nielsen AL, 2004, J BIOL CHEM, V279, P41537, DOI 10.1074/jbc.M406601200; Nishio T, 2005, NEUROSCIENCE, V132, P87, DOI 10.1016/j.neuroscience.2004.12.028; Niu CS, 2011, ONCOL REP, V26, P593, DOI 10.3892/or.2011.1308; Ogier C, 2006, GLIA, V54, P272, DOI 10.1002/glia.20349; Palu E, 2002, J NEUROSCI RES, V69, P243, DOI 10.1002/jnr.10292; Perng MD, 2008, MOL BIOL CELL, V19, P4521, DOI 10.1091/mbc.E08-03-0284; Rebetz J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001936; Roelofs RF, 2005, GLIA, V52, P289, DOI 10.1002/glia.20243; Rooprai HK, 1999, INT J DEV NEUROSCI, V17, P613, DOI 10.1016/S0736-5748(99)00051-9; Root DE, 2006, NAT METHODS, V3, P715, DOI 10.1038/NMETH924; Rousseau A, 2006, J NEUROPATH EXP NEUR, V65, P1149, DOI 10.1097/01.jnen.0000248543.90304.2b; Ruijter JM, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-2; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Skalli O, 2013, HUM PATHOL, V44, P2081, DOI 10.1016/j.humpath.2013.03.013; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Steinbock FA, 1999, BIOL CHEM, V380, P151, DOI 10.1515/BC.1999.023; TODA M, 1994, NEUROREPORT, V5, P1969, DOI 10.1097/00001756-199410000-00033; van den Berge SA, 2010, AGING CELL, V9, P313, DOI 10.1111/j.1474-9726.2010.00556.x; VELASCO ME, 1980, CANCER, V45, P484, DOI 10.1002/1097-0142(19800201)45:3<484::AID-CNCR2820450312>3.0.CO;2-9; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; Wiche Gerhard, 2011, Bioarchitecture, V1, P14; YUNG WKA, 1985, J NEURO-ONCOL, V3, P35	55	30	30	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2942	2954		10.1096/fj.13-245837	http://dx.doi.org/10.1096/fj.13-245837			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24696300				2022-12-28	WOS:000337949400018
J	Benesch, MGK; Tang, XY; Maeda, T; Ohhata, A; Zhao, YY; Kok, BPC; Dewald, J; Hitt, M; Curtis, JM; McMullen, TPW; Brindley, DN				Benesch, Matthew G. K.; Tang, Xiaoyun; Maeda, Tatsuo; Ohhata, Akira; Zhao, Yuan Y.; Kok, Bernard P. C.; Dewald, Jay; Hitt, Mary; Curtis, Jonathan M.; McMullen, Todd P. W.; Brindley, David N.			Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice	FASEB JOURNAL			English	Article						adipose tissue; lysophosphatidate; sphingosine 1-phosphate; syngeneic mouse model	LYSOPHOSPHATIDIC ACID; SERUM AUTOTAXIN; SPHINGOSINE 1-PHOSPHATE; LYSOPHOSPHOLIPASE-D; PHOSPHOLIPASE A(2); CANCER; EXPRESSION; MIGRATION; CHEMOTHERAPY; RESISTANCE	Autotaxin is a secreted enzyme that produces most extracellular lysophosphatidate, which stimulates 6 G-protein-coupled receptors. Lysophosphatidate promotes cancer cell survival, growth, migration, invasion, metastasis, and resistance to chemotherapy and radiotherapy. The present work investigated whether inhibiting autotaxin could decrease breast tumor growth and metastasis. We used a new autotaxin inhibitor (ONO-8430506; IC90=100 nM), which decreased plasma autotaxin activity by >60% and concentrations of unsaturated lysophosphatidates by >75% for 24 h compared with vehicle-treated mice. The effects of ONO-8430506 on tumor growth were determined in a syngeneic orthotopic mouse model of breast cancer following injection of 20,000 BALB/c mouse 4T1 or 4T1-12B cancer cells. We show for the first time that inhibiting autotaxin decreases initial tumor growth and subsequent lung metastatic nodules both by 60% compared with vehicle-treated mice. Significantly, 4T1 cells express negligible autotaxin compared with the mammary fat pad. Autotaxin activity in the fat pad of nontreated mice was increased 2-fold by tumor growth. Our results emphasize the importance of tumor interaction with its environment and the role of autotaxin in promoting breast cancer growth and metastasis. We also established that autotaxin inhibition could provide a novel therapeutic approach to blocking the adverse effects of lysophosphatidate in cancer.	[Benesch, Matthew G. K.; Tang, Xiaoyun; Kok, Bernard P. C.; Dewald, Jay; Brindley, David N.] Univ Alberta, Dept Biochem, Signal Transduct Res Grp, Edmonton, AB, Canada; [Zhao, Yuan Y.; Curtis, Jonathan M.] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB, Canada; [Hitt, Mary] Univ Alberta, Dept Oncol, Edmonton, AB, Canada; [McMullen, Todd P. W.] Univ Alberta, Mackenzie Hlth Sci Ctr, Dept Surg, Edmonton, AB, Canada; [Maeda, Tatsuo] Ono Pharmaceut Co, Explorat Res Labs, Tsukuba, Ibaraki, Japan; [Ohhata, Akira] Ono Pharmaceut Co, Med Chem Res Labs, Shimamoto, Osaka, Japan	University of Alberta; University of Alberta; University of Alberta; University of Alberta; Ono Pharmaceutical Co Ltd; Ono Pharmaceutical Co Ltd	Brindley, DN (corresponding author), Univ Alberta, Dept Biochem, Med Res Ctr, 357 Heritage, Edmonton, AB T6G 2S2, Canada.	david.brindley@ualberta.ca	Benesch, Matthew/GRF-0677-2022	Kok, Bernard/0000-0002-9073-9700; Benesch, Matthew/0000-0002-1326-684X	Vanier Canada Graduate Scholarship from the Government of Canada; Canadian Institutes of Health Research (CIHR); Alberta Innovates-Health Solutions; Killam Trust Award; Canadian Breast Cancer Foundation (CBCF); CBCF; CIHR; Alberta Cancer Foundation; Ono Pharmaceuticals	Vanier Canada Graduate Scholarship from the Government of Canada; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Innovates-Health Solutions; Killam Trust Award; Canadian Breast Cancer Foundation (CBCF); CBCF; CIHR(Canadian Institutes of Health Research (CIHR)); Alberta Cancer Foundation; Ono Pharmaceuticals	The authors thank Dr. Tetsuya Sugiyama (Ono Pharmaceuticals) for many helpful discussions and facilitating collaborations. ONO-8430506 and ONO-8410506 were provided by Ono Pharmaceuticals. M.G.K.B. is the recipient of a Vanier Canada Graduate Scholarship from the Government of Canada, a Canadian Institutes of Health Research (CIHR) MD/Ph.D. Studentship, a MD/Ph.D. Studentship from Alberta Innovates-Health Solutions, and a Killam Trust Award. X.T. holds a research fellowship from the Canadian Breast Cancer Foundation (CBCF). The work was also supported by grants from the CBCF, CIHR with the Alberta Cancer Foundation, and Ono Pharmaceuticals. The authors declare the following conflicts of interest: D.N.B. received consultancy payments in 2011 from Ono Pharmaceuticals and a 2 yr research grant in 2012, which partly financed this work. T.M. and A.O. are employees of Ono Pharmaceuticals, and A.O. holds a patent on the presented ATX inhibitor. T.M. and A.O. measured ONO-8430506 concentrations in mouse plasma as illustrated in Fig. 1C. The other authors declare no conflicts of interest.	Albers HMHG, 2012, CHEM REV, V112, P2593, DOI 10.1021/cr2003213; Barbayianni E, 2013, EXPERT OPIN THER PAT, V23, P1123, DOI 10.1517/13543776.2013.796364; Bekele RT, 2012, CLIN LIPIDOL, V7, P313, DOI 10.2217/CLP.12.30; Benesch MGK, 2014, FEBS LETT, V588, P2712, DOI 10.1016/j.febslet.2014.02.009; Boucher J, 2005, DIABETOLOGIA, V48, P569, DOI 10.1007/s00125-004-1660-8; Brindley DN, 2013, BBA-MOL CELL BIOL L, V1831, P74, DOI 10.1016/j.bbalip.2012.08.015; Brindley DN, 2009, BBA-MOL CELL BIOL L, V1791, P956, DOI 10.1016/j.bbalip.2009.02.007; Brindley DN, 2009, J LIPID RES, V50, pS225, DOI 10.1194/jlr.R800055-JLR200; Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575; Choi JW, 2013, BBA-MOL CELL BIOL L, V1831, P20, DOI 10.1016/j.bbalip.2012.07.015; Clair T, 2003, CANCER RES, V63, P5446; David M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009741; De Pergola G, 2013, J OBES, V2013, DOI 10.1155/2013/291546; Deng W, 2007, GASTROENTEROLOGY, V132, P1834, DOI 10.1053/j.gastro.2007.03.038; Dusaulcy R, 2011, J LIPID RES, V52, P1247, DOI 10.1194/jlr.M014985; English D, 2001, CARDIOVASC RES, V49, P588, DOI 10.1016/S0008-6363(00)00230-3; Euer N, 2002, ANTICANCER RES, V22, P733; Federico L, 2012, MOL ENDOCRINOL, V26, P786, DOI 10.1210/me.2011-1229; Ferry G, 2003, J BIOL CHEM, V278, P18162, DOI 10.1074/jbc.M301158200; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Fulkerson Z, 2011, J BIOL CHEM, V286, P34654, DOI 10.1074/jbc.M111.276725; Gaetano CG, 2009, MOL CARCINOGEN, V48, P801, DOI 10.1002/mc.20524; Hausmann J, 2011, NAT STRUCT MOL BIOL, V18, P198, DOI 10.1038/nsmb.1980; Houben AJS, 2013, J BIOL CHEM, V288, P510, DOI 10.1074/jbc.M112.358416; Hozumi H, 2013, LAB INVEST, V93, P508, DOI 10.1038/labinvest.2013.45; IMAMURA S, 1978, J BIOCHEM-TOKYO, V83, P677, DOI 10.1093/oxfordjournals.jbchem.a131960; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jeon YH, 2007, CANCER BIOL THER, V6, P781, DOI 10.4161/cbt.6.5.4005; Kehlen A, 2004, INT J CANCER, V109, P833, DOI 10.1002/ijc.20022; Koike S, 2009, J BIOL CHEM, V284, P33561, DOI 10.1074/jbc.M109.012716; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li H, 2010, FASEB J, V24, P4103, DOI 10.1096/fj.10-161356; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Masuda A, 2008, BRIT J HAEMATOL, V143, P60, DOI 10.1111/j.1365-2141.2008.07325.x; Morimoto T., 2012, World Patent, Patent No. [WO2012005227 A1, 2012005227]; MURATA J, 1994, J BIOL CHEM, V269, P30479; Murph MM, 2007, MOL CANCER RES, V5, P1201, DOI 10.1158/1541-7786.MCR-06-0338; Nakai Y, 2011, CLIN BIOCHEM, V44, P576, DOI 10.1016/j.clinbiochem.2011.03.128; Nakamura K, 2007, CLIN BIOCHEM, V40, P274, DOI 10.1016/j.clinbiochem.2006.10.009; Nakamura K, 2012, LIPIDS, V47, P927, DOI 10.1007/s11745-012-3691-0; Nakanaga K, 2010, J BIOCHEM, V148, P13, DOI 10.1093/jb/mvq052; Nam SW, 2001, CANCER RES, V61, P6938; Nikitopoulou I, 2012, J EXP MED, V209, P923, DOI 10.1084/jem.20112012; Paridaens R, 2000, J CLIN ONCOL, V18, P724, DOI 10.1200/JCO.2000.18.4.724; Popnikolov NK, 2012, TUMOR BIOL, V33, P2237, DOI 10.1007/s13277-012-0485-1; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Samadi N, 2009, ONCOGENE, V28, P1028, DOI 10.1038/onc.2008.442; Samadi N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020608; Samadi N, 2011, BIOCHIMIE, V93, P61, DOI 10.1016/j.biochi.2010.08.002; Scherer M, 2010, J LIPID RES, V51, P2001, DOI 10.1194/jlr.D005322; Scherer M, 2009, CLIN CHEM, V55, P1218, DOI 10.1373/clinchem.2008.113779; Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402; So J, 2005, GYNECOL ONCOL, V97, P870, DOI 10.1016/j.ygyno.2005.03.004; Sukocheva OA, 2003, MOL ENDOCRINOL, V17, P2002, DOI 10.1210/me.2003-0119; Sukocheva O, 2009, ENDOCRINOLOGY, V150, P4484, DOI 10.1210/en.2009-0391; Sundaram Sneha, 2013, J Carcinog, V12, P19, DOI 10.4103/1477-3163.119606; Tao K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-228; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2007, PROG LIPID RES, V46, P145, DOI 10.1016/j.plipres.2007.02.001; van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419-05; Vidot S, 2010, CELL SIGNAL, V22, P926, DOI 10.1016/j.cellsig.2010.01.017; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Zhang RH, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-11	63	81	82	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2655	2666		10.1096/fj.13-248641	http://dx.doi.org/10.1096/fj.13-248641			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24599971				2022-12-28	WOS:000339883600023
J	Hasan, S; Van der Veen, DR; Winsky-Sommerer, R; Hogben, A; Laing, EE; Koentgen, F; Dijk, DJ; Archer, SN				Hasan, Sibah; Van der Veen, Daan R.; Winsky-Sommerer, Raphaelle; Hogben, Alexandra; Laing, Emma E.; Koentgen, Frank; Dijk, Derk-Jan; Archer, Simon N.			A human sleep homeostasis phenotype in mice expressing a primate-specific PER3 variable-number tandem-repeat coding-region polymorphism	FASEB JOURNAL			English	Article						circadian; sleep deprivation; EEG; clock genes	EYE-MOVEMENT SLEEP; INTERINDIVIDUAL DIFFERENCES; TARGETED DISRUPTION; LENGTH POLYMORPHISM; CIRCADIAN-RHYTHMS; GENETIC-VARIATION; PHASE SYNDROME; ASSOCIATION	In humans, a primate-specific variable-number tandem-repeat (VNTR) polymorphism (4 or 5 repeats 54 nt in length) in the circadian gene PER3 is associated with differences in sleep timing and homeostatic responses to sleep loss. We investigated the effects of this polymorphism on circadian rhythmicity and sleep homeostasis by introducing the polymorphism into mice and assessing circadian and sleep parameters at baseline and during and after 12 h of sleep deprivation (SD). Microarray analysis was used to measure hypothalamic and cortical gene expression. Circadian behavior and sleep were normal at baseline. The response to SD of 2 electrophysiological markers of sleep homeostasis, electroencephalography (EEG) theta power during wakefulness and delta power during sleep, were greater in the Per3(5/5) mice. During recovery, the Per3(5/5) mice fully compensated for the SD-induced deficit in delta power, but the Per3(4/4) and wild-type mice did not. Sleep homeostasis-related transcripts (e. g., Homer1, Ptgs2, and Kcna2) were differentially expressed between the humanized mice, but circadian clock genes were not. These data are in accordance with the hypothesis derived from human data that the PER3 VNTR polymorphism modifies the sleep homeostatic response without significantly influencing circadian parameters.	[Hasan, Sibah; Van der Veen, Daan R.; Winsky-Sommerer, Raphaelle; Hogben, Alexandra; Laing, Emma E.; Dijk, Derk-Jan; Archer, Simon N.] Univ Surrey, Fac Hlth & Med Sci, Guildford GU2 7XH, Surrey, England; [Koentgen, Frank] Ozgene Pty Ltd, Bentley, WA, Australia	University of Surrey	Archer, SN (corresponding author), Univ Surrey, Fac Hlth & Med Sci, Guildford GU2 7XH, Surrey, England.	simon.archer@surrey.ac.uk	van der Veen, Daan R/T-1013-2017	van der Veen, Daan R/0000-0001-8037-1407	UK Biotechnology and Biological Sciences Research Council [BB/F022883/1, BB/E003672/1]; Royal Society; BBSRC [BB/E003672/1, BB/F022883/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/F022883/1, BB/E003672/1] Funding Source: researchfish	UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Royal Society(Royal Society of London); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors thank A. Slak, S. Wehrens, S. Bae, S. Maentele, B. Martynhak, and I. Wright for their help with the SD experiments. This research was supported by grants from the UK Biotechnology and Biological Sciences Research Council (BB/F022883/1 and BB/E003672/1) and the Royal Society (to D.J.D.). F.K. is director and CEO of Ozgene Pty. Ltd. (Bentley, WA, Australia). Gene expression data are archived as Ancillary Data files on University of Surrey servers (http://sleep-sysbio.fhms.surrey.ac.uk/Hasan_14/).	Adan A, 2012, CHRONOBIOL INT, V29, P1153, DOI 10.3109/07420528.2012.719971; Allebrandt KV, 2013, MOL PSYCHIATR, V18, P122, DOI 10.1038/mp.2011.142; Allebrandt KV, 2010, BIOL PSYCHIAT, V67, P1040, DOI 10.1016/j.biopsych.2009.12.026; Archer SN, 2008, SLEEP, V31, P608, DOI 10.1093/sleep/31.5.608; Archer SN, 2003, SLEEP, V26, P413, DOI 10.1093/sleep/26.4.413; ASCHOFF J, 1960, COLD SPRING HARB SYM, V25, P11, DOI 10.1101/SQB.1960.025.01.004; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; Borbely A A, 1982, Hum Neurobiol, V1, P195; Buhr Ethan D, 2013, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-642-25950-0_1; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; Dijk DJ, 2010, SLEEP MED REV, V14, P151, DOI 10.1016/j.smrv.2009.07.002; DIJK DJ, 1995, J NEUROSCI, V15, P3526; Douglas CL, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-42; Duncan D, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S4-P10; Ebisawa T, 2001, EMBO REP, V2, P342, DOI 10.1093/embo-reports/kve070; Franken P, 2006, P NATL ACAD SCI USA, V103, P7118, DOI 10.1073/pnas.0602006103; Franken P, 2009, EUR J NEUROSCI, V29, P1820, DOI 10.1111/j.1460-9568.2009.06723.x; Franken P, 2001, J NEUROSCI, V21, P2610, DOI 10.1523/JNEUROSCI.21-08-02610.2001; Franken P, 1998, AM J PHYSIOL-REG I, V275, pR1127, DOI 10.1152/ajpregu.1998.275.4.R1127; Goel N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005874; Groeger JA, 2008, SLEEP, V31, P1159; Hasan S, 2012, FASEB J, V26, P2414, DOI 10.1096/fj.11-201699; Hasan S, 2011, AM J PHYSIOL-REG I, V301, pR1821, DOI 10.1152/ajpregu.00260.2011; He Y, 2009, SCIENCE, V325, P866, DOI 10.1126/science.1174443; Hughes ED, 2007, MAMM GENOME, V18, P549, DOI 10.1007/s00335-007-9054-0; Jones KHS, 2007, J SLEEP RES, V16, P12, DOI 10.1111/j.1365-2869.2007.00561.x; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; Laing Emma, 2010, BMC Res Notes, V3, P221, DOI 10.1186/1756-0500-3-221; Lazar AS, 2012, CHRONOBIOL INT, V29, P131, DOI 10.3109/07420528.2011.641193; Lo JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045987; Maret S, 2005, SCIENCE, V310, P111, DOI 10.1126/science.1117623; Maret S, 2007, P NATL ACAD SCI USA, V104, P20090, DOI 10.1073/pnas.0710131104; Mongrain V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026622; Naylor E, 2000, J NEUROSCI, V20, P8138; Obal F, 2005, J NEUROSCI, V25, P10282, DOI 10.1523/JNEUROSCI.2572-05.2005; Pendergast JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030254; Pereira DS, 2005, SLEEP, V28, P29; Rusterholz T, 2010, SLEEP, V33, P491, DOI 10.1093/sleep/33.4.491; Saper CB, 2005, J COMP NEUROL, V493, P92, DOI 10.1002/cne.20770; Shearman LP, 2000, MOL CELL BIOL, V20, P6269, DOI 10.1128/MCB.20.17.6269-6275.2000; SOKOLOVE PG, 1978, J THEOR BIOL, V72, P131, DOI 10.1016/0022-5193(78)90022-X; Thakkar MM, 2008, NEUROSCIENCE, V153, P875, DOI 10.1016/j.neuroscience.2008.01.017; van der Veen DR, 2010, J BIOL RHYTHM, V25, P3, DOI 10.1177/0748730409356680; Vandewalle G, 2009, J NEUROSCI, V29, P7948, DOI 10.1523/JNEUROSCI.0229-09.2009; Viola AU, 2007, CURR BIOL, V17, P613, DOI 10.1016/j.cub.2007.01.073; Viola AU, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.10.024; Wisorl JP, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-20; Xu Y, 2007, CELL, V128, P59, DOI 10.1016/j.cell.2006.11.043; Yagita K, 2000, GENE DEV, V14, P1353	49	22	23	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2441	2454		10.1096/fj.13-240135	http://dx.doi.org/10.1096/fj.13-240135			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24577121	Green Published, Green Submitted			2022-12-28	WOS:000339883600006
J	Imamura, Y; Tomita, S; Imanishi, M; Kihira, Y; Ikeda, Y; Ishizawa, K; Tsuchiya, K; Tamaki, T				Imamura, Yuko; Tomita, Shuhei; Imanishi, Masaki; Kihira, Yoshitaka; Ikeda, Yasumasa; Ishizawa, Keisuke; Tsuchiya, Koichiro; Tamaki, Toshiaki			HIF-2 alpha/ARNT complex regulates hair development via induction of p21(Waf1/Cip1) and p27(Kip1)	FASEB JOURNAL			English	Article						hypoxia-inducible factor; cyclin-dependent kinase inhibitor; cell differentiation	INDUCIBLE FACTOR 1-ALPHA; SKIN DEVELOPMENT; BARRIER FUNCTION; DERMAL PAPILLA; STEM-CELLS; HYPOXIA; GENE; P53; HIF-1-ALPHA; EXPRESSION	The hypoxia-inducible factors HIF-1 alpha or HIF-2 alpha form heterodimeric complexes with the aryl hydrocarbon receptor nuclear translocator (ARNT). HIF-1 alpha/ARNT and HIF-2 alpha/ARNT complexes activate hypoxia-inducible genes that play critical roles in angiogenesis, anaerobic metabolism, and other processes in response to O-2 deprivation. HIF-2 alpha is known to regulate the function and/or differentiation of stem cells by activating the POU domain transcription factor Oct4; however, the precise underlying mechanism is unknown. This study examined the role of HIF-2 alpha/ARNT in hair development using conditional-knockout mice, in which Arnt was specifically deleted in keratinocytes. In wild-type mice, HIF-2 alpha and ARNT were highly expressed in the precortex above the hair matrix, an area containing differentiating stem cells. An analysis of hair size and type in these mice showed that loss of ARNT decreased the production of zigzag hairs, corresponding to reduced expression of HIF-2 alpha and induction of the mammalian cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1). The results suggest that the HIF-2 alpha/ARNT complex regulates hair follicle differentiation via induction of p21(Waf1/Cip1) and possibly p27(Kip1), as p27(Kip1) expression was not altered in ARNT knockout mice. The findings provide insight into a possible mechanism underlying hair growth disorders and can be useful for future studies on hair follicle response to insults, such as chemotherapy and ionizing radiation.	[Imamura, Yuko; Imanishi, Masaki; Kihira, Yoshitaka; Ikeda, Yasumasa; Tamaki, Toshiaki] Univ Tokushima, Grad Sch, Dept Pharmacol, Tokushima 770, Japan; [Ishizawa, Keisuke; Tsuchiya, Koichiro] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Med Pharmacol, Tokushima 770, Japan; [Imamura, Yuko] Hiroshima Univ, Grad Sch Adv Sci, Dept Mol Biotechnol, Higashihiroshima, Hiroshima 7398530, Japan; [Tomita, Shuhei] Tottori Univ, Fac Med, Div Mol Pharmacol, Yonago, Tottori 683, Japan	Tokushima University; Tokushima University; Hiroshima University; Tottori University	Imamura, Y (corresponding author), Hiroshima Univ, Grad Sch Adv Sci, Dept Mol Biotechnol, 1-3-1 Kagamiyama, Higashihiroshima, Hiroshima 7398530, Japan.	yukoima@hiroshima-u.ac.jp		Imanishi, Masaki/0000-0003-1305-5943; Ikeda, Yasumasa/0000-0003-4318-7349	Japan Society for the Promotion of Science (JSPS) for Young Scientists [21-10290]; Excellent Young Researcher Overseas Visit Program from JSPS; Grants-in-Aid for Scientific Research [25860063, 24590381] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS) for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Excellent Young Researcher Overseas Visit Program from JSPS; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a research fellowship from the Japan Society for the Promotion of Science (JSPS) for Young Scientists (21-10290) and the Excellent Young Researcher Overseas Visit Program from JSPS. The authors thank Nazumi Ishimaru and Yoshio Hayashi (Tokushima University) for providing instruments for the histological analysis, as well as David J. Mann (Imperial College London, London, UK) for his support.	Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elliott K, 1999, J INVEST DERMATOL, V113, P873, DOI 10.1046/j.1523-1747.1999.00797.x; Fels DR, 2005, TRENDS BIOCHEM SCI, V30, P426, DOI 10.1016/j.tibs.2005.06.009; Fuchs E, 2001, DEV CELL, V1, P13, DOI 10.1016/S1534-5807(01)00022-3; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; GALBRAITH DB, 1969, NATURE, V222, P288, DOI 10.1038/222288a0; Geng SM, 2006, J CELL SCI, V119, P4901, DOI 10.1242/jcs.03282; Grochot-Przeczek A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005803; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; HARPER JW, 1993, CELL, V75, P805; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ishizawa K, 2005, HYPERTENSION, V46, P1046, DOI 10.1161/01.HYP.0000172622.51973.f5; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kihira Y, 2011, INT J BIOCHEM CELL B, V43, P1602, DOI 10.1016/j.biocel.2011.07.009; Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Millar SE, 2002, J INVEST DERMATOL, V118, P216, DOI 10.1046/j.0022-202x.2001.01670.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohtani N, 2007, P NATL ACAD SCI USA, V104, P15034, DOI 10.1073/pnas.0706949104; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Rohwer N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012038; Rosenberger C, 2007, J INVEST DERMATOL, V127, P2445, DOI 10.1038/sj.jid.5700874; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Sharov AA, 2006, P NATL ACAD SCI USA, V103, P18166, DOI 10.1073/pnas.0608899103; Takagi S, 2003, J CLIN INVEST, V112, P1372, DOI 10.1172/JCI200318513; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Tomita S, 2000, MOL ENDOCRINOL, V14, P1674, DOI 10.1210/me.14.10.1674; VANSCOTT EJ, 1958, J INVEST DERMATOL, V31, P281, DOI 10.1038/jid.1958.121; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Xenaki G, 2008, ONCOGENE, V27, P5785, DOI 10.1038/onc.2008.192; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	42	4	4	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2517	2524		10.1096/fj.13-244079	http://dx.doi.org/10.1096/fj.13-244079			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24599965	Bronze			2022-12-28	WOS:000339883600012
J	Richardson, JR; Taylor, MM; Shalat, SL; Guillot, TS; Caudle, WM; Hossain, MM; Mathews, TA; Jones, SR; Cory-Slechta, DA; Miller, GW				Richardson, Jason R.; Taylor, Michele M.; Shalat, Stuart L.; Guillot, Thomas S., III; Caudle, W. Michael; Hossain, Muhammad M.; Mathews, Tiffany A.; Jones, Sara R.; Cory-Slechta, Deborah A.; Miller, Gary W.			Developmental pesticide exposure reproduces features of attention deficit hyperactivity disorder	FASEB JOURNAL			English	Article						ADHD; dopamine transporter; pyrethyroid; impulsivity; dopamine receptor	DEFICIT/HYPERACTIVITY DISORDER; DOPAMINE TRANSPORTER; ANIMAL-MODEL; PYRETHROID INSECTICIDES; PARKINSONS-DISEASE; MOLECULAR-GENETICS; IMPULSIVE BEHAVIOR; NUCLEUS-ACCUMBENS; MICE LACKING; RISK-FACTORS	Attention-deficit hyperactivity disorder (ADHD) is estimated to affect 8-12% of school-age children worldwide. ADHD is a complex disorder with significant genetic contributions. However, no single gene has been linked to a significant percentage of cases, suggesting that environmental factors may contribute to ADHD. Here, we used behavioral, molecular, and neurochemical techniques to characterize the effects of developmental exposure to the pyrethroid pesticide deltamethrin. We also used epidemiologic methods to determine whether there is an association between pyrethroid exposure and diagnosis of ADHD. Mice exposed to the pyrethroid pesticide deltamethrin during development exhibit several features reminiscent of ADHD, including elevated dopamine transporter (DAT) levels, hyperactivity, working memory and attention deficits, and impulsive-like behavior. Increased DAT and D1 dopamine receptor levels appear to be responsible for the behavioral deficits. Epidemiologic data reveal that children aged 6-15 with detectable levels of pyrethroid metabolites in their urine were more than twice as likely to be diagnosed with ADHD. Our epidemiologic finding, combined with the recapitulation of ADHD behavior in pesticide-treated mice, provides a mechanistic basis to suggest that developmental pyrethroid exposure is a risk factor for ADHD.	[Richardson, Jason R.; Taylor, Michele M.; Shalat, Stuart L.; Hossain, Muhammad M.] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Environm & Occupat Med & Environm, Piscataway, NJ USA; [Richardson, Jason R.; Taylor, Michele M.; Shalat, Stuart L.; Hossain, Muhammad M.] Rutgers State Univ, Robert Wood Johnson Med Sch, Inst Occupat Hlth Sci, Piscataway, NJ 08854 USA; [Guillot, Thomas S., III; Caudle, W. Michael; Miller, Gary W.] Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; [Guillot, Thomas S., III; Caudle, W. Michael; Miller, Gary W.] Emory Univ, Rollins Sch Publ Hlth, Dept Environm & Occupat Hlth, Atlanta, GA 30322 USA; [Mathews, Tiffany A.; Jones, Sara R.] Wake Forest Univ Hlth Sci, Dept Physiol & Pharmacol, Winston Salem, NC USA; [Mathews, Tiffany A.] Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; [Cory-Slechta, Deborah A.] Univ Rochester, Med Ctr, Dept Environm Med, Rochester, NY 14642 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Emory University; Emory University; Rollins School Public Health; Wake Forest University; Wake Forest University School of Medicine; Wayne State University; University of Rochester	Richardson, JR (corresponding author), Dept Environm & Occupat Med & Environm, 170 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	jricha3@eohsi.rutgers.edu	Richardson, Jason/AAG-5281-2019; Jones, Sara R/K-4816-2014	Richardson, Jason/0000-0001-6521-610X; Jones, Sara R/0000-0002-3424-7576; Miller, Gary/0000-0001-8984-1284	U.S. National Institutes of Health [R21ES013828, R01ES015991, R01ES015991-04S1, P30ES005022, T32ES012870, R01ES012702, R01DA021325, P50DA006634, T32ES007148, U54ES012068, R21ES012315]; U.S. Department of Defense [00267036]; Environmental Protection Agency STAR Fellowship;  [R01ES020415]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES012870, R01ES015991, T32ES007148, R21ES012315, P30ES005022, R21ES013828, U54ES012068, R01ES020415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007565, P01AA021099, P01AA017056, U01AA014091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA021325, P50DA006634] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Defense(United States Department of Defense); Environmental Protection Agency STAR Fellowship(United States Environmental Protection Agency); ; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Curtis Keller, Jason Mathew, Minzheng Wang, Chen Zhang, and Jessica Lam for excellent technical assistance, and also thank Dr. Eric Richfield for assistance with the autoradiography studies. This work was supported by U.S. National Institutes of Health Grants R21ES013828, R01ES015991,R01ES015991-04S1, and P30ES005022 (to J.R.R.), T32ES012870 (to W.M.C.), R01ES012702 (to D.C.S.), R01DA021325 and P50DA006634 (to S.R.J.), T32ES007148 (to M.M.T.), U54ES012068 and R21ES012315 (to G.W.M.); a U.S. Department of Defense Grant 00267036 (to G.W.M.); an Environmental Protection Agency STAR Fellowship (to T.S.G.); and R01ES020415 (to S.L.S.).	Adriani W, 2009, NEUROSCIENCE, V159, P47, DOI 10.1016/j.neuroscience.2008.11.042; Allen JL, 2013, ENVIRON HEALTH PERSP, V121, P32, DOI [10.1289/ehp.1205505, 10.1289/ehp.121-a32]; Andersen SL, 2000, NEUROSCI BIOBEHAV R, V24, P137, DOI 10.1016/S0149-7634(99)00044-5; Armstrong LE, 2013, J BIOCHEM MOL TOXIC, V27, P165, DOI 10.1002/jbt.21477; Arnsten AFT, 2006, J CLIN PSYCHIAT, V67, P7; Bakker SC, 2003, AM J HUM GENET, V72, P1251, DOI 10.1086/375143; Barr DB, 2010, ENVIRON HEALTH PERSP, V118, P742, DOI 10.1289/ehp.0901275; Berkowitz GS, 2003, ENVIRON HEALTH PERSP, V111, P79, DOI 10.1289/ehp.5619; Bloomquist JR, 2002, NEUROTOXICOLOGY, V23, P537, DOI 10.1016/S0161-813X(02)00031-1; Bobb AJ, 2005, AM J MED GENET B, V134B, P67, DOI 10.1002/ajmg.b.30142; Bouchard MF, 2010, PEDIATRICS, V125, pE1270, DOI 10.1542/peds.2009-3058; Braun JM, 2006, ENVIRON HEALTH PERSP, V114, P1904, DOI 10.1289/ehp.9478; Brockel BJ, 1998, PHARMACOL BIOCHEM BE, V60, P545, DOI 10.1016/S0091-3057(98)00023-9; Budygin EA, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0002.2002; Cardinal RN, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-37; Carey MP, 1998, BEHAV BRAIN RES, V94, P173, DOI 10.1016/S0166-4328(97)00178-2; Carpenter AC, 2012, DEV NEUROSCI-BASEL, V34, P250, DOI 10.1159/000336824; Castorina R, 2010, ENVIRON HEALTH PERSP, V118, P856, DOI 10.1289/ehp.0901568; Caudle WM, 2006, TOXICOL SCI, V92, P490, DOI 10.1093/toxsci/kfl018; Caudle WM, 2005, NEUROTOXICOLOGY, V26, P721, DOI 10.1016/j.neuro.2004.09.003; Centers for Disease Control and Prevention, 2004, NHANES AN GUID JUN 2; Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS), 2002, NAT HLTH NUTR EX SUR; Das Banerjee T, 2007, ACTA PAEDIATR, V96, P1269, DOI 10.1111/j.1651-2227.2007.00430.x; Davis LM, 2009, NEUROENDOCRINOLOGY, V89, P152, DOI 10.1159/000170586; del Campo N, 2011, BIOL PSYCHIAT, V69, pE145, DOI 10.1016/j.biopsych.2011.02.036; Donovan DM, 1999, MOL BRAIN RES, V73, P37, DOI 10.1016/S0169-328X(99)00235-1; Elwan MA, 2006, TOXICOL APPL PHARM, V211, P188, DOI 10.1016/j.taap.2005.06.003; Eubig PA, 2010, ENVIRON HEALTH PERSP, V118, P1654, DOI 10.1289/ehp.0901852; Faraone SV, 2010, PSYCHIAT CLIN N AM, V33, P159, DOI 10.1016/j.psc.2009.12.004; Fernagut PO, 2003, NEUROSCIENCE, V116, P1123, DOI 10.1016/S0306-4522(02)00778-9; Fischman AJ, 2005, BIOL PSYCHIAT, V57, P1374, DOI 10.1016/j.biopsych.2005.03.035; Fisher SE, 2002, AM J HUM GENET, V70, P1183, DOI 10.1086/340112; Froehlich TE, 2007, BIOL PSYCHIAT, V62, P243, DOI 10.1016/j.biopsych.2006.09.039; Froehlich TE, 2011, CURR PSYCHIAT REP, V13, P333, DOI 10.1007/s11920-011-0221-3; Froehlich TE, 2009, PEDIATRICS, V124, pE1054, DOI 10.1542/peds.2009-0738; Gainetdinov RR, 1997, J NEUROCHEM, V69, P1322; Gatley SJ, 1997, BIOCHEM PHARMACOL, V53, P43, DOI 10.1016/S0006-2952(96)00655-7; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gizer IR, 2009, HUM GENET, V126, P51, DOI 10.1007/s00439-009-0694-x; Guillot TS, 2008, NEUROPEPTIDES, V42, P423, DOI 10.1016/j.npep.2008.04.003; Guillot TS, 2008, J MOTOR BEHAV, V40, P568, DOI 10.3200/JMBR.40.6.568-577; Hebebrand J, 2006, MOL PSYCHIATR, V11, P196, DOI 10.1038/sj.mp.4001761; Heindel JJ, 2007, REPROD TOXICOL, V23, P257, DOI 10.1016/j.reprotox.2007.01.006; Johansen EB, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-7; KATZ RJ, 1980, PROG NEURO-PSYCHOPHA, V4, P585; KAVLOCK R, 1979, J ENVIRON PATHOL TOX, V2, P751; Krause Johanna, 2008, Expert Rev Neurother, V8, P611, DOI 10.1586/14737175.8.4.611; Madras BK, 2005, BIOL PSYCHIAT, V57, P1397, DOI 10.1016/j.biopsych.2004.10.011; Morgan MK, 2012, INT J ENV RES PUB HE, V9, P2964, DOI 10.3390/ijerph9082964; Oulhote Y, 2013, ENVIRON HEALTH PERSP, V121, P1378, DOI 10.1289/ehp.1306667; Quiros-Alcala L, 2014, ENVIRON HEALTH PERSP, V122, P1336, DOI 10.1289/ehp.1308031; Richardson JR, 2006, FASEB J, V20, P1695, DOI 10.1096/fj.06-5864fje; Roessner V, 2010, NEUROSCIENCE, V167, P1183, DOI 10.1016/j.neuroscience.2010.02.073; Sagvolden T, 2000, NEUROSCI BIOBEHAV R, V24, P31, DOI 10.1016/S0149-7634(99)00058-5; Sagvolden T, 2005, BEHAV BRAIN SCI, V28, P397, DOI 10.1017/S0140525X05000075; Salahpour A, 2008, P NATL ACAD SCI USA, V105, P4405, DOI 10.1073/pnas.0707646105; SARTER M, 1988, PSYCHOPHARMACOLOGY, V94, P491, DOI 10.1007/BF00212843; Schuh RA, 2009, NEUROTOXICOLOGY, V30, P274, DOI 10.1016/j.neuro.2008.12.015; Shafer TJ, 2005, ENVIRON HEALTH PERSP, V113, P123, DOI 10.1289/ehp.7254; Shastry BS, 2004, NEUROCHEM INT, V44, P469, DOI 10.1016/j.neuint.2003.08.011; Spencer TJ, 2005, BIOL PSYCHIAT, V57, P1293, DOI 10.1016/j.biopsych.2005.03.036; Swanson JM, 2007, NEUROPSYCHOL REV, V17, P39, DOI 10.1007/s11065-007-9019-9; U.S. National Research Council Board Agric, 1993, PEST DIETS INF CHILD; Vijayraghavan S, 2007, NAT NEUROSCI, V10, P376, DOI 10.1038/nn1846; Volkow ND, 2007, NEUROIMAGE, V34, P1182, DOI 10.1016/j.neuroimage.2006.10.014; Williams MK, 2006, ENVIRON HEALTH PERSP, V114, P1684, DOI 10.1289/ehp.9168	66	72	72	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1960	1972		10.1096/fj.14-260901	http://dx.doi.org/10.1096/fj.14-260901			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25630971	Green Published			2022-12-28	WOS:000354114600030
J	Stoler-Barak, L; Petrovich, E; Aychek, T; Gurevich, I; Tal, O; Hatzav, M; Ilan, N; Feigelson, SW; Shakhar, G; Vlodavsky, I; Alon, R				Stoler-Barak, Liat; Petrovich, Ekaterina; Aychek, Tegest; Gurevich, Irina; Tal, Orna; Hatzav, Miki; Ilan, Neta; Feigelson, Sara W.; Shakhar, Guy; Vlodavsky, Israel; Alon, Ronen			Heparanase of murine effector lymphocytes and neutrophils is not required for their diapedesis into sites of inflammation	FASEB JOURNAL			English	Article						extracellular matrix; extravasation; heparan sulfate; leukocytes; postcapillary venules	SUBENDOTHELIAL EXTRACELLULAR-MATRIX; REACTIVE LYMPH-NODES; SULFATE PROTEOGLYCANS; MAMMALIAN HEPARANASE; DENDRITIC CELLS; T-CELLS; REGULATES DEGRADATION; ENZYME HEPARANASE; CANCER METASTASIS; BASEMENT-MEMBRANE	Heparanase, the exclusive mammalian heparan sulfate-degrading enzyme, has been suggested to be utilized by leukocytes to penetrate through the dense basement membranes surrounding blood venules. Despite its established role in tumor cell invasion, heparanase function in leukocyte extravasation has never been demonstrated. We found that T(H)1/T(C)1-type effector T cells are highly enriched for this enzyme, with a 3.6-fold higher heparanase mRNA expression compared with naive lymphocytes. Using adoptive transfer of wild-type and heparanase-deficient effector T cells into inflamed mice, we show that T-cell heparanase was not required for extravasation inside inflamed lymph nodes or skin. Leukocyte extravasation through acute inflamed skin vessels was also heparanase independent. Furthermore, neutrophils emigrated to the inflamed peritoneal cavity independently of heparanase expression on either the leukocytes or on the endothelial and mesothelial barriers, and overexpression of the enzyme on neutrophils did not facilitate their emigration. However, heparanase absence significantly reduced monocyte emigration into the inflamed peritoneal cavity. These results collectively suggest that neither leukocyte nor endothelial heparanase is required for T-cell and neutrophil extravasation through inflamed vascular barriers, whereas this enzyme is required for optimal monocyte recruitment to inflamed peritoneum.	[Stoler-Barak, Liat; Petrovich, Ekaterina; Aychek, Tegest; Gurevich, Irina; Tal, Orna; Hatzav, Miki; Feigelson, Sara W.; Shakhar, Guy; Alon, Ronen] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; [Ilan, Neta; Vlodavsky, Israel] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, Haifa, Israel	Weizmann Institute of Science; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Alon, R (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	ronen.alon@weizmann.ac.il	ALON, RONEN/GRX-6987-2022	Kopitman, Ekaterina/0000-0002-6050-6404; Alon, Ronen/0000-0001-9161-6369	German-Israeli Foundation; Israel Science Foundation; Flight Attendant Medical Research Institute Foundation; Minerva Foundation, Germany	German-Israeli Foundation(German-Israeli Foundation for Scientific Research and Development); Israel Science Foundation(Israel Science Foundation); Flight Attendant Medical Research Institute Foundation; Minerva Foundation, Germany	The authors thank Dr. Jin-Ping Li (Department of Medical Biochemistry and Microbiology, University of Uppsala, Uppsala, Sweden) for generating the heparanase-knockout mice. The authors also thank Yochai Wolf for intellectual assistance. R.A. is an incumbent of the Linda Jacobs Chair in Immune and Stem Cell Research, and his research is supported by the German-Israeli Foundation, the Israel Science Foundation, the U.S.-Israel Binational Science Foundation, the Flight Attendant Medical Research Institute Foundation, and the Minerva Foundation, Germany. The authors declare no conflicts of interest.	Abboud-Jarrous G, 2008, J BIOL CHEM, V283, P18167, DOI 10.1074/jbc.M801327200; Arvatz G, 2011, CANCER METAST REV, V30, P253, DOI 10.1007/s10555-011-9288-x; BARTLETT MR, 1995, IMMUNOL CELL BIOL, V73, P113, DOI 10.1038/icb.1995.19; Benhamron S, 2006, J IMMUNOL, V176, P6417, DOI 10.4049/jimmunol.176.11.6417; Benhamron S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035602; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817; Boscacci RT, 2010, BLOOD, V116, P915, DOI 10.1182/blood-2009-11-254334; Cash JL, 2009, METHOD ENZYMOL, V461, P379, DOI 10.1016/S0076-6879(09)05417-2; Cohen SJ, 2013, BLOOD, V122, P2609, DOI 10.1182/blood-2013-04-495036; Cunha TM, 2006, J LEUKOCYTE BIOL, V80, P727, DOI 10.1189/jlb.0406244; Davis DAS, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00470; de Mestre AM, 2007, J LEUKOCYTE BIOL, V82, P1289, DOI 10.1189/jlb.0507315; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; FRIDMAN R, 1987, J CELL PHYSIOL, V130, P85, DOI 10.1002/jcp.1041300113; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goode KJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109596; Guarda G, 2007, NAT IMMUNOL, V8, P743, DOI 10.1038/ni1469; He YQ, 2012, TRANSCR-AUSTIN, V3, P130, DOI 10.4161/trns.19998; Hermano E, 2012, CELL MOL LIFE SCI, V69, P2501, DOI 10.1007/s00018-012-0930-8; Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004; Kim SH, 2011, J ENDOCRINOL, V209, P139, DOI 10.1530/JOE-10-0377; Lerner I, 2011, J CLIN INVEST, V121, P1709, DOI 10.1172/JCI43792; LIDER O, 1990, EUR J IMMUNOL, V20, P493, DOI 10.1002/eji.1830200306; LIDER O, 1995, P NATL ACAD SCI USA, V92, P5037, DOI 10.1073/pnas.92.11.5037; Lu CL, 2010, BLOOD, V115, P221, DOI 10.1182/blood-2009-06-228494; Maletto BA, 2006, BLOOD, V108, P3094, DOI 10.1182/blood-2006-04-016659; Martin-Fontecha A, 2008, J EXP MED, V205, P2561, DOI 10.1084/jem.20081212; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; MULLIGAN MS, 1992, J IMMUNOL, V148, P1847; Nadir Y, 2014, THROMB RES, V133, pS90, DOI 10.1016/S0049-3848(14)50015-1; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; Nourshargh S, 2010, NAT REV MOL CELL BIO, V11, P366, DOI 10.1038/nrm2889; Parish CR, 2006, NAT REV IMMUNOL, V6, P633, DOI 10.1038/nri1918; Parish CR, 1998, IMMUNOL CELL BIOL, V76, P104, DOI 10.1046/j.1440-1711.1998.00722.x; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Poon IKH, 2014, EUR J IMMUNOL, V44, P1016, DOI 10.1002/eji.201343645; Proebstl D, 2012, J EXP MED, V209, P1219, DOI 10.1084/jem.20111622; Sanderson RD, 2005, J CELL BIOCHEM, V96, P897, DOI 10.1002/jcb.20602; Sasaki N, 2004, J IMMUNOL, V172, P3830, DOI 10.4049/jimmunol.172.6.3830; SEWELL RF, 1989, BIOCHEM J, V264, P777, DOI 10.1042/bj2640777; Shakhar G, 2005, NAT IMMUNOL, V6, P707, DOI 10.1038/ni1210; Shulman Z, 2012, NAT IMMUNOL, V13, P67, DOI 10.1038/ni.2173; Sotnikov I, 2004, J IMMUNOL, V172, P5185, DOI 10.4049/jimmunol.172.9.5185; Spiegel A, 2008, BLOOD, V111, P4934, DOI 10.1182/blood-2007-10-116145; Stoler-Barak L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085699; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 2002, SEMIN CANCER BIOL, V12, P121, DOI 10.1006/scbi.2001.0420; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vlodavsky I, 2013, MATRIX BIOL, V32, P220, DOI 10.1016/j.matbio.2013.03.001; Zcharia E, 2005, FASEB J, V19, P211, DOI 10.1096/fj.04-1970com; Zcharia E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005181; Zhang JH, 2005, CELL MOL IMMUNOL, V2, P271	56	22	23	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2010	2021		10.1096/fj.14-265447	http://dx.doi.org/10.1096/fj.14-265447			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25634957				2022-12-28	WOS:000354114600034
J	Dillenburg-Pilla, P; Patel, V; Mikelis, CM; Zarate-Blades, CR; Doci, CL; Amornphimoltham, P; Wang, ZY; Martin, D; Leelahavanichkul, K; Dorsam, RT; Masedunskas, A; Weigert, R; Molinolo, AA; Gutkind, JS				Dillenburg-Pilla, Patricia; Patel, Vyomesh; Mikelis, Constantinos M.; Zarate-Blades, Carlos Rodrigo; Doci, Colleen L.; Amornphimoltham, Panomwat; Wang, Zhiyong; Martin, Daniel; Leelahavanichkul, Kantima; Dorsam, Robert T.; Masedunskas, Andrius; Weigert, Roberto; Molinolo, Alfredo A.; Gutkind, J. Silvio			SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/G alpha i/mTORC1 axis	FASEB JOURNAL			English	Article						mTOR; rapamycin; cancer; lymphangiogenesis; chemotaxis	MAMMALIAN TARGET; BREAST-CANCER; RAPID MOBILIZATION; CHEMOKINE RECEPTORS; HEMATOPOIETIC STEM; KINASE INHIBITOR; CXCR4 ANTAGONIST; PROGENITOR CELLS; KAPOSIS-SARCOMA; MTOR INHIBITION	Multiple human malignancies rely on C-X-C motif chemokine receptor type 4 (CXCR4) and its ligand, SDF-1/CXCL12 (stroma cell-derived factor 1/C-X-C motif chemokine 12), to metastasize. CXCR4 inhibitors promote the mobilization of bone marrow stem cells, limiting their clinical application for metastasis prevention. We investigated the CXCR4-initiated signaling circuitry to identify new potential therapeutic targets. We used HeLa human cancer cells expressing high levels of CXCR4 endogenously. We found that CXCL12 promotes their migration in Boyden chamber assays and single cell tracking. CXCL12 activated mTOR (mechanistic target of rapamycin) potently in a pertussis-sensitive fashion. Inhibition of mTOR complex 1 (mTORC1) by rapamycin [drug concentration causing 50% inhibition (IC50) = 5 nM] and mTORC1/mTORC2 by Torin2 (IC50 = 6 nM), or by knocking downkey mTORC1/2 components, Raptor and Rictor, respectively, decreased directional cell migration toward CXCL12. We developed a CXCR4-mediated spontaneous metastasis model by implanting HeLa cells in the tongue of SCID-NOD mice, in which 80% of the animals develop lymph node metastasis. It is surprising that mTORC1 disruption by Raptor knockdown was sufficient to reduce tumor growth by 60% and spontaneous metastasis by 72%, which were nearly abolished by rapamycin. In contrast, disrupting mTORC2 had no effect in tumor growth or metastasis compared with control short hairpin RNAs. These data suggest that mTORC1 may represent a suitable therapeutic target in human malignancies using CXCR4 for their metastatic spread.	[Dillenburg-Pilla, Patricia; Patel, Vyomesh; Mikelis, Constantinos M.; Doci, Colleen L.; Amornphimoltham, Panomwat; Wang, Zhiyong; Martin, Daniel; Leelahavanichkul, Kantima; Dorsam, Robert T.; Masedunskas, Andrius; Weigert, Roberto; Molinolo, Alfredo A.; Gutkind, J. Silvio] Natl Inst Dent & Craniofacial Research, Oral & Pharyngeal Canc Branch, Bethesda, MD 20892 USA; [Zarate-Blades, Carlos Rodrigo] US Natl Inst Hlth, Immunol Lab, NEI, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Research, NIH, 30 Convent Dr,Bldg 30,Room 320, Bethesda, MD 20892 USA.	sg39v@nih.gov	Mikelis, Constantinos/AGF-9423-2022; Gutkind, J. Silvio/J-1201-2016; Zárate-Bladés, Carlos R/C-9663-2015; Doci, Colleen L/M-4389-2015; Amornphimoltham, Walt/AAP-9654-2020	Gutkind, J. Silvio/0000-0002-5150-4482; Zárate-Bladés, Carlos R/0000-0002-7728-7869; Martin Izquierdo, Daniel/0000-0002-8880-9087	Intramural Research Program of U.S. National Institutes of Health, National Institute of Dental and Craniofacial Research; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000717, ZIADE000551] Funding Source: NIH RePORTER	Intramural Research Program of U.S. National Institutes of Health, National Institute of Dental and Craniofacial Research; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This research was supported by the Intramural Research Program of U.S. National Institutes of Health, National Institute of Dental and Craniofacial Research. The authors apologize to all of their colleagues for not citing some of their original studies as a result of space limitations.	Amornphimoltham P, 2013, CLIN CANCER RES, V19, P1375, DOI 10.1158/1078-0432.CCR-12-2858; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Chen G, 2012, J BIOL CHEM, V287, P12132, DOI 10.1074/jbc.M111.302299; Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614; Dancey J, 2010, NAT REV CLIN ONCOL, V7, P209, DOI 10.1038/nrclinonc.2010.21; Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; Devine SM, 2004, J CLIN ONCOL, V22, P1095, DOI 10.1200/JCO.2004.07.131; Devine SM, 2008, BLOOD, V112, P990, DOI 10.1182/blood-2007-12-130179; Duenne AA, 2000, RECENT RES CANCER, V157, P82; Dutt P, 1998, J IMMUNOL, V161, P3652; Eckhardt BL, 2012, NAT REV DRUG DISCOV, V11, P479, DOI 10.1038/nrd2372; Gan XQ, 2012, NAT CELL BIOL, V14, P686, DOI 10.1038/ncb2507; Garcia-Garcia C, 2012, CLIN CANCER RES, V18, P2603, DOI 10.1158/1078-0432.CCR-11-2750; Hernandez-Negrete I, 2007, J BIOL CHEM, V282, P23708, DOI 10.1074/jbc.M703771200; Iglesias-Bartolome R, 2012, CELL STEM CELL, V11, P401, DOI 10.1016/j.stem.2012.06.007; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Janes MR, 2013, LEUKEMIA, V27, P586, DOI 10.1038/leu.2012.276; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim EK, 2011, ONCOGENE, V30, P2954, DOI 10.1038/onc.2011.22; Kumar V, 2014, ROBBINS COTRAN PATHO; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Liu L, 2010, J BIOL CHEM, V285, P38362, DOI 10.1074/jbc.M110.141168; Liu LH, 2010, DEV CELL, V19, P845, DOI 10.1016/j.devcel.2010.11.004; Liu QS, 2011, J MED CHEM, V54, P1473, DOI 10.1021/jm101520v; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Mo W, 2013, CELL, V152, P1077, DOI 10.1016/j.cell.2013.01.053; Molinolo AA, 2012, CLIN CANCER RES, V18, P2558, DOI 10.1158/1078-0432.CCR-11-2824; Moser B, 2004, TRENDS IMMUNOL, V25, P75, DOI 10.1016/j.it.2003.12.005; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Patel V, 2011, CANCER RES, V71, P7103, DOI 10.1158/0008-5472.CAN-10-3192; Plas DR, 2009, CURR OPIN CELL BIOL, V21, P230, DOI 10.1016/j.ceb.2008.12.013; Posch C, 2013, P NATL ACAD SCI USA, V110, P4015, DOI 10.1073/pnas.1216013110; Pusic I, 2010, CURR OPIN HEMATOL, V17, P319, DOI 10.1097/MOH.0b013e328338b7d5; Rosenbluth JM, 2011, P NATL ACAD SCI USA, V108, P2076, DOI 10.1073/pnas.1011936108; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schrader AJ, 2002, BRIT J CANCER, V86, P1250, DOI 10.1038/sj.bjc.6600221; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Sotsios Y, 1999, J IMMUNOL, V163, P5954; Stallone G, 2005, NEW ENGL J MED, V352, P1317, DOI 10.1056/NEJMoa042831; Stallone G, 2008, TRANSPL INT, V21, P825, DOI 10.1111/j.1432-2277.2008.00697.x; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yanagiya A, 2012, MOL CELL, V46, P847, DOI 10.1016/j.molcel.2012.04.004; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200; Zlotnik A, 2012, IMMUNITY, V36, P705, DOI 10.1016/j.immuni.2012.05.008; Zlotnik A, 2011, NAT REV IMMUNOL, V11, P597, DOI 10.1038/nri3049; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	54	49	51	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1056	1068		10.1096/fj.14-260083	http://dx.doi.org/10.1096/fj.14-260083			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25466898	Green Published			2022-12-28	WOS:000350633000029
J	Khanna, S; Heigel, M; Weist, J; Gnyawali, S; Teplitsky, S; Roy, S; Sen, CK; Rink, C				Khanna, Savita; Heigel, Mallory; Weist, Jessica; Gnyawali, Surya; Teplitsky, Seth; Roy, Sashwati; Sen, Chandan K.; Rink, Cameron			Excessive alpha-tocopherol exacerbates microglial activation and brain injury caused by acute ischemic stroke	FASEB JOURNAL			English	Article						inflammation; microglia; antioxidant; vitamin	CEREBRAL-ARTERY OCCLUSION; VITAMIN-E SUPPLEMENTATION; NADPH OXIDASE; TOCOTRIENOL; EXPRESSION; INCREASES; PROGRESSION; RELEASE; MODEL; DEATH	The vitamin E family includes both tocopherols and tocotrienols, where alpha-tocopherol (alpha TOC) is the most bioavailable form. Clinical trials testing the therapeutic efficacy of high-dose alpha TOC against stroke have largely failed or reported negative outcomes when a "more is better" approach to supplementation (>400 IU/d) was used. This work addresses mechanisms by which supraphysiologic alpha TOC may contribute to stroke-induced brain injury. Ischemic stroke injury and the neuroinflammatory response were studied in tocopherol transfer protein-deficient mice maintained on a diet containing alpha TOC vitamin E at the equivalent human dose of 1680 IU/d. Ischemic stroke-induced brain injury was exacerbated in the presence of supraphysiologic brain alpha TOC levels. At 48 h after stroke, S100B and RAGE expression was increased in stroke-affected cortex of mice with elevated brain alpha TOC levels. Such increases were concomitant with aggravated microglial activation and neuroinflammatory signaling. A poststroke increase in markers of oxidative injury and neurodegeneration in the presence of elevated brain alpha TOC establish that at supraphysiologic levels, alpha TOC potentiates neuroinflammatory responses to acute ischemic stroke. Exacerbation of microglial activation by excessive alpha TOC likely depends on its unique cell signaling regulatory properties independent of antioxidant function. Against the background of clinical failure for high-dose alpha TOC, outcomes of this work identify risk for exacerbating stroke-induced brain injury as a result of supplementing diet with excessive levels of alpha TOC.	[Khanna, Savita; Heigel, Mallory; Weist, Jessica; Gnyawali, Surya; Teplitsky, Seth; Roy, Sashwati; Sen, Chandan K.; Rink, Cameron] Ohio State Univ, Dept Surg, Wexner Med Ctr, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Rink, C (corresponding author), 473 W 12th Ave, Columbus, OH 43210 USA.	cameron.rink@osumc.edu	Gnyawali, Surya/HGB-8982-2022; Gnyawali, Surya/AAC-3082-2020; Rink, Cameron/AAA-4484-2021; Roy, sashwati/E-3990-2011; Gnyawali, Surya/AAC-3082-2020	Gnyawali, Surya/0000-0001-8980-4889; Gnyawali, Surya/0000-0002-4214-8068; Teplitsky, Seth/0000-0001-9242-1360; Rink, Cameron/0000-0002-3149-3624	U.S. National Institutes of Health (NIH) [NS42617]; NIH [NS085272, 12SDG11780023]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS085272, R01NS042617] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the U.S. National Institutes of Health (NIH) Grant NS42617 (to C.K.S.), and in part by NIH Grants NS085272 (to C.R. and S.K.) and 12SDG11780023 (to C.R.).	Abdala-Valencia H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041054; Bachmanov AA, 2002, BEHAV GENET, V32, P435, DOI 10.1023/A:1020884312053; Bailey RL, 2011, J NUTR, V141, P261, DOI 10.3945/jn.110.133025; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Cuddihy SL, 2008, J BIOL CHEM, V283, P6915, DOI 10.1074/jbc.M702572200; Davies CA, 1999, J CEREBR BLOOD F MET, V19, P87, DOI 10.1097/00004647-199901000-00010; Ford ES, 2005, ANN INTERN MED, V143, P116, DOI 10.7326/0003-4819-143-2-200507190-00010; Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds, 2000, DIET REF INT VIT C V; Ke ZJ, 2004, NEUROCHEM INT, V45, P361, DOI 10.1016/j.neuint.2003.09.008; Khanna S, 2005, FREE RADICAL BIO MED, V39, P1310, DOI 10.1016/j.freeradbiomed.2005.06.013; Khanna S, 2005, STROKE, V36, pE144, DOI 10.1161/01.STR.0000181082.70763.22; Khanna S, 2013, J CEREBR BLOOD F MET, V33, P1197, DOI 10.1038/jcbfm.2013.68; Lefkowitz DL, 2008, FREE RADICAL BIO MED, V45, P726, DOI 10.1016/j.freeradbiomed.2008.05.021; Leppala JM, 2000, ARTERIOSCL THROM VAS, V20, P230, DOI 10.1161/01.ATV.20.1.230; Leppala JM, 2000, ARCH NEUROL-CHICAGO, V57, P1503, DOI 10.1001/archneur.57.10.1503; Lim Y, 2008, FREE RADICAL RES, V42, P387, DOI 10.1080/10715760801976600; Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Marchioli R, 2006, J CARDIOVASC MED, V7, P347, DOI 10.2459/01.JCM.0000223257.09062.17; McCary CA, 2012, BIOCHEM J, V441, P189, DOI 10.1042/BJ20111318; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; Miyamoto K, 2009, J NEUROSCI RES, V87, P556, DOI 10.1002/jnr.21851; Osakada F, 2004, NEUROPHARMACOLOGY, V47, P904, DOI 10.1016/j.neuropharm.2004.06.029; PACKER L, 1991, AM J CLIN NUTR, V53, pS1050, DOI 10.1093/ajcn/53.4.1050S; Patel V, 2012, J NUTR, V142, P513, DOI 10.3945/jn.111.151902; Polikandriotis JA, 2006, AM J RESP CELL MOL, V34, P314, DOI 10.1165/rcmb.2005-0320OC; Rink C, 2008, P NATL ACAD SCI USA, V105, P14100, DOI 10.1073/pnas.0806678105; Rink C, 2011, ANTIOXID REDOX SIGN, V14, P1777, DOI 10.1089/ars.2011.3930; Rink C, 2011, ANTIOXID REDOX SIGN, V14, P1889, DOI 10.1089/ars.2010.3474; Rink C, 2010, J CEREBR BLOOD F MET, V30, P1275, DOI 10.1038/jcbfm.2010.7; Sen CK, 2006, LIFE SCI, V78, P2088, DOI 10.1016/j.lfs.2005.12.001; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Stock C, 2006, J IMMUNOL, V177, P8560, DOI 10.4049/jimmunol.177.12.8560; TRABER MG, 1995, AM J CLIN NUTR, V62, P1501; TRAN K, 1990, BIOCHIM BIOPHYS ACTA, V1043, P189, DOI 10.1016/0005-2760(90)90295-9; van der Worp HB, 1998, STROKE, V29, P1002, DOI 10.1161/01.STR.29.5.1002; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; Wang HYJ, 2010, RAPID COMMUN MASS SP, V24, P2057, DOI 10.1002/rcm.4620; Wong M, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-110; Yoshioka H, 2011, J CEREBR BLOOD F MET, V31, P868, DOI 10.1038/jcbfm.2010.166	42	13	14	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					828	836		10.1096/fj.14-263723	http://dx.doi.org/10.1096/fj.14-263723			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25411436	Green Published			2022-12-28	WOS:000350633000010
J	Venkatraman, G; Benesch, MGK; Tang, XY; Dewald, J; McMullen, TPW; Brindley, DN				Venkatraman, Ganesh; Benesch, Matthew G. K.; Tang, Xiaoyun; Dewald, Jay; McMullen, Todd P. W.; Brindley, David N.			Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment	FASEB JOURNAL			English	Article						autotaxin; autotaxin inhibitors; breast cancer; chemoresistance; doxorubicin	TRANSCRIPTION FACTOR NRF2; PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; HUMAN NEUROBLASTOMA-CELLS; BREAST-CANCER; ANTIOXIDANT RESPONSE; MULTIDRUG-RESISTANCE; ACID RECEPTOR; HEPATOCELLULAR CANCER; HEME OXYGENASE-1; AUTOTAXIN ENPP2	The present work elucidates novel mechanisms for lysophosphatidate (LPA)-induced chemoresistance using human breast, lung, liver, and thyroid cancer cells. LPA (0.5-10 mu M) increased Nrf2 transcription factor stability and nuclear localization by <= 5-fold. This involved lysophosphatidate type 1 (LPA(1)) receptors as identified with 1 mu M wls-31 (LPA(1/2) receptor agonist) and blocking this effect with 20 mu M Ki16425 (LPA(1-3) antagonist, K-i = 0.34 mu M). Knockdown of LPA(1) by 50% to 60% with siRNA decreased Nrf2 stability and expressing LPA1, but not LPA(2/3), in human HepG2 cells increased Nrf2 stabilization. LPA-induced Nrf2 expression increased transcription of multidrug-resistant transporters and antioxidant genes by 2- to 4-fold through the antioxidant response element. This protected cells from doxorubicin-induced death. This pathway was verified in vivo by orthotopic injection of 20,000 mouse 4T1 breast cancer cells into syngeneic mice. Blocking LPA production with 10 mg/kg per d ONO-8430506 (competitive autotaxin inhibitor, IC90 = 100 nM) decreased expression of Nrf2, multidrug-resistant transporters, and antioxidant genes in breast tumors by <= 90%. Combining 4 mg/kg doxorubicin every third day with ONO-8430506 synergistically decreased tumor growth and metastasis to lungs and liver by >70%, whereas doxorubicin alone had no significant effect. This study provides the first evidence that LPA increases antioxidant gene and multidrug-resistant transporter expression. Blocking this aspect of LPA signaling provides a novel strategy for improving chemotherapy.	[Venkatraman, Ganesh; Benesch, Matthew G. K.; Tang, Xiaoyun; Dewald, Jay; Brindley, David N.] Univ Alberta, Dept Biochem, Signal Transduct Res Grp, Edmonton, AB T6G 2S2, Canada; [McMullen, Todd P. W.] Univ Alberta, Dept Surg, WC Mackenzie Hlth Sci Ctr, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Brindley, DN (corresponding author), Univ Alberta, Dept Biochem, 357 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	david.brindley@ualberta.ca	Benesch, Matthew/GRF-0677-2022	Benesch, Matthew/0000-0002-1326-684X	Canadian Breast Cancer Foundation (CBCF); Canadian Institutes of Health Research (CIHR); Alberta Cancer Foundation; Alberta Innovates-Health Solutions (AIHS); Vanier Canada Graduate Scholarship from the government of Canada; Killam Trust award; CIHR; AIHS; CBCF; Women and Children's Health Research Institute of the University of Alberta; Ono Pharmaceuticals	Canadian Breast Cancer Foundation (CBCF); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Cancer Foundation; Alberta Innovates-Health Solutions (AIHS); Vanier Canada Graduate Scholarship from the government of Canada; Killam Trust award; CIHR(Canadian Institutes of Health Research (CIHR)); AIHS; CBCF; Women and Children's Health Research Institute of the University of Alberta(University of Alberta); Ono Pharmaceuticals	The authors thank W. Santos for the gift of wls-31, and R. Wolf and Cancer Research UK for supplying AREc32 cells. The work was supported by grants to D.N.B. from the Canadian Breast Cancer Foundation (CBCF), Canadian Institutes of Health Research (CIHR), with the Alberta Cancer Foundation. G.V. received a graduate studentship from Alberta Innovates-Health Solutions (AIHS). M.G.K.B. received a Vanier Canada Graduate Scholarship from the government of Canada, a Killam Trust award, and MD/PhD studentships from CIHR and AIHS. X.T. held a research fellowship from CBCF and received a salary from the Women and Children's Health Research Institute of the University of Alberta. We thank the core microscopy, flow cytometry, and histology facilities at the University of Alberta for help with analyses. The authors declare the following conflicts of interest: D.N.B. and T.P.W.M. received consulting fees from Ono Pharmaceuticals. The remaining authors declare no conflicts of interest.	An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Apopa PL, 2008, J BIOCHEM MOL TOXIC, V22, P63, DOI 10.1002/jbt.20212; Benesch MGK, 2014, FEBS LETT, V588, P2712, DOI 10.1016/j.febslet.2014.02.009; Benesch MGK, 2014, FASEB J, V28, P2655, DOI 10.1096/fj.13-248641; Bhave SR, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00236; Bidard FC, 2008, CLIN CANCER RES, V14, P3306, DOI 10.1158/1078-0432.CCR-07-4749; Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123; Boucharaba A, 2006, P NATL ACAD SCI USA, V103, P9643, DOI 10.1073/pnas.0600979103; Braun S, 2000, J CLIN ONCOL, V18, P80, DOI 10.1200/JCO.2000.18.1.80; Brindley DN, 2013, BBA-MOL CELL BIOL L, V1831, P74, DOI 10.1016/j.bbalip.2012.08.015; Chen M, 2007, AM J PHYSIOL-CELL PH, V292, pC1927, DOI 10.1152/ajpcell.00400.2006; Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cooper AB, 2007, J GASTROINTEST SURG, V11, P1628, DOI 10.1007/s11605-007-0322-9; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Euer N, 2002, ANTICANCER RES, V22, P733; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gaetano CG, 2009, MOL CARCINOGEN, V48, P801, DOI 10.1002/mc.20524; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Harrison EM, 2006, FEBS J, V273, P2345, DOI 10.1111/j.1742-4658.2006.05224.x; Hayashi A, 2003, BIOCHEM BIOPH RES CO, V310, P824, DOI 10.1016/j.bbrc.2003.09.086; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Hozumi H, 2013, LAB INVEST, V93, P508, DOI 10.1038/labinvest.2013.45; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113; Ji LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063404; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kehlen A, 2001, CLIN EXP IMMUNOL, V123, P147, DOI 10.1046/j.1365-2249.2001.01432.x; Krech T, 2012, CANCER LETT, V315, P153, DOI 10.1016/j.canlet.2011.09.038; Kwo P, 2007, J GASTROINTEST SURG, V11, P1634; Lage H, 2008, CELL MOL LIFE SCI, V65, P3145, DOI 10.1007/s00018-008-8111-5; Lau A, 2013, ANTIOXID REDOX SIGN, V18, P91, DOI 10.1089/ars.2012.4754; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Lin SB, 2009, GASTROENTEROLOGY, V136, P1711, DOI 10.1053/j.gastro.2009.01.002; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Lohoff M, 1998, J CLIN INVEST, V101, P703, DOI 10.1172/JCI824; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Nakaso K, 2003, FEBS LETT, V546, P181, DOI 10.1016/S0014-5793(03)00517-9; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nikitopoulou I, 2012, J EXP MED, V209, P923, DOI 10.1084/jem.20112012; Pilquil C, 2006, J BIOL CHEM, V281, P38418, DOI 10.1074/jbc.M601670200; Popnikolov NK, 2012, TUMOR BIOL, V33, P2237, DOI 10.1007/s13277-012-0485-1; Rada P, 2011, MOL CELL BIOL, V31, P1121, DOI 10.1128/MCB.01204-10; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Rojo AI, 2008, J NEUROCHEM, V105, P192, DOI 10.1111/j.1471-4159.2007.05124.x; Saga H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093230; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Samadi N, 2009, ONCOGENE, V28, P1028, DOI 10.1038/onc.2008.442; Samadi N, 2011, BIOCHIMIE, V93, P61, DOI 10.1016/j.biochi.2010.08.002; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shen GX, 2009, BIOPHARM DRUG DISPOS, V30, P345, DOI 10.1002/bdd.680; Shida D, 2003, CANCER RES, V63, P1706; Shim GS, 2009, FREE RADICAL BIO MED, V47, P1619, DOI 10.1016/j.freeradbiomed.2009.09.006; Singh A, 2013, J CLIN INVEST, V123, P2921, DOI 10.1172/JCI66353; Singh A, 2010, MOL CANCER THER, V9, P2365, DOI 10.1158/1535-7163.MCT-10-0108; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Su SC, 2013, CLIN CANCER RES, V19, P6461, DOI 10.1158/1078-0432.CCR-13-1284; Sun Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006588; Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685; Trinkle-Mulcahy L, 2008, J CELL BIOL, V183, P223, DOI 10.1083/jcb.200805092; Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095; Wang XJ, 2006, CANCER RES, V66, P10983, DOI 10.1158/0008-5472.CAN-06-2298; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang HL, 2009, CANCER RES, V69, P5441, DOI 10.1158/0008-5472.CAN-09-0302	75	62	65	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					772	785		10.1096/fj.14-262659	http://dx.doi.org/10.1096/fj.14-262659			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25398768				2022-12-28	WOS:000350633000005
J	Zhang, BH; Denomme, MM; White, CR; Leung, KY; Lee, MB; Greene, NDE; Mann, MRW; Trasler, JM; Baltz, JM				Zhang, Baohua; Denomme, Michelle M.; White, Carlee R.; Leung, Kit-Yi; Lee, Martin B.; Greene, Nicholas D. E.; Mann, Mellissa R. W.; Trasler, Jacquetta M.; Baltz, Jay M.			Both the folate cycle and betaine-homocysteine methyltransferase contribute methyl groups for DNA methylation in mouse blastocysts	FASEB JOURNAL			English	Article						embryo; epigenetics; inner cell mass; methionine; S-adenosylmethionine	ONE-CARBON METABOLISM; PREIMPLANTATION EMBRYO DEVELOPMENT; METHYLENETETRAHYDROFOLATE REDUCTASE; S-ADENOSYLMETHIONINE; METHOTREXATE; MAINTENANCE; TRANSPORT; CULTURE; MICE; EXPRESSION	The embryonic pattern of global DNA methylation is first established in the inner cellmass (ICM) of the mouse blastocyst. The methyl donor S-adenosylmethionine (SAM) is produced inmost cells through the folate cycle, but only a few cell types generate SAM from betaine (N,N,N-trimethylglycine) via betaine-homocysteine methyltransferase (BHMT), which is expressed in the mouse ICM. Here, mean ICM cell numbers decreased from 18-19 in controls to 11-13 when the folate cycle was inhibited by the antifolate methotrexate and to 12-14 when BHMT expression was knocked down by antisense morpholinos. Inhibiting both pathways, however, much more severely affected ICM development (7-8 cells). Total SAMlevels in mouse blastocysts decreased significantly only when both pathways were inhibited (from 3.1 to 1.6 pmol/100 blastocysts). DNA methylation, detected as 5-methylcytosine (5-MeC) immunofluorescence in isolated ICMs, was minimally affected by inhibition of either pathway alone but decreased by at least 45-55% when both BHMT and the folate cycle were inhibited simultaneously. Effects on cell numbers and 5-MeC levels in the ICM were completely rescued by methionine (immediate SAM precursor) or SAM. Both the folate cycle and betaine/BHMT appear to contribute to a methyl pool required for normal ICM development and establishing initial embryonic DNA methylation.	[Zhang, Baohua; Lee, Martin B.; Baltz, Jay M.] Ottawa Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada; [Zhang, Baohua; Lee, Martin B.; Baltz, Jay M.] Univ Ottawa, Fac Med, Dept Obstet & Gynecol, Ottawa, ON, Canada; [Zhang, Baohua; Lee, Martin B.; Baltz, Jay M.] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Denomme, Michelle M.; White, Carlee R.; Mann, Mellissa R. W.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Obstet & Gynecol & Biochem, London, ON, Canada; [Denomme, Michelle M.; White, Carlee R.; Mann, Mellissa R. W.] Childrens Hlth Res Inst, London, ON, Canada; [Leung, Kit-Yi; Greene, Nicholas D. E.] UCL, Inst Child Hlth, Dev Biol & Canc Program, London, England; [Trasler, Jacquetta M.] McGill Univ, Montreal Childrens Hosp, Res Inst, Ctr Hlth, Montreal, PQ H3H 1P3, Canada; [Trasler, Jacquetta M.] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [Trasler, Jacquetta M.] McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; [Trasler, Jacquetta M.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Western University (University of Western Ontario); University of London; University College London; McGill University; McGill University; McGill University; McGill University	Baltz, JM (corresponding author), Ottawa Hosp, Res Inst, 501 Smyth Rd,Mailbox 411, Ottawa, ON K1H 8L6, Canada.	jbaltz@ohri.ca	Mann, Mellissa/L-9006-2015	Mann, Mellissa/0000-0002-8075-3824; Greene, Nicholas D.E./0000-0002-4170-5248; Baltz, Jay/0000-0002-9749-2480	Canadian Institutes of Health Research Operating Grant [MOP97972]; Lalor Foundation; CIHR Training Program in Reproduction, Early Development; Impact on Health [TGF96122]; Medical Research Council, London, United Kingdom [J003794]; Fonds de la Recherche du Quebec-Sante; Medical Research Council [MR/J003794/1] Funding Source: researchfish; MRC [MR/J003794/1] Funding Source: UKRI	Canadian Institutes of Health Research Operating Grant(Canadian Institutes of Health Research (CIHR)); Lalor Foundation; CIHR Training Program in Reproduction, Early Development; Impact on Health; Medical Research Council, London, United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Fonds de la Recherche du Quebec-Sante(Fonds de la Recherche en Sante du Quebec); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by Canadian Institutes of Health Research Operating Grant MOP97972 (to J.M.B. and J.M.T.). B.Z. was partially supported by a Lalor Foundation postdoctoral fellowship. M.M.D. and C.R.W. were partially supported by CIHR Training Program in Reproduction, Early Development, and the Impact on Health (TGF96122) studentships and laboratory exchange visit awards. K.Y.L. and N.D.E.G. were supported by the Medical Research Council, London, United Kingdom (J003794). J.M.T. is a James McGill Professor at McGill University and a member of the Research Institute of the McGill University Health Centre, which is supported in part by the Fonds de la Recherche du Quebec-Sante.	ALLEGRA CJ, 1986, J BIOL CHEM, V261, P6478; Anas MKI, 2008, DEVELOPMENT, V135, P4123, DOI 10.1242/dev.026575; BARAM J, 1987, J CLIN INVEST, V79, P692, DOI 10.1172/JCI112872; BIGGERS JD, 1988, AM J PHYSIOL, V255, pC419, DOI 10.1152/ajpcell.1988.255.4.C419; Bolusani S, 2011, J BIOL CHEM, V286, P5166, DOI 10.1074/jbc.M110.196840; Burren KA, 2006, J CHROMATOGR B, V844, P112, DOI 10.1016/j.jchromb.2006.07.012; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Cirio MC, 2008, DEV BIOL, V324, P139, DOI 10.1016/j.ydbio.2008.09.015; Delgado-Reyes CV, 2001, ARCH BIOCHEM BIOPHYS, V393, P184, DOI 10.1006/abbi.2001.2474; Denomme M. M., 2012, JOVE-J VIS EXP, V64, P4046; Denomme MM, 2012, REPRODUCTION, V144, P393, DOI 10.1530/REP-12-0237; Dobbs KB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066230; Fiskerstrand T, 1997, J PHARMACOL EXP THER, V282, P1305; Fleming TP, 2004, BIOL REPROD, V71, P1046, DOI 10.1095/biolreprod.104.030957; Fowler B, 2001, KIDNEY INT, V59, pS221, DOI 10.1046/j.1523-1755.2001.07851.x; Fox JT, 2008, VITAM HORM, V79, P1, DOI 10.1016/S0083-6729(08)00401-9; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; Guo HS, 2014, NATURE, V511, P606, DOI 10.1038/nature13544; Hewitson LC, 1996, MOL REPROD DEV, V43, P323, DOI 10.1002/(SICI)1098-2795(199603)43:3&lt;323::AID-MRD6&gt;3.0.CO;2-S; Hirasawa R, 2008, GENE DEV, V22, P1607, DOI 10.1101/gad.1667008; Howell CY, 2001, CELL, V104, P829, DOI 10.1016/S0092-8674(01)00280-X; Hudson QJ, 2010, HEREDITY, V105, P45, DOI 10.1038/hdy.2010.23; HUENNEKENS FM, 1994, ADV ENZYME REGUL, V34, P397, DOI 10.1016/0065-2571(94)90025-6; Ikeda S, 2012, J REPROD DEVELOP, V58, P91, DOI 10.1262/jrd.11-096H; Ikeda S, 2012, J REPROD DEVELOP, V58, P38, DOI 10.1262/jrd.2011-002; Ikeda S, 2010, J EXP ZOOL PART A, V313A, P129, DOI 10.1002/jez.581; Katz JE, 2003, MOL CELL PROTEOMICS, V2, P525, DOI 10.1074/mcp.M300037-MCP200; Kooistra M, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.111146; Kurihara Y, 2008, DEV BIOL, V313, P335, DOI 10.1016/j.ydbio.2007.10.033; Kwong WY, 2010, REPRODUCTION, V139, P705, DOI 10.1530/REP-09-0517; LAWITTS JA, 1993, METHOD ENZYMOL, V225, P153; Lawrance AK, 2011, J INHERIT METAB DIS, V34, P147, DOI 10.1007/s10545-010-9127-1; Lee MB, 2012, J BIOL CHEM, V287, P33094, DOI 10.1074/jbc.M112.365478; Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9; Market-Velker BA, 2010, BIOL REPROD, V83, P938, DOI 10.1095/biolreprod.110.085480; MENEZO Y, 1989, LIFE SCI, V44, P1601, DOI 10.1016/0024-3205(89)90455-4; MILLER JGO, 1985, J EMBRYOL EXP MORPH, V89, P149; O'Neill C, 1998, HUM REPROD, V13, P1312, DOI 10.1093/humrep/13.5.1312; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Rossant J, 2009, DEVELOPMENT, V136, P701, DOI 10.1242/dev.017178; Sakaue M, 2010, CURR BIOL, V20, P1452, DOI 10.1016/j.cub.2010.06.050; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Santos F, 2006, METH MOL B, V325, P129; Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217; Shi LJ, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-59; Siddall LS, 2002, MOL REPROD DEV, V63, P413, DOI 10.1002/mrd.10202; Sinclair KD, 2007, THERIOGENOLOGY, V67, P43, DOI 10.1016/j.theriogenology.2006.09.017; Smith ZD, 2014, NATURE, V511, P611, DOI 10.1038/nature13581; Smith ZD, 2012, NATURE, V484, P339, DOI 10.1038/nature10960; SOLTER D, 1975, P NATL ACAD SCI USA, V72, P5099, DOI 10.1073/pnas.72.12.5099; Steegers-Theunissen RPM, 2013, HUM REPROD UPDATE, V19, P640, DOI 10.1093/humupd/dmt041; Teng YW, 2011, J BIOL CHEM, V286, P36258, DOI 10.1074/jbc.M111.265348; Thouas G. A., 2001, Reprod Biomed Online, V3, P25; Tibbetts AS, 2010, ANNU REV NUTR, V30, P57, DOI 10.1146/annurev.nutr.012809.104810; Torres-Padilla ME, 2007, NATURE, V445, P214, DOI 10.1038/nature05458; Velker BAM, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.096602	56	29	32	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1069	1079		10.1096/fj.14-261131	http://dx.doi.org/10.1096/fj.14-261131			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25466894				2022-12-28	WOS:000350633000030
J	Al-Nedawi, K; Mian, MF; Hossain, N; Karimi, K; Mao, YK; Forsythe, P; Min, KK; Stanisz, AM; Kunze, WA; Bienenstock, J				Al-Nedawi, Khalid; Mian, M. Firoz; Hossain, Nazia; Karimi, Khalil; Mao, Yu-Kang; Forsythe, Paul; Min, Kevin K.; Stanisz, Andrew M.; Kunze, Wolfgang A.; Bienenstock, John			Gut commensal microvesicles reproduce parent bacterial signals to host immune and enteric nervous systems	FASEB JOURNAL			English	Article						bacterial microvesicles; immunoregulation	OUTER-MEMBRANE VESICLES; LACTOBACILLUS-REUTERI; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; INTERCELLULAR TRANSFER; DENDRITIC CELLS; MOTILITY; EXPRESSION; INDUCTION; VIRULENCE	Ingestion of a commensal bacteria, Lactobacillus rhamnosus JB-1, has potent immunoregulatory effects, and changes nerve-dependent colon migrating motor complexes (MMCs), enteric nerve function, and behavior. How these alterations occur is unknown. JB-1 microvesicles (MVs) are enriched for heat shock protein components such as chaperonin 60 heat-shock protein isolated from Escherichia coli (GroEL) and reproduce regulatory and neuronal effects in vitro and in vivo. Ingested labeled MVs were detected in murine Peyer's patch (PP) dendritic cells (DCs) within 18 h. After 3 d, PP and mesenteric lymph node DCs assumed a regulatory phenotype and increased functional regulatory CD4(+)25(+)Foxp3(+) T cells. JB-1, MVs, and GroEL similarly induced phenotypic change in cocultured DCs via multiple pathways including C-type lectin receptors specific intercellular adhesion molecule-3 grabbing non-integrin-related 1 and Dectin-1, as well as TLR-2 and -9. JB-1 and MVs also decreased the amplitude of neuronally dependent MMCs in an ex vivo model of peristalsis. Gut epithelial, but not direct neuronal application of, MVs, replicated functional effects of JB-1 on in situ patch-clamped enteric neurons. GroEL and anti-TLR-2 were without effect in this system, suggesting the importance of epithelium neuron signaling and discrimination between pathways for bacteria-neuron and -immune communication. Together these results offer a mechanistic explanation of howGram-positive commensals and probiotics may influence the host's immune and nervous systems.-Al-Nedawi, K., Mian, M. F., Hossain, N., Karimi, K., Mao, Y.-K., Forsythe, P., Min, K. K., Stanisz, A. M., Kunze, W. A., Bienenstock, J. Gut commensal microvesicles reproduce parent bacterial signals to host immune and enteric nervous systems.	[Al-Nedawi, Khalid] McMaster Univ, Div Nephrol, Hamilton, ON, Canada; [Karimi, Khalil; Forsythe, Paul] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Kunze, Wolfgang A.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Bienenstock, John] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Mian, M. Firoz; Hossain, Nazia; Karimi, Khalil; Mao, Yu-Kang; Forsythe, Paul; Min, Kevin K.; Stanisz, Andrew M.; Kunze, Wolfgang A.; Bienenstock, John] St Josephs Healthcare Hamilton, McMaster Brain Body Inst, Hamilton, ON L8N 4A6, Canada	McMaster University; McMaster University; McMaster University; McMaster University; McMaster University	Bienenstock, J (corresponding author), St Josephs Healthcare Hamilton, McMaster Brain Body Inst, Juravinski Tower Room T3303-1, Hamilton, ON L8N 4A6, Canada.	bienens@mcmaster.ca	Karimi, Khalil/ABA-4735-2020	Karimi, Khalil/0000-0002-7245-5851; , Khalid/0000-0001-5140-3799	Giovanni and Concetta Guglietti Family Foundation; National Science Engineering Council [371513-2009]; McMaster Brain-Body Institute	Giovanni and Concetta Guglietti Family Foundation; National Science Engineering Council; McMaster Brain-Body Institute	The authors acknowledge the invaluable help from Dr. Eric Bonneil (IRIC-Universite de Montreal, Quebec, Canada), who performed the proteomic analysis. The authors thank Dr. Liam O'Mahony (Swiss Institute of Allergy and Asthma Research) and Ray Grant (Alimentary Health Pharma Davos, Davos, Switzerland) for invaluable discussion and advice. This work was supported by the Giovanni and Concetta Guglietti Family Foundation, National Science Engineering Council Grant 371513-2009 (to P.F.), and the McMaster Brain-Body Institute.	Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Al-Nedawi K, 2009, P NATL ACAD SCI USA, V106, P3794, DOI 10.1073/pnas.0804543106; Alaniz RC, 2007, J IMMUNOL, V179, P7692, DOI 10.4049/jimmunol.179.11.7692; Biller SJ, 2014, SCIENCE, V343, P183, DOI 10.1126/science.1243457; Blaiotta G, 2008, APPL ENVIRON MICROB, V74, P208, DOI 10.1128/AEM.01711-07; Bravo JA, 2012, CURR OPIN PHARMACOL, V12, P667, DOI 10.1016/j.coph.2012.09.010; Bravo JA, 2011, P NATL ACAD SCI USA, V108, P16050, DOI 10.1073/pnas.1102999108; Collins SM, 2012, NAT REV MICROBIOL, V10, P735, DOI 10.1038/nrmicro2876; Cummings R.D., 2009, ANTIBODIES LECTINS G; Derrien M, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00166; Dinan TG, 2013, BIOL PSYCHIAT, V74, P720, DOI 10.1016/j.biopsych.2013.05.001; DORWARD DW, 1989, J BACTERIOL, V171, P2499, DOI 10.1128/jb.171.5.2499-2505.1989; Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09; Fanning S, 2012, P NATL ACAD SCI USA, V109, P2108, DOI 10.1073/pnas.1115621109; Forsythe P, 2007, AM J RESP CRIT CARE, V175, P561, DOI 10.1164/rccm.200606-821OC; Forsythe P, 2013, CELL MOL LIFE SCI, V70, P55, DOI 10.1007/s00018-012-1028-z; Iliev ID, 2012, SCIENCE, V336, P1314, DOI 10.1126/science.1221789; Ismail S, 2003, INFECT IMMUN, V71, P5670, DOI 10.1128/IAI.71.10.5670-5675.2003; Johansson MEV, 2011, P NATL ACAD SCI USA, V108, P4659, DOI 10.1073/pnas.1006451107; Kadurugamuwa JL, 1999, MICROBIOL-SGM, V145, P2051, DOI 10.1099/13500872-145-8-2051; Kadurugamuwa JL, 1996, J BACTERIOL, V178, P2767, DOI 10.1128/jb.178.10.2767-2774.1996; Kang CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076520; Karimi K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047556; Karimi K, 2009, AM J RESP CRIT CARE, V179, P186, DOI 10.1164/rccm.200806-951OC; Karlsson M, 2001, EUR J IMMUNOL, V31, P2892, DOI 10.1002/1521-4141(2001010)31:10<2892::AID-IMMU2892>3.0.CO;2-I; Kesty NC, 2004, EMBO J, V23, P4538, DOI 10.1038/sj.emboj.7600471; Klieve AV, 2005, APPL ENVIRON MICROB, V71, P4248, DOI 10.1128/AEM.71.8.4248-4253.2005; Kolling GL, 1999, APPL ENVIRON MICROB, V65, P1843; Konieczna P, 2012, GUT, V61, P354, DOI 10.1136/gutjnl-2011-300936; Kuehn MJ, 2012, CELL HOST MICROBE, V12, P392, DOI 10.1016/j.chom.2012.10.005; Kunze WA, 2009, J CELL MOL MED, V13, P2261, DOI 10.1111/j.1582-4934.2009.00686.x; Kwon SO, 2009, FEMS MICROBIOL LETT, V297, P150, DOI 10.1111/j.1574-6968.2009.01669.x; Lee EY, 2009, PROTEOMICS, V9, P5425, DOI 10.1002/pmic.200900338; MacDonald IA, 2012, RES MICROBIOL, V163, P607, DOI 10.1016/j.resmic.2012.10.020; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Mao YK, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2478; Mashburn LM, 2005, NATURE, V437, P422, DOI 10.1038/nature03925; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Mayer EA, 2011, NAT REV NEUROSCI, V12, P453, DOI 10.1038/nrn3071; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Rivera J, 2010, P NATL ACAD SCI USA, V107, P19002, DOI 10.1073/pnas.1008843107; Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622; Round JL, 2011, SCIENCE, V332, P974, DOI 10.1126/science.1206095; Sanchez B, 2010, MICROBIOL-SGM, V156, P3232, DOI 10.1099/mic.0.044057-0; Saygili T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049252; Schwechheimer C, 2013, BIOCHEMISTRY-US, V52, P3031, DOI 10.1021/bi400164t; Shen Y, 2012, CELL HOST MICROBE, V12, P509, DOI 10.1016/j.chom.2012.08.004; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; van Bergenhenegouwen J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089121; Wang B, 2010, NEUROGASTROENT MOTIL, V22, P98, DOI 10.1111/j.1365-2982.2009.01384.x; Wang BX, 2010, FASEB J, V24, P4078, DOI 10.1096/fj.09-153841; Wang XF, 2009, EUR J IMMUNOL, V39, P3052, DOI 10.1002/eji.200939335; Wu RY, 2013, NEUROGASTROENT MOTIL, V25, pE205, DOI 10.1111/nmo.12072; Zhu HY, 2013, MICROBES INFECT, V15, P172, DOI 10.1016/j.micinf.2012.10.001	54	85	88	1	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					684	695		10.1096/fj.14-259721	http://dx.doi.org/10.1096/fj.14-259721			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25392266				2022-12-28	WOS:000349370400029
J	Aldi, S; Marino, A; Tomita, K; Corti, F; Anand, R; Olson, KE; Marcus, AJ; Levi, R				Aldi, Silvia; Marino, Alice; Tomita, Kengo; Corti, Federico; Anand, Ranjini; Olson, Kim E.; Marcus, Aaron J.; Levi, Roberto			E-NTPDase1/CD39 modulates renin release from heart mast cells during ischemia/reperfusion: a novel cardioprotective role	FASEB JOURNAL			English	Article						ATP; renin-angiotensin system; arrhythmias; P2X(7) purinergic receptors; toxic aldehydes	ANGIOTENSIN SYSTEM; REPERFUSION ARRHYTHMIAS; RECEPTOR; ACTIVATION; ATP; ISCHEMIA; CD39; TRIPHOSPHATE; INHIBITION; INJURY	Ischemia/reperfusion (I/R) elicits renin release from cardiac mast cells (MC), thus activating a local renin-angiotensin system (RAS), culminating in ventricular fibrillation. We hypothesized that in I/R, neurogenic ATP could degranulate juxtaposed MC and that ecto-nucleoside triphosphate diphosphohydrolase 1/CD39 (CD39) on MC membrane could modulate ATP-induced renin release. We report that pharmacological inhibition of CD39 in a cultured human mastocytoma cell line (HMC-1) and murine bone marrow-derived MC with ARL67156 (100 mu M) increased ATP-induced renin release (>= 2-fold), whereas purinergic P2X(7) receptors (P2X(7)R) blockade with A740003 (3 mM) prevented it. Likewise, CD39 RNA silencing in HMC-1 increased ATP-induced renin release (>= 2-fold), whereas CD39 overexpression prevented it. Acetaldehyde, an I/R product (300 mM), elicited an 80% increase in ATP release from HMC-1, in turn, causing an autocrine 20% increase in renin release. This effect was inhibited or potentiated when CD39 was overexpressed or silenced, respectively. Moreover, P2X(7)R silencing prevented ATP- and acetaldehyde-induced renin release. I/R-induced RAS activation in ex vivo murine hearts, characterized by renin and norepinephrine overflow and ventricular fibrillation, was potentiated (similar to 2-fold) by CD39 inhibition, an effect prevented by P2X(7)R blockade. Our data indicate that by regulating ATP availability at the MC surface, CD39 modulates local renin release and thus, RAS activation, ultimately exerting a cardioprotective effect.	[Aldi, Silvia; Marino, Alice; Tomita, Kengo; Corti, Federico; Levi, Roberto] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA; [Marcus, Aaron J.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA; [Anand, Ranjini; Olson, Kim E.; Marcus, Aaron J.] Weill Cornell Med Coll, Dept Med, Div Hematol & Med Oncol, New York, NY USA; [Anand, Ranjini; Olson, Kim E.; Marcus, Aaron J.] Vet Affairs New York Harbor Healthcare Syst, Thrombosis Res Lab, New York, NY USA	Cornell University; Cornell University; Cornell University	Levi, R (corresponding author), LC419 Weill Cornell Med Coll, 1300 York Ave, New York, NY 10065 USA.	rlevi@med.cornell.edu	Corti, Federico/R-6262-2016	Corti, Federico/0000-0003-2160-245X; Marino, Alice/0000-0002-1985-6576; Tomita, Kengo/0000-0002-7310-8093	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002384, UL1TR000457] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047073, R01HL089521, R37HL047073, R01HL034215] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR002384, UL1 TR000457] Funding Source: Medline; NHLBI NIH HHS [HL047073, R01 HL034215, R37 HL047073, R01 HL089521, HL047073-23S1, HL089521, HL034215, R01 HL047073] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aldi S, 2014, J PHARMACOL EXP THER, V349, P508, DOI 10.1124/jpet.114.214122; Aldi S, 2014, AM J PATHOL, V184, P376, DOI 10.1016/j.ajpath.2013.10.016; Bauer O, 2000, NEWS PHYSIOL SCI, V15, P213, DOI 10.1152/physiologyonline.2000.15.5.213; Biran V, 2008, BRAIN PATHOL, V18, P1, DOI 10.1111/j.1750-3639.2007.00092.x; Bulanova E, 2010, PURINERG SIGNAL, V6, P3, DOI 10.1007/s11302-009-9173-z; Calvert JA, 2004, MOL PHARMACOL, V65, P139, DOI 10.1124/mol.65.1.139; Chen CH, 2014, PHYSIOL REV, V94, P1, DOI 10.1152/physrev.00017.2013; Chen SZ, 2009, AM J PHYSIOL-REG I, V297, pR1526, DOI 10.1152/ajpregu.91040.2008; CORDIS GA, 1993, J CHROMATOGR, V632, P97, DOI 10.1016/0021-9673(93)80031-3; Corti F, 2011, J PHARMACOL EXP THER, V337, P524, DOI 10.1124/jpet.111.179994; CRACK BE, 1995, BRIT J PHARMACOL, V114, P475, DOI 10.1111/j.1476-5381.1995.tb13251.x; Deaglio S, 2011, ADV PHARMACOL, V61, P301, DOI 10.1016/B978-0-12-385526-8.00010-2; Donnelly-Roberts DL, 2007, BRIT J PHARMACOL, V151, P571, DOI 10.1038/sj.bjp.0707265; Eaton P, 1999, AM J PHYSIOL-HEART C, V276, pH935, DOI 10.1152/ajpheart.1999.276.3.H935; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FLEETWOOD G, 1991, J CARDIOVASC PHARM, V17, P351, DOI 10.1097/00005344-199103000-00001; Garg S, 2006, AM J CARDIOL, V97, P921, DOI 10.1016/j.amjcard.2005.10.028; Grassi G, 2009, J NEPHROL, V22, P190; Guo LP, 2004, HEPATOLOGY, V40, P583, DOI 10.1002/hep.20369; Harada K, 1998, CIRCULATION, V97, P315; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; Iravanian S, 2008, HEART RHYTHM, V5, pS12, DOI 10.1016/j.hrthm.2008.02.025; Jalowy A, 1999, J AM SOC NEPHROL, V10, pS129; Jennings LK, 2009, THROMB HAEMOSTASIS, V102, P248, DOI 10.1160/TH09-03-0192; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kaneko H, 1998, BBA-MOL BASIS DIS, V1407, P193, DOI 10.1016/S0925-4439(98)00039-8; KIERNAN JA, 1972, Q J EXP PHYSIOL CMS, V57, P311, DOI 10.1113/expphysiol.1972.sp002164; KIERNAN JA, 1974, ARCH DERMATOL FORSCH, V251, P83, DOI 10.1007/BF00561714; Knowles AF, 2011, PURINERG SIGNAL, V7, P21, DOI 10.1007/s11302-010-9214-7; Koda K, 2010, CIRCULATION, V122, P771, DOI 10.1161/CIRCULATIONAHA.110.952481; Kuhny M, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0040-3; Kurashima Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2023; Machida T, 2005, J PHARMACOL EXP THER, V313, P570, DOI 10.1124/jpet.104.081240; Mackins CJ, 2006, J CLIN INVEST, V116, P1063, DOI 10.1172/JCI25713; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Marcus AJ, 2003, J THROMB HAEMOST, V1, P2497, DOI 10.1111/j.1538-7836.2003.00479.x; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; MEREDITH IT, 1991, NEW ENGL J MED, V325, P618, DOI 10.1056/NEJM199108293250905; Morrey C, 2010, J PHARMACOL EXP THER, V335, P76, DOI 10.1124/jpet.110.172262; Reid AC, 2007, IMMUNOL REV, V217, P123, DOI 10.1111/j.1600-065X.2007.00514.x; Schaefer U, 2007, J PHARMACOL EXP THER, V322, P1269, DOI 10.1124/jpet.107.125328; SCHOMIG A, 1990, CIRCULATION, V82, P13; Sesti C, 2003, J PHARMACOL EXP THER, V306, P238, DOI 10.1124/jpet.103.049874; Sesti C, 2002, J PHARMACOL EXP THER, V300, P605, DOI 10.1124/jpet.300.2.605; Silver RB, 2004, P NATL ACAD SCI USA, V101, P13607, DOI 10.1073/pnas.0403208101; Steiner DRS, 2003, J APPL PHYSIOL, V94, P325, DOI 10.1152/japplphysiol.00637.2002; Swindle EJ, 2007, IMMUNOL REV, V217, P186, DOI 10.1111/j.1600-065X.2007.00513.x; Tan Alex Y, 2013, Handb Clin Neurol, V117, P135, DOI 10.1016/B978-0-444-53491-0.00012-2; Veerappan A, 2008, P NATL ACAD SCI USA, V105, P1315, DOI 10.1073/pnas.0709739105; Veerappan A, 2012, AM J PHYSIOL-RENAL, V302, pF192, DOI 10.1152/ajprenal.00562.2010; von Lewinski D, 2008, EUR J HEART FAIL, V10, P1172, DOI 10.1016/j.ejheart.2008.09.014; Vural KM, 2000, ANN THORAC SURG, V69, P228, DOI 10.1016/S0003-4975(99)01052-8; Walther T, 2002, FASEB J, V16, P169, DOI 10.1096/fj.01-0601com; Yahiro E, 2003, CARDIOLOGY, V99, P61, DOI 10.1159/000069722	54	16	17	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					61	69		10.1096/fj.14-261867	http://dx.doi.org/10.1096/fj.14-261867			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25318477	Green Published			2022-12-28	WOS:000347378600007
J	Hintzpeter, J; Martin, HJ; Maser, E				Hintzpeter, Jan; Martin, Hans-Joerg; Maser, Edmund			Reduction of lipid peroxidation products and advanced glycation end-product precursors by cyanobacterial aldo-keto reductase AKR3G1-a founding member of the AKR3G subfamily	FASEB JOURNAL			English	Article						carbonyl reduction; detoxification; enzyme kinetics	SP PCC 6803; SP STRAIN PCC-6803; ALDEHYDE REDUCTASE; ALZHEIMERS-DISEASE; DIABETES-MELLITUS; OXIDATIVE STRESS; ACTIVE-SITE; FATTY-ACIDS; METHYLGLYOXAL; EXPRESSION	The purpose of this study was to investigate the origin and function of the aldo-keto reductase (AKR) superfamily as enzymes involved in the detoxification of xenobiotics. We used the cyanobacterium Synechocystis sp. PCC 6803 as a model organism and sequence alignments to find bacterial AKRs with highest identity to human enzymes. Disappearance of NADPH was monitored spectrophotometrically to calculate enzymatic activity. The molecular weight of the native protein was determined by size exclusion chromatography. Substrate docking was performed by SwissDock. Sequence alignments identified the NADPH-dependent AKR3G1 having 41.5 and 40% identity with the human enzymes AKR1B1 and AKR1B10, respectively. Highest enzymatic efficiency was observed with 4-oxonon-2-enal (4-ONE; k(cat)/K-m, 561 s(-1) mM(-1)) and 4-hydroxynonenal (k(cat)/K-m, 26.5 s(-1) mM(-1)), respectively. P74308 is the most efficient enzyme for 4-ONE discovered until now. Cooperativity of this monomeric enzyme was observed with some substrates. Enzyme inactivation or oligomerization as possible explanations for nonhyperbolic enzyme kinetics were ruled out by Selwyn's test and gel filtration. The role of the little investigated carbonyl-reducing enzymes in detoxification seems to be in fact a very old process with rarely observed nonhyperbolic enzyme kinetics as an adaptation mechanism to higher concentrations of reactive oxygen species.	[Hintzpeter, Jan; Martin, Hans-Joerg; Maser, Edmund] Univ Med Sch Schleswig Holstein, Inst Toxicol & Pharmacol Nat Scientists, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Hintzpeter, J (corresponding author), Univ Med Sch Schleswig Holstein, Inst Toxicol & Pharmacol Nat Scientists, Campus Kiel,Brunswiker Str 10, D-24105 Kiel, Germany.	hintzpeter@toxi.uni-kiel.de	Maser, Edmund/B-1728-2010					Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Asada K, 2006, PLANT PHYSIOL, V141, P391, DOI 10.1104/pp.106.082040; Asselin C, 2006, FREE RADICAL BIO MED, V41, P97, DOI 10.1016/j.freeradbiomed.2006.03.011; Baba SP, 2009, DIABETES, V58, P2486, DOI 10.2337/db09-0375; Barski OA, 2008, DRUG METAB REV, V40, P553, DOI [10.1080/03602530802431439, 10.1080/03602530802431439 ]; Berman-Frank I, 2003, RES MICROBIOL, V154, P157, DOI 10.1016/S0923-2508(03)00029-9; Bourajjaj M, 2003, BIOCHEM SOC T, V31, P1400; Cavalier-Smith T, 2000, TRENDS PLANT SCI, V5, P174, DOI 10.1016/S1360-1385(00)01598-3; Copeland RA, 2000, ENZYMES PRACTICAL IN, P109; Doorn JA, 2004, BIOCHEMISTRY-US, V43, P13106, DOI 10.1021/bi049136q; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FLYNN TG, 1982, BIOCHEM PHARMACOL, V31, P2705, DOI 10.1016/0006-2952(82)90123-X; Gemma C, 2002, J NEUROSCI, V22, P6114; Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366; He YY, 2002, PHOTOCH PHOTOBIO SCI, V1, P729, DOI 10.1039/b110365m; Hihara Y, 2003, J BACTERIOL, V185, P1719, DOI 10.1128/JB.185.5.1719-1725.2003; Horie K, 1997, J CLIN INVEST, V100, P2995, DOI 10.1172/JCI119853; Hyndman D, 2003, CHEM-BIOL INTERACT, V143, P621, DOI 10.1016/S0009-2797(02)00193-X; JAGT DLV, 1995, BBA-PROTEIN STRUCT M, V1249, P117; KANAZU T, 1991, BIOCHEM J, V279, P903, DOI 10.1042/bj2790903; Kaneko T, 1996, DNA Res, V3, P109; Kasting JF, 2002, SCIENCE, V296, P1066, DOI 10.1126/science.1071184; Kobayashi M, 2004, PLANT CELL PHYSIOL, V45, P290, DOI 10.1093/pcp/pch034; Kuhla B, 2005, ANN NY ACAD SCI, V1043, P211, DOI 10.1196/annals.1333.026; Kumar D, 2013, MOL BIOTECHNOL, V54, P292, DOI 10.1007/s12033-012-9567-y; Latifi A, 2009, FEMS MICROBIOL REV, V33, P258, DOI 10.1111/j.1574-6976.2008.00134.x; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Lee SH, 2000, CHEM RES TOXICOL, V13, P698, DOI 10.1021/tx000101a; Leonarduzzi G, 2005, MOL NUTR FOOD RES, V49, P1044, DOI 10.1002/mnfr.200500090; Lin D, 2005, CHEM RES TOXICOL, V18, P1219, DOI 10.1021/tx050080q; Liu ZF, 2003, CHEM RES TOXICOL, V16, P901, DOI 10.1021/tx0300030; Long F, 2011, PROTEIN EXPRES PURIF, V79, P16, DOI 10.1016/j.pep.2011.05.012; Malatkova P, 2010, CURR DRUG METAB, V11, P639, DOI 10.2174/138920010794233530; Martin HJ, 2009, CHEM-BIOL INTERACT, V178, P145, DOI 10.1016/j.cbi.2008.10.021; Martina HJ, 2011, CHEM-BIOL INTERACT, V191, P48, DOI 10.1016/j.cbi.2010.12.006; Matsunaga T, 2009, BIOCHEM BIOPH RES CO, V389, P128, DOI 10.1016/j.bbrc.2009.08.107; Muthenna P, 2009, FEBS LETT, V583, P3637, DOI 10.1016/j.febslet.2009.10.042; Nanjo Y, 2010, BBA-BIOENERGETICS, V1797, P1483, DOI 10.1016/j.bbabio.2010.03.014; Narawongsanont R, 2012, PROTEIN J, V31, P35, DOI 10.1007/s10930-011-9371-8; Nhan Pham Phuoc, 2007, THESIS U WURZBURG WU; O'Connor T, 1999, BIOCHEM J, V343, P487, DOI 10.1042/0264-6021:3430487; Osanai T, 2013, PLANT J, V76, P456, DOI 10.1111/tpj.12310; Pinero Estrada J. E., 2001, FARMACO, V56, P497, DOI DOI 10.1016/S0014-827X(01)01084-9; PRYOR WA, 1990, FREE RADICAL BIO MED, V8, P541, DOI 10.1016/0891-5849(90)90153-A; Rabbani N, 2012, AMINO ACIDS, V42, P1133, DOI 10.1007/s00726-010-0783-0; REYES JC, 1994, J BACTERIOL, V176, P1260, DOI 10.1128/jb.176.5.1260-1267.1994; Rindgen D, 1999, CHEM RES TOXICOL, V12, P1195, DOI 10.1021/tx990034o; Schleicher ED, 1997, J CLIN INVEST, V99, P457, DOI 10.1172/JCI119180; SELWYN MJ, 1965, BIOCHIM BIOPHYS ACTA, V105, P193, DOI 10.1016/S0926-6593(65)80190-4; Shimakawa G, 2013, BIOSCI BIOTECH BIOCH, V77, P2441, DOI 10.1271/bbb.130554; Simpson PJ, 2009, J MOL BIOL, V392, P465, DOI 10.1016/j.jmb.2009.07.023; Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835; Steiger S, 1999, J PHOTOCH PHOTOBIO B, V52, P14, DOI 10.1016/S1011-1344(99)00094-9; Suzuki K, 1998, J BIOCHEM-TOKYO, V123, P353; Toyokuni S, 2000, ANTIOXID REDOX SIGN, V2, P681, DOI 10.1089/ars.2000.2.4-681; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; Wang WX, 2009, ENVIRON TOXICOL CHEM, V28, P1655, DOI 10.1897/08-463.1; Wegener KM, 2010, MOL CELL PROTEOMICS, V9, DOI 10.1074/mcp.M110.000109; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Williams TI, 2006, NEUROBIOL AGING, V27, P1094, DOI 10.1016/j.neurobiolaging.2005.06.004; Wu LY, 2006, CAN J PHYSIOL PHARM, V84, P129, DOI 10.1139/Y05-137; Zhang WH, 2003, CHEM RES TOXICOL, V16, P512, DOI 10.1021/tx020105a	63	7	8	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					263	273		10.1096/fj.14-258327	http://dx.doi.org/10.1096/fj.14-258327			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25376835				2022-12-28	WOS:000347378600025
J	Zhang, P; Goodrich, C; Fu, CL; Dong, C				Zhang, Pu; Goodrich, Chris; Fu, Changliang; Dong, Cheng			Melanoma upregulates ICAM-1 expression on endothelial cells through engagement of tumor CD44 with endothelial E-selectin and activation of a PKC alpha-p38-SP-1 pathway	FASEB JOURNAL			English	Article						flow coculture; intracellular signaling; adhesion; cross-linkingcytokine	INTERCELLULAR-ADHESION MOLECULE-1; PROTEIN-KINASE-C; NF-KAPPA-B; COLON-CARCINOMA CELLS; TYROSINE PHOSPHORYLATION; FLOW CONDITIONS; CELLULAR MECHANOTRANSDUCTION; VARIANT ISOFORMS; BINDING-KINETICS; GENE-EXPRESSION	Cancer metastasis involves multistep adhesive interactions between tumor cells (TCs) and endothelial cells (ECs), but the molecular mechanisms of intercellular communication in the tumor microenvironment remain elusive. Using static and flow coculture systems in conjunction with flow cytometry, we discovered that certain receptors on the ECs are upregulated on melanoma cell adhesion. Direct contact but not separate coculture between human umbilical endothelial cells (HUVECs) and a human melanoma cell line (Lu1205) increased intercellular adhesion molecule 1 (ICAM-1) and E-selectin expression on HUVECs by 3- and 1.5-fold, respectively, compared with HUVECs alone. The nonmetastatic cell line WM35 failed to promote ICAM-1 expression changes in HUVECs on contact. Enzyme-linked immunosorbent assay (ELISA) revealed that EC-TC contact has a synergistic effect on the expression of the cytokines interleukin (IL)-8, IL-6, and growth-related oncogene (Gro-). By using E-selectin cross-linking and beads coated with CD44 immunopurified from Lu1205 cells, we showed that CD44/selectin ligation was responsible for the ICAM-1 up-regulation on HUVECs. Protein kinase C (PKC-) activation was found to be the downstream target of the CD44/selectin-initiated signaling, as ICAM-1 elevation was inhibited by siRNA targeting PKC or a dominant negative form of PKC (PKC DN). Western blot analysis and electrophoretic mobility shift assays (EMSAs) showed that TC-EC contact mediated p38 phosphorylation and binding of the transcription factor SP-1 to its regulation site. In conclusion, CD44/selectin binding signals ICAM-1 up-regulation on the EC surface through a PKC-p38-SP-1 pathway, which further enhances melanoma cell adhesion to ECs during metastasis.Zhang, P., Goodrich, C., Fu, C., Dong, C. Melanoma upregulates ICAM-1 expression on ECs through engagement of tumor CD44 with endothelial E-selectin and activation of a PKC-p38-SP-1 pathway.	[Zhang, Pu; Goodrich, Chris; Fu, Changliang; Dong, Cheng] Penn State Univ, Dept Biomed Engn, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Dong, C (corresponding author), Penn State Univ, 233 Hallowell Bldg, University Pk, PA 16802 USA.	cxd23@psu.edu			U.S. National Institutes of Health [CA-125707]; National Science Foundation [CBET-0729091, CBET-1330663]; NATIONAL CANCER INSTITUTE [R01CA125707] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. J. Brown (Department of Biomedical Engineering, Pennsylvania State University) and Dr. E. Gomez (Department of Chemical Engineering, Pennsylvania State University) for their helpful discussions and critical proofreading of the manuscript; Dr. D. Welch (University of Kansas, Lawrence, KS, USA), Dr. G. Roberson (Penn State Hershey Medical Center, Hershey, PA, USA), and Dr. M. Herlyn (Wistar Institute, Philadelphia, PA, USA) for providing C8161, 1205Lu, and WM35 melanoma cells, respectively; and Addgene (Cambridge, MA, USA) for providing the PKC alpha DN, PKC alpha CAT, PKC epsilon DN, and CKAR plasmids. This study was supported in part by U.S. National Institutes of Health grant CA-125707 and National Science Foundation grants CBET-0729091 and CBET-1330663.	Alves CS, 2009, J BIOL CHEM, V284, P1177, DOI 10.1074/jbc.M805144200; Bijli KM, 2008, J BIOL CHEM, V283, P14674, DOI 10.1074/jbc.M802094200; Blaheta RA, 2009, NEOPLASIA, V11, P1054, DOI 10.1593/neo.09762; Chen CC, 2000, MOL PHARMACOL, V58, P1479, DOI 10.1124/mol.58.6.1479; Chen CC, 2001, CELL SIGNAL, V13, P543, DOI 10.1016/S0898-6568(01)00171-1; Chen CS, 2008, J CELL SCI, V121, P3285, DOI 10.1242/jcs.023507; Chen JX, 2001, AM J PHYSIOL-CELL PH, V280, pC1475, DOI 10.1152/ajpcell.2001.280.6.C1475; Chen SQ, 2001, P NATL ACAD SCI USA, V98, P950, DOI 10.1073/pnas.98.3.950; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; Chiu JJ, 2007, BLOOD, V110, P519, DOI 10.1182/blood-2006-08-040097; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; Dimitroff CJ, 2001, J CELL BIOL, V153, P1277, DOI 10.1083/jcb.153.6.1277; Dong C, 2005, FRONT BIOSCI-LANDMRK, V10, P379, DOI 10.2741/1535; Dong C, 2000, J BIOMECH, V33, P35, DOI 10.1016/S0021-9290(99)00174-8; Fagerholm SC, 2005, J CELL BIOL, V171, P705, DOI 10.1083/jcb.200504016; Fan ZZ, 2013, SCI REP-UK, V3, DOI 10.1038/srep02176; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Fu CL, 2011, J BIOL CHEM, V286, P34777, DOI 10.1074/jbc.M111.281642; Fujisaki T, 1999, CANCER RES, V59, P4427; Hanley WD, 2005, CANCER RES, V65, P5812, DOI 10.1158/0008-5472.CAN-04-4557; Hanley WD, 2006, FASEB J, V20, P337, DOI 10.1096/fj.05-4574fje; Haraldsen G, 1996, J IMMUNOL, V156, P2558; Hoffman BD, 2011, NATURE, V475, P316, DOI 10.1038/nature10316; Homeister JW, 1998, BLOOD, V92, P2345, DOI 10.1182/blood.V92.7.2345.2345_2345_2352; Hu YY, 2001, J BIOL CHEM, V276, P48549, DOI 10.1074/jbc.M105513200; Hu YY, 2000, J IMMUNOL, V165, P2142, DOI 10.4049/jimmunol.165.4.2142; Huang HD, 2004, AM J PHYSIOL-CELL PH, V287, pC1, DOI 10.1152/ajpcell.00559.2003; Huang WC, 2003, J BIOL CHEM, V278, P9944, DOI 10.1074/jbc.M208521200; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Javaid K, 2003, CIRC RES, V92, P1089, DOI 10.1161/01.RES.0000072971.88704.CB; Katayama Y, 2005, J EXP MED, V201, P1183, DOI 10.1084/jem.20042014; Kaur J, 2003, AM J PHYSIOL-HEART C, V284, pH1095, DOI 10.1152/ajpheart.00016.2002; Khanna P, 2010, AM J PHYSIOL-CELL PH, V298, pC1140, DOI 10.1152/ajpcell.00242.2009; Kiely JM, 2003, J IMMUNOL, V171, P3216, DOI 10.4049/jimmunol.171.6.3216; Klemke M, 2007, J CELL PHYSIOL, V212, P368, DOI 10.1002/jcp.21029; Konstantopoulos K, 2011, ADV EXP MED BIOL, V705, P601, DOI 10.1007/978-1-4419-7877-6_32; Konstantopoulos K, 2009, ANNU REV BIOMED ENG, V11, P177, DOI 10.1146/annurev-bioeng-061008-124949; Kronschnabl M, 2003, J GEN VIROL, V84, P61, DOI 10.1099/vir.0.18703-0; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Liang S, 2005, EXP CELL RES, V310, P282, DOI 10.1016/j.yexcr.2005.07.028; Liang S, 2008, AM J PHYSIOL-CELL PH, V295, pC701, DOI 10.1152/ajpcell.00245.2008; Liang SL, 2008, AM J PHYSIOL-CELL PH, V294, pC743, DOI 10.1152/ajpcell.00250.2007; Liang SL, 2007, CANCER RES, V67, P5814, DOI 10.1158/0008-5472.CAN-06-4233; Lorenzon P, 1998, J CELL BIOL, V142, P1381, DOI 10.1083/jcb.142.5.1381; Mauro A, 2002, J CELL SCI, V115, P3587, DOI 10.1242/jcs.00037; Miho N, 2005, CARDIOVASC RES, V68, P289, DOI 10.1016/j.cardiores.2005.05.029; Min JK, 2005, J IMMUNOL, V175, P531, DOI 10.4049/jimmunol.175.1.531; Na S, 2008, P NATL ACAD SCI USA, V105, P6626, DOI 10.1073/pnas.0711704105; Nakano T, 1996, ANTICANCER RES, V16, P3577; Newton AC, 2010, AM J PHYSIOL-ENDOC M, V298, pE395, DOI 10.1152/ajpendo.00477.2009; Ozdemir T, 2012, AM J PHYSIOL-CELL PH, V302, pC1189, DOI 10.1152/ajpcell.00346.2011; Peng HH, 2005, FRONT BIOSCI-LANDMRK, V10, P1597, DOI 10.2741/1643; Peng HH, 2007, EXP CELL RES, V313, P551, DOI 10.1016/j.yexcr.2006.10.030; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; Slattery MJ, 2005, AM J PHYSIOL-CELL PH, V288, pC831, DOI 10.1152/ajpcell.00439.2004; Slattery MJ, 2003, INT J CANCER, V106, P713, DOI 10.1002/ijc.11297; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steinberg SF, 2008, PHYSIOL REV, V88, P1341, DOI 10.1152/physrev.00034.2007; Tremblay PL, 2006, ONCOGENE, V25, P6563, DOI 10.1038/sj.onc.1209664; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Wang YX, 2005, NATURE, V434, P1040, DOI 10.1038/nature03469; Williams TE, 2000, BIOPHYS J, V79, P1858, DOI 10.1016/S0006-3495(00)76435-6; Wirtz D, 2011, NAT REV CANCER, V11, P512, DOI 10.1038/nrc3080; Yago T, 2004, J CELL BIOL, V166, P913, DOI 10.1083/jcb.200403144; Yasuda M, 2001, INT IMMUNOL, V13, P1309, DOI 10.1093/intimm/13.10.1309; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445; Zhang P, 2011, J IMMUNOL, V186, P242, DOI 10.4049/jimmunol.1000494; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	72	37	38	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4591	4609		10.1096/fj.11-202747	http://dx.doi.org/10.1096/fj.11-202747			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25138157	Green Published			2022-12-28	WOS:000344050900002
J	Wang, H; Leinwand, LA; Anseth, KS				Wang, Huan; Leinwand, Leslie A.; Anseth, Kristi S.			Roles of transforming growth factor-beta 1 and OB-cadherin in porcine cardiac valve myofibroblast differentiation	FASEB JOURNAL			English	Article						aortic valve fibrosis; genome-wide transcription; alpha-smooth muscle actin	GROWTH-FACTOR-BETA; TGF-BETA; TISSUE-REPAIR; EMERGING ROLE; MATRIX; FIBROBLASTS; FIBROSIS; CELLS; HEART; MECHANISMS	Calcific aortic stenosis is a common disease, and some of its early causes are the activation and differentiation of resident fibroblasts to myofibroblasts in response to transforming growth factor beta 1 (TGF-beta 1). The aim of this study was to understand how TGF-beta 1 and its downstream effector, OB-cadherin [cadherin 11 (CDH11)], regulate porcine myofibroblast phenotypes. Based on whole-genome microarrays, 95 and 107 genes are up-and down-regulated at both the early (8 h) and the late (24 h) time points of TGF-beta 1 treatment. Gene functions related to cell adhesion, skeletal system development, and extracellular matrix are up-regulated by TGF-beta 1, whereas oxidation-reduction and steroid metabolic process are down-regulated. Notably, one of the cell adhesion molecules, CDH11, is up-regulated by similar to 2-fold through both the Smad2/3 and the ERK pathways elicited by TGF-beta 1. CDH11 mediates cell-cell contacts in both valvular fibroblasts and myofibroblasts. Knockdown of CDH11 by small interfering RNA increases the myofibroblast phenotype, including an similar to 2-fold increase in alpha-smooth muscle actin (alpha-SMA) expression and stress fiber formation. In contrast, increased binding of CDH11 through antibody treatment inhibits alpha-SMA expression. This study presents gene functional changes in response to TGF-beta 1 at the systems level and supports an inhibitory role of CDH11 in myofibroblast differentiation.	[Wang, Huan; Anseth, Kristi S.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA; [Wang, Huan; Leinwand, Leslie A.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; [Wang, Huan; Leinwand, Leslie A.; Anseth, Kristi S.] Univ Colorado, BioFrontiers Inst, Boulder, CO 80309 USA; [Anseth, Kristi S.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Anseth, KS (corresponding author), Howard Hughes Med Inst, 3415 Colorado Ave,JSCBB A315,596UCB, Boulder, CO 80303 USA.	kristi.anseth@colorado.edu		LEINWAND, LESLIE/0000-0003-1470-4810; WANG, HUAN/0000-0002-3857-5737	U.S. National Institutes of Health [R01 HL089260, R01 GM29090]; Howard Hughes Medical Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029090] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors appreciate scientific discussions with Dr. Nicholas Farina and Dr. Bradley Olwin regarding microarray analysis and thank Dr. Bradley Olwin for generously sharing software resources. The authors also thank Dr. Michael Brenner (Brigham and Women's Hospital, Boston, MA, USA) for generously sharing CDH11 antibodies. This work was supported by the U.S. National Institutes of Health (grants R01 HL089260 and R01 GM29090) and the Howard Hughes Medical Institute.	Aikawa E, 2006, CIRCULATION, V113, P1344, DOI 10.1161/CIRCULATIONAHA.105.591768; Balestrini JL, 2012, INTEGR BIOL-UK, V4, P410, DOI 10.1039/c2ib00149g; Barnes JL, 2011, KIDNEY INT, V79, P944, DOI 10.1038/ki.2010.516; Biernacka A, 2011, GROWTH FACTORS, V29, P196, DOI 10.3109/08977194.2011.595714; Blaauboer ME, 2011, BIOCHEM BIOPH RES CO, V404, P23, DOI 10.1016/j.bbrc.2010.11.033; Chang SK, 2011, P NATL ACAD SCI USA, V108, P8402, DOI 10.1073/pnas.1019437108; Chang SK, 2010, IMMUNOL REV, V233, P256, DOI 10.1111/j.0105-2896.2009.00854.x; Chen JH, 2011, ARTERIOSCL THROM VAS, V31, P590, DOI 10.1161/ATVBAHA.110.220061; Chen JH, 2009, AM J PATHOL, V174, P1109, DOI 10.2353/ajpath.2009.080750; Conte E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024663; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Duffield JS, 2013, ANNU REV PATHOL-MECH, V8, P241, DOI 10.1146/annurev-pathol-020712-163930; Follonier L, 2008, J CELL SCI, V121, P3305, DOI 10.1242/jcs.024521; Fondard O, 2005, EUR HEART J, V26, P1333, DOI 10.1093/eurheartj/ehi248; Furukawa F, 2003, HEPATOLOGY, V38, P879, DOI 10.1053/jhep.2003.50384; Garrett Q, 2004, INVEST OPHTH VIS SCI, V45, P1109, DOI 10.1167/iovs.03-0660; Gu L, 2007, ACTA PHARMACOL SIN, V28, P382, DOI 10.1111/j.1745-7254.2007.00468.x; Hinton RB, 2006, CIRC RES, V98, P1431, DOI 10.1161/01.RES.0000224114.65109.4e; Hinz B, 2004, MOL BIOL CELL, V15, P4310, DOI 10.1091/mbc.E04-05-0386; Hinz B, 2003, THROMB HAEMOSTASIS, V90, P993, DOI 10.1160/TH03-05-0328; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; Hinz B, 2012, AM J PATHOL, V180, P1340, DOI 10.1016/j.ajpath.2012.02.004; Hutcheson JD, 2013, ARTERIOSCL THROM VAS, V33, P114, DOI 10.1161/ATVBAHA.112.300278; Hutcheson JD, 2012, J MOL CELL CARDIOL, V53, P707, DOI 10.1016/j.yjmcc.2012.08.012; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; JOHNSON CM, 1987, J MOL CELL CARDIOL, V19, P1185, DOI 10.1016/S0022-2828(87)80529-1; Kloxin AM, 2010, BIOMATERIALS, V31, P1, DOI 10.1016/j.biomaterials.2009.09.025; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Lee DM, 2007, SCIENCE, V315, P1006, DOI 10.1126/science.1137306; Li L, 2012, ONCOGENE, V31, P3901, DOI 10.1038/onc.2011.541; Liu AC, 2007, AM J PATHOL, V171, P1407, DOI 10.2353/ajpath.2007.070251; Liu F, 2010, J CELL BIOL, V190, P693, DOI 10.1083/jcb.201004082; Margadant C, 2010, EMBO REP, V11, P97, DOI 10.1038/embor.2009.276; Masur SK, 1996, P NATL ACAD SCI USA, V93, P4219, DOI 10.1073/pnas.93.9.4219; Meyer-ter-Vehn T, 2006, INVEST OPHTH VIS SCI, V47, P1500, DOI 10.1167/iovs.05-0361; Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522; Niessen CM, 2011, PHYSIOL REV, V91, P691, DOI 10.1152/physrev.00004.2010; Olsen AL, 2011, AM J PHYSIOL-GASTR L, V301, pG110, DOI 10.1152/ajpgi.00412.2010; Pittet P, 2008, J CELL SCI, V121, P877, DOI 10.1242/jcs.024877; Rabkin E, 2001, CIRCULATION, V104, P2525, DOI 10.1161/hc4601.099489; Rajamannan NM, 2011, CIRCULATION, V124, P1783, DOI 10.1161/CIRCULATIONAHA.110.006767; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Schneider DJ, 2012, FASEB J, V26, P503, DOI 10.1096/fj.11-186098; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Verhoekx JSN, 2013, J INVEST DERMATOL, V133, P2664, DOI 10.1038/jid.2013.219; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Walker GA, 2004, CIRC RES, V95, P253, DOI 10.1161/01.RES.0000136520.07995.aa; Wang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069667; Wang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039969; Wang J, 2003, AM J PHYSIOL-HEART C, V285, pH1871, DOI 10.1152/ajpheart.00387.2003; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277	52	29	29	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4551	4562		10.1096/fj.14-254623	http://dx.doi.org/10.1096/fj.14-254623			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25008089	Green Published			2022-12-28	WOS:000342222700030
J	Ferrera, D; Canale, C; Marotta, R; Mazzaro, N; Gritti, M; Mazzanti, M; Capellari, S; Cortelli, P; Gasparini, L				Ferrera, Denise; Canale, Claudio; Marotta, Roberto; Mazzaro, Nadia; Gritti, Marta; Mazzanti, Michele; Capellari, Sabina; Cortelli, Pietro; Gasparini, Laura			Lamin B1 overexpression increases nuclear rigidity in autosomal dominant leukodystrophy fibroblasts	FASEB JOURNAL			English	Article						ADLD; nuclear lamina; atomic force microscopy; human fibroblasts; nucleus	ATOMIC-FORCE MICROSCOPY; PROGRESSIVE MULTIPLE-SCLEROSIS; ONSET LEUKOENCEPHALOPATHY; MECHANICAL-PROPERTIES; AUTONOMIC SYMPTOMS; BRAIN-FUNCTION; ION CHANNELS; IN-VIVO; CELLS; ENVELOPE	The architecture and structural mechanics of the cell nucleus are defined by the nuclear lamina, which is formed by A- and B-type lamins. Recently, gene duplication and protein overexpression of lamin B1 (LB1) have been reported in pedigrees with autosomal dominant leukodystrophy (ADLD). However, how the overexpression of LB1 affects nuclear mechanics and function and how it may result in pathology remain unexplored. Here, we report that in primary human skin fibroblasts derived from ADLD patients, LB1, but not other lamins, is overexpressed at the nuclear lamina and specifically enhances nuclear stiffness. Transient transfection of LB1 in HEK293 and neuronal N2a cells mimics the mechanical phenotype of ADLD nuclei. Notably, in ADLD fibroblasts, reducing LB1 protein levels by shRNA knockdown restores elasticity values to those indistinguishable from control fibroblasts. Moreover, isolated nuclei from ADLD fibroblasts display a reduced nuclear ion channel open probability on voltage-step application, suggesting that biophysical changes induced by LB1 overexpression may alter nuclear signaling cascades in somatic cells. Overall, the overexpression of LB1 in ADLD cells alters nuclear mechanics and is linked to changes in nuclear signaling, which could help explain the pathogenesis of this disease.	[Ferrera, Denise; Mazzaro, Nadia; Gasparini, Laura] Ist Italiano Tecnol, Dept Neurosci & Brain Technol, I-16163 Genoa, Italy; [Canale, Claudio] Ist Italiano Tecnol, Dept Nanophys, I-16163 Genoa, Italy; [Marotta, Roberto] Ist Italiano Tecnol, Dept Nanochem, I-16163 Genoa, Italy; [Gritti, Marta; Mazzanti, Michele] Univ Milan, Dept Biosci, Milan, Italy; [Capellari, Sabina; Cortelli, Pietro] Osped Bellaria, IRCCS, Ist Sci Neurol Bologna, Clin Neurol, Bologna, Italy; [Capellari, Sabina; Cortelli, Pietro] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy	Istituto Italiano di Tecnologia - IIT; Istituto Italiano di Tecnologia - IIT; Istituto Italiano di Tecnologia - IIT; University of Milan; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB); University of Bologna	Gasparini, L (corresponding author), Ist Italiano Tecnol, Dept Neurosci & Brain Technol, Via Morego 30, I-16163 Genoa, Italy.	laura.gasparini@iit.it	capellari, sabina/F-5545-2012; Cortelli, Pietro/K-6063-2016; Marotta, Roberto/B-5382-2014; Gasparini, Laura/G-7711-2011; Marotta, Roberto/HGV-1599-2022	capellari, sabina/0000-0003-1631-1439; Gasparini, Laura/0000-0003-3894-9898; Mazzanti, Michele/0000-0002-1819-3811; Cortelli, Pietro/0000-0002-3633-8818; Marotta, Roberto/0000-0003-0634-5483; Canale, Claudio/0000-0002-7582-6849	TELETHON Grant [GGP 10184]	TELETHON Grant(Fondazione Telethon)	We thank Dr. R. Goldman, Northwestern University (Chicago, IL, USA) and Dr. L. Cancedda, Istituto Italiano di Tecnologia (Genova, Italy) for kindly providing plasmids. We are grateful to the following colleagues of the Istituto Italiano di Tecnologia: Dr. R. Ruffilli (Dept. of Nanochemistry) for contribution to EM sample preparation; Dr. E. Albanesi (Dept. Neuroscience and Brain Technologies) for technical assistance with FACS and Dr. S. Seghezza (Dept. Nanophysics) for technical assistance with AFM studies on living cells. The present work was funded by the TELETHON Grant GGP 10184 (to L. G. and P. C).	Azeloglu EU, 2011, METHODS MOL BIOL, V736, P303, DOI 10.1007/978-1-61779-105-5_19; Bading H, 2013, NAT REV NEUROSCI, V14, P593, DOI 10.1038/nrn3531; Brussino A, 2009, EUR J NEUROL, V16, P544, DOI 10.1111/j.1468-1331.2009.02536.x; Brussino A, 2009, J NEUROL NEUROSUR PS, V80, P237, DOI 10.1136/jnnp.2008.147330; Bueckle H, 1973, SCI HARDNESS TESTING; Butin-Israeli V, 2012, TRENDS GENET, V28, P464, DOI 10.1016/j.tig.2012.06.001; Cancedda L, 2007, J NEUROSCI, V27, P5224, DOI 10.1523/JNEUROSCI.5169-06.2007; Charras GT, 2004, BIOPHYS J, V87, P2870, DOI 10.1529/biophysj.104.040436; Coffeen CM, 2000, HUM MOL GENET, V9, P787, DOI 10.1093/hmg/9.5.787; Columbaro M, 2013, BBA-MOL BASIS DIS, V1832, P411, DOI 10.1016/j.bbadis.2012.12.006; Contestabile A, 2013, J CLIN INVEST, V123, P348, DOI 10.1172/JCI64650; Cortelli P, 2012, NEUROLOGY, V79, P1726, DOI 10.1212/WNL.0b013e31826ea887; Cross SE, 2007, NAT NANOTECHNOL, V2, P780, DOI 10.1038/nnano.2007.388; Dahl KN, 2005, BIOPHYS J, V89, P2855, DOI 10.1529/biophysj.105.062554; Dahl KN, 2004, J CELL SCI, V117, P4779, DOI 10.1242/jcs.01357; Dahl KN, 2008, CIRC RES, V102, P1307, DOI 10.1161/CIRCRESAHA.108.173989; Dahl KN, 2006, P NATL ACAD SCI USA, V103, P10271, DOI 10.1073/pnas.0601058103; Dimitriadis EK, 2002, BIOPHYS J, V82, P2798, DOI 10.1016/S0006-3495(02)75620-8; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Dreesen O, 2013, J CELL BIOL, V200, P605, DOI 10.1083/jcb.201206121; Dvorak JA, 1998, EXP CELL RES, V242, P69, DOI 10.1006/excr.1998.4077; Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11-10-0884; Gasparini L, 1999, NEUROSCI LETT, V263, P197, DOI 10.1016/S0304-3940(99)00155-X; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Gasparini L, 2011, NEUROBIOL AGING, V32, P419, DOI 10.1016/j.neurobiolaging.2009.03.002; Giorgio E, 2013, HUM MUTAT, V34, P1160, DOI 10.1002/humu.22348; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HASSAN EA, 1998, BIOPHYS J, V74, P1564; JACKSON DA, 1988, J CELL SCI, V90, P365; KAUFMANN SH, 1992, CANCER RES, V52, P2847; Lammerding J, 2005, J CELL BIOL, V170, P781, DOI 10.1083/jcb.200502148; Lammerding J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670; Lammerding J, 2006, J BIOL CHEM, V281, P25768, DOI 10.1074/jbc.M513511200; Lin ST, 2009, DIS MODEL MECH, V2, P178, DOI 10.1242/dmm.001065; Lundbaek JA, 2004, J GEN PHYSIOL, V123, P599, DOI 10.1085/jgp.200308996; Magnani E, 2007, EMBO J, V26, P4546, DOI 10.1038/sj.emboj.7601878; Martins RP, 2012, ANNU REV BIOMED ENG, V14, P431, DOI [10.1146/annurev-bioeng-071910-124638, 10.1146/annurev.bioeng-071910-124638]; Matzke R, 2001, NAT CELL BIOL, V3, P607, DOI 10.1038/35078583; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; MAZZANTI M, 1994, FASEB J, V8, P231, DOI 10.1096/fasebj.8.2.7509760; Melberg A, 2006, AM J NEURORADIOL, V27, P904; Orr AG, 2009, NAT NEUROSCI, V12, P872, DOI 10.1038/nn.2341; Padiath QS, 2006, NAT GENET, V38, P1114, DOI 10.1038/ng1872; Pugh GE, 1997, J CELL SCI, V110, P2483; Quattrocolo G, 1997, EUR NEUROL, V37, P53, DOI 10.1159/000117406; Rotsch C, 1999, P NATL ACAD SCI USA, V96, P921, DOI 10.1073/pnas.96.3.921; Schape J, 2009, BIOPHYS J, V96, P4319, DOI 10.1016/j.bpj.2009.02.048; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SCHWANKHAUS JD, 1994, ARCH NEUROL-CHICAGO, V51, P757, DOI 10.1001/archneur.1994.00540200033013; Shimi T, 2011, GENE DEV, V25, P2579, DOI 10.1101/gad.179515.111; Shimi T, 2008, GENE DEV, V22, P3409, DOI 10.1101/gad.1735208; Sundblom J, 2009, AM J NEURORADIOL, V30, P328, DOI 10.3174/ajnr.A1354; Swift J, 2013, SCIENCE, V341, DOI 10.1126/science.1240104; Tang CW, 2008, J CELL SCI, V121, P1014, DOI 10.1242/jcs.020982; Tonini R, 1999, FASEB J, V13, P1395, DOI 10.1096/fasebj.13.11.1395; Tyler WJ, 2012, NAT REV NEUROSCI, V13, P867, DOI 10.1038/nrn3383; Vergnes L, 2004, P NATL ACAD SCI USA, V101, P10428, DOI 10.1073/pnas.0401424101; Wittmann M, 2009, J NEUROSCI, V29, P14687, DOI 10.1523/JNEUROSCI.1160-09.2009; Zastrow MS, 2006, J CELL SCI, V119, P239, DOI 10.1242/jcs.02728	60	46	46	2	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3906	3918		10.1096/fj.13-247635	http://dx.doi.org/10.1096/fj.13-247635			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24858279	Green Published, hybrid			2022-12-28	WOS:000340845900009
J	Haage, A; Schneider, IC				Haage, Amanda; Schneider, Ian C.			Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells	FASEB JOURNAL			English	Article						invasion; collagen; quenched cleavage peptide; blebbistatin; transglutaminase	COLLAGEN MATRICES; TISSUE INHIBITORS; FOCAL ADHESIONS; INVASION; EXPRESSION; BREAST; MIGRATION; SURFACE; PROTEOLYSIS; PROGRESSION	The pathogenesis of cancer is often driven by local invasion and metastasis. Recently, mechanical properties of the tumor microenvironment have been identified as potent regulators of invasion and metastasis, while matrix metalloproteinases (MMPs) are classically known as significant enhancers of cancer cell migration and invasion. Here we have been able to sensitively measure MMP activity changes in response to specific extracellular matrix (ECM) environments and cell contractility states. Cells of a pancreatic cancer cell line, Panc-1, up-regulate MMP activities between 3- and 10-fold with increased cell contractility. Conversely, they down-regulate MMP activities when contractility is blocked to levels seen with pan-MMP activity inhibitors. Similar, albeit attenuated, responses are seen in other pancreatic cancer cell lines, BxPC-3 and AsPC-1. In addition, MMP activity was modulated by substrate stiffness, collagen gel concentration, and the degree of collagen cross-linking, when cells were plated on collagen gels ranging from 0.5 to 5 mg/ml that span the physiological range of substrate stiffness (50-2000 Pa). Panc-1 cells showed enhanced MMP activity on stiffer substrates, whereas BxPC-3 and AsPC-1 cells showed diminished MMP activity. In addition, eliminating heparan sulfate proteoglycans using heparinase completely abrogated the mechanical induction of MMP activity. These results demonstrate the first functional link between MMP activity, contractility, and ECM stiffness and provide an explanation as to why stiffer environments result in enhanced cell migration and invasion.-Haage, A., Schneider, I. C. Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells.	[Haage, Amanda; Schneider, Ian C.] Iowa State Univ, Dept Genet Dev & Cell Biol, Ames, IA 50011 USA; [Haage, Amanda] Iowa State Univ, Mol Cellular & Dev Biol Interdept Grad Program, Ames, IA 50011 USA; [Schneider, Ian C.] Iowa State Univ, Dept Chem & Biol Engn, Ames, IA 50011 USA	Iowa State University; Iowa State University; Iowa State University	Schneider, IC (corresponding author), Iowa State Univ, Dept Chem & Biol Engn, 2114 Sweeney Hall, Ames, IA 50011 USA.	ians@iastate.edu		Schneider, Ian/0000-0002-4414-3842	National Science Foundation [0963224]; Iowa State University	National Science Foundation(National Science Foundation (NSF)); Iowa State University	The authors acknowledge Surya Mallapragada for kind use of the plate reader. The authors acknowledge support from Iowa State University for general project funding and from a National Science Foundation Academic Research Infrastructure-Recovery and Reinvestment (ARI-R<SUP>2</SUP>) grant [Civil, Mechanical, and Manufacturing Innovation (CMMI)-0963224] for funding the renovation of the research laboratories used for these studies.	Adhikari AS, 2011, J AM CHEM SOC, V133, P1686, DOI 10.1021/ja109972p; Alexander NR, 2008, CURR BIOL, V18, P1295, DOI 10.1016/j.cub.2008.07.090; Bachem MG, 2005, GASTROENTEROLOGY, V128, P907, DOI 10.1053/j.gastro.2004.12.036; Baker AM, 2013, ONCOGENE, V32, P1863, DOI 10.1038/onc.2012.202; Balduyck M, 2000, CLIN EXP METASTAS, V18, P171, DOI 10.1023/A:1006762425323; Balzer EM, 2012, FASEB J, V26, P4045, DOI 10.1096/fj.12-211441; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Bellin RM, 2009, P NATL ACAD SCI USA, V106, P22102, DOI 10.1073/pnas.0902639106; Berglund JD, 2003, BIOMATERIALS, V24, P1241, DOI 10.1016/S0142-9612(02)00506-9; Bershadsky A, 2006, CURR OPIN CELL BIOL, V18, P472, DOI 10.1016/j.ceb.2006.08.012; Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Camp RJ, 2011, J AM CHEM SOC, V133, P4073, DOI 10.1021/ja110098b; Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Duxbury MS, 2004, BIOCHEM BIOPH RES CO, V313, P992, DOI 10.1016/j.bbrc.2003.12.031; Erkan MM, 2009, NEOPLASIA, V11, P497, DOI 10.1593/neo.81618; Garbett EA, 1999, BRIT J CANCER, V81, P287, DOI 10.1038/sj.bjc.6690689; Gehler S, 2013, CRIT REV EUKAR GENE, V23, P139, DOI 10.1615/CritRevEukarGeneExpr.2013006647; Gu ZZ, 2014, MOL BIOL CELL, V25, P457, DOI 10.1091/mbc.E13-05-0260; Jerrell RJ, 2014, ACTA BIOMATER, V10, P1886, DOI 10.1016/j.actbio.2013.12.058; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kraning-Rush CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032572; Lee PF, 2013, ACTA BIOMATER, V9, P7178, DOI 10.1016/j.actbio.2013.04.001; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Maatta M, 2000, CLIN CANCER RES, V6, P2726; Maeda E, 2013, J BIOMECH, V46, P991, DOI 10.1016/j.jbiomech.2012.11.056; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Matsumoto Y, 2001, JPN J CANCER RES, V92, P429, DOI 10.1111/j.1349-7006.2001.tb01113.x; Mierke CT, 2008, EUR J CELL BIOL, V87, P669, DOI 10.1016/j.ejcb.2008.01.002; Moon JJ, 2005, J CELL PHYSIOL, V203, P166, DOI 10.1002/jcp.20220; Morgan MR, 2007, NAT REV MOL CELL BIO, V8, P957, DOI 10.1038/nrm2289; Mucha A, 1998, J BIOL CHEM, V273, P2763, DOI 10.1074/jbc.273.5.2763; Murphy G, 2008, MOL ASPECTS MED, V29, P290, DOI 10.1016/j.mam.2008.05.002; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Neumann U, 2004, ANAL BIOCHEM, V328, P166, DOI 10.1016/j.ab.2003.12.035; O Halloran DM, 2006, TISSUE ENG, V12, P1467, DOI 10.1089/ten.2006.12.1467; Ohlund D, 2008, INT J CANCER, V122, P2805, DOI 10.1002/ijc.23468; Okina E, 2009, SCAND J MED SCI SPOR, V19, P479, DOI 10.1111/j.1600-0838.2009.00941.x; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Ra HJ, 2007, MATRIX BIOL, V26, P587, DOI 10.1016/j.matbio.2007.07.001; Raub CB, 2007, BIOPHYS J, V92, P2212, DOI 10.1529/biophysj.106.097998; Robins SP, 2007, BIOCHEM SOC T, V35, P849, DOI 10.1042/BST0350849; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sabeh F, 2009, J CELL BIOL, V185, P11, DOI 10.1083/jcb.200807195; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Schram K, 2011, ENDOCRINOLOGY, V152, P2037, DOI 10.1210/en.2010-1166; Sheu MT, 2001, BIOMATERIALS, V22, P1713, DOI 10.1016/S0142-9612(00)00315-X; Shi ZD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015956; Sinkus R, 2000, PHYS MED BIOL, V45, P1649, DOI 10.1088/0031-9155/45/6/317; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Wang S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041040; Wang Y, 2012, J CELL BIOL, V196, P375, DOI 10.1083/jcb.201105153; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Wolf K, 2013, J CELL BIOL, V201, P1069, DOI 10.1083/jcb.201210152; Wolf K, 2011, TRENDS CELL BIOL, V21, P736, DOI 10.1016/j.tcb.2011.09.006; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Xue F, 2008, HEPATOL RES, V38, P810, DOI 10.1111/j.1872-034X.2008.00333.x; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yamamoto H, 2001, J CLIN ONCOL, V19, P1118, DOI 10.1200/JCO.2001.19.4.1118; Yu Q, 2000, GENE DEV, V14, P163	70	80	82	1	64	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3589	3599		10.1096/fj.13-245613	http://dx.doi.org/10.1096/fj.13-245613			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24784579	Green Submitted			2022-12-28	WOS:000340265400027
J	Narayanan, N; Pushpakumar, SB; Givvimani, S; Kundu, S; Metreveli, N; James, D; Bratcher, AP; Tyagi, SC				Narayanan, Nithya; Pushpakumar, Sathnur Basappa; Givvimani, Srikanth; Kundu, Sourav; Metreveli, Naira; James, Dexter; Bratcher, Adrienne P.; Tyagi, Suresh C.			Epigenetic regulation of aortic remodeling in hyperhomocysteinemia	FASEB JOURNAL			English	Article						DNA methylation; extracellular matrix; 5-aza-2 '-deoxycytidine	PLASMA HOMOCYSTEINE; DNA METHYLATION; BLOOD-PRESSURE; NITRIC-OXIDE; DEPENDENT VASORELAXATION; HYPERTENSION; ATHEROSCLEROSIS; DYSFUNCTION; EXPRESSION; DECREASES	Hyperhomocysteinemia (HHcy) is prevalent in patients with hypertension and is an independent risk factor for aortic pathologies. HHcy is known to cause an imbalance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), leading to the accumulation of collagen in the aorta and resulting in stiffness and development of hypertension. Although the exact mechanism of extracellular matrix (ECM) remodeling is unclear, emerging evidence implicates epigenetic regulation involving DNA methylation. Our purpose was to investigate whether 5-aza-2'-deoxycytidine (Aza), a DNA methyltransferase (DNMT1) inhibitor, reduces high blood pressure (BP) by regulating aortic ECM remodeling in HHcy. Wild-type and cystathionine beta-synthase (CBS)(+/-) HHcy mice were treated with Aza (0.5 mg/kg body weight). In HHcy mice, Aza treatment normalized the plasma homocysteine (Hcy) level and BP. Thoracic and abdominal aorta ultrasound revealed a reduction in the resistive index and wall-to-lumen ratio. Vascular response to phenylephrine, acetylcholine, and sodium nitroprusside improved after Aza in HHcy mice. Histology showed a marked reduction in collagen deposition in the aorta. Aza treatment decreased the expression of DNMT1, MMP9, TIMP1, and S-adenosyl homocysteine hydrolase (SAHH) and upregulated methylene tetrahydrofolate reductase (MTHFR). We conclude that reduction of DNA methylation by Aza in HHcy reduces adverse aortic remodeling to mitigate hypertension.	[Narayanan, Nithya; Pushpakumar, Sathnur Basappa; Givvimani, Srikanth; Kundu, Sourav; Metreveli, Naira; Tyagi, Suresh C.] Univ Louisville, Sch Med, Dept Physiol & Biophys, Louisville, KY 40202 USA; [James, Dexter; Bratcher, Adrienne P.] Univ Louisville, Dept Exercise Physiol, Louisville, KY 40202 USA	University of Louisville; University of Louisville	Tyagi, SC (corresponding author), Univ Louisville, Sch Med, Dept Physiol & Biophys, 500 South Preston St, Louisville, KY 40202 USA.	s0tyag01@louisville.edu	Kundu, Sourav/J-1531-2015	Narayanan, Nithya/0000-0001-9110-0311; KUNDU, SOURAV/0000-0001-9027-5734	U.S. National Institutes of Health [R01HL074185-10, NS-084823]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS084823] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by U.S. National Institutes of Health grants R01HL074185-10 and NS-084823. The authors declare no conflicts of interest.	Amarnath K, 2003, TALANTA, V60, P1229, DOI 10.1016/S0039-9140(03)00232-7; Basu Poulami, 2011, Int J Physiol Pathophysiol Pharmacol, V3, P266; Bednarek N, 2012, PEDIATR RES, V71, P63, DOI 10.1038/pr.2011.3; Bonsch D, 2004, J NEURAL TRANSM, V111, P1611, DOI 10.1007/s00702-004-0232-x; Chen W, 2012, MOL NUTR FOOD RES, V56, P681, DOI 10.1002/mnfr.201100799; Chicoine E, 2002, BIOCHEM BIOPH RES CO, V297, P765, DOI 10.1016/S0006-291X(02)02283-0; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; Frauchiger B, 2001, STROKE, V32, P836, DOI 10.1161/01.STR.32.4.836; Giusti B, 2004, CELL MOL BIOL, V50, P945; Gupta S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027598; Guthikonda Sasidhar, 2006, Curr Atheroscler Rep, V8, P100, DOI 10.1007/s11883-006-0046-4; Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270; Hucks D, 2004, NEPHROL DIAL TRANSPL, V19, P1999, DOI 10.1093/ndt/gfh270; Jain D, 2011, PATHOL RES PRACT, V207, P60, DOI 10.1016/j.prp.2010.05.010; Juonala M, 2006, HYPERTENSION, V48, P424, DOI 10.1161/01.HYP.0000237666.78217.47; Koullias GJ, 2004, ANN THORAC SURG, V78, P2106, DOI 10.1016/j.athoracsur.2004.05.088; Kraus JP, 1999, HUM MUTAT, V13, P362; Krishna SM, 2010, ATHEROSCLEROSIS, V212, P16, DOI 10.1016/j.atherosclerosis.2010.02.008; Krishna SM, 2013, ATHEROSCLEROSIS, V228, P295, DOI 10.1016/j.atherosclerosis.2013.02.019; Li NJ, 2002, AM J PHYSIOL-HEART C, V283, pH1237, DOI 10.1152/ajpheart.00680.2001; Lim U, 2002, AM J EPIDEMIOL, V156, P1105, DOI 10.1093/aje/kwf157; Mareckova Z, 1999, Vnitr Lek, V45, P232; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Moroz P, 2007, ANZ J SURG, V77, P329, DOI 10.1111/j.1445-2197.2007.04052.x; Narayanan Nithya, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P32; Nishimura RA, 2002, CIRCULATION, V106, P770, DOI 10.1161/01.CIR.0000027621.26167.5E; Novaro GM, 2004, HEART, V90, P802, DOI 10.1136/hrt.2003.022889; Ovechkin AV, 2006, AM J PHYSIOL-LUNG C, V291, pL905, DOI 10.1152/ajplung.00543.2005; Powers RW, 2004, HYPERTENSION, V44, P327, DOI 10.1161/01.HYP.0000137414.12119.f6; Puranik R, 2005, HEART RHYTHM, V2, P1277, DOI 10.1016/j.hrthm.2005.09.008; Pushpakumar S, 2013, J HYPERTENS, V31, P2270, DOI 10.1097/HJH.0b013e3283649b33; Rampersaud GC, 2000, AM J CLIN NUTR, V72, P998; Reddy HK, 2006, J CARDIOVASC PHARM T, V11, P65, DOI 10.1177/107424840601100106; Sander M, 1999, HYPERTENSION, V33, P937, DOI 10.1161/01.HYP.33.4.937; Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217; Sen U, 2008, AM J PHYSIOL-ENDOC M, V295, pE1205, DOI 10.1152/ajpendo.90534.2008; Sen U, 2007, AM J PHYSIOL-CELL PH, V293, pC1779, DOI 10.1152/ajpcell.00207.2007; Sen U, 2009, AM J PHYSIOL-RENAL, V297, pF410, DOI 10.1152/ajprenal.00145.2009; Sundstrom J, 2003, HYPERTENSION, V42, P1100, DOI 10.1161/01.HYP.0000101690.58391.13; Takagi H, 2005, MED HYPOTHESES, V64, P1007, DOI 10.1016/j.mehy.2004.10.017; Tang BQ, 2010, NUTRITION, V26, P1170, DOI 10.1016/j.nut.2009.10.006; Topal G, 2004, FREE RADICAL BIO MED, V36, P1532, DOI 10.1016/j.freeradbiomed.2004.03.019; Tribouilloy CM, 2000, CHEST, V118, P1685, DOI 10.1378/chest.118.6.1685; Tsai JC, 2005, ATHEROSCLEROSIS, V182, P121, DOI 10.1016/j.atherosclerosis.2005.01.038; Tyagi Neetu, 2011, Int J Physiol Pathophysiol Pharmacol, V3, P210; TYAGI SC, 1993, CLIN BIOCHEM, V26, P191, DOI 10.1016/0009-9120(93)90025-2; Ungvari Z, 2002, AM J PATHOL, V161, P145, DOI 10.1016/S0002-9440(10)64166-1; Vermeulen EGJ, 2000, LANCET, V355, P517, DOI 10.1016/S0140-6736(99)07391-2; Wang XL, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053938, 10.1371/journal.pone.0050627]; Zaina S, 2005, J NUTR, V135, P5, DOI 10.1093/jn/135.1.5; Zhang JG, 2007, CHINESE MED J-PEKING, V120, P2132, DOI 10.1097/00029330-200712010-00013	51	21	26	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3411	3422		10.1096/fj.14-250183	http://dx.doi.org/10.1096/fj.14-250183			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24739303	Green Published			2022-12-28	WOS:000340265400012
J	Kornilov, P; Peretz, A; Lee, Y; Son, K; Lee, JH; Refaeli, B; Roz, N; Rehavi, M; Choi, S; Attali, B				Kornilov, Polina; Peretz, Asher; Lee, Yoonji; Son, Karam; Lee, Jin Hee; Refaeli, Bosmat; Roz, Netta; Rehavi, Moshe; Choi, Sun; Attali, Bernard			Promiscuous gating modifiers target the voltage sensor of K(v)7.2, TRPV1, and H(v)1 cation channels	FASEB JOURNAL			English	Article						vanilloid; capsaicin; KCNQ	GATED ION CHANNELS; DEPENDENT K+ CHANNEL; POTASSIUM CHANNELS; TARANTULA TOXINS; DOMAIN; DETERMINANTS; SENSITIVITY; ACTIVATION; DISEASE; LIPIDS	Some of the fascinating features of voltage-sensing domains (VSDs) in voltage-gated cation channels (VGCCs) are their modular nature and adaptability. Here we examined the VSD sensitivity of different VGCCs to 2 structurally related nontoxin gating modifiers, NH17 and NH29, which stabilize K(v)7.2 potassium channels in the closed and open states, respectively. The effects of NH17 and NH29 were examined in Chinese hamster ovary cells transfected with transient receptor potential vanilloid 1 (TRPV1) or K(v)7.2 channels, as well as in dorsal root ganglia neurons, using the whole-cell patch-clamp technique. NH17 and NH29 exert opposite effects on TRPV1 channels, operating, respectively, as an activator and a blocker of TRPV1 currents (EC50 and IC50 values ranging from 4 to 40 mu M). Combined mutagenesis, electrophysiology, structural homology modeling, molecular docking, and molecular dynamics simulation indicate that both compounds target the VSDs of TRPV1 channels, which, like vanilloids, are involved in pi-pi stacking, H-bonding, and hydrophobic interactions. Reflecting their promiscuity, the drugs also affect the lone VSD proton channel mV-SOP. Thus, the same gating modifier can promiscuously interact with different VGCCs, and subtle differences at the VSD-ligand interface will dictate whether the gating modifier stabilizes channels in either the closed or the open state.	[Kornilov, Polina; Peretz, Asher; Refaeli, Bosmat; Roz, Netta; Rehavi, Moshe; Attali, Bernard] Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, Tel Aviv, Israel; [Lee, Yoonji; Son, Karam; Lee, Jin Hee; Choi, Sun] Ewha Womans Univ, Coll Pharm, Grad Sch Pharmaceut Sci, Natl Leading Res Lab Mol Modeling & Drug Design, Seoul, South Korea; [Lee, Yoonji; Son, Karam; Lee, Jin Hee; Choi, Sun] Ewha Womans Univ, Global Top Res Program 5, Seoul, South Korea	Tel Aviv University; Sackler Faculty of Medicine; Ewha Womans University; Ewha Womans University	Attali, B (corresponding author), Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Aviv, Israel.	sunchoi@ewha.ac.kr; battali@post.tau.ac.il	Choi, Sun/AAQ-9407-2020; LEE, YOONJI/AAU-7878-2021	LEE, YOONJI/0000-0002-2494-5792; Choi, Sun/0000-0002-7669-7954	Deutsch-Israelische Projektkooperation (DIP) fund (Deutsche Forschungsgemeinschaft) [AT 119/1-1]; Israel Science Foundation (ISF) [488/09]; National Leading Research Laboratory (NLRL) program - Ministry of Education, Science, and Technology (MEST) [2011-0028885]; National Research Foundation (NRF) of Korea	Deutsch-Israelische Projektkooperation (DIP) fund (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); Israel Science Foundation (ISF)(Israel Science Foundation); National Leading Research Laboratory (NLRL) program - Ministry of Education, Science, and Technology (MEST); National Research Foundation (NRF) of Korea(National Research Foundation of Korea)	The authors thank Dr. David Julius (University of California-San Francisco, San Francisco, CA, USA) for rTRPV1 and cTRPV1 cDNA clones, Dr. Yasushi Okamura (Osaka Univer-sity, Osaka, Japan) for the mVSOP clone, and the Korea Institute of Science and Technology Information (KISTI) Supercomputing Center (Yusong, Korea) for providing computing resources. This work was supported by the Deutsch-Israelische Projektkooperation (DIP) fund (Deutsche Forschungsgemeinschaft, AT 119/1-1) and the Israel Science Foundation (ISF; 488/09 to B.A.) and the National Leading Research Laboratory (NLRL) program (2011-0028885 to S.C.) funded by the Ministry of Education, Science, and Technology (MEST) and the National Research Foundation (NRF) of Korea. The authors declare no conflicts of interest.	Alabi AA, 2007, NATURE, V450, P370, DOI 10.1038/nature06266; ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; Ashcroft FM, 2000, ION CHANNELS DIS; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Catterall WA, 2007, TOXICON, V49, P124, DOI 10.1016/j.toxicon.2006.09.022; Chou MZ, 2004, BIOCHEMISTRY-US, V43, P2501, DOI 10.1021/bi035981h; Delmas P, 2005, NAT REV NEUROSCI, V6, P850, DOI 10.1038/nrn1785; Gavva NR, 2004, J BIOL CHEM, V279, P20283, DOI 10.1074/jbc.M312577200; Gouaux E, 2005, SCIENCE, V310, P1461, DOI 10.1126/science.1113666; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Krepkiy D, 2012, J MOL BIOL, V423, P632, DOI 10.1016/j.jmb.2012.07.015; Lee JH, 2011, J COMPUT AID MOL DES, V25, P317, DOI 10.1007/s10822-011-9421-5; Lehmann-Horn F, 1999, PHYSIOL REV, V79, P1317, DOI 10.1152/physrev.1999.79.4.1317; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; Matta JA, 2007, J PHYSIOL-LONDON, V585, P469, DOI 10.1113/jphysiol.2007.144287; Milescu M, 2013, J GEN PHYSIOL, V141, P203, DOI 10.1085/jgp.201210914; Milescu M, 2009, NAT STRUCT MOL BIOL, V16, P1080, DOI 10.1038/nsmb.1679; Murata Y, 2005, NATURE, V435, P1239, DOI 10.1038/nature03650; Nau C., 2008, V182, P85, DOI 10.1007/978-3-540-74806-9_4; Nilius B, 2005, J PHYSIOL-LONDON, V567, P35, DOI 10.1113/jphysiol.2005.088377; Peretz A, 2010, P NATL ACAD SCI USA, V107, P15637, DOI 10.1073/pnas.0911294107; Peretz A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001332; Phillips E, 2004, J BIOL CHEM, V279, P17165, DOI 10.1074/jbc.M313328200; Ramsey IS, 2006, NATURE, V440, P1213, DOI 10.1038/nature04700; Sasaki M, 2006, SCIENCE, V312, P589, DOI 10.1126/science.1122352; Swartz KJ, 2007, TOXICON, V49, P213, DOI 10.1016/j.toxicon.2006.09.024; Swartz KJ, 2008, NATURE, V456, P891, DOI 10.1038/nature07620; Swartz KJ, 2004, NAT REV NEUROSCI, V5, P905, DOI 10.1038/nrn1559; Voets T, 2004, NATURE, V430, P748, DOI 10.1038/nature02732; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Yu Frank H, 2004, Sci STKE, V2004, pre15, DOI 10.1126/stke.2532004re15; Zhang XF, 2011, J GEN PHYSIOL, V138, P341, DOI 10.1085/jgp.201110618	37	10	10	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2591	2602		10.1096/fj.14-250647	http://dx.doi.org/10.1096/fj.14-250647			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24599966				2022-12-28	WOS:000339883600018
J	Lei, Z; Xu, GL; Wang, LQ; Yang, HP; Liu, X; Zhao, J; Zhang, HT				Lei, Zhe; Xu, Guili; Wang, Longqiang; Yang, Haiping; Liu, Xia; Zhao, Jun; Zhang, Hong-Tao			MiR-142-3p represses TGF-beta-induced growth inhibition through repression of TGF beta R1 in non-small cell lung cancer	FASEB JOURNAL			English	Article						NSCLC; miRNAs; cell proliferation; epigenetic mechanism; p-SMAD3	RECEPTOR-TYPE-I; EXPRESSION; MICRORNA; PROLIFERATION; CARCINOMA; GENE; ADENOCARCINOMA; MECHANISMS; PROGNOSIS; SURVIVAL	TGF beta R1 plays an important role in TGF-beta signaling transduction and serves as a tumor suppressor. Our previous studies show that reduced expression of TGF beta R1 is common in non-small cell lung cancer (NSCLC) and TGF beta R1 variants confer risk of NSCLC. However, the epigenetic mechanisms underlying the role of TGF beta R1 in NSCLC carcinogenesis are still elusive. We investigated the function and regulation of TGF-beta signaling-based miRNAs in NSCLC. Computational algorithms predicted that the 3'=untranslated region (3'=UTR) of TGF beta R1 is a target of miR-142-3p. Here a luciferase reporter assay confirmed that miR-142-3p can directly bind to 3'=UTR of TGF beta R1. Overexpression of miR-142-3p in NSCLC A549 cells suppressed expression of TGF beta R1 mRNA and protein, while knockdown of endogenous miR142-3p led to increased expression of TGF beta R1. On TGF-beta 1 stimulation, stable overexpression of miR142-3p attenuated phosphorylation of SMAD3, an indispensable downstream effector in canonical TGF-beta/Smad signaling, via repression of TGF beta R1 in A549 cells. Furthermore, miR-142-3p-mediated down-regulation of TGF beta R1 weakened TGF-beta-induced growth inhibition effect, and this effect was reversed by stable knockdown of endogenous miR-142-3p in A549 cells. In NSCLC tissues, miR-142-3p expression was increased and inversely correlated with TGF beta R1 expression. These data demonstrate that miR-142-3p influences the proliferation of NSCLC cells through repression of TGF beta R1.	[Lei, Zhe; Xu, Guili; Wang, Longqiang; Yang, Haiping; Liu, Xia; Zhang, Hong-Tao] Soochow Univ, Lab Canc Mol Genet, Suzhou 215123, Peoples R China; [Zhao, Jun] Soochow Univ, Affiliated Hosp 1, Coll Med, Suzhou 215123, Peoples R China; [Lei, Zhe; Xu, Guili; Wang, Longqiang; Yang, Haiping; Liu, Xia; Zhao, Jun; Zhang, Hong-Tao] Suzhou Key Lab Mol Canc Genet, Suzhou, Peoples R China	Soochow University - China; Soochow University - China	Zhang, HT (corresponding author), Soochow Univ, Lab Canc Mol Genet, Coll Med, 199 Renai Rd,Sino Singapore Ind Pk, Suzhou 215123, Peoples R China.	htzhang@suda.edu.cn	Lei, Zhe/AGZ-4963-2022; Zhang, Hong-Tao/P-9661-2017	Zhang, Hong-Tao/0000-0003-4182-421X	National Natural Science Foundation of China [81372277, 81171894]; Jiangsu Province Key Provincial Talents Program [RC2011106]; Jiangsu Province Outstanding Medical Academic Leader Program [LJ201138]; 333 Project of the Jiangsu Province government; Graduate Innovation Project of Jiangsu Province [CXZZ13_0830]; Soochow Scholar Project of Soochow University; Suzhou Key Laboratory for Molecular Cancer Genetics [SZS201209]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Province Key Provincial Talents Program; Jiangsu Province Outstanding Medical Academic Leader Program; 333 Project of the Jiangsu Province government; Graduate Innovation Project of Jiangsu Province; Soochow Scholar Project of Soochow University; Suzhou Key Laboratory for Molecular Cancer Genetics	This work was supported in part by grants from the National Natural Science Foundation of China (81372277 and 81171894 to H.-T.Z.), the Jiangsu Province Key Provincial Talents Program (RC2011106 to J.Z.), the Jiangsu Province Outstanding Medical Academic Leader Program (LJ201138), the 333 Project of the Jiangsu Province government (to H.-T.Z.), the Graduate Innovation Project of Jiangsu Province (CXZZ13_0830 to Z.L.), the Soochow Scholar Project of Soochow University (to H.-T.Z.), and the Suzhou Key Laboratory for Molecular Cancer Genetics (SZS201209 to H.-T.Z.).	Boeri M, 2011, P NATL ACAD SCI USA, V108, P3713, DOI 10.1073/pnas.1100048108; Butz H, 2012, TRENDS PHARMACOL SCI, V33, P382, DOI 10.1016/j.tips.2012.04.003; Colasante A, 2003, CYTOKINE, V24, P182, DOI 10.1016/j.cyto.2003.08.008; Dews M, 2010, CANCER RES, V70, P8233, DOI 10.1158/0008-5472.CAN-10-2412; Dou LP, 2013, MOL BIOL REP, V40, P6811, DOI 10.1007/s11033-013-2798-6; Feng J, 2012, AM J CLIN PATHOL, V138, P230, DOI 10.1309/AJCPDHQFNYJZ01YG; Fukai Y, 2003, INT J CANCER, V104, P161, DOI 10.1002/ijc.10929; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Huang SS, 2005, J CELL BIOCHEM, V96, P447, DOI 10.1002/jcb.20558; Kaduthanam S, 2013, LUNG CANCER, V80, P223, DOI 10.1016/j.lungcan.2013.01.013; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kim WS, 1999, ANTICANCER RES, V19, P301; Kitisin Krit, 2007, Sci STKE, V2007, pcm1, DOI 10.1126/stke.3992007cm1; Lei Z, 2009, CANCER RES, V69, P7046, DOI 10.1158/0008-5472.CAN-08-4602; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lin RJ, 2012, J SURG ONCOL, V105, P175, DOI 10.1002/jso.22066; Ling N, 2013, ONCOL REP, V30, P2111, DOI 10.3892/or.2013.2685; MacKenzie TN, 2013, MOL CANCER THER, V12, P1266, DOI 10.1158/1535-7163.MCT-12-1231; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Meulmeester E, 2011, J PATHOL, V223, P205, DOI 10.1002/path.2785; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Park C, 2002, LUNG CANCER-J IASLC, V38, P143, DOI 10.1016/S0169-5002(02)00182-4; Qian S, 2008, BIOCHEM BIOPH RES CO, V377, P668, DOI 10.1016/j.bbrc.2008.10.052; Schneider MR, 2012, BRIT J DERMATOL, V166, P22, DOI 10.1111/j.1365-2133.2011.10568.x; Sessa R, 2013, PULM CIRC, V3, P315, DOI 10.4103/2045-8932.114758; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sun JX, 2011, ONCOL REP, V25, P685, DOI 10.3892/or.2011.1135; Tanaka K, 2013, J BIOL CHEM, V288, P23990, DOI 10.1074/jbc.M113.478891; Tokunaga H, 1999, CLIN CANCER RES, V5, P2520; Varkonyi-Gasic E, 2007, PLANT METHODS, V3, DOI 10.1186/1746-4811-3-12; Wang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073985; Wang Y, 2013, CANCER RES, V73, P4801, DOI 10.1158/0008-5472.CAN-12-3273; Wilson RC, 2013, ANNU REV BIOPHYS, V42, P217, DOI 10.1146/annurev-biophys-083012-130404; Zhang HT, 2003, LUNG CANCER-J IASLC, V40, P281, DOI 10.1016/S0169-5002(03)00121-1; Zhao J, 2008, J CANCER RES CLIN, V134, P919, DOI 10.1007/s00432-008-0392-4	37	82	83	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2696	2704		10.1096/fj.13-247288	http://dx.doi.org/10.1096/fj.13-247288			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24558198				2022-12-28	WOS:000339883600027
J	Smith, HK; Gil, CD; Oliani, SM; Gavins, FNE				Smith, Helen K.; Gil, Cristiane Damas; Oliani, Sonia M.; Gavins, Felicity N. E.			Targeting formyl peptide receptor 2 reduces leukocyte-endothelial interactions in a murine model of stroke	FASEB JOURNAL			English	Article						ischemia /reperfusion; inflammation; FPR2/ALX; Annexin A1	BLOOD-BRAIN-BARRIER; ADHESION MOLECULE-1 EXPRESSION; VIVO NEUTROPHIL ACTIVATION; CEREBRAL-ARTERY OCCLUSION; LIPOXIN A(4); IN-VIVO; MICROGLIAL ACTIVATION; MOUSE MODEL; INFLAMMATORY CYTOKINES; ISCHEMIA-REPERFUSION	Ischemia/reperfusion (I/R) injury following stroke can worsen patient outcome through excess inflammation. This study investigated the pharmacologic potential of targeting an endogenous anti-inflammatory circuit via formyl peptide receptor (FPR) 2/lipoxin receptor (ALX) (Fpr2/3 in mouse) in global cerebral I/R. Mice (C57BL/6 and Fpr2/3(-/-)) were subjected to bilateral common carotid artery occlusion, followed by reperfusion and treatment with FPR agonists: AnxA1(Ac2-26) [Annexin A1 mimetic peptide (Ac-AMVSEFLKQAWFIENEEQEYVQTVK), 2.5 mu/kg] and 15-epimer-lipoxin A4 (15-epi-LXA(4); FPR2/ALX specific, 12.5 and 100 ng/kg). Leukocyte-endothelial (L-E) interactions in the cerebral microvasculature were then quantified in vivo using intravital fluorescence microscopy. 15-epi-LXA(4) administration at the start of reperfusion reduced L-E interactions after 40 min (which was sustained at 2 h with high-dose 15-epi-LXA(4)) to levels seen in sham-operated animals. AnxA1(Ac2-26) treatment decreased leukocyte adhesion at 40 min and all L-E interactions at 2 h (up to 95%). Combined treatment with AnxA1(Ac2-26) plus FPR antagonists t-Boc-FLFLF (250 ng/kg) or WRW4 (FPR2/ALX selective, 1.4 mu/kg) abrogated the effects of AnxA1(Ac2-26) fully at 40 min. Antagonists were less effective at 2 h, which we demonstrate is likely because of their impact on early L-E interactions. Our findings indicate that FPR2/ALX activity elicits considerable control over vascular inflammatory responses during cerebral I/R and, therefore, provide evidence that targeting FPR2/ALX may be beneficial for patients who suffered from stroke.	[Smith, Helen K.; Gavins, Felicity N. E.] Louisiana State Univ, Hlth Sci Ctr, Mol & Cellular Physiol Dept, Shreveport, LA 71105 USA; [Smith, Helen K.; Gavins, Felicity N. E.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Brain Sci, London W12 0NN, England; [Gil, Cristiane Damas] Univ Fed Sao Paulo, Dept Morphol & Genet, Sao Paulo, Brazil; [Oliani, Sonia M.] Univ Fed Sao Paulo, Dept Biol, Sao Paulo, Brazil	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Imperial College London; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	Gavins, FNE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Brain Sci, Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	f.gavins@imperial.ac.uk	Damas Gil, Cristiane/E-1187-2012; DAMAS GIL, CRISTIANE/GQA-9650-2022; Oliani, Sonia Maria/E-3476-2012; Gavins, Felicity N. E./AAU-6010-2020	Damas Gil, Cristiane/0000-0001-6979-4126; Oliani, Sonia Maria/0000-0003-0918-2130; Gavins, Felicity N. E./0000-0001-7008-5423	Higher Education Funding Council for England; MRC [MC_PC_12015] Funding Source: UKRI	Higher Education Funding Council for England(UK Research & Innovation (UKRI)Higher Education Funding Council for England (HEFCE)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by Higher Education Funding Council for England.	Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Antonenko D, 2013, AM J SURG, V206, P845; Bena S., 2012, E J BRIT SOC PHARM; Biscaro B, 2012, NEURODEGENER DIS, V9, P187, DOI 10.1159/000330363; Campagne MV, 1999, J CEREBR BLOOD F MET, V19, P1354, DOI 10.1097/00004647-199912000-00009; Cooray SN, 2013, P NATL ACAD SCI USA, V110, P18232, DOI 10.1073/pnas.1308253110; Dalli J, 2012, BLOOD, V120, pE60, DOI 10.1182/blood-2012-04-423525; de Coupade C, 2003, BRIT J PHARMACOL, V140, P133, DOI 10.1038/sj.bjp.0705413; Devosse T, 2009, J IMMUNOL, V182, P4974, DOI 10.4049/jimmunol.0803128; Dufton N, 2010, J IMMUNOL, V184, P2611, DOI 10.4049/jimmunol.0903526; El Kebir D, 2009, AM J RESP CRIT CARE, V180, P311, DOI 10.1164/rccm.200810-1601OC; Fierro IM, 2003, J IMMUNOL, V170, P2688, DOI 10.4049/jimmunol.170.5.2688; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; Gavins FNE, 2007, FASEB J, V21, P1751, DOI 10.1096/fj.06-7842com; Gavins FNE, 2012, FASEB J, V26, P4977, DOI 10.1096/fj.12-205971; Gavins FNE, 2004, FASEB J, V18, P100, DOI 10.1096/fj.04-2178fje; Guilford WJ, 2004, J MED CHEM, V47, P2157, DOI 10.1021/jm030569l; Hoyte LC, 2010, J CEREBR BLOOD F MET, V30, P1178, DOI 10.1038/jcbfm.2009.287; Ishikawa M, 2003, STROKE, V34, P1777, DOI 10.1161/01.STR.0000074921.17767.F2; Ishikawa M, 2007, AM J PHYSIOL-HEART C, V292, pH2306, DOI 10.1152/ajpheart.00601.2006; Kitagawa K, 1998, J CEREBR BLOOD F MET, V18, P570, DOI 10.1097/00004647-199805000-00012; Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Levy BD, 2007, FASEB J, V21, P3877, DOI 10.1096/fj.07-8653com; Liesz A, 2009, STROKE, V40, P2849, DOI 10.1161/STROKEAHA.109.549618; Maderna P, 2010, FASEB J, V24, P4240, DOI 10.1096/fj.10-159913; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; Murakami K, 1998, BRAIN RES, V780, P304, DOI 10.1016/S0006-8993(97)01217-1; Murray PJ, 2005, P NATL ACAD SCI USA, V102, P8686, DOI 10.1073/pnas.0500419102; Norris PC, 2014, P NATL ACAD SCI USA, V111, P12746, DOI 10.1073/pnas.1404372111; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Patel FJ, 2014, CYTOKINE, V69, P234, DOI 10.1016/j.cyto.2014.06.011; Prestigiacomo CJ, 1999, STROKE, V30, P1110, DOI 10.1161/01.STR.30.5.1110; Rezkalla SH, 2002, CIRCULATION, V105, P656, DOI 10.1161/hc0502.102867; Riazi K, 2008, P NATL ACAD SCI USA, V105, P17151, DOI 10.1073/pnas.0806682105; Shouval DS, 2014, IMMUNITY, V40, P706, DOI 10.1016/j.immuni.2014.03.011; Strausbaugh HJ, 2001, J IMMUNOL, V166, P6294, DOI 10.4049/jimmunol.166.10.6294; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; TODD NV, 1986, STROKE, V17, P460, DOI 10.1161/01.STR.17.3.460; Wellons JC, 2000, BRAIN RES, V868, P14, DOI 10.1016/S0006-8993(00)02216-2; Yan BY, 2014, BRAIN RES, V1573, P63, DOI 10.1016/j.brainres.2014.05.023; Yang GM, 1997, BRAIN RES, V752, P209, DOI 10.1016/S0006-8993(96)01453-9; Ye XH, 2010, BRAIN RES, V1323, P174, DOI 10.1016/j.brainres.2010.01.079; Yenari MA, 2006, STROKE, V37, P1087, DOI 10.1161/01.STR.0000206281.77178.ac; Yenari MA, 2010, NEUROTHERAPEUTICS, V7, P378, DOI 10.1016/j.nurt.2010.07.005; Yoshioka H, 2011, J NEUROTRAUM, V28, P649, DOI 10.1089/neu.2010.1662; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhang LL, 2014, NEUROPSYCH DIS TREAT, V10, P1103, DOI 10.2147/NDT.S64236; ZHANG RL, 1995, BRAIN RES, V682, P182, DOI 10.1016/0006-8993(95)00346-R	50	51	51	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2161	2171		10.1096/fj.14-263160	http://dx.doi.org/10.1096/fj.14-263160			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25690650				2022-12-28	WOS:000354114600046
J	Cuesta, M; Cermakian, N; Boivin, DB				Cuesta, Marc; Cermakian, Nicolas; Boivin, Diane B.			Glucocorticoids entrain molecular clock components in human peripheral cells	FASEB JOURNAL			English	Article						circadian; clock genes; melatonin; shift work; cortisol	BLOOD MONONUCLEAR-CELLS; TRANSGENIC MOUSE MODEL; NIGHT-SHIFT WORK; GENE-EXPRESSION; CIRCADIAN-RHYTHMS; HUNTINGTONS-DISEASE; MESSENGER-RNA; PHASE; OSCILLATORS; LIGHT	In humans, shift work induces a desynchronization between the circadian system and the outside world, which contributes to shift work-associated medical disorders. Using a simulated night shift experiment, we previously showed that 3 d of bright light at night fully synchronize the central clock to the inverted sleep schedule, whereas the peripheral clocks located in peripheral blood mononuclear cells (PBMCs) took longer to reset. This underlines the need for testing the effects of synchronizers on both the central and peripheral clocks. Glucocorticoids display circadian rhythms controlled by the central clock and are thought to act as synchronizers of rodent peripheral clocks. In the present study, we tested whether the human central and peripheral clocks were sensitive to exogenous glucocorticoids (Cortef) administered in the late afternoon. We showed that 20 mg Cortef taken orally acutely increased PER1 expression in PBMC peripheral clocks. After 6 d of Cortef administration, the phases of central markers were not affected, whereas those of PER2-3 and BMAL1 expression in PBMCs were shifted by similar to 9.5-11.5 h. These results demonstrate, for the first time, that human peripheral clocks are entrained by glucocorticoids. Importantly, they suggest innovative interventions for shift workers and jet-lag travelers, combining synchronizing agents for the central and peripheral clocks.	[Cuesta, Marc; Boivin, Diane B.] McGill Univ, Ctr Study & Treatment Circadian Rhythms, Montreal, PQ H4H 1R3, Canada; [Cuesta, Marc; Cermakian, Nicolas] McGill Univ, Lab Mol Chronobiol, Montreal, PQ H4H 1R3, Canada; [Cuesta, Marc; Cermakian, Nicolas; Boivin, Diane B.] McGill Univ, Dept Psychiat, Douglas Mental Hlth Univ Inst, Montreal, PQ H4H 1R3, Canada	McGill University; McGill University; McGill University	Boivin, DB (corresponding author), McGill Univ, Dept Psychiat, Douglas Mental Hlth Univ Inst, Ctr Study & Treatment Circadian Rhythms, 6875 LaSalle Blvd, Montreal, PQ H4H 1R3, Canada.	diane.boivin@douglas.mcgill.ca		Cermakian, Nicolas/0000-0003-4517-9131	Canadian Institutes of Health Research Grant [MOP-66979]; Fonds de Recherche du Quebec-Sante	Canadian Institutes of Health Research Grant(Canadian Institutes of Health Research (CIHR)); Fonds de Recherche du Quebec-Sante(Fonds de la Recherche en Sante du Quebec)	The authors thank Drs. P. Boudreau and A. Shechter for help during blood drawing sessions, all of the research assistants who helped during the experiment, and all of the subjects for participation. The authors also thank Drs. S. Rheaume, A. Solignac, J. Roy, and A. Azzoug for medical supervision, Dr. D. Walker for radioimmunoassays, Dr. P. Boudreau for statistical advice, and W. H. Yeh and K. Sanders for technical help. This work was supported by Canadian Institutes of Health Research Grant MOP-66979 (to D.B.B. and N.C.), as well as a postdoctoral fellowship (to M.C.) and a salary award (to N.C.) from the Fonds de Recherche du Quebec-Sante. The authors declare no conflicts of interest.	Archer SN, 2008, SLEEP, V31, P608, DOI 10.1093/sleep/31.5.608; Asher G, 2010, CELL, V142, P943, DOI 10.1016/j.cell.2010.08.016; Balsalobre A, 2000, CURR BIOL, V10, P1291, DOI 10.1016/S0960-9822(00)00758-2; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 2002, CELL TISSUE RES, V309, P193, DOI 10.1007/s00441-002-0585-0; Boivin DB, 2003, BLOOD, V102, P4143, DOI 10.1182/blood-2003-03-0779; Boivin DB, 2002, J BIOL RHYTHM, V17, P556, DOI 10.1177/0748730402238238; Boudreau P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070813; Boudreau P, 2012, CHRONOBIOL INT, V29, P757, DOI 10.3109/07420528.2012.674592; Buhr Ethan D, 2013, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-642-25950-0_1; Cermakian N, 2009, OBES REV, V10, P25, DOI 10.1111/j.1467-789X.2009.00660.x; Cermakian N, 2011, J BIOL RHYTHM, V26, P160, DOI 10.1177/0748730410395732; Cretenet G, 2010, CELL METAB, V11, P47, DOI 10.1016/j.cmet.2009.11.002; Cuesta M, 2014, NEUROBIOL DIS, V63, P85, DOI 10.1016/j.nbd.2013.11.008; Cuesta M, 2013, GENETIC BASIS OF SLEEP AND SLEEP DISORDERS, P351; Cuesta M, 2012, NEUROBIOL DIS, V45, P145, DOI 10.1016/j.nbd.2011.07.016; Cuesta M, 2009, HORM BEHAV, V55, P338, DOI 10.1016/j.yhbeh.2008.10.015; Fukuoka Y, 2005, J BIOL RHYTHM, V20, P550, DOI 10.1177/0748730405279866; James FO, 2004, CHRONOBIOL INT, V21, P961, DOI 10.1081/CBI-200035944; James FO, 2007, CHRONOBIOL INT, V24, P1009, DOI 10.1080/07420520701800736; James FO, 2007, SLEEP, V30, P1427, DOI 10.1093/sleep/30.11.1427; JEWETT ME, 1994, J BIOL RHYTHM, V9, P295, DOI 10.1177/074873049400900310; JEWETT ME, 1991, NATURE, V350, P59, DOI 10.1038/350059a0; Kusanagi H, 2008, NEUROSCI RES, V61, P136, DOI 10.1016/j.neures.2008.01.012; Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128; Lowrey PL, 2011, ADV GENET, V74, P175, DOI 10.1016/B978-0-12-387690-4.00006-4; MEIKLE AW, 1977, AM J MED, V63, P200, DOI 10.1016/0002-9343(77)90233-9; Menet JS, 2011, CURR OPIN NEUROBIOL, V21, P849, DOI 10.1016/j.conb.2011.06.008; Ohmori K, 2013, VET J, V196, P402, DOI 10.1016/j.tvjl.2012.10.010; Refinetti R., 2006, CIRCADIAN PHYSL, V2nd; ROSENFELD P, 1993, CELL MOL NEUROBIOL, V13, P295, DOI 10.1007/BF00711575; Saini C, 2013, GENE DEV, V27, P1526, DOI 10.1101/gad.221374.113; Saini C, 2012, GENE DEV, V26, P567, DOI 10.1101/gad.183251.111; Segall LA, 2010, J MOL NEUROSCI, V42, P168, DOI 10.1007/s12031-010-9341-1; Shechter A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051929; Son GH, 2011, FRONT NEUROENDOCRIN, V32, P451, DOI 10.1016/j.yfrne.2011.07.003; Son GH, 2008, P NATL ACAD SCI USA, V105, P20970, DOI 10.1073/pnas.0806962106; Stratmann M, 2006, J BIOL RHYTHM, V21, P494, DOI 10.1177/0748730406293889; Teboul M, 2005, J MOL MED, V83, P693, DOI 10.1007/s00109-005-0697-6; van der Veen DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047692; Yamaguchi Y, 2013, SCIENCE, V342, P85, DOI 10.1126/science.1238599; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682	42	78	80	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1360	1370		10.1096/fj.14-265686	http://dx.doi.org/10.1096/fj.14-265686			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25500935				2022-12-28	WOS:000354115000022
J	Elbaz, I; Lerer-Goldshtein, T; Okamoto, H; Appelbaum, L				Elbaz, Idan; Lerer-Goldshtein, Tali; Okamoto, Hitoshi; Appelbaum, Lior			Reduced synaptic density and deficient locomotor response in neuronal activity-regulated pentraxin 2a mutant zebrafish	FASEB JOURNAL			English	Article						NARP; NPTX2; TALEN; synaptophysin; mechanosensory	DEVELOPING VISUAL-SYSTEM; LATERAL-LINE SYSTEM; BINDING PROTEIN 49; PHYLOGENETIC ANALYSIS; EXCITATORY SYNAPSES; HYPOCRETIN NEURONS; PREFRONTAL CORTEX; NARP EXPRESSION; AMPA RECEPTORS; PLASTICITY	Neuronal-activity-regulated pentraxin (NARP/NPTX2/NP2) is a secreted synaptic protein that regulates the trafficking of glutamate receptors and mediates learning, memory, and drug addiction. The role of NPTX2 in regulating structural synaptic plasticity and behavior in a developing vertebrate is indefinite. We characterized the expression of nptx2a in larvae and adult zebrafish and established a transcription activator-like effector nuclease (TALEN)-mediated nptx2a mutant (nptx2a(-/-)) to study the role of Nptx2a in regulating structural synaptic plasticity and behavior. Similar to mammals, the zebrafish nptx2a was expressed in excitatory neurons in the brain and spinal cord. Its expression was induced in response to a mechanosensory stimulus but did not change during day and night. Behavioral assays showed that loss of Nptx2a results in reduced locomotor response to light-to-dark transition states and to a sound stimulus. Live imaging of synapses using the transgenic nptx2a:GAL4VP16 zebrafish and a fluorescent presynaptic synaptophysin (SYP) marker revealed reduced synaptic density in the axons of the spinal motor neurons and the anterodorsal lateral-line ganglion (gAD), which regulate locomotor activity and locomotor response to mechanosensory stimuli, respectively. These results suggest that Nptx2a affects locomotor response to external stimuli by mediating structural synaptic plasticity in excitatory neuronal circuits.	[Elbaz, Idan; Lerer-Goldshtein, Tali; Appelbaum, Lior] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-5290002 Ramat Gan, Israel; [Elbaz, Idan; Lerer-Goldshtein, Tali; Appelbaum, Lior] Bar Ilan Univ, Leslie & Susan Gonda Multidisciplinary Brain Res, IL-5290002 Ramat Gan, Israel; [Okamoto, Hitoshi] RIKEN, Brain Sci Inst, Lab Dev Gene Regulat, Wako, Saitama, Japan	Bar Ilan University; Bar Ilan University; RIKEN	Appelbaum, L (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-5290002 Ramat Gan, Israel.	lior.appelbaum@biu.ac.il	Okamoto, Hitoshi/P-9767-2015	Okamoto, Hitoshi/0000-0002-7512-8549	Israel Science Foundation [366/11]; Brain and Behavior Research Foundation (NARSAD [18751]; Marie Curie International Reintegration Grant (IRG) [274333]	Israel Science Foundation(Israel Science Foundation); Brain and Behavior Research Foundation (NARSAD(NARSAD); Marie Curie International Reintegration Grant (IRG)(European Commission)	The authors thank Dr. Adi Tovin for technical assistance and Dr. Rachel Levy-Drummer, Head of the Biostatistics Unit, Faculty of Life Sciences, Bar-Ilan University. They also thank all members of the Appelbaum lab, and special thanks to Dr. Sally Shpungin, Prof. Zvy Dubinsky, and Mr. Tal Nathansohn for technical assistance. The authors thank Ms. Sharon Victor and Ms. Talia Levitas-Djerbi for assistance in editing the manuscript. This work was supported by the Israel Science Foundation (Grant 366/11), by the Brain and Behavior Research Foundation (NARSAD, Grant 18751), and by a Marie Curie International Reintegration Grant (IRG, Grant 274333). The authors declare no conflict of interest that would prejudice the impartiality of this work.	Agetsuma M, 2010, NAT NEUROSCI, V13, P1354, DOI 10.1038/nn.2654; Appelbaum L, 2010, NEURON, V68, P87, DOI 10.1016/j.neuron.2010.09.006; Baraban SC, 2005, NEUROSCIENCE, V131, P759, DOI 10.1016/j.neuroscience.2004.11.031; Bjartmar L, 2006, J NEUROSCI, V26, P6269, DOI 10.1523/jneurosci.4212-05.2006; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Catchen JM, 2009, GENOME RES, V19, P1497, DOI 10.1101/gr.090480.108; Chang MC, 2010, NAT NEUROSCI, V13, P1090, DOI 10.1038/nn.2621; Cho RW, 2008, NEURON, V57, P858, DOI 10.1016/j.neuron.2008.01.010; Cirelli C, 2004, NEURON, V41, P35, DOI 10.1016/S0896-6273(03)00814-6; Cirelli C, 2000, SLEEP, V23, P453; Crombag HS, 2009, NEUROPSYCHOPHARMACOL, V34, P857, DOI 10.1038/npp.2008.80; Dereeper A, 2008, NUCLEIC ACIDS RES, V36, pW465, DOI 10.1093/nar/gkn180; Dereeper A, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-8; Dodds DC, 1997, J BIOL CHEM, V272, P21488, DOI 10.1074/jbc.272.34.21488; Elbaz I, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00009; Elbaz I, 2012, J NEUROSCI, V32, P12961, DOI 10.1523/JNEUROSCI.1284-12.2012; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Gerrow Kimberly, 2007, Sci STKE, V2007, ppe56, DOI 10.1126/stke.4082007pe56; Gu Y, 2013, NEURON, V79, P335, DOI 10.1016/j.neuron.2013.05.016; HSU YC, 1995, GENOMICS, V28, P220, DOI 10.1006/geno.1995.1134; Huang P, 2011, NAT BIOTECHNOL, V29, P699, DOI 10.1038/nbt.1939; Johnson AW, 2007, J NEUROSCI, V27, P13430, DOI 10.1523/JNEUROSCI.4320-07.2007; Johnson A, 2010, LEARN MEMORY, V17, P620, DOI 10.1101/lm.1937210; Kerstetter AE, 2004, DEV DYNAM, V230, P137, DOI 10.1002/dvdy.20021; Kim SJ, 2007, NEURON, V56, P582, DOI 10.1016/j.neuron.2007.10.030; Kirkpatrick LL, 2000, J BIOL CHEM, V275, P17786, DOI 10.1074/jbc.M002254200; Koch SM, 2010, J NEUROSCI, V30, P5404, DOI 10.1523/JNEUROSCI.4893-09.2010; Lu W, 2002, EUR J NEUROSCI, V15, P2027, DOI 10.1046/j.1460-9568.2002.02036.x; Meijering E, 2004, CYTOM PART A, V58A, P167, DOI 10.1002/cyto.a.20022; Meyer D, 2014, NEURON, V82, P430, DOI 10.1016/j.neuron.2014.02.031; Meyer MP, 2006, J NEUROSCI, V26, P3604, DOI 10.1523/JNEUROSCI.0223-06.2006; O'Brien R, 2002, J NEUROSCI, V22, P4487, DOI 10.1523/JNEUROSCI.22-11-04487.2002; O'Brien RJ, 1999, NEURON, V23, P309, DOI 10.1016/S0896-6273(00)80782-5; Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701; Raible DW, 2000, J COMP NEUROL, V421, P189, DOI 10.1002/(SICI)1096-9861(20000529)421:2<189::AID-CNE5>3.0.CO;2-K; Reti IM, 2008, NEUROSCIENCE, V151, P352, DOI 10.1016/j.neuroscience.2007.10.040; Reti IM, 2002, J NEUROCHEM, V82, P1561, DOI 10.1046/j.1471-4159.2002.01141.x; Reti IM, 2002, J NEUROCHEM, V82, P935, DOI 10.1046/j.1471-4159.2002.01051.x; Reti IM, 2011, ILAR J, V52, P321, DOI 10.1093/ilar.52.3.321; Sander JD, 2011, NAT BIOTECHNOL, V29, P697, DOI 10.1038/nbt.1934; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; Sia GM, 2007, NEURON, V55, P87, DOI 10.1016/j.neuron.2007.06.020; Simmich J, 2012, PROG BRAIN RES, V196, P145, DOI 10.1016/B978-0-444-59426-6.00008-2; Thompson CL, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00165; Tsui CC, 1996, J NEUROSCI, V16, P2463; van Alphen B, 2013, J NEUROSCI, V33, P6917, DOI 10.1523/JNEUROSCI.0061-13.2013; Vatine GD, 2013, J BIOL CHEM, V288, P169, DOI 10.1074/jbc.M112.413831; Wyart C, 2011, REV NEUROSCIENCE, V22, P121, DOI 10.1515/RNS.2011.013; Xu DS, 2003, NEURON, V39, P513, DOI 10.1016/S0896-6273(03)00463-X; Zada D, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004615	50	13	13	4	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1220	1234		10.1096/fj.14-258350	http://dx.doi.org/10.1096/fj.14-258350			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25466900				2022-12-28	WOS:000354115000011
J	McGrail, DJ; Mezencev, R; Kieu, QMN; McDonald, JF; Dawson, MR				McGrail, Daniel J.; Mezencev, Roman; Kieu, Quang Minh N.; McDonald, John F.; Dawson, Michelle R.			SNAIL-induced epithelial-to-mesenchymal transition produces concerted biophysical changes from altered cytoskeletal gene expression	FASEB JOURNAL			English	Article						physical oncology; metastasis; motility; cell mechanics	DOWN-REGULATION; CELL-MIGRATION; SOLID STRESS; CANCER; STIFFNESS; DEFORMATION; PROGRESSION; MICROSCOPY; GELSOLIN; FORCE	A growing body of evidence suggests that the developmental process of epithelial-to-mesenchymal transition (EMT) is co-opted by cancer cells to metasta-size to distant sites. This transition is associated with morphologic elongation and loss of cell-cell adhesions, though little is known about how it alters cell biophysical properties critical for migration. Here, we use multiple-particle tracking (MPT) microrheology and traction force cytometry to probe how genetic induction of EMT in epithelial MCF7 breast cancer cells changes their intracellular stiffness and extracellular force exertion, respectively, relative to an empty vector control. This analysis demonstrated that EMT alone was sufficient to produce dramatic cytoskeletal softening coupled with increases in cell-exerted traction forces. Microarray analysis revealed that these changes corresponded with down-regulation of genes associated with actin cross-linking and up-regulation of genes associated with actomyosin contraction. Finally, we show that this loss of structural integrity to expedite migration could inhibit mesenchymal cell proliferation in a secondary tumor as it accumulates solid stress. This work demonstrates that not only does EMT enable escape from the primary tumor through loss of cell adhesions but it also induces a concerted series of biophysical changes enabling enhanced migration of cancer cells after detachment from the primary tumor.	[McGrail, Daniel J.; Kieu, Quang Minh N.; Dawson, Michelle R.] Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA; [Mezencev, Roman; McDonald, John F.] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; [Dawson, Michelle R.] Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	Dawson, MR (corresponding author), Georgia Inst Technol, Sch Chem & Biomol Engn, 311 Ferst Dr NW, Atlanta, GA 30332 USA.	mdawson@gatech.edu	Dawson, Michelle R/Q-7217-2019; Jain, Rakesh K/I-1384-2017; Mezencev, Roman/O-8489-2019; Mezencev, Roman/A-8573-2009; McGrail, Daniel/F-3967-2014	Dawson, Michelle R/0000-0002-2122-4711; Jain, Rakesh K/0000-0001-7571-3548; Mezencev, Roman/0000-0003-4361-7628; McGrail, Daniel/0000-0002-6669-6069	U.S. National Science Foundation (NSF) [1032527]; Georgia Tech and Emory Center for Regenerative Medicine (NSF) [1411304]; Ovarian Cancer Institute, Atlanta, GA, USA; Georgia Tech's Presidential Undergraduate Research Award; NSF [DGE-0965945]	U.S. National Science Foundation (NSF)(National Science Foundation (NSF)); Georgia Tech and Emory Center for Regenerative Medicine (NSF); Ovarian Cancer Institute, Atlanta, GA, USA; Georgia Tech's Presidential Undergraduate Research Award; NSF(National Science Foundation (NSF))	This work was funded by the U.S. National Science Foundation (NSF; 1032527), Georgia Tech and Emory Center for Regenerative Medicine (NSF; 1411304), and the Ovarian Cancer Institute, Atlanta, GA, USA. Additional funding was provided by Georgia Tech's Presidential Undergraduate Research Award (Q.K.), and by NSF Grant DGE-0965945 (D.M.). The authors declare no conflicts of interest.	Asch HL, 1996, CANCER RES, V56, P4841; Beach JR, 2011, P NATL ACAD SCI USA, V108, P17991, DOI 10.1073/pnas.1106499108; Chen J, 2011, GYNECOL ONCOL, V121, P200, DOI 10.1016/j.ygyno.2010.12.339; Crocker JC, 1996, J COLLOID INTERF SCI, V179, P298, DOI 10.1006/jcis.1996.0217; Dahl KN, 2005, BIOPHYS J, V89, P2855, DOI 10.1529/biophysj.105.062554; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; Guck J, 2005, BIOPHYS J, V88, P3689, DOI 10.1529/biophysj.104.045476; Guo M, 2013, BIOPHYS J, V105, P1562, DOI 10.1016/j.bpj.2013.08.037; Harada T, 2014, J CELL BIOL, V204, P669, DOI 10.1083/jcb.201308029; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Khatau SB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036689; Kraning-Rush CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032572; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee MH, 2012, BIOPHYS J, V102, P2731, DOI 10.1016/j.bpj.2012.05.005; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mason TG, 2000, RHEOL ACTA, V39, P371, DOI 10.1007/s003970000094; McGrail DJ, 2014, J CELL SCI, V127, P2621, DOI 10.1242/jcs.144378; McGrail DJ, 2013, EXP CELL RES, V319, P684, DOI 10.1016/j.yexcr.2012.11.017; McGrail DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033248; Mendez MG, 2014, BIOPHYS J, V107, P314, DOI 10.1016/j.bpj.2014.04.050; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Pajerowski JD, 2007, P NATL ACAD SCI USA, V104, P15619, DOI 10.1073/pnas.0702576104; Roose T, 2003, MICROVASC RES, V66, P204, DOI 10.1016/S0026-2862(03)00057-8; Sabass B, 2008, BIOPHYS J, V94, P207, DOI 10.1529/biophysj.107.113670; Seltmann K, 2013, P NATL ACAD SCI USA, V110, P18507, DOI 10.1073/pnas.1310493110; Shi W, 2010, PHARMACOGENOMICS J, V10, P310, DOI 10.1038/tpj.2010.35; Sossey-Alaoui K, 2007, AM J PATHOL, V170, P2112, DOI 10.2353/ajpath.2007.060975; Spagnol ST, 2014, INTEGR BIOL-UK, V6, P523, DOI 10.1039/c3ib40226f; Stylianopoulos T, 2013, CANCER RES, V73, P3833, DOI 10.1158/0008-5472.CAN-12-4521; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swaminathan V, 2011, CANCER RES, V71, P5075, DOI 10.1158/0008-5472.CAN-11-0247; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Taube JH, 2010, P NATL ACAD SCI USA, V107, P19132, DOI 10.1073/pnas.1015095107; The Physical Sciences-Oncology Centers Network, 2013, SCI REPORTS, V3; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ulrich TA, 2009, CANCER RES, V69, P4167, DOI 10.1158/0008-5472.CAN-08-4859; Winston JS, 2001, BREAST CANCER RES TR, V65, P11, DOI 10.1023/A:1006446108411; Wirtz D, 2011, NAT REV CANCER, V11, P512, DOI 10.1038/nrc3080; Wirtz D, 2009, ANNU REV BIOPHYS, V38, P301, DOI 10.1146/annurev.biophys.050708.133724; Wolf K, 2013, J CELL BIOL, V201, P1069, DOI 10.1083/jcb.201210152; Wu PH, 2012, NAT PROTOC, V7, P155, DOI 10.1038/nprot.2011.436; Xu WW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046609; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	49	41	44	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1280	1289		10.1096/fj.14-257345	http://dx.doi.org/10.1096/fj.14-257345			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25491311				2022-12-28	WOS:000354115000016
J	Park, H; Han, SS; Sako, Y; Pack, CG				Park, Hweon; Han, Sung-Sik; Sako, Yasushi; Pack, Chan-Gi			Dynamic and unique nucleolar microenvironment revealed by fluorescence correlation spectroscopy	FASEB JOURNAL			English	Article						nucleolar organization; diffusion coefficient; crowding effect; ATP depletion; actinomycin D	LIVING CELL-NUCLEI; CHROMATIN; MOBILITY; DIFFUSION; PROTEINS; LAMIN; ORGANIZATION; RNA; SUBCOMPARTMENTS; ACCESSIBILITY	Organization and functions of the nucleolus is maintained by mobilities and interactions of nucleolar factors. Because the nucleolus is a densely packed structure, molecular crowding effects determined by the molecular concentrations and mobilities in the nucleolus should also be important for regulating nucleolar organization and functions. However, such molecular property of nucleolar organization is not fully understood. To understand the biophysical property of nucleolar organization, the diffusional behaviors of inert green fluorescent protein (GFP) oligomers with or without nuclear localization signals (NLSs) were analyzed under various conditions by fluorescence correlation spectroscopy. Our result demonstrates that the mobility of GFPs inside the nucleolus and the nucleoplasm can be represented by single free diffusion under normal conditions, even though the mobility in the nucleolus is considerably slower than that in the chromatin region. Moreover, the free diffusion of GFPs is found to be significantly size-and NLS-dependent only in the nucleolus. Interestingly, themobility in the nucleolus is highly sensitive to ATP depletion, as well as actinomycin D (ActD) treatment. In contrast, the ultra-structure of the nucleolus was not significantly changed by ATP depletion but was changed by ActD treatment. These results suggest that the nucleolus behaves similarly to an open aqueous-phase medium with an increased molecular crowding effect that depends on both energy and transcription.	[Park, Hweon; Han, Sung-Sik] Korea Univ, Dept Life Sci, Seoul 136701, South Korea; [Sako, Yasushi] RIKEN, Cellular Informat Lab, Wako, Saitama, Japan; [Pack, Chan-Gi] Univ Ulsan, Coll Med, Asan Med Ctr, Asan Inst Life Sci, Seoul, South Korea	Korea University; RIKEN; University of Ulsan; Asan Medical Center	Han, SS (corresponding author), Korea Univ, Dept Life Sci, 145 Anam Ro, Seoul 136701, South Korea.	shan@korea.ac.kr; changipack@amc.seoul.kr	Sako, Yasushi/B-3253-2015	Sako, Yasushi/0000-0002-5707-5455	Fund for Seeds of Collaborative Research from RIKEN, Japan [29100]	Fund for Seeds of Collaborative Research from RIKEN, Japan	The authors thank Hiromi Sato (RIKEN, Wako) for technical assistance provided with the gene sequencing and cloning. C.G.P. was partly supported by the FY2012 Fund for Seeds of Collaborative Research from RIKEN (29100), Japan.	Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Bancaud A, 2009, EMBO J, V28, P3785, DOI 10.1038/emboj.2009.340; Banerjee A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083410; Brangwynne CP, 2011, P NATL ACAD SCI USA, V108, P4334, DOI 10.1073/pnas.1017150108; Cardoso MC, 2012, CURR OPIN CELL BIOL, V24, P79, DOI 10.1016/j.ceb.2011.12.009; Carmo-Fonseca M, 2002, TRENDS CELL BIOL, V12, P491, DOI 10.1016/S0962-8924(02)02387-5; Chen DY, 2005, J CELL BIOL, V168, P41, DOI 10.1083/jcb.200407182; Chen DY, 2001, J CELL BIOL, V153, P169, DOI 10.1083/jcb.153.1.169; Delloye-Bourgeois C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002456; Dross N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005041; Dundr M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000711; Finch RA, 1996, BIOCHEM BIOPH RES CO, V222, P553, DOI 10.1006/bbrc.1996.0782; Gorisch S, 2005, HISTOCHEM CELL BIOL, V123, P217, DOI 10.1007/s00418-005-0752-y; Grunwald D, 2008, BIOPHYS J, V94, P2847, DOI 10.1529/biophysj.107.115014; Grummt I, 2013, CHROMOSOMA, V122, P487, DOI 10.1007/s00412-013-0430-0; Hancock R, 2004, J STRUCT BIOL, V146, P281, DOI 10.1016/j.jsb.2003.12.008; Hayashi K, 2013, EUR PHYS J E, V36, DOI 10.1140/epje/i2013-13136-6; Hernandez-Verdun D, 2006, HISTOCHEM CELL BIOL, V125, P127, DOI 10.1007/s00418-005-0046-4; Hernandez-Verdun D, 2006, HISTOCHEM CELL BIOL, V126, P135, DOI 10.1007/s00418-006-0212-3; Hihara S, 2012, CELL REP, V2, P1645, DOI 10.1016/j.celrep.2012.11.008; Jacob MD, 2013, MOL BIOL CELL, V24, P2943, DOI 10.1091/mbc.E13-04-0223; Kiesslich T, 2003, J BIOCHEM BIOPH METH, V57, P247, DOI 10.1016/S0165-022X(03)00102-7; LEBEL S, 1987, J CELL BIOL, V105, P1099, DOI 10.1083/jcb.105.3.1099; Lee KE, 2009, J ELECTRON MICROSC, V58, P305, DOI 10.1093/jmicro/dfp019; Lide D.R., 2000, HDB CHEM PHYS, V81st; Lleres D, 2009, J CELL BIOL, V187, P481, DOI 10.1083/jcb.200907029; Martin C, 2009, J CELL SCI, V122, P1551, DOI 10.1242/jcs.046284; Martin RM, 2010, FASEB J, V24, P1066, DOI 10.1096/fj.08-128959; Matera AG, 2009, DEV CELL, V17, P639, DOI 10.1016/j.devcel.2009.10.017; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Olson MOJ, 2005, HISTOCHEM CELL BIOL, V123, P203, DOI 10.1007/s00418-005-0754-9; Pack C, 2006, BIOPHYS J, V91, P3921, DOI 10.1529/biophysj.106.079467; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Politz JC, 1998, P NATL ACAD SCI USA, V95, P6043, DOI 10.1073/pnas.95.11.6043; Raska I, 2006, CURR OPIN CELL BIOL, V18, P325, DOI 10.1016/j.ceb.2006.04.008; Romanova L, 2009, J BIOL CHEM, V284, P26685, DOI 10.1074/jbc.M109.013342; Ruggero D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003477; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Shav-Tal Y, 2005, MOL BIOL CELL, V16, P2395, DOI 10.1091/mbc.E04-11-0992; Shimi T, 2008, GENE DEV, V22, P3409, DOI 10.1101/gad.1735208; Strelkov SV, 2004, J MOL BIOL, V343, P1067, DOI 10.1016/j.jmb.2004.08.093; Trinkle-Mulcahy L, 2007, SCIENCE, V318, P1402, DOI 10.1126/science.1142033; Tsai RYL, 2005, J CELL BIOL, V168, P179, DOI 10.1083/jcb.200409053; van Steensel B, 2011, EMBO J, V30, P1885, DOI 10.1038/emboj.2011.135; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; Wachsmuth M, 2000, J MOL BIOL, V298, P677, DOI 10.1006/jmbi.2000.3692; Wachsmuth M, 2008, BBA-MOL CELL RES, V1783, P2061, DOI 10.1016/j.bbamcr.2008.07.022; ZIMMERMAN SB, 1987, P NATL ACAD SCI USA, V84, P1871, DOI 10.1073/pnas.84.7.1871	49	12	12	2	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					837	848		10.1096/fj.14-254110	http://dx.doi.org/10.1096/fj.14-254110			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25404711				2022-12-28	WOS:000350633000011
J	Jobling, AI; Guymer, RH; Vessey, KA; Greferath, U; Mills, SA; Brassington, KH; Luu, CD; Aung, KZ; Trogrlic, L; Plunkett, M; Fletcher, EL				Jobling, A. I.; Guymer, R. H.; Vessey, K. A.; Greferath, U.; Mills, S. A.; Brassington, K. H.; Luu, C. D.; Aung, K. Z.; Trogrlic, L.; Plunkett, M.; Fletcher, E. L.			Nanosecond laser therapy reverses pathologic and molecular changes in age-related macular degeneration without retinal damage	FASEB JOURNAL			English	Article						vision loss; drusen; Bruch's membrane; matrix metalloproteinase	BRUCHS MEMBRANE IMPLICATIONS; PIGMENT EPITHELIAL-CELLS; MATRIX METALLOPROTEINASES; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; MOUSE MODEL; CONVENTIONAL PHOTOCOAGULATOR; HYDRAULIC CONDUCTIVITY; GRID PHOTOCOAGULATION; GLIAL-CELL	Age-related macular degeneration (AMD) is a leading cause of vision loss, characterized by drusen deposits and thickened Bruch's membrane (BM). This study details the capacity of nanosecond laser treatment to reduce drusen and thin BM while maintaining retinal structure. Fifty patientswithAMDhad a single nanosecond laser treatment session and after 2 yr, change in drusen area was compared with an untreated cohort of patients. The retinal effect of the laser was determined in human and mouse eyes using immunohistochemistry and compared with untreated eyes. In a mouse with thickened BM (ApoEnull), the effect of laser treatment was quantified using electron microscopy and quantitative PCR. In patients with AMD, nanosecond laser treatment reduced drusen load at 2 yr. Retinal structurewas not compromised in human and mouse retina after laser treatment, with only a discrete retinal pigment epithelium (RPE) injury, and limited mononuclear cell response observed. BM was thinned in the ApoEnull mouse 3 mo after treatment (ApoEnull treated 683 +/- 38 nm, ApoEnull untreated 890 +/- 60 nm, C57Bl6J 606 +/- 43 nm), with the expression of matrix metalloproteinase-2 and -3 increased (> 260%). Nanosecond laser resolved drusen independent of retinal damage and improved BM structure, suggesting this treatment has the potential to reduceAMD progression.Jobling, A. I., Guymer, R. H., Vessey, K. A., Greferath, U., Mills, S. A., Brassington, K. H., Luu, C. D., Aung, K. Z., Trogrlic, L., Plunkett, M., Fletcher, E. L. Nanosecond laser therapy reverses pathologic andmolecular changes in agerelated macular degeneration without retinal damage.	[Jobling, A. I.; Vessey, K. A.; Greferath, U.; Mills, S. A.; Trogrlic, L.; Fletcher, E. L.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3010, Australia; [Guymer, R. H.; Brassington, K. H.; Luu, C. D.; Aung, K. Z.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Parkville, Vic 3010, Australia; [Plunkett, M.] Ellex R&D Pty Ltd, Adelaide, SA, Australia	University of Melbourne; Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne	Fletcher, EL (corresponding author), Univ Melbourne, Dept Anat & Neurosci, Grattan St, Parkville, Vic 3010, Australia.	elf@unimelb.edu.au	Trogrlic, Lidia/C-8215-2015; Fletcher, Erica/E-6364-2012; Jobling, Andrew/C-8221-2015	Trogrlic, Lidia/0000-0002-2127-7979; Fletcher, Erica/0000-0001-9412-9523; Vessey, Kirstan/0000-0003-1031-1964; Jobling, Andrew/0000-0002-7827-3135; Luu, Chi/0000-0002-7604-7097; Guymer, Robyn/0000-0002-9441-4356	National Health and Medical Research Council of Australia [1038220, 1061418, 1061419, 529905]; Victorian Science Agenda; Centre for Clinical Research Excellence Award [529923]; Victorian Government	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Science Agenda; Centre for Clinical Research Excellence Award; Victorian Government	This work was supported by the National Health and Medical Research Council of Australia (#1038220 to E.L.F.and M.P.; #1061418 to E.L.F. and A.I.J.; #1061419 to E.L.F.and K.A.V.), practitioner fellowship (#529905 to R.H.G.) and the Victorian Science Agenda ( R.H.G., E.L.F., M.P.), Centre for Clinical Research Excellence Award (#529923 to R.H.G.). The Centre for Eye Research Australia receives Operational Infrastructure Support from the Victorian Government.At the time of this work, M.P. was employed by Ellex R&D Pty Ltd. All other authors declare no competing interests.	Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458; ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520; Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459; Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018; Barathi VA, 2014, INVEST OPHTH VIS SCI, V55, P460, DOI 10.1167/iovs.13-11636; BIRNGRUBER R, 1983, HEALTH PHYS, V44, P519, DOI 10.1097/00004032-198305000-00006; Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396; Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003; BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022; BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002; Chen J, 2007, J CLIN INVEST, V117, P2758, DOI 10.1172/JCI33513; Chidlow G, 2013, INVEST OPHTH VIS SCI, V54, P2319, DOI 10.1167/iovs.12-11204; Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718; DIAZARAYA CM, 1995, J COMP NEUROL, V363, P53, DOI 10.1002/cne.903630106; Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035; DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024; Eliasieh K, 2007, INVEST OPHTH VIS SCI, V48, P2824, DOI 10.1167/iovs.06-1228; Eter N, 2008, INVEST OPHTH VIS SCI, V49, P3649, DOI 10.1167/iovs.07-1322; Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036; FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001; Fletcher EL, 2011, PROG MOL BIOL TRANSL, V100, P211, DOI 10.1016/B978-0-12-384878-9.00006-6; Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169; Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066; Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409; Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580; GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206; Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993; Gullapalli VK, 2008, EXP EYE RES, V86, P189, DOI 10.1016/j.exer.2007.10.009; Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006; Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676; Guymer RH, 2001, BRIT J OPHTHALMOL, V85, P40, DOI 10.1136/bjo.85.1.40; Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004; Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247; Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041; Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013; Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678; Jobling AI, 2013, INVEST OPHTH VIS SCI, V54, P3350, DOI 10.1167/iovs.13-11831; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367; Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219; Kaur C, 2013, J NEUROIMMUNE PHARM, V8, P66, DOI 10.1007/s11481-012-9347-2; Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2; Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030; Kumar A, 2010, INVEST OPHTH VIS SCI, V51, P2664, DOI 10.1167/iovs.09-4195; Lanzetta P, 2008, OPHTHALMOLOGY, V115, P216, DOI 10.1016/j.ophtha.2007.08.007; Lech M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/951390; Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9; MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450; Mojana F, 2011, RETINA-J RET VIT DIS, V31, P235, DOI 10.1097/IAE.0b013e3181ec80ad; MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290; Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6; Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015; Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2; PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6; Pauleikhoff D, 2000, OPHTHALMOLOGE, V97, P243, DOI 10.1007/s003470050520; Pelosini L, 2013, RETINA-J RET VIT DIS, V33, P548, DOI 10.1097/IAE.0b013e3182670fea; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; Pollack JS, 1998, ARCH OPHTHALMOL-CHIC, V116, P1633, DOI 10.1001/archopht.116.12.1633; Rhodes KM, 2009, CURR MED RES OPIN, V25, P787, DOI [10.1185/03007990902728316, 10.1185/03007990902728316 ]; Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4; Roider J., 1993, Ophthalmologe, V90, P274; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466; SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x; SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x; Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004; SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379; Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066; Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8; Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P1345, DOI 10.1167/iovs.10-6112; Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848; Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031; Treumer F, 2012, EXP EYE RES, V97, P63, DOI 10.1016/j.exer.2012.02.011; United Nations Department of Economic and Social Affairs Population Division (UN), 2013, ESAPWP228 UN DEP EC; Vessey KA, 2011, J COMP NEUROL, V519, P506, DOI 10.1002/cne.22530; Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650; WALLOW IHL, 1973, AM J OPHTHALMOL, V75, P610, DOI 10.1016/0002-9394(73)90813-1; Wood JPM, 2013, INVEST OPHTH VIS SCI, V54, P2305, DOI 10.1167/iovs.12-11203; Wood JPM, 2011, LASER SURG MED, V43, P499, DOI 10.1002/lsm.21087; Yamamoto C, 1996, GRAEF ARCH CLIN EXP, V234, P695, DOI 10.1007/BF00292356; Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585	86	62	62	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					696	710		10.1096/fj.14-262444	http://dx.doi.org/10.1096/fj.14-262444			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25392267				2022-12-28	WOS:000349370400030
J	Yu, XL; Long, YC				Yu, Xinlei; Long, Yun Chau			Autophagy modulates amino acid signaling network in myotubes: differential effects on mTORC1 pathway and the integrated stress response	FASEB JOURNAL			English	Article						skeletal muscle; protein; proteolysis; lysosome; atrophy	UBIQUITIN-PROTEASOME PATHWAY; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; SKELETAL-MUSCLE; DEGRADATION; INHIBITION; DISEASE; CELLS; FOXO3; DEXAMETHASONE	Induction of autophagy and the integrated stress response is important for amino acid homeostasis. It remains unknown whether the autophagy coregulates both mechanistic target of rapamycin complex 1 (mTORC1) signaling and the integrated stress response. In mouse C2C12 myotubes, we found that amino acid limitation induced autophagy and that the subsequent release of amino acid is required to sustain mTORC1 signaling. Inhibition of autophagy by bafilomycin A1 or chloroquine treatment during amino acid scarcity abolished mTORC1 signaling, an effect that could be rescued by inhibiting protein synthesis or amino acid supplementation, respectively. Autophagy is required to sustain the balance of both essential and nonessential amino acids during amino acid starvation, and it has a predominant role over the ubiquitin-proteasome system in the regulation of mTORC1. Inhibition of autophagy was found to activate the integrated stress response, as well as eukaryotic initiation factor 2 alpha (eIF2 alpha) and its target genes independent of amino acid availability. Conversely, autophagy induction via mTOR inhibition is sufficient to reduce eIF2 alpha phosphorylation. Thus, autophagy protects the eIF2 alpha-mediated stress response independent of amino acid supply in cultured myotubes. Our results showed that autophagy uniquely modulates mTORC1 and the integrated stress response in an amino acid-dependent and -independent manner, respectively.	[Yu, Xinlei; Long, Yun Chau] Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, Singapore 117597, Singapore	National University of Singapore	Long, YC (corresponding author), Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, MD6,Ctr Translational Med,14 Med Dr,14-01M, Singapore 117597, Singapore.	bchlongy@nus.edu.sg			Singapore Ministry of Health; National Medical Research Council; Cooperative Basic Research Grant [NMRC/BNIG/2013/2013]; Singapore Ministry of Education Academic Research Fund Tier 1 Grant [T1-2011Sep-05]	Singapore Ministry of Health(Ministry of Health-Singapore); National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cooperative Basic Research Grant; Singapore Ministry of Education Academic Research Fund Tier 1 Grant(Ministry of Education, Singapore)	The authors thank Ai Lee Chow and Dr. Rebecca Anne Jackson for comments on the manuscript. This work was supported by the Singapore Ministry of Health, National Medical Research Council, Cooperative Basic Research Grant NMRC/BNIG/2013/2013, and Singapore Ministry of Education Academic Research Fund Tier 1 Grant T1-2011Sep-05. The authors declare no conflicts of interest.	Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Jewell JL, 2013, NAT REV MOL CELL BIO, V14, P133, DOI 10.1038/nrm3522; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; Kilberg MS, 2009, TRENDS ENDOCRIN MET, V20, P436, DOI 10.1016/j.tem.2009.05.008; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Mammucari C, 2008, AUTOPHAGY, V4, P524, DOI 10.4161/auto.5905; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Masiero E, 2010, AUTOPHAGY, V6, P307, DOI 10.4161/auto.6.2.11137; Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; Ohanna M, 2005, NAT CELL BIOL, V7, P286, DOI 10.1038/ncb1231; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Raben N, 2008, HUM MOL GENET, V17, P3897, DOI 10.1093/hmg/ddn292; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; SCHIAFFINO S, 1972, J CELL BIOL, V52, P41, DOI 10.1083/jcb.52.1.41; Scott SV, 1998, CURR OPIN CELL BIOL, V10, P523, DOI 10.1016/S0955-0674(98)80068-9; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Sikalidis AK, 2011, AMINO ACIDS, V41, P159, DOI 10.1007/s00726-010-0571-x; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; SPARGO E, 1979, J ROY SOC MED, V72, P921; Suraweera A, 2012, MOL CELL, V48, P242, DOI 10.1016/j.molcel.2012.08.003; Talvas J, 2006, J NUTR, V136, P1466, DOI 10.1093/jn/136.6.1466; Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482; Vabulas RM, 2005, SCIENCE, V310, P1960, DOI 10.1126/science.1121925; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Wong E, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a006734; Wasef SZY, 2006, AM J PHYSIOL-ENDOC M, V291, pE1274, DOI 10.1052/ajpendo.00117.2006; Yorimitsu T, 2007, AUTOPHAGY, V3, P160, DOI 10.4161/auto.3653; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004	36	22	24	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					394	407		10.1096/fj.14-252841	http://dx.doi.org/10.1096/fj.14-252841			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25376834				2022-12-28	WOS:000349370400006
J	House, JS; Li, HL; DeGraff, LM; Flake, G; Zeldin, DC; London, SJ				House, John S.; Li, Huiling; DeGraff, Laura M.; Flake, Gordon; Zeldin, Darryl C.; London, Stephanie J.			Genetic variation in HTR4 and lung function: GWAS follow-up in mouse	FASEB JOURNAL			English	Article						pulmonary function; airway hyperresponsiveness; mouse models	GENOME-WIDE ASSOCIATION; OBSTRUCTIVE PULMONARY-DISEASE; SEROTONIN 5-HT4 RECEPTORS; AIRWAY HYPERRESPONSIVENESS; ASTHMA; EXPRESSION; KNOCK; IDENTIFICATION; HIPPOCAMPUS; VARIANTS	Human genome-wide association studies (GWASs) have identified numerous associations between single nucleotide polymorphisms (SNPs) and pulmonary function. Proving that there is a causal relationship between GWAS SNPs, many of which are noncoding and without known functional impact, and these traits has been elusive. Furthermore, noncoding GWAS-identified SNPs may exert trans-regulatory effects rather than impact the proximal gene. Noncoding variants in 5-hydroxytryptamine (serotonin) receptor 4 (HTR4) are associated with pulmonary function in human GWASs. To gain insight into whether this association is causal, we tested whether Htr4-null mice have altered pulmonary function. We found that HTR4-deficient mice have 12% higher baseline lung resistance and also increased methacholine-induced airway hyper responsiveness (AHR) as measured by lung resistance (27%), tissue resistance (48%), and tissue elastance (30%). Furthermore, Htr4-null mice were more sensitiveto serotonin-induced AHR. In models of exposure to bacterial lipopolysaccharide, bleomycin, and allergic airway inflammation induced by house dust mites, pulmonary function and cytokine profiles in Htr4-null mice differed little from their wild-type controls. The findings of altered baseline lung function and increased AHR in Htr4-null mice support a causal relationship between genetic variation in HTR4 and pulmonary function identified in human GWAS.	[House, John S.; Li, Huiling; DeGraff, Laura M.; Zeldin, Darryl C.; London, Stephanie J.] NIEHS, Div Intramural Res, US Natl Inst Hlth, Res Triangle Pk, NC 27709 USA; [Flake, Gordon] US Natl Inst Environm Hlth Sci, Div Natl Toxicol Program, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	London, SJ (corresponding author), NIEHS, NIH, 111 TW Alexander Dr,POB 12233,MD A3-05, Res Triangle Pk, NC 27709 USA.	london2@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018; House, John S/A-1933-2013; London, Stephanie/C-3734-2019	Zeldin, Darryl C/0000-0002-2087-7307; House, John S/0000-0002-8447-7871; London, Stephanie/0000-0003-4911-5290	Intramural NIH HHS [Z01 ES025045, Z01 ES043012] Funding Source: Medline; NIBIB NIH HHS [P41 EB015897] Funding Source: Medline; PHS HHS [Z01 025043] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES025043, ZIAES043012, ZICES102425, Z01ES043012, ZICES102546, Z01ES025045, ZIAES025045] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABRAMOWSKI D, 1995, J NEUROCHEM, V65, P782; Artigas MS, 2011, AM J RESP CRIT CARE, V184, P786, DOI 10.1164/rccm.201102-0192OC; ASHCROFT T, 1988, J CLIN PATHOL, V41, P467, DOI 10.1136/jcp.41.4.467; Azim S, 2012, BRAIN RES BULL, V87, P250, DOI 10.1016/j.brainresbull.2011.10.016; Bayer H, 2007, AM J RESP CELL MOL, V36, P85, DOI 10.1165/rcmb.2006-0151OC; Berger M, 2009, ANNU REV MED, V60, P355, DOI 10.1146/annurev.med.60.042307.110802; Bockaert J, 2004, CNS NEUROL DISORD-DR, V3, P39, DOI 10.2174/1568007043482615; BUCKNER CK, 1991, J PHARMACOL EXP THER, V257, P26; Card JW, 2006, J IMMUNOL, V177, P621, DOI 10.4049/jimmunol.177.1.621; Cho MH, 2012, HUM MOL GENET, V21, P947, DOI 10.1093/hmg/ddr524; Cho MH, 2010, NAT GENET, V42, P200, DOI 10.1038/ng.535; Compan V, 1996, EUR J NEUROSCI, V8, P2591, DOI 10.1111/j.1460-9568.1996.tb01553.x; Compan Valerie, 2004, Journal de la Societe de Biologie, V198, P37; Conductier G, 2006, EUR J NEUROSCI, V24, P1053, DOI 10.1111/j.1460-9568.2006.04943.x; COOPER DM, 1974, AM REV RESPIR DIS, V110, P708; Dackor RT, 2011, AM J PHYSIOL-LUNG C, V301, pL645, DOI 10.1152/ajplung.00176.2011; DeMeo DL, 2003, SEMIN RESP CRIT CARE, V24, P151, DOI 10.1055/s-2003-39014; Dupont LL, 2014, PULM PHARMACOL THER, V28, P60, DOI 10.1016/j.pupt.2013.10.003; Edwards SL, 2013, AM J HUM GENET, V93, P779, DOI 10.1016/j.ajhg.2013.10.012; Einstein R, 2008, P NATL ACAD SCI USA, V105, P5230, DOI 10.1073/pnas.0801319105; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; He X, 2013, AM J HUM GENET, V92, P667, DOI 10.1016/j.ajhg.2013.03.022; Hegde SS, 1996, FASEB J, V10, P1398, DOI 10.1096/fasebj.10.12.8903510; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hodge E, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-77; Hospers JJ, 2000, LANCET, V356, P1313, DOI 10.1016/S0140-6736(00)02815-4; Imboden M, 2012, J ALLERGY CLIN IMMUN, V129, P1218, DOI 10.1016/j.jaci.2012.01.074; Jean A, 2007, P NATL ACAD SCI USA, V104, P16335, DOI 10.1073/pnas.0701471104; Jones IW, 2005, TRENDS NEUROSCI, V28, P343, DOI 10.1016/j.tins.2005.04.010; Kim DK, 2012, AM J RESP CRIT CARE, V186, P1238, DOI 10.1164/rccm.201206-1013OC; Kim TH, 2011, RESPIROLOGY, V16, P630, DOI 10.1111/j.1440-1843.2011.01963.x; Li XN, 2013, J ALLERGY CLIN IMMUN, V132, P313, DOI 10.1016/j.jaci.2013.01.051; Loth DW, 2014, NAT GENET, V46, P669, DOI 10.1038/ng.3011; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; MARTIN TR, 1994, J PHARMACOL EXP THER, V268, P104; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nichols DE, 2008, CHEM REV, V108, P1614, DOI 10.1021/cr078224o; Pillai SG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000421; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; REYNOLDS GP, 1995, BRIT J PHARMACOL, V114, P993, DOI 10.1111/j.1476-5381.1995.tb13303.x; RIJCKEN B, 1995, AM J RESP CRIT CARE, V151, P1377, DOI 10.1164/ajrccm.151.5.7735588; RYBICKI BA, 1990, J CLIN EPIDEMIOL, V43, P667, DOI 10.1016/0895-4356(90)90037-P; Segu L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009529; Silverman EK, 2009, NEW ENGL J MED, V360, P2749, DOI 10.1056/NEJMcp0900449; Soler Artigas M, 2011, NAT GENET, V43, P1082, DOI 10.1038/ng.941; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Vestbo J, 1998, THORAX, V53, pS15, DOI 10.1136/thx.53.2008.S15; Wan YI, 2012, THORAX, V67, P762, DOI 10.1136/thoraxjnl-2011-201262; Wilk JB, 2000, GENET EPIDEMIOL, V19, P81, DOI 10.1002/1098-2272(200007)19:1<81::AID-GEPI6>3.0.CO;2-8; Wilk JB, 2012, AM J RESP CRIT CARE, V186, P622, DOI 10.1164/rccm.201202-0366OC; Wilk JB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000429	54	13	13	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					323	335		10.1096/fj.14-253898	http://dx.doi.org/10.1096/fj.14-253898			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25342126	Green Published			2022-12-28	WOS:000347378600030
J	Zhang, SP; Liu, H; Chuang, CL; Li, XL; Au, MG; Zhang, L; Phillips, ARJ; Scott, DW; Cooper, GJS				Zhang, Shaoping; Liu, Hong; Chuang, Chia Lin; Li, Xiaoling; Au, Maggie; Zhang, Lin; Phillips, Anthony R. J.; Scott, David W.; Cooper, Garth J. S.			The pathogenic mechanism of diabetes varies with the degree of overexpression and oligomerization of human amylin in the pancreatic islet beta cells	FASEB JOURNAL			English	Article						gene-dosage effect; apoptosis; peptide aggregation; transgenic mice; insulin resistance	AMYLOID POLYPEPTIDE; TRANSGENIC MICE; MOUSE MODEL; APOPTOSIS; CYTOTOXICITY; EXPRESSION; INSULIN; ACTIVATION; IAPP; GENE	The aggregation of human amylin (hA) to form cytotoxic structures has been closely associated with the causation of type 2 diabetes. We sought to advance understanding of how altered expression and aggregation of hA might link beta-cell degeneration with diabetes onset and progression, by comparing phenotypes between homozygous and hemizygous hA-transgenic mice. The homozygous mice displayed elevated islet hA that correlated positively with measures of oligomer formation (r = 0.91; P<0.0001). They also developed hyperinsulinemia with transient insulin resistance during the prediabetes stage and then underwent rapid beta-cell loss, culminating in severe juvenile-onset diabetes. The prediabetes stage was prolonged in the hemizygous mice, wherein beta-cell dysfunction and extensive oligomer formation occurred in adulthood at a much later stage, when hA levels were lower (r=-0.60; P<0.0001). This is the first report to show that hAevoked diabetes is associated with age, insulin resistance, progressive islet dysfunction, and beta-cell apoptosis, which interact variably to cause the different diabetes syndromes. The various levels of hA elevation cause different extents of oligomer formation in the disease stages, thus eliciting early-or adult-onset diabetes syndromes, reminiscent of type 1 and 2 diabetes, respectively. Thus, the hA-evoked diabetes phenotypes differ substantively according to degree of amylin overproduction. These findings are relevant to the understanding of the pathogenesis and the development of experimental therapeutics for diabetes.	[Zhang, Shaoping; Liu, Hong; Chuang, Chia Lin; Li, Xiaoling; Au, Maggie; Zhang, Lin; Phillips, Anthony R. J.; Scott, David W.; Cooper, Garth J. S.] Univ Auckland, Sch Biol Sci, Auckland 1010, New Zealand; [Zhang, Shaoping; Phillips, Anthony R. J.; Cooper, Garth J. S.] Univ Auckland, Fac Sci, Maurice Wilkins Ctr Mol BioDiscovery, Auckland 1010, New Zealand; [Cooper, Garth J. S.] Cent Manchester Univ Hosp, NHS Fdn Trust, Ctr Adv Discovery & Expt Therapeut, Manchester, Lancs, England; [Cooper, Garth J. S.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Med & Human Sci, Ctr Endocrinol & Diabet,Inst Human Dev, Manchester, Lancs, England	University of Auckland; University of Auckland; Oxford University Hospitals NHS Foundation Trust; University of Manchester	Cooper, GJS (corresponding author), Univ Auckland, Sch Biol Sci, 3 Symonds St, Auckland 1010, New Zealand.	g.cooper@auckland.ac.nz	Cooper, Garth JS/I-3201-2015	Cooper, Garth JS/0000-0001-5241-3163; Zhang, Shaoping/0000-0003-2969-7043	Endocore Research Associates; Maurice and Phyllis Paykel Trust; Lottery Health (New Zealand); Auckland Medical Research Foundation; University of Auckland; Department of Education (New Zealand) through the Maurice Wilkins Centre of Excellence for Molecular BioDiscovery; Ministry for Business, Innovation, and Employment, New Zealand; Health Research Council of New Zealand	Endocore Research Associates; Maurice and Phyllis Paykel Trust; Lottery Health (New Zealand); Auckland Medical Research Foundation; University of Auckland; Department of Education (New Zealand) through the Maurice Wilkins Centre of Excellence for Molecular BioDiscovery; Ministry for Business, Innovation, and Employment, New Zealand(New Zealand Ministry of Business, Innovation and Employment (MBIE)); Health Research Council of New Zealand(Health Research Council of New Zealand)	The authors thank C. A. Tse (School of Biological Sciences, University of Auckland, Auckland, New Zealand) for outstanding management, administrative assistance, and critical reading of the manuscript; A. Petzer, S. Johnson, Dr. J. Aitken, and C. C. H. Cheung for technical assistance; and the two anonymous reviewers for comprehensive analysis of the manuscript and for numerous insightful comments and suggestions that substantively strengthened the work. This work was funded by grants from Endocore Research Associates; the Maurice and Phyllis Paykel Trust; Lottery Health (New Zealand); the Auckland Medical Research Foundation; the University of Auckland; the Department of Education (New Zealand), through a grant to the Maurice Wilkins Centre of Excellence for Molecular BioDiscovery; by program grants from the Ministry for Business, Innovation, and Employment, New Zealand, and the Health Research Council of New Zealand. The study was facilitated by the Manchester Biomedical Research Centre and the UK National Institute for Health Research Greater Manchester Comprehensive Local Research Network.	Aitken JF, 2010, DIABETES, V59, P161, DOI 10.2337/db09-0548; Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc10-S062, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062]; Bonner-Weir S, 2001, DIABETES, V50, pS20, DOI 10.2337/diabetes.50.2007.S20; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Butler AE, 2003, DIABETES, V52, P2304, DOI 10.2337/diabetes.52.9.2304; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Butler AE, 2004, DIABETES, V53, P1509, DOI 10.2337/diabetes.53.6.1509; Cooper GJS, 2010, DIABETOLOGIA, V53, P1011, DOI 10.1007/s00125-010-1715-y; COOPER GJS, 1989, BIOCHIM BIOPHYS ACTA, V1014, P247, DOI 10.1016/0167-4889(89)90220-6; COOPER GJS, 1994, ENDOCR REV, V15, P163, DOI 10.1210/er.15.2.163; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; Couce M, 1996, DIABETES, V45, P1094, DOI 10.2337/diabetes.45.8.1094; DALESSIO DA, 1994, DIABETES, V43, P1457, DOI 10.2337/diabetes.43.12.1457; Despa S, 2012, CIRC RES, V110, P598, DOI [10.1161/CIRCRESAHA.111.258285, 10.1161/circresaha.111.258285]; FOX N, 1993, FEBS LETT, V323, P40, DOI 10.1016/0014-5793(93)81444-5; Goldsbury CS, 1997, J STRUCT BIOL, V119, P17, DOI 10.1006/jsbi.1997.3858; Gong W, 2007, KIDNEY INT, V72, P213, DOI 10.1038/sj.ki.5002305; Green JD, 2004, J BIOL CHEM, V279, P12206, DOI 10.1074/jbc.M312452200; HOPPENER JWM, 1993, DIABETOLOGIA, V36, P1258, DOI 10.1007/BF00400803; Hull RL, 2004, J CLIN ENDOCR METAB, V89, P3629, DOI 10.1210/jc.2004-0405; Hull RL, 2003, DIABETES, V52, P372, DOI 10.2337/diabetes.52.2.372; In't Veld P, 2011, ISLETS, V3, P131, DOI 10.4161/isl.3.4.15728; Janciauskiene S, 2000, BIOCHEM BIOPH RES CO, V267, P619, DOI 10.1006/bbrc.1999.1989; Janson J, 1996, P NATL ACAD SCI USA, V93, P7283, DOI 10.1073/pnas.93.14.7283; Janson J, 1999, DIABETES, V48, P491, DOI 10.2337/diabetes.48.3.491; Kahn SE, 1999, DIABETES, V48, P241, DOI 10.2337/diabetes.48.2.241; Kapurniotu A, 2001, BIOPOLYMERS, V60, P438, DOI 10.1002/1097-0282(2001)60:6<438::AID-BIP10182>3.0.CO;2-A; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kayed R, 2006, METHOD ENZYMOL, V413, P326, DOI 10.1016/S0076-6879(06)13017-7; Konarkowska B, 2006, FEBS J, V273, P3614, DOI 10.1111/j.1742-4658.2006.05367.x; Lin CY, 2007, DIABETES, V56, P1324, DOI 10.2337/db06-1579; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; LUKINIUS A, 1989, DIABETOLOGIA, V32, P240, DOI 10.1007/BF00285291; Maedler K, 2004, HORM RES, V62, P67, DOI 10.1159/000080503; Meier JJ, 2006, AM J PHYSIOL-ENDOC M, V291, pE1317, DOI 10.1152/ajpendo.00082.2006; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Ritzel RA, 2007, DIABETES, V56, P65, DOI 10.2337/db06-0734; Rumora L, 2002, BIOL CHEM, V383, P1751, DOI 10.1515/BC.2002.196; Soeller WC, 1998, DIABETES, V47, P743, DOI 10.2337/diabetes.47.5.743; Verchere CB, 1996, P NATL ACAD SCI USA, V93, P3492, DOI 10.1073/pnas.93.8.3492; Westermark GT, 2000, MOL MED, V6, P998, DOI 10.1007/BF03402051; WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; Wong WPS, 2008, DIABETES, V57, P2737, DOI 10.2337/db06-1755; Zhang SP, 2008, DIABETES, V57, P348, DOI 10.2337/db07-0849; Zhang SP, 2003, J BIOL CHEM, V278, P52810, DOI 10.1074/jbc.M308244200; Zhang SP, 2002, J MOL BIOL, V324, P271, DOI 10.1016/S0022-2836(02)01044-6; Zhang SP, 1999, FEBS LETT, V455, P315, DOI 10.1016/S0014-5793(99)00894-7; Zhao HL, 2009, TRANSL RES, V153, P24, DOI 10.1016/j.trsl.2008.10.009; Zraika S, 2010, DIABETOLOGIA, V53, P1046, DOI 10.1007/s00125-010-1671-6; Zraika S, 2009, DIABETOLOGIA, V52, P626, DOI 10.1007/s00125-008-1255-x	51	33	33	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5083	5096		10.1096/fj.14-251744	http://dx.doi.org/10.1096/fj.14-251744			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25138158	Green Submitted			2022-12-28	WOS:000345894500006
J	Muthukumar, S; Rajkumar, R; Rajesh, D; Saibaba, G; Liao, CC; Archunan, G; Padmanabhan, P; Gulyas, B				Muthukumar, Subramanian; Rajkumar, Ramalingam; Rajesh, Durairaj; Saibaba, Ganesan; Liao, Chen-Chung; Archunan, Govindaraju; Padmanabhan, Parasuraman; Gulyas, Balazs			Exploration of salivary proteins in buffalo: an approach to find marker proteins for estrus	FASEB JOURNAL			English	Article						SDS-PAGE; LC-MS; MS; estrous cycle; beta-enolase	ODORANT-BINDING; EXPRESSION; BOVINE; PROTEOMICS; RECEPTOR; PURIFICATION; SECRETION; PATTERN; GLANDS; SHEEP	Saliva is considered as the best source of biological material for biomarker discovery studies since it is noninvasive in comparison to other body sources. Usually buffalo cannot precisely express estrus signals. Hence, there is a need for concise methods to detect the time of estrus to ensure the success of artificial insemination. Therefore, we have established a reference proteome map on the whole saliva of buffalo during their estrous cycle with special reference to estrus. Nearly 12 bands have been observed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of whole saliva. Collectively, 179 proteins are identified with respect to different phases of the estrous cycle using mass spectrometry. On the whole, 37 proteins are exclusively expressed in the estrus phase, which include -enolase, Toll-like receptor (TLR) 4, clusterin, lactoperoxidase, serotransferrin, TGM3, UBA6, and transducin. Among the proteins, -enolase and TLR 4 were validated, and their specific expression was found during estrus as compared to other phases using immunoblot. The functional annotation reveals many as binding proteins in the estrus saliva when compared to the other phases. The present findings conclude that the proteomic approach adopted to identify the proteins from buffalo saliva around the estrous cycle may provide a new tool for screening the estrus phase. The results further conclude that the specific expression of -enolase and TLR 4 can be taken as the indicator of estrus in buffalo.Muthukumar, S., Rajkumar, R., Rajesh, D., Saibaba, G., Liao, C.-C., Archunan, G., Padmanabhan, P., Gulyas, B. Exploration of salivary proteins in buffalo: an approach to find marker proteins for estrus.	[Muthukumar, Subramanian; Rajesh, Durairaj; Saibaba, Ganesan; Archunan, Govindaraju] Bharathidasan Univ, Dept Anim Sci, Ctr Pheromone Technol, Tiruchirappalli 620024, Tamil Nadu, India; [Rajkumar, Ramalingam] ASTAR, Inst Med Biol, Singapore, Singapore; [Liao, Chen-Chung] Natl Yang Ming Univ, Prote Res Ctr, Taipei 112, Taiwan; [Padmanabhan, Parasuraman; Gulyas, Balazs] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 6375553, Singapore	Bharathidasan University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); National Yang Ming Chiao Tung University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Archunan, G (corresponding author), Bharathidasan Univ, Dept Anim Sci, Ctr Pheromone Technol, Tiruchirappalli 620024, Tamil Nadu, India.	archunan@bdu.ac.in; ppadmanabhan@ntu.edu.sg	Gulyas, Balazs/F-9508-2015; Ganesan, Saibaba/AAO-9521-2020; Durairaj, Rajesh/N-9013-2018; GOVINDARAJU, ARCHUNAN/A-9072-2019; PADMANABHAN, PARASURAMAN/AAC-1062-2021	Durairaj, Rajesh/0000-0002-3807-4174; GOVINDARAJU, ARCHUNAN/0000-0002-7094-0351; PADMANABHAN, PARASURAMAN/0000-0003-4112-4600; Ramalingam, RajKumar/0000-0003-2267-1502; Ganesan, Saibaba/0000-0002-6347-142X; Muthukumar, Subramanian/0000-0002-4317-8621	Department of Biotechnology [BT/PR/10247/AAQ/364/2007]; Indian Council of Agricultural Research (ICAR)-National Fund; University Grants Commission Special Assistance Programme (UGC-SAP); Department of Science and Technology-Promotion of University Research and Scientific Excellence (DST-PURSE), Government of India	Department of Biotechnology; Indian Council of Agricultural Research (ICAR)-National Fund(Indian Council of Agricultural Research (ICAR)); University Grants Commission Special Assistance Programme (UGC-SAP); Department of Science and Technology-Promotion of University Research and Scientific Excellence (DST-PURSE), Government of India	The authors thank Dr. Chellam Balasundaram (Emeritus Professor, Department of Animal Science, Bharathidasan University, Tiruchirappalli, TN, India) for his critical reading of the manuscript.. The financial support received from the Department of Biotechnology (BT/PR/10247/AAQ/364/2007), the Indian Council of Agricultural Research (ICAR)-National Fund, and instrumentation facility from the University Grants Commission Special Assistance Programme (UGC-SAP) and Department of Science and Technology-Promotion of University Research and Scientific Excellence (DST-PURSE), Government of India, is gratefully acknowledged The authors thank M. Dinesh [International Center for Genetic Engineering and Biotechnology (ICGEB), New Delhi, NCT, India] for providing TLR 4 antibody. S.M. thanks the Council of Scientific and Industrial Research (CSIR; New Delhi, NCT, India) for the award of a Senior Research Fellowship. P.P. and B.G. acknowledge support from the Lee Kong Chian School of Medicine (Nanyang Technological University, Singapore). The authors thank the PRIDE Team for the processing and deposition of the MS data, which have been deposited with the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository (57) with the dataset identifier PXD000816.	Anil S, 1995, Ann Dent, V54, P30; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardiovascular Proteomics Center, STRAP SOFTW TOOL RAP; CARTER RR, 1990, J ANIM SCI, V68, P2811; Caseiro A, 2013, J PROTEOME RES, V12, P1700, DOI 10.1021/pr3010343; Danell B., 1984, IND J ANIM REPROD, V5, P1; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Drost M, 2007, THERIOGENOLOGY, V68, P447, DOI 10.1016/j.theriogenology.2007.04.012; EDGAR WM, 1992, BRIT DENT J, V172, P305, DOI 10.1038/sj.bdj.4807861; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Gatlin CL, 2000, ANAL CHEM, V72, P757, DOI 10.1021/ac991025n; Gerard N, 2004, J ENDOCRINOL, V180, P203, DOI 10.1677/joe.0.1800203; HAAGENSEN DE, 1990, ANN NY ACAD SCI, V586, P161, DOI 10.1111/j.1749-6632.1990.tb17804.x; Hermann BP, 2007, MOL CELL ENDOCRINOL, V260, P100, DOI 10.1016/j.mce.2006.09.005; Hofman LF, 2001, J NUTR, V131, p1621S, DOI 10.1093/jn/131.5.1621S; Huang CM, 2004, ARCH ORAL BIOL, V49, P951, DOI 10.1016/j.archoralbio.2004.06.003; Ji H, 2014, RES VET SCI, V96, P526, DOI 10.1016/j.rvsc.2014.02.010; JONES WT, 1982, BIOCHIM BIOPHYS ACTA, V701, P382, DOI 10.1016/0167-4838(82)90241-2; Karthikeyan K, 2013, ANIM REPROD SCI, V138, P163, DOI 10.1016/j.anireprosci.2013.02.017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMKIN MS, 1993, CRIT REV ORAL BIOL M, V4, P251, DOI 10.1177/10454411930040030101; Lamy E, 2009, PHYSIOL BEHAV, V98, P393, DOI 10.1016/j.physbeh.2009.07.002; LEBIODA L, 1991, INT J BIOL MACROMOL, V13, P97, DOI 10.1016/0141-8130(91)90055-Y; LETICGAVRILOVIC A, 1990, J DENT RES, V69, P1494, DOI 10.1177/00220345900690080901; LEVINE MJ, 1993, ANN NY ACAD SCI, V694, P11; Liu Z, 2008, J ASSIST REPROD GEN, V25, P223, DOI 10.1007/s10815-008-9219-0; Marchese S, 1998, EUR J BIOCHEM, V252, P563, DOI 10.1046/j.1432-1327.1998.2520563.x; Mau M, 2006, ARCH TIERZUCHT, V49, P439, DOI 10.5194/aab-49-439-2006; MCDOUGALL EI, 1948, BIOCHEM J, V43, P99, DOI 10.1042/bj0430099; MCLAREN RD, 1987, ELECTROPHORESIS, V8, P318, DOI 10.1002/elps.1150080705; Millea KM, 2007, BBA-PROTEINS PROTEOM, V1774, P897, DOI 10.1016/j.bbapap.2007.04.017; Mirels L, 1998, J HISTOCHEM CYTOCHEM, V46, P1061, DOI 10.1177/002215549804600910; Muthukumar S, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.113852; Muthukumar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071357; PATTERSON J, 1982, Q J EXP PHYSIOL CMS, V67, P57, DOI 10.1113/expphysiol.1982.sp002624; Rajanarayanan S, 2004, THERIOGENOLOGY, V61, P861, DOI 10.1016/j.theriogenology.2003.07.004; Rajanarayanan S, 2011, RES VET SCI, V91, P301, DOI 10.1016/j.rvsc.2010.12.005; Rajkumar R, 2010, RAPID COMMUN MASS SP, V24, P3248, DOI 10.1002/rcm.4766; RATHMAN WM, 1989, J BIOL BUCCALE, V17, P199; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; Saito R, 2012, NAT METHODS, V9, P1069, DOI [10.1038/NMETH.2212, 10.1038/nmeth.2212]; Scaloni A, 2001, CELL MOL LIFE SCI, V58, P823, DOI 10.1007/PL00000903; SCHRAMM W, 1991, CLIN CHEM, V37, P114; Shimada M, 2008, DEVELOPMENT, V135, P2001, DOI 10.1242/dev.020461; Shimada M, 2006, MOL ENDOCRINOL, V20, P3228, DOI 10.1210/me.2006-0194; Shimada T, 2006, J CHEM ECOL, V32, P1149, DOI 10.1007/s10886-006-9077-0; Singh J, 2000, ANIM REPROD SCI, V60, P593, DOI 10.1016/S0378-4320(00)00109-3; Subedi K, 2007, J REPROD DEVELOP, V53, P1227, DOI 10.1262/jrd.19076; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Suthar VS, 2010, VET WORLD, V3, P94; Tabak LA, 2004, J DENT RES, V83, P196, DOI 10.1177/154405910408300301; Tang Xiaolin, 2003, Hua Xi Kou Qiang Yi Xue Za Zhi, V21, P98; Tsai H, 1998, CRIT REV ORAL BIOL M, V9, P480, DOI 10.1177/10454411980090040601; Vizcaino JA, 2013, NUCLEIC ACIDS RES, V41, pD1063, DOI 10.1093/nar/gks1262; Williams KM, 1998, ANAL CHIM ACTA, V372, P249, DOI 10.1016/S0003-2670(98)00339-0; Williams KM, 1999, ELECTROPHORESIS, V20, P1373, DOI 10.1002/(SICI)1522-2683(19990601)20:7<1373::AID-ELPS1373>3.3.CO;2-Q; Williams KM, 1999, ELECTROPHORESIS, V20, P2818, DOI 10.1002/(SICI)1522-2683(19991001)20:14&lt;2818::AID-ELPS2818&gt;3.0.CO;2-W	57	13	14	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4700	4709		10.1096/fj.14-252288	http://dx.doi.org/10.1096/fj.14-252288			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25114174				2022-12-28	WOS:000344050900011
J	Qiao, Q; Teng, XY; Wang, N; Lu, RQ; Guo, L; Zhang, X; Du, YQ; Wang, WJ; Chen, SN; Wu, Q; He, GS; Wang, YW; Hu, WG				Qiao, Qian; Teng, Xiaoyan; Wang, Na; Lu, Renquan; Guo, Lin; Zhang, Xin; Du, Yiqun; Wang, Wenjuan; Chen, Suning; Wu, Qian; He, Guangsheng; Wang, Yingwei; Hu, Weiguo			A novel CRIg-targeted complement inhibitor protects cells from complement damage	FASEB JOURNAL			English	Article						paroxysmal nocturnal hemoglobinuria; mesangioproliferative glomerulonephritis; factor H	PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; HEMOLYTIC-UREMIC SYNDROME; FACTOR-H; REGULATORY PROTEINS; ALTERNATIVE PATHWAY; MACULAR DEGENERATION; BLOOD-CELLS; ACTIVATION; GLOMERULONEPHRITIS; ECULIZUMAB	The inappropriate activation of complement may contribute to various immune diseases. The alternative pathway (AP) predominates during complement activation regardless of the initiating pathways. Hence, the main AP regulator factor H (FH) holds great potential as an attractive therapeutic intervention. In addition, complement receptor of the immunoglobulin superfamily (CRIg) has been demonstrated to inhibit AP and, more notably, still specifically binds to C3b/iC3b. We thus developed novel CRIg-targeted complement inhibitors by connecting the functional domains of CRIg and FH, which we termed CRIg-FH and CRIg-L-FH. CRIg-L-FH, slightly more potent than CRIg-FH, considerably inhibited both AP- and also classical pathway (CP)-mediated hemolysis and successfully eliminated the deposition of C3b/iC3b. Kinetic analysis further revealed that the binding affinity constant (K-D) of CRIg/FH was in the micromolar range, consistent with its long-lasting binding to complement-attacked cells. CRIg-L-FH efficiently protected aberrant erythrocytes of patients with paroxysmal nocturnal hemoglobinuria (PNH) from AP- and CP-mediated complement damage (IC50 was 22.43 and 64.69 nM, respectively). Moreover, CRIg-L-FH was found to inhibit complement activation induced by the anti-Thy1 antibody in a mesangioproliferative glomerulonephritis (MPGN) rat model. Hence, CRIg-L-FH protects glomerular mesangial cells (GMCs) from complement-mediated injury and proliferative lesions. These findings strongly suggest that CRIg/FH is a potential therapeutic drug candidate for a range of complement-mediated diseases.Qiao, Q., Teng, X., Wang, N., Lu, R., Guo, L., Zhang, X., Du, Y., Wang, W., Chen, S., Wu, Q., He, G., Wang, Y., and Hu, W. A novel CRIg-targeted complement inhibitor protects cells from complement damage.	[Qiao, Qian; Teng, Xiaoyan; Wang, Na; Lu, Renquan; Guo, Lin; Zhang, Xin; Du, Yiqun; Hu, Weiguo] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai 200032, Peoples R China; [Qiao, Qian; Teng, Xiaoyan; Wang, Na; Lu, Renquan; Guo, Lin; Zhang, Xin; Du, Yiqun; Hu, Weiguo] Fudan Univ, Inst Biomed Sci, Shanghai Med Coll, Shanghai 200032, Peoples R China; [Qiao, Qian; Teng, Xiaoyan; Wang, Na; Lu, Renquan; Guo, Lin; Zhang, Xin; Du, Yiqun; Hu, Weiguo] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200032, Peoples R China; [Hu, Weiguo] Fudan Univ, Dept Immunol, Shanghai Med Coll, Shanghai 200032, Peoples R China; [Wang, Wenjuan; Chen, Suning; Wu, Qian; He, Guangsheng] Soochow Univ, Affiliated Hosp 1, Key Lab Thrombosis & Hematostasis, Minist Hlth,Jiangsu Inst Hematol,Dept Hematol, Suzhou, Peoples R China; [Wang, Yingwei] Nanjing Med Univ, Dept Microbiol & Immunol, Nanjing, Jiangsu, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Soochow University - China; Nanjing Medical University	Hu, WG (corresponding author), Fudan Univ, Inst Canc, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.	weiguohu@fudan.edu.cn	Hu, Weiguo/AAP-2239-2021	Hu, Weiguo/0000-0002-7397-6800	National Natural Science Foundation of China [81171910]; Major State Basic Research Development Program of China [2013CB910802]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major State Basic Research Development Program of China(National Basic Research Program of China); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning	The authors thank E. Yvonne Jones (Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK) for the kind gift of pHLsec vector. This work was supported by the National Natural Science Foundation of China (81171910); the Major State Basic Research Development Program of China (2013CB910802); and the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (to W.H.). The authors declare no conflicts of interest.	Alegretti AP, 2012, CELL IMMUNOL, V277, P1, DOI 10.1016/j.cellimm.2012.06.008; Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799; Banda NK, 2009, J IMMUNOL, V183, P5928, DOI 10.4049/jimmunol.0901826; Barros MMO, 2009, TRANSFUSION, V49, P154, DOI 10.1111/j.1537-2995.2008.01936.x; Brandt J, 1996, KIDNEY INT, V49, P335, DOI 10.1038/ki.1996.50; Brodsky RA, 2008, BLOOD, V111, P1840, DOI 10.1182/blood-2007-06-094136; Fridkis-Hareli M, 2011, BLOOD, V118, P4705, DOI 10.1182/blood-2011-06-359646; GORDON DL, 1995, J IMMUNOL, V155, P348; Harboe M, 2008, J CELL MOL MED, V12, P1074, DOI 10.1111/j.1582-4934.2008.00350.x; Hebecker M, 2013, J IMMUNOL, V191, P912, DOI 10.4049/jimmunol.1300269; Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039; Hu WG, 2010, J IMMUNOL, V184, P359, DOI 10.4049/jimmunol.0902278; Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172; Katschke KJ, 2007, J EXP MED, V204, P1319, DOI 10.1084/jem.20070432; Keating GM, 2013, DRUGS, V73, P2053, DOI 10.1007/s40265-013-0147-7; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Koehl J, 2006, CURR OPIN MOL THER, V8, P529; Li Jennifer S, 2006, Expert Rev Cardiovasc Ther, V4, P649, DOI 10.1586/14779072.4.5.649; Lindorfer MA, 2010, BLOOD, V115, P2283, DOI 10.1182/blood-2009-09-244285; Liu LS, 2012, J BIOL CHEM, V287, P16410, DOI 10.1074/jbc.M111.319566; Longhurst HJ, 2007, CLIN EXP IMMUNOL, V147, P11, DOI 10.1111/j.1365-2249.2006.03256.x; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814; OLLERT MW, 1994, J IMMUNOL, V153, P2213; Parker C, 2005, BLOOD, V106, P3699, DOI 10.1182/blood-2005-04-1717; Parker CJ, 1996, STEM CELLS, V14, P396, DOI 10.1002/stem.140396; PETERS DK, 1972, CLIN EXP IMMUNOL, V11, P311; Qu HC, 2011, MOL IMMUNOL, V48, P481, DOI 10.1016/j.molimm.2010.10.004; Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20; Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Risitano AM, 2014, BLOOD, V123, P2094, DOI 10.1182/blood-2013-11-536573; Risitano AM, 2012, BLOOD, V119, P6307, DOI 10.1182/blood-2011-12-398792; Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222; Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344; Ruiz-Arguelles A, 2007, AUTOIMMUN REV, V6, P155, DOI 10.1016/j.autrev.2006.09.008; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348; Song WC, 2006, AUTOIMMUNITY, V39, P403, DOI 10.1080/08916930600739647; Tanaka T, 2005, KIDNEY INT, V68, P2714, DOI 10.1111/j.1523-1755.2005.00742.x; Thomas TC, 1996, MOL IMMUNOL, V33, P1389, DOI 10.1016/S0161-5890(96)00078-8; Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388; Turnberg D, 2005, CURR OPIN NEPHROL HY, V14, P223, DOI 10.1097/01.mnh.0000165887.75501.24; VANDERSCHOOT CE, 1990, BLOOD, V76, P1853; WEISMAN HF, 1990, T ASSOC AM PHYSICIAN, V103, P64; Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263; Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755; Zhou XH, 2008, ONCOLOGIST, V13, P954, DOI 10.1634/theoncologist.2008-0089; Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2	49	17	17	3	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4986	4999		10.1096/fj.14-258046	http://dx.doi.org/10.1096/fj.14-258046			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25114177				2022-12-28	WOS:000344050900034
J	Tonna, S; Takyar, FM; Vrahnas, C; Crimeen-Irwin, B; Ho, PWM; Poulton, IJ; Brennan, HJ; McGregor, NE; Allan, EH; Nguyen, H; Forwood, MR; Tatarczuch, L; Mackie, EJ; Martin, TJ; Sims, NA				Tonna, Stephen; Takyar, Farzin M.; Vrahnas, Christina; Crimeen-Irwin, Blessing; Ho, Patricia W. M.; Poulton, Ingrid J.; Brennan, Holly J.; McGregor, Narelle E.; Allan, Elizabeth H.; Nguyen, Huynh; Forwood, Mark R.; Tatarczuch, Liliana; Mackie, Eleanor J.; Martin, T. John; Sims, Natalie A. z			EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis	FASEB JOURNAL			English	Article						osteocyte; osteoclast; bone matrix; bone strength	PARATHYROID-HORMONE; COLLAGEN SECRETION; KAPOSI-SARCOMA; EPH RECEPTORS; TUMOR-GROWTH; IN-VIVO; INHIBITION; GENE; MICE; DIFFERENTIATION	Cells that form bone (osteoblasts) express both ephrinB2 and EphB4, and previous work has shown that pharmacological inhibition of the ephrinB2/EphB4 interaction impairs osteoblast differentiation in vitro and in vivo. The purpose of this study was to determine the role of ephrinB2 signaling in the osteoblast lineage in the process of bone formation. Cultured osteoblasts from mice with osteoblast-specific ablation of ephrinB2 showed delayed expression of osteoblast differentiation markers, a finding that was reproduced by ephrinB2, but not EphB4, RNA interference. Microcomputed tomography, histomorphometry, and mechanical testing of the mice lacking ephrinB2 in osteoblasts revealed a 2-fold delay in bone mineralization, a significant reduction in bone stiffness, and a 50% reduction in osteoblast differentiation induced by anabolic parathyroid hormone (PTH) treatment, compared to littermate sex- and age-matched controls. mRNA levels of late osteoblast differentiation markers and greater levels of osteoblast and osteocyte apoptosis, indicated by TUNEL staining and transmission electron microscopy of bone samples, and a 2-fold increase in annexin V staining and 7-fold increase in caspase 8 activation in cultured ephrinB2 deficient osteoblasts. We conclude that osteoblast differentiation and bone strength are maintained by antiapoptotic actions of ephrinB2 signaling within the osteoblast lineage.-Tonna, S., Takyar, F. M., Vrahnas, C., Crimeen-Irwin, B., Ho, P. W. M., Poulton, I. J., Brennan, H. J., McGregor, N. E., Allan, E. H., Nguyen, H., Forwood, M. R., Tatarczuch, L., Mackie, E. J., Martin, T. J., Sims, N. A. EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis.	[Tonna, Stephen; Takyar, Farzin M.; Vrahnas, Christina; Crimeen-Irwin, Blessing; Ho, Patricia W. M.; Poulton, Ingrid J.; Brennan, Holly J.; McGregor, Narelle E.; Allan, Elizabeth H.; Martin, T. John; Sims, Natalie A. z] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; [Tonna, Stephen; Takyar, Farzin M.; Vrahnas, Christina; Martin, T. John; Sims, Natalie A. z] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia; [Tatarczuch, Liliana; Mackie, Eleanor J.] Univ Melbourne, Fac Vet Sci, Parkville, Vic 3052, Australia; [Nguyen, Huynh; Forwood, Mark R.] Griffith Univ, Sch Med Sci, Griffith Hlth Inst, Gold Coast, Qld, Australia	St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne; University of Melbourne; Griffith University; Menzies Health Institute Queensland	Sims, NA (corresponding author), St Vincents Inst Med Res, Bone Cell Biol & Dis Unit, 9 Princes St, Fitzroy, Vic 3065, Australia.	nsims@svi.edu.au	Mackie, Eleanor J/B-2045-2008; Sims, Natalie Ann/A-7192-2012; Forwood, Mark/ABA-9040-2021	Mackie, Eleanor J/0000-0002-8057-5407; Sims, Natalie Ann/0000-0003-1421-8468; Tatarczuch, Liliana/0000-0001-9556-0753; Forwood, Mark/0000-0002-9963-1616	National Health and Medical Research Council (NHMRC; Australia) [620600, 1042129]; NHMRC; University of Melbourne at Melbourne Research Scholarship; Melbourne International Fee Remission Scholarship; St. Vincent's Institute Foundation; Victorian State Government Operational Infrastructure Program	National Health and Medical Research Council (NHMRC; Australia)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); University of Melbourne at Melbourne Research Scholarship; Melbourne International Fee Remission Scholarship; St. Vincent's Institute Foundation; Victorian State Government Operational Infrastructure Program	The authors thank Joshua Johnson for technical assistance, St. Vincent's BioResources Centre staff for animal care, and Carl Walkley and Brian Liddicoat for helpful advice and assistance with the preparation of lenti-Cre reagents. This work was supported by National Health and Medical Research Council (NHMRC; Australia) project grants 620600 and 1042129; N.A.S. is supported by an NHMRC Senior Research Fellowship. S.T. is supported by an NHMRC Peter Doherty Postdoctoral Fellowship. F.T. was supported by a University of Melbourne at Melbourne Research Scholarship, a Melbourne International Fee Remission Scholarship, and a St. Vincent's Institute Foundation Scholarship. St. Vincent's Institute receives support from the Victorian State Government Operational Infrastructure Program. N.A.S. and T.J.M. jointly conceived the study; S.T., F.M.T., C.V., B.C.-I., P.W.M.H., N.E.M., E.H.A., I.J.P., and H.J.B. performed experiments and carried out analyses; H.N. and M.J.F. carried out 3-point bending tests with C.V. and provided interpretation; L.T. and E.J.M. carried out TEM analysis and provided interpretation; N.A.S., T.J.M., and S.T. wrote the manuscript; all authors discussed the results and commented on the manuscript at all stages. The authors declare no conflicts of interest.	Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107; Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614; Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324; Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200; Arthur A, 2013, J BONE MINER RES, V28, P926, DOI 10.1002/jbmr.1821; Arthur A, 2011, BONE, V48, P533, DOI 10.1016/j.bone.2010.10.180; Boskey AL, 1998, BONE, V23, P187, DOI 10.1016/S8756-3282(98)00092-1; Boyadjiev SA, 2006, NAT GENET, V38, P1192, DOI 10.1038/ng1876; Cerri PS, 2005, ANAT REC PART A, V286A, P833, DOI 10.1002/ar.a.20220; Davydova N, 2012, PROTEIN EXPRES PURIF, V82, P232, DOI 10.1016/j.pep.2012.01.001; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 2000, METHOD ENZYMOL, V327, P19, DOI 10.1016/S0076-6879(00)27264-9; Frost HM, 1964, BONE BIODYNAMICS, V1st, P315; Gerety SS, 2002, DEVELOPMENT, V129, P1397; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183; Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200; Johnson RW, 2014, J BONE MINER RES, V29, P1492, DOI 10.1002/jbmr.2159; Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018; Kelly PN, 2011, CELL DEATH DIFFER, V18, P1414, DOI 10.1038/cdd.2011.17; Kertesz N, 2006, BLOOD, V107, P2330, DOI 10.1182/blood-2005-04-1655; Koolpe M, 2005, J BIOL CHEM, V280, P17301, DOI 10.1074/jbc.M500363200; Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047; Martin TJ, 2010, ADV EXP MED BIOL, V658, P51, DOI 10.1007/978-1-4419-1050-9_6; Martiny-Baron G, 2004, NEOPLASIA, V6, P248, DOI 10.1593/neo.03457; Masood R, 2005, BLOOD, V105, P1310, DOI 10.1182/blood-2004-03-0933; MELSEN F, 1980, ACTA PATH MICRO IM A, V88, P83; Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Nagase Y, 2009, J BIOL CHEM, V284, P36659, DOI 10.1074/jbc.M109.016915; Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025; Noren NK, 2009, BIOCHEM J, V422, P433, DOI 10.1042/BJ20090014; Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010; Parfitt AM, 1996, ANN INTERN MED, V125, P413, DOI 10.7326/0003-4819-125-5-199609010-00009; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Quinn JMW, 2008, J IMMUNOL, V181, P5720, DOI 10.4049/jimmunol.181.8.5720; Roche B, 2012, BONE, V50, P390, DOI 10.1016/j.bone.2011.09.051; Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Sarathchandra P, 2000, J PATHOL, V192, P385; Scehnet JS, 2009, BLOOD, V113, P254, DOI 10.1182/blood-2008-02-140020; Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215; Takyar FM, 2013, J BONE MINER RES, V28, P912, DOI 10.1002/jbmr.1820; Townley AK, 2008, J CELL SCI, V121, P3025, DOI 10.1242/jcs.031070; van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454; Walker EC, 2012, J BONE MINER RES, V27, P902, DOI 10.1002/jbmr.1506; Weiler S, 2009, DEV GROWTH DIFFER, V51, P809, DOI 10.1111/j.1440-169X.2009.01140.x; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Wilson DG, 2011, J CELL BIOL, V193, P935, DOI 10.1083/jcb.201007162; Xing WR, 2010, MOL CELL BIOL, V30, P711, DOI 10.1128/MCB.00610-09; Yadav MC, 2012, J BONE MINER RES, V27, P1722, DOI 10.1002/jbmr.1619; Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105; Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012; Zhou RP, 1998, PHARMACOL THERAPEUT, V77, P151, DOI 10.1016/S0163-7258(97)00112-5	57	53	57	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4482	4496		10.1096/fj.14-254300	http://dx.doi.org/10.1096/fj.14-254300			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24982128				2022-12-28	WOS:000342222700025
J	Zolnerciks, JK; Akkaya, BG; Snippe, M; Chiba, P; Seelig, A; Linton, KJ				Zolnerciks, Joseph K.; Akkaya, Begum G.; Snippe, Marjolein; Chiba, Peter; Seelig, Anna; Linton, Kenneth J.			The Q loops of the human multidrug resistance transporter ABCB1 are necessary to couple drug binding to the ATP catalytic cycle	FASEB JOURNAL			English	Article						ABC transporter molecular mechanism; drug efflux pump; MDR1; membrane protein; primary active transport	P-GLYCOPROTEIN REVEALS; CASSETTE TRANSPORTER; CRYSTAL-STRUCTURE; MALTOSE TRANSPORTER; MONOCLONAL-ANTIBODY; GLUTAMATE RESIDUES; ALTERNATING ACCESS; PLASMA-MEMBRANE; HIGH-AFFINITY; LIVING CELLS	For a primary active pump, such as the human ATP-binding-cassette (ABC) transporter ABCB1, coupling of drug-binding by the two transmembrane domains (TMDs) to the ATP catalytic cycle of the two nucleotide-binding domains (NBDs) is fundamental to the transport mechanism, but is poorly understood at the biochemical level. Structure data suggest that signals are transduced through intracellular loops of the TMDs that slot into grooves on the NBDs. At the base of these grooves is the Q loop. We therefore mutated the eponymous glutamine in one or both NBD Q loops and measured the effect on conformation and function by using a conformation-sensitive antibody (UIC2) and a fluorescent drug (Bodipy-verapamil), respectively. We showed that the double mutant is trapped in the inward-open state, which binds the drug, but cannot couple to the ATPase cycle. Our data also describe marked redundancy within the transport mechanism, because single-Q-loop mutants are functional for Bodipy-verapamil transport. This result allowed us to elucidate transduction pathways from twin drug-binding cavities to the Q loops using point mutations to favor one cavity over the other. Together, the data show that the Q loop is the central flexion point where the aspect of the drug-binding cavities is coupled to the ATP catalytic cycle.	[Zolnerciks, Joseph K.; Akkaya, Begum G.; Snippe, Marjolein; Linton, Kenneth J.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London E1 2AT, England; [Chiba, Peter] Med Univ Vienna, Inst Med Chem, Vienna, Austria; [Seelig, Anna] Univ Basel, Biophys Chem Biozentrum, Basel, Switzerland	University of London; Queen Mary University London; Medical University of Vienna; University of Basel	Linton, KJ (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, Ctr Cutaneous Res, 4 Newark St, London E1 2AT, England.	k.j.linton@qmul.ac.uk	Chiba, Peter/ABA-7347-2020	Chiba, Peter/0000-0003-4465-5263	Medical Research Council UK; Federation of European Biological Societies (FEBS) short-term fellowship; Queen Mary, University of London; Medical Research Council [MC_U120088463] Funding Source: researchfish; MRC [MC_U120088463] Funding Source: UKRI	Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Federation of European Biological Societies (FEBS) short-term fellowship; Queen Mary, University of London; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank T. Ritchie for practical investigations and intellectual contribution to the manuscript, M. Zwick and C. Esposito for assistance with the cytosensor experiments and valuable discussions, and T. Stockner for use of his homology model of ABCB1. This work was supported by the Medical Research Council UK and a Federation of European Biological Societies (FEBS) short-term fellowship to J.K.Z. B.G.A. is funded by Queen Mary, University of London.	Aanismaa P, 2007, BIOCHEMISTRY-US, V46, P3394, DOI 10.1021/bi0619526; Aller SG, 2009, SCIENCE, V323, P1718, DOI 10.1126/science.1168750; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; Blatter XL, 2010, BIOPHYS J, V99, P3589, DOI 10.1016/j.bpj.2010.10.033; Blott EJ, 1999, EMBO J, V18, P6800, DOI 10.1093/emboj/18.23.6800; Cakil YD, 2014, MOL PHARMACOL, V85, P420, DOI 10.1124/mol.113.088526; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Dixon PH, 2000, HUM MOL GENET, V9, P1209, DOI 10.1093/hmg/9.8.1209; Gatlik-Landwojtowicz E, 2006, BIOCHEMISTRY-US, V45, P3020, DOI 10.1021/bi051380+; Gaudet R, 2001, TECHNOL REV, V104, P20; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; Hollenstein K, 2007, NATURE, V446, P213, DOI 10.1038/nature05626; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Jin MS, 2012, NATURE, V490, P566, DOI 10.1038/nature11448; Kadaba NS, 2008, SCIENCE, V321, P250, DOI 10.1126/science.1157987; Khare D, 2009, MOL CELL, V33, P528, DOI 10.1016/j.molcel.2009.01.035; Kimura Y, 2007, BIOCHEM J, V401, P597, DOI 10.1042/BJ20060632; Landwojtowicz E, 2002, BIOCHEMISTRY-US, V41, P8050, DOI 10.1021/bi025720s; Linton KJ, 2007, PFLUG ARCH EUR J PHY, V453, P555, DOI 10.1007/s00424-006-0126-x; Litman T, 1997, BBA-MOL BASIS DIS, V1361, P147, DOI 10.1016/S0925-4439(97)00025-2; Litman T, 1997, BBA-MOL BASIS DIS, V1361, P159, DOI 10.1016/S0925-4439(97)00026-4; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2006, BIOCHEM J, V399, P351, DOI 10.1042/BJ20060715; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Martin C, 2001, BIOCHEMISTRY-US, V40, P15733, DOI 10.1021/bi011211z; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MECHETNER EB, 1992, P NATL ACAD SCI USA, V89, P5824, DOI 10.1073/pnas.89.13.5824; Nervi P, 2010, BBA-BIOMEMBRANES, V1798, P515, DOI 10.1016/j.bbamem.2009.11.022; Oldham ML, 2007, NATURE, V450, P515, DOI 10.1038/nature06264; Orelle C, 2010, P NATL ACAD SCI USA, V107, P20293, DOI 10.1073/pnas.1006544107; Parveen Z, 2011, MOL PHARMACOL, V79, P443, DOI 10.1124/mol.110.067611; Pleban K, 2005, MOL PHARMACOL, V67, P365, DOI 10.1124/mol.104.006973; Ritchie TK, 2009, METHOD ENZYMOL, V464, P211, DOI 10.1016/S0076-6879(09)64011-8; Rothnie A, 2001, EUR BIOPHYS J BIOPHY, V30, P430, DOI 10.1007/s002490100156; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Shintre CA, 2013, P NATL ACAD SCI USA, V110, P9710, DOI 10.1073/pnas.1217042110; Stockner T, 2009, FEBS J, V276, P964, DOI 10.1111/j.1742-4658.2008.06832.x; Tal N, 2013, P NATL ACAD SCI USA, V110, P5434, DOI 10.1073/pnas.1209644110; Taylor AM, 2001, BRIT J PHARMACOL, V134, P1609, DOI 10.1038/sj.bjp.0704400; Tombline G, 2004, J BIOL CHEM, V279, P31212, DOI 10.1074/jbc.M404689200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P11921, DOI 10.1021/bi001220s; Urbatsch IL, 2001, ARCH BIOCHEM BIOPHYS, V388, P171, DOI 10.1006/abbi.2001.2299; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; van der Does C, 2004, BIOL CHEM, V385, P927, DOI 10.1515/BC.2004.121; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; WALTER C, 1992, FEBS LETT, V303, P41, DOI 10.1016/0014-5793(92)80473-T; Ward A, 2007, P NATL ACAD SCI USA, V104, P19005, DOI 10.1073/pnas.0709388104; Zhou Y, 1999, ARCH BIOCHEM BIOPHYS, V367, P74, DOI 10.1006/abbi.1999.1221; Zolnerciks JK, 2007, FASEB J, V21, P3937, DOI 10.1096/fj.07-8610com	55	33	34	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4335	4346		10.1096/fj.13-245639	http://dx.doi.org/10.1096/fj.13-245639			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25016028	Green Submitted			2022-12-28	WOS:000342222700013
J	Dong, YJ; Silva, KAS; Dong, YL; Zhang, LP				Dong, Yanjun; Santos Silva, Kleiton Augusto; Dong, Yanlan; Zhang, Liping			Glucocorticoids increase adipocytes in muscle by affecting IL-4 regulated FAP activity	FASEB JOURNAL			English	Article						progenitors; dexamethasone	SKELETAL-MUSCLE; STEM-CELLS; INSULIN-RESISTANCE; SATELLITE CELLS; FIBRO/ADIPOGENIC PROGENITORS; ADIPOGENIC DIFFERENTIATION; CUSHINGS-SYNDROME; METABOLISM; MYOGENESIS; OBESITY	An increase in intramuscular adipocyte tissue (IMAT) is associated with glucose dysregulation, decreased muscle strength, and increased risk of disability. Unfortunately, the mechanisms stimulating intramuscular adipogenesis remain unclear. We found that dexamethasone (Dex) administration to mice with injured muscles stimulates the accumulation of IMAT. To identify precursors of these adipocytes, we isolated satellite cells and fibro/adipogenic progenitors (FAPs) from muscle; satellite cells did not differentiate into adipocytes even following Dex treatment. In contrast, Dex stimulated FAP differentiation into adipocytes. In vivo, we transplanted purified FAPs from transgenic, EGFP mice into the injured muscles of C57/BL6 mice and found that Dex administration stimulated adipogenesis from FAP-EGFP. The increase in adipogenesis depended on Dex-induced inhibition of interleukin-4 (IL-4). In the injured muscle of IL-4-knockout mice, the levels of adipocytes were increased, while in the injured muscles of Dex-treated mice with IL-4 injections, adipogenesis was suppressed. In cultured FAPs, IL-4 inhibited Dex-induced conversion of FAPs into adipocytes; this did not occur in FAPs expressing knockdown of the IL-4 receptor. Thus, we concluded that glucocorticoids stimulate FAPs to differentiate into adipocytes in injured muscles. This process is blocked by IL-4, suggesting that interfering with IL-4 signaling could prevent adipogenesis in muscle.	[Dong, Yanjun; Santos Silva, Kleiton Augusto; Dong, Yanlan; Zhang, Liping] Baylor Coll Med, Div Nephrol, Houston, TX 77030 USA; [Dong, Yanjun] Capital Med Univ, Beijing Zhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China; [Santos Silva, Kleiton Augusto] Univ Fed Sao Paulo, Dept Med, Div Nephrol, Sao Paulo, Brazil	Baylor College of Medicine; Capital Medical University; Universidade Federal de Sao Paulo (UNIFESP)	Zhang, LP (corresponding author), Baylor Coll Med, Div Nephrol, M-S BCM 395,One Baylor Plaza,ABBR R705, Houston, TX 77030 USA.	lipingz@bcm.edu		Silva, Kleiton/0000-0001-8230-0012; Dong, Yanjun/0000-0001-6396-8949	Satellite Health; American Diabetic Association [1-11-BS-194]; U.S. National Institutes of Health (NIH) [R37 DK37175]; Cytometry and Cell Sorting Core at Baylor College of Medicine; NIH [AI036211, CA125123, RR024574, P30 DK079638]; Pilot/Feasibility Program of the Diabetes Research Center at Baylor College of Medicine; NATIONAL CANCER INSTITUTE [P30CA125123] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037175, P30DK079638] Funding Source: NIH RePORTER	Satellite Health; American Diabetic Association(American Diabetes Association); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cytometry and Cell Sorting Core at Baylor College of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pilot/Feasibility Program of the Diabetes Research Center at Baylor College of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. William E. Mitch for his critical review. This work was supported by the generous support of Dr. and Mrs. Harold Selzman, the Norman S. Coplon extramural research grants from Satellite Health and the American Diabetic Association (1-11-BS-194) to L.Z., U.S. National Institutes of Health (NIH) grant R37 DK37175, and the Cytometry and Cell Sorting Core at Baylor College of Medicine, with funding from the NIH (AI036211, CA125123, and RR024574), and the expert assistance of Joel M. Sederstrom. The work was supported in part by the Pilot/Feasibility Program of the Diabetes Research Center at Baylor College of Medicine, with funding from the NIH (P30 DK079638).	Aguiari P, 2008, P NATL ACAD SCI USA, V105, P1226, DOI 10.1073/pnas.0711402105; Andrew R, 2002, EXP CLIN ENDOCR DIAB, V110, P284, DOI 10.1055/s-2002-34591; Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432-0436.2001.680412.x; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Asensio C, 2004, INT J OBESITY, V28, pS45, DOI 10.1038/sj.ijo.0802856; Carcamo-Orive I, 2010, J BONE MINER RES, V25, P2115, DOI 10.1002/jbmr.120; Chang YH, 2012, INT J OBESITY, V36, P993, DOI 10.1038/ijo.2011.168; Cristancho AG, 2011, NAT REV MOL CELL BIO, V12, P722, DOI 10.1038/nrm3198; DASILVA ML, 2006, J CELL SCI, V119, P2204, DOI DOI 10.1242/JCS.02932; Delmonico MJ, 2009, AM J CLIN NUTR, V90, P1579, DOI 10.3945/ajcn.2009.28047; Dong YJ, 2013, AM J PHYSIOL-ENDOC M, V305, pE367, DOI 10.1152/ajpendo.00644.2012; Dong YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058554; Duclos M, 2001, CLIN ENDOCRINOL, V55, P447, DOI 10.1046/j.1365-2265.2001.01384.x; FANG CH, 1995, J AM COLL SURGEONS, V180, P33; Feldman BJ, 2006, P NATL ACAD SCI USA, V103, P15675, DOI 10.1073/pnas.0607501103; GOLDSPINK G, 1994, NEUROMUSCULAR DISORD, V4, P183, DOI 10.1016/0960-8966(94)90019-1; Goodpaster BH, 2004, PEDIATR DIABETES, V5, P219, DOI 10.1111/j.1399-543X.2004.00071.x; Gounarides JS, 2008, ENDOCRINOLOGY, V149, P758, DOI 10.1210/en.2007-1214; Heredia JE, 2013, CELL, V153, P376, DOI 10.1016/j.cell.2013.02.053; Hilton TN, 2008, PHYS THER, V88, P1336, DOI 10.2522/ptj.20080079; Hu Zhaoyong, 2009, J Clin Invest, V119, P3059, DOI 10.1172/JCI38770; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Joe AWB, 2010, NAT CELL BIOL, V12, P153, DOI 10.1038/ncb2015; Korach-Andre M, 2005, AM J PHYSIOL-ENDOC M, V288, pE106, DOI 10.1152/ajpendo.00089.2004; LAMAS AM, 1991, J IMMUNOL, V147, P254; Mann CJ, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-21; Matsuzaki Y, 2004, IMMUNITY, V20, P87, DOI 10.1016/S1074-7613(03)00354-6; MAY RC, 1986, J CLIN INVEST, V77, P614, DOI 10.1172/JCI112344; Mito N, 2000, METABOLISM, V49, P1295, DOI 10.1053/meta.2000.9523; Nakamura K, 2012, AGING-US, V4, P40; PASTORET C, 1995, J NEUROL SCI, V129, P97, DOI 10.1016/0022-510X(94)00276-T; Rask E, 2001, J CLIN ENDOCR METAB, V86, P1418, DOI 10.1210/jc.86.3.1418; Ricardo-Gonzalez RR, 2010, P NATL ACAD SCI USA, V107, P22617, DOI 10.1073/pnas.1009152108; ROSS EJ, 1982, LANCET, V2, P646; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; Seale P, 2001, DEV CELL, V1, P333, DOI 10.1016/S1534-5807(01)00049-1; Smas CM, 1999, J BIOL CHEM, V274, P12632, DOI 10.1074/jbc.274.18.12632; Starkey JD, 2011, J HISTOCHEM CYTOCHEM, V59, P33, DOI 10.1369/jhc.2010.956995; Tauchmanova L, 2002, J CLIN ENDOCR METAB, V87, P4872, DOI 10.1210/jc.2001-011766; Tidball JG, 2010, AM J PHYSIOL-REG I, V298, pR1173, DOI 10.1152/ajpregu.00735.2009; Tuttle Lori J, 2012, J Aging Res, V2012, P172957, DOI 10.1155/2012/172957; Uezumi A, 2011, J CELL SCI, V124, P3654, DOI 10.1242/jcs.086629; Uezumi A, 2010, NAT CELL BIOL, V12, P143, DOI 10.1038/ncb2014; Young HE, 2001, ANAT RECORD, V264, P51, DOI 10.1002/ar.1128; Zhang LP, 2012, J BIOL CHEM, V287, P6177, DOI 10.1074/jbc.M111.292649; Zhang LP, 2010, J AM SOC NEPHROL, V21, P419, DOI 10.1681/ASN.2009060571; Zhang LP, 2009, AM J PATHOL, V175, P2518, DOI 10.2353/ajpath.2009.090275; Zhang LP, 2009, J AM SOC NEPHROL, V20, P604, DOI 10.1681/ASN.2008060628	48	41	42	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4123	4132		10.1096/fj.14-254011	http://dx.doi.org/10.1096/fj.14-254011			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24948596	Green Published			2022-12-28	WOS:000340845900029
J	Hutcheson, R; Chaplin, J; Hutcheson, B; Borthwick, F; Proctor, S; Gebb, S; Jadhav, R; Smith, E; Russell, JC; Rocic, P				Hutcheson, Rebecca; Chaplin, Jennifer; Hutcheson, Brenda; Borthwick, Faye; Proctor, Spencer; Gebb, Sarah; Jadhav, Rashmi; Smith, Erika; Russell, James C.; Rocic, Petra			miR-21 normalizes vascular smooth muscle proliferation and improves coronary collateral growth in metabolic syndrome	FASEB JOURNAL			English	Article						transient repetitive ischemia; insulin resistance; arteriogenesis; molecular mechanisms; cell cycle	ACTIVATION; ENDOSTATIN; ISCHEMIA; VESSELS; INSULIN; DISEASE; IMPACT; CELLS; VEGF; RAT	Inadequate cell proliferation is considered a major causative factor for impaired coronary collateral growth (CCG). Proangiogenic growth factors (GFs) stimulate cell proliferation, but their administration does not promote CCG in patients. These GFs are increased in patients with metabolic syndrome and in animal models, where CCG is impaired. Here, we investigated whether excessive cell proliferation underlies impaired CCG in metabolic syndrome. Normal [Sprague-Dawley (SD)] and metabolic syndrome [James C. Russell (JCR)] rats underwent repetitive ischemia (RI; transient, repetitive coronary artery occlusion and myocardial ischemia). We have shown that CCG was maximal at d 9 of RI in SD rats but did not occur in JCR rats. The increase in cell proliferation (PCNA, Ki-67, cyclin A, phospho-cdc2, p21Waf, p27Kip) was transient (similar to 4-fold, d 3 RI) in SD rats but greater and sustained in JCR rats (similar to 8- to 6-fold, d 3-9 RI). In JCR rats, this was associated with increased and sustained miR-21 expression and accumulation of proliferating synthetic vascular smooth muscle cells in the lumen of small arterioles, which failed to undergo outward expansion. Administration of anti-miR-21 blocked RI-induced cell proliferation and significantly improved CCG in JCR rats (similar to 60%). miR-21-dependent excessive cell proliferation in the later stages of collateral remodeling correlates with impaired CCG in metabolic syndrome.	[Hutcheson, Rebecca; Hutcheson, Brenda; Rocic, Petra] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; [Chaplin, Jennifer; Jadhav, Rashmi; Smith, Erika] Univ S Alabama, Dept Biochem & Mol Biol, Mobile, AL 36688 USA; [Gebb, Sarah] Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA; [Borthwick, Faye; Proctor, Spencer; Russell, James C.] Univ Alberta, Alberta Inst Human Nutr, Metab & Cardiovasc Dis Lab, Edmonton, AB, Canada	New York Medical College; University of South Alabama; University of South Alabama; University of Alberta	Rocic, P (corresponding author), New York Med Coll, Dept Pharmacol, 15 Dana Rd,BSB 502, Valhalla, NY 10595 USA.	petra_rocic@nymc.edu	JADHAV, RASHMI/GQI-2890-2022	Rocic, Petra/0000-0002-5781-3075; Proctor, Spencer/0000-0002-7597-5262	U.S. National Institutes of Health [R01HL093052]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093052] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by U.S. National Institutes of Health grant R01HL093052.	Cai WJ, 2009, MOL CELL BIOCHEM, V322, P161, DOI 10.1007/s11010-008-9953-8; Choy JS, 2009, AM J PHYSIOL-HEART C, V297, pH750, DOI 10.1152/ajpheart.01136.2008; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Dodd T, 2013, ARTERIOSCL THROM VAS, V33, P1339, DOI 10.1161/ATVBAHA.113.301533; Dodd T, 2011, J MOL CELL CARDIOL, V51, P1015, DOI 10.1016/j.yjmcc.2011.08.012; Hattan N, 2007, BASIC RES CARDIOL, V102, P217, DOI 10.1007/s00395-007-0646-3; Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A; Hutcheson R, 2013, ARTERIOSCL THROM VAS, V33, P727, DOI 10.1161/ATVBAHA.112.301116; Hutcheson R, 2012, EXP DIABETES RES, DOI 10.1155/2012/271028; Jadhav R, 2011, AM J PHYSIOL-HEART C, V300, pH1938, DOI 10.1152/ajpheart.00282.2010; Jialal I, 2010, ATHEROSCLEROSIS, V211, P297, DOI 10.1016/j.atherosclerosis.2010.01.036; Jones WS, 2007, CURR OPIN CARDIOL, V22, P458, DOI 10.1097/HCO.0b013e328236741b; Lim HY, 2013, CELL METAB, V17, P671, DOI 10.1016/j.cmet.2013.04.002; Liu LZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019139; Matsunaga T, 2003, AM J PHYSIOL-HEART C, V285, pH352, DOI 10.1152/ajpheart.00621.2002; Muniyappa R, 2013, REV ENDOCR METAB DIS, V14, P5, DOI 10.1007/s11154-012-9229-1; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Rayner KJ, 2014, CIRC RES, V114, P183, DOI 10.1161/CIRCRESAHA.114.300645; Reed R, 2008, ARTERIOSCL THROM VAS, V28, P61, DOI 10.1161/ATVBAHA.107.154294; Reed R, 2009, AM J PHYSIOL-HEART C, V296, pH1811, DOI 10.1152/ajpheart.00920.2008; Ruiter MS, 2010, CLIN SCI, V119, P225, DOI 10.1042/CS20100082; Russell JC, 1998, MOL CELL BIOCHEM, V188, P113, DOI 10.1023/A:1006828724405; Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979; Sasmaz H, 2009, ANGIOLOGY, V60, P164, DOI 10.1177/0003319708316007; Scatena M, 2007, ARTERIOSCL THROM VAS, V27, P2302, DOI 10.1161/ATVBAHA.107.144824; Schneider DJ, 1998, DIABETOLOGIA, V41, P141, DOI 10.1007/s001250050882; Silvestri Pasquale, 2009, Recent Pat Cardiovasc Drug Discov, V4, P109; Sodha NR, 2009, AM J PHYSIOL-HEART C, V296, pH428, DOI 10.1152/ajpheart.00283.2008; Toyota E, 2005, CIRCULATION, V112, P2108, DOI 10.1161/CIRCULATIONAHA.104.526954; Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210; Wang Y, 2009, J NUTR, V139, P2049, DOI 10.3945/jn.109.109488; WEISER MM, 1973, J BIOL CHEM, V248, P2536; Zhou X, 2010, LAB INVEST, V90, P144, DOI 10.1038/labinvest.2009.126	33	18	20	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4088	4099		10.1096/fj.14-251223	http://dx.doi.org/10.1096/fj.14-251223			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24903275	Green Published			2022-12-28	WOS:000340845900026
J	De Filippo, K; Neill, DR; Mathies, M; Bangert, M; McNeill, E; Kadioglu, A; Hogg, N				De Filippo, Katia; Neill, Daniel R.; Mathies, Meg; Bangert, Mathieu; McNeill, Eileen; Kadioglu, Aras; Hogg, Nancy			A new protective role for S100A9 in regulation of neutrophil recruitment during invasive pneumococcal pneumonia	FASEB JOURNAL			English	Article						Streptococcus pneumoniae; leukocytes; G-CSF	COLONY-STIMULATING FACTOR; MYELOID-RELATED PROTEIN-8/14; G-CSF; STREPTOCOCCUS-PNEUMONIAE; LEUKOCYTE RECRUITMENT; IMMUNE-RESPONSE; LUNG INFECTION; HOST RESPONSE; GRANULOCYTE; EXPRESSION	The S100A8/A9 heterodimer is abundantly expressed by myeloid cells, especially neutrophils, but its mechanism of action is only partially determined. In this study we investigated S100A8/A9 involvement in the host response to Streptococcus pneumoniae infection making use of S100a9(-/-) mice that lack heterodimer expression in myeloid cells. S100a9(-/-) mice that were infected intranasally with pneumococci rapidly succumbed, with 80% mortality after 48 h, whereas the majority of wild-type mice recovered. Over this time period, S100a9(-/-) mice displayed an average 6-fold reduction in circulating and lung-recruited neutrophils. Taqman analysis of S100a9(-/-) lungs revealed decreased production of a dominant subset of 5 cytokines and chemokines associated with neutrophil recruitment. The greatest differential was with the cytokine granulocyte colony-stimulating factor (G-CSF) that causes bone marrow release of neutrophils into the circulation (1900-fold difference at 48 h). Treating S100a9(-/-) mice with G-CSF reversed their increased susceptibility to infection by enhancing both circulating neutrophils and neutrophil recruitment into infected lungs, by reducing pneumococcal colony forming units, and by elevation of chemokine CXCL1, cytokine IL-6, and endogenous G-CSF proteins. Thus S100A9, potentially with its partner S100A8, makes a major contribution in the host response to pneumococcal infection by increasing circulating neutrophils principally regulation of G-CSF production.-De Filippo, K., Neill, D. R., Mathies, M., Bangert, M., McNeill, E., Kadioglu, A., Hogg, N. A new protective role for S100A9 in regulation of neutrophil recruitment during invasive pneumococcal pneumonia.	[De Filippo, Katia; Mathies, Meg; McNeill, Eileen; Hogg, Nancy] Canc Res UK London Res Inst, Leukocyte Adhes Lab, London WC2A 3LY, England; [Neill, Daniel R.; Bangert, Mathieu; Kadioglu, Aras] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England; [Neill, Daniel R.; Bangert, Mathieu; Kadioglu, Aras] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England	Cancer Research UK; University of Liverpool; University of Leicester	Hogg, N (corresponding author), Canc Res UK London Res Inst, Leukocyte Adhes Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.	nancy.hogg@cancer.org.uk	Neill, Daniel/E-1403-2012; Neill, Daniel/Q-6290-2019; Bangert, Mathieu/K-7233-2019	Neill, Daniel/0000-0002-7911-8153; Neill, Daniel/0000-0002-7911-8153; De Filippo, Katia/0000-0002-2863-8888; McNeill, Eileen/0000-0003-0971-9858; kadioglu, aras/0000-0003-1137-6321; Bangert, Mathieu/0000-0003-1320-8145				Achouiti A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002987; Averill MM, 2011, CIRCULATION, V123, P1216, DOI 10.1161/CIRCULATIONAHA.110.985523; Balakrishnan I, 2000, J INFECTION, V40, P256, DOI 10.1053/jinf.2000.0653; Bergeron Y, 1998, INFECT IMMUN, V66, P912, DOI 10.1128/IAI.66.3.912-922.1998; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Berthier S, 2003, J BIOL CHEM, V278, P25499, DOI 10.1074/jbc.M209755200; Bianchi M, 2011, J ALLERGY CLIN IMMUN, V127, P1243, DOI 10.1016/j.jaci.2011.01.021; Burdon PCE, 2008, BRIT J HAEMATOL, V142, P100, DOI 10.1111/j.1365-2141.2008.07018.x; Cheng PY, 2008, J EXP MED, V205, P2235, DOI 10.1084/jem.20080132; Corbin BD, 2008, SCIENCE, V319, P962, DOI 10.1126/science.1152449; Croce K, 2009, CIRCULATION, V120, P427, DOI 10.1161/CIRCULATIONAHA.108.814582; DEMETRI GD, 1991, BLOOD, V78, P2791; DENNY FW, 1986, AM J TROP MED HYG, V35, P1; Eash KJ, 2010, J CLIN INVEST, V120, P2423, DOI 10.1172/JCI41649; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; Endoh Y, 2009, J IMMUNOL, V182, P2258, DOI 10.4049/jimmunol.0802683; Gingles NA, 2001, INFECT IMMUN, V69, P426, DOI 10.1128/IAI.69.1.426-434.2001; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; Hierholzer C, 1997, AM J PHYSIOL-LUNG C, V273, pL1058, DOI 10.1152/ajplung.1997.273.5.L1058; HIRSCH S, 1983, IMMUNOGENETICS, V18, P229, DOI 10.1007/BF00952962; Hobbs JAR, 2003, MOL CELL BIOL, V23, P2564, DOI 10.1128/MCB.23.7.2564-2576.2003; Hoggatt J, 2011, CURR OPIN HEMATOL, V18, P231, DOI 10.1097/MOH.0b013e3283477962; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Kadioglu A, 2004, INFECT IMMUN, V72, P2689, DOI 10.1128/IAI.72.5.2689-2697.2004; Kadioglu A, 2004, TRENDS IMMUNOL, V25, P143, DOI 10.1016/j.it.2003.12.006; Kadioglu A, 2000, INFECT IMMUN, V68, P492, DOI 10.1128/IAI.68.2.492-501.2000; Kadioglu A, 2008, NAT REV MICROBIOL, V6, P288, DOI 10.1038/nrmicro1871; Kadioglu A, 2011, J IMMUNOL, V186, P5907, DOI 10.4049/jimmunol.1001533; Kohler A, 2011, BLOOD, V117, P4349, DOI 10.1182/blood-2010-09-308387; Lauw FN, 2002, J IMMUNOL, V168, P372, DOI 10.4049/jimmunol.168.1.372; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Lim WS, 2001, THORAX, V56, P296, DOI 10.1136/thorax.56.4.296; Liu FL, 1997, BLOOD, V90, P2583, DOI 10.1182/blood.V90.7.2583.2583_2583_2590; Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001; Manitz MP, 2003, MOL CELL BIOL, V23, P1034, DOI 10.1128/MCB.23.3.1034-1043.2003; Markowitz J, 2013, BBA-REV CANCER, V1835, P100, DOI 10.1016/j.bbcan.2012.10.003; McDonald B, 2010, IMMUNITY, V33, P148, DOI 10.1016/j.immuni.2010.08.006; MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431; Passey RJ, 1999, J LEUKOCYTE BIOL, V66, P549, DOI 10.1002/jlb.66.4.549; PATON JC, 1993, ANNU REV MICROBIOL, V47, P89, DOI 10.1146/annurev.mi.47.100193.000513; Quinton LJ, 2002, J INFECT DIS, V185, P1476, DOI 10.1086/340504; Raquil MA, 2008, J IMMUNOL, V180, P3366, DOI 10.4049/jimmunol.180.5.3366; Rosas M, 2010, J LEUKOCYTE BIOL, V88, P169, DOI 10.1189/jlb.0809548; Roth J, 2003, TRENDS IMMUNOL, V24, P155, DOI 10.1016/S1471-4906(03)00062-0; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Sadik CD, 2012, J LEUKOCYTE BIOL, V91, P207, DOI 10.1189/jlb.0811402; Schnekenburger J, 2008, J CELL PHYSIOL, V216, P558, DOI 10.1002/jcp.21433; Semerad CL, 2002, IMMUNITY, V17, P413, DOI 10.1016/S1074-7613(02)00424-7; Shimizu K, 2011, CIRCULATION, V124, P2920, DOI 10.1161/CIRCULATIONAHA.110.009910; Srikrishna G, 2012, J INNATE IMMUN, V4, P31, DOI 10.1159/000330095; Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639; Viemann D, 2005, BLOOD, V105, P2955, DOI 10.1182/blood-2004-07-2520; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Walker F, 2008, BLOOD, V111, P3978, DOI 10.1182/blood-2007-10-119636; Wang Y., 2014, J CLIN INVEST; Wengner AM, 2008, BLOOD, V111, P42, DOI 10.1182/blood-2007-07-099648; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085	57	32	32	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3600	3608		10.1096/fj.13-247460	http://dx.doi.org/10.1096/fj.13-247460			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24776746				2022-12-28	WOS:000340265400028
J	Tsai, RYL; Pederson, T				Tsai, Robert Y. L.; Pederson, Thoru			Connecting the nucleolus to the cell cycle and human disease	FASEB JOURNAL			English	Review						cell cycle; ribosome synthesis; cancer	RNA-POLYMERASE-I; PERINUCLEOLAR COMPARTMENT PREVALENCE; TRACT-BINDING PROTEIN; RIBOSOMAL-RNA; C-MYC; EXTRARIBOSOMAL FUNCTIONS; EMERGING TARGET; III TRANSCRIPTS; MESSENGER-RNA; DNA-DAMAGE	Long known as the center of ribosome synthesis, the nucleolus is connected to cell cycle regulation in more subtle ways. One is a surveillance system that reacts promptly when rRNA synthesis or processing is impaired, halting cell cycle progression. Conversely, the nucleolus also acts as a first-responder to growth-related stress signals. Here we review emerging concepts on how these "infraribosomal" links between the nucleolus and cell cycle progression operate in both forward and reverse gears. We offer perspectives on how new cancer therapeutic designs that target this infraribosomal mode of cell growth control may shape future clinical progress.	[Tsai, Robert Y. L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc & Stem Cell Biol, Houston, TX 77030 USA; [Pederson, Thoru] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Program Cell & Dev Dynam, Worcester, MA 01605 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Massachusetts System; University of Massachusetts Worcester	Tsai, RYL (corresponding author), Texas A&M Hlth Sci Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rtsai@ibt.tamhsc.edu; thoru.pederson@umassmed.edu		Tsai, Robert/0000-0002-8357-0812	Texas A & M Cancer Research Council Incentive Award; U.S. National Science Foundation [MCB-1051398]	Texas A & M Cancer Research Council Incentive Award; U.S. National Science Foundation(National Science Foundation (NSF))	The authors' recent and current work cited was supported by a Texas A & M Cancer Research Council Incentive Award to R.Y.T. and U.S. National Science Foundation grant MCB-1051398 to T.P.	ABELSON HT, 1974, CELL, V1, P161, DOI 10.1016/0092-8674(74)90107-X; Andrews WJ, 2013, J BIOL CHEM, V288, P4567, DOI 10.1074/jbc.M112.411611; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Burger K, 2013, BIOL CHEM, V394, P1133, DOI 10.1515/hsz-2013-0153; Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211; Bursac S, 2014, BBA-MOL BASIS DIS, V1842, P817, DOI 10.1016/j.bbadis.2013.08.014; Bursac S, 2012, P NATL ACAD SCI USA, V109, P20467, DOI 10.1073/pnas.1218535109; BUSCH H, 1963, CANCER RES, V23, P313; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Calkins AS, 2013, NUCLEIC ACIDS RES, V41, P7378, DOI 10.1093/nar/gkt502; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chan JC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001754; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Delloye-Bourgeois C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002456; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728; Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844; Drygin D, 2009, CANCER RES, V69, P7653, DOI 10.1158/0008-5472.CAN-09-1304; Du XM, 2006, MOL BIOL CELL, V17, P460, DOI 10.1091/mbc.E05-09-0848; EMERSON CP, 1971, NATURE-NEW BIOL, V232, P101, DOI 10.1038/newbio232101a0; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Ganapathi KA, 2007, BLOOD, V110, P1458, DOI 10.1182/blood-2007-02-075184; GAULDEN ME, 1958, P NATL ACAD SCI USA, V44, P553, DOI 10.1073/pnas.44.6.553; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; GREENBERG JR, 1972, NATURE, V240, P102, DOI 10.1038/240102a0; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Hannan KM, 2013, BBA-GENE REGUL MECH, V1829, P342, DOI 10.1016/j.bbagrm.2012.10.014; Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005; HOLTZMAN E, 1966, J MOL BIOL, V17, P131, DOI 10.1016/S0022-2836(66)80099-2; Hoppe S, 2009, P NATL ACAD SCI USA, V106, P17781, DOI 10.1073/pnas.0909873106; Hsu JK, 2012, J CELL BIOL, V197, P613, DOI 10.1083/jcb.201109038; Huang S, 1997, J CELL BIOL, V137, P965, DOI 10.1083/jcb.137.5.965; Jordan P, 1998, NUCLEIC ACIDS RES, V26, P2831, DOI 10.1093/nar/26.12.2831; Kamath RV, 2005, CANCER RES, V65, P246; Kenmochi N, 2000, J HUM GENET, V45, P290, DOI 10.1007/s100380070018; Kruhlak M, 2007, NATURE, V447, P730, DOI 10.1038/nature05842; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Li LY, 2011, CANCER RES, V71, P4269, DOI 10.1158/0008-5472.CAN-10-3504; Lin T, 2014, J CELL SCI, V127, P2302, DOI 10.1242/jcs.143842; Lin T, 2013, HEPATOLOGY, V58, P2176, DOI 10.1002/hep.26600; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Ma H, 2013, MOL BIOL CELL, V24, P1234; MATERA AG, 1995, J CELL BIOL, V129, P1181, DOI 10.1083/jcb.129.5.1181; Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504; Meng LJ, 2013, P NATL ACAD SCI USA, V110, P11415, DOI 10.1073/pnas.1301672110; Norton JT, 2008, CANCER-AM CANCER SOC, V113, P861, DOI 10.1002/cncr.23632; PEDERSON T, 2010, COLD SPRING HARB PER, V3; Pederson T., 2011, BIOGRAPHICAL MEMOIRS; Pederson T, 2007, FASEB J, V21, P3442, DOI 10.1096/fj.07-8766hyp; Pederson T, 2009, J CELL BIOL, V184, P771, DOI 10.1083/jcb.200812014; Pellagatti A, 2008, BRIT J HAEMATOL, V142, P57, DOI 10.1111/j.1365-2141.2008.07178.x; Peltonen K, 2014, CANCER CELL, V25, P77, DOI 10.1016/j.ccr.2013.12.009; Peltonen K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012996; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Quin JE, 2014, BBA-MOL BASIS DIS, V1842, P802, DOI 10.1016/j.bbadis.2013.12.009; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Sloan KE, 2013, CELL REP, V5, P237, DOI 10.1016/j.celrep.2013.08.049; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Stimpson KM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092432; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Stults DM, 2008, GENOME RES, V18, P13, DOI 10.1101/gr.6858507; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Uechi T, 2001, GENOMICS, V72, P223, DOI 10.1006/geno.2000.6470; Vlatkovic N, 2014, CELL MOL LIFE SCI, V71, P771, DOI 10.1007/s00018-013-1361-x; Waksman SA, 1940, P SOC EXP BIOL MED, V45, P609; Wang C, 2003, MOL BIOL CELL, V14, P2425, DOI 10.1091/mbc.E02-12-0818; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; WATANABE M, 1993, NAT GENET, V4, P268, DOI 10.1038/ng0793-268; WEBER MJ, 1972, NATURE-NEW BIOL, V235, P58, DOI 10.1038/newbio235058a0; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; ZAMECNIK PC, 1948, J BIOL CHEM, V175, P299; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang Q, 2014, SCIENCE, V343, P298, DOI 10.1126/science.1246384; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhou Xiang, 2012, Genes Cancer, V3, P298, DOI 10.1177/1947601912455200	86	65	67	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3290	3296		10.1096/fj.14-254680	http://dx.doi.org/10.1096/fj.14-254680			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24790035				2022-12-28	WOS:000340265400001
J	Gawlak, G; Tian, YF; O'Donnell, JJ; Tian, XY; Birukova, AA; Birukov, KG				Gawlak, Grzegorz; Tian, Yufeng; O'Donnell, James J., III; Tian, Xinyong; Birukova, Anna A.; Birukov, Konstantin G.			Paxillin mediates stretch-induced Rho signaling and endothelial permeability via assembly of paxillin-p42/44MAPK-GEF-H1 complex	FASEB JOURNAL			English	Article						mechanotransduction; focal adhesions; cytoskeleton; guanine nucleotide exchange factors	FOCAL ADHESION KINASE; INDUCED LUNG INJURY; TGF-BETA ACTIVATION; CYCLIC STRETCH; SHEAR-STRESS; OXIDIZED PHOSPHOLIPIDS; CELL-ADHESION; FAK PHOSPHORYLATION; MECHANICAL STRETCH; BARRIER FUNCTION	Suboptimal ventilator support or regional ventilation heterogeneity in inflamed lungs causes excessive tissue distension, which triggers stretch-induced pathological signaling and may lead to vascular leak and lung dysfunction. Focal adhesions (FAs) are cell-substrate adhesive complexes participating in cellular mechanotransduction and regulation of the Rho GTPase pathway. Stretch-induced Rho regulation remains poorly understood. We used human lung endothelial cells (ECs) exposed to pathological cyclic stretch (CS) at 18% distension to test the hypothesis that FA protein paxillin participates in CS-induced Rho activation by recruiting the Rho-specific guanine nucleotide exchange factor GEF-H1. CS induced phosphorylation of paxillin and activated p42/44-MAP kinase, Rho GTPase, and paxillin/GEF-H1/p42/44-MAPK association. CS caused nearly 2-fold increase in EC permeability, which was attenuated by paxillin knockdown. Expression of the paxillin-Y31/118F phosphorylation mutant decreased the CS-induced paxillin/GEF-H1 association (16.3 +/- 4.1%), GEF-H1 activation (28.9 +/- 9.2%), and EC permeability (28.7 +/- 8.1%) but not CS-induced p42/44-MAPK activation. Inhibition of p42/44-MAPK suppressed CS-induced paxillin/GEF-H1 interactions (15.9 +/- 7.9%), GEF-H1 activation (11.7 +/- 4.3%), and disruption of EC monolayer. Expression of GEF-H1T678A lacking p42/44-MAPK phosphorylation site attenuated Rho activation (31.2 +/- 11.6%). We conclude that MAPK-dependent targeting of GEF-H1 to paxillin is involved in the regulation of CS-induced Rho signaling and EC permeability. This study proposes a novel concept of paxillin-GEF-H1-p42/44-MAPK module as a regulator of pathological mechanotransduction.	[Gawlak, Grzegorz; Tian, Yufeng; O'Donnell, James J., III; Tian, Xinyong; Birukova, Anna A.; Birukov, Konstantin G.] Univ Chicago, Dept Med, Lung Injury Ctr, Chicago, IL 60637 USA	University of Chicago	Birukov, KG (corresponding author), Univ Chicago, Dept Med, Lung Injury Ctr, Sect Pulm & Crit Med, 5841 S Maryland Ave,MC 6026, Chicago, IL 60637 USA.	kbirukov@medicine.bsd.uchicago.edu	Birukov, Konstantin/FJB-5755-2022		National Heart, Lung, and Blood Institute, U.S. National Institutes of Health [HL-76259, HL1-07920]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL107920, R01HL076259, R01HL089257, R56HL107920] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute, U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank C. Turner (State University of New York, Syracuse, NY, USA) for providing paxillin constructs; G. Bokoch (Scripps, La Jolla, CA, USA) and K. Szaszi (St. Michael's Hospital, Toronto, ON, Canada) for providing GEF-H1 constructs and RhoA(G17A) mutant. This work was supported by Public Health Service grants HL-76259 and HL1-07920 from the National Heart, Lung, and Blood Institute, U.S. National Institutes of Health.	Abdulnour REE, 2006, AM J PHYSIOL-LUNG C, V291, pL345, DOI 10.1152/ajplung.00453.2005; Aijaz S, 2005, DEV CELL, V8, P777, DOI 10.1016/j.devcel.2005.03.003; Bershadsky AD, 2003, ANNU REV CELL DEV BI, V19, P677, DOI 10.1146/annurev.cellbio.19.111301.153011; Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002; Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725; Birukova AA, 2004, MICROVASC RES, V67, P64, DOI 10.1016/j.mvr.2003.09.007; Birukova AA, 2006, AM J PATHOL, V168, P1749, DOI 10.2353/ajpath.2006.050431; Birukova AA, 2007, AM J PHYSIOL-LUNG C, V293, pL199, DOI 10.1152/ajplung.00020.2007; Birukova AA, 2011, EXP CELL RES, V317, P859, DOI 10.1016/j.yexcr.2010.11.011; Birukova AA, 2010, AM J PHYSIOL-LUNG C, V299, pL652, DOI 10.1152/ajplung.00202.2009; Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Desai LP, 2007, AM J PHYSIOL-LUNG C, V293, pL769, DOI 10.1152/ajplung.00127.2007; DiPaolo BC, 2012, AM J PHYSIOL-LUNG C, V302, pL992, DOI 10.1152/ajplung.00175.2011; Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Garcia-Mata R, 2006, METHOD ENZYMOL, V406, P425, DOI 10.1016/S0076-6879(06)06031-9; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Guilluy C, 2011, NAT CELL BIOL, V13, P722, DOI 10.1038/ncb2254; Hammerschmidt S, 2004, AM J RESP CELL MOL, V30, P396, DOI 10.1165/rcmb.2003-0136OC; Heck JN, 2012, MOL BIOL CELL, V23, P2583, DOI 10.1091/mbc.E11-10-0876; Holinstat M, 2006, J BIOL CHEM, V281, P2296, DOI 10.1074/jbc.M511248200; Ikeda M, 1999, BIOCHEM BIOPH RES CO, V257, P668, DOI 10.1006/bbrc.1999.0532; Ingram AJ, 2000, KIDNEY INT, V58, P1431, DOI 10.1046/j.1523-1755.2000.00305.x; Jafari B., 2004, GENE, V363, P166; Jenkins RG, 2006, J CLIN INVEST, V116, P1606, DOI 10.1172/JCI27183; Kakiashvili E, 2009, J BIOL CHEM, V284, P11454, DOI 10.1074/jbc.M805933200; Kano Y, 2000, CIRC RES, V86, P425, DOI 10.1161/01.RES.86.4.425; Kito H, 2000, J APPL PHYSIOL, V89, P2391, DOI 10.1152/jappl.2000.89.6.2391; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; Ly DL, 2013, AM J PHYSIOL-CELL PH, V304, pC115, DOI 10.1152/ajpcell.00290.2012; Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS; Mehta D, 2002, J PHYSIOL-LONDON, V539, P779, DOI 10.1113/jphysiol.2001.013289; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Naruse K, 1998, ONCOGENE, V17, P455, DOI 10.1038/sj.onc.1201950; Naruse K, 1998, FEBS LETT, V441, P111, DOI 10.1016/S0014-5793(98)01528-2; Nonas S, 2008, CRIT CARE, V12, DOI 10.1186/cc6805; Orr AW, 2006, DEV CELL, V10, P11, DOI 10.1016/j.devcel.2005.12.006; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Sanchez-Esteban J, 2002, AM J PHYSIOL-LUNG C, V282, pL448, DOI 10.1152/ajplung.00399.2000; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Schwartz MA, 2008, CURR OPIN CELL BIOL, V20, P551, DOI 10.1016/j.ceb.2008.05.005; Shikata Y, 2005, EXP CELL RES, V304, P40, DOI 10.1016/j.yexcr.2004.11.001; Shikata Y, 2003, FASEB J, V17, P2240, DOI 10.1096/fj.03-0198com; Singleton PA, 2007, AM J RESP CELL MOL, V37, P222, DOI 10.1165/rcmb.2006-0327OC; Smith PG, 1998, EXP CELL RES, V239, P353, DOI 10.1006/excr.1997.3905; Su X, 2006, AM J PHYSIOL-LUNG C, V290, pL769, DOI 10.1152/ajplung.00334.2005; Tschumperlin DJ, 1999, J APPL PHYSIOL, V86, P2026, DOI 10.1152/jappl.1999.86.6.2026; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; Waheed F, 2013, MOL BIOL CELL, V24, P1068, DOI 10.1091/mbc.E12-09-0661; Xu MY, 2009, AM J PATHOL, V174, P1264, DOI 10.2353/ajpath.2009.080160	55	25	27	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3249	3260		10.1096/fj.13-245142	http://dx.doi.org/10.1096/fj.13-245142			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24706358	Green Published			2022-12-28	WOS:000337949400044
J	Blanchard, OL; Smoliga, JM				Blanchard, Otis L.; Smoliga, James M.			Translating dosages from animal models to human clinical trials-revisiting body surface area scaling	FASEB JOURNAL			English	Review						allometric scaling; allometry; dose conversion; interspecies scaling; pharmacokinetics	DRUG DEVELOPMENT; LOW BIOAVAILABILITY; HEALTHY-VOLUNTEERS; TRANS-RESVERATROL; RAT MODEL; PHARMACOKINETICS; METABOLISM; CHEMOTHERAPY; ABSORPTION; PREDICTION	Body surface area (BSA) scaling has been used for prescribing individualized dosages of various drugs and has also been recommended by the U.S. Food and Drug Administration as one method for using data from animal model species to establish safe starting dosages for first-in-human clinical trials. Although BSA conversion equations have been used in certain clinical applications for decades, recent recommendations to use BSA to derive interspecies equivalents for therapeutic dosages of drug and natural products are inappropriate. A thorough review of the literature reveals that BSA conversions are based on antiquated science and have little justification in current translational medicine compared to more advanced allometric and physiologically based pharmacokinetic modeling. Misunderstood and misinterpreted use of BSA conversions may have disastrous consequences, including underdosing leading to abandonment of potentially efficacious investigational drugs, and unexpected deadly adverse events. We aim to demonstrate that recent recommendations for BSA are not appropriate for animal-to-human dosage conversions and use pharmacokinetic data from resveratrol studies to demonstrate how confusion between the human equivalent dose and "pharmacologically active dose" can lead to inappropriate dose recommendations. To optimize drug development, future recommendations for interspecies scaling must be scientifically justified using physiologic, pharmacokinetic, and toxicology data rather than simple BSA conversion.	[Blanchard, Otis L.] Wilmore Labs Ltd Liabil Co, San Antonio, TX USA; [Smoliga, James M.] High Point Univ, Dept Phys Therapy, Sch Hlth Sci, High Point, NC 27409 USA; [Smoliga, James M.] High Point Univ, Sch Pharm, Dept Basic Pharmaceut Sci, High Point, NC 27409 USA		Smoliga, JM (corresponding author), High Point Univ, Dept Phys Therapy, Sch Hlth Sci, 833 Montlieu Ave, High Point, NC 27409 USA.	jsmoliga@highpoint.edu		Smoliga, James/0000-0002-1895-5687				Al-kahtani MA, 2004, PHYSIOL BIOCHEM ZOOL, V77, P346, DOI 10.1086/420941; Almeida L, 2009, MOL NUTR FOOD RES, V53, pS7, DOI 10.1002/mnfr.200800177; [Anonymous], 2005, GUID IND EST MAX SAF; Asensi M, 2002, FREE RADICAL BIO MED, V33, P387, DOI 10.1016/S0891-5849(02)00911-5; Atkinson AJ, 2012, CLIN PHARMACOL THER, V92, P3, DOI 10.1038/clpt.2012.67; Baker SD, 2002, JNCI-J NATL CANCER I, V94, P1883, DOI 10.1093/jnci/94.24.1883; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022; Busher JT, 1990, SERUM ALBUMIN GLOBUL, V3rd; Cao XH, 2006, PHARM RES, V23, P1675, DOI 10.1007/s11095-006-9041-2; Center for Drug Evaluation and Research, 2002, GUID IND REV EST SAF; Cheval L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046876; Cirrito JR, 2011, P NATL ACAD SCI USA, V108, P14968, DOI 10.1073/pnas.1107411108; Colom H, 2011, PHARM RES-DORDR, V28, P1606, DOI 10.1007/s11095-011-0395-8; Crowell JA, 2004, TOXICOL SCI, V82, P614, DOI 10.1093/toxsci/kfh263; Das S, 2008, PHARM RES-DORDR, V25, P2593, DOI 10.1007/s11095-008-9677-1; De Buck SS, 2007, DRUG METAB DISPOS, V35, P1766, DOI 10.1124/dmd.107.015644; de Jong M, 2010, J NUCL MED, V51, P501, DOI 10.2967/jnumed.109.065706; DiGiandomenico A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110183; DIXON RL, 1976, ENVIRON HEALTH PERSP, V13, P43, DOI 10.2307/3428236; DREYER G, 1912, PHIL T R SOC LOND, V202, P191; Dreyer G., 1910, PHILOS T ROY SOC B, V201, P133; Fan JH, 2014, BIOCHEM PHARMACOL, V87, P93, DOI 10.1016/j.bcp.2013.09.007; FELDSCHUH J, 1977, CIRCULATION, V56, P605, DOI 10.1161/01.CIR.56.4.605; GERLOWSKI LE, 1983, J PHARM SCI, V72, P1103, DOI 10.1002/jps.2600721003; Goldberg DA, 2003, CLIN BIOCHEM, V36, P79, DOI 10.1016/S0009-9120(02)00397-1; Gurney H, 2002, BRIT J CANCER, V86, P1297, DOI 10.1038/sj.bjc.6600139; Hoffman R, 2013, HEMATOLOGY BASIC PRI, V6th; Hough TA, 2002, MAMM GENOME, V13, P595, DOI 10.1007/s00335-002-2188-1; Hulbert AJ, 2014, SYSTEMS, V2, P186, DOI 10.3390/systems2020186; Johnson WD, 2011, FOOD CHEM TOXICOL, V49, P3319, DOI 10.1016/j.fct.2011.08.023; Joslin JO, 2009, J EXOT PET MED, V18, P117, DOI 10.1053/j.jepm.2009.04.002; Kaestner SA, 2007, CLIN ONCOL-UK, V19, P23, DOI 10.1016/j.clon.2006.10.010; Klebovich Imre, 1998, Pharmacy and Pharmacology Communications, V4, P129; KLEIBER M, 1947, PHYSIOL REV, V27, P511, DOI 10.1152/physrev.1947.27.4.511; KLEIBER MAX, 1932, HILGARDIA, V6, P315; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lin JH, 1998, DRUG METAB DISPOS, V26, P1202; Mahmood I, 2006, DRUG METAB DISPOS, V34, P507, DOI 10.1124/dmd.105.007187; Mahmood I, 1999, CLIN PHARMACOKINET, V36, P1, DOI 10.2165/00003088-199936010-00001; Mahmood I., 2005, INTERSPECIES PHARMAC; Mahmood I, 2007, ADV DRUG DELIVER REV, V59, P1177, DOI 10.1016/j.addr.2007.05.015; Mak IWY, 2014, AM J TRANSL RES, V6, P114; Marchetti S, 2007, BRIT J CANCER, V97, P577, DOI 10.1038/sj.bjc.6603925; Marier JF, 2002, J PHARMACOL EXP THER, V302, P369, DOI 10.1124/jpet.102.033340; Marlind J, 2008, CLIN CANCER RES, V14, P6515, DOI 10.1158/1078-0432.CCR-07-5041; McPhee F, 2012, ANTIMICROB AGENTS CH, V56, P5387, DOI 10.1128/AAC.01186-12; Meng XF, 2004, J AGR FOOD CHEM, V52, P935, DOI 10.1021/jf030582e; Muller PY, 2012, NAT REV DRUG DISCOV, V11, P751, DOI 10.1038/nrd3801; Parrott N, 2005, BASIC CLIN PHARMACOL, V96, P193, DOI 10.1111/j.1742-7843.2005.pto960308.x; PINKEL D, 1958, CANCER RES, V18, P853; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rescigno A, 2010, AAPS J, V12, P61, DOI 10.1208/s12248-009-9160-x; Rubner M., 1883, Z BIOL, V19, P536; Sawyer M, 2001, INVEST NEW DRUG, V19, P171, DOI 10.1023/A:1010639201787; SCHEIN PS, 1970, CLIN PHARMACOL THER, V11, P3; SCHMIDTNIELSEN K, 1970, FED PROC, V29, P1524; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; VONBERTALANFFY L, 1957, Q REV BIOL, V32, P217, DOI 10.1086/401873; Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885; Wenzel E, 2005, MOL NUTR FOOD RES, V49, P472, DOI 10.1002/mnfr.200500010; White CR, 2005, J EXP BIOL, V208, P1611, DOI 10.1242/jeb.01501; Yu RZ, 2007, DRUG METAB DISPOS, V35, P460, DOI 10.1124/dmd.106.012401; Zaias J, 2009, J AM ASSOC LAB ANIM, V48, P387	64	94	98	2	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1629	1634		10.1096/fj.14-269043	http://dx.doi.org/10.1096/fj.14-269043			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25657112	Bronze			2022-12-28	WOS:000354114600002
J	Chauvigne, F; Zapater, C; Stavang, JA; Taranger, GL; Cerda, J; Finn, RN				Chauvigne, Francois; Zapater, Cinta; Stavang, Jon Anders; Taranger, Geir Lasse; Cerda, Joan; Finn, Roderick Nigel			The pH sensitivity of Aqp0 channels in tetraploid and diploid teleosts	FASEB JOURNAL			English	Article						aquaporin; water transport; permeability lens; cataract	RAY-FINNED FISH; AQUAPORIN WATER PERMEABILITY; FIBER CELL-DIFFERENTIATION; MAJOR INTRINSIC PROTEIN; SALMO-SALAR L.; ATLANTIC SALMON; GENOME DUPLICATION; LENS DEVELOPMENT; EXPRESSION; EYE	Water homeostasis and the structural integrity of the vertebrate lens is partially mediated by AQP0 channels. Emerging evidence indicates that external pH may be involved in channel gating. Here we show that a tetraploid teleost, the Atlantic salmon, retains 4 aqp0 genes (aqp0a1, -0a2, -0b1, and -0b2), which are highly, but not exclusively, expressed in the lens. Functional characterization reveals that, although each paralog permeates water efficiently, the permeability is respectively shifted to the neutral, alkaline, or acidic pH in Aqp0a1, -0a2, and -0b1, whereas that of Aqp0b2 is not regulated by external pH. Mutagenesis studies demonstrate that Ser(38), His(39), and His(40) residues in the extracellular transmembrane domain of -helix 2 facing the water pore are critical for the pH modulation of water transport. To validate these findings, we show that both zebrafish Aqp0a and -0b are functional water channels with respective pH sensitivities toward alkaline or acid pH ranges and that an N-terminal allelic variant (Ser(19)) of Aqp0b exists that abolishes water transport in Xenopus laevis oocytes. The data suggest that the alkaline pH sensitivity is a conserved trait in teleost Aqp0 a-type channels, whereas mammalian AQP0 and some teleost Aqp0 b-type channels display an acidic pH permeation preference.	[Chauvigne, Francois; Stavang, Jon Anders; Finn, Roderick Nigel] Univ Bergen, Bergen High Technol Ctr, Dept Biol, N-5020 Bergen, Norway; [Chauvigne, Francois; Zapater, Cinta; Cerda, Joan] CSIC, Inst Ciencias Mar, IRTA, Barcelona, Spain; [Taranger, Geir Lasse; Finn, Roderick Nigel] Inst Marine Res, N-5024 Bergen, Norway	University of Bergen; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Mediterraneo de Investigaciones Marinas y Ambientales (CMIMA); CSIC - Instituto de Ciencias del Mar (ICM); IRTA; Institute of Marine Research - Norway	Finn, RN (corresponding author), Univ Bergen, Bergen High Technol Ctr, Dept Biol, N-5020 Bergen, Norway.	joan.cerda@irta.cat; nigel.finn@bio.uib.no	Finn, Roderick Nigel/Y-2916-2019; Zapater, Cinta/L-9406-2017; Chauvigne, Francois/D-6854-2017; Cerdà, Joan/M-1099-2016	Finn, Roderick Nigel/0000-0002-8776-3945; Zapater, Cinta/0000-0001-9326-7502; Chauvigne, Francois/0000-0001-5571-7517; Cerdà, Joan/0000-0003-2568-6398	Research Council of Norway (RCN) [224816/E40, 178837/40]; Spanish Ministry of Science and Innovation (MICINN) [AGL2010-15597]; RCN [224816/E40, 178837/40]; MICINN	Research Council of Norway (RCN)(Research Council of Norway); Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); RCN; MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission)	The authors thank Per Gunnar Fjelldal (Institute of Marine Research, Norway) for assistance during the sampling of salmon. This work was supported by Research Council of Norway (RCN) Projects 224816/E40 and 178837/40 (to R.N.F.), and Spanish Ministry of Science and Innovation (MICINN) Grant AGL2010-15597 (to J.C.). F.C. and J.A.S. were supported by postdoctoral fellowships from the RCN (224816/E40 and 178837/40, respectively); C.Z. was supported by a predoctoral fellowship (FPI) from MICINN. The authors declare no conflicts of interest.	Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Ahmad N, 2013, INT J DEV BIOL, V57, P741, DOI 10.1387/ijdb.130193jg; Allendorf F.W., 1984, P1; Ball LE, 2003, INVEST OPHTH VIS SCI, V44, P4820, DOI 10.1167/iovs.02-1317; BASSNETT S, 1992, DEV DYNAM, V194, P85, DOI 10.1002/aja.1001940202; BASSNETT S, 1987, EXP EYE RES, V44, P143, DOI 10.1016/S0014-4835(87)80032-5; Berthelot C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4657; Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012; Cerda J, 2010, J EXP ZOOL PART A, V313A, P623, DOI 10.1002/jez.634; Chauvigne F, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.110783; Chauvigne F, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-34; Chen C, 2005, NATURE, V436, P1030, DOI 10.1038/nature03894; Chepelinsky Ana B, 2009, Handb Exp Pharmacol, P265, DOI 10.1007/978-3-540-79885-9_14; Clemens D. M., 2013, INVEST OPHTH VIS SCI, P5136; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Easter SS, 1996, DEV BIOL, V180, P646; Eckert R, 2002, PFLUG ARCH EUR J PHY, V443, P843, DOI 10.1007/s00424-001-0760-2; Engelund MB, 2013, J EXP BIOL, V216, P3873, DOI 10.1242/jeb.087890; Finn RN, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000169; Finn RN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113686; Finn RN, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00044; Fischbarg J, 2012, MOL ASPECTS MED, V33, P638, DOI 10.1016/j.mam.2012.07.016; Francis P, 2000, HUM MOL GENET, V9, P2329, DOI 10.1093/oxfordjournals.hmg.a018925; Froger A, 1998, PROTEIN SCI, V7, P1458, DOI 10.1002/pro.5560070623; Froger A, 2010, INVEST OPHTH VIS SCI, V51, P6582, DOI 10.1167/iovs.10-5626; Gonen T, 2005, NATURE, V438, P633, DOI 10.1038/nature04321; Greiling TMS, 2008, SEMIN CELL DEV BIOL, V19, P94, DOI 10.1016/j.semcdb.2007.10.011; Gustafsson OSE, 2008, J EXP BIOL, V211, P1559, DOI 10.1242/jeb.016048; Gustafsson OSE, 2010, J MORPHOL, V271, P980, DOI 10.1002/jmor.10849; Hall JE, 2014, BIOPHYS J, V107, P10, DOI 10.1016/j.bpj.2014.05.023; Hamann S, 1998, AM J PHYSIOL-CELL PH, V274, pC1332, DOI 10.1152/ajpcell.1998.274.5.C1332; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Hurley IA, 2007, P ROY SOC B-BIOL SCI, V274, P489, DOI 10.1098/rspb.2006.3749; Karasawa Kaoru, 2011, Vet J, V190, pe72, DOI 10.1016/j.tvjl.2010.12.027; Katoh K, 2008, BRIEF BIOINFORM, V9, P286, DOI 10.1093/bib/bbn013; King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469; Kopera IA, 2010, PHILOS T R SOC B, V365, P1593, DOI 10.1098/rstb.2009.0251; Kroger RHH, 1999, J COMP PHYSIOL A, V184, P361, DOI 10.1007/s003590050335; Kumari SS, 2014, BIOCHEM BIOPH RES CO, V452, P986, DOI 10.1016/j.bbrc.2014.09.032; Kumari SS, 2012, MOL VIS, V18, P957; Leong JS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-279; Liu JL, 2011, J CELL SCI, V124, P198, DOI 10.1242/jcs.072652; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Macqueen DJ, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.2881; Madsen SS, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00056; Mathias RT, 2007, J MEMBRANE BIOL, V216, P1, DOI 10.1007/s00232-007-9019-y; Matson CK, 2011, NATURE, V476, P101, DOI 10.1038/nature10239; MICHEA LF, 1994, BIOCHEMISTRY-US, V33, P7663, DOI 10.1021/bi00190a021; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; Naran D, 2006, AFR ZOOL, V41, P178, DOI 10.3377/1562-7020(2006)41[178:KOTRMG]2.0.CO;2; Narumi Y, 2014, AM J MED GENET A, V164, P1272, DOI 10.1002/ajmg.a.36433; Near TJ, 2012, P NATL ACAD SCI USA, V109, P13698, DOI 10.1073/pnas.1206625109; Nemeth-Cahalan KL, 2013, J GEN PHYSIOL, V141, P287, DOI 10.1085/jgp.201210884; Nemeth-Cahalan KL, 2004, J GEN PHYSIOL, V123, P573, DOI 10.1085/jgp.200308990; Nemeth-Cahalan KL, 2000, J BIOL CHEM, V275, P6777, DOI 10.1074/jbc.275.10.6777; Ogino H, 2012, DEV BIOL, V363, P333, DOI 10.1016/j.ydbio.2012.01.006; Postlethwait J, 2004, TRENDS GENET, V20, P481, DOI 10.1016/j.tig.2004.08.001; Rato L, 2010, J MEMBRANE BIOL, V236, P215, DOI 10.1007/s00232-010-9294-x; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Schey KL, 2014, BBA-GEN SUBJECTS, V1840, P1513, DOI 10.1016/j.bbagen.2013.10.037; Schulz RW, 2010, GEN COMP ENDOCR, V165, P390, DOI 10.1016/j.ygcen.2009.02.013; Shiels A, 2001, PHYSIOL GENOMICS, V7, P179, DOI 10.1152/physiolgenomics.00078.2001; SIVAK JG, 1991, VISION RES, V31, P373, DOI 10.1016/0042-6989(91)90090-R; Sorokina EA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021122; Suyama M, 2006, NUCLEIC ACIDS RES, V34, pW609, DOI 10.1093/nar/gkl315; Swafford D. L., 2002, PAUP PHYLOGENETIC AN; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Tingaud-Sequeira A, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-38; Tipsmark CK, 2010, J EXP BIOL, V213, P368, DOI 10.1242/jeb.034785; UYENO T, 1972, SCIENCE, V175, P644, DOI 10.1126/science.175.4022.644; Vandepoele K, 2004, P NATL ACAD SCI USA, V101, P1638, DOI 10.1073/pnas.0307968100; Varadaraj K, 2005, INVEST OPHTH VIS SCI, V46, P1393, DOI 10.1167/iovs.04-1217; Verkman AS, 2003, EXP EYE RES, V76, P137, DOI 10.1016/S0014-4835(02)00303-2; Virkki LV, 2001, AM J PHYSIOL-REG I, V281, pR1994, DOI 10.1152/ajpregu.2001.281.6.R1994; Waagbo R, 2003, J FISH DIS, V26, P213, DOI 10.1046/j.1365-2761.2003.00449.x; Waagbo R, 2010, BRIT J NUTR, V104, P1460, DOI 10.1017/S0007114510002485; WALL AE, 1992, VET REC, V131, P553; Wang JT, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-96; Wang RS, 2009, ENDOCR REV, V30, P119, DOI 10.1210/er.2008-0025; Wang XN, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003645; Wride MA, 2011, PHILOS T R SOC B, V366, P1219, DOI 10.1098/rstb.2010.0324; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; Zampighi GA, 2002, EXP EYE RES, V75, P505, DOI 10.1006/exer.2002.2041; Zapater C, 2013, GEN COMP ENDOCR, V182, P24, DOI 10.1016/j.ygcen.2012.11.015; Zapater C, 2011, MOL BIOL EVOL, V28, P3151, DOI 10.1093/molbev/msr146	86	12	12	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2172	2184		10.1096/fj.14-267625	http://dx.doi.org/10.1096/fj.14-267625			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25667219	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000354114600047
J	Lastrucci, C; Baillif, V; Behar, A; Al Saati, T; Dubourdeau, M; Maridonneau-Parini, I; Cougoule, C				Lastrucci, Claire; Baillif, Vincent; Behar, Annie; Al Saati, Talal; Dubourdeau, Marc; Maridonneau-Parini, Isabelle; Cougoule, Celine			Molecular and cellular profiles of the resolution phase in a damage-associated molecular pattern (DAMP)-mediated peritonitis model and revelation of leukocyte persistence in peritoneal tissues	FASEB JOURNAL			English	Article						bioactive lipid mediators; omentum; macrophage polarization	ACUTE-INFLAMMATION; PROMOTE RESOLUTION; LIPID MEDIATORS; MILKY SPOTS; MACROPHAGES; INNATE; POLARIZATION; MIGRATION; PRODUCTS; OMENTUM	Models of microbe-elicited peritonitis have been invaluable to identify mechanisms underlying inflammation resolution, but whether resolution mechanisms differ from an inflammatory agent to another has not been determined. Thus, we analyzed the cellular and molecular components of the resolution phase of non-microbe-induced inflammation. In thioglycollate (TG)-induced peritonitis, resolution started at 12 h (T-max) and displayed a 22 h resolution interval (R-i). During resolution, lipoxin A4, resolvin (Rv) D1 and RvD2, protectin D1 (PD1), and maresin 1 (MaR1) were transiently produced while RvD5 was continually generated. In addition, docosahexaenoic acid (DHA)-derived mediators were produced to a higher extent than in microbial peritonitis. We also investigated leukocyte infiltration and clearance in peritoneal tissues surrounding the inflammatory site. In the omentum, resolution parameters, neutrophil apoptosis, and efferocytosis were similar to those of the peritoneal cavity. However, we noticed long-term persistence of M2-polarized macrophages and B-lymphocytes in the omentum after TG administration, whereas zymosan injection caused M1/M2-macrophage and T-lymphocyte persistence regardless of the magnitude of the inflammatory response. Our study indicates that some aspects of resolution are shaped in a stimulus-specific manner, and it ultimately argues that the tissues surrounding the inflammatory site must also be considered to address the inflammatory response globally.	[Lastrucci, Claire; Behar, Annie; Maridonneau-Parini, Isabelle; Cougoule, Celine] CNRS, IPBS, Dept TB & Infect Biol, Toulouse, France; [Lastrucci, Claire; Behar, Annie; Maridonneau-Parini, Isabelle; Cougoule, Celine] Univ Toulouse 3, Univ Toulouse, UPS, IPBS, F-31062 Toulouse, France; [Baillif, Vincent; Dubourdeau, Marc] Ambiotis SAS, Toulouse, France; [Al Saati, Talal] CHU Purpan, INSERM, Serv Histopathol, CREFRE UPS US006, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Maridonneau-Parini, I (corresponding author), CNRS, IPBS, UMR5089, 205 Route Narbonne,BP64182, F-31077 Toulouse, France.	isabelle.maridonneau-parini@ipbs.fr	Maridonneau-Parini, Isabelle/F-1985-2011; COUGOULE, Céline/ABB-4180-2021	Maridonneau-Parini, Isabelle/0000-0003-0189-0976	Fondation pour la Recherche Medicale [FRM: FDT20130928326]; ARC [8505]; Agence Nationale de la Recherche (ANR) [2010-01301]; FRM [DEQ20110421312]; Region Midi-Pyrenees (Platform TRI);  [HEALTH-F4-2011-282095]	Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); ARC(Australian Research Council); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); FRM(Fondation pour la Recherche Medicale); Region Midi-Pyrenees (Platform TRI)(Region Occitanie); 	The authors acknowledge Anexplo Genotoul facility at IPBS, F. Capilla and C. Salon of the Service d'Histopathologie for histological slide preparation and scanning, F.-X. Frenois of the Imag'In platform for scanning of histology slides, R. Poincloux for technical assistance with histology slide quantification and confocal microscopy analysis, G. Chene for RT-qPCR on the omentum, C.N. Serhan for PD1 standard, G. Lugo-Villarino and A. Proag for critical reading of the manuscript. C.L. was supported by a fellowship from the Fondation pour la Recherche Medicale (FRM: FDT20130928326). This work was supported in part by ARC 8505 (Platform TRI), Agence Nationale de la Recherche (ANR) 2010-01301, FRM DEQ20110421312, Region Midi-Pyrenees (Platform TRI), and Tarkinaid FP7-2007-2013 under grant agreement HEALTH-F4-2011-282095.	Ajuebor MN, 1999, J IMMUNOL, V162, P1685; Ariel A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00004; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; BARTH MW, 1995, J LEUKOCYTE BIOL, V57, P361, DOI 10.1002/jlb.57.3.361; Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107; Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009; Buckley CD, 2013, NAT REV IMMUNOL, V13, P59, DOI 10.1038/nri3362; Chiang N, 2012, NATURE, V484, P524, DOI 10.1038/nature11042; Cooper D, 2002, DIS COLON RECTUM, V45, P394, DOI 10.1007/s10350-004-6189-x; Cougoule C, 2012, EUR J CELL BIOL, V91, P938, DOI 10.1016/j.ejcb.2012.07.002; Cougoule C, 2010, BLOOD, V115, P1444, DOI 10.1182/blood-2009-04-218735; Cuzzocrea S, 2004, INTENS CARE MED, V30, P1935, DOI 10.1007/s00134-004-2353-y; Dalli J, 2013, FASEB J, V27, P2573, DOI 10.1096/fj.13-227728; Dalli J, 2013, CHEM BIOL, V20, P188, DOI 10.1016/j.chembiol.2012.11.010; Dalli J, 2012, BLOOD, V120, pE60, DOI 10.1182/blood-2012-04-423525; Fernandez-Boyanapalli R, 2010, BLOOD, V116, P4512, DOI 10.1182/blood-2010-02-272005; Fredman G, 2012, SCI REP-UK, V2, DOI 10.1038/srep00639; Fukatsu K, 1996, J AM COLL SURGEONS, V183, P450; Gautier EL, 2013, BLOOD, V122, P2714, DOI 10.1182/blood-2013-01-478206; Goulding John, 2007, Proc Am Thorac Soc, V4, P618, DOI 10.1513/pats.200706-066TH; Kajikawa M, 2015, DIABETES CARE, V38, P119, DOI 10.2337/dc14-1435; Le Faouder P, 2013, J CHROMATOGR B, V932, P123, DOI 10.1016/j.jchromb.2013.06.014; Lee HN, 2013, SEMIN IMMUNOPATHOL, V35, P151, DOI 10.1007/s00281-013-0363-y; Li YM, 1997, J IMMUNOL METHODS, V201, P183, DOI 10.1016/S0022-1759(96)00224-4; Li YS, 2013, IMMUNITY, V39, P885, DOI 10.1016/j.immuni.2013.10.011; Mallipattu SK, 2014, CURR OPIN NEPHROL HY, V23, P547, DOI 10.1097/MNH.0000000000000062; Martinez F.O., 2014, F1000PRIME REP, V6, DOI DOI 10.12703/P6-13; Navarro-Xavier RA, 2010, J IMMUNOL, V184, P1516, DOI 10.4049/jimmunol.0902866; Nessim SJ, 2013, NAT REV NEPHROL, V9, P302, DOI 10.1038/nrneph.2013.43; Netea MG, 2013, EUR J CLIN INVEST, V43, P881, DOI 10.1111/eci.12132; Newson J, 2014, BLOOD, V124, P1748, DOI 10.1182/blood-2014-03-562710; Nguyen HH, 2012, J IMMUNOL, V189, P3112, DOI 10.4049/jimmunol.1200360; Okabe Y, 2014, CELL, V157, P832, DOI 10.1016/j.cell.2014.04.016; Ortega-Gomez A, 2013, EMBO MOL MED, V5, P661, DOI 10.1002/emmm.201202382; Pasare C, 2005, ADV EXP MED BIOL, V560, P11; Rajakariarl R, 2008, BLOOD, V111, P4184, DOI 10.1182/blood-2007-08-108936; Rangel-Moreno J, 2009, IMMUNITY, V30, P731, DOI 10.1016/j.immuni.2009.03.014; Rosas M, 2010, J LEUKOCYTE BIOL, V88, P169, DOI 10.1189/jlb.0809548; Salahuddin P, 2014, CELL MOL BIOL LETT, V19, P407, DOI 10.2478/s11658-014-0205-5; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Schif-Zuck S, 2011, EUR J IMMUNOL, V41, P366, DOI 10.1002/eji.201040801; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2013, CURR OPIN PHARMACOL, V13, P632, DOI 10.1016/j.coph.2013.05.012; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Shah S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038368; Shen H, 2013, J IMMUNOL, V191, P2857, DOI 10.4049/jimmunol.1301539; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779; Stables MJ, 2011, BLOOD, V118, pE192, DOI 10.1182/blood-2011-04-345330; Titos E, 2011, J IMMUNOL, V187, P5408, DOI 10.4049/jimmunol.1100225; Verollet C., BLOOD; WIJFFELS JFAM, 1992, RES IMMUNOL, V143, P401, DOI 10.1016/S0923-2494(05)80072-0; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Yamada T, 2011, FASEB J, V25, P561, DOI 10.1096/fj.10-170027; Yamagishi S, 2012, REJUV RES, V15, P564, DOI 10.1089/rej.2012.1335	55	19	19	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1914	1929		10.1096/fj.14-259341	http://dx.doi.org/10.1096/fj.14-259341			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25609430				2022-12-28	WOS:000354114600026
J	Amrutkar, M; Cansby, E; Nunez-Duran, E; Pirazzi, C; Stahlman, M; Stenfeldt, E; Smith, U; Boren, J; Mahlapuu, M				Amrutkar, Manoj; Cansby, Emmelie; Nunez-Duran, Esther; Pirazzi, Carlo; Stahlman, Marcus; Stenfeldt, Elin; Smith, Ulf; Boren, Jan; Mahlapuu, Margit			Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH	FASEB JOURNAL			English	Article						lipid droplets; lipid metabolism; liver inflammation; NAFLD; steatohepatitis	DIFFERENTIATION-RELATED PROTEIN; NONALCOHOLIC FATTY LIVER; ADIPOSE TRIGLYCERIDE LIPASE; HORMONE-SENSITIVE LIPASE; INSULIN-RESISTANCE; ACID OXIDATION; MICE; INFLAMMATION; EXPRESSION; TISSUE	Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease, and 10% to 20% of NAFLD patients progress to nonalcoholic steatohepatitis (NASH). The molecular pathways controlling progression to NAFLD/NASH remain poorly understood. We recently identified serine/threonine protein kinase 25 (STK25) as a regulator of whole-body insulin and glucose homeostasis. This study investigates the role of STK25 in liver lipid accumulation and NASH. Stk25 transgenic mice challenged with a high-fat diet displayed a dramatic increase in liver steatosis and hepatic insulin resistance compared to wild-type siblings. Focal fibrosis, hepatocellular damage, and inflammation were readily seen in transgenic but not wild-type livers. Transgenic livers displayed reduced beta-oxidation and triacylglycerol secretion, while lipid uptake and synthesis remained unchanged. STK25 was associated with lipid droplets, colocalizing with the main hepatic lipid droplet-coating protein adipose differentiation-related protein, the level of which was increased 3.8 +/- 0.7-fold in transgenic livers (P < 0.01), while a key hepatic lipase, adipose triacylglycerol lipase, was translocated from the lipid droplets surface to the cytoplasm, providing the likely mechanism underlying the effect of STK25. In summary, STK25 is a lipid droplet-associated protein that promotes NAFLD through control of lipid release from the droplets for beta-oxidation and triacylglycerol secretion. STK25 also drives pathogenesis of NASH.	[Amrutkar, Manoj; Cansby, Emmelie; Nunez-Duran, Esther; Smith, Ulf; Mahlapuu, Margit] Univ Gothenburg, Dept Mol & Clin Med, Lundberg Lab Diabet Res, SE-41345 Gothenburg, Sweden; [Pirazzi, Carlo; Stahlman, Marcus; Stenfeldt, Elin; Boren, Jan] Univ Gothenburg, Dept Mol & Clin Med, Wallenberg Lab, SE-41345 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Mahlapuu, M (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Lundberg Lab Diabet Res, Dept Mol & Clin Med, Bla Straket 5, SE-41345 Gothenburg, Sweden.	margit.mahlapuu@gu.se	StÃhlman, Marcus/M-4597-2019; Amrutkar, Manoj/J-2848-2019	Amrutkar, Manoj/0000-0002-1868-0249; Mahlapuu, Margit/0000-0001-8740-8874; Henricsson, Marcus/0000-0002-4202-0339	Swedish Research Council; European Foundation for the Study of Diabetes/Lilly Research Program; European Foundation for the Study of Diabetes; Novo Nordisk Partnership for Diabetes Research in Europe (Dusseldorf, Germany); Novo Nordisk Foundation (Hellerup, Denmark); Diabetes Wellness Network Sweden; Swedish Diabetes Foundation; Petrus and Augusta Hedlunds Foundation (Stockholm, Sweden); Ake Wiberg Foundation (Boras, Sweden); Adlerbert Research Foundation (Gothenburg, Sweden); M. Bergvall Foundation (Stockholm, Sweden); Novo Nordisk Fonden [NNF14OC0009667, NNF14OC0010799] Funding Source: researchfish	Swedish Research Council(Swedish Research CouncilEuropean Commission); European Foundation for the Study of Diabetes/Lilly Research Program; European Foundation for the Study of Diabetes; Novo Nordisk Partnership for Diabetes Research in Europe (Dusseldorf, Germany); Novo Nordisk Foundation (Hellerup, Denmark)(Novo Nordisk Foundation); Diabetes Wellness Network Sweden; Swedish Diabetes Foundation; Petrus and Augusta Hedlunds Foundation (Stockholm, Sweden); Ake Wiberg Foundation (Boras, Sweden); Adlerbert Research Foundation (Gothenburg, Sweden); M. Bergvall Foundation (Stockholm, Sweden); Novo Nordisk Fonden(Novo Nordisk Foundation)	The authors thank Dr. Rosie Perkins for editorial support. This work was supported by grants from the Swedish Research Council, the European Foundation for the Study of Diabetes/Lilly Research Program, the European Foundation for the Study of Diabetes, the Novo Nordisk Partnership for Diabetes Research in Europe (Dusseldorf, Germany), the Novo Nordisk Foundation (Hellerup, Denmark), the Diabetes Wellness Network Sweden, the Swedish Diabetes Foundation, the Petrus and Augusta Hedlunds Foundation (Stockholm, Sweden), the Ake Wiberg Foundation (Boras, Sweden), the Adlerbert Research Foundation (Gothenburg, Sweden), and the M. Bergvall Foundation (Stockholm, Sweden).	Adiels M, 2006, DIABETOLOGIA, V49, P755, DOI 10.1007/s00125-005-0125-z; Anstee QM, 2013, NAT REV GASTRO HEPAT, V10, P330, DOI 10.1038/nrgastro.2013.41; Bostrom P, 2007, NAT CELL BIOL, V9, P1286, DOI 10.1038/ncb1648; Bugianesi E, 2005, HEPATOLOGY, V42, P987, DOI 10.1002/hep.20920; Cansby E, 2014, MOL CELL ENDOCRINOL, V393, P143, DOI 10.1016/j.mce.2014.06.014; Cansby E, 2013, FASEB J, V27, P3660, DOI 10.1096/fj.13-228494; Chang BHJ, 2010, J LIPID RES, V51, P2132, DOI 10.1194/jlr.M004515; Chang BHJ, 2006, MOL CELL BIOL, V26, P1063, DOI 10.1128/MCB.26.3.1063-1076.2006; Dalen KT, 2006, J LIPID RES, V47, P931, DOI 10.1194/jlr.M500459-JLR200; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; Ducharme NA, 2008, ENDOCRINOLOGY, V149, P942, DOI 10.1210/en.2007-1713; FOLCH J, 1957, J BIOL CHEM, V226, P497; Greenberg AS, 2011, J CLIN INVEST, V121, P2102, DOI 10.1172/JCI46069; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Imai Y, 2007, GASTROENTEROLOGY, V132, P1947, DOI 10.1053/j.gastro.2007.02.046; Kato M, 2008, SCAND J GASTROENTERO, V43, P1018, DOI 10.1080/00365520802008140; Listenberger LL, 2007, J LIPID RES, V48, P2751, DOI 10.1194/jlr.M700359-JLR200; Magnusson B, 2006, ARTERIOSCL THROM VAS, V26, P1566, DOI 10.1161/01.ATV.0000223345.11820.da; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; McManaman JL, 2013, J LIPID RES, V54, P1346, DOI 10.1194/jlr.M035063; Motomura W, 2006, BIOCHEM BIOPH RES CO, V340, P1111, DOI 10.1016/j.bbrc.2005.12.121; Nagarajan P, 2012, WORLD J GASTROENTERO, V18, P1141, DOI 10.3748/wjg.v18.i11.1141; Nerstedt A, 2012, DIABETOLOGIA, V55, P1797, DOI 10.1007/s00125-012-2511-7; Ong KT, 2011, HEPATOLOGY, V53, P116, DOI 10.1002/hep.24006; Pellicoro A, 2014, NAT REV IMMUNOL, V14, P181, DOI 10.1038/nri3623; Qi KM, 2003, JPEN-PARENTER ENTER, V27, P58, DOI 10.1177/014860710302700158; Reid BN, 2008, J BIOL CHEM, V283, P13087, DOI 10.1074/jbc.M800533200; Sapiro JM, 2009, J LIPID RES, V50, P1621, DOI 10.1194/jlr.M800614-JLR200; Senthivinayagam S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073696; Sparks JD, 2012, ARTERIOSCL THROM VAS, V32, P2104, DOI 10.1161/ATVBAHA.111.241463; Stahlman M, 2013, BBA-MOL CELL BIOL L, V1831, P1609, DOI 10.1016/j.bbalip.2013.07.009; Sundaram M, 2010, J LIPID RES, V51, P150, DOI [10.1194/jlr.M900346-JLR200, 10.1194/M900346-JLR200]; Sutti S, 2014, HEPATOLOGY, V59, P886, DOI 10.1002/hep.26749; Takahashi Y, 2012, WORLD J GASTROENTERO, V18, P2300, DOI 10.3748/wjg.v18.i19.2300; Tilg H, 2008, TRENDS ENDOCRIN MET, V19, P371, DOI 10.1016/j.tem.2008.08.005; Turpin SM, 2011, DIABETOLOGIA, V54, P146, DOI 10.1007/s00125-010-1895-5; Varela GM, 2008, AM J PHYSIOL-GASTR L, V295, pG621, DOI 10.1152/ajpgi.90204.2008; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Wei EH, 2010, CELL METAB, V11, P183, DOI 10.1016/j.cmet.2010.02.005; Wu JW, 2011, HEPATOLOGY, V54, P122, DOI 10.1002/hep.24338; Ye J, 2009, CELL METAB, V9, P177, DOI 10.1016/j.cmet.2008.12.013; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	42	56	57	2	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1564	1576		10.1096/fj.14-264937	http://dx.doi.org/10.1096/fj.14-264937			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25609431	Bronze			2022-12-28	WOS:000354115000040
J	Jia, D; Huang, L; Bischoff, J; Moses, MA				Jia, Di; Huang, Lan; Bischoff, Joyce; Moses, Marsha A.			The endogenous zinc finger transcription factor, ZNF24, modulates the angiogenic potential of human microvascular endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; transcriptional regulation; VEGF repression	GROWTH-FACTOR RECEPTOR-2; BREAST-TUMOR GROWTH; EMBRYONIC-DEVELOPMENT; TISSUE INHIBITOR; CANCER-PATIENTS; IV COLLAGENASE; GELATINASE-A; LIPOCALIN 2; IN-VIVO; EXPRESSION	We have previously identified a zinc finger transcription factor, ZNF24 (zinc finger protein 24), as a novel inhibitor of tumor angiogenesis and have demonstrated that ZNF24 exerts this effect by repressing the transcription of VEGF in breast cancer cells. Here we focused on the role of ZNF24 in modulating the angiogenic potential of the endothelial compartment. Knockdown of ZNF24 by siRNA in human primary microvascular endothelial cells (ECs) led to significantly decreased cell migration and invasion compared with control siRNA. ZNF24 knockdown consistently led to significantly impaired VEGF receptor 2 (VEGFR2) signaling and decreased levels of matrix metalloproteinase-2 (MMP-2), with no effect on levels of major regulators of MMP-2 activity such as the tissue inhibitors of metalloproteinases and MMP-14. Moreover, silencing ZNF24 in these cells led to significantly decreased EC proliferation. Quantitative PCR array analyses identified multiple cell cycle regulators as potential ZNF24 downstream targets which may be responsible for the decreased proliferation in ECs. In vivo, knockdown of ZNF24 specifically in microvascular ECs led to significantly decreased formation of functional vascular networks. Taken together, these results demonstrate that ZNF24 plays an essential role in modulating the angiogenic potential of microvascular ECs by regulating the proliferation, migration, and invasion of these cells.	[Jia, Di; Huang, Lan; Bischoff, Joyce; Moses, Marsha A.] Boston Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA; [Jia, Di; Huang, Lan; Bischoff, Joyce; Moses, Marsha A.] Boston Childrens Hosp, Dept Surg, Boston, MA 02115 USA; [Jia, Di; Huang, Lan; Bischoff, Joyce; Moses, Marsha A.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Moses, MA (corresponding author), Boston Childrens Hosp, Vasc Biol Program, Karp Family Res Bldg,300 Longwood Ave, Boston, MA 02115 USA.	marsha.moses@childrens.harvard.edu	BISCHOFF, JOYCE/K-3354-2019	BISCHOFF, JOYCE/0000-0002-6367-1974	Breast Cancer Research Foundation (New York, NY, USA); Advanced Medical Research Foundation (Brookline, MA, USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096384] Funding Source: NIH RePORTER	Breast Cancer Research Foundation (New York, NY, USA); Advanced Medical Research Foundation (Brookline, MA, USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Research reported in this study was supported by the Breast Cancer Research Foundation (New York, NY, USA) and the Advanced Medical Research Foundation (Brookline, MA, USA).	Aird WC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006429; Albanese V, 2001, HUM MOL GENET, V10, P1785, DOI 10.1093/hmg/10.17.1785; Arvey A, 2012, GENOME RES, V22, P1723, DOI 10.1101/gr.127712.111; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bozkulak EC, 2009, MOL CELL BIOL, V29, P5679, DOI 10.1128/MCB.00406-09; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chi JT, 2003, P NATL ACAD SCI USA, V100, P10623, DOI 10.1073/pnas.1434429100; Coticchia CM, 2011, GYNECOL ONCOL, V123, P295, DOI 10.1016/j.ygyno.2011.07.034; Dib H, 2012, PROTEOMICS, V12, P2547, DOI 10.1002/pmic.201200060; Edelstein LC, 2005, GENE, V359, P1, DOI 10.1016/j.gene.2005.06.022; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; Fang LH, 2013, NATURE, V498, P118, DOI 10.1038/nature12166; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; Fernandez CA, 2003, J BIOL CHEM, V278, P40989, DOI 10.1074/jbc.M306176200; Fernandez CA, 2006, BIOCHEM BIOPH RES CO, V345, P523, DOI 10.1016/j.bbrc.2006.04.083; Fernandez CA, 2010, J BIOL CHEM, V285, P41886, DOI 10.1074/jbc.M110.166439; Foradori MJ, 2014, J BIOL CHEM, V289, P14301, DOI 10.1074/jbc.M113.529982; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Han ZG, 1999, J BIOL CHEM, V274, P35741, DOI 10.1074/jbc.274.50.35741; Harper J, 2006, EXP SUPPL, V96, P223; Harper J, 2007, CANCER RES, V67, P8736, DOI 10.1158/0008-5472.CAN-07-1617; HERRON GS, 1986, J BIOL CHEM, V261, P2810; Hofmann JJ, 2007, CIRC RES, V100, P1556, DOI 10.1161/01.RES.0000266408.42939.e4; Howng SYB, 2010, GENE DEV, V24, P301, DOI 10.1101/gad.1864510; Hutchins AP, 2013, NUCLEIC ACIDS RES, V41, P2155, DOI 10.1093/nar/gks1300; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Jia D, 2013, BLOOD, V121, P707, DOI 10.1182/blood-2012-05-433045; Khalfallah O, 2008, GENE EXPR PATTERNS, V8, P148, DOI 10.1016/j.gep.2007.11.002; Khalfallah O, 2009, STEM CELLS, V27, P1643, DOI 10.1002/stem.88; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; Li JZ, 2006, EXP CELL RES, V312, P3990, DOI 10.1016/j.yexcr.2006.08.020; Liu GY, 2012, HEPATOLOGY, V55, P1830, DOI 10.1002/hep.25564; Lozito TP, 2014, MATRIX BIOL, V34, P132, DOI 10.1016/j.matbio.2013.10.003; Lv L, 2014, J VASC SURG, V59, P500, DOI 10.1016/j.jvs.2013.03.049; Ma YF, 2013, DEVELOPMENT, V140, P2203, DOI 10.1242/dev.089789; Melero-Martin JM, 2008, CIRC RES, V103, P194, DOI 10.1161/CIRCRESAHA.108.178590; Moses MA, 1998, CANCER RES, V58, P1395; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; Noghero A, 2012, ARTERIOSCL THROM VAS, V32, P2280, DOI 10.1161/ATVBAHA.112.250621; Ohno-Matsui K, 2003, INVEST OPHTH VIS SCI, V44, P5370, DOI 10.1167/iovs.03-0249; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Pories SE, 2008, CANCER EPIDEM BIOMAR, V17, P1034, DOI 10.1158/1055-9965.EPI-07-0365; Prost JF, 1999, BBA-GENE STRUCT EXPR, V1447, P278, DOI 10.1016/S0167-4781(99)00157-8; Rodrigues M, 2013, DIABETES, V62, P3863, DOI 10.2337/db13-0014; Roy R, 2006, EXP CELL RES, V312, P608, DOI 10.1016/j.yexcr.2005.11.022; Roy R, 2008, CLIN CANCER RES, V14, P6610, DOI 10.1158/1078-0432.CCR-08-1136; Roy R, 2011, J BIOL CHEM, V286, P20758, DOI 10.1074/jbc.M110.216036; Roy R, 2012, BREAST CANCER RES TR, V131, P731, DOI 10.1007/s10549-011-1431-4; Sanda T, 2010, BLOOD, V115, P1735, DOI 10.1182/blood-2009-07-235143; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Smith ER, 2008, CLIN CANCER RES, V14, P2378, DOI 10.1158/1078-0432.CCR-07-1253; Stanton H, 1998, J CELL SCI, V111, P2789; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Theret N, 1999, HEPATOLOGY, V30, P462, DOI 10.1002/hep.510300236; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wang HY, 2008, ACTA BIOCH BIOPH SIN, V40, P704, DOI 10.1111/j.1745-7270.2008.00450.x; Xie JJ, 2005, BIOCHEM BIOPH RES CO, V337, P355, DOI 10.1016/j.bbrc.2005.09.055; Yang J, 2013, FASEB J, V27, P45, DOI 10.1096/fj.12-211730; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106	60	14	14	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1371	1382		10.1096/fj.14-258947	http://dx.doi.org/10.1096/fj.14-258947			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550468	Green Published			2022-12-28	WOS:000354115000023
J	Karmouty-Quintana, H; Philip, K; Acero, LF; Chen, NY; Weng, TT; Molina, JG; Luo, FY; Davies, J; Le, NB; Bunge, I; Volcik, KA; Le, TTT; Johnston, RA; Xia, Y; Eltzschig, HK; Blackburn, MR				Karmouty-Quintana, Harry; Philip, Kemly; Acero, Luis F.; Chen, Ning-Yuan; Weng, Tingting; Molina, Jose G.; Luo, Fayong; Davies, Jonathan; Le, Ngoc-Bao; Bunge, Isabelle; Volcik, Kelly A.; Le, Thanh-Thuy T.; Johnston, Richard A.; Xia, Yang; Eltzschig, Holger K.; Blackburn, Michael R.			Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension	FASEB JOURNAL			English	Article						alternatively activated macrophages; vascular remodeling; adenosine receptors; hyaluronan	A(2B) ADENOSINE RECEPTOR; ALVEOLAR MACROPHAGES; ARTERIAL-HYPERTENSION; AIRWAY HYPERRESPONSIVENESS; GROWTH-FACTOR; DISEASE; INFLAMMATION; HYALURONAN; INJURY; MICE	Idiopathic pulmonary fibrosis (IPF) is a lethal, fibroproliferative disease. Pulmonary hypertension (PH) can develop secondary to IPF and increase mortality. Alternatively, activated macrophages (AAMs) contribute to the pathogenesis of both IPF and PH. Here we hypothesized that adenosine signaling through the ADORA2B on AAMs impacts the progression of these disorders and that conditional deletion of ADORA2B on myeloid cells would have a beneficial effect in a model of these diseases. Conditional knockout mice lacking ADORA2B on myeloid cells (Adora2B(f/f)-LysM(Cre)) were exposed to the fibrotic agent bleomycin (BLM; 0.035 U/g body weight, i. p.). At 14, 17, 21, 25, or 33 d after exposure, SpO(2), bronchoalveolar lavage fluid (BALF), and histologic analyses were performed. On day 33, lung function and cardiovascular analyses were determined. Markers for AAM and mediators of fibrosis and PH were assessed. Adora2Bf/f-LysMCre mice presented with attenuated fibrosis, improved lung function, and no evidence of PH compared with control mice exposed to BLM. These findings were accompanied by reduced expression of CD206 and arginase-1, markers for AAMs. A 10-fold reduction in IL-6 and a 5-fold decrease in hyaluronan, both linked to lung fibrosis and PH, were also observed. These data suggest that activation of the ADORA2B on macrophages plays an active role in the pathogenesis of lung fibrosis and PH.	[Karmouty-Quintana, Harry; Philip, Kemly; Acero, Luis F.; Chen, Ning-Yuan; Weng, Tingting; Molina, Jose G.; Luo, Fayong; Le, Ngoc-Bao; Bunge, Isabelle; Volcik, Kelly A.; Le, Thanh-Thuy T.; Xia, Yang; Blackburn, Michael R.] Univ Texas Med Sch Houston, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Johnston, Richard A.] Univ Texas Med Sch Houston, Dept Pediat, Houston, TX 77030 USA; [Davies, Jonathan] Baylor Coll Med, Dept Pediat, Div Neonatol Perinatal Med, Houston, TX 77030 USA; [Eltzschig, Holger K.] Univ Colorado Denver, Dept Anesthesiol, Aurora, CO USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Blackburn, MR (corresponding author), Univ Texas Med Sch Houston, Dept Biochem & Mol Biol, 6431 Fannin, Houston, TX 77030 USA.	michael.r.blackburn@uth.tmc.edu	Karmouty-Quintana, Harry/ABC-9144-2020	Karmouty-Quintana, Harry/0000-0003-4753-9823; Philip, Kemly/0000-0002-7749-9781; Blackburn, Michael/0000-0002-1394-9966; Johnston, Richard/0000-0003-0686-5139	NHLBI NIH HHS [R01 HL113574, R01 HL070952, R01-HL070952, P01 HL114457, P01-HL114457] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL113574, R01HL070952, P01HL114457] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ask K, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-16; Aytekin M, 2008, AM J PHYSIOL-LUNG C, V295, pL789, DOI 10.1152/ajplung.90306.2008; Baran CP, 2007, AM J RESP CRIT CARE, V176, P78, DOI 10.1164/rccm.200609-1279OC; Behr J, 2008, EUR RESPIR J, V31, P1357, DOI 10.1183/09031936.00171307; Belikoff BG, 2012, J IMMUNOL, V189, P3707, DOI 10.4049/jimmunol.1201207; Blackwell TS, 2014, AM J RESP CRIT CARE, V189, P214, DOI 10.1164/rccm.201306-1141WS; Chang MY, 2014, MATRIX BIOL, V35, P162, DOI 10.1016/j.matbio.2014.04.003; Chaouat A, 2009, CHEST, V136, P678, DOI 10.1378/chest.08-2420; Cloots RHE, 2013, AM J PHYSIOL-LUNG C, V305, pL364, DOI 10.1152/ajplung.00341.2012; Colgan Sean P, 2006, Purinergic Signal, V2, P351, DOI 10.1007/s11302-005-5302-5; El Chami H, 2012, PROG CARDIOVASC DIS, V55, P218, DOI 10.1016/j.pcad.2012.07.006; Frid MG, 2006, AM J PATHOL, V168, P659, DOI 10.2353/ajpath.2006.050599; Gibbons MA, 2011, AM J RESP CRIT CARE, V184, P569, DOI 10.1164/rccm.201010-1719OC; Huebner RH, 2008, BIOTECHNIQUES, V44, P507, DOI 10.2144/000112729; Johnston RA, 2008, J APPL PHYSIOL, V104, P1727, DOI 10.1152/japplphysiol.00075.2008; Karmouty-Quintana H, 2013, AM J RESP CELL MOL, V49, P1038, DOI 10.1165/rcmb.2013-0089OC; Karmouty-Quintana H, 2013, J MOL MED, V91, P173, DOI 10.1007/s00109-013-0997-1; Karmouty-Quintana H, 2012, FASEB J, V26, P2546, DOI 10.1096/fj.11-200907; Knight DA, 2003, PHARMACOL THERAPEUT, V99, P327, DOI 10.1016/S0163-7258(03)00095-0; LACRONIQUE JG, 1984, AM REV RESPIR DIS, V130, P450; Li YJ, 2011, J EXP MED, V208, P1459, DOI 10.1084/jem.20102510; Mora AL, 2006, AM J RESP CELL MOL, V35, P466, DOI 10.1165/rcmb.2006-0121OC; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; NAGAOKA I, 1990, J CLIN INVEST, V85, P2023, DOI 10.1172/JCI114669; Pedroza M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022667; Pitsiou G, 2011, RESPIRATION, V82, P294, DOI 10.1159/000327918; Prasse A, 2006, AM J RESP CRIT CARE, V173, P781, DOI 10.1164/rccm.200509-1518OC; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Sahara M, 2007, CIRCULATION, V115, P509, DOI 10.1161/CIRCULATIONAHA.106.655837; Shalaby KH, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-82; Shaykhiev R, 2009, J IMMUNOL, V183, P2867, DOI 10.4049/jimmunol.0900473; Shorr AF, 2007, EUR RESPIR J, V30, P715, DOI 10.1183/09031936.00107206; Steiner MK, 2009, CIRC RES, V104, P236, DOI 10.1161/CIRCRESAHA.108.182014; Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303; Tian W, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006674; Toldo S, 2012, J PHARMACOL EXP THER, V343, P587, DOI 10.1124/jpet.111.191288; TUDER RM, 1994, AM J PATHOL, V144, P275; Vergadi E, 2011, CIRCULATION, V123, P1986, DOI 10.1161/CIRCULATIONAHA.110.978627; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; Zhou Y, 2011, J IMMUNOL, V186, P1097, DOI 10.4049/jimmunol.1002907; Zhou Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009224; Zhou Y, 2009, PHARMACOL THERAPEUT, V123, P105, DOI 10.1016/j.pharmthera.2009.04.003; Zimmerman MA, 2013, P NATL ACAD SCI USA, V110, P12012, DOI 10.1073/pnas.1221733110	43	54	55	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					50	60		10.1096/fj.14-260182	http://dx.doi.org/10.1096/fj.14-260182			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25318478	Green Published			2022-12-28	WOS:000347378600006
J	Niu, GM; Ye, TY; Qin, LL; Bourbon, PM; Chang, C; Zhao, SQ; Li, Y; Zhou, L; Cui, PF; Rabinovitz, I; Mercurio, AM; Zhao, DZ; Zeng, HY				Niu, Gengming; Ye, Taiyang; Qin, Liuliang; Bourbon, Pierre M.; Chang, Cheng; Zhao, Shengqiang; Li, Yan; Zhou, Lei; Cui, Pengfei; Rabinovitz, Issac; Mercurio, Arthur M.; Zhao, Dezheng; Zeng, Huiyan			Orphan nuclear receptor TR3/Nur77 improves wound healing by upregulating the expression of integrin beta 4	FASEB JOURNAL			English	Article						angiogenesis; VEGF	PHOSPHOINOSITIDE 3-OH KINASE; HUMAN ENDOTHELIAL-CELLS; IN-VITRO ANGIOGENESIS; NITRIC-OXIDE SYNTHASE; NGFI-B; PERMEABILITY; CANCER; PROLIFERATION; ACTIVATION; MIGRATION	Tissue repair/wound healing, in which angiogenesis plays an important role, is a critical step in many diseases including chronic wound, myocardial infarction, stroke, cancer, and inflammation. Recently, we were the first to report that orphan nuclear receptor TR3/Nur77 is a critical mediator of angiogenesis and its associated microvessel permeability. Tumor growth and angiogenesis induced by VEGF-A, histamine, and serotonin are almost completely inhibited in Nur77 knockout mice. However, it is not known whether TR3/Nur77 plays any roles in wound healing. In these studies, skin wound-healing assay was performed in 3 types of genetically modified mice having various Nur77 activities. We found that ectopic induction of Nur77 in endothelial cells of mice is sufficient to improve skin wound healing. Although skin wound healing in Nur77 knockout mice is comparable to the wild-type control mice, the process is significantly delayed in the EC-Nur77-DN mice, in which a dominant negative Nur77 mutant is inducibly and specifically expressed in mouse endothelial cells. By a loss-of-function assay, we elucidate a novel feed-forward signaling pathway, integrin beta 4. PI3K -> Akt -> FAK, by which TR3 mediates HUVEC migration. Furthermore, TR3/Nur77 regulates the expression of integrin beta 4 by targeting its promoter activity. In conclusion, expression of TR3/Nur77 improves wound healing by targeting integrin beta 4. TR3/Nur77 is a potential candidate for proangiogenic therapy. The results further suggest that TR3/Nur77 is required for pathologic angiogenesis but not for developmental/physiologic angiogenesis and that Nur77 and its family members play a redundant role in normal skin wound healing.	[Niu, Gengming; Ye, Taiyang; Zhao, Shengqiang; Li, Yan; Zhou, Lei; Cui, Pengfei; Rabinovitz, Issac; Zhao, Dezheng; Zeng, Huiyan] Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA; [Niu, Gengming; Ye, Taiyang; Zhao, Shengqiang; Li, Yan; Zhou, Lei; Cui, Pengfei; Rabinovitz, Issac; Zhao, Dezheng; Zeng, Huiyan] Beth Israel Deaconess Med Ctr, Dept Med, Div Mol & Vasc Biol, Boston, MA 02215 USA; [Qin, Liuliang; Bourbon, Pierre M.; Rabinovitz, Issac] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; [Zhao, Dezheng] Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA 02215 USA; [Zeng, Huiyan] Harvard Univ, Sch Med, Boston, MA 02215 USA; [Niu, Gengming] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China; [Ye, Taiyang] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Obstet & Gynecol, Shanghai 200030, Peoples R China; [Chang, Cheng; Mercurio, Arthur M.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA USA; [Zhao, Shengqiang; Li, Yan] Shandong Univ, Prov Hosp, Dept Gastroenterol, Jinan 250100, Peoples R China; [Zhou, Lei] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian 710049, Peoples R China; [Zhou, Lei] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Gen Surg, Xian 710049, Peoples R China; [Cui, Pengfei] Huazhong Univ Sci & Technol, Union Hosp, Pancreat Dis Inst, Dept Gen Surg, Wuhan 430074, Peoples R China	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Fudan University; Shanghai Jiao Tong University; University of Massachusetts System; University of Massachusetts Worcester; Shandong University; Xi'an Jiaotong University; Xi'an Jiaotong University; Huazhong University of Science & Technology	Zeng, HY (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Mol & Vasc Biol, 99 Brookline Ave RN 270F, Boston, MA 02215 USA.	hzeng@caregroup.harvard.edu	NIU, NIU/AAA-1523-2022	/0000-0003-1726-3037; Ye, Taiyang/0000-0002-2640-1289	NATIONAL CANCER INSTITUTE [R01CA133235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK095873, R21DK080970] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA133235, R01CA133235] Funding Source: Medline; NIDDK NIH HHS [R01DK095873, R21DK080970, R01 DK095873, R21 DK080970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2011, CARDIOVASC RES, V90, P234, DOI 10.1093/cvr/cvr015; Bagli E, 2004, CANCER RES, V64, P7936, DOI 10.1158/0008-5472.CAN-03-3104; Baril P, 2007, ONCOGENE, V26, P2082, DOI 10.1038/sj.onc.1210009; Braiman-Wiksman L, 2007, TOXICOL PATHOL, V35, P767, DOI 10.1080/01926230701584189; Cattaneo MG, 2008, BRIT J PHARMACOL, V153, P728, DOI 10.1038/sj.bjp.0707609; Cattaneo MG, 2009, EXP CELL RES, V315, P3210, DOI 10.1016/j.yexcr.2009.06.022; Chang C, 2013, MOL CELL BIOL, V33, P3795, DOI 10.1128/MCB.00434-13; Chen HZ, 2008, CARCINOGENESIS, V29, P2078, DOI 10.1093/carcin/bgn197; Folkman J, 1997, EXS, V79, P1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996-150; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Giancotti FG, 2007, TRENDS PHARMACOL SCI, V28, P506, DOI 10.1016/j.tips.2007.08.004; Gilcrease MZ, 2004, CANCER RES, V64, P7395, DOI 10.1158/0008-5472.CAN-04-1809; Howdieshell TR, 2001, J SURG RES, V96, P173, DOI 10.1006/jsre.2001.6089; Hsu Hui-Chen, 2004, Current Drug Targets - Inflammation and Allergy, V3, P413, DOI 10.2174/1568010042634523; Ilan N, 1998, J CELL SCI, V111, P3621; Kanzleiter T, 2005, PHYSIOL GENOMICS, V24, P37, DOI 10.1152/physiolgenomics.00204.2005; Kim H, 2006, BIOCHEM BIOPH RES CO, V348, P950, DOI 10.1016/j.bbrc.2006.07.167; Lal BK, 2001, MICROVASC RES, V62, P252, DOI 10.1006/mvre.2001.2338; LEE SL, 1995, SCIENCE, V269, P532, DOI 10.1126/science.7624775; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; McMorrow JP, 2011, BIOCHEM SOC T, V39, P688, DOI 10.1042/BST0390688; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; O'Neill BT, 2005, J CLIN INVEST, V115, P2059, DOI 10.1172/JCI25900; Paulsen RE, 1995, J MOL NEUROSCI, V6, P249, DOI 10.1007/BF02736784; Pols TWH, 2007, CURR OPIN LIPIDOL, V18, P515, DOI 10.1097/MOL.0b013e3282ef77d1; Qin LL, 2013, BLOOD, V121, P2154, DOI 10.1182/blood-2012-07-443903; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Stupack DG, 2004, CURR TOP DEV BIOL, V64, P207, DOI 10.1016/S0070-2153(04)64009-9; Tang KQ, 1999, BIOCHEM BIOPH RES CO, V264, P127, DOI 10.1006/bbrc.1999.1496; Wingate AD, 2006, BIOCHEM SOC T, V34, P1107, DOI 10.1042/BST0341107; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zhang Y, 2009, PHYTOTHER RES, V23, P1205, DOI 10.1002/ptr.2479; Zhao DZ, 2011, P NATL ACAD SCI USA, V108, P12066, DOI 10.1073/pnas.1018438108	39	26	27	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					131	140		10.1096/fj.14-257550	http://dx.doi.org/10.1096/fj.14-257550			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25326539	Green Published			2022-12-28	WOS:000347378600013
J	Billeter, AT; Hellmann, J; Roberts, H; Druen, D; Gardner, SA; Sarojini, H; Galandiuk, S; Chien, SF; Bhatnagar, A; Spite, M; Polk, HC				Billeter, Adrian T.; Hellmann, Jason; Roberts, Henry; Druen, Devin; Gardner, Sarah A.; Sarojini, Harshini; Galandiuk, Susan; Chien, Sufan; Bhatnagar, Aruni; Spite, Matthew; Polk, Hiram C., Jr.			MicroRNA-155 potentiates the inflammatory response in hypothermia by suppressing IL-10 production	FASEB JOURNAL			English	Article						sepsis; peritonitis; cold exposure	RANDOMIZED CLINICAL-TRIAL; TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; THERAPEUTIC HYPOTHERMIA; INTRAOPERATIVE HYPOTHERMIA; PERIOPERATIVE HYPOTHERMIA; DENDRITIC CELLS; WOUND-INFECTION; IN-VIVO; MIR-155	Therapeutic hypothermia is commonly used to improve neurological outcomes in patients after cardiac arrest. However, therapeutic hypothermia increases sepsis risk and unintentional hypothermia in surgical patients increases infectious complications. Nonetheless, the molecular mechanisms by which hypothermia dysregulates innate immunity are incompletely understood. We found that exposure of human monocytes to cold (32 degrees C) potentiated LPS-induced production of TNF and IL-6, while blunting IL-10 production. This dysregulation was associated with increased expression of microRNA-155 (miR-155), which potentiates Toll-like receptor (TLR) signaling by negatively regulating Ship1 and Socs1. Indeed, Ship1 and Socs1 were suppressed at 32 degrees C and miR-155 antagomirs increased Ship1 and Socs1 and reversed the alterations in cytokine production in cold-exposed monocytes. In contrast, miR-155 mimics phenocopied the effects of cold exposure, reducing Ship1 and Socs1 and altering TNF and IL-10 production. In a murine model of LPS-induced peritonitis, cold exposure potentiated hypothermia and decreased survival (10 vs. 50%; P < 0.05), effects that were associated with increased miR-155, suppression of Ship1 and Socs1, and alterations in TNF and IL-10. Importantly, miR-155-deficiency reduced hypothermia and improved survival (78 vs. 32%, P < 0.05), which was associated with increased Ship1, Socs1, and IL-10. These results establish a causal role of miR-155 in the dysregulation of the inflammatory response to hypothermia.	[Billeter, Adrian T.; Roberts, Henry; Druen, Devin; Gardner, Sarah A.; Sarojini, Harshini; Galandiuk, Susan; Chien, Sufan; Polk, Hiram C., Jr.] Univ Louisville, Sch Med, Dept Surg, Price Inst Surg Res, Louisville, KY 40292 USA; [Hellmann, Jason; Bhatnagar, Aruni; Spite, Matthew] Univ Louisville, Sch Med, Diabet & Obes Ctr, Inst Mol Cardiol, Louisville, KY 40292 USA	University of Louisville; University of Louisville	Billeter, AT (corresponding author), Univ Louisville, Sch Med, Dept Surg, Price Inst Surg Res, Louisville, KY 40292 USA.	adrianbilleter@bluewin.ch; mspite@partners.org	Billeter, Adrian/O-2185-2019; Sarojini, Harshini/AAD-4870-2019; Hellmann, Jason/B-9360-2012	Sarojini, Harshini/0000-0002-3103-9712; Billeter, Adrian/0000-0001-8724-4793	Price Trust Fund; Joint Royal College of Surgeons of Edinburgh (RCSEd)/James and Emmeline Ferguson Research Fellowship Trust; U. S. National Institutes of Health [HL-106173, GM-103492, HL-116186]; Joint RCSEd/James and Emmeline Ferguson Research Fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL106173, F32HL116186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103492] Funding Source: NIH RePORTER	Price Trust Fund; Joint Royal College of Surgeons of Edinburgh (RCSEd)/James and Emmeline Ferguson Research Fellowship Trust; U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Joint RCSEd/James and Emmeline Ferguson Research Fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Donald E. Fry for insight, advice, and productive discussions and Dr. James McCracken for help with the FACS analysis of the peritoneal exudate cells. This work was funded by the Price Trust Fund, by the Joint Royal College of Surgeons of Edinburgh (RCSEd)/James and Emmeline Ferguson Research Fellowship Trust and by U. S. National Institutes of Health grants HL-106173 (to M. S.) and GM-103492 (to M. S. and A. B.). A. T. B. holds the Joint RCSEd/James and Emmeline Ferguson Research Fellowship and currently works at the Department of Surgery at the University of Heidelberg (Heidelberg, Germany). J.H. is the recipient of a National Research Service Award from the U. S. National Institutes of Health (grant HL-116186). The funding sources had no role in the production of the manuscript.	Ahmad FU, 2014, WORLD NEUROSURG, V82, P207, DOI 10.1016/j.wneu.2013.01.008; Ajuebor MN, 1999, J IMMUNOL, V162, P1685; AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51, DOI 10.1002/jlb.37.1.51; Ariel A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00004; Arons MM, 1999, CRIT CARE MED, V27, P699, DOI 10.1097/00003246-199904000-00020; Arrich J, 2012, COCHRANE DB SYST REV, V4, P9; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Beilman GJ, 2009, ANN SURG, V249, P845, DOI 10.1097/SLA.0b013e3181a41f6f; Billeter AT, 2014, SURGERY, V156, P1245, DOI 10.1016/j.surg.2014.04.024; Billeter AT, 2012, SURGERY, V151, P1, DOI 10.1016/j.surg.2011.08.006; Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107; Brock M, 2014, EUR HEART J, V35, P3203, DOI 10.1093/eurheartj/ehs060; Bukur M, 2012, J SURG RES, V175, P24, DOI 10.1016/j.jss.2011.07.003; Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Ceppi M, 2009, P NATL ACAD SCI USA, V106, P2735, DOI 10.1073/pnas.0811073106; Clark N, 2007, FASEB J, V21, P3747, DOI 10.1096/fj.06-7460com; Cremer TJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008508; Fairchild KD, 2005, AM J PHYSIOL-CELL PH, V289, pC1114, DOI 10.1152/ajpcell.00152.2005; Fairchild KD, 2004, AM J PHYSIOL-CELL PH, V287, pC422, DOI 10.1152/ajpcell.00507.2003; Fairchild KD, 2000, J INTERF CYTOK RES, V20, P1049, DOI 10.1089/107999000750053708; Fernandes ES, 2012, J IMMUNOL, V188, P5741, DOI 10.4049/jimmunol.1102147; Flores-Maldonado A, 2001, ARCH MED RES, V32, P227, DOI 10.1016/S0188-4409(01)00272-7; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Fries M, 2009, J CRIT CARE, V24, P453, DOI 10.1016/j.jcrc.2008.10.012; Geurts M, 2014, CRIT CARE MED, V42, P231, DOI 10.1097/CCM.0b013e3182a276e8; Goldszmid RS, 2012, IMMUNITY, V36, P1047, DOI 10.1016/j.immuni.2012.03.026; Hammarfjord O, 2010, J LEUKOCYTE BIOL, V88, P747, DOI 10.1189/jlb.0310155; Hou J, 2009, J IMMUNOL, V183, P2150, DOI 10.4049/jimmunol.0900707; Inaba K, 2012, J TRAUMA ACUTE CARE, V73, P1478, DOI 10.1097/TA.0b013e3182781db3; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; Jiang SY, 2013, CRIT CARE, V17, DOI 10.1186/cc12559; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kurowska-Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Li RC, 2013, CIRC RES, V112, P601, DOI 10.1161/CIRCRESAHA.112.300806; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsui T, 2014, NEUROCRIT CARE, V20, P301, DOI 10.1007/s12028-013-9911-5; McCoy CE, 2010, J BIOL CHEM, V285, P20492, DOI 10.1074/jbc.M110.102111; Meybohm P, 2010, CRIT CARE, V14, DOI 10.1186/cc8879; Monk CE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013669; Mourvillier B, 2013, JAMA-J AM MED ASSOC, V310, P2174, DOI 10.1001/jama.2013.280506; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957; Perbet S, 2011, AM J RESP CRIT CARE, V184, P1048, DOI 10.1164/rccm.201102-0331OC; Pu J, 2012, BIOCHEM BIOPH RES CO, V428, P210, DOI 10.1016/j.bbrc.2012.09.126; Schif-Zuck S, 2011, EUR J IMMUNOL, V41, P366, DOI 10.1002/eji.201040801; Seamon MJ, 2012, ANN SURG, V255, P789, DOI 10.1097/SLA.0b013e31824b7e35; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Tian DH, 2013, ANN CARDIOTHORAC SUR, V2, P148, DOI 10.3978/j.issn.2225-319X.2013.03.13; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Trotta R, 2012, BLOOD, V119, P3478, DOI 10.1182/blood-2011-12-398099; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; van Der Poll Tom, 1997, Clin Microbiol Infect, V3, P605, DOI 10.1111/j.1469-0691.1997.tb00465.x; Wang P, 2010, J IMMUNOL, V185, P6226, DOI 10.4049/jimmunol.1000491; Wenisch C, 1996, ANESTH ANALG, V82, P810, DOI 10.1097/00000539-199604000-00023; Xiao HY, 2005, CRIT CARE MED, V33, P161, DOI 10.1097/01.CCM.0000151049.19253.54; Zhu QY, 2010, J IMMUNOL, V185, P7435, DOI 10.4049/jimmunol.1000798	60	40	46	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5322	5336		10.1096/fj.14-258335	http://dx.doi.org/10.1096/fj.14-258335			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25231976	Green Published			2022-12-28	WOS:000345894500026
J	Shiomi, T; Sklepkiewicz, P; Bodine, PVN; D'Armiento, JM				Shiomi, Takayuki; Sklepkiewicz, Piotr; Bodine, Peter V. N.; D'Armiento, Jeanine M.			Maintenance of the bronchial alveolar stem cells in an undifferentiated state by secreted frizzled-related protein 1	FASEB JOURNAL			English	Article						lung; progenitor cell; SFRP1; Wnt; mouse	IDIOPATHIC PULMONARY-FIBROSIS; KERATINOCYTE GROWTH-FACTOR; LUNG-CANCER; DIFFERENTIATION; EMPHYSEMA; PATHOGENESIS; EPITHELIUM; APOPTOSIS; KINASE; AIRWAY	Bronchoalveolar stem cells (BASCs) are mobilized during injury and identified as lung progenitor cells, but the molecular regulation of this population of cells has not been elucidated. Secreted frizzled-related protein 1 (SFRP1) is a critical molecule involved in alveolar duct formation in the lung and here we demonstrate its importance in controlling cell differentiation during lung injury. Mice lacking SFRP1 exhibited a rapid repair response leading to aberrant proliferation of differentiated cells. Furthermore, SFRP1 treatment of BASCs maintained these cells in a quiescent state. In vivo overexpression of SFRP1 after injury suppressed differentiation and resulted in the accumulation of BASCs correlating with in vitro studies. These findings suggest that SFRP1 expression in the adult maintains progenitor cells within their undifferentiated state and suggests that manipulation of this pathway is a potential target to augment the lung repair process during disease.	[Shiomi, Takayuki; Sklepkiewicz, Piotr; D'Armiento, Jeanine M.] Columbia Univ, Coll Phys & Surg, Dept Anesthesiol, New York, NY 10032 USA; [Bodine, Peter V. N.] Pfizer Inc, Collegeville, PA USA	Columbia University; Pfizer	D'Armiento, JM (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Anesthesiol, 630 West 168th St,P&S 12-402, New York, NY 10032 USA.	jmd12@cumc.columbia.edu	Shiomi, Takayuki/A-2228-2014	Shiomi, Takayuki/0000-0002-4250-1204	Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research; American Heart Association; U.S. National Institutes of Health [R01 HL086936, RC1 HL100384]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC1HL100384, R01HL086936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089] Funding Source: NIH RePORTER	Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research; American Heart Association(American Heart Association); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported by the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research (T.S.), an American Heart Association Established Investigator Award (J.D.), and U.S. National Institutes of Health grants R01 HL086936 (J.D.) and RC1 HL100384 (J.D.). The authors thank Tina Zelonina and Tomoe Shiomi for technical assistance, and Professor Kiran Chada (Rutgers University, New Brunswick, NJ, USA) and Monica Goldklang (Columbia University) for critical reading of the manuscript.	ADAMSON IYR, 1974, AM J PATHOL, V77, P185; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; Bourbon JR, 2009, TRENDS MOL MED, V15, P169, DOI 10.1016/j.molmed.2009.02.003; Chilosi M, 2010, SARCOIDOSIS VASC DIF, V27, P7; Foronjy R, 2010, AM J PATHOL, V177, P598, DOI 10.2353/ajpath.2010.090803; Campelo MRG, 2011, CLIN TRANSL ONCOL, V13, P77, DOI 10.1007/s12094-011-0622-0; Giangreco A, 2002, AM J PATHOL, V161, P173, DOI 10.1016/S0002-9440(10)64169-7; Gotts JE, 2012, AM J PHYSIOL-LUNG C, V302, pL1147, DOI 10.1152/ajplung.00122.2012; Hikake T, 2009, J ENDOCRINOL, V203, P231, DOI 10.1677/JOE-09-0232; Hyatt BA, 2002, DEV DYNAM, V225, P153, DOI 10.1002/dvdy.10145; Imai K, 2002, CHEST, V121, p7S, DOI 10.1378/chest.121.3_suppl.7S; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kurinna SM, 2004, CANCER RES, V64, P7852, DOI 10.1158/0008-5472.CAN-04-1552; MAHVI D, 1977, AM J PATHOL, V86, P559; Mei Y, 2012, P NATL ACAD SCI USA, V109, P4898, DOI 10.1073/pnas.1119535109; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; PANOS RJ, 1993, J CLIN INVEST, V92, P969, DOI 10.1172/JCI116673; Rawlins EL, 2006, DEVELOPMENT, V133, P2455, DOI 10.1242/dev.02407; Rawlins EL, 2009, CELL STEM CELL, V4, P525, DOI 10.1016/j.stem.2009.04.002; Reynolds SD, 2008, STEM CELLS, V26, P1337, DOI 10.1634/stemcells.2008-0053; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sakurai MK, 2007, AM J PHYSIOL-LUNG C, V292, pL742, DOI 10.1152/ajplung.00064.2006; Selman Moises, 2006, Proc Am Thorac Soc, V3, P364, DOI 10.1513/pats.200601-003TK; Tuder Rubin M, 2006, Proc Am Thorac Soc, V3, P673, DOI 10.1513/pats.200605-124SF; ULICH TR, 1994, J CLIN INVEST, V93, P1298, DOI 10.1172/JCI117086; Wang R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014793; Zemke AC, 2009, AM J RESP CELL MOL, V41, P535, DOI 10.1165/rcmb.2008-0407OC; Zhang JW, 2008, J BIOL CHEM, V283, P9499, DOI 10.1074/jbc.R700043200	28	7	7	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5242	5249		10.1096/fj.13-242735	http://dx.doi.org/10.1096/fj.13-242735			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25212222	Green Published			2022-12-28	WOS:000345894500019
J	Wu, K; Liu, J; Zhuang, N; Wang, T				Wu, Kai; Liu, Jia; Zhuang, Na; Wang, Tao			UCP4A protects against mitochondrial dysfunction and degeneration in pink1/parkin models of Parkinson's disease	FASEB JOURNAL			English	Article						ROS; ETC; Drosophila	DOPAMINERGIC NEURON LOSS; UNCOUPLING PROTEIN-2; OXIDATIVE STRESS; DROSOPHILA-PINK1 MUTANTS; MUSCLE DEGENERATION; VCP MUTATIONS; PINK1; MECHANISMS; DEPOLARIZATION; MITOPHAGY	Genetic mutations in parkin or pink1 are the most common causes of familial Parkinson's disease. PINK1 and Parkin are components of a mitochondrial quality control pathway that degrades dysfunctional mitochondria via autophagy. Using a candidate gene approach, we discovered that overexpression of uncoupling protein 4A (ucp4A) suppresses a range of pink1 mutant phenotypes, including male sterility, locomotor defects, and muscle degeneration that result from abnormal mitochondrial morphology and function. Furthermore, UCP4A overexpression in pink1 mutants rescued mitochondria-specific phenotypes associated with mitochondrial membrane potential, production of reactive oxygen species, resistance to oxidative stress, efficiency of the electron transport chain, and mitochondrial morphology. Consistent with its role in protecting mitochondria, UCP4A rescued mitochondrial phenotypes of parkin mutant flies, as well. Finally, the genetic deletion of ucp4A resulted in increased sensitivity to oxidative stress, a phenotype that was enhanced by the loss of PINK1. Taken together, these results indicate that UCP4A prevents mitochondrial dysfunction and that modulation of UCP activity protects cells in a situation relevant for human Parkinson's disease.	[Wu, Kai; Liu, Jia; Zhuang, Na; Wang, Tao] Natl Inst Biol Sci, Beijing 102206, Peoples R China; [Liu, Jia] Beijing Normal Univ, Coll Life Sci, Beijing 100875, Peoples R China; [Zhuang, Na] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China	National Institute of Biological Sciences, Beijing; Beijing Normal University; Tsinghua University	Wang, T (corresponding author), Natl Inst Biol Sci, 7 Pk Rd,Zhongguancun Life Sci Pk, Beijing 102206, Peoples R China.	wangtao@nibs.ac.cn		Wang, Tao/0000-0002-2395-3483; Liu, Yasmine/0000-0002-6830-8023	973 grant from the Chinese Ministry of Science and Technology [2011CB812702]	973 grant from the Chinese Ministry of Science and Technology	The authors thank Y. Wang and Drs. J. Fang and Q. Bai for technical support and valuable comments. The authors thank the Bloomington Stock Center (Indiana University, Bloomington, IN, USA), Dr. Stephen Helfand (Brown University, Providence, RI, USA), Dr. Jongkyeong Chung (Seoul National University, Seoul, Korea), Dr. Leo J. Pallanck (University of Washington, Seattle, WA, USA), and Dr. Bingwei Lu (Stanford University School of Medicine, Stanford, CA, USA) for fly stocks. This work was supported by a 973 grant (2011CB812702) from the Chinese Ministry of Science and Technology (to T.W). The authors declare no conflicts of interest.	Andrews ZB, 2009, J NEUROSCI, V29, P14057, DOI 10.1523/JNEUROSCI.3890-09.2009; Andrews ZB, 2005, J NEUROSCI, V25, P184, DOI 10.1523/JNEUROSCI.4269-04.2005; Azzu V, 2010, TRENDS BIOCHEM SCI, V35, P298, DOI 10.1016/j.tibs.2009.11.001; Bartolome F, 2013, NEURON, V78, P57, DOI 10.1016/j.neuron.2013.02.028; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Brand MD, 2000, EXP GERONTOL, V35, P811, DOI 10.1016/S0531-5565(00)00135-2; Bratic A, 2013, J CLIN INVEST, V123, P951, DOI 10.1172/JCI64125; Chu ACY, 2009, FREE RADICAL BIO MED, V46, P810, DOI 10.1016/j.freeradbiomed.2008.12.015; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; Collier TJ, 2011, NAT REV NEUROSCI, V12, P359, DOI 10.1038/nrn3039; Copeland JM, 2009, CURR BIOL, V19, P1591, DOI 10.1016/j.cub.2009.08.016; Coulom H, 2004, J NEUROSCI, V24, P10993, DOI 10.1523/JNEUROSCI.2993-04.2004; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dawson TM, 2010, NEURON, V66, P646, DOI 10.1016/j.neuron.2010.04.034; Deng HS, 2008, P NATL ACAD SCI USA, V105, P14503, DOI 10.1073/pnas.0803998105; Dias V, 2013, J PARKINSON DIS, V3, P461, DOI 10.3233/JPD-130230; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Esposito G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003478; Exner N, 2012, EMBO J, V31, P3038, DOI 10.1038/emboj.2012.170; Gems D, 2008, CELL METAB, V7, P200, DOI 10.1016/j.cmet.2008.01.001; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Grunewald A, 2014, ANTIOXID REDOX SIGN, V20, P1955, DOI 10.1089/ars.2013.5737; Hanak P, 2001, FEBS LETT, V495, P137, DOI 10.1016/S0014-5793(01)02338-9; Hardy J, 2010, NEURON, V68, P201, DOI 10.1016/j.neuron.2010.10.014; Ho JWM, 2012, FREE RADICAL BIO MED, V53, P383, DOI 10.1016/j.freeradbiomed.2012.05.002; Imai Y, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001229; Islam R, 2012, NEUROBIOL DIS, V46, P137, DOI 10.1016/j.nbd.2011.12.055; Jaiswal M, 2012, ANNU REV GENET, V46, P371, DOI 10.1146/annurev-genet-110711-155456; Jin H., 2014, BIOCHIM BIOPHYS ACTA, V1842, P1282; Jin SM, 2010, J CELL BIOL, V191, P933, DOI 10.1083/jcb.201008084; Kim NC, 2013, NEURON, V78, P65, DOI 10.1016/j.neuron.2013.02.029; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klein P, 2014, EMBO J, V33, P341, DOI 10.1002/embj.201284290; Koh H, 2012, J BIOL CHEM, V287, P12750, DOI 10.1074/jbc.M111.337907; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Liu D, 2006, NEUROMOL MED, V8, P389, DOI 10.1385/NMM:8:3:389; Liu WC, 2011, P NATL ACAD SCI USA, V108, P12920, DOI 10.1073/pnas.1107332108; Martin I, 2011, ANNU REV GENOM HUM G, V12, P301, DOI 10.1146/annurev-genom-082410-101440; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Morais VA, 2014, SCIENCE, V344, P203, DOI 10.1126/science.1249161; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Narendra DP, 2011, ANTIOXID REDOX SIGN, V14, P1929, DOI 10.1089/ars.2010.3799; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035; Owusu-Ansah E, 2013, CELL, V155, P699, DOI 10.1016/j.cell.2013.09.021; Papkovskaia TD, 2012, HUM MOL GENET, V21, P4201, DOI 10.1093/hmg/dds244; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788; Plun-Favreau H, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.77; Poole AC, 2008, P NATL ACAD SCI USA, V105, P1638, DOI 10.1073/pnas.0709336105; Sanchez-Blanco A, 2006, GENETICS, V172, P1699, DOI 10.1534/genetics.105.053389; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Shulman JM, 2011, ANNU REV PATHOL-MECH, V6, P193, DOI 10.1146/annurev-pathol-011110-130242; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Tain LS, 2009, CELL DEATH DIFFER, V16, P1118, DOI 10.1038/cdd.2009.23; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; Walker DW, 2006, P NATL ACAD SCI USA, V103, P16382, DOI 10.1073/pnas.0607918103; Wang DL, 2006, P NATL ACAD SCI USA, V103, P13520, DOI 10.1073/pnas.0604661103; Whitworth AJ, 2005, P NATL ACAD SCI USA, V102, P8024, DOI 10.1073/pnas.0501078102; Yang YF, 2008, P NATL ACAD SCI USA, V105, P7070, DOI 10.1073/pnas.0711845105; Yang YF, 2006, P NATL ACAD SCI USA, V103, P10793, DOI 10.1073/pnas.0602493103; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Yun J, 2008, J NEUROSCI, V28, P14500, DOI 10.1523/JNEUROSCI.5141-08.2008	64	18	18	2	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5111	5121		10.1096/fj.14-255802	http://dx.doi.org/10.1096/fj.14-255802			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25145627				2022-12-28	WOS:000345894500008
J	Zhong, DL; Blount, P				Zhong, Dalian; Blount, Paul			Electrostatics at the membrane define MscL channel mechanosensitivity and kinetics	FASEB JOURNAL			English	Article						protein-lipid interactions; liposome reconstitution; mechanosensation; mechanosensory	PROTEIN-PROTEIN INTERACTIONS; LARGE-CONDUCTANCE MSCL; ESCHERICHIA-COLI; LIPID-INTERFACE; MYCOBACTERIUM-TUBERCULOSIS; GATING MECHANISM; ION-CHANNEL; PRESSURE; DYNAMICS; DOMAINS	The bacterial mechanosensitive channel of large conductance (MscL) serves as a biological emergency release valve, preventing the occurrence of cell lysis caused by acute osmotic stress. Its tractable nature allows it to serve as a paradigm for how a protein can directly sense membrane tension. Although much is known of the importance of the hydrophobicity of specific residues in channel gating, it has remained unclear whether electrostatics at the membrane plays any role. We studied MscL chimeras derived from functionally distinct orthologues: Escherichia coli and Staphylococcus aureus. Dissection of one set led to an observation that changing the charge of a single residue, K101, of E. coli (Ec)-MscL, effects a channel phenotype: when mutated to a negative residue, the channel is less mechanosensitive and has longer open dwell times. Assuming electrostatic interactions, we determined whether they are due to protein-protein or protein-lipid interactions by performing site-directed mutagenesis elsewhere in the protein and reconstituting channels into defined lipids, with and without negative head groups. We found that although both interactions appear to play some role, the primary determinant of the channel phenotype seems to be protein-lipid electrostatics. The data suggest a model for the role of electrostatic interactions in the dynamics of MscL gating.	[Zhong, Dalian] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Ctr Translat Neurodegenerat & Regenerat Therapy, Shanghai 200092, Peoples R China; [Zhong, Dalian; Blount, Paul] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA	Tongji University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Blount, P (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	paul.blount@utsouthwestern.edu			Welch Foundation [I-1420]; Cancer Prevention and Research Institute of Texas (CPRIT) [RP100146]; U.S. National Institutes of Health [GM061028]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061028] Funding Source: NIH RePORTER	Welch Foundation(The Welch Foundation); Cancer Prevention and Research Institute of Texas (CPRIT); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Drs. Irene Iscla, Limin Yang, and Hannah Malcolm, as well as Robin Wray and Christina Eaton, for useful discussions and critical reading of the manuscript. The study was funded by grant I-1420 of the Welch Foundation, grant RP100146 from the Cancer Prevention and Research Institute of Texas (CPRIT; http://www.cprit.state.tx.us/), and grant GM061028 from the U.S. National Institutes of Health. The authors declare no conflicts of interest.	Blount P, 1999, Methods Enzymol, V294, P458; BLOUNT P, 1993, REGUL PEPTIDES, V46, P447, DOI 10.1016/0167-0115(93)90115-O; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; Booth IR, 2012, J BACTERIOL, V194, P4802, DOI 10.1128/JB.00576-12; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Iscla I, 2012, CHANNELS, V6, P255, DOI 10.4161/chan.20756; Iscla I, 2012, BIOPHYS J, V103, P169, DOI 10.1016/j.bpj.2012.06.021; Iscla I, 2011, FASEB J, V25, P694, DOI 10.1096/fj.10-170878; Kloda A, 2006, BIOPHYS J, V90, P1992, DOI 10.1529/biophysj.105.075481; Levin G, 2004, BIOPHYS J, V86, P2862, DOI 10.1016/S0006-3495(04)74338-6; Li YZ, 2009, FASEB J, V23, P2197, DOI 10.1096/fj.09-129296; Liu ZF, 2009, NATURE, V461, P120, DOI 10.1038/nature08277; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Maurer JA, 2003, J BIOL CHEM, V278, P21076, DOI 10.1074/jbc.M302892200; Moe P, 2005, BIOCHEMISTRY-US, V44, P12239, DOI 10.1021/bi0509649; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Perozo E, 2001, J GEN PHYSIOL, V118, P193, DOI 10.1085/jgp.118.2.193; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Poolman B, 2004, BBA-BIOMEMBRANES, V1666, P88, DOI 10.1016/j.bbamem.2004.06.013; Powl AM, 2005, BIOCHEM SOC T, V33, P905, DOI 10.1042/BST0330905; Powl AM, 2005, BIOCHEMISTRY-US, V44, P5873, DOI 10.1021/bi047439e; Powl AM, 2008, BIOCHEMISTRY-US, V47, P4317, DOI 10.1021/bi702409t; Romantsov T, 2009, BBA-BIOMEMBRANES, V1788, P2092, DOI 10.1016/j.bbamem.2009.06.010; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; Yang LM, 2013, CELL REP, V3, P520, DOI 10.1016/j.celrep.2013.01.018; Zhong DL, 2014, BIOPHYS J, V106, P375, DOI 10.1016/j.bpj.2013.12.006; Zhong DL, 2013, BIOCHEMISTRY-US, V52, P5415, DOI 10.1021/bi400790j	31	5	5	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5234	5241		10.1096/fj.14-259309	http://dx.doi.org/10.1096/fj.14-259309			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25223610	Green Published			2022-12-28	WOS:000345894500018
J	Giambelluca, MS; Bertheau-Mailhot, G; Laflamme, C; Rollet-Labelle, E; Servant, MJ; Pouliot, M				Giambelluca, Miriam S.; Bertheau-Mailhot, Genevieve; Laflamme, Cynthia; Rollet-Labelle, Emmanuelle; Servant, Marc J.; Pouliot, Marc			TNF-alpha expression in neutrophils and its regulation by glycogen synthase kinase-3: A potentiating role for lithium	FASEB JOURNAL			English	Article						granulocytes; inflammation	NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; INITIATION-FACTOR 4E; POSTTRANSCRIPTIONAL REGULATION; INFLAMMATORY CYTOKINES; TRANSLATION INITIATION; RHEUMATOID-ARTHRITIS; RICH ELEMENTS; PHOSPHORYLATION; PROTEIN	Glycogen synthase kinase 3 (GSK-3) is associated with several cellular systems, including immune response. Lithium, a widely used pharmacological treatment for bipolar disorder, is a GSK-3 inhibitor. GSK-3 alpha is the predominant isoform in human neutrophils. In this study, we examined the effect of GSK-3 inhibition on the production of TNF-alpha by neutrophils. In the murine air pouch model of inflammation, lithium chloride (LiCl) amplified TNF-alpha release. In lipopolysaccharide-stimulated human neutrophils, GSK-3 inhibitors mimicked the effect of LiCl, each potentiating TNF-alpha release after 4 h, in a concentration-dependent fashion, by up to a 3-fold increase (ED50 of 1 mM for lithium). LiCl had no significant effect on cell viability. A positive association was revealed between GSK-3 inhibition and prolonged activation of the p38/MNK1/eIF4E pathway of mRNA translation. Using lysine and arginine labeled with stable heavy isotopes followed by quantitative mass spectrometry, we determined that GSK-3 inhibition markedly increases (by more than 3-fold) de novo TNF-alpha protein synthesis. Our findings shed light on a novel mechanism of control of TNF-alpha expression in neutrophils with GSK-3 regulating mRNA translation and raise the possibility that lithium could be having a hitherto unforeseen effect on inflammatory diseases.-Giambelluca, M. S., Bertheau-Mailhot, G., Laflamme, C., Rollet-Labelle, E., Servant, M. J., Pouliot, M. TNF-alpha expression in neutrophils and its regulation by glycogen synthase kinase-3: a potentiating role for lithium.	[Giambelluca, Miriam S.; Bertheau-Mailhot, Genevieve; Laflamme, Cynthia; Rollet-Labelle, Emmanuelle; Pouliot, Marc] Univ Laval, CHU Quebec, Ctr Rech, Quebec City, PQ G1V 4G2, Canada; [Giambelluca, Miriam S.; Bertheau-Mailhot, Genevieve; Laflamme, Cynthia; Rollet-Labelle, Emmanuelle; Pouliot, Marc] Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada; [Servant, Marc J.] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada	Laval University; Laval University; Universite de Montreal	Pouliot, M (corresponding author), Univ Laval, CHU Quebec, Ctr Rech, 2705 Laurier Blvd,Off T1-49, Quebec City, PQ G1V 4G2, Canada.	marc.pouliot@crchul.ulaval.ca	Pouliot, Marc/G-4103-2016	Pouliot, Marc/0000-0002-2466-5424; Giambelluca, Miriam Soledad/0000-0003-0965-4943	Canadian Institutes of Health Research (CIHR) [MOP220733]; Canadian Foundation for Innovation (CFI) [19576]; Fonds de Recherche du Quebec-Sante (FRQS); Wilbrod-Bherer Foundation	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation (CFI)(Canada Foundation for Innovation); Fonds de Recherche du Quebec-Sante (FRQS); Wilbrod-Bherer Foundation	Grants from the Canadian Institutes of Health Research (CIHR) and the Canadian Foundation for Innovation (CFI) to M. P. (MOP220733 and 19576, respectively) provided funding for this study. M. G. is the recipient of a postdoctoral fellowship from the Fonds de Recherche du Quebec-Sante (FRQS). G. B. M. received a studentship from the Wilbrod-Bherer Foundation. The authors thank Isabelle Kelly, M.Sc., Benjamin Nehme, Ph.D., and Sylvie Bourassa, Ph.D., of the Proteomics Platform of the Quebec Genomics Center for excellent technical assistance.	Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Andersson K, 2006, CYTOKINE, V33, P52, DOI 10.1016/j.cyto.2005.11.017; BAKKER JB, 1976, PSYCHOSOMATICS, V17, P143; Beurel E, 2010, TRENDS IMMUNOL, V31, P24, DOI 10.1016/j.it.2009.09.007; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CARTER TN, 1972, PSYCHOSOMATICS, V13, P325; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Chan HHL, 2000, J AFFECT DISORDERS, V57, P107, DOI 10.1016/S0165-0327(99)00064-6; Cherla RP, 2006, J LEUKOCYTE BIOL, V79, P397, DOI 10.1189/jlb.0605313; Cloutier A, 2007, J LEUKOCYTE BIOL, V81, P567, DOI 10.1189/jlb.0806536; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; Dionyssiou MG, 2013, J MOL CELL CARDIOL, V54, P35, DOI 10.1016/j.yjmcc.2012.10.013; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Dussault AA, 2006, BIOL PROCED ONLINE, V8, P1, DOI 10.1251/bpo114; Ear T, 2005, J IMMUNOL, V175, P1834, DOI 10.4049/jimmunol.175.3.1834; Ear T, 2010, J IMMUNOL, V184, P3897, DOI 10.4049/jimmunol.0902958; EDWARDS JCW, 1981, J PATHOL, V134, P147, DOI 10.1002/path.1711340205; Falvo JV, 2010, CURR DIR AUTOIMMUN, V11, P27, DOI 10.1159/000289196; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; Fortin CF, 2013, J LEUKOCYTE BIOL, V94, P693, DOI 10.1189/jlb.0113012; Giambelluca M, 2013, OA INFLAMMATION, V1, P3; Giambelluca MS, 2013, INT J BIOCHEM CELL B, V45, P2660, DOI 10.1016/j.biocel.2013.09.001; Gilbert C, 2002, J IMMUNOL METHODS, V271, P185, DOI 10.1016/S0022-1759(02)00347-2; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Han J, 1990, Eur Cytokine Netw, V1, P71; Havlis J, 2004, ANAL CHEM, V76, P3029, DOI 10.1021/ac035286f; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5; Jope RS, 1999, MOL PSYCHIATR, V4, P117, DOI 10.1038/sj.mp.4000494; Kasama Tsuyoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P273, DOI 10.2174/1568010054022114; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kraan MC, 2000, ARTHRITIS RHEUM, V43, P1488, DOI 10.1002/1529-0131(200007)43:7<1488::AID-ANR11>3.0.CO;2-G; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; Laflamme C, 2014, GENES IMMUN, V15, P224, DOI 10.1038/gene.2014.8; Lewis T, 1998, J BIOL CHEM, V273, P13781, DOI 10.1074/jbc.273.22.13781; Loffredo S, 2009, J RHEUMATOL, V36, P9, DOI 10.3899/jrheum.090210; MacAulay K, 2007, CELL METAB, V6, P329, DOI 10.1016/j.cmet.2007.08.013; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; McColl SR, 2005, FASEB J, V19, P187, DOI 10.1096/fj.05-4804fje; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; Patel S, 2008, CANCER CELL, V14, P351, DOI 10.1016/j.ccr.2008.10.013; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Pouliot M, 2002, J IMMUNOL, V169, P5279, DOI 10.4049/jimmunol.169.9.5279; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ramos CDL, 2003, CYTOKINE, V21, P214, DOI 10.1016/S1043-4666(03)00050-4; Rodionova E, 2007, BLOOD, V109, P1584, DOI 10.1182/blood-2006-06-028951; Rowse AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052658; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; Schottelius AJG, 2004, EXP DERMATOL, V13, P193, DOI 10.1111/j.0906-6705.2004.00205.x; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TRACEY KJ, 1987, SURG GYNECOL OBSTET, V164, P415; Tseng AS, 2006, CHEM BIOL, V13, P957, DOI 10.1016/j.chembiol.2006.08.004; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vines A, 2006, J BIOL CHEM, V281, P16985, DOI 10.1074/jbc.M602446200; Wang EH, 1997, CANCER RES, V57, P5426; Wang HZ, 2011, CYTOKINE, V53, P130, DOI 10.1016/j.cyto.2010.10.009; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Williams RO, 2007, CURR OPIN PHARMACOL, V7, P412, DOI 10.1016/j.coph.2007.06.001; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Woodgett J R, 2001, Sci STKE, V2001, pre12, DOI 10.1126/stke.2001.100.re12; Yeung CK, 2004, AM J CLIN DERMATOL, V5, P3, DOI 10.2165/00128071-200405010-00002; Zimmerman NP, 2008, INFLAMM BOWEL DIS, V14, P1000, DOI 10.1002/ibd.20480	73	15	16	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3679	3690		10.1096/fj.14-251900	http://dx.doi.org/10.1096/fj.14-251900			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24803542				2022-12-28	WOS:000340265400035
J	Cleaver, JE				Cleaver, James E.			Tritiated Thymidine: Xeroderma Pigmentosum and DNA Repair	FASEB JOURNAL			English	Editorial Material							DEOXYRIBONUCLEIC-ACID; MAMMALIAN CELLS; HELA-CELLS; CHROMOSOME DUPLICATION; PYRIMIDINE DIMERS; CLONAL GROWTH; TRITIUM; IRRADIATION; MUTANTS; AUTORADIOGRAPHY		Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Cleaver, JE (corresponding author), Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.	jcleaver@cc.ucsf.edu						Bishop JM., 2003, WIN NOBEL PRIZE UNEX; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; CLEAVER J, 1967, THYMIDINE METABOLISM; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLEAVER JE, 1972, SCIENCE, V177, P996, DOI 10.1126/science.177.4053.996; CLEAVER JE, 1969, P NATL ACAD SCI USA, V63, P428, DOI 10.1073/pnas.63.2.428; DJORDJEVIC B, 1967, RADIAT RES, V32, P327, DOI 10.2307/3572227; DREW RM, 1962, RADIAT RES, V16, P303, DOI 10.2307/3571160; DREW RM, 1959, RADIAT RES, V11, P535, DOI 10.2307/3570807; ELKIND MM, 1976, BIOCHEM BIOPH RES CO, V68, P691, DOI 10.1016/0006-291X(76)91200-6; FEINENDEGEN LE, 1960, EXP CELL RES, V19, P443, DOI 10.1016/0014-4827(60)90054-9; GILBERT CW, 1962, NATURE, V195, P869, DOI 10.1038/195869a0; GILBERT CW, 1965, NATURE, V208, P159, DOI 10.1038/208159a0; Howard A, 1953, HEREDITY           S, V6, P261; HUGHES WL, 1958, P NATL ACAD SCI USA, V44, P476, DOI 10.1073/pnas.44.5.476; KAVENOFF R, 1973, CHROMOSOMA, V41, P1, DOI 10.1007/BF00284071; LAJTHA LG, 1963, J CELL COMPAR PHYSL, V62, P143; LAJTHA LG, 1958, RADIAT RES, V8, P1, DOI 10.2307/3570530; LAJTHA LG, 1958, NATURE, V181, P1609, DOI 10.1038/1811609a0; LAJTHA LG, 1959, LAB INVEST, V8, P214; Nakazawa Y, 2010, DNA REPAIR, V9, P506, DOI 10.1016/j.dnarep.2010.01.015; OLIVER R, 1960, NATURE, V186, P91, DOI 10.1038/186091a0; PAINTER RB, 1990, RADIAT RES, V121, P117, DOI 10.2307/3577494; PAINTER RB, 1964, NATURE, V201, P409, DOI 10.1038/201409a0; PAINTER RB, 1961, RADIAT RES, V14, P653, DOI 10.2307/3570905; PAINTER RB, 1959, RADIAT RES, V11, P206, DOI 10.2307/3570659; PERRY RP, 1961, BIOCHIM BIOPHYS ACTA, V49, P47, DOI 10.1016/0006-3002(61)90868-X; PERRY RP, 1960, EXP CELL RES, V20, P216, DOI 10.1016/0014-4827(60)90240-8; QUASTLER H, 1959, EXP CELL RES, V17, P420, DOI 10.1016/0014-4827(59)90063-1; RASMUSSEN RE, 1964, NATURE, V203, P1360, DOI 10.1038/2031360a0; REGAN JD, 1968, BIOPHYS J, V8, P319, DOI 10.1016/S0006-3495(68)86490-2; ROWLEY J, 1963, NATURE, V197, P251, DOI 10.1038/197251a0; STRAUSS BS, 1958, RADIAT RES, V8, P234, DOI 10.2307/3570480; Taylor J. H., 1991, TRENDS BIOCHEM SCI, V19, P479; TAYLOR JH, 1957, P NATL ACAD SCI USA, V43, P122, DOI 10.1073/pnas.43.1.122; TAYLOR JH, 1989, BIOESSAYS, V10, P121, DOI 10.1002/bies.950100407; THOMPSON LH, 1970, P NATL ACAD SCI USA, V66, P377, DOI 10.1073/pnas.66.2.377; THOMPSON LH, 1980, SOMAT CELL GENET, V6, P391, DOI 10.1007/BF01542791; TROSKO JE, 1967, PHOTOCHEM PHOTOBIOL, V6, P215, DOI 10.1111/j.1751-1097.1967.tb08806.x	39	1	1	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2742	2745		10.1096/fj.14-0702ufm	http://dx.doi.org/10.1096/fj.14-0702ufm			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24990958				2022-12-28	WOS:000337949400002
J	Ablonczy, Z; Dahrouj, M; Marneros, AG				Ablonczy, Zsolt; Dahrouj, Mohammad; Marneros, Alexander G.			Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels	FASEB JOURNAL			English	Article						age-related macular degeneration; visual cycle; retinoids; choroidal neovascularization	AGE-RELATED MACULOPATHY; SUBRETINAL DRUSENOID DEPOSITS; MACULAR DEGENERATION; RANIBIZUMAB; PREVALENCE; EXPRESSION; EYES; RPE	Patients with nonexudative (dry) age-related macular degeneration (AMD) frequently also develop neovascular (wet) AMD, suggesting a common pathomechanism. Increased vascular endothelial growth factor A (VEGF-A) has been implicated in the pathogenesis of choroidal neovascularization (CNV) in neovascular AMD, while its role in nonexudative AMD that manifests with progressive retinal pigment epithelium (RPE) and photoreceptor degeneration is not well defined. Mice with overall increased VEGF-A levels develop progressive morphological features of both forms of AMD, suggesting that an increase in VEGF-A has a direct age-dependent adverse effect on RPE and photoreceptor function independently of its CNV-promoting proangiogenic effect. Here we provide evidence for this hypothesis and show that morphological RPE abnormalities and retinal thinning in mice with increased VEGF-A levels correlate with progressive age-dependent attenuation of visual function with abnormal electroretinograms and reduced retinal rhodopsin levels. Retinoid profiling revealed a progressive reduction of 11-cis and all-trans retinal in the retinas of these mice, consistent with an impaired retinoid transport between the RPE and photoreceptors. These findings suggest that increased VEGF-A leads to an age-dependent RPE and retinal dysfunction that occurs also at sites where no CNV lesions form. The data support a central role of increased VEGF-A not only in the pathogenesis of neovascular but also of nonexudative AMD.Ablonczy, Z., Dahrouj, M., Marneros, A. G. Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels.	[Ablonczy, Zsolt; Dahrouj, Mohammad] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA; [Marneros, Alexander G.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA; [Marneros, Alexander G.] Harvard Univ, Sch Med, Dept Dermatol, Charlestown, MA USA	Medical University of South Carolina; Harvard University; Massachusetts General Hospital; Harvard University	Marneros, AG (corresponding author), CNY 149,Room 3-216,CBRC,MGH East,13thSt, Charlestown, MA 02129 USA.	amarneros@mgh.harvard.edu		Marneros, Alexander/0000-0003-3866-020X	U.S. National Institutes of Health (NIH)/National Eye Institute (NEI) [NEI R01-EY019297]; NIH/NEI [NEI R01-EY019065]; Medical Scientist Training Program at the Medical University of South Carolina (MUSC); NIH/National Institute of General Medical Sciences [T32 GM008716]; Research to Prevent Blindness; South Carolina Lions Association; NATIONAL EYE INSTITUTE [R01EY019065, R01EY019297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008716] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Eye Institute (NEI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIH/NEI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Medical Scientist Training Program at the Medical University of South Carolina (MUSC); NIH/National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Research to Prevent Blindness(Research to Prevent Blindness (RPB)); South Carolina Lions Association; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Drs. Andras Nagy, Lucile Miquerol, and Annette Damert (University of Toronto, Toronto, ON, Canada) for providing VEGF-A<SUP>hyper</SUP> mice and VEGF-A<SUP>hypo</SUP> mice, Patrice Goletz for technical help, and Drs. Rosalie Crouch and Jie Fan for helpful discussions. This work was supported by a U.S. National Institutes of Health (NIH)/National Eye Institute (NEI) grant to A.G.M. (NEI R01-EY019297), an NIH/NEI grant to Z.A. (NEI R01-EY019065), funding from the Medical Scientist Training Program at the Medical University of South Carolina (MUSC; NIH/National Institute of General Medical Sciences grant T32 GM008716) to M. D., an unrestricted grant of Research to Prevent Blindness to the Department of Ophthalmology at MUSC, and the South Carolina Lions Association.	Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021; Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017; Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236; Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329; Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0; Damert A, 2002, DEVELOPMENT, V129, P1881; Fan J, 2003, P NATL ACAD SCI USA, V100, P13662, DOI 10.1073/pnas.2234461100; Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564; Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012; Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069; Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x; Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.3.CO;2-E; Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X; Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014; Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002; Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673; Miquerol L, 1999, DEV BIOL, V212, P307, DOI 10.1006/dbio.1999.9355; Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046; Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010; Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7; Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6; van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519; Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270	27	42	43	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2369	2379		10.1096/fj.13-248021	http://dx.doi.org/10.1096/fj.13-248021			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24558195	Green Published			2022-12-28	WOS:000335336000037
J	Lowenstein, J				Lowenstein, Jerome			Agent Orange and Heart Disease: Is There a Connection?	FASEB JOURNAL			English	Article									NYU Med Ctr, New York, NY 10016 USA	New York University	Lowenstein, J (corresponding author), NYU Med Ctr, New York, NY 10016 USA.	Jerome.Lowenstein@nyumc.org		Lowenstein, Jerome/0000-0002-2090-2015				Blagg CR, 2010, CLIN J AM SOC NEPHRO, V5, P2146, DOI 10.2215/CJN.07640810; Brownson P. J., 1989, CANCER, V64, P2381; Department of Veterans Affairs, 2010, DIS ASS EXP CERT HER; DUBROW R, 1988, BRIT J IND MED, V45, P25; Gondouin B, 2013, KIDNEY INT, V84, P733, DOI 10.1038/ki.2013.133; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Lowenstein J., 1997, MIDNIGHT MEAL OTHER, P88; Lowenstein J, 2011, FASEB J, V25, P1781, DOI 10.1096/fj.11-0602ufm; National Research Council, 2009, VET AG OR UPD 2008; Schecter A, 2006, ENVIRON RES, V101, P419, DOI 10.1016/j.envres.2005.12.003; Schwartz M, 1988, BR J IND MED, V45, P234; Wu DL, 2011, ARTERIOSCL THROM VAS, V31, P1260, DOI 10.1161/ATVBAHA.110.220202	12	2	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2014	28	4					1531	1533		10.1096/fj.14-0402ufm	http://dx.doi.org/10.1096/fj.14-0402ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3UC	24688078				2022-12-28	WOS:000335344300002
J	Hoch, L; Faure, H; Roudaut, H; Schoenfelder, A; Mann, A; Girard, N; Bihannic, L; Ayrault, O; Petricci, E; Taddei, M; Rognan, D; Ruat, M				Hoch, Lucile; Faure, Helene; Roudaut, Hermine; Schoenfelder, Angele; Mann, Andre; Girard, Nicolas; Bihannic, Laure; Ayrault, Olivier; Petricci, Elena; Taddei, Maurizio; Rognan, Didier; Ruat, Martial			MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor	FASEB JOURNAL			English	Article						antagonist; medulloblastoma; molecular modeling; stem cell	BASAL-CELL CARCINOMA; PATHWAY INHIBITOR; MEDULLOBLASTOMA DEVELOPMENT; ACQUIRED-RESISTANCE; CANCER; ITRACONAZOLE; ANTAGONISTS; ACTIVATION; MODULATOR; BRAIN	The Smoothened (Smo) receptor, a member of class F G protein-coupled receptors, is the main transducer of the Hedgehog (Hh) signaling pathway implicated in a wide range of developmental and adult processes. Smo is the target of anticancer drugs that bind to a long and narrow cavity in the 7-transmembrane (7TM) domain. X-ray structures of human Smo (hSmo) bound to several ligands have revealed 2 types of 7TM-directed antagonists: those binding mostly to extracellular loops (site 1, e.g., LY2940680) and those penetrating deeply in the 7TM cavity (site 2, e.g., SANT-1). Here we report the development of the acylguanidine MRT-92, which displays subnanomolar antagonist activity against Smo in various Hh cell-based assays. MRT-92 inhibits rodent cerebellar granule cell proliferation induced by Hh pathway activation through pharmacologic (half maximal inhibitory concentration [IC50] = 0.4 nM) or genetic manipulation. Using [H-3]MRT-92 (K-d = 0.3 nM for hSmo), we created a comprehensive framework for the interaction of small molecule modulators with hSmo and for understanding chemoresistance linked to hSmo mutations. Guided by molecular docking and site-directed mutagenesis data, our work convincingly confirms that MRT-92 simultaneously recognized and occupied both sites 1 and 2. Our data demonstrate the existence of a third type of Smo antagonists, those entirely filling the Smo binding cavity from the upper extracellular part to the lower cytoplasmic-proximal subpocket. Our studies should help design novel potent Smo antagonists and more effective therapeutic strategies for treating Hh-linked cancers and associated chemoresistance.	[Hoch, Lucile; Faure, Helene; Roudaut, Hermine; Ruat, Martial] CNRS, Neurosci Paris Saclay Inst, Mol Circuits Dept, Signal Transduct & Dev Neuropharmacol Team,UMR 91, F-91198 Gif Sur Yvette, France; [Schoenfelder, Angele; Mann, Andre; Girard, Nicolas; Rognan, Didier] Univ Strasbourg, CNRS, Lab Innovat Therapeut, Unite Mixte Rech 7200, Illkirch Graffenstaden, France; [Bihannic, Laure; Ayrault, Olivier] Univ Paris 11, INSERM, CNRS, Inst Curie,Ctr Univ,Unite Mixte Rech 3306,U1005, F-91405 Orsay, France; [Petricci, Elena; Taddei, Maurizio] Univ Siena, Dipartimento Biotecnol Chim & Farm, I-53100 Siena, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; University of Siena	Ruat, M (corresponding author), CNRS, Neurosci Paris Saclay Inst, Mol Circuits Dept, Signal Transduct & Dev Neuropharmacol Team,UMR 91, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	ruat@inaf.cnrs-gif.fr	Ruat, Martial/E-5544-2016; Girard, Nicolas/ABE-3618-2021; Petricci, Elena/AAB-9275-2022; Girard, Nicolas/B-3910-2017; FAURE, Helene/E-4641-2010; Rognan, Didier/B-9939-2014	Girard, Nicolas/0000-0001-9909-2299; Girard, Nicolas/0000-0003-4610-9872; Hoch, Lucile/0000-0002-7264-9031; PETRICCI, ELENA/0000-0002-9685-6342; FAURE, Helene/0000-0002-0005-9331	La Ligue contre le Cancer (Comite des Yvelines); Fondation Association pour la Recherche sur le Cancer (ARC); l'Institut National du Cancer (INCa) [R10067LS]; Marie Curie Integration Grant [FP7-PEOPLE-2011-CIG 294010]; Centre National de la Recherche Scientifique/Institut National de la Sante et de la Recherche Medicale (CNRS/INSERM); La Ligue contre le Cancer and la Fondation Recherche Medicale [FDT20140930825]; Ministere de l'Enseignement Superieur et de la Recherche; Institut Curie	La Ligue contre le Cancer (Comite des Yvelines); Fondation Association pour la Recherche sur le Cancer (ARC); l'Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Marie Curie Integration Grant; Centre National de la Recherche Scientifique/Institut National de la Sante et de la Recherche Medicale (CNRS/INSERM); La Ligue contre le Cancer and la Fondation Recherche Medicale; Ministere de l'Enseignement Superieur et de la Recherche; Institut Curie	This work has benefited from the facilities of the TEFOR Molecular Biology Unit, IMAGIF, Gif Research Center. This work was supported by grants from La Ligue contre le Cancer (Comite des Yvelines) and Fondation Association pour la Recherche sur le Cancer (ARC) to M.R. from l'Institut National du Cancer (INCa R10067LS), Marie Curie Integration Grant FP7-PEOPLE-2011-CIG 294010, Centre National de la Recherche Scientifique/Institut National de la Sante et de la Recherche Medicale (CNRS/INSERM) and Institut Curie (to O.A.). L.H. is the recipient of a doctoral fellowship from La Ligue contre le Cancer and la Fondation Recherche Medicale (FDT20140930825) and L.B. from the Ministere de l'Enseignement Superieur et de la Recherche.	Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Brinkhuizen T, 2014, J AM ACAD DERMATOL, V71, P1005, DOI 10.1016/j.jaad.2014.08.001; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Buonamici S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001599; Charytoniuk D, 2002, J PHYSIOLOGY-PARIS, V96, P9, DOI 10.1016/S0928-4257(01)00075-4; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Coulombe J, 2004, MOL CELL NEUROSCI, V25, P323, DOI 10.1016/j.mcn.2003.10.024; Dijkgraaf GJP, 2011, CANCER RES, V71, P435, DOI 10.1158/0008-5472.CAN-10-2876; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Gorojankina T, 2013, MOL PHARMACOL, V83, P1020, DOI 10.1124/mol.112.084590; Hadden MK, 2014, CHEMMEDCHEM, V9, P27, DOI 10.1002/cmdc.201300358; Hadden MK, 2013, EXPERT OPIN THER PAT, V23, P345, DOI 10.1517/13543776.2013.757304; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Hyman JM, 2009, P NATL ACAD SCI USA, V106, P14132, DOI 10.1073/pnas.0907134106; Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h; Kim DJ, 2014, J CLIN ONCOL, V32, P745, DOI 10.1200/JCO.2013.49.9525; Kim J, 2013, CANCER CELL, V23, P23, DOI 10.1016/j.ccr.2012.11.017; Kim J, 2010, CANCER CELL, V17, P388, DOI 10.1016/j.ccr.2010.02.027; Lin TL, 2012, ONCOTARGETS THER, V5, P47, DOI 10.2147/OTT.S21957; LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078-0432.CCR-10-2745; Manetti F, 2010, MOL PHARMACOL, V78, P658, DOI 10.1124/mol.110.065102; Masdeu C, 2007, NEUROREPORT, V18, P395, DOI 10.1097/WNR.0b013e32801421ce; Masdeu C, 2006, BIOCHEM BIOPH RES CO, V349, P471, DOI 10.1016/j.bbrc.2006.07.216; McMillan R, 2012, CLIN CANCER RES, V18, P4883, DOI 10.1158/1078-0432.CCR-11-2509; Nachtergaele S, 2013, ELIFE, V2, DOI 10.7554/eLife.01340; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; Rana R, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3965; Rohatgi R, 2009, P NATL ACAD SCI USA, V106, P3196, DOI 10.1073/pnas.0813373106; Roudaut H, 2011, MOL PHARMACOL, V79, P453, DOI 10.1124/mol.110.069708; Ruat M, 2014, TRENDS PHARMACOL SCI, V35, P237, DOI 10.1016/j.tips.2014.03.002; Ruat M, 2012, DIFFERENTIATION, V83, pS97, DOI 10.1016/j.diff.2011.11.011; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Sinha S, 2006, NAT CHEM BIOL, V2, P29, DOI 10.1038/nchembio753; Solinas A, 2012, J MED CHEM, V55, P1559, DOI 10.1021/jm2013369; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Tao HY, 2011, CHEM BIOL, V18, P432, DOI 10.1016/j.chembiol.2011.01.018; Teperino R, 2012, CELL, V151, P414, DOI 10.1016/j.cell.2012.09.021; van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Wang C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5355; Wang C, 2013, NATURE, V497, P338, DOI 10.1038/nature12167; Weierstall U, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4309; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408	50	43	45	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1817	1829		10.1096/fj.14-267849	http://dx.doi.org/10.1096/fj.14-267849			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25636740	Green Published			2022-12-28	WOS:000354114600018
J	Jeffery, J; Neyt, C; Moore, W; Paterson, S; Bower, NI; Chenevix-Trench, G; Verkade, H; Hogan, BM; Khanna, KK				Jeffery, Jessie; Neyt, Christine; Moore, Wade; Paterson, Scott; Bower, Neil I.; Chenevix-Trench, Georgia; Verkade, Heather; Hogan, Benjamin M.; Khanna, Kum Kum			Cep55 regulates embryonic growth and development by promoting Akt stability in zebrafish	FASEB JOURNAL			English	Article						apoptosis; PI3K/AKT pathway; cytokinesis; multinucleation	S-PHASE ARREST; CELL-CYCLE; CANCER-CELLS; MIDBODY; PROTEIN; APOPTOSIS; ACTIVATION; AUTOPHAGY; KINASE; ESCRT	CEP55 was initially described as a centrosome- and midbody-associated protein and a key mediator of cytokinesis. More recently, it has been implicated in PI3K/AKT pathway activation via an interaction with the catalytic subunit of PI3K. However, its role in embryonic development is unknown. Here we describe a cep55 nonsense mutant zebrafish with which we can study the in vivo physiologic role of Cep55. Homozygous mutants underwent extensive apoptosis by 24 hours postfertilization (hpf) concomitant with cell cycle defects, and heterozygous carriers were indistinguishable from their wild-type siblings. A similar phenotype was also observed in zebrafish injected with a cep55 morpholino, suggesting the mutant is a cep55 loss-of-function model. Further analysis revealed that Akt was destabilized in the homozygous mutants, which partially phenocopied Akt1 and Akt2 knockdown. Expression of either constitutively activated PIK3CA or AKT1 could partially rescue the homozygous mutants. Consistent with a role for Cep55 in regulation of Akt stability, treatment with proteasome inhibitor, MG132, partially rescued the homozygous mutants. Taken together, these results provide the first description of Cep55 in development and underline the importance of Cep55 in the regulation of Pi3k/Akt pathway and in particular Akt stability.	[Jeffery, Jessie; Khanna, Kum Kum] QIMR Berghofer Med Res Inst, Signal Transduct Lab, Brisbane, Qld, Australia; [Neyt, Christine; Paterson, Scott; Bower, Neil I.; Hogan, Benjamin M.] Univ Queensland, Inst Mol Biosci, Vasc Biol & Dev Lab, Brisbane, Qld, Australia; [Moore, Wade; Verkade, Heather] Monash Univ, Zebrafish Dev Genet Lab, Clayton, Vic, Australia; [Chenevix-Trench, Georgia] QIMR Berghofer Med Res Inst, Canc Genet Lab, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; Monash University; QIMR Berghofer Medical Research Institute	Khanna, KK (corresponding author), QIMR Berghofer Med Res Inst, Signal Transduct Lab, 300 Herston Rd, Brisbane, Qld, Australia.	kumkum.khanna@qimrberghofer.edu.au	Hogan, Benjamin M/J-1807-2014; Hogan, Benjamin/AAD-7410-2022; Chenevix-Trench, Georgia/AAV-2014-2020; Bower, Neil/K-1478-2014	Hogan, Benjamin M/0000-0002-0651-7065; Hogan, Benjamin/0000-0002-0651-7065; Chenevix-Trench, Georgia/0000-0002-1878-2587; Khanna, Kum Kum/0000-0001-8650-5381; Bower, Neil/0000-0002-6764-6063; Verkade, Heather/0000-0002-2817-0509	Australian Research Council [FT 011265]; National Health and Medical Research Council (NHMRC) (Australia) [ID: 613638]; Australian Zebrafish Phenomics Facility (NHMRC) [455871]	Australian Research Council(Australian Research Council); National Health and Medical Research Council (NHMRC) (Australia)(National Health and Medical Research Council (NHMRC) of Australia); Australian Zebrafish Phenomics Facility (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank Xiao Qing Chen and Jonathan Beesley for technical assistance. B.M.H. was supported by an Australian Research Council Future Fellowship (FT 011265). K.K.K. was supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (ID: 613638; Australia). Part of the experiments were supported by the Australian Zebrafish Phenomics Facility (NHMRC Grant 455871).	Altschul SF, 2005, FEBS J, V272, P5101, DOI 10.1111/j.1742-4658.2005.04945.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bastos RN, 2010, J CELL BIOL, V191, P751, DOI 10.1083/jcb.201008108; Carlton JG, 2007, SCIENCE, V316, P1908, DOI 10.1126/science.1143422; Chakraborty A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004152; Chang YC, 2012, J BIOL CHEM, V287, P4376, DOI 10.1074/jbc.M111.289108; Chen CH, 2007, ONCOGENE, V26, P4272, DOI 10.1038/sj.onc.1210207; Chen CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005052; Chen MC, 2002, PHYSIOL GENOMICS, V8, P51, DOI 10.1152/physiolgenomics.00042.2001; Cheng YC, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054262, 10.1371/journal.pone.0060503]; Cheng YC, 2013, CELL MOL LIFE SCI, V70, P935, DOI 10.1007/s00018-012-1178-z; Choorapoikayil S, 2014, BLOOD, V123, P184, DOI 10.1182/blood-2013-05-501544; Cole LK, 2001, DEV BIOL, V240, P123, DOI 10.1006/dbio.2001.0432; Ettinger AW, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1511; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; Faucherre A, 2008, ONCOGENE, V27, P1079, DOI 10.1038/sj.onc.1210730; Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335; Guse A, 2005, CURR BIOL, V15, P778, DOI 10.1016/j.cub.2005.03.041; Jeffery JM, 2010, ONCOGENE, V29, P2649, DOI 10.1038/onc.2010.37; Jensen PJ, 2010, J BIOL CHEM, V285, P17673, DOI 10.1074/jbc.M109.079343; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kettleborough RNW, 2013, NATURE, V496, P494, DOI 10.1038/nature11992; Kuo PL, 2006, MOL CANCER THER, V5, P3209, DOI 10.1158/1535-7163.MCT-06-0478; Kuo TC, 2011, NAT CELL BIOL, V13, P1214, DOI 10.1038/ncb2332; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Lee HH, 2008, SCIENCE, V322, P576, DOI 10.1126/science.1162042; Lee SR, 2005, J CELL PHYSIOL, V205, P270, DOI 10.1002/jcp.20395; Liang D, 2001, MECH DEVELOP, V108, P29, DOI 10.1016/S0925-4773(01)00468-3; Liu LH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002850; Martin KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002994; Martinez-Garay I, 2006, GENOMICS, V87, P243, DOI 10.1016/j.ygeno.2005.11.006; Martinez-Garay I, 2002, GENOMICS, V80, P259, DOI 10.1006/geno.2002.6834; Mondal G, 2012, DEV CELL, V23, P137, DOI 10.1016/j.devcel.2012.05.008; Montero-Conde C, 2008, ONCOGENE, V27, P1554, DOI 10.1038/sj.onc.1210792; Morita E, 2007, EMBO J, V26, P4215, DOI 10.1038/sj.emboj.7601850; Nasevicius A, 2000, YEAST, V17, P294, DOI 10.1002/1097-0061(200012)17:4<294::AID-YEA54>3.0.CO;2-5; Ornelas IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053517; Pohl C, 2009, NAT CELL BIOL, V11, P65, DOI 10.1038/ncb1813; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shen XY, 2014, INT J ONCOL, V44, P791, DOI 10.3892/ijo.2014.2251; Shepard JL, 2004, METHOD CELL BIOL, V76, P109; Shishodia S, 2007, BIOCHEM PHARMACOL, V74, P118, DOI 10.1016/j.bcp.2007.03.026; Shuang C., 2011, ACTA HYDROBIOL, V35, P717; Taylor JS, 2001, PHILOS T R SOC B, V356, P1661, DOI 10.1098/rstb.2001.0975; Tucker B, 2007, ZEBRAFISH, V4, P113, DOI 10.1089/zeb.2007.0508; van der Horst A, 2009, CELL CYCLE, V8, P3742, DOI 10.4161/cc.8.22.10047; van der Horst A, 2009, CANCER RES, V69, P6651, DOI 10.1158/0008-5472.CAN-09-0825; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wallace KN, 2005, MECH DEVELOP, V122, P157, DOI 10.1016/j.mod.2004.10.009; Weir NM, 2007, CANCER BIOL THER, V6, P178, DOI 10.4161/cbt.6.2.3577; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Yabe T, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000518; Yeh CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018702; Zhao WM, 2006, MOL BIOL CELL, V17, P3881, DOI 10.1091/mbc.E06-01-0015	54	19	20	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1999	2009		10.1096/fj.14-265090	http://dx.doi.org/10.1096/fj.14-265090			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25667221				2022-12-28	WOS:000354114600033
J	Wu, M; Cao, ML; He, YQ; Liu, YW; Yang, CX; Du, Y; Wang, WJ; Gao, F				Wu, Man; Cao, Manlin; He, Yiqing; Liu, Yiwen; Yang, Cuixia; Du, Yan; Wang, Wenjuan; Gao, Feng			A novel role of low molecular weight hyaluronan in breast cancer metastasis	FASEB JOURNAL			English	Article						mammary carcinoma; lymphatic invasion; biomarker; LMW-HA; prognosis	ANGIOGENIC OLIGOSACCHARIDES; HYAL1 HYALURONIDASE; PROSTATE-CANCER; CD44 CLEAVAGE; UP-REGULATION; EXPRESSION; ACID; CELLS; SERUM; FRAGMENTS	Low molecular weight hyaluronan (LMWHA), a degradation fragment of the extracellular matrix component hyaluronan (HA), has been proven to play a crucial role in cancer progression. However, no systematic clinical study of breast cancer has been performed to correlate LMW-HA levels with metastasis. In the present study, we analyzed 176 serum specimens and found for the first time that the serum LMW-HA (but not total HA) level significantly correlated with lymph node metastasis, suggesting that serum LMW-HA represents a better prognostic indicator of breast cancer progression than HA. Similarly, we found that breast cancer cell lines displaying higher invasive potential had a higher LMW-HA concentration than less-invasive cell lines. This higher LMW-HA level was accompanied by the overexpression of hyaluronan synthase (HAS2) and hyaluronidase (both HYAL1 and HYAL2). Of great importance, decreasing LMW-HA production significantly inhibited breast cancer cell migration and invasion. Overall, our results suggest that during cancer progression, cancer cells may actively remodel their microenvironment via an autocrine/paracrine-like process, resulting in elevated LMW-HA levels, which in turn may facilitate cancer progression by promoting the migration and invasion of cancer cells. Therefore, cancer-associated LMW-HA may be a more promising molecular biomarker than total HA for detecting metastasis and may have further applications inbreast cancer treatment.	[Wu, Man; He, Yiqing; Liu, Yiwen; Yang, Cuixia; Du, Yan; Wang, Wenjuan] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Mol Biol, Shanghai 20233, Peoples R China; [Cao, Manlin] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Rehabil Med, Shanghai 20233, Peoples R China; [Gao, Feng] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Mol Biol & Clin Lab, 600 Yishan Rd, Shanghai 20233, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Gao, F (corresponding author), Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Mol Biol & Clin Lab, 600 Yishan Rd, Shanghai 20233, Peoples R China.	gao3507@126.com	liu, yi/GXE-9662-2022; Wu, Man/AAH-6253-2020		National Natural Science Foundation of China [81071814, 81172027, 81272479]; Shanghai Committee of Science and Technology [10411950500, 12ZR1447400, 14YF1412200]; Program of Shanghai Leading Talents [038]; program of the Shanghai Shen-Kang Hospital Development Center [SHDC22014004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); Program of Shanghai Leading Talents; program of the Shanghai Shen-Kang Hospital Development Center	This work was supported by the National Natural Science Foundation of China (81071814, 81172027, and 81272479), the Shanghai Committee of Science and Technology (10411950500, 12ZR1447400, and 14YF1412200), the Program of Shanghai Leading Talents (038), and the program of the Shanghai Shen-Kang Hospital Development Center (SHDC22014004).	Adamia Sophia, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P3, DOI 10.2174/1568006053005056; AFIFY AM, 1993, ARCH BIOCHEM BIOPHYS, V305, P434, DOI 10.1006/abbi.1993.1443; Al'Qteishat A, 2006, BRAIN, V129, P2158, DOI 10.1093/brain/awl139; Bertrand P, 1997, INT J CANCER, V73, P327, DOI 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1; BERTRAND P, 1992, INT J CANCER, V52, P1, DOI 10.1002/ijc.2910520102; BOYLAND E, 1957, BRIT J CANCER, V11, P578, DOI 10.1038/bjc.1957.71; DAHL IMS, 1988, CANCER-AM CANCER SOC, V62, P326, DOI 10.1002/1097-0142(19880715)62:2<326::AID-CNCR2820620217>3.0.CO;2-Y; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; DELPECH B, 1990, INT J CANCER, V46, P388, DOI 10.1002/ijc.2910460309; DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134; FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3; Fujisaki T, 1999, CANCER RES, V59, P4427; Gao F, 2006, J BIOMED MATER RES B, V78B, P385, DOI 10.1002/jbm.b.30499; Itano N, 2004, J BIOL CHEM, V279, P18679, DOI 10.1074/jbc.M313178200; KUMAR S, 1989, INT J CANCER, V44, P445, DOI 10.1002/ijc.2910440311; Kung CI, 2012, ONCOL REP, V28, P1808, DOI 10.3892/or.2012.1993; Lokeshwar VB, 2005, CANCER RES, V65, P2243, DOI 10.1158/0008-5472.CAN-04-2805; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; Lokeshwar VB, 1996, CANCER RES, V56, P651; Mahoney DJ, 2001, GLYCOBIOLOGY, V11, P1025, DOI 10.1093/glycob/11.12.1025; Matou-Nasri S, 2009, INT J ONCOL, V35, P761, DOI 10.3892/ijo_00000389; Nykopp TK, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-512; PONTING J, 1992, INT J CANCER, V52, P873, DOI 10.1002/ijc.2910520607; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; Slevin M, 2004, INT J CANCER, V109, P793, DOI 10.1002/ijc.20059; Slevin M, 2002, J BIOL CHEM, V277, P41046, DOI 10.1074/jbc.M109443200; Slomiany MG, 2009, CANCER RES, V69, P4992, DOI 10.1158/0008-5472.CAN-09-0143; STERN M, 1992, MATRIX, V12, P397, DOI 10.1016/S0934-8832(11)80036-3; Stern R, 2003, GLYCOBIOLOGY, V13, p105R, DOI 10.1093/glycob/cwg112; Stern R, 2006, EUR J CELL BIOL, V85, P699, DOI 10.1016/j.ejcb.2006.05.009; Sugahara KN, 2006, J BIOL CHEM, V281, P5861, DOI 10.1074/jbc.M506740200; Tan JX, 2011, INT J CANCER, V128, P1303, DOI 10.1002/ijc.25460; Tempel C, 2000, BIOL REPROD, V63, P134, DOI 10.1095/biolreprod63.1.134; TENGBLAD A, 1980, BIOCHEM J, V185, P101, DOI 10.1042/bj1850101; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; Udabage L, 2003, GLYCOCONJUGATE J, V20, P461, DOI 10.1023/B:GLYC.0000038292.71098.35; Veiseh M, 2011, INTEGR BIOL-UK, V3, P304, DOI 10.1039/c0ib00096e; Voelcker V, 2008, EXP DERMATOL, V17, P100, DOI 10.1111/j.1600-0625.2007.00638.x; Weiss I, 2012, INT J MOL SCI, V13, P12925, DOI 10.3390/ijms131012925; Wu M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092857; Yang CX, 2012, J BIOL CHEM, V287, P43094, DOI 10.1074/jbc.M112.349209	41	127	129	2	42	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1290	1298		10.1096/fj.14-259978	http://dx.doi.org/10.1096/fj.14-259978			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550464				2022-12-28	WOS:000354115000017
J	Liu, W; Lin, YT; Yan, XL; Ding, YL; Wu, YL; Chen, WN; Lin, X				Liu, Wei; Lin, Yan-Ting; Yan, Xiao-Li; Ding, Ya-Lan; Wu, Yun-Li; Chen, Wan-Nan; Lin, Xu			Hepatitis B virus core protein inhibits Fas-mediated apoptosis of hepatoma cells via regulation of mFas/FasL and sFas expression	FASEB JOURNAL			English	Article						p53; chronic HBV infection; PTBP1; FASTK	TRAIL-INDUCED APOPTOSIS; SOLUBLE FAS/APO-1 CD95; WILD-TYPE P53; SERUM-LEVELS; HEPATOCELLULAR-CARCINOMA; RECEPTOR/LIGAND SYSTEM; NUCLEAR-LOCALIZATION; CHRONIC HBV; DNA-DAMAGE; GENE	Hepatitis B virus core protein (HBc) has been implicated in hepatocarcinogenesis through several mechanisms. Resistance of hepatitis B virus (HBV)-infected hepatocytes to apoptosis is considered one of the major contributors to the progression of chronic hepatitis to cirrhosis and ultimately to hepatocellular carcinoma. The Fas receptor/ligand (Fas/FasL) system plays a prominent role in hepatocyte death during HBV infection. Here we report that HBc mediates resistance of hepatoma cells to agonistic anti-Fas antibody (CH11)-induced apoptosis. WhenHBc was introduced into human hepatoma cells, the cells became resistant to CH11 cytotoxicity in a p53-dependent manner. HBc significantly down-regulated the expression of p53, total Fas, and membrane-bound Fas at them RNA and protein levels and reduced FasL mRNA expression. In contrast, HBc upregulated the expression of soluble forms of Fas by increasing Fas alternative mRNA splicing. Mechanistically, HBc-mediated Fas alternative mRNA splicing was associated with up-regulation of polypyrimidine tract-binding protein 1 and down-regulation of Fas-activated serine/threonine kinase. These results indicated that HBc may preventhepatocytes from Fas-induced apoptosis by the dual effects of reducing the expression of the proapoptotic form of Fas and enhancing the expression of the antiapoptotic form of the receptor, which may contribute to the survival and persistence of infected hepatocytes during chronic infection.	[Liu, Wei; Lin, Yan-Ting; Yan, Xiao-Li; Ding, Ya-Lan; Wu, Yun-Li; Chen, Wan-Nan; Lin, Xu] Fujian Med Univ, Sch Basic Med Sci, Key Lab, Minist Educ Gastrointestinal Canc, Minhou 350108, Fujian, Peoples R China; [Liu, Wei; Wu, Yun-Li; Chen, Wan-Nan; Lin, Xu] Fujian Med Univ, Dept Med Microbiol, Key Lab Tumor Microbiol, Minhou 350108, Fujian, Peoples R China	Fujian Medical University; Fujian Medical University	Lin, X (corresponding author), Fujian Med Univ, Sch Basic Med Sci, Key Lab, Minist Educ Gastrointestinal Canc, 1 Xueyuan Rd, Minhou 350108, Fujian, Peoples R China.	linxu@mail.fjmu.edu.cn	Liu, Wei/ABX-2014-2022	Liu, Wei/0000-0001-7118-815X	State Key Project Specialized for Infectious Diseases [2012ZX10002002-004-006, 2013ZX10002006-002-002]; Key Program of Scientific Research [09ZD004]; Program for Innovative Research Team in Science and Technology from Fujian Medical University [FMU-RT001]	State Key Project Specialized for Infectious Diseases; Key Program of Scientific Research; Program for Innovative Research Team in Science and Technology from Fujian Medical University	The authors thank Drs. Christopher W. J. Smith and J. Valca'rcel for providing pCMV56-Fas vector. This work was supported by grants from State Key Project Specialized for Infectious Diseases (2012ZX10002002-004-006 and 2013ZX10002006-002-002), Key Program of Scientific Research (09ZD004), and Program for Innovative Research Team in Science and Technology from Fujian Medical University (FMU-RT001).	Back SH, 2002, J BIOL CHEM, V277, P27200, DOI 10.1074/jbc.M203887200; Bortolami M, 2008, J VIRAL HEPATITIS, V15, P515, DOI 10.1111/j.1365-2893.2008.00974.x; CASCINO I, 1995, J IMMUNOL, V154, P2706; Chen WN, 2010, J GEN VIROL, V91, P2592, DOI 10.1099/vir.0.022517-0; Chen XC, 2004, VACCINE, V22, P439, DOI 10.1016/j.vaccine.2003.07.014; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Du J, 2009, CELL DEATH DIFFER, V16, P219, DOI 10.1038/cdd.2008.144; ECKHARDT SG, 1991, J VIROL, V65, P575, DOI 10.1128/JVI.65.2.575-582.1991; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08-111005; Guo YH, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-563; Hatano E, 2007, J GASTROEN HEPATOL, V22, pS43, DOI 10.1111/j.1440-1746.2006.04645.x; HATTON T, 1992, J VIROL, V66, P5232, DOI 10.1128/JVI.66.9.5232-5241.1992; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Izquierdo JM, 2005, MOL CELL, V19, P475, DOI 10.1016/j.molcel.2005.06.015; Izquierdo JM, 2008, MOL BIOL CELL, V19, P3299, DOI 10.1091/mbc.E07-11-1125; Izquierdo JM, 2007, J BIOL CHEM, V282, P1539, DOI 10.1074/jbc.C600198200; Jeong H, 2014, FEBS LETT, V588, P851, DOI 10.1016/j.febslet.2014.01.020; Jodo S, 1998, CLIN EXP IMMUNOL, V112, P166; Jodo S, 1997, CLIN EXP IMMUNOL, V107, P89, DOI 10.1046/j.1365-2249.1997.d01-901.x; Kew MC, 2010, PATHOL BIOL, V58, P273, DOI 10.1016/j.patbio.2010.01.005; KNIPPING E, 1995, BLOOD, V85, P1562, DOI 10.1182/blood.V85.6.1562.bloodjournal8561562; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Kwon JA, 2003, BIOL CHEM, V384, P203, DOI 10.1515/BC.2003.022; Li HC, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001162; Liang XH, 2007, J IMMUNOL, V178, P503, DOI 10.4049/jimmunol.178.1.503; LIAO W, 1995, J VIROL, V69, P1025, DOI 10.1128/JVI.69.2.1025-1029.1995; Lok AS, 2001, GASTROENTEROLOGY, V120, P1828, DOI 10.1053/gast.2001.24839; MILICH DR, 1986, SCIENCE, V234, P1398, DOI 10.1126/science.3491425; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nakamoto Y, 1997, J IMMUNOL, V158, P5692; Nakamura M, 2007, J HEPATOL, V46, P77, DOI 10.1016/j.jhep.2006.07.032; PONCHEL F, 1994, CANCER RES, V54, P2064; Rawat S, 2012, VIRUSES-BASEL, V4, P2945, DOI 10.3390/v4112945; Rivero M, 2002, J VIRAL HEPATITIS, V9, P107, DOI 10.1046/j.1365-2893.2002.00338.x; Robinson F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001801; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shim HY, 2011, VIROLOGY, V410, P161, DOI 10.1016/j.virol.2010.11.005; Spellman R, 2007, MOL CELL, V27, P420, DOI 10.1016/j.molcel.2007.06.016; Vakifahmetoglu H, 2006, ONCOGENE, V25, P5683, DOI 10.1038/sj.onc.1209569; Yin Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022524	46	36	40	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1113	1123		10.1096/fj.14-263822	http://dx.doi.org/10.1096/fj.14-263822			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25466893				2022-12-28	WOS:000350633000034
J	Gugusheff, JR; Ong, ZY; Muhlhausler, BS				Gugusheff, Jessica Rose; Ong, Zhi Yi; Muhlhausler, Beverly Sara			The early origins of food preferences: targeting the critical windows of development	FASEB JOURNAL			English	Review						programming; high-fat diet; reward	HIGH-FAT DIET; NUCLEUS-ACCUMBENS SHELL; VENTRAL TEGMENTAL AREA; EXCESSIVE SUGAR INTAKE; GENE-EXPRESSION; JUNK-FOOD; POSTNATAL-DEVELOPMENT; MATERNAL OBESITY; PALATABLE FOOD; ADOLESCENT DEVELOPMENT	The nutritional environment to which an individual is exposed during the perinatal period plays a crucial role in determining his or her future metabolic health outcomes. Studies in rodent models have demonstrated that excess maternal intake of high-fat and/or high-sugar "junk foods" during pregnancy and lactation can alter the development of the central reward pathway, particularly the opioid and dopamine systems, and program an increased preference for junk foods in the offspring. More recently, there have been attempts to define the critical windows of development during which the opioid and dopamine systems within the reward pathway are most susceptible to alteration and to determine whether it is possible to reverse these effects through nutritional interventions applied later in development. This review discusses the progress made to date in these areas, highlights the apparent importance of sex in determining these effects, and considers the potential implications of the findings from rodent models in the human context.	[Gugusheff, Jessica Rose; Ong, Zhi Yi; Muhlhausler, Beverly Sara] Univ Adelaide, Sch Agr Food & Wine, FOODplus Res Ctr, Adelaide, SA 5064, Australia; [Ong, Zhi Yi; Muhlhausler, Beverly Sara] Univ S Australia, Sch Pharm & Med Sci, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia; [Ong, Zhi Yi] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA	University of Adelaide; University of South Australia; University of Pennsylvania	Muhlhausler, BS (corresponding author), Univ Adelaide, Sch Agr Food & Wine, FOODplus Res Ctr, Adelaide, SA 5064, Australia.	beverly.muhlhausler@adelaide.edu.au	Croes, Huib JE/G-4012-2016	Gugusheff, Jessica/0000-0003-2327-8403; Ong, Zhi Yi/0000-0002-8300-6955	National Health and Medical Research Council of Australia; Australian Postgraduate Award	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award(Australian Government)	The authors would like to thank John Carragher for editorial assistance. B.S.M. is supported by a Career Development Award from the National Health and Medical Research Council of Australia. J.R.G. is supported by an Australian Postgraduate Award.	Adinoff B, 2004, HARVARD REV PSYCHIAT, V12, P305, DOI 10.1080/10673220490910844; Adriani W, 2004, NEUROPSYCHOPHARMACOL, V29, P869, DOI 10.1038/sj.npp.1300366; Alsio J, 2010, NEUROSCIENCE, V171, P779, DOI 10.1016/j.neuroscience.2010.09.046; Antonopoulos J, 2002, NEUROSCIENCE, V110, P245, DOI 10.1016/S0306-4522(01)00575-9; Asarian L, 2006, PHILOS T R SOC B, V361, P1251, DOI 10.1098/rstb.2006.1860; Avena NM, 2008, NEUROSCI BIOBEHAV R, V32, P20, DOI 10.1016/j.neubiorev.2007.04.019; Bassareo V, 2002, J NEUROSCI, V22, P4709, DOI 10.1523/JNEUROSCI.22-11-04709.2002; Bayol SA, 2007, BRIT J NUTR, V98, P843, DOI 10.1017/S0007114507812037; Bergevin A, 2002, NEUROPHARMACOLOGY, V42, P1065, DOI 10.1016/S0028-3908(02)00061-8; Boney CM, 2005, PEDIATRICS, V115, pE290, DOI 10.1542/peds.2004-1808; BRANA C, 1995, J COMP NEUROL, V360, P488, DOI 10.1002/cne.903600310; Brana C, 1997, MOL BRAIN RES, V48, P389, DOI 10.1016/S0169-328X(97)00114-9; Brion MJA, 2010, AM J CLIN NUTR, V91, P748, DOI 10.3945/ajcn.2009.28623; Chandler-Laney PC, 2012, PEDIATR OBES, V7, P44, DOI 10.1111/j.2047-6310.2011.00009.x; Chang GQ, 2008, J NEUROSCI, V28, P12107, DOI 10.1523/JNEUROSCI.2642-08.2008; Clancy B, 2007, NEUROTOXICOLOGY, V28, P931, DOI 10.1016/j.neuro.2007.01.014; Colantuoni C, 2002, OBES RES, V10, P478, DOI 10.1038/oby.2002.66; Davis JF, 2008, BEHAV NEUROSCI, V122, P1257, DOI 10.1037/a0013111; DREWNOWSKI A, 1992, PHYSIOL BEHAV, V51, P371, DOI 10.1016/0031-9384(92)90155-U; Erlanson-Albertsson C, 2005, BASIC CLIN PHARMACOL, V97, P61, DOI 10.1111/j.1742-7843.2005.pto_179.x; Forestell CA, 2007, PEDIATRICS, V120, P1247, DOI 10.1542/peds.2007-0858; GIRAUDO SQ, 1993, PHARMACOL BIOCHEM BE, V46, P917, DOI 10.1016/0091-3057(93)90222-F; Gorski JN, 2006, AM J PHYSIOL-REG I, V291, pR768, DOI 10.1152/ajpregu.00138.2006; Grimm JW, 2011, PSYCHOPHARMACOLOGY, V216, P219, DOI 10.1007/s00213-011-2210-y; Gugusheff JR, 2014, PHYSIOL BEHAV, V133, P14, DOI 10.1016/j.physbeh.2014.04.007; Gugusheff JR, 2013, J DEV ORIG HLTH DIS, V4, P348, DOI 10.1017/S2040174413000330; Hajnal A, 2001, BRAIN RES, V904, P76, DOI 10.1016/S0006-8993(01)02451-9; HENNING SJ, 1979, AM J PHYSIOL, V237, pR187, DOI 10.1152/ajpregu.1979.237.3.R187; Herlenius E, 2001, EARLY HUM DEV, V65, P21, DOI 10.1016/S0378-3782(01)00189-X; Johnson PM, 2010, NAT NEUROSCI, V13, P635, DOI 10.1038/nn.2519; Kelley AE, 1996, J PHARMACOL EXP THER, V278, P1499; Kirk SL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005870; Liang NC, 2006, AM J PHYSIOL-REG I, V291, pR1236, DOI 10.1152/ajpregu.00226.2006; MacDonald AF, 2003, AM J PHYSIOL-REG I, V285, pR999, DOI 10.1152/ajpregu.00271.2003; MAGNAN J, 1989, DEV BRAIN RES, V45, P275, DOI 10.1016/0165-3806(89)90045-X; Matthews PA, 2011, J PHYSIOL-LONDON, V589, P3969, DOI 10.1113/jphysiol.2011.212324; McDowell J., 1987, BRAIN RES, V434, P397; Mennella JA, 2002, EARLY HUM DEV, V68, P71, DOI 10.1016/S0378-3782(02)00008-7; MENNELLA JA, 1993, PEDIATR RES, V34, P805, DOI 10.1203/00006450-199312000-00022; Mennella JA, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.6.e88; Muhlhausler BS, 2006, FASEB J, V20, P1257, DOI 10.1096/fj.05-5241fje; Naef L, 2011, NEUROSCIENCE, V176, P225, DOI 10.1016/j.neuroscience.2010.12.037; Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578; Ong ZY, 2014, ACTA PHYSIOL, V210, P127, DOI 10.1111/apha.12132; Ong ZY, 2012, J DEV ORIG HLTH DIS, V3, P299, DOI 10.1017/S204017441200030X; Ong ZY, 2011, FASEB J, V25, P2167, DOI 10.1096/fj.10-178392; Pascual M, 2009, J NEUROCHEM, V108, P920, DOI 10.1111/j.1471-4159.2008.05835.x; PATEY G, 1980, LIFE SCI, V27, P245, DOI 10.1016/0024-3205(80)90144-7; Pelchat ML, 2002, PHYSIOL BEHAV, V76, P347, DOI 10.1016/S0031-9384(02)00757-6; Rada P, 2005, NEUROSCIENCE, V134, P737, DOI 10.1016/j.neuroscience.2005.04.043; Sahr AE, 2008, AM J PHYSIOL-REG I, V295, pR463, DOI 10.1152/ajpregu.00390.2007; Samuelsson AM, 2008, HYPERTENSION, V51, P383, DOI 10.1161/HYPERTENSIONAHA.107.101477; Saper CB, 2002, NEURON, V36, P199, DOI 10.1016/S0896-6273(02)00969-8; Selemon LD, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.7; Silveira PP, 2008, PHYSIOL BEHAV, V93, P877, DOI 10.1016/j.physbeh.2007.12.003; Smidt MP, 2007, NAT REV NEUROSCI, V8, P21, DOI 10.1038/nrn2039; SPAIN JW, 1985, J NEUROSCI, V5, P584; Spangler R, 2004, MOL BRAIN RES, V124, P134, DOI 10.1016/j.molbrainres.2004.02.013; Spear L, 2000, ALCOHOL RES HEALTH, V24, P115; Tarazi FI, 2000, INT J DEV NEUROSCI, V18, P29, DOI 10.1016/S0736-5748(99)00108-2; Teegarden SL, 2009, NEUROSCIENCE, V162, P924, DOI 10.1016/j.neuroscience.2009.05.029; Tepper JM, 1998, DEV NEUROSCI-BASEL, V20, P125, DOI 10.1159/000017308; Velkoska E, 2005, AM J PHYSIOL-ENDOC M, V288, pE1236, DOI 10.1152/ajpendo.00505.2004; Vucetic Z, 2010, ENDOCRINOLOGY, V151, P4756, DOI 10.1210/en.2010-0505; Whitaker RC, 2004, PEDIATRICS, V114, pE29, DOI 10.1542/peds.114.1.e29; Wright TM, 2011, INT J DEV NEUROSCI, V29, P785, DOI 10.1016/j.ijdevneu.2011.09.007; Zhang M, 1998, J PHARMACOL EXP THER, V285, P908; Zhang M, 2000, NEUROSCIENCE, V99, P267, DOI 10.1016/S0306-4522(00)00198-6	68	34	36	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					365	373		10.1096/fj.14-255976	http://dx.doi.org/10.1096/fj.14-255976			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25466884	Green Submitted			2022-12-28	WOS:000349370400003
J	Kim, HY; Park, JH; Won, HY; Lee, JY; Kong, G				Kim, Hey-Yon; Park, Ji-Hye; Won, Hee-Young; Lee, Jeong-Yeon; Kong, Gu			CBX7 inhibits breast tumorigenicity through DKK-1-mediated suppression of the Wnt/beta-catenin pathway	FASEB JOURNAL			English	Article						polycomb; self-renewal pathway; p300; acetylation	POLYCOMB GROUP PROTEINS; STEM-CELLS; CHROMOBOX PROTEIN; TUMOR-SUPPRESSOR; CANCER CELLS; SIGNALING PATHWAY; EXPRESSION; GENE; DICKKOPF-1; CARCINOMA	Polycomb protein chromobox homolog 7 (CBX7) is involved in several biologic processes including stem cell regulation and cancer development, but its roles in breast cancer remain unknown. Here, we demonstrate that CBX7 negatively regulates breast tumor initiation. CD44(+)/CD24(-)/ESA(+) breast stem-like cells showed diminished CBX7 expression. Furthermore, small hairpin RNA-mediated CBX7 knockdown in breast epithelial and cancer cells increased the CD44(+)/CD24(-)/ESA(+) cell population and reinforced in vitro self-renewal and in vivo tumor-initiating ability. Similarly, CBX7 overexpression repressed these effects. We also found that CBX7 inhibits the Wnt/b-catenin/T cell factor pathway by enhancing the expression of Dickkopf-1 (DKK-1), a Wnt antagonist. In particular, CBX7 increased DKK-1 transcription by cooperating with p300 acetyltransferase and subsequently enhancing the histone acetylation of the DKK-1 promoter. Furthermore, pharmacologic inhibition of DKK-1 in CBX7-overexpressing cells showed recovery of Wnt signaling and consequent rescue of the CD44(+)/CD24(-)/ESA(+) cell population. Taken together, these findings indicate that CBX7-mediated epigenetic induction of DKK-1 is crucial for the inhibition of breast tumorigenicity, suggesting that CBX7 could be a potential tumor suppressor in human breast cancer.	[Kim, Hey-Yon; Won, Hee-Young; Kong, Gu] Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea; [Park, Ji-Hye; Lee, Jeong-Yeon; Kong, Gu] Hanyang Univ, Inst Bioengn & Biopharmaceut Res, Seoul 133791, South Korea	Hanyang University; Hanyang University	Kong, G (corresponding author), Hanyang Univ, Coll Med, Dept Pathol, 17 Haengdang Dong, Seoul 133791, South Korea.	jy2jy2@hanyang.ac.kr; gkong@hanyang.ac.kr						Agur Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024225; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aloia L, 2013, DEVELOPMENT, V140, P2525, DOI 10.1242/dev.091553; Arima Y, 2012, INT J CANCER, V130, P2568, DOI 10.1002/ijc.26271; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bernard D, 2005, ONCOGENE, V24, P5543, DOI 10.1038/sj.onc.1208735; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; Cho JH, 2013, J BIOL CHEM, V288, P3406, DOI 10.1074/jbc.M112.422931; Dees C, 2014, ANN RHEUM DIS, V73, P1232, DOI 10.1136/annrheumdis-2012-203194; Endoh M, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002774; Federico A, 2009, CANCER RES, V69, P7079, DOI 10.1158/0008-5472.CAN-09-1542; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Forzati F, 2012, CELL CYCLE, V11, P1888, DOI 10.4161/cc.20022; Forzati F, 2012, J CLIN INVEST, V122, P612, DOI 10.1172/JCI58620; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Hinz S, 2008, TUMOR BIOL, V29, P323, DOI 10.1159/000170879; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang ZB, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0070077, 10.1371/journal.pone.0075007]; Hussain M, 2009, CANCER RES, V69, P3570, DOI 10.1158/0008-5472.CAN-08-2807; Jiang Z, 2010, J GASTROENTEROL, V45, P17, DOI 10.1007/s00535-009-0135-6; Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931; Karamitopoulou E, 2010, EUR J CANCER, V46, P1438, DOI 10.1016/j.ejca.2010.01.033; Klauke K, 2013, NAT CELL BIOL, V15, P353, DOI 10.1038/ncb2701; Lamb R, 2013, CELL CYCLE, V12, P2384, DOI 10.4161/cc.25403; Lee JY, 2014, ONCOGENE, V33, P1325, DOI 10.1038/onc.2013.53; Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Mansueto Gelsomina, 2010, Genes Cancer, V1, P210, DOI 10.1177/1947601910366860; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065; Morey L, 2012, CELL STEM CELL, V10, P47, DOI 10.1016/j.stem.2011.12.006; Neth P, 2006, STEM CELLS, V24, P1892, DOI 10.1634/stemcells.2005-0503; O'Loghlen A, 2012, CELL STEM CELL, V10, P33, DOI 10.1016/j.stem.2011.12.004; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Pallante P, 2010, EUR J CANCER, V46, P2304, DOI 10.1016/j.ejca.2010.05.011; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Rawson JB, 2012, NUTR CANCER, V64, P919, DOI 10.1080/01635581.2012.711418; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Scott CL, 2007, P NATL ACAD SCI USA, V104, P5389, DOI 10.1073/pnas.0608721104; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Vibhakar R, 2007, NEURO-ONCOLOGY, V9, P135, DOI 10.1215/15228517-2006-038; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Yao H, 2011, EXPERT OPIN THER TAR, V15, P873, DOI 10.1517/14728222.2011.577418; Zhang XW, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-114	48	48	51	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					300	313		10.1096/fj.14-253997	http://dx.doi.org/10.1096/fj.14-253997			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25351982				2022-12-28	WOS:000347378600028
J	Kirby, KA; Ong, YT; Hachiya, A; Laughlin, TG; Chiang, LA; Pan, Y; Moran, JL; Marchand, B; Singh, K; Gallazzi, F; Quinn, TP; Yoshimura, K; Murakami, T; Matsushita, S; Sarafianos, SG				Kirby, Karen A.; Ong, Yee Tsuey; Hachiya, Atsuko; Laughlin, Thomas G.; Chiang, Leslie A.; Pan, Yun; Moran, Jennifer L.; Marchand, Bruno; Singh, Kamalendra; Gallazzi, Fabio; Quinn, Thomas P.; Yoshimura, Kazuhisa; Murakami, Toshio; Matsushita, Shuzo; Sarafianos, Stefan G.			Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247	FASEB JOURNAL			English	Article						crystal structure; entry; HIV; single-chain variable fragment	HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; BROAD NEUTRALIZATION; BINDING MODE; V3 PEPTIDES; TYPE-1; ENVELOPE; EPITOPE; SEQUENCE	Humanized monoclonal antibody KD-247 targets the Gly(312)-Pro(313)-Gly(314)-Arg(315) arch of the third hypervariable (V3) loop of the HIV-1 surface glycoprotein. It potently neutralizes many HIV-1 clade B isolates, but not of other clades. To understand the molecular basis of this specificity, we solved a high-resolution (1.55 angstrom) crystal structure of the KD-247 antigen binding fragment and examined the potential interactions with various V3 loop targets. Unlike most antibodies, KD-247 appears to interact with its target primarily through light chain residues. Several of these interactions involve Arg(315) of the V3 loop. To evaluate the role of light chain residues in the recognition of the V3 loop, we generated 20 variants of KD-247 single-chain variable fragments with mutations in the antigen-binding site. Purified proteins were assessed for V3 loop binding using Alpha-Screen technology and for HIV-1 neutralization. Our data revealed that recognition of the clade-specificity defining residue Arg(315) of the V3 loop is based on a network of interactions that involve Tyr(L32), Tyr(L92), and Asn(L27d) that directly interact with Arg(315), thus elucidating the molecular interactions of KD-247 with its V3 loop target.	[Kirby, Karen A.; Ong, Yee Tsuey; Hachiya, Atsuko; Laughlin, Thomas G.; Chiang, Leslie A.; Pan, Yun; Moran, Jennifer L.; Marchand, Bruno; Singh, Kamalendra; Sarafianos, Stefan G.] Univ Missouri, Christopher S Bond Life Sci Ctr, Sch Med, Columbia, MO USA; [Kirby, Karen A.; Ong, Yee Tsuey; Hachiya, Atsuko; Laughlin, Thomas G.; Chiang, Leslie A.; Pan, Yun; Moran, Jennifer L.; Marchand, Bruno; Singh, Kamalendra; Sarafianos, Stefan G.] Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA; [Gallazzi, Fabio] Univ Missouri, Struct Biol Core, Columbia, MO USA; [Quinn, Thomas P.] Univ Missouri, Dept Biochem, Columbia, MO USA; [Yoshimura, Kazuhisa] Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan; [Murakami, Toshio] Chemoserotherapeut Res Inst Kaketsuken, Kumamoto, Japan; [Matsushita, Shuzo] Kumamoto Univ, Ctr AIDS Res, Div Clin Retrovirol & Infect Dis, Kumamoto, Japan	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; National Institute of Infectious Diseases (NIID); Kumamoto University	Sarafianos, SG (corresponding author), 471d Christopher S Bond Life Sci Ctr, 1201 Rollins St, Columbia, MO 65211 USA.	sarafianoss@missouri.edu		Laughlin, Thomas/0000-0001-8943-1330; Kirby, Karen A./0000-0003-2468-4796; Ong, Yee Tsuey/0000-0001-9361-2855; Sarafianos, Stefan G/0000-0002-5840-154X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI094715, R01AI076119, R21AI112417, R01AI099284, R01AI100890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM103368] Funding Source: NIH RePORTER; Canadian Institutes of Health Research Funding Source: Medline; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [AI100890, R21 AI094715, AI112417, AI099284, AI094715, R01 AI100890, R01 AI099284, AI076119, R21 AI112417, R01 AI076119, R37 AI076119] Funding Source: Medline; NIGMS NIH HHS [P50 GM103368, GM103368] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abhinandan KR, 2008, MOL IMMUNOL, V45, P3832, DOI 10.1016/j.molimm.2008.05.022; Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Barbato G, 2003, J MOL BIOL, V330, P1101, DOI 10.1016/S0022-2836(03)00611-9; Bell CH, 2008, J MOL BIOL, V375, P969, DOI 10.1016/j.jmb.2007.11.013; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Branden C., 1999, INTRO PROTEIN STRUCT; Burke V, 2009, STRUCTURE, V17, P1538, DOI 10.1016/j.str.2009.09.012; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; Checkley MA, 2011, J MOL BIOL, V410, P582, DOI 10.1016/j.jmb.2011.04.042; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; CONLEY AJ, 1994, J VIROL, V68, P6994, DOI 10.1128/JVI.68.11.6994-7000.1994; Eda Y, 2006, J VIROL, V80, P5563, DOI 10.1128/JVI.02095-05; Eda Y, 2006, J VIROL, V80, P5552, DOI 10.1128/JVI.02094-05; Eglen Richard M, 2008, Curr Chem Genomics, V1, P2, DOI 10.2174/1875397300801010002; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; Gorny MK, 2006, J VIROL, V80, P6865, DOI 10.1128/JVI.02202-05; GORNY MK, 1992, J VIROL, V66, P7538, DOI 10.1128/JVI.66.12.7538-7542.1992; Gorny MK, 2004, J VIROL, V78, P2394, DOI 10.1128/JVI.78.5.2394-2404.2004; GORNY MK, 1993, J IMMUNOL, V150, P635; Gorny MK, 2002, J VIROL, V76, P9035, DOI 10.1128/JVI.76.18.9035-9045.2002; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hatada M, 2010, J GEN VIROL, V91, P1335, DOI 10.1099/vir.0.017426-0; Hioe CE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010254; Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544; Janes R. W., 2009, ADV BIOMEDICAL SPECT, V1, P183; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; Jiang XQ, 2010, NAT STRUCT MOL BIOL, V17, P955, DOI 10.1038/nsmb.1861; Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625; Kabat EA, 1991, SEQUENCES PROTEINS I; Kessler N, 2003, PROTEIN EXPRES PURIF, V29, P291, DOI 10.1016/S1046-5928(03)00047-0; Langer G, 2008, NAT PROTOC, V3, P1171, DOI 10.1038/nprot.2008.91; Le Douce V, 2012, J ANTIMICROB CHEMOTH, V67, P1063, DOI 10.1093/jac/dkr599; Lynch RM, 2009, AIDS RES HUM RETROV, V25, P237, DOI 10.1089/aid.2008.0219; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; Matsushita Shuzo, 2005, Human Antibodies, V14, P81; MATTHEWS BW, 1985, METHOD ENZYMOL, V114, P176; Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26; Murakami T, 2009, AIDS, V23, P1485, DOI 10.1097/QAD.0b013e32832e5331; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ong YT, 2012, CELL MOL BIOL, V58, P71, DOI 10.1170/T923; Pantophlet R, 2007, VIROLOGY, V364, P441, DOI 10.1016/j.virol.2007.03.007; Parren PWHI, 1997, NAT MED, V3, P366, DOI 10.1038/nm0497-366d; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; Sreerama N, 1999, PROTEIN SCI, V8, P370; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stanfield RL, 2006, J MOL BIOL, V357, P1566, DOI 10.1016/j.jmb.2006.01.023; Stanfield RL, 2004, STRUCTURE, V12, P193, DOI 10.1016/j.str.2004.01.003; Stanfield RL, 2003, VIROLOGY, V315, P159, DOI 10.1016/S0042-6822(03)00525-7; Stanfield RL, 2006, J VIROL, V80, P6093, DOI 10.1128/JVI.00205-06; Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450; Sundberg EJ, 2009, METHODS MOL BIOL, V524, P23, DOI 10.1007/978-1-59745-450-6_2; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Gils MJ, 2013, VIROLOGY, V435, P46, DOI 10.1016/j.virol.2012.10.004; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Whitmore L, 2008, BIOPOLYMERS, V89, P392, DOI 10.1002/bip.20853; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Yoshimura K, 2006, AIDS, V20, P2065, DOI 10.1097/01.aids.0000247587.31320.fe; Yusim K, 2011, HIV MOL IMMUNOLOGY	72	1	1	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					70	80		10.1096/fj.14-252262	http://dx.doi.org/10.1096/fj.14-252262			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25351987	Green Published			2022-12-28	WOS:000347378600008
J	Bischel, LL; Sung, KE; Jimenez-Torres, JA; Mader, B; Keely, PJ; Beebe, DJ				Bischel, Lauren L.; Sung, Kyung E.; Jimenez-Torres, Jose A.; Mader, Brianah; Keely, Patricia J.; Beebe, David J.			The importance of being a lumen	FASEB JOURNAL			English	Article						tissue engineering; cell culture; tissue geometry; microtechnology; microfluidics	CELL-CULTURE; MODEL; MATRIX; ANGIOGENESIS; GEOMETRY; MORPHOGENESIS; MECHANICS	Advances in tissue engineering and microtechnology have enabled researchers to more easily generate in vitro tissue models that mimic the tissue geometry and spatial organization found in vivo (e.g., vessel or mammary duct models with tubular structures). However, the widespread adoption of these models for biological studies has been slow, in part due to the lack of direct comparisons between existing 2-dimensional and 3-dimensional cell culture models and new organotypic models that better replicate tissue structure. Using previously developed vessel and mammary duct models with 3-dimensional lumen structures, we have begun to explore this question. In a direct comparison between these next generation organotypic models and more traditional methods, we observed differences in the levels of several secreted growth factors and cytokines. In addition, endothelial vessel geometry profoundly affects the phenotypic behavior of carcinoma cells, suggesting that more traditional in vitro assays may not capture in vivo events. Here, we seek to review and add to the increasing evidence supporting the hypothesis that using cell culture models with more relevant tissue structure influences cell fate and behavior, potentially increasing the relevance of biological findings.Bischel, L. L., Sung, K. E., Jimenez-Torres, J. A., Mader, B., Keely, P. J., Beebe, D. J. The importance of being a lumen.	[Bischel, Lauren L.; Sung, Kyung E.; Jimenez-Torres, Jose A.; Mader, Brianah; Keely, Patricia J.; Beebe, David J.] Univ Wisconsin, Wisconsin Inst Med Res, Dept Biomed Engn, Carbone Comprehens Canc Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison	Beebe, DJ (corresponding author), Univ Wisconsin, Wisconsin Inst Med Res, Dept Biomed Engn, 1111 Highland Ave, Madison, WI 53706 USA.	djbeebe@wisc.edu		Sung, Kyung/0000-0001-9664-6399	U.S. National Institutes of Health [R01EB10039, NIH T32HL007889]; University of Wisconsin Graduate Engineering Research Scholars Program; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007889, T32HL007899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB010039] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Wisconsin Graduate Engineering Research Scholars Program; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	The authors thank Moon Hee Lee and Jason Able (University of Wisconsin) for providing primary endothelial cells, Victoria Seewaldt (Duke University, Durham, NC, USA) for providing the HMEC15-hTERT and HMEC-SR cell lines, and Caroline Alexander for helpful discussion. This work was supported by U.S. National Institutes of Health grants R01EB10039 and NIH T32HL007889 and the University of Wisconsin Graduate Engineering Research Scholars Program. D.J.B. has an ownership interest in BellBrook Labs, LLC (Madison, WI, USA), which has licensed technology presented in this article.	Barreto-Ortiz SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081061; Bischel LL, 2013, BIOMATERIALS, V34, P1471, DOI 10.1016/j.biomaterials.2012.11.005; Bischel LL, 2012, JALA-J LAB AUTOM, V17, P96, DOI 10.1177/2211068211426694; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Choe MM, 2003, AM J PHYSIOL-LUNG C, V285, pL427, DOI 10.1152/ajplung.00005.2003; Chrobak KM, 2006, MICROVASC RES, V71, P185, DOI 10.1016/j.mvr.2006.02.005; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; DuFort CC, 2011, NAT REV MOL CELL BIO, V12, P308, DOI 10.1038/nrm3112; Gjorevski N, 2012, BIOPHYS J, V103, P152, DOI 10.1016/j.bpj.2012.05.048; Gomez EW, 2010, J CELL BIOCHEM, V110, P44, DOI 10.1002/jcb.22545; Goubko CA, 2009, MAT SCI ENG C-MATER, V29, P1855, DOI 10.1016/j.msec.2009.02.016; Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858; Huh D, 2011, TRENDS CELL BIOL, V21, P745, DOI 10.1016/j.tcb.2011.09.005; Jeon JS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056910; Jo BH, 2000, J MICROELECTROMECH S, V9, P76, DOI 10.1109/84.825780; Katoh M, 2005, DRUG METAB DISPOS, V33, P1333, DOI 10.1124/dmd.105.005157; Khanna C, 2005, CARCINOGENESIS, V26, P513, DOI 10.1093/carcin/bgh261; Kim DH, 2012, J CELL BIOL, V197, P351, DOI 10.1083/jcb.201108062; Kim S, 2013, LAB CHIP, V13, P1489, DOI 10.1039/c3lc41320a; Kottakis F, 2011, MOL CELL, V43, P285, DOI 10.1016/j.molcel.2011.06.020; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lee JG, 2006, INVEST OPHTH VIS SCI, V47, P1376, DOI 10.1167/iovs.05-1223; Lee J, 2013, BIOMATERIALS, V34, P8140, DOI 10.1016/j.biomaterials.2013.07.074; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Nelson CM, 2006, SCIENCE, V314, P298, DOI 10.1126/science.1131000; Page H, 2013, CELL TISSUE RES, V352, P123, DOI 10.1007/s00441-012-1441-5; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Peyton SR, 2007, CELL BIOCHEM BIOPHYS, V47, P300, DOI 10.1007/s12013-007-0004-y; Polnaszek N, 2003, CANCER RES, V63, P5754; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rodriguez ML, 2013, APPL MECH REV, V65, DOI 10.1115/1.4025355; Sirica AE, 1997, HEPATOLOGY, V26, P537, DOI 10.1053/jhep.1997.v26.pm0009303480; Sung KE, 2011, INTEGR BIOL-UK, V3, P439, DOI 10.1039/c0ib00063a; Sung KE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076373; Sung KE, 2009, BIOMATERIALS, V30, P4833, DOI 10.1016/j.biomaterials.2009.05.043; Talbot NC, 2002, CELLS TISSUES ORGANS, V171, P99, DOI 10.1159/000063704; Verbridge SS, 2013, J BIOMED MATER RES A, V101, P2948, DOI 10.1002/jbm.a.34587; Walker GM, 2002, LAB CHIP, V2, P131, DOI 10.1039/b204381e; Xue NN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093590; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Zervantonakis IK, 2012, P NATL ACAD SCI USA, V109, P13515, DOI 10.1073/pnas.1210182109; Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053359; Zheng Y, 2012, P NATL ACAD SCI USA, V109, P9342, DOI 10.1073/pnas.1201240109	44	41	41	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4583	4590		10.1096/fj.13-243733	http://dx.doi.org/10.1096/fj.13-243733			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25077562	Green Published			2022-12-28	WOS:000344050900001
J	Moraga, A; Pradillo, JM; Cuartero, MI; Hernandez-Jimenez, M; Oses, M; Moro, MA; Lizasoain, I				Moraga, Ana; Pradillo, Jesus M.; Cuartero, Maria I.; Hernandez-Jimenez, Macarena; Oses, Marta; Moro, Maria A.; Lizasoain, Ignacio			Toll-like receptor 4 modulates cell migration and cortical neurogenesis after focal cerebral ischemia	FASEB JOURNAL			English	Article						innate immunity; neuroblast; proliferation; stroke	SUBVENTRICULAR ZONE; ISCHEMIA/REPERFUSION INJURY; EXPERIMENTAL STROKE; PROGENITOR CELLS; CYCLE LENGTH; ADULT BRAIN; RAT; PROLIFERATION; DAMAGE; TLR4	Toll-like receptor 4 (TLR4) mediates brain damage after stroke. Now our objective is to determine TLR4 involvement in stroke-induced neurogenesis. Stroke was induced by permanent middle cerebral artery occlusion in wild-type and TLR4-deficient mice. Stereological and densitometric analysis of immunofluorescence-labeled brain sections and FACS analysis of cell suspensions were performed. Our results show that subventricular zone (SVZ) cell proliferation after stroke depends on infarct size. Second, when comparing brains with similar lesions, TLR4 attenuated SVZ proliferation, as shown by a decrease in prominin-1(+)/EGFR(+)/nestin(-) cells (type-C cells) at 1-2 d, and in BrdU(+) cells at 7 d, in TLR4(+/+)vs. TLR4(-/-) mice. Interestingly, 7 d after the infarct, neuroblasts in TLR4(+/+) mice migrated farther distances, reaching areas closer to the lesion than those in TLR4-deficient mice. However, at 14 d, TLR4-deficient mice presented a higher number of neuroblasts in all migratory zones than the TLR4(+/+) counterparts, which suggests that TLR4 deficiency delays neuroblast migration. Consistently, TLR4(+/+) mice showed an increased number of interneurons (NeuN(+)/BrdU(+)/GAD67(+) cells) in peri-infarct cortex 14-28 d after stroke. Our data indicate that, despite a negative effect on SVZ cell proliferation, TLR4 plays an important role in stroke-induced neurogenesis by promoting neuroblasts migration and increasing the number of new cortical neurons after stroke.Moraga, A., Pradillo, J. M., Cuartero, M. I., Hernandez-Jimenez, M., Oses, M., Moro, M. A., Lizasoain, I. Toll-like receptor 4 modulates cell migration and cortical neurogenesis after focal cerebral ischemia.	[Moraga, Ana; Pradillo, Jesus M.; Cuartero, Maria I.; Hernandez-Jimenez, Macarena; Oses, Marta; Moro, Maria A.; Lizasoain, Ignacio] Univ Complutense, Fac Med, Dept Farmacol, Unidad Invest Neurovasc, E-28040 Madrid, Spain	Complutense University of Madrid	Lizasoain, I (corresponding author), Univ Complutense, Fac Med, Dept Farmacol, Unidad Invest Neurovasc, Ave Complutense S-N, E-28040 Madrid, Spain.	ignacio.lizasoain@med.ucm.es	Cuartero, Maria Isabel/E-8103-2012; PRADILLO, JESUS M/L-6344-2014; Moraga, Ana/ABD-4248-2020; Moro, María Ángeles/K-6396-2014; Lizasoain, Ignacio/K-9844-2014	Cuartero, Maria Isabel/0000-0003-4728-068X; PRADILLO, JESUS M/0000-0002-8266-7946; Moro, María Ángeles/0000-0003-1010-8237; Lizasoain, Ignacio/0000-0002-6028-7379; Hernandez Jimenez, Macarena/0000-0003-3329-3965; Moraga, Ana/0000-0001-6695-557X	Spanish Ministry of Economy and Innovation [SAF2011-23354, SAF2012-33216, CSD2010-00045]; Spanish Ministry of Health; Fondo Europeo de Desarrollo Regional (FEDER) [RET-ICS RD12/0014/003]; Regional Madrid Government [S2010/BMD-2330, S2010/BMD-2349]	Spanish Ministry of Economy and Innovation(Spanish Government); Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); Fondo Europeo de Desarrollo Regional (FEDER)(European CommissionSpanish Government); Regional Madrid Government	The authors thank Tamara Atones and Roberto Canadas for technical assistance. This work was supported by the Spanish Ministry of Economy and Innovation, grants SAF2011-23354 (I.L.), SAF2012-33216 (M.A.M.), and CSD2010-00045 (M.A.M.); by the Spanish Ministry of Health and Fondo Europeo de Desarrollo Regional (FEDER), RET-ICS RD12/0014/003 (I.L.); and by the Regional Madrid Government, grants S2010/BMD-2330 (M.A.M.) and S2010/BMD-2349 (I.L.). The authors declare no conflicts of interest.	Ao LH, 2009, AM J PHYSIOL-HEART C, V297, pH21, DOI 10.1152/ajpheart.00292.2009; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Campanella M, 2002, STROKE, V33, P586, DOI 10.1161/hs0202.103399; Cao CX, 2007, BIOCHEM BIOPH RES CO, V353, P509, DOI 10.1016/j.bbrc.2006.12.057; Caso JR, 2008, STROKE, V39, P1314, DOI 10.1161/STROKEAHA.107.498212; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; Chong AJ, 2004, J THORAC CARDIOV SUR, V128, P170, DOI 10.1016/j.jtcvs.2003.11.036; Dvoriantchikova G, 2010, MOL VIS, V16, P1907; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Hernandez-Jimenez M, 2013, STROKE, V44, P2333, DOI 10.1161/STROKEAHA.113.001715; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; LaFrance-Corey RG, 2011, JOVE-J VIS EXP, DOI 10.3791/2747; Lee SR, 2006, J NEUROSCI, V26, P3491, DOI 10.1523/JNEUROSCI.4085-05.2006; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Rolls A, 2007, NAT CELL BIOL, V9, P1081, DOI 10.1038/ncb1629; SCHULTZE B, 1981, CELL TISSUE KINET, V14, P309, DOI 10.1111/j.1365-2184.1981.tb00535.x; Sierra A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00006; Smith CM, 1998, DEV DYNAM, V213, P220, DOI 10.1002/(SICI)1097-0177(199810)213:2<220::AID-AJA7>3.0.CO;2-I; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Yan YP, 2007, J CEREBR BLOOD F MET, V27, P1213, DOI 10.1038/sj.jcbfm.9600432; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhang RL, 2006, J CEREBR BLOOD F MET, V26, P857, DOI 10.1038/sj.jcbfm.9600237	29	45	47	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4710	4718		10.1096/fj.14-252452	http://dx.doi.org/10.1096/fj.14-252452			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25063846				2022-12-28	WOS:000344050900012
J	Ho, IAW; Yulyana, Y; Sia, KC; Newman, JP; Guo, CM; Hui, KM; Lam, PYP				Ho, Ivy A. W.; Yulyana, Yulyana; Sia, Kian C.; Newman, Jennifer P.; Guo, Chang M.; Hui, Kam M.; Lam, Paula Y. P.			Matrix metalloproteinase-1-mediated mesenchymal stem cell tumor tropism is dependent on crosstalk with stromal derived growth factor 1/C-X-C chemokine receptor 4 axis	FASEB JOURNAL			English	Article						migration; MSCs; MMP-1; SDF-1; CXCR-4	PROTEASE-ACTIVATED RECEPTORS; BONE-MARROW; HEMATOPOIETIC STEM; PROGENITOR CELLS; CANCER CELLS; IN-VITRO; MIGRATION; CXCR4; EXPRESSION; THROMBIN	Human bone marrow-derived mesenchymal stem cells (MSCs) have the unique ability to home toward injuries or tumor sites. We have previously shown that the tumor-tropic property is dependent on the intrinsic expression and activity of the matrix remodeling gene, matrix metalloproteinase 1 (MMP-1). Herein, crosstalk between MMP-1/protease activated receptor 1 (PAR-1) and the G-protein coupled receptor stromal-derived growth factor 1 (SDF-1)/C-X-C chemokine receptor 4 (CXCR-4) in facilitating cell migration was investigated. Gain-of-function and RNA interference (RNAi) technology were used to evaluate the interplay between the key players. The downstream effect on the tumor-tropic migration of MSCs was investigated using modified Boyden chamber assay. Neutralizing PAR-1 activation using monoclonal antibody and targeted knockdown of MMP-1 using RNAi resulted in decreased expression of SDF-1, which was not observed in control-RNAi-transfected cells. Overexpression of CXCR-4 failed to promote MSC migration; the percentage of migrated cells toward tumor cell conditioned medium was similar to the vector-transduced and the CXCR-4-transduced MSCs. Furthermore, inhibition of SDF-1/CXCR-4 signaling using AMD3100 reduced MSC migration through the deregulation of MMP-1 promoter activities, protein expression, and metalloproteinase activity. Collectively, our results showed that MMP-1-mediated MSC tumor tropism is dependent on crosstalk with the SDF-1/CXCR-4 axis.	[Ho, Ivy A. W.; Yulyana, Yulyana; Sia, Kian C.; Newman, Jennifer P.; Lam, Paula Y. P.] Natl Canc Ctr, Humphrey Oei Inst Canc Res, Cellular & Mol Res Div, Lab Canc Gene Therapy, Singapore 169610, Singapore; [Hui, Kam M.] Natl Canc Ctr, Humphrey Oei Inst Canc Res, Cellular & Mol Res Div, Bek Chai Heah Lab Canc Gen, Singapore 169610, Singapore; [Guo, Chang M.] Singapore Gen Hosp, Dept Orthoped, Singapore, Singapore; [Hui, Kam M.; Lam, Paula Y. P.] Duke Natl Univ Singapore, Grad Sch Med, Canc & Stem Cells Biol Program, Singapore, Singapore	National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS); Singapore General Hospital; National University of Singapore	Lam, PYP (corresponding author), Natl Canc Ctr, Humphrey Oei Inst Canc Res, Cellular & Mol Res Div, Lab Canc Gene Therapy, 11 Hosp Dr, Singapore 169610, Singapore.	cmrlyp@nccs.com.sg	Ho, Ivy/T-4396-2019; Sia, Kian Chuan/AAI-4036-2021	Sia, Kian Chuan/0000-0002-2729-6345; Ho, Ivy/0000-0002-2948-3726; Hui, Kam/0000-0003-1820-1399	Singapore Stem Cells Consortium [SSCC/08/143]	Singapore Stem Cells Consortium	The authors thank Dr. Constance E. Brinckerhoff (Dartmouth Hitchcock Medical Center, Lebanon, NH, USA) for providing the MMP-1-Luc plasmid and Dr. Mark Penfold (ChemoCentryx, Mountain View, CA, USA) for providing the CXCR7 inhibitors. This work is funded by the Singapore Stem Cells Consortium (SSCC/08/143), and the authors thank the National Cancer Centre and National Medical Research (Singapore) for institutional support. The authors declare no conflicts of interest.	Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Bergmann S, 2006, ONCOL REP, V15, P889; Blackburn JS, 2009, ONCOGENE, V28, P4237, DOI 10.1038/onc.2009.272; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Carbajal KS, 2010, P NATL ACAD SCI USA, V107, P11068, DOI 10.1073/pnas.1006375107; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; Coughlin SR, 2005, J THROMB HAEMOST, V3, P1800, DOI 10.1111/j.1538-7836.2005.01377.x; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Cubedo N, 2009, MOL CELL NEUROSCI, V40, P474, DOI 10.1016/j.mcn.2009.01.003; Dar A, 2006, EXP HEMATOL, V34, P967, DOI 10.1016/j.exphem.2006.04.002; Darmoul D, 2004, MOL CANCER RES, V2, P514; Decaillot FM, 2011, J BIOL CHEM, V286, P32188, DOI 10.1074/jbc.M111.277038; Dillmann F, 2009, LEUKEMIA LYMPHOMA, V50, P1676, DOI 10.1080/10428190903150847; Eck SM, 2009, MOL CANCER RES, V7, P1033, DOI 10.1158/1541-7786.MCR-09-0015; Galipeau J, 2013, CYTOTHERAPY, V15, P2, DOI 10.1016/j.jcyt.2012.10.002; Ghadge SK, 2011, PHARMACOL THERAPEUT, V129, P97, DOI 10.1016/j.pharmthera.2010.09.011; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Ho IAW, 2008, CANCER GENE THER, V15, P553, DOI 10.1038/cgt.2008.27; Ho IAW, 2013, HISTOL HISTOPATHOL, V28, P1427, DOI 10.14670/HH-28.1427; Ho IAW, 2009, STEM CELLS, V27, P1366, DOI 10.1002/stem.50; Huang W, 2012, STEM CELLS DEV, V21, P778, DOI 10.1089/scd.2011.0126; Ip JE, 2007, MOL BIOL CELL, V18, P2873, DOI 10.1091/mbc.E07-02-0166; Janowska-Wieczorek A, 2000, EXP HEMATOL, V28, P1274, DOI 10.1016/S0301-472X(00)00532-4; Jones SW, 2006, OSTEOARTHR CARTILAGE, V14, P597, DOI 10.1016/j.joca.2006.01.007; Kaufmann R, 2007, J CELL PHYSIOL, V211, P699, DOI 10.1002/jcp.21027; Kim SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025103; Kitaori T, 2009, ARTHRITIS RHEUM-US, V60, P813, DOI 10.1002/art.24330; Lee Y, 2010, EXP DERMATOL, V19, pE44, DOI 10.1111/j.1600-0625.2009.00963.x; Li G, 2013, ONCOL REP, V29, P563, DOI 10.3892/or.2012.2164; Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007-0054; Park SA, 2011, INT J ONCOL, V38, P97, DOI 10.3892/ijo_00000828; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Reagan MR, 2011, STEM CELLS, V29, P920, DOI 10.1002/stem.645; Ryu CH, 2010, BIOCHEM BIOPH RES CO, V398, P105, DOI 10.1016/j.bbrc.2010.06.043; Sasportas LS, 2009, P NATL ACAD SCI USA, V106, P4822, DOI 10.1073/pnas.0806647106; Smadja DM, 2005, ARTERIOSCL THROM VAS, V25, P2321, DOI 10.1161/01.ATV.0000184762.63888.bd; Sonabend AM, 2008, STEM CELLS, V26, P831, DOI 10.1634/stemcells.2007-0758; Song CH, 2011, J VIROL, V85, P11069, DOI 10.1128/JVI.05318-11; Song C, 2011, CYTOTHERAPY, V13, P549, DOI 10.3109/14653249.2010.542457; Sun XJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-17; Trivedi V, 2009, CELL, V137, P332, DOI 10.1016/j.cell.2009.02.018; Wang Y, 2008, BRAIN RES, V1195, P104, DOI 10.1016/j.brainres.2007.11.068; Wang YG, 2012, EXP MOL MED, V44, P387, DOI 10.3858/emm.2012.44.6.044; Wautier F, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-104; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Zhan Y, 2012, EXP CELL RES, V318, P1641, DOI 10.1016/j.yexcr.2012.05.002	46	32	34	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4359	4368		10.1096/fj.14-252551	http://dx.doi.org/10.1096/fj.14-252551			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25271298				2022-12-28	WOS:000342222700015
J	Cook, KL; Clarke, PAG; Parmar, J; Hu, R; Schwartz-Roberts, JL; Abu-Asab, M; Warri, A; Baumann, WT; Clarke, R				Cook, Katherine L.; Clarke, Pamela A. G.; Parmar, Jignesh; Hu, Rong; Schwartz-Roberts, Jessica L.; Abu-Asab, Mones; Waerri, Anni; Baumann, William T.; Clarke, Robert			Knockdown of estrogen receptor-alpha induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death	FASEB JOURNAL			English	Article						fulvestrant; ICI 182780; apoptosis; reactive oxygen species	BOX BINDING PROTEIN-1; ACQUIRED-RESISTANCE; FACTOR-I; APOPTOSIS; MACROAUTOPHAGY; MITOCHONDRIA; EXPRESSION; INDUCTION; CONFERS	Approximately 70% of all newly diagnosed breast cancers express estrogen receptor (ER)-alpha. Although inhibiting ER action using targeted therapies such as fulvestrant (ICI) is often effective, later emergence of antiestrogen resistance limits clinical use. We used antiestrogen-sensitive and -resistant cells to determine the effect of antiestrogens/ER alpha on regulating autophagy and unfolded protein response (UPR) signaling. Knockdown of ER alpha significantly increased the sensitivity of LCC1 cells (sensitive) and also resensitized LCC9 cells (resistant) to antiestrogen drugs. Interestingly, ER alpha knockdown, but not ICI, reduced nuclear factor (erythroid-derived 2)-like (NRF)-2 (UPR-induced antioxidant protein) and increased cytosolic kelch-like ECH-associated protein (KEAP)-1 (NRF2 inhibitor), consistent with the observed increase in ROS production. Furthermore, autophagy induction by antiestrogens was prosurvival but did not prevent ER alpha knockdown-mediated death. We built a novel mathematical model to elucidate the interactions among UPR, autophagy, ER signaling, and ROS regulation of breast cancer cell survival. The experimentally validated mathematical model explains the counterintuitive result that knocking down the main target of ICI (ER alpha) increased the effectiveness of ICI. Specifically, the model indicated that ER alpha is no longer present in excess and that the effect on proliferation from further reductions in its level by ICI cannot be compensated for by increased autophagy. The stimulation of signaling that can confer resistance suggests that combining autophagy or UPR inhibitors with antiestrogens would reduce the development of resistance in some breast cancers.	[Cook, Katherine L.; Clarke, Pamela A. G.; Hu, Rong; Schwartz-Roberts, Jessica L.; Waerri, Anni; Clarke, Robert] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20057 USA; [Cook, Katherine L.; Clarke, Pamela A. G.; Hu, Rong; Schwartz-Roberts, Jessica L.; Waerri, Anni; Clarke, Robert] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; [Parmar, Jignesh] Virginia Polytech Inst & State Univ, Dept Biol Sci, Blacksburg, VA 24061 USA; [Baumann, William T.] Virginia Polytech Inst & State Univ, Bradley Dept Elect & Comp Engn, Blacksburg, VA 24061 USA; [Abu-Asab, Mones] NEI, US NIH, Immunopathol Sect, Bethesda, MD 20892 USA; [Abu-Asab, Mones] NEI, US NIH, Immunol Lab, Bethesda, MD 20892 USA	Georgetown University; Georgetown University; Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Clarke, R (corresponding author), Georgetown Univ, Med Ctr, W405A Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	clarker@georgetown.edu	Clarke, Robert/A-6485-2008	Clarke, Robert/0000-0002-9278-0854; Warri, Anni/0000-0002-0535-847X; Cook, Katherine/0000-0001-6241-0214	U.S. Department of Defense Breast Cancer Research Program Postdoctoral Fellowship [BC112023]; U.S. Department of Health and Human Services [U54-CA149147, R01-CA131465]; NATIONAL CANCER INSTITUTE [U01CA184902, U54CA149147, R01CA131465, T32CA009686] Funding Source: NIH RePORTER	U.S. Department of Defense Breast Cancer Research Program Postdoctoral Fellowship(United States Department of Defense); U.S. Department of Health and Human Services; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by a U.S. Department of Defense Breast Cancer Research Program Postdoctoral Fellowship (BC112023; to K. C.) and in part by awards from the U.S. Department of Health and Human Services (U54-CA149147 and R01-CA131465) (to R. C.). The authors declare no conflicts of interest.	Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Brunner N, 1997, CANCER RES, V57, P3486; BRUNNER N, 1993, CANCER RES, V53, P283; Chen CS, 2013, NEUROENDOCRINOLOGY, V97, P232, DOI 10.1159/000342692; Clarke R, 2001, J STEROID BIOCHEM, V76, P71, DOI 10.1016/S0960-0760(00)00193-X; Clarke R, 2001, PHARMACOL REV, V53, P25; Clarke R, 2012, CANCER RES, V72, P1321, DOI 10.1158/0008-5472.CAN-11-3213; Clarke Robert, 2011, Horm Mol Biol Clin Investig, V5, P35, DOI 10.1515/HMBCI.2010.073; Clarke R, 2009, J STEROID BIOCHEM, V114, P8, DOI 10.1016/j.jsbmb.2008.12.023; Cook KL, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-16; Cook KL, 2013, FUTURE MED CHEM, V5, P1047, DOI 10.4155/fmc.13.77; Cook KL, 2012, AUTOPHAGY, V8, P1827, DOI 10.4161/auto.21765; Cook KL, 2011, EXPERT REV ANTICANC, V11, P1283, DOI [10.1586/ERA.11.111, 10.1586/era.11.111]; Crawford AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008604; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Gomez BP, 2007, FASEB J, V21, P4013, DOI 10.1096/fj.06-7990com; Gu ZP, 2002, CANCER RES, V62, P3428; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Ishii Y, 2011, CLIN CANCER RES, V17, P2292, DOI 10.1158/1078-0432.CCR-10-1745; Jager R, 2012, BIOL CELL, V104, P259, DOI 10.1111/boc.201100055; Kiewlich D., 2009, THESIS U CALIFORNIA; Kuske B, 2006, ENDOCR-RELAT CANCER, V13, P1121, DOI 10.1677/erc.1.01257; Long XH, 2006, J BIOL CHEM, V281, P9607, DOI 10.1074/jbc.M510809200; Lozon TI, 2011, AM J PHYSIOL-LUNG C, V300, pL422, DOI 10.1152/ajplung.00166.2010; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Mattingly KA, 2008, MOL ENDOCRINOL, V22, P609, DOI 10.1210/me.2007-0029; Papa L, 2011, J CELL SCI, V124, P1396, DOI 10.1242/jcs.078220; Parmar JH, 2013, INTERFACE FOCUS, V3, DOI 10.1098/rsfs.2013.0012; Pedram A, 2006, MOL BIOL CELL, V17, P2125, DOI 10.1091/mbc.E05-11-1013; Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4; Riggins RB, 2005, VITAM HORM, V71, P201, DOI 10.1016/S0083-6729(05)71007-4; Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447; Schoenlein PV, 2009, AUTOPHAGY, V5, P400, DOI 10.4161/auto.5.3.7784; Scriven P, 2009, BRIT J CANCER, V101, P1692, DOI 10.1038/sj.bjc.6605365; Shajahan AN, 2009, DRUG NEWS PERSPECT, V22, P241, DOI 10.1358/dnp.2009.22.5.1378631; Soto-Pantoja DR, 2012, AUTOPHAGY, V8, P1628, DOI 10.4161/auto.21562; Verfaillie T, 2010, CANC LETT, V332, P249; Verfaillie T, 2010, INT J CELL BIOL, V2010; Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996	43	56	57	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3891	3905		10.1096/fj.13-247353	http://dx.doi.org/10.1096/fj.13-247353			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24858277	Green Published			2022-12-28	WOS:000340845900008
J	Jiang, H; Stabler, SP; Allen, RH; Abman, SH; Maclean, KN				Jiang, Hua; Stabler, Sally P.; Allen, Robert H.; Abman, Steven H.; Maclean, Kenneth N.			Altered hepatic sulfur metabolism in cystathionine beta-synthase-deficient homocystinuria: regulatory role of taurine on competing cysteine oxidation pathways	FASEB JOURNAL			English	Article						glutamic-oxaloacetic transaminase; thiol metabolism; transsulfuration; cysteinesulfinate decarboxylase	IN-VITRO; DIOXYGENASE; HOMOCYSTEINE; CHLORAMINE; ENZYMES; MODEL; BIOSYNTHESIS; NEUTROPHILS; EXPRESSION; GENERATION	Cystathionine beta-synthase-deficient homocystinuria (HCU) is a serious life-threatening inborn error of sulfur metabolism with poorly understood pathogenic mechanisms. We investigated the effect of HCU on hepatic cysteine oxidation in a transgenic mouse model of the disease. Cysteine dioxygenase (CDO) protein levels were 90% repressed without any change in mRNA levels. Cysteinesulfinic acid decarboxylase (CSAD) was induced at both the mRNA (8-fold) and protein (15-fold) levels. Cysteine supplementation normalized CDO protein levels without reversing the induction of CSAD. Regulatory changes in CDO and CSAD expression were proportional to homocysteine elevation, indicating a possible threshold effect. Hepatic and blood taurine levels in HCU animals were decreased by 21 and 35%, respectively, and normalized by cysteine supplementation. Expression of the cytoplasmic (GOT1) and mitochondrial (GOT2) isoforms of glutamic-oxaloacetic transaminase were repressed in HCU animals by 86 and 30%, respectively. HCU induced regulatory changes in CSAD, CDO, and GOT1 expression were normalized by taurine supplementation, indicating that cysteine is not the only sulfur compound that regulates hepatic cysteine oxidation. Collectively, our results indicate that HCU induces significant alterations of sulfur metabolism with the potential to contribute to pathogenesis and that cysteine and taurine have the potential to serve as adjunctive treatments in this disease.	[Jiang, Hua; Abman, Steven H.; Maclean, Kenneth N.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO 80045 USA; [Stabler, Sally P.; Allen, Robert H.] Univ Colorado, Hlth Sci Ctr, Dept Med, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Maclean, KN (corresponding author), Univ Colorado, Sch Med, Dept Pediat, Mail Stop 8313, Aurora, CO 80045 USA.	ken.maclean@ucdenver.edu			William R. Hummel Homocystinuria Research Fund; Hayley's Heroes research fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068702] Funding Source: NIH RePORTER	William R. Hummel Homocystinuria Research Fund; Hayley's Heroes research fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	K.N.M. gratefully acknowledges financial support from the William R. Hummel Homocystinuria Research Fund and Hayley's Heroes research fund. The authors thank Professor Martha Stipanuk (Cornell University, Ithaca, NY, USA) for useful discussions and Dr. Joe Hurt (University of Colorado) for critical reading of the manuscript.	Adam S, 2013, MOL GENET METAB, V110, P454, DOI 10.1016/j.ymgme.2013.10.003; Bella DL, 1999, AM J PHYSIOL-ENDOC M, V276, pE326, DOI 10.1152/ajpendo.1999.276.2.E326; Bella DL, 1999, AM J PHYSIOL-ENDOC M, V277, pE144, DOI 10.1152/ajpendo.1999.277.1.E144; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Gupta S, 2014, FASEB J, V28, P781, DOI 10.1096/fj.13-240770; HIRAI T, 1987, ANAL BIOCHEM, V163, P339, DOI 10.1016/0003-2697(87)90233-8; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; Jerkins AA, 1998, J NUTR, V128, P1890, DOI 10.1093/jn/128.11.1890; Jiang H, 2012, MOL GENET METAB, V107, P55, DOI 10.1016/j.ymgme.2012.04.025; Keating AK, 2011, MOL GENET METAB, V103, P330, DOI 10.1016/j.ymgme.2011.04.012; Kerr TA, 2014, HEPATOL RES, V44, pE218, DOI 10.1111/hepr.12230; Lee JI, 2004, J NUTR BIOCHEM, V15, P112, DOI 10.1016/j.jnutbio.2003.10.005; Lee PJ, 2007, J INHERIT METAB DIS, V30, P35, DOI 10.1007/s10545-006-0452-3; Maclean KN, 2012, J BIOL CHEM, V287, P31994, DOI 10.1074/jbc.M112.355172; Maclean KN, 2012, MOL GENET METAB, V105, P395, DOI 10.1016/j.ymgme.2011.11.190; Maclean KN, 2010, MOL GENET METAB, V101, P153, DOI 10.1016/j.ymgme.2010.06.010; Maclean KN, 2010, MOL GENET METAB, V101, P163, DOI 10.1016/j.ymgme.2010.06.007; Maclean KN, 2002, HUM MUTAT, V19, P641, DOI 10.1002/humu.10089; Marcinkiewicz J, 1995, J LEUKOCYTE BIOL, V58, P667, DOI 10.1002/jlb.58.6.667; McCoy JG, 2006, P NATL ACAD SCI USA, V103, P3084, DOI 10.1073/pnas.0509262103; Mudd S., 2001, METABOLIC MOL BASES, P2007; PANTEGHINI M, 1990, CLIN BIOCHEM, V23, P311, DOI 10.1016/0009-9120(90)80062-N; Qusti S, 2000, CELL BIOL TOXICOL, V16, P243, DOI 10.1023/A:1007634110983; RENTSCHLER LA, 1986, COMP BIOCHEM PHYS B, V84, P319, DOI 10.1016/0305-0491(86)90084-2; Sadiq MA, 2013, SEMIN OPHTHALMOL, V28, P313, DOI 10.3109/08820538.2013.825276; Schiff M, 2012, NEUROPEDIATRICS, V43, P295, DOI 10.1055/s-0032-1329883; STABLER SP, 1993, BLOOD, V81, P3404; Stipanuk MH, 2011, J INHERIT METAB DIS, V34, P17, DOI 10.1007/s10545-009-9006-9; STURMAN JA, 1993, PHYSIOL REV, V73, P119, DOI 10.1152/physrev.1993.73.1.119; Tang XW, 1997, J NEUROSCI, V17, P6947; Tsuboyama-Kasaoka N, 2006, ENDOCRINOLOGY, V147, P3276, DOI 10.1210/en.2005-1007; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Wojtecka-Lukasik E, 2006, INFLAMM RES, V55, pS17, DOI 10.1007/s00011-005-0021-5; Wojtecka-Lukasik E, 2005, INFLAMM RES, V54, pS21, DOI 10.1007/s00011-004-0409-3; Wu JY, 1998, ADV EXP MED BIOL, V442, P339; Ye S, 2007, J BIOL CHEM, V282, P3391, DOI 10.1074/jbc.M609337200	36	17	17	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4044	4054		10.1096/fj.14-253633	http://dx.doi.org/10.1096/fj.14-253633			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24891521	Green Published			2022-12-28	WOS:000340845900022
J	Norouzitallab, P; Baruah, K; Vandegehuchte, M; Van Stappen, G; Catania, F; Vanden Bussche, J; Vanhaecke, L; Sorgeloos, P; Bossier, P				Norouzitallab, Parisa; Baruah, Kartik; Vandegehuchte, Michiel; Van Stappen, Gilbert; Catania, Francesco; Vanden Bussche, Julie; Vanhaecke, Lynn; Sorgeloos, Patrick; Bossier, Peter			Environmental heat stress induces epigenetic transgenerational inheritance of robustness in parthenogenetic Artemia model	FASEB JOURNAL			English	Article						heat shock protein 70; DNA methylation; histone modification; stress resistance; heritability	SHOCK-PROTEIN 70S; HISTONE MODIFICATIONS; GENOME INSTABILITY; DNA METHYLATION; HSP70 GENE; FRANCISCANA; TEMPERATURE; ACETYLATION; ARABIDOPSIS; RESISTANCE	The notion that phenotypic traits emerging from environmental experiences are heritable remains under debate. However, the recent report of nonmendelian transgenerational epigenetic inheritance, i.e., the inheritance of traits not determined by the DNA sequence, might make such a phenomenon plausible. In our study, by carrying out common garden experiments, we could provide clear evidences that, on exposure to nonlethal heat shocks, a parental population of parthenogenetic (all female) Artemia (originating from one single female) experiences an increase in levels of Hsp70 production, tolerance toward lethal heat stress, and resistance against pathogenic Vibrio campbellii. Interestingly, these acquired phenotypic traits were transmitted to three successive generations, none of which were exposed to the parental stressor. This transgenerational inheritance of the acquired traits was associated with altered levels of global DNA methylation and acetylated histones H3 and H4 in the heat-shocked group compared to the control group, where both the parental and successive generations were reared at standard temperature. These results indicated that epigenetic mechanisms, such as global DNA methylation and histones H3 and H4 acetylation, have particular dynamics that are crucial in the heritability of the acquired adaptive phenotypic traits across generations.	[Norouzitallab, Parisa; Baruah, Kartik; Van Stappen, Gilbert; Sorgeloos, Patrick; Bossier, Peter] Univ Ghent, Lab Aquaculture, B-9000 Ghent, Belgium; [Norouzitallab, Parisa; Baruah, Kartik; Van Stappen, Gilbert; Sorgeloos, Patrick; Bossier, Peter] Univ Ghent, Artemia Reference Ctr, B-9000 Ghent, Belgium; [Vandegehuchte, Michiel] Univ Ghent, Lab Environm Toxicol & Aquat Ecol, B-9000 Ghent, Belgium; [Catania, Francesco] Univ Munster, Inst Evolut & Biodivers, D-48149 Munster, Germany; [Vanden Bussche, Julie; Vanhaecke, Lynn] Univ Ghent, Chem Anal Lab, Merelbeke, Belgium	Ghent University; Ghent University; Ghent University; University of Munster; Ghent University	Bossier, P (corresponding author), Univ Ghent, Lab Aquaculture, Rozier 44, B-9000 Ghent, Belgium.	peter.bossier@ugent.be	catania, francesco/AAW-1190-2020; Baruah, Kartik/ABG-1532-2020; Vanden Bussche, Julie/K-5134-2014; Bossier, Peter GM/A-8118-2008; Vanhaecke, Lynn/N-1061-2017	Baruah, Kartik/0000-0002-2060-4982; Vanden Bussche, Julie/0000-0002-3831-6663; Bossier, Peter GM/0000-0002-6165-9111; Catania, Francesco/0000-0002-2652-9397; Vandegehuchte, Michiel/0000-0002-3915-4416; Vanhaecke, Lynn/0000-0003-0400-2188; Norouzitallab, Parisa/0000-0002-1740-0444	Ghent University (BOF-PhD grant) [BOF10/DOS/031]; Belgian Science Policy Office (Belspo) AquaStress project [IUAPVII/64]; Special Research Fund of Ghent University [BOF12/BAS/042]	Ghent University (BOF-PhD grant); Belgian Science Policy Office (Belspo) AquaStress project; Special Research Fund of Ghent University(Ghent University)	This study was supported by Ghent University (BOF-PhD grant to P.N.; BOF10/DOS/031) and the Belgian Science Policy Office (Belspo) AquaStress project (IUAPVII/64/Sorgeloos). K. B. is a postdoctoral fellow of Research Foundation Flanders (FWO; Brussels, Belgium). The authors highly acknowledge the Special Research Fund of Ghent University (BOF12/BAS/042) for procuring the chemiluminescence detection system. The authors highly thank the technical staffs of the Laboratory of Aquaculture and the Artemia Reference Center at Ghent University, in particular Christ Mahieu, Anita De Haese, Brigitte Van Moffaert, and Tom Baelemans, for their assistance in rearing the animals.	Abatzopoulos TJ, 2003, HYDROBIOLOGIA, V492, P191, DOI 10.1023/A:1024826702830; Aguilera O, 2010, J APPL PHYSIOL, V109, P243, DOI 10.1152/japplphysiol.00068.2010; Ahuja I, 2010, TRENDS PLANT SCI, V15, P664, DOI 10.1016/j.tplants.2010.08.002; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Baruah K, 2013, FISH SHELLFISH IMMUN, V34, P183, DOI 10.1016/j.fsi.2012.10.025; Baruah K, 2012, AQUACULTURE, V334, P152, DOI 10.1016/j.aquaculture.2011.12.015; Baruah K, 2011, FISH SHELLFISH IMMUN, V31, P134, DOI 10.1016/j.fsi.2011.04.008; Baruah K, 2010, FISH SHELLFISH IMMUN, V29, P733, DOI 10.1016/j.fsi.2010.07.011; Baxevanis Athanasios D., 2004, Journal of Biological Research (Thessaloniki), V1, P107; Benyshek DC, 2006, DIABETOLOGIA, V49, P1117, DOI 10.1007/s00125-006-0196-5; Bilichak A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030515; Bossdorf O, 2008, ECOL LETT, V11, P106, DOI 10.1111/j.1461-0248.2007.01130.x; Boyko A, 2011, CURR OPIN PLANT BIOL, V14, P260, DOI 10.1016/j.pbi.2011.03.003; Boyko A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009514; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briski E, 2008, AQUACULTURE, V282, P19, DOI 10.1016/j.aquaculture.2008.06.034; Cannuyer J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058743; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Chen T, 2002, ARCH BIOCHEM BIOPHYS, V408, P171, DOI 10.1016/S0003-9861(02)00564-7; Clegg JS, 2000, J EXP MAR BIOL ECOL, V252, P85, DOI 10.1016/S0022-0981(00)00239-2; Correia B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053543; Crow JF, 2002, EVOLUTION, V56, P1313; De Block M, 2011, CURR OPIN PLANT BIOL, V14, P275, DOI 10.1016/j.pbi.2011.02.007; Drinkwater L.E., 1991, EXPT BIOL CYST DIAPA, P93; Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142; Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772; Franklin TB, 2010, BIOL PSYCHIAT, V68, P408, DOI 10.1016/j.biopsych.2010.05.036; Fritah S, 2009, MOL BIOL CELL, V20, P4976, DOI 10.1091/mbc.E09-04-0295; Gan JK, 2013, GENET MOL RES, V12, P809, DOI 10.4238/2013.March.15.1; Grant-Downton RT, 2006, ANN BOT-LONDON, V97, P11, DOI 10.1093/aob/mcj001; Grossniklaus U, 2013, NAT REV GENET, V14, P228, DOI 10.1038/nrg3435; Holderegger R, 2006, LANDSCAPE ECOL, V21, P793, DOI 10.1007/s10980-005-6058-6; Holliday R, 2006, EPIGENETICS-US, V1, P76, DOI 10.4161/epi.1.2.2762; Ismaeil I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054306; Iwama GK, 1998, REV FISH BIOL FISHER, V8, P35, DOI 10.1023/A:1008812500650; Jablonka E, 2002, ANN NY ACAD SCI, V981, P82; Jablonka E, 2013, PROG BIOPHYS MOL BIO, V111, P99, DOI 10.1016/j.pbiomolbio.2012.08.014; Jensen LT, 2008, CELL STRESS CHAPERON, V13, P177, DOI 10.1007/s12192-008-0020-x; Johannes F, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000530; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Koturbash I, 2006, INT J RADIAT ONCOL, V66, P327, DOI 10.1016/j.ijrobp.2006.06.012; Kultz D, 2003, J EXP BIOL, V206, P3119, DOI 10.1242/jeb.00549; Lim Unhee, 2012, Methods Mol Biol, V863, P359, DOI 10.1007/978-1-61779-612-8_23; Mirouze M, 2011, CURR OPIN PLANT BIOL, V14, P267, DOI 10.1016/j.pbi.2011.03.004; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Myers FA, 2001, J BIOL CHEM, V276, P20197, DOI 10.1074/jbc.M009472200; Nambu Z, 2008, J EXP ZOOL PART A, V309A, P17, DOI 10.1002/jez.428; Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491; Paszkowski J, 2011, CURR OPIN PLANT BIOL, V14, P195, DOI 10.1016/j.pbi.2011.01.002; Pecinka A, 2012, PLANT CELL PHYSIOL, V53, P801, DOI 10.1093/pcp/pcs044; Quinlivan EP, 2008, ANAL BIOCHEM, V373, P383, DOI 10.1016/j.ab.2007.09.031; Richards EJ, 2008, CURR OPIN GENET DEV, V18, P221, DOI 10.1016/j.gde.2008.01.014; Roberts RJ, 2010, J FISH DIS, V33, P789, DOI 10.1111/j.1365-2761.2010.01183.x; SANDERS BM, 1993, CRIT REV TOXICOL, V23, P49, DOI 10.3109/10408449309104074; Seong KH, 2011, CELL, V145, P1049, DOI 10.1016/j.cell.2011.05.029; Shankar S, 2013, PHARMACOL THERAPEUT, V138, P1, DOI 10.1016/j.pharmthera.2012.11.002; Sorgeloos P., 1980, USE BRINE SHRIMP ART, V3, P25; Sung YY, 2012, J FISH DIS, V35, P563, DOI 10.1111/j.1365-2761.2012.01397.x; Sung YY, 2007, FISH SHELLFISH IMMUN, V22, P318, DOI 10.1016/j.fsi.2006.05.008; Suter L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060364; Tetievsky A, 2010, J APPL PHYSIOL, V109, P1552, DOI 10.1152/japplphysiol.00469.2010; Thomson S, 2004, MOL CELL, V15, P585, DOI 10.1016/j.molcel.2004.08.002; Van Stappen G., 1996, INTRO BIOL ECOLOGY A, P101; Vandegehuchte MB, 2014, MUTAT RES-GEN TOX EN, V764, P36, DOI 10.1016/j.mrgentox.2013.08.008; Vandegehuchte MB, 2010, COMP BIOCHEM PHYS C, V151, P278, DOI 10.1016/j.cbpc.2009.11.007; Vanschoenwinkel B, 2010, AQUAT ECOL, V44, P771, DOI 10.1007/s10452-010-9315-y; Verhoeven KJF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038605; Verhoeven KJF, 2010, NEW PHYTOL, V185, P1108, DOI 10.1111/j.1469-8137.2009.03121.x; Whittle CA, 2009, BOTANY, V87, P650, DOI 10.1139/B09-030; Zhao YM, 2006, CELL RES, V16, P566, DOI 10.1038/sj.cr.7310074; Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905	71	77	80	1	74	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3552	3563		10.1096/fj.14-252049	http://dx.doi.org/10.1096/fj.14-252049			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24755740				2022-12-28	WOS:000340265400024
J	Kampf, C; Mardinoglu, A; Fagerberg, L; Hallstrom, BM; Edlund, K; Lundberg, E; Ponten, F; Nielsen, J; Uhlen, M				Kampf, Caroline; Mardinoglu, Adil; Fagerberg, Linn; Hallstrom, Bjorn M.; Edlund, Karolina; Lundberg, Emma; Ponten, Fredrik; Nielsen, Jens; Uhlen, Mathias			The human liver-specific proteome defined by transcriptomics and antibody-based profiling	FASEB JOURNAL			English	Article						immunohistochemistry; RNA sequencing; metabolism	GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; HEPATITIS-C; RNA-SEQ; METABOLISM; SERUM; INTEGRATION; DISEASES; DRUGS	Human liver physiology and the genetic etiology of the liver diseases can potentially be elucidated through the identification of proteins with enriched expression in the liver. Here, we combined data from RNA sequencing (RNA-Seq) and antibody-based immunohistochemistry across all major human tissues to explore the human liver proteome with enriched expression, as well as the cell type-enriched expression in hepatocyte and bile duct cells. We identified in total 477 protein-coding genes with elevated expression in the liver: 179 genes have higher expression as compared to all the other analyzed tissues; 164 genes have elevated transcript levels in the liver shared with at least one other tissue type; and an additional 134 genes have a mild level of increased expression in the liver. We identified the precise localization of these proteins through antibody-based protein profiling and the subcellular localization of these proteins through immunofluorescent-based profiling. We also identified the biological processes and metabolic functions associated with these proteins, investigated their contribution in the occurrence of liver diseases, and identified potential targets for their treatment. Our study demonstrates the use of RNA-Seq and antibody-based immunohistochemistry for characterizing the human liver proteome, as well as the use of tissue-specific proteins in identification of novel drug targets and discovery of biomarkers.	[Kampf, Caroline; Edlund, Karolina; Ponten, Fredrik] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden; [Mardinoglu, Adil; Nielsen, Jens] Chalmers Univ Technol, Dept Chem & Biol Engn, S-41296 Gothenburg, Sweden; [Fagerberg, Linn; Hallstrom, Bjorn M.; Lundberg, Emma; Nielsen, Jens] Royal Inst Technol KTH, Sci Life Lab, SE-17121 Stockholm, Sweden; [Uhlen, Mathias] Royal Inst Technol KTH, Dept Prote, Sch Biotechnol, SE-17121 Stockholm, Sweden	Uppsala University; Chalmers University of Technology; Royal Institute of Technology; Royal Institute of Technology	Uhlen, M (corresponding author), Royal Inst Technol KTH, AlbaNova Univ Ctr, SE-17121 Stockholm, Sweden.	mathias.uhlen@scilifelab.se	Uhlen, Mathias/B-3262-2016; Uhlen, Mathias/AAV-8746-2021; Mardinoglu, Adil/AAS-6360-2021; Lundberg, Emma S K/F-3891-2010; Nielsen, Jens/Q-1347-2017	Uhlen, Mathias/0000-0002-4858-8056; Fagerberg, Linn/0000-0003-0198-7137; Nielsen, Jens/0000-0002-9955-6003; Kaller Lundberg, Emma/0000-0001-7034-0850	Knut and Alice Wallenberg Foundation; Chalmers Foundation; European Directorate [HEALTH-F4-2008-201648/PROSPECTS]	Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Chalmers Foundation; European Directorate	Funding was provided by the Knut and Alice Wallenberg Foundation, Chalmers Foundation and PROSPECTS, a 7th Framework grant by the European Directorate (grant agreement HEALTH-F4-2008-201648/PROSPECTS). Pathologists and staff at the Department of Clinical Pathology, Uppsala University Hospital, are greatly acknowledged for providing the tissues used in the study; in particular, the authors thank Simin Tahmasebpoor for excellent help with preparing frozen tissues for RNA extraction. The authors also thank the staff of the Human Protein Atlas project in both Sweden and India for their efforts generating the Human Protein Atlas. The authors declare no conflicts of interest. Author contributions: M. U. conceived the study; J.N. supervised the data analysis; C. K. performed the protein analysis; A. M. performed the statistical analysis of metabolic genes; E. L. contributed to the subcellular analysis; L. F. and B. M. H. performed analysis of the RNA-Seq data and statistical analysis; F. P. provided the biopsies and material for RNA-Seq; K. E. prepared the RNA samples; A. M., C. K., J.N., and M. U. wrote the manuscript. Ancillary Data pertaining to this study (8 Microsoft Excel spreadsheets) can be accessed at the authors' website (http://www.metabolicatlas.org/livertissue).	Agren R, 2014, MOL SYST BIOL, V10, DOI 10.1002/msb.145122; Agren R, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002518; Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; Apweiler R, 2011, NUCLEIC ACIDS RES, V39, pD214, DOI 10.1093/nar/gkq1020; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baffy G, 2012, J HEPATOL, V56, P1384, DOI 10.1016/j.jhep.2011.10.027; Bell LN, 2010, HEPATOLOGY, V51, P111, DOI 10.1002/hep.23271; Castle JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011779; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Fagerberg L, 2013, J PROTEOME RES, V12, P2439, DOI 10.1021/pr300924j; Flicek P, 2012, NUCLEIC ACIDS RES, V40, pD84, DOI 10.1093/nar/gkr991; HABER B, 1995, HEPATOLOGY, V22, P906, DOI 10.1016/0270-9139(95)90314-3; HAUSSINGER D, 1985, J HEPATOL, V1, P3, DOI 10.1016/S0168-8278(85)80063-5; Hebenstreit D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.28; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang QC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026168; KABADI UM, 1985, GASTROENTEROLOGY, V88, P750, DOI 10.1016/0016-5085(85)90146-5; Kalhan SC, 2011, METABOLISM, V60, P404, DOI 10.1016/j.metabol.2010.03.006; Kampf C., 2004, CLIN PROTEOM, V1, P285, DOI DOI 10.1385/CP:1:3-4:285; Kampf C, 2012, JOVE-J VIS EXP, DOI 10.3791/3620; Kanehisa M, 2010, NUCLEIC ACIDS RES, V38, pD355, DOI 10.1093/nar/gkp896; Kmiec Z, 2001, ADV ANAT EMBRYOL CEL, V161, P1; Lake AD, 2011, DRUG METAB DISPOS, V39, P1954, DOI 10.1124/dmd.111.040592; Lanpher B, 2006, NAT REV GENET, V7, P449, DOI 10.1038/nrg1880; Lundberg E, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.106; Lundberg E, 2010, PROTEOMICS, V10, P3984, DOI 10.1002/pmic.201000125; Mardinoglu A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4083; Mardinoglu A, 2013, BIOTECHNOL J, V8, P985, DOI 10.1002/biot.201200275; Mardinoglu A, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.5; Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; Patil KR, 2005, P NATL ACAD SCI USA, V102, P2685, DOI 10.1073/pnas.0406811102; Prie D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066182; Prie D, 2009, KIDNEY INT, V75, P882, DOI 10.1038/ki.2008.643; R Development Core Team, 2013, R: A Language and Environment for Statistical Computing; Sekine S, 2011, CANCER SCI, V102, P1742, DOI 10.1111/j.1349-7006.2011.01990.x; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Teng SL, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-S1-S10; Tortora G, 2012, PRINCIPLES ANATOMY P, V13th; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Tung EKK, 2011, LIVER INT, V31, P1494, DOI 10.1111/j.1478-3231.2011.02597.x; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Varemo L, 2013, NUCLEIC ACIDS RES, V41, P4378, DOI 10.1093/nar/gkt111; Wu JM, 2010, HPB, V12, P625, DOI 10.1111/j.1477-2574.2010.00207.x; Xiao SJ, 2010, BIOINFORMATICS, V26, P1273, DOI 10.1093/bioinformatics/btq109; Yang XQ, 2011, PHYSIOL GENOMICS, V43, P457, DOI 10.1152/physiolgenomics.00178.2010; Yilmaz Y, 2010, ANN CLIN BIOCHEM, V47, P549, DOI 10.1258/acb.2010.010169; Zekri ARN, 2012, ASIAN PAC J CANCER P, V13, P5433, DOI 10.7314/APJCP.2012.13.11.5433	51	57	59	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2901	2914		10.1096/fj.14-250555	http://dx.doi.org/10.1096/fj.14-250555			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24648543				2022-12-28	WOS:000337949400015
J	Scorrano, F; Carrasco, J; Pastor-Ciurana, J; Belda, X; Rami-Bastante, A; Bacci, ML; Armario, A				Scorrano, Fabrizio; Carrasco, Javier; Pastor-Ciurana, Jordi; Belda, Xavier; Rami-Bastante, Alicia; Bacci, Maria Laura; Armario, Antonio			Validation of the long-term assessment of hypothalamic-pituitary-adrenal activity in rats using hair corticosterone as a biomarker	FASEB JOURNAL			English	Article						ACTH; chronic immobilization; chronic unpredictable stress; glucocorticoids	OF-THE-ART; CHRONIC STRESS; SALIVARY CORTISOL; FUTURE-DIRECTIONS; SEX DIFFERENCE; EXPOSURE; RESPONSES; RESPONSIVENESS; ASSOCIATIONS; ADAPTATION	The evaluation of chronic activity of the hypothalamic-pituitary-adrenal (HPA) axis is critical for determining the impact of chronic stressful situations. However, current methods have important limitations. The potential use of hair glucocorticoids as a noninvasive retrospective biomarker of long-term HPA activity is gaining acceptance in humans and wild animals. However, there is no study examining hair corticosterone (HC) in laboratory animals. The present study validates a method for measuring HC in rats and demonstrates that it properly reflects chronic HPA activity. The HC concentration was similar in male and female rats, despite higher total plasma corticosterone levels in females, tentatively suggesting that it reflects free rather than total plasma corticosterone. Exposure of male rats to 2 different chronic stress protocols (chronic immobilization and chronic unpredictable stress) resulted in similarly higher HC levels compared to controls (1.8-fold). HC also increased after a mild chronic stressor (30 min daily restraint). Chronic administration of 2 different doses of a long-acting ACTH preparation dramatically increased HC (3.1- and 21.5-fold, respectively), demonstrating that a ceiling effect in HC accumulation is unlikely under other more natural conditions. Finally, adrenalectomy significantly reduced HC. In conclusion, HC measurement in rats appears appropriate to evaluate integrated chronic changes in circulating corticosterone.	[Scorrano, Fabrizio; Bacci, Maria Laura] Univ Bologna, Fac Vet Med, Anim Physiol Unit, Dept Vet Med Sci, I-40064 Bologna, Italy; [Scorrano, Fabrizio] Univ Autonoma Barcelona, Fac Vet, Unitat Fisiol Anim, E-08193 Barcelona, Spain; [Carrasco, Javier; Pastor-Ciurana, Jordi; Belda, Xavier; Rami-Bastante, Alicia; Armario, Antonio] Univ Autonoma Barcelona, Fac Biociencies, Unitat Fisiol Anim, E-08193 Barcelona, Spain; [Carrasco, Javier; Pastor-Ciurana, Jordi; Belda, Xavier; Rami-Bastante, Alicia; Armario, Antonio] Univ Autonoma Barcelona, Inst Neurociencies, E-08193 Barcelona, Spain; [Carrasco, Javier; Pastor-Ciurana, Jordi; Belda, Xavier; Rami-Bastante, Alicia; Armario, Antonio] Inst Salud Carlos III, Red Trastornos Adict, Madrid, Spain	University of Bologna; Autonomous University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona; Instituto de Salud Carlos III	Armario, A (corresponding author), Univ Autonoma Barcelona, Dept Biol Cellular Fisiol & Immunol, Fac Biociencies, Unitat Fisiol Anim, E-08193 Barcelona, Spain.	antonio.armario@uab.es	Belda, Xavier/C-9103-2011; Armario, Antonio/C-9267-2011; Carrasco, Javier/C-9732-2011	Belda, Xavier/0000-0003-0374-9546; Armario, Antonio/0000-0001-9524-3635; Carrasco, Javier/0000-0001-6436-0863; Pastor-Ciurana, Jordi/0000-0002-3050-1012; Bacci, Maria Laura/0000-0001-6702-5868	Ministerio de Ciencia e Innovacion [SAF2008-01175, SAF2011-28313]; Instituto de Salud Carlos III (Redes Tematicas de Investigacion Cooperativa en Salud, Ministerio de Sanidad y Consumo) [RD2012-0028-0014]; Generalitat de Catalunya [SGR2014-1020]	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Instituto de Salud Carlos III (Redes Tematicas de Investigacion Cooperativa en Salud, Ministerio de Sanidad y Consumo)(Instituto de Salud Carlos III); Generalitat de Catalunya(Generalitat de Catalunya)	This study was supported by grants from Marco Polo Program 2012, Ministerio de Ciencia e Innovacion (SAF2008-01175, SAF2011-28313), Instituto de Salud Carlos III (RD2012-0028- 0014, Redes Tematicas de Investigacion Cooperativa en Salud, Ministerio de Sanidad y Consumo), and Generalitat de Catalunya (SGR2014-1020).	ALARIO P, 1987, PHYSIOL BEHAV, V40, P29, DOI 10.1016/0031-9384(87)90181-8; Armario Antonio, 2006, CNS & Neurological Disorders-Drug Targets, V5, P485, DOI 10.2174/187152706778559336; Armario A, 2012, CELL MOL NEUROBIOL, V32, P749, DOI 10.1007/s10571-012-9814-6; Atkinson HC, 1997, ENDOCRINOLOGY, V138, P3842, DOI 10.1210/en.138.9.3842; Belda X, 2004, BEHAV BRAIN RES, V154, P399, DOI 10.1016/j.bbr.2004.03.011; Bennett A, 2010, DOMEST ANIM ENDOCRIN, V39, P171, DOI 10.1016/j.domaniend.2010.04.003; Buchanan KL, 2004, ANIM BEHAV, V67, P183, DOI 10.1016/j.anbehav.2003.09.002; Campmany L, 1996, PHARMACOL BIOCHEM BE, V53, P517, DOI 10.1016/0091-3057(95)02044-6; Cone E.J., 1996, DRUG TESTING HAIR, P69; Dal-Zotto S, 2000, BEHAV BRAIN RES, V114, P175, DOI 10.1016/S0166-4328(00)00220-5; Davenport MD, 2006, GEN COMP ENDOCR, V147, P255, DOI 10.1016/j.ygcen.2006.01.005; Dettenborn L, 2010, PSYCHONEUROENDOCRINO, V35, P1404, DOI 10.1016/j.psyneuen.2010.04.006; Droste SK, 2009, J NEUROENDOCRINOL, V21, P132, DOI 10.1111/j.1365-2826.2008.01811.x; Droste SK, 2008, ENDOCRINOLOGY, V149, P3244, DOI 10.1210/en.2008-0103; Fairbanks LA, 2011, PSYCHONEUROENDOCRINO, V36, P1201, DOI 10.1016/j.psyneuen.2011.02.013; GALA RR, 1965, ENDOCRINOLOGY, V77, P841, DOI 10.1210/endo-77-5-841; Garcia A, 2000, NEUROENDOCRINOLOGY, V72, P114, DOI 10.1159/000054578; GIRALT M, 1987, PHYSIOL BEHAV, V40, P165, DOI 10.1016/0031-9384(87)90202-2; GIRALT M, 1989, PHYSIOL BEHAV, V45, P477, DOI 10.1016/0031-9384(89)90061-9; Grassi-Oliveira R, 2012, AM J DRUG ALCOHOL AB, V38, P535, DOI 10.3109/00952990.2012.694538; Hellhammer J, 2007, PSYCHONEUROENDOCRINO, V32, P80, DOI 10.1016/j.psyneuen.2006.10.005; HIROSHIGE T, 1973, NEUROENDOCRINOLOGY, V11, P306, DOI 10.1159/000122142; Karlen J, 2011, BMC CLIN PATHOL, V11, DOI 10.1186/1472-6890-11-12; King JA, 2000, BEHAV MED, V26, P67, DOI 10.1080/08964280009595753; Kintz P, 2004, FORENSIC SCI INT, V142, P127, DOI 10.1016/j.forsciint.2004.02.027; Kudielka BM, 2009, PSYCHONEUROENDOCRINO, V34, P2, DOI 10.1016/j.psyneuen.2008.10.004; Larsson CA, 2009, BMC ENDOCR DISORD, V9, DOI 10.1186/1472-6823-9-16; Lederbogen F, 2010, EUR J ENDOCRINOL, V163, P443, DOI 10.1530/EJE-10-0491; Lightman SL, 2008, EUR J PHARMACOL, V583, P255, DOI 10.1016/j.ejphar.2007.11.073; Liu LY, 2008, ANAT REC, V291, P858, DOI 10.1002/ar.20702; Macbeth BJ, 2010, CAN J ZOOL, V88, P935, DOI 10.1139/Z10-057; Manenschijn L, 2012, PSYCHONEUROENDOCRINO, V37, P1960, DOI 10.1016/j.psyneuen.2012.04.010; McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x; Meyer JS, 2012, ENDOCRINOLOGY, V153, P4120, DOI 10.1210/en.2012-1226; O'Brien KM, 2013, STRESS HEALTH, V29, P337, DOI 10.1002/smi.2475; Pastor-Ciurana J, 2014, BEHAV BRAIN RES, V265, P155, DOI 10.1016/j.bbr.2014.02.028; Pragst F, 2006, CLIN CHIM ACTA, V370, P17, DOI 10.1016/j.cca.2006.02.019; PRIESTLEY GC, 1966, J ANAT, V100, P147; Raul JS, 2004, CLIN BIOCHEM, V37, P1105, DOI 10.1016/j.clinbiochem.2004.02.010; RIONDEL AM, 1987, ACTA ENDOCRINOL-COP, V114, P47, DOI 10.1530/acta.0.1140047; Rooney NJ, 2007, PHYSIOL BEHAV, V92, P847, DOI 10.1016/j.physbeh.2007.06.011; Russell E, 2012, PSYCHONEUROENDOCRINO, V37, P589, DOI 10.1016/j.psyneuen.2011.09.009; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Skoluda N, 2012, PSYCHONEUROENDOCRINO, V37, P611, DOI 10.1016/j.psyneuen.2011.09.001; Stalder T, 2012, BRAIN BEHAV IMMUN, V26, P1019, DOI 10.1016/j.bbi.2012.02.002; STARK E, 1968, CAN J PHYSIOL PHARM, V46, P567, DOI 10.1139/y68-082; Staufenbiel SM, 2013, PSYCHONEUROENDOCRINO, V38, P1220, DOI 10.1016/j.psyneuen.2012.11.015; Ulrich-Lai YM, 2006, AM J PHYSIOL-ENDOC M, V291, pE965, DOI 10.1152/ajpendo.00070.2006; Van Uum SHM, 2008, STRESS, V11, P483, DOI 10.1080/10253890801887388; Webb E, 2010, J ARCHAEOL SCI, V37, P807, DOI 10.1016/j.jas.2009.11.010; Yamada J, 2007, NEONATOLOGY, V92, P42, DOI 10.1159/000100085; Zelena D, 2003, AM J PHYSIOL-ENDOC M, V285, pE1110, DOI 10.1152/ajpendo.00219.2003	52	30	30	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					859	867		10.1096/fj.14-254474	http://dx.doi.org/10.1096/fj.14-254474			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25398766	Green Submitted			2022-12-28	WOS:000350633000013
J	Pomari, E; Valle, LD; Pertile, P; Colombo, L; Thornton, MJ				Pomari, Elena; Valle, Luisa Dalla; Pertile, Paolo; Colombo, Lorenzo; Thornton, M. Julie			Intracrine sex steroid synthesis and signaling in human epidermal keratinocytes and dermal fibroblasts	FASEB JOURNAL			English	Article						DHEA; testosterone; estradiol; aromatase; wound healing	ESTROGEN-RECEPTOR-BETA; TRANSCRIPTIONAL CONTROL; BIOLOGICAL ACTIONS; GENE-EXPRESSION; HUMAN SKIN; IN-VITRO; DEHYDROEPIANDROSTERONE; ANDROGEN; DHEA; PROLIFERATION	Peripheral intracrine sex steroid synthesis from adrenal precursors dehydroepiandrosterone (DHEA) and DHEA-sulfate has evolved in humans. We sought to establish if there are differences in intracrine, paracrine, and endocrine regulation of sex steroids by primary cultures of human skin epidermal keratinocytes and dermal fibroblasts. Microarray analysis identified multifunctional genes modulated by steroids, quantitative RT-PCR (qRT-PCR) mRNA expression, enzymatic assay aromatase activity, scratch assay cell migration, immunocytochemistry alpha-smooth muscle actin (alpha-SMA), and collagen gel fibroblast contraction. All steroidogenic components were present, although only keratinocytes expressed the organic anion organic anion transporter protein (OATP) 2B1 transporter. Both expressed the G-protein-coupled estrogen receptor (GPER1). Steroids modulated multifunctional genes, up-regulating genes important in repair andaging [angiopoietin-like 4 (ANGPTL4), chemokine (C-X-C motif) ligand 1 (CXCL1), lamin B1 (LMNB1), and thioredoxin interacting protein (TXNIP)]. DHEA-sulfate (DHEA-S), DHEA, and 17 beta-estradiol stimulated keratinocyte andfibroblastmigration at early (4 h) and late (24-48 h) time points, suggesting involvement of genomic and nongenomic signaling. Migration was blocked by aromatase and steroid sulfatase (STS) inhibitors confirming intracrine synthesis to estrogen. Testosterone had little effect, implying it is not an intermediate. Steroids stimulated fibroblast contraction but not a-SMA expression. Mechanical wounding reduced fibroblast aromatase activity but increased keratinocyte activity, amplifying the bioavailability of intracellular estrogen. Cultured fibroblasts and keratinocytes provide a biologically relevant model system to investigate the complex pathways of sex steroid intracrinology in human skin.	[Pomari, Elena; Thornton, M. Julie] Univ Bradford, Ctr Skin Sci, Sch Life Sci, Bradford BD7 1DP, W Yorkshire, England; [Pomari, Elena; Valle, Luisa Dalla; Colombo, Lorenzo] Univ Padua, Dept Biol, Comparat Endocrinol Lab, Padua, Italy; [Pertile, Paolo] Cutech, Padua, Italy	University of Bradford; University of Padua	Thornton, MJ (corresponding author), Univ Bradford, Ctr Skin Sci, Sch Life Sci, Bradford BD7 1DP, W Yorkshire, England.	m.j.thornton@bradford.ac.uk	Dalla Valle, Luisa/G-6721-2011; Pomari, Elena/J-8184-2018; Pomari, Elena/ABG-7666-2020	Dalla Valle, Luisa/0000-0001-8097-6369; Pomari, Elena/0000-0002-5182-0231; Pomari, Elena/0000-0002-5182-0231; Thornton, M Julie/0000-0002-3395-7066	Regione Veneto [DGR 3794]	Regione Veneto(Regione Veneto)	The authors thank Ola Kamala, Susan Stevenson, Nanda Kandamany, and the Plastic Surgery and Burns Unit, University of Bradford, United Kingdom. This study was supported by Regione Veneto (DGR 3794, Azione Biotech 3 bis), Italy (HAIR ATI project no. 4), and the Centre for Skin Sciences, University of Bradford, United Kingdom.	Alexaki VI, 2009, EXP CELL RES, V315, P2275, DOI 10.1016/j.yexcr.2009.04.006; Ashcroft GS, 1999, AM J PATHOL, V155, P1137, DOI 10.1016/S0002-9440(10)65217-0; Bader RA, 2009, J BIOMAT SCI-POLYM E, V20, P1005, DOI 10.1163/156856209X444402; Baulieu EE, 2000, P NATL ACAD SCI USA, V97, P4279, DOI 10.1073/pnas.97.8.4279; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Campbell L, 2010, J EXP MED, V207, P1825, DOI 10.1084/jem.20100500; Celec P, 2003, PHYSIOL RES, V52, P397; Champliaud MF, 2003, J INVEST DERMATOL, V121, P781, DOI 10.1046/j.1523-1747.2003.12539.x; Chen F, 2005, ENDOCRINOLOGY, V146, P4568, DOI 10.1210/en.2005-0368; Dreesen O, 2013, J CELL BIOL, V200, P605, DOI 10.1083/jcb.201206121; Emmerson E, 2012, BIOGERONTOLOGY, V13, P3, DOI 10.1007/s10522-011-9322-y; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Gilliver SC, 2009, J PATHOL, V217, P73, DOI 10.1002/path.2444; Goh YY, 2010, AM J PATHOL, V177, P2791, DOI 10.2353/ajpath.2010.100129; Gopaul R, 2012, BIOFACTORS, V38, P44, DOI 10.1002/biof.191; Hagenbuch B, 2004, PFLUG ARCH EUR J PHY, V447, P653, DOI 10.1007/s00424-003-1168-y; Kandamany N, 2010, BRIT J DERMATOL, V162, P931; KILLINGER DW, 1995, J STEROID BIOCHEM, V52, P195, DOI 10.1016/0960-0760(94)00164-H; Koenen A, 2012, EUR J PHARM SCI, V47, P774, DOI 10.1016/j.ejps.2012.08.017; Kroeze KL, 2012, J INVEST DERMATOL, V132, P216, DOI 10.1038/jid.2011.245; Labrie F, 2003, ENDOCR REV, V24, P152, DOI 10.1210/er.2001-0031; Labrie F, 2013, CLIMACTERIC, V16, P205, DOI 10.3109/13697137.2012.733983; Labrie F, 1995, ANN NY ACAD SCI, V774, P16, DOI 10.1111/j.1749-6632.1995.tb17369.x; Labrie F, 2000, HORM RES, V54, P218, DOI 10.1159/000053264; Labrie F, 2000, J MOL ENDOCRINOL, V25, P1, DOI 10.1677/jme.0.0250001; LEPHART ED, 1991, METHOD ENZYMOL, V206, P477; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Makrantonaki E, 2010, EXP GERONTOL, V45, P801, DOI 10.1016/j.exger.2010.08.005; Miller KKM, 2013, STEROIDS, V78, P15, DOI 10.1016/j.steroids.2012.10.002; Nardi A, 2009, J STEROID BIOCHEM, V115, P68, DOI 10.1016/j.jsbmb.2009.02.017; O'Kane D, 2014, EXP DERMATOL, V23, P497, DOI 10.1111/exd.12452; Olde B, 2009, TRENDS ENDOCRIN MET, V20, P409, DOI 10.1016/j.tem.2009.04.006; Pedram A, 2010, MOL ENDOCRINOL, V24, P2152, DOI 10.1210/me.2010-0154; Pelletier G, 2004, HISTOL HISTOPATHOL, V19, P629, DOI 10.14670/HH-19.629; Pomari E, 2014, J INFLAMM RES, V7, P103, DOI 10.2147/JIR.S61471; Pomari E, 2013, VET IMMUNOL IMMUNOP, V156, P159, DOI 10.1016/j.vetimm.2013.10.008; Pomari E, 2009, J STEROID BIOCHEM, V115, P146, DOI 10.1016/j.jsbmb.2009.04.003; Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122; Rasmussen Cathy, 2013, Methods Mol Biol, V945, P161, DOI 10.1007/978-1-62703-125-7_11; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Roth M, 2012, BRIT J PHARMACOL, V165, P1260, DOI 10.1111/j.1476-5381.2011.01724.x; Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050; Saldanha CJ, 2009, FRONT NEUROENDOCRIN, V30, P106, DOI 10.1016/j.yfrne.2009.04.016; Samson M, 2005, J STEROID BIOCHEM, V94, P253, DOI 10.1016/j.jsbmb.2005.01.011; Sanden C, 2011, MOL PHARMACOL, V79, P400, DOI 10.1124/mol.110.069500; Sbai O, 2010, J CELL SCI, V123, P4332, DOI 10.1242/jcs.074674; SLOMINSKI A, 2013, J STEROID BIOCHEM, V137, P107, DOI [10.1016/.jsbmb.2013.02.006, DOI 10.1016/J.JSBMB.2013.02.006]; Stanway SJ, 2007, ONCOLOGIST, V12, P370, DOI 10.1634/theoncologist.12-4-370; Stevenson S, 2008, J BIOMAT SCI-POLYM E, V19, P1097, DOI 10.1163/156856208784909354; Stevenson S, 2007, CLIN INTERV AGING, V2, P283; Stevenson S, 2008, WOUND REPAIR REGEN, V16, P243, DOI 10.1111/j.1524-475X.2008.00365.x; Stevenson S, 2009, EXP DERMATOL, V18, P988, DOI 10.1111/j.1600-0625.2009.00864.x; Thornton MJ, 2006, J INVEST DERMATOL, V126, P2010, DOI 10.1038/sj.jid.5700344; Thornton MJ, 2013, DERM-ENDOCRINOL, V5, P264, DOI 10.4161/derm.23872; Thornton MJ, 2005, EXPERT OPIN THER TAR, V9, P617, DOI 10.1517/14728222.9.3.617; Thornton MJ, 2003, J INVEST DERM SYMP P, V8, P100, DOI 10.1046/j.1523-1747.2003.12181.x; Thornton MJ, 2002, EXP DERMATOL, V11, P487, DOI 10.1034/j.1600-0625.2002.110601.x; Toraldo G, 2012, WOUND REPAIR REGEN, V20, P61, DOI 10.1111/j.1524-475X.2011.00757.x; Van LT, 2010, PROG BRAIN RES, V181, P177, DOI 10.1016/S0079-6123(08)81010-2; Verdier-Sevrain S, 2006, EXP DERMATOL, V15, P83, DOI 10.1111/j.1600-0625.2005.00377.x; Webb SJ, 2006, DRUG METAB REV, V38, P89, DOI 10.1080/03602530600569877; Williams MRI, 2004, J CLIN ENDOCR METAB, V89, P4708, DOI 10.1210/jc.2003-031560; Williams MRI, 2002, J CLIN ENDOCR METAB, V87, P176, DOI 10.1210/jc.87.1.176; Wong V, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/969618; Zouboulis CC, 2007, HORM METAB RES, V39, P85, DOI 10.1055/s-2007-961807; Zouboulis CC, 2012, REJUV RES, V15, P302, DOI 10.1089/rej.2011.1249; Zouboulis Christos C, 2004, Hormones (Athens), V3, P9	67	29	31	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					508	524		10.1096/fj.14-251363	http://dx.doi.org/10.1096/fj.14-251363			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25392269	Green Submitted			2022-12-28	WOS:000349370400015
J	Boulton, SJ; Birch-Machin, MA				Boulton, Sarah Jayne; Birch-Machin, Mark A.			Impact of hyperpigmentation on superoxide flux and melanoma cell metabolism at mitochondrial complex II	FASEB JOURNAL			English	Article						bioenergetics; melanin; succinate dehydrogenase; skin; cytoprotection	HEART SUCCINATE-DEHYDROGENASE; OXIDATIVE STRESS; HUMAN SKIN; RESPIRATORY-CHAIN; DNA-DAMAGE; 3-NITROPROPIONIC ACID; FLAVOPROTEIN SUBUNIT; HYDROGEN-PEROXIDE; MELANOSOMAL PH; MELANOGENESIS	Melanogenesis is a highly conserved process of cytophotoprotection from UV radiation present in many species. Although both mitochondrial function and UV radiation insults are well-documented promoters of increased cellular stress, their individual molecular relationships with skin pigmentation have not been clearly resolved. This study provides evidence for a direct relationship between cellular melanin content, superoxide flux, and mitochondrial function at complex II. Direct and significant correlation between increased pigmentation and complex II turnover was observed in genetically different melanoma cell lines of varied basal pigmentation states (P < 0.01). The same trend was also observed when comparing genetically identical cell cultures with increasing levels of induced pigmentation (P < 0.005). The observation of increased steady-state levels of the catalytic complex II succinate dehydrogenase subunit A alongside hyperpigmentation suggested coregulation of activity and pigment production (P < 0.01). The study also presents novel evidence for a relationship between hyperpigmentation and increased superoxide-generating capacity at complex II. By amperometrically monitoring superoxide flux from differently pigmented FM55 melanocytes and their isolated mitochondria, a dynamic and responsive relationship between pigmentation, complex II function, and intracellular superoxide generation was observed (P < 0.005). The data support hyperpigmentation as a protective antioxidant mechanism in response to complex II-mediated reactive oxygen species generation.	[Boulton, Sarah Jayne; Birch-Machin, Mark A.] Newcastle Univ, Sch Med, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Birch-Machin, MA (corresponding author), Newcastle Univ, Sch Med, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	mark.birch-machin@ncl.ac.uk		Boulton, Sarah Jayne/0000-0002-3867-3644	Department of Health Funding Source: Medline	Department of Health		Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; Ancans J, 2000, FEBS LETT, V478, P57, DOI 10.1016/S0014-5793(00)01795-6; Ancans J, 2001, J INVEST DERMATOL, V117, P158, DOI 10.1046/j.0022-202x.2001.01397.x; Ancans J, 2001, EXP CELL RES, V268, P26, DOI 10.1006/excr.2001.5251; Anderson AM, 2009, BRIT J DERMATOL, V160, P924; Anderson A, 2014, REDOX BIOL, V2, P1016, DOI 10.1016/j.redox.2014.08.005; Berneburg M, 1999, J BIOL CHEM, V274, P15345, DOI 10.1074/jbc.274.22.15345; Birch-Machin MA, 2013, BRIT J DERMATOL, V169, P9, DOI 10.1111/bjd.12207; Birch-Machin MA, 1998, J INVEST DERMATOL, V110, P149, DOI 10.1046/j.1523-1747.1998.00099.x; Birch-Machin MA, 2010, MUTAGENESIS, V25, P101, DOI 10.1093/mutage/gep061; BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004; BIRCHMACHIN MA, 1992, J BIOL CHEM, V267, P11553; Cashion L., 1991, U.S. patent, Patent No. [US5017478 A, 5017478]; Dayal D, 2009, RADIAT RES, V172, P737, DOI 10.1667/RR1617.1; Denat L, 2014, J INVEST DERMATOL, V134, P1512, DOI 10.1038/jid.2014.65; Dzhandzhugazyan KN, 1998, FEBS LETT, V430, P227, DOI 10.1016/S0014-5793(98)00603-6; Hall A, 2013, ONCOTARGET, V4, P584, DOI 10.18632/oncotarget.965; Hao HX, 2009, SCIENCE, V325, P1139, DOI 10.1126/science.1175689; Henderson JR, 2009, FREE RADICAL RES, V43, P796, DOI 10.1080/10715760903062895; Hoogduijn MJ, 2004, EXP CELL RES, V294, P60, DOI 10.1016/j.yexcr.2003.11.007; Huang LS, 2006, J BIOL CHEM, V281, P5965, DOI 10.1074/jbc.M511270200; Jantschitsch C, 2003, PHOTOCH PHOTOBIO SCI, V2, P899, DOI 10.1039/b301253k; Kaelin WG, 2009, CANCER CELL, V16, P180, DOI 10.1016/j.ccr.2009.08.013; Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X; KIRKIN AF, 1995, CANCER IMMUNOL IMMUN, V41, P71, DOI 10.1007/BF01527402; Krishnan KJ, 2004, J INVEST DERMATOL, V123, P1020, DOI 10.1111/j.0022-202X.2004.23457.x; Mandavilli BS, 2005, MOL BRAIN RES, V133, P215, DOI 10.1016/j.molbrainres.2004.10.033; Meyskens Frank L. Jr., 2007, V174, P191; Minn Y, 2008, NEUROSCI LETT, V430, P142, DOI 10.1016/j.neulet.2007.10.042; MORRIS AAM, 1994, BBA-BIOENERGETICS, V1185, P125, DOI 10.1016/0005-2728(94)90203-8; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Noonan FP, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1893; Quinlan CL, 2012, J BIOL CHEM, V287, P27255, DOI 10.1074/jbc.M112.374629; Swalwell H, 2012, FREE RADICAL BIO MED, V52, P626, DOI 10.1016/j.freeradbiomed.2011.11.019; Tammeveski K, 1998, FREE RADICAL BIO MED, V25, P973, DOI 10.1016/S0891-5849(98)00182-8; Tulah AS, 2013, MITOCHONDRION, V13, P444, DOI 10.1016/j.mito.2012.11.007	36	17	17	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					346	353		10.1096/fj.14-261982	http://dx.doi.org/10.1096/fj.14-261982			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25351989	Green Submitted			2022-12-28	WOS:000347378600032
J	Elies, J; Scragg, JL; Huang, S; Dallas, ML; Huang, DY; MacDougall, D; Boyle, JP; Gamper, N; Peers, C				Elies, Jacobo; Scragg, Jason L.; Huang, Sha; Dallas, Mark L.; Huang, Dongyang; MacDougall, David; Boyle, John P.; Gamper, Nikita; Peers, Chris			Hydrogen sulfide inhibits Cav3.2 T-type Ca2+ channels	FASEB JOURNAL			English	Article							GATED CALCIUM-CHANNELS; RAT SENSORY NEURONS; SMOOTH-MUSCLE; H2S; MODULATION; CURRENTS; PAIN; PROLIFERATION; VASORELAXANT; HYPERALGESIA	The importance of H2S as a physiological signaling molecule continues to develop, and ion channels are emerging as a major family of target proteins through which H2S exerts many actions. The purpose of the present study was to investigate its effects on T-type Ca2+ channels. Using patch-clamp electrophysiology, we demonstrate that the H2S donor, NaHS (10 mu M - 1 mM) selectively inhibits Cav3.2 T-type channels heterologously expressed in HEK293 cells, whereas Cav3.1 and Cav3.3 channels were unaffected. The sensitivity of Cav3.2 channels to H2S required the presence of the redox-sensitive extracellular residue H191, which is also required for tonic binding of Zn2+ to this channel. Chelation of Zn2+ with N,N,N',N'-tetra-2-picolylethylenediamine prevented channel inhibition by H2S and also reversed H2S inhibition when applied after H2S exposure, suggesting that H2S may act via increasing the affinity of the channel for extracellular Zn2+ binding. Inhibition of native T-type channels in 3 cell lines correlated with expression of Cav3.2 and not Cav3.1 channels. Notably, H2S also inhibited native T-type (primarily Cav3.2) channels in sensory dorsal root ganglion neurons. Our data demonstrate a novel target for H2S regulation, the T-type Ca2+ channel Cav3.2, and suggest that such modulation cannot account for the pronociceptive effects of this gasotransmitter.	[Elies, Jacobo; Scragg, Jason L.; Boyle, John P.; Peers, Chris] Univ Leeds, Fac Med & Hlth, LICAMM, Div Cardiovasc & Diabet Res, Leeds LS2 9JT, W Yorkshire, England; [MacDougall, David; Gamper, Nikita] Univ Leeds, Fac Biol Sci, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; [Huang, Sha; Huang, Dongyang; Gamper, Nikita] Hebei Med Univ, Dept Pharmacol, Shijiazhuang, Peoples R China; [Dallas, Mark L.] Univ Reading, Sch Pharm, Reading, Berks, England	University of Leeds; University of Leeds; Hebei Medical University; University of Reading	Peers, C (corresponding author), Univ Leeds, Fac Med & Hlth, LICAMM, Div Cardiovasc & Diabet Res, Clarendon Way, Leeds LS2 9JT, W Yorkshire, England.	c.s.peers@leeds.ac.uk	Dallas, Mark/Q-6117-2019; Elies, Jacobo/K-7684-2017; Boyle, John/N-4868-2016	Dallas, Mark/0000-0002-5190-0522; Elies, Jacobo/0000-0002-2518-8412; Gamper, Nikita/0000-0001-5806-0207; MacDougall, David/0000-0003-1811-288X; Peers, Chris/0000-0002-8354-346X	British Heart Foundation; Medical Research Council; Hebei Medical University; MRC [G0700966] Funding Source: UKRI; British Heart Foundation [FS/10/010/28169, FS/12/42/29585, PG/11/84/29146, PG/09/013/26885] Funding Source: researchfish; Medical Research Council [G0700966] Funding Source: researchfish	British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Hebei Medical University; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors are grateful to Dr. E. Perez-Reyes (University of Virginia, Charlottesville, VA, USA) for providing the H191Q and Q172H mutant constructs. This work was supported by the British Heart Foundation (grants to C.P. and J.L.S.), the Medical Research Council (grants to C.P. and N.G.), and the Hebei Medical University (startup grant to N.G.).	Abe K, 1996, J NEUROSCI, V16, P1066; Benavides GA, 2007, P NATL ACAD SCI USA, V104, P17977, DOI 10.1073/pnas.0705710104; Boycott HE, 2013, FASEB J, V27, P3395, DOI 10.1096/fj.13-227249; Calvert JW, 2009, CIRC RES, V105, P365, DOI 10.1161/CIRCRESAHA.109.199919; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Cribbs LL, 2006, CELL CALCIUM, V40, P221, DOI 10.1016/j.ceca.2006.04.026; Dziegielewska B, 2014, PFLUG ARCH EUR J PHY, V466, P801, DOI 10.1007/s00424-014-1444-z; Fearon IM, 2000, PFLUG ARCH EUR J PHY, V441, P181, DOI 10.1007/s004240000424; Feng XM, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-4; Gong QH, 2011, J ALZHEIMERS DIS, V24, P173, DOI 10.3233/JAD-2011-110128; Ishigami M, 2009, ANTIOXID REDOX SIGN, V11, P205, DOI [10.1089/ars.2008.2132, 10.1089/ARS.2008.2132]; Jagodic MM, 2008, J NEUROPHYSIOL, V99, P3151, DOI 10.1152/jn.01031.2007; Jagodic MM, 2007, J NEUROSCI, V27, P3305, DOI 10.1523/JNEUROSCI.4866-06.2007; Jevtovic-Todorovic V, 2006, CELL CALCIUM, V40, P197, DOI 10.1016/j.ceca.2006.04.024; Kang HW, 2010, J BIOL CHEM, V285, P3271, DOI 10.1074/jbc.M109.067660; Kang HW, 2006, J BIOL CHEM, V281, P4823, DOI 10.1074/jbc.M510197200; Kashfi K, 2013, BIOCHEM PHARMACOL, V85, P689, DOI 10.1016/j.bcp.2012.10.019; Kawabata A, 2007, PAIN, V132, P74, DOI 10.1016/j.pain.2007.01.026; Kimura H, 2012, ANTIOXID REDOX SIGN, V17, P45, DOI 10.1089/ars.2011.4345; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; Kimura Y, 2010, ANTIOXID REDOX SIGN, V12, P1, DOI 10.1089/ars.2008.2282; Kirton Hannah M, 2013, Methods Mol Biol, V998, P55, DOI 10.1007/978-1-62703-351-0_4; Kuga T, 1996, CIRC RES, V79, P14, DOI 10.1161/01.RES.79.1.14; Lee JH, 1999, BIOPHYS J, V77, P3034, DOI 10.1016/S0006-3495(99)77134-1; Li L, 2011, ANNU REV PHARMACOL, V51, P169, DOI 10.1146/annurev-pharmtox-010510-100505; Linley JE, 2008, J NEUROSCI, V28, P11240, DOI 10.1523/JNEUROSCI.2297-08.2008; Liu BY, 2010, J CLIN INVEST, V120, P1240, DOI 10.1172/JCI41084; Maeda Y, 2009, PAIN, V142, P127, DOI 10.1016/j.pain.2008.12.021; Matsunami M, 2011, NEUROSCIENCE, V181, P257, DOI 10.1016/j.neuroscience.2011.02.044; Messinger RB, 2009, PAIN, V145, P184, DOI 10.1016/j.pain.2009.06.012; Mustafa AK, 2011, CIRC RES, V109, P1259, DOI 10.1161/CIRCRESAHA.111.240242; Mustafa AK, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000464; Nelson MT, 2006, CURR PHARM DESIGN, V12, P2189, DOI 10.2174/138161206777585184; Nelson MT, 2007, J NEUROSCI, V27, P12577, DOI 10.1523/JNEUROSCI.2206-07.2007; Nelson MT, 2007, J NEUROSCI, V27, P8250, DOI 10.1523/JNEUROSCI.1800-07.2007; Nelson MT, 2005, J NEUROSCI, V25, P8766, DOI 10.1523/JNEUROSCI.2527-05.2005; Paul BD, 2012, NAT REV MOL CELL BIO, V13, P499, DOI 10.1038/nrm3391; Peers C, 2012, ANTIOXID REDOX SIGN, V17, P95, DOI 10.1089/ars.2011.4359; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; Perez-Reyes E, 2014, PFLUG ARCH EUR J PHY, V466, P627, DOI 10.1007/s00424-013-1419-5; Poulsen CB, 2011, KIDNEY INT, V79, P443, DOI 10.1038/ki.2010.429; Predmore Benjamin L, 2011, Expert Rev Clin Pharmacol, V4, P83, DOI 10.1586/ecp.10.56; Rodman DM, 2005, CIRC RES, V96, P864, DOI 10.1161/01.RES.0000163066.07472.ff; Rola R, 2003, BRAIN RES, V961, P171, DOI 10.1016/S0006-8993(02)03950-1; Santoni G, 2012, BRIT J PHARMACOL, V166, P1244, DOI 10.1111/j.1476-5381.2012.01908.x; Sekiguchi F, 2014, BIOCHEM BIOPH RES CO, V445, P225, DOI 10.1016/j.bbrc.2014.01.185; Shibuya N, 2009, J BIOCHEM, V146, P623, DOI 10.1093/jb/mvp111; Shibuya N, 2009, ANTIOXID REDOX SIGN, V11, P703, DOI [10.1089/ars.2008.2253, 10.1089/ARS.2008.2253]; Short G, 2013, J PAIN, V14, pS71, DOI 10.1016/j.jpain.2013.01.623; Streng T, 2008, EUR UROL, V53, P391, DOI 10.1016/j.eururo.2007.10.024; Swayne LA, 2008, PFLUG ARCH EUR J PHY, V456, P459, DOI 10.1007/s00424-007-0390-4; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425; Takahashi T, 2010, PAIN, V150, P183, DOI 10.1016/j.pain.2010.04.022; Talley EM, 1999, J NEUROSCI, V19, P1895; Todorovic SM, 2014, PFLUG ARCH EUR J PHY, V466, P701, DOI 10.1007/s00424-014-1452-z; Todorovic SM, 2011, BRIT J PHARMACOL, V163, P484, DOI 10.1111/j.1476-5381.2011.01256.x; Todorovic SM, 2001, NEURON, V31, P75, DOI 10.1016/S0896-6273(01)00338-5; Wang R, 2012, PHYSIOL REV, V92, P791, DOI 10.1152/physrev.00017.2011; Whiteman M, 2006, BIOCHEM BIOPH RES CO, V343, P303, DOI 10.1016/j.bbrc.2006.02.154; Whiteman M, 2004, J NEUROCHEM, V90, P765, DOI 10.1111/j.1471-4159.2004.02617.x; Yang Guang-Dong, 2007, Shengli Xuebao, V59, P133; Yang GD, 2008, SCIENCE, V322, P587, DOI 10.1126/science.1162667; Zhang Y, 2013, MOL CELL BIOL, V33, P1104, DOI 10.1128/MCB.01215-12; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	64	33	34	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5376	5387		10.1096/fj.14-257113	http://dx.doi.org/10.1096/fj.14-257113			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25183670				2022-12-28	WOS:000345894500030
J	Gibellini, L; Pinti, M; Boraldi, F; Giorgio, V; Bernardi, P; Bartolomeo, R; Nasi, M; De Biasi, S; Missiroli, S; Carnevale, G; Losi, L; Tesei, A; Pinton, P; Quaglino, D; Cossarizza, A				Gibellini, Lara; Pinti, Marcello; Boraldi, Federica; Giorgio, Valentina; Bernardi, Paolo; Bartolomeo, Regina; Nasi, Milena; De Biasi, Sara; Missiroli, Sonia; Carnevale, Gianluca; Losi, Lorena; Tesei, Anna; Pinton, Paolo; Quaglino, Daniela; Cossarizza, Andrea			Silencing of mitochondrial Lon protease deeply impairs mitochondrial proteome and function in colon cancer cells	FASEB JOURNAL			English	Article						respiration; oxphos; RKO cells; mtDNA; mtRNA	QUALITY CONTROL; SUBSTRATE PROTEINS; GENERATION; APOPTOSIS; IDENTIFICATION; PROTEOLYSIS; SUPEROXIDE; BLOCKADE; STRESS	Lon is a nuclear-encoded, mitochondrial protease that assists protein folding, degrades oxidized/damaged proteins, and participates in maintaining mtDNA levels. Here we show that Lon is up-regulated in several human cancers and that its silencing in RKO colon cancer cells causes profound alterations of mitochondrial proteome and function, and cell death. We silenced Lon in RKO cells by constitutive or inducible expression of Lon shRNA. Lon-silenced cells displayed altered levels of 39 mitochondrial proteins (26% related to stress response, 14.8% to ribosome assembly, 12.7% to oxidative phosphorylation, 8.5% to Krebs cycle, 6.3% to beta-oxidation, and 14.7% to crista integrity, ketone body catabolism, and mtDNA maintenance), low levels of mtDNA transcripts, and reduced levels of oxidative phosphorylation complexes (with >90% reduction of complex I). Oxygen consumption rate decreased 7.5-fold in basal conditions, and ATP synthesis dropped from 0.25 +/- 0.04 to 0.03 +/- 0.001 nmol/mg proteins, in the presence of 2-deoxy-D-glucose. Hydrogen peroxide and mitochondrial superoxide anion levels increased by 3-and 1.3-fold, respectively. Mitochondria appeared fragmented, heterogeneous in size and shape, with dilated cristae, vacuoles, and electrondense inclusions. The triterpenoid 2-cyano3,12-dioxooleana-1,9,-dien-28-oic acid, a Lon inhibitor, partially mimics Lon silencing. In summary, Lon is essential for maintaining mitochondrial shape and function, and for survival of RKO cells.	[Gibellini, Lara; Bartolomeo, Regina; Nasi, Milena; De Biasi, Sara; Carnevale, Gianluca; Cossarizza, Andrea] Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci, I-41125 Modena, Italy; [Pinti, Marcello; Boraldi, Federica; Losi, Lorena; Quaglino, Daniela] Univ Modena & Reggio Emilia, Dept Life Sci, I-41125 Modena, Italy; [Giorgio, Valentina; Bernardi, Paolo] Univ Padua, Dept Biomed Sci, Padua, Italy; [Missiroli, Sonia; Pinton, Paolo] Univ Ferrara, Dept Morphol Surg & Expt Med, I-44100 Ferrara, Italy; [Tesei, Anna] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Biosci Lab, Meldola, Italy; [Cossarizza, Andrea] Univ Modena & Reggio Emilia, Dipartimento Sperimentale Interaziendale, Reggio Emilia, Italy	Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; University of Padua; University of Ferrara; IRCCS Meldola (IRST); Universita di Modena e Reggio Emilia	Cossarizza, A (corresponding author), Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci, Via Campi 287, I-41125 Modena, Italy.	andrea.cossarizza@unimore.it	Losi, Lorena/B-2583-2012; Giorgio, Valentina/I-6110-2016; Carnevale, Gianluca/F-8416-2017; Missiroli, Sonia/K-5769-2016; Pinti, Marcello/C-9351-2015; Nasi, Milena/J-4425-2016; De Biasi, Sara/AAB-7520-2019; Boraldi, Federica/D-1263-2015; Bernardi, Paolo/C-3656-2008; Carnevale, Gianluca/ABF-7872-2021; Tesei, Anna/C-7748-2016; Quaglino, Daniela/A-9381-2010; Pinton, Paolo/J-8025-2012; Giorgio, Valentina/O-1969-2015	Losi, Lorena/0000-0002-8483-3936; Carnevale, Gianluca/0000-0002-5348-5991; Pinti, Marcello/0000-0001-9118-1262; Nasi, Milena/0000-0003-3079-8001; De Biasi, Sara/0000-0002-3217-9821; Boraldi, Federica/0000-0002-0277-9017; Bernardi, Paolo/0000-0001-9187-3736; Carnevale, Gianluca/0000-0002-5348-5991; Tesei, Anna/0000-0002-8351-5952; Quaglino, Daniela/0000-0002-4302-5078; Pinton, Paolo/0000-0001-7108-6508; Giorgio, Valentina/0000-0002-4229-3054; Missiroli, Sonia/0000-0003-4530-617X; Cossarizza, Andrea/0000-0002-5381-1558	Associazione Italiana Ricerca sul Cancro [11341]; Ministero Istruzione, Universita, Ricerca [RBAP11S8C3]; Fondazione Cassa di Risparmio di Vignola	Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Ministero Istruzione, Universita, Ricerca(Ministry of Education, Universities and Research (MIUR)); Fondazione Cassa di Risparmio di Vignola	This work was supported by grants from Associazione Italiana Ricerca sul Cancro (grant 11341 to A.C.), Ministero Istruzione, Universita, Ricerca (grant RBAP11S8C3 to A.C. and P.B.), and Fondazione Cassa di Risparmio di Vignola (grant to M.P.).	Addis MF, 2009, PROTEOMICS, V9, P3815, DOI 10.1002/pmic.200800971; Bayot A, 2010, J BIOL CHEM, V285, P11445, DOI 10.1074/jbc.M109.065425; Bender T, 2010, PROTEOMICS, V10, P1426, DOI 10.1002/pmic.200800619; Bernstein SH, 2012, BLOOD, V119, P3321, DOI 10.1182/blood-2011-02-340075; Chen SH, 2008, NUCLEIC ACIDS RES, V36, P1273, DOI 10.1093/nar/gkm1140; Cheng CW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.204; Chiacchiera F, 2009, CELL DEATH DIFFER, V16, P1203, DOI 10.1038/cdd.2009.36; Cossarizza A, 2003, ANTIVIR THER, V8, P315; Cossarizza A, 2009, NAT PROTOC, V4, P1790, DOI 10.1038/nprot.2009.189; Friguet Bertrand, 2008, Biotechnology Journal, V3, P757, DOI 10.1002/biot.200800041; Giorgio V, 2012, BBA-BIOENERGETICS, V1817, P363, DOI 10.1016/j.bbabio.2011.10.012; Goard CA, 2014, ONCOGENE, V33, P2690, DOI 10.1038/onc.2013.228; Hoffstrom BG, 2010, NAT CHEM BIOL, V6, P900, DOI [10.1038/nchembio.467, 10.1038/NCHEMBIO.467]; Hori O, 2002, J CELL BIOL, V157, P1151, DOI 10.1083/jcb.200108103; Huang CY, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.149; Lu B, 2007, J BIOL CHEM, V282, P17363, DOI 10.1074/jbc.M611540200; Lu B, 2013, MOL CELL, V49, P121, DOI 10.1016/j.molcel.2012.10.023; Luce K, 2010, ADV EXP MED BIOL, V694, P108; Major T, 2006, MOL CELL BIOL, V26, P762, DOI 10.1128/MCB.26.3.762-776.2006; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mukhopadhyay P, 2007, NAT PROTOC, V2, P2295, DOI 10.1038/nprot.2007.327; Ngo JK, 2009, FREE RADICAL BIO MED, V46, P1042, DOI 10.1016/j.freeradbiomed.2008.12.024; Nie XB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081084; Pinti M, 2010, AIDS, V24, P841, DOI 10.1097/QAD.0b013e32833779a3; Rasheed S, 2009, BRIT J CANCER, V100, P1666, DOI 10.1038/sj.bjc.6605026; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Troiano L, 2007, NAT PROTOC, V2, P2719, DOI 10.1038/nprot.2007.405; VANDYCK L, 1994, J BIOL CHEM, V269, P238; von Janowsky B, 2005, BIOL CHEM, V386, P1307, DOI 10.1515/BC.2005.149; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Xu J, 2013, MOL CANCER THER, V12, P717, DOI 10.1158/1535-7163.MCT-12-1016-T	31	52	55	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5122	5135		10.1096/fj.14-255869	http://dx.doi.org/10.1096/fj.14-255869			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25154874	Bronze			2022-12-28	WOS:000345894500009
J	Oldenburger, A; Timens, W; Bos, S; Smit, M; Smrcka, AV; Laurent, AC; Cao, JJ; Hylkema, M; Meurs, H; Maarsingh, H; Lezoualc'h, F; Schmidt, M				Oldenburger, Anouk; Timens, Wim; Bos, Sophie; Smit, Marieke; Smrcka, Alan V.; Laurent, Anne-Coline; Cao, Junjun; Hylkema, Machteld; Meurs, Herman; Maarsingh, Harm; Lezoualc'h, Frank; Schmidt, Martina			Epac1 and Epac2 are differentially involved in inflammatory and remodeling processes induced by cigarette smoke	FASEB JOURNAL			English	Article						exchange protein; cAMP; phospholipase C epsilon	OBSTRUCTIVE PULMONARY-DISEASE; PHOSPHOLIPASE-C-EPSILON; PROTEIN-KINASE-A; GROWTH-FACTOR; CYCLIC-AMP; CRUCIAL ROLE; CAMP; MACROPHAGES; ACTIVATION; COPD	Cigarette smoke (CS) induces inflammatory responses characterized by increase of immune cells and cytokine release. Remodeling processes, such as mucus hypersecretion and extracellular matrix protein production, are also directly or indirectly induced by CS. Recently, we showed that activation of the exchange protein directly activated by cAMP (Epac) attenuates CS extract-induced interleukin (IL)-8 release from cultured airway smooth muscle cells. Using an acute, short-term model of CS exposure, we now studied the role of Epac1, Epac2, and the Epac effector phospholipase-C epsilon (PLC epsilon) in airway inflammation and remodeling in vivo. Compared to wild-type mice exposed to CS, the number of total inflammatory cells, macrophages, and neutrophils and total IL-6 release was lower in Epac2(-/-) mice, which was also the case for neutrophils and IL-6 in PLC epsilon(-/-) mice. Taken together, Epac2, acting partly via PLC epsilon, but not Epac1, enhances CS-induced airway inflammation in vivo. In total lung homogenates of Epac1(-/-) mice, MUC5AC and matrix remodeling parameters (transforming growth factor-1, collagen I, and fibronectin) were increased at baseline. Our findings suggest that Epac1 primarily is capable of inhibiting remodeling processes, whereas Epac2 primarily increases inflammatory processes in vivo.Oldenburger, A., Timens, W., Bos, S., Smit, M., Smrcka, A. V., Laurent, A.-C., Cao, J., Hylkema, M., Meurs, H., Maarsingh, H., Lezoualc'h, F., and Schmidt, M. Epac1 and Epac2 are differentially involved in inflammatory and remodeling processes induced by cigarette smoke.	[Oldenburger, Anouk; Bos, Sophie; Smit, Marieke; Meurs, Herman; Schmidt, Martina] Univ Groningen, Univ Med Ctr Groningen, Dept Mol Pharmacol, Groningen, Netherlands; [Oldenburger, Anouk; Timens, Wim; Cao, Junjun; Hylkema, Machteld; Meurs, Herman; Schmidt, Martina] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma, Groningen, Netherlands; [Oldenburger, Anouk; Timens, Wim; Cao, Junjun; Hylkema, Machteld; Meurs, Herman; Schmidt, Martina] Univ Groningen, Univ Med Ctr Groningen, COPD, Groningen, Netherlands; [Timens, Wim; Cao, Junjun; Hylkema, Machteld] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands; [Smrcka, Alan V.] Univ Rochester, Sch Med, Dept Physiol & Pharmacol, Rochester, NY USA; [Laurent, Anne-Coline; Lezoualc'h, Frank] Inst Malad Metab & Cardiovasc, INSERM, Unite Mixte Rech UMR 1048, Toulouse, France; [Laurent, Anne-Coline; Lezoualc'h, Frank] Univ Toulouse 3, F-31062 Toulouse, France; [Maarsingh, Harm] Palm Beach Atlantic Univ, Lloyd L Gregory Sch Pharm, Dept Pharmaceut Sci, W Palm Beach, FL USA	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Rochester; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Oldenburger, A (corresponding author), Univ Ctr Pharm, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	a.oldenburger@rug.nl	Schmidt, Martina/C-5339-2018; Maarsingh, Harm/AAD-5642-2019; Timens, Wim/K-5570-2013	Schmidt, Martina/0000-0003-3075-0630; Timens, Wim/0000-0002-4146-6363; Laurent, Anne-Coline/0000-0003-4382-3894	Dutch Lung Foundation [3.2.09.034]; U.S. National Institutes of Health [GM53536]; Abel Tasman Talent Program Fellowship from the University of Groningen; Region Midi-Pyrenees; Groupe de Reflexion sur la Recherche Cardiovasculaire (GRRC); Association Francaise contre les Myopathies (AFM); GRRC; AFM; Fondation pour la Recherche Medicale (FRM) [Fondation pour la Recherche Medicale (FRM; DPC20111122995]; Merck Sharpe; Dohme; Rosalind Franklin Fellowship from the University of Groningen; Deutsche Forschungsgemeinschaft [IRTG1874/1]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053536] Funding Source: NIH RePORTER	Dutch Lung Foundation; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Abel Tasman Talent Program Fellowship from the University of Groningen; Region Midi-Pyrenees(Region OccitanieRegion Provence-Alpes-Cote d'Azur); Groupe de Reflexion sur la Recherche Cardiovasculaire (GRRC); Association Francaise contre les Myopathies (AFM)(Association Francaise contre les Myopathies); GRRC; AFM(Association Francaise contre les Myopathies); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Merck Sharpe; Dohme; Rosalind Franklin Fellowship from the University of Groningen; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	A.O. was supported by a grant from the Dutch Lung Foundation (3.2.09.034); A. V. S was supported by a U.S. National Institutes of Health grant (GM53536); J.C. was the recipient of an Abel Tasman Talent Program Fellowship from the University of Groningen; A.-C. L. was the recipient of a grant from Region Midi-Pyrenees, Groupe de Reflexion sur la Recherche Cardiovasculaire (GRRC), and Association Francaise contre les Myopathies (AFM); F. L. was supported by grants from GRRC, AFM, and Fondation pour la Recherche Medicale (FRM; DPC20111122995); H. Ma. was supported by a grant from from Merck Sharpe and Dohme; M. S. was supported by a Rosalind Franklin Fellowship from the University of Groningen and a grant from the Deutsche Forschungsgemeinschaft (IRTG1874/1). The authors thank Malik Bisserier to support immunoblotting for Epac1 and Epac2.	Aronoff DM, 2005, J IMMUNOL, V174, P595, DOI 10.4049/jimmunol.174.2.595; Banner KH, 2009, BRIT J PHARMACOL, V157, P892, DOI 10.1111/j.1476-5381.2009.00170.x; Barnes PJ, 2008, CURR OPIN PHARMACOL, V8, P300, DOI 10.1016/j.coph.2008.03.001; Blacquiere MJ, 2009, EUR RESPIR J, V33, P1133, DOI 10.1183/09031936.00129608; Bruscia EM, 2009, AM J RESP CELL MOL, V40, P295, DOI 10.1165/rcmb.2008-0170OC; Bryn T, 2006, J IMMUNOL, V176, P7361, DOI 10.4049/jimmunol.176.12.7361; Chung KF, 2008, EUR RESPIR J, V31, P1334, DOI 10.1183/09031936.00018908; Chung KF, 2001, EUR RESPIR J, V18, p50S, DOI 10.1183/09031936.01.00229701; Conrotto P, 2007, J PROTEOME RES, V6, P287, DOI 10.1021/pr060427q; de Boer WI, 1998, AM J RESP CRIT CARE, V158, P1951, DOI 10.1164/ajrccm.158.6.9803053; Dhami R, 2000, AM J RESP CELL MOL, V22, P244, DOI 10.1165/ajrcmb.22.2.3809; Dodge-Kafka KL, 2005, NATURE, V437, P574, DOI 10.1038/nature03966; Dusaban SS, 2013, P NATL ACAD SCI USA, V110, P3609, DOI 10.1073/pnas.1217355110; Grandoch M, 2010, BRIT J PHARMACOL, V159, P265, DOI 10.1111/j.1476-5381.2009.00458.x; Hardin M, 2012, AM J RESP CELL MOL, V47, P203, DOI 10.1165/rcmb.2012-0011OC; Holloway RA, 2013, CURR OPIN PULM MED, V19, P95, DOI 10.1097/MCP.0b013e32835cfff5; Homma S, 2006, INT J MOL MED, V18, P933; Hu LZ, 2010, J IMMUNOL, V184, P993, DOI 10.4049/jimmunol.0901816; Insel PA, 2012, BRIT J PHARMACOL, V166, P447, DOI 10.1111/j.1476-5381.2012.01847.x; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Kiml V, 2013, AM J RESP CRIT CARE, V187, P228, DOI 10.1164/rccm.201210-1843CI; Kistemaker LEM, 2013, EUR RESPIR J, V42, P1677, DOI 10.1183/09031936.00112412; Kranenburg AR, 2005, THORAX, V60, P106, DOI 10.1136/thx.2004.023986; Lai H, 2010, J AEROSOL MED PULM D, V23, P219, DOI 10.1089/jamp.2009.0802; Lee E, 2013, J ETHNOPHARMACOL, V149, P148, DOI 10.1016/j.jep.2013.06.014; Lorenowicz MJ, 2007, ARTERIOSCL THROM VAS, V27, P1014, DOI 10.1161/ATVBAHA.106.132282; Murugan V, 2009, EXP LUNG RES, V35, P439, DOI 10.1080/01902140902759290; Nijholt IM, 2008, CELL SIGNAL, V20, P1715, DOI 10.1016/j.cellsig.2008.05.001; Oestreich EA, 2009, J BIOL CHEM, V284, P1514, DOI 10.1074/jbc.M806994200; Oka M, 2011, LAB INVEST, V91, P711, DOI 10.1038/labinvest.2011.10; Oldenburger A, 2014, AM J PHYSIOL-CELL PH, V306, pC585, DOI 10.1152/ajpcell.00183.2013; Oldenburger A, 2012, PHARMACEUTICALS, V5, P1291, DOI 10.3390/ph5121291; Oldenburger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031574; Page CP, 2012, CURR OPIN PHARMACOL, V12, P275, DOI 10.1016/j.coph.2012.02.016; Park KS, 2007, J CLIN INVEST, V117, P978, DOI 10.1172/JCI29176; Perng DW, 2004, CHEST, V126, P375, DOI 10.1378/chest.126.2.375; Postma Dirkje S, 2006, Proc Am Thorac Soc, V3, P434, DOI 10.1513/pats.200601-006AW; Raherison Chantal, 2011, Rev Prat, V61, P769; Sadana R, 2009, NEUROSIGNALS, V17, P5, DOI 10.1159/000166277; Schmidt M, 2013, PHARMACOL REV, V65, P670, DOI 10.1124/pr.110.003707; Serezani CH, 2008, AM J RESP CELL MOL, V39, P127, DOI 10.1165/rcmb.2008-0091TR; Shibasaki T, 2007, P NATL ACAD SCI USA, V104, P19333, DOI 10.1073/pnas.0707054104; Shibuya H, 2006, J DERMATOL SCI, V41, P187, DOI 10.1016/j.jdermsci.2005.10.005; Smrcka AV, 2012, CELL SIGNAL, V24, P1333, DOI 10.1016/j.cellsig.2012.01.009; Takenaka N, 2011, EUR J IMMUNOL, V41, P202, DOI 10.1002/eji.201040675; Tan KS, 2007, CELL SIGNAL, V19, P251, DOI 10.1016/j.cellsig.2006.06.007; Taylor JD, 2010, PULM PHARMACOL THER, V23, P376, DOI 10.1016/j.pupt.2010.04.003; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; Wang H, 2005, CIRC RES, V97, P1305, DOI 10.1161/01.RES.0000196578.15385.bb; Wright JL, 2007, AM J PHYSIOL-LUNG C, V292, pL125, DOI 10.1152/ajplung.00539.2005; Yokoyama U, 2008, P NATL ACAD SCI USA, V105, P6386, DOI 10.1073/pnas.0801490105; Zhang LH, 2011, J BIOL CHEM, V286, P23012, DOI 10.1074/jbc.M111.231993	52	23	24	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4617	4628		10.1096/fj.13-248930	http://dx.doi.org/10.1096/fj.13-248930			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25103224	Green Published			2022-12-28	WOS:000344050900004
J	van den Beukel, JC; Grefhorst, A; Quarta, C; Steenbergen, J; Mastroberardino, PG; Lombes, M; Delhanty, PJ; Mazza, R; Pagotto, U; van der Lely, AJ; Themmen, APN				van den Beukel, Johanna C.; Grefhorst, Aldo; Quarta, Carmelo; Steenbergen, Jacobie; Mastroberardino, Pier G.; Lombes, Marc; Delhanty, Patric J.; Mazza, Roberta; Pagotto, Uberto; van der Lely, Aart Jan; Themmen, Axel P. N.			Direct activating effects of adrenocorticotropic hormone (ACTH) on brown adipose tissue are attenuated by corticosterone	FASEB JOURNAL			English	Article						HPA axis; hypothalamic-pituitary-adrenal axis; metabolism; cold exposure	ENERGY-BALANCE; ADRENERGIC-STIMULATION; METABOLIC PHENOTYPES; NATRIURETIC PEPTIDES; CUSHINGS-SYNDROME; PERIPHERAL-BLOOD; HUMAN ADIPOCYTES; MESSENGER-RNA; CELL-ACTIVITY; ADULT HUMANS	Brown adipose tissue (BAT) and brown-like cells in white adipose tissue (WAT) can dissipate energy through thermogenesis, a process mediated by uncoupling protein 1 (UCP1). We investigated whether stress hormones ACTH and corticosterone contribute to BAT activation and browning of WAT. ACTH and corticosterone were studied in male mice exposed to 4 or 23 degrees C for 24 h. Direct effects were studied in T37i mouse brown adipocytes and primary cultured murine BAT and inguinal WAT (iWAT) cells. In vivo effects were studied using F-18-deoxyglucose positron emission tomography. Cold exposure doubled serum ACTH concentrations (P=0.03) and fecal corticosterone excretion (P=0.008). In T37i cells, ACTH dose-dependently increased Ucp1 mRNA (EC50=1.8 nM) but also induced Ucp1 protein content 88% (P=0.02), glycerol release 32% (P=0.03) and uncoupled respiration 40% (P=0.003). In cultured BAT and iWAT, ACTH elevated Ucp1 mRNA by 3-fold (P=0.03) and 3.7-fold (P=0.01), respectively. In T37i cells, corticosterone prevented induction of Ucp1 mRNA and Ucp1 protein by both ACTH and norepinephrine in a glucocorticoid receptor (GR)-dependent fashion. ACTH and GR antagonist RU486 independently doubled BAT F-18-deoxyglucose uptake (P=0.0003 and P=0.004, respectively) in vivo. Our results show that ACTH activates BAT and browning of WAT while corticosterone counteracts this.Van den Beukel, J. C., Grefhorst, A., Quarta, C., Steenbergen, J., Mastroberardino, P. G., Lombes, M., Delhanty, P. J., Mazza, R., Pagotto, U., van der Lely, A. J., Themmen, A. P. N. Direct activating effects of adrenocorticotropic hormone (ACTH) on brown adipose tissue are attenuated by corticosterone.	[van den Beukel, Johanna C.; Grefhorst, Aldo; Steenbergen, Jacobie; Delhanty, Patric J.; van der Lely, Aart Jan; Themmen, Axel P. N.] Erasmus Univ, Med Ctr, Dept Internal Med, Endocrinol Sect, Rotterdam, Netherlands; [Mastroberardino, Pier G.] Erasmus Univ, Med Ctr, Dept Genet, Rotterdam, Netherlands; [Quarta, Carmelo; Mazza, Roberta; Pagotto, Uberto] Univ Bologna, S Orsola Malpighi Hosp, Endocrinol Unit, Bologna, Italy; [Quarta, Carmelo; Mazza, Roberta; Pagotto, Uberto] Univ Bologna, S Orsola Malpighi Hosp, Dept Med & Surg Sci, Ctr Ric Biomed Appl, Bologna, Italy; [Lombes, Marc] Univ Paris 11, INSERM, Fac Med Paris Sud, Unite Mixte Rech UMR S693, Le Kremlin Bicetre, France	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	van den Beukel, JC (corresponding author), Erasmus MC, Dept Internal Med, Sect Endocrinol, Rm Ee542,POB 2040, NL-3000 CA Rotterdam, Netherlands.	j.vandenbeukel@erasmusmc.nl	Lombes, Marc/L-5933-2018; Quarta, Carmelo/AAC-1629-2020	Lombes, Marc/0000-0003-3189-023X; Quarta, Carmelo/0000-0002-1352-4239; MASTROBERARDINO, PIER GIORGIO/0000-0003-2364-4258				Armengol J, 2012, BIOCHEM J, V443, P799, DOI 10.1042/BJ20111714; Bakopanos E, 2002, MOL CELL ENDOCRINOL, V190, P29, DOI 10.1016/S0303-7207(02)00027-8; Barbatelli G, 2010, AM J PHYSIOL-ENDOC M, V298, pE1244, DOI 10.1152/ajpendo.00600.2009; Betz MJ, 2013, J CLIN ENDOCR METAB, V98, P4097, DOI 10.1210/jc.2012-3535; Bordicchia M, 2012, J CLIN INVEST, V122, P1022, DOI 10.1172/JCI59701; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Bowers SL, 2008, BRAIN BEHAV IMMUN, V22, P105, DOI 10.1016/j.bbi.2007.07.012; Burt MG, 2006, CLIN ENDOCRINOL, V64, P436, DOI 10.1111/j.1365-2265.2006.02488.x; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cannon B, 1998, ANN NY ACAD SCI, V856, P171, DOI 10.1111/j.1749-6632.1998.tb08325.x; Carey AL, 2013, DIABETOLOGIA, V56, P147, DOI 10.1007/s00125-012-2748-1; CARNES M, 1994, EXP GERONTOL, V29, P625, DOI 10.1016/0531-5565(94)90075-2; Cavigellil SA, 2005, J ENDOCRINOL, V184, P153, DOI 10.1677/joe.1.05935; Celi FS, 2009, NEW ENGL J MED, V360, P1553, DOI 10.1056/NEJMe0900466; Cheung L, 2013, NUTR DIABETES, V3, DOI 10.1038/nutd.2013.6; Cho KJ, 2005, J CELL BIOCHEM, V96, P869, DOI 10.1002/jcb.20561; Cinti S, 2002, J HISTOCHEM CYTOCHEM, V50, P21, DOI 10.1177/002215540205000103; Collins S, 2010, INT J OBESITY, V34, pS28, DOI 10.1038/ijo.2010.180; Cypess AM, 2013, NAT MED, V19, P635, DOI 10.1038/nm.3112; Cypess AM, 2012, P NATL ACAD SCI USA, V109, P10001, DOI 10.1073/pnas.1207911109; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; Deiuliis JA, 2010, LIPIDS, V45, P479, DOI 10.1007/s11745-010-3422-3; FOSTER DO, 1982, CAN J PHYSIOL PHARM, V60, P107, DOI 10.1139/y82-018; Frayn KN, 2012, AM J PHYSIOL-ENDOC M, V302, pE468, DOI 10.1152/ajpendo.00527.2011; GATTI G, 1993, BRAIN BEHAV IMMUN, V7, P16, DOI 10.1006/brbi.1993.1002; Gesta S, 2007, CELL, V131, P242, DOI 10.1016/j.cell.2007.10.004; Gondo S, 2004, GENES CELLS, V9, P1239, DOI 10.1111/j.1365-2443.2004.00801.x; HARRI M, 1981, ACTA PHYSIOL SCAND, V113, P213, DOI 10.1111/j.1748-1716.1981.tb06885.x; Hoch M, 2007, OBESITY, V15, P40, DOI 10.1038/oby.2007.525; Jespersen NZ, 2013, CELL METAB, V17, P798, DOI 10.1016/j.cmet.2013.04.011; Agulleiro MJ, 2013, MOL ENDOCRINOL, V27, P1934, DOI 10.1210/me.2013-1099; Kalsbeek A, 2012, MOL CELL ENDOCRINOL, V349, P20, DOI 10.1016/j.mce.2011.06.042; Kiwaki K, 2003, J COMP PHYSIOL B, V173, P675, DOI 10.1007/s00360-003-0377-1; Lacombe A, 2007, J ENDOCRINOL, V194, P153, DOI 10.1677/JOE-07-0102; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; Lidell ME, 2013, NAT MED, V19, P631, DOI 10.1038/nm.3017; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masera RG, 1999, EUR J ENDOCRINOL, V140, P299, DOI 10.1530/eje.0.1400299; Menssen A, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-461; Nedergaard J, 2013, NAT MED, V19, P540, DOI 10.1038/nm.3187; Penfornis P, 2000, AM J PHYSIOL-ENDOC M, V279, pE386, DOI 10.1152/ajpendo.2000.279.2.E386; PEPPER GM, 1993, CELL IMMUNOL, V151, P110, DOI 10.1006/cimm.1993.1225; Qiao SJ, 2009, ENDOCRINOLOGY, V150, P4163, DOI 10.1210/en.2009-0195; Quarta C, 2012, J MOL ENDOCRINOL, V49, pR1, DOI 10.1530/JME-12-0043; Quarta C, 2010, CELL METAB, V11, P273, DOI 10.1016/j.cmet.2010.02.015; ROCHON L, 1990, AM J PHYSIOL, V258, pC835, DOI 10.1152/ajpcell.1990.258.5.C835; Rosell M, 2014, AM J PHYSIOL-ENDOC M, V306, pE945, DOI 10.1152/ajpendo.00473.2013; Rosenwald M, 2013, NAT CELL BIOL, V15, P659, DOI 10.1038/ncb2740; ROTHWELL NJ, 1986, METABOLISM, V35, P657, DOI 10.1016/0026-0495(86)90174-5; ROTHWELL NJ, 1985, COMP BIOCHEM PHYS A, V81, P99, DOI 10.1016/0300-9629(85)90273-7; SCARPACE PJ, 1988, AM J PHYSIOL, V255, pE153, DOI 10.1152/ajpendo.1988.255.2.E153; Scarpace PJ, 2000, J ENDOCRINOL, V164, P331, DOI 10.1677/joe.0.1640331; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Sharp LZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049452; Silva JE, 1995, THYROID, V5, P481, DOI 10.1089/thy.1995.5.481; Soumano K, 2000, MOL CELL ENDOCRINOL, V165, P7, DOI 10.1016/S0303-7207(00)00276-8; Spiga F, 2011, ENDOCRINOLOGY, V152, P1448, DOI 10.1210/en.2010-1209; STRACK AM, 1995, AM J PHYSIOL-REG I, V268, pR1209, DOI 10.1152/ajpregu.1995.268.5.R1209; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0; Tseng YH, 2008, NATURE, V454, P1000, DOI 10.1038/nature07221; Viengchareun S, 2001, AM J PHYSIOL-ENDOC M, V280, pE640, DOI 10.1152/ajpendo.2001.280.4.E640; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Vitali A, 2012, J LIPID RES, V53, P619, DOI 10.1194/jlr.M018846; Vosselman MJ, 2012, DIABETES, V61, P3106, DOI 10.2337/db12-0288; Walden TB, 2009, J CELL PHYSIOL, V218, P444, DOI 10.1002/jcp.21621; Wang TJ, 2012, NEW ENGL J MED, V367, P377, DOI 10.1056/NEJMcibr1204796; Whittle AJ, 2012, CELL, V149, P871, DOI 10.1016/j.cell.2012.02.066; Wu J, 2012, CELL, V150, P366, DOI 10.1016/j.cell.2012.05.016; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; Young EA, 2004, FRONT NEUROENDOCRIN, V25, P69, DOI 10.1016/j.yfrne.2004.07.001; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915	72	58	60	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4857	4867		10.1096/fj.14-254839	http://dx.doi.org/10.1096/fj.14-254839			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25085924				2022-12-28	WOS:000344050900023
J	Amarasekera, M; Martino, D; Ashley, S; Harb, H; Kesper, D; Strickland, D; Saffery, R; Prescott, SL				Amarasekera, Manori; Martino, David; Ashley, Sarah; Harb, Hani; Kesper, Doerthe; Strickland, Deborah; Saffery, Richard; Prescott, Susan L.			Genome-wide DNA methylation profiling identifies a folate-sensitive region of differential methylation upstream of ZFP57-imprinting regulator in humans	FASEB JOURNAL			English	Article						epigenetics; developmental programming; neonate; antigen-presenting cells; T cells	EMBRYONIC STEM-CELLS; FOLIC-ACID USE; CORD BLOOD; PREGNANCY; GENE; SUPPLEMENTATION	Folate intake during pregnancy may affect the regulation of DNA methylation during fetal development. The genomic regions in the offspring that may be sensitive to folate exposure during in utero development have not been characterized. Using genome-scale profiling, we investigated DNA methylation in 2 immune cell types (CD4(+) and antigen-presenting cells) isolated from neonatal cord blood, selected on the basis of in utero folate exposure. High-folate (HF; n = 11) and low-folate (LF; n = 12) groups were selected from opposite extremes of maternal serum folate levels measured in the last trimester of pregnancy. A comparison of these groups revealed differential methylation at 7 regions across the genome. By far, the biggest effect observed was hypomethylation of a 923 bp region 3 kb upstream of the ZFP57 transcript, a regulator of DNA methylation during development, observed in both cell types. Levels of H3/H4 acetylation at ZFP57 promoter and ZFP57 mRNA expression were higher in CD4(+) cells in the HF group relative to the LF group. Hypomethylation at this region was replicated in an independent sample set. These data suggest that exposure to folate has effects on the regulation of DNA methylation during fetal development, and this may be important for health and disease.	[Amarasekera, Manori; Prescott, Susan L.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6001, Australia; [Martino, David; Ashley, Sarah; Saffery, Richard] Murdoch Childrens Res Inst, Canc & Dis Epigenet Grp, Melbourne, Vic, Australia; [Martino, David; Saffery, Richard] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Martino, David] Ctr Food & Allergy Res, Melbourne, Vic, Australia; [Ashley, Sarah] Monash Univ, Inst Med Res, Melbourne, Vic 3004, Australia; [Harb, Hani; Kesper, Doerthe] Philipps Univ, Inst Lab Med Pathobiochem & Mol Diagnost, Marburg, Germany; [Strickland, Deborah] Telethon Inst Child Hlth Res, Perth, WA, Australia	University of Western Australia; Murdoch Children's Research Institute; University of Melbourne; Monash University; University of Sydney; Westmead Institute for Medical Research; Philipps University Marburg; Telethon Kids Institute; University of Western Australia	Prescott, SL (corresponding author), Univ Western Australia, Princess Margaret Hosp, Sch Paediat & Child Hlth, POB D184, Perth, WA 6001, Australia.	susan.prescott@uwa.edu.au	Ashley, Sarah/P-1264-2017; Saffery, Richard/GLS-1976-2022; Harb, Hani/J-6517-2019; Martino, DJ/X-1753-2019; strickland, deborah/K-4597-2019; Strickland, Deborah/AGV-6937-2022; Harb, Hani/HGB-7333-2022; Prescott, Susan/H-5665-2014	Ashley, Sarah/0000-0001-9973-9742; Saffery, Richard/0000-0002-9510-4181; Harb, Hani/0000-0001-8218-2538; Martino, DJ/0000-0001-6823-4696; Strickland, Deborah/0000-0003-0114-4201; Harb, Hani/0000-0001-8218-2538; 	Australia National Health and Medical Research Council (NHMRC); NHMRC Early Career Fellowship; Victorian government	Australia National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Early Career Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Victorian government	R. S. is funded by an Australia National Health and Medical Research Council (NHMRC) Senior Research Fellowship and D. M. by an NHMRC Early Career Fellowship. Murdoch Children's Research Institute is supported by the Victorian government's Operational Infrastructure Scheme. All authors are members of the International Inflammation Network (inFLAME).	Barker DJP, 1998, CLIN SCI, V95, P115, DOI 10.1042/CS19980019; Binder AM, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-353; Chang HB, 2011, J NUTR BIOCHEM, V22, P1172, DOI 10.1016/j.jnutbio.2010.10.003; Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470; Cho CE, 2013, EPIGENETICS-US, V8, P710, DOI 10.4161/epi.24948; Dunstan JA, 2012, ALLERGY, V67, P50, DOI 10.1111/j.1398-9995.2011.02714.x; Foley DL, 2009, AM J EPIDEMIOL, V169, P389, DOI 10.1093/aje/kwn380; Fryer AA, 2011, EPIGENETICS-US, V6, P86, DOI 10.4161/epi.6.1.13392; Girardot M, 2013, EPIGENOMICS-UK, V5, P715, DOI 10.2217/epi.13.66; Gueant JL, 2013, TRENDS ENDOCRIN MET, V24, P279, DOI 10.1016/j.tem.2013.01.010; Haberg SE, 2009, ARCH DIS CHILD, V94, P180, DOI 10.1136/adc.2008.142448; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Hoyo C, 2011, EPIGENETICS-US, V6, P928, DOI 10.4161/epi.6.7.16263; Jaffe AE, 2012, INT J EPIDEMIOL, V41, P200, DOI 10.1093/ije/dyr238; Kiefte-de Jong JC, 2012, J NUTR, V142, P731, DOI 10.3945/jn.111.154948; Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161; LUMLEY J, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001056.pub2, 10.1002/14651858.CD001056, DOI 10.1002/14651858.CD001056]; Martino DJ, 2011, EPIGENETICS-US, V6, P1085, DOI 10.4161/epi.6.9.16401; Plant K, 2014, EUR J HUM GENET, V22, P568, DOI 10.1038/ejhg.2013.244; Quenneville S, 2011, MOL CELL, V44, P361, DOI 10.1016/j.molcel.2011.08.032; Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361; Sie KKY, 2013, MOL NUTR FOOD RES, V57, P677, DOI 10.1002/mnfr.201200186; Steegers-Theunissen RP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007845; Tada Y, 2015, ONCOGENE, V34, P752, DOI 10.1038/onc.2013.599; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Whitrow MJ, 2009, AM J EPIDEMIOL, V170, P1486, DOI 10.1093/aje/kwp315; Zaghouani H, 2009, TRENDS IMMUNOL, V30, P585, DOI 10.1016/j.it.2009.09.002; Zuo XP, 2012, J BIOL CHEM, V287, P2107, DOI 10.1074/jbc.M111.322644	28	58	59	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4068	4076		10.1096/fj.13-249029	http://dx.doi.org/10.1096/fj.13-249029			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24891518	Bronze, Green Published			2022-12-28	WOS:000340845900024
J	Comegna, M; Succoio, M; Napolitano, M; Vitale, M; D'Ambrosio, C; Scaloni, A; Passaro, F; Zambrano, N; Cimino, F; Faraonio, R				Comegna, Marika; Succoio, Mariangela; Napolitano, Marco; Vitale, Monica; D'Ambrosio, Chiara; Scaloni, Andrea; Passaro, Fabiana; Zambrano, Nicola; Cimino, Filiberto; Faraonio, Raffaella			Identification of miR-494 direct targets involved in senescence of human diploid fibroblasts	FASEB JOURNAL			English	Article						microRNA; proteomics; SA-beta-gal; DNA damage; p53; p21/WAF1; PCNA	CELLULAR SENESCENCE; MESSENGER-RNA; MICRORNAS; CELLS; PHENOTYPES; PROTEINS; PROMOTES; COMPLEX; CANCER; ROLES	Cellular senescence is a permanent cell cycle arrest triggered by different stimuli. We recently identified up-regulation of microRNA (miR)-494 as a component of the genetic program leading to senescence of human diploid IMR90 fibroblasts. Here, we used 2-dimensional differential gel electrophoresis (2D-DIGE) coupled to mass spectrometry to profile protein expression changes induced by adoptive overexpression of miR-494 in IMR90 cells. miR-494 induced robust perturbation of the IMR90 proteome by significantly (P <= 0.05) down-regulating a number of proteins. Combination of mass spectrometry-based identification of down-regulated proteins and bioinformatic prediction of the miR-494 binding sites on the relevant mRNAs identified 26 potential targets of miR-494. Among them, computational analysis identified 7 potential evolution-conserved miR-494 targets. Functional miR-494 binding sites were confirmed in 3'-untranslated regions (UTRs) of 4 of them [heterogeneous nuclear ribonucleoprotein A3 (hnRNPA3), protein disulfide isomerase A3 (PDIA3), UV excision repair protein RAD23 homolog B (RAD23B), and synaptotagmin-binding cytoplasmic RNA-interacting protein (SYNCRIP)/heterogeneous nuclear ribonucleoprotein Q (hnRNPQ)]. Their reduced expression correlated with miR-494 up-regulation in senescent cells. RNA interference-mediated knockdown of hnRNPA3 and, to a lesser extent, RAD23B mirrored the senescent phenotype induced by miR-494 overexpression, blunting cell proliferation and causing up-regulation of SA beta-galactosidase and DNA damage. Ectopic expression of hnRNPA3 or RAD23B slowed the appearance of the senescent phenotype induced by miR-494. Overall, these findings identify novel miR-494 direct targets that are involved in cellular senescence.-Comegna, M., Succoio, M., Napolitano, M., Vitale, M., D'Ambrosio, C., Scaloni, A., Passaro, F., Zambrano, N., Cimino, F., Faraonio, R. Identification of miR-494 direct targets involved in senescence of human diploid fibroblasts.	[Comegna, Marika; Succoio, Mariangela; Vitale, Monica; Passaro, Fabiana; Zambrano, Nicola; Cimino, Filiberto; Faraonio, Raffaella] Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, I-80131 Naples, Italy; [Napolitano, Marco; Passaro, Fabiana; Cimino, Filiberto] Ist Ric Diagnost & Nucl, Fdn SDN, Naples, Italy; [Comegna, Marika; Succoio, Mariangela; Vitale, Monica; Passaro, Fabiana; Zambrano, Nicola; Cimino, Filiberto; Faraonio, Raffaella] Ctr Genet Engn CEINGE Biotecnol Avanzate Scarl, Naples, Italy; [D'Ambrosio, Chiara; Scaloni, Andrea] CNR, Prote & Mass Spectrometry Lab, Naples, Italy	University of Naples Federico II; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); CEINGE Biotecnologie Avanzate; Consiglio Nazionale delle Ricerche (CNR)	Cimino, F (corresponding author), Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.	cimino@dbbm.unina.it; faraonio@dbbm.unina.it	Passaro, Fabiana/I-5941-2012; Zambrano, Nicola/B-9352-2014; faraonio, raffaella/K-3802-2018; D'Ambrosio, Chiara/C-2753-2012	Passaro, Fabiana/0000-0003-0150-5302; Zambrano, Nicola/0000-0001-9395-3481; D'Ambrosio, Chiara/0000-0003-2810-9270; Scaloni, Andrea/0000-0001-9362-8515; VITALE, MONICA/0000-0003-1517-7426; Faraonio, Raffaella/0000-0002-7040-6781; Comegna, Marika/0000-0002-8008-2557	Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MiUR) [MERIT RBNE08HWLZ_004, RBNE08YFN3_003]; POR Campania FESR, Project BIOFRAME	Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MiUR)(Ministry of Education, Universities and Research (MIUR)); POR Campania FESR, Project BIOFRAME	The authors thank Massimo Santoro and Tommaso Russo for the helpful discussions and for critical reading of the manuscript. This study was supported by the Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MiUR PRIN 2009, MiUR MERIT RBNE08HWLZ_004 and RBNE08YFN3_003) and by the POR Campania FESR 2007-2013, Project BIOFRAME.	Baker DJ, 2006, J CELL BIOL, V172, P529, DOI 10.1083/jcb.200507081; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Chen HH, 2012, MOL CELL BIOL, V32, P2224, DOI 10.1128/MCB.06550-11; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Cloonan N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-r126; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Faraonio R, 2012, CELL DEATH DIFFER, V19, P713, DOI 10.1038/cdd.2011.143; Faraonio R, 2002, CELL DEATH DIFFER, V9, P862, DOI 10.1038/sj.cdd.4401053; Fong YW, 2011, CELL, V147, P120, DOI 10.1016/j.cell.2011.08.038; Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11-10-0884; Fridman AL, 2008, ONCOGENE, V27, P5975, DOI 10.1038/onc.2008.213; Gorospe M, 2011, TRENDS GENET, V27, P233, DOI 10.1016/j.tig.2011.03.005; Hamada T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012971; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He YW, 2009, CELL MOL LIFE SCI, V66, P1239, DOI 10.1007/s00018-008-8532-1; Holcomb VB, 2007, MECH AGEING DEV, V128, P601, DOI 10.1016/j.mad.2007.08.006; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang PR, 2010, BBA-MOL CELL RES, V1803, P1164, DOI 10.1016/j.bbamcr.2010.06.003; Lenaz G, 2006, ANTIOXID REDOX SIGN, V8, P417, DOI 10.1089/ars.2006.8.417; Linseman DA, 2008, FRONT BIOSCI-LANDMRK, V13, P657, DOI 10.2741/2710; Liu Y, 2012, J IMMUNOL, V188, P5500, DOI 10.4049/jimmunol.1103505; Mancini M, 2012, AGING-US, V4, P843, DOI 10.18632/aging.100508; Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118; Monteleone F, 2013, PROTEOMICS, V13, P866, DOI 10.1002/pmic.201200303; Olaru AV, 2011, HEPATOLOGY, V54, P2089, DOI 10.1002/hep.24591; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Scippa GS, 2010, ELECTROPHORESIS, V31, P497, DOI 10.1002/elps.200900459; Smith-Vikos T, 2012, J CELL SCI, V125, P7, DOI 10.1242/jcs.099200; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; Talamo F, 2003, PROTEOMICS, V3, P440, DOI 10.1002/pmic.200390059; Tanaka E, 2007, BIOCHEM BIOPH RES CO, V358, P608, DOI 10.1016/j.bbrc.2007.04.177; Turner-Ivey B, 2013, ONCOGENE, V32, P5302, DOI 10.1038/onc.2012.624; Velarde MC, 2012, AGING-US, V4, P3, DOI 10.18632/aging.100423; Weilner S, 2013, EXP GERONTOL, V48, P626, DOI 10.1016/j.exger.2012.11.017; Wu SQ, 2009, EXP CELL RES, V315, P3099, DOI 10.1016/j.yexcr.2009.09.009; Xing L, 2012, MOL BIOL CELL, V23, P1500, DOI 10.1091/mbc.E11-10-0867; Yamanaka S, 2012, CELL CYCLE, V11, P2729, DOI 10.4161/cc.21105; Yi J, 2010, NUCLEIC ACIDS RES, V38, P1547, DOI 10.1093/nar/gkp1114; Yun UJ, 2011, EXP MOL MED, V43, P389, DOI 10.3858/emm.2011.43.7.042	47	28	29	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3720	3733		10.1096/fj.13-239129	http://dx.doi.org/10.1096/fj.13-239129			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24823364				2022-12-28	WOS:000340265400038
J	Chatterjee, M; Seizer, P; Borst, O; Schonberger, T; Mack, A; Geisler, T; Langer, HF; May, AE; Vogel, S; Lang, F; Gawaz, M				Chatterjee, Madhumita; Seizer, Peter; Borst, Oliver; Schoenberger, Tanja; Mack, Andreas; Geisler, Tobias; Langer, Harald F.; May, Andreas E.; Vogel, Sebastian; Lang, Florian; Gawaz, Meinrad			SDF-1 alpha induces differential trafficking of CXCR4-CXCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival	FASEB JOURNAL			English	Article						platelets; chemokine; receptor; apoptosis	CELL-SURVIVAL; CHEMOKINE RECEPTOR; PROGENITOR CELLS; ACTIVATION; APOPTOSIS; MIGRATION; ADHESION; CXCL12; INFLAMMATION; RECRUIT	Platelet-derived SDF-1 alpha (CXCL12) mediates inflammatory and regenerative mechanisms. The present study characterizes the effect of SDF-1 alpha ligation in platelets. SDF-1 alpha (0-100 mu M) dose and time dependently caused internalization of its receptor CXCR4 (28.9 +/- 1.6 vs. 16.1 +/- 1.9 in SDF-1 alpha -treated platelets), coupled to the surface externalization of CXCR7 (65.5 +/- 8 vs. 162.8 +/- 27.6 following SDF-1 alpha treatment), both in vitro and in vivo. This was inhibited in the presence of AMD3100 (100 mu M), CXCR4 blocking and vesicular transport inhibitors (brefeldin A, 10 mu M; rapamycin, 100 nM). SDF-1 alpha/CXCR-4-mediated CXCR7 translocation was significantly reduced by inhibitors of ERK1/2-(U0126-10 mu M) and cyclophilinA (CyPA)(NIM811-10 mu M) by 28 and 46%, respectively. Further, SDF-1 alpha-induced downstream phosphorylation of Erk1/2 led to CyPA-dependent ubiquitination of CXCR7, which is essential for its surface translocation. CyPA-PPIase-activity inhibitor NIM-811, Erk1/2, and E1-ligase inhibitor(PYR-41-25 mu M) significantly abolished SDF-1 alpha-driven CXCR7 ubiquitination and subsequent surface translocation. SDF-1 alpha induced CXCR7 ubiquitination, and its surface exposure was observed in wild-type murine platelets, but not in CyPA-deficient platelets. SDF-1 alpha/CXCR4-CyPA-dependent CXCR7 translocation and its subsequent ligation attenuated activation-induced apoptosis both in vitro and when administered in vivo. This antiapoptotic effect of SDF-1 alpha was abrogated by blocking CXCR7, also significantly affected in Cypa(-/-) platelets. Thus, we decipher a novel mechanism, whereby SDF-1 alpha regulates relative receptor availability in circulating platelets and exerts its prosurvival benefits.	[Chatterjee, Madhumita; Seizer, Peter; Borst, Oliver; Schoenberger, Tanja; Geisler, Tobias; Langer, Harald F.; May, Andreas E.; Vogel, Sebastian; Gawaz, Meinrad] Univ Tubingen, Med Klin 3, D-72076 Tubingen, Germany; [Lang, Florian] Univ Tubingen, Inst Physiol, D-72076 Tubingen, Germany; [Mack, Andreas] Univ Tubingen, Inst Anat, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Gawaz, M (corresponding author), Univ Tubingen, Med Klin 3, Otfried Muller Str 10, D-72076 Tubingen, Germany.	meinrad.gawaz@med.uni-tuebingen.de	Geisler, Tobias/AAO-4472-2020	Mack, Andreas/0000-0001-7591-4374; Borst, Oliver/0000-0003-4002-4085; Vogel, Sebastian/0000-0002-3284-0464; Chatterjee, Madhumita/0000-0002-3428-4107	Deutsche Forschungsgemeinschaft (Klinische Forschungsgruppe KFO-274: Platelets-Molecular Mechanisms and Translational Implications); Deutsche Forschungsgemeinschaft (Transregio-SFB: Inflammatory Cardiomyopathy)	Deutsche Forschungsgemeinschaft (Klinische Forschungsgruppe KFO-274: Platelets-Molecular Mechanisms and Translational Implications); Deutsche Forschungsgemeinschaft (Transregio-SFB: Inflammatory Cardiomyopathy)	The authors thank Ms. Christina Flaum for her technical expertise. The study was supported by the Deutsche Forschungsgemeinschaft (Klinische Forschungsgruppe KFO-274: Platelets-Molecular Mechanisms and Translational Implications, and the Transregio-SFB: Inflammatory Cardiomyopathy). The authors declare no conflicts of interest.	Sanchez-Alcaniz JA, 2011, NEURON, V69, P77, DOI 10.1016/j.neuron.2010.12.006; Borst O, 2012, CIRC RES, V111, P1297, DOI 10.1161/CIRCRESAHA.112.276444; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Canals M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034192; Chatterjee M, 2011, BLOOD, V117, P3907, DOI 10.1182/blood-2010-12-327007; Elvers M, 2012, BLOOD, V120, P1317, DOI 10.1182/blood-2011-12-398438; Gawaz M, 2005, J CLIN INVEST, V115, P3378, DOI 10.1172/JCI27196; Gleissner CA, 2008, ARTERIOSCL THROM VAS, V28, P1920, DOI 10.1161/ATVBAHA.108.169417; Guillemot E, 2012, BRIT J CANCER, V107, P1944, DOI 10.1038/bjc.2012.503; Hartmann TN, 2008, J LEUKOCYTE BIOL, V84, P1130, DOI 10.1189/jlb.0208088; Hattermann K, 2012, ONCOL REP, V27, P1348, DOI 10.3892/or.2012.1674; Kraemer BF, 2010, J MOL MED, V88, P1277, DOI 10.1007/s00109-010-0680-8; Kumar R, 2012, CELL IMMUNOL, V272, P230, DOI 10.1016/j.cellimm.2011.09.015; Langer H, 2006, CIRC RES, V98, pE2, DOI 10.1161/01.RES.0000201285.87524.9e; Lapham CK, 2002, J LEUKOCYTE BIOL, V72, P1206; Levoye A, 2009, BLOOD, V113, P6085, DOI 10.1182/blood-2008-12-196618; Leytin V, 2012, BLOOD REV, V26, P51, DOI 10.1016/j.blre.2011.10.002; Li T, 2011, J PATHOL, V223, P519, DOI 10.1002/path.2829; Liu HQ, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-147; Liu XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031063; Mahabaleshwar H, 2008, CELL ADHES MIGR, V2, P69, DOI 10.4161/cam.2.2.6027; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Massberg S, 2006, J EXP MED, V203, P1221, DOI 10.1084/jem.20051772; Mazzinghi B, 2008, J EXP MED, V205, P479, DOI 10.1084/jem.20071903; Odemis V, 2012, GLIA, V60, P372, DOI 10.1002/glia.22271; Pan H, 2008, J BIOL CHEM, V283, P623, DOI 10.1074/jbc.M704934200; Rath D, 2014, EUR HEART J, V35, P386, DOI 10.1093/eurheartj/eht448; Seizer P, 2012, J MOL CELL CARDIOL, V53, P6, DOI 10.1016/j.yjmcc.2012.03.004; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Stellos K, 2008, CIRCULATION, V117, P206, DOI 10.1161/CIRCULATIONAHA.107.714691; Thelen M, 2008, J NEUROIMMUNOL, V198, P9, DOI 10.1016/j.jneuroim.2008.04.020; Vogler M, 2011, BLOOD, V117, P7145, DOI 10.1182/blood-2011-03-344812; Wang JF, 1998, BLOOD, V92, P756, DOI 10.1182/blood.V92.3.756.415k36_756_764; Wolfe BL, 2007, J CELL BIOL, V177, P905, DOI 10.1083/jcb.200610154; Zhu B, 2012, STEM CELLS, V30, P2571, DOI 10.1002/stem.1239	36	43	44	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2864	2878		10.1096/fj.14-249730	http://dx.doi.org/10.1096/fj.14-249730			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24668750				2022-12-28	WOS:000337949400012
J	da Costa, KA; Corbin, KD; Niculescu, MD; Galanko, JA; Zeisel, SH				da Costa, Kerry-Ann; Corbin, Karen D.; Niculescu, Mihai D.; Galanko, Joseph A.; Zeisel, Steven H.			Identification of new genetic polymorphisms that alter the dietary requirement for choline and vary in their distribution across ethnic and racial groups	FASEB JOURNAL			English	Article						SNP; creatine kinase; fatty liver; muscle	PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; HOMOCYSTEINE S-METHYLTRANSFERASE; 1-CARBON METABOLISM; HEPATIC STEATOSIS; BETAINE; NUTRIENT; WOMEN; RISK; METHYLATION; HUMANS	Effect alleles (alleles with a polymorphism that is associated with the effect being measured) in a small number of single-nucleotide polymorphisms (SNPs) are known to influence the dietary requirement for choline. In this study, we examined a much larger number of SNPs (n = 200) in 10 genes related to choline metabolism for associations with development of organ dysfunction (liver or muscle) when 79 humans were fed a low-choline diet. We confirmed that effect alleles in SNPs such as the C allele of PEMT rs12325817 increase the risk of developing organ dysfunction in women when they consume a diet low in choline, and we identified novel effect alleles, such as the C allele of CHKA SNP rs7928739, that alter dietary choline requirements. When fed a low-choline diet, some people presented with muscle damage rather than liver damage; several effect alleles in SLC44A1 (rs7873937, G allele; rs2771040, G; rs6479313, G; rs16924529, A; and rs3199966, C) and one in CHKB (rs1557502, A) were more common in these individuals. This suggests that pathways related to choline metabolism are more important for normal muscle function than previously thought. In European, Mexican, and Asian Americans, and in individuals of African descent, we examined the prevalence of the effect alleles in SNPs that alter choline requirement and found that they are differentially distributed among people of different ethnic and racial backgrounds. Overall, our study has identified novel genetic variants that modulate choline requirements and suggests that the dietary requirement for choline may be different across racial and ethnic groups.	[da Costa, Kerry-Ann; Zeisel, Steven H.] Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; [da Costa, Kerry-Ann; Zeisel, Steven H.] Univ N Carolina, Sch Med, Chapel Hill, NC USA; [Galanko, Joseph A.] Univ N Carolina, Dept Med, Chapel Hill, NC USA; [Corbin, Karen D.; Niculescu, Mihai D.; Zeisel, Steven H.] Univ North Carolina Chapel Hill, Inst Nutr Res, Kannapolis, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Zeisel, SH (corresponding author), Inst Nutr Res, 500 Laureate Way, Kannapolis, NC 28081 USA.	steven_zeisel@unc.edu	Core, Mammalian Genotyping/AFU-1631-2022	Corbin, Karen/0000-0003-2065-0003	U.S. National Institutes of Health [DK55865]; University of North Carolina (UNC) Nutrition and Obesity Research Center [DK56350]; UNC Gastrointestinal Research Center [DK03498]; UNC Clinical and Translational Research Center [M01RR00046, UL1RR025747]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046, UL1RR025747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865, P30DK034987, P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of North Carolina (UNC) Nutrition and Obesity Research Center; UNC Gastrointestinal Research Center; UNC Clinical and Translational Research Center; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This research was supported by grants from the U.S. National Institutes of Health to S.H.Z. (DK55865), the University of North Carolina (UNC) Nutrition and Obesity Research Center (DK56350), the UNC Gastrointestinal Research Center (DK03498) and the UNC Clinical and Translational Research Center (M01RR00046 and UL1RR025747). The clinical study is registered at Clinical-Trials.gov (NCT00065546; http://www.clinicaltrials.gov). The authors thank the Mammalian Genotyping Core at UNC Chapel Hill for their assistance on this project, and especially Amanda Beaty for her patience and generosity. The authors also thank Mihai George Mehedint, Huili Wang, Hye Mee Hwang and Robin Betsch for their technical assistance in this study, and Fred Wright for his statistical advice. Author contributions: K.-A.D. was responsible for sample collection, genotyping, data interpretation and preparation of the manuscript; K. D. C. assisted with the genotyping, SNP analysis, and preparation of the manuscript; M.D.N. was responsible for the design and setup of the PEMT rs12325817 genotyping; J.A.G. assisted with statistical analyses; S.H.Z. was responsible for overall experimental design and data interpretation and assisted with the preparation of the manuscript. The authors declare no conflicts of interest.	Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BUCHMAN AL, 1995, HEPATOLOGY, V22, P1399, DOI 10.1002/hep.1840220510; Busby MG, 2004, J AM DIET ASSOC, V104, P1836, DOI 10.1016/j.jada.2004.09.027; Chester DN., 2011, DIETARY INTAKES CHOL; Cho E, 2006, AM J CLIN NUTR, V83, P905, DOI 10.1093/ajcn/83.4.905; Cho E, 2007, JNCI-J NATL CANCER I, V99, P1224, DOI 10.1093/jnci/djm082; Collinsova M, 2006, J NUTR, V136, P1493, DOI 10.1093/jn/136.6.1493; Corbin KD, 2013, FASEB J, V27, P1674, DOI 10.1096/fj.12-219097; da Costa KA, 2004, AM J CLIN NUTR, V80, P163; da Costa KA, 2006, FASEB J, V20, P1336, DOI 10.1096/fj.06-5734com; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Dominguez-Salas P, 2013, AM J CLIN NUTR, V97, P1217, DOI 10.3945/ajcn.112.048462; Enaw JOE, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-36; Fischer LM, 2007, AM J CLIN NUTR, V85, P1275; Fischer LM, 2010, AM J CLIN NUTR, V92, P1113, DOI 10.3945/ajcn.2010.30064; Gao XY, 2008, GENET EPIDEMIOL, V32, P361, DOI 10.1002/gepi.20310; Hung J, 2008, J AM COLL NUTR, V27, P253, DOI 10.1080/07315724.2008.10719697; Institute of Medicine, 1998, DIET REF INT THIAM R, P390, DOI [DOI 10.17226/6015, 10.17226/6015]; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kimm SYS, 2002, AM J CLIN NUTR, V75, P714, DOI 10.1093/ajcn/75.4.714; Kohlmeier M, 2005, P NATL ACAD SCI USA, V102, P16025, DOI 10.1073/pnas.0504285102; Lee JE, 2010, CANCER EPIDEM BIOMAR, V19, P884, DOI 10.1158/1055-9965.EPI-09-1295; Li ZY, 2005, J BIOL CHEM, V280, P37798, DOI 10.1074/jbc.M508575200; Michel Vera, 2012, Central Nervous System Agents in Medicinal Chemistry, V12, P70; Michel V, 2011, FOOD FUNCT, V2, P53, DOI 10.1039/c0fo00069h; Michel V, 2009, FASEB J, V23, P2749, DOI 10.1096/fj.08-121491; Mitsuhashi S, 2011, AM J HUM GENET, V88, P845, DOI 10.1016/j.ajhg.2011.05.010; Resseguie M, 2007, FASEB J, V21, P2622, DOI 10.1096/fj.07-8227com; Resseguie ME, 2011, J BIOL CHEM, V286, P1649, DOI 10.1074/jbc.M110.106922; Sambrook J., 2001, MOL CLONING LAB MANU; Shaw GM, 2006, EPIDEMIOLOGY, V17, P285, DOI 10.1097/01.ede.0000208348.30012.35; Shaw GM, 2004, AM J EPIDEMIOL, V160, P102, DOI 10.1093/aje/kwh187; Shen R, 2005, MUTAT RES-FUND MOL M, V573, P70, DOI 10.1016/j.mrfmmm.2004.07.022; Shin W, 2010, J NUTR, V140, P975, DOI 10.3945/jn.110.121186; Teng YW, 2011, J BIOL CHEM, V286, P36258, DOI 10.1074/jbc.M111.265348; Traiffort E, 2013, MOL ASPECTS MED, V34, P646, DOI 10.1016/j.mam.2012.10.011; Walkey CJ, 1999, BBA-MOL CELL BIOL L, V1436, P405, DOI 10.1016/S0005-2760(98)00147-7; Wu GS, 2010, BIOCHEM CELL BIOL, V88, P559, DOI 10.1139/O09-160; Yan JA, 2011, AM J CLIN NUTR, V93, P348, DOI 10.3945/ajcn.110.005975; Zeisel SH, 2003, J NUTR, V133, P1302; ZEISEL SH, 1995, J NUTR, V125, P3049; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156	44	44	44	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2970	2978		10.1096/fj.14-249557	http://dx.doi.org/10.1096/fj.14-249557			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24671709	Green Published, Green Submitted			2022-12-28	WOS:000337949400020
J	Dubois, V; Laurent, MR; Sinnesael, M; Cielen, N; Helsen, C; Clinckemalie, L; Spans, L; Gayan-Ramirez, G; Deldicque, L; Hespel, P; Carmeliet, G; Vanderschueren, D; Claessens, F				Dubois, Vanessa; Laurent, Michal R.; Sinnesael, Mieke; Cielen, Nele; Helsen, Christine; Clinckemalie, Liesbeth; Spans, Lien; Gayan-Ramirez, Ghislaine; Deldicque, Louise; Hespel, Peter; Carmeliet, Geert; Vanderschueren, Dirk; Claessens, Frank			A satellite cell-specific knockout of the androgen receptor reveals myostatin as a direct androgen target in skeletal muscle	FASEB JOURNAL			English	Article						mouse model; fiber type; microarray; DNA response element; hormone response element	GROWTH-FACTOR; BODY-COMPOSITION; MALE-MICE; MYOGENIC DIFFERENTIATION; SIGNALING PATHWAYS; RAT MODEL; TESTOSTERONE; EXPRESSION; STRENGTH; MASS	Androgens have well-established anabolic actions on skeletal muscle, although the direct effects of the androgen receptor (AR) in muscle remain unclear. We generated satellite cell-specific AR-knockout (satARKO) mice in which the AR is selectively ablated in satellite cells, the muscle precursor cells. Total-limb maximal grip strength is decreased by 7% in satARKO mice, with soleus muscles containing similar to 10% more type I fibers and 10% less type IIa fibers than the corresponding control littermates. The weight of the perineal levator ani muscle is markedly reduced (similar to 52%). Thus, muscle AR is involved in fiber-type distribution and force production of the limb muscles, while it is a major determinant of the perineal muscle mass. Surprisingly, myostatin (Mstn), a strong inhibitor of skeletal muscle growth, is one of the most androgen-responsive genes (6-fold reduction in satARKO) through direct transcription activation by the AR. Consequently, muscle hypertrophy in response to androgens is augmented in Mstn-knockout mice. Our finding that androgens induce Mstn signaling to restrain their own anabolic actions has implications for the treatment of muscle wasting disorders.	[Dubois, Vanessa; Laurent, Michal R.; Helsen, Christine; Clinckemalie, Liesbeth; Spans, Lien; Claessens, Frank] Katholieke Univ Leuven, Mol Endocrinol Lab, B-3000 Leuven, Belgium; [Laurent, Michal R.] Katholieke Univ Leuven, Div Gerontol & Geriatr, B-3000 Leuven, Belgium; [Sinnesael, Mieke; Carmeliet, Geert; Vanderschueren, Dirk] Katholieke Univ Leuven, Div Clin & Expt Endocrinol, B-3000 Leuven, Belgium; [Cielen, Nele; Gayan-Ramirez, Ghislaine] Katholieke Univ Leuven, Div Pneumol, B-3000 Leuven, Belgium; [Deldicque, Louise; Hespel, Peter] Katholieke Univ Leuven, Exercise Physiol Res Grp, B-3000 Leuven, Belgium	KU Leuven; KU Leuven; KU Leuven; KU Leuven; KU Leuven	Claessens, F (corresponding author), Katholieke Univ Leuven, Campus Gasthuisberg O&N1 POB 901,Herestr 49, B-3000 Leuven, Belgium.	frank.claessens@med.kuleuven.be	Laurent, Michaël R./D-5748-2011; Dubois, Vanessa/ABF-9551-2021; Claessens, Frank/M-8565-2016	Laurent, Michaël R./0000-0001-9681-8330; Dubois, Vanessa/0000-0001-8894-2980; Claessens, Frank/0000-0002-8676-7709; Deldicque, Louise/0000-0003-3393-5278; Gayan-Ramirez, Ghislaine/0000-0001-9652-7437; vanderschueren, dirk/0000-0003-1395-0104; Hespel, Peter/0000-0003-1283-2229; Helsen, Christine/0000-0003-1048-2798	Flemish Fund for Scientific Research (FWO) [G.0858.11N]; KU Leuven [OT/11/081, OT/09/035]; FWO	Flemish Fund for Scientific Research (FWO)(FWO); KU Leuven(KU Leuven); FWO(FWO)	This work was supported by research grants from the Flemish Fund for Scientific Research (FWO; G.0858.11N) and from KU Leuven (OT/11/081, OT/09/035). V. D. and M. R. L. are holders of a doctoral fellowship of the FWO. The authors thank R. Bollen, H. Debruyn, D. Schollaert, E. Van Herck, L. Deboel, R. Van Looveren, K. Moermans, and M. Ramaekers for their excellent technical assistance and their colleagues of the Molecular Endocrinology Laboratory for the helpful discussions. The authors thank Alexandra C. McPherron and Se-Jin Lee (Johns Hopkins University, Baltimore, MD, USA) for the kind gift of the Mstn-KO mice.	Axell AM, 2006, AM J PHYSIOL-ENDOC M, V291, pE506, DOI 10.1152/ajpendo.00058.2006; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; Bhasin S, 2001, AM J PHYSIOL-ENDOC M, V281, pE1172, DOI 10.1152/ajpendo.2001.281.6.E1172; Bodine SC, 2013, INT J BIOCHEM CELL B, V45, P2200, DOI 10.1016/j.biocel.2013.06.011; Braga M, 2012, MOL CELL ENDOCRINOL, V350, P39, DOI 10.1016/j.mce.2011.11.019; Callewaert F, 2010, J ENDOCRINOL, V207, P127, DOI 10.1677/JOE-10-0209; Callewaert F, 2009, FASEB J, V23, P232, DOI 10.1096/fj.08-113456; Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154; Chambon C, 2010, P NATL ACAD SCI USA, V107, P14327, DOI 10.1073/pnas.1009536107; Chen Y, 2005, J ENDOCRINOL, V186, P21, DOI 10.1677/joe.1.05976; Claessens Frank, 2008, Nucl Recept Signal, V6, pe008, DOI 10.1621/nrs.06008; De Gendt K, 2004, P NATL ACAD SCI USA, V101, P1327, DOI 10.1073/pnas.0308114100; Denayer S, 2010, MOL ENDOCRINOL, V24, P898, DOI 10.1210/me.2009-0310; Diel P, 2008, J MOL ENDOCRINOL, V40, P231, DOI 10.1677/JME-07-0175; Diel P, 2010, MOL CELL ENDOCRINOL, V330, P1, DOI 10.1016/j.mce.2010.08.015; Dubois V, 2012, CELL MOL LIFE SCI, V69, P1651, DOI 10.1007/s00018-011-0883-3; Ebner N, 2013, MATURITAS, V75, P199, DOI 10.1016/j.maturitas.2013.03.014; Estrada M, 2000, AM J PHYSIOL-ENDOC M, V279, pE132, DOI 10.1152/ajpendo.2000.279.1.E132; Fassbender A, 2012, HUM REPROD, V27, P2020, DOI 10.1093/humrep/des127; Finkelstein JS, 2013, NEW ENGL J MED, V369, P1011, DOI 10.1056/NEJMoa1206168; FITTS RH, 1994, PHYSIOL REV, V74, P49, DOI 10.1152/physrev.1994.74.1.49; Gaussin V, 2005, CARDIOVASC RES, V68, P347, DOI 10.1016/j.cardiores.2005.09.007; Gentile MA, 2010, J MOL ENDOCRINOL, V44, P55, DOI 10.1677/JME-09-0048; Gielen E, 2012, CALCIFIED TISSUE INT, V91, P161, DOI 10.1007/s00223-012-9622-5; Han HQ, 2013, INT J BIOCHEM CELL B, V45, P2333, DOI 10.1016/j.biocel.2013.05.019; Helsen C, 2012, MOL CELL BIOL, V32, P3033, DOI 10.1128/MCB.00151-12; Ibebunjo C, 2011, AM J PHYSIOL-ENDOC M, V300, pE327, DOI 10.1152/ajpendo.00402.2010; Johansen JA, 2007, J NEUROENDOCRINOL, V19, P823, DOI 10.1111/j.1365-2826.2007.01592.x; Kanisicak O, 2009, DEV BIOL, V332, P131, DOI 10.1016/j.ydbio.2009.05.554; Kovacheva EL, 2010, ENDOCRINOLOGY, V151, P628, DOI 10.1210/en.2009-1177; Lakshman KM, 2009, MOL CELL ENDOCRINOL, V302, P26, DOI 10.1016/j.mce.2008.12.019; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Li TT, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-186; Ma K, 2001, AM J PHYSIOL-ENDOC M, V281, pE1128, DOI 10.1152/ajpendo.2001.281.6.E1128; MacLean HE, 2008, FASEB J, V22, P2676, DOI 10.1096/fj.08-105726; MacLean HE, 2009, ENDOCRINOLOGY, V150, P3437, DOI 10.1210/en.2009-0438; Matsakas A, 2012, EXP PHYSIOL, V97, P125, DOI 10.1113/expphysiol.2011.063008; Matsumoto A, 1996, J NEUROENDOCRINOL, V8, P553, DOI 10.1046/j.1365-2826.1996.04899.x; McFarlane C, 2008, EXP CELL RES, V314, P317, DOI 10.1016/j.yexcr.2007.09.012; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Mendias CL, 2006, J APPL PHYSIOL, V101, P898, DOI 10.1152/japplphysiol.00126.2006; Mendler L, 2007, BIOCHEM BIOPH RES CO, V361, P237, DOI 10.1016/j.bbrc.2007.07.023; Monks DA, 2004, J COMP NEUROL, V473, P59, DOI 10.1002/cne.20088; Mosler S, 2013, INT J SPORTS MED, V34, P567, DOI 10.1055/s-0032-1312585; Mosler S, 2012, ARCH TOXICOL, V86, P109, DOI 10.1007/s00204-011-0740-z; Ophoff J, 2009, ENDOCRINOLOGY, V150, P3558, DOI 10.1210/en.2008-1509; Ophoff J, 2009, BIOCHEM BIOPH RES CO, V378, P139, DOI 10.1016/j.bbrc.2008.11.016; Raskin K, 2009, J NEUROSCI, V29, P4461, DOI 10.1523/JNEUROSCI.0296-09.2009; Rinaldi M, 2012, DIS MODEL MECH, V5, P333, DOI 10.1242/dmm.008508; Rolf C, 1998, BAILLIERE CLIN ENDOC, V12, P521, DOI 10.1016/S0950-351X(98)80305-4; Serra C, 2011, ENDOCRINOLOGY, V152, P193, DOI 10.1210/en.2010-0802; Seuntjens E, 2009, CYTOKINE GROWTH F R, V20, P449, DOI 10.1016/j.cytogfr.2009.10.005; Singh R, 2009, ENDOCRINOLOGY, V150, P1259, DOI 10.1210/en.2008-0858; Sinha-Hikim I, 2004, J CLIN ENDOCR METAB, V89, P5245, DOI 10.1210/jc.2004-0084; Storer TW, 2003, J CLIN ENDOCR METAB, V88, P1478, DOI 10.1210/jc.2002-021231; Szulc P, 2012, J CLIN ENDOCR METAB, V97, P3700, DOI 10.1210/jc.2012-1273; Vandenput L, 2002, J BONE MINER RES, V17, P2080, DOI 10.1359/jbmr.2002.17.11.2080; Vanderschueren D, 2000, ENDOCRINOLOGY, V141, P1642, DOI 10.1210/en.141.5.1642; Verrijdt G, 2002, J BIOL CHEM, V277, P35191, DOI 10.1074/jbc.M205928200; Wyce A, 2010, MOL ENDOCRINOL, V24, P1665, DOI 10.1210/me.2010-0138	61	68	75	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2979	2994		10.1096/fj.14-249748	http://dx.doi.org/10.1096/fj.14-249748			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24671706				2022-12-28	WOS:000337949400021
J	Faria, MS; Calegari-Silva, TC; Vivarini, AD; Mottram, JC; Lopes, UG; Lima, APCA				Faria, Marilia S.; Calegari-Silva, Tereza C.; Vivarini, Aislan de Carvalho; Mottram, Jeremy C.; Lopes, Ulisses Gazos; Lima, Ana Paula C. A.			Role of protein kinase R in the killing of Leishmania major by macrophages in response to neutrophil elastase and TLR4 via TNF alpha and IFN beta	FASEB JOURNAL			English	Article						ecotin; Toll; interferon; ISP2	INNATE IMMUNE-RESPONSE; NITRIC-OXIDE SYNTHASE; PKR; PEPTIDASES; ACTIVATION; EXPRESSION; INFECTION	In cutaneous leishmaniasis, Leishmania amazonensis activates macrophage double-stranded, RNA-activated protein kinase R (PKR) to promote parasite growth. In our study, Leishmania major grew normally in RAW cells, RAW-expressing dominant-negative PKR (PKR-DN) cells, and macrophages of PKR-knockout mice, revealing that PKR is dispensable for L. major growth in macrophages. PKR activation in infected macrophages with poly I: C resulted in parasite death. Fifty percent of L. major-knockout lines for the ecotin-like serine peptidase inhibitor (ISP2; Delta isp2/isp3), an inhibitor of neutrophil elastase (NE), died in RAW cells or macrophages from 129Sv mice, as a result of PKR activation. Inhibition of PKR or NE or neutralization of Toll-like receptor 4 or 2(TLR4 or TLR2) prevented the death of Delta isp2/isp3. Delta isp2/isp3 grew normally in RAW-PKR-DN cells or macrophages from 129Sv pkr(-/-), tlr2(-/-), trif(-/-), and myd88(-/-) mice, associating NE activity, PKR, and TLR responses with parasite death. Delta isp2/isp3 increased the expression of mRNA for TNF-alpha by 2-fold and of interferon beta (IFN beta) in a PKR-dependent manner. Antibodies to TNF-alpha reversed the 95% killing by Delta isp2/isp3, whereas they grew normally in macrophages from IFN receptor-knockout mice. We propose that ISP2 prevents the activation of PKR via an NE-TLR4-TLR2 axis to control innate responses that contribute to the killing of L. major.	[Faria, Marilia S.; Calegari-Silva, Tereza C.; Vivarini, Aislan de Carvalho; Lopes, Ulisses Gazos; Lima, Ana Paula C. A.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21949902 Rio De Janeiro, RJ, Brazil; [Mottram, Jeremy C.] Univ Glasgow, Coll Med Vet & Life Sci, Wellcome Trust Ctr Mol Parasitol, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland	Universidade Federal do Rio de Janeiro; University of Glasgow	Lima, APCA (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Ctr Ciencias Saude, Ilha Fundao, Av Carlos Chagas Filho 373,Bloco G,Cidade Univ, BR-21949902 Rio De Janeiro, RJ, Brazil.	anapaula@biof.ufrj.br	Lopes, Ulisses Gazos/T-6634-2019; Vivarini, Áislan/G-3249-2015; Lima, Ana Paula CA/G-4122-2012; Vivarini, Aislan/ABC-9774-2021	Vivarini, Áislan/0000-0002-2629-257X; Calegari Silva, Teresa Cristina/0000-0002-1656-3460; Mottram, Jeremy/0000-0001-5574-3766	Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ; Portuguese Research Foundation of Rio de Janeiro); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; National Council for Technological and Scientific Development); Wellcome Trust [085349]	Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ; Portuguese Research Foundation of Rio de Janeiro); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; National Council for Technological and Scientific Development)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Wellcome Trust(Wellcome TrustEuropean Commission)	The authors thank E. Lopes for technical assistance and Prof. S. Oliveira [Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil], Dr. M. Bellio [Universidade Federal do Rio de Janeiro (UFRJ)], and Dr. M. Bozza (UFRJ) for the donation of bone marrow from knockout mice. This work was supported by grants from Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ; Portuguese Research Foundation of Rio de Janeiro) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; National Council for Technological and Scientific Development). A.P.C.A.L. and U.G.L. are CNPq fellows. The Wellcome Trust Centre for Molecular Parasitology is supported by core funding from the Wellcome Trust (grant 085349).	Abu-Dayyeh I, 2010, INFECT IMMUN, V78, P2438, DOI 10.1128/IAI.00812-09; Cabanski M, 2008, AM J RESP CELL MOL, V38, P26, DOI 10.1165/rcmb.2007-0010OC; Calegari-Silva TC, 2009, IMMUNOL LETT, V127, P19, DOI 10.1016/j.imlet.2009.08.009; Cameron P, 2004, J IMMUNOL, V173, P3297, DOI 10.4049/jimmunol.173.5.3297; Danelli MGM, 2009, PHYTOCHEMISTRY, V70, P608, DOI 10.1016/j.phytochem.2009.03.009; DASILVA R, 1987, INFECT IMMUN, V55, P2802, DOI 10.1128/IAI.55.11.2802-2806.1987; Diefenbach A, 1998, IMMUNITY, V8, P77, DOI 10.1016/S1074-7613(00)80460-4; Eschenlauer SCP, 2009, CELL MICROBIOL, V11, P106, DOI 10.1111/j.1462-5822.2008.01243.x; Faria MS, 2011, J IMMUNOL, V186, P411, DOI 10.4049/jimmunol.1002175; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Kagan JC, 2008, NAT IMMUNOL, V9, P361, DOI 10.1038/ni1569; Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608; Kedzierski L, 2009, CURR MED CHEM, V16, P599, DOI 10.2174/092986709787458489; Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860; Lee JH, 2005, GLIA, V50, P66, DOI 10.1002/glia.20156; Mattner J, 2004, J IMMUNOL, V172, P7574, DOI 10.4049/jimmunol.172.12.7574; Mattner J, 2000, EUR J IMMUNOL, V30, P2257, DOI 10.1002/1521-4141(2000)30:8&lt;2257::AID-IMMU2257&gt;3.0.CO;2-U; Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634; Nylen S, 2012, PARASITE IMMUNOL, V34, P551, DOI 10.1111/pim.12007; Peacock CS, 2007, NAT GENET, V39, P839, DOI 10.1038/ng2053; Pereira RMS, 2010, FASEB J, V24, P617, DOI 10.1096/fj.09-140053; Ribeiro-Gomes FL, 2007, J IMMUNOL, V179, P3988, DOI 10.4049/jimmunol.179.6.3988; Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Vivarini AD, 2011, FASEB J, V25, P4162, DOI 10.1096/fj.11-185165; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127	28	29	32	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3050	3063		10.1096/fj.13-245126	http://dx.doi.org/10.1096/fj.13-245126			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24732131	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000337949400027
J	Hoffmann, AK; Naj, XN; Linder, S				Hoffmann, Ann-Kathrin; Naj, Xenia; Linder, Stefan			Daam1 is a regulator of filopodia formation and phagocytic uptake of Borrelia burgdorferi by primary human macrophages	FASEB JOURNAL			English	Article						formins; actin cytoskeleton; cell protrusion; coiling pseudopod	COILING PHAGOCYTOSIS; FORMIN DAAM1; MAMMALIAN FORMINS; HUMAN MONOCYTES; ARP2/3 COMPLEX; ACTIN DYNAMICS; LYME CARDITIS; HOST-DEFENSE; ACTIVATION; MECHANISM	Borrelia burgdorferi is the causative agent of Lyme disease, an infectious disease that primarily affects the skin, nervous system, and joints. Uptake of borreliae by immune cells is decisive for the course of the infection, and remodelling of the host actin cytoskeleton is crucial in this process. In this study, we showed that the actin-regulatory formin Daam1 is important in Borrelia phagocytosis by primary human macrophages. Uptake of borreliae proceeds preferentially through capture by filopodia and formation of coiling pseudopods that enwrap the spirochetes. Using immunofluorescence, we localized endogenous and overexpressed Daam1 to filopodia and to F-actin-rich uptake structures. Live-cell imaging further showed that Daam1 is enriched at coiling pseudopods that arise from the macrophage surface. This filopodia-independent step was corroborated by control experiments of phagocytic cup formation with latex beads. Moreover, siRNA-mediated knockdown of Daam1 led to a 65% reduction of borreliae-induced filopodia, and, as shown by the outside-inside staining technique, to a 50% decrease in phagocytic uptake of borreliae, as well as a 37% reduction in coiling pseudopod formation. Collectively, we showed that Daam1 plays a dual role in the phagocytic uptake of borreliae: first, as a regulator of filopodia, which are used for capturing spirochetes, and second, in the formation of the coiling pseudopod that enwraps the bacterial cell. These data identify Daam1 as a novel regulator of B. burgdorferi phagocytosis. At the same time, this is the first demonstration of a role for Daam1 in phagocytic processes in general.	[Hoffmann, Ann-Kathrin; Naj, Xenia; Linder, Stefan] Univ Med Ctr Eppendorf, Inst Med Microbiol Virol & Hyg, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Linder, S (corresponding author), Univ Med Ctr Eppendorf, Inst Med Microbiol Virol & Hyg, Martinistr 52, D-20246 Hamburg, Germany.	s.linder@uke.de			Deutsche Forschungsgemeinschaft [GRK1459, SPP1464, LI 925/2-2]; Wilhelm Sander-Stiftung [2012.26.1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Wilhelm Sander-Stiftung	The authors thank Frank Bentzien [Transfusion Medicine, Universitatsklinikum Eppendorf (UKE), Hamburg, Germany] for the buffy coats, Peter Kraiczy for the B. burgdorferi B31 WT strain, Klemens Rottner (University of Bonn, Bonn, Germany) for GFP-Daam1 and GFP-Daam1 Delta C50, Danijela Vignjevic (Institut Curie, Paris, France) for mCherry-fascin and the fascin antibody, Mirko Himmel for help and discussions, Bernd Zobiak and Virgilio Failla (UKE Microscopy Facility) for expert technical help, and Martin Aepfelbacher for constant support. Work in the S. L. laboratory is funded by Deutsche Forschungsgemeinschaft (GRK1459, SPP1464, and LI 925/2-2) and Wilhelm Sander-Stiftung (2012.26.1).	Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Aspenstrom P, 2006, EXP CELL RES, V312, P2180, DOI 10.1016/j.yexcr.2006.03.013; Berende A, 2010, EUR CYTOKINE NETW, V21, P7, DOI 10.1684/ecn.2009.0179; Biesiada Grazyna, 2010, Przegl Lek, V67, P181; Bornschlogl T, 2013, P NATL ACAD SCI USA, V110, P18928, DOI 10.1073/pnas.1316572110; Bornschlogl T, 2013, CYTOSKELETON, V70, P590, DOI 10.1002/cm.21130; Cervantes JL, 2011, P NATL ACAD SCI USA, V108, P3683, DOI 10.1073/pnas.1013776108; Charon NW, 2012, ANNU REV MICROBIOL, V66, P349, DOI 10.1146/annurev-micro-092611-150145; Cinco M, 1998, WIEN KLIN WOCHENSCHR, V110, P866; Cruz AR, 2008, INFECT IMMUN, V76, P56, DOI 10.1128/IAI.01039-07; Dames SA, 2011, BIOMOL NMR ASSIGN, V5, P47, DOI 10.1007/s12104-010-9264-3; Esue O, 2008, J MOL BIOL, V384, P324, DOI 10.1016/j.jmb.2008.09.043; Faix J, 2009, INT J BIOCHEM CELL B, V41, P1656, DOI 10.1016/j.biocel.2009.02.012; Harris ES, 2006, J BIOL CHEM, V281, P14383, DOI 10.1074/jbc.M510923200; Harris ES, 2010, CYTOSKELETON, V67, P755, DOI 10.1002/cm.20485; Harris ES, 2004, CURR BIOL, V14, pR520, DOI 10.1016/j.cub.2004.06.043; Hawley KL, 2012, P NATL ACAD SCI USA, V109, P1228, DOI 10.1073/pnas.1112078109; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; HORWITZ MA, 1984, CELL, V36, P27, DOI 10.1016/0092-8674(84)90070-9; Hovius JWR, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000447; Jaiswal R, 2013, CURR BIOL, V23, P1373, DOI 10.1016/j.cub.2013.06.013; Jaumouille V, 2011, CURR OPIN CELL BIOL, V23, P22, DOI 10.1016/j.ceb.2010.10.006; Ju R, 2010, P NATL ACAD SCI USA, V107, P6906, DOI 10.1073/pnas.1001075107; Kida YS, 2007, P NATL ACAD SCI USA, V104, P6708, DOI 10.1073/pnas.0608946104; KOERTEN HK, 1980, EXP CELL RES, V128, P470, DOI 10.1016/0014-4827(80)90084-1; Koval M, 1998, EXP CELL RES, V242, P265, DOI 10.1006/excr.1998.4110; Kress H, 2007, P NATL ACAD SCI USA, V104, P11633, DOI 10.1073/pnas.0702449104; Lee JY, 2011, J PHYS CHEM B, V115, P186, DOI 10.1021/jp108249g; Li DQ, 2011, DEVELOPMENT, V138, P303, DOI 10.1242/dev.055566; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Linder S, 2001, INFECT IMMUN, V69, P1739, DOI 10.1128/IAI.69.3.1739-1746.2001; Liu W, 2008, P NATL ACAD SCI USA, V105, P210, DOI 10.1073/pnas.0707277105; Margos G, 2011, INFECT GENET EVOL, V11, P1545, DOI 10.1016/j.meegid.2011.07.022; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Matusek T, 2008, J NEUROSCI, V28, P13310, DOI 10.1523/JNEUROSCI.2727-08.2008; Miller RK, 2011, J AM SOC NEPHROL, V22, P1654, DOI 10.1681/ASN.2010101086; Montgomery RR, 2007, INFECT IMMUN, V75, P613, DOI 10.1128/IAI.00685-06; Moriarty TJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000090; Naj X, 2013, INFECT IMMUN, V81, P1683, DOI 10.1128/IAI.01411-12; Olson CM, 2009, J IMMUNOL, V182, P3728, DOI 10.4049/jimmunol.0804111; Rittig MG, 1998, INFECT IMMUN, V66, P627, DOI 10.1128/IAI.66.2.627-635.1998; RITTIG MG, 1992, INFECT IMMUN, V60, P4205, DOI 10.1128/IAI.60.10.4205-4212.1992; Salazar JC, 2003, J IMMUNOL, V171, P2660, DOI 10.4049/jimmunol.171.5.2660; Salazar JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000444; Schonichen A, 2010, BBA-MOL CELL RES, V1803, P152, DOI 10.1016/j.bbamcr.2010.01.014; Schoumacher M, 2010, J CELL BIOL, V189, P541, DOI 10.1083/jcb.200909113; Seth A, 2006, J CELL BIOL, V174, P701, DOI 10.1083/jcb.200605006; Shin OS, 2009, J IMMUNOL, V183, P491, DOI 10.4049/jimmunol.0900724; Suhonen J, 1998, INFECT IMMUN, V66, P3433, DOI 10.1128/IAI.66.7.3433-3435.1998; Vignjevic D, 2006, J CELL BIOL, V174, P863, DOI 10.1083/jcb.200603013; Vonna L, 2007, EUR BIOPHYS J BIOPHY, V36, P145, DOI 10.1007/s00249-006-0118-y; Wang GQ, 2004, FEMS MICROBIOL LETT, V231, P219, DOI 10.1016/S0378-1097(03)00960-1; Wiedemann A, 2001, CELL MICROBIOL, V3, P693, DOI 10.1046/j.1462-5822.2001.00149.x; Wu J, 2011, INFECT IMMUN, V79, P1338, DOI 10.1128/IAI.01188-10; Zhu J, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.031914; Zhu YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037823	58	26	26	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3075	3089		10.1096/fj.13-247049	http://dx.doi.org/10.1096/fj.13-247049			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24696301				2022-12-28	WOS:000337949400029
J	Ning, C; Wen, JM; Zhang, YJ; Dai, YB; Wang, W; Zhang, WR; Qi, L; Grenz, A; Eltzschig, HK; Blackburn, MR; Kellems, RE; Xia, Y				Ning, Chen; Wen, Jiaming; Zhang, Yujin; Dai, Yingbo; Wang, Wei; Zhang, Weiru; Qi, Lin; Grenz, Almut; Eltzschig, Holger K.; Blackburn, Michael R.; Kellems, Rodney E.; Xia, Yang			Excess adenosine A2B receptor signaling contributes to priapism through HIF-1 alpha mediated reduction of PDE5 gene expression	FASEB JOURNAL			English	Article						hypoxia-inducible factor; sickle cell disease; phosphodiesterase-5	SICKLE-CELL-DISEASE; DEAMINASE-DEFICIENT MICE; ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR-I; PULMONARY INFLAMMATION; HYPOXIA; MANAGEMENT; COMPLICATIONS; CONSEQUENCES; ASSOCIATION	Priapism is featured with prolonged and painful penile erection and is prevalent among males with sickle cell disease (SCD). The disorder is a dangerous urological and hematological emergency since it is associated with ischemic tissue damage and erectile disability. Here we report that phosphodiesterase-5 (PDE5) gene expression and PDE activity is significantly reduced in penile tissues of two independent priapic models: SCD mice and adenosine deaminase (ADA)-deficient mice. Moreover, using ADA enzyme therapy to reduce adenosine or a specific antagonist to block A(2B) adenosine receptor (ADORA2B) signaling, we successfully attenuated priapism in both ADA(-/-) and SCD mice by restoring penile PDE5 gene expression to normal levels. This finding led us to further discover that excess adenosine signaling via ADORA2B activation directly reduces PDE5 gene expression in a hypoxia-inducible factor-1 alpha (HIF-1 alpha)-dependent manner. Overall, we reveal that excess adenosine-mediated ADORA2B signaling underlies reduced penile PDE activity by decreasing PDE5 gene expression in a HIF-1 alpha-dependent manner and provide new insight for the pathogenesis of priapism and novel therapies for the disease.	[Ning, Chen; Wen, Jiaming; Zhang, Yujin; Dai, Yingbo; Wang, Wei; Zhang, Weiru; Blackburn, Michael R.; Kellems, Rodney E.; Xia, Yang] Univ Texas Houston, Med Sch Houston, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Ning, Chen; Dai, Yingbo; Qi, Lin] Cent S Univ, Xiangya Hosp, Dept Urol, Changsha, Hunan, Peoples R China; [Wang, Wei; Zhang, Weiru] Cent S Univ, Xiangya Hosp, Dept Nephrol, Changsha, Hunan, Peoples R China; [Ning, Chen] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing, Peoples R China; [Wen, Jiaming; Xia, Yang] Zhejiang Univ, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China; [Grenz, Almut; Eltzschig, Holger K.] Univ Colorado, Sch Med, Dept Anesthesiol, Denver, CO USA; [Blackburn, Michael R.; Kellems, Rodney E.; Xia, Yang] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; University of Texas Health Science Center Houston; Central South University; Central South University; Capital Medical University; Zhejiang University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Texas System; University of Texas Health Science Center Houston	Xia, Y (corresponding author), Univ Texas Houston, Med Sch Houston, Dept Biochem & Mol Biol, 6431 Fannin St,MSB 6-200, Houston, TX 77030 USA.	yang.xia@uth.tmc.edu		Blackburn, Michael/0000-0002-1394-9966	U.S. National Institutes of Health [DK083559, HL119549, HL114457, HL070952, HL092188]; China Scholarship Council [2009637520]; Beijing Natural Science Foundation [7144203]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092188, R01HL113574, R01HL070952, P01HL114457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083559] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council(China Scholarship Council); Beijing Natural Science Foundation(Beijing Natural Science Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grants DK083559 (to Y.X.), HL119549 (to Y.X.), HL114457 (M.R.B., Y.X. and H.K.E.) HL070952 (to M.R.B.), and HL092188 (to H.K.E.), China Scholarship Council grant 2009637520 (to W.R.Z.), and Beijing Natural Science Foundation grant 7144203 (to C.N.). The authors declare no conflicts of interest.	Adeyoju AB, 2002, BJU INT, V90, P898, DOI 10.1046/j.1464-410X.2002.03022.x; Bennett N, 2008, J SEX MED, V5, P1244, DOI 10.1111/j.1743-6109.2008.00770.x; Bivalacqua TJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068028; Bivalacqua TJ, 2009, J SEX MED, V6, P2494, DOI 10.1111/j.1743-6109.2009.01359.x; Blackburn MR, 2000, J BIOL CHEM, V275, P32114, DOI 10.1074/jbc.M005153200; Blackburn MR, 2005, ADV IMMUNOL, V86, P1, DOI 10.1016/S0065-2776(04)86001-2; Blackburn MR, 1996, J BIOL CHEM, V271, P15203, DOI 10.1074/jbc.271.25.15203; Blackburn MR, 1998, J BIOL CHEM, V273, P5093, DOI 10.1074/jbc.273.9.5093; Boolell M, 1996, Int J Impot Res, V8, P47; Broderick GA, 2010, J SEX MED, V7, P476, DOI 10.1111/j.1743-6109.2009.01625.x; Bruno D, 2001, J UROLOGY, V166, P803, DOI 10.1016/S0022-5347(05)65841-7; Bucci M, 2010, ARTERIOSCL THROM VAS, V30, P1998, DOI 10.1161/ATVBAHA.110.209783; Burnett AL, 2011, UROL CLIN N AM, V38, P185, DOI 10.1016/j.ucl.2011.02.005; Champion HC, 2005, P NATL ACAD SCI USA, V102, P1661, DOI 10.1073/pnas.0407183102; Chunn JL, 2006, AM J PHYSIOL-LUNG C, V290, pL579, DOI 10.1152/ajplung.00258.2005; Chunn JL, 2005, J IMMUNOL, V175, P1937, DOI 10.4049/jimmunol.175.3.1937; Chunn JL, 2001, J IMMUNOL, V167, P4676, DOI 10.4049/jimmunol.167.8.4676; Colgan SP, 2012, ANNU REV PHYSIOL, V74, P153, DOI 10.1146/annurev-physiol-020911-153230; Eland IA, 2001, UROLOGY, V57, P970, DOI 10.1016/S0090-4295(01)00941-4; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Faria M, 2006, J PHARMACOL EXP THER, V319, P405, DOI 10.1124/jpet.106.107821; Field JJ, 2013, BLOOD, V121, P3329, DOI 10.1182/blood-2012-11-465963; FOWLER JE, 1991, J UROLOGY, V145, P65, DOI 10.1016/S0022-5347(17)38248-4; Hellwig-Burgel T, 2005, J INTERF CYTOK RES, V25, P297, DOI 10.1089/jir.2005.25.297; Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06-6419com; Lin CS, 2002, INT J IMPOT RES, V14, P15, DOI 10.1038/sj.ijir.3900802; Merighi S, 2007, MOL PHARMACOL, V72, P395, DOI 10.1124/mol.106.032920; Merighi S, 2006, BIOCHEM PHARMACOL, V72, P19, DOI 10.1016/j.bcp.2006.03.020; Mi T, 2008, J CLIN INVEST, V118, P1491, DOI 10.1172/JCI33467; Montague DK, 2003, J UROLOGY, V170, P1318, DOI 10.1097/01.ju.0000087608.07371.ca; Morrison BF, 2011, NAT REV UROL, V8, P223, DOI 10.1038/nrurol.2011.28; Ning C, 2012, J SEX MED, V9, P2552, DOI 10.1111/j.1743-6109.2012.02896.x; Olujohungbe A, 2013, BRIT J HAEMATOL, V160, P754, DOI 10.1111/bjh.12199; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; Paszty C, 1997, Curr Opin Hematol, V4, P88; Pryor J, 2004, J SEX MED, V1, P116, DOI 10.1111/j.1743-6109.2004.10117.x; SERJEANT GR, 1985, LANCET, V2, P1274; Wallace KL, 2010, BLOOD, V116, P5010, DOI 10.1182/blood-2010-06-290643; Wen JM, 2011, FASEB J, V25, P2823, DOI 10.1096/fj.11-181057; Zhang YJ, 2011, NAT MED, V17, P79, DOI 10.1038/nm.2280	41	28	29	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2725	2735		10.1096/fj.13-247833	http://dx.doi.org/10.1096/fj.13-247833			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24614760	Green Published			2022-12-28	WOS:000339883600030
J	Moffat, C; Pacheco, JG; Sharp, S; Samson, AJ; Bollan, KA; Huang, J; Buckland, ST; Connolly, CN				Moffat, Christopher; Pacheco, Joao Goncalves; Sharp, Sheila; Samson, Andrew J.; Bollan, Karen A.; Huang, Jeffrey; Buckland, Stephen T.; Connolly, Christopher N.			Chronic exposure to neonicotinoids increases neuronal vulnerability to mitochondrial dysfunction in the bumblebee (Bombus terrestris)	FASEB JOURNAL			English	Article						nicotinic acetylcholine receptors; neuronal culture	APIS-MELLIFERA; BEES; HYMENOPTERA; PESTICIDES; HONEYBEES; APIDAE; INSECTICIDES; POLLINATORS; TOXICITY; HAZARDS	The global decline in the abundance and diversity of insect pollinators could result from habitat loss, disease, and pesticide exposure. The contribution of the neonicotinoid insecticides (e.g., clothianidin and imidacloprid) to this decline is controversial, and key to understanding their risk is whether the astonishingly low levels found in the nectar and pollen of plants is sufficient to deliver neuroactive levels to their site of action: the bee brain. Here we show that bumblebees (Bombus terrestris audax) fed field levels [10 nM, 2.1 ppb (w/w)] of neonicotinoid accumulate between 4 and 10 nM in their brains within 3 days. Acute (minutes) exposure of cultured neurons to 10 nM clothianidin, but not imidacloprid, causes a nicotinic acetylcholine receptor-dependent rapid mitochondrial depolarization. However, a chronic (2 days) exposure to 1 nM imidacloprid leads to a receptor-dependent increased sensitivity to a normally innocuous level of acetylcholine, which now also causes rapid mitochondrial depolarization in neurons. Finally, colonies exposed to this level of imidacloprid show deficits in colony growth and nest condition compared with untreated colonies. These findings provide a mechanistic explanation for the poor navigation and foraging observed in neonicotinoid treated bumblebee colonies.	[Moffat, Christopher; Pacheco, Joao Goncalves; Sharp, Sheila; Samson, Andrew J.; Bollan, Karen A.; Huang, Jeffrey; Connolly, Christopher N.] Univ Dundee, Med Res Inst, Dundee DD1 9SY, Scotland; [Buckland, Stephen T.] Univ St Andrews, Ctr Res Ecol & Environm Modelling, St Andrews, Fife, Scotland	University of Dundee; University of St Andrews	Connolly, CN (corresponding author), Univ Dundee, Ninewells Med Sch, Med Res Inst, Mailbox 6, Dundee DD1 9SY, Scotland.	c.n.connolly@dundee.ac.uk	Pacheco, João Pedro Gonçalves/Q-1368-2019; Buckland, Stephen T/A-1998-2012	Pacheco, João Pedro Gonçalves/0000-0002-2871-7420; Huang, Jeffrey/0000-0001-9982-2298; Buckland, Stephen/0000-0002-9939-709X; Samson, Andrew James/0000-0002-4842-5126; Connolly, Christopher/0000-0002-0445-8874	Biotechnology and Biological Sciences Research Council; Natural Environment Research Council; Scottish Government; Wellcome Trust, under the Insect Pollinators Initiative (United Kingdom) Grant [BB/1000313/1]; Department for Environment, Food and Rural Affairs; Biotechnology and Biological Sciences Research Council [BB/I000313/1] Funding Source: researchfish; BBSRC [BB/I000313/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Scottish Government; Wellcome Trust, under the Insect Pollinators Initiative (United Kingdom) Grant; Department for Environment, Food and Rural Affairs(Department for Environment, Food & Rural Affairs (DEFRA)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors thank Rodrigo Velarde and Susan Fahrbach (Wake Forest University, Winston Salem, NC, USA) for help in establishing bee cultures and the Pesticide Survey Unit at Science and Advice for Scottish Agriculture for providing the data on estimated pesticide use. This work was funded jointly by the Biotechnology and Biological Sciences Research Council, the Department for Environment, Food and Rural Affairs, the Natural Environment Research Council, the Scottish Government, and The Wellcome Trust, under the Insect Pollinators Initiative (United Kingdom) Grant BB/1000313/1 (to C.N.C.). The authors declare no conflicts of interest.	Alaux C, 2010, ENVIRON MICROBIOL, V12, P774, DOI 10.1111/j.1462-2920.2009.02123.x; Bartomeus I, 2014, PEERJ, V2, DOI 10.7717/peerj.328; Casida JE, 2013, ANNU REV ENTOMOL, V58, P99, DOI 10.1146/annurev-ento-120811-153645; Catae AF, 2014, MICROSC RES TECHNIQ, V77, P274, DOI 10.1002/jemt.22339; Feltham H, 2014, ECOTOXICOLOGY, V23, P317, DOI 10.1007/s10646-014-1189-7; Fischer J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091364; Gels JA, 2002, J ECON ENTOMOL, V95, P722, DOI 10.1603/0022-0493-95.4.722; Gill RJ, 2012, NATURE, V491, P105, DOI 10.1038/nature11585; Godfray HCJ, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0558; Greenwood SM, 2007, J BIOL CHEM, V282, P26235, DOI 10.1074/jbc.M704488200; Heisenberg M, 2003, NAT REV NEUROSCI, V4, P266, DOI 10.1038/nrn1074; Henry M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5359; Henry M, 2012, SCIENCE, V336, P348, DOI 10.1126/science.1215039; Jones A, 2014, PEST MANAG SCI, V70, P1780, DOI 10.1002/ps.3836; Krupke CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029268; Manji H, 2012, NAT REV NEUROSCI, V13, P293, DOI 10.1038/nrn3229; Mares S, 2005, BRAIN BEHAV EVOLUT, V66, P50, DOI 10.1159/000085047; Mullin CA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009754; Nauen R, 1999, PESTIC SCI, V55, P265, DOI [10.1002/(SICI)1096-9063(199905)55:5&lt;608::AID-PS967&gt;3.0.CO;2-Y, 10.1002/(SICI)1096-9063(199903)55:3&lt;265::AID-PS891&gt;3.0.CO;2-C]; Nelson ME, 2003, MOL PHARMACOL, V63, P332, DOI 10.1124/mol.63.2.332; Nicodemo D, 2014, ENVIRON TOXICOL CHEM, V33, P2070, DOI 10.1002/etc.2655; Palmer MJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2648; Pareja L, 2011, INT J ENV RES PUB HE, V8, P3844, DOI 10.3390/ijerph8103844; Pilling E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077193; Rondeau G, 2014, SCI REP-UK, V4, DOI 10.1038/srep05566; Rossi CD, 2013, ARCH ENVIRON CON TOX, V65, P234, DOI 10.1007/s00244-013-9897-1; Rossler W., 2012, HONEYBEE NEUROBIOLOG, P141, DOI [DOI 10.1007/978-94-007-2099-2, 10.1007/978-94-007-2099-2]; Sandrock C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103592; Srinivasan R, 2014, PHARMACOL RES, V83, P20, DOI 10.1016/j.phrs.2014.02.005; Tasei JN, 2001, J ECON ENTOMOL, V94, P623, DOI 10.1603/0022-0493-94.3.623; Tome HVV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038406; Tomizawa M, 2000, TOXICOL APPL PHARM, V169, P114, DOI 10.1006/taap.2000.9057; Vanbergen AJ, 2013, FRONT ECOL ENVIRON, V11, P251, DOI 10.1890/120126; Whitehorn PR, 2012, SCIENCE, V336, P351, DOI 10.1126/science.1215025; Williamson SM, 2013, J EXP BIOL, V216, P1799, DOI 10.1242/jeb.083931; Zars T, 2000, CURR OPIN NEUROBIOL, V10, P790, DOI 10.1016/S0959-4388(00)00147-1	36	65	67	1	135	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2112	2119		10.1096/fj.14-267179	http://dx.doi.org/10.1096/fj.14-267179			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25634958	Green Published, hybrid			2022-12-28	WOS:000354114600042
J	Tian, D; Solodin, NM; Rajbhandari, P; Bjorklund, K; Alarid, ET; Kreeger, PK				Tian, Dan; Solodin, Natalia M.; Rajbhandari, Prashant; Bjorklund, Kelsi; Alarid, Elaine T.; Kreeger, Pamela K.			A kinetic model identifies phosphorylated estrogen receptor-alpha (ER alpha) as a critical regulator of ER alpha dynamics in breast cancer	FASEB JOURNAL			English	Article						systems biology; mathematical modeling; nuclear receptor; feedback	GENE-EXPRESSION; PROGESTERONE-RECEPTORS; ENDOCRINE RESISTANCE; SIGNALING PATHWAYS; MECHANISMS; ACTIVATION; CELLS; QUANTIFICATION; POSTMENOPAUSAL; TRANSCRIPTION	Receptor levels are a key mechanism by which cells regulate their response to stimuli. The levels of estrogen receptor- (ER) impact breast cancer cell proliferation and are used to predict prognosis and sensitivity to endocrine therapy. Despite the clinical application of this information, it remains unclear how different cellular processes interact as a system to control ER levels. To address this question, experimental results from the ER-positive human breast cancer cell line (MCF-7) treated with 17--estradiol or vehicle control were used to develop a mass-action kinetic model of ER regulation. Model analysis determined that RNA dynamics could be captured through phosphorylated ER (pER)-dependent feedback on transcription. Experimental analysis confirmed that pER-S118 binds to the estrogen receptor-1 (ESR1) promoter, suggesting that pER can feedback on ESR1 transcription. Protein dynamics required a separate mechanism in which the degradation rate for pER was 8.3-fold higher than nonphosphorylated ER. Using a model with both mechanisms, the root mean square error was 0.078. Sensitivity analysis of this combined model determined that while multiple mechanisms regulate ER levels, pER-dependent feedback elicited the strongest effect. Combined, our computational and experimental results identify phosphorylation of ER as a critical decision point that coordinates the cellular circuitry to regulate ER levels.	[Tian, Dan; Kreeger, Pamela K.] Univ Wisconsin, Dept Biomed Engn, Madison, WI USA; [Solodin, Natalia M.; Rajbhandari, Prashant; Bjorklund, Kelsi; Alarid, Elaine T.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Oncol, Madison, WI USA; [Alarid, Elaine T.; Kreeger, Pamela K.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kreeger, PK (corresponding author), Dept Biomed Engn, ECB 2154, 1550 Engn Dr, Madison, WI 53706 USA.	kreeger@wisc.edu		Kreeger, Pamela/0000-0001-8193-1007; Rajbhandari, Prashant/0000-0002-8146-3861	U.S. National Science Foundation [CBET-0951613]; National Cancer Institute [CA-159578];  [1DP2CA195766-01]; NATIONAL CANCER INSTITUTE [R01CA159578, T32CA009135, DP2CA195766] Funding Source: NIH RePORTER	U.S. National Science Foundation(National Science Foundation (NSF)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the U.S. National Science Foundation (Grant CBET-0951613; to P.K.K.) and the (Director's New Innovator Award Program, Grant 1DP2CA195766-01; to P.K.K.) and (National Cancer Institute, Grant CA-159578; to E.T.A.). The authors declare no conflicts of interest.U.S. National Institutes of Health	Alarid ET, 2006, MOL ENDOCRINOL, V20, P1972, DOI 10.1210/me.2005-0481; Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Aldridge BB, 2006, NAT CELL BIOL, V8, P1195, DOI 10.1038/ncb1497; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Atsriku C, 2009, MOL CELL PROTEOMICS, V8, P467, DOI 10.1074/mcp.M800282-MCP200; Barone I, 2010, CLIN CANCER RES, V16, P2702, DOI 10.1158/1078-0432.CCR-09-1753; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bordeaux JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036559; Callige M, 2005, MOL CELL BIOL, V25, P4349, DOI 10.1128/MCB.25.11.4349-4358.2005; Chen C, 2013, FEBS LETT, V587, P3327, DOI 10.1016/j.febslet.2013.08.022; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Chen WW, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.74; CIDLOWSKI JA, 1978, BIOL REPROD, V18, P234, DOI 10.1095/biolreprod18.2.234; Clarke R, 2001, PHARMACOL REV, V53, P25; Cohen AA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004901; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; de Leeuw R, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/232435; de-Leon SBT, 2009, DEV BIOL, V325, P317, DOI 10.1016/j.ydbio.2008.10.043; DENTON RR, 1992, J BIOL CHEM, V267, P7263; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09; FABRIS G, 1987, J STEROID BIOCHEM, V27, P171, DOI 10.1016/0022-4731(87)90307-4; Garcia-Becerra R, 2013, INT J MOL SCI, V14, P108, DOI 10.3390/ijms14010108; Giuliano M, 2011, BREAST, V20, pS42, DOI 10.1016/S0960-9776(11)70293-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.1043/1543-2165-134.6.907, 10.1200/JCO.2009.25.6529, 10.1200/JOP.777003]; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Khan SA, 1999, CANCER EPIDEM BIOMAR, V8, P867; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; Khodor YL, 2011, GENE DEV, V25, P2502, DOI 10.1101/gad.178962.111; Kholodenko BN, 1999, J BIOL CHEM, V274, P30169, DOI 10.1074/jbc.274.42.30169; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; Lebedeva G, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-138; Lumachi F, 2013, CURR MED CHEM, V20, P596, DOI 10.2174/092986713804999303; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; MARKOPOULOS C, 1988, BRIT MED J, V296, P1349, DOI 10.1136/bmj.296.6633.1349; Marsaud V, 2003, MOL ENDOCRINOL, V17, P2013, DOI 10.1210/me.2002-0269; Matthias Ruth B. H., 1997, MODELING DYNAMIC BIO; May FEB, 2014, CANCER MANAG RES, V6, P225, DOI 10.2147/CMAR.S35024; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Neugebauer KM, 2002, J CELL SCI, V115, P3865, DOI 10.1242/jcs.00073; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Patani N, 2013, INT J CANCER, V133, P1, DOI 10.1002/ijc.27997; Rajbhandari P, 2014, ONCOGENE, V33, P1438, DOI 10.1038/onc.2013.78; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; RICKETTS D, 1991, CANCER RES, V51, P1817; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; ROMAIN S, 1994, INT J CANCER, V59, P17, DOI 10.1002/ijc.2910590105; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Shanle EK, 2010, ADV DRUG DELIVER REV, V62, P1265, DOI 10.1016/j.addr.2010.08.001; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; THORPE SM, 1993, EUR J CANCER, V29A, P971, DOI 10.1016/S0959-8049(05)80204-7; Tremblay GB, 2002, CRIT REV EUKAR GENE, V12, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i1.10; Tyson JJ, 2011, NAT REV CANCER, V11, P523, DOI 10.1038/nrc3081; Valley CC, 2005, MOL CELL BIOL, V25, P5417, DOI 10.1128/MCB.25.13.5417-5428.2005; Valley CC, 2008, J MOL ENDOCRINOL, V40, P23, DOI 10.1677/JME-07-0067; Welsh AW, 2011, J CLIN ONCOL, V29, P2978, DOI 10.1200/JCO.2010.32.9706; Williams C, 2013, ECANCERMEDICALSCIENC, V7, DOI 10.3332/ecancer.2013.370; Zhou W, 2014, NAT REV CANCER, V14, P26, DOI 10.1038/nrc3622; Zwart W, 2011, WIRES SYST BIOL MED, V3, P216, DOI 10.1002/wsbm.109	64	9	9	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2022	2031		10.1096/fj.14-265637	http://dx.doi.org/10.1096/fj.14-265637			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25648997	Green Published			2022-12-28	WOS:000354114600035
J	Brun, PJ; Grijalva, A; Rausch, R; Watson, E; Yuen, JJ; Das, BC; Shudo, K; Kagechika, H; Leibel, RL; Blaner, WS				Brun, Pierre-Jacques; Grijalva, Ambar; Rausch, Richard; Watson, Elizabeth; Yuen, Jason J.; Das, Bhaskar C.; Shudo, Koichi; Kagechika, Hiroyuki; Leibel, Rudolph L.; Blaner, William S.			Retinoic acid receptor signaling is required to maintain glucose-stimulated insulin secretion and beta-cell mass	FASEB JOURNAL			English	Article						glucagon; retinoid; dominant-negative RAR; pancreatic islet; Cre recombinase	DOMINANT-NEGATIVE FORM; VITAMIN-A-DEFICIENCY; GENE-EXPRESSION; PANCREATIC-ISLETS; BINDING PROTEINS; THYROID-HORMONE; TRANSGENIC MICE; MESSENGER-RNA; RAT; ALPHA	Retinoic acid signaling is required for maintaining a range of cellular processes, including cell differentiation, proliferation, and apoptosis. We investigated the actions of all-trans-retinoic acid (atRA) signaling in pancreatic beta-cells of adult mice. atRA signaling was ablated in beta-cells by overexpressing a dominant-negative retinoic acid receptor (RAR)-alpha mutant (RARdn) using an inducible Cre-Lox system under the control of the pancreas duodenal homeobox gene promoter. Our studies establish that hypomorphism for RAR in beta-cells leads to an age-dependent decrease in plasma insulin in the fed state and in response to a glucose challenge. Glucose-stimulated insulin secretion was also impaired in islets isolated from mice expressing RARdn. Among genes that are atRA responsive, Glut2 and Gck mRNA levels were decreased in isolated islets from RARdn-expressing mice. Histologic analyses of RARdn-expressing pancreata revealed a decrease in beta-cell mass and insulin per beta-cell 1 mo after induction of the RARdn. Our results indicate that atRA signaling mediated by RARs is required in the adult pancreas for maintaining both beta-cell function and mass, and provide insights into molecular mechanisms underlying these actions.-Brun, P.-J., Grijalva, A., Rausch, R., Watson, E., Yuen, J. J., Das, B. C., Shudo, K., Kagechika, H., Leibel, R. L., Blaner, W. S. Retinoic acid receptor signaling is required to maintain glucose-stimulated insulin secretion and b-cell mass.	[Brun, Pierre-Jacques; Yuen, Jason J.; Blaner, William S.] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; [Rausch, Richard; Watson, Elizabeth; Leibel, Rudolph L.] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; [Grijalva, Ambar] Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; [Das, Bhaskar C.] Univ Kansas, Med Ctr, Dept Med, Kansas City, KS 66103 USA; [Shudo, Koichi] Res Fdn Itsuu Lab, Tokyo, Japan; [Kagechika, Hiroyuki] Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Tokyo, Japan	Columbia University; Columbia University; Columbia University; University of Kansas; University of Kansas Medical Center; Tokyo Medical & Dental University (TMDU)	Blaner, WS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	wsb2@columbia.edu		Kagechika, Hiroyuki/0000-0002-6747-1013	U.S. National Institutes of Health (NIH) National Institute on Alcohol Abuse and Alcoholism Grant [RC2-AA019413]; NIH National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK068437, R01-DK079221, R01-DK052431, P30-DK063608]; Japan Society for Promotion of Science Core-to-Core Program; Russell Berrie Foundation; A. Advanced Research Networks of Japan; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK063608, R01DK068437, P30DK026687, R01DK079221, R01DK052431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [RC2AA019413, R21AA021336] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [22136013] Funding Source: KAKEN	U.S. National Institutes of Health (NIH) National Institute on Alcohol Abuse and Alcoholism Grant; NIH National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Japan Society for Promotion of Science Core-to-Core Program(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Russell Berrie Foundation; A. Advanced Research Networks of Japan; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	These studies were supported by U.S. National Institutes of Health (NIH) National Institute on Alcohol Abuse and Alcoholism Grant RC2-AA019413 and NIH National Institute of Diabetes and Digestive and Kidney Diseases Grants R01-DK068437, R01-DK079221, R01-DK052431, and P30-DK063608, the Japan Society for Promotion of Science Core-to-Core Program, A. Advanced Research Networks of Japan, and grants from the Russell Berrie Foundation.	Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; Blumentrath J, 2001, CELL BIOCHEM FUNCT, V19, P159, DOI 10.1002/cbf.907; Cabrera-Valladares G, 1999, ENDOCRINOLOGY, V140, P3091, DOI 10.1210/en.140.7.3091; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CHERTOW BS, 1989, RES COMMUN CHEM PATH, V63, P27; CHERTOW BS, 1987, J CLIN INVEST, V79, P163, DOI 10.1172/JCI112778; CHERTOW BS, 1983, DIABETES, V32, P568, DOI 10.2337/diabetes.32.6.568; CHERTOW BS, 1993, DIABETES, V42, P1109, DOI 10.2337/diabetes.42.8.1109; CHERTOW BS, 1989, DIABETES, V38, P1544, DOI 10.2337/diabetes.38.12.1544; CLARK AR, 1995, BIOCHEM J, V309, P863, DOI 10.1042/bj3090863; Das BC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010004; Dokmanovic-Chouinard M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000137; Du AP, 2009, DIABETES, V58, P2059, DOI 10.2337/db08-0987; EIZIRIK DL, 1989, ENDOCRINOLOGY, V125, P752, DOI 10.1210/endo-125-2-752; FERNANDEZMEJIA C, 1992, ENDOCRINOLOGY, V130, P1660, DOI 10.1210/en.130.3.1660; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Gudas L. J., 1994, RETINOIDS BIOL CHEM, P443; Gudas LJ, 2012, BBA-MOL CELL BIOL L, V1821, P213, DOI 10.1016/j.bbalip.2011.08.002; Hunter CS, 2013, DIABETES, V62, P875, DOI 10.2337/db12-0952; Kane MA, 2010, P NATL ACAD SCI USA, V107, P21884, DOI 10.1073/pnas.1008859107; Kappen C, 2009, INT J DEV BIOL, V53, P935, DOI 10.1387/ijdb.082819ck; KATO M, 1985, P NATL ACAD SCI USA, V82, P2488, DOI 10.1073/pnas.82.8.2488; Kutlu B, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-3; Lee Y, 2011, DIABETES, V60, P391, DOI 10.2337/db10-0426; Mangelsdorf David J., 1994, P319; Matthews KA, 2004, J NUTR, V134, P1958, DOI 10.1093/jn/134.8.1958; Meier JJ, 2011, AM J PHYSIOL-ENDOC M, V300, pE717, DOI 10.1152/ajpendo.00315.2010; Miyazaki S, 2010, DIABETES, V59, P2854, DOI 10.2337/db09-1897; National Research Council, 2011, GUIDE CARE USE LAB A; Ostrom M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002841; Perez RJ, 2013, EXP CELL RES, V319, P2196, DOI 10.1016/j.yexcr.2013.05.032; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rajaii F, 2008, DEV BIOL, V316, P371, DOI 10.1016/j.ydbio.2008.01.041; Ramnanan CJ, 2011, DIABETES OBES METAB, V13, P118, DOI 10.1111/j.1463-1326.2011.01454.x; Ravnskjaer K, 2005, ENDOCRINOLOGY, V146, P3266, DOI 10.1210/en.2004-1430; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Ross, 2006, MODERN NUTR HLTH DIS, P351; Rosselot C, 2010, DEVELOPMENT, V137, P283, DOI 10.1242/dev.040287; Somenzi G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000836; Talchai C, 2012, CELL, V150, P1223, DOI 10.1016/j.cell.2012.07.029; Tsutusmi A, 2000, BIOCHEM BIOPH RES CO, V278, P229, DOI 10.1006/bbrc.2000.3786; Umemiya H, 1997, J MED CHEM, V40, P4222, DOI 10.1021/jm9704309; Unger RH, 2012, J CLIN INVEST, V122, P4, DOI 10.1172/JCI60016; Yanagitani A, 2004, HEPATOLOGY, V40, P366, DOI 10.1002/hep.20335	45	37	37	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					671	683		10.1096/fj.14-256743	http://dx.doi.org/10.1096/fj.14-256743			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25389133	Green Published			2022-12-28	WOS:000349370400028
J	Wang, J; Vodovotz, Y; Fan, LY; Li, YH; Liu, Z; Namas, R; Barclay, D; Zamora, R; Billiar, TR; Wilson, MA; Fan, J; Jiang, Y				Wang, Juan; Vodovotz, Yoram; Fan, Liyan; Li, Yuehua; Liu, Zheng; Namas, Rami; Barclay, Derek; Zamora, Ruben; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie; Jiang, Yong			Injury-induced MRP8/MRP14 stimulates IP-10/CXCL10 in monocytes/macrophages	FASEB JOURNAL			English	Article						IFN regulatory factor 3; myeloid-related protein; Toll-like receptor 4	NF-KAPPA-B; INDUCIBLE PROTEIN-10 PRODUCTION; DOUBLE-STRANDED-RNA; REGULATORY T-CELLS; IFN-GAMMA; NEUTROPHIL MIGRATION; RESPONSE ELEMENT; CXC CHEMOKINE; HIGH-AFFINITY; S100 FAMILY	Trauma/hemorrhagic shock is associated with morbidity and mortality due to dysregulated inflammation, which is driven in part by monocytes/macrophages stimulated by injury-induced release of damage-associated molecular pattern (DAMP) molecules. MRP8/MRP14 is an endogenous DAMP involved in various inflammatory diseases, though its mechanism of action is unclear. Circulating MRP8/MRP14 levels in human blunt trauma nonsurvivors were significantly lower than those of survivors (P < 0.001). Human monocytic THP-1 cells stimulated with MRP8/MRP14 expressed the chemokine IFN-gamma inducible protein 10 (IP-10)/CXCL10. Circulating IP-10 levels in human blunt trauma patients were correlated positively with MRP8/MRP14 levels (r = 0.396, P < 0.001), and were significantly lower in trauma nonsurvivors than in survivors (P < 0.001). We therefore sought to determine the mechanisms by which MRP8/MRP14 stimulates IP-10 in monocytes/macrophages, and found that induction of IP-10 by MRP8/MRP14 required Toll-like receptor 4 and TRIF but not MyD88. Full induction of IP-10 by MRP8/MRP14 required synergy between the transcription factors NF-kappa B and IFN regulatory factor 3 (IRF3). The receptor for IP-10 is CXCR3, and MRP8/MRP14-induced chemotaxis of CXCR3(+) cells was dependent on the production of IP-10 in monocytes/macrophages. Furthermore, in vivo study with a mouse trauma/hemorrhagic shock model showed that administration of neutralizing antibody against MRP8 prevented activation of NF-kB and IRF3 as well as IP-10 production. Thus, the current study identified a novel signaling mechanism that controls IP-10 expression in monocytes/macrophages by MRP8/MRP14, which may play an important role in injury-induced inflammation.	[Wang, Juan; Liu, Zheng; Fan, Jie; Jiang, Yong] Southern Med Univ, State Key Lab Organ Failure Res, Key Lab Transcript & Prote, Minist Educ China,Key Lab Prote Guangdong Prov, Guangzhou 510515, Guangdong, Peoples R China; [Wang, Juan; Vodovotz, Yoram; Li, Yuehua; Namas, Rami; Barclay, Derek; Zamora, Ruben; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA; [Wilson, Mark A.; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA USA; [Fan, Liyan] Univ Pittsburgh, Sch Arts & Sci, Pittsburgh, PA USA; [Vodovotz, Yoram; Billiar, Timothy R.; Fan, Jie] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA USA	Ministry of Education, China; Southern Medical University - China; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jiang, Y (corresponding author), Southern Med Univ, Dept Pathophysiol, Guangzhou 510515, Guangdong, Peoples R China.	jif7@pitt.edu; jiang48231@163.com	LI, Yue/GRS-8071-2022; Namas, Rami/AAD-5796-2020; Namas, Rami/GZK-4999-2022; Namas, Rami/AAD-5793-2020	Namas, Rami/0000-0002-8582-5321; Namas, Rami/0000-0002-8582-5321	NHLBI NIH HHS [R01 HL079669, R01-HL-079669] Funding Source: Medline; NIGMS NIH HHS [P50 GM053789, P50-GM-53789] Funding Source: Medline; BLRD VA [I01 BX002729] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM053789] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002729] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); BLRD VA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)		Agostini C, 2000, AM J RESP CRIT CARE, V162, P1466, DOI 10.1164/ajrccm.162.4.2003130; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Baker HN, 2012, JOVE-J VIS EXP, DOI 10.3791/4084; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Blackwell SE, 2003, J IMMUNOL, V170, P4061, DOI 10.4049/jimmunol.170.8.4061; Chen X, 2013, BIOCHEM BIOPH RES CO, V433, P532, DOI 10.1016/j.bbrc.2013.03.024; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Davis Beckley K, 2013, Methods Mol Biol, V1031, P27, DOI 10.1007/978-1-62703-481-4_3; Ehlermann P, 2006, CARDIOVASC DIABETOL, V5, DOI 10.1186/1475-2840-5-6; Ehrchen JM, 2009, J LEUKOCYTE BIOL, V86, P557, DOI 10.1189/jlb.1008647; Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Foell D, 2007, J LEUKOCYTE BIOL, V81, P28, DOI 10.1189/jlb.0306170; Gopal R, 2013, AM J RESP CRIT CARE, V188, P1137, DOI 10.1164/rccm.201304-0803OC; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; Herzig DS, 2012, AM J RESP CRIT CARE, V185, P291, DOI 10.1164/rccm.201108-1560OC; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hoerning A, 2011, EUR J IMMUNOL, V41, P2291, DOI 10.1002/eji.201041095; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Hunter MJ, 1998, J BIOL CHEM, V273, P12427, DOI 10.1074/jbc.273.20.12427; Ichikawa A, 2013, AM J RESP CRIT CARE, V187, P65, DOI 10.1164/rccm.201203-0508OC; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jiang Y, 2005, AM J RESP CRIT CARE, V171, P850, DOI 10.1164/rccm.200407-857OC; Jiang ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI 10.1073/pnas.0308496101; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kerkhoff C, 2001, BIOCHEMISTRY-US, V40, P241, DOI 10.1021/bi001791k; Kim S, 2013, MOL MED, V19, P88, DOI 10.2119/molmed.2012.00306; Leukert N, 2006, J MOL BIOL, V359, P961, DOI 10.1016/j.jmb.2006.04.009; Li K, 2012, HEPATOLOGY, V55, P666, DOI 10.1002/hep.24763; Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001; Liu YJ, 2009, J IMMUNOL, V182, P572, DOI 10.4049/jimmunol.182.1.572; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Majumder S, 1998, J IMMUNOL, V161, P4736; Majumder S, 1998, J NEUROSCI RES, V54, P169, DOI 10.1002/(SICI)1097-4547(19981015)54:2<169::AID-JNR5>3.0.CO;2-C; Menzel CL, 2011, MOL MED, V17, P1031, DOI 10.2119/molmed.2011.00015; Minino AM, 2011, NCHS DATA BRIEF, V2013, P1; Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805; Namas R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008406; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; OHMORI Y, 1995, J IMMUNOL, V154, P5235; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; Oppenheim JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/j.coi.2005.06.002; Rammes A, 1997, J BIOL CHEM, V272, P9496; Robinson MJ, 2002, J BIOL CHEM, V277, P3658, DOI 10.1074/jbc.M102950200; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Simard JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072138; Srikrishna G, 2001, J IMMUNOL, V166, P4678, DOI 10.4049/jimmunol.166.7.4678; Suga H, 2013, J IMMUNOL, V190, P6059, DOI 10.4049/jimmunol.1201606; Takeuchi O, 2012, NAT IMMUNOL, V13, P634, DOI 10.1038/ni.2346; Ukena SN, 2011, BLOOD, V118, pE82, DOI 10.1182/blood-2011-05-352708; Vandal K, 2003, J IMMUNOL, V171, P2602, DOI 10.4049/jimmunol.171.5.2602; Venet F, 2008, J LEUKOCYTE BIOL, V83, P523, DOI 10.1189/jlb.0607371; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Vollmer J, 2004, J ENDOTOXIN RES, V10, P431, DOI 10.1179/096805104225006534; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Zaaqoq AM, 2014, CRIT CARE MED, V42, P1487, DOI 10.1097/CCM.0000000000000248; Zanoni I, 2011, CELL, V147, P868, DOI 10.1016/j.cell.2011.09.051	60	38	44	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					250	262		10.1096/fj.14-255992	http://dx.doi.org/10.1096/fj.14-255992			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25342131	Green Published			2022-12-28	WOS:000347378600024
J	Salamun, J; Kallio, JP; Daher, W; Soldati-Favre, D; Kursula, I				Salamun, Julien; Kallio, Juha P.; Daher, Wassim; Soldati-Favre, Dominique; Kursula, Inari			Structure of Toxoplasma gondii coronin, an actin-binding protein that relocalizes to the posterior pole of invasive parasites and contributes to invasion and egress	FASEB JOURNAL			English	Article						apicomplexan parasite; gliding motility; WD40 domain	DEPOLYMERIZING FACTOR; MICRONEME DISCHARGE; CRYSTAL-STRUCTURE; GLIDING MOTILITY; MOVING JUNCTION; F-ACTIN; GENE; MODEL; POLYMERIZATION; IDENTIFICATION	Coronins are involved in the regulation of actin dynamics in a multifaceted way, participating in cell migration and vesicular trafficking. Apicomplexan parasites, which exhibit an actin-dependent gliding motility that is essential for traversal through tissues, as well as invasion of and egress from host cells, express only a single coronin, whereas higher eukaryotes possess several isoforms. We set out to characterize the 3-D structure, biochemical function, subcellular localization, and genetic ablation of Toxoplasma gondii coronin (TgCOR), to shed light on its biological role. A combination of X-ray crystallography, small-angle scattering of X-rays, and light scattering revealed the atomic structure of the conserved WD40 domain and the dimeric arrangement of the full-length protein. TgCOR binds to F-actin and increases the rate and extent of actin polymerization. In vivo, TgCOR relocalizes transiently to the posterior pole of motile and invading parasites, independent of actin dynamics, but concomitant to microneme secretory organelle discharge. TgCOR contributes to, but is not essential for, invasion and egress. Taken together, our data point toward a role for TgCOR in stabilizing newly formed, short filaments and F-actin cross-linking, as well as functions linked to endocytosis and recycling of membranes.Salamun, J., Kallio, J. P., Daher, W., Soldati-Favre, D., Kursula, I. Structure of Toxoplasma gondii coronin, an actin-binding protein that relocalizes to the posterior pole of invasive parasites and contributes to invasion and egress.	[Salamun, Julien; Daher, Wassim; Soldati-Favre, Dominique] Univ Geneva, Fac Med, Dept Microbiol & Mol Med, Geneva, Switzerland; [Kallio, Juha P.; Kursula, Inari] Helmholtz Ctr Infect Res, Ctr Struct Syst Biol, Hamburg, Germany; [Kallio, Juha P.; Kursula, Inari] German Electron Synchrotron DESY, Hamburg, Germany; [Kursula, Inari] Univ Oulu, Fac Biochem & Mol Med, Oulu, Finland	University of Geneva; Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Oulu	Kursula, I (corresponding author), DESY, CSSB HZI, Notkestr 85,Bldg 25b, D-22607 Hamburg, Germany.	dominique.soldati-favre@unige.ch; inari.kursula@helmholtz-hzi.de	DAHER, Wassim/M-7166-2017; Kursula, Inari/AHB-9980-2022; Kallio, Juha/AAE-4318-2021; DAHER, Wassim/AAB-6720-2019	DAHER, Wassim/0000-0001-9026-5333; Kursula, Inari/0000-0001-5236-7056; DAHER, Wassim/0000-0001-9026-5333; Kallio, Juha Pekka/0000-0003-3092-4012	German Ministry for Education and Research; Academy of Finland; Sigrid Juselius Foundation; Swiss National Foundation [FN3100A0-116722, FN323630-119354]; Fondation pour la Recherche Medicale; Emil Aaltonen Foundation	German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF)); Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Swiss National Foundation(Swiss National Science Foundation (SNSF)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Emil Aaltonen Foundation	The authors thank the Positron-Electron Tandem Ring Accelerator (PETRA) III/Deutsches Elektronen-Synchrotron (DESY: Hamburg, Germany) staff for excellent user support on European Molecular Biology Laboratory (EMBL) beamlines P12, P14, and P11. This work was financially supported by funding from the German Ministry for Education and Research (to I.K.), the Academy of Finland (to I.K.), the Sigrid Juselius Foundation (to I.K.), the Emil Aaltonen Foundation (to J.K.), the Swiss National Foundation (FN3100A0-116722 to D.S.-F.; MD-PhD fellowship FN323630-119354 to Institut National de la Sante et de la Recherche Medicale (to W.D.), and la Fondation pour la Recherche Medicale (to W.D.). The atomic coordinates and structure factors of the TgCOR WD40 domain have been submitted to the Protein Data Bank (PDB) under accession code 4OZU.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308; Akin O, 2008, CELL, V133, P841, DOI 10.1016/j.cell.2008.04.011; Allen ML, 1997, MOL BIOCHEM PARASIT, V88, P43, DOI 10.1016/S0166-6851(97)00069-8; Angrisano F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032188; Appleton BA, 2006, STRUCTURE, V14, P87, DOI 10.1016/j.str.2005.09.013; Baum J, 2008, CELL HOST MICROBE, V3, P188, DOI 10.1016/j.chom.2008.02.006; Bernado P, 2007, J AM CHEM SOC, V129, P5656, DOI 10.1021/ja069124n; Breinich MS, 2009, CURR BIOL, V19, P277, DOI 10.1016/j.cub.2009.01.039; Cai L, 2007, J CELL SCI, V120, P1779, DOI 10.1242/jcs.007641; Carruthers VB, 1999, BIOCHEM J, V342, P379, DOI 10.1042/0264-6021:3420379; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Chan KT, 2012, BIOCHEM J, V444, P89, DOI 10.1042/BJ20120209; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Chen YW, 2014, J NEUROSCI, V34, P2413, DOI 10.1523/JNEUROSCI.3226-13.2014; Daher W, 2012, EUKARYOT CELL, V11, P343, DOI 10.1128/EC.05192-11; Daher W, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001132; Daher W, 2009, CURR OPIN MICROBIOL, V12, P408, DOI 10.1016/j.mib.2009.06.008; de Hostos EL, 1999, TRENDS CELL BIOL, V9, P345, DOI 10.1016/S0962-8924(99)01620-7; Delbac F, 2001, J CELL BIOL, V155, P613, DOI 10.1083/jcb.200012116; Delorenzi M, 2002, BIOINFORMATICS, V18, P617, DOI 10.1093/bioinformatics/18.4.617; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Figueroa JV, 2004, ANN NY ACAD SCI, V1026, P125, DOI 10.1196/annals.1307.017; Fox BA, 2009, EUKARYOT CELL, V8, P520, DOI 10.1128/EC.00357-08; Franke D, 2009, J APPL CRYSTALLOGR, V42, P342, DOI 10.1107/S0021889809000338; Frenal K, 2010, CELL HOST MICROBE, V8, P343, DOI 10.1016/j.chom.2010.09.002; Galkin VE, 2008, J MOL BIOL, V376, P607, DOI 10.1016/j.jmb.2007.12.007; Gandhi M, 2010, J BIOL CHEM, V285, P34899, DOI 10.1074/jbc.M110.171496; Gandhi M, 2009, MOL CELL, V34, P364, DOI 10.1016/j.molcel.2009.02.029; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; Huynh MH, 2009, EUKARYOT CELL, V8, P530, DOI 10.1128/EC.00358-08; Ignatev A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033586; Jayachandran R, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001820; Kallio JP, 2014, ACTA CRYSTALLOGR F, V70, P517, DOI 10.1107/S2053230X14005196; Kammerer RA, 2005, P NATL ACAD SCI USA, V102, P13891, DOI 10.1073/pnas.0502390102; Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.121823, 10.1126/science.1218231]; Kaur S, 2014, ELIFE, V3, DOI 10.7554/eLife.00829; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; Kimura T, 2010, ARCH BIOCHEM BIOPHYS, V496, P33, DOI 10.1016/j.abb.2010.01.017; Konarev PV, 2006, J APPL CRYSTALLOGR, V39, P277, DOI 10.1107/S0021889806004699; Krieger E, 2009, PROTEINS, V77, P114, DOI 10.1002/prot.22570; Kursula I, 2008, STRUCTURE, V16, P1638, DOI 10.1016/j.str.2008.09.008; Lebrun M, 2005, CELL MICROBIOL, V7, P1823, DOI 10.1111/j.1462-5822.2005.00646.x; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mehta S, 2011, MOL BIOL CELL, V22, P1290, DOI 10.1091/mbc.E10-12-0939; Mehta S, 2010, J BIOL CHEM, V285, P6835, DOI 10.1074/jbc.M109.068155; Meissner M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.22.e115; Mohri K, 2004, J BIOL CHEM, V279, P31697, DOI 10.1074/jbc.M403351200; Morgan Reginald O., 2008, V48, P41, DOI 10.1007/978-0-387-09595-0_5; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; Murakami K, 2010, CELL, V143, P275, DOI 10.1016/j.cell.2010.09.034; NICHOLS BA, 1994, PARASITOL RES, V80, P91, DOI 10.1007/BF00933773; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Petoukhov MV, 2005, BIOPHYS J, V89, P1237, DOI 10.1529/biophysj.105.064154; Pieperhoff MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077620; Plattner F, 2008, CELL HOST MICROBE, V3, P77, DOI 10.1016/j.chom.2008.01.001; Poupel O, 1999, MICROBES INFECT, V1, P653, DOI 10.1016/S1286-4579(99)80066-5; Sahasrabuddhe AA, 2009, J CELL SCI, V122, P1691, DOI 10.1242/jcs.044651; Sahoo N, 2006, MOL BIOL CELL, V17, P895, DOI 10.1091/mbc.E05-06-0512; Sattler JM, 2011, EUR J CELL BIOL, V90, P966, DOI 10.1016/j.ejcb.2010.11.011; Schuler H, 2005, MOL BIOL CELL, V16, P4013, DOI 10.1091/mbc.E05-02-0086; Siden-Kiamos I, 2006, MOL BIOCHEM PARASIT, V150, P308, DOI 10.1016/j.molbiopara.2006.09.003; Singh BK, 2011, J BIOL CHEM, V286, P28256, DOI 10.1074/jbc.M111.211730; Skillman KM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3285; Skillman KM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002280; Soldati D, 2001, INT J PARASITOL, V31, P1293, DOI 10.1016/S0020-7519(01)00257-0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Stirnimann CU, 2010, TRENDS BIOCHEM SCI, V35, P565, DOI 10.1016/j.tibs.2010.04.003; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Tardieux I, 1998, FEBS LETT, V441, P251, DOI 10.1016/S0014-5793(98)01557-9; Terwilliger TC, 2008, ACTA CRYSTALLOGR D, V64, P61, DOI 10.1107/S090744490705024X; Tsujita K, 2010, J BIOL CHEM, V285, P6781, DOI 10.1074/jbc.M109.057018; Uetrecht AC, 2006, TRENDS CELL BIOL, V16, P421, DOI 10.1016/j.tcb.2006.06.002; Vahokoski J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004091; Vinet AF, 2014, MOL BIOL CELL, V25, P688, DOI 10.1091/mbc.E13-04-0219; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Weiss MS, 1997, J APPL CRYSTALLOGR, V30, P203, DOI 10.1107/S0021889897003907; Wetzel DM, 2003, MOL BIOL CELL, V14, P396, DOI 10.1091/mbc.E02-08-0458; Wong W, 2011, P NATL ACAD SCI USA, V108, P9869, DOI 10.1073/pnas.1018927108	81	37	39	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4729	4747		10.1096/fj.14-252569	http://dx.doi.org/10.1096/fj.14-252569			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25114175	Green Accepted			2022-12-28	WOS:000344050900014
J	Saresella, M; Piancone, F; Marventano, I; La Rosa, F; Tortorella, P; Caputo, D; Rovaris, M; Clerici, M				Saresella, Marina; Piancone, Federica; Marventano, Ivana; La Rosa, Francesca; Tortorella, Paola; Caputo, Domenico; Rovaris, Marco; Clerici, Mario			A role for the TIM-3/GAL-9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis	FASEB JOURNAL			English	Article						apoptosis; myelin basic protein; T cell	PROGRAMMED CELL-DEATH; T-CELLS; TIM-3 LIGAND; DEMYELINATING DISEASE; RHEUMATOID-ARTHRITIS; PERIPHERAL TOLERANCE; AUTOIMMUNE-DISEASE; RESPONSES; GALECTIN-9; EXPRESSION	T-cell immunoglobulin and mucin domain 3 (Tim-3) ligates galectin-9 (Gal-9); this process, resulting in the inhibition of T(h)1 responses and in the apoptosis of antigen-specific cells, is hampered by binding of the molecular adaptor human leukocyte antigen B (HLA-B)-associated transcript 3 (Bat3) to the intracellular tail of Tim-3. Apoptosis of myelin basic protein (MBP)-specific T lymphocytes correlates with reduced rates of disease progression in multiple sclerosis (MS). We extensively analyzed the Tim-3/Gal-9/Bat3 pathway in 87 patients with a diagnosis of stable relapsing-remitting MS (RRMS), primary progressive MS (PPMS), or benign MS (BEMS), as well as in 40 healthy control (HC) subjects. Results showed that MBP-specific CD4(+)Tim-3(+), CD4(+)/Gal-9(+), and CD4(+)/Tim-3(+)/AV(+) (apoptotic) T lymphocytes were augmented in the BEMS group, whereas CD4(+)/Bat3(+) and CD8(+)/Bat3(+) T lymphocytes were increased and CD4(+)/Tim-3(+)/AV(+) T cells were reduced in the PPMS group (>2 fold and P<0.05 in all cases). Blocking the Tim-3/Gal-9 interaction with specific mAb reduced T-lymphocyte apoptosis and augmented production of IFN and IL-17 in the BEMS, RRMS, and HC groups, but not in the PPMS group. The Tim-3/Gal-9 interaction favors apoptosis of MBP-specific T lymphocytes in BEMS; this process is reduced in PPMS by the up-regulation of Bat3. Therapeutic interventions aimed at silencing Bat3 could be beneficial in MS.Saresella, M., Piancone, F., Marventano, I., La Rosa, F., Tortorella, P., Caputo, D., Rovaris, M., Clerici, M. A role for the TIM-3/GAL-9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis.	[Saresella, Marina; Piancone, Federica; Marventano, Ivana; La Rosa, Francesca; Tortorella, Paola; Caputo, Domenico; Rovaris, Marco; Clerici, Mario] Fdn Don C Gnocchi, IRCCS, I-20100 Milan, Italy; [Clerici, Mario] Univ Milan, Dept Physiopathol & Transplants, Milan, Italy	IRCCS Fondazione Don Carlo Gnocchi Onlus; University of Milan	Saresella, M (corresponding author), Fdn Don C Gnocchi, IRCCS, Pzza Morandi 3, I-20100 Milan, Italy.	msaresella@dongnocchi.it	La Rosa, Francesca FLR/J-4757-2018; Piancone, Federica/K-5893-2016; Rovaris, Marco/AAA-6040-2020; Saresella, Marina/G-7810-2012	Piancone, Federica/0000-0001-7951-1169; Rovaris, Marco/0000-0001-9691-1957; Saresella, Marina/0000-0002-2295-3043; Marventano, Ivana/0000-0001-8111-3522; La Rosa, Francesca/0000-0003-3181-9505; Clerici, Mario/0000-0001-5920-6191	Ricerca Corrente (Italian Ministry of Health)	Ricerca Corrente (Italian Ministry of Health)(Ministry of Health, Italy)	This study was supported by 2012-2013 Ricerca Corrente (Italian Ministry of Health).	Anderson AC, 2007, SCIENCE, V318, P1141, DOI 10.1126/science.1148536; Anderson AC, 2006, CURR OPIN IMMUNOL, V18, P665, DOI 10.1016/j.coi.2006.09.009; Anderson AC, 2010, EUR J IMMUNOL, V40, P859, DOI 10.1002/eji.200939842; Chastain EML, 2012, IMMUNOL REV, V245, P227, DOI 10.1111/j.1600-065X.2011.01076.x; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; Freeman GJ, 2010, IMMUNOL REV, V235, P172, DOI 10.1111/j.0105-2896.2010.00903.x; Golden-Mason L, 2009, J VIROL, V83, P9122, DOI 10.1128/JVI.00639-09; Gooden MJM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065616; Hastings WD, 2009, EUR J IMMUNOL, V39, P2492, DOI 10.1002/eji.200939274; Joller N, 2012, IMMUNOL REV, V248, P122, DOI 10.1111/j.1600-065X.2012.01136.x; Kaneyama T, 2014, INT IMMUNOL, V26, P369, DOI 10.1093/intimm/dxt056; Khademi M, 2004, J IMMUNOL, V172, P7169, DOI 10.4049/jimmunol.172.11.7169; Koguchi K, 2006, J EXP MED, V203, P1413, DOI 10.1084/jem.20060210; Kyewski B, 2006, ANNU REV IMMUNOL, V24, P571, DOI 10.1146/annurev.immunol.23.021704.115601; Lee J, 2011, SCAND J RHEUMATOL, V40, P334, DOI 10.3109/03009742.2010.547871; Lee SY, 2013, J IMMUNOL, V190, P4991, DOI 10.4049/jimmunol.1300083; Li X, 2012, EXPERT OPIN THER TAR, V16, P1145, DOI 10.1517/14728222.2012.726616; Liu Y, 2010, CLIN IMMUNOL, V137, P288, DOI 10.1016/j.clim.2010.07.012; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Mueller DL, 2010, NAT IMMUNOL, V11, P21, DOI 10.1038/ni.1817; Nakae S, 2007, BLOOD, V110, P2565, DOI 10.1182/blood-2006-11-058800; Nakae S, 2007, J LEUKOCYTE BIOL, V81, P1258, DOI 10.1189/jlb.1006610; Niwa H, 2009, CLIN IMMUNOL, V132, P184, DOI 10.1016/j.clim.2009.04.012; Nylander A, 2012, J CLIN INVEST, V122, P1180, DOI 10.1172/JCI58649; Pan HF, 2010, MOL BIOL REP, V37, P395, DOI 10.1007/s11033-009-9833-7; Rabinovich GA, 2007, SCAND J IMMUNOL, V66, P143, DOI 10.1111/j.1365-3083.2007.01986.x; Rabinovich GA, 2012, ANN NY ACAD SCI, V1253, P1, DOI 10.1111/j.1749-6632.2012.06492.x; Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536; Rangachari M, 2013, J AUTOIMMUN, V45, P31, DOI 10.1016/j.jaut.2013.06.008; Rangachari M, 2012, NAT MED, V18, P1394, DOI 10.1038/nm.2871; Riou C, 2014, J VIROL, V88, P1819, DOI 10.1128/JVI.02968-13; Rodriguez-Manzanet R, 2009, IMMUNOL REV, V229, P259, DOI 10.1111/j.1600-065X.2009.00772.x; Sabatos CA, 2003, NAT IMMUNOL, V4, P1102, DOI 10.1038/ni988; Sakhdari A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040146; Sanchez-Fueyo A, 2003, NAT IMMUNOL, V4, P1093, DOI 10.1038/ni987; Saresella M, 2005, J NEUROIMMUNOL, V166, P173, DOI 10.1016/j.jneuroim.2005.05.010; Saresella M, 2008, CLIN IMMUNOL, V129, P509, DOI 10.1016/j.clim.2008.08.010; Seki M, 2008, CLIN IMMUNOL, V127, P78, DOI 10.1016/j.clim.2008.01.006; Trabattoni D, 2009, J IMMUNOL, V183, P4984, DOI 10.4049/jimmunol.0901038; Troncoso Maria F, 2012, Front Biosci (Schol Ed), V4, P864; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; Wiersma VR, 2013, MED RES REV, V33, pE102, DOI 10.1002/med.20249; Yang L, 2008, J IMMUNOL, V180, P4409, DOI 10.4049/jimmunol.180.7.4409; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271	44	22	24	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					5000	5009		10.1096/fj.14-258194	http://dx.doi.org/10.1096/fj.14-258194			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25091272				2022-12-28	WOS:000344050900035
J	Guignandon, A; Faure, C; Neutelings, T; Rattner, A; Mineur, P; Linossier, MT; Laroche, N; Lambert, C; Deroanne, C; Nusgens, B; Demets, R; Colige, A; Vico, L				Guignandon, Alain; Faure, Celine; Neutelings, Thibaut; Rattner, Aline; Mineur, Pierre; Linossier, Marie-Therese; Laroche, Norbert; Lambert, Charles; Deroanne, Christophe; Nusgens, Betty; Demets, Rene; Colige, Alain; Vico, Laurence			Rac1 GTPase silencing counteracts microgravity-induced effects on osteoblastic cells	FASEB JOURNAL			English	Article						VEGF; spaceflight; MG-63; RhoA; Cdc42	ENDOTHELIAL GROWTH-FACTOR; MATRIX ADHESIONS; MODELED MICROGRAVITY; SIMULATED MICROGRAVITY; FOCAL ADHESIONS; RHO GTPASES; IN-VITRO; VEGF; EXPRESSION; PHOSPHORYLATION	Bone cells exposed to real microgravity display alterations of their cytoskeleton and focal adhesions, two major mechanosensitive structures. These structures are controlled by small GTPases of the Ras homology (Rho) family. We investigated the effects of RhoA, Rac1, and Cdc42 modulation of osteoblastic cells under microgravity conditions. Human MG-63 osteoblast-like cells silenced for RhoGTPases were cultured in the automated Biobox bioreactor (European Space Agency) aboard the Foton M3 satellite and compared to replicate ground-based controls. The cells were fixed after 69 h of microgravity exposure for postflight analysis of focal contacts, F-actin polymerization, vascular endothelial growth factor (VEGF) expression, and matrix targeting. We found that RhoA silencing did not affect sensitivity to microgravity but that Rac1 and, to a lesser extent, Cdc42 abrogation was particularly efficient in counteracting the spaceflight-related reduction of the number of focal contacts [-50% in silenced, scrambled (SiScr) controls vs. -15% for SiRac1], the number of F-actin fibers (-60% in SiScr controls vs. -10% for SiRac1), and the depletion of matrix-bound VEGF (-40% in SiScr controls vs. -8% for SiRac1). Collectively, these data point out the role of the VEGF/Rho GTPase axis in mechanosensing and validate Rac1-mediated signaling pathways as potential targets for counteracting microgravity effects.	[Guignandon, Alain; Faure, Celine; Rattner, Aline; Linossier, Marie-Therese; Laroche, Norbert; Vico, Laurence] Univ Lyon 1, INSERM, Lab Biol Integree Tissu Osseux, U 1059, F-42023 St Etienne 2, France; [Neutelings, Thibaut; Mineur, Pierre; Lambert, Charles; Deroanne, Christophe; Nusgens, Betty; Colige, Alain] Univ Liege, Lab Connect Tissues Biol, GIGA, Sart Tilman Par Liege, Belgium; [Demets, Rene] ESTEC, HSO, BSU, Noordwijk, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Liege; European Space Agency	Guignandon, A (corresponding author), Univ Lyon 1, Fac Med, INSERM U1059, LBTO, 15 Rue Ambroise PARE, F-42023 St Etienne 2, France.	alain.guignandon@univ-st-etienne.fr	Vico, Laurence/O-1927-2018; Vico, Laurence/ABG-7239-2020	Vico, Laurence/0000-0002-2110-287X; Vico, Laurence/0000-0002-2110-287X; GUIGNANDON, Alain/0000-0002-0745-5417	ESA; European Research in Space and Terrestrial Osteoporosis (ERISTO) [14232/NL/SH, CCN3]; Microgravity Application Program (MAP) [AO-99-122, 14426]; Centre National d'Etudes Spatiales (CNES); Centre National d'Etudes Spatiales (the French space agency); Institut National de la Sant et de la Recherche Medicale (INSERM); University Jean Monnet; Institute for Science and Engineering (IFRESIS; Institute for Science and Engineering (St-Etienne); Institute for Science and Engineering (France); Center for Concepts in Mechatronics (CCM; Nuenen, The Netherlands)	ESA(European Space Agency); European Research in Space and Terrestrial Osteoporosis (ERISTO); Microgravity Application Program (MAP); Centre National d'Etudes Spatiales (CNES)(Centre National D'etudes Spatiales); Centre National d'Etudes Spatiales (the French space agency)(Centre National D'etudes Spatiales); Institut National de la Sant et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); University Jean Monnet; Institute for Science and Engineering (IFRESIS; Institute for Science and Engineering (St-Etienne); Institute for Science and Engineering (France); Center for Concepts in Mechatronics (CCM; Nuenen, The Netherlands)	The spaceflight opportunity on Foton-M3 was provided by the ESA. The authors acknowledge the support of the ESA and the Center for Concepts in Mechatronics (CCM; Nuenen, The Netherlands) for providing help during the preparation and integration of the Obadis experiment in the Biobox. This study received financial support from the ESA, European Research in Space and Terrestrial Osteoporosis (ERISTO; contract 14232/NL/SH; CCN3), the Microgravity Application Program (MAP; AO-99-122, contract 14426), and the Centre National d'Etudes Spatiales (CNES; the French space agency). Moreover, this work was supported in part by the Institut National de la Sant et de la Recherche Medicale (INSERM), the University Jean Monnet, and the Institute for Science and Engineering (IFRESIS; St-Etienne, France). The authors declare no conflicts of interest.	Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88; Anderson SM, 2011, INTEGR BIOL-UK, V3, P887, DOI 10.1039/c1ib00037c; Anderson SM, 2009, BIOMATERIALS, V30, P4618, DOI 10.1016/j.biomaterials.2009.05.030; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; Blaber EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061372; Bryan BA, 2010, FASEB J, V24, P3186, DOI 10.1096/fj.09-145102; Buravkova LB, 2010, ACTA NATURAE, V2, P28, DOI 10.32607/20758251-2010-2-1-28-35; Burger EH, 1998, BONE, V22, p127S, DOI 10.1016/S8756-3282(98)00010-6; Capulli M, 2009, J CELL BIOCHEM, V107, P240, DOI 10.1002/jcb.22120; Carmeliet G, 1997, J BONE MINER RES, V12, P786, DOI 10.1359/jbmr.1997.12.5.786; Carmeliet G, 1999, FASEB J, V13, pS129, DOI 10.1096/fasebj.13.9001.s129; Carroll B, 2013, DEV CELL, V25, P15, DOI 10.1016/j.devcel.2013.03.005; Chen TT, 2010, J CELL BIOL, V188, P595, DOI 10.1083/jcb.200906044; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308; Deroanne CF, 2005, J CELL SCI, V118, P1173, DOI 10.1242/jcs.01707; Dieriks B, 2011, MOL MED REP, V4, P17, DOI 10.3892/mmr.2010.405; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Faure C, 2008, BONE, V42, P1092, DOI 10.1016/j.bone.2008.02.011; Faure C, 2010, BIOMATERIALS, V31, P6477, DOI 10.1016/j.biomaterials.2010.05.011; Goel HL, 2012, CELL ADHES MIGR, V6, P554, DOI 10.4161/cam.22419; Guignandon A, 2001, FASEB J, V15, P2036, DOI 10.1096/fj.00-0837fje; GUIGNANDON A, 1995, CELL STRUCT FUNCT, V20, P369, DOI 10.1247/csf.20.369; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106; Higashibata Akira, 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-19; Ho TTG, 2008, J BIOL CHEM, V283, P21588, DOI 10.1074/jbc.M710033200; Ho TTG, 2011, MOL BIOL CELL, V22, P3263, DOI 10.1091/mbc.E11-01-0020; Hoang MV, 2011, BLOOD, V117, P1751, DOI 10.1182/blood-2010-05-286831; Hughes-Fulford M, 2003, ADV SPACE RES-SERIES, V32, P1585, DOI 10.1016/S0273-1177(03)90399-1; Hughes-Fulford M, 1999, FASEB J, V13, pS121; Infanger M, 2006, APOPTOSIS, V11, P749, DOI 10.1007/s10495-006-5697-7; Ingber DE, 2008, J BODYW MOV THER, V12, P198, DOI 10.1016/j.jbmt.2008.04.038; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Kumei Y, 1999, Biol Sci Space, V13, P142; Kumei Y, 2007, ANN NY ACAD SCI, V1095, P292, DOI 10.1196/annals.1397.032; Lin LJ, 2013, BIOMATERIALS, V34, P3807, DOI 10.1016/j.biomaterials.2013.01.092; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Meyers VE, 2005, J BONE MINER RES, V20, P1858, DOI 10.1359/JBMR.050611; Mitchell L, 2013, ANTIOXID REDOX SIGN, V18, P250, DOI 10.1089/ars.2012.4687; Nabavi N, 2011, BONE, V49, P965, DOI 10.1016/j.bone.2011.07.036; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Rijken P J, 1994, Adv Space Biol Med, V4, P159; Schiller HB, 2013, EMBO REP, V14, P509, DOI 10.1038/embor.2013.49; Schwarz US, 2002, BIOPHYS J, V83, P1380, DOI 10.1016/S0006-3495(02)73909-X; Sun Y, 2013, OSTEOPOROSIS INT, V24, P969, DOI 10.1007/s00198-012-2028-4; Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140-6736(00)02217-0; Wang JH, 2009, NEUROCHEM INT, V55, P710, DOI 10.1016/j.neuint.2009.07.002; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Zaidel-Bar R, 2007, J CELL SCI, V120, P137, DOI 10.1242/jcs.03314	52	22	22	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4077	4087		10.1096/fj.14-249714	http://dx.doi.org/10.1096/fj.14-249714			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24903274	Green Published			2022-12-28	WOS:000340845900025
J	Nita, II; Hershfinkel, M; Kantor, C; Rutter, GA; Lewis, EC; Sekler, I				Nita, Iulia I.; Hershfinkel, Michal; Kantor, Chase; Rutter, Guy A.; Lewis, Eli C.; Sekler, Israel			Pancreatic beta-cell Na+ channels control global Ca2+ signaling and oxidative metabolism by inducing Na+ and Ca2+ responses that are propagated into mitochondria	FASEB JOURNAL			English	Article						TTX; NCLX; MCU	STIMULATED INSULIN-SECRETION; NA+/CA2+ EXCHANGE; B-CELLS; ESSENTIAL COMPONENT; NA+-CA2+ EXCHANGER; CALCIUM UNIPORTER; CYTOPLASMIC CA2+; IMAGING REVEALS; SODIUM-CHANNEL; CYTOSOLIC CA2+	Communication between the plasma membrane and mitochondria is essential for initiating the Ca2+ and metabolic signals required for secretion in beta cells. Although voltage-dependent Na+ channels are abundantly expressed in beta cells and activated by glucose, their role in communicating with mitochondria is unresolved. Here, we combined fluorescent Na+, Ca2+, and ATP imaging, electrophysiological analysis with tetrodotoxin (TTX)-dependent block of the Na+ channel, and molecular manipulation of mitochondrial Ca2+ transporters to study the communication between Na+ channels and mitochondria. We show that TTX inhibits glucose-dependent depolarization and blocks cytosolic Na+ and Ca2+ responses and their propagation into mitochondria. TTX-sensitive mitochondrial Ca2+ influx was largely blocked by knockdown of the mitochondrial Ca2+ uniporter (MCU) expression. Knockdown of the mitochondrial Na+/Ca2+ exchanger (NCLX) and Na+ dose response analysis demonstrated that NCLX mediates the mitochondrial Na+ influx and is tuned to sense the TTX-sensitive cytosolic Na+ responses. Finally, TTX blocked glucose-dependent mitochondrial Ca2+ rise, mitochondrial metabolic activity, and ATP production. Our results show that communication of the Na+ channels with mitochondria shape both global Ca2+ and metabolism signals linked to insulin secretion in beta cells.	[Nita, Iulia I.; Hershfinkel, Michal; Sekler, Israel] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol & Cell Biol, IL-84105 Beer Sheva, Israel; [Lewis, Eli C.] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84105 Beer Sheva, Israel; [Kantor, Chase; Rutter, Guy A.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Med, Sect Cell Biol,Div Diabet Endocrinol & Metab, London, England	Ben Gurion University; Ben Gurion University; Imperial College London	Sekler, I (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol & Cell Biol, POB 653, IL-84105 Beer Sheva, Israel.	sekler@bgu.ac.il	LEWIS, ELI C/F-1552-2012; Nita, Iulia/AAF-6887-2021	LEWIS, ELI C/0000-0002-4189-2207; Rutter, Guy/0000-0001-6360-0343; Hershfinkel, Michal/0000-0003-1652-1989	Israel Science Foundation (ISF) [985/05]; German Israeli Foundation (GIF) [485/11]; ISF [513/09]; Biotechnology and Biological Sciences Research Council (UK); Welcome Trust Senior Investigator Award; UK Medical Research Council program grant; Royal Society Research Merit Award; BBSRC [BB/J015873/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/J015873/1] Funding Source: researchfish	Israel Science Foundation (ISF)(Israel Science Foundation); German Israeli Foundation (GIF)(German-Israeli Foundation for Scientific Research and Development); ISF(Israel Science Foundation); Biotechnology and Biological Sciences Research Council (UK)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Welcome Trust Senior Investigator Award; UK Medical Research Council program grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Royal Society Research Merit Award; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors thank Dr. Atsushi Miyawaki (RIKEN, Wako, Japan) for the mitopericam and Dr. Hiroyuki Noji (Osaka University, Ibaraki, Osaka, Japan) for the generous gift of AT 1.03 plasmid, as well as Dr. Ilya Fleidervish (Ben-Gurion University, Beer-Sheva, Israel) for his critical comments. I.S. was supported by Israel Science Foundation (ISF) grant 985/05 and German Israeli Foundation (GIF) grant 485/11, M.H. was supported by ISF grant 513/09, G.A.R. was supported by a project grant from the Biotechnology and Biological Sciences Research Council (UK), a Welcome Trust Senior Investigator Award, a UK Medical Research Council program grant, and a Royal Society Research Merit Award.	Akhmedov D, 2010, FASEB J, V24, P4613, DOI 10.1096/fj.10-162222; Anello M, 2005, DIABETOLOGIA, V48, P282, DOI 10.1007/s00125-004-1627-9; ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; Barnett DW, 1995, PFLUG ARCH EUR J PHY, V431, P272, DOI 10.1007/BF00410201; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Bernardinelli Y, 2006, GLIA, V54, P460, DOI 10.1002/glia.20387; Braun M, 2008, DIABETES, V57, P1618, DOI 10.2337/db07-0991; Brennan JP, 2006, CARDIOVASC RES, V72, P322, DOI 10.1016/j.cardiores.2006.08.006; CHANDLER WK, 1965, J PHYSIOL-LONDON, V180, P788, DOI 10.1113/jphysiol.1965.sp007732; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; DENTON RM, 1985, AM J PHYSIOL, V249, pE543, DOI 10.1152/ajpendo.1985.249.6.E543; Drago I, 2012, P NATL ACAD SCI USA, V109, P12986, DOI 10.1073/pnas.1210718109; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; DUNNE MJ, 1990, J MEMBRANE BIOL, V113, P131, DOI 10.1007/BF01872887; Filippin L, 2003, J BIOL CHEM, V278, P39224, DOI 10.1074/jbc.M302301200; Fleidervish IA, 1996, J PHYSIOL-LONDON, V493, P83, DOI 10.1113/jphysiol.1996.sp021366; Fleidervish IA, 2010, NAT NEUROSCI, V13, P852, DOI 10.1038/nn.2574; Gall D, 1999, BIOPHYS J, V77, P45, DOI 10.1016/S0006-3495(99)76871-2; Grapengiesser E, 1998, ENDOCRINOLOGY, V139, P3227, DOI 10.1210/en.139.7.3227; Herchuelz A, 2013, ADV EXP MED BIOL, V961, P385, DOI 10.1007/978-1-4614-4756-6_33; HILLE B, 1972, J GEN PHYSIOL, V59, P637, DOI 10.1085/jgp.59.6.637; HIRIART M, 1988, J GEN PHYSIOL, V91, P617, DOI 10.1085/jgp.91.5.617; Hiriart M, 2008, AM J PHYSIOL-ENDOC M, V295, pE1298, DOI 10.1152/ajpendo.90493.2008; Imamura H, 2009, P NATL ACAD SCI USA, V106, P15651, DOI 10.1073/pnas.0904764106; Jonkers FC, 2001, DIABETES, V50, P540, DOI 10.2337/diabetes.50.3.540; Jonkers FC, 1999, J PHYSIOL-LONDON, V520, P839, DOI 10.1111/j.1469-7793.1999.00839.x; KAWAZU S, 1978, PFLUG ARCH EUR J PHY, V375, P197, DOI 10.1007/BF00584244; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Lee B, 2003, DIABETES, V52, P965, DOI 10.2337/diabetes.52.4.965; Lewis EC, 2005, P NATL ACAD SCI USA, V102, P12153, DOI 10.1073/pnas.0505579102; Lindskog C, 2012, J PROTEOMICS, V75, P2611, DOI 10.1016/j.jprot.2012.03.008; Luciani DS, 2007, EUR J PHARMACOL, V576, P18, DOI 10.1016/j.ejphar.2007.07.055; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; Meier SD, 2006, J NEUROSCI METH, V155, P251, DOI 10.1016/j.jneumeth.2006.01.009; Meyer-Hermann ME, 2007, BIOPHYS J, V93, P2952, DOI 10.1529/biophysj.107.106096; MOORE JW, 1967, J GEN PHYSIOL, V50, P1401, DOI 10.1085/jgp.50.5.1401; Murphy E, 2009, CIRC RES, V104, P292, DOI 10.1161/CIRCRESAHA.108.189050; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Nita II, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046649; Palty R, 2004, J BIOL CHEM, V279, P25234, DOI 10.1074/jbc.M401229200; Palty R, 2010, P NATL ACAD SCI USA, V107, P436, DOI 10.1073/pnas.0908099107; Paucek P, 2004, BBA-BIOENERGETICS, V1659, P83, DOI 10.1016/j.bbabio.2004.03.019; PLANT TD, 1988, PFLUG ARCH EUR J PHY, V411, P429, DOI 10.1007/BF00587723; Poburko D, 2007, CIRC RES, V101, P1030, DOI 10.1161/CIRCRESAHA.107.155531; Poburko D, 2009, CIRC RES, V104, P104, DOI 10.1161/CIRCRESAHA.108.180612; PRENTKI M, 1983, J BIOL CHEM, V258, P7597; PRESSEL DM, 1990, J MEMBRANE BIOL, V116, P273, DOI 10.1007/BF01868466; Ravier MA, 2010, METHODS MOL BIOL, V633, P171, DOI 10.1007/978-1-59745-019-5_12; Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412; Rocheleau JV, 2004, J BIOL CHEM, V279, P31780, DOI 10.1074/jbc.M314005200; RUTTER GA, 1990, INT J BIOCHEM, V22, P1081, DOI 10.1016/0020-711X(90)90105-C; Salvalaggio PRO, 2002, TRANSPLANTATION, V74, P877, DOI 10.1097/00007890-200209270-00023; Tarasov AI, 2006, DIABETES, V55, P3075, DOI 10.2337/db06-0637; Tarasov AI, 2013, PFLUG ARCH EUR J PHY, V465, P543, DOI 10.1007/s00424-012-1177-9; Tarasov AI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039722; Van Eylen F, 2002, DIABETES, V51, P366, DOI 10.2337/diabetes.51.2.366; Verkhratsky A, 2012, MOL CELL ENDOCRINOL, V353, P45, DOI 10.1016/j.mce.2011.08.039; Vidaltamayo R, 2002, FASEB J, V16, P891, DOI 10.1096/fj.01-0934fje; Wiederkehr A, 2008, CELL CALCIUM, V44, P64, DOI 10.1016/j.ceca.2007.11.004; Yang F, 2003, J CELL BIOL, V163, P511, DOI 10.1083/jcb.200307027	60	40	42	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3301	3312		10.1096/fj.13-248161	http://dx.doi.org/10.1096/fj.13-248161			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24719357	Green Accepted			2022-12-28	WOS:000340265400003
J	Cheng, J; Edin, ML; Hoopes, SL; Li, H; Bradbury, JA; Graves, JP; DeGraff, LM; Lih, FB; Garcia, V; Shaik, JSB; Tomer, KB; Flake, GP; Falck, JR; Lee, CR; Poloyac, SM; Schwartzman, ML; Zeldin, DC				Cheng, Jennifer; Edin, Matthew L.; Hoopes, Samantha L.; Li, Hong; Bradbury, J. Alyce; Graves, Joan P.; DeGraff, Laura M.; Lih, Fred B.; Garcia, Victor; Shaik, Jafar Sadik B.; Tomer, Kenneth B.; Flake, Gordon P.; Falck, John R.; Lee, Craig R.; Poloyac, Samuel M.; Schwartzman, Michal L.; Zeldin, Darryl C.			Vascular characterization of mice with endothelial expression of cytochrome P450 4F2	FASEB JOURNAL			English	Article						CYP4F2; 20-HETE; oxidative stress; cellular proliferation; angiogenesis	URINARY 20-HYDROXYEICOSATETRAENOIC ACID; OXIDATIVE STRESS; 20-HETE SYNTHESIS; ARACHIDONIC-ACID; BLOOD-PRESSURE; NADPH-OXIDASE; RENAL INJURY; DYSFUNCTION; HYPERTENSION; ACTIVATION	Cytochrome P450 (CYP) 4A and 4F enzymes metabolize arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE). Although CYP4A-derived 20-HETE is known to have prohypertensive and proangiogenic properties, the effects of CYP4F-derived metabolites are not well characterized. To investigate the role of CYP4F2 in vascular disease, we generated mice with endothelial expression of human CYP4F2 (Tie2-CYP4F2-Tr). LC/MS/MS analysis revealed 2-fold increases in 20-HETE levels in tissues and endothelial cells (ECs), relative to wild-type (WT) controls. Tie2-CYP4F2-Tr ECs demonstrated increases in growth (267.1 +/- 33.4 vs. 205.0 +/- 13% at 48 h) and tube formation (7.7 +/- 1.1 vs. 1.6 +/- 0.5 tubes/field) that were 20-HETE dependent and associated with up-regulation of prooxidant NADPH oxidase and proangiogenic VEGF. Increases in VEGF and NADPH oxidase levels were abrogated by inhibitors of NADPH oxidase and MAPK, respectively, suggesting the possibility of crosstalk between pathways. Interestingly, IL-6 levels in Tie2-CYP4F2-Tr mice (18.6 +/- 2.7 vs. 7.9 +/- 2.7 pg/ml) were up-regulated via NADPH oxidase-and 20-HETE-dependent mechanisms. Although Tie2-CYP4F2-Tr aortas displayed increased vasoconstriction, vasorelaxation and blood pressure were unchanged. Our findings indicate that human CYP4F2 significantly increases 20-HETE production, CYP4F2-derived 20-HETE mediates EC proliferation and angiogenesis via VEGF-and NADPH oxidase-dependent manners, and the Tie2-CYP4F2-Tr mouse is a novel model for examining the pathophysiological effects of CYP4F2-derived 20-HETE in the vasculature.	[Cheng, Jennifer; Edin, Matthew L.; Hoopes, Samantha L.; Li, Hong; Bradbury, J. Alyce; Graves, Joan P.; DeGraff, Laura M.; Lih, Fred B.; Tomer, Kenneth B.; Flake, Gordon P.; Zeldin, Darryl C.] NIEHS, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; [Falck, John R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Garcia, Victor; Schwartzman, Michal L.] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; [Lee, Craig R.] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA; [Shaik, Jafar Sadik B.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Southwestern Medical Center Dallas; New York Medical College; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zeldin, DC (corresponding author), NIEHS, NIH, 111 TW Alexander Dr,Bldg 101,Rm A214, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	SHAIK, JAFAR SADIK/A-9638-2010; Li, Hong/ABE-3959-2021; Edin, Matthew/AAI-1934-2019; Zeldin, Darryl C/Y-7091-2018	SHAIK, JAFAR SADIK/0000-0001-5776-3138; Zeldin, Darryl C/0000-0002-2087-7307; Lee, Craig/0000-0003-3595-5301; Garcia, Victor/0000-0002-1849-8834; Edin, Matthew/0000-0002-7042-500X	U.S. National Institutes of Health (NIH) [DK-38226]; Robert A. Welch Foundation; NIH [GM-088199, HL-34300]; NIH, National Institute of Environmental Health Sciences [Z01 ES050167, Z01 ES025034];  [HL-34300-26A1S1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050167, ZIAES025034, ZIAES103005, Z01ES025034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088199] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert A. Welch Foundation(The Welch Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors gratefully acknowledge the staff at Xenogen Biosciences (Cranberry, NJ, USA) for assistance with pronuclear injections and generation of the Tie2-CYP4F2-Tr mice. This work was made possible by U.S. National Institutes of Health (NIH) grant DK-38226 and support from the Robert A. Welch Foundation (to J.R.F.), NIH grant GM-088199 (to C. R. L), NIH grant HL-34300 (to M. L. S.), Diversity Supplement Award HL-34300-26A1S1 (to V. G.), and funds from the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01 ES050167 to K. B. T. and Z01 ES025034 to D.C.Z.).	Alexanian A, 2012, CANCER GENOM PROTEOM, V9, P163; Alexanian A, 2009, ANTICANCER RES, V29, P3819; Amaral SL, 2003, AM J PHYSIOL-HEART C, V284, pH1528, DOI 10.1152/ajpheart.00406.2002; Athirakul K, 2008, FASEB J, V22, P4096, DOI 10.1096/fj.08-114413; Behrens MM, 2008, J NEUROSCI, V28, P13957, DOI 10.1523/JNEUROSCI.4457-08.2008; Chen P, 2005, AM J PATHOL, V166, P615, DOI 10.1016/S0002-9440(10)62282-1; Chen YM, 2006, AM J PHYSIOL-LUNG C, V291, pL378, DOI 10.1152/ajplung.00424.2005; Cheng J, 2008, AM J PHYSIOL-HEART C, V294, pH1018, DOI 10.1152/ajpheart.01172.2007; Cheng J, 2012, ARTERIOSCL THROM VAS, V32, P1917, DOI 10.1161/ATVBAHA.112.248344; Cheng J, 2010, J PHARMACOL EXP THER, V332, P57, DOI 10.1124/jpet.109.159863; Deng SM, 2010, PROG NEURO-PSYCHOPH, V34, P664, DOI 10.1016/j.pnpbp.2010.03.009; Edin ML, 2011, FASEB J, V25, P3436, DOI 10.1096/fj.11-188300; Guo AM, 2007, J PHARMACOL EXP THER, V321, P18, DOI 10.1124/jpet.106.115360; Guo AM, 2009, AM J PHYSIOL-HEART C, V297, pH602, DOI 10.1152/ajpheart.00874.2008; Hankin JA, 2000, AM J RESP CRIT CARE, V161, pS81, DOI 10.1164/ajrccm.161.supplement_1.ltta-17; Hoff U, 2011, KIDNEY INT, V79, P57, DOI 10.1038/ki.2010.377; Inoue K, 2009, AM J PHYSIOL-RENAL, V297, pF875, DOI 10.1152/ajprenal.00364.2009; Ishizuka T, 2008, J PHARMACOL EXP THER, V324, P103, DOI 10.1124/jpet.107.130336; Jacobs ER, 2006, AM J PHYSIOL-LUNG C, V291, pL369, DOI 10.1152/ajplung.00265.2004; Jiang M, 2004, CIRC RES, V94, P167, DOI 10.1161/01.RES.0000111523.12842.FC; Lasker JM, 2000, J BIOL CHEM, V275, P4118, DOI 10.1074/jbc.275.6.4118; Lassegue B, 2010, ARTERIOSCL THROM VAS, V30, P653, DOI 10.1161/ATVBAHA.108.181610; Lee CR, 2010, FASEB J, V24, P3770, DOI 10.1096/fj.10-160119; Liu H, 2008, J AM SOC NEPHROL, V19, P714, DOI 10.1681/ASN.2007060713; Liu XL, 2012, GENE, V505, P352, DOI 10.1016/j.gene.2012.02.029; Liu XL, 2009, KIDNEY INT, V75, P1288, DOI 10.1038/ki.2009.67; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Medhora M, 2008, AM J PHYSIOL-LUNG C, V294, pL902, DOI 10.1152/ajplung.00278.2007; Miyata Noriyuki, 2005, Journal of Smooth Muscle Research, V41, P175, DOI 10.1540/jsmr.41.175; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Park F, 2008, J AM SOC NEPHROL, V19, P1929, DOI 10.1681/ASN.2007070771; Powell PK, 1998, J PHARMACOL EXP THER, V285, P1327; Schuck RN, 2013, ATHEROSCLEROSIS, V227, P442, DOI 10.1016/j.atherosclerosis.2013.01.034; Singh H, 2007, HYPERTENSION, V50, P123, DOI 10.1161/HYPERTENSIONAHA.107.089599; ten Freyhaus H, 2006, CARDIOVASC RES, V71, P331, DOI 10.1016/j.cardiores.2006.01.022; Uddin MR, 1998, HYPERTENSION, V31, P242, DOI 10.1161/01.HYP.31.1.242; Wang JS, 2006, CIRC RES, V98, P962, DOI 10.1161/01.RES.0000217283.98806.a6; Ward NC, 2008, HYPERTENSION, V51, P1393, DOI 10.1161/HYPERTENSIONAHA.107.104463; Ward NC, 2005, FREE RADICAL BIO MED, V38, P1032, DOI 10.1016/j.freeradbiomed.2004.12.024; Ward NC, 2004, CIRCULATION, V110, P438, DOI 10.1161/01.CIR.0000136808.72912.D9; Wassmann S, 2004, CIRC RES, V94, P534, DOI 10.1161/01.RES.0000115557.25127.8D; Yu W, 2011, CANCER CHEMOTH PHARM, V68, P619, DOI 10.1007/s00280-010-1521-8; Zalba G, 2001, HYPERTENSION, V38, P1395, DOI 10.1161/hy1201.099611; Zeng QH, 2010, AM J PHYSIOL-HEART C, V299, pH1109, DOI 10.1152/ajpheart.00067.2010	44	25	27	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2915	2931		10.1096/fj.13-241927	http://dx.doi.org/10.1096/fj.13-241927			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24668751	Green Published, Bronze			2022-12-28	WOS:000337949400016
J	Lee, LTO; Ng, SYL; Chu, JYS; Sekar, R; Harikumar, KG; Miller, LJ; Chow, BKC				Lee, Leo T. O.; Ng, Stephanie Y. L.; Chu, Jessica Y. S.; Sekar, Revathi; Harikumar, Kaleeckal G.; Miller, Laurence J.; Chow, Billy K. C.			Transmembrane peptides as unique tools to demonstrate the in vivo action of a cross-class GPCR heterocomplex	FASEB JOURNAL			English	Article						secretin; angiotensin II; in vivo analysis	PROTEIN-COUPLED RECEPTORS; II TYPE-1 RECEPTOR; ANGIOTENSIN-II; SECRETIN RECEPTOR; CRYSTAL-STRUCTURE; AT(1) RECEPTOR; OLIGOMERIZATION; HETERODIMERS; ANTAGONIST; ACTIVATION	Angiotensin (ANGII) and secretin (SCT) share overlapping, interdependent osmoregulatory functions in brain, where SCT peptide/receptor function is required for ANGII action, yet the molecular basis is unknown. Since receptors for these peptides (AT1aR, SCTR) are coexpressed in osmoregulatory centers, a possible mechanism is formation of a cross-class receptor heterocomplex. Here, we demonstrate such a complex and its functional importance to modulate signaling. Association of AT1aR with SCTR reduced ability of SCT to stimulate cyclic adenosine monophosphate (cAMP), with signaling augmented in presence of ANGII or constitutively active AT1aR. Several transmembrane (TM) peptides of these receptors were able to affect their conformation within complexes, reducing receptor BRET signals. AT1aR TM1 affected only formation and activity of the heterocomplex, without effect on homomers of either receptor, and reduced SCT-stimulated cAMP responses in cells expressing both receptors. This peptide was active in vivo by injection into mouse lateral ventricle, thereby suppressing water-drinking behavior after hyperosmotic shock, similar to SCTR knockouts. This supports the interpretation that active conformation of AT1aR is a key modulator of cAMP responses induced by SCT stimulation of SCTR. The SCTR/AT1aR complex is physiologically important, providing differential signaling to SCT in settings of hyperosmolality or food intake, modulated by differences in levels of ANGII.	[Lee, Leo T. O.; Ng, Stephanie Y. L.; Chu, Jessica Y. S.; Sekar, Revathi; Chow, Billy K. C.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China; [Harikumar, Kaleeckal G.; Miller, Laurence J.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ USA	University of Hong Kong; Mayo Clinic; Mayo Clinic Phoenix	Chow, BKC (corresponding author), Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	bkcc@hku.hk	Sekar, Revathi/AAE-9642-2022; Lee, Leo T.O./AAB-1581-2021; Sekar, Revathi/AFE-8105-2022; Chow, Billy/D-3064-2009	Sekar, Revathi/0000-0002-6787-7742; Chow, Billy/0000-0003-3390-0307; Harikumar, Kaleeckal/0000-0003-0411-5334	Hong Kong Government RGC [770212M, CRFHKU6/CRF/11G, HKU 764812M, HKU 765011M]; U.S. National Institutes of Health [DK046577]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046577, R01DK046577] Funding Source: NIH RePORTER	Hong Kong Government RGC; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by Hong Kong Government RGC grants 770212M (to L.T.O.L.) and CRFHKU6/CRF/11G, HKU 764812M and HKU 765011M (to B.K.C.C.), and U.S. National Institutes of Health grant DK046577 (to L.J.M.).	AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; AbdAlla S, 2005, J MOL NEUROSCI, V26, P185, DOI 10.1385/JMN:26:2-3:185; Albizu L, 2010, NAT CHEM BIOL, V6, P587, DOI [10.1038/NCHEMBIO.396, 10.1038/nchembio.396]; Bock A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2028; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Canals M, 2006, J BIOL CHEM, V281, P16757, DOI 10.1074/jbc.M601121200; Chu JYS, 2007, MOL CELL BIOL, V27, P2499, DOI 10.1128/MCB.01088-06; Chu JYS, 2011, KIDNEY INT, V79, P280, DOI 10.1038/ki.2010.397; Dong MQ, 2010, BIOORG MED CHEM LETT, V20, P6040, DOI 10.1016/j.bmcl.2010.08.062; Fanelli F, 2011, CHEM REV, V111, pPR438, DOI 10.1021/cr100437t; Gao F, 2009, MOL PHARMACOL, V76, P264, DOI 10.1124/mol.109.055756; Gonzalez AD, 2012, NEUROSCIENCE, V226, P489, DOI 10.1016/j.neuroscience.2012.08.039; GRAY MA, 1988, J MEMBRANE BIOL, V105, P131, DOI 10.1007/BF02009166; Guo W, 2008, EMBO J, V27, P2293, DOI 10.1038/emboj.2008.153; Harikumar KG, 2007, J BIOL CHEM, V282, P30363, DOI 10.1074/jbc.M702325200; Harikumar KG, 2006, BIOCHEMISTRY-US, V45, P14706, DOI 10.1021/bi061107n; Huang JY, 2013, NAT STRUCT MOL BIOL, V20, P419, DOI 10.1038/nsmb.2504; Kobilka BK, 2007, TRENDS PHARMACOL SCI, V28, P397, DOI 10.1016/j.tips.2007.06.003; Kostenis E, 2005, CIRCULATION, V111, P1806, DOI 10.1161/01.CIR.0000160867.23556.7D; Lee VHY, 2010, FASEB J, V24, P5024, DOI 10.1096/fj.10-165399; Lisenbee CS, 2006, BIOCHEMISTRY-US, V45, P8216, DOI 10.1021/bi060494y; Lyngso C, 2009, MOL CELL ENDOCRINOL, V302, P203, DOI 10.1016/j.mce.2008.09.018; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Mancia F, 2008, EMBO REP, V9, P363, DOI 10.1038/embor.2008.27; Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954; Nikiforovich GV, 2005, J PEPT RES, V66, P236, DOI 10.1111/j.1399-3011.2005.00293.x; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Paxinos G, 2012, MOUSE BRAIN STEREOTA; Quitterer U, 2011, BIOCHEM BIOPH RES CO, V409, P544, DOI 10.1016/j.bbrc.2011.05.041; Rivero-Muller A, 2010, P NATL ACAD SCI USA, V107, P2319, DOI 10.1073/pnas.0906695106; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yan LP, 2010, J BIOL CHEM, V285, P2227, DOI 10.1074/jbc.M109.077180	36	35	36	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2632	2644		10.1096/fj.13-246868	http://dx.doi.org/10.1096/fj.13-246868			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24599969	Green Published			2022-12-28	WOS:000339883600021
J	Scalzo, RL; Peltonen, GL; Binns, SE; Shankaran, M; Giordano, GR; Hartley, DA; Klochak, AL; Lonac, MC; Paris, HLR; Szallar, SE; Wood, LM; Peelor, FF; Holmes, WE; Hellerstein, MK; Bell, C; Hamilton, KL; Miller, BF				Scalzo, Rebecca L.; Peltonen, Garrett L.; Binns, Scott E.; Shankaran, Mahalakshmi; Giordano, Gregory R.; Hartley, Dylan A.; Klochak, Anna L.; Lonac, Mark C.; Paris, Hunter L. R.; Szallar, Steve E.; Wood, Lacey M.; Peelor, Frederick F., III; Holmes, William E.; Hellerstein, Marc K.; Bell, Christopher; Hamilton, Karyn L.; Miller, Benjamin F.			Greater muscle protein synthesis and mitochondrial biogenesis in males compared with females during sprint interval training	FASEB JOURNAL			English	Article						stable isotope; sex differences; deuterium oxide; exercise	HUMAN SKELETAL-MUSCLE; HIGH-INTENSITY INTERVAL; BETA-ADRENERGIC STIMULATION; RESISTANCE EXERCISE; SYNTHESIS RATES; SHORT-TERM; AEROBIC EXERCISE; HEAVY-WATER; CALORIE RESTRICTION; HEALTHY-ADULTS	Improved endurance exercise performance in adult humans after sprint interval training (SIT) has been attributed to mitochondrial biogenesis. However, muscle protein synthesis (MPS) and mitochondrial biogenesis during SIT have not been measured, nor have sex-specific differences. We hypothesized that males and females would have similar rates of MPS, mitochondrial biogenesis, and synthesis of individual proteins during SIT. Deuterium oxide (D2O) was orally administered to 21 adults [11 male, 10 female; mean age, 23+/-1 yr; body mass index (BMI), 22.8+/-0.6 kg/m(2); mean+/- SE] for 4 wk, to measure protein synthesis rates while completing 9 sessions of 4-8 bouts of 30 s duration on a cycle ergometer separated by 4 min of active recovery. Samples of the vastus lateralis were taken before and 48 h after SIT. SIT increased maximum oxygen uptake (VO2max, males 43.4+/-2.1-44.0+/-2.3; females 39.5+/-0.9 - 42.5+/-1.3 ml/kg/min; P = 0.002). MPS was greater in the males than in the females in the mixed (similar to 150%; P < 0.001), cytosolic (similar to 135%; P = 0.038), and mitochondrial (similar to 135%; P = 0.056) fractions. The corresponding ontological clusters of individual proteins were significantly greater in the males than in the females (all P<0.00001). For the first time, we document greater MPS and mitochondrial biogenesis during SIT in males than in females and describe the synthetic response of individual proteins in humans during exercise training.	[Scalzo, Rebecca L.; Peltonen, Garrett L.; Binns, Scott E.; Giordano, Gregory R.; Hartley, Dylan A.; Klochak, Anna L.; Lonac, Mark C.; Paris, Hunter L. R.; Szallar, Steve E.; Wood, Lacey M.; Peelor, Frederick F., III; Bell, Christopher; Hamilton, Karyn L.; Miller, Benjamin F.] Colorado State Univ, Dept Hlth & Exercise Sci, Ft Collins, CO 80523 USA; [Shankaran, Mahalakshmi; Holmes, William E.; Hellerstein, Marc K.] KineMed Inc, Emeryville, CA USA; [Hellerstein, Marc K.] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	Colorado State University; University of California System; University of California Berkeley	Miller, BF (corresponding author), Colorado State Univ, Dept Hlth & Exercise Sci, 201 Moby B Complex, Ft Collins, CO 80523 USA.	benjamin.f.miller@colostate.edu		Miller, Benjamin/0000-0003-1647-0122	Office of Naval Research [N00014-10-1-0247]	Office of Naval Research(Office of Naval Research)	The authors thank Dr. M. Colangelo (KineMed) for assistance with the statistical analysis of proteomics data. The Office of Naval Research (N00014-10-1-0247) supported this study.	Astorino TA, 2011, EUR J APPL PHYSIOL, V111, P1279, DOI 10.1007/s00421-010-1741-y; Bartlett JD, 2012, J APPL PHYSIOL, V112, P1135, DOI 10.1152/japplphysiol.01040.2011; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Burgomaster KA, 2008, J PHYSIOL-LONDON, V586, P151, DOI 10.1113/jphysiol.2007.142109; Burgomaster KA, 2006, J APPL PHYSIOL, V100, P2041, DOI 10.1152/japplphysiol.01220.2005; Busch R, 2006, BBA-GEN SUBJECTS, V1760, P730, DOI 10.1016/j.bbagen.2005.12.023; Carter SL, 2001, CAN J PHYSIOL PHARM, V79, P386, DOI 10.1139/cjpp-79-5-386; Drake JC, 2013, J GERONTOL A-BIOL, V68, P1493, DOI 10.1093/gerona/glt047; Dreyer HC, 2010, ACTA PHYSIOL, V199, P71, DOI 10.1111/j.1748-1716.2010.02074.x; Esbjornsson M, 2009, ACTA PHYSIOL, V197, P107, DOI 10.1111/j.1748-1716.2009.01994.x; Fanara P, 2004, J BIOL CHEM, V279, P49940, DOI 10.1074/jbc.M409660200; Fuentes T, 2012, EUR J APPL PHYSIOL, V112, P1917, DOI 10.1007/s00421-011-2164-0; Fujita S, 2007, AM J PHYSIOL-ENDOC M, V292, pE77, DOI 10.1152/ajpendo.00173.2006; Gasier HG, 2011, ACTA PHYSIOL, V201, P381, DOI 10.1111/j.1748-1716.2010.02183.x; Gasier HG, 2012, METABOLISM, V61, P153, DOI 10.1016/j.metabol.2011.07.001; Gasier HG, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-31; Gibala MJ, 2006, J PHYSIOL-LONDON, V575, P901, DOI 10.1113/jphysiol.2006.112094; Gibala MJ, 2009, J APPL PHYSIOL, V106, P929, DOI 10.1152/japplphysiol.90880.2008; Harber MP, 2010, AM J PHYSIOL-REG I, V299, pR1254, DOI 10.1152/ajpregu.00348.2010; Hartman JW, 2006, APPL PHYSIOL NUTR ME, V31, P557, DOI 10.1139/h06-031; Henderson GC, 2009, FASEB J, V23, P631, DOI 10.1096/fj.08-117200; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jacobs RA, 2013, J APPL PHYSIOL, V115, P785, DOI 10.1152/japplphysiol.00445.2013; Jahn LA, 1999, J CLIN ENDOCR METAB, V84, P1007, DOI 10.1210/jc.84.3.1007; Kasumov T, 2013, AM J PHYSIOL-HEART C, V304, pH1201, DOI 10.1152/ajpheart.00933.2012; Kim PL, 2005, J PHYSIOL-LONDON, V568, P283, DOI 10.1113/jphysiol.2005.093708; Liljedahl ME, 1996, EUR J APPL PHYSIOL O, V74, P375, DOI 10.1007/s004210050089; Little JP, 2011, AM J PHYSIOL-REG I, V300, pR1303, DOI 10.1152/ajpregu.00538.2010; MacDougall JD, 1998, J APPL PHYSIOL, V84, P2138, DOI 10.1152/jappl.1998.84.6.2138; Miller BF, 2013, J GERONTOL A-BIOL, V68, P530, DOI 10.1093/gerona/gls219; Miller BF, 2012, AM J PHYSIOL-ENDOC M, V302, pE496, DOI 10.1152/ajpendo.00578.2011; Miller BF, 2012, AGING CELL, V11, P150, DOI 10.1111/j.1474-9726.2011.00769.x; Miller BF, 2005, J PHYSIOL-LONDON, V567, P1021, DOI 10.1113/jphysiol.2005.093690; Niklas P, 2010, EUR J APPL PHYSIOL, V110, P597, DOI 10.1007/s00421-010-1544-1; Parise G, 2001, J APPL PHYSIOL, V91, P1041, DOI 10.1152/jappl.2001.91.3.1041; Pikosky MA, 2006, J NUTR, V136, P379, DOI 10.1093/jn/136.2.379; Price JC, 2012, MOL CELL PROTEOMICS, V11, P1801, DOI 10.1074/mcp.M112.021204; Price JC, 2012, ANAL BIOCHEM, V420, P73, DOI 10.1016/j.ab.2011.09.007; Richards JC, 2010, J PHYSIOL-LONDON, V588, P2961, DOI 10.1113/jphysiol.2010.189886; Richards JC, 2010, MED SCI SPORT EXER, V42, P739, DOI 10.1249/MSS.0b013e3181bcab6c; Robinson MM, 2011, FASEB J, V25, P3240, DOI 10.1096/fj.11-186437; Robinson MM, 2011, AM J PHYSIOL-REG I, V301, pR327, DOI 10.1152/ajpregu.00160.2011; Robinson MM, 2010, AM J PHYSIOL-REG I, V298, pR25, DOI 10.1152/ajpregu.00524.2009; Serpiello FR, 2012, MED SCI SPORT EXER, V44, P827, DOI 10.1249/MSS.0b013e318240067e; Short KR, 2004, AM J PHYSIOL-ENDOC M, V286, pE92, DOI 10.1152/ajpendo.00366.2003; Smith GI, 2011, J APPL PHYSIOL, V110, P480, DOI 10.1152/japplphysiol.00125.2010; Smith GI, 2009, J APPL PHYSIOL, V107, P1308, DOI 10.1152/japplphysiol.00348.2009; Weber CL, 2002, J APPL PHYSIOL, V92, P1795, DOI 10.1152/japplphysiol.00546.2001; West DWD, 2012, J APPL PHYSIOL, V112, P1805, DOI 10.1152/japplphysiol.00170.2012; Wilkinson SB, 2008, J PHYSIOL-LONDON, V586, P3701, DOI 10.1113/jphysiol.2008.153916	51	93	94	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2705	2714		10.1096/fj.13-246595	http://dx.doi.org/10.1096/fj.13-246595			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24599968				2022-12-28	WOS:000339883600028
J	Cheng, Y; Feng, Y; Jansson, L; Sato, Y; Deguchi, M; Kawamura, K; Hsueh, AJ				Cheng, Yuan; Feng, Yi; Jansson, Lina; Sato, Yorino; Deguchi, Masashi; Kawamura, Kazuhiro; Hsueh, Aaron J.			Actin polymerization-enhancing drugs promote ovarian follicle growth mediated by the Hippo signaling effector YAP	FASEB JOURNAL			English	Article						Jasplakinolide; sphingosine-1-phosphate; connective tissue growth factor	SPHINGOSINE 1-PHOSPHATE; CELL-MIGRATION; ORGAN SIZE; F-ACTIN; PROTEIN; SPHINGOSINE-1-PHOSPHATE; DISRUPTION; PATHWAY; INDUCTION; REGULATOR	Hippo signaling pathway consists of conserved serine/threonine kinases to maintain optimal organ sizes. Studies have demonstrated that fragmentation of murine ovaries increases actin polymerization and disrupts Hippo signaling, leading to nuclear translocation of Hippo signaling effector Yes-associated protein (YAP) in ovarian follicles and follicle growth. For patients with polycystic ovarian syndrome showing follicle arrest, ovarian wedge resection and laser drilling promote follicle growth. Because these damaging procedures likely involve actin polymerization, we tested whether actin polymerization-promoting drugs could promote YAP translocation and stimulate follicle growth. Treatment of murine ovaries with mu M Jasplakinolide (JASP), an actin polymerization-promoting cyclic peptide, or sphingosine-1-phosphate (S1P), a follicular fluid constituent known to promote actin polymerization, increased the conversion of globular actin to the filamentous form, followed by increased nuclear YAP and expression of downstream connective tissue growth factor (CCN2). After short-term treatments with JASP or S1P, in vitro cultured and in vivo grafted ovaries showed follicle growth. Furthermore, induction of constitutively active YAP in ovarian grafts of transgenic mice enhanced follicle development, whereas treatment of human ovarian cortices with JASP or S1P increased CCN2 expression. Thus, JASP and S1P stimulate follicle growth and are potential therapeutic agents for treating polycystic ovarian syndrome and other ovarian disorders.	[Cheng, Yuan; Feng, Yi; Deguchi, Masashi; Hsueh, Aaron J.] Stanford Univ, Dept Obstet & Gynecol, Sch Med, Stanford, CA 94305 USA; [Jansson, Lina] Stanford Univ, Dept Otolaryngol, Sch Med, Stanford, CA 94305 USA; [Sato, Yorino; Kawamura, Kazuhiro] St Mariana Univ, Dept Obstet & Gynecol, Kawasaki, Kanagawa, Japan; [Kawamura, Kazuhiro] Akita Univ, Grad Sch Med, Dept Obstet & Gynecol, Akita 010, Japan	Stanford University; Stanford University; Saint Marianna University; Akita University	Hsueh, AJ (corresponding author), 300 Pasteur Dr,Room A344, Stanford, CA 94305 USA.	aaron.hsueh@stanford.edu			U.S. National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (Specialized Cooperative Centers Program in Reproduction and Infertility Research) [U54-HD068158]; Smoking Research Foundation; Takeda Science Foundation; Coordination, Support and Training Program for Translational Research, Seeds B;  [24390376];  [24659722];  [26114510]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD068158] Funding Source: NIH RePORTER	U.S. National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (Specialized Cooperative Centers Program in Reproduction and Infertility Research); Smoking Research Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Coordination, Support and Training Program for Translational Research, Seeds B; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by the U.S. National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant U54-HD068158 to A.H., as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research); Grant-in-Aid for Scientific Research (Research B [24390376], Challenging Exploratory Research [24659722], and Innovative Areas, Mechanisms Regulating Gamete Formation in Animals [26114510]); and by research funds from the Smoking Research Foundation, the Takeda Science Foundation, and the Coordination, Support and Training Program for Translational Research, Seeds B (to K.K.).	Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Becker S, 2011, BIOL REPROD, V84, P604, DOI 10.1095/biolreprod.110.084152; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cheng Y, 2013, FASEB J, V27, P2175, DOI 10.1096/fj.12-223412; Farquhar C, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001122.pub4; Fernandez BG, 2011, DEVELOPMENT, V138, P2337, DOI 10.1242/dev.063545; Fukui H, 2014, DEV CELL, V31, P128, DOI 10.1016/j.devcel.2014.08.014; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Hendriks ML, 2007, HUM REPROD UPDATE, V13, P249, DOI 10.1093/humupd/dml058; Hergovich A, 2012, BIOCHEM SOC T, V40, P124, DOI 10.1042/BST20110619; Holbourn KP, 2008, TRENDS BIOCHEM SCI, V33, P461, DOI 10.1016/j.tibs.2008.07.006; Hsueh AJW, 2015, ENDOCR REV, V36, P1, DOI 10.1210/er.2014-1020; Jansson L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032013; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kawamura K, 2013, P NATL ACAD SCI USA, V110, P17474, DOI 10.1073/pnas.1312830110; Li J, 2010, P NATL ACAD SCI USA, V107, P10280, DOI 10.1073/pnas.1001198107; Miller E, 2012, CHEM BIOL, V19, P955, DOI 10.1016/j.chembiol.2012.07.005; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Rosen H, 2009, ANNU REV BIOCHEM, V78, P743, DOI 10.1146/annurev.biochem.78.072407.103733; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; SENDEROWICZ AMJ, 1995, J NATL CANCER I, V87, P46, DOI 10.1093/jnci/87.1.46; Soleimani R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019475; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Stein IF, 1935, AM J OBSTET GYNECOL, V29, P181, DOI 10.1016/S0002-9378(15)30642-6; Visser-Grieve S, 2011, CELL RES, V21, P1513, DOI 10.1038/cr.2011.122; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Yatomi Y, 2006, CURR PHARM DESIGN, V12, P575, DOI 10.2174/138161206775474404; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zelinski MB, 2011, FERTIL STERIL, V95, P1440, DOI 10.1016/j.fertnstert.2011.01.012; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408	33	67	73	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2423	2430		10.1096/fj.14-267856	http://dx.doi.org/10.1096/fj.14-267856			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25690654	Green Published			2022-12-28	WOS:000355209500019
J	Winkle, M; van den Berg, A; Tayari, M; Sietzema, J; Terpstra, M; Kortman, G; de Jong, D; Visser, L; Diepstra, A; Kok, K; Kluiver, J				Winkle, Melanie; van den Berg, Anke; Tayari, Masoumeh; Sietzema, Jantine; Terpstra, Martijn; Kortman, Gertrud; de Jong, Debora; Visser, Lydia; Diepstra, Arjan; Kok, Klaas; Kluiver, Joost			Long noncoding RNAs as a novel component of the Myc transcriptional network	FASEB JOURNAL			English	Article						B-cell lymphoma; cancer; regulation	GENOME-WIDE ANALYSIS; LARGE GENE LISTS; C-MYC; CELL-LINE; EXPRESSION; CANCER; ACTIVATION; DIFFERENTIATION; COMPLEXES; CHROMATIN	Myc is a well-known transcription factor with important roles in cell cycle, apoptosis, and cellular transformation. Long noncoding RNAs (lncRNAs) have recently emerged as an important class of regulatory RNAs. Here, we show that lncRNAs are a main component of the Myc-regulated transcriptional program using the P493-6 tetracycline-repressible myc model. We demonstrate that both Myc-induced mRNAs and lncRNAs are significantly enriched for Myc binding sites. In contrast to Myc-repressed mRNAs, Myc-repressed lncRNAs are significantly enriched for Myc binding sites. Subcellular localization analysis revealed that compared to mRNAs, lncRNAs more often have a specific subcellular localization with a markedly higher percentage of nuclear enrichment within the Myc-repressed lncRNA set. Parallel analysis of differentially expressed lncRNAs and mRNAs identified 105 juxtaposed lncRNA-mRNA pairs, indicative for regulation in cis. To support the potential relevance of the Myc-regulated lncRNAs in cellular transformation, we analyzed their expression in primary Myc-high and Myc-low B-cell lymphomas. In total, 54% of the lncRNAs differentially expressed between the lymphoma subsets were identified as Myc-regulated in P493-6 cells. This study is the first to show that lncRNAs are an important factor within the Myc-regulated transcriptional program and indicates a marked difference between Myc-repressed lncRNAs and mRNAs.	[Winkle, Melanie; van den Berg, Anke; Tayari, Masoumeh; Sietzema, Jantine; Kortman, Gertrud; de Jong, Debora; Visser, Lydia; Diepstra, Arjan; Kluiver, Joost] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, NL-9700 RB Groningen, Netherlands; [Terpstra, Martijn; Kok, Klaas] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9700 RB Groningen, Netherlands	University of Groningen; University of Groningen	Kluiver, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	j.l.kluiver@umcg.nl	van den Berg, Anke/H-1718-2011; Kluiver, Joost/G-6406-2014	van den Berg, Anke/0000-0002-8894-2638; Kluiver, Joost/0000-0001-7650-2937; Tayari, Mina/0000-0003-3521-8782; Diepstra, Arjan/0000-0001-9239-1050	Pediatric Oncology Foundation Groningen [SKOG 14-001]; Jan Kornelis de Cock Foundation; UMCG [681564, 611006]	Pediatric Oncology Foundation Groningen; Jan Kornelis de Cock Foundation; UMCG	P493-6 B cells were the kind gift of Prof. D. Eick (Helmholtz Center Munich, Germany). The authors thank Dr. J. Guikema (Academic Medical Center, University of Amsterdam, The Netherlands) for contributing BL cases. This study is supported by a grant from the Pediatric Oncology Foundation Groningen (SKOG 14-001, to A.V.D.B., K.K., and J.K.), the Jan Kornelis de Cock Foundation (to M.W.), and UMCG (681564 to M.W. and 611006 to M.T.).	Atmadibrata B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088112; Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037; Bui Thi V, 2010, Genes Cancer, V1, P568; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Chen LL, 2008, EMBO J, V27, P1694, DOI 10.1038/emboj.2008.94; Clark MB, 2012, GENOME RES, V22, P885, DOI 10.1101/gr.131037.111; Clark MB, 2011, SEMIN CELL DEV BIOL, V22, P366, DOI 10.1016/j.semcdb.2011.01.001; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Deng KY, 2014, TUMOR BIOL, V35, P9497, DOI 10.1007/s13277-014-2511-y; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Guil S, 2012, NAT STRUCT MOL BIOL, V19, P1068, DOI 10.1038/nsmb.2428; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hu GQ, 2013, NAT IMMUNOL, V14, P1190, DOI 10.1038/ni.2712; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Li C, 2009, BLOOD, V113, P6681, DOI 10.1182/blood-2009-01-202028; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Lu LN, 2013, EMBO J, V32, P2575, DOI 10.1038/emboj.2013.182; Mattick JS, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000459; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Mestdagh P, 2010, ONCOGENE, V29, P3583, DOI 10.1038/onc.2010.106; Mondal T, 2010, GENOME RES, V20, P899, DOI 10.1101/gr.103473.109; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Rabani M, 2011, NAT BIOTECHNOL, V29, P436, DOI 10.1038/nbt.1861; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Sati S, 2012, NUCLEIC ACIDS RES, V40, P10018, DOI 10.1093/nar/gks776; Schrader A, 2012, INT J CANCER, V131, pE348, DOI 10.1002/ijc.26423; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Seitz V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026837; Slezak-Prochazka I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076647; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Swerdlow SH, 2008, WHO CLASSIFICATION T; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wan GH, 2013, CELL SIGNAL, V25, P1086, DOI 10.1016/j.cellsig.2013.02.006; Yang F, 2013, J CANCER RES CLIN, V139, P437, DOI 10.1007/s00432-012-1324-x; Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939; Zhang B, 2012, CELL REP, V2, P111, DOI 10.1016/j.celrep.2012.06.003; Zhang YF, 2012, MED SCI MONITOR, V18, pRA12, DOI 10.12659/MSM.882192; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zheng GXY, 2014, NAT STRUCT MOL BIOL, V21, P585, DOI 10.1038/nsmb.2842	50	40	40	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2338	2346		10.1096/fj.14-263889	http://dx.doi.org/10.1096/fj.14-263889			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25690653				2022-12-28	WOS:000355209500012
J	Bae, WK; Kang, K; Yu, JH; Yoo, KH; Factor, VM; Kaji, K; Matter, M; Thorgeirsson, S; Hennighausen, L				Bae, Woo Kyun; Kang, Keunsoo; Yu, Ji Hoon; Yoo, Kyung Hyun; Factor, Valentina M.; Kaji, Kosuke; Matter, Matthias; Thorgeirsson, Snorri; Hennighausen, Lothar			The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration	FASEB JOURNAL			English	Article						H3-K27 trimethylation; liver regeneration; fibrosis	STEM-CELLS; GROUP PROTEINS; POLYCOMB; COMPLEX; CANCER; LIVER; PROLIFERATION; METHYLATION; MEMORY; BMI-1	To investigate the role of enhancer of zeste homolog (EZH) 1 and EZH2 in liver homeostasis, mice were generated that carried Ezh1(-/-) and EZH2(fl/fl) alleles and an Alb-Cre transgene. Only the combined loss of EZH1 and EZH2 in mouse hepatocytes caused a depletion of global trimethylation on Lys 27 of histone H3 (H3K27me3) marks and the specific loss of over similar to 1900 genes at 3 mo of age. Ezh1(-/-),Ezh2(fl/fl)Alb-Cre mice exhibited progressive liver abnormalities manifested by the development of regenerative nodules and concomitant periportal fibrosis, inflammatory infiltration, and activation of A6-positive hepatic progenitor cells at 8 mo of age. In response to chronic treatment with carbon tetrachloride, all experimental mice, but none of the controls (n = 27 each), showed increased hepatic degeneration associated with liver dysfunction and reduced ability to proliferate. After two-thirds partial hepatectomy, mutant mice (n = 5) displayed increased liver injury and a blunted regenerative response. Genome-wide analyses at 3 mo of age identified 51 genes that had lost H3K27me3 marks, and their expression was significantly increased. These genes were involved in regulation of cell survival, fibrosis, and proliferation. H3K27me3 levels and liver physiology were unaffected in mice lacking either EZH1 globally or EZH2 specifically in hepatocytes. This work demonstrates a critical redundancy of EZH1 and EZH2 in maintaining hepatic homeostasis and regeneration.	[Bae, Woo Kyun; Kang, Keunsoo; Yu, Ji Hoon; Yoo, Kyung Hyun; Hennighausen, Lothar] NIDDK, Lab Genet & Physiol, Bethesda, MD 20892 USA; [Factor, Valentina M.; Kaji, Kosuke; Matter, Matthias; Thorgeirsson, Snorri] NCI, Ctr Canc Res, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; [Bae, Woo Kyun] Chonnam Natl Univ, Sch Med, Dept Internal Med, Kwangju, South Korea; [Kang, Keunsoo] Dankook Univ, Dept Microbiol, Cheonan, South Korea; [Yu, Ji Hoon] Daegu Gyeongbuk Med Innovat Fdn, New Drug Dev Ctr, Taegu, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Chonnam National University; Dankook University	Bae, WK (corresponding author), NIDDK, Lab Genet & Physiol, NIH, 8 Ctr Dri,Room 101, Bethesda, MD 20892 USA.	drwookyun@chonnam.ac.kr; lotharh@mail.nih.gov		Matter, Matthias/0000-0002-2005-5266; Hennighausen, Lothar/0000-0001-8319-9841	NIH NIDDK; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK075030, ZICDK071001, ZIADK061000] Funding Source: NIH RePORTER	NIH NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Harold Smith [U.S. National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases' (NIDDK) genomics core] for conducting next-generation sequencing. Alexander Tarakhovsky (Rockefeller University, New York, NY, USA) provided Ezh2 floxed mice. Ezh1 mutant mice were generated at the Research Institute of Molecular Pathology (Vienna, Austria) by Donal O'Carroll (laboratory of Thomas Jenuwein) with the help of Maria Sibilia (Laboratory of Erwin Wagner). The research was supported by the Intramural Research Program of the NIH NIDDK. The authors declare no conflicts of interest.	Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679; Bardot ES, 2013, EMBO J, V32, P1990, DOI 10.1038/emboj.2013.110; Benhamouche S, 2010, GENE DEV, V24, P1718, DOI 10.1101/gad.1938710; Ezhkova E, 2011, GENE DEV, V25, P485, DOI 10.1101/gad.2019811; FACTOR VM, 1994, AM J PATHOL, V145, P409; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Jakubowski A, 2005, J CLIN INVEST, V115, P2330, DOI 10.1172/JCI23486; Kobayashi N, 2000, HEPATOLOGY, V31, P851, DOI 10.1053/he.2000.5636; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee JM, 2012, MOL CELL, V48, P572, DOI 10.1016/j.molcel.2012.09.004; Lin T, 2013, HEPATOLOGY, V58, P2176, DOI 10.1002/hep.26600; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Mousavi K, 2012, MOL CELL, V45, P255, DOI 10.1016/j.molcel.2011.11.019; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Williams MJ, 2014, GASTROENTEROLOGY, V146, P349, DOI 10.1053/j.gastro.2013.11.034; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340	28	35	35	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1653	1662		10.1096/fj.14-261537	http://dx.doi.org/10.1096/fj.14-261537			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25477280	Green Published			2022-12-28	WOS:000354114600005
J	Hiram-Bab, S; Liron, T; Deshet-Unger, N; Mittelman, M; Gassmann, M; Rauner, M; Franke, K; Wielockx, B; Neumann, D; Gabet, Y				Hiram-Bab, Sahar; Liron, Tamar; Deshet-Unger, Naamit; Mittelman, Moshe; Gassmann, Max; Rauner, Martina; Franke, Kristin; Wielockx, Ben; Neumann, Drorit; Gabet, Yankel			Erythropoietin directly stimulates osteoclast precursors and induces bone loss	FASEB JOURNAL			English	Article						Tg6 mice; bone turnover; osteoclastogenesis; macrophages; trabecular bone	RECOMBINANT-HUMAN-ERYTHROPOIETIN; HIGH-ALTITUDE; RECEPTOR; MICE; MASS; DIFFERENTIATION; CELLS; BETA; EPO; MICROENVIRONMENT	Erythropoietin (EPO) primarily regulates red blood cell formation, and EPO serum levels are increased on hypoxic stress (e.g., anemia and altitude). In addition to anemia, recent discoveries suggest new therapeutic indications for EPO, unrelated to erythropoiesis. We investigated the skeletal role of EPO using several models of overexpression (Tg6 mice) and EPO administration (intermittent/continuous, high/low doses) in adult C57B16 female mice. Using microcomputed tomography, histology, and serum markers, we found that EPO induced a 32%-61% trabecular bone loss caused by increased bone resorption (+60%-88% osteoclast number) and reduced bone formation rate (-19 to -74%; P < 0.05 throughout). EPO targeted the monocytic lineage by increasing the number of bone monocytes/macrophages, preosteoclasts, and mature osteoclasts. In contrast to the attenuated bone formation in vivo, EPO treatment in vitro did not inhibit osteoblast differentiation and activity, suggesting an indirect effect of EPO on osteoblasts. However, EPO had a direct effect on preosteoclasts by stimulating osteoclastogenesis in isolated cultures (+60%) via the Jak2 and PI3K pathways. In summary, our findings demonstrate that EPO negatively regulates bone mass and thus bears significant clinical implications for the potential management of patients with endogenously or therapeutically elevated EPO levels.	[Hiram-Bab, Sahar; Deshet-Unger, Naamit; Neumann, Drorit] Tel Aviv Univ, Dept Cell & Dev Biol, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Hiram-Bab, Sahar; Liron, Tamar; Gabet, Yankel] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Mittelman, Moshe] Tel Aviv Univ, Sackler Fac Med, Dept Med, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel; [Gassmann, Max] Univ Zurich, Inst Vet Physiol, Vetsuisse Fac, Zurich, Switzerland; [Gassmann, Max] Univ Zurich, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland; [Rauner, Martina] Dresden Univ, Med Ctr, Dept Med 3, Dresden, Germany; [Franke, Kristin; Wielockx, Ben] Tech Univ Dresden, Inst Pathol, Dresden, Germany	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); Technische Universitat Dresden; Technische Universitat Dresden	Neumann, D (corresponding author), Tel Aviv Univ, Dept Cell & Dev Biol, Sackler Fac Med, POB 39040, IL-69978 Tel Aviv, Israel.	histo6@post.tau.ac.il; yankel@post.tau.ac.il	Wielockx, Ben/AAC-6854-2020; Gabet, Yankel/I-6244-2019	Wielockx, Ben/0000-0002-4923-2596; Gabet, Yankel/0000-0002-7494-0631; Gassmann, Max/0000-0003-2750-8878; Neumann, Drorit/0000-0002-4805-7511	Israel Science Foundation [1822/12, 1367/12]; Deutsche Forschungsgemeinschaft [RA1923/4-2]; Emmy Noether and Heisenberg programs [WI3291/1-1, WI3291/1-2, WI3291/5-1]; Elsbeth Bonhoff Foundation; Center for Regenerative Therapies Dresden (CRTD); FP7-Health European commission EpoCan Grant [282551]; Open University Research Authority (Raanana, Israel)	Israel Science Foundation(Israel Science Foundation); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Emmy Noether and Heisenberg programs; Elsbeth Bonhoff Foundation; Center for Regenerative Therapies Dresden (CRTD); FP7-Health European commission EpoCan Grant; Open University Research Authority (Raanana, Israel)	This article is dedicated to the memory of Professor Itai Bab (1945-2014) from the Hebrew University of Jerusalem. Prof. Bab participated in this study by providing guidance and technical support. The authors thank Dr. Russel S. Taichman (University of Michigan) for helpful discussion and comments on this manuscript. This work was supported by Israel Science Foundation Grants 1822/12 and 1367/12 (to Y.G.), and grants from the Deutsche Forschungsgemeinschaft to M.R. (RA1923/4-2) and B.W. (Emmy Noether and Heisenberg programs, WI3291/1-1, 1-2 and 5-1), the Elsbeth Bonhoff Foundation, and a Center for Regenerative Therapies Dresden (CRTD) seed grant (to M.R. and B.W). This work was also supported by FP7-Health European commission EpoCan Grant 282551 (to D.N. and M.G.), and a grant from the Open University Research Authority (Raanana, Israel) to Prof. Miriam C. Souroujon. We express our deepest gratitude and appreciation to our dear friend and colleague, Prof. M. Souroujon, who died during the course of this study. She will be remembered for her vision, deep insight, and exceptional scientific conduct. The authors declare no conflicts of interest.	Ahmet I, 2013, J PHARMACOL EXP THER, V345, P446, DOI 10.1124/jpet.113.202945; Alnaeeli M, 2014, DIABETES, V63, P2415, DOI 10.2337/db13-0883; Arcasoy MO, 2008, BRIT J HAEMATOL, V141, P14, DOI 10.1111/j.1365-2141.2008.07014.x; Bab I. A., 2007, MICROTOMOGRAPHIC ATL; Bakhshi H, 2013, TRAUMA MON, V17, P386, DOI 10.5812/traumamon.7099; Bartesaghi S, 2005, NEUROTOXICOLOGY, V26, P923, DOI 10.1016/j.neuro.2005.01.016; Basu M, 2013, HIGH ALT MED BIOL, V14, P150, DOI 10.1089/ham.2012.1042; BERGLUND B, 1992, SPORTS MED, V14, P289, DOI 10.2165/00007256-199214050-00002; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Chang J, 2014, ARTHRITIS RHEUMATOL, V66, P1789, DOI 10.1002/art.38403; Choi D, 2010, J EXP MED, V207, P2831, DOI 10.1084/jem.20100665; Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805; Fried W, 2009, EXP HEMATOL, V37, P1007, DOI 10.1016/j.exphem.2009.05.010; Gabet Yankel, 2011, Curr Osteoporos Rep, V9, P177, DOI 10.1007/s11914-011-0072-1; Gabet Y, 2010, BLOOD, V116, P3964, DOI 10.1182/blood-2010-01-263830; Garcia P, 2011, J ORTHOP RES, V29, P165, DOI 10.1002/jor.21219; Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507; Guillard C, 2003, J BIOL CHEM, V278, P11050, DOI 10.1074/jbc.M208834200; Guneli E, 2007, MOL MED, V13, P509, DOI 10.2119/2007-00032.Guneli; Holstein JH, 2011, BONE, V49, P1037, DOI 10.1016/j.bone.2011.08.004; Holstein JH, 2007, LIFE SCI, V80, P893, DOI 10.1016/j.lfs.2006.11.023; Jelkmann W, 2011, BLOOD, V118, P2395, DOI 10.1182/blood-2011-02-303271; Kim J, 2012, J CELL BIOCHEM, V113, P220, DOI 10.1002/jcb.23347; Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705; Lamon S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00176; Leclerc N, 2008, J CELL BIOCHEM, V103, P1938, DOI 10.1002/jcb.21587; LEE MY, 1991, BLOOD, V77, P2135; Lifshitz L, 2010, HAEMATOL-HEMATOL J, V95, P1823, DOI 10.3324/haematol.2010.025015; Lu J, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-105; Mcgee SJ, 2012, GROWTH FACTORS, V30, P22, DOI 10.3109/08977194.2011.637034; Mihmanli A, 2009, J ORAL MAXIL SURG, V67, P2337, DOI 10.1016/j.joms.2008.06.082; Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139; Myklebust JH, 2000, BLOOD, V95, P510, DOI 10.1182/blood.V95.2.510; Nakazawa Y, 2013, J NEPHROL, V26, P527, DOI 10.5301/jn.5000178; Nangaku M, 2013, KIDNEY INT, V84, P427, DOI 10.1038/ki.2013.140; Neya M, 2013, INT J SPORT PHYSIOL, V8, P366, DOI 10.1123/ijspp.8.4.366; Noh T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005438; Ohashi Y, 2013, CANCER SCI, V104, P481, DOI 10.1111/cas.12105; Peng HS, 2014, SURG TODAY, V44, P1109, DOI 10.1007/s00595-014-0889-1; Ramanath V, 2012, REV RECENT CLIN TRIA, V7, P187, DOI 10.2174/157488712802281222; Robach P, 2004, MED SCI SPORT EXER, V36, P1493, DOI 10.1249/01.MSS.0000139889.56481.E0; Rolfing JHD, 2014, STEM CELL REV REP, V10, P69, DOI 10.1007/s12015-013-9476-x; Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006; Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609; Sanchis-Gomar F, 2014, INT J CARDIOL, V171, P116, DOI 10.1016/j.ijcard.2013.12.011; Shiozawa Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010853; Singbrant S, 2011, BLOOD, V117, P5631, DOI 10.1182/blood-2010-11-320564; SPIVAK JL, 1991, BLOOD, V77, P1228; Sun HL, 2012, TISSUE ENG PT A, V18, P2095, DOI [10.1089/ten.tea.2011.0742, 10.1089/ten.TEA.2011.0742]; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tamma Roberto, 2012, Inflammation & Allergy Drug Targets, V11, P196; Tanaka H., 1992, J BONE MINER METAB, V10, P31; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Watowich SS, 2011, J INVEST MED, V59, P1067, DOI 10.2310/JIM.0b013e31820fb28c; Wish JB, 2009, ADV CHRONIC KIDNEY D, V16, P101, DOI 10.1053/j.ackd.2008.12.005; Xu H, 2014, INVEST OPHTH VIS SCI, V55, P1519, DOI 10.1167/iovs.13-13155; Yasuda Y, 2001, MARC MALPIG SYMP SER, V8, P215; Zoi K, 2008, BRIT J HAEMATOL, V141, P100, DOI 10.1111/j.1365-2141.2008.06993.x	59	75	78	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1890	1900		10.1096/fj.14-259085	http://dx.doi.org/10.1096/fj.14-259085			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25630969				2022-12-28	WOS:000354114600024
J	Topolska-Wos, AM; Shell, SM; Kilanczyk, E; Szczepanowski, RH; Chazin, WJ; Filipek, A				Topolska-Wos, Agnieszka M.; Shell, Steven M.; Kilanczyk, Ewa; Szczepanowski, Roman H.; Chazin, Walter J.; Filipek, Anna			Dimerization and phosphatase activity of calcyclin-binding protein/Siah-1 interacting protein: the influence of oxidative stress	FASEB JOURNAL			English	Article						CacyBP; SIP; ERK1/2; MAPK phosphatase; protein structure; NB2a cells	STRUCTURAL-ANALYSIS; SOLUTION SCATTERING; ALZHEIMERS-DISEASE; NEUROBLASTOMA NB2A; SELF-ASSOCIATION; BETA-CATENIN; CACYBP/SIP; CELLS; SIAH-1; TARGET	CacyBP/SIP [calcyclin-binding protein/Siah-1 [seven in absentia homolog 1 (Siah E3 ubiquitin protein ligase 1)] interacting protein] is a multifunctional protein whose activity includes acting as an ERK1/2 phosphatase. We analyzed dimerization of mouse CacyBP/SIP in vitro and in mouse neuroblastoma cell line (NB2a) cells, as well as the structure of a full-length protein. Moreover, we searched for the CacyBP/SIP domain important for dimerization and dephosphorylation of ERK2, and we analyzed the role of dimerization in ERK1/2 signaling in NB2a cells. Cell-based assays showed that CacyBP/SIP forms a homodimer in NB2a cell lysate, and biophysical methods demonstrated that CacyBP/SIP forms a stable dimer in vitro. Data obtained using small-angle X-ray scattering supported a model in which CacyBP/SIP occupies an anti-parallel orientation mediated by the N-terminal dimerization domain. Site-directed mutagenesis established that the N-terminal domain is indispensable for full phosphatase activity of CacyBP/SIP. We also demonstrated that the oligomerization state of CacyBP/SIP as well as the level of post-translational modifications and subcellular distribution of CacyBP/SIP change after activation of the ERK1/2 pathway in NB2a cells due to oxidative stress. Together, our results suggest that dimerization is important for controlling phosphatase activity of CacyBP/SIP and for regulating the ERK1/2 signaling pathway.Topolska-Wo, A. M., Shell, S. M., Kilaczyk, E., Szczepanowski, R. H., Chazin, W. J., Filipek, A. Dimerization and phosphatase activity of calcyclin-binding protein/Siah-1 interacting protein: the influence of oxidative stress.	[Topolska-Wos, Agnieszka M.; Kilanczyk, Ewa; Filipek, Anna] Polish Acad Sci, Nencki Inst Expt Biol, Warsaw, Poland; [Topolska-Wos, Agnieszka M.; Shell, Steven M.; Chazin, Walter J.] Vanderbilt Univ, Struct Biol Ctr, Nashville, TN 37235 USA; [Szczepanowski, Roman H.] Int Inst Mol & Cell Biol, Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Vanderbilt University; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Filipek, A (corresponding author), Nencki Inst Expt Biol, 3 Pasteur St, PL-02093 Warsaw, Poland.	walter.j.chazin@vanderbilt.edu; a.filipek@nencki.gov.pl	Kilanczyk, Ewa/C-8209-2018	Kilanczyk, Ewa/0000-0003-4560-0723; Filipek, Anna/0000-0001-9484-9555	European Union [MPD4-502]; U.S. National Institutes of Health, National Institute of General Medical Sciences [R01-GM075156]; National Science Centre Grant [NZ1/00595]; Nencki Institute of Experimental Biology; American Cancer Society [119569-PF-11-271-01-DMC]; U.S. Department of Energy (DOE) program Integrated Diffraction Analysis Technologies (IDAT); European Union - the European Regional Development Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075156] Funding Source: NIH RePORTER	European Union(European Commission); U.S. National Institutes of Health, National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Science Centre Grant(National Science Centre, Poland); Nencki Institute of Experimental Biology; American Cancer Society(American Cancer Society); U.S. Department of Energy (DOE) program Integrated Diffraction Analysis Technologies (IDAT)(United States Department of Energy (DOE)); European Union - the European Regional Development Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. U. Wasik (Nencki Institute of Experimental Biology, Warsaw, Poland) for help with pET28 CacyBP/SIP S22D/T23D plasmid preparation and Prof. A. Dziembowski (Institute of Biochemistry and Biophysics, Warsaw) for equipment support. This work was supported by the European Union through the European Regional Developmental Funds within the scope of the International PhD Studies in Neurobiology MPD4-502 (to A.M.T.W.), U.S. National Institutes of Health, National Institute of General Medical Sciences Grant R01-GM075156 (to W.J.C.), National Science Centre Grant NZ1/00595 (to A.F.), and by statutory funds from the Nencki Institute of Experimental Biology (Warsaw, Poland). S.M.S. is supported by Postdoctoral Fellowship 119569-PF-11-271-01-DMC from the American Cancer Society. The X-ray scattering technology and applications to the determination of macromolecular shapes and conformations were performed at the SIBYLS beamline (12.3.1) at the Advanced Light Source, Lawrence Berkeley National Laboratory, U.S. Department of Energy (DOE) program Integrated Diffraction Analysis Technologies (IDAT). Project subject carried out with use of Centre for Preclinical Research and Technology (CePT) infrastructure financed by the European Union - the European Regional Development Fund within the Operational Programme "Innovative Economy" for 2007-2013.	Behl C, 1999, PROG NEUROBIOL, V57, P301, DOI 10.1016/S0301-0082(98)00055-0; Bhattacharya S, 2005, BIOCHEMISTRY-US, V44, P9462, DOI 10.1021/bi0502689; Brosey CA, 2013, NUCLEIC ACIDS RES, V41, P2313, DOI 10.1093/nar/gks1332; Dimitrova YN, 2010, J BIOL CHEM, V285, P13507, DOI 10.1074/jbc.M109.049411; Filipek A, 1998, J NEUROCHEM, V70, P1793, DOI 10.1046/j.1471-4159.1998.70051793.x; Filipek A, 1996, BIOCHEM J, V320, P585, DOI 10.1042/bj3200585; Filipek A, 2002, J BIOL CHEM, V277, P21103, DOI 10.1074/jbc.M111010200; Filipek A, 2002, J BIOL CHEM, V277, P28848, DOI 10.1074/jbc.M203602200; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Gullberg M., 2009, NAT METHODS, V6, P686, DOI [10.1038/nmeth.f.267, DOI 10.1038/NMETH.F.267]; Jastrzebska B, 2000, J HISTOCHEM CYTOCHEM, V48, P1195, DOI 10.1177/002215540004800903; Johs A, 2011, J MOL BIOL, V413, P639, DOI 10.1016/j.jmb.2011.08.042; Jurewicz E, 2013, BBA-MOL CELL RES, V1833, P761, DOI 10.1016/j.bbamcr.2012.12.010; Kilanczyk E, 2012, BIOCHEM CELL BIOL, V90, P558, DOI [10.1139/O2012-011, 10.1139/o2012-011]; Kilanczyk E, 2011, BIOCHEM BIOPH RES CO, V404, P179, DOI 10.1016/j.bbrc.2010.11.088; Kilanczyk E, 2009, BIOCHEM BIOPH RES CO, V380, P54, DOI 10.1016/j.bbrc.2009.01.026; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee YT, 2008, BIOCHEMISTRY-US, V47, P10921, DOI 10.1021/bi801233z; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Luque-Contreras D, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/497802; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; Nyarko A, 2007, BIOCHEMISTRY-US, V46, P11331, DOI 10.1021/bi700735t; Peart JR, 2002, P NATL ACAD SCI USA, V99, P10865, DOI 10.1073/pnas.152330599; Pretto DI, 2010, BIOCHEMISTRY-US, V49, P2880, DOI 10.1021/bi9019934; Ruffels J, 2004, EUR J PHARMACOL, V483, P163, DOI 10.1016/j.ejphar.2003.10.032; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Santelli E, 2005, J BIOL CHEM, V280, P34278, DOI 10.1074/jbc.M506707200; Schneider G, 2007, BBA-MOL CELL RES, V1773, P1628, DOI 10.1016/j.bbamcr.2007.07.013; Schneider G, 2010, BBA-MOL CELL RES, V1803, P1308, DOI 10.1016/j.bbamcr.2010.07.003; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Taube M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093313; Wasik U, 2013, NEUROBIOL AGING, V34, P1380, DOI 10.1016/j.neurobiolaging.2012.11.007; Wu J, 2003, J BIOCHEM MOL BIOL, V36, P354	39	16	16	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1711	1724		10.1096/fj.14-264770	http://dx.doi.org/10.1096/fj.14-264770			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25609429	Green Published			2022-12-28	WOS:000354114600010
J	Wang, W; Dai, HE; Zhang, Y; Chandrasekar, R; Luo, L; Hiromasa, Y; Sheng, CZ; Peng, GX; Chen, SL; Tomich, JM; Reese, J; Edwards, O; Kang, L; Reeck, G; Cui, F				Wang, Wei; Dai, Huaien; Zhang, Yi; Chandrasekar, Raman; Luo, Lan; Hiromasa, Yasuaki; Sheng, Changzhong; Peng, Gongxin; Chen, Shaoliang; Tomich, John M.; Reese, John; Edwards, Owain; Kang, Le; Reeck, Gerald; Cui, Feng			Armet is an effector protein mediating aphid-plant interactions	FASEB JOURNAL			English	Article						saliva protein; salivary gland; feeding behavior; MANF; calcium binding	ACYRTHOSIPHON-PISUM; NEUROTROPHIC FACTOR; PEA APHID; SALIVARY PROTEINS; MYZUS-PERSICAE; ARABIDOPSIS-THALIANA; DOPAMINERGIC-NEURONS; POTATO APHID; IN-VIVO; MANF	Aphid saliva is predicted to contain proteins that modulate plant defenses and facilitate feeding. Armet is a well-characterized bifunctional protein in mammalian systems. Here we report a new role of Armet, namely as an effector protein in the pea aphid, Acyrthosiphon pisum. Pea aphid Armet's physical and chemical properties and its intracellular role are comparable to those reported for mammalian Armets. Uniquely, we detected Armet in aphid watery saliva and in the phloem sap of fava beans fed on by aphids. Armet's transcript level is several times higher in the salivary gland when aphids feed on bean plants than when they feed on an artificial diet. Knockdown of the Armet transcript by RNA interference disturbs aphid feeding behavior on fava beans measured by the electrical penetration graph technique and leads to a shortened life span. Inoculation of pea aphid Armet protein into tobacco leaves induced a transcriptional response that included pathogen-responsive genes. The data suggest that Armet is an effector protein mediating aphid-plant interactions.	[Wang, Wei; Luo, Lan; Kang, Le; Cui, Feng] Chinese Acad Sci, Inst Zool, State Key Lab Integrated Management Pest Insects, Beijing 100101, Peoples R China; [Wang, Wei; Chen, Shaoliang] Beijing Forestry Univ, Coll Biol Sci & Technol, Beijing, Peoples R China; [Dai, Huaien; Chandrasekar, Raman; Hiromasa, Yasuaki; Sheng, Changzhong; Tomich, John M.; Reeck, Gerald; Cui, Feng] Kansas State Univ, Dept Biochem & Mol Biophys, Manhattan, KS 66506 USA; [Zhang, Yi; Peng, Gongxin] Hebei Univ Sci & Technol, Dept Math, Hebei Lab Pharmaceut Mol Chem, Shijiazhuang, Hebei, Peoples R China; [Reese, John] Kansas State Univ, Dept Entomol, Manhattan, KS 66506 USA; [Edwards, Owain] CSIRO, Ecosyst Sci, Ctr Environm & Life Sci, Floreat, WA, Australia	Chinese Academy of Sciences; Institute of Zoology, CAS; Beijing Forestry University; Kansas State University; Hebei University of Science & Technology; Kansas State University; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Cui, F (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Integrated Management Pest Insects, Beijing 100101, Peoples R China.	reeck@ksu.edu; cuif@ioz.ac.cn	Peng, Gongxin/GYR-1891-2022; Edwards, Owain Rhys/B-9707-2008; Kang, Le/ABD-1116-2022	Edwards, Owain Rhys/0000-0003-3861-7906; Kang, Le/0000-0003-4262-2329; TOMICH, JOHN M./0000-0001-7848-8307; Cui, Feng/0000-0001-6215-7159	Strategic Priority Research Program of the Chinese Academy of Sciences [XDB11040200]; Major State Basic Research Development Program of China (973 Program) [2012CB114102]; Cooperative Research Centre for National Plant Biosecurity (Australia); Grains Research and Development Corporation (Australia); Kansas Agricultural Experiment Station [15-035-J]	Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); Major State Basic Research Development Program of China (973 Program)(National Basic Research Program of China); Cooperative Research Centre for National Plant Biosecurity (Australia); Grains Research and Development Corporation (Australia); Kansas Agricultural Experiment Station	This work was supported by grants from the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant XDB11040200), the Major State Basic Research Development Program of China (973 Program; Grant 2012CB114102), the Cooperative Research Centre for National Plant Biosecurity (Australia), the Grains Research and Development Corporation (Australia), and the Kansas Agricultural Experiment Station (publication 15-035-J).	AKEY DH, 1971, ANN ENTOMOL SOC AM, V64, P353, DOI 10.1093/aesa/64.2.353; Apostolou A, 2008, EXP CELL RES, V314, P2454, DOI 10.1016/j.yexcr.2008.05.001; Atamian HS, 2013, MOL PLANT MICROBE IN, V26, P67, DOI 10.1094/MPMI-06-12-0144-FI; BLACKMAN R.L., 1984, ORIENT INSECTS; Bos JIB, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001216; Cao HH, 2014, INSECT SCI, V21, P47, DOI 10.1111/1744-7917.12023; Carolan JC, 2011, J PROTEOME RES, V10, P1505, DOI 10.1021/pr100881q; Carolan JC, 2009, PROTEOMICS, V9, P2457, DOI 10.1002/pmic.200800692; Cherqui A, 2000, J INSECT PHYSIOL, V46, P1177, DOI 10.1016/S0022-1910(00)00037-8; Cooper WC, 2004, J CHEM ECOL, V30, P2527, DOI 10.1007/s10886-004-7948-9; Cooper WR, 2010, ENVIRON ENTOMOL, V39, P223, DOI 10.1603/EN09079; De Vos M, 2009, PLANT CELL ENVIRON, V32, P1548, DOI 10.1111/j.1365-3040.2009.02019.x; Gao LL, 2010, NEW PHYTOL, V186, P980, DOI 10.1111/j.1469-8137.2010.03229.x; Giordanengo P, 2010, CR BIOL, V333, P516, DOI 10.1016/j.crvi.2010.03.007; Guo K, 2014, BIOPHYS CHEM, V189, P25, DOI 10.1016/j.bpc.2014.03.006; Harmel N, 2008, INSECT MOL BIOL, V17, P165, DOI 10.1111/j.1365-2583.2008.00790.x; Hellens RP, 2005, PLANT METHODS, V1, DOI 10.1186/1746-4811-1-13; Hellman M, 2011, J BIOL CHEM, V286, P2675, DOI 10.1074/jbc.M110.146738; Hogenhout SA, 2009, MOL PLANT MICROBE IN, V22, P115, DOI 10.1094/MPMI-22-2-0115; Hoseki J, 2010, FEBS LETT, V584, P1536, DOI 10.1016/j.febslet.2010.03.008; Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286; Lindholm P, 2008, MOL CELL NEUROSCI, V39, P356, DOI 10.1016/j.mcn.2008.07.016; Lindholm P, 2007, NATURE, V448, P73, DOI 10.1038/nature05957; Louis J, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00213; Medina-Ortega KJ, 2013, J EXP BOT, V64, P5525, DOI 10.1093/jxb/ert325; Miles PW, 1999, BIOL REV, V74, P41, DOI 10.1017/S0006323198005271; Mizobuchi N, 2007, CELL STRUCT FUNCT, V32, P41, DOI 10.1247/csf.07001; Moran PJ, 2001, PLANT PHYSIOL, V125, P1074, DOI 10.1104/pp.125.2.1074; Mutti NS, 2008, P NATL ACAD SCI USA, V105, P9965, DOI 10.1073/pnas.0708958105; Mutti NS, 2006, J INSECT SCI, V6, DOI 10.1673/031.006.3801; Palgi M, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-134; Palgi M, 2009, P NATL ACAD SCI USA, V106, P2429, DOI 10.1073/pnas.0810996106; Parkash V, 2009, PROTEIN ENG DES SEL, V22, P233, DOI 10.1093/protein/gzn080; Petrova PS, 2003, J MOL NEUROSCI, V20, P173, DOI 10.1385/JMN:20:2:173; Pitino M, 2013, MOL PLANT MICROBE IN, V26, P130, DOI 10.1094/MPMI-07-12-0172-FI; Pitino M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025709; Rao SAK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057413; TJALLINGII WF, 1993, PHYSIOL ENTOMOL, V18, P317, DOI 10.1111/j.1365-3032.1993.tb00604.x; Tjallingii WF, 2006, J EXP BOT, V57, P739, DOI 10.1093/jxb/erj088; Will T, 2007, P NATL ACAD SCI USA, V104, P10536, DOI 10.1073/pnas.0703535104; Will T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046903; Will T, 2009, J EXP BIOL, V212, P3305, DOI 10.1242/jeb.028514; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	43	63	71	3	82	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2032	2045		10.1096/fj.14-266023	http://dx.doi.org/10.1096/fj.14-266023			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25678626				2022-12-28	WOS:000354114600036
J	Chen, X; Willette-Brown, J; Wu, XQ; Hu, Y; Howard, MZ; Hu, YL; Oppenheim, JJ				Chen, Xin; Willette-Brown, Jami; Wu, Xueqiang; Hu, Ya; Howard, M. Zack; Hu, Yinling; Oppenheim, Joost J.			IKK alpha is required for the homeostasis of regulatory T cells and for the expansion of both regulatory and effector CD4 T cells	FASEB JOURNAL			English	Article						Foxp3; proliferation; colitis; lymphopenic mouse	NF-KAPPA-B; SIGNALING PATHWAY; KINASE-ALPHA; C-REL; ACTIVATION; TNFR2; DIFFERENTIATION; EXPRESSION; PHOSPHORYLATION; COSTIMULATION	It was reported that TNF receptor type II signaling, which has the capacity to stimulate CD4(+) fork-head box P3(+) (Foxp3(+)) regulatory T cells (Tregs), activated the noncanonical NF-kappa B pathway in an IKK alpha-dependent manner. Therefore, we studied the role of IKK alpha in the homeostasis of Treg population. To this end, we generated a mouse strain with conditional knockout of IKK alpha in CD4 cells (Ikk alpha(f/f): CD4.Cre) that showed a >60% reduction in the number of Tregs in the thymus and peripheral lymphoid tissues, whereas the number of Foxp3(-) effector T cells (Teffs) remained at a normal level. The function of Tregs deficient in IKK alpha was examined using Rag1(-/-) mice cotransferred with naive CD4 cells (nCD4s). Although wild-type (WT) Tregs inhibited colitis induced by transfer of WT nCD4s, IKK alpha-deficient Tregs failed to do so, which was associated with their inability to reconstitute Rag1(-/-) mice. Furthermore, nCD4s deficient in IKK alpha also failed to reconstitute Rag1(-/-) mice and were defective in proliferative responses in vitro and in vivo. Thus, our study reveals a novel role of IKK alpha in the maintenance of a normal Treg population and in the control of expansion of CD4 T cells. These properties of IKK alpha may be exploited as therapeutic strategies in the treatment of major human diseases.	[Chen, Xin] NCI, Leidos Biomed Res Inc, Basic Sci Program, Frederick, MD 21701 USA; [Willette-Brown, Jami; Wu, Xueqiang; Hu, Ya; Howard, M. Zack; Oppenheim, Joost J.] NCI, Mol Immunoregulat Lab, Frederick, MD USA; [Willette-Brown, Jami; Hu, Yinling] NCI, Ctr Canc Res, Canc Inflammat Program, Expt Immunol Lab, Frederick, MD USA; [Chen, Xin] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa, Macao Sar, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Macau	Chen, X (corresponding author), Univ Macau, Inst Chinese Med Sci, Bldg N22, Taipa, Macao Sar, Peoples R China.	xchen@umac.mo; oppenhej@mail.nih.gov	Chen, Xin n/a/I-6601-2015; Hu, Yinling/G-5682-2015	Chen, Xin n/a/0000-0002-2628-4027; Hu, Yinling/0000-0002-4795-8537	U.S. National Institutes of Health (NIH) NCI [HHSN261200800001E]; Intramural Research Program of the NIHNCI, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC011422, ZIABC009369] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) NCI; Intramural Research Program of the NIHNCI, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Na-Young Song, Trivett L. Anna, and Czarra T. Kelli for their help in this study. The authors thank the U. S. National Cancer Institute (NCI)-Frederick Cancer Inflammation Program Fluorescence Cytometry Core (Kathleen B. Noer, Roberta M. Matthai, and Guity Mohammadi) for expert technical assistance with flow cytometry. This project has been funded in whole or in part with federal funds from the U.S. National Institutes of Health (NIH) NCI, under contract HHSN261200800001E. This research was supported (in part) by the Intramural Research Program of the NIHNCI, Center for Cancer Research.	Basak S, 2007, CELL, V128, P369, DOI 10.1016/j.cell.2006.12.033; Chang JH, 2012, NAT IMMUNOL, V13, P481, DOI 10.1038/ni.2267; Chen X, 2008, J IMMUNOL, V180, P6467, DOI 10.4049/jimmunol.180.10.6467; Chen X, 2007, J IMMUNOL, V179, P154, DOI 10.4049/jimmunol.179.1.154; Chen X, 2013, J IMMUNOL, V190, P1076, DOI 10.4049/jimmunol.1202659; Chen X, 2010, J IMMUNOL, V185, P174, DOI 10.4049/jimmunol.0903548; Chen X, 2010, EUR J IMMUNOL, V40, P1099, DOI 10.1002/eji.200940022; Corn RA, 2005, J IMMUNOL, V175, P2102, DOI 10.4049/jimmunol.175.4.2102; Dev A, 2011, CURR TOP MICROBIOL, V349, P115, DOI 10.1007/82_2010_102; Duarte JH, 2009, EUR J IMMUNOL, V39, P948, DOI 10.1002/eji.200839196; Griseri T, 2010, J EXP MED, V207, P699, DOI 10.1084/jem.20091618; Guckel E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020003; Hacker Hans, 2006, Sci STKE, V2006, pre13, DOI 10.1126/stke.3572006re13; Hamano R, 2011, EUR J IMMUNOL, V41, P2010, DOI 10.1002/eji.201041205; Housley WJ, 2011, J IMMUNOL, V186, P6779, DOI 10.4049/jimmunol.1003868; Isomura I, 2009, J EXP MED, V206, P3001, DOI 10.1084/jem.20091411; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Legarda-Addison D, 2007, J IMMUNOL, V178, P7767, DOI 10.4049/jimmunol.178.12.7767; Li L, 2011, J EXP MED, V208, P787, DOI 10.1084/jem.20091346; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Liu BG, 2008, CANCER CELL, V14, P212, DOI 10.1016/j.ccr.2008.07.017; Liu B, 2007, CELL, V129, P903, DOI 10.1016/j.cell.2007.03.056; Long MX, 2009, IMMUNITY, V31, P921, DOI 10.1016/j.immuni.2009.09.022; Mahmud SA, 2014, NAT IMMUNOL, V15, P473, DOI 10.1038/ni.2849; Min B, 2005, J IMMUNOL, V174, P6039, DOI 10.4049/jimmunol.174.10.6039; *NAT RES COUNC I L, 1996, GUID CAR US LAB AN; Oh H, 2013, IMMUNOL REV, V252, P41, DOI 10.1111/imr.12033; Rauert H, 2010, J BIOL CHEM, V285, P7394, DOI 10.1074/jbc.M109.037341; Ren H, 2002, J IMMUNOL, V168, P3721, DOI 10.4049/jimmunol.168.8.3721; Ruan QG, 2009, IMMUNITY, V31, P932, DOI 10.1016/j.immuni.2009.10.006; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sanchez-Valdepenas C, 2006, J IMMUNOL, V176, P4666, DOI 10.4049/jimmunol.176.8.4666; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177; Tai XG, 2005, NAT IMMUNOL, V6, P152, DOI 10.1038/ni1160; Tiemessen MM, 2007, P NATL ACAD SCI USA, V104, P19446, DOI 10.1073/pnas.0706832104; Torchia MLG, 2013, J IMMUNOL, V190, P549, DOI 10.4049/jimmunol.1201697; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yurchenko E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035572; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang R, 2013, J CLIN INVEST, V123, P580, DOI 10.1172/JCI65013; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	46	34	35	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					443	454		10.1096/fj.14-259564	http://dx.doi.org/10.1096/fj.14-259564			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25376833	Green Published			2022-12-28	WOS:000349370400010
J	Israeli-Rosenberg, S; Chen, C; Li, RX; Deussen, DN; Niesman, IR; Okada, H; Patel, HH; Roth, DM; Ross, RS				Israeli-Rosenberg, Sharon; Chen, Chao; Li, Ruixia; Deussen, Daniel N.; Niesman, Ingrid R.; Okada, Hideshi; Patel, Hemal H.; Roth, David M.; Ross, Robert S.			Caveolin modulates integrin function and mechanical activation in the cardiomyocyte	FASEB JOURNAL			English	Article						caveolae; focal adhesions; mechanotransduction; myocardium	FOCAL ADHESION KINASE; CARDIAC-SPECIFIC OVEREXPRESSION; HYPERTROPHIC RESPONSE; ISCHEMIA/REPERFUSION INJURY; INDUCED PHOSPHORYLATION; SIGNALING COMPONENTS; EXTRACELLULAR-MATRIX; VENTRICULAR MYOCYTES; PRESSURE-OVERLOAD; MUTANT CAVEOLIN-3	beta 1 integrins (beta 1) transduce mechanical signals in many cells, including cardiac myocytes (CM). Given their close localization, as well as their role in mechanotransduction and signaling, we hypothesized that caveolin (Cav) proteins might regulate integrins in the CM. beta 1 localization, complex formation, activation state, and signaling were analyzed using wild-type, Cav3 knockout, and Cav3 CM-specific transgenic heart and myocyte samples. Studies were performed under basal and mechanically loaded conditions. We found that: 1) beta 1 and Cav3 colocalize in CM and coimmunoprecipitate from CM protein lysates; 2) beta 1 is detected in a subset of caveolae; 3) loss of Cav3 caused reduction of beta 1D integrin isoform and active beta 1 integrin from the buoyant domains in the heart; 4) increased expression of myocyte Cav3 correlates with increased active beta 1 integrin in adult CM; 5) in vivo pressure overload of the wild-type heart results in increased activated integrin in buoyant membrane domains along with increased association between active integrin and Cav3; and 6) Cav3-deficient myocytes have perturbed basal and stretch mediated signaling responses. Thus, Cav3 protein can modify integrin function and mechanotransduction in the CM and intact heart.	[Israeli-Rosenberg, Sharon; Chen, Chao; Li, Ruixia; Okada, Hideshi; Ross, Robert S.] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; [Niesman, Ingrid R.] Univ Calif San Diego, Sch Med, Dept Anesthesiol, La Jolla, CA 92093 USA; [Israeli-Rosenberg, Sharon; Chen, Chao; Li, Ruixia; Niesman, Ingrid R.; Okada, Hideshi; Patel, Hemal H.; Roth, David M.; Ross, Robert S.] US Vet Adm, San Diego Healthcare Syst, San Diego, CA USA; [Deussen, Daniel N.; Patel, Hemal H.; Roth, David M.] Maastricht Univ, NL-6200 MD Maastricht, Netherlands	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Maastricht University	Ross, RS (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, Biomed Res Facil 2,Room 2A-17,9500 Gilman Dr, La Jolla, CA 92093 USA.	rross@ucsd.edu	Ross, Robert/ABE-1109-2020; Patel, Hemal/C-7325-2019	Ross, Robert/0000-0003-2195-8982; Niesman, Ingrid/0000-0001-9767-6629; Okada, Hideshi/0000-0002-7775-4308; Patel, Hemal/0000-0001-6722-9625	U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute [HL046345, HL088390, HL103566, HL115933, HL091071, HL107200]; U.S. Veterans Administration (VA) Merit [BX001704, BX001963, BX000783]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL088390, R01HL103566, R01HL115933, R01HL091071, R01HL107200] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000783, I01BX001963, I01BX001704] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); U.S. Veterans Administration (VA) Merit; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs(US Department of Veterans Affairs)	The authors thank A. M. Manso for helpful comments and Drs. M. Humphries and S. Craig (The University of Manchester, Manchester, UK) for the kind gift of an anti-active beta 1 integrin antibody. The authors also thank Drs. A. McCulloch, E. Pfeiffer, and A. Wright for helpful discussions and insight. This work was supported by U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute Grants HL046345, HL088390, HL103566, HL115933 (R.S.R.); U.S. Veterans Administration (VA) Merit Grant BX001704 (R.S.R.); NIH National Heart, Lung, and Blood Institute Grants HL091071 (H.H.P.), HL107200 (H.H.P. and D.M.R.); VA Merit Grant BX001963 (H.H.P.); and VA Merit Grant BX000783 (D.M.R.).	Alden KJ, 2002, AM J PHYSIOL-CELL PH, V282, pC768, DOI 10.1152/ajpcell.00494.2001; Armulik A, 2000, EXP CELL RES, V254, P55, DOI 10.1006/excr.1999.4722; Babbitt CJ, 2002, HISTOCHEM CELL BIOL, V118, P431, DOI 10.1007/s00418-002-0476-1; Bastiani M, 2009, J CELL BIOL, V185, P1259, DOI 10.1083/jcb.200903053; Bellott AC, 2005, J APPL PHYSIOL, V98, P1554, DOI 10.1152/japplphysiol.01070.2004; Burkin DJ, 2005, AM J PATHOL, V166, P253, DOI 10.1016/S0002-9440(10)62249-3; Catteruccia M, 2009, NEUROMUSCULAR DISORD, V19, P779, DOI 10.1016/j.nmd.2009.08.015; de Cavanagh EMV, 2009, AM J PHYSIOL-HEART C, V296, pH550, DOI 10.1152/ajpheart.01176.2008; de Jonge HW, 2007, CELL BIOCHEM BIOPHYS, V47, P21, DOI 10.1385/CBB:47:1:21; Echarri A, 2006, CELL CYCLE, V5, P2179, DOI 10.4161/cc.5.19.3264; Fassler R, 1996, J CELL SCI, V109, P2989; Franchini KG, 2000, CIRC RES, V87, P558, DOI 10.1161/01.RES.87.7.558; Fridolfsson HN, 2014, FASEB J; Hagiwara Y, 2000, HUM MOL GENET, V9, P3047, DOI 10.1093/hmg/9.20.3047; Head BP, 2005, J BIOL CHEM, V280, P31036, DOI 10.1074/jbc.M502540200; Head BP, 2014, BBA-BIOMEMBRANES, V1838, P532, DOI 10.1016/j.bbamem.2013.07.018; Horiguchi K, 2011, J ENDOCRINOL, V210, P29, DOI 10.1530/JOE-11-0103; Horikawa YT, 2008, J MOL CELL CARDIOL, V44, P123, DOI 10.1016/j.yjmcc.2007.10.003; Horikawa YT, 2011, J AM COLL CARDIOL, V57, P2273, DOI 10.1016/j.jacc.2010.12.032; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; Insel PA, 2005, ANN NY ACAD SCI, V1047, P166, DOI 10.1196/annals.1341.015; Insel PA, 2005, BIOCHEM SOC T, V33, P1131, DOI 10.1042/BST0331131; Israeli-Rosenberg S, 2014, CIRC RES, V114, P572, DOI 10.1161/CIRCRESAHA.114.301275; Jokhadar SZ, 2013, CELL BIOL INT, V37, P1276, DOI 10.1002/cbin.10155; Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200; Kohl P, 2003, PROG BIOPHYS MOL BIO, V82, P221, DOI 10.1016/S0079-6107(03)00024-5; Kozera L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008312; Kuppuswamy D, 2002, CIRC RES, V90, P1240, DOI 10.1161/01.RES.0000025080.78636.23; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Lal H, 2007, J MOL CELL CARDIOL, V43, P137, DOI 10.1016/j.yjmcc.2007.05.012; Lange K, 2007, CANCER RES, V67, P6163, DOI 10.1158/0008-5472.CAN-06-3348; Lee AA, 1996, AM J PHYSIOL-CELL PH, V271, pC1400, DOI 10.1152/ajpcell.1996.271.4.C1400; Lee H, 2002, J BIOL CHEM, V277, P34556, DOI 10.1074/jbc.M204367200; Lee SH, 2011, J CELL PHYSIOL, V226, P1850, DOI 10.1002/jcp.22510; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Li RX, 2012, AM J PATHOL, V180, P952, DOI 10.1016/j.ajpath.2011.12.007; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manso AM, 2013, J BIOL CHEM, V288, P4252, DOI 10.1074/jbc.M112.427484; Ohsawa Y, 2004, HUM MOL GENET, V13, P151, DOI 10.1093/hmg/ddh014; Okada H, 2013, J CLIN INVEST, V123, P4294, DOI 10.1172/JCI64216; Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841; Patel HH, 2007, FASEB J, V21, P1565, DOI 10.1096/fj.06-7719com; Pham CG, 2000, AM J PHYSIOL-HEART C, V279, pH2916, DOI 10.1152/ajpheart.2000.279.6.H2916; Ross RS, 2001, CIRC RES, V88, P1112, DOI 10.1161/hh1101.091862; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; Salanueva IJ, 2007, J CELL MOL MED, V11, P969, DOI 10.1111/j.1582-4934.2007.00109.x; Shai SY, 2002, CIRC RES, V90, P458, DOI 10.1161/hh0402.105790; Sinha B, 2011, CELL, V144, P402, DOI 10.1016/j.cell.2010.12.031; Sowa G, 2012, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00120; Swaney JS, 2006, J BIOL CHEM, V281, P17173, DOI 10.1074/jbc.M513097200; Torsoni AS, 2003, CIRC RES, V93, P140, DOI 10.1161/01.RES.0000081595.25297.1B; Tsutsumi YM, 2008, CIRCULATION, V118, P1979, DOI 10.1161/CIRCULATIONAHA.108.788331; Upla P, 2004, MOL BIOL CELL, V15, P625, DOI 10.1091/mbc.E03-08-0588; Vatta M, 2006, CIRCULATION, V114, P2104, DOI 10.1161/CIRCULATIONAHA.106.635268; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Woodman SE, 2002, J BIOL CHEM, V277, P38988, DOI 10.1074/jbc.M205511200; Zimerman B, 2004, CELL MOTIL CYTOSKEL, V58, P143, DOI 10.1002/cm.20005	58	20	20	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					374	384		10.1096/fj.13-243139	http://dx.doi.org/10.1096/fj.13-243139			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25366344	Green Published			2022-12-28	WOS:000349370400004
J	Ripps, H				Ripps, Harris			Edwin Grant Conklin (1863-1952) and the Great Divide: Creation Versus Evolution	FASEB JOURNAL			English	Editorial Material									[Ripps, Harris] Univ Illinois, Coll Med, Dept Ophthalmol & Visual Sci Anat & Cell Biol & P, Chicago, IL 60607 USA; [Ripps, Harris] Marine Biol Lab, Woods Hole, MA 02543 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Marine Biological Laboratory - Woods Hole	Ripps, H (corresponding author), Univ Illinois, Coll Med, Dept Ophthalmol & Visual Sci Anat & Cell Biol & P, Chicago, IL 60607 USA.							Blinder A., 2014, NY TIMES, pA1; Butler E. G., 1952, YB AM PHIL SOC, P5; Conklin E. G., 1919, HEREDITY ENV DEV MEN, P361; Conklin E. G., 1930, INT CLIN, V1, P1; Conklin E. G., 1935, FREEDOM RESPONSIBILI, P88; Conklin E. G., 1934, DIRECTION HUMAN EVOL, P247; Conklin E. G., 1947, ESSAYS OUR TIME, P152; Conklin E. G., 1953, 13 AM THEIR SPIRITUA, P47; CONKLIN EG, 1968, AM SCI, V56, P112; Darwin C., 1909, FDN ORIGIN SPECIES 2; Darwin C., 1959, ORIGIN SPECIES MEANS; Dawkins R., 1995, RIVER OUT EDEN, P172; Fankhauser G, 1972, Am Sci, V60, P46; Gould S. J., 2003, HEDGEHOG FOX MAGISTE, P288; Harvey E N, 1953, Science, V117, P703, DOI 10.1126/science.117.3052.703; Harvey E. N., 1958, EDWIN GRANT CONKLIN, P52; Kettner F., 1932, SPINOZA BIOSOPHER, P263; Leavis F. R., 1962, 2 CULTURES SIGNIFICA, P64; Snow C. P., 1959, REDE LECT, P58	19	0	0	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5029	5033		10.1096/fj.14-1201ufm	http://dx.doi.org/10.1096/fj.14-1201ufm			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25451677				2022-12-28	WOS:000345894500001
J	Effenberger, T; von der Heyde, J; Bartsch, K; Garbers, C; Schulze-Osthoff, K; Chalaris, A; Murphy, G; Rose-John, S; Rabe, B				Effenberger, Timo; von der Heyde, Jan; Bartsch, Kareen; Garbers, Christoph; Schulze-Osthoff, Klaus; Chalaris, Athena; Murphy, Gillian; Rose-John, Stefan; Rabe, Bjoern			Senescence-associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding	FASEB JOURNAL			English	Article						SASP; p38; exosomes; TNFRI; ICAM-1	NECROSIS-FACTOR-ALPHA; PROSTATE-CANCER CELLS; SECRETORY PHENOTYPE; CELLULAR SENESCENCE; DNA-DAMAGE; CONVERTING ENZYME; HUMAN FIBROBLASTS; FACTOR RECEPTOR; GROWTH-FACTOR; TUMOR	Cellular senescence, a state of persistent cell cycle arrest, has emerged as a potent tumor suppressor mechanism by restricting proliferation of cells at risk for neoplastic transformation. Senescent cells secrete various growth factors, cytokines, and other proteins that can either elicit the clearance of tumor cells or potentially promote tumor progression. In addition, this senescence-associated secretory phenotype (SASP) includes various factors that are synthesized as transmembrane precursors and subsequently converted into their soluble counterparts. Despite the importance of the SASP to tumor biology, it is virtually unknown how transmembrane proteins are released from senescent cancer cells. Here we show in different models of senescence that the metalloprotease A disintegrin and metalloproteinase 17 (ADAM17) is activated and releases the epidermal growth factor receptor ligand amphiregulin and tumor necrosis factor receptor I (TNFRI) from the surface of senescent cells by ectodomain shedding. ADAM17 activation involves phosphorylation of its cytoplasmic tail by mitogen-activated protein kinase (MAPK) p38. Interestingly, unlike amphiregulin and TNFRI, full-length intercellular adhesion molecule 1 (ICAM1) is released from senescent cells by microvesicles independently of ADAM17. Thus, our results suggest that transmembrane proteins can be released by two distinct mechanisms and point to a crucial role for ADAM17 in shaping the secretory profile of senescent cells.Effenberger, T., von der Heyde, J., Bartsch, K., Garbers, C., Schulze-Osthoff, K., Chalaris, A., Murphy, G., Rose-John, S., Rabe, B. Senescence-associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding.	[Effenberger, Timo; von der Heyde, Jan; Bartsch, Kareen; Garbers, Christoph; Chalaris, Athena; Rose-John, Stefan; Rabe, Bjoern] Univ Kiel, Inst Biochem, D-24118 Kiel, Germany; [Schulze-Osthoff, Klaus] Univ Tubingen, Interfac Inst Biochem, Tubingen, Germany; [Schulze-Osthoff, Klaus] German Canc Consortium DKTK, Heidelberg, Germany; [Schulze-Osthoff, Klaus] German Canc Res Ctr, Heidelberg, Germany; [Murphy, Gillian] Univ Cambridge, Canc Res UK Cambridge Inst, Dept Oncol, Cambridge, England	University of Kiel; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Rabe, B (corresponding author), Univ Kiel, Inst Biochem, Rudolf Hober Str 1, D-24118 Kiel, Germany.	brabe@biochem.uni-kiel.de	Garbers, Christoph/D-9932-2015; Rose-John, Stefan/A-7998-2010; Schulze-Osthoff, Klaus/N-9025-2013	Garbers, Christoph/0000-0003-4939-6950; Rose-John, Stefan/0000-0002-7519-3279; Schulze-Osthoff, Klaus/0000-0003-1443-2720	Deutsche Forschungsgemeinschaft (Bonn, Germany) [RA 2401/1-1, SFR 877]; Deutsche Forschungsgemeinschaft (Bonn, Germany, the Cluster of Excellence Inflammation at Interfaces)	Deutsche Forschungsgemeinschaft (Bonn, Germany)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (Bonn, Germany, the Cluster of Excellence Inflammation at Interfaces)	The authors thank Stefanie Schnell and Annett Lickert for excellent technical assistance. This work was supported by grants from the Deutsche Forschungsgemeinschaft (Bonn, Germany; project grant RA 2401/1-1 to B.R., SFR 877, project A1 to A.C. and S.R.-J.; the Cluster of Excellence Inflammation at Interfaces to S.R.-J. B.R., and A.C.).	Alexander E, 2013, J CELL SCI, V126, P3738, DOI 10.1242/jcs.128835; Bavik C, 2006, CANCER RES, V66, P794, DOI 10.1158/0008-5472.CAN-05-1716; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Chalaris A, 2007, BLOOD, V110, P1748, DOI 10.1182/blood-2007-01-067918; Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003; Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009188; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Essick E, 2008, MOL CELL BIOCHEM, V314, P151, DOI 10.1007/s11010-008-9776-7; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Garbers C, 2013, CELL CYCLE, V12, P3421, DOI 10.4161/cc.26431; Hawari FI, 2004, P NATL ACAD SCI USA, V101, P1297, DOI 10.1073/pnas.0307981100; Jorissen E, 2010, J NEUROSCI, V30, P4833, DOI 10.1523/JNEUROSCI.5221-09.2010; Kang MK, 2003, EXP CELL RES, V287, P272, DOI 10.1016/S0014-4827(03)00061-2; Kenny PA, 2007, J CLIN INVEST, V117, P337, DOI 10.1172/JCI29518; Kharaziha P, 2012, BBA-REV CANCER, V1826, P103, DOI 10.1016/j.bbcan.2012.03.006; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Lehmann BD, 2008, CANCER RES, V68, P7864, DOI 10.1158/0008-5472.CAN-07-6538; Madge LA, 1999, J BIOL CHEM, V274, P13643, DOI 10.1074/jbc.274.19.13643; MILLIS AJT, 1992, EXP CELL RES, V201, P373, DOI 10.1016/0014-4827(92)90286-H; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rodland KD, 2008, J BIOL CHEM, V283, P31477, DOI 10.1074/jbc.M800456200; Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113; Scheller J, 2011, TRENDS IMMUNOL, V32, P380, DOI 10.1016/j.it.2011.05.005; Segura E, 2005, BLOOD, V106, P216, DOI 10.1182/blood-2005-01-0220; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Soond SM, 2005, J CELL SCI, V118, P2371, DOI 10.1242/jcs.02357; Tape CJ, 2011, P NATL ACAD SCI USA, V108, P5578, DOI 10.1073/pnas.1017067108; Trad A, 2011, J IMMUNOL METHODS, V371, P91, DOI 10.1016/j.jim.2011.06.015; Tsakadze NL, 2006, J BIOL CHEM, V281, P3157, DOI 10.1074/jbc.M510797200; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Walcheck B, 2006, EUR J IMMUNOL, V36, P968, DOI 10.1002/eji.200535257; Xu PL, 2010, MOL CELL, V37, P551, DOI 10.1016/j.molcel.2010.01.034; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yamamoto K, 2012, BIOCHEM J, V445, P135, DOI 10.1042/BJ20120433	41	42	43	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4847	4856		10.1096/fj.14-254565	http://dx.doi.org/10.1096/fj.14-254565			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25077560	Bronze			2022-12-28	WOS:000344050900022
J	Corriden, R; Kilpatrick, LE; Kellam, B; Briddon, SJ; Hill, SJ				Corriden, Ross; Kilpatrick, Laura E.; Kellam, Barrie; Briddon, Stephen J.; Hill, Stephen J.			Kinetic analysis of antagonist-occupied adenosine-A(3) receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism	FASEB JOURNAL			English	Article						GPCR; dissociation; fluorescence correlation spectroscopy; fluorescent ligand	PROTEIN-COUPLED RECEPTOR; FLUORESCENCE CORRELATION SPECTROSCOPY; LIPID RAFTS; IN-VIVO; AGONIST; BINDING; MODULATION; QUANTIFICATION; COMPLEXES; DIFFUSION	In our previous work, using a fluorescent adenosine-A(3) receptor (A(3)AR) agonist and fluorescence correlation spectroscopy (FCS), we demonstrated high-affinity labeling of the active receptor (R*) conformation. In the current study, we used a fluorescent A(3)AR antagonist (CA200645) to study the binding characteristics of antagonist-occupied inactive receptor (R) conformations in membrane microdomains of individual cells. FCS analysis of CA200645-occupied A(3)ARs revealed 2 species, tau(D2) and tau(D3), that diffused at 2.29 +/- 0.35 and 0.09 +/- 0.03 mu m(2)/s, respectively. FCS analysis of a green fluorescent protein (GFP)-tagged A3AR exhibited a single diffusing species (0.105 mu m(2)/s). The binding of CA200645 to tau(D3) was antagonized by nano-molar concentrations of the A(3) antagonist MRS 1220, but not by the agonist NECA (up to 300 nM), consistent with labeling of R. CA200645 normally dissociated slowly from the A(3)AR, but inclusion of xanthine amine congener (XAC) or VUF 5455 during washout markedly accelerated the reduction in the number of particles exhibiting tau(D3) characteristics. It is notable that this effect was accompanied by a significant increase in the number of particles with tau(D2) diffusion. These data show that FCS analysis of ligand-occupied receptors provides a unique means of monitoring ligand A(3)AR residence times that are significantly reduced as a consequence of allosteric interaction across the dimer interface.	[Corriden, Ross; Kilpatrick, Laura E.; Briddon, Stephen J.; Hill, Stephen J.] Univ Nottingham, Sch Med, Sch Life Sci, Inst Cell Signalling, Nottingham, England; [Kellam, Barrie] Univ Nottingham, Ctr Biomol Sci, Sch Pharm, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham	Hill, SJ (corresponding author), Queens Med Ctr, Sch Med, Sch Life Sci, Inst Cell Signalling, Nottingham NG7 2UH, England.	stephen.hill@nottingham.ac.uk	Hill, Stephen J/M-6243-2018; Hill, Stephen/N-6753-2013; Kellam, Barrie/AAE-2960-2019	Hill, Stephen J/0000-0002-4424-239X; Hill, Stephen/0000-0002-4424-239X; Briddon, Stephen/0000-0001-8514-0827; Kellam, Barrie/0000-0003-0030-9908	UK Medical Research Council (MRC) [G0800006]; MRC [G0800006] Funding Source: UKRI; Medical Research Council [G0800006] Funding Source: researchfish	UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank the UK Medical Research Council (MRC) for financial support (grant G0800006) and Dr. L. Bridge (University of Swansea, Swansea, UK) for helpful discussions.	Albrecht-Kupper BE, 2012, PURINERG SIGNAL, V8, pS91, DOI 10.1007/s11302-011-9274-3; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Baker JG, 2003, MOL PHARMACOL, V64, P1357, DOI 10.1124/mol.64.6.1357; Baker JG, 2011, J MED CHEM, V54, P6874, DOI 10.1021/jm2008562; Bar-Yehuda S, 2011, INT J MOL MED, V28, P727, DOI 10.3892/ijmm.2011.753; Briddon S.J., 2010, G PROTEIN COUPLED RE, P169; Briddon SJ, 2004, P NATL ACAD SCI USA, V101, P4673, DOI 10.1073/pnas.0400420101; Briddon SJ, 2004, FARADAY DISCUSS, V126, P197, DOI 10.1039/b307407b; Briddon SJ, 2007, TRENDS PHARMACOL SCI, V28, P637, DOI 10.1016/j.tips.2007.09.008; Briddon SJ, 2008, BBA-MOL CELL RES, V1783, P2262, DOI 10.1016/j.bbamcr.2008.07.006; Bridge LJ, 2010, MATH BIOSCI, V223, P115, DOI 10.1016/j.mbs.2009.11.005; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; CLARK EA, 1995, BRIT J PHARMACOL, V114, P357, DOI 10.1111/j.1476-5381.1995.tb13234.x; Cohen S, 2011, J CELL PHYSIOL, V226, P2438, DOI 10.1002/jcp.22593; Cordeaux Y, 2008, FASEB J, V22, P850, DOI 10.1096/fj.07-8180com; Corriden R, 2013, EMBO REP, V14, P726, DOI 10.1038/embor.2013.89; Corriden R, 2012, PURINERG SIGNAL, V8, P587, DOI 10.1007/s11302-012-9311-x; Fredholm BB, 2011, PHARMACOL REV, V63, P1, DOI 10.1124/pr.110.003285; Gao ZG, 2003, MOL PHARMACOL, V63, P1021, DOI 10.1124/mol.63.5.1021; Gao ZG, 2001, MOL PHARMACOL, V60, P1057, DOI 10.1124/mol.60.5.1057; Gines S, 2001, MOL PHARMACOL, V59, P1314, DOI 10.1124/mol.59.5.1314; Hill SJ, 2014, BRIT J PHARMACOL, V171, P1102, DOI 10.1111/bph.12345; Hugo Gutierrez-de-Tera H., 2013, STRUCTURE, V21, P1; Insel PA, 2005, ANN NY ACAD SCI, V1047, P166, DOI 10.1196/annals.1341.015; Katritch V, 2013, ANNU REV PHARMACOL, V53, P531, DOI 10.1146/annurev-pharmtox-032112-135923; Kenakin TP, 2012, BRIT J PHARMACOL, V165, P1659, DOI 10.1111/j.1476-5381.2011.01749.x; Keov P, 2011, NEUROPHARMACOLOGY, V60, P24, DOI 10.1016/j.neuropharm.2010.07.010; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; May LT, 2010, MOL PHARMACOL, V77, P678, DOI 10.1124/mol.109.063065; May LT, 2007, ANNU REV PHARMACOL, V47, P1, DOI 10.1146/annurev.pharmtox.47.120505.105159; May LT, 2011, FASEB J, V25, P3465, DOI 10.1096/fj.11-186296; May LT, 2010, MOL PHARMACOL, V78, P511, DOI 10.1124/mol.110.064493; Middleton RJ, 2007, J MED CHEM, V50, P782, DOI 10.1021/jm061279i; Muller CE, 2011, BBA-BIOMEMBRANES, V1808, P1290, DOI 10.1016/j.bbamem.2010.12.017; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; Stoddart LA, 2012, CHEM BIOL, V19, P1105, DOI 10.1016/j.chembiol.2012.07.014; Sykes DA, 2014, MOL PHARMACOL, V85, P608, DOI 10.1124/mol.113.090209; Tendera M, 2012, CLIN RES CARDIOL, V101, P585, DOI 10.1007/s00392-012-0430-8; Tummino PJ, 2008, BIOCHEMISTRY-US, V47, P5481, DOI 10.1021/bi8002023; Vauquelin G, 2010, EXPERT OPIN DRUG DIS, V5, P927, DOI 10.1517/17460441.2010.512037; Vauquelin G, 2010, BRIT J PHARMACOL, V161, P488, DOI 10.1111/j.1476-5381.2010.00936.x; Venkatakrishnan AJ, 2013, NATURE, V494, P185, DOI 10.1038/nature11896; Vernall A. J., 2013, BRIT J PHARMACOL, V171, P1073; Whalen EJ, 2011, TRENDS MOL MED, V17, P126, DOI 10.1016/j.molmed.2010.11.004	46	46	46	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4211	4222		10.1096/fj.13-247270	http://dx.doi.org/10.1096/fj.13-247270			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24970394	Green Published, hybrid			2022-12-28	WOS:000342222700003
J	Zhao, SQ; Zhou, L; Niu, GM; Li, Y; Zhao, DZ; Zeng, HY				Zhao, Shengqiang; Zhou, Lei; Niu, Gengming; Li, Yan; Zhao, Dezheng; Zeng, Huiyan			Differential regulation of orphan nuclear receptor TR3 transcript variants by novel vascular growth factor signaling pathways	FASEB JOURNAL			English	Article						angiogenesis; IGF-1R; VEGFR2; KDR; phosphorylation	NITRIC-OXIDE SYNTHASE; NGFI-B NUR77; ENDOTHELIAL-CELLS; GENE-EXPRESSION; ANGIOGENESIS; VEGF; INSULIN; KINASE; PERMEABILITY; TR3/NUR77	Angiogenesis is a hallmark of many diseases, including cancer, ischemic heart disease, inflammation, and others. It is well known that vascular endothelial growth factor (VEGF) is the most important angiogenic factor. Recently, we demonstrated that orphan nuclear receptor TR3 (mouse Nur77 and rat NGFI-B) plays critical roles in tumor growth and angiogenesis induced by VEGF-A in vitro and in vivo. However, the signaling pathways that mediate the expression of TR3 induced by VEGF are still not completely understood. Here we reported that 3 TR3 transcript variants (TR3-TVs) are expressed at differential levels, and regulated differentially in endothelial cells. While the expression of TR3-TV1 is relatively low, the expression of TR3-TV2 is up-regulated markedly, and the expression of TR3-TV3 is up-regulated moderately in endothelial cells induced by VEGF-A. The kinetics of the induction of these TR3-TVs is different. We also found that several signaling pathways, including calcium-PLC-PKC-PKD1 pathway, NF-kappa B pathway, and MAP kinase (ERK, p38, and JNK) pathways are important for VEGF-A-induced TR3-TV2 and TR3-TV3 mRNA induction. More important, we found that VEGF-A or VEGF-E, but not VEGF-B, nor placenta growth factor (PlGF), induces the phosphorylation of insulin-like growth factor-1 receptor (IGF-1R) and the interaction of VEGF receptor 2/kinase insert domain receptor (VEGFR2/KDR) with IGF-1R, which mediates the expression of TR3-TV2, but not TR3-TV3. Taking together, we demonstrate that TR3-TVs are differentially regulated by VEGF-A and identify a novel signaling pathway by which VEGF-A and VEGF-E, but neither VEGF-B, nor PlGF, induce the interaction of VEGFR2/KDR with IGF-1R, resulting in IGF-1R transactivation to induce the high level expression of TR3-TV2. Our data not only elucidate the signaling pathways by which TR3-TVs are regulated, but extend the molecular mechanism, by which VEGF-A-induced angiogenesis. These studies should permit the development of screening assays for compounds that inhibit VEGF signaling.	[Zhao, Shengqiang; Zhou, Lei; Niu, Gengming; Li, Yan; Zhao, Dezheng; Zeng, Huiyan] Harvard Univ, Sch Med, Ctr Vasc Biol Res Div Mol, Boston, MA 02215 USA; [Zhao, Shengqiang; Zhou, Lei; Niu, Gengming; Li, Yan; Zhao, Dezheng; Zeng, Huiyan] Harvard Univ, Sch Med, Div Mol & Vasc Biol, Boston, MA 02215 USA; [Zhao, Dezheng] Harvard Univ, Sch Med, Div Gastroenterol, Dept Med,Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Zhao, Shengqiang; Li, Yan] Shandong Univ, Prov Hosp, Dept Gastroenterol, Jinan 250100, Peoples R China; [Zhou, Lei] Xi An Jiao Tong Univ, Sch Med, Dept Hepatobiliary Surg, Xian 710049, Peoples R China; [Zhou, Lei] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Gen Surg, Xian 710049, Peoples R China; [Niu, Gengming] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Shandong University; Xi'an Jiaotong University; Xi'an Jiaotong University; Fudan University	Zeng, HY (corresponding author), Harvard Univ, Sch Med, Ctr Vasc Biol Res Div Mol, 99 Brookline Ave RN270F, Boston, MA 02215 USA.	hzeng@bidmc.harvard.edu	NIU, NIU/AAA-1523-2022		U.S. National Institutes of Health [R01CA133235, R01DK095873, R21DK080970]; American Cancer Society [RSG CSM 113297]; China Scholarship Council; NATIONAL CANCER INSTITUTE [R01CA133235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK095873, R21DK080970] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); China Scholarship Council(China Scholarship Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Drs. Pengfei Cui and Taiyang Ye for their technical assistance. This work was supported by U.S. National Institutes of Health grants R01CA133235 (H.Z.), R01DK095873 (D.Z.), and R21DK080970 (D.Z.); American Cancer Society grant RSG CSM 113297 (D.Z.); and scholarships from the China Scholarship Council (S.Z., L.Z., G.N., Y.L.).	Abe Mayumi, 2001, Angiogenesis, V4, P289, DOI 10.1023/A:1016018617152; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bandoh S, 1997, J NEUROENDOCRINOL, V9, P3, DOI 10.1046/j.1365-2826.1997.00571.x; Becker PM, 2001, AM J PHYSIOL-LUNG C, V281, pL1500, DOI 10.1152/ajplung.2001.281.6.L1500; Bid HK, 2012, MOL CANCER THER, V11, P649, DOI 10.1158/1535-7163.MCT-11-0575; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; DeYoung RA, 2003, J BIOL CHEM, V278, P47104, DOI 10.1074/jbc.M307496200; Folkman J, 1997, EXS, V79, P1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996-150; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Gilbert F, 2006, BIOL PSYCHIAT, V60, P538, DOI 10.1016/j.biopsych.2006.04.023; Hayashi K, 1996, MOL CELL ENDOCRINOL, V123, P205, DOI 10.1016/S0303-7207(96)03909-3; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; Jacobs CM, 2004, J BIOL CHEM, V279, P50097, DOI 10.1074/jbc.M409145200; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Kanzleiter T, 2005, PHYSIOL GENOMICS, V24, P37, DOI 10.1152/physiolgenomics.00204.2005; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; Lal BK, 2001, MICROVASC RES, V62, P252, DOI 10.1006/mvre.2001.2338; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LEE SL, 1995, SCIENCE, V269, P532, DOI 10.1126/science.7624775; LeRoith D, 1997, NEW ENGL J MED, V336, P633, DOI 10.1056/NEJM199702273360907; Liu D, 2003, ARTERIOSCL THROM VAS, V23, P2002, DOI 10.1161/01.ATV.0000098644.03153.6F; Mavria G, 2006, CANCER CELL, V9, P33, DOI 10.1016/j.ccr.2005.12.021; NAKAOHAYASHI J, 1992, ATHEROSCLEROSIS, V92, P141, DOI 10.1016/0021-9150(92)90273-J; Qin LL, 2006, J BIOL CHEM, V281, P32550, DOI 10.1074/jbc.M604853200; Qin LL, 2013, BLOOD, V121, P2154, DOI 10.1182/blood-2012-07-443903; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SCHMID C, 1995, CELL BIOL INT, V19, P445, DOI 10.1006/cbir.1995.1088; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; WATSON MA, 1990, DEVELOPMENT, V110, P173; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhao DZ, 2011, P NATL ACAD SCI USA, V108, P12066, DOI 10.1073/pnas.1018438108	39	16	16	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4524	4533		10.1096/fj.13-248401	http://dx.doi.org/10.1096/fj.13-248401			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25016027	Green Published			2022-12-28	WOS:000342222700028
J	Aslam, MF; Frazer, DM; Faria, N; Bruggraber, SFA; Wilkins, SJ; Mirciov, C; Powell, JJ; Anderson, GJ; Pereira, DIA				Aslam, Mohamad F.; Frazer, David M.; Faria, Nuno; Bruggraber, Sylvaine F. A.; Wilkins, Sarah J.; Mirciov, Cornel; Powell, Jonathan J.; Anderson, Greg J.; Pereira, Dora I. A.			Ferroportin mediates the intestinal absorption of iron from a nanoparticulate ferritin core mimetic in mice	FASEB JOURNAL			English	Article						nanoiron; basolateral export; iron homeostasis; hepcidin; knockout mice	TRANSFERRIN-BOUND IRON; FERROUS SULFATE; GUT MICROBIOTA; HEPCIDIN; METABOLISM; EXPRESSION; IREG1; TOLERABILITY; SUPPLEMENTS; HEPHAESTIN	The ferritin core is composed of fine nanoparticulate Fe3+ oxohydroxide, and we have developed a synthetic mimetic, nanoparticulate Fe3+ polyoxohydroxide (nanoFe(3+)). The aim of this study was to determine how dietary iron derived in this fashion is absorbed in the duodenum. Following a 4 wk run-in on an Fe-deficient diet, mice with intestinal-specific disruption of the Fpn-1 gene (Fpn-KO), or littermate wild-type (WT) controls, were supplemented with Fe2+ sulfate (FeSO4), nanoFe(3+), or no added Fe for a further 4 wk. A control group was Fe sufficient throughout. Direct intestinal absorption of nanoFe(3+) was investigated using isolated duodenal loops. Our data show that FeSO4 and nanoFe(3+) are equally bioavailable in WT mice, and at wk 8 the mean +/- SEM hemoglobin increase was 18 +/- 7 g/L in the FeSO4 group and 30 +/- 5 g/L in the nanoFe(3+) group. Oral iron failed to be utilized by Fpn-KO mice and was retained in enterocytes, irrespective of the iron source. In summary, although nanoFe(3+) is taken up directly by the duodenum its homeostasis is under the normal regulatory control of dietary iron absorption, namely via ferroportin-dependent efflux from enterocytes, and thus offers potential as a novel oral iron supplement.-Aslam, M. F., Frazer, D. M., Faria, N., Bruggraber, S. F. A., Wilkins, S. J., Mirciov, C., Powell, J. J., Anderson, G. J., Pereira, D. I. A. Ferroportin mediates the intestinal absorption of iron from a nanoparticulate ferritin core mimetic in mice.	[Aslam, Mohamad F.; Faria, Nuno; Bruggraber, Sylvaine F. A.; Powell, Jonathan J.; Pereira, Dora I. A.] Elsie Widdowson Lab, MRC Human Nutr Res, Cambridge CB1 9NL, England; [Frazer, David M.; Wilkins, Sarah J.; Mirciov, Cornel; Anderson, Greg J.] Berghofer Med Res Inst, Queensland Inst Med Res, Iron Metab Lab, Brisbane, Qld, Australia; [Anderson, Greg J.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia; [Anderson, Greg J.] Univ Queensland, Sch Med, Brisbane, Qld, Australia	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland	Pereira, DIA (corresponding author), Elsie Widdowson Lab, MRC Human Nutr Res, 120 Fulbourn Rd, Cambridge CB1 9NL, England.	dora.pereira@mrc-hnr.cam.ac.uk	Anderson, Gregory J/G-4148-2013; Frazer, David M/L-3570-2014; Pereira, Dora I A/D-4634-2012	Anderson, Gregory J/0000-0002-8814-5866; Frazer, David M/0000-0003-4098-1379; Pereira, Dora I A/0000-0001-5688-4448; Mirciov, Cornel/0000-0002-9083-2614	UK Medical Research Council [U105960399]; MRC; National Health and Medical Research Council of Australia; Australian Liver Foundation; MRC [MC_U105960399] Funding Source: UKRI; Medical Research Council [1197759, MC_U105960399] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Liver Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the UK Medical Research Council (U105960399). M. F. A. is supported by an MRC Ph.D. studentship. G. J. A. is supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia. D. M. F. is the recipient of a fellowship from the Australian Liver Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no conflicts of interest but note that D. I. A. P., S. F. A. B., N. F., and J. J. P. are inventors on a patent detailing novel Fe<SUP>3+</SUP> polyoxohydroxide structures, as described herein, and that may have further potential as commercial dietary supplements (57). M. F. A., D. M. F., G. J. A., J. J. P., and D. I. A. P. designed the research; S. F. A. B. and N. J. R. F. provided the nanoFe<SUP>3+</SUP> materials; M. F. A., D. M. F., S. J. W., and C. M. conducted the research; M. F. A., D. M. F., and D. I. A. P. analyzed data; M. F. A., J. J. P., and D. I. A. P. had primary responsibility for final content. All authors read, provided input to, and approved the final manuscript.	Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Antileo E, 2013, AM J PHYSIOL-GASTR L, V304, pG655, DOI 10.1152/ajpgi.00472.2012; BARRAND MA, 1990, J PHARM PHARMACOL, V42, P279, DOI 10.1111/j.2042-7158.1990.tb05408.x; Bregman DB, 2013, AM J HEMATOL, V88, P97, DOI 10.1002/ajh.23354; BUNTING H, 1949, STAIN TECHNOL, V24, P109, DOI 10.3109/10520294909139590; Chen HJ, 2003, BLOOD, V102, P1893, DOI 10.1182/blood-2003-02-0347; COPLIN M, 1991, CLIN THER, V13, P606; Darshan D, 2011, GASTROENTEROLOGY, V141, P300, DOI 10.1053/j.gastro.2011.04.012; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003; DOREY C, 1993, BRIT J NUTR, V70, P157, DOI 10.1079/BJN19930113; Dostal A, 2012, J NUTR, V142, P271, DOI 10.3945/jn.111.148643; Drakesmith H, 2012, SCIENCE, V338, P768, DOI 10.1126/science.1224577; Dresow B, 2008, BIOMETALS, V21, P273, DOI 10.1007/s10534-007-9116-5; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Frazer DM, 2003, GUT, V52, P340, DOI 10.1136/gut.52.3.340; Frazer DM, 2002, GASTROENTEROLOGY, V123, P835, DOI 10.1053/gast.2002.35353; Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672; Ganz T, 2012, BBA-MOL CELL RES, V1823, P1434, DOI 10.1016/j.bbamcr.2012.01.014; Gunshin H, 2005, J CLIN INVEST, V115, P1258, DOI [10.1172/JCI200524356, 10.1172/JCI24356]; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hurrell RF, 2011, ANN NUTR METAB, V59, P64, DOI 10.1159/000332140; Cancelo-Hidalgo MJ, 2013, CURR MED RES OPIN, V29, P291, DOI 10.1185/03007995.2012.761599; Kalgaonkar S, 2009, J NUTR BIOCHEM, V20, P304, DOI 10.1016/j.jnutbio.2008.04.003; Kortman GAM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029968; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; Lomer MCE, 2012, BRIT J NUTR, V107, P1806, DOI 10.1017/S0007114511004971; Martin CDS, 2008, J NUTR, V138, P659, DOI 10.1093/jn/138.4.659; Mckie AT, 2008, BIOCHEM SOC T, V36, P1239, DOI 10.1042/BST0361239; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Miret S, 2003, ANNU REV NUTR, V23, P283, DOI 10.1146/annurev.nutr.23.011702.073139; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303; Ohgami RS, 2006, BLOOD, V108, P1388, DOI 10.1182/blood-2006-02-003681; Pan YH, 2009, J STRUCT BIOL, V166, P22, DOI 10.1016/j.jsb.2008.12.001; Pena-Rosas Juan P., 2012, COCHRANE DB SYST REV; Pereira DIA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081250; Powell J., 2008, UK patent, Patent No. [WO/2008/096130, 2008096130]; Powell JJ, 2005, BRIT J NUTR, V94, P804, DOI 10.1079/BJN20051542; Powell JJ, 2014, NANOMED-NANOTECHNOL, V10, P1529, DOI 10.1016/j.nano.2013.12.011; Prentice AM, 2012, BLOOD, V119, P1922, DOI 10.1182/blood-2011-11-391219; Radulescu S, 2012, CELL REP, V2, P270, DOI 10.1016/j.celrep.2012.07.003; Rebouche CJ, 2004, J BIOCHEM BIOPH METH, V58, P239, DOI 10.1016/j.jbbm.2003.11.003; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Schumann K, 2012, FOOD NUTR BULL, V33, P128, DOI 10.1177/156482651203300206; Seril DN, 2002, DIGEST DIS SCI, V47, P1266, DOI 10.1023/A:1015362228659; SIMPSON RJ, 1990, BRIT J NUTR, V63, P79, DOI 10.1079/BJN19900093; Theil EC, 2004, ANNU REV NUTR, V24, P327, DOI 10.1146/annurev.nutr.24.012003.132212; Theil EC, 2012, J NUTR, V142, P478, DOI 10.3945/jn.111.145854; Tosha T, 2012, J BIOL CHEM, V287, P13016, DOI 10.1074/jbc.M111.332734; Werner T, 2011, GUT, V60, P325, DOI 10.1136/gut.2010.216929; WHO, 2008, GLOB DAT AN; WOLLENBERG P, 1987, N-S ARCH PHARMACOL, V336, P578; World Health Organisation, 2008, GLOB TUB CONTR SURV, P1; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Zimmermann MB, 2011, BRIT J NUTR, V105, P1245, DOI 10.1017/S0007114510004903; Zimmermann MB, 2010, AM J CLIN NUTR, V92, P1406, DOI 10.3945/ajcn.110.004564	57	33	38	0	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3671	3678		10.1096/fj.14-251520	http://dx.doi.org/10.1096/fj.14-251520			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24776745	Green Published, hybrid			2022-12-28	WOS:000340265400034
J	Gautrey, HE; van Otterdijk, SD; Cordell, HJ; Mathers, JC; Strathdee, G				Gautrey, Hannah E.; van Otterdijk, Sanne D.; Cordell, Heather J.; Mathers, John C.; Strathdee, Gordon		Newcastle 85 Study Core Team	DNA methylation abnormalities at gene promoters are extensive and variable in the elderly and phenocopy cancer cells	FASEB JOURNAL			English	Article						epigenetics; aging; CpG island; cell type specific	ACUTE LYMPHOBLASTIC-LEUKEMIA; CPG-ISLAND METHYLATION; ACUTE MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR; STEM-CELLS; AGE; HYPERMETHYLATION; GENDER; PROLIFERATION; INACTIVATION	Abnormal patterns of DNA methylation are one of the hallmarks of cancer cells. The process of aging has also been associated with similar, albeit less dramatic, changes in methylation patterns, leading to the hypothesis that age-related changes in DNA methylation may partially underlie the increased risk of cancer in the elderly. Here we studied 377 participants aged 85 yr from the Newcastle 85+ Study to investigate the extent of, and interindividual variation in, age-related changes in DNA methylation at specific CpG islands. Using highly quantitative pyrosequencing analysis, we found extensive and highly variable methylation of promoter-associated CpG islands with levels ranging from 4% to 35%, even at known tumor suppressor genes such as TWIST2. Furthermore, the interindividual differences in methylation seen across this elderly population phenocopies multiple features of the altered methylation patterns seen in cancer cells. Both aging-and cancer-related methylation can occur at similar sets of genes, both result in the formation of densely methylated, and likely transcriptionally repressed, alleles, and both exhibit coordinate methylation across multiple loci. In addition, high methylation levels were associated with subsequent diagnosis of leukemia or lymphoma during a 3-yr follow-up period (P = 0.00008). These data suggest that the accumulation of age-related changes in promoter-associated CpG islands may contribute to the increased cancer risk seen during aging.	[Gautrey, Hannah E.; van Otterdijk, Sanne D.; Strathdee, Gordon] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Cordell, Heather J.] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Mathers, John C.] Newcastle Univ, Inst Ageing & Hlth, Human Nutr Res Ctr, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Strathdee, G (corresponding author), Newcastle Univ, Royal Victoria Infirm, Northern Inst Canc Res, Sir James Spence Inst, 5th Floor,Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	gordon.strathdee@ncl.ac.uk		Robinson, Louise/0000-0003-0209-2503; Jagger, Carol/0000-0002-6377-9926; Strathdee, Gordon/0000-0001-9681-8429; Davies, Karen/0000-0002-2820-9397; Mathers, John/0000-0003-3406-3002; Cordell, Heather/0000-0002-1879-5572	U.K. Medical Research Council; Biotechnology and Biological Sciences Research Council [G0500997]; Newcastle Healthcare Charity; Dunhill Medical Trust; National Institute for Health Research Newcastle Biomedical Research Centre; Rank Prize Funds; Biotechnology and Biological Sciences Research Council; MRC [G0500997, G0700718] Funding Source: UKRI; Medical Research Council [G0700718, G0500997] Funding Source: researchfish; NIHR Newcastle Biomedical Research Centre [BH111030] Funding Source: researchfish	U.K. Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Newcastle Healthcare Charity; Dunhill Medical Trust(Dunhill Medical Trust); National Institute for Health Research Newcastle Biomedical Research Centre; Rank Prize Funds; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NIHR Newcastle Biomedical Research Centre	Thanks are especially due to the 85-yr-olds of Newcastle and North Tyneside and their families and care givers, for the generous donation of their time and personal information to make the study possible. In addition we thank the research nurses (Brenda Balderson, Sally Barker, Julie Burrows, June Edwards, Julie Ferguson, Gill Hedley, Joan Hughes, Judith Hunt, Julie Kimber, and Victoria Raynor), biomarker technicians (Sam Jameson, Claire Kolenda, Craig Parker, and Anna Tang), data manager (Pauline Potts), project secretary (Lucy Farfort), and North of England Commissioning Support Unit (formerly NHS North of Tyne, working on behalf of Newcastle PCT, North Tyneside PCT, and Northumberland Care Trust), and local general practices. The baseline phase of the Newcastle 85+ Study was funded by a combined grant from the U.K. Medical Research Council and the Biotechnology and Biological Sciences Research Council (G0500997) and a grant from the Newcastle Healthcare Charity. The research was also supported by the Dunhill Medical Trust and by National Institute for Health Research Newcastle Biomedical Research Centre, based at Newcastle on Tyne Hospitals NHS Foundation Trust and Newcastle University. The Rank Prize Funds supported purchase of the pyrosequencer. H.E.G. was funded by a Ph.D. studentship from the Biotechnology and Biological Sciences Research Council, and S.D.v.O. was funded by a Ph.D. studentship from the National Institute for Health Research Newcastle Biomedical Research Centre.	Beerman I, 2013, CELL STEM CELL, V12, P413, DOI 10.1016/j.stem.2013.01.017; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877; Bock C, 2012, MOL CELL, V47, P633, DOI 10.1016/j.molcel.2012.06.019; Boks MP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006767; Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157; Chase DS, 1998, J MED GENET, V35, P413, DOI 10.1136/jmg.35.5.413; Collerton Joanna, 2007, BMC Geriatr, V7, P14, DOI 10.1186/1471-2318-7-14; Collerton J, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4904; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Di Gioia S, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-89; Fahrner JA, 2002, CANCER RES, V62, P7213; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Ferguson S, 2011, PEDIATR BLOOD CANCER, V56, P349, DOI 10.1002/pbc.22679; Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008; Gemma C, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-5-r43; Herman JG, 1996, CANCER RES, V56, P722; Hughes LAE, 2013, CANCER RES, V73, P5858, DOI 10.1158/0008-5472.CAN-12-4306; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Jacinto FV, 2007, MUTAGENESIS, V22, P247, DOI 10.1093/mutage/gem009; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kanaya T, 2003, ONCOGENE, V22, P2352, DOI 10.1038/sj.onc.1206365; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Kuang SQ, 2010, BLOOD, V115, P2412, DOI 10.1182/blood-2009-05-222208; Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]; Kwabi-Addo B, 2007, CLIN CANCER RES, V13, P3796, DOI 10.1158/1078-0432.CCR-07-0085; Martin-Ruiz C, 2011, MECH AGEING DEV, V132, P496, DOI 10.1016/j.mad.2011.08.001; McKay JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033290; Pearce MS, 2009, INT J EPIDEMIOL, V38, P932, DOI 10.1093/ije/dyn184; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Potter C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076506; Rakyan VK, 2010, GENOME RES, V20, P434, DOI 10.1101/gr.103101.109; Raval A, 2005, J CLIN ONCOL, V23, P3877, DOI 10.1200/JCO.2005.02.196; Scholz C, 2005, ANN HEMATOL, V84, P236, DOI 10.1007/s00277-004-0969-1; Strathdee G, 2007, CARCINOGENESIS, V28, P299, DOI 10.1093/carcin/bgl133; Sullivan MJ, 1999, ONCOGENE, V18, P7527, DOI 10.1038/sj.onc.1203096; Tamura G, 2004, HISTOL HISTOPATHOL, V19, P221, DOI 10.14670/HH-19.221; Tapp HS, 2013, AGING CELL, V12, P148, DOI 10.1111/acel.12030; Teschendorff AE, 2013, HUM MOL GENET, V22, pR7, DOI 10.1093/hmg/ddt375; Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109; Thathia SH, 2012, HAEMATOL-HEMATOL J, V97, P371, DOI 10.3324/haematol.2011.049593; Tong Wei-Gang, 2010, Epigenetics, V5, P499; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Wikby A, 2008, BIOGERONTOLOGY, V9, P299, DOI 10.1007/s10522-008-9138-6; Yu CE, 2013, HUM MOL GENET, V22, P5036, DOI 10.1093/hmg/ddt354; Zhang DD, 2010, AM J HUM GENET, V86, P411, DOI 10.1016/j.ajhg.2010.02.005	51	23	23	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3261	3272		10.1096/fj.13-246173	http://dx.doi.org/10.1096/fj.13-246173			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24858281	Green Submitted			2022-12-28	WOS:000337949400045
J	Roberts, VHJ; Pound, LD; Thorn, SR; Gillingham, MB; Thornburg, KL; Friedman, JE; Frias, AE; Grove, KL				Roberts, Victoria H. J.; Pound, Lynley D.; Thorn, Stephanie R.; Gillingham, Melanie B.; Thornburg, Kent L.; Friedman, Jacob E.; Frias, Antonio E.; Grove, Kevin L.			Beneficial and cautionary outcomes of resveratrol supplementation in pregnant nonhuman primates	FASEB JOURNAL			English	Article						insulin resistance; pancreas; uterine blood flow; Western-style diet	ALCOHOLIC FATTY LIVER; BLOOD-FLOW; MODEL; MICE; DIET; RESTRICTION; METABOLISM; HUMANS; OBESITY; SHEEP	Resveratrol has been proposed as a potential therapeutic to improve metabolic health during pregnancy, yet little is known about the fetal effects of this maternal dietary supplement. We hypothesized that when administered to pregnant nonhuman primates (NHPs), resveratrol would increase uterine blood flow and mitigate the harmful consequences of maternal Western-style diet (WSD) consumption. NHPs were fed a WSD (36% fat) supplemented with 0.37% resveratrol throughout pregnancy. Outcomes were compared with cohorts fed WSD alone and control chow (14% fat) to distinguish between WSD and resveratrol-specific effects in these animals. In the early third trimester, uterine blood flow was measured by Doppler ultrasound before fetal delivery and tissue collection. Resveratrol resulted in 30% maternal weight loss and improved glucose tolerance, increased uterine artery volume blood flow, and decreased placental inflammation and liver triglyceride deposition. In addition, fetal pancreatic mass was enlarged by 42%, with a 12-fold increase in proliferation by Ki67 immunohistochemistry. These results demonstrate that resveratrol use during pregnancy yields improvements in maternal and placental phenotype with beneficial effects in the fetal liver but an unexplained and concerning alteration in fetal pancreatic development, which strongly cautions against the use of resveratrol by pregnant women.	[Roberts, Victoria H. J.; Pound, Lynley D.; Frias, Antonio E.; Grove, Kevin L.] Oregon Natl Primate Res Ctr, Div Diabet Obes & Metab, Beaverton, OR 97006 USA; [Grove, Kevin L.] Oregon Natl Primate Res Ctr, Div Reprod & Dev Sci, Beaverton, OR 97006 USA; [Thorn, Stephanie R.; Friedman, Jacob E.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA; [Friedman, Jacob E.] Univ Colorado Denver, Dept Reprod Sci, Aurora, CO USA; [Gillingham, Melanie B.] Oregon Hlth & Sci Univ, Dept Med & Mol Genet, Portland, OR 97201 USA; [Thornburg, Kent L.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA; [Frias, Antonio E.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon National Primate Research Center; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Grove, KL (corresponding author), Oregon Natl Primate Res Ctr, 505 NW 185th Ave, Beaverton, OR 97006 USA.	grovek@ohsu.edu		Wesolowski, Stephanie/0000-0001-7523-0394; Gillingham, Melanie/0000-0003-0897-8268	U.S. National Institutes of Health [R24-DK-090964, P51-OD-011092, K01-DK-090199, S10-RR-024585]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK090199, R01DK079194, R24DK090964] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P51OD011092] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Diana Takahashi, Karalee Baquero, Ashley Kostrba, India Tindale, Peter Blundell, Jessica Walker, and Tyler Dean (Oregon National Primate Research Center) for technical assistance and guidance with the animal studies; Dr. Dennis Koop (Pharmacokinetics Core, Oregon Health and Science University) for developing the resveratrol assay; Melissa Kirigiti for confocal images; Anda Cornea for microscopy assistance; Barbra Mason for histology; and Francis Pau and the Endocrine Technology Support Core Laboratory (Oregon Health and Science University) for performing hormone assay measurements. This work was supported by U.S. National Institutes of Health grants R24-DK-090964 (to K.L.G., K.L.T., and J.E.F.), P51-OD-011092 (partial salary support for K.L.G. and A.E.F. and Marianas imaging use), K01-DK-090199 (S.T.), and S10-RR-024585 (Leica confocal imaging).	Acharya G, 2007, ULTRASOUND OBST GYN, V29, P401, DOI 10.1002/uog.3977; Ajmo JM, 2008, AM J PHYSIOL-GASTR L, V295, pG833, DOI 10.1152/ajpgi.90358.2008; Armitage JA, 2005, J PHYSIOL-LONDON, V565, P3, DOI 10.1113/jphysiol.2004.079756; Arrick DM, 2011, AM J PHYSIOL-HEART C, V301, pH696, DOI 10.1152/ajpheart.00312.2011; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Bourque SL, 2012, PLACENTA, V33, P449, DOI 10.1016/j.placenta.2012.01.012; Carrizzo A, 2013, HYPERTENSION, V62, P359, DOI 10.1161/HYPERTENSIONAHA.111.01009; Catalano PM, 2006, BJOG-INT J OBSTET GY, V113, P1126, DOI 10.1111/j.1471-0528.2006.00989.x; Comstock SM, 2013, MOL METAB, V2, P10, DOI 10.1016/j.molmet.2012.11.001; Crandall JP, 2012, J GERONTOL A-BIOL, V67, P1307, DOI 10.1093/gerona/glr235; Frias AE, 2011, ENDOCRINOLOGY, V152, P2456, DOI 10.1210/en.2010-1332; Grant WF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017261; HALBAN PA, 1982, ENDOCRINOLOGY, V111, P86, DOI 10.1210/endo-111-1-86; Hauge-Evans AC, 1999, DIABETES, V48, P1402, DOI 10.2337/diabetes.48.7.1402; Henson MC, 2000, BIOL REPROD, V63, P1219, DOI 10.1095/biolreprod63.5.1219; Kennedy DO, 2010, AM J CLIN NUTR, V91, P1590, DOI 10.3945/ajcn.2009.28641; Kim SY, 2007, OBESITY, V15, P986, DOI 10.1038/oby.2007.621; Konje JC, 2001, AM J OBSTET GYNECOL, V185, P608, DOI 10.1067/mob.2001.117187; Lagerstedt SA, 2001, MOL GENET METAB, V73, P38, DOI 10.1006/mgme.2001.3170; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lam YY, 2013, EXP GERONTOL, V48, P1018, DOI 10.1016/j.exger.2013.04.005; McCurdy CE, 2009, J CLIN INVEST, V119, P323, DOI 10.1172/JCI32661; Naderali EK, 2000, CLIN SCI, V98, P537, DOI 10.1042/CS19990303; Ogden CL, 2010, JAMA-J AM MED ASSOC, V303, P242, DOI 10.1001/jama.2009.2012; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Poudel R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064401; Poulsen MM, 2013, DIABETES, V62, P1186, DOI 10.2337/db12-0975; Roberts VHJ, 2012, PLACENTA, V33, P73, DOI 10.1016/j.placenta.2011.10.003; Shiozaki M, 2011, HISTOCHEM CELL BIOL, V136, P475, DOI 10.1007/s00418-011-0847-6; Singh CK, 2013, EXP BIOL MED, V238, P482, DOI 10.1177/1535370212473704; Szkudelski T, 2011, ANN NY ACAD SCI, V1215, P34, DOI 10.1111/j.1749-6632.2010.05844.x; Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002; Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09-0482; Varlamov O, 2010, AM J PHYSIOL-ENDOC M, V299, pE486, DOI 10.1152/ajpendo.00330.2010; Vetterli L, 2011, J BIOL CHEM, V286, P6049, DOI 10.1074/jbc.M110.176842; Wallace JM, 2002, AM J PHYSIOL-REG I, V282, pR1027, DOI 10.1152/ajpregu.00465.2001; Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885; Williams LD, 2009, FOOD CHEM TOXICOL, V47, P2170, DOI 10.1016/j.fct.2009.06.002; Wong RHX, 2013, J HYPERTENS, V31, P1819, DOI 10.1097/HJH.0b013e328362b9d6; You M, 2008, J NUTR, V138, P497, DOI 10.1093/jn/138.3.497	41	82	83	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2466	2477		10.1096/fj.13-245472	http://dx.doi.org/10.1096/fj.13-245472			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24563374	Green Published			2022-12-28	WOS:000339883600008
J	Mauro, L; Pellegrino, M; Giordano, F; Ricchio, E; Rizza, P; De Amicis, F; Catalano, S; Bonofiglio, D; Panno, ML; Ando, S				Mauro, Loredana; Pellegrino, Michele; Giordano, Francesca; Ricchio, Emilia; Rizza, Pietro; De Amicis, Francesca; Catalano, Stefania; Bonofiglio, Daniela; Panno, Maria Luisa; Ando, Sebastiano			Estrogen receptor-alpha drives adiponectin effects on cyclin D1 expression in breast cancer cells	FASEB JOURNAL			English	Article						AMPK; MAPK; xenografts; Sp1; corepressors	IN-VIVO; GENE-TRANSCRIPTION; SIGNALING PATHWAY; TUMOR-GROWTH; LEPTIN; SP1; ACTIVATION; PROMOTER; PROTEIN; RISK	Obesity is a risk factor for breast cancer, largely due to altered expression of various adipocytokines. As it concerns adiponectin, there are not univocal results regarding its role in breast cancer occurrence and progression. Here, we demonstrate that in animals injected with human estrogen receptor (ER)-alpha-negative MDA-MB-231 cells pretreated with adiponectin (1 and 5 mu g/ml), a significant reduction (60 and 40%, respectively) in tumor volume is observed, whereas an increased tumor growth (54 and 109%, respectively) is evidenced in the animals receiving human ER-positive MCF-7 cells. Moreover, cyclin D1 (CD1) mRNA and protein levels are decreased in MDA-MB-231 cells, whereas they are up-regulated in ER-alpha-positive cells by adiponectin. These findings fit with the opposite effects of adiponectin on CD1 promoter: 0.44- and 0.34-fold decrease in MDA-MB-231 cells and 0.63- and 0.95-fold increase in MCF-7 cells, treated with 1 and 5 mu g/ml, respectively. Functional studies indicate that these effects are mediated by the specific protein 1 motif located in the CD1 promoter. In the absence of ER-alpha, the adiponectin-mediated down-regulation of CD1 involves the recruitment of corepressors. In the presence of ER-alpha, the adiponectin-induced expression of CD1 requires the involvement of an activator complex. In conclusion, we propose that a possible mechanism through which adiponectin differently affects breast cancer growth is the opposite modulation of CD1 levels accordingly to ER-alpha expression.	[Mauro, Loredana; Pellegrino, Michele; Giordano, Francesca; Ricchio, Emilia; Rizza, Pietro; De Amicis, Francesca; Catalano, Stefania; Bonofiglio, Daniela; Panno, Maria Luisa; Ando, Sebastiano] Univ Calabria, Dept Pharm Hlth & Nutr Sci, Arcavacata Di Rende, Italy; [De Amicis, Francesca; Catalano, Stefania; Bonofiglio, Daniela; Ando, Sebastiano] Univ Calabria, Ctr Sanitario, Arcavacata Di Rende, Italy	University of Calabria; University of Calabria	Mauro, L (corresponding author), Univ Calabria, Dept Pharm Hlth & Nutr Sci, Via P Buccicubo4C, I-87036 Arcavacata Di Rende, Italy.	doclollo@yahoo.com; sebastiano.ando@unical.it	Bonofiglio, Daniela/AAV-8371-2020	Pellegrino, Michele/0000-0002-4046-4243; De Amicis, Francesca/0000-0001-7079-1037; CATALANO, Stefania/0000-0002-6352-9628; BONOFIGLIO, Daniela/0000-0002-4142-0496; GIORDANO, Francesca/0000-0002-7621-1969; RIZZA, Pietro/0000-0002-1267-3910	Associazione Italiana Ricerca sul Cancro [AIRC] [6180, 11595]; Progetti di Ricerca di Interesse Nazionale-Ministero Istruzione Universita e Ricerca [20085Y7XT5]; European Commission/Fondo Sociale Europeo/Regione Calabria	Associazione Italiana Ricerca sul Cancro [AIRC](Fondazione AIRC per la ricerca sul cancro); Progetti di Ricerca di Interesse Nazionale-Ministero Istruzione Universita e Ricerca(Ministry of Education, Universities and Research (MIUR)); European Commission/Fondo Sociale Europeo/Regione Calabria	The authors thank Dr. Pasquale Cicirelli for his technical assistance. This work was supported by the Associazione Italiana Ricerca sul Cancro [AIRC; My First AIRC Grant (MFAG) 6180 and Investigator Grant 11595], Progetti di Ricerca di Interesse Nazionale-Ministero Istruzione Universita e Ricerca (Grant 20085Y7XT5), and European Commission/Fondo Sociale Europeo/Regione Calabria (to E.R.).	Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Barb D, 2007, AM J CLIN NUTR, V86, p858S, DOI 10.1093/ajcn/86.3.858S; Benasciutti E, 2004, BLOOD, V104, P256, DOI 10.1182/blood-2003-08-2661; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Catalano S, 2003, J BIOL CHEM, V278, P28668, DOI 10.1074/jbc.M301695200; Catalano S, 2009, J CELL PHYSIOL, V218, P490, DOI 10.1002/jcp.21622; Catalano S, 2011, AM J PATHOL, V179, P1030, DOI 10.1016/j.ajpath.2011.04.026; Chen XP, 2011, MED ONCOL, V28, P1288, DOI 10.1007/s12032-010-9617-x; Dal Maso L, 2004, J CLIN ENDOCR METAB, V89, P1160, DOI 10.1210/jc.2003-031716; Dalamaga M, 2012, ENDOCR REV, V33, P547, DOI 10.1210/er.2011-1015; De Amicis F, 2009, MOL ENDOCRINOL, V23, P454, DOI 10.1210/me.2008-0267; De Siervi A, 2004, CANCER RES, V64, P743, DOI 10.1158/0008-5472.CAN-03-2505; Deepa SS, 2011, MOL ENDOCRINOL, V25, P1773, DOI 10.1210/me.2011-0082; Deepa SS, 2009, AM J PHYSIOL-ENDOC M, V296, pE22, DOI 10.1152/ajpendo.90731.2008; Dieudonne MN, 2006, BIOCHEM BIOPH RES CO, V345, P271, DOI 10.1016/j.bbrc.2006.04.076; Dos Santos E, 2008, ONCOL REP, V20, P971, DOI 10.3892/or_00000098; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; GILLETT C, 1994, CANCER RES, V54, P1812; Goktas S, 2005, UROLOGY, V65, P1168, DOI 10.1016/j.urology.2004.12.053; Grossmann ME, 2008, BRIT J CANCER, V98, P370, DOI 10.1038/sj.bjc.6604166; Hwang SL, 2014, J ALLERGY CLIN IMMUN, V134, P714, DOI 10.1016/j.jaci.2014.05.001; Hwang SL, 2013, BRIT J PHARMACOL, V169, P69, DOI 10.1111/bph.12124; Ishikawa M, 2005, CLIN CANCER RES, V11, P466; Kang JH, 2005, ARCH PHARM RES, V28, P1263, DOI 10.1007/BF02978210; Korner A, 2007, J CLIN ENDOCR METAB, V92, P1041, DOI 10.1210/jc.2006-1858; Landskroner-Eiger S, 2009, CLIN CANCER RES, V15, P3265, DOI 10.1158/1078-0432.CCR-08-2649; Lee JA, 2005, J BIOL CHEM, V280, P28061, DOI 10.1074/jbc.M414134200; Mantzoros C, 2004, J CLIN ENDOCR METAB, V89, P1102, DOI 10.1210/jc.2003-031804; Mauro L, 2007, CANCER RES, V67, P3412, DOI 10.1158/0008-5472.CAN-06-2890; Mauro L, 2014, CELL CYCLE, V13, P553, DOI 10.4161/cc.27455; Mauro L, 2010, BREAST CANCER RES TR, V121, P79, DOI 10.1007/s10549-009-0456-4; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Miyoshi Y, 2003, CLIN CANCER RES, V9, P5699; Obeid Stephanie, 2012, Cancer Biology Medicine, V9, P213, DOI 10.7497/j.issn.2095-3941.2012.04.001; Patani N, 2013, INT J CANCER, V133, P1, DOI 10.1002/ijc.27997; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Urruticoechea A, 2005, J CLIN ONCOL, V23, P7212, DOI 10.1200/JCO.2005.07.501; Walsh CA, 2012, INT J BIOL SCI, V8, P470, DOI 10.7150/ijbs.4125; Wang Y, 2006, CANCER RES, V66, P11462, DOI 10.1158/0008-5472.CAN-06-1969; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Ziemke F, 2010, AM J CLIN NUTR, V91, p258S, DOI 10.3945/ajcn.2009.28449C	45	47	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2150	2160		10.1096/fj.14-262808	http://dx.doi.org/10.1096/fj.14-262808			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25657113				2022-12-28	WOS:000354114600045
J	Chichger, H; Duong, H; Braza, J; Harrington, EO				Chichger, Havovi; Huetran Duong; Braza, Julie; Harrington, Elizabeth O.			p18, a novel adaptor protein, regulates pulmonary endothelial barrier function via enhanced endocytic recycling of VE-cadherin	FASEB JOURNAL			English	Article						endosome; adherens junction; endocytosis; lung injury	ACUTE LUNG INJURY; CELL-CELL ADHESION; IN-VIVO; VASCULAR-PERMEABILITY; TYROSINE PHOSPHORYLATION; LEUKOCYTE EXTRAVASATION; DEPENDENT ENDOCYTOSIS; ADHERENS JUNCTIONS; CATENIN COMPLEX; BETA-CATENIN	Vascular permeability is a hallmark of several disease states including acute lung injury (ALI). Endocytosis of VE-cadherin, away from the interendothelial junction (IEJ), causes acute endothelial barrier permeability. A novel protein, p18, anchors to the endosome membrane and plays a role in late endosomal signaling via MAPK and mammalian target of rapamycin. However, the fate of the VE-cadherin-positive endosome has yet to be elucidated. We sought to elucidate a role for p18 in VE-cadherin trafficking and thus endothelial barrier function, in settings of ALI. Endothelial cell (EC) resistance, whole-cell ELISA, and filtration coefficient were studied in mice or lung ECs overexpressing wild-type or nonendosomal-binding mutant p18, using green fluorescent protein as a control. We demonstrate a protective role for the endocytic protein p18 in endothelial barrier function in settings of ALI in vitro and in vivo, through enhanced recycling of VE-cadherin-positive early endosomes to the IEJ. In settings of LPS-induced ALI, we show that Src tethered to the endosome tyrosine phosphorylates p18 concomitantly with VE-cadherin internalization and pulmonary edema formation. We conclude that p18 regulates pulmonary endothelial barrier function in vitro and in vivo, by enhancing recycling of VE-cadherin-positive endosomes to the IEJ.	Providence Vet Affairs Med Ctr, Vasc Res Lab, Providence, RI USA; Brown Univ, Alpert Med Sch, Dept Med, Providence, RI 02912 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center; Brown University	Chichger, H (corresponding author), Providence VA Med Ctr, 830 Chalkstone Ave, Providence, RI 02908 USA.	havovi_chichger@brown.edu	Chichger, Havovi/Y-7117-2019; Chichger, Havovi/M-5129-2015	Chichger, Havovi/0000-0002-8549-7583; Chichger, Havovi/0000-0002-8549-7583; Harrington, Elizabeth/0000-0002-3207-5301	U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute Grant [R01 HL-67795]; American Heart Association Grant [10GRNT4160055, 13POST16860031]; COBRE NIH National Institute of General Medical Sciences Award [5P20 GM103652]; University Medicine Foundation of Rhode Island Hospital; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103652] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute Grant; American Heart Association Grant(American Heart Association); COBRE NIH National Institute of General Medical Sciences Award; University Medicine Foundation of Rhode Island Hospital; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This material is the result of work supported with resources and the use of facilities at the Providence Veterans Affairs Medical Center. The work was supported by the U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute Grant R01 HL-67795, American Heart Association Grant 10GRNT4160055, COBRE NIH National Institute of General Medical Sciences Award 5P20 GM103652, and University Medicine Foundation of Rhode Island Hospital (to E.O.H.). H.C. was supported by American Heart Association Grant 13POST16860031. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.	Adam AP, 2010, J BIOL CHEM, V285, P7045, DOI 10.1074/jbc.M109.079277; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Broermann A, 2011, J EXP MED, V208, P2393, DOI 10.1084/jem.20110525; Buttenschoen K, 2008, LANGENBECK ARCH SURG, V393, P473, DOI 10.1007/s00423-008-0317-3; Chiasson CM, 2009, MOL BIOL CELL, V20, P1970, DOI 10.1091/mbc.E08-07-0735; Chichger H, 2012, AM J PHYSIOL-LUNG C, V303, pL880, DOI 10.1152/ajplung.00169.2012; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; de Leeuw HPJC, 1998, BRIT J HAEMATOL, V103, P15, DOI 10.1046/j.1365-2141.1998.00965.x; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Durrbach A, 1996, J CELL SCI, V109, P457; Gao XP, 2000, AM J PHYSIOL-LUNG C, V279, pL1218, DOI 10.1152/ajplung.2000.279.6.L1218; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gotsch U, 1997, J CELL SCI, V110, P583; Grinnell KL, 2010, AM J PHYSIOL-LUNG C, V298, pL361, DOI 10.1152/ajplung.00374.2009; Grinnell KL, 2012, AM J RESP CELL MOL, V46, P623, DOI 10.1165/rcmb.2011-0271OC; Guillaumot P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010977; Hatanaka K, 2011, AM J PHYSIOL-HEART C, V300, pH162, DOI 10.1152/ajpheart.00650.2010; Hoshino D, 2011, J BIOL CHEM, V286, P3139, DOI 10.1074/jbc.M110.159715; Hoshino D, 2009, J BIOL CHEM, V284, P27315, DOI 10.1074/jbc.M109.041400; Knezevic N, 2009, J EXP MED, V206, P2761, DOI 10.1084/jem.20090652; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Li HH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081903; Luttrell LM, 2013, PROG MOL BIOL TRANSL, V118, P115, DOI 10.1016/B978-0-12-394440-5.00005-X; Maniatis Nikolaos A, 2012, Pulm Circ, V2, P452, DOI 10.4103/2045-8932.105033; Nada S, 2009, EMBO J, V28, P477, DOI 10.1038/emboj.2008.308; Nanes BA, 2012, J CELL BIOL, V199, P365, DOI 10.1083/jcb.201205029; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Oas RG, 2013, MOL BIOL CELL, V24, P704, DOI 10.1091/mbc.E12-06-0471; Oyaizu T, 2012, INTENS CARE MED, V38, P894, DOI 10.1007/s00134-012-2498-z; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; Schulte D, 2011, EMBO J, V30, P4157, DOI 10.1038/emboj.2011.304; Severgnini M, 2004, AM J PHYSIOL-LUNG C, V286, pL1282, DOI 10.1152/ajplung.00349.2003; Soma-Nagae T, 2013, J CELL SCI, V126, P3575, DOI 10.1242/jcs.121913; Stasyk T, 2010, PROTEOMICS, V10, P4117, DOI 10.1002/pmic.201000258; Stevens TC, 2014, AM J PHYSIOL-LUNG C, V306, pL915, DOI 10.1152/ajplung.00135.2013; Sun Y, 2009, CIRC RES, V105, P676, DOI 10.1161/CIRCRESAHA.109.201673; Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752; Takahashi Y, 2012, BIOCHEM BIOPH RES CO, V417, P1151, DOI 10.1016/j.bbrc.2011.12.082; UHLIG S, 1994, J PHARMACOL TOXICOL, V31, P85, DOI 10.1016/1056-8719(94)90047-7; Vestweber D, 2009, TRENDS CELL BIOL, V19, P8, DOI 10.1016/j.tcb.2008.10.001; Wang Y, 2013, MOL BIOL REP, V40, P3093, DOI 10.1007/s11033-012-2383-4; Xiao KY, 2005, MOL BIOL CELL, V16, P5141, DOI 10.1091/mbc.E05-05-0440; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200; Zhou MY, 1998, J CLIN INVEST, V101, P2427, DOI 10.1172/JCI407	51	24	24	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					868	881		10.1096/fj.14-257212	http://dx.doi.org/10.1096/fj.14-257212			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25404710	Green Published			2022-12-28	WOS:000350633000014
J	Alcarraz-Vizan, G; Casini, P; Cadavez, L; Visa, M; Montane, J; Servitja, JM; Novials, A				Alcarraz-Vizan, Gema; Casini, Paola; Cadavez, Lisa; Visa, Montse; Montane, Joel; Servitja, Joan-Marc; Novials, Anna			Inhibition of BACE2 counteracts hIAPP-induced insulin secretory defects in pancreatic beta-cells	FASEB JOURNAL			English	Article						amylin; BACE activity; secretase; type 2 diabetes	ISLET-AMYLOID-POLYPEPTIDE; ENDOPLASMIC-RETICULUM STRESS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; HUMAN-IAPP; DIABETES-MELLITUS; PATHWAY; PATHOGENESIS; BRAIN; OLIGOMERS	BACE2 (beta-site APP-cleaving enzyme 2) is a protease localized in the brain, where it appears to play a role in the development of Alzheimer disease (AD). It is also found in the pancreas, although its biologic function is not fully known. Amyloidogenic diseases, including AD and type 2 diabetes mellitus (T2D), share the accumulation of abnormally folded and insoluble proteins that interfere with cell function. Islet amyloid polypeptide (IAPP) deposits are a key pathogenic feature of T2D. Within this context, we found by global gene expression profiling that BACE2 was up-regulated in the rat pancreatic beta-cell line INS1E stably transfected with human IAPP gene (hIAPP-INS1E). Glucose-stimulated insulin secretion (GSIS) in hIAPP-INS1E cells was 30% lower than in INS1E cells. Additionally, INS1E cells transfected with a transient overexpression of BACE2 showed a 60% decrease in proliferation, a 3-fold increase in reactive oxygen species production, and a 25% reduction in GSIS compared to control cells. Remarkably, silencing of endogenous BACE2 in hIAPP-INS1E cells resulted in a significant improvement in GSIS (3-fold increase vs. untransfected cells), revealing the significant role of BACE2 expression in beta-cell function. Thus, BACE2 inhibition may be useful to recover insulin secretion in hIAPP-INS1E defective cells and may be proposed as a therapeutic target for T2D.	[Alcarraz-Vizan, Gema; Casini, Paola; Cadavez, Lisa; Visa, Montse; Montane, Joel; Servitja, Joan-Marc; Novials, Anna] Spanish Biomed Res Ctr Diabet & Associated Metab, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Diabet & Obes Res Lab, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Novials, A (corresponding author), IDIBAPS, Diabet & Obes Res Lab, C Rossello 149-153,5th Floor, Barcelona 08036, Spain.	anovials@clinic.ub.es	Visa, Montse/AAQ-8529-2021; Montane, Joel/ABE-6021-2021	Montane, Joel/0000-0001-9531-9580; SERVITJA, JOAN-MARC/0000-0002-1241-8004; Alcarraz-Vizan, Gema/0000-0002-2429-0597; Novials, Anna/0000-0003-0465-2949				Abdul-Hay SO, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-46; Akpinar P, 2005, CELL METAB, V2, P385, DOI 10.1016/j.cmet.2005.11.001; Altirriba J, 2010, DIABETOLOGIA, V53, P1406, DOI 10.1007/s00125-010-1728-6; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Casas S, 2008, DIABETOLOGIA, V51, P2252, DOI 10.1007/s00125-008-1111-z; Casas S, 2007, DIABETES, V56, P2284, DOI 10.2337/db07-0178; Casas S, 2010, AM J PHYSIOL-ENDOC M, V299, pE1087, DOI 10.1152/ajpendo.00420.2010; Cho YS, 2012, NAT GENET, V44, P67, DOI 10.1038/ng.1019; Clark A, 1996, BIOCHEM SOC T, V24, P594, DOI 10.1042/bst0240594; Esterhazy D, 2011, CELL METAB, V14, P365, DOI 10.1016/j.cmet.2011.06.018; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Gilbert EJ, 2013, EXPERT OPIN THER PAT, V23, P1069, DOI 10.1517/13543776.2013.818134; Gurlo T, 2010, AM J PATHOL, V176, P861, DOI 10.2353/ajpath.2010.090532; Haataja L, 2008, ENDOCR REV, V29, P303, DOI 10.1210/er.2007-0037; Holler CJ, 2012, AM J PATHOL, V180, P337, DOI 10.1016/j.ajpath.2011.09.034; Hull RL, 2009, DIABETOLOGIA, V52, P1102, DOI 10.1007/s00125-009-1329-4; Hull RL, 2004, J CLIN ENDOCR METAB, V89, P3629, DOI 10.1210/jc.2004-0405; Jonsson A, 2009, DIABETES, V58, P2409, DOI 10.2337/db09-0246; KAHN SE, 1990, DIABETES, V39, P634, DOI 10.2337/diabetes.39.5.634; Lahiri DK, 2006, J MOL NEUROSCI, V29, P65, DOI 10.1385/JMN:29:1:65; Liu X, 2013, EUR J NEUROSCI, V37, P1970, DOI 10.1111/ejn.12204; Lu A, 2009, J CELL BIOL, V184, P863, DOI 10.1083/jcb.200807186; Lu JX, 2013, CELL, V154, P1257, DOI 10.1016/j.cell.2013.08.035; Meier JJ, 2006, AM J PHYSIOL-ENDOC M, V291, pE1317, DOI 10.1152/ajpendo.00082.2006; Moreno-Asso A, 2013, DIABETOLOGIA, V56, P1761, DOI 10.1007/s00125-013-2930-0; NOVIALS A, 1993, DIABETES, V42, P1514, DOI 10.2337/diabetes.42.10.1514; Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103; Rivera JF, 2011, CELL DEATH DIFFER, V18, P415, DOI 10.1038/cdd.2010.111; Saunders A.J, 1999, SCIENCE, V286, P1255, DOI DOI 10.1126/SCIENCE.286.5443.1255A; Servitja JM, 2009, MOL CELL BIOL, V29, P2945, DOI 10.1128/MCB.01389-08; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Soty M, 2011, J BIOL CHEM, V286, P40857, DOI 10.1074/jbc.M111.232801; Southan Christopher, 2013, Frontiers in Genetics, V4, P293, DOI 10.3389/fgene.2013.00293; Southan C, 2013, EXPERT OPIN THER PAT, V23, P649, DOI 10.1517/13543776.2013.780032; Stutzer I, 2012, DIABETOLOGIA, V55, P1877, DOI 10.1007/s00125-012-2531-3; Stutzer I, 2013, J BIOL CHEM, V288, P10536, DOI 10.1074/jbc.M112.444703; Sun XL, 2006, FASEB J, V20, P1369, DOI 10.1096/FJ.05-5632COM; Sun XL, 2012, J NEUROCHEM, V120, P62, DOI 10.1111/j.1471-4159.2011.07515.x; Sun XL, 2005, FASEB J, V19, P739, DOI 10.1096/fj.04-3426com; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2014, J NEUROCHEM, V130, P4, DOI 10.1111/jnc.12715; Westermark Per, 2005, Curr Diab Rep, V5, P184, DOI 10.1007/s11892-005-0007-2; Westermark P, 2011, PHYSIOL REV, V91, P795, DOI 10.1152/physrev.00042.2009; Yamagata K, 2011, BIOCHEM BIOPH RES CO, V407, P620, DOI 10.1016/j.bbrc.2011.03.083; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang Y, 2013, NEUROSCIENCE, V250, P140, DOI 10.1016/j.neuroscience.2013.07.009; Yankner BA, 2009, J BIOL CHEM, V284, P4754, DOI 10.1074/jbc.R800018200	48	14	14	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					95	104		10.1096/fj.14-255489	http://dx.doi.org/10.1096/fj.14-255489			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25342134				2022-12-28	WOS:000347378600010
J	Jove, M; Naudi, A; Portero-Otin, M; Cabre, R; Rovira-Llopis, S; Banuls, C; Rocha, M; Hernandez-Mijares, A; Victor, VM; Pamplona, R				Jove, Mariona; Naudi, Alba; Portero-Otin, Manuel; Cabre, Rosanna; Rovira-Llopis, Susana; Banuls, Celia; Rocha, Milagros; Hernandez-Mijares, Antonio; Victor, Victor M.; Pamplona, Reinald			Plasma lipidomics discloses metabolic syndrome with a specific HDL phenotype	FASEB JOURNAL			English	Article						lipid peroxidation; lipids species; lipoprotein metabolism; mass spectrometry; peroxidizability index	CARDIOVASCULAR-DISEASE; CHOLESTEROL ABSORPTION; SCIENTIFIC STATEMENT; MASS-SPECTROMETRY; BLOOD-PLASMA; LONGEVITY; MEMBRANE; REVEALS; PROFILE; RISK	Lipidomics reveals a remarkable diversity of lipids in human plasma. In this study, we have performed an in-depth lipidomic analysis of human plasma from healthy individuals and subjects with metabolic syndrome (MetS) in order to determine the lipidomic profile that allows prognosis of a pathological subpopulation with altered high-density lipoprotein (HDL) metabolism. The MetS population was categorized as having pathological or nonpathological HDL. Anthropometric parameters, cardiovascular risk markers, and lipoprotein subclasses of HDL and low-density lipoproteins were also evaluated. Lipidomic analysis revealed 357 differential molecules that were clustered (k means) in the two groups. The molecules identified in the whole lipidome showed that MetS subjects presented lower levels of glycerolipids and higher levels of glycerophospholipids with respect to control subjects. In contrast, when only statistically differential lipids were taken into account, differences were found between the two groups in almost cases. Furthermore, levels of saturated fatty acids were higher in patients with pathological HDL levels than in controls, whereas levels of unsaturated fatty acids were lower. These results highlight the potential of lipidomics as a clinical tool for risk assessment and monitoring of disease.	[Jove, Mariona; Naudi, Alba; Portero-Otin, Manuel; Cabre, Rosanna; Pamplona, Reinald] Univ Lleida, Biomed Res Inst Lleida, Dept Expt Med, Lleida, Spain; [Rovira-Llopis, Susana; Banuls, Celia; Rocha, Milagros; Hernandez-Mijares, Antonio; Victor, Victor M.] Fdn Promot Healthcare & Biomed Res Valencian Comm, Serv Endocrinol, Valencia, Spain; [Rovira-Llopis, Susana; Banuls, Celia; Rocha, Milagros; Hernandez-Mijares, Antonio; Victor, Victor M.] Univ Valencia INCLIVA, Hosp Clin, Fdn Invest, Valencia, Spain; [Hernandez-Mijares, Antonio] Univ Valencia, Dept Med, Valencia, Spain; [Victor, Victor M.] Univ Valencia, Dept Physiol, Valencia, Spain	Universitat de Lleida; University of Valencia; University of Valencia	Victor, VM (corresponding author), Univ Valencia, Hosp Univ Doctor Peset, FISABIO, Avda Gaspar Aguilar 90, Valencia 46017, Spain.	victor.victor@uv.es; reinald.pamplona@mex.udl.cat	victor, victor/Q-4843-2019; Rocha, Milagros/ABE-4931-2020; Pamplona, Reinald/A-7359-2010; BaÃuls, Celia/H-7359-2017; Naudí, Alba/B-5594-2009; Mijares, Antonio Hernandez/D-3411-2011; VICTOR, VICTOR M/I-3270-2015; Portero-Otin, Manuel/B-7122-2009; Jové, Mariona/M-9104-2016; Rocha, Milagros/I-4987-2015; Cerviño, Alejandro/L-5853-2014; Rovira-Llopis, Susana/AAX-8666-2021; Hernandez Mijares, Antonio/D-3411-2011	Rocha, Milagros/0000-0003-2923-6546; Pamplona, Reinald/0000-0003-4337-6107; BaÃuls, Celia/0000-0001-8077-7642; Naudí, Alba/0000-0003-0699-1004; Mijares, Antonio Hernandez/0000-0003-2197-0607; Portero-Otin, Manuel/0000-0002-1823-0299; Jové, Mariona/0000-0001-5577-6162; Rocha, Milagros/0000-0003-2923-6546; Cerviño, Alejandro/0000-0001-8014-3279; Rovira-Llopis, Susana/0000-0002-8476-5128; Hernandez Mijares, Antonio/0000-0003-4099-1905; VICTOR, VICTOR/0000-0002-3027-3945	Fund for Health Research (FIS); European Regional Development Fund of the European Union (FEDER); Spanish Ministry of Health [PI11-01532]; Spanish Ministry of Science and Innovation [BFU2009-11879/BFI]; Spanish Ministry of Economy and Competitiveness [PI13/00584]; Generalitat of Catalonia [2014SGR]; Generalitat of Catalonia Predoctoral Fellowship; Ministry of Health of the Valencian Regional Government [CES10/030]; Carlos III Health Institute [CP10/0360, FI11/00637]; CIBERehd [CB06/04/0071]; PROMETEO [2010/060, PI12/01984, PI13/0073, PI13/1025]	Fund for Health Research (FIS); European Regional Development Fund of the European Union (FEDER); Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Ministry of Economy and Competitiveness(Spanish Government); Generalitat of Catalonia; Generalitat of Catalonia Predoctoral Fellowship; Ministry of Health of the Valencian Regional Government; Carlos III Health Institute(Instituto de Salud Carlos III); CIBERehd; PROMETEO	The authors acknowledge funding from the Fund for Health Research (FIS) and cofunding from the European Regional Development Fund of the European Union (FEDER), CIBERehd CB06/04/0071, PROMETEO 2010/060, PI12/01984, PI13/0073, and PI13/1025 (A.H.M, M.R., and V.M.V, respectively); from the Spanish Ministry of Health (PI11-01532, M.P.O.); the Spanish Ministry of Science and Innovation (BFU2009-11879/BFI); the Spanish Ministry of Economy and Competitiveness (PI13/00584); and the Generalitat of Catalonia (2014SGR). R.P.R.C. was funded by a Generalitat of Catalonia Predoctoral Fellowship. V.M.V. and M.R. are recipients of contracts from the Ministry of Health of the Valencian Regional Government and Carlos III Health Institute (CES10/030 and CP10/0360, respectively). S.R. is the recipient of a predoctoral fellowship from Carlos III Health Institute (FI11/00637). V.M.V. and R.P. designed the experiments; M.J., M.R., V.M.V., A.H.M., and R.P. analyzed the data; M.J., A.N., M.P.O., R.C., C.B., and S.R-L. performed the experiments; R.P. supervised the design and data interpretation; M.J., V.M.V., and R.P. wrote the manuscript, R.P. edited the manuscript. All authors discussed the results and commented on the manuscript. The authors declare no conflicts of interest.	Agency for Toxic Substances and Disease Registry, 1997, TOX PROF CHLOR; Ascaso J, 2007, AM J CARDIOVASC DRUG, V7, P39, DOI 10.2165/00129784-200707010-00004; Barzilai N, 2003, JAMA-J AM MED ASSOC, V290, P2030, DOI 10.1001/jama.290.15.2030; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boullart ACI, 2012, BBA-MOL CELL BIOL L, V1821, P867, DOI 10.1016/j.bbalip.2011.10.002; Caprari P, 1999, EXP GERONTOL, V34, P47, DOI 10.1016/S0531-5565(98)00055-2; Caro P, 2009, REJUV RES, V12, P421, DOI 10.1089/rej.2009.0902; Fahy E, 2007, NUCLEIC ACIDS RES, V35, pW606, DOI 10.1093/nar/gkm324; Fahy E, 2009, J LIPID RES, V50, pS9, DOI 10.1194/jlr.R800095-JLR200; Gonzalez-Covarrubias V, 2013, BIOGERONTOLOGY, V14, P663, DOI 10.1007/s10522-013-9450-7; Gonzalez-Covarrubias V, 2013, AGING CELL, V12, P426, DOI 10.1111/acel.12064; Graessler J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006261; Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404; Gylling H, 2007, TRANSL RES, V149, P310, DOI 10.1016/j.trsl.2006.11.012; Han XL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021643; Heijmans BT, 2006, PLOS MED, V3, P2317, DOI 10.1371/journal.pmed.0030495; Hernandez-Mijares A, 2011, CLIN NUTR, V30, P604, DOI 10.1016/j.clnu.2011.03.005; Hoefner DM, 2001, CLIN CHEM, V47, P266; Jove M, 2014, FASEB J, V28, P1071, DOI 10.1096/fj.13-234419; Jove M, 2013, SCI REP-UK, V3, DOI 10.1038/srep03346; Kind T, 2013, NAT METHODS, V10, P755, DOI 10.1038/nmeth.2551; Kulkarni H, 2013, HYPERTENSION, V62, P621, DOI 10.1161/HYPERTENSIONAHA.113.01396; Laaksonen R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000097; Miller M, 2011, CIRCULATION, V123, P2292, DOI 10.1161/CIR.0b013e3182160726; Montoliu I, 2014, AGING-US, V6, P9, DOI 10.18632/aging.100630; Naudi A, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00372; Nelson J, 2006, AM J EPIDEMIOL, V163, P903, DOI 10.1093/aje/kwj140; Ng TW, 2012, CLIN LIPIDOL, V7, P641, DOI 10.2217/CLP.12.75; Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737; Pamplona R, 2002, ANN NY ACAD SCI, V959, P475, DOI 10.1111/j.1749-6632.2002.tb02118.x; Pamplona R, 2008, BBA-BIOENERGETICS, V1777, P1249, DOI 10.1016/j.bbabio.2008.07.003; Pietilainen KH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000218; Puca AA, 2008, REJUV RES, V11, P63, DOI 10.1089/rej.2007.0566; Quehenberger O, 2011, NEW ENGL J MED, V365, P1812, DOI 10.1056/NEJMra1104901; Quehenberger O, 2010, J LIPID RES, V51, P3299, DOI 10.1194/jlr.M009449; Rhee EP, 2011, J CLIN INVEST, V121, P1402, DOI 10.1172/JCI44442; Sandra K, 2010, J CHROMATOGR A, V1217, P4087, DOI 10.1016/j.chroma.2010.02.039; Simonen P, 2000, AM J CLIN NUTR, V72, P82; Suhre K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013953; Sysi-Aho M, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002257; Trygg J, 2007, J PROTEOME RES, V6, P469, DOI 10.1021/pr060594q; Wang TJ, 2011, NAT MED, V17, P448, DOI 10.1038/nm.2307; Yang J, 2004, J CHROMATOGR B, V813, P53, DOI 10.1016/j.jchromb.2004.09.023; Yeboah J, 2010, ARTERIOSCL THROM VAS, V30, P628, DOI 10.1161/ATVBAHA.109.199281; Zheng W, 2006, BBA-BIOMEMBRANES, V1758, P1864, DOI 10.1016/j.bbamem.2006.08.009	45	36	38	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5163	5171		10.1096/fj.14-253187	http://dx.doi.org/10.1096/fj.14-253187			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25169057				2022-12-28	WOS:000345894500012
J	Neznansky, A; Blus-Kadosh, I; Yerushalmi, G; Banin, E; Opatowsky, Y				Neznansky, Avi; Blus-Kadosh, Inna; Yerushalmi, Gal; Banin, Ehud; Opatowsky, Yarden			The Pseudomonas aeruginosa phosphate transport protein PstS plays a phosphate-independent role in biofilm formation	FASEB JOURNAL			English	Article						substrate binding protein; swarming; N ' loop	DI-GMP LEVELS; BINDING PROTEIN; LIGAND-BINDING; GENE; IDENTIFICATION; REPLACEMENT; SPECIFICITY; EXPRESSION; STARVATION; RECEPTOR	Pseudomonas aeruginosa (PA) is a primary cause of nosocomial infections. A key element in PA pathogenicity is its ability to form biofilms that withstand eradication by antibiotics and the immune system. Biofilm formation is controlled by phosphate signaling and here we provide evidence that PstS, a subunit of the PA Pst phosphate transporter, has a surprising role in this process. Using X-ray crystallography, we characterized the unique underpinnings of PstS phosphate binding and identified an unusual 15-residue N' loop extension. Structure-based experiments showed that PstS-mediated phosphate uptake and biofilm formation are in fact two distinct functions. Specifically, a point mutation that abrogated phosphate binding did not eliminate biofilm formation; conversely, truncation of the N' loop diminished the ability of PA to form biofilms but had no effect on phosphate binding and uptake. This places PstS at a junction that separately controls phosphate sensing and uptake and the ultrastructure organization of bacteria.	[Neznansky, Avi; Blus-Kadosh, Inna; Yerushalmi, Gal; Banin, Ehud; Opatowsky, Yarden] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-5290002 Ramat Gan, Israel; [Blus-Kadosh, Inna; Yerushalmi, Gal; Banin, Ehud] Bar Ilan Univ, Adv Mat & Nanotechnol Inst, IL-5290002 Ramat Gan, Israel	Bar Ilan University; Bar Ilan University	Opatowsky, Y (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-5290002 Ramat Gan, Israel.	ehud.banin@biu.ac.il; yarden.opatowsky@biu.ac.il			Marie Curie International Reintegration grant [PIRG06-GA-2009-256222]; Israel Science Foundation [182/10, 1124/12]; German-Israeli Foundation [2265/2010]; National Institute for Psychobiology [223-11-12]	Marie Curie International Reintegration grant(European Commission); Israel Science Foundation(Israel Science Foundation); German-Israeli Foundation(German-Israeli Foundation for Scientific Research and Development); National Institute for Psychobiology	The authors thank Yoav Pass for help in P<SUP>32</SUP> binding experiments; the beamline scientists of beamlines BM14, ID14, ID23, and ID29 of the European Synchrotron Radiation Facility (Grenoble, France), and the staff of Berliner Elektronenspeicherring-Gesellschaft fur Synchrotronstrahlung (BESSY) II beamline BL14.1 (Belin, Germany). This work was partially supported by funds from a Marie Curie International Reintegration grant (PIRG06-GA-2009-256222, to Y.O.), the Israel Science Foundation (grants 182/10, to Y.O., and 1124/12, to E.B.), the German-Israeli Foundation (grant 2265/2010, to Y.O.), and the National Institute for Psychobiology (grant 223-11-12, to Y.O.).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; Bains M., APPL ENV MICROBIOL, V78, P6762; Bastonero S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005357; Berntsson RPA, 2010, FEBS LETT, V584, P2606, DOI 10.1016/j.febslet.2010.04.043; Blus-Kadosh I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074444; Borlee BR, 2010, MOL MICROBIOL, V75, P827, DOI 10.1111/j.1365-2958.2009.06991.x; Choi KH, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-30; Diaz M, 2005, MICROBIOL-SGM, V151, P2583, DOI 10.1099/mic.0.27983-0; Duque E., ENV MICROBIOL, V15, P36; ESPITIA C, 1989, CLIN EXP IMMUNOL, V77, P378; Esteban A, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-201; Fischer RJ, 2006, J BACTERIOL, V188, P5469, DOI 10.1128/JB.00491-06; Garnett JA, 2012, CURR PROTEIN PEPT SC, V13, P739; GERDES RG, 1977, J BACTERIOL, V131, P512, DOI 10.1128/JB.131.2.512-518.1977; Hollenstein K, 2007, NATURE, V446, P213, DOI 10.1038/nature05626; HOLLOWAY BW, 1979, MICROBIOL REV, V43, P73, DOI 10.1128/MMBR.43.1.73-102.1979; HOU CI, 1966, J BACTERIOL, V92, P851, DOI 10.1128/JB.92.4.851-855.1966; Joosten R. P. J. K., 2012, ACTA CRYSTALLOGR D, V68, P13; Krug M, 2012, J APPL CRYSTALLOGR, V45, P568, DOI 10.1107/S0021889812011715; Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u; Lewenza S, 2005, GENOME RES, V15, P583, DOI 10.1101/gr.3513905; Long F, 2008, ACTA CRYSTALLOGR D, V64, P125, DOI 10.1107/S0907444907050172; Madhusudhan KT, 2003, J BASIC MICROB, V43, P36, DOI 10.1002/jobm.200390002; Monds RD, 2001, MOL MICROBIOL, V42, P415, DOI 10.1046/j.1365-2958.2001.02641.x; Monds RD, 2007, MOL MICROBIOL, V63, P656, DOI 10.1111/j.1365-2958.2006.05539.x; Mudrak B, 2012, INFECT IMMUN, V80, P1794, DOI 10.1128/IAI.06277-11; Mueller Lukas N., 2006, BMC Ecology, V6, P1, DOI 10.1186/1472-6785-6-1; Neznansky A, 2014, ACTA CRYSTALLOGR F, V70, P906, DOI 10.1107/S2053230X14010279; Nielsen MW, 2011, JOVE-J VIS EXP, DOI 10.3791/2383; Nikata T, 1996, MOL GEN GENET, V250, P692, DOI 10.1007/s004380050122; O'May GA, 2009, MICROBIOL-SGM, V155, P1523, DOI 10.1099/mic.0.026500-0; Paas Y, 1998, TRENDS NEUROSCI, V21, P117, DOI 10.1016/S0166-2236(97)01184-3; Romero D, 2010, P NATL ACAD SCI USA, V107, P2230, DOI 10.1073/pnas.0910560107; Rybtke MT, 2012, APPL ENVIRON MICROB, V78, P5060, DOI 10.1128/AEM.00414-12; SCHWEIZER HP, 1995, GENE, V158, P15, DOI 10.1016/0378-1119(95)00055-B; SCHWEIZER HP, 1991, GENE, V97, P109, DOI 10.1016/0378-1119(91)90016-5; Shah M, 2014, FEMS MICROBIOL LETT, V352, P54, DOI 10.1111/1574-6968.12368; van Veen HW, 1997, ANTON LEEUW INT J G, V72, P299, DOI 10.1023/A:1000530927928; Vyas NK, 2003, STRUCTURE, V11, P765, DOI 10.1016/S0969-2126(03)00109-6; WANG ZM, 1994, J BIOL CHEM, V269, P25091; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; YOUNG DB, 1991, RES MICROBIOL, V142, P55, DOI 10.1016/0923-2508(91)90097-T; Zaborina O, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040043	44	15	18	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5223	5233		10.1096/fj.14-258293	http://dx.doi.org/10.1096/fj.14-258293			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25223609				2022-12-28	WOS:000345894500017
J	Quilter, CR; Cooper, WN; Cliffe, KM; Skinner, BM; Prentice, PM; Nelson, L; Bauer, J; Ong, KK; Constancia, M; Lowe, WL; Affara, NA; Dunger, DB				Quilter, Claire R.; Cooper, Wendy N.; Cliffe, Kerry M.; Skinner, Benjamin M.; Prentice, Philippa M.; Nelson, LaTasha; Bauer, Julien; Ong, Ken K.; Constancia, Miguel; Lowe, William L.; Affara, Nabeel A.; Dunger, David B.			Impact on offspring methylation patterns of maternal gestational diabetes mellitus and intrauterine growth restraint suggest common genes and pathways linked to subsequent type 2 diabetes risk	FASEB JOURNAL			English	Article						fetal programming; epigenetics; maternal environment	GENOME-WIDE ASSOCIATION; MICRONUTRIENT SUPPLEMENTATION; POSTNATAL-GROWTH; INSULIN; PREGNANCY; GLUCOSE; OBESITY; FETAL; BIRTH; LOCI	Size at birth, postnatal weight gain, and adult risk for type 2 diabetes may reflect environmental exposures during developmental plasticity and may be mediated by epigenetics. Both low birth weight (BW), as a marker of fetal growth restraint, and high birth weight (BW), especially after gestational diabetes mellitus (GDM), have been linked to increased risk of adult type 2 diabetes. We assessed DNA methylation patterns using a bead chip in cord blood samples from infants of mothers with GDM (group 1) and infants with prenatal growth restraint indicated by rapid postnatal catch-up growth (group 2), compared with infants with normal postnatal growth (group 3). Seventy-five CpG loci were differentially methylated in groups 1 and 2 compared with the controls (group 3), representing 72 genes, many relevant to growth and diabetes. In replication studies using similar methodology, many of these differentially methylated regions were associated with levels of maternal glucose exposure below that defined by GDM [the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study] or were identified as changes observed after randomized periconceptional nutritional supplementation in a Gambian cohort characterized by maternal deprivation. These studies provide support for the concept that similar epigenetic modifications may underpin different prenatal exposures and potentially increase long-term risk for diseases such as type 2 diabetes.Quilter, C. R., Cooper, W. N., Cliffe, K. M., Skinner, B. M., Prentice, P. M., Nelson, L., Bauer, J., Ong, K. K., Constancia, M., Lowe, W. L., Affara, N. A., Dunger, D. B. Impact on offspring methylation patterns of maternal gestational diabetes mellitus and intrauterine growth restraint suggest common genes and pathways linked to subsequent type 2 diabetes risk.	[Quilter, Claire R.; Cliffe, Kerry M.; Skinner, Benjamin M.; Bauer, Julien; Affara, Nabeel A.] Univ Cambridge, Dept Pathol, Mammalian Mol Genet Grp, Cambridge CB2 1QP, England; [Cooper, Wendy N.; Constancia, Miguel] Univ Cambridge, Metab Res Labs, MRC, Metab Dis Unit,Dept Obstet & Gynaecol, Cambridge CB2 1QP, England; [Cooper, Wendy N.; Prentice, Philippa M.; Ong, Ken K.; Constancia, Miguel; Dunger, David B.] Univ Cambridge, Natl Inst Hlth Res, Cambridge Biomed Res Ctr, Cambridge CB2 1QP, England; [Cooper, Wendy N.; Constancia, Miguel] Univ Cambridge, Ctr Trophoblast Res, Cambridge CB2 1QP, England; [Prentice, Philippa M.; Ong, Ken K.; Dunger, David B.] Univ Cambridge, Dept Paediat, Wellcome Trust MRC Inst Metab Sci, Cambridge CB2 1QP, England; [Nelson, LaTasha; Lowe, William L.] Northwestern Univ, Dept Med, Feinberg Sch Med Chicago, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Northwestern University; Feinberg School of Medicine	Quilter, CR (corresponding author), Univ Cambridge, Dept Pathol, Mammalian Mol Genet Grp, Tennis Court Rd, Cambridge CB2 1QP, England.	crq20@cam.ac.uk	Constancia, Miguel/F-6654-2013; Skinner, Benjamin M/A-5265-2010	Skinner, Benjamin M/0000-0002-7152-1167; Constancia, Miguel/0000-0002-8976-1679; Dunger, Professor David/0000-0002-2566-9304	UK National Institute for Health Research Cambridge Comprehensive Biomedical Research Centre; American Diabetes Association; Biotechnology and Biological Sciences Research Council [BB/F02293X/1, BB/H003312/1] Funding Source: researchfish; British Heart Foundation [FS/09/029/27902] Funding Source: researchfish; Medical Research Council [G0600717, G0600717B, MC_UU_12012/4, G1001995, MC_U106179472, MC_UU_12012/5/B, MC_UU_12015/2] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10274, NF-SI-0513-10012] Funding Source: researchfish; Wellbeing of Women [RG1644] Funding Source: researchfish; BBSRC [BB/F02293X/1, BB/H003312/1] Funding Source: UKRI; MRC [MC_U106179472, G0600717, MC_UU_12012/4, G1001995, MC_UU_12015/2] Funding Source: UKRI	UK National Institute for Health Research Cambridge Comprehensive Biomedical Research Centre; American Diabetes Association(American Diabetes Association); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Wellbeing of Women(Wellbeing of Women (WoW)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by the UK National Institute for Health Research Cambridge Comprehensive Biomedical Research Centre and grants from the American Diabetes Association and of Friends of Prentice. The authors declare no conflicts of interest.	Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410; Amine K, 2011, ANN BIOL CLIN-PARIS, V69, P671, DOI 10.1684/abc.2011.0648; Amitani M, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00051; Aouizerat BE, 2011, BMC CARDIOVASC DISOR, V11, DOI 10.1186/1471-2261-11-29; Astorri E, 2010, HORM METAB RES, V42, P955, DOI 10.1055/s-0030-1267206; Bouqbis L, 2003, TISSUE ANTIGENS, V61, P72, DOI 10.1034/j.1399-0039.2003.610106.x; Chen YA, 2011, GENOMICS, V97, P214, DOI 10.1016/j.ygeno.2010.12.004; Contreras M, 2002, INT J GYNECOL OBSTET, V78, P69; Cooper WN, 2012, FASEB J, V26, P1782, DOI 10.1096/fj.11-192708; Coyle CA, 2002, PHYSIOL BEHAV, V77, P387, DOI 10.1016/S0031-9384(02)00885-5; Ergun MA, 2011, BIOCHEM GENET, V49, P1, DOI 10.1007/s10528-010-9376-6; Fatima W, 2011, INT J PEDIATR OBES, V6, P419, DOI 10.3109/17477166.2011.608431; Finkenstedt A, 2010, J HEPATOL, V53, P1101, DOI 10.1016/j.jhep.2010.04.039; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; Genevieve D, 2005, EUR J HUM GENET, V13, P1033, DOI 10.1038/sj.ejhg.5201448; Gluckman PD, 2005, P ROY SOC B-BIOL SCI, V272, P671, DOI 10.1098/rspb.2004.3001; Gluckman PD, 2011, BIRTH DEFECTS RES C, V93, P12, DOI 10.1002/bdrc.20198; Good DJ, 2008, EXERC SPORT SCI REV, V36, P187, DOI 10.1097/JES.0b013e31818782dd; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hall E., 2013, BMC MED GENET, V23, p[14, 76]; Hamada T, 2011, NUTRITION, V27, P34, DOI 10.1016/j.nut.2009.10.012; Heard-Costa NL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000539; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Heneghan C, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000155; Ibanez L, 2006, J CLIN ENDOCR METAB, V91, P2153, DOI 10.1210/jc.2005-2778; Ichimura A, 2009, PROSTAG OTH LIPID M, V89, P82, DOI 10.1016/j.prostaglandins.2009.05.003; Kanaka-Gantenbein C, 2010, ANN NY ACAD SCI, V1205, P99, DOI 10.1111/j.1749-6632.2010.05683.x; Khulan B, 2012, HUM MOL GENET, V21, P2086, DOI 10.1093/hmg/dds026; Lillycrop KA, 2012, BEST PRACT RES CL EN, V26, P667, DOI 10.1016/j.beem.2012.03.009; Maiti A, 2012, P NATL ACAD SCI USA, V109, P8091, DOI 10.1073/pnas.1201010109; Mallone R, 2006, DIABETES-METAB RES, V22, P284, DOI 10.1002/dmrr.626; McLean M, 2006, DIABETIC MED, V23, P1213, DOI 10.1111/j.1464-5491.2006.01979.x; McMinn J, 2006, PLACENTA, V27, P540, DOI 10.1016/j.placenta.2005.07.004; Meloni Gianfranco, 2003, Med Sci Monit, V9, pCR105; Metzger BE, 2008, NEW ENGL J MED, V358, P1991, DOI 10.1056/NEJMoa0707943; Metzger BE, 2010, DIABETES CARE, V33, P676, DOI 10.2337/dc09-1848; Murea M, 2011, AM J NEPHROL, V33, P502, DOI 10.1159/000327985; Murthi P, 2006, MOL HUM REPROD, V12, P335, DOI 10.1093/molehr/gal037; National Heart Lung and Blood Institute, 2011, NHLBI FAM HEART STUD; Newton-Cheh C, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S7; Ng M. C., DIABET MED, V27, P1443; Ong KK, 2008, DIABETES CARE, V31, P2193, DOI 10.2337/dc08-1111; Ong KK, 2009, AM J CLIN NUTR, V90, P156, DOI 10.3945/ajcn.2008.27408; Ong KK, 2004, DIABETOLOGIA, V47, P1064, DOI 10.1007/s00125-004-1405-8; Ong KKL, 2000, BRIT MED J, V320, P967, DOI 10.1136/bmj.320.7240.967; Pan H, 2012, LMSGROWTH MICROSOFT; Proshchina AE, 2010, B EXP BIOL MED+, V149, P763, DOI 10.1007/s10517-010-1047-4; Seghieri G, 2002, DIABETES CARE, V25, P1761, DOI 10.2337/diacare.25.10.1761; Sobngwi E, 2003, LANCET, V361, P1861, DOI 10.1016/S0140-6736(03)13505-2; Speliotes EK, 2010, NAT GENET, V42, P937, DOI 10.1038/ng.686; van Abeelen AFM, 2012, DIABETES, V61, P2255, DOI 10.2337/db11-1559; Xie JX, 2004, P NATL ACAD SCI USA, V101, P10750, DOI 10.1073/pnas.0404044101; Yang HC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005459	53	65	67	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4868	4879		10.1096/fj.14-255240	http://dx.doi.org/10.1096/fj.14-255240			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25145626				2022-12-28	WOS:000344050900024
J	Shi, JD; Sun, J; Wang, B; Wu, MN; Zhang, J; Duan, ZQ; Wang, HX; Hu, NZ; Hu, YZ				Shi, Jiandong; Sun, Jing; Wang, Bin; Wu, Meini; Zhang, Jing; Duan, Zhiqing; Wang, Haixuan; Hu, Ningzhu; Hu, Yunzhang			Novel microRNA-like viral small regulatory RNAs arising during human hepatitis A virus infection	FASEB JOURNAL			English	Article						deep sequencing; cytoplasmic RNA virus; miRNA machinery	CONSERVED MICRORNAS; GENE-EXPRESSION; MESSENGER-RNA; STRAIN HM175; IDENTIFICATION; ADAPTATION; GROWTH; REPLICATION; ULTRAFAST; DISCOVERY	MicroRNAs (miRNAs), including host miRNAs and viral miRNAs, play vital roles in regulating host-virus interactions. DNA viruses encode miRNAs that regulate the viral life cycle. However, it is generally believed that cytoplasmic RNA viruses do not encode miRNAs, owing to inaccessible cellular miRNA processing machinery. Here, we provide a comprehensive genome-wide analysis and identification of miRNAs that were derived from hepatitis A virus (HAV; Hu/China/H2/1982), which is a typical cytoplasmic RNA virus. Using deep-sequencing and in silico approaches, we identified 2 novel virally encoded miRNAs, named hav-miR-1-5p and hav-miR-2-5p. Both of the novel virally encoded miRNAs were clearly detected in infected cells. Analysis of Dicer enzyme silencing demonstrated that HAV-derived miRNA biogenesis is Dicer dependent. Furthermore, we confirmed that HAV mature miRNAs were generated from viral miRNA precursors (pre-miRNAs) in host cells. Notably, naturally derived HAV miRNAs were biologically and functionally active and induced post-transcriptional gene silencing (PTGS). Genomic location analysis revealed novel miRNAs located in the coding region of the viral genome. Overall, our results show that HAV naturally generates functional miRNA-like small regulatory RNAs during infection. This is the first report of miRNAs derived from the coding region of genomic RNA of a cytoplasmic RNA virus. These observations demonstrate that a cytoplasmic RNA virus can naturally generate functional miRNAs, as DNA viruses do. These findings also contribute to improved understanding of host-RNA virus interactions mediated by RNA virus-derived miRNAs.-Shi, J., Sun, J., Wang, B., Wu, M., Zhang, J., Duan, Z., Wang, H., Hu, N., Hu, Y. Novel microRNA-like viral small regulatory RNAs arising during human hepatitis A virus infection.	[Shi, Jiandong; Sun, Jing; Wu, Meini; Zhang, Jing; Duan, Zhiqing; Wang, Haixuan; Hu, Ningzhu; Hu, Yunzhang] Chinese Acad Med Sci, Inst Med Biol, Peking Union Med Coll, Kunming 650118, Peoples R China; [Wang, Bin] Kunming Univ, Dept Life Sci & Biotechnol, Kunming, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medical Biology - CAMS; Peking Union Medical College; Kunming University	Hu, YZ (corresponding author), Chinese Acad Med Sci, Inst Med Biol, Kunming 650118, Peoples R China.	huyunzhangym@126.com			National High Technology Research and Development Program (863 Program) of China [2012AA02A406]; Applied and Fundamental Research Program of Yunnan Province [2013FA025]; Innovation Team Project of Yunnan Province of China; Provincial Innovation Team for Application Research on New Types of Vaccine Adjuvant, Institute of Medical Biology, Chinese Academy of Medical Sciences [2011CI140]	National High Technology Research and Development Program (863 Program) of China(National High Technology Research and Development Program of China); Applied and Fundamental Research Program of Yunnan Province; Innovation Team Project of Yunnan Province of China; Provincial Innovation Team for Application Research on New Types of Vaccine Adjuvant, Institute of Medical Biology, Chinese Academy of Medical Sciences	The authors thank Dr. Qihan Li for advice and comments made in the course of this work. The authors also thank Yue Wang, Liping Wang, and Hongzhi Cai for technical assistance. This study was supported by grants from the National High Technology Research and Development Program (863 Program) of China (2012AA02A406), Applied and Fundamental Research Program of Yunnan Province (2013FA025), and Innovation Team Project of Yunnan Province of China, Provincial Innovation Team for Application Research on New Types of Vaccine Adjuvant, Institute of Medical Biology, Chinese Academy of Medical Sciences (2011CI140). The authors declare no conflicts of interest.	Almeida MI, 2011, MUTAT RES-FUND MOL M, V717, P1, DOI 10.1016/j.mrfmmm.2011.03.009; Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; ANDERSON DA, 1987, J MED VIROL, V22, P35, DOI 10.1002/jmv.1890220106; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bennasser Y, 2011, NAT STRUCT MOL BIOL, V18, P323, DOI 10.1038/nsmb.1987; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Berezikov E, 2006, NAT GENET, V38, pS2, DOI 10.1038/ng1794; BINN LN, 1984, J CLIN MICROBIOL, V20, P28, DOI 10.1128/JCM.20.1.28-33.1984; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; COHEN JI, 1989, J VIROL, V63, P5364, DOI 10.1128/JVI.63.12.5364-5370.1989; Cullen BR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000787; Dong QH, 2012, J HERED, V103, P268, DOI 10.1093/jhered/esr127; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fischer W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012303; Frings W, 2001, J GEN VIROL, V82, P597, DOI 10.1099/0022-1317-82-3-597; GREGERSEN JP, 1988, MED MICROBIOL IMMUN, V177, P91; Grundhoff A, 2006, RNA, V12, P733, DOI 10.1261/rna.2326106; Grundhoff A, 2011, VIROLOGY, V411, P325, DOI 10.1016/j.virol.2011.01.002; Hafner M, 2008, METHODS, V44, P3, DOI 10.1016/j.ymeth.2007.09.009; Houzet L, 2011, BBA-GENE REGUL MECH, V1809, P686, DOI 10.1016/j.bbagrm.2011.05.009; Hussain M, 2014, P NATL ACAD SCI USA, V111, P2746, DOI 10.1073/pnas.1320123111; Hussain M, 2012, NUCLEIC ACIDS RES, V40, P2210, DOI 10.1093/nar/gkr848; Kaya HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073674; Kincaid RP, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003018; Kincaid RP, 2012, P NATL ACAD SCI USA, V109, P3077, DOI 10.1073/pnas.1116107109; Langlois RA, 2012, MOL THER, V20, P367, DOI 10.1038/mt.2011.244; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336; Li TT, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-186; MAO JS, 1989, J INFECT DIS, V159, P621, DOI 10.1093/infdis/159.4.621; Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108; Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626; Moore HC, 2011, RNA, V17, P555, DOI 10.1261/rna.2591611; Parameswaran P, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000764; PROVOST PJ, 1979, P SOC EXP BIOL MED, V160, P213, DOI 10.3181/00379727-160-40422; Rathjen T, 2009, FEBS LETT, V583, P1422, DOI 10.1016/j.febslet.2009.03.048; Reese TA, 2010, J VIROL, V84, P10344, DOI 10.1128/JVI.00707-10; Roberts APE, 2011, PROG MOL BIOL TRANSL, V102, P101, DOI 10.1016/B978-0-12-415795-8.00002-7; ROSS BC, 1989, J GEN VIROL, V70, P2805, DOI 10.1099/0022-1317-70-10-2805; Rouha H, 2010, NUCLEIC ACIDS RES, V38, P8328, DOI 10.1093/nar/gkq681; Rutvisuttinunt W, 2013, J VIROL METHODS, V193, P394, DOI 10.1016/j.jviromet.2013.07.001; Scaria V, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-68; Schmieder R, 2011, BIOINFORMATICS, V27, P863, DOI 10.1093/bioinformatics/btr026; Schopman NCT, 2012, NUCLEIC ACIDS RES, V40, P414, DOI 10.1093/nar/gkr719; Seo GJ, 2009, VIROLOGY, V383, P183, DOI 10.1016/j.virol.2008.11.001; Shapiro JS, 2013, WIRES RNA, V4, P463, DOI 10.1002/wrna.1169; Shapiro JS, 2012, RNA, V18, P1338, DOI 10.1261/rna.032268.112; Shapiro JS, 2010, RNA, V16, P2068, DOI 10.1261/rna.2303610; Skalsky RL, 2010, ANNU REV MICROBIOL, V64, P123, DOI 10.1146/annurev.micro.112408.134243; Sullivan CS, 2005, NATURE, V435, P682, DOI 10.1038/nature03576; Tao T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075323; Varble A, 2011, RNA BIOL, V8, P190, DOI 10.4161/rna.8.2.13983; Varble A, 2010, P NATL ACAD SCI USA, V107, P11519, DOI 10.1073/pnas.1003115107; Wei ZL, 2011, INT J BIOL SCI, V7, P180, DOI 10.7150/ijbs.7.180; Wu QF, 2010, P NATL ACAD SCI USA, V107, P1606, DOI 10.1073/pnas.0911353107; Xu Y, 2013, INT J MOL MED, V32, P1115, DOI 10.3892/ijmm.2013.1499; Yan Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019148; Zhang BH, 2009, GENE, V443, P100, DOI 10.1016/j.gene.2009.04.027; Zhao CZ, 2010, BMC PLANT BIOL, V10, DOI 10.1186/1471-2229-10-3; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	61	23	24	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4381	4393		10.1096/fj.14-253534	http://dx.doi.org/10.1096/fj.14-253534			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25002121				2022-12-28	WOS:000342222700017
J	Yao, LB; Heuser-Baker, J; Herlea-Pana, O; Zhang, N; Szweda, LI; Griffin, TM; Barlic-Dicen, J				Yao, Longbiao; Heuser-Baker, Janet; Herlea-Pana, Oana; Zhang, Nan; Szweda, Luke I.; Griffin, Timothy M.; Barlic-Dicen, Jana			Deficiency in adipocyte chemokine receptor CXCR4 exacerbates obesity and compromises thermoregulatory responses of brown adipose tissue in a mouse model of diet-induced obesity	FASEB JOURNAL			English	Article						chemotactic cytokine system; adaptive thermogenesis	INSULIN-RESISTANCE; MACROPHAGE RECRUITMENT; COLD-EXPOSURE; ADULT HUMANS; T-CELLS; FAT; MICE; INFLAMMATION; CALIBRATION; METABOLISM	The chemokine receptor CXCR4 is expressed on adipocytes and macrophages in adipose tissue, but its role in this tissue remains unknown. We evaluated whether deficiency in either adipocyte or myeloid leukocyte CXCR4 affects body weight (BW) and adiposity in a mouse model of high-fat-diet (HFD)-induced obesity. We found that ablation of adipocyte, but not myeloid leukocyte, CXCR4 exacerbated obesity. The HFD-fed adipocyte-specific CXCR4-knockout (AdCXCR4ko) mice, compared to wild-type C57BL/6 control mice, had increased BW (average: 52.0 g vs. 35.5 g), adiposity (average: 49.3 vs. 21.0% of total BW), and inflammatory leukocyte content in white adipose tissue (WAT), despite comparable food intake. As previously reported, HFD feeding increased uncoupling protein 1 (UCP1) expression (fold increase: 3.5) in brown adipose tissue (BAT) of the C57BL/6 control mice. However, no HFD-induced increase in UCP1 expression was observed in the AdCXCR4ko mice, which were cold sensitive. Thus, our study suggests that adipocyte CXCR4 limits development of obesity by preventing excessive inflammatory cell recruitment into WAT and by supporting thermogenic activity of BAT. Since CXCR4 is conserved between mouse and human, the newfound role of CXCR4 in mouse adipose tissue may parallel the role of this chemokine receptor in human adipose tissue.	[Yao, Longbiao; Heuser-Baker, Janet; Herlea-Pana, Oana; Zhang, Nan; Barlic-Dicen, Jana] Oklahoma Med Res Fdn, Cardiovasc Biol Program, Oklahoma City, OK 73104 USA; [Szweda, Luke I.; Griffin, Timothy M.] Oklahoma Med Res Fdn, Free Radical Biol & Aging Program, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation	Barlic-Dicen, J (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	jana-barlic-dicen@omrf.org	Griffin, Timothy M./V-8838-2019	Griffin, Timothy M./0000-0001-8840-9940; Zhang, Nan/0000-0002-6736-2781	U.S. National Institutes of Health; National Center for Research Resources [5 P20 RR018758-08]; National Institute of General Medical Sciences [8 P20 GM103441-08]; Oklahoma Center for the Advancement of Science and Technology [HR10-099]; Oklahoma Center for Adult Stem Cell Research [4340-03-06]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103441] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Oklahoma Center for the Advancement of Science and Technology; Oklahoma Center for Adult Stem Cell Research; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank J. Hudson for assistance with DEXA and M. Pederson-Rambo for editing the manuscript. This work was supported by grants from the U.S. National Institutes of Health, National Center for Research Resources (5 P20 RR018758-08) and National Institute of General Medical Sciences (8 P20 GM103441-08), the Oklahoma Center for the Advancement of Science and Technology (HR10-099), and the Oklahoma Center for Adult Stem Cell Research (4340-03-06). The authors declare no conflicts of intrest.	Anderson EK, 2010, CURR OPIN LIPIDOL, V21, P172, DOI 10.1097/MOL.0b013e3283393867; Bachelerie F, 2014, PHARMACOL REV, V66, P1, DOI 10.1124/pr.113.007724; Cannon B, 2010, INT J OBESITY, V34, pS7, DOI 10.1038/ijo.2010.177; Carey AL, 2013, PHARMACOL THERAPEUT, V140, P26, DOI 10.1016/j.pharmthera.2013.05.009; Chavey C, 2009, CELL METAB, V9, P339, DOI 10.1016/j.cmet.2009.03.002; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; Eash KJ, 2009, BLOOD, V113, P4711, DOI 10.1182/blood-2008-09-177287; Enerback S, 2010, INT J OBESITY, V34, pS43, DOI 10.1038/ijo.2010.183; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fromme T, 2011, AM J PHYSIOL-REG I, V300, pR1, DOI 10.1152/ajpregu.00411.2010; Garteiser P, 2013, METABOLISM, V62, P1686, DOI 10.1016/j.metabol.2013.06.009; Giralt M, 2013, ENDOCRINOLOGY, V154, P2992, DOI 10.1210/en.2013-1403; Hazan U, 2002, FASEB J, V16, P1254, DOI 10.1096/fj.01-0947fje; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; HEATON JM, 1972, J ANAT, V112, P35; Johnston SL, 2005, OBES RES, V13, P1558, DOI 10.1038/oby.2005.191; Kitade H, 2012, DIABETES, V61, P1680, DOI 10.2337/db11-1506; Levitsky DA, 2012, PUBLIC HEALTH NUTR, V15, P126, DOI 10.1017/S1368980011002187; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; Nedergaard J, 2010, CELL METAB, V11, P268, DOI 10.1016/j.cmet.2010.03.007; Nishimura S, 2013, CELL METAB, V18, P759, DOI 10.1016/j.cmet.2013.09.017; Nishimura S, 2009, NAT MED, V15, P914, DOI 10.1038/nm.1964; Ota T, 2013, DIABETES METAB J, V37, P165, DOI 10.4093/dmj.2013.37.3.165; Ouellet V, 2012, J CLIN INVEST, V122, P545, DOI 10.1172/JCI60433; Papa S, 2012, ADV EXP MED BIOL, V942, P3, DOI 10.1007/978-94-007-2869-1_1; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Saito M, 2009, DIABETES, V58, P1526, DOI 10.2337/db09-0530; Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007; Schulz TJ, 2013, BIOCHEM J, V453, P167, DOI 10.1042/BJ20130457; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Sun SY, 2012, ANNU REV NUTR, V32, P261, DOI 10.1146/annurev-nutr-071811-150623; Surmi BK, 2010, VASC PHARMACOL, V52, P27, DOI 10.1016/j.vph.2009.12.004; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Virtue S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00128; Vosselman MJ, 2013, MOL CELL ENDOCRINOL, V379, P43, DOI 10.1016/j.mce.2013.04.017; Wang CY, 2012, METHODS MOL BIOL, V821, P421, DOI 10.1007/978-1-61779-430-8_27; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Winer DA, 2011, NAT MED, V17, P610, DOI 10.1038/nm.2353; Zingaretti MC, 2009, FASEB J, V23, P3113, DOI 10.1096/fj.09-133546	41	19	19	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4534	4550		10.1096/fj.14-249797	http://dx.doi.org/10.1096/fj.14-249797			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25016030	Green Published			2022-12-28	WOS:000342222700029
J	Lee, S; Goldfinger, LE				Lee, Seunghyung; Goldfinger, Lawrence E.			RLIP76 regulates HIF-1 activity, VEGF expression and secretion in tumor cells, and secretome transactivation of endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; transcription factor; growth factors	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; GROWTH-FACTOR VEGF; PROMOTER ACTIVITY; PI3K-DEPENDENT PATHWAYS; DEPENDENT TRANSPORT; VEGF(120) RELEASE; OXIDATIVE STRESS; CANCER CELLS; LUNG-CANCER; ANGIOGENESIS	This study was undertaken to reveal the mechanisms by which RLIP76 regulates endothelial cell angiogenic responses. RLIP76 is an effector of the angiogenic modulator, R-Ras. RLIP76 is overexpressed in many tumors, required for tumor angiogenesis, and blockade of RLIP76 results in tumor regression in multiple models. We report here that RLIP76 was required for expression and secretion of vascular endothelial growth factor (VEGF) in carcinoma and melanoma cells. Conditioned medium derived from RLIP76-depleted tumor cells, but not control knockdown cells, could not stimulate proliferation, migration, or Matrigel cord formation in endothelial cell cultures, which indicates that RLIP76 regulates angiogenic components of the tumor cell secretome. Recombinant VEGF added to conditioned medium from RLIP76-knockdown tumor cells restored these endothelial cell functions. Transcriptional activity of hypoxia- inducible factor 1 (HIF-1), which drives VEGF expression, was blocked in RLIP76-depleted tumor cells. RLIP76 was required for PI3-kinase activation, known to regulate HIF-1, in these cells. However, HIF-1 alpha expression and nuclear localization were unaffected by RLIP76 knockdown, which suggests that RLIP76 regulates HIF-1 at the functional level. Thus, RLIP76 regulates tumor cell transactivation of endothelial cells via control of VEGF expression and secretion, providing a new important link in the mechanism of tumor cell induction of angiogenesis.	[Lee, Seunghyung; Goldfinger, Lawrence E.] Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Dept Anat & Cell Biol, Philadelphia, PA 19140 USA; [Goldfinger, Lawrence E.] Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19111 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Fox Chase Cancer Center	Lee, S (corresponding author), Temple Univ, Sch Med, 3420 N Broad St, Philadelphia, PA 19140 USA.	goldfinger@temple.edu			U.S. National Institutes of Health [HL093416]; American Heart Association [12POST12040257]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093416] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health grant HL093416 to L. E. G. and American Heart Association Postdoctoral Fellowship 12POST12040257 to S. L. The authors thank Jeremy G. T. Wurtzel for technical assistance. The authors declare no conflict of interest.	Aonuma M, 1999, INT J EXP PATHOL, V80, P271, DOI 10.1046/j.1365-2613.1999.00122.x; Awasthi S, 2000, BIOCHEMISTRY-US, V39, P9327, DOI 10.1021/bi992964c; AWASTHI S, 1994, J CLIN INVEST, V93, P958, DOI 10.1172/JCI117102; Awasthi S, 2002, ACTA BIOCHIM POL, V49, P855; Awasthi S, 2001, BIOCHEMISTRY-US, V40, P4159, DOI 10.1021/bi002182f; Awasthi S, 2008, CLIN CANCER RES, V14, P4372, DOI 10.1158/1078-0432.CCR-08-0145; AWASTHI YC, 1991, BIOCHEM BIOPH RES CO, V175, P1090, DOI 10.1016/0006-291X(91)91677-5; Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120; Dery MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Folkman J, 1992, Semin Cancer Biol, V3, P65; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gerber HP, 2000, CANCER RES, V60, P6253; Gille J, 2006, EXP DERMATOL, V15, P175, DOI 10.1111/j.1600-0625.2006.00400.x; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Goldfinger LE, 2006, J CELL BIOL, V174, P877, DOI 10.1083/jcb.200603111; Goldfinger LE, 2013, LUNG CANCER-TARGETS, V4, P61, DOI 10.2147/LCTT.S53672; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051; Kishimoto J, 2000, AM J PATHOL, V157, P103, DOI 10.1016/S0002-9440(10)64522-1; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Kozin SV, 2001, CANCER RES, V61, P39; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Leake K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034582; Lee CG, 2000, CANCER RES, V60, P5565; Lee S, 2012, CANCER RES, V72, P5165, DOI 10.1158/0008-5472.CAN-12-0468; Limaverde-Sousa G, 2014, CANCER TREAT REV, V40, P548, DOI 10.1016/j.ctrv.2013.11.009; Mahabeleshwar GH, 2007, SEMIN ONCOL, V34, P555, DOI 10.1053/j.seminoncol.2007.09.009; Malo MS, 2006, ANAL BIOCHEM, V350, P307, DOI 10.1016/j.ab.2005.12.018; Margutti P, 2008, BLOOD, V111, P4559, DOI 10.1182/blood-2007-05-092825; Marneros AG, 2009, HEMATOL ONCOL CLIN N, V23, P431, DOI 10.1016/j.hoc.2009.03.007; McMahon G, 2000, Oncologist, V5 Suppl 1, P3; Moriya R, 2014, BIOCHEM BIOPH RES CO, V445, P275, DOI 10.1016/j.bbrc.2014.01.120; Motl S, 2005, AM J HEALTH-SYST PH, V62, P1021, DOI 10.1093/ajhp/62.10.1021; Muz B, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2568; Nagy MA, 2011, J CANC SCI THER, V3, P35, DOI DOI 10.4172/1948-5956.1000054; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Park SH, 1995, ONCOGENE, V11, P2349; Sehrawat A, 2013, BIOCHEM PHARMACOL, V85, P1203, DOI 10.1016/j.bcp.2013.02.012; Semenza GL, 2009, CURR PHARM DESIGN, V15, P3839, DOI 10.2174/138161209789649402; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; SHARMA R, 1990, BIOCHEM BIOPH RES CO, V171, P155, DOI 10.1016/0006-291X(90)91370-8; Singhal SS, 2007, CANCER RES, V67, P4382, DOI 10.1158/0008-5472.CAN-06-4124; Singhal SS, 2009, BIOCHEM PHARMACOL, V77, P1074, DOI 10.1016/j.bcp.2008.11.013; Singhal SS, 2006, CANCER RES, V66, P2354, DOI 10.1158/0008-5472.CAN-05-3534; Singhal SS, 2005, BIOCHEM PHARMACOL, V70, P481, DOI 10.1016/j.bcp.2005.05.005; Sparano JA, 2004, CLIN CANCER RES, V10, P1206, DOI 10.1158/1078-0432.CCR-03-0238; Takahashi K, 2013, OBESITY, V21, P1625, DOI 10.1002/oby.20206; Terman BI, 2001, EINSTEIN Q J BIOL ME, V18, P59; Tsuzuki Y, 2000, CANCER RES, V60, P6248; Volm M, 1997, ANTICANCER RES, V17, P99; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Wurtzel Jeremy G T, 2012, Small GTPases, V3, P139, DOI 10.4161/sgtp.21084; Yan JP, 2013, J ETHNOPHARMACOL, V147, P456, DOI 10.1016/j.jep.2013.03.039; Yi TF, 2013, J BIOL CHEM, V288, P18732, DOI 10.1074/jbc.M113.471466; Zhao WN, 2013, INT J MOL SCI, V14, P13577, DOI 10.3390/ijms140713577; Ziello Jennifer E, 2007, Yale J Biol Med, V80, P51	61	22	22	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4158	4168		10.1096/fj.14-255711	http://dx.doi.org/10.1096/fj.14-255711			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24928198	Green Published			2022-12-28	WOS:000340845900032
J	Marco, A; Kisliouk, T; Tabachnik, T; Meiri, N; Weller, A				Marco, Asaf; Kisliouk, Tatiana; Tabachnik, Tzlil; Meiri, Noam; Weller, Aron			Overweight and CpG methylation of the Pomc promoter in offspring of high-fat-diet-fed dams are not "reprogrammed" by regular chow diet in rats	FASEB JOURNAL			English	Article						obesity; leptin; epigenetics	DNA METHYLATION; HYPOTHALAMIC PROOPIOMELANOCORTIN; DEVELOPMENTAL ORIGINS; OBESITY; LEPTIN; EXPRESSION; EXPOSURE; BRAIN; RESISTANCE; PREGNANCY	This study aimed to determine whether epigenetic malprogramming induced by high-fat diet (HFD) has an obesogenic effect on nonmated and mated female rats and their offspring. Further, it aimed to reprogram offspring's epigenetic malprogramming and phenotype by providing normal diet after weaning. Body weight (BW) was measured, and plasma and hypothalamic arcuate nuclei were collected for analysis of hormones, mRNA, and DNA CpG methylation of the promoter of Pomc, a key factor in control of food intake. In nonmated females, HFD decreased Pomc/leptin ratio by similar to 38%. This finding was associated with Pomc promoter hypermethylation. While heavier during pregnancy, during lactation HFD dams showed sharper BW decrease (2.5-fold) and loss of Pomc promoter hypermethylation. Moreover, their weight loss was correlated with demethylation (r=-0.707) and with gadd45b mRNA expression levels (r=0.905). Even though offspring of HFD dams ate standard chow from weaning, they displayed increased BW, Pomc promoter hypermethylation, and vulnerability to HFD challenge (3-fold kilocalorie intake increase). These findings demonstrate a long-term effect of maternal HFD on CpG methylation of the Pomc promoter in the offspring, which was not reprogrammed by standard chow from weaning. Further, the results suggest a possible mechanism of demethylation of the Pomc promoter following pregnancy and lactation.	[Marco, Asaf; Tabachnik, Tzlil] Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; [Marco, Asaf; Tabachnik, Tzlil; Weller, Aron] Bar Ilan Univ, Gonda Brain Res Ctr, IL-52900 Ramat Gan, Israel; [Weller, Aron] Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel; [Kisliouk, Tatiana; Meiri, Noam] Agr Res Org, Volcani Ctr, Inst Anim Sci, IL-50250 Bet Dagan, Israel	Bar Ilan University; Bar Ilan University; Bar Ilan University; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Marco, A (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	asafmarco@gmail.com	Weller, Aron/AAU-3074-2020	Weller, Aron/0000-0002-0663-4384; Meiri, Noam/0000-0002-4198-5665; /0000-0003-1804-5787	Israel Science Foundation [1532/12]	Israel Science Foundation(Israel Science Foundation)	The authors thank Yael Lavi, Lilach Eliyahu, and Tomer Cramer for help in performing part of the experiments. This research was supported by the Israel Science Foundation (grant 1532/12).	Begum G, 2013, ENDOCRINOLOGY, V154, P4560, DOI 10.1210/en.2013-1693; Blaze J, 2013, INT J DEV NEUROSCI, V31, P804, DOI 10.1016/j.ijdevneu.2013.10.001; Bouret SG, 2006, CLIN GENET, V70, P295, DOI 10.1111/j.1399-0004.2006.00684.x; Bouret SG, 2013, FRONT NEUROENDOCRIN, V34, P18, DOI 10.1016/j.yfrne.2013.01.001; Catalano PM, 2010, REPRODUCTION, V140, P365, DOI 10.1530/REP-10-0088; Champagne FA, 2006, BIOL PSYCHIAT, V59, P1227, DOI 10.1016/j.biopsych.2005.10.016; Cho CE, 2013, INT J OBESITY, V37, P1177, DOI 10.1038/ijo.2012.210; Cho CE, 2013, EPIGENETICS-US, V8, P710, DOI 10.4161/epi.24948; Clausen TD, 2008, DIABETES CARE, V31, P340, DOI 10.2337/dc07-1596; Crujeiras AB, 2013, REGUL PEPTIDES, V186, P1, DOI 10.1016/j.regpep.2013.06.012; Gomes MVD, 2013, EXP BIOL MED, V238, P859, DOI 10.1177/1535370213490630; Desai M, 2013, CURR DIABETES REP, V13, P27, DOI 10.1007/s11892-012-0344-x; Dias BG, 2014, NAT NEUROSCI, V17, P89, DOI 10.1038/nn.3594; Fan CN, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-31; Galtier-Dereure F, 2000, AM J CLIN NUTR, V71, p1242S, DOI 10.1093/ajcn/71.5.1242s; Haberman RP, 2012, EPIGENETICS-US, V7, P1008, DOI 10.4161/epi.21291; Katz A, 2006, J NEUROSCI, V26, P3899, DOI 10.1523/JNEUROSCI.0371-06.2006; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kuehnen P, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002543; Langie SAS, 2013, FASEB J, V27, P3323, DOI [10.1096/fj.12-224121, 10.1096]; Laufer BI, 2013, DIS MODEL MECH, V6, P977, DOI 10.1242/dmm.010975; Li B, 2014, INT J OBESITY, V38, P192, DOI 10.1038/ijo.2013.86; Marco A, 2013, PSYCHONEUROENDOCRINO, V38, P2844, DOI 10.1016/j.psyneuen.2013.07.011; McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003; Miranda TB, 2007, J CELL PHYSIOL, V213, P384, DOI 10.1002/jcp.21224; Novakovic B, 2014, EPIGENETICS-US, V9, P377, DOI 10.4161/epi.27248; Palou M, 2011, BRIT J NUTR, V106, P769, DOI 10.1017/S0007114511000973; Pan HT, 2014, PHYSIOL BEHAV, V130, P157, DOI 10.1016/j.physbeh.2014.04.003; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Plagemann A, 2009, J PHYSIOL-LONDON, V587, P4963, DOI 10.1113/jphysiol.2009.176156; Roth TL, 2012, DEV PSYCHOBIOL, V54, P590, DOI 10.1002/dev.20550; Rudenko A, 2013, NEURON, V79, P1109, DOI 10.1016/j.neuron.2013.08.003; Schneeberger M, 2014, J ENDOCRINOL, V220, pT25, DOI 10.1530/JOE-13-0398; Shi X, 2013, DIABETOLOGIA, V56, P925, DOI 10.1007/s00125-013-2831-2; Stevens A, 2010, ENDOCRINOLOGY, V151, P3652, DOI 10.1210/en.2010-0094; Sultan FA, 2012, J NEUROSCI, V32, P17059, DOI 10.1523/JNEUROSCI.1747-12.2012; Symonds ME, 2009, NAT REV ENDOCRINOL, V5, P604, DOI 10.1038/nrendo.2009.195; Szyf M, 2013, CHILD DEV, V84, P49, DOI 10.1111/j.1467-8624.2012.01793.x; Szyf M, 2013, NAT NEUROSCI, V16, P2, DOI 10.1038/nn.3286; Tups A, 2009, J NEUROENDOCRINOL, V21, P961, DOI 10.1111/j.1365-2826.2009.01916.x; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Wright CS, 2009, AM J HYPERTENS, V22, P215, DOI 10.1038/ajh.2008.326; Yang G, 2009, J BIOL CHEM, V284, P3719, DOI 10.1074/jbc.M804965200; Zagoory-Sharon O, 2008, INT J OBESITY, V32, P1211, DOI 10.1038/ijo.2008.58	44	60	62	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4148	4157		10.1096/fj.14-255620	http://dx.doi.org/10.1096/fj.14-255620			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24928196	Green Published			2022-12-28	WOS:000340845900031
J	Mu, LX; Tang, J; Liu, H; Shen, CB; Rong, MQ; Zhang, ZY; Lai, R				Mu, Lixian; Tang, Jing; Liu, Han; Shen, Chuanbin; Rong, Mingqiang; Zhang, Zhiye; Lai, Ren			A potential wound-healing-promoting peptide from salamander skin	FASEB JOURNAL			English	Article						TGF-beta; urodele amphibians; full-thickness incision; reepithelialization	GROWTH-FACTORS; LL-37; ANGIOGENESIS; REGENERATION; EXPRESSION; CYTOKINES; MOUSE	Although it is well known that wound healing proceeds incredibly quickly in urodele amphibians, such as newts and salamanders, little is known about skin-wound healing, and no bioactive/effector substance that contributes to wound healing has been identified from these animals. As a step toward understanding salamander wound healing and skin regeneration, a potential wound-healing-promoting peptide (tylotoin; KCVRQNNKRVCK) was identified from salamander skin of Tylototriton verrucosus. It shows comparable wound-healing-promoting ability (EC50 = 11.14 mu g/ml) with epidermal growth factor (EGF; NSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDL-KWWELR) in a murine model of full-thickness dermal wound. Tylotoin directly enhances the motility and proliferation of keratinocytes, vascular endothelial cells, and fibroblasts, resulting in accelerated reepithelialization and granulation tissue formation in the wound site. Tylotoin also promotes the release of transforming growth factor beta 1 (TGF-beta 1) and interleukin 6 (IL-6), which are essential in the wound healing response. Gene-encoded tylotoin secreted in salamander skin is possibly an effector molecule for skin wound healing. This study may facilitate understanding of the cellular and molecular events that underlie quick wound healing in salamanders.	[Mu, Lixian; Tang, Jing; Liu, Han; Shen, Chuanbin; Rong, Mingqiang; Zhang, Zhiye; Lai, Ren] Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Kunming, Yunnan, Peoples R China; [Mu, Lixian; Tang, Jing; Liu, Han; Shen, Chuanbin; Zhang, Zhiye] Univ Chinese Acad Sci, Kunming Coll Life Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Lai, R (corresponding author), Key Lab Anim Models & Human Dis Mech, 32 Jiaochangdonglu, Kunming 650223, Yunnan, Peoples R China.	rlai@mail.kiz.ac.cn		Shen, Chuanbin/0000-0002-4635-5160	Ministry of Science and Technology [2010CB529800, 2013CB911300]; National Natural Science Foundation [31025025, U1132601, U1302221, 31200590, 31260208]; Jiangsu Province [BK2012365, BE2012748]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Jiangsu Province	The authors thank all staff of the Animal Center at Kunming Institute of Zoology for taking good care of the animals; and members of the Cell Banks at Kunming Institute of Zoology for providing cells and culture instruction. This work was supported by the Ministry of Science and Technology (2010CB529800, 2013CB911300), the National Natural Science Foundation (31025025, U1132601, U1302221, 31200590, 31260208), and Jiangsu Province (BK2012365, BE2012748). The authors declare no conflicts of interest.	Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x; Cotran R. S., 1999, ROBBINS PATHOLOGIC B, P107; Davidson DJ, 2004, J IMMUNOL, V172, P1146, DOI 10.4049/jimmunol.172.2.1146; Ferris DR, 2010, DEV GROWTH DIFFER, V52, P715, DOI 10.1111/j.1440-169X.2010.01208.x; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Galeano M, 2003, DIABETOLOGIA, V46, P546, DOI 10.1007/s00125-003-1064-1; HOPKINSONWOOLLEY J, 1994, J CELL SCI, V107, P1159; KANE CJM, 1991, J CELL PHYSIOL, V148, P157, DOI 10.1002/jcp.1041480119; KIRSNER RS, 1993, DERMATOL CLIN, V11, P629, DOI 10.1016/S0733-8635(18)30216-X; Kondo T, 2010, FORENSIC SCI INT, V203, P93, DOI 10.1016/j.forsciint.2010.07.004; Kopecki Z, 2007, J PATHOL, V211, P351, DOI 10.1002/path.2113; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li J, 2007, CLIN DERMATOL, V25, P9, DOI 10.1016/j.clindermatol.2006.09.007; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Muthusamy V, 2010, ARCH DERMATOL RES, V302, P5, DOI 10.1007/s00403-009-0994-y; Niyonsaba F, 2002, IMMUNOLOGY, V106, P20, DOI 10.1046/j.1365-2567.2002.01398.x; Rodero MP, 2010, INT J CLIN EXP PATHO, V3, P643; Schett G, 2008, ANN RHEUM DIS, V67, P909, DOI 10.1136/ard.2007.074278; Scott MG, 2002, J IMMUNOL, V169, P3883, DOI 10.4049/jimmunol.169.7.3883; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Valluru M, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00089; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Yokoyama H, 2011, J INVEST DERMATOL, V131, P2477, DOI 10.1038/jid.2011.223	25	61	67	1	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3919	3929		10.1096/fj.13-248476	http://dx.doi.org/10.1096/fj.13-248476			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24868009	Green Published			2022-12-28	WOS:000340845900010
J	Deme, B; Cataye, C; Block, MA; Marechal, E; Jouhet, J				Deme, Bruno; Cataye, Celine; Block, Maryse A.; Marechal, Eric; Jouhet, Juliette			Contribution of galactoglycerolipids to the 3-dimensional architecture of thylakoids	FASEB JOURNAL			English	Article						glycolipid; neutron diffraction; hexagonal II phase; lamellar phase; membrane stacking	LIGHT-HARVESTING COMPLEX; CEREBROSIDE SULFATE; PHOTOSYSTEM-II; NEUTRON-DIFFRACTION; INDUCED AGGREGATION; PROLAMELLAR BODIES; INNER ENVELOPE; PHASE-BEHAVIOR; POLAR LIPIDS; MEMBRANES	Thylakoid membranes, the universal structure where photosynthesis takes place in all oxygenic photosynthetic organisms from cyanobacteria to higher plants, have a unique lipid composition. They contain a high fraction of 2 uncharged glycolipids, the galactoglycerolipids mono- and digalactosyldiacylglycerol (MGDG and DGDG, respectively), and an anionic sulfolipid, sulfoquinovosediacylglycerol (SQDG). A remarkable feature of the evolution from cyanobacteria to higher plants is the conservation of MGDG, DGDG, SQDG, and phosphatidylglycerol (PG), the major phospholipid of thylakoids. Using neutron diffraction on reconstituted thylakoid lipid extracts, we observed that the thylakoid lipid mixture self-organizes as a regular stack of bilayers. This natural lipid mixture was shown to switch from hexagonal II toward lamellar phase on hydration. This transition and the observed phase coexistence are modulated by the fine-tuning of the lipid profile, in particular the MGDG/DGDG ratio, and by the hydration. Our analysis highlights the critical role of DGDG as a contributing component to the membrane stacking via hydrogen bonds between polar heads of adjacent bilayers. DGDG interactions balance the repulsive electrostatic contribution of the charged lipids PG and SQDG and allow the persistence of regularly stacked membranes at high hydration. In developmental contexts or in response to environmental variations, these properties can contribute to the highly dynamic flexibility of plastid structure.	[Deme, Bruno] Inst Max Von Laue Paul Langevin, F-38042 Grenoble, France; [Cataye, Celine; Block, Maryse A.; Marechal, Eric; Jouhet, Juliette] CNRS, UMR 5168, Grenoble, France; [Cataye, Celine; Block, Maryse A.; Marechal, Eric; Jouhet, Juliette] Univ Grenoble Alpes, Grenoble, France; [Cataye, Celine; Block, Maryse A.; Marechal, Eric; Jouhet, Juliette] Commissariat Energie Atom & Energies Alternat C, DSV, IRTSV, Grenoble, France; [Cataye, Celine; Block, Maryse A.; Marechal, Eric; Jouhet, Juliette] INRA, LPCV, USC 1359, Grenoble, France	Institut Laue-Langevin (ILL); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CEA; INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Jouhet, J (corresponding author), Lab Physiol Cellulaire & Vegetale, 17 Rue Martyrs, F-38054 Grenoble 9, France.	juliette.jouhet@cea.fr	Demé, Bruno/AAG-1620-2021	Demé, Bruno/0000-0002-9523-7662	Agence Nationale de la Recherche [ANR-10-BLAN-1524, ANR-12-BIME-0005, ANR-12-JSV2-0001]; Labex Grenoble Alliance for Integrated Structural Cell Biology (GRAL)	Agence Nationale de la Recherche(French National Research Agency (ANR)); Labex Grenoble Alliance for Integrated Structural Cell Biology (GRAL)	The authors are grateful to the Institut Laue-Langevin for the allocation of beam time. C. C., M. A. B., E. M., and J.J. were supported by grants from Agence Nationale de la Recherche (ANR-10-BLAN-1524, ReGal; ANR-12-BIME-0005, DiaDom Oil, ANR-12-JSV2-0001, ChloroMitoLipid) and by the Labex Grenoble Alliance for Integrated Structural Cell Biology (GRAL).	ALLEN KD, 1988, J CELL BIOL, V107, P907, DOI 10.1083/jcb.107.3.907; [Anonymous], METHODS CHLOROPLAST; Armbruster U, 2013, PLANT CELL, V25, P2661, DOI 10.1105/tpc.113.113118; Aronsson H, 2008, PLANT PHYSIOL, V148, P580, DOI 10.1104/pp.108.123372; Austin JR, 2011, PLANT PHYSIOL, V155, P1601, DOI 10.1104/pp.110.170647; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCK MA, 1983, J BIOL CHEM, V258, P3273; Boggs JM, 2000, BIOPHYS J, V78, P874, DOI 10.1016/S0006-3495(00)76645-8; Botte CY, 2011, NAT CHEM BIOL, V7, P834, DOI 10.1038/nchembio.658; Bottier C, 2007, BBA-BIOMEMBRANES, V1768, P1526, DOI 10.1016/j.bbamem.2007.02.021; Boudiere L, 2014, BBA-BIOENERGETICS, V1837, P470, DOI 10.1016/j.bbabio.2013.09.007; Browse J, 2010, SCIENCE, V330, P185, DOI 10.1126/science.1196737; Chow WS, 2005, PHOTOCH PHOTOBIO SCI, V4, P1081, DOI 10.1039/b507310n; Collins AM, 2012, PLANT PHYSIOL, V158, P1600, DOI 10.1104/pp.111.192849; Cui YL, 2011, PLANT PHYSIOL, V155, P130, DOI 10.1104/pp.110.165589; Daum B, 2010, PLANT CELL, V22, P1299, DOI 10.1105/tpc.109.071431; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; deKruijff B, 1997, NATURE, V386, P129, DOI 10.1038/386129a0; Deme B, 2002, LANGMUIR, V18, P997, DOI 10.1021/la010723b; Deme B, 2002, BIOPHYS J, V82, P215, DOI 10.1016/S0006-3495(02)75388-5; Ding L, 2005, LANGMUIR, V21, P203, DOI 10.1021/la047876u; Dobrikova AG, 2013, PHYSIOL PLANTARUM, V147, P248, DOI 10.1111/j.1399-3054.2012.01648.x; DORMANN P, 1995, PLANT CELL, V7, P1801, DOI 10.1105/tpc.7.11.1801; Douce R, 1984, Subcell Biochem, V10, P1; DOUCE R, 1973, J BIOL CHEM, V248, P7215; Dubois M, 2001, NATURE, V411, P672, DOI 10.1038/35079541; Endow JK, 2010, PLANT SIGNAL BEHAV, V5, P721, DOI 10.4161/psb.5.6.11662; Garab G, 2000, TRENDS PLANT SCI, V5, P489, DOI 10.1016/S1360-1385(00)01767-2; GOUNARIS K, 1983, FEBS LETT, V156, P170, DOI 10.1016/0014-5793(83)80271-3; GOUNARIS K, 1986, BIOCHEM J, V237, P313, DOI 10.1042/bj2370313; GOUNARIS K, 1983, TRENDS BIOCHEM SCI, V8, P378, DOI 10.1016/0968-0004(83)90366-3; GOUNARIS K, 1983, BIOCHIM BIOPHYS ACTA, V728, P129, DOI 10.1016/0005-2736(83)90445-5; Groen D, 2011, BIOPHYS J, V100, P1481, DOI 10.1016/j.bpj.2011.02.001; Gruszecki WI, 2005, BBA-MOL BASIS DIS, V1740, P108, DOI 10.1016/j.bbadis.2004.11.015; Gunning BES, 2001, PROTOPLASMA, V215, P4, DOI 10.1007/BF01280299; Harauz G, 2009, BIOCHEMISTRY-US, V48, P8094, DOI 10.1021/bi901005f; Hartel H, 2000, BIOCHEM SOC T, V28, P729, DOI 10.1042/BST0280729; Hincha DK, 2003, BBA-BIOMEMBRANES, V1611, P180, DOI 10.1016/S0005-2736(03)00053-1; Holzl G, 2009, PLANT PHYSIOL, V150, P1147, DOI 10.1104/pp.109.139758; JACROT B, 1976, REP PROG PHYS, V39, P911, DOI 10.1088/0034-4885/39/10/001; Jahns P, 2009, BBA-BIOENERGETICS, V1787, P3, DOI 10.1016/j.bbabio.2008.09.013; Jouhet J, 2003, FEBS LETT, V544, P63, DOI 10.1016/S0014-5793(03)00477-0; Jouhet J, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00494; Kobayashi K, 2007, P NATL ACAD SCI USA, V104, P17216, DOI 10.1073/pnas.0704680104; Koshy KM, 1999, BIOPHYS J, V77, P306, DOI 10.1016/S0006-3495(99)76891-8; Koshy KM, 1996, J BIOL CHEM, V271, P3496; Krumova SB, 2008, BBA-BIOMEMBRANES, V1778, P997, DOI 10.1016/j.bbamem.2008.01.004; Krumova SB, 2010, PHOTOSYNTH RES, V105, P229, DOI 10.1007/s11120-010-9581-5; Ladygin VG, 2005, RUSS J PLANT PHYSL+, V52, P596, DOI 10.1007/s11183-005-0089-3; Latowski D, 2004, BIOCHEMISTRY-US, V43, P4417, DOI 10.1021/bi049652g; Liberton M, 2013, J BIOL CHEM, V288, P3632, DOI 10.1074/jbc.M112.416933; Lindblom G, 2002, BIOCHEMISTRY-US, V41, P11512, DOI 10.1021/bi0263098; MCDANIEL RV, 1988, BIOCHIM BIOPHYS ACTA, V940, P158, DOI 10.1016/0005-2736(88)90020-X; MCDONNEL A, 1980, J CELL BIOL, V84, P40, DOI 10.1083/jcb.84.1.40; MCINTOSH TJ, 1994, ANNU REV BIOPH BIOM, V23, P27, DOI 10.1146/annurev.bb.23.060194.000331; MENIKH A, 1993, EUR BIOPHYS J BIOPHY, V22, P249, DOI 10.1007/BF00180259; Miller W.H., 1839, TREATISE CRYSTALLOGR; Moellering ER, 2010, SCIENCE, V330, P226, DOI 10.1126/science.1191803; MURPHY DJ, 1982, FEBS LETT, V150, P19, DOI 10.1016/0014-5793(82)81297-0; Mustardy L, 2003, TRENDS PLANT SCI, V8, P117, DOI 10.1016/S1360-1385(03)00015-3; Nakanishi H, 2005, PLANT CELL PHYSIOL, V46, P467, DOI 10.1093/pcp/pci053; Nevo R, 2012, PLANT J, V70, P157, DOI 10.1111/j.1365-313X.2011.04876.x; Richard D., 1996, J NEUTRON RES, V4, P33, DOI [DOI 10.1080/10238169608200065, 10.1080/10238169608200065]; RIVAS E, 1969, J MOL BIOL, V41, P261, DOI 10.1016/0022-2836(69)90391-X; RYRIE IJ, 1980, EUR J BIOCHEM, V107, P345; Schaller S, 2011, BBA-BIOENERGETICS, V1807, P326, DOI 10.1016/j.bbabio.2010.12.017; Schaller S, 2010, BBA-BIOENERGETICS, V1797, P414, DOI 10.1016/j.bbabio.2009.12.011; Schneck E, 2011, BIOPHYS J, V100, P2151, DOI 10.1016/j.bpj.2011.03.011; Schneck E, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.041929; Schneck E, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.061924; SELSTAM E, 1984, PLANT PHYSIOL, V76, P1036, DOI 10.1104/pp.76.4.1036; SEN A, 1981, NATURE, V293, P488, DOI 10.1038/293488a0; SEN A, 1982, BIOCHIM BIOPHYS ACTA, V686, P215, DOI 10.1016/0005-2736(82)90115-8; SHIPLEY GG, 1973, BIOCHIM BIOPHYS ACTA, V311, P531; Siegel DP, 1999, BIOPHYS J, V76, P291, DOI 10.1016/S0006-3495(99)77197-3; STEWART RJ, 1993, BIOCHEMISTRY-US, V32, P10666, DOI 10.1021/bi00091a017; Tikkanen M, 2012, BBA-BIOENERGETICS, V1817, P232, DOI 10.1016/j.bbabio.2011.05.005; Torres-Franklin ML, 2007, PHYSIOL PLANTARUM, V131, P201, DOI 10.1111/j.1399-3054.2007.00943.x; WEBB MS, 1988, BIOCHIM BIOPHYS ACTA, V938, P323, DOI 10.1016/0005-2736(88)90130-7; WEBB MS, 1990, BIOCHIM BIOPHYS ACTA, V1030, P231, DOI 10.1016/0005-2736(90)90299-4; Williams WP, 1998, FEBS LETT, V422, P252, DOI 10.1016/S0014-5793(98)00019-2; Zemb T, 1999, SCIENCE, V283, P816, DOI 10.1126/science.283.5403.816	82	105	107	1	66	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3373	3383		10.1096/fj.13-247395	http://dx.doi.org/10.1096/fj.13-247395			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24736411				2022-12-28	WOS:000340265400009
J	Kataoka, S; Baba, A; Suda, Y; Takii, R; Hashimoto, M; Kawakubo, T; Asao, T; Kadowaki, T; Yamamoto, K				Kataoka, Shinsuke; Baba, Atsuyo; Suda, Yoshimitsu; Takii, Ryosuke; Hashimoto, Munetaka; Kawakubo, Tomoyo; Asao, Tetsuji; Kadowaki, Tomoko; Yamamoto, Kenji			A novel, potent dual inhibitor of Arg-gingipains and Lys-gingipain as a promising agent for periodontal disease therapy	FASEB JOURNAL			English	Article						infectious diseases; protease; protease inhibitor; pathogen	PORPHYROMONAS-GINGIVALIS W83; CYSTEINE PROTEINASE; STRUCTURAL-CHARACTERIZATION; CANINE PERIODONTITIS; CULTURE SUPERNATANT; ANIMAL-MODELS; RAT-LIVER; VIRULENCE; PURIFICATION; CATHEPSIN	The periodontal pathogen Porphyromonas gingivalis produces a unique class of cysteine proteinases termed gingipains that comprises Arg-gingipain (Rgp) and Lys-gingipain (Kgp). Growing evidence indicates that these 2 types of gingipains synergistically contribute to the entire virulence of the organism and increase the risk of periodontal disease (PD) by disrupting the host immune system and degrading the host tissue and plasma proteins. Therefore, a dual inhibitor of both gingipains would have attractive clinical potential for PD therapy. In this study, a novel, potent, dual inhibitor of Rgp and Kgp was developed through structure-based drug design, and its biological potency was evaluated in vitro and in vivo. This inhibitor had low nanomolar inhibitory potency (K-i = 40 nM for Rgp, K-i = 0.27 nM for Kgp) and good selectivity for host proteases and exhibited potent antibacterial activity against P. gingivalis by abrogating its manifold pathophysiological functions. The therapeutic potential of this inhibitor in vivo was also verified by suppressing the vascular permeability that was enhanced in guinea pigs by the organism and the gingival inflammation in beagle dog PD models. These findings suggest that a dual inhibitor of Rgp and Kgp would exhibit noteworthy anti-inflammatory activity in the treatment of PD.	[Kataoka, Shinsuke] Lion Corp, Life Sci Res Labs, Odawara, Kanagawa, Japan; [Baba, Atsuyo; Takii, Ryosuke; Hashimoto, Munetaka; Kadowaki, Tomoko; Yamamoto, Kenji] Kyushu Univ, Grad Sch Dent Sci, Dept Pharmacol, Fukuoka 8128582, Japan; [Kawakubo, Tomoyo; Yamamoto, Kenji] Kyushu Univ, Proteolysis Res Lab, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan; [Suda, Yoshimitsu; Asao, Tetsuji] Taiho Pharmaceut Corp, Tokushima Res Planning, Tokushima, Japan	Lion Corporation; Kyushu University; Kyushu University; Taiho Pharmaceutical	Yamamoto, K (corresponding author), Kyushu Univ, Proteolysis Res Lab, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan.	kyamamot@phar.kyushu-u.ac.jp						Abe N, 2004, BIOL CHEM, V385, P1041, DOI 10.1515/BC.2004.135; Abe N, 1998, J BIOCHEM, V123, P305; Albuquerque C, 2012, VET J, V191, P299, DOI 10.1016/j.tvjl.2011.08.017; Allaker R P, 1997, J Vet Dent, V14, P127; BANDO Y, 1986, J BIOCHEM-TOKYO, V100, P35, DOI 10.1093/oxfordjournals.jbchem.a121703; Beck J, 1996, J PERIODONTOL, V67, P1123, DOI 10.1902/jop.1996.67.10s.1123; BERGLUNDH T, 1991, J CLIN PERIODONTOL, V18, P616, DOI 10.1111/j.1600-051X.1991.tb00099.x; Darveau RP, 2009, DNA CELL BIOL, V28, P389, DOI 10.1089/dna.2009.0864; DeCarlo AA, 1997, J DENT RES, V76, P1260, DOI 10.1177/00220345970760060501; Genco CA, 1998, TRENDS MICROBIOL, V6, P444, DOI 10.1016/S0966-842X(98)01363-8; Genco R J, 1998, INFECT IMMUN, V19, P34; Grayson R, 2003, J CLIN PERIODONTOL, V30, P542, DOI 10.1034/j.1600-051X.2003.00301.x; Guo YH, 2010, PERIODONTOL 2000, V54, P15, DOI 10.1111/j.1600-0757.2010.00377.x; Hardham J, 2005, VET MICROBIOL, V106, P119, DOI 10.1016/j.vetmic.2004.12.018; Hashimoto M., 2003, J BIOCH, V140, P713; Holtfreter B, 2010, J CLIN PERIODONTOL, V37, P211, DOI 10.1111/j.1600-051X.2009.01517.x; Isogai H, 1999, J VET MED B, V46, P467, DOI 10.1046/j.1439-0450.1999.00249.x; Kadowaki T, 2004, MOL PHARMACOL, V66, P1599, DOI 10.1124/mol.104.004366; Kadowaki T, 2000, J BIOCHEM, V128, P153, DOI 10.1093/oxfordjournals.jbchem.a022735; Kadowaki T, 2003, CURR PROTEIN PEPT SC, V4, P451, DOI 10.2174/1389203033486992; Kadowaki T, 1998, J BIOL CHEM, V273, P29072, DOI 10.1074/jbc.273.44.29072; KADOWAKI T, 1994, J BIOL CHEM, V269, P21371; Kadowaki T, 2003, BIOL CHEM, V384, P911, DOI 10.1515/BC.2003.102; Kadowaki T, 2007, FRONT BIOSCI-LANDMRK, V12, P4800, DOI 10.2741/2428; Kitamura Y, 2002, J PERIODONTAL RES, V37, P464, DOI 10.1034/j.1600-0765.2002.01364.x; Klein T, 2008, CLIN TECH SMALL AN P, V15, P189; Kuo LC, 2008, PUBLIC HEALTH, V122, P417, DOI 10.1016/j.puhe.2007.07.004; Lalla E, 2003, ARTERIOSCL THROM VAS, V23, P1405, DOI 10.1161/01.ATV.0000082462.26258.FE; Li L, 2002, CIRCULATION, V105, P861, DOI 10.1161/hc0702.104178; Matsushita K, 2006, J PERIODONTAL RES, V41, P148, DOI 10.1111/j.1600-0765.2005.00853.x; Mezyk-Kopec R, 2005, INFECT IMMUN, V73, P1506, DOI 10.1128/IAI.73.3.1506-1514.2005; NAKAYAMA K, 1995, J BIOL CHEM, V270, P23619, DOI 10.1074/jbc.270.40.23619; Nakayama K, 1998, MOL MICROBIOL, V27, P51, DOI 10.1046/j.1365-2958.1998.00656.x; Okamoto K, 1998, J BIOL CHEM, V273, P21225, DOI 10.1074/jbc.273.33.21225; Okamoto K, 1996, J BIOCHEM-TOKYO, V120, P398; OKAMOTO K, 1995, ARCH BIOCHEM BIOPHYS, V316, P917, DOI 10.1006/abbi.1995.1123; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; Petersen PE, 2005, J PERIODONTOL, V76, P2187, DOI 10.1902/jop.2005.76.12.2187; Potempa J, 1997, BIOL CHEM, V378, P223, DOI 10.1515/bchm.1997.378.3-4.223; POTEMPA J, 1995, INFECT IMMUN, V63, P1176, DOI 10.1128/IAI.63.4.1176-1182.1995; Potempa J, 2000, PERIODONTOL 2000, V24, P153, DOI 10.1034/j.1600-0757.2000.2240108.x; Riggio MP, 2011, VET MICROBIOL, V150, P394, DOI 10.1016/j.vetmic.2011.03.001; SHAH HN, 1989, FEMS MICROBIOL LETT, V61, P213, DOI 10.1016/0378-1097(89)90199-7; Sheets SA, 2005, INFECT IMMUN, V73, P1543, DOI 10.1128/IAI.73.3.1543-1552.2005; Shi Y, 1999, J BIOL CHEM, V274, P17955, DOI 10.1074/jbc.274.25.17955; Tada H, 2002, INFECT IMMUN, V70, P3304, DOI 10.1128/IAI.70.6.3304-3307.2002; TOWATARI T, 1978, J BIOCHEM-TOKYO, V84, P659, DOI 10.1093/oxfordjournals.jbchem.a132171; TOWATARI T, 1976, FEBS LETT, V67, P284, DOI 10.1016/0014-5793(76)80548-0; Weinberg MA, 1999, J CLIN PERIODONTOL, V26, P335, DOI 10.1034/j.1600-051X.1999.260601.x; Yamamoto K, 1999, MCBU, P175; Yun PLW, 2005, INFECT IMMUN, V73, P1386, DOI 10.1128/IAI.73.3.1386-1398.2005	51	18	22	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3564	3578		10.1096/fj.14-252130	http://dx.doi.org/10.1096/fj.14-252130			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24776743				2022-12-28	WOS:000340265400025
J	Sbai, O; Monnier, C; Dode, C; Pin, JP; Hardelin, JP; Rondard, P				Sbai, Oualid; Monnier, Carine; Dode, Catherine; Pin, Jean-Philippe; Hardelin, Jean-Pierre; Rondard, Philippe			Biased signaling through G-protein-coupled PROKR2 receptors harboring missense mutations	FASEB JOURNAL			English	Article						Kallmann syndrome; beta-arrestin; prokineticin	RECESSIVE KALLMANN-SYNDROME; RESONANCE ENERGY-TRANSFER; ENDOTHELIAL GROWTH-FACTOR; HORMONE DEFICIENCY; LIVING CELLS; IDENTIFICATION; ACTIVATION; COMPLEX; LIGAND; GENES	Various missense mutations in the gene coding for prokineticin receptor 2 (PROKR2), a G-protein-coupled receptor, have been identified in patients with Kallmann syndrome. However, the functional consequences of these mutations on the different signaling pathways of this receptor have not been studied. We first showed that the wild-type PROKR2 can activate different G-protein subtypes (G(q), G(s), and G(i/o)) and recruit beta-arrestins in transfected HEK-293 cells. We then examined, for each of these signaling pathways, the effects of 9 mutations that did not significantly impair cell surface targeting or ligand binding of the receptor. Four mutant receptors showing defective G(q) signaling (R85C, R85H, R164Q, and V331M) could still recruit beta-arrestins on ligand activation, which may cause biased signaling in vivo. Conversely, the R80C receptor could activate the 3 types of G proteins but could not recruit beta-arrestins. Finally, the R268C receptor could recruit beta-arrestins and activate the G(q) and G(s) signaling pathways but could not activate the G(i/o) signaling pathway. Our results validate the concept that mutations in the genes encoding membrane receptors can bias downstream signaling in various ways, possibly leading to pathogenic and, perhaps in some cases, protective (e. g., R268C) effects.-Sbai, O., Monnier, C., Dod, C., Pin, J.-P., Hardelin, J.-P., Rondard, P. Biased signaling through G-protein-coupled PROKR2 receptors harboring missense mutations.	[Sbai, Oualid; Monnier, Carine; Pin, Jean-Philippe; Rondard, Philippe] Inst Genom Fonct, CNRS, UMR 5203, F-34094 Montpellier 5, France; [Sbai, Oualid; Monnier, Carine; Pin, Jean-Philippe; Rondard, Philippe] INSERM, U661, Montpellier, France; [Sbai, Oualid; Monnier, Carine; Pin, Jean-Philippe; Rondard, Philippe] Univ Montpellier 1&2, Montpellier, France; [Dode, Catherine] Univ Paris 05, Fac Sci Pharmaceut & Biol, EA7331, Paris, France; [Hardelin, Jean-Pierre] Inst Pasteur, INSERM, Dept Neurosci, UMRS 1120, F-75724 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite de Bordeaux	Rondard, P (corresponding author), Inst Genom Fonct, 141 Rue Cardonille, F-34094 Montpellier 5, France.	jean-pierre.hardelin@pasteur.fr; philippe.rondard@igf.cnrs.fr	Rondard, Philippe/N-9720-2018; Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X; RONDARD, Philippe/0000-0003-1134-2738	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (INSERM); Agence Nationale de la Recherche [ANR-09-GENO-017-01]; Fondation Bettencourt Schueller; Fondation pour la Recherche Medicale	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Fondation Bettencourt Schueller; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	The authors thank Dr. Guillaume Lebon for his help in preparing the 3D model of PROKR2. Quantification of the bias of signaling was performed with the technical assistance of Dr. Xavier Rovira. The intracellular calcium release HTRF and BRET experiments were performed on the ARPEGE (Pharmacology Screening-Interactome) platform facility at Institut de Genomique Fonctionnelle (Montpellier, France). This work was supported by the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Sante et de la Recherche Medicale (INSERM), and by grants from Agence Nationale de la Recherche (ANR-09-GENO-017-01) and Fondation Bettencourt Schueller. C. M. was supported by a fellowship from Fondation pour la Recherche Medicale. The authors declare no conflicts of interest.	Abreu AP, 2008, J CLIN ENDOCR METAB, V93, P4113, DOI 10.1210/jc.2008-0958; Abreu AP, 2012, MOL ENDOCRINOL, V26, P1417, DOI 10.1210/me.2012-1102; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Ayoub MA, 2007, MOL PHARMACOL, V71, P1329, DOI 10.1124/mol.106.030304; BLACK JW, 1985, BRIT J PHARMACOL, V84, P561, DOI 10.1111/j.1476-5381.1985.tb12941.x; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; CHABRE O, 1994, J BIOL CHEM, V269, P5730; Chan YM, 2009, P NATL ACAD SCI USA, V106, P11703, DOI 10.1073/pnas.0903449106; Chen JC, 2005, MOL PHARMACOL, V67, P2070, DOI 10.1124/mol.105.011619; Cole LW, 2008, J CLIN ENDOCR METAB, V93, P3551, DOI 10.1210/jc.2007-2654; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Dode C, 2006, PLOS GENET, V2, P1648, DOI 10.1371/journal.pgen.0020175; Dode C, 2009, EUR J HUM GENET, V17, P139, DOI 10.1038/ejhg.2008.206; Galandrin S, 2007, TRENDS PHARMACOL SCI, V28, P423, DOI 10.1016/j.tips.2007.06.005; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Grasberger H, 2007, J CLIN ENDOCR METAB, V92, P2816, DOI 10.1210/jc.2007-0366; Gregory KJ, 2010, J BIOL CHEM, V285, P7459, DOI 10.1074/jbc.M109.094011; Hardelin JP, 2008, SEX DEV, V2, P181, DOI 10.1159/000152034; Harrison T, 2003, SCIENCE, V301, P1734, DOI 10.1126/science.1089324; Kenakin T, 2013, NAT REV DRUG DISCOV, V12, P205, DOI 10.1038/nrd3954; Kenakin T, 2012, ACS CHEM NEUROSCI, V3, P193, DOI 10.1021/cn200111m; Leach K, 2012, ENDOCRINOLOGY, V153, P4304, DOI 10.1210/en.2012-1449; Lin DCH, 2002, J BIOL CHEM, V277, P19276, DOI 10.1074/jbc.M202139200; Lin R, 2002, J BIOL CHEM, V277, P8724, DOI 10.1074/jbc.M110594200; Liu JJ, 2012, SCIENCE, V335, P1106, DOI 10.1126/science.1215802; Liu JF, 2004, J BIOL CHEM, V279, P15824, DOI 10.1074/jbc.M313639200; Magnan R, 2013, J AM CHEM SOC, V135, P2560, DOI 10.1021/ja308784w; Marion S, 2006, J BIOL CHEM, V281, P2932, DOI 10.1074/jbc.M508074200; Monnier C, 2009, HUM MOL GENET, V18, P75, DOI 10.1093/hmg/ddn318; Nygaard R, 2013, CELL, V152, P532, DOI 10.1016/j.cell.2013.01.008; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Ostermaier MK, 2014, P NATL ACAD SCI USA, V111, P1825, DOI 10.1073/pnas.1319402111; Quoyer J, 2013, P NATL ACAD SCI USA, V110, pE5088, DOI 10.1073/pnas.1312515110; Rahmeh R, 2012, P NATL ACAD SCI USA, V109, P6733, DOI 10.1073/pnas.1201093109; Raivio T, 2012, J CLIN ENDOCR METAB, V97, pE694, DOI 10.1210/jc.2011-2938; Rajagopal S, 2010, NAT REV DRUG DISCOV, V9, P373, DOI 10.1038/nrd3024; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Sarfati J, 2010, J CLIN ENDOCR METAB, V95, P659, DOI 10.1210/jc.2009-0843; Sinisi AA, 2008, HUM REPROD, V23, P2380, DOI 10.1093/humrep/den247; Soga T, 2002, BBA-GENE STRUCT EXPR, V1579, P173, DOI 10.1016/S0167-4781(02)00546-8; Sykiotis GP, 2010, P NATL ACAD SCI USA, V107, P15140, DOI 10.1073/pnas.1009622107; Teixeira L, 2010, J CLIN INVEST, V120, P3668, DOI 10.1172/JCI43699; Tommiska J, 2013, FERTIL STERIL, V99, P815, DOI 10.1016/j.fertnstert.2012.11.003; Whalen EJ, 2011, TRENDS MOL MED, V17, P126, DOI 10.1016/j.molmed.2010.11.004	44	29	29	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3734	3744		10.1096/fj.13-243402	http://dx.doi.org/10.1096/fj.13-243402			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24830383				2022-12-28	WOS:000340265400039
J	Cheah, FC; Peskin, AV; Wong, FL; Ithnin, A; Othman, A; Winterbourn, CC				Cheah, Fook-Choe; Peskin, Alexander V.; Wong, Fei-Liang; Ithnin, Azlin; Othman, Ainoon; Winterbourn, Christine C.			Increased basal oxidation of peroxiredoxin 2 and limited peroxiredoxin recycling in glucose-6-phosphate dehydrogenase-deficient erythrocytes from newborn infants	FASEB JOURNAL			English	Article						antioxidant defense; hydrogen peroxide; hemolytic anemia	HYDROGEN-PEROXIDE; ACID; H2O2	Erythrocytes require glucose-6-phosphate dehydrogenase (G6PD) to generate NADPH and protect themselves against hemolytic anemia induced by oxidative stress. Peroxiredoxin 2 (Prx2) is a major antioxidant enzyme that requires NADPH to recycle its oxidized (disulfide-bonded) form. Our aims were to determine whether Prx2 is more highly oxidized in G6PD-deficient erythrocytes and whether these cells are able to recycle oxidized Prx2 after oxidant challenge. Blood was obtained from 61 Malaysian neonates with G6PD deficiency (average 33% normal activity) and 86 controls. Prx2 redox state was analyzed by Western blotting under nonreducing conditions. Prx2 in freshly isolated blood was predominantly reduced in both groups, but the median level of oxidation was significantly higher (8 vs 3%) and the range greater for the G6PD-deficient population. When treated with reagent H2O2, the G6PD-deficient erythrocytes were severely compromised in their ability to recycle oxidized Prx2, with only 27 or 4% reduction after 1 h treatment with 0.1 or 1 mM H2O2 respectively, compared with > 97% reduction in control erythrocytes. The accumulation of oxidized Prx2 in oxidatively stressed erythrocytes with common G6PD variants suggests that impaired antioxidant activity of Prx2 could contribute to the hemolysis and other complications associated with the condition.	[Cheah, Fook-Choe; Wong, Fei-Liang] Univ Kebangsaan Malaysia, Med Ctr, Dept Paediat, Kuala Lumpur, Malaysia; [Ithnin, Azlin] Univ Kebangsaan Malaysia, Med Ctr, Dept Pathol, Kuala Lumpur, Malaysia; [Peskin, Alexander V.; Winterbourn, Christine C.] Univ Otago Christchurch, Dept Pathol, Ctr Free Rad Res, Christchurch, New Zealand; [Winterbourn, Christine C.] Univ Otago Christchurch, Gravida Natl Ctr Growth & Dev, Christchurch, New Zealand; [Othman, Ainoon] Univ Sains Islam Malaysia, Dept Pathol, Kuala Lumpur, Malaysia	Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia; University of Otago; University of Otago; Universiti Sains Islam Malaysia	Winterbourn, CC (corresponding author), Univ Otago Christchurch, Dept Pathol, Ctr Free Rad Res, POB 4345, Christchurch, New Zealand.	christine.winterbourn@otago.ac.nz	Peskin, alexander/R-6457-2019; Cheah, Fook-Choe/AAC-9465-2021	Cheah, Fook-Choe/0000-0002-1137-6295; peskin, alexander/0000-0001-9890-6043	Ministry of Higher Education of Malaysia [UKM-FF-03-FRGS0038-2010]; Health Research Council of New Zealand	Ministry of Higher Education of Malaysia(Ministry of Education, Malaysia); Health Research Council of New Zealand(Health Research Council of New Zealand)	This work was supported by the Fundamental Research Grant Scheme (UKM-FF-03-FRGS0038-2010) from the Ministry of Higher Education of Malaysia and the Health Research Council of New Zealand. The authors thank Ms. Angeline Loh Mee-Ling, Dr. Chow Soon-Ken, and the nurses, doctors, and staff in the postnatal wards, neonatal intensive care unit, and molecular hematology laboratory of Universiti Kebangsaan Malaysia Medical Centre for their technical assistance.	Azma RZ, 2010, SE ASIAN J TROP MED, V41, P982; Bayer SB, 2013, FASEB J, V27, P3315, DOI 10.1096/fj.13-227298; Beutler E, 2008, BLOOD, V111, P16, DOI 10.1182/blood-2007-04-077412; Cappellini MD, 2008, LANCET, V371, P64, DOI 10.1016/S0140-6736(08)60073-2; Cho CS, 2010, ANTIOXID REDOX SIGN, V12, P1235, DOI 10.1089/ars.2009.2701; Gaetani GF, 1996, BLOOD, V87, P1595, DOI 10.1182/blood.V87.4.1595.bloodjournal8741595; Hall A, 2009, FEBS J, V276, P2469, DOI 10.1111/j.1742-4658.2009.06985.x; HOCHSTEIN P, 1988, FREE RADICAL BIO MED, V5, P387, DOI 10.1016/0891-5849(88)90112-8; Johnson RM, 2005, FREE RADICAL BIO MED, V39, P1407, DOI 10.1016/j.freeradbiomed.2005.07.002; Johnson RM, 2010, FREE RADICAL BIO MED, V48, P519, DOI 10.1016/j.freeradbiomed.2009.11.021; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Low FM, 2008, ANTIOXID REDOX SIGN, V10, P1621, DOI 10.1089/ars.2008.2081; Low FM, 2007, BLOOD, V109, P2611, DOI 10.1182/blood-2006-09-048728; Maisels MJ, 2004, PEDIATRICS, V114, P297; Mason PJ, 2007, BLOOD REV, V21, P267, DOI 10.1016/j.blre.2007.05.002; MOORE RB, 1991, J BIOL CHEM, V266, P18964; Nagababu E, 2013, FREE RADICAL RES, V47, P164, DOI 10.3109/10715762.2012.756138; Nkhoma ET, 2009, BLOOD CELL MOL DIS, V42, P267, DOI 10.1016/j.bcmd.2008.12.005; Peskin AV, 2007, J BIOL CHEM, V282, P11885, DOI 10.1074/jbc.M700339200; Peskin AV, 2010, BIOCHEM J, V432, P313, DOI 10.1042/BJ20101156; Poynton RA, 2014, BBA-GEN SUBJECTS, V1840, P906, DOI 10.1016/j.bbagen.2013.08.001; Rhee SG, 2011, ANTIOXID REDOX SIGN, V15, P781, DOI 10.1089/ars.2010.3393; SEIDMAN DS, 1995, J PEDIATR-US, V127, P804, DOI 10.1016/S0022-3476(95)70177-X; Stanton RC, 2012, IUBMB LIFE, V64, P362, DOI 10.1002/iub.1017; WINTERBOURN CC, 1987, J CLIN INVEST, V80, P1486, DOI 10.1172/JCI113230; WINTERBOURN CC, 1985, ENVIRON HEALTH PERSP, V64, P321, DOI 10.2307/3430020	27	13	14	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3205	3210		10.1096/fj.14-250050	http://dx.doi.org/10.1096/fj.14-250050			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24636884				2022-12-28	WOS:000337949400040
J	Gelabert-Baldrich, M; Soriano-Castell, D; Calvo, M; Lu, A; Vina-Vilaseca, A; Rentero, C; Pol, A; Grinstein, S; Enrich, C; Tebar, F				Gelabert-Baldrich, Mariona; Soriano-Castell, David; Calvo, Maria; Lu, Albert; Vina-Vilaseca, Arnau; Rentero, Carles; Pol, Albert; Grinstein, Sergio; Enrich, Carlos; Tebar, Francesc			Dynamics of KRas on endosomes: involvement of acidic phospholipids in its association	FASEB JOURNAL			English	Article						EGFR; PI3P; PS	RAS MEMBRANE ORIENTATION; K-RAS; PLASMA-MEMBRANE; H-RAS; CELLULAR MEMBRANES; MAMMALIAN-CELLS; CAAX MOTIF; PROTEINS; LOCALIZATION; RECEPTOR	The endocytic compartment is emerging as a functional platform for controlling important cellular processes. We have found that similar to 10 to 15% of total KRas, a protein that is frequently mutated in cancer, is present on endosomes, independent of its activation state. The dynamics of GFP-KRas wild-type (WT) and constitutively active or inactive mutants on endosomes were analyzed by fluorescence recovery after photobleaching (FRAP) microscopy. The measurements revealed an extraordinarily fast recovery of KRas WT [half-time (HT), similar to 1.3 s] compared to HRas, Rab5, and EGFR, with the active KRasG12V mutant being significantly faster and more mobile (HT, similar to 1 s, and similar to 82% of exchangeable fraction) than the inactive KRasS17N (HT, similar to 1.6 s, and similar to 60% of exchangeable fraction). KRas rapidly switches from the cytoplasm to the endosomal membranes by an electrostatic interaction between its polybasic region and the endosomal acidic phospholipids, mainly phosphatidylserine.	[Gelabert-Baldrich, Mariona; Soriano-Castell, David; Vina-Vilaseca, Arnau; Rentero, Carles; Pol, Albert; Enrich, Carlos; Tebar, Francesc] Univ Barcelona, Fac Med, Dept Biol Cellular Immunol & Neurociencies, IDIBAPS, Barcelona 08036, Spain; [Calvo, Maria] Univ Barcelona, Unitat Microscopia Opt Avancada, Fac Med, Ctr Cient, E-08036 Barcelona, Spain; [Calvo, Maria] Univ Barcelona, Unitat Microscopia Opt Avancada, Fac Med, Ctr Tecnol, E-08036 Barcelona, Spain; [Lu, Albert] Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA; [Pol, Albert] ICREA, Barcelona, Spain; [Grinstein, Sergio] Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; University of Barcelona; Stanford University; ICREA; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Tebar, F (corresponding author), Univ Barcelona, Fac Med, Dept Biol Cellular Immunol & Neurociencies, C Casanova 143, Barcelona 08036, Spain.	tebar@ub.edu	Rentero Alfonso, Carles/L-4430-2017; Pol, Albert/M-1865-2014; Vina-Vilaseca, Arnau/O-1779-2015; LU, ALBERT/AAB-6134-2019; Tebar, Francesc/H-1498-2015; Calvo, Maria/I-1872-2015	Rentero Alfonso, Carles/0000-0003-4684-0278; Pol, Albert/0000-0002-1750-1085; Vina-Vilaseca, Arnau/0000-0003-0447-5268; LU, ALBERT/0000-0002-7507-3330; Tebar, Francesc/0000-0002-9522-9726; Calvo, Maria/0000-0002-7473-0474; Enrich, Carlos/0000-0003-0382-2993; SORIANO-CASTELL, DAVID/0000-0002-1235-1671	Ministerio de Economia y Competitividad of Spain [BFU2012-38259]; Consolider-Ingenio from Ministerio de Innovacion, Ciencia y Tecnologia of Spain; FPI from Ministerio de Ciencia et Innovacion (MICINN) [BES2009-016850]; Generalitat de Catalunya;  [BFU2011-23745]; ICREA Funding Source: Custom	Ministerio de Economia y Competitividad of Spain(Spanish Government); Consolider-Ingenio from Ministerio de Innovacion, Ciencia y Tecnologia of Spain; FPI from Ministerio de Ciencia et Innovacion (MICINN); Generalitat de Catalunya(Generalitat de Catalunya); ; ICREA(ICREA)	The authors thank A. Bosch and E. Coll (Unitat Microscopia Optica Avancada, Centres Cientifics i Tecnologics, Universitat de Barcelona) for assistance with the confocal imaging and M. Molinos for technical assistance. This research was supported by grants BFU2012-38259 from Ministerio de Economia y Competitividad of Spain (to F. T.), Consolider-Ingenio from Ministerio de Innovacion, Ciencia y Tecnologia of Spain (to C. E. and A. P.), and BFU2011-23745 (to A. P.). M. G. is the recipient of FPI fellowship BES2009-016850 from Ministerio de Ciencia et Innovacion (MICINN). D. S. is the recipient of an FI fellowship from Generalitat de Catalunya. The authors declare no conflicts of interest.	Abankwa D, 2008, EMBO J, V27, P727, DOI 10.1038/emboj.2008.10; Abankwa D, 2010, P NATL ACAD SCI USA, V107, P1130, DOI 10.1073/pnas.0903907107; Alvarez-Moya Blanca, 2011, Small GTPases, V2, P99; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bhagatji P, 2010, BIOPHYS J, V99, P3327, DOI 10.1016/j.bpj.2010.10.001; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calvo F, 2010, BIOESSAYS, V32, P412, DOI 10.1002/bies.200900155; Chandra A, 2012, NAT CELL BIOL, V14, P148, DOI 10.1038/ncb2394; Cho KJ, 2012, J BIOL CHEM, V287, P43573, DOI 10.1074/jbc.M112.424457; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Eisenberg S, 2008, J BIOL CHEM, V283, P27279, DOI 10.1074/jbc.M804589200; Eisenberg S, 2008, CELL SIGNAL, V20, P31, DOI 10.1016/j.cellsig.2007.07.012; Elad-Sfadia G, 2004, J BIOL CHEM, V279, P34922, DOI 10.1074/jbc.M312697200; Fairn GD, 2011, J CELL BIOL, V194, P257, DOI 10.1083/jcb.201012028; Fehrenbacher N, 2009, MOL ONCOL, V3, P297, DOI 10.1016/j.molonc.2009.06.004; Figueroa C, 2001, J BIOL CHEM, V276, P28219, DOI 10.1074/jbc.M101763200; Fivaz M, 2005, J CELL BIOL, V170, P429, DOI 10.1083/jcb.200409157; Flores-Rodriguez N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024479; Frittoli E, 2011, EUR J CELL BIOL, V90, P108, DOI 10.1016/j.ejcb.2010.04.007; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gorfe AA, 2007, J MED CHEM, V50, P674, DOI 10.1021/jm061053f; Gould GW, 2009, NAT REV MOL CELL BIO, V10, P287, DOI 10.1038/nrm2652; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Jovic M, 2010, HISTOL HISTOPATHOL, V25, P99, DOI 10.14670/HH-25.99; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laude AJ, 2008, J CELL SCI, V121, P421, DOI 10.1242/jcs.020107; Le Roy C, 2005, DEV CELL, V9, P167, DOI 10.1016/j.devcel.2005.07.007; Leventis PA, 2010, ANNU REV BIOPHYS, V39, P407, DOI 10.1146/annurev.biophys.093008.131234; Leventis R, 1998, BIOCHEMISTRY-US, V37, P7640, DOI 10.1021/bi973077h; Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855; Llado A, 2004, MOL BIOL CELL, V15, P4877, DOI 10.1091/mbc.E04-02-0127; Lobert VH, 2011, PHYSIOLOGY, V26, P171, DOI 10.1152/physiol.00054.2010; Lopez-Alcala C, 2008, J BIOL CHEM, V283, P10621, DOI 10.1074/jbc.M706238200; Loubery S, 2008, TRAFFIC, V9, P492, DOI 10.1111/j.1600-0854.2008.00704.x; Lu A, 2009, J CELL BIOL, V184, P863, DOI 10.1083/jcb.200807186; Murphy JE, 2009, P NATL ACAD SCI USA, V106, P17615, DOI 10.1073/pnas.0906541106; Murray JT, 2002, TRAFFIC, V3, P416, DOI 10.1034/j.1600-0854.2002.30605.x; Nakaya M, 2008, P NATL ACAD SCI USA, V105, P9198, DOI 10.1073/pnas.0803677105; Nancy V, 2002, J BIOL CHEM, V277, P15076, DOI 10.1074/jbc.M109983200; Navarro-Lerida I, 2012, EMBO J, V31, P534, DOI 10.1038/emboj.2011.446; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Palamidessi A, 2008, CELL, V134, P135, DOI 10.1016/j.cell.2008.05.034; Pattni K, 2001, CURR BIOL, V11, P1636, DOI 10.1016/S0960-9822(01)00486-9; Petiot A, 2003, J CELL BIOL, V162, P971, DOI 10.1083/jcb.200303018; Philips MR, 2012, NAT CELL BIOL, V14, P128, DOI 10.1038/ncb2429; Prior I A, 1999, Mol Cell Biol Res Commun, V1, P162, DOI 10.1006/mcbr.1999.0126; Prior IA, 2012, SEMIN CELL DEV BIOL, V23, P145, DOI 10.1016/j.semcdb.2011.09.002; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Roy MO, 2000, BIOCHEMISTRY-US, V39, P8298, DOI 10.1021/bi000512q; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Scita G, 2010, NATURE, V463, P464, DOI 10.1038/nature08910; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Shin HW, 2005, J CELL BIOL, V170, P607, DOI 10.1083/jcb.200505128; Silvius JR, 2006, MOL BIOL CELL, V17, P192, DOI 10.1091/mbc.e05-05-0408; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Taub N, 2007, MOL BIOL CELL, V18, P4698, DOI 10.1091/mbc.E07-02-0098; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vartak N, 2010, EMBO J, V29, P2689, DOI 10.1038/emboj.2010.184; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	68	12	12	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3023	3037		10.1096/fj.13-241158	http://dx.doi.org/10.1096/fj.13-241158			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24719356				2022-12-28	WOS:000337949400025
J	Lantier, L; Fentz, J; Mounier, R; Leclerc, J; Treebak, JT; Pehmoller, C; Sanz, N; Sakakibara, I; Saint-Amand, E; Rimbaud, S; Maire, P; Marette, A; Ventura-Clapier, R; Ferry, A; Wojtaszewski, JFP; Foretz, M; Viollet, B				Lantier, Louise; Fentz, Joachim; Mounier, Remi; Leclerc, Jocelyne; Treebak, Jonas T.; Pehmoller, Christian; Sanz, Nieves; Sakakibara, Iori; Saint-Amand, Emmanuelle; Rimbaud, Stephanie; Maire, Pascal; Marette, Andre; Ventura-Clapier, Renee; Ferry, Arnaud; Wojtaszewski, Jorgen F. P.; Foretz, Marc; Viollet, Benoit			AMPK controls exercise endurance, mitochondrial oxidative capacity, and skeletal muscle integrity	FASEB JOURNAL			English	Article						glucose transport; force production	ACTIVATED PROTEIN-KINASE; GLUCOSE-UPTAKE; CONTRACTION; PHOSPHORYLATION; TRANSPORT; MICE; AMPK-ALPHA-2; DEFICIENCY; PGC-1-ALPHA; PERFORMANCE	AMP-activated protein kinase (AMPK) is a sensor of cellular energy status that plays a central role in skeletal muscle metabolism. We used skeletal muscle-specific AMPK alpha 1 alpha 2 double-knockout (mdKO) mice to provide direct genetic evidence of the physiological importance of AMPK in regulating muscle exercise capacity, mitochondrial function, and contraction-stimulated glucose uptake. Exercise performance was significantly reduced in the mdKO mice, with a reduction in maximal force production and fatigue resistance. An increase in the proportion of myofibers with centralized nuclei was noted, as well as an elevated expression of interleukin 6 (IL-6) mRNA, possibly consistent with mild skeletal muscle injury. Notably, we found that AMPK alpha 1 and AMPK alpha 2 isoforms are dispensable for contraction-induced skeletal muscle glucose transport, except for male soleus muscle. However, the lack of skeletal muscle AMPK diminished maximal ADP-stimulated mitochondrial respiration, showing an impairment at complex I. This effect was not accompanied by changes in mitochondrial number, indicating that AMPK regulates muscle metabolic adaptation through the regulation of muscle mitochondrial oxidative capacity and mitochondrial substrate utilization but not baseline mitochondrial muscle content. Together, these results demonstrate that skeletal muscle AMPK has an unexpected role in the regulation of mitochondrial oxidative phosphorylation that contributes to the energy demands of the exercising muscle.	[Lantier, Louise; Mounier, Remi; Leclerc, Jocelyne; Sanz, Nieves; Sakakibara, Iori; Maire, Pascal; Foretz, Marc; Viollet, Benoit] Inst Cochin Genet Mol, INSERM, U1016, F-75014 Paris, France; [Lantier, Louise; Mounier, Remi; Leclerc, Jocelyne; Sanz, Nieves; Sakakibara, Iori; Maire, Pascal; Foretz, Marc; Viollet, Benoit] CNRS, UMR 8104, Paris, France; [Lantier, Louise; Mounier, Remi; Leclerc, Jocelyne; Sanz, Nieves; Sakakibara, Iori; Maire, Pascal; Ferry, Arnaud; Foretz, Marc; Viollet, Benoit] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Fentz, Joachim; Treebak, Jonas T.; Pehmoller, Christian; Wojtaszewski, Jorgen F. P.] Univ Copenhagen, August Krogh Ctr, Dept Nutr Exercise & Sports, Sect Mol Physiol, Copenhagen, Denmark; [Saint-Amand, Emmanuelle; Marette, Andre] Univ Laval, Ste Foy, PQ G1K 7P4, Canada; [Rimbaud, Stephanie; Ventura-Clapier, Renee] Univ Paris 11, INSERM, U769, Chatenay Malabry, France; [Ferry, Arnaud] Univ Paris 06, CNRS, Inst Myol, INSERM,U974,UMR 7215, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Copenhagen; Laval University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Viollet, B (corresponding author), Inst Cochin Genet Mol, INSERM, U1016, Dept Endocrinol Metab & Diabet, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	benoit.viollet@inserm.fr	Viollet, Benoit/O-6927-2017; Treebak, Jonas Thue/B-4521-2017; FORETZ, Marc/O-7334-2017; Fentz, Joachim/B-1973-2015; ferry, arnaud/D-2816-2019; Maire, Pascal/E-6339-2016; Wojtaszewski, Jørgen FP/P-6583-2014; Viollet, Benoit/N-2397-2019	Viollet, Benoit/0000-0002-0121-0224; Treebak, Jonas Thue/0000-0003-1488-7012; FORETZ, Marc/0000-0001-7017-9032; Fentz, Joachim/0000-0002-9334-1298; ferry, arnaud/0000-0002-6050-4556; Wojtaszewski, Jørgen FP/0000-0001-9785-6830; Viollet, Benoit/0000-0002-0121-0224; wojtaszewski, jorgen/0000-0001-8185-3408; Marette, Andre/0000-0003-3950-5973; Pehmoller, Christian/0000-0001-7102-7727; Maire, Pascal/0000-0001-7795-0029; Ventura-Clapier, Renee/0000-0002-7488-4123	European Commission [LSHM-CT-2004-005272/EXGENESIS]; Agence Nationale de la Recherche (ANR); Association Francaise contre les Myopathies (AFM); Fondation pour la Recherche Medicale (FRM); Canadian Institutes for Health Research; Danish Council for Independent Research Medical Sciences (FSS); Novo Nordisk Foundation; University Paris Descartes; Danish Agency for Science, Technology, and Innovation; NNF Center for Basic Metabolic Research [Treebak Group] Funding Source: researchfish; Novo Nordisk Fonden [NNF14OC0009315] Funding Source: researchfish	European Commission(European CommissionEuropean Commission Joint Research Centre); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); Association Francaise contre les Myopathies (AFM)(Association Francaise contre les Myopathies); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Danish Council for Independent Research Medical Sciences (FSS)(Det Frie Forskningsrad (DFF)Danish Medical Research Council); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); University Paris Descartes; Danish Agency for Science, Technology, and Innovation; NNF Center for Basic Metabolic Research(Novo Nordisk Foundation); Novo Nordisk Fonden(Novo Nordisk Foundation)	The authors thank G. Hardie (University of Dundee, Dundee, UK) for providing the anti-AMPK alpha 1 and anti-AMPK alpha 2 antibodies, J. Melki (INSERM U788, Paris, France) for kindly providing HSA-Cre transgenic mice for breeding, and A. Schmitt (Cochin Institute electron microscopy facility) for transmission electron micrographs. This work was supported by grants from the European Commission integrated project (LSHM-CT-2004-005272/EXGENESIS) and Agence Nationale de la Recherche (ANR) to B.V., Association Francaise contre les Myopathies (AFM) to B.V. and P.M., Fondation pour la Recherche Medicale (FRM) to R.V.C., and the Canadian Institutes for Health Research to A.M. Region Ile de France contributed to the Cochin Institute animal care facility. This work was also performed as a part of the program of the University of Southern Denmark (UNIK) program Food, Fitness, and Pharma for Health and Disease (http://www.foodfitnesspharma.ku.dk). The UNIK project is supported by the Danish Ministry of Science, Technology, and Innovation. The study was funded by the Danish Council for Independent Research Medical Sciences (FSS) and the Novo Nordisk Foundation. E.S.-A. was recipient of a Bourses Doctorales de Mobilite de l'Universite (BDMU) fellowship from University Paris Descartes. J.T.T. was supported by a postdoctoral fellowship from The Danish Agency for Science, Technology, and Innovation. R.V.C. is a senior scientist at CNRS.	Abbott MJ, 2011, J APPL PHYSIOL, V111, P125, DOI 10.1152/japplphysiol.00807.2010; Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105; Athea Y, 2007, DIABETES, V56, P786, DOI 10.2337/db06-0187; Barre L, 2007, AM J PHYSIOL-ENDOC M, V292, pE802, DOI 10.1152/ajpendo.00369.2006; Birk JB, 2006, J PHYSIOL-LONDON, V577, P1021, DOI 10.1113/jphysiol.2006.120972; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Fogarty S, 2010, BIOCHEM J, V426, P109, DOI 10.1042/BJ20091372; Friedrichsen M, 2013, MOL CELL ENDOCRINOL, V366, P204, DOI 10.1016/j.mce.2012.06.013; Fujii N, 2005, J BIOL CHEM, V280, P39033, DOI 10.1074/jbc.M504208200; Hadj-Said W, 2012, MUSCLE NERVE, V45, P567, DOI 10.1002/mus.22332; Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jensen TE, 2009, ACTA PHYSIOL, V196, P155, DOI 10.1111/j.1748-1716.2009.01979.x; Jensen TE, 2007, AM J PHYSIOL-ENDOC M, V292, pE1308, DOI 10.1152/ajpendo.00456.2006; Jensen TE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002102; Jeppesen J, 2013, DIABETES, V62, P1490, DOI 10.2337/db12-1160; Joanne P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035346; Jorgensen SB, 2005, FASEB J, V19, P1146, DOI 10.1096/fj.04-3144fje; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Jorgensen SB, 2007, AM J PHYSIOL-ENDOC M, V292, pE331, DOI 10.1152/ajpendo.00243.2006; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Klein DK, 2007, AM J PHYSIOL-ENDOC M, V293, pE1242, DOI 10.1152/ajpendo.00382.2007; Kristensen JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053533; Larsen S, 2012, ACTA PHYSIOL, V205, P314, DOI 10.1111/j.1748-1716.2011.02399.x; Lee-Young RS, 2011, INT J OBESITY, V35, P982, DOI 10.1038/ijo.2010.220; Lee-Young RS, 2009, J BIOL CHEM, V284, P23925, DOI 10.1074/jbc.M109.021048; Lefort N, 2008, AM J PHYSIOL-ENDOC M, V295, pE1447, DOI 10.1152/ajpendo.90362.2008; Leick L, 2008, AM J PHYSIOL-ENDOC M, V294, pE463, DOI 10.1152/ajpendo.00666.2007; Maarbjerg SJ, 2009, AM J PHYSIOL-ENDOC M, V297, pE924, DOI 10.1152/ajpendo.90653.2008; Mettaure B, 2001, J AM COLL CARDIOL, V38, P947, DOI 10.1016/S0735-1097(01)01460-7; Miniou P, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.19.e27; MORGAN JE, 1990, J CELL BIOL, V111, P2437, DOI 10.1083/jcb.111.6.2437; Mounier R, 2013, CELL METAB, V18, P251, DOI 10.1016/j.cmet.2013.06.017; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; O'Neill HM, 2013, DIABETES METAB J, V37, P1, DOI 10.4093/dmj.2013.37.1.1; O'Neill HM, 2013, MOL CELL ENDOCRINOL, V366, P135, DOI 10.1016/j.mce.2012.06.019; O'Neill HM, 2011, P NATL ACAD SCI USA, V108, P16092, DOI 10.1073/pnas.1105062108; Rockl KSC, 2007, DIABETES, V56, P2062, DOI 10.2337/db07-0255; Roepstorff C, 2006, J PHYSIOL-LONDON, V574, P125, DOI 10.1113/jphysiol.2006.108720; Rowe GC, 2013, CELL REP, V3, P1449, DOI 10.1016/j.celrep.2013.04.023; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Scheffler TL, 2014, AM J PHYSIOL-CELL PH, V306, pC354, DOI 10.1152/ajpcell.00002.2013; Shinmura K, 2011, CIRC RES, V109, P396, DOI 10.1161/CIRCRESAHA.111.243097; Tanner CB, 2013, AM J PHYSIOL-ENDOC M, V305, pE1018, DOI 10.1152/ajpendo.00227.2013; Treebak JT, 2007, AM J PHYSIOL-ENDOC M, V292, pE715, DOI 10.1152/ajpendo.00380.2006; Treebak JT, 2014, J PHYSIOL-LONDON, V592, P351, DOI 10.1113/jphysiol.2013.266338; Treebak JT, 2009, AM J PHYSIOL-CELL PH, V297, pC1041, DOI 10.1152/ajpcell.00051.2009; Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09-0482; Vassilopoulos A, 2014, ANTIOXID REDOX SIGN, V21, P551, DOI 10.1089/ars.2013.5420; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	55	140	146	0	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3211	3224		10.1096/fj.14-250449	http://dx.doi.org/10.1096/fj.14-250449			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24652947				2022-12-28	WOS:000337949400041
J	Park, TS; Lee, HG; Moon, JK; Lee, HJ; Yoon, JW; Yun, BNR; Kang, SC; Kim, J; Kim, H; Han, JY; Han, BK				Park, Tae Sub; Lee, Hyo Gun; Moon, Jong Kook; Lee, Hong Jo; Yoon, Jong Won; Yun, Bit Na Rae; Kang, Sang-Chul; Kim, Jiho; Kim, Hyunil; Han, Jae Yong; Han, Beom Ku			Deposition of bioactive human epidermal growth factor in the egg white of transgenic hens using an oviduct-specific minisynthetic promoter	FASEB JOURNAL			English	Article						bioreactor; piggyBac transposon; primordial germ cell	PRIMORDIAL GERM-CELLS; LINE TRANSMISSION; RETROVIRAL VECTOR; FUSION GENES; CHICKENS; PIGGYBAC; MICE; TRANSPOSITION; EXPRESSION; MICROINJECTION	Currently, transgenic animals have found a wide range of industrial applications and are invaluable in various fields of basic research. Notably, deposition of transgene-encoded proteins in the egg white (EW) of hens affords optimal production of genetically engineered biomaterials. In the present study, we developed a minisynthetic promoter modulating transgene transcription specifically in the hen's oviduct, and assayed the bioactivity of human epidermal growth factor (hEGF) driven by that promoter, after partial purification of epidermal growth factor (EGF) from transgenic hen eggs. Our minisynthetic promoter driving expression of chicken codon-optimized human epidermal growth factor (cEGF) features 2 consecutive estrogen response elements of the ovalbumin (OV) promoter, ligated with a 3.0 kb OV promoter region carrying OV regulatory elements, and a 5'-UTR. Subsequently, a 3'-UTR carrying the poly-A tail sequence of the OV gene was added after incorporation of the cEGF transgene. Finally, we partially purified cEGF from transgenic hen eggs and evaluated the biofunctional activities thereof in vitro and in vivo. In the in vitro assay, EW-derived hEGF exhibited a proliferative effect on HeLa cells similar to that of commercial hEGF. In the in vivo assay, compared to the nontreated control, transgenic hen egg-derived EGF afforded slightly higher levels of re-epithelialization (via fibroplasia) and neovascularization of wounded skin of miniature pigs than did the commercial material. In conclusion, transgenic hens may be used to produce genetically engineered bioactive biomaterials driven by an oviduct-specific minisynthetic promoter.	[Park, Tae Sub] Seoul Natl Univ, Grad Sch Int Agr Technol, Gangwon Do, South Korea; [Park, Tae Sub] Seoul Natl Univ, Inst Green Bio Sci & Technol, Gangwon Do, South Korea; [Lee, Hyo Gun; Lee, Hong Jo; Yoon, Jong Won; Han, Jae Yong] Seoul Natl Univ, Coll Agr & Life Sci, Dept Agr Biotechnol, Seoul 151921, South Korea; [Moon, Jong Kook; Yun, Bit Na Rae; Kang, Sang-Chul; Kim, Jiho; Kim, Hyunil; Han, Beom Ku] Optipharm, Cheongju 363954, Chungcheongbku, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Han, JY (corresponding author), Seoul Natl Univ, Coll Agr & Life Sci, Dept Agr Biotechnol, Seoul 151921, South Korea.	jaehan@snu.ac.kr; bkhan@optipharm.co.kr		Lee, Hyo Gun/0000-0002-3286-7368	Bio-industry Technology Development Program [IPET-312060-5-2-SB020]; Ministry for Food, Agriculture, Forestry and Fisheries, Republic of Korea; Technological Innovation R&D Program - Small and Medium Business Administration (Korea) [SA112684]	Bio-industry Technology Development Program; Ministry for Food, Agriculture, Forestry and Fisheries, Republic of Korea; Technological Innovation R&D Program - Small and Medium Business Administration (Korea)	This work was supported by the Bio-industry Technology Development Program (IPET-312060-5-2-SB020), Ministry for Food, Agriculture, Forestry and Fisheries, Republic of Korea. This research was also supported by the Technological Innovation R&D Program (SA112684) funded by the Small and Medium Business Administration (Korea).	Agate RJ, 2009, P NATL ACAD SCI USA, V106, P17963, DOI 10.1073/pnas.0909139106; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Choi JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012968; Ding S, 2005, CELL, V122, P473, DOI 10.1016/j.cell.2005.07.013; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; Harvey AJ, 2002, NAT BIOTECHNOL, V20, P396, DOI 10.1038/nbt0402-396; Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041; Kamihira M, 2005, J VIROL, V79, P10864, DOI 10.1128/JVI.79.17.10864-10874.2005; Kwon SC, 2010, BIOL REPROD, V82, P1057, DOI 10.1095/biolreprod.109.081687; Lillico SG, 2007, P NATL ACAD SCI USA, V104, P1771, DOI 10.1073/pnas.0610401104; LOVE J, 1994, BIO-TECHNOL, V12, P60, DOI 10.1038/nbt0194-60; Macdonald J, 2012, P NATL ACAD SCI USA, V109, pE1466, DOI 10.1073/pnas.1118715109; Macdonald J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015518; Mizuarai S, 2001, BIOCHEM BIOPH RES CO, V286, P456, DOI 10.1006/bbrc.2001.5422; Motono M, 2010, J BIOSCI BIOENG, V109, P315, DOI 10.1016/j.jbiosc.2009.10.007; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; Park SH, 2010, THERIOGENOLOGY, V74, P805, DOI 10.1016/j.theriogenology.2010.04.005; Park TS, 2014, P NATL ACAD SCI USA, V111, P12716, DOI 10.1073/pnas.1410555111; Park TS, 2012, P NATL ACAD SCI USA, V109, P9337, DOI 10.1073/pnas.1203823109; SALTER DW, 1986, POULTRY SCI, V65, P1445, DOI 10.3382/ps.0651445; Schusser B, 2013, P NATL ACAD SCI USA, V110, P20170, DOI 10.1073/pnas.1317106110; Shin SS, 2008, FASEB J, V22, P2435, DOI 10.1096/fj.07-101485; Song G, 2011, ANN NY ACAD SCI, V1229, P69, DOI 10.1111/j.1749-6632.2011.06087.x; van de Lavoir MC, 2006, NATURE, V441, P766, DOI 10.1038/nature04831; Wang W, 2008, P NATL ACAD SCI USA, V105, P9290, DOI 10.1073/pnas.0801017105; Zhu L, 2005, NAT BIOTECHNOL, V23, P1159, DOI 10.1038/nbt1132	28	36	40	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2386	2396		10.1096/fj.14-264739	http://dx.doi.org/10.1096/fj.14-264739			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25690652				2022-12-28	WOS:000355209500016
J	Labbe, SM; Caron, A; Bakan, I; Laplante, M; Carpentier, AC; Lecomte, R; Richard, D				Labbe, Sebastien M.; Caron, Alexandre; Bakan, Inan; Laplante, Mathieu; Carpentier, Andre C.; Lecomte, Roger; Richard, Denis			In vivo measurement of energy substrate contribution to cold-induced brown adipose tissue thermogenesis	FASEB JOURNAL			English	Article						positron emission tomography; glucose uptake; glycogenesis; lipogenesis; NEFA uptake	FATTY-ACID SYNTHESIS; DE-NOVO LIPOGENESIS; ACCLIMATED RATS; NONSHIVERING THERMOGENESIS; LIPID-METABOLISM; ACTIVATION; MECHANISMS; EXPOSURE; GLUCOSE; CALORIGENESIS	The present study was designed to investigate the effects of cold on brown adipose tissue (BAT) energy substrate utilization in vivo using the positron emission tomography tracers [F-18]fluorodeoxyglucose (glucose uptake), 14(R,S)-[F-18]fluoro-6-thia-heptadecanoic acid [nonesterified fatty acid (NEFA) uptake], and [C-11]acetate (oxidative activity). The measurements were performed in rats adapted to 27 degrees C, which were acutely subjected to cold (10 degrees C) for 2 and 6 hours, and in rats chronically adapted to 10 degrees C for 21 days, which were returned to 27 degrees C for 2 and 6 hours. Cold exposure (acutely and chronically) led to increases in BAT oxidative activity, which was accompanied by concomitant increases in glucose and NEFA uptake. The increases were particularly high in cold-adapted rats and largely readily reduced by the return to a warm environment. The cold-induced increase in oxidative activity was meaningfully blunted by nicotinic acid, a lipolysis inhibitor, which emphasizes in vivo the key role of intracellular lipid in BAT thermogenesis. The changes in BAT oxidative activity and glucose and NEFA uptakes were paralleled by inductions of genes involved in not only oxidative metabolism but also in energy substrate replenishment (triglyceride and glycogen synthesis). The capacity of BAT for energy substrate replenishment is remarkable.	[Labbe, Sebastien M.; Caron, Alexandre; Bakan, Inan; Laplante, Mathieu; Richard, Denis] Univ Laval, Ctr Rech, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Carpentier, Andre C.] Ctr Hosp, Ctr Rech, Dept Med, Sherbrooke, PQ, Canada; [Lecomte, Roger] Univ Sherbrooke, Dept Nucl Med, Ctr Imagerie Mol Sherbrooke, Sherbrooke, PQ J1K 2R1, Canada; [Lecomte, Roger] Univ Sherbrooke, Dept Radiobiol, Ctr Imagerie Mol Sherbrooke, Sherbrooke, PQ J1K 2R1, Canada	Laval University; University of Sherbrooke; University of Sherbrooke	Richard, D (corresponding author), Inst Univ Cardiol & Pneumol Quebec, 2725 Chemin St Foy, Ste Foy, PQ G1V 4G5, Canada.	denis.richard@criucpq.ulaval.ca	Caron, Alexandre/J-3151-2015; LECOMTE, Roger/F-2582-2011	Caron, Alexandre/0000-0001-6939-6136; LECOMTE, Roger/0000-0002-8541-0783	Natural Sciences and Engineering Research Council of Canada [2014-06721]; Canadian Institutes of Health Research (CIHR); CIHR-GlaxoSmithKline Chair in Diabetes	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR-GlaxoSmithKline Chair in Diabetes	The authors are grateful to Jean-Francois Beaudoin for his helpful positron emission tomography scan assistance and Serge Phoenix for radiotracer synthesis. This work was supported by a grant from the Natural Sciences and Engineering Research Council of Canada (2014-06721). S.M.L. is the recipient of a Canadian Institutes of Health Research (CIHR) postdoctoral fellowship. A.C. holds a fellowship from the CIHR Training Program in Obesity/Healthy Body Weight Research. A.C.C. is the recipient of the CIHR-GlaxoSmithKline Chair in Diabetes. S.M.L. and D.R. conceived and designed the experiments. S.M.L., A.C., I.B., and D.R. collected, analyzed, and interpreted the data. All authors drafted the article or revised it critically for important intellectual content.	AHERNE W, 1966, J PATHOL BACTERIOL, V91, P223, DOI 10.1002/path.1700910126; Baba S, 2010, J NUCL MED, V51, P246, DOI 10.2967/jnumed.109.068775; Bartelt A, 2011, NAT MED, V17, P200, DOI 10.1038/nm.2297; BERTIN R, 1976, EUR J BIOCHEM, V69, P177, DOI 10.1111/j.1432-1033.1976.tb10871.x; Blondin DP, 2014, J CLIN ENDOCR METAB, V99, pE438, DOI 10.1210/jc.2013-3901; BOBBIONIHARSCH E, 1994, J APPL PHYSIOL, V76, P1106, DOI 10.1152/jappl.1994.76.3.1106; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; CARLSON LA, 1965, ANN NY ACAD SCI, V131, P119, DOI 10.1111/j.1749-6632.1965.tb34784.x; Cohade C, 2003, J NUCL MED, V44, P170; COONEY GJ, 1982, FEBS LETT, V148, P198, DOI 10.1016/0014-5793(82)80807-7; Cypess AM, 2012, P NATL ACAD SCI USA, V109, P10001, DOI 10.1073/pnas.1207911109; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; DEPOCAS F, 1978, CAN J PHYSIOL PHARM, V56, P168, DOI 10.1139/y78-023; Dulloo AG, 2004, INT J OBESITY, V28, pS29, DOI 10.1038/sj.ijo.0802861; Festuccia William T, 2011, Front Endocrinol (Lausanne), V2, P84, DOI 10.3389/fendo.2011.00084; FOSTER DO, 1974, CAN J PHYSIOL PHARM, V52, P1051, DOI 10.1139/y74-139; FOSTER DO, 1984, CAN J BIOCHEM CELL B, V62, P618, DOI 10.1139/o84-082; FOSTER DO, 1978, CAN J PHYSIOL PHARM, V56, P110, DOI 10.1139/y78-015; Fredriksson JM, 2005, FEBS LETT, V579, P5680, DOI 10.1016/j.febslet.2005.09.044; Friedli C, 1978, Experientia Suppl, V32, P259; Gille A, 2008, ANNU REV PHARMACOL, V48, P79, DOI 10.1146/annurev.pharmtox.48.113006.094746; GOUBERN M, 1986, ANN NUTR METAB, V30, P380, DOI 10.1159/000177219; Hausman GJ, 2004, J ANIM SCI, V82, P925; HIMMSHAGEN J, 1965, CAN J PHYSIOL PHARM, V43, P379, DOI 10.1139/y65-039; Li YG, 2014, EMBO REP, V15, P1069, DOI 10.15252/embr.201438775; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; LUBOSHITZKY R, 1983, INT J OBESITY, V7, P241; Mantha L, 1998, AM J PHYSIOL-REG I, V274, pR1769; MCCORMACK JG, 1977, BIOCHEM J, V166, P627, DOI 10.1042/bj1660627; Menard SL, 2010, AM J PHYSIOL-ENDOC M, V298, pE1049, DOI 10.1152/ajpendo.00560.2009; Mirbolooki MR, 2014, NUCL MED BIOL, V41, P10, DOI 10.1016/j.nucmedbio.2013.08.009; Mirbolooki MR, 2011, EJNMMI RES, V1, DOI 10.1186/2191-219X-1-30; Monge-Roffarello B, 2014, ENDOCRINOLOGY, V155, P3448, DOI 10.1210/en.2013-2092; Mottillo EP, 2014, J LIPID RES, V55, P2276, DOI 10.1194/jlr.M050005; Moura MAF, 2005, PFLUG ARCH EUR J PHY, V449, P463, DOI 10.1007/s00424-004-1353-7; Moura MAF, 2001, METABOLISM, V50, P1493, DOI 10.1053/meta.2001.27197; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NIKAMI H, 1992, BIOCHEM BIOPH RES CO, V185, P1078, DOI 10.1016/0006-291X(92)91736-A; Orava J, 2011, CELL METAB, V14, P272, DOI 10.1016/j.cmet.2011.06.012; Ouellet V, 2012, J CLIN INVEST, V122, P545, DOI 10.1172/JCI60433; PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87; PORTET R, 1976, ARCH INT PHYSIOL BIO, V84, P89, DOI 10.3109/13813457609072350; Richard D, 2011, FRONT BIOSCI-LANDMRK, V16, P1233, DOI 10.2741/3786; Ricquier Daniel, 2011, Front Endocrinol (Lausanne), V2, P85, DOI 10.3389/fendo.2011.00085; Schlogl M, 2013, J CLIN ENDOCR METAB, V98, pE1956, DOI 10.1210/jc.2013-2387; Shabalina IG, 2013, CELL REP, V5, P1196, DOI 10.1016/j.celrep.2013.10.044; Toczek J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099441; Townsend KL, 2014, TRENDS ENDOCRIN MET, V25, P168, DOI 10.1016/j.tem.2013.12.004; TRAYHURN P, 1979, FEBS LETT, V104, P13, DOI 10.1016/0014-5793(79)81075-3; van den Hoff J, 2001, J NUCL MED, V42, P1174; van der Lans AAJJ, 2013, J CLIN INVEST, V123, P3395, DOI 10.1172/JCI68993; vandenHoff J, 1996, J NUCL MED, V37, P521; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Wu QW, 2006, DIABETES, V55, P3229, DOI 10.2337/db06-0749; Xue Y, 2009, CELL METAB, V9, P99, DOI 10.1016/j.cmet.2008.11.009; Yamamoto T, 2011, BIOTECHNOL LETT, V33, P237, DOI 10.1007/s10529-010-0444-0; Yoneshiro T, 2013, J CLIN INVEST, V123, P3404, DOI 10.1172/JCI67803; YOUNG JB, 1982, J CLIN INVEST, V69, P1061, DOI 10.1172/JCI110541; Zaninovich AA, 2002, AM J PHYSIOL-ENDOC M, V283, pE496, DOI 10.1152/ajpendo.00540.2001	59	143	147	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2046	2058		10.1096/fj.14-266247	http://dx.doi.org/10.1096/fj.14-266247			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25681456				2022-12-28	WOS:000354114600037
J	Podrini, C; Koffas, A; Chokshi, S; Vinciguerra, M; Lelliott, CJ; White, JK; Adissu, HA; Williams, R; Greco, A				Podrini, Christine; Koffas, Apostolos; Chokshi, Shilpa; Vinciguerra, Manlio; Lelliott, Christopher J.; White, Jacqueline K.; Adissu, Hibret A.; Williams, Roger; Greco, Azzura			MacroH2A1 isoforms are associated with epigenetic markers for activation of lipogenic genes in fat-induced steatosis	FASEB JOURNAL			English	Article						histone methylation; bivalent promoter; histone variants; lipid uptake	IMMORTALIZED HUMAN HEPATOCYTES; GENOME-WIDE; HEPATIC STEATOSIS; HISTONE VARIANTS; LIVER-DISEASE; KNOCKOUT MICE; ATP SYNTHASE; MOUSE; EXPRESSION; CHROMATIN	The importance of epigenetic changes in the development of hepatic steatosis is largely unknown. The histone variant macroH2A1 under alternative splicing gives rise to macroH2A1.1 and macroH2A1.2. In this study, we show that the macroH2A1 isoforms play an important role in the regulation of lipid accumulation in hepatocytes. Hepatoma cell line and immortalized human hepatocytes transiently transfected or knocked down with macroH2A1 isoforms were used as in vitro model of fat-induced steatosis. Gene expressions were analyzed by quantitative PCR array and Western blot. Chromatin immunoprecipitation analysis was performed to check the association of histone H3 lysine 27 trimethylation (H3K27me3) and histone H3 lysine 4 trimethylation (H3K4me3) with the promoter of lipogenic genes. Livers from knockout mice that are resistant to lipid deposition despite a high-fat diet were used for histopathology. We found that macroH2A1.2 is regulated by fat uptake and that its overexpression caused an increase in lipid uptake, triglycerides, and lipogenic genes compared with macroH2A1.1. This suggests that macroH2A1.2 is important for lipid uptake, whereas macroH2A1.1 was found to be protective. The result was supported by a high positivity for macroH2A1.1 in knockout mice for genes targeted by macroH2A1 (Atp5a1 and Fam73b), that under a high-fat diet presented minimal lipidosis. Moreover, macroH2A1 isoforms differentially regulate the expression of lipogenic genes by modulating the association of the active (H3K4me3) and repressive (H3K27me3) histone marks on their promoters. This study underlines the importance of the replacement of noncanonical histones in the regulation of genes involved in lipid metabolism in the progression of steatosis.-Podrini, C., Koffas, A., Chokshi, S., Vinciguerra, M., Lelliott, C. J., White, J. K., Adissu, H. A., Williams, R., Greco, A. MacroH2A1 isoforms are associated with epigenetic markers for activation of lipogenic genes in fat-induced steatosis.	[Podrini, Christine; Koffas, Apostolos; Chokshi, Shilpa; Williams, Roger; Greco, Azzura] Fdn Liver Res, Inst Hepatol, London WC1E 6HX, England; [Vinciguerra, Manlio] UCL, Sch Med, Inst Liver & Digest Hlth, London W1N 8AA, England; [Lelliott, Christopher J.; White, Jacqueline K.] Wellcome Trust Sanger Inst, Mouse Genet Project, Cambridge, England; [Adissu, Hibret A.] Univ Toronto, Hosp Sick Children, Physiol & Expt Med Res Program, Toronto, ON M5G 1X8, Canada	University of London; University College London; University of London; University College London; UCL Medical School; Wellcome Trust Sanger Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Greco, A (corresponding author), Fdn Liver Res, Inst Hepatol, Epigenet Fatty Liver Dis Res Grp, 69-75 Chenies Mews, London WC1E 6HX, England.	a.greco@researchinliver.org.uk	Podrini, Christine/K-8621-2016; koffas, Apostolos/AAU-6858-2020; Vinciguerra, Manlio/N-1309-2015; adissu, hibret a/R-3282-2018	Podrini, Christine/0000-0002-5391-3378; koffas, Apostolos/0000-0002-2637-3847; Vinciguerra, Manlio/0000-0002-1768-3894; adissu, hibret a/0000-0003-3365-7466	Wellcome Trust Sanger Institute Mouse Genetics Project, Research Support Facility,; Institute of Hepatology, Foundation for Liver Research, London, United Kingdom	Wellcome Trust Sanger Institute Mouse Genetics Project, Research Support Facility,; Institute of Hepatology, Foundation for Liver Research, London, United Kingdom	The authors thank the staff from the Wellcome Trust Sanger Institute Mouse Genetics Project, Research Support Facility, and Mouse Informatics Group for excellent technical support. The authors also thank the histology support of Dr. Susan Newbigging and Lily Morikawa from the CMHD Pathology Core (www.cmhd.ca). This work was supported by the Institute of Hepatology, Foundation for Liver Research, London, United Kingdom.	Adissu HA, 2014, DIS MODEL MECH, V7, P515, DOI 10.1242/dmm.015263; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Assem M, 2004, J BIOL CHEM, V279, P22250, DOI 10.1074/jbc.M314111200; Bassett JHD, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002858; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466; Changolkar LN, 2007, MOL CELL BIOL, V27, P2758, DOI 10.1128/MCB.02334-06; Changolkar LN, 2010, MOL CELL BIOL, V30, P5473, DOI 10.1128/MCB.00518-10; Cui W, 2010, AM J TRANSL RES, V2, P95; De Gottardi A, 2007, LAB INVEST, V87, P792, DOI 10.1038/labinvest.3700590; Ehara T, 2012, DIABETES, V61, P2442, DOI 10.2337/db11-1834; Feldstein AE, 2010, SEMIN LIVER DIS, V30, P391, DOI 10.1055/s-0030-1267539; Gamble MJ, 2010, CELL CYCLE, V9, P2568, DOI 10.4161/cc.9.13.12144; Gamble MJ, 2010, GENE DEV, V24, P21, DOI 10.1101/gad.1876110; Ghoshal K, 2006, J NUTR, V136, P1522, DOI 10.1093/jn/136.6.1522; Halleck MS, 1999, PHYSIOL GENOMICS, V1, P139, DOI 10.1152/physiolgenomics.1999.1.3.139; KATAOKA H, 1991, BIOCHIM BIOPHYS ACTA, V1089, P393, DOI 10.1016/0167-4781(91)90183-M; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956; Lesch BJ, 2013, P NATL ACAD SCI USA, V110, P16061, DOI 10.1073/pnas.1315204110; Mach T, 2000, Med Sci Monit, V6, P209; McClain CJ, 2004, ALCOHOL, V34, P67, DOI 10.1016/j.alcohol.2004.07.007; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Nguyen TH, 2005, J HEPATOL, V43, P1031, DOI 10.1016/j.jhep.2005.05.036; Novikov L, 2011, MOL CELL BIOL, V31, P4244, DOI 10.1128/MCB.05244-11; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pehrson JR, 1997, J CELL BIOCHEM, V65, P107, DOI 10.1002/(SICI)1097-4644(199704)65:1<107::AID-JCB11>3.0.CO;2-H; Pogribny IP, 2009, J HEPATOL, V51, P176, DOI 10.1016/j.jhep.2009.03.021; Postic C, 2008, J CLIN INVEST, V118, P829, DOI 10.1172/JCI34275; Rappa F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054458; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Ricchi M, 2009, J GASTROEN HEPATOL, V24, P830, DOI 10.1111/j.1440-1746.2008.05733.x; Ryder E, 2013, MAMM GENOME, V24, P286, DOI 10.1007/s00335-013-9467-x; Sheedfar F, 2015, INT J OBESITY, V39, P331, DOI 10.1038/ijo.2014.91; Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163; Stefan N, 2008, ENDOCR REV, V29, P939, DOI 10.1210/er.2008-0009; Tappenden DM, 2011, TOXICOL APPL PHARM, V254, P299, DOI 10.1016/j.taap.2011.05.004; Turner BM, 2012, TRENDS GENET, V28, P436, DOI 10.1016/j.tig.2012.04.003; Volle C, 2014, CURR OPIN GENET DEV, V25, P8, DOI 10.1016/j.gde.2013.11.006; White JK, 2013, CELL, V154, P452, DOI 10.1016/j.cell.2013.06.022; WHO (World Health Organization), 1998, WORLD HLTH REP 1998	41	28	30	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1676	1687		10.1096/fj.14-262717	http://dx.doi.org/10.1096/fj.14-262717			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25526730	Green Submitted			2022-12-28	WOS:000354114600007
J	Xu, XF; Zhang, FX; Zamponi, GW; Horne, WA				Xu, Xingfu; Zhang, Fangxiong; Zamponi, Gerald W.; Horne, William A.			Solution NMR and calorimetric analysis of Rem2 binding to the Ca2+ channel beta 4 subunit: a low affinity interaction is required for inhibition of Cav2.1 Ca2+ currents	FASEB JOURNAL			English	Article						RGK proteins; brain; electrophysiology; ion channel; synaptic transmission	DEPENDENT CALCIUM-CHANNELS; MOLECULAR DETERMINANTS; RGK FAMILY; PROTEINS; EXPRESSION; COMPLEX; SURFACE; MEMBER; CORE; GEM	Rem, Rad, Kir/Gem (RGK) proteins, including Rem2, mediate profound inhibition of high-voltage activated Ca2+ channels containing intracellular regulatory beta subunits. All RGK proteins bind to voltage-gated Ca2+ channel beta subunit (Cav beta) subunits in vitro, but the necessity of the interaction for current inhibition remains controversial. This study applies NMR and calorimetric techniques to map the binding site for Rem2 on human Cav beta 4a and measure its binding affinity. Our experiments revealed 2 binding surfaces on the beta 4 guanylate kinase domain contributing to a 156 +/- 18 mu M K-d interaction: a hydrophobic pocket lined by 4 critical residues (L173, N261, H262, and V303), mutation of any of which completely disrupted binding, and a nearby surface containing 3 residues (D206, L209, and D258) that when individually mutated decreased affinity. Voltage-gated Ca2+ channel alpha 1A subunit (Cav2.1) Ca2+ currents were completely inhibited by Rem2 when co-expressed with wild-type Cav beta 4a, but were unaffected by Rem2 when coexpressed with a Cav beta 4a site 1 (L173A/V303A) or site 2 (D258A) mutant. These results provide direct evidence for a low-affinity Rem2/Cav beta 4 interaction and show definitively that the interaction is required for Cav2.1 inhibition.	[Xu, Xingfu; Horne, William A.] Michigan State Univ, Coll Vet Med, Dept Clin Sci, E Lansing, MI 48824 USA; [Zhang, Fangxiong; Zamponi, Gerald W.] Univ Calgary, Cumming Sch Med, Dept Physiol & Pharmacol, Calgary, AB, Canada	Michigan State University; University of Calgary	Horne, WA (corresponding author), Dept Clin Sci, 736 Wilson Rd, E Lansing, MI 48824 USA.	hornewil@cvm.msu.edu		Zamponi, Gerald W./0000-0002-0644-9066	U.S. National Institutes of Health, National Institute of Neurological Disorders and Stroke Grant [NS42600]; National Science Foundation Grant [IOS 0719242]; Alberta Innovates-Health Solutions; Canadian Institutes for Health Research; Natural Sciences and Engineering Research Council; Canada Research Chair; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042600] Funding Source: NIH RePORTER	U.S. National Institutes of Health, National Institute of Neurological Disorders and Stroke Grant; National Science Foundation Grant(National Science Foundation (NSF)); Alberta Innovates-Health Solutions; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr. Li Li and Ms. Heather De Feijter-Rupp for excellent technical support in all aspects of the project. This work was supported in part by U.S. National Institutes of Health, National Institute of Neurological Disorders and Stroke Grant NS42600 (to W.A.H.), and National Science Foundation Grant IOS 0719242 (to W.A.H.). F.Z. is supported by a postdoctoral fellowship from Alberta Innovates-Health Solutions. G.W.Z. is supported by grants from the Canadian Institutes for Health Research and from the Natural Sciences and Engineering Research Council and holds a Canada Research Chair. The authors declare no conflicts of interest.	Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Beguin P, 2007, J BIOL CHEM, V282, P11509, DOI 10.1074/jbc.M606423200; Beqollari D, 2014, BIOPHYS J, V106, P1950, DOI 10.1016/j.bpj.2014.03.033; Buraei Z, 2010, PHYSIOL REV, V90, P1461, DOI 10.1152/physrev.00057.2009; Chen HM, 2005, J NEUROSCI, V25, P9762, DOI 10.1523/JNEUROSCI.3111-05.2005; Correll RN, 2008, CELL SIGNAL, V20, P292, DOI 10.1016/j.cellsig.2007.10.028; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Ebert AM, 2008, PHYSIOL GENOMICS, V35, P133, DOI 10.1152/physiolgenomics.90264.2008; Fan MM, 2012, J BIOL CHEM, V287, P22749, DOI 10.1074/jbc.M111.291872; Fan MM, 2010, P NATL ACAD SCI USA, V107, P14887, DOI 10.1073/pnas.1007543107; Finlin BS, 2006, J BIOL CHEM, V281, P23557, DOI 10.1074/jbc.M604867200; Finlin BS, 2005, J BIOL CHEM, V280, P41864, DOI 10.1074/jbc.M414261200; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Flynn R, 2008, BIOCHEM BIOPH RES CO, V368, P827, DOI 10.1016/j.bbrc.2008.02.020; Flynn R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041185; Flynn R, 2010, CHANNELS, V4, P434, DOI 10.4161/chan.4.6.12865; Ghiretti AE, 2014, J NEUROSCI, V34, P392, DOI 10.1523/JNEUROSCI.1328-13.2014; Goddard T. D., SPARKY 3; Helton TD, 2002, J NEUROSCI, V22, P1573, DOI 10.1523/JNEUROSCI.22-05-01573.2002; Leipe DD, 2003, J MOL BIOL, V333, P781, DOI 10.1016/j.jmb.2003.08.040; Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; Puhl HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100694; Rajarathnam K, 2014, BBA-BIOMEMBRANES, V1838, P69, DOI 10.1016/j.bbamem.2013.05.023; Seu L, 2006, J GEN PHYSIOL, V128, P605, DOI 10.1085/jgp.200609631; Simms BA, 2014, NEURON, V82, P24, DOI 10.1016/j.neuron.2014.03.016; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Van Petegem F, 2008, STRUCTURE, V16, P280, DOI 10.1016/j.str.2007.11.010; Vaynberg J, 2006, TRENDS BIOTECHNOL, V24, P22, DOI 10.1016/j.tibtech.2005.09.006; Xu XF, 2014, BIOMOL NMR ASSIGN, V8, P217, DOI 10.1007/s12104-013-9486-2; Yang TT, 2013, BBA-BIOMEMBRANES, V1828, P1644, DOI 10.1016/j.bbamem.2012.10.005; Yang TT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037079; Yang TT, 2010, J PHYSIOL-LONDON, V588, P1665, DOI 10.1113/jphysiol.2010.187203	33	4	4	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1794	1804		10.1096/fj.14-264499	http://dx.doi.org/10.1096/fj.14-264499			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25563298	Green Published			2022-12-28	WOS:000354114600016
J	McNeill, B; Vulesevic, B; Ostojic, A; Ruel, M; Suuronen, EJ				McNeill, Brian; Vulesevic, Branka; Ostojic, Aleksandra; Ruel, Marc; Suuronen, Erik J.			Collagen matrix-induced expression of integrin alpha V beta 3 in circulating angiogenic cells can be targeted by matricellular protein CCN1 to enhance their function	FASEB JOURNAL			English	Article						biomaterial; cardiovascular disease; cell preconditioning; ischemia; neovascularization	ENDOTHELIAL PROGENITOR CELLS; HUMAN SKIN FIBROBLASTS; CYR61; MIGRATION; THERAPY; ALPHA(V)BETA(3); IDENTIFICATION; PROLIFERATION; FIBRONECTIN; MYOCARDIUM	Circulating angiogenic cells (CACs) play an important role in vascular homeostasis and hold therapeutic promise for treating a variety of cardiovascular diseases. However, further improvements are needed because the effects of CAC therapy remain minimal or transient. The regenerative potential of these cells can be improved by culture on a collagen-based matrix through the up-regulation of key integrin proteins. We found that human CAC function was enhanced by using the matricellular protein CCN1 (CYR61/CTGF/NOV family member 1) to target integrin alpha V and beta 3, which are up-regulated on matrix. Compared tomatrix-cultured CACs, CCN1-matrix CACs exhibited a 2.2-fold increase in cell proliferation, 1.8-fold greater migration toward VEGF, and 1.7-fold more incorporation into capillary-like structures in an angiogenesis assay. In vivo, intramuscular injection of CCN1-matrix-cultured CACs into ischemic hind limbs of CD-1 nude mice resulted in blood flow recovery to 80% of baseline, which was greater than matrix-cultured CACs (66%) and PBS (35%) treatment groups. Furthermore, transplanted CCN1-matrix CACs exhibited greater engraftment (11-fold) and stimulated the up-regulation of survival and angiogenic genes (>3-fold). These findings reveal the importance of cell-matrix interactions in regulating CAC function and also reveal a mechanism by which these may be exploited to enhance cell therapies for ischemic disease.	[McNeill, Brian; Vulesevic, Branka; Ostojic, Aleksandra; Ruel, Marc; Suuronen, Erik J.] Univ Ottawa, Inst Heart, Div Cardiac Surg, Ottawa, ON K1Y 4W7, Canada; [Vulesevic, Branka; Ostojic, Aleksandra; Ruel, Marc; Suuronen, Erik J.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa	Suuronen, EJ (corresponding author), Univ Ottawa, Inst Heart, Div Cardiac Surg, 40 Ruskin St,H5227, Ottawa, ON K1Y 4W7, Canada.	esuuronen@ottawaheart.ca		RUEL, MARC/0000-0002-0487-1319; Vulesevic, Branka/0000-0003-2297-2209	Canadian Institutes of Health Research (CIHR) [MOP-77536]; Ottawa Heart Institute Cardiac Surgery Endowed Chair; Ottawa Heart Institute Lawrence Soloway Research Fellowship; Research Fellowship from the Heart & Stroke Foundation of Canada; CIHR Canadian Graduate Scholarship	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Ottawa Heart Institute Cardiac Surgery Endowed Chair; Ottawa Heart Institute Lawrence Soloway Research Fellowship; Research Fellowship from the Heart & Stroke Foundation of Canada; CIHR Canadian Graduate Scholarship(Canadian Institutes of Health Research (CIHR))	This work was supported from the Canadian Institutes of Health Research (CIHR; grant MOP-77536 to M.R. and E.J.S.), and the Ottawa Heart Institute Cardiac Surgery Endowed Chair (to M.R.). B.M. was the recipient of the Ottawa Heart Institute Lawrence Soloway Research Fellowship and a Research Fellowship from the Heart & Stroke Foundation of Canada, and B.V. of a CIHR Canadian Graduate Scholarship.	Ahmadi A, 2014, BIOMATERIALS, V35, P4749, DOI 10.1016/j.biomaterials.2014.02.028; Akita T, 2003, LAB INVEST, V83, P65, DOI 10.1097/01.LAB.0000050761.67879.E4; Asahara T, 2011, STEM CELLS, V29, P1650, DOI 10.1002/stem.745; Bouvard D, 2013, NAT REV MOL CELL BIO, V14, P430, DOI 10.1038/nrm3599; Brenes RA, 2012, VASCULAR, V20, P360, DOI 10.1258/vasc.2011.201205; Campbell ID, 2011, COLD SPRING HARB PER, V1, P3, DOI DOI 10.1101/CSHPERSPECT; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2004, J BIOL CHEM, V279, P44166, DOI 10.1074/jbc.M406813200; Choi S, 2009, BLOOD, V113, P1845, DOI 10.1182/blood-2008-05-160671; Colombo E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066734; Creager MA, 2012, NEW ENGL J MED, V366, P2198, DOI 10.1056/NEJMcp1006054; Danhier F, 2012, MOL PHARMACEUT, V9, P2961, DOI 10.1021/mp3002733; Emre Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3842; Espinoza I, 2014, J CELL COMMUN SIGNAL, V8, P23, DOI 10.1007/s12079-013-0214-6; Fadini GP, 2012, CIRC RES, V110, P624, DOI 10.1161/CIRCRESAHA.111.243386; Fan D, 2014, CIRC RES, V114, P889, DOI 10.1161/CIRCRESAHA.114.302335; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Heida NM, 2010, ARTERIOSCL THROM VAS, V30, P200, DOI 10.1161/ATVBAHA.109.192807; Jin Y, 2005, AM J RESP CELL MOL, V33, P297, DOI 10.1165/rcmb.2005-0144OC; Jin YJ, 2011, CELL SIGNAL, V23, P125, DOI 10.1016/j.cellsig.2010.08.012; Karl E, 2007, CELL DEATH DIFFER, V14, P1657, DOI 10.1038/sj.cdd.4402174; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Krishnamurthy P, 2011, CIRC RES, V109, P1280, DOI 10.1161/CIRCRESAHA.111.248369; Kuraitis D, 2012, BIOMATERIALS, V33, P428, DOI 10.1016/j.biomaterials.2011.09.078; Kuraitis D, 2011, J MOL CELL CARDIOL, V51, P187, DOI 10.1016/j.yjmcc.2011.04.011; Lau LF, 2012, J CELL COMMUN SIGNAL, V6, P121, DOI 10.1007/s12079-012-0169-z; Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018-011-0778-3; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602; Mackie AR, 2011, TEX HEART I J, V38, P474; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Resch T, 2012, STEM CELL REV REP, V8, P926, DOI 10.1007/s12015-011-9332-9; Rozen S, 2000, Methods Mol Biol, V132, P365; Schmidt MR, 2012, J CARDIOVASC MED, V13, P667, DOI 10.2459/JCM.0b013e328357bff2; Silvestre JS, 2013, PHYSIOL REV, V93, P1743, DOI 10.1152/physrev.00006.2013; Sun GM, 2012, MACROMOL BIOSCI, V12, P21, DOI 10.1002/mabi.201100258; Suuronen EJ, 2009, FASEB J, V23, P1447, DOI 10.1096/fj.08-111054; You JJ, 2014, CELL SIGNAL, V26, P133, DOI 10.1016/j.cellsig.2013.08.026; Yu JX, 2009, J VASC SURG, V50, P608, DOI 10.1016/j.jvs.2009.05.049; Yu Y, 2008, EXP CELL RES, V314, P3198, DOI 10.1016/j.yexcr.2008.08.001; Zemani F, 2008, ARTERIOSCL THROM VAS, V28, P644, DOI 10.1161/ATVBAHA.107.160044	45	7	7	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1198	1207		10.1096/fj.14-261586	http://dx.doi.org/10.1096/fj.14-261586			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25466895				2022-12-28	WOS:000354115000009
J	Priestley, RS; Nickolls, SA; Alexander, SPH; Kendall, DA				Priestley, Richard S.; Nickolls, Sarah A.; Alexander, Stephen P. H.; Kendall, David A.			A potential role for cannabinoid receptors in the therapeutic action of fenofibrate	FASEB JOURNAL			English	Article						allosteric modulation; PPAR; pharmacology; drug discovery; G protein-coupled receptor	PROTEIN-COUPLED RECEPTORS; ALLOSTERIC MODULATION; PPAR-ALPHA; INTERNATIONAL-UNION; CB1 RECEPTORS; PHARMACOLOGY; LIGANDS; IDENTIFICATION; ACTIVATION; SYSTEM	Cannabinoids are reported to have actions through peroxisome proliferator-activated receptors (PPARs), which led us to investigate PPAR agonists for activity at the cannabinoid receptors. Radio-ligand binding and functional assays were conducted using human recombinant cannabinoid type 1 (CB1) or cannabinoid type 2 (CB2) receptors, as well as the guinea pig isolated ileum, using the full agonist CP55940 as a positive control. The PPAR-a agonist fenofibrate exhibited submicromolar affinity for both receptors (pK(i)CB(1), 6.3 +/- 0.1; CB2, 7.7 +/- 0.1). Functionally, fenofibrate acted as an agonist at the CB2 receptor (pEC(50), 7.7 +/- 0.1) and a partial agonist at the CB1 receptor, although with a decrease in functional response at higher concentrations, producing bell-shaped concentration-response curves. High concentrations of fenofibrate were able to increase the dissociation rate constant for [H-3]-CP55940 at the CB1 receptor, (k(fast) without: 1.2 +/- 0.2/min; with: 3.8 +/- 0.1 x 10(-2)/min) and decrease the maximal response to CP55940 (R-max, 86 +/- 2%), which is consistent with a negative allosteric modulator. Fenofibrate also reduced electrically induced contractions in isolated guinea pig ileum via CB1 receptors (pEC50, 6.0 +/- 0.4). Fenofibrate is thus identified as an example of a new class of cannabinoid receptor ligand and allosteric modulator, with the potential to interact therapeutically with cannabinoid receptors in addition to its primary PPAR target.	[Priestley, Richard S.; Alexander, Stephen P. H.; Kendall, David A.] Univ Nottingham, Sch Med, Sch Life Sci, Nottingham NG7 2UH, England; [Nickolls, Sarah A.] Neusentis Pfizer Ltd, Cambridge, England	University of Nottingham; Pfizer	Kendall, DA (corresponding author), Univ Nottingham, Sch Med, Sch Life Sci, Queens Med Ctr, E Floor, Nottingham NG7 2UH, England.	dave.kendall@nottingham.ac.uk	Alexander, Steve P/B-8105-2009	Alexander, Steve P/0000-0003-4417-497X; Priestley, Richard/0000-0002-5284-5326	Biotechnology and Biological Sciences Research Council/Neusentis-Pfizer Limited Collaborative Awards in Science and Engineering (CASE) studentship award	Biotechnology and Biological Sciences Research Council/Neusentis-Pfizer Limited Collaborative Awards in Science and Engineering (CASE) studentship award	This work was supported by a Biotechnology and Biological Sciences Research Council/Neusentis-Pfizer Limited Collaborative Awards in Science and Engineering (CASE) studentship award. The authors declare no conflicts of interest.	Baillie GL, 2013, MOL PHARMACOL, V83, P322, DOI 10.1124/mol.112.080879; Baker D, 2006, TRENDS PHARMACOL SCI, V27, P1, DOI 10.1016/j.tips.2005.11.003; Bauer M, 2012, J BIOL CHEM, V287, P36944, DOI 10.1074/jbc.M112.382481; Bosier B, 2010, BIOCHEM PHARMACOL, V80, P1, DOI 10.1016/j.bcp.2010.02.013; CALDWELL J, 1989, CARDIOLOGY, V76, P33, DOI 10.1159/000174545; Choi IY, 2013, AM J PATHOL, V182, P928, DOI 10.1016/j.ajpath.2012.11.024; Christopoulos A, 1997, EUR J PHARMACOL, V339, P153, DOI 10.1016/S0014-2999(97)01379-4; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Cluny NL, 2009, NEUROGASTROENT MOTIL, V21, P420, DOI 10.1111/j.1365-2982.2008.01248.x; Dagon Y, 2007, FASEB J, V21, P2431, DOI 10.1096/fj.06-7705com; Duncan M, 2005, ALIMENT PHARM THER, V22, P667, DOI 10.1111/j.1365-2036.2005.02648.x; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; GERARD C, 1990, NUCLEIC ACIDS RES, V18, P7142, DOI 10.1093/nar/18.23.7142; Horswill JG, 2007, BRIT J PHARMACOL, V152, P805, DOI 10.1038/sj.bjp.0707347; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Lan RX, 1999, J MED CHEM, V42, P769, DOI 10.1021/jm980363y; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; May LT, 2007, ANNU REV PHARMACOL, V47, P1, DOI 10.1146/annurev.pharmtox.47.120505.105159; Mcguinness D, 2009, J BIOMOL SCREEN, V14, P49, DOI 10.1177/1087057108327329; Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5; Murakami R, 2010, LIFE SCI, V87, P495, DOI 10.1016/j.lfs.2010.09.005; Netherland CD, 2010, ATHEROSCLEROSIS, V213, P102, DOI 10.1016/j.atherosclerosis.2010.07.060; Pagotto U, 2006, ENDOCR REV, V27, P73, DOI 10.1210/er.2005-0009; Perez-Fernandez R, 2011, ACS MED CHEM LETT, V2, P793, DOI 10.1021/ml200091q; Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004; Pertwee RG, 2006, INT J OBESITY, V30, pS13, DOI 10.1038/sj.ijo.0803272; Price MR, 2005, MOL PHARMACOL, V68, P1484, DOI 10.1124/mol.105.016162; Rakhshandehroo M, 2010, PPAR RES, V2010, DOI 10.1155/2010/612089; Sharir H, 2010, PHARMACOL THERAPEUT, V126, P301, DOI 10.1016/j.pharmthera.2010.02.004; Shore DM, 2014, J BIOL CHEM, V289, P5828, DOI 10.1074/jbc.M113.478495; Staels B, 2008, NAT CLIN PRACT CARD, V5, P542, DOI 10.1038/ncpcardio1278; Starowicz K, 2007, PHARMACOL THERAPEUT, V114, P13, DOI 10.1016/j.pharmthera.2007.01.005; Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389; Sun Y, 2007, BRIT J PHARMACOL, V152, P734, DOI 10.1038/sj.bjp.0707478; Valant C, 2008, J BIOL CHEM, V283, P29312, DOI 10.1074/jbc.M803801200; Valant C, 2012, ANNU REV PHARMACOL, V52, P153, DOI 10.1146/annurev-pharmtox-010611-134514; WAELBROECK M, 1994, MOL PHARMACOL, V46, P685; Wang XW, 2011, MOL PHARMACOL, V79, P758, DOI 10.1124/mol.110.068197; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Wright KL, 2008, BRIT J PHARMACOL, V153, P263, DOI 10.1038/sj.bjp.0707486	41	29	29	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1446	1455		10.1096/fj.14-263053	http://dx.doi.org/10.1096/fj.14-263053			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550466				2022-12-28	WOS:000354115000030
J	Rotllan, N; Chamorro-Jorganes, A; Araldi, E; Wanschel, AC; Aryal, B; Aranda, JF; Goedeke, L; Salerno, AG; Ramirez, CM; Sessa, WC; Suarez, Y; Fernandez-Hernando, C				Rotllan, Noemi; Chamorro-Jorganes, Aranzazu; Araldi, Elisa; Wanschel, Amarylis C.; Aryal, Binod; Aranda, Juan F.; Goedeke, Leigh; Salerno, Alessandro G.; Ramirez, Cristina M.; Sessa, William C.; Suarez, Yajaira; Fernandez-Hernando, Carlos			Hematopoietic Akt2 deficiency attenuates the progression of atherosclerosis	FASEB JOURNAL			English	Article						insulin resistance	INSULIN-RESISTANCE; MACROPHAGE ACTIVATION; KINASE-B; MICE; ANGIOGENESIS; POLARIZATION; DISEASE; METABOLISM; MIGRATION; CELLS	Atherosclerosis is the major cause of death and disability in diabetic and obese subjects with insulin resistance. Akt2, a phosphoinositide-dependent serine-threonine protein kinase, is highly express in insulin-responsive tissues; however, its role during the progression of atherosclerosis remains unknown. Thus, we aimed to investigate the contribution of Akt2 during the progression of atherosclerosis. Wefound that germ-line Akt2 deficient mice develop similar atherosclerotic plaques as wild-type mice despite higher plasma lipids and glucose levels. It is noteworthy that transplantation of bonemarrow cells isolated from Akt2(-/-) mice to Ldlr(-/-) mice results in marked reduction of the progression of atherosclerosis compared with Ldlr(-/-) mice transplanted with wild-type bone marrow cells. In vitro studies indicate that Akt2 is required for macrophage migration in response to proatherogenic cytokines (monocyte chemotactic protein-1 and macrophage colony-stimulating factor). Moreover, Akt2(-/-) macrophages accumulate less cholesterol and have an alternative activated orM2-type phenotype when stimulated with proinflammatory cytokines. Together, these results provide evidence that macrophage Akt2 regulates migration, the inflammatory response and cholesterol metabolism and suggest that targeting Akt2 in macrophages might be beneficial for treating atherosclerosis.	[Rotllan, Noemi; Chamorro-Jorganes, Aranzazu; Araldi, Elisa; Aryal, Binod; Aranda, Juan F.; Goedeke, Leigh; Ramirez, Cristina M.; Sessa, William C.; Suarez, Yajaira; Fernandez-Hernando, Carlos] Yale Univ, Sch Med, Vasc Biol & Therapeut Program, New Haven, CT 06510 USA; [Rotllan, Noemi; Chamorro-Jorganes, Aranzazu; Araldi, Elisa; Aryal, Binod; Aranda, Juan F.; Goedeke, Leigh; Ramirez, Cristina M.; Suarez, Yajaira; Fernandez-Hernando, Carlos] Yale Univ, Sch Med, Comparat Med Sect, Integrat Cell Signaling & Neurobiol Metab Program, New Haven, CT 06510 USA; [Rotllan, Noemi; Chamorro-Jorganes, Aranzazu; Araldi, Elisa; Wanschel, Amarylis C.; Aryal, Binod; Aranda, Juan F.; Goedeke, Leigh; Salerno, Alessandro G.; Ramirez, Cristina M.; Suarez, Yajaira; Fernandez-Hernando, Carlos] NYU, Sch Med, Leon H Charney Div Cardiol, Dept Med, New York, NY USA; [Rotllan, Noemi; Chamorro-Jorganes, Aranzazu; Araldi, Elisa; Wanschel, Amarylis C.; Aryal, Binod; Aranda, Juan F.; Goedeke, Leigh; Salerno, Alessandro G.; Ramirez, Cristina M.; Suarez, Yajaira; Fernandez-Hernando, Carlos] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; [Sessa, William C.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University; Yale University; New York University; New York University; Yale University	Fernandez-Hernando, C (corresponding author), Yale Univ, Sch Med, Amistad Res Bldg,Room 337C,10 Amistad St, New Haven, CT 06510 USA.	carlos.fernandez@yale.edu	Aranda, Juan Francisco/S-6388-2018; Wanschel, Amarylis/B-3591-2019; Chamorro-Jorganes, Aranzazu/B-1871-2019; Ramírez, Cristina/A-6975-2016; Wanschel, Amarylis/A-8452-2013; Jorganes, Aranzazu Chamorro/N-7774-2019; Salerno, Alessandro G/A-7891-2013; Sessa, William C/B-6844-2011; Rotllan, Noemi/P-1375-2014; Ramírez, Cristina/ABI-1568-2020; Araldi, Elisa/AAZ-5946-2021; Vila, Noemi Rotllan/AAQ-8050-2020	Aranda, Juan Francisco/0000-0002-5598-2465; Wanschel, Amarylis/0000-0002-5603-7983; Chamorro-Jorganes, Aranzazu/0000-0002-3505-7221; Ramírez, Cristina/0000-0003-2589-0786; Wanschel, Amarylis/0000-0001-7307-915X; Jorganes, Aranzazu Chamorro/0000-0002-3505-7221; Salerno, Alessandro G/0000-0002-7688-5904; Sessa, William C/0000-0001-5759-1938; Rotllan, Noemi/0000-0002-0587-8045; Ramírez, Cristina/0000-0003-2589-0786; Vila, Noemi Rotllan/0000-0002-0587-8045; Araldi, Elisa/0000-0002-6596-6784; Goedeke, Leigh/0000-0002-7690-1572; Chamorro Jorganes, Aranzazu/0000-0003-2648-6945; Suarez, Yajaira/0000-0003-4549-2953	U.S.National Institutes of Health (NIH) National Heart, Lung, and Blood Institute [R01HL107953, R01HL106063, R01HL105945, R01HL064793, R01HL061371]; NIH National Institute on Aging Grant [1F31AG043318]; Foundation Leducq Transatlantic Network of Excellence; Spanish Ministry (Programa Nacional de Movilidad de Recursos Humanos del Plan Nacional de I-D+i); American Heart Association [12POST9780016]; Howard Hughes Medical Institute International Student Research Fellowship; Capes Foundation, Ministry of Education of Brazil, Brazil; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000142] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064793, R01HL105945, R01HL106063, R01HL061371, R01HL107953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F31AG043318] Funding Source: NIH RePORTER	U.S.National Institutes of Health (NIH) National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH National Institute on Aging Grant; Foundation Leducq Transatlantic Network of Excellence; Spanish Ministry (Programa Nacional de Movilidad de Recursos Humanos del Plan Nacional de I-D+i); American Heart Association(American Heart Association); Howard Hughes Medical Institute International Student Research Fellowship(Howard Hughes Medical Institute); Capes Foundation, Ministry of Education of Brazil, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by U.S.National Institutes of Health (NIH) National Heart, Lung, and Blood Institute Grants R01HL107953 and R01HL106063 (to C.F.-H.), R01HL105945 (to Y.S.), R01HL064793 and R01HL061371 (to W.C.S.), and NIH National Institute on Aging Grant 1F31AG043318 (to L.G); a grant from the Foundation Leducq Transatlantic Network of Excellence (to C.F.-H.and W.C.S.); a postdoctoral fellowship from the Spanish Ministry (Programa Nacional de Movilidad de Recursos Humanos del Plan Nacional de I-D+i 2008-2011) (to N.R.); American Heart Association Grant 12POST9780016 (to C.M.R.); a Howard Hughes Medical Institute International Student Research Fellowship (to E.A.); and the Capes Foundation, Ministry of Education of Brazil, Brazil (to A.G.S.and A.C.W.).	Ackah E, 2005, J CLIN INVEST, V115, P2119, DOI 10.1172/JCI24726; Arranz A, 2012, P NATL ACAD SCI USA, V109, P9517, DOI 10.1073/pnas.1119038109; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Bornfeldt KE, 2011, CELL METAB, V14, P575, DOI 10.1016/j.cmet.2011.07.015; Chen JH, 2005, NAT MED, V11, P1188, DOI 10.1038/nm1307; Chen J, 2010, BLOOD, V115, P4237, DOI 10.1182/blood-2009-11-255323; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cohen DE, 2013, SEMIN LIVER DIS, V33, P380, DOI 10.1055/s-0033-1358519; Ding L, 2012, CELL METAB, V15, P861, DOI 10.1016/j.cmet.2012.04.020; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Fernandez-Hernando C, 2007, CELL METAB, V6, P446, DOI 10.1016/j.cmet.2007.10.007; Fernandez-Hernando C, 2009, ARTERIOSCL THROM VAS, V29, P2033, DOI 10.1161/ATVBAHA.109.196394; Gerszten RE, 2001, J BIOL CHEM, V276, P26846, DOI 10.1074/jbc.M011235200; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Gonzalez-Navarro H, 2008, ARTERIOSCL THROM VAS, V28, P2187, DOI 10.1161/ATVBAHA.108.175299; Han S, 2006, CELL METAB, V3, P257, DOI 10.1016/j.cmet.2006.02.008; Huang CX, 2013, J LIPID RES, V54, P1231, DOI 10.1194/jlr.M032482; Leavens KF, 2011, CRIT REV BIOCHEM MOL, V46, P200, DOI 10.3109/10409238.2011.562481; Li J, 2014, J CLIN INVEST, V124, P1483, DOI 10.1172/JCI72305; Locati M, 2013, ADV IMMUNOL, V120, P163, DOI 10.1016/B978-0-12-417028-5.00006-5; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Moore KJ, 2013, NAT REV IMMUNOL, V13, P709, DOI 10.1038/nri3520; Rask-Madsen C, 2010, CELL METAB, V11, P379, DOI 10.1016/j.cmet.2010.03.013; Rensing KL, 2014, CARDIOVASC RES, V101, P277, DOI 10.1093/cvr/cvt252; Ridley AJ, 2008, J MICROSC-OXFORD, V231, P518, DOI 10.1111/j.1365-2818.2008.02064.x; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Shiojima I, 2005, J CLIN INVEST, V115, P2108, DOI 10.1172/JCI24682; Tabas I, 2010, CIRC RES, V106, P58, DOI 10.1161/CIRCRESAHA.109.208488; Tsuchiya K, 2012, CELL METAB, V15, P372, DOI 10.1016/j.cmet.2012.01.018; Vergadi E, 2014, J IMMUNOL, V192, P394, DOI 10.4049/jimmunol.1300959; Zhang BG, 2009, EUR J IMMUNOL, V39, P894, DOI 10.1002/eji.200838809; Zhou GL, 2006, J BIOL CHEM, V281, P36443, DOI 10.1074/jbc.M600788200	35	27	29	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					597	610		10.1096/fj.14-262097	http://dx.doi.org/10.1096/fj.14-262097			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25392271	Green Published			2022-12-28	WOS:000349370400022
J	van Stijn, CMW; Kim, J; Lusis, AJ; Barish, GD; Tangirala, RK				van Stijn, Caroline M. W.; Kim, Jason; Lusis, Aldons J.; Barish, Grant D.; Tangirala, Rajendra K.			Macrophage polarization phenotype regulates adiponectin receptor expression and adiponectin anti-inflammatory response	FASEB JOURNAL			English	Article						adipokines; inflammation; metabolic disorder; macrophage activation; nuclear receptors	TYPE-2 DIABETIC-PATIENTS; INNATE IMMUNE-RESPONSE; ADIPOSE-TISSUE; ALTERNATIVE ACTIVATION; LIPID-METABOLISM; GENE-EXPRESSION; PPAR-GAMMA; INSULIN-RESISTANCE; TNF-ALPHA; INFLAMMATION	Adiponectin (APN), a pleiotropic adipokine that exerts anti-inflammatory, antidiabetic, and antiatherogenic effects through its receptors (AdipoRs), AdipoR1 and AdipoR2, is an important therapeutic target. Factors regulating AdipoR expression in monocyte/ macrophages are poorly understood, and the significance of polarized macrophage activation in controlling AdipoR expression and the APN-mediated inflammatory response has not been investigated. The aim of this study was to investigate whether the macrophage polarization phenotype controls the AdipoR expression and APN-mediated inflammatory response. With the use of mouse bone marrow and peritoneal macrophages, we demonstrate that classical activation (M1) of macrophages suppressed (40-60% of control) AdipoR expression, whereas alternative activation (M2) preserved it. Remarkably, the macrophage polarization phenotypes produced contrasting inflammatory responses to APN (EC50 5 mu g/ml). In M1 macrophages, APN induced proinflammatory cytokines, TNF-alpha, IL-6, and IL-12 (> 10-fold of control) and AdipoR levels. In contrast, in M2 macrophages, APN induced the anti-inflammatory cytokine IL-10 without altering AdipoR expression. Furthermore, M1 macrophages adapt to a cytokine environment by reversing AdipoR expression. APN induced AdipoR mRNA and protein expression by upregulating liver X receptor-alpha (LXR alpha) in macrophages. These results provide the first evidence that macrophage polarization is a key determinant regulating AdipoR expression and differential APN-mediated macrophage inflammatory responses, which can profoundly influence their pathogenic role in inflammatory and metabolic disorders.-van Stijn, C. M. W., Kim, J., Lusis, A. J., Barish, G. D., Tangirala, R. K. Macrophage polarization phenotype regulates adiponectin receptor expression and adiponectin anti-inflammatory response.	[van Stijn, Caroline M. W.; Kim, Jason; Tangirala, Rajendra K.] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Los Angeles, CA 90095 USA; [Lusis, Aldons J.; Tangirala, Rajendra K.] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA; [Barish, Grant D.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Northwestern University; Feinberg School of Medicine	Tangirala, RK (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, 675 Charles E Young Dr South,MRL 3-740, Los Angeles, CA 90095 USA.	rtangirala@mednet.ucla.edu			U.S. National Institutes of Health National Heart, Lung, and Blood Institute [R01-HL086566]; Dr. Alan Fogelman, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles; Carl and Roberta Deutsch Family Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086566] Funding Source: NIH RePORTER	U.S. National Institutes of Health National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Dr. Alan Fogelman, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles; Carl and Roberta Deutsch Family Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Peter Tontonoz for helpful discussion and Dr. Joey Liu, Diana Becerra, and Rima Boyajdian, for technical assistance. This work was supported by U.S. National Institutes of Health National Heart, Lung, and Blood Institute Grant R01-HL086566 (to R.K.T.); and from Dr. Alan Fogelman, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles. The authors also acknowledge support from the Carl and Roberta Deutsch Family Foundation.	Abke S, 2006, CARDIOVASC DIABETOL, V5, DOI 10.1186/1475-2840-5-17; Barish GD, 2010, GENE DEV, V24, P2760, DOI 10.1101/gad.1998010; Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34; Bjursell M, 2007, DIABETES, V56, P583, DOI 10.2337/db06-1432; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Cheng X, 2012, J BIOL CHEM, V287, P36896, DOI 10.1074/jbc.M112.409516; Chinetti G, 2004, BIOCHEM BIOPH RES CO, V314, P151, DOI 10.1016/j.bbrc.2003.12.058; Ehling A, 2006, J IMMUNOL, V176, P4468, DOI 10.4049/jimmunol.176.7.4468; EZEKOWITZ RAB, 1986, BIOCHEM BIOPH RES CO, V136, P737; Fantuzzi G, 2008, J ALLERGY CLIN IMMUN, V121, P326, DOI 10.1016/j.jaci.2007.10.018; Folco EJ, 2009, J BIOL CHEM, V284, P25569, DOI 10.1074/jbc.M109.019786; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gordon S, 2007, EUR J IMMUNOL, V37, pS9, DOI 10.1002/eji.200737638; Holland WL, 2011, NAT MED, V17, P55, DOI 10.1038/nm.2277; Holland WL, 2009, MOL PHARMACOL, V75, P740, DOI 10.1124/mol.109.054817; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Inukai K, 2005, AM J PHYSIOL-ENDOC M, V288, pE876, DOI 10.1152/ajpendo.00118.2004; Ivashkiv LB, 2011, EUR J IMMUNOL, V41, P2477, DOI 10.1002/eji.201141783; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032; Kollias A, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-14; Kumada M, 2004, CIRCULATION, V109, P2046, DOI 10.1161/01.CIR.0000127953.98131.ED; Liu YF, 2007, ENDOCRINOLOGY, V148, P683, DOI 10.1210/en.2006-0708; Lovren F, 2010, AM J PHYSIOL-HEART C, V299, pH656, DOI 10.1152/ajpheart.00115.2010; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Luo NL, 2013, ATHEROSCLEROSIS, V228, P124, DOI 10.1016/j.atherosclerosis.2013.02.026; Mandal P, 2011, J BIOL CHEM, V286, P13460, DOI 10.1074/jbc.M110.204644; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Neels JG, 2006, J CLIN INVEST, V116, P33, DOI 10.1172/JCI27280; Ogunwobi OO, 2006, REGUL PEPTIDES, V134, P105, DOI 10.1016/j.regpep.2006.02.001; Ohashi K, 2010, J BIOL CHEM, V285, P6153, DOI 10.1074/jbc.M109.088708; Okada-Iwabu M, 2013, NATURE, V503, P493, DOI 10.1038/nature12656; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Otake H, 2008, AM J CARDIOL, V101, P1, DOI 10.1016/j.amjcard.2007.07.041; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Park PH, 2007, J BIOL CHEM, V282, P21695, DOI 10.1074/jbc.M701419200; Park SH, 2011, NAT IMMUNOL, V12, P607, DOI 10.1038/ni.2043; Rovin BH, 2006, CLIN IMMUNOL, V120, P99, DOI 10.1016/j.clim.2006.01.010; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Scherer PE, 2006, DIABETES, V55, P1537, DOI 10.2337/db06-0263; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Spencer M, 2010, AM J PHYSIOL-ENDOC M, V299, pE1016, DOI 10.1152/ajpendo.00329.2010; Staiger H, 2004, DIABETES, V53, P2195, DOI 10.2337/diabetes.53.9.2195; Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342; Takemura Y, 2007, J CLIN INVEST, V117, P375, DOI 10.1172/JCI29709; Tan GD, 2005, DIABETOLOGIA, V48, P1585, DOI 10.1007/s00125-005-1835-y; Thakur V, 2006, AM J PHYSIOL-GASTR L, V290, pG998, DOI 10.1152/ajpgi.00553.2005; Tian L, 2012, ATHEROSCLEROSIS, V221, P66, DOI 10.1016/j.atherosclerosis.2011.12.014; Tsuchida A, 2005, DIABETES, V54, P3358, DOI 10.2337/diabetes.54.12.3358; van Stijn CMW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086404; Weigert J, 2008, FEBS LETT, V582, P1777, DOI 10.1016/j.febslet.2008.04.031; Wolf AM, 2004, BIOCHEM BIOPH RES CO, V323, P630, DOI 10.1016/j.bbrc.2004.08.145; Wulster-Radcliffe MC, 2004, BIOCHEM BIOPH RES CO, V316, P924, DOI 10.1016/j.bbrc.2004.02.130; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yamaguchi N, 2005, FEBS LETT, V579, P6821, DOI 10.1016/j.febslet.2005.11.019; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2007, NAT MED, V13, P332, DOI 10.1038/nm1557; Yamauchi T, 2013, CELL METAB, V17, P185, DOI 10.1016/j.cmet.2013.01.001	61	53	54	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					636	649		10.1096/fj.14-253831	http://dx.doi.org/10.1096/fj.14-253831			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25392268	Green Published			2022-12-28	WOS:000349370400025
J	Noronha-Matos, JB; Coimbra, J; Sa-e-Sousa, A; Rocha, R; Marinhas, J; Freitas, R; Guerra-Gomes, S; Ferreirinha, F; Costa, MA; Correia-de-Sa, P				Noronha-Matos, Jose Bernardo; Coimbra, Joao; Sa-e-Sousa, Ana; Rocha, Rui; Marinhas, Jose; Freitas, Rolando; Guerra-Gomes, Sonia; Ferreirinha, Fatima; Costa, Maria Adelina; Correia-de-Sa, Paulo			P2X7-induced zeiosis promotes osteogenic differentiation and mineralization of postmenopausal bone marrow-derived mesenchymal stem cells	FASEB JOURNAL			English	Article						membrane blebbing; osteogenesis; P2 purinoceptors; Rho-kinase; bone-nodule formation	DEPENDENT PROTEIN-KINASE; P2X(7) RECEPTOR; ATP RELEASE; RHO-KINASE; EXTRACELLULAR NUCLEOTIDES; HUMAN OSTEOBLASTS; MEDIATED ACTIVATION; P2X7 RECEPTORS; POLYMORPHISMS; EXPRESSION	Polymorphisms of the P2X7 receptor have been associated with increased risk of fractures in postmenopausal women. Although both osteoblasts and osteoclasts express P2X7 receptors, their function in osteogenesis remains controversial. Here, we investigated the role of the P2X7 receptor on osteogenic differentiation and mineralization of bone marrow mesenchymal stem cell (BMSC) cultures from post-menopausal women (age 71 +/- 3 yr, n = 18). We focused on the mechanisms related to intracellular [Ca2+](i) oscillations and plasma membrane-dynamics. ATP, and the P2X7 agonist BzATP (100 mu M), increased [Ca2+](i) in parallel to the formation of membrane pores permeable to TO-PRO-3 dye uptake. ATP and BzATP elicited reversible membrane blebs (zeiosis) in 38 +/- 1 and 70 +/- 1% of the cells, respectively. P2X7-induced zeiosis was Ca2+ independent, but involved phospholipase C, protein kinase C, and Rho-kinase activation. BzATP (100 mu M) progressively increased the expression of Runx-2 and Osterix transcription factors by 452 and 226% (at d 21), respectively, alkaline phosphatase activity by 88% (at d 28), and mineralization by 329% (at d 43) of BMSC cultures in a Rho-kinase-dependent manner. In summary, reversible plasma membrane zeiosis involving cytoskeleton rearrangements due to activation of the P2X7-Rho-kinase axis promotes osteogenic differentiation and mineralization of BMSCs, thus providing new therapeutic targets for postmenopausal bone loss.	[Noronha-Matos, Jose Bernardo; Coimbra, Joao; Sa-e-Sousa, Ana; Guerra-Gomes, Sonia; Ferreirinha, Fatima; Costa, Maria Adelina; Correia-de-Sa, Paulo] ICBAS UP, Lab Farmacol & Neurobiol, P-4050313 Oporto, Portugal; [Costa, Maria Adelina] ICBAS UP, Dept Quim, UMIB, P-4050313 Oporto, Portugal; [Noronha-Matos, Jose Bernardo; Coimbra, Joao; Sa-e-Sousa, Ana; Guerra-Gomes, Sonia; Ferreirinha, Fatima; Costa, Maria Adelina; Correia-de-Sa, Paulo] ICBAS UP, Ctr Drug Discovery & Innovat Med, P-4050313 Oporto, Portugal; [Rocha, Rui; Marinhas, Jose; Freitas, Rolando] Ctr Hosp Vila Nova Gaia Espinho, Serv Ortoped & Traumatol, Vila Nova De Gaia, Portugal	Universidade do Porto; Universidade do Porto; Universidade do Porto	Correia-de-Sa, P (corresponding author), ICBAS UP, Lab Farmacol & Neurobiol UMIB, Rua Jorge Viterbo Ferreira 228, P-4050313 Oporto, Portugal.	farmacol@icbas.up.pt	Sa-Sousa, Ana/J-1941-2014; Correia-De-Sá, P./F-1079-2015; Coimbra, João/L-5495-2014; Correia-de-Sá, Paulo/AAG-5901-2019; Noronha-Matos, José Bernardo AG/K-7686-2014; Ferreirinha, Fatima/K-8752-2014	Sa-Sousa, Ana/0000-0002-9429-6863; Correia-De-Sá, P./0000-0002-6114-9189; Coimbra, João/0000-0001-9138-7498; Correia-de-Sá, Paulo/0000-0002-6114-9189; Noronha-Matos, José Bernardo AG/0000-0001-6397-2104; Ferreirinha, Fatima/0000-0002-0527-1323; Costa, Maria Adelina Coelho/0000-0001-7664-2075; Guerra-Gomes, Sonia/0000-0002-6717-8941	Fundacao para a Ciencia e a Tecnologia [FCT; Fonds Europeen de Developpement Regional (FEDER)] [PTDC/SAU-OSM/73576/2006, REEQ/1168/SAU/2005, REEQ/1264/SAU/2005, PEst-OE/SAU/UI0215/2011, PEst-OE/SAU/UI0215/2014]; University of Porto/Caixa Geral de Depositos (Investigacao Cientifica na Pre-Graduacao); FCT [SRFH/BD/68584/2010]	Fundacao para a Ciencia e a Tecnologia [FCT; Fonds Europeen de Developpement Regional (FEDER)]; University of Porto/Caixa Geral de Depositos (Investigacao Cientifica na Pre-Graduacao); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	This research was partially supported by Fundacao para a Ciencia e a Tecnologia [FCT; Fonds Europeen de Developpement Regional (FEDER) funding; PTDC/SAU-OSM/73576/2006, REEQ/1168/SAU/2005, REEQ/1264/SAU/2005, PEst-OE/SAU/UI0215/2011, and PEst-OE/SAU/UI0215/2014] and by University of Porto/Caixa Geral de Depositos (Investigacao Cientifica na Pre-Graduacao) projects. J.B.N.-M. is the recipient of a Ph.D. scholarship from FCT (SRFH/BD/68584/2010). The authors thank Sara Gomes (graduate student) and Elsa Meireles (M.Sc. student) for their collaboration in some experiments. The authors also thank Mrs. Helena Costa e Silva and Belmira Silva for their technical assistance.	Costa MA, 2011, J CELL PHYSIOL, V226, P1353, DOI 10.1002/jcp.22458; Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601; Alloisio S, 2010, J NEUROCHEM, V113, P796, DOI 10.1111/j.1471-4159.2010.06649.x; Alvarenga EC, 2010, BONE, V46, P355, DOI 10.1016/j.bone.2009.09.017; Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293; Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Biswas P, 2009, J BONE MINER RES, V24, P1450, DOI [10.1359/jbmr.090306, 10.1359/JBMR.090306]; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Bobis S, 2006, FOLIA HISTOCHEM CYTO, V44, P215; Bowler WB, 1999, J BIOL CHEM, V274, P14315, DOI 10.1074/jbc.274.20.14315; Buckley KA, 2001, J BIOL CHEM, V276, P9565, DOI 10.1074/jbc.M005672200; Burnstock G, 2013, PURINERG SIGNAL, V9, P541, DOI 10.1007/s11302-013-9381-4; Carrasquero LMG, 2009, J NEUROCHEM, V110, P879, DOI 10.1111/j.1471-4159.2009.06179.x; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cheewatrakoolpong B, 2005, BIOCHEM BIOPH RES CO, V332, P17, DOI 10.1016/j.bbrc.2005.04.087; Ciciarello M, 2013, STEM CELLS DEV, V22, P1097, DOI 10.1089/scd.2012.0432; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Faria RX, 2010, N-S ARCH PHARMACOL, V382, P73, DOI 10.1007/s00210-010-0523-8; Gartland A, 2001, J BONE MINER RES, V16, P846, DOI 10.1359/jbmr.2001.16.5.846; Hayton MJ, 2005, ULTRASOUND MED BIOL, V31, P1131, DOI 10.1016/j.ultrasmedbio.2005.04.017; Henriksen Z, 2006, CELL CALCIUM, V39, P435, DOI 10.1016/j.ceca.2006.01.012; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Husted LB, 2013, OSTEOPOROSIS INT, V24, P949, DOI 10.1007/s00198-012-2035-5; Jorgensen NR, 2012, EUR J HUM GENET, V20, P675, DOI 10.1038/ejhg.2011.253; Jorgensen NR, 2002, J BIOL CHEM, V277, P7574, DOI 10.1074/jbc.M104608200; Kandabashi T, 2003, ARTERIOSCL THROM VAS, V23, P2209, DOI 10.1161/01.ATV.0000104010.87348.26; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108; Leverrier Y, 2001, NAT CELL BIOL, V3, pE91, DOI 10.1038/35070151; Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200; Maier R, 1997, BIOCHEM BIOPH RES CO, V237, P297, DOI 10.1006/bbrc.1997.7135; Avalos AM, 2009, J CELL SCI, V122, P3462, DOI 10.1242/jcs.034827; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Miyazaki T, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.385369; Morelli A, 2003, MOL BIOL CELL, V14, P2655, DOI 10.1091/mbc.02-04-0061; Nakamura E, 2000, AM J PHYSIOL-CELL PH, V279, pC510, DOI 10.1152/ajpcell.2000.279.2.C510; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; NICOTERA P, 1986, FEBS LETT, V209, P139, DOI 10.1016/0014-5793(86)81099-7; Noronha-Matos JB, 2012, J CELL PHYSIOL, V227, P2694, DOI 10.1002/jcp.23014; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ohlendorff SD, 2007, PHARMACOGENET GENOM, V17, P555, DOI 10.1097/FPC.0b013e3280951625; Orriss IR, 2006, BONE, V39, P300, DOI 10.1016/j.bone.2006.02.063; Orriss IR, 2012, BONE, V51, P389, DOI 10.1016/j.bone.2012.06.013; Orriss IR, 2009, J CELL PHYSIOL, V220, P155, DOI 10.1002/jcp.21745; Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037; Panupinthu N, 2007, J BIOL CHEM, V282, P3403, DOI 10.1074/jbc.M605620200; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Radeff JM, 2004, J BONE MINER RES, V19, P1882, DOI 10.1359/JBMR.040806; Roger S, 2010, J BIOL CHEM, V285, P17514, DOI 10.1074/jbc.M109.053082; Romanello M, 2001, BIOCHEM BIOPH RES CO, V289, P1275, DOI 10.1006/bbrc.2001.6124; Romanello M, 2006, BONE, V39, P739, DOI 10.1016/j.bone.2006.03.011; Rumney RMH, 2012, J BIOMECH, V45, P549, DOI 10.1016/j.jbiomech.2011.11.036; Sasaki Y, 2002, PHARMACOL THERAPEUT, V93, P225, DOI 10.1016/S0163-7258(02)00191-2; Soulet C, 2005, J THROMB HAEMOST, V3, P2296, DOI 10.1111/j.1538-7836.2005.01588.x; Sovenyhazy KM, 2003, NUCLEIC ACIDS RES, V31, P2561, DOI 10.1093/nar/gkg363; Sun DH, 2013, STEM CELLS, V31, P1170, DOI 10.1002/stem.1356; Tamura M, 2005, BBA-PROTEINS PROTEOM, V1754, P245, DOI 10.1016/j.bbapap.2005.06.015; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Verhoef PA, 2003, J IMMUNOL, V170, P5728, DOI 10.4049/jimmunol.170.11.5728; Wesselius A, 2011, FRONT BIOSCI-LANDMRK, V16, P2572, DOI 10.2741/3873; Xu BY, 2011, CONNECT TISSUE RES, V52, P373, DOI 10.3109/03008207.2010.541961; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	65	35	36	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5208	5222		10.1096/fj.14-257923	http://dx.doi.org/10.1096/fj.14-257923			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25169056				2022-12-28	WOS:000345894500016
J	Tarry-Adkins, JL; Fernandez-Twinn, DS; Chen, JH; Hargreaves, IP; Martin-Gronert, MS; McConnell, JM; Ozanne, SE				Tarry-Adkins, Jane L.; Fernandez-Twinn, Denise S.; Chen, Jian-Hua; Hargreaves, Iain P.; Martin-Gronert, Malgorzata S.; McConnell, Josie M.; Ozanne, Susan E.			Nutritional programming of coenzyme Q: potential for prevention and intervention?	FASEB JOURNAL			English	Article						telomeres; cardiovascular disease; aging; vascular disease	POSTNATAL-GROWTH LEADS; CATCH-UP GROWTH; OXIDATIVE STRESS; LIFE-SPAN; TELOMERE LENGTH; DNA-DAMAGE; CARDIOVASCULAR-DISEASE; SAFETY ASSESSMENT; DEFENSE CAPACITY; HEART-FAILURE	Low birth weight and rapid postnatal growth increases risk of cardiovascular-disease (CVD); however, underlying mechanisms are poorly understood. Previously, we demonstrated that rats exposed to a low-protein diet in utero that underwent postnatal catch-up growth (recuperated) have a programmed deficit in cardiac coenzyme Q (CoQ) that was associated with accelerated cardiac aging. It is unknown whether this deficit occurs in all tissues, including those that are clinically accessible. We investigated whether aortic and white blood cell (WBC) CoQ is programmed by suboptimal early nutrition and whether postweaning dietary supplementation with CoQ could prevent programmed accelerated aging. Recuperated male rats had reduced aortic CoQ [22 d (35 +/- 8.4%; P<0.05); 12 m (53 +/- 8.8%; P<0.05)], accelerated aortic telomere shortening (P<0.01), increased DNA damage (79 +/- 13% increase in nei-endonucleaseVIII-like-1), increased oxidative stress (458 +/- 67% increase in NAPDH-oxidase-4; P<0.001), and decreased mitochondrial complex II-III activity (P<0.05). Postweaning dietary supplementation with CoQ prevented these detrimental programming effects. Recuperated WBCs also had reduced CoQ (74 +/- 5.8%; P<0.05). Notably, WBC CoQ levels correlated with aortic telomere-length (P<0.0001) suggesting its potential as a diagnostic marker of vascular aging. We conclude that early intervention with CoQ in at-risk individuals may be a cost-effective and safe way of reducing the global burden of CVDs.	[Tarry-Adkins, Jane L.; Fernandez-Twinn, Denise S.; Chen, Jian-Hua; Martin-Gronert, Malgorzata S.; McConnell, Josie M.; Ozanne, Susan E.] Univ Cambridge, Inst Metab Sci, Metab Res Labs, Cambridge, England; [Hargreaves, Iain P.] UCL, Natl Hosp, Neurometabol Unit, London, England	University of Cambridge; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Tarry-Adkins, JL (corresponding author), Univ Cambridge, Metab Res Labs, Inst Metab Sci, Addenbrookes Treatment Ctr,Addenbrookes Hosp, Level 4,Box 289,Hills Rd, Cambridge CB2 0QQ, England.	janeadkins@googlemail.com	Fernandez-Twinn, Denise/B-3881-2011; Hargreaves, Iain/AAJ-6757-2020	Fernandez-Twinn, Denise/0000-0003-2610-277X; Tarry-Adkins, Jane/0000-0001-9569-6132; Ozanne, Susan/0000-0001-8753-5144	British Heart Foundation [PG/09/037/27387, FS/09/029/27902]; Medical Research Council [MC_UU_12012/4]; UK Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme at University College London Hospital (University College London); Medical Research Council [G0600717B, MC_UU_12012/5, G0600717, MC_UU_12012/5/B] Funding Source: researchfish; MRC [MC_UU_12012/4, G0600717, MC_UU_12012/5] Funding Source: UKRI	British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme at University College London Hospital (University College London); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the British Heart Foundation (PG/09/037/27387, FS/09/029/27902) and Medical Research Council (MC_UU_12012/4). S.E.O. is a British Heart Foundation Senior Fellow and a member of the Medical Research Council Metabolic Diseases Unit. I.P.H. is supported by the UK Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme at University College London Hospital (University College London).	Asimakis GK, 2002, CIRCULATION, V105, P981, DOI 10.1161/hc0802.104502; Aviv H, 2001, ATHEROSCLEROSIS, V159, P281, DOI 10.1016/S0021-9150(01)00506-8; BARKER DJP, 1989, LANCET, V2, P577; Bello RI, 2005, EXP GERONTOL, V40, P694, DOI 10.1016/j.exger.2005.07.003; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; Corstius HB, 2005, PEDIATR RES, V57, P796, DOI 10.1203/01.PDR.0000157726.65492.CD; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Fotino AD, 2013, AM J CLIN NUTR, V97, P268, DOI 10.3945/ajcn.112.040741; Hales CN, 1996, BIOCHEM SOC T, V24, P341, DOI 10.1042/bst0240341; Haussmann MF, 2003, P ROY SOC B-BIOL SCI, V270, P1387, DOI 10.1098/rspb.2003.2385; Heidinger BJ, 2012, P NATL ACAD SCI USA, V109, P1743, DOI 10.1073/pnas.1113306109; Hidaka T, 2008, BIOFACTORS, V32, P199, DOI 10.1002/biof.5520320124; Huxley RR, 2000, J HYPERTENS, V18, P815, DOI 10.1097/00004872-200018070-00002; Ikematsu H, 2006, REGUL TOXICOL PHARM, V44, P212, DOI 10.1016/j.yrtph.2005.12.002; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; Lim KJ, 2006, PEDIATR RES, V60, P83, DOI 10.1203/01.pdr.0000220361.08181.c3; Lonnrot K, 1998, BIOCHEM MOL BIOL INT, V44, P727; Minamino T, 2008, FRONT BIOSCI-LANDMRK, V13, P2971, DOI 10.2741/2902; Molyneux SL, 2009, NEW ZEAL MED J, V122, P74; Nobili Valerio, 2008, Pediatr Endocrinol Rev, V6, P241; Oikawa S, 1999, FEBS LETT, V453, P365, DOI 10.1016/S0014-5793(99)00748-6; Okuda K, 2000, ATHEROSCLEROSIS, V152, P391, DOI 10.1016/S0021-9150(99)00482-7; Organization WH, 2016, GLOBAL STATUS REPORT; Parsons JL, 2013, DNA REPAIR, V12, P326, DOI 10.1016/j.dnarep.2013.02.001; Quiles JL, 2004, EXP GERONTOL, V39, P189, DOI 10.1016/j.exger.2003.10.002; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; Richter T, 2007, EXP GERONTOL, V42, P1039, DOI 10.1016/j.exger.2007.08.005; Sander S, 2006, J CARD FAIL, V12, P464, DOI 10.1016/j.cardfail.2006.03.007; Santos-Gonzalez M, 2007, EXP GERONTOL, V42, P798, DOI 10.1016/j.exger.2007.04.013; Saretzki G, 2003, AGING CELL, V2, P141, DOI 10.1046/j.1474-9728.2003.00040.x; Shelley P, 2007, MECH AGEING DEV, V128, P681, DOI 10.1016/j.mad.2007.10.002; Sindhu RK, 2005, LIFE SCI, V76, P945, DOI 10.1016/j.lfs.2004.10.014; Skilton MR, 2006, CLIN SCI, V111, P281, DOI 10.1042/CS20060036; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Sugamura K, 2011, FREE RADICAL BIO MED, V51, P978, DOI 10.1016/j.freeradbiomed.2011.05.004; Tarry-Adkins JL, 2008, FASEB J, V22, P2037, DOI 10.1096/fj.07-099523; Tarry-Adkins JL, 2009, FASEB J, V23, P1521, DOI 10.1096/fj.08-122796; Tarry-Adkins JL, 2014, P NUTR SOC, V73, P289, DOI 10.1017/S002966511300387X; Tarry-Adkins JL, 2013, MOL METAB, V2, P480, DOI 10.1016/j.molmet.2013.09.004; Tarry-Adkins JL, 2013, FASEB J, V27, P379, DOI 10.1096/fj.12-218685; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Wenzel P, 2008, CARDIOVASC RES, V80, P280, DOI 10.1093/cvr/cvn182	43	11	11	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5398	5405		10.1096/fj.14-259473	http://dx.doi.org/10.1096/fj.14-259473			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25172893	Green Published, hybrid			2022-12-28	WOS:000345894500032
J	Dominguez, N; Estevez-Herrera, J; Borges, R; Machado, JD				Dominguez, Natalia; Estevez-Herrera, Judith; Borges, Ricardo; Machado, Jose D.			The interaction between chromogranin A and catecholamines governs exocytosis	FASEB JOURNAL			English	Article						amperometry; chromaffin; LDCV; PC12; secretion; TIRFM	SINGLE SECRETORY GRANULES; CHROMAFFIN CELLS; QUANTAL SIZE; OSMOTIC-PRESSURE; ON/OFF SWITCH; PC12 CELL; RELEASE; VESICLES; CALCIUM; PH	Chromogranins (Cgs) are acidic proteins that have been described in the large, dense core vesicles (LDCVs) of adrenal chromaffin cells and that have been shown to promote LDCV formation, even in nonsecretory cells. Catecholamines (CAs) are adsorbed by Cgs in vitro, and the absence of Cgs modifies the storage and exocytosis of CAs in chromaffin cells. In this study, we set out to assess the role of CgA in the accumulation and exocytosis of CAs in cells when the levels of CgA and CA are manipulated. We overexpressed CgA in nonsecretory HEK293 cells and in secretory PC12 cells, to study the formation, movement, and exocytosis of newly formed granules by evanescent wave microscopy. We analyzed the association of Cgs/CA by HPLC and amperometry and their role in the accumulation and exocytosis of amines, both under resting conditions and after l-DOPA overloading. To our knowledge, this is the first demonstration that CgA expression in a nonsecretory cell line facilitates the storage and exocytosis of CA. In addition, CgA overexpression causes a doubling of the accumulation of CA, although it slows down exocytosis in PC12 cells. We propose a model to explain how the CgA/CA complex governs the accumulation and exocytosis of secreted amines.Dominguez, N., Estevez-Herrera, J., Borges, R., Machado, J. D. The interaction between chromogranin A and catecholamines governs exocytosis.	[Dominguez, Natalia; Estevez-Herrera, Judith; Borges, Ricardo; Machado, Jose D.] Univ La Laguna, Fac Med, Unidad Farmacol, E-38071 Tenerife, Spain	Universidad de la Laguna	Borges, R (corresponding author), Univ La Laguna, Fac Med, Unidad Farmacol, E-38071 Tenerife, Spain.	rborges@ull.es	Dominguez, Natalia/ABG-7769-2020; Borges, Ricardo/N-3250-2014; Machado, José David/N-5210-2014; Estevez Herrera, Judith/R-5333-2018	Borges, Ricardo/0000-0003-3413-4392; Machado, José David/0000-0003-3531-7051; Dominguez, Natalia/0000-0002-2615-3414; Estevez Herrera, Judith/0000-0001-8130-2294	Spanish Ministry of Economia y Competitividad (MINECO) [BFU2010-15822, CSD2008-00005]; Formacion del Profesorado Universitario (FPU) fellowship from the Spanish Ministry of Education; Formacion del Personal Investigador (FPI) fellowship from the MINECO; CajaCanarias Foundation scholarship; Ramon y Cajal contract (MINECO) [RC-2010-06256]	Spanish Ministry of Economia y Competitividad (MINECO); Formacion del Profesorado Universitario (FPU) fellowship from the Spanish Ministry of Education(German Research Foundation (DFG)); Formacion del Personal Investigador (FPI) fellowship from the MINECO; CajaCanarias Foundation scholarship; Ramon y Cajal contract (MINECO)	The authors thank Mr. Ayoze Santana for Valuable technical assistance, Dr. Agustin Valenzuela-Fenrandez (University of La Laguna, Santa Cruz de Tenerife, Spain) for providing the HEK293 cells and anti-EGFP antibody, and Dr. Jacqueline Keighron for help in revising the manuscript. This work was supported by grants from the Spanish Ministry of Economia y Competitividad (MINECO) BFU2010-15822 and CONSOLIDER (CSD2008-00005). N.D. was the recipient of a Formacion del Profesorado Universitario (FPU) fellowship from the Spanish Ministry of Education, J.E.H. holds a Formacion del Personal Investigador (FPI) fellowship from the MINECO, A.C.S. is recipient of a CajaCanarias Foundation scholarship, and "D.M. holds a Ramon y Cajal contract (R&C-2010-06256, MINECO). The authors declare no conflicts of interests.	Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Allersma MW, 2004, MOL BIOL CELL, V15, P4658, DOI 10.1091/mbc.E04-02-0149; Barroso-Gonzalez J, 2009, J BIOL CHEM, V284, P2419, DOI 10.1074/jbc.M805311200; BORGES R, 1986, J NEUROSCI METH, V16, P289, DOI 10.1016/0165-0270(86)90054-3; Borges R, 1997, J BIOL CHEM, V272, P8325, DOI 10.1074/jbc.272.13.8325; Camacho M, 2008, J BIOL CHEM, V283, P22383, DOI 10.1074/jbc.M800552200; Colliver TL, 2001, J NEUROSCI METH, V105, P95, DOI 10.1016/S0165-0270(00)00359-9; Colliver TL, 2000, J NEUROSCI, V20, P5276, DOI 10.1523/JNEUROSCI.20-14-05276.2000; Day R, 2003, TRENDS ENDOCRIN MET, V14, P10, DOI 10.1016/S1043-2760(02)00011-5; Diaz-Vera J, 2012, FASEB J, V26, P430, DOI 10.1096/fj.11-181941; Diaz-Vera J, 2010, J NEUROSCI, V30, P950, DOI 10.1523/JNEUROSCI.2894-09.2010; Elhamdani A, 2006, J NEUROSCI, V26, P3030, DOI 10.1523/JNEUROSCI.5275-05.2006; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Gong LW, 2003, J NEUROSCI, V23, P7917; HELLE KB, 1985, ACTA PHYSIOL SCAND, V123, P21, DOI 10.1111/j.1748-1716.1985.tb07556.x; KATZ B, 1971, SCIENCE, V173, P123, DOI 10.1126/science.173.3992.123; Kim T, 2005, J NEUROSCI, V25, P6958, DOI 10.1523/JNEUROSCI.1058-05.2005; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; Machado David J., 2008, V440, P297, DOI 10.1007/978-1-59745-178-9_23; Machado JD, 2000, J BIOL CHEM, V275, P20274, DOI 10.1074/jbc.M000930200; Machado JD, 2010, CELL MOL NEUROBIOL, V30, P1181, DOI 10.1007/s10571-010-9584-y; Malosio ML, 2004, J CELL SCI, V117, P743, DOI 10.1242/jcs.00934; Mica OI, 2004, BIOCHEM J, V381, P13, DOI 10.1042/BJ20040434; Montero-Hadjadje M, 2009, J BIOL CHEM, V284, P12420, DOI 10.1074/jbc.M805607200; Montesinos MS, 2008, J NEUROSCI, V28, P3350, DOI 10.1523/JNEUROSCI.5292-07.2008; Montesinos MS, 2010, BRIT J PHARMACOL, V159, P1548, DOI 10.1111/j.1476-5381.2010.00650.x; Mosharov EV, 2003, J NEUROSCI, V23, P5835; NANAVATI C, 1993, SCIENCE, V259, P963, DOI 10.1126/science.8438154; Omiatek DM, 2010, ACS CHEM NEUROSCI, V1, P234, DOI 10.1021/cn900040e; Pihel K, 1996, BIOPHYS J, V71, P1633, DOI 10.1016/S0006-3495(96)79368-2; Poea-Guyon S, 2013, ANAL BIOANAL CHEM, V405, P3983, DOI 10.1007/s00216-013-6860-y; Pothos E, 1996, J NEUROCHEM, V66, P629; Pothos EN, 2002, J PHYSIOL-LONDON, V542, P453, DOI 10.1113/jphysiol.2002.018630; Segura F, 2000, J NEUROSCI METH, V103, P151, DOI 10.1016/S0165-0270(00)00309-5; Sombers LA, 2004, J NEUROSCI, V24, P303, DOI 10.1523/JNEUROSCI.1119-03.2004; Sombers LA, 2005, J NEUROCHEM, V93, P1122, DOI 10.1111/j.1471-4159.2005.03087.x; Steyer JA, 1999, BIOPHYS J, V76, P2262, DOI 10.1016/S0006-3495(99)77382-0; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; Sulzer D, 2000, NEURON, V28, P5; VERDUGO P, 1991, AM REV RESPIR DIS, V144, pS33, DOI 10.1164/ajrccm/144.3_pt_2.S33; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; Westerink RHS, 2008, ACTA PHYSIOL, V192, P273, DOI 10.1111/j.1748-1716.2007.01805.x; Westerink RHS, 2000, BIOCHEM BIOPH RES CO, V270, P625, DOI 10.1006/bbrc.2000.2470; Yoo SH, 2010, FASEB J, V24, P653, DOI 10.1096/fj.09-132456; YOO SH, 1991, J BIOL CHEM, V266, P7740	45	14	14	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4657	4667		10.1096/fj.14-249607	http://dx.doi.org/10.1096/fj.14-249607			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25077558				2022-12-28	WOS:000344050900007
J	Kim, J; Ko, J				Kim, Jeonghan; Ko, Jesang			Human sLZIP promotes atherosclerosis via MMP-9 transcription and vascular smooth muscle cell migration	FASEB JOURNAL			English	Article						sLZIP; matrix metalloproteinase; vascular smooth muscle cell; macrophage; atherosclerosis	NECROSIS-FACTOR-ALPHA; LEUCINE-ZIPPER PROTEIN; E-DEFICIENT MICE; MATRIX METALLOPROTEINASES; DIFFERENTIALLY AFFECTS; MACROPHAGES; EXPRESSION; MATRIX-METALLOPROTEINASE-9; DISEASE; CYTOKINES	Atherosclerosis is a chronic inflammatory response of the vascular wall, and immune responses are involved in every phase of atherosclerosis, from initiation, to progression, and finally to plaque rupture. Cytokines are the major atherogenic mediators that promote plaque formation and progression by activation of inflammatory cells. They induce expressions of matrix metalloproteinases (MMPs), leading to vascular smooth muscle cell (VSMC) migration in atherosclerotic lesions. Although chronic inflammatory mediators, including tumor necrosis factor (TNF-) and MMPs, exacerbate atherosclerosis, the molecular mechanism of atherogenesis remains unclear. In this study we investigated the role of a novel transcription factor the human small leucine zipper protein (sLZIP) in TNF--induced MMP expression, VSMC migration, and atherosclerosis progression. The proinflammatory cytokine TNF- enhanced sLZIP expression by 3-fold via activation of NF-B signaling. sLZIP induced MMP-9 transcription and the proteolytic activity of MMP-9 by 2.8- and 3.2-fold (P< 0.05), respectively, in macrophages, leading to enhancement of VSMC migration by 2.7-fold (P<0.005). sLZIP(OE/+) (sLZIP transgenic); LDLR-/- mice fed a high-cholesterol diet exhibited enhanced arterial plaque formation and increased VSMC migration from the media into the intima by 2.8- and 2.6-fold (P<0.01), respectively, compared with atherosclerosis-prone LDLR-/- mice. These results indicate that human sLZIP plays a critical role in development of atherosclerosis and can be used as a therapeutic target molecule for treatment of atherosclerosis.Kim, J., Ko, J. Human sLZIP promotes atherosclerosis via MMP-9 transcription and vascular smooth muscle cell migration.	[Kim, Jeonghan; Ko, Jesang] Korea Univ, Div Life Sci, Seoul 136701, South Korea	Korea University	Ko, J (corresponding author), Korea Univ, Div Life Sci, 5-1 Anam Dong, Seoul 136701, South Korea.	jesangko@korea.ac.kr			Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [2014R1A2A2A01002826]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT and Future Planning (2014R1A2A2A01002826)	Ait-Oufella H, 2011, ARTERIOSCL THROM VAS, V31, P969, DOI 10.1161/ATVBAHA.110.207415; Chen L, 2009, AM J PHYSIOL-HEART C, V296, pH987, DOI 10.1152/ajpheart.01158.2008; Choi ET, 2005, ARTERIOSCL THROM VAS, V25, P1020, DOI 10.1161/01.ATV.0000161275.82687.f6; Danenberg HD, 2003, J CARDIOVASC PHARM, V42, P671, DOI 10.1097/00005344-200311000-00014; George J, 2008, NAT CLIN PRACT CARD, V5, P531, DOI 10.1038/ncpcardio1279; Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001; Jang SY, 2012, CANCER LETT, V314, P185, DOI 10.1016/j.canlet.2011.09.028; Jang SW, 2007, J BIOL CHEM, V282, P11092, DOI 10.1074/jbc.M607962200; Johnson C, 2004, ARTERIOSCL THROM VAS, V24, P54, DOI 10.1161/01.ATV.0000100402.69997.C3; Johnson JL, 2011, ARTERIOSCL THROM VAS, V31, pE35, DOI 10.1161/ATVBAHA.111.225623; Kang H, 2011, J BIOL CHEM, V286, P42072, DOI 10.1074/jbc.M111.272302; Kang H, 2009, MOL ENDOCRINOL, V23, P1746, DOI 10.1210/me.2009-0009; Kim HC, 2010, CELL MOL LIFE SCI, V67, P3499, DOI 10.1007/s00018-010-0388-5; Kleemann R, 2008, CARDIOVASC RES, V79, P360, DOI 10.1093/cvr/cvn120; Ko J, 2004, FASEB J, V18, P890, DOI 10.1096/fj.03-0867fje; Koga J, 2012, VASC PHARMACOL, V57, P24, DOI 10.1016/j.vph.2012.02.011; Kwon Sang-Hee, 2008, Nutr Res Pract, V2, P134, DOI 10.4162/nrp.2008.2.2.134; Li H, 2007, MOL CELL BIOL, V27, P2676, DOI 10.1128/MCB.01748-06; Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146; Luttun A, 2004, CIRCULATION, V109, P1408, DOI 10.1161/01.CIR.0000121728.14930.DE; McKellar GE, 2009, NAT REV CARDIOL, V6, P410, DOI 10.1038/nrcardio.2009.57; Moore KJ, 2013, NAT REV IMMUNOL, V13, P709, DOI 10.1038/nri3520; Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005; Newby AC, 2006, CARDIOVASC RES, V69, P614, DOI 10.1016/j.cardiores.2005.08.002; Newby AC, 2008, ARTERIOSCL THROM VAS, V28, P2108, DOI 10.1161/ATVBAHA.108.173898; Ohta H, 2005, ATHEROSCLEROSIS, V180, P11, DOI 10.1016/j.atherosclerosis.2004.11.016; Ono H, 2004, ARTERIOSCL THROM VAS, V24, P1634, DOI 10.1161/01.ATV.0000138052.86051.0d; Poon M, 2001, ATHEROSCLEROSIS, V155, P371, DOI 10.1016/S0021-9150(00)00605-5; Rickard AJ, 2009, J MOL ENDOCRINOL, V42, P449, DOI 10.1677/JME-08-0144; Siefert SA, 2012, VASCULAR, V20, P210, DOI 10.1258/vasc.2011.201202; Skoog T, 2002, EUR HEART J, V23, P376, DOI 10.1053/euhj.2001.2805; Sung HJ, 2008, EXP MOL MED, V40, P332, DOI 10.3858/emm.2008.40.3.332; Tedgui A, 2006, PHYSIOL REV, V86, P515, DOI 10.1152/physrev.00024.2005; Xiong WF, 2009, J IMMUNOL, V183, P2741, DOI 10.4049/jimmunol.0803164	34	19	21	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					5010	5021		10.1096/fj.14-259218	http://dx.doi.org/10.1096/fj.14-259218			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25077563				2022-12-28	WOS:000344050900036
J	Wu, CH; Sui, GP; Archer, SN; Sassone-Corsi, P; Aitken, K; Bagli, D; Chen, Y				Wu, Changhao; Sui, Guiping; Archer, Simon N.; Sassone-Corsi, Paolo; Aitken, Karen; Bagli, Darius; Chen, Ying			Local receptors as novel regulators for peripheral clock expression	FASEB JOURNAL			English	Article						circadian; muscarinic; purinergic; aging	NONNEURONAL CHOLINERGIC SYSTEM; CIRCADIAN CLOCK; ATP RELEASE; ACETYLCHOLINE-RELEASE; UROTHELIAL ATP; METABOLISM; RHYTHMS; EPIGENETICS; MODULATION; CHROMATIN	Mammalian circadian control is determined by a central clock in the brain suprachiasmatic nucleus (SCN) and synchronized peripheral clocks in other tissues. Increasing evidence suggests that SCN-independent regulation of peripheral clocks also occurs. We examined how activation of excitatory receptors influences the clock protein PERIOD 2 (PER2) in a contractile organ, the urinary bladder. PERIOD2::LUCIFERASE-knock-in mice were used to report real-time PER2 circadian dynamics in the bladder tissue. Rhythmic PER2 activities occurred in the bladder wall with a cycle of approximate to 24 h and peak at approximate to 12 h. Activation of the muscarinic and purinergic receptors by agonists shifted the peak to an earlier time (7.2 +/- 2.0 and 7.2 +/- 0.9 h, respectively). PER2 expression was also sensitive to mechanical stimulation. Aging significantly dampened PER2 expression and its response to the agonists. Finally, muscarinic agonist-induced smooth muscle contraction also exhibited circadian rhythm. These data identified novel regulators, endogenous receptors, in determining local clock activity, in addition to mediating the central control. Furthermore, the local clock appears to reciprocally align receptor activity to circadian rhythm for muscle contraction. The interaction between receptors and peripheral clock represents an important mechanism for maintaining physiological functions and its dysregulation may contribute to age-related organ disorders.Wu, C., Sui, G., Archer, S. N., Sassone-Corsi, P., Aitken, K., Bagli, D., Chen, Y. Local receptors as novel regulators for peripheral clock expression.	[Wu, Changhao; Archer, Simon N.; Chen, Ying] Univ Surrey, Dept Biochem & Physiol, Guildford GU2 7XH, Surrey, England; [Sui, Guiping] Guys & St Thomas Hosp Natl Hlth Serv Trust, Oesophageal Lab, London, England; [Sassone-Corsi, Paolo] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA; [Aitken, Karen; Bagli, Darius] Univ Toronto, Hosp Sick Children, Dept Urol, Toronto, ON M5G 1X8, Canada	University of Surrey; University of California System; University of California Irvine; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Wu, CH (corresponding author), Univ Surrey, Fac Hlth & Med Sci, Dept Biochem & Physiol, Guildford GU2 7XH, Surrey, England.	c.wu@surrey.ac.uk	Aitken, KJ/AAC-5383-2019		UK Biotechnology and Biological Sciences Research Council [BB/G015554/1, BB/E010296/1, BB/E003672/1]; BBSRC [BB/E003672/1, BB/I025379/1, BB/G015554/1, BB/E010296/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/I025379/1, BB/E010296/1, BB/G015554/1, BB/E003672/1] Funding Source: researchfish	UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The work was supported by UK Biotechnology and Biological Sciences Research Council grants BB/G015554/1 (to Y. C.), BB/E010296/1 (to C. W.), and BB/E003672/1 (to S.N.A.). The authors thank Daan van der Veen for help with breeding the transgenic mice.	Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; Andersson KE, 1999, SCAND J UROL NEPHROL, V33, P67, DOI 10.1080/003655999750042178; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Bayliss M, 1999, J UROLOGY, V162, P1833, DOI 10.1016/S0022-5347(05)68247-X; Birder LA, 2010, NEUROUROL URODYNAM, V29, P598, DOI 10.1002/nau.20914; Birder LA, 2003, AM J PHYSIOL-RENAL, V285, pF423, DOI 10.1152/ajprenal.00056.2003; Birder Lori A, 2011, Handb Exp Pharmacol, P207, DOI 10.1007/978-3-642-16499-6_10; Burnstock G, 2006, BRIT J PHARMACOL, V147, pS172, DOI 10.1038/sj.bjp.0706429; Chopra B, 2005, J PHYSIOL-LONDON, V562, P859, DOI 10.1113/jphysiol.2004.071159; Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602; Diaz-Munoz M, 2000, AM J PHYSIOL-REG I, V279, pR2048, DOI 10.1152/ajpregu.2000.279.6.R2048; Duguay D, 2009, CHRONOBIOL INT, V26, P1479, DOI 10.3109/07420520903497575; Feng D, 2012, MOL CELL, V47, P158, DOI 10.1016/j.molcel.2012.06.026; Garaulet M, 2010, INT J OBESITY, V34, P1667, DOI 10.1038/ijo.2010.118; Gibson EM, 2009, EXP GERONTOL, V44, P51, DOI 10.1016/j.exger.2008.05.007; Gimble JM, 2011, CURR OPIN CLIN NUTR, V14, P554, DOI 10.1097/MCO.0b013e32834ad94b; Hanna-Mitchell AT, 2007, LIFE SCI, V80, P2298, DOI 10.1016/j.lfs.2007.02.010; Hasan S, 2012, FASEB J, V26, P2414, DOI 10.1096/fj.11-201699; Herrera GM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012298; Illi B, 2005, CIRC RES, V96, P501, DOI 10.1161/01.RES.0000159181.06379.63; Kanazawa T, 2012, J ORTHOP RES, V30, P468, DOI 10.1002/jor.21528; Kang SH, 2013, EUR J PHARMACOL, V700, P102, DOI 10.1016/j.ejphar.2012.11.053; Khapre RV, 2010, ANN MED, V42, P404, DOI 10.3109/07853890.2010.499134; Li JD, 2012, PROG BRAIN RES, V199, P119, DOI 10.1016/B978-0-444-59427-3.00028-9; Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001; Mansfield KJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/182862; Masri S, 2013, NAT REV NEUROSCI, V14, P69, DOI 10.1038/nrn3393; Masri S, 2010, NAT NEUROSCI, V13, P1324, DOI 10.1038/nn.2668; Mills IW, 2000, BJU INT, V86, P538, DOI 10.1046/j.1464-410X.2000.00768.x; Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128; Moro C, 2011, UROLOGY, V78, DOI 10.1016/j.urology.2011.08.039; Negoro H, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1812; Nishii K, 2006, NEUROSCI LETT, V401, P44, DOI 10.1016/j.neulet.2006.03.022; Praetorius HA, 2009, PURINERG SIGNAL, V5, P433, DOI 10.1007/s11302-009-9146-2; Richards J, 2012, FASEB J, V26, P3602, DOI 10.1096/fj.12-203554; Rosbash M, 2007, COLD SPRING HARB SYM, V72, P75, DOI 10.1101/sqb.2007.72.062; Sahar S, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00037; Sahar S, 2012, TRENDS ENDOCRIN MET, V23, P1, DOI 10.1016/j.tem.2011.10.005; Sassone-Corsi P, 2013, SCIENCE, V339, P148, DOI 10.1126/science.1233423; SHINKAI M, 1993, BRIT J PHARMACOL, V108, P759, DOI 10.1111/j.1476-5381.1993.tb12874.x; Siepka SM, 2007, COLD SPRING HARB SYM, V72, P251, DOI 10.1101/sqb.2007.72.052; Smith CP, 2008, NEUROCHEM INT, V52, P1068, DOI 10.1016/j.neuint.2007.11.006; Smith CP, 2005, NEUROCHEM INT, V47, P291, DOI 10.1016/j.neuint.2005.04.021; Stranahan AM, 2012, CURR ALZHEIMER RES, V9, P93; Sui GP, 2008, AM J PHYSIOL-RENAL, V295, pF688, DOI 10.1152/ajprenal.00133.2008; Sui GP, 2014, AM J PHYSIOL-RENAL, V306, pF286, DOI 10.1152/ajprenal.00291.2013; Tahara Y, 2012, CURR BIOL, V22, P1029, DOI 10.1016/j.cub.2012.04.009; Tsimakouridze EV, 2012, CHRONOBIOL INT, V29, P810, DOI 10.3109/07420528.2012.691145; Wessler I, 2003, LIFE SCI, V72, P2055, DOI 10.1016/S0024-3205(03)00083-3; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Yoshida J, 2007, NEUROUROL URODYNAM, V26, P1050, DOI 10.1002/nau.20438; Yoshida M, 2006, UROLOGY, V67, P425, DOI 10.1016/j.urology.2005.08.014; Young JS, 2012, BJU INT, V110, pE397, DOI 10.1111/j.1464-410X.2012.10966.x; Yu EA, 2011, AGING-US, V3, P479, DOI 10.18632/aging.100323; Zhang EE, 2010, NAT REV MOL CELL BIO, V11, P764, DOI 10.1038/nrm2995	55	11	11	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4610	4616		10.1096/fj.13-243295	http://dx.doi.org/10.1096/fj.13-243295			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25145629	Green Published			2022-12-28	WOS:000344050900003
J	Mukherjee, N; Jose, MD; Birkner, JP; Walko, M; Ingolfsson, HI; Dimitrova, A; Arnarez, C; Marrink, SJ; Kocer, A				Mukherjee, Nobina; Jose, Mac Donald; Birkner, Jan Peter; Walko, Martin; Ingolfsson, Helgi I.; Dimitrova, Anna; Arnarez, Clement; Marrink, Siewert J.; Kocer, Armagan			The activation mode of the mechanosensitive ion channel, MscL, by lysophosphatidylcholine differs from tension-induced gating	FASEB JOURNAL			English	Article						spectroscopy; protein-lipid interaction; mechanosensation; critical micelle concentration of LPC	COARSE-GRAINED MODEL; ESCHERICHIA-COLI; MOLECULAR-DYNAMICS; MEMBRANE-PROTEINS; MYCOBACTERIUM-TUBERCULOSIS; FUNCTIONAL RECONSTITUTION; LIPID-BILAYERS; SINGLE RESIDUE; FORCE-FIELD; SIMULATIONS	One of the best-studied mechanosensitive channels is the mechanosensitive channel of large conductance (MscL). MscL senses tension in the membrane evoked by an osmotic down shock and directly couples it to large conformational changes leading to the opening of the channel. Spectroscopic techniques offer unique possibilities to monitor these conformational changes if it were possible to generate tension in the lipid bilayer, the native environment of MscL, during the measurements. To this end, asymmetric insertion of L-alpha-lysophosphatidylcholine (LPC) into the lipid bilayer has been effective; however, how LPC activates MscL is not fully understood. Here, the effects of LPC on tension-sensitive mutants of a bacterial MscL and on MscL homologs with different tension sensitivities are reported, leading to the conclusion that the mode of action of LPC is different from that of applied tension. Our results imply that LPC shifts the free energy of gating by interfering with MscL-membrane coupling. Furthermore, we demonstrate that the fine-tuned addition of LPC can be used for controlled activation of MscL in spectroscopic studies.	[Mukherjee, Nobina; Jose, Mac Donald; Birkner, Jan Peter; Walko, Martin; Ingolfsson, Helgi I.; Dimitrova, Anna; Arnarez, Clement; Marrink, Siewert J.; Kocer, Armagan] Univ Groningen, Biomol Sci & Biotechnol Inst, Groningen, Netherlands; [Birkner, Jan Peter] Univ Groningen, Zernike Inst Adv Mat, Groningen, Netherlands; [Kocer, Armagan] Univ Groningen, Univ Med Ctr Groningen, Neurosci Dept, NL-9713 AV Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Kocer, A (corresponding author), Univ Med Ctr Groningen, Antonius Deusinglaan 1,Bldg 3215, NL-9713 AV Groningen, Netherlands.	a.kocer@umcg.nl	Institute, Zernike/W-7033-2019; Ingolfsson, Helgi I./AAQ-5946-2020; Birkner, Jan Peter/E-8316-2014; Marrink, Siewert J/G-3706-2014	Ingolfsson, Helgi I./0000-0002-7613-9143; Marrink, Siewert J/0000-0001-8423-5277; Mukherjee, Nobina/0000-0003-4655-2188; Walko, Martin/0000-0002-7160-6136; Birkner, Jan Peter/0000-0002-5536-2274; kocer, Armagan/0000-0001-7343-3139	Netherlands Organization for Scientific Research; European Research Council-Ideas Program [208814]	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); European Research Council-Ideas Program	The authors thank G. T. Robillard for critical reading of the manuscript. This work was supported by a Rubicon grant from the Netherlands Organization for Scientific Research (to H.I.I.) and European Research Council-Ideas Program Starting Grant 208814 (to A.K.). Author contributions: N.M. and A.K. designed the research; N.M. performed fluorescence experiments and analyzed data; M.D.J. and J.P.B. performed patch-clamp experiments; N.M. and A.K. analyzed patch-clamp data; A.D. performed EPR experiments; N.M. and M.W. designed the CMC experiment; N.M. determined the CMC of LPC; C.A., H.I.I., and S.J.M. performed and analyzed MD simulations; and N.M. and A.K. wrote the manuscript with input from all coauthors. The authors declare no conflicts of interest.	BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Betanzos M, 2002, NAT STRUCT BIOL, V9, P704, DOI 10.1038/nsb828; Birkner JP, 2012, P NATL ACAD SCI USA, V109, P12944, DOI 10.1073/pnas.1205270109; Blount P, 1999, TRENDS MICROBIOL, V7, P420, DOI 10.1016/S0966-842X(99)01594-2; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Bordignon E, 2012, TOP CURR CHEM, V321, P121, DOI 10.1007/128_2011_243; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chiang CS, 2004, BIOPHYS J, V86, P2846, DOI 10.1016/S0006-3495(04)74337-4; Corry B, 2010, J GEN PHYSIOL, V136, P483, DOI 10.1085/jgp.200910376; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; Dominguez A, 1997, J CHEM EDUC, V74, P1227, DOI 10.1021/ed074p1227; Esteban-Martin S, 2009, J AM CHEM SOC, V131, P15194, DOI 10.1021/ja904450t; Folgering JHA, 2005, J BIOL CHEM, V280, P8784, DOI 10.1074/jbc.M411732200; Girard P, 2004, BIOPHYS J, V87, P419, DOI 10.1529/biophysj.104.040360; Gullingsrud J, 2004, BIOPHYS J, V86, P3496, DOI 10.1529/biophysj.103.034322; Gullingsrud J, 2001, BIOPHYS J, V80, P2074, DOI 10.1016/S0006-3495(01)76181-4; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kocer A, 2007, NAT PROTOC, V2, P1426, DOI 10.1038/nprot.2007.196; Kung C, 2010, ANNU REV MICROBIOL, V64, P313, DOI 10.1146/annurev.micro.112408.134106; Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012; Louhivuori M, 2010, P NATL ACAD SCI USA, V107, P19856, DOI 10.1073/pnas.1001316107; Lundbaek JA, 2010, J R SOC INTERFACE, V7, P373, DOI 10.1098/rsif.2009.0443; Machiyama H, 2009, BIOPHYS J, V97, P1048, DOI 10.1016/j.bpj.2009.05.021; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; MANDERSLOOT JG, 1975, BIOCHIM BIOPHYS ACTA, V382, P22, DOI 10.1016/0005-2736(75)90368-5; Markin VS, 2004, PHYS BIOL, V1, P110, DOI 10.1088/1478-3967/1/2/007; Marrink SJ, 2007, J PHYS CHEM B, V111, P7812, DOI 10.1021/jp071097f; Marrink SJ, 2004, J PHYS CHEM B, V108, P750, DOI 10.1021/jp036508g; Marsh D, 2008, BBA-BIOMEMBRANES, V1778, P1545, DOI 10.1016/j.bbamem.2008.01.015; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Maurer JA, 2000, J BIOL CHEM, V275, P22238, DOI 10.1074/jbc.M003056200; Mika JT, 2013, FASEB J, V27, P882, DOI 10.1096/fj.12-214361; Moe PC, 2000, J BIOL CHEM, V275, P31121, DOI 10.1074/jbc.M002971200; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; Monticelli L, 2008, J CHEM THEORY COMPUT, V4, P819, DOI 10.1021/ct700324x; MORRIS DAN, 1980, BIOCHIM BIOPHYS ACTA, V599, P380, DOI 10.1016/0005-2736(80)90185-6; Nomura T, 2012, P NATL ACAD SCI USA, V109, P8770, DOI 10.1073/pnas.1200051109; Ollila OHS, 2011, BIOPHYS J, V100, P1651, DOI 10.1016/j.bpj.2011.02.027; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Sachs F, 2010, PHYSIOLOGY, V25, P50, DOI 10.1152/physiol.00042.2009; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Steinbacher S, 2007, CURR TOP MEMBR, V58, P1, DOI 10.1016/S1063-5823(06)58001-9; Stothard P, 2000, BIOTECHNIQUES, V28, P1102, DOI 10.2144/00286ir01; Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743; Sukharev S, 2001, BIOPHYS J, V81, P917, DOI 10.1016/S0006-3495(01)75751-7; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; van den Bogaart G, 2007, BIOPHYS J, V92, P1233, DOI 10.1529/biophysj.106.088708; Vasquez V, 2008, SCIENCE, V321, P1210, DOI 10.1126/science.1159674; Wiggins P, 2004, P NATL ACAD SCI USA, V101, P4071, DOI 10.1073/pnas.0307804101; Yefimov S, 2008, BIOPHYS J, V94, P2994, DOI 10.1529/biophysj.107.119966; Yoo J, 2009, BIOPHYS J, V97, P2267, DOI 10.1016/j.bpj.2009.07.051; Yoshimura K, 1999, BIOPHYS J, V77, P1960, DOI 10.1016/S0006-3495(99)77037-2; Yoshimura K, 2010, J R SOC INTERFACE, V7, pS307, DOI 10.1098/rsif.2010.0095.focus; Zhelev DV, 1998, BIOPHYS J, V75, P321, DOI 10.1016/S0006-3495(98)77516-2	62	32	32	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4292	4302		10.1096/fj.14-251579	http://dx.doi.org/10.1096/fj.14-251579			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24958207	Green Published			2022-12-28	WOS:000342222700009
J	Anthony, D; McQualter, JL; Bishara, M; Lim, EX; Yatmaz, S; Seow, HJ; Hansen, M; Thompson, M; Hamilton, JA; Irving, LB; Levy, BD; Vlahos, R; Anderson, GP; Bozinovski, S				Anthony, Desiree; McQualter, Jonathan L.; Bishara, Maria; Lim, Ee X.; Yatmaz, Selcuk; Seow, Huei Jiunn; Hansen, Michelle; Thompson, Michelle; Hamilton, John A.; Irving, Louis B.; Levy, Bruce D.; Vlahos, Ross; Anderson, Gary P.; Bozinovski, Steven			SAA drives proinflammatory heterotypic macrophage differentiation in the lung via CSF-1R-dependent signaling	FASEB JOURNAL			English	Article						macrophage biology; COPD; lung inflammation; ALX/FPR2 signaling	OBSTRUCTIVE PULMONARY-DISEASE; SERUM-AMYLOID-A; PROTEIN-COUPLED RECEPTOR; FORMYL PEPTIDE RECEPTOR; HUMAN MONOCYTES; ALVEOLAR MACROPHAGES; CUTTING EDGE; LIPOXIN A(4); INFLAMMATION; POLARIZATION	Serum amyloid A (SAA) is expressed locally in chronic inflammatory conditions such as chronic obstructive pulmonary disease (COPD), where macrophages that do not accord with the classic M1/M2 paradigm also accumulate. In this study, the role of SAA in regulating macrophage differentiation was investigated in vitro using human blood monocytes from healthy subjects and patients with COPD and in vivo using an airway SAA challenge model in BALB/c mice. Differentiation of human monocytes with SAA stimulated the proinflammatory monokines IL-6 and IL-1 beta concurrently with the M2 markers CD163 and IL-10. Furthermore, SAA-differentiated macrophages stimulated with lipopolysaccharide (LPS) expressed markedly higher levels of IL-6 and IL-1 beta. The ALX/FPR2 antagonist WRW4 reduced IL-6 and IL-1 beta expression but did not significantly inhibit phagocytic and efferocytic activity. In vivo, SAA administration induced the development of a CD11c(high)CD11b(high) macrophage population that generated higher levels of IL-6, IL-1 beta, and G-CSF following ex vivo LPS challenge. Blocking CSF-1R signaling effectively reduced the number of CD11c(high)CD11b(high) macrophages by 71% and also markedly inhibited neutrophilic inflammation by 80%. In conclusion, our findings suggest that SAA can promote a distinct CD11c(high)CD11b(high) macrophage phenotype, and targeting this population may provide a novel approach to treating chronic inflammatory conditions associated with persistent SAA expression.	[Anthony, Desiree; McQualter, Jonathan L.; Bishara, Maria; Lim, Ee X.; Yatmaz, Selcuk; Seow, Huei Jiunn; Hansen, Michelle; Vlahos, Ross; Anderson, Gary P.; Bozinovski, Steven] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic 3010, Australia; [Hamilton, John A.] Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia; [Thompson, Michelle; Irving, Louis B.] Royal Melbourne Hosp, Dept Resp Med, Parkville, Vic 3050, Australia; [Levy, Bruce D.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Levy, Bruce D.] Harvard Univ, Sch Med, Boston, MA USA	University of Melbourne; University of Melbourne; Royal Melbourne Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Bozinovski, S (corresponding author), Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic 3010, Australia.	bozis@unimelb.edu.au	Vlahos, Ross/AAM-3837-2020	Vlahos, Ross/0000-0001-8443-7071; Bozinovski, Steven/0000-0001-6533-8641; Anderson, Gary/0000-0001-6580-3398; Hansen, Michelle/0000-0002-2607-461X; Seow, Huei/0000-0002-4790-4811; Hamilton, John A/0000-0002-9493-9224; McQualter, Jonathan/0000-0002-3844-8009	National Health and Medical Research Council (NHMRC) of Australia; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL122531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM095467] Funding Source: NIH RePORTER	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Health and Medical Research Council (NHMRC) of Australia.	Anthony D, 2013, AM J RESP CRIT CARE, V188, P179, DOI 10.1164/rccm.201211-2139OC; BADOLATO R, 1994, J EXP MED, V180, P203, DOI 10.1084/jem.180.1.203; Baranova IN, 2010, J BIOL CHEM, V285, P8492, DOI 10.1074/jbc.M109.007526; Beckett EL, 2013, J ALLERGY CLIN IMMUN, V131, P752, DOI 10.1016/j.jaci.2012.11.053; Bozinovski S, 2008, AM J RESP CRIT CARE, V177, P269, DOI 10.1164/rccm.200705-678OC; Bozinovski S, 2013, PHARMACOL THERAPEUT, V140, P280, DOI 10.1016/j.pharmthera.2013.07.007; Bozinovski S, 2012, P NATL ACAD SCI USA, V109, P935, DOI 10.1073/pnas.1109382109; Bozinovski S, 2011, AM J RESP CELL MOL, V45, P229, DOI 10.1165/rcmb.2010-0272OC; Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97, DOI 10.1002/jlb.67.1.97; Cai L, 2005, J BIOL CHEM, V280, P2954, DOI 10.1074/jbc.M411555200; Cheng N, 2008, J IMMUNOL, V181, P22, DOI 10.4049/jimmunol.181.1.22; Cooray SN, 2013, P NATL ACAD SCI USA, V110, P18232, DOI 10.1073/pnas.1308253110; Dhaliwal K., 2012, MONOCYTES CONTROL 2, P514; Dolinay T, 2012, CURR PHARM BIOTECHNO, V13, P769, DOI 10.2174/138920112800399338; Duan M, 2012, J IMMUNOL, V189, P946, DOI 10.4049/jimmunol.1200660; El Kebir D, 2007, J IMMUNOL, V179, P616, DOI 10.4049/jimmunol.179.1.616; Filep JG, 2013, P NATL ACAD SCI USA, V110, P18033, DOI 10.1073/pnas.1317798110; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Guth AM, 2009, AM J PHYSIOL-LUNG C, V296, pL936, DOI 10.1152/ajplung.90625.2008; Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356; Harvey CJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002042; Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004; He R, 2003, BLOOD, V101, P1572, DOI 10.1182/blood-2002-05-1431; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hume DA, 2012, BLOOD, V119, P1810, DOI 10.1182/blood-2011-09-379214; Hurst JR, 2006, AM J RESP CRIT CARE, V173, P71, DOI 10.1164/rccm.200505-704OC; Jemal A, 2005, JAMA-J AM MED ASSOC, V294, P1255, DOI 10.1001/jama.294.10.1255; Kunz LIZ, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-34; Lee HY, 2008, J IMMUNOL, V181, P4332, DOI 10.4049/jimmunol.181.6.4332; Lee HY, 2006, MOL PHARMACOL, V70, P241, DOI 10.1124/mol.105.022103; Lenzo JC, 2012, IMMUNOL CELL BIOL, V90, P429, DOI 10.1038/icb.2011.58; Li Y, 2011, ONCOGENE, V30, P3887, DOI 10.1038/onc.2011.112; Liu K, 2008, AM J RESP CELL MOL, V39, P305, DOI 10.1165/rcmb.2007-0458OC; Lopez-Campos JL, 2013, INT J MED SCI, V10, P938, DOI 10.7150/ijms.6152; Maderna P, 2010, FASEB J, V24, P4240, DOI 10.1096/fj.10-159913; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Maus UA, 2006, AM J RESP CELL MOL, V35, P227, DOI 10.1165/rcmb.2005-0241OC; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; O'Hara R, 2000, ARTHRITIS RES, V2, P142, DOI 10.1186/ar78; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P2157, DOI 10.1089/ars.2007.1811; Shaykhiev R, 2009, J IMMUNOL, V183, P2867, DOI 10.4049/jimmunol.0900473; Shibata Y, 2001, IMMUNITY, V15, P557, DOI 10.1016/S1074-7613(01)00218-7; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Sung HJ, 2011, J PROTEOME RES, V10, P1383, DOI 10.1021/pr101154j; Traves SL, 2004, J LEUKOCYTE BIOL, V76, P441, DOI 10.1189/jlb.1003495; Van Gorp H, 2010, MOL IMMUNOL, V47, P1650, DOI 10.1016/j.molimm.2010.02.008; Waechter V, 2012, J IMMUNOL, V188, P1856, DOI 10.4049/jimmunol.1101788; Williams L, 2002, J LEUKOCYTE BIOL, V72, P800; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578	52	37	38	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3867	3877		10.1096/fj.14-250332	http://dx.doi.org/10.1096/fj.14-250332			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24846388	Green Published			2022-12-28	WOS:000340845900006
J	Tavernier, A; Cavin, JB; Le Gall, M; Ducroc, R; Denis, RGP; Cluzeaud, F; Guilmeau, S; Sakar, Y; Barbot, L; Kapel, N; Le Beyec, J; Joly, F; Chua, S; Luquet, S; Bado, A				Tavernier, Annabelle; Cavin, Jean-Baptiste; Le Gall, Maude; Ducroc, Robert; Denis, Raphael G. P.; Cluzeaud, Francoise; Guilmeau, Sandra; Sakar, Yassine; Barbot, Laurence; Kapel, Nathalie; Le Beyec, Johanne; Joly, Francisca; Chua, Streamson; Luquet, Serge; Bado, Andre			Intestinal deletion of leptin signaling alters activity of nutrient transporters and delayed the onset of obesity in mice	FASEB JOURNAL			English	Article						gut mucosa; energy expenditure; absorption; high-fat diet; hypothalamic neuropeptides	SHORT-BOWEL SYNDROME; FOOD-INTAKE; GLUCOSE-HOMEOSTASIS; RECEPTOR EXPRESSION; WEIGHT HOMEOSTASIS; GASTRIC LEPTIN; LUMINAL LEPTIN; BODY-WEIGHT; GUT LEPTIN; BETA-CELL	The importance of B-isoform of leptin receptor (LEPR-B) signaling in the hypothalamus, pancreas, or liver has been well characterized, but in the intestine, a unique site of entry for dietary nutrition into the body, it has been relatively ignored. To address this question, we characterized a mouse model deficient for LEPR-B specifically in intestinal epithelial cells (IECs). (LEPR)-L-IEC-B-knockout (KO) and wild-type (WT) mice were generated by Cre-Lox strategy and fed a normal or high-fat diet (HFD). The analyses of the animals involved histology and immunohistochemistry of intestinal mucosa, indirect calorimetric measurements, whole-body composition, and expression and activities of nutrient transporters. (LEPR)-L-IEC-B-KO mice exhibited a 2-fold increase in length of jejunal villi and have normal growth on a normal diet but were less susceptible (P<0.01) to HFD-induced obesity. No differences occurred in energy intake and expenditure between (LEPR)-L-IEC-B-WT and -KO mice, but (LEPR)-L-IEC-B-KO mice fed an HFD showed increased excreted fats (P<0.05). Activities of the Na+/glucose cotransporter SGLT-1 and GLUT2 were unaffected in LEPR-B-KO jejunum, while GLUT5-mediated fructose transport and PepT1-mediated peptide transport were substantially reduced (P<0.01). These data demonstrate that intestinal LEPR-B signaling is important for the onset of diet-induced obesity. They suggest that intestinal LEPR-B could be a potential per os target for prevention against obesity.	[Tavernier, Annabelle; Cavin, Jean-Baptiste; Le Gall, Maude; Ducroc, Robert; Cluzeaud, Francoise; Guilmeau, Sandra; Sakar, Yassine; Le Beyec, Johanne; Joly, Francisca; Bado, Andre] INSERM, UMRS 1149, UFR Med Paris Diderot, Sorbonne Paris Cite, F-75890 Paris 18, France; [Denis, Raphael G. P.; Luquet, Serge] Univ Paris Diderot, Sorbonne Paris Cite, CNRS, Unit Biol Fonct & Adaptat,UMR 8521, Paris, France; [Barbot, Laurence; Kapel, Nathalie] Hop La Pitie Salpetriere, Serv Coprol Fonct, Paris, France; [Le Beyec, Johanne] Univ Paris 06, Paris, France; [Joly, Francisca] Hop Beaujon, Serv Gastroenterol & Assistance Nutr, Clichy, France; [Chua, Streamson] Albert Einstein Coll Med, Dept Med Neurosci, New York, NY USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Yeshiva University	Bado, A (corresponding author), INSERM, UFR Med Paris Diderot, CRI, UMRS 1149, 16 Rue Henri Huchard, F-75890 Paris 18, France.	andre.bado@inserm.fr	Le Gall, Maude/C-3917-2017; Luquet, serge/AAT-1809-2021; Le Gall, Maude/W-2593-2019; Denis, Raphael/ABE-1758-2020; Guilmeau, Sandra/P-2318-2017	Le Gall, Maude/0000-0002-5372-4585; Luquet, serge/0000-0001-8668-6645; Le Gall, Maude/0000-0002-5372-4585; Denis, Raphael/0000-0002-7677-7460; BADO, Andre/0000-0002-8007-1460; Le Beyec - Le Bihan, johanne/0000-0002-5647-2002; Tavernier, Annabelle/0000-0002-5744-2876; Guilmeau, Sandra/0000-0002-8260-1218	Institut National de la Sant et de la Recherche Medicale (INSERM); Assistance Publique-Hopitaux de Paris (AP-HP); Institute Benjamin Delessert, Fonds d'Aide a la Recherche-Societe Nationale Francaise de Gastro-Enterologie (FARE-SNFGE), Agence Nationale de la Recherche (ANR) [Alia R10004HH]; Ile-de-France region; University Paris Diderot; U.S. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [P30-DK-026687]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026687] Funding Source: NIH RePORTER	Institut National de la Sant et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Assistance Publique-Hopitaux de Paris (AP-HP); Institute Benjamin Delessert, Fonds d'Aide a la Recherche-Societe Nationale Francaise de Gastro-Enterologie (FARE-SNFGE), Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); Ile-de-France region(Region Ile-de-France); University Paris Diderot; U.S. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Nathalie Ialy-Rado and Anissa Bouhalfia [Core Animal Facilities, Unit Mixte de Recherche en Sant (UMRS) 1149, Paris, France], and Nicolas Sorhaindo for blood analyses. Metabolic analyses in vivo were performed on the Functional and Physiological Exploration (FPE) Platform [University Paris Diderot, Sorbonne Paris Cite, Biologie Fonctionnelle et Adaptative, Centre National de la Recherche Scientifique (CNRS) Unite Mixte de Recherche (UMR) 8251, Paris, France]. Part of this work was presented at Digestive Disease Week/American Gastroenterological Association 2013 (39). A.T. was a Master Training Student, and J.-B.C. is a Ph.D. student, both under the supervision of M.L.G. This research was supported by Institut National de la Sant et de la Recherche Medicale (INSERM), Assistance Publique-Hopitaux de Paris (AP-HP), and grants from Institute Benjamin Delessert, Fonds d'Aide a la Recherche-Societe Nationale Francaise de Gastro-Enterologie (FARE-SNFGE), Agence Nationale de la Recherche (ANR)-Alia R10004HH. The FPE Platform is supported by the Ile-de-France region and University Paris Diderot. This study was partially funded by U.S. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grant P30-DK-026687 (to S.C.). The authors declare no conflicts of interest. Author contributions: A. B. initiated the study; A.T., J.-B.C., M.L.G., R.D., Y.S., and J.L.B. contributed to the design of the study and acquisition and interpretation of the data; F.C. and S.G. performed experiments; F.J., L.B., and N.K. performed bomb calorimetric analysis of stools; R.G.P.D. and S.L. performed indirect calorimetric and whole-body analysis; S.C. provided materials; J.L.B., R.D., F.J., S.C., and S.L. critically read the paper; M.L.G. and A.B. wrote the paper.	Acosta A, 2014, GUT, V63, P687, DOI 10.1136/gutjnl-2013-306235; Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Buyse M, 2001, J CLIN INVEST, V108, P1483, DOI 10.1172/JCI13219; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; Covey SD, 2006, CELL METAB, V4, P291, DOI 10.1016/j.cmet.2006.09.005; Cummings DE, 2007, J CLIN INVEST, V117, P13, DOI 10.1172/JCI30227; Dhillon H, 2006, NEURON, V49, P191, DOI 10.1016/j.neuron.2005.12.021; Drucker DJ, 2007, J CLIN INVEST, V117, P24, DOI 10.1172/JCI30076; Ducroc R, 2005, DIABETES, V54, P348, DOI 10.2337/diabetes.54.2.348; Ducroc R, 2013, GASTROENTEROLOGY, V144, pS712; Duggal P, 2011, J CLIN INVEST, V121, P1191, DOI 10.1172/JCI45294; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Guilmeau S, 2004, CURR OPIN PHARMACOL, V4, P561, DOI 10.1016/j.coph.2004.06.008; Guo KY, 2007, ENDOCRINOLOGY, V148, P3987, DOI 10.1210/en.2007-0261; Guo X, 2011, MUCOSAL IMMUNOL, V4, P294, DOI 10.1038/mi.2010.76; Huynh FK, 2010, DIABETES, V59, P3032, DOI 10.2337/db10-0074; Iqbal J, 2010, J LIPID RES, V51, P1929, DOI 10.1194/jlr.M005744; Joly F, 2009, GASTROENTEROLOGY, V136, P824, DOI 10.1053/j.gastro.2008.10.084; Joly-Amado A, 2012, EMBO J, V31, P4276, DOI 10.1038/emboj.2012.250; Layec S, 2013, AM J CLIN NUTR, V97, P100, DOI 10.3945/ajcn.112.042606; Le Gall M, 2007, J CELL PHYSIOL, V213, P834, DOI 10.1002/jcp.21245; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Leturque A, 2012, PROG MOL BIOL TRANSL, V108, P113, DOI 10.1016/B978-0-12-398397-8.00005-8; McMinn JE, 2005, AM J PHYSIOL-ENDOC M, V289, pE403, DOI 10.1152/ajpendo.00535.2004; Morioka T, 2007, J CLIN INVEST, V117, P2860, DOI 10.1172/JCI30910; Morton NM, 1998, J BIOL CHEM, V273, P26194, DOI 10.1074/jbc.273.40.26194; Pico C, 2003, BRIT J NUTR, V90, P735, DOI 10.1079/BJN2003945; Rasmussen BA, 2014, CELL METAB, V19, P155, DOI 10.1016/j.cmet.2013.11.014; Ring LE, 2010, J CLIN INVEST, V120, P2931, DOI 10.1172/JCI41985; Sakar Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007935; Scott MM, 2011, J CLIN INVEST, V121, P2413, DOI 10.1172/JCI43703; Stan S, 2001, FEBS LETT, V508, P80, DOI 10.1016/S0014-5793(01)03032-0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	39	22	22	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4100	4110		10.1096/fj.14-255158	http://dx.doi.org/10.1096/fj.14-255158			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24928195	Green Published			2022-12-28	WOS:000340845900027
J	Hulikova, A; Swietach, P				Hulikova, Alzbeta; Swietach, Pawel			Rapid CO2 permeation across biological membranes: implications for CO2 venting from tissue	FASEB JOURNAL			English	Article						carbon dioxide; metabolism; excretion; gas channels	RELATIVE CO2/NH3 SELECTIVITIES; CARBON-DIOXIDE TRANSPORT; LIPID BILAYER-MEMBRANES; INTRACELLULAR PH; TUMOR PH; PERMEABILITY; AQUAPORIN-1; ANHYDRASE; DIFFUSION; BLOOD	The degree to which cell membranes are barriers to CO2 transport remains controversial. Proteins, such as aquaporins and Rh complex, have been proposed to facilitate CO2 transport, implying that the nonchannel component of membranes must have greatly reduced CO2 permeability. To determine whether membrane CO2 permeation is rate limiting for gas transport, the spread of CO2 across multicellular tissue growths (spheroids) was measured using intracellular pH as a spatial readout. Colorectal HCT116 cells have basal water and NH3 permeability, indicating the functional absence of aquaporins and gas channels. However, CO2 diffusivity in HCT116 spheroids was only 24 +/- 4% lower than in pure water, which can be accounted for fully by volume exclusion due to proteins. Diffusivity was unaffected by blockers of aquaporins and Rh complex (Hg2+, p-chloromercuribenzoic acid, and 4,4'-diisothiocyano-2,2'-stilbene-disulfonic acid) but decreased under hypertonic conditions (by addition of 300 mOsm mannitol), which increases intracellular protein crowding. Similar CO2 diffusivity was measured in spheroids of T47D breast cells (basal water permeability) and NHDF-Ad fibroblasts (aquaporin-facilitated water permeability). In contrast, diffusivity of NH3, a smaller but less lipophilic gas, was considerably slower than in pure water, as expected from rate-limiting membrane permeation. In conclusion, membranes, even in the functional absence of proposed gas channels, do not restrict CO2 venting from tissue growths.	[Hulikova, Alzbeta; Swietach, Pawel] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3PT, England	University of Oxford	Swietach, P (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Sherrington Bldg,Parks Rd, Oxford OX1 3PT, England.	pawel.swietach@dpag.ox.ac.uk	Swietach, Pawel/AAK-4169-2020	Swietach, Pawel/0000-0002-9945-9473	Association for International Cancer Research; Royal Society; Worldwide Cancer Research [12-0027] Funding Source: researchfish	Association for International Cancer Research; Royal Society(Royal Society of London); Worldwide Cancer Research	This study was supported by the Association for International Cancer Research and the Royal Society. The authors thank Professor Richard D. Vaughan-Jones for comments on the manuscript, and mentoring, Professor Kenneth W. Spitzer (University of Utah, Salt Lake City, UT, USA) for training in the dual microperfusion technique, Dr. Daniele Dini (Imperial College London, London, UK) for discussions on fluid mechanics, and Dr. Steven Niederer (King's College London, London, UK) for advice on diffusion modeling.	Antonenko YN, 1997, BIOPHYS J, V72, P2187, DOI 10.1016/S0006-3495(97)78862-3; Boron WF, 2011, CHEMPHYSCHEM, V12, P1017, DOI 10.1002/cphc.201100034; Boron WF, 2010, EXP PHYSIOL, V95, P1107, DOI 10.1113/expphysiol.2010.055244; CLAUSS MA, 1990, CANCER RES, V50, P3487; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; Endeward V, 2006, FASEB J, V20, P1974, DOI 10.1096/fj.04-3300com; Endeward V, 2005, J PHYSIOL-LONDON, V567, P253, DOI 10.1113/jphysiol.2005.085761; Endeward V, 2008, FASEB J, V22, P64, DOI 10.1096/fj.07-9097com; Forster RE, 1998, P NATL ACAD SCI USA, V95, P15815, DOI 10.1073/pnas.95.26.15815; Geers C, 2000, PHYSIOL REV, V80, P681, DOI 10.1152/physrev.2000.80.2.681; Geyer RR, 2013, J MEMBRANE BIOL, V246, P915, DOI 10.1007/s00232-013-9593-0; Geyer RR, 2013, AM J PHYSIOL-CELL PH, V304, pC985, DOI 10.1152/ajpcell.00033.2013; GROS G, 1971, PFLUG ARCH EUR J PHY, V324, P249, DOI 10.1007/BF00586422; GUTKNECHT J, 1977, J GEN PHYSIOL, V69, P779; Holm LM, 2005, PFLUG ARCH EUR J PHY, V450, P415, DOI 10.1007/s00424-005-1399-1; Hulikova A, 2011, J BIOL CHEM, V286, P13815, DOI 10.1074/jbc.M111.219899; Itel F, 2012, FASEB J, V26, P5182, DOI 10.1096/fj.12-209916; Leem CH, 1999, J PHYSIOL-LONDON, V517, P159, DOI 10.1111/j.1469-7793.1999.0159z.x; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; Mathai JC, 2009, P NATL ACAD SCI USA, V106, P16633, DOI 10.1073/pnas.0902952106; Missner A, 2008, J BIOL CHEM, V283, P25340, DOI 10.1074/jbc.M800096200; Missner A, 2009, CHEMPHYSCHEM, V10, P1405, DOI 10.1002/cphc.200900270; Missner A, 2008, P NATL ACAD SCI USA, V105, pE123, DOI 10.1073/pnas.0809606106; Musa-Aziz R, 2009, P NATL ACAD SCI USA, V106, P5406, DOI 10.1073/pnas.0813231106; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Nitsche JM, 1999, ANNU REV BIOMED ENG, V1, P463, DOI 10.1146/annurev.bioeng.1.1.463; PEDLEY TJ, 1983, Q REV BIOPHYS, V16, P115, DOI 10.1017/S0033583500005060; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; SIMON SA, 1980, BIOCHIM BIOPHYS ACTA, V596, P352, DOI 10.1016/0005-2736(80)90122-4; Somersalo E, 2012, J THEOR BIOL, V309, P185, DOI 10.1016/j.jtbi.2012.06.016; Spitzer KW, 2000, AM J PHYSIOL-HEART C, V278, pH1371, DOI 10.1152/ajpheart.2000.278.4.H1371; Swietach P, 2010, ONCOGENE, V29, P6509, DOI 10.1038/onc.2010.455; Swietach P, 2008, J BIOL CHEM, V283, P20473, DOI 10.1074/jbc.M801330200; Swietach P, 2007, CANCER METAST REV, V26, P299, DOI 10.1007/s10555-007-9064-0; Swietach P, 2007, BIOPHYS J, V92, P641, DOI 10.1529/biophysj.106.096560; Swietach P, 2009, J BIOL CHEM, V284, P20299, DOI 10.1074/jbc.M109.006478; Tucker W. A., 1982, HDB CHEM PROPERTY ES, P17; Vanysek P., 1999, CRC HDB CHEM PHYS, P93; VAUPEL P, 1989, CANCER RES, V49, P6449; Verkman AS, 2002, J PHYSIOL-LONDON, V542, P31, DOI 10.1113/jphysiol.2002.024398; WAISBREN SJ, 1994, NATURE, V368, P332, DOI 10.1038/368332a0; WALTER A, 1986, J MEMBRANE BIOL, V90, P207, DOI 10.1007/BF01870127	43	25	27	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2762	2774		10.1096/fj.13-241752	http://dx.doi.org/10.1096/fj.13-241752			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24652949				2022-12-28	WOS:000337949400004
J	Tohme, M; Prud'homme, SM; Boulahtouf, A; Samarut, E; Brunet, F; Bernard, L; Bourguet, W; Gibert, Y; Balaguer, P; Laudet, V				Tohme, Marie; Prud'homme, Sophie M.; Boulahtouf, Abdel; Samarut, Eric; Brunet, Frederic; Bernard, Laure; Bourguet, William; Gibert, Yann; Balaguer, Patrick; Laudet, Vincent			Estrogen-related receptor gamma is an in vivo receptor of bisphenol A	FASEB JOURNAL			English	Article						endocrine disrupters; zebrafish; otolith	ZEBRAFISH DANIO-RERIO; ENVIRONMENTAL ENDOCRINE DISRUPTORS; GENE-EXPRESSION ANALYSIS; ERR-GAMMA; SMALL EXPOSURES; CDNA MICROARRAY; CELL-LINE; CHEMICALS; ACTIVATION; MECHANISMS	Bisphenol A (BPA) is an endocrine disruptor that displays estrogenic activity. Several reports suggest that BPA may have estrogen receptor-independent effects. In zebrafish, 50 mu M BPA exposure induces otic vesicle abnormalities, including otolith aggregation. The purpose of this study was to test if BPA action was mediated in vivo during zebrafish development by the orphan nuclear estrogen related receptor (ERR) gamma. Combining pharmacological and functional approaches, we demonstrate that the zebrafish ERR gamma mediates BPA-induced malformations in otoliths. Using different bisphenol derivatives, we show that different compounds can induce a similar otolith phenotype than BPA and that the binding affinity of these derivatives to the zebrafish ERR gamma correlates with their ability to induce otolith malformations. Morpholino knockdown of ERR gamma function suppresses the BPA effect on otoliths whereas overexpression of ERR gamma led to a BPA-like otolith phenotype. Moreover, a subphenotypical dose of BPA (1 mu M) combined with ERR gamma overexpression led to a full-dose (50 mu M) BPA otolith phenotype. We therefore conclude that ERR gamma mediates the otic vesicle phenotype generated by BPA. Our results suggest that the range of pathways perturbed by this compound and its potential harmful effect are larger than expected.	[Tohme, Marie; Prud'homme, Sophie M.; Samarut, Eric; Brunet, Frederic; Bernard, Laure; Laudet, Vincent] Univ Lyon 1, Ecole Normale Super Lyon, Inst Genom Fonct Lyon, CNRS,UMR 5242, F-69364 Lyon 07, France; [Boulahtouf, Abdel; Balaguer, Patrick] Ctr Reg Lutte Canc Val dAurelle Paul Lamarque, Inst Rech Cancerol Montpellier, INSERM, U896, Montpellier, France; [Bourguet, William] Univ Montpellier I, Ctr Biochim Struct, CNRS, INSERM,U1054,UMR5048, Montpellier, France; [Bourguet, William] Univ Montpellier 2, Ctr Biochim Struct, CNRS, INSERM,U1054,UMR5048, Montpellier, France; [Gibert, Yann] Deakin Sch Med, Metab Genet Dis Lab, Metab Res Unit, Waurn Ponds, Vic, Australia	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Laudet, V (corresponding author), Univ Lyon 1, Ecole Normale Super Lyon, Inst Genom Fonct Lyon, CNRS,UMR 5242, 46 Allee Italie, F-69364 Lyon 07, France.	vincent.laudet@ens-lyon.fr	Bourguet, William/Y-6600-2019; Bourguet, William/I-5569-2013; Balaguer, Patrick/I-2973-2016	Bourguet, William/0000-0002-0643-7719; Bourguet, William/0000-0002-0643-7719; Brunet, Frederic/0000-0001-5145-8925; SAMARUT, ERIC/0000-0001-7818-2009; Prud'homme, Sophie/0000-0002-7199-1839	Agence Nationale de la Recherche [ANR-01-CESA-008]; Centre National de la Recherche Scientifique; Ecole Normale Superieure de Lyon; Conventions Industrielles de Formation par la Recherche fellowship; Watchfrog Co. (Evry, France)	Agence Nationale de la Recherche(French National Research Agency (ANR)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Ecole Normale Superieure de Lyon(Grant Agency of the Czech Republic); Conventions Industrielles de Formation par la Recherche fellowship; Watchfrog Co. (Evry, France)	This work was supported by Agence Nationale de la Recherche (Kismet Program ANR-01-CESA-008), the Centre National de la Recherche Scientifique, and the Ecole Normale Superieure de Lyon. M. T. was funded via a Conventions Industrielles de Formation par la Recherche fellowship together with the Watchfrog Co. (Evry, France). Y.G. is supported from the Molecular and Medical Research Strategic Center at Deakin University. The authors thank Joanne Burden and Jean-Marc Vanacker for critical reading of the manuscript and Guillaume Holzer for help with the mutated ERR gamma plasmid.	Abad MC, 2008, J STEROID BIOCHEM, V108, P44, DOI 10.1016/j.jsbmb.2007.06.006; Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI [10.1289/ehp.8451, 10.1289/ehp.8062]; Bardet PL, 2005, EVOL DEV, V7, P223, DOI 10.1111/j.1525-142X.2005.05025.x; Bertrand S, 2007, PLOS GENET, V3, P2085, DOI 10.1371/journal.pgen.0030188; Bertrand W, 2004, MOL BIOL EVOL, V21, P1923, DOI 10.1093/molbev/msh200; Bianco S, 2012, J STEROID BIOCHEM, V130, P180, DOI 10.1016/j.jsbmb.2011.03.014; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bondesson M, 2009, REPROD TOXICOL, V28, P563, DOI 10.1016/j.reprotox.2009.06.014; Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI [10.1093/carcin/bci339, 10.1093/carcin/bgi339]; Chow WS, 2013, J APPL TOXICOL, V33, P670, DOI 10.1002/jat.2723; Cosnefroy A, 2012, TOXICOL SCI, V125, P439, DOI 10.1093/toxsci/kfr297; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; Crain DA, 2007, REPROD TOXICOL, V24, P225, DOI 10.1016/j.reprotox.2007.05.008; Duan ZH, 2008, ECOTOX ENVIRON SAFE, V71, P774, DOI 10.1016/j.ecoenv.2008.01.021; Gibert Y, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-4; Gould JC, 1998, MOL CELL ENDOCRINOL, V142, P203, DOI 10.1016/S0303-7207(98)00084-7; Hugo ER, 2008, ENVIRON HEALTH PERSP, V116, P1642, DOI 10.1289/ehp.11537; Kang JH, 2007, CRIT REV TOXICOL, V37, P607, DOI 10.1080/10408440701493103; Kausch U, 2008, ENVIRON TOXICOL, V23, P15, DOI 10.1002/tox.20306; Kim DK, 2012, J BIOL CHEM, V287, P21628, DOI 10.1074/jbc.M111.315168; Kim DK, 2011, J BIOL CHEM, V286, P38035, DOI 10.1074/jbc.M111.250613; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lam SH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028273; le Maire A, 2009, EMBO REP, V10, P367, DOI 10.1038/embor.2009.8; Li DK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065399; Lopez-Casas PP, 2012, REPROD TOXICOL, V33, P106, DOI 10.1016/j.reprotox.2011.12.012; Marmugi A, 2012, HEPATOLOGY, V55, P395, DOI 10.1002/hep.24685; Matsushima A, 2007, J BIOCHEM, V142, P517, DOI 10.1093/jb/mvm158; McCollum CW, 2011, BIRTH DEFECTS RES C, V93, P67, DOI 10.1002/bdrc.20210; Moens LN, 2007, J BIOCHEM MOL TOXIC, V21, P299, DOI 10.1002/jbt.20190; Moens LN, 2006, TOXICOL SCI, V93, P298, DOI 10.1093/toxsci/kfl057; Muncke J, 2007, ENVIRON TOXICOL, V22, P185, DOI 10.1002/tox.20255; Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P309, DOI 10.1289/ehp.0800173; N'Tumba-Byn T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051579; Narkar VA, 2011, CELL METAB, V13, P283, DOI 10.1016/j.cmet.2011.01.019; Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587; Pastva SD, 2001, CHEMOSPHERE, V45, P535, DOI 10.1016/S0045-6535(01)00018-2; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Rubin BS, 2011, J STEROID BIOCHEM, V127, P27, DOI 10.1016/j.jsbmb.2011.05.002; Sargis RM, 2010, OBESITY, V18, P1283, DOI 10.1038/oby.2009.419; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Solomon KS, 2004, DEV DYNAM, V230, P419, DOI 10.1002/dvdy.20067; Takayanagi S, 2006, TOXICOL LETT, V167, P95, DOI 10.1016/j.toxlet.2006.08.012; Takeda Y, 2009, J BIOCHEM, V146, P113, DOI 10.1093/jb/mvp049; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vandenberg LN, 2009, ENDOCR REV, V30, P75, DOI 10.1210/er.2008-0021; vom Saal FS, 2006, ENVIRON RES, V100, P50, DOI 10.1016/j.envres.2005.09.001; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Whitfield TT, 2002, DEV DYNAM, V223, P427, DOI 10.1002/dvdy.10073; Zoeller RT, 2005, MOL CELL ENDOCRINOL, V242, P10, DOI 10.1016/j.mce.2005.07.006	53	94	95	3	57	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3124	3133		10.1096/fj.13-240465	http://dx.doi.org/10.1096/fj.13-240465			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24744145				2022-12-28	WOS:000337949400033
J	Ximerakis, M; Pampalakis, G; Roumeliotis, TI; Sykioti, VS; Garbis, SD; Stefanis, L; Sotiropoulou, G; Vekrellis, K				Ximerakis, Methodios; Pampalakis, Georgios; Roumeliotis, Theodoros I.; Sykioti, Vasia-Samantha; Garbis, Spiros D.; Stefanis, Leonidas; Sotiropoulou, Georgia; Vekrellis, Kostas			Resistance of naturally secreted alpha-synuclein to proteolysis	FASEB JOURNAL			English	Article						KLK6; metalloprotease; lipidation; clearance; Parkinson's disease	SERINE-PROTEASE NEUROSIN; CLEAVAGE; FORMS; DEGRADATION; AGGREGATION; MECHANISM; DISEASE; BINDING; BREAST; OCCURS	Recent evidence suggests that specific extracellular alpha-synuclein (alpha-syn) strains are implicated in the progression of Parkinson's disease (PD) pathology. It is plausible that deregulation in the normal processing of secreted alpha-syn may be a causative risk factor for PD. To date, the degradation mechanisms involved have received very little attention. Here, we sought to investigate factors that regulate extracellular alpha-syn levels. We show, for the first time, that cell-secreted alpha-syn forms are resistant to direct proteolysis by kallikrein-related peptidase 6 (KLK6), an extracellular enzyme known to cleave recombinant alpha-syn. This differential susceptibility appears to be partially due to the association of secreted alpha-syn with lipids. We further provide evidence that secreted alpha-syn can be cleaved by KLK6 indirectly through activation of a secreted metalloprotease, suggestive of the involvement of a proteolytic cascade in the catabolism of secreted alpha-syn. Our results clearly suggest that physiological modifications affect the biochemical behavior of secreted alpha-syn and provide novel insights into mechanisms and potential targets for therapeutic interventions.	[Ximerakis, Methodios; Sykioti, Vasia-Samantha; Stefanis, Leonidas; Vekrellis, Kostas] Acad Athens, Biomed Res Fdn, Ctr Neurosci, Athens 11527, Greece; [Pampalakis, Georgios; Sotiropoulou, Georgia] Univ Patras, Sch Hlth Sci, Dept Pharm, Rion, Greece; [Roumeliotis, Theodoros I.; Garbis, Spiros D.] Univ Southampton, Fac Med, Canc Sci Unit, Southampton SO9 5NH, Hants, England; [Stefanis, Leonidas] Univ Athens, Sch Med, Dept Neurol 2, GR-11527 Athens, Greece	Academy of Athens; University of Patras; University of Southampton; Athens Medical School; National & Kapodistrian University of Athens	Vekrellis, K (corresponding author), Acad Athens, Biomed Res Fdn, Ctr Neurosci, 4 Soranou Ephessiou, Athens 11527, Greece.	vekrellis@bioacademy.gr	Ximerakis, Methodios/AAE-7642-2020; Stefanis, Leonidas/AAD-7192-2019; Garbis, Spiros D/L-3099-2013	Ximerakis, Methodios/0000-0002-2815-7558; Garbis, Spiros D/0000-0002-1050-0805	Michael J. Fox Foundation; EU FP7-MEFOPA project; Fondation Sante grant; EU FP7-REGPOT TranSMed grant	Michael J. Fox Foundation; EU FP7-MEFOPA project; Fondation Sante grant; EU FP7-REGPOT TranSMed grant	The authors thank N. Paschalidis for his assistance in cell survival assays and G. Arianoglou for ELISA measurements. Funding for this work was obtained from the Michael J. Fox Foundation (to K. V.), the EU FP7-MEFOPA project, and a 2013 Fondation Sante grant (to G. S). Additional funds were obtained from an EU FP7-REGPOT TranSMed grant.	Alvarez-Castelao B, 2014, BBA-MOL CELL RES, V1843, P352, DOI 10.1016/j.bbamcr.2013.11.018; Anderson JP, 2006, J BIOL CHEM, V281, P29739, DOI 10.1074/jbc.M600933200; Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; Bartels T, 2011, NATURE, V477, P107, DOI 10.1038/nature10324; Bayes A, 2004, BIOL CHEM, V385, P517, DOI 10.1515/BC.2004.061; Blaber SI, 2007, BIOCHEMISTRY-US, V46, P5209, DOI 10.1021/bi6025006; Boersema PJ, 2009, NAT PROTOC, V4, P484, DOI 10.1038/nprot.2009.21; Bousset L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3575; Danzer KM, 2007, J NEUROSCI, V27, P9220, DOI 10.1523/JNEUROSCI.2617-07.2007; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dettmer U, 2013, J BIOL CHEM, V288, P6371, DOI 10.1074/jbc.M112.403311; Diamandis EP, 2000, CLIN BIOCHEM, V33, P369, DOI 10.1016/S0009-9120(00)00145-4; Emmanouilidou E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022225; Emmanouilidou E, 2010, J NEUROSCI, V30, P6838, DOI 10.1523/JNEUROSCI.5699-09.2010; Fauvet B, 2012, J BIOL CHEM, V287, P28243, DOI 10.1074/jbc.M112.383711; Fauvet B, 2012, J BIOL CHEM, V287, P15345, DOI 10.1074/jbc.M111.318949; Guo JL, 2013, CELL, V154, P103, DOI 10.1016/j.cell.2013.05.057; Iwata A, 2003, HUM MOL GENET, V12, P2625, DOI 10.1093/hmg/ddg283; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Karube H, 2008, FEBS LETT, V582, P3693, DOI 10.1016/j.febslet.2008.10.001; Kasai T, 2008, NEUROSCI LETT, V436, P52, DOI 10.1016/j.neulet.2008.02.057; Kim C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2534; Kim KS, 2012, J BIOL CHEM, V287, P24862, DOI 10.1074/jbc.M112.348128; Klucky B, 2007, CANCER RES, V67, P8198, DOI 10.1158/0008-5472.CAN-07-0607; Levin J, 2009, EXP NEUROL, V215, P201, DOI 10.1016/j.expneurol.2008.10.010; Luk KC, 2012, SCIENCE, V338, P949, DOI 10.1126/science.1227157; Merlo S, 2012, MOL CELL NEUROSCI, V49, P423, DOI 10.1016/j.mcn.2012.02.005; Ogawa K, 2000, PSYCHIAT CLIN NEUROS, V54, P419, DOI 10.1046/j.1440-1819.2000.00731.x; Oikonomopoulou K, 2008, BIOL CHEM, V389, P747, DOI 10.1515/BC.2008.086; Overall CM, 2007, NAT REV MOL CELL BIO, V8, P245, DOI 10.1038/nrm2120; Pampalakis G, 2009, CANCER RES, V69, P3779, DOI 10.1158/0008-5472.CAN-08-1976; Papachristou EK, 2013, J PROTEOME RES, V12, P2078, DOI 10.1021/pr301067r; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Sotiropoulou G, 2012, CHEM CENT J, V6, DOI 10.1186/1752-153X-6-148; Spencer B, 2013, MOL THER, V21, P31, DOI 10.1038/mt.2012.66; Sung JY, 2005, J BIOL CHEM, V280, P25216, DOI 10.1074/jbc.M503341200; Tatebe H, 2010, NEUROSCI RES, V67, P341, DOI 10.1016/j.neures.2010.04.008; Trexler AJ, 2012, PROTEIN SCI, V21, P601, DOI 10.1002/pro.2056; Vekrellis K, 2011, LANCET NEUROL, V10, P1041, DOI 10.1016/S1474-4422(11)70213-7; Vekrellis K, 2009, J NEUROCHEM, V109, P1348, DOI 10.1111/j.1471-4159.2009.06054.x; Wang W, 2011, P NATL ACAD SCI USA, V108, P17797, DOI 10.1073/pnas.1113260108; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com	43	16	16	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3146	3158		10.1096/fj.13-245852	http://dx.doi.org/10.1096/fj.13-245852			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24723692				2022-12-28	WOS:000337949400035
J	Nair, P; Vilcek, J				Nair, Prashant; Vilcek, Jan			Journey to the Summits of Science: The 2014 Vilcek Foundation Prizes	FASEB JOURNAL			English	Article							NERVOUS-SYSTEM; MOTOR-NEURONS; FLOOR PLATE; CONNECTIVITY; INDUCTION; MUSCLE		[Nair, Prashant] Proceedings Natl Acad Sci USA, Washington, DC USA; [Vilcek, Jan] NYU, Sch Med, Langone Med Ctr, Dept Microbiol, New York, NY 10016 USA	National Academies of Sciences, Engineering & Medicine; New York University; NYU Langone Medical Center	Vilcek, J (corresponding author), NYU, Sch Med, Langone Med Ctr, Dept Microbiol, 522 First Ave, New York, NY 10016 USA.	jan.vilcek@nyumc.org						Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Dasen JS, 2008, CELL, V134, P304, DOI 10.1016/j.cell.2008.06.019; Dasen JS, 2005, CELL, V123, P477, DOI 10.1016/j.cell.2005.09.009; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; JESSELL TM, 1979, P NATL ACAD SCI USA, V76, P5397, DOI 10.1073/pnas.76.10.5397; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; Nair P, 2013, FASEB J, V27, P845, DOI 10.1096/fj.13-0301ufm; Nair Prashant, 2012, FASEB J, V26, P1361, DOI 10.1096/fj.12-0402ufm; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Surmeli G, 2011, CELL, V147, P653, DOI 10.1016/j.cell.2011.10.012; Superville D., 2011, HUFF POST       1021; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; Vilcek J, 2006, FASEB J, V20, P1281, DOI 10.1096/fj.06-0702ufm; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	16	1	1	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2014	28	3					1035	1040		10.1096/fj.14-0301ufm	http://dx.doi.org/10.1096/fj.14-0301ufm			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3MY	24578136				2022-12-28	WOS:000335324800001
J	Zhou, Y; Mohan, A; Moore, DC; Lin, LJ; Zhou, FL; Cao, J; Wu, Q; Qin, YX; Reginato, AM; Ehrlich, MG; Yang, WT				Zhou, Yi; Mohan, Aron; Moore, Douglas C.; Lin, Liangjun; Zhou, Frank Li; Cao, Jay; Wu, Qian; Qin, Yi-Xian; Reginato, Anthony M.; Ehrlich, Michael G.; Yang, Wentian			SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion	FASEB JOURNAL			English	Article						M-CSF; RANKL; Nfatc1	COLONY-STIMULATING FACTOR; TYROSINE-PHOSPHATASE SHP-2; ACTIVATED T-CELLS; NOONAN-SYNDROME; SIGNALING PATHWAY; NUCLEAR FACTOR; RANK LIGAND; DC-STAMP; C-FOS; DIFFERENTIATION	Genes that regulate osteoclast (OC) development and function in both physiologic and disease conditions remain incompletely understood. Shp2 (the Src homology-2 domain containing protein tyrosine phosphatase 2), a ubiquitously expressed cytoplasmic protein tyrosine phosphatase, is implicated in regulating M-CSF and receptor activator of nuclear factor-B ligand (RANKL)-evoked signaling; its role in osteoclastogenesis and bone homeostasis, however, remains unknown. Using a tissue-specific gene knockout approach, we inactivated Shp2 expression in murine OCs. Shp2 mutant mice are phenotypically osteopetrotic, featuring a marked increase of bone volume (BV)/total volume (TV) (+42.8%), trabeculae number (Tb.N) (+84.1%), structure model index (+119%), and a decrease of trabecular thickness (Tb.Th) (-34.1%) and trabecular spacing (Tb.Sp) (-41.0%). Biochemical analyses demonstrate that Shp2 is required for RANKL-induced formation of giant multinucleated OCs by up-regulating the expression of nuclear factor of activated T cells, cytoplasmic 1 (Nfatc1), a master transcription factor that is indispensable for terminal OC differentiation. Shp2 deletion, however, has minimal effect on M-CSF-dependent survival and proliferation of OC precursors. Instead, its deficiency aborts the fusion of OC precursors and formation of multinucleated OCs and decreases bone matrix resorption. Moreover, pharmacological intervention of Shp2 is sufficient to prevent preosteoclast fusion in vitro. These findings uncover a novel mechanism through which Shp2 regulates osteoclastogenesis by promoting preosteoclast fusion. Shp2 or its signaling partners could potentially serve as pharmacological targets to regulate the population of OCs locally and/or systematically, and thus treat OC-related diseases, such as periprosthetic osteolysis and osteoporosis.	[Zhou, Yi] Boston Childrens Hosp, Stem Cell Program, Boston, MA USA; [Zhou, Yi] Harvard Univ, Sch Med, Boston, MA USA; [Mohan, Aron; Moore, Douglas C.; Ehrlich, Michael G.; Yang, Wentian] Brown Univ, Dept Orthopaed, Alpert Med Sch, Providence, RI 02912 USA; [Mohan, Aron; Moore, Douglas C.; Ehrlich, Michael G.; Yang, Wentian] Rhode Isl Hosp, Providence, RI USA; [Lin, Liangjun; Qin, Yi-Xian] SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; [Zhou, Frank Li] CALTECH, Engn & Appl Sci, Pasadena, CA 91125 USA; [Cao, Jay] USDA, Grand Forks Human Nutr Res Ctr, Grand Forks, ND USA; [Wu, Qian] Univ Connecticut, Ctr Hlth, Dept Pathol & Lab Med, Farmington, CT USA; [Reginato, Anthony M.] Brown Univ, Alpert Med Sch, Div Rheumatol, Providence, RI 02912 USA; [Reginato, Anthony M.] Rhode Isl Hosp, Providence, RI USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; California Institute of Technology; United States Department of Agriculture (USDA); University of Connecticut; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Yang, WT (corresponding author), 1 Hoppin St,Coro 402E, Providence, RI 02903 USA.	wyang@lifespan.org			U.S. National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases [R21AR57156]; NIH National Institute of General Medical Sciences [P20 GM103468]; Pediatric Orthopaedic Society of North America; Orthopaedic Research and Education Foundation; U.S. Department of Agriculture Research Service [5450-51000-046-00D]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR057156, R01AR061821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103468, P20GM104937] Funding Source: NIH RePORTER; ARS [ARS-0427566] Funding Source: Federal RePORTER	U.S. National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIH National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Pediatric Orthopaedic Society of North America; Orthopaedic Research and Education Foundation; U.S. Department of Agriculture Research Service(United States Department of Agriculture (USDA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); ARS(United States Department of Agriculture (USDA)USDA Agricultural Research Service)	The authors thank Dr. Nhiem Tran for critical reading, Ms. Xiaohong Wang for histological section and staining, and Dr. T. Taniguchi for pMX-IRES-GFP and pMX-Nfatc1/IRES-GFP constructs. The authors are grateful to Mr. Howard Yang (Moses Brown High School) for assistance in performing experiments and data collection. This work was supported in part by the U.S. National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases Grant R21AR57156 (to W.Y.) and NIH National Institute of General Medical Sciences Grant P20 GM103468. This study was also aided by a grant from the Pediatric Orthopaedic Society of North America and the Orthopaedic Research and Education Foundation (to W.Y.), and the U.S. Department of Agriculture Research Service program Grant #5450-51000-046-00D (to J.C.).	Aoki K, 1999, BONE, V25, P261, DOI 10.1016/S8756-3282(99)00174-X; Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023; Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013; Bauler TJ, 2011, DIS MODEL MECH, V4, P228, DOI 10.1242/dmm.006130; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Chan G, 2011, BLOOD, V117, P4253, DOI 10.1182/blood-2010-11-319517; Chan G, 2009, BLOOD, V113, P4414, DOI 10.1182/blood-2008-10-182626; Chen LW, 2006, MOL PHARMACOL, V70, P562, DOI 10.1124/mol.106.025536; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Fornaro M, 2006, J CELL BIOL, V175, P87, DOI 10.1083/jcb.200602029; Grossmann KS, 2010, ADV CANCER RES, V106, P53, DOI 10.1016/S0065-230X(10)06002-1; Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011; Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007-0237; Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105; Lee AWM, 2006, CELL DEATH DIFFER, V13, P1900, DOI 10.1038/sj.cdd.4401884; Lee AWM, 2000, MOL CELL BIOL, V20, P6779, DOI 10.1128/MCB.20.18.6779-6798.2000; Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200; Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025; Neel B. G., 2009, HDB CELL SIGNALING, P771; Noonan JA, 2006, REV ENDOCR METAB DIS, V7, P251, DOI 10.1007/s11154-006-9021-1; Ozcivici Engin, 2008, V455, P323, DOI 10.1007/978-1-59745-104-8_22; Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253; Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001; Sweet MG, 2009, AM FAM PHYSICIAN, V79, P193; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952; Umeda S, 1999, AM J PATHOL, V155, P223, DOI 10.1016/S0002-9440(10)65116-4; Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007; Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203; Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009-1947; Xu DR, 2004, BIOCHEM J, V383, P219, DOI 10.1042/BJ20040961; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645; Yang WT, 2013, NATURE, V499, P491, DOI 10.1038/nature12396; Yang WT, 2006, DEV CELL, V10, P317, DOI 10.1016/j.devcel.2006.01.002; Yu MJ, 2009, J BIOL CHEM, V284, P32968, DOI 10.1074/jbc.M109.001016	42	19	20	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1635	1645		10.1096/fj.14-260844	http://dx.doi.org/10.1096/fj.14-260844			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25593124	Green Published, Bronze			2022-12-28	WOS:000354114600003
J	Reigstad, CS; Salmonson, CE; Rainey, JF; Szurszewski, JH; Linden, DR; Sonnenburg, JL; Farrugia, G; Kashyap, PC				Reigstad, Christopher S.; Salmonson, Charles E.; Rainey, John F., III; Szurszewski, Joseph H.; Linden, David R.; Sonnenburg, Justin L.; Farrugia, Gianrico; Kashyap, Purna C.			Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells	FASEB JOURNAL			English	Article						5-hydroxytryptamine; gnotobiotic; gut motility; host-microbe interaction; microbiome	IRRITABLE-BOWEL-SYNDROME; ENTEROENDOCRINE CELLS; IN-VITRO; MICE; EXPRESSION; MOTILITY; RECEPTORS; INTESTINE; DIET; TRANSPORTERS	Gut microbiota alterations have been described in several diseases with altered gastrointestinal (GI) motility, and awareness is increasing regarding the role of the gut microbiome in modulating GI function. Serotonin [5-hydroxytryptamine (5-HT)] is a key regulator of GI motility and secretion. To determine the relationship among gut microbes, colonic contractility, and host serotonergic gene expression, we evaluated mice that were germ-free (GF) or humanized (HM; ex-GF colonized with human gutmicrobiota). 5-HT reduced contractile duration in both GF and HM colons. Microbiota from HM and conventionally raised (CR) mice significantly increased colonic mRNAs Tph1 [(tryptophan hydroxylase) 1, rate limiting for mucosal 5-HT synthesis; P < 0.01] and chromogranin A (neuroendocrine secretion; P < 0.01), with no effect on monoamine oxidase A (serotonin catabolism), serotonin receptor 5-HT4, or mouse serotonin transporter. HM and CR mice also had increased colonic Tph1 protein (P < 0.05) and 5-HT concentrations (GF, 17 +/- 3 ng/mg; HM, 25 +/- 2 ng/mg; and CR, 35 +/- 3 ng/mg; P < 0.05). Enterochromaffin (EC) cell numbers (cells producing 5-HT) were unchanged. Short-chain fatty acids (SCFAs) promoted TPH1 transcription in BON cells (human EC cell model). Thus, gut microbiota acting through SCFAs are important determinants of enteric 5-HT production and homeostasis.	[Reigstad, Christopher S.; Salmonson, Charles E.; Rainey, John F., III; Szurszewski, Joseph H.; Linden, David R.; Farrugia, Gianrico; Kashyap, Purna C.] Mayo Clin, Enter NeuroSci Program, Rochester, MN 55905 USA; [Reigstad, Christopher S.; Salmonson, Charles E.; Rainey, John F., III; Szurszewski, Joseph H.; Farrugia, Gianrico; Kashyap, Purna C.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; [Szurszewski, Joseph H.; Linden, David R.; Farrugia, Gianrico] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA; [Sonnenburg, Justin L.] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Stanford University	Kashyap, PC (corresponding author), Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA.	kashyap.purna@mayo.edu			U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [K08 DK100638, P30DK84567, R01 DK085025]; Global Probiotic Council; Minnesota Partnership for Biotechnology and Genomics; Center for Individualized Medicine, Mayo Clinic; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK100638, P30DK084567, R01DK085025] Funding Source: NIH RePORTER	U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Global Probiotic Council; Minnesota Partnership for Biotechnology and Genomics; Center for Individualized Medicine, Mayo Clinic; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Courtney M. Townsend, Jr., for the generous gift of the BON cell line, Kristy Zodrow for administrative assistance, and Mr. Peter R. Strege for preparing the figures. This work was made possible by funding from U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Grants K08 DK100638 and P30DK84567 (to P.C.K.), and R01 DK085025 (to J.L.S.), as well as funding from the Global Probiotic Council (to P.C.K.), Minnesota Partnership for Biotechnology and Genomics (to P.C.K.), and the Center for Individualized Medicine, Mayo Clinic (to P.C.K.). C.S.R. and P.C.K. designed the research study. C.S.R., J.F.R., and C.E.S. performed the research. C.S.R., D.R.L., J.H.S., J.L.S., G.F., and P.C.K. analyzed the data and contributed to interpretation of data. C.S.R. and P.C.K. wrote the manuscript. Each author has read the final manuscript and approved it. The authors declare no conflicts of interest.	Barcenilla A, 2000, APPL ENVIRON MICROB, V66, P1654, DOI 10.1128/AEM.66.4.1654-1661.2000; Barrett E, 2012, J APPL MICROBIOL, V113, P411, DOI 10.1111/j.1365-2672.2012.05344.x; Bogunovic M, 2007, AM J PHYSIOL-GASTR L, V292, pG1770, DOI 10.1152/ajpgi.00249.2006; Chen JJ, 2001, J NEUROSCI, V21, P6348, DOI 10.1523/JNEUROSCI.21-16-06348.2001; Cote F, 2003, P NATL ACAD SCI USA, V100, P13525, DOI 10.1073/pnas.2233056100; Crowell MD, 2004, BRIT J PHARMACOL, V141, P1285, DOI 10.1038/sj.bjp.0705762; Ebert-Zavos E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058477; Esmaili A, 2009, GASTROENTEROLOGY, V137, P2074, DOI 10.1053/j.gastro.2009.09.002; Essien BE, 2013, GASTROENTEROLOGY, V144, P1466, DOI 10.1053/j.gastro.2013.01.057; EVERS BM, 1991, GASTROENTEROLOGY, V101, P303, DOI 10.1016/0016-5085(91)90004-5; Gahete MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023302; Gershon MD, 2007, GASTROENTEROLOGY, V132, P397, DOI 10.1053/j.gastro.2006.11.002; Gershon MD, 2013, CURR OPIN ENDOCRINOL, V20, P14, DOI 10.1097/MED.0b013e32835bc703; Heredia DJ, 2013, J PHYSIOL-LONDON, V591, P5939, DOI 10.1113/jphysiol.2013.256230; Hoffman JM, 2012, GASTROENTEROLOGY, V142, P844, DOI 10.1053/j.gastro.2011.12.041; HOVERSTAD T, 1986, J NUTR, V116, P1772, DOI 10.1093/jn/116.9.1772; Hu Y, 2002, J BIOL CHEM, V277, P44462, DOI 10.1074/jbc.M205784200; Jeffery IB, 2012, GUT, V61, P997, DOI 10.1136/gutjnl-2011-301501; Karaki S, 2006, CELL TISSUE RES, V324, P353, DOI 10.1007/s00441-005-0140-x; Kashyap PC, 2013, GASTROENTEROLOGY, V144, P967, DOI 10.1053/j.gastro.2013.01.047; Lee AK, 2010, NUTRITION, V26, P411, DOI 10.1016/j.nut.2009.05.007; Ley RE, 2006, APPL ENVIRON MICROB, V72, P3685, DOI 10.1128/AEM.72.5.3685-3695.2006; Li ZS, 2011, J NEUROSCI, V31, P8998, DOI 10.1523/JNEUROSCI.6684-10.2011; Liu C, 2010, NAT NEUROSCI, V13, P1190, DOI 10.1038/nn.2623; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lomasney KW, 2014, NEUROGASTROENT MOTIL, V26, P887, DOI 10.1111/nmo.12328; Mawe GM, 2013, NAT REV GASTRO HEPAT, V10, P473, DOI 10.1038/nrgastro.2013.105; McOrist AL, 2011, J NUTR, V141, P883, DOI 10.3945/jn.110.128504; Minderhoud IM, 2007, CLIN GASTROENTEROL H, V5, P714, DOI 10.1016/j.cgh.2007.02.013; Ohman Lena, 2013, Curr Gastroenterol Rep, V15, P323, DOI 10.1007/s11894-013-0323-7; PAREKH D, 1994, PANCREAS, V9, P83, DOI 10.1097/00006676-199401000-00013; Reichardt F, 2013, J PHYSIOL-LONDON, V591, P5125, DOI 10.1113/jphysiol.2013.262733; Siddique ZL, 2009, NEUROENDOCRINOLOGY, V89, P458, DOI 10.1159/000209330; Sjogren K, 2012, J BONE MINER RES, V27, P1357, DOI 10.1002/jbmr.1588; Sonnenburg JL, 2006, PLOS BIOL, V4, P2213, DOI 10.1371/journal.pbio.0040413; Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005; Stackebrandt E., 1991, NUCL ACID TECHNIQUES; Stappenbeck TS, 2002, METHOD ENZYMOL, V356, P167; Taylor NS, 2007, J CLIN MICROBIOL, V45, P2166, DOI 10.1128/JCM.00137-07; Tazoe H, 2008, J PHYSIOL PHARMACOL, V59, P251; Tazoe H, 2009, BIOMED RES-TOKYO, V30, P149, DOI 10.2220/biomedres.30.149; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Tran VS, 2004, ANN NY ACAD SCI, V1014, P179, DOI 10.1196/annals.1294.019; Tsukamoto K, 2007, AM J PHYSIOL-REG I, V293, pR64, DOI 10.1152/ajpregu.00856.2006; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197; Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106; Zhang ZF, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-23	47	551	590	30	244	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1395	1403		10.1096/fj.14-259598	http://dx.doi.org/10.1096/fj.14-259598			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550456	Green Published			2022-12-28	WOS:000354115000025
J	Wang, WL; Li, F; Sun, Y; Lei, L; Zhou, H; Lei, TL; Xia, Y; Verkman, AS; Yang, BX				Wang, Weiling; Li, Fei; Sun, Yi; Lei, Lei; Zhou, Hong; Lei, Tianluo; Xia, Yin; Verkman, A. S.; Yang, Baoxue			Aquaporin-1 retards renal cyst development in polycystic kidney disease by inhibition of Wnt signaling	FASEB JOURNAL			English	Article						water channel; MDCK; destruction complex; ADPKD	CATENIN DESTRUCTION COMPLEX; C-TERMINAL TAIL; BETA-CATENIN; CELL-MIGRATION; WATER CHANNEL; E-CADHERIN; PHOSPHORYLATION; EXPRESSION; ROLES; AQP1	Water channel aquaporin-1 (AQP1) is expressed at epithelial cell plasma membranes in renal proximal tubules and thin descending limb of Henle. Recently, AQP1 was reported to interact with beta-catenin. Here we investigated the relationship between AQP1 and Wnt signaling in in vitro and in vivo models of autosomal dominant polycystic kidney disease (PKD). AQP1 overexpression decreased beta-catenin and cyclinD1 expression, suggesting down-regulation of Wnt signaling, and coimmunoprecipitation showed AQP1 interaction with beta-catenin, glycogen synthase kinase 3 beta, LRP6, and Axin1. AQP1 inhibited cyst development and promoted branching in matrix-grown MDCK cells. In embryonic kidney cultures, AQP1 deletion increased cyst development by up to similar to 40%. Kidney size and cyst number were significantly greater in AQP1-null PKD mice than in AQP1-expressing PKD mice, with the difference mainly attributed to a greater number of proximal tubule cysts. Biochemical analysis revealed decreased beta-catenin phosphorylation and increased beta-catenin expression in AQP1-null PKD mice, suggesting enhanced Wnt signaling. These results implicate AQP1 as a novel determinant in renal cyst development that may involve inhibition of Wnt signaling by an AQP1-macromolecular signaling complex.	[Wang, Weiling; Li, Fei; Sun, Yi; Lei, Lei; Zhou, Hong; Lei, Tianluo; Yang, Baoxue] Peking Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing 100191, Peoples R China; [Wang, Weiling; Li, Fei; Sun, Yi; Lei, Lei; Zhou, Hong; Lei, Tianluo; Yang, Baoxue] Minist Educ, Key Lab Mol Cardiovasc Sci, State Key Lab Nat & Biomimet Drugs, Beijing, Peoples R China; [Xia, Yin] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Verkman, A. S.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Verkman, A. S.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA USA	Peking University; Chinese University of Hong Kong; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Yang, BX (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Pharmacol, 38 Xueyuan Lu, Beijing 100191, Peoples R China.	baoxue@bjmu.edu.cn	Xia, Yin/M-5440-2018	Xia, Yin/0000-0003-0315-7532; Li, Fei/0000-0003-2016-6422	National Natural Science Foundation of China [31200869, 81261160507, 81330074, 81170632]; Research Fund for the Doctoral Program of Higher Education [20100001110047]; 111 Project; International Science & Technology Cooperation Program of China [2012DFA11070]; U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Grant [DK35124]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for the Doctoral Program of Higher Education(Research Fund for the Doctoral Program of Higher Education of China (RFDP)); 111 Project(Ministry of Education, China - 111 Project); International Science & Technology Cooperation Program of China; U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Grant; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the National Natural Science Foundation of China (Grants 31200869, 81261160507, 81330074 and 81170632); the Research Fund for the Doctoral Program of Higher Education (Grant 20100001110047); the 111 Project; and International Science & Technology Cooperation Program of China (Grant 2012DFA11070). This work was also supported by the U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Grant DK35124. The authors thank Peter Igarashi and Stefan Somlo for the Ksp-Cre and Pkd1<SUP>flox/flox</SUP> mouse strains.	Anders C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057797; BACHINSKY DR, 1995, AM J PHYSIOL-RENAL, V268, pF398, DOI 10.1152/ajprenal.1995.268.3.F398; Baffert F, 2004, CIRC RES, V94, P984, DOI 10.1161/01.RES.0000125295.43813.1F; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Benjamin JM, 2010, J CELL BIOL, V189, P339, DOI 10.1083/jcb.200910041; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Boca M, 2007, MOL BIOL CELL, V18, P4050, DOI 10.1091/mbc.E07-02-0142; Buchholz B, 2014, KIDNEY INT, V85, P1058, DOI 10.1038/ki.2013.418; CARONE FA, 1995, KIDNEY INT, V47, P861, DOI 10.1038/ki.1995.129; Chen D, 2004, AM J PHYSIOL-RENAL, V287, pF602, DOI 10.1152/ajprenal.00015.2004; Cho EAaD G. R., 2003, FORMATION DEV NEPHRO; Cornec-Le Gall E, 2013, J AM SOC NEPHROL, V24, P1006, DOI 10.1681/ASN.2012070650; Czyzewska J, 2010, FOLIA HISTOCHEM CYTO, V48, P37, DOI 10.2478/v10042-010-0017-z; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Devuyst O, 1998, NEPHRON, V78, P116, DOI 10.1159/000044893; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fu YL, 2010, EUR J CELL BIOL, V89, P428, DOI 10.1016/j.ejcb.2010.01.002; Galli C, 2013, CLIN ORAL IMPLAN RES, V24, P921, DOI 10.1111/j.1600-0501.2012.02488.x; Hara-Chikuma M, 2006, J AM SOC NEPHROL, V17, P39, DOI 10.1681/ASN.2005080846; Harris PC, 2009, ANNU REV MED, V60, P321, DOI 10.1146/annurev.med.60.101707.125712; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Igarashi P, 2004, J AM SOC NEPHROL, V15, P2237, DOI 10.1097/01.ASN.0000136298.09488.D7; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Jia LW, 2011, MOL BIOL CELL, V22, P2031, DOI 10.1091/mbc.E11-01-0038; Kawakami T, 2013, J PATHOL, V229, P221, DOI 10.1002/path.4121; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim SE, 2013, SCIENCE, V340, P867, DOI 10.1126/science.1232389; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Kriz V, 2014, J BIOL CHEM, V289, P1128, DOI 10.1074/jbc.M113.498444; La Porta C, 2010, CELL ADHES MIGR, V4, P204, DOI 10.4161/cam.4.2.10949; Lai N, 2014, AM J RESP CELL MOL, V50, P1010, DOI 10.1165/rcmb.2013-0374OC; Lal M, 2008, HUM MOL GENET, V17, P3105, DOI 10.1093/hmg/ddn208; Lancaster MA, 2010, TRENDS MOL MED, V16, P349, DOI 10.1016/j.molmed.2010.05.004; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Liu M, 2010, J AM SOC NEPHROL, V21, P1510, DOI 10.1681/ASN.2010030237; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Magenheimer BS, 2006, J AM SOC NEPHROL, V17, P3424, DOI 10.1681/ASN.2006030295; Meng FB, 2014, STEM CELLS DEV, V23, P66, DOI 10.1089/scd.2013.0185; Monzani E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006167; Nakamura E, 2005, J PATHOL, V205, P349, DOI 10.1002/path.1718; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; Noda Y, 2010, NAT REV NEPHROL, V6, P168, DOI 10.1038/nrneph.2009.231; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Orellana SA, 1998, SEMIN NEPHROL, V18, P233; Pallone TL, 1997, AM J PHYSIOL-RENAL, V272, pF587, DOI 10.1152/ajprenal.1997.272.5.F587; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Park CH, 2010, J INVEST DERMATOL, V130, P2049, DOI 10.1038/jid.2010.62; Patel V, 2008, HUM MOL GENET, V17, P1578, DOI 10.1093/hmg/ddn045; Pathomthongtaweechai N, 2014, EUR J PHARMACOL, V724, P67, DOI 10.1016/j.ejphar.2013.12.013; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; Qian CN, 2005, J BIOL CHEM, V280, P3938, DOI 10.1074/jbc.M410697200; Roberts DM, 2011, MOL BIOL CELL, V22, P1845, DOI 10.1091/mbc.E10-11-0871; Rowe I, 2014, BIOCHEM BIOPH RES CO, V444, P473, DOI 10.1016/j.bbrc.2014.01.068; Ruiz-Ederra J, 2007, INVEST OPHTH VIS SCI, V48, P4802, DOI 10.1167/iovs.07-0537; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Shibazaki S, 2008, HUM MOL GENET, V17, P1505, DOI 10.1093/hmg/ddn039; Silva AK, 2010, MOL VIS, V16, P36; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Torres VE, 2009, KIDNEY INT, V76, P149, DOI 10.1038/ki.2009.128; Verkman AS, 2008, SEMIN NEPHROL, V28, P217, DOI 10.1016/j.semnephrol.2008.03.004; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Verkman AS, 2011, J CELL SCI, V124, P2107, DOI 10.1242/jcs.079467; Wallace DP, 2004, AM J PHYSIOL-RENAL, V287, pF639, DOI 10.1152/ajprenal.00448.2003; Wilson SJ, 2006, BBA-MOL BASIS DIS, V1762, P647, DOI 10.1016/j.bbadis.2006.04.006; Wu G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004926; Wuebken A, 2011, KIDNEY INT, V80, P135, DOI 10.1038/ki.2011.87; Yao G, 2014, HUM MOL GENET, V23, P2769, DOI 10.1093/hmg/ddt672; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhang JZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045976; Zhou H, 2012, AM J PHYSIOL-RENAL, V302, pF1234, DOI 10.1152/ajprenal.00356.2011	74	40	45	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1551	1563		10.1096/fj.14-260828	http://dx.doi.org/10.1096/fj.14-260828			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25573755	Green Published			2022-12-28	WOS:000354115000039
J	Alamo, P; Gallardo, A; Di Nicolantonio, F; Pavon, MA; Casanova, I; Trias, M; Mangues, MA; Lopez-Pousa, A; Villaverde, A; Vazquez, E; Bardelli, A; Cespedes, MV; Mangues, R				Alamo, Patricia; Gallardo, Alberto; Di Nicolantonio, Federica; Pavon, Miguel Angel; Casanova, Isolda; Trias, Manuel; Mangues, Maria Antonia; Lopez-Pousa, Antonio; Villaverde, Antonio; Vazquez, Esther; Bardelli, Alberto; Cespedes, Maria Virtudes; Mangues, Ramon			Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model	FASEB JOURNAL			English	Article						KRas mutants; in vivo models aggressiveness	CHEMOKINE RECEPTOR CXCR4; LYMPH-NODE METASTASIS; PLASMINOGEN-ACTIVATOR INHIBITOR-1; KIRSTEN RAS MUTATIONS; COLON-CANCER; KI-RAS; TUMOR-METASTASIS; POINT MUTATIONS; CELL-MIGRATION; NUDE-MICE	Although all KRas (protein that in humans is encoded by the KRas gene) point mutants are considered to have a similar prognostic capacity, their transformation and tumorigenic capacities vary widely. We compared the metastatic efficiency of KRas G12V (Kirsten rat sarcoma viral oncogene homolog with valine mutation at codon 12) and KRas G13D (Kirsten rat sarcoma viral oncogene homolog with aspartic mutation at codon 13) oncogenes in an orthotopic colorectal cancer (CRC) model. Following subcutaneous preconditioning, recombinant clones of the SW48 CRC cell line [ Kras wild- type (Kras WT)] expressing the KRas G12V or KRas G13D allele were microinjected in the mouse cecum. The percentage of animals developing lymph node metastasis was higher in KRas G12V than in KRas G13D mice. Microscopic, macroscopic, and visible lymphatic foci were 1.5- to 3.0- fold larger in KRas G12V than in KRas G13D mice (P < 0.05). In the lung, only microfoci were developed in both groups. KRas G12V primary tumors had lower apoptosis (7.0 6 1.2 vs. 7.4 6 1.0 per field, P = 0.02), higher tumor budding at the invasion front (1.2 6 0.2 vs. 0.6 6 0.1, P = 0.04), and a higher percentage of C- X- C chemokine receptor type 4 (CXCR4)- overexpressing intravasated tumor emboli (49.869.4% vs. 12.864.4%, P < 0.001) than KRas G13D tumors. KRas G12V primary tumors showed Akt activation, and b5 integrin, vascular endothelial growth factor A (VEGFA), and Serpine- 1 overexpression, whereas KRas G13D tumors showed integrin b1 and angiopoietin 2 (Angpt2) overexpression. The increased cell survival, invasion, intravasation, and specific molecular regulation observed in KRasG12Vtumors is consistent with the higher aggressiveness observed in patients with CRC expressing this oncogene.-	[Alamo, Patricia; Pavon, Miguel Angel; Casanova, Isolda; Cespedes, Maria Virtudes; Mangues, Ramon] Hosp Santa Creu & Sant Pau, Biomed Res Inst St Pau, Oncogenesis & Antitumor Drug Grp, Barcelona 08025, Spain; [Alamo, Patricia; Gallardo, Alberto; Pavon, Miguel Angel; Casanova, Isolda; Trias, Manuel; Lopez-Pousa, Antonio; Villaverde, Antonio; Vazquez, Esther; Cespedes, Maria Virtudes; Mangues, Ramon] CIBER Bioingn Biomat & Nanomed, Barcelona, Spain; [Gallardo, Alberto] Clin Girona, Dept Pathol, Girona, Spain; [Di Nicolantonio, Federica; Bardelli, Alberto] Univ Turin, Dept Oncol, Turin, Italy; [Di Nicolantonio, Federica; Bardelli, Alberto] Ist Ricovero & Cura Carattere Sci, Candiolo Canc Inst Fdn Piemonte Oncol, Turin, Italy; [Trias, Manuel] Hosp Santa Creu & Sant Pau, Dept General & Digest Surg, Barcelona, Spain; [Mangues, Maria Antonia] Hosp Santa Creu & Sant Pau, Dept Pharm, Barcelona, Spain; [Lopez-Pousa, Antonio] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain; [Villaverde, Antonio; Vazquez, Esther] Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain; [Bardelli, Alberto] Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain; [Bardelli, Alberto] FIRC, Inst Mol Oncol, Milan, Italy	Hospital of Santa Creu i Sant Pau; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau; Autonomous University of Barcelona; Autonomous University of Barcelona; IFOM - FIRC Institute of Molecular Oncology	Mangues, R (corresponding author), Hosp Santa Creu & Sant Pau, Biomed Res Inst St Pau IIB St Pau, C St Antoni Maria Claret,167, Barcelona 08025, Spain.	rmangues@santpau.cat	Mangues, Ramon/J-6396-2014; PAVON RIBAS, MIGUEL ANGEL/N-3538-2014; CASANOVA RIGAT, ISOLDA/I-5393-2014; Di Nicolantonio, Federica/A-2503-2011; Villaverde, Antonio/N-3986-2018; PAVON, MIGUEL ANGEL/N-3538-2014; BARDELLI, Alberto/J-9721-2018	Mangues, Ramon/0000-0003-2661-9525; PAVON RIBAS, MIGUEL ANGEL/0000-0003-3677-5329; CASANOVA RIGAT, ISOLDA/0000-0002-1196-4724; Di Nicolantonio, Federica/0000-0001-9618-2010; Villaverde, Antonio/0000-0002-2615-4521; Gallardo, Alberto/0000-0002-2514-2027; PAVON, MIGUEL ANGEL/0000-0001-7992-8626; Vazquez, Esther/0000-0003-1052-0424; Lopez Pousa, Antonio/0000-0003-1066-3951; BARDELLI, Alberto/0000-0003-1647-5070	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Al-Mulla F, 1998, J PATHOL, V185, P130, DOI 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M; Alamo P, 2014, DIS MODEL MECH, V7, P387, DOI 10.1242/dmm.013995; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Cao YT, 2007, CANCER RES, V67, P3835, DOI 10.1158/0008-5472.CAN-06-4056; Cespedes M V, 2006, Clin Transl Oncol, V8, P318; Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246; De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535; Defilles C, 2009, EXP CELL RES, V315, P1840, DOI 10.1016/j.yexcr.2009.03.014; Di Nicolantonio F, 2008, P NATL ACAD SCI USA, V105, P20864, DOI 10.1073/pnas.0808757105; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; Folkman J, 1983, Symp Fundam Cancer Res, V36, P201; Fukunaga S, 2006, ONCOLOGY-BASEL, V71, P204, DOI 10.1159/000106070; Gassmann P, 2009, NEOPLASIA, V11, P651, DOI 10.1593/neo.09272; George ML, 2001, NEOPLASIA, V3, P420, DOI 10.1038/sj.neo.7900186; Giger OT, 2012, MODERN PATHOL, V25, P1048, DOI 10.1038/modpathol.2012.56; Guerrero S, 2000, CANCER RES, V60, P6750; Guerrero S, 2002, FASEB J, V16, P1642, DOI 10.1096/fj.02-0050fje; Jin FY, 2012, MOL CANCER RES, V10, P1021, DOI 10.1158/1541-7786.MCR-11-0498; Kazama S, 2006, BRIT J CANCER, V94, P293, DOI 10.1038/sj.bjc.6602927; Kim J, 2005, J CLIN ONCOL, V23, P2744, DOI 10.1200/JCO.2005.07.078; Kye BH, 2012, BMC SURG, V12, DOI 10.1186/1471-2482-12-16; Lee C.C., 2005, J CANC MOLECULES, V1, P26; Lim SB, 2010, DIS COLON RECTUM, V53, P377, DOI 10.1007/DCR.0b013e3181cf8ae5; Malinowsky K, 2014, BRIT J CANCER, V110, P2081, DOI 10.1038/bjc.2014.100; Margolin DA, 2011, NEOPLASIA, V13, P874, DOI 10.1593/neo.11324; Minami T, 2013, CELL REP, V4, P709, DOI 10.1016/j.celrep.2013.07.021; Mitrovic B, 2012, MODERN PATHOL, V25, P1315, DOI 10.1038/modpathol.2012.94; MOERKERK P, 1994, CANCER RES, V54, P3376; Monaco R, 1995, J PROTEIN CHEM, V14, P721, DOI 10.1007/BF01886911; Nielsen H, 1998, BRIT MED J, V316, P829, DOI 10.1136/bmj.316.7134.829; Ottaiano A, 2006, CLIN CANCER RES, V12, P2795, DOI 10.1158/1078-0432.CCR-05-2142; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Peeters M, 2013, J CLIN ONCOL, V31, P759, DOI 10.1200/JCO.2012.45.1492; Resch A, 2013, WORLD J GASTROENTERO, V19, P8515, DOI 10.3748/wjg.v19.i46.8515; Rigamonti N, 2013, CELL REP, V4, P621, DOI 10.1016/j.celrep.2013.07.034; Sakakibara T, 2005, BRIT J CANCER, V93, P799, DOI 10.1038/sj.bjc.6602743; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Son HJ, 2008, HEPATO-GASTROENTEROL, V55, P1293; Span M, 1996, INT J CANCER, V69, P241, DOI 10.1002/(SICI)1097-0215(19960621)69:3<241::AID-IJC15>3.3.CO;2-D; Cespedes MV, 2007, AM J PATHOL, V170, P1077, DOI 10.2353/ajpath.2007.060773; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Xue GD, 2013, JNCI-J NATL CANCER I, V105, P393, DOI 10.1093/jnci/djs648; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yoshioka T, 2010, CANCER SCI, V101, P2011, DOI 10.1111/j.1349-7006.2010.01640.x; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zlobec I, 2014, BRIT J CANCER, V110, P1008, DOI 10.1038/bjc.2013.797	51	39	40	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					464	476		10.1096/fj.14-262303	http://dx.doi.org/10.1096/fj.14-262303			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25359494	Green Submitted			2022-12-28	WOS:000349370400012
J	Korte, S; Strater, AS; Druppel, V; Oberleithner, H; Jeggle, P; Grossmann, C; Fobker, M; Nofer, JR; Brand, E; Kusche-Vihrog, K				Korte, Stefanie; Straeter, Alexandra S.; Drueppel, Verena; Oberleithner, Hans; Jeggle, Pia; Grossmann, Claudia; Fobker, Manfred; Nofer, Jerzy-Roch; Brand, Eva; Kusche-Vihrog, Kristina			Feedforward activation of endothelial ENaC by high sodium	FASEB JOURNAL			English	Article						EnNaC; atomic force microscopy; endothelium; aldosterone; mineralocorticoid receptor; FAD286	EPITHELIAL NA+-CHANNEL; NITRIC-OXIDE SYNTHASE; VASCULAR ENDOTHELIUM; MINERALOCORTICOID RECEPTORS; ALDOSTERONE BIOSYNTHESIS; BLOOD-PRESSURE; PLASMA SODIUM; SALT; CELLS; HYPERTENSION	Kidney epithelial sodium channels (ENaCs) are known to be inactivated by high sodium concentrations (feedback inhibition). Recently, the endothelial sodium channel (EnNaC) was identified to control the nanomechanical properties of the endothelium. EnNaC-dependent endothelial stiffening reduces the release of nitric oxide, the hallmark of endothelial dysfunction. To study the regulatory impact of sodium on EnNaC, endothelial cells (EA.hy926 and ex vivo mouse endothelium) were incubated in aldosterone-free solutions containing either low (130 mM) or high (150 mM) sodium concentrations. By applying atomic force microscopy- based nanoindentation, an unexpected positive correlation between increasing sodium concentrations and cortical endothelial stiffness was observed, which can be attributed to functional EnNaC. In particular, an acute rise in sodium concentration (+20 mM) was sufficient to increase EnNaC membrane abundance by 90% and stiffening of the endothelial cortex by 18%. Despite the absence of exogenous aldosterone, these effects were prevented by the aldosterone synthase inhibitor FAD286 (100 nM) or the mineralocorticoid receptor (MR)-antagonist spironolactone (100 nM), indicating endogenous aldosterone synthesis and MR-dependent signaling. Interestingly, in the presence of high-sodium concentrations, FAD286 increased the transcription of the MR by 69%. Taken together, a novel feedforward activation of EnNaC by sodium is proposed that contrasts ENaC feedback inhibition in kidney.	[Korte, Stefanie; Straeter, Alexandra S.; Drueppel, Verena; Oberleithner, Hans; Jeggle, Pia; Kusche-Vihrog, Kristina] Univ Munster, Inst Physiol 2, D-48149 Munster, Germany; [Grossmann, Claudia] Univ Halle Wittenberg, Julius Bernstein Inst Physiol, D-06108 Halle, Germany; [Fobker, Manfred; Nofer, Jerzy-Roch] Univ Munster, Ctr Lab Med, D-48149 Munster, Germany; [Brand, Eva] Univ Hosp Muenster, Dept Nephrol Hypertens & Rheumatol, Munster, Germany	University of Munster; Martin Luther University Halle Wittenberg; University of Munster; University of Munster	Kusche-Vihrog, K (corresponding author), Inst Physiol 2, Robert Koch Str 27b, D-48149 Munster, Germany.	kusche@uni-muenster.de	Kampmeier, Stefanie/GNW-3599-2022	Kampmeier, Stefanie/0000-0002-5013-159X	Deutsche Forschungsgemeinschaft [OB 63/18, KU 1496/7-1]; Else-Kroner-Fresenius Stiftung [2010_A116]; Innovative Medical Research (IMF) of the University of Munster [KU 120808]; Centre of Excellence (Cells in Motion; CIM), University of Munster; COST Action TD1002; COST Action BM 1301	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Else-Kroner-Fresenius Stiftung; Innovative Medical Research (IMF) of the University of Munster; Centre of Excellence (Cells in Motion; CIM), University of Munster; COST Action TD1002; COST Action BM 1301	The authors thank Dr. Jurgen Reinhardt (Novartis, Basel, Swizerland) for kind supply of FAD286 and Marianne Wilhelmi and Anja Blanque for excellent technical assistance. The authors are grateful to Johanna Nedele (Department of Internal Medicine D, University of Munster), Lina Golle for assistance with the qRT-PCR experiments, Anne Wiesinger, and Otto Lindemann (Institute of Physiology II, University of Munster) for further technical advice. Work was supported by grants of the Deutsche Forschungsgemeinschaft (Koselleck OB 63/18, KU 1496/7-1), the Else-Kroner-Fresenius Stiftung (2010_A116), Innovative Medical Research (IMF) of the University of Munster (KU 120808), and by the Centre of Excellence (Cells in Motion; CIM), University of Munster. The authors also thank COST Action TD1002 and COST Action BM 1301 for supporting their networking activities. This paper is dedicated to the late Professor Hugh de Wardener, Imperial College London, who read and commented on a former version of this work.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Bragulat E, 2001, HYPERTENSION, V37, P444, DOI 10.1161/01.HYP.37.2.444; Brown NJ, 2013, NAT REV NEPHROL, V9, P459, DOI 10.1038/nrneph.2013.110; Caprio M, 2008, CIRC RES, V102, P1359, DOI 10.1161/CIRCRESAHA.108.174235; Cutaia M, 1996, J APPL PHYSIOL, V81, P509, DOI 10.1152/jappl.1996.81.1.509; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Delcayre C, 2000, KIDNEY INT, V57, P1346, DOI 10.1046/j.1523-1755.2000.00973.x; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Falkenstein E, 2000, KIDNEY INT, V57, P1390, DOI 10.1046/j.1523-1755.2000.00980.x; Fels J, 2010, BBA-MOL BASIS DIS, V1802, P1193, DOI 10.1016/j.bbadis.2010.03.006; Fels J, 2010, PFLUG ARCH EUR J PHY, V460, P915, DOI 10.1007/s00424-010-0871-8; FUCHS W, 1977, J PHYSIOL-LONDON, V267, P137, DOI 10.1113/jphysiol.1977.sp011805; Fujita T, 2008, J MOL MED, V86, P729, DOI 10.1007/s00109-008-0343-1; Funder JW, 2006, HYPERTENSION, V47, P634, DOI 10.1161/01.HYP.0000203732.03784.3b; Funder JW, 2004, ENDOCRINOLOGY, V145, P4793, DOI 10.1210/en.2004-1057; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Golestaneh N, 2001, BIOCHEM BIOPH RES CO, V280, P1300, DOI 10.1006/bbrc.2001.4275; Gomez-Sanchez EP, 2004, ENDOCRINOLOGY, V145, P4796, DOI 10.1210/en.2004-0295; GomezSanchez CE, 1997, ENDOCRINOLOGY, V138, P3369, DOI 10.1210/en.138.8.3369; Gorelik J, 2005, P NATL ACAD SCI USA, V102, P15000, DOI 10.1073/pnas.0507008102; He FJ, 2005, HYPERTENSION, V45, P98, DOI 10.1161/01.HYP.0000149431.79450.a2; Huang BS, 2009, AM J PHYSIOL-REG I, V296, pR994, DOI 10.1152/ajpregu.90903.2008; Jeggle P, 2013, HYPERTENSION, V61, P1053, DOI 10.1161/HYPERTENSIONAHA.111.199455; Kakizoe Y, 2009, J HYPERTENS, V27, P1679, DOI 10.1097/HJH.0b013e32832c7d23; Korte S, 2012, PFLUG ARCH EUR J PHY, V463, P269, DOI 10.1007/s00424-011-1038-y; Kusche-Vihrog K., 2014, PFLUGERS ARCH, V10, P146; Kusche-Vihrog K, 2008, PFLUG ARCH EUR J PHY, V455, P849, DOI 10.1007/s00424-007-0341-0; Kusche-Vihrog K, 2011, HYPERTENSION, V57, P231, DOI 10.1161/HYPERTENSIONAHA.110.163444; Kusche-Vihrog K, 2010, STEROIDS, V75, P544, DOI 10.1016/j.steroids.2009.09.003; Lang F, 2011, HYPERTENSION, V57, P146, DOI 10.1161/HYPERTENSIONAHA.110.164558; Lang F, 2009, EXPERT OPIN THER TAR, V13, P1303, DOI 10.1517/14728220903260807; Li J, 2009, J NUTR, V139, P447, DOI 10.3945/jn.108.097451; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lifton RP, 2002, COLD SPRING HARB SYM, V67, P445, DOI 10.1101/sqb.2002.67.445; Maier LS, 1997, AM J PHYSIOL-HEART C, V273, pH1246, DOI 10.1152/ajpheart.1997.273.3.H1246; Mazzochi C, 2006, J BIOL CHEM, V281, P6528, DOI 10.1074/jbc.M509386200; McEneaney V, 2008, MOL ENDOCRINOL, V22, P881, DOI 10.1210/me.2007-0225; Meneton P, 2005, PHYSIOL REV, V85, P679, DOI 10.1152/physrev.00056.2003; Morizane S, 2012, ARTERIOSCL THROM VAS, V32, P1194, DOI 10.1161/ATVBAHA.111.242719; Nagase M, 2007, HYPERTENSION, V50, P877, DOI 10.1161/HYPERTENSIONAHA.107.091058; Ni ZM, 2001, AM J HYPERTENS, V14, P155, DOI 10.1016/S0895-7061(00)01234-6; Oberleithner H, 2005, KIDNEY INT, V67, P1680, DOI 10.1111/j.1523-1755.2005.00263.x; Oberleithner H, 2009, P NATL ACAD SCI USA, V106, P2829, DOI 10.1073/pnas.0813069106; Oberleithner H, 2007, P NATL ACAD SCI USA, V104, P16281, DOI 10.1073/pnas.0707791104; Oberleithner H, 2006, J CELL SCI, V119, P1926, DOI 10.1242/jcs.02886; Oda T, 2001, BIOPHYS J, V80, P841, DOI 10.1016/S0006-3495(01)76063-8; PALMER LG, 1988, J GEN PHYSIOL, V92, P121, DOI 10.1085/jgp.92.1.121; Perez FR, 2009, HYPERTENSION, V53, P1000, DOI 10.1161/HYPERTENSIONAHA.108.128520; Rossier BC, 2002, J GEN PHYSIOL, V120, P67, DOI 10.1085/jgp.20028638; Sanders PW, 2009, AM J PHYSIOL-RENAL, V297, pF237, DOI 10.1152/ajprenal.00027.2009; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Stockand JD, 2002, AM J PHYSIOL-RENAL, V282, pF559, DOI 10.1152/ajprenal.00320.2001; TAKEDA R, 1995, STEROIDS, V60, P120, DOI 10.1016/0039-128X(94)00026-9; Takeda Y, 1997, HYPERTENSION, V29, P45, DOI 10.1161/01.HYP.29.1.45; Takeda Y, 2004, MOL CELL ENDOCRINOL, V217, P75, DOI 10.1016/j.mce.2003.10.012; Titze J, 2002, AM J PHYSIOL-RENAL, V283, pF134, DOI 10.1152/ajprenal.00323.2001; Titze J, 2010, CURR OPIN NEPHROL HY, V19, P385, DOI 10.1097/MNH.0b013e32833aeb3b; Volk T, 2004, PFLUG ARCH EUR J PHY, V447, P884, DOI 10.1007/s00424-003-1193-x; Wang S, 2009, MICROCIRCULATION, V16, P276, DOI 10.1080/10739680802653150; Warnock DG, 2014, NAT REV NEPHROL, V10, P146, DOI 10.1038/nrneph.2013.275; Warnock DG, 2013, HYPERTENSION, V61, P952, DOI 10.1161/HYPERTENSIONAHA.113.00768; Warnock DG, 1998, KIDNEY INT, V53, P18, DOI 10.1046/j.1523-1755.1998.00728.x; Wildling L, 2009, PFLUG ARCH EUR J PHY, V458, P223, DOI 10.1007/s00424-008-0615-1; WILLIAMS GH, 1972, J CLIN INVEST, V51, P2645, DOI 10.1172/JCI107082	64	29	30	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4015	4025		10.1096/fj.14-250282	http://dx.doi.org/10.1096/fj.14-250282			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24868010	Green Published			2022-12-28	WOS:000340845900019
J	Robert, A; Herrmann, H; Davidson, MW; Gelfand, VI				Robert, Amelie; Herrmann, Harald; Davidson, Michael W.; Gelfand, Vladimir I.			Microtubule-dependent transport of vimentin filament precursors is regulated by actin and by the concerted action of Rho- and p21-activated kinases	FASEB JOURNAL			English	Article						cytoskeleton; particle tracking; motor proteins	INTERMEDIATE-FILAMENTS; CYTOPLASMIC DYNEIN; CELL-MIGRATION; PHOSPHORYLATION; CYTOSKELETON; DYNAMICS; KINESIN; NETWORK; REORGANIZATION; FIBROBLASTS	Intermediate filaments (IFs) form a dense and dynamic network that is functionally associated with microtubules and actin filaments. We used the GFP-tagged vimentin mutant Y117L to study vimentin-cytoskeletal interactions and transport of vimentin filament precursors. This mutant preserves vimentin interaction with other components of the cytoskeleton, but its assembly is blocked at the unit-length filament (ULF) stage. ULFs are easy to track, and they allow a reliable and quantifiable analysis of movement. Our results show that in cultured human vimentin-negative SW13 cells, 2% of vimentin-ULFs move along microtubules bidirectionally, while the majority are stationary and tightly associated with actin filaments. Rapid motor-dependent transport of ULFs along microtubules is enhanced >5-fold by depolymerization of actin cytoskeleton with latrunculin B. The microtubule-dependent transport of vimentin ULFs is further regulated by Rho-kinase (ROCK) and p21-activated kinase (PAK): ROCK inhibits ULF transport, while PAK stimulates it. Both kinases act on microtubule transport independently of their effects on actin cytoskeleton. Our study demonstrates the importance of the actin cytoskeleton to restrict IF transport and reveals a new role for PAK and ROCK in the regulation of IF precursor transport.	[Robert, Amelie; Gelfand, Vladimir I.] Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, Chicago, IL 60611 USA; [Herrmann, Harald] German Canc Res Ctr, Div Mol Genet, Heidelberg, Germany; [Davidson, Michael W.] Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32306 USA; [Davidson, Michael W.] Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA	Northwestern University; Feinberg School of Medicine; Helmholtz Association; German Cancer Research Center (DKFZ); State University System of Florida; Florida State University; State University System of Florida; Florida State University	Gelfand, VI (corresponding author), Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, 303 E Chicago Ave,Ward 11-100, Chicago, IL 60611 USA.	vgelfand@northwestern.edu	Gelfand, Vladimir I/D-2545-2013; Gelfand, Vladimir/M-1974-2019	Gelfand, Vladimir I/0000-0002-6361-2798; Gelfand, Vladimir/0000-0002-6361-2798	National Institute of General Medical Science of the U. S. National Institutes of Health [P01GM09697, R01 GM52111]; American Heart Association [13POST16210010]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM096971, R01GM052111] Funding Source: NIH RePORTER	National Institute of General Medical Science of the U. S. National Institutes of Health; American Heart Association(American Heart Association); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Research reported in this publication was supported by the National Institute of General Medical Science of the U. S. National Institutes of Health under awards P01GM09697 and R01 GM52111. A. R. was supported by a fellowship from the American Heart Association (13POST16210010). The authors thank the Goldman Laboratory (Fineberg School of Medicine, Northwestern University) for sharing materials that contributed to this work and Caroline Hookway and Robert Goldman for critical reading of the manuscript.	Ally S, 2009, J CELL BIOL, V187, P1071, DOI 10.1083/jcb.200908075; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Bayless KJ, 2011, J VASC RES, V48, P369, DOI 10.1159/000324751; Burgstaller G, 2010, MOL BIOL CELL, V21, P3362, DOI 10.1091/mbc.E10-02-0094; Chan W, 2002, EUR J CELL BIOL, V81, P692, DOI 10.1078/0171-9335-00281; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Chung BM, 2013, CURR OPIN CELL BIOL, V25, P600, DOI 10.1016/j.ceb.2013.06.008; Correia I, 1999, J CELL BIOL, V146, P831, DOI 10.1083/jcb.146.4.831; Dave JM, 2013, J BIOL CHEM, V288, P30720, DOI 10.1074/jbc.M113.512467; Deacon SW, 2008, CHEM BIOL, V15, P322, DOI 10.1016/j.chembiol.2008.03.005; DHAMODHARAN R, 1995, MOL BIOL CELL, V6, P1215, DOI 10.1091/mbc.6.9.1215; Eckes B, 1998, J CELL SCI, V111, P1897; Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906; Esue O, 2006, J BIOL CHEM, V281, P30393, DOI 10.1074/jbc.M605452200; Firestone AJ, 2012, NATURE, V484, P125, DOI 10.1038/nature10936; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; Georgakopoulou S, 2009, J MOL BIOL, V386, P544, DOI 10.1016/j.jmb.2008.12.053; GOLDMAN RD, 1971, J CELL BIOL, V51, P752, DOI 10.1083/jcb.51.3.752; Goldman RD, 2012, J STRUCT BIOL, V177, P14, DOI 10.1016/j.jsb.2011.11.017; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Goto H, 2002, GENES CELLS, V7, P91, DOI 10.1046/j.1356-9597.2001.00504.x; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; Helfand BT, 2011, MOL BIOL CELL, V22, P1274, DOI 10.1091/mbc.E10-08-0699; Helfand BT, 2002, J CELL BIOL, V157, P795, DOI 10.1083/jcb.200202027; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; HOLLENBECK PJ, 1989, J CELL SCI, V92, P621; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Izawa I, 2006, CANCER SCI, V97, P167, DOI 10.1111/j.1349-7006.2006.00161.x; Kardon JR, 2009, NAT REV MOL CELL BIO, V10, P854, DOI 10.1038/nrm2804; Kim H, 2011, FEBS LETT, V585, P18, DOI 10.1016/j.febslet.2010.11.033; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Li QF, 2006, J BIOL CHEM, V281, P34716, DOI 10.1074/jbc.M607715200; Liu TG, 2010, AM J PHYSIOL-CELL PH, V299, pC363, DOI 10.1152/ajpcell.00057.2010; Lu W, 2013, CURR BIOL, V23, P1018, DOI 10.1016/j.cub.2013.04.050; Meier M, 2009, J MOL BIOL, V390, P245, DOI 10.1016/j.jmb.2009.04.067; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Minin AA, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1453, DOI 10.1134/S0006297908130063; Nekrasova OE, 2011, MOL BIOL CELL, V22, P2282, DOI 10.1091/mbc.E10-09-0766; Pan YR, 2013, J CELL SCI, V126, P657, DOI 10.1242/jcs.116624; Potokar M, 2010, GLIA, V58, P1208, DOI 10.1002/glia.21000; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; Rogel MR, 2011, FASEB J, V25, P3873, DOI 10.1096/fj.10-170795; Sakamoto Y, 2013, J CELL BIOL, V200, P249, DOI 10.1083/jcb.201206010; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Sihag RK, 2007, EXP CELL RES, V313, P2098, DOI 10.1016/j.yexcr.2007.04.010; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; STARGER JM, 1978, J CELL BIOL, V78, P93, DOI 10.1083/jcb.78.1.93; Strelkov SV, 2003, BIOESSAYS, V25, P243, DOI 10.1002/bies.10246; SUN TT, 1978, CELL, V14, P469, DOI 10.1016/0092-8674(78)90233-7; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; Takahashi K, 2009, CELL SIGNAL, V21, P695, DOI 10.1016/j.cellsig.2009.01.007; Windoffer R, 2011, J CELL BIOL, V194, P669, DOI 10.1083/jcb.201008095; Wirth A, 2003, J PHYSIOL-LONDON, V549, P489, DOI 10.1113/jphysiol.2002.033167; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147	56	45	46	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2879	2890		10.1096/fj.14-250019	http://dx.doi.org/10.1096/fj.14-250019			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24652946	Green Published			2022-12-28	WOS:000337949400013
J	Deplanche, M; El-Aouar, RA; Alekseeva, L; Ladier, E; Jardin, J; Henry, G; Azevedo, V; Miyoshi, A; Beraud, L; Laurent, F; Lina, G; Vandenesch, F; Steghens, JP; Le Loir, Y; Otto, M; Gotz, F; Berkova, N				Deplanche, Martine; El-Aouar Filho, Rachid Aref; Alekseeva, Ludmila; Ladier, Emilie; Jardin, Julien; Henry, Gwenaele; Azevedo, Vasco; Miyoshi, Anderson; Beraud, Laetitia; Laurent, Frederic; Lina, Gerard; Vandenesch, Francois; Steghens, Jean-Paul; Le Loir, Yves; Otto, Michael; Goetz, Friedrich; Berkova, Nadia			Phenol-soluble modulin alpha induces G2/M phase transition delay in eukaryotic HeLa cells	FASEB JOURNAL			English	Article						Staphylococcus aureus; cell cycle alteration; defensins; toxin; innate immune response	BETA-DEFENSIN 2; STAPHYLOCOCCUS-AUREUS; EPITHELIAL-CELLS; INFECTION; CYCLE; EXPRESSION; PROTEINS; INHIBIT; SKIN	Staphylococcus aureus is a gram-positive bacterium responsible for a wide range of infections. Host cell cycle alteration is a sophisticated mechanism used by pathogens to hijack the defense functions of host cells. We previously demonstrated that S. aureus MW2 (USA400) bacteria induced a G2/M phase transition delay in HeLa cells. We demonstrate here that this activity is triggered by culture supernatant compounds. Using size exclusion chromatography of the MW2 supernatant, followed by mass spectroscopy analysis of corresponding peaks, we identified phenol-soluble modulin (PSM) peptides as the likely candidates for this effect. Indeed, synthetic PSM1 and PSM3 caused a G2/M phase transition delay. The implication of PSM in cell cycle alteration was confirmed by comparison of S. aureus Los Angeles County clone (LAC) wild-type with the isogenic mutant LACpsm, which lacks the psm operon encoding PSM1-4. PSM-induced G2/M transition delay correlated with a decrease in the defensin genes expression suggesting a diminution of antibacterial functions of epithelial cells. By testing the supernatant of S. aureus human clinical isolates, we found that the degree of G2/M phase transition delay correlated with PSM1 production. We show that PSMs secreted by S. aureus alter the host cell cycle, revealing a newly identified mechanism for fostering an infection.	[Deplanche, Martine; El-Aouar Filho, Rachid Aref; Alekseeva, Ludmila; Ladier, Emilie; Jardin, Julien; Henry, Gwenaele; Le Loir, Yves; Berkova, Nadia] INRA, STLO, UMR1253, Agrocampus Ouest, 65 Rue St Brieuc, F-35042 Rennes, France; [Deplanche, Martine; El-Aouar Filho, Rachid Aref; Alekseeva, Ludmila; Ladier, Emilie; Jardin, Julien; Henry, Gwenaele; Le Loir, Yves; Berkova, Nadia] Agrocampus Ouest, UMR1253, STLO, Rennes, France; [El-Aouar Filho, Rachid Aref; Azevedo, Vasco; Miyoshi, Anderson] Univ Fed Minas Gerais, Inst Ciencias Biol, Belo Horizonte, MG, Brazil; [Alekseeva, Ludmila] Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow, Russia; [Beraud, Laetitia; Laurent, Frederic; Lina, Gerard; Vandenesch, Francois] Univ Lyon 1, CNRS, INSERM U111, Ctr Int Rech Infectiol,Unite Mixtes Rech5308, F-69365 Lyon, France; [Laurent, Frederic; Lina, Gerard; Vandenesch, Francois; Steghens, Jean-Paul] Hosp Civil Lyon, Lyon, France; [Otto, Michael] NIH, Lab Human Bacterial Pathogenesis, Bethesda, MD 20892 USA; [Goetz, Friedrich] Univ Tubingen, Microbial Genet, Tubingen, Germany	INRAE; Institut Agro; Agrocampus Ouest; Institut Agro; Agrocampus Ouest; Universidade Federal de Minas Gerais; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; National Institutes of Health (NIH) - USA; Eberhard Karls University of Tubingen	Berkova, N (corresponding author), INRA, STLO, UMR1253, Agrocampus Ouest, 65 Rue St Brieuc, F-35042 Rennes, France.	nadia.berkova@rennes.inra.fr	Azevedo, Vasco A.C/F-4315-2011; JARDIN, Julien/A-3241-2012; Azevedo, Vasco/B-1556-2019; Vandenesch, Francois/C-7209-2014; LAURENT, Frederic/AGM-0706-2022; LE LOIR, Yves/AAD-1879-2021	Azevedo, Vasco A.C/0000-0002-4775-2280; JARDIN, Julien/0000-0003-0520-9391; Azevedo, Vasco/0000-0002-4775-2280; Vandenesch, Francois/0000-0001-9412-7106; Le Loir, Yves/0000-0002-0355-1065; Otto, Michael/0000-0002-2222-4115; Lina, Gerard/0000-0002-9236-7998; Berkova, Nadia/0000-0001-6246-5549; laurent, frederic/0000-0003-0609-9091	French National Institute for Agricultural Research (INRA) [P10552]; U.S. National Institutes of Health, National Institute of Allergy and Infectious Diseases' Intramural Research Program; German Research Foundation [SFB766]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES; Brazil); France-Russia Bilateral Collaboration; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000904] Funding Source: NIH RePORTER	French National Institute for Agricultural Research (INRA); U.S. National Institutes of Health, National Institute of Allergy and Infectious Diseases' Intramural Research Program; German Research Foundation(German Research Foundation (DFG)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES; Brazil)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); France-Russia Bilateral Collaboration; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Gail Wagman and Mary Bret for revising the English. This work was supported by French National Institute for Agricultural Research (INRA), Ruminflame P10552 (to N.B., M.D., J.J., G.H., and Y.L.L.), the U.S. National Institutes of Health, National Institute of Allergy and Infectious Diseases' Intramural Research Program (to M.O.), and the German Research Foundation, SFB766 (to F.G.). R.A.E.-A.F. is a recipient of a Ph.D. fellowship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES; Brazil), and L.A. is a recipient of a postdoctoral fellowship (France-Russia Bilateral Collaboration). The authors declare no conflicts of interest.	Alekseeva L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063279; Alkuwaity K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042660; Berkova N, 2006, INT IMMUNOL, V18, P139, DOI 10.1093/intimm/dxh356; Bhavsar AP, 2007, NATURE, V449, P827, DOI 10.1038/nature06247; Buc E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056964; CASEWELL MW, 1986, J ANTIMICROB CHEMOTH, V18, P1; Cheung GYC, 2012, MICROBES INFECT, V14, P380, DOI 10.1016/j.micinf.2011.11.013; CHRISTIE CDC, 1988, PEDIATR INFECT DIS J, V7, P791, DOI 10.1097/00006454-198811000-00010; Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092; Cude K, 2007, J CELL BIOL, V177, P253, DOI 10.1083/jcb.200609166; Edwards AM, 2011, TRENDS MICROBIOL, V19, P184, DOI 10.1016/j.tim.2010.12.005; Foster TJ, 2014, NAT REV MICROBIOL, V12, P49, DOI 10.1038/nrmicro3161; Grosz M, 2014, CELL MICROBIOL, V16, P451, DOI 10.1111/cmi.12233; Haugwitz U, 2006, CELL MICROBIOL, V8, P1591, DOI 10.1111/j.1462-5822.2006.00733.x; Le Marechal C, 2009, J MICROBIOL METH, V79, P131, DOI 10.1016/j.mimet.2009.08.017; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Miller LS, 2011, NAT REV IMMUNOL, V11, P505, DOI 10.1038/nri3010; Nikitas G, 2011, J EXP MED, V208, P2263, DOI 10.1084/jem.20110560; Nougayrede JP, 2006, SCIENCE, V313, P848, DOI 10.1126/science.1127059; Nougayrede JP, 2005, TRENDS MICROBIOL, V13, P103, DOI 10.1016/j.tim.2005.01.002; Otri AM, 2012, INVEST OPHTH VIS SCI, V53, P757, DOI 10.1167/iovs.11-8467; Otto M, 2012, J INFECT DIS, V205, P1483, DOI 10.1093/infdis/jis248; OWEN TA, 1989, J CELL PHYSIOL, V139, P424, DOI 10.1002/jcp.1041390227; Park K, 2014, J DERMATOL SCI, V75, P94, DOI 10.1016/j.jdermsci.2014.04.011; Peschel A, 2013, NAT REV MICROBIOL, V11, P667, DOI 10.1038/nrmicro3110; Queck SY, 2008, MOL CELL, V32, P150, DOI 10.1016/j.molcel.2008.08.005; Rohrl J, 2010, J IMMUNOL, V184, P6688, DOI 10.4049/jimmunol.0903984; SUGAI M, 1992, J BIOL CHEM, V267, P2600; Surewaard BGJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002606; Tuchscherr L, 2011, EMBO MOL MED, V3, P129, DOI 10.1002/emmm.201000115; Varon C, 2014, J INFECT DIS, V209, P588, DOI 10.1093/infdis/jit539; Wang R, 2007, NAT MED, V13, P1510, DOI 10.1038/nm1656; Wu WN, 2011, J VIROL, V85, P10300, DOI 10.1128/JVI.05164-11; Zanger P, 2010, INFECT IMMUN, V78, P3112, DOI 10.1128/IAI.00078-10	34	20	21	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1950	1959		10.1096/fj.14-260513	http://dx.doi.org/10.1096/fj.14-260513			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25648996	Green Published			2022-12-28	WOS:000354114600029
J	Marois, I; Cloutier, A; Garneau, E; Lesur, O; Richter, MV				Marois, Isabelle; Cloutier, Alexandre; Garneau, Emilie; Lesur, Olivier; Richter, Martin V.			The administration of oseltamivir results in reduced effector and memory CD8(+) T cell responses to influenza and affects protective immunity	FASEB JOURNAL			English	Article						antiviral; Tamiflu; flu; adaptive immune response; immunologic consequences	NEURAMINIDASE INHIBITOR OSELTAMIVIR; RESPIRATORY-TRACT; ANTIVIRAL AGENTS; VIRUS-INFECTION; A VIRUS; MICE; H1N1; H5N1; EXPRESSION; EFFICACY	The clinical benefits of oseltamivir (Tamiflu) are well established, but the effects of antiviral treatment on the immune response are poorly understood. By use of flow cytometric analyses and the mouse model, we thoroughly investigated the impact of such a treatment on the immune response and the generation of protective immunity to influenza. We demonstrated that influenzaspecific CD8(+) effector T cell recruitment was reduced up to 81% in the lungs of mice treated with oseltamivir (5 or 50 mg/kg twice daily; EC50 49 nM in vitro) compared to saline controls, but cell generation was unaffected in draining lymph nodes. Importantly, we showed that oseltamivir administration significantly decreased the pools of tissue-resident and circulating effector memory (93.7%) and central memory CD8(+) T cells (45%) compared to saline controls. During heterologous secondary infection, a decreased memory CD8(+) T cell pool combined with reduced generation of secondary influenza-specific effectors in the lymph nodes resulted in 10-fold decreased CD8(+) T cell recall responses, which increased mouse morbidity and delayed viral clearance. Furthermore, antiviral administration led to a significant 5.7-fold decreased production of functional anti-influenza antibodies. Thus, our study demonstrates that antiviral treatment affects the development of the adaptive immune response and protective immunity against influenza.	[Marois, Isabelle; Cloutier, Alexandre; Garneau, Emilie; Lesur, Olivier; Richter, Martin V.] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Med, Div Pulm, Sherbrooke, PQ J1H 5N4, Canada; [Marois, Isabelle; Cloutier, Alexandre; Garneau, Emilie; Lesur, Olivier; Richter, Martin V.] Ctr Rech CHUS, Sherbrooke, PQ J1H 5N4, Canada; [Lesur, Olivier] CHU Sherbrooke, Intens Care Unit, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Richter, MV (corresponding author), Univ Sherbrooke, Fac Med & Hlth Sci, Dept Med, Div Pulm, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	martin.richter@usherbrooke.ca			Canadian Institutes of Health Research (CIHR) [OPP-86939]; Fonds de la recherche en sante du Quebec (FRSQ) [16116]; CIHR-Quebec Respiratory Health Training Program of the Reseau en Sante Respiratoire du FRSQ	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fonds de la recherche en sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); CIHR-Quebec Respiratory Health Training Program of the Reseau en Sante Respiratoire du FRSQ(Canadian Institutes of Health Research (CIHR))	The authors thank Drs. Denis Gris and Patrick P. McDonald for their helpful comments during the writing of the manuscript. This work was supported by grants from the Canadian Institutes of Health Research (CIHR; Grant OPP-86939) and the Fonds de la recherche en sante du Quebec (FRSQ; Grant 16116). A.C. was supported by a postdoctoral fellowship from the CIHR-Quebec Respiratory Health Training Program of the Reseau en Sante Respiratoire du FRSQ, and M.V.R. is a FRSQ Junior 2 Research Scholar.	Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279; Aoki FY, 2003, J ANTIMICROB CHEMOTH, V51, P123, DOI 10.1093/jac/dkg007; Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449; Belz GT, 2001, J IMMUNOL, V166, P4627, DOI 10.4049/jimmunol.166.7.4627; Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213; Burger RA, 2000, IMMUNOPHARMACOLOGY, V47, P45, DOI 10.1016/S0162-3109(99)00184-8; Carroll TD, 2008, J IMMUNOL, V180, P2385, DOI 10.4049/jimmunol.180.4.2385; Cloutier A, 2012, J INFECT DIS, V205, P621, DOI 10.1093/infdis/jir804; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Ely KH, 2006, J IMMUNOL, V176, P537, DOI 10.4049/jimmunol.176.1.537; Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Govorkova EA, 2007, ANTIMICROB AGENTS CH, V51, P1414, DOI 10.1128/AAC.01312-06; Govorkova EA, 2011, ANTIVIR RES, V91, P81, DOI 10.1016/j.antiviral.2011.05.008; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Hatta Y, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001139; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240; Hogan RJ, 2001, J IMMUNOL, V166, P1813, DOI 10.4049/jimmunol.166.3.1813; Holt PG, 2008, NAT REV IMMUNOL, V8, P142, DOI 10.1038/nri2236; Ilyushina NA, 2008, ANTIMICROB AGENTS CH, V52, P3889, DOI 10.1128/AAC.01579-07; Jefferson T, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008965.pub4, 10.1002/14651858.CD008965.pub3]; Kim CU, 1999, ANTIVIR CHEM CHEMOTH, V10, P141, DOI 10.1177/095632029901000401; Kohlmeier JE, 2008, IMMUNITY, V29, P101, DOI 10.1016/j.immuni.2008.05.011; Kohlmeier JE, 2011, J EXP MED, V208, P1621, DOI 10.1084/jem.20102110; Kohlmeier JE, 2009, ANNU REV IMMUNOL, V27, P61, DOI 10.1146/annurev.immunol.021908.132625; La Gruta NL, 2004, J IMMUNOL, V172, P5553, DOI 10.4049/jimmunol.172.9.5553; LaMere MW, 2011, J IMMUNOL, V186, P4331, DOI 10.4049/jimmunol.1003057; Lawrence CW, 2005, J IMMUNOL, V174, P5332, DOI 10.4049/jimmunol.174.9.5332; Leneva IA, 2000, ANTIVIR RES, V48, P101, DOI 10.1016/S0166-3542(00)00123-6; LIANG SH, 1994, J IMMUNOL, V152, P1653; Lipsitch M, 2007, PLOS MED, V4, P111, DOI 10.1371/journal.pmed.0040015; Marois I, 2012, J LEUKOCYTE BIOL, V92, P107, DOI 10.1189/jlb.1011490; Meijer A, 2009, EMERG INFECT DIS, V15, P552, DOI [10.3201/eid1504.081280, 10.3201/eid1504.181280]; Mendel DB, 1998, ANTIMICROB AGENTS CH, V42, P640, DOI 10.1128/AAC.42.3.640; Moore ML, 2007, J IMMUNOL, V178, P2651, DOI 10.4049/jimmunol.178.5.2651; Peiris JSM, 2010, CURR OPIN IMMUNOL, V22, P475, DOI 10.1016/j.coi.2010.06.003; Perrone LA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000115; Peters PH, 2001, J AM GERIATR SOC, V49, P1025, DOI 10.1046/j.1532-5415.2001.49204.x; Piqueras B, 2006, BLOOD, V107, P2613, DOI 10.1182/blood-2005-07-2965; Poland GA, 2009, CLIN INFECT DIS, V48, P1254, DOI 10.1086/598989; POTTER CW, 1979, BRIT MED BULL, V35, P69, DOI 10.1093/oxfordjournals.bmb.a071545; Powell TJ, 2006, CLIN IMMUNOL, V119, P87, DOI 10.1016/j.clim.2005.11.004; Purwar R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016245; Qiu C, 2012, CLIN INFECT DIS, V54, P17, DOI 10.1093/cid/cir753; Ray SJ, 2004, IMMUNITY, V20, P167, DOI 10.1016/S1074-7613(04)00021-4; Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802; Sanders CJ, 2011, CELL TISSUE RES, V343, P13, DOI 10.1007/s00441-010-1043-z; Sawabuchi T, 2009, RESPIROLOGY, V14, P1173, DOI 10.1111/j.1440-1843.2009.01639.x; Shinahara W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070060; Sidwell RW, 1998, ANTIVIR RES, V37, P107, DOI 10.1016/S0166-3542(97)00065-X; Stohr K, 2003, BRIT MED J, V326, P1223, DOI 10.1136/bmj.326.7401.1223; Takahashi E, 2010, MICROBES INFECT, V12, P778, DOI 10.1016/j.micinf.2010.04.013; Topham DJ, 1997, J IMMUNOL, V159, P5197; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; Tumpey TM, 2005, J VIROL, V79, P14933, DOI 10.1128/JVI.79.23.14933-14944.2005; Walsh KB, 2011, P NATL ACAD SCI USA, V108, P12018, DOI 10.1073/pnas.1107024108; Wherry EJ, 2004, J VIROL, V78, P5535, DOI 10.1128/JVI.78.11.5535-5545.2004; Wiley JA, 2001, J IMMUNOL, V167, P3293, DOI 10.4049/jimmunol.167.6.3293; Wong ZX, 2011, INFLUENZA OTHER RESP, V5, P343, DOI 10.1111/j.1750-2659.2011.00235.x	61	12	12	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					973	987		10.1096/fj.14-260687	http://dx.doi.org/10.1096/fj.14-260687			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25414485				2022-12-28	WOS:000350633000022
J	Parr, C; Mirzaei, N; Christian, M; Sastre, M				Parr, Callum; Mirzaei, Nazanin; Christian, Mark; Sastre, Magdalena			Activation of the Wnt/beta-catenin pathway represses the transcription of the beta-amyloid precursor protein cleaving enzyme (BACE1) via binding of T-cell factor-4 to BACE1 promoter	FASEB JOURNAL			English	Article						GSK3; Alzheimer's disease; DKK-1; sFRP-1	WNT SIGNALING PATHWAY; TAU-PHOSPHORYLATION; FUNCTIONAL INTERACTION; ALZHEIMERS-DISEASE; PPAR-GAMMA; DICKKOPF-1; INHIBITION; EXPRESSION; INDUCTION; MECHANISM	Alterations in the Wnt signaling pathway have been implicated in Alzheimer's disease; however, its role in the processing of the amyloid precursor protein remains unknown. In this study, activation of the Wnt pathway by overexpression of the agonist Wnt3a or beta-catenin or by inhibition of glycogen kinase synthase-3 in N2a cells resulted in a reduction in Ab levels and in the activity and expression of BACE1 (beta-APP cleaving enzyme). Conversely, inhibition of the pathway by transfection of the antagonists secreted frizzled receptor protein-1 or dickkopf-1 produced the opposite effects. Chromatin immunoprecipitation analysis demonstrated that b-catenin binds specifically to regions within the promoter of BACE1 containing putative T-cell factor/lymphoid enhancer binding factor-1 (TCF/LEF) motifs, consistent with canonical Wnt target regulation. Furthermore, cells transfected with b-catenin mutants incapable of binding to TCF/LEF increased BACE1 gene promoter activity. Interestingly, TCF4 knockdown reversed the effects of Wnt3a activation on BACE1 transcription. We found that TCF4 binds to the same region on BACE1 promoter following Wnt3a stimulation, indicating that TCF4 functions as a transcriptional repressor of BACE1 gene. In conclusion, Wnt/beta-catenin stimulation may repress BACE1 transcription via binding of TCF4 to BACE1 gene, and therefore, activation of the Wnt pathway may hold the key to new treatments of Alzheimer disease.-Parr, C., Mirzaei, N., Christian, M., and Sastre, M. Activation of the Wnt/ b-catenin pathway represses the transcription of the b-amyloid precursor protein cleaving enzyme (BACE1) via binding of T-cell factor-4 to BACE1 promoter.	[Parr, Callum; Mirzaei, Nazanin; Sastre, Magdalena] Univ London Imperial Coll Sci Technol & Med, Div Brain Sci, London W12 0NN, England; [Christian, Mark] Univ Warwick, Warwick Med Sch, Div Metab & Vasc Hlth, Coventry CV4 7AL, W Midlands, England	Imperial College London; University of Warwick	Sastre, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Div Brain Sci, Du Cane Rd, London W12 0NN, England.	m.sastre@imperial.ac.uk		Christian, Mark/0000-0002-1616-4179; Parr, Callum/0000-0002-4454-5577				Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Barker Nick, 2008, V468, P5, DOI 10.1007/978-1-59745-249-6_1; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Blauwkamp TA, 2008, EMBO J, V27, P1436, DOI 10.1038/emboj.2008.80; Brinkmeler ML, 2007, DEV BIOL, V311, P396, DOI 10.1016/j.ydbio.2007.08.046; Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381-04.2004; Chacon MA, 2008, J CELL PHYSIOL, V217, P215, DOI 10.1002/jcp.21497; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; De Ferrari GV, 2007, P NATL ACAD SCI USA, V104, P9434, DOI 10.1073/pnas.0603523104; Esposito G, 2008, J CELL MOL MED, V12, P914, DOI 10.1111/j.1582-4934.2008.00159.x; Galceran J, 2000, DEVELOPMENT, V127, P469; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Gregorieff A, 2004, EMBO J, V23, P1825, DOI 10.1038/sj.emboj.7600191; Heneka MT, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-22; Inestrosa NC, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-9; Katsouri L, 2011, J ALZHEIMERS DIS, V25, P151, DOI 10.3233/JAD-2011-101356; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Killick R, 2014, MOL PSYCHIATR, V19, P88, DOI 10.1038/mp.2012.163; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kuwabara T, 2009, NAT NEUROSCI, V12, P1097, DOI 10.1038/nn.2360; Liu JJ, 2006, MOL CELL BIOL, V26, P5827, DOI 10.1128/MCB.00441-06; Ly PTT, 2013, J CLIN INVEST, V123, P224, DOI 10.1172/JCI64516; Magdesian MH, 2008, J BIOL CHEM, V283, P9359, DOI 10.1074/jbc.M707108200; Maguschak KA, 2008, NAT NEUROSCI, V11, P1319, DOI 10.1038/nn.2198; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Moon RT, 1997, TRENDS GENET, V13, P256, DOI 10.1016/S0168-9525(97)01196-7; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; Nusse R, 2008, COLD SH Q B, V73, P59, DOI 10.1101/sqb.2008.73.035; Parr C, 2012, MOL CELL BIOL, V32, P4410, DOI 10.1128/MCB.00930-12; Purro SA, 2012, J NEUROSCI, V32, P3492, DOI 10.1523/JNEUROSCI.4562-11.2012; Rosen EY, 2011, NEURON, V71, P1030, DOI 10.1016/j.neuron.2011.07.021; Rosi MC, 2010, J NEUROCHEM, V112, P1539, DOI 10.1111/j.1471-4159.2009.06566.x; Sastre M, 2006, P NATL ACAD SCI USA, V103, P443, DOI 10.1073/pnas.0503839103; Scali C, 2006, NEUROBIOL DIS, V24, P254, DOI 10.1016/j.nbd.2006.06.016; Smartt HJM, 2012, GUT, V61, P1306, DOI 10.1136/gutjnl-2011-300817; Vacik T, 2011, CELL CYCLE, V10, P4199, DOI 10.4161/cc.10.24.18465; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wexler EM, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002282; Wisniewska MB, 2013, NEUROCHEM RES, V38, P1144, DOI 10.1007/s11064-013-0980-9; Yang G, 2006, J INVEST DERMATOL, V126, P2490, DOI 10.1038/sj.jid.5700470; Yi F, 2011, NAT CELL BIOL, V13, P762, DOI 10.1038/ncb2283; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540; Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752-08.2008; Zhang YW, 2009, NEURON, V64, P328, DOI 10.1016/j.neuron.2009.08.036	46	55	57	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					623	635		10.1096/fj.14-253211	http://dx.doi.org/10.1096/fj.14-253211			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25384422				2022-12-28	WOS:000349370400024
J	Blakeway, LV; Power, PM; Jen, FEC; Worboys, SR; Boitano, M; Clark, TA; Korlach, J; Bakaletz, LO; Jennings, MP; Peak, IR; Seib, KL				Blakeway, Luke V.; Power, Peter M.; Jen, Freda E. -C.; Worboys, Sam R.; Boitano, Matthew; Clark, Tyson A.; Korlach, Jonas; Bakaletz, Lauren O.; Jennings, Michael P.; Peak, Ian R.; Seib, Kate L.			ModM DNA methyltransferase methylome analysis reveals a potential role for Moraxella catarrhalis phasevarions in otitis media	FASEB JOURNAL			English	Article						epigenetic regulation; middle ear infection; phase variation; single-molecule; real-time genome sequencing; SMRT	NASOPHARYNGEAL BACTERIAL-COLONIZATION; PHASE VARIATION; EPIDEMIOLOGY; RESTRICTION; EXPRESSION; INFECTION; PATHOGENS; CHILDREN; SEQUENCE; VACCINE	Moraxella catarrhalis is a significant cause of otitis media and exacerbations of chronic obstructive pulmonary disease. Here, we characterize a phase-variable DNA methyltransferase (ModM), which contains 5'-CAAC-3' repeats in its open reading frame that mediate high-frequency mutation resulting in reversible on/off switching of ModM expression. Three modM alleles have been identified (modM1-3), with modM2 being the most commonly found allele. Using single-molecule, real-time (SMRT) genome sequencing and methylome analysis, we have determined that the ModM2 methylation target is 5'-GAR(m6)AC-3', and 100% of these sites are methylated in the genome of the M. catarrhalis 25239 ModM2 on strain. Proteomic analysis of ModM2 on and off variants revealed that ModM2 regulates expression of multiple genes that have potential roles in colonization, infection, and protection against host defenses. Investigation of the distribution of modM alleles in a panel of M. catarrhalis strains, isolated from the nasopharynx of healthy children or middle ear effusions from patients with otitis media, revealed a statistically significant association of modM3 with otitis media isolates. The modulation of gene expression via the ModM phase-variable regulon (phasevarion), and the significant association of the modM3 allele with otitis media, suggests a key role for ModM phasevarions in the pathogenesis of this organism.	[Blakeway, Luke V.; Power, Peter M.; Jen, Freda E. -C.; Worboys, Sam R.; Jennings, Michael P.; Peak, Ian R.; Seib, Kate L.] Griffith Univ, Inst Glyc, Southport, Qld 4215, Australia; [Peak, Ian R.] Griffith Univ, Sch Med Sci, Southport, Qld 4215, Australia; [Boitano, Matthew; Clark, Tyson A.; Korlach, Jonas] Pacific Biosci, Menlo Pk, CA USA; [Bakaletz, Lauren O.] Nationwide Childrens Hosp, Ctr Microbial Pathogenesis, Res Inst, Columbus, OH USA	Griffith University; Griffith University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital	Seib, KL (corresponding author), Griffith Univ, Inst Glyc, Parklands Dr, Southport, Qld 4215, Australia.	k.seib@griffith.edu.au	Peak, Ian R/C-5677-2009; Seib, Kate L/B-4670-2015; Bakaletz, Lauren/GMW-8490-2022; Jennings, Michael P/G-4822-2013	Seib, Kate L/0000-0002-7094-3528; Jennings, Michael P/0000-0002-1027-4684; Clark, Tyson/0000-0002-7779-3227	Australian National Health and Medical Research Council [565526]; Australian postgraduate award	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian postgraduate award(Australian Government)	This work was supported by the Australian National Health and Medical Research Council (Career Development Fellowship to K.L.S., program grant 565526 to M.P.J.). L.V.B is supported by an Australian postgraduate award. iTRAQ was performed at the Australian Proteome Analysis Facility (Melbourne, VIC, Australia), the infrastructure provided by the Australian government through the National Collaborative Research Infrastructure Strategy.	Bakaletz LO, 2010, J LEUKOCYTE BIOL, V87, P213, DOI 10.1189/jlb.0709518; Bootsma HJ, 2000, MOL MICROBIOL, V36, P93, DOI 10.1046/j.1365-2958.2000.01828.x; Clark TA, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr1146; Davie JJ, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-70; de Vries SPW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072193; de Vries SPW, 2010, J BACTERIOL, V192, P3574, DOI 10.1128/JB.00121-10; Faden H, 1997, J INFECT DIS, V175, P1440, DOI 10.1086/516477; FADEN H, 1994, J INFECT DIS, V169, P1312, DOI 10.1093/infdis/169.6.1312; Fox KL, 2007, NUCLEIC ACIDS RES, V35, P5242, DOI 10.1093/nar/gkm571; Freid V M, 1998, Vital Health Stat 13, P1; Gawthorne JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032337; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Hoopman TC, 2012, INFECT IMMUN, V80, P982, DOI 10.1128/IAI.05918-11; Hoopman TC, 2011, INFECT IMMUN, V79, P745, DOI 10.1128/IAI.01060-10; Jen FEC, 2014, ANTIMICROB AGENTS CH, V58, P4219, DOI 10.1128/AAC.00004-14; Juni E, 2007, BERGEYS MANUAL SYS B, V2; Krebes J, 2014, NUCLEIC ACIDS RES, V42, P2415, DOI 10.1093/nar/gkt1201; Lafontaine ER, 2001, J BACTERIOL, V183, P1540, DOI 10.1128/JB.183.5.1540-1551.2001; Lieberthal AS, 2004, PEDIATRICS, V113, P1451, DOI 10.1542/peds.113.5.1451; Mackenzie GA, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-304; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; Mollenkvist A, 2003, J BACTERIOL, V185, P2285, DOI 10.1128/JB.185.7.2285-2295.2003; Moxon R, 2006, ANNU REV GENET, V40, P307, DOI 10.1146/annurev.genet.40.110405.090442; Murphy TF, 2005, AM J RESP CRIT CARE, V172, P195, DOI 10.1164/rccm.200412-1747OC; Murphy TF, 1996, MICROBIOL REV, V60, P267, DOI 10.1128/MMBR.60.2.267-279.1996; Murphy TF, 2009, EXPERT REV VACCINES, V8, P655, DOI [10.1586/erv.09.28, 10.1586/ERV.09.28]; Murphy TF, 2009, CLIN INFECT DIS, V49, P124, DOI 10.1086/599375; Murray IA, 2012, NUCLEIC ACIDS RES, V40, P11450, DOI 10.1093/nar/gks891; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; Revai K, 2006, PEDIATRICS, V117, P1823, DOI 10.1542/peds.2005-1983; Revai K, 2008, CLIN INFECT DIS, V46, pE34, DOI 10.1086/525856; Roberts RJ, 2010, NUCLEIC ACIDS RES, V38, pD234, DOI 10.1093/nar/gkp874; Seib KL, 2011, FASEB J, V25, P3622, DOI 10.1096/fj.11-183590; Seib KL, 2010, VACCINE, V28, P2416, DOI 10.1016/j.vaccine.2009.12.082; Seib KL, 2002, FEMS IMMUNOL MED MIC, V32, P159; Sethi S, 2008, NEW ENGL J MED, V359, P2355, DOI 10.1056/NEJMra0800353; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Song XM, 2008, J PROTEOME RES, V7, P2952, DOI 10.1021/pr800072x; Srikhanta YN, 2005, P NATL ACAD SCI USA, V102, P5547, DOI 10.1073/pnas.0501169102; Srikhanta YN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027569; Srikhanta YN, 2010, NAT REV MICROBIOL, V8, P196, DOI 10.1038/nrmicro2283; Srikhanta YN, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000400; Vergison A, 2008, VACCINE, V26, pG5, DOI 10.1016/j.vaccine.2008.11.006; Wang W, 2007, INFECT IMMUN, V75, P4959, DOI 10.1128/IAI.00073-07; Wang W, 2007, INFECT IMMUN, V75, P2035, DOI 10.1128/IAI.00609-06; Wang W, 2014, INFECT IMMUN, V82, P2287, DOI 10.1128/IAI.01745-14; Wion D, 2006, NAT REV MICROBIOL, V4, P183, DOI 10.1038/nrmicro1350; Wu HJ, 2010, J PROTEOMICS, V73, P899, DOI 10.1016/j.jprot.2009.12.001; Zomer A, 2012, J BACTERIOL, V194, P6969, DOI 10.1128/JB.01833-12	49	58	58	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5197	5207		10.1096/fj.14-256578	http://dx.doi.org/10.1096/fj.14-256578			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25183669	Green Published			2022-12-28	WOS:000345894500015
J	Lindskog, C; Fagerberg, L; Hallstrom, B; Edlund, K; Hellwig, B; Rahnenfuhrer, J; Kampf, C; Uhlen, M; Ponten, F; Micke, P				Lindskog, Cecilia; Fagerberg, Linn; Hallstrom, Bjorn; Edlund, Karolina; Hellwig, Birte; Rahnenfuehrer, Joerg; Kampf, Caroline; Uhlen, Mathias; Ponten, Fredrik; Micke, Patrick			The lung-specific proteome defined by integration of transcriptomics and antibody-based profiling	FASEB JOURNAL			English	Article						patients; prognosis; expression analysis; in situ detection	TISSUE-SPECIFIC EXPRESSION; GENE-EXPRESSION; SQUAMOUS-CELL; RNA-SEQ; CANCER; ADENOCARCINOMA; IDENTIFICATION; SIGNATURES; DISCOVERY; TOOL	The combined action of multiple cell types is essential for the physiological function of the lung, and increased awareness of the molecular constituents characterizing each cell type is likely to advance the understanding of lung biology and disease. In the current study, we used genome-wide RNA sequencing of normal lung parenchyma and 26 additional tissue types, combined with antibody-based protein profiling, to localize the expression to specific cell types. Altogether, 221 genes were found to be elevated in the lung compared with their expression in other analyzed tissues. Among the gene products were several well-known markers, but also several proteins previously not described in the context of the lung. To link the lungspecific molecular repertoire to human disease, survival associations of pneumocyte-specific genes were assessed by using transcriptomics data from 7 non-small-cell lung cancer (NSCLC) cohorts. Transcript levels of 10 genes (SFTPB, SFTPC, SFTPD, SLC34A2, LAMP3, CACNA2D2, AGER, EMP2, NKX2-1, and NAPSA) were significantly associated with survival in the adenocarcinoma subgroup, thus qualifying as promising biomarker candidates. In summary, based on an integrated omics approach, we identified genes with elevated expression in lung and localized corresponding protein expression to different cell types. As biomarker candidates, these proteins may represent intriguing starting points for further exploration in health and disease.-Lindskog, C., Fagerberg, L., Hallstrom, B., Edlund, K., Hellwig, B., Rahnenfuhrer, J., Kampf, C., Uhlen, M., Ponten, F., Micke, P. The lung-specific proteome defined by integration of transcriptomics and antibody-based profiling.	[Lindskog, Cecilia; Kampf, Caroline; Ponten, Fredrik; Micke, Patrick] Uppsala Univ, Sci Life Lab, Rudbeck Lab, S-75185 Uppsala, Sweden; [Fagerberg, Linn; Hallstrom, Bjorn; Uhlen, Mathias] KTH Royal Inst Technol, Sci Life Lab, Stockholm, Sweden; [Edlund, Karolina; Rahnenfuehrer, Joerg] Leibniz Res Ctr Working Environm & Human Factors, Dortmund, Germany; [Hellwig, Birte] Dortmund Tech Univ, Dept Stat, Dortmund, Germany	Uppsala University; Royal Institute of Technology; Dortmund University of Technology; Leibniz Institut for Arbeitsforschung an der TU Dortmund (IFADO); Dortmund University of Technology	Ponten, F (corresponding author), Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Dag Hammarskjolds Vag 20, S-75185 Uppsala, Sweden.	fredrik.ponten@igp.uu.se	Lindskog, Cecilia/AAE-5462-2019; Uhlen, Mathias/AAV-8746-2021; Lindskog, Cecilia/AAO-2441-2021; Uhlen, Mathias/B-3262-2016	Uhlen, Mathias/0000-0002-4858-8056; Lindskog, Cecilia/0000-0001-5611-1015; Fagerberg, Linn/0000-0003-0198-7137; Rahnenfuhrer, Jorg/0000-0002-8947-440X	Knut and Alice Wallenberg Foundation; PROSPECTS, a 7th Framework grant by the European Directorate [HEALTH-F4-2008-201648/PROSPECTS]; Swedish Cancerfonden; Lions Cancerforskningsfond; Swedish Cancer Society; German Research Foundation (Deutsche Forschungsgemeinschaft) [RA 870/5-1]	Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); PROSPECTS, a 7th Framework grant by the European Directorate; Swedish Cancerfonden; Lions Cancerforskningsfond; Swedish Cancer Society(Swedish Cancer Society); German Research Foundation (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG))	The authors thank the entire staff of the Human Protein Atlas program and the Science for Life Laboratory for valuable contributions, and the Department of Pathology at the Uppsala Akademiska Hospital and the Uppsala Biobank for kindly providing the clinical diagnostics and specimens used in this study. Funding was provided by the Knut and Alice Wallenberg Foundation and PROSPECTS, a 7th Framework grant by the European Directorate (grant agreement HEALTH-F4-2008-201648/PROSPECTS), and the Swedish Cancerfonden. Parts of this work were also supported by research grants from the Lions Cancerforskningsfond and the Swedish Cancer Society (both to P.M). The work of B.H. was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, grant RA 870/5-1).	[Anonymous], 2012, PICARD SEQUENCE ALIG; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Botling J, 2013, CLIN CANCER RES, V19, P194, DOI 10.1158/1078-0432.CCR-12-1139; Boutros PC, 2009, P NATL ACAD SCI USA, V106, P2824, DOI 10.1073/pnas.0809444106; Campbell JD, 2011, RESPIROLOGY, V16, P407, DOI 10.1111/j.1440-1843.2011.01942.x; Carboni GL, 2003, ONCOGENE, V22, P615, DOI 10.1038/sj.onc.1206134; Castleman VH, 2009, AM J HUM GENET, V84, P197, DOI 10.1016/j.ajhg.2009.01.011; Corut A, 2006, AM J HUM GENET, V79, P650, DOI 10.1086/508263; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; GILLESPIE CS, 1994, NEURON, V12, P497, DOI 10.1016/0896-6273(94)90208-9; Gong HC, 2001, J MEMBRANE BIOL, V184, P35, DOI 10.1007/s00232-001-0072-7; Hebenstreit D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.28; Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547; Ho CC, 2008, LUNG CANCER, V59, P105, DOI 10.1016/j.lungcan.2007.07.024; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ishii T, 2012, COPD, V9, P409, DOI 10.3109/15412555.2012.676110; Jongeneel CV, 2005, GENOME RES, V15, P1007, DOI 10.1101/gr.4041005; Joshi N, 2012, SICKLE WINDOWED ADAP; Kampf C, 2012, JOVE-J VIS EXP, DOI 10.3791/3620; Lantuejoul S, 2009, HISTOPATHOLOGY, V54, P43, DOI 10.1111/j.1365-2559.2008.03182.x; Lee JG, 2012, LUNG CANCER, V77, P156, DOI 10.1016/j.lungcan.2012.02.013; Liu Y, 2013, AM J PATHOL, V182, P1519, DOI 10.1016/j.ajpath.2013.01.050; Mulugeta S, 2002, J BIOL CHEM, V277, P22147, DOI 10.1074/jbc.M201812200; Nordgard O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062153; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Raponi M, 2006, CANCER RES, V66, P7466, DOI 10.1158/0008-5472.CAN-06-1191; Rimkunas VM, 2012, CLIN CANCER RES, V18, P4449, DOI 10.1158/1078-0432.CCR-11-3351; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Sin DD, 2013, J CLIN ONCOL, V31, P4536, DOI 10.1200/JCO.2013.50.6105; Solis LM, 2012, CANCER-AM CANCER SOC, V118, P2889, DOI 10.1002/cncr.26584; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Sutherland KD, 2010, MOL ONCOL, V4, P397, DOI 10.1016/j.molonc.2010.05.002; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Ueno T, 2003, BRIT J CANCER, V88, P1229, DOI 10.1038/sj.bjc.6600879; Wadehra M, 2004, MOL BIOL CELL, V15, P2073, DOI 10.1091/mbc.E03-07-0488; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Zariwala MA, 2007, ANNU REV PHYSIOL, V69, P423, DOI 10.1146/annurev.physiol.69.040705.141301; Zhu CQ, 2010, J CLIN ONCOL, V28, P4417, DOI 10.1200/JCO.2009.26.4325	46	42	44	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5184	5196		10.1096/fj.14-254862	http://dx.doi.org/10.1096/fj.14-254862			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25169055				2022-12-28	WOS:000345894500014
J	Besnier, M; Galaup, A; Nicol, L; Henry, JP; Coquerel, D; Gueret, A; Mulder, P; Brakenhielm, E; Thuillez, C; Germain, S; Richard, V; Ouvrard-Pascaud, A				Besnier, Marie; Galaup, Ariane; Nicol, Lionel; Henry, Jean-Paul; Coquerel, David; Gueret, Alexandre; Mulder, Paul; Brakenhielm, Ebba; Thuillez, Christian; Germain, Stephane; Richard, Vincent; Ouvrard-Pascaud, Antoine			Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice	FASEB JOURNAL			English	Article						vascular growth; growth factors; cytokines	ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; IN-VIVO; APOPTOSIS; MOTILITY; RECEPTOR; 1B; PTP-1B; HETEROGENEITY; IMPROVEMENT	The protein tyrosine phosphatase 1B (PTP1B) modulates tyrosine kinase receptors, among which is the vascular endothelial growth factor receptor type 2 (VEGFR2), a key component of angiogenesis. Because PTP1B deficiency in mice improves left ventricular (LV) function 2 mo after myocardial infarction (MI), we hypothesized that enhanced angiogenesis early after MI via activated VEGFR2 contributes to this improvement. At 3 d after MI, capillary density was increased at the infarct border of PTP1B(-/-) mice [+ 7 +/- 2% vs. wild-type (WT), P = 0.05]. This was associated with increased extracellular signal-regulated kinase 2 phosphorylation and VEGFR2 activation (i.e., phosphorylated-Src/Src/VEGFR2 and dissociation of endothelial VEGFR2/VE-cadherin), together with higher infiltration of proangiogenic M2 macrophages within unchanged overall infiltration. In vitro, we showed that PTP1B inhibition or silencing using RNA interference increased VEGF-induced migration and proliferation of mouse heart microvascular endothelial cells as well as fibroblast growth factor (FGF)-induced proliferation of rat aortic smooth muscle cells. At 8 d after MI in PTP1B(-/-) mice, increased LV capillary density (+ 21 +/- 3% vs. WT; P< 0.05) and an increased number of small diameter arteries (15-50 mu m) were likely to participate in increased LV perfusion assessed by magnetic resonance imaging and improved LV compliance, indicating reduced diastolic dysfunction. In conclusion, PTP1B deficiency reduces MI-induced heart failure promptly after ischemia by enhancing angiogenesis, myocardial perfusion, and diastolic function.	[Besnier, Marie; Nicol, Lionel; Henry, Jean-Paul; Coquerel, David; Gueret, Alexandre; Mulder, Paul; Brakenhielm, Ebba; Thuillez, Christian; Richard, Vincent; Ouvrard-Pascaud, Antoine] INSERM, U1096, F-76183 Rouen, France; [Besnier, Marie; Nicol, Lionel; Henry, Jean-Paul; Coquerel, David; Gueret, Alexandre; Mulder, Paul; Brakenhielm, Ebba; Thuillez, Christian; Richard, Vincent; Ouvrard-Pascaud, Antoine] Univ Rouen, IRIB, Rouen, France; [Galaup, Ariane; Germain, Stephane] Coll France, INSERM, Ctr Interdisciplinary Res Biol, U1050, F-75231 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Ouvrard-Pascaud, A (corresponding author), INSERM, UFR Med Pharm, U1096, 22 Bd Gambetta, F-76183 Rouen, France.	antoine.ouvrard-pascaud@univ-rouen.fr	Brakenhielm, Ebba/E-9758-2011; Richard, Vincent/B-1059-2014; Germain, Stephane/E-2301-2016	Brakenhielm, Ebba/0000-0003-3378-8300; Richard, Vincent/0000-0003-0590-0158; Germain, Stephane/0000-0001-5992-1275; Mulder, Paul/0000-0002-5936-5704	Fondation de France; French Ministry of Research and Education; Region Haute Normandie	Fondation de France(Fondation de France); French Ministry of Research and Education; Region Haute Normandie(Region Normandie)	The authors thank Dr. Sebastien Banquet, Dr. Manuelle Debunne, and Ines Boukhalfa for valuable help; Dr. Michel L. Tremblay (Goodman Cancer Centre, McGill University, Montreal, QC, Canada) for providing the PTP1B-deficient mice; and Brigitte Dautreaux, Sylvanie Renet, and Laetitia Guedin for their excellent technical assistance. The study was supported in part by a grant from the Fondation de France. M. B. and A. G. are recipients of a Ph.D. grant from the French Ministry of Research and Education, and D. C. is a recipient of a Ph.D. grant from the Region Haute Normandie. The authors declare no conflicts of interest.	Banquet S, 2011, CIRCULATION, V124, P1059, DOI 10.1161/CIRCULATIONAHA.110.010264; Bauer WR, 1996, MAGNET RESON MED, V35, P43, DOI 10.1002/mrm.1910350107; Brechot N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003950; Buckley DA, 2002, MOL CELL BIOL, V22, P1998, DOI 10.1128/MCB.22.7.1998-2010.2002; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Chang YZ, 2006, ARTERIOSCL THROM VAS, V26, P501, DOI 10.1161/01.ATV.0000201070.71787.b8; Chatelain EH, 2011, CELL MOL LIFE SCI, V68, P2603, DOI 10.1007/s00018-010-0573-6; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Dimmeler S, 2000, CIRC RES, V87, P434; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Fang YH, 2011, J MOL CELL CARDIOL, V51, P168, DOI 10.1016/j.yjmcc.2011.05.012; Galaup A, 2012, CIRCULATION, V125, P140, DOI 10.1161/CIRCULATIONAHA.111.049072; Gomez E, 2012, J MOL CELL CARDIOL, V52, P1257, DOI 10.1016/j.yjmcc.2012.03.003; Gonzalez-Rodriguez A, 2007, J CELL PHYSIOL, V212, P76, DOI 10.1002/jcp.21004; GUMKOWSKI F, 1987, BLOOD VESSELS, V24, P11; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Hassid A, 1999, AM J PHYSIOL-HEART C, V277, pH192, DOI 10.1152/ajpheart.1999.277.1.H192; Hassid A, 1999, AM J PHYSIOL-HEART C, V277, pH1014, DOI 10.1152/ajpheart.1999.277.3.H1014; He HH, 2012, BLOOD, V120, P3152, DOI 10.1182/blood-2012-04-422758; Kakazu A, 2008, INVEST OPHTH VIS SCI, V49, P2927, DOI 10.1167/iovs.07-0709; Kober F, 2004, MAGN RESON MED, V51, P62, DOI 10.1002/mrm.10676; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Lanahan AA, 2010, DEV CELL, V18, P713, DOI 10.1016/j.devcel.2010.02.016; Markova B, 2003, BIOCHEMISTRY-US, V42, P2691, DOI 10.1021/bi0265574; Merabet N, 2012, J MOL CELL CARDIOL, V52, P660, DOI 10.1016/j.yjmcc.2011.11.015; Mulder P, 2004, CIRCULATION, V109, P1674, DOI 10.1161/01.CIR.0000118464.48959.1C; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Nahrendorf M, 2013, CIRC RES, V112, P1624, DOI 10.1161/CIRCRESAHA.113.300890; Nakamura Y, 2008, CIRC RES, V102, P1182, DOI 10.1161/CIRCRESAHA.107.167080; Song HW, 2008, APOPTOSIS, V13, P383, DOI 10.1007/s10495-008-0181-1; Stuible M, 2010, TRENDS CELL BIOL, V20, P672, DOI 10.1016/j.tcb.2010.08.013; Sun ZY, 2012, J EXP MED, V209, P1363, DOI 10.1084/jem.20111343; Vercauteren M, 2006, CIRCULATION, V114, P2498, DOI 10.1161/CIRCULATIONAHA.106.630129; Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702; Westermann D, 2009, BASIC RES CARDIOL, V104, P499, DOI 10.1007/s00395-009-0014-6; Yu J, 2005, P NATL ACAD SCI USA, V102, P10999, DOI 10.1073/pnas.0501444102	37	46	47	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3351	3361		10.1096/fj.13-245753	http://dx.doi.org/10.1096/fj.13-245753			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24760754				2022-12-28	WOS:000340265400007
J	Pfisterer, L; Meyer, R; Feldner, A; Drews, O; Hecker, M; Korff, T				Pfisterer, Larissa; Meyer, Ralph; Feldner, Anja; Drews, Oliver; Hecker, Markus; Korff, Thomas			Bortezomib protects from varicose-like venous remodeling	FASEB JOURNAL			English	Article						proteasome; myocardin; varicose veins; venous smooth muscle cell phenotype	UBIQUITIN-PROTEASOME SYSTEM; SMOOTH-MUSCLE-CELLS; RISK-FACTORS; MYOCARDIN; VEINS; DIFFERENTIATION; INSUFFICIENCY; EPIDEMIOLOGY; DEGRADATION; SUFFICIENT	Despite the high prevalence of venous diseases that are associated with and based on the structural reorganization of the venous vessel wall, not much is known about their mechanistic causes. In this context, we demonstrated that the quantity of myocardin, a transcriptional regulator of the contractile and quiescent smooth muscle cell phenotype, was diminished in proliferating synthetic venous smooth muscle cells (VSMCs) of human and mouse varicose veins by 51 and 60%, respectively. On the basis of the relevance of proteasomal activity for such phenotypic changes, we hypothesized that the observed VSMC activation is attenuated by the proteasome inhibitor bortezomib. This drug fully abolished VSMC proliferation and loss of myocardin in perfused mouse veins and blocked VSMC invasion in collagen gels by almost 80%. In line with this, topical transdermal treatment with bortezomib diminished VSMC proliferation by 80%, rescued 90% of VSMC myocardin abundance, and inhibited varicose-like venous remodeling by 67 to 72% in a mouse model. Collectively, our data indicate that the proteasome plays a pivotal role in VSMC phenotype changes during venous remodeling processes. Its inhibition protects from varicose-like vein remodeling in mice and may thus serve as a putative therapeutic strategy to treat human varicose veins.	[Pfisterer, Larissa; Meyer, Ralph; Feldner, Anja; Drews, Oliver; Hecker, Markus; Korff, Thomas] Heidelberg Univ, Inst Physiol & Pathophysiol, Div Cardiovasc Physiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Korff, T (corresponding author), Heidelberg Univ, Inst Physiol & Pathophysiol, Div Cardiovasc Physiol, Neuenheimer Feld 326, D-69120 Heidelberg, Germany.	korff@physiologie.uni-heidelberg.de			Deutsche Forschungsgemeinschaft [SFB TR23]; German Cardiac Society (DGK); German Society of Phlebology (DGP)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Cardiac Society (DGK); German Society of Phlebology (DGP)	The authors acknowledge the excellent technical assistance of Gudrun Scheib and Maria Harlacher and thank Dr. Bernhard Rumstadt (Furst-Stirum-Klinik, Bruchsal, Germany) and Dr. Stephan Rewerk (Heidelberger Praxisklinik, Heidelberg, Germany) for providing human vein samples. This work was supported by a grant from the Deutsche Forschungsgemeinschaft (SFB TR23, projects C5 and C6), the German Cardiac Society (DGK), and the German Society of Phlebology (DGP).	Atta HM, 2012, INT J VASC MED, V2012, DOI 10.1155/2012/538627; Barringhaus Kurt G, 2007, Exp Clin Cardiol, V12, P119; Beebe-Dimmer JL, 2005, ANN EPIDEMIOL, V15, P175, DOI 10.1016/j.annepidem.2004.05.015; Bunn PA, 2004, CLIN CANCER RES, V10, p4263S, DOI 10.1158/1078-0432.CCR-040011; BURKITT DP, 1976, LANCET, V2, P202; Clark A, 2010, PHLEBOLOGY, V25, P236, DOI 10.1258/phleb.2009.009045; Drews O, 2010, CIRC RES, V107, P1094, DOI 10.1161/CIRCRESAHA.110.222364; Eberhardt RT, 2005, CIRCULATION, V111, P2398, DOI 10.1161/01.CIR.0000164199.72440.08; Feldner A, 2011, FASEB J, V25, P3613, DOI 10.1096/fj.11-185975; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Gomes AV, 2006, ANTIOXID REDOX SIGN, V8, P1677, DOI 10.1089/ars.2006.8.1677; Herrmann J, 2007, CIRC RES, V101, P865, DOI 10.1161/CIRCRESAHA.107.152959; Huang JH, 2008, J CLIN INVEST, V118, P515, DOI [10.1172/JC133304, 10.1172/JCI33304]; Iannuzzi A, 2002, J VASC SURG, V36, P965, DOI 10.1067/mva.2002.128315; Korff T, 2001, FASEB J, V15, P447, DOI 10.1096/fj.00-0139com; Lee AJ, 2003, J CLIN EPIDEMIOL, V56, P171, DOI 10.1016/S0895-4356(02)00518-8; Li S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078564; Lim CS, 2009, BRIT J SURG, V96, P1231, DOI 10.1002/bjs.6798; Long XC, 2008, ARTERIOSCL THROM VAS, V28, P1505, DOI 10.1161/ATVBAHA.108.166066; Pagan J, 2013, CIRC RES, V112, P1046, DOI 10.1161/CIRCRESAHA.112.300521; Parmacek MS, 2007, CIRC RES, V100, P633, DOI 10.1161/01.RES.0000259563.61091.e8; Pfisterer L, 2012, CARDIOVASC RES, V96, P120, DOI 10.1093/cvr/cvs247; Powell SR, 2006, AM J PHYSIOL-HEART C, V291, pH1, DOI 10.1152/ajpheart.00062.2006; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; SCOTT TE, 1995, J VASC SURG, V22, P622, DOI 10.1016/S0741-5214(95)70050-1; Somers P, 2006, ANGIOLOGY, V57, P546, DOI 10.1177/0003319706293115; Tang RH, 2008, P NATL ACAD SCI USA, V105, P3362, DOI 10.1073/pnas.0705842105; Tung D, 2011, PHARMACOLOGY, V88, P100, DOI 10.1159/000330067; Tydlacka S, 2008, J NEUROSCI, V28, P13285, DOI 10.1523/JNEUROSCI.4393-08.2008; Wali MA, 2002, INT ANGIOL, V21, P337; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Weathington NM, 2013, AM J RESP CRIT CARE, V188, P530, DOI 10.1164/rccm.201304-0754PP; Wilck N, 2012, ARTERIOSCL THROM VAS, V32, P1418, DOI 10.1161/ATVBAHA.112.249342; Xie P, 2009, MOL CELL BIOL, V29, P2398, DOI 10.1128/MCB.01737-08; Yoshida T, 2004, ARTERIOSCL THROM VAS, V24, P1596, DOI 10.1161/01.ATV.0000137190.63214.c5	36	10	11	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3518	3527		10.1096/fj.14-250464	http://dx.doi.org/10.1096/fj.14-250464			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24769668				2022-12-28	WOS:000340265400021
J	Sundermeier, TR; Zhang, N; Vinberg, F; Mustafi, D; Kohno, H; Golczak, M; Bai, XD; Maeda, A; Kefalov, VJ; Palczewski, K				Sundermeier, Thomas R.; Zhang, Ning; Vinberg, Frans; Mustafi, Debarshi; Kohno, Hideo; Golczak, Marcin; Bai, Xiaodong; Maeda, Akiko; Kefalov, Vladimir J.; Palczewski, Krzysztof			DICER1 is essential for survival of postmitotic rod photoreceptor cells in mice	FASEB JOURNAL			English	Article						microRNA; retina; conditional knockout; cell survival; age-related macular degeneration	MOUSE RETINA; MACULAR DEGENERATION; MICRORNAS; EYE; IDENTIFICATION; CLUSTER; PHOTOTRANSDUCTION; INACTIVATION; PHAGOCYTOSIS; RHODOPSIN	Photoreceptor cell death is the proximal cause of blindness in many retinal degenerative disorders; hence, understanding the gene regulatory networks that promote photoreceptor survival is at the forefront of efforts to combat blindness. Down-regulation of the microRNA (miRNA)-processing enzyme DICER1 in the retinal pigmented epithelium has been implicated in geographic atrophy, an advanced form of age-related macular degeneration (AMD). However, little is known about the function of DICER1 in mature rod photoreceptor cells, another retinal cell type that is severely affected in AMD. Using a conditional-knockout (cKO) mouse model, we report that loss of DICER1 in mature postmitotic rods leads to robust retinal degeneration accompanied by loss of visual function. At 14 wk of age, cKO mice exhibit a 90% reduction in photoreceptor nuclei and a 97% reduction in visual chromophore compared with those in control littermates. Before degeneration, cKO mice do not exhibit significant defects in either phototransduction or the visual cycle, suggesting that miRNAs play a primary role in rod photoreceptor survival. Using comparative small RNA sequencing analysis, we identified rod photoreceptor miRNAs of the miR-22, miR-26, miR-30, miR-92, miR-124, and let-7 families as potential factors involved in regulating the survival of rods.-Sundermeier, T. R., Zhang, N., Vinberg, F., Mustafi, D., Kohno, H., Golczak, M., Bai, X., Maeda, A., Kefalov, V. J., Palczewski, K. DICER1 is essential for survival of postmitotic rod photoreceptor cells in mice.	[Sundermeier, Thomas R.; Zhang, Ning; Mustafi, Debarshi; Kohno, Hideo; Golczak, Marcin; Maeda, Akiko; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Bai, Xiaodong] Case Western Reserve Univ, Sch Med, Ctr RNA Mol Biol, Cleveland, OH 44106 USA; [Maeda, Akiko] Case Western Reserve Univ, Sch Med, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA; [Vinberg, Frans; Kefalov, Vladimir J.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Washington University (WUSTL)	Palczewski, K (corresponding author), Case Western Reserve Univ, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	kxp65@case.edu	Vinberg, Frans/AAK-8615-2021	Vinberg, Frans/0000-0003-3439-4979; Mustafi, Debarshi/0000-0002-9164-7488; Kefalov, Vladimir/0000-0002-1659-008X	National Eye Institute, U.S. National Institutes of Health [R01EY0022326, R24EY021126, R01EY019312, EY002687, P30EY11373]; Research to Prevent Blindness; Foundation Fighting Blindness; NATIONAL EYE INSTITUTE [F32EY022830, P30EY011373, P30EY002687, R01EY022326, R24EY021126, R01EY019312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	National Eye Institute, U.S. National Institutes of Health; Research to Prevent Blindness(Research to Prevent Blindness (RPB)); Foundation Fighting Blindness(European Commission); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Neena Haider (Harvard Medical School, Cambridge, MA, USA) and Dr. Jason Chen (Virginia Commonwealth University, Richmond, VA, USA) for providing mice, Catherine Doller and Scott Howell of the Case Western Reserve University (CWRU) Visual Science Research Center Histology and Digital Imaging Cores for assistance with histological analysis, and Dr. Leslie T. Webster, Jr. (CWRU) for comments on the article. This work was supported by funding from the National Eye Institute, U.S. National Institutes of Health (grants R01EY0022326 to K. P., R24EY021126 to K. P. and V. J. K., R01EY019312 to V. J. K., EY002687 to the Department of Ophthalmology and Visual Sciences at Washington University, and P30EY11373), Research to Prevent Blindness, and the Foundation Fighting Blindness. K. P. is the John H. Hord Professor of Pharmacology.	ARDEN GB, 1976, J PHYSIOL-LONDON, V256, P333, DOI 10.1113/jphysiol.1976.sp011328; Baudet ML, 2012, NAT NEUROSCI, V15, P29, DOI 10.1038/nn.2979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432; Conte I, 2010, P NATL ACAD SCI USA, V107, P15491, DOI 10.1073/pnas.0914785107; Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140; Damiani D, 2008, J NEUROSCI, V28, P4878, DOI 10.1523/JNEUROSCI.0828-08.2008; Decembrini S, 2009, P NATL ACAD SCI USA, V106, P21179, DOI 10.1073/pnas.0909167106; Georgi SA, 2011, DEV NEUROBIOL, V71, P1153, DOI 10.1002/dneu.20899; Georgi SA, 2010, J NEUROSCI, V30, P4048, DOI 10.1523/JNEUROSCI.4982-09.2010; Golczak M, 2010, J BIOL CHEM, V285, P9667, DOI 10.1074/jbc.M109.063941; Hackler Jr L., INVEST OPHTHALMOL VI, V51, P1823; Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102; Heikkinen H, 2008, VISION RES, V48, P264, DOI 10.1016/j.visres.2007.11.005; Hilgers V, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000396; Iida A, 2011, INVEST OPHTH VIS SCI, V52, P3008, DOI 10.1167/iovs.10-6428; Jeon CJ, 1998, J NEUROSCI, V18, P8936; Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830; Karali M., BMC GENOMICS, V11, P715; Karali M, 2007, INVEST OPHTH VIS SCI, V48, P509, DOI 10.1167/iovs.06-0866; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q; Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027; Krol J, 2010, CELL, V141, P618, DOI 10.1016/j.cell.2010.03.039; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li S, 2005, GENESIS, V41, P73, DOI 10.1002/gene.20097; Li X, 2005, CELL, V123, P1267, DOI 10.1016/j.cell.2005.10.040; Li X, 2009, CELL, V137, P273, DOI 10.1016/j.cell.2009.01.058; Lim C, 2013, NAT NEUROSCI, V16, P1544, DOI 10.1038/nn.3543; Lumayag S, 2013, P NATL ACAD SCI USA, V110, pE507, DOI 10.1073/pnas.1212655110; Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200; Makarev E, 2006, MOL VIS, V12, P1386; Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005; Mustafi D, 2013, FASEB J, V27, P4585, DOI 10.1096/fj.13-237537; Mustafi D, 2011, FASEB J, V25, P3157, DOI 10.1096/fj.11-186767; Nilsen T. W., 2013, COLD SPRING HARB PRO, V2013, P1, DOI DOI 10.1101/PDB.PR0T072611; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; Pinter R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010021; Ryan D, 2006, MOL VIS, V12, P1175; Sanuki R, 2011, NAT NEUROSCI, V14, P1125, DOI 10.1038/nn.2897; Shi G, 2007, J NEUROSCI, V27, P10084, DOI 10.1523/JNEUROSCI.2211-07.2007; Sundermeier TR, 2014, INVEST OPHTH VIS SCI, V55, P1339, DOI 10.1167/iovs.13-13564; Sundermeier TR, 2012, CELL MOL LIFE SCI, V69, P2739, DOI 10.1007/s00018-012-0976-7; Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036; Vinberg FJ, 2009, J VISION, V9, DOI 10.1167/9.12.9; Wang FE, 2010, FASEB J, V24, P1552, DOI 10.1096/fj.08-125856; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057; Xu SB, 2007, J BIOL CHEM, V282, P25053, DOI 10.1074/jbc.M700501200; Yan YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080029; Zhang N, 2013, J CLIN INVEST, V123, P121, DOI 10.1172/JCI66176; Zhu QB, 2011, J BIOL CHEM, V286, P31749, DOI 10.1074/jbc.M111.259028	52	45	45	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3780	3791		10.1096/fj.14-254292	http://dx.doi.org/10.1096/fj.14-254292			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24812086	Green Published			2022-12-28	WOS:000340265400043
J	Wan, M; Soehnlein, O; Tang, X; van der Does, AM; Smedler, E; Uhlen, P; Lindbom, L; Agerberth, B; Haeggstrom, JZ				Wan, Min; Soehnlein, Oliver; Tang, Xiao; van der Does, Anne M.; Smedler, Erik; Uhlen, Per; Lindbom, Lennart; Agerberth, Birgitta; Haeggstrom, Jesper Z.			Cathelicidin LL-37 induces time-resolved release of LTB4 and TXA(2) by human macrophages and triggers eicosanoid generation in vivo	FASEB JOURNAL			English	Article						inflammation; antimicrobial peptides; thromboxane; leukotriene; P2X(7)R	ANTIMICROBIAL PEPTIDE LL-37; HUMAN NEUTROPHILS; THROMBOXANE A(2); LEUKOTRIENE BIOSYNTHESIS; PROSTANOID BIOSYNTHESIS; HUMAN KERATINOCYTES; ACUTE-INFLAMMATION; P2X(7) RECEPTOR; ATHEROSCLEROSIS; CELLS	In humans, LL-37 and eicosanoids are important mediators of inflammation and immune responses. Here we report that LL-37 promotes leukotriene B-4 (LTB4) and thromboxane A(2) (TXA(2)) generation by human monocyte-derived macrophages (HMDMs). LL-37 evokes calcium mobilization apparently via the P2X(7) receptor (P2X(7)R), activation of ERK1/2 and p38 MAPKs, as well as cytosolic phospholipase A(2) (cPLA(2)) and 5-lipoxygenase in HMDMs, leading to an early (1 h) release of LTB4. Similarly, TXA(2) production at an early time involved the same signaling sequence along an LL-37-P2X(7)R-cPLA(2)-cyclooxygenase-1 (COX-1) axis. However, at later (6-8 h) time points, internalized LL-37 up-regulates COX-2 expression, promoting TXA(2) production. Furthermore, intraperitoneal injection of mice with murine cathelicidin-related antimicrobial peptide (mCRAMP) induces significantly higher levels of LTB4 and TXA(2) in mouse ascites rich in macrophages. Conversely, cathelicidin-deficient (Cnlp(-/-)) mice produce much less LTB4 and TXB2 in vivo in response to TNF-alpha compared with control mice. We conclude that LL-37 elicits a biphasic release of eicosanoids in macrophages with early, Ca2+ -dependent formation of LTB4 and TXA(2) followed by a late peak of TXA(2), generated via induction of COX-2 by internalized LL-37, thus allowing eicosanoid production in a temporally controlled manner. Moreover, our findings provide evidence that LL-37 is an endogenous regulator of eicosanoid-dependent inflammatory responses in vivo.	[Wan, Min; Tang, Xiao; Agerberth, Birgitta; Haeggstrom, Jesper Z.] Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden; [van der Does, Anne M.; Lindbom, Lennart] Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; [Smedler, Erik; Uhlen, Per] Karolinska Inst, Div Mol Neurobiol, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; [Soehnlein, Oliver] Univ Munich, Inst Cardiovasc Prevent, Munich, Germany; [Soehnlein, Oliver] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Soehnlein, Oliver] German Ctr Cardiovasc Res DZHK, Munich Heart Alliance, Munich, Germany	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Munich; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; German Centre for Cardiovascular Research; Munich Heart Alliance	Haeggstrom, JZ (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden.	jesper.haeggstrom@ki.se	van der Does, Anne M./AAA-2247-2022	van der Does, Anne M./0000-0002-1613-106X; Smedler, Erik/0000-0003-4609-3620; Uhlen, Per/0000-0003-1446-1062	Swedish Research Council [10350, 11217, 20854, 04342]; CIDaT, EC FP7 [201668]; Torsten Soderberg Foundation; Swedish Foundation for Strategic Research [RBd08-0014]; Swedish Cancer Society [CAN 2011/559]; Netherlands Organisation for Scientific Research (NOW; Vidi Project) [91712303]; Deutsche Forschungsgemeinschaft (DFG) [SO876/3-1, SO876/6-1, FOR809, SFB914-B08]; LMU excellence initiative; Knut and Alice Wallenberg Foundation; thematic center of cardiovascular diseases (CVP); Karolinska Institutet	Swedish Research Council(Swedish Research CouncilEuropean Commission); CIDaT, EC FP7; Torsten Soderberg Foundation; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Cancer Society(Swedish Cancer Society); Netherlands Organisation for Scientific Research (NOW; Vidi Project); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); LMU excellence initiative; Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); thematic center of cardiovascular diseases (CVP); Karolinska Institutet(Karolinska Institutet)	The authors are grateful to Dr. Fabio Luiz D'Alexandri and Mats Hamberg for help with LC-MS/MS and GC-MS analyses. This study was supported by the Swedish Research Council (10350, 11217, 20854, 04342, Linneus grant CERIC), CIDaT, EC FP7 funding (201668), the Torsten Soderberg Foundation, the Swedish Foundation for Strategic Research (RBd08-0014), and the Swedish Cancer Society (CAN 2011/559). O.S. is supported by the Netherlands Organisation for Scientific Research (NOW; Vidi Project 91712303), the Deutsche Forschungsgemeinschaft (DFG; SO876/3-1, SO876/6-1, FOR809, SFB914-B08), and the LMU excellence initiative. The Center of Live Imaging of Cells at Karolinska (CLICK) Institutet was funded by the Knut and Alice Wallenberg Foundation. J.Z.H. was supported by the thematic center of cardiovascular diseases (CVP) and a Distinguished Professor Award from Karolinska Institutet. The authors declare no conflicts of interest.	Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Arulkumaran N, 2011, EXPERT OPIN INV DRUG, V20, P897, DOI 10.1517/13543784.2011.578068; Bandholtz L, 2006, SCAND J IMMUNOL, V63, P410, DOI 10.1111/j.1365-3083.2006.001752.x; Bowdish DME, 2004, J IMMUNOL, V172, P3758, DOI 10.4049/jimmunol.172.6.3758; Chen X, 2013, BIOCHEM BIOPH RES CO, V433, P532, DOI 10.1016/j.bbrc.2013.03.024; Chotjumlong P, 2013, J INNATE IMMUN, V5, P72, DOI 10.1159/000342928; Ciornei Cristina D, 2006, BMC Cardiovasc Disord, V6, P49, DOI 10.1186/1471-2261-6-49; Cyrus T, 2007, BLOOD, V109, P3291, DOI 10.1182/blood-2006-08-044990; Daniel TO, 1999, CANCER RES, V59, P4574; Doring Y, 2012, CIRC RES, V110, P1052, DOI 10.1161/CIRCRESAHA.112.265868; Edfeldt K, 2006, ARTERIOSCL THROM VAS, V26, P1551, DOI 10.1161/01.ATV.0000223901.08459.57; Egan KM, 2005, CIRCULATION, V111, P334, DOI 10.1161/01.CIR.0000153386.95356.78; Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987; Esser J, 2010, J ALLERGY CLIN IMMUN, V126, P1032, DOI 10.1016/j.jaci.2010.06.039; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gabrielsen A, 2010, J MOL MED, V88, P795, DOI 10.1007/s00109-010-0621-6; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Haeggstrom JZ, 2011, CHEM REV, V111, P5866, DOI 10.1021/cr200246d; Kobayashi T, 2004, J CLIN INVEST, V114, P784, DOI 10.1172/JCI200421446; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Lau YE, 2005, INFECT IMMUN, V73, P583, DOI 10.1128/IAI.73.1.583-591.2005; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Levy BD, 2014, ANNU REV PHYSIOL, V76, P467, DOI 10.1146/annurev-physiol-021113-170408; Miller CM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002212; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Naraba H, 1998, J IMMUNOL, V160, P2974; Nilsson MF, 1999, INFECT IMMUN, V67, P2561, DOI 10.1128/IAI.67.5.2561-2566.1999; Niyonsaba F, 2001, EUR J IMMUNOL, V31, P1066, DOI 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Perez-Chacon G, 2009, BBA-MOL CELL BIOL L, V1791, P1103, DOI 10.1016/j.bbalip.2009.08.007; Radmark O, 2010, BIOCHEM BIOPH RES CO, V396, P105, DOI 10.1016/j.bbrc.2010.02.173; Rouzer CA, 2009, J LIPID RES, V50, pS29, DOI 10.1194/jlr.R800042-JLR200; Smith WL, 2011, CHEM REV, V111, P5821, DOI 10.1021/cr2002992; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Soehnlein O, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002531; Sorensen O, 1997, BLOOD, V90, P2796; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Tokumaru S, 2005, J IMMUNOL, V175, P4662, DOI 10.4049/jimmunol.175.7.4662; van der Does AM, 2010, J IMMUNOL, V185, P1442, DOI 10.4049/jimmunol.1000376; Wan M, 2007, FASEB J, V21, P2897, DOI 10.1096/fj.06-7974com; Wan M, 2014, J LEUKOCYTE BIOL, V95, P971, DOI 10.1189/jlb.0513304; Wan M, 2011, FASEB J, V25, P1697, DOI 10.1096/fj.10-175687; Wantha S, 2013, CIRC RES, V112, P792, DOI 10.1161/CIRCRESAHA.112.300666; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Zhang ZF, 2009, EUR J IMMUNOL, V39, P3181, DOI 10.1002/eji.200939496	50	29	29	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3456	3467		10.1096/fj.14-251306	http://dx.doi.org/10.1096/fj.14-251306			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24736410				2022-12-28	WOS:000340265400016
J	Lee, HW; Singh, TD; Lee, SW; Ha, JH; Rehemtulla, A; Ahn, BC; Jeon, YH; Lee, J				Lee, Ho Won; Singh, Thoudam Debraj; Lee, Sang-Woo; Ha, Jeoung-Hee; Rehemtulla, Alnawaz; Ahn, Byeong-Cheol; Jeon, Young Hyun; Lee, Jaetae			Evaluation of therapeutic effects of natural killer (NK) cell-based immunotherapy in mice using in vivo apoptosis bioimaging with a caspase-3 sensor	FASEB JOURNAL			English	Article						glioma; molecular imaging; Renilla luciferase	LEUKEMIA-CELLS; CANCER-CELLS; GENE; LINE; ACTIVATION; EXPRESSION; PROMOTER; VIRUSES; LIGAND; NK-92	Natural killer (NK) cell-based immunotherapy is a promising strategy for cancer treatment, and caspase-3 is an important effector molecule in NK cell-mediated apoptosis in cancers. Here, we evaluated the antitumor effects of NK cell-based immunotherapy by serial noninvasive imaging of apoptosis using a caspase-3 sensor in mice with human glioma xenografts. Human glioma cells expressing both a caspase-3 sensor as a surrogate marker for caspase-3 activation and Renilla luciferase (Rluc) as a surrogate marker for cell viability were established and referred to as D54-CR cells. Human NK92 cells were used as effector cells. Treatment with NK92 cells resulted in a time-and effector number-dependent increase in bioluminescence imaging (BLI) activity of the caspase-3 sensor in D54-CR cells in vitro. Caspase-3 activation by NK92 treatment was blocked by Z-VAD treatment in D54-CR cells. Transfusion of NK92 cells induced an increase of the BLI signal by caspase-3 activation in a dose-and time-dependent manner in D54-CR tumor-bearing mice but not in PBS-treated mice. Accordingly, sequential BLI with the Rluc reporter gene revealed marked retardation of tumor growth in the NK92-treatment group but not in the PBS-treatment group. These data suggest that noninvasive imaging of apoptosis with a caspase-3 sensor can be used as an effective tool for evaluation of therapeutic efficacy as well as for optimization of NK cell-based immunotherapy.	[Lee, Ho Won; Singh, Thoudam Debraj; Lee, Sang-Woo; Ahn, Byeong-Cheol; Jeon, Young Hyun; Lee, Jaetae] Kyungpook Natl Univ, Dept Nucl Med, Taegu, South Korea; [Ha, Jeoung-Hee] Kyungpook Natl Univ, Dept Nucl Med, Taegu, South Korea; [Rehemtulla, Alnawaz] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	Kyungpook National University; Kyungpook National University; University of Michigan System; University of Michigan	Jeon, YH (corresponding author), Kyungpook Natl Univ Hosp, Leading Edge Res Ctr Drug Discovery & Dev Diabet, 807 Hogukro, Taegu 702210, South Korea.	jeon9014@gmail.com; jaetae@knu.ac.kr	Lee, Jaetae/ABF-3980-2020; Lee, Jaetae/AAR-3317-2021	SINGH, THOUDAM DEBRAJ/0000-0003-0750-9136	Republic of Korea National Research Foundation (NRF) - Ministry of Education, Science, and Technology (MEST) [2009-0078234]; National Nuclear R&D Program through the NRF (MEST) [2012M2A2A7014020]; Repbulic of Korea Health Technology R&D Project, Ministry of Health and Welfare [A111345]; Regional Technology Innovation Program of the Ministry of Knowledge Economy (MKE) [RTI04-01-01]; Kyungpook National University Research Fund	Republic of Korea National Research Foundation (NRF) - Ministry of Education, Science, and Technology (MEST); National Nuclear R&D Program through the NRF (MEST); Repbulic of Korea Health Technology R&D Project, Ministry of Health and Welfare; Regional Technology Innovation Program of the Ministry of Knowledge Economy (MKE)(Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea); Kyungpook National University Research Fund	This work was supported by a Republic of Korea National Research Foundation (NRF) grant funded by the Ministry of Education, Science, and Technology (MEST; 2009-0078234), by the National Nuclear R&D Program through the NRF (MEST grant 2012M2A2A7014020), by the Repbulic of Korea Health Technology R&D Project, Ministry of Health and Welfare (grant A111345), by the Regional Technology Innovation Program of the Ministry of Knowledge Economy (MKE; grant RTI04-01-01), and by the Kyungpook National University Research Fund (2013).	Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Cerwenka A, 2001, NAT REV IMMUNOL, V1, P41, DOI 10.1038/35095564; Coppola JM, 2008, CLIN CANCER RES, V14, P2492, DOI 10.1158/1078-0432.CCR-07-0782; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Hori T, 2010, J ORTHOP RES, V28, P739, DOI 10.1002/jor.21056; Ishikawa E, 2004, INT J RADIAT ONCOL, V59, P1505, DOI 10.1016/j.ijrobp.2004.04.046; Jacob D, 2004, CLIN CANCER RES, V10, P3535, DOI 10.1158/1078-0432.CCR-03-0512; Jeon YH, 2010, MOL CANCER THER, V9, P126, DOI 10.1158/1535-7163.MCT-09-0540; Kepp O, 2011, NAT REV DRUG DISCOV, V10, P221, DOI 10.1038/nrd3373; Lanier LL, 2008, NAT REV IMMUNOL, V8, P259, DOI 10.1038/nri2276; Lin TY, 2002, ONCOGENE, V21, P8020, DOI 10.1038/sj.onc.1205926; McQueen KL, 2002, CURR OPIN IMMUNOL, V14, P615, DOI 10.1016/S0952-7915(02)00380-1; MELDER RJ, 1993, CANCER RES, V53, P5867; Muller T, 2008, CANCER IMMUNOL IMMUN, V57, P411, DOI 10.1007/s00262-007-0383-3; Nagashima S, 1998, BLOOD, V91, P3850, DOI 10.1182/blood.V91.10.3850.3850_3850_3861; Nowosielska EM, 2011, INT J RADIAT BIOL, V87, P202, DOI 10.3109/09553002.2010.519422; Ramakrishnan R, 2010, J CLIN INVEST, V120, P1111, DOI 10.1172/JCI40269; Reefman E, 2010, J IMMUNOL, V184, P4852, DOI 10.4049/jimmunol.0803954; Reid GSD, 2002, CLIN EXP IMMUNOL, V129, P265, DOI 10.1046/j.1365-2249.2002.01919.x; Rosen D, 2000, J IMMUNOL, V164, P3229, DOI 10.4049/jimmunol.164.6.3229; Screpanti V, 2005, MOL IMMUNOL, V42, P495, DOI 10.1016/j.molimm.2004.07.033; Shi J, 2008, BLOOD, V111, P1309, DOI 10.1182/blood-2007-03-078535; Tam YK, 2003, CYTOTHERAPY, V5, P259, DOI 10.1080/14653240310001523; Terme M, 2008, NAT IMMUNOL, V9, P486, DOI 10.1038/ni1580; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; Uherek C, 2002, BLOOD, V100, P1265, DOI 10.1182/blood.V100.4.1265.h81602001265_1265_1273; Yan Y, 1998, CLIN CANCER RES, V4, P2859; Zamai L, 2007, J IMMUNOL, V178, P4011, DOI 10.4049/jimmunol.178.7.4011	28	14	17	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2932	2941		10.1096/fj.13-243014	http://dx.doi.org/10.1096/fj.13-243014			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24736413	Green Submitted			2022-12-28	WOS:000337949400017
J	Omairi-Nasser, A; Haselkorn, R; Austin, J				Omairi-Nasser, Amin; Haselkorn, Robert; Austin, Jotham, II			Visualization of channels connecting cells in filamentous nitrogen-fixing cyanobacteria	FASEB JOURNAL			English	Article						Anabaena; heterocysts; communication; tomography	HETEROCYST-FORMING CYANOBACTERIUM; ANABAENA-SP PCC-7120; INTERCELLULAR MOLECULAR-EXCHANGE; PATTERN-FORMATION; PROTEIN; MUTANTS; DIFFERENTIATION; INTEGRITY; HETR; LOCALIZATION	Cyanobacteria, formerly called blue-green algae, are abundant bacteria that carry out green plant photosynthesis, fixing CO2 and generating O-2. Many species can also fix N-2 when reduced nitrogen sources are scarce. Many studies imply the existence of intracellular communicating channels in filamentous cyanobacteria, in particular, the nitrogen-fixing species. In a species such as Anabaena, growth in nitrogendepleted medium, in which similar to 10% of the cells differentiate into anaerobic factories for nitrogen fixation (heterocysts), requires the transport of amino acids from heterocysts to vegetative cells, and reciprocally, the transport of sugar from vegetative cells to heterocysts. Convincing physical evidence for such channels has been slim. Using improved preservation of structure by high-pressure rapid freezing of samples for electron microscopy, coupled with high-resolution 3D tomography, it has been possible to visualize and measure the dimensions of channels that breach the peptidoglycan between vegetative cells and between heterocysts and vegetative cells. The channels appear to be straight tubes, 21 nm long and 14 nm in diameter for the latter and 12 nm long and 12 nm in diameter for the former.	[Omairi-Nasser, Amin; Haselkorn, Robert; Austin, Jotham, II] Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; [Austin, Jotham, II] Univ Chicago, Adv Electron Microscopy Facil, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Haselkorn, R (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 East 58th St, Chicago, IL 60637 USA.	rh01@uchicago.edu			Ellison Medical Foundation; University of Chicago	Ellison Medical Foundation(Lawrence Ellison Foundation); University of Chicago(University of Chicago)	This work was supported by the Ellison Medical Foundation and the University of Chicago. The authors thank the Electron Microscopy Core Facility at the University of Chicago, and David Mastronarde (University of Colorado, Boulder, CO, USA) for providing essential application software and support (IMOD and Serial EM). Birgitta Bergman (Stockholm University, Stockholm, Sweden) provided useful advice. Author contributions: A.O.-N. and J.A. performed the experiments, analyzed the results, and wrote the article; R. H. suggested the project, supervised the work, and contributed to the article.	Austin JR, 2014, METHODS MOL BIOL, V1062, P473, DOI 10.1007/978-1-62703-580-4_25; BAUER CC, 1995, J BACTERIOL, V177, P1520, DOI 10.1128/jb.177.6.1520-1526.1995; Beveridge TJ, 1999, J BACTERIOL, V181, P4725, DOI 10.1128/JB.181.16.4725-4733.1999; Buikema WJ, 2001, P NATL ACAD SCI USA, V98, P2729, DOI 10.1073/pnas.051624898; BUIKEMA WJ, 1991, J BACTERIOL, V173, P1879, DOI 10.1128/jb.173.6.1879-1885.1991; Callahan SM, 2001, MOL MICROBIOL, V40, P941, DOI 10.1046/j.1365-2958.2001.02437.x; Cumino AC, 2007, PLANT PHYSIOL, V143, P1385, DOI 10.1104/pp.106.091736; Flores E, 2007, J BACTERIOL, V189, P3884, DOI 10.1128/JB.00085-07; GIDDINGS TH, 1978, CYTOBIOLOGIE, V16, P235; GIDDINGS TH, 1981, ARCH MICROBIOL, V129, P295, DOI 10.1007/BF00414700; GILKEY JC, 1986, J ELECTRON MICR TECH, V3, P177, DOI 10.1002/jemt.1060030206; Golden JW, 2003, CURR OPIN MICROBIOL, V6, P557, DOI 10.1016/j.mib.2003.10.004; Haselkorn R, 2008, MOL MICROBIOL, V70, P783, DOI 10.1111/j.1365-2958.2008.06475.x; Higa KC, 2012, MOL MICROBIOL, V83, P682, DOI 10.1111/j.1365-2958.2011.07949.x; Huang X, 2004, P NATL ACAD SCI USA, V101, P4848, DOI 10.1073/pnas.0400429101; JUTTNER F, 1983, J BACTERIOL, V155, P628; Khudyakov IY, 2004, P NATL ACAD SCI USA, V101, P16040, DOI 10.1073/pnas.0405572101; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; KUMAR A, 1981, Z ALLG MIKROBIOL, V21, P353, DOI 10.1002/jobm.3630210502; Li JH, 2003, MICROBIOL-SGM, V149, P3257, DOI 10.1099/mic.0.26462-0; Mariscal V, 2007, MOL MICROBIOL, V65, P1139, DOI 10.1111/j.1365-2958.2007.05856.x; Martin-Figueroa E, 2000, FEBS LETT, V476, P282, DOI 10.1016/S0014-5793(00)01722-1; Merino-Puerto V, 2011, MOL MICROBIOL, V82, P87, DOI 10.1111/j.1365-2958.2011.07797.x; Merino-Puerto V, 2010, MOL MICROBIOL, V75, P1159, DOI 10.1111/j.1365-2958.2009.07031.x; Mullineaux CW, 2008, EMBO J, V27, P1299, DOI 10.1038/emboj.2008.66; Nayar AS, 2007, MICROBIOL-SGM, V153, P601, DOI 10.1099/mic.0.2006/002535-0; Olive J, 1997, BBA-BIOENERGETICS, V1319, P275, DOI 10.1016/S0005-2728(96)00168-5; Sherman DM, 2000, J PHYCOL, V36, P932, DOI 10.1046/j.1529-8817.2000.99132.x; Ughy B, 2004, MICROBIOL-SGM, V150, P4147, DOI 10.1099/mic.0.27498-0; Valladares A, 2003, MOL MICROBIOL, V47, P1239, DOI 10.1046/j.1365-2958.2003.03372.x; Valladares A, 2007, J BACTERIOL, V189, P4425, DOI 10.1128/JB.00220-07; Vargas WA, 2011, PLANTA, V233, P153, DOI 10.1007/s00425-010-1288-5; WILCOX M, 1973, J CELL SCI, V13, P637; Wilk L, 2011, CELL MICROBIOL, V13, P1744, DOI 10.1111/j.1462-5822.2011.01655.x; Yoon HS, 1998, SCIENCE, V282, P935, DOI 10.1126/science.282.5390.935; Yoon HS, 2001, J BACTERIOL, V183, P2605, DOI 10.1128/JB.183.8.2605-2613.2001; Zhang LC, 2008, MOL MICROBIOL, V70, P814, DOI 10.1111/j.1365-2958.2008.06476.x	37	20	20	0	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3016	3022		10.1096/fj.14-252007	http://dx.doi.org/10.1096/fj.14-252007			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24675362				2022-12-28	WOS:000337949400024
J	Lopez-Ramirez, MA; Wu, D; Pryce, G; Simpson, JE; Reijerkerk, A; King-Robson, J; Kay, O; De Vries, HE; Hirst, MC; Sharrack, B; Baker, D; Male, DK; Michael, GJ; Romero, IA				Lopez-Ramirez, Miguel Alejandro; Wu, Dongsheng; Pryce, Gareth; Simpson, Julie E.; Reijerkerk, Arie; King-Robson, Josh; Kay, Oliver; de Vries, Helga E.; Hirst, Mark C.; Sharrack, Basil; Baker, David; Male, David Kingsley; Michael, Gregory J.; Romero, Ignacio Andres			MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation	FASEB JOURNAL			English	Article						multiple sclerosis; neurovascular dysfunction; junctional complex molecules; focal adhesion	GROWTH-FACTOR; CLAUDIN-5 EXPRESSION; ADHESION; ALPHA; CONTRIBUTES; CELLS; TRANSCRIPTOME; MORPHOGENESIS; INFLAMMATION; ACTIVATION	Blood-brain barrier (BBB) dysfunction is a hallmark of neurological conditions such as multiple sclerosis (MS) and stroke. However, the molecular mechanisms underlying neurovascular dysfunction during BBB breakdown remain elusive. MicroRNAs (miRNAs) have recently emerged as key regulators of pathogenic responses, although their role in central nervous system (CNS) microvascular disorders is largely unknown. We have identified miR-155 as a critical miRNA in neuro-inflammation at the BBB. miR-155 is expressed at the neurovascular unit of individuals with MS and of mice with experimental autoimmune encephalomyelitis (EAE). In mice, loss of miR-155 reduced CNS extravasation of systemic tracers, both in EAE and in an acute systemic inflammation model induced by lipopolysaccharide. In cultured human brain endothelium, miR-155 was strongly and rapidly upregulated by inflammatory cytokines. miR-155 up-regulation mimicked cytokine-induced alterations in junctional organization and permeability, whereas inhibition of endogenous miR-155 partially prevented a cytokine-induced increase in permeability. Furthermore, miR-155 modulated brain endothelial barrier function by targeting not only cell-cell complex molecules such as annexin-2 and claudin-1, but also focal adhesion components such as DOCK-1 and syntenin-1. We propose that brain endothelial miR-155 is a negative regulator of BBB function that may constitute a novel therapeutic target for CNS neuroinflammatory disorders.	[Lopez-Ramirez, Miguel Alejandro; Wu, Dongsheng; Hirst, Mark C.; Male, David Kingsley; Romero, Ignacio Andres] Open Univ, Dept Life Hlth & Chem Sci, Biomed Res Network, Milton Keynes MK7 6AA, Bucks, England; [Pryce, Gareth; King-Robson, Josh; Kay, Oliver; Baker, David; Michael, Gregory J.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, Ctr Neurosci & Trauma, London, England; [Simpson, Julie E.] Univ Sheffield, Sheffield Inst Translat Neurosci, Sheffield, S Yorkshire, England; [Sharrack, Basil] Univ Sheffield, Sheffield Teaching Hosp, Dept Neurol, Natl Hlth Serv NHS, Sheffield, S Yorkshire, England; [Reijerkerk, Arie; de Vries, Helga E.] Vrije Univ Amsterdam, Med Ctr, Blood Brain Barrier Res Grp, Amsterdam, Netherlands	Open University - UK; University of London; Queen Mary University London; University of Sheffield; University of Sheffield; Vrije Universiteit Amsterdam	Romero, IA (corresponding author), Open Univ, Dept Life Hlth & Chem Sci, Biomed Res Network, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.	nacho.romero@open.ac.uk	Simpson, Julie/C-7914-2009	Simpson, Julie/0000-0002-3753-4271; Male, David/0000-0002-1242-3137; de Vries, Helga/0000-0001-7904-7124; King-Robson, Josh/0000-0002-3662-9404; Hirst, Mark/0000-0003-3851-9740; Romero, Ignacio/0000-0002-0322-9180	Multiple Sclerosis Society	Multiple Sclerosis Society(National Multiple Sclerosis Society)	The authors thank J. Barkans for general laboratory infrastructure assistance; J. Brown and P. Rezaie for preparation of the MS samples for histological characterization; R. Waller for preparation of samples for LCM; and C. Hare and C. O'Rourke for reviewing the manuscript. This work was funded by the Multiple Sclerosis Society. Tissue samples and associated clinical and neuropathological data were supplied by the UK MS Tissue Bank.	ABBOTT NJ, 1992, J CELL SCI, V103, P23; Al-Izki S, 2011, MULT SCLER J, V17, P939, DOI 10.1177/1352458511400476; Lopez-Ramirez MA, 2012, J IMMUNOL, V189, P3130, DOI 10.4049/jimmunol.1103460; Baltimore D, 2008, NAT IMMUNOL, V9, P839, DOI 10.1038/ni.f.209; Beekman JM, 2008, J CELL SCI, V121, P1349, DOI 10.1242/jcs.026401; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Dunand-Sauthier I, 2011, BLOOD, V117, P4490, DOI 10.1182/blood-2010-09-308064; Epting D, 2010, CIRC RES, V107, P45, DOI 10.1161/CIRCRESAHA.109.213983; Fabis MJ, 2008, P NATL ACAD SCI USA, V105, P15511, DOI 10.1073/pnas.0807656105; Fletcher NF, 2012, GASTROENTEROLOGY, V142, P634, DOI 10.1053/j.gastro.2011.11.028; Forster C, 2008, J PHYSIOL-LONDON, V586, P1937, DOI 10.1113/jphysiol.2007.146852; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hoffmann A, 2011, TRANSL STROKE RES, V2, P106, DOI 10.1007/s12975-010-0049-x; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hwangbo C, 2010, CANCER RES, V70, P1645, DOI 10.1158/0008-5472.CAN-09-2447; Inai T, 1999, EUR J CELL BIOL, V78, P849, DOI 10.1016/S0171-9335(99)80086-7; Junker A, 2009, BRAIN, V132, P3342, DOI 10.1093/brain/awp300; Komander D, 2008, MOL BIOL CELL, V19, P4837, DOI 10.1091/mbc.E08-04-0345; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Liebner S, 2000, ACTA NEUROPATHOL, V100, P323, DOI 10.1007/s004010000180; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez-Ramirez MA, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-27; Manaenko A, 2011, J NEUROSCI METH, V195, P206, DOI 10.1016/j.jneumeth.2010.12.013; Mankertz J, 2000, J CELL SCI, V113, P2085; Murakami T, 2009, J BIOL CHEM, V284, P21036, DOI 10.1074/jbc.M109.016766; Murugaiyan G, 2011, J IMMUNOL, V187, P2213, DOI 10.4049/jimmunol.1003952; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009; Obernosterer G, 2007, NAT PROTOC, V2, P1508, DOI 10.1038/nprot.2007.153; Osada T, 2011, J CEREBR BLOOD F MET, V31, P1972, DOI 10.1038/jcbfm.2011.99; Pfeiffer F, 2011, ACTA NEUROPATHOL, V122, P601, DOI 10.1007/s00401-011-0883-2; Pottier N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006718; Reijerkerk A, 2013, J NEUROSCI, V33, P6857, DOI 10.1523/JNEUROSCI.3965-12.2013; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Schlegel N, 2009, J CELL PHYSIOL, V220, P357, DOI 10.1002/jcp.21772; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Simpson JE, 2011, NEUROBIOL AGING, V32, P1795, DOI 10.1016/j.neurobiolaging.2011.04.013; Su SC, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M110.157271; Sun HX, 2012, HYPERTENSION, V60, P1407, DOI 10.1161/HYPERTENSIONAHA.112.197301; Wolburg H, 2003, ACTA NEUROPATHOL, V105, P586, DOI 10.1007/s00401-003-0688-z; Xu GR, 2010, RNA, V16, P1610, DOI 10.1261/rna.2194910; Yao R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046082; Zaidel-Bar R, 2007, NAT CELL BIOL, V9, P858, DOI 10.1038/ncb0807-858; Ziegler WH, 2008, BIOCHEM SOC T, V36, P235, DOI 10.1042/BST0360235	47	191	197	2	55	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2551	2565		10.1096/fj.13-248880	http://dx.doi.org/10.1096/fj.13-248880			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24604078	Green Submitted, Green Accepted			2022-12-28	WOS:000339883600015
J	Xiang, C; Wang, JC; Kou, XC; Chen, XB; Qin, ZY; Jiang, Y; Sun, C; Xu, JB; Tan, W; Jin, L; Lin, DX; He, FC; Wang, HJ				Xiang, Chan; Wang, Jiucun; Kou, Xiaochen; Chen, Xiabin; Qin, Zhaoyu; Jiang, Yan; Sun, Chang; Xu, Jibin; Tan, Wen; Jin, Li; Lin, Dongxin; He, Fuchu; Wang, Haijian			Pulmonary expression of CYP2A13 and ABCB1 is regulated by FOXA2, and their genetic interaction is associated with lung cancer	FASEB JOURNAL			English	Article						xenobiotic metabolizing enzyme; gene expression regulation; polymorphism; association study; respiratory toxicology	TOBACCO-SPECIFIC CARCINOGEN; MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN; TRANSCRIPTIONAL REGULATION; METABOLIC-ACTIVATION; POSITIVE SELECTION; POLYMORPHISM; CYTOCHROME-P450; SMOKING; RISK	Inhaled xenobiotics such as tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone are mainly metabolized by phase I oxidase cytochrome P450, family 2, subfamily A, polypeptide 13 (CYP2A13), phase II conjugate UDP glucuronosyltransferase 2 family, polypeptide B17 (UGT2B17), and phase III transporter ATP-binding cassette, subfamily B (MDR/TAP), member 1 (ABCB1), with genetic polymorphisms implicated in lung cancer. Their genetic interaction and pulmonary expression regulation are largely unknown. We analyzed joint association for CYP2A13 and ABCB1 polymorphisms in 2 independent lung cancer case populations (669 and 566 patients) and 1 common control population (749 subjects), and characterized the trans-acting function of the lung development-related transcription factor forkhead box A2 (FOXA2). We undertook FOXA2 overexpression and down-regulation in lung epithelial cell lines, analyzed functional impact on the transactivation of CYP2A13, UGT2B17, and ABCB1, and measured correlation for their expressions in lung tissues. We found a substantial reduction in cancer risk (OR 0.39; 95% CI 0.25-0.61; P-interaction = 0.029) associated with combined genotypes for CYP2A13 R257C and a functionary regulatory variant in the cis element of ABCB1 synergistically targeted by GATA binding protein 6 and FOXA2. Genetic manipulation of FOXA2 consistently influenced its binding to and transactivation of the promoters of CYP2A13, UGT2B17, and ABCB1, whose mRNA and protein expressions were all consistently correlated with those of FOXA2 in both tumorous and normal lung tissues. We therefore establish FOXA2 as a core transcriptional modulator for pulmonary xenobiotic metabolic pathways and uncover an etiologically relevant interaction between CYP2A13 and ABCB1, furthering our understanding of expression and function of the xenobiotic metabolism system.	[Xiang, Chan; Wang, Jiucun; Kou, Xiaochen; Qin, Zhaoyu; Jiang, Yan; Sun, Chang; Jin, Li; He, Fuchu; Wang, Haijian] Fudan Univ, Shanghai Med Coll, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci,Inst Biomed Sci,State Key Lab Genet, Shanghai, Peoples R China; [Xiang, Chan; Wang, Jiucun; Kou, Xiaochen; Qin, Zhaoyu; Jiang, Yan; Sun, Chang; Jin, Li; He, Fuchu; Wang, Haijian] Fudan Univ, Shanghai Med Coll, Collaborat Innovat Ctr Genet & Dev,Minist Educ, Sch Life Sci,Inst Biomed Sci,Key Lab Contemporary, Shanghai, Peoples R China; [Chen, Xiabin; Tan, Wen; Lin, Dongxin] Chinese Acad Med Sci, Inst Canc, Dept Etiol & Carcinogenesis, Beijing 100730, Peoples R China; [Chen, Xiabin; Tan, Wen; Lin, Dongxin] Peking Union Med Coll, Beijing 100021, Peoples R China; [Xu, Jibin] Second Mil Med Univ, Changzheng Hosp, Dept Cardiothorac Surg, Shanghai, Peoples R China; [He, Fuchu] Beijing Inst Radiat Med, State Key Lab Prote, Beijing, Peoples R China	Fudan University; Fudan University; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Naval Medical University; Academy of Military Medical Sciences - China	Wang, HJ (corresponding author), Fudan Univ, Sch Life Sci, 2005 Songhu Rd, Shanghai 200438, Peoples R China.	haijianwang@fudan.edu.cn	Jin, Li/M-5063-2019; Jin, Li/C-1468-2009	Jin, Li/0000-0002-4546-2415; Lin, Dongxin/0000-0002-8723-8868	National Natural Science Foundation of China [81172093, 81372526]; Shanghai Rising-Star Program [12QH1400200]; Shanghai Pujiang Program [11PJD005]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Rising-Star Program; Shanghai Pujiang Program(Shanghai Pujiang Program)	The authors thank Yang Zhang, Yanyun Ma, Fengyang Yan, and Linqi Chen for experimental support. This study was supported by grants from the National Natural Science Foundation of China (81172093 and 81372526), Shanghai Rising-Star Program (12QH1400200), and Shanghai Pujiang Program (11PJD005).	Andorfer P, 2013, FEBS LETT, V587, P1504, DOI 10.1016/j.febslet.2013.03.026; Brennan P, 2002, CARCINOGENESIS, V23, P381, DOI 10.1093/carcin/23.3.381; Castell JV, 2005, EXP TOXICOL PATHOL, V57, P189, DOI 10.1016/j.etp.2005.05.008; Chen XP, 2009, ENVIRON HEALTH PERSP, V117, P1541, DOI 10.1289/ehp.0800528; Conrad C, 2002, EXP HEMATOL, V30, P887, DOI 10.1016/S0301-472X(02)00865-2; CORREA E, 1990, CANCER RES, V50, P3435; DEUTSCHWENZEL RP, 1983, JNCI-J NATL CANCER I, V71, P539; Ding XX, 2003, ANNU REV PHARMACOL, V43, P149, DOI 10.1146/annurev.pharmtox.43.100901.140251; Gallagher CJ, 2007, CANCER EPIDEM BIOMAR, V16, P823, DOI 10.1158/1055-9965.EPI-06-0823; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Haraguchi N, 2006, STEM CELLS, V24, P506, DOI 10.1634/stemcells.2005-0282; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hendrikx JJMA, 2013, INT J CANCER, V132, P2439, DOI 10.1002/ijc.27912; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Hu DG, 2010, MOL PHARMACOL, V78, P714, DOI 10.1124/mol.110.065953; Jimenez FR, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-70; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; Kedmi M, 2007, AIDS PATIENT CARE ST, V21, P653, DOI 10.1089/apc.2006.0148; Kim PM, 1996, CANCER RES, V56, P1526; Labialle S, 2002, BIOCHEM PHARMACOL, V64, P943, DOI 10.1016/S0006-2952(02)01156-5; Le Marchand L, 1998, CANCER RES, V58, P4858; Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Li Z, 2012, CELL, V148, P72, DOI 10.1016/j.cell.2011.11.026; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Megaraj V, 2014, CARCINOGENESIS, V35, P131, DOI 10.1093/carcin/bgt269; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; NAKACHI K, 1991, CANCER RES, V51, P5177; Porter JL, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-82; Praetorius C, 2013, CELL, V155, P1022, DOI 10.1016/j.cell.2013.10.022; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950; Shields PG, 2002, ONCOGENE, V21, P6870, DOI 10.1038/sj.onc.1205832; Song N, 2001, CARCINOGENESIS, V22, P11, DOI 10.1093/carcin/22.1.11; Su T, 2000, CANCER RES, V60, P5074; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Tanabe M, 2001, J PHARMACOL EXP THER, V297, P1137; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Thum T, 2006, ENVIRON HEALTH PERSP, V114, P1655, DOI 10.1289/ehp.8861; Wan HJ, 2004, P NATL ACAD SCI USA, V101, P14449, DOI 10.1073/pnas.0404424101; Wang HJ, 2007, PHARMACOGENET GENOM, V17, P667, DOI 10.1097/FPC.0b013e328165249f; Wang HJ, 2006, CANCER LETT, V240, P297, DOI 10.1016/j.canlet.2005.09.018; Wang HJ, 2009, CANCER-AM CANCER SOC, V115, P595, DOI 10.1002/cncr.24042; Wang HJ, 2003, CANCER RES, V63, P8057; Weidenfeld J, 2002, J BIOL CHEM, V277, P21061, DOI 10.1074/jbc.M111702200; Whitsett JA, 2011, AM J RESP CRIT CARE, V184, P401, DOI 10.1164/rccm.201103-0495PP; WYNDER EL, 1994, CANCER RES, V54, P5284; Xu Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-451; Xue YL, 2008, AM J HUM GENET, V83, P337, DOI 10.1016/j.ajhg.2008.08.004; Yang X, 2012, P NATL ACAD SCI USA, V109, pE2813, DOI 10.1073/pnas.1204311109; Zhang XL, 2002, J PHARMACOL EXP THER, V302, P416, DOI 10.1124/jpet.302.2.416; Zhang Z, 2014, INT J CANCER, V134, P1539, DOI 10.1002/ijc.28489	55	10	11	2	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1986	1998		10.1096/fj.14-264580	http://dx.doi.org/10.1096/fj.14-264580			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25667220				2022-12-28	WOS:000354114600032
J	Fagman, JB; Wilhelmson, AS; Motta, BM; Pirazzi, C; Alexanderson, C; De Gendt, K; Verhoeven, G; Holmang, A; Anesten, F; Jansson, JO; Levin, M; Boren, J; Ohlsson, C; Krettek, A; Romeo, S; Tivesten, A				Fagman, Johan B.; Wilhelmson, Anna S.; Motta, Benedetta M.; Pirazzi, Carlo; Alexanderson, Camilla; De Gendt, Karel; Verhoeven, Guido; Holmang, Agneta; Anesten, Fredrik; Jansson, John-Olov; Levin, Malin; Boren, Jan; Ohlsson, Claes; Krettek, Alexandra; Romeo, Stefano; Tivesten, Asa			The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice	FASEB JOURNAL			English	Article						genetically altered mice; metabolism; sex hormones	VERY-LOW-DENSITY; CAROTID ATHEROSCLEROSIS; CARDIOVASCULAR EVENTS; ENDOGENOUS ANDROGENS; POSITION STATEMENT; HEPATIC STEATOSIS; DEFICIENT MICE; BREAST-CANCER; TESTOSTERONE; WOMEN	Androgens have important cardiometabolic actions in males, but their metabolic role in females is unclear. To determine the physiologic androgen receptor (AR)-dependent actions of androgens on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background. After 8 weeks on a high-fat diet, but not on a normal chow diet, atherosclerosis in aorta was increased in ARKO females (+59% vs. control apoE-deficient mice with intact AR gene). They also displayed increased body weight (+18%), body fat percentage (+62%), and hepatic triglyceride levels, reduced insulin sensitivity, and a marked atherogenic dyslipidemia (serum cholesterol, +52%). Differences in atherosclerosis, body weight, and lipid levels between ARKO and controlmice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR. Furthermore, the AR agonist dihydrotestosterone reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis. In conclusion, we demonstrate that the AR protects against diet-induced atherosclerosis in female mice and propose that this is mediated by modulation of body composition and lipid metabolism.	[Fagman, Johan B.; Wilhelmson, Anna S.; Motta, Benedetta M.; Pirazzi, Carlo; Alexanderson, Camilla; Levin, Malin; Boren, Jan; Romeo, Stefano; Tivesten, Asa] Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc & Metab Res, Inst Med, S-41345 Gothenburg, Sweden; [De Gendt, Karel; Verhoeven, Guido] Katholieke Univ Leuven, Dept Expt Med, Lab Expt Med & Endocrinol, Leuven, Belgium; [Holmang, Agneta; Anesten, Fredrik; Jansson, John-Olov] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Physiol, Gothenburg, Sweden; [Ohlsson, Claes] Univ Gothenburg, Sahlgrenska Acad, Ctr Bone & Arthrit Res, Inst Med, Gothenburg, Sweden; [Krettek, Alexandra] Nord Sch Publ Hlth, Gothenburg, Sweden; [Krettek, Alexandra] Univ Gothenburg, Inst Med, Sahlgrenska Acad, Dept Internal Med & Clin Nutr, Gothenburg, Sweden	Sahlgrenska University Hospital; KU Leuven; University of Gothenburg; University of Gothenburg; University of Gothenburg	Tivesten, A (corresponding author), Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc & Metab Res, Bruna Straket 16, S-41345 Gothenburg, Sweden.	asa.tivesten@medic.gu.se	Ohlsson, Claes/AGP-3544-2022; Wilhelmson, Anna S/HCI-9867-2022; Ohlsson, Claes/HIR-6959-2022; Motta, Benedetta Maria/AAA-8559-2020; Romeo, Stefano/L-6861-2015	Ohlsson, Claes/0000-0002-9633-2805; Wilhelmson, Anna S/0000-0003-0640-0251; Ohlsson, Claes/0000-0002-9633-2805; Motta, Benedetta Maria/0000-0002-6681-2170; Romeo, Stefano/0000-0001-9168-4898; Levin, Malin/0000-0003-1069-5275; Bourghardt Fagman, Johan/0000-0002-1527-5280	Swedish Research Council; Avtal om Lakarutbildning och Forskning research grant in Gothenburg; Swedish Heart-Lung Foundation; Marianne and Marcus Wallenberg Foundation; Lundberg Foundation; AFA Insurance; Novo Nordisk Foundation; Novo Nordisk Fonden [NNF14OC0010799, NNF13OC0005785, NNF14OC0009321, NNF14OC0010513] Funding Source: researchfish	Swedish Research Council(Swedish Research CouncilEuropean Commission); Avtal om Lakarutbildning och Forskning research grant in Gothenburg; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Marianne and Marcus Wallenberg Foundation; Lundberg Foundation(European Commission); AFA Insurance; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Novo Nordisk Fonden(Novo Nordisk Foundation)	The authors thank Annelie Carlsson, Inger Johansson, and Annika Lundqvist for excellent technical assistance. The authors also thank Martin Adiels for statistical advice, Rosie Perkins for editing the manuscript, the Centre for Physiology and Bio-Imaging (Sahlgrenska Academy, University of Gothenburg) for assistance with metabolic characterization and blood pressure measurements, and the late Sven-Olof Olofsson for valuable discussions. This study was supported by the Swedish Research Council, a Avtal om Lakarutbildning och Forskning research grant in Gothenburg, the Swedish Heart-Lung Foundation, the Marianne and Marcus Wallenberg Foundation, the Lundberg Foundation, AFA Insurance, and the Novo Nordisk Foundation. The authors declare no conflicts of interest.	ADAMS MR, 1995, ARTERIOSCL THROM VAS, V15, P562, DOI 10.1161/01.ATV.15.5.562; Bernini GP, 1999, J CLIN ENDOCR METAB, V84, P2008, DOI 10.1210/jc.84.6.2008; Bhasin S, 2005, J CLIN ENDOCR METAB, V90, P4970, DOI 10.1210/jc.2005-1328; Bourghardt J, 2010, ENDOCRINOLOGY, V151, P5428, DOI 10.1210/en.2010-0663; Braunstein GD, 2007, J CLIN ENDOCR METAB, V92, P4091, DOI 10.1210/jc.2007-1709; Bruck B, 1997, ARTERIOSCL THROM VAS, V17, P2192, DOI 10.1161/01.ATV.17.10.2192; Chiuve SE, 2004, J CLIN ENDOCR METAB, V89, P2207, DOI 10.1210/jc.2003-031564; Christakou CD, 2008, WOMENS HEALTH, V4, P583, DOI 10.2217/17455057.4.6.583; Corbould A, 2008, DIABETES-METAB RES, V24, P520, DOI 10.1002/dmrr.872; De Gendt K, 2004, P NATL ACAD SCI USA, V101, P1327, DOI 10.1073/pnas.0308114100; Elhage R, 1997, ARTERIOSCL THROM VAS, V17, P2679, DOI 10.1161/01.ATV.17.11.2679; Fan WQ, 2005, DIABETES, V54, P1000, DOI 10.2337/diabetes.54.4.1000; Golden SH, 2002, AM J EPIDEMIOL, V155, P437, DOI 10.1093/aje/155.5.437; Graham MJ, 2013, CIRC RES, V112, P1479, DOI 10.1161/CIRCRESAHA.111.300367; Hewing B, 2012, EXPERT OPIN DRUG DIS, V7, P207, DOI 10.1517/17460441.2012.660143; Huff MW, 2013, CIRC RES, V112, P1405, DOI 10.1161/CIRCRESAHA.113.301464; Jo H, 2013, HEPATOLOGY, V57, P1366, DOI 10.1002/hep.26126; Jones TH, 2009, ATHEROSCLEROSIS, V207, P318, DOI 10.1016/j.atherosclerosis.2009.04.016; Kaczmarek A, 2003, INT J CARDIOL, V87, P53, DOI 10.1016/S0167-5273(02)00203-6; Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100; Labrie F, 2003, ENDOCR REV, V24, P152, DOI 10.1210/er.2001-0031; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; Laughlin GA, 2010, J CLIN ENDOCR METAB, V95, P740, DOI 10.1210/jc.2009-1693; Lin HY, 2008, HEPATOLOGY, V47, P1924, DOI 10.1002/hep.22252; Lin HY, 2005, DIABETES, V54, P1717, DOI 10.2337/diabetes.54.6.1717; Liu PY, 2003, ENDOCR REV, V24, P313, DOI 10.1210/er.2003-0005; Manolakou P, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-44; Mauvais-Jarvis F, 2011, TRENDS ENDOCRIN MET, V22, P24, DOI 10.1016/j.tem.2010.10.002; McInnes KJ, 2012, DIABETES, V61, P1072, DOI 10.2337/db11-1136; McRobb L, 2009, ENDOCRINOLOGY, V150, P841, DOI 10.1210/en.2008-0760; Montalcini T, 2007, NUTR METAB CARDIOVAS, V17, P705, DOI 10.1016/j.numecd.2006.09.007; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Nestler JE, 2008, NEW ENGL J MED, V358, P47, DOI 10.1056/NEJMct0707092; O'Reilly MW, 2014, J STEROID BIOCHEM, V143, P277, DOI 10.1016/j.jsbmb.2014.04.008; Obasanjo IO, 1996, METABOLISM, V45, P463, DOI 10.1016/S0026-0495(96)90220-6; Ohlsson C, 2011, J AM COLL CARDIOL, V58, P1674, DOI 10.1016/j.jacc.2011.07.019; Patel SM, 2009, J CLIN ENDOCR METAB, V94, P4776, DOI 10.1210/jc.2009-0740; Pirazzi C, 2012, J HEPATOL, V57, P1276, DOI 10.1016/j.jhep.2012.07.030; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; Rosner W, 2007, J CLIN ENDOCR METAB, V92, P405, DOI 10.1210/jc.2006-1864; Rulli SB, 2002, ENDOCRINOLOGY, V143, P4084, DOI 10.1210/en.2002-220490; Shiina H, 2006, P NATL ACAD SCI USA, V103, P224, DOI 10.1073/pnas.0506736102; Sievers C, 2010, EUR J ENDOCRINOL, V163, P699, DOI 10.1530/EJE-10-0307; Sjoberg A, 1996, J LIPID RES, V37, P275; Strong A, 2012, CURR ATHEROSCLER REP, V14, P211, DOI 10.1007/s11883-012-0248-x; Van Gaal LF, 2006, NATURE, V444, P875, DOI 10.1038/nature05487; vanVlijmen BJM, 1996, J CLIN INVEST, V97, P1184, DOI 10.1172/JCI118532; VELDHUIS JD, 1993, HUM REPROD, V8, P84, DOI 10.1093/humrep/8.suppl_2.84; von Dehn G, 2001, HORM METAB RES, V33, P110, DOI 10.1055/s-2001-12405; Walters KA, 2007, ENDOCRINOLOGY, V148, P3674, DOI 10.1210/en.2007-0248; Walters KA, 2010, HUM REPROD UPDATE, V16, P543, DOI 10.1093/humupd/dmq003; Wang XW, 2011, J CLIN ENDOCR METAB, V96, P885, DOI 10.1210/jc.2010-2061; Wierman ME, 2014, J CLIN ENDOCR METAB, V99, P3489, DOI 10.1210/jc.2014-2260; Wild RA, 2010, J CLIN ENDOCR METAB, V95, P2038, DOI 10.1210/jc.2009-2724; Yeh SY, 2003, J EXP MED, V198, P1899, DOI 10.1084/jem.20031233; Yu IC, 2008, ENDOCRINOLOGY, V149, P2361, DOI 10.1210/en.2007-0516; Zhang H, 2013, J LIPID RES, V54, P345, DOI 10.1194/jlr.M028969	57	30	33	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1540	1550		10.1096/fj.14-259234	http://dx.doi.org/10.1096/fj.14-259234			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550469	hybrid, Green Published			2022-12-28	WOS:000354115000038
J	Hijmans, BS; Tiemann, CA; Grefhorst, A; Boesjes, M; van Dijk, TH; Tietge, UJF; Kuipers, F; van Riel, NAW; Groen, AK; Oosterveer, MH				Hijmans, Brenda S.; Tiemann, Christian A.; Grefhorst, Aldo; Boesjes, Marije; van Dijk, Theo H.; Tietge, Uwe J. F.; Kuipers, Folkert; van Riel, Natal A. W.; Groen, Albert K.; Oosterveer, Maaike H.			A systems biology approach reveals the physiological origin of hepatic steatosis induced by liver X receptor activation	FASEB JOURNAL			English	Article						computational modeling; T0901317; fatty liver; FFA flux; VLDL metabolism	FATTY-ACIDS; LXR-ALPHA; LIPID-ACCUMULATION; SIGNALING PATHWAYS; TRANSFER PROTEIN; PLASMA; CHOLESTEROL; METABOLISM; GAMMA; HEPATOBILIARY	Liver X receptor (LXR) agonists exert potent antiatherosclerotic actions but simultaneously induce excessive triglyceride (TG) accumulation in the liver. To obtain a detailed insight into the underlying mechanism of hepatic TG accumulation, we used a novel computational modeling approach called analysis of dynamic adaptations in parameter trajectories (ADAPT). We revealed that both input and output fluxes to hepatic TG content are considerably induced on LXR activation and that in the early phase of LXR agonism, hepatic steatosis results from only a minor imbalance between the two. It is generally believed that LXR-induced hepatic steatosis results from increased de novo lipogenesis (DNL). In contrast, ADAPT predicted that the hepatic influx of free fatty acids is the major contributor to hepatic TG accumulation in the early phase of LXR activation. Qualitative validation of this prediction showed a 5-fold increase in the contribution of plasma palmitate to hepatic monounsaturated fatty acids on acute LXR activation, whereas DNL was not yet significantly increased. This study illustrates that complex effects of pharmacological intervention can be translated into distinct patterns of metabolic regulation through state-of-the-art mathematical modeling.	[Hijmans, Brenda S.; Boesjes, Marije; Tietge, Uwe J. F.; Kuipers, Folkert; Groen, Albert K.; Oosterveer, Maaike H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands; [van Dijk, Theo H.; Kuipers, Folkert; Groen, Albert K.] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, Groningen, Netherlands; [Tiemann, Christian A.; van Riel, Natal A. W.] Eindhoven Univ Technol, Dept Biomed Engn, NL-5600 MB Eindhoven, Netherlands; [Tiemann, Christian A.; van Riel, Natal A. W.; Groen, Albert K.] Univ Amsterdam, Netherlands Consortium Syst Biol, Amsterdam, Netherlands; [Grefhorst, Aldo] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands; [Groen, Albert K.] Univ Groningen, Groningen Ctr Syst Biol, Groningen, Netherlands	University of Groningen; University of Groningen; Eindhoven University of Technology; University of Amsterdam; Erasmus University Rotterdam; Erasmus MC; University of Groningen	Oosterveer, MH (corresponding author), Univ Med Ctr Groningen, Ctr Liver Digest & Metab Dis, Pediat Lab, POB 30-001, NL-9700 RB Groningen, Netherlands.	m.h.oosterveer@umcg.nl	oosterveer, maaike h/C-3374-2013; van Riel, Natal/J-5319-2013	van Riel, Natal/0000-0001-9375-4730; Kuipers, Folkert/0000-0003-2518-737X	Top Institute Pharma [T2-110]; European Union, FP7-HEALTH [305707]; Center for Translational Molecular Medicine, project PREDICCt [01C-104]; Dutch Heart Foundation; Dutch Diabetes Research Foundation; Dutch Kidney Foundation	Top Institute Pharma; European Union, FP7-HEALTH; Center for Translational Molecular Medicine, project PREDICCt; Dutch Heart Foundation(Netherlands Heart Foundation); Dutch Diabetes Research Foundation; Dutch Kidney Foundation	The authors thank Y. Paalvast for contributions to the revision of this manuscript. The authors thank V. W. Bloks, H. Havinga, and T. Bos for scientific discussion and excellent technical assistance. This research was funded by Top Institute Pharma (Grant T2-110) and the European Union, FP7-HEALTH (Grant 305707) and performed within the framework of the Center for Translational Molecular Medicine (www.ctmm.nl), project PREDICCt (Grant 01C-104), and supported by the Dutch Heart Foundation, Dutch Diabetes Research Foundation, and Dutch Kidney Foundation. Ppar gamma<SUP>hep-/-</SUP> mice were kindly provided by Dr. J. W. Jonker (University Medical Center Groningen).	Archer A, 2014, AM J PHYSIOL-ENDOC M, V306, pE494, DOI 10.1152/ajpendo.00410.2013; Baar RA, 2005, AM J PHYSIOL-ENDOC M, V288, pE187, DOI 10.1152/ajpendo.00256.2004; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Calkin AC, 2010, ARTERIOSCL THROM VAS, V30, P1513, DOI 10.1161/ATVBAHA.109.191197; Dib L, 2014, J LIPID RES, V55, P247, DOI 10.1194/jlr.M043422; Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI23621; DURAN M, 1988, CLIN CHEM, V34, P548; ELOVSON J, 1988, J LIPID RES, V29, P1461; FIDGE NH, 1974, CLIN CHIM ACTA, V52, P15, DOI 10.1016/0009-8981(74)90383-0; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRASER R, 1970, J LIPID RES, V11, P60; Gao MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065641; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; HOVING EB, 1988, J CHROMATOGR-BIOMED, V434, P395, DOI 10.1016/S0378-4347(88)80006-9; Hultin M, 1996, J LIPID RES, V37, P1022; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jiang XC, 2002, FRONT BIOSCI-LANDMRK, V7, pD1634, DOI 10.2741/jiang1; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; KALUZNY MA, 1985, J LIPID RES, V26, P135; Kase ET, 2005, DIABETES, V54, P1108, DOI 10.2337/diabetes.54.4.1108; KUIPERS F, 1985, GASTROENTEROLOGY, V88, P403, DOI 10.1016/0016-5085(85)90499-8; Lambert JE, 2014, GASTROENTEROLOGY, V146, P726, DOI 10.1053/j.gastro.2013.11.049; Levin N, 2005, ARTERIOSCL THROM VAS, V25, P135, DOI 10.1161/01.ATV.0000150044.84012.68; Macfarlane DP, 2011, AM J PHYSIOL-ENDOC M, V300, pE402, DOI 10.1152/ajpendo.00331.2010; Martins IJ, 1996, J LIPID RES, V37, P2696; Matsusue K, 2014, FEBS LETT, V588, P2277, DOI 10.1016/j.febslet.2014.05.012; MUSKIET FAJ, 1983, J CHROMATOGR, V278, P231, DOI 10.1016/S0378-4347(00)84782-9; Okazaki H, 2010, J BIOL CHEM, V285, P6801, DOI 10.1074/jbc.M109.079459; Oosterveer MH, 2010, PROG LIPID RES, V49, P343, DOI 10.1016/j.plipres.2010.03.002; Oosterveer MH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006066; Peng DC, 2010, ATHEROSCLEROSIS, V208, P126, DOI 10.1016/j.atherosclerosis.2009.07.016; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Plosch T, 2006, AM J PHYSIOL-GASTR L, V291, pG414, DOI 10.1152/ajpgi.00557.2005; Quinet EM, 2009, J LIPID RES, V50, P2358, DOI 10.1194/jlr.M900037-JLR200; Rao R, 1997, BIOCHEMISTRY-US, V36, P3645, DOI 10.1021/bi962776b; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Shetty S, 2012, ENDOCRINOLOGY, V153, P113, DOI 10.1210/en.2011-1339; Stenson BM, 2011, J BIOL CHEM, V286, P370, DOI 10.1074/jbc.M110.179499; Stricker D, 2008, COMPUT METH PROG BIO, V92, P135, DOI 10.1016/j.cmpb.2008.06.010; Takazawa T, 2009, J BIOL CHEM, V284, P30049, DOI 10.1074/jbc.M109.047993; Tao H, 2010, AM J PHYSIOL-ENDOC M, V298, pE68, DOI 10.1152/ajpendo.00367.2009; Tiemann CA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003166; Tiemann CA, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-174; Tietge UJF, 2000, J BIOL CHEM, V275, P10077, DOI 10.1074/jbc.275.14.10077; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Torres DM, 2012, SEMIN LIVER DIS, V32, P30, DOI 10.1055/s-0032-1306424; van der Veen JN, 2009, J BIOL CHEM, V284, P19211, DOI 10.1074/jbc.M109.014860; Weedon-Fekjaer MS, 2010, J LIPID RES, V51, P1886, DOI 10.1194/jlr.M004978; Yagyu H, 2002, J BIOL CHEM, V277, P10037, DOI 10.1074/jbc.M109966200	53	18	18	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1153	1164		10.1096/fj.14-254656	http://dx.doi.org/10.1096/fj.14-254656			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25477282	Green Submitted			2022-12-28	WOS:000354115000005
J	Kinross, KM; Montgomery, KG; Mangiafico, SP; Hare, LM; Kleinschmidt, M; Bywater, MJ; Poulton, IJ; Vrahnas, C; Henneicke, H; Malaterre, J; Waring, PM; Cullinane, C; Sims, NA; McArthur, GA; Andrikopoulos, S; Phillips, WA				Kinross, Kathryn M.; Montgomery, Karen G.; Mangiafico, Salvatore P.; Hare, Lauren M.; Kleinschmidt, Margarete; Bywater, Megan J.; Poulton, Ingrid J.; Vrahnas, Christina; Henneicke, Holger; Malaterre, Jordane; Waring, Paul M.; Cullinane, Carleen; Sims, Natalie A.; McArthur, Grant A.; Andrikopoulos, Sofianos; Phillips, Wayne A.			Ubiquitous expression of the Pik3ca(H1047R) mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly	FASEB JOURNAL			English	Article						PI3K; p110 alpha; mouse model; overgrowth syndrome; glucose metabolism	IN-VIVO; INSULIN-SECRETION; ACTIVATING MUTATIONS; METABOLIC-REGULATION; ENERGY-METABOLISM; MICE LACKING; PIK3CA CAUSE; BETA-CELLS; CANCER; KINASE	Mutations in PIK3CA, the gene encoding the p110 alpha catalytic subunit of PI3K, are among the most common mutations found in human cancer and have also recently been implicated in a range of overgrowth syndromes in humans. We have used a novel inducible "exonswitch" approach to knock in the constitutively active Pik3ca(H1047R) mutation into the endogenous Pik3ca gene of the mouse. Ubiquitous expression of the Pik3caH1047R mutation throughout the body resulted in a dramatic increase in body weight within 3 weeks of induction (mutant 150 +/- 5%; wild-type 117 +/- 3%, mean +/- SEM), which was associated with increased organ size rather than adiposity. Severe metabolic effects, including a reduction in blood glucose levels to 59 +/- 4% of baseline (11 days postinduction) and undetectable insulin levels, were also observed. Pik3ca(H1047R) mutant mice died earlier (median survival 46.5 d post-mutation induction) than wild-type control mice (100% survival > 250 days). Although deletion of Akt2 increased median survivalby 44%, neither organ overgrowth, nor hypoglycemia were rescued, indicating that both the growth and metabolic functions of constitutive PI3K activity can be Akt2 independent. This mouse model demonstrates the critical role of PI3K in the regulation of both organ size and glucose metabolism at the whole animal level.	[Kinross, Kathryn M.; Montgomery, Karen G.; Hare, Lauren M.; Phillips, Wayne A.] Peter MacCallum Canc Ctr, Surg Oncol Res Lab, East Melbourne, Vic, Australia; [Kinross, Kathryn M.; Cullinane, Carleen; McArthur, Grant A.; Phillips, Wayne A.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia; [Mangiafico, Salvatore P.; Andrikopoulos, Sofianos] Univ Melbourne, Dept Med, Austin Hlth, Heidelberg, Vic, Australia; [Kleinschmidt, Margarete; Bywater, Megan J.; Cullinane, Carleen] Peter MacCallum Canc Ctr, Translat Res Labs, East Melbourne, Vic, Australia; [Poulton, Ingrid J.; Vrahnas, Christina; Sims, Natalie A.] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; [Poulton, Ingrid J.; Vrahnas, Christina; Sims, Natalie A.] Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia; [Henneicke, Holger] Univ Sydney, ANZAC Res Inst, Bone Res Program, Sydney, NSW 2006, Australia; [Malaterre, Jordane] Peter MacCallum Canc Ctr, Differentiat & Transcript Lab, East Melbourne, Vic, Australia; [Waring, Paul M.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [McArthur, Grant A.] Peter MacCallum Canc Ctr, Mol Oncol Lab, East Melbourne, Vic 8006, Australia; [Phillips, Wayne A.] Univ Melbourne, Dept Surg, St Vincents Hosp, Fitzroy, Vic 3065, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Peter Maccallum Cancer Center; St. Vincent's Institute of Medical Research; University of Melbourne; University of Sydney; ANZAC Research Institute; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; St Vincent's Hospital Melbourne; University of Melbourne	Phillips, WA (corresponding author), Peter MacCallum Canc Ctr, Surg Oncol Res Lab, Locked Bag 1,ABeckett St PO, Melbourne, Vic 8006, Australia.	wayne.phillips@petermac.org	Bywater, Megan/X-5606-2018; Sims, Natalie Ann/A-7192-2012; Phillips, Wayne A/H-8070-2013; Henneicke, Holger/H-3383-2016; Research Institute, ANZAC/CAE-9030-2022	Bywater, Megan/0000-0002-7466-6927; Sims, Natalie Ann/0000-0003-1421-8468; Phillips, Wayne A/0000-0002-7961-638X; Henneicke, Holger/0000-0003-1746-9369; McArthur, Grant/0000-0001-8908-6071; Cullinane, Carleen/0000-0001-5833-6605	National Health and Medical Research Council of Australia [628620, 628621]; Cancer Council of Victoria	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria)	The authors thank Ryan Galea, Kevin Mills, Kerry Ardley, the animal facility staff, the Peter MacCallum Cancer Centre Department of Pathology, and the Research Division Microscopy and Histology Core Facility for their valuable advice and/or technical assistance. This work was supported, in part, by the National Health and Medical Research Council of Australia (project Grants 628620 and 628621, to W.A.P.). K.K. was supported by a grant-in-aid from the Cancer Council of Victoria.	Arya VB, 2014, J CLIN ENDOCR METAB, V99, P391, DOI 10.1210/jc.2013-3228; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cullinane C, 2005, CANCER RES, V65, P9633, DOI 10.1158/0008-5472.CAN-05-2285; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Denoyer D, 2011, J NUCL MED, V52, P115, DOI 10.2967/jnumed.110.078154; Dummler B, 2006, MOL CELL BIOL, V26, P8042, DOI 10.1128/MCB.00722-06; Durban VM, 2013, J CLIN INVEST, V123, P5104, DOI 10.1172/JCI69619; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Ford-Hutchinson AF, 2007, J BONE MINER RES, V22, P1245, DOI 10.1359/JBMR.070420; Foukas LC, 2013, EMBO MOL MED, V5, P563, DOI 10.1002/emmm.201201953; Foukas LC, 2006, NATURE, V441, P366, DOI 10.1038/nature04694; Garcia-Cao I, 2012, CELL, V149, P49, DOI 10.1016/j.cell.2012.02.030; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gundberg CM, 1998, J CLIN ENDOCR METAB, V83, P3258, DOI 10.1210/jc.83.9.3258; Hare LM, 2014, BIOCHEM J, V458, P251, DOI 10.1042/BJ20131412; Hussain K, 2011, SCIENCE, V334, P474, DOI 10.1126/science.1210878; Kaneko K, 2010, CELL METAB, V12, P619, DOI 10.1016/j.cmet.2010.11.005; Keppler-Noreuil KM, 2014, AM J MED GENET A, V164, P1713, DOI 10.1002/ajmg.a.36552; Kinross KM, 2012, J CLIN INVEST, V122, P553, DOI 10.1172/JCI59309; Kinross KM, 2011, MOL CANCER THER, V10, P1440, DOI 10.1158/1535-7163.MCT-11-0240; Kolic J, 2013, DIABETOLOGIA, V56, P1339, DOI 10.1007/s00125-013-2882-4; Kurek KC, 2012, AM J HUM GENET, V90, P1108, DOI 10.1016/j.ajhg.2012.05.006; Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047; Lindhurst MJ, 2012, NAT GENET, V44, P928, DOI 10.1038/ng.2332; Liu SJ, 2014, CANCER RES, V74, P641, DOI 10.1158/0008-5472.CAN-13-2319; Mangiafico SP, 2011, J ENDOCRINOL, V210, P335, DOI 10.1530/JOE-11-0126; Mirzaa G, 2013, GENEREVIEWS, P1993; Rios JJ, 2013, HUM MOL GENET, V22, P444, DOI 10.1093/hmg/dds440; Riviere JB, 2012, NAT GENET, V44, P934, DOI 10.1038/ng.2331; Robey RB, 2009, SEMIN CANCER BIOL, V19, P25, DOI 10.1016/j.semcancer.2008.11.010; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Smith GC, 2012, BIOCHEM J, V442, P161, DOI 10.1042/BJ20111913; Sopasakis VR, 2010, CELL METAB, V11, P220, DOI 10.1016/j.cmet.2010.02.002; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Tikoo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036924; Trejo CL, 2013, CANCER RES, V73, P6448, DOI 10.1158/0008-5472.CAN-13-0681; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8	45	18	18	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1426	1434		10.1096/fj.14-262782	http://dx.doi.org/10.1096/fj.14-262782			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550458				2022-12-28	WOS:000354115000028
J	Overstreet, JM; Samarakoon, R; Cardona-Grau, D; Goldschmeding, R; Higgins, PJ				Overstreet, Jessica M.; Samarakoon, Rohan; Cardona-Grau, Diana; Goldschmeding, Roel; Higgins, Paul J.			Tumor suppressor ataxia telangiectasia mutated functions downstream of TGF-beta 1 in orchestrating profibrotic responses	FASEB JOURNAL			English	Article						kidney fibrosis; p53; ROS; NOX	URETERAL OBSTRUCTION; TARGET GENES; LUNG INJURY; FIBROSIS; ACTIVATION; SMAD; P53; MECHANISMS; REQUIRES; DISEASE	Effective therapy to prevent organ fibrosis, which is associated with more than half of all mortalities, remains elusive. Involvement of tumor suppressor ataxia telangiectasia mutated (ATM) in the TGF-beta 1 pathway related to renal fibrosis is largely unknown. ATM activation (pATM(Ser1981)) increased 4-fold in the tubulointerstitial region of the unilateral ureteral obstruction-injured kidney in mice correlating with SMAD3 and p53(Ser15) phosphorylation and elevated levels of p22(phox) subunit of the NADPH oxidases (NOXs), and fibrotic markers, plasminogen activator inhibitor-1 (PAI-1), and fibronectin, when compared to contralateral (contra) or sham controls. In fact, ATM is rapidly phosphorylated at Ser(1981) by TGF-beta 1 stimulation. Stable silencing and pharmacologic inhibition of ATM ablated TGF-beta 1-induced p53 activation (>95%) and subsequent PAI-1, fibronectin, connective tissue growth factor, and p21 expression in human kidney 2 (HK-2) tubular epithelial cells and normal rat kidney-49 fibroblasts (NRK-49F). ATM or p53 depletion in HK-2 cells, moreover, bypassed TGF-beta 1-mediated cytostasis evident in control short hairpin RNA-expressing HK-2 cells. Interestingly, stable silencing of NOX subunits, p22(phox) and p47(phox), in HK-2 cells blocked TGF-beta 1-induced pATM(Ser1981) (>90%) and target gene induction via p53-dependent mechanisms. Furthermore, NRK-49F fibroblast proliferation triggered by conditioned media from TGF-beta 1-stimulated, control vector-transfected HK-2 cells decreased (similar to 50%) when exposed to conditioned media from ATM-deficient, TGF-beta 1-treated HK-2 cells. Thus, TGF-b1 promotes NOX-dependent ATM activation leading to p53-mediated fibrotic gene reprogramming and growth arrest in HK-2 cells. Furthermore, TGF-beta 1/ATM-initiated paracrine factor secretion by dysfunctional renal epithelium promotes interstitial fibroblast growth, suggesting a role of tubular ATM in mediating epithelial-mesenchymal cross-talk highlighting the translational benefit of targeting the NOX/ATM/p53 axis in renal fibrosis.	[Overstreet, Jessica M.; Samarakoon, Rohan; Higgins, Paul J.] Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave, Albany, NY 12208 USA; [Cardona-Grau, Diana] Albany Med Coll, Div Urol, Albany, NY 12208 USA; [Goldschmeding, Roel] Univ Med Ctr, Dept Pathol, Utrecht, Netherlands	Albany Medical College; Albany Medical College; Utrecht University; Utrecht University Medical Center	Higgins, PJ (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave, Albany, NY 12208 USA.	higginp@mail.amc.edu			U.S. National Institutes of Health National Institute of General Medical Sciences Grant [GM057242]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057242] Funding Source: NIH RePORTER	U.S. National Institutes of Health National Institute of General Medical Sciences Grant; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health National Institute of General Medical Sciences Grant GM057242 (to P.J.H.). J.M.O., R.S., and P.J.H. conceived and designed the experiments. J.M.O., R.S., and D.C.-G. performed the experiments. J.M.O. and R.S. analyzed the data. R.G. contributed key reagents/materials. J.M.O., R.S., and P.J.H. wrote the paper. The authors declare no conflicts of interest.	Anglicheau D, 2012, TRANSPLANTATION, V93, P1136, DOI 10.1097/TP.0b013e31824ef181; Aoshiba K, 2013, EXP TOXICOL PATHOL, V65, P1053, DOI 10.1016/j.etp.2013.04.001; Boder E, 1985, Kroc Found Ser, V19, P1; Chevalier RL, 2009, KIDNEY INT, V75, P1145, DOI 10.1038/ki.2009.86; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Doyle JJ, 2012, FEBS LETT, V586, P2003, DOI 10.1016/j.febslet.2012.05.027; Friedman SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004700; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; Hecker L, 2009, NAT MED, V15, P1077, DOI 10.1038/nm.2005; Kisseleva T, 2007, J GASTROEN HEPATOL, V22, pS73, DOI 10.1111/j.1440-1746.2006.04658.x; Kortlever RM, 2008, J BIOL CHEM, V283, P24308, DOI 10.1074/jbc.M803341200; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lee Chun Geun, 2006, Proc Am Thorac Soc, V3, P418, DOI 10.1513/pats.200602-017AW; Liu YH, 2011, NAT REV NEPHROL, V7, P684, DOI 10.1038/nrneph.2011.149; Overstreet JM, 2014, CELL SIGNAL, V26, P1427, DOI 10.1016/j.cellsig.2014.02.017; Paik YH, 2011, HEPATOLOGY, V53, P1730, DOI 10.1002/hep.24281; Samarakoon R, 2013, CELL SIGNAL, V25, P2198, DOI 10.1016/j.cellsig.2013.07.007; Samarakoon R, 2013, CELL SIGNAL, V25, P264, DOI 10.1016/j.cellsig.2012.10.003; Samarakoon R, 2012, CELL TISSUE RES, V347, P117, DOI 10.1007/s00441-011-1181-y; Samarakoon R, 2008, THROMB HAEMOSTASIS, V100, P976, DOI 10.1160/TH08-05-0273; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Yang L, 2011, CONTRIB NEPHROL, V174, P149, DOI 10.1159/000329385; Yang L, 2010, NAT MED, V16, P535, DOI 10.1038/nm.2144; Ying Y, 2014, J AM SOC NEPHROL, V25, P2707, DOI 10.1681/ASN.2013121270; Zhang DS, 2014, J AM SOC NEPHROL, V25, P2278, DOI 10.1681/ASN.2013080902; Zieg J, 2011, NEPHROLOGY, V16, P595, DOI 10.1111/j.1440-1797.2011.01459.x	28	24	27	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1258	1268		10.1096/fj.14-262527	http://dx.doi.org/10.1096/fj.14-262527			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25480384	Green Published			2022-12-28	WOS:000354115000014
J	Zhang, HB; Hanke-Gogokhia, C; Jiang, L; Li, XB; Wang, P; Gerstner, CD; Frederick, JM; Yang, ZL; Baehr, W				Zhang, Houbin; Hanke-Gogokhia, Christin; Jiang, Li; Li, Xiaobo; Wang, Pu; Gerstner, Cecilia D.; Frederick, Jeanne M.; Yang, Zhenglin; Baehr, Wolfgang			Mistrafficking of prenylated proteins causes retinitis pigmentosa 2	FASEB JOURNAL			English	Article						rod-cone dystrophy; ARL3; PDE6D; RP2; XLRP	RETINITIS-PIGMENTOSA-2 PROTEIN; CGMP PHOSPHODIESTERASE; OUTER SEGMENTS; DELTA-SUBUNIT; PDE-DELTA; RP2; RPGR; MUTATION; GENE; ROD	The retinitis pigmentosa 2 polypeptide (RP2) functions as a GTPase-activating protein (GAP) for ARL3 (Arf-like protein 3), a small GTPase. ARL3 is an effector of phosphodiesterase 6 Delta (PDE6D), a prenyl-binding protein and chaperone of prenylated protein in photoreceptors. Mutations in the human RP2 gene cause X-linked retinitis pigmentosa (XLRP) and cone-rod dystrophy (XL-CORD). To study mechanisms causing XLRP, we generated an RP2 knockout mouse. The RP2h(-/-) mice exhibited a slowly progressing rod-cone dystrophy simulating the human disease. RP2h(-/-) scotopic a-wave and photopic b-wave amplitudes declined at 1 mo of age and continued to decline over the next 6 mo. Prenylated PDE6 subunits and G-protein coupled receptor kinase 1 (GRK1) were unable to traffic effectively to the RP2h(-/-) outer segments. Mechanistically, absence of RP2 GAP activity increases ARL3-GTP levels, forcing PDE6D to assume a predominantly "closed" conformation that impedes binding of lipids. Lack of interaction disrupts trafficking of PDE6 and GRK1 to their destination, the photoreceptor outer segments. We propose that hyperactivity of ARL3-GTP in RP2 knockout mice and human patients with RP2 null alleles leads to XLRP resembling recessive rod-cone dystrophy.	[Zhang, Houbin; Li, Xiaobo; Wang, Pu; Yang, Zhenglin] Hosp Univ Elect Sci & Technol China, Inst Lab Med, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Sichuan, Peoples R China; [Zhang, Houbin; Li, Xiaobo; Wang, Pu; Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China; [Zhang, Houbin; Yang, Zhenglin] Univ Elect Sci & Technol China, Sch Med, Chengdu 610054, Sichuan, Peoples R China; [Hanke-Gogokhia, Christin; Jiang, Li; Gerstner, Cecilia D.; Frederick, Jeanne M.; Baehr, Wolfgang] Univ Utah, Sch Med, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA; [Baehr, Wolfgang] Univ Utah, Sch Med, Dept Neurobiol & Anat, Salt Lake City, UT 84132 USA; [Hanke-Gogokhia, Christin] Univ Potsdam, Dept Biol & Biochem, Potsdam, Germany; [Baehr, Wolfgang] Univ Utah, Dept Biol, Salt Lake City, UT 84132 USA	University of Electronic Science & Technology of China; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Potsdam; Utah System of Higher Education; University of Utah	Zhang, HB (corresponding author), Univ Utah, Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.	houbin.zhang@gmail.com; wbaehr@hsc.utah.edu	Zhang, Houbin/A-8887-2012	Zhang, Houbin/0000-0002-2968-7454	U.S. National Institutes of Health [EY020969, EY08123, EY019298, EY014800-039003]; National Science Foundation [NSFC81371030]; Research to Prevent Blindness; RPB Nelson Trust Award; NATIONAL EYE INSTITUTE [R01EY019298, P30EY014800, R01EY008123, R21EY020969] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Research to Prevent Blindness(Research to Prevent Blindness (RPB)); RPB Nelson Trust Award; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by the U.S. National Institutes of Health Grants EY020969 (to H.Z.), EY08123, EY019298 (to W.B.), and EY014800-039003 (NEI core grant); National Science Foundation Grant NSFC81371030 (to H.Z.); and unrestricted grants to the University of Utah Department of Ophthalmology from Research to Prevent Blindness (to R.P.B.). W.B. is the recipient of an RPB Senior Investigator and an RPB Nelson Trust Award.	Andreasson S, 1997, AM J OPHTHALMOL, V124, P95; Arshavsky VY, 2013, INVEST OPHTH VIS SCI, V54, P7725, DOI 10.1167/iovs.13-13281; Avasthi P, 2009, J NEUROSCI, V29, P14287, DOI 10.1523/JNEUROSCI.3976-09.2009; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAEHR W, 1982, J BIOL CHEM, V257, P6452; Bartolini F, 2002, J BIOL CHEM, V277, P14629, DOI 10.1074/jbc.M200128200; Blacque OE, 2005, CURR BIOL, V15, P935, DOI 10.1016/j.cub.2005.04.059; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branham K, 2012, INVEST OPHTH VIS SCI, V53, P8232, DOI 10.1167/iovs.12-11025; Breuer DK, 2002, AM J HUM GENET, V70, P1545, DOI 10.1086/340848; Chapple JP, 2000, HUM MOL GENET, V9, P1919, DOI 10.1093/hmg/9.13.1919; Chapple JP, 2002, INVEST OPHTH VIS SCI, V43, P2015; Constantine R, 2012, VISION RES, V75, P26, DOI 10.1016/j.visres.2012.08.012; Dandekar SS, 2004, BRIT J OPHTHALMOL, V88, P528, DOI 10.1136/bjo.2003.027979; FISHMAN GA, 1988, ARCH OPHTHALMOL-CHIC, V106, P369; Grayson C, 2002, HUM MOL GENET, V11, P3065, DOI 10.1093/hmg/11.24.3065; Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7; Holopainen JM, 2010, BIOCHEMISTRY-US, V49, P7439, DOI 10.1021/bi1005249; HUNTER DG, 1988, ARCH OPHTHALMOL-CHIC, V106, P362; Hurd T, 2010, HUM MOL GENET, V19, P4330, DOI 10.1093/hmg/ddq355; Ismail SA, 2012, EMBO J, V31, P4085, DOI 10.1038/emboj.2012.257; Ismail SA, 2011, NAT CHEM BIOL, V7, P942, DOI [10.1038/nchembio.686, 10.1038/NCHEMBIO.686]; Jayasundera T, 2010, ARCH OPHTHALMOL-CHIC, V128, P915, DOI 10.1001/archophthalmol.2010.122; Karan S, 2008, VISION RES, V48, P442, DOI 10.1016/j.visres.2007.08.020; Kuhnel K, 2006, STRUCTURE, V14, P367, DOI 10.1016/j.str.2005.11.008; Li LJ, 2013, INVEST OPHTH VIS SCI, V54, P4503, DOI 10.1167/iovs.13-12140; Linari M, 1999, P NATL ACAD SCI USA, V96, P1315, DOI 10.1073/pnas.96.4.1315; Lyubarsky AL, 2000, J NEUROSCI, V20, P2209; Matsuda T, 2007, P NATL ACAD SCI USA, V104, P1027, DOI 10.1073/pnas.0610155104; Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; Nishiguchi KM, 2004, NATURE, V427, P75, DOI 10.1038/nature02170; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Patil SB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021379; Schwahn U, 1998, NAT GENET, V19, P327, DOI 10.1038/1214; Schwarz N, 2012, VISION RES, V75, P2, DOI 10.1016/j.visres.2012.07.016; Schwarz N, 2012, HUM MOL GENET, V21, P863, DOI 10.1093/hmg/ddr520; Sharon D, 2000, INVEST OPHTH VIS SCI, V41, P2712; Shu XH, 2011, INVEST OPHTH VIS SCI, V52, P2960, DOI 10.1167/iovs.10-6800; Thomas S, 2014, HUM MUTAT, V35, P137, DOI 10.1002/humu.22470; Veltel S, 2008, FEBS LETT, V582, P2501, DOI 10.1016/j.febslet.2008.05.053; Veltel S, 2008, NAT STRUCT MOL BIOL, V15, P373, DOI 10.1038/nsmb.1396; Watzlich D., 2013, EMBO REP, V14, P465; Wright KJ, 2011, GENE DEV, V25, P2347, DOI 10.1101/gad.173443.111; Yoon JH, 2006, EXP CELL RES, V312, P1323, DOI 10.1016/j.yexcr.2005.12.026; Zhang H, 2007, P NATL ACAD SCI USA, V104, P8857, DOI 10.1073/pnas.0701681104; Zhang HB, 2006, ADV EXP MED BIOL, V572, P485; Zhang HB, 2004, J BIOL CHEM, V279, P407, DOI 10.1074/jbc.M306559200; Zhang HB, 2008, J NEUROSCI, V28, P4008, DOI 10.1523/JNEUROSCI.0317-08.2008; Zhang HB, 2012, VISION RES, V75, P19, DOI 10.1016/j.visres.2012.08.013; Zhang HB, 2011, NAT NEUROSCI, V14, P874, DOI 10.1038/nn.2835	53	44	46	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					932	942		10.1096/fj.14-257915	http://dx.doi.org/10.1096/fj.14-257915			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25422369	Green Published			2022-12-28	WOS:000350633000019
J	Adini, I; Adini, A; Bazinet, L; Watnick, RS; Bielenberg, DR; D'Amato, RJ				Adini, Irit; Adini, Avner; Bazinet, Lauren; Watnick, Randolph S.; Bielenberg, Diane R.; D'Amato, Robert J.			Melanocyte pigmentation inversely correlates with MCP-1 production and angiogenesis-inducing potential	FASEB JOURNAL			English	Article						vascular biology; endothelial cells; FMOD; NF-kappa B	MONOCYTE CHEMOATTRACTANT PROTEIN-1; FACTOR-KAPPA-B; GENE-EXPRESSION; L-TYROSINE; MACULAR DEGENERATION; ENDOTHELIAL-CELLS; L-DOPA; CHEMOTACTIC PROTEIN-1; MELANIN PIGMENTATION; VASCULAR-DISEASE	The incidence of certain angiogenesis-dependent diseases is higher in Caucasians than in African Americans. Angiogenesis is amplified in wound healing and cornea models in albino C57 mice compared with black C57 mice. Moreover, mouse and human melanocytes with low pigmentation stimulate endothelial cell (EC) proliferation and migration in vitro more than melanocytes with high pigmentation. This effect is due, in part, to the secretion of an angiogenic protein called fibromodulin (FMOD) from lowly pigmented melanocytes. Herein, we expand upon the mechanism contributing to increased angiogenesis in lighter skin and report that monocyte chemotactic protein-1 (MCP-1) is secreted by nonpigmented mouse melanocytes by 5-to 10-fold more than pigmented melanocytes. MCP-1 protein stimulates EC proliferation and migration in vitro and angiogenesis in vivo. Mechanistic studies determine that FMOD is upstream of MCP-1 and promotes its secretion from both melanocytes and activated ECs via stimulation of NF-kappa B activity. Mice injected with FMOD-neutralizing antibodies show 2.3-fold decreased levels of circulating MCP-1. Human studies confirmed that, on average, Caucasians have 2-fold higher serum levels of MCP-1 than African Americans. Taken together, this study implicates the FMOD/MCP-1 pathway in the regulation of angiogenesis by local melanocytes and suggests that melanogenic activity may protect against aberrant angiogenic diseases.-Adini, I., Adini, A., Bazinet, L., Watnick, R. S., Bielenberg, D. R., and D'Amato, R. J. Melanocyte pigmentation inversely correlates with MCP-1 production and angiogenesis-inducing potential.	[Adini, Irit; Adini, Avner; Bazinet, Lauren; Watnick, Randolph S.; Bielenberg, Diane R.; D'Amato, Robert J.] Harvard Univ, Sch Med, Boston Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Adini, I (corresponding author), Harvard Univ, Med Ctr, Boston Childrens Hosp, Vasc Biol Program, 1 Blackfan Circle, Boston, MA 02115 USA.	irit.adini@gmail.com	Adini, Avner/AAD-6141-2022		NIH National Eye Institute [R01EY012726]; NATIONAL EYE INSTITUTE [R01EY012726] Funding Source: NIH RePORTER	NIH National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The authors thank Alexeev Y. Vitali and the Wellcome Trust Functional Genomics Cell Bank for primary murine melanocyte cells and Pouya Pakneshan for helping with ELISAs. I.A. performed the experiments, analyzed the data, and wrote the manuscript. A.A. and L.B. assisted with the experiments. D.R.B. and R.S.W. edited the manuscript. R.J.D. supervised the analysis and edited the manuscript. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. National Institutes of Health (NIH). Research reported in this publication was supported, in part, by the NIH National Eye Institute under Award Number R01EY012726 ( to R.J.D.). The authors declare no conflicts of interest.	Adini A, 2009, J IMMUNOL METHODS, V342, P78, DOI 10.1016/j.jim.2008.11.016; Adini I, 2014, J CLIN INVEST, V124, P425, DOI 10.1172/JCI69404; Alexeev V, 2000, PIGM CELL RES, V13, P72, DOI 10.1034/j.1600-0749.2000.130205.x; Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950; Aplin AC, 2014, ANGIOGENESIS, V17, P147, DOI 10.1007/s10456-013-9384-3; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17; Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477; Costa Carla, 2007, Angiogenesis, V10, P149, DOI 10.1007/s10456-007-9074-0; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; ELNER SG, 1991, LAB INVEST, V64, P819; Galvez BG, 2005, J BIOL CHEM, V280, P1292, DOI 10.1074/jbc.M408673200; Goede V, 1999, INT J CANCER, V82, P765, DOI 10.1002/(SICI)1097-0215(19990827)82:5<765::AID-IJC23>3.0.CO;2-F; Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233; Hong KH, 2005, BLOOD, V105, P1405, DOI 10.1182/blood-2004-08-3178; Jobin C, 1998, J IMMUNOL, V160, P410; Kim YW, 2013, J MOL MED, V91, P323, DOI 10.1007/s00109-013-1007-3; Lee JI, 1998, J CLIN PHARMACOL, V38, P981, DOI 10.1177/009127009803801101; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Noonan DM, 2008, CANCER METAST REV, V27, P31, DOI 10.1007/s10555-007-9108-5; Parry GCN, 1998, ARTERIOSCL THROM VAS, V18, P934, DOI 10.1161/01.ATV.18.6.934; Rao P, 2010, NATURE, V466, P1115, DOI 10.1038/nature09283; Rogers MS, 2007, NAT PROTOC, V2, P2545, DOI 10.1038/nprot.2007.368; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Satchi-Fainaro R, 2005, CANCER CELL, V7, P251, DOI 10.1016/j.ccr.2005.02.007; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; SHYY YJ, 1993, J CLIN INVEST, V92, P1745, DOI 10.1172/JCI116762; SLOMINSKI A, 1990, J THEOR BIOL, V143, P123, DOI 10.1016/S0022-5193(05)80292-9; SLOMINSKI A, 1993, J THEOR BIOL, V164, P103, DOI 10.1006/jtbi.1993.1142; SLOMINSKI A, 1989, PIGM CELL RES, V2, P109, DOI 10.1111/j.1600-0749.1989.tb00170.x; Slominski A, 2014, ARCH BIOCHEM BIOPHYS, V563, P79, DOI 10.1016/j.abb.2014.06.030; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; SLOMINSKI A, 1988, J CELL SCI, V89, P287; Slominski A, 2012, PIGM CELL MELANOMA R, V25, P14, DOI 10.1111/j.1755-148X.2011.00898.x; Slominski A, 2009, EXP DERMATOL, V18, P760, DOI 10.1111/j.1600-0625.2009.00892.x; Sviderskaya EV, 2010, PIGM CELL MELANOMA R, V23, P147, DOI 10.1111/j.1755-148X.2009.00641.x; Tobe M, 2003, BIOORGAN MED CHEM, V11, P3869, DOI 10.1016/S0968-0896(03)00438-3; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004; Wang XC, 1999, INVEST OPHTH VIS SCI, V40, P477; Zhang LQ, 2011, MOL BIOL CELL, V22, P128, DOI 10.1091/mbc.E10-06-0556	43	18	20	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					662	670		10.1096/fj.14-255398	http://dx.doi.org/10.1096/fj.14-255398			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25406462	Green Published			2022-12-28	WOS:000349370400027
J	Bourne, HR				Bourne, Henry R.			Is 6 Years Too Long to Get a Ph.D. in Biomedical Science?	FASEB JOURNAL			English	Editorial Material									Univ Calif San Francisco, Sch Med, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco	Bourne, HR (corresponding author), Univ Calif San Francisco, Sch Med, Dept Cellular & Mol Pharmacol, Genentech Hall,N212F,600 16th St, San Francisco, CA 94158 USA.	henry.bourne@ucsf.edu						Alberts B, 2014, P NATL ACAD SCI USA, V111, P5773, DOI 10.1073/pnas.1404402111; Bourne H. R., 2012, NIH SUPP PHD TRAIN; Bourne HR, 2013, ELIFE, V2, DOI 10.7554/eLife.01139; Bourne HR, 2013, ELIFE, V2, DOI 10.7554/eLife.00642; Department of Health and Human Services, 2015, JUST EST APPR COMM, V1; National Institutes of Health, 2012, BIOM RES WORKF WORK; National Science Foundation, SURV GRAD STUD POSTD	7	0	0	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					357	360		10.1096/fj.15-0201ufm	http://dx.doi.org/10.1096/fj.15-0201ufm			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25649813				2022-12-28	WOS:000349370400001
J	Gerbier, R; Leroux, V; Couvineau, P; Alvear-Perez, R; Maigret, B; Llorens-Cortes, C; Iturrioz, X				Gerbier, Romain; Leroux, Vincent; Couvineau, Pierre; Alvear-Perez, Rodrigo; Maigret, Bernard; Llorens-Cortes, Catherine; Iturrioz, Xavier			New structural insights into the apelin receptor: identification of key residues for apelin binding	FASEB JOURNAL			English	Article						APJ; G protein-coupled receptor; homology models; molecular modeling; site-directed mutagenesis	PROTEIN-COUPLED RECEPTORS; ENDOGENOUS LIGAND APELIN; HUMAN APJ RECEPTOR; ANGIOTENSIN-II; EXTRACELLULAR LOOP; CARDIAC CONTRACTILITY; HIV-1 CORECEPTOR; OSMOTIC STIMULI; RAT-BRAIN; PEPTIDE	Apelin is the endogenous ligand of the orphan7-transmembrane domain GPCRAPJ, now named the apelin receptor (ApelinR). Apelin plays a prominent role in body fluid and cardiovascular homeostasis. To better understand the structural organization of the ApelinR, we built 3 homology 3-dimensional (3D) models of the human ApelinR using the validated cholecystokinin receptor-1 3D model or the X-ray structures of the beta(2)-adrenergic and CXCR4 receptors as templates. Docking of the pyroglutamyl form of apelin 13 (pE13F) into these models revealed the conservation at the bottom of the binding site of a hydrophobic cavity in which the C-terminal Phe of pE13F was embedded. In contrast, at the top of the binding site, depending on the model, different interactions were visualized between acidic residues of the ApelinR and the basic residues of pE13F. Using site-directed mutagenesis, we showed that Asp 92, Glu 172, and Asp 282 of rat ApelinR are key residues in apelin binding by interacting with Lys 8, Arg 2, and Arg 4 of pE13F, respectively. These residues are only seen in the CXCR4-based ApelinR 3D model, further validating this model. These findings bring new insights into the structural organization of the ApelinR and the mode of apelin binding.	[Gerbier, Romain; Leroux, Vincent; Couvineau, Pierre; Alvear-Perez, Rodrigo; Maigret, Bernard; Llorens-Cortes, Catherine; Iturrioz, Xavier] Coll France, CIRB, Lab Cent Neuropeptides Regulat Body Fluid Homeost, F-75005 Paris, France; [Gerbier, Romain; Leroux, Vincent; Couvineau, Pierre; Alvear-Perez, Rodrigo; Maigret, Bernard; Llorens-Cortes, Catherine; Iturrioz, Xavier] CNRS, UMR 7241, Paris, France; [Gerbier, Romain; Leroux, Vincent; Couvineau, Pierre; Alvear-Perez, Rodrigo; Maigret, Bernard; Llorens-Cortes, Catherine; Iturrioz, Xavier] INSERM, U1050, Paris, France	UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; College de France; Ecole Normale Superieure (ENS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Iturrioz, X (corresponding author), Coll France, CIRB, Lab Cent Neuropeptides Regulat Body Fluid Homeost, 11 Pl Marcelin Berthelot, F-75005 Paris, France.	c.llorens-cortes@college-de-france.fr; xavier.iturrioz@college-de-france.fr	Llorens-Cortès, catherine/AAL-3893-2021; Iturrioz, Xavier/AAS-3555-2020; GERBIER, Romain/ABF-2481-2020; ITURRIOZ, Xavier/Q-4406-2017; Llorens-Cortes, Catherine/E-5839-2016	Llorens-Cortès, catherine/0000-0002-7667-0401; Iturrioz, Xavier/0000-0001-7143-8323; ITURRIOZ, Xavier/0000-0001-7143-8323; Llorens-Cortes, Catherine/0000-0002-7667-0401; Couvineau, Pierre/0000-0002-4905-7740; Leroux, Vincent/0000-0002-4142-0883; Gerbier, Romain/0000-0003-4617-4850				Ashley EA, 2005, CARDIOVASC RES, V65, P73, DOI 10.1016/j.cardiores.2004.08.018; Audet M, 2012, CELL, V151, P14, DOI 10.1016/j.cell.2012.09.003; Azizi M, 2008, J AM SOC NEPHROL, V19, P1015, DOI 10.1681/ASN.2007070816; Berman HM, 2013, FEBS LETT, V587, P1036, DOI 10.1016/j.febslet.2012.12.029; Berry MF, 2004, CIRCULATION, V110, pII187, DOI 10.1161/01.CIR.0000138382.57325.5c; Castan-Iaurell I, 2012, TRENDS ENDOCRIN MET, V23, P234, DOI 10.1016/j.tem.2012.02.005; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Correa SAA, 2006, REGUL PEPTIDES, V134, P132, DOI 10.1016/j.regpep.2006.02.008; De Mota N, 2000, NEUROENDOCRINOLOGY, V72, P400, DOI 10.1159/000054609; De Mota N, 2004, P NATL ACAD SCI USA, V101, P10464, DOI 10.1073/pnas.0403518101; Evans NA, 2001, J NEUROCHEM, V77, P476, DOI 10.1046/j.1471-4159.2001.00269.x; Fan XJ, 2003, BIOCHEMISTRY-US, V42, P10163, DOI 10.1021/bi030049s; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; Fillion D, 2013, J BIOL CHEM, V288, P8187, DOI 10.1074/jbc.M112.442053; Galanth C, 2012, CURR PHARM DESIGN, V18, P789, DOI 10.2174/138161212799277770; Habata Y, 1999, BBA-MOL CELL RES, V1452, P25, DOI 10.1016/S0167-4889(99)00114-7; Henin J, 2006, BIOPHYS J, V90, P1232, DOI 10.1529/biophysj.105.070599; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; Howl J, 1996, BIOCHEM J, V317, P577, DOI 10.1042/bj3170577; Hsin Jen, 2008, Curr Protoc Bioinformatics, VChapter 5, DOI 10.1002/0471250953.bi0507s24; Iturrioz X, 2010, J BIOL CHEM, V285, P32627, DOI 10.1074/jbc.M110.127167; Iturrioz X, 2010, FASEB J, V24, P1506, DOI 10.1096/fj.09-140715; Japp AG, 2008, BIOCHEM PHARMACOL, V75, P1882, DOI 10.1016/j.bcp.2007.12.015; Katritch V, 2013, ANNU REV PHARMACOL, V53, P531, DOI 10.1146/annurev-pharmtox-032112-135923; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Klco JM, 2006, J BIOL CHEM, V281, P12010, DOI 10.1074/jbc.M600548200; Langelaan DN, 2013, BBA-BIOMEMBRANES, V1828, P1471, DOI 10.1016/j.bbamem.2013.02.005; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Lenkei Z, 2000, J HISTOCHEM CYTOCHEM, V48, P1553, DOI 10.1177/002215540004801112; Medhurst AD, 2003, J NEUROCHEM, V84, P1162, DOI 10.1046/j.1471-4159.2003.01587.x; Mesmin C, 2011, J PROTEOME RES, V10, P5222, DOI 10.1021/pr200725x; Messari SE, 2004, J NEUROCHEM, V90, P1290, DOI 10.1111/j.1471-4159.2004.02591.x; Millar RP, 2004, ENDOCRINOLOGY, V145, P3590, DOI 10.1210/en.2004-0461; Nicastro G, 2003, J PEPT SCI, V9, P229, DOI 10.1002/psc.449; O'Carroll AM, 2000, BBA-GENE STRUCT EXPR, V1492, P72, DOI 10.1016/S0167-4781(00)00072-5; O'Carroll AM, 2003, J NEUROENDOCRINOL, V15, P661, DOI 10.1046/j.1365-2826.2003.01044.x; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Reaux A, 2001, J NEUROCHEM, V77, P1085, DOI 10.1046/j.1471-4159.2001.00320.x; Reaux A, 2002, NEUROSCIENCE, V113, P653, DOI 10.1016/S0306-4522(02)00192-6; Reaux-Le Goazigo A, 2004, ENDOCRINOLOGY, V145, P4392, DOI 10.1210/en.2004-0384; Schioth HB, 2005, GEN COMP ENDOCR, V142, P94, DOI 10.1016/j.ygcen.2004.12.018; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Szokodi I, 2002, CIRC RES, V91, P434, DOI 10.1161/01.RES.0000033522.37861.69; Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Venkatakrishnan AJ, 2013, NATURE, V494, P185, DOI 10.1038/nature11896; Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396; YAMANO Y, 1995, J BIOL CHEM, V270, P14024, DOI 10.1074/jbc.270.23.14024; Zhou HP, 2000, ARCH BIOCHEM BIOPHYS, V373, P211, DOI 10.1006/abbi.1999.1555; Zhou NM, 2003, VIROLOGY, V317, P84, DOI 10.1016/j.virol.2003.08.026; Zhou NM, 2003, VIROLOGY, V307, P22, DOI 10.1016/S0042-6822(02)00021-1; Zhu X, 2012, WIRES COMPUT MOL SCI, V2, P167, DOI 10.1002/wcms.74	53	33	39	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					314	322		10.1096/fj.14-256339	http://dx.doi.org/10.1096/fj.14-256339			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25359495				2022-12-28	WOS:000347378600029
J	Huang, H; Langenkamp, E; Georganaki, M; Loskog, A; Fuchs, PF; Dieterich, LC; Kreuger, J; Dimberg, A				Huang, Hua; Langenkamp, Elise; Georganaki, Maria; Loskog, Angelica; Fuchs, Peder Fredlund; Dieterich, Lothar C.; Kreuger, Johan; Dimberg, Anna			VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kappa B-induced endothelial activation	FASEB JOURNAL			English	Article						leukocyte recruitment; adhesion molecule	STIMULATED RESPONSE ELEMENT; GROWTH-FACTOR; IKK-BETA; LEUKOCYTE ADHESION; INTERFERON-BETA; BLOOD-VESSELS; CELL-ADHESION; IFN-GAMMA; ANGIOGENESIS; EXPRESSION	Antiangiogenic treatment targeting the vascular endothelial growth factor (VEGF) signaling pathway is in clinical use, but its effect on vascular function and the tumor microenvironment is poorly understood. Here, we investigate cross-talk between VEGF and proinflammatory TNF-alpha signaling in endothelial cells and its impact on leukocyte recruitment. We found that cotreatment with VEGF decreased TNF-alpha-induced Jurkat cell adhesion to human microvascular endothelial cells by 40%. This was associated with inhibition of TNF-alpha-mediated regulation of 86 genes, including 2 T-lymphocyte-attracting chemokines, CXCL10 and CXCL11 [TNF-alpha concentration 1 ng/ml; 50% inhibition/inhibitory concentration (IC50) VEGF, 3 ng/ml]. Notably, VEGF directly suppressed TNF-alpha-induced gene expression through negative cross-talk with the NF-kappa B-signaling pathway, leading to an early decrease in IFN regulatory factor 1 (IRF-1) expression and reduced phosphorylation of signal transducer andactivatorof transcription 1 (p-Stat1) at later times. Inhibition of VEGF signaling in B16 melanomatumor-bearingmicebysunitinib treatmentresulted in up-regulation of CXCL10 and CXCL11 in tumor vessels, accompanied by up to 18-fold increased infiltration of CD3+ T-lymphocytes in B16 tumors. Our results demonstrate a novel role of VEGF in negative regulation of NF kappa B signaling and endothelial activation in the tumor microenvironment and provide evidence that pharmacological inhibition of VEGF signaling enhances T-lymphocyte recruitment through up-regulation of chemokinesCXCL10 and CXCL11.	[Huang, Hua; Langenkamp, Elise; Georganaki, Maria; Loskog, Angelica; Dieterich, Lothar C.; Dimberg, Anna] Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden; [Fuchs, Peder Fredlund; Kreuger, Johan] Uppsala Univ, Sci Life Lab, Biomed Ctr, Dept Med Biochem & Microbiol, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University	Dimberg, A (corresponding author), Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden.	anna.dimberg@igp.uu.se	Kreuger, Johan/HDM-1503-2022	Dieterich, Lothar/0000-0001-7908-5710; Dimberg, Anna/0000-0003-4422-9125				Baluk P, 2005, CURR OPIN GENET DEV, V15, P102, DOI 10.1016/j.gde.2004.12.005; Barkefors I, 2008, J BIOL CHEM, V283, P13905, DOI 10.1074/jbc.M704917200; Barkefors I, 2009, LAB CHIP, V9, P529, DOI 10.1039/b814691h; Bartoli M, 2003, FASEB J, V17, P1562, DOI 10.1096/fj.02-1084fje; Bose A, 2011, INT J CANCER, V129, P2158, DOI 10.1002/ijc.25863; Bouzin C, 2007, J IMMUNOL, V178, P1505, DOI 10.4049/jimmunol.178.3.1505; Buttmann M, 2007, J VASC RES, V44, P51, DOI 10.1159/000097977; Cindrova-Davies T, 2011, CARDIOVASC RES, V89, P671, DOI 10.1093/cvr/cvq346; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Croll SD, 2004, EXP NEUROL, V187, P388, DOI 10.1016/j.expneurol.2004.02.010; Darwech I, 2010, J BIOL CHEM, V285, P25522, DOI 10.1074/jbc.M110.121533; Dieterich LC, 2012, J PATHOL, V228, P378, DOI 10.1002/path.4072; Dimberg A, 2010, CURR TOP MICROBIOL, V341, P59, DOI 10.1007/82_2010_21; Dirkx AEM, 2003, CANCER RES, V63, P2322; Dirkx AEM, 2006, FASEB J, V20, P621, DOI 10.1096/fj.05-4493com; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Flati V, 2006, INT J IMMUNOPATH PH, V19, P761, DOI 10.1177/039463200601900406; Franco M, 2011, BLOOD, V118, P2906, DOI 10.1182/blood-2011-01-331694; Goebel S, 2006, AM J PHYSIOL-GASTR L, V290, pG648, DOI 10.1152/ajpgi.00466.2005; Griffioen AW, 1996, CANCER RES, V56, P1111; Griffioen AW, 1999, INT J CANCER, V80, P315, DOI 10.1002/(SICI)1097-0215(19990118)80:2<315::AID-IJC23>3.0.CO;2-L; Griffioen AW, 1996, BLOOD, V88, P667, DOI 10.1182/blood.V88.2.667.bloodjournal882667; Groom JR, 2011, IMMUNOL CELL BIOL, V89, P207, DOI 10.1038/icb.2010.158; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harikumar KB, 2014, NAT IMMUNOL, V15, P231, DOI 10.1038/ni.2810; Ho HH, 2006, J BIOL CHEM, V281, P14111, DOI 10.1074/jbc.M511797200; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Majumder S, 1998, J IMMUNOL, V161, P4736; McDonald DM, 2005, CHEST, V128, p602S, DOI 10.1378/chest.128.6_suppl.602S-a; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; OHMORI Y, 1995, J IMMUNOL, V154, P5235; Ozao-Choy J, 2009, CANCER RES, V69, P2514, DOI 10.1158/0008-5472.CAN-08-4709; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171; Shrimali RK, 2010, CANCER RES, V70, P6171, DOI 10.1158/0008-5472.CAN-10-0153; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; St Croix B, 2000, SCIENCE, V289, P1197; Venkatesh D, 2013, IMMUNITY, V38, P1025, DOI 10.1016/j.immuni.2013.01.012; Wang JJ, 2010, DIABETES, V59, P2297, DOI 10.2337/db09-1420; WU CQ, 1994, J INTERFERON RES, V14, P357, DOI 10.1089/jir.1994.14.357; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Yarilina A, 2008, NAT IMMUNOL, V9, P378, DOI 10.1038/ni1576; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	48	119	120	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					227	238		10.1096/fj.14-250985	http://dx.doi.org/10.1096/fj.14-250985			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25361735				2022-12-28	WOS:000347378600022
J	Lee, YH; Petkova, AP; Konkar, AA; Granneman, JG				Lee, Yun-Hee; Petkova, Anelia P.; Konkar, Anish A.; Granneman, James G.			Cellular origins of cold-induced brown adipocytes in adult mice	FASEB JOURNAL			English	Article						lineage tracing; adipogenesis; innervation; tyrosine hydroxylase; Myf5	WHITE ADIPOSE-TISSUE; ADIPOGENIC NICHE; FAT-CELLS; IDENTIFICATION; MOUSE; PROLIFERATION; DISTINCT; REVEALS; THERMOGENESIS; MACROPHAGES	This work investigated how cold stress induces the appearance of brown adipocytes (BAs) in brown and white adipose tissues (WATs) of adult mice. In interscapular brown adipose tissue (iBAT), cold exposure increased proliferation of endothelial cells and interstitial cells expressing platelet-derived growth factor receptor, a polypeptide (PDGFR alpha) by 3-to 4-fold. Surprisingly, brown adipogenesis and angiogenesis were largely restricted to the dorsal edge of iBAT. Although cold stress did not increase proliferation in inguinal white adipose tissue (ingWAT), the percentage of BAs, defined as multilocular adipocytes that express uncoupling protein 1, rose from undetectable to 30% of total adipocytes. To trace the origins of cold-induced BAs, we genetically tagged PDGFR(alpha+) cells and adipocytes prior to cold exposure, using Pdgfra-Cre recombinase estrogen receptor T2 fusion protein (CreER(T2)) and adiponectin-CreER(T2), respectively. In iBAT, cold stress triggered the proliferation and differentiation of PDGFR(alpha+) cells into BAs. In contrast, all newly observed BAs in ingWAT (5207 out of 5207) were derived from unilocular adipocytes tagged by adiponectin-CreER(T2)-mediated recombination. Surgical denervation of iBAT reduced cold-induced brown adipogenesis by > 85%, whereas infusion of norepinephrine (NE) mimicked the effects of cold in warm-adapted mice. NE-induced de novo brown adipogenesis in iBAT was eliminated in mice lacking beta 1-adrenergic receptors. These observations identify a novel tissue niche for brown adipogenesis in iBAT and further define depotspecific mechanisms of BA recruitment.	[Lee, Yun-Hee; Petkova, Anelia P.; Konkar, Anish A.; Granneman, James G.] Wayne State Univ, Sch Med, Ctr Integrat Metab & Endocrine Res, Detroit, MI 48201 USA	Wayne State University	Granneman, JG (corresponding author), Wayne State Univ, Sch Med, Ctr Integrat Metab & Endocrine Res, Detroit, MI 48201 USA.	jgranne@med.wayne.edu			NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076629, P30DK020572, R01DK062292] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA022453, P30 CA022453] Funding Source: Medline; NIDDK NIH HHS [R01DK62292, R01 DK076629, R01 DK062292, R01DK76629, P30 DK020572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbatelli G, 2010, AM J PHYSIOL-ENDOC M, V298, pE1244, DOI 10.1152/ajpendo.00600.2009; Bartelt A, 2011, NAT MED, V17, P200, DOI 10.1038/nm.2297; Berry R, 2013, NAT CELL BIOL, V15, P302, DOI 10.1038/ncb2696; Blondin DP, 2014, J CLIN ENDOCR METAB, V99, pE438, DOI 10.1210/jc.2013-3901; Bronnikov G, 1999, ENDOCRINOLOGY, V140, P4185, DOI 10.1210/en.140.9.4185; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; BUKOWIECKI L, 1982, AM J PHYSIOL, V242, pE353, DOI 10.1152/ajpendo.1982.242.6.E353; BUKOWIECKI LJ, 1986, AM J PHYSIOL, V250, pC880, DOI 10.1152/ajpcell.1986.250.6.C880; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; COUSIN B, 1992, J CELL SCI, V103, P931; Cypess AM, 2012, P NATL ACAD SCI USA, V109, P10001, DOI 10.1073/pnas.1207911109; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; GELOEN A, 1992, AM J PHYSIOL, V263, pR1176, DOI 10.1152/ajpregu.1992.263.6.R1176; Gensch N, 2008, DEVELOPMENT, V135, P1597, DOI 10.1242/dev.019331; Gesta S, 2007, CELL, V131, P242, DOI 10.1016/j.cell.2007.10.004; Gouon-Evans V, 2002, MOL ENDOCRINOL, V16, P2618, DOI 10.1210/me.2001-0337; Granneman JG, 2009, J BIOL CHEM, V284, P34538, DOI 10.1074/jbc.M109.068478; GRANNEMAN JG, 1984, METABOLISM, V33, P257, DOI 10.1016/0026-0495(84)90047-7; Granneman JG, 2005, AM J PHYSIOL-ENDOC M, V289, pE608, DOI 10.1152/ajpendo.00009.2005; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Harms M, 2013, NAT MED, V19, P1252, DOI 10.1038/nm.3361; Himms-Hagen J, 2000, AM J PHYSIOL-CELL PH, V279, pC670, DOI 10.1152/ajpcell.2000.279.3.C670; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; HIMMSHAGGEN J, 1969, J PHYSIOL-LONDON, V205, P393, DOI 10.1113/jphysiol.1969.sp008973; Jimenez M, 2003, EUR J BIOCHEM, V270, P699, DOI 10.1046/j.1432-1033.2003.03422.x; Tran KV, 2012, CELL METAB, V15, P222, DOI 10.1016/j.cmet.2012.01.008; Konkar AA, 2000, MOL PHARMACOL, V57, P252; Lee YH, 2014, CELL CYCLE, V13, P184, DOI 10.4161/cc.27647; Lee YH, 2012, ADIPOCYTE, V1, P230, DOI 10.4161/adip.20804; Lee YH, 2013, CELL METAB, V18, P355, DOI 10.1016/j.cmet.2013.08.003; Lee YH, 2012, CELL METAB, V15, P480, DOI 10.1016/j.cmet.2012.03.009; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Master SR, 2002, MOL ENDOCRINOL, V16, P1185, DOI 10.1210/me.16.6.1185; Moore HPH, 2005, J BIOL CHEM, V280, P43109, DOI 10.1074/jbc.M506336200; Muzik Otto, 2012, Front Endocrinol (Lausanne), V3, P15, DOI 10.3389/fendo.2012.00015; Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653; Ouellet V, 2012, J CLIN INVEST, V122, P545, DOI 10.1172/JCI60433; Petrovic N, 2010, J BIOL CHEM, V285, P7153, DOI 10.1074/jbc.M109.053942; Preibisch S, 2009, BIOINFORMATICS, V25, P1463, DOI 10.1093/bioinformatics/btp184; Rivers LE, 2008, NAT NEUROSCI, V11, P1392, DOI 10.1038/nn.2220; Rosenwald M, 2013, NAT CELL BIOL, V15, P659, DOI 10.1038/ncb2740; Sanchez-Gurmaches J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5099; Sanchez-Gurmaches J, 2012, CELL METAB, V16, P348, DOI 10.1016/j.cmet.2012.08.003; SCHNEIDERPICARD G, 1980, J LIPID RES, V21, P600; Schulz TJ, 2011, P NATL ACAD SCI USA, V108, P143, DOI 10.1073/pnas.1010929108; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Seibler J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng012; Stanford KI, 2013, J CLIN INVEST, V123, P215, DOI 10.1172/JCI62308; Tseng YH, 2010, NAT REV DRUG DISCOV, V9, P465, DOI 10.1038/nrd3138; van der Lans AAJJ, 2013, J CLIN INVEST, V123, P3395, DOI 10.1172/JCI68993; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Walden TB, 2012, AM J PHYSIOL-ENDOC M, V302, pE19, DOI 10.1152/ajpendo.00249.2011; Wang QA, 2013, NAT MED, V19, P1338, DOI 10.1038/nm.3324; Wu J, 2012, CELL, V150, P366, DOI 10.1016/j.cell.2012.05.016; Xue BZ, 2007, J LIPID RES, V48, P41, DOI 10.1194/jlr.M600287-JLR200; Yoneshiro T, 2013, J CLIN INVEST, V123, P3404, DOI 10.1172/JCI67803; Zingaretti MC, 2009, FASEB J, V23, P3113, DOI 10.1096/fj.09-133546	59	182	185	1	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					286	299		10.1096/fj.14-263038	http://dx.doi.org/10.1096/fj.14-263038			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25392270	Green Published			2022-12-28	WOS:000347378600027
J	Park, S; Fujishita, C; Komatsu, T; Kim, SE; Chiba, T; Mori, R; Shimokawa, I				Park, Seongjoon; Fujishita, Chika; Komatsu, Toshimitsu; Kim, Sang Eun; Chiba, Takuya; Mori, Ryoichi; Shimokawa, Isao			NPY antagonism reduces adiposity and attenuates age-related imbalance of adipose tissue metabolism	FASEB JOURNAL			English	Article						adipocytes; lipid metabolism; sirtuins	BODY-MASS INDEX; HORMONE-SENSITIVE LIPASE; FATTY-ACID OXIDATION; Y GENE-EXPRESSION; NEUROPEPTIDE-Y; CALORIC RESTRICTION; FEEDING-BEHAVIOR; BROWN ADIPOCYTES; ENERGY-BALANCE; SIRT1	An orexigenic hormone, neuropeptide Y (NPY), plays a role not only in the hypothalamic regulation of appetite, but also in the peripheral regulation of lipid metabolism. However, the intracellular mechanisms triggered by NPY to regulate lipid metabolism are poorly understood. Here we report that NPY deficiency reduces white adipose tissue (WAT) mass and ameliorates the age-related imbalance of adipose tissue metabolism in mice. Gene expression involved in adipogenesis/lipogenesis was found to decrease, whereas proteins involved in lipolysis increased in gonadal WAT (gWAT) of NPY-knockout mice. These changes were associated with an activated SIRT1- and PPAR gamma-mediated pathway. Moreover, the age-related decrease of de novo lipogenesis in gWAT and thermogenesis in inguinal WAT was inhibited by NPY deficiency. Further analysis using 3T3-L1 cells showed that NPY inhibited lipolysis through the Y1 receptor and enhanced lipogenesis following a reduction in cAMP response element-binding protein (CREB) and SIRT1 protein expression. Therefore, NPY appears to act as a key regulator of adipose tissue metabolism via the CREB-SIRT1 signaling pathway. Taken together, NPY deficiency reduces adiposity and ameliorates the age-related imbalance of adipose tissue metabolism, suggesting that antagonism of NPY may be a promising target for drug development to prevent age-related metabolic diseases.	[Park, Seongjoon; Fujishita, Chika; Komatsu, Toshimitsu; Kim, Sang Eun; Chiba, Takuya; Mori, Ryoichi; Shimokawa, Isao] Nagasaki Univ, Sch Med, Grad Sch Biomed Sci, Dept Pathol, Nagasaki 8528523, Japan	Nagasaki University	Park, S (corresponding author), Nagasaki Univ, Sch Med, Grad Sch Biomed Sci, Dept Pathol, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	psj10262000@yahoo.co.kr		Mori, Ryoichi/0000-0002-7596-9620; Kim, Sang-Eun/0000-0002-5811-759X	Japan Society for the Promotion of Science (JSPS) [22390042]; JSPS Asian Core Program; Grants-in-Aid for Scientific Research [25560055] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); JSPS Asian Core Program(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors are grateful to the staff at the Biomedical Research Center (Center for Frontier Life Sciences, Nagasaki University, Nagasaki City, Japan) for their technical assistance and animal care. The authos also thank Yutaka Araki, Yuko Moriyama, and Chika Matsumoto for excellent technical assistance. This work was supported by grants-in-aid for scientific research from the Japan Society for the Promotion of Science (JSPS; no. 22390042) and the JSPS Asian Core Program.	Ahn J, 2013, EMBO MOL MED, V5, P1602, DOI 10.1002/emmm.201302647; Araki S, 2004, GERONTOLOGY, V50, P206, DOI 10.1159/000078349; Bannon AW, 2000, BRAIN RES, V868, P79, DOI 10.1016/S0006-8993(00)02285-X; Barsh GS, 2002, NAT REV GENET, V3, P589, DOI [10.1038/nrn902, 10.1038/nrg862]; Beck B, 2006, PHILOS T R SOC B, V361, P1159, DOI 10.1098/rstb.2006.1855; Benz V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037794; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Bradley RL, 2005, OBES RES, V13, P653, DOI 10.1038/oby.2005.73; Cao HM, 2008, CELL, V134, P933, DOI 10.1016/j.cell.2008.07.048; Chakrabarti P, 2011, J LIPID RES, V52, P1693, DOI 10.1194/jlr.M014647; Chalkiadaki A, 2012, CELL METAB, V16, P180, DOI 10.1016/j.cmet.2012.07.003; Chao PT, 2011, CELL METAB, V13, P573, DOI 10.1016/j.cmet.2011.02.019; Chiba T, 2014, SCI REP-UK, V4, DOI 10.1038/srep04517; Choi CS, 2007, P NATL ACAD SCI USA, V104, P16480, DOI 10.1073/pnas.0706794104; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; Cohen P, 2014, CELL, V156, P304, DOI 10.1016/j.cell.2013.12.021; Dhillon SS, 2011, INT J OBESITY, V35, P198, DOI 10.1038/ijo.2010.124; Dietrich MO, 2010, J NEUROSCI, V30, P11815, DOI 10.1523/JNEUROSCI.2234-10.2010; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; Gabriely I, 2002, DIABETES, V51, P2951, DOI 10.2337/diabetes.51.10.2951; Gerhart-Hines Z, 2011, MOL CELL, V44, P851, DOI 10.1016/j.molcel.2011.12.005; GRUENEWALD DA, 1994, ENDOCRINOLOGY, V134, P2383, DOI 10.1210/en.134.6.2383; Heiman ML, 2003, ENDOCRINE, V20, P149, DOI 10.1385/ENDO:20:1-2:149; Heo M, 2003, STAT MED, V22, P1911, DOI 10.1002/sim.1218; Herman MA, 2012, NATURE, V484, P333, DOI 10.1038/nature10986; Herskovits AZ, 2013, CELL RES, V23, P746, DOI 10.1038/cr.2013.70; Ishihara A, 2006, P NATL ACAD SCI USA, V103, P7154, DOI 10.1073/pnas.0510320103; Jeong H, 2012, NAT MED, V18, P159, DOI 10.1038/nm.2559; JHANWARUNIYAL M, 1990, BRAIN RES, V536, P331, DOI 10.1016/0006-8993(90)90045-D; Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Kuriyama H, 2005, CELL METAB, V1, P41, DOI 10.1016/j.cmet.2004.11.004; Lafontan M, 2009, PROG LIPID RES, V48, P275, DOI 10.1016/j.plipres.2009.05.001; LEITER EH, 1988, FASEB J, V2, P2807, DOI 10.1096/fasebj.2.12.3044905; Martin ASG, 2006, AM J CLIN NUTR, V83, p461S, DOI 10.1093/ajcn/83.2.461s; McDonald RB, 1999, J BIOENERG BIOMEMBR, V31, P507, DOI 10.1023/A:1005404708710; Mott JW, 1999, AM J CLIN NUTR, V69, P1007; Muzumdar R, 2008, AGING CELL, V7, P438, DOI 10.1111/j.1474-9726.2008.00391.x; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Noriega LG, 2011, EMBO REP, V12, P1069, DOI 10.1038/embor.2011.151; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Reid BN, 2008, J BIOL CHEM, V283, P13087, DOI 10.1074/jbc.M800533200; Reusch JEB, 2002, J BIOL CHEM, V277, P1426, DOI 10.1074/jbc.M107923200; Rogers NH, 2012, AGING CELL, V11, P1074, DOI 10.1111/acel.12010; Rojas JM, 2012, AM J PHYSIOL-ENDOC M, V303, pE1479, DOI 10.1152/ajpendo.00351.2012; ROUBENOFF R, 1995, AM J PUBLIC HEALTH, V85, P726, DOI 10.2105/AJPH.85.5.726; Ruohonen S. T., 2012, INT J PEPT, V2012; SAHU A, 1992, MOL BRAIN RES, V15, P15, DOI 10.1016/0169-328X(92)90145-2; Serradeil-Le Gal C, 2000, FEBS LETT, V475, P150, DOI 10.1016/S0014-5793(00)01649-5; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; STANLEY BG, 1993, BRAIN RES, V604, P304; STANLEY BG, 1986, PEPTIDES, V7, P1189; Sugatani J, 2014, FASEB J, V28, P440, DOI 10.1096/fj.13-233262; Ueno M, 2008, AM J PHYSIOL-ENDOC M, V294, pE1109, DOI 10.1152/ajpendo.00016.2008; Veyrat-Durebex C, 2013, NEUROPEPTIDES, V47, P163, DOI 10.1016/j.npep.2013.01.001; WETTSTEIN JG, 1995, PHARMACOL THERAPEUT, V65, P397, DOI 10.1016/0163-7258(95)98598-K; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; Wu DY, 2007, J IMMUNOL, V179, P4829, DOI 10.4049/jimmunol.179.7.4829; Xu C, 2013, AM J TRANSL RES, V5, P412; Xue BZ, 2005, MOL CELL BIOL, V25, P8311, DOI 10.1128/MCB.25.18.8311-8322.2005; Yang JN, 2007, ACTA PHYSIOL, V190, P63, DOI 10.1111/j.1365-201X.2007.01690.x; Yang KP, 2008, FASEB J, V22, P2452, DOI 10.1096/fj.07-100735; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; Zhu M, 2004, EXP GERONTOL, V39, P1049, DOI 10.1016/j.exger.2004.03.024	64	26	27	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5337	5348		10.1096/fj.14-258384	http://dx.doi.org/10.1096/fj.14-258384			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25205743				2022-12-28	WOS:000345894500027
J	Mediero, A; Perez-Aso, M; Cronstein, BN				Mediero, Aranzazu; Perez-Aso, Miguel; Cronstein, Bruce N.			Activation of EPAC1/2 is essential for osteoclast formation by modulating NF kappa B nuclear translocation and actin cytoskeleton rearrangements	FASEB JOURNAL			English	Article						RhoA; cdc42; Rac1; FAK	BONE-RESORPTION; MOLECULAR-MECHANISM; RECEPTOR; DIFFERENTIATION; OSTEOPROTEGERIN; EXPRESSION; PROTEINS; CELLS; RANK; OSTEOPETROSIS	Bisphosphonates inhibit osteoclast differentiation/function via inhibition of Rap1A isoprenylation. As Rap1 is the effector of exchange protein directly activated by cAMP (EPAC) proteins, we determined the role of EPAC in osteoclast differentiation. We examined osteoclast differentiation as the number of primary murine/human bone-marrow precursors that differentiated into multinucleated TRAP-positive cells in the presence of EPAC-selective stimulus (8-pCTP-2-O-Me-cAMP, 100 M; 8-pCTP-2-O-Me-cAMP-AM, 1 M) or inhibitor brefeldin A (BFA), ESI-05, and ESI-09 (10 M each). Rap1 activity was assessed, and signaling events, as well as differentiation in EPAC1/2-knockdown RAW264.7 cells, were studied. Direct EPAC1/2 stimulation significantly increased osteoclast differentiation, whereas EPAC1/2 inhibition diminished differentiation (113 +/- 6%, P<0.05, and 42 +/- 10%, P<0.001, of basal, respectively). Rap1 activation was maximal 15 min after RANKL stimulation (147 +/- 9% of basal, P<0.001), whereas silencing of EPAC1/2 diminished activated Rap1 (43 +/- 13 and 20 +/- 15% of control, P<0.001) and NFkB nuclear translocation. TRAP-staining revealed no osteoclast differentiation in EPAC1/2-KO cells. Cathepsin K, NFATc1, and osteopontin mRNA expression decreased in EPAC1/2-KO cells when compared to control. RhoA, cdc42, Rac1, and FAK were activated in an EPAC1/2-dependent manner, and there was diminished cytoskeletal assembly in EPAC1/2-KO cells. In summary, EPAC1 and EPAC2 are critical signaling intermediates in osteoclast differentiation that permit RANKL-stimulated NFkB nuclear translocation and actin rearrangements. Targeting this signaling intermediate may diminish bone destruction in inflammatory arthritis.Mediero, A., Perez-Aso, M., Cronstein, B. N. Activation of EPAC1/2 is essential for osteoclast formation by modulating NFB nuclear translocation and actin cytoskeleton rearrangements.	[Mediero, Aranzazu; Perez-Aso, Miguel; Cronstein, Bruce N.] NYU, Sch Med, Dept Med, Div Translat Med, 550 First Ave,MSB251, New York, NY 10016 USA	New York University	Cronstein, BN (corresponding author), NYU, Sch Med, Dept Med, Div Translat Med, 550 First Ave,MSB251, New York, NY 10016 USA.	bruce.cronstein@nyumc.org	Mediero, Aranzazu/AAA-8362-2020	Cronstein, Bruce/0000-0002-4295-7383	U.S. National Institutes of Health [AR56672, AR56672S1, AR54897, AR046121]; New York University-Health and Hospitals Corp. Clinical and Translational Science Institute [UL1TR000038]; New York University Caregiver Intervention Center Support grant [9NIH/NCI 5 P30CA16087-310]; OSI (Melville, NY, USA); Takeda (Deerfield, IL, USA); Gilead Pharmaceuticals (Foster City, CA, USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056672, R56AR056672, P30AR046121] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New York University-Health and Hospitals Corp. Clinical and Translational Science Institute; New York University Caregiver Intervention Center Support grant; OSI (Melville, NY, USA); Takeda (Deerfield, IL, USA)(Takeda Pharmaceutical Company Ltd); Gilead Pharmaceuticals (Foster City, CA, USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by grants from the U.S. National Institutes of Health (AR56672, AR56672S1, AR54897, AR046121), the New York University-Health and Hospitals Corp. Clinical and Translational Science Institute (UL1TR000038), a New York University Caregiver Intervention Center Support grant (9NIH/NCI 5 P30CA16087-310), and grants from OSI (Melville, NY, USA), Takeda (Deerfield, IL, USA), and Gilead Pharmaceuticals (Foster City, CA, USA). A.M. and B.N.C. have filed a patent on use of adenosine A<INF>2A</INF>R agonists to prevent prosthesis loosening (U.S. patent 8,183,225), and have filed a patent on use of antinetrin-1 antibodies for the treatment of bone disease (pending). M.P-A. declares no conflicts of interest. B.N.C. holds U.S. patents 5,932,558; 6,020,321; 6,555,545; 7,795,427; adenosine A<INF>1</INF>R and A<INF>2B</INF>R antagonists to treat fatty liver (pending); adenosine A<INF>2A</INF>R agonists to prevent prosthesis loosening (pending). B.N.C. is a consultant for Bristol-Myers Squibb New York, NY, USA), Novartis (New York, NY, USA), CanFite Biopharmaceuticals (Petah-Tikva, Israel), Cypress Laboratories (Allen, TX, USA), Regeneron (Westat, DSMB; Tarrytown, NY, USA), Endocyte (West Lafayette, IN, USA), Protalex (Florham Park, NJ, USA), Allos, Inc. (Westminster, CO, USA), Savient (East Brunswick Township, NJ, USA), Gismo Therapeutics (Howard Beach NY, USA), Antares Pharmaceutical (Ewing, NJ, USA), Medivector (Boston, MA, USA), King Pharmaceutical (Bristol, TN, USA), Celizome (St. Petersburg, FL, USA), Tap Pharmaceuticals (Lake Forest, IL, USA), Prometheus Laboratories (Lake Forest, IL, USA), Sepracor (Basel, Switzerland), Amgen (Thousand Oaks, CA, USA), Combinatorx (Boston, MA, USA), Kyowa Hakka (Tokyo, Japan), Hoffman-LaRoche (Basel, Switzerland), and Avidimer Therapeutics (Ann Arbor, MI, USA). B.N.C. has stock in CanFite Biopharmaceuticals. Author contributions: B. C. and A.M. designed most of the experiments; A.M. was the primary person responsible for carrying out all experimental procedures; and M.P.A. helped with Western blot experiments.	Blair HC, 2005, BIOCHEM BIOPH RES CO, V328, P728, DOI 10.1016/j.bbrc.2004.11.077; Breckler M, 2011, CELL SIGNAL, V23, P1257, DOI 10.1016/j.cellsig.2011.03.007; Chen HJ, 2014, J MED CHEM, V57, P3651, DOI 10.1021/jm401425e; Chitu V, 2005, MOL BIOL CELL, V16, P2947, DOI 10.1091/mbc.e04-10-0914; Croke M, 2011, J CELL SCI, V124, P3811, DOI 10.1242/jcs.086280; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E; Gloerich M, 2010, ANNU REV PHARMACOL, V50, P355, DOI 10.1146/annurev.pharmtox.010909.105714; Grandoch M, 2010, BRIT J PHARMACOL, V159, P265, DOI 10.1111/j.1476-5381.2009.00458.x; Granholm S, 2007, J ENDOCRINOL, V195, P415, DOI 10.1677/JOE-07-0338; Guerrini MM, 2008, AM J HUM GENET, V83, P64, DOI 10.1016/j.ajhg.2008.06.015; Kondo H, 2002, J BONE MINER RES, V17, P1667, DOI 10.1359/jbmr.2002.17.9.1667; Lee YJ, 2012, BBA-MOL CELL RES, V1823, P971, DOI 10.1016/j.bbamcr.2011.12.011; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; McHugh KP, 2007, ADV EXP MED BIOL, V602, P107; Mediero A, 2013, BRIT J PHARMACOL, V169, P1372, DOI 10.1111/bph.12227; Mediero A, 2012, AM J PATHOL, V180, P775, DOI 10.1016/j.ajpath.2011.10.017; Ory S, 2000, J CELL SCI, V113, P1177; Park YG, 2006, INT IMMUNOPHARMACOL, V6, P947, DOI 10.1016/j.intimp.2006.01.005; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Ray BJ, 2012, J LEUKOCYTE BIOL, V92, P1021, DOI 10.1189/jlb.0512259; Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009; Saltel F, 2008, EUR J CELL BIOL, V87, P459, DOI 10.1016/j.ejcb.2008.01.001; Shahrara S, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2318; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146; Soysa NS, 2009, J BONE MINER METAB, V27, P131, DOI 10.1007/s00774-008-0026-6; Ster J, 2007, P NATL ACAD SCI USA, V104, P2519, DOI 10.1073/pnas.0611031104; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Sugimoto N, 2011, NEUROSCI LETT, V497, P55, DOI 10.1016/j.neulet.2011.04.028; Takada K, 2004, J BONE MINER METAB, V22, P12, DOI 10.1007/s00774-003-0441-7; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Yamamoto Yohei, 2005, Clin Calcium, V15, P147; Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756-3282(99)00121-0; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yoon SH, 2011, J BONE MINER RES, V26, P1217, DOI 10.1002/jbmr.310; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Yu MJ, 2011, J IMMUNOL, V187, P1797, DOI 10.4049/jimmunol.1002628; Zou W, 2013, MOL CELL BIOL, V33, P830, DOI 10.1128/MCB.00790-12	43	35	36	2	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4901	4913		10.1096/fj.14-255703	http://dx.doi.org/10.1096/fj.14-255703			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25122553	Green Published			2022-12-28	WOS:000344050900027
J	Mathews, CK				Mathews, Christopher K.			Deoxyribonucleotides as genetic and metabolic regulators	FASEB JOURNAL			English	Review						mutagenesis; nucleotide pools; oncogenes; cell cycle	RESTRICTION FACTOR SAMHD1; DNA-DAMAGE; RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; DNTP POOL; ALLOSTERIC ACTIVATION; GENOME INSTABILITY; MISMATCH REPAIR; REPLICATION; YEAST	For >35 yr, we have known that the accuracy of DNA replication is controlled in large part by the relative concentrations of the 4 canonical deoxyribonucleoside 5'-triphosphates (dNTPs) at the replisome. Since this field was last reviewed, similar to 8 yr ago, there has been increased understanding of the mutagenic pathways as they occur in living cells. At the same time, aspects of deoxyribonucleotide metabolism have been shown to be critically involved in processes as diverse as cell cycle control, protooncogene expression, cellular defense against HIV infection, replication rate control, telomere length control, and mitochondrial function. Evidence supports a relationship between dNTP pools and microsatellite repeat instability. Relationships between dNTP synthesis and breakdown in controlling steady-state pools have become better defined. In addition, new experimental approaches have allowed definitive analysis of mutational pathways induced by dNTP pool abnormalities, both in Escherichia coli and in yeast. Finally, ribonucleoside triphosphate (rNTP) pools have been shown to be critical determinants of DNA replication fidelity. These developments are discussed in this review article.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 Agr & Life Sci Bldg, Corvallis, OR 97331 USA.	mathewsc@onid.orst.edu						Ahluwalia D, 2013, P NATL ACAD SCI USA, V110, P18596, DOI 10.1073/pnas.1310849110; Ahluwalia D, 2012, DNA REPAIR, V11, P480, DOI 10.1016/j.dnarep.2012.02.001; Allouch A, 2013, P NATL ACAD SCI USA, V110, pE3997, DOI 10.1073/pnas.1306719110; Amie SM, 2013, J BIOL CHEM, V288, P25001, DOI 10.1074/jbc.C113.493619; Amie SM, 2013, J BIOL CHEM, V288, P20683, DOI 10.1074/jbc.M113.472159; Becket E, 2012, J BACTERIOL, V194, P5613, DOI 10.1128/JB.00962-12; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes A, 2007, P NATL ACAD SCI USA, V104, P1183, DOI 10.1073/pnas.0610585104; Chimploy K, 2001, J BIOL CHEM, V276, P7093, DOI 10.1074/jbc.M006232200; Clark AB, 2011, DNA REPAIR, V10, P476, DOI 10.1016/j.dnarep.2011.02.001; Clausen AR, 2013, P NATL ACAD SCI USA, V110, P16802, DOI 10.1073/pnas.1309119110; Clausen AR, 2013, DNA REPAIR, V12, P121, DOI 10.1016/j.dnarep.2012.11.006; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; Cunningham JT, 2014, CELL, V157, P1088, DOI 10.1016/j.cell.2014.03.052; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; Davidson MB, 2012, EMBO J, V31, P895, DOI 10.1038/emboj.2011.485; DRESLER SL, 1988, BIOCHEMISTRY-US, V27, P7247, DOI 10.1021/bi00419a011; Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103; Franzolin E, 2013, P NATL ACAD SCI USA, V110, P14272, DOI 10.1073/pnas.1312033110; Gawel D, 2008, J BACTERIOL, V190, P6931, DOI 10.1128/JB.00935-08; Gawel D, 2014, MUTAT RES-FUND MOL M, V759, P22, DOI 10.1016/j.mrfmmm.2013.11.003; Goldstone DC, 2011, NATURE, V480, P379, DOI 10.1038/nature10623; Gon S, 2011, P NATL ACAD SCI USA, V108, P19311, DOI 10.1073/pnas.1113664108; Gupta A, 2013, GENETICS, V193, P1095, DOI 10.1534/genetics.112.149120; Hansen EC, 2014, P NATL ACAD SCI USA, V111, pE1843, DOI 10.1073/pnas.1401706111; Hastak K, 2008, P NATL ACAD SCI USA, V105, P6314, DOI 10.1073/pnas.0802080105; Ji XY, 2013, NAT STRUCT MOL BIOL, V20, P1304, DOI 10.1038/nsmb.2692; Kamiya H, 2003, NUCLEIC ACIDS RES, V31, P517, DOI 10.1093/nar/gkg137; KOHALMI SE, 1991, J MOL BIOL, V220, P933, DOI 10.1016/0022-2836(91)90364-C; Kumar D, 2011, NUCLEIC ACIDS RES, V39, P1360, DOI 10.1093/nar/gkq829; Kumar D, 2010, NUCLEIC ACIDS RES, V38, P3975, DOI 10.1093/nar/gkq128; Kuzminov A, 2013, BIOESSAYS, V35, P306, DOI 10.1002/bies.201200128; Laureti L, 2013, DNA REPAIR, V12, P300, DOI 10.1016/j.dnarep.2013.01.009; Lazzaro F, 2012, MOL CELL, V45, P99, DOI 10.1016/j.molcel.2011.12.019; LU Q, 1995, J MOL BIOL, V254, P337, DOI 10.1006/jmbi.1995.0620; Lujan SA, 2013, MOL CELL, V50, P437, DOI 10.1016/j.molcel.2013.03.017; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Mannava S, 2008, CELL CYCLE, V7, P2392, DOI 10.4161/cc.6390; Mannava S, 2012, AGING-US, V4, P917, DOI 10.18632/aging.100512; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; MATHEWS CK, 1982, P NATL ACAD SCI-BIOL, V79, P302, DOI 10.1073/pnas.79.2.302; McElhinny SAN, 2010, NAT CHEM BIOL, V6, P774, DOI [10.1038/NCHEMBIO.424, 10.1038/nchembio.424]; McElhinny SAN, 2010, P NATL ACAD SCI USA, V107, P4949, DOI 10.1073/pnas.0914857107; Miazzi C, 2014, J BIOL CHEM, V289, P18339, DOI 10.1074/jbc.M114.571091; Nordman J, 2008, P NATL ACAD SCI USA, V105, P10197, DOI 10.1073/pnas.0802816105; Poli J, 2012, EMBO J, V31, P883, DOI 10.1038/emboj.2011.470; Powell RD, 2011, J BIOL CHEM, V286, P43596, DOI 10.1074/jbc.C111.317628; Pursell ZF, 2008, NUCLEIC ACIDS RES, V36, P2174, DOI 10.1093/nar/gkn062; Rampazzo C, 2010, MUTAT RES-GEN TOX EN, V703, P2, DOI 10.1016/j.mrgentox.2010.06.002; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Reijns MAM, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.011; Requena CE, 2014, BIOCHEM J, V459, P171, DOI 10.1042/BJ20130894; Saldivar JC, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003077; Sanchez A, 2012, MOL CELL BIOL, V32, P4445, DOI 10.1128/MCB.01062-12; Schaaper RM, 2013, DNA REPAIR, V12, P73, DOI 10.1016/j.dnarep.2012.10.011; Shen Y, 2012, NAT STRUCT MOL BIOL, V19, P98, DOI 10.1038/nsmb.2176; Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102; Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200; Srere P., 1990, P UCLA S AR LISS NEW; Tassotto ML, 2002, J BIOL CHEM, V277, P15807, DOI 10.1074/jbc.M200965200; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Tsaponina O, 2013, NUCLEIC ACIDS RES, V41, P10371, DOI 10.1093/nar/gkt820; Tsaponina O, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002061; Van Cor-Hosmer SK, 2013, J BIOL CHEM, V288, P33253, DOI 10.1074/jbc.M113.486787; Vorontsov II, 2014, J BIOL CHEM, V289, P2815, DOI 10.1074/jbc.M113.524207; Watt DL, 2011, DNA REPAIR, V10, P897, DOI 10.1016/j.dnarep.2011.05.009; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447; Wheeler LJ, 2011, J BIOL CHEM, V286, P16992, DOI 10.1074/jbc.M111.236968; Wheeler LJ, 2005, DNA REPAIR, V4, P1450, DOI 10.1016/j.dnarep.2005.09.003; Williams JS, 2012, DNA REPAIR, V11, P649, DOI 10.1016/j.dnarep.2012.05.004; Xie MH, 2014, CANCER RES, V74, P212, DOI 10.1158/0008-5472.CAN-13-1536-T; Yan JP, 2013, J BIOL CHEM, V288, P10406, DOI 10.1074/jbc.M112.443796; Yao NY, 2013, P NATL ACAD SCI USA, V110, P12942, DOI 10.1073/pnas.1309506110; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhao XL, 2002, P NATL ACAD SCI USA, V99, P3746, DOI 10.1073/pnas.062502299; Zhu CF, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3722	77	41	42	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3832	3840		10.1096/fj.14-251249	http://dx.doi.org/10.1096/fj.14-251249			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24928192	Green Published			2022-12-28	WOS:000340845900002
J	Boutin, A; Eliseeva, E; Gershengorn, MC; Neumann, S				Boutin, Alisa; Eliseeva, Elena; Gershengorn, Marvin C.; Neumann, Susanne			beta-Arrestin-1 mediates thyrotropin-enhanced osteoblast differentiation	FASEB JOURNAL			English	Article						TSH receptor; signaling; phosphokinases; bone; osteopontin	THYROID-STIMULATING HORMONE; PROTEIN-COUPLED RECEPTOR; PARATHYROID-HORMONE; KINASE-A; TSH; GROWTH; ACTIVATION; ANTAGONIST; PATHWAYS; PROMOTES	Thyrotropin (TSH) activation of the TSH receptor (TSHR), a 7-transmembrane-spanning receptor (7TMR), may have osteoprotective properties by direct effects on bone. TSHR activation by TSH phosphorylates protein kinases AKT1, p38 alpha, and ERK1/2 in some cells. We found TSH-induced phosphorylation of these kinases in 2 cell lines engineered to express TSHRs, human embryonic kidney HEK-TSHR cells and human osteoblastic U2OS-TSHR cells. In U2OS-TSHR cells, TSH up-regulated pAKT1 (7.1 +/- 0.5-fold), p38 alpha (2.9 +/- 0.4-fold), and pERK1/2 (3.1 +/- 0.2-fold), whereas small molecule TSHR agonist C2 had no or little effect on pAKT1 (1.8 +/- 0.08-fold), p38 alpha (1.2 +/- 0.09-fold), and pERK1/2 (1.6 +/- 0.19-fold). Furthermore, TSH increased expression of osteoblast marker genes ALPL (8.2 +/- 4.6-fold), RANKL (21 +/- 5.9-fold), and osteopontin (OPN; 17 +/- 5.3-fold), whereas C2 had little effect (ALPL, 1.7 +/- 0.5-fold; RANKL, 1.3 +/- 0.6-fold; and OPN, 2.2 +/- 0.7fold). beta-Arrestin-1 and -2 can mediate activatory signals by 7TMRs. TSH stimulated translocation of beta-arrestin-1 and -2 to TSHR, whereas C2 failed to translocate either beta-arrestin. Down-regulation of beta-arrestin-1 by siRNA inhibited TSH-stimulated phosphorylation of ERK1/2, p38 alpha, and AKT1, whereas down-regulation of beta-arrestin-2 increased phosphorylation of AKT1 in both cell types and of ERK1/2 in HEK-TSHR cells. Knockdown of beta-arrestin- 1 inhibited TSH-stimulated up-regulation of mRNAs for OPN by 87 +/- 1.7% and RANKL by 73 +/- 2.4%, and OPN secretion by 74 +/- 10%. We conclude that TSH enhances osteoblast differentiation in U2OS cells that is, in part, caused by activatory signals mediated by beta-arrestin- 1.	[Boutin, Alisa; Eliseeva, Elena; Gershengorn, Marvin C.; Neumann, Susanne] Natl Inst Diabet & Digest & Kidney Dis, Lab Endocrinol & Receptor Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Neumann, S (corresponding author), Natl Inst Diabet & Digest & Kidney Dis, 50 South Dr,Bldg 50 Rm 4128, Bethesda, MD 20892 USA.	susannen@intra.niddk.nih.gov			Intramural Research Program of the U.S. National Institutes of Health [1 Z01 DK047044]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK047044, ZIADK011006] Funding Source: NIH RePORTER	Intramural Research Program of the U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was supported by the Intramural Research Program of the U.S. National Institutes of Health (1 Z01 DK047044).	Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092-8674(03)00771-2; Abe E, 2007, ANN NY ACAD SCI, V1116, P383, DOI 10.1196/annals.1402.062; Allen MD, 2011, FASEB J, V25, P3687, DOI 10.1096/fj.11-188961; Baliram R, 2011, P NATL ACAD SCI USA, V108, P16277, DOI 10.1073/pnas.1110286108; Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200; Buech TRH, 2008, J BIOL CHEM, V283, P20330, DOI 10.1074/jbc.M800211200; Davies TF, 2005, J CLIN INVEST, V115, P1972, DOI 10.1172/JCI26031; De Gregorio G, 2007, ONCOGENE, V26, P2039, DOI 10.1038/sj.onc.1210011; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Ferrari SL, 2005, ENDOCRINOLOGY, V146, P1854, DOI 10.1210/en.2004-1282; Frenzel R, 2006, ENDOCRINOLOGY, V147, P3114, DOI 10.1210/en.2005-0687; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Gesty-Palmer D, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000071; Greenspan SL, 1999, ANN INTERN MED, V130, P750, DOI 10.7326/0003-4819-130-9-199905040-00016; Iacovelli L, 2001, MOL PHARMACOL, V60, P924, DOI 10.1124/mol.60.5.924; Jaschke H, 2006, J BIOL CHEM, V281, P9841, DOI 10.1074/jbc.C600014200; Kumar S, 2011, J MOL ENDOCRINOL, V46, P155, DOI 10.1530/JME-11-0006; Kuo FT, 2006, CELL SIGNAL, V18, P1914, DOI 10.1016/j.cellsig.2006.02.009; Latif R, 2009, ENDOCRIN METAB CLIN, V38, P319, DOI 10.1016/j.ecl.2009.01.006; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; Milligan G, 2008, BRIT J PHARMACOL, V153, pS216, DOI 10.1038/sj.bjp.0707490; Neumann S., 2013, 83 ANN M AM THYR ASS; Neumann S, 2009, P NATL ACAD SCI USA, V106, P12471, DOI 10.1073/pnas.0904506106; Neumann S, 2008, ENDOCRINOLOGY, V149, P5945, DOI 10.1210/en.2008-0836; Pomerance M, 2000, J BIOL CHEM, V275, P40539, DOI 10.1074/jbc.M002097200; Postiglione MP, 2002, P NATL ACAD SCI USA, V99, P15462, DOI 10.1073/pnas.242328999; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; RIVKEES SA, 1988, NEW ENGL J MED, V318, P599, DOI 10.1056/NEJM198803103181003; Salvatori L, 2009, J CELL PHYSIOL, V220, P35, DOI 10.1002/jcp.21724; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Sun L, 2008, P NATL ACAD SCI USA, V105, P4289, DOI 10.1073/pnas.0712395105; Turcu AF, 2013, J CLIN ENDOCR METAB, V98, P2153, DOI 10.1210/jc.2013-1149; Urizar E, 2005, EMBO J, V24, P1954, DOI 10.1038/sj.emboj.7600686; Vandeput F, 2003, ENDOCRINOLOGY, V144, P1341, DOI 10.1210/en.2001-211316; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Wojcicka A, 2013, BBA-GEN SUBJECTS, V1830, P3979, DOI 10.1016/j.bbagen.2012.05.005	36	42	42	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3446	3455		10.1096/fj.14-251124	http://dx.doi.org/10.1096/fj.14-251124			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24723693	Green Published			2022-12-28	WOS:000340265400015
J	Ching, BY; Ong, JLY; Chng, YR; Chen, XL; Wong, WP; Chew, SF; Ip, YK				Ching, Biyun; Ong, Jasmine L. Y.; Chng, You Rong; Chen, Xiu Ling; Wong, Wai P.; Chew, Shit F.; Ip, Yuen K.			L-gulono-gamma-lactone oxidase expression and vitamin C synthesis in the brain and kidney of the African lungfish, Protopterus annectens	FASEB JOURNAL			English	Article						estivation; ascorbate; dehydroascorbate; GULO; oxidative stress	L-ASCORBIC-ACID; INCREASED UREA SYNTHESIS; DENDRITIC SPINE DENSITY; ATPASE ALPHA-SUBUNIT; AMMONIA PRODUCTION; GULONOLACTONE OXIDASE; DEHYDROASCORBIC ACID; BIOLOGICAL SYNTHESIS; NITROGEN-METABOLISM; NONFUNCTIONAL GENE	This study aimed to test the hypothesis that the brain of Protopterus annectens expressed L-gulono-gamma-lactone oxidase (gulo/Gulo), the enzyme catalyzing the last step of ascorbate biosynthesis, and could maintain high concentrations of ascorbate during estivation. We cloned and sequenced gulo from the kidney of P. annectens and performed quantitative PCR to determine its mRNA expression in kidney and brain. Gulo activity was assayed and its protein abundance was determined by Western blot using custom-made anti-Gulo antibody. Effects of estivation on concentrations of ascorbate and dehydroascorbate in the kidney and brain were also determined. Both brain and kidney, but not liver, of P. annectens expressed gulo/Gulo. Desiccation induced P. annectens to estivate, and 6 mo of estivation led to drastic decreases in gulo/Gulo expression and ascorbate concentration in the kidney. However, high concentrations of ascorbate and ascorbate + dehydroascorbate were maintained in the brain during estivation, probably resulting from in situ ascorbate synthesis. Control fish were placed in freshwater, where they were fully active in a favorable environment unlike estivation on land. The ability to synthesize ascorbate to ameliorate oxidative stress directly in the brain might contribute to the ability of P. annectens to undergo prolonged estivation on land.	[Ching, Biyun; Ong, Jasmine L. Y.; Chng, You Rong; Chen, Xiu Ling; Wong, Wai P.; Ip, Yuen K.] Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; [Chew, Shit F.] Nanyang Technol Univ, Natl Inst Educ, Singapore 639798, Singapore	National University of Singapore; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National Institute of Education (NIE) Singapore	Ip, YK (corresponding author), Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore.	dbsipyk@nus.edu.sg	Chew, Shit Fun/I-2248-2012; Ip, Yuen Kwong/H-8041-2012	Chew, Shit Fun/0000-0003-4599-5817; Ip, Yuen Kwong/0000-0001-9124-7911	 [R-154-000-429-112]		This work was funded by grant number R-154-000-429-112. The authors thank Chan Puck Wee (Duke-National University of Singapore Graduate Medical School, Singapore, Republic of Singapore) for sharing some mouse brain samples.	Angelow S, 2003, BRAIN RES, V988, P105, DOI 10.1016/S0006-8993(03)03350-X; BODANNES RS, 1979, FEBS LETT, V105, P195, DOI 10.1016/0014-5793(79)80609-2; Butterfield DA, 2002, J NUTR BIOCHEM, V13, P444, DOI 10.1016/S0955-2863(02)00205-X; CAMMACK J, 1991, J CHROMATOGR-BIOMED, V565, P529, DOI 10.1016/0378-4347(91)80421-8; Castro MA, 2009, J NEUROCHEM, V110, P423, DOI 10.1111/j.1471-4159.2009.06151.x; CHATTERJEE IB, 1960, BIOCHEM J, V74, P193, DOI 10.1042/bj0740193; CHATTERJEE IB, 1973, SCIENCE, V182, P1271, DOI 10.1126/science.182.4118.1271; CHATTERJEE IB, 1960, BIOCHEM J, V76, P279, DOI 10.1042/bj0760279; CHAUDHURI CR, 1969, SCIENCE, V164, P435, DOI 10.1126/science.164.3878.435; Chew SF, 2014, J FISH BIOL, V84, P603, DOI 10.1111/jfb.12279; Chew SF, 2003, J EXP BIOL, V206, P3615, DOI 10.1242/jeb.00619; Chew SF, 2004, J EXP BIOL, V207, P777, DOI 10.1242/jeb.00813; Cho YS, 2007, COMP BIOCHEM PHYS B, V147, P178, DOI 10.1016/j.cbpb.2007.01.001; COHEN G, 1994, ANN NY ACAD SCI, V738, P8; DABROWSKA H, 1990, MAGNESIUM TRACE ELEM, V9, P101; DABROWSKI K, 1990, BIOL CHEM H-S, V371, P207, DOI 10.1515/bchm3.1990.371.1.207; Davies M./ B., 1991, VITAMIN C ITS CHEM B; DELANEY RG, 1977, AM J PHYSIOL, V232, pR10, DOI 10.1152/ajpregu.1977.232.1.R10; DELANEY RG, 1974, J EXP BIOL, V61, P111; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Drouin G, 2011, CURR GENOMICS, V12, P371, DOI 10.2174/138920211796429736; DYKHUIZEN DE, 1980, EXPERIENTIA, V36, P945, DOI 10.1007/BF01953807; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Ferreira-Cravo M, 2010, PROG MOL SUBCELL BIO, V49, P47, DOI 10.1007/978-3-642-02421-4_3; FISHMAN A P, 1987, P237; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; Garcia MDL, 2005, GLIA, V50, P32, DOI 10.1002/glia.20133; Gerwick L, 2007, FISH SHELLFISH IMMUN, V22, P157, DOI 10.1016/j.fsi.2006.04.003; Giusi G, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-39; Giusi G, 2011, J NEUROSCI RES, V89, P418, DOI 10.1002/jnr.22553; GROLLMAN ARTHUR P., 1957, ARCH BIOCHEM AND BIOPHYS, V69, P458, DOI 10.1016/0003-9861(57)90510-6; GUPTA SD, 1973, INT J BIOCHEM, V4, P309; Hakvoort A, 1998, BRAIN RES, V795, P247, DOI 10.1016/S0006-8993(98)00284-4; Harrison FE, 2009, FREE RADICAL BIO MED, V46, P719, DOI 10.1016/j.freeradbiomed.2008.12.018; Hermes-Lima M, 2002, COMP BIOCHEM PHYS C, V133, P537, DOI 10.1016/S1532-0456(02)00080-7; HERMESLIMA M, 1995, AM J PHYSIOL-REG I, V268, pR1386, DOI 10.1152/ajpregu.1995.268.6.R1386; Hiong KC, 2014, J COMP PHYSIOL B, V184, P571, DOI 10.1007/s00360-014-0809-0; Hiong KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071205; HUGHES RE, 1971, BRIT J NUTR, V26, P433, DOI 10.1079/BJN19710048; Ip YK, 2005, J EXP ZOOL PART A, V303A, P1054, DOI 10.1002/jez.a.237; Ip YK, 2005, J EXP ZOOL PART A, V303A, P456, DOI 10.1002/jez.a.160; Ip YK, 2010, FRONT PHYSIOL, V1, DOI 10.3389/fphys.2010.00134; Ip YK, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00362; Jenner AM, 2002, ARTERIOSCL THROM VAS, V22, P574, DOI 10.1161/01.ATV.0000013785.03265.5C; KRATZING CC, 1985, J NEUROCHEM, V44, P1623, DOI 10.1111/j.1471-4159.1985.tb08804.x; LEVINE M, 1985, J BIOL CHEM, V260, P2942; Loong AM, 2008, J COMP PHYSIOL B, V178, P351, DOI 10.1007/s00360-007-0228-6; Loong AM, 2005, J EXP ZOOL PART A, V303A, P354, DOI 10.1002/jez.a.147; MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807; Mandl J, 2009, BRIT J PHARMACOL, V157, P1097, DOI 10.1111/j.1476-5381.2009.00282.x; May JM, 1998, ARCH BIOCHEM BIOPHYS, V349, P281, DOI 10.1006/abbi.1997.0473; Miele M, 1996, J NEUROSCI METH, V70, P15, DOI 10.1016/S0165-0270(96)00094-5; Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9; MOSER MB, 1994, P NATL ACAD SCI USA, V91, P12673, DOI 10.1073/pnas.91.26.12673; Nandi A, 1997, FREE RADICAL BIO MED, V22, P1047, DOI 10.1016/S0891-5849(96)00491-1; NIKI E, 1995, AM J CLIN NUTR, V62, P1322, DOI 10.1093/ajcn/62.6.1322S; NISHIKIMI M, 1994, J BIOL CHEM, V269, P13685; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; NISHIKIMI M, 1991, AM J CLIN NUTR, V54, pS1203, DOI 10.1093/ajcn/54.6.1203s; Ohta Y, 1999, BBA-GEN SUBJECTS, V1472, P408, DOI 10.1016/S0304-4165(99)00123-3; Ojeda JL, 2008, ANAT REC, V291, P1156, DOI 10.1002/ar.20729; OKE AF, 1987, ANN NY ACAD SCI, V498, P1, DOI 10.1111/j.1749-6632.1987.tb23747.x; Page MM, 2010, J COMP PHYSIOL B, V180, P361, DOI 10.1007/s00360-009-0416-7; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; RANJAN A, 1993, ACTA NEUROCHIR, V123, P87, DOI 10.1007/BF01476291; REHNCRONA S, 1980, J NEUROCHEM, V34, P477, DOI 10.1111/j.1471-4159.1980.tb11170.x; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; RICE ME, 1995, J NEUROCHEM, V64, P1790; ROY RN, 1958, NATURE, V182, P319, DOI 10.1038/182319a0; SCHELL DA, 1993, BIOMED CHROMATOGR, V7, P267, DOI 10.1002/bmc.1130070506; SCHREIBER M, 1991, PHYSIOL RES, V40, P413; Smith HW, 1931, ECOLOGY, V12, P164, DOI 10.2307/1932938; SPECTOR R, 1977, NEW ENGL J MED, V296, P1393, DOI 10.1056/NEJM197706162962409; Toien O, 2001, AM J PHYSIOL-REG I, V281, pR572; TOUHATA K, 1995, FISHERIES SCI, V61, P729, DOI 10.2331/fishsci.61.729; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; TUCKER BW, 1987, INT J VITAM NUTR RES, V57, P289; WOOLLEY CS, 1990, J NEUROSCI, V10, P4035, DOI 10.1523/JNEUROSCI.10-12-04035.1990; Zhou XQ, 2005, AQUACULT NUTR, V11, P169, DOI 10.1111/j.1365-2095.2005.00343.x; Zhou XQ, 2003, COMP BIOCHEM PHYS A, V135, P263, DOI 10.1016/S1095-6433(03)00066-7	80	14	14	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3506	3517		10.1096/fj.14-249508	http://dx.doi.org/10.1096/fj.14-249508			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24769670				2022-12-28	WOS:000340265400020
J	Fortin, J; Boehm, U; Deng, CX; Treier, M; Bernard, DJ				Fortin, Jerome; Boehm, Ulrich; Deng, Chu-Xia; Treier, Mathias; Bernard, Daniel J.			Follicle-stimulating hormone synthesis and fertility depend on SMAD4 and FOXL2	FASEB JOURNAL			English	Article						FSH; activin; pituitary	GONADOTROPIN-RELEASING-HORMONE; BETA-SUBUNIT TRANSCRIPTION; ACTIVIN-A; RECEPTOR GENE; HYPOGONADOTROPIC HYPOGONADISM; FSH SYNTHESIS; PITUITARY; EXPRESSION; MUTATIONS; MOUSE	Follicle-stimulating hormone (FSH) is an essential regulator of gonadal function and fertility. Loss-of-function mutations in the FSHB/Fshb gene cause hypogonadotropic hypogonadism in humans and mice. Both gonadotropin-releasing hormone (GnRH) and activins, members of the transforming growth factor beta (TGF beta) superfamily, stimulate FSH synthesis; yet, their relative roles and mechanisms of action in vivo are unknown. Here, using conditional gene-targeting, we show that the canonical mediator of TGF beta superfamily signaling, SMAD4, is absolutely required for normal FSH synthesis in both male and female mice. Moreover, when the Smad4 gene is ablated in combination with its DNA binding cofactor Foxl2 in gonadotrope cells, mice make essentially no FSH and females are sterile. Indeed, the phenotype of these animals is remarkably similar to that of Fshb-knockout mice. Not only do these results establish SMAD4 and FOXL2 as essential master regulators of Fshb transcription in vivo, they also suggest that activins, or related ligands, could play more important roles in FSH synthesis than GnRH.	[Fortin, Jerome; Bernard, Daniel J.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; [Boehm, Ulrich] Univ Saarland, Sch Med, Dept Pharmacol & Toxicol, Homburg, Germany; [Deng, Chu-Xia] Natl Inst Diabet & Digest & Kidney Dis, Bethesda, MD USA; [Treier, Mathias] Max Delbruck Ctr Mol Med, Berlin, Germany	McGill University; Saarland University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Fortin, J (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Promenade Sir William Osler,Rm 1315, Montreal, PQ H3G 1Y6, Canada.	jerome.fortin@mail.mcgill.ca; daniel.bernard@mcgill.ca	Treier, Mathias/AAD-6388-2021; deng, chuxia/N-6713-2016	Bernard, Daniel/0000-0001-5365-5586	Doctoral Research Award from the Canadian Institutes of Health Research (CIHR); Samuel Solomon Fellowship in Endocrinology from the Endocrine Division and McGill Faculty of Medicine (McGill University); CIHR [MOP-89991/-123447]; DFG [BO1743/2]; U.S. National Institutes of Health/National Institute of Child Health and Human Development (Specialized Cooperative Centers Program in Reproduction Research) grant [U54-HD28934]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER	Doctoral Research Award from the Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Samuel Solomon Fellowship in Endocrinology from the Endocrine Division and McGill Faculty of Medicine (McGill University); CIHR(Canadian Institutes of Health Research (CIHR)); DFG(German Research Foundation (DFG)); U.S. National Institutes of Health/National Institute of Child Health and Human Development (Specialized Cooperative Centers Program in Reproduction Research) grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The authors thank Ken McDonald for assistance with FACS, as well as the Goodman Cancer Research Center Histology Facility (McGill University) and the Center for Bone and Periodontal Research Histology Platform (McGill University) for the preparation of histological sections. The authors also thank Dr. Alfredo Ribeiro-da-Silva for generously providing access to the Zeiss Axioplan 2 microscope and Dr. Derek Boerboom for insightful comments on ovarian histology. J.F. was supported by a Doctoral Research Award from the Canadian Institutes of Health Research (CIHR) and the Samuel Solomon Fellowship in Endocrinology from the Endocrine Division and McGill Faculty of Medicine (McGill University). This work was funded by CIHR operating grants MOP-89991/-123447 (to D.J.B.). D.J.B. was a Senior Research Scholar of the Fonds de la Recherche en Sante de Quebec. U. B. is funded by DFG BO1743/2. The University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core (Charlottesville, VA, USA) is supported by the U.S. National Institutes of Health/National Institute of Child Health and Human Development (Specialized Cooperative Centers Program in Reproduction Research) grant U54-HD28934.	AITTOMAKI K, 1995, CELL, V82, P959, DOI 10.1016/0092-8674(95)90275-9; Bernard DJ, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.113.107797; Bernard DJ, 2010, FERTIL STERIL, V93, P2465, DOI 10.1016/j.fertnstert.2010.03.034; Bernard DJ, 2004, MOL ENDOCRINOL, V18, P606, DOI 10.1210/me.2003-0264; Besecke LM, 1996, ENDOCRINOLOGY, V137, P3667, DOI 10.1210/en.137.9.3667; Bliss SP, 2010, FRONT NEUROENDOCRIN, V31, P322, DOI 10.1016/j.yfrne.2010.04.002; Blount AL, 2009, J BIOL CHEM, V284, P7631, DOI 10.1074/jbc.M806676200; Bouligand J, 2009, NEW ENGL J MED, V360, P2742, DOI 10.1056/NEJMoa0900136; BRADEN TD, 1992, ENDOCRINOLOGY, V130, P2101, DOI 10.1210/en.130.4.2101; Bristol-Gould SK, 2006, DEV BIOL, V298, P132, DOI 10.1016/j.ydbio.2006.06.025; Caligioni C. S., 2009, CURR PROTOC NEUROSCI, V41; CATTANACH BM, 1977, NATURE, V269, P338, DOI 10.1038/269338a0; Chan YM, 2009, P NATL ACAD SCI USA, V106, P11703, DOI 10.1073/pnas.0903449106; CLAY CM, 1993, J BIOL CHEM, V268, P13556; Corpuz PS, 2010, MOL ENDOCRINOL, V24, P1037, DOI 10.1210/me.2009-0425; CORRIGAN AZ, 1991, ENDOCRINOLOGY, V128, P1682, DOI 10.1210/endo-128-3-1682; Coss D, 2010, TRENDS ENDOCRIN MET, V21, P562, DOI 10.1016/j.tem.2010.05.006; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Dalkin AC, 1999, ENDOCRINOLOGY, V140, P903, DOI 10.1210/en.140.2.903; DEJONG FH, 1988, PHYSIOL REV, V68, P555, DOI 10.1152/physrev.1988.68.2.555; deRoux N, 1997, NEW ENGL J MED, V337, P1597, DOI 10.1056/NEJM199711273372205; Duval DL, 1999, ENDOCRINOLOGY, V140, P1949, DOI 10.1210/en.140.4.1949; Egashira N, 2011, MODERN PATHOL, V24, P765, DOI 10.1038/modpathol.2010.169; Ellsworth BS, 2006, MOL ENDOCRINOL, V20, P2796, DOI 10.1210/me.2005-0303; FernandezVazquez G, 1996, MOL ENDOCRINOL, V10, P356, DOI 10.1210/me.10.4.356; Fortin J, 2014, FASEB J, V28, P1474, DOI 10.1096/fj.13-237818; Fortin J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059058; Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217; Goswami D, 2005, HUM REPROD UPDATE, V11, P391, DOI 10.1093/humupd/dmi012; Gregory SJ, 2005, MOL ENDOCRINOL, V19, P237, DOI 10.1210/me.2003-0473; Ho CC, 2009, BIOL REPROD, V81, P133, DOI 10.1095/biolreprod.108.074211; HOAK DC, 1980, P NATL ACAD SCI-BIOL, V77, P4953, DOI 10.1073/pnas.77.8.4953; KERI RA, 1991, MOL ENDOCRINOL, V5, P725, DOI 10.1210/mend-5-5-725; KREMER H, 1995, NAT GENET, V9, P160, DOI 10.1038/ng0295-160; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; Lamba P, 2006, J MOL ENDOCRINOL, V36, P201, DOI 10.1677/jme.1.01961; Lamba P, 2008, ENDOCRINOLOGY, V149, P3095, DOI 10.1210/en.2007-0425; Lamba P, 2010, ENDOCRINOLOGY, V151, P5456, DOI 10.1210/en.2010-0605; Lamba P, 2009, MOL ENDOCRINOL, V23, P1001, DOI 10.1210/me.2008-0324; Layman LC, 1998, NAT GENET, V18, P14, DOI 10.1038/ng0198-14; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MATTHEWS CH, 1993, NAT GENET, V5, P83, DOI 10.1038/ng0993-83; PEDERSEN T, 1968, J REPROD FERTIL, V17, P555, DOI 10.1530/jrf.0.0170555; Rejon CA, 2013, CELL SIGNAL, V25, P1403, DOI 10.1016/j.cellsig.2013.03.002; Ruckle J, 2009, J BONE MINER RES, V24, P744, DOI 10.1359/JBMR.081208; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Singh SP, 2009, BIOL REPROD, V81, P488, DOI 10.1095/biolreprod.108.075259; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Suszko MI, 2008, MOL CELL ENDOCRINOL, V281, P27, DOI 10.1016/j.mce.2007.10.003; Suszko MI, 2003, MOL ENDOCRINOL, V17, P318, DOI 10.1210/me.2002-0081; Thackray VG, 2010, MOL CELL ENDOCRINOL, V314, P192, DOI 10.1016/j.mce.2009.09.003; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Tran S, 2013, MOL ENDOCRINOL, V27, P407, DOI 10.1210/me.2012-1286; Tran S, 2011, MOL ENDOCRINOL, V25, P1170, DOI 10.1210/me.2010-0480; Uhlenhaut NH, 2009, CELL, V139, P1130, DOI 10.1016/j.cell.2009.11.021; Wang Y, 2010, J MOL ENDOCRINOL, V44, P349, DOI 10.1677/JME-09-0142; WEISS J, 1992, NEW ENGL J MED, V326, P179, DOI 10.1056/NEJM199201163260306; Welt C, 2002, EXP BIOL MED, V227, P724, DOI 10.1177/153537020222700905; Wen S, 2008, ENDOCRINOLOGY, V149, P2701, DOI 10.1210/en.2007-1502; Wen SP, 2010, P NATL ACAD SCI USA, V107, P16372, DOI 10.1073/pnas.1000423107; WIERMAN ME, 1988, MOL ENDOCRINOL, V2, P492, DOI 10.1210/mend-2-6-492; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Zakaria MM, 2002, MOL ENDOCRINOL, V16, P1840, DOI 10.1210/me.2002-0088	64	59	60	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3396	3410		10.1096/fj.14-249532	http://dx.doi.org/10.1096/fj.14-249532			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24739304	Green Published			2022-12-28	WOS:000340265400011
J	Gibbs, PEM; Lerner-Marmarosh, N; Poulin, A; Farah, E; Maines, MD				Gibbs, Peter E. M.; Lerner-Marmarosh, Nicole; Poulin, Amelia; Farah, Elie; Maines, Mahin D.			Human biliverdin reductase-based peptides activate and inhibit glucose uptake through direct interaction with the kinase domain of insulin receptor	FASEB JOURNAL			English	Article						diabetes; heme metabolism; protein kinases	SIGNAL-TRANSDUCTION PATHWAY; IX-ALPHA REDUCTASE; CRYSTAL-STRUCTURE; TYROSINE KINASE; GENE-EXPRESSION; ISOFORM-A; KAPPA-B; IGF-II; PROTEIN; SUBSTRATE	Insulin binding changes conformation of the insulin receptor kinase (IRK) domain and initiates glucose uptake through the insulin, IGF-1, phosphatidyl inositol 3-kinase (PI3K), and MAPK pathways; human biliverdin reductase (hBVR) is an IRK substrate and pathway effector. This is the first report on hBVR peptide-mediated IRK activation and conformational change. (KYCCSRK)-K-290, which increased IRK V-max without changing K-m, stimulated glucose uptake and potentiated insulin and IGF-1 stimulation in 4 cell lines. KYCCSRK in native hBVR was necessary for the hBVR and IRK cross-activation. Peptide treatment also activated PI3K downstream effectors, Akt and ERK, phosphorylation, and Elk transcriptional activity. In cells transfected with CMV-regulated EGFP-VP-peptide plasmid, C-292 -> A mutant did not stimulate glucose uptake; K-296 -> A decreased uptake and kinase activity. KEDQYMKMTV, corresponding to hBVR's SH2-binding domain, was a potent inhibitor of glucose uptake and IRK. The mechanism of action of peptides was examined using cells expressing IRK (aa 988-1263) activated by coexpressed KYCCSRK. Three active cysmutants of IRK, with fluorophore coupled to cysteines, C-1056, C-1138, or C-1234, were examined for changes in fluorescence emission spectra in the presence of peptides. KYCCSRK and KEDQYMKMTV bound to different sites in IRK. The findings identify novel agents for activating or inhibiting insulin signaling and offer a new approach for treatment of type 2 diabetes and hypoglycemia.	[Gibbs, Peter E. M.; Lerner-Marmarosh, Nicole; Poulin, Amelia; Farah, Elie; Maines, Mahin D.] Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Maines, MD (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.	mahin_maines@urmc.rochester.edu			U.S. National Institutes of Health [ES004066]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004066] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work is supported by U.S. National Institutes of Health grant ES004066. The authors thank Dr. Tihomir Miralem for his assistance with the Akt activation analyses.	Baer K, 2001, BIOCHEMISTRY-US, V40, P14268, DOI 10.1021/bi015588g; Ciaraldi TP, 2002, METABOLISM, V51, P1171, DOI 10.1053/meta.2002.34050; COBB MH, 1989, J BIOL CHEM, V264, P18701; Ding VDH, 2002, BIOCHEM J, V367, P301, DOI 10.1042/BJ20020708; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Gibbs PEM, 2012, J BIOL CHEM, V287, P1066, DOI 10.1074/jbc.M111.279612; Gogg S, 2009, DIABETES, V58, P2238, DOI 10.2337/db08-0961; Hickerson R, 2005, J MOL BIOL, V354, P459, DOI 10.1016/j.jmb.2005.09.010; Holst J, 2006, NAT METHODS, V3, P191, DOI 10.1038/nmeth858; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kapitulnik J, 2009, TRENDS PHARMACOL SCI, V30, P129, DOI 10.1016/j.tips.2008.12.003; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Lerner-Marmarosh N, 2005, P NATL ACAD SCI USA, V102, P7109, DOI 10.1073/pnas.0502173102; Lerner-Marmarosh N, 2008, P NATL ACAD SCI USA, V105, P6870, DOI 10.1073/pnas.0800750105; Lerner-Marmarosh N, 2007, FASEB J, V21, P3949, DOI 10.1096/fj.07-8544com; Li M, 2001, DIABETES, V50, P2323, DOI 10.2337/diabetes.50.10.2323; Maines MD, 2007, J BIOL CHEM, V282, P8110, DOI 10.1074/jbc.M513427200; Maines MD, 1996, EUR J BIOCHEM, V235, P372, DOI 10.1111/j.1432-1033.1996.00372.x; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Parang K, 2001, NAT STRUCT BIOL, V8, P37; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Provost E, 2007, GENESIS, V45, P625, DOI 10.1002/dvg.20338; Qureshi SA, 2000, J BIOL CHEM, V275, P36590, DOI 10.1074/jbc.M006287200; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Standaert ML, 1999, ENDOCRINOLOGY, V140, P4470, DOI 10.1210/en.140.10.4470; Stocker R, 2004, ANTIOXID REDOX SIGN, V6, P841, DOI 10.1089/1523086041797999; Talior I, 2003, AM J PHYSIOL-ENDOC M, V285, pE295, DOI 10.1152/ajpendo.00044.2003; Trabuco LG, 2012, NUCLEIC ACIDS RES, V40, pW423, DOI 10.1093/nar/gks398; Tudor C, 2008, BIOCHEM J, V413, P405, DOI 10.1042/BJ20080018; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Vella V, 2002, J CLIN ENDOCR METAB, V87, P245, DOI 10.1210/jc.87.1.245; Ward CW, 2013, BIOESSAYS, V35, P945, DOI 10.1002/bies.201300065; Whitby FG, 2002, J MOL BIOL, V319, P1199, DOI 10.1016/S0022-2836(02)00383-2; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Won JS, 2003, J NEUROSCI, V23, P7470; Wu JH, 2008, NAT STRUCT MOL BIOL, V15, P251, DOI 10.1038/nsmb.1388	41	32	33	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2478	2491		10.1096/fj.13-247015	http://dx.doi.org/10.1096/fj.13-247015			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24568842	Green Published			2022-12-28	WOS:000339883600009
J	Leddy, HA; McNulty, AL; Lee, SH; Rothfusz, NE; Gloss, B; Kirby, ML; Hutson, MR; Cohn, DH; Guilak, F; Liedtke, W				Leddy, Holly A.; McNulty, Amy L.; Lee, Suk Hee; Rothfusz, Nicole E.; Gloss, Bernd; Kirby, Margaret L.; Hutson, Mary R.; Cohn, Daniel H.; Guilak, Farshid; Liedtke, Wolfgang			Follistatin in chondrocytes: the link between TRPV4 channelopathies and skeletal malformations	FASEB JOURNAL			English	Article						cartilage; calcium signaling; growth plate; bone morphogenetic protein	SENSITIVE ION-CHANNEL; POTENTIAL VANILLOID 4; CATION CHANNEL; VR-OAC; BONE; RECOMBINATION; EXPRESSION; MUTATIONS; ACTIVIN; MICE	Point mutations in the calcium-permeable TRPV4 ion channel have been identified as the cause of autosomal-dominant human motor neuropathies, arthropathies, and skeletal malformations of varying severity. The objective of this study was to determine the mechanism by which TRPV4 channelopathy mutations cause skeletal dysplasia. The human TRPV4(V620I) channelopathy mutation was transfected into primary porcine chondrocytes and caused significant (2.6-fold) up-regulation of follistatin (FST) expression levels. Pore altering mutations that prevent calcium influx through the channel prevented significant FST up-regulation (1.1-fold). We generated a mouse model of the TRPV4(V620I) mutation, and found significant skeletal deformities (e. g., shortening of tibiae and digits, similar to the human disease brachyolmia) and increases in Fst/TRPV4 mRNA levels (2.8-fold). FST was significantly up-regulated in primary chondrocytes transfected with 3 different dysplasia-causing TRPV4 mutations (2- to 2.3-fold), but was not affected by an arthropathy mutation (1.1-fold). Furthermore, FST-loaded microbeads decreased bone ossification in developing chick femora (6%) and tibiae (11%). FST gene and protein levels were also increased 4-fold in human chondrocytes from an individual natively expressing the TRPV4(T89I) mutation. Taken together, these data strongly support that up-regulation of FST in chondrocytes by skeletal dysplasia-inducing TRPV4 mutations contributes to disease pathogenesis.	[Leddy, Holly A.; McNulty, Amy L.; Rothfusz, Nicole E.; Guilak, Farshid] Duke Univ, Med Ctr, Dept Orthopaed, Durham, NC USA; [Lee, Suk Hee; Liedtke, Wolfgang] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA; [Gloss, Bernd] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC USA; [Kirby, Margaret L.; Hutson, Mary R.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC USA; [Liedtke, Wolfgang] Duke Univ, Med Ctr, Duke Univ Clin Pain & Palliat Care, Durham, NC USA; [Cohn, Daniel H.] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA USA; [Cohn, Daniel H.] Univ Calif Los Angeles, Orthopaed Hosp, Res Ctr, Dept Orthopaed Surg, Los Angeles, CA USA	Duke University; Duke University; Duke University; Duke University; Duke University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Guilak, F (corresponding author), Duke Univ, Med Ctr, Dept Orthopaed Surg, Orthopaed Res Labs, Box 3093, Durham, NC 27710 USA.	guilak@duke.edu; wolfgang@neuro.duke.edu	Liedtke, Wolfgang/GNH-1878-2022; Guilak, Farshid/AAF-8558-2020	Guilak, Farshid/0000-0001-7380-0330; Leddy, Holly/0000-0002-1604-2876	U.S. National Institutes of Health (NIH) [AR48182, AR48852, AG15768, AR50245, AG46927, DE018549, HD022657, AR062651]; Arthritis Foundation; NIH [P41RR11823-03]; NIH-National Institute of Neurological Disorders and Stroke Center Core grant [5P30NS061789]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022657] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR062651, R01AR048182, P01AR050245, R01AR048852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE018549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS061789] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG046927, R01AG015768] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Arthritis Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH-National Institute of Neurological Disorders and Stroke Center Core grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Stephen Johnson and Daniel Stapor for technical assistance, and Michele Yeo for assistance with Fig. 6C. The authors also thank Dr. Brian Johnstone and his laboratory for providing the ATDC5 cells. This work is supported by U.S. National Institutes of Health (NIH) grants AR48182 (F.G.), AR48852 (F.G.), AG15768 (F.G.), AR50245 (F.G.), AG46927 (F.G.), DE018549 (W.L.), HD022657 (D.C.), and AR062651 (D.C.), and by the Arthritis Foundation. Venus plasmid (pBES2) was obtained from the Yeast Resource Center (University of Washington, Seattle, WA. USA) funded under NIH grant P41RR11823-03. Recombineering and zygote injections were performed by the Duke Neurotransgenic Laboratory, supported with funding from NIH-National Institute of Neurological Disorders and Stroke Center Core grant 5P30NS061789.	Abe Y, 2004, J BONE MINER RES, V19, P1302, DOI 10.1359/JBMR.040408; Blount AL, 2008, J BIOL CHEM, V283, P7016, DOI 10.1074/jbc.M709502200; Boss V, 2001, J NEUROSCI, V21, P18, DOI 10.1523/JNEUROSCI.21-01-00018.2001; Camacho N, 2010, AM J MED GENET A, V152A, P1169, DOI 10.1002/ajmg.a.33392; Chao PHG, 2006, AM J PHYSIOL-CELL PH, V291, pC718, DOI 10.1152/ajpcell.00127.2005; Clark AL, 2010, ARTHRITIS RHEUM-US, V62, P2973, DOI 10.1002/art.27624; Eleswarapu SV, 2013, ACTA BIOMATER, V9, P5554, DOI 10.1016/j.actbio.2012.10.031; Funaba M, 1996, ENDOCRINOLOGY, V137, P4250, DOI 10.1210/en.137.10.4250; Furman BD, 2007, J ORTHOP RES, V25, P578, DOI 10.1002/jor.20331; Gajos-Michniewicz A, 2012, J BONE MINER METAB, V30, P426, DOI 10.1007/s00774-011-0347-8; Gong SC, 2002, GENOME RES, V12, P1992, DOI 10.1101/gr.476202; Guilak F, 2010, ANN NY ACAD SCI, V1192, P404, DOI 10.1111/j.1749-6632.2010.05389.x; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hurd L. M., 2013, TRANS ORTHOP RES SOC, V59; Krakow D, 2009, AM J HUM GENET, V84, P307, DOI 10.1016/j.ajhg.2009.01.021; KUETTNER KE, 1982, J CELL BIOL, V93, P743, DOI 10.1083/jcb.93.3.743; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Lamande SR, 2011, NAT GENET, V43, P1142, DOI 10.1038/ng.945; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liedtke W, 2005, CELL MOL LIFE SCI, V62, P2985, DOI 10.1007/s00018-005-5181-5; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P14531, DOI 10.1073/pnas.2235619100; Liedtke WB, 2011, P NATL ACAD SCI USA, V108, P12509, DOI 10.1073/pnas.1109199108; Liedtke Wolfgang B., 2007, P303; Liu HY, 2003, J NEUROSCI, V23, P7143, DOI 10.1523/JNEUROSCI.23-18-07143.2003; Loukin S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019533; Merino R, 1999, DEVELOPMENT, V126, P2161; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Muramatsu S, 2007, J BIOL CHEM, V282, P32158, DOI 10.1074/jbc.M706158200; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; Mutai H, 2003, CELL CALCIUM, V33, P471, DOI 10.1016/S0143-4160(03)00062-9; Muyrers J P, 2000, Genet Eng (N Y), V22, P77; Nagy A., 2003, MANIPULATING THE MOU; Nilius B, 2003, PFLUG ARCH EUR J PHY, V446, P298, DOI 10.1007/s00424-003-1028-9; Nilius B., 2004, NOVART FDN SYMP, V258, P149; Nilius B, 2004, NOVARTIS FDN S, V258, P263; Nilius Bernd, 2004, Novartis Found Symp, V258, P140; Nilius B, 2013, EMBO REP, V14, P152, DOI 10.1038/embor.2012.219; O'Conor CJ, 2014, P NATL ACAD SCI USA, V111, P1316, DOI 10.1073/pnas.1319569111; O'Conor CJ, 2013, ANN RHEUM DIS, V72, P300, DOI 10.1136/annrheumdis-2012-202272; Phan MN, 2009, ARTHRITIS RHEUM-US, V60, P3028, DOI 10.1002/art.24799; Rock MJ, 2008, NAT GENET, V40, P999, DOI 10.1038/ng.166; Rosen V, 2006, ANN NY ACAD SCI, V1068, P19, DOI 10.1196/annals.1346.005; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Yamazaki Y, 2011, BIOTECH HISTOCHEM, V86, P351, DOI 10.3109/10520295.2010.506158; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	49	27	28	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2525	2537		10.1096/fj.13-245936	http://dx.doi.org/10.1096/fj.13-245936			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24577120	Green Published			2022-12-28	WOS:000339883600013
J	O'Connell, KE; Guo, W; Serra, C; Beck, M; Wachtman, L; Hoggatt, A; Xia, DL; Pearson, C; Knight, H; O'Connell, M; Miller, AD; Westmoreland, SV; Bhasin, S				O'Connell, Karyn E.; Guo, Wen; Serra, Carlo; Beck, Matthew; Wachtman, Lynn; Hoggatt, Amber; Xia, Dongling; Pearson, Chris; Knight, Heather; O'Connell, Micheal; Miller, Andrew D.; Westmoreland, Susan V.; Bhasin, Shalender			The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques	FASEB JOURNAL			English	Article						HIV; AIDS; muscle wasting; cachexia; nonhuman primate	ACTIVE ANTIRETROVIRAL THERAPY; BODY-COMPOSITION CHANGES; CHRONIC KIDNEY-DISEASE; SKELETAL-MUSCLE MASS; WEIGHT-LOSS; CANCER CACHEXIA; GROWTH-HORMONE; HIV-INFECTION; TESTOSTERONE SUPPLEMENTATION; SIGNALING PATHWAYS	There are no approved therapies for muscle wasting in children infected with human immunodeficiency virus (HIV), which portends poor disease outcomes. To determine whether a soluble ActRIIb receptor Fc fusion protein (ActRIIB.Fc), a ligand trap for TGF-beta/activin family members including myostatin, can prevent or restore loss of lean body mass and body weight in simian immunodeficiency virus (SIV)-infected juvenile rhesus macaques (Macaca mulatta). Fourteen pair-housed, juvenile male rhesus macaques were inoculated with SIVmac239 and, 4 wk postinoculation (WPI) treated with intramuscular injections of 10mg.kg(-1).wk(-1) ActRIIB.Fc or saline placebo. Body weight, lean body mass, SIV titers, and somatometric measurements were assessed monthly for 16 wk. Age-matched SIV-infected rhesus macaques were injected with saline. Intervention groups did not differ at baseline. Gains in lean mass were significantly greater in the ActRIIB.Fc group than in the placebo group (P < 0.001). Administration of ActRIIB.Fc was associated with greater gains in body weight (P = 0.01) and upper arm circumference than placebo. Serum CD4(+) T-lymphocyte counts and SIV copy numbers did not differ between groups. Administration of ActRIIB.Fc was associated with higher muscle expression of myostatin than placebo. ActRIIB.Fc effectively blocked and reversed loss of body weight, lean mass, and fat mass in juvenile SIV-infected rhesus macaques.	[O'Connell, Karyn E.; Beck, Matthew; Wachtman, Lynn; Hoggatt, Amber; Xia, Dongling; Pearson, Chris; Knight, Heather; O'Connell, Micheal; Miller, Andrew D.; Westmoreland, Susan V.] New England Primate Res Ctr, Dept Comparat Pathol, Southborough, MA USA; [Guo, Wen; Serra, Carlo; Bhasin, Shalender] Harvard Univ, Brigham & Womens Hosp, Sch Med,Res Program Mens Hlth Aging & Metab, Boston Claude Pepper Older Americans Independence, Boston, MA 01225 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bhasin, S (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Res Program Mens Hlth Aging & Metab, Boston Claude Pepper Older Americans Independence, 221 Longwood Ave, Boston, MA 01225 USA.	sbhasin@partners.org			National Institutes of Health [T32-OD011064]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078512] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [T32OD011064] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	ActRIIB.Fc was generously provided by Carl Morris, Pfizer, Incorporated, and Ron Desrosiers kindly supplied SIVmac239. Exceptional animal care was provided by the veterinarians and veterinary technicians at New England Primate Research Center (NEPRC). SIV viral loads were analyzed by Jeff Lifson and Mike Piatak at the U.S. National Cancer Institute, AIDS and Cancer Virus Program. Excellent necropsy service was provided by Elizabeth Curran at NEPRC. The authors acknowledge the thoughtful contributions of Keith Mansfield in the conception of these studies and Elizabeth Hutto for review of the manuscript. The authors thank Drs. Thomas G. Travison and Karol Pencina for guidance in statistical analyses. This research was funded, in part, by the National Institutes of Health Grant T32-OD011064.	Braga M, 2008, APOPTOSIS, V13, P822, DOI 10.1007/s10495-008-0216-7; Burgess K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017090; Chen JL, 2014, FASEB J, V28, P1711, DOI 10.1096/fj.13-245894; Chisada S, 2011, DEV BIOL, V359, P82, DOI 10.1016/j.ydbio.2011.08.027; Cline AN, 2005, J MED PRIMATOL, V34, P303; Cuerda Cristina, 2005, Nutr Clin Pract, V20, P93; Datta-Mannan A, 2013, J PHARMACOL EXP THER, V344, P616, DOI 10.1124/jpet.112.201491; Durieux AC, 2007, ENDOCRINOLOGY, V148, P3140, DOI 10.1210/en.2006-1500; Elkina Y, 2011, J CACHEXIA SARCOPENI, V2, P143, DOI 10.1007/s13539-011-0035-5; Elliott B, 2012, ACTA PHYSIOL, V205, P324, DOI 10.1111/j.1748-1716.2012.02423.x; Erlandson KM, 2013, JAIDS-J ACQ IMM DEF, V63, P209, DOI 10.1097/QAI.0b013e318289bb7e; Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011; Freeman LM, 2004, J INFECT DIS, V189, P2010, DOI 10.1086/386290; Freeman LM, 1999, J ACQ IMMUN DEF SYND, V22, P119; Girgenrath S, 2005, MUSCLE NERVE, V31, P34, DOI 10.1002/mus.20175; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Gullett NP, 2010, AM J CLIN NUTR, V91, p1143S, DOI 10.3945/ajcn.2010.28608E; Guo W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071017; Hendricks EE, 2004, J INFECT DIS, V190, P2187, DOI 10.1086/425904; Hoshikawa Y, 2011, CANCER SCI, V102, P934, DOI 10.1111/j.1349-7006.2011.01889.x; Jackson MF, 2012, J ENDOCRINOL, V213, P263, DOI 10.1530/JOE-11-0455; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Klimek MEB, 2010, BIOCHEM BIOPH RES CO, V391, P1548, DOI 10.1016/j.bbrc.2009.12.123; Kovacheva EL, 2010, ENDOCRINOLOGY, V151, P628, DOI 10.1210/en.2009-1177; Kusko RL, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-10; Lazanas Marios C, 2003, Hormones (Athens), V2, P43; Lee SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000789; Lee SJ, 2010, MOL ENDOCRINOL, V24, P1998, DOI 10.1210/me.2010-0127; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Leyes P, 2008, ANTIVIR THER, V13, P149; Liu Gang, 2005, Curr Opin Investig Drugs, V6, P979; Liu W, 2003, J CLIN ENDOCR METAB, V88, P5490, DOI 10.1210/jc.2003-030497; LOPRINZI CL, 1993, J CLIN ONCOL, V11, P152, DOI 10.1200/JCO.1993.11.1.152; Martins T, 2014, CLIN BIOCHEM, V47, P8, DOI 10.1016/j.clinbiochem.2013.10.025; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 2002, J CLIN INVEST, V109, P595, DOI 10.1172/JCI200213562; McPherron AC, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-24; Meng Y, 2013, CELL PHYSIOL BIOCHEM, V32, P1097, DOI 10.1159/000354509; Montano M, 2007, J CLIN ENDOCR METAB, V92, P2793, DOI 10.1210/jc.2006-2722; Mosher DS, 2007, PLOS GENET, V3, P779, DOI 10.1371/journal.pgen.0030079; Moyle GJ, 2004, JAIDS-J ACQ IMM DEF, V35, P367, DOI 10.1097/00126334-200404010-00006; Mulligan K, 2007, J CLIN ENDOCR METAB, V92, P563, DOI 10.1210/jc.2006-0954; Paul PK, 2010, J CELL BIOL, V191, P1395, DOI 10.1083/jcb.201006098; Rajan VR, 2008, PEDIATR NEPHROL, V23, P527, DOI 10.1007/s00467-007-0594-z; Sako D, 2010, J BIOL CHEM, V285, P21037, DOI 10.1074/jbc.M110.114959; Sattler F, 2011, J GERONTOL A-BIOL, V66, P122, DOI 10.1093/gerona/glq183; Scherzer R, 2011, AIDS, V25, P1405, DOI 10.1097/QAD.0b013e32834884e6; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Shikuma CM, 2005, CLIN INFECT DIS, V40, P1846, DOI 10.1086/430376; Simon D, 2013, J CLIN ENDOCR METAB, V98, P2746, DOI 10.1210/jc.2012-4201; Vallerie SN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001007; Verzola D, 2011, KIDNEY INT, V79, P773, DOI 10.1038/ki.2010.494; Wagner KR, 2008, ANN NEUROL, V63, P561, DOI 10.1002/ana.21338; Wanke CA, 2000, CLIN INFECT DIS, V31, P803, DOI 10.1086/314027; Westmoreland SV, 1998, J NEUROVIROL, V4, P260, DOI 10.3109/13550289809114527; Whittemore LA, 2003, BIOCHEM BIOPH RES CO, V300, P965, DOI 10.1016/S0006-291X(02)02953-4; Wust Rob C I, 2007, Int J Chron Obstruct Pulmon Dis, V2, P289; Zhang LP, 2011, FASEB J, V25, P1653, DOI 10.1096/fj.10-176917; Zhao P, 2004, DEV DYNAM, V229, P380, DOI 10.1002/dvdy.10457; Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	61	11	11	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1165	1175		10.1096/fj.14-257543	http://dx.doi.org/10.1096/fj.14-257543			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25466897	Green Published			2022-12-28	WOS:000354115000006
J	Thaler, R; Sturmlechner, I; Spitzer, S; Riester, SM; Rumpler, M; Zwerina, J; Klaushofer, K; van Wijnen, AJ; Varga, F				Thaler, Roman; Sturmlechner, Ines; Spitzer, Silvia; Riester, Scott M.; Rumpler, Monika; Zwerina, Jochen; Klaushofer, Klaus; van Wijnen, Andre J.; Varga, Franz			Acute-phase protein serum amyloid A3 is a novel paracrine coupling factor that controls bone homeostasis	FASEB JOURNAL			English	Article						osteoblast; osteoclast; osteocyte; osteogenesis	GROWTH-FACTOR-BETA; ACUTE MYOCARDIAL-INFARCTION; C-REACTIVE PROTEIN; OSTEOCLAST DIFFERENTIATION; RHEUMATOID-ARTHRITIS; SAA PROTEIN; MATRIX METALLOPROTEINASE-13; DIETARY-CHOLESTEROL; PARATHYROID-HORMONE; ADIPOSE-TISSUE	Serum amyloid A (A-SAA/Saa3) was shown before to affect osteoblastic metabolism. Here, using RT-quantitative PCR and/or immunoblotting, we show that expression of mouse Saa3 and human SAA1 and SAA2 positively correlates with increased cellular maturation toward the osteocyte phenotype. Expression is not detected in C3H10T1/2 embryonic fibroblasts but is successively higher in preosteoblastic MC3T3-E1 cells, late osteoblastic MLO-A5 cells, and MLO-Y4 osteocytes, consistent with findings using primary bone cells from newborn mouse calvaria. Recombinant Saa3 protein functionally inhibits osteoblast differentiation as reflected by reductions in the expression of osteoblast markers and decreased mineralization in newborn mouse calvaria. Yet, Saa3 protein enhances osteoclastogenesis in mouse macrophages/monocytes based on the number of multinucleated and tartrate-resistant alkaline phosphatase-positive cells and Calcr mRNA expression. Depletion of Saa3 in MLO osteocytes results in the loss of the mature osteocyte phenotype. Recombinant osteocalcin, which is reciprocally regulated with Saa3 at the osteoblast/osteocyte transition, attenuates Saa3 expression in MLO-Y4 osteocytes. Mechanistically, Saa3 produced by MLO-Y4 osteocytes is integrated into the extracellular matrix of MC3T3-E1 osteoblasts, where it associates with the P2 purinergic receptor P2rx7 to stimulate Mmp13 expression via the P2rx7/MAPK/ERK/activator protein 1 axis. Our data suggest that Saa3 may function as an important coupling factor in bone development and homeostasis.	[Thaler, Roman; Sturmlechner, Ines; Spitzer, Silvia; Rumpler, Monika; Zwerina, Jochen; Klaushofer, Klaus; Varga, Franz] Hanusch Hosp, Trauma Ctr Meidling, Ludwig Boltzmann Inst Osteol, Dept Med 1,Wiener Gebietskrankenkasse & Allgemein, A-1140 Vienna, Austria; [Thaler, Roman; Riester, Scott M.; van Wijnen, Andre J.] Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA; [Thaler, Roman; Riester, Scott M.; van Wijnen, Andre J.] Mayo Clin, Dept Biochem, Rochester, MN 55905 USA; [Thaler, Roman; Riester, Scott M.; van Wijnen, Andre J.] Mayo Clin, Dept Mol Biol, Rochester, MN 55905 USA	Ludwig Boltzmann Institute; WGKK - Hanusch Hospital; Mayo Clinic; Mayo Clinic; Mayo Clinic	van Wijnen, AJ (corresponding author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.	vanwijnen.andre@mayo.edu; franz.varga@osteologie.at	Riester, Scott M/K-7032-2015; van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946; Sturmlechner, Ines/0000-0003-1272-5618	Fonds zur Foerderung der Wissenschaftlichen Forschung (The Austrian Science Fund) [P24370-B19]; Wiener Gebietskrankenkasse (Social Health Insurance Vienna); Allgemeine Unfallversicherungsanstalt (Austrian Social Insurance for Occupational Risks); U.S. National Institutes of Health [R01-AR049069]; Center for Regenerative Medicine at Mayo Clinic; Patrick J. Kelly Research Fellowship award; Austrian Science Fund (FWF) [P 24370] Funding Source: researchfish; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049069] Funding Source: NIH RePORTER	Fonds zur Foerderung der Wissenschaftlichen Forschung (The Austrian Science Fund); Wiener Gebietskrankenkasse (Social Health Insurance Vienna); Allgemeine Unfallversicherungsanstalt (Austrian Social Insurance for Occupational Risks); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Regenerative Medicine at Mayo Clinic; Patrick J. Kelly Research Fellowship award; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank their colleagues at Mayo Clinic for support and stimulating discussions. They are especially grateful to Florian Haider and David Neidhart (LBIO, Vienna, Austria), Eric Lewallen, Amel Dudakovic, Emily Camilleri, Jennifer Westendorf, and David Deyle (Mayo Clinic) for stimulating discussions. They also thank Dr. Masayoshi Kumegawa (Meikai University, Urayasu, Chiba, Japan) and Dr. Lynda Bonewald (University of Missouri-Kansas City, Kansas, MI, USA) for generously providing cell lines and Dr. PhilippScherer (University of Texas, Southwestern, Dallas, TX, USA) for providing a mouse Saa3 antibody. This study was supported by the Fonds zur Foerderung der Wissenschaftlichen Forschung (The Austrian Science Fund) Project P24370-B19, the Wiener Gebietskrankenkasse (Social Health Insurance Vienna), and the Allgemeine Unfallversicherungsanstalt (Austrian Social Insurance for Occupational Risks). Additional support was provided by U.S. National Institutes of Health Grant R01-AR049069 (to A.J.v.W.), as well as intramural grants from the Center for Regenerative Medicine at Mayo Clinic and a Patrick J. Kelly Research Fellowship award (to S.M.R.).	Armstrong S, 2009, J CELL SCI, V122, P136, DOI 10.1242/jcs.031534; Aubin JE, 2000, OSTEOPOROSIS INT, V11, P905, DOI 10.1007/s001980070028; Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223-013-9774-y; BETTS JC, 1991, SCAND J IMMUNOL, V34, P471, DOI 10.1111/j.1365-3083.1991.tb01570.x; Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005; Boumah CE, 2005, PROG NUCLEIC ACID RE, V80, P287, DOI 10.1016/S0079-6603(05)80007-8; Canalis E, 2009, J CELL BIOCHEM, V108, P769, DOI 10.1002/jcb.22322; Chiba T, 2009, J LIPID RES, V50, P1353, DOI 10.1194/jlr.M900089-JLR200; Chung TF, 2000, AMYLOID, V7, P105, DOI 10.3109/13506120009146246; Connolly M, 2011, ANN RHEUM DIS, V70, P1296, DOI 10.1136/ard.2010.142240; Cunnane G, 2001, CURR OPIN RHEUMATOL, V13, P67, DOI 10.1097/00002281-200101000-00011; Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749-6632.2009.05246.x; Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200; Del Fattore Andrea, 2012, Front Biosci (Elite Ed), V4, P2302; den Hartigh LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108564; Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035; Han CY, 2007, DIABETES, V56, P2260, DOI 10.2337/db07-0218; Holmbeck K, 2005, J CELL SCI, V118, P147, DOI 10.1242/jcs.01581; Im HJ, 2003, J BIOL CHEM, V278, P25386, DOI 10.1074/jbc.M302048200; Jing D, 2014, FASEB J, V28, P1582, DOI 10.1096/fj.13-237578; Johnson BD, 2004, CIRCULATION, V109, P726, DOI 10.1161/01.CIR.0000115516.54550.B1; Karsdal MA, 2003, J BIOL CHEM, V278, P44975, DOI 10.1074/jbc.M303905200; Katayama T, 2007, INT HEART J, V48, P45, DOI 10.1536/ihj.48.45; Komori Toshihisa, 2014, J Bone Metab, V21, P55, DOI 10.11005/jbm.2014.21.1.55; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kovacevic A, 2008, J CELL BIOCHEM, V103, P994, DOI 10.1002/jcb.21472; Kumon Y, 1997, J RHEUMATOL, V24, P14; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lewis KE, 2004, CIRCULATION, V110, P540, DOI 10.1161/01.CIR.0000136819.93989.E1; Li XL, 2006, ANN NY ACAD SCI, V1068, P26, DOI 10.1196/annals.1346.006; Maier W, 2005, CIRCULATION, V111, P1355, DOI 10.1161/01.CIR.0000158479.58589.0A; Malle E, 1996, EUR J CLIN INVEST, V26, P427, DOI 10.1046/j.1365-2362.1996.159291.x; Matsuoka K, 2014, J BONE MINER RES, V29, P1522, DOI 10.1002/jbmr.2187; MEEK RL, 1986, J EXP MED, V164, P2006, DOI 10.1084/jem.164.6.2006; MEEK RL, 1992, P NATL ACAD SCI USA, V89, P7949, DOI 10.1073/pnas.89.17.7949; MORRIS AG, 1981, J GEN VIROL, V53, P39, DOI 10.1099/0022-1317-53-1-39; Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452; Niemi K, 2011, J IMMUNOL, V186, P6119, DOI 10.4049/jimmunol.1002843; Olsen HG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076695; Paschalis EP, 2011, BONE, V49, P1232, DOI 10.1016/j.bone.2011.08.027; Pellegatti P, 2011, FASEB J, V25, P1264, DOI 10.1096/fj.10-169854; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pivetta E, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3047; PreciadoPatt L, 1996, J IMMUNOL, V156, P1189; Price Joanna S, 2011, Curr Osteoporos Rep, V9, P76, DOI 10.1007/s11914-011-0050-7; Reigstad CS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005842; RYGG M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P402, DOI 10.1016/0167-4781(93)90007-Z; Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430; Scheja L, 2008, EXP DIABETES RES, DOI 10.1155/2008/230837; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Sipe J, 1999, AMYLOID, V6, P67, DOI 10.3109/13506129908993291; Sommer G, 2008, J CELL BIOCHEM, V104, P2241, DOI 10.1002/jcb.21782; Subramanian S, 2008, ARTERIOSCL THROM VAS, V28, P685, DOI 10.1161/ATVBAHA.107.157685; Sun DH, 2013, STEM CELLS, V31, P1170, DOI 10.1002/stem.1356; Syberg S, 2012, J OSTEOPOROS, V2012, DOI DOI 10.1155/2012/637986; Tang SY, 2012, J BONE MINER RES, V27, P1936, DOI 10.1002/jbmr.1646; Thaler R, 2011, J CELL PHYSIOL, V226, P2505, DOI 10.1002/jcp.22595; Thaler R, 2013, FASEB J, V27, P446, DOI 10.1096/fj.12-208058; Thaler R, 2010, BONE, V46, P703, DOI 10.1016/j.bone.2009.10.038; Thorn CF, 2003, EUR J IMMUNOL, V33, P2630, DOI 10.1002/eji.200323985; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; UHLAR CM, 1994, GENOMICS, V19, P228, DOI 10.1006/geno.1994.1052; Vallon R, 2001, J IMMUNOL, V166, P2801, DOI 10.4049/jimmunol.166.4.2801; WALKER PR, 1977, J CELL PHYSIOL, V93, P89; Wesselius A, 2011, FRONT BIOSCI-LANDMRK, V16, P2572, DOI 10.2741/3873; WESTERMARK GT, 1990, AM J PATHOL, V137, P377; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; Yamada T, 2000, SCAND J IMMUNOL, V52, P7; Zerega B, 2004, MATRIX BIOL, V23, P35, DOI 10.1016/j.matbio.2004.02.002	70	22	23	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1344	1359		10.1096/fj.14-265512	http://dx.doi.org/10.1096/fj.14-265512			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25491310	Green Published			2022-12-28	WOS:000354115000021
J	Gulraiz, F; Bellinghausen, C; Bruggeman, CA; Stassen, FR				Gulraiz, Fahad; Bellinghausen, Carla; Bruggeman, Cathrien A.; Stassen, Frank R.			Haemophilus influenzae increases the susceptibility and inflammatory response of airway epithelial cells to viral infections	FASEB JOURNAL			English	Article						NTHI; HRV; RSV; coinfection; CD54	OBSTRUCTIVE PULMONARY-DISEASE; INTERCELLULAR-ADHESION MOLECULE-1; RESPIRATORY SYNCYTIAL VIRUS; RHINOVIRUS INFECTION; ICAM-1 EXPRESSION; STREPTOCOCCUS-PNEUMONIAE; ALVEOLAR MACROPHAGES; IMMUNE-RESPONSES; CYSTIC-FIBROSIS; RT-PCR	Nontypeable Haemophilus influenzae (NTHI), a common colonizer of lungs of patients with chronic obstructive pulmonary disease (COPD), can enhance expression of the cellular receptor intercellular adhesion molecule 1 (ICAM-1), which in turn can be used by major group human rhinoviruses (HRVs) for attachment. Here, we evaluated the effect of NTHI-induced up-regulation of ICAM-1 on viral replication and inflammatory responses toward different respiratory viruses. Therefore, human bronchial epithelial cells were pretreated with heat-inactivated NTHI (hi-NTHI) and subsequently infected with either HRV16 (major group), HRV1B (minor group), or respiratory syncytial virus (RSV). Pretreatment with hi-NTHI significantly up-regulated ICAM-1 in BEAS-2B cells and primary bronchial epithelial cells. Concomitantly, release of infectious HRV16 particles was increased incells pretreated withhi-NTHI. Pretreatment with hi-NTHI also caused a significant increase in HRV16 RNA, whereas replication of HRV1B and RSV were increased to a far lesser extent and only at later time points. Interestingly, release of IL-6 and IL-8 after RSV, but not HRV, infection was synergistically increased in hi-NTHI-pretreated BEAS-2B cells. In summary, exposure to hi-NTHI significantly enhanced sensitivity toward HRV16 but not HRV1B or RSV, probably through ICAM-1 up-regulation. Furthermore, hi-NTHI pretreatment may enhance the inflammatory response to RSV infection, suggesting that preexisting bacterial infections might exaggerate inflammation during secondary viral infection.	[Gulraiz, Fahad; Bellinghausen, Carla; Bruggeman, Cathrien A.; Stassen, Frank R.] Maastricht Univ, Med Ctr, NUTRIM Sch Nutr Toxicol & Metab, Dept Med Microbiol, NL-6202 AZ Maastricht, Netherlands; [Bellinghausen, Carla] Maastricht Univ, Med Ctr, NUTRIM Sch Nutr Toxicol & Metab, Dept Resp Med, NL-6202 AZ Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Stassen, FR (corresponding author), Maastricht Univ, Med Ctr, Dept Med Microbiol, P Debyelaan 25, NL-6202 AZ Maastricht, Netherlands.	f.stassen@maastrichtuniversity.nl						Avadhanula V, 2006, J VIROL, V80, P1629, DOI 10.1128/JVI.80.4.1629-1636.2006; Avadhanula V, 2006, INFECT IMMUN, V74, P830, DOI 10.1128/IAI.74.2.830-838.2006; Bandi V, 2001, AM J RESP CRIT CARE, V164, P2114, DOI 10.1164/ajrccm.164.11.2104093; Behera AK, 2001, BIOCHEM BIOPH RES CO, V280, P188, DOI 10.1006/bbrc.2000.4093; Bianco A, 2000, CLIN EXP IMMUNOL, V121, P339, DOI 10.1046/j.1365-2249.2000.01301.x; Bochkov YA, 2011, NAT MED, V17, P627, DOI 10.1038/nm.2358; Boncristiani HF, 2009, J VIROL METHODS, V161, P147, DOI 10.1016/j.jviromet.2009.06.006; Bossios A, 2008, CLIN EXP ALLERGY, V38, P1615, DOI 10.1111/j.1365-2222.2008.03058.x; Brabec-Zaruba M, 2009, J VIROL, V83, P3770, DOI 10.1128/JVI.00265-08; Chattoraj SS, 2011, INFECT IMMUN, V79, P4131, DOI 10.1128/IAI.05120-11; Chattoraj SS, 2011, THORAX, V66, P333, DOI 10.1136/thx.2010.151431; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Erkan Levent, 2008, Int J Chron Obstruct Pulmon Dis, V3, P463; Fendrick AM, 2003, ARCH INTERN MED, V163, P487, DOI 10.1001/archinte.163.4.487; Frick AG, 2000, J IMMUNOL, V164, P4185, DOI 10.4049/jimmunol.164.8.4185; Gaajetaan GR, 2012, ANTIVIR RES, V93, P39, DOI 10.1016/j.antiviral.2011.10.015; Goss CH, 2007, THORAX, V62, P360, DOI 10.1136/thx.2006.060889; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Hament JM, 2004, PEDIATR RES, V55, P972, DOI 10.1203/01.PDR.0000127431.11750.D9; Hierholzer J. C., 1996, VIROLOGY METHODS MAN, P25; Hussell T, 2009, BIOCHEM SOC T, V37, P811, DOI 10.1042/BST0370811; Ishizuka S, 2003, J INFECT DIS, V188, P1928, DOI 10.1086/379833; Kulkarni R, 2010, INFECT IMMUN, V78, P2146, DOI 10.1128/IAI.01410-09; Mallia P, 2011, AM J RESP CRIT CARE, V183, P734, DOI 10.1164/rccm.201006-0833OC; Mastrangelo P, 2013, VIRUSES-BASEL, V5, P873, DOI 10.3390/v5030873; Mohan A, 2010, RESPIROLOGY, V15, P536, DOI 10.1111/j.1440-1843.2010.01722.x; MONSO E, 1995, AM J RESP CRIT CARE, V152, P1316, DOI 10.1164/ajrccm.152.4.7551388; Murphy TF, 2004, AM J RESP CRIT CARE, V170, P266, DOI 10.1164/rccm.200403-354OC; Nichol KL, 2005, CLIN INFECT DIS, V40, P1263, DOI 10.1086/429237; Okamoto S, 2004, INFECT IMMUN, V72, P6068, DOI 10.1128/IAI.72.10.6068-6075.2004; Oliver BGG, 2008, THORAX, V63, P519, DOI 10.1136/thx.2007.081752; Othumpangat S, 2012, AM J PHYSIOL-LUNG C, V302, pL1057, DOI 10.1152/ajplung.00365.2011; Page KR, 2006, CELL MICROBIOL, V8, P185, DOI 10.1111/j.1462-5822.2005.00653.x; Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; Peltola VT, 2004, PEDIATR INFECT DIS J, V23, pS87, DOI 10.1097/01.inf.0000108197.81270.35; Prince JE, 2001, J IMMUNOL, V166, P7362, DOI 10.4049/jimmunol.166.12.7362; Roelen CAM, 2011, WORK, V39, P305, DOI 10.3233/WOR-2011-1178; Sajjan US, 2006, FASEB J, V20, P2121, DOI 10.1096/fj.06-5806fje; Sajjan U, 2008, AM J RESP CRIT CARE, V178, P1271, DOI 10.1164/rccm.200801-136OC; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sethi S, 2008, NEW ENGL J MED, V359, P2355, DOI 10.1056/NEJMra0800353; Soler N, 1999, EUR RESPIR J, V14, P1015, DOI 10.1183/09031936.99.14510159; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; Unger BL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002969; van der Sluijs KF, 2006, J INFECT DIS, V193, P214, DOI 10.1086/498911; Van Wetering S, 2000, AM J PHYSIOL-LUNG C, V278, pL51, DOI 10.1152/ajplung.2000.278.1.L51; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; Varkey JB, 2008, CURR OPIN PULM MED, V14, P89, DOI 10.1097/MCP.0b013e3282f4a99f; Vlasak M, 2005, J VIROL, V79, P7389, DOI 10.1128/JVI.79.12.7389-7395.2005; Wang J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3106; Wang JH, 2009, LARYNGOSCOPE, V119, P1406, DOI 10.1002/lary.20498; Watson K, 2006, PEDIATR INFECT DIS J, V25, P782, DOI 10.1097/01.inf.0000232705.49634.68; Wilkinson TMA, 2006, CHEST, V129, P317, DOI 10.1378/chest.129.2.317; Yoon JS, 2007, PEDIATR PULM, V42, P277, DOI 10.1002/ppul.20574	56	46	47	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					849	858		10.1096/fj.14-254359	http://dx.doi.org/10.1096/fj.14-254359			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25411435				2022-12-28	WOS:000350633000012
J	Hadzi, S; Ondracka, A; Jerala, R; Hafner-Bratkovic, I				Hadzi, San; Ondracka, Andrej; Jerala, Roman; Hafner-Bratkovic, Iva			Pathological mutations H187R and E196K facilitate subdomain separation and prion protein conversion by destabilization of the native structure	FASEB JOURNAL			English	Article						amyloid; thermodynamic stability; transmissible spongiform encephalopathies	GERSTMANN-STRAUSSLER-SCHEINKER; NMR STRUCTURE; AMYLOID FORMATION; FOLDING PATHWAY; FOLDED DOMAIN; IN-VITRO; STABILITY; INTERMEDIATE; DISEASE; STATE	The mechanism of prion protein (PrP) conversion, the key event in prion diseases, is still not understood. We investigated how perturbations of interactions between the subdomains beta 1-alpha 1-beta 2 and alpha 2-alpha 3 affect PrP conversion. In vitro fibrillization and biophysical methods were used to relate mouse PrP conversion kinetics to thermodynamic stability. We show that pathologic mutations H187R and E196K destabilize PrP (by 3.2 and 1.1 kJ/mol, respectively, at pH 7) and accelerate fibrillization. At acidic pH, the major contribution to the destabilization of PrP comes from the protonation of histidine 187 because its replacement by tyrosine led to more stable protein (by 4.2 kJ/mol at pH 4) with slower fibrillization. Furthermore, we show that the introduction of a novel histidine residue into the subdomain interface (F198H) acts as a pH-inducible switch that promotes conversion upon histidine protonation, whereas this effect is not observed when His residue is introduced at the protein surface (Y155H). We observed a strong correlation between the stability of native structure and kinetics of fibrillization of PrP variants. Our results show that pathologic mutations promote subdomain separation and suggest that stabilization of the native structure might be a viable strategy for the development of novel therapeutics for prion diseases.	[Hadzi, San; Ondracka, Andrej; Jerala, Roman; Hafner-Bratkovic, Iva] Natl Inst Chem, Dept Biotechnol, SI-1000 Ljubljana, Slovenia; [Jerala, Roman; Hafner-Bratkovic, Iva] EN FIST Ctr Excellence, Ljubljana, Slovenia	National Institute of Chemistry - Slovenia	Hafner-Bratkovic, I (corresponding author), Natl Inst Chem, Dept Biotechnol, Hajdrihova 19, SI-1000 Ljubljana, Slovenia.	iva.hafner@ki.si		Hafner Bratkovic, Iva/0000-0001-5635-931X; Ondracka, Andrej/0000-0003-4193-6027	Slovenian Research Agency [J3-5503, Z7-2059, P4-0176]; Excellent NMR-Future Innovation for Sustainable Technologies Centre of Excellence; European Union regional development funds; European Union; European Social Fund; Republic of Slovenia, Ministry for Education, Science and Sport	Slovenian Research Agency(Slovenian Research Agency - Slovenia); Excellent NMR-Future Innovation for Sustainable Technologies Centre of Excellence; European Union regional development funds(European Commission); European Union(European Commission); European Social Fund(European Social Fund (ESF)); Republic of Slovenia, Ministry for Education, Science and Sport	The authors thank Darija Oven, Irena. Skraba, Robert Bremsak, Dr. Matevz Avbelj, and Dr. Jernej Gaspersic for technical advice and Professor Peter Veranic for help with TEM imaging. They are grateful to Professor Jurij Lah for helpful suggestions, Professor Kurt Wuthrich for providing a plasmid encoding mPrP open reading frame, and Professor Adriano Aguzzi for providing POM antibodies. This work was funded by the Slovenian Research Agency (J3-5503 and Z7-2059 to I.H.-B. and P4-0176 to R.J.) and the Excellent NMR-Future Innovation for Sustainable Technologies Centre of Excellence, which is financed in part by the European Union regional development funds. This article is a part of the doctoral research of S.H., financed by the European Union, the European Social Fund, and the Republic of Slovenia, Ministry for Education, Science and Sport in the framework of the Operational Program for Human Resources Development for the period 2007-2013.	Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Anderson M, 2006, J MOL BIOL, V358, P580, DOI 10.1016/j.jmb.2006.02.007; Apetri AC, 2004, J BIOL CHEM, V279, P18008, DOI 10.1074/jbc.M313581200; Apetri AC, 2002, J BIOL CHEM, V277, P44589, DOI 10.1074/jbc.C200507200; Avbelj M, 2011, BIOCHEM BIOPH RES CO, V413, P521, DOI 10.1016/j.bbrc.2011.08.125; Bae SH, 2009, BIOCHEMISTRY-US, V48, P8120, DOI 10.1021/bi900923b; Baral PK, 2012, ACTA CRYSTALLOGR D, V68, P1501, DOI 10.1107/S0907444912037328; Beck JA, 2010, HUM MUTAT, V31, pE1551, DOI 10.1002/humu.21281; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; Bocharova OV, 2005, PROTEIN SCI, V14, P1222, DOI 10.1110/ps.041186605; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Buell AK, 2012, ANGEW CHEM INT EDIT, V51, P5247, DOI 10.1002/anie.201108040; Buell AK, 2011, J AM CHEM SOC, V133, P7737, DOI 10.1021/ja109620d; Bulawa CE, 2012, P NATL ACAD SCI USA, V109, P9629, DOI 10.1073/pnas.1121005109; Butefisch CM, 2000, NEUROLOGY, V55, P517, DOI 10.1212/WNL.55.4.517; Calzolai L, 2003, J BIOL CHEM, V278, P35592, DOI 10.1074/jbc.M303005200; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Colucci M, 2006, J NEUROPATH EXP NEUR, V65, P642, DOI 10.1097/01.jnen.0000228198.81797.4d; Dhulesia A, 2010, J AM CHEM SOC, V132, P15580, DOI 10.1021/ja103524m; Eghiaian F, 2007, P NATL ACAD SCI USA, V104, P7414, DOI 10.1073/pnas.0607745104; Fandrich M, 2007, J MOL BIOL, V365, P1266, DOI 10.1016/j.jmb.2006.11.009; Gaspersic J, 2010, FEBS J, V277, P2038, DOI 10.1111/j.1742-4658.2010.07619.x; Gerum C, 2010, J MOL BIOL, V401, P7, DOI 10.1016/j.jmb.2010.06.008; GIACCONE G, 1992, P NATL ACAD SCI USA, V89, P9349, DOI 10.1073/pnas.89.19.9349; Giachin G, 2013, MOLECULES, V18, P9451, DOI 10.3390/molecules18089451; Glockshuber R, 1997, TRENDS BIOCHEM SCI, V22, P241, DOI 10.1016/S0968-0004(97)01070-0; Gu YP, 2004, MOL BRAIN RES, V123, P37, DOI 10.1016/j.molbrainres.2004.01.006; Hafner-Bratkovic I, 2008, J NEUROCHEM, V104, P1553, DOI 10.1111/j.1471-4159.2007.05105.x; Hafner-Bratkovic I, 2012, CELL MOL LIFE SCI, V69, P4215, DOI 10.1007/s00018-012-1140-0; Hafner-Bratkovic I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024238; Hafner-Bratkovic I, 2011, PRION, V5, P56, DOI 10.4161/pri.5.2.16232; Hafner-Bratkovic I, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.213926; Hall DA, 2005, NEUROLOGY, V64, P1304, DOI 10.1212/01.WNL.0000156911.70131.06; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Hosszu LLP, 2010, BIOCHEMISTRY-US, V49, P8729, DOI 10.1021/bi100572j; Knowles TPJ, 2007, P NATL ACAD SCI USA, V104, P10016, DOI 10.1073/pnas.0610659104; Kong QZ, 2013, CELL REP, V4, P248, DOI 10.1016/j.celrep.2013.06.030; Kuwata K, 2007, P NATL ACAD SCI USA, V104, P11921, DOI 10.1073/pnas.0702671104; Langella E, 2004, BIOPHYS J, V87, P3623, DOI [10.1529/biophysj.104.043448, 10.1529/biophysj.104.043449]; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; LIN SH, 1984, BIOCHEMISTRY-US, V23, P5504, DOI 10.1021/bi00318a019; Magalhaes AC, 2002, J BIOL CHEM, V277, P33311, DOI 10.1074/jbc.M203661200; Marijanovic Z, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000426; Neudecker P, 2012, SCIENCE, V336, P362, DOI 10.1126/science.1214203; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PACE CN, 1988, J BIOL CHEM, V263, P11820; Peoc'h K, 2000, HUM MUTAT, V15; Pimpinelli F, 2005, EUR J NEUROSCI, V21, P2063, DOI 10.1111/j.1460-9568.2005.04049.x; POLAND D, 1966, BIOPOLYMERS, V4, P223, DOI 10.1002/bip.1966.360040209; Polymenidou M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003872; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rezaei H, 2002, J MOL BIOL, V322, P799, DOI 10.1016/S0022-2836(02)00856-2; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; van der Kamp MW, 2010, J MOL BIOL, V404, P732, DOI 10.1016/j.jmb.2010.09.060; van der Kamp MW, 2010, BIOPHYS J, V99, P2289, DOI 10.1016/j.bpj.2010.07.063; Vieira TCRG, 2014, FASEB J, V28, P2667, DOI 10.1096/fj.13-246777; Vieira TCRG, 2011, J AM CHEM SOC, V133, P334, DOI 10.1021/ja106725p; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6	62	11	11	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					882	893		10.1096/fj.14-255646	http://dx.doi.org/10.1096/fj.14-255646			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25416551				2022-12-28	WOS:000350633000015
J	Berkowitz, BA; Gorgis, J; Patel, A; Baameur, F; Gurevich, VV; Craft, CM; Kefalov, VJ; Roberts, R				Berkowitz, Bruce A.; Gorgis, Jawan; Patel, Ankit; Baameur, Faiza; Gurevich, Vsevolod V.; Craft, Cheryl M.; Kefalov, Vladimir J.; Roberts, Robin			Development of an MRI biomarker sensitive to tetrameric visual arrestin 1 and its reduction via light-evoked translocation in vivo	FASEB JOURNAL			English	Article						diabetes; magnetic resonance imaging; retina; rod photoreceptors	MANGANESE-ENHANCED MRI; STATIONARY NIGHT BLINDNESS; ARTICULAR-CARTILAGE; RHODOPSIN REGENERATION; DIABETIC-RETINOPATHY; PHOTORECEPTOR CELLS; ROD PHOTORECEPTORS; OGUCHI-DISEASE; FUNCTIONAL MRI; ION REGULATION	Rod tetrameric arrestin 1 ( tet- ARR1), stored in the outer nuclear layer/ inner segments in the dark, modulates photoreceptor synaptic activity; light exposure stimulates a reduction via translocation to the outer segments for terminating G- protein coupled phototransduction signaling. Here, we test the hypothesis that intraretinal spin- lattice relaxation rate in the rotating frame ( 1/ T1r), an endogenous MRI contrast mechanism, has high potential for evaluating rod tet- ARR1 and its reduction via translocation. Dark- and light- exposed mice ( null for the ARR1 gene, overexpressing ARR1, diabetic, or wild type with or without treatment with Mn2+, a calcium channel probe) were studied using 1/ T1r MRI. Immunohistochemistry and single- cell recordings of the retinas were also performed. In wild- type mice with or without treatment with Mn2+, 1/ T1r of avascular outer retina ( 64% to 72% depth) was significantly ( P < 0.05) greater in the dark than in the light; a significant ( P < 0.05) but opposite pattern was noted in the inner retina (< 50% depth). Light- evoked outer retina D1/ T1r was absent in ARR1- null mice and supernormal in overexpressing mice. In diabetic mice, the outer retinal D1/ T1r pattern suggested normal darkto- light tet- ARR1 translocation and chromophore content, conclusions confirmed ex vivo. Light- stimulated D1/ T1r in inner retina was linked to changes in blood volume. Our data support 1/ T1r MRI for noninvasively assessing rod tet- ARR1 and its reduction via protein translocation, which can be combined with other metrics of retinal function in vivo.-	[Berkowitz, Bruce A.; Gorgis, Jawan; Patel, Ankit; Roberts, Robin] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; [Berkowitz, Bruce A.] Wayne State Univ, Dept Ophthalmol, Detroit, MI 48201 USA; [Baameur, Faiza; Gurevich, Vsevolod V.] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37235 USA; [Craft, Cheryl M.] Univ So Calif, Keck Sch Med, USC Eye Inst, Mary Allen Lab Vis Res, Los Angeles, CA USA; [Craft, Cheryl M.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA USA; [Craft, Cheryl M.] Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA USA; [Kefalov, Vladimir J.] Washington Univ St Louis, Dept Ophthalmol & Visual Sci, St Louis, MO 63103 USA	Wayne State University; Wayne State University; Vanderbilt University; University of Southern California; University of Southern California; University of Southern California; Washington University (WUSTL)	Berkowitz, BA (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield, Detroit, MI 48201 USA.	baberko@med.wayne.edu	Gurevich, Vsevolod/A-3236-2008; Cote, Rick H/G-3363-2013	Gurevich, Vsevolod/0000-0002-3950-5351; Cote, Rick H/0000-0002-1573-6526; Kefalov, Vladimir/0000-0002-1659-008X	NEI NIH HHS [R01 EY019312, EY015851, EY011500, EY019312, EY021126, R01 EY015851, R01 EY011500, P30 EY002687, EY002687, R21 EY021619, R24 EY021126] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY019312, R21EY021619, R01EY015851, P30EY002687, R24EY021126, R01EY011500] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Akella SVS, 2001, MAGNET RESON MED, V46, P419, DOI 10.1002/mrm.1208; AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992; Ball SL, 2000, INVEST OPHTH VIS SCI, V41, P610; Berkowitz BA, 1998, INVEST OPHTH VIS SCI, V39, P840; Berkowitz BA, 1999, INVEST OPHTH VIS SCI, V40, P2100; Berkowitz BA, 2006, INVEST OPHTH VIS SCI, V47, P2668, DOI 10.1167/iovs.05-1588; Berkowitz Bruce A, 2013, Expert Opin Med Diagn, V7, P393, DOI 10.1517/17530059.2013.814639; Berkowitz BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029619; Berkowitz BA, 2012, MOL VIS, V18, P372; Berkowitz BA, 2010, MOL VIS, V16, P1776; Berkowitz BA, 2008, NMR BIOMED, V21, P957, DOI 10.1002/nbm.1303; Berkowitz BA, 2009, INVEST OPHTH VIS SCI, V50, P2351, DOI 10.1167/iovs.08-2918; Bissig D., 2012, MOL VIS, V18; Bissig D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056340; Bissig D, 2011, NEUROIMAGE, V58, P749, DOI 10.1016/j.neuroimage.2011.06.062; BRAEKEVELT CR, 1970, AM J ANAT, V127, P281, DOI 10.1002/aja.1001270305; BROWN B, 2010, DES ISSUES, V26, P1; Burns ME, 2006, J NEUROSCI, V26, P1036, DOI 10.1523/JNEUROSCI.3301-05.2006; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; Charagundla SR, 2003, J MAGN RESON, V162, P113, DOI 10.1016/S1090-7807(02)00197-0; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; Chen J, 1999, INVEST OPHTH VIS SCI, V40, P2978; Cheng HY, 2006, P NATL ACAD SCI USA, V103, P17525, DOI 10.1073/pnas.0605790103; de Carvalho JER, 2014, SURV OPHTHALMOL, V59, P393, DOI 10.1016/j.survophthal.2013.09.005; Duong TQ, 2014, MAGN RESON MED, V71, P1526, DOI 10.1002/mrm.24797; Garcia-Ramirez M, 2009, DIABETOLOGIA, V52, P2633, DOI 10.1007/s00125-009-1548-8; Godara P, 2012, AM J OPHTHALMOL, V154, P987, DOI 10.1016/j.ajo.2012.06.003; Grohn OHJ, 2000, J CEREBR BLOOD F MET, V20, P1457; Gurevich VV, 2011, PROG RETIN EYE RES, V30, P405, DOI 10.1016/j.preteyeres.2011.07.002; Hanson SM, 2008, BIOCHEMISTRY-US, V47, P1070, DOI 10.1021/bi7021359; Hardarson SH, 2009, INVEST OPHTH VIS SCI, V50, P2308, DOI 10.1167/iovs.08-2576; Huang SP, 2010, J NEUROSCI, V30, P9381, DOI 10.1523/JNEUROSCI.1207-10.2010; Hulvershorn J, 2005, MAGN RESON MED, V54, P1155, DOI 10.1002/mrm.20698; Jin T, 2013, NEUROIMAGE, V78, P385, DOI 10.1016/j.neuroimage.2013.04.045; Kern TS, 2010, MOL VIS, V16, P2121; Kettunen MI, 2002, MAGNET RESON MED, V48, P470, DOI 10.1002/mrm.10233; Kim M, 2011, BIOCHEMISTRY-US, V50, P2235, DOI 10.1021/bi1018607; Kirwin SJ, 2011, INVEST OPHTH VIS SCI, V52, P7654, DOI 10.1167/iovs.10-6609; KNOSPE V, 1988, CURR EYE RES, V7, P1137, DOI 10.3109/02713688809001885; Li X, 2007, OSTEOARTHR CARTILAGE, V15, P789, DOI 10.1016/j.joca.2007.01.011; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Magnotta VA, 2012, P NATL ACAD SCI USA, V109, P8270, DOI 10.1073/pnas.1205902109; Mendez A, 2003, J NEUROSCI, V23, P3124; Nair KS, 2005, NEURON, V46, P555, DOI 10.1016/j.neuron.2005.03.023; Nikonov SS, 2008, NEURON, V59, P462, DOI 10.1016/j.neuron.2008.06.011; Nusinowitz S, 1999, INVEST OPHTH VIS SCI, V40, P2848; Ostroy SE, 1998, CURR EYE RES, V17, P979, DOI 10.1076/ceyr.17.10.979.5236; OSTROY SE, 1994, INVEST OPHTH VIS SCI, V35, P3905; Paques M, 2003, INVEST OPHTH VIS SCI, V44, P4960, DOI 10.1167/iovs.02-0738; PHILP NJ, 1987, FEBS LETT, V225, P127, DOI 10.1016/0014-5793(87)81144-4; Raya JG, 2010, MAGN RESON MED, V63, P181, DOI 10.1002/mrm.22178; Regatte RR, 2003, J MAGN RESON IMAGING, V17, P114, DOI 10.1002/jmri.10228; Shih YYI, 2013, CURR EYE RES, V38, P292, DOI 10.3109/02713683.2012.756526; Shih YYI, 2011, INVEST OPHTH VIS SCI, V52, P5303, DOI 10.1167/iovs.10-6438; Smith WC, 2013, PROG MOL BIOL TRANSL, V118, P243, DOI 10.1016/B978-0-12-394440-5.00010-3; Song X, 2011, NEUROSCIENCE, V174, P37, DOI 10.1016/j.neuroscience.2010.11.009; Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068; YAMAMOTO F, 1992, EXP EYE RES, V54, P685, DOI 10.1016/0014-4835(92)90023-L; Zhi ZW, 2014, INVEST OPHTH VIS SCI, V55, P1024, DOI 10.1167/iovs.13-12864	60	6	6	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					554	564		10.1096/fj.14-254953	http://dx.doi.org/10.1096/fj.14-254953			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25351983	Green Published			2022-12-28	WOS:000349370400018
J	Ning, FK; Wang, C; Berry, KZ; Kandasamy, P; Liu, HL; Murphy, RC; Voelker, DR; Nho, CW; Pan, CH; Dai, SD; Niu, LW; Chu, HW; Zhang, GY				Ning, Fangkun; Wang, Chao; Berry, Karin Zemski; Kandasamy, Pitchaimani; Liu, Haolin; Murphy, Robert C.; Voelker, Dennis R.; Nho, Chu Won; Pan, Choel-Ho; Dai, Shaodong; Niu, Liwen; Chu, Hong-Wei; Zhang, Gongyi			Structural characterization of the pulmonary innate immune protein SPLUNC1 and identification of lipid ligands	FASEB JOURNAL			English	Article						lipid ligand; SM; DPPC	BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN; PSEUDOMONAS-AERUGINOSA INFECTION; BINDS MYCOPLASMA-PNEUMONIAE; CYSTIC-FIBROSIS AIRWAYS; GRAM-NEGATIVE BACTERIA; SURFACTANT-PROTEIN; CRYSTAL-STRUCTURE; MASS-SPECTROMETRY; HIGH-AFFINITY; HOST-DEFENSE	The short palate, lung and nasal epithelial clone 1 (SPLUNC1) protein is a member of the palate, lung, and nasal epithelium clone (PLUNC) family, also known as bactericidal/permeability-increasing (BPI) fold-containing protein, family A, member 1 (BPIFA1). SPLUNC1 is an abundant protein in human airways, but its function remains poorly understood. The lipid ligands of SPLUNC1 as well as other PLUNC family members are largely unknown, although some reports provide evidence that lipopolysaccharide (LPS) could be a lipid ligand. Unlike previous hypotheses, we found significant structural differences between SPLUNC1 and BPI. Recombinant SPLUNC1 produced in HEK 293 cells harbored several molecular species of sphingomyelin and phosphatidylcholine as its ligands. Significantly, in vitro lipid-binding studies failed to demonstrate interactions between SPLUNC1 and LPS, lipoteichoic acid, or polymyxin B. Instead, one of the major and most important pulmonary surfactant phospholipids, dipalmitoylphosphatidylcholine (DPPC), bound to SPLUNC1 with high affinity and specificity. We found that SPLUNC1 could be the first protein receptor for DPPC. These discoveries provide insight into the specific determinants governing the interaction between SPLUNC1 and lipids and also shed light on novel functions that SPLUNC1 and other PLUNC family members perform in host defense.	[Ning, Fangkun; Niu, Liwen] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; [Ning, Fangkun; Wang, Chao; Liu, Haolin; Dai, Shaodong; Chu, Hong-Wei; Zhang, Gongyi] Natl Jewish Hlth Denver, Integrated Dept Immunol, Denver, CO USA; [Ning, Fangkun; Wang, Chao; Liu, Haolin; Dai, Shaodong; Chu, Hong-Wei; Zhang, Gongyi] Univ Colorado, Denver, CO 80202 USA; [Berry, Karin Zemski; Murphy, Robert C.] Univ Colorado, Dept Pharmacol, Denver, CO USA; [Kandasamy, Pitchaimani; Voelker, Dennis R.; Chu, Hong-Wei] Natl Jewish Hlth, Dept Med, Denver, CO USA; [Nho, Chu Won; Pan, Choel-Ho] Korea Inst Sci & Technol, Funct Food Ctr, Gang Neung, South Korea	Chinese Academy of Sciences; University of Science & Technology of China, CAS; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver; National Jewish Health; Korea Institute of Science & Technology (KIST)	Niu, LW (corresponding author), Univ Sci & Technol China, Sch Life Sci, 96 Jinzhai Rd, Hefei 230027, Anhui, Peoples R China.	lwniu@ustc.edu.cn; chuh@njhealth.org	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	U.S. National Institutes of Health [HL088264, AI109219, GM80719, AI22295]; Korea Institute of Science and Technology [2Z03300]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI109219, T32AI074491, P01AI022295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080719] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Korea Institute of Science and Technology(Korea Institute of Science & Technology (KIST)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank the Howard Hughes Medical Institute, the Zuckerman/Canyon Ranch, and Alan Lapporte for supporting their X-ray and computing facilities; Dr. Philippa C. Marrack, Dr. John Kappler, Dr. Lei Yin, Dr. Laurel Lenz, and other researchers at National Jewish for their kind support; and Dr. Jennifer Kemp for editing. All datasets were collected from Howard Hughes Medical Institute beamlines 8.2.1 and 8.2.2 at the Advanced Light Source (Berkeley, CA, USA). This work was supported by the U.S. National Institutes of Health (grants HL088264 to H.W.C., AI109219 to G.Z, and GM80719 and AI22295 to P.M.) and by an intramural grant (2Z03300) from the Korea Institute of Science and Technology. The structure factors and coordinates have been deposited in PDB (identification codes 4KEG and 4N4X).	Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308; Balakrishnan A, 2013, INNATE IMMUN-LONDON, V19, P339, DOI 10.1177/1753425912465098; Bartlett J, 2011, BIOCHEM SOC T, V39, P1012, DOI 10.1042/BST0391012; Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; Bingle C. D., BIOCH SOC T, V39, P977; Bingle CD, 2000, BBA-GENE STRUCT EXPR, V1493, P363, DOI 10.1016/S0167-4781(00)00196-2; Bingle CD, 2011, BIOCHEM SOC T, V39, P977, DOI 10.1042/BST0390977; Bingle CD, 2011, BIOCHEM SOC T, V39, P961, DOI 10.1042/BST0390961; Bingle L, 2011, BIOCHEM SOC T, V39, P1023, DOI 10.1042/BST0391023; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Campos MA, 2004, AM J RESP CELL MOL, V30, P184, DOI 10.1165/rcmb.2003-0142OC; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Chiba H, 2002, J BIOL CHEM, V277, P20379, DOI 10.1074/jbc.M201089200; Chu HW, 2007, J IMMUNOL, V179, P3995, DOI 10.4049/jimmunol.179.6.3995; Chu HW, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-155; Di YP, 2011, BIOCHEM SOC T, V39, P1051, DOI 10.1042/BST0391051; DiBlasi, 2011, RESP CARE, V56, P1386; Elsbach P, 1998, CURR OPIN IMMUNOL, V10, P45, DOI 10.1016/S0952-7915(98)80030-7; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gaillard EA, 2010, PFLUG ARCH EUR J PHY, V460, P1, DOI 10.1007/s00424-010-0827-z; Gakhar L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009098; Gally F, 2011, AM J PATHOL, V178, P2159, DOI 10.1016/j.ajpath.2011.01.026; Garland AL, 2013, P NATL ACAD SCI USA, V110, P15973, DOI 10.1073/pnas.1311999110; Ghafouri B, 2004, BBA-PROTEINS PROTEOM, V1699, P57, DOI 10.1016/j.bbapap.2004.01.001; Hasegawa H, 2009, CURR OPIN STRUC BIOL, V19, P341, DOI 10.1016/j.sbi.2009.04.003; Hobbs CA, 2012, FASEB J, V26, P4348, DOI 10.1096/fj.12-207431; Kang JY, 2009, IMMUNITY, V31, P873, DOI 10.1016/j.immuni.2009.09.018; Kleiger G, 2000, J MOL BIOL, V299, P1019, DOI 10.1006/jmbi.2000.3805; Kopec KO, 2011, BIOCHEM SOC T, V39, P1033, DOI 10.1042/BST0391033; LeClair EE, 2003, J DENT RES, V82, P944, DOI 10.1177/154405910308201202; Liebisch G, 2013, J LIPID RES, V54, P1523, DOI 10.1194/jlr.M033506; Liu YF, 2001, P NATL ACAD SCI USA, V98, P6877, DOI 10.1073/pnas.121013398; Lukinskiene L, 2011, J IMMUNOL, V187, P382, DOI 10.4049/jimmunol.1001769; McGillivary G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013224; Mueller GA, 2010, J ALLERGY CLIN IMMUN, V125, P909, DOI 10.1016/j.jaci.2009.12.016; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pape T, 2004, J APPL CRYSTALLOGR, V37, P843, DOI 10.1107/S0021889804018047; Piboonpocanun S, 2005, J BIOL CHEM, V280, P9, DOI 10.1074/jbc.M411570200; Pulfer M, 2003, MASS SPECTROM REV, V22, P332, DOI 10.1002/mas.10061; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Sayeed S, 2013, INFECT IMMUN, V81, P285, DOI 10.1128/IAI.00500-12; Schumann RR, 2011, BIOCHEM SOC T, V39, P989, DOI 10.1042/BST0390989; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; Thaikoottathil JV, 2012, AM J RESP CELL MOL, V47, P253, DOI 10.1165/rcmb.2012-0064OC; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Weiss J, 2003, BIOCHEM SOC T, V31, P785, DOI 10.1042/BST0310785; Weston WM, 1999, J BIOL CHEM, V274, P13698, DOI 10.1074/jbc.274.19.13698; Willson DF, 2011, RESP CARE, V56, P1369, DOI 10.4187/respcare.01306; Zhou HD, 2006, MOL IMMUNOL, V43, P1864, DOI 10.1016/j.molimm.2005.10.021; Zhou HD, 2006, HISTOCHEM CELL BIOL, V125, P315, DOI 10.1007/s00418-005-0070-4; Zhou HD, 2008, MOL CELL BIOCHEM, V309, P191, DOI 10.1007/s11010-007-9659-3; Zhou Hou-de, 2006, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V31, P464	52	15	16	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5349	5360		10.1096/fj.14-259291	http://dx.doi.org/10.1096/fj.14-259291			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25223608	Green Published			2022-12-28	WOS:000345894500028
J	Rana, S; Rajakumar, A; Geahchan, C; Salahuddin, S; Cerdeira, AS; Burke, SD; George, EM; Granger, JP; Karumanchi, SA				Rana, Sarosh; Rajakumar, Augustine; Geahchan, Carl; Salahuddin, Saira; Cerdeira, Ana Sofia; Burke, Suzanne D.; George, Eric M.; Granger, Joey P.; Karumanchi, S. Ananth			Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1 alpha pathway	FASEB JOURNAL			English	Article						preeclampsia; hypertension; angiogenesis	UTERINE PERFUSION-PRESSURE; TYROSINE KINASE 1; SHOCK-PROTEIN 27; SOLUBLE FLT-1; SEVERE PREECLAMPSIA; ANGIOGENIC FACTORS; PREGNANT-WOMEN; BLOOD-PRESSURE; CELL-DEATH; HYPERTENSION	Up-regulation of placental soluble fms-like tyrosine kinase 1 (sFlt1) contributes to the pathogenesis of preeclampsia. To evaluate novel upstream pathways that regulate placental sFlt1 production, we screened a library of natural compounds (n=502) in human placental cell lines. Here, we report 3 compounds in the cardiac glycoside family, ouabain, gitoxigenin, and digitoxin, that inhibit placental sFlt1 production at nanomolar concentrations in vitro. We further characterized ouabain and demonstrated that it inhibits sFlt1 mRNA and protein expression in human placental cytotrophoblasts and explant cultures in a dose-and time-dependent manner. Ouabain down-regulated sFlt1 production by inhibiting hypoxia-inducible factor 1 (HIF-1 alpha) protein expression in the placenta. Furthermore, we found that phosphorylation of heat-shock protein 27 (HSP27) was necessary for ouabain to inhibit HIF-1 alpha translation. In a rat model of pregnancy-induced hypertension, ouabain reduced mean arterial pressure and enhanced placental HSP27 phosphorylation without any adverse effects on pups. Further studies are needed to explore the usefulness of targeting HIF-1 alpha/HSP27 pathway in preeclampsia.	[Rana, Sarosh; Salahuddin, Saira; Karumanchi, S. Ananth] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Rajakumar, Augustine; Geahchan, Carl; Cerdeira, Ana Sofia; Burke, Suzanne D.; Karumanchi, S. Ananth] Beth Israel Deaconess Med Ctr, Ctr Vasc Biol, Boston, MA 02215 USA; [Rana, Sarosh; Rajakumar, Augustine; Salahuddin, Saira; Burke, Suzanne D.; Karumanchi, S. Ananth] Harvard Univ, Sch Med, Boston, MA USA; [Rajakumar, Augustine; Burke, Suzanne D.; Karumanchi, S. Ananth] Howard Hughes Med Inst, Boston, MA 02115 USA; [George, Eric M.; Granger, Joey P.] Univ Mississippi, Med Ctr, Dept Physiol, Jackson, MS 39216 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Mississippi; University of Mississippi Medical Center	Rana, S (corresponding author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Kirstein 382, Boston, MA 02215 USA.	srana1@bidmc.harvard.edu	Karumanchi, Subbian Ananth/AAI-1694-2021; George, Eric/ABE-2767-2020	George, Eric/0000-0002-6622-7369; Burke, Suzanne/0000-0003-4594-4163; Cerdeira, A. Sofia/0000-0002-7643-3537	U.S. National Institutes of Health/National Institute of Child Health and Development [K08HD068398-01A1]; Gulbenkian Programme for Advanced Medical Education (Lisbon, Portugal); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K08HD068398] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL108618] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Institute of Child Health and Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Gulbenkian Programme for Advanced Medical Education (Lisbon, Portugal); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dawn McCullough, R.N., for patient placental sample collection. S. R. is supported by grant K08HD068398-01A1 (U.S. National Institutes of Health/National Institute of Child Health and Development). A.S.C is funded by the Gulbenkian Programme for Advanced Medical Education (Lisbon, Portugal). S.A.K is an investigator of the Howard Hughes Medical Institute. S.A.K. is a coinventor on multiple patents for preeclampsia markers and reports service as a consultant to Siemens Diagnostics (Munich, Germany) and has financial interest in Aggamin LLC (New York, NY, USA). The other authors report no conflicts of interest.	Abdulsid A, 2014, J REPROD IMMUNOL, V101, P89, DOI 10.1016/j.jri.2013.09.002; Acunzo J, 2012, INT J BIOCHEM CELL B, V44, P1622, DOI 10.1016/j.biocel.2012.04.002; Adair CD, 2009, J PERINATOL, V29, P284, DOI 10.1038/jp.2008.224; Adair CD, 2010, AM J PERINAT, V27, P655, DOI 10.1055/s-0030-1249762; Alexander BT, 2001, HYPERTENSION, V37, P1191, DOI 10.1161/01.HYP.37.4.1191; Backes CH, 2011, J PREGNANCY, V2011, DOI 10.1155/2011/214365; Conrad KP, 2011, SEMIN NEPHROL, V31, P15, DOI 10.1016/j.semnephrol.2010.10.003; Costantine MM, 2013, OBSTET GYNECOL, V121, P349, DOI 10.1097/AOG.0b013e31827d8ad5; Cudmore M, 2007, CIRCULATION, V115, P1789, DOI 10.1161/CIRCULATIONAHA.106.660134; Garrido C, 2012, INT J BIOCHEM CELL B, V44, P1588, DOI 10.1016/j.biocel.2012.02.022; Gilbert JS, 2010, HYPERTENSION, V55, P380, DOI 10.1161/HYPERTENSIONAHA.109.141937; Granger JP, 2006, METH MOLEC MED, V122, P383; GRAVES SW, 1995, AM J HYPERTENS, V8, P5, DOI 10.1016/0895-7061(94)00167-A; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jacobs BE, 2012, AM J PHYSIOL-HEART C, V302, pH1317, DOI 10.1152/ajpheart.00532.2011; Karumanchi SA, 2004, ENDOCRINOLOGY, V145, P4835, DOI 10.1210/en.2004-1028; Khankin EV, 2012, PREGNANCY HYPERTENS, V2, P84, DOI 10.1016/j.preghy.2011.11.002; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; MULLER P, 1965, CIRC RES, V17, P46, DOI 10.1161/01.RES.17.1.46; Murphy SR, 2013, AM J PHYSIOL-REG I, V304, pR130, DOI 10.1152/ajpregu.00069.2012; Nagamatsu T, 2004, ENDOCRINOLOGY, V145, P4838, DOI 10.1210/en.2004-0533; Oya-Ito T, 2006, J CELL BIOCHEM, V99, P279, DOI 10.1002/jcb.20781; Powe CE, 2011, CIRCULATION, V123, P2856, DOI 10.1161/CIRCULATIONAHA.109.853127; Rajakumar A, 2005, PLACENTA, V26, P563, DOI 10.1016/j.placenta.2004.09.001; Rajakumar A, 2003, PLACENTA, V24, P199, DOI 10.1053/plac.2002.0893; Rajakumar A, 2009, PLACENTA, V30, P25, DOI 10.1016/j.placenta.2008.10.006; Rajakumar A, 2001, BIOL REPROD, V64, P499, DOI 10.1093/biolreprod/64.2.499; Rana S, 2012, CIRCULATION, V125, P911, DOI 10.1161/CIRCULATIONAHA.111.054361; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; Roberts JM, 2013, OBSTET GYNECOL, V122, P1122, DOI 10.1097/01.AOG.0000437382.03963.88; Shin JK, 2009, J OBSTET GYNAECOL RE, V35, P888, DOI 10.1111/j.1447-0756.2009.01053.x; Surmon L, 2014, HYPERTENS PREGNANCY, V33, P371, DOI 10.3109/10641955.2014.903963; Thadhani R, 2011, CIRCULATION, V124, P940, DOI 10.1161/CIRCULATIONAHA.111.034793; Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664; YUAN CM, 1993, HYPERTENSION, V22, P178, DOI 10.1161/01.HYP.22.2.178; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105; Zhou CC, 2008, NAT MED, V14, P855, DOI 10.1038/nm.1856; Zhou Y, 2013, J CLIN INVEST, V123, P2862, DOI 10.1172/JCI66966	41	39	42	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4324	4334		10.1096/fj.14-252684	http://dx.doi.org/10.1096/fj.14-252684			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24970393	Green Published			2022-12-28	WOS:000342222700012
J	Tabone-Eglinger, S; Calderin-Sollet, Z; Pinon, P; Aebischer, N; Wehrle-Haller, M; Jacquier, MC; Boettiger, D; Wehrle-Haller, B				Tabone-Eglinger, Severine; Calderin-Sollet, Zuleika; Pinon, Perrine; Aebischer, Nicole; Wehrle-Haller, Monique; Jacquier, Marie-Claude; Boettiger, David; Wehrle-Haller, Bernhard			Niche anchorage and signaling through membrane-bound Kit-ligand/c-kit receptor are kinase independent and imatinib insensitive	FASEB JOURNAL			English	Article						stem cell factor; adhesion and spreading; integrin; fibronectin; mast cells	GASTROINTESTINAL STROMAL TUMORS; HEMATOPOIETIC STEM-CELLS; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; BONE-MARROW; GERMLINE MUTATION; DOMINANT ROLE; BCR-ABL; ADHESION; DOMAIN	Kit ligand (KitL) and its tyrosine kinase receptor c-kit are critical for germ cells, melanocytes, mastocytes, and hematopoietic stem cells. Alternative splicing of KitL generates membrane-bound KitL (mb-KitL) or soluble KitL, providing survival or cell migration, respectively. Here we analyzed whether c-kit can function both as an adhesion and signaling receptor to mb-KitL presented by the environmental niche. At contacts between fibroblasts and MC/9 mast cells, mb-KitL, and c-kit formed ligand/receptor clusters that formed stable complexes, which resisted dissociation by c-kit blocking mAbs and provided cell anchorage under physiological shear stresses. Clusters recruited tyrosine-phosphorylated proteins and induced spatially restricted F-actin polymerization. Mutational analysis of c-kit demonstrated kinase-independent mb-KitL/c-kit clustering, anchorage, F-actin polymerization, and Tyr567-dependent cluster phosphorylation. Kinase inhibition of c-kit by imatinib reduced cluster coalescence, but allowed cluster phosphorylation and F-actin polymerization, which required PI3K recruitment and a newly identified juxtamembrane residue. Synergies between integrin and c-kit-mediated spreading and adhesion of MC/9 cells were studied in vitro on immobilized-KitL/fibronectin surfaces. While c-kit blocking antibodies prevented spreading, imatinib blocked spreading induced by soluble-but not immobilized KitL. Thus, "mechanical" activation of c-kit provides signaling, niche-anchorage, and synergies with integrin-mediated adhesion, which is independent of kinase function and resistant to c-kit kinase inhibitors.-Tabone-Eglinger, S., Calderin-Sollet, Z., Pinon, P., Aebischer, N., Wehrle-Haller, M., Jacquier, M.-C., Boettiger, D., Wehrle-Haller, B. Niche anchorage and signaling through membrane-bound Kit-ligand/c-kit receptor are kinase independent and imatinib insensitive.	[Tabone-Eglinger, Severine; Calderin-Sollet, Zuleika; Pinon, Perrine; Aebischer, Nicole; Wehrle-Haller, Monique; Jacquier, Marie-Claude; Wehrle-Haller, Bernhard] Univ Geneva, Ctr Med Univ, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland; [Boettiger, David] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA	University of Geneva; University of Pennsylvania	Wehrle-Haller, B (corresponding author), Univ Geneva, Ctr Med Univ, Dept Cell Physiol & Metab, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	bernhard.wehrle-haller@unige.ch		TABONE-eglinger, Severine/0000-0003-4247-1321	Nevus Outreach; Geneva Cancer League; Swiss National Science foundation [31003A-130742]; Connective Tissue Cancer Network (CONTICANET); Connective Tissue Cancer Network (University of Lyon, France); Dr. Henri Dubois-Ferriere, Dinu Lipatti Foundation (Geneva, Switzerland)	Nevus Outreach; Geneva Cancer League; Swiss National Science foundation(Swiss National Science Foundation (SNSF)European Commission); Connective Tissue Cancer Network (CONTICANET); Connective Tissue Cancer Network (University of Lyon, France); Dr. Henri Dubois-Ferriere, Dinu Lipatti Foundation (Geneva, Switzerland)	The authors thank Thomas Matthes and Jozsef Kiss for critical reading of the manuscript and Jean-Yves Blay for discussion. This work was supported by research grants from Nevus Outreach, the Geneva Cancer League, and the Swiss National Science foundation (31003A-130742) to B.W.H. S.T.E. was supported by the Connective Tissue Cancer Network (CONTICANET; University of Lyon, France) and the Dr. Henri Dubois-Ferriere, Dinu Lipatti Foundation (Geneva, Switzerland). The authors declare no conflicts of interest.	ADACHI S, 1992, BLOOD, V79, P650; Agosti V, 2004, J EXP MED, V199, P867, DOI 10.1084/jem.20031983; Agosti V, 2009, EXP HEMATOL, V37, P159, DOI 10.1016/j.exphem.2008.10.009; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Barker JE, 1997, EXP HEMATOL, V25, P542; Beghini A, 2001, CANCER, V92, P657, DOI 10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D; Boettiger D, 2007, METHOD ENZYMOL, V426, P1, DOI 10.1016/S0076-6879(07)26001-X; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; Cabrita MA, 2006, J BIOL CHEM, V281, P29201, DOI 10.1074/jbc.M603921200; Comb WC, 2012, MOL CELL, V45, P719, DOI 10.1016/j.molcel.2012.01.010; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; DASTYCH J, 1994, J IMMUNOL, V152, P213; Dastych J, 1998, AM J PHYSIOL-CELL PH, V275, pC1291, DOI 10.1152/ajpcell.1998.275.5.C1291; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783; DiNitto JP, 2010, J BIOCHEM, V147, P601, DOI 10.1093/jb/mvq015; FehlnerGardiner CC, 1996, DIFFERENTIATION, V60, P317, DOI 10.1046/j.1432-0436.1996.6050317.x; Fewkes NM, 2010, BLOOD, V115, P4120, DOI 10.1182/blood-2009-10-248898; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Kimura Y, 2004, P NATL ACAD SCI USA, V101, P6015, DOI 10.1073/pnas.0305363101; KINASHI T, 1994, BLOOD, V83, P1033; Kunisaki Y, 2013, NATURE, V502, P637, DOI 10.1038/nature12612; Lennartsson J, 2012, PHYSIOL REV, V92, P1619, DOI 10.1152/physrev.00046.2011; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Maeyama H, 2001, GASTROENTEROLOGY, V120, P210; Mancini A, 2000, FEBS LETT, V482, P54, DOI 10.1016/S0014-5793(00)02036-6; Martino MM, 2013, P NATL ACAD SCI USA, V110, P4563, DOI 10.1073/pnas.1221602110; Martino MM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002614; Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; Mol CD, 2003, J BIOL CHEM, V278, P31461, DOI 10.1074/jbc.C300186200; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; Papayannopoulou T, 1998, BLOOD, V91, P2231, DOI 10.1182/blood.V91.7.2231.2231_2231_2239; Papayannopoulou T, 2001, BLOOD, V98, P2403, DOI 10.1182/blood.V98.8.2403; Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104; Paszek MJ, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000604; Paulhe F, 2009, FASEB J, V23, P3037, DOI 10.1096/fj.09-129577; Puissant A, 2012, J MOL CELL BIOL, V4, P207, DOI 10.1093/jmcb/mjs010; Resnick N, 2003, PROG BIOPHYS MOL BIO, V81, P177, DOI 10.1016/S0079-6107(02)00052-4; Robson ME, 2004, CLIN CANCER RES, V10, P1250, DOI 10.1158/1078-0432.CCR-03-0110; Roeder I, 2006, NAT MED, V12, P1181, DOI 10.1038/nm1487; Salaita K, 2010, SCIENCE, V327, P1380, DOI 10.1126/science.1181729; Scheijen B, 2002, ONCOGENE, V21, P3314, DOI 10.1038/sj.onc.1205317; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Tabone-Eglinger S, 2012, FASEB J, V26, P3738, DOI 10.1096/fj.12-206045; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TO LB, 1994, BLOOD, V84, P2930; TOKSOZ D, 1992, P NATL ACAD SCI USA, V89, P7350, DOI 10.1073/pnas.89.16.7350; Trumpp A, 2010, NAT REV IMMUNOL, V10, P201, DOI 10.1038/nri2726; Vermeulen L, 2012, LANCET ONCOL, V13, pE83, DOI 10.1016/S1470-2045(11)70257-1; Waskow C, 2007, BLOOD, V109, P5363, DOI 10.1182/blood-2006-08-039131; Wehrle-Haller Bernhard, 2007, Methods Mol Biol, V370, P173; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; YEE NS, 1994, J BIOL CHEM, V269, P31991; Zhang JM, 2010, NATURE, V463, P501, DOI 10.1038/nature08675	63	10	10	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4441	4456		10.1096/fj.14-249425	http://dx.doi.org/10.1096/fj.14-249425			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25002122				2022-12-28	WOS:000342222700022
J	Cicerchi, C; Li, NX; Kratzer, J; Garcia, G; Roncal-Jimenez, CA; Tanabe, K; Hunter, B; Rivard, CJ; Sautin, YY; Gaucher, EA; Johnson, RJ; Lanaspa, MA				Cicerchi, Christina; Li, Nanxing; Kratzer, James; Garcia, Gabriela; Roncal-Jimenez, Carlos A.; Tanabe, Katsuyuki; Hunter, Brandi; Rivard, Christopher J.; Sautin, Yuri Y.; Gaucher, Eric A.; Johnson, Richard J.; Lanaspa, Miguel A.			Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids	FASEB JOURNAL			English	Article						urate; phosphate; insulin; gluconeogenesis	ACTIVATED PROTEIN-KINASE; PHOSPHATE; FRUCTOSE; INSULIN; LIVER; MECHANISM; CELLS; EXPRESSION; HYPOTHESIS; DEAMINASE	Reduced AMP kinase (AMPK) activity has been shown to play a key deleterious role in increased hepatic gluconeogenesis in diabetes, but the mechanism whereby this occurs remains unclear. In this article, we document that another AMP-dependent enzyme, AMP deaminase (AMPD) is activated in the liver of diabetic mice, which parallels with a significant reduction in AMPK activity and a significant increase in intracellular glucose accumulation in human HepG2 cells. AMPD activation is induced by a reduction in intracellular phosphate levels, which is characteristic of insulin resistance and diabetic states. Increased gluconeogenesis is mediated by reduced TORC2 phosphorylation at Ser171 by AMPK in these cells, as well as by the up-regulation of the rate-limiting enzymes PEPCK and G6Pc. The mechanism whereby AMPD controls AMPK activation depends on the production of a specific AMP downstream metabolite through AMPD, uric acid. In this regard, humans have higher uric acid levels than most mammals due to a mutation in uricase, the enzyme involved in uric acid degradation in most mammals, that developed during a period of famine in Europe 1.5 x 10(7) yr ago. Here, working with resurrected ancestral uricases obtained from early hominids, we show that their expression on HepG2 cells is enough to blunt gluconeogenesis in parallel with an up-regulation of AMPK activity. These studies identify a key role AMPD and uric acid in mediating hepatic gluconeogenesis in the diabetic state, via a mechanism involving AMPK down-regulation and overexpression of PEPCK and G6Pc. The uricase mutation in the Miocene likely provided a survival advantage to help maintain glucose levels under condi-tions of near starvation, but today likely has a role in the pathogenesis of diabetes.	[Cicerchi, Christina; Li, Nanxing; Garcia, Gabriela; Roncal-Jimenez, Carlos A.; Tanabe, Katsuyuki; Hunter, Brandi; Rivard, Christopher J.; Johnson, Richard J.; Lanaspa, Miguel A.] Univ Colorado Denver, Sch Med, Aurora, CO 80045 USA; [Kratzer, James; Gaucher, Eric A.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA; [Sautin, Yuri Y.] Univ Florida, Sch Med, Gainesville, FL USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University System of Georgia; Georgia Institute of Technology; State University System of Florida; University of Florida	Lanaspa, MA (corresponding author), Univ Colorado Denver, Sch Med, 12700 East 19th Ave,C-281, Aurora, CO 80045 USA.	miguel.lanaspagarcia@ucdenver.edu	Gaucher, Eric/I-7313-2013; Lanaspa, Miguel/AAO-4971-2020; Tanabe, Katsuyuki/J-1341-2019	Tanabe, Katsuyuki/0000-0003-4767-5892	U.S. National Institutes of Health [HL-68607, RC4-DK090859-01, 1K01-DK095930-01, RO1-DK082509]; University of Colorado; U.S. National Institutes of Health (NIH)/National Center for Research Resources Colorado Clinical and Translational Science Institute grant [UL1 RR-025780]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK082509, RC4DK090859, K01DK095930] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Colorado; U.S. National Institutes of Health (NIH)/National Center for Research Resources Colorado Clinical and Translational Science Institute grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants HL-68607 and RC4-DK090859-01 (to R.J.J.), grant 1K01-DK095930-01 (to M. A. L.), and grant RO1-DK082509 (to G. G.) from the U.S. National Institutes of Health, and startup funds from the University of Colorado. Imaging experiments were performed at the University of Colorado Anschutz Medical Campus Advance Light Microscopy Core, supported, in part, by U.S. National Institutes of Health (NIH)/National Center for Research Resources Colorado Clinical and Translational Science Institute grant UL1 RR-025780.	Brosius FC, 2009, J AM SOC NEPHROL, V20, P2503, DOI 10.1681/ASN.2009070721; CHANEY AL, 1962, CLIN CHEM, V8, P130; Cronstein BN, 2005, PHARMACOL REV, V57, P163, DOI 10.1124/pr.57.2.3; Dermaku-Sopjani M, 2013, KIDNEY BLOOD PRESS R, V37, P547, DOI 10.1159/000355735; DORMANDY TL, 1965, J PHYSIOL-LONDON, V180, P708, DOI 10.1113/jphysiol.1965.sp007725; Guinzberg R, 2006, AM J PHYSIOL-ENDOC M, V290, pE940, DOI 10.1152/ajpendo.00173.2005; Han BW, 2005, ACTA CRYSTALLOGR F, V61, P740, DOI 10.1107/S1744309105019792; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Jansson D, 2008, P NATL ACAD SCI USA, V105, P10161, DOI 10.1073/pnas.0800796105; JOHNSON AB, 1993, METABOLISM, V42, P1217, DOI 10.1016/0026-0495(93)90284-U; Johnson RJ, 2008, MED HYPOTHESES, V71, P22, DOI 10.1016/j.mehy.2008.01.017; Johnson RJ, 2011, SEMIN NEPHROL, V31, P394, DOI 10.1016/j.semnephrol.2011.08.002; Johnson RJ, 2010, EVOL ANTHROPOL, V19, P250, DOI 10.1002/evan.20266; Johnson Richard J, 2010, Trans Am Clin Climatol Assoc, V121, P295; Johnson RJ, 2009, ENDOCR REV, V30, P96, DOI 10.1210/er.2008-0033; Kratzer JT, 2014, P NATL ACAD SCI USA, V111, P3763, DOI 10.1073/pnas.1320393111; Lanaspa MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048801; Lanaspa MA, 2012, J BIOL CHEM, V287, P40732, DOI 10.1074/jbc.M112.399899; Lanaspa MA, 2009, J BIOL CHEM, V284, P19974, DOI 10.1074/jbc.M109.001792; Lv Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056864; NEEL JV, 1962, AM J HUM GENET, V14, P353; Ouyang J., J BIOL CHEM, V286, P1; Petersen KF, 2005, PLOS MED, V2, P879, DOI 10.1371/journal.pmed.0020233; Plaideau C, 2012, FASEB J, V26, P2685, DOI 10.1096/fj.11-198168; Rajas F, 2000, DIABETES, V49, P1165, DOI 10.2337/diabetes.49.7.1165; RILEY MS, 1979, METABOLISM, V28, P191, DOI 10.1016/0026-0495(79)90063-5; Schmid AI, 2011, DIABETES CARE, V34, P448, DOI 10.2337/dc10-1076; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Tanabe K, 2012, AM J PHYSIOL-RENAL, V302, pF1151, DOI 10.1152/ajprenal.00596.2011; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; VANDENBERGHE G, 1977, BIOCHEM J, V162, P601, DOI 10.1042/bj1620601; Viollet B, 2006, J PHYSIOL-LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506; Viollet B, 2009, FRONT BIOSCI-LANDMRK, V14, P3380, DOI 10.2741/3460; Wu Chaodong, 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P51, DOI 10.2174/1568008053174769; Yoshiuchi I, 1998, J CLIN ENDOCR METAB, V83, P1016, DOI 10.1210/jc.83.3.1016; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	36	107	112	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3339	3350		10.1096/fj.13-243634	http://dx.doi.org/10.1096/fj.13-243634			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24755741	Green Published			2022-12-28	WOS:000340265400006
J	Diekman, EF; van Weeghel, M; Wanders, RJA; Visser, G; Houten, SM				Diekman, Eugene F.; van Weeghel, Michel; Wanders, Ronald J. A.; Visser, Gepke; Houten, Sander M.			Food withdrawal lowers energy expenditure and induces inactivity in long-chain fatty acid oxidation-deficient mouse models	FASEB JOURNAL			English	Article						myopathy; rhabdomyolysis; creatine kinase; thermogenesis	ACYL-COA DEHYDROGENASE; TANDEM MASS-SPECTROMETRY; BETA-OXIDATION; AMINO-ACIDS; FOLLOW-UP; DISORDERS; BEZAFIBRATE; MICE; ACYLCARNITINE; METABOLISM	Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is an inherited disorder of mitochondrial long-chain fatty acid beta-oxidation (FAO). Patients with VLCAD deficiency may present with hypoglycemia, hepatomegaly, cardiomyopathy, and myopathy. Although several mouse models have been developed to aid in the study of the pathogenesis of long-chain FAO defects, the muscular phenotype is underexposed. To address the muscular phenotype, we used a newly developed mouse model on a mixed genetic background with a more severe defect in FAO (LCAD(-/-); VLCAD(-/-)) in addition to a validated mouse model (LCAD(-/-); VLCAD(-/-)) and compared them with wildtype (WT) mice. We found that both mouse models show a 20% reduction in energy expenditure (EE) and a 3-fold decrease in locomotor activity in the unfed state. In addition, we found a 1.7 degrees C drop in body temperature in unfed LCAD(-/-); VLCAD(-/-) mice compared with WT body temperature. We conclude that food withdrawal-induced inactivity, hypothermia, and reduction in EE are novel phenotypes associated with FAO deficiency in mice. Unexpectedly, inactivity was not explained by rhabdomyolysis, but rather reflected the overall reduced capacity of these mice to generate heat. We suggest that mice are partly protected against the negative consequence of an FAO defect.	[Diekman, Eugene F.; Visser, Gepke] UMC, Wilhelmina Childrens Hosp, Dept Metab Dis, Utrecht, Netherlands; [Diekman, Eugene F.; van Weeghel, Michel; Wanders, Ronald J. A.; Houten, Sander M.] Univ Amsterdam, Dept Clin Chem, Lab Genet Metab Dis, Amsterdam, Netherlands; [Wanders, Ronald J. A.; Houten, Sander M.] Univ Amsterdam, Acad Med Ctr, Dept Pediat, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands; [Houten, Sander M.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA	Wilhelmina Kinderziekenhuis; University of Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Icahn School of Medicine at Mount Sinai	Houten, SM (corresponding author), Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, Icahn Inst Genom & Multiscale Biol, 1425 Madison Ave,Box 1498, New York, NY 10029 USA.	sander.houten@mssm.edu	van Weeghel, Michel/A-2766-2010; Houten, Sander/Y-3599-2019	Houten, Sander/0000-0002-6167-9147; van Weeghel, Michel/0000-0002-4916-2866	Netherlands Organization for Scientific Research (Vidi) [016.086.336]; ZonMW [200320006]; Metakids	Netherlands Organization for Scientific Research (Vidi)(Netherlands Organization for Scientific Research (NWO)); ZonMW(Netherlands Organization for Health Research and Development); Metakids	The authors thank M. Boek, H. te Brinke, S. Denis, and the employees of the Animal Research Institute Amsterdam for technical assistance. This work was supported by the Netherlands Organization for Scientific Research (Vidi grant 016.086.336 to SMH), ZonMW (grant 200320006) and Metakids. The authors declare no conflicts of interest.	Bakermans AJ, 2013, CARDIOVASC RES, V100, P441, DOI 10.1093/cvr/cvt212; Bakermans AJ, 2011, CIRC-CARDIOVASC IMAG, V4, P558, DOI 10.1161/CIRCIMAGING.111.963751; Bergmeyer HU, 1986, METHODS ENZYMATIC AN; Bonnefont JP, 2010, CLIN PHARMACOL THER, V88, P101, DOI 10.1038/clpt.2010.55; Bonnefont JP, 2009, NEW ENGL J MED, V360, P838, DOI 10.1056/NEJMc0806334; Bonnet D, 1999, CIRCULATION, V100, P2248, DOI 10.1161/01.CIR.100.22.2248; Casetta B, 2000, CLIN CHEM LAB MED, V38, P391, DOI 10.1515/CCLM.2000.057; Chegary M, 2009, BBA-MOL CELL BIOL L, V1791, P806, DOI 10.1016/j.bbalip.2009.05.006; Cheng LH, 2004, NAT MED, V10, P1245, DOI 10.1038/nm1116; Chuang CK, 2009, J CHROMATOGR A, V1216, P8947, DOI 10.1016/j.chroma.2009.10.074; Cox KB, 2001, HUM MOL GENET, V10, P2069, DOI 10.1093/hmg/10.19.2069; Cox KB, 2009, LAB INVEST, V89, P1348, DOI 10.1038/labinvest.2009.86; Exil VJ, 2006, AM J PHYSIOL-HEART C, V290, pH1289, DOI 10.1152/ajpheart.00811.2005; Exil VJ, 2003, CIRC RES, V93, P448, DOI 10.1161/01.RES.0000088786.19197.E4; Houten SM, 2013, HUM MOL GENET, V22, P5249, DOI 10.1093/hmg/ddt382; Houten SM, 2010, J INHERIT METAB DIS, V33, P469, DOI 10.1007/s10545-010-9061-2; Kurtz DM, 1998, P NATL ACAD SCI USA, V95, P15592, DOI 10.1073/pnas.95.26.15592; Liu J, 2011, PPAR RES, V2011, DOI 10.1155/2011/372854; MANNING NJ, 1990, J INHERIT METAB DIS, V13, P58, DOI 10.1007/BF01799333; Nouws J, 2014, HUM MOL GENET, V23, P1311, DOI 10.1093/hmg/ddt521; Oey NA, 2006, J INHERIT METAB DIS, V29, P71, DOI 10.1007/s10545-006-0199-x; Orngreen MC, 2014, NEUROLOGY, V82, P607, DOI 10.1212/WNL.0000000000000118; Piraud M, 2003, RAPID COMMUN MASS SP, V17, P1297, DOI 10.1002/rcm.1054; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Rinaldo P, 2002, ANNU REV PHYSIOL, V64, P477, DOI 10.1146/annurev.physiol.64.082201.154705; Roe CR, 2002, J CLIN INVEST, V110, P259, DOI [10.1172/JCI200215311, 10.1172/JCI0215311]; Spiekerkoetter U, 2004, MUSCLE NERVE, V29, P66, DOI 10.1002/mus.10500; ter Veld F, 2009, J LIPID RES, V50, P1556, DOI 10.1194/jlr.M800221-JLR200; van Eunen K, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003186; Virtue S, 2012, CELL METAB, V16, P665, DOI 10.1016/j.cmet.2012.10.008; Vreken P, 1999, J INHERIT METAB DIS, V22, P302, DOI 10.1023/A:1005587617745; Wanders RJA, 1999, J INHERIT METAB DIS, V22, P442, DOI 10.1023/A:1005504223140; Wanders RJA, 2010, J INHERIT METAB DIS, V33, P479, DOI 10.1007/s10545-010-9104-8	33	6	7	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2891	2900		10.1096/fj.14-250241	http://dx.doi.org/10.1096/fj.14-250241			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24648546				2022-12-28	WOS:000337949400014
J	Wang, XQ; Frank, JW; Little, DR; Dunlap, KA; Satterfield, MC; Burghardt, RC; Hansen, TR; Wu, GY; Bazer, FW				Wang, Xiaoqiu; Frank, James W.; Little, Danielle R.; Dunlap, Kathrin A.; Satterfield, M. Carey; Burghardt, Robert C.; Hansen, Thomas R.; Wu, Guoyao; Bazer, Fuller W.			Functional role of arginine during the peri-implantation period of pregnancy. I. Consequences of loss of function of arginine transporter SLC7A1 mRNA in ovine conceptus trophectoderm	FASEB JOURNAL			English	Article						development; sheep; morpholino	NITRIC-OXIDE SYNTHASE; SELECT NUTRIENTS; EMBRYONIC-DEVELOPMENT; FETAL-DEVELOPMENT; PLACENTAL GROWTH; UTERINE GLANDS; POLYAMINES; PROLIFERATION; METABOLISM; SECRETIONS	Arginine, the common substrate for production of nitric oxide (NO) and polyamines in mammals, increases in the uterine lumen during the peri-implantation period of pregnancy. However, functional roles of arginine within the uterine lumen for conceptus (embryo and extraembryonic membranes) development have not been elucidated in vivo. To assess roles of arginine in reproductive tissue for survival and development of the conceptus, we conducted an in vivo morpholino antisense oligonucleotide (MAO)-mediated knockdown of SLC7A1 mRNA, the arginine transporter in ovine conceptus trophectoderm (Tr). Translational knockdown of SLC7A1 mRNA resulted in retarded conceptus development and abnormal function compared to MAO control. Use of MAO-SLC7A1 knockdown in conceptuses decreased arginine transport (73%, P<0.01), the abundance of ornithine decarboxylase, and nitric oxide synthase (NOS3) proteins, arginine-related amino acids [citrulline (76%, P<0.05) and ornithine (40%, P<0.05)], and polyamines, which likely accounts for their retarded development. Also, no alternative arginine precursors (glutamine and glutamate), isoforms of nitric oxide synthase (NOS1 and NOS2), or alternative pathways for polyamine biosynthesis via arginine decarboxylase and agmatinase were activated to rescue conceptus development. Collectively, SLC7A1 is the key transporter of arginine by conceptus Tr, and arginine is essential for conceptus survival and development.	[Wang, Xiaoqiu; Wu, Guoyao; Bazer, Fuller W.] Texas A&M Univ, Ctr Anim Biotechnol & Genom, College Stn, TX 77843 USA; [Wang, Xiaoqiu; Dunlap, Kathrin A.; Satterfield, M. Carey; Wu, Guoyao; Bazer, Fuller W.] Texas A&M Univ, Dept Anim Sci, College Stn, TX 77843 USA; [Frank, James W.] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA; [Little, Danielle R.; Burghardt, Robert C.] Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; [Hansen, Thomas R.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Colorado State University	Bazer, FW (corresponding author), Texas A&M Univ, TAMU 2471, College Stn, TX 77843 USA.	fbazer@cvm.tamu.edu	Bazer, Fuller/AAF-4317-2021; Hansen, Thomas/GWZ-2858-2022; Wang, Xiaoqiu/AAT-4148-2021; Burghardt, Robert C./AAF-4847-2021; Wang, Xiaoqiu/AAT-3368-2021	Bazer, Fuller/0000-0002-5823-5086; Burghardt, Robert C./0000-0003-1021-8444; Wang, Xiaoqiu/0000-0001-9660-528X; Little, Danielle/0000-0001-7262-1496	Agriculture and Food Research Initiative from the U.S. Department of Agriculture National Institute of Food and Agriculture [2011-6705-20028, 2011-67015-20067]	Agriculture and Food Research Initiative from the U.S. Department of Agriculture National Institute of Food and Agriculture	This research was supported by Agriculture and Food Research Initiative competitive grants 2011-6705-20028 and 2011-67015-20067 from the U.S. Department of Agriculture National Institute of Food and Agriculture. The contributions of graduate students and postdoctoral fellows from the Laboratory of Uterine Biology and Pregnancy (Texas A&M University) are gratefully acknowledged, as is the assistance of Kendrick Leblanc, Colt Sharpton, and Caleb Wendt for management of experimental animals.	Antoniazzi AQ, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.105684; Arques O., 2012, PROTOCOL EXCHANGE, DOI [10.1038/protex.2012.008, DOI 10.1038/PROTEX.2012.008]; Bazer FW, 2012, ANN NY ACAD SCI, V1271, P88, DOI 10.1111/j.1749-6632.2012.06741.x; Bazer FW, 2012, J REPROD DEVELOP, V58, P180, DOI 10.1262/jrd.2011-019; Bazer FW, 2008, REPROD BIOL, V8, P179, DOI 10.1016/S1642-431X(12)60012-6; Bazer FW, 2009, SEMIN REPROD MED, V27, P90, DOI 10.1055/s-0028-1108013; BAZER FW, 1975, J ANIM SCI, V41, P1376, DOI 10.2527/jas1975.4151376x; Bird IM, 2003, AM J PHYSIOL-REG I, V284, pR245, DOI 10.1152/ajpregu.00108.2002; Burton GJ, 2002, J CLIN ENDOCR METAB, V87, P2954, DOI 10.1210/jc.87.6.2954; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P2261, DOI 10.1073/pnas.2627990100; CONRAD KP, 1993, FASEB J, V7, P1269, DOI 10.1096/fasebj.7.13.7691671; Dorniak P, 2013, J ANIM SCI, V91, P1627, DOI 10.2527/jas.2012-5845; Dorniak P, 2013, ENDOCRINOLOGY, V154, P931, DOI 10.1210/en.2012-1909; Dorniak P, 2011, BIOL REPROD, V84, P1119, DOI 10.1095/biolreprod.110.089979; Dunlap KA, 2006, P NATL ACAD SCI USA, V103, P14390, DOI 10.1073/pnas.0603836103; Dye JF, 2004, FASEB J, V18, P125, DOI 10.1096/fj.02-0916fje; Gao HJ, 2009, BIOL REPROD, V81, P67, DOI 10.1095/biolreprod.108.075473; Gao HJ, 2009, BIOL REPROD, V80, P602, DOI 10.1095/biolreprod.108.073890; Gao HJ, 2009, BIOL REPROD, V80, P86, DOI 10.1095/biolreprod.108.071597; Gouge RC, 1998, BIOL REPROD, V58, P875, DOI 10.1095/biolreprod58.4.875; Gray C. A., 2001, ARBS Annual Review of Biomedical Sciences, V3, P85; Gray CA, 2002, REPRODUCTION, V124, P289, DOI 10.1530/rep.0.1240289; Gray CA, 2001, BIOL REPROD, V65, P1311, DOI 10.1095/biolreprod65.5.1311; GUILLOMOT M, 1995, J REPROD FERTIL, P39; Guillomot M, 1993, REPROD MAMMALS MAN, P387; Heby O, 1995, INT J DEV BIOL, V39, P737; Iarashi K, 2010, INT J BIOCHEM CELL B, V42, P39, DOI 10.1016/j.biocel.2009.07.009; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Kim JY, 2011, BIOL REPROD, V84, P70, DOI 10.1095/biolreprod.110.085753; Kim JY, 2011, BIOL REPROD, V84, P62, DOI 10.1095/biolreprod.110.085738; Kim J, 2011, BIOL REPROD, V84, P1139, DOI 10.1095/biolreprod.110.088153; Maeda T, 2006, BIOL PHARM BULL, V29, P234, DOI 10.1248/bpb.29.234; Nishimura K, 2005, BIOCHEM J, V385, P779, DOI 10.1042/BJ20041477; ROBERTS RM, 1988, J REPROD FERTIL, V82, P875, DOI 10.1530/jrf.0.0820875; Self JT, 2004, BIOL REPROD, V70, P1444, DOI 10.1095/biolreprod.103.025486; Sengoku K, 2001, MOL REPROD DEV, V58, P262, DOI 10.1002/1098-2795(200103)58:3&lt;262::AID-MRD3&gt;3.0.CO;2-8; Spencer T E, 2004, J Anim Sci, V82 E-Suppl, pE4; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Wen HY, 2005, PLACENTA, V26, pS63, DOI 10.1016/j.placenta.2005.02.004; Wu G, 2006, J ANIM SCI, V84, P2316, DOI 10.2527/jas.2006-156; Wu G, 2011, J ANIM SCI, V89, P2017, DOI 10.2527/jas.2010-3614; Wu GY, 2013, AMINO ACIDS, V45, P241, DOI 10.1007/s00726-013-1515-z; Wu GY, 2000, AM J PHYSIOL-ENDOC M, V279, pE395, DOI 10.1152/ajpendo.2000.279.2.E395; WU GY, 1995, AM J PHYSIOL-REG I, V268, pR334; Wu GY, 1997, J NUTR, V127, P2342, DOI 10.1093/jn/127.12.2342; Wu GY, 2005, BIOL REPROD, V72, P842, DOI 10.1095/biolreprod.104.036293; Wu GY, 2004, J NUTR, V134, P2169, DOI 10.1093/jn/134.9.2169; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Wu GY, 1998, J NUTR, V128, P2395, DOI 10.1093/jn/128.12.2395	49	50	54	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2852	2863		10.1096/fj.13-248757	http://dx.doi.org/10.1096/fj.13-248757			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24627544				2022-12-28	WOS:000337949400011
J	Yoon, DS; Kim, YH; Lee, S; Lee, KM; Park, KH; Jang, Y; Lee, JW				Yoon, Dong Suk; Kim, Yun Hee; Lee, Seulgi; Lee, Kyoung-Mi; Park, Kwang Hwan; Jang, Yeonsue; Lee, Jin Woo			Interleukin-6 induces the lineage commitment of bone marrow-derived mesenchymal multipotent cells through down-regulation of Sox2 by osteogenic transcription factors	FASEB JOURNAL			English	Article						stemness; Runx2; Dlx5; cell-cell interaction; heterogeneous population	IN-VITRO CHONDROGENESIS; STEM-CELLS; STROMAL CELLS; PROGENITOR CELLS; OSTEOBLAST DIFFERENTIATION; REPLICATIVE SENESCENCE; CYTOKINE FAMILY; SELF-RENEWAL; CULTURE; EXPRESSION	Bone marrow-derived mesenchymal stromal cells (BM-MSCs) are a heterogeneous population of cells that differ in size and morphology. BM-MSCs become committed to the osteogenic lineage as senescence approaches and lose multipotency. Nevertheless, little is known about the effects of cell-cell interaction between different populations on stemness loss and lineage commitment. The current study aimed to identify mechanisms by which cell-cell interactions between heterogeneous BM-MSCs affect stemness and lineage commitment of multipotent subpopulation. The lineage commitment of primitive multipotent cells was strongly induced in the presence of cytokines secreted by senescent-like cells in a cell culture insert system. Senescent-like cells secreted higher levels of interleukin-6 (IL-6) than primitive multipotent cells in a human cytokine array. IL-6 induced the lineage commitment and stemness loss in multipotent cells by decreasing Sox2 expression. Furthermore, we confirmed that IL-6 decreased the transcriptional activity of Sox2 through up-regulation of Runx2 and Dlx5. We suggest a mechanism by which IL-6 modulates the expression of Sox2, resulting in decreased multipotency and causing primitive multipotent cells to undergo osteogenic lineage commitment. This is the first study to identify mechanisms in which the cell-cell interactions between the different populations play important roles in the stemness loss and lineage commitment of multipotent populations.	[Yoon, Dong Suk; Kim, Yun Hee; Lee, Seulgi; Lee, Kyoung-Mi; Park, Kwang Hwan; Jang, Yeonsue; Lee, Jin Woo] Yonsei Univ, Coll Med, Dept Orthopaed Surg, Seoul 120752, South Korea; [Yoon, Dong Suk; Lee, Seulgi; Lee, Kyoung-Mi; Park, Kwang Hwan; Lee, Jin Woo] Yonsei Univ, Brain Korea PLUS Project Med Sci 21, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University	Lee, JW (corresponding author), Yonsei Univ, Coll Med, Dept Orthopaed Surg 29, Seoul 120752, South Korea.	ljwos@yuhs.ac	Yoon, Dong Suk/K-1077-2019	Yoon, Dong Suk/0000-0001-5945-5569; Jang, Yeonsue/0000-0001-5683-0001; Park, Kwang Hwan/0000-0002-2110-0559; Lee, Jin Woo/0000-0002-0293-9017	National Research Foundation (NRF) of Korea - Ministry of Education, Science, and Technology [NRF-2012R1A2A2A01012263]	National Research Foundation (NRF) of Korea - Ministry of Education, Science, and Technology	This work (NRF-2012R1A2A2A01012263) was supported by the Midcareer Researcher Program through a National Research Foundation (NRF) of Korea grant funded by the Ministry of Education, Science, and Technology.	Astle MV, 2012, ONCOGENE, V31, P1949, DOI 10.1038/onc.2011.394; Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301-472X(00)00160-0; Basu-Roy U, 2010, CELL DEATH DIFFER, V17, P1345, DOI 10.1038/cdd.2010.57; Baxter MA, 2004, STEM CELLS, V22, P675, DOI 10.1634/stemcells.22-5-675; Behbahaninia M, 2011, NEUROSURGERY, V69, pN19, DOI 10.1227/01.neu.0000405596.78460.20; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F; Cheleuitte D, 1998, J CLIN ENDOCR METAB, V83, P2043, DOI 10.1210/jc.83.6.2043; Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698; Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097-4652(199910)181:1<67::AID-JCP7>3.0.CO;2-C; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365-2141.1999.01715.x; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Erices A, 2002, EXP CELL RES, V280, P24, DOI 10.1006/excr.2002.5627; Galderisi U, 2009, STEM CELLS DEV, V18, P1033, DOI 10.1089/scd.2008.0324; Go MJ, 2008, EXP CELL RES, V314, P1147, DOI 10.1016/j.yexcr.2007.11.021; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756-3282(92)90364-3; Heymann D, 2000, CYTOKINE, V12, P1455, DOI 10.1006/cyto.2000.0747; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Ho JH, 2011, CELL TRANSPLANT, V20, P1209, DOI 10.3727/096368910X546562; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Iwasaki K, 2008, J DENT RES, V87, P937, DOI 10.1177/154405910808701002; Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200; Kojima H, 2012, CELL CYCLE, V11, P730, DOI 10.4161/cc.11.4.19172; Kozhevnikova M N, 2008, Izv Akad Nauk Ser Biol, P156; Krtolica A, 2003, Adv Gerontol, V11, P109; Krtolica A, 2002, INT J BIOCHEM CELL B, V34, P1401, DOI 10.1016/S1357-2725(02)00053-5; Ksiazek K, 2009, REJUV RES, V12, P105, DOI 10.1089/rej.2009.0830; Kurz DJ, 2000, J CELL SCI, V113, P3613; Kuznetsov SA, 1997, J BONE MINER RES, V12, P1335, DOI 10.1359/jbmr.1997.12.9.1335; LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Li ZL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020526; METS T, 1981, MECH AGEING DEV, V16, P81, DOI 10.1016/0047-6374(81)90035-X; Mihara M, 2005, INT IMMUNOPHARMACOL, V5, P1731, DOI 10.1016/j.intimp.2005.05.010; Minguell JJ, 2001, EXP BIOL MED, V226, P507, DOI 10.1177/153537020122600603; Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770; Muraglia A, 2008, EUR J CELL BIOL, V87, P751, DOI 10.1016/j.ejcb.2008.04.004; Nelson Peter J, 2002, Kidney Int, V61, pS99; Neubauer M, 2005, TISSUE ENG, V11, P1840, DOI 10.1089/ten.2005.11.1840; Nicolaidou V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039871; Nishida S, 1999, J BONE MINER METAB, V17, P171, DOI 10.1007/s007740050081; Park SB, 2012, CELL DEATH DIFFER, V19, P534, DOI 10.1038/cdd.2011.137; Parrinello S, 2005, J CELL SCI, V118, P485, DOI 10.1242/jcs.01635; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rombouts WJC, 2003, LEUKEMIA, V17, P160, DOI 10.1038/sj.leu.2402763; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001; Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005; Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002; Takai Y, 2008, NAT REV MOL CELL BIO, V9, P603, DOI 10.1038/nrm2457; Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wakahara R, 2012, GENES CELLS, V17, P132, DOI 10.1111/j.1365-2443.2011.01575.x; Wang WG, 2003, TISSUE CELL, V35, P69, DOI 10.1016/S0040-8166(02)00106-4; Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623-199812000-00004; Yoon DS, 2011, CELL PROLIFERAT, V44, P428, DOI 10.1111/j.1365-2184.2011.00770.x; Yu KR, 2012, STEM CELLS, V30, P876, DOI 10.1002/stem.1052; Zaidi SK, 2007, P NATL ACAD SCI USA, V104, P19861, DOI 10.1073/pnas.0709650104	67	33	33	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3273	3286		10.1096/fj.13-248567	http://dx.doi.org/10.1096/fj.13-248567			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24719354				2022-12-28	WOS:000337949400046
J	Ni, DC; Wang, Y; Yang, X; Zhou, HZ; Hou, XM; Cao, BH; Lu, ZX; Zhao, XS; Yang, K; Huang, YH				Ni, Dongchun; Wang, Yan; Yang, Xu; Zhou, Haizhen; Hou, Xiaomin; Cao, Baohua; Lu, Zhixin; Zhao, Xinsheng; Yang, Kun; Huang, Yihua			Structural and functional analysis of the beta-barrel domain of BamA from Escherichia coli	FASEB JOURNAL			English	Article						outer membrane protein; Omp85 protein family; outer membrane protein biogenesis	OUTER-MEMBRANE PROTEINS; CRYSTAL-STRUCTURE; ESSENTIAL COMPONENT; ASSEMBLY MACHINERY; OMP85 FAMILY; BIOGENESIS; FHAC; TRANSLOCATION; CONFORMATION; FLEXIBILITY	In gram-negative bacteria, the assembly of outer membrane proteins (OMPs) requires a beta-barrel assembly machinery (BAM) complex, of which BamA is an essential and evolutionarily conserved component. To elucidate the mechanism of BamA-mediated OMP biogenesis, we determined the crystal structure of the C-terminal transmembrane domain of BamA from Escherichia coli (EcBamA) at 2.6 angstrom resolution. The structure reveals 2 distinct features. First, a portion of the extracellular side of the beta barrel is composed of 5 markedly short beta strands, and the loops stemming from these beta strands form a potential surface cavity, filled by a portion of the L6 loop that includes the conserved VRGF/Y motif found in the Omp85 family. Second, the 4 extracellular loops L3, L4, L6, and L7 of EcBamA form a dome over the barrel, stabilized by a salt-bridge interaction network. Functional data show that hydrophilic-to-hydrophobic mutations of the potential hydrophilic surface cavity and a single Arg547Ala point mutation that may destabilize the dome severely affect the function of EcBamA. Our structure of the EcBamA beta barrel and structure-based mutagenesis studies suggest that the transmembrane beta strands of OMP substrates may integrate into the outer membrane at the interface of the first and last beta strands of the EcBamA barrel, whereas the soluble loops or domains may be transported out of the cell via the hydrophilic surface cavity on dislocation of the VRGF/Y motif of L6. In addition, the dome over the barrel may play an important role in maintaining the efficiency of OMP biogenesis.	[Ni, Dongchun; Wang, Yan; Yang, Xu; Zhou, Haizhen; Hou, Xiaomin; Cao, Baohua; Huang, Yihua] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; [Ni, Dongchun; Yang, Kun] Tianjin Med Univ, Sch Publ Hlth, Tianjin, Peoples R China; [Wang, Yan] Univ Chinese Acad Sci, Beijing, Peoples R China; [Lu, Zhixin; Zhao, Xinsheng] Peking Univ, Beijing Natl Lab Mol Sci, Beijing 100871, Peoples R China; [Lu, Zhixin; Zhao, Xinsheng] Peking Univ, State Key Lab Struct Chem Unstable & Stable Speci, Beijing 100871, Peoples R China; [Lu, Zhixin; Zhao, Xinsheng] Peking Univ, Coll Chem & Mol Engn, Dept Biol Chem, Beijing 100871, Peoples R China; [Lu, Zhixin; Zhao, Xinsheng] Peking Univ, Biodynam Optic Imaging Ctr, Beijing 100871, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Tianjin Medical University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Peking University; Chinese Academy of Sciences; Peking University; Peking University; Peking University	Huang, YH (corresponding author), Chinese Acad Sci, Inst Biophys, 15 Datun Rd, Beijing 100101, Peoples R China.	yihuahuang@sun5.ibp.ac.cn			Ministry of Science and Technology [2012CB917302, 2013CB910603]; National Natural Science Foundation of China [31170698]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The authors are grateful to Dr. Thomas Silhavy (Princeton University, Princeton, NJ, USA) for generously providing E. coli strain JCM320 for functional analysis and Dr. Susan Buchanan (National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA) for providing the PDB coordinates of HdBamA and NgBamA. The authors also thank Nian Huang, Kai Zhang, Yan Zhao, Shuai Zhang, Changlin Tian, Peng Chen, Xiou Cao, Li Deng, Chuanqi Sun, and Maoshui Wang for technical assistance and the Shanghai Synchrotron Radiation Facility (Shanghai, China) beamline scientists for technical support during data collection. The coordinates and diffraction data have been deposited into PDB (http://www.rscb.org/pdb/) with accession code 4N75 for EcBamA(426-810). This work was supported by grants from the Ministry of Science and Technology (2012CB917302 and 2013CB910603 to Y.H.) and the National Natural Science Foundation of China (31170698 to Y.H.).	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Albrecht R, 2011, J BIOL CHEM, V286, P27792, DOI 10.1074/jbc.M111.238931; Chacinska A, 2009, CELL, V138, P628, DOI 10.1016/j.cell.2009.08.005; Clantin B, 2007, SCIENCE, V317, P957, DOI 10.1126/science.1143860; Dalbey RE, 2011, ANNU REV BIOCHEM, V80, P161, DOI 10.1146/annurev-biochem-060409-092524; DeLano WL, 2009, ABSTR PAP AM CHEM S, V238; Dong C, 2012, ACTA CRYSTALLOGR D, V68, P95, DOI 10.1107/S0907444911051031; Du Plessis DJF, 2011, BBA-BIOMEMBRANES, V1808, P851, DOI 10.1016/j.bbamem.2010.08.016; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gatzeva-Topalova PZ, 2008, STRUCTURE, V16, P1873, DOI 10.1016/j.str.2008.09.014; Gatzeva-Topalova PZ, 2010, STRUCTURE, V18, P1492, DOI 10.1016/j.str.2010.08.012; Gentle IE, 2005, MOL MICROBIOL, V58, P1216, DOI 10.1111/j.1365-2958.2005.04906.x; Gruss F, 2013, NAT STRUCT MOL BIOL, V20, P1318, DOI 10.1038/nsmb.2689; Guedin S, 1998, MOL MICROBIOL, V29, P763, DOI 10.1046/j.1365-2958.1998.00970.x; Hagan CL, 2011, ANNU REV BIOCHEM, V80, P189, DOI 10.1146/annurev-biochem-061408-144611; Hagan CL, 2010, SCIENCE, V328, P890, DOI 10.1126/science.1188919; Heuck A, 2011, J MOL BIOL, V406, P659, DOI 10.1016/j.jmb.2011.01.002; Jacob-Dubuisson F, 1999, J BIOL CHEM, V274, P37731, DOI 10.1074/jbc.274.53.37731; Jiang JH, 2012, INT J MOL SCI, V13, P8038, DOI 10.3390/ijms13078038; Kim KH, 2011, J BIOL CHEM, V286, P39116, DOI 10.1074/jbc.M111.298166; Kim S, 2007, SCIENCE, V317, P961, DOI 10.1126/science.1143993; Knowles TJ, 2008, MOL MICROBIOL, V68, P1216, DOI 10.1111/j.1365-2958.2008.06225.x; Knowles TJ, 2011, EMBO REP, V12, P123, DOI 10.1038/embor.2010.202; Knowles TJ, 2009, NAT REV MICROBIOL, V7, P206, DOI 10.1038/nrmicro2069; Leonard-Rivera M, 2012, J BACTERIOL, V194, P4662, DOI 10.1128/JB.00825-12; Leyton DL, 2012, NAT REV MICROBIOL, V10, P213, DOI 10.1038/nrmicro2733; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Noinaj N, 2013, NATURE, V501, P385, DOI 10.1038/nature12521; Noinaj N, 2011, J MOL BIOL, V407, P248, DOI 10.1016/j.jmb.2011.01.042; Osborne AR, 2005, ANNU REV CELL DEV BI, V21, P529, DOI 10.1146/annurev.cellbio.21.012704.133214; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paschen SA, 2005, TRENDS BIOCHEM SCI, V30, P575, DOI 10.1016/j.tibs.2005.08.009; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Ricci DP, 2012, BBA-BIOMEMBRANES, V1818, P1067, DOI 10.1016/j.bbamem.2011.08.020; Rigel NW, 2013, P NATL ACAD SCI USA, V110, P5151, DOI 10.1073/pnas.1302662110; Rigel NW, 2012, CURR OPIN MICROBIOL, V15, P189, DOI 10.1016/j.mib.2011.12.007; Robert V, 2006, PLOS BIOL, V4, P1984, DOI 10.1371/journal.pbio.0040377; Sandoval CM, 2011, J MOL BIOL, V409, P348, DOI 10.1016/j.jmb.2011.03.035; Selkrig J, 2012, NAT STRUCT MOL BIOL, V19, P506, DOI 10.1038/nsmb.2261; Stegmeier JF, 2007, BIOL CHEM, V388, P37, DOI 10.1515/BC.2007.004; Tellez R, 2012, J BACTERIOL, V194, P317, DOI 10.1128/JB.06192-11; Tommassen J, 2010, MICROBIOL-SGM, V156, P2587, DOI 10.1099/mic.0.042689-0; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Walther DM, 2009, CELL MOL LIFE SCI, V66, P2789, DOI 10.1007/s00018-009-0029-z; Webb CT, 2012, TRENDS MICROBIOL, V20, P612, DOI 10.1016/j.tim.2012.08.006; White SH, 2008, ANNU REV BIOPHYS, V37, P23, DOI 10.1146/annurev.biophys.37.032807.125904; Wu T, 2005, CELL, V121, P235, DOI 10.1016/j.cell.2005.02.015; Zhang H, 2011, ACTA CRYSTALLOGR F, V67, P734, DOI 10.1107/S1744309111014254	48	73	74	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2677	2685		10.1096/fj.13-248450	http://dx.doi.org/10.1096/fj.13-248450			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24619089				2022-12-28	WOS:000339883600025
J	Dang, XT; Eliceiri, BP; Baird, A; Costantini, TW				Dang, Xitong; Eliceiri, Brian P.; Baird, Andrew; Costantini, Todd W.			CHRFAM7A: a human-specific alpha 7-nicotinic acetylcholine receptor gene shows differential responsiveness of human intestinal epithelial cells to LPS	FASEB JOURNAL			English	Article						CHRNA7; alpha 7nAChR; dup-alpha 7nAChR; human-specific genes	PERIPHERAL-BLOOD LYMPHOCYTES; NEURONAL NICOTINIC RECEPTORS; ENTERIC GLIA CELLS; KAPPA-B EXPRESSION; BIPOLAR DISORDER; PARTIAL DUPLICATION; LINKAGE DISEQUILIBRIUM; IMMUNE HOMEOSTASIS; CHROMOSOME 15Q14; TOBACCO TOXICITY	The human genome contains a unique, distinct, and human-specific alpha 7-nicotinic acetylcholine receptor (alpha 7nAChR) gene [CHRNA7 (gene-encoding alpha 7-nicotinic acetylcholine receptor)] called CHRFAM7A (gene-encoding dup-alpha 7-nicotinic acetylcholine receptor) on a locus of chromosome 15 associated with mental illness, including schizophrenia. Located 59 upstream from the "wild-type" CHRNA7 gene that is found in other vertebrates, we demonstrate CHRFAM7A expression in a broad range of epithelial cells and sequenced the CHRFAM7A transcript found in normal human fetal small intestine epithelial (FHs) cells to prove its identity. We then compared its expression to CHRNA7 in 11 gut epithelial cell lines, showed that there is a differential response to LPS when compared to CHRNA7, and characterized the CHRFAM7A promoter. We report that both CHRFAM7A and CHRNA7 gene expression are widely distributed in human epithelial cell lines but that the levels of CHRFAM7A gene expression vary up to 5000-fold between different gut epithelial cells. A 3-hour treatment of epithelial cells with 100 ng/ml LPS increased CHRFAM7A gene expression by almost 1000-fold but had little effect on CHRNA7 gene expression. Mapping the regulatory elements responsible for CHRFAM7A gene expression identifies a 1 kb sequence in the UTR of the CHRFAM7A gene that ismodulated by LPS. Taken together, these data establish the presence, identity, and differential regulation of the human-specific CHRFAM7A gene in human gut epithelial cells. In light of the fact that CHRFAM7A expression is reported to modulate ligand binding to, and alter the activity of, the wild-type alpha 7nAChR ligand-gated pentameric ion channel, the findings point to the existence of a species-specific alpha 7nAChR response that might regulate gut epithelial function in a human-specific fashion.	[Dang, Xitong; Eliceiri, Brian P.; Baird, Andrew; Costantini, Todd W.] Univ Calif San Diego, San Diego Hlth Sci, Dept Surg, Div Trauma Surg Crit Care Burns & Acute Care Surg, San Diego, CA 92103 USA; [Dang, Xitong] Luzhou Med Coll, Cardiovasc Res Ctr, Luzhou, Sichuan, Peoples R China	University of California System; University of California San Diego; Southwest Medical University	Baird, A (corresponding author), Univ Calif San Diego, San Diego Hlth Sci, Dept Surg, Div Trauma Surg Crit Care Burns & Acute Care Surg, 212 Dickinson St,MC 8236, San Diego, CA 92103 USA.	anbaird@ucsd.edu		Baird, Andrew/0000-0003-0027-9905; Costantini, Todd/0000-0002-0215-5327; Eliceiri, Brian/0000-0003-1811-1916	NATIONAL CANCER INSTITUTE [R01CA170140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM078421] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA170140] Funding Source: Medline; NIGMS NIH HHS [P20 GM078421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbruscato TJ, 2004, J PHARMACOL EXP THER, V310, P459, DOI 10.1124/jpet.104.066274; Araud T, 2011, BIOCHEM PHARMACOL, V82, P904, DOI 10.1016/j.bcp.2011.06.018; Arredondo J, 2005, AM J PATHOL, V166, P597, DOI 10.1016/S0002-9440(10)62281-X; Arredondo J, 2007, BIOCHEM PHARMACOL, V74, P1315, DOI 10.1016/j.bcp.2007.06.026; Bakanidze George, 2013, Front Psychiatry, V4, P133, DOI 10.3389/fpsyt.2013.00133; Benfante R, 2011, J NEUROIMMUNOL, V230, P74, DOI 10.1016/j.jneuroim.2010.09.008; Canastar A, 2012, J MOL NEUROSCI, V47, P389, DOI 10.1007/s12031-011-9663-7; Carlisle DL, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-27; Casey JP, 2012, HUM GENET, V131, P565, DOI 10.1007/s00439-011-1094-6; Catassi A, 2008, MUTAT RES-REV MUTAT, V659, P221, DOI 10.1016/j.mrrev.2008.04.002; Chan KYY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036977; CHAN KY, 2012, PLOS ONE, P7; Cheadle GA, 2014, SURG INFECT, V15, P387, DOI 10.1089/sur.2013.103; Cheadle GA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069042; Chen RJ, 2008, TOXICOL SCI, V104, P283, DOI 10.1093/toxsci/kfn086; Chernyavsky AI, 2010, AM J PHYSIOL-CELL PH, V299, pC903, DOI 10.1152/ajpcell.00216.2010; Conrad B, 2007, ANNU REV GENOM HUM G, V8, P17, DOI 10.1146/annurev.genom.8.021307.110233; Conti-Fine BM, 2000, EUR J PHARMACOL, V393, P279, DOI 10.1016/S0014-2999(00)00036-4; Cooper David N., 2011, Human Genomics, V5, P99; Costantini TW, 2015, J LEUKOCYTE BIOL, V97, P247, DOI 10.1189/jlb.4RU0814-381R; Costantini TW, 2012, AM J PATHOL, V181, P478, DOI 10.1016/j.ajpath.2012.04.005; Costantini TW, 2010, AM J PHYSIOL-GASTR L, V299, pG1308, DOI 10.1152/ajpgi.00156.2010; Costantini TW, 2010, J TRAUMA, V68, P1349, DOI 10.1097/TA.0b013e3181dccea0; Costantini TW, 2009, LIFE SCI, V84, P18, DOI 10.1016/j.lfs.2008.10.007; Dalton SO, 2006, BRIT J CANCER, V95, P934, DOI 10.1038/sj.bjc.6603259; Dasgupta P, 2006, P NATL ACAD SCI USA, V103, P6332, DOI 10.1073/pnas.0509313103; Dasgupta P, 2006, CELL CYCLE, V5, P2324, DOI 10.4161/cc.5.20.3366; De Luca V, 2006, ACTA PSYCHIAT SCAND, V114, P211, DOI 10.1111/j.1600-0447.2006.00785.x; de Lucas-Cerrillo AM, 2011, J BIOL CHEM, V286, P594, DOI 10.1074/jbc.M110.180067; Egleton RD, 2008, TRENDS PHARMACOL SCI, V29, P151, DOI 10.1016/j.tips.2007.12.006; Egleton RD, 2009, PHARMACOL THERAPEUT, V121, P205, DOI 10.1016/j.pharmthera.2008.10.007; Fadgyas-Stanculete Mihaela, 2014, J Mol Psychiatry, V2, P4, DOI 10.1186/2049-9256-2-4; Flomen RH, 2006, AM J MED GENET B, V141B, P571, DOI 10.1002/ajmg.b.30306; Freedman R, 2006, GENES BRAIN BEHAV, V5, P14, DOI 10.1111/j.1601-183X.2006.00190.x; Freedman R, 2001, AM J MED GENET, V105, P20, DOI 10.1002/1096-8628(20010108)105:1<20::AID-AJMG1047>3.3.CO;2-3; Gal G, 2012, SCHIZOPHR RES, V139, P189, DOI 10.1016/j.schres.2012.04.018; Garakani Amir, 2003, Am J Ther, V10, P61, DOI 10.1097/00045391-200301000-00014; Gault J, 1998, GENOMICS, V52, P173, DOI 10.1006/geno.1998.5363; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; Guo JJ, 2008, EVID-BASED MENT HEAL, V11, P93, DOI 10.1136/ebmh.11.3.93; Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099; Hawkins BT, 2005, AM J PHYSIOL-HEART C, V289, pH212, DOI 10.1152/ajpheart.01210.2004; Hawkins BT, 2004, BRAIN RES, V1027, P48, DOI 10.1016/j.brainres.2004.08.043; Heeschen C, 2002, J CLIN INVEST, V110, P527, DOI 10.1172/JCI200214676; Hippisley-Cox J, 2007, ARCH GEN PSYCHIAT, V64, P1368, DOI 10.1001/archpsyc.64.12.1368; Hong CJ, 2004, NEUROSCI LETT, V355, P69, DOI 10.1016/j.neulet.2003.10.043; Horie M, 2010, NATURE, V463, P84, DOI 10.1038/nature08695; Iwata Y, 2007, NEUROSCI RES, V57, P194, DOI 10.1016/j.neures.2006.10.002; Khalturin K, 2009, TRENDS GENET, V25, P404, DOI 10.1016/j.tig.2009.07.006; Kim HL, 2010, PHILOS T R SOC B, V365, P2451, DOI 10.1098/rstb.2010.0004; Lam DCL, 2007, CANCER RES, V67, P4638, DOI 10.1158/0008-5472.CAN-06-4628; Long M, 2003, NAT REV GENET, V4, P865, DOI 10.1038/nrg1204; Long MY, 2013, ANNU REV GENET, V47, P307, DOI 10.1146/annurev-genet-111212-133301; Lopez-Diez R, 2013, GENOME BIOL EVOL, V5, P2420, DOI 10.1093/gbe/evt188; Maouche K, 2013, P NATL ACAD SCI USA, V110, P4099, DOI 10.1073/pnas.1216939110; Maouche K, 2009, AM J PATHOL, V175, P1868, DOI 10.2353/ajpath.2009.090212; Morishita K, 2014, J TRAUMA ACUTE CARE, V76, P610, DOI 10.1097/TA.0000000000000137; Papke RL, 1996, NEUROSCI LETT, V213, P201; Pasparakis M, 2008, MUCOSAL IMMUNOL, V1, pS54, DOI 10.1038/mi.2008.53; Perl O, 2006, NEUROPSYCHOBIOLOGY, V53, P88, DOI 10.1159/000091725; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Pillai S, 2012, CURR DRUG TARGETS, V13, P671, DOI 10.2174/138945012800398847; Riley B, 2002, GENOMICS, V79, P197, DOI 10.1006/geno.2002.6694; Savidge TC, 2006, PEDIATR RES, V59, P89, DOI 10.1203/01.pdr.0000195101.74184.e3; SCHULLER HM, 1989, BIOCHEM PHARMACOL, V38, P3439, DOI 10.1016/0006-2952(89)90112-3; Severance EG, 2009, J NEURAL TRANSM, V116, P213, DOI 10.1007/s00702-008-0164-y; Sharma G, 2002, J NEUROBIOL, V53, P524, DOI 10.1002/neu.10114; Sinkus ML, 2009, BRAIN RES, V1291, P1, DOI 10.1016/j.brainres.2009.07.041; Slominski A, 2010, AM J PHYSIOL-CELL PH, V299, pC885, DOI 10.1152/ajpcell.00324.2010; Smith NGC, 2003, GENE, V318, P169, DOI 10.1016/S0378-1119(03)00772-8; Stahl PD, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.289pe59; Tautz D, 2011, NAT REV GENET, V12, P692, DOI 10.1038/nrg3053; Thierry-Mieg D, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-s1-s12; Thomsen MS, 2011, BIPOLAR DISORD, V13, P701, DOI 10.1111/j.1399-5618.2011.00961.x; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Truyers C, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-132; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; van der Zanden EP, 2012, NEUROIMMUNOMODULAT, V19, P255, DOI 10.1159/000335185; Villiger Y, 2002, J NEUROIMMUNOL, V126, P86, DOI 10.1016/S0165-5728(02)00057-7; Wang Y, 2014, J BIOL CHEM, V289, P26451, DOI 10.1074/jbc.M114.582858; Wessler I, 2008, BRIT J PHARMACOL, V154, P1558, DOI 10.1038/bjp.2008.185; Wolf SE, 2010, J TRAUMA, V68, P1354; Zhu BQ, 2003, CANCER CELL, V4, P191, DOI 10.1016/S1535-6108(03)00219-8	83	22	23	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2292	2302		10.1096/fj.14-268037	http://dx.doi.org/10.1096/fj.14-268037			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25681457	Green Published			2022-12-28	WOS:000355209500008
J	Catoire, M; Kersten, S				Catoire, Milene; Kersten, Sander			The search for exercise factors in humans	FASEB JOURNAL			English	Review						myokines; IL-6; ANGPTL4; CCL2	HUMAN SKELETAL-MUSCLE; INTERLEUKIN-6 MESSENGER-RNA; NF-KAPPA-B; IMPROVES INSULIN SENSITIVITY; FIBROBLAST GROWTH FACTOR-21; ACUTE RESISTANCE EXERCISE; FNDC5 GENE-EXPRESSION; ADIPOSE-TISSUE; NEUROTROPHIC FACTOR; GLUCOSE-UPTAKE	Regular exercise reduces the risk for numerous chronic diseases. Exercise not only impacts the contracting skeletal muscle but also elicits systemic changes. The exact mechanisms driving the more systemic changes have yet to be resolved, but exercise factors are thought to be an important missing link. Exercise factors are proteins that are released from skeletal muscle into the circulation during exercise. They represent a subclass of myokines, which are classified as proteins secreted from skeletal muscle serving a signaling role. Here, we provide an overview of the current literature on myokines. Many studies have focused on the identification of new myokines using a variety of approaches. These studies have generated an extensive list of myokines, but so far, the functional relevance of many of these novel myokines remains unclear. Few of these myokines represent putative exercise factors. Currently, IL-6, secreted protein acidic and rich in cysteine, angiopoietin-like 4, chemokine (C-X3-C motif) ligand 1, and chemokine (C-C motif) ligand 2 have the highest potential to serve as exercise factors because for all these factors, there is clear evidence that plasma levels increase during exercise. In our view, the future focus should be on characterizing the functional role of myokines in the acute and chronic response to exercise and explore their potential as a target for metabolic diseases.	[Catoire, Milene; Kersten, Sander] Wageningen Univ, Div Human Nutr, Nutr Metab & Genom Grp, NL-6700 AP Wageningen, Netherlands	Wageningen University & Research	Kersten, S (corresponding author), POB 8129, NL-6700 EV Wageningen, Netherlands.	sander.kersten@wur.nl	Catoire, MIlène/D-9612-2016; Kersten, Sander/A-1116-2011	Kersten, Sander/0000-0003-4488-7734	Dutch Diabetes Foundation [2009.60.003]	Dutch Diabetes Foundation	This work was supported by the Dutch Diabetes Foundation (2009.60.003).	Agergaard J, 2013, MUSCLE NERVE, V47, P748, DOI 10.1002/mus.23667; Akerstrom T, 2005, J PHYSIOL-LONDON, V563, P507, DOI 10.1113/jphysiol.2004.077610; Akerstrom TCA, 2009, EXP PHYSIOL, V94, P1124, DOI 10.1113/expphysiol.2009.048983; Almada C, 2013, J PHYSIOL BIOCHEM, V69, P85, DOI 10.1007/s13105-012-0191-x; Aoi W, 2013, GUT, V62, P882, DOI 10.1136/gutjnl-2011-300776; Balducci S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049297; Bastard JP, 2002, J CLIN ENDOCR METAB, V87, P2084, DOI 10.1210/jc.87.5.2084; Besse-Patin A, 2014, INT J OBESITY, V38, P707, DOI 10.1038/ijo.2013.158; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Brahma MK, 2014, J LIPID RES, V55, P2229, DOI 10.1194/jlr.M044784; Brenmoehl J, 2014, INT J BIOL SCI, V10, P338, DOI 10.7150/ijbs.7972; Broholm C, 2008, J PHYSIOL-LONDON, V586, P2195, DOI 10.1113/jphysiol.2007.149781; Broholm C, 2011, J APPL PHYSIOL, V111, P251, DOI 10.1152/japplphysiol.01399.2010; Bruunsgaard H, 1997, J PHYSIOL-LONDON, V499, P833, DOI 10.1113/jphysiol.1997.sp021972; Busquets S, 2006, BBA-GEN SUBJECTS, V1760, P1613, DOI 10.1016/j.bbagen.2006.09.001; Carol A, 2011, INT J SPORT NUTR EXE, V21, P135, DOI 10.1123/ijsnem.21.2.135; Catoire M, 2014, PHYSIOL GENOMICS, V46, P256, DOI 10.1152/physiolgenomics.00174.2013; Catoire M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051066; Catoire M, 2014, P NATL ACAD SCI USA, V111, pE1043, DOI 10.1073/pnas.1400889111; Chan MHS, 2004, AM J PHYSIOL-REG I, V287, pR322, DOI 10.1152/ajpregu.00030.2004; Christiansen T, 2013, EUR J APPL PHYSIOL, V113, P1635, DOI 10.1007/s00421-013-2592-0; Clow C, 2010, MOL BIOL CELL, V21, P2182, DOI 10.1091/mbc.E10-02-0154; Coffey VG, 2006, AM J PHYSIOL-ENDOC M, V290, pE849, DOI 10.1152/ajpendo.00299.2005; Croft L, 2009, APPL PHYSIOL NUTR ME, V34, P1098, DOI 10.1139/H09-117; Cuppini R, 2007, ARCH ITAL BIOL, V145, P99; Dalbo VJ, 2013, EUR J NUTR, V52, P477, DOI 10.1007/s00394-012-0349-x; Della Gatta PA, 2014, BRAIN BEHAV IMMUN, V39, P80, DOI 10.1016/j.bbi.2014.01.006; Dennis RA, 2008, PHYSIOL GENOMICS, V32, P393, DOI 10.1152/physiolgenomics.00191.2007; El-Kadre LJ, 2013, CURR OPIN CLIN NUTR, V16, P564, DOI 10.1097/MCO.0b013e32836410e6; Febbraio MA, 2005, EXERC SPORT SCI REV, V33, P114, DOI 10.1097/00003677-200507000-00003; Febbraio MA, 2003, METABOLISM, V52, P939, DOI 10.1016/S0026-0495(03)00105-7; Febbraio MA, 2003, J PHYSIOL-LONDON, V549, P607, DOI 10.1113/jphysiol.2003.042374; Febbraio MA, 2004, DIABETES, V53, P1643, DOI 10.2337/diabetes.53.7.1643; Fernandez-Gonzalo R, 2013, ACTA PHYSIOL, V209, P283, DOI 10.1111/apha.12174; Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7; Fischer CP, 2004, AM J PHYSIOL-ENDOC M, V287, pE1189, DOI 10.1152/ajpendo.00206.2004; Friedmann-Bette B, 2012, J APPL PHYSIOL, V112, P289, DOI 10.1152/japplphysiol.00959.2011; Friedrichsen M, 2013, MOL CELL ENDOCRINOL, V366, P204, DOI 10.1016/j.mce.2012.06.013; Gaich G, 2013, CELL METAB, V18, P333, DOI 10.1016/j.cmet.2013.08.005; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Gray SR, 2008, CELL STRESS CHAPERON, V13, P247, DOI 10.1007/s12192-008-0019-3; Gray SR, 2009, CYTOKINE, V47, P98, DOI 10.1016/j.cyto.2009.05.011; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; Haugen F, 2010, AM J PHYSIOL-CELL PH, V298, pC807, DOI 10.1152/ajpcell.00094.2009; Hecksteden A, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-235; Helge JW, 2003, J PHYSIOL-LONDON, V546, P299, DOI 10.1113/jphysiol.2002.030437; Henningsen J, 2010, MOL CELL PROTEOMICS, V9, P2482, DOI 10.1074/mcp.M110.002113; Hiscock N, 2004, FASEB J, V18, P992, DOI 10.1096/fj.03-1259fje; Hittel DS, 2010, MED SCI SPORT EXER, V42, P2023, DOI 10.1249/MSS.0b013e3181e0b9a8; Hojman P, 2009, DIABETES, V58, P2797, DOI 10.2337/db09-0713; Holmes AG, 2004, J APPL PHYSIOL, V97, P689, DOI 10.1152/japplphysiol.00195.2004; Hubal MJ, 2008, AM J PHYSIOL-REG I, V294, pR1628, DOI 10.1152/ajpregu.00853.2007; Huh JY, 2012, METABOLISM, V61, P1725, DOI 10.1016/j.metabol.2012.09.002; Hulmi JJ, 2009, J APPL PHYSIOL, V106, P1720, DOI 10.1152/japplphysiol.00087.2009; Izumiya Y, 2008, FEBS LETT, V582, P3805, DOI 10.1016/j.febslet.2008.10.021; Jonsdottir IH, 2000, J PHYSIOL-LONDON, V528, P157, DOI 10.1111/j.1469-7793.2000.00157.x; Jorgensen LH, 2009, J HISTOCHEM CYTOCHEM, V57, P29, DOI 10.1369/jhc.2008.951954; Kadoglou NP, 2007, DIABETES CARE, V30, P719, DOI 10.2337/dc06-1149; Kamimura D, 2004, REV PHYSIOL BIOCH P, V149, P1, DOI 10.1007/s10254-003-0012-2; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Kang YS, 2010, KIDNEY INT, V78, P883, DOI 10.1038/ki.2010.263; Kawanishi N, 2010, EXERC IMMUNOL REV, V16, P105; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; Keller P, 2003, BIOCHEM BIOPH RES CO, V310, P550, DOI 10.1016/j.bbrc.2003.09.048; Kersten S, 2009, ARTERIOSCL THROM VAS, V29, P969, DOI 10.1161/ATVBAHA.108.182147; Kharitonenkov A, 2007, ENDOCRINOLOGY, V148, P774, DOI 10.1210/en.2006-1168; Kharitonenkov A, 2014, MOL METAB, V3, P221, DOI 10.1016/j.molmet.2013.12.003; Kim GY, 2010, J IMMUNOL, V184, P3946, DOI 10.4049/jimmunol.0901735; Kim HJ, 2013, DIABETES METAB J, V37, P358, DOI 10.4093/dmj.2013.37.5.358; Kim JH, 2008, J BIOL CHEM, V283, P708, DOI 10.1074/jbc.M708568200; Kim KH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063517; Kurdiova T, 2014, J PHYSIOL-LONDON, V592, P1091, DOI 10.1113/jphysiol.2013.264655; Kvorning T, 2007, J PHYSIOL-LONDON, V578, P579, DOI 10.1113/jphysiol.2006.122671; Lambernd S, 2012, DIABETOLOGIA, V55, P1128, DOI 10.1007/s00125-012-2454-z; Lancaster GI, 2014, TRENDS IMMUNOL, V35, P262, DOI 10.1016/j.it.2014.02.008; Langberg H, 2002, J PHYSIOL-LONDON, V542, P985, DOI 10.1113/jphysiol.2002.019141; Lee MS, 2012, METABOLISM, V61, P1142, DOI 10.1016/j.metabol.2012.01.012; Lee P, 2014, CELL METAB, V19, P302, DOI 10.1016/j.cmet.2013.12.017; Lee YS, 2013, CELL, V153, P413, DOI 10.1016/j.cell.2013.03.001; Leggate M, 2012, J APPL PHYSIOL, V112, P1353, DOI 10.1152/japplphysiol.01080.2011; Leggate M, 2010, CELL STRESS CHAPERON, V15, P827, DOI 10.1007/s12192-010-0192-z; Lira VA, 2010, AM J PHYSIOL-ENDOC M, V299, pE145, DOI 10.1152/ajpendo.00755.2009; Louis E, 2007, J APPL PHYSIOL, V103, P1744, DOI 10.1152/japplphysiol.00679.2007; Lu HY, 2011, FASEB J, V25, P3344, DOI 10.1096/fj.10-178939; Lundberg TR, 2012, MED SCI SPORT EXER, V44, P1680, DOI 10.1249/MSS.0b013e318256fbe8; MacDonald C, 2003, J APPL PHYSIOL, V95, P2273, DOI 10.1152/japplphysiol.00242.2003; MacKenzie MG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068743; Many G, 2013, PEDIATR EXERC SCI, V25, P12, DOI 10.1123/pes.25.1.12; Marklund P, 2013, J APPL PHYSIOL, V114, P66, DOI 10.1152/japplphysiol.01538.2011; Mathers JL, 2012, MUSCLE NERVE, V46, P407, DOI 10.1002/mus.23317; Matthews VB, 2009, DIABETOLOGIA, V52, P1409, DOI 10.1007/s00125-009-1364-1; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; McFarlane C, 2006, J CELL PHYSIOL, V209, P501, DOI 10.1002/jcp.20757; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Meex RCR, 2010, DIABETES, V59, P572, DOI 10.2337/db09-1322; Mendham AE, 2011, EUR J APPL PHYSIOL, V111, P1035, DOI 10.1007/s00421-010-1724-z; Minetto M, 2005, EUR J APPL PHYSIOL, V93, P679, DOI 10.1007/s00421-004-1241-z; Mori A, 1996, J IMMUNOL, V156, P2400; Mouisel E, 2014, AM J PHYSIOL-REG I, V307, pR444, DOI 10.1152/ajpregu.00377.2013; Mousavi K, 2006, J NEUROSCI, V26, P5739, DOI 10.1523/JNEUROSCI.5398-05.2006; Murach K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108547; Nakamura K, 2013, MUSCLE NERVE, V48, P791, DOI 10.1002/mus.23822; Nedachi T, 2008, AM J PHYSIOL-ENDOC M, V295, pE1191, DOI 10.1152/ajpendo.90280.2008; Neurath MF, 2011, CYTOKINE GROWTH F R, V22, P83, DOI 10.1016/j.cytogfr.2011.02.003; Nicholas J, 2015, INNATE IMMUN-LONDON, V21, P266, DOI 10.1177/1753425914527326; Nielsen AR, 2007, J PHYSIOL-LONDON, V584, P305, DOI 10.1113/jphysiol.2007.139618; Nieman DC, 2012, J INTERF CYTOK RES, V32, P12, DOI 10.1089/jir.2011.0038; Nieman DC, 2005, MED SCI SPORT EXER, V37, P1283, DOI 10.1249/01.mss.0000175054.99588.b1; Nieman DC, 2003, J APPL PHYSIOL, V94, P1917, DOI 10.1152/japplphysiol.01130.2002; Nieman DC, 2004, J APPL PHYSIOL, V96, P1292, DOI 10.1152/japplphysiol.01064.2003; Niess AM, 2003, EUR J APPL PHYSIOL, V89, P344, DOI 10.1007/s00421-003-0809-3; Nikolic N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033203; Nio Y, 2012, DIABETOLOGIA, V55, P3350, DOI 10.1007/s00125-012-2710-2; Norheim F, 2014, FEBS J, V281, P739, DOI 10.1111/febs.12619; Norheim F, 2011, AM J PHYSIOL-ENDOC M, V301, pE1013, DOI 10.1152/ajpendo.00326.2011; Ogborn DI, 2010, MUSCLE NERVE, V41, P385, DOI 10.1002/mus.21503; Oliveira AG, 2013, OBESITY, V21, P2545, DOI 10.1002/oby.20402; Ostrowski K, 1998, J PHYSIOL-LONDON, V513, P889, DOI 10.1111/j.1469-7793.1998.889ba.x; Ostrowski K, 1999, J PHYSIOL-LONDON, V515, P287, DOI 10.1111/j.1469-7793.1999.287ad.x; Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x; Owen BM, 2015, TRENDS ENDOCRIN MET, V26, P22, DOI 10.1016/j.tem.2014.10.002; Paoli A, 2015, J MED FOOD, V18, P137, DOI 10.1089/jmf.2014.0004; Pedersen BK, 2008, PHYSIOL REV, V88, P1379, DOI 10.1152/physrev.90100.2007; Pedersen BK, 2007, J APPL PHYSIOL, V103, P1093, DOI 10.1152/japplphysiol.00080.2007; Pedersen Bente Klarlund, 2011, J Exp Biol, V214, P337, DOI 10.1242/jeb.048074; Pedersen BK, 2004, P NUTR SOC, V63, P263, DOI 10.1079/PNS2004338; Pekkala S, 2013, J PHYSIOL-LONDON, V591, P5393, DOI 10.1113/jphysiol.2013.263707; Penkowa M, 2003, FASEB J, V17, DOI 10.1096/fj.03-0311fje; Pereira GB, 2013, CLIN PHYSIOL FUNCT I, V33, P122, DOI 10.1111/cpf.12004; Przybyla B, 2006, EXP GERONTOL, V41, P320, DOI 10.1016/j.exger.2005.12.007; Quinn LS, 2002, EXP CELL RES, V280, P55, DOI 10.1006/excr.2002.5624; Rao RR, 2014, CELL, V157, P1279, DOI 10.1016/j.cell.2014.03.065; Raschke S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073680; Raschke S, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/320724; Raschke S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062008; Rasmussen P, 2009, EXP PHYSIOL, V94, P1062, DOI 10.1113/expphysiol.2009.048512; REITMAN JS, 1984, DIABETES CARE, V7, P434, DOI 10.2337/diacare.7.5.434; Rinnov A, 2014, ENDOCRINE, V45, P271, DOI 10.1007/s12020-013-9969-z; Rios R, 2002, AM J PHYSIOL-CELL PH, V282, pC993, DOI 10.1152/ajpcell.00372.2001; Robciuc MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046212; Roberts LD, 2014, CELL METAB, V19, P96, DOI 10.1016/j.cmet.2013.12.003; Rohde T, 1997, AM J PHYSIOL-ENDOC M, V273, pE85, DOI 10.1152/ajpendo.1997.273.1.E85; Rosa JS, 2007, J PEDIATR ENDOCR MET, V20, P1293; Neto JCR, 2009, EUR J APPL PHYSIOL, V106, P697, DOI 10.1007/s00421-009-1070-1; Ryan AS, 2013, OBESITY, V21, P1350, DOI 10.1002/oby.20216; Scheler M, 2013, AM J PHYSIOL-CELL PH, V305, pC877, DOI 10.1152/ajpcell.00043.2013; Schiffer T, 2011, INT J SPORTS MED, V32, P683, DOI 10.1055/s-0031-1279732; Schwarz N, 2010, CELL MOL LIFE SCI, V67, P4233, DOI 10.1007/s00018-010-0433-4; Scott JPR, 2013, EUR J APPL PHYSIOL, V113, P1871, DOI 10.1007/s00421-013-2615-x; Scott JPR, 2011, MED SCI SPORT EXER, V43, P2297, DOI 10.1249/MSS.0b013e31822113a9; Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391; Shah R, 2011, DIABETES, V60, P1512, DOI 10.2337/db10-0956; Song HY, 2010, BIOCHEM BIOPH RES CO, V396, P961, DOI 10.1016/j.bbrc.2010.05.033; Sonnet C, 2006, J CELL SCI, V119, P2497, DOI 10.1242/jcs.02988; Staiger H, 2009, DIABETES, V58, P579, DOI 10.2337/db07-1438; Starkie RL, 2001, J PHYSIOL-LONDON, V533, P585, DOI 10.1111/j.1469-7793.2001.0585a.x; Steensberg A, 2001, J PHYSIOL-LONDON, V537, P633, DOI 10.1111/j.1469-7793.2001.00633.x; Steensberg A, 2002, AM J PHYSIOL-ENDOC M, V283, pE1272, DOI 10.1152/ajpendo.00255.2002; Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x; Steensberg A, 2001, AM J PHYSIOL-CELL PH, V281, pC1001; Stewart KJ, 2002, JAMA-J AM MED ASSOC, V288, P1622, DOI 10.1001/jama.288.13.1622; Sugama K, 2013, EXERC IMMUNOL REV, V19, P29; Suzuki K, 2003, MED SCI SPORT EXER, V35, P348, DOI 10.1249/01.MSS.0000048861.57899.04; Tamura Y, 2011, ENDOCR J, V58, P211, DOI 10.1507/endocrj.K10E-400; Tantiwong P, 2010, AM J PHYSIOL-ENDOC M, V299, pE794, DOI 10.1152/ajpendo.00776.2009; Toft AD, 2011, EUR J APPL PHYSIOL, V111, P1351, DOI 10.1007/s00421-010-1755-5; ULLUM H, 1994, J APPL PHYSIOL, V77, P93, DOI 10.1152/jappl.1994.77.1.93; Vella L, 2012, AM J PHYSIOL-REG I, V302, pR667, DOI 10.1152/ajpregu.00336.2011; Walker KS, 2004, MED SCI SPORT EXER, V36, P787, DOI 10.1249/01.MSS.0000126384.04778.29; Waskiewicz Z, 2012, EUR J APPL PHYSIOL, V112, P1679, DOI 10.1007/s00421-011-2135-5; Whittemore LA, 2003, BIOCHEM BIOPH RES CO, V300, P965, DOI 10.1016/S0006-291X(02)02953-4; Willoughby DS, 2003, INT J SPORTS MED, V24, P15, DOI 10.1055/s-2003-37197; Yahiaoui L, 2008, J PHYSIOL-LONDON, V586, P3991, DOI 10.1113/jphysiol.2008.152090; Yang HT, 2013, ENDOCRINE, V43, P579, DOI 10.1007/s12020-012-9809-6	174	86	92	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1615	1628		10.1096/fj.14-263699	http://dx.doi.org/10.1096/fj.14-263699			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25593123				2022-12-28	WOS:000354114600001
J	Du, YP; Cramer, M; Lee, CA; Tang, J; Muthusamy, A; Antonetti, DA; Jin, H; Palczewski, K; Kern, TS				Du, Yunpeng; Cramer, Megan; Lee, Chieh Allen; Tang, Jie; Muthusamy, Arivalagan; Antonetti, David A.; Jin, Hui; Palczewski, Krzysztof; Kern, Timothy S.			Adrenergic and serotonin receptors affect retinal superoxide generation in diabetic mice: relationship to capillary degeneration and permeability	FASEB JOURNAL			English	Article						GPCRs; NADPH oxidase; diabetic retinopathy; inflammation	SMOOTH-MUSCLE-CELLS; PROTEIN-COUPLED RECEPTORS; NADPH OXIDASE; OXIDATIVE STRESS; G(I)ALPHA PROTEINS; STARGARDT DISEASE; ENDOTHELIAL-CELLS; TACTILE ALLODYNIA; MOUSE MODEL; RAT RETINA	Reactive oxygen species play an important role in the pathogenesis of diabetic retinopathy. We studied the role of adrenergic and serotonin receptors in the generation of superoxide by retina and 661W retinal cells in high glucose and of the alpha(1)-adrenergic receptor (AR) on vascular lesions of the retinopathy in experimentally diabetic C57Bl/6J mice (and controls) after 2 and 8 months. Compared with 5 mM glucose, incubating cells or retinal explants in 30 mM glucose induced superoxide generation. This response was reduced or ablated by pharmacologic inhibition of the alpha(1)-AR (a G(q)-coupled receptor) or G(s)-coupled serotonin (5-HT2, 5-HT4, 5-HT6, and 5-HT7) receptors or by activation of the G(i)-coupled (2)-AR. In elevated glucose, the alpha(1)-AR produced superoxide via phospholipase C, inositol triphosphate-induced Ca2+ release, and NADPH oxidase, and pharmacologic inhibition of these reactions prevented the superoxide increase. Generation of retinal superoxide, expression of proinflammatory proteins, and degeneration of retinal capillaries in diabetes all were significantly inhibited with daily doxazosin or apocynin (inhibitors of (1)-AR and NADPH oxidase, respectively), but increased vascular permeability was not significantly affected. Adrenergic receptors, and perhaps other GPCRs, represent novel targets for inhibiting the development of important features of diabetic retinopathy.	[Du, Yunpeng; Cramer, Megan; Lee, Chieh Allen; Tang, Jie; Kern, Timothy S.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; [Muthusamy, Arivalagan; Antonetti, David A.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA; [Jin, Hui; Palczewski, Krzysztof; Kern, Timothy S.] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; [Kern, Timothy S.] Vet Adm Med Ctr, Res Serv 151, Cleveland, OH 44106 USA	Case Western Reserve University; University of Michigan System; University of Michigan; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Kern, TS (corresponding author), Case Western Reserve Univ, 441 Wood Bldg,10900 Euclid Ave, Cleveland, OH 44106 USA.	tsk@case.edu		antonetti, david/0000-0003-1130-6577	U.S. National Institutes of Health, National Eye Institute [R01EY00300, R01EY022938, R24EY021126]; Medical Research Service of the Department of Veteran Affairs; Office of Research and Technology Management at Case Western Reserve University; Services of the Case Western Reserve University Visual Science Research Center Core Facilities [P30EY11373]; NATIONAL EYE INSTITUTE [P30EY011373, R01EY000300, R01EY022938, R24EY021126, P30EY021721, R01EY012021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020572] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002117] Funding Source: NIH RePORTER	U.S. National Institutes of Health, National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Medical Research Service of the Department of Veteran Affairs; Office of Research and Technology Management at Case Western Reserve University; Services of the Case Western Reserve University Visual Science Research Center Core Facilities; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by grants from the U.S. National Institutes of Health, National Eye Institute (R01EY00300, R01EY022938, and R24EY021126), the Medical Research Service of the Department of Veteran Affairs, and the Office of Research and Technology Management at Case Western Reserve University. Services of the Case Western Reserve University Visual Science Research Center Core Facilities are acknowledged (P30EY11373). K.P. is John H. Hord Professor of Pharmacology. The authors declare no conflicts of interest.	ABBRACCHIO MP, 1991, J NEUROSCI RES, V29, P196, DOI 10.1002/jnr.490290209; Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3239, DOI 10.1167/iovs.08-1755; Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3231, DOI 10.1167/iovs.08-1754; ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953; Berkowitz BA, 2009, INVEST OPHTH VIS SCI, V50, P2351, DOI 10.1167/iovs.08-2918; Best TM, 1999, J APPL PHYSIOL, V87, P74, DOI 10.1152/jappl.1999.87.1.74; Billington CK, 2012, BRIT J PHARMACOL, V166, P401, DOI 10.1111/j.1476-5381.2011.01719.x; Brown GC, 2007, BIOCHEM SOC T, V35, P1119, DOI 10.1042/BST0351119; Buonfiglio DD, 2011, INVEST OPHTH VIS SCI, V52, P7416, DOI 10.1167/iovs.10-6756; Chan EC, 2013, INVEST OPHTH VIS SCI, V54, P7061, DOI 10.1167/iovs.13-12883; Chang JCF, 2014, J TOXICOL PATHOL, V27, P31, DOI 10.1293/tox.2013-0033; Chen Y, 2013, J CLIN INVEST, V123, P5119, DOI 10.1172/JCI69076; Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432; Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418; Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P2118, DOI 10.1167/iovs.10-6304; Descorbeth M, 2010, FREE RADICAL BIO MED, V49, P1395, DOI 10.1016/j.freeradbiomed.2010.07.023; Du YP, 2003, FREE RADICAL BIO MED, V35, P1491, DOI 10.1016/j.freeradbiomed.2003.08.018; Du Y, 2013, P NATL ACAD SCI USA, V110, P16586, DOI 10.1073/pnas.1314575110; Du YP, 2010, INVEST OPHTH VIS SCI, V51, P2158, DOI 10.1167/iovs.09-3674; Elms SC, 2013, DIABETOLOGIA, V56, P654, DOI 10.1007/s00125-012-2789-5; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Gavras I, 2001, CURR CONTR TRIALS C, V2, P257, DOI 10.1186/CVM-2-6-257; GORAYA TY, 1995, J NEUROSCI RES, V41, P518, DOI 10.1002/jnr.490410411; Gray SP, 2013, CIRCULATION, V127, P1888, DOI 10.1161/CIRCULATIONAHA.112.132159; Gubitosi-Klug RA, 2008, DIABETES, V57, P1387, DOI 10.2337/db07-1217; HADJICONSTANTINOU M, 1988, EUR J PHARMACOL, V149, P193, DOI 10.1016/0014-2999(88)90064-7; Inoue T, 2008, BBA-MOL CELL RES, V1783, P789, DOI 10.1016/j.bbamcr.2007.12.004; Jiang YD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070555; Jiang YD, 2010, EXP EYE RES, V91, P171, DOI 10.1016/j.exer.2010.04.014; Jiang YD, 2010, INVEST OPHTH VIS SCI, V51, P2730, DOI 10.1167/iovs.09-4779; Kanwar M, 2008, MICROVASC RES, V76, P189, DOI 10.1016/j.mvr.2008.04.002; Kanwar M, 2007, INVEST OPHTH VIS SCI, V48, P3805, DOI 10.1167/iovs.06-1280; Kern TS, 2007, DIABETES, V56, P373, DOI 10.2337/db05-1621; Kern TS, 2010, AM J PATHOL, V176, P2550, DOI 10.2353/ajpath.2010.091062; Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938; Kusari J, 2010, INVEST OPHTH VIS SCI, V51, P1044, DOI 10.1167/iovs.08-3293; Lee CA, 2013, INVEST OPHTHALMOL VI, V93, P135; Li GY, 2012, DIABETES, V61, P3294, DOI 10.2337/db11-1249; Li GY, 2011, MOL VIS, V17, P3156; Li Y, 2008, AM J PHYSIOL-HEART C, V294, pH2845, DOI 10.1152/ajpheart.91422.2007; Li Y, 2007, AM J PHYSIOL-HEART C, V292, pH1922, DOI 10.1152/ajpheart.01166.2006; LIVINGSTONE C, 1991, BIOCHIM BIOPHYS ACTA, V1096, P127, DOI 10.1016/0925-4439(91)90050-J; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Prabu SK, 2006, J BIOL CHEM, V281, P2061, DOI 10.1074/jbc.M507741200; Renganathan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076325; Sedeek M, 2013, J AM SOC NEPHROL, V24, P1512, DOI 10.1681/ASN.2012111112; Shen JY, 2012, P NATL ACAD SCI USA, V109, P3540, DOI 10.1073/pnas.1119201109; Steinle JJ, 2008, EXP EYE RES, V87, P30, DOI 10.1016/j.exer.2008.04.008; Suzuki F, 2002, BRIT J PHARMACOL, V135, P600, DOI 10.1038/sj.bjp.0704503; Tang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068871; Tang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062081; Thampi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034468; Usui S, 2009, J NEUROCHEM, V110, P1028, DOI 10.1111/j.1471-4159.2009.06195.x; Veenstra AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078405; Walker RJ, 2007, INVEST OPHTH VIS SCI, V48, P5276, DOI 10.1167/iovs.07-0129; Wilkinson-Berka JL, 2014, ANTIOXID REDOX SIGN, V20, P2726, DOI 10.1089/ars.2013.5357; Woldemussie E, 2007, VISUAL NEUROSCI, V24, P745, DOI 10.1017/S0952523807070605; Yamamori T, 2000, FEBS LETT, V467, P253, DOI 10.1016/S0014-5793(00)01167-4; ZARBIN MA, 1986, BRAIN RES, V374, P75, DOI 10.1016/0006-8993(86)90396-3; Zheng L, 2007, DIABETOLOGIA, V50, P1987, DOI 10.1007/s00125-007-0734-9	61	37	38	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2194	2204		10.1096/fj.14-269431	http://dx.doi.org/10.1096/fj.14-269431			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25667222	Green Submitted, Green Published			2022-12-28	WOS:000354114600049
J	Fentz, J; Kjobsted, R; Birk, JB; Jordy, AB; Jeppesen, J; Thorsen, K; Schjerling, P; Kiens, B; Jessen, N; Viollet, B; Wojtaszewski, JFP				Fentz, Joachim; Kjobsted, Rasmus; Birk, Jesper B.; Jordy, Andreas B.; Jeppesen, Jacob; Thorsen, Kasper; Schjerling, Peter; Kiens, Bente; Jessen, Niels; Viollet, Benoit; Wojtaszewski, Jorgen F. P.			AMPK alpha is critical for enhancing skeletal muscle fatty acid utilization during in vivo exercise in mice	FASEB JOURNAL			English	Article						CD36; fat oxidation; glucose uptake; physical activity; TBC1D1	ACTIVATED PROTEIN-KINASE; GLUCOSE-UPTAKE; PALMITATE UPTAKE; MALONYL-COA; INSULIN; TBC1D1; TRANSPORT; CONTRACTION; BINDING; PHOSPHORYLATION	The importance of AMPK in regulation of fatty acid (FA) oxidation in skeletal muscle with contraction/exercise is unresolved. Using a mouse model lacking both AMPK1 and -2 in skeletal muscle specifically (mdKO), we hypothesized that FA utilization would be impaired in skeletal muscle. AMPK mdKO mice displayed normal respiratory exchange ratio (RER) when fed chow or a high-fat diet, or with prolonged fasting. However, in vivo treadmill exercise at the same relative intensity induced a higher RER in AMPK mdKO mice compared to wild-type (WT = 0.81 +/- 0.01 (sem); mdKO = 0.87 +/- 0.02 (sem); P < 0.01), indicating a decreased utilization of FA. Further, ex vivo contraction-induced FA oxidation was impaired in AMPK mdKO muscle, suggesting that the increased RER during exercise originated from decreased skeletal muscle FA oxidation. A decreased muscle protein expression of CD36 (cluster of differentiation 36) and FABPpm (plasma membrane fatty acid binding protein) (by approximate to 17-40%), together with fully abolished TBC1D1 (tre-2/USP6, BUB2, cdc16 domain family member 1) Ser(237) phosphorylation during contraction/exercise in AMPK mdKO mice, may impair FA transport capacity and FA transport protein translocation to sarcolemma, respectively. AMPK is thus required for normal FA metabolism during exercise and muscle contraction.Fentz, J., KjObsted, R., Birk, J. B., Jordy, A. B., Jeppesen, J., Thorsen, K., Schjerling, P., Kiens, B., Jessen, N., Viollet, B., Wojtaszewski, J. F. P. AMPK is critical for enhancing skeletal muscle fatty acid utilization during in vivo exercise in mice.	[Fentz, Joachim; Kjobsted, Rasmus; Birk, Jesper B.; Jordy, Andreas B.; Jeppesen, Jacob; Kiens, Bente; Wojtaszewski, Jorgen F. P.] Univ Copenhagen, August Krogh Ctr, Dept Nutr Exercise & Sports, Sect Mol Physiol, DK-2100 Copenhagen, Denmark; [Thorsen, Kasper; Jessen, Niels] Aarhus Univ Hosp, Dept Mol Med, DK-8000 Aarhus, Denmark; [Schjerling, Peter] Univ Copenhagen, Bispebjerg Hosp, Inst Sports Med, Dept Orthoped Surg, DK-2100 Copenhagen, Denmark; [Schjerling, Peter] Univ Copenhagen, Fac Hlth & Med Sci, Ctr Hlth Aging, DK-2100 Copenhagen, Denmark; [Viollet, Benoit] INSERM, Inst Cochin, U1016, Paris, France; [Viollet, Benoit] CNRS, Unites Mixtes Rech 8104, Paris, France; [Viollet, Benoit] Univ Descartes, Sorbonne Paris Cite, Paris, France	University of Copenhagen; Aarhus University; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Wojtaszewski, JFP (corresponding author), Univ Copenhagen, August Krogh Ctr, Dept Nutr Exercise & Sports, Sect Mol Physiol, Univ Pk 13, DK-2100 Copenhagen, Denmark.	jwojtaszewski@nexs.ku.dk	Jessen, Niels/E-1731-2011; Schjerling, Peter/F-6194-2011; Birk, Jesper B/D-3523-2015; Viollet, Benoit/O-6927-2017; Kjøbsted, Rasmus/AAY-8228-2020; Viollet, Benoit/N-2397-2019; Kiens, Bente/B-1375-2015	Schjerling, Peter/0000-0001-7138-3211; Birk, Jesper B/0000-0001-9775-4789; Viollet, Benoit/0000-0002-0121-0224; Kjøbsted, Rasmus/0000-0002-0628-4994; Viollet, Benoit/0000-0002-0121-0224; Jessen, Niels/0000-0001-5613-7274; wojtaszewski, jorgen/0000-0001-8185-3408; Kiens, Bente/0000-0001-5705-5625	Danish Ministry of Science, Technology and Innovation; Danish Council for Independent Research Medical Sciences (FSS); Novo Nordisk Foundation; Danish Diabetes Academy; Novo Nordisk Fonden [NNF14OC0012009] Funding Source: researchfish	Danish Ministry of Science, Technology and Innovation; Danish Council for Independent Research Medical Sciences (FSS)(Det Frie Forskningsrad (DFF)Danish Medical Research Council); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Diabetes Academy; Novo Nordisk Fonden(Novo Nordisk Foundation)	This work was carried out as a part of the research programs "Physical activity and nutrition for improvement of health" funded by the University of Copenhagen Excellence Program for Interdisciplinary Research; and the UNIK project: Food, Fitness & Pharma for Health and Disease (http://www.foodfitnesspharma.ku.dk) supported by the Danish Ministry of Science, Technology and Innovation. The study was funded by the Danish Council for Independent Research Medical Sciences (FSS) and the Novo Nordisk Foundation. J.F. was the recipient of a Ph.D. fellowship from the Danish Diabetes Academy funded by the Novo Nordisk Foundation. The authors acknowledge the assistance of Betina Bolmgren, Nicoline Resen Andersen, and Irene Bech Nielsen, Section of Molecular Physiology, August Krogh Centre, Department of Nutrition, Exercise and Sports, University of Copenhagen, and Anja Jokipii and Ida Trondhjem Haakansson, Institute of Sports Medicine Copenhagen, Bispebjerg Hospital (Copenhagen, Denmark). The authors also appreciate the kind donation of antibodies by D. G. Hardie (Division of Molecular Physiology, College of Life Sciences, University of Dundee, Scotland, United Kingdom), M. Mahlapuu (Lundberg Laboratory for Diabetes Research, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden), and J. Calles-Escandon (Wake Forest University, Winston-Salem, NC, USA).	Bonen A, 2007, AM J PHYSIOL-ENDOC M, V292, pE1740, DOI 10.1152/ajpendo.00579.2006; BROOKS GA, 1994, J APPL PHYSIOL, V76, P2253, DOI 10.1152/jappl.1994.76.6.2253; Chabowski A, 2005, FEBS LETT, V579, P2428, DOI 10.1016/j.febslet.2004.11.118; Chabowski A, 2007, PROSTAG LEUKOTR ESS, V77, P345, DOI 10.1016/j.plefa.2007.10.017; Chadt A., 2014, DIABETES IN PRESS; Chadt A, 2008, NAT GENET, V40, P1354, DOI 10.1038/ng.244; Chao LC, 2012, J LIPID RES, V53, P2610, DOI 10.1194/jlr.M029355; Clarke DC, 2004, PHYSIOL GENOMICS, V17, P31, DOI 10.1152/physiolgenomics.00190.2003; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Dokas J, 2013, ENDOCRINOLOGY, V154, P3502, DOI 10.1210/en.2012-2147; Dzamko N, 2008, J PHYSIOL-LONDON, V586, P5819, DOI 10.1113/jphysiol.2008.159814; Fueger PT, 2007, J PHYSIOL-LONDON, V582, P801, DOI 10.1113/jphysiol.2007.132902; Fueger PT, 2005, J PHYSIOL-LONDON, V566, P533, DOI 10.1113/jphysiol.2005.085043; Fueger PT, 2004, AM J PHYSIOL-ENDOC M, V286, pE77, DOI 10.1152/ajpendo.00309.2003; Glatz JFC, 2010, PHYSIOL REV, V90, P367, DOI 10.1152/physrev.00003.2009; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Holloway GP, 2007, J PHYSIOL-LONDON, V582, P393, DOI 10.1113/jphysiol.2007.135301; Jeppesen J, 2011, J LIPID RES, V52, P699, DOI 10.1194/jlr.M007138; Jeppesen J, 2013, DIABETES, V62, P1490, DOI 10.2337/db12-1160; Jhun BS, 2004, BIOCHEM BIOPH RES CO, V318, P372, DOI 10.1016/j.bbrc.2004.04.035; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; KRAEGEN EW, 1985, AM J PHYSIOL, V248, pE353; Lantier L, 2014, FASEB J, V28, P3211, DOI 10.1096/fj.14-250449; Lee-Young RS, 2009, J BIOL CHEM, V284, P23925, DOI 10.1074/jbc.M109.021048; Luiken JJFP, 2003, DIABETES, V52, P1627, DOI 10.2337/diabetes.52.7.1627; Luiken JJFP, 1999, J LIPID RES, V40, P1007; Maarbjerg SJ, 2009, AM J PHYSIOL-ENDOC M, V297, pE924, DOI 10.1152/ajpendo.90653.2008; McFarlan JT, 2012, J BIOL CHEM, V287, P23502, DOI 10.1074/jbc.M111.315358; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; Miniou P, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.19.e27; Miura S, 2013, AM J PHYSIOL-ENDOC M, V305, pE213, DOI 10.1152/ajpendo.00114.2013; Miura S, 2009, AM J PHYSIOL-ENDOC M, V296, pE47, DOI 10.1152/ajpendo.90690.2008; O'Neill HM, 2011, P NATL ACAD SCI USA, V108, P16092, DOI 10.1073/pnas.1105062108; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PASSONNEAU JV, 1967, ANAL BIOCHEM, V19, P315, DOI 10.1016/0003-2697(67)90167-4; Pehmoller C, 2009, AM J PHYSIOL-ENDOC M, V297, pE665, DOI 10.1152/ajpendo.00115.2009; Sag D, 2008, J IMMUNOL, V181, P8633, DOI 10.4049/jimmunol.181.12.8633; Samovski D, 2012, J LIPID RES, V53, P709, DOI 10.1194/jlr.M023424; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; Stephenson EJ, 2014, BBA-GEN SUBJECTS, V1840, P1285, DOI 10.1016/j.bbagen.2013.12.004; Storlien L, 2004, P NUTR SOC, V63, P363, DOI 10.1079/PNS2004349; Szekeres F, 2012, AM J PHYSIOL-ENDOC M, V303, pE524, DOI 10.1152/ajpendo.00605.2011; Treebak JT, 2014, J PHYSIOL-LONDON, V592, P351, DOI 10.1113/jphysiol.2013.266338; Treebak JT, 2009, AM J PHYSIOL-CELL PH, V297, pC1041, DOI 10.1152/ajpcell.00051.2009; Turcotte LP, 2000, MOL CELL BIOCHEM, V210, P53, DOI 10.1023/A:1007046929776; Vichaiwong K, 2010, BIOCHEM J, V431, P311, DOI 10.1042/BJ20101100; Wang SB, 2010, J BIOL CHEM, V285, P19976, DOI 10.1074/jbc.M110.102467; WINDER WW, 1990, AM J PHYSIOL, V259, pE266, DOI 10.1152/ajpendo.1990.259.2.E266; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299	49	57	61	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1725	1738		10.1096/fj.14-266650	http://dx.doi.org/10.1096/fj.14-266650			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25609422				2022-12-28	WOS:000354114600011
J	Jiang, Y; Wang, S; Zhao, YY; Lin, CZ; Zhong, F; Jin, L; He, FC; Wang, HJ				Jiang, Yan; Wang, Sheng; Zhao, Yuanyuan; Lin, Chengzhao; Zhong, Fan; Jin, Li; He, Fuchu; Wang, Haijian			Histone H3K9 demethylase JMJD1A modulates hepatic stellate cells activation and liver fibrosis by epigenetically regulating peroxisome proliferator-activated receptor gamma	FASEB JOURNAL			English	Article						liver fibrogenesis; adipogenic transcription factor; PPAR gamma; HSC biology	MYOFIBROBLAST TRANSDIFFERENTIATION; MOLECULAR-MECHANISMS; LYSINE METHYLATION; DNA METHYLATION; GROWTH-FACTOR; STEM-CELLS; JHDM2A; DIFFERENTIATION; TRANSCRIPTION; FIBROGENESIS	As a central event in liver fibrogenesis, hepatic stellate cell (HSC) transdifferentiation involves loss of regulation by adipogenic transcription factors such as peroxisome proliferator-activated receptor gamma; (PPAR gamma), which is epigenetically silenced during HSC activation. We hypothesized that JMJD1A, an H3K9 demethylase involved in adipogenic metabolism, could regulate PPAR gamma. In human HSC cell line, rat primary HSCs, and carbontetrachloride-induced mouse liver fibrogenesis model, we down-regulated the expression of JMJD1A using small interfering or short hairpin RNAs, and overexpressed its wild-type and mutant. We analyzed the effects of JMJD1A manipulation on the histone di-methyl-H3K9 (H3k9me2) status of PPAR gamma gene and the expression of PPAR gamma and fibrosis markers using chromatin immunoprecipitation, real-time quantitative RT-PCR and Western blot, and also investigated the in vitro and in vivo consequences on liver fibrosis and necrosis by Masson or hematoxylin-eosin staining, respectively. JMJD1A knockdown in HSCs correlated with reinforced H3K9me2 in the PPAR gamma gene promoter, and its down-regulation in both mRNA and protein led to increased expression of fibrosis markers, which could be consistently rescued by JMJD1A overexpression. Jmjd1a knockdown in situ resulted in significantly increased expression of alpha-smooth muscle actin (P = 0.005) and Col1a (P = 0.036), strengthened production of collagens (P = 0.028), and remarkably enhanced necrosis (P = 0.007) 4 weeks after treatment. This study suggests JMJD1A as a novel epigenetic regulator that modulates HSC activation and liver fibrosis through targeting PPAR gamma gene expression.	[Jiang, Yan; Wang, Sheng; Zhao, Yuanyuan; Lin, Chengzhao; Zhong, Fan; Jin, Li; He, Fuchu; Wang, Haijian] Fudan Univ, Shanghai Med Coll, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci,Inst Biomed Sci,State Key Lab Genet, Shanghai 200032, Peoples R China; [Jiang, Yan; Wang, Sheng; Zhao, Yuanyuan; Lin, Chengzhao; Zhong, Fan; Jin, Li; He, Fuchu; Wang, Haijian] Fudan Univ, Shanghai Med Coll, Collaborat Innovat Ctr Genet & Dev,Minist Educ, Sch Life Sci,Inst Biomed Sci,Key Lab Contemporary, Shanghai 200032, Peoples R China; [Jiang, Yan; He, Fuchu] Fudan Univ, Dept Chem, Shanghai 200032, Peoples R China; [He, Fuchu] Beijing Proteome Res Ctr, Beijing Inst Radiat Med, State Key Lab Prote, Beijing, Peoples R China	Fudan University; Fudan University; Fudan University; Academy of Military Medical Sciences - China	He, FC (corresponding author), Fudan Univ, Sch Life Sci, Yixueyuan Rd 138, Shanghai 200032, Peoples R China.	hefc@nic.bmi.ac.cn; haijianwang@fudan.edu.cn	Jin, Li/M-5063-2019; ZHAO, YUAN/HCI-5831-2022; Jin, Li/C-1468-2009	Jin, Li/0000-0002-4546-2415	National Science and Technology Major [2012ZX10002]; National Natural Science Foundation of China [81172093, 81372526, 31301050]; Shanghai Rising-Star Program Grant [12QH1400200]; Shanghai Pujiang Program Grant [11PJD005]	National Science and Technology Major; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Rising-Star Program Grant; Shanghai Pujiang Program Grant	This study was supported by National Science and Technology Major Project 2012ZX10002, National Natural Science Foundation of China Grants 81172093, 81372526, and 31301050, Shanghai Rising-Star Program Grant 12QH1400200, and Shanghai Pujiang Program Grant 11PJD005. The authors declare no conflicts of interest.	Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Hazra S, 2004, J BIOL CHEM, V279, P11392, DOI 10.1074/jbc.M310284200; Hu B, 2010, AM J PATHOL, V177, P21, DOI 10.2353/ajpath.2010.090999; Inagaki T, 2009, GENES CELLS, V14, P991, DOI 10.1111/j.1365-2443.2009.01326.x; Jenuwein T, 2006, FEBS J, V273, P3121, DOI 10.1111/j.1742-4658.2006.05343.x; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Kuroki S, 2013, SCIENCE, V341, P1106, DOI 10.1126/science.1239864; Lee MJ, 2013, J CELL MOL MED, V17, P1188, DOI 10.1111/jcmm.12098; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Mann J, 2007, CELL DEATH DIFFER, V14, P275, DOI 10.1038/sj.cdd.4401979; Mann J, 2013, CURR OPIN RHEUMATOL, V25, P101, DOI 10.1097/BOR.0b013e32835b13e1; Mann J, 2010, GASTROENTEROLOGY, V138, P705, DOI 10.1053/j.gastro.2009.10.002; Mederacke I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3823; Miyahara T, 2000, J BIOL CHEM, V275, P35715, DOI 10.1074/jbc.M006577200; Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946; Nakamura T, 2012, NATURE, V486, P415, DOI 10.1038/nature11093; O'Neill LP, 2003, METHODS, V31, P76, DOI 10.1016/S1046-2023(03)00090-2; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; PINZANI M, 1994, HEPATOLOGY, V19, P701, DOI 10.1002/hep.1840190323; Saile B, 1999, HEPATOLOGY, V30, P196, DOI 10.1002/hep.510300144; Senoo H, 2010, CELL BIOL INT, V34, P1247, DOI 10.1042/CBI20100321; She HY, 2005, J BIOL CHEM, V280, P4959, DOI 10.1074/jbc.M410078200; Shu Jian-chang, 2004, Zhonghua Gan Zang Bing Za Zhi, V12, P353; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Tsukamoto H, 2006, J GASTROEN HEPATOL, V21, pS102, DOI 10.1111/j.1440-1746.2006.04573.x; Tsukamoto H, 2011, HEPATOL RES, V41, P675, DOI 10.1111/j.1872-034X.2011.00804.x; Wang YX, 2010, CELL RES, V20, P124, DOI 10.1038/cr.2010.13; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Zeybel M, 2012, NAT MED, V18, P1369, DOI 10.1038/nm.2893; Zhang F, 2012, CELL SIGNAL, V24, P596, DOI 10.1016/j.cellsig.2011.11.008; Zhu NL, 2010, J BIOL CHEM, V285, P30463, DOI 10.1074/jbc.M110.156703	35	29	33	6	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1830	1841		10.1096/fj.14-251751	http://dx.doi.org/10.1096/fj.14-251751			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25609425				2022-12-28	WOS:000354114600019
J	Moreno, M; Ortega, F; Xifra, G; Ricart, W; Fernandez-Real, JM; Moreno-Navarrete, JM				Moreno, Maria; Ortega, Francisco; Xifra, Gemma; Ricart, Wifredo; Manuel Fernandez-Real, Jose; Maria Moreno-Navarrete, Jose			Cytosolic aconitase activity sustains adipogenic capacity of adipose tissue connecting iron metabolism and adipogenesis	FASEB JOURNAL			English	Article						adipocyte differentiation; knockdown; NADPH	MITOCHONDRIAL BIOGENESIS; INSULIN SENSITIVITY; REGULATORY PROTEIN-1; PPAR-GAMMA; OXIDATIVE STRESS; LIPID-METABOLISM; DIETARY IRON; RESISTANCE; MICE; ROSIGLITAZONE	To gain insight into the regulation of intracellular iron homeostasis in adipose tissue, we investigated the role of iron regulatory protein 1/cytosolic aconitase 1 (ACO1). ACO1 gene expression and activity increased in parallel to expression of adipogenic genes during differentiation of both murine 3T3-L1 cells and human preadipocytes. Lentiviral knockdown (KD) of Aco1 in 3T3-L1 preadipocytes led to diminished cytosolic aconitase activity and isocitrate dehydrogenase 1 (NADP(+)), soluble (Idh1) mRNA levels, decreased intracellular NADPH: NADP ratio, and impaired adipogenesis during adipocyte differentiation. In addition, Aco1 KD in fully differentiated 3T3-L1 adipocytes decreased lipogenic, Idh1, Adipoq, and Glut4 gene expression. A bidirectional cross-talk was found between intracellular iron levels and ACO1 gene expression and protein activity. Although iron in excess, known to increase reactive oxygen species production, and iron depletion both resulted in decreased ACO1 mRNA levels and activity, Aco1 KD led to reduced gene expression of transferrin receptor (Tfrc) and transferrin, disrupting intracellular iron uptake. In agreement with these findings, in 2 human independent cohorts (n = 85 and n = 38), ACO1 gene expression was positively associated with adipogenic markers in subcutaneous and visceral adipose tissue. ACO1 gene expression was also positively associated with the gene expression of TFRC while negatively linked to ferroportin (solute carrier family 40 (iron-regulated transporter), member 1) mRNA levels. Altogether, these results suggest that ACO1 activity is required for the normal adipogenic capacity of adipose tissue by connecting iron, energy metabolism, and adipogenesis.	[Maria Moreno-Navarrete, Jose] Inst Invest Biomed Girona, CIBEROBN CB06 03 010, Dept Endocrinol Diabetol & Nutr, Girona, Spain; Inst Salud Carlos III, Girona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Instituto de Salud Carlos III	Moreno-Navarrete, JM (corresponding author), Hosp Girona Dr Josep Trueta, Sect Diabet Endocrinol & Nutr, Carretera Franca S-N, Girona 17007, Spain.	jmoreno@idibgi.org	Ortega, Francisco José J/F-3883-2016; Fernández-Real, Jose Manuel/AGH-3599-2022; Moreno-Navarrete, José María/H-9772-2015; Moreno-Navarrete, José María/ABG-5548-2021	Ortega, Francisco José J/0000-0003-2111-769X; Fernández-Real, Jose Manuel/0000-0002-7442-9323; Moreno-Navarrete, José María/0000-0002-2883-511X; Moreno-Navarrete, José María/0000-0002-2883-511X; Ricart, Wifredo/0000-0002-3452-9098	Instituto de Salud Carlos III (ISCIII; Girona, Spain) [FIS-PI11/00214, FIS-PI12/02631]	Instituto de Salud Carlos III (ISCIII; Girona, Spain)	The authors acknowledge the technical assistance of Isabel Alonso [Institut d'Investigacio Biomedica de Girona (IdIBGi)], Emili Loshuertos (IdIBGi), and Oscar Rovira (IdIBGi). This work was partially supported by Research Grants FIS-PI11/00214 and FIS-PI12/02631 from the Instituto de Salud Carlos III (ISCIII; Girona, Spain). CIBEROBN Fisiopatologia de la Obesidad y Nutricion is an initiative from the ISCIII.	Chen JQ, 2013, ANAL BIOCHEM, V442, P97, DOI 10.1016/j.ab.2013.07.022; Dongiovanni P, 2013, AM J PATHOL, V182, P2254, DOI 10.1016/j.ajpath.2013.02.019; Enguix N, 2013, MOL METAB, V2, P215, DOI 10.1016/j.molmet.2013.05.004; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Festa M, 2000, J BIOL CHEM, V275, P36708, DOI 10.1074/jbc.M004988200; Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421; Hsiao G, 2011, AM J PHYSIOL-ENDOC M, V300, pE164, DOI 10.1152/ajpendo.00219.2010; Juurinen L, 2008, J CLIN ENDOCR METAB, V93, P118, DOI 10.1210/jc.2007-1825; Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021; Koh HJ, 2004, J BIOL CHEM, V279, P39968, DOI 10.1074/jbc.M402260200; Lefterova MI, 2008, GENE DEV, V22, P2941, DOI 10.1101/gad.1709008; Liew YF, 2005, J NUTR, V135, P2151, DOI 10.1093/jn/135.9.2151; LUZZATTO L, 2001, METABOLIC MOL BASES, V3, P4517; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Moreno-Navarrete JM, 2014, DIABETOLOGIA, V57, P1957, DOI 10.1007/s00125-014-3298-5; Moreno-Navarrete JM, 2014, DIABETES CARE, V37, P1092, DOI 10.2337/dc13-1602; Medina-Gomez G, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030064; Nam WS, 2012, BBA-MOL BASIS DIS, V1822, P1181, DOI 10.1016/j.bbadis.2012.04.003; Narahari J, 2000, J BIOL CHEM, V275, P16227, DOI 10.1074/jbc.M910450199; Nguyen, 2011, NAT METHODS, V8, pv, DOI [10.1038/nmeth.f.353, DOI 10.1038/NMETH.F.353]; Orr JS, 2014, DIABETES, V63, P421, DOI 10.2337/db13-0213; Ortega FJ, 2010, OBESITY, V18, P13, DOI 10.1038/oby.2009.202; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Popovic Z, 2007, FEBS J, V274, P3108, DOI 10.1111/j.1742-4658.2007.05843.x; Qatanani M, 2013, DIABETES, V62, P855, DOI 10.2337/db12-0399; Ranganathan G, 2006, J LIPID RES, V47, P2444, DOI 10.1194/jlr.M600248-JLR200; Rensvold JW, 2013, CELL REP, V3, P237, DOI 10.1016/j.celrep.2012.11.029; Rodriguez-Cuenca S, 2012, FASEB J, V26, P1835, DOI 10.1096/fj.11-193631; Rong JX, 2007, DIABETES, V56, P1751, DOI 10.2337/db06-1135; Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807; Shechter I, 2003, J LIPID RES, V44, P2169, DOI 10.1194/jlr.M300285-JLR200; Tong WH, 2007, BIOMETALS, V20, P549, DOI 10.1007/s10534-006-9047-6; Volz K, 2008, CURR OPIN STRUC BIOL, V18, P106, DOI 10.1016/j.sbi.2007.12.010; Wang FF, 2013, P NATL ACAD SCI USA, V110, P18656, DOI 10.1073/pnas.1314863110; Wilson-Fritch L, 2003, MOL CELL BIOL, V23, P1085, DOI 10.1128/MCB.23.3.1085-1094.2003; Xu YZ, 2010, FASEB J, V24, P609, DOI 10.1096/fj.09-135731; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7	37	20	20	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1529	1539		10.1096/fj.14-258996	http://dx.doi.org/10.1096/fj.14-258996			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550467	Bronze			2022-12-28	WOS:000354115000037
J	Ashmore, T; Fernandez, BO; Evans, CE; Huang, Y; Branco-Price, C; Griffin, JL; Johnson, RS; Feelisch, M; Murray, AJ				Ashmore, Tom; Fernandez, Bernadette O.; Evans, Colin E.; Huang, Yun; Branco-Price, Cristina; Griffin, Julian L.; Johnson, Randall S.; Feelisch, Martin; Murray, Andrew J.			Suppression of erythropoiesis by dietary nitrate	FASEB JOURNAL			English	Article						kidney; oxygen sensing; hypoxia	NITRIC-OXIDE; IN-VIVO; GENE-EXPRESSION; HYPOXIA; ALTITUDE; HUMANS; TISSUE; ADAPTATION; ANEMIA; CELLS	In mammals, hypoxia-triggered erythropoietin release increases red blood cell mass to meet tissue oxygen demands. Using male Wistar rats, we unmask a previously unrecognized regulatory pathway of erythropoiesis involving suppressor control by the NO metabolite and ubiquitous dietary component nitrate. We find that circulating hemoglobin levels are modulated by nitrate at concentrations achievable by dietary intervention under normoxic and hypoxic conditions; a moderate dose of nitrate administered via the drinking water (7 mg NaNO3/kg body weight/d) lowered hemoglobin concentration and hematocrit after 6 d compared with nonsupplemented/NaCl-supplemented controls. The underlying mechanism is suppression of hepatic erythropoietin expression associated with the downregulation of tissue hypoxia markers, suggesting increased pO(2). At higher nitrate doses, however, a partial reversal of this effect occurred; this was accompanied by increased renal erythropoietin expression and stabilization of hypoxia-inducible factors, likely brought about by the relative anemia. Thus, hepatic and renal hypoxia-sensing pathways act in concert to modulate hemoglobin in response to nitrate, converging at an optimal minimal hemoglobin concentration appropriate to the environmental/physiologic situation. Suppression of hepatic erythropoietin expression by nitrate may thus act to decrease blood viscosity while matching oxygen supply to demand, whereas renal oxygen sensing could act as a brake, averting a potentially detrimental fall in hematocrit.	[Ashmore, Tom; Evans, Colin E.; Huang, Yun; Branco-Price, Cristina; Johnson, Randall S.; Murray, Andrew J.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England; [Ashmore, Tom; Griffin, Julian L.] Univ Cambridge, Dept Biochem, Cambridge CB2 3EG, England; [Fernandez, Bernadette O.; Feelisch, Martin] Univ Southampton, Fac Med Clin & Expt Sci, Southampton, Hants, England	University of Cambridge; University of Cambridge; University of Southampton	Murray, AJ (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Downing St, Cambridge CB2 3EG, England.	ajm267@cam.ac.uk	Feelisch, Martin/C-3042-2008; Johnson, Randall/AAM-1189-2021; Fernandez, Bernadette/AAG-7202-2020	Feelisch, Martin/0000-0003-2320-1158; Johnson, Randall/0000-0002-4084-6639; Fernandez, Bernadette/0000-0001-6337-0381; Evans, Colin/0000-0002-9251-357X; Murray, Andrew/0000-0002-0929-9315	British Heart Foundation Studentship [FS/09/050]; Research Councils UK; WYNG Foundation of Hong Kong; European Union Framework 7 Inheritance project; Wellcome Trust Principal research fellowship; Faculty of Medicine, University of Southampton; BBSRC [BB/H013539/1, BB/H013539/2] Funding Source: UKRI; MRC [MC_UP_A090_1006] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/H013539/1, BB/H013539/2] Funding Source: researchfish; Medical Research Council [MC_UP_A090_1006] Funding Source: researchfish	British Heart Foundation Studentship; Research Councils UK(UK Research & Innovation (UKRI)); WYNG Foundation of Hong Kong; European Union Framework 7 Inheritance project; Wellcome Trust Principal research fellowship(Wellcome Trust); Faculty of Medicine, University of Southampton; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by British Heart Foundation Studentship FS/09/050 (to T.A.). A.J.M. thanks the Research Councils UK for supporting his academic fellowship and the WYNG Foundation of Hong Kong for support. J.L.G is supported by the European Union Framework 7 Inheritance project, R.S.J. is supported by a Wellcome Trust Principal research fellowship, and M.F. is supported by funds from the Faculty of Medicine, University of Southampton.	Ashmore T, 2014, J PHYSIOL-LONDON, V592, P4715, DOI 10.1113/jphysiol.2014.275263; Beall CM, 2010, P NATL ACAD SCI USA, V107, P11459, DOI 10.1073/pnas.1002443107; Bryan NS, 2004, P NATL ACAD SCI USA, V101, P4308, DOI 10.1073/pnas.0306706101; CARO J, 1981, J LAB CLIN MED, V98, P860; Cokic VP, 2008, CURR TOP DEV BIOL, V82, P169, DOI 10.1016/S0070-2153(07)00007-5; Dame C, 1998, BLOOD, V92, P3218, DOI 10.1182/blood.V92.9.3218; Eckardt KU, 2005, EUR J CLIN INVEST, V35, P13, DOI 10.1111/j.1365-2362.2005.01525.x; Erzurum SC, 2007, P NATL ACAD SCI USA, V104, P17593, DOI 10.1073/pnas.0707462104; Evans CE, 2014, ARTERIOSCL THROM VAS, V34, P565, DOI 10.1161/ATVBAHA.113.302998; Evans CE, 2010, ARTERIOSCL THROM VAS, V30, P2443, DOI 10.1161/ATVBAHA.110.215038; Fandrey J, 2004, AM J PHYSIOL-REG I, V286, pR977, DOI 10.1152/ajpregu.00577.2003; Fandrey J, 2012, BLOOD, V120, P1760, DOI 10.1182/blood-2012-06-433201; Grocott MPW, 2009, NEW ENGL J MED, V360, P140, DOI 10.1056/NEJMoa0801581; Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104; Jelkmann W, 2011, J PHYSIOL-LONDON, V589, P1251, DOI 10.1113/jphysiol.2010.195057; Kang MJ, 2005, BIOGERONTOLOGY, V6, P27, DOI 10.1007/s10522-004-7381-z; Kim JW, 2012, CANCER RES, V72, P3187, DOI 10.1158/0008-5472.CAN-12-0534; Larsen FJ, 2011, CELL METAB, V13, P149, DOI 10.1016/j.cmet.2011.01.004; Levett DZ, 2011, SCI REP-UK, V1, DOI 10.1038/srep00109; Lundberg JO, 2008, NAT REV DRUG DISCOV, V7, DOI [10.1038/nrd2466, 10.1038/nrd2466-c2]; Martin DS, 2010, CRIT CARE, V14, DOI 10.1186/cc9078; Martin DS, 2010, EXP PHYSIOL, V95, P880, DOI 10.1113/expphysiol.2009.051656; MAXWELL PH, 1993, KIDNEY INT, V44, P1149, DOI 10.1038/ki.1993.362; Paliege A, 2010, KIDNEY INT, V77, P312, DOI 10.1038/ki.2009.460; Pannala AS, 2003, FREE RADICAL BIO MED, V34, P576, DOI 10.1016/S0891-5849(02)01353-9; Querbes W, 2012, BLOOD, V120, P1916, DOI 10.1182/blood-2012-04-423715; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Richalet JP, 2005, AM J RESP CRIT CARE, V172, P1427, DOI 10.1164/rccm.200505-807OC; Roberts L. D., 2014, DIABETES IN PRESS; Scortegagna M, 2005, BLOOD, V105, P3133, DOI 10.1182/blood-2004-05-1695; Siervo M, 2011, FREE RADICAL BIO MED, V51, P795, DOI 10.1016/j.freeradbiomed.2011.05.032; Simonson TS, 2010, SCIENCE, V329, P72, DOI 10.1126/science.1189406; Suliman HB, 2004, BLOOD, V104, P43, DOI 10.1182/blood-2003-07-2240; Todorov V, 2000, PFLUG ARCH EUR J PHY, V439, P445, DOI 10.1007/s004240050961; Tsui AKY, 2014, AM J PHYSIOL-REG I, V307, pR13, DOI 10.1152/ajpregu.00411.2013	35	14	14	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1102	1112		10.1096/fj.14-263004	http://dx.doi.org/10.1096/fj.14-263004			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25422368	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000350633000033
J	Gomez-Rodriguez, V; Orbe, J; Martinez-Aguilar, E; Rodriguez, JA; Fernandez-Alonso, L; Serneels, J; Bobadilla, M; Perez-Ruiz, A; Collantes, M; Mazzone, M; Paramo, JA; Roncal, C				Gomez-Rodriguez, Violeta; Orbe, Josune; Martinez-Aguilar, Esther; Rodriguez, Jose A.; Fernandez-Alonso, Leopoldo; Serneels, Jens; Bobadilla, Miriam; Perez-Ruiz, Ana; Collantes, Maria; Mazzone, Massimiliano; Paramo, Jose A.; Roncal, Carmen			Functional MMP-10 is required for efficient tissue repair after experimental hind limb ischemia	FASEB JOURNAL			English	Article						hypoxia; inflammation; matrix metalloproteinase; regeneration	MUSCLE-CELL MIGRATION; MATRIX METALLOPROTEINASE-10; ENDOTHELIAL-CELLS; CHEMOKINE EXPRESSION; EXTRACELLULAR-MATRIX; POTENTIAL ROLE; GRO-ALPHA; TNF-ALPHA; REGENERATION; ATHEROSCLEROSIS	We studied the role of matrix metallo-proteinase-10 (MMP-10) during skeletal muscle repair after ischemia using a model of femoral artery excision in wild-type (WT) and MMP-10 deficient (Mmp10(-/-)) mice. Functional changes were analyzed by small animal positron emission tomography and tissue morphology by immunohistochemistry. Gene expression and protein analysis were used to study the molecular mechanisms governed by MMP-10 in hypoxia. Early after ischemia, MMP-10 deficiency resulted in delayed tissue reperfusion (10%, P < 0.01) and in increased necrosis (2-fold, P < 0.01), neutrophil (4-fold, P < 0.01), and macrophage (1.5-fold, P < 0.01) infiltration. These differences at early time points resulted in delayed myotube regeneration in Mmp10(-/-) soleus at later stages (regeneratingmyofibers: 30 +/- 9% WTvs. 68 +/- 10% Mmp10(-/-), P < 0.01). The injection of MMP-10 into Mmp10(-/-) mice rescued the observed phenotype. A molecular analysis revealed higher levels of Cxcl1 mRNA (10-fold, P<0.05) and protein (30%) in the ischemic Mmp10(-/-) muscle resulting from a lack of transcriptional inhibition by MMP-10. This was further confirmed using siRNA against MMP-10 in vivo. Our results demonstrate an important role of MMP-10 for proper muscle repair after ischemia, and suggest that chemokine regulation such as Cxcl1 by MMP-10 is involved in muscle regeneration.	[Gomez-Rodriguez, Violeta; Orbe, Josune; Rodriguez, Jose A.; Paramo, Jose A.; Roncal, Carmen] Univ Navarra, Ctr Appl Med Res CIMA, Div Cardiovasc Sci, Lab Atherothrombosis, E-31080 Pamplona, Spain; [Bobadilla, Miriam; Perez-Ruiz, Ana] Univ Navarra, Ctr Appl Med Res CIMA, Div Canc, Cell Therapy Area, E-31080 Pamplona, Spain; [Martinez-Aguilar, Esther; Fernandez-Alonso, Leopoldo] Complejo Hop Navarra, Dept Vasc Surg, Pamplona, Spain; [Serneels, Jens; Mazzone, Massimiliano] VIB, Vesalius Res Ctr, Lab Mol Oncol & Angiogenesis, Leuven, Belgium; [Serneels, Jens; Mazzone, Massimiliano] Katholieke Univ Leuven, Dept Oncol, Vesalius Res Ctr, Lab Mol Oncol & Angiogenesis, Leuven, Belgium; [Collantes, Maria] CIMA, Small Anim Imaging Res Unit, Pamplona, Spain; [Collantes, Maria] Clin Univ Navarra, Pamplona, Spain	University of Navarra; University of Navarra; Flanders Institute for Biotechnology (VIB); KU Leuven; University of Navarra	Paramo, JA (corresponding author), CIMA, Div Cardiovasc Sci, Lab Atherothrombosis, Ave Pio XII 55, Navarra 31008, Spain.	japaramo@unav.es; croncalm@unav.es	Orbe, Josune/D-3082-2017; Rodriguez, Jose/G-7324-2015; Collantes, María/A-4641-2015; Pérez-Ruiz, Ana/I-2910-2015; Bobadilla, Miriam/H-9780-2015; Paramo, Jose A/D-6552-2017	Orbe, Josune/0000-0001-6300-7670; Rodriguez, Jose/0000-0002-2094-264X; Collantes, María/0000-0003-1162-1470; Pérez-Ruiz, Ana/0000-0002-9901-057X; Bobadilla, Miriam/0000-0002-7719-3483; Paramo, Jose A/0000-0003-1497-6242; Mazzone, Massimiliano/0000-0001-8824-4015; Roncal, Carmen/0000-0003-0616-9600	UTE Project CIMA (University of Navarra); European network ERANET [PRI-PIMNEU-2011-1334]; Ministerio de Salud [PI12/00710]; Ministerio de Educacion y Ciencia [SAF2009-12039]; Red de Investigacion Cardiovascular RIC [D12/0042/0009]; Foundation for Applied Medical Research (FIMA); Spanish Ministry of Science and Innovation [MICINN-PTQ-09-02-01941]	UTE Project CIMA (University of Navarra); European network ERANET; Ministerio de Salud; Ministerio de Educacion y Ciencia(Spanish Government); Red de Investigacion Cardiovascular RIC; Foundation for Applied Medical Research (FIMA); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This work was supported by UTE Project CIMA (University of Navarra), the European network ERANET (PRI-PIMNEU-2011-1334), the Ministerio de Salud (PI12/00710), the Ministerio de Educacion y Ciencia (SAF2009-12039), and Red de Investigacion Cardiovascular RIC (D12/0042/0009). V.G.R. was supported by a fellowship from the Foundation for Applied Medical Research (FIMA). C.R. was supported by the Spanish Ministry of Science and Innovation (MICINN-PTQ-09-02-01941). The authors thank W. Parks (University of Washington, Seattle) for kindly providing Mmp10<SUP>-/-</SUP> mice and L. Montori for technical assistance.	Bechara C, 2007, MED SCI MONITOR, V13, pRA87; Bedair H, 2007, J APPL PHYSIOL, V102, P2338, DOI 10.1152/japplphysiol.00670.2006; Bobadilla M, 2014, STEM CELLS DEV, V23, P1417, DOI 10.1089/scd.2013.0491; Brzoska E, 2012, BIOL CELL, V104, P722, DOI 10.1111/boc.201200022; Burbridge M. F., 2002, Angiogenesis, V5, P215, DOI 10.1023/A:1023889805133; Busti C, 2010, INTERN EMERG MED, V5, P13, DOI 10.1007/s11739-009-0283-y; Chang SR, 2006, CELL, V126, P321, DOI 10.1016/j.cell.2006.05.040; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chen XP, 2009, CELL ADHES MIGR, V3, P337, DOI 10.4161/cam.3.4.9338; Cheng XW, 2007, CIRC RES, V100, P904, DOI 10.1161/01.RES.0000260801.12916.b5; Coll B, 2010, KIDNEY INT, V78, P1275, DOI 10.1038/ki.2010.329; Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3; Dean RA, 2008, BLOOD, V112, P3455, DOI 10.1182/blood-2007-12-129080; Frisdal E, 2000, NEUROPATH APPL NEURO, V26, P11, DOI 10.1046/j.1365-2990.2000.00210.x; Gill JH, 2004, NEOPLASIA, V6, P777, DOI 10.1593/neo.04283; Griffin CA, 2010, J CELL SCI, V123, P3052, DOI 10.1242/jcs.066241; Hatfield KJ, 2010, CURR MED CHEM, V17, P4448; Hirsch AT, 2012, CIRCULATION, V125, P1449, DOI 10.1161/CIR.0b013e31824c39ba; Issa R, 2006, AM J PHYSIOL-LUNG C, V291, pL66, DOI 10.1152/ajplung.00384.2005; Johnson C, 2004, CIRC RES, V94, P262, DOI 10.1161/01.RES.0000111527.42357.62; Karalaki M, 2009, IN VIVO, V23, P779; Kassim SY, 2007, INFECT IMMUN, V75, P5640, DOI 10.1128/IAI.00799-07; Kharraz Y, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/491497; Lo HM, 2014, ACTA PHARMACOL SIN, V35, P339, DOI 10.1038/aps.2013.182; Lo HM, 2013, INT J MOL SCI, V14, P10090, DOI 10.3390/ijms140510090; Lorente L, 2009, CRIT CARE, V13, DOI 10.1186/cc8115; Martinez C, 2005, J PATHOL, V206, P100, DOI 10.1002/path.1755; Montero I, 2006, J AM COLL CARDIOL, V47, P1369, DOI 10.1016/j.jacc.2005.10.070; Muhs BE, 2004, J SURG RES, V117, P249, DOI 10.1016/j.jss.2003.09.009; Ohtake Y, 2006, J CELL SCI, V119, P3822, DOI 10.1242/jcs.03158; Orbe J, 2011, CIRCULATION, V124, P2909, DOI 10.1161/CIRCULATIONAHA.111.047100; Orbe J, 2007, J THROMB HAEMOST, V5, P91, DOI 10.1111/j.1538-7836.2006.02276.x; Orbe J, 1999, HAEMATOLOGICA, V84, P306; Peng H, 2012, PROTEIN CELL, V3, P875, DOI 10.1007/s13238-012-2092-8; Penuelas I, 2007, J NUCL MED, V48, P1216, DOI 10.2967/jnumed.106.039180; Rodriguez JA, 2008, FRONT BIOSCI-LANDMRK, V13, P2916, DOI 10.2741/2896; Saunders WB, 2005, J CELL SCI, V118, P2325, DOI 10.1242/jcs.02360; Starr AE, 2012, J BIOL CHEM, V287, P5848, DOI 10.1074/jbc.M111.314609; Tidball JG, 2010, AM J PHYSIOL-REG I, V298, pR1173, DOI 10.1152/ajpregu.00735.2009; Van Themsche C, 2004, J IMMUNOL, V173, P3605, DOI 10.4049/jimmunol.173.6.3605; Wang W, 2009, AM J PATHOL, V174, P541, DOI 10.2353/ajpath.2009.080509; Wilkins-Port CE, 2007, CELLS TISSUES ORGANS, V185, P116, DOI 10.1159/000101312; Zimowska M, 2012, TISSUE ENG PT A, V18, P1183, DOI [10.1089/ten.tea.2011.0459, 10.1089/ten.TEA.2011.0459]	43	15	15	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					960	972		10.1096/fj.14-259689	http://dx.doi.org/10.1096/fj.14-259689			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25414484	Green Submitted			2022-12-28	WOS:000350633000021
J	Grasa, P; Ploutarchou, P; Williams, SA				Grasa, Patricia; Ploutarchou, Panayiota; Williams, Suzannah A.			Oocytes lacking O-glycans alter follicle development and increase fertility by increasing follicle FSH sensitivity, decreasing apoptosis, and modifying GDF9:BMP15 expression	FASEB JOURNAL			English	Article						ovary; C1galt1; T-syn; ovulation rate; endocrine profile	GROWTH-DIFFERENTIATION FACTOR-9; BONE MORPHOGENETIC PROTEIN-15; ANTI-MULLERIAN HORMONE; PROGRAMMED CELL-DEATH; STIMULATING-HORMONE; GRANULOSA-CELLS; MOUSE OVARY; OVULATION RATE; IN-VITRO; CUMULUS CELL	The number of eggs ovulated varies within and between species and is influenced by many variables. However, the regulatory mechanisms remain poorly understood. We previously demonstrated a key role for the oocyte because mice generating oocytes deficient in core 1-derived O-glycans ovulate similar to 40-50% more eggs than Controls. Herewe analyze the basis of this phenotype using Mutant [core 1 beta 1,3-galactosyltransferase 1 (C1galt1)(FF): zona pellucida glycoprotein 3 Cre (ZP3Cre)] and Control (C1galt1FF) female mice. In culture, Mutant follicles exhibited delayed antrum formation [indicative of follicle stimulant hormone (FSH) dependence] and increased sensitivity to FSH. Although the Mutant estrous cycle was extended, comprehensive endocrine changes were not observed; rather FSH, LH, inhibin B, and anti-Mullerian hormone were temporally altered, revealing estrous cycle stage-specific modifications to the hypothalamic-pituitary-gonadal axis. At proestrus, when FSH levels were decreased in Mutants, ovaries contained more, smaller, preantral follicles. Mutant follicles exhibited reduced levels of apoptosis, and both B-cell lymphoma 2 (Bcl-2) and BCL-2associated X protein (Bax) were altered compared with Controls. Mutant ovaries also had an increase in the expression ratio of growth differentiation factor 9 (GDF9): bone morphogenetic protein 15 (BMP15) at diestrus. On the basis of these data, we propose that modified oocyte glycoproteins alter GDF9: BMP15 expression modifying follicle development resulting in the generation of more follicles. Thus, the oocyte is a key regulator of follicle development and has a crucial role in determining ovulation rate.-	[Grasa, Patricia; Ploutarchou, Panayiota; Williams, Suzannah A.] Univ Oxford, Womens Ctr, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England	University of Oxford	Williams, SA (corresponding author), Univ Oxford, Womens Ctr, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Level 3, Oxford OX3 9DU, England.	suzannah.williams@obs-gyn.ox.ac.uk		Williams, Suzannah/0000-0003-1798-976X	John Fell Fund Oxford University Press (University of Oxford)	John Fell Fund Oxford University Press (University of Oxford)	The authors thank Dr. Norah Spears, Dr. Tamara Sirey, Charlotte Holdsworth, Sophie Robin, and members of the animal house facility for technical assistance and Heidy Kaune for critical reading of the manuscript. This work was supported by the John Fell Fund Oxford University Press (University of Oxford).	ADASHI EY, 1992, ENDOCRIN METAB CLIN, V21, P1; Baker SJ, 1999, HUM REPROD UPDATE, V5, P153, DOI 10.1093/humupd/5.2.153; Barnett KR, 2006, HUM REPROD UPDATE, V12, P537, DOI 10.1093/humupd/dml022; Batista F, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.098103; Cai JH, 2007, BIOTECHNIQUES, V42, P503, DOI 10.2144/000112400; Carabatsos MJ, 1998, DEV BIOL, V204, P373, DOI 10.1006/dbio.1998.9087; Cortvrindt R, 1997, HUM REPROD, V12, P759, DOI 10.1093/humrep/12.4.759; Crawford JL, 2012, MOL CELL ENDOCRINOL, V348, P339, DOI 10.1016/j.mce.2011.09.033; Cui LL, 2011, THERIOGENOLOGY, V75, P867, DOI 10.1016/j.theriogenology.2010.10.029; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; DORRINGTON JH, 1983, J STEROID BIOCHEM, V19, P17, DOI 10.1016/S0022-4731(83)80003-X; Durlinger ALL, 2002, ENDOCRINOLOGY, V143, P1076, DOI 10.1210/en.143.3.1076; Durlinger ALL, 1999, ENDOCRINOLOGY, V140, P5789, DOI 10.1210/en.140.12.5789; Durlinger ALL, 2001, ENDOCRINOLOGY, V142, P4891, DOI 10.1210/en.142.11.4891; Edson MA, 2010, ENDOCRINOLOGY, V151, P358, DOI 10.1210/en.2009-0760; Eppig JJ, 2001, REPRODUCTION, V122, P829, DOI 10.1530/rep.0.1220829; FINDLAY JK, 1993, BIOL REPROD, V48, P15, DOI 10.1095/biolreprod48.1.15; FORTUNE JE, 1994, BIOL REPROD, V50, P225, DOI 10.1095/biolreprod50.2.225; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; Gifford JAH, 2009, BIOL REPROD, V80, P1282, DOI 10.1095/biolreprod.108.072280; Gilchrist RB, 2008, HUM REPROD UPDATE, V14, P159, DOI 10.1093/humupd/dmm040; Gosden R, 1997, BRIT MED BULL, V53, P644; HARTSHORNE GM, 1994, HUM REPROD, V9, P1003, DOI 10.1093/oxfordjournals.humrep.a138624; HILLIER SG, 1994, HUM REPROD, V9, P188, DOI 10.1093/oxfordjournals.humrep.a138480; HIRSHFIELD AN, 1978, BIOL REPROD, V19, P597, DOI 10.1095/biolreprod19.3.597; HIRSHFIELD AN, 1981, J ENDOCRINOL, V88, P67, DOI 10.1677/joe.0.0880067; Hussein MR, 2005, HUM REPROD UPDATE, V11, P162, DOI 10.1093/humupd/dmi001; Knight PG, 2006, REPRODUCTION, V132, P191, DOI 10.1530/rep.1.01074; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; Langhammer M, 2014, REPRODUCTION, V147, P427, DOI 10.1530/REP-13-0425; Lin JY, 2012, REPRODUCTION, V144, P557, DOI 10.1530/REP-12-0267; Matsuda F, 2012, J REPROD DEVELOP, V58, P44, DOI 10.1262/jrd.2011-012; Matzuk MM, 2002, SCIENCE, V296, P2178, DOI 10.1126/science.1071965; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; McGee EA, 1997, BIOL REPROD, V57, P990, DOI 10.1095/biolreprod57.5.990; McGee EA, 2000, ENDOCR REV, V21, P200, DOI 10.1210/er.21.2.200; McIntosh CJ, 2008, BIOL REPROD, V79, P889, DOI 10.1095/biolreprod.108.068163; McIntosh CJ, 2012, REPRODUCTION, V143, P195, DOI 10.1530/REP-11-0336; McMahon HE, 2008, ENDOCRINOLOGY, V149, P2807, DOI 10.1210/en.2007-1550; McNatty KP, 2005, GENET SEL EVOL, V37, pS25, DOI 10.1051/gse:2004029; McNeilly JR, 2011, BIOL REPROD, V85, P584, DOI 10.1095/biolreprod.110.086264; Mottershead DG, 2012, MOL HUM REPROD, V18, P121, DOI 10.1093/molehr/gar056; Murray AA, 2008, MOL HUM REPROD, V14, P75, DOI 10.1093/molehr/gam092; NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Orisaka M, 2006, MOL ENDOCRINOL, V20, P2456, DOI 10.1210/me.2005-0357; Otsuka F, 2000, J BIOL CHEM, V275, P39523, DOI 10.1074/jbc.M007428200; Otsuka F, 2001, J BIOL CHEM, V276, P11387, DOI 10.1074/jbc.M010043200; Otsuka F, 2011, MOL REPROD DEV, V78, P9, DOI 10.1002/mrd.21265; Pawlowski J, 2000, P NATL ACAD SCI USA, V97, P529, DOI 10.1073/pnas.97.2.529; PEDERSEN T, 1968, J REPROD FERTIL, V17, P555, DOI 10.1530/jrf.0.0170555; Pelosi E, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2861; Peng J, 2013, P NATL ACAD SCI USA, V110, pE776, DOI 10.1073/pnas.1218020110; Reader KL, 2011, REPRODUCTION, V142, P123, DOI 10.1530/REP-10-0490; Rodgers RJ, 2010, BIOL REPROD, V82, P1021, DOI 10.1095/biolreprod.109.082941; SCHWARTZ NB, 1974, BIOL REPROD, V10, P236, DOI 10.1095/biolreprod10.2.236; Seifer D. B., 2014, J ASSIST REPROD GENE; Shi SL, 2004, MOL CELL BIOL, V24, P9920, DOI 10.1128/MCB.24.22.9920-9929.2004; Slot KA, 2006, J ENDOCRINOL, V188, P179, DOI 10.1677/joe.1.06165; Su WH, 2010, IUBMB LIFE, V62, P852, DOI 10.1002/iub.398; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Tsujimoto H, 2001, CLIN EXP IMMUNOL, V126, P355, DOI 10.1046/j.1365-2249.2001.01675.x; van Delft MF, 2006, CELL RES, V16, P203, DOI 10.1038/sj.cr.7310028; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vitt UA, 2000, BIOL REPROD, V62, P370, DOI 10.1095/biolreprod62.2.370; Wang XL, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.108365; Welt CK, 2001, J CLIN ENDOCR METAB, V86, P330, DOI 10.1210/jc.86.1.330; WHITTEN WK, 1956, J ENDOCRINOL, V13, P399, DOI 10.1677/joe.0.0130399; WHITTEN WK, 1959, J ENDOCRINOL, V18, P102, DOI 10.1677/joe.0.0180102; Williams SA, 2008, FASEB J, V22, P2273, DOI 10.1096/fj.07-101709; Williams SA, 2007, J CELL SCI, V120, P1341, DOI 10.1242/jcs.004291; Wu XM, 2004, MOL ENDOCRINOL, V18, P1509, DOI 10.1210/me.2003-0399; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854	73	9	9	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					525	539		10.1096/fj.14-253757	http://dx.doi.org/10.1096/fj.14-253757			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25416550				2022-12-28	WOS:000349370400016
J	Zhou, Z; Hu, TS; Xu, ZH; Lin, ZH; Zhang, ZS; Feng, T; Zhu, LC; Rong, YP; Shen, H; Luk, JM; Zhang, XW; Qin, N				Zhou, Zheng; Hu, Taishan; Xu, Zhiheng; Lin, Zhaohu; Zhang, Zhisen; Feng, Teng; Zhu, Liangcheng; Rong, Yiping; Shen, Hong; Luk, John M.; Zhang, Xiongwen; Qin, Ning			Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides	FASEB JOURNAL			English	Article						disulfide cyclization; HCC xenograft; TEAD-YAP crystal structure	ORGAN SIZE CONTROL; YES-ASSOCIATED PROTEIN; TRANSCRIPTION FACTORS; CELL-PROLIFERATION; SIGNALING PATHWAY; APOPTOSIS; VALIDATION; STABILITY; MUTATION; ROLES	Hippo signaling pathway is emerging as a novel target for anticancer therapy because it plays key roles in organ size control and tumorigenesis. As the downstream effectors, Yes-associated protein (YAP)transcriptional enhancer activation domain family member (TEAD) association is essential for YAP-driven oncogenic activity, while TEAD is largely dispensable for normal tissue growth. We present the design of YAP-like peptides (17mer) to occupy the interface 3 on TEAD. Introducing cysteines at YAP sites 87 and 96 can induce disulfide formation, as confirmed by crystallography. The engineered peptide significantly improves the potency in disrupting YAP-TEAD interaction in vitro. To confirm that blocking YAP-TEAD complex formation by directly targeting on TEAD is a valid approach, we report a significant reduction in tumor growth rate in a hepatocellular carcinoma xenograft model after introducing the dominant-negative mutation (Y406H) of TEAD1 to abolish YAP-TEAD interaction. Our results suggest that targeting TEAD is a promising strategy against YAP-induced oncogenesis.-Zhou, Z., Hu, T., Xu, Z., Lin, Z., Zhang, Z., Feng, T., Zhu, L., Rong, Y., Shen, H., Luk, J. M., Zhang, X., Qin, N. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.	[Zhou, Zheng; Hu, Taishan; Xu, Zhiheng; Lin, Zhaohu; Zhang, Zhisen; Feng, Teng; Zhu, Liangcheng; Rong, Yiping; Shen, Hong; Luk, John M.; Zhang, Xiongwen; Qin, Ning] Roche Innovat Ctr Shanghai, Shanghai 201203, Peoples R China		Zhou, Z (corresponding author), Roche Innovat Ctr Shanghai, Bldg 5,Lane 720,Cai Lun Rd, Shanghai 201203, Peoples R China.	joe.zhou.jz2@roche.com	Luk, John/A-4085-2008	Luk, John/0000-0002-6323-7940				Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308; Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693; Battye TGG, 2011, ACTA CRYSTALLOGR D, V67, P271, DOI 10.1107/S0907444910048675; Bechara C, 2013, FEBS LETT, V587, P1693, DOI 10.1016/j.febslet.2013.04.031; Chen LM, 2010, GENE DEV, V24, P290, DOI 10.1101/gad.1865310; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Cottini F, 2014, NAT MED, V20, P599, DOI 10.1038/nm.3562; Daniels DS, 2007, J AM CHEM SOC, V129, P14578, DOI 10.1021/ja0772445; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061; Fossdal R, 2004, HUM MOL GENET, V13, P975, DOI 10.1093/hmg/ddh106; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Gentilucci L, 2010, CURR PHARM DESIGN, V16, P3185, DOI 10.2174/138161210793292555; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hilman D, 2011, MOL BIOL EVOL, V28, P2403, DOI 10.1093/molbev/msr065; Hruby VJ, 2002, NAT REV DRUG DISCOV, V1, P847, DOI 10.1038/nrd939; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kitagawa M, 2007, BIOCHEM BIOPH RES CO, V361, P1022, DOI 10.1016/j.bbrc.2007.07.129; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810; Liu AM, 2010, EXPERT OPIN THER TAR, V14, P855, DOI 10.1517/14728222.2010.499361; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lu J, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/187070; Luk JM, 2014, NAT MED, V20, P587, DOI 10.1038/nm.3593; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Park HW, 2013, TRENDS PHARMACOL SCI, V34, P581, DOI 10.1016/j.tips.2013.08.006; Pernot M, 2011, EXPERT OPIN DRUG MET, V7, P793, DOI 10.1517/17425255.2011.574126; Pobbati AV, 2013, CANCER BIOL THER, V14, P390, DOI 10.4161/cbt.23788; Pobbati AV, 2012, STRUCTURE, V20, P1135, DOI 10.1016/j.str.2012.04.004; Roxin A, 2012, FUTURE MED CHEM, V4, P1601, DOI [10.4155/FMC.12.75, 10.4155/fmc.12.75]; Sawada A, 2008, MOL CELL BIOL, V28, P3177, DOI 10.1128/MCB.01759-07; Stanger BZ, 2012, GENE DEV, V26, P1263, DOI 10.1101/gad.196501.112; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang ZZ, 2014, ACS MED CHEM LETT, V5, P993, DOI 10.1021/ml500160m; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001	50	96	102	2	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					724	732		10.1096/fj.14-262980	http://dx.doi.org/10.1096/fj.14-262980			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25384421				2022-12-28	WOS:000349370400032
J	Yu, WQ; Sun, XF; Robson, SC; Hill, WG				Yu, Weiqun; Sun, Xiaofeng; Robson, Simon C.; Hill, Warren G.			ADP-induced bladder contractility is mediated by P2Y(12) receptor and temporally regulated by ectonucleotidases and adenosine signaling	FASEB JOURNAL			English	Article						detrusor; urinary tract; myography; micturition; mechanotransduction	RAT URINARY-BLADDER; SMOOTH-MUSCLE-CELLS; ATROPINE-RESISTANT; PURINERGIC NEUROTRANSMISSION; ANTITHROMBOTIC DRUGS; HUMAN PLATELETS; PIG; IDENTIFICATION; MECHANISMS; EXPRESSION	Purinergic signaling comprises one key pathway in modulating bladder smooth muscle (BSM) contractility, disorders of which become highly prevalent with aging. ADP was first observed to modulate BSM contractility >40 yr ago, yet the underlying molecular mechanism still remains unclear. Here, we demonstrate, using myography, that ADP and ADP beta S dose-dependently induce mouse BSM contraction, and ADP-induced BSM contraction is blocked by a selective P2Y(12) receptor (P2Y(12)R) antagonist, PSB 0739 (25 mu M), but is unaffected by P2Y(1) and P2Y(13) receptor antagonists. P2Y(12)R in BSM exhibits distinct pharmacological properties that are different from P2Y(12)R in platelets. After an immediate contraction, prolonged exposure to ADP causes BSM to become refractory to further ADP-mediated contraction. However, in mice lacking ecto-nucleotidases Entpd1 (ATP -> ADP -> AMP) or Nt5e (AMP -> adenosine), or by inhibiting adenosine signaling, the refractory response was altered, resulting in repeated BSM contractions in response to repeated ADP (0.1-1 mM) stimulation. Our data indicate that P2Y(12)R undergoes slow desensitization; ADP-P2Y(12) signaling is tightly regulated by Entpd1/Nt5e activity and adenosine receptors; and ADP-adenosine signaling play an important role in modulating P2X-mediated BSM contraction. The identification of P2Y(12)R in BSM, and the current clinical availability of P2Y(12)R inhibitors, such as clopidogrel, offers potentially novel treatment strategies for bladder contractility disorders.	[Yu, Weiqun; Hill, Warren G.] Beth Israel Deaconess Med Ctr, Div Nephrol, Lab Voiding Dysfunct, Boston, MA 02215 USA; [Sun, Xiaofeng; Robson, Simon C.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Yu, WQ (corresponding author), Beth Israel Deaconess Med Ctr, RN390,99 Brookline Ave, Boston, MA 02215 USA.	wyu2@bidmc.harvard.edu	Robson, Simon C./AAA-8537-2021; Hill, Warren/AAM-1917-2020	Hill, Warren/0000-0002-2772-7264	U.S. National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health [DK-095922, DK-083299, AI045897, CA164970]; NATIONAL CANCER INSTITUTE [R21CA164970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI045897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K99DK095922, R01DK083299] Funding Source: NIH RePORTER	U.S. National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health (http://nih.gov/) grants DK-095922 (to W.Y.), DK-083299 (to W.G.H.), and AI045897 and CA164970 (to S.C.R.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors declare no conflicts of interest.	Andersson KE, 2004, PHYSIOL REV, V84, P935, DOI 10.1152/physrev.00038.2003; Aronsson P, 2010, BASIC CLIN PHARMACOL, V107, P603, DOI 10.1111/j.1742-7843.2010.00554.x; Bayliss M, 1999, J UROLOGY, V162, P1833, DOI 10.1016/S0022-5347(05)68247-X; Berridge MJ, 2008, J PHYSIOL-LONDON, V586, P5047, DOI 10.1113/jphysiol.2008.160440; BURNSTOCK G, 1984, BRIT J PHARMACOL, V82, P369, DOI 10.1111/j.1476-5381.1984.tb10771.x; BURNSTOCK G, 1972, BRIT J PHARMACOL, V44, P451, DOI 10.1111/j.1476-5381.1972.tb07283.x; BURNSTOCK G, 1972, BRIT J PHARMACOL, V46, P234, DOI 10.1111/j.1476-5381.1972.tb06868.x; Burnstock Geoffrey, 2011, Front Biosci (Elite Ed), V3, P896; Cattaneo M, 2004, BIOCHEM PHARMACOL, V68, P1995, DOI 10.1016/j.bcp.2004.06.026; Coyne KS, 2009, BJU INT, V104, P352, DOI 10.1111/j.1464-410X.2009.08427.x; Dixon AK, 1996, BRIT J PHARMACOL, V118, P1461, DOI 10.1111/j.1476-5381.1996.tb15561.x; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Evans DJW, 2009, CIRCULATION, V119, P116, DOI 10.1161/CIRCULATIONAHA.107.762690; Filippov AK, 2000, BRIT J PHARMACOL, V129, P1063, DOI 10.1038/sj.bjp.0703185; FINKBEINER AE, 1980, UROLOGY, V16, P650, DOI 10.1016/0090-4295(80)90582-8; Fontana P, 2003, CIRCULATION, V108, P989, DOI 10.1161/01.CIR.0000085073.69189.88; Ford Anthony P D W, 2011, Handb Exp Pharmacol, P485, DOI 10.1007/978-3-642-16499-6_22; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Fry CH, 2012, AM J PHYSIOL-RENAL, V302, pF1447, DOI 10.1152/ajprenal.00436.2011; Gachet C, 2012, PURINERG SIGNAL, V8, P609, DOI 10.1007/s11302-012-9303-x; Geiger J, 1999, ARTERIOSCL THROM VAS, V19, P2007, DOI 10.1161/01.ATV.19.8.2007; Gopalakrishnan SM, 2002, J PHARMACOL EXP THER, V300, P910, DOI 10.1124/jpet.300.3.910; Guidetti GF, 2008, J BIOL CHEM, V283, P28795, DOI 10.1074/jbc.M801588200; Hardy AR, 2005, BLOOD, V105, P3552, DOI 10.1182/blood-2004-07-2893; HASHIMOTO M, 1995, BRIT J PHARMACOL, V115, P636, DOI 10.1111/j.1476-5381.1995.tb14979.x; Hogberg C, 2010, INT J CARDIOL, V142, P187, DOI 10.1016/j.ijcard.2008.12.091; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; HUMPHRIES RG, 1994, BRIT J PHARMACOL, V113, P1057, DOI 10.1111/j.1476-5381.1994.tb17100.x; Kennedy C, 2007, J NEUROSCI, V27, P845, DOI 10.1523/JNEUROSCI.3115-06.2007; Lee CW, 2011, AM J CARDIOL, V108, P799, DOI 10.1016/j.amjcard.2011.05.008; Liu GM, 2005, AM J PHYSIOL-RENAL, V288, pF1220, DOI 10.1152/ajprenal.00449.2004; MACFARLANE DE, 1983, J CLIN INVEST, V71, P420, DOI 10.1172/JCI110786; McMurray G, 1998, BRIT J PHARMACOL, V123, P1579, DOI 10.1038/sj.bjp.0701774; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; Naramatsu M, 1997, BRIT J PHARMACOL, V122, P558, DOI 10.1038/sj.bjp.0700157; O'Reilly BA, 2001, BJU INT, V87, P617, DOI 10.1046/j.1464-410x.2001.02179.x; PALEA S, 1993, J UROLOGY, V150, P2007, DOI 10.1016/S0022-5347(17)35955-4; PALEA S, 1994, J PHARMACOL EXP THER, V269, P193; Palmer RK, 1998, MOL PHARMACOL, V54, P1118, DOI 10.1124/mol.54.6.1118; Rauch BH, 2010, ARTERIOSCL THROM VAS, V30, P2434, DOI 10.1161/ATVBAHA.110.213702; Ruggieri MR, 2006, NAT CLIN PRACT UROL, V3, P206, DOI 10.1038/ncpuro0456; SIBLEY GNA, 1984, J PHYSIOL-LONDON, V354, P431, DOI 10.1113/jphysiol.1984.sp015386; Staritz P, 2009, INT J CARDIOL, V133, P341, DOI 10.1016/j.ijcard.2007.12.118; SUZUKI H, 1994, BRIT J PHARMACOL, V112, P117, DOI 10.1111/j.1476-5381.1994.tb13039.x; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Uvin P, 2013, EUR UROL, V64, P502, DOI 10.1016/j.eururo.2013.05.031; Wihlborg AK, 2004, ARTERIOSCL THROM VAS, V24, P1810, DOI 10.1161/01.ATV.0000142376.30582.ed; Wu C, 2004, J PHYSIOL-LONDON, V559, P231, DOI 10.1113/jphysiol.2004.067934; Yoshida M, 2004, UROLOGY, V63, P17, DOI 10.1016/j.urology.2003.11.003; Yoshida M, 2001, EXP GERONTOL, V36, P99, DOI 10.1016/S0531-5565(00)00175-3; Yu WQ, 2013, FASEB J, V27, P1895, DOI 10.1096/fj.12-219006; Yu WQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018704; Zhang FL, 2001, J BIOL CHEM, V276, P8608, DOI 10.1074/jbc.M009718200; Zhong XT, 2004, FEBS LETT, V562, P111, DOI 10.1016/S0014-5793(04)00191-7	54	12	12	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5288	5298		10.1096/fj.14-255885	http://dx.doi.org/10.1096/fj.14-255885			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25208846	Green Published			2022-12-28	WOS:000345894500023
J	Gwak, Y; Jung, W; Lee, Y; Kim, JS; Kim, CG; Ju, JH; Song, C; Hyun, JK; Jin, E				Gwak, Yunho; Jung, Woongsic; Lee, Yew; Kim, Ji Sook; Kim, Chul Geun; Ju, Ji-Hyun; Song, Chihong; Hyun, Jae-Kyung; Jin, EonSeon			An intracellular antifreeze protein from an Antarctic microalga that responds to various environmental stresses	FASEB JOURNAL			English	Article						Chaetoceros neogracile; immunogold labeling; ice-binding site	ICE-BINDING PROTEINS; CIS-ACTING ELEMENTS; SEA-ICE; REGULATORY ELEMENTS; STRUCTURE PREDICTION; DEHYDRATION STRESS; GENE-EXPRESSION; PROMOTER; LIGHT; IDENTIFICATION	The structure and function of the Antarctic marine diatom Chaetoceros neogracile antifreeze protein (Cn-AFP), as well as its expression levels and characteristics of the ice-binding site, were analyzed in the present study. In silico analysis revealed that the Cn-AFP promoter contains both light- and temperature-responsive elements. Northern and Western blot analyses demonstrated that both Cn-AFP transcript and protein expression were strongly and rapidly stimulated by freezing, as well as temperature and high light stress. Immunogold labeling revealed that Cn-AFP is preferentially localized to the intracellular space near the chloroplast membrane. Recombinant Cn-AFP had clear antifreeze activity. Protein-folding simulation was used to predict the putative ice-binding sites in Cn-AFP, and site-directed mutagenesis of the Cn-AFP b-face confirmed their identification.Gwak, Y., Jung, W., Lee, Y., Kim, J. S., Kim, C. G., Ju, J.-H., Song, C., Hyun, J.-K., Jin, E. An intracellular antifreeze protein from an Antarctic microalga that responds to various environmental stresses.	[Gwak, Yunho; Jung, Woongsic; Lee, Yew; Kim, Ji Sook; Kim, Chul Geun; Ju, Ji-Hyun; Jin, EonSeon] Hanyang Univ, Res Inst Nat Sci, Dept Life Sci, Seoul 133791, South Korea; [Jung, Woongsic] Korea Polar Res Inst, Div Polar Life Sci, Inchon, South Korea; [Song, Chihong; Hyun, Jae-Kyung] Korea Basic Sci Inst, Div Electron Microscop Res, Taejon, South Korea	Hanyang University; Korea Institute of Ocean Science & Technology (KIOST); Korea Polar Research Institute (KOPRI); Korea Basic Science Institute (KBSI)	Jin, E (corresponding author), Hanyang Univ, Res Inst Nat Sci, Dept Life Sci, Seoul 133791, South Korea.	hjk022@kbsi.re.kr; esjin@hanyang.ac.kr	Jin, EonSeon/AAW-6839-2020; Hyun, Jaekyung/AAK-2521-2020	Jin, EonSeon/0000-0001-5691-0124; Hyun, Jaekyung/0000-0003-2914-537X; Kim, Chul Geun/0000-0002-5848-3338	Korea Carbo Capture and Sequestration (CCS) Research and Development (R&D) Center (KCRC) - Korean government [Ministry of Science, Information, Communications and Technology (ICT), and Future Planning; National Research Foundation (NRF)] [2014M1A8A1049273]; NRF of Korea [NRF-C1ABA001-2010-0020501]	Korea Carbo Capture and Sequestration (CCS) Research and Development (R&D) Center (KCRC) - Korean government [Ministry of Science, Information, Communications and Technology (ICT), and Future Planning; National Research Foundation (NRF)]; NRF of Korea	This work was supported by a Korea Carbo Capture and Sequestration (CCS) Research and Development (R&D) Center (KCRC), grant funded by the Korean government [Ministry of Science, Information, Communications and Technology (ICT), and Future Planning; National Research Foundation (NRF)-2014M1A8A1049273]. This research was also supported by the NRF of Korea (grant NRF-C1ABA001-2010-0020501)	Abe H, 2003, PLANT CELL, V15, P63, DOI 10.1105/tpc.006130; Agarwal M, 2006, J BIOL CHEM, V281, P37636, DOI 10.1074/jbc.M605895200; Bayer-Giraldi M, 2010, ENVIRON MICROBIOL, V12, P1041, DOI 10.1111/j.1462-2920.2009.02149.x; Chang WC, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-561; Choi HG, 2008, NOVA HEDWIGIA, P7; Daraselia ND, 1996, PLANT PHYSIOL, V112, P727, DOI 10.1104/pp.112.2.727; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DIAZDELEON F, 1993, PLANT PHYSIOL, V101, P1117, DOI 10.1104/pp.101.3.1117; Doucet D, 2000, EUR J BIOCHEM, V267, P6082, DOI 10.1046/j.1432-1327.2000.01694.x; DUMAN JG, 1976, COMP BIOCHEM PHYS B, V54, P375, DOI 10.1016/0305-0491(76)90260-1; FELDBRUGGE M, 1994, PLANT CELL, V6, P1607, DOI 10.1105/tpc.6.11.1607; Garnham CP, 2011, P NATL ACAD SCI USA, V108, P7363, DOI 10.1073/pnas.1100429108; GIULIANO G, 1988, P NATL ACAD SCI USA, V85, P7089, DOI 10.1073/pnas.85.19.7089; Graether SP, 2000, NATURE, V406, P325, DOI 10.1038/35018610; Graether SP, 2004, EUR J BIOCHEM, V271, P3285, DOI 10.1111/j.1432-1033.2004.04256.x; Griffith M, 2004, TRENDS PLANT SCI, V9, P399, DOI 10.1016/j.tplants.2004.06.007; Gwak IG, 2010, MAR BIOTECHNOL, V12, P630, DOI 10.1007/s10126-009-9250-x; Hartmann U, 2005, PLANT MOL BIOL, V57, P155, DOI 10.1007/s11103-004-6910-0; Higo K, 1999, NUCLEIC ACIDS RES, V27, P297, DOI 10.1093/nar/27.1.297; Howard EI, 2011, J MOL RECOGNIT, V24, P724, DOI 10.1002/jmr.1130; Hudson ME, 2003, PLANT PHYSIOL, V133, P1605, DOI 10.1104/pp.103.030437; Hwang YS, 2008, BIOCHEM BIOPH RES CO, V367, P635, DOI 10.1016/j.bbrc.2007.12.176; Janech MG, 2006, J PHYCOL, V42, P410, DOI 10.1111/j.1529-8817.2006.00208.x; Jiang C, 1996, PLANT MOL BIOL, V30, P679, DOI 10.1007/BF00049344; Jiao YL, 2005, PLANT CELL, V17, P3239, DOI 10.1105/tpc.105.035840; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Jung G, 2007, J MICROBIOL BIOTECHN, V17, P1330; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; Kondo H, 2012, P NATL ACAD SCI USA, V109, P9360, DOI 10.1073/pnas.1121607109; Lauersen KJ, 2011, CRYOBIOLOGY, V62, P194, DOI 10.1016/j.cryobiol.2011.03.003; Lee JH, 2012, J BIOL CHEM, V287, P11460, DOI 10.1074/jbc.M111.331835; Lescot M, 2002, NUCLEIC ACIDS RES, V30, P325, DOI 10.1093/nar/30.1.325; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Marshall CB, 2002, FEBS LETT, V529, P261, DOI 10.1016/S0014-5793(02)03355-0; Middleton AJ, 2012, J MOL BIOL, V416, P713, DOI 10.1016/j.jmb.2012.01.032; Middleton AJ, 2009, FEBS LETT, V583, P815, DOI 10.1016/j.febslet.2009.01.035; NG NFL, 1992, J BIOL CHEM, V267, P16069; Nishimiya Y, 2008, J MOL BIOL, V382, P734, DOI 10.1016/j.jmb.2008.07.042; Piechulla B, 1998, PLANT MOL BIOL, V38, P655, DOI 10.1023/A:1006094015513; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Raymond JA, 2007, FEMS MICROBIOL ECOL, V61, P214, DOI 10.1111/j.1574-6941.2007.00345.x; Raymond JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035968; Raymond JA, 2009, J PHYCOL, V45, P130, DOI 10.1111/j.1529-8817.2008.00623.x; Reyes JC, 2004, PLANT PHYSIOL, V134, P1718, DOI 10.1104/pp.103.037788; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Scotter AJ, 2006, CRYOBIOLOGY, V53, P229, DOI 10.1016/j.cryobiol.2006.06.006; Simpson SD, 2003, PLANT J, V33, P259, DOI 10.1046/j.1365-313X.2003.01624.x; Sorhannus U, 2011, EVOL BIOINFORM, V7, P279, DOI 10.4137/EBO.S8321; Thomas DN, 2002, SCIENCE, V295, P641, DOI 10.1126/science.1063391; Uhlig C, 2011, CRYOBIOLOGY, V63, P220, DOI 10.1016/j.cryobiol.2011.08.005; URAO T, 1993, PLANT CELL, V5, P1529, DOI 10.1105/tpc.5.11.1529; von Gromoff ED, 2006, NUCLEIC ACIDS RES, V34, P4767, DOI 10.1093/nar/gkl602; Wenkel S, 2006, PLANT CELL, V18, P2971, DOI 10.1105/tpc.106.043299; Zhou DX, 1999, TRENDS PLANT SCI, V4, P210, DOI 10.1016/S1360-1385(99)01418-1	56	16	17	2	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4924	4935		10.1096/fj.14-256388	http://dx.doi.org/10.1096/fj.14-256388			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25114178				2022-12-28	WOS:000344050900029
J	Yang, XH; Yang, JG; Li, L; Sun, LY; Yi, X; Han, X; Si, WZ; Yan, RR; Chen, Z; Xie, GJ; Li, WJ; Shang, YF; Liang, J				Yang, Xiaohan; Yang, Jianguo; Li, Lei; Sun, Luyang; Yi, Xia; Han, Xiao; Si, Wenzhe; Yan, Ruorong; Chen, Zhe; Xie, Guojia; Li, Wanjin; Shang, Yongfeng; Liang, Jing			PAAT, a novel ATPase and trans-regulator of mitochondrial ABC transporters, is critically involved in the maintenance of mitochondrial homeostasis	FASEB JOURNAL			English	Article						oxidative stress; NBD domain; cell death; iron metabolism	LINKED SIDEROBLASTIC ANEMIA; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; SIGNATURE SEQUENCE; DNA-DAMAGE; GENE; IDENTIFICATION; MEMBRANE; HOMOLOGY; MUTATION	ATP-binding cassette (ABC) transporters are implicated in a diverse range of physiological and pathophysiological processes, such as cholesterol and lipid transportation and multidrug resistance. Despite the considerable efforts made in understanding of the cellular function of ABC proteins, the regulation mechanism of this type of protein is still poorly defined. Here we report the identification and functional characterization of a novel ATPase protein, protein associated with ABC transporters (PAAT), in humans. PAAT contains a nucleotide-binding domain (NBD)-like domain and a signal for intramitochondrial sorting. We showed that PAAT is localized in both the cytoplasm and the mitochondria and has an intrinsic ATPase activity. PAAT physically interacts with the 3 known mitochondrial inner membrane ABC proteins, ABCB7, ABCB8, and ABCB10, but not ABCB1, ABCB6, or ABCG2, and functionally regulates the transport of ferric nutrients and heme biosynthesis. Significantly, PAAT deficiency promotes cell death, reduces mitochondrial potential, and sensitizes mitochondria to oxidative stress-induced DNA damages. Our experiments revealed that PAAT is a novel ATPase and a trans-regulator of mitochondrial ABC transporters that plays an important role in the maintenance of mitochondrial homeostasis and cell survival.Yang, X., Yang, J., Li, L., Sun, L., Yi, X., Han, X., Si, W., Yan, R., Chen, Z., Xie, G., Li, W., Shang, Y., Liang, J. PAAT, a novel ATPase and trans-regulator of mitochondrial ABC transporters, is critically involved in the maintenance of mitochondrial homeostasis.	[Yang, Xiaohan; Yang, Jianguo; Li, Lei; Sun, Luyang; Yi, Xia; Han, Xiao; Si, Wenzhe; Yan, Ruorong; Chen, Zhe; Xie, Guojia; Li, Wanjin; Shang, Yongfeng; Liang, Jing] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100191, Peoples R China; [Si, Wenzhe; Shang, Yongfeng] Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Tianjin, Peoples R China	Peking University; Tianjin Medical University	Liang, J (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.	liang_jing@hsc.pku.edu.cn	Han, Xiao/A-1109-2017; Chen, Zhe/AAA-3235-2020	Han, Xiao/0000-0002-5395-4022; Chen, Zhe/0000-0002-5303-9879; Xie, Guojia/0000-0002-8250-6157; Han, Xiao/0000-0002-6024-6286	National Natural Science Foundation of China [81130048, 30921062, 31371372, 31371301]; Ministry of Science and Technology of China 973 Program [2011CB504204, 2014CB542004]; Beijing Municipal Natural Science Foundation [7132128]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China 973 Program(Ministry of Science and Technology, ChinaNational Basic Research Program of China); Beijing Municipal Natural Science Foundation(Beijing Natural Science Foundation)	This work was supported by National Natural Science Foundation of China grants 81130048 and 30921062 to Y.S.), 31371372 (to X.Y.), and 31371301 (to J.L.); Ministry of Science and Technology of China 973 Program grants 2011CB504204 (to Y.S.) and 2014CB542004 (to J.L.); and Beijing Municipal Natural Science Foundation grant 7132128 (to X.Y.).	ALLIGNET J, 1992, GENE, V117, P45, DOI 10.1016/0378-1119(92)90488-B; Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Ardehali H, 2005, CIRC RES, V97, P740, DOI 10.1161/01.RES.0000186277.12336.11; Bekri S, 2000, BLOOD, V96, P3256; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Burke MA, 2007, TRANSL RES, V150, P73, DOI 10.1016/j.trsl.2007.03.002; Cavadini P, 2007, BLOOD, V109, P3552, DOI 10.1182/blood-2006-08-041632; Chavan H, 2013, J BIOL CHEM, V288, P22658, DOI 10.1074/jbc.M113.485284; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen W, 2009, P NATL ACAD SCI USA, V106, P16263, DOI 10.1073/pnas.0904519106; Chou KC, 2001, PROTEIN ENG, V14, P75, DOI 10.1093/protein/14.2.75; Chou KC, 2007, BIOCHEM BIOPH RES CO, V357, P633, DOI 10.1016/j.bbrc.2007.03.162; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; Dassa E, 2001, RES MICROBIOL, V152, P211, DOI 10.1016/S0923-2508(01)01194-9; Davidson AL, 2008, MICROBIOL MOL BIOL R, V72, P317, DOI 10.1128/MMBR.00031-07; De Domenico I, 2008, NAT REV MOL CELL BIO, V9, P72, DOI 10.1038/nrm2295; Dean M, 2001, J LIPID RES, V42, P1007; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Graf SA, 2004, J BIOL CHEM, V279, P42954, DOI 10.1074/jbc.M405040200; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; Helias V, 2012, NAT GENET, V44, P170, DOI 10.1038/ng.1069; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Hogue DL, 1999, J MOL BIOL, V285, P379, DOI 10.1006/jmbi.1998.2259; Ichikawa Y, 2012, P NATL ACAD SCI USA, V109, P4152, DOI 10.1073/pnas.1119338109; Jacquet E, 2008, J BIOL CHEM, V283, P25332, DOI 10.1074/jbc.M800418200; Krishnamurthy PC, 2006, NATURE, V443, P586, DOI 10.1038/nature05125; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Li RF, 2009, EMBO J, V28, P2763, DOI 10.1038/emboj.2009.211; Lill R, 2001, RES MICROBIOL, V152, P331, DOI 10.1016/S0923-2508(01)01204-9; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Melin P, 2004, BIOCHEM PHARMACOL, V67, P2187, DOI 10.1016/j.bcp.2004.02.022; Mitsuhashi N, 2000, J BIOL CHEM, V275, P17536, DOI 10.1074/jbc.275.23.17536; Nociari MM, 1998, J IMMUNOL METHODS, V213, P157, DOI 10.1016/S0022-1759(98)00028-3; Paterson JK, 2007, BIOCHEMISTRY-US, V46, P9443, DOI 10.1021/bi700015m; Paytubi S, 2009, J BIOL CHEM, V284, P24061, DOI 10.1074/jbc.M109.031625; Puntarulo Susana, 2005, Molecular Aspects of Medicine, V26, P299, DOI 10.1016/j.mam.2005.07.001; Ramaen O, 2005, BIOCHEM J, V391, P481, DOI 10.1042/BJ20050897; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Rees DC, 2009, NAT REV MOL CELL BIO, V10, P218, DOI 10.1038/nrm2646; ROSS JI, 1990, MOL MICROBIOL, V4, P1207, DOI 10.1111/j.1365-2958.1990.tb00696.x; Rothfuss O, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp1082; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; Shani N, 1997, HUM MOL GENET, V6, P1925, DOI 10.1093/hmg/6.11.1925; Shirihai OS, 2000, EMBO J, V19, P2492, DOI 10.1093/emboj/19.11.2492; Sinclair PR, 2001, CURR PROTOC TOXICOL, V8; SMITH FE, 1984, CLIN BIOCHEM, V17, P306, DOI 10.1016/S0009-9120(84)90613-1; Szentpetery Z, 2004, J BIOL CHEM, V279, P41670, DOI 10.1074/jbc.M406484200; Taketani S, 2003, BLOOD, V101, P3274, DOI 10.1182/blood-2002-04-1212; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514	55	12	12	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4821	4834		10.1096/fj.14-254045	http://dx.doi.org/10.1096/fj.14-254045			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25063848				2022-12-28	WOS:000344050900020
J	Palczewski, G; Amengual, J; Hoppel, CL; von Lintig, J				Palczewski, Grzegorz; Amengual, Jaume; Hoppel, Charles L.; von Lintig, Johannes			Evidence for compartmentalization of mammalian carotenoid metabolism	FASEB JOURNAL			English	Article						BCO1; BCO2; beta-carotene; zeaxanthin; vitamin A	BETA-CAROTENE; RETINOIC ACID; VITAMIN-A; EXCENTRIC CLEAVAGE; IN-VITRO; MACULAR DEGENERATION; ENZYMATIC CLEAVAGE; ESCHERICHIA-COLI; RAT-LIVER; IDENTIFICATION	The critical role of retinoids (vitamin A and its derivatives) for vision, reproduction, and survival has been well established. Vitamin A is produced from dietary carotenoids such as beta-carotene by centric cleavage via the enzyme BCO1. The biochemical and molecular identification of a second structurally related beta-carotene metabolizing enzyme, BCO2, has led to a prolonged debate about its relevance in vitamin A biology. While BCO1 cleaves provitamin A carotenoids, BCO2 is more promiscuous and also metabolizes non-provitamin A carotenoids such as zeaxanthin into long-chain apo-carotenoids. Herein we demonstrate, in cell lines, that human BCO2 is associated with the inner mitochondrial membrane. Different human BCO2 isoforms possess cleavable N-terminal leader sequences critical for mitochondrial import. Subfractionation of murine hepatic mitochondria confirmed the localization of BCO2 to the inner mitochondrial membrane. Studies in BCO2-knockout mice revealed that zeaxanthin accumulates in the inner mitochondrial membrane; in contrast, beta-carotene is retained predominantly in the cytoplasm. Thus, we provide evidence for a compartmentalization of carotenoid metabolism that prevents competition between BCO1 and BCO2 for the provitamin and the production of noncanonical beta-carotene metabolites.-Palczewski, G., Amengual, J., Hoppel, C. L., von Lintig, J. Evidence for compartmentalization of mammalian carotenoid metabolism.	[Palczewski, Grzegorz] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; [Amengual, Jaume; Hoppel, Charles L.; von Lintig, Johannes] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Hoppel, Charles L.] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	von Lintig, J (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol W333, 10900 Euclid Ave, Cleveland, OH 44106 USA.	jxv99@case.edu		von Lintig, Johannes/0000-0002-2079-2143	U.S. National Institute of Health [EY019641, EY02551]; visual science training program [T32-EY07157]; NATIONAL EYE INSTITUTE [T32EY007157, R01EY019641] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); visual science training program; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The authors thank Dr. Marcin Golczak [Case Western Reserve University (CWRU)] for help with LC-MS analysis of carotenoids and apo-carotenoids. The authors thank Dr. Janos Kerner (CWRU) and Dr. Mariana Rosca (CWRU) for help with methods in mitochondrial preparation. The authors thank Hiral Patel (CWRU) for assaying mitochondrial fractions for purity. The authors are grateful to Dr. Philip Kiser (CWRU) for helping with modeling of carotenoid oxygenases. The authors are grateful to Dr. Hisashi Fujioka and the Case Electron Microscopy Core Facility for assistance with immunogold staining and imaging. The authors are grateful to Dr. Hansgeorg Ernst (BASF, Ludwigshafen, Germany) for the gift of apo-carotenoid standards. The authors thank Maryanne Pendergast and the Neurosciences Imaging Center for assistance with confocal microscopy. This work was supported by U.S. National Institute of Health grants EY019641 and EY02551 and the visual science training program T32-EY07157.	Amengual J, 2013, J BIOL CHEM, V288, P34081, DOI 10.1074/jbc.M113.501049; Amengual J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020644; Amengual J, 2011, FASEB J, V25, P948, DOI 10.1096/fj.10-173906; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Berry SD, 2009, GENETICS, V182, P923, DOI 10.1534/genetics.109.101741; Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200; Borel P, 1998, J LIPID RES, V39, P2250; Bouvier F, 2003, PLANT CELL, V15, P47, DOI 10.1105/tpc.006536; Burri BJ, 2004, ARCH BIOCHEM BIOPHYS, V430, P110, DOI 10.1016/j.abb.2004.04.028; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; D'Ambrosio DN, 2011, NUTRIENTS, V3, P63, DOI 10.3390/nu3010063; Duester G, 2008, CELL, V134, P921, DOI 10.1016/j.cell.2008.09.002; Eriksson J, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000010; Eroglu A, 2013, J LIPID RES, V54, P1719, DOI 10.1194/jlr.R039537; Eroglu A, 2012, J BIOL CHEM, V287, P15886, DOI 10.1074/jbc.M111.325142; Eroglu A, 2010, ARCH BIOCHEM BIOPHYS, V504, P11, DOI 10.1016/j.abb.2010.07.025; FALOONA GR, 1969, BIOCHEMISTRY-US, V8, P4497, DOI 10.1021/bi00839a041; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLOVER J, 1960, VITAM HORM, V18, P371; Golczak M, 2010, J BIOL CHEM, V285, P9667, DOI 10.1074/jbc.M109.063941; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Hall JA, 2011, IMMUNITY, V35, P13, DOI 10.1016/j.immuni.2011.07.002; HANSEN S, 1988, BIOCHEMISTRY-US, V27, P200, DOI 10.1021/bi00401a030; Hessel S, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706763200; Ho CC, 2007, AM J CLIN NUTR, V85, P770, DOI 10.1093/ajcn/85.3.770; HOPPEL C, 1979, J BIOL CHEM, V254, P4164; HOPPEL CL, 1972, J BIOL CHEM, V247, P832; Hu KQ, 2006, J BIOL CHEM, V281, P19327, DOI 10.1074/jbc.M512095200; Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200; Kiser PD, 2012, P NATL ACAD SCI USA, V109, pE2747, DOI 10.1073/pnas.1212025109; Kiser PD, 2009, P NATL ACAD SCI USA, V106, P17325, DOI 10.1073/pnas.0906600106; Kowatz T, 2013, ARCH BIOCHEM BIOPHYS, V539, P214, DOI 10.1016/j.abb.2013.05.007; Krinsky N, 2001, NUTR REV, V59, P309; Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459; Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y; Lindqvist A, 2002, J BIOL CHEM, V277, P23942, DOI 10.1074/jbc.M202756200; Lindqvist A, 2005, J HISTOCHEM CYTOCHEM, V53, P1403, DOI 10.1369/jhc.5A6705.2005; Lindqvist A, 2007, J NUTR, V137, P2346, DOI 10.1093/jn/137.11.2346; Lobo GP, 2012, DEVELOPMENT, V139, P2966, DOI 10.1242/dev.079632; Mein JR, 2011, ARCH BIOCHEM BIOPHYS, V506, P109, DOI 10.1016/j.abb.2010.11.005; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; Moise AR, 2005, TRENDS PLANT SCI, V10, P178, DOI 10.1016/j.tplants.2005.02.006; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Reboul E, 2011, PROG LIPID RES, V50, P388, DOI 10.1016/j.plipres.2011.07.001; Rhinn M, 2012, DEVELOPMENT, V139, P843, DOI 10.1242/dev.065938; Sabour-Pickett S, 2012, MOL NUTR FOOD RES, V56, P270, DOI 10.1002/mnfr.201100219; SanGiovanni JP, 2012, AM J CLIN NUTR, V96, p1223S, DOI 10.3945/ajcn.112.038240; SHARMA RV, 1976, BIOCHEM J, V158, P377, DOI 10.1042/bj1580377; TANG GW, 1991, BIOCHEMISTRY-US, V30, P9829, DOI 10.1021/bi00105a003; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Tian R, 2010, ANIM GENET, V41, P253, DOI 10.1111/j.1365-2052.2009.01990.x; Tibaduiza EC, 2002, J NUTR, V132, P1368, DOI 10.1093/jn/132.6.1368; Vage DI, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-10; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; von Lintig J, 2001, ARCH BIOCHEM BIOPHYS, V385, P47, DOI 10.1006/abbi.2000.2096; von Lintig J, 2012, J BIOL CHEM, V287, P1627, DOI 10.1074/jbc.R111.303990; von Lintig J, 2010, ANNU REV NUTR, V30, P35, DOI 10.1146/annurev-nutr-080508-141027; von Lintig J, 2010, TRENDS BIOCHEM SCI, V35, P400, DOI 10.1016/j.tibs.2010.01.005; WANG XD, 1992, ARCH BIOCHEM BIOPHYS, V293, P298, DOI 10.1016/0003-9861(92)90399-H; WANG XD, 1991, ARCH BIOCHEM BIOPHYS, V285, P8, DOI 10.1016/0003-9861(91)90322-A; Wolf G, 2001, NUTR REV, V59, P116; Ziouzenkova O, 2007, MOL ENDOCRINOL, V21, P77, DOI 10.1210/me.2006-0225	66	67	67	2	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4457	4469		10.1096/fj.14-252411	http://dx.doi.org/10.1096/fj.14-252411			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25002123	Green Published			2022-12-28	WOS:000342222700023
J	Novoyatleva, T; Sajjad, A; Pogoryelov, D; Patra, C; Schermuly, RT; Engel, FB				Novoyatleva, Tatyana; Sajjad, Amna; Pogoryelov, Denys; Patra, Chinmoy; Schermuly, Ralph T.; Engel, Felix B.			FGF1-mediated cardiomyocyte cell cycle reentry depends on the interaction of FGFR-1 and Fn14	FASEB JOURNAL			English	Article						heart; signaling; TWEAK	FIBROBLAST-GROWTH-FACTOR; FACTOR-KAPPA-B; HEART DEVELOPMENT; FACTOR RECEPTOR-1; DNA-SYNTHESIS; WEAK INDUCER; MYOCYTE PROLIFERATION; ADULT CARDIOMYOCYTES; CARDIAC REGENERATION; ENDOTHELIAL-CELLS	Fibroblast growth factors (FGFs) signal through FGF receptors (FGFRs) mediating a broad range of cellular functions during embryonic development, as well as disease and regeneration during adulthood. Thus, it is important to understand the underlying molecular mechanisms that modulate this system. Here, we show that FGFR-1 can interact with the TNF receptor superfamily member fibroblast growth factor-inducible molecule 14 (Fn14) resulting in cardiomyocyte cell cycle reentry. FGF1-induced cell cycle reentry in neonatal cardiomyocytes could be blocked by Fn14 inhibition, while TWEAK-induced cell cycle activation was inhibited by blocking FGFR-1 signaling. In addition, costimulation experiments revealed a synergistic effect of FGF1 and TWEAK in regard to cardiomyocyte cell cycle induction via PI3K/Akt signaling. Overexpression of Fn14 with either FGFR-1 long [FGFR-1(L)] or FGFR-1 short [FGFR-1(S)] isoforms resulted after FGF1/TWEAK stimulation in cell cycle reentry of >40% adult cardiomyocytes. Finally, coimmunoprecipitation and proximity ligation assays indicated that endogenous FGFR-1 and Fn14 interact with each other in cardiomyocytes. This interaction was strongly enhanced in the presence of their corresponding ligands, FGF1 and TWEAK. Taken together, our data suggest that FGFR-1/Fn14 interaction may represent a novel endogenous mechanism to modulate the action of these receptors and their ligands and to control cardiomyocyte cell cycle reentry.	[Novoyatleva, Tatyana; Sajjad, Amna; Patra, Chinmoy; Engel, Felix B.] Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodeling, Bad Nauheim, Germany; [Sajjad, Amna] Univ Faisalabad, Govt Coll, Faisalabad, Pakistan; [Pogoryelov, Denys] Goethe Univ Frankfurt, Inst Biochem, Membrane Transport Machineries Grp, Frankfurt, Germany; [Schermuly, Ralph T.] Univ Giessen, Dept Pulm Pharmacotherapy, D-35390 Giessen, Germany; [Engel, Felix B.] Univ Erlangen Nurnberg, Inst Pathol, Dept Nephropathol, D-91054 Erlangen, Germany	Max Planck Society; Government College University Faisalabad; Goethe University Frankfurt; Justus Liebig University Giessen; University of Erlangen Nuremberg	Engel, FB (corresponding author), Univ Erlangen Nurnberg, Inst Pathol, Dept Nephropathol, Univ Str 22, D-91054 Erlangen, Germany.	tatyana.novoyatleva@innnere.med.uni-giessen.de; felix.engel@uk-erlangen.de	Engel, Felix/A-1767-2008	Engel, Felix/0000-0003-2605-3429; Schermuly, Ralph/0000-0002-5167-6970; Patra, Chinmoy/0000-0003-3849-5187; Sajjad, Amna/0000-0001-8478-8138	Alexander von Humboldt Foundation; Behrens-Weise-Stiftung; Emerging Fields Initiative Cell Cycle in Disease and Regeneration (CYDER) of the Friedrich Alexander University (Erlangen-Nurnberg, Germany)	Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); Behrens-Weise-Stiftung; Emerging Fields Initiative Cell Cycle in Disease and Regeneration (CYDER) of the Friedrich Alexander University (Erlangen-Nurnberg, Germany)	The authors thank Michael Berens (Translational Genomics Research Institute, Phoenix, AZ, USA), Ken Walsh (Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA), and Thomas Braun (Max Planck Institute for Heart and Lung Research) for adenoviral constructs and David Zebrowski for critical reading of the manuscript. The authors are grateful to Petra Freund and Stefanie Viehmann for technical assistance and Miriam Damm for the technical suggestions regarding the PLA assay. This work was supported by the Alexander von Humboldt Foundation (Sofja Kovalevskaja Award to F.B.E.), the Behrens-Weise-Stiftung, and the Emerging Fields Initiative Cell Cycle in Disease and Regeneration (CYDER) of the Friedrich Alexander University (Erlangen-Nurnberg, Germany).	Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Baxter FO, 2006, DEVELOPMENT, V133, P3485, DOI 10.1242/dev.02502; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Bersell K, 2009, CELL, V138, P257, DOI 10.1016/j.cell.2009.04.060; Bhatnagar S, 2012, CURR MOL MED, V12, P3, DOI 10.2174/156652412798376107; Borroto-Escuela DO, 2012, J NEUROSCI, V32, P6295, DOI 10.1523/JNEUROSCI.4203-11.2012; Brown SAN, 2003, BIOCHEM J, V371, P395, DOI 10.1042/BJ20021730; Burkly LC, 2011, IMMUNOL REV, V244, P99, DOI 10.1111/j.1600-065X.2011.01054.x; Carey DJ, 1997, BIOCHEM J, V327, P1; Chorianopoulos E, 2010, BASIC RES CARDIOL, V105, P301, DOI 10.1007/s00395-009-0046-y; Cuevas P, 1997, GROWTH FACTORS, V15, P29, DOI 10.3109/08977199709002110; Dell'Era P, 2003, CIRC RES, V93, P414, DOI 10.1161/01.RES.0000089460.12061.E1; Dogra C, 2006, J BIOL CHEM, V281, P10327, DOI 10.1074/jbc.M511131200; Donohue PJ, 2003, ARTERIOSCL THROM VAS, V23, P594, DOI 10.1161/01.ATV.0000062883.93715.37; Ebelt H, 2005, CIRC RES, V96, P509, DOI 10.1161/01.RES.0000159705.17322.57; Engel FB, 2005, GENE DEV, V19, P1175, DOI 10.1101/gad.1306705; Engel FB, 2003, MOL CELL BIOL, V23, P555, DOI 10.1128/MCB.23.2.555-565.2003; Engel FB, 1999, CIRC RES, V85, P294, DOI 10.1161/01.RES.85.3.294; Engel FB, 2006, P NATL ACAD SCI USA, V103, P15546, DOI 10.1073/pnas.0607382103; ENGELMANN GL, 1993, CIRC RES, V72, P7, DOI 10.1161/01.RES.72.1.7; Eulalio A, 2012, NATURE, V492, P376, DOI 10.1038/nature11739; Faraone D, 2006, BLOOD, V107, P1896, DOI 10.1182/blood-2005-04-1524; Furdui CM, 2006, MOL CELL, V21, P711, DOI 10.1016/j.molcel.2006.01.022; Gargano N, 1997, J NEUROSCI RES, V50, P1; Goetz R, 2013, NAT REV MOL CELL BIO, V14, P166, DOI 10.1038/nrm3528; Graves Lee M, 2002, Mol Interv, V2, P208, DOI 10.1124/mi.2.4.208; Gresch O, 2004, METHODS, V33, P151, DOI 10.1016/j.ymeth.2003.11.009; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; Harada N, 2002, BIOCHEM BIOPH RES CO, V299, P488, DOI 10.1016/S0006-291X(02)02670-0; Itoh N, 2011, J BIOCHEM, V149, P121, DOI 10.1093/jb/mvq121; JIN Y, 1994, J MOL CELL CARDIOL, V26, P1449, DOI 10.1006/jmcc.1994.1164; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KARDAMI E, 1990, MOL CELL BIOCHEM, V92, P129; LIU L, 1995, AM J PHYSIOL-HEART C, V268, pH1927, DOI 10.1152/ajpheart.1995.268.5.H1927; Lu SY, 2008, BIOCHEM BIOPH RES CO, V373, P270, DOI 10.1016/j.bbrc.2008.06.029; Mahmoud AI, 2013, NATURE, V497, P249, DOI 10.1038/nature12054; Marguerie A, 2006, CARDIOVASC RES, V71, P50, DOI 10.1016/j.cardiores.2006.03.021; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; Mustonen E, 2010, ACTA PHYSIOL, V199, P11, DOI 10.1111/j.1748-1716.2010.02080.x; Nissen LJ, 2007, J CLIN INVEST, V117, P2766, DOI 10.1172/JCI32479; Novoyatleva T, 2010, CARDIOVASC RES, V85, P681, DOI 10.1093/cvr/cvp360; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Pellieux C, 2001, J CLIN INVEST, V108, P1843, DOI 10.1172/JCI200113627; Poling J, 2011, ARTERIOSCL THROM VAS, V31, P2297, DOI 10.1161/ATVBAHA.111.232835; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Sheikh F, 1999, CARDIOVASC RES, V42, P696, DOI 10.1016/S0008-6363(99)00008-5; Smyth LA, 2005, HYPERTENSION, V46, P100, DOI 10.1161/01.HYP.0000167991.82153.16; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; SPEIR E, 1992, CIRC RES, V71, P251, DOI 10.1161/01.RES.71.2.251; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Steiling H, 2003, CURR OPIN BIOTECH, V14, P533, DOI 10.1016/j.copbio.2003.08.003; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tran NL, 2005, J BIOL CHEM, V280, P3483, DOI 10.1074/jbc.M409906200; Tseng YT, 2005, AM J PHYSIOL-HEART C, V289, pH1834, DOI 10.1152/ajpheart.00435.2005; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; van Amerongen MJ, 2008, J CELL MOL MED, V12, P2233, DOI 10.1111/j.1582-4934.2008.00439.x; Wajant H, 2013, BRIT J PHARMACOL, V170, P748, DOI 10.1111/bph.12337; WANAKA A, 1991, DEVELOPMENT, V111, P455; Weinberg JM, 2011, KIDNEY INT, V79, P151, DOI 10.1038/ki.2010.435; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001; Winkles JA, 2008, NAT REV DRUG DISCOV, V7, P411, DOI 10.1038/nrd2488; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; Zebrowski DC, 2013, REV PHYSIOL BIOCH P, V165, P67, DOI 10.1007/112_2013_12	66	16	17	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2492	2503		10.1096/fj.13-243576	http://dx.doi.org/10.1096/fj.13-243576			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24571920				2022-12-28	WOS:000339883600010
J	Narita, K; Sasamoto, S; Koizumi, S; Okazaki, S; Nakamura, H; Inoue, T; Takeda, S				Narita, Keishi; Sasamoto, Shohei; Koizumi, Schuichi; Okazaki, Shizuka; Nakamura, Hideki; Inoue, Takafumi; Takeda, Sen			TRPV4 regulates the integrity of the blood-cerebrospinal fluid barrier and modulates transepithelial protein transport	FASEB JOURNAL			English	Article						subcellular localization; calcium imaging; actin	CHOROID-PLEXUS EPITHELIUM; CATION CHANNEL TRPV4; BRAIN-BARRIER; RECEPTOR; EXPRESSION; RECRUITMENT; ACTIVATION; CELLS; ENTRY; CA2+	The diffusion of materials from systemic circulation to the central nervous system (CNS) is restricted by the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB). Choroid plexus epithelial cells (CPECs) of the brain ventricles constitute the BCSFB and regulate the infiltration of plasma proteins as well as immune cells into the interstitium of the CNS. The barrier function is altered in pathologic conditions. However, the regulatory mechanism of BCSFB is not fully understood. Here, we investigated the function of transient receptor potential vanilloid 4 (TRPV4), a polymodally gated divalent cation channel that is highly expressed in CPECs. TRPV4 was localized broadly on the apical membrane in swine CPECs, in contrast with an intense ciliary localization found on other cell types. Treatment with the TRPV4-specific agonist, GSK1016790A (GSK; EC50 34 nM), induced a robust calcium influx and an immediate serine/threonine protein phosphorylation. The agonist treatment induced a marked decrease in the amount of filamentous actin and disintegrated the cell junctions in 10-20 minutes. In contrast, inhibition of the basal TRPV4 activity with the TRPV4-specific antagonist, HC067047 (HC; IC50 74 nM), reduced the basolateral-to-apical transport of alpha-2-macroglobulin (A2M). Overall, this study demonstrated a novel physiologic function of TRPV4 in the regulation of BCSFB permeability.	[Narita, Keishi; Sasamoto, Shohei; Takeda, Sen] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Anat & Cell Biol, Chuo Ku, Yamanashi 4093898, Japan; [Koizumi, Schuichi] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Neuropharmacol, Chuo Ku, Yamanashi 4093898, Japan; [Okazaki, Shizuka; Nakamura, Hideki; Inoue, Takafumi] Waseda Univ, Dept Life Sci & Med Biosci, Shinjuku Ku, Tokyo, Japan	University of Yamanashi; University of Yamanashi; Waseda University	Takeda, S (corresponding author), Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Anat & Cell Biol, Chuo Ku, Yamanashi 4093898, Japan.	stakeda@yamanashi.ac.jp	Inoue, Takafumi/AAM-9533-2020; Takeda, Sen/I-8462-2012; Narita, Keishi/E-3539-2010; Koizumi, Schuichi/E-8568-2010	Inoue, Takafumi/0000-0002-2728-0060; Takeda, Sen/0000-0001-7090-2139; Narita, Keishi/0000-0002-7602-8523; Koizumi, Schuichi/0000-0001-6184-3106; Nakamura, Hideki/0000-0003-2749-8323	Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) [19590188]; Yamada Science Foundation; MEXT [22770190, 26440094]	Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Yamada Science Foundation; MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The authors acknowledge contributions from the following colleagues: Prof. Ryohei Kato and Mikiko Yoda for preparation of tissue sections; Drs. Youichi Shinozaki, Keisuke Shibata, and Eiji Shigetomi for helping with Ca<SUP>2+</SUP> imaging; Dr. Ryohei Komatsu for helping with the ATP assay; Prof. Masao Saito for TEER measurement; the staff of Yamanashi Meat Logistics Center and Yamanashi Meat Hygiene Inspection Office for isolation of swine choroid plexus tissue; Mamiko Otagiri for performing routine laboratory works; and Kazuko Sawanobori for secretarial assistance. This research was supported by the Grant-in-Aid for Scientific Research (C) from Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT; 19590188), and the Yamada Science Foundation to S.T., and Grants-in-Aid for Young Scientists (B) (22770190) and Scientific Research (C) (26440094) from MEXT to K.N.	BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; Brightman M W, 1968, Prog Brain Res, V29, P19; Brown RC, 2008, MICROCIRCULATION, V15, P359, DOI 10.1080/10739680701762656; Everaerts W, 2010, P NATL ACAD SCI USA, V107, P19084, DOI 10.1073/pnas.1005333107; Fernandez J, 1998, ELECTROPHORESIS, V19, P1036, DOI 10.1002/elps.1150190619; Filosa JA, 2013, J CARDIOVASC PHARM, V61, P113, DOI 10.1097/FJC.0b013e318279ba42; Gradilone SA, 2007, P NATL ACAD SCI USA, V104, P19138, DOI 10.1073/pnas.0705964104; Hama H, 2011, NAT NEUROSCI, V14, P1481, DOI 10.1038/nn.2928; Honda A, 2010, J BIOL CHEM, V285, P31362, DOI 10.1074/jbc.M110.150540; Imura A, 2007, SCIENCE, V316, P1615, DOI 10.1126/science.1135901; Imura Y, 2013, GLIA, V61, P1320, DOI 10.1002/glia.22517; Kanoh Y, 1997, BIOCHEM MOL BIOL INT, V43, P269; KLUGE H, 1986, J NEUROL, V233, P195, DOI 10.1007/BF00314017; Knowland D, 2014, NEURON, V82, P603, DOI 10.1016/j.neuron.2014.03.003; Kohler R, 2006, ARTERIOSCL THROM VAS, V26, P1495, DOI 10.1161/01.ATV.0000225698.36212.6a; Kotttgen M, 2008, J CELL BIOL, V182, P437, DOI 10.1083/jcb.200805124; Kottgen M, 2005, PFLUG ARCH EUR J PHY, V451, P286, DOI 10.1007/s00424-005-1417-3; Lechner SG, 2011, NEURON, V69, P332, DOI 10.1016/j.neuron.2010.12.028; Lehtinen MK, 2011, NEURON, V69, P893, DOI 10.1016/j.neuron.2011.01.023; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Lorenzo IM, 2008, P NATL ACAD SCI USA, V105, P12611, DOI 10.1073/pnas.0803970105; Mochizuki T, 2009, J BIOL CHEM, V284, P21257, DOI 10.1074/jbc.M109.020206; Narita K, 2012, BIOL OPEN, V1, P815, DOI 10.1242/bio.20121081; Narita K, 2010, TRAFFIC, V11, P287, DOI 10.1111/j.1600-0854.2009.01016.x; Nonami Y, 2013, CYTOSKELETON, V70, P797, DOI 10.1002/cm.21132; Ottervald J, 2010, J PROTEOMICS, V73, P1117, DOI 10.1016/j.jprot.2010.01.004; Reboldi A, 2009, NAT IMMUNOL, V10, P514, DOI 10.1038/ni.1716; Redzic ZB, 2005, CURR TOP DEV BIOL, V71, P1, DOI 10.1016/S0070-2153(05)71001-2; Redzic Z, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-3; Reiter B, 2006, FASEB J, V20, P1802, DOI 10.1096/fj.06-5772com; Sawamoto K, 2006, SCIENCE, V311, P629, DOI 10.1126/science.1119133; Schwartz M, 2014, EMBO J, V33, P7, DOI 10.1002/embj.201386609; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Shibasaki K, 2007, J NEUROSCI, V27, P1566, DOI 10.1523/JNEUROSCI.4284-06.2007; Shigetomi E, 2008, J NEUROSCI, V28, P6659, DOI 10.1523/JNEUROSCI.1717-08.2008; Sonkusare SK, 2012, SCIENCE, V336, P597, DOI 10.1126/science.1216283; Stockinger W, 1998, J BIOL CHEM, V273, P32213, DOI 10.1074/jbc.273.48.32213; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Takayama Y, 2014, FASEB J, V28, P2238, DOI 10.1096/fj.13-243436; Thorneloe KS, 2008, J PHARMACOL EXP THER, V326, P432, DOI 10.1124/jpet.108.139295; Tian W, 2004, AM J PHYSIOL-RENAL, V287, pF17, DOI 10.1152/ajprenal.00397.2003; URADE Y, 1993, P NATL ACAD SCI USA, V90, P9070, DOI 10.1073/pnas.90.19.9070; VANDEURS B, 1979, J CELL BIOL, V80, P662, DOI 10.1083/jcb.80.3.662; Wang FS, 2013, J NEUROSCI, V33, P17404, DOI 10.1523/JNEUROSCI.2178-13.2013; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Willette RN, 2008, J PHARMACOL EXP THER, V326, P443, DOI 10.1124/jpet.107.134551; Xu XP, 2009, CHANNELS, V3, P156, DOI 10.4161/chan.3.3.8555; Zlokovic BV, 2000, ENDOCRINOLOGY, V141, P1434, DOI 10.1210/en.141.4.1434	50	27	27	2	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2247	2259		10.1096/fj.14-261396	http://dx.doi.org/10.1096/fj.14-261396			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25681460				2022-12-28	WOS:000355209500004
J	Enesa, K; Moll, HP; Luong, L; Ferran, C; Evans, PC				Enesa, Karine; Moll, Herwig P.; Luong, Le; Ferran, Christiane; Evans, Paul C.			A20 suppresses vascular inflammation by recruiting proinflammatory signaling molecules to intracellular aggresomes	FASEB JOURNAL			English	Article						NF-kappa B; molecular mechanism; receptor interacting protein	NF-KAPPA-B; ZINC-FINGER PROTEIN; LINEAR POLYUBIQUITIN; ENDOTHELIAL-CELLS; ACTIVATION; UBIQUITINATION; BINDING; COMPLEX; AGGREGATION; INHIBITION	A20 protects against pathologic vascular remodeling by inhibiting the inflammatory transcription factor NF-kappa B. A20's function has been attributed to ubiquitin editing of receptor-interacting protein 1 (RIP1) to influence activity/stability. The validity of this mechanism was tested using a murine model of transplant vasculopathy and human cells. Mouse C57BL/6 aortae transduced with adenoviruses containing A20 (or beta-galactosidase as a control) were allografted into major histocompatibility complex-mismatched BALB/c mice. Primary endothelial cells, smooth muscle cells, or transformed epithelial cells (all human) were transfected with wild-type A20 or with catalytically inactive mutants as a control. NF-kappa B activity and intracellular localization of RIP1 was monitored by reporter gene assay, immunofluorescent staining, and Western blotting. Native and catalytically inactive versions of A20 had similar inhibitory effects on NF-kappa B activity (-70% vs. -76%; P > 0.05). A20 promoted localization of RIP1 to insoluble aggresomes in murine vascular allografts and in human cells (53% vs. 0%) without altering RIP1 expression, and this process was increased by the assembly of polyubiquitin chains (87% vs. 28%; P < 0.05). A20 captures polyubiquitinated signaling intermediaries in insoluble aggresomes, thus reducing their bioavailability for downstream NF-kappa B signaling. This novel mechanism contributes to protection from vasculopathy in transplanted organs treated with exogenous A20.	[Enesa, Karine; Luong, Le] Univ London Imperial Coll Sci Technol & Med, British Heart Fdn Cardiovasc Sci, London, England; [Moll, Herwig P.; Ferran, Christiane] Harvard Univ, Sch Med, Vasc Biol Res Ctr, Div Vasc & Endovasc Surg, Cambridge, MA 02138 USA; [Moll, Herwig P.; Ferran, Christiane] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Transplant Inst,Dept Surg, Cambridge, MA 02138 USA; [Evans, Paul C.] Univ Sheffield, Dept Cardiovasc Sci, Sheffield S10 2RX, S Yorkshire, England; [Evans, Paul C.] Univ Sheffield, INSIGNEO Inst Silico Med, Sheffield S10 2RX, S Yorkshire, England	Imperial College London; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; University of Sheffield; University of Sheffield	Evans, PC (corresponding author), Univ Sheffield, Dept Cardiovasc Sci, Fac Med Dent & Hlth, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	paul.evans@sheffield.ac.uk	Moll, Herwig P./H-2836-2019	Moll, Herwig P./0000-0001-6438-9068; Evans, Paul/0000-0001-7975-681X	British Heart Foundation; National Heart and Lung Institute, Imperial College London, United Kingdom; U.S. National Institutes of Health R01 Grant [HL080130, DK063275]; Austrian Science Fund Grant [J3398-BW23]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086741, R01HL080130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK063275, R01DK063275] Funding Source: NIH RePORTER	British Heart Foundation(British Heart Foundation); National Heart and Lung Institute, Imperial College London, United Kingdom; U.S. National Institutes of Health R01 Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Austrian Science Fund Grant; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Drs. Shuang Feng and Cleide G. da Silva for technical assistance. This work was funded by the British Heart Foundation and the National Heart and Lung Institute, Imperial College London, United Kingdom (to P.C.E.), and U.S. National Institutes of Health R01 Grants HL080130 and DK063275 (to C.F.). H.P.M. was supported by Austrian Science Fund Grant J3398-BW23. The authors declare no conflicts of interest.	Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196; Bosanac I, 2010, MOL CELL, V40, P548, DOI 10.1016/j.molcel.2010.10.009; Chen ZJJ, 2012, IMMUNOL REV, V246, P95, DOI 10.1111/j.1600-065X.2012.01108.x; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Damrauer SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017715; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Enesa K, 2008, J BIOL CHEM, V283, P18582, DOI 10.1074/jbc.M801312200; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Evans PC, 2004, BIOCHEM J, V378, P727, DOI 10.1042/BJ20031377; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; GARCIAVALDECASAS JC, 1995, TRANSPLANTATION, V60, P662, DOI 10.1097/00007890-199510150-00008; Gerlach B, 2011, NATURE, V471, P591, DOI 10.1038/nature09816; Grabbe C, 2011, NAT REV MOL CELL BIO, V12, P295, DOI 10.1038/nrm3099; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Iha H, 2008, EMBO J, V27, P629, DOI 10.1038/emboj.2008.5; Jaattela M, 1996, J IMMUNOL, V156, P1166; Kim WJ, 2005, MOL CELL BIOL, V25, P2450, DOI 10.1128/MCB.25.6.2450-2462.2005; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kulathu Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2567; Kummer MP, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt258; Kunter U, 2003, TRANSPLANTATION, V75, P3, DOI 10.1097/00007890-200301150-00002; Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019; Li LY, 2009, BBA-MOL CELL RES, V1793, P346, DOI 10.1016/j.bbamcr.2008.09.013; Liu H, 2013, NEUROTOX RES, V24, P191, DOI 10.1007/s12640-013-9377-4; Lu TT, 2013, IMMUNITY, V38, P896, DOI 10.1016/j.immuni.2013.03.008; Lutz J, 2008, J MOL MED, V86, P1329, DOI 10.1007/s00109-008-0405-4; Olzmann JA, 2007, J CELL BIOL, V178, P1025, DOI 10.1083/jcb.200611128; Oshima S, 2009, NATURE, V457, P906, DOI 10.1038/nature07575; Partridge J, 2007, FASEB J, V21, P3553, DOI 10.1096/fj.06-8059com; Patel VI, 2006, FASEB J, V20, P1418, DOI 10.1096/fj.05-4981com; Riederer BM, 2011, EXP BIOL MED, V236, P268, DOI 10.1258/ebm.2010.010327; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Schmukle AC, 2012, J CELL SCI, V125, P549, DOI 10.1242/jcs.091793; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Siracuse JJ, 2012, TRANSPLANTATION, V93, P373, DOI 10.1097/TP.0b013e3182419829; Skaug B, 2011, MOL CELL, V44, P559, DOI 10.1016/j.molcel.2011.09.015; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Tanaka M, 2004, CIRCULATION, V110, pII200, DOI 10.1161/01.CIR.0000138390.81640.54; Tannous P, 2008, CIRCULATION, V117, P3070, DOI 10.1161/CIRCULATIONAHA.107.763870; Tokunaga F, 2012, EMBO J, V31, P3856, DOI 10.1038/emboj.2012.241; Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5; Verhelst K, 2012, EMBO J, V31, P3845, DOI 10.1038/emboj.2012.240; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xu MQ, 2009, J SURG RES, V152, P35, DOI 10.1016/j.jss.2008.04.029	49	10	10	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1869	1878		10.1096/fj.14-258533	http://dx.doi.org/10.1096/fj.14-258533			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25667218	Green Published			2022-12-28	WOS:000354114600022
J	Makino, A; Abe, M; Murate, M; Inaba, T; Yilmaz, N; Hullin-Matsuda, F; Kishimoto, T; Schieber, NL; Taguchi, T; Arai, H; Anderluh, G; Parton, RG; Kobayashi, T				Makino, Asami; Abe, Mitsuhiro; Murate, Motohide; Inaba, Takehiko; Yilmaz, Neval; Hullin-Matsuda, Francoise; Kishimoto, Takuma; Schieber, Nicole L.; Taguchi, Tomohiko; Arai, Hiroyuki; Anderluh, Gregor; Parton, Robert G.; Kobayashi, Toshihide			Visualization of the heterogeneous membrane distribution of sphingomyelin associated with cytokinesis, cell polarity, and sphingolipidosis	FASEB JOURNAL			English	Article						lipid binding protein; lipid raft; membrane lipids; sphingolipid; toxins	PORE-FORMING TOXIN; ATOMIC-FORCE MICROSCOPY; LIPID PHASE COEXISTENCE; EQUINATOXIN-II; PLASMA-MEMBRANE; EPITHELIAL-CELLS; ACID SPHINGOMYELINASE; ELECTRON-MICROSCOPY; ACTINIA-EQUINA; SEA-ANEMONE	Sphingomyelin (SM) is a major sphingolipid in mammalian cells and is reported to form specific lipid domains together with cholesterol. However, methods to examine the membrane distribution of SM are limited. We demonstrated in model membranes that fluorescent protein conjugates of 2 specific SM-binding toxins, lysenin (Lys) and equinatoxin II (EqtII), recognize different membrane distributions of SM; Lys exclusively binds clustered SM, whereas EqtII preferentially binds dispersed SM. Freeze-fracture immunoelectron microscopy showed that clustered but not dispersed SM formed lipid domains on the cell surface. Glycolipids and the membrane concentration of SM affect the SM distribution pattern on the plasma membrane. Using derivatives of Lys and EqtII as SM distribution-sensitive probes, we revealed the exclusive accumulation ofSM clusters in the midbody at the time of cytokinesis. Interestingly, apical membranes of differentiated epithelial cells exhibited dispersed SM distribution, whereas SM was clustered in basolateral membranes. Clustered but not dispersed SM was absent from the cell surface of acid sphingomyelinase-deficient Niemann-Pick type A cells. These data suggest that both the SM content and membrane distribution are crucial for pathophysiological events bringing therapeutic perspective in the role of SM membrane distribution.	[Makino, Asami; Abe, Mitsuhiro; Murate, Motohide; Inaba, Takehiko; Yilmaz, Neval; Hullin-Matsuda, Francoise; Kishimoto, Takuma; Kobayashi, Toshihide] RIKEN, Lipid Biol Lab, Wako, Saitama 3510198, Japan; [Hullin-Matsuda, Francoise; Kobayashi, Toshihide] Univ Lyon, INSERM, U1060, Villeurbanne, France; [Schieber, Nicole L.; Parton, Robert G.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld, Australia; [Parton, Robert G.] Univ Queensland, Ctr Microscopy & Microanal, St Lucia, Qld, Australia; [Taguchi, Tomohiko; Arai, Hiroyuki] Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan; [Anderluh, Gregor] Univ Ljubljana, Natl Inst Chem, Ljubljana, Slovenia; [Anderluh, Gregor] Univ Ljubljana, Biotech Fac, Dept Biol, Ljubljana, Slovenia	RIKEN; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Queensland; University of Queensland; University of Tokyo; National Institute of Chemistry - Slovenia; University of Ljubljana; University of Ljubljana	Kobayashi, T (corresponding author), RIKEN, Lipid Biol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	kobayasi@riken.jp	KOBAYASHI, TOSHIHIDE/S-8313-2019; Kobayashi, Toshihide/B-6298-2015; Carmen, Team1/Y-7382-2019; Kishimoto, Takuma/AAP-1813-2021; Hullin-Matsuda, Françoise/N-3880-2017; Abe, Mitsuhiro/C-3602-2017; Taguchi, Tomohiko/I-5014-2019; Anderluh, Gregor/C-6905-2014; Parton, Robert/C-5673-2009	KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; Kobayashi, Toshihide/0000-0002-4811-7270; Carmen, Team1/0000-0003-4234-1746; Hullin-Matsuda, Françoise/0000-0002-6042-2841; Taguchi, Tomohiko/0000-0003-0464-6370; Anderluh, Gregor/0000-0002-9916-8465; Lab, Carmen/0000-0002-5935-3236; Abe, Mitsuhiro/0000-0002-6244-1771; Parton, Robert/0000-0002-7494-5248; Inaba, Takehiko/0000-0002-8770-4662; Schieber, Nicole L./0000-0002-3212-5057	Lipid Dynamics Program	Lipid Dynamics Program	The authors are grateful to R. Nakazawa for DNA sequence analysis and S. Jones for critical reading. They thank Dr. T. Watanabe and Carl Zeiss Microscopy Co. Ltd., Japan, for structured illumination microscopy images, and also thank the members of T. K.' s laboratory for their support, critical reading, and discussion. This work was supported by Lipid Dynamics Program, Cellular System Program and Integrated Lipidology Programof RIKEN, Grants-in-Aid for Scientific Research 23790115 (to A. M.), 23590251 (to M. M.), 24770135 (to T. Ki.), 23460081 (to F. H.-M.), and 22390018 and 25293015 (to T. Ko.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Naito Foundation. This work was supported by fellowships and a grant from the National Health and Medical Research Council of Australia (to R. G. P., Grants 569542 and 1037320). The authors acknowledge the facilities as well as the scientific and technical assistance of the Australian Microscopy & Microanalysis Research Facility at the Centre for Microscopy and Microanalysis, The University of Queensland. G. A. acknowledges the support of the Slovenian Research Agency.	Abe M, 2014, BBA-MOL CELL BIOL L, V1841, P720, DOI 10.1016/j.bbalip.2013.07.003; Abe M, 2012, MOL CELL BIOL, V32, P1396, DOI 10.1128/MCB.06113-11; Akashi K, 1996, BIOPHYS J, V71, P3242, DOI 10.1016/S0006-3495(96)79517-6; Anderluh G, 1996, BIOCHEM BIOPH RES CO, V220, P437, DOI 10.1006/bbrc.1996.0391; Athanasiadis A, 2001, STRUCTURE, V9, P341, DOI 10.1016/S0969-2126(01)00592-5; Bakrac B, 2008, J BIOL CHEM, V283, P18665, DOI 10.1074/jbc.M708747200; Bakrac B, 2010, J BIOL CHEM, V285, P22186, DOI 10.1074/jbc.M110.105122; Barlic A, 2004, J BIOL CHEM, V279, P34209, DOI 10.1074/jbc.M313817200; Bezombes C, 2001, FASEB J, V15, P297; BHAKDI S, 1985, INFECT IMMUN, V47, P52; Bhat HB, 2013, J LIPID RES, V54, P2933, DOI 10.1194/jlr.D041731; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; Bohdanowicz M, 2013, PHYSIOL REV, V93, P69, DOI 10.1152/physrev.00002.2012; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; Carquin M, 2014, J LIPID RES, V55, P1331, DOI 10.1194/jlr.M048538; CHALVARDJIAN A, 1970, ANAL BIOCHEM, V36, P225, DOI 10.1016/0003-2697(70)90352-0; De Colibus L, 2012, STRUCTURE, V20, P1498, DOI 10.1016/j.str.2012.06.011; de Haan L, 2004, MOL MEMBR BIOL, V21, P77, DOI 10.1080/09687680410001663267; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; Fairn GD, 2011, J CELL BIOL, V194, P257, DOI 10.1083/jcb.201012028; Fanning AS, 2012, MOL BIOL CELL, V23, P577, DOI 10.1091/mbc.E11-09-0791; Feigenson GW, 2001, BIOPHYS J, V80, P2775, DOI 10.1016/S0006-3495(01)76245-5; Fujimoto K, 1997, HISTOCHEM CELL BIOL, V107, P87, DOI 10.1007/s004180050092; Fujita A, 2007, MOL BIOL CELL, V18, P2112, DOI 10.1091/mbc.E07-01-0071; Fujita A, 2009, P NATL ACAD SCI USA, V106, P9256, DOI 10.1073/pnas.0900216106; Galvan C, 2008, MOL BIOL CELL, V19, P509, DOI 10.1091/mbc.E07-05-0439; Garcia PS, 2012, TOXICON, V60, P724, DOI 10.1016/j.toxicon.2012.05.018; Hammond AT, 2005, P NATL ACAD SCI USA, V102, P6320, DOI 10.1073/pnas.0405654102; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hong Q, 2002, J BIOL CHEM, V277, P41916, DOI 10.1074/jbc.M204625200; Hubbard A L, 1991, Semin Cell Biol, V2, P365; Hullin-Matsuda F, 2007, J LIPID RES, V48, P1997, DOI 10.1194/jlr.M700154-JLR200; Ikenouchi J, 2013, J CELL SCI, V126, P3585, DOI 10.1242/jcs.122325; Ikenouchi J, 2012, J BIOL CHEM, V287, P9525, DOI 10.1074/jbc.M111.327064; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Ishitsuka R, 2004, BIOPHYS J, V86, P296, DOI 10.1016/S0006-3495(04)74105-3; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Kiyokawa E, 2005, J BIOL CHEM, V280, P24072, DOI 10.1074/jbc.M502244200; Kiyokawa E, 2004, BIOCHEMISTRY-US, V43, P9766, DOI 10.1021/bi049561j; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; Kristan K, 2004, J BIOL CHEM, V279, P46509, DOI 10.1074/jbc.M406193200; Lawrence JC, 2003, BIOPHYS J, V84, P1827, DOI 10.1016/S0006-3495(03)74990-X; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621; Marsh D., 2013, HDB LIPID BILAYERS, DOI 10.1201/9781420088335-8; Maulik PR, 1996, BIOCHEMISTRY-US, V35, P8025, DOI 10.1021/bi9528356; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; Miyaji M, 2005, J EXP MED, V202, P249, DOI 10.1084/jem.20041685; Miyanari Y, 2013, NAT STRUCT MOL BIOL, V20, P1321, DOI 10.1038/nsmb.2680; Mizuno H, 2011, CHEM SCI, V2, P1548, DOI 10.1039/c1sc00169h; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Murate M, 2010, BIOCHEMISTRY-US, V49, P4732, DOI 10.1021/bi100007u; Nixon SJ, 2009, TRAFFIC, V10, P131, DOI 10.1111/j.1600-0854.2008.00859.x; Perry GLW, 2004, ENVIRON MODELL SOFTW, V19, P559, DOI 10.1016/j.envsoft.2003.07.004; Pike LJ, 2005, J BIOL CHEM, V280, P26796, DOI 10.1074/jbc.M503805200; RIPLEY BD, 1979, J ROY STAT SOC B MET, V41, P368; Rojko N, 2014, BIOPHYS J, V106, P1630, DOI 10.1016/j.bpj.2013.11.4507; Sahai E, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-14; Sampaio JL, 2011, P NATL ACAD SCI USA, V108, P1903, DOI 10.1073/pnas.1019267108; Schon P, 2008, BIOPHYS J, V95, P691, DOI 10.1529/biophysj.108.129981; SCHOENENBERGER CA, 1994, J CELL SCI, V107, P527; Shimada Y, 2002, EUR J BIOCHEM, V269, P6195, DOI 10.1046/j.1432-1033.2002.03338.x; SIMONS K, 1992, COLD SPRING HARB SYM, V57, P611, DOI 10.1101/SQB.1992.057.01.067; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Singh B, 2014, ANNU REV PHYSIOL, V76, P275, DOI 10.1146/annurev-physiol-021113-170406; Sobo K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000391; Uchida Y, 2011, P NATL ACAD SCI USA, V108, P15846, DOI 10.1073/pnas.1109101108; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; VAN MEER G, 1982, EMBO J, V1, P847, DOI 10.1002/j.1460-2075.1982.tb01258.x; Wang T, 2012, BIOCHEMISTRY-US, V51, P74, DOI 10.1021/bi2011652; Yachi R, 2012, GENES CELLS, V17, P720, DOI 10.1111/j.1365-2443.2012.01621.x; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; Yamaji-Hasegawa A, 2003, J BIOL CHEM, V278, P22762, DOI 10.1074/jbc.M213209200; Yilmaz N, 2013, BIOPHYS J, V105, P1397, DOI 10.1016/j.bpj.2013.07.052; Yuan CB, 2002, BIOPHYS J, V82, P2526, DOI 10.1016/S0006-3495(02)75596-3; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39	78	61	62	1	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					477	493		10.1096/fj.13-247585	http://dx.doi.org/10.1096/fj.13-247585			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25389132	hybrid			2022-12-28	WOS:000349370400013
J	Rodriguez-Contreras, D; Aslan, H; Feng, XH; Tran, K; Yates, PA; Kamhawi, S; Landfear, SM				Rodriguez-Contreras, Dayana; Aslan, Hamide; Feng, Xiuhong; Tran, Khoa; Yates, Phillip A.; Kamhawi, Shaden; Landfear, Scott M.			Regulation and biological function of a flagellar glucose transporter in Leishmania mexicana: a potential glucose sensor	FASEB JOURNAL			English	Article						environmental sensing; Leishmania parasites; protein expression; transceptor; TaV2A peptide	NUCLEOSIDE TRANSPORTER; TRYPANOSOMA-CRUZI; PRIMARY CILIUM; SEQUENCE; EXPRESSION; NUTRIENT; PROTEIN; HEXOSE; GENE; GENERATION	In Leishmania mexicana parasites, a unique glucose transporter, LmxGT1, is selectively targeted to the flagellar membrane, suggesting a possible sensory role that is often associated with ciliary membrane proteins. Expression of LmxGT1 is down-regulated similar to 20-fold by increasing cell density but is up-regulated similar to 50-fold by depleting glucose from the medium, and the permease is strongly down-regulated when flagellated insect-stage promastigotes invade mammalian macrophages and transform into intracellular amastigotes. Regulation of LmxGT1 expression by glucose and during the lifecycle operates at the level of protein stability. Significantly, Delta lmxgt1 null mutant, grown in abundant glucose, undergoes catastrophic loss of viability when parasites deplete glucose from the medium, a property not exhibited by wild-type or add-back lines. These results suggest that LmxGT1 may function as a glucose sensor that allows parasites to enter the stationary phase when they deplete glucose and that in the absence of this sensor, parasites do not maintain viability when they run out of glucose. However, alternate roles for LmxGT1 in monitoring glucose availability are considered. The absence of known sensory receptors with defined ligands and biologic functions in Leishmania and related kinetoplastid parasites underscores the potential significance of these observations.	[Rodriguez-Contreras, Dayana; Feng, Xiuhong; Tran, Khoa; Landfear, Scott M.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA; [Yates, Phillip A.] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; [Aslan, Hamide; Kamhawi, Shaden] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	Oregon Health & Science University; Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Landfear, SM (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	landfear@ohsu.edu	SUAU, Hamide ASLAN/AAD-7710-2019	SUAU, Hamide ASLAN/0000-0002-8528-0202	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR023432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920, R01AI023682, F32AI096854, R37AI023682] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCRR NIH HHS [S10 RR023432, S10-RR023432] Funding Source: Medline; NIAID NIH HHS [AI023682, R37 AI023682, AI25920, R01 AI023682, F32 AI096854, R01 AI025920] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATES PA, 1994, EXP PARASITOL, V79, P215, DOI 10.1006/expr.1994.1084; BATES PA, 1993, PARASITOL TODAY, V9, P143, DOI 10.1016/0169-4758(93)90181-E; Berbari NF, 2009, CURR BIOL, V19, pR526, DOI 10.1016/j.cub.2009.05.025; Buchanan KT, 2005, J BIOL CHEM, V280, P40104, DOI 10.1074/jbc.M505777200; Burchmore RJS, 1998, J BIOL CHEM, V273, P29118, DOI 10.1074/jbc.273.44.29118; Burchmore RJS, 2003, P NATL ACAD SCI USA, V100, P3901, DOI 10.1073/pnas.0630165100; Clayton C, 2007, MOL BIOCHEM PARASIT, V156, P93, DOI 10.1016/j.molbiopara.2007.07.007; da Silva LM, 2010, P NATL ACAD SCI USA, V107, P11965, DOI 10.1073/pnas.1004599107; El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631; ENGMAN DM, 1989, J BIOL CHEM, V264, P18627; Feng XH, 2013, MOL MICROBIOL, V87, P412, DOI 10.1111/mmi.12106; Feng XH, 2011, MOL BIOCHEM PARASIT, V175, P39, DOI 10.1016/j.molbiopara.2010.08.008; Figarella K, 2007, MOL MICROBIOL, V65, P1006, DOI 10.1111/j.1365-2958.2007.05845.x; Fulwiler AL, 2011, MOL BIOCHEM PARASIT, V175, P209, DOI 10.1016/j.molbiopara.2010.10.008; Gluenz E, 2010, FASEB J, V24, P3117, DOI 10.1096/fj.09-151381; Gluenz E, 2010, CURR OPIN MICROBIOL, V13, P473, DOI 10.1016/j.mib.2010.05.008; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Heras SR, 2006, CELL MOL LIFE SCI, V63, P1449, DOI 10.1007/s00018-006-6038-2; Holsbeeks I, 2004, TRENDS BIOCHEM SCI, V29, P556, DOI 10.1016/j.tibs.2004.08.010; Hundal HS, 2009, AM J PHYSIOL-ENDOC M, V296, pE603, DOI 10.1152/ajpendo.91002.2008; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; Jin S, 2007, J CELL SCI, V120, P379, DOI 10.1242/jcs.03349; Kamhawi S, 2000, PARASITOLOGY, V121, P25, DOI 10.1017/S0031182099006125; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; Landfear SM, 2011, EUKARYOT CELL, V10, P483, DOI 10.1128/EC.00287-10; Maric D, 2010, CURR OPIN MICROBIOL, V13, P466, DOI 10.1016/j.mib.2010.06.001; Miranda M, 2007, MOL INTERV, V7, P157, DOI 10.1124/mi.7.3.7; Mittra B, 2013, J EXP MED, V210, P401, DOI 10.1084/jem.20121368; Naderer T, 2008, CELL MICROBIOL, V10, P301, DOI 10.1111/j.1462-5822.2007.01096.x; Oberholzer M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.010538; Ortiz D, 2010, MOL MICROBIOL, V78, P108, DOI 10.1111/j.1365-2958.2010.07328.x; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; Pazour GJ, 2003, CURR OPIN CELL BIOL, V15, P105, DOI 10.1016/S0955-0674(02)00012-1; PIPER RC, 1995, J CELL BIOL, V128, P499, DOI 10.1083/jcb.128.4.499; Richard D, 2004, J BIOL CHEM, V279, P54494, DOI 10.1074/jbc.M409264200; Rodrigues Juliany Cola Fernandes, 2014, Subcell Biochem, V74, P1, DOI 10.1007/978-94-007-7305-9_1; Rodriguez-Contreras D, 2007, MOL BIOCHEM PARASIT, V153, P9, DOI 10.1016/j.molbiopara.2007.01.010; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Seyfang A, 2000, J BIOL CHEM, V275, P5687, DOI 10.1074/jbc.275.8.5687; Seyfang A, 1999, MOL BIOCHEM PARASIT, V104, P121, DOI 10.1016/S0166-6851(99)00138-3; Thevelein JM, 2009, MOL BIOL EVOL, V26, P2407, DOI 10.1093/molbev/msp168; Tran KD, 2013, J BIOL CHEM, V288, P22721, DOI 10.1074/jbc.M113.483461; Tran KD, 2012, J CELL SCI, V125, P3293, DOI 10.1242/jcs.103028; Tull D, 2004, MOL BIOL CELL, V15, P4775, DOI 10.1091/mbc.E04-06-0457; Valdes R, 2004, BIOCHEMISTRY-US, V43, P6793, DOI 10.1021/bi049873m; Vince JE, 2011, INT J PARASITOL, V41, P791, DOI 10.1016/j.ijpara.2011.02.003; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zhang WW, 2013, EUKARYOT CELL, V12, P70, DOI 10.1128/EC.00263-12	49	29	29	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					11	24		10.1096/fj.14-251991	http://dx.doi.org/10.1096/fj.14-251991			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25300620	Green Published			2022-12-28	WOS:000347378600003
J	Kumar, P; Smith, T; Rahman, K; Mells, JE; Thorn, NE; Saxena, NK; Anania, FA				Kumar, Pradeep; Smith, Tekla; Rahman, Khalidur; Mells, Jamie E.; Thorn, Natalie E.; Saxena, Neeraj K.; Anania, Frank A.			Adiponectin modulates focal adhesion disassembly in activated hepatic stellate cells: implication for reversing hepatic fibrosis	FASEB JOURNAL			English	Article						FAK; Shp2; vinculin; APPL1; myofibroblasts	TYROSINE-PHOSPHATASE SHP2; LIVER FIBROSIS; KUPFFER CELLS; T-CADHERIN; LEPTIN; MECHANISMS; MIGRATION; RATS; PHOSPHORYLATION; DIFFERENTIATION	Previous evidence indicates that adiponectin possesses antifibrogenic activity in inhibiting liver fibrosis. Therapeutic strategies, however, are limited by adiponectin quaternary structure and effective concentrations in circulation. Here we postulate a novel molecular mechanism, whereby adiponectin targets focal adhesion kinase (FAK) activity and disrupts key features of the fibrogenic response. Adiponectin-null (Ad(-/-)) mice and wild-type littermates were exposed to either saline or carbon tetrachloride (CCl4) for 6 wk. CCl4-gavaged mice were also injected with attenuated adenoviral adiponectin (Ad-Adn) or Ad-LacZ for 2 wk. Hepatic stellate cells (HSCs) were treated with or without adiponectin to elucidate signal transduction mechanisms. In vivo delivery of Ad-Adn markedly attenuates CCl4-induced expression of key integrin proteins and markers of HSC activation: alpha v, beta 3, beta 1, alpha 2(I) collagen, and alpha-smooth muscle actin. Confocal experiments of liver tissues demonstrated that adiponectin delivery also suppressed vinculin and p-FAK activity in activated HSCs. In vitro, adiponectin induced dephosphorylation of FAK, mediated by a physical association with activated tyrosine phosphatase, Shp2. Conversely, Shp2 knockdown by siRNA significantly attenuated adiponectin-induced FAK deactivation, and expression of TIMP1 and alpha 2(I) collagen was abolished in the presence of adiponectin and si-FAK. Finally, we documented that either adiponectin or the synthetic peptide with adiponectin properties, ADP355, suppressed p-FAK in synthetic matrices with stiffness measurements of 9 and 15 kPa, assessed by immunofluorescent imaging and quantitation. The in vivo and in vitro data presented indicate that disassembly of focal adhesion complexes in HSCs is pivotal for hepatic fibrosis therapy, now that small adiponectin-like peptides are available.-Kumar, P., Smith, T., Rahman, K., Mells, J. E., Thorn, N. E., Saxena, N. K., Anania, F. A. Adiponectin modulates focal adhesion disassembly in activated hepatic stellate cells: implication for reversing hepatic fibrosis.	[Kumar, Pradeep; Smith, Tekla; Rahman, Khalidur; Mells, Jamie E.; Thorn, Natalie E.; Anania, Frank A.] Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; [Saxena, Neeraj K.] Univ Maryland, Sch Med, Div Gastroenterol & Hepatol, Baltimore, MD 21201 USA	Emory University; University System of Maryland; University of Maryland Baltimore	Anania, FA (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 615 Michael St,Ste 201, Atlanta, GA 30322 USA.	fanania@emory.edu	Raeman, Reben/AAF-7282-2021	Raeman, Reben/0000-0002-3914-1797	U.S. Public Health Service [DK062092]; U.S. Department of Veterans Affairs [I01BX001746]; Emory University; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062092, R01DK062092] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001746] Funding Source: NIH RePORTER	U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); U.S. Department of Veterans Affairs(US Department of Veterans Affairs); Emory University; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	The authors thank Dr. Rebecca Wells and her laboratory staff (University of Pennsylvania, Philadelphia, PA, USA) for intellectual input with respect to experimental outcome and their assistance in helping with the glass coverslip experiments. This work was supported by grants from the U.S. Public Health Service (DK062092), the U.S. Department of Veterans Affairs (I01BX001746), and Emory University, all awarded to F.A.A.	Asada K, 2007, INT J MOL MED, V20, P725; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Christou GA, 2014, J ENDOCRINOL, V221, pR49, DOI 10.1530/JOE-13-0578; Dadson K, 2014, J CELL BIOCHEM, V115, P785, DOI 10.1002/jcb.24722; Dechene A, 2010, HEPATOLOGY, V52, P1008, DOI 10.1002/hep.23754; Denzel MS, 2010, J CLIN INVEST, V120, P4342, DOI 10.1172/JCI43464; Ding XK, 2005, AM J PATHOL, V166, P1655, DOI 10.1016/S0002-9440(10)62476-5; Friedman SL, 2004, NAT CLIN PRACT GASTR, V1, P98, DOI 10.1038/ncpgasthep0055; Friedman SL, 2010, NAT REV GASTRO HEPAT, V7, P425, DOI 10.1038/nrgastro.2010.97; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; Grossmann KS, 2010, ADV CANCER RES, V106, P53, DOI 10.1016/S0065-230X(10)06002-1; Handy JA, 2011, BIOCHEM J, V440, P385, DOI 10.1042/BJ20102148; Henderson NC, 2007, CLIN SCI, V112, P265, DOI 10.1042/CS20060242; Henderson NC, 2013, NAT MED, V19, P1617, DOI 10.1038/nm.3282; Huang YS, 2012, BRAIN DEV-JPN, V34, P674, DOI 10.1016/j.braindev.2011.10.011; Kitade M, 2006, HEPATOLOGY, V44, P983, DOI 10.1002/hep.21338; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Shuangwei, 2012, Front Med, V6, P275, DOI 10.1007/s11684-012-0216-4; Liu ML, 2012, J BIOL CHEM, V287, P26087, DOI 10.1074/jbc.M112.372292; Machado MV, 2014, MAYO CLIN PROC, V89, P120, DOI 10.1016/j.mayocp.2013.10.009; Mair M, 2011, FRONT BIOSCI-LANDMRK, V16, P2794, DOI 10.2741/3886; Nerstedt A, 2013, MOL CELL ENDOCRINOL, V375, P68, DOI 10.1016/j.mce.2013.05.013; Nigro E, 2013, INT J BIOCHEM CELL B, V45, P1145, DOI 10.1016/j.biocel.2013.03.003; Okada-Iwabu M, 2013, NATURE, V503, P493, DOI 10.1038/nature12656; Olsen AL, 2011, AM J PHYSIOL-GASTR L, V301, pG110, DOI 10.1152/ajpgi.00412.2010; Otvos L, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-90; Parsons CJ, 2004, HEPATOLOGY, V40, P1106, DOI 10.1002/hep.20425; Qamar A, 2006, DIGEST DIS SCI, V51, P1697, DOI 10.1007/s10620-006-9244-8; Rafiq K, 2006, J BIOL CHEM, V281, P19781, DOI 10.1074/jbc.M513040200; Rosenbloom J, 2013, BBA-MOL BASIS DIS, V1832, P1088, DOI 10.1016/j.bbadis.2012.12.007; Rovida E, 2008, J HEPATOL, V48, P107, DOI 10.1016/j.jhep.2007.08.010; Sam F, 2010, ENDOCRINOLOGY, V151, P322, DOI 10.1210/en.2009-0806; Saxena NK, 2004, FASEB J, V18, P1612, DOI 10.1096/fj.04-1847fje; Shen C, 2012, FRONT BIOSCI-LANDMRK, V17, P2356, DOI 10.2741/4057; Van Rossen E, 2009, HISTOCHEM CELL BIOL, V131, P313, DOI 10.1007/s00418-008-0544-2; Wang JH, 2009, GASTROENTEROLOGY, V137, P713, DOI 10.1053/j.gastro.2009.04.011	37	29	29	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5172	5183		10.1096/fj.14-253229	http://dx.doi.org/10.1096/fj.14-253229			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25154876	Green Published			2022-12-28	WOS:000345894500013
J	Du, J; Ma, X; Shen, B; Huang, Y; Birnbaumer, L; Yao, XQ				Du, Juan; Ma, Xin; Shen, Bing; Huang, Yu; Birnbaumer, Lutz; Yao, Xiaoqiang			TRPV4, TRPC1, and TRPP2 assemble to form a flow-sensitive heteromeric channel	FASEB JOURNAL			English	Article						endothelial cells; shear stress; Ca2+; mesenteric artery	VASCULAR ENDOTHELIAL-CELLS; INDUCED CA2+ INFLUX; CATION CHANNEL; NITRIC-OXIDE; SUBUNITS; EXPRESSION; ARTERIAL; COMPLEX; PKD2	Transient receptor potential (TRP) channels, a superfamily of ion channels, can be divided into 7 subfamilies, including TRPV, TRPC, TRPP, and 4 others. Functional TRP channels are tetrameric complexes consisting of 4 pore-forming subunits. The purpose of this study was to explore the heteromerization of TRP subunits crossing different TRP subfamilies. Two-step coimmunoprecipitation (co-IP) and fluorescence resonance energy transfer (FRET) were used to determine the interaction of the different TRP subunits. Patch-clamp and cytosolic Ca2+ measurements were used to determine the functional role of the ion channels in flow conditions. The analysis demonstrated the formation of a heteromeric TRPV4-C1-P2 complex in primary cultured rat mesenteric artery endothelial cells (MAECs) and HEK293 cells that were cotransfected with TRPV4, TRPC1, and TRPP2. In functional experiments, pore-dead mutants for each of these 3 TRP isoforms nearly abolished the flow-induced cation currents and Ca2+ increase, suggesting that all 3 TRPs contribute to the ion permeation pore of the channels. We identified the first heteromeric TRP channels composed of subunits from 3 different TRP subfamilies. Functionally, this heteromeric TRPV4-C1-P2 channel mediates the flow-induced Ca2+ increase in native vascular endothelial cells.Du, J., Ma, X., Shen, B., Huang, Y., Birnbaumer, L., Yao, X. TRPV4, TRPC1, and TRPP2 assemble to form a flow-sensitive heteromeric channel.	[Du, Juan; Ma, Xin; Shen, Bing; Huang, Yu; Yao, Xiaoqiang] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Du, Juan; Ma, Xin; Shen, Bing; Huang, Yu; Yao, Xiaoqiang] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Du, Juan; Shen, Bing] Anhui Med Univ, Dept Physiol, He Fei, Peoples R China; [Birnbaumer, Lutz] NIEHS, US NIH, Res Triangle Pk, NC 27709 USA	Chinese University of Hong Kong; Chinese University of Hong Kong; Anhui Medical University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Yao, XQ (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China.	yao2068@cuhk.edu.hk	Yao, Xiaoqiang/I-5413-2016; Huang, Yu/K-2866-2017	Yao, Xiaoqiang/0000-0002-0687-8186; Huang, Yu/0000-0002-1277-6784	Hong Kong Research Grants Council [CUHK478011, CUHK478710, T13-706/11, AoE/M-05/12]; U.S. National Institutes of Health [Z01-ES-101684]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES101643, ZIAES101684, Z01ES101684] Funding Source: NIH RePORTER	Hong Kong Research Grants Council(Hong Kong Research Grants Council); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank J. Li, X. Wang, and J. Guo, (Anhui Medical University), who performed co-IP and immunostaining experiments in the revision phase of the manuscript. This work was supported by grants CUHK478011, CUHK478710, T13-706/11, and AoE/M-05/12 from the Hong Kong Research Grants Council and by the Intramural Research Program of the U.S. National Institutes of Health (project Z01-ES-101684; to L.B.).	AbouAlaiwi WA, 2009, CIRC RES, V104, P860, DOI 10.1161/CIRCRESAHA.108.192765; Bahre H, 2014, BIOCHEM BIOPH RES CO, V443, P1195, DOI 10.1016/j.bbrc.2013.12.108; Bai CX, 2008, EMBO REP, V9, P472, DOI 10.1038/embor.2008.29; Barakat AI, 1999, CIRC RES, V85, P820, DOI 10.1161/01.RES.85.9.820; Cheng W, 2010, PROTEIN CELL, V1, P802, DOI 10.1007/s13238-010-0108-9; Harada J, 2003, J BIOL CHEM, V278, P38998, DOI 10.1074/jbc.M307112200; Hartmannsgruber V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000827; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Kotttgen M, 2008, J CELL BIOL, V182, P437, DOI 10.1083/jcb.200805124; Kwan HY, 2003, CIRC RES, V92, P286, DOI 10.1161/01.RES.0000054625.24468.08; Lipowsky HH, 1995, FLOW DEPENDENT REGUL; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Ma R, 2005, MOL CELL BIOL, V25, P8285, DOI 10.1128/MCB.25.18.8285-8298.2005; Ma X., 2011, BIOCH BIOPHYIS ACTA, V1808, P2789; Ma X, 2010, ARTERIOSCL THROM VAS, V30, P851, DOI 10.1161/ATVBAHA.109.196584; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; Ohata H, 2001, CIRC RES, V88, P925, DOI 10.1161/hh0901.090300; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Yang XR, 2006, AM J PHYSIOL-LUNG C, V290, pL1267, DOI 10.1152/ajplung.00515.2005; Yao X, 2000, FASEB J, V14, P932, DOI 10.1096/fasebj.14.7.932; Yao XQ, 2003, TRENDS PHARMACOL SCI, V24, P263, DOI 10.1016/S0165-6147(03)00122-6; Zheng J, 2002, NEURON, V36, P891, DOI 10.1016/S0896-6273(02)01099-1	25	79	81	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4677	4685		10.1096/fj.14-251652	http://dx.doi.org/10.1096/fj.14-251652			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25114176	Green Published, Bronze			2022-12-28	WOS:000344050900009
J	Foster, SR; Blank, K; Hoe, LES; Behrens, M; Meyerhof, W; Peart, JN; Thomas, WG				Foster, Simon R.; Blank, Kristina; Hoe, Louise E. See; Behrens, Maik; Meyerhof, Wolfgang; Peart, Jason N.; Thomas, Walter G.			Bitter taste receptor agonists elicit G-protein-dependent negative inotropy in the murine heart	FASEB JOURNAL			English	Article						Tas2r; GPCR; Langendorff; cardiovascular system	PERFUSED MOUSE HEART; G-BETA-GAMMA; SIGNALING PATHWAYS; ISCHEMIA-REPERFUSION; CELLS; CHLOROQUINE; GUSTDUCIN; CHANNEL; EXPRESSION; MECHANISM	G-protein-coupled receptors (GPCRs) are key mediators in cardiovascular physiology, yet frontline therapies for heart disease target only a small fraction of the cardiac GPCR repertoire. Moreover, there is emerging evidence that GPCRs implicated in taste (Tas1r and Tas2rs) have specific functions beyond the oral cavity. Our recent description of these receptors in heart tissue foreshadows a potential novel role in cardiac cells. In this study, we identified novel agonist ligands for cardiac-Tas2rs to enable the functional investigation of these receptors in heart tissue. Five Tas2rs cloned from heart tissue were screened against a panel of 102 natural or synthetic bitter compounds in a heterologous expression system. We identified agonists for Tas2r108, Tas2r137, and Tas2r143 that were then tested in Langendorff-perfused mouse hearts (from 8-wk-old male C57BL/6 mice). All Tas2r agonists tested exhibited concentration-dependent effects, with agonists for Tas2r108 and Tas2r137, leading to a similar to 40% decrease in left ventricular developed pressure and an increase in aortic pressure, respectively. These responses were abrogated in the presence of G alpha(i) and G beta gamma inhibitors (pertussis toxin and gallein). This study represents the first demonstration of profound Tas2r agonist-induced, G protein-dependent effects on mouse heart function.	[Foster, Simon R.; Thomas, Walter G.] Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; [Blank, Kristina; Behrens, Maik; Meyerhof, Wolfgang] German Inst Human Nutr DIfE Potsdam Rehbrucke, Dept Mol Genet, Nuthetal, Germany; [Hoe, Louise E. See; Peart, Jason N.] Griffith Univ, Griffith Hlth Inst, Gold Coast, Qld, Australia	University of Queensland; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Griffith University; Menzies Health Institute Queensland	Thomas, WG (corresponding author), Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia.	w.thomas@uq.edu.au	Hoe, Louise E See/C-6650-2017; Foster, Simon R./I-1552-2014; Thomas, Walter/I-2208-2015; Behrens, Maik/B-6753-2016	Hoe, Louise E See/0000-0003-0553-205X; Foster, Simon R./0000-0003-3034-1351; Thomas, Walter/0000-0003-0685-2952; Behrens, Maik/0000-0003-2082-8860	Australian National Health and Medical Research Council (NHMRC) [1024726]; National Heart Foundation of Australia [G-12B-6532]; Australian Postgraduate Award; National Heart Foundation of Australia; Australian Research Council	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); National Heart Foundation of Australia(National Heart Foundation of Australia); Australian Postgraduate Award(Australian Government); National Heart Foundation of Australia(National Heart Foundation of Australia); Australian Research Council(Australian Research Council)	This work was supported by project grants awarded to W.G.T. from the Australian National Health and Medical Research Council (NHMRC; 1024726) and the National Heart Foundation of Australia (G-12B-6532); an Australian Postgraduate Award scholarship to S.R.F.; a scholarship from the National Heart Foundation of Australia to L.S.H.; and a Future Fellowship from the Australian Research Council to J.N.P.	Ammon C., 2002, Archives of Physiology and Biochemistry, V110, P137, DOI 10.1076/apab.110.1.137.908; Assanasen Paraya, 2002, Clin Allergy Immunol, V17, P101; BACQ ZM, 1949, BRIT J PHARM CHEMOTH, V4, P162, DOI 10.1111/j.1476-5381.1949.tb00530.x; Ballestero JA, 2005, MOL PHARMACOL, V68, P822, DOI 10.1124/mol.105.014431; BEAMISH RE, 1945, CAN MED ASSOC J, V53, P236; Behrens M, 2004, BIOCHEM BIOPH RES CO, V319, P479, DOI 10.1016/j.bbrc.2004.05.019; Bonacci TM, 2006, SCIENCE, V312, P443, DOI 10.1126/science.1120378; Brockhoff A, 2007, J AGR FOOD CHEM, V55, P6236, DOI 10.1021/jf070503p; Brockhoff A, 2011, J NEUROSCI, V31, P14775, DOI 10.1523/JNEUROSCI.2923-11.2011; Broskova Z, 2013, PHYTOTHER RES, V27, P1018, DOI 10.1002/ptr.4825; Bufe B, 2002, NAT GENET, V32, P397, DOI 10.1038/ng1014; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Cocco G, 2010, EUR J INTERN MED, V21, P503, DOI 10.1016/j.ejim.2010.09.010; Cosmetic Ingredient Review Expert, 2001, INT J TOXICOL, V20, P23; Demion M, 2007, CARDIOVASC RES, V73, P531, DOI 10.1016/j.cardiores.2006.11.023; Deshpande DA, 2010, NAT MED, V16, P1299, DOI 10.1038/nm.2237; DeWire SM, 2011, CIRC RES, V109, P205, DOI 10.1161/CIRCRESAHA.110.231308; Dietrich A, 2011, ADV EXP MED BIOL, V704, P781, DOI 10.1007/978-94-007-0265-3_41; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; Enns GM, 2007, NEW ENGL J MED, V356, P2282, DOI 10.1056/NEJMoa066596; Falagas ME, 2008, EXPERT REV ANTI-INFE, V6, P593, DOI 10.1586/14787210.6.5.593; Finger TE, 2003, P NATL ACAD SCI USA, V100, P8981, DOI 10.1073/pnas.1531172100; Foster SR, 2014, PHARMACOL THERAPEUT, V142, P41, DOI 10.1016/j.pharmthera.2013.11.004; Foster SR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064579; Hakak Y, 2003, FEBS LETT, V550, P11, DOI 10.1016/S0014-5793(03)00762-2; Headrick JP, 2001, EXP PHYSIOL, V86, P703, DOI 10.1111/j.1469-445X.2001.tb00035.x; Huang LQ, 1999, NAT NEUROSCI, V2, P1055, DOI 10.1038/15981; Iguchi N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023165; Inesi G, 2008, BIOCHEM BIOPH RES CO, V369, P182, DOI 10.1016/j.bbrc.2007.11.161; Jang HJ, 2007, P NATL ACAD SCI USA, V104, P15069, DOI 10.1073/pnas.0706890104; Jeon TI, 2008, J CLIN INVEST, V118, P3693, DOI 10.1172/JCI36461; Kenakin T, 2013, NAT REV DRUG DISCOV, V12, P205, DOI 10.1038/nrd3954; Kesavan R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061393; KLEINSCHWARTZ W, 1991, VET HUM TOXICOL, V33, P545; KREBS HA, 1983, BIOCHEM J, V214, P657, DOI 10.1042/bj2140657; Kruse M, 2009, J CLIN INVEST, V119, P2737, DOI 10.1172/JCI38292; Lagerstrom MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518; Lakhter AJ, 2013, J INVEST DERMATOL, V133, P2247, DOI 10.1038/jid.2013.56; Lebret T, 2002, EUR UROL, V41, P608, DOI 10.1016/S0302-2838(02)00175-6; Lehmann DM, 2008, MOL PHARMACOL, V73, P410, DOI 10.1124/mol.107.041780; Levit A, 2014, FASEB J, V28, P1181, DOI 10.1096/fj.13-242594; Lim YJ, 2009, ARCH PHARM RES, V32, P367, DOI 10.1007/s12272-009-1309-8; Liu H, 2010, CIRC-CARDIOVASC GENE, V3, P374, DOI 10.1161/CIRCGENETICS.109.930867; Mace OJ, 2009, J PHYSIOL-LONDON, V587, P195, DOI 10.1113/jphysiol.2008.159616; Maeda K, 1996, J PHARMACOL EXP THER, V276, P765; Margolskee RF, 2007, P NATL ACAD SCI USA, V104, P15075, DOI 10.1073/pnas.0706678104; Meens MJPMT, 2012, BRIT J PHARMACOL, V166, P297, DOI 10.1111/j.1476-5381.2011.01774.x; Meyerhof W, 2010, CHEM SENSES, V35, P157, DOI 10.1093/chemse/bjp092; Millan MJ, 2000, SYNAPSE, V35, P79, DOI 10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X; Moore-Morris T, 2009, MOL PHARMACOL, V75, P1108, DOI 10.1124/mol.108.054155; Mueller KL, 2005, NATURE, V434, P225, DOI 10.1038/nature03352; Ozeck M, 2004, EUR J PHARMACOL, V489, P139, DOI 10.1016/j.ejphar.2004.03.004; Pal D, 2012, CARCINOGENESIS, V33, P2424, DOI 10.1093/carcin/bgs276; Park JY, 2003, ANTIMICROB AGENTS CH, V47, P3464, DOI 10.1128/AAC.47.11.3464-3469.2003; Parvez S, 2006, PHYTOTHER RES, V20, P921, DOI 10.1002/ptr.1954; Peart JN, 2006, AM J PHYSIOL-HEART C, V291, pH1746, DOI 10.1152/ajpheart.00233.2006; Perez CA, 2002, NAT NEUROSCI, V5, P1169, DOI 10.1038/nn952; Piao L, 2012, CIRCULATION, V126, P2859, DOI 10.1161/CIRCULATIONAHA.112.109868; Redfern CH, 2000, P NATL ACAD SCI USA, V97, P4826, DOI 10.1073/pnas.97.9.4826; Regard JB, 2008, CELL, V135, P561, DOI 10.1016/j.cell.2008.08.040; Reichelt ME, 2009, EXP PHYSIOL, V94, P54, DOI 10.1113/expphysiol.2008.043554; Ren XY, 2009, FRONT INTEGR NEUROSC, V3, DOI 10.3389/neuro.07.012.2009; Roosterman D, 1997, J NEUROENDOCRINOL, V9, P741, DOI 10.1046/j.1365-2826.1997.00632.x; Rozengurt N, 2006, AM J PHYSIOL-GASTR L, V291, pG792, DOI 10.1152/ajpgi.00074.2006; Saha P, 2006, CANCER LETT, V244, P252, DOI 10.1016/j.canlet.2005.12.036; Schwan A. L., 2001, ENCY REAGENTS ORGANI; Shah AS, 2009, SCIENCE, V325, P1131, DOI 10.1126/science.1173869; Shaw RM, 2013, CARDIOVASC RES, V98, P177, DOI 10.1093/cvr/cvt021; Slack JP, 2010, CURR BIOL, V20, P1104, DOI 10.1016/j.cub.2010.04.043; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; Stas P, 2008, INT J CARDIOL, V127, pE80, DOI 10.1016/j.ijcard.2007.04.055; Storms W, 2005, J ASTHMA, V42, P79, DOI 10.1081/JAS-52017; Swithers SE, 2010, PHYSIOL BEHAV, V100, P55, DOI 10.1016/j.physbeh.2009.12.021; Tan XH, 2014, BRIT J PHARMACOL, V171, P646, DOI 10.1111/bph.12460; Tiede I, 2003, J CLIN INVEST, V111, P1133, DOI 10.1172/JCI200316432; Tonnesmann E, 2013, IMMUNOPHARM IMMUNOT, V35, P434, DOI 10.3109/08923973.2013.780078; Ueda T, 2003, J NEUROSCI, V23, P7376; Watanabe H, 2008, PHARMACOL THERAPEUT, V118, P337, DOI 10.1016/j.pharmthera.2008.03.008; Wauson EM, 2012, MOL CELL, V47, P851, DOI 10.1016/j.molcel.2012.08.001; Wu SV, 2002, P NATL ACAD SCI USA, V99, P2392, DOI 10.1073/pnas.042617699; Yan WT, 2001, AM J PHYSIOL-CELL PH, V280, pC742, DOI 10.1152/ajpcell.2001.280.4.C742; Zhang CH, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001501; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200	84	55	56	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4497	4508		10.1096/fj.14-256305	http://dx.doi.org/10.1096/fj.14-256305			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25002118				2022-12-28	WOS:000342222700026
J	Schiffer, TA; Ekblom, B; Lundberg, JO; Weitzberg, E; Larsen, FJ				Schiffer, Tomas A.; Ekblom, Bjorn; Lundberg, Jon O.; Weitzberg, Eddie; Larsen, Filip J.			Dynamic regulation of metabolic efficiency explains tolerance to acute hypoxia in humans	FASEB JOURNAL			English	Article						mitochondria; maximum power principle; mitochondrial oxygen affinity; altitude	SKELETAL-MUSCLE MITOCHONDRIA; MAXIMAL OXYGEN-UPTAKE; CYTOCHROME-C-OXIDASE; OXIDATIVE-PHOSPHORYLATION; ENDURANCE PERFORMANCE; CYCLING EFFICIENCY; EXERCISE ECONOMY; CARDIAC-OUTPUT; HIGH-ALTITUDE; SEA-LEVEL	The maximum power principle dictates that open biological systems tend to self-organize to a level of efficiency that allows maximal power production. Applying this principle to cellular energetics and whole-body physiology would suggest that for every metabolic challenge, an optimal efficiency exists that maximizes power production. On exposure to hypoxia, it would be favorable if metabolic efficiency would rapidly adjust so as to better preserve work performance. We tested this idea in humans by measuring metabolic efficiency and exercise tolerance under normoxic (FiO2=20.9%) and hypoxic (FiO2=16%) conditions, where FiO2 is fraction of inhaled oxygen. The results were compared with respirometric analyses of skeletal muscle mitochondria from the same individuals. We found that among healthy trained subjects (n=14) with a wide range of metabolic efficiency (ME), those with a high ME during normoxic exercise were able to better maintain exercise capacity (W-max) in hypoxia. On hypoxic exposure, these subjects acutely decreased their efficiency from 19.2 to 17.4%, thereby likely shifting it closer to a degree of efficiency where maximal power production is achieved. In addition, mitochondria from these subjects had a lower intrinsic respiration compared to subjects that showed a large drop in Wmax in hypoxia An acute shift in efficiency was also demonstrated in isolated mitochondria exposed to physiological levels of hypoxia as P/O ratio increased from 0.9 to 1.3 with hypoxic exposure. These findings suggest the existence of a physiological adaptive response by which metabolic efficiency is dynamically optimized to maximize power production.	[Schiffer, Tomas A.; Lundberg, Jon O.; Weitzberg, Eddie; Larsen, Filip J.] Karolinska Inst, Dept Physiol & Pharmacol, S-11486 Stockholm, Sweden; [Ekblom, Bjorn] Swedish Sch Sports & Hlth Sci, Astrand Lab Work Physiol, Stockholm, Sweden	Karolinska Institutet; Swedish School of Sport & Health Sciences	Larsen, FJ (corresponding author), Karolinska Inst, Nanna Svartz 2, S-11486 Stockholm, Sweden.	filip.larsen@ki.se	Schiffer, Tomas/X-1343-2018	Schiffer, Tomas/0000-0002-9077-2682; Lundberg, Jon/0000-0002-0174-5210				Bassett DR, 2000, MED SCI SPORT EXER, V32, P70, DOI 10.1097/00005768-200001000-00012; Benoit H, 1997, INT J SPORTS MED, V18, P101, DOI 10.1055/s-2007-972603; BROUWER E, 1957, ACTA PHYSIOL PHARM N, V6, P795; CERRETELLI P, 1992, RESPIRATION, V59, P24; Clerc P, 2007, J BIOENERG BIOMEMBR, V39, P158, DOI 10.1007/s10863-007-9074-1; Curran LS, 1998, AM J PHYS ANTHROPOL, V105, P21, DOI 10.1002/(SICI)1096-8644(199801)105:1<21::AID-AJPA3>3.0.CO;2-G; Fukuda T, 2010, INT HEART J, V51, P170, DOI 10.1536/ihj.51.170; Gnaiger E, 2000, P NATL ACAD SCI USA, V97, P11080, DOI 10.1073/pnas.97.20.11080; Gore CJ, 2001, ACTA PHYSIOL SCAND, V173, P275, DOI 10.1046/j.1365-201X.2001.00906.x; HOCHACHKA PW, 1991, J APPL PHYSIOL, V70, P1720, DOI 10.1152/jappl.1991.70.4.1720; HOWALD H, 1990, INT J SPORTS MED, V11, pS10, DOI 10.1055/s-2007-1024847; Jacobs RA, 2011, J APPL PHYSIOL, V111, P1422, DOI 10.1152/japplphysiol.00625.2011; Jacobs RA, 2012, FASEB J, V26, P5192, DOI 10.1096/fj.12-218206; Kadenbach B, 2000, FREE RADICAL BIO MED, V29, P211, DOI 10.1016/S0891-5849(00)00305-1; Karsenti E, 2008, NAT REV MOL CELL BIO, V9, P255, DOI 10.1038/nrm2357; Katayama K, 2003, HIGH ALT MED BIOL, V4, P291, DOI 10.1089/152702903769192250; KRAMER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5807, DOI 10.1073/pnas.80.19.5807; Kudin A, 2002, MOL BIOL REP, V29, P89, DOI 10.1023/A:1020374924550; Lador F, 2013, RESP PHYSIOL NEUROBI, V186, P206, DOI 10.1016/j.resp.2013.01.017; Lapuente-Brun E, 2013, SCIENCE, V340, P1567, DOI 10.1126/science.1230381; Larsen FJ, 2011, FASEB J, V25, P2843, DOI 10.1096/fj.11-182139; Larsen FJ, 2011, CELL METAB, V13, P149, DOI 10.1016/j.cmet.2011.01.004; Latshang TD, 2013, SCAND J MED SCI SPOR, V23, P458, DOI 10.1111/j.1600-0838.2011.01403.x; LAWLER J, 1988, J APPL PHYSIOL, V64, P1486, DOI 10.1152/jappl.1988.64.4.1486; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Levett DZ, 2012, FASEB J, V26, P1431, DOI 10.1096/fj.11-197772; Lundby C, 2007, SCAND J MED SCI SPOR, V17, P281, DOI 10.1111/j.1600-0838.2006.00530.x; Lundby C, 2002, ACTA PHYSIOL SCAND, V176, P195, DOI 10.1046/j.1365-201X.2002.01030.x; Mogensen M, 2006, J PHYSIOL-LONDON, V571, P669, DOI 10.1113/jphysiol.2005.101691; Mollard P, 2007, EUR J APPL PHYSIOL, V100, P663, DOI 10.1007/s00421-007-0457-0; ODUM HT, 1955, AM SCI, V43, P331; Ponsot E, 2010, AM J PHYSIOL-REG I, V298, pR558, DOI 10.1152/ajpregu.00216.2009; Prieur F, 2005, MED SCI SPORT EXER, V37, P664, DOI 10.1249/01.MSS.0000159140.11938.97; Richardson RS, 2001, J APPL PHYSIOL, V91, P2679, DOI 10.1152/jappl.2001.91.6.2679; Saltin B., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P209; SALTIN B, 1967, J APPL PHYSIOL, V23, P353, DOI 10.1152/jappl.1967.23.3.353; STUCKI JW, 1980, EUR J BIOCHEM, V109, P269, DOI 10.1111/j.1432-1033.1980.tb04792.x	37	7	7	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4303	4311		10.1096/fj.14-251710	http://dx.doi.org/10.1096/fj.14-251710			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24970395				2022-12-28	WOS:000342222700010
J	Li, PC; Wei, XC; Guan, YJ; Chen, Q; Zhao, TC; Sun, CQ; Wei, L				Li, Pengcui; Wei, Xiaochun; Guan, Yingjie; Chen, Qian; Zhao, Tingcun; Sun, Changqi; Wei, Lei			MicroRNA-1 regulates chondrocyte phenotype by repressing histone deacetylase 4 during growth plate development	FASEB JOURNAL			English	Article						differentiation; HDAC4; Runx2; collagen X	INDIAN HEDGEHOG; RUNX2 CONTRIBUTES; GENE-REGULATION; DIFFERENTIATION; PROLIFERATION; HYPERTROPHY; EXPRESSION; TARGET; DYSREGULATION; MATURATION	MicroRNAs (miRs) are noncoding RNAs (17-25 nt) that control translation and/or mRNA degradation. Using Northern blot analysis, we identified that miR-1 is specifically expressed in growth plate cartilage in addition to muscle tissue, but not in brain, intestine, liver, or lung. We obtained the first evidence that miR-1 is highly expressed in the hypertrophic zone of the growth plate, with an 8-fold increase compared with the proliferation zone; this location coincides with the Ihh and Col X expression regions in vivo. MiR-1 significantly induces chondrocyte proliferation and differentiation. We further identified histone deacetylase 4 (HDAC4) as a target of miR-1. HDAC4 negatively regulates chondrocyte hypertrophy by inhibiting Runx2, a critical transcription factor for chondrocyte hypertrophy. MiR-1 inhibits both endogenous HDAC4 protein by 2.2-fold and the activity of a reporter gene bearing the 3'-untranslated region (UTR) of HDAC4 by 3.3-fold. Conversely, knockdown of endogenous miR-1 relieves the repression of HDAC4. Deletion of the miR-1 binding site in HDAC4 3'-UTR or mutated miR-1 abolishes miR-1-mediated inhibition of the reporter gene activity. Overexpression of HDAC4 reverses miR-1 induction of chondrocyte differentiation markers Col X and Ihh. HDAC4 inhibits Runx2 promoter activity in a dosage-dependent manner. Thus, miR-1 plays an important role in the regulation of the chondrocyte phenotype during the growth plate development via direct targeting of HDAC4.	[Li, Pengcui; Wei, Xiaochun; Wei, Lei] Shanxi Med Univ, Hosp 2, Dept Orthopaed, Shanxi Key Lab Bone & Soft Tissue Injury Repair, Taiyuan, Peoples R China; [Guan, Yingjie; Chen, Qian; Sun, Changqi; Wei, Lei] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Orthopaed, Providence, RI 02903 USA; [Zhao, Tingcun] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Surg, Providence, RI 02903 USA	Shanxi Medical University; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Wei, L (corresponding author), Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Orthopaed, Corp Off West,Suite 402H,1 Hoppin St, Providence, RI 02903 USA.	lei_wei@brown.edu	Chen, Qian/C-4354-2011	Chen, Qian/0000-0003-4406-5618	U.S. National Insitutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR059142]; NIH/National Institute of General Medical Sciences [P20GM104937]; National Science Foundation of China [81071495, 81171676, 31271033]; SXNSF [2011011042]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104937] Funding Source: NIH RePORTER	U.S. National Insitutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases; NIH/National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); SXNSF; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The project was supported by grants R01AR059142 from U.S. National Insitutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases and P20GM104937 from NIH/National Institute of General Medical Sciences, National Science Foundation of China grants 81071495, 81171676 and 31271033, SXNSF 2011011042. The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH. The authors gratefully acknowledge Dr. Ericka M. Bueno for help with the manuscript preparation and editorial services.	Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Correa D, 2010, DEV CELL, V19, P533, DOI 10.1016/j.devcel.2010.09.008; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Eulalio A, 2007, GENE DEV, V21, P2558, DOI 10.1101/gad.443107; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Guan YJ, 2011, FASEB J, V25, P4457, DOI 10.1096/fj.11-185132; Guan YJ, 2012, AM J PHYSIOL-CELL PH, V303, pC33, DOI 10.1152/ajpcell.00348.2011; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kobayashi T, 2008, P NATL ACAD SCI USA, V105, P1949, DOI 10.1073/pnas.0707900105; Lai LP, 2005, J CELL BIOCHEM, V96, P1163, DOI 10.1002/jcb.20635; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Li FF, 2011, J BONE MINER RES, V26, P2899, DOI 10.1002/jbmr.504; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; Lin ZQ, 2009, P NATL ACAD SCI USA, V106, P12103, DOI 10.1073/pnas.0811371106; Liu XL, 2011, CELL PHYSIOL BIOCHEM, V27, P391, DOI 10.1159/000327966; Qu DZ, 2011, ANAL BIOCHEM, V417, P112, DOI 10.1016/j.ab.2011.05.037; Redfern AD, 2013, P NATL ACAD SCI USA, V110, P6536, DOI 10.1073/pnas.1301620110; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Wang Y, 2008, CLIN GENET, V74, P307, DOI 10.1111/j.1399-0004.2008.01075.x; Wei F, 2012, OSTEOARTHR CARTILAGE, V20, P755, DOI 10.1016/j.joca.2012.03.010; Wei L, 2010, J ORTHOP RES, V28, P900, DOI 10.1002/jor.21093; Wei L, 2010, DEV BIOL, V341, P236, DOI 10.1016/j.ydbio.2010.02.033; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zhang Y, 2000, J BIOL CHEM, V275, P32628, DOI 10.1074/jbc.M002594200; Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030; Zheng QP, 2003, J CELL BIOL, V162, P833, DOI 10.1083/jcb.200211089	35	35	41	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3930	3941		10.1096/fj.13-249318	http://dx.doi.org/10.1096/fj.13-249318			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24858276	Green Published			2022-12-28	WOS:000340845900011
J	Tani, Y; Isobe, Y; Imoto, Y; Segi-Nishida, E; Sugimoto, Y; Arai, H; Arita, M				Tani, Yukako; Isobe, Yosuke; Imoto, Yuki; Segi-Nishida, Eri; Sugimoto, Yukihiko; Arai, Hiroyuki; Arita, Makoto			Eosinophils control the resolution of inflammation and draining lymph node hypertrophy through the proresolving mediators and CXCL13 pathway in mice	FASEB JOURNAL			English	Article						lipid mediator; lipoxygenase	LIPID MEDIATORS; IN-VIVO; MACROPHAGES; CHEMOKINE; FOLLICLES; RECEPTOR; LYMPHANGIOGENESIS; NEUTROPHILS; EXPRESSION; LIPOXINS	Resolution of inflammation is critical to restoration of tissue function after an inflammatory response. We previously demonstrated that 12/15-lipoxygenase (12/15-LOX)-expressing eosinophils contribute to this process in murine zymosan-induced peritonitis. In this study, eosinophils promoted resolution by regulating expression of macrophage CXCL13. Microarray analysis revealed that eosinophils significantly increased (similar to 3-fold) the expression of macrophage CXCL13 by a 12/15-LOX-dependent mechanism. CXCL13 depletion caused a resolution defect, with the reduced appearance of phagocytes carrying engulfed zymosan in the draining lymph nodes. Inflamed lymph node hypertrophy, a critical feature of the resolution process, was reduced by similar to 60% in eosinophil-deficient mice, and adoptive transfer of eosinophils or administration of CXCL13 corrected this defect. Administration of the 12/15-LOX-derived mediator lipoxin A(4) (LXA(4)) increased the expression of CXCL13 and restored the defect of lymph node hypertrophy in eosinophil-deficient mice. These results demonstrate that eosinophils control the resolution of inflammation and draining lymph node hypertrophy through proresolving lipid mediators and the CXCL13 pathway in mice.	[Tani, Yukako; Isobe, Yosuke; Arai, Hiroyuki; Arita, Makoto] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan; [Isobe, Yosuke; Arita, Makoto] RIKEN Ctr Integrat Med Sci, Lab Metabol, Kanagawa, Japan; [Arita, Makoto] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Saitama, Japan; [Imoto, Yuki; Segi-Nishida, Eri] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Kyoto, Japan; [Sugimoto, Yukihiko] Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmaceut Biochem, Kumamoto, Japan	University of Tokyo; RIKEN; Japan Science & Technology Agency (JST); Kyoto University; Kumamoto University	Arita, M (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	marita@mol.f.u-tokyo.ac.jp	Segi-Nishida, Eri/K-5059-2019; Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X; Arita, Makoto/0000-0001-9902-0463; Segi-Nishida, Eri/0000-0002-0803-6513	Japanese Science and Technology Agency Precursory Research for Embryonic Science and Technology (PRESTO); Ministry of Education, Culture, Sports, Science, and Technology of Japan; Grants-in-Aid for Scientific Research [25460096] Funding Source: KAKEN	Japanese Science and Technology Agency Precursory Research for Embryonic Science and Technology (PRESTO); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Michiko Kamio and Ryo Iwamoto (Business-Academia Collaborative Laboratory, Graduate School of Pharmaceutical Sciences, University of Tokyo) for skillful technical assistance. This study was supported by the Japanese Science and Technology Agency Precursory Research for Embryonic Science and Technology (PRESTO) and a grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to M. A.). The authors report no conflicts of interest.	Angeli V, 2006, IMMUNITY, V24, P203, DOI 10.1016/j.immuni.2006.01.003; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Ansel KM, 2002, IMMUNITY, V16, P67, DOI 10.1016/S1074-7613(01)00257-6; Arita M, 2012, J BIOCHEM, V152, P313, DOI 10.1093/jb/mvs092; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Bellingan GJ, 1996, J IMMUNOL, V157, P2577; COLGAN SP, 1993, J CLIN INVEST, V92, P75, DOI 10.1172/JCI116601; Cupedo T, 2005, J IMMUNOL, V174, P21, DOI 10.4049/jimmunol.174.1.21; Cyster JG, 2000, IMMUNOL REV, V176, P181; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Kataru RP, 2009, BLOOD, V113, P5650, DOI 10.1182/blood-2008-09-176776; LARSEN GL, 1983, ANNU REV IMMUNOL, V1, P335, DOI 10.1146/annurev.iy.01.040183.002003; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Lawrence T, 2007, INT J EXP PATHOL, V88, P85, DOI 10.1111/j.1365-2613.2006.00507.x; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Luther SA, 2003, J EXP MED, V197, P1191, DOI 10.1084/jem.20021294; Mebius RE, 2003, NAT REV IMMUNOL, V3, P292, DOI 10.1038/nri1054; Mebius RE, 1996, P NATL ACAD SCI USA, V93, P11019, DOI 10.1073/pnas.93.20.11019; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2005, PROSTAG LEUKOTR ESS, V73, P141, DOI 10.1016/j.plefa.2005.05.002; Stables MJ, 2011, BLOOD, V118, pE192, DOI 10.1182/blood-2011-04-345330; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; van de Pavert SA, 2009, NAT IMMUNOL, V10, P1193, DOI 10.1038/ni.1789; Wu D, 2011, SCIENCE, V332, P243, DOI 10.1126/science.1201475; Yamada T, 2011, FASEB J, V25, P561, DOI 10.1096/fj.10-170027; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; Zhang X, 2008, J PATHOL, V214, P161, DOI 10.1002/path.2284	36	27	27	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4036	4043		10.1096/fj.14-251132	http://dx.doi.org/10.1096/fj.14-251132			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24891522	Green Published			2022-12-28	WOS:000340845900021
J	Yarborough, M				Yarborough, Mark			Taking steps to increase the trustworthiness of scientific research	FASEB JOURNAL			English	Article						public trust; quality improvement	THERAPEUTIC MISCONCEPTION; INTEGRITY; CONSENT; TRIALS	To enjoy the public's trust, the research community must first be clear about what it is expected to do and then avoid the incidents that prevent it from meeting those expectations. Among other things, there are expectations that published scientific results will be reliable, that research has the potential to contribute to the common good, and that research will be conducted ethically. Consequently, the scientific community needs to avoid lapses that prevent it from meeting these three expectations. This requires a strong commitment to trustworthy research practices, as well as mechanisms that diminish lapses that inevitably occur in complex endeavors such as scientific research. The author presents a model to assess the strength of commitment to trustworthy research and explores proven quality assurance mechanisms that can diminish lapses in research injurious to the public's trust. Some mechanisms identify in advance ways that things can go wrong so that steps can be taken to prevent them from going wrong in the first place. Other mechanisms investigate past errors or near misses to discover their causes so that they can be addressed to avoid similar future instances. The author explains why such methods are useful to efforts to promote research worthy of the public's trust.	Univ Calif Davis, Bioeth Program, Sacramento, CA 95817 USA	University of California System; University of California Davis	Yarborough, M (corresponding author), Univ Calif Davis, Bioeth Program, 4150 V St,Suite G100, Sacramento, CA 95817 USA.	mark.yarborough@ucdmc.ucdavis.edu	Yarborough, Mark/L-4098-2019	Yarborough, Mark/0000-0001-8188-4968	U.S. National Institutes of Health [TR 000002]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000002] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The author thanks Dr. Jeffrey Elias, Dr. Lee Hilborne, Dr. Michael S. Wilkes, and anonymous reviewers for helpful editorial comments pertaining to portions of the manuscript. A portion of the author's time was supported by the U.S. National Institutes of Health, through grant TR 000002.	American Association for the Advancement of Science, 2010, AAAS MISS; [Anonymous], 2010, NATURE, V466, P7; Apkon M, 2004, QUAL SAF HEALTH CARE, V13, P265, DOI 10.1136/qshc.2003.007443; APPELBAUM PS, 1982, INT J LAW PSYCHIAT, V5, P319, DOI 10.1016/0160-2527(82)90026-7; Basken P., 2010, CHRON HIGHER ED; Cicerone RJ, 2010, SCIENCE, V327, P624, DOI 10.1126/science.1187612; Drenth P., 2010, FOSTSERING RES INTEG; Hardin Russell, 2002, RUSSELL SAGE FDN SER; Hudson P, 2003, QUAL SAF HEALTH CARE, V12, pI7, DOI 10.1136/qhc.12.suppl_1.i7; II BRISPE, 2013, 2 STAT 2 BRAZ M RES; Jasny BR, 2011, SCIENCE, V334, P1225, DOI 10.1126/science.334.6060.1225; Kass NE, 2011, J GEN INTERN MED, V26, P1324, DOI 10.1007/s11606-011-1778-6; Kimmelman J, 2007, HASTINGS CENT REP, V37, P36, DOI 10.1353/hcr.2007.0092; Liverman C.T., 2013, CTSA PROGRAM NIH OPP; Opel DJ, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2; Rayner S., 2010, SCI TRUST EXPERT GRO; Research Triangle Institute, 1996, SURV ACC EX IND RES; Rooney J. J., 2004, QUAL PROG, V37, P45; Shamoo AE, 2013, ACCOUNT RES, V20, P369, DOI 10.1080/08989621.2013.822259; Steneck N., 2010, 2 WORLD C RES INT JU; U.S. Department of Health and Human Services, 2012, FUND OPP ANN NUMB RF; U.S. Department of Veterans Affairs, 2007, VA NATL CTR PAT SAF; Wu AW, 2008, JAMA-J AM MED ASSOC, V299, P685, DOI 10.1001/jama.299.6.685; Yarborough M, 2009, ACAD MED, V84, P472, DOI 10.1097/ACM.0b013e31819a8aa6; Yarborough MA, 2013, MAYO CLIN PROC, V88, P442, DOI 10.1016/j.mayocp.2013.03.001	25	7	7	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3841	3846		10.1096/fj.13-246603	http://dx.doi.org/10.1096/fj.13-246603			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24928193	Green Published, Green Submitted			2022-12-28	WOS:000340845900003
J	Sipila, K; Haag, S; Denessiouk, K; Kapyla, J; Peters, EC; Denesyuk, A; Hansen, U; Konttinen, Y; Johnson, MS; Holmdahl, R; Heino, J				Sipila, Kalle; Haag, Sabrina; Denessiouk, Konstantin; Kapyla, Jarmo; Peters, Eric C.; Denesyuk, Alexander; Hansen, Uwe; Konttinen, Yrjo; Johnson, Mark S.; Holmdahl, Rikard; Heino, Jyrki			Citrullination of collagen II affects integrin-mediated cell adhesion in a receptor-specific manner	FASEB JOURNAL			English	Article						PAD; rheumatoid arthritis	MESENCHYMAL STEM-CELLS; ALPHA-2-BETA-1 INTEGRIN; BINDING-SITES; ACTIVATION; IDENTIFICATION; MOUSE; ALPHA(1)BETA(1); ALPHA-1-BETA-1; INFLAMMATION; RECOGNIZES	Citrullinated collagen II (CII) is a well-known autoantigen in rheumatoid arthritis (RA). However, the direct effects of CII citrullination on cell behavior have not been described. To study whether citrullination of CII could affect cellular functions, we measured the adhesion of 3 different cell types (human Saos2 osteosarcoma cells, human synovial fibroblasts, and rat mesenchymal stem cells) with impedance-based technology. The binding of different collagen receptor integrins to citrullinated collagen was studied by CHO cell lines, each overexpressing 1 of the 4 human collagen receptors on the cell surface, and with solid-phase binding assays, using the recombinant human integrin alpha I-1, alpha I-2, alpha I-10, and alpha I-11 domains. Collagen citrullination decreased the adhesion of synovial fibroblasts similar to 50% (P<0.05) and mesenchymal stem cells similar to 40% (P<0.05) by specifically decreasing the binding of integrins alpha(10)beta(1) and alpha(11)beta(1) to arginine-containing motifs, such as GFOGER. In contrast, citrullination had only a minor effect on the function of alpha(1)beta(1) and alpha(2)beta(1) integrins, which have been reported to play a critical role in regulating leukocyte function. Molecular modeling was used to explain the detected functional differences at the structural level. Given that the integrins regulate cell metabolism, proliferation, and migration, we suggest that collagen citrullination modifies the pathogenesis of RA. Here, CII citrullination was shown to decrease the survival of mesenchymal stem cells.-Sipil, K., Haag, S., Denessiouk, K., Kapyla, J., Peters, E. C., Denesyuk, A., Hansen, U., Konttinen, Y., Johnson, M. S., Holmdahl, R., Heino, J. Citrullination of collagen II affects integrin-mediated cell adhesion in a receptor-specific manner.	[Sipila, Kalle; Kapyla, Jarmo; Heino, Jyrki] Univ Turku, Dept Biochem, FI-20014 Turku, Finland; [Holmdahl, Rikard] Univ Turku, Med Res Lab, FI-20014 Turku, Finland; [Haag, Sabrina; Holmdahl, Rikard] Karolinska Inst, Dept Med Biochem & Biophys, Div Med Inflammat Res, Stockholm, Sweden; [Denessiouk, Konstantin; Denesyuk, Alexander; Johnson, Mark S.] Abo Akad Univ, Dept Biosci, Struct Bioinformat Lab, Turku, Finland; [Peters, Eric C.] Novartis Res Fdn, Genom Inst, San Diego, CA USA; [Hansen, Uwe] Muenster Univ Hosp, Dept Physiol Chem & Pathobiochem, Munster, Germany; [Konttinen, Yrjo] Univ Helsinki, Inst Clin Med, Dept Med, Helsinki, Finland	Finland National Institute for Health & Welfare; University of Turku; University of Turku; Karolinska Institutet; Abo Akademi University; Novartis; University of Munster; University of Helsinki	Heino, J (corresponding author), Univ Turku, Dept Biochem, Vatselankatu 2,3rd Floor, FI-20014 Turku, Finland.	jyrki.heino@utu.fi	Peters, Eric/W-2739-2019; Holmdahl, Rikard/AAI-7682-2020	Kapyla, Jarmo/0000-0003-3036-713X	Academy of Finland; Sigfrid Juselius Foundation; Turku Doctoral Programme of Biomedical Science; Swedish Research Council; Strategic Research Foundation; K. A. Wallenberg Foundation; Abo Akademi Center for Excellence in Cell Stress and Aging; European Community [HEALTH-F2-2008-223404]; European Union Innovative Medicines Inititative [115142]	Academy of Finland(Academy of Finland); Sigfrid Juselius Foundation; Turku Doctoral Programme of Biomedical Science; Swedish Research Council(Swedish Research CouncilEuropean Commission); Strategic Research Foundation; K. A. Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Abo Akademi Center for Excellence in Cell Stress and Aging; European Community(European Commission); European Union Innovative Medicines Inititative	The authors thank H. Niskanen, MSc, for performing the flow cytometric analyses for the Supplemental Material. The research was supported by grants from the Academy of Finland, the Sigfrid Juselius Foundation, the Turku Doctoral Programme of Biomedical Science, the Swedish Research Council, the Strategic Research Foundation, the K. A. Wallenberg Foundation, and the Abo Akademi Center for Excellence in Cell Stress and Aging. The research also received funding from the European Community's Framework programs under grant agreements Masterswitch (HEALTH-F2-2008-223404) and the European Union Innovative Medicines Inititative project BeTheCure 115142. The authors declare no conflicts of interest.	ANDERSSON M, 1990, EUR J IMMUNOL, V20, P1061, DOI 10.1002/eji.1830200517; Ben-Horin S, 2004, CLIN IMMUNOL, V113, P119, DOI 10.1016/j.clim.2004.06.007; Bengtsson T, 2005, J CELL SCI, V118, P929, DOI 10.1242/jcs.01678; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blaschke UK, 2000, J BIOL CHEM, V275, P10370, DOI 10.1074/jbc.275.14.10370; Burkhardt H, 2005, EUR J IMMUNOL, V35, P1643, DOI 10.1002/eji.200526000; Connors WL, 2007, J BIOL CHEM, V282, P14675, DOI 10.1074/jbc.M700759200; de Fougerolles AR, 2000, J CLIN INVEST, V105, P721, DOI 10.1172/JCI7911; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Foulquier C, 2007, ARTHRITIS RHEUM-US, V56, P3541, DOI 10.1002/art.22983; Gardner H, 1999, J CELL SCI, V112, P263; Gouttenoire J, 2010, EUR J CELL BIOL, V89, P307, DOI 10.1016/j.ejcb.2009.10.018; Hao G, 2009, J AM SOC MASS SPECTR, V20, P723, DOI 10.1016/j.jasms.2008.12.012; Heino J, 2007, BIOESSAYS, V29, P1001, DOI 10.1002/bies.20636; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; Kapyla J, 2004, J BIOL CHEM, V279, P51677, DOI 10.1074/jbc.M409412200; Kehrel B, 1998, BLOOD, V91, P491; Kinloch A, 2008, ARTHRITIS RHEUM, V58, P2287, DOI 10.1002/art.23618; Klareskog L, 2011, SEMIN IMMUNOL, V23, P92, DOI 10.1016/j.smim.2011.01.014; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Konitsiotis AD, 2008, J BIOL CHEM, V283, P6861, DOI 10.1074/jbc.M709290200; KONTTINEN YT, 1989, J RHEUMATOL, V16, P339; Lahti M, 2011, J BIOL CHEM, V286, P43343, DOI 10.1074/jbc.M111.261909; Lebbink RJ, 2006, J EXP MED, V203, P1419, DOI 10.1084/jem.20052554; Lebbink RJ, 2009, MATRIX BIOL, V28, P202, DOI 10.1016/j.matbio.2009.03.005; Lehtonen JV, 2004, J COMPUT AID MOL DES, V18, P401, DOI 10.1007/s10822-004-3752-4; Licklider LJ, 2002, ANAL CHEM, V74, P3076, DOI 10.1021/ac025529o; MacFarlane RJ, 2013, EXPERT OPIN THER TAR, V17, P243, DOI 10.1517/14728222.2013.746954; Mccall-Culbreath KD, 2008, BLOOD, V111, P3562, DOI 10.1182/blood-2007-08-107664; Mirtti T, 2006, INT J CANCER, V118, P889, DOI 10.1002/ijc.21430; Moelants EAV, 2013, CYTOKINE, V61, P161, DOI 10.1016/j.cyto.2012.09.011; Mortier A, 2011, EXP CELL RES, V317, P642, DOI 10.1016/j.yexcr.2010.11.016; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Olsen BR, 1997, INT J BIOCHEM CELL B, V29, P555, DOI 10.1016/S1357-2725(96)00100-8; Orgel JPRO, 2011, CONNECT TISSUE RES, V52, P18, DOI 10.3109/03008207.2010.511354; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Peters MA, 2012, ARTHRITIS RHEUM-US, V64, P1359, DOI 10.1002/art.33487; Popov C, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.71; Raducanu A, 2009, J BIOL CHEM, V284, P23780, DOI 10.1074/jbc.M109.039347; Raynal N, 2006, J BIOL CHEM, V281, P3821, DOI 10.1074/jbc.M509818200; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; Shelef MA, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4083; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; Uysal H, 2010, IMMUNOL REV, V233, P9, DOI 10.1111/j.0105-2896.2009.00853.x; Uysal H, 2009, J EXP MED, V206, P449, DOI 10.1084/jem.20081862; Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357; Wang YM, 2009, J CELL BIOL, V184, P205, DOI 10.1083/jcb.200806072; Xu HF, 2011, MATRIX BIOL, V30, P16, DOI 10.1016/j.matbio.2010.10.004; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200; Zutter MM, 2007, IMMUNOBIOLOGY, V212, P343, DOI 10.1016/j.imbio.2006.11.013	55	28	28	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3758	3768		10.1096/fj.13-247767	http://dx.doi.org/10.1096/fj.13-247767			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24823363				2022-12-28	WOS:000340265400041
J	Coward, WR; Feghali-Bostwick, CA; Jenkins, G; Knox, AJ; Pang, LH				Coward, William R.; Feghali-Bostwick, Carol A.; Jenkins, Gisli; Knox, Alan J.; Pang, Linhua			A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis	FASEB JOURNAL			English	Article						histone hypermethylation; DNA methylation; histone deacetylation; antifibrotic gene; lung fibroblasts	SMALL-MOLECULE INHIBITOR; BINDING PROTEIN MECP2; HISTONE METHYLTRANSFERASE; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; LUNG FIBROBLASTS; EXPRESSION; CONTRIBUTE; CHROMATIN; ENHANCER	Selective silencing of the cyclooxygenase-2 (COX-2) gene with the loss of the antifibrotic mediator prostaglandin E-2 contributes to the fibrotic process in idiopathic pulmonary fibrosis (IPF). This study explored the role of G9a- and enhancer of zeste homolog 2 (EZH2)-mediated methylation of histone H3 lysine 9 (H3K9me3) and histone H3 lysine 27 (H3K27me3) in COX-2 silencing in IPF. Chromatin immunoprecipitation (ChIP) and re-ChIP assays demonstrated marked increases in H3K9me3, H3K27me3, and DNA methylation, together with their respective modifying enzymes G9a, EZH2, and DNA methyltransferases (Dnmts) and respective binding proteins heterochromatin protein 1 (HP1), polycomb protein complex 1 (PRC1) and methyl CpG binding protein 2 (MeCP2), at the COX-2 promoter in lung fibroblasts from patients with IPF (F-IPFs) compared with fibroblasts from nonfibrotic lungs. HP1, EZH2, and MeCP2 in turn were associated with additional repressive chromatin modifiers in F-IPFs. G9a and EZH2 inhibitors and small interfering RNAs and the Dnmt1 inhibitor markedly reduced H3K9me3 (49-79%), H3K27me3 (44-81%), and DNA methylation (61-97%) at the COX-2 promoter. These reductions were correlated with increased histone H3 and H4 acetylation, resulting in COX-2 mRNA and protein reexpression in F-IPFs. Our results support a central role for G9a- and EZH2-mediated histone hypermethylation and a model of bidirectional, mutually reinforcing, and interdependent crosstalk between histone hypermethylation and DNA methylation in COX-2 epigenetic silencing in IPF.	[Coward, William R.; Jenkins, Gisli; Knox, Alan J.; Pang, Linhua] Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England; [Coward, William R.; Jenkins, Gisli; Knox, Alan J.; Pang, Linhua] Univ Nottingham, City Hosp, Nottingham Resp Biomed Res Unit, Nottingham NG5 1PB, England; [Feghali-Bostwick, Carol A.] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pang, LH (corresponding author), Univ Nottingham, City Hosp, Div Resp Med, Clin Sci Bldg, Nottingham NG5 1PB, England.	linhua.pang@nottingham.ac.uk	Jenkins, Gisli/R-8143-2017	Jenkins, Gisli/0000-0002-7929-2119; Knox, Alan/0000-0002-5906-4143	UK Medical Research Council [G0600890, MR/K003259/1]; Wellcome Trust [088751]; MRC [G0600890, MR/K003259/1] Funding Source: UKRI; Medical Research Council [G0600890, MR/K003259/1] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the UK Medical Research Council (grants G0600890 and MR/K003259/1) and the Wellcome Trust (grant 088751).	Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646; BOROK Z, 1991, AM REV RESPIR DIS, V144, P1080, DOI 10.1164/ajrccm/144.5.1080; Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957; Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833; Choi JY, 2013, APOPTOSIS, V18, P99, DOI 10.1007/s10495-012-0768-4; Coward WR, 2010, MOL CELL BIOL, V30, P2874, DOI 10.1128/MCB.01527-09; Coward WR, 2009, MOL CELL BIOL, V29, P4325, DOI 10.1128/MCB.01776-08; Dackor RT, 2011, AM J PHYSIOL-LUNG C, V301, pL645, DOI 10.1152/ajplung.00176.2011; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Failla M, 2009, AM J RESP CELL MOL, V41, P50, DOI 10.1165/rcmb.2007-0438OC; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Hodges RJ, 2004, AM J PATHOL, V165, P1663, DOI 10.1016/S0002-9440(10)63423-2; Hublitz P, 2009, INT J DEV BIOL, V53, P335, DOI 10.1387/ijdb.082717ph; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Keerthisingam CB, 2001, AM J PATHOL, V158, P1411, DOI 10.1016/S0002-9440(10)64092-8; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; Kondo Y, 2007, HEPATOL RES, V37, P974, DOI 10.1111/j.1872-034X.2007.00141.x; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee JK, 2013, BIOCHEM BIOPH RES CO, V438, P647, DOI 10.1016/j.bbrc.2013.07.128; Liu XQ, 2004, AM J PHYSIOL-CELL PH, V286, pC1089, DOI 10.1152/ajpcell.00461.2003; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Pang LH, 2002, FASEB J, V16, P1435, DOI 10.1096/fj.02-0169fje; Pero R, 2011, INT J MED MICROBIOL, V301, P140, DOI 10.1016/j.ijmm.2010.06.009; Petkova DK, 2003, HISTOPATHOLOGY, V43, P381, DOI 10.1046/j.1365-2559.2003.01718.x; Pilewski JM, 2005, AM J PATHOL, V166, P399, DOI 10.1016/S0002-9440(10)62263-8; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Sanders YY, 2011, AM J RESP CELL MOL, V45, P16, DOI 10.1165/rcmb.2010-0154OC; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Song SH, 2001, CANCER RES, V61, P4628; Toyota M, 2000, CANCER RES, V60, P4044; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; WILBORN J, 1995, J CLIN INVEST, V95, P1861, DOI 10.1172/JCI117866	36	66	72	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3183	3196		10.1096/fj.13-241760	http://dx.doi.org/10.1096/fj.13-241760			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24652950	hybrid, Green Published			2022-12-28	WOS:000337949400038
J	Dwivedi, N; Neeli, I; Schall, N; Wan, H; Desiderio, DM; Csernok, E; Thompson, PR; Dali, H; Briand, JP; Muller, S; Radic, M				Dwivedi, Nishant; Neeli, Indira; Schall, Nicolas; Wan, Haibao; Desiderio, Dominic M.; Csernok, Elena; Thompson, Paul R.; Dali, Hayet; Briand, Jean-Paul; Muller, Sylviane; Radic, Marko			Deimination of linker histones links neutrophil extracellular trap release with autoantibodies in systemic autoimmunity	FASEB JOURNAL			English	Article						inflammation; autoimmune disorders; peptidylarginine deiminase; chromatin	LUPUS-ERYTHEMATOSUS; CLASSIFICATION CRITERIA; INTERACTION SURFACE; ARGININE DEIMINASE; H1 VARIANTS; CITRULLINATION; ANTIBODIES; PHOSPHORYLATION; NUCLEOSOME; PAD4	Autoantibodies to nuclear antigens arise in human autoimmune diseases, but a unifying pathogenetic mechanism remains elusive. Recently we reported that exposure of neutrophils to inflammatory conditions induces the citrullination of core histones by peptidylarginine deiminase 4 (PAD4) and that patients with autoimmune disorders produce autoantibodies that recognize such citrullinated histones. Here we identify histone H1 as an additional substrate of PAD4, localize H1 within neutrophil extracellular traps, and detect autoantibodies to citrullinated H1 in 6% of sera from patients with systemic lupus erythematosus and Sjogren's syndrome. No preference for deiminated H1 was observed in healthy control sera and sera from patients with scleroderma or rheumatoid arthritis. We map binding to the winged helix of H1 and determine that citrulline 53 represents a key determinant of the autoantibody epitope. In addition, we quantitate RNA for H1 histone subtypes in mature human neutrophils and identify citrulline residues by liquid chromatography and tandem mass spectrometry. Our results indicate that deimination of linker histones generates new autoantibody epitopes with enhanced potential for stimulating autoreactive human B cells.	[Dwivedi, Nishant; Neeli, Indira; Radic, Marko] Univ Tennessee, Ctr Hlth Sci, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA; [Wan, Haibao; Desiderio, Dominic M.] Univ Tennessee, Ctr Hlth Sci, Dept Neurol, Charles B Stout Neurosci Mass Spectrometry Lab, Memphis, TN 38163 USA; [Schall, Nicolas; Dali, Hayet; Briand, Jean-Paul; Muller, Sylviane] CNRS, Inst Biol Mol & Cellulaire, Lab Excellence Medalis, F-67084 Strasbourg, France; [Csernok, Elena] Med Univ Lubeck, Dept Rheumatol, Klinikum Bad Bramstedt, Bad Bramstedt, Germany; [Thompson, Paul R.] Scripps Res Inst Florida, Jupiter, FL USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Lubeck; Scripps Research Institute	Radic, M (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Microbiol Immunol & Biochem, 858 Madison Ave, Memphis, TN 38163 USA.	mradic@uthsc.edu	Muller, Sylviane/J-5319-2014	Radic, Marko/0000-0002-8004-282X; Dwivedi, Nishant/0000-0003-3812-4917	Lupus Research Institute of New York; Dana Foundation Program in Human Immunology; French Centre National de la Recherche Scientifique; Laboratory of Excellence Medalis [ANR-10-LABX-0034]; Initiative of Excellence (IdEx); Strasbourg University; ImmuPharma France; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079357] Funding Source: NIH RePORTER	Lupus Research Institute of New York; Dana Foundation Program in Human Immunology; French Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Laboratory of Excellence Medalis; Initiative of Excellence (IdEx); Strasbourg University; ImmuPharma France; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors gratefully acknowledge Dr. Jean-Francois Kleinmann (Strasbourg University Hospitals, Strasbourg, France), for providing patient sera used in these studies; the insightful and critical comments of Dr. Marc Monestier (Temple University, Philadelphia, PA, USA); and the technical expertise of Tim Higgins (Senior Illustrator, University of Tennessee Health Science Center, Memphis, TN, USA). This work was supported by research funding provided by the Lupus Research Institute of New York and the Dana Foundation Program in Human Immunology. Research was supported in part by the French Centre National de la Recherche Scientifique, the Laboratory of Excellence Medalis (ANR-10-LABX-0034), Initiative of Excellence (IdEx), Strasbourg University, and ImmuPharma France.	Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; Andrade F, 2010, ARTHRITIS RHEUM-US, V62, P1630, DOI 10.1002/art.27439; [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; Berends ETM, 2010, J INNATE IMMUN, V2, P576, DOI 10.1159/000319909; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brinkmann V, 2007, NAT REV MICROBIOL, V5, P577, DOI 10.1038/nrmicro1710; Brinkmann V, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00413; Brown DT, 2006, NAT STRUCT MOL BIOL, V13, P250, DOI 10.1038/nsmb1050; Christophorou MA, 2014, NATURE, V507, P104, DOI 10.1038/nature12942; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Daigo K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00378; Dwivedi N, 2014, ANN RHEUM DIS, V73, P483, DOI 10.1136/annrheumdis-2013-203844; Dwivedi N, 2012, ARTHRITIS RHEUM-US, V64, P982, DOI 10.1002/art.33432; el-Azhary RA, 2006, INT J DERMATOL, V45, P1296, DOI 10.1111/j.1365-4632.2006.02891.x; Fauchais AL, 2010, AUTOIMMUN REV, V9, P595, DOI 10.1016/j.autrev.2010.05.004; Froy O, 2009, ANN NY ACAD SCI, V1173, P365, DOI 10.1111/j.1749-6632.2009.04622.x; Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107; Garcia-Romo GS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001201; George EM, 2010, J BIOL CHEM, V285, P20891, DOI 10.1074/jbc.M110.108639; Happel N, 2009, GENE, V431, P1, DOI 10.1016/j.gene.2008.11.003; Hemmers S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022043; Kearney PL, 2005, BIOCHEMISTRY-US, V44, P10570, DOI 10.1021/bi050292m; Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959; Khandpur R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005580; Kim K, 2008, J BIOL CHEM, V283, P9113, DOI 10.1074/jbc.M708205200; Knight JS, 2013, J CLIN INVEST, V123, P2981, DOI 10.1172/JCI67390; Lande R, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001180; Leshner M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00307; Li PX, 2010, J EXP MED, V207, P1853, DOI 10.1084/jem.20100239; Li YQ, 2011, SURGERY, V150, P442, DOI 10.1016/j.surg.2011.07.003; Mackey-Cushman SL, 2011, GENES IMMUN, V12, P559, DOI 10.1038/gene.2011.31; Manolova I, 2001, RHEUMATOL INT, V20, P197; Millan-Arino L, 2014, NUCLEIC ACIDS RES, V42, P4474, DOI 10.1093/nar/gku079; MULLER S, 1984, EMBO J, V3, P2431, DOI 10.1002/j.1460-2075.1984.tb02150.x; Muller S, 2008, LUPUS, V17, P431, DOI 10.1177/0961203308090030; Neeli I, 2008, J IMMUNOL, V180, P1895, DOI 10.4049/jimmunol.180.3.1895; Neeli I, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00038; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Polyanichko A, 2005, BIOPOLYMERS, V78, P329, DOI 10.1002/bip.20299; Pradhan Vandana D, 2004, J Assoc Physicians India, V52, P533; Pratesi F, 2014, ANN RHEUM DIS, V73, P1414, DOI 10.1136/annrheumdis-2012-202765; Proost P, 2008, J EXP MED, V205, P2085, DOI 10.1084/jem.20080305; Radic M, 2013, GENET EPIGENETICS, V5, P63, DOI 10.4137/GEG.S12144; Radic M, 2013, SEMIN IMMUNOPATHOL, V35, P465, DOI 10.1007/s00281-013-0376-6; Rohrbach AS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00360; Schett G, 2002, LUPUS, V11, P704, DOI 10.1191/0961203302lu247oa; SENSHU T, 1995, J INVEST DERMATOL, V105, P163, DOI 10.1111/1523-1747.ep12317070; Sokolove J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035296; STEMMER C, 1994, MOL IMMUNOL, V31, P1037, DOI 10.1016/0161-5890(94)90099-X; Sun XY, 2008, J CLIN LAB ANAL, V22, P271, DOI 10.1002/jcla.20248; Syed SH, 2010, P NATL ACAD SCI USA, V107, P9620, DOI 10.1073/pnas.1000309107; Tamiya H, 2006, RHEUMATOL INT, V27, P147, DOI 10.1007/s00296-006-0173-9; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Vogler C, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001234; von Kockritz-Blickwede M, 2008, BLOOD, V111, P3070, DOI 10.1182/blood-2007-07-104018; Vossenaar ER, 2003, ARTHRITIS RHEUM-US, V48, P2489, DOI 10.1002/art.11229; Wang YM, 2009, J CELL BIOL, V184, P205, DOI 10.1083/jcb.200806072; Wei LH, 2013, J MED CHEM, V56, P1715, DOI 10.1021/jm301755q; Willis V, 2011, J IMMUNOL, V186, P4396, DOI 10.4049/jimmunol.1001620; Wisniewski JR, 2007, MOL CELL PROTEOMICS, V6, P72, DOI 10.1074/mcp.M600255-MCP200; Zhang XS, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002112; Zheng YP, 2010, J CELL BIOL, V189, P407, DOI 10.1083/jcb.201001148	65	49	50	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2840	2851		10.1096/fj.13-247254	http://dx.doi.org/10.1096/fj.13-247254			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24671707	Green Published			2022-12-28	WOS:000337949400010
J	Nordman, JC; Kabbani, N				Nordman, Jacob C.; Kabbani, Nadine			Microtubule dynamics at the growth cone are mediated by alpha 7 nicotinic receptor activation of a G alpha q and IP3 receptor pathway	FASEB JOURNAL			English	Article						choline; heterotrimeric G protein; calcium stores; PIP2; EB3	INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; PROTEIN-KINASE-C; ACETYLCHOLINE-RECEPTOR; MODULATION; NEURONS; PHOSPHORYLATION; CALCINEURIN; MECHANISMS; SUBUNITS; GAMMA	The alpha 7 nicotinic receptor (alpha 7) plays an important role in neuronal growth and structural plasticity in the developing brain. We have recently characterized a G-protein-signaling pathway regulated by alpha 7 that directs the growth of neurites in developing neural cells. Now we show that choline activation of alpha 7 promotes a rise in intracellular calcium from local ER stores via G alpha q signaling, leading to IP3 receptor (IP3R) activation at the growth cone of differentiating PC12 cells. A mutant alpha 7 significantly attenuated in calcium conductance (D44A; P<0.001) was found to be unable to promote IP3R signaling and calcium store release. In addition, calcium elevation via alpha 7 correlates with a significant attenuation in the rate of microtubule invasion of the growth cone (P<0.001). This process was also attenuated in the D44A mutant and blocked by an inhibitor of the IP3R, suggesting that calcium flow through the alpha 7 channel and activation of the G alpha q pathway are necessary for growth. Taken together, the findings reveal an inhibitory mechanism of alpha 7 on cytoskeletal growth via the intracellular calcium activity of the receptor channel and the G alpha q signaling pathway at the growth cone.	[Nordman, Jacob C.; Kabbani, Nadine] George Mason Univ, Krasnow Inst Adv Study, Dept Mol Neurosci, Fairfax, VA 22030 USA	George Mason University	Kabbani, N (corresponding author), Krasnow Inst Adv Study, 4400 Univ Dr, Fairfax, VA 22030 USA.	nkabbani@gmu.edu		Nordman, Jacob/0000-0003-2513-7831	Wings for Life Spinal Cord Research grant award	Wings for Life Spinal Cord Research grant award	The authors thank Dr. Jerrel Yakel and Ms. Pattie Lamb (National Institute of Environmental Health Science, Research Triangle Park, NC, USA) for receptor constructs. The authors also thank Justin King for technical assistance. This work is supported by a Wings for Life Spinal Cord Research grant award.	Akerboom J, 2012, J NEUROSCI, V32, P13819, DOI 10.1523/JNEUROSCI.2601-12.2012; Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; Berg DK, 2002, J NEUROBIOL, V53, P512, DOI 10.1002/neu.10116; Campbell NR, 2010, J NEUROSCI, V30, P8734, DOI 10.1523/JNEUROSCI.0931-10.2010; Changeux JP, 2010, NAT REV NEUROSCI, V11, P389, DOI 10.1038/nrn2849; Chisari M, 2009, PLOS ONE, V4, pA181, DOI 10.1371/journal.pone.0007797; Colon-Saez JO, 2014, PFLUG ARCH EUR J PHY, V466, P1571, DOI 10.1007/s00424-013-1385-y; Colon-Saez JO, 2011, J PHYSIOL-LONDON, V589, P3163, DOI 10.1113/jphysiol.2011.209494; Criado M, 2011, J NEUROCHEM, V119, P40, DOI 10.1111/j.1471-4159.2011.07398.x; del Barrio L, 2011, BRIT J PHARMACOL, V162, P94, DOI 10.1111/j.1476-5381.2010.01034.x; Dent E. W., 2011, COLD SPRING HARB PER, V3, pii; deSouza N, 2002, J BIOL CHEM, V277, P39397, DOI 10.1074/jbc.M207059200; Dwyer Jennifer B., 2008, Birth Defects Research, V84, P30, DOI 10.1002/bdrc.20118; Fernandes C, 2006, GENES BRAIN BEHAV, V5, P433, DOI 10.1111/j.1601-183X.2005.00176.x; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Fischer H, 2005, J NEUROSCI, V25, P3571, DOI 10.1523/JNEUROSCI.4971-04.2005; Gomez TM, 2006, NAT REV NEUROSCI, V7, P115, DOI 10.1038/nrn1844; GUNNING PW, 1981, J NEUROSCI, V1, P1085; He Y, 2005, J CELL BIOL, V168, P697, DOI 10.1083/jcb.200407191; Henley J, 2004, TRENDS CELL BIOL, V14, P320, DOI 10.1016/j.tcb.2004.04.006; Kabbani N, 2007, P NATL ACAD SCI USA, V104, P20570, DOI 10.1073/pnas.0710314104; Kabbani N, 2013, BIOESSAYS, V35, P1025, DOI 10.1002/bies.201300082; Kalil K, 2014, NAT REV NEUROSCI, V15, P7, DOI 10.1038/nrn3650; KATER SB, 1991, J NEUROSCI, V11, P891; Kelly TAN, 2010, J NEUROSCI RES, V88, P3024, DOI 10.1002/jnr.22478; Khiroug SS, 2002, J PHYSIOL-LONDON, V540, P425, DOI 10.1113/jphysiol.2001.013847; Krizanova O, 2003, GEN PHYSIOL BIOPHYS, V22, P295; Lautermilch NJ, 2000, J NEUROSCI, V20, P315, DOI 10.1523/JNEUROSCI.20-01-00315.2000; LINDSTROM J, 1990, CIBA F SYMP, V152, P23; LINDSTROM J, 1990, CIBA F SYMP, V152, P23; Liu M, 2010, J NEUROSCI, V30, P14896, DOI 10.1523/JNEUROSCI.3739-10.2010; Liu QS, 1999, J NEUROSCI, V19, P10280; Lozada AF, 2012, J NEUROSCI, V32, P7651, DOI 10.1523/JNEUROSCI.6246-11.2012; Marx A, 2013, MOL BIOL CELL, V24, P1544, DOI 10.1091/mbc.E12-08-0573; MUKAI H, 1992, J BIOL CHEM, V267, P16237; Myatt D. R., 2008, BMC NEUROSCI S1, V9, pP81; Nadar VC, 2008, CURR BIOL, V18, P1972, DOI 10.1016/j.cub.2008.11.021; Nakata H, 2005, MOL PHARMACOL, V67, P695, DOI 10.1124/mol.104.003913; Nordman JC, 2014, J NEUROCHEM, V129, P649, DOI 10.1111/jnc.12641; Nordman JC, 2014, MOL PHARMACOL, V85, P50, DOI 10.1124/mol.113.088484; Nordman JC, 2012, J CELL SCI, V125, P5502, DOI 10.1242/jcs.110379; Placzek AN, 2005, MOL PHARMACOL, V68, P1863, DOI 10.1124/mol.105.016402; Shoop RD, 2000, J NEUROSCI, V20, P4021; Stepanova T, 2003, J NEUROSCI, V23, P2655; Vanderheyden V, 2009, BBA-MOL CELL RES, V1793, P959, DOI 10.1016/j.bbamcr.2008.12.003; Yamaguchi Y, 2006, J BIOL CHEM, V281, P31627, DOI 10.1074/jbc.M606992200; Yevenes GE, 2003, NAT NEUROSCI, V6, P819, DOI 10.1038/nn1095; Young JW, 2011, GENES BRAIN BEHAV, V10, P720, DOI 10.1111/j.1601-183X.2011.00711.x; Zhong CB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082719	49	21	23	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2995	3006		10.1096/fj.14-251439	http://dx.doi.org/10.1096/fj.14-251439			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24687992	Green Published			2022-12-28	WOS:000337949400022
J	Proellocks, NI; Herrmann, S; Buckingham, DW; Hanssen, E; Hodges, EK; Elsworth, B; Morahan, BJ; Coppel, RL; Cooke, BM				Proellocks, Nicholas I.; Herrmann, Susann; Buckingham, Donna W.; Hanssen, Eric; Hodges, Emma K.; Elsworth, Brendan; Morahan, Belinda J.; Coppel, Ross L.; Cooke, Brian M.			A lysine-rich membrane-associated PHISTb protein involved in alteration of the cytoadhesive properties of Plasmodium falciparum-infected red blood cells	FASEB JOURNAL			English	Article						malaria; pathogenesis; cytoskeleton; exported proteins	PARASITE PROTEINS; HUMAN ERYTHROCYTES; MALARIA PARASITES; HOST ERYTHROCYTE; MAURERS CLEFTS; CYTOADHERENCE; VIRULENCE; PFEMP1; EXPORT; KAHRP	The genomes of malaria parasites (Plasmodium spp.) contain a family of genes encoding proteins with a Plasmodium helical interspersed subtelomeric (PHIST) domain, most of which are predicted to be exported into the parasite-infected human red blood cell (iRBC). Here, using transgenic parasites and a combination of cellular, biochemical, and biophysical assays, we have characterized and determined the function of a novel member of the PHIST protein family in Plasmodium falciparum, termed lysine-rich membrane-associated PHISTb (LyMP). LyMP was shown to associate directly with the cytoskeleton of iRBCs where it plays a role in their abnormal ability to adhere to a protein expressed on vascular endothelial cells, resulting in sequestration. Deletion of LyMP dramatically reduced adhesion of iRBCs to CD36 by 55%, which was completely restored to wild-type levels on complementation. Intriguingly, in the absence of LyMP, formation of RBC membrane knobs and the level of surface exposure of the parasites' major cytoadhesive ligand, PfEMP1, were identical to those for the parental parasite line, demonstrating for the first time an additional mechanism that enhances cytoadherence of iRBCs beyond those already recognized. Our findings identify LyMP as a previously unknown RBC cytoskeletal-binding protein that is likely to be of major significance in the complex pathophysiology of falciparum malaria.	[Proellocks, Nicholas I.; Herrmann, Susann; Buckingham, Donna W.; Hodges, Emma K.; Elsworth, Brendan; Morahan, Belinda J.; Coppel, Ross L.; Cooke, Brian M.] Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia; [Herrmann, Susann; Hanssen, Eric] Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Melbourne, Vic 3010, Australia	Monash University; University of Melbourne	Cooke, BM (corresponding author), Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia.	brian.cooke@monash.edu	Coppel, Ross L/A-6626-2008; Hanssen, Eric/A-7217-2013; Proellochs, Nick/ABB-5634-2020	Coppel, Ross L/0000-0002-4476-9124; Hanssen, Eric/0000-0002-4064-1844; Proellochs, Nick/0000-0003-3750-1135; HERRMANN, SUSANN/0000-0002-4953-5685	National Health and Medical Research Council of Australia (NHMRC); Faculty of Medicine, Nursing and Health Sciences of Monash University; Australian Postgraduate Award	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Faculty of Medicine, Nursing and Health Sciences of Monash University; Australian Postgraduate Award(Australian Government)	The authors thank Dr. Alexander Maier (Australian National University, Canberra) for providing the antiserum against PFB0090c (J-dots) and are grateful to the Australian Red Cross Blood Service for generously providing human RBCs for malaria culture. B. M. C. was supported by the National Health and Medical Research Council of Australia (NHMRC). The authors also acknowledge the Faculty of Medicine, Nursing and Health Sciences of Monash University for supporting N.I.P. with a Faculty Bridging Fellowship that enabled this work. E.H. was supported by an Australian Postgraduate Award.	Akinyi S, 2012, MOL MICROBIOL, V84, P816, DOI 10.1111/j.1365-2958.2012.08060.x; Boddey JA, 2009, TRAFFIC, V10, P285, DOI 10.1111/j.1600-0854.2008.00864.x; Cooke BM, 2006, J CELL BIOL, V172, P899, DOI 10.1083/jcb.200509122; Cooke BM, 2005, VET PARASITOL, V132, P273, DOI 10.1016/j.vetpar.2005.07.002; Cooke BM, 2004, TRENDS PARASITOL, V20, P581, DOI 10.1016/j.pt.2004.09.008; Cooke BM, 2004, SEMIN HEMATOL, V41, P173, DOI 10.1053/j.seminhematol.2004.01.004; Cooke BM, 2001, ADV PARASIT, V50, P1, DOI 10.1016/S0065-308X(01)50029-9; Cooke Brian M, 2002, Methods Mol Med, V72, P561, DOI 10.1385/1-59259-271-6:561; Cooke Brian M, 2002, Methods Mol Med, V72, P571, DOI 10.1385/1-59259-271-6:571; COPPEL RL, 1992, MOL BIOCHEM PARASIT, V50, P335, DOI 10.1016/0166-6851(92)90231-8; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; Cranmer SL, 1997, T ROY SOC TROP MED H, V91, P363, DOI 10.1016/S0035-9203(97)90110-3; Dluzewski A., 1984, T R SOC TROP MED HYG, V78, P622; Ganesan SM, 2011, MOL BIOCHEM PARASIT, V177, P29, DOI 10.1016/j.molbiopara.2011.01.004; Glenister FK, 2009, BLOOD, V113, P919, DOI 10.1182/blood-2008-05-157735; Glenister FK, 2002, BLOOD, V99, P1060, DOI 10.1182/blood.V99.3.1060; Gruring C, 2012, CELL HOST MICROBE, V12, P717, DOI 10.1016/j.chom.2012.09.010; Gruing C., 2011, NAT COMMUN, V2, P165; Haldar K, 2007, ANNU REV PATHOL-MECH, V2, P217, DOI 10.1146/annurev.pathol.2.010506.091913; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Kats LM, 2014, INT J PARASITOL, V44, P319, DOI 10.1016/j.ijpara.2014.01.003; Kilili GK, 2011, EUKARYOT CELL, V10, P1439, DOI 10.1128/EC.05180-11; Kulzer S, 2010, CELL MICROBIOL, V12, P1398, DOI 10.1111/j.1462-5822.2010.01477.x; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Maier AG, 2008, CELL, V134, P48, DOI 10.1016/j.cell.2008.04.051; Maier AG, 2006, MOL BIOCHEM PARASIT, V150, P118, DOI 10.1016/j.molbiopara.2006.06.014; Maier AG, 2009, NAT REV MICROBIOL, V7, P341, DOI 10.1038/nrmicro2110; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; Mayer C, 2012, J BIOL CHEM, V287, P7182, DOI 10.1074/jbc.M111.330779; McMillan PJ, 2013, CELL MICROBIOL, V15, P1401, DOI 10.1111/cmi.12125; Mundwiler-Pachlatko E., 2013, P NATL ACAD SCI USA, V110, P1; Nilsson S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046980; Nunes MC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011747; Oh SS, 2000, MOL BIOCHEM PARASIT, V108, P237, DOI 10.1016/S0166-6851(00)00227-9; Oyelade J, 2011, INFECT GENET EVOL, V11, P755, DOI 10.1016/j.meegid.2010.11.006; Pallavi R, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-236; Parish LA, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-160; Pei XH, 2005, J BIOL CHEM, V280, P31166, DOI 10.1074/jbc.M505298200; Przyborski JM, 2003, MOL BIOCHEM PARASIT, V132, P17, DOI 10.1016/S0166-6851(03)00212-3; Rug M, 2006, BLOOD, V108, P370, DOI 10.1182/blood-2005-11-4624; Sachs JD, 2002, SCIENCE, V298, P122, DOI 10.1126/science.1077900; Sargeant TJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-2-r12; Saridaki T, 2009, TRAFFIC, V10, P137, DOI 10.1111/j.1600-0854.2008.00860.x; Slot JW, 2007, NAT PROTOC, V2, P2480, DOI 10.1038/nprot.2007.365; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Waller KL, 2007, BBA-BIOMEMBRANES, V1768, P2145, DOI 10.1016/j.bbamem.2007.04.027; Waller KL, 1999, J BIOL CHEM, V274, P23808, DOI 10.1074/jbc.274.34.23808; Waller KL, 2002, MOL BIOCHEM PARASIT, V119, P125, DOI 10.1016/S0166-6851(01)00395-4; Ward P, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-79; Waterkeyn JG, 2000, EMBO J, V19, P2813, DOI 10.1093/emboj/19.12.2813; Wickham Mark E., 2001, EMBO (European Molecular Biology Organization) Journal, V20, P5636, DOI 10.1093/emboj/20.20.5636; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973	52	37	38	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3103	3113		10.1096/fj.14-250399	http://dx.doi.org/10.1096/fj.14-250399			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24706359				2022-12-28	WOS:000337949400031
J	Sarkis, J; Rocha, J; Maniti, O; Jouhet, J; Vie, V; Block, MA; Breton, C; Marechal, E; Girard-Egrot, A				Sarkis, Joe; Rocha, Joana; Maniti, Ofelia; Jouhet, Juliette; Vie, Veronique; Block, Maryse A.; Breton, Christelle; Marechal, Eric; Girard-Egrot, Agnes			The influence of lipids on MGD1 membrane binding highlights novel mechanisms for galactolipid biosynthesis regulation in chloroplasts	FASEB JOURNAL			English	Article						monogalactosyldiacylglycerol synthase; thylakoid biogenesis; plastid envelope; Langmuir monolayer; atomic force microscopy	AIR-WATER-INTERFACE; PHOSPHOLIPID MONOLAYERS; PHOSPHATE DEPRIVATION; HUMAN DYSTROPHIN; INNER ENVELOPE; PLANT-CELLS; ROD DOMAIN; SYNTHASE; PROTEINS; MONOGALACTOSYLDIACYLGLYCEROL	Mono- and digalactosyldiacylglycerol (MGDG and DGDG) are the most abundant lipids of photosynthetic membranes (thylakoids). In Arabidopsis green tissues, MGD1 is the main enzyme synthesizing MGDG. This monotopic enzyme is embedded in the inner envelope membrane of chloroplasts. DGDG synthesis occurs in the outer envelope membrane. Although the suborganellar localization of MGD1 has been determined, it is still not known how the lipid/glycolipid composition influences its binding to the membrane. The existence of a topological relationship between MGD1 and "embryonic" thylakoids is also unknown. To investigate MGD1 membrane binding, we used a Langmuir membrane model allowing the tuning of both lipid composition and packing. Surprisingly, MGD1 presents a high affinity to MGDG, its product, which maintains the enzyme bound to the membrane. This positive feedback is consistent with the low level of diacylglycerol, the substrate of MGD1, in chloroplast membranes. By contrast, MGD1 is excluded from membranes highly enriched in, or made of, pure DGDG. DGDG therefore exerts a retrocontrol, which is effective on the overall synthesis of galactolipids. Previously identified activators, phosphatidic acid and phosphatidylglycerol, also play a role on MGD1 membrane binding via electrostatic interactions, compensating the exclusion triggered by DGDG. The opposite effects of MGDG and DGDG suggest a role of these lipids on the localization of MGD1 in specific domains. Consistently, MGDG induces the self-organization of MGD1 into elongated and reticulated nanostructures scaffolding the chloroplast membrane.	[Sarkis, Joe; Maniti, Ofelia; Girard-Egrot, Agnes] Univ Lyon 1, CNRS, UMR 5246,ICBMS, Equipe Genie Enzymat Membranes Biomimet & Assembl, F-69622 Villeurbanne, France; [Rocha, Joana; Breton, Christelle] Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales CERMAV, Grenoble, France; [Jouhet, Juliette; Block, Maryse A.; Marechal, Eric] Univ Grenoble Alpes, Commissariat Energie Atom & Energies Alternat CEA, Lab Physiol Cellulaire & Vegetale, CNRS,INRA,UMR 5168, Grenoble, France; [Vie, Veronique] Univ Rennes 1, CNRS, UMR 6251, IPR, Rennes, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Universite de Rennes	Girard-Egrot, A (corresponding author), CNRS, UMR 5246, GEMBAS Team, ICBMS, Bat Curien,43 Bd 11 Novembre 1918, F-69622 Villeurbanne, France.	agnes.girard-egrot@univ-lyon1.fr	GIRARD-EGROT, Agnès/AAP-5586-2020; Maniti, Ofélia/AAQ-5624-2021	GIRARD-EGROT, Agnès/0000-0003-2612-3124; Sarkis, Joe/0000-0002-9342-7198	Agence National de la Recherche [ANR-10-BLAN-1524]	Agence National de la Recherche(French National Research Agency (ANR))	The authors are indebted to the Agence National de la Recherche for financial support of the ReGal project (grant ANR-10-BLAN-1524). The authors thank Christian Salesse for helpful discussions.	Amann KJ, 1998, J BIOL CHEM, V273, P28419, DOI 10.1074/jbc.273.43.28419; [Anonymous], METHODS CHLOROPLAST; Awai K, 2001, P NATL ACAD SCI USA, V98, P10960, DOI 10.1073/pnas.181331498; Banc A, 2007, LANGMUIR, V23, P13066, DOI 10.1021/la702037k; BLAUDEZ D, 1993, APPL SPECTROSC, V47, P869, DOI 10.1366/0003702934415273; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; Boisselier E, 2012, LANGMUIR, V28, P9680, DOI 10.1021/la301135z; Botte C, 2005, J BIOL CHEM, V280, P34691, DOI 10.1074/jbc.M505622200; Bottier C, 2007, BBA-BIOMEMBRANES, V1768, P1526, DOI 10.1016/j.bbamem.2007.02.021; Boudiere L, 2012, MOL BIOSYST, V8, P2023, DOI 10.1039/c2mb25067e; Calvez P, 2011, LANGMUIR, V27, P1373, DOI 10.1021/la104097n; Calvez P, 2009, BIOCHIMIE, V91, P718, DOI 10.1016/j.biochi.2009.03.018; CASWELL DS, 1987, J AM CHEM SOC, V109, P2796, DOI 10.1021/ja00243a037; DeWolf C, 1997, BIOPHYS J, V72, P2599, DOI 10.1016/S0006-3495(97)78903-3; Dubots E, 2010, J BIOL CHEM, V285, P6003, DOI 10.1074/jbc.M109.071928; Girard-Egrot A, 2004, J MOL BIOL, V335, P321, DOI 10.1016/j.jmb.2003.10.028; GOUNARIS K, 1983, TRENDS BIOCHEM SCI, V8, P378, DOI 10.1016/0968-0004(83)90366-3; Guillemin Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009066; Ta HP, 2011, LANGMUIR, V27, P4797, DOI 10.1021/la103788r; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Jarvis P, 2000, P NATL ACAD SCI USA, V97, P8175, DOI 10.1073/pnas.100132197; Jouhet J, 2004, J CELL BIOL, V167, P863, DOI 10.1083/jcb.200407022; Jouhet J, 2003, FEBS LETT, V544, P63, DOI 10.1016/S0014-5793(03)00477-0; Joyard J., 1996, MEMBRANES SPECIALIZE, P179; Kobayashi K, 2007, P NATL ACAD SCI USA, V104, P17216, DOI 10.1073/pnas.0704680104; Lee AG, 2000, CURR BIOL, V10, pR377, DOI 10.1016/S0960-9822(00)00477-2; Legardinier S, 2009, J MOL BIOL, V389, P546, DOI 10.1016/j.jmb.2009.04.025; Miege C, 1999, EUR J BIOCHEM, V265, P990, DOI 10.1046/j.1432-1327.1999.00801.x; Pitcher WH, 2002, BBA-BIOMEMBRANES, V1564, P107, DOI 10.1016/S0005-2736(02)00405-4; Rocha J, 2013, BIOCHIMIE, V95, P700, DOI 10.1016/j.biochi.2012.11.011; ROTHSCHILD KJ, 1989, P NATL ACAD SCI USA, V86, P9832, DOI 10.1073/pnas.86.24.9832; Sarkis J, 2011, J BIOL CHEM, V286, P30481, DOI 10.1074/jbc.M111.243881; Schladitz C, 1999, BIOPHYS J, V77, P3305, DOI 10.1016/S0006-3495(99)77161-4; Venien-Bryan C, 1998, BIOPHYS J, V74, P2649, DOI 10.1016/S0006-3495(98)77970-6	35	21	22	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3114	3123		10.1096/fj.14-250415	http://dx.doi.org/10.1096/fj.14-250415			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24692595				2022-12-28	WOS:000337949400032
J	Takai, S; Yasumatsu, K; Inoue, M; Iwata, S; Yoshida, R; Shigemura, N; Yanagawa, Y; Drucker, DJ; Margolskee, RF; Ninomiya, Y				Takai, Shingo; Yasumatsu, Keiko; Inoue, Mayuko; Iwata, Shusuke; Yoshida, Ryusuke; Shigemura, Noriatsu; Yanagawa, Yuchio; Drucker, Daniel J.; Margolskee, Robert F.; Ninomiya, Yuzo			Glucagon-like peptide-1 is specifically involved in sweet taste transmission	FASEB JOURNAL			English	Article						gustation; transmitter; incretin	VASOACTIVE-INTESTINAL-PEPTIDE; COEXPRESSION PATTERNS; CHORDA TYMPANI; ATP RELEASE; RECEPTOR; CELLS; EXPRESSION; GUSTDUCIN; CHOLECYSTOKININ; GLP-1	Five fundamental taste qualities (sweet, bitter, salty, sour, umami) are sensed by dedicated taste cells (TCs) that relay quality information to gustatory nerve fibers. In peripheral taste signaling pathways, ATP has been identified as a functional neurotransmitter, but it remains to be determined how specificity of different taste qualities is maintained across synapses. Recent studies demonstrated that some gut peptides are released from taste buds by prolonged application of particular taste stimuli, suggesting their potential involvement in taste information coding. In this study, we focused on the function of glucagon-like peptide-1 (GLP-1) in initial responses to taste stimulation. GLP-1 receptor (GLP-1R) null mice had reduced neural and behavioral responses specifically to sweet compounds compared to wild-type (WT) mice. Some sweet responsive TCs expressed GLP-1 and its receptors were expressed in gustatory neurons. GLP-1 was released immediately from taste bud cells in response to sweet compounds but not to other taste stimuli. Intravenous administration of GLP-1 elicited transient responses in a subset of sweet-sensitive gustatory nerve fibers but did not affect other types of fibers, and this response was suppressed by pre-administration of the GLP-1R antagonist Exendin-4(3-39). Thus GLP-1 may be involved in normal sweet taste signal transmission in mice.	[Takai, Shingo; Inoue, Mayuko; Iwata, Shusuke; Yoshida, Ryusuke; Shigemura, Noriatsu; Ninomiya, Yuzo] Kyushu Univ, Grad Sch Dent Sci, Sect Oral Neurosci, Fukuoka 8128582, Japan; [Yasumatsu, Keiko; Ninomiya, Yuzo] Kyushu Univ, Res & Dev Ctr Taste & Odor Sensing, Div Sensory Physiol, Fukuoka 8128582, Japan; [Yanagawa, Yuchio] Gunma Univ, Grad Sch Med, Dept Genet & Behav Neurosci, Maebashi, Gunma 371, Japan; [Yanagawa, Yuchio] JST, CREST, Maebashi, Gunma, Japan; [Drucker, Daniel J.] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada; [Margolskee, Robert F.] Monell Chem Senses Ctr, Philadelphia, PA 19104 USA	Kyushu University; Kyushu University; Gunma University; Japan Science & Technology Agency (JST); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Monell Chemical Senses Center	Ninomiya, Y (corresponding author), Kyushu Univ, Grad Sch Dent Sci, Sect Oral Neurosci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	ninomoiya.yuzo.285@m.kyushu-u.ac.jp	Drucker, Daniel J/A-4092-2010	Iwata, Shusuke/0000-0001-8655-3471; Shigemura, Noriatsu/0000-0002-3061-6362; Margolskee, Robert/0000-0002-9572-2887	KAKENHI from Japan Society for the promotion of science [18077004, 18109013, 23249081, 20689034, 23689076]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003155, P30DC011735, R01DC014105, R01DC003055] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [15K11044, 15K11043] Funding Source: KAKEN	KAKENHI from Japan Society for the promotion of science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Dr. Charles Pyke (Novo Nordisk A/S) for providing the GLP-1R antibody. This work was supported by KAKENHI 18077004, 18109013, 23249081 (Y.N.), 20689034 (N.S.), 23689076 (R.Y.) for Scientific Research from Japan Society for the promotion of science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no competing financial interests.	Bo XN, 1999, NEUROREPORT, V10, P1107, DOI 10.1097/00001756-199904060-00037; Chandrashekar J, 2006, NATURE, V444, P288, DOI 10.1038/nature05401; Clapp TR, 2004, J COMP NEUROL, V468, P311, DOI 10.1002/cne.10963; Damak S, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-96; Dotson CD, 2013, SEMIN CELL DEV BIOL, V24, P232, DOI 10.1016/j.semcdb.2013.01.004; Elson AET, 2010, FASEB J, V24, P3960, DOI 10.1096/fj.10-158105; Feng XH, 2008, ACTA HISTOCHEM, V110, P151, DOI 10.1016/j.acthis.2007.10.005; Finger TE, 2005, SCIENCE, V310, P1495, DOI 10.1126/science.1118435; Fujita Y, 2009, AM J PHYSIOL-ENDOC M, V296, pE473, DOI 10.1152/ajpendo.90636.2008; Geraedts MCP, 2013, J NEUROSCI, V33, P7559, DOI 10.1523/JNEUROSCI.0372-13.2013; Hansen L, 1999, ENDOCRINOLOGY, V140, P5356, DOI 10.1210/en.140.11.5356; Hansotia T, 2005, REGUL PEPTIDES, V128, P125, DOI 10.1016/j.regpep.2004.07.019; HERNESS MS, 1989, NEUROSCIENCE, V33, P411, DOI 10.1016/0306-4522(89)90220-0; Herness S, 2002, J NEUROSCI, V22, P10018; Holst JJ, 2007, PHYSIOL REV, V87, P1409, DOI 10.1152/physrev.00034.2006; Huang AL, 2006, NATURE, V442, P934, DOI [10.1038/nature05084, 10.1038/nature050084]; Huang YJ, 2007, P NATL ACAD SCI USA, V104, P6436, DOI 10.1073/pnas.0611280104; Ishida Y, 2009, J COMP NEUROL, V514, P131, DOI 10.1002/cne.22000; Ishimaru Y, 2006, P NATL ACAD SCI USA, V103, P12569, DOI 10.1073/pnas.0602702103; Jang HJ, 2007, P NATL ACAD SCI USA, V104, P15069, DOI 10.1073/pnas.0706890104; Kataoka S, 2008, CHEM SENSES, V33, P243, DOI 10.1093/chemse/bjm083; KELLING ST, 1983, SCIENCE, V219, P412, DOI 10.1126/science.6849142; Lu SG, 2003, NEUROSCI LETT, V351, P157, DOI 10.1016/j.neulet.2003.07.016; Margolskee RF, 2007, P NATL ACAD SCI USA, V104, P15075, DOI 10.1073/pnas.0706678104; Martin B, 2009, ANN NY ACAD SCI, V1170, P98, DOI 10.1111/j.1749-6632.2009.03920.x; MontroseRafizadeh C, 1997, J BIOL CHEM, V272, P21201, DOI 10.1074/jbc.272.34.21201; Murata Y, 2010, J NEUROPHYSIOL, V104, P896, DOI 10.1152/jn.00414.2010; NAGAHAMA S, 1985, J GEN PHYSIOL, V85, P431, DOI 10.1085/jgp.85.3.431; Nakabayashi H, 1996, AM J PHYSIOL-ENDOC M, V271, pE808, DOI 10.1152/ajpendo.1996.271.5.E808; Ninomiya Y, 1999, J NEUROPHYSIOL, V81, P3087, DOI 10.1152/jn.1999.81.6.3087; NINOMIYA Y, 1995, AM J PHYSIOL-REG I, V268, pR1019, DOI 10.1152/ajpregu.1995.268.4.R1019; Ohara-Imaizumi M, 2009, BIOCHEM BIOPH RES CO, V390, P16, DOI 10.1016/j.bbrc.2009.09.043; Romanov RA, 2007, EMBO J, V26, P657, DOI 10.1038/sj.emboj.7601526; Roper SD, 2013, SEMIN CELL DEV BIOL, V24, P71, DOI 10.1016/j.semcdb.2012.12.002; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; Shen T, 2005, NEUROSCIENCE, V130, P229, DOI 10.1016/j.neuroscience.2004.09.017; Shigemura N, 2013, J NEUROSCI, V33, P6267, DOI 10.1523/JNEUROSCI.5599-12.2013; Shin YK, 2008, J NEUROCHEM, V106, P455, DOI 10.1111/j.1471-4159.2008.05397.x; Shin YK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012729; Steinert RE, 2011, CLIN NUTR, V30, P524, DOI 10.1016/j.clnu.2011.01.007; Tamamaki N, 2003, J COMP NEUROL, V467, P60, DOI 10.1002/cne.10905; Taruno A, 2013, NATURE, V495, P223, DOI 10.1038/nature11906; Tomchik SM, 2007, J NEUROSCI, V27, P10840, DOI 10.1523/JNEUROSCI.1863-07.2007; Vandenbeuch A, 2013, P NATL ACAD SCI USA, V110, P14789, DOI 10.1073/pnas.1309468110; Vandenbeuch A, 2010, J NEUROSCI, V30, P14695, DOI 10.1523/JNEUROSCI.1570-10.2010; Wong GT, 1999, J NEUROSCI, V19, P5802, DOI 10.1523/JNEUROSCI.19-14-05802.1999; Yasumatsu K, 2012, J PHYSIOL-LONDON, V590, P1155, DOI 10.1113/jphysiol.2011.211920; Yoshida R, 2006, J NEUROPHYSIOL, V96, P3088, DOI 10.1152/jn.00409.2006; Yoshida R, 2010, INT REV CEL MOL BIO, V279, P101, DOI 10.1016/S1937-6448(10)79004-3; Yoshida R, 2010, P NATL ACAD SCI USA, V107, P935, DOI 10.1073/pnas.0912048107; Yoshida R, 2009, J PHYSIOL-LONDON, V587, P4425, DOI 10.1113/jphysiol.2009.175075; Zhao FL, 2005, P NATL ACAD SCI USA, V102, P11100, DOI 10.1073/pnas.0501988102	52	49	51	0	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2268	2280		10.1096/fj.14-265355	http://dx.doi.org/10.1096/fj.14-265355			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25678625	Green Published			2022-12-28	WOS:000355209500006
J	Nakanishi, K; Kakiguchi, K; Yonemura, S; Nakano, A; Morishima, N				Nakanishi, Keiko; Kakiguchi, Kisa; Yonemura, Shigenobu; Nakano, Akihiko; Morishima, Nobuhiro			Transient Ca2+ depletion from the endoplasmic reticulum is critical for skeletal myoblast differentiation	FASEB JOURNAL			English	Article						ER deformation; ER stress; myoblast fusion; STIM1	UNFOLDED PROTEIN RESPONSE; PLASMA-MEMBRANE; SARCOPLASMIC-RETICULUM; CYCLOPIAZONIC ACID; MUSCLE; STRESS; FUSION; CELL; ER; CHANNELS	Endoplasmic reticulum (ER) stress is a cellular condition in which unfolded proteins accumulate in the ER because of various but specific causes. Physiologic ER stress occurs transiently during myoblast differentiation, and although its cause remains unknown, it plays a critical role in myofiber formation. To examine the mechanism underlying ER stress, we monitored ER morphology during differentiation of murine myoblasts. Novel ER-derived structures transiently appeared prior to myoblast fusion both in vitro and in vivo. Electron microscopy studies revealed that these structures consisted of pseudoconcentric ER cisternae with narrow lumens. Similar structures specifically formed by pharmacologically induced ER Ca2+ depletion, and inhibition of ER Ca2+ efflux channels in differentiating myoblasts considerably suppressed ER-specific deformation and ER stress signaling. Thus, we named the novel structures stress-activated response to Ca2+ depletion (SARC) bodies. Prior to SARC body formation, stromal interaction molecule 1 (STIM1), an ER Ca2+ sensor protein, formed ER Ca2+ depletion-specific clusters. Furthermore, myoblast differentiation manifested by myoblast fusion did not proceed under the same conditions as inhibition of ER Ca2+ depletion. Altogether, these observations suggest that ER Ca2+ depletion is a prerequisite for myoblast fusion, causing both physiologic ER stress signaling and SARC body formation.Nakanishi, K., Kakiguchi, K., Yonemura, S., Nakano, A., Morishima, N. Transient Ca2+ depletion from the endoplasmic reticulum is critical for skeletal myoblast differentiation.	[Nakanishi, Keiko; Nakano, Akihiko; Morishima, Nobuhiro] RIKEN, Adv Sci Inst, Mol Membrane Biol Lab, Wako, Saitama 3510198, Japan; [Kakiguchi, Kisa; Yonemura, Shigenobu] RIKEN, Ctr Dev Biol, Electron Microscope Lab, Kobe, Hyogo, Japan; [Nakano, Akihiko] Univ Tokyo, Grad Sch Sci, Bunkyo Ku, Tokyo 113, Japan	RIKEN; RIKEN; University of Tokyo	Morishima, N (corresponding author), RIKEN, Lipid Biol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	morishim@riken.jp	Nakano, Akihiko/G-4942-2014; Morishima, Nobuhiro/D-3946-2017; Nakano, Akihiko/A-6420-2016	Nakano, Akihiko/0000-0003-3635-548X; Nakano, Akihiko/0000-0003-3635-548X	RIKEN Bioarchitect Research Project; RIKEN Cellular System Program; RIKEN Incentive Research Grant; Japan Society for the Promotion of Science	RIKEN Bioarchitect Research Project; RIKEN Cellular System Program; RIKEN Incentive Research Grant; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	The authors thank Tetsuya Tajima and Kaori Higuchi (RIKEN BSI-Olympus Collaboration Center) for technical support with fluorescent microscopy, Takashi Yoshiura (Yokogawa Electric Group) for support with 3-dimensional image reconstruction, and Yasue Ichikawa and Rie Nakazawa for DNA sequencing. K.N. was a Research Fellow of the Japan Society for the Promotion of Science. This work was supported in part by grants from the RIKEN Bioarchitect Research Project (to N.M.), RIKEN Cellular System Program (to N.M.), RIKEN Incentive Research Grant (to N.M.), and Japan Society for the Promotion of Science (to N.M. and K.N.). The authors declare no conflicts of interest.	Arnold HH, 2000, CURR TOP DEV BIOL, V48, P129; Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; Bijlenga P, 2000, P NATL ACAD SCI USA, V97, P7627, DOI 10.1073/pnas.97.13.7627; Borgese N, 2006, CURR OPIN CELL BIOL, V18, P358, DOI 10.1016/j.ceb.2006.06.008; Camello C, 2002, CELL CALCIUM, V32, P355, DOI 10.1016/S0143416002001926; Caridha D, 2008, ANTIMICROB AGENTS CH, V52, P684, DOI 10.1128/AAC.00874-07; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Chan YHM, 2010, ORGANOGENESIS, V6, P88, DOI 10.4161/org.6.2.11464; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Constantin B, 1996, CELL CALCIUM, V19, P365, DOI 10.1016/S0143-4160(96)90109-8; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; EZERMAN EB, 1967, J CELL BIOL, V35, P405, DOI 10.1083/jcb.35.2.405; Finger F, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005671; Friday BB, 2003, DIFFERENTIATION, V71, P217, DOI 10.1046/j.1432-0436.2003.710303.x; Hamanaka RB, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003638; Hochreiter-Hufford AE, 2013, NATURE, V497, P263, DOI 10.1038/nature12135; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; LI WWF, 1993, J BIOL CHEM, V268, P12003; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Martonosi A, 2000, DEV SARCOPLASMIC RET; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Mekahli D, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004317; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakanishi K, 2005, J CELL BIOL, V169, P555, DOI 10.1083/jcb.200412024; Nakanishi K, 2007, FASEB J, V21, P2994, DOI 10.1096/fj.06-6408com; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; ORCI L, 1993, P NATL ACAD SCI USA, V90, P11089, DOI 10.1073/pnas.90.23.11089; Palnitkar SS, 1997, BIOCHEM J, V326, P847, DOI 10.1042/bj3260847; Parys JB, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005093; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; PRZYBYLSKI RJ, 1989, IN VITRO CELL DEV B, V25, P830; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; Rutkowski DT, 2010, J CELL BIOL, V189, P783, DOI 10.1083/jcb.201003138; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Shibata Y, 2006, CELL, V126, P435, DOI 10.1016/j.cell.2006.07.019; Shibata Y, 2010, CELL, V143, P774, DOI 10.1016/j.cell.2010.11.007; Shin KS, 1996, DEV BIOL, V175, P14, DOI 10.1006/dbio.1996.0091; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Snapp EL, 2003, J CELL BIOL, V163, P257, DOI 10.1083/jcb.200306020; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Todd DJ, 2009, J EXP MED, V206, P2151, DOI 10.1084/jem.20090738; Valdes JA, 2013, J CELL PHYSIOL, V228, P1452, DOI 10.1002/jcp.24298; Vandecaetsbeek I, 2011, COLD SPRING HARB PER, V3; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Xu PY, 2006, BIOCHEM BIOPH RES CO, V350, P969, DOI 10.1016/j.bbrc.2006.09.134; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200	53	19	19	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2137	2149		10.1096/fj.14-261529	http://dx.doi.org/10.1096/fj.14-261529			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25678623				2022-12-28	WOS:000354114600044
J	Yan, J; Almilaji, A; Schmid, E; Elvira, B; Shimshek, DR; van der Putten, H; Wagner, CA; Shumilina, E; Lang, F				Yan, Jing; Almilaji, Ahmad; Schmid, Evi; Elvira, Bernat; Shimshek, Derya R.; van der Putten, Herman; Wagner, Carsten A.; Shumilina, Ekaterina; Lang, Florian			Leucine-rich repeat kinase 2-sensitive Na+/Ca2+ exchanger activity in dendritic cells	FASEB JOURNAL			English	Article						Ca2+ signaling; Crohn's disease; Parkinson's disease; CD86; LPS	NA/CA EXCHANGE; PARKINSONS-DISEASE; CA2+ TRANSPORT; CALCIUM-ENTRY; MAST-CELLS; T-CELLS; LRRK2; MACROPHAGES; EXPRESSION; ASSOCIATION	Gene variants of the leucine-rich repeat kinase 2 (LRRK2) are associated with susceptibility to Parkinson's disease (PD). Besides brain and periphery, LRRK2 is expressed in various immune cells including dendritic cells (DCs), antigen-presenting cells linking innate and adaptive immunity. However, the function of LRRK2 in the immune system is still incompletely understood. Here, Ca2+-signaling was analyzed in DCs isolated from gene-targeted mice lacking lrrk2 (Lrrk2(-/-)) and their wild-type littermates (Lrrk2(+/+)). According to Western blotting, Lrrk2 was expressed in Lrrk2(+/+) DCs but not in Lrrk2(-/-)DCs. Cytosolic Ca2+ levels ([Ca2+](i)) were determined utilizing Fura-2 fluorescence and whole cell currents to decipher electrogenic transport. The increase of [Ca2+](i) following inhibition of sarcoendoplasmatic Ca2+-ATPase with thapsigargin (1 mu M) in the absence of extracellular Ca2+ (Ca2+-release) and the increase of [Ca2+](i) following subsequent readdition of extracellular Ca2+ (SOCE) were both significantly larger in Lrrk2(-/-) than in Lrrk2(+/+) DCs. The augmented increase of [Ca2+](i) could have been due to impaired Ca2+ extrusion by K+-independent (NCX) and/or K+-dependent (NCKX) Na+/Ca2+-exchanger activity, which was thus determined from the increase of [Ca2+](i), ([Ca2+](i)), and current following abrupt replacement of Na+ containing (130 mM) and Ca2+ free (0 mM) extracellular perfusate by Na+ free (0 mM) and Ca2+ containing (2 mM) extracellular perfusate. As a result, both slope and peak of [Ca2+](i) as well as Na+/Ca2+ exchanger-induced current were significantly lower in Lrrk2(-/-) than in Lrrk2(+/+) DCs. A 6 or 24 hour treatment with the LRRK2 inhibitor GSK2578215A (1 mu M) significantly decreased NCX1 and NCKX1 transcript levels, significantly blunted Na+/Ca2+-exchanger activity, and significantly augmented the increase of [Ca2+](i) following Ca2+-release and SOCE. In conclusion, the present observations disclose a completely novel functional significance of LRRK2, i.e., the up-regulation of Na+/Ca2+ exchanger transcription and activity leading to attenuation of Ca2+-signals in DCs.Yan, J., Almilaji, A., Schmid, E., Elvira, B., Shimshek, D. R., van der Putten, H., Wagner, C. A., Shumilina, E., Lang, F. Leucine-rich repeat kinase 2-sensitive Na+/Ca2(+) exchanger activity in dendritic cells.	[Yan, Jing; Almilaji, Ahmad; Schmid, Evi; Elvira, Bernat; Shumilina, Ekaterina; Lang, Florian] Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; [Shimshek, Derya R.; van der Putten, Herman] Novartis Inst BioMed Res, Dept Neurosci, Basel, Switzerland; [Wagner, Carsten A.] Univ Zurich, Inst Physiol, Zurich, Switzerland; [van der Putten, Herman] Natl Contest Life Fdn, Hamburg, Germany; [Schmid, Evi] Univ Childrens Hosp Tubingen, Dept Pediat Surg & Pediat Urol, Tubingen, Germany	Eberhard Karls University of Tubingen; Novartis; University of Zurich; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL	Lang, F (corresponding author), Univ Tubingen, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de	; Elvira, Bernat/A-2404-2017	Yan, Jing/0000-0002-0307-1635; Elvira, Bernat/0000-0003-0434-2238; Shimshek, Derya/0000-0001-8602-7850	Deutsche Forschungsgemeinschaft DFG [SFB 766, GRK 1302/1]; Michael J. Fox Foundation for Parkinson Research	Deutsche Forschungsgemeinschaft DFG(German Research Foundation (DFG)); Michael J. Fox Foundation for Parkinson Research	The authors gratefully acknowledge the technical assistance of E. Faber and Melanie Hauth and the meticulous preparation of the manuscript by Tanja Loch and Sari Rube. J.Y. and A.A. are first authors of this work. This work was supported by the Deutsche Forschungsgemeinschaft DFG (SFB 766; GRK 1302/1) to F.L. and by the Michael J. Fox Foundation for Parkinson Research to C.A.W. The authors declare no conflicts of interest.	Aki D, 2008, GENES CELLS, V13, P199, DOI 10.1111/j.1365-2443.2007.01159.x; Aneiros E, 2005, J IMMUNOL, V174, P119, DOI 10.4049/jimmunol.174.1.119; BALASUBRAMANYAM M, 1994, J CLIN INVEST, V94, P2002, DOI 10.1172/JCI117553; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Berridge MJ, 2006, CELL CALCIUM, V40, P405, DOI 10.1016/j.ceca.2006.09.002; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bird GS, 2008, METHODS, V46, P204, DOI 10.1016/j.ymeth.2008.09.009; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Canitano A, 2002, ANN NY ACAD SCI, V976, P394; Cherra SJ, 2013, AM J PATHOL, V182, P474, DOI 10.1016/j.ajpath.2012.10.027; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Connolly SF, 2007, IMMUNOL RES, V39, P115, DOI 10.1007/s12026-007-0076-1; den Haan JMM, 2000, P NATL ACAD SCI USA, V97, P12950, DOI 10.1073/pnas.97.24.12950; Dzamko N, 2012, BIOCHEM SOC T, V40, P1134, DOI 10.1042/BST20120119; Gardet A, 2010, J IMMUNOL, V185, P5577, DOI 10.4049/jimmunol.1000548; Hakimi M, 2011, J NEURAL TRANSM, V118, P795, DOI 10.1007/s00702-011-0653-2; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hassin-Baer S, 2009, J NEUROL, V256, P483, DOI 10.1007/s00415-009-0117-x; Herchuelz A, 2007, ANN NY ACAD SCI, V1099, P456, DOI 10.1196/annals.1387.048; Herrmann TL, 2007, J LEUKOCYTE BIOL, V82, P686, DOI 10.1189/jlb.0107045; Herzig MC, 2011, HUM MOL GENET, V20, P4209, DOI 10.1093/hmg/ddr348; Hsu SF, 2001, J IMMUNOL, V166, P6126, DOI 10.4049/jimmunol.166.10.6126; Kelly EK, 2010, J IMMUNOL, V184, P5545, DOI 10.4049/jimmunol.0901293; Khananshvili D, 2014, PFLUG ARCH EUR J PHY, V466, P43, DOI 10.1007/s00424-013-1405-y; Kimura M, 1999, AM J PHYSIOL-HEART C, V277, pH911, DOI 10.1152/ajpheart.1999.277.3.H911; Koski GK, 1999, J IMMUNOL, V163, P82; Kuss M, 2014, J NEUROCHEM, V129, P980, DOI 10.1111/jnc.12668; Lytton J, 2007, BIOCHEM J, V406, P365, DOI 10.1042/BJ20070619; Mamais A, 2014, J NEUROCHEM, V129, P895, DOI 10.1111/jnc.12691; Matzner N, 2008, J IMMUNOL, V181, P6803, DOI 10.4049/jimmunol.181.10.6803; Miklavc P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084926; Moehle MS, 2012, J NEUROSCI, V32, P1602, DOI 10.1523/JNEUROSCI.5601-11.2012; Nurbaeva MK, 2012, FASEB J, V26, P3049, DOI 10.1096/fj.12-204024; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Reppel M, 2007, ANN NY ACAD SCI, V1099, P361, DOI 10.1196/annals.1387.065; Roberts DE, 2012, BRIT J PHARMACOL, V165, P922, DOI 10.1111/j.1476-5381.2011.01600.x; Rumpel E, 2000, BIOPHYS J, V79, P2975, DOI 10.1016/S0006-3495(00)76534-9; Russo I, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-52; Schmitt R, 1999, AM J PHYSIOL-RENAL, V276, pF367, DOI 10.1152/ajprenal.1999.276.3.F367; Sipido KR, 2007, ANN NY ACAD SCI, V1099, P339, DOI 10.1196/annals.1387.066; Staiano RL, 2009, EUR J IMMUNOL, V39, P1405, DOI 10.1002/eji.200838792; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Thevenet J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021519; Tintinger GR, 2004, BIOCHEM PHARMACOL, V67, P2263, DOI 10.1016/j.bcp.2004.02.029; Venetucci LA, 2007, ANN NY ACAD SCI, V1099, P315, DOI 10.1196/annals.1387.033; Visser F, 2007, PHYSIOLOGY, V22, P185, DOI 10.1152/physiol.00001.2007; Visser F, 2007, J BIOL CHEM, V282, P4453, DOI 10.1074/jbc.M610582200; Vukcevic M, 2008, J BIOL CHEM, V283, P34913, DOI 10.1074/jbc.M804472200; Yamazaki S, 2009, J DERMATOL SCI, V54, P69, DOI 10.1016/j.jdermsci.2009.02.001; Zhang FR, 2009, NEW ENGL J MED, V361, P2609, DOI 10.1056/NEJMoa0903753; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	54	14	15	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1701	1710		10.1096/fj.14-264028	http://dx.doi.org/10.1096/fj.14-264028			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25609428				2022-12-28	WOS:000354114600009
J	Zhang, JY; Sadowska, GB; Chen, XD; Park, SY; Kim, JE; Bodge, CA; Cummings, E; Lim, YP; Makeyev, O; Besio, WG; Gaitanis, J; Banks, WA; Stonestreet, BS				Zhang, Jiyong; Sadowska, Grazyna B.; Chen, Xiaodi; Park, Seon Yeong; Kim, Jeong-Eun; Bodge, Courtney A.; Cummings, Erin; Lim, Yow-Pin; Makeyev, Oleksandr; Besio, Walter G.; Gaitanis, John; Banks, William A.; Stonestreet, Barbara S.			Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus	FASEB JOURNAL			English	Article						development; ischemia; monoclonal; permeability; tight junction proteins	NECROSIS-FACTOR-ALPHA; JUNCTION PROTEIN EXPRESSION; WHITE-MATTER LESIONS; MICROVESSEL ENDOTHELIAL-CELLS; FOCAL CEREBRAL-ISCHEMIA; FETAL SHEEP; MATRIX METALLOPROTEINASES; HYPOXIA-ISCHEMIA; MONOCLONAL-ANTIBODIES; ACUTE HYPEROSMOLALITY	Impaired blood-brain barrier function represents an important component of hypoxic-ischemic brain injury in the perinatal period. Proinflammatory cytokines could contribute to ischemia-related blood-brain barrier dysfunction. IL-6 increases vascular endothelial cell monolayer permeability in vitro. However, contributions of IL-6 to blood-brain barrier abnormalities have not been examined in the immature brain in vivo. We generated pharmacologic quantities of ovine-specific neutralizing anti-IL-6 mAbs and systemically infused mAbs into fetal sheep at 126 days of gestation after exposure to brain ischemia. Anti-IL-6 mAbs were measured by ELISA in fetal plasma, cerebral cortex, and cerebrospinal fluid, blood-brain barrier permeability was quantified using the blood-to-brain transfer constant in brain regions, and IL-6, tight junction proteins, and plasmalemma vesicle protein (PLVAP) were detected by Western immunoblot. Anti-IL-6 mAb infusions resulted in increases in mAb (P < 0.05) in plasma, brain parenchyma, and cerebrospinal fluid and decreases in brain IL-6 protein. Twenty-four hours after ischemia, anti-IL-6 mAb infusions attenuated ischemia-related increases in blood-brain barrier permeability and modulated tight junction and PLVAP protein expression in fetal brain. We conclude that inhibiting the effects of IL-6 protein with systemic infusions of neutralizing antibodies attenuates ischemia-related increases in blood-brain barrier permeability by inhibiting IL-6 and modulates tight junction proteins after ischemia.Zhang, J., Sadowska, G. B., Chen, X., Park, S. Y., Kim, J.-E., Bodge, C. A., Cummings, E., Lim, Y.-P., Makeyev, O., Besio, W. G., Gaitanis, J., Banks, W. A., Stonestreet, B. S. Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus.	[Zhang, Jiyong; Sadowska, Grazyna B.; Chen, Xiaodi; Park, Seon Yeong; Kim, Jeong-Eun; Bodge, Courtney A.; Cummings, Erin; Stonestreet, Barbara S.] Brown Univ, Women & Infants Hosp Rhode Isl, Alpert Med Sch, Dept Pediat, Providence, RI 02905 USA; [Lim, Yow-Pin] ProThera Biol Inc, Providence, RI USA; [Makeyev, Oleksandr; Besio, Walter G.] Univ Rhode Isl, Dept Elect Comp & Biomed Engn, Kingston, RI 02881 USA; [Gaitanis, John] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Neurol, Providence, RI 02905 USA; [Banks, William A.] Univ Washington, Geriatr Res Educ & Clin Ctr, Dept Med, Div Gerontol & Geriatr Med,Vet Affairs Puget Soun, Seattle, WA 98195 USA	Brown University; Women & Infants Hospital Rhode Island; University of Rhode Island; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Geriatric Research Education & Clinical Center; University of Washington; University of Washington Seattle	Stonestreet, BS (corresponding author), Brown Univ, Women & Infants Hosp Rhode Isl, Alpert Med Sch, Dept Pediat, 101 Dudley St, Providence, RI 02905 USA.	bstonestreet@wihri.org	Banks, William A/K-1330-2017	Banks, William A/0000-0002-0496-3619; Makeyev, Oleksandr/0000-0003-2648-0500; Chen, Xiaodi/0000-0002-1860-2814	U.S. National Institutes of Health, National Institute of General Medical Sciences (NIH NIGMS) [1R01-HD-057100, RI-INBRE P20RR016457-11]; Institutional Development Award from the NIH NIGMS [P20 RR018728, P20GM103537]; American Heart Association [13POST16860015]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD057100] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016457, P20RR018728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103537] Funding Source: NIH RePORTER	U.S. National Institutes of Health, National Institute of General Medical Sciences (NIH NIGMS); Institutional Development Award from the NIH NIGMS; American Heart Association(American Heart Association); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors gratefully acknowledge the gift of the ovine IL-6 pQE30 vector and mouse monoclonal cell lines from Commonwealth Scientific and Industrial Research Organization, Livestock Industries (Victoria, Australia), that enabled the production of IL-6 protein and anti-IL-6 mAb, respectively. This work was supported by The U.S. National Institutes of Health, National Institute of General Medical Sciences (NIH NIGMS) Awards 1R01-HD-057100 and RI-INBRE P20RR016457-11; an Institutional Development Award from the NIH NIGMS Grants P20 RR018728 and P20GM103537; and a postdoctoral fellowship award from American Heart Association Grant 13POST16860015. The authors declare no conflicts of interest.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Abbruscato TJ, 1999, J PHARMACOL EXP THER, V289, P668; Abraham CS, 1996, NEUROSCI LETT, V208, P85; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Atwal JK, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002254; Back SA, 2006, J CHILD NEUROL, V21, P582, DOI 10.1177/08830738060210070101; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Banks WA, 2002, PEPTIDES, V23, P2223, DOI 10.1016/S0196-9781(02)00261-9; Banks WA, 2007, EXP NEUROL, V206, P248, DOI 10.1016/j.expneurol.2007.05.005; BARLOW RM, 1969, J COMP NEUROL, V135, P249, DOI 10.1002/cne.901350302; Bauman MD, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.47; Benjelloun N, 1999, STROKE, V30, P1916, DOI 10.1161/01.STR.30.9.1916; Bernhard C G, 1967, Prog Brain Res, V26, P60; BRALET AM, 1979, STROKE, V10, P34, DOI 10.1161/01.STR.10.1.34; Brimberg L, 2013, MOL PSYCHIATR, V18, P1171, DOI 10.1038/mp.2013.101; Brown RC, 2002, STROKE, V33, P1706, DOI 10.1161/01.STR.0000016405.06729.83; Brunssen SH, 2013, BRAIN BEHAV IMMUN, V27, P42, DOI 10.1016/j.bbi.2012.08.017; Cai ZW, 1998, DEV BRAIN RES, V109, P265, DOI 10.1016/S0165-3806(98)00080-7; Carson-Walter EB, 2005, CLIN CANCER RES, V11, P7643, DOI 10.1158/1078-0432.CCR-05-1099; Chai Z, 1996, J EXP MED, V183, P311, DOI 10.1084/jem.183.1.311; Chen X, 2013, J COMP PATHOL, V148, P252, DOI 10.1016/j.jcpa.2012.06.001; Chen X, 2012, NEUROSCIENCE, V226, P89, DOI 10.1016/j.neuroscience.2012.08.043; Chen X., 2015, NEUROBIOL DIS; Chiesa C, 2003, EUR J CLIN INVEST, V33, P352, DOI 10.1046/j.1365-2362.2003.01136.x; Chiesa C, 2003, CLIN CHEM, V49, P60, DOI 10.1373/49.1.60; Cohen SS, 2013, NEUROIMMUNOMODULAT, V20, P264, DOI 10.1159/000350470; COOK CJ, 1987, J DEV PHYSIOL, V9, P429; COOK CJ, 1987, J DEV PHYSIOL, V9, P441; CSERR HF, 1987, AM J PHYSIOL, V253, pF522, DOI 10.1152/ajprenal.1987.253.3.F522; Dammann O, 2000, J PEDIATR-US, V136, P433, DOI 10.1016/S0022-3476(00)90004-0; Dammann O, 1997, PEDIATR RES, V42, P1, DOI 10.1203/00006450-199707000-00001; del Zoppo GJ, 2009, NEUROSCIENCE, V158, P972, DOI 10.1016/j.neuroscience.2008.08.028; Desai TR, 2002, J SURG RES, V104, P118, DOI 10.1006/jsre.2002.6415; Dickey EJ, 2011, J VET INTERN MED, V25, P1231, DOI 10.1111/j.1939-1676.2011.00818.x; Ellison VJ, 2005, PEDIATR RES, V57, P282, DOI 10.1203/01.PDR.0000148286.53572.95; Fischer S, 2002, MICROVASC RES, V63, P70, DOI 10.1006/mvre.2001.2367; Fischer S, 1999, AM J PHYSIOL-CELL PH, V276, pC812; Fujimoto M, 2008, J CEREBR BLOOD F MET, V28, P1674, DOI 10.1038/jcbfm.2008.59; GIBSON KJ, 1995, J PHYSIOL-LONDON, V485, P835, DOI 10.1113/jphysiol.1995.sp020773; Goussev S, 2003, J NEUROSURG, V99, P188, DOI 10.3171/spi.2003.99.2.0188; Gu Y, 2012, J NEUROCHEM, V120, P147, DOI 10.1111/j.1471-4159.2011.07542.x; Gu Yong, 2011, Front Biosci (Schol Ed), V3, P1216; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Hagberg H, 1996, PEDIATR RES, V40, P603, DOI 10.1203/00006450-199610000-00015; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Hnasko R, 2006, CELL CYCLE, V5, P2012, DOI 10.4161/cc.5.17.3216; Huber JD, 2001, AM J PHYSIOL-HEART C, V280, pH1241, DOI 10.1152/ajpheart.2001.280.3.H1241; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; ITO U, 1979, STROKE, V10, P542, DOI 10.1161/01.STR.10.5.542; Kaur C, 2008, CURR NEUROVASC RES, V5, P71, DOI 10.2174/156720208783565645; Kim CR, 2006, REPROD FERT DEVELOP, V18, P413, DOI 10.1071/RD05114; Kumar A, 2008, PEDIATRICS, V122, pE722, DOI 10.1542/peds.2008-0269; Lai MC, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/609813; Lakhan SE, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00032; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Leviton A, 2011, J PEDIATR-US, V158, P897, DOI 10.1016/j.jpeds.2010.11.059; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Longo M, 2009, Minerva Ginecol, V61, P421; LOTZ M, 1988, J EXP MED, V167, P1253, DOI 10.1084/jem.167.3.1253; Malaeb S, 2009, J CHILD NEUROL, V24, P1119, DOI 10.1177/0883073809338066; Malaeb SN, 2007, BRAIN RES, V1160, P11, DOI 10.1016/j.brainres.2007.05.043; MALLARD EC, 1993, PEDIATR RES, V33, P61, DOI 10.1203/00006450-199301000-00013; Mark KS, 2002, AM J PHYSIOL-HEART C, V282, pH1485, DOI 10.1152/ajpheart.00645.2001; MartinAncel A, 1997, PEDIATRICS, V100, P789, DOI 10.1542/peds.100.5.789; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; McCarthy KM, 2000, J CELL SCI, V113, P1277; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McWaters P, 2000, VET IMMUNOL IMMUNOP, V73, P155, DOI 10.1016/S0165-2427(99)00158-0; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Nedelcu J, 1999, PEDIATR RES, V46, P297, DOI 10.1203/00006450-199909000-00008; OHNO K, 1978, AM J PHYSIOL, V235, pH299, DOI 10.1152/ajpheart.1978.235.3.H299; Pantoni L, 1998, ARTERIOSCL THROM VAS, V18, P503, DOI 10.1161/01.ATV.18.4.503; Petersson KH, 2002, PEDIATR RES, V51, P768, DOI 10.1203/01.PDR.0000017486.64723.D1; POUSSET F, 1994, DEV BRAIN RES, V81, P143, DOI 10.1016/0165-3806(94)90078-7; Prout AP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039043; Prout AP, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.08.020; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rezaie P, 2002, NEUROPATHOLOGY, V22, P106, DOI 10.1046/j.1440-1789.2002.00438.x; Roelfsema V, 2004, J CEREBR BLOOD F MET, V24, P877, DOI 10.1097/01.WCB.0000123904.17746.92; Ron NP, 2005, REPROD FERT DEVELOP, V17, P535, DOI 10.1071/RD03044; Sadowska GB, 2006, J SOC GYNECOL INVEST, V13, P248, DOI 10.1016/j.jsgi.2006.02.012; Sadowska GB, 2012, INT J DEV NEUROSCI, V30, P457, DOI 10.1016/j.ijdevneu.2012.06.001; Sadowska GB, 2010, AM J PHYSIOL-HEART C, V298, pH179, DOI 10.1152/ajpheart.00828.2009; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Samland H, 2003, J NEUROSCI RES, V73, P176, DOI 10.1002/jnr.10635; Sas A, 2008, NEUROCHEM RES, V33, P2281, DOI 10.1007/s11064-008-9715-8; Schlachetzki F, 2002, J NEUROCHEM, V81, P203, DOI 10.1046/j.1471-4159.2002.00840.x; SEOW HF, 1994, VET IMMUNOL IMMUNOP, V41, P229, DOI 10.1016/0165-2427(94)90099-X; Shankaran S, 2010, NEW ENGL J MED, V362, P1051, DOI 10.1056/NEJMc0912848; Shrivastava K, 2013, DEV NEUROSCI-BASEL, V35, P212, DOI 10.1159/000348432; Shue EH, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-29; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Stonestreet BS, 2006, AM J PHYSIOL-REG I, V291, pR1031, DOI 10.1152/ajpregu.00883.2005; Stonestreet BS, 2012, J CEREBR BLOOD F MET, V32, P115, DOI 10.1038/jcbfm.2011.114; STONESTREET BS, 1989, AM J PHYSIOL, V257, pR1199, DOI 10.1152/ajpregu.1989.257.5.R1199; STONESTREET BS, 1993, AM J PHYSIOL, V265, pH1098, DOI 10.1152/ajpheart.1993.265.4.H1098; Stonestreet BS, 1996, AM J PHYSIOL-REG I, V271, pR1594, DOI 10.1152/ajpregu.1996.271.6.R1594; Stonestreet BS, 2000, AM J PHYSIOL-REG I, V279, pR468, DOI 10.1152/ajpregu.2000.279.2.R468; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/neu.2004.21.1706; Suzuki S, 2009, J CEREBR BLOOD F MET, V29, P464, DOI 10.1038/jcbfm.2008.141; SZAFLARSKI J, 1995, STROKE, V26, P1093, DOI 10.1161/01.STR.26.6.1093; Thorns V, 2002, J NEUROIMMUNOL, V127, P22, DOI 10.1016/S0165-5728(02)00072-3; Tita ATN, 2010, CLIN PERINATOL, V37, P339, DOI 10.1016/j.clp.2010.02.003; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Van Wagoner NJ, 1999, J NEUROSCI, V19, P5236; Virgintino D, 2002, NEUROSCIENCE, V115, P145, DOI 10.1016/S0306-4522(02)00374-3; Virgintino D, 2014, J NEUROPATH EXP NEUR, V73, P495, DOI 10.1097/NEN.0000000000000071; WILLIAMS CE, 1992, ANN NEUROL, V31, P14, DOI 10.1002/ana.410310104; WOOD PR, 1990, VET IMMUNOL IMMUNOP, V25, P37, DOI 10.1016/0165-2427(90)90108-5; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X; Yoon BH, 1997, AM J OBSTET GYNECOL, V177, P19, DOI 10.1016/S0002-9378(97)70432-0; Yoon BH, 1996, AM J OBSTET GYNECOL, V174, P1433, DOI 10.1016/S0002-9378(96)70585-9; Yoon BH, 1997, AM J OBSTET GYNECOL, V177, P406, DOI 10.1016/S0002-9378(97)70206-0; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334; Zhang Y, 2001, J NEUROIMMUNOL, V114, P168, DOI 10.1016/S0165-5728(01)00242-9	117	48	51	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1739	1753		10.1096/fj.14-258822	http://dx.doi.org/10.1096/fj.14-258822			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25609424	Green Published			2022-12-28	WOS:000354114600012
J	Bartoszewska, S; Kochan, K; Piotrowski, A; Kamysz, W; Ochocka, RJ; Collawn, JF; Bartoszewski, R				Bartoszewska, Sylwia; Kochan, Kinga; Piotrowski, Arkadiusz; Kamysz, Wojciech; Ochocka, Renata J.; Collawn, James F.; Bartoszewski, Rafal			The hypoxia-inducible miR-429 regulates hypoxia-inducible factor-1 alpha expression in human endothelial cells through a negative feedback loop	FASEB JOURNAL			English	Article						hypoxamiR; angiogenesis; VEGF A; HIF-2; miRNA	FACTOR-I; MESSENGER-RNA; GENE-TRANSCRIPTION; TUMOR-SUPPRESSOR; FACTOR 1-ALPHA; PROTEIN; TARGET; RESPONSES; HIF-1; DEGRADATION	Hypoxia-inducible factors (HIFs) 1 and 2 are dimeric alpha/beta transcription factors that regulate cellular responses to low oxygen. HIF-1 is induced first, whereas HIF-2 is associated with chronic hypoxia. To determine how HIF1AmRNA, the inducible subunit of HIF-1, is regulated during hypoxia, we followed HIF1A mRNA levels in primary HUVECs over 24 hours using quantitative PCR. HIF1A and VEGF A (VEGFA) mRNA, a transcriptional target of HIF-1, increased similar to 2.5- and 8-fold at 2-4 hours, respectively. To determine how the mRNAs were regulated, we identified a microRNA (miRNA), miR-429, that destabilized HIF1A message and decreased VEGFA mRNA by inhibiting HIF1A. Target protector analysis, which interferes with miRNA-mRNA complex formation, confirmed that miR-429 targeted HIF1A message. Desferoxamine treatment, which inhibits the hydroxylases that promote HIF-1 alpha protein degradation, stabilized HIF-1 activity during normoxic conditions and elevated miR-429 levels, demonstrating that HIF-1 promotes miR-429 expression. RNA-sequencing-based transcriptome analysis indicated that inhibition of miRNA-429 in HUVECs up-regulated 209 mRNAs, a number of which regulate angiogenesis. The results demonstrate that HIF-1 is in a negative regulatory loop with miR-429, that miR-429 attenuates HIF-1 activity by decreasing HIF1A message during the early stages of hypoxia before HIF-2 is activated, and this regulatory network helps explain the HIF-1 transition to HIF-2 during chronic hypoxia in endothelial cells.	[Bartoszewska, Sylwia; Kamysz, Wojciech] Med Univ Gdansk, Dept Inorgan Chem, Gdansk, Poland; [Kochan, Kinga; Piotrowski, Arkadiusz; Ochocka, Renata J.; Bartoszewski, Rafal] Med Univ Gdansk, Dept Biol & Pharmaceut Bot, Gdansk, Poland; [Collawn, James F.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA	Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk; University of Alabama System; University of Alabama Birmingham	Collawn, JF (corresponding author), Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, 1918 Univ Ave,MCLM 395, Birmingham, AL 35294 USA.	jcollawn@uab.edu; rafalbar@gumed.edu.pl	Bartoszewska, Sylwia/L-3922-2019; Bartoszewski, Rafal A/D-6311-2011; Piotrowski, Arkadiusz/A-5484-2010	Bartoszewska, Sylwia/0000-0001-8063-1272; Bartoszewski, Rafal A/0000-0002-2864-6757; Kamysz, Wojciech/0000-0001-5335-3043; Piotrowski, Arkadiusz/0000-0002-0823-0607; Collawn, James/0000-0002-2528-2759	National Science Center Opportunities for Promoting Understanding through Synthesis Program [DEC-2011/03/B/NZ3/04387]; U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [5R01DK060065]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060065] Funding Source: NIH RePORTER	National Science Center Opportunities for Promoting Understanding through Synthesis Program; U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Zsuzsa Bebok for helpful discussions and initial support and the Heflin Center for Genomics Sciences Core Facility for performing the RNA-sequencing analysis. All of the experiments described here besides the RNA-sequencing analysis were performed in the Department of Pharmaceutical Botany at the Medical University of Gdansk. This work has been supported by the National Science Center Opportunities for Promoting Understanding through Synthesis Program under contract DEC-2011/03/B/NZ3/04387 to R.B. and a U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Grant 5R01DK060065 to J.F.C.	Alexiou P, 2010, NUCLEIC ACIDS RES, V38, pD137, DOI 10.1093/nar/gkp888; Bartoszewski R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092128; Bartoszewski R, 2011, J BIOL CHEM, V286, P41862, DOI 10.1074/jbc.M111.304956; Bartoszewski R, 2011, METHOD ENZYMOL, V491, P3, DOI 10.1016/B978-0-12-385928-0.00001-8; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Bosch-Marce M, 2007, CIRC RES, V101, P1310, DOI 10.1161/CIRCRESAHA.107.153346; Bruning U, 2011, MOL CELL BIOL, V31, P4087, DOI 10.1128/MCB.01276-10; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Chan SY, 2010, CELL CYCLE, V9, P1072, DOI 10.4161/cc.9.6.11006; Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790; Chen J, 2011, GYNECOL ONCOL, V121, P200, DOI 10.1016/j.ygyno.2010.12.339; Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133; DERRICK TR, 1994, MED SCI SPORT EXER, V26, P919; Du R, 2014, MOL BIOL CELL, V25, P2650, DOI 10.1091/mbc.E14-01-0044; Fandrey J, 2006, CARDIOVASC RES, V71, P642, DOI 10.1016/j.cardiores.2006.05.005; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Gehrke SG, 2003, BLOOD, V101, P3288, DOI 10.1182/blood-2002-07-2192; Goodsell DS, 2002, ONCOLOGIST, V7, P569, DOI 10.1634/theoncologist.7-6-569; Greco S, 2014, ANTIOXID REDOX SIGN, V21, P1202, DOI 10.1089/ars.2013.5403; Greco S, 2014, ANTIOXID REDOX SIGN, V21, P1164, DOI 10.1089/ars.2014.6083; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Hatipoglu OF, 2009, J BIOL CHEM, V284, P16325, DOI 10.1074/jbc.M109.001313; Hebert C, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-5; Hicks K., 2014, FASEB J, V28; Ho JJD, 2012, J BIOL CHEM, V287, P29003, DOI 10.1074/jbc.M112.373365; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kim JH, 2012, ONCOL REP, V28, P1701, DOI 10.3892/or.2012.2012; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Koh MY, 2008, MOL CELL BIOL, V28, P7081, DOI 10.1128/MCB.00773-08; Koh MY, 2012, TRENDS BIOCHEM SCI, V37, P364, DOI 10.1016/j.tibs.2012.06.004; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Larionov A, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-62; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee ST, 2010, STROKE, V41, P1646, DOI 10.1161/STROKEAHA.110.579649; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li JP, 2007, MOL CELL BIOL, V27, P7345, DOI 10.1128/MCB.02201-06; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Madanecki P, 2013, CELL MOL BIOL LETT, V18, P47, DOI 10.2478/s11658-012-0037-0; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Manisterski M, 2010, CELL CYCLE, V9, P3723, DOI 10.4161/cc.9.18.12931; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; Michiels C, 2004, AM J PATHOL, V164, P1875, DOI 10.1016/S0002-9440(10)63747-9; Mole DR, 2001, IUBMB LIFE, V52, P43; Persano L, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.153; Piret JP, 2002, ANN NY ACAD SCI, V973, P443, DOI 10.1111/j.1749-6632.2002.tb04680.x; Prabhakar NR, 2012, PHYSIOL REV, V92, P967, DOI 10.1152/physrev.00030.2011; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Schmid T, 2004, BIOCHEM J, V380, P289, DOI 10.1042/BJ20031299; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Staton AA, 2011, NAT PROTOC, V6, P2035, DOI 10.1038/nprot.2011.423; Storz G, 2004, CURR OPIN MICROBIOL, V7, P140, DOI 10.1016/j.mib.2004.02.015; Takata K, 2008, MOL CANCER THER, V7, P1551, DOI 10.1158/1535-7163.MCT-07-0428; Thomas JD, 2007, RNA, V13, P1116, DOI 10.1261/rna.534807; Thomson DW, 2011, NUCLEIC ACIDS RES, V39, P6845, DOI 10.1093/nar/gkr330; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Veschini L, 2007, BLOOD, V109, P2565, DOI 10.1182/blood-2006-06-032664; Ziello Jennifer E, 2007, Yale J Biol Med, V80, P51	69	90	92	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1467	1479		10.1096/fj.14-267054	http://dx.doi.org/10.1096/fj.14-267054			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550463	Green Published			2022-12-28	WOS:000354115000032
J	Muter, J; Lucas, ES; Chan, YW; Brighton, PJ; Moore, JD; Lacey, L; Quenby, S; Lam, EWF; Brosens, JJ				Muter, Joanne; Lucas, Emma S.; Chan, Yi-Wah; Brighton, Paul J.; Moore, Jonathan D.; Lacey, Lauren; Quenby, Siobhan; Lam, Eric W. -F.; Brosens, Jan J.			The clock protein period 2 synchronizes mitotic expansion and decidual transformation of human endometrial stromal cells	FASEB JOURNAL			English	Article						endometrium; circadian rhythm; cell cycle; miscarriage	DIFFERENTIAL EXPRESSION ANALYSIS; CIRCADIAN CLOCK; GENE-EXPRESSION; DOWN-REGULATION; PER2; RECEPTOR; MOUSE; TRANSCRIPTION; ACTIVATION; TISSUES	Implantation requires coordinated interactions between the conceptus and surrounding decidual cells, but the involvement of clock genes in this process is incompletely understood. Circadian oscillations are predicated on transcriptional-translational feedback loops, which balance the activities of the transcriptional activators CLOCK (circadian locomotor output cycles kaput) and brain muscle arnt-like 1 and repressors encoded by PER (Period) and Cryptochrome genes. We show that loss of PER2 expression silences circadian oscillations in decidualizing human endometrial stromal cells (HESCs). Downregulation occurred between 12 and 24 hours following differentiation and coincided with reduced CLOCK binding to a noncanonical E-box enhancer in the PER2 promoter. RNA sequencing revealed that premature inhibition of PER2 by small interfering RNA knockdown leads to a grossly disorganized decidual response. Gene ontology analysis highlighted a preponderance of cell cycle regulators among the 1121 genes perturbed upon PER2 knockdown. Congruently, PER2 inhibition abrogated mitotic expansion of differentiating HESCs by inducing cell cycle block at G2/M. Analysis of 70 midluteal endometrial biopsies revealed an inverse correlation between PER2 transcript levels and the number of miscarriages in women suffering reproductive failure (Spearman rank test, rho = -0.3260; P = 0.0046). Thus, PER2 synchronizes endometrial proliferation with initiation of aperiodic decidual gene expression; uncoupling of these events may cause recurrent pregnancy loss.	[Muter, Joanne; Lucas, Emma S.; Brighton, Paul J.; Lacey, Lauren; Quenby, Siobhan; Brosens, Jan J.] Univ Warwick, Warwick Med Sch, Div Translat & Syst Med, Coventry CV4 7AL, W Midlands, England; [Chan, Yi-Wah; Moore, Jonathan D.] Univ Warwick, Warwick Syst Biol Ctr, Coventry CV4 7AL, W Midlands, England; [Lam, Eric W. -F.] Univ London Imperial Coll Sci Technol & Med, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, London, England	University of Warwick; University of Warwick; Imperial College London	Brosens, JJ (corresponding author), Univ Hosp, Warwick Med Sch, Clin Sci Res Inst, Dept Reprod Hlth, Coventry CV2 2DX, W Midlands, England.	j.j.brosens@warwick.ac.uk	Lam, Eric W-F/AAW-8566-2020; Lucas, Emma S/I-2719-2013; Moore, Jonathan D/D-1796-2013	Lam, Eric W-F/0000-0003-1274-3576; Lucas, Emma S/0000-0002-8571-8921; Moore, Jonathan D/0000-0002-5486-0407; Brosens, Jan/0000-0003-0116-9329; Quenby, Siobhan/0000-0003-3221-5471	Biomedical Research Unit in Reproductive Health; University Hospitals Coventry; Warwickshire National Health Service Trust; Warwick Medical School; Warwick Chancellor's studentship; Biotechnology and Biological Sciences Research Council [BBS/B/03785] Funding Source: researchfish; Engineering and Physical Sciences Research Council [1234732] Funding Source: researchfish	Biomedical Research Unit in Reproductive Health; University Hospitals Coventry; Warwickshire National Health Service Trust; Warwick Medical School; Warwick Chancellor's studentship; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by the Biomedical Research Unit in Reproductive Health, a joint initiative between the University Hospitals Coventry and Warwickshire National Health Service Trust and Warwick Medical School. J.M. is the recipient of a Warwick Chancellor's studentship. The authors declare no conflicts of interest.	Al-Sabbagh M, 2012, MOL CELL ENDOCRINOL, V358, P208, DOI 10.1016/j.mce.2011.10.035; Al-Sabbagh M, 2011, ENDOCRINOLOGY, V152, P730, DOI 10.1210/en.2010-0899; Albrecht U, 2007, COLD SPRING HARB SYM, V72, P95, DOI 10.1101/sqb.2007.72.001; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Boden MJ, 2013, PROG BIOPHYS MOL BIO, V113, P387, DOI 10.1016/j.pbiomolbio.2013.01.003; Brosens JJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep03894; Brosens JJ, 1999, ENDOCRINOLOGY, V140, P4809, DOI 10.1210/en.140.10.4809; Chappell PE, 2003, J NEUROSCI, V23, P11202; Chu A, 2013, ENDOCRINOLOGY, V154, P2924, DOI 10.1210/en.2013-1080; Dolatshad H, 2009, REPROD FERT DEVELOP, V21, P1, DOI 10.1071/RD08223; Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072; Gellersen B, 2014, ENDOCR REV, V35, P851, DOI 10.1210/er.2014-1045; Gery S, 2007, ONCOGENE, V26, P7916, DOI 10.1038/sj.onc.1210585; Grimaldi B, 2009, INT J BIOCHEM CELL B, V41, P81, DOI 10.1016/j.biocel.2008.08.035; Grimaldi G, 2011, MOL ENDOCRINOL, V25, P1892, DOI 10.1210/me.2011-1139; Hwang-Verslues WW, 2013, P NATL ACAD SCI USA, V110, P12331, DOI 10.1073/pnas.1222684110; Jones MC, 2006, P NATL ACAD SCI USA, V103, P16272, DOI 10.1073/pnas.0603002103; Karman BN, 2006, BIOL REPROD, V75, P624, DOI 10.1095/biolreprod.106.050732; Kennaway DJ, 2003, MOL HUM REPROD, V9, P503, DOI 10.1093/molehr/gag067; Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207; Koyanagi S, 2011, J BIOL CHEM, V286, P32416, DOI 10.1074/jbc.M111.258970; Lal S, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003926; Lamas M, 1996, PHILOS T R SOC B, V351, P561, DOI 10.1098/rstb.1996.0055; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee J, 2008, MOL CELL BIOL, V28, P6056, DOI 10.1128/MCB.00583-08; Leitao B, 2010, FASEB J, V24, P1541, DOI 10.1096/fj.09-149153; Li QX, 2007, J BIOL CHEM, V282, P31725, DOI 10.1074/jbc.M704723200; Mantena SR, 2006, P NATL ACAD SCI USA, V103, P1870, DOI 10.1073/pnas.0507261103; Markson JS, 2009, FEBS LETT, V583, P3938, DOI 10.1016/j.febslet.2009.11.021; Miki T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3444; Morin LP, 2013, EXP NEUROL, V243, P4, DOI 10.1016/j.expneurol.2012.06.026; Nakamura TJ, 2008, AM J PHYSIOL-ENDOC M, V295, pE1025, DOI 10.1152/ajpendo.90392.2008; Nakamura TJ, 2005, J NEUROSCI RES, V82, P622, DOI 10.1002/jnr.20677; O'Neill JS, 2008, SCIENCE, V320, P949, DOI 10.1126/science.1152506; O'Neill John S, 2013, Handb Exp Pharmacol, P67, DOI 10.1007/978-3-642-25950-0_4; Ogasawara M, 2000, FERTIL STERIL, V73, P300, DOI 10.1016/S0015-0282(99)00495-1; Pilorz V, 2008, REPRODUCTION, V135, P559, DOI 10.1530/REP-07-0434; Pohnke Y, 2004, J CLIN ENDOCR METAB, V89, P5233, DOI 10.1210/jc.2004-0012; Rai R, 2006, LANCET, V368, P601, DOI 10.1016/S0140-6736(06)69204-0; Ratajczak CK, 2012, REPROD FERT DEVELOP, V24, P759, DOI 10.1071/RD11164; Ratajczak CK, 2009, ENDOCRINOLOGY, V150, P1879, DOI 10.1210/en.2008-1021; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Ripperger JA, 2010, PROTEIN REV, V12, P37, DOI 10.1007/978-1-4419-1262-6_2; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Salker M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010287; Salker MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052252; Salker MS, 2011, NAT MED, V17, P1509, DOI 10.1038/nm.2498; Stocker LJ, 2014, OBSTET GYNECOL, V124, P99, DOI 10.1097/AOG.0000000000000321; Stojkovic K, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00069; Sun CM, 2010, PATHOL ONCOL RES, V16, P403, DOI 10.1007/s12253-009-9227-0; Talbi S, 2006, ENDOCRINOLOGY, V147, P1097, DOI 10.1210/en.2005-1076; Telgmann R, 1998, HUM REPROD UPDATE, V4, P472, DOI 10.1093/humupd/4.5.472; Thoennissen NH, 2012, LEUKEMIA LYMPHOMA, V53, P1577, DOI 10.3109/10428194.2012.658792; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Uchikawa M, 2011, CHRONOBIOL INT, V28, P1, DOI 10.3109/07420528.2010.522289; Wagner GP, 2012, THEOR BIOSCI, V131, P281, DOI 10.1007/s12064-012-0162-3; Wang W, 2010, ENDOCRINOLOGY, V151, P3929, DOI 10.1210/en.2009-1437; Yoo SH, 2005, P NATL ACAD SCI USA, V102, P2608, DOI 10.1073/pnas.0409763102	59	26	27	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1603	1614		10.1096/fj.14-267195	http://dx.doi.org/10.1096/fj.14-267195			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25573754	Green Published, hybrid			2022-12-28	WOS:000354115000043
J	O'Hara, L; McInnes, K; Simitsidellis, I; Morgan, S; Atanassova, N; Slowikowska-Hilczer, J; Kula, K; Szarras-Czapnik, M; Milne, L; Mitchell, RT; Smith, LB				O'Hara, Laura; McInnes, Kerry; Simitsidellis, Ioannis; Morgan, Stephanie; Atanassova, Nina; Slowikowska-Hilczer, Jolanta; Kula, Krzysztof; Szarras-Czapnik, Maria; Milne, Laura; Mitchell, Rod T.; Smith, Lee B.			Autocrine androgen action is essential for Leydig cell maturation and function, and protects against late-onset Leydig cell apoptosis in both mice and men	FASEB JOURNAL			English	Article						testis; testosterone; estrogen; steroidogenesis; spermatogenesis	ESTROGEN SULFOTRANSFERASE; METABOLIC SYNDROME; SERTOLI-CELLS; GERM-CELL; TESTICULAR FEMINIZATION; RECEPTOR EXPRESSION; INTERSTITIAL-CELLS; NERVOUS-SYSTEM; SMOOTH-MUSCLE; STEM-CELLS	Leydig cell number and function decline as men age, and low testosterone is associated with all "Western" cardio-metabolic disorders. However, whether perturbed androgen action within the adult Leydig cell lineage predisposes individuals to this late-onset degeneration remains unknown. To address this, we generated a novel mouse model in which androgen receptor (AR) is ablated from similar to 75% of adult Leydig stem cell/cell progenitors, from fetal life onward (Leydig cell AR knockout mice), permitting interrogation of the specific roles of autocrine Leydig cell AR signaling through comparison to adjacent AR-retaining Leydig cells, testes from littermate controls, and to human testes, including from patients with complete androgen insensitivity syndrome (CAIS). This revealed that autocrine AR signaling is dispensable for the attainment of final Leydig cell number but is essential for Leydig cell maturation and regulation of steroidogenic enzymes in adulthood. Furthermore, these studies reveal that autocrine AR signaling in Leydig cells protects against late-onset degeneration of the seminiferous epithelium in mice and inhibits Leydig cell apoptosis in both adult mice and patients with CAIS, possibly via opposing aberrant estrogen signaling. We conclude that autocrine androgen action within Leydig cells is essential for the lifelong support of spermatogenesis and the development and lifelong health of Leydig cells.	[O'Hara, Laura; Simitsidellis, Ioannis; Morgan, Stephanie; Milne, Laura; Mitchell, Rod T.; Smith, Lee B.] Univ Edinburgh, Queens Med Res Inst, MRC, Ctr Reprod Hlth, Edinburgh EH16 4TJ, Midlothian, Scotland; [McInnes, Kerry] Univ Edinburgh, Queens Med Res Inst, BHF Ctr Cardiovasc Sci, Edinburgh EH16 4TJ, Midlothian, Scotland; [Atanassova, Nina] Bulgarian Acad Sci, Inst Expt Morphol & Anthropol Museum, Sofia, Bulgaria; [Slowikowska-Hilczer, Jolanta; Kula, Krzysztof] Med Univ Lodz, Dept Androl & Reprod Endocrinol, Lodz, Poland; [Szarras-Czapnik, Maria] Childrens Mem Hlth Inst, Clin Endocrinol & Diabetol, Warsaw, Poland	University of Edinburgh; University of Edinburgh; Bulgarian Academy of Sciences; Medical University Lodz; Children's Memorial Health Institute	Smith, LB (corresponding author), Univ Edinburgh, Queens Med Res Inst, MRC, Ctr Reprod Hlth, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	lee.smith@ed.ac.uk	Simitsidellis, Ioannis/J-9600-2019; Atanassova, Nina/AAH-2722-2021	Simitsidellis, Ioannis/0000-0002-9764-3330; Atanassova, Nina/0000-0002-9032-3588; Szarras-Czapnik, Maria/0000-0003-4928-9557; Smith, Lee/0000-0002-4103-3074; O'Hara, Laura/0000-0001-7790-9261; Mitchell, Rod/0000-0003-4650-3765	Medical Research Council [G1100354/1]; Wellcome Trust [098522]; Polish Ministry of Science [N N407 277339]; MRC [G1100354] Funding Source: UKRI; Medical Research Council [G1100354] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Polish Ministry of Science(Ministry of Science and Higher Education, Poland); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank Lyndsey Cruickshanks, Nathan Jeffery, Mike Dodds, Mike Millar, Nancy Evans, Ruth Hamblin, and Dr. Forbes Howie for technical support, Dr. Karel De Gendt and Professor Guido Verhoeven for provision of the AR<SUP>flox</SUP> mouse line, and Professors Iain J. McEwan and Richard Sharpe for comments on the manuscript. L.O., R.T.M., and L.B.S. conceived and designed the study. L.O., K.M., L.M., I.S., S.M., and N.A. carried out experiments. L.O., R.T.M., and L.B.S. analyzed the results. J. S.-H., K.K., M.S.-C., and R.T.M. provided novel resources. L.O. and L.B.S. wrote the paper. This work was funded by Medical Research Council Program Grant Award G1100354/1 (to L.B.S.); Wellcome Trust Intermediate Clinical Fellowship (Grant 098522) (to R.T.M.); and Polish Ministry of Science Award (Grant N N407 277339) (to J.S.-H.).	Aggarwal A, 2009, MOL REPROD DEV, V76, P1076, DOI 10.1002/mrd.21074; Anand-Ivell RJK, 2006, BIOL REPROD, V74, P945, DOI 10.1095/biolreprod.105.048165; Baker PJ, 2001, REPRODUCTION, V122, P553, DOI 10.1530/reprod/122.4.553; Beattie MC, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.107052; BLACKBURN WR, 1973, BIOL REPROD, V9, P9, DOI 10.1093/biolreprod/9.1.9; Brinster CJ, 2003, BIOL REPROD, V69, P412, DOI 10.1095/biolreprod.103.016519; Chen HL, 2009, MOL CELL ENDOCRINOL, V306, P9, DOI 10.1016/j.mce.2009.01.023; De Bruyn R, 2011, METHODS MOL BIOL, V776, P81, DOI 10.1007/978-1-61779-243-4_6; De Gendt K, 2004, P NATL ACAD SCI USA, V101, P1327, DOI 10.1073/pnas.0308114100; De Gendt K, 2005, ENDOCRINOLOGY, V146, P4117, DOI 10.1210/en.2005-0300; Del Borgo MP, 2006, J BIOL CHEM, V281, P13068, DOI 10.1074/jbc.M600472200; Drake AJ, 2009, ENDOCRINOLOGY, V150, P5055, DOI 10.1210/en.2009-0700; Eguchi J, 2011, CELL METAB, V13, P249, DOI 10.1016/j.cmet.2011.02.005; Eisenberg ML, 2012, J UROLOGY, V187, P594, DOI 10.1016/j.juro.2011.10.041; Faria MJS, 2003, MICROSC MICROANAL, V9, P68, DOI 10.1017/S1431927603030101; Farrell JB, 2008, DIABETES EDUCATOR, V34, P799, DOI 10.1177/0145721708323100; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Ge R. S., 1996, LEYDIG CELL, P159; GOLDSTEIN JL, 1972, J CLIN INVEST, V51, P1647, DOI 10.1172/JCI106966; Haisenleder DJ, 2011, ENDOCRINOLOGY, V152, P4443, DOI 10.1210/en.2011-1501; Hazra R, 2013, ENDOCRINOLOGY, V154, P3410, DOI 10.1210/en.2012-2273; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Huang ZH, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.103382; Hughes IA, 2012, LANCET, V380, P1419, DOI 10.1016/S0140-6736(12)60071-3; Jeyasuria P, 2004, MOL ENDOCRINOL, V18, P1610, DOI 10.1210/me.2003-0404; Jiang M, 2009, MOL ENDOCRINOL, V23, P1927, DOI 10.1210/me.2009-0103; Kawamura K, 2004, P NATL ACAD SCI USA, V101, P7323, DOI 10.1073/pnas.0307061101; Kilcoyne KR, 2014, P NATL ACAD SCI USA, V111, pE1924, DOI 10.1073/pnas.1320735111; Kupelian V, 2006, J CLIN ENDOCR METAB, V91, P843, DOI 10.1210/jc.2005-1326; Kupelian V, 2008, J CLIN ENDOCR METAB, V93, P3403, DOI 10.1210/jc.2008-0054; Lague E, 2008, ENDOCRINOLOGY, V149, P4688, DOI 10.1210/en.2008-0310; Landreh L, 2013, MOL CELL ENDOCRINOL, V372, P96, DOI 10.1016/j.mce.2013.03.019; Laughlin GA, 2008, J CLIN ENDOCR METAB, V93, P68, DOI 10.1210/jc.2007-1792; Lee KY, 2013, DIABETES, V62, P864, DOI 10.2337/db12-1089; Li XD, 2006, ENDOCRINOLOGY, V147, P1271, DOI 10.1210/en.2005-0654; Luo LD, 2006, J ANDROL, V27, P240, DOI 10.2164/jandrol.05075; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; MAJDIC G, 1995, J ENDOCRINOL, V147, P285, DOI 10.1677/joe.0.1470285; Martens K, 2010, FEBS LETT, V584, P1054, DOI 10.1016/j.febslet.2010.01.061; McEwan IJ, 2012, MOL BIOSYST, V8, P82, DOI 10.1039/c1mb05249g; McInnes KJ, 2012, DIABETES, V61, P1072, DOI 10.2337/db11-1136; Midzak AS, 2009, MOL CELL ENDOCRINOL, V299, P23, DOI 10.1016/j.mce.2008.07.016; MURPHY L, 1991, INT J ANDROL, V14, P66, DOI 10.1111/j.1365-2605.1991.tb01064.x; MURPHY L, 1991, J ENDOCRINOL, V131, P443, DOI 10.1677/joe.0.1310443; NEAVES WB, 1985, BIOL REPROD, V33, P259, DOI 10.1095/biolreprod33.1.259; NEAVES WB, 1984, J CLIN ENDOCR METAB, V59, P756, DOI 10.1210/jcem-59-4-756; O'Hara L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084541; O'Hara Laura, 2012, BMC Res Notes, V5, P16, DOI 10.1186/1756-0500-5-16; O'Hara L, 2011, ENDOCRINOLOGY, V152, P718, DOI 10.1210/en.2010-0928; O'Shaughnessy PJ, 2000, ENDOCRINOLOGY, V141, P2631, DOI 10.1210/en.141.7.2631; O'Shaughnessy PJ, 2002, J CELL SCI, V115, P3491; Ochsner SA, 2012, PHYSIOL GENOMICS, V44, P853, DOI 10.1152/physiolgenomics.00033.2012; Payne A.H., 2007, LEYDIG CELL HLTH DIS; Pye SR, 2014, J CLIN ENDOCR METAB, V99, P1357, DOI 10.1210/jc.2013-2052; Qian YM, 1999, ENDOCRINOLOGY, V140, P1048, DOI 10.1210/en.140.3.1048; Qian YM, 2001, ENDOCRINOLOGY, V142, P5342, DOI 10.1210/en.142.12.5342; Raskin K, 2009, J NEUROSCI, V29, P4461, DOI 10.1523/JNEUROSCI.0296-09.2009; Rebourcet D, 2014, DEVELOPMENT, V141, P2139, DOI 10.1242/dev.107029; Saad F, 2009, J STEROID BIOCHEM, V114, P40, DOI 10.1016/j.jsbmb.2008.12.022; SHAN LX, 1995, ENDOCRINOLOGY, V136, P3856, DOI 10.1210/en.136.9.3856; SHARPE RM, 1988, J ENDOCRINOL, V117, P19, DOI 10.1677/joe.0.1170019; Shima Y, 2013, MOL ENDOCRINOL, V27, P63, DOI 10.1210/me.2012-1256; Simanainen U, 2011, AM J PHYSIOL-ENDOC M, V301, pE727, DOI 10.1152/ajpendo.00580.2010; Smith L, 2011, REPRODUCTION, V141, P151, DOI 10.1530/REP-10-0404; Smith LB, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002697; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; SUZUKI K, 1995, SCAND J UROL NEPHROL, V29, P65, DOI 10.3109/00365599509180541; Tan KAL, 2005, ENDOCRINOLOGY, V146, P2674, DOI 10.1210/en.2004-1630; Tang SHE, 2002, GENESIS, V32, P199, DOI 10.1002/gene.10030; Tong MH, 2005, NAT MED, V11, P153, DOI 10.1038/nm1184; Tong MH, 2002, ENDOCRINOLOGY, V143, P3144, DOI 10.1210/en.143.8.3144; Tyndall V, 2012, REPRODUCTION, V143, P21, DOI 10.1530/REP-11-0239; Welsh M, 2012, INT J ANDROL, V35, P25, DOI 10.1111/j.1365-2605.2011.01150.x; Welsh M, 2011, ENDOCRINOLOGY, V152, P3541, DOI 10.1210/en.2011-0282; Welsh M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013632; Welsh M, 2010, ENDOCRINOLOGY, V151, P3374, DOI 10.1210/en.2009-1339; Welsh M, 2009, FASEB J, V23, P4218, DOI 10.1096/fj.09-138347; Welsh M, 2009, ENDOCRINOLOGY, V150, P2472, DOI 10.1210/en.2008-0529; Wranicz JK, 2005, INT J CARDIOL, V101, P105, DOI 10.1016/j.ijcard.2004.07.010; Xu QQ, 2007, ENDOCRINE, V32, P96, DOI 10.1007/s12020-007-9015-0; Yeap BB, 2010, CURR OPIN ENDOCRINOL, V17, P269, DOI 10.1097/MED.0b013e3283383031; Yoshida S, 2010, DEV GROWTH DIFFER, V52, P311, DOI 10.1111/j.1440-169X.2010.01174.x; Yu IC, 2008, ENDOCRINOLOGY, V149, P2361, DOI 10.1210/en.2007-0516; Yu WP, 2014, J CLIN INVEST, V124, P2709, DOI 10.1172/JCI59901; Zumoff B, 1988, Acta Med Scand Suppl, V723, P153	86	61	62	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					894	910		10.1096/fj.14-255729	http://dx.doi.org/10.1096/fj.14-255729			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25404712	Green Published, hybrid			2022-12-28	WOS:000350633000016
J	Huuskes, BM; Wise, AF; Cox, AJ; Lim, EX; Payne, NL; Kelly, DJ; Samuel, CS; Ricardo, SD				Huuskes, Brooke M.; Wise, Andrea F.; Cox, Alison J.; Lim, Ee X.; Payne, Natalie L.; Kelly, Darren J.; Samuel, Chrishan S.; Ricardo, Sharon D.			Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy	FASEB JOURNAL			English	Article						interstitial kidney injury; macrophage infiltration; transforming growth factor-beta; myofibroblast differentiation; collagen deposition; matrix metalloproteinase	ACUTE KIDNEY INJURY; UNILATERAL URETERAL OBSTRUCTION; ISCHEMIA-REPERFUSION INJURY; STROMAL CELLS; TUBULOINTERSTITIAL FIBROSIS; INTERSTITIAL FIBROSIS; MATRIX METALLOPROTEINASES; MOLECULE-1 EXPRESSION; MYOCARDIAL-INFARCTION; RELAXIN DECREASES	Chronic kidney disease (CKD) results from the development of fibrosis, ultimately leading to endstage renal disease (ESRD). Although human bone marrow-derived mesenchymal stem cells (MSCs) can accelerate renal repair following acute injury, the establishment of fibrosis during CKD may affect their potential to influence regeneration capacity. Here we tested the novel combination of MSCs with the antifibrotic serelaxin to repair and protect the kidney 7 d post-unilateral ureteral obstruction (UUO), when fibrosis is established. Male C57BL6 mice were sham-operated or UUO-inured (n = 4-6) and received vehicle, MSCs (1 3 106), serelaxin (0.5 mg/ kg per d), or the combination of both. In vivo tracing studies with luciferin/ enhanced green fluorescent protein (eGFP)-taggedMSCs showed specific localization in the obstructed kidney where they remained for 36 h. Combination therapy conferred significant protection from UUO-induced fibrosis, as indicated by hydroxyproline analysis (P < 0.001 vs. vehicle, P < 0.05 vs. MSC or serelaxin alone). This was accompanied by preserved structural architecture, decreased tubular epithelial injury (P < 0.01 vs. MSCs alone), macrophage infiltration, and myofibroblast localization in the kidney (both P < 0.01 vs. vehicle). Combination therapy also stimulated matrix metalloproteinase (MMP)-2 activity over either treatment alone (P < 0.05 vs. either treatment alone). These results suggest that the presence of an antifibrotic in conjunction with MSCsameliorates established kidneyfibrosis and augments tissue repair to a greater extent than either treatment alone.-	[Huuskes, Brooke M.; Wise, Andrea F.; Lim, Ee X.; Ricardo, Sharon D.] Monash Univ, Dept Anat & Dev Biol, Clayton, Vic 3800, Australia; [Samuel, Chrishan S.] Monash Univ, Dept Pharmacol, Clayton, Vic 3800, Australia; [Cox, Alison J.; Kelly, Darren J.] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia; [Payne, Natalie L.] Monash Univ, ARMI, Clayton, Vic 3800, Australia	Monash University; Monash University; St Vincent's Hospital Melbourne; University of Melbourne; Australian Regenerative Medicine Institute; Monash University	Ricardo, SD (corresponding author), Monash Univ, Dept Anat & Dev Biol, Clayton, Vic 3800, Australia.	chrishan.samuel@monash.edu; sharon.ricardo@monash.edu		Kelly, Darren/0000-0003-4850-3929; Wise, Andrea F./0000-0002-9387-4465; Ricardo, Sharon/0000-0003-1724-3669				Ali G, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-75; Alikhan MA, 2011, AM J PATHOL, V179, P1243, DOI 10.1016/j.ajpath.2011.05.037; Anders HJ, 2003, KIDNEY INT, V63, P401, DOI 10.1046/j.1523-1755.2003.00750.x; Bennett RG, 2014, LIVER INT, V34, P416, DOI 10.1111/liv.12247; Bi B, 2007, J AM SOC NEPHROL, V18, P2486, DOI 10.1681/ASN.2007020140; Bitto A, 2013, CLIN SCI, V125, P575, DOI 10.1042/CS20130105; BOHLE A, 1987, AM J NEPHROL, V7, P421, DOI 10.1159/000167514; Braga TT, 2012, MOL MED, V18, P1231, DOI 10.2119/molmed.2012.00131; Burst VR, 2010, NEPHRON EXP NEPHROL, V114, pE107, DOI 10.1159/000262318; Chevalier RL, 2009, KIDNEY INT, V75, P1145, DOI 10.1038/ki.2009.86; Chow BSM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042714; Cochrane AL, 2005, J AM SOC NEPHROL, V16, P3623, DOI 10.1681/ASN.2004090771; Danielson LA, 2006, J AM SOC NEPHROL, V17, P1325, DOI 10.1681/ASN.2005121307; Eun LY, 2011, TISSUE CELL, V43, P238, DOI 10.1016/j.tice.2011.04.002; Formigli L, 2007, J CELL MOL MED, V11, P1087, DOI 10.1111/j.1582-4934.2007.00111.x; Garber SL, 2003, AM J NEPHROL, V23, P8, DOI 10.1159/000066302; Garber SL, 2001, KIDNEY INT, V59, P876, DOI 10.1046/j.1523-1755.2001.059003876.x; Goldsmith LT, 2009, ANN NY ACAD SCI, V1160, P130, DOI 10.1111/j.1749-6632.2008.03800.x; Heeg MHJ, 2005, KIDNEY INT, V68, P96, DOI 10.1111/j.1523-1755.2005.00384.x; Hewitson TD, 2007, ENDOCRINOLOGY, V148, P660, DOI 10.1210/en.2006-0814; Hewitson TD, 2010, ENDOCRINOLOGY, V151, P4938, DOI 10.1210/en.2010-0286; Hossain MA, 2011, BIOCHEMISTRY-US, V50, P1368, DOI 10.1021/bi1013968; Humphreys BD, 2008, ANNU REV MED, V59, P311, DOI 10.1146/annurev.med.59.061506.154239; Humphreys BD, 2013, J CLIN INVEST, V123, P4023, DOI 10.1172/JCI45361; Imberti B, 2007, J AM SOC NEPHROL, V18, P2921, DOI 10.1681/ASN.2006121318; Jeyabalan A, 2007, ADV EXP MED BIOL, V612, P65; Lange C, 2005, KIDNEY INT, V68, P1613, DOI 10.1111/j.1523-1755.2005.00573.x; LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218; Lee S, 2011, J AM SOC NEPHROL, V22, P317, DOI 10.1681/ASN.2009060615; Lekawanvijit S, 2012, AM J PHYSIOL-HEART C, V302, pH1884, DOI 10.1152/ajpheart.00967.2011; Liu YH, 2006, KIDNEY INT, V69, P213, DOI 10.1038/sj.ki.5000054; Liu YL, 2012, CELL IMMUNOL, V276, P144, DOI 10.1016/j.cellimm.2012.05.001; Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007-0054; Masterson R, 2004, NEPHROL DIAL TRANSPL, V19, P544, DOI 10.1093/ndt/gfg598; Medina A, 2002, PEDIATR NEPHROL, V17, P1005, DOI 10.1007/s00467-002-0979-y; Mias C, 2009, STEM CELLS, V27, P2734, DOI 10.1002/stem.169; Moodley Y, 2009, AM J PATHOL, V175, P303, DOI 10.2353/ajpath.2009.080629; Mookerjee I, 2009, FASEB J, V23, P1219, DOI 10.1096/fj.08-120857; Morigi M, 2004, J AM SOC NEPHROL, V15, P1794, DOI 10.1097/01.ASN.0000128974.07460.34; Morigi M, 2008, STEM CELLS, V26, P2075, DOI 10.1634/stemcells.2007-0795; Nankivell Brian J., 2003, New England Journal of Medicine, V349, P2326, DOI 10.1056/NEJMoa020009; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Payne NL, 2013, CELL TRANSPLANT, V22, P1409, DOI 10.3727/096368912X657620; Perico N, 2005, KIDNEY INT, V68, pS21, DOI 10.1111/j.1523-1755.2005.09804.x; Perico N, 2011, CLIN J AM SOC NEPHRO, V6, P412, DOI 10.2215/CJN.04950610; Puri TS, 2010, AM J PHYSIOL-RENAL, V298, pF1024, DOI 10.1152/ajprenal.00384.2009; Reinders MEJ, 2014, CURR OPIN ORGAN TRAN, V19, P54, DOI 10.1097/MOT.0000000000000032; Reinders MEJ, 2013, STEM CELL TRANSL MED, V2, P107, DOI 10.5966/sctm.2012-0114; Ries C, 2007, BLOOD, V109, P4055, DOI 10.1182/blood-2006-10-051060; Ronco P, 2007, SEMIN NEPHROL, V27, P352, DOI 10.1016/j.semnephrol.2007.02.006; Roy L, 2013, KIDNEY INT, V84, P570, DOI 10.1038/ki.2013.103; Samuel CS, 2007, CELL MOL LIFE SCI, V64, P1539, DOI 10.1007/s00018-007-6543-y; Samuel CS, 2011, LAB INVEST, V91, P675, DOI 10.1038/labinvest.2010.198; Samuel CS, 2009, CURR OPIN NEPHROL HY, V18, P9, DOI 10.1097/MNH.0b013e32831b7096; Samuel CS, 2004, KIDNEY INT, V65, P2054, DOI 10.1111/j.1523-1755.2004.00628.x; Samuel CS, 2002, FASEB J, V16, P121, DOI 10.1096/fj.02-0449fje; Schrepfer S, 2007, TRANSPL P, V39, P573, DOI 10.1016/j.transproceed.2006.12.019; Semedo P, 2009, INT IMMUNOPHARMACOL, V9, P677, DOI 10.1016/j.intimp.2008.12.008; Takamiya Y, 2013, NEPHROL DIAL TRANSPL, V28, P55, DOI 10.1093/ndt/gfs387; Tan JM, 2012, JAMA-J AM MED ASSOC, V307, P1169, DOI 10.1001/jama.2012.316; Teerlink JR, 2013, LANCET, V381, P29, DOI 10.1016/S0140-6736(12)61855-8; Teerlink JR, 2009, LANCET, V373, P1429, DOI 10.1016/S0140-6736(09)60622-X; Togel F, 2008, AM J PHYSIOL-RENAL, V295, pF315, DOI 10.1152/ajprenal.00098.2008; Togel F, 2007, AM J PHYSIOL-RENAL, V292, pF1626, DOI 10.1152/ajprenal.00339.2006; Ueno T, 2013, KIDNEY INT, V84, P297, DOI 10.1038/ki.2013.81; van Dijk A, 2011, STEM CELL RES, V7, P219, DOI 10.1016/j.scr.2011.06.003; van Timmeren MM, 2006, AM J PHYSIOL-RENAL, V291, pF456, DOI 10.1152/ajprenal.00403.2005; Wise AF, 2014, AM J PHYSIOL-RENAL, V306, pF1222, DOI 10.1152/ajprenal.00675.2013; Wise AF, 2012, NEPHROLOGY, V17, P1, DOI 10.1111/j.1440-1797.2011.01501.x; WOESSNER JF, 1995, METHOD ENZYMOL, V248, P510; Xing L, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt489; Yoshida T, 2012, NEPHROL DIAL TRANSPL, V27, P2190, DOI 10.1093/ndt/gfr618; Zeisberg M, 2010, J AM SOC NEPHROL, V21, P1819, DOI 10.1681/ASN.2010080793; Zhang PL, 2008, KIDNEY INT, V73, P608, DOI 10.1038/sj.ki.5002697; Zhang Y, 2012, EUR J HEART FAIL, V14, P549, DOI 10.1093/eurjhf/hfs011; Zhao L, 1999, ENDOCRINOLOGY, V140, P445, DOI 10.1210/en.140.1.445	76	51	52	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					540	553		10.1096/fj.14-254789	http://dx.doi.org/10.1096/fj.14-254789			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25395452				2022-12-28	WOS:000349370400017
J	Curtis, VF; Ehrentraut, SF; Campbell, EL; Glover, LE; Bayless, A; Kelly, CJ; Kominsky, DJ; Colgan, SP				Curtis, Valerie F.; Ehrentraut, Stefan F.; Campbell, Eric L.; Glover, Louise E.; Bayless, Amanda; Kelly, Caleb J.; Kominsky, Douglas J.; Colgan, Sean P.			Stabilization of HIF through inhibition of Cullin-2 neddylation is protective in mucosal inflammatory responses	FASEB JOURNAL			English	Article						hypoxia; intestinal epithelia; inflammation	BOWEL-DISEASE; EXPERIMENTAL COLITIS; SUSCEPTIBILITY LOCI; NEDD8 MODIFICATION; INTESTINAL INJURY; HYPOXIA; SUPPLEMENTATION; UBIQUITINATION; IDENTIFICATION; PATHOGENESIS	There is interest in understanding post-translational modifications of proteins in inflammatory disease. Neddylation is the conjugation of the molecule neural precursor cell expressed, developmentally down-regulated 8 (NEDD8) to promote protein stabilization. Cullins are a family of NEDD8 targets important in the stabilization and degradation of proteins, such as hypoxia-inducible factor (HIF; via Cullin-2). Here, we elucidate the role of human deneddylase-1 (DEN-1, also called SENP8) in inflammatory responses in vitro and in vivo and define conditions for targeting neddylation in models of mucosal inflammation. HIF provides protection in inflammatory models, so we examined the contribution of DEN-1 to HIF stabilization. Pharmacologic targeting of neddylation activity with MLN4924 (IC50, 4.7 nM) stabilized HIF-1 alpha, activated HIF promoter activity by 2.5-fold, and induced HIF-target genes in human epithelial cells up to 5-fold. Knockdown of DEN-1 in human intestinal epithelial cells resulted in increased kinetics in barrier formation, decreased permeability, and enhanced barrier restitution by 2 +/- 0.5-fold. Parallel studies in vivo revealed that MLN4924 abrogated disease severity in murine dextran sulfate sodium colitis, including weight loss, colon length, and histologic severity. We conclude that DEN-1 is a regulator of cullin neddylation and fine-tunes the inflammatory response in vitro and in vivo. Pharmacologic inhibition of cullin neddylation may provide a therapeutic opportunity in mucosal inflammatory disease.	[Curtis, Valerie F.; Ehrentraut, Stefan F.; Campbell, Eric L.; Glover, Louise E.; Bayless, Amanda; Kelly, Caleb J.; Kominsky, Douglas J.; Colgan, Sean P.] Univ Bonn, Mucosal Inflammat Program, Bonn, Germany; [Curtis, Valerie F.; Campbell, Eric L.; Glover, Louise E.; Bayless, Amanda; Kelly, Caleb J.; Colgan, Sean P.] Univ Bonn, Dept Med, Bonn, Germany; [Ehrentraut, Stefan F.] Univ Bonn, Dept Anesthesiol, Bonn, Germany; [Kominsky, Douglas J.] Univ Colorado, Dept Anesthesiol & Perioperat Med, Aurora, CO 80045 USA	University of Bonn; University of Bonn; University of Bonn; University of Colorado System; University of Colorado Anschutz Medical Campus	Colgan, SP (corresponding author), Univ Colorado, Mucosal Inflammat Program, Anschutz Med Campus,12700 East 19th Ave,MS B-146, Aurora, CO 80045 USA.	sean.colgan@ucdenver.edu	Campbell, Eric/N-5357-2015	Campbell, Eric/0000-0003-0744-6577; Kelly, Caleb/0000-0003-4861-1479; Glover, Louise/0000-0001-9056-1810; Ehrentraut, Stefan/0000-0001-5747-6737	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050189, R01DK104713, R01DK103712, R01DK050189, R01DK095491, R01DK103639, R37DK050189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008497] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002182] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60569, R01 HL060569] Funding Source: Medline; NIDDK NIH HHS [R01 DK103712, R01 DK104713, R01 DK095491, DK50189, R37 DK050189, DK95491, R29 DK050189, R01 DK050189, R01 DK103639] Funding Source: Medline; NIGMS NIH HHS [T32 GM008497] Funding Source: Medline; BLRD VA [I01 BX002182] Funding Source: Medline; VA [5I01BX002182-04] Funding Source: Federal RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); BLRD VA; VA(US Department of Veterans Affairs)		Amir RE, 2002, J BIOL CHEM, V277, P23253, DOI 10.1074/jbc.M200967200; Boh BK, 2011, J MOL BIOL, V409, P136, DOI 10.1016/j.jmb.2011.03.023; Brownell JE, 2010, MOL CELL, V37, P102, DOI 10.1016/j.molcel.2009.12.024; Colgan SP, 2012, ANNU REV PHYSIOL, V74, P153, DOI 10.1146/annurev-physiol-020911-153230; Colgan SP, 2010, NAT REV GASTRO HEPAT, V7, P281, DOI 10.1038/nrgastro.2010.39; Collier-Hyams LS, 2005, J IMMUNOL, V175, P4194, DOI 10.4049/jimmunol.175.7.4194; Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385; Ehrentraut SF, 2013, J IMMUNOL, V190, P392, DOI 10.4049/jimmunol.1202041; Ehrentraut SF, 2012, INFLAMM BOWEL DIS, V18, P1378, DOI 10.1002/ibd.22859; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Glover LE, 2013, P NATL ACAD SCI USA, V110, P19820, DOI 10.1073/pnas.1302840110; Glover LE, 2011, GASTROENTEROLOGY, V140, P1748, DOI 10.1053/j.gastro.2011.01.056; Hou YQ, 2014, BRIT J NUTR, V111, P1748, DOI 10.1017/S0007114514000038; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Keely S, 2014, MUCOSAL IMMUNOL, V7, P114, DOI 10.1038/mi.2013.29; Khoury J, 2007, J CLIN INVEST, V117, P703, DOI 10.1172/JCI30049; Kumar A, 2009, J IMMUNOL, V182, P538, DOI 10.4049/jimmunol.182.1.538; Leonel AJ, 2013, BRIT J NUTR, V109, P1396, DOI 10.1017/S000711451200342X; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; MacManus CF, 2011, FASEB J, V25, P1856, DOI 10.1096/fj.10-170316; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McGovern DPB, 2010, NAT GENET, V42, P332, DOI 10.1038/ng.549; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Mikus P, 2005, SEMIN CELL DEV BIOL, V16, P462, DOI 10.1016/j.semcdb.2005.03.002; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Rivas MA, 2011, NAT GENET, V43, P1066, DOI 10.1038/ng.952; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Sufan RI, 2006, NEOPLASIA, V8, P956, DOI 10.1593/neo.06520; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Wu K, 2003, J BIOL CHEM, V278, P28882, DOI 10.1074/jbc.M302888200; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802	35	36	37	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					208	215		10.1096/fj.14-259663	http://dx.doi.org/10.1096/fj.14-259663			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25326537	Green Published			2022-12-28	WOS:000347378600020
J	Morhayim, J; van de Peppel, J; Demmers, JAA; Kocer, G; Nigg, AL; van Driel, M; Chiba, H; van Leeuwen, JP				Morhayim, Jess; van de Peppel, Jeroen; Demmers, Jeroen A. A.; Kocer, Gulistan; Nigg, Alex L.; van Driel, Marjolein; Chiba, Hideki; van Leeuwen, Johannes P.			Proteomic signatures of extracellular vesicles secreted by nonmineralizing and mineralizing human osteoblasts and stimulation of tumor cell growth	FASEB JOURNAL			English	Article						bioactivity; intercellular communication; prostate cancer; protein cargo	MATRIX VESICLES; RIBOSOMAL-PROTEINS; EXOSOMAL PROTEINS; MEMBRANE-VESICLES; PROSTATE-CANCER; MICROVESICLES; BONE; DIFFERENTIATION; EXPRESSION; RESOLUTION	Beyond forming bone, osteoblasts play pivotal roles in various biologic processes, including hematopoiesis and bone metastasis. Extracellular vesicles (EVs) have been implicated in intercellular communication via transfer of proteins and nucleic acids between cells. We focused on the proteomic characterization of nonmineralizing (NMOBs) and mineralizing (MOBs) human osteoblast (SV-HFOs) EVs and investigated their effect on human prostate cancer (PC3) cells by microscopic, proteomic, and gene expression analyses. Proteomic analysis showed that 97% of the proteins were shared among NMOB and MOB EVs, and 30% were novel osteoblast-specific EV proteins. Label-free quantification demonstrated mineralization stage-dependent 5-fold enrichment of 59 and 451 EV proteins in NMOBs and MOBs, respectively. Interestingly, bioinformatic analyses of the osteoblast EV proteomes and EV-regulated prostate cancer gene expression profiles showed that they converged on pathways involved in cell survival and growth. This was verified by in vitro proliferation assays where osteoblast EV uptake led to 2-fold increase in PC3 cell growth compared to cell-free culture medium-derived vesicle controls. Our findings elucidate the mineralization stage-specific protein content of osteoblast-secreted EVs, show a novel way by which osteoblasts communicate with prostate cancer, and open up innovative avenues for therapeutic intervention.	[Morhayim, Jess; van de Peppel, Jeroen; Kocer, Gulistan; van Driel, Marjolein; van Leeuwen, Johannes P.] Erasmus Univ, Med Ctr, Dept Internal Med, NL-3015 CN Rotterdam, Netherlands; [Morhayim, Jess; van de Peppel, Jeroen; Kocer, Gulistan; van Driel, Marjolein; van Leeuwen, Johannes P.] Erasmus Univ, Med Ctr, Erasmus MC Stem Cell & Regenerat Med Inst, NL-3015 CN Rotterdam, Netherlands; [Demmers, Jeroen A. A.] Erasmus Univ, Med Ctr, Prote Ctr, NL-3015 CN Rotterdam, Netherlands; [Nigg, Alex L.] Erasmus Univ, Med Ctr, Dept Pathol, NL-3015 CN Rotterdam, Netherlands; [Chiba, Hideki] Fukushima Med Univ, Sch Med, Dept Basic Pathol, Fukushima, Japan	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Fukushima Medical University	van Leeuwen, JP (corresponding author), Erasmus Univ, Med Ctr, Dept Internal Med, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	j.vanleeuwen@erasmusmusmc.nl	van de Peppel, Jeroen/K-6683-2019; Demmers, Jeroen AA/F-4046-2016; van Leeuwen, Johannes/D-5015-2014; van Driel, Marjolein/K-6745-2019	van de Peppel, Jeroen/0000-0002-6524-727X; Demmers, Jeroen AA/0000-0002-8757-9611; van Leeuwen, Johannes/0000-0002-2282-4006; Kocer, Gulistan/0000-0003-3449-7388; Morhayim, Jess/0000-0001-7610-9342				Al-Nedawi K, 2009, CELL CYCLE, V8, P2014, DOI 10.4161/cc.8.13.8988; Alves RDAM, 2011, J PROTEOME RES, V10, P4725, DOI 10.1021/pr200522n; Alves RDAM, 2010, J PROTEOME RES, V9, P4688, DOI 10.1021/pr100400d; Anderson HC, 2005, FRONT BIOSCI-LANDMRK, V10, P822, DOI 10.2741/1576; BAB I, 1992, EMBO J, V11, P1867, DOI 10.1002/j.1460-2075.1992.tb05238.x; Balcerzak M, 2008, PROTEOMICS, V8, P192, DOI 10.1002/pmic.200700612; Bruedigam C., 2011, CURR PROTOC STEM CEL, V17, pt1H, DOI [10.1002/9780470151808.sc01h03s17, DOI 10.1002/9780470151808.SC01H03S17]; Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197; Ciocca DR, 2010, INT J HYPERTHER, V26, P737, DOI 10.3109/02656731003776968; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Collino F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011803; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2009, NAT PROTOC, V4, P698, DOI 10.1038/nprot.2009.36; Eijken M, 2006, MOL CELL ENDOCRINOL, V248, P87, DOI 10.1016/j.mce.2005.11.034; Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07-8080com; Glaschick S, 2007, J BIOL PHYS, V33, P433, DOI 10.1007/s10867-008-9084-1; HELL S, 1992, OPT COMMUN, V93, P277, DOI 10.1016/0030-4018(92)90185-T; Hosseini-Beheshti E, 2012, MOL CELL PROTEOMICS, V11, P863, DOI 10.1074/mcp.M111.014845; Hristov M, 2004, BLOOD, V104, P2761, DOI 10.1182/blood-2003-10-3614; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Katsuda T, 2013, PROTEOMICS, V13, P1637, DOI 10.1002/pmic.201200373; Lai MD, 2007, CURR GENOMICS, V8, P43; MARKS SC, 1988, AM J ANAT, V183, P1, DOI 10.1002/aja.1001830102; Mathivanan S, 2012, NUCLEIC ACIDS RES, V40, pD1241, DOI 10.1093/nar/gkr828; Meckes DG, 2013, P NATL ACAD SCI USA, V110, pE2925, DOI 10.1073/pnas.1303906110; Morhayim J, 2014, ARCH BIOCHEM BIOPHYS, V561, P38, DOI 10.1016/j.abb.2014.05.011; Nahar NN, 2008, J BONE MINER METAB, V26, P514, DOI 10.1007/s00774-008-0859-z; Oh S, 2013, CANCER RES, V73, P5110, DOI 10.1158/0008-5472.CAN-13-0578; Ohno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180; Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000; Proff P, 2009, CLIN ORAL INVEST, V13, P355, DOI 10.1007/s00784-009-0268-2; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Ratajczak MZ, 2012, LEUKEMIA, V26, P1166, DOI 10.1038/leu.2011.389; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Shifrin DA, 2013, MOL BIOL CELL, V24, P1253, DOI 10.1091/mbc.E12-08-0572; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Stoop MP, 2008, J PROTEOME RES, V7, P4841, DOI 10.1021/pr800489a; Sun Nian-Kang, 2005, Chang Gung Med J, V28, P673; Taichman RS, 2005, BLOOD, V105, P2631, DOI 10.1182/blood-2004-06-2480; Tetta C, 2011, ORGANOGENESIS, V7, P105, DOI 10.4161/org.7.2.15782; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Thouverey C, 2011, J PROTEOMICS, V74, P1123, DOI 10.1016/j.jprot.2011.04.005; Urano T, 2004, BIOCHEM BIOPH RES CO, V319, P795, DOI 10.1016/j.bbrc.2004.05.056; Vaarala MH, 1998, INT J CANCER, V78, P27, DOI 10.1002/(SICI)1097-0215(19980925)78:1<27::AID-IJC6>3.3.CO;2-A; van Cappellen A. W., 2012, ENHANCEMENT OPTICAL; van Dommelen SM, 2012, J CONTROL RELEASE, V161, P635, DOI 10.1016/j.jconrel.2011.11.021; Varga Z, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.23298; Wang M, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-6; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; Xiao Z, 2007, J CELL PHYSIOL, V210, P325, DOI 10.1002/jcp.20826; Zhang YQ, 2014, BIOMATERIALS, V35, P4390, DOI 10.1016/j.biomaterials.2014.02.003	54	48	50	3	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					274	285		10.1096/fj.14-261404	http://dx.doi.org/10.1096/fj.14-261404			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25359493	Green Submitted			2022-12-28	WOS:000347378600026
J	Brule, C; Perzo, N; Joubert, JE; Sainsily, X; Leduc, R; Castel, H; Prezeau, L				Brule, Cedric; Perzo, Nicolas; Joubert, Jane-Eileen; Sainsily, Xavier; Leduc, Richard; Castel, Helene; Prezeau, Laurent			Biased signaling regulates the pleiotropic effects of the urotensin II receptor to modulate its cellular behaviors	FASEB JOURNAL			English	Article						G-protein-coupled receptor; partial agonism; G-protein signaling; beta-arrestin signaling	PROTEIN-KINASE-C; RAT; RESPONSES; LIGAND; IDENTIFICATION; PROLIFERATION; INVOLVEMENT; ANTAGONIST; MECHANISMS; REVEALS	Biased agonism by G-protein-coupled receptor ligands has opened up strategies for targeted physiological or therapeutic actions. We hypothesized that urotensin II (UII)-derived peptides displayed unexpected physiological effects because of such biased signaling on the UII human urotensin (hUT) receptor. We determined the coupling to G proteins and beta-arrestins of the UII-activated hUT receptor expressed in HEK293 using bioluminescence resonance energy transfer (BRET) biosensors, as well as the production of IP1-3 and cAMP using homogenous time-resolved Forster resonance energy transfer (FRET) (HTRF)-based assays. The activated receptor coupled to G(i1), G(oA), G(q), and G(13), excluding G(s), and recruited beta-arrestins 1 and 2. Integration of these pathways led to a 2-phase kinetic phosphorylation of ERK1/2 kinases. The tested peptides induced three different profiles: UII, urotensin-related peptide (URP), and UII4-11 displayed the full profile; [Orn(8)] UII and [Orn(5)] URP activated G proteins, although with pEC(50)s 5-10 x higher, and did not or barely recruited beta-arrestin; urantide also failed to recruit beta-arrestin but displayed a reversed rank order for G(i) and G(q) vs. G(o) pEC(50)s (-8.79 +/- 0.20, -8.43 +/- 0.21, and -7.86 +/- 0.36, respectively, for urantide, -7.87 +/- 0.10, -7.23 -0.27, and -8.55 +/- 0.19, respectively, for [Orn5] URP) and was a partial agonist of all G-protein pathways. Interestingly, the peptides differently modulated cell survival but similarly induced cell migration and adhesion. Thus, we demonstrate biased signaling between beta-arrestin and G proteins, and between G-protein subtypes, which dictates the receptor's cellular responses.-Brule, C., Perzo, N., Joubert, J.-E., Sainsily, X., Leduc, R., Castel, H., Prezeau, L. Biased signaling regulates the pleiotropic effects of the urotensin II receptor to modulate its cellular behaviors.	[Brule, Cedric; Perzo, Nicolas; Sainsily, Xavier; Leduc, Richard] Univ Sherbrooke, Fac Med & Hlth Sci, Inst Pharmacol Sherbrooke, Dept Pharmacol, Sherbrooke, PQ J1K 2R1, Canada; [Brule, Cedric; Prezeau, Laurent] CNRS, Inst Genom Fonct, UMR 5203, Montpellier, France; [Brule, Cedric; Prezeau, Laurent] INSERM, U661, Montpellier, France; [Brule, Cedric; Prezeau, Laurent] Univ Montpellier I, UMR 5203, Montpellier, France; [Brule, Cedric; Prezeau, Laurent] Univ Montpellier 2, UMR 5203, Montpellier, France; [Perzo, Nicolas; Joubert, Jane-Eileen; Castel, Helene] Univ Rouen, PERENE, IRIB,U982, DC2N,INSERM,Lab Neuronal & Neuroendocrine Commun, Mont St Aignan, France	University of Sherbrooke; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Prezeau, L (corresponding author), Inst Genom Fonct, F-34000 Montpellier, France.	laurent.prezeau@igf.cnrs.fr	castel, helene/B-8675-2009	castel, helene/0000-0002-8972-5555	Institut National de la Sante et de la Recherche Medicale (INSERM); University of Rouen; Agence Nationale de la Recherche (ANR) Chemot-x ProG; Canadian Institute of Health Research (CIHR) grant	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Rouen; Agence Nationale de la Recherche (ANR) Chemot-x ProG(French National Research Agency (ANR)); Canadian Institute of Health Research (CIHR) grant(Canadian Institutes of Health Research (CIHR))	The authors thank J. C. Bologna and M. Quiles, who set up the beta-arrestin experiments, and J. C. Bologna, who taught C.B. the BRET technique. The authors also thank C. Hounsou for help with the experiments measuring the inhibition of cAMP production using the V2 receptor cotransfection method and C. Lecointre for technical assistance and experimental help for cell adhesion, migration, and proliferation assays. The authors also acknowledge Claire Vol, Odile Lecha, and Marion Vereecke for their technical help. The G<INF>i</INF>, G<INF>o</INF>, IP1, cAMP, beta-arrestin, internalization, and ERK functional experiments were performed using the Arpege Pharmacology Screening Interactome platform facility at the Institut de Genomique Fonctionnelle (Montpellier, France). L.P.'s team was Equipe Fondation pour la Recherche Medicale (FRM) DEQ20130326522. H.C. and J.E.J. were supported by the Institut National de la Sante et de la Recherche Medicale (INSERM), the University of Rouen, and Agence Nationale de la Recherche (ANR) Chemot-x ProG. C.B., N.P., and R. L. were supported by a Canadian Institute of Health Research (CIHR) grant. R.L., H.C., and L.P. are equal lead authors.	Alvarez-Curto E, 2011, MOL PHARMACOL, V80, P1033, DOI 10.1124/mol.111.074674; Ames RS, 1999, NATURE, V401, P282, DOI 10.1038/45809; Ayoub MA, 2009, J BIOL CHEM, V284, P29136, DOI 10.1074/jbc.M109.042333; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Camarda V, 2002, BRIT J PHARMACOL, V137, P311, DOI 10.1038/sj.bjp.0704895; Castel H, 2006, J NEUROCHEM, V99, P582, DOI 10.1111/j.1471-4159.2006.04130.x; Chatenet D, 2004, PEPTIDES, V25, P1819, DOI 10.1016/j.peptides.2004.04.019; Desrues L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036319; Douglas SA, 2004, BRIT J PHARMACOL, V142, P921, DOI 10.1038/sj.bjp.0705743; Douglas SA, 2003, CURR OPIN PHARMACOL, V3, P159, DOI 10.1016/S1471-4892(03)00012-2; Grieco P, 2011, J CELL BIOCHEM, V112, P341, DOI 10.1002/jcb.22933; Guerrini R, 2005, J PEPT SCI, V11, P85, DOI 10.1002/psc.590; Guo D, 2012, BRIT J PHARMACOL, V166, P1846, DOI 10.1111/j.1476-5381.2012.01897.x; Holleran BJ, 2007, BIOCHEM J, V402, P51, DOI 10.1042/BJ20060943; Holleran BJ, 2009, BIOCHEM PHARMACOL, V77, P1374, DOI 10.1016/j.bcp.2009.01.013; Jarry M, 2010, BIOCHEM J, V428, P113, DOI 10.1042/BJ20090867; Katano Y, 2000, EUR J PHARMACOL, V402, pR5; Kenakin T, 2013, NAT REV DRUG DISCOV, V12, DOI 10.1038/nrd3954-c2; Labarrere P, 2003, J ENZYM INHIB MED CH, V18, P77, DOI 10.1080/1475636031000093507; Leprince J, 2008, PEPTIDES, V29, P658, DOI 10.1016/j.peptides.2007.08.014; Liu AMF, 2005, J BIOL CHEM, V280, P34617, DOI 10.1074/jbc.M504264200; Liu JJ, 2012, SCIENCE, V335, P1106, DOI 10.1126/science.1215802; MacLean MR, 2000, BRIT J PHARMACOL, V130, P201, DOI 10.1038/sj.bjp.0703314; Maurel D, 2008, NAT METHODS, V5, P561, DOI [10.1038/nmeth.1213, 10.1038/NMETH.1213]; Ong KL, 2005, CARDIOVASC DRUG THER, V19, P65, DOI 10.1007/s10557-005-6899-x; Portnoy A, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00054; Proulx CD, 2005, BIOCHEM J, V385, P115, DOI 10.1042/BJ20040807; Rives ML, 2009, EMBO J, V28, P2195, DOI 10.1038/emboj.2009.177; Ross B, 2010, AM J PHYSIOL-REG I, V298, pR1156, DOI 10.1152/ajpregu.00706.2009; Rossowski WJ, 2002, EUR J PHARMACOL, V438, P159, DOI 10.1016/S0014-2999(02)01341-9; Sanchez-Fernandez G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084174; Sauzeau V, 2001, CIRC RES, V88, P1102, DOI 10.1161/hh1101.092034; Segain JP, 2007, J IMMUNOL, V179, P901, DOI 10.4049/jimmunol.179.2.901; Sidharta PN, 2009, BRIT J CLIN PHARMACO, V68, P502, DOI 10.1111/j.1365-2125.2009.03480.x; Song W, 2006, N-S ARCH PHARMACOL, V373, P148, DOI 10.1007/s00210-006-0057-2; Sugo T, 2003, BIOCHEM BIOPH RES CO, V310, P860, DOI 10.1016/j.bbrc.2003.09.102; Tzanidis A, 2003, CIRC RES, V93, P246, DOI 10.1161/01.RES.0000084382.64418.BC; Vergura R, 2004, N-S ARCH PHARMACOL, V370, P347, DOI 10.1007/s00210-004-0991-9; White CD, 2008, MOL ENDOCRINOL, V22, P2520, DOI 10.1210/me.2008-0122; Yi KH, 2012, PEPTIDES, V33, P87, DOI 10.1016/j.peptides.2011.11.016; Zhang YG, 2008, J HYPERTENS, V26, P1119, DOI 10.1097/HJH.0b013e3282fa1412; Ziltener P, 2002, J RECEPT SIGNAL TR R, V22, P155, DOI 10.1081/RRS-120014593; Zimmerman B, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002522	43	35	36	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5148	5162		10.1096/fj.14-249771	http://dx.doi.org/10.1096/fj.14-249771			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25183668				2022-12-28	WOS:000345894500011
J	Manni, S; Kisko, K; Schleier, T; Missimer, J; Ballmer-Hofer, K				Manni, Sandro; Kisko, Kaisa; Schleier, Thomas; Missimer, Jack; Ballmer-Hofer, Kurt			Functional and structural characterization of the kinase insert and the carboxy terminal domain in VEGF receptor 2 activation	FASEB JOURNAL			English	Article						tyrosine kinase receptor; activation; SAXS; phosphorylation	GROWTH-FACTOR RECEPTOR; RAY SOLUTION SCATTERING; TRANSMEMBRANE DOMAIN; TYROSINE KINASES; EGF RECEPTOR; SIGNAL-TRANSDUCTION; HELIX INTERACTIONS; ADAPTER PROTEIN; LIGAND-BINDING; DIMERIZATION	Vascular endothelial growth factors (VEGFs) regulate blood and lymphatic vessel development and homeostasis. VEGF receptor 2 (VEGFR-2) is the major receptor involved in vasculogenesis and angiogenesis and regulates endothelial cell survival, migration, and mitogenesis. Ligand-mediated receptor dimerization instigates transmembrane signaling, thereby promoting activation of the intracellular kinase domain. The intracellular part of the receptor comprises the juxtamembrane domain, the catalytic kinase domain, the kinase insert domain (KID), and the carboxy terminal domain (CD). Here we show that the CD inhibits VEGFR-2 activity in the absence of ligand, whereas the KID, particularly a tyrosine residue in this domain (Y951), is indispensable for downstream signaling by the activated kinase. Because of the lack of crystallographic data for the complete kinase domain, we applied size-exclusion chromatography, multiangle laser scattering, analytical ultracentrifugation, and small-angle X-ray scattering to build and functionally validate structural models. Our data show substantial conformational changes of the kinase when it is switched from the inactive, unphosphorylated state to the active, phosphorylated state. Finally, we structurally characterized recombinantly produced protein complexes between VEGFR-2 and T cell-specific adapter protein, a molecule involved in downstream signaling by VEGFR-2.Manni, S., Kisko, K., Schleier, T., Missimer, J., Ballmer-Hofer, K. Functional and structural characterization of the kinase insert and the carboxy terminal domain in VEGF receptor 2 activation.	[Manni, Sandro; Kisko, Kaisa; Schleier, Thomas; Missimer, Jack; Ballmer-Hofer, Kurt] Paul Scherrer Inst, CH-5232 Villigen, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Ballmer-Hofer, K (corresponding author), Paul Scherrer Inst, CH-5232 Villigen, Switzerland.	kurt.ballmer@psi.ch		Ballmer-Hofer, Kurt/0000-0002-3800-9129	Swiss National Science Foundation [31003A-130463]; Oncosuisse [OC2 01200-08-2007]; Novartis Stiftung fur Medizinisch-Biologische Forschung [10C61]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Oncosuisse; Novartis Stiftung fur Medizinisch-Biologische Forschung	The authors are grateful for the support and critical comments by the beam line staff, in particular Dr. Andreas Menzel (cSAXS beamline, Swiss Light Source, Villigen, Switzerland) and also thank Dr. Dmitry Veprintsev for introducing them to AUC technology and data interpretation and for critical reading of the article. This work was supported by the Swiss National Science Foundation (grant 31003A-130463 issued to K.B.-H.), by Oncosuisse (grant OC2 01200-08-2007 issued to K.B.-H.), and by the Novartis Stiftung fur Medizinisch-Biologische Forschung (grant 10C61 issued to K.B.-H.).	Bae JH, 2010, MOL CELLS, V29, P443, DOI 10.1007/s10059-010-0080-5; Bae JH, 2010, P NATL ACAD SCI USA, V107, P2866, DOI 10.1073/pnas.0914157107; Barleon B, 1997, J BIOL CHEM, V272, P10382; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Bocharov EV, 2008, J BIOL CHEM, V283, P6950, DOI 10.1074/jbc.M709202200; Brozzo MS, 2012, BLOOD, V119, P1781, DOI 10.1182/blood-2011-11-390922; Chen XY, 2008, P NATL ACAD SCI USA, V105, P18267, DOI 10.1073/pnas.0807762105; Cymer F, 2010, CELL ADHES MIGR, V4, P299, DOI 10.4161/cam.4.2.11191; Dosch DD, 2010, FASEB J, V24, P32, DOI 10.1096/fj.09-132670; Endres NF, 2013, CELL, V152, P543, DOI 10.1016/j.cell.2012.12.032; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Finger C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000547; Fitzgerald DJ, 2006, NAT METHODS, V3, P1021, DOI 10.1038/nmeth983; Franke D, 2009, J APPL CRYSTALLOGR, V42, P342, DOI 10.1107/S0021889809000338; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; Hyde CAC, 2012, MOL CELL BIOL, V32, P3802, DOI 10.1128/MCB.06787-11; Jura N, 2009, CELL, V137, P1293, DOI 10.1016/j.cell.2009.04.025; Kelleher FC, 2013, CARCINOGENESIS, V34, P2198, DOI 10.1093/carcin/bgt254; Kisko K, 2011, FASEB J, V25, P2980, DOI 10.1096/fj.11-185397; Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502; Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301; Lange G, 2003, J MED CHEM, V46, P5184, DOI 10.1021/jm020970s; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Leppanen VM, 2013, P NATL ACAD SCI USA, V110, P12960, DOI 10.1073/pnas.1301415110; Leppanen VM, 2011, BLOOD, V117, P1507, DOI 10.1182/blood-2010-08-301549; Leppanen VM, 2010, P NATL ACAD SCI USA, V107, P2425, DOI 10.1073/pnas.0914318107; Li E, 2006, J MOL BIOL, V356, P600, DOI 10.1016/j.jmb.2005.11.077; Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709; Matsumoto T, 2006, J ATHEROSCLER THROMB, V13, P130, DOI 10.5551/jat.13.130; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; Meyer RD, 2004, J BIOL CHEM, V279, P735, DOI 10.1074/jbc.M305575200; Mi LZ, 2011, NAT STRUCT MOL BIOL, V18, P984, DOI 10.1038/nsmb.2092; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Petoukhov MV, 2007, J APPL CRYSTALLOGR, V40, pS223, DOI 10.1107/S0021889807002853; Ruch C, 2007, NAT STRUCT MOL BIOL, V14, P249, DOI 10.1038/nsmb1202; Schlessinger J., 2014, COLD SPRING HARB PER, V6; Schneider D, 2004, J MOL BIOL, V343, P799, DOI 10.1016/j.jmb.2004.08.083; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Smith SO, 2002, BIOCHEMISTRY-US, V41, P9321, DOI 10.1021/bi012117l; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; Sun ZY, 2012, J EXP MED, V209, P1363, DOI 10.1084/jem.20111343; Tao Q, 2001, J BIOL CHEM, V276, P21916, DOI 10.1074/jbc.M100763200; Verstraete K, 2011, BLOOD, V118, P60, DOI 10.1182/blood-2011-01-329532; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Wriggers W, 2001, J APPL CRYSTALLOGR, V34, P773, DOI 10.1107/S0021889801012869; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Yang Y, 2008, P NATL ACAD SCI USA, V105, P7681, DOI 10.1073/pnas.0802896105; Yang Y, 2010, P NATL ACAD SCI USA, V107, P1906, DOI 10.1073/pnas.0914052107; Yuzawa S, 2007, CELL, V130, P323, DOI 10.1016/j.cell.2007.05.055; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	50	11	11	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4914	4923		10.1096/fj.14-256206	http://dx.doi.org/10.1096/fj.14-256206			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25114179				2022-12-28	WOS:000344050900028
J	Rivas, DA; Lessard, SJ; Rice, NP; Lustgarten, MS; So, K; Goodyear, LJ; Parnell, LD; Fielding, RA				Rivas, Donato A.; Lessard, Sarah J.; Rice, Nicholas P.; Lustgarten, Michael S.; So, Kawai; Goodyear, Laurie J.; Parnell, Laurence D.; Fielding, Roger A.			Diminished skeletal muscle microRNA expression with aging is associated with attenuated muscle plasticity and inhibition of IGF-1 signaling	FASEB JOURNAL			English	Article						noncoding RNA; genomics; humans; resistance exercise	NUTRITION EXAMINATION SURVEY; RESISTANCE EXERCISE; GENE-EXPRESSION; ENDURANCE EXERCISE; NATIONAL-HEALTH; UNITED-STATES; METABOLISM; MOUSE; MASS; AGE	Older individuals have a reduced capacity to induce muscle hypertrophy with resistance exercise (RE), which may contribute to the age-induced loss of muscle mass and function, sarcopenia. We tested the novel hypothesis that dysregulation of microRNAs (miRNAs) may contribute to reduced muscle plasticity with aging. Skeletal muscle expression profiling of protein-coding genes and miRNA was performed in younger (YNG) and older (OLD) men after an acute bout of RE. 21 miRNAs were altered by RE in YNG men, while no RE-induced changes in miRNA expression were observed in OLD men. This striking absence in miRNA regulation in OLD men was associated with blunted transcription of mRNAs, with only 42 genes altered in OLD men vs. 175 in YNG men following RE, demonstrating a reduced adaptability of aging muscle to exercise. Integrated bioinformatics analysis identified miR-126 as an important regulator of the transcriptional response to exercise and reduced lean mass in OLD men. Manipulation of miR-126 levels in myocytes, in vitro, revealed its direct effects on the expression of regulators of skeletal muscle growth and activation of insulin growth factor 1 (IGF-1) signaling. This work identifies a mechanistic role of miRNA in the adaptation of muscle to anabolic stimulation and reveals a significant impairment in exercise-induced miRNA/mRNA regulation with aging.	[Rivas, Donato A.; Rice, Nicholas P.; Lustgarten, Michael S.; So, Kawai; Fielding, Roger A.] Tufts Univ, Nutr Exercise Physiol & Sarcopenia Lab, Boston, MA 02111 USA; [Parnell, Laurence D.] Tufts Univ, Jean Mayer Human Nutr Res Ctr Aging, USDA, Nutr Genom Lab, Boston, MA 02111 USA; [Lessard, Sarah J.; Goodyear, Laurie J.] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; [Lessard, Sarah J.; Goodyear, Laurie J.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Tufts University; Tufts University; United States Department of Agriculture (USDA); Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Rivas, DA (corresponding author), Tufts Univ, Jean Mayer Human Nutr Res Ctr Aging, Nutr Exercise Physiol & Sarcopenia Lab, Boston, MA 02111 USA.	donato.rivas@tufts.edu	Rivas, Donato A/N-6613-2017	Rivas, Donato A/0000-0002-4500-6233	U.S. Department of Agriculture (USDA) [58-1950-0014]; Boston Claude D. Pepper Center Older American Independence Centers (OAIC) [1P30AG031679]; Boston Claude D. Pepper Center OAIC; William Randolph Hearst Fellowship in Clinical and Translational Research; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG031679] Funding Source: NIH RePORTER	U.S. Department of Agriculture (USDA)(United States Department of Agriculture (USDA)); Boston Claude D. Pepper Center Older American Independence Centers (OAIC); Boston Claude D. Pepper Center OAIC; William Randolph Hearst Fellowship in Clinical and Translational Research; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This material is based on the work supported by the U.S. Department of Agriculture (USDA), under agreement 58-1950-0014. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the USDA. Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the USDA. The study was also supported by the Boston Claude D. Pepper Center Older American Independence Centers (OAIC; 1P30AG031679). D.A.R. is supported by a Research Career Development Core Fellowship from the Boston Claude D. Pepper Center OAIC. S.J.L. is supported by the William Randolph Hearst Fellowship in Clinical and Translational Research.	Akasaki Y, 2014, AGING CELL, V13, P80, DOI 10.1111/acel.12153; Alsharidah M, 2013, AGING CELL, V12, P333, DOI 10.1111/acel.12051; Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bates DJ, 2009, BBA-GEN SUBJECTS, V1790, P970, DOI 10.1016/j.bbagen.2009.03.028; Bhatnagar S, 2012, CURR MOL MED, V12, P3, DOI 10.2174/156652412798376107; Boehm M, 2006, CELL CYCLE, V5, P837, DOI 10.4161/cc.5.8.2688; Chaillou T, 2013, J APPL PHYSIOL, V115, P1065, DOI 10.1152/japplphysiol.00611.2013; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; Davidsen PK, 2011, J APPL PHYSIOL, V110, P309, DOI 10.1152/japplphysiol.00901.2010; Dennis RA, 2008, PHYSIOL GENOMICS, V32, P393, DOI 10.1152/physiolgenomics.00191.2007; Drummond MJ, 2011, PHYSIOL GENOMICS, V43, P595, DOI 10.1152/physiolgenomics.00148.2010; Drummond MJ, 2008, AM J PHYSIOL-ENDOC M, V295, pE1333, DOI 10.1152/ajpendo.90562.2008; Durham WJ, 2010, FASEB J, V24, P4117, DOI 10.1096/fj.09-150177; Egan B, 2013, CELL METAB, V17, P162, DOI 10.1016/j.cmet.2012.12.012; Feng HZ, 2013, AM J PHYSIOL-CELL PH, V304, pC1002, DOI 10.1152/ajpcell.00005.2013; Fichtlscherer S, 2010, CIRC RES, V107, P677, DOI 10.1161/CIRCRESAHA.109.215566; Fielding RA, 2011, J AM MED DIR ASSOC, V12, P249, DOI 10.1016/j.jamda.2011.01.003; Fluck M, 2006, J EXP BIOL, V209, P2239, DOI 10.1242/jeb.02149; Greco S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039732; Hawley JA, 2008, ACTA PHYSIOL, V192, P127, DOI 10.1111/j.1748-1716.2007.01783.x; Hulsmans M, 2013, CURR PHARM DESIGN, V19, P5704, DOI 10.2174/13816128113199990364; Hwee DT, 2014, AGING CELL, V13, P92, DOI 10.1111/acel.12150; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026; Janssen I, 2004, J AM GERIATR SOC, V52, P80, DOI 10.1111/j.1532-5415.2004.52014.x; Jozsi AC, 2000, MECH AGEING DEV, V120, P45, DOI 10.1016/S0047-6374(00)00178-0; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102; Keren A, 2006, MOL CELL ENDOCRINOL, V252, P224, DOI 10.1016/j.mce.2006.03.017; Kim J, 2010, MOL BIOL REP, V37, P3567, DOI 10.1007/s11033-010-0005-6; Kitamura T, 2007, J CLIN INVEST, V117, P2477, DOI 10.1172/JCI32054; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lange KHW, 2002, J CLIN ENDOCR METAB, V87, P513, DOI 10.1210/jc.87.2.513; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Long YC, 2011, MOL CELL BIOL, V31, P430, DOI 10.1128/MCB.00983-10; McCarthy JJ, 2007, J APPL PHYSIOL, V102, P306, DOI 10.1152/japplphysiol.00932.2006; Mikkelsen UR, 2013, MECH AGEING DEV, V134, P531, DOI 10.1016/j.mad.2013.11.004; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; Moon SS, 2014, ENDOCR J, V61, P61, DOI 10.1507/endoc; Moore KJ, 2013, J LIPID RES, V54, P1159, DOI 10.1194/jlr.E036954; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; Muroya S, 2013, J ANIM SCI, V91, P90, DOI 10.2527/jas.2012-5371; Nana-Sinkam SP, 2013, CLIN PHARMACOL THER, V93, P98, DOI 10.1038/clpt.2012.192; Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051; Nielsen S, 2010, J PHYSIOL-LONDON, V588, P4029, DOI 10.1113/jphysiol.2010.189860; Olivieri Fabiola, 2013, Frontiers in Genetics, V4, P121, DOI 10.3389/fgene.2013.00121; Pardo PS, 2011, J BIOL CHEM, V286, P2559, DOI 10.1074/jbc.M110.149153; Patel CJ, 2013, INT J EPIDEMIOL, V42, P1795, DOI 10.1093/ije/dyt208; Perrini S, 2010, J ENDOCRINOL, V205, P201, DOI 10.1677/JOE-09-0431; Raue U, 2006, J APPL PHYSIOL, V101, P53, DOI 10.1152/japplphysiol.01616.2005; Raue U, 2012, J APPL PHYSIOL, V112, P1625, DOI 10.1152/japplphysiol.00435.2011; Richardson K, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-504; Rivas DA, 2012, J APPL PHYSIOL, V113, P1727, DOI 10.1152/japplphysiol.00412.2012; Ryu HS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017343; Safdar A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005610; Schaap LA, 2009, J GERONTOL A-BIOL, V64, P1183, DOI 10.1093/gerona/glp097; Serna E, 2012, SCI REP-UK, V2, DOI 10.1038/srep00961; Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005; Timmons JA, 2011, EXERC SPORT SCI REV, V39, P218, DOI 10.1097/JES.0b013e31822ba9e1; Wang XNH, 2013, CURR OPIN CLIN NUTR, V16, P258, DOI 10.1097/MCO.0b013e32835f81b9; Wei R, 2013, GENE, V518, P246, DOI 10.1016/j.gene.2013.01.038; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Zambon AC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r61; Zampetaki A, 2010, CIRC RES, V107, P810, DOI 10.1161/CIRCRESAHA.110.226357; Zhang J, 2008, BIOCHEM BIOPH RES CO, V377, P136, DOI 10.1016/j.bbrc.2008.09.089	68	88	92	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4133	4147		10.1096/fj.14-254490	http://dx.doi.org/10.1096/fj.14-254490			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24928197	Green Published			2022-12-28	WOS:000340845900030
J	Conley, SM; Al-Ubaidi, MR; Han, ZC; Naash, MI				Conley, Shannon M.; Al-Ubaidi, Muayyad R.; Han, Zongchao; Naash, Muna I.			Rim formation is not a prerequisite for distribution of cone photoreceptor outer segment proteins	FASEB JOURNAL			English	Article						RDS; degeneration; morphogenesis; retina	NUCLEOTIDE-GATED CHANNEL; NA/CA-K EXCHANGER; DISK MORPHOGENESIS; MEMBRANE-PROTEIN; ROD; PERIPHERIN/RDS; BINDING; MODEL; NRL; OLIGOMERIZATION	Retinal degeneration slow (RDS/PRPH2) is critical for the formation of the disc/lamella rim in photoreceptor outer segments (OSs), but plays a different role in rods vs. cones. Without RDS, rods fail to form OSs, however, cones lacking RDS (in the rds(-/-) / Nrl (-/-)) exhibit balloon-like OSs devoid of lamellae. We show that distribution of most proteins in the lamella and PM domains is preserved even in the absence of RDS, rim, and lamella structures. However, the rim protein prominin-1 exhibits altered trafficking and OS localization, suggesting that proper targeting and distribution of rim proteins may require RDS. Our ultrastructural studies show that in cones, OS formation is initiated by the growth of opsin-containing membrane with RDS-mediated rim formation as a secondary step. This is directly opposite to rods and significantly advances our understanding of the role of the rim in cone OS morphogenesis. Furthermore, our results suggest that the unique folded lamella architecture of the cone OS may maximize density or proximity of phototransduction proteins, but is not required for OS function or for protein distribution and retention in different membrane domains.	[Conley, Shannon M.; Al-Ubaidi, Muayyad R.; Han, Zongchao; Naash, Muna I.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Naash, MI (corresponding author), OUHSC, Dept Cell Biol, 940 Stanton L Young Blvd BMSB 781, Oklahoma City, OK 73104 USA.	muna-naash@ouhsc.edu		Han, Zongchao/0000-0002-2019-395X	U.S. National Eye Institute [EY10609, EY018512]; Foundation Fighting Blindness; Knights Templar Eye Foundation; Oklahoma Center for the Advancement of Science and Technology; NATIONAL EYE INSTITUTE [R55EY010609, R01EY010609, F32EY018512, R56EY010609] Funding Source: NIH RePORTER	U.S. National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Foundation Fighting Blindness(European Commission); Knights Templar Eye Foundation; Oklahoma Center for the Advancement of Science and Technology; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by the U.S. National Eye Institute (EY10609, M.I.N.; EY018512, S. M. C.); the Foundation Fighting Blindness (M.I.N. and M. R. A.); the Knights Templar Eye Foundation (Z.H.), and the Oklahoma Center for the Advancement of Science and Technology (S. M. C., Z.H., and M.I.N.). The authors thank Mr. Justin Burnett, Ms. Barb Nagel, and Ms. Reem Alomer for their technical assistance. The compacted DNA NPs were generated in collaboration with Dr. Mark Cooper at Copernicus Therapeutics, Inc. (Cleveland, OH, USA). Antibodies (as detailed in Materials and Methods) were generously shared by Dr. Cheryl Craft (University of Southern California, Los Angeles, CA, USA), Dr. Jonathan Lytton (University of Calgary Health Sciences Center, Calgary, AB, Canada), Dr. Xi-Qin Ding (University of Oklahoma Health Sciences Center), Dr. Eric Pierce (Massachusetts Eye and Ear Infirmary, Boston, MA, USA), and Dr. David Garbers (University of Texas Southwestern Medical Center, Dallas, TX, USA). Mice were generously shared by Dr. Anand Swaroop, (Nrl<SUP>-/-</SUP>, National Eye Institute, Bethesda, MD, USA), and Dr. Neeraj Agarwal (rds<SUP>-/-</SUP>, U.S. National Institutes of Health, Bethesda, MD, USA). The authors declare no conflicts of interest.	ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117; ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659; Bauer PJ, 2002, ANN NY ACAD SCI, V976, P325; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; Boesze-Battaglia K, 2000, METHOD ENZYMOL, V316, P65; Cai X, 2010, FASEB J, V24, P1178, DOI 10.1096/fj.09-139147; Cai X, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005290; Chakraborty D, 2008, BIOCHEMISTRY-US, V47, P1144, DOI 10.1021/bi701807c; Chakraborty D, 2010, HUM MOL GENET, V19, P4799, DOI 10.1093/hmg/ddq410; Chakraborty D, 2009, HUM MOL GENET, V18, P797, DOI 10.1093/hmg/ddn406; Chuang JZ, 2007, CELL, V130, P535, DOI 10.1016/j.cell.2007.06.030; Clarke G, 2000, NAT GENET, V25, P67, DOI 10.1038/75621; Conley SM, 2008, CURR OPIN MOL THER, V10, P456; Craig SEL, 2010, INVEST OPHTH VIS SCI, V51, P3244, DOI 10.1167/iovs.09-4879; Craig Sonya E L, 2008, J Ocul Biol Dis Infor, V1, P73, DOI 10.1007/s12177-008-9011-5; Daniele LL, 2005, INVEST OPHTH VIS SCI, V46, P2156, DOI 10.1167/iovs.04-1427; ECKMILLER MS, 1987, J CELL BIOL, V105, P2267, DOI 10.1083/jcb.105.5.2267; Fariss RN, 1997, J COMP NEUROL, V387, P148, DOI 10.1002/(SICI)1096-9861(19971013)387:1<148::AID-CNE12>3.0.CO;2-Q; Farjo R, 2006, J CELL BIOL, V173, P59, DOI 10.1083/jcb.200509036; Farjo R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000038; Fitzgerald JB, 2008, ADV EXP MED BIOL, V613, P327, DOI 10.1007/978-0-387-74904-4_38; Han Z, 2012, INVEST OPHTH VIS SCI, V53, P361, DOI 10.1167/iovs.11-8635; Han ZC, 2012, J CLIN INVEST, V122, P3221, DOI 10.1172/JCI64833; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Kim TSY, 1998, J BIOL CHEM, V273, P16561, DOI 10.1074/jbc.273.26.16561; Kizhatil K, 2009, SCIENCE, V323, P1614, DOI 10.1126/science.1169789; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; Li XF, 2006, J BIOL CHEM, V281, P6273, DOI 10.1074/jbc.M512137200; Liu Q, 2004, J NEUROSCI, V24, P6427, DOI 10.1523/JNEUROSCI.1335-04.2004; Matveev AV, 2008, J NEUROCHEM, V106, P2042, DOI 10.1111/j.1471-4159.2008.05548.x; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; Nishimura DY, 2004, P NATL ACAD SCI USA, V101, P16588, DOI 10.1073/pnas.0405496101; Nour M, 2004, INVEST OPHTH VIS SCI, V45, P2514, DOI 10.1167/iovs.04-0065; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Schwarzer A, 1997, BIOCHEMISTRY-US, V36, P13667, DOI 10.1021/bi9710232; Schwarzer A, 2000, J BIOL CHEM, V275, P13448, DOI 10.1074/jbc.275.18.13448; STEINBERG RH, 1980, J COMP NEUROL, V190, P501, DOI 10.1002/cne.901900307; Stricker HM, 2005, BIOCHEM J, V388, P605, DOI 10.1042/BJ20041960; VAUGHAN DK, 1989, INVEST OPHTH VIS SCI, V30, P339; Weigmann A, 1997, P NATL ACAD SCI USA, V94, P12425, DOI 10.1073/pnas.94.23.12425; Wrigley JDJ, 2000, J BIOL CHEM, V275, P13191, DOI 10.1074/jbc.C900853199; YOUNG RW, 1971, J CELL BIOL, V49, P303, DOI 10.1083/jcb.49.2.303; Zacchigna S, 2009, J NEUROSCI, V29, P2297, DOI 10.1523/JNEUROSCI.2034-08.2009; Zhu XM, 2003, J NEUROSCI, V23, P6152, DOI 10.1523/JNEUROSCI.23-14-06152.2003	47	14	14	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3468	3479		10.1096/fj.14-251397	http://dx.doi.org/10.1096/fj.14-251397			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24736412	Green Published			2022-12-28	WOS:000340265400017
J	Fujita, N; Hirose, Y; Tran, CM; Chiba, K; Miyamoto, T; Toyama, Y; Shapiro, IM; Risbud, MV				Fujita, Nobuyuki; Hirose, Yuichiro; Tran, Cassie M.; Chiba, Kazuhiro; Miyamoto, Takeshi; Toyama, Yoshiaki; Shapiro, Irving M.; Risbud, Makarand V.			HIF-1-PHD2 axis controls expression of syndecan 4 in nucleus pulposus cells	FASEB JOURNAL			English	Article						cartilage; hypoxia; intervertebral disc	HUMAN INTERVERTEBRAL DISC; HEPARAN-SULFATE; TNF-ALPHA; FACTOR (HIF)-1-ALPHA; GENE-EXPRESSION; AGGRECAN GENE; GROWTH-FACTOR; HYPOXIA; HIF-1-ALPHA; DIFFERENTIATION	Intervertebral disc degeneration is the leading cause of chronic back pain. Recent studies show that raised level of SDC4, a cell-surface heparan sulfate (HS) proteoglycan, plays a role in pathogenesis of disc degeneration. However, in nucleus pulposus (NP) cells of the healthy intervertebral disc, the mechanisms that control expression of SDC4 and its physiological function are unknown. Hypoxia induced SDC4 mRNA and protein expression by similar to 2.4- and 4.4-fold (P<0.05), respectively, in NP cells. While the activity of the SDC4 promoter containing hypoxia response element (HRE) was induced 2-fold (P<0.05), the HRE mutation decreased the activity by 40% in hypoxia. Transfections with plasmids coding prolyl-4-hydroxylase domain protein 2 (PHD2) and ShPHD2 show that hypoxic expression of SDC4 mRNA and protein is regulated by PHD2 through controlling hypoxia-inducible factor 1 alpha (HIF-1 alpha) levels. Although overexpression of HIF-1 alpha significantly increased SDC4 protein levels, stable suppression of HIF-1 alpha and HIF-1 beta decreased SDC4 expression by 50% in human NP cells. Finally, suppression of SDC4 expression, as well as HS function, resulted in an similar to 2-fold increase in sex-determining region Y (SRY)-box 9 (Sox9) mRNA, and protein (P<0.05) and simultaneous increase in Sox9 transcriptional activity and target gene expression. Taken together, our findings suggest that in healthy discs, SDC4, through its HS side chains, contributes to maintenance of the hypoxic tissue niche by controlling baseline expression of Sox9.	[Fujita, Nobuyuki; Hirose, Yuichiro; Tran, Cassie M.; Shapiro, Irving M.; Risbud, Makarand V.] Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA; [Fujita, Nobuyuki; Hirose, Yuichiro; Tran, Cassie M.; Shapiro, Irving M.; Risbud, Makarand V.] Thomas Jefferson Univ, Grad Program Cell & Dev Biol, Philadelphia, PA 19107 USA; [Fujita, Nobuyuki; Hirose, Yuichiro; Miyamoto, Takeshi; Toyama, Yoshiaki] Keio Univ, Sch Med, Dept Orthopaed Surg, Tokyo, Japan; [Chiba, Kazuhiro] Kitasato Univ, Kitasato Inst Hosp, Dept Orthopaed Surg, Tokyo, Japan	Jefferson University; Jefferson University; Keio University; Kitasato University	Risbud, MV (corresponding author), Thomas Jefferson Univ, Dept Orthopaed Surg, 1025 Walnut St,Ste 511 Curtis Bldg, Philadelphia, PA 19107 USA.	makarand.risbud@jefferson.edu			U.S. National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01-AR050087, R01-AR055655]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR055655, R01AR050087] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by grants from the U.S. National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR050087 and R01-AR055655). The authors report no conflicts of interest.	Adluri RS, 2011, ANTIOXID REDOX SIGN, V15, P1789, DOI 10.1089/ars.2010.3769; Agrawal A, 2007, AM J PHYSIOL-CELL PH, V293, pC621, DOI 10.1152/ajpcell.00538.2006; Agrawal A, 2008, ARTHRITIS RHEUM-US, V58, P3798, DOI 10.1002/art.24073; Amarilio R, 2007, DEVELOPMENT, V134, P3917, DOI 10.1242/dev.008441; Bartels EM, 1998, SPINE, V23, P1, DOI 10.1097/00007632-199801010-00001; Chang SC, 2011, J BIOL CHEM, V286, P44391, DOI 10.1074/jbc.M111.285361; Chen YL, 2004, MOL BIOL CELL, V15, P5635, DOI 10.1091/mbc.E04-06-0490; Cully Megan, 2013, Nat Rev Rheumatol, V9, P136, DOI 10.1038/nrrheum.2013.22; Dahia CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035944; Echtermeyer F, 2009, NAT MED, V15, P1072, DOI 10.1038/nm.1998; Fu J, 2010, J BIOL CHEM, V285, P8927, DOI 10.1074/jbc.M109.078600; Fuerer C, 2010, DEV DYNAM, V239, P184, DOI 10.1002/dvdy.22067; Fujita N, 2005, BIOCHEM BIOPH RES CO, V338, P1890, DOI 10.1016/j.bbrc.2005.10.166; Fujita N, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.375964; Fujita N, 2012, J BIOL CHEM, V287, P16975, DOI 10.1074/jbc.M111.334466; Fujita N, 2012, J BONE MINER RES, V27, P401, DOI 10.1002/jbmr.538; Gruber HE, 2005, SPINE, V30, P2593, DOI 10.1097/01.brs.0000187877.30149.83; Han Y, 2008, MOL CELL BIOL, V28, P4999, DOI 10.1128/MCB.00695-08; HASSLER O, 1969, ACTA ORTHOP SCAND, V40, P765, DOI 10.3109/17453676908989540; Huegel J, 2013, DEV BIOL, V377, P100, DOI 10.1016/j.ydbio.2013.02.008; Johansen JL, 2010, J NEUROCHEM, V115, P209, DOI 10.1111/j.1471-4159.2010.06917.x; Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06-6419com; Lafont JE, 2007, ARTHRITIS RHEUM, V56, P3297, DOI 10.1002/art.22878; O'Connell MP, 2009, J BIOL CHEM, V284, P28704, DOI 10.1074/jbc.M109.028498; Okuyama E, 2013, J BIOCHEM, V154, P41, DOI 10.1093/jb/mvt024; Rajpurohit R, 2002, CELL TISSUE RES, V308, P401, DOI 10.1007/s00441-002-0563-6; Risbud MV, 2006, J CELL BIOCHEM, V98, P152, DOI 10.1002/jcb.20765; Risbud MV, 2005, SPINE, V30, P2503, DOI 10.1097/01.brs.0000186326.82747.13; Robins JC, 2005, BONE, V37, P313, DOI 10.1016/j.bone.2005.04.040; RUDERT M, 1993, ACTA ORTHOP SCAND, V64, P37, DOI 10.3109/17453679308994524; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Smith MF, 2006, GLYCOBIOLOGY, V16, P221, DOI 10.1093/glycob/cwj061; Sowter HM, 2003, CANCER RES, V63, P6130; Sun QM, 2009, J BIOL CHEM, V284, P32066, DOI 10.1074/jbc.M109.057166; Takeda Y, 2011, NATURE, V479, P122, DOI 10.1038/nature10507; Tkachenko E, 2005, CIRC RES, V96, P488, DOI 10.1161/01.RES.0000159708.71142.c8; Tran CM, 2013, J BIOL CHEM, V288, P12654, DOI 10.1074/jbc.M112.448860; Wang JR, 2011, J BIOL CHEM, V286, P39738, DOI 10.1074/jbc.M111.264549; Xue J, 2010, GASTROENTEROLOGY, V138, P606, DOI 10.1053/j.gastro.2009.09.049; Yano F, 2005, BIOCHEM BIOPH RES CO, V333, P1300, DOI 10.1016/j.bbrc.2005.06.041; Yeramian A, 2011, LAB INVEST, V91, P859, DOI 10.1038/labinvest.2011.58; Yoon ST, 2003, SPINE, V28, P1773, DOI 10.1097/01.BRS.0000083204.44190.34; Zeng Y, 2007, J BONE MINER RES, V22, P1851, DOI 10.1359/JBMR.070620	43	27	29	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2455	2465		10.1096/fj.13-243741	http://dx.doi.org/10.1096/fj.13-243741			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24558194	Green Published			2022-12-28	WOS:000339883600007
J	Brehm, A; Geraghty, P; Campos, M; Garcia-Arcos, I; Dabo, AJ; Gaffney, A; Eden, E; Jiang, XC; D'Armiento, J; Foronjy, R				Brehm, Anthony; Geraghty, Patrick; Campos, Michael; Garcia-Arcos, Itsaso; Dabo, Abdoulaye Jules; Gaffney, Adam; Eden, Edward; Jiang, Xian-Cheng; D'Armiento, Jeanine; Foronjy, Robert			Cathepsin G degradation of phospholipid transfer protein (PLTP) augments pulmonary inflammation	FASEB JOURNAL			English	Article						lung; lipopolysaccharide; protease; signaling	LUNG-PROTECTIVE IMMUNITY; HIGH-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; NF-KAPPA-B; CIGARETTE-SMOKE; CHOLESTEROL EFFLUX; ATHEROSCLEROTIC LESIONS; CELLULAR CHOLESTEROL; COPD PATIENTS; HUMAN PLASMA	Phospholipid transfer protein (PLTP) regulates phospholipid transport in the circulation and is highly expressed within the lung epithelium, where it is secreted into the alveolar space. Since PLTP expression is increased in chronic obstructive pulmonary disease (COPD), this study aimed to determine how PLTP affects lung signaling and inflammation. Despite its increased expression, PLTP activity decreased by 80% in COPD bronchoalveolar lavage fluid (BALF) due to serine protease cleavage, primarily by cathepsin G. Likewise, PLTP BALF activity levels decreased by 20 and 40% in smoke-exposed mice and in the media of smoke-treated small airway epithelial (SAE) cells, respectively. To assess how PLTP affected inflammatory responses in a lung injury model, PLTP siRNA or recombinant protein was administered to the lungs of mice prior to LPS challenge. Silencing PLTP at baseline caused a 68% increase in inflammatory cell infiltration, a 120 and 340% increase in ERK and NF-B activation, and increased MMP-9, IL1, and IFN- levels after LPS treatment by 39, 140, and 190%, respectively. Conversely, PLTP protein administration countered these effects in this model. Thus, these findings establish a novel anti-inflammatory function of PLTP in the lung and suggest that proteolytic cleavage of PLTP by cathepsin G may enhance the injurious inflammatory responses that occur in COPD.Brehm, A., Geraghty, P., Campos, M., Garcia-Arcos, I., Dabo, A. J., Gaffney, A., Eden, E., Jiang, X.-C., D'Armiento, J., Foronjy, R. Cathepsin G degradation of phospholipid transfer protein (PLTP) augments pulmonary inflammation.	[Brehm, Anthony; Geraghty, Patrick; Dabo, Abdoulaye Jules; Eden, Edward; Foronjy, Robert] Mt Sinai Hlth Syst, Div Pulm & Crit Care Med, St Lukes Roosevelt Hosp, New York, NY 10019 USA; [Campos, Michael] Univ Miami, Miller Sch Med, Div Pulm & Crit Care Med, Miami, FL 33136 USA; [Garcia-Arcos, Itsaso; D'Armiento, Jeanine] Columbia Univ, Dept Med, New York, NY USA; [Garcia-Arcos, Itsaso; D'Armiento, Jeanine] Columbia Univ, Dept Anesthesiol, New York, NY USA; [Gaffney, Adam] Harvard Brigham & Womans Hosp, Dept Med, Boston, MA USA; [Jiang, Xian-Cheng] Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA	Icahn School of Medicine at Mount Sinai; Mount Sinai St. Luke's; Mount Sinai West; University of Miami; Columbia University; Columbia University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Foronjy, R (corresponding author), Mt Sinai Hlth Syst, Dept Med, St Lukes Roosevelt, Antenucci Bldg,432 West 58th St,Rm 311, New York, NY 10019 USA.	rforonjy@chpnet.org	Campos, Michael/X-2025-2019	Geraghty, Patrick/0000-0003-1647-5505; Garcia-Arcos, Itsaso/0000-0002-4190-3252; Gaffney, Adam/0000-0001-7326-0661; Campos, Michael/0000-0001-5485-9062	Flight Attendant Medical Research Institute [YCSA 24039, CIA 074047, YCSA 113380]; U.S. National Institutes of Health (NIH) [5R01HL-098528-04]; NIH [R01HL-086936]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL098528, R01HL086936] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Robert Brocia, Marie Dagota, and the James P. Mara Center for Lung Disease (Pulmonary Division, St. Luke's Roosevelt Hospital) for their support. This work was supported by grants made available to R.F. [Flight Attendant Medical Research Institute: YCSA 24039, CIA 074047; U.S. National Institutes of Health (NIH): 5R01HL-098528-04], P. G. (Flight Attendant Medical Research Institute: YCSA 113380), and J.D. (NIH: R01HL-086936). The authors report no conflicts of interest.	Albers JJ, 2012, BBA-MOL CELL BIOL L, V1821, P345, DOI 10.1016/j.bbalip.2011.06.013; Attia N, 2007, TOHOKU J EXP MED, V213, P129, DOI 10.1620/tjem.213.129; Bailey D, 2010, J LIPID RES, V51, P785, DOI 10.1194/jlr.M001875; Barnes PJ, 2009, EUR RESPIR J, V33, P1165, DOI 10.1183/09031936.00128008; Bergin DA, 2010, J CLIN INVEST, V120, P4236, DOI 10.1172/JCI41196; Cheung MC, 2010, BIOCHEMISTRY-US, V49, P7314, DOI 10.1021/bi100359f; Chmelar J, 2011, BLOOD, V117, P736, DOI 10.1182/blood-2010-06-293241; Churg A, 2002, AM J RESP CRIT CARE, V166, P849, DOI 10.1164/rccm.200202-097OC; Cowburn AS, 2008, CHEST, V134, P606, DOI 10.1378/chest.08-0422; D'Armiento JM, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-113; D'Armiento JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056352; DAY JR, 1994, J BIOL CHEM, V269, P9388; de Vries R, 2008, ATHEROSCLEROSIS, V196, P733, DOI 10.1016/j.atherosclerosis.2006.12.027; Desrumaux C, 2004, FASEB J, V18, P296, DOI 10.1096/fj.04-2400fje; Desrumaux CM, 2003, J LIPID RES, V44, P1453, DOI 10.1194/jlr.M200281-JLR200; Dong WJ, 2009, J NEUROSCI RES, V87, P3176, DOI 10.1002/jnr.22137; Doz E, 2008, J IMMUNOL, V180, P1169, DOI 10.4049/jimmunol.180.2.1169; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Foronjy RF, 2006, AM J RESP CRIT CARE, V173, P623, DOI 10.1164/rccm.200506-850OC; Gautier T, 2011, BIOCHEM SOC T, V39, P984, DOI 10.1042/BST0390984; Geraghty P, 2013, AM J RESP CELL MOL, V49, P721, DOI 10.1165/rcmb.2013-0026OC; Geraghty P, 2011, J BIOL CHEM, V286, P30211, DOI 10.1074/jbc.M111.238824; Goldklang M, 2012, AM J PHYSIOL-LUNG C, V302, pL1200, DOI 10.1152/ajplung.00454.2010; Guo L, 2012, ISLAMIC HIST CIVILIZ, V93, P227; Guo ZW, 1999, J NUTR, V129, P1984, DOI 10.1093/jn/129.11.1984; Hahn I, 2011, INFECT IMMUN, V79, P4893, DOI 10.1128/IAI.05593-11; Hailman E, 1996, J BIOL CHEM, V271, P12172, DOI 10.1074/jbc.271.21.12172; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hsia CCW, 2010, AM J RESP CRIT CARE, V181, P394, DOI 10.1164/rccm.200809-1522ST; Imai K, 2002, CHEST, V121, p7S, DOI 10.1378/chest.121.3_suppl.7S; Jiang XC, 2002, J BIOL CHEM, V277, P31850, DOI 10.1074/jbc.M205077200; Jiang XC, 1998, J BIOL CHEM, V273, P15714, DOI 10.1074/jbc.273.25.15714; Kamocki K, 2013, AM J RESP CELL MOL, V48, P87, DOI 10.1165/rcmb.2012-0254OC; Langen RCJ, 2012, AM J RESP CELL MOL, V47, P288, DOI 10.1165/rcmb.2011-0119OC; Larsson L, 2004, INDOOR AIR, V14, P421, DOI 10.1111/j.1600-0668.2004.00290.x; Lee M, 2003, J BIOL CHEM, V278, P13539, DOI 10.1074/jbc.M210847200; Levels JHM, 2007, BBA-MOL CELL BIOL L, V1771, P1429, DOI 10.1016/j.bbalip.2007.10.001; Maryanoff BE, 2010, AM J RESP CRIT CARE, V181, P247, DOI 10.1164/rccm.200904-0627OC; Mercer BA, 2004, J BIOL CHEM, V279, P17690, DOI 10.1074/jbc.M313842200; Moerland M, 2008, ARTERIOSCL THROM VAS, V28, P1277, DOI 10.1161/ATVBAHA.108.165084; Murdoch SJ, 2003, J LIPID RES, V44, P1705, DOI 10.1194/jlr.M300073-JLR200; O'Brien KD, 2003, CIRCULATION, V108, P270, DOI 10.1161/01.CIR.0000079163.97653.CD; Oka T, 2000, J LIPID RES, V41, P1651; Oram JF, 2008, J BIOL CHEM, V283, P11541, DOI 10.1074/jbc.M800117200; Paone G, 2011, DIS MARKERS, V31, P91, DOI [10.1155/2011/139493, 10.3233/DMA-2011-0807]; Rahman I, 2006, EUR RESPIR J, V28, P219, DOI 10.1183/09031936.06.00053805; Roth MD, 2006, CHEST, V130, P1334, DOI 10.1378/chest.130.5.1334; Schlitt A, 2003, ARTERIOSCL THROM VAS, V23, P1857, DOI 10.1161/01.ATV.0000094433.98445.7F; Schlitt A, 2009, J LIPID RES, V50, P723, DOI 10.1194/jlr.M800414-JLR200; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469, DOI 10.1164/arrd.1977.116.3.469; Sethi S, 2010, EUR RESPIR J, V35, P1209, DOI 10.1183/09031936.00081409; Steinwede K, 2012, J IMMUNOL, V188, P4476, DOI 10.4049/jimmunol.1103346; van Tol A, 2002, CURR OPIN LIPIDOL, V13, P135, DOI 10.1097/00041433-200204000-00004; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; Vuletic S, 2011, BBA-MOL CELL RES, V1813, P1917, DOI 10.1016/j.bbamcr.2011.06.013; Vuletic S, 2003, J LIPID RES, V44, P1113, DOI 10.1194/jlr.M300046-JLR200; Wallace AM, 2012, TOXICOL SCI, V126, P589, DOI 10.1093/toxsci/kfr351; Wang T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-36; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Wolfbauer G, 1999, BBA-MOL CELL BIOL L, V1439, P65, DOI 10.1016/S1388-1981(99)00077-3; Yang XP, 2003, ARTERIOSCL THROM VAS, V23, P1601, DOI 10.1161/01.ATV.0000085841.55248.13; Zheng T, 2005, J IMMUNOL, V174, P8106, DOI 10.4049/jimmunol.174.12.8106	63	29	32	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2318	2331		10.1096/fj.13-246843	http://dx.doi.org/10.1096/fj.13-246843			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24532668	Green Published			2022-12-28	WOS:000335336000033
J	Belogurov, A; Kuzina, E; Kudriaeva, A; Kononikhin, A; Kovalchuk, S; Surina, Y; Smirnov, I; Lomakin, Y; Bacheva, A; Stepanov, A; Karpova, Y; Lyupina, Y; Kharybin, O; Melamed, D; Ponomarenko, N; Sharova, N; Nikolaev, E; Gabibov, A				Belogurov, Alexey, Jr.; Kuzina, Ekaterina; Kudriaeva, Anna; Kononikhin, Alexey; Kovalchuk, Sergey; Surina, Yelena; Smirnov, Ivan; Lomakin, Yakov; Bacheva, Anna; Stepanov, Alexey; Karpova, Yaroslava; Lyupina, Yulia; Kharybin, Oleg; Melamed, Dobroslav; Ponomarenko, Natalia; Sharova, Natalia; Nikolaev, Eugene; Gabibov, Alexander			Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity	FASEB JOURNAL			English	Article						immunoproteasome; antigen presentation; oligodendrocytes; experimental autoimmune encephalomyelitis; multiple sclerosis	CD8(+) T-CELLS; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; PEPTIDE; IMMUNOPROTEASOMES; OLIGODENDROCYTES; PROTEASOMES; INHIBITORS; COMPLEX; ANTIGEN	Recent findings indicate that the ubiquitin-proteasome system is involved in the pathogenesis of cancer as well as autoimmune and several neurodegenerative diseases, and is thus a target for novel therapeutics. One disease that is related to aberrant protein degradation is multiple sclerosis, an autoimmune disorder involving the processing and presentation of myelin autoantigens that leads to the destruction of axons. Here, we show that brain-derived proteasomes from SJL mice with experimental autoimmune encephalomyelitis (EAE) in an ubiquitin-independent manner generate significantly increased amounts of myelin basic protein peptides that induces cytotoxic lymphocytes to target mature oligodendrocytes ex vivo. Ten times enhanced release of immunogenic peptides by cerebral proteasomes from EAE-SJL mice is caused by a dramatic shift in the balance between constitutive and beta 1i(high) immunoproteasomes in the CNS of SJL mice with EAE. We found that during EAE, beta 1i is increased in resident CNS cells, whereas beta 5i is imported by infiltrating lymphocytes through the blood-brain barrier. Peptidyl epoxyketone specifically inhibits brain-derived beta 1i(high) immunoproteasomes in vitro (k(obs)/[I] = 240 M(-1)s(-1)), and at a dose of 0.5 mg/kg, it ameliorates ongoing EAE in vivo. Therefore, our findings provide novel insights into myelin metabolism in pathophysiologic conditions and reveal that the beta 1i subunit of the immunoproteasome is a potential target to treat autoimmune neurologic diseases.	[Belogurov, Alexey, Jr.; Kuzina, Ekaterina; Kudriaeva, Anna; Kovalchuk, Sergey; Surina, Yelena; Smirnov, Ivan; Lomakin, Yakov; Stepanov, Alexey; Ponomarenko, Natalia; Gabibov, Alexander] Russian Acad Sci, Inst Bioorgan Chem, Moscow 117871, Russia; [Belogurov, Alexey, Jr.; Smirnov, Ivan] Kazan Fed Univ, Kazan, Republic Of Tat, Russia; [Belogurov, Alexey, Jr.; Gabibov, Alexander] Russian Acedemy Sci, Inst Gene Biol, Moscow, Russia; [Kuzina, Ekaterina; Smirnov, Ivan; Bacheva, Anna; Gabibov, Alexander] Moscow MV Lomonosov State Univ, Dept Chem, Moscow, Russia; [Kononikhin, Alexey; Nikolaev, Eugene] Moscow Inst Phys & Technol, Dolgoprudnyi, Russia; [Kononikhin, Alexey; Nikolaev, Eugene] Russian Acad Sci, Inst Energy Problems Chem Phys, Moscow 117871, Russia; [Kovalchuk, Sergey] Res Inst Physicochem Med, Moscow, Russia; [Karpova, Yaroslava; Lyupina, Yulia; Kharybin, Oleg; Sharova, Natalia] Russian Acad Sci, Inst Dev Biol, Moscow 117871, Russia; [Nikolaev, Eugene] Russian Acad Med Sci, Inst Biomed Chem, Moscow, Russia; [Melamed, Dobroslav] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Kazan Federal University; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Lomonosov Moscow State University; Moscow Institute of Physics & Technology; Russian Academy of Sciences; N.N. Semenov Federal Research Centre for Chemical Physics, Russian Academy of Sciences; Lopukhin Federal Research & Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency; Russian Academy of Sciences; Koltzov Institute of Developmental Biology of the Russian Academy of Sciences; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry; Shamir Medical Center (Assaf Harofeh); Tel Aviv University	Gabibov, A (corresponding author), Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, V-437, Moscow 117871, Russia.	gabibov@mx.ibch.ru	Kovalchuk, Sergey I/J-3247-2014; Sharova, Natalia P/B-8361-2014; Lomakin, Yakov/ABF-7470-2020; Smirnov, Ivan/N-5635-2017; Kudriaeva, Anna/P-5893-2017; Nikolaev, Eugene N/N-4498-2013; Lomakin, Yakov/F-9700-2017; Bacheva, Anna/J-7128-2012; Kononikhin, Alexey/L-3171-2013; Stepanov, Alexey/AAN-8721-2020; Belogurov, Alexey/L-5859-2017; Lyupina, Yulia V/B-8365-2014; Stepanov, Aleksey L/L-5856-2017; Kharybin, Oleg/E-1730-2016	Kovalchuk, Sergey I/0000-0001-5273-3431; Lomakin, Yakov/0000-0002-3514-5395; Smirnov, Ivan/0000-0002-0384-6568; Kudriaeva, Anna/0000-0003-1163-9929; Nikolaev, Eugene N/0000-0001-6209-2068; Lomakin, Yakov/0000-0002-3514-5395; Bacheva, Anna/0000-0002-2169-211X; Stepanov, Alexey/0000-0003-1616-4408; Belogurov, Alexey/0000-0002-2033-9621; Lyupina, Yulia V/0000-0002-9903-3544; Stepanov, Aleksey L/0000-0002-2481-2631; Kuzina, Ekaterina/0000-0002-5468-0262; Kharybin, Oleg/0000-0002-5656-0862	Russian Scientific Foundation project "Molecular mechanism and physiologic significance of the ubiquitin-independent proteasomal degradation of the proteins" [14-14-00585]; Russian Foundation for Basic Research Grant [13-04-40277-H];  [CII 2445.2013.4]	Russian Scientific Foundation project "Molecular mechanism and physiologic significance of the ubiquitin-independent proteasomal degradation of the proteins"(Russian Science Foundation (RSF)); Russian Foundation for Basic Research Grant(Russian Foundation for Basic Research (RFBR)); 	The reported study was performed under the frame of Russian Scientific Foundation project Grant 14-14-00585 "Molecular mechanism and physiologic significance of the ubiquitin-independent proteasomal degradation of the proteins," partially supported by Russian Foundation for Basic Research Grant 13-04-40277-H and Fellowship CII 2445.2013.4 (to A.B.). The work was performed according to the Russian Government Program of Competitive Growth of Kazan Federal University.	ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; Basler M, 2012, J IMMUNOL, V189, P1868, DOI 10.4049/jimmunol.1103592; Belogurov AA, 2008, J IMMUNOL, V180, P1258, DOI 10.4049/jimmunol.180.2.1258; Belogurov AA, 2013, FASEB J, V27, P222, DOI 10.1096/fj.12-213975; Belogurov A, 2014, J BIOL CHEM, V289, P17758, DOI 10.1074/jbc.M113.544247; Belogurov A, 2009, BIOESSAYS, V31, P1161, DOI 10.1002/bies.200900020; Berthelot L, 2008, EUR J IMMUNOL, V38, P1889, DOI 10.1002/eji.200838023; Cardozo C, 1998, J BIOL CHEM, V273, P16764, DOI 10.1074/jbc.273.27.16764; Caudill CM, 2006, J IMMUNOL, V176, P4075, DOI 10.4049/jimmunol.176.7.4075; Chen WS, 2001, J EXP MED, V193, P1319, DOI 10.1084/jem.193.11.1319; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; Collombet JM, 2006, NEUROSCI LETT, V398, P337, DOI 10.1016/j.neulet.2006.01.029; Fissolo N, 2008, EUR J IMMUNOL, V38, P2401, DOI 10.1002/eji.200838413; Fissolo N, 2009, MOL CELL PROTEOMICS, V8, P2090, DOI 10.1074/mcp.M900001-MCP200; Frausto RF, 2007, J NEUROIMMUNOL, V192, P124, DOI 10.1016/j.jneuroim.2007.09.024; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Gardner RC, 2000, BIOCHEM J, V346, P447, DOI 10.1042/0264-6021:3460447; Groettrup M, 2010, NAT REV IMMUNOL, V10, P72, DOI 10.1038/nri2687; Groll M, 2006, P NATL ACAD SCI USA, V103, P4576, DOI 10.1073/pnas.0600647103; Guillaume B, 2010, P NATL ACAD SCI USA, V107, P18599, DOI 10.1073/pnas.1009778107; HAUSER SL, 1986, ANN NEUROL, V19, P578, DOI 10.1002/ana.410190610; Hensley SE, 2010, J IMMUNOL, V184, P4115, DOI 10.4049/jimmunol.0903003; Ho YK, 2007, CHEM BIOL, V14, P419, DOI 10.1016/j.chembiol.2007.03.008; Huseby ES, 2001, J EXP MED, V194, P669, DOI 10.1084/jem.194.5.669; Jurewicz A, 1998, J IMMUNOL, V160, P3056; Kuzina ES, 2013, DOKL BIOCHEM BIOPHYS, V453, P300, DOI 10.1134/S1607672913060070; LAATSCH RH, 1962, J EXP MED, V115, P777, DOI 10.1084/jem.115.4.777; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; Mishto M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009287; Moebius J, 2010, EUR J IMMUNOL, V40, P3439, DOI 10.1002/eji.201040620; Na SY, 2008, BRAIN, V131, P2353, DOI 10.1093/brain/awn148; Na SY, 2012, IMMUNITY, V37, P134, DOI 10.1016/j.immuni.2012.04.009; Nathan JA, 2013, CELL, V152, P1184, DOI 10.1016/j.cell.2013.01.037; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PANITCH HS, 1987, LANCET, V1, P893; PETTE M, 1990, P NATL ACAD SCI USA, V87, P7968, DOI 10.1073/pnas.87.20.7968; Ponomarenko NA, 2006, P NATL ACAD SCI USA, V103, P281, DOI 10.1073/pnas.0509849103; Raule M, 2014, BBA-MOL CELL RES, V1843, P1942, DOI 10.1016/j.bbamcr.2014.05.005; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rosenberg PA, 2003, J NEUROSCI RES, V71, P237, DOI 10.1002/jnr.10472; Schmidtke G, 1998, J EXP MED, V187, P1641, DOI 10.1084/jem.187.10.1641; Seifert U, 2010, CELL, V142, P613, DOI 10.1016/j.cell.2010.07.036; Sobottka B, 2009, AM J PATHOL, V175, P1160, DOI 10.2353/ajpath.2009.090340; Steinman L, 2001, J EXP MED, V194, pF27, DOI 10.1084/jem.194.5.F27; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; WEBB C, 1974, LANCET, V2, P66; Zheng JZ, 2012, J NEUROCHEM, V121, P486, DOI 10.1111/j.1471-4159.2012.07699.x	49	32	36	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1901	1913		10.1096/fj.14-259333	http://dx.doi.org/10.1096/fj.14-259333			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25634956	Green Published, hybrid			2022-12-28	WOS:000354114600025
J	Parang, B; Rosenblatt, D; Williams, AD; Washington, MK; Revetta, F; Short, SP; Reddy, VK; Hunt, A; Shroyer, NF; Engel, ME; Hiebert, SW; Williams, CS				Parang, Bobak; Rosenblatt, Daniel; Williams, Amanda D.; Washington, Mary K.; Revetta, Frank; Short, Sarah P.; Reddy, Vishruth K.; Hunt, Aubrey; Shroyer, Noah F.; Engel, Michael E.; Hiebert, Scott W.; Williams, Christopher S.			The transcriptional corepressor MTGR1 regulates intestinal secretory lineage allocation	FASEB JOURNAL			English	Article						Notch signaling; Paneth cells; CBFA2T2	EPITHELIAL-CELL LINES; STEM-CELLS; PROGENITOR CELLS; TARGET; FATE; DIFFERENTIATION; ESTABLISHMENT; INHIBITORS; DELETION; PATHWAY	Notch signaling largely determines intestinal epithelial cell fate. High Notch activity drives progenitors toward absorptive enterocytes by repressing secretory differentiation programs, whereas low Notch permits secretory cell assignment. Myeloid translocation gene-related 1 (MTGR1) is a transcriptional corepressor in the myeloid translocation gene/Eight-Twenty-One family. Given that Mtgr12/2 mice have a dramatic reduction of intestinal epithelial secretory cells, we hypothesized that MTGR1 is a key repressor of Notch signaling. In support of this, transcriptome analysis of laser capture microdissected Mtgr1(-/-) intestinal crypts revealed Notch activation, and secretory markers Mucin2, Chromogranin A, and Growth factor-independent 1 (Gfi1) were down-regulated in Mtgr1(-/-) whole intestines and Mtgr1(-/-) enteroids. We demonstrate that MTGR1 is in a complex with Suppressor of Hairless Homolog, a key Notch effector, and represses Notch-induced Hairy/Enhancer of Split 1 activity. Moreover, pharmacologic Notch inhibition using a g-secretase inhibitor (GSI) rescued the hyperproliferative baseline phenotype in the Mtgr1(-/-) intestine and increased production of goblet and enteroendocrine lineages in Mtgr1(-/-) mice. GSI increased Paneth cell production in wild-type mice but failed to do so in Mtgr1(-/-) mice. We determined that MTGR1 can interact with GFI1, a transcriptional corepressor required for Paneth cell differentiation, and repress GFI1 targets. Overall, the data suggest that MTGR1, a transcriptional corepressor well characterized in hematopoiesis, plays a critical role in intestinal lineage allocation.	[Parang, Bobak; Rosenblatt, Daniel; Short, Sarah P.; Reddy, Vishruth K.; Williams, Christopher S.] Vanderbilt Univ, Dept Med, Div Gastroenterol, Nashville, TN 37232 USA; [Parang, Bobak; Rosenblatt, Daniel; Short, Sarah P.; Reddy, Vishruth K.; Williams, Christopher S.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37235 USA; [Washington, Mary K.; Revetta, Frank] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN 37235 USA; [Hunt, Aubrey; Hiebert, Scott W.] Vanderbilt Univ, Dept Biochem, Nashville, TN USA; [Williams, Amanda D.] Lipscomb Univ, Dept Biol, Nashville, TN USA; [Shroyer, Noah F.] Baylor Univ, Sch Med, Div Pediat Gastroenterol, Houston, TX 77030 USA; [Engel, Michael E.] Univ Utah, Div Pediat Hematol Oncol, Salt Lake City, UT USA; [Hiebert, Scott W.; Williams, Christopher S.] Tennessee Valley Hlth Care Syst, Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Williams, Christopher S.] Tennessee Valley Hlth Care Syst, Vet Affairs, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Baylor University; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Williams, CS (corresponding author), Vanderbilt Univ, Sch Med, 1065D MRB-IV,B2215 Garland Ave, Nashville, TN 37232 USA.	christopher.williams@vanderbilt.edu	Williams, Christopher/W-3524-2019	Williams, Christopher/0000-0002-1541-579X; Shroyer, Noah/0000-0002-5934-2852; Reddy, Vishruth/0000-0002-9150-7784; Short, Sarah/0000-0001-9606-7370	U.S. National Institutes of Health (NIH) [K08DK080221, R01DK092306, R01CA1428260, K08DK080190, R01CA178030, P30DK058404, P50CA095103, F30DK096718-01, T32 GM07347]; Office of Medical Research, U.S. Department of Veterans Affairs [1I01BX001426, ACS-RSG116552]; National Cancer Institute Cancer Center Support Grant [P30CA068485]; St. Baldrick's Foundation; CTSA award from the National Center for Advancing Translational Sciences [UL1TR000445]; NATIONAL CANCER INSTITUTE [P50CA095103, R01CA142826, P30CA068485, R01CA178030] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, K08DK080221, K08DK080190, R01DK092306, F30DK096718, R01DK099204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001426] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of Medical Research, U.S. Department of Veterans Affairs; National Cancer Institute Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); St. Baldrick's Foundation; CTSA award from the National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	The authors would like to thank the members of the C.S.W. lab for helpful discussions and proofing of the manuscript. The authors would also like to thank Robert Whitehead and the Vanderbilt DDRC Novel Cell Line Development Subcore for their assistance in generating the Mtgr1<SUP>-/-</SUP> MSIE line, and Dr. Tarik Moroy for graciously providing reagents to M.E.E. This work was supported by the U.S. National Institutes of Health (NIH) Grants K08DK080221 (to C.S.W.), R01DK092306 (to N.F.S.), R01CA1428260 (to N.F.S.), K08DK080190 (to M.E.E.) R01CA178030 (to S.W.H), P30DK058404 (Vanderbilt Digestive Disease Research Center), P50CA095103 (to M.K.W.), F30DK096718-01 (to B.P.), and T32 GM07347 (NIH/National Institute of General Medical Sciences) (to B.P.), Merit Review Grants from the Office of Medical Research, U.S. Department of Veterans Affairs 1I01BX001426 (to C.S.W.), and ACS-RSG116552 (to C.S.W.). This publication was also supported in part by the National Cancer Institute Cancer Center Support Grant P30CA068485. This publication was also supported by the St. Baldrick's Foundation (to M.E.E.). This publication was also supported by CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the NIH.	Amann JM, 2005, MOL CELL BIOL, V25, P9576, DOI 10.1128/MCB.25.21.9576-9585.2005; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Barker N, 2012, CELL STEM CELL, V11, P452, DOI 10.1016/j.stem.2012.09.009; Barrett CW, 2011, CANCER RES, V71, P1302, DOI 10.1158/0008-5472.CAN-10-3317; Bernard JK, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.400846; Bjerknes M, 2010, DEV BIOL, V345, P49, DOI 10.1016/j.ydbio.2010.06.021; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; Chyla BJ, 2008, MOL CELL BIOL, V28, P6234, DOI 10.1128/MCB.00404-08; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100; Durand A, 2012, P NATL ACAD SCI USA, V109, P8965, DOI 10.1073/pnas.1201652109; Engel ME, 2010, MOL CELL BIOL, V30, P1852, DOI 10.1128/MCB.01342-09; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Hunt A, 2011, MOL CELL BIOL, V31, P2544, DOI 10.1128/MCB.01458-10; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Katoh M, 2007, INT J ONCOL, V30, P247; Kazanjian A, 2010, GASTROENTEROLOGY, V139, P918, DOI 10.1053/j.gastro.2010.05.081; Kim TH, 2012, P NATL ACAD SCI USA, V109, P3932, DOI 10.1073/pnas.1113890109; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Martinez JA, 2006, GASTROENTEROLOGY, V131, P579, DOI 10.1053/j.gastro.2006.06.009; Moore AC, 2008, MOL CELL BIOL, V28, P977, DOI 10.1128/MCB.01242-07; Musch MW, 2004, INFECT IMMUN, V72, P3187, DOI 10.1128/IAI.72.6.3187-3194.2004; Noah TK, 2011, EXP CELL RES, V317, P2702, DOI 10.1016/j.yexcr.2011.09.006; Pellegrinet L, 2011, GASTROENTEROLOGY, V140, P1230, DOI 10.1053/j.gastro.2011.01.005; Riccio O, 2008, EMBO REP, V9, P377, DOI 10.1038/embor.2008.7; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Shroyer NF, 2005, GENE DEV, V19, P2412, DOI 10.1101/gad.1353905; Stamataki D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024484; Stanger BZ, 2005, P NATL ACAD SCI USA, V102, P12443, DOI 10.1073/pnas.0505690102; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; van Es JH, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1017; Vassen L, 2006, EMBO J, V25, P2409, DOI 10.1038/sj.emboj.7601124; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Whitehead RH, 2009, AM J PHYSIOL-GASTR L, V296, pG455, DOI 10.1152/ajpgi.90381.2008; Zecchini V, 2005, GENE DEV, V19, P1686, DOI 10.1101/gad.341705	37	9	10	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					786	795		10.1096/fj.14-254284	http://dx.doi.org/10.1096/fj.14-254284			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25398765	Green Published			2022-12-28	WOS:000350633000006
J	Morrison, A; Chen, L; Wang, JL; Zhang, M; Yang, H; Ma, YN; Budanov, A; Lee, JH; Karin, M; Li, J				Morrison, Alex; Chen, Li; Wang, Jinli; Zhang, Ming; Yang, Hui; Ma, Yina; Budanov, Andrei; Lee, Jun Hee; Karin, Michael; Li, Ji			Sestrin2 promotes LKB1-mediated AMPK activation in the ischemic heart	FASEB JOURNAL			English	Article						AMP-activated protein kinase; scaffold protein; ischemia	PROTEIN-KINASE; REPERFUSION INJURY; MYOCARDIAL-ISCHEMIA; SENESCENT HEART; GLUCOSE-UPTAKE; TROPONIN-I; STRESS; LKB1; PHOSPHORYLATION; IDENTIFICATION	The regulation of AMPK in the ischemic heart remains incompletely understood. Recent evidence implicates the role of Sestrin2 in the AMPK signaling pathway, and it is hypothesized that Sestrin2 plays an influential role during myocardial ischemia to promote AMPK activation. Sestrin2 protein was found to be expressed in adult cardiomyocytes and accumulated in the heart during ischemic conditions. Sestrin2 knockout (KO) mice were used to determine the importance of Sestrin2 during ischemia and reperfusion (I/R) injury. When wild-type (WT) and Sestrin2 KO mice were subjected to in vivo I/R, myocardial infarct size was significantly greater in Sestrin2 KO compared with WT hearts. Similarly, Langendorff perfused hearts indicated exacerbated postischemic contractile function in Sestrin2 KO hearts compared with WT. Ischemic AMPK activation was found to be impaired in the Sestrin2 KO hearts. Immunoprecipitation of Sestrin2 demonstrated an association with AMPK. Moreover, liver kinase B1 (LKB1), a major AMPK upstream kinase, was associated with the Sestrin2-AMPK complex in a time-dependent manner during ischemia, whereas this interaction was nearly abolished in Sestrin2 KO hearts. Thus, Sestrin2 plays an important role in cardioprotection against I/R injury, serving as an LKB1-AMPK scaffold to initiate AMPK activation during ischemic insults.	[Morrison, Alex; Wang, Jinli; Ma, Yina; Li, Ji] SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA; [Chen, Li; Zhang, Ming] Jilin Univ, Dept Pharmacol, Coll Basic Med, Changchun, Jilin, Peoples R China; [Yang, Hui] Capital Med Univ, Dept Pathol, Sch Basic Med Sci, Beijing, Peoples R China; [Budanov, Andrei] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA USA; [Lee, Jun Hee] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Karin, Michael] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Jilin University; Capital Medical University; Virginia Commonwealth University; University of Michigan System; University of Michigan; University of California System; University of California San Diego	Li, J (corresponding author), SUNY Buffalo, Dept Pharmacol & Toxicol, 3435 Main St, Buffalo, NY 14214 USA.	jli23@buffalo.edu	Budanov, Andrei V/HGD-5487-2022; Zhang, Ming/E-4888-2016	Budanov, Andrei V/0000-0002-7943-1000; Lee, Jun Hee/0000-0002-2200-6011	American Heart Association [12GRNT11620029, 14IRG18290014]; American Diabetes Association Basic Sciences [1-14-BS-131]; U.S. National Institutes of Health National Cancer Institute Grant [5R01CA172660]; National Natural Science Foundation of China Grant [81200195]; Ellison Foundation; NATIONAL CANCER INSTITUTE [R01CA172660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG049835, R21AG044820] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); American Diabetes Association Basic Sciences; U.S. National Institutes of Health National Cancer Institute Grant; National Natural Science Foundation of China Grant(National Natural Science Foundation of China (NSFC)); Ellison Foundation(Lawrence Ellison Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors acknowledge Xingchi Chen and Yanqing Wang for excellent contributions in testing the AICAR-treated HeLa cells and performing real-time RT-PCR to measure Sestrin2 mRNA levels. This work was supported by American Heart Association Grants 12GRNT11620029 and 14IRG18290014, American Diabetes Association Basic Sciences Grant 1-14-BS-131, U.S. National Institutes of Health National Cancer Institute Grant 5R01CA172660, National Natural Science Foundation of China Grant 81200195, and the Ellison Foundation. This work was presented in part at the 2011 and 2012 American Heart Association Scientific Sessions and at the 2013 Experimental Biology Meeting.	Altarejos JY, 2005, J BIOL CHEM, V280, P183, DOI 10.1074/jbc.M411810200; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Baron SJ, 2005, CIRC RES, V96, P337, DOI 10.1161/01.RES.0000155723.53868.d2; BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; Budanou AV, 2010, EMBO MOL MED, V2, P388, DOI 10.1002/emmm.201000097; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Budanov AV, 2002, ONCOGENE, V21, P6017, DOI 10.1038/sj.onc.1205877; Chen S, 2014, LIFE SCI, V98, P75, DOI 10.1016/j.lfs.2014.01.006; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Costa R, 2012, J THROMB HAEMOST, V10, P1736, DOI 10.1111/j.1538-7836.2012.04833.x; Dhanasekaran DN, 2007, ONCOGENE, V26, P3185, DOI 10.1038/sj.onc.1210411; Essler S, 2009, FEBS LETT, V583, P3531, DOI 10.1016/j.febslet.2009.10.017; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Kim AS, 2009, ACTA PHYSIOL, V196, P37, DOI 10.1111/j.1748-1716.2009.01978.x; Kim AS, 2011, J MOL CELL CARDIOL, V51, P24, DOI 10.1016/j.yjmcc.2011.03.003; Lee JH, 2012, CELL METAB, V16, P311, DOI 10.1016/j.cmet.2012.08.004; Lee JH, 2010, SCIENCE, V327, P1223, DOI 10.1126/science.1182228; Li J, 2005, CIRC RES, V97, P872, DOI 10.1161/01.RES.0000187458.77026.10; Li J, 2004, AM J PHYSIOL-ENDOC M, V287, pE834, DOI 10.1152/ajpendo.00234.2004; Ma H, 2010, CIRCULATION, V122, P282, DOI 10.1161/CIRCULATIONAHA.110.953208; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36; Miller EJ, 2008, NATURE, V451, P578, DOI 10.1038/nature06504; Morrison A, 2011, AM J PHYSIOL-HEART C, V301, pH895, DOI 10.1152/ajpheart.00137.2011; Morrison A, 2011, BIOCHEM PHARMACOL, V82, P195, DOI 10.1016/j.bcp.2011.04.004; Moussa A, 2012, ACTA PHARM SIN B, V2, P368, DOI 10.1016/j.apsb.2012.06.001; Olson N, 2011, AM J PHYSIOL-LUNG C, V301, pL993, DOI 10.1152/ajplung.00250.2011; Peeters H, 2003, HUM GENET, V112, P573, DOI 10.1007/s00439-003-0917-5; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Sakamoto K, 2006, AM J PHYSIOL-ENDOC M, V290, pE780, DOI 10.1152/ajpendo.00443.2005; Sanli T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032035; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tong C, 2013, FASEB J, V27, P4332, DOI 10.1096/fj.12-216473; Wang J, 2013, J THROMB HAEMOST, V11, P1020, DOI 10.1111/jth.12243; Wang J, 2011, J THROMB HAEMOST, V9, P1308, DOI 10.1111/j.1538-7836.2011.04331.x; Wang JY, 2013, CIRCULATION, V128, P225, DOI 10.1161/CIRCULATIONAHA.112.000862; Young LH, 2008, CIRCULATION, V117, P832, DOI 10.1161/CIRCULATIONAHA.107.713115	41	129	138	2	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					408	417		10.1096/fj.14-258814	http://dx.doi.org/10.1096/fj.14-258814			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25366347	Green Published, Green Submitted			2022-12-28	WOS:000349370400007
J	Wen, L; Fu, LZ; Guo, XG; Chen, YL; Shi, YB				Wen, Luan; Fu, Liezhen; Guo, Xiaogang; Chen, Yonglong; Shi, Yun-Bo			Histone methyltransferase Dot1L plays a role in postembryonic development in Xenopus tropicalis	FASEB JOURNAL			English	Article						epigenetics; histone modification; activation mark; organogenesis	THYROID-HORMONE RECEPTOR; EFFECTOR NUCLEASES TALENS; INTESTINAL STEM-CELLS; SET-DOMAIN; H3K79 METHYLATION; HUMAN GENOME; TRANSCRIPTION; GENE; CHROMATIN; H3	Histone methylations have been implicated to play important roles in diverse cellular processes. Of particular interest is the methylation of histone H3K79, which is catalyzed by an evolutionarily conserved methyltransferase, disruptor of telomeric silencing (Dot1)-like (Dot1L). To investigate the role of Dot1L during vertebrate development, we have generated a Dot1L-specific transcription activator-like effector nuclease (TALEN) nuclease to knockdown endogenous Dot1L in Xenopus tropicalis, a diploid species highly related to the well-known developmental model Xenopus laevis, a pseudotetraploid amphibian. We show that the TALEN was extremely efficient in mutating Dot1L when expressed in fertilized eggs, creating essentially Dot1L knockout embryos with little H3K79 methylation. Importantly, we observed that Dot1L knockdown had no apparent effect on embryogenesis because normally feeding tadpoles were formed, consistent with the lack of maternal Dot1L expression. On the other hand, Dot1L knockdown severely retarded the growth of the tadpoles and led to tadpole lethality prior to metamorphosis. These findings suggest that Dot1L and H3K79 methylation play an important role for tadpole growth and development prior to metamorphosis into a frog. Our findings further reveal interesting similarities and differences between Xenopus and mouse development and suggest the existence of 2 separate phases of vertebrate development with distinct requirements for epigenetic modifications.	[Wen, Luan; Fu, Liezhen; Shi, Yun-Bo] NICHHD, NIH, Program Cellular Regulat & Metab, Sect Mol Morphogenesis, Bethesda, MD 20892 USA; [Guo, Xiaogang; Chen, Yonglong] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou, Guangdong, Peoples R China	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS	Shi, YB (corresponding author), NICHHD, NIH, Bldg 18T Room 106,18 Lib Dr MSC 5431, Bethesda, MD 20892 USA.	shi@helix.nih.gov	Wen, Luan/ABH-3991-2020	Wen, Luan/0000-0001-9408-8709; Wen, Luan/0000-0001-5080-0469; Shi, Yun-Bo/0000-0002-6330-0639	Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, U.S. National Institutes of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER	Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, U.S. National Institutes of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This research was supported in part by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, U.S. National Institutes of Health. The authors declare no conflicts of interest.	Nguyen AT, 2011, GENE DEV, V25, P1345, DOI 10.1101/gad.2057811; Barry ER, 2010, EXPERT OPIN THER TAR, V14, P405, DOI 10.1517/14728221003623241; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Barth TK, 2010, TRENDS BIOCHEM SCI, V35, P618, DOI 10.1016/j.tibs.2010.05.006; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cao Y, 2001, MECH DEVELOP, V102, P243, DOI 10.1016/S0925-4773(01)00295-7; Dillon SC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-227; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Hasebe T, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-18; Ishizuya-Oka A, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-37; Jones B, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000190; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lei Y, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-21; Lei Y, 2012, P NATL ACAD SCI USA, V109, P17484, DOI 10.1073/pnas.1215421109; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Matsuura K, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-25; Matsuura K, 2012, ENDOCRINOLOGY, V153, P961, DOI 10.1210/en.2011-1736; Maunakea AK, 2010, CIRC RES, V107, P327, DOI 10.1161/CIRCRESAHA.110.222463; Min JR, 2003, CELL, V112, P711, DOI 10.1016/S0092-8674(03)00114-4; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Ooga M, 2008, BIOL REPROD, V78, P413, DOI 10.1095/biolreprod.107.063453; Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103; Shanower GA, 2005, GENETICS, V169, P173, DOI 10.1534/genetics.104.033191; Shi Y.-B., 1999, AMPHIBIAN METAMORPHO; Shi YB, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-42; Singer MS, 1998, GENETICS, V150, P613; TATA JR, 1993, BIOESSAYS, V15, P239, DOI 10.1002/bies.950150404; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Wang ZB, 2009, CURR OPIN GENET DEV, V19, P127, DOI 10.1016/j.gde.2009.02.001; Wen LA, 2010, DEV DYNAM, V239, P2198, DOI 10.1002/dvdy.22356	33	22	23	2	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					385	393		10.1096/fj.14-252171	http://dx.doi.org/10.1096/fj.14-252171			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25366346	Green Published			2022-12-28	WOS:000349370400005
J	Buendia, P; de Oca, A; Madueno, JA; Merino, A; Martin-Malo, A; Aljama, P; Ramirez, R; Rodriguez, M; Carracedo, J				Buendia, Paula; Montes de Oca, Addy; Madueno, Juan Antonio; Merino, Ana; Martin-Malo, Alejandro; Aljama, Pedro; Ramirez, Rafael; Rodriguez, Mariano; Carracedo, Julia			Endothelial microparticles mediate inflammation-induced vascular calcification	FASEB JOURNAL			English	Article						HUVECs; VSMC calcification; BMP-2 osteogenic differentiation; TNF-alpha	BONE MORPHOGENETIC PROTEIN-2; NECROSIS-FACTOR-ALPHA; FACTOR-KAPPA-B; APOPTOTIC CELLS; VESICLES; PROTAGONISTS; ATTRACTION; ACTIVATION; PHAGOCYTES; INITIATION	Stimulation of endothelial cells (ECs) with TNF-alpha causes an increase in the expression of bone morphogenetic protein-2 (BMP-2) and the production of endothelial microparticles (EMPs). BMP-2 is known to produce osteogenic differentiation of vascular smooth muscle cells (VSMCs). It was found that EMPs from TNF-alpha- stimulated endothelial cells (HUVECs) contained a significant amount of BMP-2 and were able to enhance VSMC osteogenesis and calcification. Calcium content was greater in VSMCs exposed to EMPs from TNF-alpha-treated HUVECs than EMPs from nontreated HUVECs (3.56 +/- 0.57 vs. 1.48 +/- 0.56 mu g/mg protein; P < 0.05). The increase in calcification was accompanied by up-regulation of Cbfa1 (osteogenic transcription factor) and down-regulation of SM22 alpha (VSMC lineage marker). Inhibition of BMP-2 by small interfering RNA reduced the VSMC calcification induced by EMPs from TNF-alpha- treated HUVECs. Similar osteogenic capability was observed in EMPs from both patients with chronic kidney disease and senescent cells, which also presented a high level of BMP-2 expression. Labeling of EMPs with CellTracker shows that EMPs are phagocytized by VSMCs under all conditions (with or without high phosphate, control, and EMPs from TNF-alpha-treated HUVECs). Our data suggest that EC damage results in the release of EMPs with a high content of calcium and BMP-2 that are able to induce calcification and osteogenic differentiation of VSMCs.	[Buendia, Paula; Montes de Oca, Addy; Madueno, Juan Antonio; Martin-Malo, Alejandro; Aljama, Pedro; Rodriguez, Mariano; Carracedo, Julia] Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba, Fdn Invest Biomed Cordoba, Cordoba 14004, Spain; [Merino, Ana] Hosp Univ Bellvitge, IDIBELL, Lab Expt Nephrol, Barcelona, Spain; [Martin-Malo, Alejandro; Aljama, Pedro; Ramirez, Rafael; Rodriguez, Mariano] Hosp Univ Reina Sofia, Nephrol Unit, Cordoba 14004, Spain; [Ramirez, Rafael] Univ Alcala de Henares, Dept Physiol, Madrid, Spain; [Buendia, Paula; Montes de Oca, Addy; Merino, Ana; Martin-Malo, Alejandro; Aljama, Pedro; Ramirez, Rafael; Rodriguez, Mariano; Carracedo, Julia] Inst Salud Carlos III, Madrid, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Universidad de Alcala; Instituto de Salud Carlos III	Rodriguez, M (corresponding author), Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba, Menendez Pidal S-N, Cordoba 14004, Spain.	juanm.rodriguez.sspa@juntadeandalucia.es	Ramirez, Rafael/B-3249-2019; Carracedo, Julia/ABG-2464-2020; Carracedo, Julia/L-2012-2015; Merino, Ana/L-8347-2017	Carracedo, Julia/0000-0002-8422-812X; Carracedo, Julia/0000-0002-8422-812X; Rodriguez, Mariano/0000-0002-9380-6614; Rafael, Ramirez/0000-0003-4598-339X				Aikawa E, 2007, CIRCULATION, V116, P2841, DOI 10.1161/CIRCULATIONAHA.107.732867; Al-Aly Z, 2008, TRANSL RES, V151, P233, DOI 10.1016/j.trsl.2007.12.005; Amabile N, 2010, SEMIN THROMB HEMOST, V36, P907, DOI 10.1055/s-0030-1267044; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Au-Yeung KKW, 2004, CIRC RES, V94, P28, DOI 10.1161/01.RES.0000108264.67601.2C; Bellasi A, 2011, J NEPHROL, V24, pS11, DOI 10.5301/JN.2011.7744; Breitbach M, 2007, BLOOD, V110, P1362, DOI 10.1182/blood-2006-12-063412; Caplan A, 2009, J PATHOL, V217, P318, DOI 10.1002/path.2469; Collett GDM, 2005, CIRC RES, V96, P930, DOI 10.1161/01.RES.0000163634.51301.0d; Csiszar A, 2006, AM J PATHOL, V168, P629, DOI 10.2353/ajpath.2006.050284; Csiszar A, 2005, CIRCULATION, V111, P2364, DOI 10.1161/01.CIR.0000164201.40634.1D; Curtis AM, 2013, VASC MED, V18, P204, DOI 10.1177/1358863X13499773; Dalfino G, 2010, ATHEROSCLEROSIS, V211, P418, DOI 10.1016/j.atherosclerosis.2010.04.023; Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161; Faure V, 2006, J THROMB HAEMOST, V4, P566, DOI 10.1111/j.1538-7836.2005.01780.x; Golub EE, 2009, BBA-GEN SUBJECTS, V1790, P1592, DOI 10.1016/j.bbagen.2009.09.006; Kapustin AN, 2011, CIRC RES, V109, pE1, DOI 10.1161/CIRCRESAHA.110.238808; Kim SJ, 2002, J EXP MED, V196, P655, DOI 10.1084/jem.20020542; Kramann R, 2011, ARTERIOSCL THROM VAS, V31, pE45, DOI 10.1161/ATVBAHA.111.228601; Kunter U, 2007, J AM SOC NEPHROL, V18, P1754, DOI 10.1681/ASN.2007010044; Lafarge S, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-64; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Li XW, 2008, ATHEROSCLEROSIS, V199, P271, DOI 10.1016/j.atherosclerosis.2007.11.031; Loyer X, 2014, CIRC RES, V114, P345, DOI 10.1161/CIRCRESAHA.113.300858; Mause SF, 2010, CIRC RES, V107, P1047, DOI 10.1161/CIRCRESAHA.110.226456; de Oca AM, 2010, J BONE MINER RES, V25, P1996, DOI 10.1002/jbmr.93; Mueller RB, 2007, AUTOIMMUNITY, V40, P342, DOI 10.1080/08916930701356911; New SEP, 2013, ARTERIOSCL THROM VAS, V33, P1753, DOI 10.1161/ATVBAHA.112.300128; New SEP, 2011, CIRC RES, V108, P1381, DOI 10.1161/CIRCRESAHA.110.234146; New SEP, 2011, CIRC J, V75, P1305, DOI 10.1253/circj.CJ-11-0395; Radcliff K, 2005, CIRC RES, V96, P398, DOI 10.1161/01.RES.0000157671.47477.71; Raida M, 2006, INT J MOL MED, V18, P735; Ramirez R, 2007, CONTRIB NEPHROL, V158, P210, DOI 10.1159/000107252; Rautou PE, 2011, CIRC RES, V109, P593, DOI 10.1161/CIRCRESAHA.110.233163; Shantsila E, 2010, J THROMB HAEMOST, V8, P2358, DOI 10.1111/j.1538-7836.2010.04007.x; Shao JS, 2006, ARTERIOSCL THROM VAS, V26, P1423, DOI 10.1161/01.ATV.0000220441.42041.20; Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070; Tesfamariam B, 2007, VASC PHARMACOL, V46, P229, DOI 10.1016/j.vph.2006.11.005; Wu ZH, 2013, EUR REV MED PHARMACO, V17, P2420	39	94	99	2	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					173	181		10.1096/fj.14-249706	http://dx.doi.org/10.1096/fj.14-249706			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25342130				2022-12-28	WOS:000347378600017
J	Ramnath, R; Foster, RR; Qiu, Y; Cope, G; Butler, MJ; Salmon, AH; Mathieson, PW; Coward, RJ; Welsh, GI; Satchell, SC				Ramnath, Raina; Foster, Rebecca R.; Qiu, Yan; Cope, George; Butler, Matthew J.; Salmon, Andrew H.; Mathieson, Peter W.; Coward, Richard J.; Welsh, Gavin I.; Satchell, Simon C.			Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor alpha : a contributor to endothelial cell glycocalyx dysfunction	FASEB JOURNAL			English	Article						heparan sulfate; microvascular permeability	HEPARAN-SULFATE PROTEOGLYCANS; DIABETIC-NEPHROPATHY; GLOMERULAR ENDOTHELIUM; GENE-EXPRESSION; ALBUMINURIA; SULODEXIDE; BARRIER; TNF; MICROALBUMINURIA; MECHANISM	The endothelial surface glycocalyx is a hydrated mesh in which proteoglycans are prominent. It is damaged in diseases associated with elevated levels of tumor necrosis factor (TNF-). We investigated the mechanism of TNF--induced disruption of the glomerular endothelial glycocalyx. We used conditionally immortalized human glomerular endothelial cells (GEnCs), quantitative PCR arrays, Western blotting, immunoprecipitation, immunofluorescence, and dot blots to examine the effects of TNF-. TNF- induced syndecan 4 (SDC4) mRNA up-regulation by 2.5-fold, whereas cell surface SDC4 and heparan sulfate (HS) were reduced by 36 and 30%, respectively, and SDC4 and sulfated glycosaminoglycan in the culture medium were increased by 52 and 65%, respectively, indicating TNF--induced shedding. Small interfering (siRNA) knockdown of SDC4 (by 52%) caused a corresponding loss of cell surface HS of similar magnitude (38%), and immunoprecipitation demonstrated that SDC4 and HS are shed as intact proteoglycan ectodomains. All of the effects of TNF- on SDC4 and HS were abrogated by the metalloproteinase (MMP) inhibitor batimastat. Also abrogated was the associated 37% increase in albumin passage across GEnC monolayers. Specific MMP9 knockdown by siRNA similarly blocked TNF- effects. SDC4 is the predominant HS proteoglycan in the GEnC glycocalyx. TNF--induced MMP9-mediated shedding of SDC4 is likely to contribute to the endothelial glycocalyx disruption observed in diabetes and inflammatory states.Ramnath, R., Foster, R. R., Qiu, Y., Cope, G., Butler, M. J., Salmon, A. H., Mathieson, P. W., Coward, R. J., Welsh, G. I., Satchell, S. C. Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor : a contributor to endothelial cell glycocalyx dysfunction.	[Ramnath, Raina; Foster, Rebecca R.; Qiu, Yan; Cope, George; Butler, Matthew J.; Salmon, Andrew H.; Mathieson, Peter W.; Coward, Richard J.; Welsh, Gavin I.; Satchell, Simon C.] Univ Bristol, Sch Clin Sci, Acad Renal Unit, Bristol, Avon, England	University of Bristol	Satchell, SC (corresponding author), Acad Renal Unit, Dorothy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, England.	s.c.satchell@bristol.ac.uk	Foster, Rebecca/GSM-6886-2022; Ramnath, Raina/AAO-1180-2020; Foster, Becky/ABC-4433-2020	Foster, Rebecca/0000-0002-9645-1476; Welsh, Gavin Iain/0000-0002-2148-6658; Coward, Richard/0000-0001-6183-2546; Butler, Matthew/0000-0002-9814-8008; Ramnath, Raina/0000-0001-8472-5081	Diabetes UK [10/0004003]; British Heart Foundation Basic Science Intermediate Research Fellowship [FS/10/017/28249]; MRC [MR/K010492/1, G0802829] Funding Source: UKRI; British Heart Foundation [PG/12/51/29705, FS/10/017/28249] Funding Source: researchfish; Kidney Research UK [ST5/2012, RP45/2013] Funding Source: researchfish; Medical Research Council [G0802829, MR/K010492/1] Funding Source: researchfish	Diabetes UK(Diabetes UK); British Heart Foundation Basic Science Intermediate Research Fellowship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Kidney Research UK(Kidney Research UK (KRUK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors are grateful to Amy Russell (Academic Renal Unit, University of Bristol) for her technical assistance with the isolation of human GEnCs and Dr. Donald Fraser (Institute of Nephrology, Cardiff University, Cadiff, UK) for assistance with running the TEDAs. The work was funded by a Diabetes UK project grant (10/0004003). R.R.F. was supported by a British Heart Foundation Basic Science Intermediate Research Fellowship (FS/10/017/28249). The authors declare no conflicts of interest.	Adembri C, 2011, CRIT CARE, V15, DOI 10.1186/cc10559; Bass MD, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.264pe18; Bjornson A, 2005, AM J PHYSIOL-RENAL, V288, pF748, DOI 10.1152/ajprenal.00202.2004; Granqvist ABR, 2006, AM J PHYSIOL-RENAL, V291, pF722, DOI 10.1152/ajprenal.00433.2005; Blouza S, 2010, J NEPHROL, V23, P415; Broekhuizen LN, 2010, DIABETOLOGIA, V53, P2646, DOI 10.1007/s00125-010-1910-x; Brule S, 2006, GLYCOBIOLOGY, V16, P488, DOI 10.1093/glycob/cwj098; Chappell D, 2009, CARDIOVASC RES, V83, P388, DOI 10.1093/cvr/cvp097; Chappell D, 2009, BASIC RES CARDIOL, V104, P78, DOI 10.1007/s00395-008-0749-5; Chen SJ, 2010, KIDNEY INT, V78, P1088, DOI 10.1038/ki.2010.136; Couchman JR, 2010, ANNU REV CELL DEV BI, V26, P89, DOI 10.1146/annurev-cellbio-100109-104126; Fan QL, 2003, KIDNEY INT, V64, P1978, DOI 10.1046/j.1523-1755.2003.00312.x; Foster RR, 2013, AM J PATHOL, V183, P604, DOI 10.1016/j.ajpath.2013.04.019; Friedl J, 2002, BLOOD, V100, P1334, DOI 10.1182/blood.V100.4.1334.h81602001334_1334_1339; GAMBARO G, 1992, KIDNEY INT, V42, P285, DOI 10.1038/ki.1992.288; Gharagozlian S, 2009, BMC CLIN PATHOL, V9, DOI 10.1186/1472-6890-9-7; Gil N, 2012, DIABETES, V61, P208, DOI 10.2337/db11-1024; Haraldsson B, 2008, PHYSIOL REV, V88, P451, DOI 10.1152/physrev.00055.2006; Henry CBS, 2000, AM J PHYSIOL-HEART C, V279, pH2815, DOI 10.1152/ajpheart.2000.279.6.H2815; Jeansson M, 2006, DIABETOLOGIA, V49, P2200, DOI 10.1007/s00125-006-0319-z; Jensen JS, 2000, HYPERTENSION, V35, P898, DOI 10.1161/01.HYP.35.4.898; Karon J, 2007, BLOOD PURIFICAT, V25, P510, DOI 10.1159/000113011; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Lassalle P, 1996, J BIOL CHEM, V271, P20458, DOI 10.1074/jbc.271.34.20458; Levick JR, 2010, CARDIOVASC RES, V87, P198, DOI 10.1093/cvr/cvq062; Manon-Jensen T, 2010, FEBS J, V277, P3876, DOI 10.1111/j.1742-4658.2010.07798.x; Fernandez-Real JM, 2012, ACTA DIABETOL, V49, P301, DOI 10.1007/s00592-011-0349-y; Masola V, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-213; Multhaupt HAB, 2009, J PHYSIOL PHARMACOL, V60, P31; Nair S, 2008, J NEPHROL, V21, P400; Navarro JF, 2005, KIDNEY INT, V68, P98; Navarro-Gonzalez JF, 2008, J AM SOC NEPHROL, V19, P433, DOI 10.1681/ASN.2007091048; Navarro-Gonzalez JF, 2009, CYTOKINE GROWTH F R, V20, P165, DOI 10.1016/j.cytogfr.2009.02.005; Nieuwdorp M, 2006, DIABETES, V55, P1127, DOI 10.2337/diabetes.55.04.06.db05-1619; Ostrowski SR, 2013, CRIT CARE, V17, DOI 10.1186/cc12532; Pruessmeyer J, 2010, J BIOL CHEM, V285, P555, DOI 10.1074/jbc.M109.059394; Pyke C, 1997, NEPHRON, V77, P461, DOI 10.1159/000190325; Ramani VC, 2012, J BIOL CHEM, V287, P9952, DOI 10.1074/jbc.M111.330803; Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8; Rops AL, 2007, KIDNEY INT, V72, P1204, DOI 10.1038/sj.ki.5002514; Salmon AHJ, 2012, J PATHOL, V226, P562, DOI 10.1002/path.3964; Satchell SC, 2008, DIABETOLOGIA, V51, P714, DOI 10.1007/s00125-008-0961-8; Satchell SC, 2006, KIDNEY INT, V69, P1633, DOI 10.1038/sj.ki.5000277; Satchell SC, 2004, J AM SOC NEPHROL, V15, P566, DOI 10.1097/01.ASN.0000115397.22519.03; Satchell S, 2013, NAT REV NEPHROL, V9, P717, DOI 10.1038/nrneph.2013.197; Satchell SC, 2012, KIDNEY INT, V82, P949, DOI 10.1038/ki.2012.258; Sato T, 2003, J BIOL CHEM, V278, P3063, DOI 10.1074/jbc.M208886200; Satoh M, 2010, MICROCIRCULATION, V17, P103, DOI 10.1111/j.1549-8719.2009.00010.x; Schalkwijk CG, 2005, CLIN SCI, V109, P143, DOI 10.1042/CS20050025; Singh A, 2011, AM J PHYSIOL-RENAL, V300, pF40, DOI 10.1152/ajprenal.00103.2010; Singh A, 2007, J AM SOC NEPHROL, V18, P2885, DOI 10.1681/ASN.2007010119; Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055852; Strand ME, 2013, FEBS J, V280, P2228, DOI 10.1111/febs.12161; Sulikowska B, 2006, AM J NEPHROL, V26, P621, DOI 10.1159/000098195; Tamsma JT, 1996, NEPHROL DIAL TRANSPL, V11, P182; Tan XH, 2012, AM J PHYSIOL-LUNG C, V302, P1700, DOI 10.1152/ajplung.00167.2011; Weinbaum S, 2007, ANNU REV BIOMED ENG, V9, P121, DOI 10.1146/annurev.bioeng.9.060906.151959; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786	58	78	80	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4686	4699		10.1096/fj.14-252221	http://dx.doi.org/10.1096/fj.14-252221			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25122554				2022-12-28	WOS:000344050900010
J	Oberli, A; Slater, LM; Cutts, E; Brand, F; Mundwiler-Pachlatko, E; Rusch, S; Masik, MFG; Erat, MC; Beck, HP; Vakonakis, I				Oberli, Alexander; Slater, Leanne M.; Cutts, Erin; Brand, Francoise; Mundwiler-Pachlatko, Esther; Rusch, Sebastian; Masik, Martin F. G.; Erat, Michele C.; Beck, Hans-Peter; Vakonakis, Ioannis			A Plasmodium falciparum PHIST protein binds the virulence factor PfEMP1 and comigrates to knobs on the host cell surface	FASEB JOURNAL			English	Article						cytoadherence; exported proteins; interactions; malaria; protein structure	RED-BLOOD-CELLS; HISTIDINE-RICH PROTEIN; ERYTHROCYTE-MEMBRANE PROTEIN-1; MALARIA PARASITES; INFECTED ERYTHROCYTES; MAURERS CLEFTS; LIFE-CYCLE; IDENTIFICATION; TRAFFICKING; SKELETON	Uniquely among malaria parasites, Plasmodium falciparum-infected erythrocytes (iRBCs) develop membrane protrusions, known as knobs, where the parasite adhesion receptor P. falciparum erythrocyte membrane protein 1 (PfEMP1) clusters. Knob formation and the associated iRBC adherence to host endothelium are directly linked to the severity of malaria and are functional manifestations of protein export from the parasite to the iRBC. A family of exported proteins featuring Plasmodium helical interspersed subtelomeric (PHIST) domains has attracted attention, with members being implicated in host-parasite protein interactions and differentially regulated in severe disease and among parasite isolates. Here, we show that PHIST member PFE1605w binds the PfEMP1 intracellular segment directly with K-d = 5 +/- 0.6 mu M, comigrates with PfEMP1 during export, and locates in knobs. PHIST variants that do not locate in knobs (MAL8P1.4) or bind PfEMP1 30 times more weakly (PFI1780w) used as controls did not display the same pattern. We resolved the first crystallographic structure of a PHIST protein and derived a partial model of the PHIST-PfEMP1 interaction from nuclear magnetic resonance. We propose that PFE1605w reinforces the PfEMP1-cytoskeletal connection in knobs and discuss the possible role of PHIST proteins as interaction hubs in the parasite exportome.-Oberli, A., Slater, L. M., Cutts, E., Brand, F., Mundwiler-Pachlatko, E., Rusch, S., Masik, M. F. G., Erat, M. C., Beck, H.-P., Vakonakis, I. A Plasmodium falciparum PHIST protein binds the virulence factor PfEMP1 and comigrates to knobs on the host cell surface.	[Oberli, Alexander; Brand, Francoise; Mundwiler-Pachlatko, Esther; Rusch, Sebastian; Beck, Hans-Peter] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Oberli, Alexander; Brand, Francoise; Mundwiler-Pachlatko, Esther; Rusch, Sebastian; Beck, Hans-Peter] Univ Basel, Basel, Switzerland; [Slater, Leanne M.; Cutts, Erin; Masik, Martin F. G.; Erat, Michele C.; Vakonakis, Ioannis] Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University of Oxford	Beck, HP (corresponding author), Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	hans-peter.beck@unibas.ch; ioannis.vakonakis@bioch.ox.ac.uk		Cutts, Erin E./0000-0003-3290-4293; Beck, Hans-Peter/0000-0001-8326-4834	Wellcome Trust for the Oxford Biochemistry NMR facility [094872/Z/10/Z, 088497/Z/09/Z]; Swiss National Science Foundation [31003A_132709/1, 31003A_149297/1]; BBSRC [BB/J008265/1] Funding Source: UKRI	Wellcome Trust for the Oxford Biochemistry NMR facility; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The authors are grateful to David Staunton, Nick Soffe, Edward Lowe, and Philip Fowler for the upkeep of the supporting facilities at Oxford Biochemistry and to Henning Stahlberg and his team at the Center for Cellular Imaging and NanoAnalytics (C-CINA) and the Image Core Facility, Biozentrum, University of Basel, for the access and support. The authors acknowledge the Diamond Light Source (Harwell, UK) for access to synchrotron beamlines and the Oxford Protein Production Facility (Harwell, UK) for assistance with expression of PHIST domains. This work received support from the Wellcome Trust for the Oxford Biochemistry NMR facility (grant 094872/Z/10/Z, grant 088497/Z/09/Z to I.V., and a Ph.D. studentship to E.C.). The cell biological part of this study was supported by the Swiss National Science Foundation (grants 31003A_132709/1 and 31003A_149297/1).	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Bricogne G., 2011, BUSTER VERSION 2 10; Chen QJ, 2000, CLIN MICROBIOL REV, V13, P439, DOI 10.1128/CMR.13.3.439-450.2000; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Claessens A, 2012, P NATL ACAD SCI USA, V109, pE1772, DOI 10.1073/pnas.1120461109; Cooke BM, 2006, J CELL BIOL, V172, P899, DOI 10.1083/jcb.200509122; Cooke BM, 2001, ADV PARASIT, V50, P1, DOI 10.1016/S0065-308X(01)50029-9; Crabb BS, 2004, METH MOL B, V270, P263; de Koning-Ward TF, 2009, NATURE, V459, P945, DOI 10.1038/nature08104; DeLano W.L, PYMOL MOL GRAPHICS S; Eksi S, 2005, MOL BIOCHEM PARASIT, V143, P90, DOI 10.1016/j.molbiopara.2005.05.010; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Florens L, 2004, MOL BIOCHEM PARASIT, V135, P1, DOI 10.1016/j.molbiopara.2003.12.007; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Flueck C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000569; Gruring C, 2012, METHOD ENZYMOL, V506, P81, DOI 10.1016/B978-0-12-391856-7.00029-9; Gruring C, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1169; Heiber A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003546; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Knuepfer E, 2005, MOL MICROBIOL, V58, P1039, DOI 10.1111/j.1365-2958.2005.04895.x; Kyes S, 2001, ANNU REV MICROBIOL, V55, P673, DOI 10.1146/annurev.micro.55.1.673; LaCount DJ, 2005, NATURE, V438, P103, DOI 10.1038/nature04104; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Magowan C, 2000, BBA-MOL BASIS DIS, V1502, P461, DOI 10.1016/S0925-4439(00)00069-7; Maier AG, 2008, CELL, V134, P48, DOI 10.1016/j.cell.2008.04.051; Maier AG, 2007, BLOOD, V109, P1289, DOI 10.1182/blood-2006-08-043364; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; Mayer C, 2012, J BIOL CHEM, V287, P7182, DOI 10.1074/jbc.M111.330779; McMillan PJ, 2013, CELL MICROBIOL, V15, P1401, DOI 10.1111/cmi.12125; Mundwiler-Pachlatko E, 2013, P NATL ACAD SCI USA, V110, P19987, DOI 10.1073/pnas.1309247110; Nguitragool W, 2011, CELL, V145, P665, DOI 10.1016/j.cell.2011.05.002; Oh SS, 2000, MOL BIOCHEM PARASIT, V108, P237, DOI 10.1016/S0166-6851(00)00227-9; Pachlatko E, 2010, MOL MICROBIOL, V77, P1136, DOI 10.1111/j.1365-2958.2010.07278.x; Parish LA, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-160; Proellocks NI, 2014, FASEB J, V28, P3103, DOI 10.1096/fj.14-250399; Regev-Rudzki N, 2013, CELL, V153, P1120, DOI 10.1016/j.cell.2013.04.029; Rovira-Graells N, 2012, GENOME RES, V22, P925, DOI 10.1101/gr.129692.111; Sanders PR, 2005, J BIOL CHEM, V280, P40169, DOI 10.1074/jbc.M509631200; Sargeant TJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-2-r12; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shen Y, 2008, P NATL ACAD SCI USA, V105, P4685, DOI 10.1073/pnas.0800256105; Shen Y, 2009, J BIOMOL NMR, V44, P213, DOI 10.1007/s10858-009-9333-z; Silvestrini F, 2005, MOL BIOCHEM PARASIT, V143, P100, DOI 10.1016/j.molbiopara.2005.04.015; Spielmann T, 2003, MOL BIOL CELL, V14, P1529, DOI 10.1091/mbc.E02-04-0240; Spycher C, 2003, J BIOL CHEM, V278, P35373, DOI 10.1074/jbc.M305851200; Spycher C, 2008, MOL MICROBIOL, V68, P1300, DOI 10.1111/j.1365-2958.2008.06235.x; TAYLOR DW, 1987, MOL BIOCHEM PARASIT, V25, P165, DOI 10.1016/0166-6851(87)90005-3; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Weng HB, 2014, BBA-BIOMEMBRANES, V1838, P185, DOI 10.1016/j.bbamem.2013.09.014; Wickham Mark E., 2001, EMBO (European Molecular Biology Organization) Journal, V20, P5636, DOI 10.1093/emboj/20.20.5636; Young JA, 2005, MOL BIOCHEM PARASIT, V143, P67, DOI 10.1016/j.molbiopara.2005.05.007	57	59	59	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4420	4433		10.1096/fj.14-256057	http://dx.doi.org/10.1096/fj.14-256057			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24983468	hybrid, Green Published			2022-12-28	WOS:000342222700020
J	Casadevall, A; Steen, RG; Fang, FC				Casadevall, Arturo; Steen, R. Grant; Fang, Ferric C.			Sources of error in the retracted scientific literature	FASEB JOURNAL			English	Article						bibliometric analysis; biomedical publishing; ethics	HUMAN BASOPHIL DEGRANULATION; RESPONSIVE BREAST-CANCER; CONFER IMMUNE PRIVILEGE; GROUP 1-98 TRIAL; CELL-LINES; CROSS-CONTAMINATION; CD95 LIGAND; MULTIDRUG-RESISTANCE; POSTMENOPAUSAL WOMEN; TAMOXIFEN RESPONSE	Retraction of flawed articles is an important mechanism for correction of the scientific literature. We recently reported that the majority of retractions are associated with scientific misconduct. In the current study, we focused on the subset of retractions for which no misconduct was identified, in order to identify the major causes of error. Analysis of the retraction notices for 423 articles indexed in PubMed revealed that the most common causes of error-related retraction are laboratory errors, analytical errors, and irreproducible results. The most common laboratory errors are contamination and problems relating to molecular biology procedures (e.g., sequencing, cloning). Retractions due to contamination were more common in the past, whereas analytical errors are now increasing in frequency. A number of publications that have not been retracted despite being shown to contain significant errors suggest that barriers to retraction may impede correction of the literature. In particular, few cases of retraction due to cell line contamination were found despite recognition that this problem has affected numerous publications. An understanding of the errors leading to retraction can guide practices to improve laboratory research and the integrity of the scientific literature. Perhaps most important, our analysis has identified major problems in the mechanisms used to rectify the scientific literature and suggests a need for action by the scientific community to adopt protocols that ensure the integrity of the publication process.	[Casadevall, Arturo] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; [Casadevall, Arturo] Albert Einstein Coll Med, Div Infect Dis, Dept Med, Bronx, NY 10461 USA; [Steen, R. Grant] MediCC, Chapel Hill, NC USA; [Fang, Ferric C.] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA; [Fang, Ferric C.] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Casadevall, A (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	arturo.casadevall@einstein.yu.edu		Steen, R. Grant/0000-0003-3386-6575; Fang, Ferric/0000-0002-3243-110X				Alberts B, 2011, SCIENCE, V332, P1149, DOI 10.1126/science.332.6034.1149-a; Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; [Anonymous], 1792, COMMUNICATION; [Anonymous], 2013, ECONOMIST; Atkinson I, 2012, J CLIN NURS, V21, P2730, DOI 10.1111/j.1365-2702.2012.04353.x; BAGENAL FS, 1990, LANCET, V336, P606; Barallon R, 2010, IN VITRO CELL DEV-AN, V46, P727, DOI 10.1007/s11626-010-9333-z; Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BENVENISTE J, 1994, NATURE, V370, P322, DOI 10.1038/370322a0; Brown EN, 2007, ACTA CRYSTALLOGR D, V63, P941, DOI 10.1107/S0907444907033847; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Capes-Davis A, 2010, INT J CANCER, V127, P1, DOI 10.1002/ijc.25242; Casadevall A., 2013, PROJECT SYNDICATE; Casadevall A, 2012, INFECT IMMUN, V80, P891, DOI 10.1128/IAI.06183-11; CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; CHOW YK, 1993, NATURE, V364, P679, DOI 10.1038/364679a0; Couzin-Frankel J, 2012, SCIENCE, V337, P1031, DOI 10.1126/science.337.6098.1031; DAVENAS E, 1988, NATURE, V333, P816, DOI 10.1038/333816a0; Drexler HG, 2003, LEUKEMIA, V17, P416, DOI 10.1038/sj.leu.2402799; Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081; EMINI EA, 1993, NATURE, V364, P679, DOI 10.1038/364679b0; Erb TJ, 2012, SCIENCE, V337, P467, DOI 10.1126/science.1218455; Fanelli D, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001563; Fang FC, 2012, P NATL ACAD SCI USA, V109, P17028, DOI 10.1073/pnas.1212247109; Fang FC, 2011, INFECT IMMUN, V79, P3855, DOI 10.1128/IAI.05661-11; FLEISCHMANN M, 1989, J ELECTROANAL CHEM, V263, P187; FLEISCHMANN M, 1989, J ELECTROANAL CHEM, V261, P301, DOI 10.1016/0022-0728(89)80006-3; Franzen S, 2007, J AM CHEM SOC, V129, P15340, DOI 10.1021/ja076054r; GOODARE H, 1994, BRIT MED J, V308, P593; Grcar JF, 2013, AM SCI, V101, P16, DOI 10.1511/1990.100.16; Gugliotti LA, 2004, SCIENCE, V304, P850, DOI 10.1126/science.1095678; HIRST SJ, 1993, NATURE, V366, P525, DOI 10.1038/366525a0; Husten L., 2013, FORBES; Johnson G., 2014, NY TIMES; Johnson VE, 2013, P NATL ACAD SCI USA, V110, P19313, DOI 10.1073/pnas.1313476110; Joppa LN, 2013, SCIENCE, V340, P814, DOI 10.1126/science.1231535; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Knight LA, 2011, METHODS MOL BIOL, V731, P115, DOI 10.1007/978-1-61779-080-5_10; Labandeira-Rey M, 2007, SCIENCE, V315, P1130, DOI 10.1126/science.1137165; LARDER BA, 1993, NATURE, V365, P451, DOI 10.1038/365451a0; Loscalzo J, 2012, CIRCULATION, V125, P1211, DOI 10.1161/CIRCULATIONAHA.112.098244; MacArthur D, 2012, NATURE, V487, P427, DOI 10.1038/487427a; MacLeod RAF, 1999, INT J CANCER, V83, P555; MADDOX J, 1988, NATURE, V334, P287, DOI 10.1038/334287a0; McGauran N, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-37; Miller G, 2006, SCIENCE, V314, P1856, DOI 10.1126/science.314.5807.1856; MISKELLY GM, 1989, SCIENCE, V246, P793, DOI 10.1126/science.246.4931.793; Nakamura Y, 2012, J NATL CANCER I, V104, P1264, DOI 10.1093/jnci/djs304; Nardone RM, 2007, CELL BIOL TOXICOL, V23, P367, DOI 10.1007/s10565-007-9019-9; Neff J., 2014, NEWS OBSERVER; NELSONREES WA, 1981, SCIENCE, V212, P446, DOI 10.1126/science.6451928; Phuchareon J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006040; PINHOLSTER G, 1994, SCIENCE, V264, P197, DOI 10.1126/science.8146647; Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439-c1; QUIK M, 1993, MOL PHARMACOL, V44, P678; Ram K, 2013, SOURCE CODE BIOL MED, V8, DOI 10.1186/1751-0473-8-7; Reaves ML, 2012, SCIENCE, V337, P470, DOI 10.1126/science.1219861; Regan MM, 2012, JNCI-J NATL CANCER I, V104, P441, DOI 10.1093/jnci/djs125; Rekers H, 2004, CONTRACEPTION, V70, P433, DOI 10.1016/j.contraception.2004.07.004; Rojas A, 2008, ACTA PHARMACOL SIN, V29, P877, DOI 10.1111/j.1745-7254.2008.00809.x; Rosmalen JGM, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001143; SALAMON MH, 1990, NATURE, V344, P401, DOI 10.1038/344401a0; Shelomi M, 2013, SCI ENG ETHICS, V19, P381, DOI 10.1007/s11948-011-9339-2; Steen RG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068397; STEINSCHNEIDER A, 1972, PEDIATRICS, V50, P646; Struys MMRF, 2010, ANESTHESIOLOGY, V112, P1056, DOI 10.1097/ALN.0b013e3181d536df; Sun F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015703; ter Riet G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043404; Tomkins JL, 2011, SCIENCE, V333, P1220, DOI 10.1126/science.333.6047.1220-a; TRAVER JAY R., 1951, PROC ENT SOC WASHINGTON, V53, P1; Vasilevsky NA, 2013, PEERJ, V1, DOI 10.7717/peerj.148; Vaux DL, 1998, NATURE, V394, P133, DOI 10.1038/28067; Villaruz AE, 2009, J INFECT DIS, V200, P724, DOI 10.1086/604728; Wager E, 2011, J MED ETHICS, V37, P567, DOI 10.1136/jme.2010.040964; Wolfe-Simon F, 2011, SCIENCE, V332, P1163, DOI 10.1126/science.1197258; Wyatt MA, 2011, SCIENCE, V333, P1381; Wyatt MA, 2010, SCIENCE, V329, P294, DOI 10.1126/science.1188888; Yagita H, 1996, NATURE, V379, P682, DOI 10.1038/379682a0; Zarychanski R, 2013, JAMA-J AM MED ASSOC, V309, P678, DOI 10.1001/jama.2013.430	80	47	48	3	99	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3847	3855		10.1096/fj.14-256735	http://dx.doi.org/10.1096/fj.14-256735			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24928194	Green Published			2022-12-28	WOS:000340845900004
J	Sekar, R; Chow, BKC				Sekar, Revathi; Chow, Billy K. C.			Secretin receptor-knockout mice are resistant to high-fat diet-induced obesity and exhibit impaired intestinal lipid absorption	FASEB JOURNAL			English	Article						postprandial triglyceride release; CD36; enterocytes; positive feedback loop; long chain fatty acid	POSTPRANDIAL LIPOPROTEINS; ENTEROENDOCRINE CELLS; ADIPOSE-TISSUE; MOUSE; METABOLISM; EXPRESSION; DISEASE; BODY; CD36; ATHEROSCLEROSIS	Secretin, a classical gastrointestinal hormone released from S cells in response to acid and dietary lipid, regulates pleiotropic physiological functions, such as exocrine pancreatic secretion and gastric motility. Subsequent to recently proposed revisit on secretin's metabolic effects, we have confirmed lipolytic actions of secretin during starvation and discovered a hormone-sensitive lipase-mediated mechanistic pathway behind. In this study, a 12 wk high-fat diet (HFD) feeding to secretin receptor-knockout (SCTR-/-) mice and their wild-type (SCTR+/+) littermates revealed that, despite similar food intake, SCTR-/- mice gained significantly less weight (SCTR+/+ : 49.6 +/- 0.9 g; SCTR-/- : 44.7 +/- 1.4 g; P< 0.05) and exhibited lower body fat content. These SCTR-/- mice have corresponding alleviated HFD-associated hyperleptinemia and improved glucose/insulin tolerance. Further analyses indicate that SCTR-/- have impaired intestinal fatty acid absorption while having similar energy expenditure and locomotor activity. Reduced fat absorption in the intestine is further supported by lowered postprandial triglyceride concentrations in circulation in SCTR-/- mice. In jejunal cells, transcript and protein levels of a key fat absorption regulator, cluster of differentiation 36 (CD36), was reduced in knockout mice, while transcript of Cd36 and fatty-acid uptake in isolated enterocytes was stimulated by secretin. Based on our findings, a novel positive feedback pathway involving secretin and CD36 to enhance intestinal lipid absorption is being proposed.	[Sekar, Revathi; Chow, Billy K. C.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Chow, BKC (corresponding author), Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	bkcc@hku.hk	Chow, Billy/D-3064-2009; Sekar, Revathi/AAE-9642-2022; Sekar, Revathi/AFE-8105-2022	Chow, Billy/0000-0003-3390-0307; Sekar, Revathi/0000-0002-6787-7742	Hong Kong Government Research Grants Council grants [7648/12]; General Research Fund (GRF) [763809]; GRF [17 105514]; Collaborative Research Fund grant [HKU6/CRF/11G]; University of Hong Kong Committee on Research and Conference Grants grant [201111159046]	Hong Kong Government Research Grants Council grants; General Research Fund (GRF); GRF; Collaborative Research Fund grant; University of Hong Kong Committee on Research and Conference Grants grant	This work was supported by Hong Kong Government Research Grants Council grants 7648/12, General Research Fund (GRF) 763809, and GRF 17 105514; Collaborative Research Fund grant HKU6/CRF/11G; and University of Hong Kong Committee on Research and Conference Grants grant 201111159046 to B. K. C. C. The authors sincerely thank Dr. Leo Lee and Dr. Ruby Hoo for their help in body composition and indirect calorimetry instrument obtainment. The authors declare no conflicts of interest.	Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34; Cheng CYY, 2011, NEUROPSYCHOPHARMACOL, V36, P459, DOI 10.1038/npp.2010.178; Chu JYS, 2007, MOL CELL BIOL, V27, P2499, DOI 10.1128/MCB.01088-06; Chu JYS, 2011, KIDNEY INT, V79, P280, DOI 10.1038/ki.2010.397; Cullen P, 2000, AM J CARDIOL, V86, P943, DOI 10.1016/S0002-9149(00)01127-9; Deng QH, 2009, CHEM-EUR J, V15, P10707, DOI 10.1002/chem.200901895; Drover VA, 2005, J CLIN INVEST, V115, P1290, DOI 10.1172/JCI200521514; Egerod KL, 2012, ENDOCRINOLOGY, V153, P5782, DOI 10.1210/en.2012-1595; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fukuda M, 2000, JPN J PHYSIOL, V50, P215, DOI 10.2170/jjphysiol.50.215; Gaidhu MP, 2010, AM J PHYSIOL-CELL PH, V298, pC961, DOI 10.1152/ajpcell.00547.2009; Gomez-Ambrosi J, 2004, FASEB J, V18, P215, DOI 10.1096/fj.03-0591fje; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GREEN GM, 1989, AM J PHYSIOL, V256, pG1016, DOI 10.1152/ajpgi.1989.256.6.G1016; Habib AM, 2012, ENDOCRINOLOGY, V153, P3054, DOI 10.1210/en.2011-2170; HERBERG L, 1974, J LIPID RES, V15, P580; Jandacek RJ, 2004, GASTROENTEROLOGY, V127, P139, DOI 10.1053/j.gastro.2004.04.007; JONES PJH, 1985, AM J CLIN NUTR, V42, P769, DOI 10.1093/ajcn/42.5.769; Karpe F, 1999, J INTERN MED, V246, P341, DOI 10.1046/j.1365-2796.1999.00548.x; KARPE F, 1994, ATHEROSCLEROSIS, V106, P83, DOI 10.1016/0021-9150(94)90085-X; Koves K, 2011, J MOL NEUROSCI, V43, P109, DOI 10.1007/s12031-010-9408-z; Lam IPY, 2008, INT REV CYTOL, V265, P159, DOI 10.1016/S0074-7696(07)65004-9; Lee VHY, 2010, FASEB J, V24, P5024, DOI 10.1096/fj.10-165399; Liao JF, 2005, J LIPID RES, V46, P597, DOI 10.1194/jlr.D400023-JLR200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lo CM, 2010, GASTROENTEROLOGY, V138, P1997, DOI 10.1053/j.gastro.2010.01.044; LU YX, 1995, AM J PHYSIOL-GASTR L, V268, pG1012, DOI 10.1152/ajpgi.1995.268.6.G1012; Lynes M, 2011, AM J PHYSIOL-REG I, V301, pR1738, DOI 10.1152/ajpregu.00235.2011; Mayo KE, 2003, PHARMACOL REV, V55, P167, DOI 10.1124/pr.55.1.6; Mellitzer G, 2011, CURR OPIN LIPIDOL, V22, P171, DOI 10.1097/MOL.0b013e32834622a2; Mellitzer G, 2010, J CLIN INVEST, V120, P1708, DOI 10.1172/JCI40794; Miegueu P., 2012, INT J OBES LOND, V37, P366; Nauli AM, 2006, GASTROENTEROLOGY, V131, P1197, DOI 10.1053/j.gastro.2006.08.012; Ng SSM, 2002, MOL NEUROBIOL, V26, P97, DOI 10.1385/MN:26:1:097; PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336; Proctor SD, 1998, EUR J CLIN INVEST, V28, P497; Proctor SD, 2002, CURR OPIN LIPIDOL, V13, P461, DOI 10.1097/00041433-200210000-00001; Ravussin Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085876; Sekar R., 2013, J LIPID RES, V55; Sekar R, 2013, GEN COMP ENDOCR, V181, P18, DOI 10.1016/j.ygcen.2012.11.017; SHIDO O, 1989, JPN J PHYSIOL, V39, P359, DOI 10.2170/jjphysiol.39.359; Shim J, 2009, J LIPID RES, V50, P491, DOI 10.1194/jlr.M800400-JLR200; Siu FKY, 2006, ANN NY ACAD SCI, V1070, P561, DOI 10.1196/annals.1317.081; Stanford KI, 2013, J CLIN INVEST, V123, P215, DOI 10.1172/JCI62308; Sundaresan S, 2013, FASEB J, V27, P1191, DOI 10.1096/fj.12-217703; Thi TTT, 2011, J BIOL CHEM, V286, P25201, DOI 10.1074/jbc.M111.233551; Tupone D, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00014; Winzell MS, 2004, DIABETES, V53, pS215, DOI 10.2337/diabetes.53.suppl_3.S215; Xie Y, 2003, AM J PHYSIOL-GASTR L, V285, pG735, DOI 10.1152/ajpgi.00202.2003; Yung WH, 2001, J NEUROSCI, V21, P7063, DOI 10.1523/JNEUROSCI.21-18-07063.2001	50	20	21	5	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3494	3505		10.1096/fj.13-247536	http://dx.doi.org/10.1096/fj.13-247536			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24769669				2022-12-28	WOS:000340265400019
J	Thulin, JD; Bradfield, JF; Bergdall, VK; Conour, LA; Grady, AW; Hickman, DL; Norton, JN; Wallace, JM				Thulin, Joseph D.; Bradfield, John F.; Bergdall, Valerie K.; Conour, Laura A.; Grady, Andrew W.; Hickman, Debra L.; Norton, John N.; Wallace, Jeanne M.			The cost of self-imposed regulatory burden in animal research	FASEB JOURNAL			English	Article						compliance; oversight; standards; policies		U.S. federal regulations and standards governing the care and use of research animals enacted in the mid-to late 1980s, while having positive effects on the welfare and quality of the animals, have resulted in dramatic increases in overall research costs. In addition to the expenses of housing and caring for animals according to the standards, establishing the requisite internal compliance bureaucracies has markedly driven up costs, in both institutional monetary expenditures and lost research effort. However, many institutions are increasing these costs even further through additional self-imposed regulatory burden, typically characterized by overly complex compliance organizations and unnecessary policies and procedures. We discuss the sources of this self-imposed burden and recommend strategies for avoiding it while preserving an appropriate focus on animal well-being and research success.	[Thulin, Joseph D.] Med Coll Wisconsin, Biomed Resource Ctr, Milwaukee, WI 53226 USA; [Bradfield, John F.] Assoc Assessment & Accreditat Lab Anim Care, Frederick, MD USA; [Bergdall, Valerie K.] Ohio State Univ, Univ Lab Anim Resources, Columbus, OH 43210 USA; [Conour, Laura A.] Princeton Univ, Lab Anim Resources, Princeton, NJ 08544 USA; [Grady, Andrew W.] Univ Mississippi, Med Ctr, Lab Anim Facil, Jackson, MS 39216 USA; [Hickman, Debra L.] Indiana Univ, Sch Med, Lab Anim Resources, Indianapolis, IN USA; [Norton, John N.] Duke Univ, Div Lab Anim Resources, Durham, NC USA; [Wallace, Jeanne M.] Vanderbilt Univ, Div Anim Care, Nashville, TN 37235 USA	Medical College of Wisconsin; University System of Ohio; Ohio State University; Princeton University; University of Mississippi; University of Mississippi Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Duke University; Vanderbilt University	Thulin, JD (corresponding author), Med Coll Wisconsin, Biomed Resource Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jthulin@mcw.edu						Guyton A. C., 1988, USE LAB ANIMALS BIOM, P81; Guyton A. C., 1988, SCIENTIST; Haywood JR, 2008, ILAR J, V49, P426, DOI 10.1093/ilar.49.4.426; National Research Council, 2011, GUIDE CARE USE LAB A	4	13	12	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3297	3300		10.1096/fj.14-254094	http://dx.doi.org/10.1096/fj.14-254094			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24784580				2022-12-28	WOS:000340265400002
J	Oduwole, OO; Vydra, N; Wood, NEM; Samanta, L; Owen, L; Keevil, B; Donaldson, M; Naresh, K; Huhtaniemi, IT				Oduwole, Olayiwola O.; Vydra, Natalia; Wood, Nicholas E. M.; Samanta, Luna; Owen, Laura; Keevil, Brian; Donaldson, Mandy; Naresh, Kikkeri; Huhtaniemi, Ilpo T.			Overlapping dose responses of spermatogenic and extragonadal testosterone actions jeopardize the principle of hormonal male contraception	FASEB JOURNAL			English	Article						azoospermia; oligozoospermia; hypothalamic-pituitary-testicular axis	FOLLICLE-STIMULATING-HORMONE; LUTEINIZING-HORMONE; ENANTHATE; AZOOSPERMIA; INDUCTION; PLASMA; TESTIS	Testosterone (T), alone or in combination with progestin, provides a promising approach to hormonal male contraception. Its principle relies on enhanced negative feedback of exogenous T to suppress gonadotropins, thereby blocking the testicular T production needed for spermatogenesis, while simultaneously maintaining the extragonadal androgen actions, such as potency and libido, to avoid hypogonadism. A serious drawback of the treatment is that a significant proportion of men do not reach azoospermia or severe oligozoospermia, commensurate with contraceptive efficacy. We tested here, using hypogonadal luteinizing hormone/choriongonadotropin receptor (LHCGR) knockout (LHR-/-) mice, the basic principle of the T-based male contraceptive method, that a specific T dose could maintain extragonadal androgen actions without simultaneously activating spermatogenesis. LHR-/- mice were treated with increasing T doses, and the responses of their spermatogenesis and extragonadal androgen actions (including gonadotropin suppression and sexual behavior) were assessed. Conspicuously, all dose responses to T were practically superimposable, and no dose of T could be defined that would maintain sexual function and suppress gonadotropins without simultaneously activating spermatogenesis. This finding, never addressed in clinical contraceptive trials, is not unexpected in light of the same androgen receptor mediating androgen actions in all organs. When extrapolated to humans, our findings may jeopardize the current approach to hormonal male contraception and call for more effective means of inhibiting intratesticular T production or action, to achieve consistent spermatogenic suppression.	[Oduwole, Olayiwola O.; Vydra, Natalia; Wood, Nicholas E. M.; Samanta, Luna; Huhtaniemi, Ilpo T.] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Dept Surg & Canc, London W12 0NN, England; [Naresh, Kikkeri] Univ London Imperial Coll Sci Technol & Med, Imperial Coll Healthcare, Natl Hlth Serv Trust, Dept Histopathol, London W12 0NN, England; [Vydra, Natalia] Marie Curie Sklodowska Univ, Mem Canc Ctr, Gliwice, Poland; [Vydra, Natalia] Inst Oncol, Gliwice, Poland; [Samanta, Luna] Ravenshaw Univ, Sch Life Sci, Dept Zool, Biochem Lab, Cuttack, Orissa, India; [Owen, Laura; Keevil, Brian] Univ S Manchester Hosp, Dept Biochem, Manchester M20 8LR, Lancs, England; [Donaldson, Mandy] Charing Cross Hosp, Imperial Coll Healthcare, Natl Hlth Serv Trust, Dept Clin Biochem, London, England	Imperial College London; Imperial College London; Maria Curie-Sklodowska University; Maria Sklodowska-Curie National Research Institute of Oncology; Ravenshaw University; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Imperial College London	Huhtaniemi, IT (corresponding author), Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Dept Surg & Canc, Hammersmith Campus,Cane Rd, London W12 0NN, England.	ilpo.huhtaniemi@imperial.ac.uk	Samanta, Luna/H-4206-2019; keevil, brian/AAP-6147-2020	Samanta, Luna/0000-0002-2969-0071; Oduwole, Olayiwola/0000-0003-3840-7335; Vydra, Natalia/0000-0001-7749-7770; Naresh, Kikkeri N/0000-0003-3807-3638	Wellcome Trust [082101/Z/07/Z]; MRC [0600002]	Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Prof. Jimmy Bell [Metabolic and Molecular Imaging Group, Medical Research Council (MRC) Clinical Sciences Centre, Imperial College London] for his valuable advice on the body composition analysis. The authors also thank Jennifer H. Steel (Institute of Reproductive and Developmental Biology, Imperial College London) for advice on histology, and Tuula Hamalainen, Taina Kirjonen, and Anu Salminen (Department of Physiology, University of Turku, Turku, Finland) for the gonadotropin assay. This work was supported by the Wellcome Trust Programme, grant 082101/Z/07/Z, and the MRC, grant 0600002 to I.T.H.	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; AMANN RP, 1962, AM J ANAT, V110, P69, DOI 10.1002/aja.1001100107; Anderson RA, 2002, ENDOCR REV, V23, P735, DOI 10.1210/er.2002-0002; [Anonymous], 1990, Lancet, V336, P955; Aribarg A, 1996, FERTIL STERIL, V65, P821; CUNNINGHAM GR, 1979, ENDOCRINOLOGY, V105, P177, DOI 10.1210/endo-105-1-177; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GEISSLER WM, 1994, NAT GENET, V7, P34, DOI 10.1038/ng0594-34; Gu XQ, 2003, J CLIN ENDOCR METAB, V88, P562, DOI 10.1210/jc.2002-020447; Gu YQ, 2009, J CLIN ENDOCR METAB, V94, P1910, DOI 10.1210/jc.2008-1846; Guerif F, 2002, INT J ANDROL, V25, P358, DOI 10.1046/j.1365-2605.2002.00382.x; HAAVISTO AM, 1993, ENDOCRINOLOGY, V132, P1687, DOI 10.1210/en.132.4.1687; HANDELSMAN DJ, 1995, FERTIL STERIL, V63, P125, DOI 10.1016/S0015-0282(16)57307-5; Handelsman DJ, 1999, ENDOCRINOLOGY, V140, P3938, DOI 10.1210/en.140.9.3938; HUHTANIEMI I, 1985, J CLIN ENDOCR METAB, V61, P698, DOI 10.1210/jcem-61-4-698; Huhtaniemi I, 2010, PROG BRAIN RES, V181, P273, DOI 10.1016/S0079-6123(08)81015-1; Ilani N, 2011, ASIAN J ANDROL, V13, P579, DOI 10.1038/aja.2010.133; KORENBROT CC, 1977, BIOL REPROD, V17, P298, DOI 10.1095/biolreprod17.2.298; Matthiesson KL, 2005, J CLIN ENDOCR METAB, V90, P5647, DOI 10.1210/jc.2005-0639; MCLACHLAN RI, 1995, TRENDS ENDOCRIN MET, V6, P95, DOI 10.1016/1043-2760(94)00215-P; McLachlan RI, 2002, J ANDROL, V23, P149; Meriggiola MC, 1996, J CLIN ENDOCR METAB, V81, P3018, DOI 10.1210/jc.81.8.3018; Mustonen MVJ, 1997, BIOCHEM J, V325, P199, DOI 10.1042/bj3250199; Narula A, 2002, J CLIN ENDOCR METAB, V87, P3399, DOI 10.1210/jc.87.7.3399; Nieschlag E, 2010, Handb Exp Pharmacol, P197, DOI 10.1007/978-3-642-02062-9_11; Nixon JP, 2010, OBESITY, V18, P1652, DOI 10.1038/oby.2009.471; O'Donnell L., 2012, TESTOSTERONE ACTION; Ogawa S, 1999, P NATL ACAD SCI USA, V96, P12887, DOI 10.1073/pnas.96.22.12887; Owen LJ, 2012, ANN CLIN BIOCHEM, V49, P600, DOI 10.1258/acb.2012.012037; ROBERTS KP, 1991, ANN NY ACAD SCI, V637, P90, DOI 10.1111/j.1749-6632.1991.tb27303.x; RUSSELL LD, 1977, ANAT RECORD, V187, P347, DOI 10.1002/ar.1091870307; SANTULLI R, 1990, ENDOCRINOLOGY, V126, P95, DOI 10.1210/endo-126-1-95; Segatelli TM, 2004, J ANDROL, V25, P872; Sharpe Richard M., 1994, P1363; Shetty G, 2000, ENDOCRINOLOGY, V141, P1735, DOI 10.1210/en.141.5.1735; SINGH J, 1995, ENDOCRINOLOGY, V136, P5311, DOI 10.1210/en.136.12.5311; STEINBERGER E, 1971, PHYSIOL REV, V51, P1, DOI 10.1152/physrev.1971.51.1.1; SUN YT, 1989, ENDOCRINOLOGY, V125, P1000, DOI 10.1210/endo-125-2-1000; TURNER TT, 1984, ENDOCRINOLOGY, V115, P1925, DOI 10.1210/endo-115-5-1925; van Casteren JIJ, 2000, BIOL REPROD, V62, P886, DOI 10.1095/biolreprod62.4.886; WALLACE EM, 1993, J CLIN ENDOCR METAB, V77, P290, DOI 10.1210/jc.77.1.290; Weiss J, 1999, LAB ANIM, V33, P192, DOI 10.1258/002367799780578417; WING TY, 1982, AM J ANAT, V165, P13, DOI 10.1002/aja.1001650103; Zhang FP, 2003, P NATL ACAD SCI USA, V100, P13692, DOI 10.1073/pnas.2232815100; Zhang FP, 2001, MOL ENDOCRINOL, V15, P172, DOI 10.1210/me.15.1.172	45	17	17	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2566	2576		10.1096/fj.13-249219	http://dx.doi.org/10.1096/fj.13-249219			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24599970	Green Published, hybrid			2022-12-28	WOS:000339883600016
J	Vianello, S; Consolaro, F; Bich, C; Cancela, JM; Roulot, M; Lanchec, E; Touboul, D; Brunelle, A; Israel, M; Benoit, E; de la Porte, S				Vianello, Sara; Consolaro, Francesca; Bich, Claudia; Cancela, Jose-Manuel; Roulot, Morgane; Lanchec, Erwan; Touboul, David; Brunelle, Alain; Israel, Maurice; Benoit, Evelyne; de la Porte, Sabine			Low doses of arginine butyrate derivatives improve dystrophic phenotype and restore membrane integrity in DMD models	FASEB JOURNAL			English	Article						mdx; mass spectrometry imaging; neuromuscular excitability; calcium homeostasis	DUCHENNE MUSCULAR-DYSTROPHY; ION MASS-SPECTROMETRY; MDX MOUSE MODEL; BETA-HEMOGLOBINOPATHIES; DECREASES INFLAMMATION; SKELETAL MYOTUBES; GENE-EXPRESSION; MUSCLE; CALCIUM; MICE	A new approach to treating Duchenne muscular dystrophy was investigated by using the ester or amide covalent association of arginine [nitric oxide (NO) pathway] and butyrate [histone deacetylase (HDAC) inhibition] in mdx mice and patient myotubes. Two prodrugs were synthesized, and the beneficial effects on dystrophic phenotype were studied. Nerve excitability abnormalities detected in saline-treated mice were almost totally rescued in animals treated at low doses (50-100 mg/kg/d). Force and fatigue resistance were improved approximate to 60% and 3.5-fold, respectively, and the percentage of necrosis in heart sections was reduced approximate to 90% in the treated mice. A decrease of >50% in serum creatine kinase indicated an overall improvement in the muscles. Restoration of membrane integrity was studied directly by measuring the reduction (approximate to 74%) of Evans blue incorporation in the limb muscles of the treated animals, the increase in utrophin level, and the normalization of lipid composition of the heart. In cultures of human myotubes (primary cells and cell line), both prodrugs and HDAC inhibitors increased by 2- to 4-fold the utrophin level, which was correctly localized at the membrane. beta-Dystroglycan and embryonic myosin protein levels were also increased. Finally, a 50% reduction in the number of spontaneous Ca2+ spikes was observed after treatment with NO synthase substrate and HDAC inhibitors. Overall, the beneficial effects were obtained with doses 10 (in vivo) and 5 (in vitro) times lower than those of the salt formulation. Altogether, these data constitute proof of principle of the beneficial effects of low doses of arginine butyrate derivatives on muscular dystrophy, enhancing the NO pathway and inhibiting HDAC.	[Vianello, Sara; Consolaro, Francesca; Roulot, Morgane; Israel, Maurice; Benoit, Evelyne; de la Porte, Sabine] CNRS, Inst Neurobiol Alfred Fessard, FRC 2118, UPR 3294, F-91198 Gif Sur Yvette, France; [Bich, Claudia; Lanchec, Erwan; Touboul, David] CNRS, Ctr Rech Gif, Inst Chim Subst Nat, UPR 2301, F-91198 Gif Sur Yvette, France; [Cancela, Jose-Manuel; Lanchec, Erwan] Univ Paris 11, CNRS, Ctr Neurosci Paris Sud, UMR 8195, Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Universite Jean Monnet	de la Porte, S (corresponding author), CNRS, Inst Neurobiol Alfred Fessard, UPR 3294, Ave Terrasse,Bat 32-33, F-91198 Gif Sur Yvette, France.	sabine.delaporte@inaf.cnrs-gif.fr	de la Porte, Sabine/N-5275-2018; de la PORTE, Sabine/AAE-4208-2022; Brunelle, Alain/L-3889-2013	de la PORTE, Sabine/0000-0002-7725-8646; Brunelle, Alain/0000-0001-6526-6481; Bich, Claudia/0000-0002-8243-4018; Cancela, Jose-Manuel/0000-0002-6234-1500; Touboul, David/0000-0003-2751-774X; BENOIT, Evelyne/0000-0001-5501-0888	Eusopean Community (EC) [QLRI-CT-2002-02769]	Eusopean Community (EC)	The authors thank Dr. D. Boerio for having introduced the techniques of recording neuromuscular excitability to their laboratory; Kamel Mamchaoui (Hopital Pitie-Salpetriere, Paris, France) for technical help with the cell line cultures; the French Banque de Tissus pour la Recherche (BTR; Institut de Myologie, Paris, France) for providing human muscles; and Drs. Vincent Mouly (Hopital Pitie-Salpetriere, Paris, France) and Francesco Muntoni (Centre for Neuromuscular Disease, London, UK) for providing the human cell lines. The BTR is a partner of the EuroBioBank network funded by the Eusopean Community (EC) under the Fifth Framework Program (QLRI-CT-2002-02769). The authors declare no conflicts of interest.	Altamirano F, 2012, J BIOL CHEM, V287, P20876, DOI 10.1074/jbc.M112.344929; Banks GB, 2009, MOL CELL NEUROSCI, V40, P433, DOI 10.1016/j.mcn.2008.12.011; Benabdellah F, 2009, NEUROBIOL DIS, V36, P252, DOI 10.1016/j.nbd.2009.07.013; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Boerio D, 2009, J PERIPHER NERV SYST, V14, P45, DOI 10.1111/j.1529-8027.2009.00205.x; Bostock H, 1998, MUSCLE NERVE, V21, P137, DOI 10.1002/(SICI)1097-4598(199802)21:2<137::AID-MUS1>3.0.CO;2-C; Consalvi S, 2013, MOL MED, V19, P79, DOI 10.2119/molmed.2013.00011; Constantin B, 2006, J MUSCLE RES CELL M, V27, P375, DOI 10.1007/s10974-006-9085-2; Fairclough RJ, 2011, EXP PHYSIOL, V96, P1101, DOI 10.1113/expphysiol.2010.053025; Finkel RS, 2010, J CHILD NEUROL, V25, P1158, DOI 10.1177/0883073810371129; Fisher R, 2001, NEUROMUSCULAR DISORD, V11, P713, DOI 10.1016/S0960-8966(01)00220-6; Gordon BS, 2013, CLIN NUTR, V32, P104, DOI 10.1016/j.clnu.2012.06.003; Goyenvalle A, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-8; Gurpur PB, 2009, AM J PATHOL, V174, P999, DOI 10.2353/ajpath.2009.080537; Hnia K, 2008, AM J PATHOL, V172, P1509, DOI 10.2353/ajpath.2008.071009; Hori YS, 2011, J PHARMACOL EXP THER, V338, P784, DOI 10.1124/jpet.111.183210; Kikuchi K, 2012, ANNU REV CELL DEV BI, V28, P719, DOI 10.1146/annurev-cellbio-101011-155739; Marchand E, 2004, EXP CELL RES, V297, P363, DOI 10.1016/j.yexcr.2004.02.032; Marques MJ, 2007, ANAT REC, V290, P181, DOI 10.1002/ar.20421; Meregalli M, 2010, BIODRUGS, V24, P237, DOI 10.2165/11534300-000000000-00000; Minetti GC, 2006, NAT MED, V12, P1147, DOI 10.1038/nm1479; Ozawa E, 1999, MOL CELL BIOCHEM, V190, P143, DOI 10.1023/A:1006974613418; PERRINE SP, 1993, EXPERIENTIA, V49, P133, DOI 10.1007/BF01989417; Perrine SP, 2008, PEDIATR ANN, V37, P339, DOI 10.3928/00904481-20080501-10; Perrine SR, 2007, BLOOD, V109, P2571, DOI 10.1182/blood-2006-01-024703; Pichavant C, 2011, MOL THER, V19, P830, DOI 10.1038/mt.2011.59; Quinlan JG, 2004, NEUROMUSCULAR DISORD, V14, P491, DOI 10.1016/j.nmd.2004.04.007; Simplicio AL, 2008, MOLECULES, V13, P519, DOI 10.3390/molecules13030519; Spurney CF, 2008, NEUROMUSCULAR DISORD, V18, P371, DOI 10.1016/j.nmd.2008.03.008; Tahallah N, 2008, J LIPID RES, V49, P438, DOI 10.1194/jlr.M700421-JLR200; Touboul D, 2005, J LIPID RES, V46, P1388, DOI 10.1194/jlr.M500058-JLR200; Touboul D, 2004, EUR J MASS SPECTROM, V10, P657, DOI 10.1255/ejms.671; Vianello S, 2013, FASEB J, V27, P2256, DOI 10.1096/fj.12-215723; Weinberg RS, 2005, BLOOD, V105, P1807, DOI 10.1182/blood-2004-02-0454; Whitehead NP, 2006, CLIN EXP PHARMACOL P, V33, P657, DOI 10.1111/j.1440-1681.2006.04394.x; Yiu EM, 2008, NEUROL INDIA, V56, P236	36	10	10	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2603	2619		10.1096/fj.13-244798	http://dx.doi.org/10.1096/fj.13-244798			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24604079				2022-12-28	WOS:000339883600019
J	Wu, XD; Qi, X; Liang, MF; Li, C; Cardona, CJ; Li, DX; Xing, Z				Wu, Xiaodong; Qi, Xian; Liang, Mifang; Li, Chuan; Cardona, Carol J.; Li, Dexin; Xing, Zheng			Roles of viroplasm-like structures formed by nonstructural protein NSs in infection with severe fever with thrombocytopenia syndrome virus	FASEB JOURNAL			English	Article						nucleoprotein; viral replication; bunyavirus	HEPATITIS-C VIRUS; LIPID DROPLETS; BUNYAMWERA-VIRUS; FATTY-ACID; VIRAL-RNA; ROTAVIRUS REPLICATION; DOWN-REGULATION; CORE PROTEIN; KINASE PKR; IN-VIVO	Severe fever with thrombocytopenia syndrome (SFTS) virus is an emerging bunyavirus that causes a hemorrhagic fever with a high mortality rate. The virus is likely tick-borne and replicates primarily in hemopoietic cells, which may lead to disregulation of proinflammatory cytokine induction and loss of leukocytes and platelets. The viral genome contains L, M, and S segments encoding a viral RNA polymerase, glycoproteins G(n) and G(c), nucleoprotein (NP), and a nonstructural S segment (NSs) protein. NSs protein is involved in the regulation of host innate immune responses and suppression of IFN beta-promoter activities. In this article, we demonstrate that NSs protein can form viroplasm-like structures (VLSs) in infected and transfected cells. NSs protein molecules interact with one another, interact with NP, and were associated with viral RNA in infected cells, suggesting that NSs protein may be involved in viral replication. Furthermore, we observed that NSs-formed VLS colocalized with lipid droplets and that inhibitors of fatty acid biosynthesis decreased VLS formation or viral replication in transfected and infected cells. Finally, we have demonstrated that viral dsRNAs were also localized in VLS in infected cells, suggesting that NSs-formed VLS may be implicated in the replication of SFTS bunyavirus. These findings identify a novel function of nonstructural NSs in SFTSV-infected cells where it is a scaffolding component in a VLS functioning as a virus replication factory. This function is in addition to the role of NSs protein in modulating host responses that will broaden our understanding of viral pathogenesis of phleboviruses.	[Wu, Xiaodong; Xing, Zheng] Nanjing Univ, Sch Med, Nanjing 210008, Jiangsu, Peoples R China; [Wu, Xiaodong; Xing, Zheng] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210008, Jiangsu, Peoples R China; [Wu, Xiaodong; Xing, Zheng] Nanjing Univ, Jiangsu Key Lab Mol Med, Nanjing 210008, Jiangsu, Peoples R China; [Qi, Xian] Jiangsu Prov Ctr Dis Prevent & Control, Nanjing, Jiangsu, Peoples R China; [Liang, Mifang; Li, Chuan; Li, Dexin] China Ctr Dis Prevent & Control, Beijing, Peoples R China; [Cardona, Carol J.; Xing, Zheng] Univ Minnesota, St Paul, MN 55108 USA	Nanjing University; Nanjing University; Nanjing University; Chinese Center for Disease Control & Prevention; University of Minnesota System; University of Minnesota Twin Cities	Xing, Z (corresponding author), Univ Minnesota, 300D Vet Sci Bldg,1971 Commonwealth Ave, St Paul, MN 55108 USA.	zxing@umn.edu	Xing, Zheng/G-8366-2011; Xing, Zheng/O-3137-2015	Xing, Zheng/0000-0002-7288-0268; Xing, Zheng/0000-0002-7288-0268	Minnesota Rapid Agricultural Response Fund (RARF); Vice President Office of Research (VPOR), University of Minnesota at Twin Cities; State Key Laboratory of Pharmaceutical Biotechnology of Nanjing University [KF-GN-201407]; Jiangsu Province Key Medical Talent Foundation [RC2011084]; Natural Science Foundation of Jiangsu Province [BK20131450]; 333 Projects of Jiangsu Province	Minnesota Rapid Agricultural Response Fund (RARF); Vice President Office of Research (VPOR), University of Minnesota at Twin Cities; State Key Laboratory of Pharmaceutical Biotechnology of Nanjing University; Jiangsu Province Key Medical Talent Foundation; Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); 333 Projects of Jiangsu Province	This work was supported by the Minnesota Rapid Agricultural Response Fund (RARF) and a grant-in-aid (to Z.X.) from the Vice President Office of Research (VPOR), University of Minnesota at Twin Cities. It was also supported by the State Key Laboratory of Pharmaceutical Biotechnology of Nanjing University (grant KF-GN-201407 to Z.X.), and the Jiangsu Province Key Medical Talent Foundation (RC2011084), the Natural Science Foundation of Jiangsu Province (BK20131450), and the 333 Projects of Jiangsu Province (to X.Q.).	ALTENBURG BC, 1980, J GEN VIROL, V46, P75, DOI 10.1099/0022-1317-46-1-75; Billecocq A, 2004, J VIROL, V78, P9798, DOI 10.1128/JVI.78.18.9798-9806.2004; Billecocq A, 2008, VIROLOGY, V378, P377, DOI 10.1016/j.virol.2008.05.033; BISHOP DHL, 1986, ADV VIRUS RES, V31, P1, DOI 10.1016/S0065-3527(08)60261-4; Blakqori G, 2003, J GEN VIROL, V84, P1207, DOI 10.1099/vir.0.18876-0; Boulant S, 2007, J GEN VIROL, V88, P2204, DOI 10.1099/vir.0.82898-0; Bouloy M, 2001, J VIROL, V75, P1371, DOI 10.1128/JVI.75.3.1371-1377.2001; Bridgen A, 2001, P NATL ACAD SCI USA, V98, P664, DOI 10.1073/pnas.98.2.664; Cheung W, 2010, J VIROL, V84, P6782, DOI 10.1128/JVI.01757-09; Contin R, 2010, J GEN VIROL, V91, P1782, DOI 10.1099/vir.0.019133-0; Eichwald C, 2004, J GEN VIROL, V85, P625, DOI 10.1099/vir.0.19611-0; Fabbretti E, 1999, J GEN VIROL, V80, P333, DOI 10.1099/0022-1317-80-2-333; Fontana J, 2008, CELL MICROBIOL, V10, P2012, DOI 10.1111/j.1462-5822.2008.01184.x; Gai ZT, 2012, J INFECT DIS, V206, P1095, DOI 10.1093/infdis/jis472; Gaunt ER, 2013, J GEN VIROL, V94, P1576, DOI 10.1099/vir.0.049635-0; Gaunt ER, 2013, J GEN VIROL, V94, P1310, DOI 10.1099/vir.0.050146-0; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; Habjan M, 2008, J GEN VIROL, V89, P2157, DOI 10.1099/vir.0.2008/002097-0; Habjan M, 2009, J VIROL, V83, P4365, DOI 10.1128/JVI.02148-08; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Ikegami T, 2006, J VIROL, V80, P2933, DOI 10.1128/JVI.80.6.2933-2940.2006; Ikegami T, 2005, J VIROL, V79, P5606, DOI 10.1128/JVI.79.9.5606-5615.2005; Ikegami T, 2009, ANN NY ACAD SCI, V1171, pE75, DOI 10.1111/j.1749-6632.2009.05054.x; Ikegami T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000287; Kalveram B, 2013, VIROLOGY, V435, P415, DOI 10.1016/j.virol.2012.09.031; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Kumar Y, 2006, CURR BIOL, V16, P1646, DOI 10.1016/j.cub.2006.06.060; Le May N, 2004, CELL, V116, P541, DOI 10.1016/S0092-8674(04)00132-1; McMullan LK, 2012, NEW ENGL J MED, V367, P834, DOI 10.1056/NEJMoa1203378; Metcalfe MJ, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.70; Miyanari Y, 2007, NAT CELL BIOL, V9, P1089, DOI 10.1038/ncb1631; Netherton C, 2007, ADV VIRUS RES, V70, P101, DOI 10.1016/S0065-3527(07)70004-0; Netherton CL, 2011, CURR OPIN VIROL, V1, P381, DOI 10.1016/j.coviro.2011.09.008; Novoa RR, 2005, BIOL CELL, V97, P147, DOI 10.1042/BC20040058; Pizer ES, 2000, CANCER RES, V60, P213; Qu BQ, 2012, J VIROL, V86, P8388, DOI 10.1128/JVI.00612-12; REED L. J., 1938, AMER JOUR HYG, V27, P493; Samsa MM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000632; Schmaljohn C.S., 2007, FIELDS VIROLOGY, P1741; Shavinskaya A, 2007, J BIOL CHEM, V282, P37158, DOI 10.1074/jbc.M707329200; SIMONS JF, 1992, J VIROL, V66, P4233, DOI 10.1128/JVI.66.7.4233-4241.1992; Streitenfeld H, 2003, J VIROL, V77, P5507, DOI 10.1128/JVI.77.9.5507-5511.2003; Sun YL, 2012, J INFECT DIS, V206, P1085, DOI 10.1093/infdis/jis452; VANDELOOSDRECHT AA, 1994, J IMMUNOL METHODS, V174, P311, DOI 10.1016/0022-1759(94)90034-5; Weber F, 2002, J VIROL, V76, P7949, DOI 10.1128/JVI.76.16.7949-7955.2002; Weber F, 2001, VIROLOGY, V281, P67, DOI 10.1006/viro.2000.0774; Wu XD, 2014, J VIROL, V88, P3067, DOI 10.1128/JVI.03510-13; Xing Z, 2011, AM J RESP CELL MOL, V44, P24, DOI 10.1165/rcmb.2009-0120OC; Yadani FZ, 1999, J VIROL, V73, P5018, DOI 10.1128/JVI.73.6.5018-5025.1999; Yu XJ, 2011, NEW ENGL J MED, V364, P1523, DOI 10.1056/NEJMoa1010095; Zhang YZ, 2012, J VIROL, V86, P2864, DOI 10.1128/JVI.06192-11	51	48	55	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2504	2516		10.1096/fj.13-243857	http://dx.doi.org/10.1096/fj.13-243857			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24599967				2022-12-28	WOS:000339883600011
J	Kalbitz, M; Grailer, JJ; Fattahi, F; Jajou, L; Herron, TJ; Campbell, KF; Zetoune, FS; Bosmann, M; Sarma, JV; Huber-Lang, M; Gebhard, F; Loaiza, R; Valdivia, HH; Jalife, J; Russell, MW; Ward, PA				Kalbitz, Miriam; Grailer, Jamison J.; Fattahi, Fatemeh; Jajou, Lawrence; Herron, Todd J.; Campbell, Katherine F.; Zetoune, Firas S.; Bosmann, Markus; Sarma, J. Vidya; Huber-Lang, Markus; Gebhard, Florian; Loaiza, Randall; Valdivia, Hector H.; Jalife, Jose; Russell, Mark W.; Ward, Peter A.			Role of extracellular histones in the cardiomyopathy of sepsis	FASEB JOURNAL			English	Article						complement; NLRP3 inflammasome; cardiomyocytes; echocardiogram/Doppler; polymicrobial sepsis	VII-ACTIVATING PROTEASE; MAMMALIAN EPITHELIUM; DIASTOLIC FUNCTION; CECAL LIGATION; INDUCED DAMAGE; MECHANISMS; CALCIUM; HEART; MEDIATORS; TLR2	The purpose of this study was to define the relationship in polymicrobial sepsis (in adult male C57BL/6 mice) between heart dysfunction and the appearance in plasma of extracellular histones. Procedures included induction of sepsis by cecal ligation and puncture and measurement of heart function using echocardiogram/Doppler parameters. We assessed the ability of histones to cause disequilibrium in the redox status and intracellular [Ca2+](i) levels in cardiomyocytes (CMs) (from mice and rats). We also studied the ability of histones to disturb both functional and electrical responses of hearts perfused with histones. Main findings revealed that extracellular histones appearing in septic plasma required C5a receptors, polymorphonuclear leukocytes (PMNs), and the Nacht-, LRR-, and PYD-domains-containing protein 3 (NLRP3) inflammasome. In vitro exposure of CMs to histones caused loss of homeostasis of the redox system and in [Ca2+](i), as well as defects in mitochondrial function. Perfusion of hearts with histones caused electrical and functional dysfunction. Finally, in vivo neutralization of histones in septic mice markedly reduced the parameters of heart dysfunction. Histones caused dysfunction in hearts during polymicrobial sepsis. These events could be attenuated by histone neutralization, suggesting that histones may be targets in the setting of sepsis to reduce cardiac dysfunction.	[Kalbitz, Miriam; Grailer, Jamison J.; Fattahi, Fatemeh; Jajou, Lawrence; Zetoune, Firas S.; Sarma, J. Vidya; Ward, Peter A.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Russell, Mark W.] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; [Kalbitz, Miriam; Huber-Lang, Markus; Gebhard, Florian] Univ Hosp Ulm, Dept Orthopaed Trauma Hand Plast & Reconstruct Su, Ulm, Germany; [Herron, Todd J.; Campbell, Katherine F.; Loaiza, Randall; Valdivia, Hector H.; Jalife, Jose] Univ Michigan, Ctr Arrhythmia Res, Ann Arbor, MI 48109 USA; [Bosmann, Markus] Univ Med Ctr, Ctr Thrombosis & Hemostasis, Mainz, Germany; [Bosmann, Markus] Univ Med Ctr, Dept Hematol Oncol & Pneumol, Mainz, Germany	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Ulm University; University of Michigan System; University of Michigan; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd,7520 MSRB I,Box 5602, Ann Arbor, MI 48109 USA.	pward@umich.edu	Huber-Lang, Markus/AAJ-2209-2020; Jalife, Jose/L-4833-2015; Jalife, Jose/AAJ-9156-2021	Jalife, Jose/0000-0003-0080-3500; Jalife, Jose/0000-0003-0080-3500; Bosmann, Markus/0000-0003-2773-1033	U.S. National Institutes of Health (NIH) National Cancer Institute; O'Brien Renal Center; University of Michigan Medical School; Endowment for the Basic Sciences; Department of Cell and Developmental Biology (University of Michigan); NIH [GM-29507, GM-61656, T32-HL007517-29]; Deutsche Forschungsgemeinschaft [KA 3740, BO 3482/3-1, HU823/302]; Federal Ministry of Education and Research [01EO1003]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007517, R01HL122352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061656, R37GM029507, R01GM029507] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); O'Brien Renal Center; University of Michigan Medical School; Endowment for the Basic Sciences; Department of Cell and Developmental Biology (University of Michigan); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Rainer Muche (University of Ulm, Institute for Epidemiology and Biometric Medicine) for assistance with statistical analyses. They also thank Beverly Schumann, Sue Scott, Melissa Rennells, and Robin Kunkel for excellent assistance in the preparation of the manuscript. The authors acknowledge support from the Microscopy and Image-analysis Laboratory, which is a multiuser imaging facility supported by a grant from the U.S. National Institutes of Health (NIH) National Cancer Institute, the O'Brien Renal Center, the University of Michigan Medical School, by the Endowment for the Basic Sciences, and by the Department of Cell and Developmental Biology (University of Michigan). This study was supported by grants from the NIH (GM-29507 and GM-61656 to P.A.W. and T32-HL007517-29 to J.J.G.), the Deutsche Forschungsgemeinschaft Fellowship (Project KA 3740) to M.K., Deutsche Forschungsgemeinschaft (BO 3482/3-1) to M.B., Federal Ministry of Education and Research (01EO1003) to M.B., and Deutsche Forschungsgemeinschaft (HU823/302) to M.H.L. The authors declare no conflicts of interest.	Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC; Allam R, 2012, J AM SOC NEPHROL, V23, P1375, DOI 10.1681/ASN.2011111077; BAKER CC, 1983, SURGERY, V94, P331; Boluyt MO, 2004, J APPL PHYSIOL, V96, P822, DOI 10.1152/japplphysiol.01026.2003; Bosmann M, 2013, FASEB J, V27, P5010, DOI 10.1096/fj.13-236380; Boyd JH, 2006, CARDIOVASC RES, V72, P384, DOI 10.1016/j.cardiores.2006.09.011; Celes MRN, 2013, PATHOBIOLOGY, V80, P70, DOI 10.1159/000341640; Charpentier J, 2004, CRIT CARE MED, V32, P660, DOI 10.1097/01.CCM.0000114827.93410.D8; Denk S, 2012, EUR SURG RES, V48, P171, DOI 10.1159/000338194; Dessap AM, 2014, INTENS CARE MED, V40, P1746, DOI 10.1007/s00134-014-3428-z; Feng Y, 2011, INT J INFLAMM, V2011, DOI 10.4061/2011/170352; Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107; Gerard NP, 2005, J BIOL CHEM, V280, P39677, DOI 10.1074/jbc.C500287200; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Grailer JJ, 2014, J IMMUNOL, V192, P5974, DOI 10.4049/jimmunol.1400368; Hanson CJ, 2004, CURR BIOL, V14, pR933, DOI 10.1016/j.cub.2004.10.019; Hassoun SM, 2008, CRIT CARE MED, V36, P2590, DOI 10.1097/CCM.0b013e3181844276; Herron TJ, 2007, CIRC RES, V100, P1182, DOI 10.1161/01.RES.0000264102.00706.4e; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; JAFRI SM, 1990, CRIT CARE MED, V18, P709, DOI 10.1097/00003246-199007000-00005; Kaestner L, 2009, J VIS EXP; Kanse SM, 2012, J IMMUNOL, V188, P2858, DOI 10.4049/jimmunol.1103029; Kleine TJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1925, DOI 10.1152/ajpcell.1997.273.6.C1925; KLEINE TJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1114, DOI 10.1152/ajpcell.1995.268.5.C1114; Knowlton A. A., 2013, J CARDIOVASC PHARM; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P1389, DOI 10.1097/TA.0b013e318270d595; Louch WE, 2011, J MOL CELL CARDIOL, V51, P288, DOI 10.1016/j.yjmcc.2011.06.012; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Minamikawa T, 1999, J CELL SCI, V112, P2419; MONESTIER M, 1993, MOL IMMUNOL, V30, P1069, DOI 10.1016/0161-5890(93)90153-3; Munt B, 1998, CRIT CARE MED, V26, P1829, DOI 10.1097/00003246-199811000-00023; Nakahara M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075961; Oikonomopoulou K, 2012, SEMIN IMMUNOPATHOL, V34, P151, DOI 10.1007/s00281-011-0280-x; Ostrowski SR, 2013, J CRIT CARE, V28, P586, DOI 10.1016/j.jcrc.2013.04.010; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; Pieske B, 1999, CIRC RES, V85, P38; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214; Rudiger A, 2007, CRIT CARE MED, V35, P1599, DOI 10.1097/01.CCM.0000266683.64081.02; Rudiger A, 2013, CURR VASC PHARMACOL, V11, P187; Santos CXC, 2011, FREE RADICAL BIO MED, V50, P777, DOI 10.1016/j.freeradbiomed.2011.01.003; Semeraro F, 2011, BLOOD, V118, P1952, DOI 10.1182/blood-2011-03-343061; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Takasu O, 2013, AM J RESP CRIT CARE, V187, P509, DOI 10.1164/rccm.201211-1983OC; Tingare A, 2013, BIOCHEM SOC T, V41, P789, DOI 10.1042/BST20130012; Xu J, 2011, J IMMUNOL, V187, P2626, DOI 10.4049/jimmunol.1003930; Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053; Xu KY, 1997, CIRC RES, V80, P76, DOI 10.1161/01.RES.80.1.76; Yamamichi S, 2011, BIOCHEM BIOPH RES CO, V409, P483, DOI 10.1016/j.bbrc.2011.05.030; Zhang YX, 2012, FREE RADICAL BIO MED, V53, P1531, DOI 10.1016/j.freeradbiomed.2012.07.010; Zima AV, 2006, CARDIOVASC RES, V71, P310, DOI 10.1016/j.cardiores.2006.02.019	52	74	82	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2185	2193		10.1096/fj.14-268730	http://dx.doi.org/10.1096/fj.14-268730			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25681459	Green Published, Green Submitted			2022-12-28	WOS:000354114600048
J	Castro-Garcia, P; Diaz-Moreno, M; Gil-Gas, C; Fernandez-Gomez, FJ; Honrubia-Gomez, P; Alvarez-Simon, CB; Sanchez-Sanchez, F; Cano, JCC; Almeida, F; Blanco, V; Jordan, J; Mira, H; Ramirez-Castillejo, C				Castro-Garcia, Paola; Diaz-Moreno, Maria; Gil-Gas, Carmen; Fernandez-Gomez, Francisco J.; Honrubia-Gomez, Paloma; Belen Alvarez-Simon, Carmen; Sanchez-Sanchez, Francisco; Castillo Cano, Juan Carlos; Almeida, Francisco; Blanco, Vicente; Jordan, Joaquin; Mira, Helena; Ramirez-Castillejo, Carmen			Defects in subventricular zone pigmented epithelium-derived factor niche signaling in the senescence-accelerated mouse prone-8	FASEB JOURNAL			English	Article						self-renewal; neural stem cell; PEDF; accelerated senescence; long-term LRC	NEURAL STEM-CELLS; ADULT MAMMALIAN FOREBRAIN; MURINE MODEL; PAX6; BRAIN; MAINTENANCE; EXPRESSION; NEURONS; CANCER; PEDF	We studied potential changes in the sub-ventricular zone (SVZ) stem cell niche of the senescence-accelerated mouse prone-8 (SAM-P8) aging model. Bromodeoxyuridine (BrdU) assays with longtime survival revealed a lower number of label-retaining stem cells in the SAM-P8 SVZ compared with the SAM-Resistant 1 (SAM-R1) control strain. We also found that in SAM-P8 niche signaling is attenuated and the stem cell pool is less responsive to the self-renewal niche factor pigmented epithelium-derived factor (PEDF). Protein analysis demonstrated stable amounts of the PEDF ligand in the SAM-P8 SVZ niche; however, SAM-P8 stem cells present a significant expression decrease of patatin-like phospholipase domain containing 2, a receptor for PEDF (PNPLA2-PEDF) receptor, but not of laminin receptor (LR), a receptor for PEDF (LR-PEDF) receptor. We observed changes in self-renewal related genes (hairy and enhancer of split 1 (Hes1), hairy and enhancer of split 1 (Hes5), Sox2] and report that although these genes are down-regulated in SAM-P8, differentiation genes (Pax6) are up-regulated and neurogenesis is increased. Finally, sheltering mammalian telomere complexes might be also involved given a down-regulation of telomeric repeat binding factor 1 (Terf1) expression was observed in SAM-P8 at young age periods. Differences between these 2 models, SAM-P8 and SAM-R1 controls, have been previously detected at more advanced ages. We now describe alterations in the PEDF signaling pathway and stem cell self-renewal at a very young age, which could be involved in the premature senescence observed in the SAM-P8 model.	[Castro-Garcia, Paola; Gil-Gas, Carmen; Honrubia-Gomez, Paloma; Belen Alvarez-Simon, Carmen; Ramirez-Castillejo, Carmen] Univ Castilla La Mancha, Ctr Reg Invest Biomed, Lab Celulas Madre, Albacete, Spain; [Diaz-Moreno, Maria; Mira, Helena] Inst Salud Carlos III, Unidad Func Invest Enfermedades Cron, Madrid, Spain; [Fernandez-Gomez, Francisco J.; Jordan, Joaquin] Univ Castilla La Mancha, Dept Ciencias Med, Grp Neurofarmacol, Albacete, Spain; [Sanchez-Sanchez, Francisco] Univ Castilla La Mancha, Fac Med Albacete, Area Genet, Albacete, Spain; [Sanchez-Sanchez, Francisco; Jordan, Joaquin] Univ Castilla La Mancha, Inst Invest Discapacidades Neurol, Albacete, Spain; [Castillo Cano, Juan Carlos; Almeida, Francisco; Blanco, Vicente] Univ La Laguna, Dept Estadis IO & Computac, E-38207 San Cristobal la Laguna, Canarias, Spain	Universidad de Castilla-La Mancha; Instituto de Salud Carlos III; Unidad Funcional de Investigacion de Enfermedades Cronicas (UFIEC); Universidad de Castilla-La Mancha; Universidad de Castilla-La Mancha; Universidad de Castilla-La Mancha; Universidad de la Laguna	Ramirez-Castillejo, C (corresponding author), 12 October Hosp UFIEC, ISCIII, Carretera Majadahonda Pozuelo Km 2, Madrid 28220, Spain.	cramirezcastillejo@externos.isciii.es	, francisco/ABF-7718-2021; Fernández-Gómez, Francisco José/GOP-0463-2022; Castro-Garcia, Paola/GMX-3341-2022; Blanco, Vicente/K-9678-2014; Ramirez-Castillejo, Carmen/S-7276-2019; Almeida, Francisco/L-1746-2014	Blanco, Vicente/0000-0003-1166-6310; Ramirez-Castillejo, Carmen/0000-0002-1877-3381; Almeida, Francisco/0000-0002-1279-9636; Fernandez-Gomez, Francisco Jose/0000-0002-7891-8634; Mira, Helena/0000-0001-8574-9544	Asociacion Espanola Contra el Cancer; program of the Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria) [PI081746]; Ministerio de Sanidad y Consumo [04005-00]; Consejeria de Sanidad from Junta de Comunidades de Castilla-La Mancha [PI2007/55]; Comision Interministerial de Ciencia y Tecnologia [SAF2008-05143-C03-1]; Spanish Ministerio de Economia y Competitividad, Fondo de Investigacion Sanitaria [PI12/101]; Comunidad de Madrid [S2010/BMD-2336]; Consejo Nacional de Ciencia y Tecnologia; Spanish Ministerio de Educacion;  [205933]	Asociacion Espanola Contra el Cancer; program of the Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria); Ministerio de Sanidad y Consumo(Instituto de Salud Carlos III); Consejeria de Sanidad from Junta de Comunidades de Castilla-La Mancha(Junta de Comunidades de Castilla-La Mancha); Comision Interministerial de Ciencia y Tecnologia(Consejo Interinstitucional de Ciencia y Tecnologia (CICYT)); Spanish Ministerio de Economia y Competitividad, Fondo de Investigacion Sanitaria; Comunidad de Madrid(Comunidad de Madrid); Consejo Nacional de Ciencia y Tecnologia(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Spanish Ministerio de Educacion(Spanish Government); 	The authors thank Rafael Hortiguela for technical support. This work was supported by grants from the Asociacion Espanola Contra el Cancer, the program of the Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria PI081746), and Ministerio de Sanidad y Consumo (04005-00), the Consejeria de Sanidad from Junta de Comunidades de Castilla-La Mancha (PI2007/55); Grant SAF2008-05143-C03-1 from Comision Interministerial de Ciencia y Tecnologia to J.J. and Grant PI12/101 from the Spanish Ministerio de Economia y Competitividad, Fondo de Investigacion Sanitaria and S2010/BMD-2336 from Comunidad de Madrid to H.M. C.R.C. was investigator of the "Ramon y Cajal Programme" from the Spanish "Ministerio de Educacion y Ciencia". P.C.G. has a Consejo Nacional de Ciencia y Tecnologia fellowship for foreign study (Mexico City, Mexico); ID Scholarship 205933. M.D.M. is a recipient of a predoctoral fellowship (FPU) from the Spanish Ministerio de Educacion. The authors declare that no competing financial interests exist and also declare no sources of funding and no contracts relating to this research.	Alvarez-Buylla A, 2002, BRAIN RES BULL, V57, P751, DOI 10.1016/S0361-9230(01)00770-5; Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Andreu-Agullo C, 2009, NAT NEUROSCI, V12, P1514, DOI 10.1038/nn.2437; Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002; Batista LFZ, 2014, PROG MOL BIOL TRANSL, V125, P67, DOI 10.1016/B978-0-12-397898-1.00003-7; Bernard A, 2009, J BIOL CHEM, V284, P10480, DOI 10.1074/jbc.M809259200; Blasco M. A., 2014, INT S ADV ONC THER R; Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.3.CO;2-D; Carlson ME, 2007, AGING CELL, V6, P371, DOI 10.1111/j.1474-9726.2007.00286.x; Castillo CA, 2009, EXP GERONTOL, V44, P453, DOI 10.1016/j.exger.2009.04.006; Castillo J. C., 2014, 1 WORKSH APPL PAR CO; Chambers SM, 2007, PLOS BIOL, V5, P1750, DOI 10.1371/journal.pbio.0050201; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Diaz-Moreno M, 2013, NEUROBIOL AGING, V34, P2623, DOI 10.1016/j.neurobiolaging.2013.05.011; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1997, J NEUROSCI, V17, P5046; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Donate LE, 2011, PHILOS T R SOC B, V366, P76, DOI 10.1098/rstb.2010.0291; Ehm O, 2010, J NEUROSCI, V30, P13794, DOI 10.1523/JNEUROSCI.1567-10.2010; Favaro R, 2009, NAT NEUROSCI, V12, P1248, DOI 10.1038/nn.2397; Flood JF, 1998, NEUROSCI BIOBEHAV R, V22, P1; Galli R, 2003, CIRC RES, V92, P598, DOI 10.1161/01.RES.0000065580.02404.F4; Gang BZ, 2011, BRAIN RES, V1389, P183, DOI 10.1016/j.brainres.2011.03.039; Gomez-Lopez S, 2011, GLIA, V59, P1588, DOI 10.1002/glia.21201; Gritti A, 2002, J NEUROSCI, V22, P437, DOI 10.1523/JNEUROSCI.22-02-00437.2002; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Fernandez-Gomez FJ, 2008, CHEM-BIOL INTERACT, V175, P332, DOI 10.1016/j.cbi.2008.05.010; Fernandez-Gomez FJ, 2010, J NEUROSCI RES, V88, P155, DOI 10.1002/jnr.22177; Kallos MS, 1999, BIOTECHNOL BIOENG, V65, P589, DOI 10.1002/(SICI)1097-0290(19991205)65:5<589::AID-BIT12>3.0.CO;2-S; Kioussi C, 1999, P NATL ACAD SCI USA, V96, P14378, DOI 10.1073/pnas.96.25.14378; Klapper W, 2001, J NEUROSCI RES, V64, P252, DOI 10.1002/jnr.1073.abs; Kohwi M, 2005, J NEUROSCI, V25, P6997, DOI 10.1523/JNEUROSCI.1435-05.2005; Kojima T, 2006, MOL CELL BIOCHEM, V293, P63, DOI 10.1007/s11010-006-2680-0; Kuimov AN, 2004, BIOCHEMISTRY-MOSCOW+, V69, P117, DOI 10.1023/B:BIRY.0000018941.81962.1c; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Manuel M, 2005, BRAIN RES BULL, V66, P387, DOI 10.1016/j.brainresbull.2005.02.006; Martinez P, 2011, NAT REV CANCER, V11, P161, DOI 10.1038/nrc3025; Martinez P, 2010, AGING CELL, V9, P653, DOI 10.1111/j.1474-9726.2010.00596.x; Martinez P, 2009, GENE DEV, V23, P2060, DOI 10.1101/gad.543509; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Notari L, 2006, J BIOL CHEM, V281, P38022, DOI 10.1074/jbc.M600353200; Osumi N, 2001, TOHOKU J EXP MED, V193, P163, DOI 10.1620/tjem.193.163; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Pernot F, 2010, J NEUROSCI RES, V88, P1000, DOI 10.1002/jnr.22282; Porlan E, 2013, NAT NEUROSCI, V16, P1567, DOI 10.1038/nn.3545; Pumiglia K, 2006, NAT NEUROSCI, V9, P299, DOI 10.1038/nn0306-299; Ramirez-Castillejo C, 2006, NAT NEUROSCI, V9, P331, DOI 10.1038/nn1657; Roobrouck VD, 2008, EXP CELL RES, V314, P1937, DOI 10.1016/j.yexcr.2008.03.006; Santos A, 2007, LECT NOTES COMPUT SC, V4758, P225; Sevigny JJ, 2008, NEUROLOGY, V71, P1702, DOI 10.1212/01.wnl.0000335163.88054.e7; Smith CP, 2007, EXP EYE RES, V85, P817, DOI 10.1016/j.exer.2007.08.017; Steinle JJ, 2008, J GERONTOL A-BIOL, V63, P135, DOI 10.1093/gerona/63.2.135; Takeda T, 1997, EXP GERONTOL, V32, P117, DOI 10.1016/S0531-5565(96)00068-X; Takeda T, 1997, EXP GERONTOL, V32, P105, DOI 10.1016/S0531-5565(96)00036-8; Tomobe K, 2005, PHYSIOL BEHAV, V84, P505, DOI 10.1016/j.physbeh.2004.12.012; Van Kirk CA, 2011, MOL VIS, V17, P1261; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7	59	6	6	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1480	1492		10.1096/fj.13-244442	http://dx.doi.org/10.1096/fj.13-244442			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25636741				2022-12-28	WOS:000354115000033
J	Sun, DW; Nakao, S; Xie, F; Zandi, S; Bagheri, A; Kanavi, MR; Samiei, S; Soheili, ZS; Frimmel, S; Zhang, ZY; Ablonczy, Z; Ahmadieh, H; Hafezi-Moghadam, A				Sun, Dawei; Nakao, Shintaro; Xie, Fang; Zandi, Souska; Bagheri, Abouzar; Kanavi, Mozhgan Rezaei; Samiei, Shahram; Soheili, Zahra-Soheila; Frimmel, Sonja; Zhang, Zhongyu; Ablonczy, Zsolt; Ahmadieh, Hamid; Hafezi-Moghadam, Ali			Molecular imaging reveals elevated VEGFR-2 expression in retinal capillaries in diabetes: a novel biomarker for early diagnosis	FASEB JOURNAL			English	Article						retinopathy; endothelial injury; probe development; preventive care	ENDOTHELIAL GROWTH-FACTOR; METABOLIC SYNDROME; RETINOPATHY; VESSELS; LEUKOCYTE; INJURY; MODEL	Diabetic retinopathy (DR) is a microvascular complication of diabetes and a leading cause of vision loss. Biomarkers and methods for early diagnosis of DR are urgently needed. Using a new molecular imaging approach, we show up to 94% higher accumulation of custom designed imaging probes against vascular endothelial growth factor receptor 2 (VEGFR-2) in retinal and choroidal vessels of diabetic animals (P<0.01), compared to normal controls. More than 80% of the VEGFR-2 in the diabetic retina was in the capillaries, compared to 47% in normal controls (P<0.01). Angiography in rabbit retinas revealed microvascular capillaries to be the location for VEGF-A-induced leakage, as expressed by significantly higher rate of fluorophore spreading with VEGF-A injection when compared to vehicle control (26 +/- 2 vs. 3 +/- 1 mu m/s, P<0.05). Immunohistochemistry showed VEGFR-2 expression in capillaries of diabetic animals but not in normal controls. Macular vessels from diabetic patients (n=7) showed significantly more VEGFR-2 compared to nondiabetic controls (n=5) or peripheral retinal regions of the same retinas (P<0.01 in both cases). Here we introduce a new approach for early diagnosis of DR and VEGFR-2 as a molecular marker. VEGFR-2 could become a key diagnostic target, one that might help to prevent retinal vascular leakage and proliferation in diabetic patients.	[Sun, Dawei; Nakao, Shintaro; Xie, Fang; Zandi, Souska; Frimmel, Sonja; Zhang, Zhongyu; Hafezi-Moghadam, Ali] Brigham & Womens Hosp, Ctr Excellence Funct & Mol Imaging, Boston, MA 02115 USA; [Sun, Dawei; Nakao, Shintaro; Xie, Fang; Zandi, Souska; Frimmel, Sonja; Zhang, Zhongyu; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Sun, Dawei; Nakao, Shintaro; Xie, Fang; Zandi, Souska; Frimmel, Sonja; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; [Sun, Dawei; Nakao, Shintaro; Xie, Fang; Zandi, Souska; Frimmel, Sonja; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA; [Sun, Dawei; Xie, Fang] Harbin Med Univ, Affiliated Hosp 2, Dept Ophthalmol, Harbin, Peoples R China; [Bagheri, Abouzar; Kanavi, Mozhgan Rezaei; Ahmadieh, Hamid] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran; [Samiei, Shahram] High Inst Res & Educ Transfus Med, Blood Transfus Res Ctr, Tehran, Iran; [Soheili, Zahra-Soheila] Natl Inst Genet Engn & Biotechnol, Tehran, Iran; [Ablonczy, Zsolt] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary; Harbin Medical University; Shahid Beheshti University Medical Sciences; Medical University of South Carolina	Hafezi-Moghadam, A (corresponding author), Brigham & Womens Hosp, 221 Longwood Ave, Boston, MA 02115 USA.	ahm@bwh.harvard.edu	Ahmadieh, Hamid/M-4853-2017; Kanavi, Mozhgan Rezaei/AAX-9617-2020; Bagheri, Abouzar/I-3673-2018; Soheili, Zahra-Soheila/W-8316-2018	Ahmadieh, Hamid/0000-0002-8139-2661; Kanavi, Mozhgan Rezaei/0000-0002-1497-2260; Bagheri, Abouzar/0000-0001-8040-5056; Zandi, Souska/0000-0001-9351-4278; Hafezi-Moghadam, Ali/0000-0002-5336-0697; Soheili, Zahra-Soheila/0000-0003-1292-465X	U.S. National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases through Diabetes Complications Consortium award [25732-30]; BrightFocus Foundation; Malaysian Palm Oil Board; National Natural Science Foundation of China grant [81171381]; Heilongjiang [LC2011C27]; NIH/National Eye Institute [R01-EY019065]; Research to Prevent Blindness; South Carolina Lions Association; NATIONAL EYE INSTITUTE [R01EY019065] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases through Diabetes Complications Consortium award; BrightFocus Foundation(BrightFocus Foundation); Malaysian Palm Oil Board; National Natural Science Foundation of China grant(National Natural Science Foundation of China (NSFC)); Heilongjiang; NIH/National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Research to Prevent Blindness(Research to Prevent Blindness (RPB)); South Carolina Lions Association; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by the U.S. National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases through Diabetes Complications Consortium award 25732-30, the BrightFocus Foundation, the Malaysian Palm Oil Board, National Natural Science Foundation of China grant 81171381, Heilongjiang overseas fund grant LC2011C27, NIH/National Eye Institute grant R01-EY019065 (Z.A.), an unrestricted grant of Research to Prevent Blindness to the Department of Ophthalmology at the Medical University of South Carolina, and the South Carolina Lions Association. D. S., S.N., F.X., S.Z., A.B., M.R.K., S.S., Z.S.S., S.F., and Z.A. performed the research; D.S., S.N.,Z.S.S., H.A., and A.H.-M. analyzed the data; and A. H.-M. wrote the paper. The authors declare no conflicts of interest.	AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Frank RN, 2009, CURR OPIN INVEST DR, V10, P327; Garland RC, 2011, FASEB J, V25, P1284, DOI 10.1096/fj.10-160051; Hafezi-Moghadam A, 2004, AM J PHYSIOL-CELL PH, V286, pC876, DOI 10.1152/ajpcell.00500.2003; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; Hata Y, 2008, JPN J OPHTHALMOL, V52, P16, DOI 10.1007/s10384-007-0487-5; Ikram MK, 2013, DIABETES CARE, V36, P750, DOI 10.2337/dc12-1554; ISHIBASHI T, 1995, ARCH OPHTHALMOL-CHIC, V113, P227, DOI 10.1001/archopht.1995.01100020111041; ISHIBASHI T, 1993, BRIT J OPHTHALMOL, V77, P574, DOI 10.1136/bjo.77.9.574; Jardeleza MSR, 2009, SEMIN OPHTHALMOL, V24, P87, DOI 10.1080/08820530902800330; Leenders W, 2001, INT J CANCER, V91, P327, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1052>3.3.CO;2-N; Lorenzi M, 2001, DIABETOLOGIA, V44, P791, DOI 10.1007/s001250100544; Miyahara S, 2008, FASEB J, V22, P1973, DOI 10.1096/fj.07-096891; Murakami T, 2006, INVEST OPHTH VIS SCI, V47, P5529, DOI 10.1167/iovs.06-0373; Nakao S, 2011, BLOOD, V117, P1081, DOI 10.1182/blood-2010-02-267427; Noda K, 2014, FASEB J, V28, P2038, DOI 10.1096/fj.12-215715; Noda K, 2010, FASEB J, V24, P2443, DOI 10.1096/fj.09-152678; Sherwin R, 2012, J CLIN ENDOCR METAB, V97, P4293, DOI 10.1210/jc.2012-3487; Sun DW, 2010, FASEB J, V24, P1532, DOI 10.1096/fj.09-148981; Xie F, 2010, AM J PATHOL, V177, P39, DOI 10.2353/ajpath.2010.100007	22	15	15	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3942	3951		10.1096/fj.14-251934	http://dx.doi.org/10.1096/fj.14-251934			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24903276	Green Published			2022-12-28	WOS:000340845900012
J	Ganesh, SK; Morissette, R; Xu, Z; Schoenhoff, F; Griswold, BF; Yang, JD; Tong, L; Yang, ML; Hunker, K; Sloper, L; Kuo, SN; Raza, R; Milewicz, DM; Francomano, CA; Dietz, HC; Van Eyk, J; McDonnell, NB				Ganesh, Santhi K.; Morissette, Rachel; Xu, Zhi; Schoenhoff, Florian; Griswold, Benjamin F.; Yang, Jiandong; Tong, Lan; Yang, Min-Lee; Hunker, Kristina; Sloper, Leslie; Kuo, Shinie; Raza, Rafi; Milewicz, Dianna M.; Francomano, Clair A.; Dietz, Harry C.; Van Eyk, Jennifer; McDonnell, Nazli B.			Clinical and biochemical profiles suggest fibromuscular dysplasia is a systemic disease with altered TGF-10.1096/fj.14-251207 beta expression and connective tissue features	FASEB JOURNAL			English	Article						biomarker; FMD; TGF-beta; pathway aneurysm; human genetics	GROWTH-FACTOR-BETA; MAGNETIC-RESONANCE SCANS; EHLERS-DANLOS-SYNDROME; MARFAN-SYNDROME; RENOVASCULAR HYPERTENSION; ARTERIAL FIBRODYSPLASIA; ASYMPTOMATIC SUBJECTS; JOINT HYPERMOBILITY; CAROTID-ARTERY; DISORDERS	Fibromuscular dysplasia (FMD) is a rare, nonatherosclerotic arterial disease for which the molecular basis is unknown. We comprehensively studied 47 subjects with FMD, including physical examination, spine magnetic resonance imaging, bone densitometry, and brain magnetic resonance angiography. Inflammatory biomarkers in plasma and transforming growth factor beta (TGF-beta) cytokines in patient-derived dermal fibroblasts were measured by ELISA. Arterial pathology other than medial fibrodysplasia with multifocal stenosis included cerebral aneurysm, found in 12.8% of subjects. Extra-arterial pathology included low bone density (P< 0.001); early onset degenerative spine disease (95.7%); increased incidence of Chiari I malformation (6.4%) and dural ectasia (42.6%); and physical examination findings of a mild connective tissue dysplasia (95.7%). Screening for mutations causing known genetically mediated arteriopathies was unrevealing. We found elevated plasma TGF-beta 1 (P = 0.009), TGF-beta 2 (P = 0.004) and additional inflammatory markers, and increased TGF-beta 1 (P = 0.0009) and TGF-beta 2 (P = 0.0001) secretion in dermal fibroblast cell lines from subjects with FMD compared to age-and gender-matched controls. Detailed phenotyping of patients with FMD allowed us to demonstrate that FMD is a systemic disease with alterations in common with the spectrum of genetic syndromes that involve altered TGF-beta signaling and offers TGF-beta as a marker of FMD.	[Ganesh, Santhi K.; Tong, Lan; Yang, Min-Lee; Hunker, Kristina; Kuo, Shinie] Univ Michigan, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA; [Ganesh, Santhi K.; Tong, Lan; Yang, Min-Lee; Hunker, Kristina; Kuo, Shinie] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; [Morissette, Rachel; Xu, Zhi; Griswold, Benjamin F.; Yang, Jiandong; Sloper, Leslie; Raza, Rafi; McDonnell, Nazli B.] NIA, Lab Clin Invest, Baltimore, MD 21225 USA; [Schoenhoff, Florian; Van Eyk, Jennifer] Johns Hopkins Univ, Dept Med, Johns Hopkins Bayview Prote Ctr, Baltimore, MD USA; [Milewicz, Dianna M.] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Div Med Genet, Houston, TX 77030 USA; [Francomano, Clair A.] Greater Baltimore Med Ctr, Towson, MD USA; [Dietz, Harry C.] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Sch Med, Baltimore, MD USA; [Dietz, Harry C.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; University of Texas System; University of Texas Health Science Center Houston; Greater Baltimore Medical Center; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	McDonnell, NB (corresponding author), NIA, Clin Unit, 5th Floor,3001 S Hanover St, Baltimore, MD 21225 USA.	sganesh@umich.edu; nazli.mcdonnell@gmail.com		Yang, Min-Lee/0000-0003-2823-8320; Schoenhoff, Florian/0000-0002-3311-4595	Intramural Research Program of the U.S. National Institutes of Health (NIH), National Institute on Aging; University of Michigan [R00HL089413]; Johns Hopkins Institutional Clinical and Translational Science Award (CTSA) grant [1U54RR023561-01A1]; American Recovery and Reinvestment Act (ARRA) Novel Biomarkers in Aortic Aneurysms and Acute Aortic Dissection grant [5RC1HL100021-02]; National Heart, Lung, and Blood Institute/NIH [P30HL101290]; Doris Duke Charitable Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL089413, RC1HL100021, P30HL101290] Funding Source: NIH RePORTER	Intramural Research Program of the U.S. National Institutes of Health (NIH), National Institute on Aging; University of Michigan(University of Michigan System); Johns Hopkins Institutional Clinical and Translational Science Award (CTSA) grant; American Recovery and Reinvestment Act (ARRA) Novel Biomarkers in Aortic Aneurysms and Acute Aortic Dissection grant; National Heart, Lung, and Blood Institute/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research was supported in part by the Intramural Research Program of the U.S. National Institutes of Health (NIH), National Institute on Aging. FACS analysis studies were supported in part by grant R00HL089413 at the University of Michigan. The Johns Hopkins Institutional Clinical and Translational Science Award (CTSA) grant 1U54RR023561-01A1 and the American Recovery and Reinvestment Act (ARRA) Novel Biomarkers in Aortic Aneurysms and Acute Aortic Dissection grant 5RC1HL100021-02 were used for plasma biomarker studies. S. K. G. was supported by grants from the National Heart, Lung, and Blood Institute/NIH (P30HL101290) and the Doris Duke Charitable Foundation. S. K. G. and N.B.M. are unpaid medical advisors for the nonprofit Fibromuscular Dysplasia Society of America (FMDSA). No FMDSA funds were used in this study.	Akhurst RJ, 2012, NAT GENET, V44, P838, DOI 10.1038/ng.2366; AOYAMA T, 1995, AM J MED GENET, V58, P169, DOI 10.1002/ajmg.1320580216; Arnett DK, 2005, CIRCULATION, V112, P3884, DOI 10.1161/CIRCULATIONAHA.105.549857; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623-199072080-00008; CHATILLON JD, 1990, PRESSE MED, V19, P661; Dolan AL, 2003, J RHEUMATOL, V30, P799; Doyle AJ, 2012, NAT GENET, V44, P1249, DOI 10.1038/ng.2421; Erkula G, 2010, J BONE JOINT SURG AM, V92A, P1876, DOI 10.2106/JBJS.I.01140; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; GLADSTIEN K, 1980, CLIN GENET, V17, P115; Hakim AJ, 2004, ARTHRITIS RHEUM-US, V50, P2640, DOI 10.1002/art.20376; HARRISON EG, 1971, MAYO CLIN PROC, V46, P161; Kisilevsky R, 2012, AMYLOID, V19, P5, DOI 10.3109/13506129.2011.654294; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LANCMAN M, 1991, STROKE, V22, P269, DOI 10.1161/01.STR.22.2.269; Leadbetter WF, 1938, J UROLOGY, V39, P611, DOI 10.1016/S0022-5347(17)71895-2; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Ling S, 2012, MINI-REV MED CHEM, V12, P175, DOI 10.2174/138955712798995057; Loeys BL, 2005, NAT GENET, V37, P275, DOI 10.1038/ng1511; MAS JL, 1987, STROKE, V18, P1037, DOI 10.1161/01.STR.18.6.1037; Matt P, 2009, CIRCULATION, V120, P526, DOI 10.1161/CIRCULATIONAHA.108.841981; Milewicz DM, 2010, GENET MED, V12, P196, DOI 10.1097/GIM.0b013e3181cdd687; Milhorat TH, 2007, J NEUROSURG-SPINE, V7, P601, DOI 10.3171/SPI-07/12/601; Morissette R, 2014, CIRC-CARDIOVASC GENE, V7, P80, DOI 10.1161/CIRCGENETICS.113.000280; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; NORMAND J, 1995, IN VITRO CELL DEV-AN, V31, P447; Olin JW, 2012, CIRCULATION, V126, P2925, DOI 10.1161/CIRCULATIONAHA.112.149500; Olin JW, 2012, CIRCULATION, V125, P3182, DOI 10.1161/CIRCULATIONAHA.112.091223; Olin JW, 2011, J VASC SURG, V53, P826, DOI 10.1016/j.jvs.2010.10.066; Poloskey SL, 2012, VASC MED, V17, P371, DOI 10.1177/1358863X12459650; Rodrigues VJ, 2009, AM J NEURORADIOL, V30, P1614, DOI 10.3174/ajnr.A1651; Rose PS, 2000, GENET MED, V2, P278, DOI 10.1097/00125817-200009000-00002; Savard S, 2012, CIRCULATION, V126, P3062, DOI 10.1161/CIRCULATIONAHA.112.117499; SCHIEVINK WI, 1994, STROKE, V25, P2492, DOI 10.1161/01.STR.25.12.2492; SCHIEVINK WI, 1989, NEUROSURGERY, V25, P482; Shultz SJ, 2006, J ORTHOP RES, V24, P124, DOI 10.1002/jor.20021; Slovut DP, 2004, NEW ENGL J MED, V350, P1862, DOI 10.1056/NEJMra032393; Smith WB, 1996, J IMMUNOL, V157, P360; St Hilaire C, 2011, NEW ENGL J MED, V364, P432, DOI [10.1056/NEJMoa0912923, 10.1056/NEJMc1102515]; Stanley J C, 1984, Dis Mon, V30, P1, DOI 10.1016/0011-5029(84)90009-9; STANLEY JC, 1975, ARCH SURG-CHICAGO, V110, P561; STANLEY JC, 1975, ARCH SURG-CHICAGO, V110, P922; Tanaka T, 2009, AM J HUM GENET, V84, P477, DOI 10.1016/j.ajhg.2009.02.011; Tanemoto M, 2007, HYPERTENS RES, V30, P999, DOI 10.1291/hypres.30.999; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277	48	49	52	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3313	3324		10.1096/fj.14-251207	http://dx.doi.org/10.1096/fj.14-251207			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24732132	Green Published, Green Submitted			2022-12-28	WOS:000340265400004
J	Hoermann, G; Blatt, K; Greiner, G; Putz, EM; Berger, A; Herrmann, H; Cerny-Reiterer, S; Gleixner, KV; Walz, C; Hoetzenecker, K; Mullauer, L; Reiter, A; Sotlar, K; Sexl, V; Valent, P; Mayerhofer, M				Hoermann, Gregor; Blatt, Katharina; Greiner, Georg; Putz, Eva Maria; Berger, Angelika; Herrmann, Harald; Cerny-Reiterer, Sabine; Gleixner, Karoline V.; Walz, Christoph; Hoetzenecker, Konrad; Muellauer, Leonhard; Reiter, Andreas; Sotlar, Karl; Sexl, Veronika; Valent, Peter; Mayerhofer, Matthias			CD52 is a molecular target in advanced systemic mastocytosis	FASEB JOURNAL			English	Article						CAMPATH-1; RAS G12V; alemtuzumab; mast cell leukemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; MONOCLONAL-ANTIBODY CAMPATH-1H; NEOPLASTIC MAST-CELLS; C-KIT; THERAPEUTIC TARGET; CATALYTIC DOMAIN; ACTIVATING MUTATIONS; GENE-EXPRESSION; RAS ACTIVATION; ONCOSTATIN M	Advanced systemic mastocytosis (SM) is an aggressive hematopoietic neoplasm with poor prognosis and short survival times. So far, no curative therapy is available for affected patients. We have identified the cell surface antigen CD52 (CAMPATH-1) as a molecular target expressed abundantly on the surface of primary neoplastic mast cells (MCs) in patients with advanced SM. In contrast, neoplastic MCs of patients with indolent SM and normal MCs expressed only low levels or did not express CD52. To study the mechanisms of CD52 expression and the value of this antigen as a potential therapeutic target, we generated a human MC cell line, designated MCPV-1, by lentiviral immortalization of cord blood-derived MC progenitor cells. Functional studies revealed that activated RAS profoundly promotes surface expression of CD52. The CD52-targeting antibody alemtuzumab induced cell death in CD52(+) primary neoplastic MCs obtained from patients with SM as well as in MCPV-1 cells. NSG mice xenotransplanted with MCPV-1 cells survived significantly longer after treatment with alemtuzumab (median survival: 31 d untreated vs. 46 d treated; P = 0.0012). We conclude that CD52 is a novel marker and potential therapeutic target in neoplastic MCs in patients with advanced SM.	[Hoermann, Gregor; Greiner, Georg] Med Univ Vienna, Dept Lab Med, Vienna, Austria; [Blatt, Katharina; Cerny-Reiterer, Sabine; Gleixner, Karoline V.; Valent, Peter] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria; [Hoetzenecker, Konrad] Med Univ Vienna, Div Thorac Surg, Dept Surg, Vienna, Austria; [Muellauer, Leonhard] Med Univ Vienna, Dept Pathol, Vienna, Austria; [Putz, Eva Maria; Berger, Angelika; Sexl, Veronika] Univ Vet Med Vienna, Inst Pharmacol & Toxicol, Vienna, Austria; [Herrmann, Harald; Cerny-Reiterer, Sabine; Valent, Peter] Ludwig Boltzmann Cluster Oncol, Vienna, Austria; [Walz, Christoph; Sotlar, Karl] Univ Munich, Inst Pathol, D-80539 Munich, Germany; [Reiter, Andreas] Univ Med Mannheim, Med Univ Klin, Mannheim, Germany; [Mayerhofer, Matthias] Hanusch Hosp, Ludwig Boltzmann Inst Osteol, A-1140 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; University of Veterinary Medicine Vienna; Ludwig Boltzmann Institute; University of Munich; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ludwig Boltzmann Institute; WGKK - Hanusch Hospital	Mayerhofer, M (corresponding author), Hanusch Hosp, Ludwig Boltzmann Inst Osteol, Heinrich Collin Str 30, A-1140 Vienna, Austria.	matthias.mayerhofer@meduniwien.ac.at	Gamperl, Susi/V-2715-2019; Hoermann, Gregor/B-8832-2016; Test, PV/U-9451-2019; König, Eva Maria/AAF-4041-2019; Test, Test/Y-7921-2019; Hermann, Harald/E-7073-2018; Valent, Peter/B-8533-2016; Müllauer, Leonhard/GSN-9884-2022; Sexl, Veronika/B-8657-2016	Gamperl, Susi/0000-0003-0456-5095; Hoermann, Gregor/0000-0002-7374-4380; König, Eva Maria/0000-0002-9990-4477; Hermann, Harald/0000-0002-5095-4641; Valent, Peter/0000-0003-0456-5095; Müllauer, Leonhard/0000-0002-3399-078X; Berger, Angelika/0000-0001-8775-2405; Sexl, Veronika/0000-0001-9363-0412; Putz, Eva Maria/0000-0002-5309-4114; Greiner, Georg/0000-0002-0917-4117; Gleixner, Karoline/0000-0001-5753-0203; Hoetzenecker, Konrad/0000-0001-6775-7460	Fonds zur Forderung der Wissenschaftlichen Forschung in Osterreich (FWF) grant [P26079-B13, SFB F4704-B20]; Austrian Science Fund (FWF) [P 26079] Funding Source: researchfish	Fonds zur Forderung der Wissenschaftlichen Forschung in Osterreich (FWF) grant; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	The authors thank Elisabeth Wieser and Lukas Kenner (Department of Pathology, Medical University of Vienna, Vienna, Austria) for help with electron microscopy, Andrea Alvarez Hernandez and Ingrid Simonitsch-Klupp (Department of Pathology, Medical University of Vienna) for help with immunochemistry double staining, Hans-Peter Horny (Institute of Pathology, Ludwig Maximilians University, Munich, Germany) for reviewing immunohistochemistry data, Andreas Jung (Institute of Pathology, Ludwig Maximilians University) for help with RAS mutational analysis, and Katharina Worda (Department of Gynecology, Medical University of Vienna) for providing CB samples. The authors also thank Gunther Hofbauer and Andreas Spittler (Cell Sorting Core Unit, Medical University of Vienna) for technical support. This study was supported by the Fonds zur Forderung der Wissenschaftlichen Forschung in Osterreich (FWF) grant P26079-B13 and SFB F4704-B20. The authors declare no conflicts of interest.	Akin C, 2004, ANNU REV MED, V55, P419, DOI 10.1146/annurev.med.55.091902.103822; Akin C, 2003, EXP HEMATOL, V31, P686, DOI 10.1016/S0301-472X(03)00112-7; Arock M, 2010, EXPERT REV HEMATOL, V3, P497, DOI [10.1586/ehm.10.42, 10.1586/EHM.10.42]; Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Elad-Sfadia G, 2002, J BIOL CHEM, V277, P37169, DOI 10.1074/jbc.M205698200; Feger F, 2002, INT ARCH ALLERGY IMM, V127, P110, DOI 10.1159/000048179; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Fritsche-Polanz R, 2001, BRIT J HAEMATOL, V113, P357, DOI 10.1046/j.1365-2141.2001.02783.x; Gao JS, 2011, FEBS LETT, V585, P693, DOI 10.1016/j.febslet.2011.01.033; Georgin-Lavialle S, 2013, BLOOD, V121, P1285, DOI 10.1182/blood-2012-07-442400; Golay J, 2004, HAEMATOLOGICA, V89, P1476; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hale C, 1996, IMMUNOLOGY, V88, P183, DOI 10.1111/j.1365-2567.1996.tb00003.x; Hale G, 2001, J BIOL REG HOMEOS AG, V15, P386; Hanssens K, 2014, HAEMATOLOGICA, V99, P830, DOI 10.3324/haematol.2013.095133; Hoermann G, 2012, FASEB J, V26, P894, DOI 10.1096/fj.11-193078; Hoermann G, 2011, AM J PATHOL, V178, P2344, DOI 10.1016/j.ajpath.2011.01.020; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; Hu YP, 2009, IMMUNOLOGY, V128, P260, DOI 10.1111/j.1365-2567.2009.03115.x; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kondo R, 2007, BLOOD, V110, P661, DOI 10.1182/blood-2006-10-054411; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Malbec O, 2007, J IMMUNOL, V178, P6465, DOI 10.4049/jimmunol.178.10.6465; MATTESON EL, 1995, ARTHRITIS RHEUM, V38, P1187, DOI 10.1002/art.1780380903; Mayerhofer M, 2008, J IMMUNOL, V180, P5466, DOI 10.4049/jimmunol.180.8.5466; Mone AP, 2006, LEUKEMIA, V20, P272, DOI 10.1038/sj.leu.2404014; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Osterborg A, 1996, BRIT J HAEMATOL, V93, P151, DOI 10.1046/j.1365-2141.1996.450989.x; Osterborg A, 1997, J CLIN ONCOL, V15, P1567, DOI 10.1200/JCO.1997.15.4.1567; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rao SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039416; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Saito Y, 2011, LEUKEMIA, V25, P921, DOI 10.1038/leu.2011.36; Salmon P, 2000, MOL THER, V2, P404, DOI 10.1006/mthe.2000.0141; Santos DD, 2006, CLIN LYMPHOMA MYELOM, V6, P478, DOI 10.3816/CLM.2006.n.029; Schwaab J, 2013, BLOOD, V122, P2460, DOI 10.1182/blood-2013-04-496448; Siders WM, 2010, LEUKEMIA LYMPHOMA, V51, P1293, DOI 10.3109/10428191003777963; Sobering AK, 2004, CELL, V117, P637, DOI 10.1016/j.cell.2004.05.003; Stanglmaier M, 2004, ANN HEMATOL, V83, P634, DOI 10.1007/s00277-004-0917-0; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846; Teodosio C, 2013, J ALLERGY CLIN IMMUN, V131, P1213, DOI 10.1016/j.jaci.2012.12.674; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; Valent P, 2004, EUR J CLIN INVEST, V34, P41, DOI 10.1111/j.0960-135X.2004.01369.x; Valent P, 2003, LEUKEMIA RES, V27, P635, DOI 10.1016/S0145-2126(02)00168-6; VALENT P, 1989, BLOOD, V73, P1778; Wilson TM, 2011, HAEMATOL-HEMATOL J, V96, P459, DOI 10.3324/haematol.2010.031690; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Zappulla JP, 2005, J EXP MED, V202, P1635, DOI 10.1084/jem.20050807; Zent CS, 2008, LEUKEMIA RES, V32, P1849, DOI 10.1016/j.leukres.2008.05.014; Zhang PL, 2007, ANN CLIN LAB SCI, V37, P148	55	20	22	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3540	3551		10.1096/fj.14-250894	http://dx.doi.org/10.1096/fj.14-250894			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24760752				2022-12-28	WOS:000340265400023
J	McDade, JR; Archambeau, A; Michele, DE				McDade, Joel R.; Archambeau, Ashley; Michele, Daniel E.			Rapid actin-cytoskeleton-dependent recruitment of plasma membrane-derived dysferlin at wounds is critical for muscle membrane repair	FASEB JOURNAL			English	Article						pHluorin; endocytosis	MUSCULAR-DYSTROPHY; VENTRICULAR MYOCYTES; STRESS; CONTRACTION; CAVEOLIN-3; EXOCYTOSIS; BINDING; PROTEIN; MG53	Deficits in membrane repair may contribute to disease progression in dysferlin-deficient muscular dystrophy. Dysferlin, a type-II transmembrane phospholipid-binding protein, is hypothesized to regulate fusion of repair vesicles with the sarcolemma to facilitate membrane repair, but the dysferlin-containing compartments involved in membrane repair and the mechanism by which these compartments contribute to resealing are unclear. A dysferlin-pHluorin [dysf-pH-sensitive green fluorescent protein (pHGFP)] muscle-specific transgenic mouse was developed to examine the dynamic behavior and subcellular localization of dysferlin during membrane repair in adult skeletal muscle fibers. Live-cell confocal microscopy of uninjured adult dysf-pHGFP muscle fibers revealed that dysferlin is highly enriched in the sarcolemma and transverse tubules. Laser-wounding induced rapid recruitment of similar to 30 mu m of local dysferlin-containing sarcolemma, leading to formation of stable dysferlin accumulations surrounding lesions, endocytosis of dysferlin, and formation of large cytoplasmic vesicles from distal regions of the fiber. Disruption of the actin cytoskeleton decreased recruitment of sarcolemma-derived dysferlin to lesions in dysf-pHGFP fibers without affecting endocytosis and impaired membrane resealing in wild-type fibers, similar to findings in dysferlin deficiency (a 2-fold increase in FM1-43 uptake). Our data support a new mechanism whereby recruitment of sarcolemma-derived dysferlin creates an active zone of high lipid-binding activity at wounds to interact with repair vesicles and facilitate membrane resealing in skeletal muscle.-McDade, J. R., Archambeau, A., Michele, D. E. Rapid actin-cytoskeleton-dependent recruitment of plasma membrane-derived dysferlin at wounds is critical for muscle membrane repair.	[McDade, Joel R.; Archambeau, Ashley; Michele, Daniel E.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Michele, Daniel E.] Univ Michigan, Div Mol Med & Genet, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Michele, DE (corresponding author), Univ Michigan, Dept Mol & Integrat Physiol, NCRC Bldg 26-214S 2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	dmichele@umich.edu		McDade, Joel/0000-0003-2182-6090; Cuttitta, Ashley/0000-0002-2400-4087	American Heart Association [12PRE12050130]; Systems and Integrative Biology Training Grant; National Heart, Lung, and Blood Institute (U.S. National Institutes of Health, Bethesda MD, USA) [HL-080388, HL-895800]; Muscular Dystrophy Association; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); Systems and Integrative Biology Training Grant; National Heart, Lung, and Blood Institute (U.S. National Institutes of Health, Bethesda MD, USA); Muscular Dystrophy Association(Muscular Dystrophy Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank W. Filipiak and T. Saunders for preparation of TG mice and the Transgenic Animal Model Core of the University of Michigan's Biomedical Research Core Facilities. The pHluorin GFP construct was a kind gift from Dr. G. Miesenbock (Oxford University, Oxford, UK) and J. Rothman (Yale School of Medicine, Yale University, New Haven, CT, USA), and the MCK promoter was a kind gift from Drs. J. Chamberlain (University of Washington, Seattle, WA, USA) and S. Hauschka (University of Washington). The University of Michigan Microscopy and Image Analysis Laboratory (MIL) provided expert support for confocal microscopy. Core support was provided by the University of Michigan Cancer Center (P30 CA046592) and the University of Michigan Rheumatic Diseases Research Core Center (P30 AR048310). This work was supported by an American Heart Association (12PRE12050130) and Systems and Integrative Biology Training Grant (to J. M.) and National Heart, Lung, and Blood Institute (U.S. National Institutes of Health, Bethesda MD, USA) grants HL-080388 and HL-895800 and a grant from the Muscular Dystrophy Association (to D.M.).	Abreu-Blanco MT, 2011, J CELL BIOL, V193, P455, DOI 10.1083/jcb.201011018; Anderson LVB, 1999, HUM MOL GENET, V8, P855, DOI 10.1093/hmg/8.5.855; Azakir BA, 2012, J BIOL CHEM, V287, P27629, DOI 10.1074/jbc.M112.391722; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Becker K., 2011, ADV PROTOCOLS ANIMAL, P99, DOI 10.1007/978-3-642-20792-1_6; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; Burrone J, 2006, NAT PROTOC, V1, P2970, DOI 10.1038/nprot.2006.449; Cai CX, 2009, J BIOL CHEM, V284, P15894, DOI 10.1074/jbc.M109.009589; Cai CX, 2009, NAT CELL BIOL, V11, P56, DOI 10.1038/ncb1812; Chiu YH, 2009, HUM MOL GENET, V18, P1976, DOI 10.1093/hmg/ddp121; Corrotte M, 2013, ELIFE, V2, DOI 10.7554/eLife.00926; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; De Morree A., 2013, J BIOL CHEM; Demonbreun AR, 2014, AM J PATHOL, V184, P248, DOI 10.1016/j.ajpath.2013.09.009; Demonbreun AR, 2011, HUM MOL GENET, V20, P779, DOI 10.1093/hmg/ddq522; Eddleman CS, 1997, P NATL ACAD SCI USA, V94, P4745, DOI 10.1073/pnas.94.9.4745; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Fuson K, 2014, STRUCTURE, V22, P104, DOI 10.1016/j.str.2013.10.001; Glover LE, 2010, ANN NEUROL, V67, P384, DOI 10.1002/ana.21926; Gumerson JD, 2010, AM J PHYSIOL-CELL PH, V299, pC1430, DOI 10.1152/ajpcell.00192.2010; Han R, 2007, J CLIN INVEST, V117, P1805, DOI 10.1172/JCI30848; Hauser MA, 2000, MOL THER, V2, P16, DOI 10.1006/mthe.2000.0089; Hernandez-Deviez DJ, 2006, HUM MOL GENET, V15, P129, DOI 10.1093/hmg/ddi434; Illarioshkin SN, 2000, NEUROLOGY, V55, P1931, DOI 10.1212/WNL.55.12.1931; Kerr JP, 2013, P NATL ACAD SCI USA, V110, P20831, DOI 10.1073/pnas.1307960110; Lapidos KA, 2004, CIRC RES, V94, P1023, DOI 10.1161/01.RES.0000126574.61061.25; Lek A, 2013, J NEUROSCI, V33, P5085, DOI 10.1523/JNEUROSCI.3560-12.2013; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Mandato CA, 2001, J CELL BIOL, V154, P785, DOI 10.1083/jcb.200103105; Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761; McDade J. R., 2013, HUM MOL GENET; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Moench I, 2013, EXP PHYSIOL, V98, P1164, DOI 10.1113/expphysiol.2013.072470; Piccolo F, 2000, ANN NEUROL, V48, P902, DOI 10.1002/1531-8249(200012)48:6<902::AID-ANA11>3.3.CO;2-Q; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Roche JA, 2011, J HISTOCHEM CYTOCHEM, V59, P964, DOI 10.1369/0022155411423274; Roostalu U, 2012, DEV CELL, V22, P515, DOI 10.1016/j.devcel.2011.12.008; Sankaranarayanan S, 2000, BIOPHYS J, V79, P2199, DOI 10.1016/S0006-3495(00)76468-X; Sharma A, 2010, ARTERIOSCL THROM VAS, V30, P2196, DOI 10.1161/ATVBAHA.110.208108; Shefer Gabi, 2005, Methods Mol Biol, V290, P281; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Tian QH, 2012, J MOL CELL CARDIOL, V52, P113, DOI 10.1016/j.yjmcc.2011.09.001; Waddell LB, 2011, J NEUROPATH EXP NEUR, V70, P302, DOI 10.1097/NEN.0b013e31821350b0	45	57	58	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3660	3670		10.1096/fj.14-250191	http://dx.doi.org/10.1096/fj.14-250191			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24784578	Green Published, Green Submitted			2022-12-28	WOS:000340265400033
J	Perez-Diaz, S; Johnson, LA; DeKroon, RM; Moreno-Navarrete, JM; Alzate, O; Fernandez-Real, JM; Maeda, N; Arbones-Mainar, JM				Perez-Diaz, Sergio; Johnson, Lance A.; DeKroon, Robert M.; Moreno-Navarrete, Jose M.; Alzate, Oscar; Fernandez-Real, Jose M.; Maeda, Nobuyo; Arbones-Mainar, Jose M.			Polymerase I and transcript release factor (PTRF) regulates adipocyte differentiation and determines adipose tissue expandability	FASEB JOURNAL			English	Article						senescence; glucose intolerance; telomeres	DIET-INDUCED OBESITY; CELLULAR SENESCENCE; 3T3-L1 ADIPOCYTES; INSULIN-RECEPTOR; GENE-EXPRESSION; MICE; CAVEOLAE; CELLS; DYSLIPIDEMIA; PROTEIN	Impaired adipogenesis renders an adipose tissue unable to expand, leading to lipotoxicity and conditions such as diabetes and cardiovascular disease. While factors important for adipogenesis have been studied extensively, those that set the limits of adipose tissue expansion remain undetermined. Feeding a Western-type diet to apolipoprotein E2 knock-in mice, a model of metabolic syndrome, produced 3 groups of equally obese mice: mice with normal glucose tolerance, hyperinsulinemic yet glucose-tolerant mice, and prediabetic mice with impaired glucose tolerance and reduced circulating insulin. Using proteomics, we compared subcutaneous adipose tissues from mice in these groups and found that the expression of PTRF (polymerase I and transcript release factor) associated selectively with their glucose tolerance status. Lentiviral and pharmacologically overexpressed PTRF, whose function is critical for caveola formation, compromised adipocyte differentiation of cultured 3T3-L1cells. In human adipose tissue, PTRF mRNA levels positively correlated with markers of lipolysis and cellular senescence. Furthermore, a negative relationship between telomere length and PTRF mRNA levels was observed in human subcutaneous fat. PTRF is associated with limited adipose tissue expansion underpinning the key role of caveolae in adipocyte regulation. Furthermore, PTRF may be a suitable adipocyte marker for predicting pathological obesity and inform clinical management.-Perez-Diaz, S., Johnson, L. A., DeKroon, R. M., Moreno-Navarrete, J. M., Alzate, O., Fernandez-Real, J. M., Maeda, N., Arbones-Mainar, J. M. Polymerase I and transcript release factor (PTRF) regulates adipocyte differentiation and determines adipose tissue expandability.	[Perez-Diaz, Sergio; Arbones-Mainar, Jose M.] Hosp Univ Miguel Servet, Inst Aragones Ciencias Salud, Unidad Invest Traslac, Adipocyte & Fat Biol Lab AdipoFat, Zaragoza 50009, Spain; [Johnson, Lance A.; Maeda, Nobuyo] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [DeKroon, Robert M.; Alzate, Oscar] Univ N Carolina, Univ North Carolina Syst Prote Ctr, Chapel Hill, NC USA; [Moreno-Navarrete, Jose M.] Hosp Dr Josep Trueta, Inst Invest Biomed Girona IdlBGi, Dept Diabet Endocrinol & Nutr, Girona, Spain; [Moreno-Navarrete, Jose M.; Fernandez-Real, Jose M.; Arbones-Mainar, Jose M.] Inst Salud Carlos III, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Madrid, Spain	Miguel Servet University Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III	Arbones-Mainar, JM (corresponding author), Hosp Univ Miguel Servet, Inst Aragones Ciencias Salud, Unidad Invest Traslac, Adipocyte & Fat Biol Lab AdipoFat, Zaragoza 50009, Spain.	jmarbones.iacs@aragon.es	Fernandez-Real, Jose Manuel/L-5897-2014; Moreno-Navarrete, José María/ABG-5548-2021; Arbones-Mainar, Jose M/AGL-8624-2022; Moreno-Navarrete, José María/H-9772-2015	Moreno-Navarrete, José María/0000-0002-2883-511X; Arbones-Mainar, Jose M/0000-0002-8982-3737; Moreno-Navarrete, José María/0000-0002-2883-511X; Fernandez-Real, Jose Manuel/0000-0002-7442-9323; Perez Diaz, Sergio/0000-0003-1032-3121; Alzate, Oscar/0000-0002-1083-2551	Instituto de Salud Carlos III (Madrid, Spain); European Commission [Marie-Curie Action: 303717-APOMET]; U.S. National Institutes of Health [HL042360]; Diputacion General de Aragon (Madrid, Spain); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042630] Funding Source: NIH RePORTER	Instituto de Salud Carlos III (Madrid, Spain)(Instituto de Salud Carlos III); European Commission(European CommissionEuropean Commission Joint Research Centre); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Diputacion General de Aragon (Madrid, Spain); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors are grateful to Dr. Trono (Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland) and Dr. Helenius (Eidgenossische Technische Hochschule Zurich, Zurich, Switzerland) for the generous gifts of the lentiviral expression system and the Ptrf1-mEGFP plasmid, respectively. The authors also acknowledge the invaluable technical assistance made by Ms. Pilar Garcia-Sobreviela (Instituto Aragones de Ciencias de la Salud) to the present work. Likewise, the authors thank Drs. E. Fernadez-Vizarra (University of Cambridge, Cambridge, UK), J. Osada (Universidad de Zaragoza, Zaragoza, Spain), and R. Kohler (Instituto Aragones de Ciencias de la Salud) for their critical reading. This work was supported by the Miguel Servet program from the Instituto de Salud Carlos III (Madrid, Spain), by the Marie-Curie Action: 303717-APOMET from the European Commission to J. M. A.-M., and by U.S. National Institutes of Health grant HL042360 to N. M. S. P.-D. was partially supported by a pre-doctoral fellowship from the Diputacion General de Aragon (Madrid, Spain). The authors declare no conflicts of interest.	Aboulaich N, 2004, BIOCHEM J, V383, P237, DOI 10.1042/BJ20040647; Aboulaich N, 2006, BIOCHEM BIOPH RES CO, V350, P657, DOI 10.1016/j.bbrc.2006.09.094; Aboulaich N, 2011, DIABETES, V60, P757, DOI 10.2337/db10-0744; ABUELHEIGA L, 1995, P NATL ACAD SCI USA, V92, P4011, DOI 10.1073/pnas.92.9.4011; Arbones-Mainar JM, 2008, INT J OBESITY, V32, P1595, DOI 10.1038/ijo.2008.143; Arbones-Mainar JM, 2006, ATHEROSCLEROSIS, V189, P318, DOI 10.1016/j.atherosclerosis.2006.01.015; Arbones-Mainar JM, 2010, FASEB J, V24, P3809, DOI 10.1096/fj.10-159517; Arner E, 2010, DIABETES, V59, P105, DOI 10.2337/db09-0942; Bai L, 2011, CELL RES, V21, P1088, DOI 10.1038/cr.2011.56; Bitar M. S., 2013, AM J PHYSIOL-ENDOC M, V305; Cao H, 2008, LIPIDS HEALTH DIS, V7, DOI 10.1186/1476-511X-7-3; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Cong YS, 2006, MECH AGEING DEV, V127, P332, DOI 10.1016/j.mad.2005.12.005; DeKroon RM, 2011, J PROTEOME RES, V10, P1632, DOI 10.1021/pr1009788; Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001; Gonzalez-Munoz E, 2009, ENDOCRINOLOGY, V150, P3493, DOI 10.1210/en.2008-1520; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Haffner SM, 2006, OBESITY, V14, p121S, DOI 10.1038/oby.2006.291; Hallenborg P, 2012, CELL DEATH DIFFER, V19, P1381, DOI 10.1038/cdd.2012.15; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayer A, 2010, TRAFFIC, V11, P361, DOI 10.1111/j.1600-0854.2009.01023.x; Hennuyer N, 2005, ARTERIOSCL THROM VAS, V25, P1897, DOI 10.1161/01.ATV.0000175756.56818.ee; Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042; Jansa P, 1998, EMBO J, V17, P2855, DOI 10.1093/emboj/17.10.2855; Jernas M, 2006, FASEB J, V20, P1540, DOI 10.1096/fj.05-5678fje; Johnson LA, 2011, DIABETES, V60, P2285, DOI 10.2337/db11-0466; Kilpelainen TO, 2011, NAT GENET, V43, P753, DOI 10.1038/ng.866; Kim CA, 2008, J CLIN ENDOCR METAB, V93, P1129, DOI 10.1210/jc.2007-1328; Kim JY, 2008, AM J PHYSIOL-ENDOC M, V294, pE654, DOI 10.1152/ajpendo.00104.2007; Kozak LP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011015; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Kuhel DG, 2013, DIABETES, V62, P382, DOI 10.2337/db12-0390; Liu LB, 2008, CELL METAB, V8, P310, DOI 10.1016/j.cmet.2008.07.008; Lord CC, 2012, DIABETES, V61, P355, DOI 10.2337/db11-0994; Moreno-Navarrete JM, 2013, DIABETES, V62, P1923, DOI 10.2337/db12-0977; Molchadsky A, 2013, CELL DEATH DIFFER, V20, P774, DOI 10.1038/cdd.2013.9; Moreno-Navarrete JM, 2010, INT J OBESITY, V34, P1345, DOI 10.1038/ijo.2010.49; Osorio C, 2007, NEUROBIOL AGING, V28, P1853, DOI 10.1016/j.neurobiolaging.2006.08.011; Ost A, 2005, J BIOL CHEM, V280, P5, DOI 10.1074/jbc.C400429200; Park JS, 2005, MECH AGEING DEV, V126, P551, DOI 10.1016/j.mad.2004.11.014; Pilch PF, 2011, TRENDS ENDOCRIN MET, V22, P318, DOI 10.1016/j.tem.2011.04.001; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Sakoda H, 2000, DIABETES, V49, P1700, DOI 10.2337/diabetes.49.10.1700; Sanchez E, 2013, BBA-BIOENERGETICS, V1827, P285, DOI 10.1016/j.bbabio.2012.11.003; Scherer PE, 2006, DIABETES, V55, P1537, DOI 10.2337/db06-0263; Shiri-Sverdlov R, 2006, J HEPATOL, V44, P732, DOI 10.1016/j.jhep.2005.10.033; Stefan N, 2008, ARCH INTERN MED, V168, P1609, DOI 10.1001/archinte.168.15.1609; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; Tchkonia T, 2010, AGING CELL, V9, P667, DOI 10.1111/j.1474-9726.2010.00608.x; Vanschoonbeek K, 2008, ARTERIOSCL THROM VAS, V28, P2023, DOI 10.1161/ATVBAHA.107.156992; Virtue S, 2008, PLOS BIOL, V6, P1819, DOI 10.1371/journal.pbio.0060237; Volonte D, 2011, J BIOL CHEM, V286, P28657, DOI 10.1074/jbc.C111.235119; Wang H, 2009, J BIOL CHEM, V284, P32116, DOI 10.1074/jbc.M109.006726; Wildman RP, 2008, ARCH INTERN MED, V168, P1617, DOI 10.1001/archinte.168.15.1617; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	56	22	23	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3769	3779		10.1096/fj.14-251165	http://dx.doi.org/10.1096/fj.14-251165			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24812087	Green Published			2022-12-28	WOS:000340265400042
J	Balasubramanian, A; Kawahara, G; Gupta, VA; Rozkalne, A; Beauvais, A; Kunkel, LM; Gussoni, E				Balasubramanian, Anuradha; Kawahara, Genri; Gupta, Vandana A.; Rozkalne, Anete; Beauvais, Ariane; Kunkel, Louis M.; Gussoni, Emanuela			Fam65b is important for formation of the HDAC6-dysferlin protein complex during myogenic cell differentiation	FASEB JOURNAL			English	Article						myoblast; acetylation; zebrafish; muscular dystrophy	GIRDLE MUSCULAR-DYSTROPHY; HISTONE DEACETYLASE INHIBITORS; MEF2 TRANSCRIPTION FACTOR; MYOBLAST FUSION; MUSCLE DIFFERENTIATION; SKELETAL MYOGENESIS; ADHESION MOLECULE; ZEBRAFISH EMBRYOS; MEMBRANE REPAIR; NUCLEAR EXPORT	Previously, we identified family with sequence similarity 65, member B (Fam65b), as a protein transiently up-regulated during differentiation and fusion of human myogenic cells. Silencing of Fam65b expression results in severe reduction of myogenin expression and consequent lack of myoblast fusion. The molecular function of Fam65b and whether misregulation of its expression could be causative of muscle diseases are unknown. Protein pulldowns were used to identify Fam65b-interacting proteins in differentiating human muscle cells and regenerating muscle tissue. In vitro, human muscle cells were treated with histone-deacetylase (HDAC) inhibitors, and expression of Fam65b and interacting proteins was studied. Nontreated cells were used as controls. In vivo, expression of Fam65b was downregulated in developing zebrafish to determine the effects on muscle development. Fam65b binds to HDAC6 and dysferlin, the protein mutated in limb girdle muscular dystrophy 2B. The tricomplex Fam65b-HDAC6-dysferlin is transient, and Fam65b expression is necessary for the complex to form. Treatment of myogenic cells with pan-HDAC or HDAC6-specific inhibitors alters Fam65b expression, while dysferlin expression does not change. Inhibition of Fam65b expression in developing zebrafish results in abnormal muscle, with low birefringence, tears at the myosepta, and increased embryo lethality. Fam65b is an essential component of the HDAC6-dysferlin complex. Down-regulation of Fam65b in developing muscle causes changes consistent with muscle disease.	[Balasubramanian, Anuradha; Kawahara, Genri; Gupta, Vandana A.; Rozkalne, Anete; Kunkel, Louis M.; Gussoni, Emanuela] Boston Childrens Hosp, Program Genom, Boston, MA 02115 USA; [Balasubramanian, Anuradha; Kawahara, Genri; Gupta, Vandana A.; Rozkalne, Anete; Kunkel, Louis M.; Gussoni, Emanuela] Boston Childrens Hosp, Div Genet, Boston, MA 02115 USA; [Kunkel, Louis M.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA; [Beauvais, Ariane] Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON, Canada; [Kunkel, Louis M.; Gussoni, Emanuela] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; University of Ottawa; Ottawa Hospital Research Institute; Harvard University; Harvard Medical School	Gussoni, E (corresponding author), Boston Childrens Hosp, Div Genet & Genom, 3 Blackfan Circle, Boston, MA 02115 USA.	gussoni@enders.tch.harvard.edu	Gussoni, Emanuela/AAL-6150-2021	Gussoni, Emanuela/0000-0002-9915-3677; Gupta, Vandana/0000-0002-4057-8451	U.S. National Institute of Child Health and Human Development; U.S. National Institutes of Health [1R01AR060317-01]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR062601, R01AR060317] Funding Source: NIH RePORTER	U.S. National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors are grateful to Dr. Matthew Alexander, Dr. Natassia Vieira, and Dr. Angela Lek for helpful discussions. The authors thank Suzan Lazo-Kallanian (Hematologic Neoplasia Core facility, Dana Farber Cancer Institute, Boston, MA, USA) for assistance with the FACS isolation of primary myoblasts. The F59 antibody developed by F. E. Stockdale was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the U.S. National Institute of Child Health and Human Development and maintained by the University of Iowa (Iowa City, IA, USA). The authors thank Dr. Stuart L. Schreiber and Dr. Ralph Mazitschek (Harvard University, Cambridge, MA, USA) for their generous gift of tubacin and niltubacin inhibitors. This work was supported by the U.S. National Institutes of Health (1R01AR060317-01 to E. G.). The authors declare no conflicts of interest.	Abmayr SM, 2012, DEVELOPMENT, V139, P641, DOI 10.1242/dev.068353; Azakir BA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010122; Backs J, 2006, J CLIN INVEST, V116, P1853, DOI 10.1172/JCI27438; Bakay M, 2006, BRAIN, V129, P996, DOI 10.1093/brain/awl023; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; Bassett DI, 2003, DEVELOPMENT, V130, P5851, DOI 10.1242/dev.00799; Bassett DI, 2003, HUM MOL GENET, V12, pR265, DOI 10.1093/hmg/ddg279; Bentzinger CF, 2012, COLD SPRING HARB PER, V4; BISCHOFF R, 1969, J CELL BIOL, V41, P188, DOI 10.1083/jcb.41.1.188; Boyault C, 2007, ONCOGENE, V26, P5468, DOI 10.1038/sj.onc.1210614; Buckingham M, 2006, CURR OPIN GENET DEV, V16, P525, DOI 10.1016/j.gde.2006.08.008; Cerletti M, 2006, J CELL SCI, V119, P3117, DOI 10.1242/jcs.03056; Chang SR, 2005, P NATL ACAD SCI USA, V102, P8120, DOI 10.1073/pnas.0503275102; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Colussi C, 2010, PROTEOM CLIN APPL, V4, P71, DOI 10.1002/prca.200900116; Conacci-Sorrell M, 2011, CELL CYCLE, V10, P604, DOI 10.4161/cc.10.4.14794; Conacci-Sorrell M, 2010, CELL, V142, P480, DOI 10.1016/j.cell.2010.06.037; Consalvi S, 2011, MOL MED, V17, P457, DOI 10.2119/molmed.2011.00049; Davis DB, 2000, HUM MOL GENET, V9, P217, DOI 10.1093/hmg/9.2.217; de Luna N, 2006, J BIOL CHEM, V281, P17092, DOI 10.1074/jbc.M601885200; Demonbreun AR, 2010, FASEB J, V24, P1284, DOI 10.1096/fj.09-136309; di Bari MG, 2006, EMBO REP, V7, P727, DOI 10.1038/sj.embor.7400700; Di Fulvio S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028563; Doherty KR, 2005, DEVELOPMENT, V132, P5565, DOI 10.1242/dev.02155; Etard C, 2010, J CELL BIOL, V189, P527, DOI 10.1083/jcb.200912125; Glover LE, 2010, ANN NEUROL, V67, P384, DOI 10.1002/ana.21926; GUNDERSEN GG, 1989, J CELL BIOL, V109, P2275, DOI 10.1083/jcb.109.5.2275; Guyon JR, 2007, BBA-MOL BASIS DIS, V1772, P205, DOI 10.1016/j.bbadis.2006.07.003; Guyon JR, 2005, EXP CELL RES, V304, P105, DOI 10.1016/j.yexcr.2004.10.032; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Iezzi S, 2004, DEV CELL, V6, P673, DOI 10.1016/S1534-5807(04)00107-8; Kawahara G, 2011, BIOCHEM BIOPH RES CO, V413, P358, DOI 10.1016/j.bbrc.2011.08.105; Kawahara G, 2010, HUM MOL GENET, V19, P623, DOI 10.1093/hmg/ddp528; KONIGSBERG IR, 1971, DEV BIOL, V26, P133, DOI 10.1016/0012-1606(71)90113-8; Kozikowski AP, 2008, J MED CHEM, V51, P4370, DOI 10.1021/jm8002894; Lapan AD, 2012, HUM MOL GENET, V21, P3668, DOI 10.1093/hmg/dds196; Lapan AD, 2012, METHODS MOL BIOL, V798, P3, DOI 10.1007/978-1-61779-343-1_1; Lek A, 2013, J NEUROSCI, V33, P5085, DOI 10.1523/JNEUROSCI.3560-12.2013; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Lo HP, 2008, NEUROMUSCULAR DISORD, V18, P34, DOI 10.1016/j.nmd.2007.08.009; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Nebbioso A, 2020, EMBO REP, V21, DOI [10.1038/embor.2009.88, 10.15252/embr.202051028]; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Nishino TG, 2008, BIOCHEM BIOPH RES CO, V377, P852, DOI 10.1016/j.bbrc.2008.10.079; Rahimov F, 2011, PHYSIOL GENOMICS, V43, P398, DOI 10.1152/physiolgenomics.00223.2010; Rey M, 2011, EUR J CELL BIOL, V90, P128, DOI 10.1016/j.ejcb.2010.09.004; Rochlin K, 2010, DEV BIOL, V341, P66, DOI 10.1016/j.ydbio.2009.10.024; Schejter ED, 2010, CURR OPIN CELL BIOL, V22, P566, DOI 10.1016/j.ceb.2010.08.009; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514; Tran ADA, 2007, J CELL SCI, V120, P1469, DOI 10.1242/jcs.03431; Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003; von der Hagen M, 2005, NEUROMUSCULAR DISORD, V15, P863, DOI 10.1016/j.nmd.2005.09.002; Welle S, 2009, AM J PHYSIOL-ENDOC M, V296, pE567, DOI 10.1152/ajpendo.90862.2008; Wu Y, 2010, J BIOL CHEM, V285, P3554, DOI 10.1074/jbc.M109.063354; YAFFE D, 1965, DEV BIOL, V11, P300, DOI 10.1016/0012-1606(65)90062-X; Yoon S, 2007, DEV BIOL, V301, P70, DOI 10.1016/j.ydbio.2006.11.002; Zhang XH, 2007, MOL CELL, V27, P197, DOI 10.1016/j.molcel.2007.05.033; Zilberman Y, 2009, J CELL SCI, V122, P3531, DOI 10.1242/jcs.046813	66	16	23	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					2955	2969		10.1096/fj.13-246470	http://dx.doi.org/10.1096/fj.13-246470			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24687993	Green Published			2022-12-28	WOS:000337949400019
J	Young, BE; Cooper, EM; McIntyre, AW; Kent, T; Witter, F; Harris, ZL; O'Brien, KO				Young, Bridget E.; Cooper, Elizabeth M.; McIntyre, Allison W.; Kent, Tera; Witter, Frank; Harris, Z. Leah; O'Brien, Kimberly O.			Placental vitamin D receptor (VDR) expression is related to neonatal vitamin D status, placental calcium transfer, and fetal bone length in pregnant adolescents	FASEB JOURNAL			English	Article						25(OH)D; 1; 25(OH)2D; gestation; calcidiol	PARATHYROID-HORMONE; 1,25-DIHYDROXYVITAMIN D-3; GENE-EXPRESSION; BIRTH-WEIGHT; IN-UTERO; 25-HYDROXYVITAMIN-D; SUPPLEMENTATION; TRANSPORTER; METABOLISM; LACTATION	The purpose of the study was to identify determinants of placental vitamin D receptor (VDR) expression and placental calcium (Ca) transfer among pregnant adolescents. Placental tissue was obtained in 94 adolescents (18 yr) at term. In 12 of these teens, stable Ca isotopes were given intravenously (Ca-42) and orally (Ca-44) early in labor. Placental VDR expression was assessed via Western blot and validated by RT-PCR. Maternal-to-fetal Ca transfer was calculated as the enrichment in cord blood at delivery relative to maternal serum enrichment 2 h postdosing. Isotopic study outcomes were examined in relation to fetal long bone length, placental VDR, serum 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)(2)D], and parathyroid hormone (PTH) in maternal circulation and cord blood at delivery. Placental VDR expression was inversely associated with neonatal 25(OH)D (P=0.012) and positively with neonatal 1,25(OH)(2)D (P=0.006). Placental VDR was a positive predictor of fetal femur length Z score (P=0.018; R-2=0.06) and was positively correlated with maternal-to-fetal transfer of intravenous Ca-42 (P=0.004; R-2=0.62). The fetus may regulate placental VDR expression given the significant associations with neonatal vitamin D metabolites. The association between placental VDR and fetal long bone length may indicate a role for VDR in fetal bone development, potentially by mediating transplacental Ca transfer.Young, B. E., Cooper, E. M., McIntyre, A. W., Kent, T., Witter, F., Harris, Z. L., O'Brien, K. O. Placental vitamin D receptor (VDR) expression is related to neonatal vitamin D status, placental calcium transfer, and fetal bone length in pregnant adolescents.	[Young, Bridget E.; Kent, Tera; O'Brien, Kimberly O.] Cornell Univ, Dept Nutr Sci, Ithaca, NY 14853 USA; [Cooper, Elizabeth M.; McIntyre, Allison W.] Univ Rochester, Sch Med, Rochester, NY USA; [Witter, Frank; Harris, Z. Leah] Johns Hopkins Sch Med, Baltimore, MD USA	Cornell University; University of Rochester; Johns Hopkins University; Johns Hopkins Medicine	O'Brien, KO (corresponding author), Cornell Univ, Dept Nutr Sci, 230 Savage Hall, Ithaca, NY 14853 USA.	koo4@cornell.edu		Harris, Zena Leah/0000-0003-0110-8438				ABRAMS SA, 1992, J BONE MINER RES, V7, P287, DOI 10.1002/jbmr.5650070307; Belkacemi L, 2005, MOL CELL ENDOCRINOL, V236, P31, DOI 10.1016/j.mce.2005.03.002; Bond H, 2008, J PHYSIOL-LONDON, V586, P2015, DOI 10.1113/jphysiol.2007.149104; Brannon PM, 2011, ANNU REV NUTR, V31, P89, DOI 10.1146/annurev.nutr.012809.104807; Chang SC, 2003, AM J CLIN NUTR, V77, P1248, DOI 10.1093/ajcn/77.5.1248; CHEN TC, 1990, J NUTR BIOCHEM, V1, P320, DOI 10.1016/0955-2863(90)90068-V; Dilworth MR, 2010, P NATL ACAD SCI USA, V107, P3894, DOI 10.1073/pnas.0911710107; Essley B, 2011, J DEV ORIG HLTH DIS, V2, P272, DOI 10.1017/S2040174411000511; Evans KN, 2004, J SOC GYNECOL INVEST, V11, P263, DOI 10.1016/j.jsgi.2004.02.002; Fischer D, 2007, CLIN EXP OBSTET GYN, V34, P80; GERTNER JM, 1980, J PEDIATR-US, V97, P637, DOI 10.1016/S0022-3476(80)80029-1; Halhali A, 2010, J STEROID BIOCHEM, V121, P448, DOI 10.1016/j.jsbmb.2010.03.008; Hollis BW, 2011, J BONE MINER RES, V26, P2341, DOI 10.1002/jbmr.463; Institute of Medicine, 2011, DIETARY REFERENCE IN; Jaacks LM, 2011, J NUTR, V141, P1267, DOI 10.3945/jn.110.135798; Jansson T, 2006, PLACENTA, V27, pS91, DOI 10.1016/j.placenta.2005.11.010; Javaid MK, 2006, LANCET, V367, P36, DOI 10.1016/S0140-6736(06)67922-1; Karras SN, 2014, OSTEOPOROSIS INT, V25, P795, DOI 10.1007/s00198-013-2468-5; Kato S, 2002, HORM RES, V57, P73, DOI 10.1159/000057955; Kovacs CS, 2012, ANNU REV NUTR, V32, P97, DOI 10.1146/annurev-nutr-071811-150742; Kovacs CS, 2005, AM J PHYSIOL-ENDOC M, V289, pE133, DOI 10.1152/ajpendo.00354.2004; Kovacs CS, 1997, ENDOCR REV, V18, P832, DOI 10.1210/er.18.6.832; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; Lewis S, 2010, MOL NUTR FOOD RES, V54, P1092, DOI 10.1002/mnfr.201000044; Ma R, 2012, AM J PHYSIOL-ENDOC M, V303, pE928, DOI 10.1152/ajpendo.00279.2012; Mahon P, 2010, J BONE MINER RES, V25, P14, DOI 10.1359/jbmr.090701; MARKESTAD T, 1984, AM J CLIN NUTR, V40, P1057, DOI 10.1093/ajcn/40.5.1057; Martin R, 2007, BONE, V40, P1203, DOI 10.1016/j.bone.2006.12.060; Meyer MB, 2006, MOL ENDOCRINOL, V20, P1447, DOI 10.1210/me.2006-0031; MOORE ES, 1985, PEDIATR RES, V19, P566, DOI 10.1203/00006450-198506000-00013; Morley R, 2006, J CLIN ENDOCR METAB, V91, P906, DOI 10.1210/jc.2005-1479; Morley R, 2009, EUR J CLIN NUTR, V63, P802, DOI 10.1038/ejcn.2008.55; Namgung R, 2000, P NUTR SOC, V59, P55, DOI 10.1017/S0029665100000070; Novakovic B, 2009, J BIOL CHEM, V284, P14838, DOI 10.1074/jbc.M809542200; O'Brien KO, 2014, J CLIN ENDOCR METAB, V99, P1348, DOI 10.1210/jc.2013-1366; Pike JW, 2010, ENDOCRIN METAB CLIN, V39, P255, DOI 10.1016/j.ecl.2010.02.007; Pospechova K, 2009, MOL CELL ENDOCRINOL, V299, P178, DOI 10.1016/j.mce.2008.12.003; Rummens K, 2003, PEDIATR RES, V54, P466, DOI 10.1203/01.PDR.0000081302.06915.D3; SHANY S, 1984, AM J CLIN NUTR, V40, P1290, DOI 10.1093/ajcn/40.6.1290; Sibley CP, 2010, PLACENTA, V31, pS70, DOI 10.1016/j.placenta.2009.12.020; Strid H, 2003, PLACENTA, V24, P445, DOI 10.1053/plac.2002.0941; Suzuki Y, 2008, J BONE MINER RES, V23, P1249, DOI [10.1359/jbmr.080314, 10.1359/JBMR.080314]; TUAN RS, 1991, J CELL SCI, V98, P333; Wagner CL, 2012, NUTRIENTS, V4, P208, DOI 10.3390/nu4030208; YERGEY AL, 1987, BIOMED ENVIRON MASS, V14, P603, DOI 10.1002/bms.1200141105; Young BE, 2012, AM J CLIN NUTR, V95, P1103, DOI 10.3945/ajcn.111.023861; Young BE, 2012, J BONE MINER RES, V27, P177, DOI 10.1002/jbmr.526; Zehnder D, 2002, AM J PATHOL, V161, P105, DOI 10.1016/S0002-9440(10)64162-4	48	25	26	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2029	2037		10.1096/fj.13-246736	http://dx.doi.org/10.1096/fj.13-246736			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24558197				2022-12-28	WOS:000335336000008
J	Yasuda, D; Imura, Y; Ishii, S; Shimizu, T; Nakamura, M				Yasuda, Daisuke; Imura, Yuki; Ishii, Satoshi; Shimizu, Takao; Nakamura, Motonao			The atypical N-glycosylation motif, Asn-Cys-Cys, in human GPR109A is required for normal cell surface expression and intracellular signaling	FASEB JOURNAL			English	Article						Nicotinic acid receptor; N-linked glycosylation; Asn-X-Cys motif; STT3B; receptor activation	SITE-DIRECTED MUTAGENESIS; NICOTINIC-ACID RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; LINKED GLYCOSYLATION; QUALITY-CONTROL; MOLECULAR-IDENTIFICATION; ENDOPLASMIC-RETICULUM; PROTEIN-STRUCTURE; PUMA-G; SEQUENCE	Asparagine-linked glycosylation (N-glycosylation) is necessary for the proper folding of secreted and membrane proteins, including GPCRs. Thus, many GPCRs possess the N-glycosylation motif Asn-X-Ser/Thr at their N-termini and/or extracellular loops. We found that human GPR109A (hGPR109A) has an N-glycosylation site at Asn(17) in the N-terminal atypical motif, Asn(17)-Cys(18)-Cys(19). Why does hGPR109A require the atypical motif, rather than the typical sequence? Here we show that Asn(17)-Cys(18)-Cys(19) sequence of hGPR109A possesses 2 biologic roles. First, Asn(17)-X-Cys(19) contributed to hGPR109A N-glycosylation by acting as an atypical motif. This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor. Second, the X-Cys(18)-Cys(19) dicysteine is indispensable for hGPR109A function. Substitution of Cys(18) or Cys(19) residue to Ala impaired G(i)-mediated signaling via hGPR109A. We propose the disulfide bond formations of these residues with other Cys existed in the extracellular loops for the proper folding. Together, these results suggest that the atypical motif Asn(17)-Cys(18)-Cys(19) is crucial for the normal surface trafficking and function of hGPR109A.	[Yasuda, Daisuke; Imura, Yuki; Shimizu, Takao; Nakamura, Motonao] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 113, Japan; [Yasuda, Daisuke; Ishii, Satoshi] Akita Univ, Fac Med, Dept Immunol, Akita 010, Japan; [Shimizu, Takao] Natl Ctr Global Hlth & Med, Dept Lipid Signaling, Tokyo, Japan; [Shimizu, Takao] Okayama Univ Sci, Fac Sci, Dept Life Sci, Okayama, Okayama 7000005, Japan	University of Tokyo; Akita University; National Center for Global Health & Medicine - Japan; Okayama University of Science	Nakamura, M (corresponding author), Okayama Univ Sci, Fac Sci, Dept Life Sci, Kita Ku, 1-1 Ridai Cho, Okayama, Okayama 7000005, Japan.	moto-nakamura@dls.ous.ac.jp	Shimizu, Takao/AAV-7052-2021	Yasuda, Daisuke/0000-0001-5513-0695	Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science (Global COE program); Center for NanoBio Integration at the University of Tokyo; Grants-in-Aid for Scientific Research [25116703] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (Global COE program); Center for NanoBio Integration at the University of Tokyo; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors are grateful to Dr. Y. Kita (University of Tokyo), Dr. H. Shindou (National Center for Global Health and Medicine), and Drs. N. Akahoshi and T. Ohto (Akita University), and to all members of their laboratory for technical advice and useful discussions. The authors also thank Mrs. C. Kanokoda and Mrs. Y. Sugimoto-Aruga for their technical support. This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to D.Y., M.N., and T.S.), and grants from the Japan Society for the Promotion of Science (Global COE program) and the Center for NanoBio Integration at the University of Tokyo.	Araki T, 1998, ARCH BIOCHEM BIOPHYS, V351, P250, DOI 10.1006/abbi.1997.0564; BAUSE E, 1979, FEBS LETT, V108, P341, DOI 10.1016/0014-5793(79)80559-1; Bisello A, 1996, BIOCHEMISTRY-US, V35, P15890, DOI 10.1021/bi962111+; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen QA, 2010, AM J PHYSIOL-ENDOC M, V299, pE62, DOI 10.1152/ajpendo.00067.2010; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; Digby JE, 2012, ARTERIOSCL THROM VAS, V32, P582, DOI 10.1161/ATVBAHA.111.236315; Dong CM, 2007, BBA-BIOMEMBRANES, V1768, P853, DOI 10.1016/j.bbamem.2006.09.008; FUKUSHIMA Y, 1995, BIOCHEM J, V310, P553, DOI 10.1042/bj3100553; Gil GC, 2009, PROTEOMICS, V9, P2555, DOI 10.1002/pmic.200800775; Giuffrida MG, 1997, J PROTEIN CHEM, V16, P747, DOI 10.1023/A:1026359715821; Hirota N, 2010, J BIOL CHEM, V285, P5931, DOI 10.1074/jbc.M109.066282; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Innamorati G, 1996, MOL PHARMACOL, V50, P467; JENSEN CH, 1994, EUR J BIOCHEM, V225, P83, DOI 10.1111/j.1432-1033.1994.00083.x; Kohno T, 2002, FASEB J, V16, P983, DOI 10.1096/fj.01-0809com; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Krogh TN, 1997, EUR J BIOCHEM, V244, P334, DOI 10.1111/j.1432-1033.1997.00334.x; Kuei C, 2011, MOL PHARMACOL, V80, P848, DOI 10.1124/mol.111.074500; Markkanen PMH, 2008, J BIOL CHEM, V283, P29086, DOI 10.1074/jbc.M801880200; Marshall R D, 1974, Biochem Soc Symp, P17; Matsui T, 2011, GLYCOBIOLOGY, V21, P994, DOI 10.1093/glycob/cwq198; Michineau S, 2004, BIOL CHEM, V385, P49, DOI 10.1515/BC.2004.007; NODA K, 1994, J BIOL CHEM, V269, P6743; Offermanns S, 2006, TRENDS PHARMACOL SCI, V27, P384, DOI 10.1016/j.tips.2006.05.008; RANDS E, 1990, J BIOL CHEM, V265, P10759; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ruddock LW, 2006, J CELL SCI, V119, P4373, DOI 10.1242/jcs.03225; Ruiz-Canada C, 2009, CELL, V136, P272, DOI 10.1016/j.cell.2008.11.047; Rutz C, 2006, J BIOL CHEM, V281, P24910, DOI 10.1074/jbc.M601554200; Sato C, 2000, J BIOCHEM-TOKYO, V127, P65, DOI 10.1093/oxfordjournals.jbchem.a022585; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SAWUTZ DG, 1987, MOL PHARMACOL, V32, P565; Shukla AK, 2006, BIOCHEM BIOPH RES CO, V349, P6, DOI 10.1016/j.bbrc.2006.07.210; Siffroi-Fernandez S, 2002, EUR J BIOCHEM, V269, P4930, DOI 10.1046/j.1432-1033.2002.03192.x; Soga T, 2003, BIOCHEM BIOPH RES CO, V303, P364, DOI 10.1016/S0006-291X(03)00342-5; STENFLO J, 1982, J BIOL CHEM, V257, P2180; Tan CM, 2003, J BIOL CHEM, V278, P35678, DOI 10.1074/jbc.M301888200; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; Tunaru S, 2005, MOL PHARMACOL, V68, P1271, DOI 10.1124/mol.105.015750; Tunaru S, 2003, NAT MED, V9, P352, DOI 10.1038/nm824; Valliere-Douglass JF, 2010, J BIOL CHEM, V285, P16012, DOI 10.1074/jbc.M109.096412; Vance BA, 1997, J BIOL CHEM, V272, P23117, DOI 10.1074/jbc.272.37.23117; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; Wanders D, 2011, DIABETES OBES METAB, V13, P685, DOI 10.1111/j.1463-1326.2011.01400.x; Whitaker GM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032675; Wise A, 2003, J BIOL CHEM, V278, P9869, DOI 10.1074/jbc.M210695200; Xiao YP, 2011, J BIOL CHEM, V286, P22991, DOI 10.1074/jbc.M110.204271; Yasuda D, 2009, FASEB J, V23, P1470, DOI 10.1096/fj.08-125385; Zielinska DF, 2010, CELL, V141, P897, DOI 10.1016/j.cell.2010.04.012	51	12	12	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2412	2422		10.1096/fj.14-267096	http://dx.doi.org/10.1096/fj.14-267096			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25690651	Green Published			2022-12-28	WOS:000355209500018
J	Schenkel, LC; Singh, RK; Michel, V; Zeisel, SH; da Costa, KA; Johnson, AR; Mudd, HS; Bakovic, M				Schenkel, Laila C.; Singh, Ratnesh K.; Michel, Vera; Zeisel, Steven H.; da Costa, Kerry-Ann; Johnson, Amy R.; Mudd, Harvey S.; Bakovic, Marica			Mechanism of choline deficiency and membrane alteration in postural orthostatic tachycardia syndrome primary skin fibroblasts	FASEB JOURNAL			English	Article						choline transport; CTL1/SLC44A1; mitochondria; phospholipids	TRANSPORTER-LIKE PROTEIN-1; RAT-LIVER MITOCHONDRIA; ONE-CARBON METABOLITES; MASS-SPECTROMETRY; S-ADENOSYLMETHIONINE; PHOSPHATIDYLETHANOLAMINE; CELLS; NUTRIENT; WOMEN; PHOSPHATIDYLCHOLINE	Fibroblasts from a patient with postural orthostatic tachycardia syndrome (POTS), who presented with low plasma choline and betaine, were studied to determine the metabolic characteristics of the choline deficiency. Choline is required for the synthesis of the phospholipid phosphatidylcholine (PC) and for betaine, an important osmoregulator. Here, choline transport, lipid homeostasis, and mitochondria function were analyzed in skin fibroblasts from POTS and compared with control cells. The choline transporter-like protein 1/solute carrier 44A1 (CTL1/SLC44A1) and mRNA expression were 2-3 times lower in POTS fibroblasts, and choline uptake was reduced 60% (P < 0.05). Disturbances of membrane homeostasis were observed by reduced ratios between PC:phosphatidylethanolamine and sphingomyelin:cholesterol, as well as by modified phospholipid fatty acid composition. Choline deficiency also impaired mitochondria function, which was observed by a reduction in oxygen consumption, mitochondrial potential, and glycolytic activity. When POTS cells were treated with choline, transporter was up-regulated, and uptake of choline increased, offering an option for patient treatment. The characteristics of the POTS fibroblasts described here represent a first model of choline and CTL1/SLC44A1 deficiency, in which choline transport, membrane homeostasis, and mitochondrial function are impaired.Schenkel, L. C., Singh, R. K., Michel, V., Zeisel, S. H., da Costa, K.-A., Johnson, A. R., Mudd, H. S., Bakovic, M. Mechanism of choline deficiency and membrane alteration in postural orthostatic tachycardia syndrome primary skin fibroblasts.	[Schenkel, Laila C.; Singh, Ratnesh K.; Michel, Vera; Bakovic, Marica] Univ Guelph, Dept Human Hlth & Nutr Sci, Guelph, ON N1G 2W1, Canada; [Zeisel, Steven H.] Univ N Carolina, Inst Nutr Res, Kannapolis, NC USA; [Zeisel, Steven H.; Johnson, Amy R.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA; [da Costa, Kerry-Ann] Toxicol Serv Inc, Chapel Hill, NC USA; [Mudd, Harvey S.] NIMH, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	University of Guelph; University of North Carolina; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Bakovic, M (corresponding author), Univ Guelph, Dept Human Hlth & Nutr Sci, Anim Sci & Nutr Bldg,Room 346,50 Stone Rd East, Guelph, ON N1G 2W1, Canada.	mbakovic@uoguelph.ca		Schenkel, Laila Cigana/0000-0003-4939-6790	National Sciences and Engineering Research Council of Canada; Ontario Ministry of Agriculture, Food and Rural Affairs	National Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Ontario Ministry of Agriculture, Food and Rural Affairs	All the authors wish to acknowledge Dr. Harvey S. Mudd (1927-2014) who assembled this team of scientists to examine the metabolic disorder presented in this paper in order to understand it and give the patient possible treatment options. Dr. Mudd was a thoughtful and generous collaborator, and this paper brings to fruition his tireless efforts, although he did not live to see its completion. The authors acknowledge the support of Michael Leadley and the Analytical Facility for Bioactive Molecules, Sick Kids Centre, Toronto, in assisting with the lipidomics analysis. This study was supported by operating grants from the National Sciences and Engineering Research Council of Canada and the Ontario Ministry of Agriculture, Food and Rural Affairs (to M.B.).	Aoyama C, 2000, J LIPID RES, V41, P452; Bakewell L, 2006, BRIT J NUTR, V96, P93, DOI 10.1079/BJN20061801; Benarroch EE, 2012, MAYO CLIN PROC, V87, P1214, DOI 10.1016/j.mayocp.2012.08.013; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bollag W B, 1998, Methods Mol Biol, V105, P151; Courtenay ES, 2000, BIOCHEMISTRY-US, V39, P4455, DOI 10.1021/bi992887l; D'Alessandro S, 2011, BIOCHEM PHARMACOL, V82, P476, DOI 10.1016/j.bcp.2011.06.002; Davis SR, 2005, J NUTR, V135, P1040, DOI 10.1093/jn/135.5.1040; Dominguez-Salas P, 2013, AM J CLIN NUTR, V97, P1217, DOI 10.3945/ajcn.112.048462; Ejsing CS, 2009, P NATL ACAD SCI USA, V106, P2136, DOI 10.1073/pnas.0811700106; Fernandez-Roig S, 2013, AM J CLIN NUTR, V97, P1252, DOI 10.3945/ajcn.112.054189; FILIPOWICZ CM, 1983, BIOCHIM BIOPHYS ACTA, V734, P373, DOI 10.1016/0005-2736(83)90138-4; Fischer LM, 2007, AM J CLIN NUTR, V85, P1275; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fullerton MD, 2006, AM J PHYSIOL-CELL PH, V290, pC1230, DOI 10.1152/ajpcell.00255.2005; Gallazzini M, 2009, PHYSIOLOGY, V24, P245, DOI 10.1152/physiol.00009.2009; Gibellini F, 2010, IUBMB LIFE, V62, P414, DOI 10.1002/iub.337; Graeve M, 2009, J CHROMATOGR B, V877, P1815, DOI 10.1016/j.jchromb.2009.05.004; Guo WX, 2005, FREE RADICAL BIO MED, V39, P641, DOI 10.1016/j.freeradbiomed.2005.04.013; Han XL, 2003, J LIPID RES, V44, P1071, DOI 10.1194/jlr.R300004-JLR200; Hishikawa D, 2014, J LIPID RES, V55, P799, DOI 10.1194/jlr.R046094; Horio M, 2001, NEPHROL DIAL TRANSPL, V16, P483, DOI 10.1093/ndt/16.3.483; Kamath AV, 2003, J NUTR, V133, P2607, DOI 10.1093/jn/133.8.2607; KAPLAN CP, 1993, FEBS LETT, V321, P24, DOI 10.1016/0014-5793(93)80613-Y; Koc H, 2002, ANAL CHEM, V74, P4734, DOI 10.1021/ac025624x; Li ZY, 2006, CELL METAB, V3, P321, DOI 10.1016/j.cmet.2006.03.007; LIN CS, 1986, J PROTEIN CHEM, V5, P193, DOI 10.1007/BF01025488; Michel V, 2006, EXP BIOL MED, V231, P490; Michel V. H., 2010, EXPRESSION SUBCELLUL; Michel V, 2011, FOOD FUNCT, V2, P53, DOI 10.1039/c0fo00069h; Michel V, 2009, FASEB J, V23, P2749, DOI 10.1096/fj.08-121491; O'Donoghue N, 2009, BBA-BIOENERGETICS, V1787, P1135, DOI 10.1016/j.bbabio.2009.04.014; Ohvo-Rekila H, 2002, PROG LIPID RES, V41, P66, DOI 10.1016/S0163-7827(01)00020-0; Stabler SP, 2004, CLIN CHEM, V50, P365, DOI 10.1373/clinchem.2003.026252; Teodoro JS, 2008, MITOCHONDRION, V8, P367, DOI 10.1016/j.mito.2008.07.008; van der Veen JN, 2014, DIABETES, V63, P2620, DOI 10.2337/db13-0993; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Yabuki M, 2009, ARCH BIOCHEM BIOPHYS, V485, P88, DOI 10.1016/j.abb.2009.02.007; Yuan ZF, 2006, PHYSIOL GENOMICS, V26, P76, DOI 10.1152/physiolgenomics.00107.2005; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061; ZEISEL SH, 1989, BIOCHEM J, V259, P725, DOI 10.1042/bj2590725; ZEISEL SH, 1992, J AM COLL NUTR, V11, P473	43	11	12	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1663	1675		10.1096/fj.14-258566	http://dx.doi.org/10.1096/fj.14-258566			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25466896	Green Published, Green Submitted			2022-12-28	WOS:000354114600006
J	Zimberlin, CD; Lancini, C; Sno, R; Rosekrans, SL; McLean, CM; Vlaming, H; van den Brink, GR; Bots, M; Medema, JP; Dannenberg, JH				Zimberlin, Cheryl D.; Lancini, Cesare; Sno, Rachel; Rosekrans, Sanne L.; McLean, Chelsea M.; Vlaming, Hanneke; van den Brink, Gijs R.; Bots, Michael; Medema, Jan Paul; Dannenberg, Jan-Hermen			HDAC1 and HDAC2 collectively regulate intestinal stem cell homeostasis	FASEB JOURNAL			English	Article						organoids; histone deacetylase inhibitor; histone deacetylase; MS-275	HISTONE DEACETYLASES; SELF-RENEWAL; CANCER; EXPRESSION; WNT; TUMORIGENESIS; COLON; PROLIFERATION; EPITHELIUM; INDUCTION	Histone deacetylases (HDACs) are posttranslational modifiers that deacetylate proteins. Despite their crucial role in numerous biological processes, the use of broad-range HDAC inhibitors (HDACi), has shown clinical efficacy. However, undesired side effects highlight the necessity to better understand the biology of different HDACs and target the relevant HDACs. Using a novel mouse model, in which HDAC1 and HDAC2 can be simultaneously deleted in the intestine of adult mice, we show that the simultaneous deletion of HDAC1 and HDAC2 leads to a rapid loss of intestinal homeostasis. Importantly, this deletion cannot be sustained, and 8 days after initial ablation, stem cells that have escaped HDAC1 or HDAC2 deletion swiftly repopulate the intestinal lining. In vitro ablation of HDAC1 and HDAC2 using intestinal organoid cultures resulted in a down-regulation of multiple intestinal stem cell markers and functional loss of clonogenic capacity. Importantly, treatment of wild-type organoids with class I-specific HDACi MS-275 also induced a similar loss of stemness, providing a possible rationale for the gastrointestinal side effects often observed in HDACi-treated patients. In conclusion, these data show that HDAC1 and HDAC2 have a redundant function and are essential to maintain intestinal homeostasis.	[Zimberlin, Cheryl D.; Bots, Michael; Medema, Jan Paul] Univ Amsterdam, Acad Med Ctr, Ctr Expt Mol Med, Lab Expt Oncol & Radiobiol, NL-1105 AZ Amsterdam, Netherlands; [Lancini, Cesare; Sno, Rachel; McLean, Chelsea M.; Vlaming, Hanneke; Dannenberg, Jan-Hermen] Netherlands Canc Inst, Div Gene Regulat, NL-1066 CX Amsterdam, Netherlands; [Rosekrans, Sanne L.; van den Brink, Gijs R.] Univ Amsterdam, Acad Med Ctr, Tygat Inst Liver & Intestinal Res, NL-1105 AZ Amsterdam, Netherlands; [Medema, Jan Paul] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands; [Medema, Jan Paul] Canc Genom Ctr, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University	Dannenberg, JH (corresponding author), Netherlands Canc Inst, Div Gene Regulat, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.dannenberg@nki.nl		Medema, Jan Paul/0000-0003-3045-2924; McLean, Chelsea/0000-0002-3548-3482; Vlaming, Hanneke/0000-0003-1743-6428	Dutch Cancer Society [KWF-2007-3978, KWF NKI 2009-4511, UvA2009-4416, UvA2012-5735]; Netherlands Organization for Scientific Research [NWO-VIDI 864.07.008]; Netherlands Organization for Scientific Research (Gravitation; Zwaartekracht); Maag, Lever en Darm Stichting (MLDS) [FP13-07]; Alpe d'Huzes/Dutch Cancer Society (CONNECTION)	Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Netherlands Organization for Scientific Research (Gravitation; Zwaartekracht); Maag, Lever en Darm Stichting (MLDS); Alpe d'Huzes/Dutch Cancer Society (CONNECTION)	The authors thank Martijn Koppens for providing the in vitro beta-NF protocol. The authors thank Ton Schrauwers, Corine van Langen, Auke Zwerver, Cor Spaan, and Dienke Jonkers for excellent animal care. J.P.M. and J.-H.D. share senior authorship. This work was supported by grants from the Dutch Cancer Society (KWF-2007-3978) and Netherlands Organization for Scientific Research (NWO-VIDI 864.07.008) (to J.H.D.). H.V. and C.M.M. are supported by a grant from the Dutch Cancer Society (KWF NKI 2009-4511). J.P.M. is supported by the Dutch Cancer Society (UvA2009-4416 and UvA2012-5735), the Netherlands Organization for Scientific Research (Gravitation; Zwaartekracht), Maag, Lever en Darm Stichting (MLDS) (FP13-07), and Alpe d'Huzes/Dutch Cancer Society (CONNECTION).	Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Clevers H, 2013, NATURE, V495, P53, DOI 10.1038/nature11958; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Guan JS, 2009, NATURE, V459, P55, DOI 10.1038/nature07925; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Heath JP, 1996, CELL BIOL INT, V20, P139, DOI 10.1006/cbir.1996.0018; Heideman MR, 2013, BLOOD, V121, P2038, DOI 10.1182/blood-2012-08-450916; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Kemp R, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh090; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212; Montgomery RL, 2007, GENE DEV, V21, P1790, DOI 10.1101/gad.1563807; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Prasetyanti PR, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-126; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Santoro F, 2013, BLOOD, V121, P3459, DOI 10.1182/blood-2012-10-461988; Trivedi CM, 2007, NAT MED, V13, P324, DOI 10.1038/nm1552; Turgeon N, 2014, AM J PHYSIOL-GASTR L, V306, pG594, DOI 10.1152/ajpgi.00393.2013; Turgeon N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073785; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Wilting RH, 2010, EMBO J, V29, P2586, DOI 10.1038/emboj.2010.136; Winter M, 2013, EMBO J, V32, P3176, DOI 10.1038/emboj.2013.243; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X; Zimmermann S, 2007, CANCER RES, V67, P9047, DOI 10.1158/0008-5472.CAN-07-0312	35	29	31	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					2070	2080		10.1096/fj.14-257931	http://dx.doi.org/10.1096/fj.14-257931			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25648995				2022-12-28	WOS:000354114600039
J	Arik, AJ; Hun, LV; Quicke, K; Piatt, M; Ziegler, R; Scaraffia, PY; Badgandi, H; Riehle, MA				Arik, Anam J.; Hun, Lewis V.; Quicke, Kendra; Piatt, Michael; Ziegler, Rolf; Scaraffia, Patricia Y.; Badgandi, Hemant; Riehle, Michael A.			Increased Akt signaling in the mosquito fat body increases adult survivorship	FASEB JOURNAL			English	Article						Aedes aegypti; aging; Anopheles stephensi; insulin signaling; vitellogenin	YELLOW-FEVER MOSQUITO; LIFE-SPAN; STRESS RESISTANCE; OXIDATIVE STRESS; INSULIN-RECEPTOR; DROSOPHILA; LONGEVITY; FITNESS; LONG; REPRODUCTION	Akt signaling regulates diverse physiologies in a wide range of organisms. We examine the impact of increased Akt signaling in the fat body of 2 mosquito species, the Asian malaria mosquito Anopheles stephensi and the yellow fever mosquito Aedes aegypti. Overexpression of a myristoylated and active form of A. stephensi and Ae. aegypti Akt in the fat body of transgenic mosquitoes led to activation of the downstream signaling molecules forkhead box O (FOXO) and p70 S6 kinase in a tissue and blood meal-specific manner. In both species, increased Akt signaling in the fat body after blood feeding significantly increased adult survivorship relative to nontransgenic sibling controls. In A. stephensi, survivorship was increased by 15% to 45%, while in Ae. aegypti, it increased 14% to 47%. Transgenic mosquitoes fed only sugar, and thus not expressing active Akt, had no significant difference in survivorship relative to nontransgenic siblings. Expression of active Akt also increased expression of fat body vitellogenin, but the number of viable eggs did not differ significantly between transgenic and nontransgenic controls. This work demonstrates a novel mechanism of enhanced survivorship through increased Akt signaling in the fat bodies of multiple mosquito genera and provides new tools to unlock the molecular underpinnings of aging in eukaryotic organisms.	[Arik, Anam J.; Hun, Lewis V.; Piatt, Michael; Ziegler, Rolf; Riehle, Michael A.] Univ Arizona, Dept Entomol, Tucson, AZ 85721 USA; [Quicke, Kendra] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Scaraffia, Patricia Y.] Tulane Univ, Sch Publ Hlth & Trop Med, Vector Borne Infect Dis Res Ctr, Dept Trop Med, New Orleans, LA USA; [Badgandi, Hemant] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA	University of Arizona; Emory University; Tulane University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Riehle, MA (corresponding author), Univ Arizona, Dept Entomol, 1140 E South Campus Dr,Forbes 410, Tucson, AZ 85721 USA.	mriehle@ag.arizona.edu	Riehle, Michael A/O-2852-2017	Badgandi, Hemant/0000-0001-6181-4241; Scaraffia, Patricia/0000-0003-2985-933X; Riehle, Michael/0000-0001-9747-3872	U.S. National Institutes of Health National Institute of Allergies and Infectious Diseases [AI073745, AI088092]; Grand Challenges Exploration grant from the Bill and Melinda Gates Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI088092, R01AI073745] Funding Source: NIH RePORTER	U.S. National Institutes of Health National Institute of Allergies and Infectious Diseases; Grand Challenges Exploration grant from the Bill and Melinda Gates Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by the U.S. National Institutes of Health National Institute of Allergies and Infectious Diseases Grants AI073745 to M.A.R. and AI088092 to P.Y.S.; and a Grand Challenges Exploration grant from the Bill and Melinda Gates Foundation. The authors thank Dr. Frank Ramberg for his assistance in maintaining the TG mosquito colonies and Dr. Jenya Antonova for her advice and guidance.	Amenya DA, 2010, INSECT MOL BIOL, V19, P263, DOI 10.1111/j.1365-2583.2009.00986.x; Antonova Y., 2012, INSECT ENDOCRINOL, P63, DOI DOI 10.1016/B978-0-12-384749-2.10002-0; Arik Anam J., 2009, BMC Physiology, V9, P15, DOI 10.1186/1472-6793-9-15; Arrese EL, 2010, ANNU REV ENTOMOL, V55, P207, DOI 10.1146/annurev-ento-112408-085356; Bai H, 2012, AGING CELL, V11, P978, DOI 10.1111/acel.12000; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; Catteruccia F, 2003, SCIENCE, V299, P1225, DOI 10.1126/science.1081453; Clements AN., 1992, BIOL MOSQUITOES DEV; Corby-Harris V, 2010, PLOS PATHOG, V6, DOI [10.1371/journal.ppat.1001003, 10.1371/annotation/738ac91f-8c41-4bf5-9a39-bddf0b777a89]; Dong YM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002458; Flatt T, 2011, EXP GERONTOL, V46, P369, DOI 10.1016/j.exger.2010.10.008; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Garsin DA, 2003, SCIENCE, V300, P1921, DOI 10.1126/science.1080147; Gems D, 2013, ANNU REV PHYSIOL, V75, P621, DOI 10.1146/annurev-physiol-030212-183712; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Gronke S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000857; Hauck ES, 2013, MICROBES INFECT, V15, P775, DOI 10.1016/j.micinf.2013.05.006; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Hyun J, 2011, FLY, V5, P53, DOI 10.4161/fly.5.1.14080; Irvin N, 2004, P NATL ACAD SCI USA, V101, P891, DOI 10.1073/pnas.0305511101; Isaacs AT, 2012, P NATL ACAD SCI USA, V109, pE1922, DOI 10.1073/pnas.1207738109; Jenkins NL, 2004, P ROY SOC B-BIOL SCI, V271, P2523, DOI 10.1098/rspb.2004.2897; Kang MA, 2008, J EXP BIOL, V211, P741, DOI 10.1242/jeb.012955; Keaney M, 2004, FREE RADICAL BIO MED, V37, P239, DOI 10.1016/j.freeradbiomed.2004.04.005; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kokoza V, 2001, INSECT BIOCHEM MOLEC, V31, P1137, DOI 10.1016/S0965-1748(01)00120-5; Li CY, 2008, J HERED, V99, P275, DOI 10.1093/jhered/esn004; Magwere T, 2006, MECH AGEING DEV, V127, P356, DOI 10.1016/j.mad.2005.12.009; Moreira LA, 2004, GENETICS, V166, P1337, DOI 10.1534/genetics.166.3.1337; Mukhopadhyay A, 2007, TRENDS CELL BIOL, V17, P65, DOI 10.1016/j.tcb.2006.12.004; Nirmala X, 2006, INSECT BIOCHEM MOLEC, V36, P694, DOI 10.1016/j.ibmb.2006.05.011; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paaby AB, 2009, FLY, V3, P29, DOI 10.4161/fly.3.1.7771; Petrovski G, 2010, J CELL MOL MED, V14, P2543, DOI 10.1111/j.1582-4934.2010.01196.x; Piper MDW, 2008, J INTERN MED, V263, P179, DOI 10.1111/j.1365-2796.2007.01906.x; Piper MDW, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030057; Promislow DEL, 1996, GENETICS, V143, P839; Raikhel AS, 2002, INSECT BIOCHEM MOLEC, V32, P1275, DOI 10.1016/S0965-1748(02)00090-5; Rera M, 2011, CELL METAB, V14, P623, DOI 10.1016/j.cmet.2011.09.013; Riehle MA, 1999, INSECT BIOCHEM MOLEC, V29, P855, DOI 10.1016/S0965-1748(99)00084-3; Roy SG, 2007, INSECT BIOCHEM MOLEC, V37, P1317, DOI 10.1016/j.ibmb.2007.08.004; Selman C, 2008, FASEB J, V22, P807, DOI 10.1096/fj.07-9261com; Selman C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016144; Sgro CM, 1999, SCIENCE, V286, P2521, DOI 10.1126/science.286.5449.2521; Toivonen JM, 2009, MOL CELL ENDOCRINOL, V299, P39, DOI 10.1016/j.mce.2008.07.005; Wessells RJ, 2004, NAT GENET, V36, P1275, DOI 10.1038/ng1476	48	21	22	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1404	1413		10.1096/fj.14-261479	http://dx.doi.org/10.1096/fj.14-261479			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550465	Green Published			2022-12-28	WOS:000354115000026
J	Heissler, SM; Chinthalapudi, K; Sellers, JR				Heissler, Sarah M.; Chinthalapudi, Krishna; Sellers, James R.			Kinetic characterization of the sole nonmuscle myosin-2 from the model organism Drosophila melanogaster	FASEB JOURNAL			English	Article						actin; blebbistatin; cytoskeleton; transient kinetics; rotamer	BLEBBISTATIN INHIBITION; CYTOPLASMIC MYOSIN; MOTOR DOMAIN; DICTYOSTELIUM-DISCOIDEUM; MUSCLE MYOSIN; ACTIN; MORPHOGENESIS; PROTEIN; OOGENESIS; MECHANISM	Nonmuscle myosin-2 is the primary enzyme complex powering contractility of the F-actin cytoskeleton in the model organism Drosophila. Despite myosin's essential function in fly development and homeostasis, its kinetic features remain elusive. The purpose of this in vitro study is a detailed steady-state and presteady-state kinetic characterization of the Drosophila nonmuscle myosin-2 motor domain. Kinetic features are a slow steady-state ATPase activity, high affinities for F-actin and ADP, and a low duty ratio. Comparative analysis of the overall enzymatic signatures across the nonmuscle myosin-2 complement from model organisms indicates that the Drosophila protein resembles nonmuscle myosin-2s from metazoa rather than protozoa, though modulatory aspects of myosin motor function are distinct. Drosophila nonmuscle myosin-2 is uniquely insensitive toward blebbistatin, a commonly used myosin-2 inhibitor. An in silico modeling approach together with kinetic studies indicate that the nonconsensus amino acid Met466 in the Drosophila nonmuscle myosin-2 active-site loop switch-2 acts as blebbistatin desensitizer. Introduction of the M466I mutation sensitized the protein for blebbistatin, resulting in a half-maximal inhibitory concentration of 36.3 +/- 4.1 mu M. Together, these data show that Drosophila nonmuscle myosin-2 is a bona fide molecular motor and establish an important link between switch-2 and blebbistatin sensitivity.	[Heissler, Sarah M.; Sellers, James R.] NHLBI, Lab Mol Physiol, NIH, Bethesda, MD 20892 USA; [Chinthalapudi, Krishna] Scripps Res Inst, Dept Canc Biol, Cell Adhes Lab, Jupiter, FL USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Scripps Research Institute	Sellers, JR (corresponding author), NHLBI, Lab Mol Physiol, NIH, 50 South Dr,B50-3523, Bethesda, MD 20892 USA.	sellersj@nhlbi.nih.gov	Chinthalapudi, Krishna/B-4550-2018	Chinthalapudi, Krishna/0000-0003-3669-561X	U.S. National Institutes of Health National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL001786] Funding Source: NIH RePORTER	U.S. National Institutes of Health National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Adam C. Martin (Massachusetts Institute of Technology, Cambridge, MA, USA) for the Drosophila nonmuscle myosin-2 cDNA and the polycistronic expression vector encoding for Sqh and Mlc-c. They also thank Fang Zhang for the preparation of F-actin. J.R.S. was funded by the Intramural Research Program of the U.S. National Institutes of Health National Heart, Lung, and Blood Institute.	Aldaz S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2763; Allingham JS, 2005, NAT STRUCT MOL BIOL, V12, P378, DOI 10.1038/nsmb908; Bloor JW, 2001, DEV BIOL, V239, P215, DOI 10.1006/dbio.2001.0452; Cao Y, 2014, BIOCHEMISTRY-US, V53, P350, DOI 10.1021/bi401236c; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; Dunbrack RL, 2002, CURR OPIN STRUC BIOL, V12, P431, DOI 10.1016/S0959-440X(02)00344-5; Ferreira T, 2014, DEV BIOL, V394, P277, DOI 10.1016/j.ydbio.2014.08.008; Franke JD, 2007, HUM MOL GENET, V16, P3160, DOI 10.1093/hmg/ddm279; Franke JD, 2010, DEV BIOL, V345, P117, DOI 10.1016/j.ydbio.2010.06.028; Furch M, 2000, BIOCHEMISTRY-US, V39, P11602, DOI 10.1021/bi000985x; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Guzik-Lendrum S, 2013, J BIOL CHEM, V288, P9532, DOI 10.1074/jbc.M112.441238; Guzik-Lendrum S, 2011, J BIOL CHEM, V286, P21755, DOI 10.1074/jbc.M111.218669; Heissler SM, 2013, J BIOL CHEM, V288, P26709, DOI 10.1074/jbc.M113.485946; Heissler SM, 2013, CELL MOL LIFE SCI, V70, P1, DOI 10.1007/s00018-012-1002-9; Heissler SM, 2011, J BIOL CHEM, V286, P21191, DOI 10.1074/jbc.M110.212290; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kovacs M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200; Kuhlman PA, 1998, J MUSCLE RES CELL M, V19, P491, DOI 10.1023/A:1005304408812; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; LEHRER SS, 1972, BIOCHEMISTRY-US, V11, P1211, DOI 10.1021/bi00757a015; Limouze J, 2004, J MUSCLE RES CELL M, V25, P337, DOI 10.1007/s10974-004-6060-7; Ma Xuefei, 2014, Bioarchitecture, V4, P88, DOI 10.4161/bioa.29766; MAHAJANMIKLOS S, 1994, DEV BIOL, V165, P336, DOI 10.1006/dbio.1994.1257; Martin AC, 2009, NATURE, V457, P495, DOI 10.1038/nature07522; MILLAR NC, 1983, FEBS LETT, V160, P141, DOI 10.1016/0014-5793(83)80954-5; Moore JR, 2012, CIRC RES, V111, P375, DOI 10.1161/CIRCRESAHA.110.223842; Murphy CT, 2001, NAT CELL BIOL, V3, P311, DOI 10.1038/35060110; Nagy A, 2013, J BIOL CHEM, V288, P709, DOI 10.1074/jbc.M112.424671; Okumura T, 2010, DEV BIOL, V344, P693, DOI 10.1016/j.ydbio.2010.05.501; Ramamurthy B, 2004, BIOCHEMISTRY-US, V43, P14832, DOI 10.1021/bi0490284; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Seabrooke S, 2011, J NEUROPHYSIOL, V105, P1966, DOI 10.1152/jn.00718.2010; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Shu S, 2005, P NATL ACAD SCI USA, V102, P1472, DOI 10.1073/pnas.0409528102; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129; Vasquez CG, 2014, J CELL BIOL, V206, P435, DOI 10.1083/jcb.201402004; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; WHEATLEY S, 1995, DEVELOPMENT, V121, P1937; Yang Z, 2012, J STRUCT BIOL, V179, P269, DOI 10.1016/j.jsb.2011.09.006; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29; Zhao FQ, 2008, BIOPHYS J, V95, P3322, DOI 10.1529/biophysj.108.137067	48	18	18	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1456	1466		10.1096/fj.14-266742	http://dx.doi.org/10.1096/fj.14-266742			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25636739	Green Published			2022-12-28	WOS:000354115000031
J	Rodriguez-Carballo, E; Gamez, B; Mendez-Lucas, A; Sanchez-Freutrie, M; Zorzano, A; Bartrons, R; Alcantara, S; Perales, JC; Ventura, F				Rodriguez-Carballo, Edgardo; Gamez, Beatriz; Mendez-Lucas, Andres; Sanchez-Freutrie, Manuela; Zorzano, Antonio; Bartrons, Ramon; Alcantara, Soledad; Carlos Perales, Jose; Ventura, Francesc			p38 alpha function in osteoblasts influences adipose tissue homeostasis	FASEB JOURNAL			English	Article						bone; NPY; metabolism; adipocyte; energy expenditure; osteocalcin	ACID-CONTAINING PROTEIN; NEUROPEPTIDE-Y; IN-VIVO; PERIPHERAL MECHANISMS; ENERGY-METABOLISM; KINASE PATHWAYS; INDUCED OBESITY; KNOCKOUT MICE; BODY-WEIGHT; BONE MASS	The skeleton acts as an endocrine organ that regulates energy metabolism and calcium and phosphorous homeostasis through the secretion of osteocalcin (Oc) and fibroblast growth factor 23 (FGF23). However, evidence suggests that osteoblasts secrete additional unknown factors that contribute to the endocrine function of bone. To search for these additional factors, we generated mice with a conditional osteoblast-specific deletion of p38 alpha MAPK known to display profound defects in bone homeostasis. Herein, we show that impaired osteoblast function is associated with a strong decrease in body weight and adiposity (P < 0.01). The differences in adiposity were not associated with diminished caloric intake, but rather reflected 20% increased energy expenditure and the up-regulation of uncoupling protein-1 (Ucp1) in white adipose tissue (WAT) and brown adipose tissue (BAT) (P < 0.05). These alterations in lipid metabolism and energy expenditure were correlated with a decrease in the bloodlevels of neuropeptide Y (NPY) (40% lower) rather than changes in the serum levels of insulin, Oc, or FGF23. Among all Npy-expressing tissues, only bone and primary osteoblasts showed a decline in Npy expression (P < 0.01). Moreover, the intraperitoneal administration of recombinant NPY partially restored the WAT weight and adipocyte size of p38 alpha-deficient mice (P < 0.05). Altogether, these results further suggest that, in addition to Oc, other bone-derived signals affect WAT and energy expenditure contributing to the regulation of energy metabolism.	[Rodriguez-Carballo, Edgardo; Gamez, Beatriz; Mendez-Lucas, Andres; Bartrons, Ramon; Carlos Perales, Jose; Ventura, Francesc] Univ Barcelona, Dept Ciencies Fisiol 2, Inst Invest Biomed Bellvitge, E-08907 Lhospitalet De Llobregat, Spain; [Alcantara, Soledad] Univ Barcelona, Dept Patol & Terapeut, Inst Invest Biomed Bellvitge, E-08907 Lhospitalet De Llobregat, Spain; [Sanchez-Freutrie, Manuela; Zorzano, Antonio] Univ Barcelona, Dept Bioquim & Biol Mol, Barcelona, Spain; [Sanchez-Freutrie, Manuela; Zorzano, Antonio] Inst Biomed Res, Barcelona, Spain; [Sanchez-Freutrie, Manuela; Zorzano, Antonio] Inst Salud Carlos III, Ctr Invest Biomed Red CIBER Diabet & Enfermedades, Madrid, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Instituto de Salud Carlos III	Ventura, F (corresponding author), Univ Barcelona, IDIBELL, Dept Ciencies Fisiol 2, C Feixa Llarga S-N, E-08907 Lhospitalet De Llobregat, Spain.	fventura@ub.edu	PERALES, JOSE C./AAC-3156-2019; Zorzano, Antonio/R-5479-2018; Ventura, Francesc/K-9700-2014; Alcantara, Soledad/K-3648-2014; PERALES, JOSE C. C/D-5586-2012; Lucas, Andres Mendez/AAG-7488-2020; Ventura, Francesc/ABG-2285-2020; PERALES, JOSE C/J-7457-2017	PERALES, JOSE C./0000-0001-7363-2226; Ventura, Francesc/0000-0001-9673-9405; Alcantara, Soledad/0000-0003-3313-2715; PERALES, JOSE C. C/0000-0001-7363-2226; Lucas, Andres Mendez/0000-0002-0725-4375; Ventura, Francesc/0000-0001-9673-9405; PERALES, JOSE C/0000-0001-7363-2226; Rodriguez-Carballo, Eddie/0000-0003-4321-508X	Ministry of Education and Science of Spain [BFU2011-24254]; Fundacio La Marato de TV3; Instituto de Salud Carlos III [RETIC RD06/0020]; Institut d'Investigacio Biomedica de Bellvitge (Barcelona, Spain)	Ministry of Education and Science of Spain(Spanish Government); Fundacio La Marato de TV3; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Institut d'Investigacio Biomedica de Bellvitge (Barcelona, Spain)	The authors thank Dr. K. Zhang and Dr. L. Bonewald for the IDG-SW3 and the MLO-Y4 cell lines. The authors also thank A. Angelo, E. Sanchez-Garcia, E. Adanero, Dr. E. Castano, and Dr. B. Torrejon for technical assistance, and C. Saldarriaga for assistance in graphic design. The authors also acknowledge B. Gamarra, A. Gimeno, and A. Altafaj for assistance in animal handling, and Drs. M. J. Ortuno and A. Ulsamer for critical discussions on the topics associated with this work. Dr. E. Rodriguez-Carballo received a fellowship from the Institut d'Investigacio Biomedica de Bellvitge (Barcelona, Spain). This work was supported through the Ministry of Education and Science of Spain (Grant BFU2011-24254), Fundacio La Marato de TV3, and Instituto de Salud Carlos III (Grant RETIC RD06/0020).	Asada N, 2013, CELL STEM CELL, V12, P737, DOI 10.1016/j.stem.2013.05.001; Baldock PA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008415; Bulloch JM, 2014, PHARMACOL THERAPEUT, V143, P61, DOI 10.1016/j.pharmthera.2014.02.005; Cinti S, 2009, AM J PHYSIOL-ENDOC M, V297, pE977, DOI 10.1152/ajpendo.00183.2009; Davey RA, 2012, TRANSGENIC RES, V21, P885, DOI 10.1007/s11248-011-9581-z; de Ferranti S, 2008, CLIN CHEM, V54, P945, DOI 10.1373/clinchem.2007.100156; Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105; Foresta C, 2010, J CLIN ENDOCR METAB, V95, P3502, DOI 10.1210/jc.2009-2557; GARRARD G, 1974, J ANAT, V117, P531; Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561; Gelfo F, 2011, PEPTIDES, V32, P1320, DOI 10.1016/j.peptides.2011.03.023; Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev-cellbio-101512-122347; Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285; Han SP, 2005, PEPTIDES, V26, P2603, DOI 10.1016/j.peptides.2005.05.024; Hirsch D, 2012, CELL MOL NEUROBIOL, V32, P645, DOI 10.1007/s10571-011-9793-z; HOOPER ACB, 1978, J ANAT, V127, P117; Hu MC, 2013, ANNU REV PHYSIOL, V75, P503, DOI 10.1146/annurev-physiol-030212-183727; Igwe JC, 2009, J CELL BIOCHEM, V108, P621, DOI 10.1002/jcb.22294; Ortuno MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612; Kageyama H, 2012, NEUROPEPTIDES, V46, P285, DOI 10.1016/j.npep.2012.09.007; Kajimura D, 2013, CELL METAB, V17, P901, DOI 10.1016/j.cmet.2013.04.009; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; Karsenty G, 2012, NATURE, V481, P314, DOI 10.1038/nature10763; Kos K, 2007, AM J PHYSIOL-ENDOC M, V293, pE1335, DOI 10.1152/ajpendo.00333.2007; Kuo LE, 2007, NAT MED, V13, P803, DOI 10.1038/nm1611; Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047; Ma YY, 2012, MOL CELLS, V33, P611, DOI 10.1007/s10059-012-0053-y; Matic I, 2012, J MUSCULOSKEL NEURON, V12, P209; Nunes AF, 2010, FEBS J, V277, P263, DOI 10.1111/j.1742-4658.2009.07482.x; Oury F, 2013, J CLIN INVEST, V123, P2421, DOI 10.1172/JCI65952; Oury F, 2011, CELL, V144, P796, DOI 10.1016/j.cell.2011.02.004; Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010; Pi M, 2011, J BONE MINER RES, V26, P1680, DOI 10.1002/jbmr.390; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P3374, DOI 10.1073/pnas.73.10.3374; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; Reid IR, 2008, OSTEOPOROSIS INT, V19, P595, DOI 10.1007/s00198-007-0492-z; Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480; Rodriguez-Carballo E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102032; Rosser J, 2012, METHODS MOL BIOL, V816, P67, DOI 10.1007/978-1-61779-415-5_6; Sato M, 2013, CELL METAB, V18, P749, DOI 10.1016/j.cmet.2013.09.014; Shi YC, 2013, CELL METAB, V17, P236, DOI 10.1016/j.cmet.2013.01.006; Shi YC, 2012, BONE, V50, P430, DOI 10.1016/j.bone.2011.10.001; Shi YC, 2011, OBESITY, V19, P2137, DOI 10.1038/oby.2011.99; Sindelar DK, 2004, ENDOCRINOLOGY, V145, P3363, DOI 10.1210/en.2003-1727; Sindelar DK, 2002, DIABETES, V51, P778, DOI 10.2337/diabetes.51.3.778; Singer K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057929; Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221; Swart I, 2002, AM J PHYSIOL-REG I, V283, pR1020, DOI 10.1152/ajpregu.00501.2001; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; Thouverey C, 2012, CELL MOL LIFE SCI, V69, P3115, DOI 10.1007/s00018-012-0983-8; Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200; Wang FQ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0062988, 10.1371/journal.pone.0061792, 10.1371/journal.pone.0069284, 10.1371/journal.pone.0064373, 10.1371/journal.pone.0080480, 10.1371/journal.pone.0078025]; Wang LY, 2004, BONE, V34, P499, DOI 10.1016/j.bone.2003.11.022; Wei JW, 2014, J CLIN INVEST, V124, P1781, DOI 10.1172/JCI72323; Wei JW, 2014, DIABETES, V63, P1021, DOI 10.2337/db13-0887; Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465; Yoshikawa Y, 2011, J BONE MINER RES, V26, P2012, DOI 10.1002/jbmr.417; Zhang L, 2010, INT J OBESITY, V34, P357, DOI 10.1038/ijo.2009.232	58	12	13	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1414	1425		10.1096/fj.14-261891	http://dx.doi.org/10.1096/fj.14-261891			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550462				2022-12-28	WOS:000354115000027
J	Oghumu, S; Terrazas, CA; Varikuti, S; Kimble, J; Vadia, S; Yu, LB; Seveau, S; Satoskar, AR				Oghumu, Steve; Terrazas, Cesar A.; Varikuti, Sanjay; Kimble, Jennifer; Vadia, Stephen; Yu, Lianbo; Seveau, Stephanie; Satoskar, Abhay R.			CXCR3 expression defines a novel subset of innate CD8(+) T cells that enhance immunity against bacterial infection and cancer upon stimulation with IL-15	FASEB JOURNAL			English	Article						granzyme; interferon; Listeria; cytokine; cytotoxicity	LISTERIA-MONOCYTOGENES INFECTION; RECEPTOR-BETA CHAIN; CATHEPSIN-W; MICE; PROTECTION; DISTINCT; ITK; DEFICIENT; LINEAGES; ABSENCE	Innate CD8(+) T cells are a heterogeneous population with developmental pathways distinct from conventional CD8(+) T cells. However, their biology, classification, and functions remain incompletely understood. We recently demonstrated the existence of a novel population of chemokine (C-X-C motif) receptor 3 (CXCR3)-positive innate CD8(+) T cells. Here, we investigated the functional properties of this subset and identified effector molecules and pathways which mediate their function. Adoptive transfer of IL-15 activated CXCR3(+) innate CD8(+) T cells conferred increased protection against Listeria monocytogenes infection in susceptible IFN-gamma(-/-) mice compared with similarly activated CXCR3(-) subset. This was associated with enhanced proliferation and IFN-gamma production in CXCR3(+) cells. Further, CXCR3(+) innate cells showed enhanced cytotoxicity against a tumor cell line in vitro. In depth analysis of the CXCR3(+) subset showed increased gene expression of Ccl5, Klrc1, CtsW, GP49a, IL-2R beta, Atp5e, and Ly6c but reduced IFN-gamma R2 and Art2 beta. Ingenuity pathway analysis revealed an up-regulation of genes associated with T-cell activation, proliferation, cytotoxicity, and translational initiation in CXCR3(+) populations. Our results demonstrate that CXCR3 expression in innate CD8(+) T cells defines a subset with enhanced cytotoxic potential and protective antibacterial immune functions. Immunotherapeutic approaches against infectious disease and cancer could utilize CXCR3(+) innate CD8(+) T-cell populations as novel clinical intervention strategies.	[Oghumu, Steve; Terrazas, Cesar A.; Varikuti, Sanjay; Kimble, Jennifer; Satoskar, Abhay R.] Ohio State Univ, Med Ctr, Dept Pathol, Columbus, OH 43210 USA; [Oghumu, Steve] Ohio State Univ, Coll Dent, Dept Oral Biol, Columbus, OH 43210 USA; [Vadia, Stephen; Seveau, Stephanie; Satoskar, Abhay R.] Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; [Yu, Lianbo] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA; [Seveau, Stephanie] Ohio State Univ, Dept Microbial Infect & Immun, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Satoskar, AR (corresponding author), Dept Pathol, 1645 Neil Ave, Columbus, OH 43210 USA.	abhay.satoskar@osumc.edu	yu, lianbo/B-3472-2010; Satoskar, Abhay/AAB-7748-2019; Oghumu, Steve/Z-3320-2019	Vadia, Stephen/0000-0001-9071-4573	U.S. National Institutes of Health (NIH) [R03-AI090231, RC4-AI092624, R34-AI100789, R21-AT004160, R03-CA164399]; NIH National Institute of Dental and Craniofacial Research [T32DE014320]; National Council of Science and Technology, Mexico (CONACYT); NATIONAL CANCER INSTITUTE [R03CA164399] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT004160] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R34AI100789, RC4AI092624, R03AI090231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T32DE014320] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); National Council of Science and Technology, Mexico (CONACYT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the U.S. National Institutes of Health (NIH) (Grants R03-AI090231, RC4-AI092624, R34-AI100789, R21-AT004160, and R03-CA164399) (to A.R.S.), NIH National Institute of Dental and Craniofacial Research (Training Grant T32DE014320) (to S.O.), and National Council of Science and Technology, Mexico (CONACYT) (to C.T.).	BACH EA, 1995, SCIENCE, V270, P1215, DOI 10.1126/science.270.5239.1215; Berg LJ, 2007, NAT REV IMMUNOL, V7, P479, DOI 10.1038/nri2091; Berg RE, 2005, J IMMUNOL, V175, P1751, DOI 10.4049/jimmunol.175.3.1751; Berg RE, 2003, J EXP MED, V198, P1583, DOI 10.1084/jem.20031051; Broussard C, 2006, IMMUNITY, V25, P93, DOI 10.1016/j.immuni.2006.05.011; Cerwenka A, 1999, J EXP MED, V189, P423, DOI 10.1084/jem.189.2.423; Chenoweth MJ, 2012, J IMMUNOL, V188, P4149, DOI 10.4049/jimmunol.1101883; Cho HS, 2011, J IMMUNOL, V186, P489, DOI 10.4049/jimmunol.1002639; D'Orazio SEF, 2006, J IMMUNOL, V177, P7146, DOI 10.4049/jimmunol.177.10.7146; D'Orazio SEF, 2003, J IMMUNOL, V171, P291, DOI 10.4049/jimmunol.171.1.291; Dhanji S, 2006, J IMMUNOL, V177, P138, DOI 10.4049/jimmunol.177.1.138; Dubois S, 2006, P NATL ACAD SCI USA, V103, P12075, DOI 10.1073/pnas.0605212103; Grange M, 2013, J IMMUNOL, V191, P3712, DOI 10.4049/jimmunol.1300319; Grange M, 2012, CANCER RES, V72, P76, DOI 10.1158/0008-5472.CAN-11-2187; Hu J, 2007, EUR J IMMUNOL, V37, P2892, DOI 10.1002/eji.200737311; Huang WS, 2013, J IMMUNOL, V190, P2490, DOI 10.4049/jimmunol.1202988; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Itsumi M, 2009, EUR J IMMUNOL, V39, P1784, DOI 10.1002/eji.200839106; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Lee KH, 2000, J IMMUNOL, V165, P4970, DOI 10.4049/jimmunol.165.9.4970; Mitani A, 1999, IMMUNOLOGY, V97, P92; Oghumu S, 2014, IMMUNOLOGY, V143, P109, DOI 10.1111/imm.12293; Oghumu S, 2013, J IMMUNOL, V190, P2229, DOI 10.4049/jimmunol.1201170; Perera LP, 1999, J IMMUNOL, V162, P2606; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; Rosas LE, 2005, EUR J IMMUNOL, V35, P515, DOI 10.1002/eji.200425422; Seaman MS, 2000, J IMMUNOL, V165, P5192, DOI 10.4049/jimmunol.165.9.5192; Shrestha N, 2012, J BIOL CHEM, V287, P28738, DOI 10.1074/jbc.M112.375915; Shrikant PA, 2010, IMMUNOL RES, V46, P12, DOI 10.1007/s12026-009-8130-9; Sintes J, 2013, J IMMUNOL, V190, P21, DOI 10.4049/jimmunol.1202435; Stoeckle C, 2009, EXP HEMATOL, V37, P266, DOI 10.1016/j.exphem.2008.10.011; Tau GZ, 2000, J EXP MED, V192, P977, DOI 10.1084/jem.192.7.977; Thompson LJ, 2006, J IMMUNOL, V177, P1746, DOI 10.4049/jimmunol.177.3.1746; Verykokakis M, 2010, IMMUNITY, V33, P203, DOI 10.1016/j.immuni.2010.07.013; Wex T, 2003, FEBS LETT, V552, P115, DOI 10.1016/S0014-5793(03)00895-0; Woodland DL, 2003, CURR OPIN IMMUNOL, V15, P336, DOI 10.1016/S0952-7915(03)00037-2; Xu HL, 2006, J EXP MED, V203, P449, DOI 10.1084/jem.20051866	38	15	17	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1019	1028		10.1096/fj.14-264507	http://dx.doi.org/10.1096/fj.14-264507			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25466888	Green Published			2022-12-28	WOS:000350633000026
J	Rath, S; Das, L; Kokate, SB; Pratheek, BM; Chattopadhyay, S; Goswami, C; Chattopadhyay, R; Crowe, SE; Bhattacharyya, A				Rath, Suvasmita; Das, Lopamudra; Kokate, Shrikant Babanrao; Pratheek, B. M.; Chattopadhyay, Subhasis; Goswami, Chandan; Chattopadhyay, Ranajoy; Crowe, Sheila Eileen; Bhattacharyya, Asima			Regulation of Noxa-mediated apoptosis in Helicobacter pylori-infected gastric epithelial cells	FASEB JOURNAL			English	Article						JNK; cytochrome c; gastric cancer; myeloid cell leukemia 1; mitochondrial fragmentation	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BCL-2 FAMILY-MEMBERS; CANCER CELLS; BH3-ONLY PROTEINS; FACTOR-I; ACTIVATION; EXPRESSION; MCL-1; DEATH; PATHWAY	Helicobacter pylori induces the antiapoptotic protein myeloid cell leukemia 1 (Mcl1) in human gastric epithelial cells (GECs). Apoptosis of oncogenic protein Mcl1-expressing cells is mainly regulated by Noxa-mediated degradation of Mcl1. We wanted to elucidate the status of Noxa in H. pylori-infected GECs. For this, various GECs such as AGS, MKN45, and KATO III were either infected with H. pylori or left uninfected. The effect of infection was examined by immunoblotting, immunoprecipitation, chromatin immunoprecipitation assay, in vitro binding assay, flow cytometry, and confocal microscopy. Infected GECs, surgical samples collected from patients with gastric adenocarcinoma as well as biopsy samples from patients infected with H. pylori showed significant up-regulation of both Mcl1 and Noxa compared with noninfected samples. Coexistence of Mcl1 and Noxa was indicative of an impaired Mcl-Noxa interaction. We proved that Noxa was phosphorylated at Ser(13) residue by JNK in infected GECs, which caused cytoplasmic retention of Noxa. JNK inhibition enhanced Mcl1-Noxa interaction in the mitochondrial fraction of infected cells, whereas overexpression of nonphosphorylatable Noxa resulted in enhanced mitochondria-mediated apoptosis in the infected epithelium. Because phosphorylation-dephosphorylation can regulate the apoptotic function of Noxa, this could be a potential target molecule for future treatment approaches for H. pylori-induced gastric cancer.	[Rath, Suvasmita; Das, Lopamudra; Kokate, Shrikant Babanrao; Pratheek, B. M.; Chattopadhyay, Subhasis; Goswami, Chandan; Bhattacharyya, Asima] Natl Inst Sci Educ & Res, Sch Biol Sci, Bhubaneswar 751005, Odisha, India; [Chattopadhyay, Ranajoy; Crowe, Sheila Eileen] Univ Virginia, Dept Med, Charlottesville, VA USA	National Institute of Science Education & Research (NISER); University of Virginia	Bhattacharyya, A (corresponding author), Natl Inst Sci Educ & Res, Sch Biol Sci, Bhubaneswar 751005, Odisha, India.	asima@niser.ac.in	Bhattacharyya, Asima/J-7423-2012; Rath, Suvasmita/N-7915-2017	Bhattacharyya, Asima/0000-0001-7292-6644; Rath, Suvasmita/0000-0001-8738-1560	Rapid Grant for Young Investigators (RGYI), Department of Biotechnology, India; Fast Track Grant, Science and Engineering Research Board, India; U.S. National Institutes of Health [R01-DK61769]; American Gastroenterological Association (AGA) Funderburg Research Scholar Award; Indian Council of Medical Research (ICMR) fellowship; Department of Atomic Energy (DAE), India; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061769] Funding Source: NIH RePORTER	Rapid Grant for Young Investigators (RGYI), Department of Biotechnology, India; Fast Track Grant, Science and Engineering Research Board, India; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Gastroenterological Association (AGA) Funderburg Research Scholar Award; Indian Council of Medical Research (ICMR) fellowship; Department of Atomic Energy (DAE), India(Department of Atomic Energy (DAE)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by a Rapid Grant for Young Investigators (RGYI), Department of Biotechnology, India, and a Fast Track Grant, Science and Engineering Research Board, India (to A.B.); the U.S. National Institutes of Health Grant R01-DK61769 and an American Gastroenterological Association (AGA) Funderburg Research Scholar Award (to S.E.C.); an Indian Council of Medical Research (ICMR) fellowship (to S.R.); and a fellowship from Department of Atomic Energy (DAE), India (to L.D. and S.B.K.).	Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Ashktorab H, 2004, GUT, V53, P805, DOI 10.1136/gut.2003.024372; Bhattacharyya A, 2010, AM J PHYSIOL-GASTR L, V299, pG1177, DOI 10.1152/ajpgi.00372.2010; Bhattacharyya A, 2009, GASTROENTEROLOGY, V136, P2258, DOI 10.1053/j.gastro.2009.02.014; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ding SZ, 2008, J GASTROEN HEPATOL, V23, pE67, DOI 10.1111/j.1440-1746.2007.04912.x; Ding SZ, 2007, INFECT IMMUN, V75, P4030, DOI 10.1128/IAI.00172-07; Domek MJ, 2001, HELICOBACTER, V6, P110, DOI 10.1046/j.1523-5378.2001.00016.x; Germain M, 2008, J BIOL CHEM, V283, P6384, DOI 10.1074/jbc.M707762200; Giam M, 2008, ONCOGENE, V27, pS128, DOI 10.1038/onc.2009.50; Gomez-Bougie P, 2011, BIOCHEM BIOPH RES CO, V413, P460, DOI 10.1016/j.bbrc.2011.08.118; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hassan M, 2008, ONCOGENE, V27, P4557, DOI 10.1038/onc.2008.90; Iseki H, 1997, SURGERY, V122, P187, DOI 10.1016/S0039-6060(97)90008-8; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kodama Y, 2009, GASTROENTEROLOGY, V136, P1423, DOI 10.1053/j.gastro.2008.12.064; Liu WS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029466; Lowman XH, 2010, MOL CELL, V40, P823, DOI 10.1016/j.molcel.2010.11.035; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; Matsumoto A, 2011, DIGEST DIS SCI, V56, P999, DOI 10.1007/s10620-010-1420-1; Matsumoto Y, 2007, NAT MED, V13, P470, DOI 10.1038/nm1566; Nakamura J, 2009, ONCOL REP, V22, P693, DOI 10.3892/or_00000489; Nardone G, 2004, J PATHOL, V202, P305, DOI 10.1002/path.1512; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104; Park JH, 2003, CLIN CANCER RES, V9, P433; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Piret JP, 2005, J BIOL CHEM, V280, P9336, DOI 10.1074/jbc.M411858200; Ploner C, 2008, ONCOGENE, V27, pS84, DOI 10.1038/onc.2009.46; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Snider JL, 2008, J BIOL CHEM, V283, P13952, DOI 10.1074/jbc.M800289200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tromp JM, 2012, CLIN CANCER RES, V18, P487, DOI 10.1158/1078-0432.CCR-11-1440; TSAI LH, 1993, DEVELOPMENT, V119, P1029; Umehara S, 2003, ONCOGENE, V22, P8337, DOI 10.1038/sj.onc.1207028; Vela L, 2013, J BIOL CHEM, V288, P4935, DOI 10.1074/jbc.M112.422204; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang LK, 2009, J SURG ONCOL, V100, P396, DOI 10.1002/jso.21344; Warr MR, 2008, CURR MOL MED, V8, P138; Wei A, 2008, GASTROENTEROLOGY, V134, P1412, DOI 10.1053/j.gastro.2008.01.072; Wei JX, 2012, P NATL ACAD SCI USA, V109, pE2543, DOI 10.1073/pnas.1205664109; Wei JX, 2010, GASTROENTEROLOGY, V139, P1333, DOI 10.1053/j.gastro.2010.06.018; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Xue Y, 2008, MOL CELL PROTEOMICS, V7, P1598, DOI 10.1074/mcp.M700574-MCP200; Zhang L, 2011, CELL DEATH DIFFER, V18, P864, DOI 10.1038/cdd.2010.152	48	20	21	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					796	806		10.1096/fj.14-257501	http://dx.doi.org/10.1096/fj.14-257501			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25404713	Green Published			2022-12-28	WOS:000350633000007
J	Bjorkgren, I; Gylling, H; Turunen, H; Huhtaniemi, I; Strauss, L; Poutanen, M; Sipila, P				Bjorkgren, Ida; Gylling, Helena; Turunen, Heikki; Huhtaniemi, Ilpo; Strauss, Leena; Poutanen, Matti; Sipila, Petra			Imbalanced lipid homeostasis in the conditional Dicer1 knockout mouse epididymis causes instability of the sperm membrane	FASEB JOURNAL			English	Article						RNA interference; infertility; sperm maturation; cholesterol; polyunsaturated fatty acids	POLYUNSATURATED FATTY-ACIDS; PLASMA-MEMBRANE; IN-VITRO; TYROSINE PHOSPHORYLATION; CHOLESTEROL HOMEOSTASIS; MAMMALIAN SPERMATOZOA; LUTEINIZING-HORMONE; MATURATION; CAPACITATION; SPHINGOMYELIN	During epididymal sperm maturation, the lipid content of the sperm membrane is modified, which facilitates sperm motility and fertility. However, little is known about the mechanisms regulating the maturation process. By generating a conditional knockout (cKO) of Dicer1 in the proximal part of the mouse epididymis, we studied the role of RNA interference in epididymal functions. The Dicer1 cKO epididymis displayed an altered lipid homeostasis associated with a 0.6-fold reduction in the expression of the gene elongation of very long chain fatty acids-like 2, an enzyme needed for production of long-chain polyunsaturated fatty acids (PUFAs). Furthermore, the expression of several factors involved in cholesterol synthesis was up-regulated. Accordingly, the Dicer1 cKO sperm membrane showed a 0.7-fold decrease in long-chain PUFAs, whereas the amount of cholesterol in acrosome-reacted sperm displayed a 1.7-fold increase. The increased cholesterol:PUFA ratio of the sperm membrane caused breakage of the neck and acrosome region and immotility of sperm. Dicer1 cKO mice sperm also displayed reduced ability to bind to and fertilize the oocyte in vitro. This study thus shows that Dicer1 is critical for lipid synthesis in the epididymis, which directly affects sperm membrane integrity and male fertility.	[Bjorkgren, Ida; Turunen, Heikki; Strauss, Leena; Poutanen, Matti] Univ Turku, Inst Biomed, Dept Physiol, Turku, Finland; [Bjorkgren, Ida] Turku Doctoral Programme Biomed Sci, Turku, Finland; [Gylling, Helena] Univ Eastern Finland, Dept Clin Nutr, Inst Publ Hlth & Clin Nutr, Kuopio, Finland; [Gylling, Helena] Univ Helsinki, Dept Med, Div Internal Med, FIN-00014 Helsinki, Finland; [Huhtaniemi, Ilpo] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London, England; [Strauss, Leena; Poutanen, Matti] Univ Turku, Turku Ctr Dis Modeling, Turku, Finland; [Poutanen, Matti] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Gothenburg, Sweden; [Sipila, Petra] Univ Helsinki, Inst Biomed, Dept Physiol, FIN-00014 Helsinki, Finland; [Sipila, Petra] Univ Helsinki, Lab Anim Ctr, FIN-00014 Helsinki, Finland	University of Turku; University of Eastern Finland; University of Helsinki; Imperial College London; University of Turku; University of Gothenburg; University of Helsinki; University of Helsinki	Sipila, P (corresponding author), Univ Helsinki, POB 63, FIN-00014 Helsinki, Finland.	petra.sipila@helsinki.fi	Strauss, Leena/AAY-8824-2021; Sipilä, Petra/GYE-3323-2022; Poutanen, Matti/I-1700-2018	Poutanen, Matti/0000-0002-8953-1734; Sipila, Petra/0000-0001-8187-7143; Bjorkgren, Ida/0000-0001-6678-2672; Strauss, Leena/0000-0002-5682-205X				Aksoy Y, 2006, PROSTAG LEUKOTR ESS, V75, P75, DOI 10.1016/j.plefa.2006.06.002; Am-In N, 2011, THERIOGENOLOGY, V75, P897, DOI 10.1016/j.theriogenology.2010.10.032; AVELDANO MI, 1992, BIOCHEM J, V283, P235, DOI 10.1042/bj2830235; AWANO M, 1993, J REPROD FERTIL, V99, P375, DOI 10.1530/jrf.0.0990375; Bjorkgren I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038457; Buffone MG, 2009, J ANDROL, V30, P552, DOI 10.2164/jandrol.108.006551; Castellini C, 2003, REPROD NUTR DEV, V43, P91, DOI 10.1051/rnd:2003008; Cavelier C, 2006, BBA-MOL CELL BIOL L, V1761, P655, DOI 10.1016/j.bbalip.2006.04.012; Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471; Christova Y, 2002, J ANDROL, V23, P384; Cornwall GA, 2009, HUM REPROD UPDATE, V15, P213, DOI 10.1093/humupd/dmn055; Cross NL, 2000, BIOL REPROD, V63, P1129, DOI 10.1095/biolreprod63.4.1129; Cross NL, 1998, BIOL REPROD, V59, P7, DOI 10.1095/biolreprod59.1.7; Cross NL, 2003, BIOL REPROD, V69, P529, DOI 10.1095/biolreprod.102.013052; Dickson RC, 2000, METHOD ENZYMOL, V311, P3; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; EVANS RW, 1979, J REPROD FERTIL, V57, P189, DOI 10.1530/jrf.0.0570189; Flesch FM, 2000, BBA-REV BIOMEMBRANES, V1469, P197, DOI 10.1016/S0304-4157(00)00018-6; Frenette G, 2001, MOL REPROD DEV, V59, P115, DOI 10.1002/mrd.1013; Furland NE, 2007, J BIOL CHEM, V282, P18151, DOI 10.1074/jbc.M700709200; HAAVISTO AM, 1993, ENDOCRINOLOGY, V132, P1687, DOI 10.1210/en.132.4.1687; Haidl G, 1997, HUM REPROD, V12, P2720, DOI 10.1093/humrep/12.12.2720; HALL JC, 1991, J ANDROL, V12, P76; Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102; Hermo L, 2002, MOL REPROD DEV, V63, P394, DOI 10.1002/mrd.90023; HUHTANIEMI I, 1985, J CLIN ENDOCR METAB, V61, P698, DOI 10.1210/jcem-61-4-698; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; Jokela H, 2010, ENDOCRINOLOGY, V151, P1884, DOI 10.1210/en.2009-0928; Kerkhofs S, 2012, FASEB J, V26, P4360, DOI 10.1096/fj.11-202283; Kronke M, 1999, CHEM PHYS LIPIDS, V101, P109, DOI 10.1016/S0009-3084(99)00059-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765; Lin Y, 1996, BIOL REPROD, V55, P1133, DOI 10.1095/biolreprod55.5.1133; Mann T., 1964, BIOCH SEMEN MALE REP, DOI 10.5694/j.1326-5377.1965.tb72030.x; MANN T, 1981, MALE REPRODUCTIVE FU, P212; MIETTINEN TA, 1988, J LIPID RES, V29, P43; Moon YA, 2001, J BIOL CHEM, V276, P45358, DOI 10.1074/jbc.M108413200; Mourvaki E, 2010, THERIOGENOLOGY, V73, P629, DOI 10.1016/j.theriogenology.2009.10.019; NIKOLOPOULOU M, 1985, BIOCHIM BIOPHYS ACTA, V815, P486, DOI 10.1016/0005-2736(85)90377-3; Oh JS, 2009, MOL CELLS, V28, P441, DOI 10.1007/s10059-009-0140-x; Ouvrier A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026966; Ouvrier A, 2009, J LIPID RES, V50, P1766, DOI 10.1194/jlr.M800657-JLR200; PARKS JE, 1985, BIOL REPROD, V32, P653, DOI 10.1095/biolreprod32.3.653; PORN MI, 1993, J LIPID RES, V34, P1385; Pyttel S, 2014, THERIOGENOLOGY, V82, P396, DOI 10.1016/j.theriogenology.2014.04.017; Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862; Rejraji H, 2006, BIOL REPROD, V74, P1104, DOI 10.1095/biolreprod.105.049304; Robaire B, 2000, E SCHERING RES FDN W, P229; ROBINSON BS, 1992, J BIOL CHEM, V267, P1746; Rooke JA, 2001, REPRODUCTION, V121, P315, DOI 10.1530/rep.0.1210315; Safarinejad MR, 2011, ANDROLOGIA, V43, P38, DOI 10.1111/j.1439-0272.2009.01013.x; Schwarz A, 2013, CELL TISSUE RES, V353, P549, DOI 10.1007/s00441-013-1633-7; Sipila P, 2002, MOL ENDOCRINOL, V16, P2603, DOI 10.1210/me.2002-0100; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1025, P152; SonnenbergRiethmacher E, 1996, GENE DEV, V10, P1184, DOI 10.1101/gad.10.10.1184; Stoffel W, 2008, EMBO J, V27, P2281, DOI 10.1038/emboj.2008.156; Stroud CK, 2009, J LIPID RES, V50, P1870, DOI 10.1194/jlr.M900039-JLR200; Sullivan R, 2013, REPRODUCTION, V146, pR21, DOI 10.1530/REP-13-0058; SUZUKI F, 1988, J ULTRA MOL STRUCT R, V100, P39, DOI 10.1016/0889-1605(88)90057-2; Tavilani H, 2006, ANDROLOGIA, V38, P173, DOI 10.1111/j.1439-0272.2006.00735.x; Travis AJ, 2002, J CLIN INVEST, V110, P731, DOI [10.1172/JCI200216392, 10.1172/JCI0216392]; Turunen HT, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.092403; van Casteren JIJ, 2000, BIOL REPROD, V62, P886, DOI 10.1095/biolreprod62.4.886; Wang Y, 2008, J LIPID RES, V49, P1538, DOI 10.1194/jlr.M800123-JLR200; Wertheimer EV, 2008, J BIOL CHEM, V283, P35539, DOI 10.1074/jbc.M804586200; Yeung CH, 1999, BIOL REPROD, V61, P1062, DOI 10.1095/biolreprod61.4.1062; Zadravec D, 2011, J LIPID RES, V52, P245, DOI 10.1194/jlr.M011346; Zanetti SR, 2010, BIOCHIMIE, V92, P1886, DOI 10.1016/j.biochi.2010.08.015	68	41	43	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					433	442		10.1096/fj.14-259382	http://dx.doi.org/10.1096/fj.14-259382			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25366345				2022-12-28	WOS:000349370400009
J	Das, RK; Banerjee, S; Shapiro, BH				Das, Rajat Kumar; Banerjee, Sarmistha; Shapiro, Bernard H.			Irreversible perinatal imprinting of adult expression of the principal sex-dependent drug-metabolizing enzyme CYP2C11	FASEB JOURNAL			English	Article						growth hormone; sexual dimorphisms; SOCS2; STAT5b; testosterone; development	CIRCULATING GROWTH-HORMONE; SEXUALLY DIMORPHIC EXPRESSION; MONOSODIUM GLUTAMATE; GENDER-DIFFERENCES; MALE-RATS; HEPATIC CYTOCHROME-P-450; SUBOPTIMAL ACTIVATION; REGULATING EXPRESSION; SIGNAL-TRANSDUCTION; GONADAL-STEROIDS	We proposed to determine whether, like other sexual dimorphisms, drug metabolism is permanently imprinted by perinatal hormones, resulting in its irreversible sex-dependent expression. We treated newborn male rats with monosodium glutamate (MSG), a total growth hormone (GH) blocker, and, using cultured hepatocytes, examined expression of adult CYP2C11, the predominant cytochrome-P450 expressed only in males, as well as the signal transduction pathway by which episodic GH solely regulates the isoform's expression. In addition, adolescent hypophysectomized (hypox) male rats served as controls in which GH was eliminated after the critical imprinting period. Whereas renaturalization of the masculine episodic GH profile restored normal male-like levels of CYP2C11, as well as CYP2C12, in hepatocytes from hypox rats, the cells derived from the MSG-treated rats were completely unresponsive. Moreover, GH exposure of hepatocytes from hypox rats resulted in normal induction, activation, nuclear translocation, and binding to the CYP2C11 promoter of the signal transducers mediating GH regulation of CYP2C11 expression, which dramatically contrasted with the complete unresponsiveness of the MSG-derived hepatocytes, also associated with hypermethylation of GH-response elements in the CYP2C11 promoter. Lastly, neonatal MSG treatment had no adverse effect on postnatal and adult testosterone levels. The results demonstrate that the sexually dimorphic expression of CYP2C11 is irreversibly imprinted shortly after birth by a hormone other than the customary testosterone, but likely by GH.	[Das, Rajat Kumar; Banerjee, Sarmistha; Shapiro, Bernard H.] Univ Penn, Sch Vet Med, Labs Biochem, Philadelphia, PA 19104 USA	University of Pennsylvania	Shapiro, BH (corresponding author), Univ Penn, Sch Vet Med, Labs Biochem, 3800 Spruce St, Philadelphia, PA 19104 USA.	shapirob@vet.upenn.edu			U.S. National Institutes of Health, Eunice Kennedy Shriver National Institute; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD061285] Funding Source: NIH RePORTER	U.S. National Institutes of Health, Eunice Kennedy Shriver National Institute; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The authors acknowledge Drs. Ravindra N. Dhir and Chellappagounder Thangavel for their generous help and valuable suggestions. This work was supported by the U.S. National Institutes of Health, Eunice Kennedy Shriver National Institute	Adler N. T., 1981, NEUROENDOCRINOLOGY R, P555; AGRAWAL AK, 1995, AM J PHYSIOL-ENDOC M, V268, pE439, DOI 10.1152/ajpendo.1995.268.3.E439; Agrawal AK, 2000, J PHARMACOL EXP THER, V293, P1027; Agrawal AK, 2000, J PHARMACOL EXP THER, V292, P228; ANDERSON PJB, 1982, J ENDOCRINOL, V92, P419, DOI 10.1677/joe.0.0920419; BAKKE JL, 1978, NEUROENDOCRINOLOGY, V26, P220, DOI 10.1159/000122829; BANDIERA S, 1992, ARCH BIOCHEM BIOPHYS, V296, P286, DOI 10.1016/0003-9861(92)90574-G; BARTKE A, 1973, ENDOCRINOLOGY, V92, P1223, DOI 10.1210/endo-92-4-1223; Bengtsson B. A., 1999, GROWTH HORMONE, P359; Burman P, 1997, J CLIN ENDOCR METAB, V82, P550, DOI 10.1210/jc.82.2.550; CHUNG LWK, 1980, MOL PHARMACOL, V18, P543; Csaba G, 2008, CELL BIOCHEM FUNCT, V26, P1, DOI 10.1002/cbf.1412; DADA MO, 1984, ENDOCRINOLOGY, V115, P996, DOI 10.1210/endo-115-3-996; DANNAN GA, 1986, J BIOL CHEM, V261, P728; Das RK, 2013, ENDOCR RES, V38, P105, DOI 10.3109/07435800.2012.723294; Das RK, 2013, J ENDOCRINOL, V216, P87, DOI 10.1530/JOE-12-0255; Dhir RN, 2007, DRUG METAB DISPOS, V35, P2102, DOI 10.1124/dmd.107.017475; Dhir RN, 2006, J PHARMACOL EXP THER, V316, P87, DOI 10.1124/jpet.105.093773; DOHLER KD, 1975, ENDOCRINOLOGY, V97, P898; Elfarra AA, 1998, DRUG METAB DISPOS, V26, P779; Enokida H, 2004, CANCER RES, V64, P5956, DOI 10.1158/0008-5472.CAN-04-0081; Gathercole LL, 2013, VITAM HORM, V91, P1, DOI 10.1016/B978-0-12-407766-9.00001-8; GOLDMAN AS, 1970, H-S Z PHYSIOL CHEM, V351, P426; Greenhalgh CJ, 2004, GROWTH HORM IGF RES, V14, P200, DOI 10.1016/j.ghir.2003.12.011; GUSTAFSSON J, 1974, ENDOCRINOLOGY, V95, P891, DOI 10.1210/endo-95-3-891; Hannemann F, 2007, BBA-GEN SUBJECTS, V1770, P330, DOI 10.1016/j.bbagen.2006.07.017; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Hines M, 2011, ANNU REV NEUROSCI, V34, P69, DOI 10.1146/annurev-neuro-061010-113654; Hubina E, 2004, HORM METAB RES, V36, P247; JANSSON JO, 1985, ENDOCRINOLOGY, V117, P1881, DOI 10.1210/endo-117-5-1881; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; JENNES L, 1984, BRAIN RES, V308, P245, DOI 10.1016/0006-8993(84)91063-1; Johansson A. G., 1999, Journal of Endocrinological Investigation, V22, P58; Johansson AG, 1999, J CLIN ENDOCR METAB, V84, P2002, DOI 10.1210/jc.84.6.2002; Jorgensen JOL, 2005, FRONT HORM RES, V33, P1, DOI 10.1159/000088338; Karlsson H, 1999, MOL CELL ENDOCRINOL, V154, P37, DOI 10.1016/S0303-7207(99)00101-X; Kaufhold A, 2002, J PHARMACOL EXP THER, V302, P490, DOI 10.1124/jpet.102.034785; KRAMER RE, 1979, J PHARMACOL EXP THER, V208, P19; Kuromaru R, 1998, J CLIN ENDOCR METAB, V83, P3890, DOI 10.1210/jc.83.11.3890; Landsman T, 2005, J BIOL CHEM, V280, P37471, DOI 10.1074/jbc.M504125200; LEGRAVEREND C, 1992, FASEB J, V6, P711, DOI 10.1096/fasebj.6.2.1537461; LEMKEYJOHNSTON N, 1974, J NEUROPATH EXP NEUR, V33, P74, DOI 10.1097/00005072-197401000-00006; LeRoith D, 2005, J CLIN INVEST, V115, P233, DOI 10.1172/JCI200524228; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Luczak ED, 2009, ANNU REV PHYSIOL, V71, P1, DOI 10.1146/annurev.physiol.010908.163156; MACGEOCH C, 1984, J BIOL CHEM, V259, P5433; MACLEOD JN, 1987, XENOBIOTICA, V17, P1095, DOI 10.3109/00498258709044208; MORGAN ET, 1985, J BIOL CHEM, V260, P1895; Nebert DW, 2000, PHARMACOLOGY, V61, P124, DOI 10.1159/000028393; OHNO S, 1979, P140; OMALLEY K, 1971, BMJ-BRIT MED J, V3, P607, DOI 10.1136/bmj.3.5775.607; Pampori NA, 1999, ENDOCRINOLOGY, V140, P1245, DOI 10.1210/en.140.3.1245; Pampori NA, 1996, MOL PHARMACOL, V50, P1148; PAMPORI NA, 1991, BIOCHEM PHARMACOL, V41, P1299, DOI 10.1016/0006-2952(91)90101-A; PAMPORI NA, 1991, ACTA ENDOCRINOL-COP, V124, P283, DOI 10.1530/acta.0.1240283; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RESKO JA, 1968, J ENDOCRINOL, V40, P485, DOI 10.1677/joe.0.0400485; RYAN DE, 1990, PHARMACOL THERAPEUT, V45, P153, DOI 10.1016/0163-7258(90)90029-2; Shapiro B H, 1985, Prog Clin Biol Res, V171, P151; SHAPIRO BH, 1989, ENDOCRINOLOGY, V125, P2935, DOI 10.1210/endo-125-6-2935; SHAPIRO BH, 1995, INT J BIOCHEM CELL B, V27, P9, DOI 10.1016/1357-2725(94)00056-5; SHAPIRO BH, 1980, SCIENCE, V209, P418, DOI 10.1126/science.7384816; SHAPIRO BH, 1985, LIFE SCI, V36, P1169, DOI 10.1016/0024-3205(85)90234-6; Soares DV, 2004, GROWTH HORM IGF RES, V14, P436, DOI 10.1016/j.ghir.2004.06.004; Span JPT, 2001, J CLIN ENDOCR METAB, V86, P4161, DOI 10.1210/jc.86.9.4161; Strom SC, 1996, METHOD ENZYMOL, V272, P388, DOI 10.1016/S0076-6879(96)72044-X; Tarnopolsky MA, 1999, MOD NUTR SER, P179; Thangavel C, 2006, DRUG METAB DISPOS, V34, P410, DOI 10.1124/dmd.105.007716; Thangavel C, 2004, MOL CELL ENDOCRINOL, V220, P31, DOI 10.1016/j.mce.2004.04.002; Thangavel C, 2008, DRUG METAB DISPOS, V36, P1884, DOI 10.1124/dmd.108.021451; Thangavel C, 2007, ENDOCRINOLOGY, V148, P2894, DOI 10.1210/en.2006-1333; Thangavel C, 2011, ENDOCRINOLOGY, V152, P4813, DOI 10.1210/en.2011-1274; Verma AS, 2005, MOL PHARMACOL, V67, P891, DOI 10.1124/mol.104.005454; Wani JH, 1996, TOXICOL APPL PHARM, V137, P295, DOI 10.1006/taap.1996.0083; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; Waxman DJ, 2000, PRINCIPLES OF MOLECULAR REGULATION, P55	78	8	8	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4111	4122		10.1096/fj.13-248864	http://dx.doi.org/10.1096/fj.13-248864			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24942648	Green Published			2022-12-28	WOS:000340845900028
J	Yardehnavi, N; Behdani, M; Bagheri, KP; Mahmoodzadeh, A; Khanahmad, H; Shahbazzadeh, D; Habibi-Anbouhi, M; Ghassabeh, GH; Muyldermans, S				Yardehnavi, Najmeh; Behdani, Mahdi; Bagheri, Kamran Pooshang; Mahmoodzadeh, Amir; Khanahmad, Hossein; Shahbazzadeh, Delavar; Habibi-Anbouhi, Mahdi; Ghassabeh, Gholamreza Hassanzadeh; Muyldermans, Serge			A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation	FASEB JOURNAL			English	Article						scorpionism; nanobody; phage display; heavy-chain antibody; HCAb	TOXIN; AFFINITY; NANOBODY; DOMAINS; HEAVY; VENOM	Hemiscorpius lepturus scorpionism poses one of the most dangerous health problems in many parts of the world. The common therapy consists of using antivenom antibody fragments derived from a polyclonal immune response raised in horses. However, this immunotherapy creates serious side effects, including anaphylactic shock sometimes even leading to death. Thus, many efforts have been made to introduce new replacement therapeutics that cause less adverse reactions. One of the most attractive approaches to replacing the available therapy is offered by single-domain antibody fragments, or nanobodies (Nbs). We immunized dromedaries with H. lepturus toxin and identified a functional recombinant Nb (referred to as F7Nb) against heminecrolysin (HNc), the major known hemolytic and dermonecrotic fraction of H. lepturus venom. This Nb was retrieved from the immune library by phage display selection. The in vitro neutralization tests indicated that 17.5 nmol of the F7Nb can inhibit 45% of the hemolytic activity of 1 EC100 (7.5 mu g/ml) of HNc. The in vivo neutralization tests demonstrated that F7Nb had good antihemolytic and antidermonecrotic effects against HNc in all tested mice. Surprisingly, F7Nb (8.75 nmol) neutralized 1 LD100 of HNc (10 mu g) via an intracerebroventricular route or 1 LD100 (80 mu g) via a subcutaneous route. All of the control mice died. Hence, this Nb is a potential leading novel candidate for treating H. lepturus scorpionism in the near future.	[Yardehnavi, Najmeh; Behdani, Mahdi; Bagheri, Kamran Pooshang; Mahmoodzadeh, Amir; Shahbazzadeh, Delavar] Pasteur Inst Iran, Biotechnol Res Ctr, Venom & Biotherapeut Mol Lab, Tehran, Iran; [Habibi-Anbouhi, Mahdi] Pasteur Inst Iran, Natl Cell Bank Iran, Tehran, Iran; [Khanahmad, Hossein] Isfahan Univ Med Sci, Dept Genet & Mol Biol, Esfahan, Iran; [Ghassabeh, Gholamreza Hassanzadeh] VIB, NSF, Brussels, Belgium; [Muyldermans, Serge] VIB, Struct Biol Res Ctr, Brussels, Belgium; [Ghassabeh, Gholamreza Hassanzadeh; Muyldermans, Serge] Vrije Univ Brussel, Lab Cellular & Mol Immunol, Brussels, Belgium	Le Reseau International des Instituts Pasteur (RIIP); Pasteur Institute of Iran; Le Reseau International des Instituts Pasteur (RIIP); Pasteur Institute of Iran; Isfahan University Medical Science; Flanders Institute for Biotechnology (VIB); Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Shahbazzadeh, D (corresponding author), Pasteur Inst Iran, Biotechnol Res Ctr, Pastor St, Tehran 1316543551, Iran.	shahbazzadeh@pasteur.ac.ir	Habibi-Anbouhi, Mahdi/Q-1681-2016; Behdani, Mahdi/ABG-3723-2021; Yardehnavi, Najmeh/J-4682-2016; Muyldermans, Serge V/C-6418-2016; Khanahmad, Hossein/W-1688-2017; Behdani, Mahdi/W-3322-2017; Shahbazzadeh, Delavar/J-4577-2017; Bagheri, Kamran Pooshang/G-4856-2018; Muyldermans, Serge/AAC-7374-2019	Habibi-Anbouhi, Mahdi/0000-0002-3151-152X; Behdani, Mahdi/0000-0002-4839-5123; Yardehnavi, Najmeh/0000-0001-9298-1480; Muyldermans, Serge V/0000-0002-3678-3575; Behdani, Mahdi/0000-0002-4839-5123; Bagheri, Kamran Pooshang/0000-0003-0125-3918; Muyldermans, Serge/0000-0002-3678-3575; Mahmoodzadeh, Amir/0000-0002-0523-8152	Pasteur Institute of Iran	Pasteur Institute of Iran	This work was a segment of a research project supported by a grant from Pasteur Institute of Iran. N.Y. and M.B. are equal first authors.	Al-Badri ZM, 2008, BIOMACROMOLECULES, V9, P2805, DOI 10.1021/bm800569x; Alvarenga LM, 2003, TOXICON, V42, P725, DOI 10.1016/j.toxicon.2003.09.006; Ardekani L. S., 2013, INT J INFECT DIS; BEATTY JD, 1987, J IMMUNOL METHODS, V100, P173, DOI 10.1016/0022-1759(87)90187-6; Behdani M., 2010, Tehran University Medical Journal, V68, P268; Behdani M, 2012, MOL IMMUNOL, V50, P35, DOI 10.1016/j.molimm.2011.11.013; Ben Abderrazek R, 2011, PROTEIN ENG DES SEL, V24, P727, DOI 10.1093/protein/gzr037; Borchani L, 2011, TOXICON, V58, P130, DOI 10.1016/j.toxicon.2011.05.016; BouhaoualaZahar B, 1996, EUR J BIOCHEM, V238, P653, DOI 10.1111/j.1432-1033.1996.0653w.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chippaux JP, 2008, ACTA TROP, V107, P71, DOI 10.1016/j.actatropica.2008.05.021; Conrath KE, 2001, J BIOL CHEM, V276, P7346, DOI 10.1074/jbc.M007734200; Dehghani R., 2016, REV STATUS SCORPION, P73; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Hmila I, 2008, MOL IMMUNOL, V45, P3847, DOI 10.1016/j.molimm.2008.04.011; Hmila I, 2010, FASEB J, V24, P3479, DOI 10.1096/fj.09-148213; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Lefranc MP, 2005, DEV COMP IMMUNOL, V29, P185, DOI 10.1016/j.dci.2004.07.003; Lin Y, 2011, AFR J BIOTECHNOL, V10, P18294, DOI 10.5897/AJB11.2640; Muyldermans S, 2001, J Biotechnol, V74, P277; Sambrook J., 2001, MOL CLONING LAB MANU; Shahbazzadeh D, 2007, BIOCHEM J, V404, P89, DOI 10.1042/BJ20061404; Srairi-Abid N, 2008, FEBS J, V275, P4641, DOI 10.1111/j.1742-4658.2008.06607.x; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Thys B, 2010, ANTIVIR RES, V87, P257, DOI 10.1016/j.antiviral.2010.05.012; Valavi E, 2008, Indian J Nephrol, V18, P166, DOI 10.4103/0971-4065.45293; Vincke Cecile, 2012, Methods Mol Biol, V911, P15, DOI 10.1007/978-1-61779-968-6_2; World Health Organization, 2008, PROP WHO GUID PROD C	29	17	22	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4004	4014		10.1096/fj.13-247478	http://dx.doi.org/10.1096/fj.13-247478			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24891523	Green Published			2022-12-28	WOS:000340845900018
J	Cano-Penalver, JL; Griera, M; Serrano, I; Rodriguez-Puyol, D; Dedhar, S; de Frutos, S; Rodriguez-Puyol, M				Luis Cano-Penalver, Jose; Griera, Mercedes; Serrano, Isabel; Rodriguez-Puyol, Diego; Dedhar, Shoukat; de Frutos, Sergio; Rodriguez-Puyol, Manuel			Integrin-linked kinase regulates tubular aquaporin-2 content and intracellular location: a link between the extracellular matrix and water reabsorption	FASEB JOURNAL			English	Article						nephrogenic diabetes insipidus; fibrosis; chronic renal disease	RENAL COLLECTING DUCT; PRINCIPAL CELLS; INTERSTITIAL FIBROSIS; AQP2 TRAFFICKING; EPITHELIAL-CELLS; APICAL MEMBRANE; BINDING PROTEIN; UP-REGULATION; VASOPRESSIN; EXPRESSION	One of the clinical alterations observed in chronic renal disease (CRD) is the impaired urine concentration, known as diabetes insipidus (DI). Tubulointerstitial fibrosis of the kidney is also a pathological finding observed in CRD and involves composition of extracellular matrix (ECM). However, an association between these two events has not been elucidated. In this study, we showed that the extracellular-to-intracellular scaffold protein integrin-linked kinase (ILK) regulates expression of tubular water channel aquaporin-2 (AQP2) and its apical membrane presence in the renal tubule. Basally, polyuria and decreased urine osmolality were present in ILK conditional-knockdown (cKD-ILK) adult mice compared with nondepleted ILK littermates. No changes were observed in arginine-vasopressin (AVP) blood levels, renal receptor (V2R), or AQP3 expression. However, tubular AQP2 was decreased in expression and apical membrane presence in cKD-ILK mice, where the canonical V2R/cAMP axis activation is still functional, but independent of the absence of ILK. Thus, cKD-ILK constitutes a nephrogenic diabetes insipidus (NDI) model. AQP2 and ILK colocalize in cultured inner medullary collecting duct (mIMCD3) cells. Specific ILK siRNAs and collagen I (Col) decrease ILK and AQP2 levels and AQP2 presence on the membrane of tubular mIMCD3 cells, which impairs the capacity of the cells to transport water under hypotonic stress. The present work points to ILK as a therapeutic target in NDI.-Cano-Penalver, J. L., Griera, M., Serrano, I., Rodriguez-Puyol, D., Dedhar, S., de Frutos, S., Rodriguez-Puyol, M. Integrin-linked kinase regulates tubular aquaporin-2 content and intracellular location: a link between the extracellular matrix and water reabsorption.	[Luis Cano-Penalver, Jose; Griera, Mercedes; de Frutos, Sergio; Rodriguez-Puyol, Manuel] Univ Alcala De Henares, Physiol Unit, Dept Syst Biol, Madrid 28805, Spain; [Luis Cano-Penalver, Jose; Griera, Mercedes; Rodriguez-Puyol, Diego; de Frutos, Sergio; Rodriguez-Puyol, Manuel] Inst Salud Carlos III, Inst Reina Sofia Invest Renal, Madrid, Spain; [Luis Cano-Penalver, Jose; Griera, Mercedes; Rodriguez-Puyol, Diego; de Frutos, Sergio; Rodriguez-Puyol, Manuel] Inst Salud Carlos III, Red Invest Renal REDinREN, Madrid, Spain; [Serrano, Isabel; Dedhar, Shoukat] British Columbia Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada; [Rodriguez-Puyol, Diego] Hosp Principe Asturias, Biomed Res Fdn, Madrid, Spain; [Rodriguez-Puyol, Diego] Hosp Principe Asturias, Dept Nephrol, Madrid, Spain	Universidad de Alcala; Instituto de Salud Carlos III; Instituto de Salud Carlos III; British Columbia Cancer Agency; Prince of Asturias University Hospital; Prince of Asturias University Hospital	de Frutos, S (corresponding author), Univ Alcala De Henares, Fac Med, Unidad Fisiol, Dept Biol Sistemas, Madrid 28805, Spain.	sergio.frutos@uah.es	Puyol, Diego Rodriguez/AAG-9752-2020; de Frutos, Sergio/AAE-7761-2021; Puyol, Manuel Rodriguez/AAG-7049-2020	Puyol, Diego Rodriguez/0000-0002-9125-9311; de Frutos, Sergio/0000-0002-1225-5911; Puyol, Manuel Rodriguez/0000-0002-5230-6664; Dedhar, Shoukat/0000-0003-4355-1657	Spanish Ministerio de Ciencia e Innovacion [SAF 2010-16198]; Spanish Ministerio de Sanidad (Fondo de Investigaciones Sanitarias) [PI1101630]; Instituto de Salud Carlos III [RD06/0016/0002, RD12/0021/0006]; Spanish Ministerio de Educacion y Ciencia; REDinREN program	Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Spanish Ministerio de Sanidad (Fondo de Investigaciones Sanitarias); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spanish Ministerio de Educacion y Ciencia(Spanish Government); REDinREN program	The authors thank Dr. N. Troyano for participating in the establishment of the cKD-ILK mouse model in our laboratory. This work was supported by grants from the Spanish Ministerio de Ciencia e Innovacion (SAF 2010-16198) and the Spanish Ministerio de Sanidad (Fondo de Investigaciones Sanitarias; PI1101630). Funding for the program Investigacion en Red Cooperativa [Red de Investigacion Renal (REDinREN)] came from Instituto de Salud Carlos III (RD06/0016/0002 and RD12/0021/0006). J. L. C.-P. was supported by a fellowship from the Spanish Ministerio de Educacion y Ciencia. S. D. F. was supported by the REDinREN program.	Borghese MFA, 2011, NEPHRON EXTRA, V1, P124, DOI 10.1159/000333066; Balasubramanian L, 2008, PFLUG ARCH EUR J PHY, V456, P747, DOI 10.1007/s00424-007-0371-7; Bouley R, 2000, J CLIN INVEST, V106, P1115, DOI 10.1172/JCI9594; Bustamante M, 2005, AM J PHYSIOL-RENAL, V288, pF334, DOI 10.1152/ajprenal.00180.2004; CAMPS J, 1983, CLIN CHEM, V29, P882; Chou CL, 2004, J BIOL CHEM, V279, P49026, DOI 10.1074/jbc.M408565200; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; De Frutos S, 2005, J AM SOC NEPHROL, V16, P2626, DOI 10.1681/ASN.2004070587; El-Aouni C, 2006, J AM SOC NEPHROL, V17, P1334, DOI 10.1681/ASN.2005090921; Gonzalez-Ramos M, 2013, FREE RADICAL BIO MED, V61, P416, DOI 10.1016/j.freeradbiomed.2013.04.029; Gonzalez-Ramos M, 2013, INT J BIOCHEM CELL B, V45, P232, DOI 10.1016/j.biocel.2012.10.001; Hasler U, 2008, J BIOL CHEM, V283, P28095, DOI 10.1074/jbc.M801071200; Hasler U, 2006, J AM SOC NEPHROL, V17, P1521, DOI 10.1681/ASN.2005121317; Kamsteeg EJ, 2006, P NATL ACAD SCI USA, V103, P18344, DOI 10.1073/pnas.0604073103; Kim HY, 2011, AM J PHYSIOL-RENAL, V301, pF151, DOI 10.1152/ajprenal.00519.2010; LEMLEY KV, 1991, KIDNEY INT, V39, P370, DOI 10.1038/ki.1991.49; Li YJ, 2009, J AM SOC NEPHROL, V20, P1907, DOI 10.1681/ASN.2008090930; Liu YH, 2010, J AM SOC NEPHROL, V21, P212, DOI 10.1681/ASN.2008121226; Lu HJ, 2008, AM J PHYSIOL-RENAL, V295, pF290, DOI 10.1152/ajprenal.00072.2008; Maric K, 1998, AM J PHYSIOL-RENAL, V275, pF796, DOI 10.1152/ajprenal.1998.275.5.F796; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; Mistry AC, 2009, AM J PHYSIOL-RENAL, V297, pF292, DOI 10.1152/ajprenal.00196.2009; Moeller HB, 2013, ENDOCR REV, V34, P278, DOI 10.1210/er.2012-1044; Moeller HB, 2012, PFLUG ARCH EUR J PHY, V464, P133, DOI 10.1007/s00424-012-1129-4; MUALLEM S, 1992, J BIOL CHEM, V267, P17658; Nedvetsky PI, 2010, J AM SOC NEPHROL, V21, P1645, DOI 10.1681/ASN.2009111190; Pisitkun T, 2008, AM J PHYSIOL-RENAL, V295, pF1030, DOI 10.1152/ajprenal.90339.2008; Randriamboavonjy V, 2012, BLOOD, V120, P415, DOI 10.1182/blood-2011-12-399980; Rao R, 2010, J AM SOC NEPHROL, V21, P428, DOI 10.1681/ASN.2009060672; Rauchman MI, 1997, AM J PHYSIOL-RENAL, V273, pF9, DOI 10.1152/ajprenal.1997.273.1.F9; Rinschen MM, 2010, P NATL ACAD SCI USA, V107, P3882, DOI 10.1073/pnas.0910646107; Roos KP, 2012, AM J PHYSIOL-RENAL, V302, pF78, DOI 10.1152/ajprenal.00397.2011; Ruiz-Torres MP, 2007, INT J BIOCHEM CELL B, V39, P133, DOI 10.1016/j.biocel.2006.07.012; Serrano I, 2013, CARDIOVASC RES, V99, P535, DOI 10.1093/cvr/cvt131; Serrano I, 2012, EXP CELL RES, V318, P2470, DOI 10.1016/j.yexcr.2012.08.001; Sproul A, 2011, AM J PHYSIOL-RENAL, V301, pF44, DOI 10.1152/ajprenal.00666.2010; Tajika Y, 2004, ENDOCRINOLOGY, V145, P4375, DOI 10.1210/en.2004-0073; Takata K, 2004, J PHARMACOL SCI, V96, P255, DOI 10.1254/jphs.FMJ04004X3; Tamma G, 2001, AM J PHYSIOL-RENAL, V281, pF1092, DOI 10.1152/ajprenal.0091.2001; Tamma G, 2011, CELL PHYSIOL BIOCHEM, V27, P739, DOI 10.1159/000330082; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Walker RJ, 2013, AM J PHYSIOL-RENAL, V304, pF300, DOI 10.1152/ajprenal.00182.2012; Wickstrom SA, 2011, TRENDS CELL BIOL, V21, P266, DOI 10.1016/j.tcb.2011.02.003; Wu W, 2009, AM J PHYSIOL-RENAL, V297, pF210, DOI 10.1152/ajprenal.90260.2008; Yamaguchi I, 2012, NEPHRON EXP NEPHROL, V120, pE20, DOI 10.1159/000332026; Yang BX, 2006, AM J PHYSIOL-RENAL, V291, pF465, DOI 10.1152/ajprenal.00494.2005; Yasuhara A, 2008, CIRCULATION, V118, P2146, DOI 10.1161/CIRCULATIONAHA.108.787259; Yasui M, 1997, AM J PHYSIOL-RENAL, V272, pF443, DOI 10.1152/ajprenal.1997.272.4.F443; Zelenina M, 2000, EUR BIOPHYS J BIOPHY, V29, P165, DOI 10.1007/PL00006645; Zou LB, 2011, J CLIN ENDOCR METAB, V96, pE1399, DOI 10.1210/jc.2011-0426	50	17	20	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3645	3659		10.1096/fj.13-249250	http://dx.doi.org/10.1096/fj.13-249250			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24784577	Bronze			2022-12-28	WOS:000340265400032
J	Yu, M; Liang, W; Wen, S; Zhao, T; Zhu, MX; Li, HH; Long, Q; Wang, M; Cheng, X; Liao, YH; Yuan, J				Yu, Miao; Liang, Wei; Wen, Shuang; Zhao, Tong; Zhu, Ming-Xin; Li, Huan-Huan; Long, Qi; Wang, Min; Cheng, Xiang; Liao, Yu-Hua; Yuan, Jing			EphB2 contributes to human naive B-cell activation and is regulated by miR-185	FASEB JOURNAL			English	Article						tyrosine kinases; microRNA; Notch1	SYSTEMIC-LUPUS-ERYTHEMATOSUS; ADHESION KINASE; RECEPTORS; DIFFERENTIATION; EXPRESSION; MICE; MICRORNAS; PHENOTYPE; MIGRATION; PATHWAY	EphB2 is an important member of the receptor tyrosine kinases. Recently, EphB2 was shown to facilitate T-cell migration and monocyte activation. However, the effects of EphB2 on B cells remain unknown. In this study, the expression of EphB2 on B cells was tested by Western blot, and the roles of EphB2 in B-cell proliferation, cytokine secretion, and immunoglobulin (Ig) production were evaluated using EphB2 siRNA interference in human B cells from healthy volunteers. Our study revealed that EphB2 was distributed on naive B cells and was up-regulated on activated B cells. Moreover, B-cell proliferation (decreased by 22%, P<0.05), TNF-alpha secretion (decreased by 40%, P < 0.01) and IgG production (decreased by 26%, P < 0.05) were depressed concordantly with the downregulated EphB2 expression. Subsequently, we screened microRNAs that could regulate EphB2 expression in B cells, and discovered that miR-185 directly targeted to EphB2 mRNA and suppressed its expression. Furthermore, miR-185 overexpression inhibited B-cell activation, and the inhibitor of miR-185 enhanced B-cell activation. Moreover, abatement of EphB2 through miR-185 mimics or EphB2 siRNA attenuated the activation of Src-p65 and Notch1 signaling pathways in human B cells. Our study first suggested that EphB2 was involved in human naive B cell activation through Src-p65 and Notch1 signaling pathways and could be regulated by miR-185.-Yu, M., Liang, W., Wen, S., Zhao, T., Zhu, M.-X., Li, H.-H., Long, Q., Wang, M., Cheng, X., Liao, Y.-H., Yuan, J. EphB2 contributes to human naive B-cell activation and is regulated by miR-185.	[Yu, Miao; Liang, Wei; Wen, Shuang; Zhao, Tong; Zhu, Ming-Xin; Li, Huan-Huan; Long, Qi; Wang, Min; Cheng, Xiang; Liao, Yu-Hua; Yuan, Jing] Huazhong Univ Sci & Technol, Tongji Med Coll, Lab Cardiovasc Immunol, Inst Cardiol,Union Hosp, Wuhan 430074, Peoples R China	Huazhong University of Science & Technology	Liao, YH (corresponding author), Union Hosp, Inst Cardiol, Lab Cardiovasc Immunol, Jie Fang Ave 1277, Wuhan 430022, Peoples R China.	liaoyh27@126.com; yhelen13@163.com	饭, 蔡/AAI-5850-2020		National Natural Science Foundation of China [81100158]; National Science and Technology Support Program [2011BAI11B00, 2011BAI11B23]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Support Program	This work was supported by the National Natural Science Foundation of China (81100158), and the National Science and Technology Support Program (2011BAI11B00, 2011BAI11B23).	Alfaro D, 2008, IMMUNOLOGY, V125, P131, DOI 10.1111/j.1365-2567.2008.02828.x; Baxter AG, 2002, NAT REV IMMUNOL, V2, P439, DOI 10.1038/nri823; Biyashev D, 2012, BLOOD, V119, P2679, DOI 10.1182/blood-2011-07-370635; Brantley-Sieders DM, 2005, FASEB J, V19, P1884, DOI 10.1096/fj.05-4038fje; Braun J, 2011, ARTERIOSCL THROM VAS, V31, P297, DOI 10.1161/ATVBAHA.110.217646; Cheng PY, 2001, J IMMUNOL, V167, P4458, DOI 10.4049/jimmunol.167.8.4458; de Yebenes VG, 2013, IMMUNOL REV, V253, P25, DOI 10.1111/imr.12046; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Doreau A, 2009, NAT IMMUNOL, V10, P778, DOI 10.1038/ni.1741; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Guo QY, 2013, BLOOD, V121, P4875, DOI 10.1182/blood-2012-08-452425; Kang SG, 2013, NAT IMMUNOL, V14, P849, DOI 10.1038/ni.2648; Korade-Mirnics Z, 2000, J LEUKOCYTE BIOL, V68, P603; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Lin LN, 2013, ONCOL REP, V30, P1239, DOI 10.3892/or.2013.2596; Liu Y, 2013, ARTHRITIS RHEUM-US, V65, P1603, DOI 10.1002/art.37912; Maillard I, 2005, ANNU REV IMMUNOL, V23, P945, DOI 10.1146/annurev.immunol.23.021704.115747; Mok YT, 2013, J IMMUNOL, V191, P3037, DOI 10.4049/jimmunol.1301289; Osborne BA, 2007, NAT REV IMMUNOL, V7, P64, DOI 10.1038/nri1998; Pasquale EB, 2004, NAT NEUROSCI, V7, P417, DOI 10.1038/nn0504-417; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Salvucci O, 2006, BLOOD, V108, P2914, DOI 10.1182/blood-2006-05-023341; Stimamiglio MA, 2010, J LEUKOCYTE BIOL, V88, P483, DOI 10.1189/jlb.0210079; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; Vilen BJ, 1997, J IMMUNOL, V159, P231; Wang SD, 2012, ONCOGENE, V31, P5132, DOI 10.1038/onc.2012.16; Ying Z, 2013, CANCER RES, V73, P990, DOI 10.1158/0008-5472.CAN-12-2895; Yu M, 2013, J CLIN IMMUNOL, V33, P1002, DOI 10.1007/s10875-013-9889-y; Zhang YJ, 2013, CELL SIGNAL, V25, P2769, DOI 10.1016/j.cellsig.2013.08.044	33	14	14	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3609	3617		10.1096/fj.13-247759	http://dx.doi.org/10.1096/fj.13-247759			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24803541				2022-12-28	WOS:000340265400029
J	Choi, YJ; Yoon, Y; Lee, KY; Hien, TT; Kang, KW; Kim, KC; Lee, J; Lee, MY; Lee, SM; Kang, DH; Lee, BH				Choi, You-Jin; Yoon, Yujin; Lee, Kang-Yo; Hien, Tran Thi; Kang, Keon Wook; Kim, Kyong-Cheol; Lee, Jeewoo; Lee, Moo-Yeol; Lee, Seung Mi; Kang, Duk-Hee; Lee, Byung-Hoon			Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis	FASEB JOURNAL			English	Article						eNOS; hypertension	ENDOPLASMIC-RETICULUM STRESS; CARDIOVASCULAR-DISEASE; CELL FUNCTION; HYPERTENSION; RAT; HYPERURICEMIA; ACTIVATION; SYNTHASE; AORTA; RISK	Endothelial dysfunction is defined as impairment of the balance between endothelium-dependent vasodilation and constriction. Despite evidence of uric acid-induced endothelial dysfunction, a relationship with insulin resistance has not been clearly established. In this study, we investigated the role of vascular insulin resistance in uric acid-induced endothelial dysfunction. Uric acid inhibited insulin-induced endothelial nitric oxide synthase (eNOS) phosphorylation and NO production more substantially than endothelin-1 expression in HUVECs, with IC50 of 51.0, 73.6, and 184.2, respectively. Suppression of eNOS phosphorylation and NO production by uric acid was PI3K/Akt-dependent, as verified by the transfection with p110. Treatment of rats with the uricase inhibitor allantoxanamide induced mild hyperuricemia and increased mean arterial pressure by 25%. While hyperuricemic rats did not show systemic insulin resistance, they showed impaired vasorelaxation induced by insulin by 56%. A compromised insulin response in terms of the Akt/eNOS pathway was observed in the aortic ring of hyperuricemic rats. Coadministration with allopurinol reduced serum uric acid levels and blood pressure and restored the effect of insulin on Akt-eNOS pathway and vasorelaxation. Taken together, uric acid induced endothelial dysfunction by contributing to vascular insulin resistance in terms of insulin-induced NO production, potentially leading to the development of hypertension.	[Choi, You-Jin; Yoon, Yujin; Lee, Kang-Yo; Hien, Tran Thi; Kang, Keon Wook; Kim, Kyong-Cheol; Lee, Jeewoo; Lee, Byung-Hoon] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Choi, You-Jin; Yoon, Yujin; Lee, Kang-Yo; Hien, Tran Thi; Kang, Keon Wook; Kim, Kyong-Cheol; Lee, Jeewoo; Lee, Byung-Hoon] Seoul Natl Univ, Coll Med, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; [Lee, Seung Mi] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 151742, South Korea; [Lee, Moo-Yeol] Dongguk Univ, Coll Pharm, Goyang, South Korea; [Lee, Seung Mi] Seoul Metropolitan Boramae Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea; [Kang, Duk-Hee] Ewha Womans Univ, Sch Med, Dept Internal Med, Div Nephrol, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Dongguk University; Ewha Womans University	Lee, BH (corresponding author), Seoul Natl Univ, Coll Pharm, Gwanak Ro 1, Seoul 151742, South Korea.	lee@snu.ac.kr	Lee, Byung-Hoon/L-7490-2018	Lee, Jeewoo/0000-0002-7832-6719	Korea Healthcare Technology R&D Project, Ministry for Health, Welfare, and Family Affairs, Republic of Korea [A100096]; National Research Foundation of Korea (NRF) - Korea government (MSIP) [2007-0056817]	Korea Healthcare Technology R&D Project, Ministry for Health, Welfare, and Family Affairs, Republic of Korea; National Research Foundation of Korea (NRF) - Korea government (MSIP)	This study was supported by grants of the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare, and Family Affairs, Republic of Korea (A100096) and by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP; 2007-0056817).	Clerk LH, 2006, DIABETES, V55, P1436, DOI 10.2337/db05-1373; Dehghan A, 2008, DIABETES CARE, V31, P361, DOI 10.2337/dc07-1276; Dincer HE, 2002, CLEV CLIN J MED, V69, P594, DOI 10.3949/ccjm.69.8.594; Eringa EC, 2004, AM J PHYSIOL-HEART C, V287, pH2043, DOI 10.1152/ajpheart.00067.2004; Gersch C, 2008, NUCLEOS NUCLEOT NUCL, V27, P967, DOI 10.1080/15257770802257952; Go YM, 2001, AM J PHYSIOL-HEART C, V281, pH2705, DOI 10.1152/ajpheart.2001.281.6.H2705; HOLMES EW, 1979, ARTHRITIS RHEUM, V22, P737, DOI 10.1002/art.1780220707; Hong Q, 2012, CELL CALCIUM, V51, P402, DOI 10.1016/j.ceca.2012.01.003; Huang PL, 2009, TRENDS ENDOCRIN MET, V20, P295, DOI 10.1016/j.tem.2009.03.005; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JOHNSON WJ, 1978, LIFE SCI, V23, P2239, DOI 10.1016/0024-3205(78)90210-2; Johnson-Delaney C, 1996, EXOTIC ANIMAL COMPAN; Kang DH, 2005, J AM SOC NEPHROL, V16, P3553, DOI 10.1681/ASN.2005050572; Kim JA, 2006, CIRCULATION, V113, P1888, DOI 10.1161/CIRCULATIONAHA.105.563213; Li SS, 2013, NEPHROLOGY, V18, P682, DOI 10.1111/nep.12127; Liu ZQ, 2009, J CLIN ENDOCR METAB, V94, P3543, DOI 10.1210/jc.2009-0027; Lovren F, 2009, AM J PHYSIOL-ENDOC M, V296, pE1440, DOI 10.1152/ajpendo.90780.2008; Mangge Harald, 2008, Diabetes Care, V31, pe21, DOI 10.2337/dc07-2411; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mazzali M, 2001, HYPERTENSION, V38, P1101, DOI 10.1161/hy1101.092839; MILLER RC, 1985, BRIT J PHARMACOL, V85, P481, DOI 10.1111/j.1476-5381.1985.tb08885.x; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Muniyappa R, 2007, ENDOCR REV, V28, P463, DOI 10.1210/er.2007-0006; Nakagawa T, 2006, AM J PHYSIOL-RENAL, V290, pF625, DOI 10.1152/ajprenal.00140.2005; Nakanishi N, 2003, EUR J EPIDEMIOL, V18, P523, DOI 10.1023/A:1024600905574; Niskanen LK, 2004, ARCH INTERN MED, V164, P1546, DOI 10.1001/archinte.164.14.1546; Noone DG, 2013, J PEDIATR-US, V162, P128, DOI 10.1016/j.jpeds.2012.06.008; Noronha BT, 2005, DIABETES, V54, P1082, DOI 10.2337/diabetes.54.4.1082; Papezikova I, 2013, FREE RADICAL RES, V47, P82, DOI 10.3109/10715762.2012.747677; Park JH, 2013, NITRIC OXIDE-BIOL CH, V32, P36, DOI 10.1016/j.niox.2013.04.003; Perlstein TS, 2006, HYPERTENSION, V48, P1031, DOI 10.1161/01.HYP.0000248752.08807.4c; Potenza MA, 2005, AM J PHYSIOL-HEART C, V289, pH813, DOI 10.1152/ajpheart.00092.2005; Rask-Madsen C, 2007, NAT CLIN PRACT ENDOC, V3, P46, DOI 10.1038/ncpendmet0366; Santos CXC, 1999, ARCH BIOCHEM BIOPHYS, V372, P285, DOI 10.1006/abbi.1999.1491; Schulman IH, 2007, AM J PHYSIOL-HEART C, V293, pH853, DOI 10.1152/ajpheart.00138.2007; Short RA, 2005, SEMIN NEPHROL, V25, P25, DOI 10.1016/j.semnephrol.2004.09.005; So A, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2509; Szasz T, 2010, J PHARMACOL EXP THER, V333, P758, DOI 10.1124/jpet.109.160184; Taniguchi Y, 2001, J HYPERTENS, V19, P1209, DOI 10.1097/00004872-200107000-00005; Wu GY, 2009, BIOFACTORS, V35, P21, DOI 10.1002/biof.3; Zecchin HG, 2007, DIABETES, V56, P1014, DOI 10.2337/db05-1147; Zhang WL, 2009, CLIN CHEM, V55, P2026, DOI 10.1373/clinchem.2009.124891; Zharikov S, 2008, AM J PHYSIOL-CELL PH, V295, pC1183, DOI 10.1152/ajpcell.00075.2008; Zhou QG, 2012, AM J PHYSIOL-HEART C, V303, pH1154, DOI 10.1152/ajpheart.00407.2012	44	126	146	2	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3197	3204		10.1096/fj.13-247148	http://dx.doi.org/10.1096/fj.13-247148			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24652948				2022-12-28	WOS:000337949400039
J	Sweigard, JH; Yanai, R; Gaissert, P; Saint-Geniez, M; Kataoka, K; Thanos, A; Stahl, GL; Lambris, JD; Connor, KM				Sweigard, J. Harry; Yanai, Ryoji; Gaissert, Philipp; Saint-Geniez, Magali; Kataoka, Keiko; Thanos, Aristomenis; Stahl, Gregory L.; Lambris, John D.; Connor, Kip M.			The alternative complement pathway regulates pathological angiogenesis in the retina	FASEB JOURNAL			English	Article						neovascularization; innate immune system; factor b; Cd55; oxygen-induced retinopathy	ENDOTHELIAL GROWTH-FACTOR; DECAY-ACCELERATING FACTOR; CHOROIDAL NEOVASCULARIZATION; RETINOPATHY; INHIBITION; EXPRESSION; MOUSE; MODEL; ACTIVATION; PATHOGENESIS	A defining feature in proliferative retinopathies is the formation of pathological neovessels. In these diseases, the balance between neovessel formation and regression determines blindness, making the modulation of neovessel growth highly desirable. The role of the immune system in these retinopathies is of increasing interest, but it is not completely understood. We investigated the role of the alternative complement pathway during the formation and resolution of aberrant neovascularization. We used alternative complement pathway-deficient (Fb(-/-)) mice and age- and strain-matched control mice to assess neovessel development and regression in an oxygen-induced retinopathy (OIR) mouse model. In the control mice, we found increased transcription of Fb after OIR treatment. In the Fb(-/-) mice, we prepared retinal flat-mounts and identified an increased number of neovessels, peaking at postnatal day 17 (P17; P = 0.001). Subjecting human umbilical vein endothelial cells (HUVECs) to low oxygen, mimicking a characteristic of neovessels, decreased the expression of the complement inhibitor Cd55. Finally, using laser capture microdissection (LCM) to isolate the neovessels after OIR, we found decreased expression of Cd55 (P = 0.005). Together, our data implicate the alternative complement pathway in facilitating neovessel clearance by down-regulating the complement inhibitor Cd55 specifically on neovessels, allowing for their targeted removal while leaving the established vasculature intact.	[Sweigard, J. Harry; Yanai, Ryoji; Gaissert, Philipp; Kataoka, Keiko; Thanos, Aristomenis; Connor, Kip M.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab,Dept Ophthalmol, Boston, MA 02114 USA; [Saint-Geniez, Magali] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; [Stahl, Gregory L.] Harvard Univ, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Sch Med,Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02114 USA; [Lambris, John D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Schepens Eye Research Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Pennsylvania	Connor, KM (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA.	kip_connor@meei.harvard.edu	Lambris, John/Q-5633-2018; SAINT-GENIEZ, MAGALI/P-3509-2019; Kataoka, Keiko/B-2806-2016	Lambris, John/0000-0002-9370-5776; SAINT-GENIEZ, MAGALI/0000-0001-9897-138X; Kataoka, Keiko/0000-0002-8795-6536; Stahl, Gregory/0000-0002-4805-8119; Connor, Kip/0000-0002-2048-9080	National Eye Institute of the U.S. National Institutes of Health (NIH) [R01EY022084-01/S1, EY020633-02, AI068730, T32EY007145, P30EY014104]; Howe Laboratory endowment of the Massachusetts Eye and Ear Infirmary; March of Dimes Foundation [5-FY09-535]; Research to Prevent Blindness; Massachusetts Lions Eye Research Fund, Inc.; Japan Eye Bank Association; NATIONAL EYE INSTITUTE [P30EY014104, R01EY020633, R01EY023682, T32EY007145, R01EY022084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI068730] Funding Source: NIH RePORTER	National Eye Institute of the U.S. National Institutes of Health (NIH); Howe Laboratory endowment of the Massachusetts Eye and Ear Infirmary; March of Dimes Foundation(March of Dimes); Research to Prevent Blindness(Research to Prevent Blindness (RPB)); Massachusetts Lions Eye Research Fund, Inc.; Japan Eye Bank Association; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Research reported in this publication was supported by the National Eye Institute of the U.S. National Institutes of Health (NIH) under award numbers R01EY022084-01/S1 (K.M.C.), EY020633-02 and AI068730 (J.D.L.), T32EY007145 (J.H.S.), and P30EY014104. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Additional support was provided by the Howe Laboratory endowment of the Massachusetts Eye and Ear Infirmary; March of Dimes Foundation (5-FY09-535); a Research to Prevent Blindness unrestricted grant; Massachusetts Lions Eye Research Fund, Inc. (K.M.C.); and an award from the Japan Eye Bank Association (to R.Y.).	Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Brodsky SV, 2009, TRANSPLANTATION, V88, P457, DOI 10.1097/TP.0b013e3181b0517d; Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0; Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591; Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821; Gardiner TA, 2005, AM J PATHOL, V166, P637, DOI 10.1016/S0002-9440(10)62284-5; HAMILTON KK, 1990, BLOOD, V76, P2572; Harris CL, 1999, BIOCHEM J, V341, P821, DOI 10.1042/0264-6021:3410821; Harris CL, 2007, J IMMUNOL, V178, P352, DOI 10.4049/jimmunol.178.1.352; Hoang MV, 2011, BBA-MOL BASIS DIS, V1812, P549, DOI 10.1016/j.bbadis.2010.08.008; Hoang MV, 2010, ANGIOGENESIS, V13, P269, DOI 10.1007/s10456-010-9184-y; Hourcade D, 2000, IMMUNOPHARMACOLOGY, V49, P103, DOI 10.1016/S0162-3109(00)80296-9; Kemper C, 2001, CLIN EXP IMMUNOL, V124, P180, DOI 10.1046/j.1365-2249.2001.01458.x; Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014; Langer HF, 2010, BLOOD, V116, P4395, DOI 10.1182/blood-2010-01-261503; Mechoulam Hadas, 2003, Am J Pharmacogenomics, V3, P261, DOI 10.2165/00129785-200303040-00004; Morita M, 2003, EMBO J, V22, P1134, DOI 10.1093/emboj/cdg117; Moulton KS, 2006, CURR OPIN LIPIDOL, V17, P548, DOI 10.1097/01.mol.0000245261.71129.f0; Nauta AJ, 2002, EUR J IMMUNOL, V32, P783, DOI 10.1002/1521-4141(200203)32:3<783::AID-IMMU783>3.0.CO;2-Q; Nilsson B, 2012, IMMUNOBIOLOGY, V217, P1106, DOI 10.1016/j.imbio.2012.07.008; Okroj M, 2009, CANCER IMMUNOL IMMUN, V58, P1771, DOI 10.1007/s00262-009-0685-8; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; Pedersen ED, 2007, MOL IMMUNOL, V44, P2459, DOI 10.1016/j.molimm.2006.10.022; Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001; Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Ramaglia V, 2009, MOL IMMUNOL, V46, P1892, DOI 10.1016/j.molimm.2009.01.017; Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; Roumenina LT, 2011, J IMMUNOL METHODS, V365, P8, DOI 10.1016/j.jim.2010.12.020; Rus H, 2006, AUTOIMMUNITY, V39, P395, DOI 10.1080/08916930600739605; Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246; Sasidharan C K, 2003, Indian J Pediatr, V70, P359, DOI 10.1007/BF02723597; Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2; Song WC, 2004, CURR DIRECT AUTOIMMU, V7, P181; Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176; Stem MS, 2013, CURR MED CHEM, V20, P3241, DOI 10.2174/09298673113209990027; Suzuki H, 2013, J IMMUNOL, V191, P4431, DOI 10.4049/jimmunol.1202242; Vakeva A, 1998, APMIS, V106, P1149; VANDERSCHOOT CE, 1990, BLOOD, V76, P1853; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Weidemann A, 2010, GLIA, V58, P1177, DOI 10.1002/glia.20997; Yanai R, 2012, ADV EXP MED BIOL, V946, P161, DOI 10.1007/978-1-4614-0106-3_10; Zhang L, 2003, CANCER RES, V63, P3403; ZIMMERMANN A, 1990, VIRCHOWS ARCH A, V417, P299, DOI 10.1007/BF01605780	50	30	31	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3171	3182		10.1096/fj.14-251041	http://dx.doi.org/10.1096/fj.14-251041			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24668752	Green Published			2022-12-28	WOS:000337949400037
J	Patrick, RP; Ames, BN				Patrick, Rhonda P.; Ames, Bruce N.			Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism	FASEB JOURNAL			English	Review						brain function; oxytocin; prenatal; autoimmunity; behavior; vasopressin	MESSENGER-RNA LEVELS; TRYPTOPHAN-HYDROXYLASE ISOFORM; WHOLE-BLOOD SEROTONIN; ESSENTIAL FATTY-ACIDS; D-BINDING PROTEIN; SPECTRUM DISORDERS; BRAIN-SEROTONIN; SEX-DIFFERENCES; D DEFICIENCY; 25-HYDROXYVITAMIN D	Serotonin and vitamin D have been proposed to play a role in autism; however, no causal mechanism has been established. Here, we present evidence that vitamin D hormone (calcitriol) activates the transcription of the serotonin-synthesizing gene tryptophan hydroxylase 2 (TPH2) in the brain at a vitamin D response element (VDRE) and represses the transcription of TPH1 in tissues outside the blood-brain barrier at a distinct VDRE. The proposed mechanism explains 4 major characteristics associated with autism: the low concentrations of serotonin in the brain and its elevated concentrations in tissues outside the bloodbrain barrier; the low concentrations of the vitamin D hormone precursor 25-hydroxyvitamin D [25(OH) D3]; the high male prevalence of autism; and the presence of maternal antibodies against fetal brain tissue. Two peptide hormones, oxytocin and vasopressin, are also associated with autism and genes encoding the oxytocin- neurophysin I preproprotein, the oxytocin receptor, and the arginine vasopressin receptor contain VDREs for activation. Supplementation with vitamin D and tryptophan is a practical and affordable solution to help prevent autism and possibly ameliorate some symptoms of the disorder.	[Patrick, Rhonda P.; Ames, Bruce N.] Childrens Hosp Oakland, Res Inst, Nutr & Metab Ctr, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Patrick, RP (corresponding author), Childrens Hosp Oakland, Res Inst, Nutr & Metab Ctr, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	R.P.P.rpatrick@chori.org; bames@chori.org			David and Annette Jorgensen Foundation; Ames CHORI Foundation	David and Annette Jorgensen Foundation; Ames CHORI Foundation	R.P.P. is grateful for support from the David and Annette Jorgensen Foundation and to the Ames CHORI Foundation for the earlier part of this project. The authors thank Giovanna Ames, Sofia Ames, Sam Barondes, Barry Bochner, Eugene Bolotin, Louann Brizendine, John Cannell, Mark Haussler, Janet King, Ron Krauss, Joyce McCann, Daniel Patrick, Margie Profet, Bill Rutter, and Renee Wachtel for comments and suggestions on the manuscript. The authors are also grateful to Barry Bochner for a preprint of Boccuto et al. (24) that set us on this search for the link between vitamin D and serotonin.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th ed., DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]; Ames BN, 2006, P NATL ACAD SCI USA, V103, P17589, DOI 10.1073/pnas.0608757103; Ames BN, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/725071; Amminger GP, 2007, BIOL PSYCHIAT, V61, P551, DOI 10.1016/j.biopsych.2006.05.007; Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107; Anderson GM, 2002, J AM ACAD CHILD PSY, V41, P1513, DOI 10.1097/00004583-200212000-00025; Anney R, 2012, HUM MOL GENET, V21, P4781, DOI 10.1093/hmg/dds301; [Anonymous], 2011, Obstet Gynecol, V118, P197, DOI 10.1097/AOG.0b013e318227f06b; ASBERG M, 1973, CLIN PHARMACOL THER, V14, P277; Austin MC, 1999, J NEUROCHEM, V72, P2065, DOI 10.1046/j.1471-4159.1999.0722065.x; Auyeung B, 2009, PSYCHOL SCI, V20, P144, DOI 10.1111/j.1467-9280.2009.02279.x; BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; Bailey RL, 2012, J ACAD NUTR DIET, V112, P657, DOI 10.1016/j.jand.2012.01.026; Baio J., 2012, MORBIDITY MORTALITY, V61; Bales KL, 2007, NEUROSCIENCE, V144, P38, DOI 10.1016/j.neuroscience.2006.09.009; Barnevik-Olsson M, 2008, DEV MED CHILD NEUROL, V50, P598, DOI 10.1111/j.1469-8749.2008.03036.x; Barnevik-Olsson M, 2010, DEV MED CHILD NEUROL, V52, P1167, DOI 10.1111/j.1469-8749.2010.03812.x; Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002; Batabyal D, 2007, J AM CHEM SOC, V129, P15690, DOI 10.1021/ja076186k; Bauman MD, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.47; Begeer S, 2009, J AUTISM DEV DISORD, V39, P142, DOI 10.1007/s10803-008-0611-5; BELISLE S, 1980, J CLIN ENDOCR METAB, V50, P117, DOI 10.1210/jcem-50-1-117; Bell JG, 2004, PROSTAG LEUKOTR ESS, V71, P201, DOI 10.1016/j.plefa.2004.03.008; BENNETTCLARKE CA, 1994, J NEUROSCI, V14, P7594; Bethea CL, 2000, BIOL PSYCHIAT, V47, P562, DOI 10.1016/S0006-3223(99)00156-0; Bhasin TK, 2007, J AUTISM DEV DISORD, V37, P667, DOI 10.1007/s10803-006-0194-y; Bielsky IF, 2004, NEUROPSYCHOPHARMACOL, V29, P483, DOI 10.1038/sj.npp.1300360; Bloom G, 2005, EVOL HUM BEHAV, V26, P301, DOI 10.1016/j.evolhumbehav.2004.10.002; Boccuto L, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-16; Bodnar LM, 2007, J NUTR, V137, P447, DOI 10.1093/jn/137.2.447; Bonnin A, 2011, NATURE, V472, P347, DOI 10.1038/nature09972; Boylan CB, 2007, BEHAV BRAIN RES, V176, P94, DOI 10.1016/j.bbr.2006.08.026; Braunschweig D, 2013, Transl Psychiatry, V3, pe277, DOI 10.1038/tp.2013.50; Brimberg L, 2013, MOL PSYCHIATR, V18, P1171, DOI 10.1038/mp.2013.101; Busse B, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006286; Byrdwell WC, 2008, AM J CLIN NUTR, V88, p554S, DOI 10.1093/ajcn/88.2.554S; Cannell JJ, 2008, MED HYPOTHESES, V70, P750, DOI 10.1016/j.mehy.2007.08.016; CAO X, 1993, J BIOL CHEM, V268, P27371; CARLSSON M, 1985, J NEURAL TRANSM, V63, P297, DOI 10.1007/BF01252033; CARLSSON M, 1988, N-S ARCH PHARMACOL, V338, P345; CARLSSON M, 1988, PROG NEURO-PSYCHOPH, V12, P53, DOI 10.1016/0278-5846(88)90061-9; Casanova MF, 2002, NEUROLOGY, V58, P428, DOI 10.1212/WNL.58.3.428; Chabbi-Achengli Y, 2012, P NATL ACAD SCI USA, V109, P2567, DOI 10.1073/pnas.1117792109; Chambers ES, 2011, CURR ALLERGY ASTHM R, V11, P29, DOI 10.1007/s11882-010-0161-8; Chen JJ, 2001, J NEUROSCI, V21, P6348, DOI 10.1523/JNEUROSCI.21-16-06348.2001; Chugani DC, 1999, ANN NEUROL, V45, P287, DOI 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9; Chun RF, 2012, CELL BIOCHEM FUNCT, V30, P445, DOI 10.1002/cbf.2835; Chun RF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030773; Chun RF, 2010, J CLIN ENDOCR METAB, V95, P3368, DOI 10.1210/jc.2010-0195; Cook E H Jr, 1990, J Neuropsychiatry Clin Neurosci, V2, P268; Coon H, 2005, AM J MED GENET B, V135B, P42, DOI 10.1002/ajmg.b.30168; Crockett MJ, 2009, ANN NY ACAD SCI, V1167, P76, DOI 10.1111/j.1749-6632.2009.04506.x; Dalton KM, 2005, NAT NEUROSCI, V8, P519, DOI 10.1038/nn1421; Daly EM, 2012, ARCH GEN PSYCHIAT, V69, P1003, DOI 10.1001/archgenpsychiatry.2012.513; de Theije CGM, 2011, EUR J PHARMACOL, V668, pS70, DOI 10.1016/j.ejphar.2011.07.013; Dealberto MJ, 2011, ACTA PSYCHIAT SCAND, V123, P339, DOI 10.1111/j.1600-0447.2010.01662.x; DEUFEMIA P, 1995, BIOMED PHARMACOTHER, V49, P288, DOI 10.1016/0753-3322(96)82645-X; Dijkstra SH, 2007, ARCH DIS CHILD, V92, P750, DOI 10.1136/adc.2006.105577; Dolen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518; Domes G, 2014, NEUROPSYCHOPHARMACOL, V39, P698, DOI 10.1038/npp.2013.254; Durkin MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011551; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Elster A, 2003, ARCH PEDIAT ADOL MED, V157, P867, DOI 10.1001/archpedi.157.9.867; Fallarino F, 2006, TRANSPL IMMUNOL, V17, P58, DOI 10.1016/j.trim.2006.09.017; Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752; Fernell E, 1997, DEV MED CHILD NEUROL, V39, P313; Fernell E, 2010, ACTA PAEDIATR, V99, P743, DOI 10.1111/j.1651-2227.2010.01755.x; FERNSTROM JD, 1977, METABOLISM, V26, P207, DOI 10.1016/0026-0495(77)90057-9; FERNSTROM JD, 1972, SCIENCE, V178, P414, DOI 10.1126/science.178.4059.414; Fink G, 1999, BEHAV BRAIN RES, V105, P53, DOI 10.1016/S0166-4328(99)00082-0; Flores G, 2005, PEDIATRICS, V115, pE183, DOI 10.1542/peds.2004-1474; FOLSTEIN S, 1977, J CHILD PSYCHOL PSYC, V18, P297, DOI 10.1111/j.1469-7610.1977.tb00443.x; Fombonne E, 2003, JAMA-J AM MED ASSOC, V289, P87, DOI 10.1001/jama.289.1.87; Garrett-Mayer E, 2012, AM J CLIN NUTR, V96, P332, DOI 10.3945/ajcn.112.034256; Gaspar P, 2003, NAT REV NEUROSCI, V4, P1002, DOI 10.1038/nrn1256; Georgieff MK, 2005, PEDIATR RES, V57, p99R, DOI 10.1203/01.PDR.0000160542.69840.0F; Gershon Michael D, 2012, Trans Am Clin Climatol Assoc, V123, P268; Ghia JE, 2009, GASTROENTEROLOGY, V137, P1649, DOI 10.1053/j.gastro.2009.08.041; Gijsman HJ, 2002, J CLIN PSYCHOPHARM, V22, P183, DOI 10.1097/00004714-200204000-00012; Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604; Goin-Kochel RP, 2007, AUTISM, V11, P279, DOI 10.1177/1362361307076857; Golan D, 2013, BRAIN BEHAV IMMUN, V32, P180, DOI 10.1016/j.bbi.2013.04.010; Golarai G, 2006, CLIN NEUROSCI RES, V6, P145, DOI 10.1016/j.cnr.2006.08.001; Gong ZL, 2014, NEUROREPORT, V25, P23, DOI 10.1097/WNR.0000000000000034; Grant WB, 2013, DERM-ENDOCRINOL, V5, DOI 10.4161/derm.22942; Grant WB, 2009, DERM-ENDOCRINOL, V1, P223, DOI 10.4161/derm.1.4.9500; Gutknecht L, 2009, EUR NEUROPSYCHOPHARM, V19, P266, DOI 10.1016/j.euroneuro.2008.12.005; Guzman YF, 2013, NAT NEUROSCI, V16, P1185, DOI 10.1038/nn.3465; Hallmayer J, 2011, ARCH GEN PSYCHIAT, V68, P1095, DOI 10.1001/archgenpsychiatry.2011.76; HARDIN CM, 1973, BRAIN RES, V59, P437, DOI 10.1016/0006-8993(73)90287-4; Haussler MR, 2008, NUTR REV, V66, pS98, DOI 10.1111/j.1753-4887.2008.00093.x; Haussler MR, 2011, BEST PRACT RES CL EN, V25, P543, DOI 10.1016/j.beem.2011.05.010; Hediger ML, 2008, J AUTISM DEV DISORD, V38, P848, DOI 10.1007/s10803-007-0453-6; Heikkinen J, 2004, CLIN EXP IMMUNOL, V136, P373, DOI 10.1111/j.1365-2249.2004.02441.x; Hiroi R, 2011, NEUROSCIENCE, V176, P120, DOI 10.1016/j.neuroscience.2010.12.019; Hiroi R, 2006, BIOL PSYCHIAT, V60, P288, DOI 10.1016/j.biopsych.2005.10.019; Hohmann CF, 2007, BRAIN RES, V1139, P163, DOI 10.1016/j.brainres.2006.12.095; Holick MF, 2006, MAYO CLIN PROC, V81, P353, DOI 10.4065/81.3.353; Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S; Holick MF, 2008, AM J CLIN NUTR, V87, p1080S; Holick Michael F, 2011, J Clin Endocrinol Metab, V96, P1; Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021; Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.biopsych.2006.05.030; Horovitz M, 2011, DEV NEUROREHABIL, V14, P208, DOI 10.3109/17518423.2011.566596; Horvath Karoly, 2002, Curr Gastroenterol Rep, V4, P251, DOI 10.1007/s11894-002-0071-6; Hranilovic D, 2007, J AUTISM DEV DISORD, V37, P1934, DOI 10.1007/s10803-006-0324-6; Hsieh JC, 2014, J ENDOCRINOL, V220, P165, DOI 10.1530/JOE-13-0212; Huang CH, 2008, AM J MED GENET B, V147B, P903, DOI 10.1002/ajmg.b.30720; Hudson C, 2007, CAN J PHYSIOL PHARM, V85, P928, DOI 10.1139/Y07-082; Innis SM, 2007, J NUTR, V137, P855, DOI 10.1093/jn/137.4.855; Janusonis S, 2006, J NEUROCHEM, V99, P1019, DOI 10.1111/j.1471-4159.2006.04150.x; Jarquin VG, 2011, J DEV BEHAV PEDIATR, V32, P179, DOI 10.1097/DBP.0b013e31820b4260; Kadauke S, 2009, BBA-GENE REGUL MECH, V1789, P17, DOI 10.1016/j.bbagrm.2008.07.002; Kane MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048975; Kasahara AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065785; Kato S, 2007, CURR OPIN NEPHROL HY, V16, P297, DOI 10.1097/MNH.0b013e3281c55f16; Keen DV, 2010, BRIT J PSYCHIAT, V196, P274, DOI 10.1192/bjp.bp.109.065490; Kennel K. A., 2010, MAYO CLIN P, V85, P752; Kim SJ, 2002, MOL PSYCHIATR, V7, P503, DOI 10.1038/sj.mp.4001125; Klaiman C, 2013, J CHILD ADOL PSYCHOP, V23, P320, DOI 10.1089/cap.2012.0127; Kliemann D, 2012, J NEUROSCI, V32, P9469, DOI 10.1523/JNEUROSCI.5294-11.2012; Kolevzon A, 2006, J CLIN PSYCHIAT, V67, P407, DOI 10.4088/JCP.v67n0311; Koszewski NJ, 1999, MOL ENDOCRINOL, V13, P455, DOI 10.1210/me.13.3.455; Kremer R, 1996, J BIOL CHEM, V271, P16310, DOI 10.1074/jbc.271.27.16310; Kuriyama S, 2002, DEV MED CHILD NEUROL, V44, P284; Lambert GW, 2002, LANCET, V360, P1840, DOI 10.1016/S0140-6736(02)11737-5; Leboyer M, 1999, BIOL PSYCHIAT, V45, P158, DOI 10.1016/S0006-3223(97)00532-5; Leon-Ponte M, 2007, BLOOD, V109, P3139, DOI 10.1182/blood-2006-10-052787; Li N, 2011, AM J PATHOL, V178, P662, DOI 10.1016/j.ajpath.2010.10.028; Lim MM, 2004, NATURE, V429, P754, DOI 10.1038/nature02539; Liptak GS, 2008, J DEV BEHAV PEDIATR, V29, P152, DOI 10.1097/DBP.0b013e318165c7a0; Lisse TS, 2011, STEROIDS, V76, P331, DOI 10.1016/j.steroids.2011.01.002; Luxwolda MF, 2012, BRIT J NUTR, V108, P1557, DOI 10.1017/S0007114511007161; Lyall K, 2013, AM J EPIDEMIOL, V178, P209, DOI 10.1093/aje/kws433; Ma WJ, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-22; Magnusson C, 2012, BRIT J PSYCHIAT, V201, P109, DOI 10.1192/bjp.bp.111.095125; Malek ZS, 2005, EUR J NEUROSCI, V22, P895, DOI 10.1111/j.1460-9568.2005.04264.x; Mandell DS, 2009, AM J PUBLIC HEALTH, V99, P493, DOI 10.2105/AJPH.2007.131243; Mandell DS, 2002, J AM ACAD CHILD PSY, V41, P1447, DOI 10.1097/00004583-200212000-00016; MANN JJ, 1992, BIOL PSYCHIAT, V32, P243; MARTINEAU J, 1988, J AUTISM DEV DISORD, V18, P435, DOI 10.1007/BF02212198; Mazer C, 1997, BRAIN RES, V760, P68, DOI 10.1016/S0006-8993(97)00297-7; MCBRIDE PA, 1989, ARCH GEN PSYCHIAT, V46, P213; McCann JC, 2008, FASEB J, V22, P982, DOI 10.1096/fj.07-9326rev; McCann JC, 2011, FASEB J, V25, P1793, DOI 10.1096/fj.11-180885; McCann JC, 2009, AM J CLIN NUTR, V90, P889, DOI 10.3945/ajcn.2009.27930; McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P993; McQueen JK, 1997, MOL BRAIN RES, V45, P13, DOI 10.1016/S0169-328X(96)00233-1; Meguid NA, 2008, CLIN BIOCHEM, V41, P1044, DOI 10.1016/j.clinbiochem.2008.05.013; Mellor AL, 2001, NAT IMMUNOL, V2, P64, DOI 10.1038/83183; Meyer-Lindenberg A, 2009, MOL PSYCHIATR, V14, P968, DOI 10.1038/mp.2008.54; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3; Moffitt TE, 1998, BIOL PSYCHIAT, V43, P446, DOI 10.1016/S0006-3223(97)00340-5; Moskowitz DS, 2001, NEUROPSYCHOPHARMACOL, V25, P277, DOI 10.1016/S0893-133X(01)00219-6; Mousain-Bosc M, 2006, MAGNESIUM RES, V19, P46; Mulder EJ, 2004, J AM ACAD CHILD PSY, V43, P491, DOI 10.1097/00004583-200404000-00016; Mulder EJ, 2010, NEUROPSYCHOBIOLOGY, V61, P27, DOI 10.1159/000258640; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Nakamura K, 2006, J NEUROSCI, V26, P530, DOI 10.1523/JNEUROSCI.1835-05.2006; Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x; Neumeyer AM, 2013, J AUTISM DEV DISORD, V43, P1623, DOI 10.1007/s10803-012-1709-3; Nexon L, 2009, EUR J NEUROSCI, V30, P1790, DOI 10.1111/j.1460-9568.2009.06986.x; Nguyen Ly, 2007, Cultur Divers Ethnic Minor Psychol, V13, P18, DOI 10.1037/1099-9809.13.1.18; Nordahl CW, 2013, BRAIN BEHAV IMMUN, V30, P61, DOI 10.1016/j.bbi.2013.01.084; Orabona GM, 2009, BRAIN RES, V1250, P14, DOI 10.1016/j.brainres.2008.11.007; Pallotta MT, 2011, NAT IMMUNOL, V12, P870, DOI 10.1038/ni.2077; Passamonti L, 2012, BIOL PSYCHIAT, V71, P36, DOI 10.1016/j.biopsych.2011.07.033; Patrick L., 2005, AUTISM ASPERGERS DIG, P36; PecinsThompson M, 1996, J NEUROSCI, V16, P7021; Powe CE, 2013, NEW ENGL J MED, V369, P1991, DOI 10.1056/NEJMoa1306357; Prufer K, 1997, CELL MOL BIOL, V43, P543; Punyko J, 2009, AUTISM SPECTRUM DISO; Rai D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038893; Reed P, 2012, J AUTISM DEV DISORD, V42, P947, DOI 10.1007/s10803-011-1324-8; RENNER KJ, 1985, EXP BRAIN RES, V58, P198; Ross A. C., 2013, DIETARY REFERENCE IN; Sanchez RL, 2005, MOL BRAIN RES, V135, P194, DOI 10.1016/j.molbrainres.2004.12.011; Schaaf CP, 2011, NEURON, V70, P806, DOI 10.1016/j.neuron.2011.05.025; Sharp T, 2007, TRENDS PHARMACOL SCI, V28, P629, DOI 10.1016/j.tips.2007.10.009; SJOSTROM R, 1972, EUR J CLIN PHARMACOL, V4, P170, DOI 10.1007/BF00561141; Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025; STROM M, 1992, P SOC EXP BIOL MED, V199, P369, DOI 10.3181/00379727-199-43371; Sugden D, 2003, J NEUROCHEM, V86, P1308, DOI 10.1046/j.1471-4159.2003.01959.x; Sumner BEH, 1999, MOL BRAIN RES, V73, P119, DOI 10.1016/S0169-328X(99)00243-0; Swaab DF, 2004, GYNECOL ENDOCRINOL, V19, P301, DOI 10.1080/09513590400018231; Tansey KE, 2011, MOL AUTISM, V2, DOI 10.1186/2040-2392-2-3; Tilburgs T, 2006, PLACENTA, V27, pS47, DOI 10.1016/j.placenta.2005.11.008; Toell A, 2000, BIOCHEM J, V352, P301, DOI 10.1042/0264-6021:3520301; Tordjman S, 2001, MOL PSYCHIATR, V6, P434, DOI 10.1038/sj.mp.4000873; Turner EH, 2006, PHARMACOL THERAPEUT, V109, P325, DOI 10.1016/j.pharmthera.2005.06.004; Turunen MM, 2007, NUCLEIC ACIDS RES, V35, P2734, DOI 10.1093/nar/gkm179; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vancassel S, 2001, PROSTAG LEUKOTR ESS, V65, P1, DOI 10.1054/plef.2001.0281; Waldman M, 2008, ARCH PEDIAT ADOL MED, V162, P1026, DOI 10.1001/archpedi.162.11.1026; Walther DJ, 2003, BIOCHEM PHARMACOL, V66, P1673, DOI 10.1016/S0006-2952(03)00556-2; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Wassink TH, 2004, MOL PSYCHIATR, V9, P968, DOI 10.1038/sj.mp.4001503; White SW, 2007, J AUTISM DEV DISORD, V37, P1858, DOI 10.1007/s10803-006-0320-x; Whitehouse AJO, 2013, J AUTISM DEV DISORD, V43, P1495, DOI 10.1007/s10803-012-1676-8; Whitehouse AJO, 2012, PEDIATRICS, V129, P485, DOI 10.1542/peds.2011-2644; Whitfield G. K., 2005, NUCL VITAMIN D RECEP; Wilson CA, 2007, REPRODUCTION, V133, P331, DOI 10.1530/REP-06-0078; Wilson ME, 2011, HORM BEHAV, V59, P353, DOI 10.1016/j.yhbeh.2010.08.004; Wortsman J, 2000, AM J CLIN NUTR, V72, P690, DOI 10.1093/ajcn/72.3.690; WURTMAN RJ, 1986, APPETITE, V7, P99, DOI 10.1016/S0195-6663(86)80055-1; Xu W, 2005, BIOCHEM CELL BIOL, V83, P418, DOI 10.1139/O05-057; Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098; Yamasue H, 2012, J NEUROSCI, V32, P14109, DOI 10.1523/JNEUROSCI.3327-12.2012; Yang SY, 2012, NEUROSCI RES, V73, P333, DOI 10.1016/j.neures.2012.05.012; Yirmiya N, 2006, MOL PSYCHIATR, V11, P488, DOI 10.1038/sj.mp.4001812; Zafeiriou DI, 2009, CURR NEUROPHARMACOL, V7, P150, DOI 10.2174/157015909788848848	212	213	225	0	55	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2398	2413		10.1096/fj.13-246546	http://dx.doi.org/10.1096/fj.13-246546			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24558199				2022-12-28	WOS:000339883600003
J	Vieira, TCRG; Cordeiro, Y; Caughey, B; Silva, JL				Vieira, Tuane C. R. G.; Cordeiro, Yraima; Caughey, Byron; Silva, Jerson L.			Heparin binding confers prion stability and impairs its aggregation	FASEB JOURNAL			English	Article						glycosaminoglycan; neurodegeneration	INTRAVENTRICULAR PENTOSAN POLYSULFATE; CREUTZFELDT-JAKOB-DISEASE; PROTEASE-RESISTANT PRP; SULFATE PROTEOGLYCANS; ALZHEIMERS-DISEASE; SYNTHETIC PEPTIDES; MAMMALIAN PRIONS; FIBRIL FORMATION; CULTURED-CELLS; CELLULAR PRP	The conversion of the prion protein (PrP) into scrapie PrP (PrPSc) is a central event in prion diseases. Several molecules work as cofactors in the conversion process, including glycosaminoglycans (GAGs). GAGs exhibit a paradoxical effect, as they convert PrP into protease-resistant PrP (PrP-res) but also exert protective activity. We compared the stability and aggregation propensity of PrP and the heparin-PrP complex through the application of different in vitro aggregation approaches, including real-time quaking-induced conversion (RT-QuIC). Transmissible spongiform encephalopathy-associated forms from mouse and hamster brain homogenates were used to seed RT-QuIC-induced fibrillization. In our study, interaction between heparin and cellular PrP (PrPC) increased thermal PrP stability, leading to an 8-fold decrease in temperature-induced aggregation. The interaction of low-molecular-weight heparin (LMWHep) with the PrP N- or C-terminal domain affected not only the extent of PrP fibrillization but also its kinetics, lowering the reaction rate constant from 1.04 to 0.29 s(-1) and increasing the lag phase from 12 to 19 h in RT-QuIC experiments. Our findings explain the protective effect of heparin in different models of prion and prion-like neurodegenerative diseases and establish the groundwork for the development of therapeutic strategies based on GAGs.	[Vieira, Tuane C. R. G.; Silva, Jerson L.] Univ Fed Rio de Janeiro, Ctr Nacl Ressonncia Magnet Nucl Jiri Jonas, Inst Bioqum Med Leopoldo Meis, Inst Nacl Ciencia Tecnol Biol Estrutural E Bioima, Rio De Janeiro, Brazil; [Cordeiro, Yraima] Univ Fed Rio de Janeiro, Fac Far, Rio De Janeiro, Brazil; [Caughey, Byron] NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, US Natl Inst Hlth, Hamilton, MT 59840 USA	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim, Bloco E Sala 10, BR-21941590 Rio De Janeiro, RJ, Brazil.	tuane@bioqmed.ufrj.br; jerson@bioqmed.ufrj.br	SILVA, JERSON Lima/GRF-1442-2022; Vieira, Tuane CRG/F-4550-2014; Cordeiro, Yraima/J-7619-2012; Silva, Jerson/J-8984-2014	SILVA, JERSON Lima/0000-0001-9523-9441; Vieira, Tuane CRG/0000-0002-3574-5411; Cordeiro, Yraima/0000-0003-4278-212X; Silva, Jerson/0000-0001-9523-9441	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ); CNPq; Instituto Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem (CNPq INCT Program); FAPERJ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001087] Funding Source: NIH RePORTER	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Instituto Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem (CNPq INCT Program); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank A. Hughson for purifying the recombinant PrP and for preparing the brain homogenate samples and G. and L. Raymond for technical assistance. T.C.R.G.V. received a postdoctoral fellowship from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) through the Science Without Borders Internship Program and from Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ). This work was supported by grants from CNPq, Instituto Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem (CNPq INCT Program) and FAPERJ.	Abid K, 2010, FEBS LETT, V584, P2409, DOI 10.1016/j.febslet.2010.04.040; Adjou KT, 2003, J GEN VIROL, V84, P2595, DOI 10.1099/vir.0.19073-0; Adrover M, 2010, J BIOL CHEM, V285, P21004, DOI 10.1074/jbc.M110.111815; Ancsin JB, 2003, AMYLOID, V10, P67, DOI 10.3109/13506120309041728; Baskakov IV, 2005, BIOCHEMISTRY-US, V44, P2339, DOI 10.1021/bi048322t; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; Caughey B, 2006, ACCOUNTS CHEM RES, V39, P646, DOI 10.1021/ar050068p; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; Caughey B, 2006, NATURE, V443, P803, DOI 10.1038/nature05294; Chesebro B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000800; Cobb NJ, 2007, P NATL ACAD SCI USA, V104, P18946, DOI 10.1073/pnas.0706522104; Cohen FE, 1999, J MOL BIOL, V293, P313, DOI 10.1006/jmbi.1999.2990; Cordeiro Y, 2004, J BIOL CHEM, V279, P32354, DOI 10.1074/jbc.M404295200; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Cortijo-Arellano M, 2008, BIOCHEM BIOPH RES CO, V368, P238, DOI 10.1016/j.bbrc.2008.01.049; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; Deleault NR, 2007, P NATL ACAD SCI USA, V104, P9741, DOI 10.1073/pnas.0702662104; Deleault NR, 2012, P NATL ACAD SCI USA, V109, P8546, DOI 10.1073/pnas.1204498109; Deleault NR, 2005, J BIOL CHEM, V280, P26873, DOI 10.1074/jbc.M503973200; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Dudas B, 2008, NEURODEGENER DIS, V5, P200, DOI 10.1159/000113702; Ermonval M, 2003, BIOCHIMIE, V85, P33, DOI 10.1016/S0300-9084(03)00040-3; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Gomes MPB, 2008, J BIOL CHEM, V283, P19616, DOI 10.1074/jbc.M802102200; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; Hafner-Bratkovic I, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.213926; Harrison PM, 1999, J MOL BIOL, V286, P593, DOI 10.1006/jmbi.1998.2497; Hijazi N, 2005, J BIOL CHEM, V280, P17057, DOI 10.1074/jbc.M411314200; Holmes BB, 2013, P NATL ACAD SCI USA, V110, pE3138, DOI 10.1073/pnas.1301440110; Honda H, 2012, NEUROPATHOLOGY, V32, P124, DOI 10.1111/j.1440-1789.2011.01245.x; Horonchik L, 2005, J BIOL CHEM, V280, P17062, DOI 10.1074/jbc.M500122200; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kaneko K, 1997, J MOL BIOL, V270, P574, DOI 10.1006/jmbi.1997.1135; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Kong QZ, 2013, CELL REP, V4, P248, DOI 10.1016/j.celrep.2013.06.030; Kuwata K, 2007, P NATL ACAD SCI USA, V104, P11921, DOI 10.1073/pnas.0702671104; LADOGANA A, 1992, J GEN VIROL, V73, P661, DOI 10.1099/0022-1317-73-3-661; Larramendy-Gozalo C, 2007, J GEN VIROL, V88, P1062, DOI 10.1099/vir.0.82286-0; Lee KS, 2007, P NATL ACAD SCI USA, V104, P9551, DOI 10.1073/pnas.0703910104; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Leveugle B, 1998, J NEUROCHEM, V70, P736; Lindahl U, 2007, THROMB HAEMOSTASIS, V98, P109, DOI 10.1160/Th07-04-0310; Ma Q, 2002, THROMB RES, V105, P447, DOI 10.1016/S0049-3848(02)00050-6; Martins PM, 2013, PRION, V7, P136, DOI 10.4161/pri.23111; Morris AM, 2009, BBA-PROTEINS PROTEOM, V1794, P375, DOI 10.1016/j.bbapap.2008.10.016; Murayama Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013152; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Orru CD, 2012, PRION, V6, P147, DOI 10.4161/pri.19430; Parry A, 2007, J NEUROL NEUROSUR PS, V78, P733, DOI 10.1136/jnnp.2006.104505; Perez M, 1998, BIOCHEM J, V335, P369, DOI 10.1042/bj3350369; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rumjon A, 2012, INT J NEPHROL RENOV, V5, P37, DOI 10.2147/IJNRD.S19165; Schatzl HM, 1997, J MOL BIOL, V265, P257, DOI 10.1006/jmbi.1996.0791; SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; Silva JL, 2010, ACCOUNTS CHEM RES, V43, P271, DOI 10.1021/ar900179t; Smirnovas V, 2011, NAT STRUCT MOL BIOL, V18, P504, DOI 10.1038/nsmb.2035; Solforosi L, 2007, J BIOL CHEM, V282, P7465, DOI 10.1074/jbc.M610051200; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Terada T, 2010, ACTA NEUROL SCAND, V121, P127, DOI 10.1111/j.1600-0404.2009.01272.x; Turnbaugh JA, 2012, J NEUROSCI, V32, P8817, DOI 10.1523/JNEUROSCI.1103-12.2012; van der Kamp MW, 2010, J MOL BIOL, V404, P732, DOI 10.1016/j.jmb.2010.09.060; Vascellari S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048969; Vieira TCRG, 2011, J AM CHEM SOC, V133, P334, DOI 10.1021/ja106725p; Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997; Whittle IR, 2006, ACTA NEUROCHIR, V148, P677, DOI 10.1007/s00701-006-0772-y; Wilham JM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001217; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Yokoyama T, 2011, NEUROSCI LETT, V498, P119, DOI 10.1016/j.neulet.2011.04.072; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; Zhu H, 2001, MOL MED, V7, P517, DOI 10.1007/BF03401857	80	46	46	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2667	2676		10.1096/fj.13-246777	http://dx.doi.org/10.1096/fj.13-246777			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24648544	Green Published			2022-12-28	WOS:000339883600024
J	Noda, K; Nakao, S; Zandi, S; Sun, DW; Hayes, KC; Hafezi-Moghadam, A				Noda, Kousuke; Nakao, Shintaro; Zandi, Souska; Sun, Dawei; Hayes, K. C.; Hafezi-Moghadam, Ali			Retinopathy in a novel model of metabolic syndrome and type 2 diabetes: new insight on the inflammatory paradigm	FASEB JOURNAL			English	Article						adhesion molecules; adipokines; Nile grass rat	ADHESION MOLECULE-1; HYPERGLYCEMIC RAT; HUMAN RETINA; NILE RAT; CELLS; MICE; COMPLICATIONS; PERMEABILITY; LEUKOSTASIS; EXPRESSION	The pathogenesis of diabetic retinopathy (DR) in metabolic syndrome (MetS) and type 2 diabetes (T2D) is not well studied, partly because an appropriate model has not been developed. Recently, we introduced a novel model of spontaneous T2D and MetS that replicates the relevant features of the human disease. In the current study, we investigated the retinal vascular changes in these animals. Experimental DR in streptozotocin (STZ)-injected rodents is described as an inflammatory disease, in which intercellular adhesion molecule 1 (ICAM-1) plays a key role. In comparison, advanced diabetes (HbA1c>10%) in the Nile grass rat (NGR) was associated with lower ICAM-1 protein expression when compared with that in normal or moderately diabetic animals. Vascular cell adhesion molecule 1 (VCAM-1) expression, however, was unaffected by the disease state. As opposed to the STZ-induced model of DR, in diabetic NGRs, most leukocytes accumulated in the retinal arteries. Consistent with the ICAM-1 reduction, leukocyte accumulation was significantly reduced in advanced disease. Similarly, leukocyte adhesions were significantly lower, with elevated plasma triglycerides (>200 mg/dl), and cholesterol (>240 mg/dl). However, these adhesions were significantly higher in animals with higher plasma insulin (>5 IU/ml) and leptin (>20 ng/ml), suggesting a role for these hormones in diabetic retinal leukostasis. Diabetic NGRs showed substantial retinal endothelial injury, primarily in the microvessels, including vascular tortuosity, obliterated acellular capillaries, and pericyte ghosts. The NGR provides a convenient and realistic model for investigation of retinal changes in MetS/T2D with convincing advantages over the commonly used STZ-induced T1D. Noda, K., Nakao, S., Zandi, S., Sun, D., Hayes, K. C., Hafezi-Moghadam, A. Retinopathy in a novel model of metabolic syndrome and type 2 diabetes: new insight on the inflammatory paradigm.	[Noda, Kousuke; Nakao, Shintaro; Zandi, Souska; Sun, Dawei; Hafezi-Moghadam, Ali] Brigham & Womens Hosp, Ctr Excellence Funct & Mol Imaging, Boston, MA 02115 USA; [Nakao, Shintaro; Zandi, Souska; Sun, Dawei; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Noda, Kousuke] Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Sapporo, Hokkaido, Japan; [Nakao, Shintaro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka 812, Japan; [Sun, Dawei] Harbin Med Univ, Dept Ophthalmol, Affiliated Hosp 2, Harbin, Peoples R China; [Hayes, K. C.] Brandeis Univ, Dept Biol, Foster Biomed Res Lab, Waltham, MA 02254 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Hokkaido University; Kyushu University; Harbin Medical University; Brandeis University	Hafezi-Moghadam, A (corresponding author), Brigham & Womens Hosp, 221 Longwood Ave, Boston, MA 02115 USA.	ahm@bwh.harvard.edu		Hafezi-Moghadam, Ali/0000-0002-5336-0697; Zandi, Souska/0000-0001-9351-4278	U.S. National Institutes of Health (NIH) DiaComp award; Bausch & Lomb (Rochester, NY, USA); Japanese Eye Bank Association; Tear Film and Ocular Surface Society Young Investigator fellowship; Malaysian Palm Oil Board; Bright Focus Foundation	U.S. National Institutes of Health (NIH) DiaComp award; Bausch & Lomb (Rochester, NY, USA); Japanese Eye Bank Association; Tear Film and Ocular Surface Society Young Investigator fellowship; Malaysian Palm Oil Board; Bright Focus Foundation(BrightFocus Foundation)	The authors thank A. Schering, F. Xie, A. Auerbach, J. Bolsinger, and A. Pronczuk for technical assistance, and R. Garland for help with manuscript preparation. This work was supported by the U.S. National Institutes of Health (NIH) DiaComp award (to A.H.-M.), overseas research fellowship awards from Bausch & Lomb (Rochester, NY, USA; to K.N. and S.N.), a fellowship award from the Japanese Eye Bank Association (to K.N. and S.N.), a Tear Film and Ocular Surface Society Young Investigator fellowship (to S.N. under the mentorship of A.H.-M.), and by the Malaysian Palm Oil Board and the Bright Focus Foundation.	Adamis AP, 2002, BRIT J OPHTHALMOL, V86, P363, DOI 10.1136/bjo.86.4.363; Amos A F, 1997, Diabet Med, V14 Suppl 5, pS1; Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635; Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153; Biddinger SB, 2006, ANNU REV PHYSIOL, V68, P123, DOI 10.1146/annurev.physiol.68.040104.124723; Bolsinger J, 2013, J NUTR BIOCHEM, V24, P1945, DOI 10.1016/j.jnutbio.2013.06.004; Chaabo F, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-29; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chen WQ, 2003, INVEST OPHTH VIS SCI, V44, P5016, DOI 10.1167/iovs.03-0418; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; COLEMAN DL, 1974, DIABETOLOGIA, V10, P607, DOI 10.1007/BF01221993; DULIN WE, 1970, DIABETOLOGIA, V6, P317, DOI 10.1007/BF01212245; Faggioni R, 2001, FASEB J, V15, P2565, DOI 10.1096/fj.01-0431rev; Garmy-Susini B, 2005, J CLIN INVEST, V115, P1542, DOI 10.1172/JCI23445; Gesta S, 2007, CELL, V131, P242, DOI 10.1016/j.cell.2007.10.004; Hafezi-Moghadam A, 2007, FASEB J, V21, P464, DOI 10.1096/fj.06-6390com; Hammes HP, 2011, DIABETES, V60, P9, DOI 10.2337/db10-0454; Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107; Hughes JM, 2004, BRIT J OPHTHALMOL, V88, P566, DOI 10.1136/bjo.2003.021204; IKEDA H, 1981, DIABETES, V30, P1045, DOI 10.2337/diabetes.30.12.1045; Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807; Jariyapongskul A, 2003, CLIN HEMORHEOL MICRO, V29, P331; KAWANO K, 1992, DIABETES, V41, P1422, DOI 10.2337/diabetes.41.11.1422; MASUDA M, 1990, DIABETES, V39, P466, DOI 10.2337/diabetes.39.4.466; MCLEOD DS, 1995, AM J PATHOL, V147, P642; Miyahara S, 2004, AM J PATHOL, V164, P1697, DOI 10.1016/S0002-9440(10)63728-5; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Miyamoto K, 1998, INVEST OPHTH VIS SCI, V39, P2190; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; Nguyen TT, 2009, CURR DIABETES REP, V9, P277, DOI 10.1007/s11892-009-0043-4; Noda K, 2010, FASEB J, V24, P2443, DOI 10.1096/fj.09-152678; PORTHA B, 1991, DIABETES, V40, P486, DOI 10.2337/diabetes.40.4.486; Reaven G, 2004, ENDOCRIN METAB CLIN, V33, P283, DOI 10.1016/j.ecl.2004.03.002; ROBERTSON RP, 1973, J CLIN INVEST, V52, P1620, DOI 10.1172/JCI107340; Sasase T, 2006, DIABETES OBES METAB, V8, P501, DOI 10.1111/j.1463-1326.2005.00535.x; Sasongko MB, 2011, DIABETOLOGIA, V54, P2409, DOI 10.1007/s00125-011-2200-y; SCHRODER S, 1991, AM J PATHOL, V139, P81; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Skondra D, 2008, INVEST OPHTH VIS SCI, V49, P726, DOI 10.1167/iovs.07-0405; TAYLOR PD, 1994, BRIT J PHARMACOL, V111, P42, DOI 10.1111/j.1476-5381.1994.tb14021.x	40	38	43	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2014	28	5					2038	2046		10.1096/fj.12-215715	http://dx.doi.org/10.1096/fj.12-215715			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AG3RA	24571922	Green Published			2022-12-28	WOS:000335336000009
J	Paula, FMM; Leite, NC; Vanzela, EC; Kurauti, MA; Freitas-Dias, R; Carneiro, EM; Boschero, AC; Zoppi, CC				Paula, Flavia M. M.; Leite, Nayara C.; Vanzela, Emerielle C.; Kurauti, Mirian A.; Freitas-Dias, Ricardo; Carneiro, Everardo M.; Boschero, Antonio C.; Zoppi, Claudio C.			Exercise increases pancreatic beta-cell viability in a model of type 1 diabetes through IL-6 signaling	FASEB JOURNAL			English	Article						apoptosis; cytokine signaling myokines; pancreatic islets	STIMULATED INSULIN-SECRETION; ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE; IN-VITRO; NITRIC-OXIDE; INTERLEUKIN-6; CYTOKINES; SURVIVAL; INFLAMMATION; NEUTROPHIL	Type 1 diabetes (T1D) is provoked by an autoimmune assault against pancreatic cells. Exercise training enhances beta cell mass in T1D. Here, we investigated how exercise signals beta cells in T1D condition. For this, we used several approaches. Wild-type and IL-6 knockout (KO) C57BL/6 mice were exercised. Afterward, islets from control and trained mice were exposed to inflammatory cytokines (IL-1 beta plus IFN-gamma). Islets from control mice and beta-cell lines (INS-1E and MIN6) were incubated with serum from control or trained mice or medium obtained from 5-aminoimidazole-4 carboxamide1-beta-D-ribofuranoside (AICAR)-treated C2C12 skeletal muscle cells. Subsequently, islets and beta cells were exposed to IL-1 beta plus IFN-gamma. Proteins were assessed by immunoblotting, apoptosis was determined by DNA-binding dye propidium iodide fluorescence, and NO center dot was estimated by nitrite. Exercise reduced 25, 75, and 50% of the IL-1 beta plus IFN-gamma-induced iNOS, nitrite, and cleaved caspase-3 content, respectively, in pancreatic islets. Serum from trained mice and medium from AICAR-treated C2C12 cells reduced beta-cell death, induced by IL-1 beta plus IFN-gamma treatment, in 15 and 38%, respectively. This effect was lost in samples treated with IL-6 inhibitor or with serum from exercised IL-6 KO mice. In conclusion, muscle contraction signals beta-cell survival in T1D through IL-6.	[Paula, Flavia M. M.; Leite, Nayara C.; Vanzela, Emerielle C.; Kurauti, Mirian A.; Freitas-Dias, Ricardo; Carneiro, Everardo M.; Boschero, Antonio C.; Zoppi, Claudio C.] Univ Estadual Campinas, Inst Biol, Dept Struct & Funct Biol, BR-13083865 Campinas, SP, Brazil; [Freitas-Dias, Ricardo] Univ Pernambuco, Dept Phys Therapy, Lab Exercise Physiol & Genet, Petrolina, Brazil	Universidade Estadual de Campinas; Universidade de Pernambuco (UPE)	Zoppi, CC (corresponding author), Univ Estadual Campinas, Inst Biol, Dept Struct & Funct Biol, POB 6109, BR-13083865 Campinas, SP, Brazil.	czoppi@unicamp.br	Carneiro, Everardo/D-4758-2012; Kurauti, Mirian Ayumi/K-3309-2012; Boschero, Antonio/O-7525-2014; Vanzela, Emerielle/AAJ-1679-2021; Dias, Ricardo Freitas/E-1657-2013	Kurauti, Mirian Ayumi/0000-0003-2431-8120; Boschero, Antonio/0000-0003-3829-8570; Vanzela, Emerielle C/0000-0001-8487-9320; Leite, Nayara/0000-0003-4436-6947	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Brazil); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (Brazil)	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by research grants from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Brazil) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (Brazil).	Al-Jarrah M, 2013, NEUROREHABILITATION, V32, P141, DOI 10.3233/NRE-130831; Andersen JI, 2014, BIOCHEM BIOPH RES CO, V450, P1083, DOI 10.1016/j.bbrc.2014.06.124; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Baeza-Raja B, 2004, MOL BIOL CELL, V15, P2013, DOI 10.1091/mbc.E03-08-0585; BORDIN S, 1995, J MEMBRANE BIOL, V148, P177; Bouzakri K, 2011, DIABETES, V60, P1111, DOI 10.2337/db10-1178; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calegari VC, 2012, J APPL PHYSIOL, V112, P711, DOI 10.1152/japplphysiol.00318.2011; Calegari VC, 2011, J BIOL CHEM, V286, P12870, DOI 10.1074/jbc.M110.173021; Calegari VC, 2011, J ENDOCRINOL, V208, P257, DOI 10.1530/JOE-10-0450; Carey AL, 2006, DIABETES, V55, P2688, DOI 10.2337/db05-1404; Chavoshan B, 2012, RESP MED, V106, P269, DOI 10.1016/j.rmed.2011.07.018; Choi SE, 2004, TRANSPL IMMUNOL, V13, P43, DOI 10.1016/j.trim.2004.04.001; Choi SB, 2006, J ENDOCRINOL, V190, P471, DOI 10.1677/joe.1.06400; Coskun O, 2004, TOHOKU J EXP MED, V203, P145, DOI 10.1620/tjem.203.145; DICOSMO BF, 1994, INT IMMUNOL, V6, P1829, DOI 10.1093/intimm/6.12.1829; Eizirik DL, 2009, NAT REV ENDOCRINOL, V5, P219, DOI 10.1038/nrendo.2009.21; Eizirik DL, 2001, DIABETOLOGIA, V44, P2115, DOI 10.1007/s001250100021; Ellingsgaard H, 2008, P NATL ACAD SCI USA, V105, P13163, DOI 10.1073/pnas.0801059105; Finucane OM, 2012, P NUTR SOC, V71, P622, DOI 10.1017/S0029665112000730; Fuqua JS, 2013, METABOLISM, V62, P911, DOI 10.1016/j.metabol.2013.01.016; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Handschin C, 2007, J CLIN INVEST, V117, P3463, DOI 10.1172/JCI31785; Haxhi J, 2013, ANN NUTR METAB, V62, P14, DOI 10.1159/000343788; Huang HH, 2011, EXP DIABETES RES, DOI 10.1155/2011/481427; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; Jones SA, 2005, J IMMUNOL, V175, P3463, DOI 10.4049/jimmunol.175.6.3463; Kaplanski G, 2003, TRENDS IMMUNOL, V24, P25, DOI 10.1016/S1471-4906(02)00013-3; Kelly M, 2009, DIABETES, V58, P1953, DOI 10.2337/db08-1293; Matthews VB, 2010, DIABETOLOGIA, V53, P2431, DOI 10.1007/s00125-010-1865-y; McGown C, 2014, CLIN LIVER DIS, V18, P41, DOI 10.1016/j.cld.2013.09.012; Munoz-Canoves P, 2013, FEBS J, V280, P4131, DOI 10.1111/febs.12338; Nogueira TC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003532; Osundiji MA, 2013, ENDOCRIN METAB CLIN, V42, P1, DOI 10.1016/j.ecl.2012.11.006; Park H, 2003, ANN NY ACAD SCI, V1005, P242, DOI 10.1196/annals.1288.036; Paula FMM, 2013, MOL CELL ENDOCRINOL, V374, P56, DOI 10.1016/j.mce.2013.04.009; Pedersen BK, 2013, COMPR PHYSIOL, V3, P1337, DOI 10.1002/cphy.c120033; Pedersen BK, 2012, NAT REV ENDOCRINOL, V8, P457, DOI 10.1038/nrendo.2012.49; Pedersen BK, 2006, ESSAYS BIOCHEM, V42, P105, DOI 10.1042/bse0420105; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Radtke S, 2010, J CELL SCI, V123, P947, DOI 10.1242/jcs.065326; Rezende EL, 2006, J EXP BIOL, V209, P115, DOI 10.1242/jeb.01883; Ropelle ER, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000465; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; SCOTT AM, 1981, DIABETOLOGIA, V21, P470; Serrano AL, 2008, CELL METAB, V7, P33, DOI 10.1016/j.cmet.2007.11.011; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Su SH, 2011, BIOCHEM BIOPH RES CO, V405, P58, DOI 10.1016/j.bbrc.2010.12.123; Sun SY, 2012, ANNU REV NUTR, V32, P261, DOI 10.1146/annurev-nutr-071811-150623; Suzuki T, 2011, DIABETES, V60, P537, DOI 10.2337/db10-0796; Szalai Z, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/925981; Tonoli C, 2012, SPORTS MED, V42, P1059, DOI 10.2165/11635380-000000000-00000; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; White PJ, 2014, NAT MED, V20, P664, DOI 10.1038/nm.3549; Wright HL, 2014, RHEUMATOLOGY, V53, P1321, DOI 10.1093/rheumatology/keu035	55	43	44	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1805	1816		10.1096/fj.14-264820	http://dx.doi.org/10.1096/fj.14-264820			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25609426				2022-12-28	WOS:000354114600017
J	Ost, M; Keipert, S; van Schothorst, EM; Donner, V; van der Stelt, I; Kipp, AP; Petzke, KJ; Jove, M; Pamplona, R; Portero-Otin, M; Keijer, J; Klaus, S				Ost, Mario; Keipert, Susanne; van Schothorst, Evert M.; Donner, Verena; van der Stelt, Inge; Kipp, Anna P.; Petzke, Klaus-Juergen; Jove, Mariona; Pamplona, Reinald; Portero-Otin, Manuel; Keijer, Jaap; Klaus, Susanne			Muscle mitohormesis promotes cellular survival via serine/glycine pathway flux	FASEB JOURNAL			English	Article						amino acid metabolism; metabolic reprogramming; mitochondrial myopathy; oxidative stress tolerance; polyamines	UNCOUPLING PROTEIN-1 EXPRESSION; UBIQUITIN-PROTEASOME PATHWAY; HUMAN SKELETAL-MUSCLE; ANTIOXIDANT DEFENSE; GENE-EXPRESSION; RECEPTOR-GAMMA; MOUSE MODEL; CATHEPSIN-L; KEY ROLE; METABOLISM	Recent studies on mouse and human skeletal muscle (SM) demonstrated the important link between mitochondrial function and the cellular metabolic adaptation. To identify key compensatory molecular mechanisms in response to chronic mitochondrial distress, we analyzed mice with ectopic SM respiratory uncoupling in uncoupling protein 1 transgenic (UCP1-TG) mice as model of muscle-specific compromised mitochondrial function. Here we describe a detailed metabolic reprogramming profile associated with mitochondrial perturbations in SM, triggering an increased protein turnover and amino acid metabolism with induced biosynthetic serine/1-carbon/glycine pathway and the longevity-promoting polyamine spermidine as well as the trans-sulfuration pathway. This is related to an induction of NADPH-generating pathways and glutathione metabolism as an adaptive mitohormetic response and defense against increased oxidative stress. Strikingly, consistent muscle retrograde signaling profiles were observed in acute stress states such as muscle cell starvation and lipid overload, muscle regeneration, and heart muscle inflammation, but not in response to exercise. We provide conclusive evidence for a key compensatory stress-signaling network that preserves cellular function, oxidative stress tolerance, and survival during conditions of increased SM mitochondrial distress, a metabolic reprogramming profile so far only demonstrated for cancer cells and heart muscle.	[Ost, Mario; Keipert, Susanne; Donner, Verena; Kipp, Anna P.; Petzke, Klaus-Juergen; Klaus, Susanne] German Inst Human Nutr, Potsdam, Germany; [van Schothorst, Evert M.; van der Stelt, Inge; Keijer, Jaap] Wageningen Univ, Human & Anim Physiol, NL-6700 AP Wageningen, Netherlands; [Jove, Mariona; Pamplona, Reinald; Portero-Otin, Manuel] Univ Lleida, Biomed Res Inst, Lleida, Spain	Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Wageningen University & Research; Universitat de Lleida	Klaus, S (corresponding author), German Inst Human Nutr, Inst Ernahrungsforsch Potsdam Rehbrucke, Arthur Scheunert Allee 114-116, D-14558 Nuthetal, Germany.	klaus@dife.de	Jové, Mariona/M-9104-2016; Portero-Otin, Manuel/B-7122-2009; Keipert, Susanne/V-2464-2017; Klaus, Susanne/P-9299-2018; Pamplona, Reinald/A-7359-2010; Keijer, Jaap/J-8089-2013	Jové, Mariona/0000-0001-5577-6162; Portero-Otin, Manuel/0000-0002-1823-0299; Keipert, Susanne/0000-0002-6618-7379; Klaus, Susanne/0000-0001-8726-185X; Pamplona, Reinald/0000-0003-4337-6107; Ost, Mario/0000-0002-1811-2049; Coleman, Verena/0000-0003-3045-4620; Kipp, Anna Patricia/0000-0002-3307-1038; van Schothorst, Evert/0000-0002-3036-5903; Keijer, Jaap/0000-0002-9720-7491	European Union [244995]; Leibniz Society [SAW-2013-FBN-3]; Spanish Ministry of Economy and Competitiveness [PI13/00584, PI11/01532]; Generalitat of Catalounya [2014SGR168]	European Union(European Commission); Leibniz Society; Spanish Ministry of Economy and Competitiveness(Spanish Government); Generalitat of Catalounya	This research received funding from the European Union's Seventh Framework Program FP7 2007-2013 under Grant Agreement 244995 (BIOCLAIMS Project) and from the Leibniz Society (SAW-2013-FBN-3) as well as grants from the Spanish Ministry of Economy and Competitiveness (PI13/00584, PI11/01532) and the Generalitat of Catalounya (2014SGR168). The authors thank A. Sylvester, A. Voigt, I. Walter, C. Borchert, S. Deubel, L. Duivenvoorde, and A. Bunschoten for excellent technical assistance.	Adjeitey CNK, 2013, AM J PHYSIOL-ENDOC M, V305, pE405, DOI 10.1152/ajpendo.00057.2013; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barash IA, 2004, AM J PHYSIOL-CELL PH, V286, pC355, DOI 10.1152/ajpcell.00211.2003; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brigelius-Flohe R, 2002, METHOD ENZYMOL, V347, P101; Brooks NE, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00099; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Couplan E, 2002, J BIOL CHEM, V277, P43079, DOI 10.1074/jbc.M206726200; Crunkhorn S, 2007, J BIOL CHEM, V282, P15439, DOI 10.1074/jbc.M611214200; Deval C, 2001, BIOCHEM J, V360, P143, DOI 10.1042/0264-6021:3600143; Dogan SA, 2014, CELL METAB, V19, P458, DOI 10.1016/j.cmet.2014.02.004; Duivenvoorde LPM, 2011, J MOL ENDOCRINOL, V47, P81, DOI 10.1530/JME-11-0001; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Ebert SM, 2012, J BIOL CHEM, V287, P27290, DOI 10.1074/jbc.M112.374777; Ellinger JJ, 2011, J BIOMOL NMR, V49, P221, DOI 10.1007/s10858-011-9481-9; Endo J, 2009, CIRC RES, V105, P1118, DOI 10.1161/CIRCRESAHA.109.206607; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Gates AC, 2007, CELL METAB, V6, P497, DOI 10.1016/j.cmet.2007.10.010; Kalko SG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-91; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Ham DJ, 2014, CLIN NUTR, V33, P448, DOI 10.1016/j.clnu.2013.06.013; Hoevenaars FPM, 2012, GENES NUTR, V7, P399, DOI 10.1007/s12263-011-0262-6; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Johnson ML, 2013, TRENDS ENDOCRIN MET, V24, P247, DOI 10.1016/j.tem.2012.12.003; Joseph AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069327; Kalhan SC, 2012, J BIOL CHEM, V287, P19786, DOI 10.1074/jbc.R112.357194; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Keipert S, 2013, AM J PHYSIOL-ENDOC M, V304, pE495, DOI 10.1152/ajpendo.00518.2012; Keipert S, 2014, AM J PHYSIOL-ENDOC M, V306, pE469, DOI 10.1152/ajpendo.00330.2013; Keipert S, 2011, AGING CELL, V10, P122, DOI 10.1111/j.1474-9726.2010.00648.x; Keipert S, 2010, BBA-BIOENERGETICS, V1797, P324, DOI 10.1016/j.bbabio.2009.11.008; Kim KH, 2013, NAT MED, V19, P83, DOI 10.1038/nm.3014; Klaus S, 2005, PHYSIOL GENOMICS, V21, P193, DOI 10.1152/physiolgenomics.00299.2004; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lehti TM, 2006, AM J PHYSIOL-ENDOC M, V290, pE900, DOI 10.1152/ajpendo.00444.2005; Lira VA, 2013, FASEB J, V27, P4184, DOI 10.1096/fj.13-228486; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lu SC, 2000, CURR TOP CELL REGUL, V36, P95; Macpherson PCD, 2011, J CELL BIOCHEM, V112, P2149, DOI 10.1002/jcb.23136; Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008; Minois N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.139; Minois N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102435; Minois N, 2014, GERONTOLOGY, V60, P319, DOI 10.1159/000356748; Neschen S, 2008, PHYSIOL GENOMICS, V33, P333, DOI 10.1152/physiolgenomics.00226.2007; Ost M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094689; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Owusu-Ansah E, 2013, CELL, V155, P699, DOI 10.1016/j.cell.2013.09.021; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Powers SK, 2012, AM J PHYSIOL-ENDOC M, V303, pE31, DOI 10.1152/ajpendo.00609.2011; Rangwala SM, 2010, J BIOL CHEM, V285, P22619, DOI 10.1074/jbc.M110.125401; Ristow M, 2010, EXP GERONTOL, V45, P410, DOI 10.1016/j.exger.2010.03.014; Ristow M, 2009, P NATL ACAD SCI USA, V106, P8665, DOI 10.1073/pnas.0903485106; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Shi Y, 2013, AM J PHYSIOL-REG I, V304, pR343, DOI 10.1152/ajpregu.00139.2012; Silva JM, 2009, NEUROBIOL DIS, V34, P357, DOI 10.1016/j.nbd.2009.02.005; Stack C, 2014, HUM MOL GENET, V23, P3716, DOI 10.1093/hmg/ddu080; Stevenson EJ, 2005, J APPL PHYSIOL, V98, P1396, DOI 10.1152/japplphysiol.01055.2004; Tedeschi PM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.393; Tenhunen O, 2006, CIRC RES, V99, P485, DOI 10.1161/01.RES.0000238387.85144.92; Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310; Van der Meer-Van Kraaij C, 2003, FASEB J, V17, P1277, DOI 10.1096/fj.02-1036com; van Helden YGJ, 2010, CELL MOL LIFE SCI, V67, P2039, DOI 10.1007/s00018-010-0341-7; van Schothorst EM, 2007, ANAL BIOCHEM, V363, P315, DOI 10.1016/j.ab.2007.01.016; VANHALL G, 1995, J PHYSIOL-LONDON, V489, P251, DOI 10.1113/jphysiol.1995.sp021047; Vazquez A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025881; WAALKES TP, 1957, J LAB CLIN MED, V50, P733; Weimer S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4563; Wikoff WR, 2008, J CLIN INVEST, V118, P2661, DOI 10.1172/JCI34138; Yamazaki Y, 2010, BIOCHEM J, V427, P171, DOI 10.1042/BJ20091346; Zhao P, 2002, J BIOL CHEM, V277, P30091, DOI 10.1074/jbc.M202668200	77	45	45	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1314	1328		10.1096/fj.14-261503	http://dx.doi.org/10.1096/fj.14-261503			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25491309				2022-12-28	WOS:000354115000019
J	Guan, HF; Zhao, LB; Cao, HJ; Chen, AM; Xiao, J				Guan, Hanfeng; Zhao, Libo; Cao, Huijuan; Chen, Anmin; Xiao, Jun			Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss	FASEB JOURNAL			English	Article						osteoclast; osteoporosis; RANK; NF-kappa B	SOLUBLE EPOXIDE HYDROLASE; NECROSIS-FACTOR-ALPHA; FACTOR-KAPPA-B; EPOXYEICOSATRIENOIC ACIDS; SIGNALING PATHWAYS; IN-VIVO; CARDIOVASCULAR-DISEASES; THERAPEUTIC TARGET; RECEPTOR ACTIVATOR; ENDOTHELIAL-CELLS	Epoxyeicosatrienoic acids (EETs) are products of arachidonic acid metabolism catalyzed by cytochrome P450 epoxygenases. These small molecules are autocrine and paracrine lipid mediators with important roles in inflammation, cardiovascular function, and angiogenesis. Recent evidence has highlighted EETs as potent promoters of organ regeneration and malignant metastasis. We speculated that EETs might impact osteoclastogenesis and bone loss. Using both in vitro and in vivo studies, we observed that EETs significantly attenuated bone loss and inhibited osteoclast formation and activity, which were associated with a decreased receptor activator of NF-kappa B ligand (RANKL): osteoprotegerin ratio and serum levels of TNF-alpha and IL-1 beta. At the molecular level, EETs abrogated RANKL-induced activation of NF-kappa B, activator protein-1 (AP-1), and MAPKs, including ERK and JNK, but not p38, during osteoclast formation. EETs also prevented the production of reactive oxygen species (ROS) following RANKL stimulation. As a result, EETs suppressed osteoclast-specific gene expression, including tartrate resistant acid phosphatase (TRAP), cathepsin K (CK), matrix metalloproteinase (MMP)-9, and receptor activator of NF-kappa B (RANK). In conclusion, our findings demonstrate that EETs inhibit osteoclastogenesis through modulation of multiple pathways both upstream and downstream of RANKL signaling. The administration or stabilized endogenous levels of EETs could represent a novel therapeutic strategy for osteoclast-related disorders, such as rheumatoid arthritis and postmenopausal osteoporosis.	[Guan, Hanfeng; Zhao, Libo; Chen, Anmin; Xiao, Jun] Huazhong Univ Sci & Technol, Dept Orthopaed Surg, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China; [Cao, Huijuan] Chinese Acad Sci, Shenzhen Inst Adv Technol, Translat Med Res & Dev Ctr, Shenzhen, Guangdong, Peoples R China	Huazhong University of Science & Technology; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS	Xiao, J (corresponding author), Huazhong Univ Sci & Technol, Dept Orthopaed Surg, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.	xiaojun301@sina.com		Xiao, Jun/0000-0001-6472-1833; Guan, Hanfeng/0000-0002-4683-601X	National Natural Science Foundation of China [81101788, 81272058, 81171696]; Special Fund for nonprofit Health industry [201002018]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Special Fund for nonprofit Health industry; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry(Scientific Research Foundation for the Returned Overseas Chinese Scholars)	The authors thank Dr. Chang Chen at the Tongji School of Pharmacy, Huazhong University of Science & Technology for measurement of EETs levels in the bone tissue. They are grateful to colleague Dr. Jing Li in Department of Orthopaedic Surgery for preparation of Fig. 9. This study was supported in part by National Natural Science Foundation of China (No. 81101788 to H.G., No. 81272058 to J.X., No. 81171696 to A.C.) and Special Fund for nonprofit Health industry (NO. 201002018 to A.C.) and Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (to H.G.).	Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; Chen JK, 2002, P NATL ACAD SCI USA, V99, P6029, DOI 10.1073/pnas.092671899; Chen JK, 1998, J BIOL CHEM, V273, P29254, DOI 10.1074/jbc.273.44.29254; Dhanasekaran A, 2008, AM J PHYSIOL-HEART C, V294, pH724, DOI 10.1152/ajpheart.00979.2007; Dhanasekaran A, 2006, AM J PHYSIOL-HEART C, V291, pH517, DOI 10.1152/ajpheart.00953.2005; Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23; Fleming I, 2001, CIRC RES, V89, P753, DOI 10.1161/hh2101.099268; Fromel T, 2012, P NATL ACAD SCI USA, V109, P9995, DOI 10.1073/pnas.1206493109; Gao YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040258; Gross GJ, 2008, AM J PHYSIOL-HEART C, V294, pH2838, DOI 10.1152/ajpheart.00186.2008; Guan HF, 2013, J PATHOL, V229, P775, DOI 10.1002/path.4164; Guan HF, 2010, BLOOD, V116, P1469, DOI 10.1182/blood-2009-12-256446; Imig JD, 2002, HYPERTENSION, V39, P690, DOI 10.1161/hy0202.103788; Imig JD, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001773; Imig JD, 2010, J CARDIOVASC PHARM, V56, P329, DOI 10.1097/FJC.0b013e3181e96e0c; Imig JD, 2009, NAT REV DRUG DISCOV, V8, P794, DOI 10.1038/nrd2875; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259; Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066; Koerner IP, 2008, FRONT BIOSCI-LANDMRK, V13, P2833, DOI 10.2741/2889; Kwak HB, 2008, MOL CELLS, V26, P436; Lee CR, 2010, FASEB J, V24, P3770, DOI 10.1096/fj.10-160119; Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood-2004-09-3662; Lee SE, 2001, J BIOL CHEM, V276, P49343, DOI 10.1074/jbc.M103642200; Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006-291X(03)00695-8; Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242; Liu Y, 2005, P NATL ACAD SCI USA, V102, P16747, DOI 10.1073/pnas.0508081102; Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179; Mundy GR, 2007, NUTR REV, V65, pS147, DOI 10.1301/nr.2007.dec.S147-S151; Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Panigrahy D, 2013, P NATL ACAD SCI USA, V110, P13528, DOI 10.1073/pnas.1311565110; Panigrahy D, 2012, J CLIN INVEST, V122, P178, DOI 10.1172/JCI58128; Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698; Sasaki H., 2009, J MED INVEST, V56, P33; Schmelzer KR, 2005, P NATL ACAD SCI USA, V102, P9772, DOI 10.1073/pnas.0503279102; Seubert JM, 2007, PROSTAG OTH LIPID M, V82, P50, DOI 10.1016/j.prostaglandins.2006.05.017; Smith KR, 2005, P NATL ACAD SCI USA, V102, P2186, DOI 10.1073/pnas.0409591102; Spector AA, 2009, J LIPID RES, V50, pS52, DOI 10.1194/jlr.R800038-JLR200; Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Vanella L, 2011, PROSTAG OTH LIPID M, V96, P54, DOI 10.1016/j.prostaglandins.2011.07.005; Wang DZ, 2012, J CLIN INVEST, V122, P19, DOI 10.1172/JCI61453; Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448; Xu XZ, 2011, ADV DRUG DELIVER REV, V63, P597, DOI 10.1016/j.addr.2011.03.006; Yang SL, 2007, AM J PHYSIOL-HEART C, V293, pH142, DOI 10.1152/ajpheart.00783.2006; Yang WQ, 2007, J PHARMACOL EXP THER, V321, P1023, DOI 10.1124/jpet.107.119651; Yu XF, 2004, J BONE MINER RES, V19, P2065, DOI 10.1359/JBMR.040910	52	48	51	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1092	1101		10.1096/fj.14-262055	http://dx.doi.org/10.1096/fj.14-262055			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25466887				2022-12-28	WOS:000350633000032
J	Alhouayek, M; Bottemanne, P; Subramanian, KV; Lambert, DM; Makriyannis, A; Cani, PD; Muccioli, GG				Alhouayek, Mireille; Bottemanne, Pauline; Subramanian, Kumar V.; Lambert, Didier M.; Makriyannis, Alexandros; Cani, Patrice D.; Muccioli, Giulio G.			N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis	FASEB JOURNAL			English	Article						endocannabinoid; 2-AG; Crohn's disease; PF-3845; N-acyltaurine	INFLAMMATORY-BOWEL-DISEASE; SODIUM-INDUCED COLITIS; ENDOCANNABINOID SYSTEM; VANILLOID RECEPTOR-1; SENSORY NEURONS; ALPHA; MODEL; INVOLVEMENT; PROTECTS; LIGANDS	N-Palmitoylethanolamine or palmitoylethanolamide (PEA) is an anti-inflammatory compound that was recently shown to exert peroxisome proliferatoractivated receptor-alpha-dependent beneficial effects on colon inflammation. The actions of PEA are terminated following hydrolysis by 2 enzymes: fatty acid amide hydrolase (FAAH), and the less-studied N-acylethanolaminehydrolyzing acid amidase (NAAA). This study aims to investigate the effects of inhibiting the enzymes responsible for PEA hydrolysis in colon inflammation in order to propose a potential therapeutic target for inflammatory bowel diseases (IBDs). Two murine models of IBD were used to assess the effects of NAAA inhibition, FAAH inhibition, and PEA on macroscopic signs of colon inflammation, macrophage/ neutrophil infiltration, and the expression of proinflammatory mediators in the colon, as well as on the colitis-related systemic inflammation. NAAA inhibition increases PEA levels in the colon and reduces colon inflammation and systemic inflammation, similarly to PEA. FAAH inhibition, however, does not increase PEA levels in the colon and does not affect the macroscopic signs of colon inflammation or immune cell infiltration. This is the first report of an anti-inflammatory effect of a systemically administered NAAA inhibitor. BecauseNAAA is the enzyme responsible for the control ofPEAlevels in the colon, we put forth this enzyme as a potential therapeutic target in chronic inflammation in general and IBDin particular.-Alhouayek, M., Bottemanne, P., Subramanian, K. V., Lambert, D. M., Makriyannis, A., Cani, P. D., and Muccioli, G. G. NAcylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.	[Alhouayek, Mireille; Bottemanne, Pauline; Muccioli, Giulio G.] Catholic Univ Louvain, Louvain Drug Res Inst, Bioanal & Pharmacol Bioact Lipids Res Grp, B-1200 Brussels, Belgium; [Alhouayek, Mireille; Lambert, Didier M.] Catholic Univ Louvain, Louvain Drug Res Inst, Med Chem Res Grp, B-1200 Brussels, Belgium; [Cani, Patrice D.] Catholic Univ Louvain, Louvain Drug Res Inst, Metab & Nutr Res Grp, B-1200 Brussels, Belgium; [Subramanian, Kumar V.; Makriyannis, Alexandros] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA	Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Northeastern University	Muccioli, GG (corresponding author), Catholic Univ Louvain, Louvain Drug Res Inst, Bioanal & Pharmacol Bioact Lipids Res Grp, Av E Mounier 72 B1-72-01, B-1200 Brussels, Belgium.	giulio.muccioli@uclouvain.be	Alhouayek, Mireille/R-5058-2018; Makriyannis, Alexandros/GRF-1518-2022; D., Cani Patrice/M-8055-2016	Alhouayek, Mireille/0000-0002-9193-0718; Makriyannis, Alexandros/0000-0003-3272-3687; D., Cani Patrice/0000-0003-2040-2448; Bottemanne, Pauline/0000-0003-0414-4127; Muccioli, Giulio/0000-0002-1600-9259	ERC Starting Grant (European Research Council) [336452-ENIGMO]; FRS-FNRS, Belgium [CC 1.5.034.10, FRFC 2.4555.08]; IBD Research Foundation; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003801, R37DA003801, P01DA009158] Funding Source: NIH RePORTER	ERC Starting Grant (European Research Council); FRS-FNRS, Belgium(Fonds de la Recherche Scientifique - FNRS); IBD Research Foundation; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank Therese Timmerman and Owein Guillemot-Legris for their assistance. P.D.C. is a research associate from the FRS-FNRS (Fonds de la Recherche Scientifique), Belgium, and recipient of ERC Starting Grant 2013 (European Research Council, Starting Grant 336452-ENIGMO). G.G.M. is the recipient of a subsidy from the Fonds Speciaux de Recherches (Universite catholique de Louvain) and from the FRS-FNRS, Belgium (Grants CC 1.5.034.10 and FRFC 2.4555.08). A.M. is a postdoctoral researcher from the FRS-FNRS, Belgium. They are also grateful to the IBD Research Foundation for their kind financial support. The authors declare no conflicts of interest.	Ahn K, 2009, CHEM BIOL, V16, P411, DOI 10.1016/j.chembiol.2009.02.013; Alhouayek M, 2014, DRUG DISCOV TODAY, V19, P1632, DOI 10.1016/j.drudis.2014.06.007; Alhouayek M, 2013, P NATL ACAD SCI USA, V110, P17558, DOI 10.1073/pnas.1314017110; Alhouayek M, 2012, TRENDS MOL MED, V18, P615, DOI 10.1016/j.molmed.2012.07.009; Alhouayek M, 2011, FASEB J, V25, P2711, DOI 10.1096/fj.10-176602; Aviello G, 2008, J MOL MED, V86, P413, DOI 10.1007/s00109-008-0305-7; Berdyshev E, 1998, LIFE SCI, V63, pPL125, DOI 10.1016/S0024-3205(98)00324-5; Borrelli F, 2009, BEST PRACT RES CL EN, V23, P33, DOI 10.1016/j.beem.2008.10.003; BRADLEY PP, 1982, BLOOD, V60, P618; Capasso R, 2005, GASTROENTEROLOGY, V129, P941, DOI 10.1053/j.gastro.2005.06.018; Capasso R, 2001, BRIT J PHARMACOL, V134, P945, DOI 10.1038/sj.bjp.0704339; Conigliaro R, 2011, MINERVA MED, V102, P141; Costa B, 2002, BRIT J PHARMACOL, V137, P413, DOI 10.1038/sj.bjp.0704900; Costa B, 2008, PAIN, V139, P541, DOI 10.1016/j.pain.2008.06.003; Cuzzocrea S, 2004, LAB INVEST, V84, P1643, DOI 10.1038/labinvest.3700185; Cuzzocrea S, 2008, MOL PHARMACOL, V73, P323, DOI 10.1124/mol.107.041475; D'Agostino G, 2012, NEUROPSYCHOPHARMACOL, V37, P1784, DOI 10.1038/npp.2012.25; Darmani NA, 2005, NEUROPHARMACOLOGY, V48, P1154, DOI 10.1016/j.neuropharm.2005.01.001; Esposito G, 2014, GUT, V63, P1300, DOI 10.1136/gutjnl-2013-305005; Fegley D, 2005, J PHARMACOL EXP THER, V313, P352, DOI 10.1124/jpet.104.078980; Fichna J, 2012, NEUROGASTROENT MOTIL, V24, pe557, DOI 10.1111/j.1365-2982.2012.01999.x; Hesselink JMK, 2013, J PAIN RES, V6, P239, DOI 10.2147/JPR.S42417; Holzer P, 2011, PHARMACOL THERAPEUT, V131, P142, DOI 10.1016/j.pharmthera.2011.03.006; Izzo AA, 2008, J MOL MED, V86, P89, DOI 10.1007/s00109-007-0248-4; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Kihara N, 2003, GUT, V52, P713, DOI 10.1136/gut.52.5.713; Kim JJ, 2012, JOVE-J VIS EXP, DOI 10.3791/3678; Kimball ES, 2004, NEUROGASTROENT MOTIL, V16, P811, DOI 10.1111/j.1365-2982.2004.00549.x; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; Lambert DM, 2007, CURR OPIN CLIN NUTR, V10, P735, DOI 10.1097/MCO.0b013e3282f00061; Lambert DM, 1999, BBA-MOL CELL BIOL L, V1440, P266, DOI 10.1016/S1388-1981(99)00132-8; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; Long JZ, 2011, J LIPID RES, V52, P337, DOI 10.1194/jlr.M012153; Loria F, 2008, EUR J NEUROSCI, V28, P633, DOI 10.1111/j.1460-9568.2008.06377.x; Luongo L, 2013, CNS NEUROL DISORD-DR, V12, P45, DOI 10.2174/1871527311312010009; Marquez L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006893; Mechoulam R, 2013, ANNU REV PSYCHOL, V64, P21, DOI 10.1146/annurev-psych-113011-143739; Melmed GY, 2010, NAT REV GASTRO HEPAT, V7, P110, DOI 10.1038/nrgastro.2009.218; Mowat C, 2011, GUT, V60, P571, DOI 10.1136/gut.2010.224154; Muccio GG, 2008, ANAL BIOCHEM, V373, P220, DOI 10.1016/j.ab.2007.09.030; Muccioli GG, 2007, J NEUROSCI, V27, P2883, DOI 10.1523/JNEUROSCI.4830-06.2007; Muccioli GG, 2010, DRUG DISCOV TODAY, V15, P474, DOI 10.1016/j.drudis.2010.03.007; Ponzano S, 2013, J MED CHEM, V56, P6917, DOI 10.1021/jm400739u; Riccardi L, 2009, SHOCK, V31, P308, DOI 10.1097/SHK.0b013e31818339e7; Rousseaux C, 2005, J EXP MED, V201, P1205, DOI 10.1084/jem.20041948; Saghatelian A, 2004, BIOCHEMISTRY-US, V43, P14332, DOI 10.1021/bi0480335; Saghatelian A, 2006, BIOCHEMISTRY-US, V45, P9007, DOI 10.1021/bi0608008; Scuderi C, 2013, CNS NEUROL DISORD-DR, V12, P62, DOI 10.2174/1871527311312010011; Solorzano C, 2009, P NATL ACAD SCI USA, V106, P20966, DOI 10.1073/pnas.0907417106; Storr MA, 2008, J MOL MED, V86, P925, DOI 10.1007/s00109-008-0359-6; Strober W, 2007, J CLIN INVEST, V117, P514, DOI 10.1172/JCI30587; Suarez J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037729; Sugiura T, 2004, J NEUROSCI, V24, P9521, DOI 10.1523/JNEUROSCI.2639-04.2004; Szitter I, 2010, J MOL NEUROSCI, V42, P80, DOI 10.1007/s12031-010-9366-5; Tarzia G, 2006, CHEMMEDCHEM, V1, P130, DOI 10.1002/cmdc.200500017; Ueda N, 2001, J BIOL CHEM, V276, P35552, DOI 10.1074/jbc.M106261200; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41; Zhu C, 2011, MOL PHARMACOL, V79, P786, DOI 10.1124/mol.110.070201	58	79	80	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					650	661		10.1096/fj.14-255208	http://dx.doi.org/10.1096/fj.14-255208			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25384424	Green Published			2022-12-28	WOS:000349370400026
J	Martinez-Vega, R; Garrido, F; Partearroyo, T; Cediel, R; Zeisel, SH; Martinez-Alvarez, C; Varela-Moreiras, G; Varela-Nieto, I; Pajares, MA				Martinez-Vega, Raquel; Garrido, Francisco; Partearroyo, Teresa; Cediel, Rafael; Zeisel, Steven H.; Martinez-Alvarez, Concepcion; Varela-Moreiras, Gregorio; Varela-Nieto, Isabel; Pajares, Maria A.			Folic acid deficiency induces premature hearing loss through mechanisms involving cochlear oxidative stress and impairment of homocysteine metabolism	FASEB JOURNAL			English	Article						apoptosis; dietary restriction; hair cell loss; hyperhomocysteinemia; methionine cycle	GUINEA-PIG COCHLEA; INNER-EAR; S-METHYLTRANSFERASE; REACTIVE OXYGEN; METHIONINE METABOLISM; GLUTATHIONE SYNTHESIS; ADENOSINE KINASE; MICE; MOUSE; NOISE	Nutritional imbalance is emerging as a causative factor of hearing loss. Epidemiologic studies have linked hearing loss to elevated plasma total homocysteine (tHcy) and folate deficiency, and have shown that folate supplementation lowers tHcy levels potentially ameliorating age-related hearing loss. The purpose of this study was to address the impact of folate deficiency on hearing loss and to examine the underlying mechanisms. For this purpose, 2-mo-old C57BL/6J mice (Animalia Chordata Mus musculus) were randomly divided into 2 groups (n = 65 each) that were fed folate-deficient (FD) or standard diets for 8 wk. HPLC analysis demonstrated a 7-fold decline in serum folate and a 3-fold increase in tHcy levels. FD mice exhibited severe hearing loss measured by auditory brainstem recordings and TUNEL-positive-apoptotic cochlear cells. RT-quantitative PCR and Western blotting showed reduced levels of enzymes catalyzing homocysteine (Hcy) production and recycling, together with a 30% increase in protein homocysteinylation. Redox stress was demonstrated by decreased expression of catalase, glutathione peroxidase 4, and glutathione synthetase genes, increased levels of manganese superoxide dismutase, and NADPH oxidase-complex adaptor cytochrome b-245, alpha-polypeptide (p22phox) proteins, and elevated concentrations of glutathione species. Altogether, our findings demonstrate, for the first time, that the relationship between hyperhomocysteinemia induced by folate deficiency and premature hearing loss involves impairment of cochlear Hcy metabolism and associated oxidative stress.	[Martinez-Vega, Raquel; Garrido, Francisco; Cediel, Rafael; Varela-Nieto, Isabel; Pajares, Maria A.] UAM, CSIC, Inst Biomed Res Alberto Sols, Madrid 28029, Spain; [Martinez-Vega, Raquel; Cediel, Rafael; Varela-Nieto, Isabel] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras, Unidad 761, Madrid, Spain; [Partearroyo, Teresa; Varela-Moreiras, Gregorio] Univ CEU San Pablo, Dept Ciencias Farmaceut & Salud, Fac Farm, Madrid, Spain; [Cediel, Rafael] Univ Complutense Madrid, Fac Vet, Hosp Clin Vet, Madrid, Spain; [Zeisel, Steven H.] Univ North Carolina Chapel Hill, Inst Nutr Res, Kannapolis, NC USA; [Martinez-Alvarez, Concepcion] Univ Complutense Madrid, Fac Med, Dept Anat & Embriol Humana 1, Madrid, Spain; [Varela-Nieto, Isabel; Pajares, Maria A.] Inst Invest Sanitaria La Paz, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III; San Pablo CEU University; Complutense University of Madrid; University of North Carolina; University of North Carolina Chapel Hill; Complutense University of Madrid	Varela-Nieto, I (corresponding author), UAM, CSIC, Inst Biomed Res Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	ivarela@iib.uam.es	Partearroyo, Teresa/J-7322-2017; Cediel-Algovia, Rafael/L-5274-2018; Pajares, Maria Angeles/I-5952-2012; Varela-Nieto, Isabel/G-5289-2015	Partearroyo, Teresa/0000-0002-4401-1233; Cediel-Algovia, Rafael/0000-0003-4594-8105; Pajares, Maria Angeles/0000-0002-4714-9051; Varela-Nieto, Isabel/0000-0003-3077-0500; MARTINEZ ALVAREZ, MARIA CONCEPCION/0000-0002-8089-3173; VARELA-MOREIRAS, GREGORIO/0000-0001-5158-4999	Ministerio de Ciencia e Innovacion [BFU2009-08977, SAF2011-24391, PS09/0176]; European Union; National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [DK056350]; Puleva BioFoods; JAE-CSIC predoctoral program; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); European Union(European Commission); National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Puleva BioFoods; JAE-CSIC predoctoral program; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Estela Maldonado from Complutense University of Madrid, Silvia Murillo-Cuesta from the Noninvasive Neurofunctional Evaluation facility, and the team from the Genomics facility (both from IIBM, CSIC-UAM) for the technical support provided. The authors also warmly thank their colleagues at the Neurobiology of Hearing group for sharing unpublished data and helpful discussions. R.M.-V. is supported by a fellowship from the JAE-CSIC predoctoral program. This work was supported by grants from the Ministerio de Ciencia e Innovacion (BFU2009-08977 to M. A. P., SAF2011-24391 to I. V.-N., and PS09/01762 to C.M.-A.), the European Union (FP7-AFHELO and TARGEAR to I.V.-N.), U.S. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (Grant DK056350 to S.H.Z.), and Puleva BioFoods (to I.V.-N., G.V.-M., and M.A.P.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no conflicts of interest.	Aburto MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030790; Attias J, 2012, AUDIOL NEURO-OTOL, V17, P309, DOI 10.1159/000339356; Banerjee R, 2012, J BIOL CHEM, V287, P4397, DOI 10.1074/jbc.R111.287995; Banfi B, 2004, J BIOL CHEM, V279, P46065, DOI 10.1074/jbc.M403046200; Cadoni G, 2004, ACTA OTO-LARYNGOL, V124, P608, DOI 10.1080/00016480410016216; Camarero G, 2001, J NEUROSCI, V21, P7630, DOI 10.1523/JNEUROSCI.21-19-07630.2001; Cediel R, 2006, EUR J NEUROSCI, V23, P587, DOI 10.1111/j.1460-9568.2005.04584.x; Cohen-Salmon M, 2007, P NATL ACAD SCI USA, V104, P6229, DOI 10.1073/pnas.0605108104; Delgado M, 2008, CELL MOL LIFE SCI, V65, P2080, DOI 10.1007/s00018-008-8201-4; Delgado M, 2014, ANTIOXID REDOX SIGN, V20, P2541, DOI 10.1089/ars.2013.5342; Dror AA, 2009, ANNU REV GENET, V43, P411, DOI 10.1146/annurev-genet-102108-134135; Durga J, 2006, NEUROBIOL AGING, V27, P482, DOI 10.1016/j.neurobiolaging.2005.03.002; Durga J, 2007, ANN INTERN MED, V146, P1, DOI 10.7326/0003-4819-146-1-200701020-00003; Emmett SD, 2014, MED HYPOTHESES, V82, P6, DOI 10.1016/j.mehy.2013.09.028; Feng H, 2011, MOL CELL BIOCHEM, V353, P291, DOI 10.1007/s11010-011-0798-1; Gok U, 2004, AURIS NASUS LARYNX, V31, P19, DOI 10.1016/j.anl.2003.09.001; Gonzalez B, 2003, BIOCHEM J, V370, P945, DOI 10.1042/BJ20021510; Gonzalez B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050329; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; HORNE DW, 1988, CLIN CHEM, V34, P2357; Houston DK, 1999, AM J CLIN NUTR, V69, P564; Ison JR, 2007, JARO-J ASSOC RES OTO, V8, P539, DOI 10.1007/s10162-007-0098-3; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Jakubowski H, 2011, ADV CLIN CHEM, V55, P81, DOI 10.1016/B978-0-12-387042-1.00005-8; Jiang H, 2007, NEUROBIOL AGING, V28, P1605, DOI 10.1016/j.neurobiolaging.2006.06.025; JOHNSSON LG, 1972, ANN OTO RHINOL LARYN, V81, P364, DOI 10.1177/000348947208100307; Karli R, 2013, ACTA OTORHINOLARYNGO, V33, P243; Keithley EM, 2005, HEARING RES, V209, P76, DOI 10.1016/j.heares.2005.06.009; Keithley EM, 2004, HEARING RES, V188, P21, DOI 10.1016/S0378-5955(03)00365-4; Kujawa SG, 2009, J NEUROSCI, V29, P14077, DOI 10.1523/JNEUROSCI.2845-09.2009; Kundu S, 2012, HEARING RES, V284, P42, DOI 10.1016/j.heares.2011.12.006; Kundu S, 2009, MOL CELL BIOCHEM, V332, P215, DOI 10.1007/s11010-009-0194-2; Lambeth JD, 2014, ANNU REV PATHOL-MECH, V9, P119, DOI 10.1146/annurev-pathol-012513-104651; Lasisi AO, 2010, OTOLARYNG HEAD NECK, V143, P826, DOI 10.1016/j.otohns.2010.08.031; Li X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026728; Li-Korotky HS, 2012, GERONTOLOGIST, V52, P265, DOI 10.1093/geront/gnr159; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Liu XZ, 2007, J PATHOL, V211, P188, DOI 10.1002/path.2102; Lu SC, 2013, BBA-GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008; Lu SC, 2012, PHYSIOL REV, V92, P1515, DOI 10.1152/physrev.00047.2011; Maestro-de-las-Casas C, 2013, BIRTH DEFECTS RES A, V97, P587, DOI 10.1002/bdra.23176; Makishima K., 1978, OTOLARYNGOLOGY, V86; Maldonado E, 2011, CELLS TISSUES ORGANS, V194, P406, DOI 10.1159/000323213; Massimo F, 2012, INT J AUDIOL, V51, P800, DOI 10.3109/14992027.2012.705904; Mosharov E, 2000, BIOCHEMISTRY-US, V39, P13005, DOI 10.1021/bi001088w; Murillo-Cuesta S, 2012, MOL MED, V18, P260, DOI 10.2119/molmed.2011.00328; Nathaniel GN., 2008, OPEN ENZYME INHIBITI, V1, P34, DOI [10.2174/1874940200801010034, DOI 10.2174/1874940200801010034]; Ohlemiller KK, 2006, BRAIN RES, V1091, P89, DOI 10.1016/j.brainres.2006.03.017; Pajares MA, 2006, CELL MOL LIFE SCI, V63, P2792, DOI 10.1007/s00018-006-6249-6; Pajares MA, 2013, FEBS LETT, V587, P1711, DOI 10.1016/j.febslet.2013.04.034; Pajares Maria A, 2011, Adv Enzymol Relat Areas Mol Biol, V78, P449; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PUEL JL, 1991, HEARING RES, V51, P255, DOI 10.1016/0378-5955(91)90042-8; Quintana-Cabrera R, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1722; Radi R, 2013, J BIOL CHEM, V288, P26464, DOI 10.1074/jbc.R113.472936; Rahman I, 2006, NAT PROTOC, V1, P3159, DOI 10.1038/nprot.2006.378; Rodriguez-de la Rosa L, 2012, NEUROBIOL DIS, V46, P476, DOI 10.1016/j.nbd.2012.02.013; Rodriguez-de la Rosa L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087536; ROSEN S, 1965, B NEW YORK ACAD MED, V41, P1052; Roth TN, 2011, EUR ARCH OTO-RHINO-L, V268, P1101, DOI 10.1007/s00405-011-1597-8; Sanchez-Alcazar JA, 2003, BIOCHEM J, V370, P609, DOI 10.1042/BJ20021623; Sanchez-Calderon H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008699; Sliwinska-Kowalska M, 2012, NOISE HEALTH, V14, P274, DOI 10.4103/1463-1741.104893; Tabuchi K, 2011, CURR MED CHEM, V18, P4866, DOI 10.2174/092986711797535254; Tamura T., 1990, CONT ISSUES CLIN NU, V13, P121; Teng YW, 2011, J BIOL CHEM, V286, P36258, DOI 10.1074/jbc.M111.265348; Tropitzsch A, 2014, TOXICOL LETT, V227, P203, DOI 10.1016/j.toxlet.2014.03.022; Uchida Y, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-35; Vlajkovic SM, 2013, HEARING RES, V304, P145, DOI 10.1016/j.heares.2013.07.012; Vlajkovic SM, 2011, EXP GERONTOL, V46, P905, DOI 10.1016/j.exger.2011.08.001; Vlajkovic SM, 2010, J NEUROSCI RES, V88, P2598, DOI 10.1002/jnr.22421; Yamada K, 2000, J NUTR, V130, P1894, DOI 10.1093/jn/130.8.1894	72	39	40	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					418	432		10.1096/fj.14-259283	http://dx.doi.org/10.1096/fj.14-259283			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25384423	Green Submitted, Green Published			2022-12-28	WOS:000349370400008
J	Abdullah, L; Evans, JE; Ferguson, S; Mouzon, B; Montague, H; Reed, J; Crynen, G; Emmerich, T; Crocker, M; Pelot, R; Mullan, M; Crawford, F				Abdullah, Laila; Evans, James E.; Ferguson, Scott; Mouzon, Benoit; Montague, Hannah; Reed, Jon; Crynen, Gogce; Emmerich, Tanja; Crocker, Madison; Pelot, Robert; Mullan, Michael; Crawford, Fiona			Lipidomic analyses identify injury-specific phospholipid changes 3 mo after traumatic brain injury	FASEB JOURNAL			English	Article						controlled cortical impact; mass spectrometry; phosphatidylcholine; phosphatidylethanolamine; phosphatidylinositol; sphingomyelin	CORTICAL IMPACT INJURY; FREE FATTY-ACIDS; SIGNAL-TRANSDUCTION; MEMORY DEFICITS; SPATIAL MEMORY; AXONAL INJURY; RAT-BRAIN; MEDIATORS; LIPOPROTEINS; ACTIVATION	Phospholipid (PL) abnormalities are observed in the cerebrospinal fluid of patients with traumatic brain injury (TBI), suggesting their role in TBI pathology. Therefore, PL levels were examined in a TBI mouse model that received 1.8 mm deep controlled cortical impact injury or craniectomy only (control). The rotarod and Barnes maze acquisition and probe tests were performed within 2 wk after injury, with another probe test performed 3 mo postinjury. Liquid chromatography/mass spectrometry analyses were performed on lipid extracts from several brain regions and plasma from injured and control mice collected at 3 mo postinjury. Compared to controls, injured mice with sensorimotor and learning deficits had decreased levels of cortical and cerebellar phosphatidylcholine (PC) and phosphatidylethanolamine (PE) levels, while hippocampal PC, sphingomyelin and PE levels were elevated. Ether PE levels were lower in the cortices and plasma of injured animals. Polyunsaturated fatty acid-containing PC and PE species, particularly ratios of docosahexaenoic acid (DHA) to arachidonic acid, were lower in the hippocampi and cortices and plasma of injured mice. Given the importance of DHA in maintaining neuronal function and resolving inflammation and of peroxisomes in synthesis of ether PLs, normalizing these PLs may be a useful strategy for treating the chronic pathology of TBI.	[Abdullah, Laila; Evans, James E.; Ferguson, Scott; Mouzon, Benoit; Montague, Hannah; Reed, Jon; Crynen, Gogce; Emmerich, Tanja; Crocker, Madison; Pelot, Robert; Mullan, Michael; Crawford, Fiona] Roskamp Inst, Sarasota, FL 34243 USA; [Abdullah, Laila; Evans, James E.; Ferguson, Scott; Mouzon, Benoit; Reed, Jon; Crynen, Gogce; Emmerich, Tanja; Pelot, Robert; Crawford, Fiona] James A Haley Vet Affairs Hosp, Tampa, FL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	Abdullah, L (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	labdullah@rfdn.org		Emmerich, Tanja/0000-0001-5064-7150	Congressionally Directed Medical Research Program award [W81XWH-10-1-0759]; U.S. Department of Veterans Affairs Merit award	Congressionally Directed Medical Research Program award; U.S. Department of Veterans Affairs Merit award(US Department of Veterans Affairs)	This work is made possible through a Congressionally Directed Medical Research Program award (W81XWH-10-1-0759) and a U.S. Department of Veterans Affairs Merit award to F.C. The authors also thank Ariel Gonzalez for his contribution to lipidomic analyses. The contents do not represent the views of the Department of Veterans Affairs or the U.S. Government.	Abdullah L, 2012, NEUROMOL MED, V14, P349, DOI 10.1007/s12017-012-8192-z; Ando S, 2005, MASS SPECTROM REV, V24, P865, DOI 10.1002/mas.20045; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Brauer AU, 2003, NAT NEUROSCI, V6, P572, DOI 10.1038/nn1052; Braverman NE, 2012, BBA-MOL BASIS DIS, V1822, P1442, DOI 10.1016/j.bbadis.2012.05.008; Crawford F, 2012, J NEUROTRAUM, V29, P246, DOI 10.1089/neu.2011.1789; da Silva TF, 2012, BBA-MOL BASIS DIS, V1822, P1501, DOI 10.1016/j.bbadis.2012.05.014; Desai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086472; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; Driskell JA, 2007, SPORTS NUTR FATS PRO; Erdman J., 2011, NUTR TRAUMATIC BRAIN; FADEN AI, 1992, AM J PHYSIOL, V263, pR909, DOI 10.1152/ajpregu.1992.263.4.R909; Farias SE, 2011, J TRAUMA, V71, P1211, DOI 10.1097/TA.0b013e3182092c62; Farooqui AA, 2001, NEUROSCIENTIST, V7, P232, DOI 10.1177/107385840100700308; Farooqui AA, 2007, J NEUROSCI RES, V85, P1834, DOI 10.1002/jnr.21268; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Ferguson S, 2010, NEUROSCIENCE, V168, P811, DOI 10.1016/j.neuroscience.2010.01.031; Finkelstein E., 2006, INCIDENCE EC BURDEN, DOI [10.1093/acprof:oso/9780195179484.001.0001, DOI 10.1093/ACPROF:OSO/9780195179484.001.0001]; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frisardi V, 2011, PROG LIPID RES, V50, P313, DOI 10.1016/j.plipres.2011.06.001; Fujimoto S, 2004, HEART VESSELS, V19, P19, DOI 10.1007/s00380-003-0725-9; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hamilton JA, 2007, J MOL NEUROSCI, V33, P2, DOI 10.1007/s12031-007-0060-1; Hankin JA, 2011, J AM SOC MASS SPECTR, V22, P1014, DOI 10.1007/s13361-011-0122-z; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Homayoun P, 1997, J NEUROCHEM, V69, P199; Hunt RF, 2012, EPILEPSY RES, V99, P167, DOI 10.1016/j.eplepsyres.2011.10.011; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; King JA, 2004, NEUROPSYCHOLOGY, V18, P405, DOI 10.1037/0894-4105.18.3.405; Lin YH, 2007, J LIPID RES, V48, P2709, DOI 10.1194/jlr.M700369-JLR200; Liu F, 2006, FEBS LETT, V580, P6269, DOI 10.1016/j.febslet.2006.10.033; Lohner K, 1996, CHEM PHYS LIPIDS, V81, P167, DOI 10.1016/0009-3084(96)02580-7; Lu KT, 2011, J NEUROTRAUM, V28, P441, DOI 10.1089/neu.2010.1473; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Meyer U, 2010, PSYCHOPHARMACOLOGY, V208, P531, DOI 10.1007/s00213-009-1754-6; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Nguyen LN, 2014, NATURE, V509, P503, DOI 10.1038/nature13241; Pasvogel AE, 2010, BIOL RES NURS, V11, P325, DOI 10.1177/1099800409346056; Patil SS, 2009, BEHAV BRAIN RES, V198, P58, DOI 10.1016/j.bbr.2008.10.029; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Polozova A, 2007, J MOL NEUROSCI, V33, P56, DOI 10.1007/s12031-007-0039-y; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Purdon AD, 2002, NEUROCHEM RES, V27, P1641, DOI 10.1023/A:1021635027211; Russell KL, 2013, PROSTAG LEUKOTR ESS, V89, P97, DOI 10.1016/j.plefa.2013.05.004; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sawada Masato, 2013, Keio Journal of Medicine, V62, P13, DOI 10.2302/kjm.2012-0005-RE; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c; Sierra A, 2015, BRAIN STRUCT FUNCT, V220, P781, DOI 10.1007/s00429-013-0683-7; Spector AA, 2001, J MOL NEUROSCI, V16, P159, DOI 10.1385/JMN:16:2-3:159; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Taber KH, 2010, PTSD RES Q, V21, P1, DOI DOI 10.1037/E571972010-002; U.S. Centers for Disease Control and Prevention National Institutes of Health Department of Defense and Department of Veterans Affairs Leadership Panel, 2013, REP C TRAUM BRAIN IN; Vance DE, 2008, N COMP BIOC, P1; VANCE JE, 1994, J NEUROCHEM, V62, P329; Wallace D, 2012, J MIL VETERANS HEALT, V20, P10; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yu GF, 2013, CLIN CHIM ACTA, V421, P7, DOI 10.1016/j.cca.2013.02.030; Zhou ZG, 2011, LIPIDS, V46, P879, DOI 10.1007/s11745-011-3575-8	69	54	55	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5311	5321		10.1096/fj.14-258228	http://dx.doi.org/10.1096/fj.14-258228			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25208845				2022-12-28	WOS:000345894500025
J	Grosso, H; Woo, JM; Lee, KW; Im, JY; Masliah, E; Junn, E; Mouradian, MM				Grosso, Hilary; Woo, Jong-Min; Lee, Kang-Woo; Im, Joo-Young; Masliah, Eliezer; Junn, Eunsung; Mouradian, M. Maral			Transglutaminase 2 exacerbates alpha-synuclein toxicity in mice and yeast	FASEB JOURNAL			English	Article						Parkinson's disease; protein misfolding; neurodegeneration	TISSUE TRANSGLUTAMINASE; PARKINSONS-DISEASE; MOUSE MODEL; MEMBRANE INTERACTIONS; CROSS-LINKING; INHIBITION; NEURON; ACCUMULATION; AGGREGATION; MECHANISMS	alpha-Synuclein is a key pathogenic protein that aggregates in hallmark lesions in Parkinson's disease and other alpha-synucleinopathies. Prior in vitro studies demonstrated that it is a substrate for cross-linking by transglutaminase 2 (TG2) into higher-order species. Here we investigated whether this increased aggregation occurs in vivo and whether TG2 exacerbates alpha-synuclein toxicity in Mus musculus and Saccharomyces cerevisiae. Compared with alpha-synuclein transgenic (Syn(Tg)) mice, animals double transgenic for human alpha-synuclein and TG2 (TG2(Tg)/Syn(Tg)) manifested greater high-molecular-weight insoluble species of alpha-synuclein in brain lysates and developed alpha-synuclein aggregates in the synaptic vesicle fraction. In addition, larger proteinase K-resistant aggregates developed, along with increased thioflavin-S-positive amyloid fibrils. This correlated with an exaggerated neuroinflammatory response, as seen with more astrocytes and microglia. Further neuronal damage was suggested by greater morphological disruption of nerve fibers and a trend toward decreased c-Fos immunoreactive neurons. Finally, the performance of TG2(Tg)/Syn(Tg) animals on motor behavioral tasks was worse relative to Syn(Tg) mice. Greater toxicity of alpha-synuclein was also demonstrated in yeast cells coexpressing TG2. Our findings demonstrate that TG2 promotes the aggregation of alpha-synuclein in vivo and that this is associated with aggravated toxicity of alpha-synuclein and its downstream neuropathologic consequences.	[Grosso, Hilary; Woo, Jong-Min; Lee, Kang-Woo; Im, Joo-Young; Junn, Eunsung; Mouradian, M. Maral] Rutgers RWJMS, Dept Neurol, Ctr Neurodegenerat & Neuroimmunol Dis, Piscataway, NJ 08854 USA; [Masliah, Eliezer] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California San Diego	Mouradian, MM (corresponding author), Rutgers RWJMS, 683 Hoes Ln West,Rm 180, Piscataway, NJ 08854 USA.	m.mouradian@rutgers.edu	Grosso Jasuktar, Hilary/AGX-7358-2022	Grosso Jasuktar, Hilary/0000-0002-1441-2191; Lipton, Stuart/0000-0002-3490-1259; Mouradian, M. Maral/0000-0002-9937-412X	U.S. National Institutes of Health (NIH) [AG-18440, AG-022074, NS-070898, NS-059869, NS-073994, AT-006868]; National Center for Complementary & Integrative Health [R01AT006868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070898, R01NS073994, P30NS076411, R01NS059869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018440, P50AG005131, P01AG022074, R37AG018440] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	E.M. is supported by U.S. National Institutes of Health (NIH) grants AG-18440 and AG-022074. E.J. is supported by NIH grant NS-070898. M.M.M. is the William Dow Lovett Professor of Neurology and is supported by NIH grants NS-059869, NS-073994, and AT-006868. The authors thank Dr. Gail V. Johnson (University of Rochester, Rochester, NY, USA) for providing TG2<SUP>Tg</SUP> mice, and Dr. Takeshi Iwatsubo (University of Tokyo, Tokyo, Japan) for p-alpha-synuclein antibody. The authors declare no conflicts of interest.	Andringa G, 2004, FASEB J, V18, P932, DOI 10.1096/fj.03-0829fje; Auluck PK, 2010, ANNU REV CELL DEV BI, V26, P211, DOI 10.1146/annurev.cellbio.042308.113313; Butterfield SM, 2010, ANGEW CHEM INT EDIT, V49, P5628, DOI 10.1002/anie.200906670; Campisi A, 2004, FEBS LETT, V578, P80, DOI 10.1016/j.febslet.2004.10.074; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Chiba-Falek O, 2001, HUM MOL GENET, V10, P3101, DOI 10.1093/hmg/10.26.3101; Citron BA, 2002, NEUROCHEM INT, V40, P69, DOI 10.1016/S0197-0186(01)00062-6; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Cookson MR, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-9; D'Eletto M, 2009, AUTOPHAGY, V5, P1145, DOI 10.4161/auto.5.8.10040; Deacon RMJ, 2006, NAT PROTOC, V1, P1117, DOI 10.1038/nprot.2006.170; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Filiano AJ, 2008, FASEB J, V22, P2662, DOI 10.1096/fj.07-097709; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Grosso H, 2012, PHARMACOL THERAPEUT, V133, P392, DOI 10.1016/j.pharmthera.2011.12.003; Gundemir S, 2012, BBA-MOL CELL RES, V1823, P406, DOI 10.1016/j.bbamcr.2011.09.012; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Iismaa SE, 2009, PHYSIOL REV, V89, P991, DOI 10.1152/physrev.00044.2008; Iwata M, 2005, NEUROSCI LETT, V386, P145, DOI 10.1016/j.neulet.2005.06.004; Jeitner TM, 2009, J NEUROCHEM, V109, P160, DOI 10.1111/j.1471-4159.2009.05843.x; Junn E, 2003, P NATL ACAD SCI USA, V100, P2047, DOI 10.1073/pnas.0438021100; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kajihara H, 2001, BRAIN RES, V909, P92, DOI 10.1016/S0006-8993(01)02640-3; KANO T, 1995, NEUROREPORT, V6, P2197, DOI 10.1097/00001756-199511000-00023; Karpuj MV, 2002, NAT MED, V8, P143, DOI 10.1038/nm0202-143; Kim C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2534; Koob AO, 2010, EXP NEUROL, V221, P267, DOI 10.1016/j.expneurol.2009.11.015; Kurz A, 2012, J NEURAL TRANSM, V119, P297, DOI 10.1007/s00702-011-0717-3; Lam HA, 2011, J NEUROSCI RES, V89, P1091, DOI 10.1002/jnr.22611; Lee HJ, 2010, J BIOL CHEM, V285, P9262, DOI 10.1074/jbc.M109.081125; Lee KW, 2011, J NEUROSCI, V31, P6963, DOI 10.1523/JNEUROSCI.6513-10.2011; Lee VMY, 2006, NEURON, V52, P33, DOI 10.1016/j.neuron.2006.09.026; Masliah E, 2005, NEURON, V46, P857, DOI 10.1016/j.neuron.2005.05.010; Mastroberardino P, 2002, CELL DEATH DIFFER, V9, P873, DOI 10.1038/sj.cdd.4401093; McConoughey SJ, 2010, EMBO MOL MED, V2, P349, DOI 10.1002/emmm.201000084; Nemes Z, 2009, J BIOL CHEM, V284, P27252, DOI 10.1074/jbc.M109.033969; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Palop JJ, 2003, P NATL ACAD SCI USA, V100, P9572, DOI 10.1073/pnas.1133381100; Przedborski S, 2010, MOVEMENT DISORD, V25, pS55, DOI 10.1002/mds.22638; Quinn L, 2008, BRIT J PHARMACOL, V154, P226, DOI 10.1038/bjp.2008.78; Rockenstein E, 2002, J NEUROSCI RES, V68, P568, DOI 10.1002/jnr.10231; Sager TN, 2010, BEHAV BRAIN RES, V208, P444, DOI 10.1016/j.bbr.2009.12.014; Schmid AW, 2009, J BIOL CHEM, V284, P13128, DOI 10.1074/jbc.M809067200; Siegel M, 2007, PHARMACOL THERAPEUT, V115, P232, DOI 10.1016/j.pharmthera.2007.05.003; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Su XM, 2008, NEUROBIOL AGING, V29, P1690, DOI 10.1016/j.neurobiolaging.2007.04.006; Sun AY, 2002, J HISTOCHEM CYTOCHEM, V50, P463, DOI 10.1177/002215540205000403; Tucholski J, 2006, J NEUROCHEM, V97, P582, DOI 10.1111/j.1471-4159.2006.03780.x; Vermes I, 2004, MOVEMENT DISORD, V19, P1252, DOI 10.1002/mds.20197; Wilhelmus MMM, 2011, BRAIN PATHOL, V21, P130, DOI 10.1111/j.1750-3639.2010.00429.x; Zhang X, 2007, NEUROSCIENCE, V150, P950, DOI 10.1016/j.neuroscience.2007.09.059	55	15	15	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4280	4291		10.1096/fj.14-251413	http://dx.doi.org/10.1096/fj.14-251413			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24970392	Green Published			2022-12-28	WOS:000342222700008
J	Zhang, S; Zis, O; Ly, PTT; Wu, YL; Zhang, ST; Zhang, MM; Cai, F; Bucala, R; Shyu, WC; Song, WH				Zhang, Si; Zis, Odysseus; Ly, Philip T. T.; Wu, Yili; Zhang, Shuting; Zhang, Mingming; Cai, Fang; Bucala, Richard; Shyu, Woei-Cherng; Song, Weihong			Down-regulation of MIF by NF kappa B under hypoxia accelerated neuronal loss during stroke	FASEB JOURNAL			English	Article						macrophage migration inhibitory factor; caspase-3; nuclear factor kappa B	MIGRATION-INHIBITORY FACTOR; BINDING PROTEIN CREB; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; ALZHEIMERS-DISEASE; CELL-DEATH; MACROPHAGE; CYTOKINE; GENE; ACTIVATION	Neuronal apoptosis is one of the major causes of poststroke neurological deficits. Inflammation during the acute phase of stroke results in nuclear translocation of NF kappa B in affected cells in the infarct area. Macrophage migration inhibitory factor (MIF) promotes cardiomyocyte survival in mice following heart ischemia. However, the role of MIF during stroke remains limited. In this study, we showed that MIF expression is down-regulated by 0.75 +/- 0.10-fold of the control in the infarct area in the mouse brains. Two functional cis-acing NF kappa B response elements were identified in the human MIF promoter. Dual activation of hypoxia and NF kappa B signaling resulted in significant reduction of MIF promoter activity to 0.86 +/- 0.01-fold of the control. Furthermore, MIF reduced caspase-3 activation and protected neurons from oxidative stress- and in vitro ischemia/reperfusion-induced apoptosis. H2O2 significantly induced cell death with 12.81 +/- 0.58-fold increase of TUNEL-positive cells, and overexpression of MIF blocked the H2O2-induced cell death. Disruption of the MIF gene in MIF-knockout mice resulted in caspase-3 activation, neuronal loss, and increased infarct development during stroke in vivo. The infarct volume was increased from 6.51 +/- 0.74% in the wild-type mice to 9.07 +/- 0.66% in the MIF-knockout mice. Our study demonstrates that MIF exerts a neuronal protective effect and that down-regulation of MIF by NF kappa B-mediated signaling under hypoxia accelerates neuronal loss during stroke. Our results suggest that MIF is an important molecule for preserving a longer time window for stroke treatment, and strategies to maintain MIF expression at physiological level could have beneficial effects for stroke patients.-Zhang, S., Zis, O., Ly, P. T. T., Wu, Y., Zhang, S., Zhang, M., Cai, F., Bucala, R., Shyu, W.-C., Song, W. Down-regulation of MIF by NF kappa B under hypoxia accelerated neuronal loss during stroke.	[Zhang, Si; Zis, Odysseus; Ly, Philip T. T.; Wu, Yili; Zhang, Shuting; Zhang, Mingming; Cai, Fang; Song, Weihong] Univ British Columbia, Dept Psychiat, Grad Program Neurosci, Townsend Family Labs,Brain Res Ctr, Vancouver, BC V6T IZ3, Canada; [Bucala, Richard] Yale Univ, Dept Med, New Haven, CT 06520 USA; [Bucala, Richard] Yale Univ, Dept Pathol, New Haven, CT USA; [Shyu, Woei-Cherng] China Med Univ & Hosp, Dept Neurol, Ctr Neuropsychiat, Taichung, Taiwan; [Shyu, Woei-Cherng] China Med Univ & Hosp, Grad Inst Immunol, Taichung, Taiwan	University of British Columbia; Yale University; Yale University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Song, WH (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Westbrook Mall, Vancouver, BC V6T 1Z3, Canada.	weihong@mail.ubc.ca	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X; wu, yili/0000-0002-2369-6974	Canadian Institutes of Health Research (CIHR) [MOP-97825]; Jack Brown and Family Alzheimer's Research Foundation; U.S. National Institutes of Health [AI042310]; National Sciences and Engineering Research Council of Canada-Canada Graduate Scholarships Doctoral (NSERC-CGSD); UBC 4YF Scholarship; Chinese Scholarship Council; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI042310, R01AI042310] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Jack Brown and Family Alzheimer's Research Foundation; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Sciences and Engineering Research Council of Canada-Canada Graduate Scholarships Doctoral (NSERC-CGSD); UBC 4YF Scholarship; Chinese Scholarship Council(China Scholarship Council); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Dr. Cheryl Wellington [University of British Columbia (UBC)] for providing the BV-2 cell line. This work was supported by Canadian Institutes of Health Research (CIHR) operating grant MOP-97825, the Jack Brown and Family Alzheimer's Research Foundation (to W.S.), and U.S. National Institutes of Health grant AI042310 (to R.B.). W.S. is the holder of the Tier 1 Canada Research Chair in Alzheimer's Disease. Si Z. is the recipient of a National Sciences and Engineering Research Council of Canada-Canada Graduate Scholarships Doctoral (NSERC-CGSD) scholarship and a UBC 4YF Scholarship. M.Z. is supported by UBC 4YF Scholarship. Sh.Z. was supported by the Chinese Scholarship Council award. The authors declare no conflicts of interest.	Al-Abed Y, 2005, J BIOL CHEM, V280, P36541, DOI 10.1074/jbc.C500243200; Amaral FA, 2007, AM J PATHOL, V171, P1887, DOI 10.2353/ajpath.2007.060642; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Bacher M, 1998, MOL MED, V4, P217, DOI 10.1007/BF03401919; Bacher M, 2010, MOL MED, V16, P116, DOI 10.2119/molmed.2009.00123; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bakirtzi K, 2009, J NEUROSCI, V29, P5193, DOI 10.1523/JNEUROSCI.0858-09.2009; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baugh JA, 2006, BIOCHEM BIOPH RES CO, V347, P895, DOI 10.1016/j.bbrc.2006.06.148; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Cai F, 2008, J NEUROCHEM, V105, P512, DOI 10.1111/j.1471-4159.2007.05167.x; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chen CH, 2011, INT J NEUROPSYCHOPH, V18, P1, DOI DOI 10.1017/S1461145711000149; Chen CM, 2012, J ELECTRON MATER, V41, P1, DOI 10.1007/s11664-011-1777-8; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Huang FP, 2003, J NEUROSCI RES, V73, P698, DOI 10.1002/jnr.10654; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Inacio AR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-75; Inacio AR, 2011, J CEREBR BLOOD F MET, V31, P1093, DOI 10.1038/jcbfm.2010.194; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Koebernick H, 2002, P NATL ACAD SCI USA, V99, P13681, DOI 10.1073/pnas.212488699; Koga K, 2011, ANTIOXID REDOX SIGN, V14, P1191, DOI 10.1089/ars.2010.3163; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; Ly PTT, 2013, J CLIN INVEST, V123, P224, DOI 10.1172/JCI64516; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; Miller EJ, 2008, NATURE, V451, P578, DOI 10.1038/nature06504; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102; Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029; Nakayama K, 2013, J BIOL CHEM, V288, P22584, DOI 10.1074/jbc.M112.421636; Nguyen MT, 2003, J IMMUNOL, V170, P3337, DOI 10.4049/jimmunol.170.6.3337; Nguyen MT, 2003, J BIOL CHEM, V278, P33654, DOI 10.1074/jbc.M301735200; Niizuma K, 2009, J NEUROCHEM, V109, P133, DOI 10.1111/j.1471-4159.2009.05897.x; PARALKAR V, 1994, GENOMICS, V19, P48, DOI 10.1006/geno.1994.1011; Rassaf T, 2014, CARDIOVASC RES, V102, P321, DOI 10.1093/cvr/cvu071; Ridder DA, 2009, NEUROSCIENCE, V158, P995, DOI 10.1016/j.neuroscience.2008.07.007; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Stephenson D, 2000, J CEREBR BLOOD F MET, V20, P592, DOI 10.1097/00004647-200003000-00017; Stockley JH, 2007, BIOCHEM SOC T, V35, P574, DOI 10.1042/BST0350574; Sun XL, 2006, FASEB J, V20, P1369, DOI 10.1096/FJ.05-5632COM; Szeto HH, 2006, AAPS J, V8, pE521, DOI 10.1208/aapsj080362; Tong Y, 2005, J NEURAL TRANSM, V112, P455, DOI 10.1007/s00702-004-0255-3; Waeber G, 1998, MOL ENDOCRINOL, V12, P698, DOI 10.1210/me.12.5.698; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang LJ, 2009, STROKE, V40, P973, DOI 10.1161/STROKEAHA.108.530535; Welford SM, 2006, GENE DEV, V20, P3366, DOI 10.1101/gad.1471106; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Xu Q, 2012, J NEUROCHEM, V122, P251, DOI 10.1111/j.1471-4159.2012.07676.x; Zhang L, 2003, STROKE, V34, P1790, DOI 10.1161/01.STR.0000077016.55891.2E; Zhang XM, 2010, BRAIN RES, V1343, P143, DOI 10.1016/j.brainres.2010.04.027; Zhou WH, 2006, MOL CELL BIOL, V26, P3353, DOI 10.1128/MCB.26.9.3353-3364.2006; Ziegler G, 2011, J CEREBR BLOOD F MET, V31, P757, DOI 10.1038/jcbfm.2010.161	63	35	39	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4394	4407		10.1096/fj.14-253625	http://dx.doi.org/10.1096/fj.14-253625			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24970391	Green Published			2022-12-28	WOS:000342222700018
J	Esteva-Font, C; Cil, O; Phuan, PW; Su, T; Lee, S; Anderson, MO; Verkman, AS				Esteva-Font, Cristina; Cil, Onur; Phuan, Puay-Wah; Su, Tao; Lee, Sujin; Anderson, Marc O.; Verkman, A. S.			Diuresis and reduced urinary osmolality in rats produced by small-molecule UT-A-selective urea transport inhibitors	FASEB JOURNAL			English	Article						kidney; diuretic; drug discovery	CONCENTRATING DEFECT; CONFORMER GENERATION; NANOMOLAR POTENCY; MICE LACKING; PROTEIN; FAMILY; KIDNEY; MODEL; PERFORMANCE; PHYSIOLOGY	Urea transport (UT) proteins of the UT-A class are expressed in epithelial cells in kidney tubules, where they are required for the formation of a concentrated urine by countercurrent multiplication. Here, using a recently developed high-throughput assay to identify UT-A inhibitors, a screen of 50,000 synthetic small molecules identified UT-A inhibitors of aryl-thiazole, gamma-sultambenzosulfonamide, aminocarbonitrile butene, and 4-isoxazolamide chemical classes. Structure-activity analysis identified compounds that inhibited UT-A selectively by a noncompetitive mechanism with IC50 down to similar to 1 mu M. Molecular modeling identified putative inhibitor binding sites on rat UT-A. To test compound efficacy in rats, formulations and administration procedures were established to give therapeutic inhibitor concentrations in blood and urine. We found that intravenous administration of an indole thiazole or a gamma-sultambenzosulfonamide at 20 mg/kg increased urine output by 3-5-fold and reduced urine osmolality by similar to 2-fold compared to vehicle control rats, even under conditions of maximum antidiuresis produced by 1-deamino-8-D-arginine vasopressin (DDAVP). The diuresis was reversible and showed urea > salt excretion. The results provide proof of concept for the diuretic action of UT-A-selective inhibitors. UT-A inhibitors are first in their class salt-sparing diuretics with potential clinical indications in volume-overload edemas and high-vasopressin- associated hyponatremias.	[Esteva-Font, Cristina; Cil, Onur; Phuan, Puay-Wah; Su, Tao; Lee, Sujin; Verkman, A. S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Esteva-Font, Cristina; Cil, Onur; Phuan, Puay-Wah; Su, Tao; Lee, Sujin; Verkman, A. S.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; [Anderson, Marc O.] San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; California State University System; San Francisco State University	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med, 1246 Hlth Sci East Tower, San Francisco, CA 94143 USA.	alan.verkman@ucsf.edu	Su, Tao/T-4411-2019; Cil, Onur/AAK-5166-2020	Su, Tao/0000-0002-9148-6127; Cil, Onur/0000-0001-5178-0199; Lee, Sujin/0000-0001-6701-1730	U.S. National Institutes of Health [DK101373, DK35124, DK72517, EB00415, EY13574]; Fulbright Program; Hacettepe University (Ankara, Turkey) Scientific Recearch Unit [BAB6091]; Ministry of Education, Culture, and Sports of Spain; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, P30DK072517, R01DK101373, R01DK035124] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fulbright Program; Hacettepe University (Ankara, Turkey) Scientific Recearch Unit; Ministry of Education, Culture, and Sports of Spain; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by grants DK101373, DK35124, DK72517, EB00415, and EY13574 from the U.S. National Institutes of Health (A. S. V.), a grant from the Fulbright Program and the Ministry of Education, Culture, and Sports of Spain (C. E-F.), and grant BAB6091 from the Hacettepe University (Ankara, Turkey) Scientific Recearch Unit (O. C.). The authors acknowledge OpenEye Scientific (Santa Fe, NM, USA) for its Academic Site License program.	Anderson MO, 2012, J MED CHEM, V55, P5942, DOI 10.1021/jm300491y; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Bagnasco SM, 2003, AM J PHYSIOL-RENAL, V284, pF3, DOI 10.1152/ajprenal.00260.2002; Bankir L, 2012, KIDNEY INT, V81, P1179, DOI 10.1038/ki.2012.67; Bondock S, 2013, EUR J MED CHEM, V62, P270, DOI 10.1016/j.ejmech.2012.12.050; Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197; Cil O, 2012, HUM EXP TOXICOL, V31, P1050, DOI 10.1177/0960327112459205; Denton JS, 2013, AM J PHYSIOL-RENAL, V305, pF931, DOI 10.1152/ajprenal.00230.2013; Diana P, 2011, CHEMMEDCHEM, V6, P1300, DOI 10.1002/cmdc.201100078; Doran JJ, 2006, AM J PHYSIOL-REG I, V290, pR1446, DOI 10.1152/ajpregu.00352.2004; Esteva-Font C, 2013, CHEM BIOL, V20, P1235, DOI 10.1016/j.chembiol.2013.08.005; Fenton RA, 2005, J AM SOC NEPHROL, V16, P1583, DOI 10.1681/ASN.2005010031; Fenton RA, 2004, P NATL ACAD SCI USA, V101, P7469, DOI 10.1073/pnas.0401704101; Fenton RA, 2002, AM J PHYSIOL-RENAL, V283, pF817, DOI 10.1152/ajprenal.00263.2001; Fenton RA, 2008, CURR OPIN NEPHROL HY, V17, P513, DOI 10.1097/MNH.0b013e3283050969; Fenton RA, 2009, PFLUG ARCH EUR J PHY, V458, P169, DOI 10.1007/s00424-008-0612-4; Frohlich O, 2006, AM J PHYSIOL-CELL PH, V291, pC600, DOI 10.1152/ajpcell.00413.2005; Galietta LJV, 2001, FEBS LETT, V499, P220, DOI 10.1016/S0014-5793(01)02561-3; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X; Hawkins PCD, 2012, J CHEM INF MODEL, V52, P2919, DOI 10.1021/ci300314k; Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x; Klein JD, 2013, FASEB J, V27; Klein JD, 2012, PFLUG ARCH EUR J PHY, V464, P561, DOI 10.1007/s00424-012-1157-0; Knepper MA, 2013, KIDNEY INT, V83, P991, DOI 10.1038/ki.2013.94; Lei TL, 2011, AM J PHYSIOL-RENAL, V301, pF1251, DOI 10.1152/ajprenal.00404.2011; Levin EJ, 2012, P NATL ACAD SCI USA, V109, P11194, DOI 10.1073/pnas.1207362109; Levin MH, 2007, FASEB J, V21, P551, DOI 10.1096/fj.06-6979com; Li F, 2013, KIDNEY INT, V83, P1076, DOI 10.1038/ki.2013.62; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Liu Y, 2013, BIOORG MED CHEM LETT, V23, P3338, DOI 10.1016/j.bmcl.2013.03.089; Lucien N, 1998, J BIOL CHEM, V273, P12973, DOI 10.1074/jbc.273.21.12973; MAYRAND RR, 1983, J GEN PHYSIOL, V81, P221, DOI 10.1085/jgp.81.2.221; McGann M, 2012, J COMPUT AID MOL DES, V26, P897, DOI 10.1007/s10822-012-9584-8; Pannabecker TL, 2013, AM J PHYSIOL-REG I, V304, pR488, DOI 10.1152/ajpregu.00456.2012; Ren JX, 2011, J CHEM INF MODEL, V51, P1364, DOI 10.1021/ci100464b; Sands JM, 2007, J AM SOC NEPHROL, V18, P670, DOI 10.1681/ASN.2006121314; Sands JM, 2014, ANNU REV PHYSIOL, V76, P387, DOI 10.1146/annurev-physiol-021113-170350; Sands JM, 2013, CHEM BIOL, V20, P1201, DOI 10.1016/j.chembiol.2013.10.003; Sands JM, 2009, SEMIN NEPHROL, V29, P178, DOI 10.1016/j.semnephrol.2009.03.008; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; Sands JM, 2004, CURR OPIN NEPHROL HY, V13, P525, DOI 10.1097/00041552-200409000-00008; Shayakul C, 2004, PFLUG ARCH EUR J PHY, V447, P603, DOI 10.1007/s00424-003-1124-x; Shayakul C, 2013, MOL ASPECTS MED, V34, P313, DOI 10.1016/j.mam.2012.12.003; Smith CP, 2009, EXP PHYSIOL, V94, P180, DOI 10.1113/expphysiol.2008.043042; Snyder DS, 2011, J MED CHEM, V54, P5468, DOI 10.1021/jm200505e; Stewart G, 2011, BRIT J PHARMACOL, V164, P1780, DOI 10.1111/j.1476-5381.2011.01377.x; Uchida S, 2005, MOL CELL BIOL, V25, P7357, DOI 10.1128/MCB.25.16.7357-7363.2005; Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n; Yang B, 2002, J BIOL CHEM, V277, P10633, DOI 10.1074/jbc.M200207200; Yao CJ, 2012, J AM SOC NEPHROL, V23, P1210, DOI 10.1681/ASN.2011070751	50	17	22	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3878	3890		10.1096/fj.14-253872	http://dx.doi.org/10.1096/fj.14-253872			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24843071	Green Published			2022-12-28	WOS:000340845900007
J	Olivier-Van Stichelen, S; Dehennaut, V; Buzy, A; Zachayus, JL; Guinez, C; Mir, AM; El Yazidi-Belkoura, I; Copin, MC; Boureme, D; Loyaux, D; Ferrara, P; Lefebvre, T				Olivier-Van Stichelen, Stephanie; Dehennaut, Vanessa; Buzy, Armelle; Zachayus, Jean-Luc; Guinez, Celine; Mir, Anne-Marie; El Yazidi-Belkoura, Ikram; Copin, Marie-Christine; Boureme, Didier; Loyaux, Denis; Ferrara, Pascual; Lefebvre, Tony			O-GlcNAcylation stabilizes beta-catenin through direct competition with phosphorylation at threonine 41	FASEB JOURNAL			English	Article						Wnt signaling; cancer; ETD-MS/MS	INCIDENT COLORECTAL-CANCER; CARBOHYDRATE-METABOLISM; GLCNAC GLYCOSYLATION; LACTIC-ACID; CELL-GROWTH; PATHWAY; ACTIVATION; MUTATIONS; TUMORS; RISK	Dysfunctions in Wnt signaling increase beta-catenin stability and are associated with cancers, including colorectal cancer. In addition, beta-catenin degradation is decreased by nutrient-dependent O-GlcNAcylation. Human colon tumors and colons from mice fed high-carbohydrate diets exhibited higher amounts of beta-catenin and O-GlcNAc relative to healthy tissues and mice fed a standard diet, respectively. Administration of the O-GlcNAcase inhibitor thiamet G to mice also increased colonic expression of beta-catenin. By ETD-MS/MS, we identified 4 O-GlcNAcylation sites at the N terminus of beta-catenin (S23/T40/T41/T112). Furthermore, mutation of serine and threonine residues within the D box of beta-catenin reduced O-GlcNAcylation by 75%. Interestingly, elevating O-GlcNAcylation in human colon cell lines drastically reduced phosphorylation at T41, a key residue of the D box responsible for beta-catenin stability. Analyses of beta-catenin O-GlcNAcylation mutants reinforced T41 as the most crucial residue that controls the beta-catenin degradation rate. Finally, inhibiting O-GlcNAcylation decreased the beta-catenin/beta-catenin interaction necessary for mucosa integrity, whereas O-GlcNAcase silencing improved this interaction. These results suggest that O-GlcNAcylation regulates not only the stability of beta-catenin, but also affects its localization at the level of adherens junctions. Accordingly, we propose that O-GlcNAcylation of beta-catenin is a missing link between the glucose metabolism deregulation observed in metabolic disorders and the development of cancer.	[Olivier-Van Stichelen, Stephanie; Dehennaut, Vanessa; Guinez, Celine; Mir, Anne-Marie; El Yazidi-Belkoura, Ikram; Lefebvre, Tony] Univ Lille 1, CNRS, Unit Struct & Funct Glycobiol, UMR 8576,IFR 147, F-59655 Villeneuve Dascq, France; [Buzy, Armelle; Zachayus, Jean-Luc; Boureme, Didier; Loyaux, Denis; Ferrara, Pascual] Sanofi Aventis Res & Dev, Exploratory Unit Syst Biol, Toulouse, France; [Copin, Marie-Christine] Univ Lille 2, Tumor Bank, Reg Reference Ctr Canc, Ctr Hosp Reg Univ Lille CHRU, Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Sanofi-Aventis; Sanofi France; Universite de Lille - ISITE; CHU Lille; Universite de Lille	Lefebvre, T (corresponding author), Univ Lille 1, CNRS, Unit Struct & Funct Glycobiol, UMR 8576,IFR 147, F-59655 Villeneuve Dascq, France.	tony.lefebvre@univ-lille1.fr	El Yazidi-Belkoura, Ikram/AAE-8805-2022; dehennaut, vanessa/I-7435-2018; Lefebvre, Tony/AAW-9169-2021; Lefebvre, Tony/AAZ-1724-2021; olivier-van stichelen, Stephanie/AAH-9328-2021	dehennaut, vanessa/0000-0001-6421-0793; Lefebvre, Tony/0000-0001-9883-2240; olivier-van stichelen, Stephanie/0000-0002-2033-5241; EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509	Ligue Contre le Cancer/Comite du Nord; Association pour la Recherche sur le Cancer; Region Nord-Pas de Calais (Cancer Regional Program), Lille 1 University; Centre National de la Recherche Scientifique; Ligue Contre le Cancer	Ligue Contre le Cancer/Comite du Nord(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Region Nord-Pas de Calais (Cancer Regional Program), Lille 1 University(Region Hauts-de-France); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Ligue Contre le Cancer(Ligue nationale contre le cancer)	The authors thank Prof. D. Vocadlo (Simon Fraser University, Burnaby, BC, Canada), who provided NButGT and Ac-5SGlcNAc; Dr. C. Couturier (Biology Institute of Lille, France), who provided the HA-ubiquitin expression; Dr. C. Liu (University of Kentucky, Lexington, KY, USA), who provided pCS2+beta-catenin-2XFlag (WT and TM); the Site de Recherche Integree sur le Cancer ONCOLille, and the Tumor Bank [Regional Reference Center in Cancer, Centre Hospitalier Regional Universitaire (CHRU)] of Lille (Lille, France) for providing colon tumor tissues and matching tumor-adjacent normal tissues; and Michelle Bond [National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), U.S. National Institutes of Health, Bethesda, MD, USA] for editing the English in the manuscript and for helpful comments. This work was supported by the Ligue Contre le Cancer/Comite du Nord, the Association pour la Recherche sur le Cancer, the Region Nord-Pas de Calais (Cancer Regional Program), Lille 1 University, and the Centre National de la Recherche Scientifique. V. D. is the recipient of a postdoctoral fellowship from the Ligue Contre le Cancer. The authors declare no conflicts of interest.	Ahmed RL, 2006, CANCER-AM CANCER SOC, V107, P28, DOI 10.1002/cncr.21950; Bek S, 2002, J CELL SCI, V115, P4743, DOI 10.1242/jcs.00154; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cori CF, 1925, J BIOL CHEM, V64, P11; Cori CF, 1925, J BIOL CHEM, V65, P397; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; Dossus L, 2008, BEST PRACT RES CL EN, V22, P551, DOI 10.1016/j.beem.2008.08.003; Fardini Y, 2013, FRONT ENDOCRINOL, V4, DOI 10.3389/fendo.2013.00099; Gloster TM, 2011, NAT CHEM BIOL, V7, P174, DOI 10.1038/NCHEMBIO.520; Guinez C, 2008, FASEB J, V22, P2901, DOI 10.1096/fj.07-102509; Hanover JA, 2010, BBA-GEN SUBJECTS, V1800, P80, DOI 10.1016/j.bbagen.2009.07.017; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatsell S, 2003, J BIOL CHEM, V278, P37745, DOI 10.1074/jbc.M301346200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Khaw KT, 2004, CANCER EPIDEM BIOMAR, V13, P915; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Lefebvre T, 2004, J CELL BIOCHEM, V93, P999, DOI 10.1002/jcb.20242; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547; Ma F, 2014, GENE, V535, P191, DOI 10.1016/j.gene.2013.11.035; Ma ZY, 2013, AMINO ACIDS, V45, P719, DOI 10.1007/s00726-013-1543-8; Ma ZY, 2013, J BIOL CHEM, V288, P15121, DOI 10.1074/jbc.M113.470047; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Meng WX, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002899; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Olivier-Van Stichelen Stephanie, 2012, Am J Physiol Endocrinol Metab, V302, pE417, DOI 10.1152/ajpendo.00390.2011; Pais R, 2009, WORLD J GASTROENTERO, V15, P5141, DOI 10.3748/wjg.15.5141; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Su YY, 2008, MOL CELL, V32, P652, DOI 10.1016/j.molcel.2008.10.023; van Noort M, 2002, EXP CELL RES, V276, P264, DOI 10.1006/excr.2002.5520; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Winer IS, 2006, J BIOL CHEM, V281, P26181, DOI 10.1074/jbc.M604217200; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278	43	93	97	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3325	3338		10.1096/fj.13-243535	http://dx.doi.org/10.1096/fj.13-243535			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24744147	Green Published			2022-12-28	WOS:000340265400005
J	Perez-Burgos, A; Mao, YK; Bienenstock, J; Kunze, WA				Perez-Burgos, Azucena; Mao, Yu-Kang; Bienenstock, John; Kunze, Wolfgang A.			The gut-brain axis rewired: adding a functional vagal nicotinic "sensory synapse"	FASEB JOURNAL			English	Article						synaptic transmission; enteric nervous system; primary afferent neuron; Lactobacillus; vagus	INTRAGANGLIONIC LAMINAR ENDINGS; ENTERIC NERVOUS-SYSTEM; LACTOBACILLUS-REUTERI; MYENTERIC NEURONS; INTERSTITIAL-CELLS; ACTION-POTENTIALS; RAT; MOUSE; RELEASE; STIMULATION	It is generally accepted that intestinal sensory vagal fibers are primary afferent, responding nonsynaptically to luminal stimuli. The gut also contains intrinsic primary afferent neurons (IPANs) that respond to luminal stimuli. A psychoactive Lactobacillus rhamnosus (JB-1) that affects brain function excites both vagal fibers and IPANs. We wondered whether, contrary to its primary afferent designation, the sensory vagus response to JB-1 might depend on IPAN to vagal fiber synaptic transmission. We recorded ex vivo single- and multiunit afferent action potentials from mesenteric nerves supplying mouse jejunal segments. Intramural synaptic blockade with Ca2+ channel blockers reduced constitutive or JB-1-evoked vagal sensory discharge. Firing of 60% of spontaneously active units was reduced by synaptic blockade. Synaptic or nicotinic receptor blockade reduced firing in 60% of vagal sensory units that were stimulated by luminal JB-1. In control experiments, increasing or decreasing IPAN excitability, respectively increased or decreased nerve firing that was abolished by synaptic blockade or vagotomy. We conclude that >50% of vagal afferents function as interneurons for stimulation by JB-1, receiving input from an intramural functional "sensory synapse." This was supported by myenteric plexus nicotinic receptor immunohistochemistry. These data offer a novel therapeutic target to modify pathological gut-brain axis activity.	[Perez-Burgos, Azucena; Mao, Yu-Kang; Bienenstock, John; Kunze, Wolfgang A.] St Josephs Healthcare, McMaster Brain Body Inst, Hamilton, ON L8N 4A6, Canada; [Bienenstock, John] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Bienenstock, John] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Kunze, Wolfgang A.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University; McMaster University	Kunze, WA (corresponding author), St Josephs Healthcare, McMaster Brain Body Inst, Juravinski Innovat Tower,50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada.	kunzew@mcmaster.ca			National Science and Engineering Research Council (NSERC) [371955-2009]; Consejo Nacional de Ciencia y Tecnologia postdoctoral fellowship	National Science and Engineering Research Council (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Consejo Nacional de Ciencia y Tecnologia postdoctoral fellowship	The authors thank the McMaster Brain-Body Institute for financial support for this research. The research was also supported by a grant to W.A.K. from the National Science and Engineering Research Council (NSERC; 371955-2009). A.P.B. was supported by the Consejo Nacional de Ciencia y Tecnologia postdoctoral fellowship. A.P.B. performed the experiments, analyzed the data, and contributed to drafting and editing the manuscript. Y.M. performed the vagotomies and immunohistochemistry. J.B. contributed to editing the manuscript. W.A.K. designed the research, helped analyze the data, and drafted the manuscript. All authors approved the manuscript for publication. Experiments were conducted in the McMaster Brain-Body Institute at St Joseph's Healthcare Hamilton. The authors declare no conflicts of interest.	Bercik P, 2012, NEUROGASTROENT MOTIL, V24, P405, DOI 10.1111/j.1365-2982.2012.01906.x; Bercik P, 2011, NEUROGASTROENT MOTIL, V23, P1132, DOI 10.1111/j.1365-2982.2011.01796.x; Berthoud HR, 1997, ANAT EMBRYOL, V195, P183, DOI 10.1007/s004290050037; Berthoud HR, 2004, NEUROGASTROENT MOTIL, V16, P28, DOI 10.1111/j.1743-3150.2004.00471.x; Berthoud HR, 2000, AUTON NEUROSCI-BASIC, V85, P1, DOI 10.1016/S1566-0702(00)00215-0; Bertrand PP, 2006, J PHYSIOL-LONDON, V577, P689, DOI 10.1113/jphysiol.2006.117804; Bertrand PP, 2009, FRONT NEUROSCI-SWITZ, V3, DOI 10.3389/neuro.21.003.2009; Bertrand PP, 2010, AUTON NEUROSCI-BASIC, V153, P47, DOI 10.1016/j.autneu.2009.08.002; Bertrand PP, 2003, NEUROSCIENTIST, V9, P243, DOI 10.1177/1073858403253768; Bertrand PP, 1997, AM J PHYSIOL-GASTR L, V273, pG422; Blackshaw LA, 2007, NEUROGASTROENT MOTIL, V19, P1, DOI 10.1111/j.1365-2982.2006.00871.x; Blackshaw LA, 2011, NEUROGASTROENT MOTIL, V23, P591, DOI 10.1111/j.1365-2982.2011.01719.x; BLAIR EL, 1959, J PHYSIOL-LONDON, V148, P437, DOI 10.1113/jphysiol.1959.sp006298; Bonaz B, 2013, NEUROGASTROENT MOTIL, V25, P208, DOI 10.1111/nmo.12076; Booth CE, 2008, NEUROGASTROENT MOTIL, V20, P149, DOI 10.1111/j.1365-2982.2007.01003.x; Bravo JA, 2012, CURR OPIN PHARMACOL, V12, P667, DOI 10.1016/j.coph.2012.09.010; Bravo JA, 2011, P NATL ACAD SCI USA, V108, P16050, DOI 10.1073/pnas.1102999108; BULBRING EDITH, 1958, QUART JOUR EXPTL PHYSIOL, V43, P26; Collins SM, 2012, NAT REV MICROBIOL, V10, P735, DOI 10.1038/nrmicro2876; Dochray G. J., 2009, TXB GASTROENTEROLOGY, P86; Dogiel A. S., 1899, Arch Anat, P130; Forsythe P, 2013, CELL MOL LIFE SCI, V70, P55, DOI 10.1007/s00018-012-1028-z; Forsythe P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041234; Furness J. B., 2009, TXB GASTROENTEROLOGY, P40; Furness J.B., 2006, ENTERIC NERVOUS SYST; Furness JB, 1998, PROG NEUROBIOL, V54, P1, DOI 10.1016/S0301-0082(97)00051-8; GERSHON MD, 1993, J NEUROBIOL, V24, P199, DOI 10.1002/neu.480240207; Gershon MD, 1999, HOSP PRACT, V34, P31, DOI 10.3810/hp.1999.07.153; Goedert M, 2013, NAT REV NEUROL, V9, P13, DOI 10.1038/nrneurol.2012.242; Gulbransen BD, 2009, GASTROENTEROLOGY, V136, P1349, DOI 10.1053/j.gastro.2008.12.058; Hirst G. D., 1972, J PHYSL, V225, p60P; HIRST GDS, 1974, J PHYSIOL-LONDON, V236, P303, DOI 10.1113/jphysiol.1974.sp010436; HIRST GDS, 1973, NATURE-NEW BIOL, V243, P54; Hubsch M, 2013, NEUROGASTROENT MOTIL, V25, pE560, DOI 10.1111/nmo.12161; Kamiya T, 2006, GUT, V55, P191, DOI 10.1136/gut.2005.070987; KUNZE WAA, 1995, NEUROSCIENCE, V66, P1, DOI 10.1016/0306-4522(95)00067-S; Kunze WA, 2009, J CELL MOL MED, V13, P2261, DOI 10.1111/j.1582-4934.2009.00686.x; Lal S, 2001, AM J PHYSIOL-GASTR L, V281, pG907, DOI 10.1152/ajpgi.2001.281.4.G907; Langley JN, 1905, J PHYSIOL-LONDON, V33, P34; Mao YK, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2478; Mao YK, 2006, J NEUROPHYSIOL, V96, P998, DOI 10.1152/jn.00204.2006; Mayer EA, 2011, NAT REV NEUROSCI, V12, P453, DOI 10.1038/nrn3071; McCarthy E L, 1934, Science, V80, P100, DOI 10.1126/science.80.2065.100; Mueller MH, 2009, AM J PHYSIOL-GASTR L, V297, pG655, DOI 10.1152/ajpgi.00128.2009; Naidoo V, 2010, NEUROGASTROENT MOTIL, V22, pE353, DOI 10.1111/j.1365-2982.2010.01596.x; Nguyen TV, 2007, J NEUROPHYSIOL, V97, P2024, DOI 10.1152/jn.00935.2006; PALOUZIERPAULIGNAN B, 1992, EUR J NEUROSCI, V4, P1123, DOI 10.1111/j.1460-9568.1992.tb00139.x; Pan H, 2000, J NEUROSCI, V20, P3295, DOI 10.1523/JNEUROSCI.20-09-03295.2000; Perez-Burgos A, 2013, AM J PHYSIOL-GASTR L, V304, pG211, DOI 10.1152/ajpgi.00128.2012; Phillips RJ, 2010, AUTON NEUROSCI-BASIC, V153, P90, DOI 10.1016/j.autneu.2009.07.009; Powley TL, 2008, NEUROGASTROENT MOTIL, V20, P69, DOI 10.1111/j.1365-2982.2007.00990.x; Powley TL, 2011, J COMP NEUROL, V519, P644, DOI 10.1002/cne.22541; Raab M, 2004, HISTOCHEM CELL BIOL, V122, P445, DOI 10.1007/s00418-004-0703-z; Raab M, 2003, CELL TISSUE RES, V312, P141, DOI 10.1007/s00441-003-0721-5; Racke K, 1996, BEHAV BRAIN RES, V73, P83; Rugiero F, 2002, J PHYSIOL-LONDON, V538, P447, DOI 10.1113/jphysiol.2001.013051; SCHEMANN M, 1992, AM J PHYSIOL, V263, pG709, DOI 10.1152/ajpgi.1992.263.5.G709; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; Tan LL, 2010, NEUROSCIENCE, V166, P564, DOI 10.1016/j.neuroscience.2009.12.034; Trueta C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00319; van der Kleij H, 2008, AM J PHYSIOL-REG I, V295, pD1131, DOI 10.1152/ajpregu.90434.2008; Walter GC, 2009, J NEUROSCI METH, V178, P1, DOI 10.1016/j.jneumeth.2008.11.003; Wang B, 2010, NEUROGASTROENT MOTIL, V22, P98, DOI 10.1111/j.1365-2982.2009.01384.x; Wang BX, 2010, FASEB J, V24, P4078, DOI 10.1096/fj.09-153841; Winston JH, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00022; Wood JD, 2010, CURR OPIN GASTROEN, V26, P102, DOI 10.1097/MOG.0b013e328334df4f; Zaidi ZF, 1997, NEUROSCIENCE, V80, P861, DOI 10.1016/S0306-4522(96)00664-1	68	63	63	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3064	3074		10.1096/fj.13-245282	http://dx.doi.org/10.1096/fj.13-245282			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24719355				2022-12-28	WOS:000337949400028
J	Zhang, J; Lazarenko, OP; Blackburn, ML; Badger, TM; Ronis, MJJ; Chen, JR				Zhang, Jian; Lazarenko, Oxana P.; Blackburn, Michael L.; Badger, Thomas M.; Ronis, Martin J. J.; Chen, Jin-Ran			Soy protein isolate down-regulates caveolin-1 expression to suppress osteoblastic cell senescence pathways	FASEB JOURNAL			English	Article						isoflavone; estrogen; p53	MESENCHYMAL STEM-CELLS; FEMALE RATS; GENISTEIN AGLYCONE; GENE-EXPRESSION; BONE LOSS; IN-VIVO; ESTROGEN; DIFFERENTIATION; CONSUMPTION; SKIN	It has been suggested that the beneficial effects of soy protein isolate (SPI) on bone quality are due to either stimulation of estrogenic signaling via isoflavones or through a novel and as yet uncharacterized nonestrogenic pathway. In our study, SPI-fed rat serum inhibited the osteoblastic cell senescence pathway. This effect was accompanied by stimulation of cell differentiation, proliferation, and significant restoration of replicative senescent bone marrow mesenchymal ST2 cells (passaged 30 times). These effects were reproduced in bone from 5-wk-old intact and 10-wk-old ovariectomized female rats fed SPI diets. Caveolin-1 and p53 expression was decreased in bone in SPI-fed, but not in 17 beta-estradiol (E2)-treated rats. In cell culture studies, membranous caveolin-1 and nuclear p53 expression was greater in replicative senescent ST2 cell cultures than in earlier passaged cells. SPI-fed rat serum significantly down-regulated both caveolin-1 and p53 in senescent and nonsenescent cells. Replicative senescent ST2 cells exhibited a strong association among caveolin-1, p53, and mouse double minute 2 homologue (mdm2), which was inhibited by SPI-fed rat serum. Overexpression of caveolin-1 in ST2 cells resulted in increased expression of p53 and p21, whereas, knockdown of caveolin-1 using shRNA led to increases in mdm2 and eliminated SPI-fed rat serum's effects on p53 and p21 expression. In contrast, manipulation of caveolin-1 expression did not affect the actions of E2 or isoflavones on p53 expression in either ST2 or OB6 cells. These results suggest that caveolin-1 is a mediator of nonestrogenic SPI effects on bone cells.	[Zhang, Jian; Lazarenko, Oxana P.; Blackburn, Michael L.; Badger, Thomas M.; Ronis, Martin J. J.; Chen, Jin-Ran] Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA; [Zhang, Jian; Lazarenko, Oxana P.; Blackburn, Michael L.; Badger, Thomas M.; Ronis, Martin J. J.; Chen, Jin-Ran] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Ronis, Martin J. J.] Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Chen, JR (corresponding author), Arkansas Childrens Nutr Ctr, Slot 512-20B,15 Childrens Way, Little Rock, AR 72202 USA.	chenjinran@uams.edu			U.S. Department of Agriculture/Agricultural Research Service [6251-51000-003]	U.S. Department of Agriculture/Agricultural Research Service(United States Department of Agriculture (USDA)USDA Agricultural Research Service)	The authors thank M. Ferguson and H. Pittman for technical assistance. This work was supported in part by a U.S. Department of Agriculture/Agricultural Research Service grant (Current Research Information System ID 6251-51000-003) to the Arkansas Children's Nutrition Center.	Andres A, 2012, PEDIATRICS, V129, P1134, DOI 10.1542/peds.2011-3121; Arjmandi BH, 1996, J NUTR, V126, P161, DOI 10.1093/jn/126.1.161; Backesjo CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415; Badger TM, 2002, J NUTR, V132, p559S, DOI 10.1093/jn/132.3.559S; Baker N, 2012, J CELL BIOCHEM, V113, P3773, DOI 10.1002/jcb.24252; Bitto A, 2010, CURR MED CHEM, V17, P3007, DOI 10.2174/092986710791959738; Chen JR, 2008, EXP BIOL MED, V233, P1348, DOI 10.3181/0802-RM-63; Chen JR, 2010, J BONE MINER RES, V25, P2399, DOI 10.1002/jbmr.137; Chen JR, 2009, J NUTR, V139, P1839, DOI 10.3945/jn.109.109041; Chen JR, 2009, J BONE MINER RES, V24, P221, DOI 10.1359/JBMR.081011; Cho KA, 2003, J BIOL CHEM, V278, P27789, DOI 10.1074/jbc.M208105200; Choi HR, 2011, AGING CELL, V10, P148, DOI 10.1111/j.1474-9726.2010.00654.x; Dewi FN, 2012, J NUTR, V142, P1829, DOI 10.3945/jn.112.161711; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Finch CE, 2014, J STEROID BIOCHEM, V142, P132, DOI 10.1016/j.jsbmb.2013.03.010; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; Gu LW, 2006, J NUTR, V136, P1215, DOI 10.1093/jn/136.5.1215; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Huang W, 2012, ACTA PHARMACOL SIN, V33, P668, DOI 10.1038/aps.2011.189; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kurzer M. S., 2008, Inflammopharmacology, V16, P227, DOI 10.1007/s10787-008-8021-z; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; Messina M, 2010, J NUTR, V140, p2289S, DOI 10.3945/jn.110.124107; Nechuta SJ, 2012, AM J CLIN NUTR, V96, P123, DOI 10.3945/ajcn.112.035972; Park NH, 2013, INT J COSMETIC SCI, V35, P136, DOI 10.1111/ics.12014; Polito F, 2012, BRIT J PHARMACOL, V165, P994, DOI 10.1111/j.1476-5381.2011.01619.x; Prisby RD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048564; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Revollo JR, 2013, TRENDS BIOCHEM SCI, V38, P160, DOI 10.1016/j.tibs.2012.12.004; Ronis MJJ, 2012, ENDOCRINOLOGY, V153, P6021, DOI 10.1210/en.2012-1591; Rubin J, 2007, J BONE MINER RES, V22, P1408, DOI 10.1359/jbmr.070601; Setchell KDR, 2001, J AM COLL NUTR, V20, p354S, DOI 10.1080/07315724.2001.10719168; Shivshankar P, 2012, AM J RESP CELL MOL, V47, P28, DOI 10.1165/rcmb.2011-0349OC; Shupnik MA, 1998, J CLIN ENDOCR METAB, V83, P3965, DOI 10.1210/jc.83.11.3965; Sousa-Nunes R, 2011, NATURE, V471, P508, DOI 10.1038/nature09867; Tai TY, 2012, OSTEOPOROSIS INT, V23, P1571, DOI 10.1007/s00198-011-1750-7; Volonte D, 2011, J BIOL CHEM, V286, P28657, DOI 10.1074/jbc.C111.235119; WEST MD, 1989, EXP CELL RES, V184, P138, DOI 10.1016/0014-4827(89)90372-8; Zhang J, 2013, AGE, V35, P807, DOI 10.1007/s11357-012-9412-z; Zhang J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035736; Zhang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024486; Zou HF, 2011, MECH AGEING DEV, V132, P533, DOI 10.1016/j.mad.2011.11.001	44	14	15	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3134	3145		10.1096/fj.13-243659	http://dx.doi.org/10.1096/fj.13-243659			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24719353				2022-12-28	WOS:000337949400034
J	Akbari, P; Braber, S; Gremmels, H; Koelink, PJ; Verheijden, KAT; Garssen, J; Fink-Gremmels, J				Akbari, Peyman; Braber, Saskia; Gremmels, Hendrik; Koelink, Pim J.; Verheijden, Kim A. T.; Garssen, Johan; Fink-Gremmels, Johanna			Deoxynivalenol: a trigger for intestinal integrity breakdown	FASEB JOURNAL			English	Article						Caco-2 cells; TEER; tight junction proteins	TIGHT JUNCTION PROTEINS; BARRIER FUNCTION; SUBCELLULAR-LOCALIZATION; EPITHELIAL-CELLS; CROHNS-DISEASE; PREGNANT-WOMEN; IN-VITRO; PERMEABILITY; EXPRESSION; CLAUDIN-4	Disintegration of the colonic epithelial barrier is considered a key event in the initiation and progression of inflammatory bowel and celiac disease. As the primary etiology of these diseases remains unknown, we hypothesized that the trichothecene deoxynivalenol (DON), a fungal metabolite found in grain-based human diets, might be one of the triggers resulting in an impairment of the intestinal tight junction network preceding an inflammatory response. Using horizontal impedance measurements, we demonstrate that DON disintegrates a human Caco-2 cell monolayer within <1 h after exposure to concentrations as low as 1.39 mu M. This initial trigger is followed by a decrease in transepithelial resistance and an increased permeability of marker molecules, such as lucifer yellow and FITC-labeled dextran. In parallel, the increase in paracellular transport of FITC-dextran is demonstrated in vivo in B6C3F(1) mice, challenged orally with DON. In vitro claudin protein levels are decreased and correlated with a displacement within the cells in vitro and in vivo, accompanied by a compensatory up-regulation of mRNA levels of claudins and their binding partner ZO-1. In treated mice, alterations in villus architecture in the entire intestinal tract resemble the disintegration of the epithelial barrier, a characteristic of chronic inflammatory bowel disease.	[Akbari, Peyman; Braber, Saskia; Fink-Gremmels, Johanna] Univ Utrecht, Div Vet Pharm Pharmacol & Toxicol, NL-3508 TC Utrecht, Netherlands; [Koelink, Pim J.; Verheijden, Kim A. T.; Garssen, Johan] Univ Utrecht, Fac Sci, Utrecht Inst Pharmaceut Sci, Div Pharmacol, NL-3508 TC Utrecht, Netherlands; [Gremmels, Hendrik] Univ Med Ctr Utrecht, Dept Hypertens & Nephrol, Utrecht, Netherlands; [Garssen, Johan] Nutricia Res, Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University; Utrecht University Medical Center; Danone Nutricia	Braber, S (corresponding author), Univ Utrecht, Yalelaan 104, NL-3584 CM Utrecht, Netherlands.	s.braber@uu.nl	garssen, johan/I-7159-2016; Verheijden, Kim/K-4088-2017; Fink-Gremmels, Johanna/G-3707-2012; Gremmels, Hendrik/G-3185-2012	Verheijden, Kim/0000-0003-4622-4299; Gremmels, Hendrik/0000-0002-7818-620X	European Union, European Regional Development Fund; Netherlands Ministry of Economic Affairs, Agriculture, and Innovation; European Commission Peaks in the Delta in East Netherlands program; Municipality of Groningen (The Netherlands); Provinces of Groningen (The Netherlands); Provinces of Fryslan (The Netherlands); Provinces of Drenthe (The Netherlands); Netherlands Carbohydrate Competence Center (CCC) [WP25]; Nutricia Research (Utrecht, The Netherlands); FrieslandCampina (Amersfoort, The Netherlands)	European Union, European Regional Development Fund; Netherlands Ministry of Economic Affairs, Agriculture, and Innovation(Ministry of Economic Affairs, Netherlands); European Commission Peaks in the Delta in East Netherlands program; Municipality of Groningen (The Netherlands)(Netherlands Government); Provinces of Groningen (The Netherlands); Provinces of Fryslan (The Netherlands); Provinces of Drenthe (The Netherlands); Netherlands Carbohydrate Competence Center (CCC); Nutricia Research (Utrecht, The Netherlands); FrieslandCampina (Amersfoort, The Netherlands)	This project is jointly financed by the European Union, European Regional Development Fund; The Netherlands Ministry of Economic Affairs, Agriculture, and Innovation; the European Commission Peaks in the Delta in East Netherlands program; the Municipality of Groningen (The Netherlands); the Provinces of Groningen, Fryslan, and Drenthe (The Netherlands); The Netherlands Carbohydrate Competence Center (CCC; WP25; http://www.cccresearch.nl); Nutricia Research (Utrecht, The Netherlands); and FrieslandCampina (Amersfoort, The Netherlands). The authors thank Rob Bleumink (Center for Cell Imaging, Faculty of Veterinary Medicine, Utrecht University) for his help with the fluorescent imaging.	Abassi YA, 2009, CHEM BIOL, V16, P712, DOI 10.1016/j.chembiol.2009.05.011; AZCONAOLIVERA JI, 1995, TOXICOL APPL PHARM, V133, P109, DOI 10.1006/taap.1995.1132; Balda MS, 2008, J CELL SCI, V121, P3677, DOI 10.1242/jcs.023887; Blikslager AT, 2007, PHYSIOL REV, V87, P545, DOI 10.1152/physrev.00012.2006; Bruewer M, 2005, FASEB J, V19, P923, DOI 10.1096/fj.04-3260com; CANIL C, 1993, INFECT IMMUN, V61, P2755, DOI 10.1128/IAI.61.7.2755-2762.1993; Danicke S, 2004, ARCH ANIM NUTR, V58, P169, DOI 10.1080/00039420410001667548; DeMeo MT, 2002, J CLIN GASTROENTEROL, V34, P385, DOI 10.1097/00004836-200204000-00003; Dombrink-Kurtzman MA, 2010, J FOOD PROTECT, V73, P1073, DOI 10.4315/0362-028X-73.6.1073; Fujita H, 2006, J HISTOCHEM CYTOCHEM, V54, P933, DOI 10.1369/jhc.6A6944.2006; Fujita K, 2000, FEBS LETT, V476, P258, DOI 10.1016/S0014-5793(00)01744-0; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; He KY, 2012, TOXICOL APPL PHARM, V265, P10, DOI 10.1016/j.taap.2012.09.017; Hepworth SJ, 2012, FOOD ADDIT CONTAM A, V29, P269, DOI 10.1080/19440049.2010.551301; Heyman M, 2012, GUT, V61, P1355, DOI 10.1136/gutjnl-2011-300327; HOLLANDER D, 1986, ANN INTERN MED, V105, P883, DOI 10.7326/0003-4819-105-6-883; Ivanov AI, 2004, NOVART FDN SYMP, V263, P124; IVANOV AI, 2004, NOVART FDN SYMP, V263, P211; Ivanov Andrei I, 2004, Novartis Found Symp, V263, P115; Kasuga F, 1998, MYCOPATHOLOGIA, V142, P161, DOI 10.1023/A:1006923808748; KIRKLAND SC, 1985, CANCER RES, V45, P3790; Kolf-Clauw M, 2009, TOXICOL IN VITRO, V23, P1580, DOI 10.1016/j.tiv.2009.07.015; Lutz KL, 1997, J PHARM SCI, V86, P977, DOI 10.1021/js970134j; Matsuda M, 2004, J CELL SCI, V117, P1247, DOI 10.1242/jcs.00972; McLaughlin J, 2004, AM J PHYSIOL-CELL PH, V287, pC1412, DOI 10.1152/ajpcell.00007.2004; Menard S, 2010, MUCOSAL IMMUNOL, V3, P247, DOI 10.1038/mi.2010.5; MOOLENBEEK C, 1981, LAB ANIM, V15, P57, DOI 10.1258/002367781780958577; Mutch DM, 2004, PHYSIOL GENOMICS, V17, P11, DOI 10.1152/physiolgenomics.00150.2003; Odenwald MA, 2013, CLIN GASTROENTEROL H, V11, P1075, DOI 10.1016/j.cgh.2013.07.001; Pestka JJ, 2010, ARCH TOXICOL, V84, P663, DOI 10.1007/s00204-010-0579-8; Pestka JJ, 2010, TOXINS, V2, P1300, DOI 10.3390/toxins2061300; Pinton P, 2012, TOXICOL SCI, V130, P180, DOI 10.1093/toxsci/kfs239; Pinton P, 2010, J NUTR, V140, P1956, DOI 10.3945/jn.110.123919; Pinton P, 2009, TOXICOL APPL PHARM, V237, P41, DOI 10.1016/j.taap.2009.03.003; Prasad S, 2005, LAB INVEST, V85, P1139, DOI 10.1038/labinvest.3700316; PRELUSKY DB, 1988, FUND APPL TOXICOL, V10, P276, DOI 10.1016/0272-0590(88)90312-0; Rahner C, 2001, GASTROENTEROLOGY, V120, P411, DOI 10.1053/gast.2001.21736; Reeves PG, 1997, J NUTR, V127, pS838; Sarkanj B, 2013, FOOD CHEM TOXICOL, V62, P231, DOI 10.1016/j.fct.2013.08.043; SCHNEEBERGER EE, 1992, AM J PHYSIOL, V262, pL647, DOI 10.1152/ajplung.1992.262.6.L647; Sergent T, 2006, TOXICOL LETT, V164, P167, DOI 10.1016/j.toxlet.2005.12.006; Sun MJ, 2012, ANAL BIOCHEM, V425, P96, DOI 10.1016/j.ab.2012.03.010; Suzuki T, 2013, CELL MOL LIFE SCI, V70, P631, DOI 10.1007/s00018-012-1070-x; Tamagawa H, 2003, LAB INVEST, V83, P1045, DOI 10.1097/01.LAB.0000078741.55670.6E; Turner PC, 2011, FOOD ADDIT CONTAM A, V28, P1220, DOI 10.1080/19440049.2011.584070; Urcan E, 2010, DENT MATER, V26, P51, DOI 10.1016/j.dental.2009.08.007; Van de Walle J, 2010, TOXICOL APPL PHARM, V245, P291, DOI 10.1016/j.taap.2010.03.012; Videmann B, 2007, FOOD CHEM TOXICOL, V45, P1938, DOI 10.1016/j.fct.2007.04.011; Warth B, 2012, TOXICOL LETT, V211, P85, DOI 10.1016/j.toxlet.2012.02.023; Will C, 2008, PERITON DIALYSIS INT, V28, P577; Wu X, 2008, AM J PHYSIOL-GASTR L, V294, pG295, DOI 10.1152/ajpgi.00173.2007; Yu P, 2000, CRIT CARE MED, V28, P2573, DOI 10.1097/00003246-200007000-00065; Zeissig S, 2007, GUT, V56, P61, DOI 10.1136/gut.2006.094375	56	97	106	1	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2414	2429		10.1096/fj.13-238717	http://dx.doi.org/10.1096/fj.13-238717			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24568843				2022-12-28	WOS:000339883600004
J	Beier, UH; Angelin, A; Akimova, T; Wang, LQ; Liu, YJ; Xiao, HY; Koike, MA; Hancock, SA; Bhatti, TR; Han, RX; Jiao, J; Veasey, SC; Sims, CA; Baur, JA; Wallace, DC; Hancock, WW				Beier, Ulf H.; Angelin, Alessia; Akimova, Tatiana; Wang, Liqing; Liu, Yujie; Xiao, Haiyan; Koike, Maya A.; Hancock, Saege A.; Bhatti, Tricia R.; Han, Rongxiang; Jiao, Jing; Veasey, Sigrid C.; Sims, Carrie A.; Baur, Joseph A.; Wallace, Douglas C.; Hancock, Wayne W.			Essential role of mitochondrial energy metabolism in Foxp3(+) T-regulatory cell function and allograft survival	FASEB JOURNAL			English	Article						histone deacetylase; immunity; immunometabolism; immunoregulation; transplant survival	ENHANCER FACTOR-2 MEF2; MOLECULAR-MECHANISMS; EFFECTOR; IMMUNOMETABOLISM; EXPRESSION; MEMORY; DIFFERENTIATION; INFLAMMATION; INHIBITION; ACTIVATION	Conventional T (Tcon) cells and Foxp3(+) T-regulatory (Treg) cells are thought to have differing metabolic requirements, but little is known of mitochondrial functions within these cell populations in vivo. In murine studies, we found that activation of both Tcon and Treg cells led to myocyte enhancer factor 2 (Mef2)-induced expression of genes important to oxidative phosphorylation (OXPHOS). Inhibition of OXPHOS impaired both Tcon and Treg cell function compared to wild-type cells but disproportionally affected Treg cells. Deletion of Pgc1 alpha or Sirt3, which are key regulators of OXPHOS, abrogated Treg-dependent suppressive function and impaired allograft survival. Mef2 is inhibited by histone/protein deacetylase-9 (Hdac9), and Hdac9 deletion increased Treg suppressive function. Hdac9(-/-) Treg showed increased expression of Pgc1 alpha and Sirt3, and improved mitochondrial respiration, compared to wild-type Treg cells. Our data show that key OXPHOS regulators are required for optimal Treg function and Treg-dependent allograft acceptance. These findings provide a novel approach to increase Treg function and give insights into the fundamental mechanisms by which mitochondrial energy metabolism regulates immune cell functions in vivo.	[Beier, Ulf H.; Xiao, Haiyan; Jiao, Jing] Childrens Hosp Philadelphia, Dept Pediat, Div Nephrol, Philadelphia, PA 19104 USA; [Angelin, Alessia; Koike, Maya A.; Hancock, Saege A.; Wallace, Douglas C.] Childrens Hosp Philadelphia, Ctr Mitochondrial & Epigen Med, Philadelphia, PA 19104 USA; [Akimova, Tatiana; Wang, Liqing; Liu, Yujie; Bhatti, Tricia R.; Han, Rongxiang; Hancock, Wayne W.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Div Transplant Immunol, Philadelphia, PA 19104 USA; [Akimova, Tatiana; Wang, Liqing; Liu, Yujie; Bhatti, Tricia R.; Han, Rongxiang; Hancock, Wayne W.] Childrens Hosp Philadelphia, Biesecker Ctr Pediat Liver Dis, Philadelphia, PA 19104 USA; [Akimova, Tatiana; Wang, Liqing; Liu, Yujie; Bhatti, Tricia R.; Han, Rongxiang; Hancock, Wayne W.] Univ Penn, Philadelphia, PA 19104 USA; [Veasey, Sigrid C.] Univ Penn, Dept Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA; [Sims, Carrie A.; Baur, Joseph A.] Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; [Sims, Carrie A.; Baur, Joseph A.] Univ Penn, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA; [Sims, Carrie A.] Univ Penn, Hosp Univ Penn, Div Traumatol & Surg Crit Care, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Hancock, WW (corresponding author), 916 B ARC,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	whancock@mail.med.upenn.edu		Akimova, Tatiana/0000-0003-2767-8762; Beier, Ulf/0000-0002-3672-572X	U.S. National Institutes of Health [K08AI095353, AI073489, AI095276, NS21325, NS070298, AG24373, DIC73691]; Simons Foundation [205844]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079588, R01HL124576, R01HL123331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI095353, P01AI073489, R56AI095276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K08GM097614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328, R01NS021325, R01NS070298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024373, RF1AG054104] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Simons Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The work was supported by the U.S. National Institutes of Health (Grants K08AI095353, AI073489, AI095276, NS21325, NS070298, AG24373, and DIC73691), as well as Simons Foundation (Grant 205844).	Akimova T, 2012, AM J TRANSPLANT, V12, P3449, DOI 10.1111/j.1600-6143.2012.04269.x; Akimova T, 2010, CLIN IMMUNOL, V136, P348, DOI 10.1016/j.clim.2010.04.018; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Battke F, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-121; Beier UH, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002873; Beier UH, 2011, CURR OPIN IMMUNOL, V23, P670, DOI 10.1016/j.coi.2011.07.002; Beier UH, 2011, MOL CELL BIOL, V31, P1022, DOI 10.1128/MCB.01206-10; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Chi H, 2012, NAT REV IMMUNOL, V12, P325, DOI 10.1038/nri3198; Czubryt MP, 2004, RECENT PROG HORM RES, V59, P105, DOI 10.1210/rp.59.1.105; de Zoeten EF, 2010, GASTROENTEROLOGY, V138, P583, DOI 10.1053/j.gastro.2009.10.037; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Feuerer M, 2009, NAT IMMUNOL, V10, P689, DOI 10.1038/ni.1760; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Issa F, 2013, TRENDS IMMUNOL, V34, P107, DOI 10.1016/j.it.2012.11.003; Kim do Y, 2012, PLOS ONE, V7; Kong XX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011707; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Marelli-Berg FM, 2012, IMMUNOLOGY, V136, P363, DOI 10.1111/j.1365-2567.2012.03583.x; Mathis D, 2011, NAT REV IMMUNOL, V11, P81, DOI 10.1038/nri2922; Maus MV, 2014, BLOOD, V123, P2625, DOI 10.1182/blood-2013-11-492231; McDonald L., 1998, KETOGENIC DIET COMPL, V1; Michalek RD, 2011, P NATL ACAD SCI USA, V108, P18348, DOI 10.1073/pnas.1108856108; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Mockler MB, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00107; Mukhopadhyay P, 2007, NAT PROTOC, V2, P2295, DOI 10.1038/nprot.2007.327; Nath N, 2009, J IMMUNOL, V182, P8005, DOI 10.4049/jimmunol.0803563; Nishikawa H, 2010, INT J CANCER, V127, P759, DOI 10.1002/ijc.25429; Ostroukhova M, 2012, AM J PHYSIOL-LUNG C, V302, pL300, DOI 10.1152/ajplung.00221.2011; Pearce EL, 2010, CURR OPIN IMMUNOL, V22, P314, DOI 10.1016/j.coi.2010.01.018; Pearce EL, 2009, NATURE, V460, P103, DOI 10.1038/nature08097; Pollizzi KN, 2014, NAT REV IMMUNOL, V14, P435, DOI 10.1038/nri3701; Procaccini C, 2010, IMMUNITY, V33, P929, DOI 10.1016/j.immuni.2010.11.024; Rathmell JC, 2012, IMMUNOL REV, V249, P5, DOI 10.1111/j.1600-065X.2012.01158.x; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Swanson BJ, 1998, MOL IMMUNOL, V35, P445, DOI 10.1016/S0161-5890(98)00058-3; Tao R, 2005, J IMMUNOL, V175, P5774, DOI 10.4049/jimmunol.175.9.5774; Tao R, 2007, NAT MED, V13, P1299, DOI 10.1038/nm1652; van der Windt GJW, 2012, IMMUNOL REV, V249, P27, DOI 10.1111/j.1600-065X.2012.01150.x; van der Windt GJW, 2012, IMMUNITY, V36, P68, DOI 10.1016/j.immuni.2011.12.007; Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386; Wang LQ, 2009, NAT REV DRUG DISCOV, V8, P969, DOI 10.1038/nrd3031; Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	49	152	154	4	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2315	2326		10.1096/fj.14-268409	http://dx.doi.org/10.1096/fj.14-268409			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25681462	Green Published			2022-12-28	WOS:000355209500010
J	He, KM; Xing, R; Yan, XH; Tian, AJ; Zhang, ML; Yuan, JH; Lv, ZZ; Fang, XH; Li, ZJ; Zhang, YY				He, Kangmin; Xing, Rui; Yan, Xiaohua; Tian, Aiju; Zhang, Mingliang; Yuan, Jinghe; Lv, Zhizhen; Fang, Xiaohong; Li, Zijian; Zhang, Youyi			Mammalian actin-binding protein 1/HIP-55 is essential for the scission of clathrin-coated pits by regulating dynamin-actin interaction	FASEB JOURNAL			English	Article						membrane trafficking; adaptor protein; quantitative live-cell imaging	MEDIATED ENDOCYTOSIS; ADAPTER PROTEIN; CYTOSKELETON; ACTIVATION; RECEPTORS; GTPASE	Actin and dynamin work cooperatively to drive the invagination and scission of clathrin-coated pits (CCPs). However, little is known about the mechanism that orchestrates the spatiotemporal recruitment of dynamin and actin. Here, we have identified the mammalian actin-binding protein 1 (mAbp1; also called HIP-55 or SH3P7), which could bind toclathrin, actin, as well as dynamin, as an adaptor that links the dynamic recruitment of dynamin and actin for the scission of CCPs. Live-cell imaging reveals that mAbp1 is specifically recruited at a late stage of the long-lived CCPs. mAbp1 knockdown impaired CCP scission by reducing dynamin recruitment at the plasma membrane. However, actin disruption remarkably eliminates mAbp1 recruitment and thus dynamin recruitment. These data suggest that by binding to both clathrin and F-actin, mAbp1 is specifically recruited at a late stage of CCP formation, which subsequently recruits dynamin to CCPs.	[He, Kangmin; Xing, Rui; Tian, Aiju; Zhang, Mingliang; Lv, Zhizhen; Li, Zijian; Zhang, Youyi] Peking Univ, Hosp 3, Inst Vasc Med, Beijing 100871, Peoples R China; [He, Kangmin; Xing, Rui; Tian, Aiju; Zhang, Mingliang; Lv, Zhizhen; Li, Zijian; Zhang, Youyi] Peking Univ, Acad Adv Interdisciplinary Studies, Key Lab Cardiovascular Mol Biol & Regulatory Pept, Key Lab Mol Cardiovasc Sci,Minist Educ,Minist Hlt, Beijing 100871, Peoples R China; [He, Kangmin; Xing, Rui; Tian, Aiju; Zhang, Mingliang; Lv, Zhizhen; Li, Zijian; Zhang, Youyi] Beijing Key Lab Cardiovasc Receptors Res, Beijing 100871, Peoples R China; [He, Kangmin; Yuan, Jinghe; Fang, Xiaohong] Chinese Acad Sci, Inst Chem, Key Lab Mol Nanostruct & Nanotechnol, Beijing Natl Lab Mol Sci, Beijing 100080, Peoples R China; [Yan, Xiaohua] Tsinghua Univ, Tsinghua Peking Ctr Life Sci, Sch Life Sci, Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China	Peking University; Peking University; Chinese Academy of Sciences; Institute of Chemistry, CAS; Tsinghua University	Li, ZJ (corresponding author), 49 Huayuan North Rd, Beijing 100191, Peoples R China.	lizijian@bjmu.edu.cn; zhangyy@bjmu.edu.cn	Yan, Xiaohua/J-4922-2015	Yan, Xiaohua/0000-0002-7528-5771; Zhang, Mingliang/0000-0003-2285-3592	National Key Basic Research Program of the People's Republic of China [2013CB933701, 2012CB518000, 2011CB503903]; Natural Science Foundation of China [81471893, 81070078, 81270157, 81270159]; Emory Global Health Institute (Atlanta, GA, USA)	National Key Basic Research Program of the People's Republic of China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Emory Global Health Institute (Atlanta, GA, USA)	The authors sincerely thank Dr. Haian Fu (Emory University, Atlanta, GA, USA) for the HIP-55/mammalian actin-binding protein 1 plasmid, HIP-55/mammalian actin-binding protein 1-knockdown cell line, and valuable discussions. The authors thank Laura Smales for helping with language editing. The authors also thank Drs. Sanford M. Simon, Richard D. Minshall, and Lois E. Greene for their generous gifts of the clathrin-Discosoma sp. red fluorescent protein, enhanced green fluorescent proteina-adaptin, caveolin-1-enhanced green fluorescent protein, and enhanced green fluorescent protein-clathrin. This work was supported by the National Key Basic Research Program of the People's Republic of China (2013CB933701, 2012CB518000, and 2011CB503903) and the Natural Science Foundation of China (81471893, 81070078, 81270157, and 81270159). This work was supported in part by the Emory Global Health Institute (Atlanta, GA, USA).	Aguet F, 2013, DEV CELL, V26, P279, DOI 10.1016/j.devcel.2013.06.019; Boulant S, 2011, NAT CELL BIOL, V13, P1124, DOI 10.1038/ncb2307; Chen C, 2012, BRIT J PHARMACOL, V166, P676, DOI 10.1111/j.1476-5381.2011.01785.x; Collins A, 2011, CURR BIOL, V21, P1167, DOI 10.1016/j.cub.2011.05.048; Connert S, 2006, EMBO J, V25, P1611, DOI 10.1038/sj.emboj.7601053; Cortesio CL, 2010, MOL BIOL CELL, V21, P186, DOI 10.1091/mbc.E09-02-0106; Daumke O, 2014, CELL, V156, P882, DOI 10.1016/j.cell.2014.02.017; Ensenat D, 1999, J BIOL CHEM, V274, P33945, DOI 10.1074/jbc.274.48.33945; Ferguson S, 2009, DEV CELL, V17, P811, DOI 10.1016/j.devcel.2009.11.005; Ferguson SM, 2012, NAT REV MOL CELL BIO, V13, P75, DOI 10.1038/nrm3266; Grassart A, 2014, J CELL BIOL, V205, P721, DOI 10.1083/jcb.201403041; Kessels MM, 2000, MOL BIOL CELL, V11, P393, DOI 10.1091/mbc.11.1.393; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kirchhausen T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016725; Larbolette O, 1999, MOL CELL BIOL, V19, P1539; Li ZJ, 2014, ONCOTARGET, V5, P3197, DOI 10.18632/oncotarget.1900; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Mooren OL, 2012, ANNU REV BIOCHEM, V81, P661, DOI 10.1146/annurev-biochem-060910-094416; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Onabajo OO, 2008, J IMMUNOL, V180, P6685, DOI 10.4049/jimmunol.180.10.6685; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Perrais D, 2005, DEV CELL, V9, P581, DOI 10.1016/j.devcel.2005.10.002; Rappoport J, 2004, TRAFFIC, V5, P327, DOI 10.1111/j.1600-0854.2004.00187.x; Rappoport JZ, 2006, AM J PHYSIOL-CELL PH, V291, pC1072, DOI 10.1152/ajpcell.00160.2006; Sverdlov M, 2009, MOL BIOL CELL, V20, P4531, DOI 10.1091/mbc.E08-10-0997; Taylor MJ, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001302; Taylor MJ, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000604; Ungewickell EJ, 2007, CURR OPIN CELL BIOL, V19, P417, DOI 10.1016/j.ceb.2007.05.003; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085	30	7	8	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2495	2503		10.1096/fj.14-264259	http://dx.doi.org/10.1096/fj.14-264259			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25690657				2022-12-28	WOS:000355209500026
J	Li, XW; Montine, KS; Keene, CD; Montine, TJ				Li, Xianwu; Montine, Kathleen S.; Keene, C. Dirk; Montine, Thomas J.			Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E-2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia	FASEB JOURNAL			English	Article						apolipoprotein E genotype; PGE(2); Alzheimer disease; neuroinflammation; brain immunity	TARGETED REPLACEMENT; A-BETA; ALZHEIMER-DISEASE; APOE GENOTYPE; CUTTING EDGE; MOUSE MODEL; NSAID USE; E GENE; ALLELE; TLR	Several lines of evidence support immune response in brain as a mechanism of injury in Alzheimer disease (AD). Moreover, immune activation is heightened in apolipoprotein E (APOE) epsilon 4 carriers; inhibitors of prostaglandin (PG) synthesis show a partially protective effect on AD risk from APOE epsilon 4; and genetic variants in triggering receptor expressed on myeloid cells 2 (TREM2) are a rare but potent risk for AD. We tested the hypothesis that APOE epsilon 4 inheritance modulates both the PGE(2) pathway and TREM2 expression using primary murine microglia from targeted replacement (TR) APOE3/3 and APOE4/4 mice. Microglial cyclooxygenase-2, microsomal PGE synthase, and PGE(2) expression were increased 2- to 25-fold in both genotypes by TLR activators; however, this induction was significantly (P < 0.01) greater in TR APOE4/4 microglia with TLR3 and TLR4 activators. Microglial TREM2 expression was reduced approximately 85% by all TLR activators; this reduction was approximately one-third greater in microglia from TR APOE4/4 mice. Importantly, both receptor-associated protein and a nuclear factor -light-chain-enhancer inhibitor blocked TR APOE4/4-dependent effects on the PGE(2) pathway but not on TREM2 expression. These data demonstrate complementary, but mechanistically distinct, regulation of pro- and anti-inflammatory mediators in TR APOE4/4 murine microglia that yields a more proinflammatory state than with TR APOE3/3.Li, X., Montine, K. S., Keene, C. D., Montine, T. J. Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E-2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia.	[Li, Xianwu; Montine, Kathleen S.; Keene, C. Dirk; Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle	Li, XW (corresponding author), Univ Washington, Dept Pathol, Box 359645, Seattle, WA 98104 USA.	xli@uw.edu	Keene, Christopher D/N-1806-2015	Keene, Christopher/0000-0002-5291-1469; Montine, Kathleen/0000-0003-2110-8363	U.S. National Institutes of Health (NIH) National Institute of Environmental Health Sciences [R01-ES016754]; NIH National Institute on Aging [P50-AG05136]; NIH National Institute of Neurological Disorders and Stroke [P50-NS062684]; Nancy and Buster Alvord Endowment; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS062684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005136] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) National Institute of Environmental Health Sciences; NIH National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Nancy and Buster Alvord Endowment; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Samantha Rice and Leanne Hellstern for assistance with animal husbandry, K. Arumuganathan and Jingjing Tang for assistance with flow cytometry, Eiron Cudaback for scientific input, and Aimee Schantz and Carol Arnold for administrative support. This work was funded by the U.S. National Institutes of Health (NIH) National Institute of Environmental Health Sciences (Grant R01-ES016754), NIH National Institute on Aging (Grant P50-AG05136), NIH National Institute of Neurological Disorders and Stroke (Grant P50-NS062684) and the Nancy and Buster Alvord Endowment.	Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; Chouery E, 2008, HUM MUTAT, V29, pE194, DOI 10.1002/humu.20836; Cole GM, 2010, CNS NEUROL DISORD-DR, V9, P140, DOI 10.2174/187152710791011991; Cudaback E, 2014, BIOCHEM PHARMACOL, V88, P565, DOI 10.1016/j.bcp.2013.12.014; Cudaback E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-192; Cudaback E, 2011, FASEB J, V25, P2082, DOI 10.1096/fj.10-176891; Egensperger R, 1998, BRAIN PATHOL, V8, P439; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Hamerman JA, 2006, J IMMUNOL, V177, P2051, DOI 10.4049/jimmunol.177.4.2051; Hayden KM, 2007, NEUROLOGY, V69, P275, DOI 10.1212/01.wnl.0000265223.25679.2a; Hsieh CL, 2009, J NEUROCHEM, V109, P1144, DOI 10.1111/j.1471-4159.2009.06042.x; Ito H, 2012, EUR J IMMUNOL, V42, P176, DOI 10.1002/eji.201141679; Jiang T, 2014, NEUROBIOL AGING, V35, P1243, DOI 10.1016/j.neurobiolaging.2013.11.026; Jones BM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00094; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kanekiyo T, 2014, NEURON, V81, P740, DOI 10.1016/j.neuron.2014.01.045; Keene CD, 2011, CURR OPIN NEUROBIOL, V21, P920, DOI 10.1016/j.conb.2011.08.002; Klunemann HH, 2005, NEUROLOGY, V64, P1502, DOI 10.1212/01.WNL.0000160304.00003.CA; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Larionov A, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-62; Li XW, 2013, J NEUROIMMUNE PHARM, V8, P87, DOI 10.1007/s11481-012-9380-1; Li XW, 2012, FASEB J, V26, P3075, DOI 10.1096/fj.11-200279; Li XW, 2011, GLIA, V59, P569, DOI 10.1002/glia.21125; Lue LF, 2015, BRAIN PATHOL, V25, P469, DOI 10.1111/bpa.12190; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Maezawa I, 2004, J NEUROCHEM, V91, P1312, DOI 10.1111/j.1471-4159.2004.02818.x; Maezawa I, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-10; Maezawa I, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-21; Maezawa I, 2006, FASEB J, V20, P797, DOI 10.1096/fj.05-5423fje; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; McGeer PL, 2007, NEUROBIOL AGING, V28, P639, DOI 10.1016/j.neurobiolaging.2006.03.013; Melchior B, 2010, ASN NEURO, V2, P157, DOI 10.1042/AN20100010; Moir RD, 1999, BIOCHEMISTRY-US, V38, P4595, DOI 10.1021/bi982437d; Mosconi L, 2008, BIOL PSYCHIAT, V63, P609, DOI 10.1016/j.biopsych.2007.05.030; Ng S, 2013, NEUROTOXICOLOGY, V37, P85, DOI 10.1016/j.neuro.2013.03.012; Paloneva J, 2002, AM J HUM GENET, V71, P656, DOI 10.1086/342259; Paradowska-Gorycka A, 2013, HUM IMMUNOL, V74, P730, DOI 10.1016/j.humimm.2013.02.003; Pasqualetti P, 2009, AGING CLIN EXP RES, V21, P102, DOI 10.1007/BF03325217; Rodriguez GA, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-111; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Saura J, 2003, J NEUROCHEM, V85, P1455, DOI 10.1046/j.1471-4159.2003.01788.x; Schellenberg GD, 2012, ACTA NEUROPATHOL, V124, P305, DOI 10.1007/s00401-012-0996-2; Sessa G, 2004, EUR J NEUROSCI, V20, P2617, DOI 10.1111/j.1460-9568.2004.03729.x; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; Szekely CA, 2008, NEUROLOGY, V70, P17, DOI 10.1212/01.wnl.0000284596.95156.48; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Town T, 2006, J IMMUNOL, V176, P3804, DOI 10.4049/jimmunol.176.6.3804; Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520; Valla J, 2010, J ALZHEIMERS DIS, V22, P307, DOI 10.3233/JAD-2010-100129; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE; Yang Y, 2013, AM J PATHOL, V183, P905, DOI 10.1016/j.ajpath.2013.05.009	56	35	35	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1754	1762		10.1096/fj.14-262683	http://dx.doi.org/10.1096/fj.14-262683			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25593125	Green Published			2022-12-28	WOS:000354114600013
J	Etheridge, T; Rahman, M; Gaffney, CJ; Shaw, D; Shephard, F; Magudia, J; Solomon, DE; Milne, T; Blawzdziewicz, J; Constantin-Teodosiu, D; Greenhaff, PL; Vanapalli, SA; Szewczyk, NJ				Etheridge, Timothy; Rahman, Mizanur; Gaffney, Christopher J.; Shaw, Debra; Shephard, Freya; Magudia, Jignesh; Solomon, Deepak E.; Milne, Thomas; Blawzdziewicz, Jerzy; Constantin-Teodosiu, Dumitru; Greenhaff, Paul L.; Vanapalli, Siva A.; Szewczyk, Nathaniel J.			The integrin-adhesome is required to maintain muscle structure, mitochondrial ATP production, and movement forces in Caenorhabditis elegans	FASEB JOURNAL			English	Article						dystrophy; mitochondria; calpain; focal adhesion	GIRDLE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; CALPAIN 3; PROTEIN; GENE; LOCOMOTION; KINASE; LOCALIZATION; COSTAMERES; COMPONENTS	The integrin-adhesome network, which contains >150 proteins, is mechano-transducing and located at discreet positions along the cell-cell and cell-extracellular matrix interface. A small subset of the integrin-adhesome is known to maintain normal muscle morphology. However, the importance of the entire adhesome for muscle structure and function is unknown. We used RNA interference to knock down 113 putative Caenorhabditis elegans homologs constituting most of the mammalian adhesome and 48 proteins known to localize to attachment sites in C. elegans muscle. In both cases, we found >90% of components were required for normal muscle mitochondrial structure and/or proteostasis vs. empty vector controls. Approximately half of these, mainly proteins that physically interact with each other, were also required for normal sarcomere and/or adhesome structure. Next we confirmed that the dystrophy observed in adhesome mutants associates with impaired maximal mitochondrial ATP production (P < 0.01), as well as reduced probability distribution of muscle movement forces compared with wild-type animals. Our results show that the integrin-adhesome network as a whole is required for maintaining both muscle structure and function and extend the current understanding of the full complexities of the functional adhesome in vivo.	[Etheridge, Timothy] Univ Exeter, Dept Sport & Hlth Sci, Coll Life & Environm Sci, Exeter EX1 2LU, Devon, England; [Shaw, Debra] Univ Exeter, Coll Engn Math & Phys Sci, Exeter EX1 2LU, Devon, England; [Rahman, Mizanur; Solomon, Deepak E.; Vanapalli, Siva A.] Texas Tech Univ, Dept Chem Engn, Lubbock, TX 79409 USA; [Blawzdziewicz, Jerzy] Texas Tech Univ, Dept Engn Mech, Lubbock, TX 79409 USA; [Gaffney, Christopher J.; Shaw, Debra; Magudia, Jignesh; Milne, Thomas; Constantin-Teodosiu, Dumitru; Greenhaff, Paul L.; Szewczyk, Nathaniel J.] Univ Nottingham, Sch Life Sci & Med, Med Res Council, Arthrit Res UK Ctr Musculoskeletal Ageing Res, Nottingham, England; [Shephard, Freya] Univ Nottingham, Sch Vet Med & Sci, Nottingham, Leics, England	University of Exeter; University of Exeter; Texas Tech University System; Texas Tech University; Texas Tech University System; Texas Tech University; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Nottingham; University of Nottingham	Etheridge, T (corresponding author), Univ Exeter, Dept Sport & Hlth Sci, Coll Life & Environm Sci, St Lukes Campus, Exeter EX1 2LU, Devon, England.	t.etheridge@exeter.ac.uk		Greenhaff, Paul/0000-0003-4403-0490; Gaffney, Christopher/0000-0001-7990-2792; Szewczyk, Nathaniel/0000-0003-4425-9746; Etheridge, Timothy/0000-0002-3588-8711; Constantin-Teodosiu, Dumitru/0000-0002-8448-5564	Medical Research Council [G0801271]; U.S. National Institutes of Health [AR-054342]; University of Nottingham; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054342] Funding Source: NIH RePORTER; Medical Research Council [MR/K00414X/1] Funding Source: researchfish; MRC [G0801271, MR/K00414X/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Nottingham; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by Medical Research Council Grant G0801271 and U.S. National Institutes of Health Grant AR-054342. C.G. is in receipt of a University of Nottingham doctoral training fellowship. Mitochondrial ATP production measurements were funded by the University of Nottingham.	ALP PR, 1976, BIOCHEM J, V154, P689, DOI 10.1042/bj1540689; BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141; BRENNER S, 1974, GENETICS, V77, P71; Crossland H, 2013, AM J PHYSIOL-ENDOC M, V305, pE183, DOI 10.1152/ajpendo.00541.2012; de Boer MD, 2007, J PHYSIOL-LONDON, V585, P241, DOI 10.1113/jphysiol.2007.142828; Ermolova N, 2011, HUM MOL GENET, V20, P3331, DOI 10.1093/hmg/ddr239; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; Etheridge T, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002471; Fisher K, 2013, BIOL OPEN, V2, P1354, DOI 10.1242/bio.20136007; Flicek P, 2013, NUCLEIC ACIDS RES, V41, pD48, DOI 10.1093/nar/gks1236; Fluck M, 1999, AM J PHYSIOL-CELL PH, V277, pC152, DOI 10.1152/ajpcell.1999.277.1.C152; FRANCIS GR, 1985, J CELL BIOL, V101, P1532, DOI 10.1083/jcb.101.4.1532; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Geiger B, 2002, CELL, V110, P139, DOI 10.1016/S0092-8674(02)00831-0; Ghanbari A, 2012, J MICROMECH MICROENG, V22, DOI 10.1088/0960-1317/22/9/095009; Harris TW, 2010, NUCLEIC ACIDS RES, V38, pD463, DOI 10.1093/nar/gkp952; Hauerslev S, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-43; Hobert O, 1999, J CELL BIOL, V144, P45, DOI 10.1083/jcb.144.1.45; Hoehndorf R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060847; Johari S, 2013, LAB CHIP, V13, P1699, DOI 10.1039/c3lc41403e; Klossner S, 2009, EUR J APPL PHYSIOL, V106, P389, DOI 10.1007/s00421-009-1032-7; Koller A, 2005, ELECTROPHORESIS, V26, P2470, DOI 10.1002/elps.200500024; Konieczny P, 2008, J CELL BIOL, V181, P667, DOI 10.1083/jcb.200711058; Kramerova I, 2008, HUM MOL GENET, V17, P3271, DOI 10.1093/hmg/ddn223; Kramerova I, 2009, HUM MOL GENET, V18, P3194, DOI 10.1093/hmg/ddp257; Lebart MC, 2006, FEBS J, V273, P3415, DOI 10.1111/j.1742-4658.2006.05350.x; Lecroisey C, 2007, J MUSCLE RES CELL M, V28, P79, DOI 10.1007/s10974-007-9104-y; Lehmann S, 2012, GENES-BASEL, V3, P686, DOI 10.3390/genes3040686; Lehmann S, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-71; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Mackey AL, 2008, J APPL PHYSIOL, V105, P1620, DOI 10.1152/japplphysiol.90952.2008; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; Meissner B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019937; Meissner B, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000537; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; Moerman Donald G, 2006, WormBook, P1; Moulder GL, 2010, J MOL BIOL, V403, P516, DOI 10.1016/j.jmb.2010.08.055; Nahabedian JF, 2012, METHODS, V56, P95, DOI 10.1016/j.ymeth.2011.11.005; Ojima K, 2011, J MOL BIOL, V407, P439, DOI 10.1016/j.jmb.2011.01.057; Ojima K, 2010, J CLIN INVEST, V120, P2672, DOI 10.1172/JCI40658; Ono K, 2003, J CELL SCI, V116, P2073, DOI 10.1242/jcs.00421; Piekny AJ, 2000, GENETICS, V156, P1671; Plenefisch JD, 2000, DEVELOPMENT, V127, P1197; Rogalski TM, 2000, J CELL BIOL, V150, P253, DOI 10.1083/jcb.150.1.253; Rogalski TM, 2003, GENETICS, V163, P905; Shaye DD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020085; Shephard F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024686; Sparrow JC, 2009, NAT REV MOL CELL BIO, V10, P293, DOI 10.1038/nrm2634; Ugural AC, 2003, ADV STRENGTH APPL EL; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Wang HV, 2008, J CELL BIOL, V180, P1037, DOI 10.1083/jcb.200707175; Warner A, 2011, MOL BIOL CELL, V22, P2551, DOI 10.1091/mbc.E10-12-0941; Wibom R, 2002, ANAL BIOCHEM, V311, P139, DOI 10.1016/S0003-2697(02)00424-4; Xu XJ, 2007, EXP CELL RES, V313, P2465, DOI 10.1016/j.yexcr.2007.03.017; Zaidel-Bar R, 2007, NAT CELL BIOL, V9, P858, DOI 10.1038/ncb0807-858; Zaidel-Bar R, 2010, J CELL SCI, V123, P1385, DOI 10.1242/jcs.066183; Zdinak LA, 1997, J CELL BIOCHEM, V67, P143, DOI 10.1002/(SICI)1097-4644(19971001)67:1<143::AID-JCB15>3.3.CO;2-F	57	20	21	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1235	1246		10.1096/fj.14-259119	http://dx.doi.org/10.1096/fj.14-259119			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25491313	Green Published, hybrid			2022-12-28	WOS:000354115000012
J	Jaeger, C; Sandu, C; Malan, A; Mellac, K; Hicks, D; Felder-Schmittbuhl, MP				Jaeger, Catherine; Sandu, Cristina; Malan, Andre; Mellac, Katell; Hicks, David; Felder-Schmittbuhl, Marie-Paule			Circadian organization of the rodent retina involves strongly coupled, layer-specific oscillators	FASEB JOURNAL			English	Article						clock; circadian rhythms; bioluminescence; period	RAT RETINA; SUPRACHIASMATIC NUCLEUS; CLOCK PROTEIN; DOPAMINE; EXPRESSION; GENE; PHOTORECEPTORS; LOCALIZATION; RECEPTORS; RELEASE	Rhythmic physiology is central to retinal function and survival and adapts vision to daily light intensity changes. Mammalian retina rhythmically releases melatonin when cultured under constant conditions, and the occurrence of clock gene [e.g., Period(Per)] expression has been shown for most cellular layers. However, contribution of the distinct layers to genesis of circadian rhythms within the retina is still debated. To characterize their endogenous oscillatory capacity and their communication at the whole-tissue level, we used a vibratome-based method toisolate individual or paired retina cellular layers from the mPer2(Luc) mouse and Per1-luciferase (Per1-Luc) rat, and real-time recorded bioluminescence. We report that each layer of the mouse retina harbors a self-sustained oscillator whose period is significantly longer (similar to 26 hours) than in whole-retina explants (similar to 22.9 hours), indicating that the period is correlated with the degree of coupling. Accordingly, the maximal period (similar to 29 hours) is reached upon complete enzymatic dissociation of the retina. By using pharmacological approaches, we demonstrate that connection between retina oscillators involves gap junctions but only minor contribution from the main retina neuro-chemicals. Taken together with results from Per1-Luc rats, these data show that mammalian retina consists of a network of layer-specific oscillators whose period is determined by their connectivity.	[Jaeger, Catherine; Sandu, Cristina; Malan, Andre; Hicks, David; Felder-Schmittbuhl, Marie-Paule] Univ Strasbourg, Inst Cellular & Integrat Neurosci, Dept Neurobiol Rhythms, Natl Ctr Sci Res UPR3212, F-67084 Strasbourg, France; [Mellac, Katell] Univ Strasbourg, Unit Math & Comp Sci, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Felder-Schmittbuhl, MP (corresponding author), Univ Strasbourg, Inst Cellular & Integrat Neurosci, Dept Neurobiol Rhythms, UPR 3212,CNRS, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	feldermp@inci-cnrs.unistra.fr		Jaeger, Catherine/0000-0001-8519-8893	association Retina France; French Research and Education Ministry; Retina France; Fondation Berthe Fouassier; Neurex network (TriNeuron - Program Interreg IV Upper Rhine - European Regional Development Fund	association Retina France; French Research and Education Ministry; Retina France; Fondation Berthe Fouassier; Neurex network (TriNeuron - Program Interreg IV Upper Rhine - European Regional Development Fund	The authors thank Dr. Sophie Reibel, Dr. Dominique Sage, Aurore Senser, Laurence Huck, and Nicolas Lethenet from Chronobiotron Unite Mixte de Service 3415 (Strasbourg, France) for animal care. The authors are grateful to Dr. Michael Menaker for kindly providing the Per1-Luc rats. This work was supported by grants from the association Retina France and fellowships from the French Research and Education Ministry and Retina France (to C.J.) and from the Fondation Berthe Fouassier (to C.S.). Publication costs are supported by the Neurex network (TriNeuron - Program Interreg IV Upper Rhine - European Regional Development Fund; www.neurex.org.	Bloomfield SA, 2009, NAT REV NEUROSCI, V10, P495, DOI 10.1038/nrn2636; Buonfiglio DC, 2014, MOL VIS, V20, P742; Dkhissi-Benyahya O, 2013, CELL MOL LIFE SCI, V70, P3435, DOI 10.1007/s00018-013-1338-9; Dorenbos R, 2007, VISUAL NEUROSCI, V24, P573, DOI 10.1017/S0952523807070538; Etchegaray JP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010303; Feigenspan A, 1998, J NEUROSCI, V18, P6776; Fontaine V, 1998, J NEUROSCI, V18, P9662; Freeman GM, 2013, J NEUROPHYSIOL, V110, P103, DOI 10.1152/jn.00220.2013; Gallego M, 2007, NAT REV MOL CELL BIO, V8, P139, DOI 10.1038/nrm2106; Garbarino-Pico E, 2004, J NEUROSCI RES, V76, P642, DOI 10.1002/jnr.20126; Garcia-Fernandez JA, 2007, NEUROSCI LETT, V419, P55, DOI 10.1016/j.neulet.2007.03.054; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gustincich S, 1997, NEURON, V18, P723, DOI 10.1016/S0896-6273(00)80313-X; Iuvone PM, 2005, PROG RETIN EYE RES, V24, P433, DOI 10.1016/j.preteyeres.2005.01.003; Jeon CJ, 1998, J NEUROSCI, V18, P8936; Koinuma S, 2013, EUR J NEUROSCI, V38, P2832, DOI 10.1111/ejn.12308; Kojima S, 2011, J CELL SCI, V124, P311, DOI 10.1242/jcs.065771; LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063; LAVAIL MM, 1980, INVEST OPHTH VIS SCI, V19, P407; Liu AC, 2007, CELL, V129, P605, DOI 10.1016/j.cell.2007.02.047; Liu XQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050602; McMahon DG, 2014, PROG RETIN EYE RES, V39, P58, DOI 10.1016/j.preteyeres.2013.12.001; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Namihira M, 1999, NEUROSCI LETT, V271, P1, DOI 10.1016/S0304-3940(99)00407-3; Partch CL, 2014, TRENDS CELL BIOL, V24, P90, DOI 10.1016/j.tcb.2013.07.002; Peirson SN, 2006, BIOCHEM BIOPH RES CO, V351, P800, DOI 10.1016/j.bbrc.2006.10.118; Puopolo M, 2001, NEURON, V30, P211, DOI 10.1016/S0896-6273(01)00274-4; Renna JM, 2007, VISUAL NEUROSCI, V24, P503, DOI 10.1017/S0952523807070241; Ribelayga C, 2008, NEURON, V59, P790, DOI 10.1016/j.neuron.2008.07.017; Ribelayga C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011020; Ruan GX, 2006, P NATL ACAD SCI USA, V103, P9703, DOI 10.1073/pnas.0601940103; Ruan GX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038985; Ruan GX, 2008, PLOS BIOL, V6, P2248, DOI 10.1371/journal.pbio.0060249; Sandu C, 2011, EUR J NEUROSCI, V34, P507, DOI 10.1111/j.1460-9568.2011.07772.x; Schneider K, 2010, J NEUROCHEM, V115, P585, DOI 10.1111/j.1471-4159.2010.06953.x; TAMAI M, 1978, INVEST OPHTH VIS SCI, V17, P558; TERMAN JS, 1993, BRAIN RES, V605, P256; Thoreson WB, 1999, PROG RETIN EYE RES, V18, P765, DOI 10.1016/S1350-9462(98)00031-7; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Tosini G, 2007, FASEB J, V21, P3866, DOI 10.1096/fj.07-8371com; Welsh DK, 2010, ANNU REV PHYSIOL, V72, P551, DOI 10.1146/annurev-physiol-021909-135919; Witkovsky P, 2004, DOC OPHTHALMOL, V108, P17, DOI 10.1023/B:DOOP.0000019487.88486.0a; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Yujnovsky I, 2006, P NATL ACAD SCI USA, V103, P6386, DOI 10.1073/pnas.0510691103	45	30	31	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1493	1504		10.1096/fj.14-261214	http://dx.doi.org/10.1096/fj.14-261214			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25573753	Green Submitted			2022-12-28	WOS:000354115000034
J	Shih, DM; Yu, JM; Vergnes, L; Dali-Youcef, N; Champion, MD; Devarajan, A; Zhang, PX; Castellani, LW; Brindley, DN; Jamey, C; Auwerx, J; Reddy, ST; Ford, DA; Reue, K; Lusis, AJ				Shih, Diana M.; Yu, Janet M.; Vergnes, Laurent; Dali-Youcef, Nassim; Champion, Matthew D.; Devarajan, Asokan; Zhang, Peixiang; Castellani, Lawrence W.; Brindley, David N.; Jamey, Carole; Auwerx, Johan; Reddy, Srinivasa T.; Ford, David A.; Reue, Karen; Lusis, Aldons J.			PON3 knockout mice are susceptible to obesity, gallstone formation, and atherosclerosis	FASEB JOURNAL			English	Article						bile acid; cholesterol; hyperlipidemia; mitochondria; mitochondria-associated membrane	TANDEM MASS-SPECTROMETRY; HIGH-DENSITY LIPOPROTEIN; HUMAN SERUM PARAOXONASE; BILE-ACID METABOLISM; OXIDATIVE STRESS; ENDOPLASMIC-RETICULUM; DEFICIENT MICE; SCAVENGER RECEPTOR; BIOLOGICAL SAMPLES; HEPATIC STEATOSIS	We report the engineering and characterization of paraoxonase-3 knockout mice (Pon3KO). The mice were generally healthy but exhibited quantitative alterations in bile acid metabolism and a 37% increased body weight compared to the wild-type mice on a high fat diet. PON3 was enriched in the mitochondria-associated membrane fraction of hepatocytes. PON3 deficiency resulted in impaired mitochondrial respiration, increased mitochondrial superoxide levels, and increased hepatic expression of inflammatory genes. PON3 deficiency did not influence atherosclerosis development on an apolipoprotein E null hyperlipidemic background, but it did lead to a significant 60% increase in atherosclerotic lesion size in Pon3KO mice on the C57BL/6J background when fed a cholate-cholesterol diet. On the diet, the Pon3KO had significantly increased plasma intermediate-density lipoprotein/LDL cholesterol and bile acid levels. They also exhibited significantly elevated levels of hepatotoxicity markers in circulation, a 58% increase in gallstone weight, a 40% increase in hepatic cholesterol level, and increased mortality. Furthermore, Pon3KO mice exhibited decreased hepatic bile acid synthesis and decreased bile acid levels in the small intestine compared with wild-type mice. Our study suggests a role for PON3 in the metabolism of lipid and bile acid as well as protection against atherosclerosis, gallstone disease, and obesity.	[Shih, Diana M.; Castellani, Lawrence W.; Reddy, Srinivasa T.; Lusis, Aldons J.] Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA; [Yu, Janet M.; Lusis, Aldons J.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Vergnes, Laurent; Zhang, Peixiang; Lusis, Aldons J.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA; [Devarajan, Asokan; Reddy, Srinivasa T.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Reue, Karen] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; [Reue, Karen] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; [Dali-Youcef, Nassim] Illkirch & Hop Univ Strasbourg, IGBMC, Strasbourg, France; [Jamey, Carole] Univ Strasbourg, Toxicol Lab, Strasbourg, France; [Champion, Matthew D.; Ford, David A.] St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; [Champion, Matthew D.; Ford, David A.] St Louis Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO 63104 USA; [Brindley, David N.] Univ Alberta, Edmonton, AB, Canada; [Auwerx, Johan] Ecole Polytech Fed Lausanne, Sch Life Sci, Lab Integrat & Syst Physiol, Lausanne, Switzerland	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Saint Louis University; Saint Louis University; University of Alberta; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Shih, DM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, 10833 Conte Ave,A2-237 CHS, Los Angeles, CA 90095 USA.	dshih@mednet.ucla.edu	Auwerx, Johan/ABE-9307-2021; DALI-YOUCEF, Nassim/O-2549-2016; Ford, David/D-1819-2018	DALI-YOUCEF, Nassim/0000-0001-6958-1331; vergnes, laurent/0000-0002-8804-589X; Ford, David/0000-0002-0029-1560; Auwerx, Johan/0000-0002-5065-5393	U.S. National Institutes of Health (NIH) [HL030568-26A1, R01 HL074214, RR019232]; National Center for Research Resources [S10RR026744, NIH P01 HL028481, 2 RO1 HL71776]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026744, S10RR019232] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071776, P01HL028481, R01HL074214, P01HL030568] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Yu-Rong Xia, Yi-Shou Shi, Yonghong Meng, Judy Wu, Xu-Ping Wang, Zhiqiang Zhou, and Sarada Charugundla for excellent technical support. This study was supported by the following grants: U.S. National Institutes of Health (NIH) HL030568-26A1 (to A.J.L. and D.M.S.), and R01 HL074214 and RR019232 (to D.A.F.); National Center for Research Resources S10RR026744 and NIH P01 HL028481 (to K.R.), and 2 RO1 HL71776 (to S.T.R. and D.M.S.).	Akahoshi N, 2008, HUM MOL GENET, V17, P1994, DOI 10.1093/hmg/ddn097; Altenhofer S, 2010, J BIOL CHEM, V285, P24398, DOI 10.1074/jbc.M110.118604; Argmann C. A., 2006, CURRENT PROTOCOLS MO; Bhattacharyya T, 2008, JAMA-J AM MED ASSOC, V299, P1265, DOI 10.1001/jama.299.11.1265; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bowden JA, 2011, ANAL BIOCHEM, V417, P202, DOI 10.1016/j.ab.2011.06.015; Costa LG, 1999, CHEM-BIOL INTERACT, V119, P429, DOI 10.1016/S0009-2797(99)00055-1; Csaki LS, 2013, PROG LIPID RES, V52, P305, DOI 10.1016/j.plipres.2013.04.001; Davis RA, 2002, J LIPID RES, V43, P533; de Brito OM, 2010, EMBO J, V29, P2715, DOI 10.1038/emboj.2010.177; Devarajan A, 2011, ANTIOXID REDOX SIGN, V14, P341, DOI 10.1089/ars.2010.3430; DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078; Draganov DI, 2000, J BIOL CHEM, V275, P33435, DOI 10.1074/jbc.M004543200; Dwyer JR, 2012, P NATL ACAD SCI USA, V109, pE2486, DOI 10.1073/pnas.1205221109; FOLCH J, 1957, J BIOL CHEM, V226, P497; Han XL, 2001, ANAL BIOCHEM, V295, P88, DOI 10.1006/abio.2001.5178; Han XL, 2005, MASS SPECTROM REV, V24, P367, DOI 10.1002/mas.20023; HASSETT C, 1991, BIOCHEMISTRY-US, V30, P10141, DOI 10.1021/bi00106a010; Hayashi T, 2009, TRENDS CELL BIOL, V19, P81, DOI 10.1016/j.tcb.2008.12.002; Horke S, 2007, CIRCULATION, V115, P2055, DOI 10.1161/CIRCULATIONAHA.106.681700; Hung YC, 2006, FEBS LETT, V580, P849, DOI 10.1016/j.febslet.2005.12.102; Jarvik GP, 2000, ARTERIOSCL THROM VAS, V20, P2441, DOI 10.1161/01.ATV.20.11.2441; Kassel KM, 2011, AM J PATHOL, V179, P2278, DOI 10.1016/j.ajpath.2011.07.015; Kempster SL, 2012, AM J PHYSIOL-ENDOC M, V302, pE103, DOI 10.1152/ajpendo.00357.2011; Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705; Lim JX, 2013, FASEB J, V27, P4757, DOI 10.1096/fj.13-232702; Lu SY, 2010, DNA CELL BIOL, V29, P407, DOI 10.1089/dna.2010.1024; Lu XL, 2011, CELL STRESS CHAPERON, V16, P539, DOI 10.1007/s12192-011-0265-7; Mackness B, 2003, CIRCULATION, V107, P2775, DOI 10.1161/01.CIR.0000070954.00271.13; MACKNESS MI, 1988, BIOCHEM J, V250, P539, DOI 10.1042/bj2500539; Mardones P, 2001, J LIPID RES, V42, P170; Martin LJ, 2012, CIRC RES, V111, P516, DOI 10.1161/CIRCRESAHA.112.276667; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Ng CJ, 2006, J BIOL CHEM, V281, P29491, DOI 10.1074/jbc.M605379200; Ng CJ, 2001, J BIOL CHEM, V276, P44444, DOI 10.1074/jbc.M105660200; Ozer EA, 2005, FEMS MICROBIOL LETT, V253, P29, DOI 10.1016/j.femsle.2005.09.023; Precourt LP, 2011, ATHEROSCLEROSIS, V214, P20, DOI 10.1016/j.atherosclerosis.2010.08.076; Reddy ST, 2001, ARTERIOSCL THROM VAS, V21, P542, DOI 10.1161/01.ATV.21.4.542; Rogers GW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021746; Rosenblat M, 2003, ARTERIOSCL THROM VAS, V23, P468, DOI 10.1161/01.ATV.0000059385.95664.4D; Rothem L, 2007, FREE RADICAL BIO MED, V43, P730, DOI 10.1016/j.freeradbiomed.2007.05.003; Rozenberg O, 2003, FREE RADICAL BIO MED, V34, P774, DOI 10.1016/S0891-5849(02)01429-6; Sayin SI, 2013, CELL METAB, V17, P225, DOI 10.1016/j.cmet.2013.01.003; Schweikert EM, 2012, CELL DEATH DIFFER, V19, P1549, DOI 10.1038/cdd.2012.35; Shih DM, 2007, CIRC RES, V100, P1200, DOI 10.1161/01.RES.0000264499.48737.69; Shih DM, 2010, ADV EXP MED BIOL, V660, P73, DOI 10.1007/978-1-60761-350-3_8; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Sokol TJ, 2005, J PEDIATR GASTR NUTR, V41, P235, DOI 10.1097/01.MPG.0000170600.80640.88; Stoltz DA, 2009, J BIOL CHEM, V284, P35564, DOI 10.1074/jbc.M109.051706; Subramanian S, 2011, J LIPID RES, V52, P1626, DOI 10.1194/jlr.M016246; Teiber JF, 2008, INFECT IMMUN, V76, P2512, DOI 10.1128/IAI.01606-07; Thomas C, 2008, NAT REV DRUG DISCOV, V7, P678, DOI 10.1038/nrd2619; Tward A, 2002, CIRCULATION, V106, P484, DOI 10.1161/01.CIR.0000023623.87083.4F; Ventre J, 1997, DIABETES, V46, P1526, DOI 10.2337/diabetes.46.9.1526; Vergnes L, 2006, J LIPID RES, V47, P745, DOI 10.1194/jlr.M500553-JLR200; Vergnes L, 2003, J BIOL CHEM, V278, P42774, DOI 10.1074/jbc.M306022200; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Westrick RJ, 2010, P NATL ACAD SCI USA, V107, P16904, DOI 10.1073/pnas.1012050107; Wieckowski MR, 2009, NAT PROTOC, V4, P1582, DOI 10.1038/nprot.2009.151; Yang K, 2008, ADIPOSE TISSUE PROTO; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; Zhang P, 2008, J LIPID RES, V49, P1519, DOI 10.1194/jlr.M800061-JLR200	66	29	32	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1185	1197		10.1096/fj.14-260570	http://dx.doi.org/10.1096/fj.14-260570			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25477283	Green Published			2022-12-28	WOS:000354115000008
J	Hammer, A; Oladimeji, P; De Las Casas, LE; Diakonova, M				Hammer, Alan; Oladimeji, Peter; De Las Casas, Luis E.; Diakonova, Maria			Phosphorylation of tyrosine 285 of PAK1 facilitates beta PIX/GIT1 binding and adhesion turnover	FASEB JOURNAL			English	Article						JAK2 kinase; prolactin; cell spreading; breast cancer cells	BREAST-CANCER-CELLS; GROWTH-FACTOR-I; NUCLEOTIDE EXCHANGE FACTORS; HUMAN PROLACTIN RECEPTOR; PAXILLIN KINASE LINKER; P21-ACTIVATED KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; LD4 MOTIF; CYTOSKELETAL REORGANIZATION; INTEGRIN ALPHA-V-BETA-5	The p21-activated serine-threonine kinase (PAK1) regulates cell motility and adhesion. We have previously shown that the prolactin (PRL)-activated tyrosine kinase JAK2 phosphorylates PAK1 in vivo and in vitro and identified tyrosines 153, 201, and 285 in PAK1 as sites of JAK2 tyrosyl phosphorylation. Here, we further investigate the role of the tyrosyl phosphorylated PAK1 (pTyr-PAK1) in regulation of cell adhesion. We use human breast cancer T47D cell lines that stably overexpress PAK1 wild type or PAK1 Y3F mutant in which these 3 JAK2 phosphorylation sites were mutated to phenylalanine. We demonstrate that PRL/JAK2-dependent phosphorylation of these tyrosines promotes a motile phenotype in the cells upon adhesion, participates in regulation of cell adhesion on collagen IV, and is required for maximal PAK1 kinase activity. Downregulation of PAK1 abolishes the effect of PAK1 on cell adhesion. We show that the tyrosyl phosphorylation of PAK1 promotes PAK1 binding to beta-PAK1-interacting guanine-nucleotide exchange factor (beta PIX) and G protein-coupled receptor kinase-interacting target 1 (GIT1), phosphorylation of paxillin on Ser273, and formation and distribution of adhesion complexes. Using phosphospecific antibodies (Abs) directed to single phosphorylated tyrosines on PAK1, we identified Tyr285 as a site of PRL-dependent phosphorylation of PAK1 by JAK2. Furthermore, using PAK1 Y285F mutant, we provide evidence for a role of pTyr285 in cell adhesion, enhanced beta PIX/GIT1 binding, and adhesion turnover. Our immunohistochemistry analysis demonstrates that pTyr285-PAK1 may modulate PAK1 signaling during tumor progression.	[Hammer, Alan; Oladimeji, Peter; Diakonova, Maria] Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; [De Las Casas, Luis E.] Univ Toledo, Dept Pathol, Toledo, OH 43606 USA	University System of Ohio; University of Toledo; University System of Ohio; University of Toledo	Diakonova, M (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	mdiakon@utnet.utoledo.edu		Oladimeji, Peter/0000-0003-2050-5949	U.S. National Institutes of Health [R01-DK88127]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088127] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors are grateful to Dr. Rider (University of Toledo, Toledo, OH, USA) for making T47D cell lines stably expressing GFP, PAK1 WT, or PAK1 Y3F and for characterization of anti-phospho-Tyr-specific Abs. They also thank Dr. Garcia-Mata (University of Toledo) for providing cDNA encoding RFP-vinculin, help with video microscopy, and very helpful discussion; Dr. Webb (Wadsworth Center, New York State Department of Health, Albany, NY, USA) for providing cDNA encoding mCherry-paxillin (Vanderbilt University, Nashville, TN, USA); Dr. Martin Myers (University of Michigan, Ann Arbor, MI, USA) for providing cDNAs encoding JAK2 constructs; and the Michigan Diabetes Research and Training Center Hybridoma Core for the production of the ascites containing mouse alpha myc monoclonal Ab. This work was supported by the U.S. National Institutes of Health (Grant R01-DK88127) (to M.D.).	Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Aksamitiene E, 2011, CELL SIGNAL, V23, P1794, DOI 10.1016/j.cellsig.2011.06.014; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; BONNETERRE J, 1987, CANCER RES, V47, P4724; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Butler AA, 1997, J BIOL CHEM, V272, P27660, DOI 10.1074/jbc.272.44.27660; Canbay E, 1997, BIOCHEM J, V324, P231, DOI 10.1042/bj3240231; Carver KC, 2009, MOL CELL ENDOCRINOL, V307, P1, DOI 10.1016/j.mce.2009.03.014; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chen TC, 2012, INVEST OPHTH VIS SCI, V53, P1539, DOI 10.1167/iovs.11-9203; Clevenger CV, 2009, TRENDS ENDOCRIN MET, V20, P223, DOI 10.1016/j.tem.2009.03.001; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; de Oca PM, 2005, LAB INVEST, V85, P633, DOI 10.1038/labinvest.3700256; Deakin NO, 2008, J CELL SCI, V121, P2435, DOI 10.1242/jcs.018044; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Delorme-Walker VD, 2011, J CELL BIOL, V193, P1289, DOI 10.1083/jcb.201010059; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Diakonova M, 2002, MOL BIOL CELL, V13, P402, DOI 10.1091/mbc.01-05-0273; Dong JM, 2009, BIOCHEM J, V418, P173, DOI 10.1042/BJ20080170; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036; GINSBURG E, 1995, CANCER RES, V55, P2591; Hammer A, 2013, MOL ENDOCRINOL, V27, P455, DOI 10.1210/me.2012-1291; He H, 2004, CANCER BIOL THER, V3, P96, DOI 10.4161/cbt.3.1.643; Herrera R, 1998, J CELL SCI, V111, P1039; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kline JB, 2001, MOL ENDOCRINOL, V15, P832, DOI 10.1210/me.15.5.832; Kloek C, 2002, J BIOL CHEM, V277, P41547, DOI 10.1074/jbc.M205148200; LaPensee EW, 2010, ENDOCR-RELAT CANCER, V17, pR91, DOI 10.1677/ERC-09-0253; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Li QW, 2008, NEOPLASIA, V10, P314, DOI 10.1593/neo.07970; Li ZL, 2010, MOL BIOL CELL, V21, P3317, DOI 10.1091/mbc.E10-03-0245; Liby K, 2003, BREAST CANCER RES TR, V79, P241, DOI 10.1023/A:1023956223037; Liu FM, 2010, MOL CELL BIOL, V30, P1971, DOI 10.1128/MCB.01247-09; Loo TH, 2004, MOL CELL BIOL, V24, P3849, DOI 10.1128/MCB.24.9.3849-3859.2004; Manabe R, 2002, J CELL SCI, V115, P1497; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Maulik G, 2002, CLIN CANCER RES, V8, P620; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; Miller SL, 2007, ONCOGENE, V26, P4668, DOI 10.1038/sj.onc.1210264; Miller SL, 2005, MOL ENDOCRINOL, V19, P939, DOI 10.1210/me.2004-0443; Molli PR, 2009, ONCOGENE, V28, P2545, DOI 10.1038/onc.2009.119; Nayal A, 2006, J CELL BIOL, V173, P587, DOI 10.1083/jcb.200509075; Oakes SR, 2007, ONCOGENE, V26, P543, DOI 10.1038/sj.onc.1209838; Paris S, 2003, BIOCHEM J, V372, P391, DOI 10.1042/BJ20030047; Parrini Maria Carla, 2012, Cell Logist, V2, P78; Parrini MC, 2009, J BIOL CHEM, V284, P24133, DOI 10.1074/jbc.M109.015271; Peris L, 2006, J CELL BIOL, V174, P839, DOI 10.1083/jcb.200512058; Perks CC, 2004, BRIT J CANCER, V91, P305, DOI 10.1038/sj.bjc.6601947; Premont RT, 2004, CELL SIGNAL, V16, P1001, DOI 10.1016/j.cellsig.2004.02.002; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Rennefahrt UEE, 2007, J BIOL CHEM, V282, P15667, DOI 10.1074/jbc.M700253200; Rider L, 2007, J BIOL CHEM, V282, P30985, DOI 10.1074/jbc.M701794200; Rider L, 2013, MOL ENDOCRINOL, V27, P1048, DOI 10.1210/me.2012-1322; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Robertson SA, 2009, MOL CELL BIOL, V29, P3367, DOI 10.1128/MCB.00278-09; Ryu H, 2000, J IMMUNOL, V165, P2116, DOI 10.4049/jimmunol.165.4.2116; Sachdev S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-12; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schaller MD, 2001, BIOCHEM J, V360, P57, DOI 10.1042/0264-6021:3600057; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Schmalzigaug R, 2007, CELL SIGNAL, V19, P1733, DOI 10.1016/j.cellsig.2007.03.010; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SHIU RPC, 1984, CANCER RES, V44, P1178; Smith SD, 2008, J CELL SCI, V121, P3729, DOI 10.1242/jcs.027680; Stofega MR, 2004, MOL BIOL CELL, V15, P2965, DOI 10.1091/mbc.E03-08-0604; Tapia JA, 1999, BBA-MOL CELL RES, V1448, P486, DOI 10.1016/S0167-4889(98)00157-8; ten Klooster JP, 2006, J CELL BIOL, V172, P759, DOI 10.1083/jcb.200509096; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Tworoger SS, 2006, CANCER LETT, V243, P160, DOI 10.1016/j.canlet.2006.01.032; Vadlamudi RK, 2004, EMBO REP, V5, P154, DOI 10.1038/sj.embor.7400079; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vicente-Manzanares M, 2011, J CELL SCI, V124, P3923, DOI 10.1242/jcs.095653; Vicente-Manzanares M, 2009, J CELL SCI, V122, P199, DOI 10.1242/jcs.018564; Vonderhaar BK, 1998, PHARMACOL THERAPEUT, V79, P169, DOI 10.1016/S0163-7258(98)00017-5; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; Wagner KU, 2008, J MAMMARY GLAND BIOL, V13, P93, DOI 10.1007/s10911-008-9062-z; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Webb DJ, 2005, J CELL SCI, V118, P4925, DOI 10.1242/jcs.02563; Wells CM, 2010, J CELL SCI, V123, P1663, DOI 10.1242/jcs.055707; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Zaidel-Bar R, 2007, J CELL SCI, V120, P137, DOI 10.1242/jcs.03314; Zaidel-Bar R, 2010, J CELL SCI, V123, P1385, DOI 10.1242/jcs.066183; Zegers MMP, 2003, EMBO J, V22, P4155, DOI 10.1093/emboj/cdg398; Zhang HQ, 2002, J CELL BIOL, V158, P1287, DOI 10.1083/jcb.200207008; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zhao ZS, 2005, BIOCHEM J, V386, P201, DOI 10.1042/BJ20041638; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682	116	10	10	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					943	959		10.1096/fj.14-259366	http://dx.doi.org/10.1096/fj.14-259366			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25466889	Green Published			2022-12-28	WOS:000350633000020
J	Schmetterer, KG; Neunkirchner, A; Wojta-Stremayr, D; Leitner, J; Steinberger, P; Pickl, WF				Schmetterer, Klaus G.; Neunkirchner, Alina; Wojta-Stremayr, Daniela; Leitner, Judith; Steinberger, Peter; Pickl, Winfried F.			STAT3 governs hyporesponsiveness and granzyme B-dependent suppressive capacity in human CD4(+) T cells	FASEB JOURNAL			English	Article						regulatory T cells; Tr1 cells	REGULATORY-CELLS; IN-VIVO; TRANSCRIPTION FACTOR; DENDRITIC CELLS; UP-REGULATION; TR1 CELLS; ERYTHROCYTE RECEPTOR; EFFECTOR FUNCTION; CUTTING EDGE; C-MAF	Signal transducer and activator of transcription 3 (STAT3) integrates key signals of cell surface immune receptors, yet its precise role in cluster of differentiation (CD)4(+)T cells is not well-established. Current research has indicated T-helper cell 17-inducing roles but also tolerogenic roles. To address this issue, human T cells were transduced with the constitutively active STAT3 mutant STAT3C. Following stimulation, STAT3C(+) T cells upregulated IL-10 (4.1 +/- 0.5-fold; P < 0.001) and granzyme B (2.5 +/- 1.2, P < 0.05) secretion, combined with significantly reduced IFN-gamma (35 +/- 5%), IL-2 (57 +/- 4%), TNF-alpha (64 +/- 8%), and IL-13 (89 +/- 3%) secretion (P< 0.001). CD3/CD2- or CD3/CD28-activated STAT3C+ T cells revealed reduced proliferation (53.4 +/- 23.5% and 70.5 +/- 10.4%, respectively), which was independent of IL-10 production and significantly suppressed effector T cell proliferation by 68.7 +/- 10.6% and 65.9 +/- 2.6%, respectively (P < 0.001). Phenotypically, STAT3C-transgenic CD4(+) T cells resembled effector T cells regarding expression of T regulatory cell markers, but up-regulated granzyme B expression levels by 2.4-fold (P < 0.05). Suppression was cell contact dependent and mediated by granzyme B-induced cell death, but was independent of IL-10 and TGF-beta. Notably, peripheral blood CD4(+)CD45RA(-)lymphocyte activation gene-3(+)CD49(+) type 1 regulatory T cells revealed activation-induced hyperphosphorylation of STAT3. In agreement, pharmacological inhibition of STAT3 activation partially reverted hyporesponsiveness of peripheral type 1 regulatory T cells (increasing their division index from 0.46 +/- 0.11 to 0.89 +/- 0.04; P < 0.01). These observations indicate a clear-cut relation between activation of STAT3 and the acquisition of a tolerogenic program, which is also used by peripheral blood type 1 regulatory T cells.	[Schmetterer, Klaus G.; Neunkirchner, Alina; Wojta-Stremayr, Daniela; Leitner, Judith; Steinberger, Peter; Pickl, Winfried F.] Med Univ Vienna, Inst Immunol, Ctr Pathophysiol Infectiol & Immunol, A-1090 Vienna, Austria; [Schmetterer, Klaus G.; Neunkirchner, Alina; Wojta-Stremayr, Daniela; Pickl, Winfried F.] Christian Doppler Lab Immunomodulat, Vienna, Austria; [Schmetterer, Klaus G.] Med Univ Vienna, Dept Lab Med, Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Pickl, WF (corresponding author), Med Univ Vienna, Inst Immunol, Ctr Pathophysiol Infectiol & Immunol, Lazarettgasse 19, A-1090 Vienna, Austria.	winfried.pickl@meduniwien.ac.at		Pickl, Winfried F./0000-0003-0430-4952; Schmetterer, Klaus/0000-0001-9328-4871; Leitner, Judith/0000-0002-7156-1759; Steinberger, Peter/0000-0001-6848-4097	Austrian Science Fund [SFB-F4609]; Christian Doppler Society; Biomay AG	Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Society; Biomay AG	The authors thank Ms. Doris Trapin (Institute of Immunology, Vienna, Austria) for expert technical assistance and Dr. Richard Mulligan (Children's Hospital, Boston, MA, USA) for sharing the pMD. gagpol expression construct with us. This work was supported by Austrian Science Fund grant SFB-F4609, the Christian Doppler Society, and Biomay AG.	Aarts-Riemens T, 2008, EUR J IMMUNOL, V38, P1381, DOI 10.1002/eji.200737590; Allan SE, 2008, MOL THER, V16, P194, DOI 10.1038/sj.mt.6300341; Andolfi G, 2012, MOL THER, V20, P1778, DOI 10.1038/mt.2012.71; Apetoh L, 2010, NAT IMMUNOL, V11, P854, DOI 10.1038/ni.1912; Asquith B, 2006, P R SOC B, V273, P1165, DOI 10.1098/rspb.2005.3432; Awasthi A, 2007, NAT IMMUNOL, V8, P1380, DOI 10.1038/ni1541; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Bidere N, 2002, J BIOL CHEM, V277, P32339, DOI 10.1074/jbc.M205153200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chaudhry A, 2011, IMMUNITY, V34, P566, DOI 10.1016/j.immuni.2011.03.018; Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702; Che KF, 2012, MOL MED, V18, P1169, DOI 10.2119/molmed.2012.00103; Cheng FD, 2003, IMMUNITY, V19, P425, DOI 10.1016/S1074-7613(03)00232-2; Derdak SV, 2006, P NATL ACAD SCI USA, V103, P13144, DOI 10.1073/pnas.0602283103; Fitzgerald DC, 2007, NAT IMMUNOL, V8, P1372, DOI 10.1038/ni1540; Gagliani N, 2013, NAT MED, V19, P739, DOI 10.1038/nm.3179; Gondek DC, 2005, J IMMUNOL, V174, P1783, DOI 10.4049/jimmunol.174.4.1783; Gregori S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00030; Grossman WJ, 2004, BLOOD, V104, P2840, DOI 10.1182/blood-2004-03-0859; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Groux H, 1998, J IMMUNOL, V160, P3188; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; Herrmann A, 2010, CANCER RES, V70, P7455, DOI 10.1158/0008-5472.CAN-10-0736; HOLTER W, 1986, J EXP MED, V163, P654, DOI 10.1084/jem.163.3.654; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Iwasaki Y, 2013, EUR J IMMUNOL, V43, P1063, DOI 10.1002/eji.201242942; Kaebisch R, 2014, J IMMUNOL, V192, P316, DOI 10.4049/jimmunol.1302476; Kam CM, 2000, BBA-PROTEIN STRUCT M, V1477, P307, DOI 10.1016/S0167-4838(99)00282-4; Kwon MJ, 2012, J IMMUNOL, V188, P5887, DOI 10.4049/jimmunol.1102941; Leb VM, 2008, J ALLERGY CLIN IMMUN, V121, P64, DOI 10.1016/j.jaci.2007.10.006; Leb VM, 2009, J ALLERGY CLIN IMMUN, V124, P121, DOI 10.1016/j.jaci.2009.04.008; Leitner J, 2010, J IMMUNOL METHODS, V362, P131, DOI 10.1016/j.jim.2010.09.020; Levings MK, 2001, J IMMUNOL, V166, P5530, DOI 10.4049/jimmunol.166.9.5530; Levings MK, 2005, BLOOD, V105, P1162, DOI 10.1182/blood-2004-03-1211; Magnani CF, 2011, EUR J IMMUNOL, V41, P1652, DOI 10.1002/eji.201041120; Mathur AN, 2007, J IMMUNOL, V178, P4901, DOI 10.4049/jimmunol.178.8.4901; Matta BM, 2012, J IMMUNOL, V188, P5227, DOI 10.4049/jimmunol.1103382; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; Murugaiyan G, 2009, J IMMUNOL, V183, P2435, DOI 10.4049/jimmunol.0900568; Neunkirchner A, 2011, J IMMUNOL, V187, P4077, DOI 10.4049/jimmunol.1003220; Nguyen KD, 2008, EUR J IMMUNOL, V38, P2034, DOI 10.1002/eji.200738082; Oh HM, 2011, J BIOL CHEM, V286, P30888, DOI 10.1074/jbc.M111.253500; Ozcan E, 2008, J ALLERGY CLIN IMMUN, V122, P1054, DOI 10.1016/j.jaci.2008.10.023; Pallandre JR, 2007, J IMMUNOL, V179, P7593, DOI 10.4049/jimmunol.179.11.7593; Popow I, 2013, AM J TRANSPLANT, V13, P3103, DOI 10.1111/ajt.12514; Pot C, 2009, J IMMUNOL, V183, P797, DOI 10.4049/jimmunol.0901233; Schmetterer KG, 2011, J ALLERGY CLIN IMMUN, V127, P238, DOI 10.1016/j.jaci.2010.10.023; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Sharma V, 2006, J IMMUNOL, V176, P97, DOI 10.4049/jimmunol.176.1.97; Steinberger P, 2004, J IMMUNOL, V172, P2352, DOI 10.4049/jimmunol.172.4.2352; Stumhofer JS, 2007, NAT IMMUNOL, V8, P1363, DOI 10.1038/ni1537; Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957; Taylor A, 2009, MOL IMMUNOL, V46, P622, DOI 10.1016/j.molimm.2008.07.031; Veldman C, 2004, J IMMUNOL, V172, P6468, DOI 10.4049/jimmunol.172.10.6468; Wakkach A, 2001, J IMMUNOL, V167, P3107, DOI 10.4049/jimmunol.167.6.3107; Wang H, 2011, IMMUNOL LETT, V136, P21, DOI 10.1016/j.imlet.2010.11.007; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Williams LM, 2007, J BIOL CHEM, V282, P6965, DOI 10.1074/jbc.M609101200; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	62	14	14	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					759	771		10.1096/fj.14-257584	http://dx.doi.org/10.1096/fj.14-257584			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25398767	hybrid, Green Published			2022-12-28	WOS:000350633000004
J	Kapogiannis, D; Boxer, A; Schwartz, JB; Abner, EL; Biragyn, A; Masharani, U; Frassetto, L; Petersen, RC; Miller, BL; Goetzl, EJ				Kapogiannis, Dimitrios; Boxer, Adam; Schwartz, Janice B.; Abner, Erin L.; Biragyn, Arya; Masharani, Umesh; Frassetto, Lynda; Petersen, Ronald C.; Miller, Bruce L.; Goetzl, Edward J.			Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease	FASEB JOURNAL			English	Article						insulin resistance; dementia; senescence	SERINE/THREONINE PHOSPHORYLATION; TAU-HYPERPHOSPHORYLATION; GLUCOSE-METABOLISM; CLINICAL-TRIALS; ADAS-COG; IN-VIVO; RESISTANCE; IRS-1; MECHANISMS; SENSITIVITY	Insulin resistance causes diminished glucose uptake in similar regions of the brain in Alzheimer's disease (AD) and type 2 diabetes mellitus (DM2). Brain tissue studies suggested that insulin resistance is caused by low insulin receptor signaling attributable to its abnormal association with more phospho (P)-serine-type 1 insulin receptor substrate (IRS-1) and less P-tyrosine-IRS-1. Plasma exosomes enriched for neural sources by immunoabsorption were obtained once from 26 patients with AD, 20 patients with DM2, 16 patients with frontotemporal dementia (FTD), andmatched case control subjects. At 2 time points, they were obtained from 22 others when cognitively normal and 1 to 10 yr later when diagnosed with AD. Mean exosomal levels of extracted P-serine 312-IRS-1 and P-pantyrosine- IRS-1 by ELISA and the ratio of P-serine 312-IRS-1 to P-pan-tyrosine-IRS-1 (insulin resistance factor, R) for AD and DM2 and P-serine 312-IRS-1 and R for FTD were significantly different from those for case control subjects. The levels of R for AD were significantly higher than those for DM2 or FTD. Stepwise discriminant modeling showed correct classification of 100% of patients with AD, 97.5% of patients with DM2, and 84% of patients with FTD. In longitudinal studies of 22 patients with AD, exosomal levels of P-serine 312-IRS-1, P-pan-tyrosine-IRS-1, and R were significantly different 1 to 10 yr before and at the time of diagnosis comparedwith control subjects. Insulin resistance reflected in R values from this blood test is higher for patients with AD, DM2, and FTD than case control subjects; higher for patients with AD than patients with DM2 or FTD; and accurately predicts development of AD up to 10 yr prior to clinical onset.-Kapogiannis, D., Boxer, A., Schwartz, J. B., Abner, E. L., Biragyn, A., Masharani, U., Frassetto, L., Petersen, R. C., Miller, B. L., Goetzl, E. J. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease.	[Kapogiannis, Dimitrios; Biragyn, Arya; Goetzl, Edward J.] NIA, Intramural Res Program, Baltimore, MD 21224 USA; [Boxer, Adam; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA; [Schwartz, Janice B.; Goetzl, Edward J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Schwartz, Janice B.; Masharani, Umesh; Frassetto, Lynda; Goetzl, Edward J.] Jewish Home San Francisco, San Francisco, CA USA; [Abner, Erin L.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Petersen, Ronald C.] Mayo Clin, Rochester, MN USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Kentucky; Mayo Clinic	Goetzl, EJ (corresponding author), UCSF, Geriatr Res Ctr, 1719 Broderick St, San Francisco, CA 94115 USA.	edward.goetzl@ucsf.edu	Schwartz, Janice/K-6354-2019; frassetto, lynda/AAY-7834-2020; Kapogiannis, Dimitrios/AAW-4934-2020	Kapogiannis, Dimitrios/0000-0003-2181-3118	U.S.National Institutes of Health (NIH) NIA; United Kingdom Alzheimer's Disease Center [P30-AG028383]; NATIONAL INSTITUTE ON AGING [ZIAAG000975, P50AG023501, P30AG028383, R01AG038791] Funding Source: NIH RePORTER	U.S.National Institutes of Health (NIH) NIA; United Kingdom Alzheimer's Disease Center; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors are grateful to Lynn Kane (JHSF), Anna Karydas (UCSF MAC), Dana Swenson-Dravis and Matthew Miller (Mayo Clinic), Sonya Anderson (University of Kentucky), and Olga Carlson and Melissa Swaby Intramural Research Program of the National Institute on Aging (NIA) for organizing and distributing clinical materials and data and for providing access to analytical systems.They also thank Judith H.Goetzl for expert preparation of graphic illustrations.This studywas funded by the U.S.National Institutes of Health (NIH) NIA (to A.Bi., D.K.), United Kingdom Alzheimer's Disease Center grant P30-AG028383 (to E.L.A.), and an unrestricted supply grant for methodologic development from Nanosomix, Incorporated (to E.J.G.).D.K., J.B.S., E.L.A., A.Bi., U.M., L.F., R.C.P., and B.L.M.declare no potential conflicts of interest. E.J.G. has filed a provisional application with the U.S. Patent Office for the methodology described in this report; Nanosomix, Incorporated, supports the research but provides no salary, expense reimbursement, or fees and does not influence the processes of research or publication. A. B. reports grants from the NIH/NIA; grants from Tau Research Consortium; grants from Corticobasal Degeneration Solutions; grants, personal fees, and nonfinancial support from Archer Biosciences; grants from Allon Therapeutics; personal fees from Acetylon; personal fees from Ipierian; grants from Genentech; grants from Bristol-Myers Squibb; grants from TauRx; grants from Alzheimer's Association; grants from Bluefield Project to Cure FTD; grants from Association for Frontotemporal Degeneration; grants from Alzheimer's Drug Discovery Foundation; grants from EnVivo; grants from C2N Diagnostics; grants from Pfizer; grants from Eli Lilly for support outside the submitted work.	Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Amoui M, 2001, J ENDOCRINOL, V171, P153, DOI 10.1677/joe.0.1710153; Baker LD, 2011, ARCH NEUROL-CHICAGO, V68, P51, DOI 10.1001/archneurol.2010.225; Bosco D, 2011, J CELL MOL MED, V15, P1807, DOI 10.1111/j.1582-4934.2011.01318.x; Cano SJ, 2010, J NEUROL NEUROSUR PS, V81, P1363, DOI 10.1136/jnnp.2009.204008; Carlson CJ, 2004, BIOCHEM BIOPH RES CO, V316, P533, DOI 10.1016/j.bbrc.2004.02.082; Cersosimo E, 2006, DIABETES-METAB RES, V22, P423, DOI 10.1002/dmrr.634; Copps KD, 2012, DIABETOLOGIA, V55, P2565, DOI 10.1007/s00125-012-2644-8; Craft S, 2004, LANCET NEUROL, V3, P169, DOI 10.1016/S1474-4422(04)00681-7; Crane PK, 2013, NEW ENGL J MED, V369, P540, DOI [10.1056/NEJMoa1215740, 10.1056/NEJMc1311765]; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; Duarte Ana I, 2012, J Aging Res, V2012, P384017, DOI 10.1155/2012/384017; Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Fiandaca M. S., ALZHEIMERS DEMENT, DOI [10.1016/j.jalz.2014.06.008, DOI 10.1016/J.JALZ.2014.06.008]; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; Gorno-Tempini M. L., NEUROLOGY, V76, P1006; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Hancer NJ, 2014, J BIOL CHEM, V289, P12467, DOI 10.1074/jbc.M114.554162; Herschkovitz A, 2007, J BIOL CHEM, V282, P18018, DOI 10.1074/jbc.M610949200; Irizarry MC, 2008, J ALZHEIMERS DIS, V14, P301; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Moloney AM, 2010, NEUROBIOL AGING, V31, P224, DOI 10.1016/j.neurobiolaging.2008.04.002; Neumann KF, 2008, CURR ALZHEIMER RES, V5, P438, DOI 10.2174/156720508785908919; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Planel E, 2007, J NEUROSCI, V27, P13635, DOI 10.1523/JNEUROSCI.3949-07.2007; Qiu CX, 2014, ANN NEUROL, V75, P138, DOI 10.1002/ana.24063; Rascovsky K, 2011, BRAIN, V134, P2456, DOI 10.1093/brain/awr179; Samuel VT, 2012, CELL, V148, P852, DOI 10.1016/j.cell.2012.02.017; Schioth HB, 2012, MOL NEUROBIOL, V46, P4, DOI 10.1007/s12035-011-8229-6; Schrijvers EMC, 2010, NEUROLOGY, V75, P1982, DOI 10.1212/WNL.0b013e3181ffe4f6; Schubert M, 2004, P NATL ACAD SCI USA, V101, P3100, DOI 10.1073/pnas.0308724101; Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Talbot K, 2012, J CLIN INVEST, V122, P1316, DOI 10.1172/JCI59903; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; Yi ZP, 2007, DIABETES, V56, P1508, DOI 10.2337/db06-1355; Zhao WQ, 2009, J BIOL CHEM, V284, P18742, DOI 10.1074/jbc.M109.011015	39	219	224	0	50	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					589	596		10.1096/fj.14-262048	http://dx.doi.org/10.1096/fj.14-262048			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25342129	Green Published			2022-12-28	WOS:000349370400021
J	Lescale, C; Schenten, V; Djeghloul, D; Bennabi, M; Gaignier, F; Vandamme, K; Strazielle, C; Kuzniak, I; Petite, H; Dosquet, C; Frippiat, JP; Goodhardt, M				Lescale, Chloe; Schenten, Veronique; Djeghloul, Dounia; Bennabi, Meriem; Gaignier, Fanny; Vandamme, Katleen; Strazielle, Catherine; Kuzniak, Isabelle; Petite, Herve; Dosquet, Christine; Frippiat, Jean-Pol; Goodhardt, Michele			Hind limb unloading, a model of spaceflight conditions, leads to decreased B lymphopoiesis similar to aging	FASEB JOURNAL			English	Article						bone remodeling; B-cell differentiation; gravity; immunosenescence	HEMATOPOIETIC STEM-CELLS; AMPHIBIAN PLEURODELES-WALTL; MOUSE BONE-MARROW; IMMUNE-SYSTEM; LYMPHOID PROGENITORS; SUSPENDED MICE; TRANSCRIPTION; EXPRESSION; LINEAGE; NICHE	Within the bone marrow, the endosteal niche plays a crucial role in B-cell differentiation. Because spaceflight is associated with osteoporosis, we investigated whether changes in bone microstructure induced by a ground-based model of spaceflight, hind limb unloading (HU), could affect B lymphopoiesis. To this end, we analyzed both bone parameters and the frequency of early hematopoietic precursors and cells of theBlineage after 3, 6, 13, and 21 d of HU. We found that limb disuse leads to a decrease in both bone microstructure and the frequency of B-cell progenitors in the bone marrow. Although multi-potent hematopoietic progenitors were not affected by HU, a decrease in B lymphopoiesis was observed as of the common lymphoid progenitor (CLP) stage with a major block at the progenitor B (pro-B) to precursor B (pre-B) cell transition (5-to 10-fold decrease). Themodifications in B lymphopoiesis were similar to those observed in aged mice and, as with aging, decreased B-cell generation in HU mice was associated with reduced expression of B-cell transcription factors, early B-cell factor (EBF) and Pax5, and an alteration in STAT5-mediated IL-7 signaling. These findings demonstrate that mechanical unloading of hind limbs results in a decrease in early B-cell differentiation resembling age-related modifications in B lymphopoiesis.	[Lescale, Chloe; Djeghloul, Dounia; Bennabi, Meriem; Kuzniak, Isabelle; Dosquet, Christine; Goodhardt, Michele] Univ Paris 07, Inst Univ Hematol, Paris, France; [Lescale, Chloe; Djeghloul, Dounia; Bennabi, Meriem; Kuzniak, Isabelle; Dosquet, Christine; Goodhardt, Michele] INSERM, UMRS 940, Paris, France; [Schenten, Veronique; Gaignier, Fanny; Strazielle, Catherine; Frippiat, Jean-Pol] Lorraine Univ, Stress Immun Pathogens Lab, EA7300, Vandoeuvre Les Nancy, France; [Vandamme, Katleen; Petite, Herve] Fac Med Lariboisiere, UMR CNRS 7052, Paris, France	UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); UDICE-French Research Universities; Universite Paris Cite	Goodhardt, M (corresponding author), Hop St Louis, IUH, UMRS1126, Paris, France.	jean-pol.frippiat@univ-lorraine.fr; michele.goodhardt@univ-paris-diderot.fr	Petite, Herve/E-3478-2016	Petite, Herve/0000-0003-1694-5060; Lescale, Chloe/0000-0003-0622-1149; Frippiat, Jean-Pol/0000-0002-4027-6269; GOODHARDT, Michele/0000-0003-2722-3514	Institut National de la Sante et de la Recherche Medicale; Fondation pour la Recherche Medicale; Centre National d'Etudes Spatiales (CNES); Agence Nationale de la Recherche [ANR NT09-632666]; Universite and the Region de Lorraine; CNES postdoctoral fellowship; CNES; Region Lorraine doctoral fellowship; FWO-Vlaanderen (Fund for Scientific Research-Flanders, Belgium) postdoctoral fellowship	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Centre National d'Etudes Spatiales (CNES)(Centre National D'etudes Spatiales); Agence Nationale de la Recherche(French National Research Agency (ANR)); Universite and the Region de Lorraine(Region Grand-Est); CNES postdoctoral fellowship; CNES(Centre National D'etudes Spatiales); Region Lorraine doctoral fellowship(Region Grand-Est); FWO-Vlaanderen (Fund for Scientific Research-Flanders, Belgium) postdoctoral fellowship(FWO)	The authors thank Dr. L. Vico and Dr. M.-H. Lafage-Proust, Saint-Etienne, France, for advice concerning the HU protocol and for providing HU cages. They also thank the X-ray platform IMOSAR. This work was supported by grants from the Institut National de la Sante et de la Recherche Medicale, the Fondation pour la Recherche Medicale, the Centre National d'Etudes Spatiales (CNES), the Agence Nationale de la Recherche (ANR NT09-632666), the Universite and the Region de Lorraine. V.S. was supported by a CNES postdoctoral fellowship, F.G. was supported by a CNES and Region Lorraine doctoral fellowship, and K.V. was supported by a FWO-Vlaanderen (Fund for Scientific Research-Flanders, Belgium) postdoctoral fellowship.	Adolfsson J, 2001, IMMUNITY, V15, P659, DOI 10.1016/S1074-7613(01)00220-5; Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; Ahdjoudj S, 2002, J BONE MINER RES, V17, P668, DOI 10.1359/jbmr.2002.17.4.668; Allman D, 2005, IMMUNOL REV, V205, P18, DOI 10.1111/j.0105-2896.2005.00269.x; Amblard D, 2003, J BONE MINER RES, V18, P561, DOI 10.1359/jbmr.2003.18.3.561; ARMSTRONG JW, 1995, J APPL PHYSIOL, V78, P968, DOI 10.1152/jappl.1995.78.3.968; Baek K, 2008, J APPL PHYSIOL, V104, P1086, DOI 10.1152/japplphysiol.01209.2007; Bascove M, 2011, FASEB J, V25, P2947, DOI 10.1096/fj.11-185215; Bascove M, 2009, FASEB J, V23, P1607, DOI 10.1096/fj.08-121327; Boxio R, 2005, J APPL PHYSIOL, V98, P905, DOI 10.1152/japplphysiol.00957.2004; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cancro MP, 2009, TRENDS IMMUNOL, V30, P313, DOI 10.1016/j.it.2009.04.005; Clark MR, 2014, NAT REV IMMUNOL, V14, P69, DOI 10.1038/nri3570; Davis TA, 1996, J LEUKOCYTE BIOL, V60, P69, DOI 10.1002/jlb.60.1.69; Dias S, 2005, J EXP MED, V201, P971, DOI 10.1084/jem.20042393; Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885; DUNN CDR, 1985, AVIAT SPACE ENVIR MD, V56, P419; Ergen AV, 2012, BLOOD, V119, P2500, DOI 10.1182/blood-2011-11-391730; Frippiat JP, 2013, MOL IMMUNOL, V56, P434, DOI 10.1016/j.molimm.2013.06.011; Gaignier F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092664; GARVY BA, 1993, IMMUNOLOGY, V80, P587; Geiger H, 2013, NAT REV IMMUNOL, V13, P376, DOI 10.1038/nri3433; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Gueguinou N, 2009, J LEUKOCYTE BIOL, V86, P1027, DOI 10.1189/jlb.0309167; Hagman J, 2005, TRENDS IMMUNOL, V26, P455, DOI 10.1016/j.it.2005.07.001; Huin-Schohn C, 2013, FASEB J, V27, P333, DOI 10.1096/fj.12-217547; Ichiki AT, 1996, J LEUKOCYTE BIOL, V60, P37, DOI 10.1002/jlb.60.1.37; KIMZEY SL, 1976, AVIAT SPACE ENVIR MD, V47, P383; Kohler A, 2009, BLOOD, V114, P290, DOI 10.1182/blood-2008-12-195644; Kollet O, 2013, LEUKEMIA, V27, P2006, DOI 10.1038/leu.2013.154; Kollet Orit, 2012, Inflammation & Allergy Drug Targets, V11, P170; KONSTANTINOVA IV, 1993, J LEUKOCYTE BIOL, V54, P189, DOI 10.1002/jlb.54.3.189; Lai AY, 2005, J IMMUNOL, V175, P5016, DOI 10.4049/jimmunol.175.8.5016; Lescale C, 2010, AGING CELL, V9, P410, DOI 10.1111/j.1474-9726.2010.00566.x; Lew PS, 2009, CAN J PHYSIOL PHARM, V87, P839, DOI 10.1139/Y09-074; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Malin S, 2010, CURR OPIN IMMUNOL, V22, P168, DOI 10.1016/j.coi.2010.02.004; Mercier FE, 2012, NAT REV IMMUNOL, V12, P49, DOI 10.1038/nri3132; Miller JP, 2003, J IMMUNOL, V171, P2326, DOI 10.4049/jimmunol.171.5.2326; Momken I, 2011, FASEB J, V25, P3646, DOI 10.1096/fj.10-177295; Morey-Holton E, 2005, ADV SPACE B, V10, P7, DOI 10.1016/S1569-2574(05)10002-1; Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984; Mourcin F, 2011, BLOOD, V117, P6552, DOI 10.1182/blood-2010-12-323113; Nechanitzky R, 2013, NAT IMMUNOL, V14, P867, DOI 10.1038/ni.2641; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Ortega MT, 2009, J APPL PHYSIOL, V106, P548, DOI 10.1152/japplphysiol.91138.2008; Rothenberg EV, 2014, ANNU REV IMMUNOL, V32, P283, DOI 10.1146/annurev-immunol-032712-100024; Sakata T, 1999, J BONE MINER RES, V14, P1596, DOI 10.1359/jbmr.1999.14.9.1596; Saxena R, 2011, J BONE MINER METAB, V29, P111, DOI 10.1007/s00774-010-0201-4; Sievanen H, 2010, ARCH BIOCHEM BIOPHYS, V503, P146, DOI 10.1016/j.abb.2010.07.008; Sonnenfeld G, 2003, ADV SPACE RES-SERIES, V32, P1473, DOI 10.1016/S0273-1177(03)90383-8; Sonnenfeld G, 1992, J APPL PHYSIOL, V73, p191S; Sonnenfeld Gerald, 2005, Gravit Space Biol Bull, V18, P31; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; VACEK A, 1991, FOLIA BIOL-PRAGUE, V37, P35; Vernikos J, 2010, GERONTOLOGY, V56, P157, DOI 10.1159/000252852; Wang KX, 2007, P NATL ACAD SCI USA, V104, P14777, DOI 10.1073/pnas.0703236104; Wang LD, 2011, NAT REV MOL CELL BIO, V12, P643, DOI 10.1038/nrm3184; Weiskopf D, 2009, TRANSPL INT, V22, P1041, DOI 10.1111/j.1432-2277.2009.00927.x; Xie YC, 2009, NATURE, V457, P97, DOI 10.1038/nature07639	60	40	44	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					455	463		10.1096/fj.14-259770	http://dx.doi.org/10.1096/fj.14-259770			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25376832				2022-12-28	WOS:000349370400011
J	Aijima, R; Wang, B; Takao, T; Mihara, H; Kashio, M; Ohsaki, Y; Zhang, JQ; Mizuno, A; Suzuki, M; Yamashita, Y; Masuko, S; Goto, M; Tominaga, M; Kido, MA				Aijima, Reona; Wang, Bing; Takao, Tomoka; Mihara, Hiroshi; Kashio, Makiko; Ohsaki, Yasuyoshi; Zhang, Jing-Qi; Mizuno, Atsuko; Suzuki, Makoto; Yamashita, Yoshio; Masuko, Sadahiko; Goto, Masaaki; Tominaga, Makoto; Kido, Mizuho A.			The thermosensitive TRPV3 channel contributes to rapid wound healing in oral epithelia	FASEB JOURNAL			English	Article						ambient temperature; oral mucosa; wound repair	GROWTH-FACTOR-RECEPTOR; OLMSTED SYNDROME; CALCIUM INFLUX; EGF RECEPTOR; ION CHANNELS; ATP RELEASE; SKIN; KERATINOCYTES; ACTIVATION; CELLS	The oral cavity provides an entrance to the alimentary tract to serve as a protective barrier against harmful environmental stimuli. The oral mucosa is susceptible to injury because of its location; nonetheless, it has faster wound healing than the skin and less scar formation. However, the molecular pathways regulating this wound healing are unclear. Here, we show that transient receptor potential vanilloid 3 (TRPV3), a thermosensitive Ca2+-permeable channel, is more highly expressed in murine oral epithelia than in the skin by quantitative RT-PCR. We found that temperatures above 33 degrees C activated TRPV3 and promoted oral epithelial cell proliferation. The proliferation rate in the oral epithelia of TRPV3 knockout (TRPV3KO) mice was less than that of wild-type (WT) mice. We investigated the contribution of TRPV3 to wound healing using a molar tooth extraction model and found that oral wound closure was delayed in TRPV3KO mice compared with that in WT mice. TRPV3 mRNA was up-regulated in wounded tissues, suggesting that TRPV3 may contribute to oral wound repair. We identified TRPV3 as an essential receptor in heat-induced oral epithelia proliferation and wound healing. Our findings suggest that TRPV3 activation could be a potential therapeutic target for wound healing in skin and oral mucosa.	[Aijima, Reona; Wang, Bing; Takao, Tomoka; Ohsaki, Yasuyoshi; Zhang, Jing-Qi; Kido, Mizuho A.] Kyushu Univ, Grad Sch Dent Sci, Dept Mol Cell Biol & Oral Anat, Fukuoka 8128582, Japan; [Aijima, Reona; Yamashita, Yoshio; Goto, Masaaki] Saga Univ, Fac Med, Dept Oral & Maxillofacial Surg, Saga 840, Japan; [Aijima, Reona; Masuko, Sadahiko] Saga Univ, Fac Med, Dept Anat & Physiol, Div Histol & Neuroanat, Saga 840, Japan; [Mihara, Hiroshi; Kashio, Makiko; Tominaga, Makoto] Natl Inst Nat Sci, Natl Inst Physiol Sci, Okazaki Inst Integrat Biosci, Div Cell Signaling, Okazaki, Aichi 4448585, Japan; [Mizuno, Atsuko; Suzuki, Makoto] Jichi Med Univ, Dept Pharmacol, Shimotsuke, Japan	Kyushu University; Saga University; Saga University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Okazaki Institute for Integrative Bioscience (OIIB); Jichi Medical University	Kido, MA (corresponding author), Kyushu Univ, Grad Sch Dent Sci, Dept Mol Cell Biol & Oral Anat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	kido@dent.kyushu-u.ac.jp	Takao, Tomoka/K-1568-2015; Mihara, Hiroshi/AAE-3961-2021	Takao, Tomoka/0000-0002-6519-2301; Kashio, Makiko/0000-0001-6404-2339	Grants-in-Aid for Scientific Research [25462562] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Angus-Hill ML, 2011, P NATL ACAD SCI USA, V108, P4914, DOI 10.1073/pnas.1102300108; Block ER, 2004, J BIOL CHEM, V279, P24307, DOI 10.1074/jbc.M401058200; Cals-Grierson MM, 2004, NITRIC OXIDE-BIOL CH, V10, P179, DOI 10.1016/j.niox.2004.04.005; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chen L, 2012, J DENT RES, V91, P871, DOI 10.1177/0022034512454435; Cheng XP, 2010, CELL, V141, P331, DOI 10.1016/j.cell.2010.03.013; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Cordeiro JV, 2013, NAT REV MOL CELL BIO, V14, P249, DOI 10.1038/nrm3541; Damann N, 2008, CURR BIOL, V18, pR880, DOI 10.1016/j.cub.2008.07.063; Danso-Abeam D, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-79; Denning MF, 2000, EXP DERMATOL, V9, P192, DOI 10.1034/j.1600-0625.2000.009003192.x; Gonzales CB, 2014, ORAL ONCOL, V50, P437, DOI 10.1016/j.oraloncology.2013.12.023; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Horiuchi K, 2007, MOL BIOL CELL, V18, P176, DOI 10.1091/mbc.E06-01-0014; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Huang SM, 2008, J NEUROSCI, V28, P13727, DOI 10.1523/JNEUROSCI.5741-07.2008; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kashio M, 2012, P NATL ACAD SCI USA, V109, P6745, DOI 10.1073/pnas.1114193109; Kido MA, 2003, J DENT RES, V82, P393, DOI 10.1177/154405910308200513; Lai-Cheong JE, 2012, BRIT J DERMATOL, V167, P440, DOI 10.1111/j.1365-2133.2012.11115.x; Lansdown ABG, 2002, WOUND REPAIR REGEN, V10, P271, DOI 10.1046/j.1524-475X.2002.10502.x; Lin ZM, 2012, AM J HUM GENET, V90, P558, DOI 10.1016/j.ajhg.2012.02.006; Mandadi S, 2009, PFLUG ARCH EUR J PHY, V458, P1093, DOI 10.1007/s00424-009-0703-x; Mashu S., 2004, PAIN RES, V19, P123; Mazie AR, 2006, J CELL SCI, V119, P1645, DOI 10.1242/jcs.02858; Mihara H, 2011, J PHYSIOL-LONDON, V589, P3471, DOI 10.1113/jphysiol.2011.207829; Miyamoto T, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1371; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Moqrich A, 2005, SCIENCE, V307, P1468, DOI 10.1126/science.1108609; Moran MM, 2004, CURR OPIN NEUROBIOL, V14, P362, DOI 10.1016/j.conb.2004.05.003; Nilius B, 2014, J PHYSIOL-LONDON, V592, P295, DOI 10.1113/jphysiol.2013.255968; Oudhoff MJ, 2009, J DENT RES, V88, P846, DOI 10.1177/0022034509342951; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; RATH EM, 1990, J ORAL MAXIL SURG, V48, P1181, DOI 10.1016/0278-2391(90)90534-9; Repertinger SK, 2004, J INVEST DERMATOL, V123, P982, DOI 10.1111/j.0022-202X.2004.23478.x; SCIUBBA JJ, 1978, J ORAL PATHOL MED, V7, P214, DOI 10.1111/j.1600-0714.1978.tb01596.x; Shimohira D, 2009, HISTOCHEM CELL BIOL, V132, P423, DOI 10.1007/s00418-009-0616-y; Steinhoff M, 2009, J INVEST DERMATOL, V129, P531, DOI 10.1038/jid.2008.440; STOSCHECK CM, 1992, J INVEST DERMATOL, V99, P645, DOI 10.1111/1523-1747.ep12668143; Szpaderska AM, 2003, J DENT RES, V82, P621, DOI 10.1177/154405910308200810; Takayama Y, 2014, FASEB J, V28, P2238, DOI 10.1096/fj.13-243436; TIMPL R, 1979, J BIOL CHEM, V254, P9933; Ueda T, 2009, BIOCHEM BIOPH RES CO, V383, P130, DOI 10.1016/j.bbrc.2009.03.143; Wang B, 2011, J DENT RES, V90, P163, DOI 10.1177/0022034510385459; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Xiao R, 2008, J BIOL CHEM, V283, P6162, DOI 10.1074/jbc.M706535200; Xu HX, 2006, NAT NEUROSCI, V9, P628, DOI 10.1038/nn1692; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; Xu SH, 2011, CURR BIOL, V21, P1960, DOI 10.1016/j.cub.2011.10.050; Yamada T, 2010, EXP EYE RES, V90, P121, DOI 10.1016/j.exer.2009.09.020; Yin J, 2007, J CELL SCI, V120, P815, DOI 10.1242/jcs.03389	53	51	52	3	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					182	192		10.1096/fj.14-251314	http://dx.doi.org/10.1096/fj.14-251314			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25351988				2022-12-28	WOS:000347378600018
J	Csoka, B; Nemeth, ZH; Toro, G; Koscso, B; Kokai, E; Robson, SC; Enjyoji, K; Rolandelli, RH; Erdelyi, K; Pacher, P; Hasko, G				Csoka, Balazs; Nemeth, Zoltan H.; Toero, Gabor; Koscso, Balazs; Kokai, Endre; Robson, Simon C.; Enjyoji, Keiichi; Rolandelli, Rolando H.; Erdelyi, Katalin; Pacher, Pal; Hasko, Gyoergy			CD39 improves survival in microbial sepsis by attenuating systemic inflammation	FASEB JOURNAL			English	Article						interleukin; TNF; MIP; lung; kidney	ISCHEMIA-REPERFUSION INJURY; A(2B) ADENOSINE RECEPTORS; MURINE SEPTIC PERITONITIS; ECTO-5'-NUCLEOTIDASE CD73; POLYMICROBIAL SEPSIS; TRIPHOSPHATE DIPHOSPHOHYDROLASE-1; DECREASES MORTALITY; HEPATIC-INJURY; MACROPHAGES; DYSFUNCTION	Sepsis remains the leading cause of morbidity and mortality in critically ill patients. Excessive inflammation is a major cause of organ failure and mortality in sepsis. Ectonucleoside triphosphate diphosphohydrolase 1, ENTPDase1 (CD39) is a cell surface nucleotide-metabolizing enzyme, which degrades the extracellular purines ATP and ADP, thereby regulating purinergic receptor signaling. Although the role of purinergic receptor signaling in regulating inflammation and sepsis has been addressed previously, the role of CD39 in regulating the host's response to sepsis is unknown. We found that the CD39 mimic apyrase (250 U/kg) decreased and knockout or pharmacologic blockade with sodium polyoxotungstate (5 mg/kg; IC50 approximate to 10 mu M) of CD39 increased mortality of mice with polymicrobial sepsis induced by cecal ligation and puncture. CD39 decreased inflammation, organ damage, immune cell apoptosis, and bacterial load. Use of bone marrow chimeric mice revealed that CD39 expression on myeloid cells decreases inflammation in septic mice. CD39 expression is upregulated during sepsis in mice, as well as in both murine and human macrophages stimulated with Escherichia coli. Moreover, E. coli increases CD39 promoter activity in macrophages. Altogether, these data indicate CD39 as an evolutionarily conserved inducible protective pathway during sepsis. We propose CD39 as a novel therapeutic target in the management of sepsis.	[Csoka, Balazs; Nemeth, Zoltan H.; Koscso, Balazs; Hasko, Gyoergy] Rutgers New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA; [Csoka, Balazs; Koscso, Balazs; Hasko, Gyoergy] Rutgers New Jersey Med Sch, Ctr Immun & Inflammat, Newark, NJ 07103 USA; [Nemeth, Zoltan H.; Rolandelli, Rolando H.] Morristown Med Ctr, Dept Surg, Morristown, NJ USA; [Toero, Gabor; Kokai, Endre; Hasko, Gyoergy] Univ Debrecen, Med & Hlth Sci Ctr, Dept Med Chem, H-4012 Debrecen, Hungary; [Robson, Simon C.; Enjyoji, Keiichi] Beth Israel Deaconess Med Ctr, Dept Med, Gastroenterol & Transplant Inst, Boston, MA 02215 USA; [Robson, Simon C.; Enjyoji, Keiichi] Harvard Univ, Sch Med, Boston, MA USA; [Erdelyi, Katalin; Pacher, Pal] NIAAA, Bethesda, MD USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Atlantic Health System; University of Debrecen; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Hasko, G (corresponding author), Rutgers New Jersey Med Sch, Dept Surg, 185 South Orange Ave, Newark, NJ 07103 USA.	haskoge@njms.rutgers.edu	Robson, Simon C./AAA-8537-2021; Pacher, Pal/B-6378-2008	Pacher, Pal/0000-0001-7036-8108; Koscso, Balazs/0000-0001-9676-2066	Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [R01GM66189, R01 GM066189] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000375] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		[Anonymous], 2009, CHEST; Antonioli L, 2013, TRENDS MOL MED, V19, P355, DOI 10.1016/j.molmed.2013.03.005; Ayala A, 1996, SHOCK, V6, pS27, DOI 10.1097/00024382-199610001-00007; Baek AE, 2013, FASEB J, V27, P4419, DOI 10.1096/fj.13-234625; Cavaillon JM, 2005, CRIT CARE MED, V33, pS506, DOI 10.1097/01.CCM.0000185502.21012.37; Cohen ES, 2002, AM J RESP CRIT CARE, V166, P16, DOI 10.1164/rccm.200109-014OC; Cohen HB, 2013, BLOOD, V122, P1935, DOI 10.1182/blood-2013-04-496216; Colgan Sean P, 2006, Purinergic Signal, V2, P351, DOI 10.1007/s11302-005-5302-5; Csoka B., 2013, DIABETES; Csoka B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006409; Csoka B, 2012, FASEB J, V26, P376, DOI 10.1096/fj.11-190934; Csoka B, 2010, J IMMUNOL, V185, P542, DOI 10.4049/jimmunol.0901295; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Eckle T, 2007, CIRCULATION, V115, P1581, DOI 10.1161/CIRCULATIONAHA.106.669697; Eltzschig HK, 2004, BLOOD, V104, P3986, DOI 10.1182/blood-2004-06-2066; Eltzschig HK, 2009, BLOOD, V113, P224, DOI 10.1182/blood-2008-06-165746; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; FIRESTEIN GS, 1994, J IMMUNOL, V152, P5853; Gallos G, 2005, AM J PHYSIOL-RENAL, V289, pF369, DOI 10.1152/ajprenal.00470.2004; Garcia AE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026035; Grenz A, 2008, PLOS MED, V5, P968, DOI 10.1371/journal.pmed.0050137; Grenz A, 2007, J AM SOC NEPHROL, V18, P833, DOI 10.1681/ASN.2006101141; Grenz A, 2007, FASEB J, V21, P2863, DOI 10.1096/fj.06-7947com; Hart ML, 2008, GASTROENTEROLOGY, V135, P1739, DOI 10.1053/j.gastro.2008.07.064; Hart ML, 2008, FASEB J, V22, P2784, DOI 10.1096/fj.07-103911; Hart ML, 2011, J IMMUNOL, V186, P4367, DOI 10.4049/jimmunol.0903617; Hart ML, 2010, J IMMUNOL, V184, P4017, DOI 10.4049/jimmunol.0901851; Hasko G, 2000, BRIT J PHARMACOL, V129, P909, DOI 10.1038/sj.bjp.0703134; Hasko G, 2011, J IMMUNOL, V187, P4256, DOI 10.4049/jimmunol.1003379; Hollebeeck S, 2011, TOXICOL LETT, V206, P268, DOI 10.1016/j.toxlet.2011.08.010; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Junger WG, 2011, NAT REV IMMUNOL, V11, P201, DOI 10.1038/nri2938; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kohler D, 2007, CIRCULATION, V116, P1784, DOI 10.1161/CIRCULATIONAHA.107.690180; Lee HT, 2006, AM J PHYSIOL-REG I, V291, pR959, DOI 10.1152/ajpregu.00034.2006; Leibovici L, 1997, SCAND J INFECT DIS, V29, P71, DOI 10.3109/00365549709008668; Levesque SA, 2010, EUR J IMMUNOL, V40, P1473, DOI 10.1002/eji.200939741; Liao H, 2010, J BIOL CHEM, V285, P14791, DOI 10.1074/jbc.M110.116905; Lu W, 2007, J PHARMACOL EXP THER, V323, P157, DOI 10.1124/jpet.107.124545; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; Nakav S, 2010, NEPHROL DIAL TRANSPL, V25, P931, DOI 10.1093/ndt/gfp542; Nemeth ZH, 2006, J IMMUNOL, V176, P5616, DOI 10.4049/jimmunol.176.9.5616; Oberholzer A, 2001, SHOCK, V16, P83, DOI 10.1097/00024382-200116020-00001; Peters E, 2014, AM J KIDNEY DIS, V63, P1038, DOI 10.1053/j.ajkd.2013.11.027; Reutershan J, 2009, FASEB J, V23, P473, DOI 10.1096/fj.08-119701; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Robertson CM, 2006, MICROBES INFECT, V8, P1382, DOI 10.1016/j.micinf.2005.12.016; Sansom FM, 2007, CELL MICROBIOL, V9, P1922, DOI 10.1111/j.1462-5822.2007.00924.x; Santos RF, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000387; Stearns-Kurosawa DJ, 2011, ANNU REV PATHOL-MECH, V6, P19, DOI 10.1146/annurev-pathol-011110-130327; Sullivan GW, 2004, J INFECT DIS, V189, P1897, DOI 10.1086/386311; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; van der Poll T, 2008, LANCET INFECT DIS, V8, P32, DOI 10.1016/S1473-3099(07)70265-7; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354	55	40	40	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					25	36		10.1096/fj.14-253567	http://dx.doi.org/10.1096/fj.14-253567			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25318479	Green Published			2022-12-28	WOS:000347378600004
J	Trucco, LD; Andreoli, V; Nunez, NG; Maccioni, M; Bocco, JL				Daniel Trucco, Lucas; Andreoli, Veronica; Gonzalo Nunez, Nicolas; Maccioni, Mariana; Bocco, Jose Luis			Kruppel-like factor 6 interferes with cellular transformation induced by the H-ras oncogene	FASEB JOURNAL			English	Article						tumor suppressor; c-Jun N-terminal kinase; p21	TUMOR-SUPPRESSOR GENE; TRANSCRIPTION FACTOR KLF6; N-TERMINAL KINASE; C-JUN; HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; LUNG-CANCER; IN-VIVO; JNK; ACTIVATION	KLF6 is a member of the Kruppel-like factor family of transcription factors, with diverse roles in the regulation of cell physiology, including proliferation, signal transduction, and apoptosis. Mutations or down-regulation of KLF6 have been described in several human cancers. In this work, we found that KLF6-knockdown resulted in the formation of transformed foci and allowed the spontaneous conversion of NIH3T3 cells to a tumorigenic state. We further assessed the role of KLF6 in the context of oncogenic Ras. We showed that KLF6 was up-regulated by H-Ras(G12V) expression in a Jun N-terminal kinase (JNK)dependent manner, correlated with enhanced klf6 promoter activity. We found that ectopic KLF6 expression induced a G1-phase cell cycle arrest, thereby decreasing the cell proliferation rate. In addition, constitutive KLF6 expression impaired H-Ras(G12V)-mediated loss of density-dependent growth inhibition and anchoragei-ndependent growth. Moreover, growth of H-Ras(G12V)-driven tumors was reduced in mice challenged with cells stably expressing KLF6. KLF6 expression correlated with the up-regulation of p21, whereas neither p53 induction nor apoptotic cell death was detected. Further, p21 knockdown impaired KLF6-induced cell cycle arrest. These findings provide novel evidence highlighting KLF6 function in response to malignant transformation, suggesting the relevance of KLF6 in controlling cell proliferation and hindering tumorigenesis.	[Daniel Trucco, Lucas; Andreoli, Veronica; Gonzalo Nunez, Nicolas; Maccioni, Mariana; Bocco, Jose Luis] Univ Nacl Cordoba, Fac Ciencias Quim, CONICET, Ctr Invest Bioquim Clin & Inmunol CIBICI,,Dept Bi, RA-5000 Cordoba, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba	Bocco, JL (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, CONICET, CIBICI,Dept Bioquim Clin, Haya Torre & Medina Allende,Ciudad Univ, RA-5000 Cordoba, Argentina.	jbocco@fcq.unc.edu.ar		Bocco, Jose Luis/0000-0002-9682-1270	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Agencia Nacional de Promocion Cientifica y Tecnologica [Proyecto de Investigacion en Ciencia y Tecnologia (PICT)] [2007-01630, PICT 2011-0435]; Secretaria de Ciencia y Tecnologia, Universidad Nacional de Cordoba and Instituto Nacional del Cancer-Argentina; CONICET fellowship	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Agencia Nacional de Promocion Cientifica y Tecnologica [Proyecto de Investigacion en Ciencia y Tecnologia (PICT)]; Secretaria de Ciencia y Tecnologia, Universidad Nacional de Cordoba and Instituto Nacional del Cancer-Argentina; CONICET fellowship(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET))	The authors thank Drs. R. Weinberg, S. Temple, and O. Coso for their kind gifts of plasmids; the entire Centro de Investigaciones en Bioquimica Clinica e Inmunologia (CIBICI; Universidad Nacional de Cordoba, Cordoba, Argentina) team for their encouragement and support-particularly, Dr. J. P. Nicola for critically reading the manuscript; G. Panzetta-Dutari and L. Patrito for stimulating discussions; and P. Abadie, M. P. Crespo and F. Navarro for excellent technical assistance. This work was supported by grants from Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Agencia Nacional de Promocion Cientifica y Tecnologica [Proyecto de Investigacion en Ciencia y Tecnologia (PICT) 2007-01630 and PICT 2011-0435]; Secretaria de Ciencia y Tecnologia, Universidad Nacional de Cordoba and Instituto Nacional del Cancer-Argentina. L.D.T., V.A., and N.G.N. were supported by a CONICET fellowship. M. M. and J. L. B. are Investigator members of CONICET. The authors declare no conflicts of interest.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Andreoli V, 2010, IUBMB LIFE, V62, P896, DOI 10.1002/iub.396; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bureau C, 2009, CURR GENOMICS, V10, P353, DOI 10.2174/138920209788921010; Cellurale C, 2012, CANCER RES, V72, P472, DOI 10.1158/0008-5472.CAN-11-1628; Cellurale C, 2011, MOL CELL BIOL, V31, P1565, DOI 10.1128/MCB.01122-10; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cox Adrienne D, 2010, Small GTPases, V1, P2; Das M, 2011, GENE DEV, V25, P634, DOI 10.1101/gad.1989311; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Der CJ, 2007, CELL, V129, P855, DOI 10.1016/j.cell.2007.05.031; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Difeo A, 2009, DRUG RESIST UPDATE, V12, P1, DOI 10.1016/j.drup.2008.11.001; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001; Fernandez-Zapico ME, 2011, BIOCHEM J, V435, P529, DOI 10.1042/BJ20100773; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Gehrau RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008929; Gutierrez GJ, 2010, J BIOL CHEM, V285, P14217, DOI 10.1074/jbc.M110.121848; Hatami R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004688; Hideshima T, 2003, ONCOGENE, V22, P8797, DOI 10.1038/sj.onc.1206919; Hubner A, 2012, P NATL ACAD SCI USA, V109, P12046, DOI 10.1073/pnas.1209660109; Jacobsen K, 2002, ONCOGENE, V21, P3058, DOI 10.1038/sj.onc.1205423; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Khatlani TS, 2007, ONCOGENE, V26, P2658, DOI 10.1038/sj.onc.1210050; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Li WQ, 2004, J BIOL CHEM, V279, P37398, DOI 10.1074/jbc.M405730200; Mathiasen DP, 2012, ONCOGENE, V31, P390, DOI 10.1038/onc.2011.230; Matsumoto N, 2006, BLOOD, V107, P1357, DOI 10.1182/blood-2005-05-1916; McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Moon DO, 2009, EXP MOL MED, V41, P665, DOI 10.3858/emm.2009.41.9.073; Narla G, 2007, ONCOGENE, V26, P4428, DOI 10.1038/sj.onc.1210223; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Nishigaki K, 2005, J VIROL, V79, P12752, DOI 10.1128/JVI.79.20.12752-12762.2005; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; QUELLE DE, 1995, CELL, V83, P993; Racca AC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022438; Sangodkar J, 2012, J CLIN INVEST, V122, P2637, DOI 10.1172/JCI62058; Schramek D, 2011, NAT GENET, V43, P212, DOI 10.1038/ng.767; She QB, 2002, CANCER RES, V62, P1343; Slavin D, 1999, BIOL REPROD, V61, P1586, DOI 10.1095/biolreprod61.6.1586; Slavin DA, 2004, ONCOGENE, V23, P8196, DOI 10.1038/sj.onc.1208020; Solomon H, 2010, DISCOV MED, V9, P448; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Tahara E, 2009, CANCER BIOL THER, V8, P801, DOI 10.4161/cbt.8.9.8186; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Yea S, 2008, GASTROENTEROLOGY, V134, P1521, DOI 10.1053/j.gastro.2008.02.015	55	9	9	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5262	5276		10.1096/fj.14-251884	http://dx.doi.org/10.1096/fj.14-251884			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25212220	Green Published			2022-12-28	WOS:000345894500021
J	Aarabi, M; Balakier, H; Bashar, S; Moskovtsev, SI; Sutovsky, P; Librach, CL; Oko, R				Aarabi, Mahmoud; Balakier, Hanna; Bashar, Siamak; Moskovtsev, Sergey I.; Sutovsky, Peter; Librach, Clifford L.; Oko, Richard			Sperm-derived WW domain-binding protein, PAWP, elicits calcium oscillations and oocyte activation in humans and mice	FASEB JOURNAL			English	Article						fertilization; reproductive biology	PHOSPHOLIPASE-C-ZETA; MOUSE EGG ACTIVATION; KIT TYROSINE KINASE; CA2+ OSCILLATIONS; PLC-ZETA; INTRACELLULAR CALCIUM; MEDIATED ACTIVATION; PERINUCLEAR THECA; HUMAN SPERMATOZOA; TRUNCATED FORM	Mammalian zygotic development is initiated by sperm-mediated intracellular calcium oscillations, followed by activation of metaphase II-arrested oocytes. Sperm postacrosomal WW binding protein (PAWP) fulfils the criteria set for an oocyte-activating factor by inducing oocyte activation and being stored in the perinuclear theca, the sperm compartment whose content is first released into oocyte cytoplasm during fertilization. However, proof that PAWP initiates mammalian zygotic development relies on demonstration that it acts upstream of oocyte calcium oscillations. Here, we show that PAWP triggers calcium oscillations and pronuclear formation in human and mouse oocytes similar to what is observed during intracytoplasmic sperm injection (ICSI). Most important, sperm-induced calcium oscillations are blocked by coinjection of a competitive inhibitor, derived from the WWI domain-binding motif of PAWP, implying the requirement of sperm PAWP and an oocyte-derived WWI domain protein substrate of PAWP for successful fertilization. Sperm-delivered PAWP is, therefore, a unique protein with a nonredundant role during human and mouse fertilization, required to trigger zygotic development. Presented data confirm our previous findings in non-mammalian models and suggest potential applications of PAWP in the diagnosis and treatment of infertility.-Aarabi, M., Balakier, H., Bashar, S., Moskovtsev, S. I., Sutovsky, P., Librach, C. L., and Oko, R. Sperm-derived WW domain-binding protein, PAWP, elicits calcium oscil-lations and oocyte activation in humans and mice.	[Aarabi, Mahmoud; Oko, Richard] Queens Univ, Sch Med, Dept Biomed & Mol Sci, Kingston, ON K7L 3N6, Canada; [Aarabi, Mahmoud] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [Balakier, Hanna; Bashar, Siamak; Moskovtsev, Sergey I.; Librach, Clifford L.] CReATe Fertil Ctr, Toronto, ON, Canada; [Moskovtsev, Sergey I.; Librach, Clifford L.] Univ Toronto, Dept Obstet & Gynecol, Toronto, ON, Canada; [Sutovsky, Peter] Univ Missouri, Sch Med, Div Anim Sci, Columbia, MO USA; [Sutovsky, Peter] Univ Missouri, Sch Med, Dept Obstet Gynecol & Womens Hlth, Columbia, MO USA	Queens University - Canada; McGill University; University of Toronto; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Oko, R (corresponding author), Queens Univ, Sch Med, Dept Biomed & Mol Sci, Botterell Hall,Rm 927, Kingston, ON K7L 3N6, Canada.	ro3@queensu.ca	Aarabi, Mahmoud/AAN-2984-2021	Sutovsky, Peter/0000-0002-9231-2823	Canadian Institutes of Health Research [MOP-84440]; U.S. Department of Agriculture/National Institute of Food and Agriculture [2011-67015-20025]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); U.S. Department of Agriculture/National Institute of Food and Agriculture(United States Department of Agriculture (USDA))	The authors are grateful to Dr. Hugh Clarke and Dr. Jiao Suzuki (McGill University, Montreal, Quebec, Canada) and Dr. Young-Joo Yi (University of Missouri, Columbia, MO, USA) for their generous help in optimization of mouse ICSI. The authors appreciate technical advice for mouse calcium imaging from Dr. Christopher Ward, Mr. Jeffrey Mewburn and Mr. Matthew Gordon (Queen's University, Kingston, ON, Canada); and for human calcium imaging from Mr. Paul Paroutis (Hospital for Sick Children, Toronto, ON, Canada). The authors acknowledge the great assistance from Ms. Wei Xu (Queen's University) on sample collection and analysis. The authors are grateful to the physicians, nurses, and staff of the CReATe Fertility Centre (Toronto, ON, Canada), especially to Ms. Agata Sojecki for assistance in human ICSI. The authors are also indebted to infertile couples who generously agreed to donate their surplus gametes for this study. This study was supported by a Canadian Institutes of Health Research grant (MOP-84440 to R.O.). Work in the laboratory of P.S. was supported by award 2011-67015-20025 from the U.S. Department of Agriculture/National Institute of Food and Agriculture; no such funds were used for work with donated human oocytes.	Aarabi M, 2014, FERTIL STERIL, V102, P440, DOI 10.1016/j.fertnstert.2014.05.003; Aarabi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033496; Aarabi M, 2010, MOL REPROD DEV, V77, P249, DOI 10.1002/mrd.21140; Balakier H, 2012, FERTIL STERIL, V98, DOI 10.1016/j.fertnstert.2012.04.015; Bedford-Guaus SJ, 2011, BIOL REPROD, V85, P78, DOI 10.1095/biolreprod.110.089466; Browaeys-Poly E, 2007, CELL SIGNAL, V19, P2540, DOI 10.1016/j.cellsig.2007.08.002; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Dale B, 2010, REPROD BIOMED ONLINE, V21, P1, DOI 10.1016/j.rbmo.2010.02.015; Ferrer M, 2012, CELL TISSUE RES, V349, P881, DOI 10.1007/s00441-012-1429-1; Grasa P, 2008, HUM REPROD, V23, P2513, DOI 10.1093/humrep/den280; Harada Y, 2007, DEV BIOL, V306, P797, DOI 10.1016/j.ydbio.2007.04.019; Ito J, 2011, MOL REPROD DEV, V78, P846, DOI 10.1002/mrd.21359; Kashir J, 2013, FERTIL STERIL, V99, P107, DOI 10.1016/j.fertnstert.2012.09.001; Kennedy CE, 2014, MOL REPROD DEV, V81, P436, DOI 10.1002/mrd.22309; KIMURA Y, 1995, BIOL REPROD, V52, P709, DOI 10.1095/biolreprod52.4.709; Kimura Y, 1998, BIOL REPROD, V58, P1407, DOI 10.1095/biolreprod58.6.1407; Mehlmann LM, 2005, REPRODUCTION, V129, P557, DOI 10.1530/rep.1.00638; Morozumi K, 2006, P NATL ACAD SCI USA, V103, P17661, DOI 10.1073/pnas.0608183103; Muciaccia B, 2010, HUM REPROD, V25, P2188, DOI 10.1093/humrep/deq168; NIGGLI E, 1994, AM J PHYSIOL, V266, pC303, DOI 10.1152/ajpcell.1994.266.1.C303; Nomikos M, 2005, J BIOL CHEM, V280, P31011, DOI 10.1074/jbc.M500629200; Oko R, 2009, J REPROD IMMUNOL, V83, P2, DOI 10.1016/j.jri.2009.05.008; Reynolds CH, 2008, J BIOL CHEM, V283, P18177, DOI 10.1074/jbc.M709715200; Rogers NT, 2004, REPRODUCTION, V128, P697, DOI 10.1530/rep.1.00484; Runft LL, 2000, DEVELOPMENT, V127, P3227; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Runft LL, 1999, DEV BIOL, V214, P399, DOI 10.1006/dbio.1999.9415; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Sette C, 2002, EMBO J, V21, P5386, DOI 10.1093/emboj/cdf553; Sette C, 1998, J CELL BIOL, V142, P1063, DOI 10.1083/jcb.142.4.1063; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; Sutovsky P, 2003, MICROSC RES TECHNIQ, V61, P362, DOI 10.1002/jemt.10350; Swann K, 2013, CELL CALCIUM, V53, P55, DOI 10.1016/j.ceca.2012.11.001; Takahashi A, 1999, PHYSIOL REV, V79, P1089, DOI 10.1152/physrev.1999.79.4.1089; Tovich PR, 2004, BIOL REPROD, V71, P1182, DOI 10.1095/biolreprod.104.030445; Wu ATH, 2007, DEV BIOL, V312, P471, DOI 10.1016/j.ydbio.2007.08.051; Wu ATH, 2007, J BIOL CHEM, V282, P12164, DOI 10.1074/jbc.M609132200; XU Z, 1994, DEVELOPMENT, V120, P1851; Yoneda A, 2006, REPRODUCTION, V132, P393, DOI 10.1530/rep.1.01018; Young C, 2009, FERTIL STERIL, V91, P2230, DOI 10.1016/j.fertnstert.2008.05.021	40	85	89	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4434	4440		10.1096/fj.14-256495	http://dx.doi.org/10.1096/fj.14-256495			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24970390				2022-12-28	WOS:000342222700021
J	Anderson, D; Najafzadeh, M; Gopalan, R; Ghaderi, N; Scally, AJ; Britland, ST; Jacobs, BK; Reynolds, PD; Davies, J; Wright, AL; Al-Ghazal, S; Sharpe, D; Denyer, MC				Anderson, Diana; Najafzadeh, Mojgan; Gopalan, Rajendran; Ghaderi, Nader; Scally, Andrew J.; Britland, Stephen T.; Jacobs, Badie K.; Reynolds, P. Dominic; Davies, Justin; Wright, Andrew L.; Al-Ghazal, Shariff; Sharpe, David; Denyer, Morgan C.			Sensitivity and specificity of the empirical lymphocyte genome sensitivity (LGS) assay: implications for improving cancer diagnostics	FASEB JOURNAL			English	Article						blood test; susceptibility	STRAND BREAKS; COMET ASSAY; DNA-DAMAGE; IN-VITRO; PROMOTER METHYLATION; T-CELLS; UVA; VIVO; TRANSFORMATION; INFLAMMATION	Lymphocyte responses from 208 individuals: 20 with melanoma, 34 with colon cancer, and 4 with lung cancer (58), 18 with suspected melanoma, 28 with polyposis, and 10 with COPD (56), and 94 healthy volunteers were examined. The natural logarithm of the Olive tail moment (OTM) was plotted for exposure to UVA through 5 different agar depths (100 cell measurements/depth) and analyzed using a repeated measures regression model. Responses of patients with cancer plateaued after treatment with different UVA intensities, but returned toward control values for healthy volunteers. For precancerous conditions and suspected cancers, intermediate responses occurred. ROC analysis of mean log OTMs, for cancers plus precancerous/suspect conditions vs. controls, cancer vs. precancerous/suspect conditions plus controls, and cancer vs. controls, gave areas under the curve of 0.87, 0.89, and 0.93, respectively (P< 0.001). Optimization allowed test sensitivity or specificity to approach 100% with acceptable complementary measures. This modified comet assay could represent a stand-alone test or an adjunct to other investigative procedures for detecting cancer.	[Anderson, Diana; Najafzadeh, Mojgan; Gopalan, Rajendran; Ghaderi, Nader; Denyer, Morgan C.] Univ Bradford, Sch Life Sci, Bradford BD7 1DP, W Yorkshire, England; [Scally, Andrew J.] Univ Bradford, Sch Hlth Studies, Bradford BD7 1DP, W Yorkshire, England; [Britland, Stephen T.] Wolverhampton Univ, Fac Sci & Engn, Wolverhampton WV1 1DJ, W Midlands, England; [Jacobs, Badie K.; Reynolds, P. Dominic; Davies, Justin; Wright, Andrew L.; Al-Ghazal, Shariff; Sharpe, David] Bradford Royal Infirm, Bradford BD9 6RJ, W Yorkshire, England	University of Bradford; University of Bradford; University of Wolverhampton; Bradford Royal Infirmary	Anderson, D (corresponding author), Univ Bradford, Richmond Rd, Bradford BD7 1DP, W Yorkshire, England.	d.anderson1@bradford.ac.uk	Anderson, Diana/J-6472-2015	Anderson, Diana/0000-0001-9673-0398; Gopalan, Rajendran/0000-0003-3873-0079	Research and Knowledge Transfer Support (University of Bradford); Yorkshire Concept; Yorkshire Forward Yorkshire Enterprise Fellowship	Research and Knowledge Transfer Support (University of Bradford); Yorkshire Concept; Yorkshire Forward Yorkshire Enterprise Fellowship	The authors thank David Squire and William Finch for very helpful discussion. The authors acknowledge support from the Research and Knowledge Transfer Support (University of Bradford), Yorkshire Concept, and the Yorkshire Forward Yorkshire Enterprise Fellowship. D.A., M.N., R.G., S.T.B., D. ., and M.C.D. are all named inventors on the patents associated with this modified comet assay (40, 41). The patents are wholly owned by the University of Bradford, but an independent company, Oncascan Ltd. (Abingdon, UK), has been established by external investors to commercialize the assay. The other authors declare no conflicts of interest.	Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792; Albertini RJ, 2000, MUTAT RES-REV MUTAT, V463, P111, DOI 10.1016/S1383-5742(00)00049-1; Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170; AUSTOKER J, 1994, BMJ-BRIT MED J, V309, P517, DOI 10.1136/bmj.309.6953.517; Bai J, 2012, J CANCER RES CLIN, V138, P991, DOI 10.1007/s00432-012-1172-8; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Ben-Baruch A, 2006, SEMIN CANCER BIOL, V16, P38, DOI 10.1016/j.semcancer.2005.07.006; Boinon D, 2014, PSYCHO-ONCOLOGY, V23, P291, DOI 10.1002/pon.3420; Cancer Research UK, LIF RISK CANC; Chen X, 2012, INT J CANCER, V130, P1620, DOI 10.1002/ijc.26177; Chimonidou M, 2013, CLIN BIOCHEM, V46, P235, DOI 10.1016/j.clinbiochem.2012.09.015; Collins AR, 2004, MOL BIOTECHNOL, V26, P249, DOI 10.1385/MB:26:3:249; Cortat B, 2013, PHOTOCH PHOTOBIO SCI, V12, P1483, DOI 10.1039/c3pp50023c; Curt G A, 2000, Oncologist, V5, P353, DOI 10.1634/theoncologist.5-5-353; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhawan A., 2009, ISSUES TOXICOLOGY; Franks Peter J, 2004, Int J Low Extrem Wounds, V3, P87, DOI 10.1177/1534734604264864; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Greinert R, 2012, NUCLEIC ACIDS RES, V40, P10263, DOI 10.1093/nar/gks824; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hartmann A, 2003, MUTAGENESIS, V18, P45, DOI 10.1093/mutage/18.1.45; Hoyert DL, 2006, PEDIATRICS, V117, P168, DOI 10.1542/peds.2005-2587; Ikehata H, 2013, PHOTOCH PHOTOBIO SCI, V12, P1319, DOI 10.1039/c3pp25444e; Jiang Y, 2009, BIOPHYS J, V96, P1151, DOI 10.1016/j.bpj.2008.10.030; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Katz MR, 2003, HEAD NECK-J SCI SPEC, V25, P103, DOI 10.1002/hed.10174; Kumaravel TS, 2006, MUTAT RES-GEN TOX EN, V605, P7, DOI 10.1016/j.mrgentox.2006.03.002; Kumaravel TS, 2009, CELL BIOL TOXICOL, V25, P53, DOI 10.1007/s10565-007-9043-9; Leszinski G, 2012, ANTICANCER RES, V32, P2199; Lovell DP, 1999, TERATOGEN CARCIN MUT, V19, P109, DOI 10.1002/(SICI)1520-6866(1999)19:2<109::AID-TCM4>3.0.CO;2-5; Luker K, 2013, OCCUP MED-OXFORD, V63, P494, DOI 10.1093/occmed/kqt104; Mariotto AB, 2011, JNCI-J NATL CANCER I, V103, P117, DOI 10.1093/jnci/djq495; Najafzadeh M, 2012, MUTAGENESIS, V27, P351, DOI 10.1093/mutage/ger087; NEEL JV, 1989, GENOME, V31, P853, DOI 10.1139/g89-150; Osipov AN, 2014, FREE RADICAL BIO MED, V73, P34, DOI 10.1016/j.freeradbiomed.2014.04.027; Pepe MS, 2003, BIOMETRICS, V59, P133, DOI 10.1111/1541-0420.00016; Poeta ML, 2012, GENE CHROMOSOME CANC, V51, P1133, DOI 10.1002/gcc.21998; Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229; Sharpe D. T., 2008, World patent application, Patent No. [WO 2008050134A2, 2008050134]; Shridhar V, 2001, CANCER RES, V61, P5895; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Svobodova AR, 2012, ARCH DERMATOL RES, V304, P407, DOI 10.1007/s00403-012-1212-x; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; Tsui KH, 2000, J UROLOGY, V163, P1090, DOI 10.1016/S0022-5347(05)67699-9; TSUI KH, 2000, J UROLOGY, V163, P1295; UK Office for National Statistics, 2012, SER MB1, V1; Wang X, 2011, J CLIN INVEST, V121, P3834, DOI 10.1172/JCI37210; Wischermann K, 2008, ONCOGENE, V27, P4269, DOI 10.1038/onc.2008.70	48	19	20	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4563	4570		10.1096/fj.14-254748	http://dx.doi.org/10.1096/fj.14-254748			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25063845				2022-12-28	WOS:000342222700031
J	Haridas, D; Ponnusamy, MP; Chugh, S; Lakshmanan, I; Seshacharyulu, P; Batra, SK				Haridas, Dhanya; Ponnusamy, Moorthy P.; Chugh, Seema; Lakshmanan, Imayavaramban; Seshacharyulu, Parthasarathy; Batra, Surinder K.			MUC16: molecular analysis and its functional implications in benign and malignant conditions	FASEB JOURNAL			English	Review						MUC16; domain structure; cancer; animal model	OVARIAN-CANCER ANTIGEN; MEMBRANE-ASSOCIATED MUCINS; OCULAR SURFACE EPITHELIA; TUMOR-MARKERS; DIFFERENTIAL-DIAGNOSIS; BREAST-CANCER; HUMAN AIRWAY; PERITONEAL METASTASIS; MONOCLONAL-ANTIBODY; O-GLYCOSYLATION	MUC16 is a high-molecular-weight glycoprotein that is expressed by the various epithelial cell surfaces of the human body to protect the cell layer from a myriad of insults. It is the largest mucin known to date, with an similar to 22,152 aa sequence. Structurally, MUC16 is characterized into 3 distinct domains: the amino terminal, the tandem repeat, and the carboxyl terminal domain, with each domain having unique attributes. The extracellular portion of MUC16 is shed into the bloodstream and serves as a biomarker for diagnosing and monitoring patients with cancer; however, its functional role in cancer is yet to be elucidated. Several factors contribute to this challenge, which include the large protein size; the extensive glycosylation that the protein undergoes, which confers functional heterogeneity; lack of specific antibodies that detect the unique domains of MUC16; and the existence of splicing variants. Despite these limitations, MUC16 has been established as a molecule of significant application in cancer. Hence, in this review, we discuss the various aspects of MUC16, which include its discovery, structure, and biological significance both in benign and malignant conditions with an attempt to dissect its functional relevance.	[Haridas, Dhanya; Ponnusamy, Moorthy P.; Chugh, Seema; Lakshmanan, Imayavaramban; Seshacharyulu, Parthasarathy; Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Batra, Surinder K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu	Seshacharyulu, Parthasarathy/AGL-7648-2022	Seshacharyulu, Parthasarathy/0000-0002-2348-3901; lakshmanan, Imayavaramban/0000-0003-1733-2223; Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X				Akita K, 2013, EUR J CELL BIOL, V92, P257, DOI 10.1016/j.ejcb.2013.10.005; Albertsmeyer AC, 2010, EXP EYE RES, V90, P444, DOI 10.1016/j.exer.2009.12.009; Ali M, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-4; Andersch-Bjorkman Y, 2007, MOL CELL PROTEOMICS, V6, P708, DOI 10.1074/mcp.M600439-MCP200; Antonsen SL, 2013, ACTA OBSTET GYN SCAN, V92, P1313, DOI 10.1111/aogs.12235; Argueso P, 2003, INVEST OPHTH VIS SCI, V44, P2487, DOI 10.1167/iovs.02-0862; Argueso P, 2003, INVEST OPHTH VIS SCI, V44, P86, DOI 10.1167/iovs.02-0181; Argueso P, 2009, J BIOL CHEM, V284, P23037, DOI 10.1074/jbc.M109.033332; Ataseven H, 2009, J CLIN LAB ANAL, V23, P244, DOI 10.1002/jcla.20323; Bae CH, 2012, CLIN EXP OTORHINOLAR, V5, P161, DOI 10.3342/ceo.2012.5.3.161; Bafna S, 2010, ONCOGENE, V29, P2893, DOI 10.1038/onc.2010.87; Bast RC, 2005, INT J GYNECOL CANCER, V15, P274, DOI 10.1111/j.1525-1438.2005.00441.x; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Belisle JA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-118; Bennett EP, 2012, GLYCOBIOLOGY, V22, P736, DOI 10.1093/glycob/cwr182; BISCHOF P, 1993, EUR J OBSTET GYN R B, V49, P93, DOI 10.1016/0028-2243(93)90131-U; Blalock TD, 2008, INVEST OPHTH VIS SCI, V49, P1864, DOI 10.1167/iovs.07-1081; Blalock TD, 2007, INVEST OPHTH VIS SCI, V48, P4509, DOI 10.1167/iovs.07-0430; Boivin M, 2009, GYNECOL ONCOL, V115, P407, DOI 10.1016/j.ygyno.2009.08.007; Bressan A, 2013, DIS MARKERS, V34, P257, DOI [10.3233/DMA-130968, 10.1155/2013/917898]; Byrd JC, 2004, CANCER METAST REV, V23, P77, DOI 10.1023/A:1025815113599; Caffery B, 2008, MOL VIS, V14, P2547; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; Cedres S, 2011, CLIN LUNG CANCER, V12, P172, DOI 10.1016/j.cllc.2011.03.019; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chaube A, 2006, J SURG ONCOL, V93, P665, DOI 10.1002/jso.20534; Chauhan SC, 2006, MODERN PATHOL, V19, P1386, DOI 10.1038/modpathol.3800646; Chen KW, 2013, J PROTEOME RES, V12, P1408, DOI 10.1021/pr3010474; Chen SH, 2013, SCI REP-UK, V3, DOI 10.1038/srep01870; Chen SH, 2012, FASEB J, V26, P1349, DOI 10.1096/fj.11-195669; Chen YJ, 2007, CANCER RES, V67, P4924, DOI 10.1158/0008-5472.CAN-06-4512; Cheon DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004675; Comamala M, 2011, BRIT J CANCER, V104, P989, DOI 10.1038/bjc.2011.34; Cwik G, 2006, ARCH SURG-CHICAGO, V141, P968, DOI 10.1001/archsurg.141.10.968; Davies JR, 2007, INT J BIOCHEM CELL B, V39, P1943, DOI 10.1016/j.biocel.2007.05.013; DAVIS HM, 1986, CANCER RES, V46, P6143; DELOSFRAILES MT, 1993, TUMOR BIOL, V14, P18, DOI 10.1159/000217821; Devarbhavi H, 2002, MAYO CLIN PROC, V77, P538, DOI 10.4065/77.6.538; Dogru M, 2008, ALLERGY, V63, P1324, DOI 10.1111/j.1398-9995.2008.01781.x; Duraisamy S, 2006, GENE, V373, P28, DOI 10.1016/j.gene.2005.12.021; Einama T, 2011, PANCREAS, V40, P1276, DOI 10.1097/MPA.0b013e318221bed8; Einerhand AWC, 2002, EUR J GASTROEN HEPAT, V14, P757, DOI 10.1097/00042737-200207000-00008; Fendrick JL, 1997, TUMOR BIOL, V18, P278, DOI 10.1159/000218041; Fujimura T, 2002, ENDOSCOPY, V34, P569, DOI 10.1055/s-2002-33228; Gebauer F, 2013, GUT, V62, P741, DOI 10.1136/gutjnl-2011-300629; Geng XF, 2013, INT J BIOL MARKER, V28, P216, DOI 10.5301/jbm.5000001; Gipson IK, 2005, E SCHERING RES FDN W, V52, P219; Gipson IK, 1999, BIOL REPROD, V60, P58, DOI 10.1095/biolreprod60.1.58; Gipson IK, 2003, INT REV CYTOL, V231, P1, DOI 10.1016/S0074-7696(03)31001-0; Gipson IK, 2008, BIOL REPROD, V78, P134, DOI 10.1095/biolreprod.106.058347; Govindarajan B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032418; Govindarajan B, 2010, EXP EYE RES, V90, P655, DOI 10.1016/j.exer.2010.02.014; Gubbels JAA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-50; Gubbels JAA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-11; Guimbaud R, 1998, AM J GASTROENTEROL, V93, P2397, DOI 10.1016/S0002-9270(98)00575-9; HALILA H, 1985, TUMOUR BIOL, V6, P207; Haridas D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026839; Hassan Raffit, 2007, Cancer Immun, V7, P20; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; He CZ, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-87; Higashi M, 2012, PATHOBIOLOGY, V79, P101, DOI 10.1159/000335164; Hori Y, 2004, INVEST OPHTH VIS SCI, V45, P114, DOI 10.1167/iovs.03-0903; Hori Y, 2005, INVEST OPHTH VIS SCI, V46, P4050, DOI 10.1167/iovs.05-0627; Hovenberg HW, 1996, BIOCHEM J, V318, P319, DOI 10.1042/bj3180319; Huffmeier U, 2009, J MED GENET, V46, P736, DOI 10.1136/jmg.2008.065029; INATOMI T, 1995, INVEST OPHTH VIS SCI, V36, P1818; Inatomi T, 1996, INVEST OPHTH VIS SCI, V37, P1684; Jager K, 2007, HISTOCHEM CELL BIOL, V127, P433, DOI 10.1007/s00418-006-0246-6; Kaneko O, 2009, J BIOL CHEM, V284, P3739, DOI 10.1074/jbc.M806776200; Kesimer M, 2013, MUCOSAL IMMUNOL, V6, P379, DOI 10.1038/mi.2012.81; Kesimer M, 2009, FASEB J, V23, P1858, DOI 10.1096/fj.08-119131; Kim ES, 2013, TUBERCULOSIS, V93, P222, DOI 10.1016/j.tube.2012.10.014; Kohlgraf KG, 2003, CANCER RES, V63, P5011; KONISHI I, 1994, J SOC GYNECOL INVEST, V1, P89, DOI 10.1177/107155769400100118; Kutteh WH, 1996, J SOC GYNECOL INVEST, V3, P216, DOI 10.1016/1071-5576(96)00013-5; Lagendijk JH, 1999, J CLIN PATHOL, V52, P283, DOI 10.1136/jcp.52.4.283; Lakshmanan I, 2012, ONCOGENE, V31, P805, DOI 10.1038/onc.2011.297; Lloyd KO, 2001, TUMOR BIOL, V22, P77, DOI 10.1159/000050600; LUNDGREN JD, 1985, ANN ALLERGY, V55, P5; MACDONALD F, 1988, BRIT J CANCER, V58, P505, DOI 10.1038/bjc.1988.251; Maeda T, 2004, J BIOL CHEM, V279, P13174, DOI 10.1074/jbc.M309417200; Mantelli F, 2008, CURR OPIN ALLERGY CL, V8, P477, DOI 10.1097/ACI.0b013e32830e6b04; MARTINEZ AR, 1994, FERTIL STERIL, V61, P843; Miralles C, 2003, ANN SURG ONCOL, V10, P150, DOI 10.1245/ASO.2003.05.015; MOLINA R, 1991, CLIN CHEM, V37, P1379; Moniaux N, 2001, FRONT BIOSCI-LANDMRK, V6, pD1192, DOI 10.2741/Moniaux; Moritani S, 2008, HUM PATHOL, V39, P666, DOI 10.1016/j.humpath.2007.09.009; Mylonas I, 2003, ANTICANCER RES, V23, P1075; Nustad K, 1996, TUMOR BIOL, V17, P196, DOI 10.1159/000217982; Nustad K, 2002, TUMOR BIOL, V23, P303, DOI 10.1159/000068570; O'Brien TJ, 2002, TUMOR BIOL, V23, P154, DOI 10.1159/000064032; O'Brien TJ, 2001, TUMOR BIOL, V22, P348, DOI 10.1159/000050638; OBRIEN TJ, 1986, AM J OBSTET GYNECOL, V155, P50, DOI 10.1016/0002-9378(86)90076-1; Patankar MS, 2005, GYNECOL ONCOL, V99, P704, DOI 10.1016/j.ygyno.2005.07.030; Rachagani S, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-68; Rachagani S, 2009, BIOFACTORS, V35, P509, DOI 10.1002/biof.64; Radhakrishnan P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073356; Rao TD, 2010, APPL IMMUNOHISTO M M, V18, P462, DOI 10.1097/PAI.0b013e3181dbfcd2; Reinartz S, 2012, EUR J CANCER, V48, P1558, DOI 10.1016/j.ejca.2011.07.004; Rump A, 2004, J BIOL CHEM, V279, P9190, DOI 10.1074/jbc.M312372200; Rustin GJS, 2010, LANCET, V376, P1155, DOI 10.1016/S0140-6736(10)61268-8; Seelenmeyer C, 2003, J CELL SCI, V116, P1305, DOI 10.1242/jcs.00312; Seo KY, 2007, CORNEA, V26, P709, DOI 10.1097/ICO.0b013e31804f5a09; Sheng YH, 2012, J GASTROEN HEPATOL, V27, P28, DOI 10.1111/j.1440-1746.2011.06909.x; Shimizu A, 2012, CANCER SCI, V103, P739, DOI 10.1111/j.1349-7006.2012.02214.x; Shukla Vijay K, 2006, Trop Gastroenterol, V27, P160; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sikaris KA, 2011, HEART LUNG CIRC, V20, P634, DOI 10.1016/j.hlc.2010.08.001; Silverman HS, 2002, GLYCOCONJUGATE J, V19, P379, DOI 10.1023/B:GLYC.0000004009.24191.d3; Spurr-Michaud S, 2007, EXP EYE RES, V84, P939, DOI 10.1016/j.exer.2007.01.018; Streppel MM, 2012, HUM PATHOL, V43, P1755, DOI 10.1016/j.humpath.2012.01.005; Sumiyoshi M, 2008, INVEST OPHTH VIS SCI, V49, P197, DOI 10.1167/iovs.07-1038; Theriault C., 2011, GYNECOL ONCOL, V121, P434; Togami S, 2010, J OBSTET GYNAECOL RE, V36, P588, DOI 10.1111/j.1447-0756.2010.01221.x; Tornos C, 2005, AM J SURG PATHOL, V29, P1482, DOI 10.1097/01.pas.0000176429.88702.36; Torres MP, 2012, CURR PHARM DESIGN, V18, P2472; Tyler C, 2012, AM J REPROD IMMUNOL, V68, P28, DOI 10.1111/j.1600-0897.2012.01113.x; Vujisic S, 2002, AM J REPROD IMMUNOL, V48, P355, DOI 10.1034/j.1600-0897.2002.01088.x; Walinda E, 2014, J BIOL CHEM, V289, P13890, DOI 10.1074/jbc.M114.555441; Wang F, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-14; Wang Y, 2008, DIFFERENTIATION, V76, P1081, DOI 10.1111/j.1432-0436.2008.00295.x; Weiland F, 2012, INT J MOL SCI, V13, P10568, DOI 10.3390/ijms130810568; Weiland F, 2012, INT J MOL SCI, V13, P9942, DOI 10.3390/ijms13089942; Whitehouse C, 2002, EUR J BIOCHEM, V269, P538, DOI 10.1046/j.0014-2956.2001.02681.x; Whitehouse C, 2003, GYNECOL ONCOL, V88, pS152, DOI 10.1006/gyno.2002.6708; Wickstrom C, 1998, BIOCHEM J, V334, P685, DOI 10.1042/bj3340685; Wilder JL, 2003, GYNECOL ONCOL, V89, P233, DOI 10.1016/S0090-8258(03)00051-9; Woo HJ, 2010, ARCH OTOLARYNGOL, V136, P603, DOI 10.1001/archoto.2010.71; Wreschner DH, 2002, PROTEIN SCI, V11, P698, DOI 10.1110/ps.16502; Wu YM, 2009, J PROTEOME RES, V8, P1876, DOI 10.1021/pr8008379; Xue XY, 2012, ONCOL LETT, V3, P234, DOI 10.3892/ol.2011.452; Yin BWT, 2002, INT J CANCER, V98, P737, DOI 10.1002/ijc.10250; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200; Yu DF, 2013, INT J MOL SCI, V14, P11145, DOI 10.3390/ijms140611145; Yue TT, 2009, MOL CELL PROTEOMICS, V8, P1697, DOI 10.1074/mcp.M900135-MCP200; Zeimet AG, 1998, TUMOR BIOL, V19, P275, DOI 10.1159/000030018	138	69	71	4	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4183	4199		10.1096/fj.14-257352	http://dx.doi.org/10.1096/fj.14-257352			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25002120				2022-12-28	WOS:000342222700001
J	Hess, KC; Liu, JJ; Manfredi, G; Muhlschlegel, FA; Buck, J; Levin, LR; Barrientos, A				Hess, Kenneth C.; Liu, Jingjing; Manfredi, Giovanni; Muehlschlegel, Fritz A.; Buck, Jochen; Levin, Lonny R.; Barrientos, Antoni			A mitochondrial CO2-adenylyl cyclase-cAMP signalosome controls yeast normoxic cytochrome c oxidase activity	FASEB JOURNAL			English	Article						Cyrl; mitochondrial energy metabolism; normoxic Cox5a; hypoxic Cox5b	SOLUBLE ADENYLYL-CYCLASE; OXYGEN-REGULATED ISOFORMS; SACCHAROMYCES-CEREVISIAE; PROTEIN-PHOSPHORYLATION; CARBONIC-ANHYDRASE; ATP; RESPIRATION; EXPRESSION; SUBUNITS; TRANSCRIPTION	Mitochondria, the major source of cellular energy in the form of ATP, respond to changes in substrate availability and bioenergetic demands by employing rapid, short-term, metabolic adaptation mechanisms, such as phosphorylation-dependent protein regulation. In mammalian cells, an intramitochondrial CO2-adenylyl cyclase (AC)-cyclic AMP (cAMP)-protein kinase A (PKA) pathway regulates aerobic energy production. One target of this pathway involves phosphorylation of cytochrome c oxidase (COX) subunit 4-iso-form 1 (COX4i1), which modulates COX allosteric regulation by ATP. However, the role of the CO2-sAC-cAMP-PKA signalosome in regulating COX activity and mitochondrial metabolism and its evolutionary conservation remain to be fully established. We show that in Saccharomyces cerevisiae, normoxic COX activity measured in the presence of ATP is 55% lower than in the presence of ADP. Moreover, the adenylyl cyclase Cyr1 activity is present in mitochondria, and it contributes to the ATP-mediated regulation of COX through the normoxic subunit Cox5a, homologue of human COX4i1, in a bicarbonate-sensitive manner. Furthermore, we have identified 2 phosphorylation targets in Cox5a (T65 and S43) that modulate its allosteric regulation by ATP. These residues are not conserved in the Cox5b-containing hypoxic enzyme, which is not regulated by ATP. We conclude that across evolution, a CO2-sAC-cAMP-PKA axis regulates normoxic COX activity.-Hess, K. C., Liu, J., Manfredi, G., Muhlschlegel, F. A., Buck, J., Levin, L. R., Barrientos, A. A mitochondrial CO2-adenylyl cyclase-cAMP signalosome controls yeast normoxic cytochrome c oxidase activity.	[Hess, Kenneth C.; Buck, Jochen; Levin, Lonny R.] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA; [Manfredi, Giovanni] Weill Cornell Med Coll, Brain & Mind Res Inst, New York, NY USA; [Liu, Jingjing; Barrientos, Antoni] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [Barrientos, Antoni] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Muehlschlegel, Fritz A.] Univ Kent, Sch Biosci, Canterbury, Kent, England	Cornell University; Cornell University; University of Miami; University of Miami; University of Kent	Barrientos, A (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, 1600 NW 10th Ave,RMSB 2067, Miami, FL 33136 USA.	abarrientos@med.miami.edu	Levin, Lonny R/A-7215-2011; Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070; Levin, Lonny/0000-0002-5204-6356	Muscular Dystrophy Association; U.S. National Institutes of Health (NIH) [GM-071775, GM-088999A, GM-062328, HD-059913]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD059913] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088999, R01GM107442, R01GM105781, R01GM071775, R01GM062328] Funding Source: NIH RePORTER	Muscular Dystrophy Association(Muscular Dystrophy Association); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Dr. Flavia Fontanesi and Dr. Iliana Soto for critically reading the manuscript. The authors thank Dr. Christof Taxis (Philipps Universitat Marburg, Marburg, Germany) for providing the cyr1 yeast mutant strain. This study was supported by the Muscular Dystrophy Association (to A.B. and G.M.) and by U.S. National Institutes of Health (NIH) grants GM-071775 (to A.B.); GM-088999A (to G.M.); and GM-062328 and HD-059913 (to J.B. and L.R.L.). J.B. and L.R.L. own equity interest in CEP Biotech (Tamarac, FL, USA), which has licensed commercialization of a panel of monoclonal antibodies directed against sAC. The other authors declare no conflicts of interest.	Acin-Perez R, 2011, J BIOL CHEM, V286, P30423, DOI 10.1074/jbc.M111.266379; Acin-Perez R, 2011, CELL METAB, V13, P712, DOI 10.1016/j.cmet.2011.03.024; Acin-Perez R, 2009, EMBO MOL MED, V1, P392, DOI 10.1002/emmm.200900046; Acin-Perez R, 2009, CELL METAB, V9, P265, DOI 10.1016/j.cmet.2009.01.012; ALLEN LA, 1995, J BIOL CHEM, V270, P110, DOI 10.1074/jbc.270.1.110; Appukuttan A, 2012, CARDIOVASC RES, V93, P340, DOI 10.1093/cvr/cvr306; Arnold S, 1997, EUR J BIOCHEM, V249, P350, DOI 10.1111/j.1432-1033.1997.t01-1-00350.x; Barrientos A, 2004, EMBO J, V23, P3472, DOI 10.1038/sj.emboj.7600358; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Barrientos A., 2009, CURR PROTOC HUM GENE, V19, P13, DOI DOI 10.1002/0471142905.HG1903S63; Barrientos A, 2012, AGING-US, V4, P578, DOI 10.18632/aging.100485; Belotti F, 2012, BBA-MOL CELL RES, V1823, P1208, DOI 10.1016/j.bbamcr.2012.04.016; Bender E, 2000, FEBS LETT, V466, P130, DOI 10.1016/S0014-5793(99)01773-1; Bitterman JL, 2013, J PHARMACOL EXP THER, V347, P589, DOI 10.1124/jpet.113.208496; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Burke PV, 1998, J EXP BIOL, V201, P1163; Castello PR, 2008, P NATL ACAD SCI USA, V105, P8203, DOI 10.1073/pnas.0709461105; Das J, 2004, MOL BIOL EVOL, V21, P1572, DOI 10.1093/molbev/msh161; Di Benedetto G, 2013, CELL METAB, V17, P965, DOI 10.1016/j.cmet.2013.05.003; DiPilato LM, 2004, P NATL ACAD SCI USA, V101, P16513, DOI 10.1073/pnas.0405973101; DODGSON SJ, 1980, P NATL ACAD SCI-BIOL, V77, P5562, DOI 10.1073/pnas.77.9.5562; Elleuche S, 2010, MICROBIOL-SGM, V156, P23, DOI 10.1099/mic.0.032581-0; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Fang JK, 2007, FEBS LETT, V581, P1302, DOI 10.1016/j.febslet.2007.02.042; Follmann K, 1998, BIOCHEM MOL BIOL INT, V45, P1047; FRAENKEL DG, 1985, P NATL ACAD SCI USA, V82, P4740, DOI 10.1073/pnas.82.14.4740; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Grimsrud PA, 2012, CELL METAB, V16, P672, DOI 10.1016/j.cmet.2012.10.004; Hall RA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001193; Henriksen P, 2012, MOL CELL PROTEOMICS, V11, P1510, DOI 10.1074/mcp.M112.017251; Henry RP, 1996, ANNU REV PHYSIOL, V58, P523, DOI 10.1146/annurev.ph.58.030196.002515; Hess KC, 2005, DEV CELL, V9, P249, DOI 10.1016/j.devcel.2005.06.007; HODGE MR, 1989, MOL CELL BIOL, V9, P1958, DOI 10.1128/MCB.9.5.1958; Horvat S, 2006, J NEUROCHEM, V99, P937, DOI 10.1111/j.1471-4159.2006.04134.x; Huttemann M, 2001, GENE, V267, P111, DOI 10.1016/S0378-1119(01)00385-7; Jain P, 2003, ANTIMICROB AGENTS CH, V47, P3195, DOI 10.1128/AAC.47.10.3195-3201.2003; Jungbluth M, 2012, EUKARYOT CELL, V11, P1021, DOI 10.1128/EC.05240-11; Klengel T, 2005, CURR BIOL, V15, P2021, DOI 10.1016/j.cub.2005.10.040; Kumar S, 2009, J BIOL CHEM, V284, P14760, DOI 10.1074/jbc.M900925200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefkimmiatis K, 2013, J CELL BIOL, V202, P453, DOI 10.1083/jcb.201303159; Liu JJ, 2013, ANTIOXID REDOX SIGN, V19, P1916, DOI 10.1089/ars.2012.4589; Longo VD, 2012, CELL METAB, V16, P18, DOI 10.1016/j.cmet.2012.06.002; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2355, DOI 10.1073/pnas.79.7.2355; McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054; MCENTEE CM, 1993, MOL GEN GENET, V241, P213, DOI 10.1007/BF00280219; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; MITTS MR, 1990, MOL CELL BIOL, V10, P3873, DOI 10.1128/MCB.10.8.3873; Mogensen EG, 2006, EUKARYOT CELL, V5, P103, DOI 10.1128/EC.5.1.103-111.2006; MULLER G, 1989, BIOCHEMISTRY-US, V28, P9968; Ocampo A, 2012, CELL METAB, V16, P55, DOI 10.1016/j.cmet.2012.05.013; Pierron D, 2012, BBA-BIOENERGETICS, V1817, P590, DOI 10.1016/j.bbabio.2011.07.007; Poyton RO, 1999, RESP PHYSIOL, V115, P119, DOI 10.1016/S0034-5687(99)00028-6; RAHMAN MU, 1995, BIOCHEM BIOPH RES CO, V214, P188, DOI 10.1006/bbrc.1995.2273; Reinders J, 2007, MOL CELL PROTEOMICS, V6, P1896, DOI 10.1074/mcp.M700098-MCP200; Reinders J, 2006, J PROTEOME RES, V5, P1543, DOI 10.1021/pr050477f; RODEL G, 1985, J BACTERIOL, V161, P7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sander M, 1997, BIOCHEMISTRY-US, V36, P6100, DOI 10.1021/bi970048y; Santangelo GM, 2006, MICROBIOL MOL BIOL R, V70, P253, DOI 10.1128/MMBR.70.1.253-282.2006; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Soto IC, 2012, BBA-BIOENERGETICS, V1817, P883, DOI 10.1016/j.bbabio.2011.09.005; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; Tait SWG, 2012, J CELL SCI, V125, P807, DOI 10.1242/jcs.099234; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Valsecchi F, 2013, PHYSIOLOGY, V28, P199, DOI 10.1152/physiol.00004.2013; Zaman S, 2008, ANNU REV GENET, V42, P27, DOI 10.1146/annurev.genet.41.110306.130206; Zee JM, 2006, BIOCHEM CELL BIOL, V84, P859, DOI 10.1139/O06-201	74	24	24	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4369	4380		10.1096/fj.14-252890	http://dx.doi.org/10.1096/fj.14-252890			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25002117	Green Published			2022-12-28	WOS:000342222700016
J	Rogerson, FM; Yao, YZ; Young, MJ; Fuller, PJ				Rogerson, Fraser M.; Yao, Yi-Zhou; Young, Morag J.; Fuller, Peter J.			Identification and characterization of a ligand-selective mineralocorticoid receptor coactivator	FASEB JOURNAL			English	Article						aldosterone; cortisol; nuclear receptors	MAMMARY-GLAND DEVELOPMENT; NUCLEAR RECEPTORS; CELL DIFFERENTIATION; ALDOSTERONE BINDING; IN-VITRO; ACTIVATION; PROTEIN; SPECIFICITY; MECHANISMS; TESMIN	The mineralocorticoid receptor (MR) is unique in responding to 2 physiological ligands: aldosterone and cortisol. In epithelial tissues, aldosterone selectivity is determined by the activity of 11 beta-hydroxysteroid dehydrogenase type 2. In other tissues, cortisol is the primary ligand. To understand the structural determinants of ligand-specific MR activation, we sought to identify coregulatory molecules that interact with the ligand-binding domain (LBD) of the MR. A yeast-2-hybrid (Y2H) kidney cDNA library was screened with the human MR-LBD in the presence of aldosterone and cortisol. One clone, identified as aldosterone-specific in the Y2H assay, exhibited a 7-fold greater response, aldosterone vs. cortisol, in a mammalian-2hybrid (M2H) assay. This clone encodes the region of the tesmin gene that has 2 leucine-x-x-leucine-leucine (LxxLL) motifs. Full-length tesmin coactivates (>2-fold) MR-mediated transactivation in the presence of aldosterone, but not of cortisol; this specificity is observed with a range of promoters. GST pulldown and coimmunoprecipitation of the MR by tesmin supports a direct interaction, mediated by the 2 LxxLL motifs. Tesmin thus represents a novel MR coregulator that exhibits a differential interaction, providing further evidence of the adoption of ligand-dependent conformations by the MR-LBD.	[Rogerson, Fraser M.; Yao, Yi-Zhou; Young, Morag J.; Fuller, Peter J.] Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia	Prince Henry's Institute of Medical Research	Fuller, PJ (corresponding author), Prince Henrys Inst Med Res, POB 5152, Clayton, Vic 3168, Australia.	peter.fuller@princehenrys.org		Fuller, Peter/0000-0002-0948-2072; Young, Morag/0000-0003-0450-5375	Australia National Health and Medical Research Council [1002559, 1002575]; Endocrine Society through a bridge grant; National Heart Foundation of Australia through a project grant; Victorian Government's Operational Infrastructure Support Program	Australia National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Endocrine Society through a bridge grant; National Heart Foundation of Australia through a project grant(National Heart Foundation of Australia); Victorian Government's Operational Infrastructure Support Program	The authors thank the following individuals for the generous gifts of research materials: Prof. R. M. Evans (Salk Institute, La Jolla, CA, USA) for the pRShGR and pRShMR plasmids; Prof. S. Nordeen (University of Denver, Denver, CO, USA) for the PGC-1 alpha expression plasmid; Prof. G. Ooi (Prince Henry's Institute, Melbourne, VIC, Australia) for the pRen-LUC plasmid; Prof. D. Pearce (University of California, San Francisco, CA, USA) for the pTAT1-LUC and pTAT3-LUC plasmids; Prof. C. Thomas (University of Iowa, Iowa City, IA, USA) for the alpha ENaC-LUC plasmid; Prof. C. Clarke (University of Sydney, Westmead, NSW, Australia) for the pRen-LUC plasmid and the PR expression plasmid; Prof. B. Katzenellenbogen (University of Illinois at Urbana-Champaign, Urbana, IL, USA) for the ERE-LUC plasmid and the ER alpha expression plasmid; Prof. S. Lim-Tio (Westmead Hospital, Westmead, NSW, Australia) for the SRC-1e expression plasmid; Prof. T. Ziera (University of California, San Francisco, CA, USA) for the pGILZ-LUC and pCNKsRE-LUC plasmids; Prof. W. Tilley (University of Adelaide, Adelaide, SA, Australia) for the MMTV-LUC and pAAR3-tk-LUC plasmids and the AR expression plasmid; and Prof. C. Gomez-Sanchez (University of Mississippi Medical Center, Jackson, MS, USA) for the MR antisera. The authors also thank C. Thiedeman and S. Panckridge for help in preparation of the manuscript. This work was supported by the Australia National Health and Medical Research Council through a Career Fellowship (1002559 to P.J.F.) and a project grant (1002575); by the Endocrine Society through a bridge grant; and by the National Heart Foundation of Australia through a project grant. Prince Henry's Institute is supported by the Victorian Government's Operational Infrastructure Support Program.	Andersen SU, 2007, J EXP BOT, V58, P3657, DOI 10.1093/jxb/erm215; Armstrong P. W., 2004, NEW ENGL J MED, V364, P79; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; Berger S, 1998, P NATL ACAD SCI USA, V95, P9424, DOI 10.1073/pnas.95.16.9424; Bledsoe RK, 2005, J BIOL CHEM, V280, P31283, DOI 10.1074/jbc.M504098200; Cachofeiro V, 2008, J STEROID BIOCHEM, V109, P331, DOI 10.1016/j.jsbmb.2008.03.005; Chang CY, 2005, MOL ENDOCRINOL, V19, P2478, DOI 10.1210/me.2005-0072; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Fagart J, 2005, NAT STRUCT MOL BIOL, V12, P554, DOI 10.1038/nsmb939; Fuller PJ, 2005, HYPERTENSION, V46, P1227, DOI 10.1161/01.HYP.0000193502.77417.17; Fuse H, 2000, MOL ENDOCRINOL, V14, P889, DOI 10.1210/me.14.6.889; Glass CK, 2000, GENE DEV, V14, P121; GOMEZSANCHEZ EP, 1990, AM J PHYSIOL, V258, pE649, DOI 10.1152/ajpendo.1990.258.4.E649; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Hultman ML, 2005, MOL ENDOCRINOL, V19, P1460, DOI 10.1210/me.2004-0537; Jiang PP, 2010, P NATL ACAD SCI USA, V107, P6765, DOI 10.1073/pnas.1001814107; Joels M, 2008, TRENDS NEUROSCI, V31, P1, DOI 10.1016/j.tins.2007.10.005; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Khanna S, 2011, TOXICOLOGY, V287, P46, DOI 10.1016/j.tox.2011.05.013; Kitagawa H, 2002, MOL CELL BIOL, V22, P3698, DOI 10.1128/MCB.22.11.3698-3706.2002; Kitagawa H, 2014, MOL CELL BIOL, V34, P916, DOI 10.1128/MCB.00018-14; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Kralli A, 1996, J BIOL CHEM, V271, P17152, DOI 10.1074/jbc.271.29.17152; Li Y, 2005, MOL CELL, V19, P367, DOI 10.1016/j.molcel.2005.06.026; Lopez FJ, 2008, ENDOCRINOLOGY, V149, P2080, DOI 10.1210/en.2007-1353; Lu NZ, 2006, PHARMACOL REV, V58, P782, DOI 10.1124/pr.58.4.9; Massaad C, 1997, MOL PHARMACOL, V51, P285, DOI 10.1124/mol.51.2.285; Matsuura T, 2002, J INORG BIOCHEM, V88, P183, DOI 10.1016/S0162-0134(01)00377-4; Meijer OC, 2005, ENDOCRINOLOGY, V146, P1438, DOI 10.1210/en.2004-0411; Mihailidou AS, 2006, STEROIDS, V71, P277, DOI 10.1016/j.steroids.2005.09.017; Miner JN, 2007, ENDOCRINOLOGY, V148, P363, DOI 10.1210/en.2006-0793; Murai-Takeda A, 2010, J BIOL CHEM, V285, P8084, DOI 10.1074/jbc.M109.053371; NORDEEN SK, 1995, STEROIDS, V60, P97, DOI 10.1016/0039-128X(94)00001-S; O'Malley BW, 2008, MOL ENDOCRINOL, V22, P2213, DOI 10.1210/me.2008-0201; Obradovic D, 2004, MOL PHARMACOL, V65, P761, DOI 10.1124/mol.65.3.761; Oh JH, 2005, MAMM GENOME, V16, P942, DOI 10.1007/s00335-005-0075-2; Olesen C, 2004, MOL REPROD DEV, V67, P116, DOI 10.1002/mrd.20007; Pascual-Le Tallec L, 2005, MOL ENDOCRINOL, V19, P1158, DOI 10.1210/me.2004-0331; Pascual-Le Tallec L, 2003, MOL ENDOCRINOL, V17, P2529, DOI 10.1210/me.2003-0299; Pippal JB, 2009, MOL ENDOCRINOL, V23, P1360, DOI 10.1210/me.2009-0032; Pitt B, 2003, CIRCULATION, V108, P1831, DOI 10.1161/01.CIR.0000091405.00772.6E; Portilla D, 2002, KIDNEY INT, V62, P1208, DOI 10.1046/j.1523-1755.2002.00553.x; Rogerson FM, 2003, MOL CELL ENDOCRINOL, V200, P45, DOI 10.1016/S0303-7207(02)00413-6; Rogerson FM, 1999, J BIOL CHEM, V274, P36305, DOI 10.1074/jbc.274.51.36305; Rogerson FM, 2007, MOL ENDOCRINOL, V21, P817, DOI 10.1210/me.2006-0246; Sasaki H, 2007, J CLIN ENDOCR METAB, V92, P616, DOI 10.1210/jc.2006-0898; Sato A, 1996, ENDOCRINOLOGY, V137, P4145, DOI 10.1210/en.137.10.4145; Savkur RS, 2004, J PEPT RES, V63, P207, DOI 10.1111/j.1399-3011.2004.00126.x; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sugihara T, 1999, GENOMICS, V57, P130, DOI 10.1006/geno.1999.5756; Sutou S, 2003, BIOL REPROD, V68, P1861, DOI 10.1095/biolreprod.102.005603; Thomas M, 2007, AM J PHYSIOL-HEART C, V293, pH2361, DOI 10.1152/ajpheart.00200.2007; Viengchareun S., 2007, NUCL RECEPT SIGNAL, V5, P1; Weiss RE, 2002, ENDOCRINOLOGY, V143, P1554, DOI 10.1210/en.143.4.1554; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; WRIGHT APH, 1992, J BIOL CHEM, V267, P11191; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yang J, 2011, MOL ENDOCRINOL, V25, P32, DOI 10.1210/me.2010-0193; Yokota K, 2007, J BIOL CHEM, V282, P1998, DOI 10.1074/jbc.M607741200; Young MJ, 2008, CURR OPIN NEPHROL HY, V17, P174, DOI 10.1097/MNH.0b013e3282f56854; Zennaro MC, 2001, MOL ENDOCRINOL, V15, P1586, DOI 10.1210/me.15.9.1586; Ziera T, 2009, FASEB J, V23, P3936, DOI 10.1096/fj.09-134759	62	24	25	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4200	4210		10.1096/fj.13-242479	http://dx.doi.org/10.1096/fj.13-242479			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24907116				2022-12-28	WOS:000342222700002
J	Musiani, D; Konda, JD; Pavan, S; Torchiaro, E; Sassi, F; Noghero, A; Erriquez, J; Perera, T; Olivero, M; Di Renzo, MF				Musiani, Daniele; Konda, John David; Pavan, Simona; Torchiaro, Erica; Sassi, Francesco; Noghero, Alessio; Erriquez, Jessica; Perera, Timothy; Olivero, Martina; Di Renzo, Maria Flavia			Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy	FASEB JOURNAL			English	Article						hepatocyte growth factor receptor; EGFR	FUMARASE TUMOR-SUPPRESSOR; CANCER-CELLS; PROSTATE-CANCER; GASTRIC-CANCER; SOMATIC MUTATIONS; MAMMALIAN HSP27; BREAST-CANCER; GROWTH-FACTOR; IN-VITRO; CHEMOTHERAPY	The tyrosine kinase encoded by the MET oncogene is activated by gene mutation or amplification in tumors, which in most instances maintain addiction, i.e., dependency, to MET activation. This makes MET an attractive candidate for targeted therapies. Here we show that, in 3/3 MET-addicted human gastric cancer cell lines, MET kinase inhibition resulted in a 3- to 4-fold increased expression of the antiapoptotic small heat-shock protein of 27 kDa (HSP27, HSPB1). HSP27 increase depended on the inhibition of the MEK/ERK pathway and on heat-shock factor 1 (HSF1) and hypoxia-inducible factor-1 alpha (HIF-1 alpha) regulation. Importantly, HSP27-silenced MET-addicted cells underwent 2- and 3-fold more apoptosis following MET inhibition in vitro and in vivo, respectively. Likewise, in human cancer cells susceptible to epidermal growth factor receptor (EGFR) inhibition, EGFR inhibitors induced HSP27 expression and were strengthened by HSP27 suppression. In control cell lines that were not affected by drugs targeting MET or EGFR, these drugs did not induce HSP27 increase. Therefore, in cancer therapies targeting the MET pathway, the induction of HSP27 might limit the efficacy of anti-MET agents. As HSP27 increase also impairs the effectiveness of EGFR inhibitors and is known to protect cells from chemotherapeutics, the induction of HSP27 by targeted agents might strongly affect the success of combination treatments.	[Musiani, Daniele; Konda, John David; Pavan, Simona; Torchiaro, Erica; Noghero, Alessio; Olivero, Martina; Di Renzo, Maria Flavia] Univ Turin, Sch Med, Dept Oncol, I-10060 Turin, Italy; [Musiani, Daniele; Konda, John David; Pavan, Simona; Torchiaro, Erica; Erriquez, Jessica; Olivero, Martina; Di Renzo, Maria Flavia] Candiolo Canc Inst, FPO, IRCCS, Canc Genet Lab, Candiolo, Italy; [Sassi, Francesco] Candiolo Canc Inst, FPO, IRCCS, Mol Pharmacol Lab, Candiolo, Italy; [Noghero, Alessio] Candiolo Canc Inst, FPO, IRCCS, Lab Vasc Oncol, Candiolo, Italy; [Perera, Timothy] Janssen Res & Dev, Beerse, Belgium	University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; IRCCS Fondazione del Piemonte per l'Oncologia; IRCCS Fondazione del Piemonte per l'Oncologia; Johnson & Johnson; Janssen Pharmaceuticals	Di Renzo, MF (corresponding author), Univ Turin, Sch Med, Candiolo Canc Inst, Dept Oncol,Lab Canc Genet,FPO IRCCS, SP 142,Km 3 95, I-10060 Turin, Italy.		Torchiaro, Erica/AAW-3628-2020; sassi, francesco/AAB-6844-2020; Musiani, Daniele/N-8121-2017; olivero, martina/J-4811-2018; DI RENZO, Maria Flavia/B-6091-2012; NOGHERO, Alessio/AAL-1573-2020	Torchiaro, Erica/0000-0002-8984-882X; sassi, francesco/0000-0002-4741-0408; olivero, martina/0000-0002-6815-3498; DI RENZO, Maria Flavia/0000-0002-5093-3373; NOGHERO, Alessio/0000-0002-8266-9247; Musiani, Daniele/0000-0001-6851-2633; erriquez, jessica/0000-0002-7152-0930	IG grant [13050]; Special Program Molecular Clinical Oncology 5xMille of the Italian Association of Cancer Research (AIRC) Project [9970]; Cariplo Foundation grant; Progetto di Ateneo-Compagnia di San Paolo grant [ORTO11RKTW]	IG grant; Special Program Molecular Clinical Oncology 5xMille of the Italian Association of Cancer Research (AIRC) Project(Fondazione AIRC per la ricerca sul cancro); Cariplo Foundation grant; Progetto di Ateneo-Compagnia di San Paolo grant	The authors thank Livio Trusolino for the helpful discussion and critical reading of the manuscript, Dr. Luca Cirillo for enthusiastic help in performing experiments, Dr. Davide Zecchin [Laboratory of Molecular Genetics, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy] for providing p53 shRNA, and Silvia Giordano (Department of Oncology, University of Torino School of Medicine, Turin, Italy) for providing K-Ras G12V. This work has been supported by the following grants to M. F. D.: 2012 IG grant 13050 and 2010 Special Program Molecular Clinical Oncology 5xMille of the Italian Association of Cancer Research (AIRC) Project 9970, a Cariplo Foundation grant, and Progetto di Ateneo-Compagnia di San Paolo grant ORTO11RKTW. Conflicts of interest: T. P. is a full-time employee and shareholder of Janssen Research and Development (Beerse, Belgium). The other authors declare no conflicts of interest.	Acunzo J, 2012, INT J BIOCHEM CELL B, V44, P1622, DOI 10.1016/j.biocel.2012.04.002; Akerfelt M, 2010, NAT REV MOL CELL BIO, V11, P545, DOI 10.1038/nrm2938; Andrieu C, 2010, ONCOGENE, V29, P1883, DOI 10.1038/onc.2009.479; Arrigo AP, 2012, CURR MOL MED, V12, P1151, DOI 10.2174/156652412803306693; Arrigo AP, 2007, ADV EXP MED BIOL, V594, P14; Arts HJG, 1999, INT J CANCER, V84, P234, DOI 10.1002/(SICI)1097-0215(19990621)84:3<234::AID-IJC6>3.0.CO;2-9; Asaoka Y, 2010, BIOCHEM BIOPH RES CO, V394, P1042, DOI 10.1016/j.bbrc.2010.03.120; Bardella C, 2012, MOL CELL BIOL, V32, P3081, DOI 10.1128/MCB.06160-11; Baylot V, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.104; Bertotti A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2102er11; Bhargavan B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.57; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Coltella N, 2006, INT J CANCER, V118, P2981, DOI 10.1002/ijc.21766; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Conroy SE, 1998, BRIT J CANCER, V77, P1875, DOI 10.1038/bjc.1998.312; Cornford PA, 2000, CANCER RES, V60, P7099; Costa B, 2010, FASEB J, V24, P2680, DOI 10.1096/fj.09-146928; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Dunn EF, 2011, ONCOGENE, V30, P561, DOI 10.1038/onc.2010.430; Eguchi R, 2008, PROTEOMICS, V8, P2897, DOI 10.1002/pmic.200800055; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Gao CL, 2000, INT J CANCER, V88, P191, DOI 10.1002/1097-0215(20001015)88:2<191::AID-IJC7>3.3.CO;2-1; Garrido C, 2012, INT J BIOCHEM CELL B, V44, P1588, DOI 10.1016/j.biocel.2012.02.022; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Gibert B, 2011, ONCOGENE, V30, P3672, DOI 10.1038/onc.2011.73; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Jackson AL, 2010, NAT REV DRUG DISCOV, V9, P57, DOI 10.1038/nrd3010; Kang SH, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-286; Kostenko S, 2009, CELL MOL LIFE SCI, V66, P3289, DOI 10.1007/s00018-009-0086-3; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; Lanneau D, 2010, THESCIENTIFICWORLDJO, V10, P1543, DOI 10.1100/tsw.2010.152; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Lu Y, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-63; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; Okamoto W, 2012, MOL CANCER THER, V11, P1557, DOI 10.1158/1535-7163.MCT-11-0934; Pandey P, 2000, ONCOGENE, V19, P1975, DOI 10.1038/sj.onc.1203531; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Shinohara T, 2002, PROG RETIN EYE RES, V21, P341, DOI 10.1016/S1350-9462(02)00007-1; Stella GM, 2011, HUM MUTAT, V32, P44, DOI 10.1002/humu.21374; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Wettstein G, 2012, INT J BIOCHEM CELL B, V44, P1680, DOI 10.1016/j.biocel.2012.05.024; Whitlock NA, 2005, INVEST OPHTH VIS SCI, V46, P1092, DOI 10.1167/iovs.04-0043; Zoubeidi A, 2012, INT J BIOCHEM CELL B, V44, P1646, DOI 10.1016/j.biocel.2012.04.010; Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057	45	29	30	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					4055	4067		10.1096/fj.13-247924	http://dx.doi.org/10.1096/fj.13-247924			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24903273	Green Published			2022-12-28	WOS:000340845900023
J	Pankratz, S; Bittner, S; Herrmann, AM; Schuhmann, MK; Ruck, T; Meuth, SG; Wiendl, H				Pankratz, Susann; Bittner, Stefan; Herrmann, Alexander M.; Schuhmann, Michael K.; Ruck, Tobias; Meuth, Sven G.; Wiendl, Heinz			Human CD4(+)HLA-G(+) regulatory T cells are potent suppressors of graft-versus-host disease in vivo	FASEB JOURNAL			English	Article						human leukocyte antigen G; immune tolerance; humanized mouse model; membrane potential of tT(reg) cells	CYCLIC ADENOSINE-MONOPHOSPHATE; HUMAN PERIPHERAL-BLOOD; CENTRAL-NERVOUS-SYSTEM; HLA-G EXPRESSION; MULTIPLE-SCLEROSIS; EX-VIVO; ACTIVATION; TOLERANCE; FOXP3; INFLAMMATION	CD4(+) T cells expressing the immunotolerizing molecule HLA-G have been described as a unique human thymus-derived regulatory T (tT(reg)) cell subset involved in immunoregulation and parenchymal homeostasis during infectious and autoimmune inflammation. We compared properties and molecular characteristics of human CD4(+) HLA-G(+) with those of CD4(+) CD25(+) FoxP3-expressing tT(reg) cells using in vitro studies of T-cell receptor (TCR) signaling, single-cell electrophysiology, and functional in vivo studies. Both tT(reg) populations are characterized by alterations in proximal-signaling pathways on TCR stimulation and a hyperpolarization of the plasma membrane when compared to conventional CD4(+) T cells. However, both clearly differ in phenotype and pattern of secreted cytokines, which results in distinct mechanisms of suppression: While CD4(+) HLA-G(+) cells secrete high levels of inhibitory molecules (IL-10, soluble HLA-G, IL-35), CD4(+) CD25(+) FoxP3(+) cells express these molecules at significantly lower levels and seem to exert their function mainly in a contact-dependent manner via cyclic adenosine-monophosphate. Finally we demonstrate that human CD4(+) HLA-G(+) tT(reg) cells significantly ameliorated graft-versus-host disease in a humanized mouse model as a first proof of their in vivo relevance. Our data further characterize and establish CD4(+) HLA-G(+) cells as a potent human tT(reg) population that can modulate polyclonal adaptive immune responses in vivo and thus being a promising candidate for potential clinical applications in the future.	[Pankratz, Susann; Bittner, Stefan; Herrmann, Alexander M.; Ruck, Tobias; Meuth, Sven G.; Wiendl, Heinz] Univ Munster, Dept Neurol, D-48149 Munster, Germany; [Meuth, Sven G.] Univ Munster, Dept Neuropathophysiol, Inst Physiol 1, D-48149 Munster, Germany; [Schuhmann, Michael K.] Univ Wurzburg, Dept Neurol, Wurzburg, Germany	University of Munster; University of Munster; University of Wurzburg	Wiendl, H (corresponding author), Univ Munster, Dept Neurol, Albert Schweitzer Campus 1, D-48149 Munster, Germany.	heinz.wiendl@ukmuenster.de	Ruck, Tobias/AAH-4627-2021; Meuth, Sven G/HHM-8941-2022; Ruck, Tobias/AAQ-3703-2020; Wiendl, Heinz/AAX-6041-2021	Meuth, Sven G/0000-0003-2571-3501; Ruck, Tobias/0000-0001-6332-8650; Eichler (born Pankratz), Susann/0000-0003-3321-3232; Bittner, Stefan/0000-0003-2179-3655; Wiendl, Heinz/0000-0003-4310-3432	Innovative Medizinische Forschung [IMF Bl111316]; Competence Network for Multiple Sclerosis - Federal Ministry of Education and Research [FKZ 01GI0907]; German Research Foundation [Deutsche Forschungsgemeinschaft (DFG)] [CRC Transregio 128-A9, CRC Transregio 128-B1, WI 1722/6-1]; DFG, Cells-in-Motion Cluster of Excellence, University of Munster [EXC 1003-CiM]	Innovative Medizinische Forschung; Competence Network for Multiple Sclerosis - Federal Ministry of Education and Research; German Research Foundation [Deutsche Forschungsgemeinschaft (DFG)](German Research Foundation (DFG)); DFG, Cells-in-Motion Cluster of Excellence, University of Munster	The authors are grateful to Prof. Dr. Jerzy-Roch Nofer (Center for Laboratory Medicine, University Hospital Munster, Munster, Germany) for GPT measurements, Prof. Dr. Lydia M. Sorokin (Institute for Physiological Chemistry and Pathobiochemistry, Munster University, Munster, Germany) for providing the purified anti-CD3 mAb, and the Department of Transfusion Medicine (University of Munster, Munster, Germany) for providing the fresh LRS chambers. This work was supported by Innovative Medizinische Forschung (IMF Bl111316) to S. B. and S. G. M.; the Competence Network for Multiple Sclerosis, funded by the Federal Ministry of Education and Research (FKZ 01GI0907), to H. W.; the German Research Foundation [Deutsche Forschungsgemeinschaft (DFG), CRC Transregio 128-A9, B1. and WI 1722/6-1] to H. W.; and by the DFG, Cells-in-Motion Cluster of Excellence (EXC 1003-CiM), University of Munster, to S. B., S. G. M., and H. W. All authors approved the final manuscript and had input in revising it for intellectual content and style. The authors declare no conflicts of interest.	Abbas AK, 2013, NAT IMMUNOL, V14, P307, DOI 10.1038/ni.2554; Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112; Baecher-Allan C, 2002, J IMMUNOL, V169, P6210, DOI 10.4049/jimmunol.169.11.6210; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Bartelt RR, 2013, WIRES SYST BIOL MED, V5, P101, DOI 10.1002/wsbm.1194; Becker C, 2009, BLOOD, V114, P1263, DOI 10.1182/blood-2009-02-206730; Bittner S, 2010, BRAIN PATHOL, V20, P999, DOI 10.1111/j.1750-3639.2010.00407.x; Bittner S, 2009, BRAIN, V132, P2501, DOI 10.1093/brain/awp163; Bodor J, 2012, EUR J IMMUNOL, V42, P1375, DOI 10.1002/eji.201141578; Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306; Costantino CM, 2008, EUR J IMMUNOL, V38, P921, DOI 10.1002/eji.200738104; Costantino CM, 2008, J CLIN IMMUNOL, V28, P697, DOI 10.1007/s10875-008-9236-x; Crellin NK, 2007, BLOOD, V109, P2014, DOI 10.1182/blood-2006-07-035279; de Andres C, 2007, J NEUROIMMUNOL, V182, P204, DOI 10.1016/j.jneuroim.2006.09.012; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; Feger U, 2007, CLIN EXP IMMUNOL, V147, P412, DOI 10.1111/j.1365-2249.2006.03271.x; Feger U, 2007, BLOOD, V110, P568, DOI 10.1182/blood-2006-11-057125; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Goodman WA, 2012, CRIT REV IMMUNOL, V32, P65, DOI 10.1615/CritRevImmunol.v32.i1.40; Huang YH, 2011, CELL MOL LIFE SCI, V68, P407, DOI 10.1007/s00018-010-0582-5; Huang YH, 2009, ANN NEUROL, V66, P171, DOI 10.1002/ana.21705; Huang YH, 2009, J LEUKOCYTE BIOL, V86, P273, DOI 10.1189/jlb.1008649; Jonuleit H, 2002, J EXP MED, V196, P255, DOI 10.1084/jem.20020394; Jonuleit H, 2005, METH MOLEC MED, V109, P285; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Klein M, 2012, J IMMUNOL, V188, P1091, DOI 10.4049/jimmunol.1102045; Li C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003140; Marek N, 2010, HUM IMMUNOL, V71, P666, DOI 10.1016/j.humimm.2010.05.002; Meuth SG, 2005, PFLUG ARCH EUR J PHY, V450, P111, DOI 10.1007/s00424-004-1377-z; Meuth SG, 2008, J BIOL CHEM, V283, P14559, DOI 10.1074/jbc.M800637200; Miyara M, 2007, TRENDS MOL MED, V13, P108, DOI 10.1016/j.molmed.2007.01.003; Moes N, 2010, GASTROENTEROLOGY, V139, P770, DOI 10.1053/j.gastro.2010.06.006; Mutis T, 2006, CLIN CANCER RES, V12, P5520, DOI 10.1158/1078-0432.CCR-06-0035; Niedbala W, 2007, EUR J IMMUNOL, V37, P3021, DOI 10.1002/eji.200737810; Olson BM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00315; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Schmetterer KG, 2012, FASEB J, V26, P2253, DOI 10.1096/fj.11-193672; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Stephens LA, 2001, EUR J IMMUNOL, V31, P1247, DOI 10.1002/1521-4141(200104)31:4<1247::AID-IMMU1247>3.0.CO;2-M; Strasser SI, 2000, HEPATOLOGY, V32, P1265, DOI 10.1053/jhep.2000.20067; Tsang JYS, 2006, J LEUKOCYTE BIOL, V80, P145, DOI 10.1189/jlb.0605344; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Xiao L, 2013, CHINESE MED J-PEKING, V126, P2652, DOI 10.3760/cma.j.issn.0366-6999.20122228; Zozulya AL, 2008, NAT CLIN PRACT NEURO, V4, P384, DOI 10.1038/ncpneuro0832	47	44	47	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3435	3445		10.1096/fj.14-251074	http://dx.doi.org/10.1096/fj.14-251074			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24744146				2022-12-28	WOS:000340265400014
J	Ma, JJ; Yang, BY; Yu, SF; Zhang, YN; Zhang, XL; Lao, SH; Chen, XC; Li, BQ; Wu, CY				Ma, Jiangjun; Yang, Binyan; Yu, Sifei; Zhang, Yannan; Zhang, Xianlan; Lao, Suihua; Chen, Xinchun; Li, Baiqing; Wu, Changyou			Tuberculosis antigen-induced expression of IFN-alpha in tuberculosis patients inhibits production of IL-1 beta	FASEB JOURNAL			English	Article						BCG; TB-Ag; PFMCs	MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; I INTERFERONS; INFLAMMASOME ACTIVATION; HUMAN MACROPHAGES; PLEURAL FLUID; INFECTION; CELLS; INTERLEUKIN-1; INDUCTION	The mechanism by which IFN-alpha regulates the host response to Mycobacterium tuberculosis (M. tb) infection in humans is poorly understood. In the present study, we found that freshly isolated pleural fluid mononuclear cells (PFMCs) from tuberculous pleural effusion but not peripheral blood mononuclear cells (PBMCs) spontaneously expressed IFN-alpha and IL-1 beta in vivo. In addition, exogenous IFN-alpha significantly inhibited production of IL-1 beta in PFMCs after stimulation with Bacillus Calmette-Guerin (BCG). To further evaluate the effect of endogenous IFN-alpha on BCG-induced IL-1 beta production, a neutralizing antibody to IFN-alpha was added to the cultures of BCG-stimulated PFMCs. As expected, neutralization of IFN-alpha by antibody significantly enhanced the production of IL-1 beta. Notably, we showed that IFN-alpha inhibited production of IL-1 beta through 2 distinct mechanisms: IFN-alpha signaling, via the STAT1 transcription factor, suppressed caspase-1-dependent IL-1 beta maturation, and IFN-alpha induced the production of IL-10 in a STAT1-dependent manner in which IL-10 reduced the abundance of IL-1 beta. In contrast, we found that IFN-alpha enhanced the production of IFN-gamma, and IFN-gamma also suppressed IL-1 beta production in the PFMCs during BCG stimulation. Our findings demonstrate that IFN-alpha employs distinct pathways for regulating IL-1 beta production and reveal that in the case of M. tb infection, the induction of IFN-alpha and IFN-gamma might be associated with M. tb immune escape and disease progression in infected humans.	[Ma, Jiangjun; Yang, Binyan; Yu, Sifei; Zhang, Yannan; Wu, Changyou] Sun Yat Sen Univ, Zhongshan Sch Med, Inst Immunol, Guangzhou 510080, Guangdong, Peoples R China; [Ma, Jiangjun; Yang, Binyan; Yu, Sifei; Zhang, Yannan; Wu, Changyou] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control Res, Guangzhou 510080, Guangdong, Peoples R China; [Zhang, Xianlan; Lao, Suihua] Chest Hosp Guangzhou, Guangzhou, Guangdong, Peoples R China; [Chen, Xinchun] Guangdong Med Coll, Shenzhen Peoples Hosp 3, Shenzhen Key Lab Infect & Immun, Shenzhen, Peoples R China; [Li, Baiqing] Bengbu Med Coll, Immunol Res Ctr, Dept Immunol, Bengbu, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangdong Medical University; Bengbu Medical College	Wu, CY (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Inst Immunol, 74 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.	changyou_wu@yahoo.com			Program of China [2013ZX10003007-002-003]; National Nature Science Foundation of China [31170833]; Guangdong Provincial Department of Science and Technology Plan Projects of China [2012B040304008]	Program of China; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Department of Science and Technology Plan Projects of China	This work was supported by the Program of China during the Twelfth Five-Year Plan Period (2013ZX10003007-002-003), National Nature Science Foundation of China (31170833), and Guangdong Provincial Department of Science and Technology Plan Projects of China (2012B040304008). The authors declare no conflicts of interest.	Apte RN, 2008, IMMUNOL REV, V222, P222, DOI 10.1111/j.1600-065X.2008.00615.x; Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5; Behar SM, 2010, NAT REV MICROBIOL, V8, P668, DOI 10.1038/nrmicro2387; Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247; Bouchonnet F, 2002, INFECT IMMUN, V70, P3020, DOI 10.1128/IAI.70.6.3020-3025.2002; Carlsson F, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000895; Cooper AM, 2011, MUCOSAL IMMUNOL, V4, P252, DOI 10.1038/mi.2011.13; Cooper AM, 2000, INFECT IMMUN, V68, P6879, DOI 10.1128/IAI.68.12.6879-6882.2000; Cosma CL, 2003, ANNU REV MICROBIOL, V57, P641, DOI 10.1146/annurev.micro.57.030502.091033; Desvignes L, 2012, J IMMUNOL, V188, P6205, DOI 10.4049/jimmunol.1200255; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinarello CA, 2010, ARTHRITIS RHEUM-US, V62, P3140, DOI 10.1002/art.27663; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Dye C, 2010, SCIENCE, V328, P856, DOI 10.1126/science.1185449; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Fremond CM, 2007, J IMMUNOL, V179, P1178, DOI 10.4049/jimmunol.179.2.1178; Garlanda C, 2007, J IMMUNOL, V179, P3119, DOI 10.4049/jimmunol.179.5.3119; Giosue S, 1998, AM J RESP CRIT CARE, V158, P1156, DOI 10.1164/ajrccm.158.4.9803065; Gonzalez-Navajas JM, 2012, NAT REV IMMUNOL, V12, P125, DOI 10.1038/nri3133; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Guler R, 2011, VACCINE, V29, P1339, DOI 10.1016/j.vaccine.2010.10.045; Harding CV, 2010, NAT REV MICROBIOL, V8, P296, DOI 10.1038/nrmicro2321; Li L, 2011, IMMUNOBIOLOGY, V216, P477, DOI 10.1016/j.imbio.2010.09.003; Li Q, 2011, IMMUNOL LETT, V138, P113, DOI 10.1016/j.imlet.2011.03.008; Li Q, 2011, CELL MOL IMMUNOL, V8, P172, DOI 10.1038/cmi.2010.80; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; Master SS, 2008, CELL HOST MICROBE, V3, P224, DOI 10.1016/j.chom.2008.03.003; Mayer-Barber KD, 2011, IMMUNITY, V35, P1023, DOI 10.1016/j.immuni.2011.12.002; Mayer-Barber KD, 2010, J IMMUNOL, V184, P3326, DOI 10.4049/jimmunol.0904189; Monack DM, 2004, NAT REV MICROBIOL, V2, P747, DOI 10.1038/nrmicro955; Monroe KM, 2010, CELL MICROBIOL, V12, P881, DOI 10.1111/j.1462-5822.2010.01478.x; Novikov A, 2011, J IMMUNOL, V187, P2540, DOI 10.4049/jimmunol.1100926; Palmero D, 1999, INT J TUBERC LUNG D, V3, P214; Prabhakar S, 2003, INFECT IMMUN, V71, P2487, DOI 10.1128/IAI.71.5.2487-2497.2003; Qiao D, 2011, SCAND J IMMUNOL, V73, P330, DOI 10.1111/j.1365-3083.2011.02512.x; Rayamajhi M, 2010, J EXP MED, V207, P327, DOI 10.1084/jem.20091746; Redford PS, 2011, MUCOSAL IMMUNOL, V4, P261, DOI 10.1038/mi.2011.7; Redford PS, 2010, EUR J IMMUNOL, V40, P2200, DOI 10.1002/eji.201040433; Remoli ME, 2002, J IMMUNOL, V169, P366, DOI 10.4049/jimmunol.169.1.366; Shi SP, 2005, J IMMUNOL, V175, P3318, DOI 10.4049/jimmunol.175.5.3318; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Stanley SA, 2007, J IMMUNOL, V178, P3143, DOI 10.4049/jimmunol.178.5.3143; Stern JNH, 2009, IMMUNOL RES, V45, P1, DOI 10.1007/s12026-008-8024-2; Taki S, 2002, CYTOKINE GROWTH F R, V13, P379, DOI 10.1016/S1359-6101(02)00023-0; Trinchieri G, 2010, J EXP MED, V207, P2053, DOI 10.1084/jem.20101664; Turner J, 2002, J IMMUNOL, V169, P6343, DOI 10.4049/jimmunol.169.11.6343; Volkman HE, 2010, SCIENCE, V327, P466, DOI 10.1126/science.1179663; Ward CM, 2007, EUR J PEDIATR, V166, P981, DOI 10.1007/s00431-006-0339-1	48	17	19	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2014	28	7					3238	3248		10.1096/fj.13-247056	http://dx.doi.org/10.1096/fj.13-247056			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AJ8JN	24675363				2022-12-28	WOS:000337949400043
J	Mediero, A; Wilder, T; Perez-Aso, M; Cronstein, BN				Mediero, Aranzazu; Wilder, Tuere; Perez-Aso, Miguel; Cronstein, Bruce N.			Direct or indirect stimulation of adenosine A(2A) receptors enhances bone regeneration as well as bone morphogenetic protein-2	FASEB JOURNAL			English	Article						CGS21680; dipyridamole; bone formation; osteoclast; osteoblast	OSTEOCLAST FORMATION; ACTIVATION; DIFFERENTIATION; INFLAMMATION; TRANSPORTER; EXPRESSION; DEFECTS; SAFETY; CELLS; A(1)	Promoting bone regeneration and repair of bone defects is a need that has not been well met to date. We have previously found that adenosine, acting via A(2A) receptors (A2AR) promotes wound healing and inhibits inflammatory osteolysis and hypothesized that A2AR might be a novel target to promote bone regeneration. Therefore, we determined whether direct A2AR stimulation or increasing endogenous adenosine concentrations via purine transport blockade with dipyridamole regulates bone formation. We determined whether coverage of a 3 mm trephine defect in a mouse skull with a collagen scaffold soaked in saline, bone morphogenetic protein-2 (BMP-2; 200 ng), 1 mu M CGS21680 (A2AR agonist, EC50 = 160 nM), or 1 mu M dipyridamole (EC50 = 32 nM) promoted bone regeneration. Microcomputed tomography examination demonstrated that CGS21680 and dipyridamole markedly enhanced bone regeneration as well as BMP-2 8 wk after surgery (60 +/- 2%, 79 +/- 2%, and 75 +/- 1% bone regeneration, respectively, vs. 32 +/- 2% in control, P < 0.001). Blockade by a selective A2AR antagonist (ZM241385, 1 mu M) or deletion of A2AR abrogated the effect of CGS21680 and dipyridamole on bone regeneration. Both CGS21680 and dipyridamole treatment increased alkaline phosphatase-positive osteoblasts and diminished tartrate resistance acid phosphatase-positive osteoclasts in the defects. In vivo imaging with a fluorescent dye for new bone formation revealed a strong fluorescent signal in treated animals that was equivalent to BMP-2. In conclusion, stimulation of A2AR by specific agonists or by increasing endogenous adenosine levels stimulates new bone formation as well as BMP-2 and represents a novel approach to stimulating bone regeneration.	NYU, Langone Med Ctr, Dept Med, Div Translat Med, New York, NY 10016 USA; NYU, Langone Med Ctr, Dept Med, Div Rheumatol, New York, NY 10016 USA	New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center	Cronstein, BN (corresponding author), NYU, Sch Med, Dept Med, Div Translat Med, 550 First Ave,MSB251, New York, NY 10016 USA.	bruce.cronstein@nyumc.org	Mediero, Aranzazu/AAA-8362-2020	Mediero, Aranzazu/0000-0002-5368-574X; Cronstein, Bruce/0000-0002-4295-7383; Pintor, Jesus/0000-0002-9191-7679; Perez-Aso, Miguel/0000-0002-4703-4182	U.S. National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR56672, AR54897, AR046121]; NIH National Heart, Lung, and Blood Institute [RC1-HL100815]; New York University Health and Hospitals Corporation (NYU-HHC) Clinical and Translational Science Institute [UL1TR000038]; New York University Caregiver Intervention (NYUCI) Center support grant from NIH National Cancer Institute [5-P30CA16087-310]; Takeda; Celgene; AstraZeneca; Gilead Pharmaceuticals; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001445, UL1TR000038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC1HL100815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR056672, R01AR056672, R01AR054897, P30AR046121] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIH National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); New York University Health and Hospitals Corporation (NYU-HHC) Clinical and Translational Science Institute; New York University Caregiver Intervention (NYUCI) Center support grant from NIH National Cancer Institute; Takeda(Takeda Pharmaceutical Company Ltd); Celgene(Bristol-Myers SquibbCelgene Corporation); AstraZeneca(AstraZeneca); Gilead Pharmaceuticals(Gilead Sciences); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank the New York University School of Medicine Histology Core for help with immunostainings. This work was supported by U.S. National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases Grants AR56672, AR54897, AR046121 and NIH National Heart, Lung, and Blood Institute Grant RC1-HL100815; New York University Health and Hospitals Corporation (NYU-HHC) Clinical and Translational Science Institute (Grant UL1TR000038); New York University Caregiver Intervention (NYUCI) Center support grant from NIH National Cancer Institute Grant 5-P30CA16087-310; and grants from Takeda, Celgene, AstraZeneca, and Gilead Pharmaceuticals. A.M. and B.N.C. have filed a patent on the use of dipyridamole-coated matrices to promote bone growth and have received a patent for the use of adenosine A2AR agonists to prevent prosthesis loosening (patent number 8183225). A.M. and B.N.C. have filed a patent on the use of anti-netrin-1 antibodies for the treatment of bone disease (pending). B.N.C. holds patents 5,932,558; 6,020,321; 6,555,545; and 7,795,427-adenosine A1R and A<INF>2B</INF>R antagonists to treat fatty liver (pending). B.N.C. is a consultant for Bristol-Myers Squibb, Novartis, Eli Lilly & Co., CanFite Biopharmaceuticals, Cypress Laboratories, Regeneron (Westat, DSMB), Endocyte, Protalex, Allos, Inc., Savient, Gismo Therapeutics, Antares Pharmaceutical, Medivector, King Pharmaceutical, Celizome, Tap Pharmaceuticals, Prometheus Laboratories, Sepracor, Amgen, Combinatorx, Kyowa Hakka, Hoffman-LaRoche, and Avidimer Therapeutics and has stock in CanFite Biopharmaceuticals. M.P.-A. and T.W. declare no conflicts of interest.	Costa MA, 2011, J CELL PHYSIOL, V226, P1353, DOI 10.1002/jcp.22458; Boden SD, 2002, SPINE, V27, P2662, DOI 10.1097/00007632-200212010-00005; Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023; Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994; Cerqueira MD, 2004, AM J CARDIOL, V94, p33D; Chan ESL, 2010, NAT REV RHEUMATOL, V6, P175, DOI 10.1038/nrrheum.2010.5; Chaudary N, 2004, CARDIOVASC RES, V61, P780, DOI 10.1016/j.cardiores.2003.11.031; Cook SD, 2002, J INVEST SURG, V15, P69, DOI 10.1080/08941930290085822; Cooper GM, 2010, PLAST RECONSTR SURG, V125, P1685, DOI 10.1097/PRS.0b013e3181cb63a3; De Mattei M, 1999, BIOELECTROMAGNETICS, V20, P177, DOI 10.1002/(SICI)1521-186X(1999)20:3<177::AID-BEM4>3.0.CO;2-#; den Boer FC, 2003, J ORTHOP RES, V21, P521, DOI 10.1016/S0736-0266(02)00205-X; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Evans BAJ, 2006, J BONE MINER RES, V21, P228, DOI 10.1359/JBMR.051021; Fredholm BB, 2011, PHARMACOL REV, V63, P1, DOI 10.1124/pr.110.003285; Frey JL, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.5; Gharibi B, 2012, INT J OBESITY, V36, P397, DOI 10.1038/ijo.2011.129; Gharibi B, 2011, J BONE MINER RES, V26, P2112, DOI 10.1002/jbmr.424; Glassman SD, 2011, SPINE, V36, P1849, DOI 10.1097/BRS.0b013e3181d133d0; Harmatys KM, 2013, MOL PHARMACEUT, V10, P4263, DOI 10.1021/mp400357v; He W, 2012, PURINERG SIGNAL, V8, P327, DOI 10.1007/s11302-012-9292-9; He WJ, 2013, FASEB J, V27, P3446, DOI 10.1096/fj.13-231233; Kara FM, 2010, FASEB J, V24, P2325, DOI 10.1096/fj.09-147447; Kara FM, 2010, ARTHRITIS RHEUM-US, V62, P534, DOI 10.1002/art.27219; Katebi M, 2009, J LEUKOCYTE BIOL, V85, P438, DOI 10.1189/jlb.0908520; Khoa ND, 2006, MOL PHARMACOL, V69, P1311, DOI 10.1124/mol.105.016857; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; Knowles HJ, 2010, FASEB J, V24, P4648, DOI 10.1096/fj.10-162230; LAM JYT, 1988, J AM COLL CARDIOL, V11, P585, DOI 10.1016/0735-1097(88)91535-5; Lassailly F, 2010, BLOOD, V115, P5347, DOI 10.1182/blood-2009-05-224030; LETTE J, 1995, J NUCL CARDIOL, V2, P3, DOI 10.1016/S1071-3581(05)80003-0; Li HJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002353; Mediero A, 2015, ARTHRITIS RHEUMATOL, V67, P849, DOI 10.1002/art.38971; Mediero A, 2013, BRIT J PHARMACOL, V169, P1372, DOI 10.1111/bph.12227; Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001; Mediero A, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003393; Mediero A, 2012, AM J PATHOL, V180, P775, DOI 10.1016/j.ajpath.2011.10.017; Montesinos MC, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1914; Morote-Garcia JC, 2009, GASTROENTEROLOGY, V136, P607, DOI 10.1053/j.gastro.2008.10.037; Onishi T, 1998, BONE, V22, P605, DOI 10.1016/S8756-3282(98)00056-8; Pape HC, 2010, J ORTHOP TRAUMA, V24, P522, DOI 10.1097/BOT.0b013e3181ed1361; Pennycooke M, 2001, BIOCHEM BIOPH RES CO, V280, P951, DOI 10.1006/bbrc.2000.4205; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Riley EH, 1996, CLIN ORTHOP RELAT R, P39, DOI 10.1097/00003086-199603000-00006; Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004; SCHMITZ JP, 1986, CLIN ORTHOP RELAT R, P299, DOI 10.1097/00003086-198604000-00036; Spiro AS, 2010, J ORTHOP RES, V28, P785, DOI 10.1002/jor.21044; Takedachi M, 2012, J CELL PHYSIOL, V227, P2622, DOI 10.1002/jcp.23001; Tsiridis E, 2007, INJURY, V38, pS11, DOI 10.1016/j.injury.2007.02.006; Utting JC, 2006, EXP CELL RES, V312, P1693, DOI 10.1016/j.yexcr.2006.02.007; van Gaalen SM, 2010, TISSUE ENG PART B-RE, V16, P209, DOI [10.1089/ten.teb.2009.0503, 10.1089/ten.TEB.2009.0503]; White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264-007-0422-x; Yang ZQ, 2006, CIRCULATION, V114, P2056, DOI 10.1161/CIRCULATIONAHA.106.649244; Yang ZQ, 2005, CIRCULATION, V111, P2190, DOI 10.1161/01.CIR.0000163586.62253.A5	53	61	65	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1577	1590		10.1096/fj.14-265066	http://dx.doi.org/10.1096/fj.14-265066			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25573752	Green Published			2022-12-28	WOS:000354115000041
J	Piazzi, M; Blalock, WL; Bavelloni, A; Faenza, I; Raffini, M; Tagliavini, F; Manzoli, L; Cocco, L				Piazzi, Manuela; Blalock, William L.; Bavelloni, Alberto; Faenza, Irene; Raffini, Mirco; Tagliavini, Francesca; Manzoli, Lucia; Cocco, Lucio			PI-PLC beta 1b affects Akt activation, cyclin E expression, and caspase cleavage, promoting cell survival in pro-B-lymphoblastic cells exposed to oxidative stress	FASEB JOURNAL			English	Article						ROS; MAPK; PKR; leukemia; effector caspases	PHOSPHOLIPASE C-BETA-1; HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; MYELOID-LEUKEMIA; UP-REGULATION; MDS PATIENTS; NUCLEAR; PROTEIN; DEATH; DIFFERENTIATION	The phosphoinositide-dependent signal transduction pathway has been implicated in the control of a variety of biologic processes, such as the regulation of cellular metabolism and homeostasis, cell proliferation and differentiation, and apoptosis. One of the key players in the regulation of inositol lipid signaling is the phospholipase C beta 1 (PI-PLC beta 1), that hydrolyzes phosphatidylinositol 4,5-bisphosphate [PtIns(4,5)P2], giving rise to the second messengers inositol triphosphate and diacylglicerol. PI-PLC beta 1 has been associated with the regulation of several cellular functions, some of which have not yet been fully understood. In particular, it has been reported that PI-PLC beta 1 protects murine fibroblasts from oxidative stress-induced cell death. The mediators of oxidative stress, reactive oxygen species (ROS), have been shown to regulate major epigenetic processes, causing the silencing of tumor suppressors and enhancing the proliferation of leukemic cells under oxidative stress. Investigation of the interplay between ROS, PI-PLC beta 1, and their signaling mediators in leukemia might therefore reveal innovative targets of pharmacological therapy in the treatment for leukemia. In this work, we demonstrate that in pro-B-lymphoblastic cells (Ba/F3), treated with H2O2, PI-PLC beta 1b conferred resistance to cell death, promoting cell cycle progression and cell proliferation and influencing the expression of cyclin A and E. Interestingly, we found that, expression of PI-PLC beta 1b affects the activity of caspase-3, caspase-7, and of several protein kinases induced by oxidative stress. In particular, PI-PLC beta 1b expression completely abolished the phosphorylation of Erk1/2 MAP kinases, down-regulated phosphatase and tensin homolog (PTEN), and up-regulated the phosphorylation of Akt, thereby sustaining cellular proliferation.	[Piazzi, Manuela; Faenza, Irene; Manzoli, Lucia; Cocco, Lucio] Univ Bologna, Dept Biomed Sci, Cell Signaling Lab, I-40126 Bologna, Italy; [Blalock, William L.; Bavelloni, Alberto; Raffini, Mirco] Ist Ortoped Rizzoli, Struttura Complessa Lab Musculoskeletal Cell Biol, Bologna, Italy; [Blalock, William L.; Tagliavini, Francesca] Natl Res Council Italy, Inst Mol Genet, Bologna, Italy; [Bavelloni, Alberto; Raffini, Mirco] Ist Ortoped Rizzoli, RAMSES Lab, Bologna, Italy	University of Bologna; IRCCS Istituto Ortopedico Rizzoli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); IRCCS Istituto Ortopedico Rizzoli	Piazzi, M (corresponding author), Univ Bologna, Dept Biomed Sci, Cell Signaling Lab, Via Irnerio 48, I-40126 Bologna, Italy.	manuela.piazzi3@unibo.it	Faenza, Irene/AAC-4606-2022; Bavelloni, Alberto/E-5726-2019; Piazzi, Manuela/AAD-5016-2020; Piazzi, Manuela/K-2147-2016; Cocco, Lucio/AAI-2206-2020; Blalock, William L/C-6959-2019; Tagliavini, Francesca/N-5154-2015	Faenza, Irene/0000-0002-5227-3567; Bavelloni, Alberto/0000-0002-6467-1431; Piazzi, Manuela/0000-0002-9072-2757; Piazzi, Manuela/0000-0002-9072-2757; Cocco, Lucio/0000-0002-9206-8277; Blalock, William L/0000-0002-8045-4840; Tagliavini, Francesca/0000-0001-5679-2156	Italian Ministero dell'Istruzione, dell'Universita e della Ricerca-Fondo per gli Investimenti della Ricerca di Base (MIUR-FIRB) Human ProteomeNet; Italian MIUR-FIRB [RBAP10447J]; "5 x 1000" fund	Italian Ministero dell'Istruzione, dell'Universita e della Ricerca-Fondo per gli Investimenti della Ricerca di Base (MIUR-FIRB) Human ProteomeNet; Italian MIUR-FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); "5 x 1000" fund	The authors thank Dr. Aurelio Valmori, Dr. Elisabetta Longo, and Dr. Luca Cattini for technical assistance. This work was supported by the Italian Ministero dell'Istruzione, dell'Universita e della Ricerca-Fondo per gli Investimenti della Ricerca di Base (MIUR-FIRB) 2010 Human ProteomeNet; Italian MIUR-FIRB 2010 (RBAP10447J); and the "5 x 1000" fund to the SC Laboratory of Musculoskeletal Cell Biology, Rizzoli Orthopedic Institute. The authors declare no conflicts of interest.	Bahk YY, 1998, BBA-LIPID LIPID MET, V1389, P76, DOI 10.1016/S0005-2760(97)00128-8; Bai XC, 2002, BIOCHEM J, V363, P395, DOI 10.1042/0264-6021:3630395; Bertagnolo V, 2007, CARCINOGENESIS, V28, P1638, DOI 10.1093/carcin/bgm078; Blalock WL, 2011, LEUKEMIA, V25, P236, DOI 10.1038/leu.2010.264; Blalock WL, 2009, J CELL PHYSIOL, V221, P232, DOI 10.1002/jcp.21848; Chetram MA, 2013, MOL CELL BIOCHEM, V376, P63, DOI 10.1007/s11010-012-1549-7; Faenza I, 2003, J CELL PHYSIOL, V195, P446, DOI 10.1002/jcp.10264; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095; Fiume R, 2009, FASEB J, V23, P957, DOI 10.1096/fj.08-121244; Follo MY, 2012, LEUKEMIA, V26, P2474, DOI 10.1038/leu.2012.133; Follo MY, 2008, LEUKEMIA, V22, P2267, DOI 10.1038/leu.2008.122; Follo Matilde Y., 2013, Advances in Biological Regulation, V53, P2, DOI 10.1016/j.jbior.2012.09.009; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Jones DR, 2013, FASEB J, V27, P1644, DOI 10.1096/fj.12-218842; Keune WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003223; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Lee YH, 2000, LIFE SCI, V67, P827, DOI 10.1016/S0024-3205(00)00677-9; Li L, 2011, CANCER CELL, V20, P591, DOI 10.1016/j.ccr.2011.09.011; Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matteucci A, 1998, CANCER RES, V58, P5057; Monturiol-Gross L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086475; O'Carroll SJ, 2009, CELL SIGNAL, V21, P926, DOI 10.1016/j.cellsig.2009.02.002; Piazzi M, 2013, MOL CELL PROTEOMICS, V12, P2220, DOI 10.1074/mcp.M113.029686; Poli A, 2013, CELL CYCLE, V12, P1713, DOI 10.4161/cc.24806; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Rello S, 2005, APOPTOSIS, V10, P201, DOI 10.1007/s10495-005-6075-6; Shiizaki Shigeru, 2013, Advances in Biological Regulation, V53, P135, DOI 10.1016/j.jbior.2012.09.006; Sinha D, 2004, J BIOL CHEM, V279, P10962, DOI 10.1074/jbc.M312048200; Stone JR, 2006, ANTIOXID REDOX SIGN, V8, P243, DOI 10.1089/ars.2006.8.243; Toyokuni S, 2006, ANTIOXID REDOX SIGN, V8, P1373, DOI 10.1089/ars.2006.8.1373; van Boxtel R, 2013, CELL DEATH DIFFER, V20, P1219, DOI 10.1038/cdd.2013.81; van Gorp AGM, 2006, CANCER RES, V66, P10760, DOI 10.1158/0008-5472.CAN-06-1111; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Waris G, 2006, J CARCINOG, V5, P14, DOI [10.1186/1477-3163-5-14, DOI 10.1186/1477-3163-5-14]; Yang JY, 2004, BIOCHEM PHARMACOL, V68, P1027, DOI 10.1016/j.bcp.2004.03.043; Yasuda E, 2008, BIOL PHARM BULL, V31, P719, DOI 10.1248/bpb.31.719; Zhou FL, 2013, J LEUKOCYTE BIOL, V94, P423, DOI 10.1189/jlb.0113006; Zhuang SG, 2007, AM J PHYSIOL-RENAL, V292, pF440, DOI 10.1152/ajprenal.00170.2006	40	7	9	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1383	1394		10.1096/fj.14-259051	http://dx.doi.org/10.1096/fj.14-259051			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550457				2022-12-28	WOS:000354115000024
J	Woeller, CF; O'Loughlin, CW; Pollock, SJ; Thatcher, TH; Feldon, SE; Phipps, RP				Woeller, Collynn F.; O'Loughlin, Charles W.; Pollock, Stephen J.; Thatcher, Thomas H.; Feldon, Steven E.; Phipps, Richard P.			Thy1 (CD90) controls adipogenesis by regulating activity of the Src family kinase, Fyn	FASEB JOURNAL			English	Article						adipose tissue; fibroblasts; obesity; PPAR gamma	PPAR-GAMMA; MYOFIBROBLAST DIFFERENTIATION; FIBROBLAST SUBSETS; LUNG FIBROBLASTS; CELLS; GROWTH; PHOSPHORYLATION; TRANSITION; INHIBITION; EXPRESSION	Worldwide obesity rates are at epidemic levels, and new insight into the regulation of obesity and adipogenesis are required. Thy1 (CD90), a cell surface protein with an enigmatic function, is expressed on subsets of fibroblasts and stem cells. We used a diet-induced obesity model to show that Thy1-null mice gain weight at a faster rate and gain 30% more weight than control C57BL/6 mice. During adipogenesis, Thy1 expression is lost in mouse 3T3-L1 cells. Overexpression of Thy1 blocked adipocyte formation and reduced mRNA and protein expression of an adipocyte marker, fatty acid-binding protein 4, by 5-fold. Although preadipocyte fibroblasts expressed Thy1 mRNA and protein, adipocytes from mouse and human fat tissue had almost undetectable Thy1 levels. Thy1 decreases the activity of the adipogenic transcription factor PPAR gamma by more than 60% as shown by PPAR gamma-dependent reporter assays. Using both genetic and pharmacologic approaches, we show Thy1 expression dampens PPAR gamma by inhibiting the activity of the Src-family kinase, Fyn. Thus, these studies reveal Thy1 blocks adipogenesis and PPARg by inhibiting Fyn and support the idea that Thy1 is a novel therapeutic target in obesity.	[Woeller, Collynn F.; Pollock, Stephen J.; Thatcher, Thomas H.; Phipps, Richard P.] Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA; [O'Loughlin, Charles W.; Feldon, Steven E.; Phipps, Richard P.] Univ Rochester, Sch Med & Dent, Flaum Eye Inst, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Phipps, RP (corresponding author), Univ Rochester, MRBX, Box 850,Rm 3-11104,601 Elmwood Ave, Rochester, NY 14642 USA.	richard_phipps@urmc.rochester.edu	Woeller, Collynn/U-3877-2019	Thatcher, Thomas/0000-0001-7177-3041; Feldon, Steven/0000-0003-0603-9312; Woeller, Collynn/0000-0001-7197-5057; Pollock, Stephen/0000-0002-2091-1675	U.S. National Institutes of Health National Eye Institute [ES-023032, EY-023239, ES-001247]; Research to Prevent Blindness Foundation; Rochester/Finger Lakes Eye Tissue Bank; NATIONAL EYE INSTITUTE [R01EY023239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES023032, P30ES001247] Funding Source: NIH RePORTER	U.S. National Institutes of Health National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Research to Prevent Blindness Foundation(Research to Prevent Blindness (RPB)); Rochester/Finger Lakes Eye Tissue Bank; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This research was supported by the U.S. National Institutes of Health National Eye Institute (Grants ES-023032, EY-023239, and ES-001247); an unrestricted grant from the Research to Prevent Blindness Foundation; and a research grant from the Rochester/Finger Lakes Eye & Tissue Bank.	BARBONI E, 1995, J CELL SCI, V108, P487; Barbosa FL, 2010, EXP EYE RES, V91, P92, DOI 10.1016/j.exer.2010.04.007; Bastie CC, 2007, CELL METAB, V5, P371, DOI 10.1016/j.cmet.2007.04.005; Beissert S, 1998, J IMMUNOL, V161, P5296; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Borensztajn K, 2010, AM J PATHOL, V177, P2753, DOI 10.2353/ajpath.2010.091107; Bradley JE, 2013, LAB INVEST, V93, P365, DOI 10.1038/labinvest.2012.178; Choi JH, 2010, NATURE, V466, P451, DOI 10.1038/nature09291; Cohen PY, 2009, AM J RESP CELL MOL, V40, P231, DOI 10.1165/rcmb.2007-0348OC; Conrad DM, 2009, CELL SIGNAL, V21, P1298, DOI 10.1016/j.cellsig.2009.03.014; Cristia E, 2007, J PEDIATR GASTR NUTR, V45, pS127, DOI 10.1097/MPG.0b013e31812e680b; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Galie PA, 2011, CARDIOVASC PATHOL, V20, P325, DOI 10.1016/j.carpath.2010.10.001; Garcia-Bates TM, 2008, CLIN CANCER RES, V14, P6414, DOI 10.1158/1078-0432.CCR-08-0457; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Gupta RK, 2012, CELL METAB, V15, P230, DOI 10.1016/j.cmet.2012.01.010; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hudak Carolyn S, 2013, Front Endocrinol (Lausanne), V4, P79, DOI 10.3389/fendo.2013.00079; Hueber AO, 1997, CURR BIOL, V7, P705, DOI 10.1016/S0960-9822(06)00300-9; Jing K, 2009, BBA-MOL CELL BIOL L, V1791, P816, DOI 10.1016/j.bbalip.2009.04.010; Juonala M, 2011, NEW ENGL J MED, V365, P1876, DOI 10.1056/NEJMoa1010112; Kollert F, 2013, ARTHRIT CARE RES, V65, P281, DOI 10.1002/acr.21799; Koumas L, 2003, AM J PATHOL, V163, P1291, DOI 10.1016/S0002-9440(10)63488-8; Koumas L, 2002, EUR J IMMUNOL, V32, P477, DOI 10.1002/1521-4141(200202)32:2<477::AID-IMMU477>3.0.CO;2-U; Lee K, 2003, J CLIN INVEST, V111, P453, DOI 10.1172/JCI15924; Lefterova MI, 2009, TRENDS ENDOCRIN MET, V20, P107, DOI 10.1016/j.tem.2008.11.005; Lehmann GM, 2008, THYROID, V18, P959, DOI 10.1089/thy.2007.0407; Lehmann GM, 2010, AM J PHYSIOL-CELL PH, V299, pC672, DOI 10.1152/ajpcell.00451.2009; Liu Y, 2006, MOL CELL BIOCHEM, V281, P77, DOI 10.1007/s11010-006-0388-9; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Mason JC, 1996, J IMMUNOL, V157, P874; Meyer-Ter-Vehn T, 2006, INVEST OPHTH VIS SCI, V47, P4895, DOI 10.1167/iovs.06-0118; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; Park HH, 2010, AM J RHINOL ALLERGY, V24, P348, DOI 10.2500/ajra.2010.24.3520; Park KW, 2008, CELL METAB, V8, P454, DOI 10.1016/j.cmet.2008.11.001; PHIPPS RP, 1989, AM J RESP CELL MOL, V1, P65, DOI 10.1165/ajrcmb/1.1.65; Rege TA, 2006, BBA-MOL CELL RES, V1763, P991, DOI 10.1016/j.bbamcr.2006.08.008; Sampson N, 2011, MOL ENDOCRINOL, V25, P503, DOI 10.1210/me.2010-0340; Sandbo N, 2011, TRANSL RES, V158, P181, DOI 10.1016/j.trsl.2011.05.004; Sanders YY, 2011, AM J RESP CELL MOL, V45, P16, DOI 10.1165/rcmb.2010-0154OC; Sato M, 2009, AM J TRANSPLANT, V9, P1027, DOI 10.1111/j.1600-6143.2009.02605.x; Selige J, 2011, J CELL PHYSIOL, V226, P1970, DOI 10.1002/jcp.22529; Shan B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011662; Shukla MN, 2009, AM J RESP CELL MOL, V40, P643, DOI 10.1165/rcmb.2008-0217OC; Sobral LM, 2011, J PERIODONTOL, V82, P642, DOI 10.1902/jop.2010.100510; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Sun YT, 2005, BIOCHEMISTRY-US, V44, P14455, DOI 10.1021/bi0509090; Tan Xiao-yue, 2005, Zhonghua Yi Xue Za Zhi, V85, P2607; Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829; Varisco BM, 2012, AM J RESP CELL MOL, V46, P765, DOI 10.1165/rcmb.2011-0316OC; Xie XS, 2009, J ETHNOPHARMACOL, V122, P35, DOI 10.1016/j.jep.2008.11.020; Yamada E, 2010, CELL METAB, V11, P113, DOI 10.1016/j.cmet.2009.12.010; Yang YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081866	53	43	47	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					920	931		10.1096/fj.14-257121	http://dx.doi.org/10.1096/fj.14-257121			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25416548	Green Published			2022-12-28	WOS:000350633000018
J	Russell, S; Duquette, M; Liu, J; Drapkin, R; Lawler, J; Petrik, J				Russell, Samantha; Duquette, Mark; Liu, Joyce; Drapkin, Ronny; Lawler, Jack; Petrik, Jim			Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer	FASEB JOURNAL			English	Article						antiangiogenic; metronomic; vessel normalization	GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; PHASE-1 TRIAL; TUMOR-GROWTH; MOUSE MODEL; METRONOMIC CHEMOTHERAPY; PANCREATIC-CANCER; UP-REGULATION; ABT-510; ANGIOGENESIS	Most women are diagnosed with epithelial ovarian cancer ( EOC) at advanced stage, where therapies have limited effectiveness and the long- term survival rate is low. We evaluated the effects of combined antiangiogenic and chemotherapy treatments on advanced stage EOC. Treatment of EOC cells with a recombinant version of the thrombospondin- 1 type I repeats ( 3TSR) induced more apoptotic cell death ( 36.5 6 9.6%) in vitro compared to untreated controls ( 4.1 6 1.4). In vivo, tumors were induced in an orthotopic, syngeneic mouse model of advanced stage EOC. Mice were treated with 3TSR ( 4 mg/ kg per day) alone or in combination with chemotherapy drugs delivered with maximum tolerated dose or metronomic scheduling. Pretreatment with 3TSR induced tumor regression, normalized tumor vasculature, and improved uptake of chemotherapy drugs. Combination 3TSR and metronomic chemotherapy induced the greatest tumor regression ( 6.2- fold reduction in size compared to PBS- treated controls) and highest survival when treatment was initiated at advanced stage. 3TSR binding to its receptor, CD36 ( cluster of differentiation 36), increased binding of CD36 and SHP- 1, which significantly inhibited phosphorylation of the VEGF receptor. In this study, we describe a novel treatment approach and mechanism of action with 3TSR and chemotherapy that induces regression of advanced stage EOC and significantly improves survival.-	[Russell, Samantha; Petrik, Jim] Univ Guelph, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; [Duquette, Mark; Lawler, Jack] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA; [Liu, Joyce; Drapkin, Ronny] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	University of Guelph; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Petrik, J (corresponding author), Univ Guelph, 50 Stone Rd, Guelph, ON N1G 2W1, Canada.	jpetrik@uoguelph.ca	Drapkin, Ronny/E-9944-2016; Lawler, Jack/AAJ-1379-2020	Drapkin, Ronny/0000-0002-6912-6977; Russell, Samantha/0000-0002-1593-993X	NATIONAL CANCER INSTITUTE [R01CA130895] Funding Source: NIH RePORTER; Canadian Institutes of Health Research [450084] Funding Source: Medline; NCI NIH HHS [R01 CA130895, CA130895] Funding Source: Medline; NINDS NIH HHS [NS077797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adamcic U, 2012, NEOPLASIA, V14, P612, DOI 10.1593/neo.11948; Allegrini G, 2004, CANCER CHEMOTH PHARM, V53, P261, DOI 10.1007/s00280-003-0712-y; Berkenblit A, 2005, J REPROD MED, V50, P426; Bocci G, 2012, NEOPLASIA, V14, P833, DOI 10.1593/neo.12772; Borofsky SE, 2013, ABDOM IMAGING, V38, P265, DOI 10.1007/s00261-012-9913-3; Calzada MJ, 2004, J BIOL CHEM, V279, P41734, DOI 10.1074/jbc.M406267200; Campbell N, 2011, MOL CANCER THER, V10, P1876, DOI 10.1158/1535-7163.MCT-11-0402; Campbell NE, 2010, NEOPLASIA, V12, P275, DOI 10.1593/neo.91880; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Chu LY, 2013, BLOOD, V122, P1822, DOI 10.1182/blood-2013-01-482315; Clauss A, 2010, NEOPLASIA, V12, P161, DOI 10.1593/neo.91542; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Dawson DW, 1999, MOL PHARMACOL, V55, P332, DOI 10.1124/mol.55.2.332; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gately S, 2001, CANCER J, V7, P427; Gordon MS, 2008, CANCER-AM CANCER SOC, V113, P3420, DOI 10.1002/cncr.23953; Greenaway J, 2008, GYNECOL ONCOL, V108, P385, DOI 10.1016/j.ygyno.2007.10.035; Greenaway J, 2009, MOL CANCER THER, V8, P64, DOI 10.1158/1535-7163.MCT-08-0864; Harries M, 2002, LANCET ONCOL, V3, P537, DOI 10.1016/S1470-2045(02)00847-1; Harries M, 2002, LANCET ONCOL, V3, P529, DOI 10.1016/S1470-2045(02)00846-X; Horowitz A, 2012, CELL SIGNAL, V24, P1810, DOI 10.1016/j.cellsig.2012.05.007; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kamat AA, 2007, CANCER RES, V67, P281, DOI 10.1158/0008-5472.CAN-06-3282; Kelley RK, 2013, BRIT J CANCER, V109, P1725, DOI 10.1038/bjc.2013.553; LAWLER J, 1989, BLOOD, V74, P2022; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; Li L, 2004, ANTICANCER RES, V24, P1973; Longuespee R, 2012, CANCER METAST REV, V31, P713, DOI 10.1007/s10555-012-9383-7; Mayer EL, 2012, BREAST CANCER RES TR, V136, P169, DOI 10.1007/s10549-012-2256-5; Miao WM, 2001, CANCER RES, V61, P7830; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Quesada AJ, 2005, CELL DEATH DIFFER, V12, P649, DOI 10.1038/sj.cdd.4401615; Ren B, 2009, CANCER RES, V69, P3856, DOI 10.1158/0008-5472.CAN-08-2940; Sahora AI, 2012, J VET INTERN MED, V26, P1169, DOI 10.1111/j.1939-1676.2012.00966.x; Scharovsky OG, 2009, CURR ONCOL, V16, P91; Sher I, 2009, INT J CANCER, V124, P553, DOI 10.1002/ijc.23963; Short SM, 2005, J CELL BIOL, V168, P643, DOI 10.1083/jcb.200407060; Simons M, 2012, PHYSIOLOGY, V27, P213, DOI 10.1152/physiol.00016.2012; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Uronis HE, 2013, CANCER MED-US, V2, P316, DOI 10.1002/cam4.65; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Recouvreux MV, 2012, ENDOCRINOLOGY, V153, P3861, DOI 10.1210/en.2012-1007; Yap R, 2005, CLIN CANCER RES, V11, P6678, DOI 10.1158/1078-0432.CCR-05-0621; Yee KO, 2004, AM J PATHOL, V165, P541, DOI 10.1016/S0002-9440(10)63319-6; Yigit R, 2010, GYNECOL ONCOL, V117, P366, DOI 10.1016/j.ygyno.2010.01.019; Zhang J, 2014, ONCOL LETT, V7, P95, DOI 10.3892/ol.2013.1650; Zhang XF, 2005, CLIN CANCER RES, V11, P2337, DOI 10.1158/1078-0432.CCR-04-1900; Zhang XF, 2007, CLIN CANCER RES, V13, P3968, DOI 10.1158/1078-0432.CCR-07-0245; Zhang XF, 2009, FASEB J, V23, P3368, DOI 10.1096/fj.09-131649; Zhou MY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081858	55	40	42	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					576	588		10.1096/fj.14-261636	http://dx.doi.org/10.1096/fj.14-261636			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25395453	Green Published			2022-12-28	WOS:000349370400020
J	Aguer, C; McCoin, CS; Knotts, TA; Thrush, AB; Ono-Moore, K; McPherson, R; Dent, R; Hwang, DH; Adams, SH; Harper, ME				Aguer, Celine; McCoin, Colin S.; Knotts, Trina A.; Thrush, A. Brianne; Ono-Moore, Kikumi; McPherson, Ruth; Dent, Robert; Hwang, Daniel H.; Adams, Sean H.; Harper, Mary-Ellen			Acylcarnitines: potential implications for skeletal muscle insulin resistance	FASEB JOURNAL			English	Article						fatty acid beta-oxidation; mitochondria; inflammation; oxidative stress; myotubes	CARNITINE ACETYLTRANSFERASE; SUPEROXIDE-PRODUCTION; GLUCOSE-TOLERANCE; BETA-OXIDATION; FAT OXIDATION; INHIBITION; PALMITATE; HUMANS; CELLS; EXPRESSION	Insulin resistance may be linked to incomplete fatty acid beta-oxidation and the subsequent increase in acylcarnitine species in different tissues including skeletal muscle. It is not known if acylcarnitines participate in muscle insulin resistance or simply reflect dysregulated metabolism. The aims of this study were to determine whether acylcarnitines can elicit muscle insulin resistance and to better understand the link between incomplete muscle fatty acid beta-oxidation, oxidative stress, inflammation, and insulin-resistance development. Differentiated C2C12, primary mouse, and human myotubes were treated with acylcarnitines (C4: 0, C14: 0, C16: 0) or with palmitate with or without carnitine acyltransferase inhibition by mildronate. Treatment with C4: 0, C14: 0, and C16: 0 acylcarnitines resulted in 20-30% decrease in insulin response at the level of Akt phosphorylation and/or glucose uptake. Mildronate reversed palmitate-induced insulin resistance concomitant with an similar to 25% decrease in short-chain acylcarnitine and acetylcarnitine secretion. Although proinflammatory cytokines were not affected under these conditions, oxidative stress was increased by 2-3 times by short-or long-chain acylcarnitines. Acylcarnitine-induced oxidative stress and insulin resistance were reversed by treatment with antioxidants. Results are consistent with the conclusion that incomplete muscle fatty acid beta-oxidation causes acylcarnitine accumulation and associated oxidative stress, raising the possibility that these metabolites play a role in muscle insulin resistance.	[Aguer, Celine; Thrush, A. Brianne; Harper, Mary-Ellen] Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; [McCoin, Colin S.; Adams, Sean H.] Univ Calif Davis, Mol Cellular & Integrat Physiol Grad Program, Davis, CA 95616 USA; [McCoin, Colin S.; Knotts, Trina A.; Ono-Moore, Kikumi; Adams, Sean H.] ARS, Obes & Metab Res Unit, USDA, Western Human Nutr Res Ctr, Davis, CA USA; [Knotts, Trina A.; Ono-Moore, Kikumi; Hwang, Daniel H.; Adams, Sean H.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; [McPherson, Ruth] Univ Ottawa Heart Inst, Div Cardiol, Ottawa, ON, Canada; [Dent, Robert] Ottawa Hosp, Weight Management Clin, Ottawa, ON, Canada; [Hwang, Daniel H.] ARS, Immun & Dis Prevent Res Unit, USDA, Western Human Nutr Res Ctr, Davis, CA USA	University of Ottawa; University of California System; University of California Davis; United States Department of Agriculture (USDA); University of California System; University of California Davis; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; Ottawa Hospital Research Institute; United States Department of Agriculture (USDA)	Harper, ME (corresponding author), Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada.	seanharrisonadams@gmail.com; mharper@uottawa.ca	Aguer, Celine/U-7848-2019; ADAMS, SEAN/N-9262-2018	Aguer, Celine/0000-0001-8828-8472; Harper, Mary-Ellen/0000-0003-3864-5886; McCoin, Colin/0000-0002-8557-6441; ADAMS, SEAN/0000-0002-9515-2319	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078328] Funding Source: NIH RePORTER; CIHR [MOP57810] Funding Source: Medline; NIDDK NIH HHS [R01DK078328-02S1, R01 DK078328, R01DK078328-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); CIHR(Canadian Institutes of Health Research (CIHR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams SH, 2009, J NUTR, V139, P1073, DOI 10.3945/jn.108.103754; Aguer C, 2010, DIABETOLOGIA, V53, P1151, DOI 10.1007/s00125-010-1708-x; Aguer C, 2013, FASEB J, V27, P4213, DOI 10.1096/fj.13-234302; Aguer C, 2013, BBA-MOL BASIS DIS, V1832, P1624, DOI 10.1016/j.bbadis.2013.05.008; Aguer C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028536; Anderson EJ, 2009, J CLIN INVEST, V119, P573, DOI 10.1172/JCI37048; Baillet L, 2000, J BIOL CHEM, V275, P36766, DOI 10.1074/jbc.M008265200; Befroy DE, 2007, DIABETES, V56, P1376, DOI 10.2337/db06-0783; Bonnard C, 2008, J CLIN INVEST, V118, P789, DOI 10.1172/JCI32601; Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003; Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200; Coll T, 2008, J BIOL CHEM, V283, P11107, DOI 10.1074/jbc.M708700200; Costford SR, 2009, DIABETOLOGIA, V52, P2405, DOI 10.1007/s00125-009-1480-y; Fisher-Wellman KH, 2012, TRENDS ENDOCRIN MET, V23, P142, DOI 10.1016/j.tem.2011.12.008; Georges B, 2000, BIOCHEM PHARMACOL, V59, P1357, DOI 10.1016/S0006-2952(00)00265-3; Gillingham MB, 2013, AM J PHYSIOL-ENDOC M, V305, pE1299, DOI 10.1152/ajpendo.00225.2013; Glass CK, 2012, CELL METAB, V15, P635, DOI 10.1016/j.cmet.2012.04.001; Henriksen EJ, 2011, FREE RADICAL BIO MED, V51, P993, DOI 10.1016/j.freeradbiomed.2010.12.005; Hoehn KL, 2008, CELL METAB, V7, P421, DOI 10.1016/j.cmet.2008.04.005; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Jaudzems K, 2009, J ENZYM INHIB MED CH, V24, P1269, DOI 10.3109/14756360902829527; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Keung W, 2013, DIABETES, V62, P711, DOI 10.2337/db12-0259; Knotts TA, 2009, PPAR RES, V2009, DOI 10.1155/2009/867678; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; Krogh-Madsen R, 2006, AM J PHYSIOL-ENDOC M, V291, pE108, DOI 10.1152/ajpendo.00471.2005; Lambertucci RH, 2008, J CELL PHYSIOL, V216, P796, DOI 10.1002/jcp.21463; Mailloux RJ, 2011, BIOCHEM J, V437, P301, DOI 10.1042/BJ20110571; Melegh B, 1999, J INHERIT METAB DIS, V22, P827, DOI 10.1023/A:1005562209034; Minkler P. E. S. M., 2012, 60 ASMS C MASS SPECT; Mogensen M, 2007, DIABETES, V56, P1592, DOI 10.2337/db06-0981; Muoio DM, 2012, CELL METAB, V15, P764, DOI 10.1016/j.cmet.2012.04.005; Noland RC, 2009, J BIOL CHEM, V284, P22840, DOI 10.1074/jbc.M109.032888; Nowotny B, 2013, DIABETES, V62, P2240, DOI 10.2337/db12-1179; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Plomgaard P, 2005, DIABETES, V54, P2939, DOI 10.2337/diabetes.54.10.2939; POURFARZAM M, 1994, CLIN CHEM, V40, P2267; Rutkowsky JM, 2014, AM J PHYSIOL-ENDOC M, V306, pE1378, DOI 10.1152/ajpendo.00656.2013; Sampey BP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038812; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Schooneman MG, 2013, DIABETES, V62, P1, DOI 10.2337/db12-0466; Ukropcova B, 2005, J CLIN INVEST, V115, P1934, DOI 10.1172/JCI24332; Weigert C, 2004, J BIOL CHEM, V279, P23942, DOI 10.1074/jbc.M312692200; Wolf M, 2013, J CLIN ENDOCR METAB, V98, pE1137, DOI 10.1210/jc.2012-3976; Zhang LY, 2010, BBA-MOL CELL BIOL L, V1801, P1, DOI 10.1016/j.bbalip.2009.09.014	45	140	143	2	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					336	345		10.1096/fj.14-255901	http://dx.doi.org/10.1096/fj.14-255901			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25342132	Green Published			2022-12-28	WOS:000347378600031
J	Doonan, PJ; Chandramoorthy, HC; Hoffman, NE; Zhang, XQ; Cardenas, C; Shanmughapriya, S; Rajan, S; Vallem, S; Chen, XW; Foskett, JK; Cheung, JY; Houser, SR; Madesh, M				Doonan, Patrick J.; Chandramoorthy, Harish C.; Hoffman, Nicholas E.; Zhang, Xueqian; Cardenas, Cesar; Shanmughapriya, Santhanam; Rajan, Sudarsan; Vallem, Sandhya; Chen, Xiongwen; Foskett, J. Kevin; Cheung, Joseph Y.; Houser, Steven R.; Madesh, Muniswamy			LETM1-dependent mitochondrial Ca2+ flux modulates cellular bioenergetics and proliferation	FASEB JOURNAL			English	Article						Wolf-Hirschhorn syndrome; cell cycle; metabolism; reactive oxygen species	WOLF-HIRSCHHORN-SYNDROME; PERMEABILITY TRANSITION PORE; CALCIUM UNIPORTER; ESSENTIAL COMPONENT; CYCLOPHILIN-D; CYTOCHROME-C; LETM1; PROTEIN; GENE; SUPEROXIDE	Dysregulation of mitochondrial Ca2+-dependent bioenergetics has been implicated in various pathophysiological settings, including neurodegeneration and myocardial infarction. Although mitochondrial Ca2+ transport has been characterized, and several molecules, including LETM1, have been identified, the functional role of LETM1-mediated Ca2+ transport remains unresolved. This study examines LETM1-mediated mitochondrial Ca2+ transport and bioenergetics in multiple cell types, including fibroblasts derived from patients with Wolf-Hirschhorn syndrome (WHS). The results show that both mitochondrial Ca2+ influx and efflux rates are impaired in LETM1 knockdown, and similar phenotypes were observed in EF hand, (D676A D688K)LETM1 mutant-overexpressed cells, and in cells derived from patients with WHS. Although LETM1 levels were lower in WHS-derived fibroblasts, the mitochondrial Ca2+ uniporter components MCU, MCUR1, and MICU1 remain unaltered. In addition, the MCU mitoplast patch-clamp current (I-MCU) was largely unaffected in LETM1-knockdown cells. Silencing of LETM1 also impaired basal mitochondrial oxygen consumption, possibly via complex IV inactivation and ATP production. Remarkably, LETM1 knockdown also resulted in increased reactive oxygen species production. Further, LETM1 silencing promoted AMPK activation, autophagy, and cell cycle arrest. Reconstitution of LETM1 or antioxidant overexpression rescued mitochondrial Ca2+ transport and bioenergetics. These findings reveal the role of LETM1-dependent mitochondrial Ca2+ flux in shaping cellular bioenergetics.Doonan, P J., Chandramoorthy, H. C., Hoffman, N. E., Zhang, X., Cardenas, C., Shanmughapriya, S., Rajan, S., Vallem, S., Chen, X., Foskett, J. K., Cheung, J. Y., Houser, S. R., Madesh, M. LETM1-dependent mitochondrial Ca2+ flux modulates cellular bioenergetics and proliferation.	[Doonan, Patrick J.; Chandramoorthy, Harish C.; Hoffman, Nicholas E.; Shanmughapriya, Santhanam; Rajan, Sudarsan; Vallem, Sandhya; Madesh, Muniswamy] Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19140 USA; [Doonan, Patrick J.; Chandramoorthy, Harish C.; Hoffman, Nicholas E.; Zhang, Xueqian; Shanmughapriya, Santhanam; Rajan, Sudarsan; Vallem, Sandhya; Cheung, Joseph Y.; Madesh, Muniswamy] Temple Univ, Ctr Translat Med, Sch Med, Philadelphia, PA 19140 USA; [Chen, Xiongwen; Houser, Steven R.] Temple Univ, Cardiovasc Res Ctr, Sch Med, Philadelphia, PA 19140 USA; [Chen, Xiongwen; Houser, Steven R.] Temple Univ, Dept Physiol, Cardiovasc Res Ctr, Philadelphia, PA 19140 USA; [Cardenas, Cesar] Univ Chile, Inst Biomed Sci, Anat & Dev Biol Program, Santiago, Chile; [Foskett, J. Kevin] Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Universidad de Chile; University of Pennsylvania	Madesh, M (corresponding author), Temple Univ, Dept Biochem, 3500 N Broad St,950 MERB, Philadelphia, PA 19140 USA.	madeshm@temple.edu	Chandramoorthy, Harish C/A-6533-2019; Cardenas, Julio C/I-3221-2013; Chen, Xiongwen/D-5988-2012; Shanmughapriya, Santhanam/P-2828-2017	Chen, Xiongwen/0000-0002-3829-5815; Shanmughapriya, Santhanam/0000-0003-1041-8198; Foskett, J. Kevin/0000-0002-8854-0268; Chinna Konda Chandramoorthy, Harish/0000-0002-8780-8971	U.S. National Institutes of Health [R01HL-086699, R01HL-119306, 1S10RR-027327-01]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR027327] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL119306, R01HL088243, R01HL086699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM056328, R01GM109882] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Drs. Donald L. Gill and Walter J. Koch for their comments on the manuscript. The authors thank Maggie Cheung and Karthik Mallilamkaraman for their cell culture work. This work was supported by the U.S. National Institutes of Health (R01HL-086699, R01HL-119306 and 1S10RR-027327-01 to MM).	Baines CP, 2010, ANNU REV PHYSIOL, V72, P61, DOI 10.1146/annurev-physiol-021909-135929; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Cardenas C, 2010, CELL, V142, P270, DOI 10.1016/j.cell.2010.06.007; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; Dimmer KS, 2008, HUM MOL GENET, V17, P201, DOI 10.1093/hmg/ddm297; Endele S, 1999, GENOMICS, V60, P218, DOI 10.1006/geno.1999.5881; Fieni F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2325; Halestrap A, 2005, NATURE, V434, P578, DOI 10.1038/434578a; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Hamanaka RB, 2010, TRENDS BIOCHEM SCI, V35, P505, DOI 10.1016/j.tibs.2010.04.002; Hanley-Lopez J, 1998, J PEDIATR-US, V133, P141, DOI 10.1016/S0022-3476(98)70194-5; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Hawkins BJ, 2007, MOL BIOL CELL, V18, P2002, DOI 10.1091/mbc.E06-09-0830; Hawkins BJ, 2010, J BIOL CHEM, V285, P26494, DOI 10.1074/jbc.M110.143164; HIRSCHHORN K, 1965, HUMANGENETIK, V1, P479; Hoffman NE, 2014, MOL BIOL CELL, V25, P936, DOI 10.1091/mbc.E13-08-0502; Hoffman NE, 2013, CELL REP, V5, P1576, DOI 10.1016/j.celrep.2013.11.026; Irrinki KM, 2011, MOL CELL BIOL, V31, P3745, DOI 10.1128/MCB.05303-11; Jiang DW, 2013, P NATL ACAD SCI USA, V110, pE2249, DOI 10.1073/pnas.1308558110; Jiang DW, 2009, SCIENCE, V326, P144, DOI 10.1126/science.1175145; Joiner MLA, 2012, NATURE, V491, P269, DOI 10.1038/nature11444; Jones RG, 2007, IMMUNITY, V27, P268, DOI 10.1016/j.immuni.2007.05.023; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Madesh M, 2005, J CELL BIOL, V170, P1079, DOI 10.1083/jcb.200505022; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Madesh M, 2009, MOL CELL BIOL, V29, P3099, DOI 10.1128/MCB.01845-08; Mallilankaraman K, 2013, NAT CELL BIOL, V15, P123, DOI 10.1038/ncb2669; Mallilankaraman K, 2012, NAT CELL BIOL, V14, P1336, DOI 10.1038/ncb2622; Mallilankaraman K, 2012, CELL, V151, P630, DOI 10.1016/j.cell.2012.10.011; McQuibban AG, 2010, HUM MOL GENET, V19, P987, DOI 10.1093/hmg/ddp563; Miller BA, 2014, J BIOL CHEM, V289, P7615, DOI 10.1074/jbc.M113.533851; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nowikovsky K, 2004, J BIOL CHEM, V279, P30307, DOI 10.1074/jbc.M403607200; Nowikovsky K, 2012, J GEN PHYSIOL, V139, P445, DOI 10.1085/jgp.201110757; Palty R, 2010, P NATL ACAD SCI USA, V107, P436, DOI 10.1073/pnas.0908099107; Pan X, 2013, NAT CELL BIOL, V15, P1464, DOI 10.1038/ncb2868; Perocchi F, 2010, NATURE, V467, P291, DOI 10.1038/nature09358; Plovanich M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055785; Raffaello A, 2013, EMBO J, V32, P2362, DOI 10.1038/emboj.2013.157; Sancak Y, 2013, SCIENCE, V342, P1379, DOI 10.1126/science.1242993; Santo-Domingo J, 2012, J GEN PHYSIOL, V139, P415, DOI 10.1085/jgp.201110767; Schlickum S, 2004, GENOMICS, V83, P254, DOI 10.1016/j.ygeno.2003.08.013; Sheu SS, 2012, J GEN PHYSIOL, V139, P391, DOI 10.1085/jgp.201210819; Tamai S, 2008, J CELL SCI, V121, P2588, DOI 10.1242/jcs.026625; Tsai MF, 2014, J GEN PHYSIOL, V143, P67, DOI 10.1085/jgp.201311096; Vagnozzi RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006479; Waldeck-Weiermair M, 2011, J BIOL CHEM, V286, P28444, DOI 10.1074/jbc.M111.244517; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302	52	79	79	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4936	4949		10.1096/fj.14-256453	http://dx.doi.org/10.1096/fj.14-256453			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25077561	Green Published			2022-12-28	WOS:000344050900030
J	Husse, J; Leliavski, A; Tsang, AH; Oster, H; Eichele, G				Husse, Jana; Leliavski, Alexei; Tsang, Anthony H.; Oster, Henrik; Eichele, Gregor			The light-dark cycle controls peripheral rhythmicity in mice with a genetically ablated suprachiasmatic nucleus clock	FASEB JOURNAL			English	Article						circadian; synaptotagmin10	GENE-EXPRESSION; CIRCADIAN CLOCK; LOCOMOTOR-ACTIVITY; ADRENAL-GLAND; BEHAVIOR; REVEALS; LESIONS; GLUCOCORTICOIDS; ELIMINATE; PACEMAKER	The mammalian circadian timing system consists of a master pacemaker in the suprachiasmatic nucleus (SCN), which is thought to synchronize peripheral clocks in various organs with each other and with external time. Our knowledge about the role of the SCN clock is based mainly on SCN lesion and transplantation studies. We have now directly deleted the SCN clock using the Cre/LoxP system and investigated how this affects synchronization of peripheral rhythms. Impaired locomotor activity and arrhythmic clock gene expression in the SCN confirm that the SCN clockwork was efficiently abolished in our mouse model. Nonetheless, under light-dark (LD) conditions, peripheral clocks remained rhythmic and synchronized to the LD cycle, and phase relationships between peripheral clocks were sustained. Adaptation to a shifted LD cycle was accelerated in SCN clock-deficient mice. Moreover, under zeitgeber-free conditions, rhythmicity of the peripheral clock gene expression was initially dampened, and after several days peripheral clocks were desynchronized. These findings suggest that the SCN clock is dispensable for the synchronization of peripheral clocks to the LD cycle. A model describing an SCN clock-independent pathway that synchronizes peripheral clocks with the LD cycle is discussed.Husse, J., Leliavski, A., Tsang, A. H., Oster, H., Eichele, G. The light-dark cycle controls peripheral rhythmicity in mice with a genetically ablated suprachiasmatic nucleus clock.	[Husse, Jana; Leliavski, Alexei; Tsang, Anthony H.; Oster, Henrik; Eichele, Gregor] Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany	Max Planck Society	Oster, H (corresponding author), Med Univ Lubeck, Dept Med 1, Chronophysiol Grp, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	henrik.oster@uksh.de	Oster, Henrik/O-4426-2019; Leliavski, Alexei/N-9333-2017	Oster, Henrik/0000-0002-1414-7068; Tsang, Anthony/0000-0002-3673-6365; Leliavski, Alexei/0000-0003-0279-9226	Sleep and Biological Rhythms Toronto (University of Toronto, Toronto, ON, Canada); Max Planck Society	Sleep and Biological Rhythms Toronto (University of Toronto, Toronto, ON, Canada); Max Planck Society(Max Planck SocietyFoundation CELLEX)	H.O. is a Lichtenberg fellow of the Volkswagen Foundation. J.H. was supported by a fellowship from Sleep and Biological Rhythms Toronto (University of Toronto, Toronto, ON, Canada).. This work was supported by the Max Planck Society. The authors declare no conflicts of interest.	Abraham D, 2006, J BIOL RHYTHM, V21, P169, DOI 10.1177/0748730406288040; Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; Albrecht U, 2012, NEURON, V74, P246, DOI 10.1016/j.neuron.2012.04.006; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Batschelet E., 1981, CIRCULAR STAT BIOL; Brown Steven A, 2013, Handb Exp Pharmacol, P45, DOI 10.1007/978-3-642-25950-0_3; Buhr Ethan D, 2013, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-642-25950-0_1; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Cheng MY, 2002, NATURE, V417, P405, DOI 10.1038/417405a; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Davidson AJ, 2009, EUR J NEUROSCI, V29, P171, DOI 10.1111/j.1460-9568.2008.06534.x; Guo HN, 2005, P NATL ACAD SCI USA, V102, P3111, DOI 10.1073/pnas.0409734102; Guo HG, 2006, J NEUROSCI, V26, P6406, DOI 10.1523/JNEUROSCI.4676-05.2006; Hara R, 2001, GENES CELLS, V6, P269, DOI 10.1046/j.1365-2443.2001.00419.x; Husse J, 2011, J BIOL RHYTHM, V26, P379, DOI 10.1177/0748730411415363; Ishida A, 2005, CELL METAB, V2, P297, DOI 10.1016/j.cmet.2005.09.009; Jud C, 2005, BIOL PROCED ONLINE, V7, P101, DOI 10.1251/bpo109; Kalsbeek A, 2010, J NEUROENDOCRINOL, V22, P362, DOI 10.1111/j.1365-2826.2010.01956.x; Kasukawa T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023228; Kiessling S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092959; Kiessling S, 2010, J CLIN INVEST, V120, P2600, DOI 10.1172/JCI41192; Ko CH, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000513; Lamia KA, 2008, P NATL ACAD SCI USA, V105, P15172, DOI 10.1073/pnas.0806717105; Long MA, 2005, NAT NEUROSCI, V8, P61, DOI 10.1038/nn1361; Marcheva B, 2010, NATURE, V466, P627, DOI 10.1038/nature09253; Maywood ES, 2011, P NATL ACAD SCI USA, V108, P14306, DOI 10.1073/pnas.1101767108; Meyer-Bernstein EL, 1999, ENDOCRINOLOGY, V140, P207, DOI 10.1210/en.140.1.207; Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; NIIJIMA A, 1993, PHYSIOL BEHAV, V54, P555, DOI 10.1016/0031-9384(93)90249-F; NIIJIMA A, 1992, J AUTONOM NERV SYST, V40, P155, DOI 10.1016/0165-1838(92)90026-D; Ono D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080615; Oster H, 2006, J BIOL RHYTHM, V21, P350, DOI 10.1177/0748730406293053; Oster H, 2006, CELL METAB, V4, P163, DOI 10.1016/j.cmet.2006.07.002; Paxinos G., 2008, MOUSE BRAIN STEREOTA; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REFINETTI R, 1994, J COMP PHYSIOL A, V175, P223, DOI 10.1007/BF00215118; Saini C, 2013, GENE DEV, V27, P1526, DOI 10.1101/gad.221374.113; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Schwartz WJ, 2011, P NATL ACAD SCI USA, V108, P17219, DOI 10.1073/pnas.1107848108; Sellix MT, 2010, CURR BIOL, V20, pR266, DOI 10.1016/j.cub.2010.01.045; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; Storch KF, 2007, CELL, V130, P730, DOI 10.1016/j.cell.2007.06.045; Tahara Y, 2012, CURR BIOL, V22, P1029, DOI 10.1016/j.cub.2012.04.009; Terazono H, 2003, P NATL ACAD SCI USA, V100, P6795, DOI 10.1073/pnas.0936797100; Yao Z, 2014, SCIENCE, V343, P1516, DOI 10.1126/science.1251285; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101	47	84	85	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4950	4960		10.1096/fj.14-256594	http://dx.doi.org/10.1096/fj.14-256594			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25063847				2022-12-28	WOS:000344050900031
J	Salanova, M; Gelfi, C; Moriggi, M; Vasso, M; Vigano, A; Minafra, L; Bonifacio, G; Schiffl, G; Gutsmann, M; Felsenberg, D; Cerretelli, P; Blottner, D				Salanova, Michele; Gelfi, Cecilia; Moriggi, Manuela; Vasso, Michele; Vigano, Agnese; Minafra, Luigi; Bonifacio, Gaetano; Schiffl, Gudrun; Gutsmann, Martina; Felsenberg, Dieter; Cerretelli, Paolo; Blottner, Dieter			Disuse deterioration of human skeletal muscle challenged by resistive exercise superimposed with vibration: evidence from structural and proteomic analysis	FASEB JOURNAL			English	Article						bed rest; atrophy; ultrastructure; countermeasures; protein expression	FOCAL ADHESION KINASE; HEAVY-CHAIN ISOFORMS; TERM BED REST; TENASCIN-C; SHORTENING VELOCITY; FAST HINDLIMB; FIBERS; EXPRESSION; RAT; PROTEIN	In the present bed rest (BR) study, 23 volunteers were randomized into 3 subgroups: 60 d BR control (Ctr); BR with resistive exercise (RE; lower-limb load); and resistive vibration exercise (RVE; RE with superimposed vibration). The aim was to analyze by confocal and electron microscopy the effects of vibration on myofibril and filament integrity in soleus (Sol) and vastus lateralis (VL) muscle; differential proteomics of contractile, cytoskeletal, and costameric proteins (TN-C, ROCK1, and FAK); and expression of PGC1 and atrophy-related master genes MuRF1 and MuRF2. RVE (but not RE) preserved myofiber size and phenotype in Sol and VL by overexpressing MYBPC1 (42%, P0.01), WDR1 (39%, P0.01), sarcosin (84%, P0.01), and CKM (20%, P0.01) and prevented myofibrillar ultrastructural damage as detectable by MuRF1 expression. In Sol, cytoskeletal and contractile proteins were normalized by RVE, and TN-C increased (59%, P0.01); the latter also with RE (108%, P0.01). In VL, the outcomes of both RVE (acting on sarcosin and desmin) and RE (by way of troponinT-slow and MYL2) were similar. RVE appears to be a highly efficient countermeasure protocol against muscle atrophy and ultrastructural and molecular dysregulation induced by chronic disuse.Salanova, M., Gelfi, C., Moriggi, M., Vasso, M., Vigan, A., Minafra, L., Bonifacio, G., Schiffl, G., Gutsmann, M., Felsenberg, D., Cerretelli, P., Blottner, D. Disuse deterioration of human skeletal muscle challenged by resistive exercise superimposed with vibration: evidence from structural and proteomic analysis.	[Salanova, Michele; Schiffl, Gudrun; Gutsmann, Martina; Blottner, Dieter] Charite, Inst Anat, Neuromuscular Grp, Ctr Space Med Berlin, D-10115 Berlin, Germany; [Felsenberg, Dieter] Charite, Ctr Muscle & Bone Res ZMK, D-10115 Berlin, Germany; [Gelfi, Cecilia; Moriggi, Manuela; Vigano, Agnese] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy; [Gelfi, Cecilia; Vasso, Michele; Cerretelli, Paolo] CNR, Inst Bioimaging & Mol Physiol, Segrate, Italy; [Gelfi, Cecilia] Ist Ricovero & Cura Carattere Sci IRCCS Policlin, San Donato Milanese, Italy; [Vasso, Michele; Minafra, Luigi] CNR Lab Tecnol Oncol LATO, Inst Bioimaging & Mol Physiol, Cefalu, Italy; [Bonifacio, Gaetano] Univ Lausanne, Dept Pharmacol & Toxicol, Lausanne, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Milan; Consiglio Nazionale delle Ricerche (CNR); IRCCS Policlinico San Donato; University of Lausanne	Salanova, M (corresponding author), Charite, Neuromuscular Grp, Campus Charite Mitte,Philippstr 12, D-10115 Berlin, Germany.	michele.salanova@charite.de; cecilia.gelfi@unimi.it	Minafra, L/AFR-1042-2022; MORIGGI, MANUELA/AAB-5477-2021; Gelfi, Cecilia/L-1490-2016	Minafra, L/0000-0003-3112-4519; MORIGGI, MANUELA/0000-0002-4718-0307; Gelfi, Cecilia/0000-0002-2996-6912; Blottner, Dieter/0000-0003-0355-3340; VASSO, MICHELE/0000-0003-0431-0981	European Space Agency (ESA) [14431/02/NL/SH2]; German Aerospace Center (DER) [50WB0821, 50WB0720]; Fondo per gli Investimenti della Ricerca di Base (FIRB) [RBRN07BMCF]; Agenzia Spaziale Italiana (ASI); Telethon [GGP11082]; FP7-BIO-NMD project [241665]	European Space Agency (ESA)(European Space Agency); German Aerospace Center (DER); Fondo per gli Investimenti della Ricerca di Base (FIRB)(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Agenzia Spaziale Italiana (ASI)(Agenzia Spaziale Italiana (ASI)); Telethon(Fondazione Telethon); FP7-BIO-NMD project	The Second Berlin Bed Rest Study (BBR-2) was supported by grant 14431/02/NL/SH2 from the European Space Agency (ESA) and German Aerospace Center (DER), grant 50WB0821 (D.B.), and grant 50WB0720 (D.F.). The authors thank D. L. Belavy for his help as BBR-2 study coordinator; Ms. Petra Schrade for the technical support during the ultrastuctural analysis; S. Krasnici and J. Fakler (Traumatology Unit, Charite Campus Benjamin Franklin, Berlin, Germany) for excellence in muscle biopsy sampling; and Andrew Clarke for the language editorial work. Anti-MuRF2 antibodies were a kind gift of C. Krone and S. Labeit (Mannheim University, Mannheim, Germany). BBR-2 was also sponsored by Novotec Medical GmbH (Pforzheim, Germany) and Charite Universitatsmedizin Berlin. Special thanks to the volunteers and the staff of the Radiology Department and all the enthusiastic :members participating in BBR-2. Proteomics and mechanotransduction assessment were carried out at die University of Milan by the node of The Italian Human Proteomic Network, coordinated by C.G. and financially supported by Fondo per gli Investimenti della Ricerca di Base (FIRB; grant. RBRN07BMCF to CC.), Agenzia Spaziale Italiana (ASI; to P.C.), Telethon (grant GGP11082 to C.G.), and the FP7-BIO-NMD project (grant 241665 to C.G.).	Adams GR, 2003, J APPL PHYSIOL, V95, P2185, DOI 10.1152/japplphysiol.00346.2003; Andersen JL, 1999, J APPL PHYSIOL, V86, P455, DOI 10.1152/jappl.1999.86.2.455; Baldwin KM, 1996, MED SCI SPORT EXER, V28, P983, DOI 10.1097/00005768-199608000-00008; BAR A, 1988, FEBS LETT, V235, P153, DOI 10.1016/0014-5793(88)81253-5; Belavy DL, 2010, J MUSCULOSKEL NEURON, V10, P207; Benjamini Y, 2000, J EDUC BEHAV STAT, V25, P60, DOI 10.3102/10769986025001060; Bershadsky AD, 2003, ANNU REV CELL DEV BI, V19, P677, DOI 10.1146/annurev.cellbio.19.111301.153011; BETTO DD, 1986, BIOCHEM BIOPH RES CO, V138, P981, DOI 10.1016/S0006-291X(86)80592-7; Blottner D, 2006, EUR J APPL PHYSIOL, V97, P261, DOI 10.1007/s00421-006-0160-6; Booth FW, 1997, INT J SPORTS MED, V18, pS265, DOI 10.1055/s-2007-972723; BOTTINELLI R, 1994, J MUSCLE RES CELL M, V15, P413, DOI 10.1007/BF00122115; Caiozzo VJ, 1996, J APPL PHYSIOL, V80, P1503, DOI 10.1152/jappl.1996.80.5.1503; CHIQUETEHRISMANN R, 1994, J CELL BIOL, V127, P2093, DOI 10.1083/jcb.127.6.2093; Cochrane DJ, 2009, MUSCLE NERVE, V40, P420, DOI 10.1002/mus.21330; Durieux AC, 2007, BIOCHEM SOC T, V35, P1312, DOI 10.1042/BST0351312; EDGERTON VR, 1995, J APPL PHYSIOL, V78, P1733, DOI 10.1152/jappl.1995.78.5.1733; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; Fluck M, 2002, J EXP BIOL, V205, P2337; Fluck M, 2008, P NATL ACAD SCI USA, V105, P13662, DOI 10.1073/pnas.0805365105; GRANIT R, 1956, ACTA PHYSIOL SCAND, V37, P114, DOI 10.1111/j.1748-1716.1956.tb01347.x; Ito K, 2004, HYPERTENSION, V43, P156, DOI 10.1161/01.HYP.0000114602.82140.a4; Jarvinen TAH, 2003, J CELL SCI, V116, P857, DOI 10.1242/jcs.00303; Leger B, 2006, J PHYSIOL-LONDON, V576, P923, DOI 10.1113/jphysiol.2006.116715; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Mackey AL, 2011, FASEB J, V25, P1943, DOI 10.1096/fj.10-176487; Marouga R, 2005, ANAL BIOANAL CHEM, V382, P669, DOI 10.1007/s00216-005-3126-3; Midwood KS, 2009, J CELL COMMUN SIGNAL, V3, P287, DOI 10.1007/s12079-009-0075-1; Moriggi M, 2010, PROTEOMICS, V10, P3756, DOI 10.1002/pmic.200900817; Pasini E, 2012, EXP GERONTOL, V47, P23, DOI 10.1016/j.exger.2011.10.003; Quach NL, 2006, DEV BIOL, V293, P38, DOI 10.1016/j.ydbio.2005.12.040; Rittweger J, 2010, BONE, V46, P137, DOI 10.1016/j.bone.2009.08.051; Salanova M, 2008, J ANAT, V212, P306, DOI 10.1111/j.1469-7580.2008.00854.x; Salanova M, 2008, HISTOCHEM CELL BIOL, V130, P105, DOI 10.1007/s00418-008-0399-6; Salanova M, 2011, FASEB J, V25, P4312, DOI 10.1096/fj.11-186049; Salanova M, 2009, HISTOCHEM CELL BIOL, V132, P383, DOI 10.1007/s00418-009-0624-y; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schenck U, 1996, ACTA CYTOL, V40, P73; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; Schiaffino S, 2011, PHYSIOL REV, V91, P1447, DOI 10.1152/physrev.00031.2010; Schuenke MD, 2009, EUR J APPL PHYSIOL, V106, P885, DOI 10.1007/s00421-009-1091-9; Smith Temple F., 2008, V48, P20, DOI 10.1007/978-0-387-09595-0_3; TERMIN A, 1989, EUR J BIOCHEM, V186, P749, DOI 10.1111/j.1432-1033.1989.tb15269.x; Traon APL, 2007, EUR J APPL PHYSIOL, V101, P143, DOI 10.1007/s00421-007-0474-z; Trappe S, 2004, J PHYSIOL-LONDON, V557, P501, DOI 10.1113/jphysiol.2004.062166; Vigano A, 2011, PROTEOMICS, V11, P4202, DOI 10.1002/pmic.201000804; Viswanathan S, 2006, NAT PROTOC, V1, P1351, DOI 10.1038/nprot.2006.234; Widrick JJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1690	48	34	36	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4748	4763		10.1096/fj.14-252825	http://dx.doi.org/10.1096/fj.14-252825			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25122557				2022-12-28	WOS:000344050900015
J	Kim, EY; Sturgill, JL; Hait, NC; Avni, D; Valencia, EC; Maceyka, M; Lima, S; Allegood, J; Huang, WC; Zhang, SJ; Milstien, S; Conrad, D; Spiegel, S				Kim, Eugene Y.; Sturgill, Jamie L.; Hait, Nitai C.; Avni, Dorit; Valencia, Evelyn C.; Maceyka, Michael; Lima, Santiago; Allegood, Jeremy; Huang, Wei-Ching; Zhang, Shijun; Milstien, Sheldon; Conrad, Daniel; Spiegel, Sarah			Role of sphingosine kinase 1 and sphingosine-1-phosphate in CD40 signaling and IgE class switching	FASEB JOURNAL			English	Article						B cells; NF-kappa B; sphingolipids; inflammation	NECROSIS-FACTOR-ALPHA; GERMINAL CENTER FORMATION; B-CELLS; TNF-ALPHA; AIRWAY INFLAMMATION; LYMPHOCYTE EGRESS; MARGINAL ZONE; MOUSE MODEL; IN-VITRO; INHIBITOR	The tumor necrosis factor (TNF) receptor family member CD40 plays an essential role in the activation of antigen-presenting cells, B cell maturation, and immunoglobulin (Ig) class switching critical for adaptive immunity. Although the bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P) and the kinase that produces it, sphingosine kinase 1 (SphK1), have long been implicated in the actions of TNF mediated by engagement of TNFR1, nothing is yet known of their role in CD40-mediated events. We have now found that ligation of CD40 activates and translocates SphK1 to the plasma membrane, leading to generation of S1P. SphK1 inhibition in human tonsil B cells, as well as inhibition or deletion of SphK1 in mouse splenic B cells, significantly reduced CD40-mediated Ig class switching and plasma cell differentiation ex vivo. Optimal activation of downstream CD40 signaling pathways, including NF-kappa B, p38, and JNK, also required SphK1. In mice treated with a SphK1 inhibitor or in SphK1(-/-) mice, isotype switching to antigen-specific IgE was decreased in vivo by 70 and 55%, respectively. Our results indicate that SphK1 is important for CD40-mediated B cell activation and regulation of humoral responses and suggest that targeting SphK1 might be a useful therapeutic approach to control antigen-specific IgE production.	[Kim, Eugene Y.; Hait, Nitai C.; Avni, Dorit; Valencia, Evelyn C.; Maceyka, Michael; Lima, Santiago; Allegood, Jeremy; Huang, Wei-Ching; Milstien, Sheldon; Spiegel, Sarah] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; [Sturgill, Jamie L.; Conrad, Daniel] Virginia Commonwealth Univ, Sch Med, Dept Microbiol & Immunol, Richmond, VA 23298 USA; [Zhang, Shijun] Virginia Commonwealth Univ, Sch Med, Dept Med Chem, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, 1101 E Marshall St, Richmond, VA 23298 USA.	sspiegel@vcu.edu	Maceyka, Michael/B-9277-2008	Sturgill, Jamie/0000-0001-8856-3227; Avni, Dorit/0000-0002-0444-881X	U.S. National Institutes of Health (NIH) [R37GM043880, R01 AI50094, U19AI077435]; NIH grant [T32HL094290, P30CA16059, P30NS047463]; NATIONAL CANCER INSTITUTE [R01CA061774, P30CA016059] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL094290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077435, R01AI050094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R25GM090084, R37GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047463] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr. Michael Karin (University of California-San Diego, La Jolla, CA, USA) for kindly providing HEK-CD40 cells. This study was supported by U.S. National Institutes of Health (NIH) grants R37GM043880 and R01 AI50094 (S.S.) and in part by U19AI077435 (S.S. and D.C.). E.Y.K. and S.L. were supported by NIH grant T32HL094290. Flow cytometry was supported in part by NIH grant P30CA16059 to the Virginia Commonwealth University (VCU) Massey Cancer Center, and microscopy was performed at the VCU Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, by NIH grant P30NS047463.	Allende ML, 2010, J EXP MED, V207, P1113, DOI 10.1084/jem.20092210; Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128; Baker DA, 2010, J IMMUNOL, V185, P2570, DOI 10.4049/jimmunol.1000644; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Billich A, 2005, CELL SIGNAL, V17, P1203, DOI 10.1016/j.cellsig.2004.12.005; Bishop G. A., 2003, CYTOKINE GROWTH FACT, V14, P297; Bishop GA, 2004, NAT REV IMMUNOL, V4, P775, DOI 10.1038/nri1462; Caven TH, 2007, CELL IMMUNOL, V247, P49, DOI 10.1016/j.cellimm.2007.07.007; Chan HS, 2013, BBA-MOL CELL BIOL L, V1831, P147, DOI 10.1016/j.bbalip.2012.07.005; Chiba Y, 2010, J PHARMACOL SCI, V114, P304, DOI 10.1254/jphs.10202FP; Cho SW, 1997, CELL IMMUNOL, V180, P36, DOI 10.1006/cimm.1997.1174; Cinamon G, 2004, NAT IMMUNOL, V5, P713, DOI 10.1038/ni1083; Cinamon G, 2008, NAT IMMUNOL, V9, P54, DOI 10.1038/ni1542; Cyster JG, 2012, ANNU REV IMMUNOL, V30, P69, DOI 10.1146/annurev-immunol-020711-075011; De Palma C, 2006, ARTERIOSCL THROM VAS, V26, P99, DOI 10.1161/01.ATV.0000194074.59584.42; Diesner SC, 2012, IMMUNOL LETT, V141, P210, DOI 10.1016/j.imlet.2011.10.006; Donovan EE, 2010, EUR J IMMUNOL, V40, P688, DOI 10.1002/eji.200939858; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; Gallagher E, 2007, NAT IMMUNOL, V8, P57, DOI 10.1038/ni1421; Gohda M, 2008, J IMMUNOL, V180, P5335, DOI 10.4049/jimmunol.180.8.5335; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Green JA, 2011, NAT IMMUNOL, V12, P672, DOI 10.1038/ni.2047; Grigorova IL, 2009, NAT IMMUNOL, V10, P58, DOI 10.1038/ni.1682; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Harikumar KB, 2014, NAT IMMUNOL, V15, P231, DOI 10.1038/ni.2810; Hasbold J, 1998, EUR J IMMUNOL, V28, P1040, DOI 10.1002/(SICI)1521-4141(199803)28:03<1040::AID-IMMU1040>3.3.CO;2-0; Henry Brian, 2013, Handb Exp Pharmacol, P77, DOI 10.1007/978-3-7091-1368-4_4; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; Kabashima K, 2006, J EXP MED, V203, P2683, DOI 10.1084/jem.20061289; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Li ZW, 2003, J IMMUNOL, V170, P4630, DOI 10.4049/jimmunol.170.9.4630; Maceyka M, 2008, MOL CELL BIOL, V28, P5687, DOI 10.1128/MCB.00465-08; Matsuzawa A, 2008, SCIENCE, V321, P663, DOI 10.1126/science.1157340; Mills DM, 2007, P NATL ACAD SCI USA, V104, P6359, DOI 10.1073/pnas.0700296104; Nagahashi M, 2012, CANCER RES, V72, P726, DOI 10.1158/0008-5472.CAN-11-2167; Nishiuma T, 2008, AM J PHYSIOL-LUNG C, V294, pL1085, DOI 10.1152/ajplung.00445.2007; Olivera A, 2007, IMMUNITY, V26, P287, DOI 10.1016/j.immuni.2007.02.008; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; Paugh SW, 2008, BLOOD, V112, P1382, DOI 10.1182/blood-2008-02-138958; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Price MM, 2013, J ALLERGY CLIN IMMUN, V131, P501, DOI 10.1016/j.jaci.2012.07.014; Rabah D, 2002, IMMUNOLOGY, V106, P503, DOI 10.1046/j.1365-2567.2002.01435.x; Rickert RC, 2011, IMMUNOL REV, V244, P115, DOI 10.1111/j.1600-065X.2011.01067.x; Scherer EQ, 2010, STROKE, V41, P2618, DOI 10.1161/STROKEAHA.110.593327; Schnute ME, 2012, BIOCHEM J, V444, P79, DOI 10.1042/BJ20111929; Snider AJ, 2009, FASEB J, V23, P143, DOI 10.1096/fj.08-118109; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974; Sturgill JL, 2011, J NEUROIMMUNOL, V233, P80, DOI 10.1016/j.jneuroim.2010.11.014; Terstappen L, 1990, BLOOD, V9, P1739; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200	56	8	11	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4347	4358		10.1096/fj.14-251611	http://dx.doi.org/10.1096/fj.14-251611			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25002116	Green Published			2022-12-28	WOS:000342222700014
J	Yang, H; Salz, T; Zajac-Kaye, M; Liao, DQ; Huang, SM; Qiu, Y				Yang, Hui; Salz, Tal; Zajac-Kaye, Maria; Liao, Daiqing; Huang, Suming; Qiu, Yi			Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators	FASEB JOURNAL			English	Article						Sp1; Sp3; SET1; p300	HUMAN COLON-CANCER; HUMAN COLORECTAL-CANCER; G1/S TRANSITION; CYCLE ARREST; DNA-BINDING; EXPRESSION; ACETYLATION; INHIBITOR; SP1; APOPTOSIS	Histone deacetylases (HDACs) that deacetylate histone and nonhistone proteins play crucial roles in a variety of cellular processes. The overexpression of HDACs is reported in many cancer types and is directly linked to accelerated cell proliferation and survival. However, little is known about how HDAC expression is regulated in cancer cells. In this study, we found that HDAC1 and HDAC2 promoters are regulated through collaborative binding of transcription factors Sp1/Sp3 and epigenetic modulators, including histone H3K4 methyltransferase SET1 and histone acetyltransferase p300, whose levels are also elevated in colon cancer cell lines and patient samples. Interestingly, Sp1 and Sp3 differentially regulate HDAC1 and HDAC2 promoter activity. In addition, Sp1/Sp3 recruits SET1 and p300 to the promoters. SET1 knockdown (KD) results in a loss of the H3K4 trimethylation mark at the promoters, as well as destabilizes p300 at the promoters. Conversely, p300 also influences SET1 recruitment and H3K4me3 level, indicating a crosstalk between p300 and SET1. Further, SET1 KD reduces Sp1 binding to the HDAC1 promoter through the increase of Sp1 acetylation. These results indicate that interactions among transcription factors and epigenetic modulators orchestrate the activation of HDAC1 and HDAC2 promoter activity in colon cancer cells.	[Yang, Hui; Zajac-Kaye, Maria; Liao, Daiqing; Qiu, Yi] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL USA; [Salz, Tal; Huang, Suming] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Qiu, Y (corresponding author), 2033 Mowry Rd,Room 356, Gainesville, FL 32610 USA.	sumingh@ufl.edu; qiuy@ufl.edu		, Yi/0000-0002-3282-6072	U.S. National Institutes of Health [R01-HL-095674, R01-HL-091929, R01-HL-090589]; Florida Bankhead Coley Research Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090589, R01HL095674, R01HL091929] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Florida Bankhead Coley Research Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Dr. Bowen Yan for excellent technical assistance. This work was supported by U.S. National Institutes of Health grants R01-HL-095674 (to Y.Q.), R01-HL-091929 (to S.H.), and R01-HL-090589 (to S.H.) and a Florida Bankhead Coley Research Foundation grant (to Y.Q.). The authors declare no conflicts of interest.	Abaza MSI, 2012, TUMOR BIOL, V33, P1951, DOI 10.1007/s13277-012-0456-6; Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Bracker TU, 2009, INT J ONCOL, V35, P909, DOI 10.3892/ijo_00000406; Brunmeir R, 2009, INT J DEV BIOL, V53, P275, DOI 10.1387/ijdb.082649rb; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; CHU E, 1993, MOL PHARMACOL, V43, P527; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Enroth S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-450; Flatmark K, 2006, RADIAT ONCOL, V1, DOI 10.1186/1748-717X-1-25; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haberland M, 2009, P NATL ACAD SCI USA, V106, P7751, DOI 10.1073/pnas.0903139106; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Higashijima J, 2011, ONCOL REP, V26, P343, DOI 10.3892/or.2011.1312; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006; Iyer NG, 2007, ONCOGENE, V26, P21, DOI 10.1038/sj.onc.1209771; Lee JS, 2010, CELL, V142, P682, DOI 10.1016/j.cell.2010.08.011; Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010; Liu L, 2010, BIOCHEM BIOPH RES CO, V392, P190, DOI 10.1016/j.bbrc.2010.01.011; Loboda A, 2010, MOL CELLS, V29, P435, DOI 10.1007/s10059-010-0067-2; Ma WL, 2008, BIOL REPROD, V79, P289, DOI 10.1095/biolreprod.107.067082; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Martin DGE, 2006, MOL CELL BIOL, V26, P7871, DOI 10.1128/MCB.00573-06; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Meng J, 2012, ONCOL REP, V28, P384, DOI 10.3892/or.2012.1793; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Salz T, 2014, CANCER RES, V74, P775, DOI 10.1158/0008-5472.CAN-13-1400; Schuettengruber B, 2003, MOL CELL BIOL, V23, P6993, DOI 10.1128/MCB.23.19.6993-7004.2003; Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07; Spange S, 2009, INT J BIOCHEM CELL B, V41, P185, DOI 10.1016/j.biocel.2008.08.027; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Tang ZY, 2013, CELL, V154, P297, DOI 10.1016/j.cell.2013.06.027; Taverna SD, 2006, MOL CELL, V24, P785, DOI 10.1016/j.molcel.2006.10.026; Valin A, 2013, MOL CELL BIOL, V33, P1582, DOI 10.1128/MCB.00323-12; Waby JS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-275; Wada T, 2009, J BIOL CHEM, V284, P30673, DOI 10.1074/jbc.M109.042242; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; WILLSON JKV, 1987, CANCER RES, V47, P2704; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Wilson AJ, 2010, CANCER RES, V70, P609, DOI 10.1158/0008-5472.CAN-09-2327; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yang T, 2012, J BIOL CHEM, V287, P40279, DOI 10.1074/jbc.M112.349704; Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599; Yang YH, 2008, CANCER RES, V68, P4833, DOI 10.1158/0008-5472.CAN-08-0644; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zeng YY, 1998, J BIOL CHEM, V273, P28921, DOI 10.1074/jbc.273.44.28921; Zhu P, 2004, CELL CYCLE, V3, P1240, DOI 10.4161/cc.3.10.1195	57	42	43	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4265	4279		10.1096/fj.14-250654	http://dx.doi.org/10.1096/fj.14-250654			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24948597	Green Published			2022-12-28	WOS:000342222700007
J	Asgari, E; Farrar, CA; Lynch, N; Ali, YM; Roscher, S; Stover, C; Zhou, WD; Schwaeble, WJ; Sacks, SH				Asgari, Elham; Farrar, Conrad A.; Lynch, Nicholas; Ali, Youssif M.; Roscher, Silke; Stover, Cordula; Zhou, Wuding; Schwaeble, Wilhelm J.; Sacks, Steven H.			Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4	FASEB JOURNAL			English	Article						kidney transplantation; inflammation	ISCHEMIA/REPERFUSION INJURY; MYOCARDIAL-ISCHEMIA; NATURAL ANTIBODY; SKELETAL-MUSCLE; PATHWAY; ACTIVATION; MICE; IGM; INNATE; TRANSPLANTATION	Mannan-binding lectin-associated serine protease 2 (MASP-2) has been described as the essential enzyme for the lectin pathway (LP) of complement activation. Since there is strong published evidence indicating that complement activation via the LP critically contributes to ischemia reperfusion (IR) injury, we assessed the effect of MASP-2 deficiency in an isogenic mouse model of renal transplantation. The experimental transplantation model used included nephrectomy of the remaining native kidney at d 5 post-transplantation. While wild-type (WT) kidneys grafted into WT recipients (n=7) developed acute renal failure (control group), WT grafts transplanted into MASP-2-deficient recipients (n=7) showed significantly better kidney function, less C3 deposition, and less IR injury. In the absence of donor or recipient complement C4 (n=7), the WT to WT phenotype was preserved, indicating that the MASP-2-mediated damage was independent of C4 activation. This C4-bypass MASP-2 activity was confirmed in mice deficient for both MASP-2 and C4 (n=7), where the protection from postoperative acute renal failure was no greater than in mice with MASP-2 deficiency alone. Our study highlights the role of LP activation in renal IR injury and indicates that injury occurs through MASP-2-dependent activation events independent of C4.	[Asgari, Elham; Farrar, Conrad A.; Zhou, Wuding; Sacks, Steven H.] Kings Coll London, Med Res Council Ctr Transplantat, London, England; [Lynch, Nicholas; Ali, Youssif M.; Roscher, Silke; Stover, Cordula; Schwaeble, Wilhelm J.] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England	University of London; King's College London; University of Leicester	Asgari, E (corresponding author), Guys Hosp, Kings Coll London, MRC Ctr Transplantat, London SE1 9RT, England.	asgelham@gmail.com	Ali, Youssif M./P-9593-2018	Ali, Youssif M./0000-0003-3124-9848; Schwaeble, Wilhelm/0000-0001-8927-0864; Sacks, Steven/0000-0001-6361-9095; Lynch, Nicholas/0000-0003-3803-3329; Stover, Cordula/0000-0002-0125-4868	Wellcome Trust [079772]; Kidney Research UK grant [TF9]; Medical Research Council Centre for Transplantation, Guy's Hospital, King's College; Department of Health, National Institute for Health Research comprehensive Biomedical Research Centre award; King's College London; King's College Hospital NHS Foundation Trust; Medical Research Council [MR/J006742/1, G0600892] Funding Source: researchfish; MRC [G1000191, G0700859, G0501425, G0801952, G0600892] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); Kidney Research UK grant(Kidney Research UK (KRUK)); Medical Research Council Centre for Transplantation, Guy's Hospital, King's College(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health, National Institute for Health Research comprehensive Biomedical Research Centre award; King's College London; King's College Hospital NHS Foundation Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by grant 079772 from The Wellcome Trust to W.J.S. and S. H. S., Kidney Research UK grant TF9 to E. A., and the Medical Research Council Centre for Transplantation, Guy's Hospital, King's College and the Department of Health, National Institute for Health Research comprehensive Biomedical Research Centre award to Guy's and St. Thomas' National Health Service (NHS) Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. MASP-2-deficient mice were produced by C. S., and anti-MASP-2 mAb was produced by Y.M.A. The authors declare no conflicts of interest. W.J.S. and S. H. S. equally share the senior authorship.	Ali YM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002793; Boros P, 2006, AM J TRANSPLANT, V6, P652, DOI 10.1111/j.1600-6143.2005.01228.x; Busche MN, 2009, AM J PHYSIOL-HEART C, V297, pH1853, DOI 10.1152/ajpheart.00049.2009; Cervera A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008433; Chan RK, 2006, J IMMUNOL, V177, P8080, DOI 10.4049/jimmunol.177.11.8080; Collard CD, 2000, AM J PATHOL, V156, P1549, DOI 10.1016/S0002-9440(10)65026-2; Damman J, 2008, TRANSPLANTATION, V85, P923, DOI 10.1097/TP.0b013e3181683cf5; de Vries B, 2004, AM J PATHOL, V165, P1677, DOI 10.1016/S0002-9440(10)63424-4; Diepenhorst GMP, 2009, ANN SURG, V249, P889, DOI 10.1097/SLA.0b013e3181a38f45; Farrar CA, 2004, AM J PATHOL, V164, P133, DOI 10.1016/S0002-9440(10)63104-5; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; Gal P, 2005, J BIOL CHEM, V280, P33435, DOI 10.1074/jbc.M506051200; Hart ML, 2005, J IMMUNOL, V174, P6373, DOI 10.4049/jimmunol.174.10.6373; Hirano M, 2012, GLYCOBIOLOGY, V22, P84, DOI 10.1093/glycob/cwr107; Jordan JE, 2001, CIRCULATION, V104, P1413, DOI 10.1161/hc3601.095578; KALINA SL, 1993, AUST NZ J SURG, V63, P213, DOI 10.1111/j.1445-2197.1993.tb00521.x; LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109; Lewis AG, 2008, CLIN EXP IMMUNOL, V153, P117, DOI 10.1111/j.1365-2249.2008.03678.x; Mastellos D, 2003, IMMUNOL RES, V27, P367, DOI 10.1385/IR:27:2-3:367; McMullen ME, 2006, IMMUNOBIOLOGY, V211, P759, DOI 10.1016/j.imbio.2006.06.011; Moller-Kristensen M, 2005, SCAND J IMMUNOL, V61, P426, DOI 10.1111/j.1365-3083.2005.01591.x; Osthoff M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021338; Park P, 2001, J AM SOC NEPHROL, V12, P1383, DOI 10.1681/ASN.V1271383; Patel H, 2006, J AM SOC NEPHROL, V17, P1102, DOI 10.1681/ASN.2005101116; Peng Q, 2012, J AM SOC NEPHROL, V23, P1474, DOI 10.1681/ASN.2011111072; Schwaeble WJ, 2011, P NATL ACAD SCI USA, V108, P7523, DOI 10.1073/pnas.1101748108; Selander B, 2006, J CLIN INVEST, V116, P1425, DOI 10.1172/JCI25982; Shoskes DA, 1998, TRANSPLANTATION, V66, P1697, DOI 10.1097/00007890-199812270-00022; Stover CM, 1999, J IMMUNOL, V163, P6848; Thurman JM, 2003, J IMMUNOL, V170, P1517, DOI 10.4049/jimmunol.170.3.1517; Thurman JM, 2006, J AM SOC NEPHROL, V17, P707, DOI 10.1681/ASN.2005070698; van der Pol P, 2012, AM J TRANSPLANT, V12, P877, DOI 10.1111/j.1600-6143.2011.03887.x; Walsh MC, 2005, J IMMUNOL, V175, P541, DOI 10.4049/jimmunol.175.1.541; Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; Williams JP, 1999, J APPL PHYSIOL, V86, P938, DOI 10.1152/jappl.1999.86.3.938; Wyss-Coray T, 2002, P NATL ACAD SCI USA, V99, P10837, DOI 10.1073/pnas.162350199; Zhang M, 2006, J EXP MED, V203, P141, DOI 10.1084/jem.20050390; Zhang M, 2008, MOL IMMUNOL, V45, P4036, DOI 10.1016/j.molimm.2008.06.013; Zhang M, 2007, MOL IMMUNOL, V44, P103, DOI 10.1016/j.molimm.2006.06.022; Zhang M, 2006, J IMMUNOL, V177, P4727, DOI 10.4049/jimmunol.177.7.4727; Zheng XF, 2008, AM J PATHOL, V173, P973, DOI 10.2353/ajpath.2008.080103; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	43	60	62	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3996	4003		10.1096/fj.13-246306	http://dx.doi.org/10.1096/fj.13-246306			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24868011	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000340845900017
J	Vargas, A; Zhou, SF; Ethier-Chiasson, M; Flipo, D; Lafond, J; Gilbert, C; Barbeau, B				Vargas, Amandine; Zhou, Shufeng; Ethier-Chiasson, Maude; Flipo, Denis; Lafond, Julie; Gilbert, Caroline; Barbeau, Benoit			Syncytin proteins incorporated in placenta exosomes are important for cell uptake and show variation in abundance in serum exosomes from patients with preeclampsia	FASEB JOURNAL			English	Article						HERV; villous cytotrophoblasts; fusogenic protein; microvesicles; biomarker	FUNCTIONAL-CHARACTERIZATION; HUMAN BLOOD; FAS LIGAND; HERV-W; RECEPTOR; EXPRESSION; PREGNANCY; GLYCOPROTEIN; MECHANISM; VESICLES	Exosomes are extracellular vesicles that mediate intercellular communication and are involved in several biological processes. The objective of our study was to determine whether endogenous retrovirus group WE, member l (ERVWE1)/syncytin-1 and endogenous retrovirus group FRD, member 1 (ERVFRDE1)/syncytin-2, encoded by human endogenous retrovirus (HERV) envelope (env) genes, are present at the surface of exosomes produced by placenta-derived villous cytotrophoblasts and whether they play a role in cellular uptake of exosomes. In addition, we sought to determine whether these proteins are present in various abundances in serum-derived exosomes from normal pregnant women vs. women with preeclampsia (PE). Isolated exosomes were analyzed for their content by Western blot, a bead-associated flow cytometry approach, and a syncytin-2 ELISA. Binding and uptake were tested through confocal and electron microscopy using the BeWo choriocarcinoma cell line. Quality control of exosome preparations consisted of detection of exosomal and nonexosomal markers. Exosome-cell interactions were compared between cells incubated in the presence of control exosomes, syncytin-1 or syncytin-2-deprived exosomes, or exosomes solely bearing the uncleaved forms of these HERV env proteins. From our data, we conclude that villous cytotrophoblast exosomes are positive for both env proteins and are rapidly taken up by BeWo cells in a syncytin-1- and syncytin-2-dependent manner and that syncytin-2 is reduced in serum-derived exosomes from women with PE when compared to exosomes from normal pregnant women.-Vargas, A., Zhou, S., Ethier-Chiasson, M., Flipo, D., Lafond, J., Gilbert, C., Barbeau, B. Syncytin proteins incorporated in placenta exosomes are important for cell uptake and show variation in abundance in serum exosomes from patients with preeclampsia.	[Vargas, Amandine; Zhou, Shufeng; Ethier-Chiasson, Maude; Flipo, Denis; Lafond, Julie; Barbeau, Benoit] Univ Quebec, Dept Sci Biol, Montreal, PQ, Canada; [Vargas, Amandine; Zhou, Shufeng; Ethier-Chiasson, Maude; Flipo, Denis; Lafond, Julie; Barbeau, Benoit] Univ Quebec, Ctr Rech BioMed, Montreal, PQ, Canada; [Gilbert, Caroline] Univ Laval, Fac Med, Ctr Hosp Univ Quebec, Ctr Rech, Quebec City, PQ G1K 7P4, Canada	University of Quebec; University of Quebec Montreal; University of Quebec; University of Quebec Montreal; Laval University	Barbeau, B (corresponding author), Univ Quebec, Dept Sci Biol, SB R860,2080 St Urbain, Montreal, PQ, Canada.	barbeau.benoit@uqam.ca	Barbeau, Benoit/A-1174-2010	Barbeau, Benoit/0000-0002-4108-8155; Gilbert, Caroline/0000-0003-2722-1180; Zhou, Shufeng/0000-0003-2715-9823	Natural Sciences and Engineering Research Council of Canada (NSERC); Canadian Institutes of Health Research (CIHR) [MOP130561]; NSERC; Fonds de la Recherche en Sante du Quebec; CIHR/HIV/AIDS initiative	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); CIHR/HIV/AIDS initiative	The authors thank Emilie Larocque and Diane Gingras for excellent technical assistance. This work was supported by a discovery grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) and by an operating grant from the Canadian Institutes of Health Research (CIHR; MOP130561; to B. B.). A. V. held an Alexander Graham Bell Canada Graduate Scholarship from NSERC. C. G. is the recipient of a Junior 1 Scholarship from the Fonds de la Recherche en Sante du Quebec and a New Investigator Award from the CIHR/HIV/AIDS initiative. B. B. holds a Canada Research Chair in human retrovirology (tier 2).	Abrahams VM, 2004, MOL HUM REPROD, V10, P55, DOI 10.1093/molehr/gah006; ACIEN P, 1990, INT J GYNECOL OBSTET, V32, P229, DOI 10.1016/0020-7292(90)90350-T; Audibert F, 2005, LANCET, V365, P1367, DOI 10.1016/S0140-6736(05)66350-7; Benirschke K., 2000, PATHOLOGY HUMAN PLAC; Blaise S, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-19; Blaise S, 2003, P NATL ACAD SCI USA, V100, P13013, DOI 10.1073/pnas.2132646100; Blond JL, 2000, J VIROL, V74, P3321, DOI 10.1128/JVI.74.7.3321-3329.2000; Bonifacino JS, 2003, NAT REV MOL CELL BIO, V4, P409, DOI 10.1038/nrm1099; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Cantin R, 2008, J IMMUNOL METHODS, V338, P21, DOI 10.1016/j.jim.2008.07.007; Chen CP, 2008, BIOL REPROD, V79, P815, DOI 10.1095/biolreprod.108.069765; Cheynet V, 2005, J VIROL, V79, P5585, DOI 10.1128/JVI.79.9.5585-5593.2005; Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003; DEGROOTE G, 1983, CLIN CHEM, V29, P115; Esnault C, 2008, P NATL ACAD SCI USA, V105, P17532, DOI 10.1073/pnas.0807413105; Frangsmyr L, 2005, MOL HUM REPROD, V11, P35, DOI 10.1093/molehr/gah129; Frendo JL, 2003, MOL CELL BIOL, V23, P3566, DOI 10.1128/MCB.23.10.3566-3574.2003; Hedlund M, 2009, J IMMUNOL, V183, P340, DOI 10.4049/jimmunol.0803477; Holder BS, 2012, PLACENTA, V33, P460, DOI 10.1016/j.placenta.2012.02.012; Holder BS, 2012, IMMUNOLOGY, V136, P184, DOI 10.1111/j.1365-2567.2012.03568.x; Izquierdo-Useros N, 2011, CELL MICROBIOL, V13, P10, DOI 10.1111/j.1462-5822.2010.01542.x; Johnstone RM, 2006, BLOOD CELL MOL DIS, V36, P315, DOI 10.1016/j.bcmd.2005.12.001; Keith JC, 2002, AM J OBSTET GYNECOL, V187, P1122, DOI 10.1067/mob.2002.128512; Keller S, 2007, KIDNEY INT, V72, P1095, DOI 10.1038/sj.ki.5002486; Knerr I, 2002, AM J OBSTET GYNECOL, V186, P210, DOI 10.1067/mob.2002.119636; Lakkaraju A, 2008, TRENDS CELL BIOL, V18, P199, DOI 10.1016/j.tcb.2008.03.002; Lavillette D, 1998, J VIROL, V72, P9955, DOI 10.1128/JVI.72.12.9955-9965.1998; Luo SS, 2009, BIOL REPROD, V81, P717, DOI 10.1095/biolreprod.108.075481; Mangeney M, 2007, P NATL ACAD SCI USA, V104, P20534, DOI 10.1073/pnas.0707873105; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Mears R, 2004, PROTEOMICS, V4, P4019, DOI 10.1002/pmic.200400876; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; MIDGLEY AR, 1963, SCIENCE, V141, P349, DOI 10.1126/science.141.3578.349; Mincheva-Nilsson L, 2006, J IMMUNOL, V176, P3585, DOI 10.4049/jimmunol.176.6.3585; Mincheva-Nilsson L, 2010, AM J REPROD IMMUNOL, V63, P520, DOI 10.1111/j.1600-0897.2010.00822.x; Morelli AE, 2004, BLOOD, V104, P3257, DOI 10.1182/blood-2004-03-0824; Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Redman CWG, 2012, PLACENTA, V33, pS48, DOI 10.1016/j.placenta.2011.12.006; Roberts JM, 2005, LANCET, V366, P961, DOI 10.1016/S0140-6736(05)67349-7; Sabapatha A, 2006, AM J REPROD IMMUNOL, V56, P345, DOI 10.1111/j.1600-0897.2006.00435.x; Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)71003-5; Taylor DD, 2006, J IMMUNOL, V176, P1534, DOI 10.4049/jimmunol.176.3.1534; Taylor DD, 2011, METHODS MOL BIOL, V728, P235, DOI 10.1007/978-1-61779-068-3_15; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Tolosa JM, 2012, PLACENTA, V33, P933, DOI 10.1016/j.placenta.2012.08.004; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; Vargas A, 2011, REPROD SCI, V18, P1085, DOI 10.1177/1933719111404608; Vargas A, 2009, J MOL BIOL, V392, P301, DOI 10.1016/j.jmb.2009.07.025; Walker JJ, 2000, LANCET, V356, P1260, DOI 10.1016/S0140-6736(00)02800-2	52	119	126	2	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3703	3719		10.1096/fj.13-239053	http://dx.doi.org/10.1096/fj.13-239053			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24812088				2022-12-28	WOS:000340265400037
J	Jiang, HW; Wang, YQ; Viniegra, A; Sima, C; McCulloch, CA; Glogauer, M				Jiang, Hongwei; Wang, Yongqiang; Viniegra, Ana; Sima, Corneliu; McCulloch, Christopher A.; Glogauer, Michael			Adseverin plays a role in osteoclast differentiation and periodontal disease-mediated bone loss	FASEB JOURNAL			English	Article						osteoclastogenesis; fusion; actin; bone resorption	CELL-CELL FUSION; ACTIN RING; GELSOLIN; PROTEIN; RESORPTION; PODOSOMES; EXOCYTOSIS; EXPRESSION; REGULATORS; MICE	Osteoclast differentiation and function are highly dependent on the assembly and turnover of actin filaments, but little is known about the roles of actin binding proteins in these processes. Adseverin (Ads), a member of the gelsolin superfamily of actin capping and severing proteins, regulates actin filament turnover and can regulate the turnover of cortical actin filaments of chromaffin cells during exocytosis. Using a conditional Ads knockout mouse model, we confirmed our previous finding in cultured cells that Ads plays a role in osteoclastogenesis (OCG) and actin cytoskeletal organization in osteoclasts. Here we show that Ads is required for osteoclast formation and that when alveolar bone resorption is experimentally induced in mice, genetic deletion of Ads prevents osteoclast-mediated bone loss. Further, when Ads-null osteoclasts are cultured, they exhibit defective OCG, disorganized podosome-based actin filament superstructures, and decreased bone resorption. Reintroduction of Ads into Ads-null osteoclast precursor cells restored these osteoclast defects. Collectively, these data demonstrate a unique and osteoclast-specific role for Ads in OCG and osteoclast function.	[Jiang, Hongwei; Wang, Yongqiang; Viniegra, Ana; Sima, Corneliu; McCulloch, Christopher A.; Glogauer, Michael] Univ Toronto, Fac Dent, Matrix Dynam Grp, Toronto, ON M5S 1A1, Canada; [Jiang, Hongwei] Sun Yat Sen Univ, Guanghua Sch Stomatol, Dept Operat Dent & Endodont, Guangzhou 510275, Guangdong, Peoples R China; [Jiang, Hongwei] Guangdong Prov Key Lab Stomatol, Guangzhou, Guangdong, Peoples R China	University of Toronto; Sun Yat Sen University	Glogauer, M (corresponding author), Room 221,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	michael.glogauer@utoronto.ca	Glogauer, Michael/D-2504-2011	Viniegra, Ana/0000-0002-7100-2252; Sima, Corneliu/0000-0003-3526-4850	National Nature Science Foundation of China [81100742]; Natural Science Foundation of Guangdong Province [S2013010015833]; Canadian Institutes of Health Research Team [TBO-122068]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Canadian Institutes of Health Research Team(Canadian Institutes of Health Research (CIHR))	The authors gratefully acknowledge Siavash Hassanpour for the preparation of the recombinant TAT-Ads protein, and Chunxiang Sun for mice genotyping. This work was supported by National Nature Science Foundation of China Grant 81100742, Natural Science Foundation of Guangdong Province Grant S2013010015833, and Canadian Institutes of Health Research Team Grant TBO-122068 (to C.A.M. and M.G.).	Abmayr SM, 2012, DEVELOPMENT, V139, P641, DOI 10.1242/dev.068353; Blangy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045909; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Castro CHM, 2004, J CELL SCI, V117, P2853, DOI 10.1242/jcs.01133; Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665; Chiu WSM, 2004, GENESIS, V39, P178, DOI 10.1002/gene.20041; Chumnarnsilpa S, 2009, P NATL ACAD SCI USA, V106, P13719, DOI 10.1073/pnas.0812383106; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Di Benedetto G, 2008, CIRC RES, V103, P836, DOI 10.1161/CIRCRESAHA.108.174813; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; Gotz A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060642; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; Hassanpour S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109078; Helming L, 2009, TRENDS CELL BIOL, V19, P514, DOI 10.1016/j.tcb.2009.07.005; Henriksen K, 2007, OSTEOPOROSIS INT, V18, P681, DOI 10.1007/s00198-006-0286-8; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008; KANEHISA J, 1990, BONE, V11, P287, DOI 10.1016/8756-3282(90)90082-A; Lee CYS, 2009, IMPLANT DENT, V18, P492, DOI 10.1097/ID.0b013e3181c6837c; Lueck A, 2000, BIOCHEMISTRY-US, V39, P5274, DOI 10.1021/bi992871v; Lueck A, 1998, J CELL SCI, V111, P3633; MAEKAWA S, 1990, J BIOL CHEM, V265, P10940; Nurminsky D, 2007, DEV BIOL, V302, P427, DOI 10.1016/j.ydbio.2006.09.052; Pene TD, 2005, J NEUROCHEM, V92, P780, DOI 10.1111/j.1471-4159.2004.02907.x; RODRIGUEZ DCA, 1990, EMBO J, V9, P43; SAKURAI T, 1991, J BIOL CHEM, V266, P15979; Shilagardi K, 2013, SCIENCE, V340, P359, DOI 10.1126/science.1234781; Silacci P, 2004, CELL MOL LIFE SCI, V61, P2614, DOI 10.1007/s00018-004-4225-6; Sima C, 2014, AM J PATHOL, V184, P472, DOI 10.1016/j.ajpath.2013.10.018; Spinardi L, 2006, EUR J CELL BIOL, V85, P191, DOI 10.1016/j.ejcb.2005.08.005; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; Wang YQ, 2008, J BONE MINER RES, V23, P260, DOI 10.1359/JBMR.071013; Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200; Woo JT, 2000, J BONE MINER RES, V15, P650, DOI 10.1359/jbmr.2000.15.4.650; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645; Yang GZ, 2008, BIOCHEM BIOPH RES CO, V366, P352, DOI 10.1016/j.bbrc.2007.11.106	36	13	14	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2015	29	6					2281	2291		10.1096/fj.14-265744	http://dx.doi.org/10.1096/fj.14-265744			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CJ0ZF	25681458				2022-12-28	WOS:000355209500007
J	Ramunas, J; Yakubov, E; Brady, JJ; Corbel, SY; Holbrook, C; Brandt, M; Stein, J; Santiago, JG; Cooke, JP; Blau, HM				Ramunas, John; Yakubov, Eduard; Brady, Jennifer J.; Corbel, Stephane Y.; Holbrook, Colin; Brandt, Moritz; Stein, Jonathan; Santiago, Juan G.; Cooke, John P.; Blau, Helen M.			Transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells	FASEB JOURNAL			English	Article						nucleoside modified mRNA; telomerase; senescence; proliferative capacity	DUCHENNE MUSCULAR-DYSTROPHY; REVERSE-TRANSCRIPTASE; LIFE-SPAN; SELF-RENEWAL; CANCER; SENESCENCE; EXPRESSION; LENGTH; MICE; REJUVENATION	Telomere extension has been proposed as a means to improve cell culture and tissue engineering and to treat disease. However, telomere extension by nonviral, nonintegrating methods remains inefficient. Here we report that delivery of modified mRNA encoding TERT to human fibroblasts and myoblasts increases telomerase activity transiently (24-48 h) and rapidly extends telomeres, after which telomeres resume shortening. Three successive transfections over a 4 d period extended telomeres up to 0.9 kb in a cell type-specific manner in fibroblasts and myoblasts and conferred an additional 28 +/- 1.5 and 3.4 +/- 0.4 population doublings (PDs), respectively. Proliferative capacity increased in a dose-dependent manner. The second and third transfections had less effect on proliferative capacity than the first, revealing a refractory period. However, the refractory period was transient as a later fourth transfection increased fibroblast proliferative capacity by an additional 15.2 +/- 1.1 PDs, similar to the first transfection. Overall, these treatments led to an increase in absolute cell number of more than 10(12)-fold. Notably, unlike immortalized cells, all treated cell populations eventually stopped increasing in number and expressed senescence markers to the same extent as untreated cells. This rapid method of extending telomeres and increasing cell proliferative capacity without risk of insertional mutagenesis should have broad utility in disease modeling, drug screening, and regenerative medicine.	[Ramunas, John; Brady, Jennifer J.; Corbel, Stephane Y.; Holbrook, Colin; Brandt, Moritz; Blau, Helen M.] Stanford Univ, Sch Med, Baxter Lab Stem Cell Biol,Clin Sci Res Ctr, Dept Microbiol & Immunol,Inst Stem Cell Biol & Re, Stanford, CA 94305 USA; [Yakubov, Eduard; Cooke, John P.] Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Stanford, CA 94305 USA; [Stein, Jonathan] SpectraCell Labs Inc, Houston, TX USA; [Santiago, Juan G.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Blau, HM (corresponding author), Stanford Univ, Sch Med, Baxter Lab Stem Cell Biol, 269 Campus Dr,CCSR 4215, Stanford, CA 94305 USA.	hblau@stanford.edu	Brandt, Moritz/ABB-5621-2021	Cooke, John/0000-0003-0033-9138; Santiago, Juan/0000-0001-8652-5411	Stanford Bio-X Grant [IIP5-31]; U.S. National Institutes of Health (NIH) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR063963]; NIH National Heart, Lung, and Blood Institute (NHLBI) [U01HL100397]; NIH National Institute on Aging [AG044815-01]; Federal Ministry of Education and Research Grant BMBF [01EO1003]; University of Maryland [SR00002307]; NIH NHLBI [U01HL099997]; Baxter Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL100397, R01HL095716, U01HL099997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR063963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG044815] Funding Source: NIH RePORTER	Stanford Bio-X Grant; U.S. National Institutes of Health (NIH) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases; NIH National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Federal Ministry of Education and Research Grant BMBF(Federal Ministry of Education & Research (BMBF)); University of Maryland; NIH NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Baxter Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Elizabeth Blackburn (University of California, San Francisco) for helpful discussions. They appreciate the technical assistance of Luis Batista (in the laboratory of Steve Artandi, Stanford University) and Linda Ward (SpectraCell, Inc.). They also thank Robert Weinberg for depositing the pBABE-neo-hTERT plasmid at Addgene. This work was supported by Stanford Bio-X Grant IIP5-31 to J.G.S. and H.M.B., U.S. National Institutes of Health (NIH) Director's Transformative Research Award R01AR063963 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to H.M.B., NIH National Heart, Lung, and Blood Institute (NHLBI) Grant U01HL100397 to H.M.B. and J.P.C, NIH National Institute on Aging Grant AG044815-01 to H.M.B.., Federal Ministry of Education and Research Grant BMBF 01EO1003 to M.B., University of Maryland, Baltimore Subaward SR00002307 (on NIH NHLBI Grant U01HL099997) to H.M.B. and J.G.S., and funding from the Baxter Foundation to H.M.B. J.R., E.Y., J.P.C., and H.M.B. are inventors on patents for use of modified mRNA for telomere extension.	Ahmed S, 2008, J CELL SCI, V121, P1046, DOI 10.1242/jcs.019372; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Allsopp R, 2012, CELL RES, V22, P614, DOI 10.1038/cr.2012.6; Armanios M, 2012, NAT REV GENET, V13, P693, DOI 10.1038/nrg3246; Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Batista LFZ, 2011, NATURE, V474, P399, DOI 10.1038/nature10084; de Jesus BB, 2012, EMBO MOL MED, V4, P691, DOI 10.1002/emmm.201200245; de Jesus BB, 2011, AGING CELL, V10, P604, DOI 10.1111/j.1474-9726.2011.00700.x; de Jesus BB, 2011, CELL STEM CELL, V8, P3, DOI 10.1016/j.stem.2010.12.013; Binet R, 2009, CANCER RES, V69, P9183, DOI 10.1158/0008-5472.CAN-09-1016; Blackburn EH, 2005, FEBS LETT, V579, P859, DOI 10.1016/j.febslet.2004.11.036; Blackburn EH, 2011, CANCER PREV RES, V4, P473, DOI 10.1158/1940-6207.CAPR-11-0066; Blackburn EH, 2010, CANCER PREV RES, V3, P394, DOI 10.1158/1940-6207.CAPR-10-0051; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Calado RT, 2012, LEUKEMIA, V26, P700, DOI 10.1038/leu.2011.272; Calado Rodrigo, 2012, F1000 Med Rep, V4, P8, DOI 10.3410/M4-8; Cawthon RM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkn1027; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Cifuentes-Rojas C, 2012, MUTAT RES-FUND MOL M, V730, P20, DOI 10.1016/j.mrfmmm.2011.10.003; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; CRISTOFA.VJ, 1969, MED EXP, V19, P313; Cristofalo VJ, 2004, MECH AGEING DEV, V125, P827, DOI 10.1016/j.mad.2004.07.010; de Lange T, 2009, SCIENCE, V326, P948, DOI 10.1126/science.1170633; Andrade LND, 2012, HUM MOL GENET, V21, P3825, DOI 10.1093/hmg/dds211; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Eitan E, 2012, EMBO MOL MED, V4, P313, DOI 10.1002/emmm.201200212; Gilbert PM, 2010, SCIENCE, V329, P1078, DOI 10.1126/science.1191035; Greber B, 2011, EMBO J, V30, P4874, DOI 10.1038/emboj.2011.407; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Haendeler J, 2009, ARTERIOSCL THROM VAS, V29, P929, DOI 10.1161/ATVBAHA.109.185546; Harley CB, 2011, REJUV RES, V14, P45, DOI 10.1089/rej.2010.1085; Harley CB, 2005, CURR MOL MED, V5, P205, DOI 10.2174/1566524053586671; Harley CB, 2002, ONCOGENE, V21, P494, DOI 10.1038/sj.onc.1205076; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603; Kariko K, 2012, MOL THER, V20, P948, DOI 10.1038/mt.2012.7; Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635; Kormann MSD, 2011, NAT BIOTECHNOL, V29, P154, DOI 10.1038/nbt.1733; Lansdorp PM, 2005, TRENDS BIOCHEM SCI, V30, P388, DOI 10.1016/j.tibs.2005.05.004; Lawless C, 2010, EXP GERONTOL, V45, P772, DOI 10.1016/j.exger.2010.01.018; Le RR, 2014, CELL STEM CELL, V14, P27, DOI 10.1016/j.stem.2013.11.005; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287; Matsushita H, 2001, CIRC RES, V89, P793, DOI 10.1161/hh2101.098443; Mogford JE, 2006, HUM GENE THER, V17, P651, DOI 10.1089/hum.2006.17.651; Mohsin S, 2013, CIRC RES, V113, P1169, DOI 10.1161/CIRCRESAHA.113.302302; Mourkioti F, 2013, NAT CELL BIOL, V15, P895, DOI 10.1038/ncb2790; Perez-Rivero G, 2006, CIRCULATION, V114, P309, DOI 10.1161/CIRCULATIONAHA.105.611111; Pucci F, 2013, CELL STEM CELL, V12, P479, DOI 10.1016/j.stem.2013.01.018; Sacco A, 2010, CELL, V143, P1059, DOI 10.1016/j.cell.2010.11.039; Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787; Sahin E, 2010, NATURE, V464, P520, DOI 10.1038/nature08982; Shay JW, 2001, RADIAT RES, V155, P188, DOI 10.1667/0033-7587(2001)155[0188:TATIFC]2.0.CO;2; Signer RAJ, 2013, CELL STEM CELL, V12, P152, DOI 10.1016/j.stem.2013.01.001; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; Steinert S, 2000, BIOCHEM BIOPH RES CO, V273, P1095, DOI 10.1006/bbrc.2000.3080; Suhr ST, 2009, PLOS ONE, V4, DOI [10.1371/journal.pone.0008124, 10.1371/journal.pone.0014095]; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; Takubo K, 2010, GERIATR GERONTOL INT, V10, pS197, DOI 10.1111/j.1447-0594.2010.00605.x; Tavernier G, 2011, J CONTROL RELEASE, V150, P238, DOI 10.1016/j.jconrel.2010.10.020; Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596; Vaziri H, 2010, REGEN MED, V5, P345, DOI 10.2217/RME.10.21; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang F, 2012, CELL RES, V22, P757, DOI 10.1038/cr.2011.201; Wang YH, 2013, MOL THER, V21, P358, DOI 10.1038/mt.2012.250; WEBSTER C, 1990, SOMAT CELL MOLEC GEN, V16, P557, DOI 10.1007/BF01233096; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu YL, 2006, J CELL SCI, V119, P2797, DOI 10.1242/jcs.03001; Wyatt H. D. M., 2009, THESIS U CALGARY CAL; Xi LH, 2014, NUCLEIC ACIDS RES, V42, P8565, DOI 10.1093/nar/gku560; Yakubov E, 2010, BIOCHEM BIOPH RES CO, V394, P189, DOI 10.1016/j.bbrc.2010.02.150; Zhu CH, 2007, AGING CELL, V6, P515, DOI 10.1111/j.1474-9726.2007.00306.x; Zimmermann S, 2008, CELL TISSUE RES, V331, P79, DOI 10.1007/s00441-007-0469-4	78	57	63	2	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1930	1939		10.1096/fj.14-259531	http://dx.doi.org/10.1096/fj.14-259531			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25614443	Green Published			2022-12-28	WOS:000354114600027
J	Flannigan, KL; Agbor, TA; Motta, JP; Ferraz, JGP; Wang, R; Buret, AG; Wallace, JL				Flannigan, Kyle L.; Agbor, Terence A.; Motta, Jean-Paul; Ferraz, Jose G. P.; Wang, Rui; Buret, Andre G.; Wallace, John L.			Proresolution effects of hydrogen sulfide during colitis are mediated through hypoxia-inducible factor-1 alpha	FASEB JOURNAL			English	Article						inflammation; healing; ulcer; inflammatory bowel disease; gasotransmitter	EPITHELIAL-CELLS; FACTOR-I; INFLAMMATION; H2S; RESOLUTION; MODEL; RAT; INHIBITOR; INDUCTION; CYCLOOXYGENASE-2	During a course of colitis, production of the gaseous mediator hydrogen sulfide (H2S) is markedly up-regulated at sites of mucosal damage and contributes significantly to healing and resolution of inflammation. The signaling mechanisms through which H2S promotes resolution of colitis are unknown. We hypothesized that the beneficial effects of H2S in experimental colitis are mediated via stabilization of hypoxia-inducible factor (HIF)-1 alpha. The hapten dinitrobenzene sulfonic acid was used to induce colitis in rats and mice. This resulted in an elevated expression of the H2S producing enzyme, cystathionine gamma-lyase (CSE), and HIF-1 alpha at sites of mucosal ulceration, and the expression of these 2 enzymes followed a similar pattern throughout the course of colitis. This represented a functionally important relationship because the loss of CSE-derived H2S production led to decreased HIF-1 alpha stabilization and exacerbation of colitis. Furthermore, application of an H2S-releasing molecule, diallyl disulfide (DADS), stabilized colonic HIF-1 alpha expression, up-regulated hypoxia-responsive genes, and reduced the severity of disease during peak inflammation. Importantly, the ability of DADS to promote the resolution of colitis was abolished when coadministered with an inhibitor of HIF-1 alpha in vivo (PX-478). DADS was also able to maintain HIF-1 alpha expression at a later point incolitis, when HIF-1 alpha levels would have normally returned to control levels, and to enhance resolution. Finally, we found that HIF-1 alpha stabilization inhibited colonic H2S production and may represent a negative feedback mechanism to prevent prolonged HIF-1 alpha stabilization. Our findings demonstrate an important link between H2S and HIF-1 alpha in the resolution of inflammation and injury during colitis and provide mechanistic insights into the therapeutic value ofH(2)S donors.	[Flannigan, Kyle L.; Agbor, Terence A.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Motta, Jean-Paul; Buret, Andre G.] Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; [Ferraz, Jose G. P.] Univ Calgary, Dept Med, Calgary, AB T2N 1N4, Canada; [Wallace, John L.] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB T2N 4N1, Canada; [Wang, Rui] Lakehead Univ, Dept Biol, Thunder Bay, ON P7B 5E1, Canada	McMaster University; University of Calgary; University of Calgary; University of Calgary; Lakehead University	Wallace, JL (corresponding author), Univ Calgary, Dept Physiol & Pharmacol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	altapharm@hotmail.com	Wang, Rui/C-7824-2012; Motta, Jean-Paul/A-8844-2014; Wallace, John/AAL-3763-2021	Wang, Rui/0000-0003-3825-3620; Motta, Jean-Paul/0000-0002-9464-0695; 	Canadian Institutes of Health Research; Crohn's and Colitis Canada	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Crohn's and Colitis Canada	The authors thank Webb McKnight for his assistance. The work described in this paper was supported by grants to J.L.W. from the Canadian Institutes of Health Research and Crohn's and Colitis Canada.	Abe K, 1996, J NEUROSCI, V16, P1066; Ajuebor MN, 2000, AM J PHYSIOL-GASTR L, V279, pG238; Benavides GA, 2007, P NATL ACAD SCI USA, V104, P17977, DOI 10.1073/pnas.0705710104; BOUGHTONSMITH NK, 1988, AGENTS ACTIONS, V25, P115, DOI 10.1007/BF01969102; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Budde MW, 2010, MOL BIOL CELL, V21, P212, DOI 10.1091/mbc.E09-03-0199; Bynoe MS, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/260983; Cai ZQ, 2013, P NATL ACAD SCI USA, V110, P17462, DOI 10.1073/pnas.1317158110; Calvert JW, 2010, ANTIOXID REDOX SIGN, V12, P1203, DOI 10.1089/ars.2009.2882; Campbell EL, 2014, IMMUNITY, V40, P66, DOI 10.1016/j.immuni.2013.11.020; Chavez-Pina AE, 2008, BRIT J PHARMACOL, V155, P857, DOI 10.1038/bjp.2008.316; Colgan SP, 2010, NAT REV GASTRO HEPAT, V7, P281, DOI 10.1038/nrgastro.2010.39; Cummins EP, 2008, GASTROENTEROLOGY, V134, P156, DOI 10.1053/j.gastro.2007.10.012; Curtis VF, 2015, FASEB J, V29, P208, DOI 10.1096/fj.14-259663; Dufton N, 2012, SCI REP-UK, V2, DOI 10.1038/srep00499; Fiorucci S, 2007, BRIT J PHARMACOL, V150, P996, DOI 10.1038/sj.bjp.0707193; Flannigan KL, 2014, P NATL ACAD SCI USA, V111, P13559, DOI 10.1073/pnas.1413390111; Flannigan KL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071962; Flannigan KL, 2011, AM J PHYSIOL-GASTR L, V301, pG188, DOI 10.1152/ajpgi.00105.2011; Fu M, 2012, P NATL ACAD SCI USA, V109, P2943, DOI 10.1073/pnas.1115634109; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Glover LE, 2011, GASTROENTEROLOGY, V140, P1748, DOI 10.1053/j.gastro.2011.01.056; Jacoby JJ, 2010, J THORAC ONCOL, V5, P940, DOI 10.1097/JTO.0b013e3181dc211f; Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Keely S, 2009, FASEB J, V23, P1338, DOI 10.1096/fj.08-125344; Koh MY, 2008, MOL CANCER THER, V7, P90, DOI 10.1158/1535-7163.MCT-07-0463; Lagoutte E, 2010, BBA-BIOENERGETICS, V1797, P1500, DOI 10.1016/j.bbabio.2010.04.004; Lin F, 2004, J IMMUNOL, V172, P3836, DOI 10.4049/jimmunol.172.6.3836; Louis NA, 2005, FASEB J, V19, P950, DOI 10.1096/fj.04-3251com; Louis NA, 2008, J IMMUNOL, V180, P4246, DOI 10.4049/jimmunol.180.6.4246; Lowie BJ, 2011, AM J PHYSIOL-GASTR L, V301, pG835, DOI 10.1152/ajpgi.00077.2011; Mariggio MA, 1998, IMMUNOPHARM IMMUNOT, V20, P399, DOI 10.3109/08923979809034822; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; Mathai JC, 2009, P NATL ACAD SCI USA, V106, P16633, DOI 10.1073/pnas.0902952106; Mimoun S, 2012, ANTIOXID REDOX SIGN, V17, P1, DOI 10.1089/ars.2011.4186; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9; Motta J. P., 2014, INFLAMMATOR IN PRES; Mustafa AK, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000464; Palinkas Z, 2015, BRIT J PHARMACOL, V172, P1516, DOI 10.1111/bph.12769; Peng YJ, 2010, P NATL ACAD SCI USA, V107, P10719, DOI 10.1073/pnas.1005866107; Predmore BL, 2012, AM J PHYSIOL-HEART C, V302, pH2410, DOI 10.1152/ajpheart.00044.2012; Reuter BK, 1996, J CLIN INVEST, V98, P2076, DOI 10.1172/JCI119013; Robinson A, 2008, GASTROENTEROLOGY, V134, P145, DOI 10.1053/j.gastro.2007.09.033; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Szabo C, 2011, BRIT J PHARMACOL, V164, P853, DOI 10.1111/j.1476-5381.2010.01191.x; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; Wallace JL, 2005, BRIT J PHARMACOL, V145, P275, DOI 10.1038/sj.bjp.0706201; WALLACE JL, 1995, J PHARMACOL TOXICOL, V33, P237, DOI 10.1016/1056-8719(95)00001-X; Wallace JL, 2007, FASEB J, V21, P4070, DOI 10.1096/fj.07-8669com; Wallace JL, 2015, ANTIOXID REDOX SIGN, V22, P398, DOI 10.1089/ars.2014.5901; Wallace JL, 2012, ANTIOXID REDOX SIGN, V17, P58, DOI 10.1089/ars.2011.4351; Wallace JL, 2010, ANTIOXID REDOX SIGN, V12, P1125, DOI 10.1089/ars.2009.2900; Wallace JL, 2009, GASTROENTEROLOGY, V137, P569, DOI 10.1053/j.gastro.2009.04.012; Welsh S, 2004, MOL CANCER THER, V3, P233; WRIGHT NA, 1993, GASTROENTEROLOGY, V104, P12, DOI 10.1016/0016-5085(93)90830-6; Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06-6270fje; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	60	40	40	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1591	1602		10.1096/fj.14-266015	http://dx.doi.org/10.1096/fj.14-266015			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25550470				2022-12-28	WOS:000354115000042
J	Fu, Q; McKnight, RA; Callaway, CW; Yu, X; Lane, RH; Majnik, AV				Fu, Qi; McKnight, Robert A.; Callaway, Christopher W.; Yu, Xing; Lane, Robert H.; Majnik, Amber V.			Intrauterine growth restriction disrupts developmental epigenetics around distal growth hormone response elements on the rat hepatic IGF-1 gene	FASEB JOURNAL			English	Article						prenatal; enhancer; methylation; histone; DNA	RNA-POLYMERASE-II; CHROMATIN CHANGES ACCOMPANY; UTEROPLACENTAL INSUFFICIENCY; HISTONE MODIFICATIONS; SIGNAL TRANSDUCER; RETARDED FETAL; H3K9 METHYLATION; DNA METHYLATION; BINDING-SITES; EXPRESSION	Intrauterine growth restriction (IUGR) decreases serum IGF-1 levels. Postnatal IGF-1 expression is transcriptionally regulated by growth hormone (GH) through growth hormone response elements (GHREs). We hypothesized that IUGR disrupts the normal developmental maturation of hepatic IGF-1 intron 2 growth hormone response element (IN2GHRE) histone methylation of key lysines and DNA methylation. We also evaluated a 5' distal weak enhancer (IGF-1 5'-upstream region growth hormone response element; 5URGHRE) as a GHRE specificity control. IUGR was induced through a well-characterized model of bilateral uterine artery ligation of the pregnant rat. Offspring livers were tested at d 0 and 21. Chromatin immunoprecipitation and bisulfite sequencing quantified epigenetic characteristics. We found that distinct age-related developmental patterns of histone and DNA methylation characterize each GHRE. Development increased H3K4 trimethylation (me3) in both GHREs. However, H3K9me3 decreased with age at IN2GHRE and increased with age at 5URGHRE. IUGR altered the developmental pattern of H3K4me3 and K9me3 around the GHREs in a sex-specific manner at d 21. Developmental and IUGR-induced DNA methylation occurred in a GHRE-, CpG site-, and sex-specific manner. We conclude that IUGR disrupts developmental epigenetics around distal GHREs on the rat hepatic IGF-1 gene.	[Fu, Qi; Lane, Robert H.; Majnik, Amber V.] Med Coll Wisconsin, Dept Pediat, Div Neonatol, Milwaukee, WI 53226 USA; [McKnight, Robert A.; Callaway, Christopher W.; Yu, Xing] Univ Utah, Dept Pediat, Div Neonatol, Salt Lake City, UT USA	Medical College of Wisconsin; Utah System of Higher Education; University of Utah	Majnik, AV (corresponding author), TBRC CRI, Room C2485,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	amajnik@mcw.edu		Callaway, Christopher/0000-0003-2072-0972	Department of Pediatrics at the Medical College of Wisconsin	Department of Pediatrics at the Medical College of Wisconsin	The authors thank the Department of Pediatrics at the Medical College of Wisconsin for their support and guidance.	Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Baserga M, 2005, AM J PHYSIOL-REG I, V289, pR1348, DOI 10.1152/ajpregu.00211.2005; Bates KA, 2009, MOL PSYCHIATR, V14, P469, DOI 10.1038/mp.2008.96; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; Brinkman AB, 2006, EMBO REP, V7, P628, DOI 10.1038/sj.embor.7400686; BUSSEY ME, 1985, PEDIATR RES, V19, P363, DOI 10.1203/00006450-198519040-00010; Chia DJ, 2010, MOL ENDOCRINOL, V24, P2038, DOI 10.1210/me.2010-0234; Chia DJ, 2010, J BIOL CHEM, V285, P17636, DOI 10.1074/jbc.M110.117697; Chia DJ, 2010, MOL ENDOCRINOL, V24, P779, DOI 10.1210/me.2009-0430; Chia DJ, 2006, J BIOL CHEM, V281, P3190, DOI 10.1074/jbc.M510204200; Clodfelter KH, 2006, MOL ENDOCRINOL, V20, P1333, DOI 10.1210/me.2005-0489; Conti E, 2004, CIRCULATION, V110, P2260, DOI 10.1161/01.CIR.0000144309.87183.FB; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Davey HW, 2001, ENDOCRINOLOGY, V142, P3836, DOI 10.1210/en.142.9.3836; Ekram MB, 2012, EPIGENETICS-US, V7, P370, DOI 10.4161/epi.19462; Eleswarapu S, 2008, ENDOCRINOLOGY, V149, P2230, DOI 10.1210/en.2007-1344; Flanagan DE, 2000, AM J PHYSIOL-ENDOC M, V278, pE700, DOI 10.1152/ajpendo.2000.278.4.E700; Fu Q, 2004, PHYSIOL GENOMICS, V20, P108, DOI 10.1152/physiolgenomics.00175.2004; Fu Q, 2006, FASEB J, V20, P2127, DOI 10.1096/fj.06-6179fje; Fu Q, 2009, FASEB J, V23, P2438, DOI 10.1096/fj.08-124768; Gerber M, 2003, J BIOL CHEM, V278, P26303, DOI 10.1074/jbc.R300014200; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Ke X, 2006, PHYSIOL GENOMICS, V25, P16, DOI 10.1152/physiolgenomics.00093.2005; Ke XR, 2005, AM J PHYSIOL-REG I, V288, pR1038, DOI 10.1152/ajpregu.00701.2004; KIKUCHI K, 1992, J BIOL CHEM, V267, P21505; Kim A, 2007, MOL CELL BIOL, V27, P1271, DOI 10.1128/MCB.01684-06; Kolasinska-Zwierz P, 2009, NAT GENET, V41, P376, DOI 10.1038/ng.322; Lane RH, 2003, PEDIATR RES, V53, p149A; Lane RH, 2003, PEDIATR RES, V53, P994, DOI 10.1203/01.PDR.0000064583.40495.51; Lane RH, 2002, ENDOCRINOLOGY, V143, P2486, DOI 10.1210/en.143.7.2486; Lane RH, 1998, PEDIATR RES, V43, P563, DOI 10.1203/00006450-199805000-00001; Lane RH, 2001, BRAIN RES, V895, P186, DOI 10.1016/S0006-8993(01)02074-1; Lane RH, 2001, AM J PHYSIOL-REG I, V280, pR183, DOI 10.1152/ajpregu.2001.280.1.R183; Lane RH, 1999, AM J PHYSIOL-ENDOC M, V276, pE135, DOI 10.1152/ajpendo.1999.276.1.E135; Lane RH, 1996, BIOCHEM MOL MED, V59, P192, DOI 10.1006/bmme.1996.0087; Lane RH, 1996, PEDIATR RES, V39, P390, DOI 10.1203/00006450-199603000-00003; Lanning NJ, 2006, REV ENDOCR METAB DIS, V7, P225, DOI 10.1007/s11154-007-9025-5; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; OGATA ES, 1986, METABOLISM, V35, P970, DOI 10.1016/0026-0495(86)90064-8; OGATA ES, 1985, PEDIATR RES, V19, P32, DOI 10.1203/00006450-198501000-00010; Pham TD, 2003, AM J PHYSIOL-REG I, V285, pR962, DOI 10.1152/ajpregu.00201.2003; Rosenfeld JA, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-143; Rosenfeld RG, 2009, HORM RES, V71, P71, DOI 10.1159/000192440; Rotwein P, 2012, TRENDS ENDOCRIN MET, V23, P186, DOI 10.1016/j.tem.2012.01.001; Sadiq HF, 1999, BRAIN RES, V823, P96, DOI 10.1016/S0006-8993(99)01145-2; Santhanam M, 2013, MOL ENDOCRINOL, V27, P2080, DOI 10.1210/me.2013-1181; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schmidl C, 2009, GENOME RES, V19, P1165, DOI 10.1101/gr.091470.109; Schwartz S, 2009, NAT STRUCT MOL BIOL, V16, P990, DOI 10.1038/nsmb.1659; Simmons RA, 2001, DIABETES, V50, P2279, DOI 10.2337/diabetes.50.10.2279; Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X; Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716; Sugathan A, 2013, MOL CELL BIOL, V33, P3594, DOI 10.1128/MCB.00280-13; Tachibana M, 2007, EMBO J, V26, P3346, DOI 10.1038/sj.emboj.7601767; Tanaka S, 2011, NAT IMMUNOL, V12, P77, DOI 10.1038/ni.1966; Tilgner H, 2009, NAT STRUCT MOL BIOL, V16, P996, DOI 10.1038/nsmb.1658; Torres-Aleman I, 2010, DEV NEUROBIOL, V70, P384, DOI 10.1002/dneu.20778; Tsirka AE, 2001, J ENDOCRINOL, V169, P373, DOI 10.1677/joe.0.1690373; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06; Vidal OM, 2007, MOL ENDOCRINOL, V21, P293, DOI 10.1210/me.2006-0096; Wang Y, 2005, J BIOL CHEM, V280, P10955, DOI 10.1074/jbc.M412808200; Werner H, 2014, EUR NEUROPSYCHOPHARM, V24, P1947, DOI 10.1016/j.euroneuro.2014.01.020; Wilhelm BT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r82; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; Woelfle J, 2003, J BIOL CHEM, V278, P22696, DOI 10.1074/jbc.M301362200; World Medical A. & American Physiological, 2002, AM J PHYSIOL-REG I, V283, pR281; Xiao TJ, 2007, MOL CELL BIOL, V27, P721, DOI 10.1128/MCB.01628-06; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Yakar S, 2001, DIABETES, V50, P1110, DOI 10.2337/diabetes.50.5.1110; Yu R, 2003, MOL CELL ENDOCRINOL, V204, P31, DOI 10.1016/S0303-7207(03)00145-X; Zhang YJ, 2012, MOL CELL BIOL, V32, P880, DOI 10.1128/MCB.06312-11; Zinkhan EK, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/930364	79	25	27	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1176	1184		10.1096/fj.14-258442	http://dx.doi.org/10.1096/fj.14-258442			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25466885				2022-12-28	WOS:000354115000007
J	Badoud, F; Perreault, M; Zulyniak, MA; Mutch, DM				Badoud, Flavia; Perreault, Maude; Zulyniak, Michael A.; Mutch, David M.			Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals	FASEB JOURNAL			English	Review						cardiometabolic risk; obesity; biomarkers	BODY-MASS INDEX; INSULIN-RESISTANCE; URIC-ACID; POSTMENOPAUSAL WOMEN; CARDIOVASCULAR-DISEASE; OXIDATIVE STRESS; VISCERAL FAT; DIFFERENTIATES OBESE; ADIPOKINE PROFILE; GENE-EXPRESSION	Obesity is a risk factor for the development of type 2 diabetes and cardiovascular disease. However, it is now recognized that a subset of individuals have reduced cardiometabolic risk despite being obese. Paradoxically, a subset of lean individuals is reported to have high risk for cardiometabolic complications. These distinct subgroups of individuals are referred to as metabolically unhealthy normal weight (MUNW) and metabolically healthy obese (MHO). Although the clinical relevance of these subgroups remains debated, evidence shows a critical role for white adipose tissue (WAT) function in the development of these phenotypes. The goal of this review is to provide an overview of our current state of knowledge regarding the molecular and metabolic characteristics of WAT associated with MUNW and MHO. In particular, we discuss the link between different WAT depots, immune cell infiltration, and adipokine production with MUNW and MHO. Furthermore, we also highlight recent molecular insights made with genomic technologies showing that processes such as oxidative phosphorylation, branched-chain amino acid catabolism, and fatty acid beta-oxidation differ between these phenotypes. This review provides evidence that WAT function is closely linked with cardiometabolic risk independent of obesity and thus contributes to the development of MUNW and MHO.	[Badoud, Flavia; Perreault, Maude; Zulyniak, Michael A.; Mutch, David M.] Univ Guelph, Dept Human Hlth & Nutr Sci, Guelph, ON N1G 2W1, Canada	University of Guelph	Mutch, DM (corresponding author), Univ Guelph, Dept Human Hlth & Nutr Sci, Guelph, ON N1G 2W1, Canada.	dmutch@uoguelph.ca		Mutch, David/0000-0002-0908-7259; Zulyniak, Michael/0000-0003-4944-5521				Aguilar-Salinas CA, 2008, J CLIN ENDOCR METAB, V93, P4075, DOI 10.1210/jc.2007-2724; Appleton SL, 2013, DIABETES CARE, V36, P2388, DOI 10.2337/dc12-1971; Arnlov J, 2010, CIRCULATION, V121, P230, DOI 10.1161/CIRCULATIONAHA.109.887521; Badoud F, 2014, J PROTEOME RES, V13, P3455, DOI 10.1021/pr500416v; Bastien M, 2014, PROG CARDIOVASC DIS, V56, P369, DOI 10.1016/j.pcad.2013.10.016; Batch BC, 2013, METABOLISM, V62, P961, DOI 10.1016/j.metabol.2013.01.007; Bednarek-Tupikowska G, 2012, ENDOKRYNOL POL, V63, P447; Bluher M, 2013, BEST PRACT RES CL EN, V27, P163, DOI 10.1016/j.beem.2013.02.005; Bluher M, 2010, CURR OPIN LIPIDOL, V21, P38, DOI 10.1097/MOL.0b013e3283346ccc; Bohm A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093148; Bouchard L, 2010, AM J CLIN NUTR, V91, P309, DOI 10.3945/ajcn.2009.28085; Brochu M, 2001, J CLIN ENDOCR METAB, V86, P1020, DOI 10.1210/jc.86.3.1020; Burgdorf KS, 2012, DIABETOLOGIA, V55, P105, DOI 10.1007/s00125-011-2320-4; Camhi SM, 2013, J OBES, V2013, DOI 10.1155/2013/984613; Cancello R, 2006, DIABETES, V55, P1554, DOI 10.2337/db06-0133; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Conus F, 2004, J CLIN ENDOCR METAB, V89, P5013, DOI 10.1210/jc.2004-0265; Cusi K, 2010, CURR DIABETES REP, V10, P306, DOI 10.1007/s11892-010-0122-6; Dai XP, 2012, AUTON NEUROSCI-BASIC, V167, P66, DOI 10.1016/j.autneu.2011.10.006; De Lorenzo A, 2007, AM J CLIN NUTR, V85, P40, DOI 10.1093/ajcn/85.1.40; de Luca C, 2008, FEBS LETT, V582, P97, DOI 10.1016/j.febslet.2007.11.057; Di Renzo L, 2006, Eur Rev Med Pharmacol Sci, V10, P191; Di Renzo L, 2010, OBESITY, V18, P2125, DOI 10.1038/oby.2010.50; Ding C, 2012, BRIT J NUTR, V108, P1915, DOI 10.1017/S0007114512003285; Doumatey AP, 2012, J ENDOCRINOL METAB, V2, P51, DOI 10.4021/jem95w; Dvorak RV, 1999, DIABETES, V48, P2210, DOI 10.2337/diabetes.48.11.2210; Eglit T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073273; Elisha B, 2010, DIABETES METAB, V36, P319, DOI 10.1016/j.diabet.2010.03.004; Esser N, 2013, DIABETOLOGIA, V56, P2487, DOI 10.1007/s00125-013-3023-9; Esteghamati A, 2014, DIABETES METAB; Fabbrini E, 2013, GASTROENTEROLOGY, V145, P366, DOI 10.1053/j.gastro.2013.04.010; FACCHINI F, 1991, JAMA-J AM MED ASSOC, V266, P3008, DOI 10.1001/jama.266.21.3008; Floegel A, 2013, DIABETES, V62, P639, DOI 10.2337/db12-0495; Hardy OT, 2011, SURG OBES RELAT DIS, V7, P60, DOI 10.1016/j.soard.2010.05.013; Heitmann BL, 2012, OBES REV, V13, P910, DOI 10.1111/j.1467-789X.2012.01007.x; Hur YM, 2008, INT J OBESITY, V32, P1455, DOI 10.1038/ijo.2008.144; Hyun YJ, 2008, OBESITY, V16, P784, DOI 10.1038/oby.2007.127; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Karelis AD, 2008, DIABETES METAB, V34, P183, DOI 10.1016/j.diabet.2007.11.004; Karelis AD, 2005, J CLIN ENDOCR METAB, V90, P4145, DOI 10.1210/jc.2005-0482; Karelis AD, 2004, J CLIN ENDOCR METAB, V89, P2569, DOI 10.1210/jc.2004-0165; Katsuki A, 2003, DIABETES CARE, V26, P2341, DOI 10.2337/diacare.26.8.2341; Khan UI, 2014, OBESITY, V22, P786, DOI 10.1002/oby.20139; Khan UI, 2011, ATHEROSCLEROSIS, V217, P179, DOI 10.1016/j.atherosclerosis.2011.01.007; Kim M, 2013, METABOLISM, V62, P554, DOI 10.1016/j.metabol.2012.10.006; Kloting N, 2010, AM J PHYSIOL-ENDOC M, V299, pE506, DOI 10.1152/ajpendo.00586.2009; Kuk JL, 2009, DIABETES CARE, V32, P2297, DOI 10.2337/dc09-0574; Kwon BJ, 2013, METABOLISM, V62, P952, DOI 10.1016/j.metabol.2013.01.006; Lackey DE, 2014, AM J PHYSIOL-ENDOC M, V306, pE233, DOI 10.1152/ajpendo.00476.2013; Lee SH, 2011, CLIN ENDOCRINOL, V75, P475, DOI 10.1111/j.1365-2265.2011.04085.x; Lemoine AY, 2012, J CLIN ENDOCR METAB, V97, pE775, DOI 10.1210/jc.2011-2649; Malik VS, 2013, NAT REV ENDOCRINOL, V9, P13, DOI 10.1038/nrendo.2012.199; Mangge H, 2013, OBESITY, V21, pE71, DOI 10.1002/oby.20061; Marini M., 2013, ACTA DIABETOL, V51, P1; Marques-Vidal P, 2010, NUTR METAB CARDIOVAS, V20, P669, DOI 10.1016/j.numecd.2009.06.001; Mathur Sandeep Kumar, 2013, Indian J Endocrinol Metab, V17, P446, DOI 10.4103/2230-8210.111639; Matsuura F, 1998, METABOLISM, V47, P929, DOI 10.1016/S0026-0495(98)90346-8; McLaugblin T, 2007, DIABETOLOGIA, V50, P1707, DOI 10.1007/s00125-007-0708-y; Meigs JB, 2006, J CLIN ENDOCR METAB, V91, P2906, DOI 10.1210/jc.2006-0594; Messier V, 2010, OBESITY, V18, P911, DOI 10.1038/oby.2009.364; Messier V, 2010, METABOLISM, V59, P20, DOI 10.1016/j.metabol.2009.06.020; MOLL PP, 1991, AM J HUM GENET, V49, P1243; Mutch DM, 2011, AM J CLIN NUTR, V94, P1399, DOI 10.3945/ajcn.110.006858; Naukkarinen J, 2014, DIABETOLOGIA, V57, P167, DOI 10.1007/s00125-013-3066-y; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; O'Connell J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009997; Ogorodnikova AD, 2013, OBESITY, V21, P1726, DOI 10.1002/oby.20200; Ogorodnikova AD, 2012, OBESITY, V20, P651, DOI 10.1038/oby.2011.243; Oliveros E, 2014, PROG CARDIOVASC DIS, V56, P426, DOI 10.1016/j.pcad.2013.10.003; Pataky Z, 2010, INT J OBESITY, V34, pS18, DOI 10.1038/ijo.2010.235; Perreault M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088539; Phillips CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076188; Phillips CM, 2013, J CLIN ENDOCR METAB, V98, pE1610, DOI 10.1210/jc.2013-2038; Piya MK, 2013, J ENDOCRINOL, V216, pT1, DOI 10.1530/JOE-12-0498; Primeau V, 2011, INT J OBESITY, V35, P971, DOI 10.1038/ijo.2010.216; Qatanani M, 2013, DIABETES, V62, P855, DOI 10.2337/db12-0399; Rosen ED, 2014, CELL, V156, P20, DOI 10.1016/j.cell.2013.12.012; Ruderman N, 1998, DIABETES, V47, P699, DOI 10.2337/diabetes.47.5.699; Samocha-Bonet D, 2014, OBES REV, V15, P697, DOI 10.1111/obr.12199; Schroder H, 2014, EUR J NUTR, V53, P1345, DOI 10.1007/s00394-013-0635-2; Shea JL, 2011, OBESITY, V19, P624, DOI 10.1038/oby.2010.174; Shin MJ, 2006, INT J OBESITY, V30, P1529, DOI 10.1038/sj.ijo.0803304; Srdic B, 2010, EXP CLIN ENDOCR DIAB, V118, P713, DOI 10.1055/s-0030-1254165; Stefan N, 2008, DIABETES, V57, P2762, DOI 10.2337/db08-0538; Stefan N, 2008, ARCH INTERN MED, V168, P1609, DOI 10.1001/archinte.168.15.1609; Stefan N, 2016, NEPHROL DIAL TRANSPL, V31, P726, DOI 10.1093/ndt/gfu081; Stefan N, 2013, LANCET DIABETES ENDO, V1, P152, DOI 10.1016/S2213-8587(13)70062-7; Stefan N, 2013, NAT MED, V19, P394, DOI 10.1038/nm.3116; Stefan N, 2013, NAT REV ENDOCRINOL, V9, P144, DOI 10.1038/nrendo.2012.258; Sun K, 2012, P NATL ACAD SCI USA, V109, P5874, DOI 10.1073/pnas.1200447109; Tchernof A, 2013, PHYSIOL REV, V93, P359, DOI 10.1152/physrev.00033.2011; Thomas EL, 2012, NUTR RES REV, V25, P150, DOI 10.1017/S0954422412000054; Tsushima Y, 2013, J BIOL CHEM, V288, P27138, DOI 10.1074/jbc.M113.485094; Tynan GA, 2014, DIABETES, V63, P2037, DOI 10.2337/db13-1476; van Beek L, 2014, METABOLISM, V63, P492, DOI 10.1016/j.metabol.2013.12.002; van der A DL, 2014, OBESITY, V22, P557, DOI 10.1002/oby.20480; Velho S, 2010, EUR J CLIN NUTR, V64, P1043, DOI 10.1038/ejcn.2010.114; Wahl S, 2012, OBESITY FACTS, V5, P660, DOI 10.1159/000343204; Weghuber D, 2013, EXP CLIN ENDOCR DIAB, V121, P384, DOI 10.1055/s-0033-1341440; Wiklund PK, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-40; Wildman RP, 2011, OBESITY, V19, P1482, DOI 10.1038/oby.2010.332; Xu XJ, 2012, J LIPID RES, V53, P792, DOI 10.1194/jlr.P022905; Yoo HK, 2013, KOREAN J FAM MED, V34, P19, DOI 10.4082/kjfm.2013.34.1.19; You TJ, 2004, J CLIN ENDOCR METAB, V89, P5517, DOI 10.1210/jc.2004-0480; Zhang MZ, 2014, METAB SYNDR RELAT D, V12, P185, DOI 10.1089/met.2013.0102; Zhao RX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085770	106	79	85	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					748	758		10.1096/fj.14-263913	http://dx.doi.org/10.1096/fj.14-263913			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25411437				2022-12-28	WOS:000350633000003
J	Goodspeed, D; Seferovic, MD; Holland, W; Mcknight, RA; Summers, SA; Branch, DW; Lane, RH; Aagaard, KM				Goodspeed, Danielle; Seferovic, Maxim D.; Holland, William; Mcknight, Robert A.; Summers, Scott A.; Branch, D. Ware; Lane, Robert H.; Aagaard, Kjersti M.			Essential nutrient supplementation prevents heritable metabolic disease in multigenerational intrauterine growth-restricted rats	FASEB JOURNAL			English	Article						one-carbon pathway; epigenomics; methyl donors; IGF-1; obesity	COACTIVATOR-1 GENE-EXPRESSION; FACTOR BINDING PROTEIN-1; ONE-CARBON METABOLISM; UTEROPLACENTAL INSUFFICIENCY; DNA METHYLATION; INSULIN-RESISTANCE; FETAL-GROWTH; SKELETAL-MUSCLE; ADULT HYPERTENSION; EPIGENETIC CHANGES	Intrauterine growth restriction (IUGR) confers heritable alterations in DNA methylation, rendering risk of adult metabolic syndrome (MetS). Because CpG methylation is coupled to intake of essential nutrients along the one-carbon pathway, we reasoned that essential nutrient supplementation (ENS) may abrogate IUGR-conferred multigenerational MetS. Pregnant Sprague-Dawley rats underwent bilateral uterine artery ligation causing IUGR in F1. Among the F2 generation, IUGR lineage rats were underweight at birth (6.7 vs. 8.0 g, P < 0.0001) and obese by adulthood (p160: 613 vs. 510 g; P < 0.0001). Dual energy X-ray absorptiometry studies revealed increased central fat mass (Delta+40 g), accompanied by dyslipidemic (>30% elevated, P < 0.05) serum triglycerides (139 mg/dl), very-LDLs (27.8 mg/dl), and fatty acids (632 mu M). Hyperglycemic-euglycemic clamp studies and glucose tolerance testing revealed insulin resistance. Conversely, IUGR lineage ENS-fed rats did not manifest MetS, with significantly lower body weight (p160: 410 g), >5-fold less central fat mass, normal hepatic glucose efflux, and >70% reduced circulating triglycerides and very-LDLs compared with IUGR control-fed F2 offspring (P < 0.01). Moreover, increased methylation of the IGF-1 P2 transcriptional start site among IUGR lineage F2 offspring was reversed in ENS (P < 0.04). This is an initial demonstration that supplementation along the one-carbon pathway abrogates adult morbidity and associated epigenomic modifications of IGF-1 in a rodent model of multigenerational MetS.	[Goodspeed, Danielle; Seferovic, Maxim D.; Aagaard, Kjersti M.] Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; [Holland, William] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; [Mcknight, Robert A.] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Branch, D. Ware] Univ Utah, Dept Obstet & Gynecol, Salt Lake City, UT USA; [Summers, Scott A.] Duke Natl Univ Singapore, Grad Sch Med, Program Cardiovasc & Metab Dis, Singapore, Singapore; [Lane, Robert H.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Lane, Robert H.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA	Baylor College of Medicine; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; National University of Singapore; Medical College of Wisconsin; Children's Hospital of Wisconsin	Aagaard, KM (corresponding author), Baylor Coll Med, Div Maternal Fetal Med, One Baylor Plaza,Jones 314, Houston, TX 77030 USA.	aagaardt@bcm.tmc.edu	/AAE-5384-2020		U.S. National Institutes of Health (NIH) [DP21DP2OD001500-01]; U.S. NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development Reproductive Scientist Development Program [5K12HD00849]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000849] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD001500] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development Reproductive Scientist Development Program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Xing Yu for the technical contributions made during this project. Funding for this project was provided by U.S. National Institutes of Health (NIH) Grant DP21DP2OD001500-01 ("Mapping the Fetal Primate Epigenome and Metabolome"), and the U.S. NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development Reproductive Scientist Development Program Grant 5K12HD00849 ("Transgenerational Growth Restriction through Altered Placental Epigenetics") (to K.A.).	Abu Shehab M, 2009, J PROTEOME RES, V8, P5325, DOI 10.1021/pr900633x; Ahrens M, 2013, CELL METAB, V18, P296, DOI 10.1016/j.cmet.2013.07.004; Anderson OS, 2012, J NUTR BIOCHEM, V23, P853, DOI 10.1016/j.jnutbio.2012.03.003; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; Baserga M, 2005, AM J PHYSIOL-REG I, V289, pR1348, DOI 10.1152/ajpregu.00211.2005; Baserga M, 2004, EARLY HUM DEV, V79, P93, DOI 10.1016/j.earlhumdev.2004.04.015; Baserga M, 2006, AM J PHYSIOL-REG I, V291, pR412, DOI 10.1152/ajpregu.00880.2005; Baserga M, 2009, EARLY HUM DEV, V85, P361, DOI 10.1016/j.earlhumdev.2008.12.015; Benyshek DC, 2006, DIABETOLOGIA, V49, P1117, DOI 10.1007/s00125-006-0196-5; Cordero P, 2013, GENES NUTR, V8, P105, DOI 10.1007/s12263-012-0300-z; Cordero P, 2013, MOL GENET METAB, V110, P388, DOI 10.1016/j.ymgme.2013.08.022; Cornier MA, 2008, ENDOCR REV, V29, P777, DOI 10.1210/er.2008-0024; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; Dominguez-Salas P, 2013, AM J CLIN NUTR, V97, P1217, DOI 10.3945/ajcn.112.048462; Dominguez-Salas P, 2012, P NUTR SOC, V71, P154, DOI 10.1017/S0029665111003338; Eckel RH, 2010, LANCET, V375, P181, DOI 10.1016/S0140-6736(09)61794-3; ERVIN RB, 2009, NATL HLTH STAT REPOR, V13, P1; Fischer LM, 2010, AM J CLIN NUTR, V92, P1113, DOI 10.3945/ajcn.2010.30064; Fu Q, 2004, PHYSIOL GENOMICS, V20, P108, DOI 10.1152/physiolgenomics.00175.2004; Fu Q, 2006, FASEB J, V20, P2127, DOI 10.1096/fj.06-6179fje; Fu Q, 2009, FASEB J, V23, P2438, DOI 10.1096/fj.08-124768; Gallo LA, 2012, J PHYSIOL-LONDON, V590, P617, DOI 10.1113/jphysiol.2011.219147; Ganu RS, 2012, ILAR J, V53, P306, DOI 10.1093/ilar.53.3-4.306; Gong L, 2010, EPIGENETICS-US, V5, P619, DOI 10.4161/epi.5.7.12882; Grossniklaus U, 2013, NAT REV GENET, V14, P228, DOI 10.1038/nrg3435; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Haluzik M, 2003, DIABETES, V52, P2483, DOI 10.2337/diabetes.52.10.2483; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002; Howie GJ, 2009, J PHYSIOL-LONDON, V587, P905, DOI 10.1113/jphysiol.2008.163477; Jahangir E, 2009, VASC MED, V14, P239, DOI 10.1177/1358863X08100834; Jimenez-Chillaron JC, 2009, DIABETES, V58, P460, DOI 10.2337/db08-0490; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Kassi E, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-48; Ke X, 2006, PHYSIOL GENOMICS, V25, P16, DOI 10.1152/physiolgenomics.00093.2005; Kim JK, 2009, METHODS MOL BIOL, V560, P221, DOI 10.1007/978-1-59745-448-3_15; Koklu E, 2007, ACTA PAEDIATR, V96, P1858, DOI 10.1111/j.1651-2227.2007.00531.x; Lambrot R, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3889; Lane RH, 2003, PEDIATR RES, V53, P994, DOI 10.1203/01.PDR.0000064583.40495.51; Lane RH, 2002, ENDOCRINOLOGY, V143, P2486, DOI 10.1210/en.143.7.2486; Lane RH, 2001, AM J PHYSIOL-REG I, V280, pR183, DOI 10.1152/ajpregu.2001.280.1.R183; Lane RH, 2001, PEDIATR RES, V50, P83, DOI 10.1203/00006450-200107000-00016; Lane RH, 1999, AM J PHYSIOL-ENDOC M, V276, pE135, DOI 10.1152/ajpendo.1999.276.1.E135; LUKASKI HC, 1993, J NUTR, V123, P438, DOI 10.1093/jn/123.suppl_2.438; MacLennan NK, 2004, PHYSIOL GENOMICS, V18, P43, DOI 10.1152/physiolgenomics.00042.2004; Maloney CA, 2011, J NUTR, V141, P95, DOI 10.3945/jn.109.119453; Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114; Netchine I, 2009, J CLIN ENDOCR METAB, V94, P3913, DOI 10.1210/jc.2009-0452; Niculescu MD, 2002, J NUTR, V132, p2333S, DOI 10.1093/jn/132.8.2333S; OGATA ES, 1986, METABOLISM, V35, P970, DOI 10.1016/0026-0495(86)90064-8; OGATA ES, 1985, PEDIATR RES, V19, P32, DOI 10.1203/00006450-198501000-00010; Painter RC, 2008, BJOG-INT J OBSTET GY, V115, P1243, DOI 10.1111/j.1471-0528.2008.01822.x; Park JH, 2008, J CLIN INVEST, V118, P2316, DOI [10.1172/JC133655, 10.1172/JCI33655]; Resseguie M, 2007, FASEB J, V21, P2622, DOI 10.1096/fj.07-8227com; Schwitzgebel VM, 2009, MOL CELL ENDOCRINOL, V304, P78, DOI 10.1016/j.mce.2009.02.019; Seferovic MD, 2009, ENDOCRINOLOGY, V150, P220, DOI 10.1210/en.2008-0657; Seki Y, 2012, ENDOCRINOLOGY, V153, P1031, DOI 10.1210/en.2011-1805; Simmons RA, 2001, DIABETES, V50, P2279, DOI 10.2337/diabetes.50.10.2279; Sjogren K, 2001, DIABETES, V50, P1539, DOI 10.2337/diabetes.50.7.1539; Skilton MR, 2005, LANCET, V365, P1484, DOI 10.1016/S0140-6736(05)66419-7; Sohi G, 2011, MOL ENDOCRINOL, V25, P785, DOI 10.1210/me.2010-0395; Suter M, 2011, FASEB J, V25, P714, DOI 10.1096/fj.10-172080; Tan Y, 2012, TOXICOL LETT, V214, P279, DOI 10.1016/j.toxlet.2012.09.007; Thamotharan M, 2007, AM J PHYSIOL-ENDOC M, V292, pE1270, DOI 10.1152/ajpendo.00462.2006; Thompson RF, 2010, J BIOL CHEM, V285, P15111, DOI 10.1074/jbc.M109.095133; Tosh DN, 2010, AM J PHYSIOL-GASTR L, V299, pG1023, DOI 10.1152/ajpgi.00052.2010; Tran M, 2013, J ENDOCRINOL, V217, P105, DOI 10.1530/JOE-12-0560; Van den Veyver IB, 2002, ANNU REV NUTR, V22, P255, DOI 10.1146/annurev.nutr.22.010402.102932; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Waterland RA, 2007, FASEB J, V21, P3380, DOI 10.1096/fj.07-8229com; Watson CS, 2006, ENDOCRINOLOGY, V147, P1175, DOI 10.1210/en.2005-0606; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Woods KA, 2000, J CLIN ENDOCR METAB, V85, P1407, DOI 10.1210/jc.85.4.1407; Ye JM, 2001, DIABETES, V50, P411, DOI 10.2337/diabetes.50.2.411; Zheng SS, 2011, EPIGENETICS-US, V6, P161, DOI 10.4161/epi.6.2.13472	81	22	22	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					807	819		10.1096/fj.14-259614	http://dx.doi.org/10.1096/fj.14-259614			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25395450	Green Published			2022-12-28	WOS:000350633000008
J	Heghinian, MD; Mejia, M; Adams, DJ; Godenschwege, TA; Mari, F				Heghinian, Mari D.; Mejia, Monica; Adams, David J.; Godenschwege, Tanja A.; Mari, Frank			Inhibition of cholinergic pathways in Drosophila melanogaster by alpha-conotoxins	FASEB JOURNAL			English	Article						synaptic transmission; nicotinic acetylcholine receptors; giant fiber system; Conus brunneus	NICOTINIC ACETYLCHOLINE-RECEPTORS; NOREPINEPHRINE RELEASE; SELECTIVITY; ANTAGONIST; D-ALPHA-7; AGONISTS; MODELER; BINDING; ESCAPE; SYSTEM	Nicotinic acetylcholine receptors (nAChRs) play a pivotal role in synaptic transmission of neuronal signaling pathways and are fundamentally involved in neuronal disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. In vertebrates, cholinergic pathways can be selectively inhibited by alpha-conotoxins; we show that in the model organism Drosophila, the cholinergic component of the giant fiber system is inhibited by alpha-conotoxins MII, AuIB, BuIA, EI, PeIA, and ImI. The injection of 45 pmol/fly of each toxin dramatically decreases the response of the giant fiber to dorsal longitudinal muscle (GF-DLM) connection to 20 +/- 13.9% for MII; 26 +/- 13.7% for AuIB, 12 +/- 9.9% for BuIA, 30 +/- 11.3% for EI, 1 +/- 1% for PeIA, and 34 +/- 15.4% for ImI. Through bioassay-guided fractionation of the venom of Conus brunneus, we found BruIB, an alpha-conotoxin that inhibits Drosophila nicotinic receptors but not its vertebrate counterparts. GF-DLM responses decreased to 43.7 +/- 8.02% on injection of 45 pmol/fly of BruIB. We manipulated the D alpha 7 nAChR to mimic the selectivity of its vertebrate counterpart by placing structurally guided point mutations in the conotoxin-binding site. This manipulation rendered vertebrate-like behavior in the Drosophila system, enhancing the suitability of Drosophila as an in vivo tool to carry out studies related to human neuronal diseases.	[Heghinian, Mari D.; Mari, Frank] Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA; [Mejia, Monica; Godenschwege, Tanja A.] Florida Atlantic Univ, Dept Biol Sci, Boca Raton, FL 33431 USA; [Adams, David J.] RMIT Univ, Hlth Innovat Res Inst, Melbourne, Vic 3001, Australia	State University System of Florida; Florida Atlantic University; State University System of Florida; Florida Atlantic University; Royal Melbourne Institute of Technology (RMIT)	Mari, F (corresponding author), Florida Atlantic Univ, Dept Chem & Biochem, 777 Glades Rd, Boca Raton, FL 33431 USA.	mari@fau.edu	Adams, David John/K-3578-2019; Godenschwege, Tanja A/A-2830-2010	Adams, David John/0000-0002-7030-2288; Godenschwege, Tanja A/0000-0003-3322-4134	U.S. National Institutes of Health National Institute for Neurological Disorders and Stroke Grant [R21NS06637]; Australian Research Council (ARC) Grant [DP1093115]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS066371] Funding Source: NIH RePORTER	U.S. National Institutes of Health National Institute for Neurological Disorders and Stroke Grant; Australian Research Council (ARC) Grant(Australian Research Council); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was funded by U.S. National Institutes of Health National Institute for Neurological Disorders and Stroke Grant R21NS06637 (to F.M. and T.A.G.); and Australian Research Council (ARC) Grant DP1093115 (to F.M. and D.J.A.). D.J.A. is an ARC Australian Professorial Fellow.	Akondi KB, 2014, CHEM REV, V114, P5815, DOI 10.1021/cr400401e; Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008; Allen MJ, 2006, SEMIN CELL DEV BIOL, V17, P31, DOI 10.1016/j.semcdb.2005.11.011; Azam L, 2005, J BIOL CHEM, V280, P80, DOI 10.1074/jbc.M406281200; Azam L, 2010, FASEB J, V24, P5113, DOI 10.1096/fj.10-166272; Daly NL, 2011, J BIOL CHEM, V286, P10233, DOI 10.1074/jbc.M110.196170; Dupuis J, 2012, NEUROSCI BIOBEHAV R, V36, P1553, DOI 10.1016/j.neubiorev.2012.04.003; Ellison M, 2004, BIOCHEMISTRY-US, V43, P16019, DOI 10.1021/bi048918g; Fayyazuddin A, 2006, PLOS BIOL, V4, P420, DOI 10.1371/journal.pbio.0040063; Franco A, 2006, PROG MOLEC, V43, P83, DOI 10.1007/978-3-540-30880-5_4; Franco A, 2012, BIOCHEM PHARMACOL, V83, P419, DOI 10.1016/j.bcp.2011.11.006; Grishin AA, 2013, J BIOL CHEM, V288, P34428, DOI 10.1074/jbc.M113.512582; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Jones CK, 2012, NEUROPSYCHOPHARMACOL, V37, P16, DOI 10.1038/npp.2011.199; Lansdell SJ, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-73; Lee D, 1999, J NEUROSCI, V19, P5311; Luo SQ, 1998, J NEUROSCI, V18, P8571; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; McIntosh JM, 2005, J BIOL CHEM, V280, P30107, DOI 10.1074/jbc.M504102200; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; Mejia M., 2012, JOVE-J VIS EXP, V62, pe3597; Mejia M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064685; Mejia M, 2010, TOXICON, V56, P1398, DOI 10.1016/j.toxicon.2010.08.005; Moller C, 2005, BIOCHEMISTRY-US, V44, P15986, DOI 10.1021/bi0511181; Papke RL, 2014, BIOCHEM PHARMACOL, V89, P1, DOI 10.1016/j.bcp.2014.01.029; Ping Y, 2012, FLY, V6, P153, DOI 10.4161/fly.20775; Pucci L, 2011, FASEB J, V25, P3775, DOI 10.1096/fj.10-179853; Puillandre N, 2014, MOL PHYLOGENET EVOL, V78, P290, DOI 10.1016/j.ympev.2014.05.023; Rogers JP, 2000, J MOL BIOL, V304, P911, DOI 10.1006/jmbi.2000.4247; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; Thany SH, 2007, TRENDS PHARMACOL SCI, V28, P14, DOI 10.1016/j.tips.2006.11.006; Ulens C, 2006, P NATL ACAD SCI USA, V103, P3615, DOI 10.1073/pnas.0507889103; Webb B, 2014, METHODS MOL BIOL, V1137, P1, DOI 10.1007/978-1-4939-0366-5_1; Yang Z, 2012, J STRUCT BIOL, V179, P269, DOI 10.1016/j.jsb.2011.09.006; Yu RL, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002011	36	7	8	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1011	1018		10.1096/fj.14-262733	http://dx.doi.org/10.1096/fj.14-262733			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25466886	Green Published			2022-12-28	WOS:000350633000025
J	Uemura, Y; Shibata, R; Kanemura, N; Ohashi, K; Kambara, T; Hiramatsu-Ito, M; Enomoto, T; Yuasa, D; Joki, Y; Matsuo, K; Ito, M; Hayakawa, S; Ogawa, H; Murohara, T; Ouchi, N				Uemura, Yusuke; Shibata, Rei; Kanemura, Noriyoshi; Ohashi, Koji; Kambara, Takahiro; Hiramatsu-Ito, Mizuho; Enomoto, Takashi; Yuasa, Daisuke; Joki, Yusuke; Matsuo, Kazuhiro; Ito, Masanori; Hayakawa, Satoko; Ogawa, Hayato; Murohara, Toyoaki; Ouchi, Noriyuki			Adipose-derived protein omentin prevents neointimal formation after arterial injury	FASEB JOURNAL			English	Article						AMPK; VSMC; remodeling	MUSCLE-CELL PROLIFERATION; KINASE; ASSOCIATION; INFLAMMATION; INHIBITION; INTELECTIN; DISEASE; OBESITY	Obesity is highly linked with the development of vascular diseases. Omentin is a circulating adipokine that is downregulated in patients with cardiovascular diseases. In this study, we investigated the role of omentin in regulation of vascular remodeling in response to injury. Wild-type (WT) mice were treated intravenously with adenoviral vectors encoding human omentin (Ad-OMT) or control beta-gal and subjected to arterial wire injury. Ad-OMT treatment reduced the neointimal thickening and the frequencies of bromodeoxyuridine-positive proliferating cells in injured arteries. Treatment of vascular smooth muscle cells (VSMCs) with human omentin protein at a physiologic concentration led to suppression of growth and ERK phosphorylation after stimulation with various growth factors. Omentin stimulated AMPK signaling in VSMCs, and blockade of AMPK reversed omentin-mediated inhibition of VSMC growth and ERK phosphorylation. Furthermore, fat-specific human omentin transgenic (OMT-TG) mice exhibited reduced neointimal thickening and vascular cell growth following vascular injury. AMPK activation was enhanced in injured arteries in OMT-TG mice, and administration of AMPK inhibitor reversed the reduction of neointimal hyperplasia in OMT-TG mice. These data indicate that omentin attenuates neointimal formation after arterial injury and suppresses VSMC growth through AMPK-dependent mechanisms. Thus, omentin can represent a novel target molecule for the prevention of vascular disorders.	[Uemura, Yusuke; Shibata, Rei; Kanemura, Noriyoshi; Kambara, Takahiro; Hiramatsu-Ito, Mizuho; Enomoto, Takashi; Yuasa, Daisuke; Joki, Yusuke; Matsuo, Kazuhiro; Ito, Masanori; Hayakawa, Satoko; Ogawa, Hayato; Murohara, Toyoaki] Nagoya Univ, Grad Sch Med, Dept Cardiol, Nagoya, Aichi 4668550, Japan; [Ohashi, Koji; Ouchi, Noriyuki] Nagoya Univ, Grad Sch Med, Dept Mol Cardiovasc Med, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Shibata, R (corresponding author), Nagoya Univ, Grad Sch Med, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	rshibata@med.nagoya-u.ac.jp; nouchi@med.nagoya-u.ac.jp	OHASHI, Koji/I-7307-2014; Murohara, Toyoaki/M-4958-2014; OUCHI, Noriyuki/I-7306-2014	Enomoto, Takashi/0000-0002-7370-8013; Hiramatsu-Ito, Mizuho/0000-0003-1740-1794				Batista CMDS, 2007, DIABETES, V56, P1655, DOI 10.2337/db06-1506; Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488; Erlinge D, 1998, GEN PHARMACOL-VASC S, V31, P1, DOI 10.1016/S0306-3623(97)00420-5; Gennaro G, 2004, CIRCULATION, V110, P3367, DOI 10.1161/01.CIR.0000147773.86866.CD; Igata M, 2005, CIRC RES, V97, P837, DOI 10.1161/01.RES.0000185823.73556.06; Kataoka Y, 2014, J AM COLL CARDIOL, V63, P2722, DOI 10.1016/j.jacc.2014.03.032; Komiya T, 1998, BIOCHEM BIOPH RES CO, V251, P759, DOI 10.1006/bbrc.1998.9513; Kondo M, 2009, J BIOL CHEM, V284, P1718, DOI 10.1074/jbc.M805301200; Lu JX, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-58; Maruyama S, 2012, J BIOL CHEM, V287, P408, DOI 10.1074/jbc.M111.261818; Matsuzawa Y, 2006, NAT CLIN PRACT CARD, V3, P35, DOI 10.1038/ncpcardio0380; Miyabe M, 2014, CARDIOVASC RES, V103, P111, DOI 10.1093/cvr/cvu105; Nagata D, 2004, CIRCULATION, V110, P444, DOI 10.1161/01.CIR.0000136025.96811.76; Nielsen S, 1997, CURR OPIN LIPIDOL, V8, P200, DOI 10.1097/00041433-199708000-00002; Ogawa Y, 2007, P NATL ACAD SCI USA, V104, P7432, DOI 10.1073/pnas.0701600104; Ohashi K, 2010, J BIOL CHEM, V285, P6153, DOI 10.1074/jbc.M109.088708; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Pan HY, 2010, DIABETES RES CLIN PR, V88, P29, DOI 10.1016/j.diabres.2010.01.013; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Shibata R, 2004, NAT MED, V10, P1384, DOI 10.1038/nm1137; Shibata R, 2005, NAT MED, V11, P1096, DOI 10.1038/nm1295; Shibata R, 2012, DIABETOL METAB SYNDR, V4, DOI 10.1186/1758-5996-4-37; Shibata R, 2011, HYPERTENS RES, V34, P1309, DOI 10.1038/hr.2011.130; Shibata R, 2011, ATHEROSCLEROSIS, V219, P811, DOI 10.1016/j.atherosclerosis.2011.08.017; Song P, 2011, CIRC RES, V109, P1230, DOI 10.1161/CIRCRESAHA.111.250423; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; Tsuji S, 2001, J BIOL CHEM, V276, P23456, DOI 10.1074/jbc.M103162200; Tsuji S, 2007, GLYCOBIOLOGY, V17, P1045, DOI 10.1093/glycob/cwm075; Uemura Y, 2013, FASEB J, V27, P25, DOI 10.1096/fj.12-213744; Yamawaki H, 2011, BIOCHEM BIOPH RES CO, V408, P339, DOI 10.1016/j.bbrc.2011.04.039; Yamawaki H, 2010, BIOCHEM BIOPH RES CO, V393, P668, DOI 10.1016/j.bbrc.2010.02.053; Yang RZ, 2006, AM J PHYSIOL-ENDOC M, V290, pE1253, DOI 10.1152/ajpendo.00572.2004; Yoo HJ, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-103; Zhong X, 2011, ACTA PHARMACOL SIN, V32, P873, DOI 10.1038/aps.2011.26	34	46	50	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					141	151		10.1096/fj.14-258129	http://dx.doi.org/10.1096/fj.14-258129			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25300621				2022-12-28	WOS:000347378600014
J	Boon, MR; Kooijman, S; van Dam, AD; Pelgrom, LR; Berbee, JFP; Visseren, CAR; van Aggele, RC; van den Hoek, AM; Sips, HCM; Lombes, M; Havekes, LM; Tamsma, JT; Guigas, B; Meijer, OC; Jukema, JW; Rensen, PCN				Boon, Mariette R.; Kooijman, Sander; van Dam, Andrea D.; Pelgrom, Leonard R.; Berbee, Jimmy F. P.; Visseren, Cheryl A. R.; van Aggele, Robin C.; van den Hoek, Anita M.; Sips, Hetty C. M.; Lombes, Marc; Havekes, Louis M.; Tamsma, Jouke T.; Guigas, Bruno; Meijer, Onno C.; Jukema, J. Wouter; Rensen, Patrick C. N.			Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity	FASEB JOURNAL			English	Article						rimonabant; sympathetic nervous system; uncoupling protein 1	INCREASES HDL-CHOLESTEROL; ENDOCANNABINOID SYSTEM; ANTAGONIST RIMONABANT; CARDIOMETABOLIC RISK; ENERGY-EXPENDITURE; INVERSE AGONIST; WEIGHT; LIPOPROTEIN; OVERWEIGHT; EXPRESSION	The endocannabinoid system is an important player in energy metabolism by regulating appetite, lipolysis, and energy expenditure. Chronic blockade of the cannabinoid 1 receptor (CB1R) leads to long-term maintenance of weight loss and reduction of dyslipidemia in experimental and human obesity. The molecular mechanism by which CB1R blockade reverses dyslipidemia in obesity has not yet been clarified. In this study, we showed that CB1R blockade with the systemic CB1R blocker rimonabant enhanced whole-body energy expenditure and activated brown adipose tissue (BAT), indicated by increased expression of genes involved in BAT thermogenesis and decreased lipid droplet size in BAT. This was accompanied by selectively increased triglyceride (TG) uptake by BAT and lower plasma TG levels. Interestingly, the effects on BAT activation were still present at thermoneutrality and could be recapitulated by using the strictly peripheral CB1R antagonist AM6545, indicatingdirect peripheral activation of BAT. Indeed, CB1R blockade directly activated T37i brown adipocytes, resulting in enhanced uncoupled respiration, most likely via enhancing cAMP/PKA signaling via the adrenergic receptor pathway. Our data indicate that selective targeting of the peripheral CB1R in BAT has therapeutic potential in attenuating dyslipidemia and obesity.	[Boon, Mariette R.; Kooijman, Sander; van Dam, Andrea D.; Pelgrom, Leonard R.; Berbee, Jimmy F. P.; Visseren, Cheryl A. R.; van Aggele, Robin C.; Sips, Hetty C. M.; Havekes, Louis M.; Tamsma, Jouke T.; Meijer, Onno C.; Rensen, Patrick C. N.] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL-2300 RC Leiden, Netherlands; [Havekes, Louis M.; Jukema, J. Wouter] Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands; [Guigas, Bruno] Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands; [Guigas, Bruno] Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 RC Leiden, Netherlands; [Boon, Mariette R.; Kooijman, Sander; van Dam, Andrea D.; van Aggele, Robin C.; Sips, Hetty C. M.; Havekes, Louis M.; Meijer, Onno C.; Rensen, Patrick C. N.] Einthoven Lab Expt Vasc Med, Leiden, Netherlands; [Havekes, Louis M.] TNO Biosci, Leiden, Netherlands; [Lombes, Marc] INSERM, Unite 693, Le Kremlin Bicetre, France	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Organization Applied Science Research; Institut National de la Sante et de la Recherche Medicale (Inserm)	Boon, MR (corresponding author), Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, Post Zone C7Q,POB 9600, NL-2300 RC Leiden, Netherlands.	m.r.boon@lumc.nl	Pelgrom, Leonard/GVT-0523-2022; Lombes, Marc/L-5933-2018; Kooijman, Sander/S-3857-2016; Guigas, Bruno/M-2515-2015; Boon, Mariëtte/O-3660-2016; Rensen, Patrick C.N./D-7176-2018; meijer, onno c/D-8070-2018; Jukema, J. Wouter/ABD-6503-2021	Lombes, Marc/0000-0003-3189-023X; Kooijman, Sander/0000-0002-0014-5571; Guigas, Bruno/0000-0002-8856-5799; Rensen, Patrick C.N./0000-0002-8455-4988; meijer, onno c/0000-0002-8394-6859; Jukema, J. Wouter/0000-0002-3246-8359; Pelgrom, Leonard/0000-0002-8422-6810	Board of Directors of Leiden University Medical Center (LUMC); Netherlands Heart Foundation [2009T087]; Netherlands Cardiovascular Research Initiative; Dutch Heart Foundation; Dutch Federation of University Medical Centers; Netherlands Organisation for Health Research and Development; Royal Netherlands Academy of Sciences [CVON2011-19]	Board of Directors of Leiden University Medical Center (LUMC); Netherlands Heart Foundation(Netherlands Heart Foundation); Netherlands Cardiovascular Research Initiative; Dutch Heart Foundation(Netherlands Heart Foundation); Dutch Federation of University Medical Centers; Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development); Royal Netherlands Academy of Sciences	M.R.B. is supported by a grant from the Board of Directors of Leiden University Medical Center (LUMC). P.C.N.R. is an established investigator of the Netherlands Heart Foundation (grant 2009T087). The authors also acknowledge support from the Netherlands Cardiovascular Research Initiative, the Dutch Heart Foundation, the Dutch Federation of University Medical Centers, the Netherlands Organisation for Health Research and Development, and the Royal Netherlands Academy of Sciences for the GENIUS project Generating the Best Evidence-Based Pharmaceutical Targets for Atherosclerosis (CVON2011-19). The authors also thank Lianne van der Wee and Trea Streefland (Department of Endocrinology, LUMC) for excellent technical assistance. The excellent help and valuable scientific input from Johanna C. van den Beukel, Gardi J. Voortman, Edith C. H. Friesema, and Aldo Grefhorst (Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands) is highly appreciated.	Addy C, 2008, CELL METAB, V7, P68, DOI 10.1016/j.cmet.2007.11.012; Bajzer M, 2011, DIABETOLOGIA, V54, P3121, DOI 10.1007/s00125-011-2302-6; Bakker LEH, 2014, LANCET DIABETES ENDO, V2, P210, DOI 10.1016/S2213-8587(13)70156-6; Bartelt A, 2011, NAT MED, V17, P200, DOI 10.1038/nm.2297; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bluher M, 2006, DIABETES, V55, P3053, DOI 10.2337/db06-0812; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; de Haan W, 2008, ATHEROSCLEROSIS, V197, P57, DOI 10.1016/j.atherosclerosis.2007.08.001; De Petrocellis L, 2004, BRIT J PHARMACOL, V141, P765, DOI 10.1038/sj.bjp.0705666; Despres JP, 2005, NEW ENGL J MED, V353, P2121, DOI 10.1056/NEJMoa044537; Eckardt K, 2009, DIABETOLOGIA, V52, P664, DOI 10.1007/s00125-008-1240-4; Engeli S, 2005, DIABETES, V54, P2838, DOI 10.2337/diabetes.54.10.2838; FEURER I, 1986, NUTR CLIN PRACT, V1, P43, DOI DOI 10.1177/088453368600100106; Gary-Bobo M, 2007, HEPATOLOGY, V46, P122, DOI 10.1002/hep.21641; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Hu CX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019423; Jbilo O, 2005, FASEB J, V19, P1567, DOI 10.1096/fj.04-3177fje; Jong MC, 2001, J LIPID RES, V42, P1578; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; Molhoj S, 2010, EUR J PHARMACOL, V646, P38, DOI 10.1016/j.ejphar.2010.08.006; Ortega-Molina A, 2012, CELL METAB, V15, P382, DOI 10.1016/j.cmet.2012.02.001; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Pagotto U, 2006, ENDOCR REV, V27, P73, DOI 10.1210/er.2005-0009; Pi-Sunyer F, 2006, JAMA-J AM MED ASSOC, V295, P761, DOI 10.1001/jama.295.7.761; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RENSEN PCN, 1995, NAT MED, V1, P221, DOI 10.1038/nm0395-221; Tam J, 2010, J CLIN INVEST, V120, P2953, DOI 10.1172/JCI42551; Tedesco L, 2008, DIABETES, V57, P2028, DOI 10.2337/db07-1623; Trillou CR, 2003, AM J PHYSIOL-REG I, V284, pR345, DOI 10.1152/ajpregu.00545.2002; Trillou CR, 2004, INT J OBESITY, V28, P640, DOI 10.1038/sj.ijo.0802583; Tseng YH, 2008, NATURE, V454, P1000, DOI 10.1038/nature07221; Turu G, 2010, J MOL ENDOCRINOL, V44, P75, DOI 10.1677/JME-08-0190; van der Hoogt CC, 2007, J LIPID RES, V48, P1763, DOI 10.1194/jlr.M700108-JLR200; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; Van Klinken JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036162; Verty ANA, 2009, OBESITY, V17, P254, DOI 10.1038/oby.2008.509; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Westerterp M, 2006, ARTERIOSCL THROM VAS, V26, P2552, DOI 10.1161/01.ATV.0000243925.65265.3c; Whittle AJ, 2012, CELL, V149, P871, DOI 10.1016/j.cell.2012.02.066; Wu HM, 2011, MOL PHARMACOL, V80, P859, DOI 10.1124/mol.111.072769; ZAMBON A, 1993, J LIPID RES, V34, P1021; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915	46	72	75	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5361	5375		10.1096/fj.13-247643	http://dx.doi.org/10.1096/fj.13-247643			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25154875				2022-12-28	WOS:000345894500029
J	Fournier, AJ; Rajbhandari, L; Shrestha, S; Venkatesan, A; Ramesh, KT				Fournier, Adam J.; Rajbhandari, Labchan; Shrestha, Shiva; Venkatesan, Arun; Ramesh, K. T.			In vitro and in situ visualization of cytoskeletal deformation under load: traumatic axonal injury	FASEB JOURNAL			English	Article						traumatic brain injury; spinal cord injury; cyto-skeleton micromechanics; microfluidics; confocal	STRETCH-INJURY; DYNAMIC INSTABILITY; MICROTUBULES; ORGANIZATION; MECHANISMS; PROTEIN; DAMAGE	It is difficult to obtain insight into the mechanisms occurring within live cells during mechanical loading, because this complex environment is dynamic and evolving. This is a particular challenge from a subcellular mechanics perspective, where temporal and spatial information on the evolving cytoskeletal structures is required under loading. Using fluorescently labeled proteins, we visualize 3-dimensional live subcellular cytoskeletal populations under mechanical loading using a high-resolution confocal microscope. The mechanical forces are determined using a computational (finite element) model that is validated by integrating instrumentation into the testing platform. Transfected microtubules and neurofilaments of E17 rat neuronal axons are imaged before, during, and after loading. Comparisons between unloaded and loaded live cells demonstrate both spatial and temporal changes for cytoskeletal populations within the imaged volume. NF signal decreases by 24%, yet the microtubule signal exhibits no significant change 20-35 s after loading. Transmission electron microscopy assesses cytoskeletal structure spatial distribution for undeformed and deformed axons. While cytoskeletal degeneration occurs at prolonged time intervals following loads, our data provides insights into real time cytoskeletal evolution occurring in situ. Our findings suggest that, for axons undergoing traumatic injury in response to applied mechanical loads, changes at the substructural level of neurofilaments may precede microtubule rupture and degeneration.	[Fournier, Adam J.; Ramesh, K. T.] Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA; [Rajbhandari, Labchan; Shrestha, Shiva; Venkatesan, Arun] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Ramesh, KT (corresponding author), Johns Hopkins Univ, Dept Mech Engn, Latrobe 200, Baltimore, MD 21218 USA.	avenkat2@jhmi.edu; ramesh@jhu.edu	Ramesh, KT/D-5451-2009	Ramesh, KT/0000-0003-2659-4698	Hopkins Extreme Materials Institute (HEMI); U.S. Army	Hopkins Extreme Materials Institute (HEMI); U.S. Army(United States Department of DefenseUnited States Army)	The authors thank Professor Nitish Thakor (Department of Biomedical Engineering, Johns Hopkins University) and his student, Bhaskar Chennuri, for assistance with building the microcompression platform used in this research. The authors also thank the Johns Hopkins University School of Medicine Microscope Facility for usage of the imaging equipment, technical expertise, and invaluable advice in performing this research, Dr. Suneil Hosmane for providing discussion and direction labeling methodologies, and Aman Shah and Kyle Kirwan for their technical assistance. This work is supported by funding from the Hopkins Extreme Materials Institute (HEMI) and the U.S. Army.	Aberts B, 2008, MOL BIOL CELL; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BLACK MM, 1989, J NEUROSCI, V9, P358; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cai Q, 2000, Space Med Med Eng (Beijing), V13, P263; Chang R, 2009, J MOL BIOL, V391, P648, DOI 10.1016/j.jmb.2009.06.045; Chetta J, 2010, CYTOSKELETON, V67, P650, DOI 10.1002/cm.20478; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Chung RS, 2005, J NEUROTRAUM, V22, P1081, DOI 10.1089/neu.2005.22.1081; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; Daga RR, 2006, NAT CELL BIOL, V8, P1108, DOI 10.1038/ncb1480; De Stefano N, 1998, BRAIN, V121, P1469, DOI 10.1093/brain/121.8.1469; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Gennarelli T. A., 1993, HEAD INJURY, V2, P108; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Hermann R, 1996, HISTOCHEM CELL BIOL, V106, P31; Hosmane S, 2011, LAB CHIP, V11, P3888, DOI 10.1039/c1lc20549h; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Koike T, 2008, NEUROCHEM INT, V52, P751, DOI 10.1016/j.neuint.2007.09.007; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Li Jin-sheng, 2002, Space Med Med Eng (Beijing), V15, P339; Ludin B, 1998, TRENDS CELL BIOL, V8, P72, DOI 10.1016/S0962-8924(97)01169-0; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Mukhopadhyay R, 2004, BIOESSAYS, V26, P1017, DOI 10.1002/bies.20088; OBRIEN ET, 1990, BIOCHEMISTRY-US, V29, P6648, DOI 10.1021/bi00480a014; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Ouyang H, 2010, MICR UGIM 2010 18 BI, P1; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Taber K. H., 2007, J NEUROPSYCHIATRY CL, V19; TAKEMURA R, 1992, J CELL SCI, V103, P953; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tonami K, 2007, MOL CELL BIOL, V27, P2548, DOI 10.1128/MCB.00992-06; Uribe J. A. H., 2011, P 26 INT S BALL MIAM, P187	45	8	9	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5277	5287		10.1096/fj.14-251942	http://dx.doi.org/10.1096/fj.14-251942			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25205740				2022-12-28	WOS:000345894500022
J	Dunford, LJ; Sinclair, KD; Kwong, WY; Sturrock, C; Clifford, BL; Giles, TC; Gardner, DS				Dunford, Louise J.; Sinclair, Kevin D.; Kwong, Wing Y.; Sturrock, Craig; Clifford, Bethan L.; Giles, Tom C.; Gardner, David S.			Maternal protein-energy malnutrition during early pregnancy in sheep impacts the fetal ornithine cycle to reduce fetal kidney microvascular development	FASEB JOURNAL			English	Article						polyamines; renal	INTRAUTERINE GROWTH RESTRICTION; LONG-TERM CONSEQUENCES; BIRTH-WEIGHT; NUTRIENT RESTRICTION; BLOOD-PRESSURE; DNA METHYLATION; POLYAMINES; NUTRITION; DIET; RISK	This paper identifies a common nutritional pathway relating maternal through to fetal protein-energy malnutrition (PEM) and compromised fetal kidney development. Thirty-one twin-bearing sheep were fed either a control (n=15) or low-protein diet (n=16, 17 vs. 8.7 g crude protein/MJ metabolizable energy) from d 0 to 65 gestation (term, approximate to 145 d). Effects on the maternal and fetal nutritional environment were characterized by sampling blood and amniotic fluid. Kidney development was characterized by histology, immunohistochemistry, vascular corrosion casts, and molecular biology. PEM had little measureable effect on maternal and fetal macronutrient balance (glucose, total protein, total amino acids, and lactate were unaffected) or on fetal growth. PEM decreased maternal and fetal urea concentration, which blunted fetal ornithine availability and affected fetal hepatic polyamine production. For the first time in a large animal model, we associated these nutritional effects with reduced micro- but not macrovascular development in the fetal kidney. Maternal PEM specifically impacts the fetal ornithine cycle, affecting cellular polyamine metabolism and microvascular development of the fetal kidney, effects that likely underpin programming of kidney development and function by a maternal low protein diet.Dunford, L. J., Sinclair, K. D., Kwong, W. Y., Sturrock, C., Clifford, B. L., Giles, T. C., Gardner, D. S.. Maternal protein-energy malnutrition during early pregnancy in sheep impacts the fetal ornithine cycle to reduce fetal kidney microvascular development.	[Dunford, Louise J.; Gardner, David S.] Univ Nottingham, Sch Vet Med & Sci, Loughborough LE12 5RD, Leics, England; [Sinclair, Kevin D.; Kwong, Wing Y.; Sturrock, Craig; Clifford, Bethan L.] Univ Nottingham, Sch Biosci, Loughborough LE12 5RD, Leics, England; [Giles, Tom C.] Univ Nottingham, Adv Data Anal Ctr, Loughborough LE12 5RD, Leics, England	University of Nottingham; University of Nottingham; University of Nottingham	Gardner, DS (corresponding author), Univ Nottingham, Sch Vet Med & Sci, Sutton Bonington Campus, Loughborough LE12 5RD, Leics, England.	david.gardner@nottingham.ac.uk	Gardner, David S/A-7484-2010; Sturrock, Craig/N-6422-2017	Gardner, David S/0000-0002-6490-2412; Sturrock, Craig/0000-0002-5333-8502; Sinclair, Kevin/0000-0002-6375-215X; Dunford, Louise/0000-0003-3739-697X	British Heart Foundation Ph.D. studentship [FS/09/011/26562]; Society for Endocrinology Early Career grant; British Heart Foundation [FS/09/011/26562] Funding Source: researchfish	British Heart Foundation Ph.D. studentship; Society for Endocrinology Early Career grant; British Heart Foundation(British Heart Foundation)	The authors acknowledge Dr. Jim Craigon for statistical advice on the manuscript. L.J.D. was supported by a British Heart Foundation Ph.D. studentship (FS/09/011/26562) and a Society for Endocrinology Early Career grant. The experiments were conducted at the School of Veterinary Medicine and Science (Sutton Bonington Campus, University of Nottingham, Loughborough, UK). D.S.G., LJ.D., and K.D.S conceived and designed the experiments; LJ.D., D.S.G., K.D.S., W.Y.K., C.S., B.L.C., and T.G. conducted research; L.J.D. and D.S.G. analyzed and interpreted research; and D.S.G., L.J.D., and K.D.S. wrote the paper. D.S.G. has primary responsibility for its final content, and all authors have approved the final version of the manuscript.	Agricultural Research Council, 1980, NUTR REQ RUM LIV; Aitken I., 2007, DIS SHEEP, V4th ed.; Alderman G., 1993, ENERGY PROTEIN REQUI; ALEXANDER G, 1964, J REPROD FERTIL, V7, P289, DOI 10.1530/jrf.0.0070289; Barcroft J, 1936, J PHYSIOL-LONDON, V88, P56, DOI 10.1113/jphysiol.1936.sp003422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Battaglia FC, 2002, PLACENTA, V23, pS3, DOI 10.1053/plac.2002.0812; BATTAGLIA FC, 1978, PHYSIOL REV, V58, P499, DOI 10.1152/physrev.1978.58.2.499; BATTAGLIA FC, 1988, ANNU REV NUTR, V8, P43, DOI 10.1146/annurev.nu.08.070188.000355; Bell AW, 2002, NUTR RES REV, V15, P211, DOI 10.1079/NRR200239; Black RE, 2013, LANCET, V382, P427, DOI 10.1016/S0140-6736(13)60937-X; BLAXTER KL, 1957, P NUTR SOC, V16, P52, DOI 10.1079/PNS19570013; Boujendar S, 2003, J NUTR, V133, P2820, DOI 10.1093/jn/133.9.2820; Boujendar S, 2002, DIABETOLOGIA, V45, P856, DOI 10.1007/s00125-002-0833-6; Conen D, 2010, CIRCULATION, V122, P764, DOI 10.1161/CIRCULATIONAHA.110.947978; Cowley AW, 1997, AM J PHYSIOL-REG I, V273, pR1, DOI 10.1152/ajpregu.1997.273.1.R1; Cox LA, 2006, J PHYSIOL-LONDON, V572, P67, DOI 10.1113/jphysiol.2006.106872; de Boer MP, 2008, HYPERTENSION, V51, P928, DOI 10.1161/HYPERTENSIONAHA.107.101881; Dubreuil P, 2005, VET REC, V156, P636, DOI 10.1136/vr.156.20.636; EATON SB, 1985, NEW ENGL J MED, V312, P283, DOI 10.1056/NEJM198501313120505; Ekegren T, 2005, ANAL BIOCHEM, V338, P179, DOI 10.1016/j.ab.2004.11.040; Ferraz MLF, 2008, PEDIATR NEPHROL, V23, P257, DOI 10.1007/s00467-007-0654-4; Fowden AL, 1998, P NUTR SOC, V57, P113, DOI 10.1079/PNS19980017; Graham NS, 2011, ANIMAL, V5, P861, DOI 10.1017/S1751731110002533; Guo JK, 2010, ANNU REV PHYSIOL, V72, P357, DOI 10.1146/annurev.physiol.010908.163245; Hammond J, 1932, GROWTH DEV MUTTON QU; Harding JE, 2001, INT J EPIDEMIOL, V30, P15, DOI 10.1093/ije/30.1.15; Heby O, 1995, INT J DEV BIOL, V39, P737; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; Humphreys BD, 2011, P NATL ACAD SCI USA, V108, P9226, DOI 10.1073/pnas.1100629108; KULHANEK JF, 1974, AM J PHYSIOL, V226, P1257, DOI 10.1152/ajplegacy.1974.226.5.1257; Kunkel PA, 1930, B JOHNS HOPKINS HOSP, V47, P285; Kwon H, 2004, BIOL REPROD, V71, P901, DOI 10.1095/biolreprod.104.029645; Leese HJ, 2012, REPRODUCTION, V143, P417, DOI 10.1530/REP-11-0484; Lemley CO, 2013, ANIMAL, V7, P1500, DOI 10.1017/S1751731113001006; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li YP, 2010, DIABETES, V59, P2400, DOI 10.2337/db10-0385; Lloyd LJ, 2012, J PHYSIOL-LONDON, V590, P377, DOI 10.1113/jphysiol.2011.220186; Luyckx VA, 2005, KIDNEY INT, V68, pS68, DOI 10.1111/j.1523-1755.2005.09712.x; Mandal S, 2013, P NATL ACAD SCI USA, V110, P2169, DOI 10.1073/pnas.1219002110; MCCANCE RA, 1962, LANCET, V2, P621; McDonald TJ, 2013, BRIT J NUTR, V109, P1382, DOI 10.1017/S0007114512003261; McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003; Miller VM, 2012, AM J PHYSIOL-REG I, V302, pR1023, DOI 10.1152/ajpregu.00105.2012; Mondy WL, 2009, TISSUE ENG PART C-ME, V15, P729, DOI [10.1089/ten.tec.2008.0583, 10.1089/ten.TEC.2008.0583]; Nijland MJ, 2007, J PHYSIOL-LONDON, V579, P643, DOI 10.1113/jphysiol.2006.122101; Ojeda NB, 2008, ADV CHRONIC KIDNEY D, V15, P101, DOI 10.1053/j.ackd.2008.01.001; Park MH, 2010, AMINO ACIDS, V38, P491, DOI 10.1007/s00726-009-0408-7; PENNELL JP, 1975, J CLIN INVEST, V55, P399, DOI 10.1172/JCI107944; Popkin BM, 2006, AM J CLIN NUTR, V84, P289, DOI 10.1093/ajcn/84.2.289; Popkin BM, 2001, J NUTR, V131, p871S, DOI 10.1093/jn/131.3.871S; RABINOWITZ L, 1973, KIDNEY INT, V4, P188, DOI 10.1038/ki.1973.101; Raznahan A, 2012, P NATL ACAD SCI USA, V109, P11366, DOI 10.1073/pnas.1203350109; Rees WD, 1999, BRIT J NUTR, V81, P243, DOI 10.1017/S0007114599000446; REUSENS B, 1995, NESTLE NUTR WORKS SE, V35, P187; Rhodes P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007393; Ritz E, 2011, NAT REV NEPHROL, V7, P137, DOI 10.1038/nrneph.2011.1; ROBINSON JJ, 1977, J AGR SCI, V88, P539, DOI 10.1017/S0021859600037229; ROBINSON JJ, 1967, BRIT J NUTR, V21, P879, DOI 10.1079/BJN19670088; ROSSO P, 1979, J NUTR, V109, P1887, DOI 10.1093/jn/109.11.1887; RUSSEL AJF, 1969, J AGR SCI, V72, P451, DOI 10.1017/S0021859600024874; Saini P, 2009, NATURE, V459, P118, DOI 10.1038/nature08034; Sandovici I, 2011, P NATL ACAD SCI USA, V108, P5449, DOI 10.1073/pnas.1019007108; Sinclair KD, 1998, REPROD FERT DEVELOP, V10, P263, DOI 10.1071/R98021; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Thurner S, 2013, P NATL ACAD SCI USA, V110, P4703, DOI 10.1073/pnas.1215626110; Wagner R, 2011, MICROSC MICROANAL, V17, P215, DOI 10.1017/S1431927610094201; WALLACE LR, 1948, J AGR SCI, V38, P243, DOI 10.1017/S0021859600006079; Whincup PH, 2008, JAMA-J AM MED ASSOC, V300, P2886, DOI 10.1001/jama.2008.886; Wintour E M, 1997, Equine Vet J Suppl, P51; World Health Organization (WHO), 2011, NUTR LANDSC INF SYST; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Wu GY, 1998, J NUTR, V128, P894, DOI 10.1093/jn/128.5.894; Yamashina S, 2007, J GASTROEN HEPATOL, V22, pS62, DOI 10.1111/j.1440-1746.2006.04655.x; Zandi-Nejad K, 2006, HYPERTENSION, V47, P502, DOI 10.1161/01.HYP.0000198544.09909.1a	75	15	18	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4880	4892		10.1096/fj.14-255364	http://dx.doi.org/10.1096/fj.14-255364			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25077559	Green Published, hybrid, Green Submitted, Green Accepted			2022-12-28	WOS:000344050900025
J	Farrington, GK; Caram-Salas, N; Haqqani, AS; Brunette, E; Eldredge, J; Pepinsky, B; Antognetti, G; Baumann, E; Ding, W; Garber, E; Jiang, SS; Delaney, C; Boileau, E; Sisk, WP; Stanimirovic, DB				Farrington, Graham K.; Caram-Salas, Nadia; Haqqani, Arsalan S.; Brunette, Eric; Eldredge, John; Pepinsky, Blake; Antognetti, Giovanna; Baumann, Ewa; Ding, Wen; Garber, Ellen; Jiang, Susan; Delaney, Christie; Boileau, Eve; Sisk, William P.; Stanimirovic, Danica B.			A novel platform for engineering blood-brain barrier-crossing bispecific biologics	FASEB JOURNAL			English	Article						single-domain antibody; neuropeptides; drug delivery	OPIOID RECEPTOR DESENSITIZATION; SINGLE-DOMAIN ANTIBODIES; HUMAN INSULIN-RECEPTOR; CENTRAL-NERVOUS-SYSTEM; NEONATAL FC-RECEPTOR; CEREBROSPINAL-FLUID; DRUG-DELIVERY; RAT-BRAIN; MONOCLONAL-ANTIBODY; INTERSTITIAL FLUID	The blood-brain barrier (BBB) prevents the access of therapeutic antibodies to central nervous system (CNS) targets. The engineering of bispecific antibodies in which a therapeutic arm is combined with a BBB-transcytosing arm can significantly enhance their brain delivery. The BBB-permeable single-domain antibody FC5 was previously isolated by phenotypic panning of a naive llama single-domain antibody phage display library. In this study, FC5 was engineered as a mono- and bivalent fusion with the human Fc domain to optimize it as a modular brain delivery platform. In vitro studies demonstrated that the bivalent fusion of FC5 with Fc increased the rate of transcytosis (P-app) across brain endothelial monolayer by 25% compared with monovalent fusion. Up to a 30-fold enhanced apparent brain exposure (derived from serum and cerebrospinal fluid pharmacokinetic profiles) of FC5- compared with control domain antibody-Fc fusions after systemic dosing in rats was observed. Systemic pharmacological potency was evaluated in the Hargreaves model of inflammatory pain using the BBB-impermeable neuropeptides dalargin and neuropeptide Y chemically conjugated with FC5-Fc fusion proteins. Improved serum pharmacokinetics of Fc-fused FC5 contributed to a 60-fold increase in pharmacological potency compared with the single-domain version of FC5; bivalent and monovalent FC5 fusions with Fc exhibited similar systemic pharmacological potency. The study demonstrates that modular incorporation of FC5 as the BBB-carrier arm in bispecific antibodies or antibody-drug conjugates offers an avenue to develop pharmacologically active biotherapeutics for CNS indications.Farrington, G. K., Caram-Salas, N., Haqqani, A. S., Brunette, E., Eldredge, J., Pepinsky, B., Antognetti, G., Baumann, E., Ding, W., Garber, E., Jiang, S., Delaney, C., Boileau, E., Sisk, W. P., Stanimirovic, D. B. A novel platform for engineering blood-brain barrier-crossing bispecific biologics.	[Farrington, Graham K.; Eldredge, John; Pepinsky, Blake; Antognetti, Giovanna; Garber, Ellen; Sisk, William P.] Biogen Idec Inc, Cambridge, MA USA; [Caram-Salas, Nadia; Haqqani, Arsalan S.; Brunette, Eric; Baumann, Ewa; Ding, Wen; Jiang, Susan; Delaney, Christie; Boileau, Eve; Stanimirovic, Danica B.] Natl Res Council Canada, Ottawa, ON K1A 0R6, Canada	Biogen; National Research Council Canada	Stanimirovic, DB (corresponding author), Natl Res Council Canada, 1200 Montreal Rd,Bldg M54, Ottawa, ON K1A 0R6, Canada.	graham.farrington@biogenidec.com; danica.stanimirovic@nrc-cnrc.gc.ca	Caram-Salas, Nadia L/F-1977-2019; Salas, Nadia Lizeth Caram/AAG-4767-2020	Salas, Nadia Lizeth Caram/0000-0002-1894-9498	Biogen Idec; National Research Council of Canada	Biogen Idec(Biogen); National Research Council of Canada	The authors thank Luc Tessier (National Research Council of Canada) for maintenance of nanoLC-SRM instruments; Ellen Rohde (Biogen Wet) for running and analyzing PKs of various molecules in rats; Chioma Nwankwo, You Li, and Nels Pederson for cloning of yarious molecules; Jorge Sanchez-Salazar and Tom Cameron for cell line development and expression; and Monika Vecchi, Susan Foley, YuTing Huang, Yaping Sun, and Dingyi Wen for review of mass spectrometry analysis. The study was funded through program support from Biogen Idec based on yearly program reviews and prioritization, and through National Research Council of Canada support for the strategic program Therapeutics Beyond Brain Barriers.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; Abulrob A, 2005, J NEUROCHEM, V95, P1201, DOI 10.1111/j.1471-4159.2005.03463.x; ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U; Boado RJ, 2013, BIOTECHNOL BIOENG, V110, P1456, DOI 10.1002/bit.24795; Boado RJ, 2009, DRUG METAB DISPOS, V37, P2299, DOI 10.1124/dmd.109.028787; Caljon G, 2012, BRIT J PHARMACOL, V165, P2341, DOI 10.1111/j.1476-5381.2011.01723.x; Coloma MJ, 2000, PHARMACEUT RES, V17, P266, DOI 10.1023/A:1007592720793; Couch JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005338; CSERR HF, 1981, AM J PHYSIOL, V240, pF319, DOI 10.1152/ajprenal.1981.240.4.F319; Dang VC, 2012, BRIT J PHARMACOL, V165, P1704, DOI 10.1111/j.1476-5381.2011.01482.x; Dang VC, 2009, J NEUROSCI, V29, P3322, DOI 10.1523/JNEUROSCI.4749-08.2009; de Lange ECM, 2002, CLIN PHARMACOKINET, V41, P691, DOI 10.2165/00003088-200241100-00001; Demeule M, 2008, J NEUROCHEM, V106, P1534, DOI 10.1111/j.1471-4159.2008.05492.x; Dirks NL, 2010, CLIN PHARMACOKINET, V49, P633, DOI 10.2165/11535960-000000000-00000; Farrington G. K., 2009, U. S. patent, Patent No. [20090252729A1, 20090252729]; Fluttert M, 2000, LAB ANIM, V34, P372, DOI 10.1258/002367700780387714; Gan L. S., 2013, INT J CELL BIOL, V2013; Garberg P, 2005, TOXICOL IN VITRO, V19, P299, DOI 10.1016/j.tiv.2004.06.011; Giragossian C, 2013, CURR DRUG METAB, V14, P764, DOI 10.2174/13892002113149990099; Haqqani Arsalan S., 2008, V439, P241, DOI 10.1007/978-1-59745-188-8_17; Haqqani AS, 2013, MOL PHARMACEUT, V10, P1542, DOI 10.1021/mp3004995; Haqqani AS, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-4; Hartz AMS, 2011, CURR PHARM BIOTECHNO, V12, P656; Hristodorov D, 2013, MOL BIOTECHNOL, V54, P1056, DOI 10.1007/s12033-012-9612-x; Hussack G, 2011, J BIOL CHEM, V286, P8961, DOI 10.1074/jbc.M110.198754; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Iqbal U, 2010, BRIT J PHARMACOL, V160, P1016, DOI 10.1111/j.1476-5381.2010.00742.x; Iqbal U, 2011, METHODS MOL BIOL, V686, P465, DOI 10.1007/978-1-60761-938-3_24; Johanson CE, 2011, METHODS MOL BIOL, V686, P101, DOI 10.1007/978-1-60761-938-3_4; Jones AR, 2007, PHARM RES-DORDR, V24, P1759, DOI 10.1007/s11095-007-9379-0; KORNHUBER ME, 1986, J NEUROSCI METH, V17, P63, DOI 10.1016/0165-0270(86)90035-X; Lin D, 2013, J PROTEOME RES, V12, P5996, DOI 10.1021/pr400877e; Lin JH, 2008, CURR DRUG METAB, V9, P46, DOI 10.2174/138920008783331077; MATTSON G, 1993, MOL BIOL REP, V17, P167, DOI 10.1007/BF00986726; Muruganandam A, 2001, FASEB J, V15, P240, DOI 10.1096/fj.01-0343fje; Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449; Niewoehner J, 2014, NEURON, V81, P49, DOI 10.1016/j.neuron.2013.10.061; Nirogi R, 2009, J NEUROSCI METH, V178, P116, DOI 10.1016/j.jneumeth.2008.12.001; Ohshima-Hosoyama S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039036; Pardridge WM, 2002, NEURON, V36, P555, DOI 10.1016/S0896-6273(02)01054-1; PARDRIDGE WM, 1991, J PHARMACOL EXP THER, V259, P66; PAXINOS G, 1985, J NEUROSCI METH, V13, P139, DOI 10.1016/0165-0270(85)90026-3; Pepinsky RB, 2011, J PHARMACOL EXP THER, V339, P519, DOI 10.1124/jpet.111.183483; Rousselle C, 2003, J PHARMACOL EXP THER, V306, P371, DOI 10.1124/jpet.102.048520; SARNA G, 1984, J PHYSIOL-PARIS, V79, P536; Shen DD, 2004, ADV DRUG DELIVER REV, V56, P1825, DOI 10.1016/j.addr.2004.07.011; Stanimirovic DB, 2012, J CEREBR BLOOD F MET, V32, P1207, DOI 10.1038/jcbfm.2012.25; Strazielle N, 2013, MOL PHARMACEUT, V10, P1473, DOI 10.1021/mp300518e; SZENTISTVANYI I, 1984, AM J PHYSIOL, V246, pF835, DOI 10.1152/ajprenal.1984.246.6.F835; Tanha J, 2002, J IMMUNOL METHODS, V263, P97, DOI 10.1016/S0022-1759(02)00027-3; Tanha Jamshid, 2003, Methods Mol Med, V89, P435; Van Bockstaele F, 2009, CURR OPIN INVEST DR, V10, P1212; Vaughn DE, 1997, BIOCHEMISTRY-US, V36, P9374, DOI 10.1021/bi970841r; Vincke Cecile, 2012, Methods Mol Biol, V911, P15, DOI 10.1007/978-1-61779-968-6_2; Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942; Wolak DJ, 2013, MOL PHARMACEUT, V10, P1492, DOI 10.1021/mp300495e; YAN Q, 1994, EXP NEUROL, V127, P23, DOI 10.1006/exnr.1994.1076; Yu YJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002230	59	84	92	0	50	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4764	4778		10.1096/fj.14-253369	http://dx.doi.org/10.1096/fj.14-253369			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25070367	Green Submitted, Bronze			2022-12-28	WOS:000344050900016
J	Fu, SB; Tar, MT; Melman, A; Davies, KP				Fu, Shibo; Tar, Moses Tarndie; Melman, Arnold; Davies, Kelvin Paul			Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells	FASEB JOURNAL			English	Article						priapism; sickle cell disease; hypoxia inducible factor-1a; A2B-adenosine receptor; sialorphin	INDUCIBLE FACTOR-1-ALPHA; NITRIC-OXIDE; NEUTRAL ENDOPEPTIDASE; ERECTILE DYSFUNCTION; SUBMANDIBULAR-GLAND; BLOOD-FLOW; PRIAPISM; EXPRESSION; RAT; ADENOSINE	Men with sickle cell disease (SCD) risk developing priapism. Recognizing that SCD is a disease of hypoxia, we investigated the effect of hypoxia on gene expression in corporal smooth muscle (CSM) cells. Rat CSM cells in vitro were treated with CoCl2 or low oxygen tension to mimic hypoxia. Hypoxic conditions increased expression of genes previously associated with priapism in animal models. Variable coding sequence a1 (Vcsa1; the rat opiorphin homologue, sialorphin), hypoxia-inducible factor 1a (Hif-1a), and A2B adenosine receptor (a2br) were increased by 10-, 4-, and 6-fold, respectively, by treatment with CoCl2, whereas low oxygen tension caused increases in expression of 3-, 4-, and 1.5-fold, respectively. Sialorphin-treated CSM cells increased expression of Hif-1a and a2br by 4-fold, and vcsa1-siRNA treatment reduced expression by similar to 50%. Using a Hif-1a inhibitor, we demonstrated up-regulation of a2br by sialorphin is dependent on Hif-1a, and knockdown of vcsa1 expression with vcsa1-siRNA demonstrated that hypoxic-upregulation of Hif-1a is dependent on vcsa1. In CSM from a SCD mouse, there was 15-fold up-regulation of opiorphin at a life stage prior to priapism. We conclude that in CSM, opiorphins are master regulators of the hypoxic response. Opiorphin up-regulation in response to SCD-associated hypoxia activates CSM "relaxant" pathways; excessive activation of these pathways results in priapism.-Fu, S., Tar, M. T., Melman, A., Davies, K. P. Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells.	[Fu, Shibo; Tar, Moses Tarndie; Melman, Arnold; Davies, Kelvin Paul] Albert Einstein Coll Med, Dept Urol, Bronx, NY 10461 USA; [Davies, Kelvin Paul] Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Davies, KP (corresponding author), Albert Einstein Coll Med, Dept Urol, Bronx, NY 10461 USA.	kelvin.davies@einstein.yu.edu	Fu, Shi-bo/ABE-1277-2020	Davies, Kelvin/0000-0002-0201-9210	U.S. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [R01DK087872]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK087872, R01DK087872] Funding Source: NIH RePORTER	U.S. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK087872 to K.P.D.	Abern MR, 2009, J UROLOGY, V182, P1401, DOI 10.1016/j.juro.2009.06.040; Befani C, 2013, INT J BIOCHEM CELL B, V45, P2359, DOI 10.1016/j.biocel.2013.07.025; Bivalacqua TJ, 2012, J SEX MED, V9, P79, DOI 10.1111/j.1743-6109.2011.02288.x; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; Calenda GL, 2011, AM J PHYSIOL-HEART C, V301, pH1353, DOI 10.1152/ajpheart.00383.2011; Chachami G, 2004, AM J RESP CELL MOL, V31, P544, DOI 10.1165/rcmb.2003-0426OC; Chua RG, 2009, MOL CELL ENDOCRINOL, V303, P67, DOI 10.1016/j.mce.2009.02.001; Dai YB, 2009, J SEX MED, V6, P292, DOI 10.1111/j.1743-6109.2008.01187.x; Davies K. P., 2006, J SEX MED, V3, P414; Davies KP, 2007, BJU INT, V99, P431, DOI 10.1111/j.1464-410X.2006.06577.x; Dufour E., 2013, BIOCH ANAL BIOCH, V2, P136, DOI DOI 10.4172/2161-1009.1000136; EMOND AM, 1980, ARCH INTERN MED, V140, P1434, DOI 10.1001/archinte.140.11.1434; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Han YH, 2006, PROTEOMICS, V6, P3262, DOI 10.1002/pmic.200500754; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Huang Y, 2003, LEUKEMIA, V17, P2065, DOI 10.1038/sj.leu.2403141; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Javelot H, 2010, J PHYSIOL PHARMACOL, V61, P355; Kanika ND, 2009, AM J PHYSIOL-CELL PH, V297, pC916, DOI 10.1152/ajpcell.00656.2008; Kato Gregory J, 2009, Am J Hematol, V84, P618, DOI 10.1002/ajh.21475; KIMMELSTIEL P, 1948, AM J MED SCI, V216, P11, DOI 10.1097/00000441-194807000-00002; Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06-6419com; Lagoda G, 2014, FASEB J, V28, P76, DOI 10.1096/fj.13-228817; Lee K, 2007, J MED CHEM, V50, P1675, DOI 10.1021/jm0610292; Lee K, 2010, BIOCHEM PHARMACOL, V80, P982, DOI 10.1016/j.bcp.2010.06.018; Mathison RD, 2012, CHEM IMMUNOL ALLERGY, V98, P176, DOI 10.1159/000336513; Maxwell PH, 2005, EXP PHYSIOL, V90, P791, DOI 10.1113/expphysiol.2005.030924; Melman A, 2000, INT J IMPOT RES, V12, pS133, DOI 10.1038/sj.ijir.3900592; Melman A, 2006, HUM GENE THER, V17, P1165, DOI 10.1089/hum.2006.17.1165; Melman A, 2009, THESCIENTIFICWORLDJO, V9, P846, DOI 10.1100/tsw.2009.102; Mi T, 2008, J CLIN INVEST, V118, P1491, DOI 10.1172/JCI33467; Nagaoka T, 2002, INVEST OPHTH VIS SCI, V43, P3037; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Roemeling-van Rhijn M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00203; ROSINSKICHUPIN I, 1993, J HISTOCHEM CYTOCHEM, V41, P1645, DOI 10.1177/41.11.8409372; Rougeot C, 2003, P NATL ACAD SCI USA, V100, P8549, DOI 10.1073/pnas.1431850100; ROUGEOT C, 1994, EUR J BIOCHEM, V219, P765, DOI 10.1111/j.1432-1033.1994.tb18556.x; Rougeot C, 2000, PEPTIDES, V21, P443, DOI 10.1016/S0196-9781(00)00158-3; SEGAL SS, 1992, NEWS PHYSIOL SCI, V7, P152; Sengupta T, 2011, MOL CELL BIOL, V31, P3885, DOI 10.1128/MCB.05089-11; Sun KQ, 2013, CURR OPIN HEMATOL, V20, P215, DOI 10.1097/MOH.0b013e32835f55f9; Tong Y, 2008, J UROLOGY, V180, P760, DOI 10.1016/j.juro.2008.03.187; Triantafyllou A, 2008, FREE RADICAL BIO MED, V44, P657, DOI 10.1016/j.freeradbiomed.2007.10.050; Triantafyllou A, 2006, FREE RADICAL RES, V40, P847, DOI 10.1080/10715760600730810; TRONIKLEROUX D, 1994, GENE, V142, P175; Wen J, 2010, J SEX MED, V7, P3011, DOI 10.1111/j.1743-6109.2009.01552.x; Wisner A, 2006, P NATL ACAD SCI USA, V103, P17979, DOI 10.1073/pnas.0605865103; Yang YF, 2011, NEUROSCIENCE, V196, P25, DOI 10.1016/j.neuroscience.2011.08.059; Yuan JH, 2008, ASIAN J ANDROL, V10, P88, DOI 10.1111/j.1745-7262.2008.00314.x	51	14	16	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3633	3644		10.1096/fj.13-248708	http://dx.doi.org/10.1096/fj.13-248708			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24803544	Green Published			2022-12-28	WOS:000340265400031
J	Zhang, R; Ran, HH; Cai, LL; Zhu, L; Sun, JF; Peng, L; Liu, XJ; Zhang, LN; Fang, Z; Fan, YY; Cui, G				Zhang, Ran; Ran, Hai-Hong; Cai, Li-Li; Zhu, Li; Sun, Jun-Fang; Peng, Liang; Liu, Xiao-Juan; Zhang, Lan-Ning; Fang, Zhou; Fan, Yong-Yan; Cui, Geng			Simulated microgravity-induced mitochondrial dysfunction in rat cerebral arteries	FASEB JOURNAL			English	Article						hindlimb unweighting; oxidative stress; NADPH oxidase	MANGANESE SUPEROXIDE-DISMUTASE; MESENTERIC SMALL ARTERIES; CELL-ADHESION MOLECULE-1; OXIDATIVE STRESS; VASCULAR DYSFUNCTION; NADPH OXIDASES; ENDOTHELIAL DYSFUNCTION; CAROTID ARTERIES; HEART-FAILURE; HYPERTENSION	Exposure to microgravity results in cardiovascular deconditioning, and cerebrovascular oxidative stress injury has been suggested to occur. To elucidate the mechanism for this condition, we investigated whether simulated microgravity induces mitochondrial dysfunction in rat arteries. Four-week hindlimb unweighting (HU) was used to simulate microgravity in rats. Mitochondrial reactive oxygen species (ROS), mitochondrial membrane potential (Delta psi m), mitochondrial permeability transition pore (mPTP) opening, mitochondrial respiratory control ratio (RCR), MnSOD/GPx activity and expression, and mitochondrial malondialdehyde (MDA) were examined in rat cerebral and mesenteric VSMCs. Compared with the control rats, mitochondrial ROS levels, mPTP opening, and MDA content increased significantly (P<0.001, P<0.01, and P<0.01, respectively), Delta psi m, RCR, MnSOD/GPx activity (P<0.001 for Delta psi m and RCR; P<0.05 for MnSOD; and P<0.001 for GPx activity) and protein abundance of mitochondrial MnSOD/GPx-1 decreased (P<0.001 for MnSOD and GPx-1) in HU rat cerebral but not mesenteric arteries. Chronic treatment with NADPH oxidase inhibitor apocynin and mitochondria-targeted antioxidant mitoTempol promoted recovery of mitochondrial function in HU rat cerebral arteries, but exerted no effects on HU rat mesenteric arteries. Therefore, simulated microgravity resulted in cerebrovascular mitochondrial dysfunction, and crosstalk between NADPH oxidase and mitochondria participated in the process.	[Zhang, Ran; Sun, Jun-Fang; Peng, Liang; Liu, Xiao-Juan; Zhang, Lan-Ning; Fang, Zhou; Fan, Yong-Yan] Chinese Peoples Liberat Army, Inst Geriatr Cardiol, Gen Hosp, Beijing 100853, Peoples R China; [Ran, Hai-Hong] Chinese Peoples Liberat Army, Dept Geriatr Hematol, Gen Hosp, Beijing 100853, Peoples R China; [Cai, Li-Li] Chinese Peoples Liberat Army, Dept Clin Lab Med, Gen Hosp, Beijing 100853, Peoples R China; [Cui, Geng] Chinese Peoples Liberat Army, Dept Osteol, Gen Hosp, Beijing 100853, Peoples R China; [Zhu, Li] Second Mil Med Univ, Changhai Hosp, Shanghai, Peoples R China	Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Naval Medical University	Cui, G (corresponding author), Chinese Peoples Liberat Army, Dept Osteol, Gen Hosp, 28 Fuxing Rd, Beijing 100853, Peoples R China.	bjzhangran@126.com	Zhang, Ran/ABB-5587-2021		National Natural Science Foundation of China [81101468, 81030002/H02]; Beijing NOVO Program [XX2013105]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing NOVO Program	This work was supported by the National Natural Science Foundation of China (81101468 and 81030002/H02) and the Beijing NOVO Program (XX2013105). The authors declare no conflicts of interest.	Afolayan AJ, 2012, AM J PHYSIOL-LUNG C, V303, pL870, DOI 10.1152/ajplung.00098.2012; Bao JX, 2007, AVIAT SPACE ENVIR MD, V78, P852; Brandes RP, 2010, HYPERTENSION, V56, P17, DOI 10.1161/HYPERTENSIONAHA.108.120295; Cheng Jiu-Hua, 2009, Shengli Xuebao, V61, P386; Chrissobolis S, 2008, HYPERTENSION, V51, P872, DOI 10.1161/HYPERTENSIONAHA.107.103572; Convertino Victor A, 2002, J Gravit Physiol, V9, P1; Dai DF, 2012, CIRC RES, V110, P1109, DOI 10.1161/CIRCRESAHA.111.246140; Dai DF, 2012, CARDIOVASC RES, V93, P79, DOI 10.1093/cvr/cvr274; Dikalov S, 2011, FREE RADICAL BIO MED, V51, P1289, DOI 10.1016/j.freeradbiomed.2011.06.033; Dikalov SI, 2014, ANTIOXID REDOX SIGN, V20, P281, DOI 10.1089/ars.2012.4918; Dikalov SI, 2013, AM J PHYSIOL-HEART C, V305, pH1417, DOI 10.1152/ajpheart.00089.2013; Dikalov SI, 2013, ANTIOXID REDOX SIGN, V19, P1085, DOI 10.1089/ars.2012.4604; Dikalova AE, 2010, CIRC RES, V107, P106, DOI 10.1161/CIRCRESAHA.109.214601; Ding Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020008; Doughan AK, 2008, CIRC RES, V102, P488, DOI 10.1161/CIRCRESAHA.107.162800; Faraci FM, 2004, ARTERIOSCL THROM VAS, V24, P1367, DOI 10.1161/01.ATV.0000133604.20182.cf; Freed JK, 2013, ARTERIOSCL THROM VAS, V33, P673, DOI 10.1161/ATVBAHA.13.301039; Fu ZJ, 2004, AM J PHYSIOL-HEART C, V287, pH1505, DOI 10.1152/ajpheart.00143.2004; Fukai T, 2011, ANTIOXID REDOX SIGN, V15, P1583, DOI 10.1089/ars.2011.3999; Gao Fang, 2007, Shengli Xuebao, V59, P821; Gao L, 2008, VET CLIN N AM-SMALL, V38, P137, DOI 10.1016/j.cvsm.2007.10.004; GOLDSTEIN MA, 1992, J APPL PHYSIOL, V73, pS94, DOI 10.1152/jappl.1992.73.2.S94; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Handy DE, 2009, J BIOL CHEM, V284, P11913, DOI 10.1074/jbc.M900392200; Hargens AR, 1996, MED SCI SPORT EXER, V28, P977, DOI 10.1097/00005768-199608000-00007; Javadov S, 2009, J PHARMACOL EXP THER, V330, P670, DOI 10.1124/jpet.109.153213; Kang HY, 2013, CELL BIOCHEM BIOPHYS, V66, P121, DOI 10.1007/s12013-012-9460-0; Kluge MA, 2013, CIRC RES, V112, P1171, DOI 10.1161/CIRCRESAHA.111.300233; Lassegue B, 2012, CIRC RES, V110, P1364, DOI 10.1161/CIRCRESAHA.111.243972; Lin LJ, 2009, J APPL PHYSIOL, V107, P1710, DOI 10.1152/japplphysiol.00493.2009; Madamanchi NR, 2007, CIRC RES, V100, P460, DOI 10.1161/01.RES.0000258450.44413.96; Miller JD, 2010, AM J PHYSIOL-HEART C, V298, pH1600, DOI 10.1152/ajpheart.01108.2009; Miller MW, 2013, AM J PHYSIOL-HEART C, V304, pH1624, DOI 10.1152/ajpheart.00987.2012; Morbidelli L, 2005, BIOCHEM BIOPH RES CO, V334, P491, DOI 10.1016/j.bbrc.2005.06.124; Oelze M, 2014, HYPERTENSION, V63, P390, DOI 10.1161/HYPERTENSIONAHA.113.01602; Panov A, 2005, J BIOL CHEM, V280, P42026, DOI 10.1074/jbc.M508628200; Ren XL, 2011, CLIN EXP PHARMACOL P, V38, P683, DOI 10.1111/j.1440-1681.2011.05565.x; Taylor CR, 2013, FASEB J, V27, P2282, DOI 10.1096/fj.12-222687; Tsutsui H, 2009, CARDIOVASC RES, V81, P449, DOI 10.1093/cvr/cvn280; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Wenzel P, 2008, CARDIOVASC RES, V80, P280, DOI 10.1093/cvr/cvn182; Xi Q, 2005, CIRC RES, V97, P354, DOI 10.1161/01.RES.0000177669.29525.78; Xue JH, 2007, AM J PHYSIOL-HEART C, V293, pH691, DOI 10.1152/ajpheart.01229.2006; Xue JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019775; Zang Q, 2007, J APPL PHYSIOL, V102, P103, DOI 10.1152/japplphysiol.00359.2006; Zhan CD, 2004, J HYPERTENS, V22, P2025, DOI 10.1097/00004872-200410000-00027; Zhang LF, 2001, J APPL PHYSIOL, V91, P2415, DOI 10.1152/jappl.2001.91.6.2415; Zhang LF, 2013, EUR J APPL PHYSIOL, V113, P2873, DOI 10.1007/s00421-013-2597-8; Zhang R, 2008, J PHYSIOL SCI, V58, P67, DOI 10.2170/physiolsci.RP010707; Zhang R, 2012, J PHYSIOL BIOCHEM, V68, P99, DOI 10.1007/s13105-011-0123-1; Zhang R, 2010, EXCLI J, V9, P195; Zhang R, 2009, J APPL PHYSIOL, V106, P251, DOI 10.1152/japplphysiol.01278.2007	52	27	32	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2715	2724		10.1096/fj.13-245654	http://dx.doi.org/10.1096/fj.13-245654			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24604081				2022-12-28	WOS:000339883600029
J	Aguilar, A; Wagstaff, KM; Suarez-Sanchez, R; Zinker, S; Jans, DA; Cisneros, B				Aguilar, Areli; Wagstaff, Kylie M.; Suarez-Sanchez, Rocio; Zinker, Samuel; Jans, David A.; Cisneros, Bulmaro			Nuclear localization of the dystrophin-associated protein alpha-dystrobrevin through importin alpha 2/beta 1 is critical for interaction with the nuclear lamina/maintenance of nuclear integrity	FASEB JOURNAL			English	Article						nuclear import; lamin B1; nuclear envelope; nuclear morphology	ZINC-FINGER DOMAIN; MUSCULAR-DYSTROPHIES; BETA-DYSTROGLYCAN; IN-VITRO; SIGNAL; CELLS; ENVELOPE; COMPLEX; MUSCLE; IDENTIFICATION	Although alpha-dystrobrevin (DB) is assembled into the dystrophin-associated protein complex, which is central to cytoskeletal organization, it has also been found in the nucleus. Here we delineate the nuclear import pathway responsible for nuclear targeting of alpha-DB for the first time, together with the importance of nuclear alpha-DB in determining nuclear morphology. We map key residues of the nuclear localization signal of alpha-DB within the zinc finger domain (ZZ) using various truncated versions of the protein, and site-directed mutagenesis. Pulldown, immunoprecipitation, and AlphaScreen assays showed that the importin (IMP) alpha 2/beta 1 heterodimer interacts with high affinity with the ZZ domain of alpha-DB. In vitro nuclear import assays using antibodies to specific importins, as well as in vivo studies using siRNA or a dominant negative importin construct, confirmed the key role of IMP alpha 2/beta 1 in alpha-DB nuclear translocation. Knockdown of alpha-DB expression perturbed cell cycle progression in C2C12 myoblasts, with decreased accumulation of cells in S phase and, significantly, altered localization of lamins A/C, B1, and B2 with accompanying gross nuclear morphology defects. Because alpha-DB interacts specifically with lamin B1 in vivo and in vitro, nuclear alpha-DB would appear to play a key role in nuclear shape maintenance through association with the nuclear lamina.	[Aguilar, Areli; Zinker, Samuel; Cisneros, Bulmaro] Dept Genet Biol Mol, Centro Investigac Estudios Avanzados Inst Politec, Mexico City, DF, Mexico; [Aguilar, Areli; Zinker, Samuel; Cisneros, Bulmaro] Inst Politecn Nacl, Ctr Invest Estudios Avanzados, Dept Genet & Biol Mol, Mexico City, DF, Mexico; [Wagstaff, Kylie M.; Jans, David A.] Monash Univ, Dept Biochem & Mol Biol, Nucl Signalling Lab, Clayton, Vic, Australia; [Suarez-Sanchez, Rocio] Inst Nacl Rehabil, Dept Genet, Lab Med Genom, Mexico City 07360, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Monash University	Cisneros, B (corresponding author), Av IPN 2508,Col San Pedro Zacatenco, Mexico City 07360, DF, Mexico.	david.jans@monash.edu; bcisnero@cinvestav.mx		Wagstaff, Kylie/0000-0003-4791-1410; Jans, David/0000-0001-5115-4745	Consejo Nacional de Ciencia y Tecnologia (CONACyT), Mexico [54858]; National Health and Medical Research Council, Australia [APP1002486]	Consejo Nacional de Ciencia y Tecnologia (CONACyT), Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by Consejo Nacional de Ciencia y Tecnologia (CONACyT), Mexico (Grant 54858 to B.C.), and the National Health and Medical Research Council, Australia (Grant APP1002486 to D.A.J.). The authors thank Juan de Dios Gomez-Lopez for performing the pulldown assays.	Baliga BC, 2003, J BIOL CHEM, V278, P4899, DOI 10.1074/jbc.M211512200; Beetz C, 2004, BIOCHEM BIOPH RES CO, V318, P1079, DOI 10.1016/j.bbrc.2004.03.195; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; Borutinskaite VV, 2011, MOL BIOL REP, V38, P3001, DOI 10.1007/s11033-010-9965-9; Bruening W, 1996, FEBS LETT, V393, P41, DOI 10.1016/0014-5793(96)00853-8; Burke B, 2013, NAT REV MOL CELL BIO, V14, P13, DOI 10.1038/nrm3488; Cerna J, 2006, J MOL BIOL, V362, P954, DOI 10.1016/j.jmb.2006.07.075; Crisp M, 2008, FEBS LETT, V582, P2023, DOI 10.1016/j.febslet.2008.05.001; De Castro SCP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003059; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Forwood JK, 2001, J BIOL CHEM, V276, P46575, DOI 10.1074/jbc.M101668200; Fuentes-Mera L, 2006, EXP CELL RES, V312, P3023, DOI 10.1016/j.yexcr.2006.06.002; Funkhouser CM, 2013, P NATL ACAD SCI USA, V110, P3248, DOI 10.1073/pnas.1300215110; Ghildyal R, 2005, BIOCHEMISTRY-US, V44, P12887, DOI 10.1021/bi050701e; Gonzalez-Ramirez R, 2008, J CELL BIOCHEM, V105, P735, DOI 10.1002/jcb.21870; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; Hatayama M, 2008, HUM MOL GENET, V17, P3459, DOI 10.1093/hmg/ddn239; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; Lara-Chacon B, 2010, J CELL BIOCHEM, V110, P706, DOI 10.1002/jcb.22581; Martin C, 2010, CHROMOSOME RES, V18, P525, DOI 10.1007/s10577-010-9137-8; Martinez-Vieyra IA, 2013, BBA-MOL CELL RES, V1833, P698, DOI 10.1016/j.bbamcr.2012.11.019; MATHENY C, 1994, J BIOL CHEM, V269, P8176; Mercuri E, 2013, LANCET, V381, P845, DOI 10.1016/S0140-6736(12)61897-2; Metzinger L, 1997, HUM MOL GENET, V6, P1185, DOI 10.1093/hmg/6.7.1185; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; Nakamori M, 2011, INT J MOL SCI, V12, P1660, DOI 10.3390/ijms12031660; Navakauskiene R, 2012, J PROTEOMICS, V75, P3291, DOI 10.1016/j.jprot.2012.03.041; Newey SE, 2001, J BIOL CHEM, V276, P6645, DOI 10.1074/jbc.M008305200; Pandya K, 2002, J BIOL CHEM, V277, P16304, DOI 10.1074/jbc.M200866200; Peters MF, 1997, J BIOL CHEM, V272, P31561, DOI 10.1074/jbc.272.50.31561; Rothballer A, 2013, CHROMOSOMA, V122, P415, DOI 10.1007/s00412-013-0417-x; Rothballer A, 2013, NUCLEUS-PHILA, V4, P29, DOI 10.4161/nucl.23387; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; Villarreal-Silva M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023504; Wagstaff KM, 2006, ANAL BIOCHEM, V348, P49, DOI 10.1016/j.ab.2005.10.029; Yamasaki H, 2005, GENES CELLS, V10, P455, DOI 10.1111/j.1365-2443.2005.00850.x; Yang ML, 1999, J BIOL CHEM, V274, P27399, DOI 10.1074/jbc.274.39.27399; Yasuhara N, 2007, NAT CELL BIOL, V9, P72, DOI 10.1038/ncb1521; Young JC, 2011, FASEB J, V25, P3958, DOI 10.1096/fj.10-176941; Yu Z, 1998, J ENDOCRINOL, V159, P53, DOI 10.1677/joe.0.1590053	43	10	10	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1842	1858		10.1096/fj.14-257147	http://dx.doi.org/10.1096/fj.14-257147			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25636738				2022-12-28	WOS:000354114600020
J	Pol, JG; Lekbaby, B; Redelsperger, F; Klamer, S; Mandouri, Y; Ahodantin, J; Bieche, I; Lefevre, M; Souque, P; Charneau, P; Gadessaud, N; Kremsdorf, D; Soussan, P				Pol, Jonathan G.; Lekbaby, Bouchra; Redelsperger, Francois; Klamer, Sofieke; Mandouri, Yassmina; Ahodantin, James; Bieche, Ivan; Lefevre, Marine; Souque, Philippe; Charneau, Pierre; Gadessaud, Noemie; Kremsdorf, Dina; Soussan, Patrick			Alternative splicing-regulated protein of hepatitis B virus hacks the TNF-alpha-stimulated signaling pathways and limits the extent of liver inflammation	FASEB JOURNAL			English	Article						TAK1; HBSP; hepadnavirus; liver injury	NF-KAPPA-B; ACTIVATED KINASE 1; GENE-EXPRESSION; TRANSGENIC MICE; JNK ACTIVATION; HEPG2 CELLS; MOUSE-LIVER; IN-VIVO; TAK1; RNA	Hepatitis B splicing-regulated protein (HBSP) of the hepatitis B virus (HBV) was uncovered a few years ago but its function remains unknown. HBSP expression occurs from a spliced viral transcript that increases during the course of liver disease. This study aimed at characterizing the impact of HBSP on cellular signaling pathways in vitro and on liver pathogenesis in transgenic (Tg) mice. By RT-qPCR array, NF-kappa B-inducible genes appeared modulated in HepG2 cells transduced with a HBSP-encoding lentivirus. Using luciferase and Western blot assays, we observed a decreased activation of the NF-kappa B pathway in HBSP-expressing cells following TNF-alpha treatment, as illustrated by lower levels of phosphorylated I kappa B-alpha. Meanwhile, the level of phosphorylated JNK increased together with the sensitivity to apoptosis. The contrasting effects on JNK and I kappa B-alpha activation upon TNF-alpha stimulation matched with a modulated maturation of TGF-beta-activated kinase 1 (TAK1) kinase, assessed by 2-dimensional SDS-PAGE. Inhibition of the NF-kappa B pathway by HBSP was confirmed in the liver of HBSP Tg mice and associated with a significant decrease of chemically induced chronic liver inflammation, as assessed by immunohistochemistry. In conclusion, HBSP contributes to limit hepatic inflammation during chronic liver disease and may favor HBV persistence by evading immune response.	[Pol, Jonathan G.; Lekbaby, Bouchra; Redelsperger, Francois; Klamer, Sofieke; Mandouri, Yassmina; Ahodantin, James; Kremsdorf, Dina; Soussan, Patrick] INSERM, Pathogenese Hepatites Virales B & Immunotherapie, U845, Paris, France; [Pol, Jonathan G.; Lekbaby, Bouchra; Redelsperger, Francois; Klamer, Sofieke; Mandouri, Yassmina; Ahodantin, James; Kremsdorf, Dina; Soussan, Patrick] Inst Pasteur, Dept Virol, Paris, France; [Pol, Jonathan G.; Lekbaby, Bouchra; Redelsperger, Francois; Klamer, Sofieke; Mandouri, Yassmina; Ahodantin, James; Kremsdorf, Dina; Soussan, Patrick] Univ Necker, Univ Paris Descartes, Ctr Hosp, Paris, France; [Bieche, Ivan] Fac Pharmaceut Sci, Genet Mol Lab, Paris, France; [Lefevre, Marine] Hop Tenon, Serv Anatomopathol, F-75970 Paris, France; [Souque, Philippe; Charneau, Pierre] Inst Pasteur, CNRS, Virol Mol & Vectorol, Unite Rech Associee 3015, Paris, France; [Gadessaud, Noemie] Lab L RB126, Paris, France; [Soussan, Patrick] Hop Tenon, Virol Lab, F-75970 Paris, France; [Soussan, Patrick] Univ Paris 06, Ctr Hosp Univ Tenon, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Soussan, P (corresponding author), CHU Broussais, INSERM, U845, 96 Rue Didot, F-75014 Paris, France.	patrick.soussan@inserm.fr	Ahodantin, James/AAB-7216-2022; CHARNEAU, Pierre/M-1565-2017; Pol, Jonathan/R-6507-2016; Bièche, Ivan/O-7399-2017; soussan, patrick/O-9801-2017; Ahodantin, James/AAK-3326-2020; Kremsdorf, Dina/O-9797-2017	Ahodantin, James/0000-0003-4405-2593; CHARNEAU, Pierre/0000-0003-1184-5773; Pol, Jonathan/0000-0002-8355-7562; Bièche, Ivan/0000-0002-2430-5429; soussan, patrick/0000-0003-2706-7371; Ahodantin, James/0000-0003-4405-2593; 	French Ministry of Research; INSERM; Agence Nationale de la Recherche sur le SIDA-VIH et les Hepatites Virales [12229]	French Ministry of Research(Ministry of Research, FranceEuropean Commission); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Agence Nationale de la Recherche sur le SIDA-VIH et les Hepatites Virales(French National Research Agency (ANR))	The authors thank Raphaelle Desvaux and Nicolas Goudin (Microscopy and Histology core facilities, INSERM U845), Hualin Wang (INSERM U1135) for helpful technical assistance, Prof.Sallenave (Pasteur Institute, Paris, France) and Dr. Le Goffic (French National Institute for Agricultural Research;INRA, Jouy en Josas) for helpful discussion and providing viral vectors. J.G.P. and F.R. received support from the French Ministry of Research. This work was supported by grants from INSERM and the Agence Nationale de la Recherche sur le SIDA-VIH et les Hepatites Virales (Grant number 12229).	Asselah T, 2005, GASTROENTEROLOGY, V129, P2064, DOI 10.1053/j.gastro.2005.09.010; Bayliss J, 2013, J HEPATOL, V59, P1022, DOI 10.1016/j.jhep.2013.06.018; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Broglie P, 2010, J BIOL CHEM, V285, P2333, DOI 10.1074/jbc.M109.090522; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen JY, 2010, J MED VIROL, V82, P2019, DOI 10.1002/jmv.21918; Chen WN, 2012, J VIROL, V86, P13533, DOI 10.1128/JVI.02095-12; Cho G, 2000, BIOCHEM BIOPH RES CO, V269, P191, DOI 10.1006/bbrc.2000.2240; Giannini C, 2003, HEPATOLOGY, V38, P114, DOI 10.1053/jhep.2003.50265; Golan-Gerstl R, 2011, CANCER RES, V71, P4464, DOI 10.1158/0008-5472.CAN-10-4410; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Gunther S, 1997, VIROLOGY, V238, P363, DOI 10.1006/viro.1997.8863; Hamidi A, 2012, J BIOL CHEM, V287, P123, DOI 10.1074/jbc.M111.285122; Hosel M, 2009, HEPATOLOGY, V50, P1773, DOI 10.1002/hep.23226; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Inokuchi S, 2010, P NATL ACAD SCI USA, V107, P844, DOI 10.1073/pnas.0909781107; Inokuchi-Shimizu S, 2014, J CLIN INVEST, V124, P3566, DOI 10.1172/JCI74068; Kim YS, 2002, HEPATOLOGY, V36, P1498, DOI 10.1053/jhep.2002.36942; Liu D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091658; Liu SB, 2002, INFECT IMMUN, V70, P3433, DOI 10.1128/IAI.70.7.3433-3442.2002; Lu YW, 2008, IUBMB LIFE, V60, P700, DOI 10.1002/iub.108; Mancini-Bourgine M, 2007, J VIROL, V81, P4963, DOI 10.1128/JVI.02619-06; Peppa D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001227; Quetier I, 2013, J HEPATOL, V59, P285, DOI 10.1016/j.jhep.2013.03.021; Redelsperger F, 2012, VIROLOGY, V431, P21, DOI 10.1016/j.virol.2012.05.008; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; Scholz R, 2010, J BIOL CHEM, V285, P25753, DOI 10.1074/jbc.M109.093468; Schwabe RF, 2006, GASTROENTEROLOGY, V130, P1886, DOI 10.1053/j.gastro.2006.01.038; Scott MJ, 2010, J HEPATOL, V53, P693, DOI 10.1016/j.jhep.2010.04.026; Scott MJ, 2009, HEPATOLOGY, V49, P1695, DOI 10.1002/hep.22839; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; Sene D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001184; Soussan P, 2000, J CLIN INVEST, V105, P55, DOI 10.1172/JCI8098; Soussan P, 2003, J HEPATOL, V38, P343, DOI 10.1016/S0168-8278(02)00422-1; Soussan P, 2008, J INFECT DIS, V198, P218, DOI 10.1086/589623; Suzuki S, 2007, J BIOL CHEM, V282, P25177, DOI 10.1074/jbc.C700065200; TERRE S, 1991, J VIROL, V65, P5539; Wang YJ, 2006, J BIOL CHEM, V281, P15258, DOI 10.1074/jbc.M512953200; Wang YJ, 2010, HEPATOLOGY, V52, P2118, DOI 10.1002/hep.23929; WU HL, 1991, J VIROL, V65, P1680, DOI 10.1128/JVI.65.4.1680-1686.1991; Wullaert A, 2006, BIOCHEM PHARMACOL, V72, P1090, DOI 10.1016/j.bcp.2006.07.003; Xia ZP, 2009, NATURE, V461, P114, DOI 10.1038/nature08247; Yamamoto M, 2006, NAT IMMUNOL, V7, P962, DOI 10.1038/ni1367	44	14	17	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2015	29	5					1879	1889		10.1096/fj.14-258715	http://dx.doi.org/10.1096/fj.14-258715			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZJ	25630972				2022-12-28	WOS:000354114600023
J	Henkels, KM; Mallets, ER; Dennis, PB; Gomez-Cambronero, J				Henkels, Karen M.; Mallets, Elizabeth R.; Dennis, Patrick B.; Gomez-Cambronero, Julian			S6K is a morphogenic protein with a mechanism involving Filamin-A phosphorylation and phosphatidic acid binding	FASEB JOURNAL			English	Article						cytoskeleton signaling; cell morphology; morphogenesis; breast cancer; cell invasion	ACTIN CYTOSKELETON; CELL-MIGRATION; IN-VITRO; KINASE; MTOR; SITE	Change of cell shape in vivo plays many roles that are central to life itself, such as embryonic development, inflammation, wound healing, and pathologic processes such as cancer metastasis. Nonetheless, the spatiotemporal mechanisms that control the concerted regulation of cell shape remain understudied. Here, we show that ribosomal S6K, which is normally considered a protein involved in protein translation, is a morphogenic protein. Its presence in cells alters the overall organization of the cell surface and cell circularity [(4 pi x area)/(perimeter)(2)] from 0.47 +/- 60.06 units in mock-treated cells to 0.09 +/- 6 0.03 units in S6K-overexpressing macrophages causing stellation and arborization of cell shape. This effect was partially reversed in cells expressing a kinase-inactive S6K mutant and was fully reversed in cells silenced with small interference RNA. Equally important is that S6K is itself regulated by phospholipids, specifically phosphatidic acid, whereby 300 nM 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), but not the control 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), binds directly to S6K and causes an similar to 2.9-fold increase in S6K catalytic activity. This was followed by an increase in Filamin A (FLNA) functionality as measured by phospho-FLNA (S-2152) expression and by a subsequent elevation of actin nucleation. This reliance of S6K on phosphatidic acid (PA), a curvature-inducing phospholipid, explained the extra-large perimeter of cells that overexpressed S6K. Furthermore, the diversity of the response to S6K in several unrelated cell types (fibroblasts, leukocytes, and invasive cancer cells) that we report here indicates the existence of an underlying common mechanism inmammalian cells. This new signaling set, PA-S6K-FLNA-actin, sheds light for the first time into the morphogenic pathway of cytoskeletal structures that are crucial for adhesion and cell locomotion during inflammation and metastasis.	[Henkels, Karen M.; Mallets, Elizabeth R.; Gomez-Cambronero, Julian] Wright State Univ, Boonshoft Sch Med, Dept Biochem & Mol Biol, Dayton, OH 45435 USA; [Dennis, Patrick B.] US Air Force, Res Lab, Mat & Mfg Directorate, Wright Patterson AFB, OH 45433 USA	Wright State University Dayton; United States Department of Defense; United States Air Force	Gomez-Cambronero, J (corresponding author), Wright State Univ, Boonshoft Sch Med, Dept Biochem & Mol Biol, 3640 Colonel Glenn Highway, Dayton, OH 45435 USA.	julian.cambronero@wright.edu			U.S. National Institutes of Health National Heart, Lung, and Blood Institute [HL056653-14]; American Heart Association [13GRNT17230097]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056653, R29HL056653] Funding Source: NIH RePORTER	U.S. National Institutes of Health National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors acknowledge Dr. Francisco Alvarez (Emory University) for helpful discussions on cell morphology and Marium Husain and Francis Speranza for technical contribution on the transfection efficiency/cell viability assay and actin polymerization and phagocytosis experiments, respectively. This work was supported by the U.S. National Institutes of Health National Heart, Lung, and Blood Institute Grant HL056653-14, and the American Heart Association Grant 13GRNT17230097.	Bedolla RG, 2009, CLIN CANCER RES, V15, P788, DOI 10.1158/1078-0432.CCR-08-1402; Bergert M, 2012, P NATL ACAD SCI USA, V109, P14434, DOI 10.1073/pnas.1207968109; Berven LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/j.yexer.2003.12.032; BUSSOLINO F, 1991, J CLIN INVEST, V87, P986, DOI 10.1172/JCI115107; Cretel E, 2008, CELL MOL BIOENG, V1, P5, DOI 10.1007/s12195-008-0009-7; Doolittle LK, 2013, METHODS MOL BIOL, V1046, P273, DOI 10.1007/978-1-62703-538-5_16; Dowler Simon, 2002, Sci STKE, V2002, ppl6, DOI 10.1126/stke.2002.129.pl6; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Frondorf K, 2010, J BIOL CHEM, V285, P15837, DOI 10.1074/jbc.M109.070524; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Ip CKM, 2011, ONCOGENE, V30, P2420, DOI 10.1038/onc.2010.615; Lee A, 2000, DEV DYNAM, V217, P257, DOI 10.1002/(SICI)1097-0177(200003)217:3<257::AID-DVDY4>3.0.CO;2-5; Lehman N, 2007, FASEB J, V21, P1075, DOI 10.1096/fj.06-6652com; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nakamura F, 2007, J CELL BIOL, V179, P1011, DOI 10.1083/jcb.200707073; PATA I, 1992, GENE, V121, P387, DOI 10.1016/0378-1119(92)90149-J; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Sato Makoto, 2005, Anatomical Science International, V80, P19; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Tweedy L, 2013, SCI REP-UK, V3, DOI 10.1038/srep02606; WANG E, 1979, J CELL BIOL, V83, P320, DOI 10.1083/jcb.83.2.320; Wessels D, 1998, CELL MOTIL CYTOSKEL, V41, P225, DOI 10.1002/(SICI)1097-0169(1998)41:3<225::AID-CM4>3.3.CO;2-9; Woo MS, 2004, MOL CELL BIOL, V24, P3025, DOI 10.1128/MCB.24.7.3025-3035.2004; Zhang CB, 2012, P NATL ACAD SCI USA, V109, P1667, DOI 10.1073/pnas.1110730109	26	6	6	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1299	1313		10.1096/fj.14-260992	http://dx.doi.org/10.1096/fj.14-260992			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25512366	Green Published			2022-12-28	WOS:000354115000018
J	Xu, LL; Huang, S; Hou, YH; Liu, Y; Ni, M; Meng, FB; Wang, KX; Rui, YF; Jiang, XH; Li, G				Xu, Liangliang; Huang, Shuo; Hou, Yonghui; Liu, Yang; Ni, Ming; Meng, Fanbiao; Wang, Kuixing; Rui, Yunfeng; Jiang, Xiaohua; Li, Gang			Sox11-modified mesenchymal stem cells (MSCs) accelerate bone fracture healing: Sox11 regulates differentiation and migration of MSCs	FASEB JOURNAL			English	Article						osteogenesis; chondrogenesis; BMP/Smad; fracture repair	REGENERATION; RECEPTOR; MARROW; TISSUE; CXCR4; GENE; CHEMOKINE; PROTEINS	Mesenchymal stem cells (MSCs) are a promising cell resource for tissue engineering. Sry-related high-mobility group box 11 (Sox11) plays critical roles in neural development and organogenesis. In the present study, we investigated the role of Sox11 in regulating trilineage differentiation (osteogenesis, adipogenesis, and chondrogenesis) and migration of MSCs, and explored the effect of systemically administrated Sox11-modified MSCs on bone fracture healing using the rat model of open femur fracture. Our results demonstrated that Sox11 overexpression increased the trilineage differentiation and migration of MSCs, as well as cell viability under oxidative stress. The effect of Sox11 on osteogenesis was confirmed by ectopic bone formation assay conducted in nude mice. In addition, we found that Sox11 could activate the bone morphogenetic protein (BMP)/Smad signaling pathway in MSCs. By dual-luciferase reporter assay, we also demonstrated that Sox11 could transcriptionally activate runt-related transcription factor 2 (Runx2) and CXC chemokine receptor-4 (CXCR4) expression. The activation of the BMP/Smad signaling pathway and Runx2, CXCR4 expression may have a synergic effect, which largely contributed to the effect of Sox11 on MSC fate determination and migration. Finally, using an open femur fracture model in rats, we found that a larger number of MSCs stably expressing Sox11 migrated to the fracture site and improved bone fracture healing. Taken together, our study shows that Sox11 is an important regulator of MSC differentiation and migration, and Sox11-modified MSCs may have clinical implication for accelerating bone fracture healing, which can reduce the delayed unions or nonunions.	[Xu, Liangliang; Huang, Shuo; Liu, Yang; Ni, Ming; Meng, Fanbiao; Wang, Kuixing; Rui, Yunfeng; Li, Gang] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Orthopaed & Traumatol, Shatin, Hong Kong, Peoples R China; [Xu, Liangliang; Hou, Yonghui] Chinese Univ Hong Kong, Prince Wales Hosp, Sch Biomed Sci, Stem Cell & Regenerat Theme, Shatin, Hong Kong, Peoples R China; [Xu, Liangliang; Hou, Yonghui] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Jiang, Xiaohua; Li, Gang] Chinese Univ Hong Kong, Sch Biomed Sci, Epithelial Cell Biol Res Ctr, Shatin, Hong Kong, Peoples R China; [Jiang, Xiaohua; Li, Gang] Chinese Univ Hong Kong, Sch Biomed Sci, MOE Key Lab Regenerat Med, Shatin, Hong Kong, Peoples R China; [Li, Gang] Chinese Univ Hong Kong, Shenzhen Res Inst, CUHK ACC Space Med Ctr Hlth Maintenance Musculosk, Shenzhen, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen	Li, G (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Room 904, Shatin, Hong Kong, Peoples R China.	gangli@cuhk.edu.hk	Liangliang, XU/K-9185-2019; jiang, cynthia xiaohua/F-7580-2017; H, Leo/AAK-9668-2020; Li, Gang/J-7830-2018	Liangliang, XU/0000-0002-5249-7480; jiang, cynthia xiaohua/0000-0002-7372-4961; H, Leo/0000-0001-9495-4339; Li, Gang/0000-0002-3981-2239	National Natural Science Foundation of China [81371946]; Hong Kong Government Research Grant Council; General Research Fund [CUHK471110, CUHK470813]; National Basic Science and Development Programme of People's Republic of China (973 Programme) [2012CB518105]; SMART program; Lui Che Woo Institute of Innovative Medicine; Faculty of Medicine; Chinese University of Hong Kong; Lui Che Woo Foundation Limited, Hong Kong	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hong Kong Government Research Grant Council; General Research Fund; National Basic Science and Development Programme of People's Republic of China (973 Programme); SMART program; Lui Che Woo Institute of Innovative Medicine; Faculty of Medicine; Chinese University of Hong Kong(Chinese University of Hong Kong); Lui Che Woo Foundation Limited, Hong Kong	The authors thank Dr. Jin Wang and Mr. Chiwai Man and Sien Lin for their technical support and advice. This work was supported by the National Natural Science Foundation of China (81371946), Hong Kong Government Research Grant Council, and General Research Fund (Grants CUHK471110 and CUHK470813 to G.L.). This study was also supported in part by the National Basic Science and Development Programme of People's Republic of China (973 Programme 2012CB518105), SMART program, Lui Che Woo Institute of Innovative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, and a donation from the Lui Che Woo Foundation Limited, Hong Kong. The authors declare no conflicts of interest.	Azuma T, 1999, DNA Res, V6, P357, DOI 10.1093/dnares/6.5.357; BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Cheng ZK, 2008, MOL THER, V16, P571, DOI 10.1038/sj.mt.6300374; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Granero-Molto F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103; Hao YJ, 2007, BONE, V41, P631, DOI 10.1016/j.bone.2007.06.006; He YX, 2012, OSTEOPOROSIS INT, V23, P377, DOI 10.1007/s00198-011-1812-x; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kubo H, 2009, GENES CELLS, V14, P407, DOI 10.1111/j.1365-2443.2009.01281.x; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kutner RH, 2009, NAT PROTOC, V4, P495, DOI 10.1038/nprot.2009.22; Li Y, 2007, BIOCHEM BIOPH RES CO, V356, P780, DOI 10.1016/j.bbrc.2007.03.049; Lin L, 2011, DEV DYNAM, V240, P52, DOI 10.1002/dvdy.22489; Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542; Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067; Nagasawa T, 2000, INT J HEMATOL, V72, P408; Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357; Shi HF, 2010, BONE, V46, P1299, DOI 10.1016/j.bone.2009.11.028; Shi MX, 2007, HAEMATOLOGICA, V92, P897, DOI 10.3324/haematol.10669; Sock E, 2004, MOL CELL BIOL, V24, P6635, DOI 10.1128/mcb.24.15.6635-6644.2004; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tagil M, 2010, BONE, V46, P852, DOI 10.1016/j.bone.2009.11.009; Tran D, 2000, DERMATOL SURG, V26, P197, DOI 10.1046/j.1524-4725.2000.09220.x; Tsai LK, 2010, NEUROPSYCHOPHARMACOL, V35, P2225, DOI 10.1038/npp.2010.97; Tse WT, 2000, BLOOD, V96, p241A; Victoria G, 2009, INDIAN J ORTHOP, V43, P117, DOI 10.4103/0019-5413.50844; Wu XW, 2007, ANN NY ACAD SCI, V1116, P29, DOI 10.1196/annals.1402.053; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Yoon BS, 2004, J CELL BIOCHEM, V93, P93, DOI 10.1002/jcb.20211	35	52	54	3	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29	4					1143	1152		10.1096/fj.14-254169	http://dx.doi.org/10.1096/fj.14-254169			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH5ZN	25466891				2022-12-28	WOS:000354115000004
J	Watanabe, S; Sato, K; Hasegawa, N; Kurihara, T; Matsutani, K; Sanada, K; Hamaoka, T; Fujita, S; Iemitsu, M				Watanabe, Shinya; Sato, Koji; Hasegawa, Natsuki; Kurihara, Toshiyuki; Matsutani, Kenji; Sanada, Kiyoshi; Hamaoka, Takafumi; Fujita, Satoshi; Iemitsu, Motoyuki			Serum C1q as a novel biomarker of sarcopenia in older adults	FASEB JOURNAL			English	Article						aging; fibrosis; skeletal muscle; resistance training	SKELETAL-MUSCLE; SATELLITE CELLS; EXERCISE; AGE; INFLAMMATION; EXPRESSION; RESPONSES; PATHWAY; FRAILTY; HEALTH	Aging-induced elevation in C1q secretion activates the Wnt signaling pathway in muscles, leading to the development of muscle fibrosis. However, the association between serum C1q level and muscle mass and strength remains unclear in humans. The aim of the study was to elucidate whether serum C1q level is associated with aging-and resistance training-induced changes in muscle mass and strength. First, in a cross-sectional study, we investigated the association between serum C1q level and muscle mass and strength in 131 healthy subjects, aged 20-81 yr. Second, in an intervention study, we examined the association between the effects of serum C1q level and muscle mass and strength on 12wk resistance training in 11 healthy older adults (60-81 yr). In the cross-sectional study, serum C1q level increased with aging and was negatively correlated with muscle mass and strength. Furthermore, 12 wk resistance training in older adults reduced the age-associated elevation in serum C1q levels. The training effect of serum C1q level significantly correlated with the change in the cross-sectional area of the thigh (r = -0.703; P < 0.01). Serum C1q level may reflect loss of muscle mass; therefore, C1q may be a novel biomarker of sarcopenia.	[Watanabe, Shinya; Sato, Koji; Hasegawa, Natsuki; Kurihara, Toshiyuki; Matsutani, Kenji; Sanada, Kiyoshi; Hamaoka, Takafumi; Fujita, Satoshi; Iemitsu, Motoyuki] Ritsumeikan Univ, Fac Sport & Hlth Sci, Kusatsu, Shiga 5258577, Japan	Ritsumeikan University	Iemitsu, M (corresponding author), Ritsumeikan Univ, Fac Sport & Hlth Sci, 1-1-1 Nojihigashi, Kusatsu, Shiga 5258577, Japan.	iemitsu@fc.ritsumei.ac.jp		Sanada, Kiyoshi/0000-0003-3703-4098; WATANABE, SHINYA/0000-0003-1369-9001	Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI) [26282199, 25560378, 22680050]; Grants-in-Aid for Scientific Research [25560378] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI #26282199 and #25560378 to M.I. and #22680050 to S.F.). The authors declare no conflicts of interest.	Adamo ML, 2006, AGEING RES REV, V5, P310, DOI 10.1016/j.arr.2006.05.001; Arnold AS, 2011, GERONTOLOGY, V57, P37, DOI 10.1159/000281883; Arthur ST, 2012, INT J BIOL SCI, V8, P731, DOI 10.7150/ijbs.4262; Bandeen-Roche K, 2006, J GERONTOL A-BIOL, V61, P262, DOI 10.1093/gerona/61.3.262; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; Caron AZ, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-185; Day K, 2010, DEV BIOL, V340, P330, DOI 10.1016/j.ydbio.2010.01.006; Ensrud KE, 2007, J GERONTOL A-BIOL, V62, P744, DOI 10.1093/gerona/62.7.744; Faulkner JA, 2007, CLIN EXP PHARMACOL P, V34, P1091, DOI 10.1111/j.1440-1681.2007.04752.x; Fujita S, 2009, DIABETOLOGIA, V52, P1889, DOI 10.1007/s00125-009-1430-8; Gasier HG, 2011, ACTA PHYSIOL, V201, P381, DOI 10.1111/j.1748-1716.2010.02183.x; Goodpaster BH, 2001, J APPL PHYSIOL, V90, P2157, DOI 10.1152/jappl.2001.90.6.2157; Haddad F, 2002, J APPL PHYSIOL, V93, P394, DOI 10.1152/japplphysiol.01153.2001; Kadi F, 2004, J PHYSIOL-LONDON, V558, P1005, DOI 10.1113/jphysiol.2004.065904; Legoedec J, 1997, MOL IMMUNOL, V34, P735, DOI 10.1016/S0161-5890(97)00093-X; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; Lynch GS, 2007, PHARMACOL THERAPEUT, V113, P461, DOI 10.1016/j.pharmthera.2006.11.004; Montero-Fernandez N, 2013, EUR J PHYS REHAB MED, V49, P131; Naito AT, 2012, CELL, V149, P1298, DOI 10.1016/j.cell.2012.03.047; Peake J, 2010, AM J PHYSIOL-REG I, V298, pR1485, DOI 10.1152/ajpregu.00467.2009; PETRY F, 1991, J IMMUNOL, V147, P3988; Ryall JG, 2008, BIOGERONTOLOGY, V9, P213, DOI 10.1007/s10522-008-9131-0; Sato K, 2008, AM J PHYSIOL-ENDOC M, V294, pE961, DOI 10.1152/ajpendo.00678.2007; Sato K, 2014, FASEB J, V28, P1891, DOI 10.1096/fj.13-245480; Schaap LA, 2009, J GERONTOL A-BIOL, V64, P1183, DOI 10.1093/gerona/glp097; Schrager MA, 2007, J APPL PHYSIOL, V102, P919, DOI 10.1152/japplphysiol.00627.2006; Sousa-Victor P, 2014, NATURE, V506, P316, DOI 10.1038/nature13013; TENNER AJ, 1986, BIOCHEM J, V233, P451, DOI 10.1042/bj2330451; Verdijk LB, 2014, AGE, V36, P545, DOI 10.1007/s11357-013-9583-2; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406	30	36	40	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2015	29	3					1003	1010		10.1096/fj.14-262154	http://dx.doi.org/10.1096/fj.14-262154			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CC8QK	25491308				2022-12-28	WOS:000350633000024
J	Sayedyahossein, S; Xu, SX; Rudkouskaya, A; McGavin, MJ; McCormick, JK; Dagnino, L				Sayedyahossein, Samar; Xu, Stacey X.; Rudkouskaya, Alena; McGavin, Martin J.; McCormick, John K.; Dagnino, Lina			Staphylococcus aureus keratinocyte invasion is mediated by integrin-linked kinase and Rac1	FASEB JOURNAL			English	Article						staphylococcal colonization; epidermis; bacterial invasion	HOST-PATHOGEN INTERACTIONS; RECEPTOR; REVEALS; SKIN; INTERNALIZATION; INACTIVATION; EXPRESSION; SECRETION; MIGRATION; PROTEINS	Staphylococcus aureus is a major component of the skinmicrobiota and causes a large number of serious infections. S. aureus first interacts with epidermal keratinocytes to breach the epidermal barrier through mechanisms not fully understood. By use of primary keratinocytes from mice with epidermis-restricted Ilk gene inactivation and control integrin-linked kinase (ILK)-expressing littermates, weinvestigated the role of ILKin epidermal S. aureus invasion. Heat-killed, but not live, bacteria were internalized to Rab5- and Rab7-positive phagosomes, and incubation with keratinocyte growth factor increased their uptake 2.5-fold. ILK-deficient mouse keratinocytes internalized bacteria 2- to 4-fold less efficiently than normal cells. The reduced invasion by live S. aureus of ILK-deficient cells was restored in the presence of exogenous, constitutively active Rac1. Thus, Rac1 functions downstream from ILK during invasion. Further, invasion by S. aureus of Rac1-deficient cells was 2.5-fold lower than in normal cells. Paradoxically, staphylococcal cutaneous penetration of mouse skin explants with ILK-deficient epidermis was 35-fold higher than that of normal skin, indicating defects in epidermal barrier function in the absence of ILK. Thus, we identified an ILK-Rac1 pathway essential for bacterial invasion of keratinocytes, and established ILK as a key contributor to prevent invasive staphylococcal cutaneous infection.-Sayedyahossein, S., Xu, S. X., Rudkouskaya, A., McGavin, M. J., McCormick, J. K., Dagnino, L. Staphylococcus aureus keratinocyte invasion is mediated by integrin-linked kinase and Rac1. FASEB J. 29, 711-723 (2015). www.fasebj.org	[Sayedyahossein, Samar; Rudkouskaya, Alena; Dagnino, Lina] Childrens Hlth Res Inst, Dept Physiol & Pharmacol, London, ON, Canada; [Sayedyahossein, Samar; Rudkouskaya, Alena; Dagnino, Lina] Lawson Hlth Res Inst, London, ON, Canada; [Xu, Stacey X.; McGavin, Martin J.; McCormick, John K.] Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Med Sci Bldg, London, ON N6A 5C1, Canada.	ldagnino@uwo.ca	McCormick, John/E-4232-2015	Sayedyahossein, Samar/0000-0003-1773-4740; McCormick, John/0000-0003-3742-7289; McGavin, Martin/0000-0001-5955-0689; Dagnino, Lina/0000-0003-1483-5159; Rudkouskaya, Alena/0000-0002-3632-9743	Canadian Institutes of Health Research; Child Health Research Institute Quality of Life Programme	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Child Health Research Institute Quality of Life Programme	The authors thank Drs. R. Kothary and M. Glogauer for their gift of Ilk<SUP>f/f</SUP>; mT/mG and Rac<SUP>f/f</SUP> mice, respectively. They also thank Dr. R. Lodge for vectors encoding GFP-labeled Rab proteins. This work was funded by grants from the Canadian Institutes of Health Research (to L.D.). S.S. was supported with funds from the Child Health Research Institute Quality of Life Programme.	Adhikary G, 2008, J LEUKOCYTE BIOL, V83, P991, DOI 10.1189/jlb.1107783; Agerer F, 2005, J CELL SCI, V118, P2189, DOI 10.1242/jcs.02328; Akhtar N, 2013, NAT CELL BIOL, V15, P17, DOI 10.1038/ncb2646; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Aufiero B, 2007, INT J DERMATOL, V46, P687, DOI 10.1111/j.1365-4632.2007.03161.x; Borisova M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-2; Carabeo R, 2011, CELL MICROBIOL, V13, P1460, DOI 10.1111/j.1462-5822.2011.01651.x; Charpentier E, 2004, APPL ENVIRON MICROB, V70, P6076, DOI 10.1128/AEM.70.10.6076-6085.2004; Dagnino L, 2011, J CELL COMMUN SIGNAL, V5, P81, DOI 10.1007/s12079-011-0124-4; Dagnino L, 2010, METHODS MOL BIOL, V585, P93, DOI 10.1007/978-1-60761-380-0_8; Das S, 2011, P NATL ACAD SCI USA, V108, P2136, DOI 10.1073/pnas.1014775108; Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7; Edwards AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018899; Fang L, 2014, CELL SIGNAL, V26, P806, DOI 10.1016/j.cellsig.2013.12.016; Foster TJ, 2014, NAT REV MICROBIOL, V12, P49, DOI 10.1038/nrmicro3161; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Ho E, 2012, CELL ADHES MIGR, V6, P168, DOI 10.4161/cam.20399; Ho E, 2012, MOL BIOL CELL, V23, P492, DOI 10.1091/mbc.E11-07-0596; Ho E, 2009, MOL BIOL CELL, V20, P3033, DOI 10.1091/mbc.E09-01-0050; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Ivanova IA, 2009, ONCOGENE, V28, P52, DOI 10.1038/onc.2008.354; Kintarak S, 2004, INFECT IMMUN, V72, P5668, DOI 10.1128/IAI.72.10.5668-5675.2004; Kirschner N, 2012, ANN NY ACAD SCI, V1257, P158, DOI 10.1111/j.1749-6632.2012.06554.x; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; Krishna S, 2012, CURR OPIN MICROBIOL, V15, P28, DOI 10.1016/j.mib.2011.11.003; Lin YT, 2007, CLIN REV ALLERG IMMU, V33, P167, DOI 10.1007/s12016-007-0044-5; Loffler B, 2014, INT J MED MICROBIOL, V304, P170, DOI 10.1016/j.ijmm.2013.11.011; Lorenz K, 2007, J CELL BIOL, V177, P501, DOI 10.1083/jcb.200608125; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Nakrieko KA, 2008, MOL BIOL CELL, V19, P1462, DOI 10.1091/mbc.E07-06-0526; Nakrieko Kerry-Ann, 2013, Methods Mol Biol, V989, P21, DOI 10.1007/978-1-62703-330-5_3; Nakrieko KA, 2011, MOL BIOL CELL, V22, P2532, DOI 10.1091/mbc.E11-01-0035; Niebuhr M, 2010, EXP DERMATOL, V19, P873, DOI 10.1111/j.1600-0625.2010.01140.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; O'Meara RW, 2013, J NEUROSCI, V33, P9781, DOI 10.1523/JNEUROSCI.5582-12.2013; Rudkouskaya A, 2014, MOL BIOL CELL, V25, P620, DOI 10.1091/mbc.E13-08-0499; Sayedyahossein S, 2013, INT REV CEL MOL BIO, V302, P321, DOI 10.1016/B978-0-12-407699-0.00006-6; Sayedyahossein S, 2012, FASEB J, V26, P4218, DOI 10.1096/fj.12-207852; Stefani S, 2012, INT J ANTIMICROB AG, V39, P273, DOI 10.1016/j.ijantimicag.2011.09.030; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Tzircotis G, 2011, J CELL SCI, V124, P2897, DOI 10.1242/jcs.084269; Utaida S, 2003, MICROBIOL-SGM, V149, P2719, DOI 10.1099/mic.0.26426-0; van der Kooi-Pol MM, 2014, INT J MED MICROBIOL, V304, P195, DOI 10.1016/j.ijmm.2013.11.012; Vespa A, 2005, MOL BIOL CELL, V16, P4084, DOI 10.1091/mbc.e05-02-0087; Wu XF, 2014, CURR OPIN CELL BIOL, V29, P1, DOI 10.1016/j.ceb.2014.02.003; Zecconi A, 2013, IMMUNOL LETT, V150, P12, DOI 10.1016/j.imlet.2013.01.004	48	26	26	3	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2015	29	2					711	723		10.1096/fj.14-262774	http://dx.doi.org/10.1096/fj.14-262774			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CB1ET	25416549				2022-12-28	WOS:000349370400031
J	Clark, AA; Dotson, CD; Elson, AET; Voigt, A; Boehm, U; Meyerhof, W; Steinle, NI; Munger, SD				Clark, Adam A.; Dotson, Cedrick D.; Elson, Amanda E. T.; Voigt, Anja; Boehm, Ulrich; Meyerhof, Wolfgang; Steinle, Nanette I.; Munger, Steven D.			TAS2R bitter taste receptors regulate thyroid function	FASEB JOURNAL			English	Article						G protein-coupled receptor; iodide; thyroxine; thyrocyte; T2R	OLD ORDER AMISH; IODIDE EFFLUX; ALCOHOL-CONSUMPTION; CHEMOSENSORY CELLS; EATING BEHAVIOR; GENE TAS2R38; FAMILY; PHENYLTHIOCARBAMIDE; SENSITIVITY; EXPRESSION	Dysregulation of thyroid hormones triiodothyronine and thyroxine (T3/T4) can impact metabolism, body composition, and development. Thus, it is critical to identify novel mechanisms that impact T3/T4 production. We found that type 2 taste receptors (TAS2Rs), which are activated by bitter-tasting compounds such as those found in many foods and pharmaceuticals, negatively regulate thyroid-stimulating hormone (TSH)-dependent Ca2+ increases and TSH-dependent iodide efflux in thyrocytes. Immunohistochemical Tas2r-dependent reporter expression and real-time PCR analyses reveal that human and mouse thyrocytes and the Nthy-Ori 3-1 human thyrocyte line express several TAS2Rs. Five different agonists for thyrocyte-expressed TAS2Rs reduced TSH-dependent Ca2+ release in Nthy-Ori 3-1 cells, but not basal Ca2+ levels, in a dose-dependent manner. Ca2+ responses were unaffected by 6-n-propylthiouracil, consistent with the expression of an unresponsive variant of its cognate receptor, TAS2R38, in these cells. TAS2R agonists also inhibited basal and TSH-dependent iodide efflux. Furthermore, a common TAS2R42 polymorphism is associated with increased serum T4 levels in a human cohort. Our findings indicate that TAS2Rs couple the detection of bitter-tasting compounds to changes in thyrocyte function and T3/T4 production. Thus, TAS2Rs may mediate a protective response to overingestion of toxic materials and could serve as new druggable targets for therapeutic treatment of hypo-or hyperthyroidism.	[Clark, Adam A.; Dotson, Cedrick D.; Elson, Amanda E. T.; Munger, Steven D.] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; [Clark, Adam A.; Munger, Steven D.] Univ Maryland, Sch Med, Toxicol Program, Baltimore, MD 21201 USA; [Elson, Amanda E. T.; Munger, Steven D.] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA; [Steinle, Nanette I.; Munger, Steven D.] Univ Maryland, Sch Med, Dept Med, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA; [Voigt, Anja; Meyerhof, Wolfgang] German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Genet, Nuthetal, Germany; [Boehm, Ulrich] Univ Saarland, Sch Med, Dept Pharmacol & Toxicol, Homburg, Germany	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Saarland University	Munger, SD (corresponding author), Univ Florida, Coll Med, Dept Pharmacol & Therapeut, 1200 Newell Dr,ARB 5-204,POB 100267, Gainesville, FL 32610 USA.	steven.munger@ufl.edu		Dotson, Cedrick/0000-0003-0992-1191; Elson, Amanda/0000-0002-5744-5954	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010110] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC010110] Funding Source: Medline; NIDDK NIH HHS [P30 DK072488] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; Allen AL, 2013, CHEM SENSES, V38, P379, DOI 10.1093/chemse/bjt017; Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Behrens M, 2007, J NEUROSCI, V27, P12630, DOI 10.1523/JNEUROSCI.1168-07.2007; Behrens M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040304; Behrens M, 2011, PHYSIOL BEHAV, V105, P4, DOI 10.1016/j.physbeh.2011.02.010; Bufe B, 2005, CURR BIOL, V15, P322, DOI 10.1016/j.cub.2005.01.047; Campa D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045232; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Clark AA, 2012, FASEB J, V26, P4827, DOI 10.1096/fj.12-215087; Congreve M, 2011, J MED CHEM, V54, P4283, DOI 10.1021/jm200371q; Conneely KN, 2007, AM J HUM GENET, V81, P1158, DOI 10.1086/522036; CORDA D, 1985, J BIOL CHEM, V260, P9230; Crofton KM, 2008, INT J ANDROL, V31, P209, DOI 10.1111/j.1365-2605.2007.00857.x; Deshpande DA, 2010, NAT MED, V16, P1299, DOI 10.1038/nm.2237; Dotson CD, 2012, CHEM SENSES, V37, P737, DOI 10.1093/chemse/bjs063; Dotson CD, 2010, APPETITE, V54, P93, DOI 10.1016/j.appet.2009.09.011; Dotson CD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003974; Duffy VB, 2004, ALCOHOL CLIN EXP RES, V28, P1629, DOI 10.1097/01.ALC.0000145789.55183.D4; Dumont J., 2011, ONTOGENY ANATOMY MET; Fong PY, 2011, J PHYSIOL-LONDON, V589, P5929, DOI 10.1113/jphysiol.2011.218594; Foster SR, 2014, FASEB J, V28, P4497, DOI 10.1096/fj.14-256305; Foster SR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064579; Franklyn JA, 2012, LANCET, V379, P1155, DOI 10.1016/S0140-6736(11)60782-4; Hayes JE, 2011, CHEM SENSES, V36, P311, DOI 10.1093/chemse/bjq132; Hinrichs AL, 2006, AM J HUM GENET, V78, P103, DOI 10.1086/499253; Hsueh WC, 2000, DIABETES CARE, V23, P595, DOI 10.2337/diacare.23.5.595; Jang HJ, 2007, P NATL ACAD SCI USA, V104, P15069, DOI 10.1073/pnas.0706890104; Jeon TI, 2008, J CLIN INVEST, V118, P3693, DOI 10.1172/JCI36461; Jeon TI, 2011, BIOCHEM J, V438, P33, DOI 10.1042/BJ20110009; Kim U, 2005, HUM MUTAT, V26, P199, DOI 10.1002/humu.20203; Kim UK, 2003, SCIENCE, V299, P1221, DOI 10.1126/science.1080190; Lee RJ, 2014, J CLIN INVEST, V124, P1393, DOI 10.1172/JCI72094; Lee RJ, 2012, J CLIN INVEST, V122, P4145, DOI 10.1172/JCI64240; Levit A, 2014, FASEB J, V28, P1181, DOI 10.1096/fj.13-242594; Matsunami H, 2000, NATURE, V404, P601, DOI 10.1038/35007072; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; Meyerhof W, 2010, CHEM SENSES, V35, P157, DOI 10.1093/chemse/bjp092; Mueller KL, 2005, NATURE, V434, P225, DOI 10.1038/nature03352; NAGASAKA A, 1976, J CLIN ENDOCR METAB, V43, P152, DOI 10.1210/jcem-43-1-152; Pfaffl MW., 2006, REAL TIME PCR, P63; Powell JG, 2004, ONCOGENE, V23, P3634, DOI 10.1038/sj.onc.1207399; Prandi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082820; Pronin AN, 2007, CURR BIOL, V17, P1403, DOI 10.1016/j.cub.2007.07.046; RASPE E, 1994, ENDOCRINOLOGY, V135, P986, DOI 10.1210/en.135.3.986; Robinett KS, 2011, AM J RESP CELL MOL, V45, P1069, DOI 10.1165/rcmb.2011-0061OC; Shah AS, 2009, SCIENCE, V325, P1131, DOI 10.1126/science.1173869; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Soranzo N, 2005, CURR BIOL, V15, P1257, DOI 10.1016/j.cub.2005.06.042; Timpson NJ, 2005, AM J CLIN NUTR, V81, P1005; Tizzano M, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-3; Tizzano M, 2010, P NATL ACAD SCI USA, V107, P3210, DOI 10.1073/pnas.0911934107; Wang JC, 2007, ALCOHOL CLIN EXP RES, V31, P209, DOI 10.1111/j.1530-0277.2006.00297.x; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1108, DOI 10.1210/endo-114-4-1108; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1090, DOI 10.1210/endo-114-4-1090; Wu SV, 2002, P NATL ACAD SCI USA, V99, P2392, DOI 10.1073/pnas.042617699; Xu J, 2013, MOL HUM REPROD, V19, P17, DOI 10.1093/molehr/gas040; Yang RB, 2007, J COMP NEUROL, V502, P883, DOI 10.1002/cne.21317	59	90	91	1	74	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2015	29	1					164	172		10.1096/fj.14-262246	http://dx.doi.org/10.1096/fj.14-262246			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AY1UX	25342133	Green Published			2022-12-28	WOS:000347378600016
J	Wall, EH; Hewitt, SC; Case, LK; Lin, CY; Korach, KS; Teuscher, C				Wall, Emma H.; Hewitt, Sylvia C.; Case, Laure K.; Lin, Chin-Yo; Korach, Kenneth S.; Teuscher, Cory			The role of genetics in estrogen responses: a critical piece of an intricate puzzle	FASEB JOURNAL			English	Review						genotype; reproductive tissue	QUANTITATIVE TRAIT LOCI; MOUSE MAMMARY-GLAND; RECEPTOR-ALPHA; OPPOSITE-SEX; IN-VIVO; TRANSCRIPTION FACTORS; STRAIN DIFFERENCES; NUCLEAR RECEPTOR; ADULT TWINS; RUNX FAMILY	The estrogens are female sex hormones that are involved in a variety of physiological processes, including reproductive development and function, wound healing, and bone growth. They are mainly known for their roles in reproductive tissues-specifically, 17 beta-estradiol (E-2), the primary estrogen, which is secreted by the ovaries and induces cellular proliferation and growth of the uterus and mammary glands. In addition to the role of estrogens in promoting tissue growth and development during normal physiological states, they have a well-established role in determining susceptibility to disease, particularly cancer, in reproductive tissues. The responsiveness of various tissues to estrogen is genetically controlled, with marked quantitative variation observed across multiple species, including humans. This variation presents both researchers and clinicians with a veritable physiological puzzle, the pieces of which-many of them unknown-are complex and difficult to fit together. Although genetics is known to play a major role in determining sensitivity to estrogens, there are other factors, including parent of origin and the maternal environment, that are intimately linked to heritable phenotypes but do not represent genotype, per se. The objectives of this review article were to summarize the current knowledge of the role of genotype, and uterine and neonatal environments, in phenotypic variation in the response to estrogens; to discuss recent findings and the potential mechanisms involved; and to highlight exciting research opportunities for the future.	[Wall, Emma H.; Case, Laure K.; Teuscher, Cory] Univ Vermont, Dept Med & Pathol, Burlington, VT 05405 USA; [Hewitt, Sylvia C.; Korach, Kenneth S.] US Natl Inst Hlth, Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA; [Lin, Chin-Yo] Univ Houston, Ctr Nucl Receptors & Cell Signaling, Houston, TX USA	University of Vermont; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Houston System; University of Houston	Teuscher, C (corresponding author), Univ Vermont, C331 Given Med Bldg, Burlington, VT 05405 USA.	c.teuscher@uvm.edu	Hewitt, Sylvia/W-8752-2019	Hewitt, Sylvia/0000-0001-7713-0805; Korach, Kenneth/0000-0002-7765-418X	Intramural Research Program of the U.S. National Institutes of Health, National Institute of Environmental Health Sciences grant [Z01ES70065]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES070065, ZIAES070065] Funding Source: NIH RePORTER	Intramural Research Program of the U.S. National Institutes of Health, National Institute of Environmental Health Sciences grant; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This research was supported, in part, by the Intramural Research Program of the U.S. National Institutes of Health, National Institute of Environmental Health Sciences grant Z01ES70065.	Aagaard MM, 2011, BBA-MOL BASIS DIS, V1812, P824, DOI 10.1016/j.bbadis.2010.12.018; Abiola O, 2003, NAT REV GENET, V4, P911, DOI 10.1038/nrg1206; Abot A, 2013, ENDOCRINOLOGY, V154, P2222, DOI 10.1210/en.2012-2059; Adlanmerini M, 2014, P NATL ACAD SCI USA, V111, pE283, DOI 10.1073/pnas.1322057111; Ahlbory-Dieker DL, 2009, MOL ENDOCRINOL, V23, P1544, DOI 10.1210/me.2009-0045; Altmae S, 2011, HUM REPROD UPDATE, V17, P813, DOI 10.1093/humupd/dmr034; Arao Y, 2011, P NATL ACAD SCI USA, V108, P14986, DOI 10.1073/pnas.1109180108; Aupperlee MD, 2009, ENDOCRINOLOGY, V150, P1485, DOI 10.1210/en.2008-1459; Bartol FF, 2013, J ANIM SCI, V91, P696, DOI 10.2527/jas.2012-5764; Bartol FF, 2012, MOL CELL ENDOCRINOL, V354, P16, DOI 10.1016/j.mce.2011.10.008; Bartol FF, 2009, ANN NY ACAD SCI, V1160, P158, DOI 10.1111/j.1749-6632.2008.03820.x; Beck-Peccoz P, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-9; Biddie SC, 2014, MOL ENDOCRINOL, V28, P3, DOI 10.1210/me.2013-1247; BLAIR SM, 1957, ENDOCRINOLOGY, V61, P643, DOI 10.1210/endo-61-6-643; Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307; Bulynko YA, 2011, BIOCHEMISTRY-US, V50, P313, DOI 10.1021/bi101762x; Cameron NM, 2008, J NEUROENDOCRINOL, V20, P795, DOI 10.1111/j.1365-2826.2008.01725.x; Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334; Case LK, 2010, CELL IMMUNOL, V260, P119, DOI 10.1016/j.cellimm.2009.10.002; Cerhan JR, 2000, J NATL CANCER I, V92, P261, DOI 10.1093/jnci/92.3.261; Chadwick CC, 2005, P NATL ACAD SCI USA, V102, P2543, DOI 10.1073/pnas.0405841102; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; CLARINGBOLD PJ, 1955, J ENDOCRINOL, V12, P9, DOI 10.1677/joe.0.0120009; Clark James H., 1994, P1011; Cohen-Bendahan CCC, 2005, HORM BEHAV, V47, P230, DOI 10.1016/j.yhbeh.2004.10.006; Costa RA, 2009, BRAZ J MED BIOL RES, V42, P1143, DOI 10.1590/S0100-879X2009005000042; Davis RC, 2012, PHYSIOL GENOMICS, V44, P1, DOI 10.1152/physiolgenomics.00003.2011; Dekkers JCM, 2002, NAT REV GENET, V3, P22, DOI 10.1038/nrg701; Doll A, 2009, INT J CANCER, V125, P257, DOI 10.1002/ijc.24330; Drasher ML, 1952, J HERED, V46, P190; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; EVEN MD, 1992, J REPROD FERTIL, V96, P709, DOI 10.1530/jrf.0.0960709; Fu XY, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2849; GANDELMAN R, 1977, NATURE, V266, P722, DOI 10.1038/266722a0; Gao H, 2011, MOL CELL ENDOCRINOL, V334, P83, DOI 10.1016/j.mce.2010.09.002; GARDNER W. U., 1935, American Journal of Cancer, V25, P282; Gibson DA, 2012, MOL CELL ENDOCRINOL, V348, P361, DOI 10.1016/j.mce.2011.09.026; Girard GM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1660; Gould KA, 2005, MAMM GENOME, V16, P854, DOI 10.1007/s00335-005-0070-7; Griffith JS, 1997, AM J PATHOL, V150, P2223; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Helsen C, 2012, MOL CELL ENDOCRINOL, V348, P411, DOI 10.1016/j.mce.2011.07.025; Hewitt SC, 2003, MOL ENDOCRINOL, V17, P2070, DOI 10.1210/me.2003-0146; Hewitt SC, 2014, MOL ENDOCRINOL, V28, P899, DOI 10.1210/me.2014-1051; Hewitt SC, 2012, MOL ENDOCRINOL, V26, P887, DOI 10.1210/me.2011-1311; Hewitt SC, 2009, MOL ENDOCRINOL, V23, P2111, DOI 10.1210/me.2009-0356; Hovey RC, 2004, ADV EXP MED BIOL, V554, P219; Hurd PL, 2008, ARCH SEX BEHAV, V37, P9, DOI 10.1007/s10508-007-9259-z; Ip S, 2009, BREASTFEED MED, V4, pS17, DOI 10.1089/bfm.2009.0050; Ip Stanley, 2007, Evid Rep Technol Assess (Full Rep), P1; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Jakacka M, 2002, MOL ENDOCRINOL, V16, P2188, DOI 10.1210/me.2001-0174; Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751; Johnson AB, 2012, MOL CELL ENDOCRINOL, V348, P430, DOI 10.1016/j.mce.2011.04.021; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; KINSLEY CH, 1986, PHYSIOL BEHAV, V36, P793, DOI 10.1016/0031-9384(86)90434-8; Krausz C, 2007, ARCH ANDROLOGY, V53, P125, DOI 10.1080/01485010701271786; Krementsov DN, 2013, TOXICOL SCI, V135, P91, DOI 10.1093/toxsci/kft141; Kumar Raj, 2011, J Amino Acids, V2011, P812540, DOI 10.4061/2011/812540; Kumar R, 2012, ENDOCR REV, V33, P271, DOI 10.1210/er.2011-1033; Kurz SG, 2008, ENDOCRINOLOGY, V149, P3850, DOI 10.1210/en.2008-0173; LEE AE, 1983, J NATL CANCER I, V71, P1265; LEITER EH, 1989, FASEB J, V3, P2231, DOI 10.1096/fasebj.3.11.2673897; Levin ER, 2008, BREAST CANCER RES TR, V108, P351, DOI 10.1007/s10549-007-9618-4; Li CY, 2005, J BONE MINER RES, V20, P2150, DOI 10.1359/JBMR.050819; Li SF, 2003, ANN NY ACAD SCI, V983, P161, DOI 10.1111/j.1749-6632.2003.tb05971.x; Li Y, 2014, ENVIRON HEALTH PERSP, V122, P262, DOI 10.1289/ehp.1307351; Lille FR, 1916, SCIENCE, V43, P611, DOI 10.1126/science.43.1113.611; Loehlin JC, 2000, BEHAV GENET, V30, P19, DOI 10.1023/A:1002082325784; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; Loutradis D, 2012, CURR PHARM BIOTECHNO, V13, P417, DOI 10.2174/138920112799361954; Manigrasso MB, 2008, CALCIFIED TISSUE INT, V82, P465, DOI 10.1007/s00223-008-9144-3; Mather K, 1943, BIOL REV CAMB PHILOS, V18, P32, DOI 10.1111/j.1469-185X.1943.tb00287.x; Matsuda KI, 2012, REV ENDOCR METAB DIS, V13, P163, DOI 10.1007/s11154-012-9202-z; Mauvais-Jarvis F, 2011, TRENDS ENDOCRIN MET, V22, P24, DOI 10.1016/j.tem.2010.10.002; McBryan J, 2008, J MAMMARY GLAND BIOL, V13, P159, DOI 10.1007/s10911-008-9075-7; McDevitta MA, 2008, MOL CELL ENDOCRINOL, V290, P24, DOI 10.1016/j.mce.2008.04.003; Miller DJ, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.105056; MIXNER JP, 1957, P SOC EXP BIOL MED, V95, P87, DOI 10.3181/00379727-95-23129; Moon HJ, 2009, ARCH TOXICOL, V83, P601, DOI 10.1007/s00204-008-0400-0; NAGAI JIRO, 1957, ENDOCRINOL JAPON, V4, P12; Nakai M, 1999, J ANDROL, V20, P626; Naylor MJ, 2002, DEV DYNAM, V225, P100, DOI 10.1002/dvdy.10133; NONNEMAN DJ, 1992, BIOL REPROD, V47, P723, DOI 10.1095/biolreprod47.5.723; O'Malley BW, 2012, MOL ENDOCRINOL, V26, P1646, DOI 10.1210/me.2012-1114; Padula AM, 2005, ANIM REPROD SCI, V87, P93, DOI 10.1016/j.anireprosci.2004.09.008; Peacock M, 2002, ENDOCR REV, V23, P303, DOI 10.1210/er.23.3.303; Pedram A, 2014, DEV CELL, V29, P482, DOI 10.1016/j.devcel.2014.04.016; Peper JS, 2009, EUR J ENDOCRINOL, V160, P739, DOI 10.1530/EJE-08-0915; Perez MC, 1996, BIOL REPROD, V54, P249, DOI 10.1095/biolreprod54.1.249; Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369; Planaguma J, 2005, J PATHOL, V207, P422, DOI 10.1002/path.1853; Pollard JW, 2001, BREAST CANCER RES, V3, P230, DOI 10.1186/bcr301; Rajnoch C, 2003, DEV DYNAM, V226, P388, DOI 10.1002/dvdy.10242; Richards JB, 2012, NAT REV GENET, V13, P576, DOI 10.1038/nrg3228; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279; Roper RJ, 1999, ENDOCRINOLOGY, V140, P556, DOI 10.1210/en.140.2.556; Rota A, 2002, GEN COMP ENDOCR, V129, P39, DOI 10.1016/S0016-6480(02)00514-2; Ryan BC, 2002, NEUROSCI BIOBEHAV R, V26, P665, DOI 10.1016/S0149-7634(02)00038-6; SAAL FSV, 1980, SCIENCE, V208, P597, DOI 10.1126/science.7367881; SAAL FSV, 1985, BIOL REPROD, V32, P1116, DOI 10.1095/biolreprod32.5.1116; Schaffer BS, 2006, CANCER RES, V66, P7793, DOI 10.1158/0008-5472.CAN-06-0143; SHIMKIN MB, 1946, J NATL CANCER I, V7, P71; SHIMKIN MICHAEL B., 1941, JOUR NATION CANCER INST, V1, P599; Shull JD, 2007, MAMM GENOME, V18, P657, DOI 10.1007/s00335-007-9052-2; SILBERBERG M, 1951, P SOC EXP BIOL MED, V76, P161, DOI 10.3181/00379727-76-18423; Simpson E R, 2006, Ernst Schering Found Symp Proc, P45; SINGH DV, 1970, J NATL CANCER I, V45, P657; Smits BMG, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003549; Smits BMG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2933; Spearow JL, 1999, SCIENCE, V285, P1259, DOI 10.1126/science.285.5431.1259; Spearow JL, 2001, APMIS, V109, P356, DOI 10.1034/j.1600-0463.2001.090504.x; Stender JD, 2010, MOL CELL BIOL, V30, P3943, DOI 10.1128/MCB.00118-10; Swerdlow AJ, 1997, LANCET, V350, P1723, DOI 10.1016/S0140-6736(97)05526-8; TANKSLEY SD, 1993, ANNU REV GENET, V27, P205, DOI 10.1146/annurev.ge.27.120193.001225; Thornton MJ, 2013, DERM-ENDOCRINOL, V5, P264, DOI 10.4161/derm.23872; Timms BG, 1999, J UROLOGY, V161, P1694, DOI 10.1016/S0022-5347(05)69007-6; TRENTIN JJ, 1950, CANCER RES, V10, P580; van Anders SM, 2006, HORM BEHAV, V49, P315, DOI 10.1016/j.yhbeh.2005.08.003; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; vomSaal FS, 1997, P NATL ACAD SCI USA, V94, P2056; VOMSAAL FS, 1990, BIOL REPROD, V43, P751, DOI 10.1095/biolreprod43.5.751; Wall EH, 2014, ENDOCRINOLOGY, V155, P3025, DOI 10.1210/en.2013-1910; Wall EH, 2013, FASEB J, V27, P1874, DOI 10.1096/fj.12-213462; Washburn LR, 2007, J AUTOIMMUN, V28, P19, DOI 10.1016/j.jaut.2006.11.006; Watson CJ, 2008, SEMIN CELL DEV BIOL, V19, P401, DOI 10.1016/j.semcdb.2008.07.021; Welboren WJ, 2007, MOL ONCOL, V1, P138, DOI 10.1016/j.molonc.2007.04.001; Wend Korinna, 2012, Front Endocrinol (Lausanne), V3, P19, DOI 10.3389/fendo.2012.00019; WHITTEN PL, 1995, P SOC EXP BIOL MED, V208, P82; Wilson ME, 2011, HORM BEHAV, V59, P353, DOI 10.1016/j.yhbeh.2010.08.004; Winuthayanon W, 2010, P NATL ACAD SCI USA, V107, P19272, DOI 10.1073/pnas.1013226107; Xu J., 1998, SCIENCE, V279, P1922; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Yant J, 1998, BREAST, V7, P269, DOI 10.1016/S0960-9776(98)90094-7; Yu B, 2010, BIOMED ENVIRON SCI, V23, P357, DOI 10.1016/S0895-3988(10)60076-1; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111	137	19	20	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5042	5054		10.1096/fj.14-260307	http://dx.doi.org/10.1096/fj.14-260307			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	25212221	Green Published			2022-12-28	WOS:000345894500003
J	Hasbi, A; Perreault, ML; Shen, MYF; Zhang, L; To, R; Fan, T; Nguyen, T; Ji, XD; O'Dowd, BF; George, SR				Hasbi, Ahmed; Perreault, Melissa L.; Shen, Maurice Y. F.; Zhang, Lucia; To, Ryan; Fan, Theresa; Tuan Nguyen; Ji, Xiaodong; O'Dowd, Brian F.; George, Susan R.			A peptide targeting an interaction interface disrupts the dopamine D1-D2 receptor heteromer to block signaling and function in vitro and in vivo: effective selective antagonism	FASEB JOURNAL			English	Article						GPCR oligomerization; heterooligomer; depression; behavioral despair	MEDIATED CALCIUM SIGNAL; D2 RECEPTOR; ELECTROSTATIC INTERACTIONS; D-1; D1; OLIGOMERIZATION; PHARMACOLOGY; ACTIVATION; OCCUPANCY; COMPLEXES	Although the dopamine D1-D2 receptor heteromer has emerging physiological relevance and a postulated role in different neuropsychiatric disorders, such as drug addiction, depression, and schizophrenia, there is a need for pharmacological tools that selectively target such receptor complexes in order to analyze their biological and pathophysiological functions. Since no selective antagonists for the D1-D2 heteromer are available, serial deletions and point mutations were used to precisely identify the amino acids involved in an interaction interface between the receptors, residing within the carboxyl tail of the D1 receptor that interacted with the D2 receptor to form the D1-D2 receptor heteromer. It was determined that D1 receptor carboxyl tail residues (404)Glu and (405)Glu were critical in mediating the interaction with the D2 receptor. Isolated mutation of these residues in the D1 receptor resulted in the loss of agonist activation of the calcium signaling pathway mediated through the D1-D2 receptor heteromer. The physical interaction between the D1 and D2 receptor could be disrupted, as shown by coimmunoprecipitation and BRET analysis, by a small peptide generated from the D1 receptor sequence that contained these amino acids, leading to a switch in G-protein affinities and loss of calcium signaling, resulting in the inhibition of D1-D2 heteromer function. The use of the D1-D2 heteromer-disrupting peptide in vivo revealed a pathophysiological role for the D1-D2 heteromer in the modulation of behavioral despair. This peptide may represent a novel pharmacological tool with potential therapeutic benefits in depression treatment.Hasbi, A., Perreault, M. L., Shen, M. Y. F., Zhang, L., To, R., Fan, T., Nguyen, T., Ji, X., O'Dowd, B. F., George, S. R. A peptide targeting an interaction interface disrupts the dopamine D1-D2 receptor heteromer to block signaling and function in vitro and in vivo: effective selective antagonism.	[Hasbi, Ahmed; Perreault, Melissa L.; Shen, Maurice Y. F.; Fan, Theresa; Tuan Nguyen; O'Dowd, Brian F.; George, Susan R.] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada; [Hasbi, Ahmed; Perreault, Melissa L.; Shen, Maurice Y. F.; Zhang, Lucia; To, Ryan; Fan, Theresa; Tuan Nguyen; Ji, Xiaodong; O'Dowd, Brian F.; George, Susan R.] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada; [George, Susan R.] Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto	George, SR (corresponding author), Univ Toronto, Dept Pharmacol & Toxicol, Med Sci Bldg,1 Kings Coll Cir, Toronto, ON M5S 1A8, Canada.	s.george@utoronto.ca	George, Susan R/P-9669-2018; George, Susan/W-7494-2019; Perreault, Melissa L/N-2867-2017	Perreault, Melissa L/0000-0002-5775-8950	U.S. National Institutes of Health, National Institute on Drug Abuse [DA007223]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007223] Funding Source: NIH RePORTER	U.S. National Institutes of Health, National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by a grant from the U.S. National Institutes of Health, National Institute on Drug Abuse (DA007223). S.R.G. is the holder of a Tier 1 Canada Research Chair in Molecular Neuroscience. The authors declare no conflicts of interest..	Aizman O, 2000, NAT NEUROSCI, V3, P226, DOI 10.1038/72929; Andringa G, 1999, EUR J PHARMACOL, V364, P33, DOI 10.1016/S0014-2999(98)00825-5; Beaulieu JM, 2011, PHARMACOL REV, V63, P182, DOI 10.1124/pr.110.002642; Chun LS, 2013, MOL PHARMACOL, V84, P190, DOI 10.1124/mol.113.085175; Ciruela F, 2004, ANAL CHEM, V76, P5354, DOI 10.1021/ac049295f; DEVENEY AM, 1995, BRIT J PHARMACOL, V116, P2120, DOI 10.1111/j.1476-5381.1995.tb16420.x; Fuxe K, 2009, J ACUPUNCT MERIDIAN, V2, P1, DOI 10.1016/S2005-2901(09)60011-X; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; George Susan R, 2007, ScientificWorldJournal, V7, P58; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hasbi A, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-26; Hasbi A, 2010, CURR OPIN PHARMACOL, V10, P93, DOI 10.1016/j.coph.2009.09.011; Hasbi A, 2009, P NATL ACAD SCI USA, V106, P21377, DOI 10.1073/pnas.0903676106; Huang JY, 2013, NAT STRUCT MOL BIOL, V20, P419, DOI 10.1038/nsmb.2504; Jackson SN, 2009, J AM SOC MASS SPECTR, V20, P176, DOI 10.1016/j.jasms.2008.08.021; Jackson SN, 2005, J PROTEOME RES, V4, P2360, DOI 10.1021/pr050261d; Jin LQ, 2003, J NEUROCHEM, V85, P378, DOI 10.1046/j.1471-4159.2003.01698.x; Lee SP, 2004, J BIOL CHEM, V279, P35671, DOI 10.1074/jbc.M401923200; Lee SP, 2003, BIOCHEMISTRY-US, V42, P11023, DOI 10.1021/bi0345539; Lukasiewicz S, 2009, FEBS J, V276, P760, DOI 10.1111/j.1742-4658.2008.06822.x; Maggio R, 2009, PARKINSONISM RELAT D, V15, pS2, DOI 10.1016/S1353-8020(09)70826-0; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Navarro G, 2010, J BIOL CHEM, V285, P27346, DOI 10.1074/jbc.M110.115634; Neve KA, 2004, J RECEPT SIG TRANSD, V24, P165, DOI 10.1081/LRST-200029981; Ng J, 2010, NEUROSCIENCE, V165, P535, DOI 10.1016/j.neuroscience.2009.10.017; O'Dowd BF, 2013, BIOCHEM BIOPH RES CO, V431, P586, DOI 10.1016/j.bbrc.2012.12.139; O'Dowd BF, 2012, BIOCHEM BIOPH RES CO, V417, P23, DOI 10.1016/j.bbrc.2011.11.027; O'Dowd BF, 2011, EUR J PHARMACOL, V658, P74, DOI 10.1016/j.ejphar.2011.02.030; Pei L, 2010, NAT MED, V16, P1393, DOI 10.1038/nm.2263; Perreault ML, 2014, NEUROPSYCHOPHARMACOL, V39, P156, DOI 10.1038/npp.2013.148; Perreault ML, 2013, INT J NEUROPSYCHOPH, V16, P477, DOI 10.1017/S1461145712000685; Perreault ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033348; Perreault ML, 2010, J BIOL CHEM, V285, P36625, DOI 10.1074/jbc.M110.159954; Rapoport M, 2009, EXPERT OPIN DRUG DEL, V6, P453, DOI [10.1517/17425240902887029, 10.1517/17425240902887029 ]; Rashid AJ, 2007, TRENDS PHARMACOL SCI, V28, P551, DOI 10.1016/j.tips.2007.10.001; Rashid AJ, 2007, P NATL ACAD SCI USA, V104, P654, DOI 10.1073/pnas.0604049104; So CH, 2007, MOL PHARMACOL, V72, P450, DOI 10.1124/mol.107.034884; Verma V, 2010, J BIOL CHEM, V285, P35092, DOI 10.1074/jbc.M109.088625; Woods AS, 2004, J PROTEOME RES, V3, P478, DOI 10.1021/pr034091l	39	40	41	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2014	28	11					4806	4820		10.1096/fj.14-254037	http://dx.doi.org/10.1096/fj.14-254037			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AS1OU	25063849	Green Published			2022-12-28	WOS:000344050900019
J	Vernochet, C; Damilano, F; Mourier, A; Bezy, O; Mori, MA; Smyth, G; Rosenzweig, A; Larsson, NG; Kahn, CR				Vernochet, Cecile; Damilano, Federico; Mourier, Arnaud; Bezy, Olivier; Mori, Marcelo A.; Smyth, Graham; Rosenzweig, Anthony; Larsson, Nils-Goeran; Kahn, C. Ronald			Adipose tissue mitochondrial dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatosteatosis, and cardiovascular complications	FASEB JOURNAL			English	Article						TFAM; WAT; BAT; diabetes; hypertension; cardiomegaly	TRANSCRIPTION-FACTOR; HIV-INFECTION; GENERALIZED LIPODYSTROPHY; COPY NUMBER; MICE; OBESITY; DNA; ADIPONECTIN; MAINTENANCE; INSIGHTS	Mitochondrial dysfunction in adipose tissue occurs in obesity, type 2 diabetes, and some forms of lipodystrophy, but whether this dysfunction contributes to or is the result of these disorders is unknown. To investigate the physiological consequences of severe mitochondrial impairment in adipose tissue, we generated mice deficient in mitochondrial transcription factor A (TFAM) in adipocytes by using mice carrying adiponectin-Cre and TFAM floxed alleles. These adiponectin TFAM-knockout (adipo-TFAM-KO) mice had a 75-81% reduction in TFAM in the subcutaneous and intra-abdominal white adipose tissue (WAT) and interscapular brown adipose tissue (BAT), causing decreased expression and enzymatic activity of proteins in complexes I, III, and IV of the electron transport chain (ETC). This mitochondrial dysfunction led to adipocyte death and inflammation in WAT and a whitening of BAT. As a result, adipo-TFAM-KO mice were resistant to weight gain, but exhibited insulin resistance on both normal chow and high-fat diets. These lipodystrophic mice also developed hypertension, cardiac hypertrophy, and cardiac dysfunction. Thus, isolated mitochondrial dysfunction in adipose tissue can lead a syndrome of lipodystrophy with metabolic syndrome and cardiovascular complications.-Vernochet, C., Damilano, F., Mourier, A., Bezy, O., Mori, M. A., Smyth, G., Rosenzweig, A., Larsson, N.-G., Kahn, C. R. Adipose tissue mitochondrial dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatosteatosis, and cardiovascular complications.	[Vernochet, Cecile; Bezy, Olivier; Mori, Marcelo A.; Smyth, Graham; Kahn, C. Ronald] Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02215 USA; [Vernochet, Cecile; Damilano, Federico; Bezy, Olivier; Mori, Marcelo A.; Smyth, Graham; Rosenzweig, Anthony; Kahn, C. Ronald] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Damilano, Federico; Rosenzweig, Anthony] Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, Boston, MA 02215 USA; [Mourier, Arnaud; Larsson, Nils-Goeran] Max Planck Inst Biol Ageing, Dept Mitochondrial Biol, Cologne, Germany	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Max Planck Society	Kahn, CR (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	c.ronald.kahn@joslin.harvard.edu	MOURIER, Arnaud/F-9657-2019; Kahn, Ronald/AAY-2435-2021; Mori, Marcelo A/R-2881-2018; MOURIER, Arnaud/I-8117-2012; Rosenzweig, Anthony/AAD-7893-2019	MOURIER, Arnaud/0000-0002-5413-611X; Kahn, Ronald/0000-0002-7583-9228; Mori, Marcelo A/0000-0001-7112-5263; MOURIER, Arnaud/0000-0002-5413-611X; Larsson, Nils-Goran/0000-0001-5100-996X; Bezy, Olivier/0000-0003-4367-5043	U.S. National Institutes of Health (NIH) [R01-DK082659]; Eli Lilly Foundation; Joslin Diabetes Research Center (NIH) [P30-DK036836]; Mary K. Iacocca Professorship; NIH [R01-HL094677]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL094677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK082659, R01DK033201] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eli Lilly Foundation(Eli Lilly); Joslin Diabetes Research Center (NIH); Mary K. Iacocca Professorship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health (NIH) grant R01-DK082659 (C.R.K.), a grant from the Eli Lilly Foundation, Joslin Diabetes Research Center (NIH grant P30-DK036836), the Mary K. Iacocca Professorship, and NIH grant R01-HL094677 (A.R.).	Ahima RS, 2006, OBESITY, V14, P242, DOI 10.1038/oby.2006.317; Apostolova N, 2011, TRENDS PHARMACOL SCI, V32, P715, DOI 10.1016/j.tips.2011.07.007; Asin-Cayuela J, 2007, TRENDS BIOCHEM SCI, V32, P111, DOI 10.1016/j.tibs.2007.01.003; Campbell CT, 2012, BBA-GENE REGUL MECH, V1819, P921, DOI 10.1016/j.bbagrm.2012.03.002; Caron M, 2004, AIDS, V18, P2127, DOI 10.1097/00002030-200411050-00004; De Pauw A, 2009, AM J PATHOL, V175, P927, DOI 10.2353/ajpath.2009.081155; Dela F, 2013, INT J BIOCHEM CELL B, V45, P11, DOI 10.1016/j.biocel.2012.09.019; Farmer SR, 2008, GENE DEV, V22, P1269, DOI 10.1101/gad.1681308; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Garg A, 2004, ENDOCRIN METAB CLIN, V33, P305, DOI 10.1016/j.ecl.2004.03.003; Gaspari M, 2004, BBA-BIOENERGETICS, V1659, P148, DOI 10.1016/j.bbabio.2004.10.003; Giralt M, 2011, BEST PRACT RES CL EN, V25, P487, DOI 10.1016/j.beem.2010.12.001; Gusev K, 2009, CIRC RES, V105, P42, DOI 10.1161/CIRCRESAHA.108.189779; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; Herichova I, 2013, Endocr Regul, V47, P39; Ho JE, 2009, HEART, V95, P1193, DOI 10.1136/hrt.2008.161463; Kaaman M, 2007, DIABETOLOGIA, V50, P2526, DOI 10.1007/s00125-007-0818-6; Kang D, 2007, MITOCHONDRION, V7, P39, DOI 10.1016/j.mito.2006.11.017; Koh EH, 2007, DIABETES, V56, P2973, DOI 10.2337/db07-0510; Kusminski CM, 2012, TRENDS ENDOCRIN MET, V23, P435, DOI 10.1016/j.tem.2012.06.004; Lamounier-Zepter V, 2008, MOL CELL ENDOCRINOL, V280, P39, DOI 10.1016/j.mce.2007.09.012; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Lee KY, 2013, DIABETES, V62, P864, DOI 10.2337/db12-1089; Lupsa BC, 2010, MEDICINE, V89, P245, DOI 10.1097/MD.0b013e3181e9442f; Massiera F, 2001, FASEB J, V15, P2727, DOI 10.1096/fj.01-0457fje; Mori MA, 2012, CELL METAB, V16, P336, DOI 10.1016/j.cmet.2012.07.017; Nelson MD, 2013, AM J CARDIOL, V112, P1019, DOI 10.1016/j.amjcard.2013.05.036; Onen NF, 2010, HIV CLIN TRIALS, V11, P100, DOI 10.1310/hct1102-100; Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016; Patti ME, 2010, ENDOCR REV, V31, P364, DOI 10.1210/er.2009-0027; Ricquier D, 2005, P NUTR SOC, V64, P47, DOI 10.1079/PNS2004408; Rivard K, 2011, AM J PHYSIOL-HEART C, V301, pH2018, DOI 10.1152/ajpheart.01092.2010; Romano AD, 2014, CURR PHARM DESIGN, V20, P2978, DOI 10.2174/13816128113196660700; Rottman JN, 2007, ECHOCARDIOGR-J CARD, V24, P83, DOI 10.1111/j.1540-8175.2006.00356.x; Scherrer-Crosbie M, 2010, J MOL CELL CARDIOL, V48, P512, DOI 10.1016/j.yjmcc.2009.07.004; Shibata R, 2012, CURR MED CHEM, V19, P5459, DOI 10.2174/092986712803833164; Vernochet C, 2012, CELL METAB, V16, P765, DOI 10.1016/j.cmet.2012.10.016; Villarroya J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029691; Villarroya J, 2009, OBESITY, V17, P1814, DOI 10.1038/oby.2009.152; Ye RS, 2013, MOL METAB, V2, P133, DOI 10.1016/j.molmet.2013.04.001; Yvan-Charvet L, 2011, KIDNEY INT, V79, P162, DOI 10.1038/ki.2010.391	41	104	106	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4408	4419		10.1096/fj.14-253971	http://dx.doi.org/10.1096/fj.14-253971			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	25005176	Green Published			2022-12-28	WOS:000342222700019
J	Yan, J; Ginsberg, SD; Powers, B; Alldred, MJ; Saltzman, A; Strupp, BJ; Caudill, MA				Yan, Jian; Ginsberg, Stephen D.; Powers, Brian; Alldred, Melissa J.; Saltzman, Arthur; Strupp, Barbara J.; Caudill, Marie A.			Maternal choline supplementation programs greater activity of the phosphatidylethanolamine N-methyltransferase (PEMT) pathway in adult Ts65Dn trisomic mice	FASEB JOURNAL			English	Article						Alzheimer's disease; docosahexaenoic acid; Down syndrome; fetal programming; phosphatidylcholine	DOWN-SYNDROME; MOUSE MODEL; ALZHEIMERS-DISEASE; BASAL FOREBRAIN; DOCOSAHEXAENOIC ACID; SPATIAL MEMORY; ABNORMALITIES; DEMENTIA; ALTERS; METABOLISM	Maternal choline supplementation (MCS) induces lifelong cognitive benefits in the Ts65Dn mouse, a trisomic mouse model of Down syndrome and Alzheimer's disease. To gain insight into the mechanisms underlying these beneficial effects, we conducted a study to test the hypothesis that MCS alters choline metabolism in adult Ts65Dn offspring. Deuterium-labeled methyl-d9-choline was administered to adult Ts65Dn and disomic (2N) female littermates born to choline-unsupplemented or choline-supplemented Ts65Dn dams. Enrichment of d9-choline metabolites (derived from intact choline) and d3 + d6-choline metabolites [produced when cholinederived methyl groups are used by phosphatidylethanolamine N-methyltransferase (PEMT)] was measured in harvested tissues. Adult offspring (both Ts65Dn and 2N) of choline-supplemented (vs. choline-unsupplemented) dams exhibited 60% greater (P <= 0.007) activity of hepatic PEMT, which functions in de novo choline synthesis and produces phosphatidylcholine (PC) enriched in docosahexaenoic acid. Higher (P<0.001) enrichment of PEMT-derived d3 and d6 metabolites was detected in liver, plasma, and brain in both genotypes but to a greater extent in the Ts65Dn adult offspring. MCS also yielded higher (P<0.05) d9 metabolite enrichments in liver, plasma, and brain. These data demonstrate that MCS exerts lasting effects on offspring choline metabolism, including up-regulation of the hepatic PEMT pathway and enhanced provision of choline and PEMT-PC to the brain.	[Yan, Jian; Powers, Brian; Strupp, Barbara J.; Caudill, Marie A.] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; [Ginsberg, Stephen D.; Alldred, Melissa J.; Saltzman, Arthur] Nathan S Kline Inst Psychiat Res, Ctr Dementia Res, Orangeburg, NY USA; [Ginsberg, Stephen D.; Alldred, Melissa J.] NYU, Langone Med Ctr, Dept Psychiat, New York, NY USA; [Ginsberg, Stephen D.; Alldred, Melissa J.] NYU, Langone Med Ctr, Dept Physiol & Neurosci, New York, NY USA	Cornell University; Nathan Kline Institute for Psychiatric Research; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center	Caudill, MA (corresponding author), Cornell Univ, Div Nutr Sci, 228 Savage Hall, Ithaca, NY 14853 USA.	mac379@cornell.edu	, SDG/AAB-3329-2022	Ginsberg, Stephen/0000-0002-1797-4288	U.S. National Institutes of Health [HD057564, AG043375, AG017617, AG014449]; Alzheimer's Association [IIRG-12-237253]; NATIONAL INSTITUTE ON AGING [R01AG043375, P01AG017617, P01AG014449] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alzheimer's Association(Alzheimer's Association); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was funded by the U.S. National Institutes of Health (HD057564, AG043375, AG017617, and AG014449) and the Alzheimer's Association (IIRG-12-237253). The funding sources had no role in the study design, interpretation of the data, and/or publication of the results. The authors thank Olga Malysheva for expert technical assistance.	Alldred MJ, 2012, NEUROBIOL DIS, V45, P751, DOI 10.1016/j.nbd.2011.10.022; Bachmanov AA, 2002, BEHAV GENET, V32, P435, DOI 10.1023/A:1020884312053; Belichenko NP, 2009, J NEUROSCI, V29, P5938, DOI 10.1523/JNEUROSCI.1547-09.2009; Blusztajn JK, 2013, CLIN CHEM LAB MED, V51, P591, DOI 10.1515/cclm-2012-0635; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Chew TW, 2011, J NUTR, V141, P1475, DOI 10.3945/jn.111.138859; CHUNG SY, 1995, J NUTR, V125, P1484; Davisson M T, 1993, Prog Clin Biol Res, V384, P117; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Duchon A, 2011, MAMM GENOME, V22, P674, DOI 10.1007/s00335-011-9356-0; Eilander A, 2007, PROSTAG LEUKOTR ESS, V76, P189, DOI 10.1016/j.plefa.2007.01.003; ESCORIHUELA RM, 1995, NEUROSCI LETT, V199, P143, DOI 10.1016/0304-3940(95)12052-6; Ferrier D. R., 2013, LIPPINCOTTS ILLUSTRA, P322; GINSBERG SD, 1995, J NEUROCHEM, V65, P2800; Ginsberg SD, 2011, BRAIN STRUCT FUNCT, V216, P347, DOI 10.1007/s00429-011-0315-z; Granholm AC, 2003, HIPPOCAMPUS, V13, P905, DOI 10.1002/hipo.10130; Granholm ACE, 2000, EXP NEUROL, V161, P647, DOI 10.1006/exnr.1999.7289; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; Holtzman DM, 1996, P NATL ACAD SCI USA, V93, P13333, DOI 10.1073/pnas.93.23.13333; Hyde LA, 2001, BEHAV NEUROSCI, V115, P1239, DOI 10.1037//0735-7044.115.6.1239; Insausti AM, 1998, NEUROSCI LETT, V253, P175, DOI 10.1016/S0304-3940(98)00641-7; Jacobs PA, 1995, ADV GENET, V33, P101, DOI 10.1016/S0065-2660(08)60332-6; Kelley CM, 2014, J COMP NEUROL, V522, P1390, DOI 10.1002/cne.23492; Kelley CM, 2014, BRAIN PATHOL, V24, P33, DOI 10.1111/bpa.12073; Koc H, 2002, ANAL CHEM, V74, P4734, DOI 10.1021/ac025624x; Kurt MA, 2000, BRAIN RES, V858, P191, DOI 10.1016/S0006-8993(00)01984-3; Leverenz JB, 1998, EXP NEUROL, V150, P296, DOI 10.1006/exnr.1997.6777; Li ZY, 2007, J BIOL CHEM, V282, P10283, DOI 10.1074/jbc.M611726200; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Lorenzi H, 2010, BIOTECHNIQUES, V48, P35, DOI 10.2144/000113342; MANN DMA, 1986, NEUROPATH APPL NEURO, V12, P447, DOI 10.1111/j.1365-2990.1986.tb00053.x; Meck WH, 2008, FRONT INTEGR NEUROSC, V1, DOI 10.3389/neuro.07.007.2007; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; Meck WH, 2003, NEUROSCI BIOBEHAV R, V27, P385, DOI 10.1016/S0149-7634(03)00069-1; Moon J, 2010, BEHAV NEUROSCI, V124, P346, DOI 10.1037/a0019590; Parker SE, 2010, BIRTH DEFECTS RES A, V88, P1008, DOI 10.1002/bdra.20735; Pynn CJ, 2011, J LIPID RES, V52, P399, DOI 10.1194/jlr.d011916; REEVES RH, 1995, NAT GENET, V11, P177, DOI 10.1038/ng1095-177; ROSSOR MN, 1984, BRIT MED J, V288, P961, DOI 10.1136/bmj.288.6422.961; Scheltens P, 2012, J ALZHEIMERS DIS, V31, P225, DOI 10.3233/JAD-2012-121189; Sheehan R, 2014, CURR OPIN PSYCHIATR, V27, P143, DOI 10.1097/YCO.0000000000000032; Thomas JD, 2010, BIRTH DEFECTS RES A, V88, P827, DOI 10.1002/bdra.20713; Velazquez R, 2013, NEUROBIOL DIS, V58, P92, DOI 10.1016/j.nbd.2013.04.016; Visootsak Jeannie, 2007, Curr Psychiatry Rep, V9, P135; Watkins SM, 2003, J NUTR, V133, P3386, DOI 10.1093/jn/133.11.3386; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; Wong-Goodrich SJE, 2011, HIPPOCAMPUS, V21, P584, DOI 10.1002/hipo.20783; Wurtman RJ, 2008, METABOLISM, V57, pS6, DOI 10.1016/j.metabol.2008.07.007; Wurtman RJ, 2009, ANNU REV NUTR, V29, P59, DOI 10.1146/annurev-nutr-080508-141059; Yan J, 2013, AM J CLIN NUTR, V98, P1459, DOI 10.3945/ajcn.113.066092; Yan JA, 2011, AM J CLIN NUTR, V93, P348, DOI 10.3945/ajcn.110.005975; Yang YL, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0006.2000	54	11	11	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2014	28	10					4312	4323		10.1096/fj.14-251736	http://dx.doi.org/10.1096/fj.14-251736			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AP6XU	24963152	Green Published			2022-12-28	WOS:000342222700011
J	Bliss, KT; Tsukada, T; Novak, SM; Dorovkov, MV; Shah, SP; Nworu, C; Kostyukova, AS; Gregorio, CC				Bliss, Katherine T.; Tsukada, Takehiro; Novak, Stefanie Mares; Dorovkov, Maxim V.; Shah, Samar P.; Nworu, Chinedu; Kostyukova, Alla S.; Gregorio, Carol C.			Phosphorylation of tropomodulin1 contributes to the regulation of actin filament architecture in cardiac muscle	FASEB JOURNAL			English	Article						post-translational modification; sarcomere	BINDING PROTEIN-C; TROPOMYOSIN BINDING; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; POINTED ENDS; N-TERMINUS; TROPONIN-I; F-ACTIN; KINASE; TRPM7	Tropomodulin1 (Tmod1) is an actin-capping protein that plays an important role in actin filament pointed-end dynamics and length in striated muscle. No mechanisms have been identified to explain how Tmod1's functional properties are regulated. The purpose of this investigation was to explore the functional significance of the phosphorylation of Tmod1 at previously identified Thr54. Rat cardiomyocytes were assessed for phosphorylation of Tmod1 using Pro-Q Diamond staining and P-32 labeling. Green fluorescent protein-tagged phosphorylation-mimic (T54E) and phosphorylation-deficient (T54A) versions of Tmod1 were expressed in cultured cardiomyocytes, and the ability of these mutants to assemble and restrict actin lengths was observed. We report for the first time that Tmod1 is phosphorylated endogenously in cardiomyocytes, and phosphorylation at Thr54 causes a significant reduction in the ability of Tmod1 to assemble to the pointed end compared with that of the wild type (WT; 48 vs. 78%, respectively). In addition, overexpression of Tmod1-T54E restricts actin filament lengths by only similar to 3%, whereas Tmod1-WT restricts the lengths significantly by similar to 8%. Finally, Tmod1-T54E altered the actin filament-capping activity in polymerization assays. Taken together, our data suggest that pointed-end assembly and Tmod1's thin filament length regulatory function are regulated by its phosphorylation state.	[Bliss, Katherine T.; Tsukada, Takehiro; Novak, Stefanie Mares; Nworu, Chinedu; Gregorio, Carol C.] Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ USA; [Bliss, Katherine T.; Tsukada, Takehiro; Novak, Stefanie Mares; Nworu, Chinedu; Gregorio, Carol C.] Univ Arizona, Sarver Mol Cardiovasc Res Program, Tucson, AZ USA; [Dorovkov, Maxim V.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; [Kostyukova, Alla S.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA; [Kostyukova, Alla S.] Washington State Univ, Sch Chem Engn & Bioengn, Pullman, WA USA	University of Arizona; University of Arizona; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Washington State University	Gregorio, CC (corresponding author), Dept Cellular & Mol Med, 1656 E Mabel St,MRB 315, Tucson, AZ 85724 USA.	gregorio@email.arizona.edu			U.S. National Institutes of Health [HL083146, HL108625, HL081386, GM081688, 1F31HL 117520]; American Heart Association [0825870G, 10PRE3780013, 12PRE11900038]; Grants-in-Aid for Scientific Research [25860147] Funding Source: KAKEN; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083146, R01HL108625, R01HL081386, F31HL117520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081688] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	dThe authors thank Ellen Taylor, Marcus DiMarco, Verena Koenning, Katrina Garvey, and Laura Arguedas for generating rat cardiomyocyte cultures and for technical assistance, Lucy Kotlyanskaya for assistance with biochemistry, Dr. Mien-sheng Chu and Marcela Berumen for generating the GFP-Tmod1 adenovirus, Dr. Gregory Rogers and Dr. Daniel Buster for assistance with the <SUP>32</SUP>P phosphorylation analysis experiments and for providing llama GFP-binding protein conjugated beads, and the Rutgers Aresty Research Center for Undergraduates (New Brunswick, NJ, USA) that allowed S. P. S. to work in the laboratory of A. S. K. This work was supported by the U.S. National Institutes of Health (grants HL083146 and HL108625 to C. C. G., HL081386 to the late Dr. Jeffrey Walker, GM081688 to A. S. K., and predoctoral fellowship 1F31HL 117520 to S.M.N.) and the American Heart Association (grant 0825870G to T. T. and predoctoral fellowships 10PRE3780013 to K. T. B. and 12PRE11900038 to S.M.N.).	Almenar-Queralt A, 1999, J CELL SCI, V112, P1111; Anderson BR, 2010, J STRUCT BIOL, V170, P270, DOI 10.1016/j.jsb.2010.02.002; Barefield D, 2010, J MOL CELL CARDIOL, V48, P866, DOI 10.1016/j.yjmcc.2009.11.014; Buster DW, 2013, J CELL BIOL, V201, P49, DOI 10.1083/jcb.201207183; Chu X, 2003, AM J PHYSIOL-HEART C, V284, pH1827, DOI 10.1152/ajpheart.00947.2002; Clark K, 2006, EMBO J, V25, P290, DOI 10.1038/sj.emboj.7600931; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Cooper JA, 2008, INT REV CEL MOL BIO, V267, P183, DOI 10.1016/S1937-6448(08)00604-7; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; Dorovkov M. V., 2008, Biofizika, V53, P943; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FASMAN GD, 1989, TRENDS BIOCHEM SCI, V14, P295, DOI 10.1016/0968-0004(89)90068-6; Fowler VM, 2003, J BIOL CHEM, V278, P40000, DOI 10.1074/jbc.M306895200; Fritz-Six KL, 2003, J CELL BIOL, V163, P1033, DOI 10.1083/jcb.200308164; Gokhin DS, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/103069; Greenfield NJ, 2005, BIOPHYS J, V88, P372, DOI 10.1529/biophysj.104.051128; Greenfield NJ, 2001, J MOL BIOL, V312, P833, DOI 10.1006/jmbi.2001.4982; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; GUSTAFSON TA, 1987, J BIOL CHEM, V262, P13316; Hanft LM, 2013, J PHYSIOL-LONDON, V591, P4535, DOI 10.1113/jphysiol.2013.258400; Hidalgo C, 2009, CIRC RES, V105, P631, DOI 10.1161/CIRCRESAHA.109.198465; Hollrigl A, 2007, DIFFERENTIATION, V75, P616, DOI 10.1111/j.1432-0436.2007.00163.x; Huang XP, 2002, EXP BIOL MED, V227, P1039, DOI 10.1177/153537020222701113; ITO M, 1995, DEV BIOL, V167, P317, DOI 10.1006/dbio.1995.1026; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Kim TY, 2012, BIOCHEM BIOPH RES CO, V417, P1030, DOI 10.1016/j.bbrc.2011.12.085; Kobayashi T, 2008, PFLUG ARCH EUR J PHY, V457, P37, DOI 10.1007/s00424-008-0511-8; Kotter S, 2013, CARDIOVASC RES, V99, P648, DOI 10.1093/cvr/cvt144; Kooij V, 2013, J MOL CELL CARDIOL, V60, P116, DOI 10.1016/j.yjmcc.2013.04.012; Kostyukova A, 2000, EUR J BIOCHEM, V267, P6470, DOI 10.1046/j.1432-1327.2000.01738.x; Kostyukova AS, 2006, BIOCHEMISTRY-US, V45, P12068, DOI 10.1021/bi060899i; Kostyukova AS, 2005, BIOCHEMISTRY-US, V44, P4905, DOI 10.1021/bi047468p; Kostyukova AS, 2004, J BIOL CHEM, V279, P5066, DOI 10.1074/jbc.M311186200; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Krieger I, 2002, BIOPHYS J, V83, P2716, DOI 10.1016/S0006-3495(02)75281-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Layland J, 2005, CARDIOVASC RES, V66, P12, DOI 10.1016/j.cardiores.2004.12.022; LeWinter MM, 2010, CIRCULATION, V121, P2137, DOI 10.1161/CIRCULATIONAHA.109.860171; Littlefield R, 2001, NAT CELL BIOL, V3, P544, DOI 10.1038/35078517; Littlefield RS, 2008, SEMIN CELL DEV BIOL, V19, P511, DOI 10.1016/j.semcdb.2008.08.009; McKeown CR, 2008, CIRC RES, V103, P1241, DOI 10.1161/CIRCRESAHA.108.178749; Middelbeek J, 2010, CELL MOL LIFE SCI, V67, P875, DOI 10.1007/s00018-009-0215-z; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Ono Y, 2005, DEV BIOL, V282, P336, DOI 10.1016/j.ydbio.2005.03.015; Pappas CT, 2008, MOL BIOL CELL, V19, P1837, DOI 10.1091/mbc.E07-07-0690; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Sah R, 2013, P NATL ACAD SCI USA, V110, pE3037, DOI 10.1073/pnas.1311865110; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Shaffer JF, 2009, J BIOL CHEM, V284, P12318, DOI 10.1074/jbc.M808850200; Solaro RJ, 2008, J BIOL CHEM, V283, P26829, DOI 10.1074/jbc.R800037200; Solaro RJ, 2011, J BIOL CHEM, V286, P9935, DOI 10.1074/jbc.R110.197731; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Su LT, 2011, BIOCHEM J, V434, P513, DOI 10.1042/BJ20101678; Su LT, 2006, J BIOL CHEM, V281, P11260, DOI 10.1074/jbc.M512885200; Sussman MA, 1998, CIRC RES, V82, P94; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; Wagner LM, 2002, MOL VIS, V8, P394; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; Weith A, 2012, J MOL CELL CARDIOL, V52, P219, DOI 10.1016/j.yjmcc.2011.09.019; Wijnker PJM, 2013, AM J PHYSIOL-HEART C, V304, pH260, DOI 10.1152/ajpheart.00498.2012; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8; Yamasaki R, 2002, CIRC RES, V90, P1181, DOI 10.1161/01.RES.0000021115.24712.99	63	7	7	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2014	28	9					3987	3995		10.1096/fj.13-246009	http://dx.doi.org/10.1096/fj.13-246009			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN8HU	24891520	Green Published			2022-12-28	WOS:000340845900016
J	Arjomand, A; Baker, MA; Li, C; Buckle, AM; Jans, DA; Loveland, KL; Miyamoto, Y				Arjomand, Arash; Baker, Mark A.; Li, Chen; Buckle, Ashley M.; Jans, David A.; Loveland, Kate L.; Miyamoto, Yoichi			The alpha-importome of mammalian germ cell maturation provides novel insights for importin biology	FASEB JOURNAL			English	Article						nuclear transport; spermatogenesis; mass spectrometry; nuclear localization signal	NUCLEAR-LOCALIZATION SIGNAL; NUCLEOCYTOPLASMIC TRANSPORT; KARYOPHERIN ALPHA; IDENTIFICATION; RECOGNITION; EXPRESSION; PROTEINS; EXPORT	Importin alpha proteins function as adaptors to connect a cargo protein and importin beta 1 in the classical nuclear import pathway. Here we measure for the first time the stoichiometry of importins alpha 2, alpha 3, alpha 4, and beta 1 in primary cells corresponding to 2 successive stages of rat spermatogenesis: meiotic spermatocytes and haploid round spermatids. Importin alpha 2 levels were more than 2-fold higher in spermatocytes than in spermatids, while importins alpha 4 and beta 1 levels did not differ significantly. We performed a comprehensive proteomics analysis to identify binding proteins in spermatocytes and spermatids using recombinant importin alpha 2 and alpha 4 proteins. Among the 100 candidate partners, 42 contained a strong classical nuclear localization signal (cNLS; score of> 6 by cNLS Mapper), while 8 nuclear proteins lacked any cNLS. In addition, we developed a new strategy to predict which cargoes bind to importin alpha through the conserved C-terminal acidic domain (ARM repeats 9-10), and provided functional validation of a predicted importin alpha C-terminal binding segment in Senataxin and Smarca4. Evaluation of this set of candidate binding partners from spermatogenic cells using several bioinformatics approaches provides new evidence that individual importin alpha s may serve unique and nonredundant roles in mediating cellular differentiation.	[Arjomand, Arash; Li, Chen; Buckle, Ashley M.; Jans, David A.; Loveland, Kate L.; Miyamoto, Yoichi] Monash Univ, Dept Biochem & Mol Biol, Sch Biol Sci, Clayton, Vic 3800, Australia; [Loveland, Kate L.] Monash Univ, Dept Anat & Dev Biol, Sch Biol Sci, Clayton, Vic 3800, Australia; [Arjomand, Arash; Baker, Mark A.; Jans, David A.; Loveland, Kate L.] Australian Res Council, Ctr Excellence Biotechnol & Dev, Canberra, ACT, Australia; [Baker, Mark A.] Univ Newcastle, Prior Res Ctr Reprod Sci, Sch Environm & Life Sci, Callaghan, NSW 2308, Australia	Monash University; Monash University; University of Newcastle	Loveland, KL (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Sch Biomed Sci, Bldg 76,Wellington Rd, Clayton, Vic 3800, Australia.	kate.loveland@monash.edu	Buckle, Ashley/P-8366-2016; Loveland, Kate L/X-4404-2019	Buckle, Ashley/0000-0003-2943-9044; Loveland, Kate L/0000-0002-5750-8046; Jans, David/0000-0001-5115-4745; Li, Chen/0000-0002-1847-754X	Australian Research Council [DP0878102]; Australian Research Council Centre of Excellence in Biotechnology and Development [CE0348239]; National Health and Medical Research Council [ID545916, APP1002486]	Australian Research Council(Australian Research Council); Australian Research Council Centre of Excellence in Biotechnology and Development(Australian Research Council); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	The authors dedicate this manuscript to their colleague Prof. Norman Hecht, whose many contributions as a scientist and a friend enabled the discoveries presented in this study. The authros thank Moira O'Bryan (Monash University) for supply of the anti-ACRBP antibody and Yutaka Ogawa (Osaka University, Osaka, Japan) for the pGEX6P-importins alpha 2 Delta C (1-409 aa) construct. This work was supported in part by grants from the Australian Research Council (Discovery Project; DP0878102 to K. L. L. and Y.M.) and from the Australian Research Council Centre of Excellence in Biotechnology and Development (CE0348239 to K. L. L. and D.A.J.). K. L. L. and D.A.J. were supported by National Health and Medical Research Council Fellowships (ID545916 and APP1002486) and Y.M. by an Australian Research Council Fellowship (DP0878102).	Baker MA, 2004, J BIOL CHEM, V279, P4811, DOI 10.1074/jbc.M311020200; Baker MA, 2013, PROTEOMICS, V13, P61, DOI 10.1002/pmic.201200350; Becherel OJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003435; Christiansen A, 2013, CANCER LETT, V331, P18, DOI 10.1016/j.canlet.2012.12.013; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hachet V, 2004, EMBO J, V23, P1526, DOI 10.1038/sj.emboj.7600154; HOFMANN MC, 1992, EXP CELL RES, V201, P417, DOI 10.1016/0014-4827(92)90291-F; Hogarth CA, 2006, DEV DYNAM, V235, P253, DOI 10.1002/dvdy.20569; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kosugi S, 2009, P NATL ACAD SCI USA, V106, P10171, DOI 10.1073/pnas.0900604106; Kosugi S, 2009, J BIOL CHEM, V284, P478, DOI 10.1074/jbc.M807017200; Kotera I, 2005, EMBO J, V24, P942, DOI 10.1038/sj.emboj.7600587; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lindsay ME, 2002, CELL, V110, P349, DOI 10.1016/S0092-8674(02)00836-X; Lo JCY, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002969; LOVELAND KL, 1993, MOL REPROD DEV, V36, P440, DOI 10.1002/mrd.1080360406; Major AT, 2011, BBA-MOL CELL RES, V1813, P1668, DOI 10.1016/j.bbamcr.2011.03.008; Miyamoto Y, 2002, EMBO J, V21, P5833, DOI 10.1093/emboj/cdf569; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; Miyamoto Y, 2013, BBA-MOL CELL RES, V1833, P731, DOI 10.1016/j.bbamcr.2012.11.005; Miyamoto Y, 2012, BBA-GENE REGUL MECH, V1819, P616, DOI 10.1016/j.bbagrm.2012.01.015; Tran MH, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.096842; Moroianu J, 1997, P NATL ACAD SCI USA, V94, P9699, DOI 10.1073/pnas.94.18.9699; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Ogawa Y, 2012, TRAFFIC, V13, P934, DOI 10.1111/j.1600-0854.2012.01367.x; Ogawa Y, 2010, MOL BIOL CELL, V21, P630, DOI 10.1091/mbc.E09-05-0374; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Riddick G, 2005, J CELL BIOL, V168, P1027, DOI 10.1083/jcb.200409024; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Tsuji L, 1997, FEBS LETT, V416, P30, DOI 10.1016/S0014-5793(97)01092-2; Wang JG, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.097097; Whiley PAF, 2012, INT J ANDROL, V35, P158, DOI 10.1111/j.1365-2605.2011.01202.x; Yasuda Y, 2012, EMBO J, V31, P83, DOI 10.1038/emboj.2011.360; Yasuhara N, 2013, DEV CELL, V26, P123, DOI 10.1016/j.devcel.2013.06.022; Yasuharaa N, 2009, SEMIN CELL DEV BIOL, V20, P590, DOI 10.1016/j.semcdb.2009.05.003; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475	43	15	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3480	3493		10.1096/fj.13-244913	http://dx.doi.org/10.1096/fj.13-244913			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24790034				2022-12-28	WOS:000340265400018
J	Burk, RF; Hill, KE; Motley, AK; Winfrey, VP; Kurokawa, S; Mitchell, SL; Zhang, WQ				Burk, Raymond F.; Hill, Kristina E.; Motley, Amy K.; Winfrey, Virginia P.; Kurokawa, Suguru; Mitchell, Stuart L.; Zhang, Wanqi			Selenoprotein P and apolipoprotein E receptor-2 interact at the blood-brain barrier and also within the brain to maintain an essential selenium pool that protects against neurodegeneration	FASEB JOURNAL			English	Article						choroid plexus; megalin	NEUROLOGICAL DYSFUNCTION; MOUSE-BRAIN; EXPRESSION; MAINTENANCE; DELETION; MICE; TRANSPORT; BINDING; KIDNEY; DOMAIN	Selenoprotein P (Sepp1) and its receptor, apolipoprotein E receptor 2 (apoER2), account for brain retaining selenium better than other tissues. The primary sources of Sepp1 in plasma and brain are hepatocytes and astrocytes, respectively. ApoER2 is expressed in varying amounts by tissues; within the brain it is expressed primarily by neurons. Knockout of Sepp1 or apoER2 lowers brain selenium from similar to 120 to similar to 50 ng/g and leads to severe neurodegeneration and death in mild selenium deficiency. Interactions of Sepp1 and apoER2 that protect against this injury have not been characterized. We studied Sepp1, apoER2, and brain selenium in knockout mice. Immunocytochemistry showed that apoER2 mediates Sepp1 uptake at the blood-brain barrier. When Sepp1(-/-) or apoER2(-/-) mice developed severe neurodegeneration caused by mild selenium deficiency, brain selenium was similar to 35 ng/g. In extreme selenium deficiency, however, brain selenium of similar to 12 ng/g was tolerated when both Sepp1 and apoER2 were intact in the brain. These findings indicate that tandem Sepp1-apoER2 interactions supply selenium for maintenance of brain neurons. One interaction is at the blood-brain barrier, and the other is within the brain. We postulate that Sepp1 inside the blood-brain barrier is taken up by neurons via apoER2, concentrating brain selenium in them.-Burk, R. F., Hill, K. E., Motley, A. K., Winfrey, V. P., Kurokawa, S., Mitchell, S. L., Zhang, W. Selenoprotein P and apolipoprotein E receptor-2 interact at the blood-brain barrier and also within the brain to maintain an essential selenium pool that protects against neurodegeneration.	[Burk, Raymond F.; Hill, Kristina E.; Motley, Amy K.; Winfrey, Virginia P.; Kurokawa, Suguru; Mitchell, Stuart L.; Zhang, Wanqi] Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37212 USA	Vanderbilt University	Burk, RF (corresponding author), Vanderbilt Univ Sch Med, 1030C Med Res Bldg 4, Nashville, TN 37232 USA.	raymond.burk@vanderbilt.edu	Mitchell, Stuart L/S-3419-2017; 张, 万起/M-5158-2019	Mitchell, Stuart L/0000-0001-9066-1088; 	U.S. National Institutes of Health [R37 ES-002497, 5P30 DK-058404, 5P30 ES-000267]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES002497, P30ES000267] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors are grateful to Teri D. Stevenson for animal husbandry and to Dr. William E. Valentine for a critical reading of the manuscript and helpful suggestions for its improvement. The work reported here was supported by U.S. National Institutes of Health grants R37 ES-002497, 5P30 DK-058404, and 5P30 ES-000267. The authors declare no conflicts of interest.	BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Burk RF, 2007, J NEUROSCI, V27, P6207, DOI 10.1523/JNEUROSCI.1153-07.2007; Burk RF, 2013, FASEB J, V27, P3249, DOI 10.1096/fj.13-231852; Burk RF, 2009, BBA-GEN SUBJECTS, V1790, P1441, DOI 10.1016/j.bbagen.2009.03.026; Chiu-Ugalde J, 2010, BIOCHEM J, V431, P103, DOI 10.1042/BJ20100779; Christensen EI, 2002, NAT REV MOL CELL BIO, V3, P258, DOI 10.1038/nrm778; Clatworthy AE, 1999, NEUROSCIENCE, V90, P903, DOI 10.1016/S0306-4522(98)00489-8; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hill KE, 2004, J NUTR, V134, P157, DOI 10.1093/jn/134.1.157; Hill KE, 2007, J BIOL CHEM, V282, P10972, DOI 10.1074/jbc.M700436200; Hill KE, 2012, J BIOL CHEM, V287, P40414, DOI 10.1074/jbc.M112.421404; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; KOH TS, 1983, J ASSOC OFF ANA CHEM, V66, P918; Kurokawa S, 2014, J BIOL CHEM, V289, P9195, DOI 10.1074/jbc.M114.549014; Kurokawa S, 2014, FREE RADICAL BIO MED, V69, P67, DOI 10.1016/j.freeradbiomed.2014.01.010; Kurokawa S, 2012, J BIOL CHEM, V287, P28717, DOI 10.1074/jbc.M112.383521; May P, 2005, CELL MOL LIFE SCI, V62, P2325, DOI 10.1007/s00018-005-5231-z; Michalke B, 2011, J ANAL ATOM SPECTROM, V26, P165, DOI 10.1039/c0ja00106f; Nakayama A, 2007, J NUTR, V137, P690, DOI 10.1093/jn/137.3.690; Olson GE, 2008, J BIOL CHEM, V283, P6854, DOI 10.1074/jbc.M709945200; Olson GE, 2007, J BIOL CHEM, V282, P12290, DOI 10.1074/jbc.M611403200; Peters MM, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-12; Pitts MW, 2012, NEUROSCIENCE, V208, P58, DOI 10.1016/j.neuroscience.2012.02.017; Renko K, 2008, BIOCHEM J, V409, P741, DOI 10.1042/BJ20071172; Scharpf M, 2007, J NEURAL TRANSM, V114, P877, DOI 10.1007/s00702-006-0617-0; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; SHEEHAN TMT, 1990, CLIN CHEM, V36, P2124; Spector R, 2006, PHARM RES-DORDR, V23, P2515, DOI 10.1007/s11095-006-9091-5; Trotter JH, 2011, J NEUROSCI, V31, P14413, DOI 10.1523/JNEUROSCI.3135-11.2011; Valentine WM, 2008, J NEUROPATH EXP NEUR, V67, P68, DOI 10.1097/NEN.0b013e318160f347; WALLACE E, 1983, GAMETE RES, V7, P377, DOI 10.1002/mrd.1120070409; Wirth EK, 2010, FASEB J, V24, P844, DOI 10.1096/fj.09-143974; Yang XG, 2000, BBA-GEN SUBJECTS, V1474, P390, DOI 10.1016/S0304-4165(00)00035-0; Zhang Y, 2008, J BIOL CHEM, V283, P2427, DOI 10.1074/jbc.M707951200; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	35	81	82	4	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3579	3588		10.1096/fj.14-252874	http://dx.doi.org/10.1096/fj.14-252874			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24760755	Green Published, Bronze			2022-12-28	WOS:000340265400026
J	Tian, S; Hui, XW; Fan, ZZ; Li, QS; Zhang, JW; Yang, X; Ma, XL; Huang, BR; Chen, D; Chen, H				Tian, Shuo; Hui, Xiwu; Fan, Zhenzhen; Li, Qinshan; Zhang, Junwen; Yang, Xia; Ma, Xiaoli; Huang, Bingren; Chen, Deng; Chen, Hong			Suppression of hepatocellular carcinoma proliferation and hepatitis B surface antigen secretion with interferon-lambda 1 or PEG-interferon-lambda 1	FASEB JOURNAL			English	Article						tumor apoptosis; antitumor therapy	ANTITUMOR-ACTIVITY; VIRAL-HEPATITIS; GENE-EXPRESSION; ALPHA THERAPY; TUMOR-GROWTH; IN-VIVO; VIRUS; LAMBDA; RECURRENCE; APOPTOSIS	Hepatocellular carcinoma (HCC) is a common cancer associated with chronic hepatitis B virus (HBV) infection. Conventional interferon-alpha (IFN-alpha) and pegylated IFNs (PEG-IFNs) approved for chronic HBV infection treatment can reduce the risk of HCC but are not suitable for the majority of patients and cause significant side effects. IFN-lambda 1 is a type III IFN with antiviral, antiproliferative, and immunomodulatory functions similar to type I IFNs but with fewer side effects. However, the tolerability and antitumor activity of PEG-IFN-lambda 1 in HCC xenograft mice are unknown. In vitro IFN-lambda 1 treatment of Hep3B and Huh7 human hepatoma cell lines increased MHC class I expression, activated JAK-STAT signaling pathways, induced IFN-stimulated gene expression, and inhibited hepatitis B surface antigen (HBsAg) expression. IFN-lambda 1 treatment also caused 23.2 and 19.9% growth inhibition of Hep3B and Huh7 cells, respectively, and promoted cellular apoptosis. PEG-IFN-lambda 1, but not IFN-lambda 1 treatment, significantly suppressed tumor growth (P = 0.002) and induced tumor cell apoptosis in a Hep3B cell xenograft mouse model without significant weight loss or toxicity. PEG-IFN-lambda 1 also significantly inhibited (P = 0.000) serum HBsAg secretion from Hep3B xenograft tumors in vivo. Thus, PEG-IFN-lambda 1 can suppress Hep3B xenograft tumor growth and inhibit HBsAg production and may be a potential treatment for HBV-related HCC.	[Tian, Shuo; Hui, Xiwu; Fan, Zhenzhen; Li, Qinshan; Zhang, Junwen; Yang, Xia; Ma, Xiaoli; Huang, Bingren; Chen, Deng; Chen, Hong] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Biochem & Mol Biol, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; [Tian, Shuo; Hui, Xiwu; Fan, Zhenzhen; Li, Qinshan; Zhang, Junwen; Yang, Xia; Ma, Xiaoli; Huang, Bingren; Chen, Deng; Chen, Hong] Peking Union Med Coll, Sch Basic Med, Beijing 100021, Peoples R China; [Hui, Xiwu] CSPC ZhongQi Pharmaceut Technol, Shijiazhuang, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Chen, H (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	chendeng2001@hotmail.com; hchen@public.bta.net.cn	hui, xiwu/AAO-3650-2021		National Laboratory of Medical Molecular Biology of China	National Laboratory of Medical Molecular Biology of China	The authors are grateful to the National Laboratory of Medical Molecular Biology of China for grant support.	Abushahba W, 2010, CANCER IMMUNOL IMMUN, V59, P1059, DOI 10.1007/s00262-010-0831-3; Bell SJ, 2008, BIOCONJUGATE CHEM, V19, P299, DOI 10.1021/bc070131q; Brand S, 2005, AM J PHYSIOL-GASTR L, V289, pG960, DOI 10.1152/ajpgi.00126.2005; Chae SY, 2010, MOL CANCER THER, V9, P1719, DOI 10.1158/1535-7163.MCT-09-1076; Chen HC, 1997, ANTIVIR RES, V34, P137, DOI 10.1016/S0166-3542(97)01031-0; Doyle SE, 2006, HEPATOLOGY, V44, P896, DOI 10.1002/hep.21312; Duan ZF, 2006, CLIN CANCER RES, V12, P5055, DOI 10.1158/1078-0432.CCR-06-0861; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Guenterberg KD, 2010, MOL CANCER THER, V9, P510, DOI 10.1158/1535-7163.MCT-09-0461; Hong SH, 2007, VIRUS RES, V126, P245, DOI 10.1016/j.virusres.2007.03.006; HSU SL, 1993, J BIOL CHEM, V268, P23093; Hui XW, 2011, CANCER LETT, V311, P141, DOI 10.1016/j.canlet.2011.07.004; Ikeda K, 2005, J GASTROEN HEPATOL, V20, P95, DOI 10.1111/j.1440-1746.2004.03527.x; Jiang DK, 2013, NAT GENET, V45, P72, DOI 10.1038/ng.2483; Kim TH, 2011, BIOCONJUGATE CHEM, V22, P1631, DOI 10.1021/bc200187k; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; La QH, 2010, EUR J CANCER, V46, P180, DOI 10.1016/j.ejca.2009.10.002; Lee D, 2012, DIGEST DIS, V30, P568, DOI 10.1159/000343068; Li W, 2008, CELL PROLIFERAT, V41, P960, DOI 10.1111/j.1365-2184.2008.00558.x; Lin SM, 1999, HEPATOLOGY, V29, P971, DOI 10.1002/hep.510290312; Lok ASF, 2007, HEPATOLOGY, V45, P507, DOI 10.1002/hep.21513; Marcellin P, 2005, J VIRAL HEPATITIS, V12, P333, DOI 10.1111/j.1365-2893.2005.00599.x; Meager A, 2005, CYTOKINE, V31, P109, DOI 10.1016/j.cyto.2005.04.003; Michielsen P, 2011, ACTA GASTRO-ENT BELG, V74, P4; Miller DM, 2009, ANN NY ACAD SCI, V1182, P80, DOI 10.1111/j.1749-6632.2009.05241.x; Muir AJ, 2010, HEPATOLOGY, V52, P822, DOI 10.1002/hep.23743; Nguyen VTT, 2009, J VIRAL HEPATITIS, V16, P453, DOI 10.1111/j.1365-2893.2009.01117.x; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Qu LS, 2010, J SURG ONCOL, V102, P796, DOI 10.1002/jso.21741; Qu LS, 2010, J GASTROINTEST SURG, V14, P1111, DOI 10.1007/s11605-010-1211-1; Robek MD, 2005, J VIROL, V79, P3851, DOI 10.1128/JVI.79.6.3851-3854.2005; Sato A, 2006, J IMMUNOL, V176, P7686, DOI 10.4049/jimmunol.176.12.7686; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Someya T, 2006, J GASTROENTEROL, V41, P1206, DOI 10.1007/s00535-006-1912-0; Sommereyns C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000017; Tanaka M, 2011, J EPIDEMIOL, V21, P401, DOI 10.2188/jea.JE20100190; Wang L, 2000, HEPATOLOGY, V32, P43, DOI 10.1053/jhep.2000.8525; Wang YJ, 2010, J CONTROL RELEASE, V145, P306, DOI 10.1016/j.jconrel.2010.04.021; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Xie YF, 2007, J BIOTECHNOL, V129, P472, DOI 10.1016/j.jbiotec.2007.01.018; Yan YL, 2013, CANCER BIOTHER RADIO, V28, P124, DOI 10.1089/cbr.2012.1247; Zhou ZL, 2007, J VIROL, V81, P7749, DOI 10.1128/JVI.02438-06; Zhuang PY, 2010, J CANCER RES CLIN, V136, P1891, DOI 10.1007/s00432-010-0848-1; Zitzmann K, 2006, BIOCHEM BIOPH RES CO, V344, P1334, DOI 10.1016/j.bbrc.2006.04.043	46	9	12	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2014	28	8					3528	3539		10.1096/fj.14-250704	http://dx.doi.org/10.1096/fj.14-250704			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AN0HM	24769671				2022-12-28	WOS:000340265400022
J	Fazal, L; Azibani, F; Bihry, N; Coutance, G; Polidano, E; Merval, R; Vodovar, N; Launay, JM; Delcayre, C; Samuel, JL				Fazal, Loubina; Azibani, Feriel; Bihry, Nicolas; Coutance, Guillaume; Polidano, Evelyne; Merval, Regine; Vodovar, Nicolas; Launay, Jean-Marie; Delcayre, Claude; Samuel, Jane-Lise			Akt-mediated cardioprotective effects of aldosterone in type 2 diabetic mice	FASEB JOURNAL			English	Article						physiopathology; heart; insulin; IGF-1 receptor	MINERALOCORTICOID RECEPTOR ANTAGONISTS; HEART-FAILURE; INSULIN-RESISTANCE; GROWTH-FACTOR; CARDIOVASCULAR-SYSTEM; ENDOTHELIAL FUNCTION; CARDIAC FIBROSIS; ANIMAL-MODELS; ANGIOGENESIS; DYSFUNCTION	Studies have shown that aldosterone would have angiogenic effects and therefore would be beneficial in the context of cardiovascular diseases. We thus investigated the potential involvement of aldosterone in triggering a cardiac angiogenic response in the context of type-2 diabetes and the molecular pathways involved. Male 3-wk-old aldosterone synthase (AS)-overexpressing mice and their control wild-type (WT) littermates were fed a standard or high-fat, high-sucrose (HFHS) diet. After 6 mo of diet treatment, mice were euthanized, and cardiac samples were assayed by RT-PCR, immunoblotting, and immunohistology. HFHS diet induced type-2 diabetes in WT (WT-D) and AS (AS-D) mice. VEGFa mRNAs decreased in WT-D (-43%, P<0.05 vs. WT) and increased in AS-D mice (+236%, P<0.01 vs. WT-D). In WT-D mouse hearts, the proapoptotic p38MAPK was activated (P<0.05 vs. WT and AS-D), whereas Akt activity decreased (-64%, P<0.05 vs. WT). The AS mice, which exhibited a cardiac up-regulation of IGF1-R, showed an increase in Akt phosphorylation when diabetes was induced (P<0.05 vs. WT and AS-D). Contrary to WT-D mice, AS-D mouse hearts did not express inflammatory markers and exhibited a normal capillary density (P<0.05 vs. WT-D). To our knowledge, this is the first study providing new insights into the mechanisms whereby aldosterone prevents diabetes-induced cardiac disorders.	[Fazal, Loubina; Azibani, Feriel; Bihry, Nicolas; Coutance, Guillaume; Polidano, Evelyne; Merval, Regine; Vodovar, Nicolas; Launay, Jean-Marie; Delcayre, Claude; Samuel, Jane-Lise] Hop Lariboisiere, INSERM, UMR S 942, F-75475 Paris 10, France; [Bihry, Nicolas; Launay, Jean-Marie; Samuel, Jane-Lise] Hop Lariboisiere, Assistance Publ Hop Paris AP HP, Dept Biochem, F-75475 Paris, France; [Fazal, Loubina; Coutance, Guillaume; Delcayre, Claude; Samuel, Jane-Lise] Paris Diderot Univ, Paris, France; [Launay, Jean-Marie] Paris Descartes Univ, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Samuel, JL (corresponding author), Hop Lariboisiere, INSERM, UMR S 942, 41 Blvd Chapelle, F-75475 Paris 10, France.	jane-lise.samuel@inserm.fr	Coutance, Guillaume/ABE-9491-2020; Vodovar, Nicolas/S-2947-2019	Coutance, Guillaume/0000-0003-4939-2175; Samuel, Jane-Lise/0000-0002-7346-2404; Vodovar, Nicolas/0000-0001-8087-387X	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (INSERM); Universite Paris-Diderot; Fondation de France; Interface grant INSERM-Assistance Publique-Hopitaux de Paris (APHP); Societe Francaise d'Hypertension Arterielle (SFHTA); Universite Paris Diderot; Groupe de Reflexion sur la Recherche Cardiovasculaire (GRRC); European Commission [305507]	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite Paris-Diderot; Fondation de France(Fondation de France); Interface grant INSERM-Assistance Publique-Hopitaux de Paris (APHP); Societe Francaise d'Hypertension Arterielle (SFHTA); Universite Paris Diderot; Groupe de Reflexion sur la Recherche Cardiovasculaire (GRRC); European Commission(European CommissionEuropean Commission Joint Research Centre)	This work was supported by Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris-Diderot, the Fondation de France, Interface grant INSERM-Assistance Publique-Hopitaux de Paris (APHP) and the Societe Francaise d'Hypertension Arterielle (SFHTA). L.F. is supported by a Ph.D. training grant from Universite Paris Diderot and Groupe de Reflexion sur la Recherche Cardiovasculaire (GRRC). N.V. is supported by a postdoctoral fellowship from the European Commission's Seventh Framework program under grant agreement 305507 (HOMAGE). The authors declare no conflicts of interest. L.F., C.D., and J.L.S. wrote the manuscript, researched and analyzed data, and contributed to discussion of data; F.A., J.M.L., and N.V. participated in the discussion and reviewed the manuscript; J.M.L., E.P., and R.M. researched data; N.B. and G.C. performed the echocardiography on mice; C.D. contributed to design of the experiments and discussion and reviewed and edited the manuscript; J.L.S. is the guarantor of this work and, as such, had access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.	Abbas A, 2011, DIABETES, V60, P2169, DOI 10.2337/db11-0197; Azibani F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038197; Bonnard C, 2008, J CLIN INVEST, V118, P789, DOI 10.1172/JCI32601; Burton TR, 2009, CELL DEATH DIFFER, V16, P515, DOI 10.1038/cdd.2008.185; Cascella T, 2010, ENDOCRINOLOGY, V151, P5851, DOI 10.1210/en.2010-0350; Chatzigeorgiou A, 2009, IN VIVO, V23, P245; Cohen-Solal A, 2008, J CARD FAIL, V14, P615, DOI 10.1016/j.cardfail.2008.04.001; Cook SA, 2010, EUR HEART J, V31, P100, DOI 10.1093/eurheartj/ehp396; Daniels A, 2009, ACTA PHYSIOL, V195, P321, DOI 10.1111/j.1748-1716.2008.01936.x; Davies JI, 2004, DIABETOLOGIA, V47, P1687, DOI 10.1007/s00125-004-1510-8; Felcht M, 2012, J CLIN INVEST, V122, P1991, DOI 10.1172/JCI58832; Garnier A, 2004, CIRCULATION, V110, P1819, DOI 10.1161/01.CIR.0000142858.44680.27; Gray S, 2011, TRENDS ENDOCRIN MET, V22, P394, DOI 10.1016/j.tem.2011.05.001; Hill JA, 2008, NEW ENGL J MED, V358, P1370, DOI 10.1056/NEJMra072139; Huynh K, 2012, DIABETOLOGIA, V55, P1544, DOI 10.1007/s00125-012-2495-3; Jiang TX, 2012, BLOOD, V120, P2330, DOI 10.1182/blood-2012-01-406108; Kaji K, 2010, HEPATOL RES, V40, P540, DOI 10.1111/j.1872-034X.2010.00636.x; Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051; Kim JK, 2005, DIABETES, V54, P1657, DOI 10.2337/diabetes.54.6.1657; Koitabashi N, 2012, NAT REV CARDIOL, V9, P147, DOI 10.1038/nrcardio.2011.172; Krug AW, 2008, HYPERTENSION, V51, P1252, DOI 10.1161/HYPERTENSIONAHA.107.109439; Lastra G, 2010, NAT REV CARDIOL, V7, P577, DOI 10.1038/nrcardio.2010.123; Laustsen PG, 2007, MOL CELL BIOL, V27, P1649, DOI 10.1128/MCB.01110-06; Liu J, 2009, NAT MED, V15, P940, DOI 10.1038/nm.1994; Maron BA, 2008, CURR OPIN INVEST DR, V9, P963; Messaoudi S, 2009, FASEB J, V23, P2176, DOI 10.1096/fj.08-125302; Michel F, 2004, CIRCULATION, V109, P1933, DOI 10.1161/01.CIR.0000127112.36796.9B; Milliez P, 2009, AM J PHYSIOL-HEART C, V296, pH435, DOI 10.1152/ajpheart.00591.2008; O'Neill BT, 2005, J CLIN INVEST, V115, P2059, DOI 10.1172/JCI25900; Park CW, 2009, DIABETES, V58, P2666, DOI 10.2337/db09-0136; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Rees DA, 2005, DIABETIC MED, V22, P359, DOI 10.1111/j.1464-5491.2005.01499.x; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; Wada T, 2010, ENDOCRINOLOGY, V151, P2040, DOI 10.1210/en.2009-0869; Xue Q, 2009, ARTERIOSCL THROM VAS, V29, P1172, DOI 10.1161/ATVBAHA.109.185918; Zannad F, 2012, EUR HEART J, V33, P2782, DOI 10.1093/eurheartj/ehs257	36	8	8	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2430	2440		10.1096/fj.13-239822	http://dx.doi.org/10.1096/fj.13-239822			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24558200				2022-12-28	WOS:000339883600005
J	Ghosh, S; Wanders, D; Stone, KP; Van, NT; Cortez, CC; Gettys, TW				Ghosh, Sujoy; Wanders, Desiree; Stone, Kirsten P.; Van, Nancy T.; Cortez, Cory C.; Gettys, Thomas W.			A systems biology analysis of the unique and overlapping transcriptional responses to caloric restriction and dietary methionine restriction in rats	FASEB JOURNAL			English	Article						obesity; animal models; insulin sensitivity; amino acid sensing	AMINO-ACID STARVATION; ADIPOSE-TISSUE; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; ACTIN CYTOSKELETON; SIGNAL TRANSDUCER; OXIDATIVE STRESS; INFLAMMATION; ADIPOGENESIS; METABOLISM	Dietary methionine restriction (MR) and calorie restriction (CR) each improve metabolic health and extend life span. We used comprehensive transcriptome profiling and systems biology analysis to interrogate the unique and overlapping molecular responses in rats provided these dietary regimens for 20 mo after weaning. Microarray analysis was conducted on inguinal white adipose (IWAT), brown adipose tissue (BAT), liver, and skeletal muscle. Compared to controls, CR-induced transcriptomic responses (absolute fold change >= 1.5 and P <= 0.05) were comparable in IWAT, BAT, and liver (similar to 800 genes). MR-induced effects were largely restricted to IWAT and liver (similar to 2400 genes). Pathway enrichment and gene-coexpression analyses showed that induction of fatty acid synthesis in IWAT was common to CR and MR, whereas immunity and proinflammatory signaling pathways were specifically down-regulated in MR-treated IWAT and liver (FDR <= 0.07-0.3). BAT demonstrated consistent down-regulation of PPAR-signaling under CR and MR, whereas muscle was largely unaffected. Interactome analysis identified CR-specific down-regulation of cytoskeletal matrix components in IWAT and MR-specific up-regulation of ribosomal genes in liver (FDR <= 0.001). Transcriptomic down-regulation of inflammation genes by MR in IWAT was consistent with upstream inhibition of STAT3. Together, these results provide an integrated picture of the breadth of transcriptional responses to MR and CR among key metabolic tissues.	[Ghosh, Sujoy; Gettys, Thomas W.] Pennington Biomed Res Ctr, Lab Computat Biol, Baton Rouge, LA 70808 USA; [Ghosh, Sujoy; Wanders, Desiree; Stone, Kirsten P.; Van, Nancy T.; Cortez, Cory C.; Gettys, Thomas W.] Pennington Biomed Res Ctr, Lab Nutrient Sensing & Adipocyte Signaling, Baton Rouge, LA 70808 USA; [Ghosh, Sujoy] Duke Natl Univ Singapore, Grad Sch Med, Cardiovasc & Metab Disorders Res Program, Singapore, Singapore	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National University of Singapore	Gettys, TW (corresponding author), Pennington Biomed Res Ctr, Lab Nutrient Sensing & Adipocyte Signaling, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	gettystw@pbrc.edu	Gettys, Thomas W/N-1964-2017; Ghosh, Sujoy/I-3729-2017; Stone, Kirsten/AAB-3804-2019	Gettys, Thomas W/0000-0001-7125-7995; Ghosh, Sujoy/0000-0002-7601-165X; Stone, Kirsten/0000-0001-5511-1638; Wanders, Desiree/0000-0003-2638-3954	American Diabetes Association (ADA) [1-12-BS-58]; U.S. National Institutes of Health (NIH) [DK-096311]; ADA [7-13-MI-05]; NIH [1F32DK098918-01, P20-GM103528, P30 DK072476]; Mouse Metabolic Phenotyping Center Consortium (NIH) [U24DK076169]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK098918, R01DK096311, U24DK076169, P30DK072476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103528] Funding Source: NIH RePORTER	American Diabetes Association (ADA)(American Diabetes Association); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ADA(American Diabetes Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mouse Metabolic Phenotyping Center Consortium (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by American Diabetes Association (ADA) grant 1-12-BS-58 (T.W.G.), U.S. National Institutes of Health (NIH) grant DK-096311 (T.W.G.), ADA grant 7-13-MI-05 (T.W.G.), NIH grant 1F32DK098918-01 (D.W.), and the Mouse Metabolic Phenotyping Center Consortium (NIH grant U24DK076169). This work also made use of the Genomics and the Cell Biology and Bioimaging core facilities at the Pennington Biomedical Research Center, supported by NIH grants P20-GM103528 (T.W.G.) and P30 DK072476. The authors acknowledge the excellent technical assistance of Kelly Dille and Mollye Baker, and the clerical support of Cindi Tramonte.	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Barzilai N, 2001, J NUTR, V131, p903S, DOI 10.1093/jn/131.3.903S; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cernkovich ER, 2008, ENDOCRINOLOGY, V149, P1581, DOI 10.1210/en.2007-1148; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; Curtis JM, 2010, DIABETES, V59, P1132, DOI 10.2337/db09-1105; Deyl Z, 1975, Adv Exp Med Biol, V53, P359; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]; Gaccioli F, 2006, J BIOL CHEM, V281, P17929, DOI 10.1074/jbc.M600341200; Hasek BE, 2013, DIABETES, V62, P3362, DOI 10.2337/db13-0501; Hasek BE, 2010, AM J PHYSIOL-REG I, V299, pR728, DOI 10.1152/ajpregu.00837.2009; Henegar C, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r14; Higami Y, 2006, J NUTR, V136, P343, DOI 10.1093/jn/136.2.343; HITOMI Y, 1993, BIOSCI BIOTECH BIOCH, V57, P1216, DOI 10.1271/bbb.57.1216; Huang HY, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002691; Huffman DM, 2010, INTERD T GERONT GERI, V37, P1, DOI 10.1159/000319991; Huffman DM, 2009, BBA-GEN SUBJECTS, V1790, P1117, DOI 10.1016/j.bbagen.2009.01.008; Ishii K, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-37; Jhun JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078843; Kawaguchi N, 2003, J CELL SCI, V116, P3893, DOI 10.1242/jcs.00699; Kemnitz JW, 2011, ILAR J, V52, P66, DOI 10.1093/ilar.52.1.66; Kimball SR, 2002, J NUTR, V132, P883; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; Malloy VL, 2006, AGING CELL, V5, P305, DOI 10.1111/j.1474-9726.2006.00220.x; MCCAY CM, 1989, NUTRITION, V5, P155; MCGOWN E, 1973, J NUTR, V103, P109, DOI 10.1093/jn/103.1.109; Muzumdar R, 2008, AGING CELL, V7, P438, DOI 10.1111/j.1474-9726.2008.00391.x; Newman MEJ, 2006, P NATL ACAD SCI USA, V103, P8577, DOI 10.1073/pnas.0601602103; O'Sullivan K. E., 2013, J GASTROINTEST CANC; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Omodei D, 2011, FEBS LETT, V585, P1537, DOI 10.1016/j.febslet.2011.03.015; ORENTREICH N, 1993, J NUTR, V123, P269; Petrovic V, 2006, COMP BIOCHEM PHYS C, V142, P60, DOI 10.1016/j.cbpc.2005.10.004; Priceman SJ, 2013, P NATL ACAD SCI USA, V110, P13079, DOI 10.1073/pnas.1311557110; Prifti E, 2010, BIOINFORMATICS, V26, P3083, DOI 10.1093/bioinformatics/btq591; Przanowski P, 2014, J MOL MED, V92, P239, DOI 10.1007/s00109-013-1090-5; Richard AJ, 2014, BBA-MOL BASIS DIS, V1842, P431, DOI 10.1016/j.bbadis.2013.05.030; RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743; Schiller ZA, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt230; Simon R, 2007, CANCER INFORM, V3, P11; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Stewart WC, 1999, BBA-MOL CELL RES, V1452, P188, DOI 10.1016/S0167-4889(99)00129-9; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Svensson PA, 2011, INT J MOL MED, V27, P227, DOI 10.3892/ijmm.2010.566; Swindell WR, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-585; Wanders D, 2014, BIOFACTORS, V40, P13, DOI 10.1002/biof.1111; Weindruch R, 2001, J NUTR, V131, p918S, DOI 10.1093/jn/131.3.918S; Wu GM, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r53; Yang WL, 2014, HUM MOL GENET, V23, P502, DOI 10.1093/hmg/ddt444; Ye JP, 2010, AGING-US, V2, P361, DOI 10.18632/aging.100155; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhou Z, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-109	53	33	33	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2014	28	6					2577	2590		10.1096/fj.14-249458	http://dx.doi.org/10.1096/fj.14-249458			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AM5GA	24571921	Green Published			2022-12-28	WOS:000339883600017
